<SEC-DOCUMENT>0001193125-22-183362.txt : 20220628
<SEC-HEADER>0001193125-22-183362.hdr.sgml : 20220628
<ACCEPTANCE-DATETIME>20220628075841
ACCESSION NUMBER:		0001193125-22-183362
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		125
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220628
DATE AS OF CHANGE:		20220628

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Roivant Sciences Ltd.
		CENTRAL INDEX KEY:			0001635088
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				981173944
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40782
		FILM NUMBER:		221046508

	BUSINESS ADDRESS:	
		STREET 1:		CLARENDON HOUSE, 2 CHURCH STREET
		CITY:			HAMILTON HM11
		STATE:			D0
		ZIP:			HM11
		BUSINESS PHONE:		441-295-5950

	MAIL ADDRESS:	
		STREET 1:		CLARENDON HOUSE
		STREET 2:		2 CHURCH STREET
		CITY:			HAMILTON
		STATE:			D0
		ZIP:			HM11
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d307489d10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:roiv="http://roivant.com/20220331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>Form 10-K</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style=""><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P04_01_2021To03_31_2022">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityRegistrantName" id="hidden50657982" contextRef="P04_01_2021To03_31_2022">Roivant Sciences Ltd.</ix:nonNumeric><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" id="hidden50658326" contextRef="PAsOn03_31_2022_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2">0.10</ix:nonFraction><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" id="hidden50658327" contextRef="PAsOn03_31_2022_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="2">0.12</ix:nonFraction><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P04_01_2021To03_31_2022">0001635088</ix:nonNumeric><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="hidden50658054" contextRef="PAsOn03_31_2022" unitRef="Unit_USD_per_Share" decimals="8">0.00000003</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="hidden50658055" contextRef="PAsOn03_31_2021" unitRef="Unit_USD_per_Share" decimals="8">0.00000003</ix:nonFraction><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P04_01_2021To03_31_2022">FY</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P04_01_2021To03_31_2022">--03-31</ix:nonNumeric><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="hidden50658913" contextRef="PAsOn03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="8">0.00000003</ix:nonFraction><ix:nonNumeric name="roiv:Numberoftradingdaystomeetearnoutpricethreshold" id="hidden50659038" contextRef="P04_01_2021To03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis">P20D</ix:nonNumeric><ix:nonNumeric name="roiv:Numberoftradingdaystomeetearnoutpricethreshold" id="hidden50659039" contextRef="P04_01_2021To03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis">P20D</ix:nonNumeric><ix:nonNumeric name="roiv:Tradingdayperiodforearnoutshares" id="hidden50659043" contextRef="P04_01_2021To03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis">P30D</ix:nonNumeric><ix:nonNumeric name="roiv:Tradingdayperiodforearnoutshares" id="hidden50659044" contextRef="P04_01_2021To03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsTwentyDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis">P30D</ix:nonNumeric><ix:nonNumeric name="roiv:Lockupperiodofcommonshares" id="hidden50659059" contextRef="P04_01_2021To03_31_2022_LockUpPeriodNineMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">P36M</ix:nonNumeric><ix:nonNumeric name="roiv:Lockupperiodofcommonshares" id="hidden50659060" contextRef="P04_01_2021To03_31_2022_LockUpPeriodThreeMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">P36M</ix:nonNumeric><ix:nonNumeric name="roiv:Lockupperiodwarrants" id="hidden50659065" contextRef="P04_01_2021To03_31_2022_LockUpPeriodSixMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">P36M</ix:nonNumeric><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" id="hidden50659171" contextRef="P04_01_2021To03_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="2">0.01</ix:nonFraction><ix:footnote id="FN_162816" xml:lang="en-US">Retroactively restated for the stock subdivision as described in Note 3.</ix:footnote ><ix:footnote id="FN_162812" xml:lang="en-US">Primarily Greater China and United Kingdom activity</ix:footnote ><ix:footnote id="FN_162813" xml:lang="en-US">Primarily related to operations in the United States, Switzerland, the United Kingdom, and other jurisdictions with statutory tax rates different than the Bermuda rate.</ix:footnote ><ix:footnote id="FN_162811" xml:lang="en-US">Primarily entities which are centrally managed and controlled in the United Kingdom</ix:footnote ><ix:footnote id="FN_162815" xml:lang="en-US">Refer to Note 10, &#8220;Share-Based Compensation&#8221; for details regarding settlement of CVARs.</ix:footnote ></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="roiv-20220331.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="roiv-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="roiv-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="roiv-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="roiv-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="P04_01_2021To03_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2021To05_01_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-05-01</xbrli:startDate> <xbrli:endDate>2021-05-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2021To09_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-09-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_01_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-05-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_21_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2021To11_01_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-11-01</xbrli:startDate> <xbrli:endDate>2021-11-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_01_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-10-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommonStockMemberusgaapFairValueByAssetClassAxis_DatavantMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:DatavantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommonStockMemberusgaapFairValueByAssetClassAxis_DatavantMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:DatavantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_TaxAuthorityInOtherJurisdictionsMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >roiv:TaxAuthorityInOtherJurisdictionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_GBsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CHsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:CH</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >roiv:EmployeeRelatedExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >roiv:OtherGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:RSLEquityPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_UnitedStatesAndCanadaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >roiv:UnitedStatesAndCanadaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:ImmunovantINCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_DatavantHoldingsIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:DatavantHoldingsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:SubsidiaryEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_NovaquestMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:NovaquestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CombinedCompanyMembersrtOwnershipAxis_DatavantMergerMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:DatavantMergerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >roiv:CombinedCompanyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivPublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >roiv:RoivPublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivPrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >roiv:RoivPrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivLiabilityInstrumentsMeasuredAtFairValueMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >roiv:RoivLiabilityInstrumentsMeasuredAtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivEarnoutSharesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >roiv:RoivEarnoutSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:MontesArchimedesAcquisitionCorpMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_MaacClassBSharesMemberusgaapStatementClassOfStockAxis_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:MontesArchimedesAcquisitionCorpMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >roiv:MaacClassBSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >roiv:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_MaacClassASharesMemberusgaapStatementClassOfStockAxis_RoivantWarrantMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >roiv:RoivantWarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >roiv:MaacClassASharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis_PipeFinancingMemberROIVAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:MontesArchimedesAcquisitionCorpMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:AgreementAxis" >roiv:PipeFinancingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsEighteenPerDollarMemberROIVTriggeringEventAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >roiv:RedemptionOfRoivantWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis" >roiv:SharePriceEqualOrExceedsEighteenPerDollarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsTenDollarMemberROIVTriggeringEventAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis" >roiv:SharePriceEqualOrExceedsTenDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >roiv:RedemptionOfRoivantWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsEighteenPerDollarMemberROIVTriggeringEventAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis" >roiv:SharePriceEqualOrExceedsEighteenPerDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_LockUpPeriodOneMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis" >roiv:LockUpPeriodOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_LockUpPeriodTwoMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis" >roiv:LockUpPeriodTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_LockUpPeriodThreeMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis" >roiv:LockUpPeriodThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_LockUpPeriodSevenMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis" >roiv:LockUpPeriodSevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_LockUpPeriodEightMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis" >roiv:LockUpPeriodEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_LockUpPeriodNineMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis" >roiv:LockUpPeriodNineMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_LockUpPeriodFourMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis" >roiv:LockUpPeriodFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_LockUpPeriodFiveMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis" >roiv:LockUpPeriodFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_LockUpPeriodSixMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis" >roiv:LockUpPeriodSixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RoivantWarrantMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >roiv:RoivantWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsTwentyDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis" >roiv:SponsorSupportAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis" >roiv:SharePriceEqualOrExceedsTwentyDollarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis" >roiv:SharePriceEqualOrExceedsFifteenDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis" >roiv:SponsorSupportAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_EarnoutSharesMemberusgaapStatementEquityComponentsAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:EarnoutSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_EarnoutSharesMemberusgaapStatementEquityComponentsAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:EarnoutSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_DatavantMemberdeiLegalEntityAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:DatavantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_DatavantMemberdeiLegalEntityAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:DatavantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_EarnoutSharesMemberusgaapStatementEquityComponentsAxis_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >roiv:LiabilityInstrumentsMeasuredAtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:EarnoutSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >roiv:LiabilityInstrumentsMeasuredAtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >roiv:PharmanvanthSevenGmbhMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommercialMilestoneMemberusgaapTransactionTypeAxis_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >roiv:PharmanvanthSevenGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis" >roiv:CommercialMilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_DevelopmentAndRegulatoryMilestoneMemberusgaapTransactionTypeAxis_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >roiv:PharmanvanthSevenGmbhMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis" >roiv:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CantorFitzgeraldCo.MemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >roiv:CantorFitzgeraldCo.Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_MasterSubscriptionAgreementMemberROIVAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:AgreementAxis" >roiv:MasterSubscriptionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ProductServiceAgreementMemberROIVAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:AgreementAxis" >roiv:ProductServiceAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CollaborationAgreementWithBlueprintMedicinesMemberROIVAgreementAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:AgreementAxis" >roiv:CollaborationAgreementWithBlueprintMedicinesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis" >roiv:RegulatoryMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:NovaquestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >roiv:SumitomoOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >roiv:SumitomoOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_MaximumMembersrtRangeAxis_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >roiv:SumitomoOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_DatavantMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:DatavantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_DatavantMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:DatavantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >roiv:EmployeeRelatedExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >roiv:OtherGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ImmunovantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:GenevantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >roiv:SiliconTherapeuticsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:SiliconTherapeuticsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >roiv:LiabilityInstrumentsMeasuredAtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_NovaquestMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:NovaquestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >roiv:SumitomoOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivLiabilityInstrumentsMeasuredAtFairValueMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >roiv:RoivLiabilityInstrumentsMeasuredAtFairValueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_LaboratoryandotherequipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >roiv:LaboratoryandotherequipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_LaboratoryandotherequipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >roiv:LaboratoryandotherequipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:AgreementAxis" >roiv:TransitionServicesAndStrategicCooperationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_RoivantSciencesLtd.MemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:RoivantSciencesLtd.Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:RSLEquityPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:RestrictedStockAndPerformanceStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:RSLEquityPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:AgreementAxis" >roiv:TransitionServicesAndStrategicCooperationAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SumitomoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_SubsidiaryEquityIncentivePlansMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:SubsidiaryEquityIncentivePlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_OtherMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >roiv:OtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_CHsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:CH</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_BMsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:BM</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_CollaborationAgreementWithBlueprintMedicinesMemberROIVAgreementAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:AgreementAxis" >roiv:CollaborationAgreementWithBlueprintMedicinesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_MaximumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_MinimumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_CHsrtStatementGeographicalAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:CH</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_CHsrtStatementGeographicalAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:CH</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_MaximumMembersrtRangeAxis_UnitedStatesAndCanadaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >roiv:UnitedStatesAndCanadaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_MinimumMembersrtRangeAxis_UnitedStatesAndCanadaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >roiv:UnitedStatesAndCanadaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_DatavantHoldingsIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:DatavantHoldingsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >roiv:PharmanvanthSevenGmbhMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_CommonStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_WarrantMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_StockOptionsAndPerformanceStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >roiv:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_TwoThousandAndTwentyCvarsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >roiv:TwoThousandAndTwentyCvarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_NovemberTwoThousandAndTwentyOneCvarsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >roiv:NovemberTwoThousandAndTwentyOneCvarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_EarnOutSharesNonvestedMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >roiv:EarnOutSharesNonvestedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_PrivatePlacementWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_PublicWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >roiv:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_OtherInstrumentsIssuedMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >roiv:OtherInstrumentsIssuedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_SumitomoOptionsMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SumitomoOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_EarnoutSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:EarnoutSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_DatavantMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:DatavantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_DatavantMergerMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:DatavantMergerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis_PipeFinancingMemberROIVAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:AgreementAxis" >roiv:PipeFinancingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:MontesArchimedesAcquisitionCorpMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis" >roiv:SharePriceEqualOrExceedsFifteenDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis" >roiv:SponsorSupportAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis" >roiv:SponsorSupportAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis" >roiv:SharePriceEqualOrExceedsFifteenDollarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SharePriceEqualOrExceedsTwentyDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis" >roiv:SharePriceEqualOrExceedsTwentyDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis" >roiv:SponsorSupportAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_SharePriceEqualOrExceedsTwentyDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis" >roiv:SponsorSupportAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis" >roiv:SharePriceEqualOrExceedsTwentyDollarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis" >roiv:SponsorSupportAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis" >roiv:SharePriceEqualOrExceedsFifteenDollarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SharePriceEqualOrExceedsTenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis" >roiv:SharePriceEqualOrExceedsTenDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis" >roiv:SponsorSupportAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SharePriceEqualOrExceedsTwentyDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis" >roiv:SponsorSupportAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis" >roiv:SharePriceEqualOrExceedsTwentyDollarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsEighteenPerDollarMemberROIVTriggeringEventAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis" >roiv:SharePriceEqualOrExceedsEighteenPerDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >roiv:RedemptionOfRoivantWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis" >roiv:SponsorSupportAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis" >roiv:SharePriceEqualOrExceedsFifteenDollarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsTwentyDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis" >roiv:SharePriceEqualOrExceedsTwentyDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis" >roiv:SponsorSupportAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_LockUpPeriodOneMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis" >roiv:LockUpPeriodOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_LockUpPeriodTwoMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MinimumMembersrtRangeAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis" >roiv:LockUpPeriodTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_LockUpPeriodTwoMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis" >roiv:LockUpPeriodTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_LockUpPeriodSevenMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis" >roiv:LockUpPeriodSevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_LockUpPeriodEightMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis" >roiv:LockUpPeriodEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_LockUpPeriodNineMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis" >roiv:LockUpPeriodNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_LockUpPeriodThreeMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis" >roiv:LockUpPeriodThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_LockUpPeriodSixMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis" >roiv:LockUpPeriodSixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_LockUpPeriodFiveMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis" >roiv:LockUpPeriodFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_LockUpPeriodFourMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis" >roiv:LockUpPeriodFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:MaacIndependentDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:MaacSponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_RoivantWarrantMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >roiv:RoivantWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_RoivantWarrantMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >roiv:RoivantWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsEighteenDollarMemberROIVTriggeringEventAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis" >roiv:SharePriceEqualOrExceedsEighteenDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsTenDollarMemberROIVTriggeringEventAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis" >roiv:SharePriceEqualOrExceedsTenDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >roiv:RedemptionOfRoivantWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >roiv:RedemptionOfRoivantWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RoivantCommonSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_AssetPurchaseAgreementMemberROIVAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:AgreementAxis" >roiv:AssetPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To03_31_2022_March2020CappedValueAppreciationRightsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:March2020CappedValueAppreciationRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:AgreementAxis" >roiv:TransitionServicesAndStrategicCooperationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SumitomoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:AgreementAxis" >roiv:TransitionServicesAndStrategicCooperationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_SubsidiaryEquityIncentivePlansMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:SubsidiaryEquityIncentivePlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_OtherMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >roiv:OtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_CHsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:CH</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_BMsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:BM</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:DatavantHoldingsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:GenevantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >roiv:SiliconTherapeuticsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_OtherInstrumentsIssuedMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >roiv:OtherInstrumentsIssuedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_StockOptionsAndPerformanceStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >roiv:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_TwoThousandAndTwentyCvarsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >roiv:TwoThousandAndTwentyCvarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:RSLEquityPlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2021To11_01_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-11-01</xbrli:startDate> <xbrli:endDate>2021-11-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-10-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:ImmunovantINCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:DatavantHoldingsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_27_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:DatavantHoldingsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_27_2021To07_27_2021_DatavantMergerMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:DatavantMergerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-27</xbrli:startDate> <xbrli:endDate>2021-07-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2021To11_30_2021_HemavantSciencesGmbhMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >roiv:HemavantSciencesGmbhMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-11-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2021To11_30_2021_SecondTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >roiv:SiliconTherapeuticsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis" >roiv:SecondTrancheMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-11-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2021To11_30_2021_SecondTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis" >roiv:SecondTrancheMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:SiliconTherapeuticsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-11-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2021To11_30_2021_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >roiv:PharmanvanthSevenGmbhMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-11-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2021To11_30_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-11-01</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_HemavantSciencesGmbhMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >roiv:HemavantSciencesGmbhMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2019_PrimeRateMemberusgaapVariableRateAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:PrimeRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2021_AssetPurchaseAgreementMemberROIVAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:AgreementAxis" >roiv:AssetPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2021_RevenueInterestPurchaseAndSaleAgreementMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >roiv:RevenueInterestPurchaseAndSaleAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:NovaquestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis" >roiv:RegulatoryMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:NovaquestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2018_CommercialMilestoneMemberusgaapTransactionTypeAxis_NovaquestMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:NovaquestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis" >roiv:CommercialMilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:NovaquestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-10-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2021To05_31_2021_RevenueInterestPurchaseAndSaleAgreementMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >roiv:RevenueInterestPurchaseAndSaleAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-05-01</xbrli:startDate> <xbrli:endDate>2021-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_GSKMembersrtCounterpartyNameAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >roiv:GSKMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis" >roiv:RegulatoryMilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_RoivrevenueInterestPurchaseAndSaleAgreementMemberMemberusgaapFinancialInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >roiv:RoivrevenueInterestPurchaseAndSaleAgreementMemberMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WelichemBiotechIncMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >roiv:WelichemBiotechIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_GSKMembersrtCounterpartyNameAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis" >roiv:RegulatoryMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >roiv:GSKMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_31_2022To05_31_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WelichemBiotechIncMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >roiv:WelichemBiotechIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-31</xbrli:startDate> <xbrli:endDate>2022-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_31_2017_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-10-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2022To03_01_2022_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:AgreementAxis" >roiv:TransitionServicesAndStrategicCooperationAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SumitomoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-01</xbrli:startDate> <xbrli:endDate>2022-03-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_14_2022_CantorFitzgeraldCo.MemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >roiv:CantorFitzgeraldCo.Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_14_2022To02_14_2022_CantorFitzgeraldCo.MemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >roiv:CantorFitzgeraldCo.Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-14</xbrli:startDate> <xbrli:endDate>2022-02-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:ImmunovantINCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ImmunovantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:ImmunovantINCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2020To05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:ImmunovantINCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-05-01</xbrli:startDate> <xbrli:endDate>2020-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:ImmunovantINCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-09-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:ImmunovantINCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-09-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_01_2021_SkMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >roiv:SkMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SkMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >roiv:SkMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2018To04_30_2018_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:GenevantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-04-01</xbrli:startDate> <xbrli:endDate>2018-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_31_2020To07_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:GenevantSciencesLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-31</xbrli:startDate> <xbrli:endDate>2020-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_31_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:GenevantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-31</xbrli:startDate> <xbrli:endDate>2020-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:GenevantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:DatavantHoldingsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To01_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2020To11_30_2020_AffivantSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:AffivantSciencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-11-01</xbrli:startDate> <xbrli:endDate>2020-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2020To11_30_2020_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:MilestoneEventsAxis" >roiv:FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-11-01</xbrli:startDate> <xbrli:endDate>2020-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2020To11_30_2020_AffivantSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:AffivantSciencesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-11-01</xbrli:startDate> <xbrli:endDate>2020-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2020To11_30_2020_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:MilestoneEventsAxis" >roiv:FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-11-01</xbrli:startDate> <xbrli:endDate>2020-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2020To11_30_2020_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:MilestoneEventsAxis" >roiv:FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-11-01</xbrli:startDate> <xbrli:endDate>2020-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2020To11_30_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-11-01</xbrli:startDate> <xbrli:endDate>2020-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To12_31_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2021To03_31_2021_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >roiv:SumitomoOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2021To03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >roiv:SiliconTherapeuticsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2021To03_31_2021_FirstTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis" >roiv:FirstTrancheMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:SiliconTherapeuticsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2021To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:SiliconTherapeuticsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:GenevantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2021To09_30_2021_PriovantMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >roiv:PriovantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-09-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2021To09_30_2021_PriovantMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:PriovantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-09-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2021To09_30_2021_AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMemberROIVEventAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:EventAxis" >roiv:AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-09-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:GenevantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:RSLEquityPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:RSLEquityPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:RestrictedStockAndPerformanceStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:RSLEquityPlansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:RestrictedStockAndPerformanceStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RedeemableNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_RedeemableNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_RedeemableNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Day" > <xbrli:measure>utr:Day</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month" > <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_CAD" > <xbrli:measure>iso4217:CAD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_EUR" > <xbrli:measure>iso4217:EUR</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Segment" > <xbrli:measure>roiv:Segment</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Y" > <xbrli:measure>utr:Y</xbrli:measure> </xbrli:unit><ix:relationship fromRefs="Fact_50658022" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658023" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658024" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658025" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658038" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658039" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658040" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658041" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658042" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658043" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658044" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658045" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658046" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658047" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658048" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658049" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658092" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658093" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658095" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658096" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658097" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658098" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658101" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658102" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658103" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658104" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658105" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658109" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658110" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658111" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658112" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658113" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658114" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658115" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658116" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658117" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658118" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658119" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658120" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658121" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658122" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658123" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658124" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658125" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658154" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658155" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658156" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658157" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658198" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658199" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658202" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658203" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658204" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658205" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658206" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658207" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658208" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658209" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658210" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658211" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658212" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658213" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658214" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658215" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658229" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658230" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658231" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658232" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658233" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658234" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658241" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658242" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658243" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658244" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658245" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658246" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658253" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658254" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658255" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658256" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658257" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658258" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658259" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658266" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658267" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658268" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658269" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658273" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658274" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658275" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658276" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658279" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658280" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658281" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658282" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658283" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658284" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658285" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658286" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658287" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658337" toRefs="FN_162812"/><ix:relationship fromRefs="Fact_50658338" toRefs="FN_162812"/><ix:relationship fromRefs="Fact_50658381" toRefs="FN_162813"/><ix:relationship fromRefs="Fact_50658382" toRefs="FN_162813"/><ix:relationship fromRefs="Fact_50658399" toRefs="FN_162813"/><ix:relationship fromRefs="Fact_50658400" toRefs="FN_162813"/><ix:relationship fromRefs="Fact_50658687" toRefs="FN_162811"/><ix:relationship fromRefs="Fact_50658688" toRefs="FN_162811"/><ix:relationship fromRefs="Fact_50658691" toRefs="FN_162812"/><ix:relationship fromRefs="Fact_50658692" toRefs="FN_162812"/><ix:relationship fromRefs="Fact_50658903" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658909" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658910" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658921" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658924" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658925" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658929" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658930" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658935" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658936" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658937" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658938" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50658972" toRefs="FN_162815"/><ix:relationship fromRefs="Fact_50658973" toRefs="FN_162815"/><ix:relationship fromRefs="Fact_50659118" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50659119" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50659120" toRefs="FN_162816"/><ix:relationship fromRefs="Fact_50659121" toRefs="FN_162816"/></ix:resources></ix:header></div><div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 17pt;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Washington, D.C. 20549 </div></div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P04_01_2021To03_31_2022">10-K</ix:nonNumeric></div> </div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Mark One) </div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentAnnualReport" contextRef="P04_01_2021To03_31_2022" format="ixt:fixed-true">&#9746;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P04_01_2021To03_31_2022" format="ixt:date-monthname-day-year-en">March 31, <ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P04_01_2021To03_31_2022">2022</ix:nonNumeric></ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">OR </div></div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P04_01_2021To03_31_2022" format="ixt:fixed-false">&#9744;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">For the transition period from <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Commission File Number: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="P04_01_2021To03_31_2022">001-40782</ix:nonNumeric></div> </div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 22pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 22pt; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden50657982">ROIVANT SCIENCES LTD.</span> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of Registrant as specified in its Charter) </div></div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 48%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P04_01_2021To03_31_2022" format="ixt-sec:edgarprovcountryen">Bermuda</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P04_01_2021To03_31_2022">98-1173944</ix:nonNumeric></div></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(State or other jurisdiction of</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">incorporation or organization)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(I.R.S. Employer</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Identification No.)</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P04_01_2021To03_31_2022">Suite 1, 3rd Floor</ix:nonNumeric></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P04_01_2021To03_31_2022"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">11-12</div> St. James&#8217;s Square</ix:nonNumeric></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P04_01_2021To03_31_2022">London</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P04_01_2021To03_31_2022">SW1Y 4LB</ix:nonNumeric></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCountry" contextRef="P04_01_2021To03_31_2022" format="ixt-sec:countrynameen">United Kingdom</ix:nonNumeric></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Not Applicable</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Address of principal executive offices)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Zip Code)</div></div></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:CountryRegion" contextRef="P04_01_2021To03_31_2022">+44</ix:nonNumeric> <ix:nonNumeric name="dei:CityAreaCode" contextRef="P04_01_2021To03_31_2022">207</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P04_01_2021To03_31_2022">400 3347</ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Registrant&#8217;s telephone number, including area code) </div></div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered pursuant to Section&#160;12(b) of the Act: </div></div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 32%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 32%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title of each class</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Trading<div style="display:inline;">&#160;</div></div></div><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Symbol(s)</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name of each exchange</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">on which registered</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P04_01_2021To03_31_2022_CommonStockMemberusgaapStatementClassOfStockAxis">Common Shares, $0.0000000341740141 per share</ix:nonNumeric> <ix:nonNumeric name="dei:Security12bTitle" contextRef="P04_01_2021To03_31_2022_WarrantMemberusgaapStatementClassOfStockAxis">Redeemable Warrants, each whole warrant exercisable for one Common Share at an exercise price of $11.50 per share</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P04_01_2021To03_31_2022_CommonStockMemberusgaapStatementClassOfStockAxis">ROIV</ix:nonNumeric></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P04_01_2021To03_31_2022_WarrantMemberusgaapStatementClassOfStockAxis">ROIVW</ix:nonNumeric></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P04_01_2021To03_31_2022_CommonStockMemberusgaapStatementClassOfStockAxis" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P04_01_2021To03_31_2022_WarrantMemberusgaapStatementClassOfStockAxis" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered pursuant to Section&#160;12(g) of the Act: None </div></div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="P04_01_2021To03_31_2022">No</ix:nonNumeric>&#160;&#160; &#9746; </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="P04_01_2021To03_31_2022">No</ix:nonNumeric>&#160;&#160; &#9746; </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P04_01_2021To03_31_2022">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160; &#9744; </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-T</div> (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P04_01_2021To03_31_2022">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160; &#9744; </div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 14%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 64%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 17%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 2%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P04_01_2021To03_31_2022" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9746;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P04_01_2021To03_31_2022" format="ixt:fixed-true">&#9746;</ix:nonNumeric></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 3pt; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Emerging&#160;growth&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P04_01_2021To03_31_2022" format="ixt:fixed-true">&#9746;</ix:nonNumeric></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P04_01_2021To03_31_2022" format="ixt:fixed-true">&#9746;</ix:nonNumeric> </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" contextRef="P04_01_2021To03_31_2022" format="ixt:fixed-false">&#9744;</ix:nonNumeric> </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant is a shell company (as defined in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;12b-2</div> of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric name="dei:EntityShellCompany" contextRef="P04_01_2021To03_31_2022" format="ixt:fixed-false">&#9746;</ix:nonNumeric> </div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;">The aggregate market value of the voting and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> common equity held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> of the registrant based upon the closing price of the registrant&#8217;s common shares, par value $0.0000000341740141 per share (the &#8220;Common Shares&#8221;), on The Nasdaq Global Market on October&#160;1, 2021 was approximately $<ix:nonFraction name="dei:EntityPublicFloat" contextRef="PAsOn10_01_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,115,587,985</ix:nonFraction>. The registrant has elected to use October&#160;1, 2021, which was the initial trading <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">date for the registrant&#8217;s Common Shares<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">on The Nasdaq Global Market, as the calculation date because on September&#160;30, 2021 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter) the registrant was a privately held company. Common Shares held by each executive officer and director and by each other person who may be deemed an affiliate of the registrant have been excluded from this computation. The determination of affiliate status for this purpose is not necessarily a conclusive determination for other purposes.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June 21, 2022 there were</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn06_21_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">700,765,918</ix:nonFraction>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">Common Shares outstanding.</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">DOCUMENTS INCORPORATED BY REFERENCE </div></div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;">Specified portions of the registrant&#8217;s proxy statement to be issued in conjunction with the registrant&#8217;s 2022 Annual Meeting of Stockholders, which is expected to be filed not later than 120&#160;days after the registrant&#8217;s fiscal year ended March&#160;31, 2022, are incorporated by reference into Part&#160;III of this Annual Report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-K.</div> Except as expressly incorporated by reference, the registrant&#8217;s proxy statement shall not be deemed to be a part of this Annual Report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-K.</div> </div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">TABLE OF CONTENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 9%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 86%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom307489_1">PART I</a></div>. </div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_2">Business</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1A.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_3">Risk Factors</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">82</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1B.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_4">Unresolved Staff Comments</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;2.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_5">Properties</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;3.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_6">Legal Proceedings</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;4.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_7">Mine Safety Disclosures</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom307489_8">PART II</a></div>. </div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;5.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_9">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">166</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;6.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_10">[Reserved]</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">167</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;7.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_11">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">167</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;7A.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_12">Quantitative and Qualitative Disclosures about Market Risk</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">184</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;8.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_13">Financial Statements and Supplementary Data</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">184</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;9.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_14">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">227</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;9A.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_15">Controls and Procedures</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">227</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;9B.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_16">Other Information</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">227</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;9C.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_17">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">227</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom307489_18"><span style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="font-weight:bold;display:inline;">Part III</span></span></a></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> </div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;10.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_19">Directors, Executive Officers and Corporate Governance</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">228</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;11.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_20">Executive Compensation</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">228</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;12.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_21">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">228</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;13.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_22">Certain Relationships and Related Transactions, and Director Independence</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">228</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;14.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_23">Principal Accountant Fees and Services</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">228</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom307489_24">Part IV</a></div>. </div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;15.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_25">Exhibits, Financial Statement Schedules</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">229</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;16.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_26">Form 10-K Summary</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">229</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><a href="#rom307489_27">Signatures</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">237</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">i </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summary Risk Factors </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">You should consider carefully the risks described under &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> Unless the context otherwise requires, references in this section to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Roivant&#8221; and the &#8220;Company&#8221; refer to Roivant Sciences Ltd. and its subsidiaries and affiliates, as the context requires. A summary of the risks that could materially and adversely affect our business, financial condition, operating results and prospects include the following: </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Business and Industry </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our limited operating history and the inherent uncertainties and risks involved in biopharmaceutical product development may make it difficult for us to execute on our business model and for you to assess our future viability. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may never achieve or maintain profitability. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to successfully market our products, acquire or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> new products or product candidates, complete the development and commercialization of our products and product candidates and continue to pursue our drug discovery efforts. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have limited experience as a commercial company and the marketing and sale of VTAMA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (tapinarof) or any future products may be unsuccessful or less successful than anticipated. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">We may not be successful in our efforts to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">acquire,&#160;in-license&#160;or</div> discover new product candidates. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We face risks associated with the allocation of capital and personnel across our businesses. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We face risks associated with the Vant structure. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The global pandemic resulting from the outbreak of the novel strain of coronavirus, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SARS-CoV-2,</div></div> which causes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> could adversely impact our business, including the marketing of our products and our ongoing clinical trials and preclinical studies. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical trials and&#160;preclinical&#160;studies are very expensive, time-consuming, difficult to design and implement and involve uncertain outcomes. We may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials or&#160;preclinical&#160;studies on the expected timelines, if at all. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our approach to the discovery and development of product candidates from our small molecule discovery engine is unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any product candidates from these platforms. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain of our product candidates are novel, complex and difficult to manufacture. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Obtaining approval of a new drug is an extensive, lengthy, expensive and inherently uncertain process, and the FDA or another regulator may delay, limit or deny approval. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of product candidates that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our products and product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval, cause us to suspend or discontinue clinical trials, abandon further development or limit the scope of any approved label or market acceptance. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We depend on the knowledge and skills of our senior leaders and may not be able to manage our business effectively if we are unable to attract and retain key personnel. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ii </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will need to expand our organization and may experience difficulties in managing this growth, which could disrupt operations. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to obtain and maintain patent and other intellectual property protection for our technology, products and product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">If the patent applications we hold or have <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> with respect to our products or product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our current and future products or product candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize our products. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent terms and their scope may be inadequate to protect our competitive position on current and future products and product candidates for an adequate amount of time. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Securities, Our Jurisdiction of Incorporation and Certain Tax Matters </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If our performance does not meet market expectations, the price of our securities may decline. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have incurred and will continue to incur increased costs as a result of operating as a public company and our management has devoted and will continue to devote a substantial amount of time to new compliance initiatives. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our failure to timely and effectively implement controls and procedures required by Section&#160;404(a) of the Sarbanes-Oxley Act could have a material adverse effect on our business. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Anti-takeover provisions in our memorandum of association, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> and Bermuda law could delay or prevent a change in control, limit the price investors may be willing to pay in the future for our Common Shares and could entrench management. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our largest shareholders and certain members of our management own a significant percentage of our Common Shares and will be able to exert significant control over matters subject to shareholder approval. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward-Looking Statements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">This Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> contains statements, including matters discussed under Part I, Item 1A. &#8220;Risk Factors,&#8221; Part I, Item 3. &#8220;Legal Proceedings&#8221; and Part II, Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and in other sections of this report, that are &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act and Section&#160;21E of the Exchange Act. Our forward-looking statements include, but are not limited to, statements regarding our or our management team&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;would&#8221; and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The forward-looking statements contained in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> are based on our current expectations and beliefs concerning future developments and their potential effects on us taking into account information currently available to us. There can be no assurance that future developments affecting us will be those that we have anticipated. Should one or more of these risks or uncertainties materialize, they could cause our actual results to differ materially from the forward-looking statements. Some factors that could cause actual results to differ include, but are not limited to risk associated with: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our limited operating history and risks involved in biopharmaceutical product development; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">iii </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our limited experience as a commercial-stage company and ability to successfully commercialize VTAMA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (tapinarof); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to raise additional capital to fund our business on acceptable terms or at all; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the fact that we will likely incur significant operating losses for the foreseeable future; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the impact of public health outbreaks, epidemics or pandemics (such as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic) on our business (including our clinical trials and preclinical studies), operations and financial condition and results; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">our ability to acquire, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or discover new product candidates; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our Vant structure and the potential that we may fail to capitalize on certain development opportunities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">clinical trials and preclinical studies, which are very expensive, time-consuming, difficult to design and implement and involve uncertain outcomes; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the unproven nature of our approach to the discovery and development of product candidates from our small molecule discovery engine; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the novelty, complexity and difficulty of manufacturing certain of our products and product candidates, including any manufacturing problems that result in delays in development or commercialization of our products and product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">difficulties we may face in enrolling and retaining patients in clinical trials and/or clinical development activities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the results of our clinical trials not supporting our proposed claims for a product candidate; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">changes in interim, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> and/or preliminary data from our clinical trials changing as more data becoming available or being delayed due to audit and verification process; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in product manufacturing or formulation that could lead to the incurrence of costs or delays; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the failure of any third-party we contract with to conduct, supervise and monitor our clinical trials to perform in a satisfactory manner or to comply with applicable requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the fact that obtaining approvals for new drugs is a lengthy, extensive, expensive and unpredictable process that may end with our inability to obtain regulatory approval by the FDA or other regulatory agencies in other jurisdictions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the failure of our clinical trials to demonstrate substantial evidence of the safety and efficacy of our products and product candidates, including, but not limited to, scenarios in which our products and product candidates may cause adverse effects that could delay regulatory approval, discontinue clinical trials, limit the scope of approval or generally result in negative media coverage of us; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our inability to obtain regulatory approval for a product or product candidate in certain jurisdictions, even if we are able to obtain approval in certain other jurisdictions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to effectively manage growth and to attract and retain key personnel; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any business, legal, regulatory, political, operational, financial and economic risks associated with conducting business globally; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to obtain and maintain patent and other intellectual property protection for our technology, products and product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inadequacy of patent terms and their scope to protect our competitive position; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the failure to issue (or the threatening of their breadth or strength of protection) or provide meaningful exclusivity for our current and future products and product candidates of our patent applications that we hold or have <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed;</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">iv </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the fact that we do not currently and may not in the future own or license any issued composition of matter patents covering certain of our products and product candidates and our inability to be certain that any of our other issued patents will provide adequate protection for such products and product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the fact that our largest shareholders (and certain members of our management team) own a significant percentage of our stock and will be able to exert significant control over matters subject to shareholder approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the outcome of any pending or potential litigation, including but not limited to our expectations regarding the outcome of any such litigation and costs and expenses associated with such litigation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in applicable laws or regulations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the possibility that we may be adversely affected by other economic, business and/or competitive factors; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any other risks and uncertainties, including those described under Part I, Item 1A. &#8220;Risk Factors.&#8221; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">These risks are not exhaustive. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">v </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom307489_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART I </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="rom307489_2" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;1.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BUSINESS </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">References to &#8220;Roivant,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; in the following section refer to Roivant Sciences Ltd. and its subsidiaries, unless the context otherwise requires. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are building the next-generation &#8220;big pharma&#8221; company, organized to harness modern technologies and computational tools as well as the entrepreneurial spirit of nimble biotechnology companies at scale. Our mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are a diverse team of experienced drug developers, scientists, physicians, company builders, data scientists and engineers, biopharma investors, physicists and business development professionals dedicated to improving the lives of patients. At Roivant, we combine our team&#8217;s extensive experience and multi-disciplinary expertise with innovative technologies to identify and advance potentially transformative medicines. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We deploy a hypothesis-driven approach to identify novel or clinically-validated targets and biological pathways in areas of high unmet medical need. We then seek to acquire, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or discover promising drug candidates against those targets or pathways. Our small molecule discovery engine is powered by leading computational physics and machine learning (&#8220;ML&#8221;) capabilities for in silico drug design. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We develop drugs and drug candidates in subsidiary companies we call &#8220;Vants&#8221; with a distinct approach to sourcing talent, aligning incentives and deploying technology. Each of our Vant teams is built with deep relevant expertise to promote successful execution of our development strategy. Our Vants continue to benefit from the support of the Roivant platform and technologies that are built to address inefficiencies in the drug discovery, development and commercialization process. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our agile Vant model has allowed us to rapidly add capabilities in diverse therapeutic areas, including immunology, dermatology and oncology, and modalities, including biologics, topicals and bifunctional small molecules. We have launched and taken public multiple Vants, resulting in an aggregate ownership stake of approximately $589&#160;million in our publicly-traded Vants as of March&#160;31, 2022 (inclusive of the value of certain shares of Myovant Sciences Ltd. as to which Roivant has a return right under certain circumstances). The Vant model also enables a modular approach to the monetization of therapies we advance through development, allowing us to pursue commercialization of some products independently, while selectively establishing partnerships for other Vants or divesting of the Vants entirely. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since our founding in 2014, we have: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">commercially launched VTAMA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (tapinarof) cream 1% for the treatment of plaque psoriasis in adults; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">conducted nine international Phase 3 trials, the last eight of which have been successful; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consummated a $3&#160;billion upfront partnership with Sumitomo Pharma (&#8220;Sumitomo&#8221;); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">received five FDA approvals for drugs developed by Vants launched by Roivant, including VTAMA and four drugs that received FDA approval after their transfer to Sumitomo; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">built a broad and differentiated pipeline of drugs and drug candidates ranging from early discovery to commercial stage; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">launched Roivant Discovery, our small molecule discovery engine, consisting of a collection of advanced computational physics capabilities, integrated with an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> wet lab facility. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes selected commercial and development-stage pipeline products and product candidates. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 25%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Product/Product Candidate</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Indication</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Vant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Modality</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Phase</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VTAMA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (tapinarof)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Psoriasis</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Topical</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Commercial</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VTAMA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (tapinarof)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Atopic Dermatitis</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Topical</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Phase 3</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Batoclimab</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Myasthenia Gravis</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Immunovant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Biologic</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Phase 3</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Batoclimab</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Thyroid Eye Disease</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Immunovant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Biologic</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Phase 3</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Batoclimab</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Warm&#160;Autoimmune&#160;Hemolytic&#160;Anemia</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Immunovant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Biologic</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Phase 2 or 3</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Batoclimab</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Other Indications</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Immunovant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Biologic</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Phase 2 or 3</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Brepocitinib</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Dermatomyositis</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Priovant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Small Molecule</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Phase 3</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Brepocitinib</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Systemic Lupus Erythematosus</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Priovant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Small Molecule</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Phase 2*</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Brepocitinib</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Other Indications</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Priovant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Small Molecule</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Phase 2</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Namilumab</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Sarcoidosis</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Kinevant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Biologic</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Phase 2</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RVT-2001</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Transfusion-Dependent Anemia in<br/>Patients with Lower-Risk MDS</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Hemavant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Small&#160;Molecule</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Phase 1/2</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AFVT-2101</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Solid Tumors</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Affivant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Biologic</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Preclinical</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note: All preclinical and clinical stage drugs in our current pipeline are investigational and subject to health authority approval. Pipeline reflects both ongoing preclinical and clinical trials and expected upcoming trials. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">* Reflects an ongoing trial that is designed to serve as one of two potentially registrational trials for b</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">repocitinib</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">.</div></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g307489g26b78.jpg" style="width: 500px; height: 360px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have elected to wind down the development of Aruvant&#8217;s ARU-1801 after considering the future development costs of the program, the current market environment and the clinical and commercial profile of the drug. For more information on our cost optimization and pipeline reprioritization initiative, refer to &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Recent Developments.&#8221; </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of our mission to redefine &#8220;big pharma,&#8221; we aim to develop transformative medicines faster for diseases for which there are no approved therapies or the current standard of care treatment has significant limitations or drawbacks. We believe we are uniquely positioned to accomplish this by: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leveraging complementary approaches to identify or discover promising drug candidates:</div></div></div></div> We assembled our current development-stage product candidate pipeline by leveraging our business development expertise and vast network of industry relationships to relentlessly pursue opportunities to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or acquire programs where we believe we can deliver successful outcomes on accelerated timelines. In addition, our small molecule discovery engine allows us to design, optimize and validate our own novel product candidates, providing us with another avenue to pursue compelling targets or pathways and further expand our pipeline. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Creating nimble, entrepreneurial Vants</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">:</div></div> Vants operate similarly to independent biotechnology companies where each management team is focused on its respective mission and is economically incentivized to maximize value through Vant-specific equity grants. Each of our Vant teams is built with deep relevant expertise to ensure successful execution of its particular development strategy. The Vant model is designed to facilitate rapid decision making and calculated risk taking, by empowering, aligning and incentivizing Vant teams around the outcomes of their specific products or product candidates. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Developing and deploying proprietary technologies:</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>We believe we are able to develop transformative medicines faster by building and applying computational tools to drug discovery, development and commercialization. We occupy a unique position at the intersection of biopharma and technology, having built our capabilities in parallel, optimizing each for synergy with the other, in contrast to big pharma who have added software tools to legacy workflows or technology startups that lack experience developing drugs. Vants have access to, and are supported by, these technologies. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Allocating capital to maximize R&amp;D efficiency:</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>We apply an objective, rigorous decision framework across the drug development process designed to ensure resources and capital are continuously directed towards programs we believe have a higher probability of success and away from those that fail to meet our internal hurdles. We centralize capital allocation decisions at the Roivant level, while distributing operational decisions to the Vants, allowing us to strategically deploy capital in high growth areas, regardless of potentially competing operational priorities. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Maintaining a diversified pipeline with various risk profiles:</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>We have built a broad and differentiated pipeline that includes a commercial drug and several drug candidates across different therapeutic areas, phases of development, modalities and geographies. This approach limits our exposure to several concentrated scientific and biological risks and allows us to pursue multiple innovative hypotheses across our portfolio as we seek to develop therapies for patient populations with high unmet need. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Designing creative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;win-win&#8221;</div> deal structures:</div></div></div></div> We structure our partnerships to balance risk and the potential for future value creation. We ensure that a significant proportion of near-term expenses go toward development, allowing us to stage our investment and align incentives as well as limit losses in the event of a setback. Our scale and proven track record of developing successful product candidates assures partners that we are uniquely capable of maximizing value for patients and investors. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Providing operating leverage through centralized support functions:</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>Our model allows us to accelerate Vant formation and maturation by centralizing and sharing certain support functions across various Vants. Vants also benefit from access to our vast network of scientific experts, physicians and technologists to help optimize their clinical development and plans for commercialization. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Through continued investment in our model, we believe we are well-positioned to advance our current pipeline through regulatory approval and commercialization, expand our pipeline through novel drug discovery and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> and acquisition transactions, and execute on our vision of transforming the delivery of healthcare to patients. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Process </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Discover </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We focus on developing potentially transformative medicines that address areas of significant unmet medical need. We take a hypothesis-driven approach, focusing on compelling pathways, targets and drug classes that we believe lack established leaders, and we proactively pursue or discover drugs that align with our hypotheses. We focus on building diversification and varied risk profiles into our pipeline and are agnostic to therapeutic area, stage of development and drug modality. We leverage internally developed technologies as well as a multi-disciplinary team with diverse backgrounds to evaluate the universe of targets and biological pathways that we deem compelling. Once we have built conviction around a specific target or biological pathway, we look for assets to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or acquire, and/or design novel drugs through our small molecule discovery engine. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our ability to rapidly identify and execute <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> opportunities is underpinned by our diverse business development team, which consists of former investment professionals and experienced R&amp;D and data scientists. Our track record in R&amp;D and our ability to implement creative deal structures ensures that we are a favored development partner and are able to acquire assets on attractive terms with shared risk and aligned incentives. We have been successful <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> drugs from global pharmaceutical companies, small biotech startups and academic centers around the world, and we are proud of our deep network of academic and industry partners. Our goal is to add multiple potentially category-creating or category-leading drugs to our pipeline each year through this <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> strategy, a pace which is consistent with our track record over the past several years. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a complement to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> strategy, we also apply our hypothesis-driven approach to our small molecule discovery engine, ensuring we direct our efforts toward high value pathways, targets and drug classes. We have world-leading capabilities in computational physics for drug design, with an advanced computational physics platform integrated with a proprietary supercomputing cluster and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">wet-lab</div> facility equipped for generating a broad range of experimental data. We have also built a ML platform, VantAI, tailored to the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in silico</div></div> design and optimization of novel protein degraders in development at Proteovant. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our small molecule discovery engine has broad capabilities across multiple categories of small molecules and has three initial areas of focus: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Heterobifunctionals and molecular glues: </div></div></div></div>We are building an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-to-end</div></div> platform for the discovery of protein degraders, a therapeutic approach with broad potential applicability to diseases associated with protein overactivity and with no incumbent leader. Our capabilities in targeted protein degradation include a long-term partnership with a leading academic lab, the ability to optimize our degraders using both computational physics and ML and our well-established clinical development capabilities. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Covalency:</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>We have assembled a team of experts in the field of chemoproteomics to build a proprietary human Disease Reactome database enabled by translational disease models to better understand the areas and opportunities around discovering and developing covalent binders of proteins. The combination of experimental data with physics-based computational methods allows us to assess relative pocket ligandability and protein high order structure to predict optimal covalent adduct structures and optimize molecules with desired reactivity. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Deficiency to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">best-in-class:</div></div></div></div></div></div> We also use our physics-based capabilities to evaluate existing small molecules&#8212;either development stage or commercially available&#8212;that have already demonstrated therapeutic potential but have well understood limitations, such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-target</div> effects or binding limitations, which we believe may enable us to rapidly optimize these small molecules and bring them into the clinic as potentially <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">best-in-class</div></div> candidates. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We anticipate that our small molecule discovery engine will expand our development-stage pipeline by generating candidates to advance through the launch of potential new Vants, or to integrate with existing Vants if there is appropriate therapeutic area overlap, in either case taking advantage of Roivant&#8217;s established clinical development capabilities. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Develop </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe the Vant model accelerates successful execution due to three key factors: nimble teams, incentive alignment and robust governance. We build Vant teams with deep, relevant expertise to promote successful execution of development strategy. By keeping Vant teams focused and generally small, we strive to eliminate excessive bureaucracy, thereby facilitating rapid decision-making and ultimately accelerating outcomes. Vants are built as entrepreneurial biotech companies, where each Vant leader is compensated with significant upside potential in the form of Vant equity. By aligning employee incentives with successful Vant outcomes, we encourage Vant leaders to take calculated risks and implement strategies that we believe differentiate the speed and creativity of their development capabilities from legacy large pharmaceutical companies, where drug developers may face asymmetric downside in the event of failure and where upside equity, if granted, is diluted by many diverse projects. Vants are also supported through a robust governance structure that is centralized at Roivant. Our governance team ensures accountability for execution at Vants and allows us to capture synergies through shared technology and certain future shared commercial functions, while at the same time providing access to a broad range of Roivant resources when Vants face critical strategic questions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Commercialize or monetize </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Vant model is designed to maximize the value of each drug that we successfully develop and generate returns for shareholders through the independent commercialization of products, partnerships with pharmaceutical and biotechnology companies or the selective sale of Vants. Our primary objective is to launch commercial products ourselves, but we may sell or partner Vants or specific drugs based on the facts and circumstances, including, without limitation, the strategic rationale and financial return potential. In May 2022, we launched our first commercial product, VTAMA for the treatment of psoriasis. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Technologies </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our platform leverages technologies that are designed to optimize each stage of the drug discovery, development and commercialization process. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in silico</div></div> small molecule discovery engine at Roivant Discovery is powered by our QUAISAR (QUantum, AI and Structure-Activity Relationships) capabilities. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The key components of our small molecule discovery engine include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A quantum mechanics-based molecular dynamics software platform to predict the interactions, energies and conformational behavior of targets and generate novel drug candidates.</div></div></div></div> We can simulate hundreds of molecules per day and make predictions for drug design, enabling the optimization of properties such as binding affinity, selectivity, membrane permeability and solubility. We also have a suite of molecular dynamics and simulation tools to generate additional insights regarding individual atomic contributions to binding properties and conformational dynamics. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A supercomputing cluster composed of over 800 graphics processing units</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">. </div></div>Our supercomputing cluster allows us to run molecular simulations at biologically meaningful timescales predicting not only affinity but also how biomolecules will respond at an atomic level to perturbations such as mutation, phosphorylation, protonation, or the addition or removal of a ligand and functionally important structural changes in proteins. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A suite of degrader-specific ML tools.</div></div></div></div> We have developed a novel protein contact-first workflow that utilizes information about known protein-protein interactions to build new degraders that can effectively stabilize <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">target-E3</div> interfaces; a degron knowledge graph, which we believe to be industry-leading, to map the ubiquitin proteasome system; and a unique model, based on millions of carefully curated protein stability datapoints, to predict degradation. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A wet lab fully equipped for synthetic chemistry, crystallography, biophysics, biochemistry and biology</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> laboratories are tightly integrated with our computational physics platform to directly augment simulations with biophysical data as well as validate simulation predictions. Certain experimental techniques enable more accurate and efficient simulations on targets where we lack crystal structures. Combined with homology modeling and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">X-ray</div> crystallography, this allows for the simultaneous design of chemical matter against a target while refining atomistic structural models and solving high-resolution crystal structures. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our QUAISAR capabilities allow us to predict how molecules will interact by using principles of quantum physics and statistical mechanics to computationally model the forces and energies of molecular systems at atomic scale. Based on internal and published benchmarks, we believe that the speed and accuracy of binding free energy calculations in QUAISAR are on par with the best commercially available tool, Schr&#246;dinger&#8217;s FEP+, and superior to open-source methods. Further, we believe our ability to augment QUAISAR simulations with experimental biophysical data generated in-house creates a sustainable advantage compared to competitors, especially for complex conformational changes in biomolecules. These QUAISAR capabilities power <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in silico</div></div> assays that allow us to predict binding affinity between a ligand and protein, decompose energetics into atomic contributions, predict conformational dynamics of a protein as it shifts from active to inactive states, and identify potentially novel binding sites on a protein. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As we have developed drugs in clinical trials, we have also built technologies to improve the process of running such trials. We have aggregated many of these at our subsidiary Lokavant. Lokavant&#8217;s software integrates real-time data from ongoing clinical trials and monitors risks related to time, cost and quality. Its proprietary data model serves as a &#8220;common language&#8221; for trial operational data and ensures that all trial data sources are ingested, harmonized and aggregated into a central database, allowing the trial sponsor to access operational trial data in near-real time. This approach is a substantial departure from traditional operations which typically share different types of trial data asynchronously and on multi-week delays. Algorithms trained on a proprietary dataset of operational metadata from over 2,000 trials are designed to identify the most important risks with sufficient time to empower researchers to implement interventions to mitigate those risks and deliver trial results on budget and on time. Lokavant&#8217;s software is in use in Roivant&#8217;s late stage clinical trials, as well as trials being conducted by other sponsors and contract research organizations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In designing development and commercialization strategies for our pipeline of drugs, we also identified significant shortcomings with commercially available patient data. Today, healthcare data is siloed across multiple fragmented data sources, limiting the ability to generate a comprehensive understanding of patient health. Datavant, a company which we founded and in which we maintain a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest, is working to address this problem. In June 2021, Datavant entered into a definitive merger agreement with Ciox Health, a leader in clinical data exchange. The combined entity, named Datavant, is the nation&#8217;s largest health data ecosystem, enabling patients, providers, payers, health data analytics companies, patient-facing applications, government agencies, and life science companies to securely exchange their patient-level data. At the closing of the transaction in July 2021, Roivant received approximately $320&#160;million in cash and a minority equity ownership interest in the combined entity. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will continue to execute against our goal of building the next-generation pharmaceutical company by fully integrating modern technologies at each stage of the drug discovery, development and commercialization process. We believe that there is significant opportunity to address inefficiencies within these processes, and we expect to build technologies where we find commercially available tools nonexistent or insufficient for our needs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Key Catalysts </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have a robust calendar of key potential near-term catalysts, including the selected items set forth below. In addition, we plan to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> multiple potentially category-leading drugs per year. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:13%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Vant</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Catalyst</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expected&#160;Timing</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Dermavant</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Updates on commercial launch of VTAMA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Ongoing</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Topline data from VTAMA Phase 3 trials in atopic dermatitis</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">1H 2023</td> </tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="2" style="height:3.75pt">&#160;</td>
<td colspan="2" style="height:3.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Immunovant</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Topline data from batoclimab Phase 3 trial in MG</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">2H 2024</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Initiate two additional pivotal programs, including TED</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">2H 2022</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Announce two new indications</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">August&#160;2022</td> </tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="2" style="height:3.75pt">&#160;</td>
<td colspan="2" style="height:3.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Priovant</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Topline data from potentially registrational brepocitinib Phase 2 trial in systemic lupus erythematosus</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2H 2023</td> </tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="2" style="height:3.75pt">&#160;</td>
<td colspan="2" style="height:3.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Kinevant</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Topline data from namilumab Phase 2 trial in sarcoidosis</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">1H 2024</td> </tr>
<tr style="font-size:1pt">
<td style="height:3.75pt">&#160;</td>
<td colspan="2" style="height:3.75pt">&#160;</td>
<td colspan="2" style="height:3.75pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Hemavant</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Data from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RVT-2001</div> Phase 1/2 trial in lower-risk MDS</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">2H 2023</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note: References are to calendar years. All catalyst timings are based on current expectations and, where applicable, contingent on FDA feedback, and may be subject to change. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The below table summarizes the estimated exclusivity periods in the U.S. for select products and product candidates: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:35%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td style="width:30%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td style="width:29%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Vant</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Product or&#160;Product</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Candidate</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Estimated U.S.</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Exclusivity&#160;/ IP&#160;Coverage</div></div> </td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center;">Dermavant</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">VTAMA<div style="font-size:85%; vertical-align:top;display:inline;;font-size:9.4px">&#174;</div> (tapinarof)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">2038</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center;">Immunovant</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">IMVT-1401</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Later of (i) 2035 or (ii) 12 years post U.S. approval</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center;">Priovant</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Brepocitinib</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">2039</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center;">Kinevant</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Namilumab</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">12&#160;years&#160;post&#160;U.S.&#160;approval</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center;">Hemavant</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RVT-2001</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">2036</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note: References are to calendar years. Estimated U.S. exclusivity is based on (i) for VTAMA, the expected expiry date of the U.S. drug substance patent covering the active ingredient in VTAMA, (ii) for IMVT-1401 and namilumab, the expected expiration of U.S. regulatory exclusivity, (iii) for brepocitinib, the expected expiry date of any patent to issue from a pending application covering the crystalline form of the molecule (in addition to a composition of matter patent with an expected expiry date in 2035) and (iv) for RVT-2001, the expected expiry date of the patent covering the crystalline form of the molecule (in addition to a composition of matter patent with an expected expiry date in 2035). Exclusivity does not give effect to any potential patent term extensions. For more information, please refer to &#8220;&#8212;Intellectual Property&#8221; and &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221; </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width: 8.5in; text-align: left; margin-left: auto; margin-right: auto; text-indent: 0px;"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt;">The table below summarizes select potential future payment obligations from acquisitions,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensings</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>and subsequent financings for select products and product candidates:</div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 10pt; width: 816px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 88.5781px; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; width: 8.03125px; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 114px; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; width: 8.03125px; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 298.578px; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; width: 8.03125px; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 290.75px; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Vant</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Product or<br/>Product<br/>Candidate</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestones</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalty</div></div></div> </td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dermavant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">VTAMA<div style="font-size: 11.3333px; vertical-align: top;;display:inline;">&#174;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(tapinarof)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1.5em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;&#163;100M (~$126M on the date of achievement) milestone to GSK following VTAMA U.S. approval and CAD$25M (approximately $20M on the date of achievement) milestone to Welichem upon the first U.S. VTAMA commercial sale; to be paid using $160M RIPSA funding received in June 2022</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1.5em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Up to CAD$75M in remaining commercial milestones to Welichem, with CAD$35M payable upon VTAMA first U.S. commercial sale for atopic dermatitis and the remainder payable as first commercial sales are achieved in various ex-U.S. countries</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; text-indent: -1.5em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Additional milestones owed to NovaQuest in connection with two 2018 financings that are accounted for as debt</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1.5em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Low single-digit to high single-digit tiered percentage of quarterly revenues based on achievement of specified net sales thresholds, up to a $344M cap, to be paid to an investor group in exchange for $160M RIPSA funding received in June 2022, following VTAMA approval</div></div> </td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Immunovant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">IMVT-1401</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1.5em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Up to a maximum of $442.5M upon the achievement of certain development, regulatory and sales milestone events</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1.5em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">&#8226;&#8195;&#8202;Tiered royalties on net sales ranging from<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>digits to<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-teens</div></div> </td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Priovant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">Brepocitinib</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1.5em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Mid tens-of-millions sales milestone payment if aggregate net sales in a given year exceed a mid hundred-of-millions amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1.5em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Tiered sub-teens royalty on net sales</div></div> </td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kinevant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">Namilumab</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1.5em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Up to $40M upon the achievement of certain milestones</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1.5em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">&#8226;&#8195;&#8202;Tiered royalties on net sales ranging from<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-teens</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>to<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-teens</div></div> </td> </tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hemavant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RVT-2001</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1.5em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Up to $65M in development and regulatory milestones for the first indication; up to $18M in payments for each additional indication; up to $295M in commercial milestone payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1.5em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">&#8226;&#8195;&#8202;Tiered high single-digit to<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-teens</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>royalty on net sales</div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note: The summaries above do not purport to be complete. Please refer to &#8220;&#8212;Asset Acquisition and License Agreements; Other Vant Agreements&#8221; and the agreements themselves, filed as exhibits to this Annual Report on Form<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>for more information on the terms of these agreements.</div></div></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8</div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below summarizes our ownership of our subsidiary companies and certain affiliates as of March&#160;31, 2022: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Roivant Ownership</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Vant</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basic<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">1</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fully&#160;Diluted<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">2</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dermavant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Immunovant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">%<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">3</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">%<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">3</div>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Priovant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proteovant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kinevant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hemavant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Affivant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Arbutus</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">3</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24</td>
<td style="vertical-align: bottom; white-space: nowrap;">%<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">3</div>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lokavant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Datavant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note: Excludes early-stage pipeline of protein degraders and inhibitors being developed through our small molecule discovery engine. Ownership figures as of March 31, 2022. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">1. Basic ownership refers to Roivant&#8217;s percentage ownership of the issued and outstanding common and preferred shares (if applicable) of the entity. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2. Fully diluted ownership refers to Roivant&#8217;s percentage ownership of all outstanding equity interests of the entity, including unvested RSUs as well as options and warrants, in each case whether vested or unvested. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">3. Denotes entities that are publicly traded. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">*As of March 31, 2022, the Company&#8217;s minority equity interest in Datavant represented approximately 17% of the outstanding Class A units. Datavant&#8217;s capital structure includes several classes of preferred units that, among other features, have liquidation preferences and conversion features. Upon conversion of such preferred units into Class A units, the Company&#8217;s ownership interest would be diluted. For more information on Roivant&#8217;s ownership interest in Datavant, please refer to Note 4 to Roivant&#8217;s consolidated financial statements included in this Annual Report on Form 10-K. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Dermavant Overview </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Overview</div>: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dermavant is marketing VTAMA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults. The FDA approved VTAMA for the topical treatment of mild, moderate, and severe plaque psoriasis in May 2022. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dermavant is also developing VTAMA for the treatment of atopic dermatitis in adults and children and expects to release topline results from its Phase 3 clinical trials in the first half of calendar year 2023. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Dermavant&#8217;s earlier stage development pipeline includes an additional novel aryl hydrocarbon receptor (&#8220;AhR&#8221;) agonist, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-506,</div> with a similar profile to VTAMA. Dermavant is developing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-506</div> for the treatment of immunological and inflammatory diseases. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lead program</div>: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VTAMA is a novel, once daily, steroid-free topical cream approved in the US for the treatment of plaque psoriasis in adults. Dermavant is developing VTAMA for the treatment of atopic dermatitis in adults and children as young as age two. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VTAMA directly targets the AhR, a key regulator of skin homeostasis and inflammation. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Disease overview</div>: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plaque psoriasis is a chronic, inflammatory disease of the skin characterized by lesions consisting of red patches and plaques with silvery scales. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Atopic dermatitis, the most common type of eczema, is a chronic condition characterized by dry, itchy skin. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Psoriasis and atopic dermatitis affect approximately 8&#160;million and 26&#160;million people in the United States, respectively. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Limitations of current treatment</div>: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Topical corticosteroids (&#8220;TCS&#8221;) are the most common first-line therapies but they typically cannot be used for longer than four weeks due to the risk of significant side effects. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">While oral and biologic therapies have become increasingly available, they are often limited to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">moderate-to-severe</div></div> disease with often complicated access, reimbursement and utilization management requirements. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Clinical data</div>: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We completed two pivotal Phase 3 clinical trials, PSOARING 1 and PSOARING 2, for the use of VTAMA in treating mild, moderate, and severe plaque psoriasis in adults. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In both pivotal Phase 3 trials, which enrolled over 500 patients each, VTAMA met its primary endpoint and secondary endpoints with clinically meaningful and statistically significant results. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Our long-term open-label PSOARING 3 study provides supportive evidence of VTAMA&#8217;s increased therapeutic effect beyond the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-week</div> double-blind treatment periods, suggesting treatment durability over time, as well as supportive evidence of a remittive effect, measured by time until disease worsening following treatment discontinuation. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Development plan and upcoming milestones</div>: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA approved VTAMA for the once daily topical treatment of adults with plaque psoriasis in May 2022. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VTAMA is the first topical novel chemical entity launched for plaque psoriasis in the U.S. in 25 years, offering a favorable mix of treatment effect, safety, tolerability, durability on therapy, and remittive effect. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2021, we dosed the first patient in our Phase 3 clinical trials of VTAMA for the treatment of atopic dermatitis, ADORING 1 and ADORING 2. We expect to report topline data from ADORING 1 and ADORING 2 in the first half of calendar year 2023. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roivant ownership: </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, we own 100% of the issued and outstanding common shares of Dermavant and 83% on a fully-diluted basis. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Launch of VTAMA for Treatment of Adults with Plaque Psoriasis </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA approved VTAMA for the treatment of adults with mild, moderate or severe plaque psoriasis in May 2022. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Dermavant has built a highly specialized commercial sales organization focused on high value dermatology healthcare providers and their patients and implementing a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;best-in-class&#8221;</div></div> payor reimbursement and patient point of sale access strategy, which we believe ensures broad patient access at launch. As psoriasis patients are predominantly managed by dermatologists, we have deployed a team of approximately 100 specialty sales professionals focused on a core target base of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-decile</div> dermatologists who write more than 80% of all commercial prescriptions in the psoriasis market. We believe a scientifically oriented, customer-focused team will allow us to reach the approximately 6,000 highest value dermatology healthcare providers. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For markets outside of the U.S., we may opportunistically seek strategic collaborations to maximize the commercial opportunities for VTAMA, if approved. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since acquiring VTAMA in 2018, we have expanded our intellectual property portfolio with multiple patents, which are expected to provide intellectual property protection until 2038. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VTAMA for the Treatment of Psoriasis and Atopic Dermatitis </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">VTAMA is a novel, once daily, cosmetically elegant, steroid-free topical cream. VTAMA directly targets the AhR, a key regulator of skin homeostasis and inflammation, to help reduce Th17 and Th2 cytokines, two <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-inflammatory</div> pathways implicated in plaque psoriasis and atopic dermatitis, respectively, increase antioxidant activity, and promote skin barrier restoration. VTAMA cream is designed to be easy to apply, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-greasy</div> and odorless, which we believe makes it cosmetically elegant. To date, over 2,200 subjects have been enrolled in 18 clinical trials of VTAMA and predecessor formulations of VTAMA cream. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Psoriasis and atopic dermatitis </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Psoriasis and atopic dermatitis affect hundreds of millions of people globally each year, impacting their quality of life, including their physical health, psychological state, and overall well-being. While topical therapies are the foundation of treatment, many patients fail to achieve their desired outcome due to subpar efficacy, tolerability and safety concerns, application site restrictions and limits on duration of therapy. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Psoriasis is a chronic, inflammatory disease with skin lesions characterized by red patches and plaques with silvery scale that affects an estimated 8&#160;million people in the United States. Its most common form, psoriasis vulgaris or plaque psoriasis, constitutes approximately 80 to 90% of all cases of psoriasis. Psoriasis severity is typically classified by body surface area (&#8220;BSA&#8221;) involvement: mild (less than 3% BSA), moderate (3% to 10% BSA) and severe (greater than 10% BSA). Based on this classification, approximately 80% of patients with psoriasis in the United States have mild to moderate disease, which is most often amenable to topical treatment. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11 </div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Atopic dermatitis is the most common type of eczema, affecting more than 9.6&#160;million children and about 16.5&#160;million adults in the United States. It is a chronic condition characterized by dry, itchy skin that often turns into a red rash. Atopic dermatitis can come and go for years or throughout life and can overlap with other types of eczema. Atopic dermatitis has a complex pathophysiology involving genetic, immunologic and environmental factors, culminating in skin barrier dysfunction and immune system dysregulation. The condition occurs most frequently in children (15 to 30% worldwide). Approximately 60% of those who develop atopic dermatitis show symptoms in the first year of life and up to 90% show symptoms by five years of age. While more prevalent in infancy and adolescence, one in ten people will develop atopic dermatitis. Approximately 89% of adult patients have mild to moderate atopic dermatitis, while 11% have severe atopic dermatitis. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">TCSs are commonly used as the first-line therapy for the treatment of inflammatory skin conditions, such as psoriasis and atopic dermatitis. They are broadly available in generic form and carry FDA class labeling that restrict their duration of use, typically to no more than four weeks, and their location of use, prohibiting use in sensitive skin areas such as the face, groin, or axillae (armpit). While many people experience improvement with TCS, the continual long-term use of TCS has the potential to cause significant side effects including skin atrophy. As a result, healthcare professionals and patients are limited to intermittent treatment cycles of TCS therapy, leading to frequent disease flares and recurrence of disease, providing an inadequate solution for chronic conditions in immuno-dermatology. Topical calcineurin inhibitors (&#8220;TCI&#8221;) are an additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-steroidal</div> option for the topical treatment of atopic dermatitis, but their use is limited by safety concerns, including black box warnings of malignancy reported in patients treated with TCIs. Oral and biologic therapies have become increasingly available but are often limited to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">moderate-to-severe</div></div> psoriasis and atopic dermatitis patients which comprise the smallest percentage of the affected populations. While biologics have proven to be very effective, their use has also been limited by concerns with systemic side effects, high cost, and reimbursement and access restrictions. Oral therapies are functionally limited to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">moderate-to-severe</div></div> psoriasis patients. Oral therapies also have significant side effects and have not achieved the same level of efficacy as biologics. Additionally, recent FDA action regarding Janus kinase inhibitors (&#8220;JAKs&#8221;) have resulted in restrictive labeling and black box warnings relating to safety concerns with the product class, including oral and topical forms, and including for the topical treatment of atopic dermatitis. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Given the limitations associated with TCS, other topicals, orals, and biologics therapies, patients with inflammatory skin conditions often report dissatisfaction with their current treatment options. We see an opportunity for a novel, once daily topical treatment like VTAMA to fill the need for a long-term treatment option for plaque psoriasis and atopic dermatitis. Additionally, we believe that VTAMA has the potential to be used as a complementary therapy with biologics and oral therapies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Psoriasis and atopic dermatitis represent the two largest markets in immuno-dermatology and are expected to reach total sales of approximately $31&#160;billion in the U.S. and $44&#160;billion globally by 2026. Topical treatments serve as the foundation of dermatologic treatment, representing 83% of all U.S. prescriptions written by dermatologists in 2020. Annual U.S. prescriptions for both psoriasis and atopic dermatitis are outlined below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">TCS</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Vitamin&#160;D&#160;/<br/>Combos /<br/>Retinoids</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Biologics</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Otezla</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other&#160;Oral</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Annual Scripts for PsO (2020)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">~2.35M</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">~508K</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">~1.05M</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">~258K</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">~241K</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">TCS</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">TCI</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Eucrisa</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dupixent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Annual Scripts for AD (2020)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">~16.4M</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">~996K</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">~352K</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">~344K</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g307489g28b91.jpg" style="width: 605px; height: 283px;"/></div> </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Source: EvaluatePharma </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VTAMA for the Treatment of Psoriasis </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We completed two pivotal Phase 3 clinical trials, PSOARING 1 and PSOARING 2, evaluating the use of VTAMA in treating mild, moderate and severe plaque psoriasis in adults. In both of these trials, which enrolled over 500 patients each, VTAMA met its primary endpoint and all secondary endpoints with clinically meaningful and statistically significant results as well as favorable safety and tolerability findings. At week 12, 35.4% and 40.2% of patients treated with VTAMA in PSOARING 1 and PSOARING 2, respectively, achieved the primary efficacy endpoint of a Physician Global Assessment (PGA) score of clear (0)&#160;or almost clear (1)&#160;with a minimum <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-grade</div> improvement from baseline as compared to 6.0% and 6.3% of patients treated with vehicle control cream (p&lt;0.0001; p&lt;0.0001). When this endpoint was evaluated over time, rapid onset of activity was observed with separation emerging by the first evaluation trial visit (week 2) and statistically significant differences between VTAMA and vehicle control cream at week 4 and continuing at all measured time points thereafter. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VTAMA met all secondary endpoints with statistical significance in PSOARING 1 and PSOARING 2, including a key secondary endpoint, the proportion of subjects with &#8805;75% improvement in Psoriasis Area and Severity Index (PASI75). In PSOARING 1 and 2, 36.1% and 47.6% of patients achieved PASI75 at Week 12 with VTAMA 1% cream QD vs 10.2% and 6.9% for vehicle control cream, respectively. Additionally, the proportion of patients with &#8805;90% improvement in Psoriasis Area and Severity Index (PASI90) at Week 12, also a secondary endpoint, was statistically significantly higher in both VTAMA groups compared with vehicle control cream (p=0.0005 and p&lt;0.0001). In PSOARING 1 and PSOARING 2, 18.8% and 20.9% of patients treated with VTAMA, respectively, achieved PASI90 compared to 1.6% and 2.5%, respectively, of patients treated with vehicle control cream. The PASI assessment is a more quantitative assessment of disease activity relative to the PGA and provides additional insight into a drug&#8217;s impact on disease modification. Similar to what was observed with PGA, evaluating reduction in the burden of disease via a PASI assessment confirms rapid onset of action with separation of VTAMA from vehicle control cream control at week 2, and statistically significant differences were noted as early as week 4 and each evaluation thereafter. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, VTAMA was observed to be well-tolerated, consistent with previous trials, and had low discontinuation rates due to adverse events (&#8220;AEs&#8221;), no treatment related serious adverse events (&#8220;SAEs&#8221;), and minimal severe application site reactions. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AEs were generally mild to moderate in nature with the majority consisting of localized skin reactions. Overall trial discontinuations due to adverse events were 5.6% in PSOARING 1 and 5.8% in PSOARING 2. Trial discontinuation rates due to folliculitis were 1.8% in PSOARING 1 and 0.9% in PSOARING 2. No VTAMA-related serious adverse events were observed, and over 90% of eligible patients enrolled in the open-label, long-term extension study. To date, over 2,200 subjects have been enrolled in 18 clinical trials of VTAMA and predecessor formulations of VTAMA cream.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g307489g30c61.jpg" style="width: 605px; height: 240px;"/></div> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Patients with PGA of 2 (mild) and PGA of 4 (severe) limited to ~10% each of the total randomized population; ~80% of the total randomized population with PGA of 3 (moderate); &#8224;Patients electing not to participate in LTE had <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> visit 4 weeks after completion of treatment period. BSA, body surface area; LTE, long-term extension; PASI75, &#8805; 75% improvement in Psoriasis Area and Severity Index; PASI90, &#8805; 90% improvement in Psoriasis Area and Severity Index; PGA, Physician Global Assessment; QD, once daily. 1. Clinicaltrials.gov; NCT03956355. 2. Clinicaltrials.gov; NCT03983980. 3. Clinicaltrials.gov; NCT04053387. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g307489g32c71.jpg" style="width: 561px; height: 390px;"/></div> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g307489g32c36.jpg" style="width: 561px; height: 394px;"/></div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g307489g35c14.jpg" style="width: 605px; height: 289px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The images below show rapid and complete clearance of plaque psoriasis in a patient achieving the defined trial endpoint. At baseline, this patient&#8217;s PGA score was 3, indicative of moderate disease, and the PASI score was 17.6. The baseline image demonstrates classic plaque psoriasis with well-demarcated erythematous scaling plaques. At week 4, the PGA had decreased from 3 to 2 and the PASI from 17.6 to 4, the latter having passed the threshold 75% reduction in PASI (PASI75). The target plaques on the forearm completely resolved. At week 12, both the PGA and PASI scores were 0, indicating complete clearance of disease. PGA and PASI are global efficacy assessments. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g307489g35d33.jpg" style="width: 605px; height: 308px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2021, we reported the final results from our long-term open-label study, PSOARING 3, which showed that 58.2% of subjects who entered the PSOARING 3 study with a PGA score of &#8805; 2 achieved a PGA score of 0 or 1 at least once during the study. Although PSOARING 3 was not a vehicle-controlled study like the&#160;PSOARING 1 and PSOARING 2 studies, we believe these data provide supportive evidence regarding </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">VTAMA&#8217;s potential therapeutic effect beyond the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-week</div> double-blind treatment periods utilized in the prior PSOARING studies. In addition, 312 out of 763 subjects (40.9%) achieved complete disease clearance (PGA score of 0) at least once during the study. We observed no evidence of tachyphylaxis, or a diminishing response to treatment, throughout the study, which we believe suggests treatment durability over time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Relatedly, in our clinical trials, including data from our PSOARING 3 long-term open-label study, we have also observed that some patients treated with VTAMA maintained clinically meaningful disease control for an extended period of time after therapy had been discontinued. In PSOARING 3, subjects discontinued applying VTAMA when they achieved complete clearance of their disease (PGA=0). These subjects were then followed, and the time to first worsening (defined as PGA &#8805; 2) was utilized to determine the maintenance of clinical benefit off therapy. We refer to maintenance of clear/almost clear (PGA 0/1) while off therapy as remittive effect. At the completion of the Week 12 visit of the PSOARING 1 and PSOARING 2 trials, subjects were offered enrollment in the PSOARING 3 long-term open-label study. Subjects with a PGA &#8805; 1 began treatment with VTAMA cream applied QD until they achieved a PGA score of 0. Treatment was then discontinued and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-initiated</div> when a patient&#8217;s psoriasis subsequently worsened (PGA&#160;&#8805; 2). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In PSOARING 3, for subjects entering the study with a PGA score of 0 (79/763), the median time to disease worsening (defined as a PGA score of &#8805; 2) following complete disease clearance and treatment discontinuation was approximately 115 days. In addition, among patients entering PSOARING 3 with or achieving a PGA score of 0 (312/763), the mean total duration of time to disease worsening following treatment discontinuation was approximately 130 days. We believe these additional clinical observations confirm the long-term effectiveness of VTAMA cream 1% QD and differentiate it from other topical therapies. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VTAMA for the Treatment of Atopic Dermatitis </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In 2017, GSK completed a multi-center randomized, double-blind, vehicle cream-controlled Phase 2b clinical trial of VTAMA for the treatment of atopic dermatitis in 247 adult (aged 18 to 65 years) and adolescent (aged 12 to 17 years) patients. Patients were randomized equally to six treatment groups: VTAMA cream 0.5%, VTAMA cream 1% or vehicle cream, each applied to atopic dermatitis lesions either QD or BID. The primary endpoint was the percentage of patients who achieved a minimum <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-point</div> improvement in the Investigator Global Assessment (&#8220;IGA&#8221;) score and an assessment of &#8220;clear&#8221; or &#8220;almost clear&#8221; skin at week 12. These cases were considered a &#8220;treatment success.&#8221; Secondary endpoints included the percentage of patients with at least a 75% improvement in Eczema Area and Severity Index (EASI) from baseline. Efficacy was evaluated in the intent-to-treat (&#8220;ITT&#8221;) population. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overall, the percentage of patients achieving treatment success was much higher for both VTAMA concentrations than vehicle cream, with a robust dose response. 53% of patients who applied VTAMA cream 1% BID and 46% of those who applied it QD were considered a treatment success. This compares favorably to the 24% and 28% of pateints who achieved a treatment success for the BID and QD vehicle cream groups, respectively. At week 12, 60% and 51% of patients treated with VTAMA cream 1% BID and QD, respectively, achieved EASI75. The treatment effect across adults and adolescents was observed to be consistent. Patient-reported outcome data was collected during the Phase 2b clinical trial, including data on reduction in the severity of pruritus. At week 12, more patients treated with VTAMA cream 1% (78% of patients treated BID and 87% of patients treated QD) reported &#8220;moderately improved&#8221; to &#8220;very improved&#8221; pruritus, compared to patients treated with vehicle cream (47% of patients treated BID and 64% of patients treated QD). </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">IGA score 0 or 1 and </div></div>&#8805;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-grade</div> improvement at Week 8 </div></div> </div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primary Endpoint was at 12 Weeks: Assessed in ITT Population (NRI Analysis) </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g307489g38e50.jpg" style="width: 605px; height: 330px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">IGA response: IGA score of 0 or 1 and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8805;2-grade</div> improvement from baseline. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">*</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Difference versus vehicle cream is statistically significant at p=0.05 level (the 95% confidence interval excludes 0). </div></div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VTAMA was observed to be well-tolerated in this Phase 2b trial for atopic dermatitis, with the majority of AEs reported as mild or moderate in severity. In the trial, AEs were considered treatment-related (&#8220;TEAEs&#8221;) in 10% to 19% of patients across the treatment arms. The most commonly reported TEAEs were folliculitis, application-site pain and atopic dermatitis. TEAEs led to permanent discontinuation of treatment in 4% of dosed patients (seven patients from treatment groups total) compared to 7% of patients receiving vehicle cream (six patients total). Only one patient (tapinarof 1% BID) experienced a SAE of anxiety and hyperactive disorder, which was not considered to be related to treatment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In September 2021, we dosed our first patent in the ADORING 1 and ADORING 2 trials, two identically designed, multi-center, randomized, vehicle-controlled, double-blind parallel Phase 3 clinical trials of VTAMA for the treatment of atopic dermatitis. We expect to release topline data from these studies in the first half of calendar year 2023. The two trials will enroll up to 800 patients across both trials to evaluate the safety and efficacy of VTAMA cream, 1% dosed once daily for 8 weeks versus vehicle cream QD in patients aged two years and older who have moderate to severe atopic dermatitis. The primary endpoint of both studies will be the percentage of patients achieving a Validated Investigator Global Assessment for Atopic Dermatitis <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(vIGA-AD</div><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#8482;</div>), of 0 or 1 with at least a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-grade</div> improvement from baseline at week 8. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, we have initiated ADORING 3, a long-term, open-label, extension study to evaluate the safety and efficacy of VTAMA cream 1% in patients with atopic dermatitis. Subjects in the study will include those who have previously completed treatment with VTAMA or vehicle in ADORING 1 or ADORING 2, as well as </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">subjects who have completed a maximal use PK study, and those pediatric subjects who would not qualify for inclusion in ADORING 1 or 2 due to milder or more severe disease. ADORING 3 will consist of up to 48 weeks of VTAMA cream 1%, and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">7-day</div> safety <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> period. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Potential Benefits of VTAMA&#8212;Limitations of Current Treatments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">VTAMA in plaque psoriasis </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe VTAMA has several key attributes that position it favorably over current standard of care treatments in plaque psoriasis, including TCS therapies: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g307489g22s22.jpg" style="width: 605px; height: 332px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the clinically meaningful and statistically significant reduction in psoriasis symptoms VTAMA demonstrated in both Phase 3 trials, coupled with no label restrictions on duration of use and no label safety warnings or precautions, we believe VTAMA will be used broadly and potentially chronically on any skin lesion regardless of location on the body. We believe the Phase 3 data we have generated and the data observed in our open-label, long-term extension study support the chronic use of VTAMA, potentially in place of other topical and oral treatments, for the treatment of mild, moderate and severe plaque psoriasis in adults. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">VTAMA&#8217;s potential in atopic dermatitis </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">TCS, especially <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-to-mid</div></div> potency TCS, represent the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">standard-of-care</div></div> for atopic dermatitis treatment. Although they are used commonly, TCS pose a specific concern in pediatric patients due to the risk of systemic absorption, hypothalamic-pituitary-adrenal axis suppression, skin thinning and other potential side effects. The increased body surface area to mass ratio in children results in increased absorption and systemic exposure. The American Academy of Dermatology guidelines suggest limiting long-term use of TCS in children to avoid the risk of systemic side effects. As such, 86% of U.S. patients report dissatisfaction with current treatment options for atopic dermatitis according to the National Eczema Association. There is also considerable concern among many parents about treating their children with steroids, which can be an obstacle to treatment for physicians. Due to these risks and patient dissatisfaction, health care providers are less likely to use them long-term in children and also in sensitive skin areas such as the face or diaper/groin area. In addition, topical PDE4 inhibitors </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">developed to treat atopic dermatitis have been associated with side effects including application site burning and stinging. Topical calcineurin inhibitors are an additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-steroidal</div> option for the topical treatment of atopic dermatitis; however, their use has been limited by safety including boxed warnings of malignancy (e.g., skin and lymphoma) having been reported in patients treated with topical calcineurin inhibitors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Patients whose disease flares despite topical treatments may be prescribed systemic agents such as oral corticosteroids or oral cyclosporine to rapidly relieve severe signs and symptoms of the disease. While these are effective as temporary treatments of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">flare-ups,</div> extended use has been associated with many potential side effects or adverse events. Systemic steroids, such as prednisone, can lead to symptom relief, but their use is not recommended to induce stable remission due to numerous side effects associated with steroids and the propensity of severe disease flares upon abrupt treatment cessation. Cyclosporine is also generally not recommended for use lasting longer than one to two years, as it has been associated with renal toxicity, hirsutism, nausea and lymphoma. Based on data from the 2014 Adelphi U.S. AD Disease Specific Program, over 58% of adults with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">moderate-to-severe</div></div> atopic dermatitis have disease which physicians consider to be inadequately controlled by these therapeutic modalities. While biologic therapies are more efficacious, as is the case in psoriasis, use of therapies such as the recently approved Dupixent is limited to patients with significant disease burden as they are expensive, necessitate frequent injections, entail regular physician appointments, have potential systemic toxicities and often require laboratory monitoring. Additionally, recent FDA action regarding JAK inhibitors has resulted in restrictive labeling and black box warnings relating to safety concerns with the product class, both oral and topical forms, including for the topical treatment of atopic dermatitis. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We believe VTAMA has the potential to fill the need for a long-term treatment option for atopic dermatitis. We also believe that VTAMA has the potential to offer significant clinical advancement to address the incessant flare cycle experienced by atopic dermatitis patients that is the result of the short-term use limitation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">standard-of-care</div></div> TCS. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">VTAMA sales and marketing potential in atopic dermatitis </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If VTAMA is approved by the FDA for the treatment of atopic dermatitis, we plan to expand our psoriasis sales team to be able to reach additional specialists who see a significant amount of atopic dermatitis patients, such as pediatric dermatologists and allergists. Based on our commercial team&#8217;s experience developing and launching dermatology products in U.S., we believe we can effectively reach the psoriasis and atopic dermatitis core target base with a highly specialized sales team of 125 to 150 total sales representatives. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-506</div> for Immunology and Inflammatory Diseases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-506</div> is an early stage drug candidate that is a novel AhR agonist with a similar activity profile to VTAMA.&#160;We are evaluating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-506</div> as a potential differentiated treatment option for immunology and inflammatory diseases. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-506</div> is a unique, new chemical entity protected by a composition of matter patent having a natural expiration date in 2041. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Immunovant Overview </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Overview:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Immunovant is developing batoclimab for the treatment of Myasthenia Gravis (&#8220;MG&#8221;), Thyroid Eye Disease (&#8220;TED&#8221;) and Warm Autoimmune Hemolytic Anemia (&#8220;WAIHA&#8221;). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lead program:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Batoclimab is a novel, fully human monoclonal antibody targeting the neonatal fragment crystallizable receptor (&#8220;FcRn&#8221;). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Designed to be optimized as a simple, self-administered subcutaneous (&#8220;SC&#8221;) injection with dosing that we believe can be tailored based on disease severity and stage. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In nonclinical studies and in clinical trials conducted to date, batoclimab has been observed to reduce immunoglobulin G (&#8220;IgG&#8221;) antibody levels. High levels of pathogenic IgG antibodies drive a variety of autoimmune diseases and, as a result, we believe batoclimab has the potential for broad application in related disease areas. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Disease overview:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MG is an autoimmune disorder associated with muscle weakness and fatigue. The estimated prevalence of MG is 17.8 per 100,000, with up to 59,000 people in the U.S., and 24.2 per 100,000, or approximately 126,000 cases in Europe. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TED is an autoimmune inflammatory disorder that affects the muscles and tissues surrounding the eyes, and in severe cases can be sight-threatening. TED has an estimated annual incidence of 9.7 in 100,000 in the U.S. and 4.8 in 100,000 Europe. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">WAIHA is a rare hematologic disease in which autoantibodies mediate hemolysis, or the destruction of red blood cells (&#8220;RBCs&#8221;), affecting approximately 40,000 patients in the U.S. and 71,000 patients in Europe. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Limitations of current treatments:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Early-stage disease: corticosteroids and immunosuppressants. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Later-stage disease: intravenous immunoglobulin (&#8220;IVIg&#8221;), or plasma exchange. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Approaches are limited by delayed onset of action, waning therapeutic benefit over time and unfavorable safety profiles. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Clinical data:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the highest dose cohorts in the Phase 1 clinical trial, four weekly SC administrations of 680 mg resulted in a mean maximum reduction of serum IgG levels of 78%, with a standard deviation of 2%.&#160;Injection site reactions were similar between batoclimab and placebo arms. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As previously disclosed, we voluntarily paused dosing in our early phase clinical studies to evaluate batoclimab-induced elevations in total cholesterol and low density lipoprotein (&#8220;LDL&#8221;) levels observed in some trial subjects. After evaluation of the available safety data and following discussions with multiple regulatory agencies, we are continuing the clinical development of batoclimab. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">In 2019, we initiated an open-label, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-arm</div> Phase 2a clinical trial of batoclimab for the treatment of TED. The majority of subjects (four of seven) evaluated at the end of treatment experienced a greater than or equal to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-point</div> improvement in clinical activity score (CAS) and three of seven subjects were proptosis responders, defined as a greater than or equal to 2mm reduction in proptosis in the study eye. In 2019, we initiated a randomized, masked, placebo-controlled Phase 2b clinical trial of batoclimab in TED. Our voluntary pause in dosing in February 2021 resulted in unblinding this trial and the primary </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">endpoint was not significant. However, our analysis of exploratory endpoints from this trial increased our confidence in the anti-FcRn mechanism of action for patients with TED, and they provide part of the basis for our interest in moving forward with further development of in this indication. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">In 2019, we initiated a multi-center, randomized, blinded, placebo-controlled Phase 2a clinical trial of batoclimab for the treatment of MG. As evaluated in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-specified,</div> pooled analysis of 15 subjects who completed Day 42 of the trial, batoclimab-treated subjects (N=10) showed a clinical improvement in both the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">MG-ADL</div> scale and the MGC scale. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Development plan and upcoming milestones:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">As previously disclosed in December 2021, we achieved alignment with the FDA Division of Neurology 1 to move forward with our pivotal trial of batoclimab as a treatment for MG. We have initiated our Phase 3 study in MG which is now open for enrollment. We expect <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> data from this Phase 3 trial to be available in the second half of calendar year 2024. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">We plan to initiate two Phase 3 clinical trials to evaluate batoclimab for the treatment of TED in the second half of calendar year 2022, and we expect <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> results from both Phase 3 trials to be available in the first half of calendar year 2025. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We plan to announce two new indications by August 2022, and we expect one of the three indications, including WAIHA, to be initiated as a pivotal trial in calendar year 2022. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Roivant ownership:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022 we own 63% of the issued and outstanding shares of Immunovant common stock and 58% on a fully diluted basis. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Batoclimab </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Batoclimab is a novel, fully human monoclonal antibody that selectively binds to and inhibits FcRn. In nonclinical studies and in clinical trials conducted to date, batoclimab has been observed to reduce IgG antibody levels. High levels of pathogenic IgG antibodies drive a variety of autoimmune diseases and, as a result, we believe batoclimab has the potential for broad application in these disease areas. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to generating clinically meaningful IgG reductions, batoclimab has been designed from inception to be a fixed-dose, self-administered SC injection on a convenient weekly, or less frequent, dosing schedule. Batoclimab has been dosed in small volumes (e.g., 2 mL) and with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">27-gauge</div> needle, while still generating therapeutically relevant pharmacodynamic activity, important attributes that we believe will drive patient preference and market adoption. We believe that batoclimab, if developed and approved for commercial sale, would be differentiated from currently available, more invasive treatments for advanced <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IgG-mediated</div> autoimmune diseases. The patent family directed to the composition of matter of batoclimab has a natural projected expiration date in 2035 in the U.S. and in foreign jurisdictions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In several nonclinical studies and in a multi-part Phase 1 clinical trial in healthy volunteers, intravenous and SC delivery of batoclimab was generally well tolerated and demonstrated dose-dependent IgG antibody reductions.&#160;In the highest dose cohorts in the Phase 1 clinical trial, four weekly SC administrations of 680 mg resulted in a mean maximum reduction of serum IgG levels of 78%, with a standard deviation of 2%.&#160;Injection site reactions were similar between batoclimab and placebo arms. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mechanism of action </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The neonatal fragment crystallizable receptor, or FcRn plays a pivotal role in preventing the degradation of IgG antibodies. The physiologic function of FcRn is to modulate the catabolism of IgG antibodies. FcRn intercepts IgG, which would otherwise be degraded in lysosomes. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FcRn-IgG</div> complex is then recycled to the </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cell surface and free IgG is released back into circulation. Anti-FcRn antibodies bind to FcRn, thereby preventing it from recycling IgG antibodies back to circulation. As a result, IgG is increasingly delivered to lysosomes for degradation. The inhibition of FcRn, such as through use of an anti-FcRn antibody, has been shown to reduce levels of pathogenic IgG antibodies, suggesting utility in the many autoimmune diseases associated with high levels of such IgG antibodies. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Batoclimab for the Treatment of MG </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">MG overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MG is an autoimmune disorder associated with muscle weakness and fatigue. MG patients develop antibodies that lead to an immunological attack on critical signaling receptor proteins at the junction between nerve and muscle cells, thereby inhibiting the ability of nerves to communicate properly with muscles. This leads to muscle weakness intensified by activity, which can be localized exclusively to ocular muscles or which can be more generalized throughout the body including muscles of respiration. Patients with localized ocular disease suffer from more limited symptoms, including droopy eyelids and blurred or double vision due to compromise of eye movements. The vast majority of MG patients demonstrate elevated serum levels of acetylcholine receptor (&#8220;AChR&#8221;) antibodies which disrupt signal transmission between nerve fibers and muscle fibers. These antibodies ultimately lead to fluctuating muscle weakness and fatigue. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The prevalence of MG is estimated to be 17.8 per 100,000, with up to 59,000 cases in the U.S. Third-party studies estimate the prevalence in Europe for MG as 24.2 per 100,000, or approximately 126,000 cases. MG can occur at any age; however, the age of onset tends to follow a bimodal distribution. Early onset disease usually occurs in individuals between 10 to 30 years old and predominantly affects females. Later onset disease usually occurs in individuals over 50 years old and predominantly affects males. As with many autoimmune diseases, there are no known genetic alterations that specifically cause MG, and in most patients, it arises spontaneously. Approximately 3% of patients have a primary relative with MG, suggesting that there are genetic factors that may predispose development of the disease, but these genes have yet to be identified. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The symptoms of the disease can be transient and in the early stages of the disease can remit spontaneously. However, as the disease progresses, symptom-free periods become less frequent and disease exacerbations can last for months or remain chronic. After 15 to 20 years, some weakness often becomes fixed, with the most severely affected muscles frequently becoming atrophic. Many patients find it difficult to perform daily activities due to both insufficient improvement in symptoms even after treatment and in some the complicating long-term side effects of oral corticosteroids, a common treatment for MG. Approximately 15% to 20% of MG patients will experience at least one myasthenic crisis over their lifetimes. During myasthenic crisis, the impairment of muscles required to breathe can become life-threatening, leading to death in approximately 2% to 5% of cases. Up to 90% of patients in myasthenic crisis require intubation and mechanical ventilation leading to hospital stays lasting a median of 17 days. Over half of the patients who survive such a crisis remain functionally dependent upon discharge from the hospital. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Very early stage MG is symptomatically treated with acetylcholinesterase inhibitors such as pyridostigmine. As the disease progresses, patients are typically treated with immunosuppressive agents such as glucocorticoids, azathioprine, mycophenolate mofetil and cyclosporine. Thymectomy may be indicated for treatment in patients with evidence of a thymoma and can be considered for treatment in some younger patients who do not have evidence of thymoma. As MG becomes more advanced, patients can be treated during exacerbations with IVIg, which provides therapeutic benefit through multiple potential mechanisms including the saturation of FcRn. Physicians direct patients with more advanced chronic disease and patients in times of crisis to therapies that reduce levels of circulating IgG antibodies via plasma exchange or a variant of this plasma exchange, immunoadsorption. The most recent agents approved for MG are eculizumab and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ravulizumab-cwvz,</div> two complement C5 inhibitors, the use of which are&#160;limited to patients refractory to available therapy with anti-AChR-positive MG. Efgartigimod, an anti-FcRn antibody fragment, was recently approved for the treatment of MG in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. We believe there is room to </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">improve upon this current treatment paradigm for MG, as some of these treatments can leave patients with burdensome administration requirements, significant side effects or long wait times to see treatment effect. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In 2019, we initiated a multi-center, randomized, blinded, placebo-controlled Phase 2a clinical trial of batoclimab for the treatment of MG. As evaluated in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-specified,</div> pooled analysis of 15 subjects who completed Day 42 of the trial, batoclimab-treated subjects (N=10) showed a clinical improvement in both the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">MG-ADL</div> scale and the MGC scale. We believe, based upon our review of data from this Phase 2a trial of batoclimab in MG, that there is&#160;sufficient proof of concept to pursue a pivotal trial to evaluate batoclimab for the treatment of MG. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As previously disclosed in December 2021, we achieved alignment with the FDA Division of Neurology 1 to move forward with our pivotal trial of batoclimab as a treatment for MG. We have initiated our Phase 3 study in MG which is now open for enrollment. We expect <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> data from this Phase 3 trial to be available in the second half of calendar year 2024. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our trial is designed to address unmet patient needs and differentiate batoclimab from other treatments. Key features of the trial include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12-week Induction Period: Includes doses of 680 mg SC injection weekly (&#8220;SC QW&#8221;) or anchor dose of 340 mg SC QW compared to placebo. The objective is to achieve maximum efficacy at the beginning of treatment and determine the potential benefit of 680 mg SC QW (i.e., speed and depth of clinical response). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12-week Maintenance Period: Includes anchor doses of 340 mg SC QW and 340 mg SC injection once every two weeks compared to placebo to assess lower effective maintenance doses with potentially fewer side effects related to long term IgG suppression or serum analyte changes. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">52-week</div> Long Term Extension: Includes long term safety assessment of the 2 maintenance doses; also includes tailored dosing allowing for treatment of disease exacerbations with short-term, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-induction</div> dosing of batoclimab (680 mg SC QW x 4 weeks) followed by resumption of 340 mg SC QW. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MG Phase 3 Trial Design (N ~ 210) </div></div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g307489g23s23.jpg" style="width: 458px; height: 249px;"/></div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">QW = weekly, Q2W = once every two weeks, SC = subcutaneous injection </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Batoclimab for the Treatment of TED </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">TED overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TED, also referred to as Graves&#8217; Ophthalmopathy or GO, is a sight-threatening autoimmune inflammatory disorder that affects the muscles and tissues surrounding the eyes. Initial symptoms may include a dry and gritty ocular sensation, sensitivity to light, excessive tearing, double vision, and a sensation of pressure behind the eyes. At diagnosis, many patients with TED have retraction of their upper eyelids, swelling and redness surrounding the eyes, and protrusion of their eyeballs (proptosis). In some cases, swelling and stiffness of the eye muscles prevent the eyes from working together causing double vision. Approximately 3% to 5% of TED patients have a severe manifestation of the disease causing intense pain, inflammation, sight-threatening corneal ulcers, or optic neuropathy requiring surgical intervention. Decompression surgery to improve ocular function or rehabilitative surgery to improve quality of life is required in up to 20% of TED patients. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TED is most commonly caused by IgG autoantibodies that form against the thyroid-stimulating hormone receptor (&#8220;TSHR&#8221;). These anti-TSHR antibodies activate cells in the extraocular space that highly express TSHR, such as fibroblasts and adipocytes. Fibroblast activation causes cell proliferation and the production of hyaluronan, a substance that contributes directly to the swelling associated with TED. Hyaluronan also serves as an inflammatory signal leading to the synthesis of cytokines that cause recruitment of lymphocytes leading to extensive tissue inflammation and remodeling. Adipocyte activation leads to hyperplasia of the adipose tissue surrounding the eye causing protrusion of the eyeballs and compression of the optic nerve. Levels of anti-TSHR autoantibodies correlate positively with clinical features of TED and influence its prognosis. Exposure to other inflammatory agents, such as cigarette smoke, leads to exacerbation of the disease resulting in more severe symptoms. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to anti-TSHR autoantibodies, antibodies that activate the insulin-like growth factor 1 receptor (&#8220;IGF1R&#8221;) may also contribute to TED. TSHR and IGF1R have functional overlaps and stimulation of either receptor may lead to activation of similar biochemical pathways implicated in TED. Published studies investing this pathway have led to the discovery that the IGF1R and TSHR form a receptor complex where IGF1R can augment the signaling of TSHR. The exact nature of the interaction between IGF1R and TSHR continues to be investigated; however, experimental evidence suggests that the effects of TSHR stimulating antibodies are only partially blocked by an IGF1R antagonist while they may be completely blocked with a TSHR antagonist. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TED has an estimated annual incidence of 9.7 in 100,000 in the U.S. and 4.8 in 100,000 in Europe. The natural history of TED begins with an inflammatory phase lasting between six and 24 months that is characterized by lymphocyte infiltration, fibroblast proliferation and increases in adipose tissue. The first line of treatment for TED patients is generally immunosuppressive therapy, including high doses of corticosteroids. Treatment of patients with immunosuppressive therapies during this active inflammatory phase can lead to reduction in symptoms and can alter the course of the disease. However, once the initial inflammatory phase is over, immunosuppressive therapies are ineffective and levels of fibrosis that have developed as the result of acute inflammation are only reversible by surgery. We estimate that 15,000 to 20,000 patients in the United States have active inflammatory TED each year and are eligible for treatment with therapy directed at the causative anti-TSHR antibodies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a first option, patients with active TED are treated with immunosuppressive therapy such as high doses of corticosteroids, typically administered intravenously or orally. Corticosteroids are not effective in all patients, and approximately <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of patients will relapse. This therapy is associated with an increased risk of acute and severe organ damage, bone thinning, weight gain, diabetes, hypertension, osteoporosis and depression. In January 2020, the FDA approved Horizon Therapeutics&#8217; Tepezza (teprotumumab), an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-IGF-1R</div></div> antibody, for the treatment of TED. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Orbital radiation therapy is used as a means of reducing the infiltration of lymphocytes and can be used in conjunction with corticosteroids or immunosuppressive therapy. Similar to these anti-inflammatory and immunosuppressive drugs, radiation therapy is most effective in the active stage of TED. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">25 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Patients with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">moderate-to-severe</div></div> active TED not responding to corticosteroids can be treated with cyclosporine or mycophenolate mofetil, two broad immunosuppressive drugs. These drugs are associated with numerous side effects related both to their general immunosuppressive effects as well as to inherent toxicities, such as hypertension, kidney disease and gastrointestinal toxicity. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Small case studies have identified rituximab as an alternate way of inducing immunosuppression in patients with TED. Rituximab (Roche) is a monoclonal antibody that binds to an antigen specific to B cells, leading to their destruction. However, rituximab is associated with the potential for serious side effects, such as infusion-related reactions. Rare cases of progressive multifocal encephalopathy and other viral infections have also been reported. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Surgery is considered to be a treatment option in patients with a highly active disease who have been treated with corticosteroids or immunosuppressive therapy but continue to have progressive disease. The goal of surgery is to reduce the pressure causing proptosis, reduced eye movement and loss of visual acuity. Because of its invasive nature, surgery is typically reserved for inactive disease. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In 2019, we initiated an open-label, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-arm</div> Phase 2a clinical trial of batoclimab for the treatment of TED. The majority of subjects (four of seven) evaluated at the end of treatment experienced a greater than or equal to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-point</div> improvement in clinical activity score (CAS). Three of seven subjects were proptosis responders; a proptosis response was defined as a greater than or equal to 2mm improvement in the study eye. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2019, we initiated a randomized, masked, placebo-controlled Phase 2b clinical trial of batoclimab in TED. Our voluntary pause in dosing in February 2021 resulted in unblinding this trial and the primary endpoint was not significant. However, our analysis of exploratory endpoints from this trial increased our confidence in the anti-FcRn mechanism of action for patients with TED, and they provide part of the basis for our interest in moving forward with further development of TED. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We recently achieved alignment with the FDA Division of Ophthalmology to move forward in TED. We plan to initiate two Phase 3 clinical trials to evaluate batoclimab for the treatment of TED in the second half of calendar year 2022. For each of the two Phase 3 trials of batoclimab in TED, we expect that approximately 100 subjects will enter the trial and be randomized to either a treatment arm or placebo arm. Subjects randomized to the treatment arm will be dosed with 680 mg of batoclimab QW for 12 weeks followed by 340 mg of batoclimab QW for 12 weeks. This batoclimab-treated group of subjects will be compared to subjects that are dosed with placebo QW for 24 weeks. This treatment period will last for 24 weeks and the primary efficacy endpoint will be measured as proptosis responders at Week 24 vs placebo where responders are defined as &#8805; 2 mm reduction from baseline in proptosis in the study eye without deterioration of &#8805; 2 mm increase in the fellow eye. We expect <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> results from both Phase 3 trials to be available in the first half of calendar year 2025. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Batoclimab for the Treatment of WAIHA </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">WAIHA overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">WAIHA is a rare hematologic disease in which autoantibodies mediate hemolysis, or the destruction of red blood cells (&#8220;RBCs&#8221;). The clinical presentation is variable and most commonly includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-specific</div> symptoms of anemia such as fatigue, weakness, skin paleness and shortness of breath. Symptoms typically develop chronically over several weeks to months; however rapid progression over a span of days has also been observed. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In severe cases, hemoglobin levels are unable to meet the body&#8217;s oxygen demand, which can lead to heart attacks, heart failure and even death. Though the exact causes of WAIHA are unknown, roughly half of cases occur in patients with an underlying lymphoproliferative or autoimmune disease, most commonly chronic lymphocytic leukemia, rheumatoid arthritis, or systemic lupus erythematosus. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In WAIHA, autoantibodies react with surface proteins on RBCs at temperatures at or above 37&#176; Celsius, or normal body temperature. These antibodies are of the IgG subtype in most patients. WAIHA is differentiated from cold autoimmune hemolytic anemia, or cold agglutinin disease, which shares a similar clinical presentation but is triggered by autoantibodies that react at temperatures below 37&#176; Celsius. In WAIHA, antibody-coated RBCs are removed from circulation primarily in the spleen, where they are destroyed by macrophages. Studies have suggested the severity of WAIHA correlates with the amount and potency of autoantibodies present. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The annual incidence of WAIHA in the United States and Europe is estimated at one to three in 100,000 persons. Based on published estimates, we believe that there are approximately 40,000 patients in the U.S. and 71,000 patients in Europe living with WAIHA. The disease may be more common in females, with some sources suggesting a 2:1 female predominance. Peak incidence occurs during the sixth and seventh decades of life, however, WAIHA can occur in children as well. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">High doses of corticosteroids (&gt;1 mg/kg of prednisone) are typically the first-line treatment option for WAIHA and lead to initial disease control in approximately <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">70-85%</div> of cases. Once initial disease control is achieved, doses of steroids are tapered. However, only 33% of patients maintain sustained disease control once steroids are discontinued and, as a result, the majority of patients will require either long-term steroid treatment or additional therapies. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patients with persistent disease despite use of corticosteroids and rituximab may be offered a course of other immunosuppressive drugs, such as cyclophosphamide, mycophenolate mofetil or azathioprine sirolimus. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RBC transfusions are indicated in patients who require immediate stabilization. Such patients are monitored closely for evidence of a transfusion reaction. In contrast to other treatment modalities that lead to nonspecific suppression of the immune system, batoclimab may offer a more targeted approach for reducing levels of the causative IgG species responsible for most cases of WAIHA. We believe this could provide a favorable therapeutic window and avoid the significant side effects associated with less targeted immunosuppression. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following expected discussions with the hematology division of the FDA, we intend to initiate a randomized, placebo-controlled study of batoclimab as a treatment for WAIHA. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">27 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Batoclimab and Atorvastatin drug-drug interaction (&#8220;DDI&#8221;) trial </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In March 2022, we announced that we initiated a Phase 1 DDI study in healthy volunteers to characterize the PK profile of atorvastatin (40 mg daily (&#8220;q day&#8221;) with and without the coadministration of batoclimab 680 mg SC QW (see figure below).&#160;Key secondary objectives are to compare the change from baseline in lipid levels observed with SC QW batoclimab (680 mg or 340 mg SC) alone or in combination with varying doses of atorvastatin.&#160;Preliminary results from the initial 2 cohorts dosed in the study (680 mg SC QW with and without 40 mg atorvastatin q day) suggest that, at these doses, atorvastatin negates the batoclimab-induced increase in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">LDL-cholesterol.&#160;We</div> believe, based on these preliminary data and feedback from physicians, that a batoclimab-induced increase in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">LDL-cholesterol</div> can be managed with anti-lipid therapy as needed. Results from the additional cohorts studied are expected to be available by the end of calendar year 2022. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g307489g24s24.jpg" style="width: 401px; height: 282px;"/></div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">QW = weekly, QD = daily, SC = subcutaneous injection </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Potential New Indications </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We continue to evaluate potential new indications for batoclimab by considering a number of factors including, but not limited to, degree of unmet medical need, potential benefit offered by the treatment, target patient population size, and commercial potential. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have identified additional attractive indications with high unmet need and scientific rationale for anti-FcRn therapy. We also believe that certain indications with existing anti-FcRn programs offer a significant opportunity to provide unique patient benefits and therefore represent a strong potential opportunity. As previously disclosed, we plan to announce two new indications by August 2022. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">28 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Proteovant Overview </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Overview:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proteovant is focused on the discovery and development of a robust pipeline of protein degraders targeting indications in oncology and immunology. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Protein degradation:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Protein degraders are a novel class of small molecules that target and destroy cellular proteins, rather than inhibiting them. Degraders are engineered to induce the degradation of specific disease-causing proteins through the ubiquitin-proteasome system, which ordinarily tags and degrades proteins that have been misfolded or have already fulfilled their biological function. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In heterobifunctional degraders, the protein ligand domain, commonly referred to as a &#8220;warhead,&#8221; targets the specific protein of interest. At the other end of the complex, the ligase ligand recruits a specific E3 ubiquitin ligase. Both ends of the complex are connected by a linker that orients the target protein and E3 ligase in a cooperative ternary complex, driving ubiquitination. Similar to heterobifunctional degraders, molecular-glue-type degraders are small molecules that induce a novel interaction between a ligand of an E3 ubiquitin ligase and a target protein, leading to proteolysis of the target via the ubiquitin-proteasome system. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe degraders represent a promising new approach to drug previously &#8220;undruggable&#8221; targets and transform the treatment of diseases with significant unmet medical need. Degraders open a new set of opportunities for small molecule drug development and have multiple distinct potential advantages over inhibitors, including that they: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">are not bound by &#8220;inhibitory&#8221; requirements, meaning they can target historically &#8220;undruggable&#8221; proteins, including transcription factors and scaffolding proteins that lack a catalytic pocket; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">may achieve efficacy at lower doses to decrease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-target</div> dose-limiting toxicities; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">have demonstrated protein depletion in tumors that have shown resistance to specific inhibitors. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Proteovant&#8217;s degrader strategy:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proteovant is positioned for leadership in the field of targeted protein degradation given its long-term sponsored research agreement (&#8220;SRA&#8221;) with a leading academic lab, its internal R&amp;D capabilities, as well as degrader-specific machine learning capabilities. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proteovant is leveraging leading protein degrader capabilities via its SRA with the lab of Dr.&#160;Shaomeng Wang, a world-renowned scientist focused on the discovery of protein degraders, at the University of Michigan. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proteovant has assembled a world-class team of scientists and drug developers with deep drug hunting capabilities in the field of small molecule degrader development to support its internal degrader discovery and development efforts. The core skill sets of the Proteovant team span all aspects of drug discovery and development, including medicinal chemistry, biology and structural biology, which is also supported by access to next generation wet labs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Proteovant has an exclusive partnership with VantAI, which, through its focus on <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in silico</div></div> design, has developed a number of powerful and distinctive tools to support induced proximity related drug discovery, including: </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">A novel protein contact-first workflow that utilizes information about known protein-protein interactions to design new degraders that can effectively stabilize <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">target-E3</div> interfaces; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A degron knowledge graph, which we believe to be industry-leading, that maps the ubiquitin proteasome system and enables the analysis of interactions between E3 ligases and degrons as well as the protein components that bind to E3 ligases and regulate degradation; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">29 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A unique model for predicting degradation based on millions of carefully curated protein stability datapoints. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Pipeline:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proteovant has a broad pipeline of programs across oncology and immunology indications, and its protein degrader structures include hererobifunctionals and molecular glues. The protein degraders in Proteovant&#8217;s pipeline range from early target validation through later stages of preclinical development. Select targets include STAT3, CBP/p300, and SMARCA2/4. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to Proteovant&#8217;s wholly owned pipeline, Proteovant has an ongoing strategic collaboration with Blueprint Medicines, pursuant to which the two companies intend to advance up to two novel protein degrader compounds into development candidates. In addition, the collaboration includes an option to expand to up to two additional novel protein degrader target programs. As a part of the collaboration, VantAI will deploy its technology for degrader generation and optimization. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Development plan and upcoming milestones:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Proteovant aims to generate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-2</div> INDs per year beginning in 2024. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Roivant ownership:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, we own 60% of the issued and outstanding common shares of Proteovant and 54% on a fully diluted basis. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Genevant Overview </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Overview</div>: </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant is a technology-focused nucleic acid delivery and development company with two delivery platforms&#8212;a lipid nanoparticle (&#8220;LNP&#8221;) platform and a ligand conjugate platform&#8212;an expansive intellectual property portfolio and deep scientific expertise, currently focused on partnering with other pharmaceutical or biotechnology companies to enable the development of nucleic acid therapeutics for unmet medical needs. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Delivery platforms:</div> </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant has two delivery platforms: LNP and ligand conjugate. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LNP platform: </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Proven technology as demonstrated by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">head-to-head</div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vivo </div></div>ionizable lipid study assessing LNP potency and immune stimulation </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Clinically validated for hepatocyte and vaccine applications and in various stages of development for other traditionally <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">hard-to-reach</div></div> tissues and cell types, including lung, eye, central nervous system, and hepatic stellate and immune cells </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Approximately 750 issued patents and pending patent applications as of June 15, 2022 </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ligand conjugate platform: </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Novel GalNAc ligands with demonstrated ability to deliver to the liver in preclinical studies </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">In preclinical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">head-to-head</div></div> testing, demonstrated equal or better preclinical potency, assessed by duration and magnitude of knockdown, compared to a current industry benchmark </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Applying delivery expertise to design novel extrahepatic ligands to expand therapeutic reach </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Collaboration-based business model:</div> </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant uses its expertise in the delivery of nucleic acid therapeutics to develop optimal delivery systems for its collaborators&#8217; identified payloads or target tissues. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Genevant collaboration-based business model is to seek some or all of upfront payments, R&amp;D reimbursements, and milestones and royalties (or profit share) upon success, while also retaining certain rights in the delivery-related intellectual property developed in the context of the collaboration for potential use or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-license.</div> </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some current collaboration partners include BioNTech, Takeda, Sarepta, Gritstone, ST Pharm, 2seventy bio, Chulalongkorn University (through its Vaccine Research Center), and Providence Therapeutics. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Clinical data:</div> </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant LNP technology has been in clinical testing in over a dozen distinct product candidates, representing hundreds of subjects of clinical experience. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Genevant LNP technology is included in the first <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RNA-LNP</div> product to receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approval,</div> Alnylam&#8217;s Onpattro (patisiran). </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Roivant ownership:</div> </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, we own 83% of the issued and outstanding common shares of Genevant and 67% on a fully diluted basis. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nucleic Acid Therapeutics </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nucleic acid therapeutics represent an emerging modality that we believe may overcome challenges associated with traditional small molecule drug development in the treatment of genetically defined disease. The </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">vast majority of human proteins are considered &#8220;undruggable&#8221; by small molecules based on their protein structure. Nucleic acid therapeutics circumvent the question of whether or not a target is undruggable by impacting protein expression itself. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The field of nucleic acid therapeutics has gained significant momentum in recent years, with FDA approval of Alnylam&#8217;s Onpattro and Givlaari (givosiran), and approval of multiple mRNA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccines. There is a substantial pipeline of nucleic acid therapeutics in clinical development that further underscores the transformative potential of nucleic acid therapeutics in the near term. However, nucleic acid therapeutics remain challenged by obstacles in the delivery of nucleic acids to specific cell types. RNA molecules cannot passively cross most cell membranes given their large size and negative charge, and therefore must be administered in conjunction with a delivery technology to ensure transport to target cell types. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We work with two proprietary technologies, LNP delivery and ligand conjugate delivery, to improve the likelihood of clinical success of nucleic acid therapeutics. We licensed intellectual property with respect to each of these technologies from Arbutus Biopharma in 2018. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are focused on expanding our platforms into novel tissue types by leveraging the scientific expertise of several members of the technical team that originally developed or advanced the technologies at Arbutus and its predecessors. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lipid Nanoparticle Platform </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our LNP technology platform is designed to deliver nucleic acids, including mRNA, siRNA, antisense and gene editing constructs. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some key features of our LNP technology are: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Multi-component formulations that contain specialized lipids optimized for potency and tolerability, are capable of encapsulating a broad range of nucleic acid payloads, and have limited constraints on nucleic acid composition, structure or size </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">2.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A manufacturing process developed and scaled to produce stable uniform dispersion of colloidal nanoparticles with particle size appropriate for parenteral or intramuscular administration </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">3.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Efficient intracellular delivery of nucleic acids to cell cytoplasm via engineered active endosomal escape mechanism </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g307489g25s25.jpg" style="width: 460px; height: 266px;"/><br/></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">head-to-head</div></div> study comparing multiple LNP formulations varying only the key ionizable lipid, a newer Genevant formulation outperformed third-party formulations. In particular, our formulation showed superior potency and avoidance of immune stimulation relative to others, including when compared with the LNP utilized in the first <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RNA-LNP</div> therapeutic, Alnylam&#8217;s Onpattro (&#8220;MC3&#8221; in figure below). </div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Genevant LNP Outperformed Third-Party LNPs in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Head-to-Head</div></div> Study </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g307489g26s26.jpg" style="width: 601px; height: 441px;"/><br/></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">* Key lipid of first <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">siRNA-LNP</div> (Alnylam&#8217;s Onpattro) </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, Genevant LNP technology has entered the clinic with more than a dozen distinct product candidates, representing hundreds of subjects of clinical experience. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">33 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Substantial clinical experience with Genevant LNP technology </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g307489g27s27.jpg" style="width: 605px; height: 282px;"/><br/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With this track record of success, we are now also focusing our LNP capabilities on historically challenging cell and tissue types, including hepatic stellate cells (&#8220;HSCs&#8221;). </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Historically, attempts to address certain diseases have been limited by the inability to access specific cell types outside of the hepatocyte. We have demonstrated our ability to deliver nucleic acid therapeutics to challenging targets by accessing HSCs in preclinical studies. The activation of HSCs is well established as a central driver of fibrosis, and thus technologies that target activated HSCs may be key to addressing certain liver diseases. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In preclinical studies, delivery of RNAi to HSCs via Genevant&#8217;s LNP technology demonstrated selective knockdown of an HSC target with minimal activity in hepatocytes, as shown below. Additional preclinical studies support our ability to design LNPs to deliver nucleic acids to the lung, and we believe that our scientific expertise will over time lead to the ability to direct LNPs toward additional cell and tissue types, such as the central nervous system, immune cells and the eye. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">34 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LNP delivery of siRNA to HSCs demonstrated selective knockdown of target mRNA in mice with minimal activity in hepatocytes </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g307489g28s28.jpg" style="width: 449px; height: 286px;"/><br/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ligand Conjugate Platform </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to our LNP platform, we also have a proprietary RNAi ligand conjugate platform. Novel ligands can successfully deliver siRNA and certain other oligonucleotides to hepatocytes, and our expertise enables the design of novel ligands with the potential to expand delivery capability to other cell types such as hepatic stellate cells. Our ligand conjugate technology has demonstrated equal or better preclinical potency, assessed by duration and magnitude of knockdown compared to current industry benchmark. We currently have an allowed US patent and multiple patent applications pending with respect to our ligand conjugate platform. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">35 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g307489g11i11.jpg" style="width: 600px; height: 344px;"/><br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g307489g22i22.jpg" style="width: 600px; height: 156px;"/><br/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are developing a next-generation ligand conjugate platform that we refer to as &#8220;RNAi 2.0.&#8221; Our RNAi 2.0 platform has demonstrated superior strength and duration of knockdown compared to legacy ligand conjugates (&#8220;RNAi 1.0&#8221;) in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">head-to-head</div></div> preclinical study in nonhuman primates. In addition, our RNAi 2.0 platform: </div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contains intrinsic endosomolytic properties </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Has demonstrated marked <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vivo</div></div> enhancement in potency </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Has maintained a subcutaneous dosing regimen and is expected to be dosed subcutaneously in clinical trials </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remains compatible with other ligand types </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">36 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Next Generation RNAi 2.0 Conjugate Platform Shows Improved Potency, Magnitude and Duration of Knockdown </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g307489g33i33.jpg" style="width: 600px; height: 238px;"/><br/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Strategy </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant seeks to partner with other pharmaceutical or biotechnology companies in the development of RNA therapeutics, crafting mutually beneficial collaborations that allow collaboration partners to access innovative technologies while providing Genevant the opportunity to leverage our expertise to expand the technology and its therapeutic application. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This provides the following benefits to collaborators: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Access to validated technology to deliver nucleic acid therapeutics for hepatocyte or vaccine applications </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Potential to deliver RNA payloads to historically <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">challenging-to-reach</div></div> tissue or cell types, as well as nucleic acid design capabilities </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No need to build internal delivery expertise or build intellectual property estate from scratch in an increasingly complex field </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This provides the following benefits to Genevant: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opportunity to expand core delivery technology and capabilities, maintaining leadership position in nucleic acid delivery </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Typically, the ability to exploit certain rights to delivery-related intellectual property developed in the context of collaboration ourselves or with other collaborators </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opportunity to generate revenue through deal structures including some combination of upfront payments, R&amp;D reimbursements and additional milestones and royalties upon successful outcomes </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To date, Genevant has partnered with leading companies with a shared vision of advancing innovative nucleic acid medicines to transform the lives of patients. Our collaborations currently include: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gritstone</div></div>&#8212;Access to Genevant&#8217;s LNP technology for use in Gritstone&#8217;s self-amplifying RNA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccine program </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gritstone</div></div>&#8212;Access to LNP technology for use with self-amplifying RNA for an unspecified indication </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">37 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sarepta</div></div>&#8212;Research collaboration and option agreement for the delivery of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">LNP-gene</div> editing therapeutics for specified neuromuscular diseases; Genevant will design and collaborate with Sarepta in the development of muscle targeted LNPs to be applied to gene editing targets in multiple indications, including Duchenne muscular dystrophy </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">BioNTech</div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;Co-development</div> in up to five rare diseases with high unmet medical need, and access to LNP technology for use with BioNTech&#8217;s mRNA for a specified number of oncology targets </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Takeda</div></div>&#8212;Access to LNP technology to develop nucleic acid therapeutics directed to specified targets in HSC to treat liver fibrosis </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Takeda</div></div>&#8212;Access to LNP technology to develop nonviral gene therapies for up to two rare liver diseases </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ST Pharm</div></div>&#8212;Access to Genevant&#8217;s LNP technology for use in specified territories in ST Pharm&#8217;s mRNA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccine program </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Providence</div></div>&#8212;Access to Genevant&#8217;s LNP technology for use in Providence&#8217;s mRNA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccine program </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2seventy</div></div>&#8212;Access to LNP technology to develop gene editing therapies for hemophilia A </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chulalongkorn University</div></div>&#8212;Access to LNP technology for use in specified Asian territories in its mRNA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccine program </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Potential Benefits of Genevant&#8217;s Delivery Platforms </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Robust and expansive patent portfolio.</div></div> As of June 15, 2022, there are approximately 750 issued patents and pending patent applications for our LNP platform, including coverage directed to individual lipid structure, particle composition, particle morphology, manufacturing and mRNA-containing LNP formulations. As we continue to develop these technologies, we expect to have the opportunity to expand our intellectual property portfolio further, to enhance protection and support additional licensing opportunities. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Experienced leadership team.</div></div> Our leadership team has deep technical expertise in nucleic acid drug development and a track record of executing successfully in innovative areas. We believe this positions Genevant to expand delivery to historically challenging tissues and cell types, thereby creating potential opportunities for creative collaboration. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Manufacturing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how.</div></div></div> Since inception, we have made strategic investments in expanding our manufacturing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how.</div> Our manufacturing process is rapid and reproducible, has intellectual property protection and is capable of commercial scale. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expansive Patent Portfolio </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our LNP platform is protected with a robust patent portfolio, covering a wide range of aspects required for successful nucleic acid delivery. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our patents are directed to: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Lipid structures, including cationic and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PEG-lipids;</div> </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Particle compositions, including commonly used ranges of lipid ratios for nucleic acid-containing particles; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nucleic acid-containing particles with certain structural characteristics; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">mRNA-containing LNP formulations; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Various aspects of our manufacturing process. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">38 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Priovant Overview </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Overview</div>: </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Priovant is developing brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1, for the treatment of dermatomyositis (&#8220;DM&#8221;), systemic lupus erythematosus (&#8220;SLE&#8221;) and other immune-mediated diseases. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lead program</div>: </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Brepocitinib is a potentially <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class,</div></div> orally administered, small molecule inhibitor of TYK2 and JAK1 that suppresses signaling of TYK2- and JAK1-dependent cytokines linked to autoimmunity, including type I and type II interferon, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-12,</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-23.</div> </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Disease overview</div>: </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">DM is a chronic, immune-mediated disease of the skin and muscles. Patients with DM usually present with a characteristic skin rash and proximal muscle weakness, which may lead to significant functional impairment or disfigurement. Patients with DM are at a substantially increased risk of interstitial lung disease, malignancy, and heart failure, contributing to an estimated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-year</div> mortality rate of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-40%.</div> </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">SLE is a chronic, immune-mediated connective tissue disease that can impact nearly all major organ systems. The most common manifestations of SLE are cutaneous and musculoskeletal symptoms, although neurological, gastrointestinal, hematological, and renal symptoms are regularly observed as well. Patients with SLE are at a substantially increased risk of infection and cardiovascular disease, contributing to estimated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15-year</div> mortality rates of 9% and 15%, respectively. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We estimate that there are approximately 37,000 adult DM patients and up to 300,000 adult SLE patients in the US. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Limitations of current treatments</div>: </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corticosteroids, disease-modifying antirheumatic drugs (&#8220;DMARDs&#8221;), and immunosuppressants, administered alone or in combination, are traditional therapies for patients with DM and SLE. Many of these therapies are associated with significant toxicities and limited efficacy. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">For patients with DM who do not respond adequately to traditional therapies, IVIg (OCTAGAM 10%) is an important <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> treatment. However, clinical trial data from the Phase 3 ProDERM study of IVIg in patients with DM and case reports from years of prior <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> use confirm that even with IVIg, many patients with DM continue to suffer from residual disease activity. Moreover, IVIg administration is burdensome, typically requiring several hours of infusion therapy for multiple days each month. IVIg also has a black box warning for serious risks, including thrombosis and kidney failure. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">For patients with SLE who do not respond adequately to traditional therapies, belimumab (BENLYSTA) and anifrolumab (SAPHNELO) are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> biologic treatments. However, in each of belimumab&#8217;s BLISS Phase 3 program and anifrolumab&#8217;s TULIP Phase 3 program, the clinical trial data demonstrates that many patients failed to respond to these therapies, and both therapies are administered intravenously or subcutaneously. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Clinical data</div>: </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Brepocitinib has been evaluated in five completed placebo-controlled Phase 2 studies in immune-mediated diseases (psoriatic arthritis, plaque psoriasis, ulcerative colitis, alopecia areata, and hidradenitis suppurativa). In all five of these studies, treatment with brepocitinib was associated with statistically significant and clinically meaningful efficacy. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 91%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 35%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 18%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 28%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 11%; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Study Population</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">N<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">1</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Brepocitinib Dose</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Primary Endpoint Result</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Statistical</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Significance</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Psoriatic Arthritis</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">218</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">30 mg once daily</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">23.4% placebo-adjusted ACR20 RR at week 16</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">P = 0.0197</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plaque Psoriasis</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">212</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">30 mg once daily</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">-10.1 placebo-adjusted CFB in PASI score at week 12</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">P &lt; 0.0001</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ulcerative Colitis</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">167</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">30 mg once daily</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">-2.28 placebo-adjusted CFB in Mayo Score at week 8</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">P = 0.0005</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alopecia Areata</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">94<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">2</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">30 mg once daily<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">3</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">49.18 placebo-adjusted CFB in SALT Score at week 24</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">P&#160;&lt;&#160;0.0001<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">4</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hidradenitis Suppurativa</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">100</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">45&#160;mg&#160;once&#160;daily<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">5</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">18.7% placebo-adjusted HiSCR rate at week 16</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">P =&#160;0.0298<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">4</div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overall study N represents patients randomized to all brepocitinib dose levels or placebo and excludes patients randomized to other agents. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">2.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes patients from initial 24-week study period only. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">3.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">60 mg QD for 4 weeks followed by 30 mg QD for 20 weeks. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">4.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">One-sided p-value (pre-specified statistical analysis). </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">5.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Brepocitinib 45 mg once daily was the only dose evaluated in this study. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ACR20: American College of Rheumatology 20% Improvement; RR: Response Rate; CFB: Change From Baseline; PASI: Psoriasis Area and Severity Index; SALT: Severity of Alopecia Tool; HiSCR: Hidradenitis Suppurativa Clinical Response </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Brepocitinib&#8217;s safety database includes over 1,000 exposed participants evaluated in 14 completed Phase 1 and Phase 2 studies and three ongoing Phase 1 and Phase 2 studies. In these studies, brepocitinib was generally safe and well-tolerated, and rates of JAK class treatment-emergent adverse events (&#8220;TEAEs&#8221;) of interest were comparable to those observed in the development programs of approved JAK inhibitors. Collectively, these data suggest a safety profile that is similar to those of approved JAK inhibitors. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Brepocitinib has not been evaluated in DM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">to-date.</div> However, several <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> JAK inhibitors have been clinically validated in DM patients refractory to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">standard-of-care</div></div> therapies, as reported in more than 100 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> case reports and in an open-label clinical trial. In addition, since DM pathobiology is driven by dysregulations in cytokines whose signaling is mediated by both TYK2 and JAK1, we believe that, with its unique dual inhibition of both TYK2 and JAK1, brepocitinib, as compared to inhibitors selective to either TYK2 or JAK1 has the potential to demonstrate superior clinical efficacy in DM. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Brepocitinib has not been evaluated in SLE <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">to-date.</div> However, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> and investigational JAK inhibitors have completed successful <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">proof-of-concept</div></div> studies in SLE patients. And, like DM, SLE pathobiology is driven by dysregulations in cytokines whose signaling is mediated by both TYK2 and JAK1. We believe that, with its unique dual inhibition of both TYK2 and JAK1, brepocitinib, as compared to inhibitors selective to either TYK2 or JAK1, has the potential to demonstrate superior clinical efficacy in SLE. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Development plan and upcoming milestones</div>: </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Priovant is currently conducting a large randomized, controlled Phase 3 study of brepocitinib in patients with refractory dermatomyositis. This study will enroll approximately 225 subjects in total and will evaluate 15 mg and 30 mg of brepocitinib once-daily compared to placebo. The primary endpoint of this study is the mean Total Improvement Score (&#8220;TIS&#8221;), a validated myositis improvement index, at Week 52. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Brepocitinib is currently being evaluated in a large, randomized controlled Phase 2B study in patients with moderate to severe active SLE. This study will enroll approximately 350 subjects in total and will evaluate 15 mg, 30 mg, and 45 mg of brepocitinib once-daily compared to placebo. The primary </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">40 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">endpoint of this study is the Systemic Lupus Erythematosus Responder Index <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SRI-4&#8221;),</div> a validated SLE improvement index, at Week 52. Priovant anticipates receiving topline results from this study in the second half of 2023. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Priovant is also evaluating brepocitinib for the development of hidradenitis suppurativa and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infectious</div> uveitis. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Roivant ownership</div>: </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, we own 75% of the issued and outstanding shares of Priovant and 70% on a fully diluted basis. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The below schematics show the trial designs for the ongoing DM Phase 3 and SLE Phase 2B trials: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g307489g44i44.jpg" style="width: 600px; height: 198px;"/><br/></div><div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g307489g55i55.jpg" style="width: 600px; height: 234px;"/><br/></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style:italic;display:inline;">Note: The sample size for the SLE trial is subject to a protocol amendment which requires review and approval in multiple territories. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">41 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Kinevant Overview </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Overview:</div> </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kinevant is focused on developing namilumab for sarcoidosis and potentially other diseases. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lead program:</div> </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Namilumab is a fully human <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-GM-CSF</div></div> monoclonal antibody with broad potential in inflammatory and autoimmune diseases being developed with potentially the least frequent dosing schedule among subcutaneous <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-GM-CSFs</div></div> in Phase 2 clinical trials, with a single dose every four weeks after an initial loading period. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Disease overview:</div> </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Sarcoidosis is a multi-system inflammatory disease characterized by the presence of non-necrotizing granulomas believed to be formed by an exaggerated immune response to unidentified antigens. Sarcoidosis primarily affects the lungs and lymphatic system, though sarcoidosis may damage any organ. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF,</div> a key pathogenic cytokine, has been implicated in multiple parts of the granulomatous response. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sarcoidosis affects approximately 200,000 people in the United States, with over 90% of cases presenting with pulmonary involvement. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An estimated 54% of pulmonary sarcoidosis patients are diagnosed, and approximately 90% of these patients receive some form of treatment. Market research with HCPs and third-party analysis of claims data suggest that approximately 25% of diagnosed and treated pulmonary sarcoidosis would be eligible for treatment with second-line or later therapy. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Limitations of current treatments:</div> </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corticosteroids are the most widely used treatment for sarcoidosis, but they carry significant side effects when used longer-term. Second- and third-line treatment options, including immunosuppressive therapies and biologics, are limited by slow onset, safety risk, inconsistent effectiveness, and reimbursement challenges, leaving significant unmet medical need that could be met by a novel biologic. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Clinical data:</div> </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Early clinical data in pharmacokinetic/pharmacodynamic (PK/PD) and subsequent Phase 2 studies showed namilumab to be well-tolerated with a single subcutaneous injection given up to every four weeks. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In a Phase 1 study of healthy volunteers with a single subcutaneous injection, namilumab was observed to be generally well-tolerated. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">In a Phase 2 trial in patients with moderate to severe rheumatoid arthritis conducted by Takeda, namilumab demonstrated decreased disease activity compared to placebo. In this trial, patients were given a subcutaneous injection of either 20, 80, or 150 mg of namilumab four times over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ten-week</div> period. Over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-week</div> study period, 14 of 27 (52%) subjects receiving placebo and 45 of 81 (56%) receiving namilumab experienced a treatment-emergent adverse event (TEAE). The most common TEAEs were nasopharyngitis, dyspnea, bronchitis, and headache. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Development plan and upcoming milestones:</div> </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have initiated a Phase 2 trial to evaluate the safety and efficacy of namilumab in pulmonary sarcoidosis, with a readout expected in the first half of 2024. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">42 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Roivant ownership:</div> </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, we own 88% of the issued and outstanding common shares of Kinevant, and 83% on a fully diluted basis. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The below schematic shows the trial design for the Phase 2 trial in pulmonary sarcoidosis: </div></div><div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g307489g66i66.jpg" style="width: 552px; height: 241px;"/><br/></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">43 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Hemavant Overview </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Overview</div>: </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Hemavant is developing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RVT-2001,</div> a small molecule SF3B1 modulator, for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes (&#8220;MDS&#8221;). </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lead program</div>: </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RVT-2001</div> is a potentially <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class,</div></div> orally administered, small molecule SF3B1 modulator that corrects SF3B1 mutation-induced splicing defects in mRNA transcripts that encode proteins thought to be associated with the development of MDS. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Disease overview</div>: </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Myelodysplastic syndromes are a group of hematologic malignancies in which immature blood cells in the bone marrow do not mature and become healthy blood cells. MDS patients are at risk for symptoms related to anemia, infection and bleeding, and they have variable survival expectations and rates of progression to acute myeloid leukemia. Assessment of prognosis is a key aspect in selecting therapy for the patient with MDS, and prognostic models broadly differentiate patients into either lower-risk MDS or higher-risk MDS. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that there are approximately 115,000 MDS patients in the US, with approximately 17,000 new MDS cases per year, two thirds of which are lower-risk MDS. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Limitations of current treatments</div>: </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chronic anemia in patients with MDS requires regular and repeated red blood cell (&#8220;RBC&#8221;) transfusions, creating a significant burden for patients and an increased risk of organ toxicity from iron overload. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">One of the primary goals of treatment is to reduce or eliminate RBC transfusion dependence while minimizing treatment-related toxicity. The first line of treatment for most lower-risk MDS patients consists of erythropoiesis-stimulating agents (&#8220;ESAs&#8221;), which are ineffective in over 50% of patients. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">For patients who fail ESAs, the available treatment options depend on mutational status and disease phenotypes. In 2020, Reblozyl (luspatercept) became the only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> therapy for lower-risk MDS patients who are ring sideroblast positive and who have failed an ESA. Although Reblozyl can lead to transfusion independence, it is ineffective in over 50% of patients and is most effective in patients with a low transfusion burden. Reblozyl is delivered as an injection and is associated with numerous adverse events, including fatigue, a significant concern for patients already experiencing fatigue from anemia. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Clinical data</div>: </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">In the dose-escalation portion of an ongoing Phase 1/2 study, over 30% (6/19) of patients with lower-risk, transfusion-dependent MDS treated with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RVT-2001</div> became <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RBC-transfusion</div> independent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;RBC-TI&#8221;),</div> with a median duration of treatment of approximately two years for responders. The dose-escalation portion of the study was conducted in a highly refractory patient population, which we believe may have decreased the observed treatment response relative to what would be expected in a less refractory target population. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">In the dose-escalation portion of this ongoing Phase 1/2 study, which had a total of 84 patients with acute myeloid leukemia (&#8220;AML&#8221;), chronic myelomonocytic leukemia or MDS, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RVT-2001</div> was observed to be generally well-tolerated, with the majority of events being classified as Grade 1. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Development plan and upcoming milestones</div>: </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have amended the IND for the ongoing open-label Phase 1/2 trial to add a dose-optimization cohort. We are enrolling a less refractory patient population in the dose-optimization cohort than the </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">44 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">population from which the first 19 lower-risk, transfusion-dependent MDS patients were drawn during the dose-escalation portion by excluding patients with prior exposure to lenalidomide or hypomethylating agents. We are targeting a genetically defined subpopulations by enrolling only lower-risk MDS patients with SF3B1 mutations. In addition, we are evaluating baseline expression of TMEM14C transcripts as a potential biomarker predictive of response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RVT-2001,</div> since among the 7 MDS patients with the highest levels of aberrant TMEM14C transcripts in the dose-escalation portion of this Phase 1/2 trial, 71% (5/7) became <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RBC-TI.</div> We also aim to strengthen the phamacodynamic effect by optimizing the dosage of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RVT-2001.</div> We expect data from the dose-optimization cohort of the Phase 1/2 trial to be available in 2023. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our initial plan is to position RVT-3002 as second line therapy in SF3B1-mutated patients, with the potential to expand to other spliceosome mutations and ultimately first line treatment. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roivant ownership: </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, we own 100% of the issued and outstanding common shares of Hemavant and 100% on a fully diluted basis. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The below schematic shows the trial design for the dose-optimization cohort of our ongoing Phase 1/2 study: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g307489g77i77.jpg" style="width: 600px; height: 191px;"/><br/></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">45 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Affivant Overview </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Overview:</div> </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Affivant is focused on the future development and commercialization of AFVT-2101 and other bispecific antibodies through its licensing and strategic collaboration agreement with Affimed to develop and commercialize novel innate cell engagers for multiple cancer targets. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lead program:</div> </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AFVT-2101 is a preclinical immune-engaging bispecific antibody licensed from Affimed with potential applicability to several solid tumor indications. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bispecific innate cell engagers (&#8220;ICE&#8221;), which are generated by Affimed&#8217;s Redirected Optimized Cell Killing (&#8220;ROCK&#8221;) platform technology, are a novel class of drugs that activate the innate immune system and trigger a concerted anti-tumoral immune response. These bispecific antibodies consist of tumor-associated antigen binding domains, which cause high affinity and high specificity binding to the tumor surface, and immune cell binding domains, which bind and activate specific immune cell subsets able to kill the tumor cell. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AFVT-2101 is an ICE program whose Fc region is fused to two high affinity CD16A binding single chain variable regions to maximize NK cell and macrophage engagement. The biological target of AFVT-2101&#8217;s tumor-associated antigen binding domain has been clinically validated via other targeted agents (mAb and ADC), including both evidence of single agent activity and a generally well-tolerated safety profile of the corresponding mAb in published studies. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe AFVT-2101 has potential applicability across several highly prevalent solid tumor types, providing the optionality to pursue multiple large-market indications. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Preclinical data:</div> </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">In a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">head-to-head</div></div> preclinical study, AFVT-2101&#8217;s potency, as measured by target cell killing, exceeded that of a monoclonal antibody (&#8220;mAb&#8221;) that has been clinically validated against the same tumor target. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AFVT-2101&#8217;s potency also exceeded the potency of antibody-drug conjugate (&#8220;ADC&#8221;) agents that have been clinically validated against the same tumor target, as reported in published preclinical studies. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on preclinical and clinical experiences with other ICE antibodies in separate studies, we believe that the tolerability of AFVT-2101 has the potential to be superior to that observed to date with ADCs in published literature. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Development plan and upcoming milestones:</div> </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect to file an IND for AFVT-2101 in the first half of calendar year 2023. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to a collaboration and licensing agreement between Affivant and Affimed, Affimed is conducting a significant portion of the AFVT-2101 preclinical work for the collaboration under the governance of a Joint Steering Committee controlled by Affivant. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Pursuant to the agreement Affivant will be responsible for submitting any IND or equivalent for AFVT-2101, and will be responsible for all future clinical development and commercialization worldwide, with Affimed retaining an option for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-promotion.</div> </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also have the option to license from Affimed additional ICE molecules directed against targets that are not (a)&#160;currently licensed or optioned to third parties or (b)&#160;directed against targets included in Affimed&#8217;s current pipeline. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Roivant ownership:</div> </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, we own 100% of the issued and outstanding common shares of Affivant and 99% on a fully diluted basis. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset Acquisition and License Agreements; Other Vant Agreements </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">GSK and Welichem Agreements </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2018, our subsidiary Dermavant Sciences GmbH (&#8220;DSG&#8221;) acquired the worldwide rights (other than for China) with respect to certain intellectual property rights retained by Welichem Biotech Inc. (&#8220;Welichem&#8221;) to VTAMA and related compounds from Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Ltd. (collectively, &#8220;GSK&#8221;) pursuant to an asset purchase agreement (the &#8220;GSK Agreement&#8221;). GSK previously acquired rights to a predecessor formulation of VTAMA from Welichem pursuant to an asset purchase agreement between GSK and Welichem entered into in May 2012 (the &#8220;Welichem Agreement&#8221;). Under the GSK Agreement, DSG made an upfront payment of &#163;150.0&#160;million (approximately $191 million) to GSK. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DSG is also obligated to pay GSK &#163;100.0&#160;million (approximately $126 million on the date of achievement) within 70 days following the receipt of marketing approval of VTAMA in the United States. The GSK Agreement does not require DSG to pay any royalties on sales of VTAMA following commercialization or make any commercial milestone payments, except for milestones owed to Welichem as described below. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, under the GSK Agreement, DSG assumed all obligations under the Welichem Agreement, including initially up to CAD$180.0 million in potential development and commercial milestone payments, of which CAD$80.0 million have been achieved and paid as of March 31, 2022. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, in connection with the GSK Agreement, DSG and GlaxoSmithKline Trading Services Limited (&#8220;GSK Trading&#8221;) entered into a clinical manufacturing and supply agreement for VTAMA pursuant to which DSG obtained an existing supply of VTAMA drug product and drug substance as well as additional supply of VTAMA drug product for clinical trials on a cost plus basis. As required under the GSK Agreement, in April 2019, DSG and GSK Trading also entered into a commercial manufacturing and supply agreement (the &#8220;Commercial Supply Agreement&#8221;) pursuant to which DSG will obtain VTAMA drug product and drug substance from GSK Trading. Under the Commercial Supply Agreement, GSK Trading will provide development services to prepare for the manufacture and supply of VTAMA at commercial scale. DSG will obtain commercial supply of VTAMA on a cost plus basis under the Commercial Supply Agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaboration and License Agreement with Japan Tobacco Inc. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In January 2020, DSG entered into a collaboration and license agreement with Japan Tobacco Inc. (&#8220;Japan Tobacco&#8221;) (the &#8220;Japan Tobacco Agreement&#8221;). Pursuant to the Japan Tobacco Agreement, DSG granted Japan Tobacco exclusive rights to develop, register and market tapinarof in Japan for the treatment of dermatological diseases and conditions, including psoriasis and atopic dermatitis. In connection with the Japan Tobacco Agreement, Japan Tobacco has signed an exclusive license with its subsidiary, Torii, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">for&#160;co-development&#160;and</div> commercialization of tapinarof in Japan. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Japan Tobacco Agreement, DSG has received (i) an upfront payment of $60.0 mllion in January 2020 and (ii) a payment of $10.0 million in December 2021 related to development milestones that were achieved, and DSG may receive up to an additional $43.0 million upon the achievement of certain development milestones for tapinarof in psoriasis and atopic dermatitis. In addition, DSG will be entitled to tiered purchase prices specified in the Japan Tobacco Agreement in consideration of DSG&#8217;s commercial supply of tapinarof to Japan Tobacco under the terms of a separate commercial supply agreement to be negotiated by the parties. DSG also has the right to receive royalties, to be negotiated by the parties and consistent with the purchase prices, based on product sales of tapinarof in the indications to the extent that DSG is no longer responsible for supplying tapinarof to Japan Tobacco. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Japan Tobacco Agreement will remain in effect until expiration of the obligation to pay royalties, unless terminated in accordance with the following: (1)&#160;for any reason by Japan Tobacco upon written notice to </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DSG, which notice must be provided (x)&#160;at least 90 days in advance, if the termination is prior to regulatory approval of tapinarof in Japan for any dermatological disease or condition, and (y)&#160;at least 180 days in advance, if the termination is subsequent to regulatory approval of tapinarof in Japan for any dermatological disease or condition; (2)&#160;by either party upon written notice for the other party&#8217;s material breach if such party fails to cure such breach within the specified cure period; or (3)&#160;by DSG if Japan Tobacco or its affiliates or sublicenses participate in a challenge to certain of our patents. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant Financing Agreements&#8212;Dermavant Revenue Interest Purchase and Sale Agreement </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In May 2021, DSG, as seller, entered into a Revenue Interest Purchase and Sale Agreement (the &#8220;RIPSA&#8221;) with XYQ Luxco, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NovaQuest&#160;Co-Investment&#160;Fund</div> XVII, L.P., an affiliate of NovaQuest Capital Management, LLC, and MAM Tapir Lender, LLC, an affiliate of Marathon Asset Management, L.P. (collectively, the &#8220;Purchasers&#8221;), together with U.S. Bank National Association, as collateral agent. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2022, following satisfaction of the funding conditions set forth in the RIPSA, including receipt of marketing approval from the FDA for VTAMA (received in May 2022), the Purchasers paid DSG a total of $160.0&#160;million in accordance with the terms and conditions set forth in the RIPSA (the &#8220;Purchase Price&#8221;). In consideration therefor, each of the Purchasers has the right to receive a low single-digit to high single-digit tiered percentage of quarterly revenues based on the achievement of specified net sales thresholds for VTAMA in the U.S., up to a cap of $344.0 million. Payments of such quarterly revenues to the Purchasers under the RIPSA are secured by a security interest in certain VTAMA-related assets, including intellectual property rights and certain other assets that are owned by, licensed to or otherwise controlled by DSG related to the development and commercialization of VTAMA. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The RIPSA contains certain representations and warranties and covenants applicable to DSL and its subsidiaries. The RIPSA also contains certain Events of Default (as defined in the RIPSA) such as the breach of payment and other obligations, bankruptcy-related events and cross-defaults with respect to other related documents and agreements creating indebtedness. The occurrence of an Event of Default following the Purchasers&#8217; funding of the Purchase Price triggers DSG&#8217;s obligation to pay an Event of Default Fee (as defined in the RIPSA) of $160.0&#160;million, less revenue payments previously paid, as liquidated damages. In addition, the occurrence of a change of control of DSG prior to the Purchasers funding the Purchase Price triggers DSG&#8217;s right, but not the obligation, to terminate the RIPSA by payment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;Pre-Funding&#160;Change</div> of Control Option Price (as defined in the RIPSA) to all of the Purchasers, which varies based on the date of termination and certain milestones with respect to VTAMA. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant Financing Agreements&#8212;Dermavant Credit Agreement with XYQ Luxco </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2021, our subsidiaries Dermavant Sciences Ltd. (&#8220;DSL&#8221;), Dermavant Holdings Limited, Dermavant Sciences IRL Limited and DSG, as borrowers (the &#8220;Borrowers&#8221;), and certain other subsidiaries of DSL, as initial guarantors, entered into a credit agreement (the &#8220;Credit Agreement&#8221;) with XYQ Luxco, as lender, and U.S. Bank National Association, as collateral agent. The Credit Agreement provides for a term loan of $40.0&#160;million (the &#8220;Term Loan&#8221;), the proceeds of which were used by the Borrowers to repay in full and terminate an existing credit facility with Hercules Capital Inc., with the remaining proceeds to be used for working capital and other general corporate purposes. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Term Loan bears interest at a fixed interest rate of 10.0% per annum, with interest paid quarterly in arrears until maturity in May 2026, at which time the principal amount is due. The Borrowers have the option to prepay the Term Loan in whole or in part, subject to (i)&#160;until May 2023, a prepayment premium of 5.0% of the principal amount being repaid (plus the present value of all future scheduled interest on the principal being prepaid that would accrue through May 2023 calculated based on a discount rate equal to the treasury rate plus 100 basis points, except in the event the prepayment is due to a change of control), (ii) from May 2023 to May 2024, a prepayment premium of 5.0% of the principal amount being repaid, and (iii)&#160;from May 2024 to May </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">48 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025, a prepayment premium of 2.5% of the principal amount being repaid. From May 2025 through maturity, the Term Loan may be prepaid in whole or in part without a prepayment premium. Optional and mandatory prepayment of the Term Loan, as well as other forms of prepayment, repayment, applications or reductions, will also require that DSL pays an Exit Fee (as defined in the Credit Agreement), calculated based on the amount so prepaid, repaid, applied or reduced. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Borrowers&#8217; obligations under the Credit Agreement are unconditionally guaranteed by the initial guarantors and secured by first priority security interests in substantially all of the tangible and intangible assets of the Borrowers and guarantors, including certain intellectual property rights, bank accounts, any and all insurance receivables, intercompany receivables and/or trade receivables and certain quotas and/or participation rights. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar financings, including a covenant against the occurrence of a &#8220;change in control&#8221; (subject to the Borrowers&#8217; right to prepay the Term Loan), financial reporting obligations and certain limitations on indebtedness, liens (including on intellectual property and other assets), investments, distributions (including dividends), collateral, transfers, mergers or acquisitions, taxes, corporate changes and deposit accounts. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Credit Agreement contains a minimum cash covenant that requires the initial Borrowers and the guarantors thereunder to maintain a minimum cash balance of $10.0&#160;million until the earlier of (a)&#160;a Qualified IPO (as defined in the Credit Agreement), (b) an Ultimate Parent Spinout (as defined in the Credit Agreement), and (c)&#160;the date that XYQ Luxco, in its capacity as a purchaser under the RIPSA, has received cumulative payments from DSG under the RIPSA in an aggregate amount equal to its pro rata portion of the funding amount thereunder. The Credit Agreement also contains customary events of default (subject, in certain instances, to specified grace periods) including, but not limited to, the failure to make payments of interest, premium, fees, indemnity or principal under the Term Loan, the failure to comply with certain covenants and agreements specified in the Credit Agreement, defaults in respect of certain other indebtedness and certain events relating to bankruptcy or insolvency. If any event of default occurs, the principal, premium, if any, interest and any other monetary obligations on all the then outstanding amounts under the Term Loan may become due and payable immediately. Upon the occurrence of an event of default, a default interest rate of an additional 2% per year may be applied to the outstanding principal balance, and the lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Credit Agreement. Upon the occurrence of certain bankruptcy and insolvency events, the obligations under the Credit Agreement would automatically become due and payable. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On the closing date of the Term Loan and in accordance with the Credit Agreement, DSL issued to XYQ Luxco a warrant to purchase an aggregate of 1,199,072 common shares of DSL. The warrant is exercisable at any time until the earlier of (x)&#160;seven years from the date of issuance and (y)&#160;three years from the closing of an underwritten initial public offering of DSL&#8217;s common shares pursuant to an effective registration statement. The warrant includes customary registration rights and customary anti-dilution provisions for the common shares underlying the warrant in respect of certain corporate events (including share splits, share combinations, share dividends and other recapitalization transactions). </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Immunovant </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">License Agreement with HanAll Biopharma Co., Ltd. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2017, our wholly owned subsidiary, Roivant Sciences GmbH (&#8220;RSG&#8221;), entered into a license agreement with HanAll Biopharma Co., Ltd. (&#8220;HanAll&#8221;) (the &#8220;HanAll Agreement&#8221;). Under the HanAll Agreement, RSG received <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(i)&#160;the&#160;non-exclusive&#160;right</div> to manufacture and (ii)&#160;the exclusive, royalty-bearing right to develop, import and use the antibody referred to as IMVT-1401 and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">certain&#160;back-up&#160;and</div> next-generation antibodies, and products containing such antibodies, and to commercialize such products, in the United States, </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">49 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Canada, Mexico, the E.U., the U.K., Switzerland, the Middle East, North Africa and Latin America (the &#8220;HanAll Licensed Territory&#8221;), for all human and animal uses. RSG also received the right to grant a sublicense, with prior written notice to HanAll of such sublicense, to: (i)&#160;a third-party in any country in the HanAll Licensed Territory outside of the United States and E.U.; (ii) an affiliate of RSG in any country in the HanAll Licensed Territory; and (iii)&#160;a third-party in the United States and E.U. only after submission of a biologics license application in the United States or a Marketing Authorization Application in the E.U. Pursuant to the HanAll Agreement, RSG granted to HanAll an exclusive, royalty-free license under certain RSG <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">patents,&#160;know-how&#160;and</div> other intellectual property relating to such antibodies and products to develop, manufacture and commercialize such antibodies and products for use outside of the HanAll Licensed Territory. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2018, Immunovant Sciences GmbH, (&#8220;ISG&#8221;) obtained and assumed all rights, title, interest and obligations under the HanAll Agreement from RSG, including all rights to IMVT-1401 in the HanAll Licensed Territory, for an aggregate purchase price of $37.8&#160;million. HanAll and RSG have agreed that neither they nor certain of their affiliates will clinically develop or commercialize certain competitive products in the HanAll Licensed Territory. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the HanAll Agreement, the parties may choose to collaborate on a research program directed to the research and development of next generation FcRn inhibitors in accordance with an agreed plan and budget. ISG is obligated to reimburse HanAll for half of such research and development expenses incurred by HanAll, up to an aggregate reimbursement amount of $20.0&#160;million. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the HanAll Agreement, RSG made an upfront payment of $30.0&#160;million to HanAll in December 2017. In May 2019, ISG achieved its first development and regulatory milestone, which resulted in a $10.0&#160;million milestone payment that ISG subsequently paid to HanAll in August 2019. ISG will be responsible for future contingent payments and royalties, including up to a maximum of $442.5&#160;million upon the achievement of certain development, regulatory and sales milestone events. ISG is also obligated to pay HanAll tiered royalties ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;mid-single&#160;digits</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">to&#160;mid-teens&#160;on</div> net sales of licensed products, subject to standard offsets and reductions as set forth in the HanAll Agreement. These royalty obligations apply on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;product-by-product&#160;and&#160;country-by-country&#160;basis</div></div></div></div> and end upon the latest of (i)&#160;the date on which the last valid claim of the licensed patents that cover such licensed product in such country expires, (ii)&#160;the date on which the data or market exclusivity for such licensed product in such country expires or (iii) 11 years after the first commercial sale of such licensed product in such country. The HanAll Agreement will expire on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;product-by-product&#160;basis</div></div> on the expiration of the last royalty term with respect to a given licensed product, unless earlier terminated. ISG may terminate the HanAll Agreement in its entirety without cause upon 180&#160;days&#8217; written notice following 30 days of discussion. Either party may terminate the HanAll Agreement upon 60&#160;days&#8217; written notice for uncured material breach (or 30 days in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">case&#160;of&#160;non-payment),&#160;or&#160;immediately</div> upon written notice if the other party files a voluntary petition, is subject to a substantiated involuntary petition or for certain other solvency events. HanAll may terminate the HanAll Agreement if ISG or its affiliates challenge the validity or enforceability of any of the licensed patents. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proteovant </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Michigan Research Agreement </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January 2018, our subsidiary Oncopia entered into a research agreement with the Regents of the University of Michigan (the &#8220;University of Michigan&#8221;) (the &#8220;Michigan Research Agreement&#8221;). Pursuant to the Michigan Research Agreement, Oncopia and the University of Michigan are collaborating to discover and optimize small molecule protein degraders. Any intellectual property developed under the Michigan Research Agreement that is directed to certain targets will be licensed by the University of Michigan to Oncopia pursuant to the Michigan License Agreement, as described below. Pursuant to the Michigan Research Agreement, Oncopia is obligated to provide a low eight-digit amount in funding between 2021 and 2023. Unless earlier terminated based on customary termination rights or extended by mutual agreement, the Research Agreement continues until December 2023. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">50 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Michigan License Agreement </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2020, Oncopia entered into an amended and restated patent license agreement with the University of Michigan (the &#8220;Michigan License Agreement&#8221;), pursuant to which the University of Michigan granted Oncopia an exclusive, worldwide, sublicensable license under certain patents related to certain existing small molecule protein degraders and certain future small molecule protein degraders that may be developed under the Michigan Research Agreement to make, use and commercialize certain products covered by such patents. Such license grant is subject to, among other things, certain rights required to be granted under prior research or sponsorship agreements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the Michigan License Agreement, Oncopia is obligated to pay the University of Michigan a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-to-mid</div></div> single-digit royalty on net sales of each licensed product. Oncopia&#8217;s royalty obligations apply on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product,</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country&#160;basis</div></div> and end upon the expiration of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;last-to-expire&#160;valid</div></div> claim of the licensed patents under the University of Michigan Agreement which covers such licensed product in such country. The patents and pending patent applications, if granted, currently licensed under the Michigan License Agreement are expected to expire as early as 2037, and as late as 2042, without giving effect to any potential patent term extensions or patent term adjustments. Oncopia is obligated to pay the University of Michigan minimum annual royalties in the low five-digit range from March 2021 until the first commercial sale of a licensed product, at which time such minimum annual royalties will increase to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low&#160;six-digit&#160;amount.</div> Oncopia may also be obligated to pay up to a maximum of a high seven-digit amount in development and commercial milestone payments on a per product basis. Unless earlier terminated based on customary termination rights, the term of the Michigan License Agreement will continue until the expiration of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;last-to-expire&#160;valid</div></div> claim of the licensed patents. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Genevant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cross-License Agreement with Arbutus Biopharma Corporation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In April 2018, our subsidiary, Genevant Sciences Ltd. (together with its subsidiaries, &#8220;Genevant&#8221;), entered into a cross-license agreement with our affiliate, Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;), which the parties amended twice in June 2018 (as amended, the &#8220;Arbutus Cross-License Agreement&#8221;). Pursuant to the Arbutus Cross-License Agreement Arbutus granted Genevant an exclusive, sublicensable, worldwide, transferable, irrevocable and perpetual license under certain patents <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and&#160;know-how&#160;relating</div> to Arbutus&#8217;s lipid nanoparticle and GaINAc technology <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">for&#160;RNA-based&#160;applications</div> other than hepatitis B virus (&#8220;HBV&#8221;), and certain other excluded fields. The license is subject to certain rights which have previously been licensed by Arbutus to other third parties. Under the Arbutus Cross-License Agreement, Genevant granted back to Arbutus an exclusive, sublicensable, worldwide, irrevocable, perpetual, royalty-free license under the intellectual property licensed under the Arbutus Cross-License Agreement and certain intellectual property acquired by Genevant after the effective date of the Arbutus Cross-License Agreement for applications involving the treatment and prevention of HBV. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Genevant is obligated to pay Arbutus tiered low single-digit percentage royalties on sales of products covered by the licensed patents. If Genevant sublicenses intellectual property licensed from Arbutus or collaborates with any third-party to develop, manufacture or commercialize any products covered by the intellectual property licensed by Arbutus, it will be required to pay Arbutus the lesser of (i)&#160;up to 20% of the Royalty-Related Receipts (as defined in the Arbutus Cross-License Agreement) received by Genevant from such sublicensees or collaborators and (ii)&#160;tiered low single-digit royalties on net sales by sublicensees. Genevant&#8217;s royalty obligations apply on&#160;a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product,&#160;country-by-country&#160;basis</div></div></div></div> and end on the date on which the last valid claim of the licensed patents in such country that covers such licensed product expires. The patents and pending patent applications, if granted, currently licensed under the Arbutus Cross-License Agreement are expected to expire as early as 2023, and as late as 2039, without giving effect to any potential patent term extensions or patent term adjustments. Unless earlier terminated based on customary termination rights, the Arbutus Cross-License Agreement will continue until the expiration of Genevant&#8217;s royalty obligations. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">51 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2021, Arbutus and Genevant Sciences GmbH, as an assignee of Genevant, entered into the third amendment (the &#8220;Amendment&#8221;) to the Arbutus Cross License Agreement, which, among other things, clarified the treatment of proceeds received by Genevant from an action for infringement by any third parties of Arbutus&#8217;s intellectual property licensed to Genevant. In such an infringement action, Arbutus would be entitled to receive, after deduction of litigation costs, 20% of the proceeds received by Genevant or, if less, tiered low single-digit royalties on net sales of the infringing product (inclusive of the proceeds from litigation or settlement, which would be treated as net sales). The Amendment also clarified that, if a third-party sublicensee of intellectual property licensed by Genevant from Arbutus commercializes a sublicensed product, Arbutus becomes entitled to receive a specified percentage of certain revenue that may be received by Genevant for such sublicense, including royalties, commercial milestones and other sales related revenue, or, if less, tiered low single-digit royalties on net sales of the sublicensed product. The specified percentage is 20% in the case of a mere sublicense (i.e., naked sublicense) by Genevant without additional contribution and 14% in the case of a bona fide collaboration with Genevant. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Hemavant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">License Agreement with Eisai Co. Ltd. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2021, our subsidiary, Pharmavant 7 GmbH (&#8220;Hemavant&#8221;), entered into a license agreement with Eisai Co. Ltd. (&#8220;Eisai&#8221;) (the &#8220;Eisai License Agreement&#8221;). Pursuant to the Eisai License Agreement, Eisai granted Hemavant (i)&#160;an exclusive, worldwide, sublicensable, royalty-bearing license under certain patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and (ii)&#160;a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> worldwide, sublicensable, royalty-bearing license under certain additional patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and inventions, in each case, to develop, manufacture and commercialize the compound known as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RVT-2001</div> and products incorporating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RVT-2001</div> (&#8220;licensed products&#8221;) for all human and animal uses. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Hemavant paid Eisai an upfront fee of $15.0&#160;million, consisting of (i) $8.0&#160;million in cash and (ii)&#160;newly issued Roivant Common Shares with a value of $7.0&#160;million. Hemavant may also be obligated to pay up to a maximum of $65.0&#160;million in development and regulatory milestone payments (with respect to the product for the first indication) and up to a maximum of $18.0&#160;million in payments (with respect to the product for each additional indication) and up to a maximum of $295.0&#160;million in commercial milestone payments. Hemavant may also be obligated to pay a tiered high single-digit to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-teens</div> royalty, subject to certain customary reductions, on net sales of licensed products. Hemavant&#8217;s royalty obligations apply on a licensed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-licensed</div></div> product, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> basis commencing on the first commercial sale of such licensed product in such country and ending upon the latest of (i)&#160;the date on which the last valid claim of the licensed patents that cover the licensed product in such country expires, (ii)&#160;ten years after the first commercial sale of such licensed product in such country and (iii)&#160;the date on which the regulatory exclusivity for such licensed product in such country expires. Unless earlier terminated based on customary termination rights, the Eisai License Agreement will continue in effect until it expires (i)&#160;on a licensed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-licensed</div></div> product and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> basis upon the expiration of the royalty term with respect to such licensed product in such country and (ii)&#160;in its entirety upon the expiration of all applicable royalty obligations with respect to all licensed products in all countries. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Priovant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">License and Collaboration Agreement with Pfizer, Inc. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In September 2021, our subsidiary, Priovant Therapeutics, Inc. (&#8220;Priovant&#8221;), entered into a license and collaboration agreement with Pfizer, Inc. (&#8220;Pfizer&#8221;) (the &#8220;Pfizer License Agreement&#8221;). Pursuant to the Pfizer License Agreement, Pfizer granted Priovant (i)&#160;an exclusive, worldwide, sublicensable, royalty-bearing license under certain patents and (ii)&#160;a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> worldwide, sublicensable, royalty-bearing license under certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> in each case, to develop, manufacture and commercialize Brepo and TYK2 compounds and products incorporating such compounds for all human and animal uses. In exchange for Pfizer&#8217;s inventory of these compounds, Priovant paid Pfizer $10.0&#160;million. Priovant also granted back to Pfizer (i)&#160;an exclusive, </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">52 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">sublicensable, royalty-bearing license under certain patents and (ii)&#160;a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> sublicensable, royalty-bearing license under certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> in each case, to commercialize (x)&#160;Brepo and products incorporating such compound outside of the U.S. and Japan, and (y)&#160;TYK2 compounds and products incorporating such compound outside of the U.S., in each case for all human and animal uses. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Priovant is obligated to pay Pfizer a mid tens-of-millions sales milestone payment if aggregate net sales of its licensed products in Priovant&#8217;s territory in a given year exceed a mid hundreds-of-millions amount. Pfizer is obligated to pay Priovant a low tens-of-millions milestone payment if aggregate net sales of its licensed products outside of Priovant&#8217;s territory in a given year exceed a mid hundreds-of-millions amount. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Priovant is obligated to pay Pfizer a tiered, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-teens</div> royalty, on aggregate net sales of its licensed products in Priovant&#8217;s territory. Pfizer is obligated to pay Priovant a tiered high single-digit to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-teens</div> royalty, on aggregate net sales of its licensed products outside of Priovant&#8217;s territory. Each of Priovant&#8217;s and Pfizer&#8217;s royalty obligations apply on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> basis and end upon the expiration of a customary royalty term, which is the latest of (a) a certain amount of years following the first commercial sale of the applicable products in the applicable country, (b)&#160;the date on which the regulatory exclusivity provided by the applicable government authority for the applicable products in that country expires and (c)&#160;the date upon which the use, sale, offer for sale or importation of such product in such country would no longer be covered by a valid claim of a licensed product right. Either party may terminate for the other party&#8217;s uncured breach and Priovant has the right to terminate for convenience. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual Property </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for current and future products and product candidates, technologies <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and&#160;know-how;&#160;to</div> operate without infringing, misappropriating or otherwise violating the proprietary rights of others; and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, filing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">or&#160;in-licensing&#160;U.S.</div> and foreign patents and patent applications related to our proprietary technology, inventions and improvements that are important to the development and implementation of our business. We may also rely on trade <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">secrets,&#160;know-how,&#160;continuing</div> technological innovation and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">potential&#160;in-licensing&#160;opportunities</div> to develop and maintain our proprietary position. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The patent positions of companies like us are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the fields of genetic therapy, cell therapy, biologics or pharmaceutical products generally has emerged in the United States or in Europe, among other countries. Changes in the patent laws and rules, either by legislation, judicial decisions, or regulatory interpretation in other countries may diminish our ability to protect our inventions and enforce our intellectual property rights, and more generally could affect the value of our intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell, importing or otherwise commercializing any of our patented inventions, either directly or indirectly, will depend in part on our success in obtaining, defending and enforcing patent claims that cover our technology, inventions, and improvements. We cannot be sure that any patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our product candidates and technology. Moreover, our issued patents and those that may issue in the future may not guarantee us the right to practice our technology in relation to the commercialization of our product candidates or technology. The area of patents and other intellectual property rights in biotechnology is an evolving one with many risks and uncertainties, which may prevent us from commercializing our current and future products and product candidates and practicing our proprietary technology. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our issued patents and those that may issue in the future may be challenged, narrowed, circumvented or invalidated, which could limit our ability to stop competitors from marketing related products or technologies </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">53 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">or limit the length of the term of patent protection that we may have for our current and future products and product candidates and technologies. In addition, the rights granted under any issued patents may not provide us with complete protection or competitive advantages against competitors or other third parties with similar technology. Furthermore, our competitors may independently develop similar technologies that achieve similar outcomes but with different approaches. For these reasons, we may have competition for our product candidates. Moreover, the time required for development, testing and regulatory review of our product candidates may shorten the length of effective patent protection following commercialization. For this and other risks related to our proprietary technology, inventions, improvements, platforms and product candidates, please see the section entitled &#8220;Risk&#160;Factors&#8212;Risks Related to Roivant&#8217;s Business and Industry&#8212;Risks Related to Our Intellectual Property.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patents and Patent Applications </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of May&#160;1, 2022, DSG is the exclusive owner of patent families that include six issued U.S. patents and at least 10 pending U.S. patent applications, as well as more than 25 issued patents and more than 50 pending patent applications in other jurisdictions, including the European Union and Japan, relating to VTAMA, the synthesis of VTAMA, intermediates made in the synthesis, the drug substance crystal form, topical formulations of VTAMA and uses thereof in certain diseases and disorders. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">One of these patent families is directed to the topical formulation of VTAMA, and its use to treat plaque psoriasis, that Dermavant has evaluated in Phase 3 clinical trials, as well as its use to treat atopic dermatitis which has been evaluated in Phase 2b clinical trials, which includes a patent that was issued in the United States and has a natural expiration date in 2036, without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. This formulation patent includes 113 claims directed to topical, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">homogeneous,&#160;oil-in-water&#160;micro-emulsions</div></div> containing VTAMA, an oil phase, a surfactant and other specific ingredients. DSG also owns an issued patent in the United States covering methods of using the patented formulations to treat inflammatory diseases, including psoriasis and atopic dermatitis. Like the formulation patent, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;method-of-use&#160;patent</div></div> has a natural expiration date in 2036 in the United States, without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. The foreign counterpart formulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and&#160;method-of-use&#160;applications</div></div> are pending, and if patents issue from these applications, they will also have a natural expiration date in 2036, without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DSG also owns a drug substance (&#8220;DS&#8221;) patent in the United States covering the high purity crystal form of VTAMA, as DS, the DS synthesis and several novel intermediates that are formed in the synthesis. This DS patent has a natural expiration date in 2038, without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. DSG has also filed foreign counterpart DS applications that are still pending in foreign jurisdictions and, if patents issue from these applications, they will similarly have a natural expiration date in 2038, without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">IMVT-1401 </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Following ISG&#8217;s assumption of all rights, title, interest and obligations under the HanAll Agreement from&#160;RSG in December 2018, by virtue of the license of patent rights under the HanAll Agreement, ISG is the exclusive licensee of technology directed to IMVT-1401, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">certain&#160;back-up&#160;and</div> next-generation antibodies, and products containing such antibodies, in the licensed territory. As of May&#160;1, 2022, the patent portfolio </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">54 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">includes pending patent applications and/or issued patent(s) in the United States and numerous foreign jurisdictions. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">The&#160;in-licensed&#160;patent</div> portfolio includes a patent family that discloses anti-FcRn antibodies, pharmaceutical compositions thereof, methods of treating autoimmune disease using the same, polynucleotides encoding such antibodies, expression vectors including such polynucleotides, host cells transfected with such recombinant expression vectors, methods of manufacturing such antibodies and methods of detecting FcRn in vivo or in vitro using such antibodies. This patent family includes an issued U.S. patent with claims directed to an isolated anti-FcRn antibody or antigen-binding fragment thereof, and a pharmaceutical composition comprising such antibody or antigen-binding fragment thereof as well as a second issued U.S. patent with claims directed to an isolated anti-FcRn antibody or antigen-binding fragment thereof, a pharmaceutical composition thereof as well as methods of treating various autoimmune diseases using such antibody or antigen-binding fragment, polynucleotides and expression vectors encoding the same, host cells capable of expressing the same and methods of producing such antibody or antigen-binding fragment. The patents and pending applications of this patent family, if issued, are expected to expire as early as 2035, in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. In addition, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patent portfolio includes another patent family that discloses a formulation for an anti-FcRn antibody with any patent issued therefrom expected to expire in 2041. For information regarding ISG&#8217;s license agreement with HanAll, please see &#8220;&#8212;Asset Acquisitions and License Arrangements.&#8221; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, as of May&#160;1, 2022, independent of the licensed patent portfolio, ISG has a patent family directed to methods of treating thyroid eye disease using anti-FcRn antibodies that includes patent applications in the United States as well as foreign counterparts in certain jurisdictions within its licensed territory and another patent family that includes an internationally filed patent application directed to methods of treating warm autoimmune hemolytic anemia using anti-FcRn antibodies. Any patent issued from these patent families is expected to expire in 2039 and 2040, respectively, exclusive of any patent term adjustment or extension. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proteovant </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As of May&#160;1, 2022, we own, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-own</div> or have licensed rights to 28 patent families containing four issued U.S. patents, two issued European patents, 26 patents in a number of other jurisdictions and containing at least 80 pending patent applications in the U.S., Europe and a number of other jurisdictions. These patents and pending applications, if issued, are expected to expire as early as 2037, without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Genevant </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As of May&#160;1, 2022, we own <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">or&#160;co-own&#160;18</div> patent families containing at least 44 issued patents and at least 64 pending patent applications in the U.S., European Union and numerous other jurisdictions, including claims relating to lipid nanoparticle delivery technology and polymers. These patents and pending applications, if issued, are expected to expire between 2024 and 2041, in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of May&#160;1, 2022, we have licensed 37 patent families containing at least 479 issued patents and at least 217 pending patent applications in the U.S., European Union and numerous other jurisdictions, including claims relating to delivery systems. These patents and pending applications, if issued, are expected to expire between 2021 and 2039,&#160;in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Hemavant </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of May&#160;1, 2022, Hemavant has exclusively licensed rights to four patent families containing at least 87 issued patents and 27 pending patent applications in the U.S. and other jurisdictions, including the European </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">55 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Union and Japan, with claims covering a composition of matter, a polymorph, methods of treating MDS, and biomarkers for MDS. These exclusively licensed patents and pending applications, if issued, are expected to expire as early as 2037, in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of May&#160;1, 2022 Hemavant has <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusively</div> licensed rights to three patent families containing at least 12 issued patents and 28 pending patent applications in the U.S. and other jurisdictions with claims covering methods of treating splice mutant cancers, spliceosome mutations, and combinations of a spliceosome modulator and a BCL inhibitor. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusively</div> licensed patents and pending applications, if issued, are expected to expire as early as 2037, in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Priovant </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of May&#160;1, 2022, Priovant Therapeutics, Inc. has (1)&#160;exclusively licensed rights to four patent families for brepocitinib containing at least 149 issued patents and 77 pending patent applications in the U.S. and other jurisdictions, including the European Union and Japan, with claims covering a composition of matter, a crystalline form, a topical formulation, and a process for making brepocitinib.&#160;These patents and pending applications, if issued, are expected to expire as early as 2035, in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees, and (2)&#160;exclusively licensed rights to four patent families for brepocitinib containing at least 105 issued patents and 65 pending patent applications in the U.S. and other jurisdictions, including the European Union and Japan, with claims covering a composition of matter, a method of treating hidradenitis, a method of treating ulcerative colitis, and a crystalline form.&#160;These patents and pending applications, if issued, are expected to expire as early as 2037, in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade Secrets </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition to our reliance on patent protection for our inventions, product candidates and research programs, we also rely on trade <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">secrets,&#160;know-how,&#160;continuing</div> technological innovation and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">potential&#160;in-licensing&#160;opportunities</div> to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality and invention assignment agreements with our commercial partners, collaborators, employees and consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with an employee or a third-party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors or other third parties. As a result, we may not be able to meaningfully protect our trade secrets. For more information regarding the risks related to our intellectual property, see &#8220;Risk&#160;Factors&#8212;Risks Related to Roivant&#8217;s Business and Industry&#8212;Risks Related to Our Intellectual Property.&#8221; </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government Regulation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research, development, manufacture, testing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products, as well as diagnostics, and any future product candidates. Generally, before a new drug, biologic or diagnostic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved, authorized, or cleared by the applicable regulatory authority. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">56 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. Government Regulation of Drug and Biological Products </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act (the &#8220;FDCA&#8221;) and its implementing regulations and biologics under the FDCA and the Public Health Service Act (the &#8220;PHSA&#8221;), and their implementing regulations. Both drugs and biologics also are subject to other federal, state and local statutes and regulations, such as those related to competition. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or following approval may subject an applicant to administrative actions or judicial sanctions. These actions and sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold, untitled or warning letters, voluntary or mandatory product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, debarment from producing or marketing drug products or biologics, disqualification from conducting research, and civil or criminal fines or penalties. Any agency or judicial enforcement action could have a material adverse effect on our business, the market acceptance of our products and our reputation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our product candidates must be approved by the FDA through either an NDA or a BLA (as defined below) process before they may be legally marketed in the United States. The process generally involves the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with GLP requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approval by an IRB, or independent ethics committee at each clinical trial site before each human trial may be initiated; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations and requirements, GCP requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">submission to the FDA of an NDA or BLA; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a determination by the FDA within 60 days of its receipt of an NDA or BLA to accept the filing for review; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">satisfactory completion of one or more <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA&#160;pre-approval&#160;inspections</div> of the manufacturing facility or facilities where the drug or biologic will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug or biologic&#8217;s identity, strength, quality and purity; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">potential FDA inspection of the clinical trial sites that generated the data in support of the NDA or BLA and/or us as the sponsor; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">payment of user fees for FDA review of the NDA or BLA (unless a fee waiver applies); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">agreement with FDA on the final labeling for the product and the design and implementation of any required REMS; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FDA review and approval of the NDA or BLA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug or biologic in the United&#160;States. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and the regulatory scheme for drugs and biologics is evolving and subject to change at any time. We cannot be certain that any approvals for our product candidates will be granted on a timely basis, or at all. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">57 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preclinical Studies </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Before testing any drug or biological product candidate in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as in vitro and animal studies to assess safety and in some cases to establish a rationale for therapeutic use. In the U.S., the conduct of preclinical studies is subject to federal and state regulations and requirements, including GLP regulations for nonclinical (e.g., safety/toxicology) studies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the U.S., an IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans, and must become effective before human clinical trials may begin. Some long-term preclinical testing, such as animal tests of reproductive AEs and carcinogenicity, may continue, and additional preclinical testing may commence, after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. Additionally, the review of information in an IND submission may prompt FDA to, among other things, scrutinize existing INDs or marketed products and could generate requests for information or clinical holds on other product candidates or programs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Trials </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. In the U.S., each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Information about certain clinical trials, including clinical trial results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA or BLA. The FDA will accept a well-designed and well-conducted foreign clinical study not conducted under an IND if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical trials generally are conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3, and may overlap or be combined. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, side effect tolerability and safety of the product candidate. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">58 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 2 clinical trials involve studies in disease-affected patients to evaluate proof of concept and/or determine the dose required to produce the desired benefits. At the same time, safety and further PK and PD information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy is conducted. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product labeling. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In March 2022, the FDA finalized a guidance entitled &#8220;Expansion Cohorts: Use <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in&#160;First-In-Human</div></div> Clinical Trials to Expedite Development of Oncology Drugs and Biologics,&#8221; the draft of which was released in August 2018. This final guidance outlines how drug developers can utilize an adaptive trial design commonly referred to as a seamless trial design in early stages of oncology drug development, i.e., <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;first-in-human</div></div> clinical trial, to compress early phases of trials into one continuous trial called an expansion cohort trial. Information to support the design of individual expansion cohorts are included in IND applications and assessed by FDA. Expansion cohort trials can potentially bring efficiency to drug development and reduce developmental costs and time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA or BLA or post-approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators 15&#160;days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected AEs, findings from other studies or animal or in vitro testing that suggest a significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than seven calendar days after the sponsor&#8217;s initial receipt of the information. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 1, Phase 2, Phase 3 and other types of clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated check points based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidates do not undergo unacceptable deterioration over their shelf life. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">59 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">FDA Review Process </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following completion of the clinical trials, data are analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of an NDA or BLA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. The NDA or BLA is a request for approval to market the drug or biologic for one or more specified indications and must contain proof of safety and efficacy for a drug or safety, purity and potency for a biologic. The application may include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of FDA. FDA approval of an NDA or BLA must be obtained before a drug or biologic may be marketed in the United States. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the Prescription Drug User Fee Act (the &#8220;PDUFA&#8221;), as amended, each NDA or BLA must be accompanied by a user fee. FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs or BLAs for products designated as orphan drugs, unless the product also includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;non-orphan&#160;indication.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The FDA reviews all submitted NDAs and BLAs before it accepts them for filing, and may request additional information rather than accepting the NDA or BLA for filing. The FDA must make a decision on accepting an NDA or BLA for filing within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is accepted for filing, the FDA begins <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">an&#160;in-depth&#160;review</div> of the NDA or BLA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA targets ten months, from the filing date, in which to complete its initial review of a new molecular entity NDA or original BLA and respond to the applicant, and six months from the filing date of a new molecular entity NDA or original BLA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs or BLAs, and the review process is often extended by FDA requests for additional information or clarification. During <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19&#160;pandemic,</div> because of travel and other restrictions, the FDA has significantly curtailed its inspection program. The reduction <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in&#160;pre-approval&#160;inspections</div> has resulted in delays to some product approvals. Even with the increase in FDA inspections, there may be delays to product approvals in the future based on a resurgence of problems with respect to the FDA&#8217;s ability to conduct inspections and then, even after a complete resumption of the FDA&#8217;s normal inspection program, a possible backlog in applications under review by the agency. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA has developed the Oncology Center of Excellence RTOR pilot program to facilitate a more efficient review process for certain oncology product candidates. Although this program allows FDA to begin reviewing clinical data prior to submission of a complete NDA or BLA, the program is not intended to change the PDUFA review timelines. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Before approving an NDA or BLA, the FDA will typically conduct <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;pre-approval&#160;inspection</div> of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel products or products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">60 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">which could result in extensive discussions between the FDA and the applicant during the review process. After the FDA evaluates an NDA or BLA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug or biologic with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the NDA or BLA identified by the FDA. The Complete Response Letter may require the applicant to obtain additional clinical data, including the potential requirement to conduct additional pivotal Phase 3 clinical trial(s) and/or to complete other significant and time-consuming requirements related to clinical trials, or to conduct additional preclinical studies or manufacturing activities. If a Complete Response Letter is issued, the applicant may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application or request an opportunity for a hearing. Even if such data and information are submitted, the FDA may decide that the NDA or BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Orphan Drug Designation and Exclusivity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication but that could be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">used&#160;off-label&#160;in</div> the orphan indication. Orphan drug exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if our product is determined to be contained within the scope of the competitor&#8217;s product for the same indication or disease. If we pursue marketing approval for an indication broader than the orphan drug designation we have received, we may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rare Pediatric Disease Designation and Priority Review Vouchers </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the FDCA, as amended, the FDA incentivizes the development of drugs and biologics that meet the definition of a &#8220;rare pediatric disease,&#8221; defined to mean a serious or life-threatening disease in which the serious of life-threatening manifestations primarily affect individuals aged from birth to 18 years and the disease affects fewer than 200,000 individuals in the United States or affects more than 200,000 in the United States and for which there is no reasonable expectation that the cost of developing and making in the United States a drug for such disease or condition will be received from sales in the United States of such drug. The sponsor of a product candidate for a rare pediatric disease may be eligible for a voucher that can be used to obtain a priority review for </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">61 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a subsequent human drug or biologic application after the date of approval of the rare pediatric disease drug product, referred to as a priority review voucher (a &#8220;PRV&#8221;). A sponsor may request rare pediatric disease designation from the FDA prior to the submission of its NDA or BLA. A rare pediatric disease designation does not guarantee that a sponsor will receive a PRV upon approval of its NDA or BLA. Moreover, a sponsor who chooses not to submit a rare pediatric disease designation request may nonetheless receive a PRV upon approval of their marketing application if they request such a voucher in their original marketing application and meet all of the eligibility criteria. If a PRV is received, it may be sold or transferred an unlimited number of times. Congress has extended the PRV program through September&#160;30, 2024, with the potential for PRVs to be granted through September&#160;30, 2026. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expedited Development and Review Programs </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A sponsor may seek to develop and obtain approval of its product candidates under programs designed to accelerate the development, FDA review and approval of new drugs and biologics that meet certain criteria. For example, the FDA has a fast-track program that is intended to expedite or facilitate the process for reviewing new drugs and biologics that are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to both the product and the specific indication for which it is being studied. For a fast track-designated product, the FDA may consider sections of the NDA or BLA for review on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application. The sponsor can request the FDA to designate the product for fast-track status any time before receiving NDA or BLA approval, but ideally no later than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;pre-NDA&#160;or&#160;pre-BLA&#160;meeting.</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A product submitted to the FDA for marketing, including under a fast-track program, may be eligible for other types of FDA programs intended to expedite development or review, such as priority review and accelerated approval. Priority review means that, for an NDA for a new molecular entity or original BLA, the FDA sets a target date for FDA action on the marketing application at six months after accepting the application for filing as opposed to ten months. A product is eligible for priority review if it is designed to treat a serious or life-threatening disease condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biologic designated for priority review in an effort to facilitate the review. If criteria are not met for priority review, the NDA for a new molecular entity or original BLA is subject to the standard FDA review period of ten months after FDA accepts the application for filing. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A product may also be eligible for accelerated approval if it is designed to treat a serious or life-threatening disease or condition, generally provides a meaningful advantage over other available therapies, and demonstrates an effect on either a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (&#8220;IMM&#8221;), that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the disease or condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">approval&#160;pre-approval&#160;of</div> promotional materials, which could adversely impact the timing of the commercial launch of the product. FDA may withdraw approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, a drug or biologic may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">62 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If the FDA designates a breakthrough therapy, it may take actions appropriate to expedite the development and review of the application, which may include holding meetings with the sponsor and the review team throughout the development of the therapy; providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable; involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate, which may result in smaller trials or more efficient trials that require less time to complete and may minimize the number of patients exposed to a potentially less efficacious treatment. Breakthrough therapy designation comes with all of the benefits of fast-track designation, which means that the sponsor may file sections of the NDA or BLA for review on a rolling basis if certain conditions are satisfied, including an agreement with the FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA has also announced the availability of the RTOR pilot program for oncology product candidates that are likely to demonstrate substantial improvements over available therapy, which may include drugs previously granted breakthrough therapy designation for the same or other indications and candidates meeting other criteria for other expedited programs, such as fast track and priority review. Submissions for RTOR consideration should also have straightforward study designs and endpoints that can be easily interpreted (such as overall survival or progression free survival). Acceptance into the RTOR pilot does not guarantee or influence approvability of the application, which is subject to the usual benefit-risk evaluation by FDA reviewers, but the program allows FDA to review data earlier, before an applicant formally submits a complete application. The RTOR pilot program does not affect FDA&#8217;s PDUFA timelines. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, priority review, accelerated approval, breakthrough therapy and RMAT designation do not change the standards for approval. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pediatric Information and Pediatric Exclusivity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Under the Pediatric Research Equity Act (the &#8220;PREA&#8221;), certain NDAs and BLAs and certain supplements to an NDA or BLA must contain data to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. The Food and Drug Administration Safety and Innovation Act (the &#8220;FDASIA&#8221;), amended the FDCA to require that a sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan (&#8220;PSP&#8221;), within 60 days of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">an&#160;end-of-Phase&#160;2</div></div> meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">63 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">A drug or biologic product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">This&#160;six-month&#160;exclusivity,</div> which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">an&#160;FDA-issued&#160;&#8220;Written</div> Request&#8221; for such a study. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Post-Marketing Requirements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Following approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and record-keeping activities, reporting of adverse experiences and certain problems in the manufacturing process, complying with promotion and advertising requirements, which include restrictions on promoting products for unapproved uses or patient populations (known <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as&#160;&#8220;off-label&#160;use&#8221;)</div> and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available products <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">for&#160;off-label&#160;uses,</div> manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">of&#160;off-label&#160;uses</div> and any promotion that is false or misleading, and a company that is found to have improperly <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">promoted&#160;off-label&#160;uses</div> or in a false or misleading manner may be subject to significant liability, including investigation by federal and state authorities. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use or first publication. Further, if there are any modifications to the drug or biologic, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA/BLA or NDA/BLA supplement, which may require the development of additional data or preclinical studies and clinical trials. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The FDA may also place other conditions on approvals including the requirement for a REMS, to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS. The FDA will not approve the NDA or BLA without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">for&#160;non-compliance&#160;with</div> regulatory standards or if problems occur following initial marketing. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP regulations. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations that require, among other things, quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved drugs or biologics are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. The discovery of violative conditions, including failure to conform to cGMP regulations, could result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved NDA or BLA, including recall. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once an approval is granted, the FDA may issue enforcement letters or withdraw the approval of the product if compliance with regulatory requirements and standards is not maintained or if problems occur after the drug or biologic reaches the market. Corrective action could delay drug or biologic distribution and require significant time and financial expenditures. Later discovery of previously unknown problems with a drug or biologic, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">64 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restrictions on the marketing or manufacturing of the drug or biologic, suspension of the approval, complete withdrawal of the drug from the market or product recalls; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fines, warning letters or holds on post-approval clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal of the FDA to approve applications or supplements to approved applications, or suspension or revocation of drug or biologic approvals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">drug or biologic seizure or detention, or refusal to permit the import or export of drugs; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">injunctions or the imposition of civil or criminal penalties; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">debarment from producing or marketing drug products or biologics. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Regulation of Companion Diagnostics </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Success of certain product candidates may depend, in part, on the development and commercialization of a companion diagnostic. A companion diagnostic is a medical device, often an<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;in vitro</div></div>&#160;device, which provides information that is essential for the safe and effective use of a corresponding drug or biological product. Companion diagnostics can identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. Companion diagnostics are generally regulated as medical devices by the FDA. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption or FDA exercise of enforcement discretion applies, diagnostic tests generally require marketing clearance through the premarket notification process (&#8220;510(k) clearance&#8221;) or premarket approval from the FDA prior to commercialization. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To obtain 510(k) clearance for a medical device, or for certain modifications to devices that have received 510(k) clearance, a manufacturer must submit a premarket notification demonstrating that the proposed device is substantially equivalent to a previously cleared 510(k) device or to a preamendment device that was in commercial distribution before May&#160;28, 1976, or other predicate devices, for which the FDA has not yet called for the submission of a premarket approval application (&#8220;PMA&#8221;). In making a determination that the device is substantially equivalent to a predicate device, the FDA compares the proposed device to the predicate device or predicate devices and assesses whether the subject device is comparable to the predicate device or predicate devices with respect to intended use, technology, design and other features which could affect safety and effectiveness. If the FDA determines that the subject device is substantially equivalent to the predicate device or predicate devices, the subject device may be cleared for marketing. The 510(k) premarket notification pathway generally takes from three to twelve months from the date the application is completed, but can take significantly longer. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">PMA applications must be supported by valid scientific evidence, which typically requires extensive data, including technical, preclinical, clinical and manufacturing data, to demonstrate to the FDA&#8217;s satisfaction the safety and effectiveness of the device. For diagnostic tests, a PMA, typically includes data regarding analytical and clinical validation studies. As part of its review of the PMA, the FDA will typically conduct <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;pre-approval&#160;inspection</div> of the manufacturing facility or facilities to ensure compliance with the Quality System Regulation (the &#8220;QSR&#8221;), which requires manufacturers to follow design, testing, control, corrective and </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">65 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">preventative action, documentation, and other quality assurance procedures. The FDA&#8217;s review of an initial PMA application is generally required by statute to take six months, although the process typically takes longer, and may require several years to complete. If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA. If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny the approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. Once granted, PMA approval may be withdrawn by the FDA if compliance with post-approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing. Once cleared or approved, the companion diagnostic device must adhere to post-marketing requirements including the requirements of FDA&#8217;s quality system regulation, adverse event reporting, recalls and corrections along with product marketing requirements and limitations. Like drug and biologic makers, companion diagnostic makers are subject to unannounced FDA inspections at any time during which the FDA is able to conduct an inspection of the product(s) and the company&#8217;s facilities for compliance with its authorities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">FDA has taken the position that developers of companion diagnostic tests associated with novel therapeutic products should seek clearance or approval at the same time that the therapeutic developer seeks approval. FDA has recognized that contemporaneous clearance or approval of a companion diagnostic with a therapeutic is not always possible, though FDA has indicated that coordination of contemporaneous clearances/approvals is a policy goal. In October 2018, FDA issued a safety alert warning against the use of unapproved or uncleared genetic tests to predict patient response to specific medications. While FDA has historically exercised enforcement discretion against laboratory developed tests&#8212;tests which are developed and performed in a single Clinical Laboratory Improvement Amendments (&#8220;CLIA&#8221;) certified laboratory&#8212;the 2018 alert and a subsequent 2019 Warning Letter against Inova Genomics Laboratory suggest that FDA may prioritize for enforcement certain uncleared or unapproved tests marketed as companion diagnostic tests. Subsequently, FDA has attempted to encourage collaboration between<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;in vitro</div></div>&#160;diagnostic test developers and therapeutic developers and to clarify FDA expectations as to companion diagnostic labeling, particularly through guidance in the oncology area. In June 2021, the Verifying Accurate Leading-edge IVCT Development Act of 2021 (the &#8220;VALID Act&#8221;) was introduced in the U.S. House of Representatives and Senate. Similar to the 2020 iteration of the bill, among other things, the VALID Act would likely classify all companion diagnostic tests as requiring FDA premarket review and would formalize and arguably expand FDA&#8217;s regulatory authority over diagnostic testing. Though passage of the VALID Act is uncertain, strong bipartisan support remains for some kind of diagnostic testing legislative reform in the near term. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Biosimilars and Exclusivity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Certain of our product candidates, including IMVT-1401,&#160;are regulated as biologics. An abbreviated approval pathway for biological products shown to be similar to, or interchangeable with, an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-licensed</div> reference biological product was created by the Biologics Price Competition and Innovation Act of 2009 (the &#8220;BPCI Act&#8221;), as part of the Affordable Care Act (the &#8220;ACA&#8221;). This amendment to the PHSA, in part, attempts to minimize duplicative testing. Biosimilarity, which requires that the biological product be highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch. Complexities associated with the larger, and often more complex, structure of biological products as compared to small molecule drugs, </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">66 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">as well as the processes by which such products are manufactured, pose significant hurdles to implementation that are still being worked out by the FDA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A reference biological product is granted four and twelve year exclusivity periods from the time of first licensure of the product. The FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product, and the FDA will not approve an application for a biosimilar or interchangeable product based on the reference biological product until twelve years after the date of first licensure of the reference product. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity, or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity, or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#8220;first licensure&#8221; of a biological product is determined on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;case-by-case&#160;basis</div></div> with data submitted by the sponsor. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Regulatory Matters </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, including the Centers for Medicare and Medicaid Services (the &#8220;CMS&#8221;), the Office of Inspector General and Office for Civil Rights, other divisions of the Department of HHS, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&#160;&amp; Health Administration, the Environmental Protection Agency and state and local governments. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Healthcare providers, physicians, and third-party payors will play a primary role in making clinically-appropriate decisions enabling patient access to any products for which we obtain marketing approval. Our current and future arrangements with healthcare providers and physicians and any future arrangements with third-party payers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any drugs for which we obtain marketing approval. In the United States, these laws include: the federal Anti-Kickback Statute, the False Claims Act, and HIPAA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration, directly or indirectly, in cash or in kind, that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by imprisonment, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Drug manufacturers can be held liable under the federal civil False Claims Act, which imposes civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities (including manufacturers) for, among other things, knowingly presenting, or causing to be presented to federal programs </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">67 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">(including Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. Penalties for a False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties for each separate false claim; the potential for exclusion from participation in federal healthcare programs, which would preclude reimbursement of our products under the Medicare and Medicaid programs; and, although the federal False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. The government may deem manufacturers to have &#8220;caused&#8221; the submission of false or fraudulent claims by, for example, providing certain billing or coding information to customers or promoting a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product&#160;off-label.&#160;Claims</div> which include items or services resulting from a violation of the federal Anti-Kickback Statute are false or fraudulent claims for purposes of the False Claims Act. Our future marketing and activities relating to federal, state, and commercial reimbursement for our products, and the sale and marketing of our product candidates, are subject to scrutiny under this law. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HIPAA created federal criminal statutes that prohibit among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the federal Anti-Kickback Statute a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to data privacy and security regulations administered and enforced by the federal government as well as statutes and regulations adopted in the states in which we conduct our business. At the federal level, the FDA regulations for the protection of human research subjects require that we protect the privacy of personal information and obtain appropriate informed consent in connection with research using identifiable subject information or identifiable biological samples. In addition, the data privacy and security regulations implementing HIPAA impose strict limitations on the use and disclosure of individually identifiable health information, including for research purposes. Civil and criminal penalties may be imposed on entities subject to HIPAA, both by the HHS Office for Civil Rights and by state attorneys general, who have the authority to file civil actions for damages or injunctions in federal courts to enforce the HIPAA privacy and security regulations and to seek attorney&#8217;s fees and costs associated with pursuing such actions. In addition, the Federal Trade Commission has broad authority to investigate and initiate enforcement actions regarding any activity affecting the privacy or security of personal information that it deems deceptive or unfair. At the state level, a rapidly growing body of privacy and data protection laws impose requirements and restrictions, some of which are more stringent than federal law and many of which differ from each other in significant ways, thus complicating compliance efforts. Failure to comply with these laws can result in the imposition of significant civil and criminal penalties. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, the federal Physician Payments Sunshine Act (the &#8220;Sunshine Act&#8221;), within the ACA, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, physicians, certain other healthcare professionals, and teaching hospitals and to report annually certain ownership and investment interests held by physicians, certain other healthcare professionals, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">68 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">and their immediate family members. Effective January&#160;1, 2022, these reporting obligations were extended to include transfers of value made to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">certain&#160;non-physician&#160;providers</div> such as physician assistants and nurse practitioners. In addition, many states also govern the reporting of payments or other transfers of value, many of which differ from each other in significant ways, are often not preempted, and may have a more prohibitive effect than the Sunshine Act, thus further complicating compliance efforts. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Similar federal, state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services. Such laws are generally broad and are enforced by various state agencies and private actions. Also, many states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant federal government compliance guidance, and require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, individual imprisonment, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from the business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Current and Future Legislation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States and some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">69 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For example, in March 2010, the ACA was enacted in the United States. The ACA includes measures that have significantly changed, and are expected to continue to significantly change, the way healthcare is financed by both governmental and private insurers. Among the changes made by the ACA to preexisting law of importance to the pharmaceutical industry are that the ACA: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#8217; rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs to 23.1% of average manufacturer price (&#8220;AMP&#8221;), and adding a new rebate calculation for &#8220;line extensions&#8221; (i.e., new formulations, such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability by modifying the statutory definition of AMP. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">imposed a requirement on manufacturers of branded drugs to provide a 70% (increased pursuant to the Bipartisan Budget Act of 2018, effective as of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019)&#160;point-of-sale&#160;discount</div></div> off the negotiated price of branded drugs dispensed to Medicare Part D beneficiaries in the coverage gap (i.e., &#8220;donut hole&#8221;) as a condition for a manufacturer&#8217;s outpatient drugs being covered under Medicare Part D. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">extended a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expanded the entities eligible for discounts under the 340B Drug Discount Program. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">established a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">imposed an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs, apportioned among these entities according to their market share in certain government healthcare programs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. The research conducted by the Patient-Centered Outcomes Research Institute may affect the market for certain pharmaceutical products. The ACA established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. Most recently, the Supreme Court upheld the constitutionality of the law in June 2021; however, future legal disputes remain possible. Additionally, Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA, and the law may be subjected to various Executive Orders and/or regulatory action to expand or reduce the scope of the law, based on the administration controlling the White House. The implementation of the ACA is ongoing, and the law may continue to exert significant pressure on pharmaceutical pricing and our profitability. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Moreover, in May 2018, the Trump administration released its &#8220;Blueprint to Lower Drug Prices and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Reduce&#160;Out-of-Pocket&#160;Costs,&#8221;</div></div> or the Blueprint, and former President Trump also issued a number of Executive Orders in 2020 that were aimed at lowering the prices of prescription drugs. Some rules enacted under the Trump Administration have been stayed as a result of pending litigation or are under review or have been rescinded by the Biden Administration and/or Congress. For example, a rule enacted under the Trump Administration known as the &#8220;Most Favored Nations&#8221; rule would set Medicare Part B reimbursement at an amount no higher than the lowest price that a drug manufacturer receives on a particular product in an index of foreign countries. This rule currently was the subject of litigation, and was formally rescinded the Biden Administration in August 2021. Other initiatives under the Trump administration have taken effect. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a form of drug utilization management, for Part B drugs beginning January&#160;1, 2020. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">70 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect in April 2013, following passage of the Bipartisan Budget Act of 2013, and will remain in effect through 2029 unless additional congressional action is taken. However, pursuant to the CARES Act and subsequent legislation, these reductions were suspended starting on May&#160;1, 2020 due to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19&#160;pandemic.</div> Recently enacted legislation extended the suspension through March 2022, with a 1% cut through the end of June 2022, after which the cuts would return to 2%unless additional Congressional action is taken. Additionally, the American Rescue Plan Act of 2021 eliminates the Medicaid unit rebate cap effective as of January&#160;1, 2024, and the removal of this rebate cap could significantly impact our Medicaid rebate liability beginning in 2024. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There also have been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, require drug pricing negotiations in Medicare, redesign the Part D benefit to lower patient costs and overall spending, introduce enhanced transparency measures into drug pricing, and reform government program reimbursement methodologies for drugs, for example, by introducing inflationary penalties for Parts B and D drugs. The Biden Administration has indicated that lowering prescription drug prices is a priority. In July 2021, President Biden issued an executive order pertaining to drug pricing, which expressed support for legislation allowing direct negotiation in Medicare Part D and inflationary rebates, and directed various executive branch agencies to take actions to lower drug prices and promote generic competition. Additionally, on November&#160;19, 2021, the House passed the Build Back Better Act, which among other provisions, would permit the Secretary of HHS to negotiate certain high-expenditure Part D drugs, impose inflationary rebates for Part D drugs, and redesign the Part D benefit. The Senate Finance Committee introduced a modified version of the legislation on December&#160;11, 2021, but negotiations have since stalled. Although the House and Senate versions of this legislation would grant certain exceptions for &#8220;small biotech drugs&#8221; and &#8220;specified small manufacturers,&#8221; if passed, we cannot predict how these exceptions would be implemented and their impact on Roivant. Ultimately, we cannot predict whether these or other drug pricing initiatives will be adopted in the future. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. Reforms could have an adverse effect on anticipated revenues from product candidates and may affect our overall financial condition and ability to develop product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biotherapeutic product pricing, including restrictions on pricing or reimbursement at the state government level, limitations on discounts to patients, marketing cost disclosure and transparency measures, and, in some cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing, including the National Medicaid Pooling Initiative. In particular, the obligation to provide notices of price increases to purchasers under laws such as California&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SB-17</div> may influence customer ordering patterns for our products, which in turn may increase the volatility of our revenues as a reflection of changes in inventory volumes. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Packaging and Distribution in the United States </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If our products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">71 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, exclusion from federal healthcare programs, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements; (ii)&#160;additions or modifications to product labeling; (iii)&#160;the recall or discontinuation of our products; or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other U.S. Environmental, Health and Safety Laws and Regulations </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may be subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. Patent Term Restoration and Marketing Exclusivity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Depending upon the timing, duration and specifics of FDA approval of our future product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit restoration of the patent term of up to five years as compensation for patent term lost during the FDA regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. The patent-term restoration period is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">generally&#160;one-half&#160;the</div> time between the effective date of an IND and the submission date of an NDA or BLA plus the time between the submission date of an NDA or BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">72 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restoration of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA or BLA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Marketing exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">of&#160;non-patent&#160;marketing</div> exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infringement.</div> The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">European Union and United Kingdom Drug Development </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union (commonly referred to as Brexit). Thereafter, on March&#160;29, 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty. The United Kingdom formally left the European Union on January&#160;31, 2020. A transition period began on February&#160;1, 2020, during which EU pharmaceutical law remained applicable in the United Kingdom. However this ended on December&#160;31, 2020. On December&#160;30, 2020, the United Kingdom and European Union signed the Trade and Cooperation Agreement, which includes an agreement on free trade between the two parties. Since the regulatory framework in the United Kingdom covering the quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorizations, commercial sales, and distribution of pharmaceutical products is derived from EU Directives and Regulations, Brexit could materially impact the future regulatory regime which applies to products and the approval of product candidates in the United Kingdom, as the UK legislation now has the potential to diverge from EU legislation. It remains to be seen how Brexit will impact regulatory requirements for medicinal products and devices in the United Kingdom in the long term. The MHRA has published detailed guidance for industry and organizations to follow now the transition period is over, which will be updated as the United Kingdom&#8217;s regulatory position on medicinal products and medical devices evolves over time. There are also a number of ongoing consultations on the future legislation in the UK. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the EEA, which is comprised of the Member States of the European Union plus Norway, Iceland and Liechtenstein, and United Kingdom, our future products also may be subject to extensive regulatory requirements. As in the United States, medicinal products can be marketed only if a marketing authorization from the relevant competent authority has been obtained. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Similar to the United States, the various phases of preclinical and clinical research in the EEA and United Kingdom are subject to significant regulatory controls. The EU Clinical Trials Directive 2001/20/EC (the &#8220;Directive&#8221;) sought to harmonize the EU clinical trials regulatory framework, setting out common rules for the control and authorization of clinical trials in the EU, the EU Member States have transposed and applied the provisions of the Directive differently into their national laws, including in the UK. This has led to significant variations in the Member State regimes. Under this regime, before a clinical trial can be initiated it must be </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">73 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approved in each of the EU/UK countries where the trial is to be conducted by two distinct bodies: the National Competent Authority (the &#8220;NCA&#8221;), and one or more Ethics Committees (&#8220;ECs&#8221;). Under this regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the country where they occurred. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The EU clinical trials legislation is undergoing a transition process due to the application of a new Clinical Trials Regulation (EU) No 536/2014 (the &#8220;Regulation&#8221;), which is mainly aimed at harmonizing and streamlining clinical trial authorization, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing their transparency. In April 2014, the EU adopted the Regulation, which started to apply on January&#160;31, 2022 and replaced the current Directive. Specifically, the new Regulation, which is directly applicable in all Member States without the need for EU Member States to transpose it into national law, aims at simplifying and streamlining the approval of clinical trials in the EU. For instance, the new Regulation provides for a streamlined application procedure via a single entry point and strictly defined deadlines for the assessment of clinical trial applications. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following Brexit, this Regulation is not applicable in the UK, and the national legislation put in place to implement the Directive continues to apply to trials conducted in the UK. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">European Union and United Kingdom Drug Marketing </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Much like the federal Anti-Kickback Statue prohibition in the United States, the provision of benefits or advantages to physicians and/or healthcare organizations to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order, administration or use of medicinal products is also prohibited in the EEA and United Kingdom. EU Directive 2001/83/EC, which is the Directive governing medicinal products for human use, as implemented in the relevant Member State and the UK, the national anti-bribery laws of the European Union Member States, and the Bribery Act 2010 in the UK, as well as the industry Codes of Practice that are based on the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code of Practice, collectively govern the provision of benefits or advantages to induce or reward improper performance. Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the Directive governing medicinal products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the national laws of the EU Member States, as well as in the UK Human Medicines Regulations 2012 and so remains applicable in the UK despite its departure from the EU. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depending on the applicable national rules in the EU Member States and the UK, payments and other transfers of value made to physicians, physician associations, medical students, healthcare organizations, patient organizations and other stakeholders in the EU Member States, the UK and Member States of the EEA must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual country. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the relevant country. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">European Union and United Kingdom Drug Review and Approval </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the EEA, medicinal products can only be commercialized after obtaining a marketing authorization (&#8220;MA&#8221;). There are two main types of marketing authorizations for innovative medicinal products, which, however, are based on largely identical regulatory rules, requirements and timelines, including the requirements concerning the presentation and content of the application for marketing authorization. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The centralized MA is issued by the European Commission through the centralized procedure, based on the opinion of the Committee for Medicinal Products for Human Use (the &#8220;CHMP&#8221;), of the EMA, </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">74 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and is valid throughout the entire territory of the EEA. The centralized procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced-therapy medicinal products (gene-therapy, somatic cell-therapy or tissue-engineered medicines) and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EEA </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the centralized procedure. If a product is to be authorized in more than one Member State, the assessment procedure is coordinated between the relevant EU Member States. Where a product has already been authorized for marketing in a Member State of the EEA, the national MA can be recognized in another Member States through the mutual recognition procedure. If the product has not received a national MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the decentralized procedure. Under the decentralized procedure an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State (the &#8220;RMS&#8221;). The competent authority of the RMS coordinates the preparation of a draft assessment report, a draft summary of the product characteristics (the &#8220;SmPC&#8221;), and a draft of the labeling and package leaflet, which are sent to the other Member States (referred to as the Concerned Member States) for their final approval. If the Concerned Member States raise no objections, based on a potential serious risk to public health, to the assessment, SmPC, labeling, or packaging circulated by the RMS, the coordinated procedures is closed, and the product is subsequently granted a national MA in all the Member States (i.e., in the RMS and the Concerned Member States). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the above-described procedures, during the assessment of the documents submitted in the MAA and before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Now that the United Kingdom (which comprises Great Britain and Northern Ireland) has left the European Union, Great Britain is no longer covered by centralized MAs (under the Northern Irish Protocol of the Withdrawal Agreement, centralized MAs will continue to apply in Northern Ireland). All medicinal products with a valid centralized MA as of December 31, 2020 were automatically converted to MAs valid in Great Britain on January, 1 2021 (unless the MA holder opted out of this procedure). For a period of two years from January 1, 2021 (although this may be extended), the Medicines and Healthcare products Regulatory Agency (the &#8220;MHRA&#8221;), the UK medicines regulator, may rely on a decision taken by the European Commission on the approval of a new MA in the centralized procedure, in order to more quickly grant a new MA valid in Great Britain. A separate application will, however, still be required and the MHRA has the right to undertake its own assessment of the dossier. The MHRA also has the power to have regard to MAs approved in EEA Member States through decentralized or mutual recognition procedures with a view to more quickly granting a MA in the United Kingdom or Great Britain. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">European Union and United Kingdom Data Protection and Market Exclusivity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the EEA and UK, innovative medicinal products, approved on the basis of a full dossier of preclinical and clinical data as part of the MAA, qualify for eight years of data protection upon marketing authorization and an additional two years of market exclusivity. The data protection, if granted, prevents generic or biosimilar applicants from referencing the innovator&#8217;s preclinical and clinical trial data contained in the dossier of the reference innovative product when applying for a generic or biosimilar MA in the EEA/UK, for a period of eight </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">75 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">years from the date of authorization of the reference product. During the additional two-year period of market exclusivity, a generic or biosimilar marketing authorization application can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar product can be marketed until the expiration of the market exclusivity. The overall ten-year period can be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are determined to bring a significant clinical benefit in comparison with currently approved therapies. Even if an innovative medicinal product gains the prescribed period of data protection, however, another company may market another version of the product if such company obtained a MA based on a marketing authorization application with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials (i.e. without cross-referencing to the data within the reference innovative product). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">European Union and United Kingdom Orphan Designation and Exclusivity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the EEA, the European Commission, based on the scientific assessment from the EMA&#8217;s Committee for Orphan Medicinal Products, grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions and either (i)&#160;such condition affects not more than five in 10,000 persons in the EEA, or (ii)&#160;it is unlikely that the development of the medicine would generate sufficient return to justify the necessary investment in its development. In either case, the applicant must also demonstrate that no satisfactory method of diagnosis, prevention or treatment has been authorized (or, if a method exists, the product would be a significant benefit to those affected compared to the product available). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the EEA, orphan drug designation entitles a party to benefits such as scientific advice (protocol assistance) and financial incentives such as reduction of fees or fee waivers. In addition, if the criteria for orphan designation are found to be maintained at the time of authorization of the product, ten years of market exclusivity is granted following grant of an orphan marketing authorization. During this market exclusivity period, neither the EMA nor the European Commission nor any of the competent authorities in the EEA Members States can accept an application or grant a marketing authorization for a &#8220;similar medicinal product&#8221; for the same indication. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. This orphan exclusivity period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. Market exclusivity may also be broken, so a similar product may be authorized for the same indication, in very select cases, such as if (i)&#160;it is established that a similar medicinal product is safer, more effective or otherwise clinically superior to the authorized product; (ii)&#160;the marketing authorization holder consents to the grant of the similar product; or (iii)&#160;the marketing authorization holder cannot supply enough orphan medicinal product. Orphan drug designation must be requested before submitting an application for marketing approval. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The upcoming legislative reforms in the EU, which are part of the new EU Pharmaceutical Strategy and some of which could materialize in 2022, may result in a reduction of market exclusivity periods for orphan medicinal products, and or imposition of additional requirements for grant of such exclusivity. In addition, the strategy envisages changes to the concept of unmet medical need and considers introducing novel rewards for medicines addressing an unmet medical need. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">From January&#160;1, 2021, a separate process for orphan drug designation has applied in Great Britain. There is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">no&#160;pre-marketing&#160;authorization</div> orphan designation step required (as there is in the EEA), and the application for orphan designation will be reviewed by the MHRA at the time of the marketing authorization application. The criteria are the same as in the EEA, save that they apply to Great Britain only (e.g., there must be no satisfactory method of diagnosis, prevention or treatment of the condition concerned in Great Britain). Orphan exclusivity granted to a centralized marketing authorization will also apply in Northern Ireland. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">76 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">European Union and United Kingdom Pediatric Investigation Plan </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the EEA and UK, MAAs for new medicinal products have to include the results of studies conducted in the pediatric population, in compliance with a pediatric investigation plan (a &#8220;PIP&#8221;), agreed with the EMA&#8217;s Pediatric Committee (a &#8220;PDCO&#8221;) or MHRA as relevant. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which marketing authorization is being sought. The PDCO/MHRA can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO/MHRA when this data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. If a marketing authorization is obtained and trial results are included in the product information, even when negative, and the product is approved in all Member <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">States,&#160;non-orphan&#160;products</div> are eligible for six months&#8217; supplementary protection certificate extension. In the case of orphan medicinal products, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;two-year&#160;extension</div> of the orphan market exclusivity may be available. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As noted above, the upcoming legislative reforms in the EU, which are part of the new EU Pharmaceutical Strategy may result in a reduction of the above pediatric rewards and/or imposition of additional requirements for grant of rewards. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">European Union and United Kingdom data protection regime </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The processing of personal data, including health data, in the EEA is governed by the General Data Protection Regulation (the &#8220;GDPR&#8221;), which became effective May&#160;25, 2018. The GDPR applies to any company established in the EEA and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data subjects in the European Union or EEA or the monitoring of the behavior of data subjects in the European Union or EEA. The GDPR enhances data protection obligations for data controllers of personal data, including<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;inter alia</div></div>&#160;stringent requirements relating to lawful and legitimate basis and purposes for the processing of personal data, the consent of data subjects, expanded disclosures about how personal data is used, requirements to conduct privacy impact assessments for &#8220;high risk&#8221; processing, limitations on retention of personal data, appointment of a data protection officers, conclusion of data processing agreements, mandatory data breach notification and &#8220;privacy by design&#8221; requirements, and creates direct obligations on service providers acting as data processors. The GDPR also imposes strict rules on the transfer of personal data outside of the EEA to countries that do not ensure an adequate level of protection, like the United&#160;States. Until recently, one such data transfer mechanism was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;EU-US&#160;Privacy</div> Shield, but the Privacy Shield was invalidated for international transfers of personal data in July 2020 by the CJEU. The CJEU upheld the validity of standard contractual clauses (&#8220;SCCs&#8221;) as a legal mechanism to transfer personal data but companies relying on SCCs will, subject to additional guidance from regulators in the EEA and the U.K., need to evaluate and implement supplementary measures that provide privacy protections additional to those provided under SCCs. It remains to be seen whether SCCs will remain available and whether additional means for lawful data transfers will become available. Moreover, the competent authorities and courts in a number of EU Member States increasingly scrutinize and question the GDPR compliance of processing of personal data by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">US-based</div> entities or entities with links to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">US-based</div> entities, independently of whether personal data is actually transferred outside the EEA. Failure to comply with the requirements of the GDPR and the related national data protection laws of the EEA Member States may result in fines up to &#8364;20&#160;million or 4% of a company&#8217;s global annual revenues for the preceding financial year, whichever is higher. Moreover, the GDPR grants data subjects the right to claim material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and&#160;non-material&#160;damages</div> resulting from infringement of the GDPR. In June 2021, the CJEU issued a ruling that expanded the scope of the &#8220;one stop shop&#8221; under the GDPR. According to the ruling, the competent authorities of EU Member States may, under certain strict conditions, bring claims to their national courts against a company for breaches of the GDPR, including unlawful cross-border processing activities, even </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">77 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">such company does not have an establishment in the EU member state in question and the competent authority bringing the claim is not the lead supervisory authority. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, further to the United Kingdom&#8217;s exit from the European Union on January&#160;31, 2020, the GDPR ceased to apply in the United Kingdom at the end of the transition period on December&#160;31, 2020. However, as of January&#160;1, 2021, the United Kingdom&#8217;s European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December&#160;31, 2020 but subject to certain UK specific amendments) into UK law, referred to as the UK GDPR. The UK GDPR and the UK Data Protection Act 2018 set out the United Kingdom&#8217;s data protection regime, which is independent from but aligned to the European Union&#8217;s data protection regime. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-compliance</div> with the UK GDPR may result in monetary penalties of up to &#163;17.5&#160;million or 4% of worldwide revenue, whichever is higher. With respect to transfers of personal data from the EEA to the United Kingdom, on June&#160;28, 2021 the European Commission issued an adequacy decision in respect of the UK&#8217;s data protection framework, enabling data transfers from EU member states to the UK to continue without requiring organizations to put in place contractual or other measures in order to lawfully transfer personal data between the territories. While it is intended to last for at least four years, the European Commission may unilaterally revoke the adequacy decision at any point, and if this occurs it could lead to additional costs and increase our overall risk exposure. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rest of the World Regulation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For other countries outside of the European Union and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Additionally, the clinical trials must be conducted in accordance with GCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Additional Laws and Regulations Governing International Operations </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we further expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The U.S. Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;), prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. Further, other anti-corruption laws, such as the UK Bribery Act, are broader and can regulate payments <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">to&#160;non-governmental&#160;entities.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United&#160;States, or the sharing with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">certain&#160;non-U.S.&#160;nationals,</div> of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">78 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Coverage and Reimbursement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Successful commercialization of new drug products depends in part on the extent to which reimbursement for those drug products will be available from government programs, such as Medicare and Medicaid, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drug products they will pay for and establish reimbursement levels. The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford a drug product. Sales of drug products depend substantially, both domestically and abroad, on the extent to which the costs of drugs products are covered or paid for by the federal or national government as well as commercial managed care organizations, pharmacy benefit managers, and similar healthcare management organizations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment, and efforts of third-party payors to contain or reduce health care costs may adversely affect our ability to establish or maintain appropriate prices for our products or any drugs that we may develop and commercialize. Such efforts include the use of accumulator adjustment programs that do not consider amounts paid by pharmaceutical copay assistance programs as counting towards a patient&#8217;s deductible or other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> costs. Under new rules promulgated by CMS that will take effect January&#160;1, 2023, such accumulator adjustment (or similar) programs could affect the amount of rebates owed by manufacturers under the Medicaid Drug Rebate Program or affect our ability to offer various forms of patient support, including copay assistance. This regulation is subject to ongoing litigation; however, we cannot predict if the rule ultimately will be overturned or rescinded. At the same time, however, certain states have passed laws prohibiting third-party payors from utilizing accumulator programs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government authorities and third-party payors also have attempted to control costs by limiting coverage and the amount of reimbursement for particular drug products. In many countries, the prices of drug products are subject to varying price control mechanisms as part of national health systems. In general, the prices of drug products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for drug products, but monitor and control company profits. Accordingly, in markets outside the United States, the acquisition costs and reimbursement for drug products may lower than within the United States. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, the decisions about reimbursement for new drug products under the Medicare program are made by CMS, an agency within HHS. CMS determines coverage standards for products reimbursed by Medicare, and private payors often adopt coverage standards established by CMS for the commercial marketplace. However, no uniform policy of coverage and reimbursement for drug products exists among third-party payors and coverage and reimbursement levels for drug products can differ significantly from payor to payor. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Third-party payors may limit coverage to specific products on an approved list or formulary, which might not include all of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;FDA-approved&#160;products</div> for a particular indication. Also, third-party payors may refuse to include a particular branded drug on their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or another alternative is available. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">79 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Further, due to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19&#160;pandemic,</div> millions of individuals have lost or are expected to lose employer-based insurance coverage, which may adversely affect our ability to successfully commercialize our products. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (the &#8220;MMA&#8221;), established the Medicare Part D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Parts A and B, Part D coverage is not standardized. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for drugs for which we obtain marketing approval. Any negotiated prices for any of our products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">from&#160;non-governmental&#160;payors.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a drug product to receive federal reimbursement under the Medicaid or Medicare Part B programs, a manufacturer must enter into agreements with the Secretary of HHS to participate in the Medicaid Drug Rebate Program and the 340B drug discount program. Under the Medicaid Drug Rebate Program, manufacturers are obligated to pay rebates to the State Medicaid Programs on each unit of the manufacturer&#8217;s drugs that are reimbursed by State Medicaid Programs&#8212;both with regard to Medicaid Fee for Service and Medicaid Managed Care. Additionally, under the 340B drug discount program, manufacturers extend discounts to &#8220;covered entities&#8221; eligible to participate in the 340B program, including various hospital providers. The required 340B discount on a given product is calculated based on the average manufacturer price (&#8220;AMP&#8221;) and Medicaid rebate amounts reported and paid by the manufacturer under the Medicaid Drug Rebate Program. As of 2010, the ACA expanded the types of entities eligible to receive discounted 340B pricing, although under current law these newly eligible entities (with the exception of children&#8217;s hospitals) will not be eligible to receive discounted 340B pricing on drugs that receive an orphan designation by the FDA. As 340B drug pricing is determined based on AMP and Medicaid rebate data, revisions to the statute and regulations governing the Medicaid Drug Rebate Program may cause the required 340B discount to increase. Additional legislation surrounding the 340B program, including which providers are eligible for the program, may be enacted in the future. These developments could affect our profitability. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, there also is significant uncertainty related to the insurance coverage and reimbursement of cell or genetic therapy products. Although a new rule finalized by CMS for the Medicaid Drug Rebate Program increased flexibility regarding the manner in which manufacturers may offer value-based discounting arrangements, and following a regulatory delay, is expected to take effect on July&#160;1, 2022. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the effectiveness of different treatments for the same illness. The plan for the research was published in 2012 by the Department of HHS, the Agency for Healthcare Research and Quality and the National Institutes for Health, and periodic reports on the status of the research and related expenditures are made to Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of our drug candidates, if any such drug or the condition that they are intended to treat are the subject of a trial. It is also possible that comparative effectiveness research demonstrating benefits in a competitor&#8217;s drug could adversely affect the sales of our drug candidate. If third-party payors do not consider our drugs to be cost-effective compared to other available therapies, they may not cover our drugs after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our drugs on a profitable basis. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">80 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These laws, and future state and federal healthcare reform measures may be adopted in the future, any of which may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Outside of the United States, the pricing of pharmaceutical products and medical devices is subject to governmental control in many countries. For example, in the European Union and UK, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness of a particular therapy to currently available therapies <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">or&#160;so-called&#160;health</div> technology assessments, in order to obtain reimbursement or pricing approval. Other countries may allow companies to fix their own prices for products, but monitor and control product volumes or the amount of profit made on those profits, and issue guidance to physicians to limit prescriptions. Efforts to control prices and utilization of pharmaceutical products and medical devices will likely continue as countries attempt to manage healthcare expenditures. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Human Capital Management </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, we and our subsidiaries had approximately 863 full-time employees, including 791 in the United States. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our human capital objectives include sourcing, recruiting, retaining, incentivizing and developing our existing and future employees. We seek to create nimble, entrepreneurial Vants that operate similarly to independent biotechnology companies where each management team, comprised of world-class drug developers and clinical operators, is solely focused on their respective Vant&#8217;s mission. Our and our Vants&#8217; equity incentive plans are designed to attract, retain and motivate selected employees, consultants and directors through the granting of share-based compensation awards to encourage focus and calculated risk-taking. In connection with becoming a public company, we expect to continue to hire additional personnel and to implement procedures and processes to address public company regulatory requirements and customary practices. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate and Other Information </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We were registered as an exempted limited company in Bermuda in 2014, under the name Valor Biotechnology Ltd. In November 2014 we changed our name to Roivant Sciences Ltd. Our principal executive offices are located at Suite 1, 3rd <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Floor,&#160;11-12&#160;St.</div> James&#8217;s Square, London SW1Y 4LB, United Kingdom. Our telephone number is +44 207 400 3347. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our web page address is https://roivant.com. Our investor relations website is located at https://investor.roivant.com/. We will make available free of charge on our investor relations website under &#8220;SEC Filings&#8221; our Annual Reports <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on&#160;Form&#160;10-K,&#160;Quarterly</div> Reports on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-Q,&#160;Current</div> Reports on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;8-K,&#160;our</div> directors&#8217; and officers&#8217; Section&#160;16 Reports and any amendments to those reports after filing or furnishing such materials to the SEC. Additionally, the SEC maintains an internet site that contains reports, proxy and information statements and other information. The address of the SEC&#8217;s website is www.sec.gov. References to our website address do not constitute incorporation by reference of the information contained on the website, and the information contained on the website is not part of this document or any other document that we file with or furnish to the SEC. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an &#8220;emerging growth company&#8221; (an &#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act of 2012. As an EGC, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002 and reduced disclosure obligations regarding executive compensation. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">81 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="rom307489_3" style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;1A.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RISK FACTORS </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our business involves a high degree of risk. You should carefully consider the risks described below, together with the other information contained in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> including &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the consolidated financial statements and the related notes, as well as the risks, uncertainties and other information set forth in the reports and other materials filed or furnished by us and our majority-controlled subsidiary, Immunovant, Inc. (&#8220;Immunovant&#8221;), with the SEC. We cannot assure you that any of the events discussed in the risk factors below will not occur. These risks could have a material and adverse impact on our business, prospects, results of operations, financial condition and cash flows. If any such events were to happen, the trading shares of our Common Shares could decline, and you could lose all or part of your investment. Unless the context otherwise requires, references in this section to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Roivant&#8221; and the &#8220;Company&#8221; refer to Roivant Sciences Ltd. and its subsidiaries and affiliates. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Business and Industry </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks Related to Our Financial Position and Strategy </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our limited operating history and the inherent uncertainties and risks involved in biopharmaceutical product development may make it difficult for us to execute on our business model and for you to assess our future viability. We have not generated significant revenue from our operations since inception, and there is no guarantee that we will do so in the future. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are a newly commercial-stage biopharmaceutical and healthcare technology company with a limited operating history upon which you can evaluate our business and prospects. We were formed in April 2014, and our operations to date have been limited to acquiring or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> product candidates, efforts to discover new product candidates through our small molecule discovery engine, the creation or acquisition of healthcare technology companies and products, starting or acquiring subsidiary businesses, which we refer to as the Vants, in which to house biopharmaceutical products, product candidates or technologies, and hiring management teams to operate the Vants and oversee the development of our products, product candidates and technologies. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have recently commenced our transition from a clinical-stage to a company with commercial-stage assets. In May 2022, VTAMA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (tapinarof) for the treatment of adults with plaque psoriasis received regulatory approval in the U.S. VTAMA is not currently approved in any other jurisdictions and we do not have any other product candidates that have received regulatory approvals in the U.S. or in any other jurisdiction. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to execute on our business model and generate revenues depends on a number of factors including our ability to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">successfully commercialize VTAMA; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">identify new acquisition or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> opportunities; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">successfully complete ongoing preclinical studies and clinical trials and obtain regulatory approvals for our current and future products and product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">successfully identify new product candidates through our small molecule discovery engine and advance those product candidates into preclinical studies and clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">successfully market our healthcare technology products and services; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">raise additional funds when needed and on terms acceptable to us; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">attract and retain experienced management and advisory teams; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">add operational, financial and management information systems and personnel, including personnel to support clinical, preclinical manufacturing and commercialization efforts and operations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">launch commercial sales of future product candidates, whether alone or in collaboration with others, including establishing sales, marketing and distribution systems; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">initiate and continue relationships with third-party suppliers and manufacturers and have commercial quantities of products and product candidates manufactured at acceptable cost and quality levels and in compliance with the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) and other regulatory requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">set acceptable prices for products and product candidates and obtain coverage and adequate reimbursement from third-party payors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">achieve market acceptance of products and product candidates in the medical community and with third-party payors and consumers; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maintain, expand and protect our intellectual property portfolio. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we cannot successfully execute on these objectives, our business may not succeed and the price of our Common Shares may be negatively impacted. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Because of the numerous risks and uncertainties associated with biopharmaceutical product development and commercialization, we are unable to predict the timing or amount of increased expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. Our expenses could increase beyond expectations if we are required by the FDA or comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities to perform studies or clinical trials in addition to those that are currently anticipated or to otherwise provide data beyond that which we currently believe is necessary to support an application for marketing approval or to continue clinical development, or if there are any delays in any of our or our future collaborators&#8217; clinical trials or the development of our product candidates that we may identify. We anticipate incurring significant costs associated with commercializing VTAMA and any future product candidates, if approved, as well as ongoing compliance efforts. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may never be able to develop new marketable drugs or successfully commercialize a marketable drug or achieve profitability. To become profitable, we must succeed in developing and commercializing products that generate significant revenue. Revenue from the sale of any products or product candidate for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the territories for which we have or may gain regulatory approval, the accepted price for the product, the ability to obtain reimbursement at any price, the strength and term of patent exclusivity for the product, the competitive landscape of the product market, and whether we own the commercial rights for that territory. For example, even though VTAMA for the treatment of adults with plaque psoriasis has received regulatory approval in the U.S., we can provide no assurances that we will be able to achieve profitability based on sales in that indication alone or that we will be able to receive approval of and commercialize VTAMA in other indications or in other jurisdictions. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to achieve sustained profitability would depress the value of our company and could impair our ability to raise capital, expand our business, expand our pipeline, market our products and, if approved, product candidates, and continue our operations. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our shareholders&#8217; equity and working capital. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may never achieve or maintain profitability. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to gain regulatory approval or become commercially viable. While we have received regulatory approval for one product candidate, VTAMA for the treatment of adults with plaque psoriasis in the U.S., we have yet to receive marketing approval for any of our other product candidates anywhere in the world and we have not generated meaningful product revenues from the commercial sale of our biopharmaceutical products. We cannot estimate with precision the extent of our future losses. We may never generate meaningful product revenue from the commercial sales of our products or, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">83 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if approved, product candidates or achieve or maintain profitability. It is possible that we will continue to incur substantial operating losses for the foreseeable future. Our ability to generate meaningful product revenue and achieve profitability is dependent on the ability to complete the development of our products and product candidates, obtain necessary regulatory approvals for our current and future products and product candidates and manufacture and successfully market our current and future products and product candidates alone or in collaboration with others. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to successfully market our products, acquire or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> new products or product candidates, complete the development and commercialization of our products and product candidates and continue to pursue our drug discovery efforts. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Acquiring or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing,</div> discovering, developing, commercializing and marketing biopharmaceutical products and product candidates is expensive and time consuming, and we expect to require additional capital to acquire or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> new products or product candidates, pursue the development and commercialization of our current and future products and product candidates, and continue our drug discovery efforts. We are also responsible for payments to third parties under our license and acquisition agreements, including milestone and royalty payments. Because of the inherent uncertainties in these activities &#8211; including the outcome of preclinical and clinical trials and the regulatory approval process &#8211; we cannot reasonably estimate the actual amounts necessary to successfully complete the development, regulatory approval process and commercialization of our product candidates or any future product candidates. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our future funding requirements, both near- and long-term, will depend on many factors, including, but not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the time and costs necessary to complete our ongoing, planned and future clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the time and costs necessary to pursue regulatory approvals for our current and future product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the costs associated with future acquisitions or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> transactions; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the progress, timing, scope and costs of our preclinical studies, clinical trials and other related activities, including the ability to enroll patients in a timely manner for our ongoing and planned clinical trials and potential future clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the costs associated with our ongoing, planned and future preclinical studies and other drug discovery activities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to successfully identify and negotiate acceptable terms for third-party supply and contract manufacturing agreements with contract manufacturing organizations (&#8220;CMOs&#8221;); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the costs of obtaining adequate clinical and commercial supplies of raw materials and drug products for our products and product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to successfully commercialize VTAMA, including: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the manufacturing, selling and marketing costs associated with VTAMA, including the cost and timing of expanding sales and marketing capabilities or entering into strategic collaborations with third parties; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the amount and timing of sales and other revenues from VTAMA, including the sales price and the availability of adequate third-party reimbursement. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights, including current and future patent infringement actions brought against third parties; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">84 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us or any of our current or future products or product candidates; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to hire, attract and retain qualified personnel. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We cannot be certain that additional capital will be available to us or the Vants on acceptable terms, or at all. If we or the Vants are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> and acquisition, discovery, development, commercialization and marketing activities. In addition, attempting to secure additional capital may divert the time and attention of our management from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> activities and harm our business. Because of the numerous risks and uncertainties associated with our business, we are unable to estimate the amounts of increased capital outlays, operating expenditures and capital requirements associated with our current and future product development programs and discovery efforts. Moreover, risks associated with broader market conditions including high levels of inflation and market volatility, both of which have been observed in recent months, may further adversely impact our ability to obtain financing on acceptable terms or at all. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect that significant additional capital will be needed in the future to continue our planned operations. Until such time, if ever, that we can generate substantial revenues, we expect to continue to finance our cash needs through a combination of equity offerings, debt financings, strategic alliances and license and development agreements or other collaborations at Roivant and the Vants. To the extent that we raise additional capital by issuing equity securities at Roivant or the Vants, our existing shareholders&#8217; ownership, or our ownership in the Vants, may experience substantial dilution, and the terms of these securities may include liquidation or other preferences that could harm the rights of our shareholders. Additionally, any agreements for future debt or preferred equity financings, if available, may involve covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our products and product candidates, future revenue streams, research programs or technologies or grant licenses on terms that may not be favorable to us. The foregoing restrictions associated with potential sources of additional capital may make it more difficult for us to raise additional capital or to pursue business opportunities, including potential acquisitions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If adequate funds are not available to us, we may be required to forego potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> or acquisition opportunities, delay, limit or terminate one or more development or discovery programs, scale back marketing efforts for our current and future products or be unable to expand operations or otherwise capitalize on business opportunities, which could materially affect our business, prospects, financial condition and results of operations. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have limited experience as a commercial company and the marketing and sale of </div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">VTAMA</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> or any future products may be unsuccessful or less successful than anticipated.</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2022, the FDA approved VTAMA for the treatment of adults with plaque psoriasis in the U.S. While we have launched VTAMA in the U.S., we have limited experience as a commercial company and therefore face significant risks and uncertainties relating to the commercialization of VTAMA and any future products that receive marketing approval, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to recruit and retain effective sales, marketing and customer service personnel; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to obtain access to physicians or persuade adequate numbers of physicians to prescribe VTAMA and any future products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inability to manufacture and to price VTAMA and any future products at a price point sufficient to ensure an adequate and attractive level of profitability; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the extent to which coverage and adequate reimbursement for these products will be available from government health administration authorities, private health insurers and other organizations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">85 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the risks associated with potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-promotion</div> or partnership agreements, including the failure to realize the expected benefits of such arrangements; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other unforeseen costs, expenses and risks associated with the commercialization of biopharmaceutical products, including compliance costs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, in preparation for our commercial launch of VTAMA, we expect to significantly increase the amount of cash we spend in order to expand our commercial infrastructure. We expect this level of increased cash spending to increase into calendar year 2023. The increased level of cash spending will support our transition to an integrated commercial biopharmaceutical company and to support the commercialization of VTAMA. To the extent that we are able to gain regulatory approval for VTAMA in any other jurisdiction besides the U.S. or to gain regulatory approval for any of our other product candidates in any jurisdiction, we would expect to incur additional increased cash costs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our limited experience as a commercial-stage company means that there is limited information about our ability to overcome many of the risks and uncertainties encountered by companies commercializing products in the biopharmaceutical industry, including the risks and uncertainties outlined above. Further, as we continue to develop and seek regulatory approval of additional product and products candidates, as well as additional indications for VTAMA, and to pursue regulatory approvals for VTAMA and other products and product candidates outside the U.S., it could be difficult for us to obtain and devote the resources necessary to successfully manage our commercialization efforts. If we are unable to manage the risks and uncertainties associated with the commercialization of VTAMA and any future products or product candidates that receive marketing approval, we may be unable to generate significant revenues from the sales of these products and product candidates to achieve profitability, which will materially affect our business, prospects, financial condition and results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be successful in our efforts to acquire, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or discover new product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The success of our business depends in part on our ability to successfully identify new product candidates, whether through acquisitions or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> transactions or through our internal discovery capabilities. Our acquisition and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> efforts focus on identifying assets in development by third parties across a diverse range of therapeutic areas that, in our view, are underserved or undervalued. Our strategy often entails designing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-cost</div> studies that result in quick <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;go/no-go&#8221;</div> decisions when deciding whether or how to proceed with future development for a given asset, once acquired. We may decide to proceed with the development of a product candidate on this basis and later determine that the more costly and time intensive trials do not support the initial value the product candidate was thought to hold. Even if a product candidate does prove to be valuable, its value may be less than anticipated at the time of investment. We may also face competition for attractive investment opportunities. A number of entities compete with us for such opportunities, many of which have considerably greater financial and technical resources. If we are unable to identify a sufficient number of such product candidates, or if the product candidates that we identify do not prove to be as valuable as anticipated, we will not be able to generate returns and implement our investment strategy and our business and results of operations may suffer materially. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our drug discovery efforts are centered on our small molecule discovery engine. As a company we have relatively limited experience in drug discovery generally, with targeted protein degradation and covalency as approaches to target inhibition and with computational discovery as a technology. Our future success depends, in part, on our ability to successfully use these approaches and technologies to identify promising new product candidates and eventually advance those product candidates through preclinical studies and clinical trials. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Only a limited number of product candidates using the approaches of targeted protein degradation or covalency have been approved in the United States or Europe. The data underlying the feasibility of developing therapeutic products based on these approaches remains both preliminary and limited. We have not yet succeeded </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">86 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and may not succeed in advancing any product candidates developed using our small molecule discovery engine into clinical trials, demonstrating the efficacy and safety of such product candidates or obtaining regulatory approval thereafter. As a result, it is difficult to predict the time and cost of product candidate development from our small molecule discovery engine and we cannot predict whether the application of these approaches will result in the development and regulatory approval of any products. Any problems we experience in the future related to this platform or any of our related development programs may cause significant delays or unanticipated costs or may prevent the development of a commercially viable product. Any of these factors may prevent us from completing our preclinical studies or any clinical trials that we may initiate or commercializing any internally discovered product candidates we may develop on a timely or profitable basis, if at all. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we believe that our computational discovery platform has the potential to identify more promising molecules than traditional research methods and to accelerate drug discovery efforts, our focus on using our platform technology to discover and design molecules with therapeutic potential may not result in the discovery and development of commercially viable products for us. Computational discovery is a relatively new approach to drug development. As an organization, we have not yet developed any product candidates using this technology that have advanced into clinical trials and we may fail to identify potential product candidates for clinical development. Even if we are able to advance product candidates identified through our computational discovery platform into clinical trials, those trials may not be successful in demonstrating the efficacy and safety of such product candidates and, as a result, we may not be able to obtain regulatory approvals for those product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Any such failure to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or acquire new product candidates from third parties, or to discover new product candidates using our small molecule discovery engine or computational discovery platforms, would have a material adverse effect on our business, financial condition, results of operations and prospects. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We face risks associated with the allocation of capital and personnel across our businesses. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Because we have limited financial and management resources, we have to make challenging decisions regarding the allocation of capital and personnel across our businesses. We face certain risks associated with these decisions and may fail to capitalize on viable commercial product candidates or profitable market opportunities. For example, we may decide not to pursue a particular <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> or acquisition opportunity, or a potential target indication for a product candidate, that later proves to have greater commercial potential than our current and planned development programs and product candidates. Similarly, our management&#8217;s attention to one product or product candidate may divert their attention from another opportunity that ultimately might have proven more successful. Our spending on current and future research and development programs and other future product candidates may not yield any commercially viable future product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such future product candidate. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additionally, we may pursue additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licenses</div> or acquisitions of product candidates or programs, which entails additional risk to us. Identifying, selecting and acquiring promising product candidates requires substantial technical, financial and human resources expertise. Efforts to do so may not result in the actual acquisition or in-license of a successful product candidate, potentially resulting in a diversion of our management&#8217;s time and the expenditure of our resources with no resulting benefit. For example, if we are unable to identify programs that ultimately result in approved products, we may spend material amounts of our capital and other resources evaluating, acquiring and developing products that ultimately do not provide a return on our investment. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">87 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We face risks associated with the Vant structure. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our products and product candidates are developed at our Vants, which operate similarly to independent biopharmaceutical companies. While we believe that there are significant competitive advantages to this structure, as compared to traditional pharmaceutical companies or smaller biopharma companies, the Vant structure also poses certain risks for our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Operating the Vants independently, rather than under a centralized, consolidated management team, may result in increased costs at the Vants, as certain functions or processes, including sales and marketing, clinical and nonclinical personnel, business development, finance, accounting, human resources and legal functions, are replicated across the Vants. There may also be certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">start-up</div> costs, associated with the establishment of a new Vant or integration of a newly acquired business into a Vant, which are greater under the Vant model than they would be under a centralized model. The use of the Vant model may also entail increased costs for us, including the time and expenses associated with hiring Vant CEOs and management teams, overseeing Vant equity incentive arrangements and managing compliance-related risks, including the internal controls, reporting systems and procedures necessary for us to operate as a public company. We may also be exposed to increased &#8220;key employee&#8221; risks, in the event a Vant CEO were to depart, including the loss of other senior Vant personnel, potentially resulting in adverse impacts to commercialization or development work at the Vant. These increased expenses, complexities and other challenges may make using and scaling the Vant model more challenging and costly than it would be for a traditional pharmaceutical company to both operate and expand the number of product candidates under development, which could have a material adverse effect on our consolidated business, financial condition, results of operations or prospects. This decentralized model could also make compliance with applicable laws and regulations more challenging to monitor and may expose us to increased costs that could, in turn, harm our business, financial condition, results of operations or prospects. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, a single or limited number of the Vants may, now or in the future, comprise a large proportion of our value. Similarly, a large proportion of our consolidated revenues may be derived from one or a small number of Vants. For example, our only approved product, VTAMA, was developed and is being commercialized by Dermavant, one of our Vants. Any adverse development at Dermavant or any other Vant, including the loss of key members of management, the termination of a key license agreement or other loss of the intellectual property underlying a product or product candidate or the failure of a clinical trial for a product candidate under development at the Vant, could have a material adverse effect on our consolidated business, financial condition, results of operations or prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We manage the Vants in part through our designees who serve on the Vant boards of directors. In their capacities as directors, those individuals owe fiduciary duties to the Vants and their shareholders under applicable law, which may at times require them to take actions that are not directly in our interest. To the extent any such actions have an adverse effect on the value of our ownership interest in the Vant, it could further adversely impact our consolidated business, financial condition, results of operations or prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The global pandemic resulting from the outbreak of the novel strain of coronavirus, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SARS-CoV-2,</div></div> which causes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> could adversely impact our business, including the marketing of our products and our ongoing clinical trials and preclinical studies. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Public health crises such as pandemics or similar outbreaks could adversely impact our business. In December 2019, a novel strain of coronavirus, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SARS-CoV-2,</div></div> which causes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> emerged. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> has since spread globally, including to the countries in which we and our business partners conduct business. Governments in affected regions have implemented, and may continue to implement or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-implement,</div> safety precautions, including quarantines, travel restrictions, business closures, cancellations of public gatherings and other measures they deem necessary. Like many other organizations and individuals, we and our employees have taken additional steps to avoid or reduce infection, including limiting travel and implementing remote work arrangements. We will continue to actively monitor the situation and may take further actions that could alter our </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">88 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">business operations as may be required by national, state or local authorities, or that we determine are in the best interests of our employees and shareholders. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have experienced, and may in the future experience, disruptions as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> or future pandemics that severely impact our business, commercial and marketing activities, clinical trials and preclinical studies, including: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to sell and market our current and future products and, if approved, product candidates, including as a result of government- or employer-imposed remote work orders and travel and workplace visitor restrictions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a decrease in patient health care utilization due to quarantines, travel restrictions, work from home orders or other public health measures; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays or disruptions in our commercial supply chain including as a result of quarantines, travel restrictions, work from home orders or other public health measures; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays or difficulties in enrolling patients in our clinical trials, and the consequences of such delays or difficulties, including terminating clinical trials prematurely; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays or disruptions in nonclinical experiments due to unforeseen circumstances at contract research organizations (&#8220;CROs&#8221;), and vendors along their supply chain; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> being forced to quarantine or not accepting home health visits; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures (particularly any procedures that may be deemed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-essential),</div> which may impact the integrity of subject data and clinical study endpoints; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">interruption or delays in the operations of the FDA and comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory agencies, which may impact review and approval timelines; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">limitations on employee resources that would otherwise be focused on the conduct of our clinical trials and preclinical studies, including because of sickness of employees or their families, the desire of employees to avoid contact with large groups of people and increased reliance on working from home or mass transit disruptions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other disruptions to our business generally, including remote working activities and the implementation of new health and safety requirements for our employees; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">waiver or suspension of patent or other intellectual property rights. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">These and other factors arising from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, including risks relating to the resurgence or emergence of new variants of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SARS-CoV-2,</div></div> including variants and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-variants</div> thereof, the efficacy and availability of vaccines and rates of vaccination (including vaccine booster shots), the pandemic worsening in countries that are already afflicted with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> or the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic continuing to spread to additional countries or returning to countries where the pandemic has been partially contained, could further adversely impact our ability to market our products and conduct clinical trials and other business activities, and could have a material adverse impact on our operations and financial condition and results. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">89 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">To the extent the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic adversely affects our business, operations and financial results, it may also have the effect of heightening many of the other risks described elsewhere, such as those relating to our clinical development operations, the supply chain for our ongoing and planned clinical trials and our ability to seek and receive regulatory approvals for our product candidates. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We face risks associated with potential future payments related to our products and product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our asset <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> transactions typically involve low upfront payments combined with milestone and royalty payments contingent upon the achievement of certain future development and commercial events. These arrangements generally involve a payment or payments upon the achievement of certain regulatory milestones, including regulatory approval, and then royalty payments upon the achievement of specified levels of sales, which can extend for up to the life of a product. Some of these payments may become due before a product is generating revenues, in which case we may not have sufficient funds available to meet our obligations. If this were to occur, we would default on our payment obligations and could face penalties, delays in commercialization or development activities or reputational damage. Even for a product that is commercialized and generating revenue, payments could become due that are so large that the investment is not profitable or is less profitable than anticipated. For example, this could occur if at the time of the initial investment, we overestimated the value of the product and agreed to a payment schedule using these inflated estimates. If we are unable to make milestone and royalty payments related to our product candidates when due, our business and prospects could suffer. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our investment strategy and future growth relies on a number of assumptions, some or all which may not be realized. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our investment strategy and plans for future growth rely on a number of assumptions, including, in the case of our products and product candidates, assumptions related to adoption of a particular therapy, incidence and prevalence of an indication, use of a product or product candidate versus competitor therapies and size of the addressable patient populations. Some or all of these assumptions may be incorrect. We cannot accurately predict whether our products or product candidates will achieve significant market acceptance in line with these assumptions or whether there will be a market for our products or product candidates that reaches the anticipated size. If any of these assumptions are incorrect or overstated, our results and future prospects will be materially and adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We face risks associated with past and future acquisitions, partnerships, alliances or other strategic transactions. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have historically and may in the future enter into various types of corporate transactions, including acquisitions, strategic partnerships, alliances or collaborations and licensing transactions. These past and future transactions pose certain risks to our business, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">increased operating expenses and cash requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the assumption of indebtedness or contingent liabilities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the issuance of our or our subsidiaries&#8217; equity securities which would result in dilution to existing shareholders; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">assimilation of operations, intellectual property and products, including difficulties associated with integrating new personnel; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">diversion of management time and focus away from operating our business; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the loss of key personnel and uncertainties in our ability to maintain key business relationships; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">risks and uncertainties associated with the counterparty to any such transaction; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">90 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our inability to eventually generate revenue from acquired technology or products or product candidates sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">litigation or other claims, including claims from terminated employees, customers, former shareholders or other third parties. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, if we undertake such a transaction, we may issue dilutive securities, assume or incur debt obligations, incur large <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> expenses and acquire intangible assets that could result in significant future amortization expenses, any of which could have a material adverse effect on our business, prospects, financial condition or results of operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, any such transactions may be complex, time-consuming and expensive to execute and may be subject to regulatory requirements that could impact our business. There can be no guarantee that we will be able to successfully consummate such acquisitions or other transactions, which could result in a significant diversion of management and other employee time, as well as substantial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> costs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any acquisitions or other transactions are not completed for any reason, we may incur significant costs and the market price of our Common Shares may decline. In addition, even if an acquisition or other transaction is consummated, the integration of the acquired business, product or other assets into our Company may be complex and time-consuming, and we may not achieve the anticipated benefits, cost-savings or growth opportunities we expect. Potential difficulties that may be encountered in the integration process include the following: integrating personnel, operations and systems; coordinating geographically dispersed organizations; distracting management and employees from current operations; maintaining the existing business relationships of the acquired company; and managing inefficiencies associated with integrating the operations of the Company and the acquired business, product or other assets. For biopharmaceutical businesses we have acquired or may acquire in the future, or alliances or joint ventures in the biopharmaceutical industry, we may encounter numerous difficulties in developing, manufacturing and marketing any new products or product candidates related to such businesses, which may delay or prevent us from realizing the expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, alliance or partnership, we will achieve the expected synergies to justify the transaction. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our failure to address these risks or other problems encountered in connection with past or future acquisitions, partnerships or strategic alliances could cause us to fail to realize the anticipated benefits of these transactions, incur unanticipated liabilities and harm our business generally. There is also a risk that current or future acquisitions will result in the shareholder litigation, incurrence of debt, contingent liabilities, amortization expenses or incremental operating expenses, any of which could harm our financial condition or results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we obtain a controlling interest in additional companies in the future, it could adversely affect our operating results and the value of our Common Shares, thereby disrupting our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of our strategy, we expect to form and invest in additional wholly-owned and majority-owned subsidiaries. Investments in our existing and any future subsidiaries involve numerous risks, including, but not necessarily limited to, risks related to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">conducting research and development activities in new therapeutic areas or treatment approaches in which we have little to no experience; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">diversion of financial and managerial resources from existing operations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">actual or potential conflicts among new and existing Vants to the extent they have overlapping or competing areas of focus or pipeline products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">91 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">successfully negotiating a proposed acquisition, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or investment in a timely manner and at a price or on terms and conditions favorable to us; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">successfully combining and integrating a potential acquisition into our existing business to fully realize the benefits of such acquisition; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the impact of regulatory reviews on a proposed acquisition, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or investment; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the outcome of any legal proceedings that may be instituted with respect to the proposed acquisition, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or investment. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If we fail to properly evaluate potential acquisitions, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licenses,</div> investments or other transactions associated with the creation of new research and development programs or the maintenance of existing ones, we might not achieve the anticipated benefits of any such transaction, we might incur costs in excess of what we anticipate, and management resources and attention might be diverted from other necessary or valuable activities. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our business may suffer reputational harm due to our inability to successfully commercialize VTAMA or other failures of our product candidates, which could have further adverse impacts on our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our inability to successfully commercialize VTAMA or the failure of any of our product candidates in ongoing or future clinical trials or preclinical studies, in addition to having a direct adverse impact on our business and prospects, could also have a lasting negative impact on our reputation, which could, in turn, impact our ability to successfully enter into future licensing arrangements or other transactions with potential counterparties, raise future capital or attract key personnel to join us. As a result, our business and prospects would be materially harmed and our results of operations and financial condition would likely suffer materially. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks Related to the Development of Our Products and Product Candidates </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical trials and preclinical studies are very expensive, time-consuming, difficult to design and implement and involve uncertain outcomes. We may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials or preclinical studies on the expected timelines, if at all. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our biopharmaceutical product candidates that are in clinical development or preclinical studies will require, as applicable, extensive clinical testing before a New Drug Application (&#8220;NDA&#8221;) or other similar application for regulatory approval, such as a Biologics License Application (&#8220;BLA&#8221;) or an application for marketing authorization in the European Union (&#8220;EU&#8221;) or United Kingdom (&#8220;UK&#8221;), may be submitted, or extensive preclinical testing before an Investigational New Drug application (&#8220;IND&#8221;) or an application for authorization to conduct a clinical trial in the EU or UK may be submitted, a Clinical Trial Application (&#8220;CTA&#8221;). We cannot provide any assurance that we will submit an IND, NDA, CTA or other similar application for regulatory approval for our product candidates within projected timeframes or whether any such application will be approved by the relevant regulatory authorities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical trials and preclinical studies are very expensive, time-consuming and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. For instance, the FDA, an institutional review board (&#8220;IRB&#8221;), an Ethics Committee (&#8220;EC&#8221;) or other regulatory authorities may not agree with the proposed analysis plans or trial design for the clinical trials of our product candidates, and during any such review, may identify unexpected efficacy or safety concerns, which may delay the effective date of an IND or approval of an NDA, BLA or similar application. The FDA, the European Medicines Agency (&#8220;EMA&#8221;) or the European Commission or other relevant regulatory authority may also find that the benefits of any product candidate in any applicable indication do not outweigh its risks in a manner sufficient to grant regulatory approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA or other regulatory authorities may also not agree with the scope of our proposed investigational plan. For example, they may find that our proposed development program is not sufficient to support a marketing </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">92 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">authorization application, or that the proposed indication is considered to be too broad. Moreover, the FDA or other regulatory authorities may also refuse or impose certain restrictions on our reliance on data supporting our clinical trial application or marketing authorization application should such data originate from studies outside of the relevant jurisdiction or be affected by regulatory <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance,</div> including issues of data integrity. In the EU, data derived from clinical trials that were conducted outside the EU cannot be used to support a CTA unless the clinical trial was registered on a relevant database. In each case, this could delay the clinical development and authorization timeline for a given product candidate. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Failures can occur at any stage of development, including clinical trials or preclinical studies, and we could encounter problems that cause us to abandon or repeat clinical trials or preclinical studies. In addition, results from clinical trials or preclinical studies may require further evaluation, delaying the next stage of development or submission of an IND or an NDA or similar application. Further, product candidates in later stages of clinical trials may fail to show the desired safety and efficacy results despite having successfully progressed through preclinical and earlier stage clinical trials. Such product candidates may exhibit safety signals in later stage clinical trials that they did not exhibit in earlier studies or trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in, or the discontinuation of, advanced clinical trials with a product candidate due to lack of efficacy or adverse safety findings, despite having promising results in earlier trials or studies. Likewise, the results of early clinical trials or preclinical studies of our product candidates may not be predictive of the results of future development programs. There can also be no assurance that the results of studies conducted by collaborators or other third parties with similar product candidates in similar indications will be viewed favorably or indicative of our own future trial results. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The commencement and completion of preclinical studies and clinical trials may be delayed by several factors, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure to obtain regulatory authorization to commence a clinical trial or reaching consensus with regulatory authorities regarding the design or implementation of our studies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">other regulatory issues, including the receipt of any inspectional observations on FDA&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form-483,</div> Warning or Untitled Letters, clinical holds, or complete response letters or similar communications/objections by other regulatory authorities; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unforeseen safety issues, or subjects experiencing severe or unexpected adverse events; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">occurrence of serious adverse events in trials of the same class of agents conducted by other sponsors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">lack of effectiveness during clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">resolving any dosing issues, including those raised by the FDA or other regulatory authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability to reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">slower than expected rates of patient recruitment or failure to recruit suitable patients to participate in a trial; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure to add a sufficient number of clinical trial sites; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unanticipated impact from changes in or modifications to protocols or clinical trial design, including those that may be required by the FDA or other regulatory authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability or unwillingness of clinical investigators or study participants to follow our clinical and other applicable protocols or applicable regulatory requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an IRB or EC refusing to approve, suspending, or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">premature discontinuation of study participants from clinical trials or missing data; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">93 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure to manufacture or release sufficient quantities of our product candidates or failure to obtain sufficient quantities of active comparator medications for our clinical trials, if applicable, that in each case meet our quality standards, for use in clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability to monitor patients adequately during or after treatment; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inappropriate unblinding of trial results. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, disruptions caused by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials.&#160;Further, we, the FDA or other regulatory authorities may suspend our clinical trials in an entire country at any time, or an IRB/EC may suspend our clinical trial sites within any country, if it appears that we or our collaborators are failing to conduct a trial in accordance with the protocol, applicable regulatory requirements, including Good Clinical Practice (&#8220;GCP&#8221;) regulations, that we are exposing participants to unacceptable health risks, or if the FDA or other regulatory authority finds deficiencies in our IND or equivalent applications for other countries or in the manner in which clinical trials are conducted. Therefore, we cannot predict with any certainty the schedule for commencement and completion of future clinical trials. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our product candidates could be harmed, and our ability to generate product revenue from any of our product candidates, if approved, may be delayed. In addition, any delays in our clinical trials could increase our costs, cause a decline in our share price, slow down the approval process, and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may harm our business, financial condition and results of operations. In addition, many of the factors that cause or lead to a termination or suspension of, or delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. We may make formulation or manufacturing changes to our product candidates, in which case we may need to conduct additional preclinical or clinical studies to bridge our modified product candidates to earlier versions. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be able to bring product candidates to market before we do, and the commercial viability of our product candidates could be significantly reduced. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or other regulatory authorities. The FDA or other regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected the integrity of the study. The FDA or other regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing and authorization applications by the FDA or other regulatory authorities, as the case may be, and may ultimately lead to the denial of marketing approval of any of our product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, for our products or product candidates that are in clinical development, prior to our acquisition of the rights to those products or product candidates we had no involvement with or control over the preclinical or clinical development of those products or product candidates. We are therefore dependent on our licensing and other transaction partners having conducted such research and development in accordance with the applicable protocols and legal, regulatory and scientific standards, having accurately reported the results of all clinical trials and other research they conducted prior to our acquisition of the rights to those products or product candidates, having correctly collected and interpreted the data from these trials and other research and having supplied us with complete information, data sets and reports required to adequately demonstrate the results reported through the date of our acquisition of these products or product candidates. Problems associated with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-acquisition</div> development of our products or product candidates could result in increased costs and delays in the commercialization of our products or development of our product candidates, which could harm our ability to generate any future revenue from sales of products or, if approved, product candidates. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">94 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our approach to the discovery and development of product candidates from our </div></div></div></div>small molecule discovery engine <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">is unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any product candidates from this platform. </div></div></div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Treating diseases using targeted protein degradation, covalency and similar approach is novel and unproven. Our future success depends in part on the successful development of these new therapeutic approaches. Very few small molecule product candidates using targeted protein degradation or covalency have been tested in humans. Only a limited number of product candidates using targeted protein degradation or covalency have been approved in the United States or Europe and the data underlying the feasibility of developing these types of therapeutic products remains both preliminary and limited. If any adverse learnings are made by other developers of protein degraders or covalent inhibitors, development of these product candidates could be materially impacted, which could in turn adversely impact our financial condition and future growth. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The scientific research that forms the basis of our efforts to develop product candidates from our small molecule discovery engine is ongoing and the scientific evidence to support the feasibility of developing these treatments is both preliminary and limited. In addition, we may be unable to replicate the scientific evidence supporting these product candidates observed by our academic collaborators in commercial laboratories. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, certain cancer patients have shown inherent primary resistance to approved drugs that inhibit disease-causing proteins and other patients have developed acquired secondary resistance to these inhibitors. Although we believe our product candidates may have the ability to degrade the specific mutations that confer resistance to currently marketed inhibitors of disease-causing enzymes, any inherent primary or acquired secondary resistance to our product candidates in patients, or if the research proves to be contradicted, would prevent or diminish their clinical benefit. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have not yet completed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IND-enabling</div> work for, or initiated a clinical trial of, any product candidate associated with our small molecule discovery engine and we have not yet assessed the safety of any of these product candidates in humans. Although some of our product candidates have produced observable results in animal studies, there is a limited safety data set for their effects in animals. In addition, these product candidates may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. As a result, there could be adverse effects from treatment with any of our current or future products or product candidates that we cannot predict at this time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, the regulatory approval process for novel product candidates such as those associated with our small molecule discovery engine is uncertain and can be more expensive and take longer than for other, better-known or extensively studied classes of product candidates. Although other companies are also developing therapeutics based on targeted protein degradation and similar approaches, only a limited number of product candidates of this type have been approved in the United States or Europe. As a result, it is difficult for us to predict the time and cost of developing our product candidates and we cannot predict whether any of our product candidates will receive marketing approval or achieve commercial acceptance. Any development problems we experience in the future related to our small molecule discovery engine or any of our related research programs may cause significant delays or unanticipated costs or may prevent the development of a commercially viable product. Any of these factors may prevent us from completing our preclinical studies or any clinical trials that we may initiate, as well as from commercializing any product candidates we may develop on a timely or profitable basis, if at all. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Certain of our products and product candidates are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in our development or commercialization programs or otherwise harm our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The manufacturing processes our CMOs use to produce our products and product candidates are complex, novel and, in the case of our product candidates, have not necessarily been validated for commercial use. Several </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">95 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">factors could cause production interruptions, including equipment malfunctions, facility contamination, raw material shortages or contamination, natural disasters, disruption in utility services, human error or disruptions in the operations of our suppliers. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our biologic product candidates may require processing steps that are more complex than those required for most small molecule drugs. Moreover, unlike small molecules, the physical and chemical properties of biologics generally cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that the product is consistent from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lot-to-lot</div></div> or will perform in the intended manner. Accordingly, our CMOs must employ multiple steps to control the manufacturing process to assure that the process is reproducible and the product candidate is made strictly and consistently in compliance with the process. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims or insufficient inventory to conduct clinical trials or supply commercial markets. We may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet the FDA, the EU or other applicable standards or specifications with consistent and acceptable production yields and costs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the FDA, the EMA and other regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other comparable regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay product launches or clinical trials, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our CMOs also may encounter problems hiring and retaining the experienced scientific, quality assurance, quality-control and manufacturing personnel needed to operate our manufacturing processes, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. Any problems in our CMOs&#8217; manufacturing processes or facilities could result in delays in planned clinical trials and increased costs, and could make us a less attractive collaborator for potential partners, including larger biopharmaceutical companies and academic research institutions, which could limit access to additional attractive development programs. Problems in any of our manufacturing processes could restrict our ability to meet potential future market demand for our products or to conduct clinical trials with our product candidates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may encounter difficulties enrolling and retaining patients in clinical trials, and clinical development activities could thereby be delayed or otherwise adversely affected. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may encounter delays or difficulties in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials for our products or product candidates on current timelines, or at all, and even once enrolled we may be unable to retain a sufficient number of patients to complete any of our clinical trials for these products or product candidates. Enrollment in our clinical trials may also be slower than we anticipate, or be stopped, leading to delays in the development timelines for our products and product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Patient enrollment and retention in clinical trials depends on many factors, including the size of the patient population, the nature of the trial protocol, our ability to recruit clinical trial investigators with the appropriate competencies and experience, delays in enrollment due to travel or quarantine policies, or other factors, related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> the existing body of safety and efficacy data with respect to the study drug, the number and nature of competing treatments and ongoing clinical trials of competing drugs for the same indication, the proximity of patients to clinical sites, the eligibility criteria for the trial and the proportion of patients screened that meets those criteria, our ability to obtain and maintain patient consents and our ability to successfully complete prerequisite studies before enrolling certain patient populations. For certain of our products and product candidates, including batoclimab, which targets certain rare autoimmune indications, there are limited patient </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">96 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">pools from which to draw in order to complete our clinical trials in a timely and cost-effective manner. In addition, for certain of our early-stage development programs, there may be a limited number of sites where it is feasible to run clinical trials, making such programs particularly susceptible to delays caused by issues at those sites. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Furthermore, any negative results or new safety signals we may report in clinical trials of our products or product candidates may make it difficult or impossible to recruit and retain patients in other clinical trials we are conducting or to resume enrolling patients once a paused clinical trial has been resumed. For example, in February 2021, our subsidiary, Immunovant, voluntarily paused dosing in its clinical trials for batoclimab globally due to elevated total cholesterol and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-density</div> lipoprotein (&#8220;LDL&#8221;) levels observed in some patients treated with batoclimab, resulting in a delay in Immunovant&#8217;s development of batoclimab. In current and future trials of batoclimab, it may be more difficult for Immunovant to recruit and retain patients for such clinical trials. Similarly, negative results reported by our competitors about their drug candidates may negatively affect patient recruitment in our clinical trials. Also, marketing authorization of competitors in this same class of drugs may impair our ability to enroll patients into our clinical trials, delaying or potentially preventing us from completing recruitment of one or more of our trials. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our products and product candidates, or could render further development impracticable. In addition, we expect to rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials, and, while we intend to enter into agreements governing their services, we will be limited in our ability to compel their actual performance. Any such delays in our current or future clinical trials could have a material adverse impact on our operations and financial condition and results. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The results of our clinical trials may not support our proposed claims for our products or product candidates, or regulatory approvals on a timely basis or at all, and the results of earlier studies and trials may not be predictive of future trial results. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the results of later clinical trials will replicate the results of prior preclinical studies and earlier clinical trials. For example, we cannot assure you that the reductions in IgG antibodies that we have observed to date in our clinical trials of batoclimab will be observed in any future clinical trials. Likewise, promising interim results or other preliminary analyses do not ensure that the clinical trial as a whole will be successful and may lack statistical significance, which would further limit the reliability of such interim or preliminary data. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered significant setbacks in, or the discontinuation of, clinical trials, even after promising results were seen with their product candidates in earlier preclinical studies or clinical trials. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unobserved adverse events. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As previously disclosed, our subsidiary, Immunovant, voluntarily paused dosing in its early phase clinical studies to evaluate batoclimab-induced elevations in total cholesterol and LDL levels observed in some trial subjects. In December 2021, Immunovant achieved alignment with the FDA Division of Neurology 1 to move forward with its pivotal study of batoclimab as treatment for myasthenia gravis (&#8220;MG&#8221;) and initiated its Phase 3 trial in MG in June 2022. Following expected discussions with the FDA Division of Hematology, Immunovant intends to initiate a randomized, placebo-controlled study of batoclimab as treatment for warm autoimmune hemolytic anemia (&#8220;WAIHA&#8221;). In addition, Immunovant recently achieved alignment with the FDA Division of Ophthalmology to move forward in thyroid eye disease (&#8220;TED&#8221;). It plans to initiate its pivotal program for batoclimab in TED in calendar year 2022. Immunovant continues to evaluate potential new indications for batoclimab and plans to announce two new indications by August 2022. Immunovant expects one of its three indications beyond MG and TED to be initiated as a pivotal study in calendar year 2022. Failure to successfully </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">97 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">complete or replicate clinical trials of batoclimab and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market batoclimab would significantly harm our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The results of preclinical studies and early clinical trials of our products and product candidates may not be predictive of the results of later-stage clinical trials. Products and product candidates in later stage clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical and initial clinical trials. A future failure of a clinical trial to meet its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-specified</div> endpoints may cause us to abandon development of the product candidate in question. Any delay in, or termination of, our clinical trials will prevent or delay the submission of an NDA or other similar applications to the FDA or other relevant comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities and, ultimately, our ability to commercialize our products or, if approved, our product candidates, and generate product revenues. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our claims for differentiation or the effectiveness or safety of our products and product candidates. The FDA has substantial discretion in the review and approval process and may disagree that our data support the differentiated claims we propose. In addition, only a small percentage of product candidates under development result in the submission of an NDA or other similar application to the FDA and other comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities and even fewer are approved for commercialization. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interim, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">From time to time, and in some countries, in line with the applicable requirements set out in legislation and guidance, we may publicly disclose preliminary or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> data from our clinical trials, which is based on a preliminary analysis of then-available <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> data. These results and related findings and conclusions are subject to change following a full analysis of all data related to the particular trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the preliminary and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Top-line</div> data also remain subject to audit and verification procedures that may result in the final data being materially different from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> data we previously reported. As a result, preliminary and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> or interim data and final data could significantly harm our business prospects. Further, disclosure of preliminary or interim data by us or by our competitors could result in increased volatility in the price of our shares. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, other parties, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of a particular product or product candidate and our business in general. In addition, the information we choose or are required to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our products and product candidates, our business, operating results, prospects or financial condition may be harmed. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">98 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in methods of product manufacturing or formulation may result in additional costs or delay. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As our products and product candidates proceed through the development process, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause products or product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. Such changes may also require additional testing, FDA notification or FDA approval. Similar requirements apply in other jurisdictions. This could delay the completion, or result in the abandonment, of clinical trials, require the conduct of bridging clinical trials, the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our products and product candidates and jeopardize our ability to commence sales and generate revenues. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We rely on third parties to conduct, supervise and monitor our clinical trials, and if those third parties perform in an unsatisfactory manner or fail to comply with applicable requirements, it may harm our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and we expect to have limited influence over their actual performance. In addition, we rely upon CROs to monitor and manage data for our clinical programs, as well as the execution of future nonclinical studies. We expect to control only certain aspects of our CROs&#8217; activities. Nevertheless, we will be responsible for ensuring that each of our studies is conducted in accordance with the applicable contract, protocol, legal, regulatory and scientific standards and that clinical trial sites meet applicable protocol and regulatory requirements. Our reliance on CROs does not relieve us of our regulatory or specified contractual responsibilities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We and our CROs are required to comply with Good Laboratory Practices (&#8220;GLPs&#8221;) and GCPs, which are regulations and guidelines enforced by the FDA and other comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities, which also require compliance with the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (&#8220;ICH&#8221;) guidelines for any of our products and product candidates that are in preclinical and clinical development. The regulatory authorities enforce GCP regulations through periodic inspections of trial sponsors, principal investigators and clinical trial sites. Although we may rely on CROs to conduct our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GLP-compliant</div> nonclinical studies and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GCP-compliant</div> clinical trials, we remain responsible for ensuring that each of our GLP nonclinical studies and GCP clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations. Our expected reliance on the CROs does not relieve us of our regulatory responsibilities. If we or our CROs fail to comply with GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities may reject our marketing authorization applications and require us to perform additional clinical trials before approving our marketing applications. Accordingly, if our CROs fail to comply with these regulations or other applicable laws, regulations or standards, or fail to recruit a sufficient number of subjects, we may be required to repeat clinical trials, which would delay the regulatory approval process. Failure by any future CROs to properly execute study protocols in accordance with applicable law could also create product liability and healthcare regulatory risks for us as sponsors of those studies. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our CROs are independent, third-party organizations and we do not control whether they devote sufficient time, attention and resources to our clinical and nonclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities which could harm our competitive position. We face the risk of potential unauthorized disclosure or infringement, misappropriation or other violation of our intellectual property by CROs, which may reduce our trade secret and intellectual property protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">99 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approval for, or successfully commercialize any product or product candidate that we develop. As a result, our financial results and the commercial prospects for any product or product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenues could be delayed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If our relationships with these CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms or in a timely manner. Switching or adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can adversely impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with the CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We do not have our own manufacturing capabilities and rely on third parties to produce clinical and commercial supplies of our products and product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not own or operate, and do not expect to own or operate, facilities for product manufacturing, storage and distribution or testing. Accordingly, we rely on third parties to produce commercial and clinical supplies of our products and product candidates. For example, Dermavant and GSK have entered into manufacturing and supply agreements pursuant to which GSK is providing both commercial drug product and drug substance for VTAMA as well as drug product and drug substance for Dermavant&#8217;s ongoing Phase III clinical trial of VTAMA in atopic dermatitis. If GSK does not fulfill its obligations under these agreements, Dermavant&#8217;s ability to sell VTAMA commercially and conduct its ongoing and future clinical trials with VTAMA may be adversely impacted. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Third-party vendors may be difficult to identify for our product process and formulation development and manufacturing due to special capabilities required, and they may not be able to meet our quality standards. In addition, certain of our third-party manufacturers and suppliers may encounter delays in providing their services as a result of supply chain constraints. If any third-party manufacturers or third parties in the supply chain for materials used in the production of our products or product candidates are adversely impacted by supply chain constraints, our supply chain may be disrupted, limiting our ability to manufacture our products for commercialization and products or product candidates for our preclinical studies, clinical trials and research and development activities. Any significant delay in the supply of a product or product candidate, or the raw material components thereof, for either commercialization or an ongoing clinical trial, due to the need to replace a third-party manufacturer or otherwise, could considerably delay marketing efforts for the product in question or the completion of clinical trials, product testing and potential regulatory approval of the product candidate in question. If our manufacturers or we are unable to purchase these raw materials after regulatory approval has been obtained for our products or product candidates, the commercial launch of our products or product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenue from the sale of our products or product candidates and may require notification to the FDA or other regulatory authorities. Moreover, as a result of projected supply constraints for certain materials used in the production of our products or product candidates, we have in the past and may in the future reserve manufacturing capacity in advance of receiving required efficacy or safety results from our clinical trials, which may involve committing substantial financial resources to current or future products or product candidates that may never be approved or achieve commercialization at scale or at all. In addition, legislative, executive and regulatory proposals are pending to, among other things, prevent drug shortages, improve pandemic preparedness and reduce the dependency of the United States on foreign supply chains and manufacturing. While we are still assessing these developments, they could impact our selection and utilization of CMOs, vendors and other suppliers and could have a material adverse impact on our business, financial condition and results of operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The facilities used by our contract manufacturers to manufacture our products and product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit an NDA or other similar </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">100 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">application to the FDA. Such facilities must also register with the FDA. Similar requirements apply in other jurisdictions. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with Current Good Manufacturing Practice (&#8220;cGMP&#8221;) requirements for the manufacture of products and product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities, we will not be able to secure or maintain regulatory approval for our products or product candidates. In addition, we have limited control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities do not approve these facilities for the manufacture of our products or product candidates or if they withdraw any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to market our products and develop, obtain regulatory approval for or market our product candidates, if approved. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, our reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured our products and product candidates ourselves, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability to meet our product specifications and quality requirements consistently; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delay or inability to procure or expand sufficient manufacturing capacity; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">manufacturing and product quality issues related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">scale-up</div> of manufacturing; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">costs and validation of new equipment and facilities required for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">scale-up;</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure to comply with applicable laws, regulations and standards, including cGMP and similar standards; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">deficient or improper record-keeping; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability to negotiate manufacturing agreements with third parties under commercially reasonable terms; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reliance on a limited number of sources, and in some cases, single sources for product components, such that if we are unable to secure a sufficient supply of these product components, we will be unable to manufacture and sell our products or product candidates in a timely fashion, in sufficient quantities or under acceptable terms; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">lack of qualified backup suppliers for those components that are currently purchased from a sole or single source supplier; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier or other regulatory sanctions related to the manufacturer of another company&#8217;s product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">carrier disruptions or increased costs that are beyond our control; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure to deliver our products or product candidates under specified storage conditions and in a timely manner. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of these events could lead to clinical trial delays, cost overruns, delay or failure to obtain regulatory approval or impact our ability to successfully commercialize our products and product candidates as well as potential product liability litigation, product recalls or product withdrawals. Some of these events could be the basis for FDA or other regulatory authority action, including injunction, recall, seizure, total or partial suspension of production, or suspension or revocation of manufacturing/import authorizations and GMP certificates. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If the contract manufacturing facilities on which we rely do not continue to meet regulatory requirements or are unable to meet our requirements, including providing an adequate supply, our business will be harmed. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">All entities involved in the preparation of products and product candidates for clinical trials or commercial sale, including our existing CMOs for all of our products and product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP, or similar regulatory requirements outside the United States. These regulations govern manufacturing processes and procedures, including record-keeping, and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our products and product candidates. Our failure, or the failure of third-party manufacturers, to comply with applicable regulations could result in the issuance of inspectional observations on FDA&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form-483,</div> Warning or Untitled Letters, similar communications or objections by other authorities, public safety alerts identifying our company or products and sanctions being imposed on us, including clinical holds, import alerts, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, suspension of production, seizures or recalls of products or product candidates, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect clinical or commercial supplies of our products and product candidates. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We and/or our CMOs must supply all necessary documentation in support of an NDA or similar regulatory application on a timely basis, and must adhere to regulations enforced by the FDA and other regulatory agencies through their facilities inspection program. Some of our CMOs have never produced a commercially approved pharmaceutical product and therefore have not obtained the requisite regulatory authority approvals to do so. The facilities and quality systems of some or all of our third-party contractors must pass a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> inspection for compliance with the applicable regulations as a condition of regulatory approval of our products and product candidates. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our products and product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Although we oversee the CMOs, we cannot control the manufacturing process of, and are completely dependent on, our CMO partners for compliance with the regulatory requirements. If these facilities do not pass a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> plant inspection, regulatory approval of the products and product candidates may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The regulatory authorities also may, at any time following approval of a product for sale, inspect the manufacturing facilities of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third-party to implement, and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additionally, if supply from one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through a supplemental NDA or similar regulatory filing, which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. In some cases, the technical skills required to manufacture our products and product candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">back-up</div> or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product or product candidate according to the specifications previously </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">102 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">submitted to the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies, which could require the conduct of additional clinical trials. Accordingly, switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These factors could cause us to incur higher costs and could cause the delay or termination of clinical trials, regulatory submissions, required approvals, or commercialization of our products and product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks Related to Regulatory Approval and Commercialization of Our Products and Product Candidates </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Obtaining approval of a new drug is an extensive, lengthy, expensive and inherently uncertain process, and the FDA or another regulator may delay, limit or deny approval. If we are unable to obtain regulatory approval in one or more jurisdictions for any products or product candidates, our business will be substantially harmed. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We cannot commercialize a product until the appropriate regulatory authorities have reviewed and approved the product candidate. Approval by the FDA and comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities is lengthy and unpredictable, and depends upon numerous factors, including substantial discretion of the regulatory authorities. Approval policies, regulations, or the type and amount of nonclinical or clinical data necessary to gain approval may change during the course of a product candidate&#8217;s development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. While we have obtained regulatory approval in the U.S. for one of our product candidates, VTAMA, it is possible that other current and future product candidates will not be successful in obtaining regulatory approval. In addition, we cannot be certain that any products or product candidates that receive regulatory approval will be successfully commercialized. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Obtaining marketing approval of a new drug is an extensive, lengthy, expensive and inherently uncertain process and the FDA or other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities may delay, limit or deny approval of a product candidate for many reasons, including: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may not be able to demonstrate that a product candidate is safe and effective as a treatment for the targeted indications, and in the case of our product candidates regulated as biological products, that the product candidate is safe, pure and potent for use in its targeted indication, to the satisfaction of the FDA or other relevant regulatory authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the FDA or other relevant regulatory authorities may require additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> studies or clinical trials, which would increase costs and prolong development timelines; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the results of clinical trials may not meet the level of statistical or clinical significance required by the FDA or other relevant regulatory authorities for marketing approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FDA or other relevant regulatory authorities may disagree with the number, design, size, conduct or implementation of clinical trials, including the design of proposed preclinical and early clinical trials of any future product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the CROs that we retain to conduct clinical trials may take actions outside of our control, or otherwise commit errors or breaches of protocols, that adversely impact the clinical trials and ability to obtain marketing approvals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">103 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FDA or other relevant regulatory authorities may not find the data from nonclinical, preclinical studies or clinical trials sufficient to demonstrate that the clinical and other benefits of a product candidate outweigh its safety risks; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FDA or other relevant regulatory authorities may disagree with an interpretation of data or significance of results from nonclinical, preclinical studies or clinical trials or may require additional studies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FDA or other relevant regulatory authorities may not accept data generated at clinical trial sites; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if an NDA, BLA or a similar application is reviewed by an advisory committee, the FDA or other relevant regulatory authority, as the case may be, may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval of our application or may recommend that the FDA or other relevant regulatory authorities, as the case may be, require, as a condition of approval, additional nonclinical, preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FDA or other relevant regulatory authorities may require development of a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) or its equivalent, as a condition of approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FDA or other relevant regulatory authorities may require additional post-marketing studies and/or patient registries for product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FDA or other relevant regulatory authorities may find the chemistry, manufacturing and controls data insufficient to support the quality of our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FDA or other relevant regulatory authorities may identify deficiencies in the manufacturing processes or facilities of third-party manufacturers; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FDA or other relevant regulatory authorities may change their approval policies or adopt new regulations. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For example, the FDA launched Project Optimus in 2021 as an initiative to reform the dose optimization and dose selection paradigm in oncology drug development, which was driven by the FDA&#8217;s concerns that the current paradigm for dose selection may result in doses and schedules of molecularly targeted therapies that are inadequately characterized before initiating pivotal trials. Through collaboration with the biopharmaceutical industry, academia and other stakeholders, the FDA&#8217;s goal for this initiative is to advance an oncology dose-finding and dose optimization paradigm that emphasizes dose selections that maximize efficacy as well as safety and tolerability. In support of this initiative, the FDA may request sponsors of oncology product candidates to conduct dose optimization studies <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-</div> or post-approval. The FDA also continues to develop and finalize guidance documents and implement initiatives regarding the development and clinical research of oncology product candidates. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our future success depends significantly on our ability to successfully complete clinical trials for our product candidates, obtain regulatory approval and then successfully commercialize those product candidates. Any inability to successfully initiate, conduct or complete clinical trials could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional nonclinical studies or clinical trials to bridge data obtained from our modified product candidates to data obtained from nonclinical and clinical research conducted using earlier versions of these product candidates. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize product candidates and may harm our business and results of operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Delays in the initiation, conduct or completion of any clinical trial of our product candidates will increase our costs, slow down the product candidate development and approval process and delay or potentially </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">104 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">jeopardize our ability to receive regulatory approvals, commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Any of these events could have a material adverse effect on our business, prospects, financial condition and results of operations and have a negative impact on the price of our Common Shares. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of product candidates that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive nonclinical studies, preclinical studies and clinical trials that the applicable product candidate is both safe and effective for use in each target indication, and in the case of our product candidates regulated as biological products, that the product candidate is safe, pure, and potent for use in its targeted indication. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support additional marketing approvals. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations. In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results of the trials are not satisfactory to the FDA or comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even when regulatory approval is secured for a product or product candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit its commercial potential. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our products and product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval, cause us to suspend or discontinue clinical trials, abandon further development or limit the scope of any approved label or market acceptance. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adverse events caused by or associated with our products and product candidates have caused us and could, in the future, cause us, other reviewing entities, clinical trial sites or regulatory authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval. If an unacceptable frequency or severity of adverse events or new safety signals are reported in our clinical trials for our product candidates or any future product candidates, our ability to obtain regulatory approval for such product candidates may be negatively impacted. Treatment-related side effects arising from, or those perceived to arise from, our product candidates or those from other companies targeting similar diseases, could also affect patient recruitment or the ability of enrolled patients to complete their participation in our clinical trials or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. For example, as previously disclosed, our subsidiary Immunovant voluntarily paused dosing in early phase clinical studies for batoclimab globally to evaluate batoclimab-induced elevations in total cholesterol and LDL levels </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">105 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">observed in some trial subjects. After evaluation of the available safety data and following discussions with multiple regulatory agencies, Immunovant is continuing its clinical development of batoclimab. While Immunovant does not expect that increases in LDL over a short-term treatment duration would pose a safety concern for patients, the risk-benefit profile of long-term administration of batoclimab will need to incorporate any unfavorable effects on lipid profiles. These occurrences have harmed, and any reoccurrence may continue to harm our business, financial condition and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, if any of our products, or any future product candidates that are approved, cause serious or unexpected side effects, a number of potentially significant negative consequences could result, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory authorities may withdraw, suspend, vary, or limit their approval of the product or require a REMS (or equivalent outside the United States) to impose restrictions on its distribution or other risk management measures; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory authorities may require that we recall a product; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">additional restrictions being imposed on the distribution, marketing or manufacturing processes of the products or any components thereof, including a &#8220;black box&#8221; warning or contraindication on product labels or communications containing warnings or other safety information about the product; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications, require other labeling changes of a product or require field alerts or other communications to physicians, pharmacies or the public; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be required to change the way a product is administered or distributed, conduct additional clinical trials, change the labeling of a product or conduct additional post-marketing studies or surveillance; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be required to repeat preclinical studies or clinical trials or terminate programs for a product candidate, even if other studies or trials related to the program are ongoing or have been successfully completed; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be sued and held liable for harm caused to patients, or may be subject to fines, restitution or disgorgement of profits or revenues; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">physicians may stop prescribing a product; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reimbursement may not be available for a product; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may elect to discontinue the sale of our products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our products may become less competitive; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our reputation may suffer. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected products or product candidates, substantially increase the costs of commercializing our products or product candidates in the future and have a negative impact on the price of our Common Shares. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The regulatory approval processes of the FDA and comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities are lengthy, time consuming and inherently unpredictable, and gaining approval for a product candidate in one country or jurisdiction does not guarantee that we will be able to obtain approval for or commercialize it in any other jurisdiction, which would limit our ability to realize our full market potential. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Prior to obtaining approval to commercialize a product candidate in any jurisdiction, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities, that such product candidate is safe and effective and, as applicable, pure and potent for its intended use. Results from nonclinical studies and clinical trials can be </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">106 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">interpreted in different ways. Even if we believe the nonclinical or clinical data for a product candidate are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> basis regarding safety and efficacy. Approval of a product candidate by the FDA does not ensure approval by regulatory authorities in any other country or jurisdiction outside the United States. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation, as well as additional administrative review periods. Seeking regulatory approval could result in difficulties and costs for us and require additional nonclinical studies or clinical trials, which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We have one product, VTAMA, which has been approved by the FDA for the treatment of plaque psoriasis in adults in the U.S., but do not have any other products approved for sale in the U.S. or any other jurisdiction, including in international markets, and we do not have significant experience in obtaining regulatory approval in other markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">FDA approval for a product candidate in the United States does not guarantee that we will be able to or that we will make efforts to obtain approval for or commercialize our product candidates in any other jurisdiction, which would limit our ability to realize the drug candidate&#8217;s full market potential. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have one product, VTAMA, approved by the FDA for the treatment of plaque psoriasis in adults in the U.S. In order to market VTAMA or any of our other products or product candidates outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and effectiveness. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional or different administrative review periods from those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be sold in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Seeking regulatory approval outside of the United States could result in difficulties and costs and require additional nonclinical studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates in those countries. The regulatory approval process outside of the United States may include all of the risks associated with obtaining FDA approval. Other than VTAMA, we do not have any products or product candidates approved for sale in any jurisdiction, including international markets, and we do not have significant experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approval in international markets is delayed, our target market will be reduced and our ability to realize the full market potential of our products will be harmed. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Following regulatory approvals for our products and product candidates, we will continue to face extensive ongoing quality and regulatory obligations and continued regulatory review, which may result in significant additional expense, and our products may face future development and quality or regulatory compliance difficulties. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have one product, VTAMA, approved by the FDA for the treatment of plaque psoriasis in adults in the U.S. Any product or product candidate for which we obtain marketing approval will be subject to extensive and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">107 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ongoing regulatory requirements, including for manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, traceability, conduct of potential post-marketing studies and post-marketing submission requirements, export, import, advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment of registration and drug listing requirements, continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of drug product samples to physicians, prior notification/review and/or approval of advertising and promotional materials by the competent authorities, record-keeping and GCP requirements for any clinical trials that we conduct post-approval. Even when marketing approval of a product or product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including any requirement to implement a REMS. When a product or product candidate receives marketing approval, the accompanying label may limit the approved use of the drug or the FDA or other regulatory authorities may require that contraindications, warnings or precautions, including in some cases, a boxed warning, be included in the product labeling, which could limit sales of the product. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The FDA and other relevant regulatory authorities may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. Failure to complete such post-marketing requirements in accordance with the timelines and conditions set forth by the FDA and other relevant regulatory authorities could significantly increase costs, result in regulatory enforcement, or delay, limit or ultimately restrict the commercialization of such product. The FDA and other relevant regulatory authorities closely regulate the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling and that promotional and advertising materials and communications are truthful and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-misleading.</div> Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, regulatory authorities impose stringent restrictions on manufacturers&#8217; communications and if we do not market our products or product candidates for their approved indications or in a manner which regulators believe to be truthful and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-misleading,</div> we may be subject to enforcement action. Moreover, in the EU we will be prohibited from promoting prescription-only medicinal products to individuals who are not healthcare professionals. Violations of the Federal Food, Drug, and Cosmetic Act in the United States and other comparable laws and regulations in other jurisdictions relating to the promotion of prescription drugs may lead to enforcement actions and investigations by the FDA, Department of Justice, State Attorneys General and other comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory agencies alleging violations of United States federal and state health care fraud and abuse laws, as well as state consumer protection laws and comparable laws in other jurisdictions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, later discovery of previously unknown adverse events or other problems with our products or product candidates, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may negatively impact our business and the price of our Common Shares and may yield various results, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restrictions on the manufacture of such products or product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restrictions on the labeling or marketing of such products or product candidates, including a &#8220;black box&#8221; warning or contraindication on the product label or communications containing warnings or other safety information about the product; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restrictions on product distribution or use; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">requirements to conduct post-marketing studies or clinical trials, or any regulatory holds on our clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">requirement of a REMS (or equivalent outside the United States); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warning or Untitled Letters or similar communications from other relevant regulatory authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">108 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">withdrawal of the product or product candidates from the market; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal to approve pending applications or supplements to approved applications that we submit; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">recall of products or product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fines, restitution or disgorgement of profits or revenues; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">suspension, variation or withdrawal of marketing approvals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal to permit the import or export of our products or product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">seizure of our products or product candidates; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">lawsuits, injunctions or the imposition of civil or criminal penalties. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-compliance</div> by us or any current or future collaborator with regulatory requirements, including safety monitoring or pharmacovigilance can also result in significant financial penalties. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our failure to maintain or continuously improve our quality management program could have an adverse effect upon our business, subject us to regulatory actions and cause patients to lose confidence in us or our products, among other negative consequences. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Quality management plays an essential role in the manufacturing of drugs or drug products, conducting clinical trials, preventing defects, improving our product candidates and services and assuring the safety and efficacy of our products and product candidates. We seek to maintain a robust quality management program which includes the following broad pillars of quality: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">monitoring and assuring regulatory compliance for clinical trials, manufacturing and testing of good applicable practice (&#8220;GxP&#8221;) (e.g., GCP, GLP and GMP regulated) products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">monitoring and providing oversight of all GxP suppliers (e.g., contract development manufacturing organizations and CROs); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establishing and maintaining an integrated, robust quality management system for clinical, manufacturing, supply chain and distribution operations; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cultivating a proactive, preventative quality culture and employee and supplier training to ensure quality. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our future success depends on our ability to maintain and continuously improve our quality management program. A quality or safety issue may result in adverse inspection reports, warning letters, monetary sanctions, injunctions to halt manufacture and distribution of drugs or drug products, civil or criminal sanctions, costly litigation, refusal of a government to grant approvals and licenses, restrictions on operations or withdrawal, suspension or variation of existing approvals and licenses. An inability to address a quality or safety issue in an effective and timely manner may also cause negative publicity, or a loss of patient confidence in us or our products or product candidates, which may result in difficulty in successfully launching products and the loss of potential future sales, which could have an adverse effect on our business, financial condition, and results of operations. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Breakthrough Therapy Designation, Fast Track Designation, Regenerative Medicine Advanced Therapy Designation or Orphan Drug Designation by the FDA or other relevant regulatory authorities, even if granted for any product candidate, may not lead to a faster development, regulatory review or approval process, and does not necessarily increase the likelihood that any product candidate will receive marketing approval in the United States or other jurisdictions. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have sought, or may in the future seek, Breakthrough Therapy Designation, Fast Track Designation, Regenerative Medicine Advanced Therapy Designation or Orphan Drug Designation for certain of our product candidates. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">109 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed on potentially less efficacious control regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe a product candidate meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy Designation for a product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if a product candidate qualifies as a breakthrough therapy, the FDA may later decide that such product candidate no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently, there has been heightened scrutiny of the accelerated approval pathway, with some stakeholders advocating for reform. The U.S. Department of Health and Human Services (&#8220;HHS&#8221;) Office of Inspector General has initiated an assessment of how the FDA implements the accelerated approval pathway. In addition, members of Congress have introduced proposed legislation to revise the statutory accelerated approval pathway, including with respect to FDA&#8217;s ability to rapidly withdraw products and indications for which effectiveness is not confirmed in post-marketing studies. At this time, it is not clear what impact, if any, these developments may have on the statutory accelerated approval pathway or our business, financial condition results of operations, or prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a therapy is intended for the treatment of a serious or life-threatening condition and the therapy demonstrates the potential to address unmet medical needs for this condition, the therapy sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not necessarily experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track Designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory authorities in some jurisdictions, including the United States and the European Economic Area (the &#8220;EEA&#8221;), may designate drugs and biologics for relatively small patient populations as orphan drugs. In the United States, the FDA may designate a drug or biologic as an orphan drug if it is intended to treat a rare disease or condition, which is defined as a disease or condition that affects fewer than 200,000 individuals annually in the United States or for which there is no reasonable expectation that costs of research and development of the drug for the disease or condition can be recovered by sales of the drug in the United States. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug or biologic for the same orphan indication for that time period. In the United States, in order for a product to receive orphan drug exclusivity, FDA must not have previously approved a drug considered the same drug for the same orphan indication, or the subsequent drug must be shown to be clinically superior to such a previously approved same drug. The applicable period of marketing exclusivity is seven years in the United States. A similar data exclusivity scheme exists in the EEA. The European Commission, on the basis of a scientific opinion by the EMA&#8217;s Committee for Orphan Medicinal Products grants Orphan Drug Designation to promote the development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition affecting not more </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">110 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">than five in 10,000 persons in the EU. Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the drug or biological product. In any event, Orphan Drug Designation is granted only if there is no satisfactory method of diagnosis, prevention, or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition. Orphan designation in the EU entitles a party to certain benefits, such as scientific assistance (protocol assistance), financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This orphan market exclusivity period prevents the European Commission, EMA and the competent authorities of the EU Member States from accepting an application or granting marketing authorization for any similar medicinal product intended for the same orphan indication. The orphan market exclusivity applies in parallel to the &#8220;normal&#8221; data and market exclusivity in the EEA, whereby no company can make reference to (rely on) the innovator drug company&#8217;s preclinical and clinical data in order to obtain a marketing authorization for eight years from the date of the first approval of the innovator drug in the EEA and no generic drug can be marketed for ten years from the first approval of the innovator drug in the EEA; the innovator drug may qualify for an extra year&#8217;s protection. This additional one year of marketing exclusivity may be obtained where the innovator company is granted a marketing authorization for a significant new indication for the relevant medicinal product. In such a situation, the generic company can only market their product after 11 years from the first grant of the innovator company&#8217;s marketing authorization for the product in the EEA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug or biologic to meet the needs of patients with the rare disease or condition. In the EEA, orphan drug designation, and the related benefits, may be lost if it is established before the market authorization is granted that the designation criteria are no longer met. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, the ten year orphan market exclusivity in the EEA may be reduced to six years if the orphan drug designation criteria are no longer met at the end of the fifth year since grant of the approval, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA or the European Commission can subsequently approve the same drug for a different condition or the same condition if the FDA or the EMA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In the EEA, a marketing authorization may also be granted, for the same therapeutic indication, to a competitor with a similar medicinal product during the exclusivity period if we are unable to supply sufficient quantities of the medicinal product for which we received marketing authorization. Upcoming legislative reforms in the EU may result in a reduction of market exclusivity periods for orphan medicinal products, changes to the concept of unmet medical need and/or imposition of additional requirements for grant of such exclusivity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, a recent Eleventh Circuit decision in Catalyst Pharmaceuticals, Inc. vs. FDA regarding interpretation of the Orphan Drug Act exclusivity provisions as applied to drugs approved for orphan indications narrower than the drug&#8217;s orphan designation has the potential to significantly broaden the scope of orphan drug exclusivity for such products. Depending on how broadly FDA applies the Catalyst decision, it could fundamentally change how companies rely on, or seek to work around, orphan drug exclusivity. Legislation has been introduced that may reverse the Catalyst decision, and may be enacted as part of the reauthorization of user fees later this year. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">111 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Receipt of marketing approval for our products and product candidates does not guarantee that they will achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The commercial success of our products and product candidates will depend upon their degree of market acceptance by physicians, patients, third-party payors and others in the medical community. Receipt of marketing approval for our products and product candidates does not guarantee that they will gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. The degree of market acceptance for any product or product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the efficacy and safety of such products and product candidates as demonstrated in pivotal clinical trials and published in peer-reviewed journals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the potential and perceived advantages compared to alternative treatments, including any similar generic treatments; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the ability to offer these products for sale at competitive prices; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the ability to offer appropriate patient financial assistance programs, such as commercial insurance <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-pay</div> assistance; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">convenience and ease of dosing and administration compared to alternative treatments; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the clinical indications for which the product or product candidate is approved by FDA or comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory agencies; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">product labeling or product insert requirements of the FDA or other comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities, including any limitations, contraindications or warnings contained in a product&#8217;s approved labeling; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restrictions on how the product is dispensed or distributed; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the timing of market introduction of competitive products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">publicity concerning these products or competing products and treatments; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the strength of marketing and distribution support; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">favorable third-party coverage and sufficient reimbursement; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the prevalence and severity of any side effects or adverse events. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales of medical products also depend on the willingness of physicians to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe, therapeutically effective and cost effective. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups and the viewpoints of influential physicians can affect the willingness of other physicians to prescribe such products. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If approved, our product candidates regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the &#8220;Affordable Care Act&#8221; or &#8220;ACA&#8221;), includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (the &#8220;BPCIA&#8221;), which created an abbreviated approval pathway under section 351(k) of the Public Health Service Act (&#8220;PHSA&#8221;) for biological products that are biosimilar to or interchangeable with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">an&#160;FDA-licensed&#160;reference</div> biological product. Under the BPCIA, a section 351(k) application for a biosimilar or interchangeable product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">112 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">biosimilar or interchangeable product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">this&#160;12-year&#160;period</div> of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product submitted under section 351(a) of the PHSA containing the competing sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#8217;s product. The law is complex and is still being interpreted and implemented by the FDA and the FDA only approved the first interchangeable biosimilar in July 2021. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. In addition, the Further Consolidated Appropriations Act, 2020, which incorporated the framework from the Creating and Restoring Equal Access To Equivalent Samples legislation, purports to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products, including by allowing generic drug, 505(b)(2) NDA or biosimilar developers to obtain access to branded drug and biological product samples. While the full impact of these provisions is unclear at this time, its provisions do have the potential to facilitate the development and future approval of biosimilar versions of our products, introducing biosimilar competition that could have a material adverse impact on our business, financial condition and results of operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Whether approval of a biological product qualifies for reference product exclusivity turns on whether FDA consider the approval a &#8220;first licensure.&#8221; Not every licensure of a biological product is considered a &#8220;first licensure&#8221; that gives rise to its own exclusivity period. We believe that our product candidates approved as a biological product under a BLA should qualify for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;12-year&#160;period</div> of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">for&#160;non-biological&#160;products</div> is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. If competitors are able to obtain marketing approval for biosimilars referencing our products, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are unable to continue to expand our sales, marketing and distribution capabilities or enter into agreements with third parties to sell, market and distribute our products and product candidates, we may not be successful in commercializing those products and, if approved, product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are currently in the process of establishing an infrastructure for the sales, marketing and distribution of VTAMA, which was approved by the FDA in May 2022 for the treatment of plaque psoriasis in adults in the U.S. The costs of establishing and maintaining this infrastructure may exceed the cost-effectiveness of doing so. In order to effectively market our products and, if approved, product candidates, we must continue to expand our sales, distribution, marketing, compliance, managerial and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-technical</div> capabilities or make arrangements with third parties to perform these services. To achieve commercial success for our products and, if approved, product candidates, we will need an effective sales and marketing organization or to outsource these functions to third parties. To the extent we seek to do so, there is no guarantee that we will be able to enter into collaborations or strategic partnerships with third parties to engage in commercialization activities with respect to our products or product candidates. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time consuming and could delay any product launch. If the commercial launch of a product or, if approved, product candidate for which we recruit a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition commercialization personnel. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">113 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Factors that may inhibit our efforts to commercialize a product or, if approved, product candidate on our own include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs, and other support personnel; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future approved products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and other acceptance by payors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inability to price products at a sufficient price point to ensure an adequate and attractive level of profitability; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unforeseen costs and expenses associated with creating an independent commercialization organization. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of a product or, if approved, product candidate, we may be forced to delay commercialization or reduce the scope of our sales or marketing activities. If we elect to increase our expenditures to fund commercialization activities ourselves, we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds, we will not be able to bring a product or, if approved, product candidate to market or generate product revenue. We could enter into arrangements with collaborative partners at an earlier stage than otherwise would be ideal and we may be required to relinquish certain rights to our products or product candidate or otherwise agree to terms unfavorable to us, any of which may have an adverse effect on our business, operating results and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If we enter into arrangements with third parties to perform sales, marketing, commercial support and distribution services, our product revenue or the profitability of product revenue may be lower than if we were to market and sell any products we may develop internally. In addition, we may not be successful in entering into arrangements with third parties to commercialize our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively or may expose us to legal and regulatory risk by not adhering to regulatory requirements and restrictions governing the sale and promotion of prescription drug products, including those restricting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> promotion. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our products or, if approved, product candidates. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our current and future relationships with investigators, health care professionals, consultants, third-party payors, patient support, charitable organizations, customers, and others are subject to applicable healthcare regulatory laws, which could expose us to penalties and other risks. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our business operations and current and potential future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient support, charitable organizations, customers, and others, expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws regulate the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our products and, if approved, product candidates. Such laws include, without limitation: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the federal Anti-Kickback Statute, which is a criminal law that prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">114 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program (such as Medicare and Medicaid). The term &#8220;remuneration&#8221; has been broadly interpreted by the federal government to include anything of value. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain activities from prosecution, the exceptions and safe harbors are drawn narrowly, and arrangements may be subject to scrutiny or penalty if they do not fully satisfy all elements of an available exception or safe harbor. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation; in addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. Violations of the federal Anti-Kickback Statute may result in civil monetary penalties up to $100,000 for each violation. Civil penalties for such conduct can further be assessed under the federal False Claims Act. Violations can also result in criminal penalties, including criminal fines and imprisonment of up to 10 years. Similarly, violations can result in exclusion from participation in government healthcare programs, including Medicare and Medicaid; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the federal false claims laws, including the False Claims Act, which imposes civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent; knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim; or knowingly making or causing to be made, a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. When an entity is determined to have violated the federal civil False Claims Act, the government may impose civil fines and penalties currently ranging from $11,803 to $23,607 for each false claim or statement for penalties assessed after December&#160;13, 2021, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the federal health care fraud statute (established by Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;)), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false or fraudulent statements relating to healthcare matters; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Administrative Simplification provisions of HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and their implementing regulations, which impose obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information on health plans, health care clearing houses and most healthcare providers (collectively, &#8220;covered entities&#8221;), and such covered entities&#8217; &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities that create, receive or obtain protected health information in connection with providing a service for or on behalf of the covered entity; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">various privacy, cybersecurity and data protection laws, rules and regulations at the international, federal, state and local level impose obligations with respect to safeguarding the privacy, security, and cross-border transmission of personal data and health information; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the federal Civil Monetary Penalties Law, which authorizes the imposition of substantial civil monetary penalties against an entity that engages in activities including, among others (1)&#160;knowingly presenting, or causing to be presented, a claim for services not provided as claimed or that is otherwise false or fraudulent in any way; (2)&#160;arranging for or contracting with an individual or entity that is excluded </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">115 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">from participation in federal health care programs to provide items or services reimbursable by a federal health care program; (3)&#160;violations of the federal Anti-Kickback Statute; or (4)&#160;failing to report and return a known overpayment; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the government information related to payments or other &#8220;transfers of value&#8221; made to physicians, certain other healthcare providers, and teaching hospitals, and requires applicable manufacturers and group purchasing organizations to report annually to the government ownership and investment interests held by the physicians described above and their immediate family members and payments or other &#8220;transfers of value&#8221; to such physician owners (covered manufacturers are required to submit reports to the government by the 90th day of each calendar year); and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">analogous state and EU and foreign national laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> third-party payors, including private insurers, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and several recently passed state laws that require disclosures related to state agencies and/or commercial purchasers with respect to certain price increases that exceed a certain level as identified in the relevant statutes, some of which contain ambiguous requirements that government officials have not yet clarified; and EU and foreign national laws prohibiting promotion of prescription-only medicinal products to individuals other than healthcare professionals, governing strictly all aspects of interactions with healthcare professionals and healthcare organizations, including prior notification, review and/or approval of agreements with healthcare professionals, and requiring public disclosure of transfers of value made to a broad range of stakeholders, including healthcare professionals, healthcare organizations, medical students, physicians associations, patient organizations and editors of specialized press. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of these or any other applicable health regulatory laws that may apply to us, we may be subject to significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Even the mere issuance of a subpoena, civil investigative demand or the fact of an investigation alone, regardless of the merit, may result in negative publicity, a drop in our share price and other harm to our business, financial condition and our results of operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">116 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The United States and many other jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could restrict or regulate post-approval activities for our products and affect our ability to profitably sell our products, and prevent or delay marketing approval of our current and any future product candidates. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements; (ii)&#160;additions or modifications to product labeling; (iii)&#160;the recall or discontinuation of our products; or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs, including costs for pharmaceuticals. For example, in March 2010, the ACA was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjects biological products to potential competition by lower-cost biosimilars, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and creates a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-sale</div></div> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future, with unpredictable and uncertain results. Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. The law appears likely to continue the downward pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in 2013, and, due to subsequent legislative amendments, will after a pause in early 2022 remain in effect through 2031 unless additional Congressional action is taken. Pursuant to the CARES Act and subsequent legislation, these reductions were suspended from May&#160;1, 2020 through March&#160;31, 2022 due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of the sequester. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and reform government program reimbursement methodologies for drugs. Current Congressional proposals include direct price negotiation by Medicare in Medicare Parts B and D, international reference pricing for certain Medicare drugs, and inflationary rebates on Part B and Part D drugs whose prices </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">117 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">increase above a certain amount, and Part D drug benefit redesign. At the federal level, the former Trump administration released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. HHS implemented several of these provisions to date. In May 2019, Centers for Medicare and Medicaid Services (the &#8220;CMS&#8221;), issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs beginning January&#160;1, 2020. Additionally, on November&#160;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. This rulemaking also created a new safe harbor for price reductions reflected at the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-sale,</div></div> as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. However, Congress adopted a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-year</div> moratorium on implementation or enforcement of the rule as a part of the Infrastructure Investment and Jobs Act. In July 2021, President Biden issued an executive order pertaining to drug pricing, which expressed support for legislation allowing direct negotiation in Medicare Part D and inflationary rebates, and directed various executive branch agencies to take actions to lower drug prices and promote generic competition. Moreover, on November&#160;19, 2021, the House passed the Build Back Better Act, which among other provisions, would permit the Secretary of HHS to negotiate certain high-expenditure Part D drugs, impose inflationary rebates for Part D drugs, and redesign the Part D benefit. The Senate Finance Committee introduced a modified version of the legislation on December&#160;11, 2021, but negotiations have since stalled. Although the House and Senate versions of this legislation would grant certain exceptions for &#8220;small biotech drugs&#8221; and &#8220;specified small manufacturers,&#8221; if passed, we cannot predict how these exceptions would be implemented and their impact on Roivant. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, upcoming legislative and policy changes in the EU, some of which may materialize as early as 2022, are aimed at increasing accessibility and affordability of medicinal products, as well as at increased cooperation between the EU Member States. Such initiatives may further impact the price and reimbursement status of our products in the future. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There have been, and likely will continue to be, legislative and regulatory proposals at the national and state levels in jurisdictions around the world directed at containing or lowering the cost of healthcare, including prescription drugs. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products and, if approved, our product candidates. Such reforms could have an adverse effect on anticipated revenue from our products and, if approved, product candidates and may affect our overall financial condition and ability to develop future product candidates and obtain marketing approval for those product candidates. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the demand for our products and, if approved, product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to receive or set a price that we believe is fair for our products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to generate revenue and achieve or maintain profitability; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the amount of taxes that we are required to pay; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the availability of capital. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect that healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement and new payment methodologies. This could lower the price that we receive for our products and, if approved, product candidates. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">118 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">us from being able to generate sufficient revenue, attain profitability or successfully commercialize our products and, if approved, product candidates. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Coverage and adequate reimbursement may not be available for our products and, if approved, product candidates, which could make it difficult for us to profitably sell our products and, if approved, product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market acceptance and sales of our products and, if approved, product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and product candidates and related treatments will be available from third-party payors, including government health administration authorities and private health insurers. The pricing and reimbursement of our products and, if approved, product candidates, must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our products and, if approved, product candidates, will be adversely affected. The manner and level at which reimbursement is provided for services related to our products and product candidates (e.g., for administration of our products to patients) is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our products and, if approved, product candidates. There is no assurance that our products or, if approved, product candidates, would achieve adequate coverage and reimbursement levels. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the United States, no uniform policy of coverage and reimbursement exists among third-party payors. Third-party payors decide which drugs they will pay for and establish reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product or, if approved, product candidate will be made on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">plan-by-plan</div></div> basis. One payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage, and adequate reimbursement, for the product. Additionally, a third-party payor&#8217;s decision to provide coverage for a drug does not imply that an adequate reimbursement rate will be approved. Each plan determines whether or not it will provide coverage for a drug, what amount it will pay the manufacturer for the drug, on what tier of its formulary the drug will be placed and whether to require step therapy. The position of a drug on a formulary generally determines the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> that a patient will need to make to obtain the drug and can strongly influence the adoption of a drug by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our product or, if approved, product candidates, unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of the product or product candidate. Further, from time to time, typically on an annual basis, payment rates are updated and revised by third-party payors. Such updates could impact the demand for our products or, if approved, product candidates, to the extent that patients who are prescribed our products or, if approved, product candidates, are not separately reimbursed for the cost of the product. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Even if we obtain adequate levels of reimbursement, third-party payors, such as government or private healthcare insurers, carefully review and increasingly question the coverage of, and challenge the prices charged for, products. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Increasingly, third-party payors are requiring that pharmaceutical companies provide them with predetermined discounts from list prices and are challenging the prices for products. We may also be required to conduct expensive pharmacoeconomic studies to justify the coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand for, or the price of, any product or, if approved, product candidate. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize any product or, if approved, product candidate that we develop. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">119 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, there have been a number of legislative and regulatory proposals to change the healthcare system in the United States and in some other jurisdictions that could affect our ability to profitably sell any product or, if approved, product candidate. These legislative and regulatory changes may negatively impact the reimbursement for any product or, if approved, product candidate. There can be no assurance that our products or, if approved, product candidates, will be considered medically reasonable and necessary, that they will be considered cost-effective by third-party payors, that coverage or an adequate level of reimbursement will be available, or that reimbursement policies and practices in the United States and in other countries where our products and, if approved, product candidates, are sold will not harm our ability to profitably sell our products and, if approved, product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our products or, if approved, product candidates. In addition to continuing pressure on prices and cost containment measures, legislative developments in the EU or the EU Member States may harm our ability to profitably sell our products and, if approved, product candidates. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national EU Member States law. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. The healthcare budgetary constraints in most countries have resulted in restrictions on the pricing and reimbursement of medicines. In markets outside of the United States and EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. All of this could affect our ability to commercialize our products and, if approved, product candidates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent federal legislation and actions by state and local governments may permit reimportation of drugs from foreign countries into the United States, including foreign countries where the drugs are sold at lower prices than in the United States, which could materially adversely affect our operating results. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We may face competition in the United States for our products and, if approved, product candidates, from therapies sourced from foreign countries that have placed price controls on pharmaceutical products. In the United States, the Medicare Modernization Act (&#8220;MMA&#8221;) contains provisions that may change U.S. importation laws and expand pharmacists&#8217; and wholesalers&#8217; ability to import cheaper versions of an approved drug and competing products from Canada, where there are government price controls. These changes to U.S. importation laws will not take effect unless and until the Secretary of the HHS certifies that the changes will pose no additional risk to the public&#8217;s health and safety and will result in a significant reduction in the cost of products to consumers. On September&#160;23, 2020, the Secretary of HHS made such certification to Congress, and on October&#160;1, 2020, the FDA published a final rule that allows for the importation of certain prescription drugs from Canada. Under the final rule, States and Indian Tribes, and in certain future circumstances pharmacists and wholesalers, may submit importation program proposals to the FDA for review and authorization. Since the issuance of the final rule, on November&#160;23, 2020, several industry groups filed federal lawsuits in the U.S. District Court for the District of Columbia, requesting injunctive relief to prevent implementation of the rule. Further, authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. On September&#160;25, 2020, CMS stated drugs imported by States under this rule will not be eligible for federal rebates under Section&#160;1927 of the Social Security Act and manufacturers would not report these drugs for &#8220;best price&#8221; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. Separately, the FDA also issued a final guidance document outlining a pathway for manufacturers to obtain an additional National Drug Code (&#8220;NDC&#8221;), for an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> drug that was originally intended to be marketed in a foreign country and that was authorized for sale in that foreign country. In addition, the July 2021 executive order pertaining to drug pricing directs the FDA to support and work with States and Indian Tribes to develop importation plans to import prescription drugs from Canada under the MMA and final rule. If implemented, importation of drugs from Canada may materially and adversely affect the price we receive for our products and, if approved, product candidates. The regulatory and market implications of the final rule and guidance are </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">120 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unknown at this time. Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation under certain circumstances. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for our products and, if approved, product candidates and adversely affect our future revenues and prospects for profitability. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Risks Related to Our Business and Industry </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We depend on the knowledge and skills of our senior leaders and may not be able to manage our business effectively if we are unable to attract and retain key personnel. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have benefited substantially from the leadership, performance and vision of our senior leaders, in particular, our founder and Chairman, Vivek Ramaswamy, our Principal Executive Officer, Matthew Gline, and other senior executives at Roivant and the Vants. We rely greatly on the investment experience and medical and scientific expertise of our senior leadership team to identify product candidates and guide future investments and opportunities, as well as the drug development expertise of our and the Vants&#8217; senior leadership to guide the preclinical and clinical development of our product candidates. Our success will depend on our ability to retain our current management team. In addition, while we expect to engage in an orderly transition process as we integrate newly appointed officers and managers, we face a variety of risks and uncertainties related to management transition, including diversion of management attention from business concerns, failure to retain other key personnel or loss of institutional knowledge. Competition for senior leadership in the healthcare investment industry is intense, and we cannot guarantee that we will be able to retain our key personnel or that of our Vants. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our senior leaders and key employees may terminate their positions with us at any time. Due to the small number of employees at some of the Vants, the loss of a key employee may have a larger impact on our business. In particular, we rely on a limited number of employees in certain key jurisdictions, including the United Kingdom (the &#8220;U.K.&#8221;), Switzerland and Bermuda. If we lose one or more members of our or the Vants&#8217; senior leadership teams or other key employees, our ability to successfully implement our business strategies could be adversely impacted. Replacing these individuals may be difficult, cause disruption and may take an extended period of time due to the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of, and commercialize product candidates successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate additional key personnel. We do not maintain &#8220;key person&#8221; insurance for any members of our senior leadership team or other employees. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To encourage valuable employees to remain at our company, in addition to salary and cash incentives, we have provided certain equity awards that vest over time. The value to employees of equity awards that vest over time may be significantly affected by movements in our share price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain invaluable employees, members of our management, scientific and development teams may terminate their employment with us at any time. Although we have employment agreements with our key employees, certain of these employment agreements provide for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">at-will</div> employment, which means that any of our employees could leave our employment at any time. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-level</div> and senior managers as well as junior, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-level</div> and senior scientific and medical personnel. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We will need to expand our organization and may experience difficulties in managing this growth, which could disrupt operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with our continued growth, we expect to hire, either directly or through our current or future affiliates, additional employees for our managerial, finance and accounting, clinical, scientific and engineering, regulatory, operational, manufacturing, sales and marketing teams. We may have difficulties in connection with </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">121 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">identifying, hiring, integrating and retaining new personnel. Future growth would impose significant additional responsibilities on management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, management may need to divert a disproportionate amount of its attention away from our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of operations across our entities, which may result in weaknesses in infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our future growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and ability to commercialize product candidates and new technologies and compete effectively will partly depend on our ability to effectively manage any future growth. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many of the other pharmaceutical and healthcare technology companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer operating history in the industry than us. They also may provide more diverse opportunities and better chances for career advancement. Some of these opportunities may be more appealing to high-quality candidates and consultants than what we have to offer. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can discover and develop our products and product candidates will be harmed, which could negatively impact our financial condition, results of operations and cash flows. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our international operations may expose us to business, legal, regulatory, political, operational, financial and economic risks associated with conducting business globally. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Part of our business strategy involves potential expansion internationally with third-party collaborators to seek regulatory approval for our products and product candidates globally. Doing business internationally involves a number of risks, including but not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">multiple conflicting and changing laws and regulations such as tax laws, export and import restrictions, employment laws, anti-bribery and anti-corruption laws, regulatory requirements and other governmental approvals, permits and licenses; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure by us or our collaborators to obtain appropriate licenses or regulatory approvals for the sale or use of our products or, if approved, product candidates, in various countries; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">difficulties in managing operations in different jurisdictions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">complexities associated with managing multiple payor-reimbursement regimes or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">self-pay</div> systems; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial risks, such as longer payment cycles, difficulty enforcing contracts and collecting accounts receivable and exposure to currency exchange rate fluctuations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">varying protection for intellectual property rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure to comply with the United States Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;), including its books and records provisions and its anti-bribery provisions, the United Kingdom Bribery Act 2010 (the &#8220;U.K. Bribery Act&#8221;), and similar anti-bribery and anti-corruption laws in other jurisdictions, for example by failing to maintain accurate information and control over sales or distributors&#8217; activities. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of these risks, if encountered, could significantly harm our future international expansion and operations and, consequently, negatively impact our financial condition, results of operations and cash flows. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">122 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to invest in and expand our business and meet our financial obligations, to attract and retain third-party contractors and collaboration partners and to raise additional capital depends on our operating and financial performance, which, in turn, is subject to numerous factors, including the prevailing economic and political conditions and financial, business and other factors beyond our control, such as the rate of unemployment, the number of uninsured persons in the United States, political influences and inflationary pressures. For example, an overall decrease in or loss of insurance coverage among individuals in the United States as a result of unemployment, underemployment or the repeal of certain provisions of the ACA may decrease the demand for healthcare services and pharmaceuticals. If fewer patients are seeking medical care because they do not have insurance coverage, we may experience difficulties in commercializing our products and, if approved, product candidates and our business, results of operations, financial condition and cash flows could be adversely affected. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets upon which pharmaceutical and biopharmaceutical companies such as us are dependent for sources of capital. In the past, global financial crises have caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including a reduced ability to raise additional capital when needed on acceptable terms, if at all, and weakened demand for our products and, if approved, product candidates. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve certain regulatory approvals before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize our products and, if approved, product candidates and ultimately harm our financial condition. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The development and commercialization of new drug products is highly competitive. Now and in the future we may face competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide with respect to our products and product candidates. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development and commercialization of products and product candidates for the treatment of the indications that we are also pursuing. Examples of such competing products include, but are not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roflumilast, a PDE4 inhibitor, a potential competitor to VTAMA, which in May 2022 was approved by the FDA for the treatment of plaque psoriasis in adults in the U.S. under the brand name VTAMA cream and which is also in development by Dermavant for the topical treatment of atopic dermatitis; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ruxolitinib, a topical Janus kinase inhibitor, a potential competitor to VTAMA, in development by Dermavant for the topical treatment of atopic dermatitis; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Teprotumumab, an insulin-like growth <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">factor-1</div> receptor inhibitor, which in January 2020 was approved by the FDA for the treatment of TED, a potential competitor to batoclimab, in development by Immunovant for the treatment of TED and other autoimmune diseases; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VYVGART<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#8482;</div> (efgartigimod alfa-fcab), a neonatal Fc receptor blocker, which in December 2021 was approved by the FDA for the treatment of MG in adults who test positive for the anti-acetylcholine </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">123 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">receptor antibody, a potential competitor to batoclimab, in development by Immunovant for the treatment of MG and other autoimmune diseases; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Efgartigimod, an anti-FcRn antibody fragment, nipocalimab, an anti-FcRn antibody, Zilucoplan, a peptide inhibitor of C5, and inebilizumab, a CD19-targeted humanized monoclonal antibody, all potential competitors to batoclimab, in development by Immunovant for the treatment of MG and other autoimmune diseases; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Ultomiris <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Ravulizumab-cwvz),</div> a complement inhibitor, which in April 2022 was approved by the FDA for the treatment of generalized MG in adults who are anti-acetylcholine receptor antibody-positive, a potential competitor to batoclimab, in development by Immunovant for the treatment of MG and other autoimmune diseases; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rituximab, a monoclonal antibody, a potential competitor to batoclimab, in development by Immunovant for the treatment of TED, WAIHA and other autoimmune diseases; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fostamatinib, a syk inhibitor, ibrutinib, a BTK inhibitor, and ANX005, an antibody inhibitor, all potential competitors to batoclimab, in development by Immunovant for the treatment of WAIHA and other autoimmune diseases; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of these or other competitors, including competitors for our other product candidates, receive FDA approval before we do, our products or product candidates would not be the first treatment on the market, and our market share may be limited. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than our products and product candidates. Furthermore, currently approved products could be discovered to have application for treatment of our targeted disease indications or similar indications, which could give such products significant regulatory and market timing advantages over our products and product candidates. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from the FDA for indications that we are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our products or product candidates uneconomical or obsolete and we may not be successful in marketing our products or, if approved, any product candidates we may develop against competitors. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity and/or enforceability of our patents relating to our competitors&#8217; products and our competitors may allege that our products or product candidates infringe, misappropriate or otherwise violate their intellectual property. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for our products and, if approved, any product candidates we may develop. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">124 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The markets in which our healthcare technology Vants participate are competitive, and if we do not compete effectively, our business and operating results could be adversely affected. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The overall market for healthcare technologies and software is global, rapidly evolving, competitive and subject to changing technology and shifting customer focus. Our healthcare technology Vants, including Lokavant, a clinical trial technology company, face competition from well-established providers of similar solutions, certain of which may have long-standing relationships with many of our current and potential customers, including large biopharmaceutical companies. We also face competition from solutions that biopharmaceutical companies develop internally and from smaller companies that offer products and services directed at more specific markets than we target, enabling these smaller competitors to focus a greater proportion of their efforts and resources on these markets, as well as a large number of companies that have been founded with the goal of applying machine learning technologies to drug discovery. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many of our competitors are able to devote greater resources to the development, promotion, and sale of their software solutions and services. Third parties with greater available resources and the ability to initiate or withstand substantial price competition could acquire our current or potential competitors. Our competitors may also establish cooperative relationships among themselves or with third parties that may further enhance their product offerings or resources. If our competitors&#8217; products, services or technologies become more accepted than our solutions, if our competitors are successful in bringing their products or services to market earlier than ours, if our competitors are able to respond more quickly and effectively to new or changing opportunities, technologies, or customer requirements, or if their products or services are more technologically capable than ours, then the business and prospects of these Vants could be adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We and our subsidiaries are subject to litigation and investigation risks which could adversely affect our business, results of operations and financial condition and could cause the market value of our Common Shares to decline. Insurance coverage may not be available for, or adequate to cover, all potential exposure for litigation and other business risks. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We and our subsidiaries are from time to time subject to various litigation matters and claims, including regulatory proceedings, administrative proceedings, securities litigation and other lawsuits, and governmental investigations. In addition, we and our subsidiaries may receive requests for information from governmental agencies in connection with their regulatory or investigatory authority or from private third parties pursuant to subpoena. These proceedings may be complex and prolonged, and may occupy the resources of our and our subsidiaries&#8217; management and employees. These proceedings are also costly to prosecute and defend and may involve substantial awards or damages payable by us or our subsidiaries if not favorably resolved. We and our subsidiaries may be required to pay substantial amounts or grant certain rights on unfavorable terms in order to settle such proceedings. We also face risks relating to litigation arising from judgments made by us and the Vants as to the materiality of any developments in our businesses, including with respect to preclinical and clinical data, and the resulting disclosure (or lack thereof) may give rise to securities litigation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We maintain insurance policies for certain litigation and various business risks, but such policies may not be adequate to compensate us for any or all potential losses. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance, if available, may not cover all claims made against us and defending a suit, regardless of its merit, could be costly and divert management&#8217;s attention. Because of the uncertain nature of litigation, investigations and insurance coverage decisions, it is not possible to predict the outcome of these matters as they arise from time to time, and they could have a material adverse effect on our and our subsidiaries&#8217; business, results of operations, and financial condition, could impact our ability to consummate a transaction that is challenged or otherwise subject to such litigation and could cause the market value of our Common Shares to decline. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">125 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not hold a controlling stake in certain of our subsidiaries and thus may not be able to direct our business or the development of our product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For certain of the Vants, including Arbutus and Sio Gene Therapies, we hold less than a majority ownership interest or are otherwise limited in our ability to direct or control the business and the development of the product candidates or technologies at the Vant. In addition, for certain other Vants, including Immunovant, we may in the future come to hold less than a majority ownership interest in the Vant. Furthermore, even if we own a majority ownership interest in a Vant, we may not necessarily be able to control the outcome of certain corporate actions. If the business or development of a product candidate at one of these Vants were to face challenges, we would be adversely affected as a result and would be limited in our ability to cause or influence the Vant in question to take appropriate remediative actions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our business and operations would suffer in the event of system failures, cyber-attacks or a deficiency in our cyber-security. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our computer systems, as well as those of various third parties on which we presently rely, or may rely on in the future, including our CROs and other contractors, consultants and law and accounting firms, may sustain damage from or otherwise be subject to computer viruses, unauthorized access, data breaches, phishing attacks, cybercriminals, natural disasters (including hurricanes and earthquakes), terrorism, war and telecommunication and electrical failures. Such information technology systems are additionally vulnerable to security breaches from inadvertent or intentional actions by our employees, third-party vendors, contractors, consultants, business partners, and/or other third parties. Any of the foregoing may compromise our system infrastructure, or that of our third-party vendors and other contractors and consultants, or lead to data leakage. The risks of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by traditional computer &#8220;hackers,&#8221; threat actors, personnel (such as through theft or misuse), sophisticated nation-state and nation-state-supported actors, sovereign governments and cyber terrorists, have generally increased over time, including for geopolitical reasons and in conjunction with military conflicts and defense activities, along with the number, intensity and sophistication of attempted attacks and intrusions from around the world. During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including cyber-attacks that could materially disrupt our systems and operations, supply chain and ability to produce, sell and distribute our products and product candidates. In addition, there may be an increased risk of cybersecurity attacks due to the onset of hostilities by Russia towards Ukraine, including cybersecurity attacks perpetrated by Russia or others at its direction in response to economic sanctions and other actions taken against Russia as a result of its invasion of Ukraine. Any increase in such attacks on us or our third-party vendors or other systems could adversely affect our network systems or other operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We generally require our third-party providers to implement effective security measures and to identify and correct for any such failures, deficiencies or breaches. Although we seek to supervise such third parties&#8217; security measures, our ability to do so is limited. If the information technology systems of our third-party vendors and other contractors and consultants become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event and to develop and implement protections to prevent future events of this nature from occurring. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot anticipate all possible types of security threats and we cannot guarantee that our data protection efforts and our investments in information technology will prevent significant breakdowns, data leakages, security breaches in our systems, or those of our third-party vendors and other contractors and consultants, or other cyber incidents that could have a material adverse effect upon our reputation, business, operations, or financial condition. If any of the aforementioned security events were to occur, it could result in a material disruption of our commercialization efforts, drug development programs and other business operations. For example, the loss of nonclinical or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, we rely on third parties to supply components for and to manufacture our product candidates and to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">126 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and reputational damage and the commercialization efforts for our products and further development of any product candidate could be delayed. The costs related to significant security breaches or disruptions could be material and exceed the limits of the cybersecurity insurance we maintain against such risks. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are subject to stringent privacy, data protection and information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies and contractual obligations could adversely affect our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide. Failure to comply with applicable privacy and data security laws and regulations could result in enforcement actions against us, including possible fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are numerous U.S. federal and state laws and regulations related to the privacy, data protection and security of personal information. At the federal level, regulations promulgated pursuant to HIPAA establish privacy and security standards for &#8220;covered entities&#8221; (group health plans and most healthcare providers) that limit the use and disclosure of individually identifiable health information those entities receive or create (&#8220;protected health information&#8221;), and require the implementation of administrative, physical and technological safeguards to protect the security, confidentiality, integrity and availability of electronic protected health information. While we generally are not subject to HIPAA in our business, we do business with various entities that are subject to HIPAA and we have to expend resources to understand their obligations, adjust contractual relationships in light of those obligations, or otherwise modify our business practices. Congress has considered expanding the scope of the HIPAA privacy and security regulations and we may in the future become subject to them or parallel regulations ourselves, which would require us to make additional expenditures and create additional risks. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, many U.S. states in which we operate have laws that protect the privacy and security of personal information. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance efforts. For example, the California Confidentiality of Medical Information Act (the &#8220;CMIA&#8221;), a statute similar to HIPAA that expressly applies to pharmaceutical companies as well as companies that provide certain technologies for processing personal health information, imposes stringent data privacy and security requirements and obligations with respect to the personal health information of California residents. Among other things, the CMIA requires that a pharmaceutical company obtain a signed, written authorization from a patient or company employee in order to disclose his or her personal health information, with limited exceptions, and requires security measures to protect such information. The CMIA authorizes administrative fines and civil penalties of up to $25,000 for willful violations and up to $250,000 if the violation is for purposes of financial gain, as well as criminal fines. In addition, another more recently enacted California law, the California Consumer Privacy Act of 2018 (the &#8220;CCPA&#8221;), requires us to provide notice to California residents regarding the personal information we collect, use and share and to honor such residents&#8217; privacy rights, including the right to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> of the sale of their personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data security breaches that result in the compromise of highly sensitive personal information, which may increase the likelihood of, and risks associated with, data breach litigation. As of January&#160;1, 2023, the CCPA regime will become more complex and enforcement may increase, pursuant to amendments adopted pursuant to the California Privacy Rights Act (the &#8220;CPRA&#8221;), a ballot initiative that passed in November 2020. The CPRA, among other things, created a new state </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">127 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">agency, the California Privacy Protection Agency, to implement and enforce the CCPA and the CPRA. The CPRA also gave California residents new rights to limit uses and disclosures of &#8220;sensitive personal information,&#8221; including personal health information, and the right to opt out of the sharing of personal information for targeted online advertising. California&#8217;s aggressive steps to protect consumer privacy have been followed by similar actions in other states, including Virginia, Colorado, Utah and Connecticut, all of which have enacted CCPA/CPRA-like laws to provide their respective residents with similar rights. New legislation anticipated to be enacted in various other states will continue to shape the data privacy environment nationally. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to confidential, sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance efforts. The effects on our business of this growing body of privacy and data protection laws are potentially significant, and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Outside of the United States, laws, regulations and standards in many jurisdictions apply broadly to the collection, use, retention, security, disclosure, transfer and other processing of personal information. For example, in EEA, the collection and use of personal data is governed by the provisions of the General Data Protection Regulation (the &#8220;GDPR&#8221;). The GDPR came into effect in May 2018, superseding the European Union Data Protection Directive, and imposing more stringent data privacy and security requirements on companies in relation to the processing of personal data. The GDPR, together with national legislation, regulations and guidelines of the EU member states governing the processing of personal data, impose strict obligations on controllers, including <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter alia</div></div>: (i)&#160;accountability and transparency requirements, and enhanced requirements for obtaining valid consent; (ii)&#160;obligations to consider data protection as any new products or services are developed and to limit the amount of personal data processed; (iii)&#160;obligations to comply with data protection rights of data subjects; and (iv)&#160;reporting of certain personal data breaches to the supervisory authority without undue delay (and no later than 72 hours where feasible). The GDPR also prohibits the transfer of personal data from the EEA to countries outside of the EEA unless made to a country deemed to have adequate data privacy laws by the European Commission or a data transfer mechanism has been put in place. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EU-US</div> Privacy Shield, but the Privacy Shield was invalidated for international transfers of personal data in July 2020 by the Court of Justice of the European Union (&#8220;CJEU&#8221;). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The CJEU upheld the validity of standard contractual clauses (&#8220;SCCs&#8221;) as a legal mechanism to transfer personal data but companies relying on SCCs will, subject to additional guidance from regulators in the EEA and the U.K., need to evaluate and implement supplementary measures that provide privacy protections additional to those provided under SCCs. Due to potential legal challenges, it remains to be seen whether SCCs will remain a valid legal mechanism and whether additional means for lawful data transfers will become available. In June 2021, the European Commission adopted new SCCs that are designed to be a mechanism by which entities can transfer personal information out of the EEA to jurisdictions that the European Commission has not found to provide an adequate level of protection. Currently, the SCCs are a valid mechanism to transfer personal information outside of the EEA. The SCCs, however, require parties that rely upon that legal mechanism to comply with additional obligations, such as conducting transfer impact assessments to determine whether additional security measures are necessary to protect the transferred personal information. The new SCCs may increase the legal risks and liabilities under European privacy, data protection, and information security laws. Given that, at present, there are few, if any, viable alternatives to the SCCs, any transfers by us or our vendors of personal information from Europe may not comply with European data protection law, which may increase our exposure to the GDPR&#8217;s heightened sanctions for violations of its cross-border data transfer restrictions and may prohibit our transfer of E.U. personal information outside of the E.U. (including clinical trial data), and may adversely impact our operations, product development and ability to provide our products. Moreover, the competent authorities and courts in a number of EU Member States increasingly scrutinize and question the GDPR compliance of processing of personal data by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">US-based</div> entities or entities with links to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">US-based</div> entities, independently of whether personal data is actually transferred outside the EEA. The GDPR authorizes fines for certain violations of up to 4% of global annual revenue or &#8364;20&#160;million, whichever is greater. Such fines are in addition to any civil litigation claims by customers and data subjects. European data protection authorities may </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">128 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">interpret the GDPR and national laws differently and impose additional requirements, which contributes to the complexity of processing personal data in or from the EEA. In June 2021, the CJEU issued a ruling that expanded the scope of the &#8220;one stop shop&#8221; under the GDPR. According to the ruling, the competent authorities of EU Member States may, under certain strict conditions, bring claims to their national courts against a company for breaches of the GDPR, including unlawful cross-border processing activities, even such company does not have an establishment in the EU member state in question and the competent authority bringing the claim is not the lead supervisory authority.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, as of January&#160;1, 2021, and the expiry of transitional arrangements agreed to between the United Kingdom and EU (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">i.e</div></div>., following the United Kingdom&#8217;s exit from the EU&#8212;otherwise known as Brexit), data processing in the United Kingdom is governed by a United Kingdom version of the GDPR (combining the GDPR and the Data Protection Act 2018), exposing us to two parallel regimes, each of which potentially authorizes similar fines and other potentially divergent enforcement actions for certain violations. With respect to transfers of personal data from the EEA to the United Kingdom, on June&#160;28, 2021 the European Commission issued an adequacy decision in respect of the United Kingdom&#8217;s data protection framework, enabling data transfers from EU member states to the United Kingdom to continue without requiring organizations to put in place contractual or other measures in order to lawfully transfer personal data between the territories. While it is intended to last for at least four years, the European Commission may unilaterally revoke the adequacy decision at any point, and if this occurs it could lead to additional costs and increase our overall risk exposure. Moreover, other countries have also passed or are considering passing laws requiring local data residency or restricting the international transfer of data. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we or our third-party service providers are unable to properly protect the privacy and security of personal information, or other sensitive data we process in our business, we could be found to have breached our contracts. Further, if we fail to comply with applicable privacy laws, we could face civil and criminal penalties. Enforcement activity from state Attorneys General and agencies such as the California Privacy Protection Agency, the Federal Trade Commission, EU Data Protection Authorities and other regulatory authorities in relation to privacy and cybersecurity matters can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In the United States, the threat of class action lawsuits based on data security breaches or alleged unfair practices adds a further layer of risk. We cannot be sure how these privacy laws and regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Data privacy remains an evolving landscape at both the domestic and international level, with new laws and regulations being adopted and coming into effect. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. Significant resources are needed to understand and comply with this changing landscape. Failure to comply with federal, state and international laws regarding privacy and security of personal information could expose us to penalties under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices or unwind certain lines of business, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even absent any findings that we have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">129 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our or our affiliates&#8217; employees, independent contractors, principal investigators, consultants, commercial collaborators, service providers and other vendors or potential collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could harm our results of operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are exposed to the risk that our or our affiliates&#8217; employees and contractors, including principal investigators, CROs, CMOs, consultants, commercial collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing and the FDA&#8217;s GCP, GLP and GMP standards; federal, state and foreign healthcare fraud and abuse laws and data privacy; or laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing, bribery, corruption, antitrust violations and other abusive practices. These laws may restrict or prohibit a wide range of business activities, including research, manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creating fraudulent data in our nonclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee or third-party misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, we are subject to the risk that a person, including any person who may have engaged in any fraud or misconduct, or government agency could allege such fraud or other misconduct, even if none occurred. Furthermore, we rely on our CROs and clinical trial sites to adequately report data from our ongoing clinical trials. Moreover, in some instances, our licensing partners conduct clinical trials with respect to product candidates in different territories and we rely on any such partners to share data from their ongoing clinical trials as required under our agreements with such partners. For example, any failure by such parties to adequately report safety signals to us in a timely manner from any such trials may also affect the approvability of our product candidates or cause delays and disruptions for the approval of our product candidates, if at all. If our or our affiliates&#8217; employees, independent contractors, principal investigators, consultants, commercial collaborators, service providers or other vendors are alleged or found to be in violation of any such regulatory standards or requirements, or become subject to a corporate integrity agreement or similar agreement and curtailment of our operations, it could have a significant impact on our business and financial results, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, suspension or delay in our clinical trials, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, FDA debarment, contractual damages, reputational harm, diminished profits and future earnings, and additional reporting requirements and oversight, any of which could harm our ability to operate our business and our results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of our products and, if approved, product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The sale of our products, including VTAMA, which was approved by the FDA in May 2022 for the treatment of plaque psoriasis in adults in the U.S. and the use of our existing product candidates in clinical trials expose us to the risk of product liability claims. Product liability claims might be brought against us by consumers, health care providers, other pharmaceutical companies or others taking or otherwise coming into contact with our products or product candidates. On occasion, large judgments have been awarded in class action lawsuits where drugs have had unanticipated harmful effects. If we cannot successfully defend ourselves against </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">130 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays in or an inability to commercialize VTAMA, and any future products for which we obtain marketing approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">impairment of our business reputation and significant negative media attention; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delay or termination of clinical trials, or withdrawal of participants from our clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">significant costs to defend the related litigation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">distraction of management&#8217;s attention from our primary business; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">substantial monetary awards to patients or other claimants; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">decreased demand for our products, existing product candidates or any future product candidate, if approved; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">loss of revenue. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The product liability insurance we currently carry, and any additional product liability insurance coverage we acquire in the future, may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. We have acquired insurance coverage which extends to liabilities arising from the sale of our products; however, there is no assurance that we will be able to maintain this insurance coverage on commercially reasonable terms or in adequate amounts or that this coverage will be sufficient to cover any losses arising from any claims related to our products or, if approved, product candidates. A successful product liability claim or series of claims brought against us could adversely affect our results of operations and business, including preventing or limiting the commercialization of our products and, if approved, product candidates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Certain of our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">131 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We or the third parties upon whom we depend may be adversely affected by earthquakes, outbreak of disease&#160;or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our offices, that damaged critical infrastructure, such as the manufacturing facilities of our third-party CMOs, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our limited earthquake and flood insurance coverage, could have a material adverse effect on our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The increasing use of social media platforms presents new risks and challenges. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Social media is increasingly being used to communicate about our research, products, product candidates, investigational medicines and the diseases our products, product candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, patients may use social media channels to comment on their experience in an ongoing blinded clinical study or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our development candidates and investigational medicines. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. Furthermore, our employees, affiliates and/or business partners may use social media for their personal use, and their activities on social media or in other forums could result in adverse publicity for us. Any negative publicity as a result of social media posts, whether or not such claims are accurate, could adversely impact us. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business. The use of social media also creates additional risks in the EEA and the UK where promotion of prescription-only medicines to patients and the general public is strictly prohibited. Social media content that is generated, shared or liked by our company or our directors, employees, staff or other representatives may potentially be perceived or construed as constituting prohibited promotion of prescription-only medicinal products and trigger enforcement and penalties. This is an area of increased scrutiny in both the EEA and the UK. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The United Kingdom&#8217;s withdrawal from the European Union may adversely impact our ability to obtain regulatory approvals of our products and product candidates in the European Union and may require us to incur additional expenses in order to develop, manufacture and commercialize our products and product candidates in the European Union. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are centrally managed and controlled in the United Kingdom. The United Kingdom formally exited the EU, commonly referred to as Brexit, on January&#160;31, 2020. Under the terms of its departure, the United Kingdom entered a transition period (the &#8220;Transition Period&#8221;), during which it continued to follow all EU rules. The Transition Period ended on December&#160;31, 2020. A trade and cooperation agreement which outlines the trading relationship between the U.K. and E.U. now that the transition period has concluded, applied provisionally from January&#160;1, 2021 and formally entered into force on May&#160;1, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There is considerable uncertainty resulting from a lack of precedent and the complexity of the United Kingdom and the EU&#8217;s intertwined legal regimes as to how Brexit (following the Transition Period) will impact </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">132 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the life sciences industry in the UK and Europe, including our company, including with respect to ongoing or future clinical trials. The impact will largely depend on the model and means by which the United Kingdom&#8217;s relationship with the EU is governed post-Brexit and the extent to which the United Kingdom chooses to further diverge from the EU regulatory framework. For example, following the Transition Period, Great Britain is no longer covered by the centralized procedures for obtaining <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EU-wide</div> marketing authorizations and our products will therefore require a separate marketing authorization to allow us to market such products in Great Britain. By way of additional example, the EU Clinical Trials Regulations which govern the conduct of clinical trials in the E.U. entered into application in January 2022 and consequently do not apply in the U.K. It is unclear as to whether the relevant authorities in the EU and the United Kingdom are adequately prepared for the additional administrative burden caused by Brexit. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from or delay us commercializing our products and, if approved, product candidates in the United Kingdom and/or the EEA and restrict our ability to generate revenue and achieve and sustain profitability. In the short term, following the expiry of the Transition Period there have been disrupted import and export processes due to a lack of administrative processing capacity by the respective United Kingdom and EU customs agencies that, if continued, may delay time-sensitive shipments and may negatively impact our product supply chain. Further, under current plans, orphan designation in the United Kingdom (or Great Britain, depending on whether there is a prior centralized marketing authorization in the EEA) following Brexit is to be based on the prevalence of the condition in Great Britain as opposed to the current position where prevalence in the EU is the determinant. It is therefore possible that conditions that are currently designated as orphan conditions in the United Kingdom will no longer be and that conditions are not currently designated as orphan conditions in the European Union will be designated as such in the United Kingdom. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or EEA for our products and product candidates, which could significantly and materially harm our business. There is a degree of uncertainty regarding the overall impact that Brexit will have on (i)&#160;the marketing of pharmaceutical products, (ii)&#160;the process to obtain regulatory approval in the United Kingdom for product candidates or (iii)&#160;the award of exclusivities that are normally part of the EU legal framework (for instance Supplementary Protection Certificates, Pediatric Extensions or Orphan exclusivity). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Brexit may also result in a reduction of funding to the EMA once the United Kingdom no longer makes financial contributions to European institutions, such as the EMA. If funding to the EMA is so reduced, it could create delays in the EMA issuing regulatory approvals for our products and product candidates and, accordingly, have a material adverse effect on our business, financial condition, results of operations or prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, we may be required to pay taxes or duties or be subjected to other hurdles in connection with the importation of our products or product candidates into the EU, or we may incur expenses in establishing a manufacturing facility in the EU in order to circumvent such hurdles. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom or the EU for our products and product candidates, or incur significant additional expenses to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result of Brexit, other EU Member States may seek to conduct referenda with respect to their continuing membership with the EU. Given these possibilities and others we may not anticipate, as well as the absence of comparable precedent, it is unclear what financial, regulatory and legal implications the withdrawal of the United Kingdom from the EU will have and how such withdrawal will affect us, and the full extent to which our business could be adversely affected. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">133 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks Related to Our Intellectual Property </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are unable to obtain and maintain patent and other intellectual property protection for our technology, products and product candidates, or if the scope of the intellectual property protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We rely, and will continue to rely, upon a combination of patents, trademarks, trade secret protection and confidentiality agreements with employees, consultants, collaborators, advisors and other third parties to protect the intellectual property related to our brand, current and future drug development programs, products and product candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our current and future products and product candidates. We seek to protect our proprietary position by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> or acquiring intellectual property and filing patent applications in the United States and abroad related to our current and future development programs, products and product candidates, defending our intellectual property rights against third-party challenges and enforcing our intellectual property rights to prevent third-party infringement. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Furthermore, there is always a risk that our licensed or owned issued patents and any pending and future patent applications may not protect our products or product candidates, in whole or in part, and may not effectively prevent others from commercializing competitive products or product candidates, or that an alteration to our products or product candidates or processes may provide sufficient basis for a competitor to avoid infringing our patent claims. The risks associated with patent rights generally apply to patent rights that we <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> now or in the future, as well as patent rights that we may own now or in the future. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disclosure</div> and confidentiality agreements with parties who have access to confidential or patentable aspects of their research and development output, such as employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to obtain patent protection. In addition, while we have <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-publication</div> review procedures in effect, premature or inadvertent publication of potentially patentable subject matter could preclude our ability to obtain patent protection. We may choose not to seek patent protection for certain innovations, products or product candidates and may choose not to pursue patent protection in certain jurisdictions, and under the laws of certain jurisdictions, patents or other intellectual property rights may be unavailable or limited in scope and, in any event, any patent protection we obtain may be limited. As a result, our products and, if approved, product candidates may not be protected by patents in all jurisdictions. We generally apply for patents in those countries where we intend to make, have made, use, offer for sale, or sell products and product candidates and where we assess the risk of infringement to justify the cost of seeking patent protection. However, we do not seek protection in all countries where we intend to sell products and, if approved, product candidates and we may not accurately predict all the countries where patent protection would ultimately be desirable. If we fail to timely file a patent application in any such country or major market, we may be precluded from doing so at a later date. The patent applications that we own or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> may fail to result in issued patents with claims that cover products or product candidates in the United States or in other countries. We may also inadvertently make statements to regulatory agencies during the regulatory approval process that may be inconsistent with positions that have been taken during prosecution of our patents, which may result in such patents being narrowed, invalidated or held unenforceable in enforcement and other adversarial proceedings. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The patent applications that we own or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> may fail to result in issued patents with claims that cover our current and future products or product candidates in the United States or in other countries. Our pending patent applications at the Patent Cooperation Treaty (the &#8220;PCT&#8221;) are not eligible to become issued patents until, among other things, we file a national stage patent application within 30 months in the countries in which we seek patent protection. If we do not timely file any national stage patent applications, we may lose our priority </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">134 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">date with respect to our PCT patent applications and any patent protection on the inventions disclosed in such PCT patent applications. We cannot guarantee any current or future patents will provide us with any meaningful protection or competitive advantage. For example, any issued patents might not cover the pharmaceutical composition of the product or product candidate that is ultimately commercialized. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application or be used to invalidate an issued patent. The examination process may require us to narrow our claims, which may limit the scope of patent protection that we may ultimately obtain. Even if patents do successfully issue and even if such patents cover our current and future products and product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowly construed, invalidated, or held unenforceable, any of which could limit our ability to prevent competitors and other third parties from developing and marketing similar products or product candidates or limit the length of terms of patent protection we may have for our products, product candidates and technologies. Other companies may also design around technologies we have patented, licensed or developed. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing products or product candidates, or practicing our own patented technology, or impose a substantial royalty burden to do so. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any products or, if approved, product candidates. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product or product candidate under patent protection could be reduced. If any of our patents are challenged, invalidated, circumvented by third parties or otherwise limited or expire prior to the commercialization of our products or, if approved, product candidates, and if we do not own or have exclusive rights to other enforceable patents protecting our products, product candidates or other technologies, competitors and other third parties could market products or product candidates and use processes that are substantially similar to, or superior to, ours and our business would suffer. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If the patent applications we hold or have <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> with respect to our products or product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our current and future products or product candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize our products. Any such outcome could have a materially adverse effect on our business. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. The standards that the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;) and its counterparts in other countries use to grant patents are not always applied predictably or uniformly. In addition, the laws of countries other than the United States may not protect our rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in such jurisdictions. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other parties have developed technologies that may be related or competitive to our own technologies and such parties may have filed or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our own or licensed patent applications or issued patents. Furthermore, publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">135 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">products or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies, products and product candidates. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Patent reform legislation in the United States, including the Leahy-Smith America Invents Act (&#8220;the Leahy-Smith Act&#8221;), could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act was signed into law on September&#160;16, 2011 and includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to challenge the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter partes</div></div> review, and derivation proceedings. After March&#160;15, 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third-party was the first to invent the claimed invention. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications, our ability to obtain future patents, and the enforcement or defense of our issued patents, all of which could harm our business, financial condition, results of operations and prospects. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. We are currently and may in the future be subject to third-party <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-issuance</div> submissions of prior art to the USPTO or its equivalents and we or our licensors have in the past, and may in the future, become involved in opposition, derivation, reexamination, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter partes</div></div> review, post-grant review or interference proceedings in the U.S. or in other jurisdictions challenging our patent rights or the patent rights of others. A third-party may also claim that our owned or licensed patent rights are invalid or unenforceable in a litigation. For example, three U.S. patents (U.S. Patent Nos. 8,058,069, 9,364,435 and 9,404,127) relating to lipid nanoparticle molar ratios and the aggregation of lipid nanoparticles that Genevant Sciences GmbH, as assignee of Genevant Sciences Ltd. (&#8220;Genevant&#8221;), exclusively licensed from Arbutus Biopharma Corp. (&#8220;Arbutus&#8221;) were the subject of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter partes </div></div>review proceedings brought by Moderna Therapeutics, Inc. (&#8220;Moderna&#8221;) before the Patent Trial and Appeal Board of the USPTO (&#8220;PTAB&#8221;). The PTAB upheld all claims of U.S. Patent No.&#160;8,058,069, invalidated some of the claims of U.S. Patent No.&#160;9,364,435 and invalidated all claims of U.S. Patent No.&#160;9,404,127. The United States Court of Appeals for the Federal Circuit (the &#8220;Federal Circuit&#8221;) heard oral arguments with respect to U.S. Patent Nos. 8,058,069 and 9,364,435 in October 2021. On December&#160;1, 2021, the Federal Circuit issued decisions in both proceedings. The Federal Circuit affirmed the PTAB&#8217;s decision that upheld all claims of U.S. Patent 8,058,069. The Federal Circuit affirmed the PTAB&#8217;s decision invalidating certain claims of U.S. Patent 9,364,435 but dismissed Moderna&#8217;s appeal with respect to those claims that the PTAB upheld for lack of standing. The Federal Circuit vacated and remanded the PTAB&#8217;s decision on U.S. Patent No.&#160;9,494,127. The PTAB&#8217;s decision with respect to U.S. Patent No.&#160;9,494,127 had been held in administrative abeyance pending a review following a recent Supreme Court ruling in an unrelated case. The matter is now pending before the Federal Circuit and briefing is complete. We expect that the Federal Circuit will schedule oral arguments to take place later this calendar year. Additionally, one European patent (EU patent no. EP2279254) relating to lipid nanoparticle molar ratios that Genevant exclusively licensed from Arbutus is the subject of an opposition proceeding brought by Merck Sharp&#160;&amp; Dohme Corporation and Moderna at the European Patent Office Opposition Division. Genevant may commence litigation at any time to enforce its patent rights against infringers. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The outcome following legal assertions of invalidity and unenforceability is unpredictable. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology, products or product candidates and compete </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">136 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">directly with us, without payment to us, result in our inability to manufacture or commercialize products and, if approved, product candidates without infringing third-party patent rights or result in our breach of agreements pursuant to which we license such rights to our collaborators or licensees. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products or product candidates. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology, products and product candidates, or limit the duration of the patent protection of our technology, products and product candidates. Such challenges also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Even if they are unchallenged, our owned and licensed patents and pending patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our owned or licensed patents by developing similar or alternative technologies or therapeutics in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infringing</div> manner. For example, a third-party may develop a competitive product that provides benefits similar to one or more of our products or product candidates but that falls outside the scope of our patent protection. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however the life of a patent, and the protection it affords, are limited. Without patent protection for our current or future products and product candidates, it may be open to competition from generic versions of such products or product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to our own and, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patent terms and their scope may be inadequate to protect our competitive position on current and future products and product candidates for an adequate amount of time. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-provisional</div> filing date. In certain instances, the patent term may be adjusted to add additional days to compensate for delays incurred by the USPTO in issuing the patent. Also, the patent term may be extended for a period of time to compensate for at least a portion of the time a product or product candidate was undergoing FDA regulatory review. However, the life of a patent, and the protection it affords, are limited. Even if patents covering products or product candidates are obtained, once the patent life has expired, we may be open to competition from other products or product candidates, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new products and product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. For example, the patent covering the use of VTAMA as an active ingredient to treat psoriasis and atopic dermatitis, but not limited to any formulation, expired in December 2020. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to our products and product candidates. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We do not currently and may not in the future own or license any issued composition of matter patents covering certain of our products or product candidates, including VTAMA, and we cannot be certain that any of our other issued patents will provide adequate protection for such products or product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Composition-of-matter</div></div> patents on the active pharmaceutical ingredient (&#8220;API&#8221;) in prescription drug products are generally considered to be the strongest form of intellectual property protection for drug products because those types of patents provide protection without regard to any particular method of use or manufacture </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">137 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">or formulation of the API used. While we generally seek composition of matter patents for our products and product candidates, such patents may not be available for all of our products and product candidates. For example, we do not own or have a license to any issued composition of matter patents in the United States or any other jurisdiction with respect to VTAMA. Instead, we rely on an issued U.S. patent claiming topical formulations of VTAMA, including the formulation studied in Phase 3 trials and approved by the FDA, and an issued U.S. patent covering methods of using the patented topical formulations to treat inflammatory diseases, including psoriasis and atopic dermatitis. The formulation and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">method-of-use</div></div> patents have natural expiration dates in 2036. We additionally rely on a drug substance (&#8220;DS&#8221;) patent covering the high purity commercial crystal form of the DS, the commercial DS synthesis and several novel intermediates that are formed in the synthesis, which has a natural expiration date in 2038. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Method-of-use</div></div> patents protect the use of a product for the specified method and formulation patents cover formulations of the API. These types of patents do not prevent a competitor or other third-party from developing or marketing an identical product for an indication that is outside the scope of the patented method or from developing a different formulation that is outside the scope of the patented formulation. Moreover, with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">method-of-use</div></div> patents, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label,</div> or patients may do so themselves. Although <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> use may infringe or contribute to the infringement of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">method-of-use</div></div> patents, the practice is common, and this type of infringement is difficult to prevent or prosecute. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our owned and licensed patents and pending patent applications, if issued, may not adequately protect our intellectual property or prevent competitors or others from designing around our patent claims to circumvent our owned or licensed patents by developing similar or alternative technologies or therapeutics in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infringing</div> manner. If the breadth or strength of protection provided by the patents and patent applications we own or license with respect to our products and product candidates is not sufficient to impede such competition or is otherwise threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our products and, if approved, product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we do not obtain protection under the Hatch-Waxman Amendments by extending the patent term, our business may be harmed. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our commercial success will largely depend on our ability to obtain and maintain patent and other intellectual property in the United States and other countries with respect to our proprietary technology, products, product candidates and our target indications. Given the amount of time required for the development, testing and regulatory review of products and product candidates, patents protecting our products and product candidates might expire before or shortly after such candidate begins to be commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depending upon the timing, duration and specifics of FDA marketing approval of product candidates, one or more of our U.S. patents may be eligible for a limited patent term extension (&#8220;PTE&#8221;) under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years beyond the normal expiration of the patent as compensation for patent term lost during development and the FDA regulatory review process, which is limited to the approved indication (and potentially additional indications approved during the period of extension) covered by the patent. This extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and is limited to only one patent that covers the approved product, the approved use of the product, or a method of manufacturing the product. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. We may not be granted an </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">138 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time-period or the scope of patent protection afforded could be less than we request. Even if we are able to obtain an extension, the patent term may still expire before or shortly after we receive FDA marketing approval for a given product or product candidate. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to extend the expiration date of our existing patents or obtain new patents with longer expiry dates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to obtain approval of competing product candidates following our patent expiration and launch their product earlier than might otherwise be the case. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with these requirements. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and other patent agencies in other jurisdictions in several stages over the lifetime of the patent. The USPTO and various national or international patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our licensing partners to pay these fees due to U.S. and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> patent agencies and to take the necessary action to comply with these requirements with respect to our licensed intellectual property. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-compliance</div> events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent applications, failure to respond to official actions within prescribed time limits, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-payment</div> of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our current and future products and product candidates, our competitors might be able to enter the market earlier than anticipated, which would have an adverse effect on our business. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We rely on certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents and other intellectual property rights in connection with our development of certain products and product candidates and, if we fail to comply with our obligations under our existing and any future intellectual property licenses with third parties, we could lose license rights that are important to our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to commercialize products and develop and eventually, if approved, commercialize product candidates is dependent on licenses to patent rights and other intellectual property granted to it by third parties. Further, development and commercialization of our current and future products and product candidates may require us to enter into additional license or collaboration agreements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our current license agreements impose, and future agreements may impose, various development, diligence, commercialization and other obligations on us and require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. If we fail to comply with our obligations under these licenses, our licensors may have the right to terminate these license agreements, in which event we may not be able to market our products and product candidates. Termination of any of our license agreements or reduction or elimination of our licensed rights may also result in our having to negotiate new or reinstated licenses with less favorable terms. Additionally, certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement, either of </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">139 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">which could harm our business, financial condition, results of operations and prospects. For example, disputes may arise with respect to our current or future licensing agreement include disputes relating to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the scope of rights granted under the license agreement and other interpretation-related issues; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our financial or other obligations under the license agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the extent to which our technology, products or product candidates infringe on intellectual property of the licensor that is not subject to the licensing agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the sublicensing of patent and other rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our diligence obligations under the license agreements and what activities satisfy those diligence obligations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the inventorship or ownership of inventions and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the priority of invention of patented technology. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize our products and product candidates. If our licenses are terminated, we may lose our rights to develop and market our technology, products and product candidates, lose patent protection for our products, product candidates and technology, experience significant delays in the development and commercialization of our products and product candidates, or incur liability for damages. In addition, we may need to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties, including our competitors, to receive licenses to a portion of the intellectual property that is subject to our existing licenses and to compete with our products and product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, if our licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical or competitive to ours and we may be required to cease our development and commercialization of certain of our products and product candidates. Moreover, if disputes over intellectual property that we license prevent or impair our ability to maintain other licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected products or product candidates. In addition, certain of these license agreements, may not be assignable by us without the consent of the respective licensor, which may have an adverse effect on our ability to engage in certain transactions. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain or enforce the patents, covering technology that it licenses from third parties. Therefore, we cannot be certain that these or other patents will be prosecuted, maintained and enforced in a manner consistent with the best interests of our business. Additionally, we may not have sufficient ability to provide input into the patent prosecution, maintenance and defense process with respect to such patents, and our licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents. If our current or future licensors or collaboration partners fail to obtain, maintain, defend, protect or enforce any patents or patent applications licensed to us, our rights to such patents and patent applications may be reduced or eliminated and our right to develop and commercialize products and product candidates that are the subject of such licensed rights could be adversely affected. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, certain of our current and future licenses may not provide us with exclusive rights to use the licensed intellectual property and technology, or may not provide us with rights to use such intellectual property </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">140 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology, products and product candidates in the future. The intellectual property portfolio licensed to us by our licensors at least in some respects, may therefore be used by such licensors or licensed to third parties, and such third parties may have certain enforcement rights with respect to such intellectual property. For example, Immunovant does not have rights to develop, manufacture, use or commercialize batoclimab or file or enforce patents relating to these assets in territories other than the United States, Canada, Mexico, the EU, the U.K., Switzerland, the Middle East, North Africa and Latin America, as such rights in other jurisdictions have been retained by HanAll Biopharma Co., Ltd. (&#8220;HanAll&#8221;) or licensed by HanAll to third parties. Additionally, Dermavant does not have the right to develop, manufacture, use or commercialize VTAMA in China, including Hong Kong, Macau or Taiwan, as such rights were retained by Welichem Biotech Inc. or licensed to third parties. Patents licensed to us could be put at risk of being invalidated or interpreted narrowly in litigation filed by or against our licensors or another licensee or in administrative proceedings brought by or against our licensors or another licensee in response to such litigation or for other reasons. As a result, we may not be able to prevent competitors or other third parties from developing and commercializing competitive products, including in territories covered by our licenses. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Third-party claims or litigation alleging infringement, misappropriation or other violations of third-party patents or other proprietary rights or seeking to invalidate our patents or other proprietary rights, may delay or prevent the development and commercialization of our current and future products and product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our commercial success depends in part on our avoidance of infringement, misappropriation and other violations of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe, misappropriate or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Our competitors or other third parties may assert infringement claims against us, alleging that our products or product candidates are covered by their patents. We cannot be certain that we do not infringe existing patents or that we will not infringe patents that may be granted in the future. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation and administrative law proceedings,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> inter partes</div></div> review, and post-grant review before the USPTO, as well as oppositions and similar processes in other jurisdictions. Numerous U.S. and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility, the risk increases that our products, product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our products or product candidates. We could also be required to pay damages, which could be significant, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed such patents. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our products or product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover any of our products or product candidates, the holders of any such patents may be able to block our ability to commercialize such products or, if approved, product candidates, unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product or, if approved, product candidate, unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. Claims that we have </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">141 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and inventions, which could be time-consuming and divert the attention of senior management. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our products or, if approved, product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against it, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products or product candidates, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our products or, if approved, product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our products or, if approved, product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our products or product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because the competitors have substantially greater financial and other resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays or prohibit us from manufacturing, marketing or otherwise commercializing our products or, if approved, product candidates. Any uncertainties resulting from the initiation and continuation of any litigation could adversely impact our ability to raise additional funds or otherwise harm our business, results of operation, financial condition or cash flows. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could adversely impact the price of our Common Shares. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might harm our ability to develop and market our products and product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot guarantee that any of our or our licensors&#8217; patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is or may be relevant to or necessary for the commercialization of products or product candidates in any jurisdiction. Patent applications in the United States and elsewhere are not published until approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. In addition, U.S. patent applications filed before November&#160;29, 2000 and certain U.S. patent applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Therefore, patent applications covering our products and product candidates could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our current </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">142 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and future products and product candidates, or the use thereof, provided such pending patent applications result in issued patents. Our ability to develop and market our current and future products and product candidate can be adversely affected in jurisdictions where such patents are issued. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products or, if approved, product candidates. We may incorrectly determine that our products or product candidates are not covered by a third-party patent or may incorrectly predict whether a third-party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect and we may incorrectly conclude that a third-party patent is invalid or unenforceable. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our current and future products and, if approved, product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our products or, if approved, product candidates, that are held to be infringing. We might, if possible, also be forced to redesign products or product candidates so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Competitors may infringe, misappropriate or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file and prosecute legal claims against one or more third parties, which can be expensive and time-consuming, even if ultimately successful. For example, in February 2022, Roivant&#8217;s subsidiary, Genevant Sciences, and Arbutus Biopharma Corporation filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna, Inc. and an affiliate seeking damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna&#8217;s vaccine for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> (the &#8220;Moderna Action&#8221;). In addition, in March 2022, Acuitas Therapeutics Inc. filed a lawsuit in the United States District Court for the Southern District of New York against Genevant Sciences and Arbutus Biopharma Corporation seeking a declaratory judgment that U.S. Patents 8,058,069, 8,492,359, 8,822,668, 9,006,417, 9,364,435, 9,404,127, 9,504,651, 9,518,272, and 11,141,378 are not infringed by the manufacture, use, offer for sale, sale or importation into the United States of COMIRNATY, Pfizer&#8217;s and BioNTech&#8217;s vaccine for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and are otherwise invalid (the &#8220;Acuitas Action&#8221;). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. The standards that courts use to interpret patents are not always applied predictably or uniformly and can change, particularly as new technologies develop. As a result, we cannot predict with certainty how much protection, if any, will be given to our patents if we attempt to enforce them and they are challenged in court and if any such suits, including the Moderna Action and the Acuitas Action, will ultimately be resolved successfully. Further, even if we prevail against an infringer in U.S. district court, there is always the risk that the infringer will file an appeal and the district court judgment will be overturned at the appeals court and/or that an adverse decision will be issued by the appeals court relating to the validity or enforceability of our patents. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly in a manner insufficient to achieve our business objectives, or could put our patent applications at risk of not issuing. The initiation of a claim against a </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">143 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">third-party may also cause the third-party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-enablement</div> or lack of written description or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-statutory</div> subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter partes</div></div> review, or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third-party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future products or product candidates. Such a loss of patent protection could harm our business. Additionally, any adverse outcome could allow third parties to commercialize our products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if we establish infringement, we may not seek, or the court may decide not to grant, an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. We may not be able to detect or prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our Common Shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We may not have sufficient financial or other resources to adequately conduct the Moderna Action, the Acuitas Action or any other such litigation or proceedings. Some of our competitors or other third parties may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Because of the expense and uncertainty of litigation, we may conclude that even if a third-party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our shareholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-litigious</div> action or solution. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Because many of the patents we own or have licensed are owned or licensed by our subsidiaries, and in certain cases by subsidiaries that are not or will not be directly commercializing products, we may not be in a position to obtain a permanent injunction against a third-party that is found to infringe our patents. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many patents that we own or have licensed are assigned to or licensed by our direct or indirect subsidiaries. For example, any patents that Immunovant has licensed are assigned to its wholly-owned subsidiary Immunovant Sciences GmbH and any patents that Dermavant owns or has licensed are assigned to its wholly-owned subsidiary Dermavant Sciences GmbH. If a third-party is found to be infringing such patents, we and our direct subsidiaries may not be able to permanently enjoin the third-party from making, using, offering for sale or selling the infringing product or activity for the remaining life of such patent in the United States or other jurisdictions </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">144 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">when the patent is assigned to a subsidiary, which is not the entity that is or would be commercializing a potentially competitive product or service. In such a circumstance, such third-party may be able to compete with us or our subsidiaries, which could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products and product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States or USPTO rules and regulations could increase the uncertainties and costs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The United States has recently enacted and implemented wide-ranging patent reform legislation. In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and pending patent applications. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. For example, the Biden administration has indicated its support for a proposal at the World Trade Organization to waive patent rights with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccines. Any waiver of our patent or other intellectual property protection by the U.S. and other foreign governments, including with respect to Genevant&#8217;s licensed lipid nanoparticle (&#8220;LNP&#8221;) delivery technology as used in connection with messenger RNA vaccine delivery, could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Depending on actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by United States and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, the United States federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-up</div> license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;march-in</div> rights.&#8221; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">March-in</div> rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; For example, the research resulting in certain of our acquired or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patent rights and technology for certain products or product candidates was funded in part by the U.S. federal government. As a result, the federal government may have certain rights to such patent rights and technology, which include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">march-in</div> rights. If the federal government decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. The federal government&#8217;s rights may also permit it to disclose our confidential information to third parties and to exercise <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">march-in</div> rights to use or allow third parties to use our licensed technology. The federal government can exercise its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">march-in</div> rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, or because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. Further, the recipient of U.S. government funding is required to comply with </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">145 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">certain other requirements, including timely disclosing the inventions claimed in such patent rights to the U.S. government and timely electing title to such inventions. The U.S. government has the right to take title to such intellectual property rights if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, our rights in such inventions may be subject to certain requirements to manufacture products or product candidates embodying such inventions in the United States. We cannot be certain that our current or future licensors will comply with the disclosure or reporting requirements of the Bayh-Dole Act at all times or be able to rectify any lapse in compliance with these requirements. Any exercise by the government of any of the foregoing rights or by any third-party of its reserved rights could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The validity, scope and enforceability of any patents listed in the Orange Book that cover our products or product candidates, or patents that cover our biologic product candidates, can be challenged by third parties. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If a third-party files an application under Section&#160;505(b)(2) or an abbreviated new drug application (&#8220;ANDA&#8221;) under Section&#160;505(j) with respect to any of our products or, if approved, product candidates, for a generic product containing any of our products or product candidates, including VTAMA (which, following the natural expiration of our method of use patent family, will be protected only by our formulation patent), and relies in whole or in part on studies conducted by or for us, the third-party will be required to certify to the FDA that either: (1)&#160;there is no patent information listed in the Orange Book with respect to our NDA for the applicable product or, if approved, product candidate; (2)&#160;the patents listed in the Orange Book have expired; (3)&#160;the listed patents have not expired, but will expire on a particular date and approval is sought after patent expiration; or (4)&#160;the listed patents are invalid or will not be infringed by the manufacture, use or sale of the third-party&#8217;s generic product. A certification under 21 CFR &#167;&#160;314.94(a)(12)(i)(A)(4) that the new product will not infringe the Orange Book-listed patents for the applicable product or, if approved, product candidate, or that such patents are invalid, is called a paragraph IV certification. If the third-party submits a paragraph IV certification to the FDA, a notice of the paragraph IV certification must also be sent to us once the third-party&#8217;s ANDA is accepted for filing by the FDA. We may then initiate a lawsuit to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45 days of receipt of the notice automatically prevents the FDA from approving the third-party&#8217;s ANDA until the earliest of 30 months or the date on which the patent expires, the lawsuit is settled, or the court reaches a decision in the infringement lawsuit in favor of the third-party. If we do not file a patent infringement lawsuit within the required <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">45-day</div> period, the third-party&#8217;s ANDA will not be subject to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-month</div> stay of FDA approval. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Moreover, a third-party may challenge the current patents, or patents that may issue in the future, within our portfolio, which could result in the invalidation of some or all of the patents that might otherwise be eligible for listing in the Orange Book for one of our products. If a third-party successfully challenges all of the patents that might otherwise be eligible for listing in the Orange Book for one of our products before an ANDA or 505(b)(2) NDA is filed we will be unable to obtain a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-month</div> stay of FDA approval of a 505(b)(2) or ANDA. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For example, our three issued U.S. patents covering VTAMA may not provide adequate protection from competitive products developed by 505(b)(1) NDA, 505(b)(2) NDA or 505(j) ANDA applicants containing paragraph IV certifications if such applicants are able to design around the three patents. One or more competitors may circumvent these patents by filing a marketing application with the FDA under Sections 505(b)(2) or 505(j) of the Federal Food, Drug and Cosmetic Act containing a paragraph IV certification for a competitive product containing the active moiety in VTAMA and successfully challenging the validity of the three patents or successfully designing around the three patents. Any successful challenge against the three patents and/or designing around one or more of the patents could result in a generic version of VTAMA being commercialized before the expiration of the three patents. If the three patents are successfully challenged or designed around, our business, results of operations, financial condition and prospects would be harmed. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">146 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">For biologics, the BPCIA provides a mechanism for one or more third parties to seek FDA approval to manufacture or sell a biosimilar or interchangeable versions of brand name biological product candidates. Due to the large size and complexity of biological product candidates, as compared to small molecules, a biosimilar must be &#8220;highly similar&#8221; to the reference product with &#8220;no clinically meaningful differences between the two.&#8221; The BPCIA does not require reference product sponsors to list patents in the FDA&#8217;s Orange Book and does not include an automatic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-month</div> stay of FDA approval upon the timely filing of a lawsuit. The BPCIA, however, does require a formal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-litigation</div> process which includes the exchange of information between a biosimilar applicant and a reference biologic sponsor that includes the identification of relevant patents and each parties&#8217; basis for infringement and invalidity. After the exchange of this information, we may then initiate a lawsuit within 30 days to defend the patents identified in the exchange. If the biosimilar applicant successfully challenges the asserted patent claims, it could result in the invalidation of, or render unenforceable, some or all of the relevant patent claims or result in a finding of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infringement.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unsuccessful in enforcing our patents against generics or biosimilars, our products could face competition prior to the expiration of the patents which cover such products, which could have a material adverse effect on our business, financial condition, results of operations and prospects. Furthermore, any such litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert management&#8217;s attention from our core business, and may result in unfavorable results that could limit our ability to prevent third parties from competing with our products and product candidates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be able to protect our intellectual property rights throughout the world. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Filing, prosecuting and defending patents on products and product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly developing countries, and the breadth of patent claims allowed can be inconsistent. In addition, the laws of some countries do not protect intellectual property rights to the same extent as laws of the United States. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing product candidates made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and product candidates and may also export infringing products and product candidates to territories where we have patent protection, but enforcement is not as strong as that in the United States. These product candidates may compete with our products or product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not have patent rights in all countries in which a market may exist. Moreover, in jurisdictions where we do have patent rights, proceedings to enforce such rights could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and our patent applications at risk of not issuing. Additionally, such proceedings could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Thus, we may not be able to stop a competitor from marketing and selling in other countries products and product candidates and services that are the same as or similar to our products and product candidates, and our competitive position would be harmed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many companies have encountered significant problems in protecting and defending intellectual property rights in other jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products and product candidates, which could make it difficult for us to stop the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">147 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">infringement of our patents or marketing of competing products or product candidates in violation of our proprietary rights generally. Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many countries, including European Union countries, India, Japan and China, have compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In those countries, we may have limited remedies, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are unable to protect the confidentiality of any trade secrets, our business and competitive position would be harmed. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition to seeking patents for our products and product candidates, we may rely on trade secrets, including unpatented software, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> technology and other proprietary information, to maintain our competitive position. We seek to protect this software and information, in part, by entering into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disclosure</div> and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Because we rely and expect to continue to rely on third parties to manufacture our current and future products and product candidates, and we collaborate and expect to continue to collaborate with third parties on the development of current and future products and product candidates, we must, at times, share trade secrets with them. We also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in the market. Further, adequate remedies may not exist in the event of unauthorized use or disclosure. Given that our proprietary position is based, in part, on our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">148 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">certain limited publication rights. Policing unauthorized use of our or our licensors&#8217; intellectual property is difficult, expensive and time-consuming, and we may be unable to determine the extent of any unauthorized use. Moreover, enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Despite our efforts to protect our trade secrets, our competitors and other third parties may discover our trade secrets, including our proprietary software, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s or other third-party&#8217;s discovery of our trade secrets, including our proprietary software, would impair our competitive position and have an adverse impact on our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We cannot guarantee that we have entered into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disclosure,</div> confidentiality agreements, material transfer agreements or consulting agreements with each party that may have or have had access to our trade secrets or proprietary software, technology and processes. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets and proprietary software, and we may not be able to obtain adequate remedies for such breaches. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets, including our proprietary software, were to be lawfully obtained or independently developed by a competitor or other third-party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets, including our proprietary software, were to be disclosed to or independently developed by a competitor or other third-party, our competitive position would be harmed. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Certain software utilized in our computational drug discovery efforts may include third-party open source software. Any failure to comply with the terms of one or more open source software licenses could adversely affect our business, subject us to litigation, or create potential liability. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain software utilized in our computational drug discovery efforts may include third-party open source software and we expect to continue to incorporate open source software in the future. The use of open source software involves a number of risks, many of which cannot be eliminated and could negatively affect our business. For example, we cannot ensure that we have effectively monitored our use of open source software or that we are in compliance with the terms of the applicable open source licenses or our current policies and procedures. There have been claims against companies that use open source software asserting that the use of such open source software infringes the claimants&#8217; intellectual property rights. As a result, we could be subject to suits by third parties claiming infringement on such third parties&#8217; intellectual property rights. Litigation could be costly for us to defend, have a negative effect on our business, financial condition and results of operations, or require us to devote additional research and development resources to modify our computational drug discovery platform. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of open source software may entail greater risks than use of third-party commercial software, as open source licensors generally do not provide warranties, controls on the origin of the software or other contractual protections regarding infringement claims or the quality of the code, including with respect to security vulnerabilities. In addition, certain open source licenses require that source code for software programs that interact with such open source software be made available to the public at no cost and that any modifications or derivative works to such open source software continue to be licensed under the same terms as the open source software license. The terms of various open source licenses have not been interpreted by courts in the relevant jurisdictions, and there is a risk that such licenses could be construed in a manner that imposes unanticipated conditions or restrictions on our ability to market our solutions. By the terms of certain open source licenses, if </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">149 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">portions of our proprietary software are determined to be subject to an open source license or if we combine our proprietary software with open source software in a certain manner, we could be required to release the source code of our proprietary software and to make our proprietary software available under open source licenses, each of which could reduce or eliminate the effectiveness of our computational discovery efforts. We may also face claims alleging noncompliance with open source license terms or misappropriation or other violation of open source technology. Any of these events could create liability for us and damage our reputation, which could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We employ individuals who were previously employed at universities or other software, biotechnology or pharmaceutical companies, including our licensors, competitors or potential competitors. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to not use the confidential information of their former employer, we may be subject to claims that we or our employees, consultants, independent contractors or other third parties have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our owned or licensed patents or patent applications. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property, which could limit our ability to stop others from using or commercializing similar technology and therapeutics, without payment to us, could limit the duration of the patent protection covering our technology, products and product candidates and could result in our inability to develop, manufacture or commercialize our products and product candidates without infringing third-party patent rights. Such intellectual property rights could be awarded to a third-party, and we could be required to obtain a license from such third-party to commercialize our current or future products and product candidates. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. Moreover, any such litigation or the threat thereof may harm our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would harm our business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We rely on a combination of internally developed and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> intellectual property rights and we or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents, trade secrets, or other intellectual property as an inventor or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-inventor.</div> For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or other third parties who are involved in developing our products and product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our products or product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could harm our business, financial condition, results of operations and prospects. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, while it is our policy to require our employees, contractors and other third parties who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">150 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our invention assignment agreements may not be self-executing or may be breached, and we may not have adequate remedies for any such breach. Additionally, we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Furthermore, individuals executing agreements with us may have preexisting or competing obligations to a third-party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities, and have a harmful effect on the success of our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims, including the Moderna Action and the Acuitas Action, may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could adversely impact the price of our Common Shares. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to pursue our commercialization efforts, continue our clinical trials and internal research programs or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> needed technology or other future product candidates. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary to pursue our commercialization efforts, continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development collaborations that would help us commercialize our products or, if approved, product candidates. Any of the foregoing could harm our business, financial condition, results of operations and prospects. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be successful in obtaining necessary intellectual property rights to future product candidates through acquisitions and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licenses.</div> </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A third-party may hold intellectual property, including patent rights, that are important or necessary to the development of our product candidates. Accordingly, we may seek to acquire or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> patented or proprietary technologies to develop such product candidates or to grow our product offerings and technology portfolio. However, we may be unable to acquire or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> intellectual property rights relating to, or necessary for, any such product candidate or technology from third parties on commercially reasonable terms or at all. Even if we are able to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> any such necessary intellectual property, it could be on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> terms, thereby giving our competitors and other third parties access to the same intellectual property licensed to us, and it could require us to make substantial licensing and royalty payments. In that event, we may be unable to develop or commercialize such product candidates or technology. We may also be unable to identify product candidates or technology that we believe are an appropriate strategic fit for our company and protect intellectual property relating to, or necessary for, such product candidate and technology. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> and acquisition of third-party intellectual property rights for any future product candidate is a competitive area, and a number of more established companies are also pursuing strategies to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or acquire third-party intellectual property rights for product candidates that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">151 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">resources and greater clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. If we are unable to successfully obtain rights to additional technologies or product candidates, our business, financial condition, results of operations and prospects for growth could suffer. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, we expect that competition for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> or acquisition of third-party intellectual property rights for any future product candidate and technologies that are attractive to us may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. We may be unable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or acquire the third-party intellectual property rights for product candidates or technology on terms that would allow us to make an appropriate return on our investment. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Any trademarks we have obtained or may obtain may be infringed or successfully challenged, resulting in harm to our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We rely on trademarks as one means to distinguish our products from the products and product candidates of our competitors. Our current and future trademark applications in the United States and in other jurisdictions may not be allowed or may subsequently be opposed, challenged, infringed, circumvented, declared generic or determined to be infringing other marks. Additionally, once we select new trademarks and apply to register them, our trademark applications may not be approved. Third parties have in the past opposed, are currently opposing and may in the future oppose or attempt to cancel our trademark applications or trademarks, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand products or product candidates, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks and we may not have adequate resources to enforce our trademarks. If we attempt to enforce our trademarks and assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Once granted, patents may remain open to invalidity challenges including opposition, interference, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-examination,</div> post-grant review, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter partes</div></div> review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">152 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, if a third-party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">others may be able to make formulations or compositions that are the same as or similar to our products or product candidates, but that are not covered by the claims of the patents that we own; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">others may be able to make product candidates that are similar to our products or product candidates that we intend to commercialize that are not covered by the patents that we exclusively licensed and have the right to enforce; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we, our licensor or any collaborators might not have been the first to make or reduce to practice the inventions covered by the issued patents or pending patent applications that we own or have exclusively licensed; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we or our licensor or any collaborators might not have been the first to file patent applications covering certain of our inventions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">it is possible that our pending patent applications will not lead to issued patents; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and then use the information learned from such activities to develop competitive product candidates for sale in our major commercial markets; and we may not develop additional proprietary technologies that are patentable; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">third parties performing manufacturing or testing for us using our products, product candidates or technologies could use the intellectual property of others without obtaining a proper license; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights over that intellectual property; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">we may not develop or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> additional proprietary technologies that are patentable; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may not be able to obtain and maintain necessary licenses on commercially reasonable terms, or at all; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the patents of others may harm our business; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">we may choose not to file a patent application in order to maintain certain trade secrets or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> and a third-party may subsequently file a patent application covering such intellectual property. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Should any of these events occur, they could significantly harm our business and results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to our Securities, our Jurisdiction of Incorporation and Certain Tax Matters </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If our performance does not meet market expectations, the price of our securities may decline. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If our performance does not meet market expectations, the price of our Common Shares may decline. In addition, even if an active market for our Common Shares develops and continues, the trading price of our Common Shares could be volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control. Prior to the Business Combination, there was not a public market for our Common Shares, and trading in our Common Shares was not active. Any of the factors listed below could have a material adverse effect on the price of our Common Shares. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">153 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Factors affecting the trading price of our Common Shares may include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">actual or anticipated fluctuations in our quarterly and annual financial results or the quarterly and annual financial results of companies perceived to be similar to it; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in the market&#8217;s expectations about operating results; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our operating results failing to meet market expectations in a particular period; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a Vant&#8217;s operating results failing to meet market expectations in a particular period, which could impact the market prices of shares of a public Vant or the valuation of a private Vant, and in turn adversely impact the trading price of our Common Shares; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">receipt of marketing approval for a product or product candidate in one or more jurisdictions, or the failure to receive such marketing approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the results of clinical trials or preclinical studies conducted by us and the Vants; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in financial estimates and recommendations by securities analysts concerning us, the Vants or the biopharmaceutical industry and market in general; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">operating and stock price performance of other companies that investors deem comparable to us; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in laws and regulations affecting our and the Vants&#8217; businesses; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the outcome of litigation or other claims or proceedings, including governmental and regulatory proceedings, against us or the Vants; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in our capital structure, such as future issuances of securities or the incurrence of debt; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the volume of our Common Shares available for public sale and the relatively limited free float of our Common Shares; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any significant change in our board of directors or management; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">sales of substantial amounts of our Common Shares by directors, executive officers or significant shareholders or the perception that such sales could occur; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">general economic and political conditions such as recessions, interest rates, fuel prices, international currency fluctuations and acts of war or terrorism. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Broad market and industry factors may depress the market price of our Common Shares irrespective of our or the Vants&#8217; operating performance. The stock market in general has experienced price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of the particular companies affected. The trading prices and valuations of these stocks, and of our securities, may not be predictable. A loss of investor confidence in the market for companies engaging in digital payments or the stocks of other companies which investors perceive to be similar to us could depress our stock price regardless of our business, prospects, financial conditions or results of operations. A decline in the market price of our Common Shares also could adversely affect our ability to issue additional securities and our ability to obtain additional financing in the future. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our warrant agreement designates the courts of the State of New York or the United States District Court for the Southern District of New York as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by holders of our Warrants, which could limit the ability of warrant holders to obtain a favorable judicial forum for disputes with our company. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our warrant agreement provides that, subject to applicable law, (i)&#160;any action, proceeding or claim against us arising out of or relating in any way to the warrant agreement, including under the Securities Act, will be brought and enforced in the courts of the State of New York or the United States District Court for the Southern </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">154 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">District of New York, and (ii)&#160;that we irrevocably submit to such jurisdiction, which jurisdiction shall be the exclusive forum for any such action, proceeding or claim. We waive any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding the foregoing, these provisions of the warrant agreement do not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal district courts of the United States of America are the sole and exclusive forum. Any person or entity purchasing or otherwise acquiring any interest in any of our Warrants shall be deemed to have notice of and to have consented to the forum provisions in our warrant agreement. If any action, the subject matter of which is within the scope the forum provisions of the warrant agreement, is filed in a court other than a court of the State of New York or the United States District Court for the Southern District of New York (a &#8220;foreign action&#8221;) in the name of any holder of our Warrants, such holder shall be deemed to have consented to: (x)&#160;the personal jurisdiction of the state and federal courts located in the State of New York in connection with any action brought in any such court to enforce the forum provisions (an &#8220;enforcement action&#8221;) and (y)&#160;having service of process made upon such warrant holder in any such enforcement action by service upon such warrant holder&#8217;s counsel in the foreign action as agent for such warrant holder. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">This <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">choice-of-forum</div></div> provision may limit a warrant holder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with our company, which may discourage such lawsuits. Warrant holders who do bring a claim in a court of the State of New York or the United States District Court for the Southern District of New York could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the State of New York. Alternatively, if a court were to find this provision of our warrant agreement inapplicable or unenforceable with respect to one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could materially and adversely affect our business, financial condition and results of operations and result in a diversion of the time and resources of our management and board of directors. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may amend the terms of the Warrants in a manner that may be adverse to holders of Public Warrants with the approval by the holders of at least 50% of the then outstanding Public Warrants. As a result, the exercise price of your Warrants could be increased, the exercise period could be shortened and the number of shares purchasable upon exercise of a warrant could be decreased, all without your approval. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Warrants were initially issued by MAAC in registered form under a warrant agreement between Continental Stock Transfer&#160;&amp; Trust Company (&#8220;CST&#8221;), as warrant agent. In connection with the consummation of the Business Combination, American Stock Transfer&#160;&amp; Trust Company assumed CST&#8217;s responsibilities as warrant agent under the warrant agreement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The warrant agreement provides that the terms of the Warrants may be amended without the consent of any holder for the purpose of (i)&#160;curing any ambiguity or correct any mistake or defective provision (ii)&#160;amending the provisions relating to cash dividends on common stock as contemplated by and in accordance with the warrant agreement or (iii)&#160;adding or changing any provisions with respect to matters or questions arising under the warrant agreement as the parties to the warrant agreement may deem necessary or desirable and that the parties deem to not adversely affect the rights of the registered holders of the Warrants, provided that the approval by the holders of at least 50% of the then-outstanding Public Warrants is required to make any change that adversely affects the interests of the registered holders of Public Warrants. Accordingly, we may amend the terms of the Public Warrants in a manner adverse to a holder if holders of at least 50% of the then outstanding Public Warrants approve of such amendment. Although our ability to amend the terms of the Public Warrants with the consent of at least 50% of the then outstanding Public Warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the Warrants, convert the Warrants into cash, shorten the exercise period or decrease the number of our Common Shares purchasable upon exercise of a warrant. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">155 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have incurred and will continue to incur increased costs as a result of operating as a public company and our management has devoted and will continue to devote a substantial amount of time to new compliance initiatives. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a public company, we have incurred and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company, and these expenses may increase even more after we are no longer an emerging growth company, as defined in Section&#160;2(a) of the Securities Act. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the Dodd-Frank Act, as well as rules adopted, and to be adopted, by the SEC and the Nasdaq. Our management and other personnel have devoted and will continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have substantially increased our legal and financial compliance costs and made some activities more time-consuming and costly. For example, these rules and regulations have made it more difficult and more expensive for us to obtain blended director and officer liability insurance and forced us to forego securities and corporate protection coverage. We cannot predict or estimate the amount or timing of additional costs we have incurred and will continue to incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our failure to timely and effectively implement controls and procedures required by Section&#160;404(a) of the Sarbanes-Oxley Act could have a material adverse effect on our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a public company, we are required to provide management&#8217;s attestation on internal controls as required under Section&#160;404(a) of the Sarbanes-Oxley&#160;Act. The standards required for a public company under Section&#160;404(a) of the Sarbanes-Oxley&#160;Act are significantly more stringent than those required of us as a privately-held&#160;company. If we are not successful in implementing the additional requirements of Section&#160;404(a) in a timely manner or with adequate compliance, we may not be able to assess whether our internal controls over financial reporting are effective, which may subject us to adverse regulatory consequences and could harm investor confidence and the market price of our securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Failure to properly implement internal controls on a timely basis may lead to the identification of one or more material weaknesses or control deficiencies in the future, which may prevent us from being able to report our financial results accurately on a timely basis or help prevent fraud, and could cause our reported financial results to be materially misstated and result in the loss of investor confidence or delisting and cause the market price of our Common Shares to decline. If we have material weaknesses in the future, it could affect the financial results that we report or create a perception that those financial results do not fairly state our financial position or results of operations. Either of those events could have an adverse effect on the value of our Common Shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, even if we conclude that our internal control over financial reporting provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP, because of its inherent limitations, internal control over financial reporting may not prevent or detect fraud or misstatements. Failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm our results of operations or cause us to fail to meet our future reporting obligations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may redeem your unexpired Warrants prior to their exercise at a time that is disadvantageous to you, thereby making your Warrants worthless. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have the ability to redeem outstanding Warrants at any time after they become exercisable and prior to their expiration, at a price of $0.01 per warrant, provided that the last reported sales price of our Common Shares is equal to or exceeds $18.00 per share (as adjusted for share sub divisions, share capitalizations, rights issuances, subdivisions, reorganizations, recapitalizations and the like) for any 20 trading days within a 30 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">trading-day</div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">156 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">period ending on the third trading day prior to the date they send the notice of redemption to the warrant holders. If and when the Warrants become redeemable by us, we may not exercise our redemption right if the issuance of shares upon exercise of the Warrants is not exempt from registration or qualification under applicable state blue sky laws or if we are unable to effect such registration or qualification. We will use our best efforts to register or qualify such shares under the blue sky laws of the state of residence in those states in which the Warrants were offered by us. Redemption of the outstanding Warrants could force an investor to (i)&#160;to exercise their Warrants and pay the exercise price therefor at a time when it may be disadvantageous for an investor to do so, (ii)&#160;for an investor to sell their Warrants at the then-current market price when they might otherwise wish to hold their Warrants or (iii)&#160;to accept the nominal redemption price which, at the time the outstanding Warrants are called for redemption, is likely to be substantially less than the market value of an investors Warrants. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, we may redeem an investor&#8217;s Warrants at any time after they become exercisable and prior to their expiration at a price of $0.10 per warrant upon a minimum of 30 days&#8217; prior written notice of redemption provided that holders will be able to exercise their Warrants prior to redemption for a number of Common Shares determined based on the redemption date and the fair market value of our Common Shares. The value received upon exercise of the Warrants (1)&#160;may be less than the value the holders would have received if they had exercised their Warrants at a later time where the underlying share price is higher and (2)&#160;may not compensate the holders for the value of the Warrants, including because the number of shares received is capped at 0.361 Common Shares per warrant (subject to adjustment) irrespective of the remaining life of the Warrants. None of the Private Placement Warrants will be redeemable by us so long as they are held by the MAAC Sponsor or its permitted transferees. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our management will have the ability to require holders of our Warrants to exercise such Warrants on a cashless basis, which will cause holders to receive fewer Common Shares upon their exercise of the Warrants than they would have received had they been able to exercise their Warrants for cash. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we call the Public Warrants for redemption after the redemption criteria have been satisfied, our management will have the option to require any holder that wishes to exercise their warrant (including any Warrants held by the MAAC Sponsor, MAAC&#8217;s former officers or directors, other purchasers of MAAC&#8217;s founders&#8217; units, or their permitted transferees) to do so on a &#8220;cashless basis.&#8221; If our management chooses to require holders to exercise their Warrants on a cashless basis, the number of Common Shares received by a holder upon exercise will be fewer than it would have been had such holder exercised his warrant for cash. This will have the effect of reducing the potential &#8220;upside&#8221; of the holder&#8217;s investment in our company. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect our business, investments and results of operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to laws and regulations enacted by national, regional and local governments. In particular, we will be required to comply with certain SEC and other legal requirements. Compliance with, and monitoring of, applicable laws and regulations may be difficult, time consuming and costly. Those laws and regulations and their interpretation and application may also change from time to time and those changes could have a material adverse effect on our business, investments and results of operations. In addition, a failure to comply with applicable laws or regulations, as interpreted and applied, could have a material adverse effect on our business and results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anti-takeover provisions in our memorandum of association and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> and under Bermuda law could delay or prevent a change in control, limit the price investors may be willing to pay in the future for our Common Shares and could entrench management. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our memorandum of association and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> contain provisions that could make it more difficult for a third-party to acquire us without the consent of our board of directors. These provisions provide for: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a classified board of directors with staggered three-year terms; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">157 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the ability of our board of directors to determine the powers, preferences and rights of preference shares and to cause us to issue the preference shares without shareholder approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the ability of our board of directors to prevent the transfer of capital stock, or the exercise of rights with respect to our capital stock, if the effect of such transfer or exercise of rights would result in a shareholder holding more than 9.9% of the total issued and outstanding shares of our capital stock on a fully diluted basis; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">requiring advance notice for shareholder proposals and nominations and placing limitations on convening shareholder meetings. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These provisions may make more difficult the removal of management and may discourage transactions that otherwise could involve payment of a premium over prevailing market prices for our securities. These provisions could also discourage proxy contests and make it more difficult for you and other shareholders to elect directors of your choosing and cause us to take corporate actions other than those you desire, any of which could harm our share price. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our largest shareholders and certain members of our management own a significant percentage of our Common Shares and are able to exert significant control over matters subject to shareholder approval. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our founder and certain of our largest shareholders hold a significant percentage of our Common Shares. As a result, these holders have the ability to substantially influence us and exert significant control through this ownership position and, in the case of certain holders, service on our board of directors. For example, these holders may be able to control elections of directors, issuance of equity, including to our employees under equity incentive plans, amendments of our organizational documents, or approval of any merger, amalgamation, sale of assets or other major corporate transaction. These holders&#8217; interests may not always coincide with our corporate interests or the interests of other shareholders, and it may exercise its voting and other rights in a manner with which you may not agree or that may not be in the best interests of our other shareholders. So long as these holders continue to own a significant amount of our equity, they will continue to be able to strongly influence and effectively control our decisions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Future sales and issuances of our or the Vants&#8217; equity securities or rights to purchase equity securities, including pursuant to our or the Vants&#8217; equity incentive and other compensatory plans, will result in additional dilution of the percentage ownership of our shareholders and could cause our share price to fall. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We and the Vants will need additional capital in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, including in our subsidiaries, our shareholders may experience substantial dilution. We or the Vants may sell securities, including convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell Common Shares, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. In addition, new investors could gain rights superior to our existing shareholders. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to our 2021 Equity Incentive Plan (the &#8220;2021 EIP&#8221;), we are authorized to grant options and other share-based awards to our employees, directors and consultants. The aggregate number of shares initially reserved for issuance under the 2021 EIP increases annually on the first day of each fiscal year during the term of the plan in an amount equal to the lesser of (i) 5% of the number of our Common Shares outstanding as of the day of the immediately preceding fiscal year and (ii)&#160;such number of our Common Shares as determined by our board of directors in its discretion. As a result of this annual increase, or if our board of directors elects in the future to make any additional increase in the number of shares available for future grant under the 2021 EIP, and if our shareholders approve of any such additional increase, our shareholders may experience additional dilution, and our share price may fall. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">158 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of options and other share-based awards pursuant to equity incentive plans at the Vants may indirectly have a similar effect of diluting your ownership in us since a portion of the value of our Common Shares is tied to the value of the Vants, which would be diluted in the event of a grant of options or other similar equity grants to the employees of the Vants. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If securities analysts publish negative evaluations of our shares, the price of our Common Shares could decline. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The trading market for our securities will be influenced by the research and reports that industry or securities analysts may publish about us, our business, market or competitors. If any of the analysts who may cover us change their recommendation regarding our Common Shares adversely, or provide more favorable relative recommendations about its competitors, the price of our Common Shares would likely decline. If any analyst who may cover us were to cease coverage or fail to regularly publish reports, we could lose visibility in the financial markets, which in turn could cause our share price or trading volume to decline. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our founder and certain of our largest shareholders own a substantial portion of our Common Shares. As a result, there may be&#160;limited&#160;liquidity&#160;for our Common Shares. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our founder and certain of our largest shareholders hold a significant percentage of our Common Shares. Certain of these shareholders remain subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> arrangements in respect of a portion of their Common Shares and as a result there may be limited liquidity in the trading market for our Common Shares during the period in which these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> agreements are in effect. In addition, even once the applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> periods expire, the liquidity for our Common Shares may remain limited given the substantial holdings of such shareholders, which could make the price of our Common Shares more volatile and may make it more difficult for investors to buy or sell large amounts of our Common Shares. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Because there are no current plans to pay cash dividends on our Common Shares for the foreseeable future, you may not receive any return on investment unless you sell our Common Shares for a price greater than that which you paid for it. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our may retain future earnings, if any, for future operations, expansion and debt repayment and has no current plans to pay any cash dividends for the foreseeable future. Any decision to declare and pay dividends as a public company in the future will be made at the discretion of our board of directors and will depend on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions, applicable law and other factors that our board of directors may deem relevant. In addition, our ability to pay dividends may be limited by covenants of any existing and future outstanding indebtedness we or our subsidiaries incur. As a result, you may not receive any return on an investment in our Common Shares unless you sell your shares of for a price greater than that which you paid for them. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are an exempted company limited by shares incorporated under the laws of Bermuda and it may be difficult for you to enforce judgments against us or our directors and executive officers. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are an exempted company limited by shares incorporated under the laws of Bermuda. As a result, the rights of our shareholders are governed by Bermuda law and our memorandum of association and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws.</div> The rights of shareholders under Bermuda law may differ from the rights of shareholders of companies incorporated in another jurisdiction. It may be difficult for investors to enforce in the U.S. judgments obtained in U.S. courts against us based on the civil liability provisions of the U.S. securities laws. It is doubtful whether courts in Bermuda will enforce judgments obtained in other jurisdictions, including the U.S., against us or our directors or officers under the securities laws of those jurisdictions or entertain actions in Bermuda against us or our directors or officers under the securities laws of other jurisdictions. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">159 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bermuda law differs from the laws in effect in the U.S. and may afford less protection to our shareholders. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are incorporated under the laws of Bermuda. As a result, our corporate affairs are governed by the Bermuda Companies Act 1981, as amended (the &#8220;Companies Act&#8221;), which differs in some material respects from laws typically applicable to U.S. corporations and shareholders, including the provisions relating to interested directors, amalgamations, mergers and acquisitions, takeovers, shareholder lawsuits and indemnification of directors. Generally, the duties of directors and officers of a Bermuda company are owed to the company only. Shareholders of Bermuda companies typically do not have rights to take action against directors or officers of the company and may only do so in limited circumstances. Shareholder class actions are not available under Bermuda law. The circumstances in which shareholder derivative actions may be available under Bermuda law are substantially more proscribed and less clear than they would be to shareholders of U.S. corporations. The Bermuda courts, however, would ordinarily be expected to permit a shareholder to commence an action in the name of a company to remedy a wrong to the company where the act complained of is alleged to be beyond the corporate power of the company or illegal or would result in the violation of the company&#8217;s memorandum of association or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws.</div> Furthermore, consideration would be given by a Bermuda court to acts that are alleged to constitute a fraud against the minority shareholders or, for instance, where an act requires the approval of a greater percentage of the company&#8217;s shareholders than those who actually approved it. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">When the affairs of a company are being conducted in a manner that is oppressive or prejudicial to the interests of some shareholders, one or more shareholders may apply to the Supreme Court of Bermuda, which may make such order as it sees fit, including an order regulating the conduct of the company&#8217;s affairs in the future or ordering the purchase of the shares of any shareholders by other shareholders or by the company. Additionally, under our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> and as permitted by Bermuda law, each shareholder will waive any claim or right of action against our directors or officers for any action taken by directors or officers in the performance of their duties, except for actions involving fraud or dishonesty. In addition, the rights of our shareholders and the fiduciary responsibilities of our directors under Bermuda law are not as clearly established as under statutes or judicial precedent in existence in jurisdictions in the U.S., particularly the State of Delaware. Therefore, our shareholders may have more difficulty protecting their interests than would shareholders of a corporation incorporated in a jurisdiction within the U.S. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">There are regulatory limitations on the ownership and transfer of our Common Shares. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Common shares may be offered or sold in Bermuda only in compliance with the provisions of the Companies Act and the Bermuda Investment Business Act 2003, which regulates the sale of securities in Bermuda. In addition, the Bermuda Monetary Authority must approve all issues and transfers of shares of a Bermuda exempted company. However, the Bermuda Monetary Authority has, pursuant to its statement of June&#160;1, 2005, given its general permission under the Exchange Control Act 1972 and related regulations for the issue and free transfer of our Common Shares to and among persons who are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-residents</div> of Bermuda for exchange control purposes as long as the shares are listed on an appointed stock exchange, which includes Nasdaq. Additionally, we have sought and have obtained a specific permission from the Bermuda Monetary Authority for the issue and transfer of our Common Shares up to the amount of our authorized capital from time to time, and options, warrants, depository receipts, rights, loan notes, debt instruments and our other securities to persons resident and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-resident</div> for exchange control purposes with the need for prior approval of such issue or transfer. The general permission or the specific permission would cease to apply if we were to cease to be listed on the Nasdaq or another appointed stock exchange. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may become subject to unanticipated tax liabilities and higher effective tax rates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are incorporated under the laws of Bermuda. We are centrally managed and controlled in the U.K., and under current U.K. tax law, a company which is centrally managed and controlled in the U.K. is regarded as resident in the U.K. for taxation purposes. Accordingly, we expect to be subject to U.K. taxation on our income and gains, and subject to U.K.&#8217;s controlled foreign company rules, except where an exemption applies. We may </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">160 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be treated as a dual resident company for U.K. tax purposes. As a result, our right to claim certain reliefs from U.K. tax may be restricted, and changes in law or practice in the U.K. could result in the imposition of further restrictions on our right to claim U.K. tax reliefs. We may also become subject to income, withholding or other taxes in certain jurisdictions by reason of our activities and operations, and it is also possible that taxing authorities in any such jurisdictions could assert that we are subject to greater taxation than we currently anticipate, including as a result of the denial of treaty benefits that we may claim. Any such additional tax liability could materially adversely affect our results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The intended tax effects of our corporate structure and intercompany arrangements depend on the application of the tax laws of various jurisdictions and on how we operate our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are incorporated under the laws of Bermuda and are centrally managed and controlled in the UK. We currently have subsidiaries in the U.S., U.K., Switzerland and certain other jurisdictions. If we succeed in growing our business, we expect to conduct increased operations through our subsidiaries in various countries and tax jurisdictions, in part through intercompany service agreements between our subsidiaries and us. In that case, our corporate structure and intercompany transactions, including the manner in which we develop and use our intellectual property, will be organized so that we can achieve our business objectives in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-efficient</div> manner and in compliance with applicable transfer pricing rules and regulations. If two or more affiliated companies are located in different countries or tax jurisdictions, the tax laws and regulations of each country generally will require that transfer prices be the same as those between unrelated companies dealing at arm&#8217;s length and that appropriate documentation be maintained to support the transfer prices. While we believe that we operate in compliance with applicable transfer pricing laws and intend to continue to do so, our transfer pricing procedures are not binding on applicable taxing authorities. If taxing authorities in any of these countries were to successfully challenge our transfer prices as not reflecting arm&#8217;s length transactions between two or more affiliated companies, they could require such affiliated companies to adjust their transfer prices and thereby reallocate the income between such affiliated companies to reflect these revised transfer prices, which could result in a higher tax liability to us. In addition, if the country from which the income is reallocated does not agree with the reallocation, both countries could tax the same income, resulting in double taxation. If taxing authorities were to allocate income to a higher tax jurisdiction, subject our income to double taxation or assess interest and penalties, it would increase its consolidated tax liability, which could adversely affect our financial condition, results of operations and cash flows. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant judgment is required in evaluating our tax positions and determining our provision for income taxes. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. For example, our effective tax rates could be adversely affected by changes in foreign currency exchange rates or by changes in the relevant tax, accounting, and other laws (including tax treaties), regulations, principles, and interpretations. As we intend to operate in numerous countries and taxing jurisdictions, the application of tax laws can be subject to diverging and sometimes conflicting interpretations by tax authorities of these jurisdictions. It is not uncommon for taxing authorities in different countries to have conflicting views, for instance, with respect to, among other things, the manner in which the arm&#8217;s length standard is applied for transfer pricing purposes, or with respect to the valuation of intellectual property. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, tax laws are dynamic and subject to change as new laws are passed and new interpretations of the law are issued or applied. We continue to assess the impact of such changes in tax laws and interpretations on our business and may determine that changes to our structure, practice, tax positions or the manner in which we conduct our business are necessary in light of such changes and developments in the tax laws of other jurisdictions in which we operate. Such changes may nevertheless be ineffective in avoiding an increase in our consolidated tax liability, which could adversely affect our financial condition, results of operations and cash flows. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">161 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in our effective tax rate may reduce our net income in future periods. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our tax position could be adversely impacted by changes in tax rates, tax laws, tax practice, tax treaties or tax regulations or changes in the interpretation thereof by the tax authorities in Europe (including the U.K. and Switzerland), the U.S., Bermuda and other jurisdictions, as well as being affected by certain changes currently proposed by the Organization for Economic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-operation</div> and Development and their action plan on Base Erosion and Profit Shifting. Such changes may become more likely as a result of recent economic trends in the jurisdictions in which we operate, particularly if such trends continue. If such a situation were to arise, it could adversely impact our tax position and our effective tax rate. Failure to manage the risks associated with such changes, or misinterpretation of the laws providing such changes, could result in costly audits, interest, penalties, and reputational damage, which could adversely affect our business, results of our operations, and our financial condition. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our actual effective tax rate may vary from our expectation and that variance may be material. A number of factors may increase our future effective tax rates, including: (1)&#160;the jurisdictions in which profits are determined to be earned and taxed; (2)&#160;the resolution of issues arising from any future tax audits with various tax authorities; (3)&#160;changes in the valuation of our deferred tax assets and liabilities; (4)&#160;increases in expenses not deductible for tax purposes, including transaction costs and impairments of goodwill in connection with acquisitions; (5)&#160;changes in the taxation of stock-based compensation; (6)&#160;changes in tax laws (including tax treaties) or the interpretation of such tax laws (including tax treaties) and changes in U.S. generally accepted accounting principles; and (7)&#160;challenges to the transfer pricing policies related to our structure. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The IRS may not agree that we should be treated as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation for U.S. federal income tax purposes. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Under current U.S. federal income tax law, a corporation generally will be considered to be a U.S. corporation for U.S. federal income tax purposes only if it is created or organized in the United States or under the law of the United States or of any state thereof. Accordingly, under generally applicable U.S. federal income tax rules, since we were not created or organized in the United States or under the law of the United States or of any state thereof but are instead a Bermuda incorporated entity and tax resident of the U.K., we would generally be classified as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation. Section&#160;7874 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) and the Treasury regulations promulgated thereunder, however, contain specific rules that may cause a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation to be treated as a U.S. corporation for U.S. federal income tax purposes. If it were determined that we are treated as a U.S. corporation for U.S. federal income tax purposes under Section&#160;7874 of the Code and the Treasury regulations promulgated thereunder, we would be liable for U.S. federal income tax on our income just like any other U.S. corporation and certain distributions made by us to our shareholders that are not &#8220;United States persons as defined in the Code (&#8220;U.S. holders&#8221;) would be subject to U.S. withholding tax. We believe that we should not be treated as a U.S. corporation for U.S. federal income tax purposes under Section&#160;7874 of the Code. However, the application of Section&#160;7874 of the Code is complex and is subject to detailed Treasury regulations that could be impacted by changes in such Treasury regulations with possible retroactive effect, and the interpretation of Treasury regulations relating to the required ownership of us is subject to uncertainty for which there is limited guidance regarding their application. Accordingly, there can be no assurance that the IRS will not take a contrary position to those described above or that a court will not agree with a contrary position of the IRS in the event of litigation. You are urged to consult your tax advisor to determine the tax consequences if the classification of us as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation is not respected. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. holders that own 10% or more of the combined voting power or value of our Common Shares may suffer adverse tax consequences because we and our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> subsidiaries may be characterized as &#8220;controlled foreign corporations&#8221; (&#8220;CFCs&#8221;) under Section&#160;957(a) of the Code. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation is considered a CFC if more than 50% of (1)&#160;the total combined voting power of all classes of stock of such corporation entitled to vote, or (2)&#160;the total value of the stock of such corporation, is </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">162 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">owned, or is considered as owned by applying certain constructive ownership rules, by U.S. shareholders (U.S. persons who own stock representing 10% or more of the combined voting power or value of all outstanding stock of such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation) on any day during the taxable year of such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation. Certain U.S. shareholders of a CFC generally are required to include currently in gross income such shareholders&#8217; share of the CFC&#8217;s &#8220;Subpart F income,&#8221; a portion of the CFC&#8217;s earnings to the extent the CFC holds certain U.S. property, and a portion of the CFC&#8217;s &#8220;global intangible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-taxed</div> income&#8221; (as defined under Section&#160;951A of the Code). Such U.S. shareholders are subject to current U.S. federal income tax with respect to such items, even if the CFC has not made an actual distribution to such shareholders. &#8220;Subpart F income&#8221; includes, among other things, certain passive income (such as income from dividends, interests, royalties, rents and annuities or gain from the sale of property that produces such types of income) and certain sales and services income arising in connection with transactions between the CFC and a person related to the CFC. &#8220;Global intangible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-taxed</div> income&#8221; may include most of the remainder of a CFC&#8217;s income over a deemed return on its tangible assets. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We believe that we will not be classified as a CFC in the current taxable year. However, our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> subsidiaries will be classified as CFCs in the current taxable year. For U.S. holders who hold 10% or more of the combined voting power or value of our Common Shares, this may result in adverse U.S. federal income tax consequences, such as current U.S. taxation of Subpart F income (regardless of whether we make any distributions), taxation of amounts treated as global intangible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-taxed</div> income under Section&#160;951A of the Code with respect to such shareholder, and being subject to certain reporting requirements with the IRS. Any such U.S. holder who is an individual generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a U.S. corporation. If you are a U.S. holder who holds 10% or more of the combined voting power or value of our Common Shares, you should consult your own tax advisors regarding the U.S. tax consequences of acquiring, owning, or disposing of our Common Shares. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. holders of our Common Shares may suffer adverse tax consequences if we are characterized as a passive foreign investment company. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generally, if, for any taxable year, at least 75% of our gross income is passive income, or at least 50% of the average quarterly value of our assets is attributable to assets that produce passive income or are held for the production of passive income, including cash, we would be characterized as a passive foreign investment company (a &#8220;PFIC&#8221;) for U.S. federal income tax purposes. For purposes of these tests, passive income generally includes dividends, interest, gains from the sale or exchange of investment property and rents and royalties other than rents and royalties which are received from unrelated parties in connection with the active conduct of a trade or business. Additionally, if we own (directly or indirectly) at least 25% (by value) of the stock of another corporation, for purposes of determining whether we are a PFIC, generally we would be treated as if we held our proportionate share of the assets of such other corporation and received directly our proportionate share of the income of such other corporation (the &#8220;Look-Through Rule&#8221;) and generally we would retain the character of such assets and income as if they were held directly by us rather than by such other corporation (but see below for the discussion on an exception to the Look-Through Rule). If we are characterized as a PFIC, U.S. holders of our Common Shares may suffer adverse tax consequences, including having gains realized on the sale of our Common Shares treated as ordinary income rather than capital gain, the loss of the preferential tax rate applicable to dividends received on our Common Shares by individuals who are U.S. holders, and having interest charges apply to certain distributions by us and the proceeds of sales or other dispositions of our Common Shares that result in a gain to the U.S. holder. In addition, special information reporting may be required. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our status as a PFIC will depend on the nature and composition of our income and the nature, composition and value of our assets from time to time. The 50% passive asset test described above is generally based on the fair market value of each asset. If we are a CFC (determined by disregarding certain downward attribution rules) and not publicly traded for the relevant taxable year, however, the test shall be applied based on the adjusted basis of our assets. Because our Common Shares should be considered to be &#8220;publicly traded&#8221; for the taxable year that ended on March&#160;31, 2022, we would apply the 50% passive asset test using the fair market value of our assets. In addition, our status may also depend, in part, on how quickly we utilize our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cash&#160;on-hand&#160;and</div> cash from future financings in our business. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">163 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Treasury regulations adopted in 2021, or the (the &#8220;2021 Regulations&#8221;), modify certain of the rules described above. The 2021 Regulations generally apply to taxable years of shareholders beginning on or after January&#160;14, 2021. A shareholder, however, may choose to apply such rules for any open taxable year beginning before January&#160;14, 2021, provided that, with respect to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation being tested for PFIC status, the shareholder consistently applies certain of the provisions of the 2021 Regulations and certain other Treasury regulations for such year and all subsequent years. Investors who are U.S. holders should consult their own tax advisors regarding the impact and applicability of the 2021 Regulations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the foregoing, with respect to the taxable year that ended on March&#160;31, 2022, we believe that we were not a PFIC based in part on our belief that we were not classified as a CFC in the taxable year that ended on March&#160;31, 2022 and based upon the fair market value of our assets, including any goodwill and intangible property, and the nature and composition of our income and assets. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our status as a PFIC is a fact-intensive determination made on an annual basis, which is subject to uncertainties, including but not limited to the fact that the value of our assets for purposes of the PFIC determination may be affected by the trading value of our Common Shares, which could fluctuate significantly. The total value of our assets for purposes of the PFIC asset test frequently (though not invariably) may be inferred using the market price of our ordinary shares, which may fluctuate considerably and thereby affect the determination of our PFIC status for future taxable year. Our U.S. counsel expresses no opinion with respect to our PFIC status for the current or future taxable years. We will endeavor to determine our PFIC status for each taxable year and make such determination available to U.S. holders. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The determination of our PFIC status is impacted by structures and arrangements we have implemented that are intended in part to mitigate the possibility that we will be classified as a PFIC. There can be no assurance that the IRS will not successfully challenge these structures and arrangements, which may result in an adverse impact on the determination of whether we are classified as a PFIC in the current and future taxable years. In addition, the 2021 Regulations, of which we are continuing to assess the impact, may also adversely affect the treatment of these structures and arrangements with respect to our PFIC status. For example, as discussed above, the Look-Through Rule generally applies with respect to our 25% or more owned subsidiaries. If we are subject to the accumulated earnings tax (or waive any benefit under any treaty which would otherwise prevent the imposition of such tax) and we own at least 25% (by value) of the stock of a U.S. corporation (a &#8220;25%-owned U.S. corporation&#8221;), then for purposes of determining our PFIC status, generally any stock of a U.S. corporation (such corporation, a &#8220;second-tier U.S. corporation,&#8221; and such stock, &#8220;qualified stock&#8221;) held by such 25%-owned U.S. corporation shall be treated as an asset which does not produce passive income (and is not held for the production of passive income) and any amount included in gross income with respect to such stock shall not be treated as passive income (the &#8220;Look-Through Rule Exception&#8221;). Accordingly, since we have waived any benefit under any treaty which would otherwise prevent the imposition of the accumulated earnings tax, we expect that the Look-Through Rule Exception applies to us and, for purposes of determining our PFIC status, any qualified stock held by our subsidiaries that are 25%-owned U.S. corporations are expected not to be treated as passive assets and any amount included in gross income with respect to such stock are expected not to be treated as passive income. Though we expect that the Look-Through Rule Exception applies to us, such determination, however, is subject to uncertainties. For example, the 2021 Regulations adopted an anti-abuse rule with respect to the application of the Look-Through Rule Exception. According to the anti-abuse rule, the Look-Through Rule Exception will not apply if a principal purpose for the formation of, acquisition of, or holding of stock of the 25%-owned U.S. corporation or the second-tier U.S. corporation, or for the capitalization or other funding of the second-tier U.S. corporation, is to hold passive assets through the second-tier U.S. corporation to avoid classification of the foreign corporation as a PFIC. While we do not believe that such anti-abuse rule will apply to us in light of the legislative history of the Look-Through Rule Exception as well as the nature and composition of our income and the nature, composition and value of our assets, there is no assurance regarding the application of the anti-abuse rule with respect to our PFIC status in our past, current, or future taxable years. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investors who are U.S. holders are urged to consult their own tax advisors regarding the application of the Look-Through Rule, the Look-Through Rule Exception, and the anti-abuse rule. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">164 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom307489_4" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;1B. UNRESOLVED STAFF COMMENTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div id="rom307489_5" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;2. PROPERTIES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our principal executive offices are located at Suite 1, 3rd Floor, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">11-12</div> St. James&#8217;s Square, London, United Kingdom SW1Y 4LB. Our registered office is located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. Certain of our subsidiaries and affiliates also have business operations in New York, New York, Boston, Massachusetts and Basel, Switzerland. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our subsidiary Roivant Sciences, Inc. subleases 83,340 square feet of office space located in New York, New York, pursuant to a sublease agreement that expires in October 2032. Certain of our subsidiaries and affiliates also lease office space in Boston, Massachusetts and Basel, Switzerland. We do not own any properties. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that our and our subsidiaries&#8217; leased facilities are in good condition and are well maintained and that our current arrangements will be sufficient to meet our needs for the foreseeable future and that any required additional space will be available on commercially reasonable terms to meet space requirements if they arise. </div></div> <div id="rom307489_6" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;3. LEGAL PROCEEDINGS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, we may become involved in legal or regulatory proceedings arising in the ordinary course of our business. We do not currently, however, expect any such legal proceedings to have a material adverse effect on our business, operating results or financial condition. However, depending on the nature and timing of a given dispute, an unfavorable resolution could materially affect our current or future results of operations or cash flows. </div></div> <div id="rom307489_7" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;4. MINE SAFETY DISCLOSURES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">165 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom307489_8" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART II </div></div></div> <div id="rom307489_9" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market Information </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Common Shares began trading on The Nasdaq Global Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;ROIV&#8221; on October&#160;1, 2021. Prior to that date, there was no public trading market for our Common Shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrants to purchase our Common Shares originally began trading on The Nasdaq Stock Market LLC as units under the symbol &#8220;MAACU&#8221; on October&#160;6, 2020, in connection with the initial public offering of Montes Archimedes Acquisition Corp. (&#8220;MAAC&#8221;). Following the completion of the Business Combination with MAAC on September&#160;30, 2021, we assumed MAAC&#8217;s obligations under the warrants and they began trading on The Nasdaq Global Market under the symbol &#8220;ROIVW&#8221; on October&#160;1, 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June 21, 2022, there were 145 holders of record of our Common Shares and two holders of record of warrants to purchase our Common Shares. The actual number of holders of our Common Shares and warrants is greater than these numbers of record holders and includes stockholders who are beneficial owners but whose Common Shares or warrants are held in street name by banks, brokers and other nominees. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend Policy </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have never declared or paid cash dividends on our capital stock. We intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities Authorized for Issuance under Equity Compensation Plans </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Information about our equity compensation plans in Item 12 of Part III of this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> is incorporated herein by reference. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales of Unregistered Securities and Use of Proceeds </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;15, 2022, we issued 145,986 Common Shares to CF Principal Investments, LLC in consideration for its irrevocable commitment to purchase Common Shares pursuant to a Common Shares Purchase Agreement, dated as of February&#160;14, 2022, by and between us and CF Principal Investments, LLC in connection with an equity line facility with an aggregate line of $250.0&#160;million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April 21, 2022, we issued 1,455,719 Common Shares to Silicon Therapeutics LLC in connection with the Agreement and Plan of Merger, dated as of February&#160;2, 2021, by and among Roivant, Silicon Insite, Inc., Silicon TX China and Silicon Therapeutics LLC, as consideration in connection with the transaction, with an aggregate value of approximately $5.4 million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We issued the foregoing securities in transactions not involving an underwriter and not requiring registration under Section&#160;5 of the Securities Act of 1933, as amended, in reliance on the exemption afforded by Section&#160;4(a)(2) thereof. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Except as set forth above or reported in our Quarterly Reports on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> for the quarters ended September&#160;30, 2021 and December&#160;31, 2021, there were no other sales of unregistered securities for the year ended March&#160;31, 2022. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">166 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom307489_10" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;6. [RESERVED] </div></div></div> <div id="rom307489_11" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following discussion and analysis of Roivant&#8217;s financial condition and results of operations should be read in conjunction with Roivant&#8217;s consolidated financial statements and notes to those statements included elsewhere in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Roivant&#8217;s actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors. Please see &#8220;Forward-Looking Statements&#8221; and &#8220;Risk Factors&#8221; in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> Our fiscal year ends on March&#160;31 and our fiscal quarters end on June&#160;30, September&#160;30 and December 31. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are building the next-generation &#8220;big pharma&#8221; company, organized to harness modern technologies and computational tools as well as the entrepreneurial spirit of nimble biotechnology companies at scale. Our mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are a diverse team of experienced drug developers, scientists, physicians, company builders, data scientists and engineers, biopharma investors, physicists and business development professionals dedicated to improving the lives of patients. At Roivant, we combine our team&#8217;s extensive experience and multi-disciplinary expertise with innovative technologies to identify and advance potentially transformative medicines. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We deploy a hypothesis-driven approach to identify novel or clinically-validated targets and biological pathways in areas of high unmet medical need. We then seek to acquire, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or discover promising drug candidates against those targets or pathways. Our small molecule discovery engine is powered by leading computational physics and machine learning (&#8220;ML&#8221;) capabilities for in silico drug design. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We develop drugs and drug candidates in subsidiary companies we call &#8220;Vants&#8221; with a distinct approach to sourcing talent, aligning incentives and deploying technology. Each of our Vant teams is built with deep relevant expertise to promote successful execution of our development strategy. Our Vants continue to benefit from the support of the Roivant platform and technologies that are built to address inefficiencies in the drug discovery, development and commercialization process. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our agile Vant model has allowed us to rapidly add capabilities in diverse therapeutic areas, including immunology, dermatology and oncology, and modalities, including biologics, topicals and bifunctional small molecules. The Vant model also enables a modular approach to the monetization of therapies we advance through development, allowing us to pursue commercialization of some products independently, while selectively establishing partnerships for other Vants or divesting of the Vants entirely. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since our inception in 2014, we have focused substantially all of our efforts and financial resources on acquiring and developing our product candidates and expanding our platform and technologies. For the years ended March&#160;31, 2022 and 2021, we incurred net losses of $924.1&#160;million and $900.2&#160;million, respectively. As of March&#160;31, 2022, we had cash and cash equivalents of approximately $2.1&#160;billion and an accumulated deficit of approximately $2.8&#160;billion. Through March&#160;31, 2022, we had not generated any revenue from the sale of our product candidates. Through our subsidiary Dermavant Sciences Ltd., we have launched our first commercial product, VTAMA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (tapinarof) cream, following approval by the FDA in May 2022. Through March&#160;31, 2022, our revenue, primarily generated through license agreements as well as from subscription and service-based fees, has not been significant. Our operations to date have been financed primarily through the sale of equity securities, sale of subsidiary interests, debt financings and revenue generated from licensing and collaboration arrangements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">167 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Developments </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In May 2022, VTAMA cream was approved by the FDA as the first and only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> steroid-free topical medication in its class for the treatment of plaque psoriasis in adult patients. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the approval of VTAMA cream by the FDA in May 2022, Dermavant Sciences Ltd. (together with its wholly owned subsidiaries, &#8220;Dermavant&#8221;) received $160.0&#160;million in June 2022 pursuant to the terms of the revenue interest purchase and sale agreement (the &#8220;RIPSA&#8221;) as described in Note 7, &#8220;Long-Term Debt and Loan Commitment&#8221; of our audited financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Also, as a result of FDA approval, Dermavant achieved a regulatory milestone to GSK of &#163;100.0&#160;million (approximately $126 million on the date of achievement), which will be paid within 70 calendar days of FDA approval. Additionally, the first sale of VTAMA cream in May 2022 resulted in the achievement of a milestone to Welichem Biotech Inc. of CAD$25.0&#160;million (approximately $20 million on the date of achievement), which will be paid within 60 calendar days of the invoice date. Dermavant intends to primarily use the RIPSA proceeds for the payment of these obligations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Roivant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have implemented a company-wide cost optimization and pipeline reprioritization initiative to reduce our expected operating expenses and preserve our capital resources. As part of this initiative, we have discontinued the development of several programs, including ARU-1801, LSVT-1701, DMVT-502, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-503,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-504</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01,</div></div> to focus our capital on the potentially most valuable and meaningful opportunities for patients in our pipeline, including our programs at newly launched Priovant. We elected to wind down the development of ARU-1801 after considering the future development costs of the program, the current market environment, and the clinical and commercial profile of the product candidate. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic continues to present global public health and economic challenges. Although some of our clinical development timelines have been impacted by delays related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, we have not experienced material financial impact on our business and operations as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. However, the impact on our future results will largely depend on future developments related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> which are highly uncertain and cannot be predicted with confidence, such as the emergence of new variants, the ultimate duration and spread of the outbreak, the continuing impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on financial markets and the global economy, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain, treat, and prevent the disease, including the availability and effectiveness of vaccines. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For additional information about risks and uncertainties related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic that may impact our business, financial condition and results of operations, see the section titled &#8220;Risk Factors&#8221; included elsewhere in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Components of Results of Operations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue, net </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Through March&#160;31, 2022, we have not generated any revenues from the sale of our product candidates. Our revenue through March&#160;31, 2022 primarily includes the recognition of upfront payments received in connection with license agreements. Revenue is also generated by subscription and service-based fees. Our revenue recognized from inception through March&#160;31, 2022 has not been significant. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">168 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With the approval of VTAMA cream for the treatment of plaque psoriasis in adult patients by the FDA in May 2022, we began to recognize product revenues after our initial product launch. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cost of revenues </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Through March&#160;31, 2022, our cost of revenues primarily relates to subscription and service-based revenue recognized for the use of technology developed and consists primarily of employee, hosting, and third-party data costs. Our cost of revenues through March&#160;31, 2022 has not been significant. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With the approval of VTAMA cream for the treatment of plaque psoriasis in adult patients by the FDA in May 2022, we began to recognize cost of product revenues after our initial product launch. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and development expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses consist mainly of costs incurred in connection with the discovery and development of our product candidates. Research and development expenses primarily include the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Program-specific costs, including direct third-party costs, which include expenses incurred under agreements with contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;), manufacturing costs in connection with producing materials for use in conducting nonclinical and clinical studies, the cost of consultants who assist with the development of our product candidates on a program-specific basis, investigator grants, sponsored research, and any other third-party expenses directly attributable to the development of our product candidates. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unallocated internal costs, including: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">employee-related expenses, such as salaries, share-based compensation, and benefits, for research and development personnel; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other expenses that are not allocated to a specific program. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Research and development activities will continue to be central to our business model. We anticipate that our research and development expenses will increase for the foreseeable future as we advance our product candidates through preclinical studies and clinical trials, as well as acquire new product candidates. In addition, we expect our research and development expenses to increase in the future, including as a result of our small molecule discovery engine (&#8220;Roivant Discovery&#8221;), comprising advanced computational physics and machine learning capabilities, integrated with an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> wet lab facility. Research and development expenses will also be driven by the number of drug candidates from Roivant Discovery that we advance through preclinical studies and clinical trials. We expect higher employee-related expenses, including higher share-based compensation expenses, as well as higher consulting costs as we hire additional resources to support increasing development activity. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The duration, costs and timing of preclinical studies and clinical trials of our product candidates will depend on a variety of factors that include, but are not limited to, the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the scope, rate of progress, expense and results of our preclinical development activities, any future clinical trials of our product candidates, and other research and development activities that we may conduct; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the number and scope of preclinical and clinical programs we decide to pursue; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the uncertainties in clinical trial design and patient enrollment or drop out or discontinuation rates; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the number of doses that patients receive; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the countries in which the trials are conducted; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">our ability to secure and leverage adequate CRO support for the conduct of clinical trials; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">our ability to establish an appropriate safety and efficacy profile for our product candidates; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">169 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the timing, receipt and terms of any approvals from applicable regulatory authorities; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the potential additional safety monitoring or other studies requested by regulatory agencies; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the significant and changing government regulation and regulatory guidance; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to establish clinical and commercial manufacturing capabilities, or make arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the impact of any business interruptions to our operations due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to maintain a continued acceptable safety profile of our product candidates following approval of our product candidates. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The successful development of our product candidates is highly uncertain, and we cannot reasonably estimate the costs that will be necessary to complete the remainder of the development of our product candidates. In addition, the probability of success for our product candidates will depend on numerous factors, including competition, manufacturing capability and commercial viability. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">For the year ended March&#160;31, 2022, we began reporting acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;) expense as a separate line item in our consolidated statements of operations. Acquired IPR&amp;D expenses include consideration for the purchase of IPR&amp;D through asset acquisitions and license agreements as well as payments made in connection with asset acquisitions and license agreements upon the achievement of development milestones. These expenses were previously recorded in &#8220;Research and development&#8221; on the consolidated statements of operations. Prior periods have been revised to conform to the current period presentation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consideration for the purchase of IPR&amp;D through asset acquisitions and license agreements includes cash upfront payments, shares and other liability instruments issued, and fair value of future contingent consideration payments. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General and administrative expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">General and administrative expenses consist primarily of employee-related expenses, such as salaries, share-based compensation, and benefits, for general and administrative personnel, including those responsible for the identification and acquisition or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> of new drug candidates as well as for overseeing Vant operations and facilitating the use of our platform and technologies at Vants. General and administrative expenses also consist of legal and accounting fees, consulting services and other operating costs relating to corporate matters and daily operations. Additionally, general and administrative expenses include costs incurred relating to the identification, acquisition or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> and technology transfer of promising drug candidates along with costs incurred relating to the integration of new technologies. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect expenses to increase in future periods as we continue to expand our sales and marketing infrastructure and general administrative functions. These increases will likely include salaries, sales incentive compensation, share-based compensation and travel expenses associated with our sales force, which began promoting VTAMA cream in the United States following approval by the FDA in May 2022, as well as expected costs associated with the further build out of our commercial operations functions. We anticipate these expenses to further increase if any of our other current or future product candidates receives regulatory approval in the United States or another jurisdiction. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Change in fair value of investments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of investments includes the unrealized loss (gain) on equity investments in publicly-traded companies, including Sio Gene Therapies Inc. (&#8220;Sio&#8221;) and Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;) as </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">170 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">well as our equity investment in Heracles Parent, L.L.C., the parent entity of the Datavant business (&#8220;Datavant&#8221;), following Datavant&#8217;s merger with a wholly-owned subsidiary of Heracles Parent, L.L.C., the parent company of CIOX Health, (the &#8220;Datavant Merger&#8221;) in July 2021 at which point our minority equity interest in Datavant became subject to the equity method of accounting. We have elected the fair value option to account for these investments. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Gain on sale of investment </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on sale of investment resulted from the Datavant Merger in July 2021. Prior to the Datavant Merger, our investment in Datavant was accounted for using the measurement alternative to fair value. At closing of the Datavant Merger, we received approximately $320&#160;million in cash and a minority equity interest in the combined company, which became subject to the equity method of accounting. We recognized a gain as a result of this transaction. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Change in fair value of debt and liability instruments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Change in fair value of debt and liability instruments primarily includes the unrealized (gain) loss relating to the measurement and recognition of fair value on a recurring basis of certain liabilities, including debt issued by a wholly-owned subsidiary of Dermavant Sciences Ltd. to NovaQuest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Fund VIII, L.P. (the &#8220;NovaQuest Facility&#8221;), and other liability instruments, including warrant and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">earn-out</div> share liabilities issued in connection with our business combination with Montes Archimedes Acquisition Corp. (&#8220;MAAC&#8221;) as well as options granted to Sumitomo Dainippon Pharma Co., Ltd. (&#8220;Sumitomo&#8221;) to purchase our ownership interests in certain subsidiaries (the &#8220;Sumitomo Options&#8221;) before the termination of those options in June 2021. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Gain on termination of Sumitomo Options </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Gain on termination of Sumitomo Options resulted from the completion of transactions contemplated by an Asset Purchase Agreement entered into with Sumitomo and its subsidiary Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (&#8220;SPC&#8221;) in May 2021. The transactions contemplated by the Asset Purchase Agreement closed in June 2021. Pursuant to the Asset Purchase Agreement: (i)&#160;Sumitomo terminated all of its existing options to acquire our ownership interest in certain subsidiaries; (ii)&#160;we transferred and assigned to SPC all of our intellectual property, development and commercialization rights for (a)&#160;lefamulin in Mainland China, Taiwan, Hong Kong, and Macau (collectively &#8220;Greater China&#8221;), (b) vibegron in Mainland China, (c)&#160;rodatristat ethyl in Greater China and South Korea and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(d)&#160;RVT-802</div> in Greater China and South Korea; (iii)&#160;Sumitomo agreed to pay us $5.0&#160;million in cash; and (iv)&#160;Sumitomo entered into an agreement with us to pursue future collaborations with Genevant Sciences Ltd. (&#8220;Genevant&#8221;). We received the cash payment, net of certain withholding taxes, in August 2021. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on deconsolidation of subsidiary resulted from the determination that we no longer had a controlling financial interest in certain subsidiaries. Gain on consolidation of unconsolidated entity resulted from the remeasurement of our previously held interest in Genevant following the consolidation of Genevant as of July 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other expense, net </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense, net consists of interest expense resulting from interest accrued on long-term debt and the amortization of debt discount and issuance costs, losses from our equity method investment prior to consolidation in July 2020, interest income on our cash and cash equivalents, and other miscellaneous (income) expense. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">171 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income tax expense </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense is recorded for the jurisdictions in which we do business. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded when, after consideration of all positive and negative evidence, it is not more likely than not that our deferred tax assets will be realizable. When uncertain tax positions exist, we recognize the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net loss attributable to noncontrolling interests </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to noncontrolling interests consists of the portion of net loss of those consolidated entities that is not allocated to us. Changes in the amount of net loss attributable to noncontrolling interests are directly impacted by the net loss of our consolidated entities and changes in ownership percentages. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Results of Operations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comparison of the years ended March&#160;31, 2022 and 2021 </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth our results of operations for the years ended March&#160;31, 2022 and 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,286</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,966</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,057</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,909</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">483,035</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">236,626</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">246,409</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,894</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">596,132</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(456,238</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">775,033</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">259,878</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">515,155</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,406,928</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,094,693</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">312,235</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,351,642</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,070,898</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(280,744</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87,291</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(95,533</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on sale of investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(443,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(443,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of debt and liability instruments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,354</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(33,199</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on termination of Sumitomo Options</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(66,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(66,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,041</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(115,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110,323</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,435</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,701</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(923,747</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(898,547</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(25,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">369</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,317</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(924,116</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(900,233</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23,883</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to noncontrolling interests</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(78,854</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(90,999</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,145</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to Roivant Sciences Ltd.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(845,262</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(809,234</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(36,028</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">172 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Variance analysis for years ended March&#160;31, 2022 and 2021 </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue, net </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,286</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue, net increased by $31.5&#160;million to $55.3&#160;million for the year ended March&#160;31, 2022 compared to $23.8&#160;million for the year ended March&#160;31, 2021. The increase was primarily related to payments received in connection with license agreements and the license of technology. Additionally, we recognized revenue relating to the sales of clinical product as well as milestone income at Dermavant. Revenue generated was not significant in either period presented. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cost of revenues </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,966</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,057</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,909</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenues increased by $6.9&#160;million to $9.0&#160;million for the year ended March&#160;31, 2022 compared to $2.1&#160;million for the year ended March&#160;31, 2021, consistent with increased revenue. Cost of revenues was not significant in either period presented. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and development expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the years ended March&#160;31, 2022 and 2021, our research and development expenses consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Program-specific costs:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Batoclimab</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,181</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49,236</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tapinarof</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64,496</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,002</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,494</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Brepocitinib</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,890</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,890</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,312</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,347</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,035</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AFVT-2101</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,657</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,782</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-2801</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">784</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,247</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LSVT-1701</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,067</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,383</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,684</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Namilumab</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">820</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,925</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other program-specific costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60,660</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,558</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,102</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total program-specific costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">285,039</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">161,912</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">123,127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unallocated internal costs:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63,735</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,637</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,098</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Personnel-related expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">103,827</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,646</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58,181</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,434</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,431</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,003</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total research and development expenses</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">483,035</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">236,626</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">246,409</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">173 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses increased by $246.4&#160;million to $483.0&#160;million for the year ended March&#160;31, 2022 compared to $236.6&#160;million for the year ended March&#160;31, 2021, primarily due to increases in program-specific costs of $123.1&#160;million, personnel-related expenses of $58.2&#160;million, and share-based compensation of $41.1&#160;million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The increase of $123.1&#160;million in program-specific costs largely reflects the progression of our programs and drug discovery. Program-specific costs for Dermavant&#8217;s tapinarof program increased by $30.5&#160;million, largely resulting from purchases of clinical product as we prepared for commercial launch and incurred costs associated with our Phase 3 clinical program in atopic dermatitis. Program specific costs for Priovant Therapeutics, Inc.&#8217;s (&#8220;Priovant&#8221;) brepocitinib program were $24.9&#160;million for the year ended March&#160;31, 2022, reflecting costs incurred since the acquisition of brepocitinib in September 2021. Program-specific costs for Immunovant&#8217;s batoclimab program increased by $17.9&#160;million, primarily reflecting activities to advance the clinical development of batoclimab in current and potentially new indications. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The increase of $58.2&#160;million in personnel-related expenses was primarily driven by an increase in headcount to support the progression of our programs and drug discovery. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The increase of $41.1&#160;million in share-based compensation expense was primarily due to the achievement of the liquidity event vesting condition for certain equity instruments upon the closing of the Business Combination in September 2021, resulting in the recognition of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> expense of $22.9&#160;million relating to cumulative service rendered between the grant date of the respective awards and completion of the Business Combination and continued recognition of expense over the requisite service periods. Historically, we did not recognize share-based compensation expense related to these equity instruments as the liquidity event requirement had not been met and was not deemed probable of being met. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development expenses </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consideration for the purchase of IPR&amp;D</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">97,412</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">591,916</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(494,504</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Development milestone payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,482</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,216</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Total acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,894</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">596,132</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(456,238</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development expenses decreased by $456.2&#160;million to $139.9&#160;million for the year ended March&#160;31, 2022 compared to $596.1&#160;million for the year ended March&#160;31, 2021. The decrease was primarily due to higher consideration for the purchase of IPR&amp;D during the year ended March&#160;31, 2021 as a result of the following: consideration of $399.6&#160;million attributed to IPR&amp;D relating to the acquisition of the business of Silicon Therapeutics; consideration of $116.5&#160;million relating to the stock purchase agreement to acquire Oncopia; $41.4&#160;million attributed to IPR&amp;D as part of the consolidation of Genevant, which was previously accounted for as an equity method investment; and consideration relating to the licensing and strategic collaboration agreement with Affimed N.V. During the year ended March&#160;31, 2022, acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development expenses included consideration for the purchase of IPR&amp;D of $82.1&#160;million relating to the acquisition of brepocitinib by Priovant and $14.1&#160;million relating to a license agreement entered by Hemavant Sciences GmbH with Eisai Co., Ltd. Additionally, acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development expenses for year ended March&#160;31, 2022 included a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> milestone expense of CAD$50.0 million ($39.3&#160;million) due to the achievement of a development milestone relating to Dermavant&#8217;s tapinarof program. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">174 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General and administrative expenses </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">775,033</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">259,878</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">515,155</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">General and administrative expenses increased by $515.2&#160;million to $775.0&#160;million for the year ended March&#160;31, 2022 compared to $259.9&#160;million for the year ended March&#160;31, 2021. The increase was primarily due to increases in share-based compensation expense of $438.9&#160;million primarily as a result of the achievement of the liquidity event vesting condition for certain equity instruments upon the closing of the Business Combination in September 2021, resulting in the recognition of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> expense of $350.0&#160;million relating to cumulative service rendered between the grant date of the respective awards and completion of the Business Combination and continued recognition of expense over the requisite service periods. Historically, we did not recognize share-based compensation expense related to these equity instruments as the liquidity event requirement had not been met and was not deemed probable of being met. Additionally, general and administrative expenses for Dermavant have increased as we prepared for commercial launch. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Change in fair value of investments </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87,291</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(95,533</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of investments was an unrealized loss of $87.3&#160;million and unrealized gain of $95.5&#160;million for the years ended March&#160;31, 2022 and 2021, respectively. The change of $182.8&#160;million was primarily driven by changes in the public share prices of Arbutus and Sio as well as the change in fair value of our investment in Datavant following the completion of the Datavant Merger in July 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Gain on sale of investment </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on sale of investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(443,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(443,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on sale of investment was $443.8&#160;million for the year ended March&#160;31, 2022 due to the Datavant Merger in July 2021 at which point we received approximately $320&#160;million in cash and a minority equity stake in the combined company. See &#8220;Components of Results of Operations&#8212;Gain on sale of investment&#8221; above for additional information. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Change in fair value of debt and liability instruments </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of debt and liability instruments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,354</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(33,199</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of debt and liability instruments was an unrealized gain of $3.4&#160;million and unrealized loss of $29.8&#160;million for the years ended March&#160;31, 2022 and 2021, respectively. Change in fair value of debt and liability instruments for the year ended March&#160;31, 2022 primarily consisted of an unrealized gain of $30.8&#160;million </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">175 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">relating to the warrant and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">earn-out</div> share liabilities issued as part of the Business Combination, partially offset by an unrealized loss of $27.3&#160;million relating to the NovaQuest facility, which was largely due to the passage of time and increased probabilities of success as a result of advancement in the stage of development of the product candidate. Change in fair value of debt and liability instruments for the year ended March&#160;31, 2021 primarily consisted of an unrealized loss of $61.0&#160;million relating to the NovaQuest Facility, partially offset by an unrealized gain of $33.5&#160;million relating to the Sumitomo Options. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Gain on termination of Sumitomo Options </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on termination of Sumitomo Options</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(66,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(66,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on termination of Sumitomo Options was $66.5&#160;million for the year ended March&#160;31, 2022 due to the completion of transactions contemplated by the Asset Purchase Agreement entered into with Sumitomo and SPC. See &#8220;Components of Results of Operations&#8212;Gain on termination of Sumitomo Options&#8221; above for additional information. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,041</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(115,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110,323</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity was $5.0&#160;million and $115.4&#160;million for the years ended March&#160;31, 2022 and 2021, respectively. The gain of $5.0&#160;million for the year ended March&#160;31, 2021 resulted from the deconsolidation of a subsidiary. Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity for the year ended March&#160;31, 2021 primarily related to a gain of $86.5&#160;million on the deconsolidation of Datavant in April 2020 and a gain of $28.8&#160;million resulting from the remeasurement of our previously held interest in Genevant upon its consolidation in July 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Capital Resources </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the years ended March&#160;31, 2022 and 2021, we incurred net losses of $924.1&#160;million and $900.2&#160;million, respectively. As of March&#160;31, 2022, we had cash and cash equivalents of approximately $2.1&#160;billion and our accumulated deficit was approximately $2.8&#160;billion. Through March&#160;31, 2022, we have not generated any revenues from the sale of our product candidates. Through our subsidiary Dermavant, we have launched our first commercial product, VTAMA cream, following approval by the FDA in May 2022. Our revenue through March&#160;31, 2022, primarily generated through license agreements as well as from subscription and service-based fees, has not been significant. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our short-term and long-term liquidity requirements as of March&#160;31, 2022 included: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual payments related to our long-term debt (see Note 7, &#8220;Long-Term Debt and Loan Commitment&#8221; of our audited financial statements); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obligations under our operating leases (see Note 12, &#8220;Leases&#8221; of our audited financial statements); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">certain commitments to Palantir Technologies Inc. (&#8220;Palantir&#8221;) totaling $30.0&#160;million related to a master subscription agreement entered in May 2021 for access to Palantir&#8217;s proprietary software for a five-year period; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">176 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">certain commitments to Samsung Biologics Co., Ltd. (&#8220;Samsung&#8221;) pursuant to a Product Service Agreement entered between Immunovant and Samsung by which Samsung will manufacture and supply Immunovant with batoclimab drug substance for commercial sale and perform other manufacturing-related services with respect to batoclimab. The minimum purchase commitment related to this agreement is estimated to be approximately $36.0&#160;million. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, we have certain payment obligations under various asset acquisition and license agreements. Under these agreements we are required to make milestone payments upon successful completion and achievement of certain development, regulatory and commercial milestones. The payment obligations under the asset acquisition and license agreements are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones, and we will be required to make milestone payments and royalty payments in connection with the sale of products developed under these agreements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In May 2022, VTAMA (tapinarof) cream was approved by the FDA as the first and only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> steroid-free topical medication in its class for the treatment of plaque psoriasis in adult patients. As a result of FDA approval, Dermavant achieved a regulatory milestone to GSK of &#163;100.0&#160;million (approximately $126 million on the date of achievement), which will be paid within 70 calendar days of FDA approval. Additionally, the first sale of VTAMA cream in May 2022 resulted in the achievement of a milestone to Welichem Biotech Inc. of CAD$25.0&#160;million (approximately $20 million on the date of achievement), which will be paid within 60 calendar days of the invoice date. Dermavant intends to primarily use the RIPSA proceeds for the payment of these obligations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Apart from the above mentioned regulatory milestones related to VTAMA (tapinarof) cream, the payment obligations under our asset acquisition and license agreements are contingent upon future events and the amount, timing, and likelihood of such payments are not know. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We enter into agreements in the normal course of business with CROs and other vendors for clinical trials and with vendors for preclinical studies and other services and products for operating purposes, which are generally cancelable upon written notice. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We expect our existing cash and cash equivalents will be sufficient to fund our committed operating expenses and capital expenditure requirements for at least the next twelve months based on current operating plans and financial forecasts. However, we have based this estimate on assumptions that may prove to be wrong, which may require us to use our capital resources sooner than expected. See &#8220;Forward-Looking Statements&#8221; and &#8220;Risk Factors&#8221; in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our operations to date have been financed primarily through the sale of equity securities, sale of subsidiary interests, debt financings and revenue generated from licensing and collaboration arrangements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">RSL Equity Financing Transactions </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since inception, we have completed multiple equity financing transactions, including the following: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, in connection with the Sumitomo Transaction, we raised net proceeds of approximately $999.2&#160;million in connection with the sale of our common shares to Sumitomo. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2021, we completed our Business Combination with MAAC, a special purpose acquisition company, as well as concurrent PIPE Financing. In connection with the Business Combination and PIPE Financing, we received approximately $213.4&#160;million in cash at closing. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;14, 2022, we entered into a committed equity facility (the &#8220;Facility&#8221;) with an affiliate of Cantor Fitzgerald&#160;&amp; Co. (&#8220;Cantor&#8221;). Under the terms of the Facility, Cantor has committed to purchase up to an aggregate of $250.0&#160;million in our common shares from time to time at our request, subject to certain limitations and the satisfaction of certain conditions. Any sales of our common shares to Cantor under the Facility will be made at 99% of the volume-weighted average price of our common shares on Nasdaq on a given trading day. In </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">177 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consideration for entry into the Facility, we paid Cantor an upfront commitment fee in the form of 145,986 common shares. As of March&#160;31, 2022, $250.0&#160;million of our common shares remained available for sale under the Facility. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Sumitomo Transaction </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, we closed the Sumitomo Transaction, including the transfer of our ownership interest in five Vants&#8212;Myovant Sciences Ltd., Urovant Sciences Ltd., Enzyvant Therapeutics Ltd., Altavant Sciences Ltd., and Spirovant Sciences Ltd.&#8212;to Sumitovant Biopharma Ltd. (&#8220;Sumitovant&#8221;), a wholly-owned subsidiary of Sumitomo. In addition, in connection with the Sumitomo Transaction, we (i)&#160;granted Sumitomo options to purchase all, or in the case of Dermavant, 75%, of our ownership interests in six other subsidiaries and (ii)&#160;provided Sumitomo and Sumitovant with certain rights over and access to our proprietary technology platforms, DrugOme and Digital Innovation. In exchange for these components of the Sumitomo Transaction, we received approximately $1.9&#160;billion in cash, which was in addition to the approximately $999.2&#160;million from the sale of our common shares to Sumitomo as discussed above. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, we completed a transaction with Sumitomo pursuant to which Sumitomo terminated its existing options to acquire our equity interests in certain of our subsidiaries. See &#8220;Components of Results of Operations&#8212;Gain on termination of Sumitomo Options&#8221; above for additional information. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Vant Equity Financing Transactions </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since inception, we have completed multiple Vant equity financing transactions, including the following: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Immunovant </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, Immunovant raised $111.0&#160;million (including $5.1&#160;million related to common shares purchased by us) through a business combination with Health Sciences Acquisition Corporation, a special purpose acquisition company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, during the years ended March&#160;31, 2021 and 2020, Immunovant issued shares of common stock for an aggregate net proceeds of $384.9&#160;million (including an aggregate of $27.5&#160;million of shares of common stock purchased by us) in private financings, underwritten public offerings, and warrant exercises. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proteovant </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2020, following Proteovant Sciences, Inc&#8217;s (&#8220;Proteovant&#8221;) acquisition of Oncopia in November 2020, SK, Inc. (formerly known as SK Holdings Co., Ltd.) (&#8220;SK&#8221;) entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) pursuant to which SK agreed to make a $200.0&#160;million equity investment in Proteovant, representing an ownership interest of 40.0% on the closing date. In January 2021, in accordance with the terms of the Subscription Agreement, SK made the first payment of $100.0&#160;million to Proteovant. In July 2021, Proteovant collected the subscription receivable relating to the second $100.0&#160;million payment due under the SK Subscription Agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Vant Debt Financings </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since inception, we have completed multiple Vant debt financings, including the following: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2019, Dermavant entered into a loan and security agreement (the &#8220;Hercules Loan Agreement&#8221;) with Hercules, pursuant to which Dermavant borrowed an aggregate of $20.0&#160;million. In May 2021, all amounts outstanding under the Hercules Loan Agreement were repaid using the proceeds from the $40.0&#160;million senior secured credit facility entered into by Dermavant in May 2021, and Dermavant terminated the Hercules Loan Agreement. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">178 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Following the approval of VTAMA cream by the FDA in May 2022, Dermavant received $160.0&#160;million in June 2022 pursuant to the terms of the revenue interest purchase and sale agreement entered with XYQ Luxco, NovaQuest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Fund XVII, L.P., an affiliate of NovaQuest Capital Management, LLC, and MAM Tapir Lender, LLC, an affiliate of Marathon Asset Management, L.P., together with U.S. Bank National Association, as collateral agent. Under the terms of the RIPSA, the Purchasers procured a capped single-digit revenue interest in net sales of tapinarof for all dermatological indications in the United States, up to a cap of $344.0 million, in exchange for $160.0 million in committed funding to be paid to Dermavant, conditional based on the approval of tapinarof by the FDA. As described above, Dermavant intends to primarily use the RIPSA proceeds for the payment of certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> milestone obligations that became payable upon the approval and commercialization of VTAMA (tapinarof) cream for the treatment of plaque psoriasis in adult patients in the United States. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Other </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Datavant </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2021, we received approximately $320&#160;million in cash as a result of the Datavant Merger. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Funding Requirements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We expect our expenses to increase in connection with our ongoing activities, particularly as we advance the discovery efforts, preclinical activities, clinical trials and potential commercialization of our product candidates. Additionally, we expect to incur significant commercialization expenses with respect to VTAMA cream. Our operating results, including our net losses, may fluctuate significantly from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">quarter-to-quarter</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-year,</div></div> depending on the timing of our planned clinical trials, our expenditures on other research and development activities and our commercialization efforts. We anticipate that our expenses will increase substantially as we: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fund preclinical studies and clinical trials for our product candidates, which we are pursuing or may choose to pursue in the future; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fund the manufacturing of drug substance and drug product of our product candidates in development; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">seek to identify, acquire, develop and commercialize additional product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">invest in activities related to the discovery of novel drugs and advancement of our internal programs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">integrate acquired technologies into a comprehensive regulatory and product development strategy; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maintain, expand and protect our intellectual property portfolio; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">hire scientific, clinical, quality control and administrative personnel; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">add operational, financial and management information systems and personnel, including personnel to support our drug development efforts; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">achieve milestones under our agreements with third parties that will require us to make substantial payments to those parties; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">seek regulatory approvals for any product candidates that successfully complete clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">build out our sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize VTAMA and any drug candidates for which we may obtain regulatory approval; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">operate as a public company. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect to continue to finance our cash needs through a combination of our cash on hand and future equity offerings, debt financings, sales of subsidiaries, and collaborations, strategic alliances or marketing, distribution, licensing or similar arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">179 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">these securities may include liquidation or other preferences that adversely affect your rights as a common shareholder. Any agreements for future debt or preferred equity financings, if available, may involve covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution, licensing or similar arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. Adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates, grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves or potentially discontinue operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Flows </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a summary of our cash flows for the years ended March&#160;31, 2022 and 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(677,729</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(552,138</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by (used in) investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">303,295</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(31,702</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">306,792</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">456,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Activities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Cash flow from operating activities represents the cash receipts and disbursements related to all of our activities other than investing and financing activities. Cash flow from operating activities is derived from adjusting our net loss for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> items and changes in working capital. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For the year ended March&#160;31, 2022, cash used in operating activities increased by $125.6&#160;million to $677.7&#160;million compared to the year ended March&#160;31, 2021. This increase was primarily driven by an increase in cash required to fund operations, particularly as a result of the progression of Vant programs and payments made for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> milestone expense and purchases of clinical product as we prepared for a commercial launch of VTAMA cream and incurred costs associated with our Phase 3 clinical program in atopic dermatitis at Dermavant. Additionally, in November 2021, we made a $50.0&#160;million cash payment related to the previously-disclosed $100.0&#160;million second tranche of consideration due in connection with the acquisition of Silicon Therapeutics, LLC. The remaining consideration was settled by the issuance of 6,348,057 of our common shares. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investing Activities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flow from investing activities includes cash used for acquisitions, net of cash acquired; proceeds from investments; dispositions, net of cash disposed; capital expenditures; and purchases of equity securities and other investments. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended March&#160;31, 2022, cash flow from investing activities changed by $335.0&#160;million to net cash provided by investing activities of $303.3&#160;million from net cash used in investing activities of $31.7&#160;million for the year ended March&#160;31, 2021. This change in cash flow from investing activities is primarily due to approximately $320&#160;million in cash we received as a result of the Datavant Merger. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">180 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financing Activities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended March&#160;31, 2022, cash provided by financing activities decreased by $149.5&#160;million to $306.8&#160;million compared to the year ended March&#160;31, 2021. During the year ended March&#160;31, 2022, proceeds were generated by the completion of our Business Combination and PIPE financing in September 2021, payment of the subscription receivable due to Proteovant by SK in July 2021, and the senior secured credit facility entered into by Dermavant and certain of its subsidiaries with XYQ Luxco, as lender, and U.S. Bank National Association, as collateral agent, partially offset by cash used to repay all amounts outstanding under a previously existing loan and security agreement with Hercules Capital, Inc. During the year ended March&#160;31, 2021, cash provided by financing activities was primarily driven by the issuance of equity by our majority-owned subsidiaries, Immunovant and Proteovant. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Critical Accounting Policies and Significant Judgments and Estimates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The preparation of these financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingencies as of the dates of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. In accordance with U.S. GAAP, we evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, or experience. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We define our critical accounting policies as those under U.S. GAAP that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">While our significant accounting policies are described in more detail in Note 2, &#8220;Summary of Significant Accounting Policies&#8221; in our consolidated financial statements included elsewhere in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses consist primarily of costs incurred in connection with the discovery and development of our product candidates. We expense research and development costs as incurred. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We accrue expense for preclinical studies and clinical trial activities performed by vendors based upon estimates of the proportion of work completed. We determine such estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions with our internal personnel and external service providers as to the progress or stage of completion and the agreed-upon fee to be paid for such services. However, actual costs and timing of preclinical studies and clinical trials are highly uncertain, subject to risks, and may change depending upon a number of factors, including our clinical development plan. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the accrual is adjusted accordingly. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">181 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Compensation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recognize compensation costs related to share-based awards granted to employees, directors, and consultants based on the estimated fair value of the awards on the date of grant. The grant date fair value of the stock-based awards is recognized over the requisite service period, which is generally the vesting period of the respective awards. We may grant awards with graded-vesting features. When such awards have only service vesting requirements, we elected to record share-based compensation expense on a straight-line basis. If awards with graded-vesting features contain performance or market conditions, then we record share-based compensation expense using the accelerated attribution method. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We estimate the fair value of stock options using the Black-Scholes option-pricing model, which requires assumptions, including the fair value of our common shares prior to our initial public offering, volatility, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options, and our expected dividend yield. Certain assumptions used in our Black-Scholes option-pricing model represent management&#8217;s best estimates and involve a number of variables, uncertainties and assumptions and the application of management&#8217;s judgment, as they are inherently subjective. If any assumptions change, our stock-based compensation expense could be materially different in the future. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These subjective assumptions are estimated as follows: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair value of common share</div></div>&#8212;Prior to the closing of the Business Combination, as a privately held company, we estimated the fair value of the shares of common stock underlying our share-based awards on each grant date. To determine the fair value of our common shares underlying option grants, we considered, among other things, valuations of our common share prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. The estimation of the fair value of the common shares considered factors including the following: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the prices of our common shares sold to investors in arm&#8217;s length transactions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the estimated present value of our future cash flows; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our business, financial condition and results of operations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our forecasted operating performance; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the illiquid nature of our common shares; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">industry information such as market size and growth; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">market capitalization of comparable companies and the estimated value of transactions such companies have engaged in; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">macroeconomic conditions. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We apply a similar methodology to estimate the fair value of the shares of common stock underlying share-based awards issued by our privately held Vants. Following the closing of the Company&#8217;s business combination with MAAC, our common shares became publicly traded and we began determining the fair value of each common share underlying share-based awards based on the closing price of our common shares as reported by Nasdaq on the date of grant. Therefore, it will not be necessary to determine the fair value of the new stock-based award pursuant to the methodology described above. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected term</div></div>&#8212;We have generally elected to use the &#8220;simplified method&#8221; for estimating the expected term of options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally 10 years). </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">182 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected volatility</div></div>&#8212;Prior to the closing of the Business Combination, we were a privately held company and did not have any trading history for our common shares; accordingly, the expected volatility was estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty. We apply similar methodology to estimate the expected volatility at our privately held Vants. Because we do not have an extended trading history for our shares of common stock since the closing of the Business Combination, the method used to estimate the expected volatility remained unchanged. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk-free interest rate</div></div>&#8212;The risk-free rate assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of our stock options at the time of the grant. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected dividend yield</div></div>&#8212;We have not issued any dividends in our history and do not expect to issue dividends over the life of the options; therefore, we have estimated the dividend yield to be zero. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2, &#8220;Summary of Significant Accounting Policies&#8221; in our consolidated financial statements included elsewhere in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Implications of Being an Emerging Growth Company and Smaller Reporting Company </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are an &#8220;emerging growth company&#8221; within the meaning of the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). As an emerging growth company, we may take advantage of certain exemptions from various public company reporting requirements, including the requirement that our internal control over financial reporting be audited by our independent registered public accounting firm pursuant to Section&#160;404 of the Sarbanes-Oxley Act, certain requirements related to the disclosure of executive compensation in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> and in our periodic reports and proxy statements, and the requirement that we hold a nonbinding advisory vote on executive compensation and any golden parachute payments. We have also taken advantage of the ability to provide reduced disclosure of financial information in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> such as being permitted to include only two years of audited financial information and two years of selected financial information in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure. We may take advantage of these exemptions until we are no longer an emerging growth company. Section&#160;107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. In other words, an &#8220;emerging growth company&#8221; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to avail ourselves of this extended transition period, and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. However, because we have taken advantage of certain reduced reporting requirements, the information contained herein may be different from the information you receive from other public companies in which you hold shares. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the date of the first sale of Roivant common shares pursuant to an effective registration statement or (b)&#160;in which we have total annual gross revenue of at least $1.07&#160;billion (as adjusted for inflation pursuant to SEC rules from time to time), and (2)&#160;the date on which (x)&#160;we are deemed to be a large accelerated filer, which means the market value of Roivant common shares that are held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> exceeds $700&#160;million as of the prior September 30th, or (y)&#160;the date on which we have issued more than $1.0&#160;billion in nonconvertible debt during the prior three-year period. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">183 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Additionally, we are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K.</div> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i)&#160;the market value of our common shares held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> exceeds $250&#160;million as of the end of that year&#8217;s second fiscal quarter, or (ii)&#160;our annual revenues exceeded $100&#160;million during such completed fiscal year and the market value of our common shares held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> exceeds $700&#160;million as of the end of that year&#8217;s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies more difficult. </div> <div id="rom307489_12" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under SEC rules and regulations, because we are considered to be a &#8220;smaller reporting company,&#8221; we are not required to provide the information required by this item in this report. </div></div> <div id="rom307489_13" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">184 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roivant Sciences Ltd. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Index to Consolidated Financial Statements </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 95%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 1.5pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx307489_f100">Report of Independent Registered Public Accounting Firm (PCAOB ID No. <ix:nonNumeric name="dei:AuditorFirmId" contextRef="P04_01_2021To03_31_2022">42</ix:nonNumeric>) </a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18<div style="display:inline;">6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Financial Statements</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx307489_f1">Consolidated Balance Sheets as of March&#160;31, 2022 and 2021</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1<div style="display:inline;">87</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx307489_f2">Consolidated Statements of Operations for the Years Ended March&#160;31, 2022 and 2021</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1<div style="display:inline;">88</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx307489_f3">Consolidated Statements of Comprehensive Loss for the Years Ended March&#160;31, 2022 and 2021</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1<div style="display:inline;">89</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx307489_f4">Consolidated Statements of Shareholders&#8217; Equity and Redeemable Noncontrolling Interest for the Years Ended March&#160;31, 2022 and 2021</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19<div style="display:inline;">0</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx307489_f5">Consolidated Statements of Cash Flows for the Years Ended March&#160;31, 2022 and 2021</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19<div style="display:inline;">1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx307489_f6">Notes to Consolidated Financial Statements</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19<div style="display:inline;">2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">185 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx307489_f100" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Shareholders and the Board of Directors of Roivant Sciences Ltd. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated balance sheets of Roivant Sciences Ltd. (the Company) as of March&#160;31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, shareholders&#8217; equity and redeemable noncontrolling interest and cash flows for each of the two years in the period ended March&#160;31, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at March&#160;31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended March&#160;31, 2022, in conformity with U.S. generally accepted accounting principles. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ <ix:nonNumeric name="dei:AuditorName" contextRef="P04_01_2021To03_31_2022">Ernst &amp; Young LLP</ix:nonNumeric> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2016. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:AuditorLocation" contextRef="P04_01_2021To03_31_2022">Iselin, New Jersey</ix:nonNumeric> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June&#160;28, 2022 </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">186 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div id="tx307489_f1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Balance Sheets </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands, except share and per share amounts) </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,060,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,055,044</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,903</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77,701</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">82,220</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,146,523</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,186,995</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,905</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,044</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,279</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash, net of current portion</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,731</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,931</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments measured at fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">325,834</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">188,978</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">100,563</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,092</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,197</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,585,129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,589,692</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities, Redeemable Noncontrolling Interest and Shareholders&#8217; Equity</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,583</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">127,531</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">76,936</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,398</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,313</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred consideration liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DeferredConsiderationLiabilityCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DeferredConsiderationLiabilityCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,147</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,918</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">708</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,244</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">184,367</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">218,961</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments measured at fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:LiabilityInstrumentsMeasuredAtFairValue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">44,912</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:LiabilityInstrumentsMeasuredAtFairValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">67,893</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, noncurrent</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,384</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt (includes $<ix:nonFraction name="us-gaap:LongTermDebtFairValue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">177,400</ix:nonFraction> and $<ix:nonFraction name="us-gaap:LongTermDebtFairValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">150,100</ix:nonFraction> accounted for under the fair value option at March&#160;31, 2022 and 2021, respectively)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">210,025</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">170,280</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue, noncurrent</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,740</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,183</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,169</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">523,695</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">527,687</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies (Note 13)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Redeemable noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders&#8217; equity:<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Common shares, par value $<span style="-sec-ix-hidden:hidden50658054">0.00000003</span><span style="-sec-ix-hidden:hidden50658055">41740141</span> per share, <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">7,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">694,975,965</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">651,576,293</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2022 and 2021, respectively</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="Fact_50658038">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="Fact_50658039">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658041">4,421,614</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658040">3,814,805</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Subscription receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:SubscriptionsReceivable" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="Fact_50658043">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:SubscriptionsReceivable" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658042">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658045">2,763,724</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658044">1,918,462</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive (loss) income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658047">946</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658046">1,445</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders&#8217; equity attributable to Roivant Sciences Ltd.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658049">1,656,944</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658048">1,797,788</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Noncontrolling interests</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658022">381,999</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658023">241,726</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shareholders&#8217; equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658024">2,038,943</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658025">2,039,514</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Total liabilities, redeemable noncontrolling interest and shareholders&#8217;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>equity</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,585,129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,589,692</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Retroactively restated for the stock subdivision as described in Note 3. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">87</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div></div> <div id="tx307489_f2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Operations </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands, except share and per share amounts) </div></div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,286</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,795</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:OperatingCosts" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,966</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:OperatingCosts" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,057</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development (includes $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2021To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">63,735</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,637</ix:nonFraction> of share-based compensation expense for the years ended March&#160;31, 2022 and 2021, respectively)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">483,035</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">236,626</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:AcquiredInProcessResearchAndDevelopmentExpense" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">139,894</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:AcquiredInProcessResearchAndDevelopmentExpense" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">596,132</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative (includes $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2021To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">501,221</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,321</ix:nonFraction> of share-based compensation expense for the years ended March&#160;31, 2022 and 2021, respectively)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">775,033</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">259,878</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,406,928</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,094,693</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,351,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,070,898</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">87,291</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">95,533</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on sale of investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainOnSaleOfInvestments" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">443,754</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainOnSaleOfInvestments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of debt and liability instruments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,354</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">29,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on termination of Sumitomo Options</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:EquityInterestOptionToThirdPartyPurchaserGainOnTermination" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">66,472</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:EquityInterestOptionToThirdPartyPurchaserGainOnTermination" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,041</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,435</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8,701</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">923,747</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">898,547</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">369</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">924,116</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">900,233</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to noncontrolling interests</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">78,854</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">90,999</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to Roivant Sciences Ltd.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">845,262</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">809,234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net loss per common share&#8212;basic and diluted(1)</div><br/></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="Fact_50658157">1.26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="Fact_50658156">1.28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares outstanding&#8212;basic and diluted<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="Fact_50658155">669,753,458</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="Fact_50658154">630,046,720</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Retroactively restated for the stock subdivision as described in Note 3. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">88</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a><br/></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div></div> <div id="tx307489_f3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Comprehensive Loss </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands) </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">924,116</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">900,233</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive loss:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation adjustment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,271</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other comprehensive (loss) income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,271</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">926,387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">896,407</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive loss attributable to noncontrolling interests</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">78,734</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">90,967</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive loss attributable to Roivant Sciences Ltd.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">847,653</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">805,440</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">89</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div></div> <div id="tx307489_f4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Shareholders&#8217; Equity and Redeemable Noncontrolling Interest </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands, except share data) </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 46%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="30" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shareholders&#8217; Equity<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable<br/>Noncontrolling<br/>Interest</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common <div style="text-indent: 0px;;display:inline;">Stock</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/>Capital</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subscription<br/>Receivable</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Noncontrolling<br/>Interests</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Shareholders&#8217;<br/>Equity</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 46%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Balance at March&#160;31, 2020</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" contextRef="PAsOn03_31_2020_RedeemableNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658125">22,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_50658115">628,779,048</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="Fact_50658121">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658116">3,143,739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="Fact_50658122">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658117">2,349</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658118">1,109,228</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658119">54,042</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658120">2,086,204</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Issuance of the Company&#8217;s common shares</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_01_2020To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_50658092">21,077,155</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658095">301,744</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658096">301,744</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Issuance of subsidiary common shares, net</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesNetValue" contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658111">324,995</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesNetValue" contextRef="P04_01_2020To03_31_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658112">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesNetValue" contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658113">231,102</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesNetValue" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658114">456,097</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Issuance of subsidiary common shares to the <br/>Company</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658109">11,692</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658110">11,692</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Exercise of subsidiary stock options and <br/>vesting of subsidiary restricted stock units</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658285">522</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658286">385</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658287">907</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Deconsolidation of subsidiary</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DeconsolidationOfSubsidiary" contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658281">3,054</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DeconsolidationOfSubsidiary" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658282">3,054</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Consolidation of unconsolidated entity</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ConsolidationOfUnconsolidatedEntity" contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658279">9,178</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ConsolidationOfUnconsolidatedEntity" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658280">9,178</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Repurchase of equity awards</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:RepurchaseOfEquityAwards" contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658273">113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:RepurchaseOfEquityAwards" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658274">113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Cash contribution to majority-owned <br/>subsidiaries</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658266">1,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658267">1,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2020To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658253">1,720,090</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658254">57,252</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658255">27,706</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658256">84,958</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Foreign currency translation adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P04_01_2020To03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658241">3,794</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658242">32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658243">3,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658229">809,234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658230">90,999</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658231">900,233</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Balance at March&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" contextRef="PAsOn03_31_2021_RedeemableNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658123">22,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_50658198">651,576,293</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="Fact_50658213">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658202">3,814,805</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658203">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658204">1,445</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658205">1,918,462</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658206">241,726</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658207">2,039,514</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Issuance of subsidiary warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryWarrants" contextRef="P04_01_2021To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658103">2,051</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryWarrants" contextRef="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658104">24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryWarrants" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658105">2,075</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap; text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Issuance of the Company&#8217;s common shares <br/>upon closing of Business Combination and <br/>PIPE Financing, net of issuance costs</div></div><br/></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" contextRef="P04_01_2021To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_50658903">32,372,478</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" contextRef="P04_01_2021To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658909">129,097</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658910">129,097</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Issuance of the Company&#8217;s <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;<br/>related to settlement of transaction <br/>consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" contextRef="P04_01_2021To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_50658921">840,398</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Issuance of subsidiary preferred shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryPreferredShares" contextRef="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658924">70,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryPreferredShares" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658925">70,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Issuance of subsidiary common and preferred <br/>shares to the Company</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany" contextRef="P04_01_2021To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658929">52,189</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany" contextRef="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658930">52,189</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Payment of subscription receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent" contextRef="P04_01_2021To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658935">40,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent" contextRef="P04_01_2021To03_31_2022_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658936">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent" contextRef="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658937">40,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658938">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Repurchase of equity awards</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:RepurchaseOfEquityAwards" contextRef="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658275">2,247</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:RepurchaseOfEquityAwards" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658276">2,247</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Issuance of the Company&#8217;s <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_01_2021To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_50658093">7,369,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P04_01_2021To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658097">57,167</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658098">57,167</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Issuance of common stock upon warrants <br/>exercise</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfStockUponWarrantsExerciseShares" contextRef="P04_01_2021To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_50659118">60,021</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfStockUponWarrantsExerciseValue" contextRef="P04_01_2021To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50659121">778</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfStockUponWarrantsExerciseValue" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50659120">778</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Stock options exercised and restricted stock <br/>units vested and settled</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled" contextRef="P04_01_2021To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_50659119">2,757,775</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P04_01_2021To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658101">412</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658102">412</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Deconsolidation of subsidiary</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DeconsolidationOfSubsidiary" contextRef="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658283">3,578</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DeconsolidationOfSubsidiary" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658284">3,578</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Cash contributions to majority-owned <br/>subsidiaries</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" contextRef="P04_01_2021To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658268">10,219</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" contextRef="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658269">10,219</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2021To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658257">519,712</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658258">45,244</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658259">564,956</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Foreign currency translation adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P04_01_2021To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658244">2,391</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658245">120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658246">2,271</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2021To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658232">845,262</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658233">78,854</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658234">924,116</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Balance at March&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" contextRef="PAsOn03_31_2022_RedeemableNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658124">22,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_50658199">694,975,965</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="Fact_50658214">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658208">4,421,614</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="Fact_50658215">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658209">946</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658210">2,763,724</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658211">381,999</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658212">2,038,943</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Retroactively restated for the stock subdivision as described in Note 3. </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0</div></div></div> </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div></div> <div id="tx307489_f5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Cash Flows </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands) </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from operating activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">924,116</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">900,233</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash used in operating activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:NonCashAcquiredInProcessResearchAndDevelopment" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">78,223</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:NonCashAcquiredInProcessResearchAndDevelopment" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">351,523</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">564,956</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">84,958</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">87,291</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">95,533</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on sale of investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainOnSaleOfInvestments" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">443,754</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainOnSaleOfInvestments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of debt and liability instruments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,354</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">29,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,041</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on termination of Sumitomo Options</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:GainOnTerminationOfEquityInterestOptions" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,472</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:GainOnTerminationOfEquityInterestOptions" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from equity method investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,750</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,819</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">16,978</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in assets and liabilities, net of effects from acquisition and divestiture:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,403</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,752</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,595</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred consideration liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredLiabilities" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">50,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredLiabilities" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,865</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,497</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,969</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,297</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,383</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">677,729</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">552,138</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from investing activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">320,170</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of property and equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,436</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,806</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IncreaseDecreaseInOtherInvestingNet" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">561</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:IncreaseDecreaseInOtherInvestingNet" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,896</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by (used in) investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">303,295</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">31,702</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from financing activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from Business Combination and PIPE Financing</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromBusinessCombinationAndPipeFinancing" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">213,424</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromBusinessCombinationAndPipeFinancing" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of subsidiary common shares, net of issuance costs paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">455,756</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from payment of subscription receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromPaymentOfSubscriptionReceivable" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromPaymentOfSubscriptionReceivable" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from subsidiary debt financings, net of financing costs paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromSubsidiaryDebtFinancingsNet" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromSubsidiaryDebtFinancingsNet" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of long-term debt by subsidiary</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,590</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment of offering costs and loan origination costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:PaymentForOfferingAndLoanCosts" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,297</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:PaymentForOfferingAndLoanCosts" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">286</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:ProceedsFromAndPaymentForOtherFinancingActivities" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,145</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromAndPaymentForOtherFinancingActivities" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">794</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">306,792</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">456,264</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in cash, cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">67,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">127,576</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash at beginning of period</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,141,676</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,269,252</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash at end of period</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,074,034</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,141,676</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> investing and financing activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subscription receivable related to issuance of subsidiary common shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:OtherNonCashTransactions" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,035</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:OtherNonCashTransactions" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,531</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure of cash paid:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">916</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,076</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,535</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,017</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">1</div></div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div id="tx307489_f6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <ix:nonNumeric name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1&#8212;Description of Business and Liquidity </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Description of Business </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roivant Sciences Ltd. (inclusive of its consolidated subsidiaries, the &#8220;Company&#8221; or &#8220;RSL&#8221;) aims to improve health by rapidly delivering innovative medicines and technologies to patients. The Company does this by building biotech and healthcare technology companies (&#8220;Vants&#8221;) and deploying technology to drive greater efficiency in research and development and commercialization.&#160;In addition to biopharmaceutical subsidiaries, the Company also builds technology Vants focused on improving the process of developing and commercializing medicines. The Company was founded on April&#160;7, 2014 as a Bermuda exempted limited company. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">VTAMA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (tapinarof) cream was approved by the United States Food and Drug Administration (&#8220;FDA&#8221;) in May 2022 as the first and only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> steroid-free topical medication in its class for the treatment of plaque psoriasis in adult patients. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has determined that it has <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> operating and reporting segment as it allocates resources and assesses financial performance on a consolidated basis. The Company&#8217;s subsidiaries are wholly owned subsidiaries and majority-owned or controlled subsidiaries. Refer to Note 4, &#8220;Investments&#8221; for further discussion of the Company&#8217;s investments in unconsolidated entities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;30, 2021, RSL completed its business combination with Montes Archimedes Acquisition Corp. (&#8220;MAAC&#8221;), a special purpose acquisition company, and began trading on Nasdaq under the ticker symbol &#8220;ROIV.&#8221; Refer to Note 3, &#8220;Business Combination with MAAC&#8221; for additional details. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Liquidity </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has incurred significant losses and negative cash flows from operations since its inception. As of March&#160;31, 2022, the Company had cash and cash equivalents of approximately $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.1</ix:nonFraction>&#160;billion and its accumulated deficit was approximately $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-8" scale="9" sign="-" format="ixt:num-dot-decimal">2.8</ix:nonFraction>&#160;billion. For the years ended March&#160;31, 2022 and 2021, the Company incurred net losses of $<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">924.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">900.2</ix:nonFraction>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million, respectively. The Company has historically financed its operations primarily through the sale of equity securities, sale of subsidiary interests, debt financings and revenue generated from licensing and collaboration arrangements. Through March&#160;31, 2022, the Company had not generated any revenue from the sale of its product candidates. Through its subsidiary Dermavant Sciences Ltd., the Company has launched its first commercial product, VTAMA cream, following approval by the FDA in May 2022. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals to market its product candidates, dependence on key products, dependence on third-party service providers, such as contract research organizations, and protection of intellectual property rights. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company intends to raise such additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates or take other steps to conserve capital. The Company expects its existing cash and cash equivalents will be sufficient to fund its committed operating expenses and capital expenditure requirements for at least the next </div>12<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months from the date of issuance of these consolidated financial statements.</div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true" continuedAt="TextSelection_50658885"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2&#8212;Summary of Significant Accounting Policies </div></div></div> <ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Basis of Presentation and Principles of Consolidation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s fiscal year ends on March&#160;31, and its fiscal quarters end on June&#160;30, September&#160;30, and December 31. </div></div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying audited consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).&#160;&#160;&#160;&#160; </div></div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the accounts of RSL and the subsidiaries in which it has a controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of common stock ownership interest retained in the respective operations by the noncontrolling parties. The Company presents noncontrolling interests as a component of shareholders&#8217; equity on its consolidated balance sheets. </div></div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for changes in its ownership interest in its subsidiaries while control is retained as equity transactions. The carrying amount of the noncontrolling interest is adjusted to reflect the change in RSL&#8217;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received or paid and the amount by which the noncontrolling interest is adjusted is recognized within shareholders&#8217; equity attributable to RSL. </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Use of Estimates </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </div></div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Additionally, the Company assessed the impact that the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> pandemic has had on its operations and financial results as of March&#160;31, 2022 and through the issuance of these consolidated financial statements. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses. </div></div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P04_01_2021To03_31_2022" escape="true" continuedAt="TextSelection_50658740"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Concentrations</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_50658885" continuedAt="TextSelectionAppend_50658885_1"> <ix:continuation id="TextSelection_50658740"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">T</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">he Company has long-lived assets in different geographic locations. As of March 31, 2022 and 2021, a majority of the Company&#8217;s long-lived assets were located in the United States. </div></div></div></div> </ix:continuation> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> <div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">(D) Cash, Cash Equivalents, and Restricted Cash </div></div></div></div> <div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company considers all highly liquid investments purchased with original maturities of three months or less to</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> be cash equivalents. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash classified as a current asset consists of legally restricted </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> bearing deposit accounts relating to the Company&#8217;s corporate credit card programs. Restricted cash classified as a long-term asset consists of restricted deposit accounts related to irrevocable standby letters of credit. As of March&#160;31, 2021, restricted cash classified as a current asset included $</div><ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">75.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million held in escrow for the purpose of fulfilling certain indemnification obligations. The full escrow amount of $</div><ix:nonFraction name="roiv:ProceedsFromReleaseOfEscrowDeposit" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">75.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was disbursed to the Company in June 2021.</div></div> <ix:nonNumeric name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash as reported in the accompanying consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the accompanying consolidated balance sheets as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,060,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,055,044</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,634</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">86,632</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:CashAndCashEquivalentsAndRestrictedCash" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,074,034</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:CashAndCashEquivalentsAndRestrictedCash" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,141,676</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(E) Contingencies </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible. </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true" continuedAt="TextSelection_50658748"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(F) Property and Equipment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, consisting primarily of computers, laboratory and other equipment, furniture and fixtures, software, and leasehold improvements, is recorded at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement or sale, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation of property and equipment is recorded using the straight-line method over the estimated useful lives of the related assets once the asset has been placed in service. Leasehold improvements are amortized using the straight-line method over the estimated useful life or remaining lease term, whichever is shorter. <ix:nonNumeric name="roiv:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true" continuedAt="TextSelection_50658850">The following table provides the range of estimated useful lives used for each asset type:</ix:nonNumeric> </div></div> <ix:continuation id="TextSelection_50658850"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 39%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 59%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated Useful Life</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computers</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P04_01_2021To03_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">3</ix:nonNumeric> years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory&#160;and&#160;other&#160;equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P04_01_2021To03_31_2022_LaboratoryandotherequipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">5</ix:nonNumeric> - <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P04_01_2021To03_31_2022_LaboratoryandotherequipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">10</ix:nonNumeric> years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P04_01_2021To03_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">7</ix:nonNumeric> years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Software</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P04_01_2021To03_31_2022_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">3</ix:nonNumeric> years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P04_01_2021To03_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">Lesser of estimated useful life or remaining lease term</ix:nonNumeric></td> </tr> </table> </ix:continuation></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a><br/></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_50658885_1" continuedAt="TextSelectionAppend_50658885_2"> <ix:continuation id="TextSelection_50658748"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company reviews the recoverability of all long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable. Recoverability is measured by comparison of the book values of the assets to the future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets.</div> </ix:continuation> </ix:continuation> <div style="margin-top: 1em; margin-bottom: 1em"></div> <ix:continuation id="TextSelectionAppend_50658885_2" continuedAt="TextSelectionAppend_50658885_3"> <ix:nonNumeric name="us-gaap:InvestmentPolicyTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(G<div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">)</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> Investments </div></div></div></div> <div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Investments in equity securities may be accounted for using (i)&#160;the fair value option if elected, (ii)&#160;fair value through earnings if fair value is readily determinable or (iii)&#160;for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the measurement alternative is made for each eligible investment. </div></div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company has elected the fair value option to account for certain investments over which the Company has significant influence. The Company believes the fair value option best reflects the underlying economics of the investment. See Note 4, &#8220;Investments.&#8221; </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(H) Research and Development Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. Preclinical and clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. R&amp;D costs primarily consist of costs associated with preclinical studies and clinical trials, including amounts paid to contract research organizations, contract manufacturing organizations, and other third parties that conduct R&amp;D activities on behalf of the Company, as well as employee-related expenses, such as salaries, share-based compensation, and benefits, for employees engaged in R&amp;D activities. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:InProcessResearchAndDevelopmentPolicy" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">(I) Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Process</div> Research and Development Expenses </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">For the year ended March&#160;31, 2022, the Company began reporting acquired </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in-process</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> research and development (&#8220;IPR&amp;D&#8221;) expense as a separate line item in its consolidated statements of operations. Acquired IPR&amp;D expenses include consideration for the purchase of IPR&amp;D through asset acquisitions and license agreements as well as payments made in connection with asset acquisitions and license agreements upon the achievement of development milestones. These expenses were previously recorded in &#8220;Research and development&#8221; on the consolidated statements of operations. Prior periods have been revised to conform to the current period presentation. </div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> agreements for </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in-process</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> research and development projects (&#8220;IPR&amp;D&#8221;) to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> agreement for IPR&amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as acquired </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in-process</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> research and development expense in its consolidated statements of operations. Payments for milestones achieved and payments for a product license prior to regulatory approval of the product are expensed in the period incurred. Milestone payments made in connection with regulatory approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset. </div></div></div></ix:nonNumeric> <ix:nonNumeric name="roiv:GeneralAndAdministrativeExpensesPolicyTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true" continuedAt="TextSelection_50658891"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(J) General and Administrative Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">General and administrative (&#8220;G&amp;A&#8221;) expenses consist primarily of employee-related expenses for G&amp;A personnel, including those responsible for the identification and acquisition or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> of new drug candidates as well as for overseeing Vant operations and facilitating the use of the Company&#8217;s platform and technologies at Vants. G&amp;A expenses also consist of legal and accounting fees, consulting services and other operating costs </div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">9<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_50658885_3" continuedAt="TextSelectionAppend_50658885_4"> <ix:continuation id="TextSelection_50658891"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">relating to corporate matters and daily operations. G&amp;A expenses include costs incurred relating to the identification, acquisition or </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in-license</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> and technology transfer of promising drug candidates along with costs incurred relating to the integration of new technologies.</div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </ix:continuation> <div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">(K) Leases </div></div></div></div> <div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company determines if an arrangement includes a lease at the inception of the agreement. For each of the Company&#8217;s lease arrangements, the Company records a </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> asset representing the Company&#8217;s right to use an underlying asset for the lease term and a lease liability representing the Company&#8217;s obligation to make lease payments. Operating lease </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> assets and operating lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the expected lease term. If the interest rate implicit in the Company&#8217;s leases is not readily determinable, in determining the weighted-average discount rate used to</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> calculate the net present value of lease payments, the Company utilizes an estimate of its incremental borrowing rate. The Company&#8217;s incremental borrowing rates are determined based on the term of the lease, the economic environment of the lease, and the effect of collateralization. Lease expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term and variable lease costs are expensed as incurred. </div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company elected the practical expedient not to apply the recognition and measurement requirements to short-term leases, which is any lease with a term of one year or less as of the lease commencement date. Leases may require the Company to pay additional amounts for taxes, insurance, maintenance, and other expenses, which are generally referred to as </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> components. The Company has elected the practical expedient to combine lease and </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> components. If a lease includes options to extend the lease term, the Company does not assume the option will be exercised in its initial lease term assessment unless there is reasonable certainty that the Company will renew based on an assessment of economic factors present as of the lease commencement date. </div></div></div></ix:nonNumeric> <div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">(L) Income Taxes </div></div></div></div> <div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded when, after consideration of all positive and negative evidence, it is not more likely than not that the Company&#8217;s deferred tax assets will be realizable. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </div></div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P04_01_2021To03_31_2022" escape="true" continuedAt="TextSelection_50658890"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(M) Share-Based Compensation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based awards to employees, directors, and consultants, including stock options, restricted stock units, performance options and capped value appreciation rights, are measured at fair value on the date of the grant and that fair value is recognized as share-based compensation expense in the Company&#8217;s consolidated statements of operations over the requisite service period of the respective award. The estimated fair value of awards that contain performance conditions is expensed when the Company concludes that it is probable that the </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_50658885_4" continuedAt="TextSelectionAppend_50658885_5"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <ix:continuation id="TextSelection_50658890"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">performance condition will be achieved. The Company may grant awards with graded-vesting features. When such awards have only service vesting requirements, the Company elected to record share-based compensation expense on a straight-line basis. If awards with graded-vesting features contain performance or market conditions, then the Company records share-based compensation expense using the accelerated attribution method. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">The Company measures the fair value of its stock options that only have service vesting requirements or performance-based options without market conditions using the Black-Scholes option pricing model. For performance-based awards with market conditions, the Company determines the fair value of the awards as of the grant date using a Monte Carlo simulation model. When determining the grant-date fair value of stock-based awards, management further considers whether an adjustment is required to the observable market price or volatility of the Company&#8217;s common stock that is used in the valuation as a result of material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-public</div> information, if that information is expected to result in a material increase in share price. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Certain assumptions need to be made with respect to utilizing the Black-Scholes option pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate and the fair value of the Company&#8217;s shares of common stock. Since the Company has limited option exercise history, it has generally elected to estimate the expected life of an award based upon the &#8220;simplified method&#8221; with the continued use of this method extended until such time the Company has sufficient exercise history. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. The expected share price volatility for the Company&#8217;s common shares is estimated by taking the average historical price volatility for industry peers. The Company accounts for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-vesting</div> award forfeitures when they occur. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">One of the inputs to the Black-Scholes option pricing model is the fair value of the Company&#8217;s common shares. Prior to the closing of its business combination with MAAC, as a privately held company, the Company estimated the fair value of the shares of common stock underlying its share-based awards on each grant date. Given the absence of a public trading market, and in accordance with the American Institute of Certified Public Accountants&#8217; Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, the Company exercised reasonable judgment and considered numerous objective and subjective factors to determine its best estimate of the fair value of its common shares. The estimation of the fair value of the common shares considered factors including the following: the prices of the Company&#8217;s common shares sold to investors in arm&#8217;s length transactions; the estimated present value of the Company&#8217;s future cash flows; the Company&#8217;s business, financial condition and results of operations; the Company&#8217;s forecasted operating performance; the illiquid nature of the Company&#8217;s common shares; industry information such as market size and growth; market capitalization of comparable companies and the estimated value of transactions such companies have engaged in; and macroeconomic conditions. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies a similar methodology to estimate the fair value of the shares of common stock underlying share-based awards issued by its privately held Vants. Following the closing of the Company&#8217;s business combination with MAAC, RSL&#8217;s common shares became publicly traded and the Company began determining the fair value of each common share underlying share-based awards based on the closing price of its common shares as reported by Nasdaq on the date of grant. Therefore, it will not be necessary to determine the fair value of the new stock-based award pursuant to the methodology described above. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="background: none; letter-spacing: 0px; top: 0px; text-decoration: none;;display:inline;"> </div></div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true" continuedAt="TextSelection_50658888"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">(N) Fair Value Measurements </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs</div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">197</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_50658885_5" continuedAt="TextSelectionAppend_50658885_6"> <ix:continuation id="TextSelection_50658888" continuedAt="TextSelectionAppend_50658888_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a three-tier fair value hierarchy that distinguishes among the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-Valuations</div> are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-Valuations</div> are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-Valuations</div> are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s financial instruments include shares of common stock of Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;); shares of common stock of Sio Gene Therapies Inc. (&#8220;Sio&#8221;); shares of common stock of Heracles Parent, L.L.C., the parent entity of Datavant (as defined and discussed in Note 4, &#8220;Investments&#8221;); liability instruments issued, including the Roivant Warrants and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares (each as defined in Note 3, &#8220;Business Combination with MAAC&#8221;) liabilities issued in connection with the Company&#8217;s business combination with MAAC (as discussed in Note 3, &#8220;Business Combination with MAAC&#8221;); the deferred consideration liability; its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and long-term debt. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The shares of Arbutus and Sio common stock and investments in common stock with a readily determinable fair value are classified as Level&#160;1, and their fair value is determined based upon quoted market prices in an active market. In October 2021, shares of Arbutus&#8217; Series A participating convertible preferred shares (&#8220;Arbutus Preferred Shares&#8221;) held by the Company were converted into shares of common stock of Arbutus pursuant to mandatory conversion provisions. Prior to conversion, the Arbutus Preferred Shares held by the Company were classified as Level&#160;2 as the fair value of such preferred shares was determined based upon the quoted market price of Arbutus common stock into which such preferred shares were convertible. The shares of common stock of Heracles Parent, L.L.C., the parent entity of Datavant (as defined and discussed in Note 4, &#8220;Investments&#8221;), and liability instruments issued, excluding the Public Warrants (as defined and discussed in Note 3, &#8220;Business Combination with MAAC&#8221;), are classified as Level&#160;3 within the fair value hierarchy as the assumptions and estimates used in the valuations are unobservable in the market. The Public Warrants are publicly traded and therefore are classified as Level&#160;1 as the Public Warrants have a readily determinable fair value. Cash, accounts payable, and the deferred consideration liability are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature. The deferred consideration liability was based on a fixed monetary amount, and payment was based solely on the passage of time. The deferred consideration liability was settled in November 2021 by payment of $<ix:nonFraction name="roiv:CashPaidToSettleDeferredConsiderationLiability" contextRef="P11_01_2021To11_01_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">50.0</ix:nonFraction>&#160;million in cash as well as the issuance of <ix:nonFraction name="roiv:StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability" contextRef="P11_01_2021To11_01_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,348,057</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the Company&#8217;s <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares. Money market funds are included in Level&#160;1 of the fair value hierarchy and are valued at the closing price reported by an actively traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly owned subsidiaries, &#8220;Dermavant&#8221;), which is stated at amortized cost, approximates fair value based on current interest rates for similar types of borrowings and therefore is included in Level&#160;2 of the fair value hierarchy. Long-term debt issued by Dermavant for which the </div></div></div> </ix:continuation> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">198</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_50658885_6" continuedAt="TextSelectionAppend_50658885_7"> <ix:continuation id="TextSelectionAppend_50658888_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fair value option has been elected is included in Level&#160;3 of the fair value hierarchy as the assumptions and estimates used in the valuation are unobservable in the market. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(O) Foreign Currency </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and liabilities of foreign operations are translated using exchange rates in effect at the balance sheet date and their results of operations are translated using average exchange rates for the year. Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Adjustments resulting from the translation of the financial statements of the Company&#8217;s foreign functional currency subsidiaries into U.S. dollars are excluded from the determination of net loss and are accumulated in a separate component of shareholders&#8217; equity. Foreign exchange transaction gains and losses are included in &#8220;Other expense, net&#8221; in the Company&#8217;s statements of operations. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true" continuedAt="TextSelection_50658886"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(P) Revenue Recognition </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes revenue when its customer <div style="letter-spacing: 0px; top: 0px;;display:inline;">obtains </div>control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for its arrangements, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when or as the Company satisfies a performance obligation. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, assessing the recognition and future reversal of variable consideration, and determining and applying appropriate methods of measuring progress for performance obligations satisfied over time. These judgments are discussed in more detail below. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licenses of intellectual property:</div></div> If the licenses to intellectual property are determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are not distinct from other promises, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition accordingly. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Milestone payments: </div></div>At the inception of each arrangement that includes research, development or regulatory milestone payments, the Company<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis in earnings in the period of the adjustment. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalties and commercial milestone payments: </div></div>For arrangements that include sales-based royalties, including commercial milestone payments<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>based on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-specified</div> level of sales, the Company </div> </td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">199</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_50658885_7"><ix:continuation id="TextSelection_50658886">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon performance of the licensee. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue is also generated by certain technology-focused Vants from subscription and service-based fees recognized for the use of certain technology developed by these Vants. Subscription revenue is recognized ratably over the contract period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade Receivables, Net </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in customer credit profiles. The Company reserves against trade receivables for estimated losses that may arise from a customer&#8217;s inability to pay, and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated losses was de minimis as of March&#160;31, 2022 and 2021. Trade receivables, net is included in &#8220;Other current assets&#8221; on the accompanying consolidated balance sheets. </div></div> </ix:continuation> <ix:nonNumeric name="roiv:WarrantliabilitiesPolicyTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Q) Warrant Liabilities </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company classifies the Roivant Warrants as liabilities. At the end of each reporting period, changes in fair value during the period are recognized within the consolidated statements of operations. The Company will continue to adjust the carrying value of the liability associated with the Roivant Warrants for changes in the fair value until the earlier of a) the exercise or expiration of the Roivant Warrants or b) the redemption of the Roivant Warrants. Issuance costs incurred that were attributable to the Roivant Warrants were expensed as incurred. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(R) Recently Adopted Accounting Pronouncements </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06,</div> &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06&#8221;).</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current U.S. GAAP. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> also removes certain settlement conditions that are required for equity contracts to qualify for the derivatives scope exception, which will permit more equity contracts to qualify for it. Either a modified retrospective transition method or a fully retrospective transition method is permissible for the adoption of this standard. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> is effective for fiscal years beginning after December&#160;15, 2021, including interim periods within those fiscal years. The early-adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> on April&#160;1, 2021 did not have a material impact on the Company&#8217;s consolidated financial statements. </div></div></ix:nonNumeric></ix:continuation> <ix:nonNumeric name="us-gaap:BusinessCombinationDisclosureTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true" continuedAt="TextSelection_50658995"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3&#8212;Business Combination with MAAC </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;30, 2021 (the &#8220;Closing Date&#8221;), in <div style="letter-spacing: 0px; top: 0px;;display:inline;">accordance </div>with the Business Combination Agreement, as amended (the &#8220;Business Combination Agreement&#8221;), RSL completed its previously announced business combination (the &#8220;Business Combination&#8221;) with MAAC, through the merger of RSL&#8217;s wholly owned subsidiary, Rhine Merger Sub, Inc., with MAAC (the &#8220;Merger&#8221;), with MAAC surviving the Merger as a wholly owned subsidiary of RSL. As MAAC does not represent a business for accounting purposes and its primary asset represents cash and cash equivalents, the Business Combination was treated as an equity contribution in exchange for the issuance of RSL shares. The net assets of MAAC were stated at historical cost, with no goodwill or other intangible assets recorded. Reported amounts from operations included herein prior to the Business Combination are those of RSL. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0</div></div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_50658995" continuedAt="TextSelectionAppend_50658995_1"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On the Closing Date prior to the effective time of the Merger (the &#8220;Effective Time&#8221;), RSL effected a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="roiv:StockholdersEquityNoteStockSplitExchangeRatio1" contextRef="PAsOn03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="roiv:StockholdersEquityNoteStockSplitExchangeRatio1" contextRef="PAsOn03_31_2022_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">2.9262</ix:nonFraction></ix:nonFraction>-for-1</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">stock subdivision based on the fixed exchange ratio established in the Business Combination. The shares, equity awards and net loss per share available to holders of the Company&#8217;s <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px;;display:inline;">stock</div></div> prior to the Business Combination, have been retroactively restated to reflect the fixed exchange ratio.</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the terms of the Business Combination Agreement, at the Effective Time: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">a.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each share of MAAC Class&#160;A common stock (the &#8220;MAAC Class&#160;A Shares&#8221;) and each share of MAAC Class&#160;B common stock (the &#8220;MAAC Class&#160;B Shares&#8221;) that were outstanding immediately before the Effective Time (other than treasury shares and any shares held by Patient Square Capital LLC (the &#8220;MAAC Sponsor&#8221;), any affiliate of the MAAC Sponsor or any of MAAC&#8217;s independent directors (the &#8220;MAAC Independent Directors&#8221;) or its transferee) were automatically canceled and extinguished and converted into one <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div>hare of RSL (the &#8220;Roivant Common Share&#8221;), </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">b.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each MAAC Class&#160;B Share that was outstanding immediately before the Effective Time and held by the MAAC Sponsor, any affiliate of the MAAC Sponsor or any of the MAAC Independent Directors or its transferee were automatically canceled and extinguished and converted into a number of Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares based on an exchange ratio of <ix:nonFraction name="roiv:ExchangeRatioOfMAACClassBToRoivantCommonShares" contextRef="PAsOn03_31_2022_MaacClassBSharesMemberusgaapStatementClassOfStockAxis_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction>, with a portion of such Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares issued to the MAAC Sponsor, any affiliate of the MAAC Sponsor, any MAAC Independent Director or its transferee by virtue of the Merger being subject to the vesting and other terms and conditions set forth in the Sponsor Support Agreement (as more fully described below), </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">c.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each warrant to purchase MAAC Class&#160;A Shares that was outstanding immediately before the Effective Time was converted automatically into a right to acquire a Roivant Common Share (a &#8220;Roivant Warrant&#8221;) at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn03_31_2022_MaacClassASharesMemberusgaapStatementClassOfStockAxis_RoivantWarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> per share, subject to certain adjustments. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the Merger, the Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div>hares and the Roivant Warrants began trading on the Nasdaq Global Market under the ticker symbols &#8220;ROIV&#8221; and &#8220;ROIVW,&#8221; respectively, on October&#160;1, 2021. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="background: none; letter-spacing: 0px; top: 0px; text-decoration: none;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Business Combination, RSL entered into subscription agreements with certain investors, whereby it issued </div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_01_2021To03_31_2022_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis_PipeFinancingMemberROIVAgreementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">22,000,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">hares at $</div><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn03_31_2022_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis_PipeFinancingMemberROIVAgreementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share for an aggregate purchase price of $</div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P04_01_2021To03_31_2022_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis_PipeFinancingMemberROIVAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">220.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;PIPE Financing&#8221;). The PIPE Financing closed simultaneously with the consummation of the Business Combination.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the Business Combination and PIPE Financing, the Company received $<ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn03_31_2022_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis_PipeFinancingMemberROIVAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">213.4</ix:nonFraction>&#160;million in cash at closing (the &#8220;Closing&#8221;), net of deferred underwriting expenses and unpaid expenses incurred by MAAC in connection with the transaction. The Company incurred $<ix:nonFraction name="roiv:Costsincurredrelatedtofinancing" contextRef="P04_01_2021To03_31_2022_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis_PipeFinancingMemberROIVAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">24.4</ix:nonFraction>&#160;million in costs directly related to the Business Combination and PIPE Financing, such as banker fees and costs associated with third-party legal, accounting and other professional services. Upon Closing, these costs, which had been capitalized on the Company&#8217;s balance sheet were recorded as a reduction of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital with the exception of $<ix:nonFraction name="roiv:Allocationoftransactioncostsincurredtowarrantsandearnoutshares" contextRef="PAsOn03_31_2022_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.4</ix:nonFraction>&#160;million, which were expensed as they represent the allocation of the transaction costs associated with the Roivant Warrants and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares liabilities. Transaction costs were allocated to the Roivant Warrants and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares liabilities based on the fair value of such instruments out of the total consideration. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sponsor Support Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the execution of the Business Combination Agreement, MAAC, the MAAC Sponsor, Roivant and each of the MAAC Independent Directors, entered into the Sponsor Support Agreement, which was subsequently amended on June&#160;9, 2021, to reflect the MAAC Independent Directors and Roivant entering into respective </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> Agreements, and further amended on September&#160;30, 2021. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Sponsor Support Agreement, among other things: </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">a.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_01_2021To03_31_2022_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,033,591</ix:nonFraction> Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares issued to the MAAC Sponsor and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_01_2021To03_31_2022_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction> Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares issued to each MAAC Independent Director (collectively, the &#8220;<ix:nonFraction name="roiv:Portionofsharesubjecttoearnout" contextRef="P04_01_2021To03_31_2022_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares&#8221;), each in respect </div> </td> </tr> </table> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div> </div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_50658995_1" continuedAt="TextSelectionAppend_50658995_2">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">of its MAAC Class&#160;B Shares, will vest if the closing price of Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares is greater than or equal to $<ix:nonFraction name="roiv:EarnOutSharePrice" contextRef="PAsOn03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">15.00</ix:nonFraction> over any <span style="-sec-ix-hidden:hidden50659038">twenty</span> out of <span style="-sec-ix-hidden:hidden50659044">thirty</span> trading day period during the Vesting Period (defined below). </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">b</div>.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_01_2021To03_31_2022_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SharePriceEqualOrExceedsTwentyDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,016,796</ix:nonFraction> Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares issued to the MAAC Sponsor and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_01_2021To03_31_2022_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_SharePriceEqualOrExceedsTwentyDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,000</ix:nonFraction> Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares issued to each MAAC Independent Director (collectively, the &#8220;<ix:nonFraction name="roiv:Portionofsharesubjecttoearnout" contextRef="P04_01_2021To03_31_2022_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SharePriceEqualOrExceedsTenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction>% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares&#8221; and, together with the <ix:nonFraction name="roiv:Portionofsharesubjecttoearnout" contextRef="P04_01_2021To03_31_2022_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SharePriceEqualOrExceedsTwentyDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Earn-Out</div> Shares&#8221;), each in respect of its MAAC Class&#160;B Shares, will vest if the closing price of Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares is greater than or equal to $<ix:nonFraction name="roiv:EarnOutSharePrice" contextRef="PAsOn03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsTwentyDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">20.00</ix:nonFraction> over any <span style="-sec-ix-hidden:hidden50659039">twenty</span> out of <span style="-sec-ix-hidden:hidden50659043">thirty</span> trading day period during the Vesting Period (as defined below). </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The remaining number of Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares issued to the MAAC Sponsor and each MAAC Independent Director are not subject to the vesting conditions described above (the &#8220;Retained Shares&#8221;). </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">The Vesting Period represents the period commencing on November&#160;9, 2021, the date on which the registration statement on Form </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">S-1</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> required to be filed by the Company in connection with the PIPE Financing was declared effective, and ending no later than September&#160;30, 2026 (the &#8220;Vesting Period&#8221;). The Vesting Period will, if a definitive purchase agreement with respect to a Sale (as defined in the Sponsor Support Agreement) is entered into on or prior to the end of such period, be extended to the earlier of one day after the consummation of such Sale and the termination of such definitive transaction agreement, and if a Sale occurs during such Vesting Period, then all of the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> Shares unvested as of such time will automatically vest immediately prior to the consummation of such Sale. If any </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> Shares have not vested on or prior to the end of such Vesting Period, then such </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> Shares will be forfeited. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">The </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> Shares require liability classification and are classified as &#8220;Liability instruments measured at fair value&#8221; on the consolidated balance sheets. The </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> Shares liability is subject to remeasurement at each balance sheet date with changes in fair value recognized in the Company&#8217;s statement of operations. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> Agreements </div></div></div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;1, 2021 and June&#160;9, 2021, RSL, on the one hand, and the MAAC Sponsor, the MAAC Independent Directors and certain Roivant equityholders, on the other hand, entered into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> agreements, pursuant to which, among other things, the MAAC Sponsor, the MAAC Independent Directors and such Roivant equityholders have agreed not to effect any sale or distribution of the Roivant Common Shares (including those underlying incentive equity awards or Roivant Warrants) held by the MAAC Sponsor, the MAAC Independent Directors or such equityholders as of immediately following the Closing during the applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period, subject to customary exceptions. </div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="background: none; letter-spacing: 0px; top: 0px; text-decoration: none;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period applicable to Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares held by the MAAC Sponsor and MAAC Independent Directors as of immediately following the Closing will be (i)&#160;with respect to <ix:nonFraction name="roiv:Percentageofsharessubjecttolockupfordefinedperiodoftime" contextRef="PAsOn03_31_2022_LockUpPeriodOneMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% of the Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares held by the MAAC Sponsor and MAAC Independent Directors, <ix:nonNumeric name="roiv:Lockupperiodofcommonshares" contextRef="P04_01_2021To03_31_2022_LockUpPeriodOneMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" format="ixt-sec:durwordsen">six months</ix:nonNumeric> following the Closing, which expired on March&#160;30, 2022, (ii) with respect to an additional <ix:nonFraction name="roiv:Percentageofsharessubjecttolockupfordefinedperiodoftime" contextRef="PAsOn03_31_2022_LockUpPeriodTwoMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% of the Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares held by the MAAC Sponsor and MAAC Independent Directors, the earlier of <ix:nonNumeric name="roiv:Lockupperiodofcommonshares" contextRef="P04_01_2021To03_31_2022_LockUpPeriodTwoMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MinimumMembersrtRangeAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" format="ixt-sec:durwordsen">twelve months</ix:nonNumeric> following the achievement of certain price-based vesting restrictions or <ix:nonNumeric name="roiv:Lockupperiodofcommonshares" contextRef="P04_01_2021To03_31_2022_LockUpPeriodTwoMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" format="ixt-sec:durwordsen">six years</ix:nonNumeric> from the Closing and (iii)&#160;with respect to <ix:nonFraction name="roiv:Percentageofsharessubjecttolockupfordefinedperiodoftime" contextRef="PAsOn03_31_2022_LockUpPeriodThreeMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of the Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares held by the MAAC Sponsor and MAAC Independent Directors, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden50659060">thirty</span>-six</div> months following the Closing. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares underlying warrants held by the MAAC Sponsor as of immediately following the Closing will be subject to a corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period for (a)&#160;with respect to <ix:nonFraction name="roiv:Percentageofwarrantssubjecttolockupfordefinedperiodoftime" contextRef="PAsOn03_31_2022_LockUpPeriodFourMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% of such warrants held by the MAAC Sponsor, <ix:nonNumeric name="roiv:Lockupperiodwarrants" contextRef="P04_01_2021To03_31_2022_LockUpPeriodFourMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" format="ixt-sec:durwordsen">six months</ix:nonNumeric> from the Closing, which expired on March&#160;30, 2022, (b) with respect to an additional <ix:nonFraction name="roiv:Percentageofwarrantssubjecttolockupfordefinedperiodoftime" contextRef="PAsOn03_31_2022_LockUpPeriodFiveMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% of such warrants held by the MAAC Sponsor, <ix:nonNumeric name="roiv:Lockupperiodwarrants" contextRef="P04_01_2021To03_31_2022_LockUpPeriodFiveMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" format="ixt-sec:durwordsen">twelve months</ix:nonNumeric> from Closing and (c)&#160;with respect to <ix:nonFraction name="roiv:Percentageofwarrantssubjecttolockupfordefinedperiodoftime" contextRef="PAsOn03_31_2022_LockUpPeriodSixMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of such warrants held by the MAAC Sponsor, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden50659065">thirty-</span>six</div> months from the Closing. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period applicable to Roivant Common Shares held by certain Roivant equityholders as of immediately following the Closing (including those underlying incentive equity awards) will be (x)&#160;with respect </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></div> </div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_50658995_2" continuedAt="TextSelectionAppend_50658995_3"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">to <ix:nonFraction name="roiv:Percentageofsharessubjecttolockupfordefinedperiodoftime" contextRef="PAsOn03_31_2022_LockUpPeriodSevenMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% of the Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares held by such Roivant equityholders (including those underlying incentive equity awards), <ix:nonNumeric name="roiv:Lockupperiodofcommonshares" contextRef="P04_01_2021To03_31_2022_LockUpPeriodSevenMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" format="ixt-sec:durwordsen">six months</ix:nonNumeric> following the Closing, which expired on March&#160;30, 2022, (y) with respect to an additional <ix:nonFraction name="roiv:Percentageofsharessubjecttolockupfordefinedperiodoftime" contextRef="PAsOn03_31_2022_LockUpPeriodEightMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% of the Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares held by such Roivant equityholders (including those underlying incentive equity awards), <ix:nonNumeric name="roiv:Lockupperiodofcommonshares" contextRef="P04_01_2021To03_31_2022_LockUpPeriodEightMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" format="ixt-sec:durwordsen">twelve months</ix:nonNumeric> following the Closing and (z)&#160;with respect to <ix:nonFraction name="roiv:Percentageofsharessubjecttolockupfordefinedperiodoftime" contextRef="PAsOn03_31_2022_LockUpPeriodNineMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of the Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares (including those underlying incentive equity awards) held by such Roivant equityholders, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden50659059">thirty</span>-six</div> months following the Closing. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Common Stock Warrants </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the effective time of the Merger, <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,214,365</ix:nonFraction> Roivant Warrants that were held by the MAAC Sponsor at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn03_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> (the &#8220;Private Placement Warrants&#8221;) and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">20,535,896</ix:nonFraction> Roivant Warrants held by MAAC&#8217;s shareholders at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn03_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> (the &#8220;Public Warrants&#8221;) were converted into the right to acquire Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares. Pursuant to the agreement governing the Roivant Warrants, the Roivant Warrants became exercisable <ix:nonNumeric name="roiv:Timetowarrantexercisability" contextRef="P04_01_2021To03_31_2022_RoivantWarrantMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday">30</ix:nonNumeric> days following the completion of the Business Combination. The Roivant Warrants will expire <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn03_31_2022_RoivantWarrantMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durwordsen">five years</ix:nonNumeric> after the completion of the Business Combination, or earlier upon redemption or liquidation. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Private Placement Warrants are generally identical to the Public Warrants, except that (i)&#160;the Private Placement Warrants (including the <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">c</div></div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">stock</div></div></div>&#160;issuable upon exercise of the Private Placement Warrants) were not transferable, assignable or salable until</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<ix:nonNumeric name="roiv:Timetowarrantexercisability" contextRef="P04_01_2021To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_RoivantWarrantMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday">30</ix:nonNumeric> days after the completion of the Business Combination (ii)&#160;they will not be redeemable by the Company when the price per share of Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares equals or exceeds $<ix:nonFraction name="roiv:Shareredemptiontriggerprice" contextRef="P04_01_2021To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsEighteenDollarMemberROIVTriggeringEventAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">18.00</ix:nonFraction>, and (iii)&#160;the Private Placement Warrants may be exercised by holders on a cashless basis. If the Private Placement Warrants are held by holders other than our sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by Roivant in all redemption scenarios and exercisable by the holders on the same basis as the Public Warrants. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Roivant Warrants require liability classification and are classified as &#8220;Liability instruments measured at fair value&#8221; on the consolidated balance sheets. The Private Placement Warrants liability and Public Warrants liability are subject to remeasurement at each balance sheet date with changes in fair value recognized in the Company&#8217;s statement of operations. As of March&#160;31, 2022, <ix:nonFraction name="roiv:CommonStockWarrants" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">60,021</ix:nonFraction> Roivant Warrants have been exercised and none redeemed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of Roivant Warrants when the price per share of Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div>hares equals or exceeds $18.00. </div></div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may redeem the outstanding Roivant Warrants for cash (except with respect to the Private Placement Warrants): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $<ix:nonFraction name="roiv:Classofwarrantsredemptionpriceperunit" contextRef="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsEighteenPerDollarMemberROIVTriggeringEventAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction> per Roivant Warrant; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon a minimum of <ix:nonNumeric name="roiv:Classofwarrantsredemptionnoticeperiod" contextRef="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsEighteenPerDollarMemberROIVTriggeringEventAxis" format="ixt-sec:durday">30</ix:nonNumeric> days&#8217; prior written notice of redemption; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">if, and only if, the last reported sale price of&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div></div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">stock</div></div></div> for any</div>&#160;<ix:nonNumeric name="roiv:Numberoftradingdaystomeetwarrantredemptionthreshold" contextRef="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsEighteenPerDollarMemberROIVTriggeringEventAxis" format="ixt-sec:durday">20</ix:nonNumeric> trading days within a <ix:nonNumeric name="roiv:Tradingdayperiodforwarrantredemption" contextRef="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsEighteenPerDollarMemberROIVTriggeringEventAxis" format="ixt-sec:durday"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30</div></ix:nonNumeric><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-trading</div> day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrantholders (the &#8220;Reference Value&#8221;) equals or exceeds $<ix:nonFraction name="roiv:Stockpricetriggerforredemptionofwarrants" contextRef="PAsOn03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsEighteenPerDollarMemberROIVTriggeringEventAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">18.00</ix:nonFraction> per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like). </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">However, in this case, the Company will not redeem the Roivant Warrants unless an effective registration statement under the Securities Act covering the Roivant Common Shares issuable upon exercise of the Roivant Warrants is effective and a current prospectus relating to those Roivant Common Shares is available throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> redemption period. Any such exercise would not be on a &#8220;cashless&#8221; basis and would require the exercising warrantholder to pay the exercise price for each Roivant Warrant being exercised. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">0<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_50658995_3"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of Roivant Warrants when the price per share of Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div>hares equals or exceeds $10.00. </div></div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may redeem the outstanding Roivant Warrants (except as described herein with respect to the Private Placement Warrants): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at $<ix:nonFraction name="roiv:Classofwarrantsredemptionpriceperunit" contextRef="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsTenDollarMemberROIVTriggeringEventAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.10</ix:nonFraction> per Roivant Warrant upon a minimum of <ix:nonNumeric name="roiv:Classofwarrantsredemptionnoticeperiod" contextRef="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsTenDollarMemberROIVTriggeringEventAxis" format="ixt-sec:durday">30</ix:nonNumeric> days&#8217; prior written notice of redemption provided that holders will be able to exercise their Roivant Warrants on a cashless basis prior to redemption and receive that number of Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares determined by reference to an agreed table based on the redemption date and the &#8220;fair market value&#8221; of the Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares;</div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if, and only if, the Reference Value equals or exceeds $<ix:nonFraction name="roiv:Stockpricetriggerforredemptionofwarrants" contextRef="PAsOn03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsTenDollarMemberROIVTriggeringEventAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per share (as adjusted for stock splits, stock dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like); and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if the Reference Value is less than $<ix:nonFraction name="roiv:Stockpricetriggerforredemptionofwarrants" contextRef="PAsOn03_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsEighteenPerDollarMemberROIVTriggeringEventAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">18.00</ix:nonFraction> per share (as adjusted for stock splits, stock dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like), the Private Placement Warrants must also concurrently be called for redemption on the same terms (except as described herein with respect to a holder&#8217;s ability to cashless exercise its warrants) as the outstanding Public Warrants, as described above. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For these purposes, &#8220;fair market value&#8221; of Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares shall mean the volume-weighted average price of&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares for the</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<ix:nonNumeric name="roiv:PeriodForFairMarketValueDetermination" contextRef="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" format="ixt-sec:durday">10</ix:nonNumeric> trading days immediately following the date on which the notice of redemption is sent to warrantholders. In no event will the Roivant Warrants be exercisable in connection with this redemption feature for more than <ix:nonFraction name="roiv:MaximumRedemptionFeaturePerWarrant" contextRef="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal">0.361</ix:nonFraction> Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Common Shares</div></div> per Roivant Warrant (subject to adjustment). </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true" continuedAt="TextSelection_50658849"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 4&#8212;Investments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investment in Arbutus </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2017, pursuant to a subscription agreement entered into by RSL and Arbutus, RSL acquired <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn10_31_2017_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">16,013,540</ix:nonFraction> shares of common stock of Arbutus and <ix:nonFraction name="roiv:PreferredStockOwnedBalanceSharesOfArbutus" contextRef="PAsOn10_31_2017_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,164,000</ix:nonFraction> Arbutus Preferred Shares, which converted into <ix:nonFraction name="roiv:InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock" contextRef="PAsOn10_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">22,833,922</ix:nonFraction> shares of Arbutus common stock in October 2021. The Company accounts for its investment in Arbutus as an equity method investment accounted for using the fair value option. Due to the Company&#8217;s significant influence over operating and financial policies, Arbutus is considered a related party of the Company. At March&#160;31, 2022, RSL held approximately <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">26</ix:nonFraction>% of issued and outstanding shares of Arbutus. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2022 and 2021, the aggregate fair value of the Company&#8217;s investment in Arbutus was $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">115.8</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">129.4</ix:nonFraction>&#160;million, respectively, with the Company recognizing an unrealized loss on its investment in Arbutus of $<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P04_01_2021To03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">13.6</ix:nonFraction>&#160;million and an unrealized gain of $<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P04_01_2020To03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">90.2</ix:nonFraction>&#160;million in the accompanying consolidated statements of operations for the years ended March&#160;31, 2022 and 2021. The fair value of the Company&#8217;s investment was determined using the closing price of Arbutus&#8217;s common stock on March&#160;31, 2022 and 2021 of $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.98</ix:nonFraction> and $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.33</ix:nonFraction>, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investment in Sio </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2020, RSL&#8217;s ownership interest in Sio fell below 50.0%, and as a result, the Company deconsolidated Sio. The Company accounts for its investment in Sio as an equity method investment accounted for using the fair value option. Due to the Company&#8217;s significant influence over operating and financial policies, Sio is considered a related party of the Company. At March&#160;31, 2022, RSL held approximately <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn03_31_2022_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% of Sio&#8217;s issued and outstanding common shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At March&#160;31, 2022 and 2021, the fair value of the Company&#8217;s investment in Sio was $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2022_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.4</ix:nonFraction>&#160;million<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>and<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>$<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">48.5</ix:nonFraction>&#160;million, respectively, with the Company recognizing an unrealized loss on its investment in Sio of $<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P04_01_2021To03_31_2022_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">36.1</ix:nonFraction>&#160;million and an unrealized gain of $<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P04_01_2020To03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.2</ix:nonFraction>&#160;million in the accompanying consolidated statements of operations for the years ended March&#160;31, 2022 and 2021, respectively. The fair value of common shares held by the Company was determined using the closing price of Sio&#8217;s common stock on March&#160;31, 2022 and 2021 of $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn03_31_2022_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.67</ix:nonFraction> and $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.61</ix:nonFraction>, respectively. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">0<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_50658849"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investment in Datavant </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2020, following an equity raise completed by Datavant Holdings, Inc. (&#8220;Datavant&#8221;) along with a restructuring of Datavant&#8217;s equity classes, it was determined that RSL no longer controlled Datavant. As such, the Company deconsolidated Datavant as of April 2020. Due to the Company&#8217;s significant influence over operating and financial policies, Datavant is considered a related party of the Company. Upon deconsolidation, the Company recorded its investment in Datavant based on the fair value of Datavant preferred shares held of $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn04_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">99.0</ix:nonFraction>&#160;million. Prior to the Datavant Merger (defined below), the Company accounted for its investment in Datavant using the measurement alternative to fair value. Under the measurement alternative, the investment is remeasured upon observable price changes in orderly transactions or upon impairment, if any. The Company recognized a gain on deconsolidation of $<ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="P04_01_2020To03_31_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">86.5</ix:nonFraction>&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. In July 2020, Datavant issued and sold additional preferred shares to RSL at a price consistent with that of the initial round of Datavant&#8217;s Series B equity raise, which resulted in an increase in the carrying value of the Company&#8217;s investment to $<ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn07_31_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.6</ix:nonFraction>&#160;million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, Datavant and Heracles Parent, L.L.C. (referred to herein as &#8220;Ciox Parent&#8221; and, after the closing of the Datavant Merger (as defined below), &#8220;Datavant&#8221;), a provider of healthcare information services and technology solutions to hospitals, health systems, physician practices and authorized recipients of protected health records in the United States, primarily through its wholly owned subsidiary CIOX Health, LLC, entered into a definitive agreement to merge Datavant with and into a newly formed wholly owned subsidiary of Ciox Parent (the &#8220;Datavant Merger&#8221;). The merger closed on July&#160;27, 2021. At closing, the Company received approximately $<ix:nonFraction name="roiv:ProceedsFromSaleOfInvestment" contextRef="P07_27_2021To07_27_2021_DatavantMergerMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">320</ix:nonFraction>&#160;million in cash and a minority equity stake in Ciox Parent. As a result of the transaction, the Company recognized a gain on remeasurement of $<ix:nonFraction name="roiv:GainOnMeasurementOfInvestment" contextRef="P04_01_2021To03_31_2022_DatavantMergerMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">443.8</ix:nonFraction>&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2022. As of March&#160;31, 2022, the Company&#8217;s minority equity interest represented approximately <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn03_31_2022_CombinedCompanyMembersrtOwnershipAxis_DatavantMergerMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">17</ix:nonFraction>% of the outstanding Class&#160;A units in Ciox Parent. Ciox Parent&#8217;s capital structure includes several classes of preferred units that, among other features, have liquidation preferences and conversion features. Upon conversion of such preferred units into Class&#160;A units, the Company&#8217;s ownership interest would be diluted. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the completion of the Datavant Merger, the Company&#8217;s minority equity interest became subject to the equity method of accounting. At such time, the fair value option was elected to continuously remeasure the investment to fair value each reporting period with changes in fair value reflected in earnings. As of March&#160;31, 2022 and July&#160;27, 2021, the fair value of the Company&#8217;s investment was $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2022_DatavantHoldingsIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">193.9</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn07_27_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">224.1</ix:nonFraction>&#160;million, respectively, with the Company recognizing an unrealized loss on its investment of $<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P04_01_2021To03_31_2022_DatavantHoldingsIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">30.2</ix:nonFraction>&#160;million for the year ended March&#160;31, 2022. The fair value of the Company&#8217;s investment was determined using valuation models that incorporate significant unobservable inputs and is classified as a Level&#160;3 measurement within the fair value hierarchy. Refer to Note 14, &#8220;Fair Value Measurements&#8221; for more information. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Investment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company holds an additional equity investment that is measured using the fair value option. The fair value of this investment was $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2022_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.1</ix:nonFraction>&#160;million as of March&#160;31, 2022 and 2021, respectively. </div></div> </ix:continuation> <ix:nonNumeric name="roiv:AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true" continuedAt="TextSelection_50658848"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 5&#8212;Asset Acquisitions and License Agreements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the years ended March&#160;31, 2022 and 2021, the Company, directly or indirectly through Vants, completed the following key asset acquisitions and license agreements. The Company evaluated the below agreements, except the collaboration agreement entered into between Proteovant Therapeutics, Inc. and Blueprint Medicines Corporation (&#8220;Blueprint Medicines&#8221;) that is evaluated separately below, and determined that the acquired assets did not meet the definition of a business as substantially all the fair value of the assets acquired were concentrated in a single asset or group of similar assets and/or the acquired assets were not capable of producing outputs due to the lack of an assembled workforce and early stage of development and thus, each transaction was accounted for as an asset acquisition. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">0<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div> </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_50658848" continuedAt="TextSelectionAppend_50658848_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company then evaluated whether each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development asset had an alternative future use and concluded it did not. As a result, the Company recorded the consideration attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development under the below agreements as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development expense in the accompanying consolidated statements of operations for the years ended March&#160;31, 2022 and 2021. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Genevant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In July 2020, RSL increased its investment in Genevant Sciences Ltd. (&#8220;Genevant&#8221;) as part of a recapitalization transaction (the &#8220;Recapitalization&#8221;). Genevant, an entity focused on the discovery, development, and commercialization of a broad range of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RNA-based</div> therapeutics enabled by Arbutus&#8217; proprietary lipid nanoparticle and ligand conjugate delivery technologies, was created in April 2018 as part of an agreement between RSL and Arbutus. As part of the initial transaction entered into in April 2018, RSL contributed $<ix:nonFraction name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="P04_01_2018To04_30_2018_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">38.7</ix:nonFraction>&#160;million in cash, including transaction costs, for an equity ownership interest in Genevant. Prior to the Recapitalization, RSL accounted for its investment in Genevant under the equity method of accounting as it had determined that it was not the primary beneficiary of Genevant since it did not have the power to direct its most significant activities. Additionally, RSL made additional investments in the form of promissory notes issued by Genevant amounting to $<ix:nonFraction name="us-gaap:NotesReceivableRelatedParties" contextRef="PAsOn06_30_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.1</ix:nonFraction>&#160;million aggregate principal amount outstanding (the &#8220;Genevant Outstanding Notes&#8221;) prior to the Recapitalization. RSL applied its share of losses relating to its equity method investment in Genevant against the Company&#8217;s carrying value of its investment in Genevant&#8217;s common shares and against the carrying value of the Genevant Outstanding Notes. The carrying value of RSL&#8217;s investment in Genevant was reduced to zero prior to the Recapitalization. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Recapitalization, the following transactions were completed: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_31_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">74,272,043</ix:nonFraction> common shares to RSL for an aggregated purchase price of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P07_31_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.5</ix:nonFraction>&#160;million; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="P07_31_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.1</ix:nonFraction>&#160;million aggregate principal amount of the Genevant Outstanding Notes were converted into <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P07_31_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">54,526,549</ix:nonFraction> common shares; and </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_31_2020To07_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">9,057,566</ix:nonFraction> common shares to Arbutus for an aggregated purchase price of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P07_31_2020To07_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.5</ix:nonFraction>&#160;million. </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the Recapitalization, RSL held an <ix:nonFraction name="roiv:PercentageOfControllingInterestHeld" contextRef="PAsOn07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">82.9</ix:nonFraction>% controlling interest in Genevant. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrent with the Recapitalization, the composition of Genevant&#8217;s Board of Directors was restructured to include two directors designated by RSL and one director who is a senior officer of Genevant. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result of the Recapitalization and changes to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws,</div> RSL determined that it controls the most significant activities of Genevant and is the primary beneficiary of Genevant following the Recapitalization. As such, RSL began consolidating Genevant into the Company&#8217;s consolidated financial statements from the date of the Recapitalization. The Company evaluated the acquired set of assets and activities and determined that the acquired set did not meet the definition of a business and thus the transaction was not considered a business combination. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The transactions completed as part of the Recapitalization represent an acquisition achieved in stages, which required the remeasurement of RSL&#8217;s previously held interest in Genevant. As such, RSL&#8217;s investments in Genevant were remeasured to fair value of $<ix:nonFraction name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" contextRef="PAsOn03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.8</ix:nonFraction>&#160;million, also resulting in a gain of $<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P04_01_2020To03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.8</ix:nonFraction>&#160;million that was recognized in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. Along with the fair value of noncontrolling interests in Genevant of $<ix:nonFraction name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.2</ix:nonFraction>&#160;million and cash paid of $<ix:nonFraction name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" contextRef="P04_01_2020To03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.5</ix:nonFraction>&#160;million for common shares of Genevant as part of the Recapitalization, total consideration paid was $<ix:nonFraction name="roiv:BusinessAcquisitionConsiderationTransferred" contextRef="P07_01_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">58.5</ix:nonFraction>&#160;million. Of this amount, $<ix:nonFraction name="roiv:AcquiredInProcessResearchAndDevelopmentExpense" contextRef="P04_01_2020To03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">41.4</ix:nonFraction>&#160;million was attributed to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development, which was determined by the Company to have not reached technological feasibility and therefore have no alternative future use. Accordingly, the Company recorded $<ix:nonFraction name="roiv:AcquiredInProcessResearchAndDevelopmentExpense" contextRef="P04_01_2020To03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">41.4</ix:nonFraction>&#160;million as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development expense in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. </div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">0<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div> </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_50658848_1" continuedAt="TextSelectionAppend_50658848_2"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proteovant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2020, Proteovant Sciences, Inc. (formerly known as Pharmavant 5, Inc.) (together with its wholly owned subsidiaries, &#8220;Proteovant&#8221;) entered into a stock purchase agreement to acquire Oncopia Therapeutics, Inc. (&#8220;Oncopia&#8221;), a preclinical biotechnology company developing small molecule protein degraders primarily against certain oncology targets. Upfront proceeds to Oncopia&#8217;s shareholders were $<ix:nonFraction name="roiv:PaymentForUpfrontPayments" contextRef="PAsOn11_30_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">105.0</ix:nonFraction>&#160;million, prior to certain adjustments in accordance with the terms of the agreement. Proteovant is also obligated to make future development and commercial milestone payments of up to $<ix:nonFraction name="roiv:FutureDevelopmentAndCommercialMilestonePayments" contextRef="P01_01_2021To01_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction>&#160;million for the first product targeting each of the two specified initial targets, and up to $<ix:nonFraction name="roiv:FutureDevelopmentAndCommercialMilestonePayments" contextRef="P11_01_2020To11_30_2020_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">51.0</ix:nonFraction>&#160;million for the first product targeting each of certain specified additional molecular targets. Additionally, the Company&#8217;s investments in promissory notes issued by Oncopia for an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="P11_01_2020To11_30_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.5</ix:nonFraction>&#160;million were settled through either conversion to equity or cancellation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Oncopia&#8217;s intellectual property was developed by the University of Michigan laboratory run by Oncopia&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-founder</div> (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Co-Founder&#8221;).</div> In connection with Proteovant&#8217;s acquisition, Oncopia amended and restated its existing license agreements with the University of Michigan. Under the new license agreement, Oncopia will be obligated to make future development and commercial milestone payments of up to $<ix:nonFraction name="roiv:FutureDevelopmentAndCommercialMilestonePayments" contextRef="P11_01_2020To11_30_2020_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.6</ix:nonFraction>&#160;million for the first product for each molecular target covered by intellectual property included in the agreement, in addition to paying tiered royalties on net sales ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-</div> to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single</div> digits, subject to certain adjustments. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Founder&#8217;s</div> lab at the University of Michigan had been providing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> discovery and optimization services to Oncopia under a sponsored research agreement (the &#8220;SRA&#8221;). Immediately after closing the acquisition, Oncopia extended the SRA through at least December&#160;31, 2023, and expanded the potential molecular targets to be pursued under the SRA. As revised, Oncopia is obligated to pay the University of Michigan approximately $<ix:nonFraction name="roiv:PaymentUnderSponsoredResearchAgreement" contextRef="P11_01_2020To11_30_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.5</ix:nonFraction>&#160;million under the SRA. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Lastly, in connection with the acquisition of Oncopia, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Founder</div> entered into an agreement with the Company to serve as a consultant. In exchange for these services, the Company has agreed to grant the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Founder</div> RSL restricted stock units for which the majority will vest upon achievement of development milestones for products directed to targets for which no milestones are payable to Oncopia shareholders and the remaining portion will be subject to time-based service requirements. These restricted stock units were also subject to a liquidity requirement to vest, which was achieved upon the closing of the Business Combination. The Company will also make a cash payment to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Founder</div> upon achievement of development milestones for each such product. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the year ended March&#160;31, 2021, the Company recorded $<ix:nonFraction name="roiv:AcquiredInProcessResearchAndDevelopmentExpense" contextRef="P04_01_2020To03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">116.5</ix:nonFraction>&#160;million, relating to the net upfront cash payment of $<ix:nonFraction name="roiv:UpfrontCashPayments" contextRef="P04_01_2020To03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">101.2</ix:nonFraction>&#160;million, settlement of promissory notes receivable, including accrued interest, of $<ix:nonFraction name="us-gaap:RepaymentOfNotesReceivableFromRelatedParties" contextRef="P04_01_2020To03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.9</ix:nonFraction>&#160;million, and fair value of future contingent consideration payments of $<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.4</ix:nonFraction>&#160;million, as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development expense in the accompanying consolidated statements of operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2020, RSL, Proteovant and SK, Inc. (formerly known as SK Holdings Co., Ltd.) (&#8220;SK&#8221;) entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) pursuant to which SK agreed to make a $<ix:nonFraction name="us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets" contextRef="PAsOn12_31_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">200.0</ix:nonFraction>&#160;million equity investment in Proteovant, representing an ownership interest of <ix:nonFraction name="us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" contextRef="P12_01_2020To12_31_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">40.0</ix:nonFraction>% on the closing date. In January 2021, in accordance with the terms of the Subscription Agreement, SK made the first payment of $<ix:nonFraction name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" contextRef="PAsOn01_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction>&#160;million to Proteovant. SK made the second payment of $<ix:nonFraction name="roiv:FutureDevelopmentAndCommercialMilestonePayments" contextRef="P11_01_2020To11_30_2020_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction>&#160;million to Proteovant in July 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2022, Proteovant entered into a collaboration agreement with Blueprint Medicines pursuant to which the parties will jointly research and advance up to two novel protein degrader compounds into development candidates, as well as up to two additional novel protein degrader target programs as may be mutually agreed to by the Blueprint Medicines and Proteovant (each a target program). Under the terms of the collaboration agreement, Proteovant received a nonrefundable, upfront payment of $<ix:nonFraction name="roiv:NonRefundableUpfrontPaymentReceived" contextRef="P04_01_2021To03_31_2022_CollaborationAgreementWithBlueprintMedicinesMemberROIVAgreementAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction>&#160;million in March 2022 and will be eligible to receive up to an additional $<ix:nonFraction name="roiv:PotentialMilestonePaymentReceivable" contextRef="P04_01_2021To03_31_2022_CollaborationAgreementWithBlueprintMedicinesMemberROIVAgreementAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">632.0</ix:nonFraction>&#160;million in contingent milestone payments including</div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">0<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div> </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_50658848_2" continuedAt="TextSelectionAppend_50658848_3"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">specified research, development, regulatory and commercialization milestones and tiered percentage royalties on a licensed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-licensed</div></div> product basis ranging from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-</div> to high-single digits on net sales on the first two target programs, subject to adjustment in specified circumstances. If Proteovant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opts-in</div> to the second target program (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Opt-In</div> Right&#8221;), the parties will jointly develop and commercialize such compounds and will split profits and losses of that program equally in the United States along with global development costs. Additionally, development and regulatory milestone payments for the second target or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-in</div> target program will be reduced, and Proteovant will only be eligible to receive commercialization milestone payments and royalties on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ex-United</div> States sales of products relating to such target program. In addition, the parties may jointly extend the collaboration, with the same structure and financial terms, for up to two additional target programs through additional funding by Blueprint Medicines and Proteovant&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Opt-In</div> Right would extend to the second of such additional target programs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Proteovant will be performing research and development activities throughout the period until Blueprint Medicines can exercise its option to obtain a worldwide, exclusive license to develop and commercialize any licensed compound, subject to Proteovant&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Opt-In</div> Right. Proteovant initially recorded the $<ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="PAsOn03_31_2022_CollaborationAgreementWithBlueprintMedicinesMemberROIVAgreementAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction>&#160;million upfront payment as deferred revenue on the accompanying consolidated financial statements and will recognize it as revenue as the services are provided. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Affivant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2020, RSL and its indirect subsidiary Affivant Sciences GmbH (&#8220;Affivant&#8221;) entered into a licensing and strategic collaboration agreement with Affimed N.V. (&#8220;Affimed&#8221;) to develop and commercialize novel innate cell engagers for multiple cancer targets in exchange for consideration that includes $<ix:nonFraction name="roiv:UpfrontCashPayments" contextRef="P11_01_2020To11_30_2020_AffivantSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.0</ix:nonFraction>&#160;million in upfront cash and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-paid</div> R&amp;D funding and $<ix:nonFraction name="roiv:StockIssuedDuringPeriodValue" contextRef="P11_01_2020To11_30_2020_AffivantSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction>&#160;million of newly issued shares in RSL. Affimed could receive further short-term proceeds in the form of option fees contingent on the commencement of additional programs contemplated under the agreement. Affimed is eligible to receive up to an additional approximately $<ix:nonFraction name="roiv:FutureDevelopmentAndCommercialMilestonePayments" contextRef="P11_01_2020To11_30_2020_AffivantSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.0</ix:nonFraction>&#160;billion in milestones over time upon achievement of specified development, regulatory and commercial milestones, as well as tiered royalties on net sales. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquisition of Silicon Therapeutics </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">In March 2021, the Company completed the acquisition of the business of Silicon Therapeutics, LLC (&#8220;Silicon Therapeutics&#8221;), a physics-driven computational drug discovery company, for total consideration of approximately $<ix:nonFraction name="roiv:BusinessAcquisitionConsiderationTransferred" contextRef="P03_01_2021To03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">450.0</ix:nonFraction>&#160;million, with additional cash payments payable subject to the satisfaction of certain regulatory and commercial milestones. This acquisition did not include one of Silicon Therapeutics&#8217; subsidiaries, Silicon SWAT, Inc. Approximately $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" contextRef="P03_01_2021To03_31_2021_FirstTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">350.0</ix:nonFraction>&#160;million of the consideration was payable primarily in the <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ompany&#8217;s </div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px;;display:inline;">stock</div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"> at or near closing of the acquisition (the &#8220;First Tranche&#8221;). At closing of the acquisition, the Company issued <ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="P03_01_2021To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">21,409,764</ix:nonFraction> </div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"> and paid approximately $<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P03_01_2021To03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">14.0</ix:nonFraction>&#160;million in cash, net of cash received, to Silicon Therapeutics after giving effect to certain transaction adjustments and holdbacks. The remainder of the First Tranche was paid in a combination of </div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"> and cash as certain holdbacks were released. In November 2021, the Company transferred the remaining $<ix:nonFraction name="roiv:BusinessAcquisitionConsiderationTransferred" contextRef="P11_01_2021To11_30_2021_SecondTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction>&#160;million (the &#8220;Second Tranche Consideration&#8221;) to Silicon Therapeutics through a $<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="P11_01_2021To11_30_2021_SecondTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">50.0</ix:nonFraction>&#160;million cash payment and the issuance of <ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="P11_01_2021To11_30_2021_SecondTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,348,057</ix:nonFraction> of the Company&#8217;s <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The transaction was accounted for as an asset acquisition as substantially all of the fair value of the assets acquired were concentrated in a single asset, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">in-process</div> research and development related to the computational drug discovery platform that designs and develops small molecule therapeutics. For accounting purposes, the fair value of consideration transferred was $<ix:nonFraction name="roiv:BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="PAsOn03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">402.4</ix:nonFraction>&#160;million, consisting of $<ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" contextRef="PAsOn03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">281.7</ix:nonFraction>&#160;million relating to the fair value of <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares</div> issued upfront and expected to be issued shortly thereafter; $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">105.1</ix:nonFraction>&#160;million relating to the fair value of liabilities due to the sellers, including the Second Tranche Consideration, future contingent consideration payments, and closing consideration to be paid in cash; and cash of $<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.6</ix:nonFraction>&#160;million paid at closing. Of this amount, $<ix:nonFraction name="roiv:AcquiredInProcessResearchAndDevelopmentExpense" contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">399.6</ix:nonFraction>&#160;million was attributed to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">in-process</div> research and development, which was determined to </div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">08</div> </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_50658848_3" continuedAt="TextSelectionAppend_50658848_4"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">have no alternative future use. Accordingly, the Company recorded $<ix:nonFraction name="roiv:AcquiredInProcessResearchAndDevelopmentExpense" contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">399.6</ix:nonFraction>&#160;million as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development expense in the accompanying consolidated statement of operations for the year ended March&#160;31, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the transaction, the vesting of certain outstanding Silicon Therapeutics share-based compensation awards held by employees of Silicon Therapeutics was discretionarily accelerated at closing. As a result, the Company recorded share-based compensation expense of $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">23.5</ix:nonFraction>&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">In addition, certain share-based compensation awards of Silicon Therapeutics were exchanged with restricted </div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px;;display:inline;">stock</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"> of the Company, subject to certain service-based vesting requirements, with a fair value of $<ix:nonFraction name="roiv:FairValueOfCommonShares" contextRef="PAsOn03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">22.6</ix:nonFraction>&#160;million. Of this amount, $<ix:nonFraction name="roiv:FairValueOfRestrictedStock" contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.6</ix:nonFraction>&#160;million was attributed to precombination service and therefore included in the total fair value of consideration transferred. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Priovant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In September 2021, Priovant Therapeutics, Inc. (&#8220;Priovant&#8221;) entered into a license and collaboration agreement with Pfizer, Inc. (&#8220;Pfizer&#8221;) (the &#8220;Pfizer License Agreement&#8221;). The transaction was accounted for as an asset acquisition as the acquired assets did not meet the definition of a business. The fair value of consideration transferred was $<ix:nonFraction name="roiv:AcquiredInProcessResearchAndDevelopmentExpense" contextRef="P09_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">82.1</ix:nonFraction>&#160;million, consisting of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P09_01_2021To09_30_2021_PriovantMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">70.0</ix:nonFraction>&#160;million of preferred stock issued to Pfizer, representing a dilution-protected minority ownership interest in Priovant; a $<ix:nonFraction name="roiv:UpfrontCashPayments" contextRef="P09_01_2021To09_30_2021_PriovantMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction>&#160;million upfront cash payment; and $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" contextRef="P09_01_2021To09_30_2021_PriovantMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.1</ix:nonFraction>&#160;million relating to other obligations. The acquired rights, which included the licensed rights, starting materials and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> inventory for each drug candidate, represent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development assets, which were determined to have no alternative future use. Accordingly, the Company recorded $<ix:nonFraction name="roiv:AcquiredInProcessResearchAndDevelopmentExpense" contextRef="P09_01_2021To09_30_2021_PriovantMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">82.1</ix:nonFraction>&#160;million as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development expense in the accompanying consolidated statements of operations for the year ended March&#160;31, 2022. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Priovant is obligated to pay Pfizer a mid tens-of-millions sales milestone payment if aggregate net sales of its licensed products in Priovant&#8217;s territory in a given year exceed a mid hundreds-of-millions amount. Pfizer is obligated to pay Priovant a low tens-of-millions sales milestone payment if aggregate net sales of its licensed products outside of Priovant&#8217;s territory in a given year exceed a mid hundreds-of-millions amount. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Priovant is obligated to pay Pfizer a tiered, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-teens</div> royalty, on aggregate net sales of its licensed products in Priovant&#8217;s territory. Pfizer is obligated to pay Priovant a tiered high single-digit to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-teens</div> royalty, on aggregate net sales of its licensed products outside of Priovant&#8217;s territory. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Hemavant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2021, Hemavant Sciences GmbH (&#8220;Hemavant&#8221;), a wholly owned subsidiary of the Company, entered into a license agreement with Eisai Co., Ltd. (&#8220;Eisai&#8221;) (the &#8220;Eisai License Agreement&#8221;). Pursuant to the Eisai License Agreement, Eisai granted Hemavant (i)&#160;an exclusive, worldwide, sublicensable, royalty-bearing license under certain patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">know-how</div> and (ii)&#160;a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">non-exclusive,</div> worldwide, sublicensable, royalty-bearing license under certain additional patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">know-how</div> and inventions, in each case, to develop, manufacture and commercialize the compound known as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">RVT-2001</div> and products incorporating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">RVT-2001</div> for all human and animal uses. In exchange for the rights, the Company made an upfront payment to Eisai consisting of $<ix:nonFraction name="roiv:UpfrontCashPayments" contextRef="P11_01_2021To11_30_2021_HemavantSciencesGmbhMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.0</ix:nonFraction>&#160;million in cash and the issuance of $<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" contextRef="P11_01_2021To11_30_2021_HemavantSciencesGmbhMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.0</ix:nonFraction>&#160;million in shares of the Company&#8217;s <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px;;display:inline;">stock</div></div></div> at an agreed price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn11_30_2021_HemavantSciencesGmbhMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">8.00</ix:nonFraction> per share. Hemavant may also be obligated to pay up to a maximum of $<ix:nonFraction name="roiv:MilestonePaymentPayable" contextRef="PAsOn03_31_2022_DevelopmentAndRegulatoryMilestoneMemberusgaapTransactionTypeAxis_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">65.0</ix:nonFraction>&#160;million in development and regulatory milestone payments (with respect the product for the first indication) and up to a maximum of $<ix:nonFraction name="roiv:PayableForEachAdditionalProductIndication" contextRef="PAsOn03_31_2022_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">18.0</ix:nonFraction>&#160;million in payments (with respect to the product for each additional indication) and up to a maximum of $<ix:nonFraction name="roiv:MilestonePaymentPayable" contextRef="PAsOn03_31_2022_CommercialMilestoneMemberusgaapTransactionTypeAxis_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">295.0</ix:nonFraction>&#160;million in commercial milestone payments. Hemavant may also be obligated to pay a tiered high single-digit to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">sub-teens</div> royalty, subject to certain customary reductions, on net sales of licensed products. </div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">09</div> </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_50658848_4"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The transaction was accounted for as an asset acquisition as the acquired assets did not meet the definition of a business. The acquired rights, which include the licensed rights and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">in-process</div> inventory of the drug candidate, represent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">in-process</div> research and development assets that were determined to have no alternative future use. The fair value of the <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="P11_01_2021To11_30_2021_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">874,957</ix:nonFraction> shares of the Company&#8217;s <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px;;display:inline;">stock</div></div></div> issued to Eisai based on the closing price as of the effective date of the Eisai License Agreement was $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P11_01_2021To11_30_2021_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.1</ix:nonFraction>&#160;million. Accordingly, the Company recorded $<ix:nonFraction name="roiv:AcquiredInProcessResearchAndDevelopmentExpense" contextRef="P04_01_2021To03_31_2022_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">14.1</ix:nonFraction>&#160;million as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">in-process</div> research and development expense in the accompanying consolidated statements of operations for the year ended March&#160;31, 2022. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 6&#8212;Accrued Expenses </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses at March&#160;31, 2022 and 2021 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">66,188</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,755</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation-related expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2022_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">44,262</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2021_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,552</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other general and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2022_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,081</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2021_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,629</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">127,531</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">76,936</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:LongTermDebtTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true" continuedAt="TextSelection_50658842"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 7&#8212;Long-Term Debt and Loan Commitment </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Long-Term Debt </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfDebtTableTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt, net consists of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal amount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DebtInstrumentValue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">217,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DebtInstrumentValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">170,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exit fee / end of term charge</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DebtInstrumentExitFeeAndEndOfTermCharge" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DebtInstrumentExitFeeAndEndOfTermCharge" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,390</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: unamortized debt discount and issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,375</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total debt, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">210,025</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">170,280</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total long-term debt, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">210,025</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">170,280</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> </ix:nonNumeric> </div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_50658842" continuedAt="TextSelectionAppend_50658842_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2019, Dermavant entered into a loan and security agreement (the &#8220;Hercules Loan Agreement&#8221;) with Hercules Capital, Inc. (&#8220;Hercules&#8221;), pursuant to which Dermavant borrowed an aggregate of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn05_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction>&#160;million, which </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">bore interest at a variable per annum rate at the greater of (i) <ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" contextRef="PAsOn05_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.95</ix:nonFraction>% or (ii)&#160;the prime rate plus <ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" contextRef="PAsOn05_31_2019_PrimeRateMemberusgaapVariableRateAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.45</ix:nonFraction>%. Dermavant was also obligated to pay an end of term charge of $<ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="PAsOn05_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.4</ix:nonFraction>&#160;million. Following the achievement of certain milestones, the term loan maturity was extended to June&#160;1, 2023 with interest-only monthly payments through December 2021. All amounts outstanding under the Hercules Loan Agreement were repaid in May 2021 using the proceeds from a $<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P05_01_2021To05_01_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.0</ix:nonFraction>&#160;million senior secured credit facility (the &#8220;Credit Facility&#8221;) entered into by Dermavant and certain of its subsidiaries in May 2021 with XYQ Luxco S.A.R.L (&#8220;XYQ Luxco&#8221;), as lender, and U.S. Bank National Association, as collateral agent. The Credit Facility has a <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P05_01_2021To05_01_2021" format="ixt-sec:durwordsen">five-year</ix:nonNumeric> maturity and bears an interest rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn05_01_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">10.0</ix:nonFraction>% per annum. Interest is payable quarterly in arrears on the last day of each calendar quarter through the maturity date. A lump sum principal payment is due on the maturity date. Dermavant is also obligated to pay an exit fee of $<ix:nonFraction name="roiv:DebtInstrumentExitFeeAndEndOfTermCharge" contextRef="PAsOn05_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction>&#160;million. The exit fee can be reduced to $<ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="PAsOn05_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction>&#160;million upon achievement of certain equity milestones defined in the agreement, which are not deemed likely as of March&#160;31, 2022. In connection with the funding of the Credit Facility, Dermavant issued a warrant to XYQ Luxco to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="PAsOn05_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,199,072</ix:nonFraction> common shares of Dermavant at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn05_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction> per common share.</div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21<div style="letter-spacing: 0px; top: 0px;;display:inline;">0</div></div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div><ix:continuation id="TextSelectionAppend_50658842_1"> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with Dermavant&#8217;s acquisition of tapinarof from GlaxoSmithKline Intellectual Property Development Ltd. and Glaxo Group Limited (collectively &#8220;GSK&#8221;) pursuant to an asset purchase agreement (the &#8220;GSK Agreement&#8221;), Dermavant and NovaQuest </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Fund VIII, L.P. (&#8220;NovaQuest&#8221;) entered into a funding agreement (the &#8220;NovaQuest Agreement&#8221;). Pursuant to the NovaQuest Agreement, Dermavant borrowed $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in </div>August 2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">17.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in </div>October 2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> in exchange for an obligation to make certain variable future payments calculated as a function of the achievement of regulatory and commercial milestones or events of termination. The aggregate maximum amount of regulatory milestone payments that Dermavant could be required to make under the NovaQuest Agreement is $</div><ix:nonFraction name="roiv:MaximumMilestonePaymentObligation" contextRef="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">440.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, with $<ix:nonFraction name="roiv:MilestonePaymentDueOverSixYearPeriod" contextRef="PAsOn03_31_2022_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">176.3</ix:nonFraction> million due over a six-year period paid quarterly following the U.S. regulatory approval of VTAMA in May 2022. The maximum aggregate amount of commercial milestone payments is $</div><ix:nonFraction name="roiv:MaximumMilestonePaymentObligation" contextRef="PAsOn08_31_2018_CommercialMilestoneMemberusgaapTransactionTypeAxis_NovaquestMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">141.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. In some circumstances, Dermavant may be able to offset certain of the regulatory milestone payments with up to $</div><ix:nonFraction name="roiv:MaximumMilestonePaymentOffsetAmount" contextRef="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">88.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of the commercial milestone payments. At issuance, the Company concluded that certain features of the long-term debt would be considered derivatives that would require bifurcation. In lieu of bifurcating various features in the agreement, the Company has elected the fair value option for this financial instrument and will record the changes in the fair value within the statements of operations at the end of each reporting period. Direct costs and fees related to the debt issued under the NovaQuest Agreement were recognized in earnings. As of March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the fair value of the debt was $</div><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2022_NovaquestMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">177.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2021_NovaquestMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">150.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively. Refer to Note </div>14<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, &#8220;Fair Value Measurements&#8221; for additional details regarding the fair value measurement.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Debt Maturities </div></div></div> <ix:nonNumeric name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Annual maturities, including the exit fee, of debt outstanding as of&#160;March&#160;31, 2022&#160;are as follows (in thousands). Long term debt issued by Dermavant for which the fair value option has been elected is excluded from the below as the repayment terms are variable. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ending March&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">45,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:LongTermDebtExcludingDebtWithFairValueOption" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">45,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Loan Commitment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In May 2021, Dermavant, as seller, entered into a $<ix:nonFraction name="roiv:CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" contextRef="P05_01_2021To05_31_2021_RevenueInterestPurchaseAndSaleAgreementMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">160.0</ix:nonFraction>&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million revenue interest purchase and sale agreement (the &#8220;RIPSA&#8221;) for its investigational product tapinarof with XYQ Luxco, NovaQuest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Fund XVII, L.P., an affiliate of NovaQuest Capital Management, LLC, and MAM Tapir Lender, LLC, an affiliate of Marathon Asset Management, L.P. (collectively, the &#8220;Purchasers&#8221;), together with U.S. Bank National Association, as collateral agent. Under the terms of the RIPSA, the Purchasers procured a capped single-digit revenue interest in net sales of tapinarof for all dermatological indications in the United States, up to a cap of $<ix:nonFraction name="roiv:CommittedFundingUnderRIPSA" contextRef="PAsOn05_31_2021_RevenueInterestPurchaseAndSaleAgreementMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">344.0</ix:nonFraction>&#160;million, in exchange for </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="roiv:CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" contextRef="P05_01_2021To05_31_2021_RevenueInterestPurchaseAndSaleAgreementMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">160.0</ix:nonFraction>&#160;million in committed funding to be paid to Dermavant, conditional based on the approval of tapinarof by the FDA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VTAMA (tapinarof) cream was approved by the FDA in May 2022. Refer to Note 17, &#8220;Subsequent Events&#8221; for more information.</div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 8&#8212;Related Party Transactions</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sumitomo Dainippon Pharma Co., Ltd. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In May 2021, the Company entered into an Asset Purchase Agreement with Sumitomo Dainippon Pharma Co., Ltd. (&#8220;Sumitomo&#8221;) and its subsidiary Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (&#8220;SPC&#8221;) (the &#8220;Asset Purchase Agreement&#8221;). The transactions contemplated by the Asset Purchase Agreement closed in June 2021. Pursuant to the Asset Purchase Agreement: (i)&#160;Sumitomo terminated all of its existing options to acquire the Company&#8217;s equity interests in certain of its subsidiaries (the &#8220;Sumitomo Options&#8221;); (ii) the Company transferred and assigned to SPC all of its intellectual property, development and commercialization rights for (a)&#160;lefamulin in Mainland China, Taiwan, Hong Kong, and Macau (collectively &#8220;Greater China&#8221;), (b) vibegron in Mainland China, (c)&#160;rodatristat ethyl in Greater China and South Korea and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(d)&#160;RVT-802</div> in Greater China and South Korea; (iii)&#160;Sumitomo agreed to pay the Company $<ix:nonFraction name="roiv:AssetPurchaseTransactionConsiderationReceivedInCash" contextRef="PAsOn05_31_2021_AssetPurchaseAgreementMemberROIVAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction>&#160;million in cash; and (iv)&#160;Sumitomo entered into an agreement with the Company to pursue future collaborations with Genevant. The Company received the cash payment, net of certain withholding taxes, in August 2021. The Company recorded a gain on the termination of the Sumitomo Options of $<ix:nonFraction name="roiv:EquityInterestOptionToThirdPartyPurchaserGainOnTermination" contextRef="P04_01_2021To03_31_2022_AssetPurchaseAgreementMemberROIVAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">66.5</ix:nonFraction>&#160;million, consisting of the fair value of the Sumitomo Options on the date of termination and the cash payment, in the accompanying consolidated statements of operations for the year ended March&#160;31, 2022. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transition Services Agreement and Strategic Cooperation Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">In December 2019, RSL and Sumitomo completed the transactions contemplated by the transaction agreement by and between RSL and Sumitomo, dated as of October 31, 2019 (the &#8220;Sumitomo Transaction Agreement&#8221;). Concurrent with entry into the Sumitomo Transaction Agreement, RSL and Sumitomo entered into the following agreements: (i)&#160;a transition services agreement (the &#8220;TSA&#8221;), pursuant to which the parties agreed to provide certain transitional services to one another at cost for a specified period of time following the closing date and (ii)&#160;a strategic cooperation agreement (the &#8220;SCA&#8221;), providing for certain technology-related collaborations. Pursuant to the terms of the TSA and the SCA, RSL billed Sumitomo </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="roiv:AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" contextRef="P04_01_2021To03_31_2022_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">million and</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $<ix:nonFraction name="roiv:AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" contextRef="P04_01_2020To03_31_2021_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.4</ix:nonFraction>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">million, net of amounts billed by Sumitomo to RSL, during the years ended March&#160;31, 2022 and 2021, respectively. Additionally, during each of the years ended March&#160;31, 2022 and 2021, the Company paid Sumitomo a </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="roiv:AccessFeePaidToRelatedParty" contextRef="P04_01_2021To03_31_2022_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="roiv:AccessFeePaidToRelatedParty" contextRef="P04_01_2020To03_31_2021_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction></ix:nonFraction>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million DrugOme access fee pursuant to the SCA. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;1, 2022, RSL and Sumitomo amended the SCA. In connection with the amendment, RSL agreed to pay Sumitomo an aggregate of </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="roiv:AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary" contextRef="P03_01_2022To03_01_2022_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.5</ix:nonFraction>&#160;million. This consideration was expensed during the year ended March&#160;31, 2022. </div></div></ix:nonNumeric> </div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true" continuedAt="TextSelection_50658878"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 9&#8212;Shareholders&#8217; Equity </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) RSL Common <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Stock</div> </div></div></div></div> <div style="letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;30, 2021 in connection with the closing of the Business Combination, the Company effected a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="roiv:StockHoldersEquityNoteStockSplitExchangeRatio1" contextRef="PAsOn03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">2.9262</ix:nonFraction>-for-1</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> stock subdivision based on the fixed exchange ratio established in the Business Combination. All per share amounts and number of shares in the consolidated financial statements and related notes have been retroactively restated to reflect the stock split.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, in connection with the closing of the Business Combination, the Company adjusted its authorized share capital to equal <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">7,000,000,000</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">c</div></div></div></div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">s</div></div></div></div>hares, par value $<span style="-sec-ix-hidden:hidden50658913">0.00000003</span>41740141 per share. Each <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">c</div></div></div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div>hare has the right to <ix:nonNumeric name="us-gaap:CommonStockVotingRights" contextRef="P04_01_2021To03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">one vote</ix:nonNumeric>. The holders of <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">s</div></div>hares are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared by the board of directors since the Company&#8217;s inception.</div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-indent: 0px;;font-weight: bold;"></div> <ix:continuation id="TextSelection_50658878"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Committed Equity Facility</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;14, 2022, the Company entered into a committed equity facility (the &#8220;Facility&#8221;) with an affiliate of Cantor Fitzgerald&#160;&amp; Co. (&#8220;Cantor&#8221;). Under the terms of the Facility, Cantor has committed to purchase up to an aggregate of $<ix:nonFraction name="us-gaap:PurchaseObligation" contextRef="PAsOn02_14_2022_CantorFitzgeraldCo.MemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">250.0</ix:nonFraction>&#160;million in the Company&#8217;s </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div>hares<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from time to time at the request of the Company, subject to certain limitations and the satisfaction of certain conditions. Any sales of the <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div></div>ompany&#8217;s </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div>hares<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to Cantor under the Facility will be made at <ix:nonFraction name="roiv:PercentageOfCommonSharesVolumeWeightedAveragePrice" contextRef="P02_14_2022To02_14_2022_CantorFitzgeraldCo.MemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">99</ix:nonFraction>% of the volume-weighted average price of the Company&#8217;s </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div>hares<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> on Nasdaq on a given trading day. In consideration for entry into the Facility, the <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ompany paid Cantor an upfront commitment fee in the form of <ix:nonFraction name="roiv:UpfrontCommitmentFeeNumberOfSharesIssued" contextRef="P02_14_2022To02_14_2022_CantorFitzgeraldCo.MemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">145,986</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div>hares<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. As of March&#160;31, 2022, $<ix:nonFraction name="roiv:CommonSharesValueAvailableForSale" contextRef="PAsOn03_31_2022_CantorFitzgeraldCo.MemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">250.0</ix:nonFraction>&#160;million of the Company&#8217;s </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div>hares<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> remained available for sale under the Facility. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Consolidated Vant Equity Transactions </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Immunovant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2020 and September 2020, Immunovant, Inc. achieved the first and second earnout milestones as defined in the share exchange agreement with Health Sciences Acquisitions Corporation. As a result, all of the <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_30_2020_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction> earnout shares of Immunovant, Inc.&#8217;s common stock were issued, including <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2021_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2021_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">17,547,938</ix:nonFraction></ix:nonFraction> shares of common stock issued to RSL. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2020, Immunovant, Inc. completed an underwritten public offering of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">9,613,365</ix:nonFraction> shares of its common stock, including <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,034,483</ix:nonFraction> shares of common stock purchased by RSL, at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">14.50</ix:nonFraction> per share for net proceeds to Immunovant, Inc. of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">131.0</ix:nonFraction>&#160;million, after deducting underwriting discounts and commissions and offering expenses. The proceeds included $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction>&#160;million received from RSL. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2020, Immunovant, Inc.&#8217;s <ix:nonFraction name="roiv:ClassOfWarrantOrRightExercisable" contextRef="PAsOn05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction> outstanding warrants became exercisable for an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction> shares of Immunovant, Inc.&#8217;s common stock at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> per share. An aggregate of <ix:nonFraction name="roiv:ClassOfWarrantOrRightExercisable" contextRef="PAsOn03_31_2022_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">11,438,290</ix:nonFraction> outstanding warrants were exercised for an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2022_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,719,145</ix:nonFraction> shares of Immunovant, Inc.&#8217;s common stock at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> per share, for net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P05_01_2020To05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">65.8</ix:nonFraction>&#160;million. The remaining <ix:nonFraction name="roiv:ClassOfWarrantOrRightCanceled" contextRef="P05_01_2020To05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">61,710</ix:nonFraction> warrants were cancelled. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2020, Immunovant, Inc. completed an underwritten public offering of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P09_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,060,606</ix:nonFraction> shares of its common stock, including <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P09_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">380,000</ix:nonFraction> shares of common stock purchased by RSL, at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">33.00</ix:nonFraction> per share for net proceeds to Immunovant, Inc. of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P09_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">188.1</ix:nonFraction>&#160;million, after deducting underwriting discounts and commissions and offering expenses. The proceeds included $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P09_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.5</ix:nonFraction>&#160;million received from RSL. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proteovant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2021, Proteovant collected the subscription receivable relating to the second $<ix:nonFraction name="roiv:SubscriptionReceived" contextRef="PAsOn07_01_2021_SkMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction>&#160;million payment due under a subscription agreement entered into with SK, Inc. (&#8220;SK&#8221;) in December 2020 pursuant to which SK agreed to make a $<ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="PAsOn12_31_2020_SkMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">200.0</ix:nonFraction>&#160;million equity investment in Proteovant, representing an ownership interest of <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn12_31_2020_SkMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">40.0</ix:nonFraction>% on the closing date. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true" continuedAt="TextSelection_50658834"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 10&#8212;Share-Based Compensation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Share-Based Compensation Expense </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense was as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense recognized as:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2021To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">63,735</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,637</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2021To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">501,221</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,321</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">564,956</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">84,958</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> <ix:continuation id="TextSelection_50658834" continuedAt="TextSelectionAppend_50658834_1"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The achievement of the liquidity event vesting condition for certain equity instruments upon the closing of the Business Combination resulted in the recognition of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> expense of $<ix:nonFraction name="roiv:OneTimeCatchUpExpense" contextRef="P09_01_2021To09_30_2021_AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMemberROIVEventAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">372.9</ix:nonFraction>&#160;million in September 2021 relating to cumulative service rendered between the grant date of the respective awards and completion of the Business Combination. This <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> expense is reflected in the accompanying consolidated statements of operations for the year ended March&#160;31, 2022. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) RSL Equity Incentive Plans </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">RSL has three equity incentives plans: the Roivant Sciences Ltd. 2021 Equity Incentive Plan (the &#8220;RSL 2021 EIP&#8221;), the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan (the &#8220;RSL 2015 EIP&#8221;), and the Roivant Sciences Ltd. Amended and Restated 2015 Restricted Stock Unit Plan (the &#8220;2015R Plan&#8221;) (collectively, the &#8220;RSL Equity Plans&#8221;). The RSL 2021 EIP was approved and adopted in connection with the Business Combination and became effective immediately prior to closing. Since the effective date of the RSL 2021 EIP, no further stock awards have been or will be made under the RSL 2015 EIP. Additionally, no further stock awards will be made under the 2015R Plan. As of March&#160;31, 2022,</div></div>&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn03_31_2022_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">69,300,000</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">of the Company&#8217;s <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares were reserved for issuance under the RSL 2021 EIP. The number of <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares reserved for issuance under the RSL 2021 EIP will automatically increase on April&#160;1 of each year by an amount equal to the lesser of (i)</div></div>&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="P04_01_2021To03_31_2022_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">of the <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares outstanding as of the last day of the immediately preceding fiscal year and (ii)&#160;such number of <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares as determined by our board of directors in its discretion. The RSL 2021 EIP has a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ten-year</div> term. The Company&#8217;s employees, directors, and consultants are eligible to receive incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock awards under the RSL 2021 EIP. At March&#160;31, 2022, a total of</div>&#160;<ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn03_31_2022_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">59,373,756</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div>ommon <div style="display:inline;">s</div>hares were available for future grants under the RSL 2021 EIP. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">All RSL <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares issuable on exercise of vested options or settlement of other equity instruments that were issued and outstanding as of the closing of the Business Combination were subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period expired on March&#160;30, 2022. </div></div> </ix:continuation></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_50658834_1" continuedAt="TextSelectionAppend_50658834_2"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options and Performance Stock Options </div></div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Activity for stock options and performance stock options under the RSL Equity Plans for the year ended March&#160;31, 2022 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual&#160;Life<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic&#160;Value<br/> (in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options outstanding at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn03_31_2021_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">69,687,308</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn03_31_2021_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P04_01_2020To03_31_2021_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">5.89</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P04_01_2021To03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">12,181,127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P04_01_2021To03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.76</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P04_01_2021To03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">101,436</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P04_01_2021To03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">4.06</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Canceled</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P04_01_2021To03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,402,095</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P04_01_2021To03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.86</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options outstanding at March&#160;31, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">80,364,904</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.37</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P04_01_2021To03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">5.50</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,899</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options exercisable at March&#160;31, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">39,236,351</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P04_01_2021To03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">4.70</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,456</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate intrinsic value is calculated as the difference between the exercise price of all outstanding and exercisable options and the fair value of the Company&#8217;s <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">stock</div></div> at March&#160;31, 2022. At March&#160;31, 2022, total unrecognized compensation expense related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> stock options and performance stock options was approximately </div>$<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn03_31_2022_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">149.7</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">million and is expected to be recognized over a weighted-average period of approximately</div></div></div>&#160;<ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P04_01_2021To03_31_2022_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">2.63</ix:nonNumeric> years.<br/></div> </ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div> </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_50658834_2" continuedAt="TextSelectionAppend_50658834_3"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2022 and 2021, there were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn03_31_2022_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">39,236,351</ix:nonFraction> and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn03_31_2021_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">16,193,146</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">vested stock options and performance stock options, respectively. Vesting for performance stock options was subject to a liquidity event vesting requirement in addition to time-based service requirements. The liquidity event vesting requirement was met upon closing of the Business Combination on September 30, 2021. </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company estimated the fair value of each stock option on the date of grant using the Black-Scholes closed form option-pricing model applying the weighted average assumptions in the following table. No performance stock options were granted during the years ended March&#160;31, 2022 and 2021. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assumptions</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock price volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P04_01_2021To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">81.70</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">74.84</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected risk free interest rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P04_01_2021To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.43</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term, in years</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P04_01_2021To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">6.25</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">6.25</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P04_01_2021To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="roiv:ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional information regarding stock options and performance stock options is set forth below (in thousands, except per share data). </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intrinsic value of options exercised</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IntrinsicValueOfOptionsExercised" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IntrinsicValueOfOptionsExercised" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Grant date fair value of options vested</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">210,487</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,711</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average grant date fair value per share of stock options granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">6.85</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">8.67</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units and Performance Stock Units </div></div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Activity for restricted stock units and performance stock units under the RSL Equity Plans for the year ended March&#160;31, 2022 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;Restricted<br/> Stock Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/> Grant Date Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2021_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">7,294,028</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2021_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.86</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P04_01_2021To03_31_2022_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">20,948,227</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P04_01_2021To03_31_2022_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.44</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P04_01_2021To03_31_2022_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,111,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P04_01_2021To03_31_2022_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.60</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P04_01_2021To03_31_2022_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,173,956</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P04_01_2021To03_31_2022_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.79</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2022</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2022_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">21,956,749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2022_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total fair value of restricted stock units and performance stock units vested during the year ended March&#160;31, 2022 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P04_01_2021To03_31_2022_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">59.3</ix:nonFraction>&#160;million. Vesting for both restricted stock units and performance stocks units was subject to a liquidity event vesting requirement. There were <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P04_01_2020To03_31_2021_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> vested restricted stock units or performance stock units at March&#160;31, 2021 as the liquidity event vesting requirement was not met until the closing of the Business Combination on September&#160;30, 2021. Restricted stock units vest upon the achievement of time-based service requirements. The vesting of performance stock units requires that certain performance conditions are achieved during the performance period and is subject to continued service requirements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At March&#160;31, 2022, total unrecognized compensation expense related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> restricted stock units and performance stock units was approximately $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn03_31_2022_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">155.8</ix:nonFraction>&#160;million. Unrecognized compensation expense relating to restricted stock units and performance stock units that are deemed probable of vesting is expected to be recognized over a weighted-average period of approximately <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P04_01_2021To03_31_2022_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">2.97</ix:nonNumeric> years.</div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div> </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_50658834_3" continuedAt="TextSelectionAppend_50658834_4"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Capped Value Appreciation Rights </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">March 2020 CVAR Grants </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2020, the Company granted capped value appreciation rights (&#8220;CVARs&#8221;) that will pay at settlement the excess in shares of (a)&#160;the lesser of (i)&#160;the fair market value of a <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;"><div style="display:inline;">c</div></div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;"><div style="display:inline;">s</div></div></div>hare as of the settlement date or (ii)&#160;the cap of $12.68, over (b)&#160;the hurdle price of either $6.40 or $11.50, as applicable to each grant. On March&#160;30, 2022, the Company amended the outstanding CVARs that were granted in March 2020. Pursuant to the amendment, in the event any CVARs have satisfied the time-based service and liquidity event vesting requirements (&#8220;service-vested CVARs&#8221;) but have not satisfied the applicable hurdle price on an applicable measurement date, then such CVARs will be deemed to remain outstanding and the applicable award holder will be provided the right to earn such CVARs if the hurdle price is satisfied on subsequent annual &#8220;hurdle measurement dates&#8221; prior to the original expiration date of the CVARs, being March&#160;31, 2026. The &#8220;hurdle measurement dates&#8221; are March&#160;30 of each of years 2023 through 2026. If the hurdle price is not satisfied on any such subsequent annual hurdle measurement date prior to the expiration date of the CVARs, then the CVARs will be forfeited in their entirety on the expiration date. This amendment was accounted for as a modification and resulted in an aggregate of approximately $<ix:nonFraction name="roiv:IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment" contextRef="P04_01_2021To03_31_2022_March2020CappedValueAppreciationRightsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.9</ix:nonFraction>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million of incremental fair value. Incremental fair value associated with CVARs that do not require further service for vesting was recognized in full on March&#160;30, 2022. The Company will recognize the incremental fair value for CVARs that require future service for vesting over the remaining requisite service </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">period.</div></div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> </ix:continuation></div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_50658834_4" continuedAt="TextSelectionAppend_50658834_5"> <ix:nonNumeric name="roiv:ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock" contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" escape="true"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Activity</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">for CVARs under the RSL 2015 EIP for the year ended March&#160;31, 2022 is as follows:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;CVARs</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-service-vested</div> CVARs balance at March&#160;31, 2021</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">32,447,626</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.72</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service-vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">18,213,910</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">435,630</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-service-vested</div> CVARs balance at March&#160;31, 2022</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">13,798,086</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">At March&#160;31, 2022, there were 18,213,910 service-vested CVARs. The hurdle price was not satisfied for these service-vested CVARs and as such they remain outstanding. The total fair value of CVARs that service-vested during the year ended March&#160;31, 2022 was</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">22.3</ix:nonFraction>&#160;million. There were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> service-vested CVARs at March&#160;31, 2021 as the liquidity event vesting requirement was not met until the closing of the Business Combination on September&#160;30, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At March&#160;31, 2022, total unrecognized compensation expense related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-service-vested</div> CVARs was approximately $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.1</ix:nonFraction>&#160;million and is expected to be recognized over a weighted-average period of approximately <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">1.74</ix:nonNumeric> years. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">November 2021 CVAR Grants </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2021, the Company made <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> grants of <ix:nonFraction name="roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares" contextRef="P11_01_2021To11_30_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,317,350</ix:nonFraction> CVARs in the aggregate under the RSL 2021 EIP to eligible participants. The CVARs are eligible to vest based on the satisfaction of service-based and performance-based vesting requirements. The performance-based vesting requirement was achieved in December 2021. Vested CVARs will be settled in <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">c</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div>hares, up to a specified cap price.</div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div><ix:continuation id="TextSelectionAppend_50658834_5"> <ix:nonNumeric name="roiv:ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock" contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis" escape="true"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Activity for CVARs under the RSL 2021 EIP for the year ended March&#160;31, 2022 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"></td>
<td style="width: 14%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 14%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;CVARs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,317,350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">4.95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">32,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">4.71</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2022</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,285,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">4.95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td></tr></table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At March&#160;31, 2022, total unrecognized compensation expense related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> CVARs was approximately $19.3&#160;million and is expected to be recognized over a weighted-average period of approximately 3.13 years. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Employee Stock Purchase Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">In September 2021, the Company adopted the Roivant Sciences Ltd. Employee Stock Purchase Plan (the &#8220;RSL ESPP&#8221;), which provides for the granting of an option to purchase <div style="display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares of RSL to eligible employees, as defined by the RSL ESPP. As of March&#160;31, 2022, the maximum number of <div style="display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares reserved and available for purchase under the RSL ESPP was</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn03_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">13,900,000</ix:nonFraction>. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">The total number of <div style="display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares available for purchase under the RSL ESPP will be increased annually on April&#160;1 of each year during the term of the plan in an amount equal to the least of (i)</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> <ix:nonFraction name="roiv:IncrementOfEmployeeStockPurchasePlan" contextRef="PAsOn03_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">13,900,000</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"><div style="display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares, (ii)</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden50659171">one</span> </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">percent of the aggregate number of <div style="display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares outstanding (on a fully diluted basis) on the last day of the immediately preceding Company fiscal year and (iii)&#160;such lesser number of <div style="display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares as determined by the board of directors; provided that the maximum number of <div style="display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares that may be issued under the RSL ESPP during the term of the plan is</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<ix:nonFraction name="roiv:EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable" contextRef="P04_01_2021To03_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">147,447,650</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares.</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 8pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(D) Subsidiary Equity Incentive Plans</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Certain wholly owned and majority-owned or controlled subsidiaries of RSL adopt their own equity incentive plan (&#8220;EIP&#8221;). Each EIP is generally structured so that the applicable subsidiary, and its affiliates&#8217; employees, directors, officers and consultants are eligible to receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> and incentive stock options, stock appreciation rights, restricted share awards, restricted stock unit awards, and other share awards under their respective EIP. The Company recorded share-based compensation expense of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2021To03_31_2022_SubsidiaryEquityIncentivePlansMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">47.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To03_31_2021_SubsidiaryEquityIncentivePlansMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">29.1</ix:nonFraction>&#160;million for the years ended March&#160;31, 2022 and 2021, respectively, related to subsidiary EIPs. At March&#160;31, 2022, total unrecognized compensation expense related to subsidiary EIPs was approximately $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn03_31_2022_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">134.5</ix:nonFraction>&#160;million. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true" continuedAt="TextSelection_50658863"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 11&#8212;Income Taxes </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true" continuedAt="TextSelection_50658856"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The loss before income taxes and the related expense/(benefit) are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bermuda<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2021To03_31_2022_BMsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658687">390,831</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2020To03_31_2021_BMsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658688">227,471</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2021To03_31_2022_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">747,953</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2020To03_31_2021_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">212,921</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Switzerland</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2021To03_31_2022_CHsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">544,870</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2020To03_31_2021_CHsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">424,494</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2021To03_31_2022_OtherMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658692">21,755</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2020To03_31_2021_OtherMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658691">33,661</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total loss before income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">923,747</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">898,547</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily entities which are centrally managed and controlled in the United Kingdom </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily Greater China and United Kingdom activity </div></div></td></tr></table> </ix:nonNumeric> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">17</div></div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div><ix:continuation id="TextSelection_50658863" continuedAt="TextSelectionAppend_50658863_1"> <ix:continuation id="TextSelection_50658856">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current taxes:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bermuda</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P04_01_2021To03_31_2022_BMsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021_BMsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P04_01_2021To03_31_2022_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">223</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,365</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Switzerland</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P04_01_2021To03_31_2022_CHsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021_CHsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P04_01_2021To03_31_2022_OtherMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658338">592</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021_OtherMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_50658337">321</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">369</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred taxes:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bermuda</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P04_01_2021To03_31_2022_BMsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021_BMsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P04_01_2021To03_31_2022_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Switzerland</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P04_01_2021To03_31_2022_CHsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021_CHsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P04_01_2021To03_31_2022_OtherMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021_OtherMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total income tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">369</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:continuation> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="clear: both; max-height: 0pt; text-indent: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelectionAppend_50658863_1" continuedAt="TextSelectionAppend_50658863_2">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily Greater China and United Kingdom activity </div></div></div></td></tr></table><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of income tax provision/(benefit) computed at the Bermuda statutory rate to income tax expense reflected in the consolidated financial statements is as follows (in thousands, except percentages): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit at Bermuda statutory rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign rate differential<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658400">179,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_50658382">19.38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_50658399">150,778</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_50658381">16.78</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Permanent disallowed IPR&amp;D</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,347</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">1.66</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">111,432</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">12.40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Tax-effect</div> of changes in the fair value of investments and loss from equity method investment</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15,169</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">1.64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,472</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nontaxable gain on sale of investment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationDispositionOfAssets" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">84,313</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationDispositionOfAssets" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nontaxable gain on deconsolidation of business</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">958</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">0.10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">16,438</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">1.83</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nondeductible executive compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">2.81</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">905</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">0.10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Tax deficiencies (excess tax benefits) from share-based compensation</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,918</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">1.40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">439</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.05</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other permanent adjustments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationDeductionsOther" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,912</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">1.18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationDeductionsOther" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,457</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">0.28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research tax credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">1.09</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,555</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">1.17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">205,811</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">22.28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,046</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.46</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax rate changes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,444</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,443</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">0.27</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8,933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">0.97</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total income tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">369</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">0.04</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">0.19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily related to operations in the United States, Switzerland, the United Kingdom, and other jurisdictions with statutory tax rates different than the Bermuda rate. </div></div></div></td></tr></table></ix:nonNumeric> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s effective tax rates for the years ended March&#160;31, 2022 and 2021 was (<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">0.04</ix:nonFraction>)% and (<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">0.19</ix:nonFraction>)%, respectively, driven by the Company&#8217;s jurisdictional earnings by location and a valuation allowance that eliminates the Company&#8217;s global net deferred tax assets.</div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div><ix:continuation id="TextSelectionAppend_50658863_2" continuedAt="TextSelectionAppend_50658863_3"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred taxes reflect the tax effects of the differences between the amounts recorded as assets and liabilities for financial reporting purposes and the comparable amounts recorded for income tax purposes. </div><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true" continuedAt="TextSelection_50658860">Significant components of the deferred tax assets (liabilities) at March&#160;31, 2022 and 2021 are as follows (in thousands):</ix:nonNumeric>&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;</div><ix:continuation id="TextSelection_50658860"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research tax credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,155</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,063</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,544</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,564</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">312,749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">202,906</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">93,177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,623</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DeferredTaxAssetsLeaseLiabilities" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,406</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DeferredTaxAssetsLeaseLiabilities" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,638</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,651</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,303</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subtotal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">530,682</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">323,097</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">512,736</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">303,287</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DeferredTaxLiabilitiesDepreciation" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,397</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DeferredTaxLiabilitiesDepreciation" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,214</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DeferredTaxLiabilitiesRightOfUseAssets" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,661</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DeferredTaxLiabilitiesRightOfUseAssets" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,908</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,888</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,688</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets/(liabilities)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has Federal net operating losses in Switzerland, the <div style="letter-spacing: 0px; top: 0px;;display:inline;">United </div>States, the United Kingdom and other jurisdictions in the amount of $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn03_31_2022_CHsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1,749.2</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn03_31_2022_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">244.1</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn03_31_2022_GBsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.1</ix:nonFraction>&#160;million, and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn03_31_2022_TaxAuthorityInOtherJurisdictionsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">98.4</ix:nonFraction>&#160;million, respectively. The Switzerland net operating losses will expire in varying amounts between <ix:nonNumeric name="us-gaap:OperatingLossCarryforwardsExpirationDate" contextRef="P04_01_2021To03_31_2022_CHsrtStatementGeographicalAxis_MinimumMembersrtRangeAxis" format="ixt:date-monthname-day-year-en">March 31, 2025</ix:nonNumeric> and <ix:nonNumeric name="us-gaap:OperatingLossCarryforwardsExpirationDate" contextRef="P04_01_2021To03_31_2022_CHsrtStatementGeographicalAxis_MaximumMembersrtRangeAxis" format="ixt:date-monthname-day-year-en">March 31, 2029</ix:nonNumeric>. The United States net operating losses can be carried forward indefinitely with utilization limited to <ix:nonFraction name="roiv:AnnualNOLUtilizationLimitationPercentage" contextRef="P04_01_2021To03_31_2022_USsrtStatementGeographicalAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">80</ix:nonFraction>% of future taxable income for tax years beginning on or after January&#160;1, 2021, while the United Kingdom and other net operating losses can be carried forward indefinitely as well, with an annual limitation on utilization. The Company has generated net operating losses from United States state and local jurisdictions in the amount of $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn03_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">94.8</ix:nonFraction>&#160;million which will expire in varying amounts between <ix:nonNumeric name="us-gaap:OperatingLossCarryforwardsExpirationDate" contextRef="P04_01_2021To03_31_2022_MinimumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" format="ixt:date-monthname-day-year-en">March 31, 2035</ix:nonNumeric> and <ix:nonNumeric name="us-gaap:OperatingLossCarryforwardsExpirationDate" contextRef="P04_01_2021To03_31_2022_MaximumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" format="ixt:date-monthname-day-year-en">March 31, 2042</ix:nonNumeric>. The Company has generated $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn03_31_2022_UnitedStatesAndCanadaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">27.2</ix:nonFraction>&#160;million of research tax credit carryforwards primarily in the United States and Canada, which will expire in varying amounts between <ix:nonNumeric name="us-gaap:TaxCreditCarryforwardExpirationDate" contextRef="P04_01_2021To03_31_2022_MinimumMembersrtRangeAxis_UnitedStatesAndCanadaMembersrtStatementGeographicalAxis" format="ixt:date-monthname-day-year-en">March 31, 2035</ix:nonNumeric> and <ix:nonNumeric name="us-gaap:TaxCreditCarryforwardExpirationDate" contextRef="P04_01_2021To03_31_2022_MaximumMembersrtRangeAxis_UnitedStatesAndCanadaMembersrtStatementGeographicalAxis" format="ixt:date-monthname-day-year-en">March 31, 2042</ix:nonNumeric>. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company assesses the realizability of the deferred tax assets at each balance sheet date based on available positive and negative evidence in order to determine the amount which is more likely than not to be realized and record a valuation allowance as necessary. Due to the Company&#8217;s cumulative loss position which provides significant negative evidence difficult to overcome, the Company has recorded a valuation allowance of $<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">512.7</ix:nonFraction>&#160;million as of March&#160;31, 2022, representing the portion of the deferred tax asset that is not more likely than not to be realized. For the period April&#160;1, 2021 through March&#160;31, 2022, the valuation allowance increased by $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">209.4</ix:nonFraction>&#160;million, primarily as a result of corresponding increases in our global net operating losses, as well as increased costs related to share-based compensation. The amount of the deferred tax asset considered realizable could be adjusted for future factors that would impact the assessment of the objective and subjective evidence of the Company. The Company will continue to assess the realizability of deferred tax assets at each balance sheet date in order to determine the amount, if any, required for a valuation allowance. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are outside basis differences related to the Company&#8217;s investment in subsidiaries for which no deferred taxes have been recorded as these would not be subject to tax on repatriation as Bermuda has no tax regime for Bermuda exempted limited companies, and the United Kingdom tax regime relating to company distributions and sales generally provides for exemption from tax for most overseas profits, subject to certain exceptions. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to tax and is required to file United States, United Kingdom, and Switzerland federal income tax returns, as well as income tax returns in various state, local, and foreign jurisdictions. The</div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">19</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div><ix:continuation id="TextSelectionAppend_50658863_3"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Company<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">is subject to tax examinations for tax years ended March&#160;31, 2018 and forward in major taxing jurisdictions. Tax audits and examinations can involve complex issues, interpretations and judgments. The resolution of matters may span multiple years particularly if subject to litigation or negotiation. The Company believes it has appropriately recorded its tax position using reasonable estimates and assumptions, however, the potential tax benefits may impact the results of operations or cash flows in the period of resolution, settlement or when the statutes of limitations expire. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s unrecognized tax benefit activity during the year ended March&#160;31, 2022 was not material to the Company&#8217;s consolidated financial statements. There were no unrecognized tax benefits recorded as of March&#160;31, 2021. <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction> interest and penalties related to unrecognized tax benefits were recorded as of March&#160;31, 2022 or March&#160;31, 2021. </div></div></ix:continuation> <ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true" continuedAt="TextSelection_50658821"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 12&#8212;Leases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s operating leases consist primarily of real estate leases, including those entered into by certain wholly owned and majority-owned or controlled subsidiaries of RSL. </div></div> <ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of operating lease expense for the Company were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,649</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,931</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">326</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">237</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,227</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">704</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,202</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,872</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> </ix:nonNumeric> </div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:LeasesOfLesseeDisclosureTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true" continuedAt="TextSelection_50658816"><ix:continuation id="TextSelection_50658821" continuedAt="TextSelectionAppend_50658821_1"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px;;display:inline;">Information related to the Company&#8217;s operating lease right-of-use assets and operating lease liabilities was as follows (in thousands, except periods and percentages):&#160;</div></div></ix:continuation></ix:nonNumeric><ix:continuation id="TextSelectionAppend_50658821_1"> <ix:continuation id="TextSelection_50658816"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">During&#160;the&#160;Year&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,403</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,830</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,035</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;202<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn03_31_2022" format="ixt-sec:duryear">9.0</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn03_31_2021" format="ixt-sec:duryear">9.6</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn03_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn03_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table></ix:continuation> <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, maturities of operating lease liabilities were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ending March&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,714</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,672</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,455</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,363</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,680</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,783</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">100,667</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: present value adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:OperatingLeaseLiabilityPresentValueAdjustments" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,996</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: tenant improvement allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:LesseeOperatingLeaseLiabilityTenantImprovementAllowance" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,805</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">73,866</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22<div style="letter-spacing: 0px; top: 0px;;display:inline;">0</div></div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true" continuedAt="TextSelection_50658881"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 13&#8212;Commitments and Contingencies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Commitments </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Long-Term Debt </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is obligated to make contractual payments related to its long-term debt. Refer to Note 7, &#8220;Long-Term Debt and Loan Commitment&#8221; for further information. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lease Commitments </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has operating leases, consisting primarily of real estate leases. Refer to Note 12, &#8220;Leases&#8221; for further information. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Commitments </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2021, the Company entered into a master subscription agreement with Palantir Technologies Inc. (&#8220;Palantir&#8221;) for access to Palantir&#8217;s proprietary software for a five-year period. As of March&#160;31, 2022, the remaining minimum payments for this software subscription are $<ix:nonFraction name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" contextRef="PAsOn03_31_2022_MasterSubscriptionAgreementMemberROIVAgreementAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">30.0</ix:nonFraction>&#160;million. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2021, the Company&#8217;s subsidiary, Immunovant, Inc. (&#8220;Immunovant&#8221;), entered into a Product Service Agreement with Samsung Biologics Co., Ltd. (&#8220;Samsung&#8221;) by which Samsung will manufacture and supply Immunovant with batoclimab drug substance for commercial sale and perform other manufacturing-related services with respect to batoclimab. As of March&#160;31, 2022, the minimum purchase commitment related to this agreement is estimated to be approximately $<ix:nonFraction name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" contextRef="PAsOn03_31_2022_ProductServiceAgreementMemberROIVAgreementAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">36.0</ix:nonFraction>&#160;million. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company, primarily through its subsidiaries, has entered into commitments under various asset acquisition and license agreements. Additionally, the Company through its subsidiaries enters into agreements with contract service providers to assist in the performance of its R&amp;D activities. Expenditures to contract research organizations and contract manufacturing organizations represent significant costs in the clinical development of its product candidates. Subject to required notice periods and certain obligations under binding purchase orders, the Company can elect to discontinue the work under these agreements at any time. The Company expects to enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require upfront payments and long-term commitments of capital resources. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Loss Contingencies </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company accrues for loss contingencies when available information indicates that it is probable that a liability has been incurred and the amount of such loss can be reasonably estimated, and if the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation or claim, including an estimable range, if possible. The Company is currently not involved in any legal proceedings with a probable and estimable material loss. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Immunovant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the Company&#8217;s subsidiary, Immunovant, has previously disclosed, in February 2021, a putative securities class action complaint was filed against Immunovant and certain of its current and former officers in the U.S. District Court for the Eastern District of New York on behalf of a class consisting of those who acquired Immunovant&#8217;s securities from October&#160;2, 2019 and February&#160;1, 2021. The complaint alleged that Immunovant and certain of its officers violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, by making false and misleading statements regarding the safety of batoclimab and seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div> </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_50658881"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;29, 2021, the U.S. District Court appointed a lead plaintiff. On February&#160;1, 2022, the lead plaintiff filed an amended complaint adding both (i)&#160;the Company and (ii)&#160;Immunovant&#8217;s directors and underwriters as defendants, and asserting additional claims under Section&#160;11, 12(a)(2), and 15 of the Securities Act of 1933, which was further amended by an amended complaint filed on March&#160;15, 2022. On May&#160;27, 2022, defendants, including the Company, filed motions to dismiss that amended complaint. The Company intends to vigorously defend the case and has not recorded a liability related to this lawsuit because, at this time, the Company is unable to reasonably estimate possible losses or determine whether an unfavorable outcome is either probable or remote. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In March 2022, Acuitas Therapeutics Inc. filed a lawsuit in the U.S. District Court for the Southern District of New York against two of the Company&#8217;s affiliates, Genevant and Arbutus, seeking a declaratory judgment that U.S. Patents 8,058,069, 8,492,359, 8,822,668, 9,006,417, 9,364,435, 9,404,127, 9,504,651, 9,518,272, and 11,141,378 are not infringed by the manufacture, use, offer for sale, sale or importation into the United States of COMIRNATY, Pfizer&#8217;s and BioNTech&#8217;s vaccine for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and are otherwise invalid. Each of Genevant and Arbutus intend to vigorously defend the case and neither they nor the Company have recorded a liability related to this lawsuit. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Indemnification Agreements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. The Company also indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits. The maximum amount of potential future indemnification is unlimited; however, the Company currently maintain director and officer liability insurance, which may cover certain liabilities arising from our obligation to indemnify our directors. The Company has not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. To date, the Company has not incurred any material costs and have not accrued any liabilities related to such obligations in the consolidated financial statements as of March&#160;31, 2022 and 2021. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></div> </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P04_01_2021To03_31_2022_RoivantSciencesLtd.MemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_50658877"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 14&#8212;Fair Value Measurements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recurring Fair Value Measurements </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of&#160;March&#160;31, 2022 and 2021, by level, within the fair value hierarchy (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 33%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;as&#160;of<br/> March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;as&#160;of<br/> March&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,297,844</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,297,844</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,420,597</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,420,597</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Datavant Class&#160;A units</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapFairValueByAssetClassAxis_DatavantMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">193,963</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapFairValueByAssetClassAxis_DatavantMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">193,963</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_DatavantMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_DatavantMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Sio common shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,447</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,447</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,487</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,487</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Arbutus common shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115,765</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115,765</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">53,325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">53,325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Arbutus convertible preferred shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">76,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">76,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other investments</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,659</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,659</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,429,715</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">193,963</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,623,678</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,533,538</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">76,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,609,575</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt issued by Dermavant to NovaQuest</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">177,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">177,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">150,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">150,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments measured at fair value<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" contextRef="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,019</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" contextRef="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,893</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" contextRef="PAsOn03_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">44,912</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">67,893</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">67,893</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,019</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">204,293</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">222,312</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">217,993</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">217,993</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">At March&#160;31, 2022, Level&#160;1 includes the fair value of the Public Warrants of $<ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivPublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">18.0</ix:nonFraction>&#160;million, and Level&#160;3 includes the fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares of $<ix:nonFraction name="us-gaap:NonfinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivEarnoutSharesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.2</ix:nonFraction>&#160;million, Private Placement Warrants of $<ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivPrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.1</ix:nonFraction>&#160;million, and other liability instruments issued of $<ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivLiabilityInstrumentsMeasuredAtFairValueMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.6</ix:nonFraction>&#160;million. At March&#160;31, 2021, Level&#160;3 includes the fair value of the Sumitomo Options of $<ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">62.4</ix:nonFraction>&#160;million and other liability instrument issued of $<ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivLiabilityInstrumentsMeasuredAtFairValueMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.5</ix:nonFraction>&#160;million. </div></td></tr></table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no transfers of assets between Level&#160;1 and Level&#160;2 of the fair value measurement hierarchy that occurred during the years ended March&#160;31, 2022 and 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Level&#160;3 Disclosures </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures its Level&#160;3 assets and liabilities at fair value based on significant inputs not observable in the market, which causes them to be classified as a Level&#160;3 measurement within the fair value hierarchy. The valuation of the Level&#160;3 assets and liabilities uses assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions and estimates on an ongoing basis as additional data impacting the assumptions and estimates are obtained. Changes in the fair value related to updated assumptions and estimates are recorded within the statements of operations at the end of each reporting period. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of Level&#160;3 assets and liabilities may change significantly as additional data are obtained, impacting the Company&#8217;s assumptions regarding probabilities of potential scenarios used to estimate fair value. In evaluating this information, considerable judgment is required to interpret the data used to develop the </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div> </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_50658877" continuedAt="TextSelectionAppend_50658877_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">assumptions and estimates. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company&#8217;s results of operations in future periods. </div></div> <ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in fair value of the Level&#160;3 assets during the&#160;year ended March&#160;31, 2022&#160;were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of investment in Datavant at recognition date</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment" contextRef="P04_01_2021To03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">224,147</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of investment in Datavant, included in net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" contextRef="P04_01_2021To03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">30,184</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">193,963</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no Level&#160;3 assets held during the year ended March&#160;31, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in fair value of the Level&#160;3 liabilities during the&#160;years ended March&#160;31, 2022 and 2021 were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">191,473</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of debt and liability instruments, included in net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P04_01_2020To03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments disposed due to deconsolidation of subsidiary</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" contextRef="P04_01_2020To03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">217,993</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of liability instrument issued</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P04_01_2021To03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,634</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of debt and liability instruments, included in net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P04_01_2021To03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,226</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Settlements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne" contextRef="P04_01_2021To03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">88</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Termination of DSP Options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P04_01_2021To03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">61,472</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">204,293</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Datavant </div></div></div> <ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="P04_01_2021To03_31_2022_DatavantMemberdeiLegalEntityAxis" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company elected the fair value option to account for the investment in Datavant. The estimate of fair value for this investment was determined using the income approach and implementation of the option pricing method (&#8220;OPM&#8221;). The OPM allows for the allocation of a company&#8217;s equity value among the various equity capital owners (preferred and common shareholders). The OPM uses the preferred shareholders&#8217; liquidation preferences, participation rights, dividend policy, and conversion rights to determine how proceeds from a liquidity event shall be distributed among the various ownership classes at a future date. The fair value was calculated using significant unobservable inputs including the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 23%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Point Estimate Used</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Input</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:FairValueAssetMeasurementInput" contextRef="PAsOn03_31_2022_DatavantMemberdeiLegalEntityAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">110.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:FairValueAssetMeasurementInput" contextRef="PAsOn03_31_2022_DatavantMemberdeiLegalEntityAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.62</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt issued by Dermavant to NovaQuest </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the debt instrument as of&#160;March&#160;31, 2022 and 2021 represents the fair value of amounts payable to NovaQuest using the Monte Carlo simulation method under the income approach determined by using probability assessments of the expected future payments through 2032 and applying discount rates ranging from <span style="-sec-ix-hidden:hidden50658326">10</span>% to <span style="-sec-ix-hidden:hidden50658327">12</span>%. The future payments are based on significant inputs that are not observable in the market which are subject to remeasurement at each reporting date. The estimates of fair value may not be indicative of the amounts that could ultimately be paid by Dermavant to NovaQuest. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div> </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_50658877_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares </div></div> <ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="P04_01_2021To03_31_2022_EarnoutSharesMemberusgaapStatementEquityComponentsAxis" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares issued as part of the Business Combination was calculated using the Monte Carlo simulation method under the income approach. The model was structured to include the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> periods to which the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares are subject. Refer to Note 3, &#8220;Business Combination with MAAC&#8221; for additional details. Significant unobservable inputs used to calculate the fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares included the following: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 25%; vertical-align: bottom;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Point&#160;Estimate&#160;Used</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Input</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;31,&#160;2022</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><ix:nonFraction name="roiv:FairValueAssetMeasurementInput" contextRef="PAsOn03_31_2022_EarnoutSharesMemberusgaapStatementEquityComponentsAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">82.3</ix:nonFraction>%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><ix:nonFraction name="roiv:FairValueAssetMeasurementInput" contextRef="PAsOn03_31_2022_EarnoutSharesMemberusgaapStatementEquityComponentsAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.43</ix:nonFraction>%</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of March&#160;31, 2022, the fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares was $<ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2022_EarnoutSharesMemberusgaapStatementEquityComponentsAxis_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.2</ix:nonFraction>&#160;million. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares are included in &#8220;Liability instruments measured at fair value&#8221; in the accompanying consolidated balance sheets. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private Placement Warrants </div></div></div> <ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="P04_01_2021To03_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Private Placement Warrants issued as part of the Business Combination was calculated using the Monte Carlo simulation method under the income approach. The model was structured to incorporate the redemption features as discussed in Note 3, &#8220;Business Combination with MAAC&#8221; and the added restriction by which the Company cannot redeem the Private Warrants if the Reference Value is greater than $18.00. Significant unobservable inputs used to calculate the fair value of the Private Placement Warrants included the following: </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 25%; vertical-align: bottom;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Point&#160;Estimate&#160;Used</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Input</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;31,&#160;2022</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><ix:nonFraction name="roiv:FairValueAssetMeasurementInput" contextRef="PAsOn03_31_2022_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">56.5</ix:nonFraction>%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><ix:nonFraction name="roiv:FairValueAssetMeasurementInput" contextRef="PAsOn03_31_2022_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.43</ix:nonFraction>%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term (in years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn03_31_2022_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:num-dot-decimal">4.50</ix:nonFraction></td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, the fair value of the Private Placement Warrants was $<ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn03_31_2022_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.1</ix:nonFraction>&#160;million. The Private Placement Warrants are included in &#8220;Liability instruments measured at fair value&#8221; in the accompanying consolidated balance sheets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sumitomo Options </div></div></div> <ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="P04_01_2021To03_31_2022_SumitomoOptionsMemberdeiLegalEntityAxis" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to termination in June 2021, the fair value of the options to acquire the Company&#8217;s interest in certain of its subsidiaries, which were granted to Sumitomo under the Sumitomo Transaction Agreement, was calculated using significant unobservable inputs including the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Range&#160;or&#160;Point<br/> Estimate Used</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Input</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time to expiration (in years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: center;"><ix:nonNumeric name="roiv:AlternativeInvestmentExpectedTerm" contextRef="P03_01_2021To03_31_2021_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis" format="ixt-sec:duryear">3.59</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: center;"><ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="PAsOn03_31_2021_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">0.52</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="PAsOn03_31_2021_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_pure" decimals="-2" scale="3" format="ixt:num-dot-decimal">89.0</ix:nonFraction>%&#160;-&#160;<ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="PAsOn03_31_2021_MaximumMembersrtRangeAxis_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_pure" decimals="-2" scale="3" format="ixt:num-dot-decimal">95.0</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, the Company completed a transaction with Sumitomo pursuant to which Sumitomo terminated all of its existing options to acquire the Company&#8217;s equity interests in certain subsidiaries. As of March&#160;31, 2021, the fair value of the Sumitomo Options was $<ix:nonFraction name="roiv:EquityInterestOptionToThirdPartyPurchase" contextRef="PAsOn03_31_2021_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">62.4</ix:nonFraction>&#160;million, which is included in &#8220;Liability instruments measured at fair value&#8221; in the accompanying consolidated balance sheets. See Note 8, &#8220;Related Party Transactions&#8221; for additional information. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="us-gaap:OtherOperatingIncomeAndExpenseTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 15&#8212;Other Expense, Net </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense, net was as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from equity method investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,750</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">369</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,418</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,041</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,809</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:OtherIncomeExpense" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,237</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:OtherIncomeExpense" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,560</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:OtherOperatingIncomeExpensesNet" contextRef="P04_01_2021To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,435</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:OtherOperatingIncomeExpensesNet" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,701</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 16&#8212;Net Loss per Common Share </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">Basic net loss per common share is computed by dividing net loss attributable to Roivant Sciences Ltd. by the weighted-average number of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to Roivant Sciences Ltd. by the diluted weighted-average number of common stock outstanding during the period.</div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">For periods of loss, diluted loss per share is calculated similar to basic loss per share as the effect of including all potentially dilutive common stock equivalents is anti-dilutive. All outstanding common stock equivalents have been excluded from the computation of diluted loss per share because their effect was anti-dilutive due to the net loss.</div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022 and 2021, potentially dilutive securities were as follows: </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options and performance stock options</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_01_2021To03_31_2022_StockOptionsAndPerformanceStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">80,364,904</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_01_2020To03_31_2021_StockOptionsAndPerformanceStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">69,687,308</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Restricted stock units and performance stock units <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(non-vested)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_01_2021To03_31_2022_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">21,956,749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_01_2020To03_31_2021_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">7,294,028</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">March 2020 CVARs<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_01_2021To03_31_2022_TwoThousandAndTwentyCvarsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_50658972">32,011,996</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_01_2020To03_31_2021_TwoThousandAndTwentyCvarsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="Fact_50658973">32,447,626</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">November 2021 CVARs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_01_2021To03_31_2022_NovemberTwoThousandAndTwentyOneCvarsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,285,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Restricted <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">stock</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(non-vested)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_01_2021To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">741,405</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,720,090</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(non-vested)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_01_2021To03_31_2022_EarnOutSharesNonvestedMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,080,387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private Placement Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_01_2021To03_31_2022_PrivatePlacementWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,214,365</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_01_2021To03_31_2022_PublicWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">20,475,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other instruments issued</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_01_2021To03_31_2022_OtherInstrumentsIssuedMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,103,577</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_01_2020To03_31_2021_OtherInstrumentsIssuedMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,458,543</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Refer to Note 10, &#8220;Share-Based Compensation&#8221; for details regarding settlement of CVARs. </div></div></div> </td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P04_01_2021To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 17&#8212;Subsequent Events </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In May 2022, VTAMA (tapinarof) cream was approved by the FDA as the first and only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> steroid-free topical medication in its class for the treatment of plaque psoriasis in adult patients. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the approval of VTAMA cream by the FDA in May 2022, Dermavant received $<ix:nonFraction name="roiv:GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement" contextRef="P04_01_2022To06_30_2022_RoivrevenueInterestPurchaseAndSaleAgreementMemberMemberusgaapFinancialInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">160.0</ix:nonFraction>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million in June 2022 pursuant to the terms of the RIPSA as described in Note 7, &#8220;Long-Term Debt and Loan Commitment.&#8221; </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Also, as a result of FDA approval, Dermavant achieved a regulatory milestone to GSK of &#163;<ix:nonFraction name="roiv:MilestonePaymentPayable" contextRef="PAsOn06_30_2022_GSKMembersrtCounterpartyNameAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction>&#160;million (approximately $<ix:nonFraction name="roiv:MilestonePaymentPayable" contextRef="PAsOn06_30_2022_GSKMembersrtCounterpartyNameAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">126</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million on the date of achievement), which will be paid within</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<ix:nonNumeric name="roiv:MilestonePaymentPeriod" contextRef="P04_01_2022To06_30_2022_GSKMembersrtCounterpartyNameAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt-sec:durday">70</ix:nonNumeric> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">calendar days of FDA approval. Additionally, the first sale of VTAMA cream in May 2022 resulted in the achievement of a milestone to Welichem Biotech Inc. of CAD$</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="roiv:MilestonePaymentPayable" contextRef="PAsOn06_30_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WelichemBiotechIncMembersrtCounterpartyNameAxis" unitRef="Unit_CAD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction>&#160;million (approximately $<ix:nonFraction name="roiv:MilestonePaymentPayable" contextRef="PAsOn06_30_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WelichemBiotechIncMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">million on the date of achievement), which will be paid within</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> <ix:nonNumeric name="roiv:MilestonePaymentPeriod" contextRef="P05_31_2022To05_31_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WelichemBiotechIncMembersrtCounterpartyNameAxis" format="ixt-sec:durday">60</ix:nonNumeric> calendar days of the invoice date. Dermavant intends to primarily use the RIPSA proceeds for the payment of these obligations. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a><br/></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom307489_14" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div id="rom307489_15" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;9A. CONTROLS AND PROCEDURES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Evaluation of Disclosure Controls and Procedures </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our management, with the participation of our Principal Executive Officer, our Principal Financial Officer and our Principal Accounting Officer, evaluated the effectiveness of our disclosure controls and procedures as of March&#160;31, 2022 and concluded that our disclosure controls and procedures were effective as of that date. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(e)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(e)</div> under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive, principal financial and principal accounting officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in Internal Control over Financial Reporting </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">No change in our internal control over financial reporting (as defined in Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(f)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(f)</div> under the Exchange Act) occurred during the year ended March&#160;31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management&#8217;s Annual Report on Internal Control over Financial Reporting </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">This Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> does not include a report of management&#8217;s assessment regarding internal control over financial reporting or an attestation report of our independent registered public accounting firm due to a transition period established by rules of the SEC for newly public companies. </div> <div id="rom307489_16" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;9B. OTHER INFORMATION </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div id="rom307489_17" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">227 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom307489_18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART III </div></div></div> <div id="rom307489_19" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except as set forth below, the information required by this Item is incorporated by reference from our definitive proxy statement for our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year ended March&#160;31, 2022. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer and persons performing similar functions. A current copy of the code is posted on the Corporate Governance section of our website, which is located at investor.roivant.com/corporate-governance. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for our principal executive officer, principal financial officer, principal accounting officer or persons performing similar functions, or any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K.</div> </div> <div id="rom307489_20" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;11. EXECUTIVE COMPENSATION </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The information required by this Item is incorporated by reference from our definitive proxy statement for our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year ended March&#160;31, 2022. </div></div> <div id="rom307489_21" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The information required by this Item is incorporated by reference from our definitive proxy statement for our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year ended March&#160;31, 2022. </div></div> <div id="rom307489_22" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The information required by this Item is incorporated by reference from our definitive proxy statement for our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year ended March&#160;31, 2022. </div></div> <div id="rom307489_23" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;14. PRINCIPAL ACCOUNTING FEES AND SERVICES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The information required by this Item is incorporated by reference from our definitive proxy statement for our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year ended March&#160;31, 2022. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">228 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom307489_24" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART IV </div></div></div> <div id="rom307489_25" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">(a) The following documents are filed as part of this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K:</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Financial Statements: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a list of the consolidated financial statements included herein, see &#8220;Index to Consolidated Financial Statements&#8221; under Part I, Item 8 of this Annual Report on Form&#160;10-K. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Financial Statement Schedules: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All schedules have been omitted because of the absence of conditions under which they are required or because the required information, where material, is shown in the financial statements, financial notes or supplementary financial information. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">(b) Exhibits required by Item 601 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K:</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The exhibits listed in the accompanying Exhibit Index are filed as part of, or incorporated by reference into, this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="rom307489_26" style="width: 9%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;16.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> SUMMARY </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibits </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 41%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exhibit</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="5" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Incorporated by Reference</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing Date</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Form</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">File No.</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exhibit</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;2.1+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d307489dex21.htm">Business Combination Agreement, dated as of May&#160;1, 2021, by and among Montes Archimedes Acquisition Corp., Roivant Sciences Ltd. and Rhine Merger Sub, Inc. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;2.2#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex22.htm#cov">Agreement and Plan of Merger, dated as of February&#160;2, 2021, by and among Roivant Sciences Ltd., Silicon Insite, Inc., Silicon TX China, Silicon Therapeutics, LLC and Silicon SWAT, Inc. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4/A</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">2.2</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">July&#160;1, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;2.3#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex23.htm#cov">Stock Purchase Agreement, dated as of November&#160;6, 2020, by and among Oncopia Therapeutics, Inc., Pharmavant 5, Inc., certain selling securityholders and certain seller representatives </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4/A</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">2.3</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">July&#160;1, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;2.4#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex24.htm">Amendment No.&#160;1 to the Stock Purchase Agreement, dated as of November&#160;17, 2020, by and among Oncopia Therapeutics, Inc., Pharmavant 5, Inc., certain selling securityholders and WRYP Stockholders Services, LLC </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4/A</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">2.4</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">July&#160;1, 2021</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">229 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 40%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exhibit</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="5" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Incorporated by Reference</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing Date</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Form</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">File No.</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exhibit</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;2.5*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000110465919059171/a19-21684_1ex7d04.htm">Transaction Agreement, dated as of October&#160;31, 2019, by and among Sumitomo Dainippon Pharma Co., Ltd., Vant Alliance Ltd., Roivant Sciences Ltd., Enzyvant Therapeutics Ltd., Altavant Sciences Ltd. and Spirovant Sciences Ltd. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">SC&#160;13D/A</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">7.04</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">November&#160;4,&#160;2019</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;2.6#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex26.htm">Asset Purchase Agreement, dated as of July&#160;10, 2018, by and among GlaxoSmithKline Intellectual Property Development Ltd., Glaxo Group Limited and Dermavant Sciences GmbH </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">2.6</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">May&#160;14, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;2.7#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex27.htm">Asset Purchase Agreement, dated as of May&#160;29, 2012, by and between Glaxo Group Limited and Welichem Biotech Inc. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">2.7</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">May&#160;14, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;2.8#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex28.htm">First Amendment to the Asset Purchase Agreement, dated as of August&#160;31, 2012, by and between Glaxo Group Limited and Welichem Biotech, Inc. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">2.8</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">May&#160;14, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;2.9+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d307489dex29.htm">Amendment No.&#160;1 to the Business Combination Agreement, dated June&#160;9, 2021, by and among Montes Archimedes Acquisition Corp., Roivant Sciences Ltd. and Rhine Merger Sub, Inc. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;3.1*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex31.htm">Memorandum of Association of Roivant Sciences Ltd. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4/A</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">3.1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">July&#160;1, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;3.2*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521288885/d230641dex31.htm">Amended and Restated <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bye-laws</span> of Roivant Sciences Ltd. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-40782</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">3.1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">October&#160;1, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;4.1*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1819263/000110465920114035/tm2033018d1_ex4-1.htm">Warrant Agreement between Continental Stock Transfer&#160;&amp; Trust Company and Montes Archimedes Acquisition Corp. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39597</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">4.1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">October&#160;13, 2020</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;4.2*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062dex45.htm">Specimen Ordinary Share Certificate of Roivant Sciences Ltd. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4/A</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">4.5</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">August&#160;3, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;4.3*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062dex46.htm">Specimen Warrant Certificate of Roivant Sciences Ltd. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4/A</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">4.6</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">August&#160;3, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;4.4*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1819263/000110465920114035/tm2033018d1_ex4-1.htm">Form of Warrant Assumption Agreement, by and between Montes Archimedes Acquisition Corp., Roivant Sciences Ltd. and American Stock Transfer&#160;&amp; Trust Company, LLC </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4/A</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">4.7</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">August&#160;3, 2021</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">230 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 43%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exhibit</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="5" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Incorporated by Reference</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing Date</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Form</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">File No.</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exhibit</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.1+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d307489dex101.htm">Third Amended and Restated Registration Rights Agreement, dated as of May&#160;1, 2021, by and among Roivant Sciences Ltd. and the parties thereto </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.2+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d307489dex102.htm">Form of Subscription Agreement </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.3+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d307489dex103.htm">Sponsor Support Agreement, dated as of May&#160;1, 2021, by and among Roivant Sciences Ltd., Montes Archimedes Acquisition Corp., Patient Square Capital LLC and certain shareholders of Roivant Sciences Ltd. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.4+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d307489dex104.htm">Form of Transaction Support Agreement, dated as of May&#160;1, 2021, by and among Roivant Sciences Ltd., Montes Archimedes Acquisition Corp. and certain shareholders of Roivant Sciences Ltd. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.5*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1819263/000110465920114035/tm2033018d1_ex10-1.htm">Investment Management Trust Agreement between Continental Stock Transfer&#160;&amp; Trust Company and Montes Archimedes Acquisition Corp. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39597</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">October&#160;13, 2020</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.6#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1764013/000119312519321147/d839382dex106.htm">License Agreement, dated as of December&#160;19, 2017, by and between HanAll Biopharma Co., Ltd. and Roivant Sciences GmbH </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-38906</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.6</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">December&#160;20,&#160;2019</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.7#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex107.htm">Collaboration and License Agreement, dated as of January&#160;15, 2020, by and between Dermavant Sciences GmbH and Japan Tobacco Inc. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.7</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">May&#160;14, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.8#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex108.htm">Clinical Manufacturing and Supply Agreement, dated August&#160;20, 2018, by and between Dermavant Sciences GmbH and GlaxoSmithKline Trading Services Limited </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.8</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">May&#160;14, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.9#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex109.htm">Commercial Manufacturing and Supply Agreement, dated April&#160;1, 2019, by and between Dermavant Sciences GmbH and GlaxoSmithKline Trading Services Limited </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.9</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">May&#160;14, 2021</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">231 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 43%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exhibit</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="5" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Incorporated by Reference</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing Date</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Form</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">File No.</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exhibit</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.10#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1010.htm">Funding Agreement, dated as of July&#160;10, 2018, by and between Dermavant Sciences GmbH and NovaQuest <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</span> Fund VIII, L.P. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.10</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">May&#160;14, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.11#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1011.htm">First Amendment to Funding Agreement, dated as of October&#160;11, 2018, by and between Dermavant Sciences GmbH and NovaQuest <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</span> Fund VIII, L.P. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.11</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">May&#160;14, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.12#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1447028/000144702820000118/a2020-q210xqex103cross.htm">Cross License Agreement, dated as of April&#160;11, 2018, by and between Genevant Sciences Ltd. and Arbutus Biopharma Corporation </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-34949</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.3</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">August&#160;7,&#160;2020</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.13#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1447028/000144702820000118/a2020-q210xqex1041stam.htm">First Amendment to Cross License Agreement, dated as of June&#160;27, 2018, by and among Genevant Sciences Ltd., Genevant Sciences GmbH and Arbutus Biopharma Corporation </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-34949</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.4</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">August&#160;7, 2020</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.14#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1447028/000144702820000118/a2020-q210xqex105secon.htm">Second Amendment to Cross License Agreement, dated as of June&#160;27, 2018, by and among Genevant Sciences Ltd., Genevant Sciences GmbH and Arbutus Biopharma Corporation </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-34949</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.5</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">August&#160;7, 2020</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.15#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1020.htm">Research Agreement, dated as of January&#160;1, 2018, by and between Oncopia Therapeutics, LLC and the Regents of the University of Michigan </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4/A</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.20</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">July&#160;1, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.16#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1021.htm">Fifth Amendment to the Sponsored Research Agreement, dated as of November&#160;19, 2020, by and between Oncopia Therapeutics, Inc. and the Regents of the University of Michigan </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4/A</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.21</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">July&#160;1, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.17#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1022.htm">Amended and Restated Patent License Agreement, dated as of November&#160;16, 2020, by and between Oncopia Therapeutics, Inc. and the Regents of the University of Michigan </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4/A</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.22</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">July&#160;1,&#160;2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.18#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1023.htm">Investors&#8217; Rights Agreement, dated as of January&#160;11, 2021, by and among Pharmavant 5, Inc., Roivant Sciences Ltd. and SK Holdings Co., Ltd. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4/A</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.23</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">July&#160;1, 2021</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">232 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 39%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exhibit</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="5" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Incorporated by Reference</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing Date</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Form</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">File No.</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exhibit</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.19*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1024.htm">Form of Indemnity Agreement </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4/A</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.24</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">July&#160;1, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.20*&#094;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1025.htm">Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.25</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">May&#160;14,&#160;2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.21*&#094;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000095010321015700/dp159512_ex9901.htm">Roivant Sciences Ltd. 2021 Equity Incentive Plan </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-260173</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">99.1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">October&#160;8,&#160;2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.22*&#094;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1027.htm">Amended and Restated Employment Agreement between Roivant Sciences, Inc. and Vivek Ramaswamy, dated as of May&#160;14, 2021 </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.27</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">May&#160;14, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.23*&#094;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1028.htm">Executive Employment Agreement between Roivant Sciences, Inc. and Matthew Gline, dated as of May&#160;14, 2021 </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.28</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">May&#160;14, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.24*&#094;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1029.htm">Executive Employment Agreement between Roivant Sciences, Inc. and Eric Venker, dated as of May&#160;14, 2021 </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.29</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">May&#160;14, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.25*&#094;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1030.htm">Executive Employment Agreement between Roivant Sciences, Inc. and Benjamin Zimmer, dated as of May&#160;14, 2021 </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.30</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">May&#160;14, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.26#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1031.htm#cov">Credit Agreement by and among Dermavant Sciences Ltd., Dermavant Holdings Limited, Dermavant Sciences IRL Limited, Dermavant Sciences GmbH, certain subsidiaries of Dermavant Sciences Ltd., XYQ Luxco S.A.R.L. and U.S. Bank National Association, as collateral agent, dated as of May&#160;14, 2021 </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4/A</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.31</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">July&#160;1, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.27#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1032.htm">Revenue Interest Purchase and Sale Agreement by and among Dermavant Sciences GmbH, certain purchasers and U.S. Bank National Association as collateral agent, dated as of May&#160;14, 2021 </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4/A</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-256165</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.32</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">July&#160;1, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.28+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d307489dex1028.htm">Amendment No.&#160;1 to the Support Agreement, dated as of June&#160;9, 2021, by and among Roivant Sciences Ltd., Montes Archimedes Acquisition Corp., Patient Square Capital LLC and certain shareholders of Roivant Sciences Ltd. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">233 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 40%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exhibit</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="5" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Incorporated by Reference</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing Date</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Form</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">File No.</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exhibit</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.29*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521288885/d230641dex101.htm">Amendment No.&#160;2 to the Support Agreement, dated as of September&#160;30, 2021, by and among Roivant Sciences Ltd., Montes Archimedes Acquisition Corp., Patient Square Capital LLC and certain shareholders of Roivant Sciences Ltd. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-40782</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">October&#160;1, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.30*&#094;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000095010321015700/dp159512_ex9902.htm">Roivant Sciences Ltd. Employee Stock Purchase Plan </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-260173</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">99.2</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">October&#160;8, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.31#&#8224;*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521328922/d203748dex101.htm">Agreement and General Release Between Roivant Sciences Ltd., Roivant Sciences, Inc. and Benjamin Zimmer </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-40782</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">November&#160;15,&#160;2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.32#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521365107/d268332dex1037.htm">Third Amendment to Cross License Agreement, dated December&#160;9, 2021, by and between Genevant Sciences GmbH and Arbutus Biopharma Corporation </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-261853</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.37</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">December&#160;22, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.33*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521365107/d268332dex1038.htm">Bonus Award Letter from Roivant Sciences Inc. to Benjamin Zimmer, dated as of December&#160;21, 2021 </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">333-261853</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.38</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">December&#160;22, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.34#&#8224;*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312522039433/d12341dex101.htm">Exclusive License Agreement, dated as of November&#160;24, 2021, by and between Eisai Co. Ltd and Pharmavant 7 GmbH </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-40782</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">February&#160;14, 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.35#*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312522039426/d276297dex101.htm">Common Shares Purchase Agreement, dated as of February&#160;14, 2022, by and between Roivant Sciences Ltd. and CF Principal Investments LLC </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-40782</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">10.1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">February&#160;14, 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.36#&#8224;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d307489dex1036.htm">Investor Rights Agreement, dated as of September 13, 2021, by and among Priovant Holdings, Inc., Roivant Sciences Ltd. and Pfizer Inc. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.37#&#8224;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d307489dex1037.htm">License&#160;and Collaboration Agreement, dated as of September 13, 2021,&#160;by&#160;and between Pfizer Inc. and Priovant, Inc. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.38#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d307489dex1038.htm">Amendment No. 1 to License and Collaboration Agreement, dated as of June 10, 2022, by and between Pfizer Inc. and Priovant, Inc. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;21.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d307489dex211.htm">List of Subsidiaries of Roivant Sciences Ltd. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">234 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 41%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exhibit</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="5" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Incorporated by Reference</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing Date</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Form</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">File No.</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exhibit</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;23.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d307489dex231.htm">Consent of Ernst&#160;&amp; Young LLP, Independent Registered Public Accounting Firm of Roivant Sciences Ltd. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;24.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="#tx307489_sp241">Power of Attorney (included on signature page) </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;31.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d307489dex311.htm">Certification of Principal Executive Officer Pursuant to Rules <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-14(a)</span> and <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-14(a)</span> under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;31.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d307489dex312.htm">Certification of Principal Financial Officer Pursuant to Rules <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-14(a)</span> and <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-14(a)</span> under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;32.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d307489dex321.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;32.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d307489dex322.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.INS</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Instance Document</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.SCH</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Schema Document</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.CAL</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.DEF</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Definition Linkbase Document</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.LAB</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Label Linkbase Document</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.PRE</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">104</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Filed herewith</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">235 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">#</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Portions of this exhibit have been omitted because they are both (i)&#160;not material and (ii)&#160;would likely cause competitive harm to Roivant Sciences Ltd. if publicly disclosed. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">+</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This exhibit was previously filed with the Company&#8217;s Form S-4 (File No. 333-256165). For administrative convenience, the Company has re-filed this exhibit with this Form 10-K. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#8224;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K.</div> The registrant hereby undertakes to furnish supplementally a copy of any omitted exhibit or schedule upon request by the Securities and Exchange Commission. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Previously filed </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">In accordance with Item 601(b)(32)(ii) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K</div> and SEC Release Nos. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">33-8238</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">34-47986,</div> Final Rule: Management&#8217;s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> and will not be deemed &#8220;filed&#8221; for purpose of Section&#160;18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#094;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management contract or compensatory plan or arrangement required to be filed as an exhibit to this Form&#160;10-K pursuant to Item 15(b). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">236 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom307489_27" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SIGNATURES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 5%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 3%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 44%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="3" style="vertical-align: top;">Roivant Sciences Ltd.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; padding-bottom: 0.375pt;">Date: June&#160;28, 2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt; font-size: 0px;"></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.375pt;">By:</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">/s/ Matt Maisak</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Name: Matt Maisak</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">Title: Authorized Signatory</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div id="tx307489_sp241" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">POWER OF ATTORNEY </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Richard&#160;Pulik, Jo Chen and Matt Maisak, as their true and lawful <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">attorney-in-fact</div></div> and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to the Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">attorney-in-fact</div></div> and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she could do in person, hereby ratifying and confirming all that said <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">attorney-in-fact</div></div> and agent, or his substitutes, may lawfully do or cause to be done by virtue hereof. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 35%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 39%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Signature</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Date</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Matthew Gline</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matthew Gline</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Executive Officer and Director</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Principal Executive Officer)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">June&#160;28,&#160;2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Richard Pulik</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Richard Pulik</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Financial Officer</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Principal Financial Officer)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">June&#160;28, 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Rakhi Kumar</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rakhi Kumar</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Accounting Officer</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Principal Accounting Officer)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">June&#160;28, 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Vivek Ramaswamy</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vivek Ramaswamy</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">June&#160;28, 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Andrew Lo</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Andrew Lo</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">June&#160;28, 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Keith Manchester</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Keith Manchester</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">June&#160;28, 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Ilan Oren</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ilan Oren</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">June&#160;28, 2022</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">237 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 35%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 39%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Signature</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Date</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Daniel Gold</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Daniel Gold</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">June&#160;28, 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Masayo Tada</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Masayo Tada</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">June&#160;28, 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Patrick Machado</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patrick Machado</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">June&#160;28, 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ James C. Momtazee</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">James C. Momtazee</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">June&#160;28, 2022</td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">238 </div></div> </div> </div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>d307489dex21.htm
<DESCRIPTION>EX-2.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-2.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 2.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BUSINESS COMBINATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BY AND AMONG </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTES
ARCHIMEDES ACQUISITION CORP., </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RHINE MERGER SUB, INC., </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ROIVANT SCIENCES
LTD. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DATED AS OF MAY&nbsp;1, 2021 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TABLE OF CONTENTS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><U>P<SMALL>AGE</SMALL> </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;1 CERTAIN DEFINITIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Definitions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;2 MERGER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>23</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing Transactions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing of the Transactions Contemplated by this Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Fractional Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Treatment of Company Equity Awards</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transfer Agent Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Withholding</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;3 REPRESENTATIONS AND WARRANTIES RELATING
TO&nbsp;THE&nbsp;GROUP&nbsp;COMPANIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>29</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organization and Qualification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Capitalization of the Group Companies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authority</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Financial Statements; Undisclosed Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Consents and Requisite Governmental Approvals; No&nbsp;Violations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Permits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Material Contracts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Changes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance with Applicable Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Merger Sub Activities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Environmental Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Labor Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Brokers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.19</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Real and Personal Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.20</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transactions with Affiliates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.21</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Data Privacy and Security</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.22</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Business Practices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.23</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Information Supplied</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.24</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regulatory Compliance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.25</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Investment Company Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.26</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SEC Filings and Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.27</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Other Representations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.28</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>EXCLUSIVITY OF REPRESENTATIONS AND WARRANTIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;4 REPRESENTATIONS AND WARRANTIES RELATING TO MAAC</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>52</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organization and Qualification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authority</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Consents and Requisite Governmental Approvals; No Violations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Brokers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Information Supplied</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Capitalization of MAAC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SEC Filings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Trust Account</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No MAAC Material Adverse Effect</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Material Contracts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transactions with Affiliates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance with Applicable Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>MAAC&#146;s Business Activities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Internal Controls; Listing; Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Undisclosed Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.19</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Business Practices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.20</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PIPE Financing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.21</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Investigation; No Other Representations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.22</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>EXCLUSIVITY OF REPRESENTATIONS AND WARRANTIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;5 COVENANTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>64</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conduct of Business of the Group Companies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Efforts to Consummate; Transaction Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Confidentiality and Access to Information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Public Announcements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exclusive Dealing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preparation of Registration Statement / Proxy Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>MAAC Shareholder Approval</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Merger Sub Shareholder Approval</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conduct of Business of MAAC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Nasdaq Listing; MAAC Public Filings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Trust Account</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company Shareholder Approval</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>MAAC Indemnification; Directors&#146; and Officers&#146; Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company Indemnification; Directors&#146; and Officers&#146; Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Post-Closing Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PCAOB Financials</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company Post-Closing Incentive Equity Plan; Company Post-Closing Employee Stock Purchase Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.19</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.20</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company Related Party Transactions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.21</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conduct of Business of Merger Sub</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.22</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notice of Certain Events</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.23</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PIPE Subscription Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;6 CONDITIONS TO CONSUMMATION OF THE TRANSACTIONS CONTEMPLATED BY THIS
AGREEMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>88</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to the Obligations of the Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Other Conditions to the Obligations of MAAC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Other Conditions to the Obligations of the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;7 TERMINATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>91</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;8 MISCELLANEOUS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>93</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Non-Survival</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Entire Agreement; Assignment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Amendment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Governing Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Fees and Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Construction; Interpretation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exhibits and Schedules</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Parties in Interest</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Counterparts; Electronic Signatures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Knowledge of Company; Knowledge of MAAC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Recourse</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Extension; Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver of Jury Trial</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Submission to Jurisdiction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Remedies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Trust Account Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ANNEXES AND EXHIBITS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Annex A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">PIPE Investors</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of PIPE Subscription Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit B</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Transaction Support Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit C</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Registration Rights Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit D</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit E</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Company Post-Closing <FONT STYLE="white-space:nowrap">Bye-laws</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Company Shareholder Written Consent</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit G</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Roivant Sciences Ltd. 2021 Equity Incentive Plan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit H</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Company Post-Closing Employee Stock Purchase Plan Term Sheet</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BUSINESS COMBINATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This BUSINESS COMBINATION AGREEMENT (this &#147;<U>Agreement</U>&#148;), dated as of May&nbsp;1, 2021, is made by and among Montes Archimedes
Acquisition Corp., a Delaware corporation (&#147;<U>MAAC</U>&#148;), Roivant Sciences Ltd., a Bermuda exempted limited company (the &#147;<U>Company</U>&#148;), and Rhine Merger Sub, Inc., a Delaware corporation and a direct wholly owned Subsidiary
of the Company (&#147;<U>Merger Sub</U>&#148;). MAAC, the Company and Merger Sub shall be referred to herein from time to time collectively as the &#147;<U>Parties</U>.&#148; Capitalized terms used but not otherwise defined herein have the meanings
set forth in <U>Section</U><U></U><U>&nbsp;1.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, (a)&nbsp;MAAC is a blank check company incorporated as a Delaware
corporation on July&nbsp;6, 2020 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses,&nbsp;and (b)&nbsp;Merger Sub is, as of the
date of this Agreement, a direct wholly owned Subsidiary of the Company formed for purposes of consummating the transactions contemplated by this Agreement and the applicable Ancillary Documents; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to the Governing Documents of MAAC, MAAC is required to provide an opportunity for the holders of MAAC Class&nbsp;A Shares
to have their outstanding MAAC Class&nbsp;A Shares redeemed on the terms and subject to the conditions set forth therein in connection with obtaining the MAAC Shareholder Approval; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as of the date of this Agreement, Patient Square Capital LLC, a Delaware limited liability company (the &#147;<U>MAAC
Sponsor</U>&#148;), owns 10,167,956 MAAC Class&nbsp;B Shares and 10,214,365 MAAC Warrants; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution of
this Agreement, the MAAC Sponsor, MAAC and the Company are entering into the sponsor support agreement (the &#147;<U>Sponsor Support Agreement</U>&#148;), pursuant to which (i)&nbsp;the MAAC Sponsor has agreed to, among other things, (a)&nbsp;vote
in favor of this Agreement and the transactions contemplated hereby (including the Merger), (b) subject to, and conditioned upon the occurrence of and effective as of immediately prior to, the Effective Time, waive any adjustment to the conversion
ratio set forth in the Governing Documents of MAAC or any other anti-dilution or similar protection, in each case, with respect to the MAAC Class&nbsp;B Shares (whether resulting from the transactions contemplated by the PIPE Subscription Agreements
or otherwise), and (c)&nbsp;subject to, and conditioned upon the occurrence of and effective as of immediately after, the Effective Time, subject a number Company Post-Closing Common Shares determined pursuant to the Sponsor Support Agreement to
vesting requirements that are tied to the share price of the Company Post-Closing Common Shares following the Effective Time, in each case, on the terms and subject to the conditions set forth in the Sponsor Support Agreement and (ii)&nbsp;the MAAC
Sponsor will, subject to, and conditioned upon the occurrence of and effective as of, the Effective Time, be granted certain registration rights with respect to its Company Post-Closing Common Shares; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, prior to the Closing Date or on the Closing Date prior to the Effective Time&nbsp;and prior to the consummation of the matters
described in the following recital, the Company <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Shares shall be converted and redesignated into Company Voting Common Shares, in accordance with the Company
<FONT STYLE="white-space:nowrap">Bye-Laws,</FONT> on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis (the &#147;<U><FONT STYLE="white-space:nowrap">Non-Voting</FONT> Share Conversion</U>&#148;),
subject to the expiration or termination of any applicable waiting period under the HSR Act with respect to the <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Share Conversion; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date prior to the Effective Time, the Company shall (a)&nbsp;cause
each Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Share to be divided into a number of Company Post-Closing Common Shares equal to the Exchange Ratio and (b)&nbsp;amend and restate the Company
<FONT STYLE="white-space:nowrap">Bye-Laws,</FONT> in each case, on the terms and subject to the terms and conditions set forth in this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution of this Agreement, each of the investors set forth on <U>Annex A</U> hereto (collectively, the
&#147;<U>PIPE Investors</U>&#148;) is entering into a subscription agreement, substantially in the form attached hereto as <U>Exhibit A</U> (collectively, the &#147;<U>PIPE</U><U></U><U>&nbsp;Subscription Agreements</U>&#148;), pursuant to which,
among other things, each PIPE Investor has agreed to subscribe for and purchase on the Closing Date immediately prior to the Effective Time, and MAAC has agreed to issue and sell to each such PIPE Investor on the Closing Date immediately prior to
the Effective Time, the number of MAAC Class&nbsp;A Shares set forth in the applicable PIPE Subscription Agreement in exchange for the purchase price set forth therein (the equity financing under all PIPE Subscription Agreements, collectively, the
&#147;<U>PIPE Financing</U>&#148;), in each case, on the terms and subject to the conditions set forth in the applicable PIPE Subscription Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date, promptly following the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps and at the Effective
Time, Merger Sub will merge with and into MAAC, with MAAC continuing as the surviving corporation in the merger and, after giving effect to such merger, (a)&nbsp;MAAC will be a wholly owned Subsidiary of the Company, (b)&nbsp;each MAAC Class&nbsp;A
Share and each MAAC Class&nbsp;B Share not held by the MAAC Sponsor or its Affiliates, in each case, issued and outstanding as of immediately prior to the Effective Time (including, for the avoidance of doubt, each MAAC Class&nbsp;A Share issued to
the PIPE Investors pursuant to the PIPE Subscription Agreements (but excluding, for the avoidance of doubt, (i)&nbsp;any MAAC Class&nbsp;A Shares and MAAC Class&nbsp;B Shares held by MAAC as treasury stock or by the MAAC Sponsor or its Affiliates
and (ii)&nbsp;any MAAC Class&nbsp;A Shares redeemed in a MAAC Shareholder Redemption)), will be automatically converted as of the Effective Time into one Company Post-Closing Common Share, and (c)&nbsp;each MAAC Class&nbsp;B Share held by the MAAC
Sponsor and its Affiliates issued and outstanding as of immediately prior to the Effective Time will be automatically converted as of the Effective Time into the number of Company Post-Closing Common Shares equal to the Sponsor Exchange Ratio, in
each case, on the terms and subject to the conditions set forth in this Agreement and the applicable Ancillary Documents; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
concurrently with the execution of this Agreement, the Significant Company Shareholders will duly execute and deliver to MAAC and the Company a transaction support agreement, substantially in the form attached hereto as <U>Exhibit B</U>
(collectively, the &#147;<U>Transaction Support Agreements</U>&#148;), pursuant to which, in the case of each such Transaction Support Agreement, each such Significant Company Shareholder will agree to, among other things, (i)&nbsp;be bound by and
subject to certain covenants and agreements related to, or in furtherance of, the transactions contemplated by this Agreement and the Ancillary Documents, including the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps and
(ii)&nbsp;take, or cause to be taken, any actions necessary or advisable to cause certain existing Company agreements to be terminated effective as of the Closing;<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution of this Agreement, the Significant Company
Shareholders are entering into the Third Amended and Restated Registration Rights Agreement, substantially in the form attached hereto as <U>Exhibit C</U> (the &#147;<U>Registration Rights Agreement</U>&#148;), pursuant to which, among other things,
certain Company Shareholders will, subject to, and conditioned upon and effective as of, the Effective Time, be granted certain registration rights with respect to their respective Company Post-Closing Common Shares, in each case, on the terms and
subject to the conditions set forth therein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution of this Agreement, each of the Company, certain
Company Shareholders and the MAAC Sponsor are entering into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, substantially in the form attached hereto as <U>Exhibit D</U> (the &#147;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement</U>&#148;), pursuant to which, among other things, subject to, and conditioned upon and effective as of, the Effective Time, such Company Shareholders and the MAAC Sponsor will agree not to effect any sale or distribution of all or a
portion of, as applicable, the Equity Securities of the Company held by any of them during the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> periods described therein; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the board of directors of MAAC (the &#147;<U>MAAC Board</U>&#148;) has (a)&nbsp;determined that it is in the best interests of MAAC
and its stockholders, and declared it advisable, to enter into this Agreement and the Ancillary Documents to which MAAC is or will be a party and to consummate the transactions contemplated hereby and thereby (including the Merger), (b) approved
this Agreement, the Ancillary Documents to which MAAC is or will be a party and the consummation of the transactions contemplated hereby and thereby (including the Merger) and (c)&nbsp;recommended, among other things, approval and adoption of this
Agreement, the Ancillary Documents to which MAAC is or will be a party and the consummation of the transactions contemplated by hereby or thereby (including the Merger) by the holders of MAAC Shares entitled to vote thereon; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the board of directors of Merger Sub has approved this Agreement, the Ancillary Documents to which Merger Sub is or will be a party
and the transactions contemplated hereby and thereby (including the Merger); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company, as the sole stockholder of Merger Sub,
will as promptly as reasonably practicable (and in any event within one (1)&nbsp;Business Day) following the date of this Agreement, approve and adopt this Agreement, the Ancillary Documents to which Merger Sub is or will be a party and the
transactions contemplated hereby and thereby (including the Merger); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution hereof, the Company is
delivering to MAAC the Company Shareholder Written Consent duly executed by the Significant Company Shareholders; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the board of
directors of the Company (the &#147;<U>Company Board</U>&#148;) has (a)&nbsp;unanimously approved this Agreement, the Ancillary Documents to which the Company is or will be a party and the consummation of the transactions contemplated hereby and
thereby (including the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps and the Merger), (b)&nbsp;recommended, among other things, the entry into this Agreement and the Ancillary Documents to which the Company is or will be a party
and the consummation of the transactions contemplated hereby and thereby (including the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps and the Merger) to the holders of the Company Pre-Closing Common Shares entitled to vote
thereon for their approval and (c)&nbsp;given reasonable advance written notice of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps and the Merger in accordance with the Company <FONT STYLE="white-space:nowrap">Bye-Laws</FONT>
to the Company Shareholders (including the &#147;Lot Large Shareholders&#148; (as defined therein)); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, each of the Parties intends for U.S. federal income tax purposes that (a)&nbsp;this
Agreement constitutes a &#147;plan of reorganization&#148; within the meaning of Section&nbsp;368 of the Code and Treasury Regulations promulgated thereunder, (b)&nbsp;the Merger qualifies as a &#147;reorganization&#148; within the meaning of
Section&nbsp;368(a) of the Code and (c)&nbsp;the exchange of MAAC Class&nbsp;A Shares or MAAC Class&nbsp;B Shares for Company Post-Closing Common Shares pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)(vii)</U>, other than with respect to any <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders who are U.S. persons and who will be &#147;five-percent transferee shareholders&#148; within the meaning of Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.367(a)-3(c)(5)(ii)</FONT> but who do not enter into gain recognition agreements within the meaning of Treasury Regulations Sections <FONT STYLE="white-space:nowrap">1.367(a)-3(c)(1)(iii)(B)</FONT> and <FONT
STYLE="white-space:nowrap">1.367(a)-8,</FONT> qualifies for an exception to Section&nbsp;367(a)(1) of the Code (<U>clauses (a)</U>&nbsp;through <U>(c)</U>, collectively, the &#147;<U>Intended Tax Treatment</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and the mutual promises set forth herein and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN
DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.1 </B><B><U>Definitions</U></B>. As used in this Agreement, the following terms have the
respective meanings set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Additional MAAC SEC Reports</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.7</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Adjusted CVAR Award</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.4(d)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Adjusted Option</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.4(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Adjusted RSU Award</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.4(c)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; means, with respect to any Person, any other Person who directly
or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person; <U>provided</U> that no Public Group Company shall be deemed to be an Affiliate of any Private Group Company for purposes
hereof. The term &#147;<U>control</U>&#148; means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or
otherwise, and the terms &#147;<U>controlled</U>&#148; and &#147;<U>controlling</U>&#148; have meanings correlative thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Aggregate Trust Account Proceeds</U>&#148; means the aggregate cash proceeds that are or would be (assuming that the Closing occurs)
released to MAAC (or any designees thereof) from the Trust Account on the Closing Date in connection with the transactions contemplated hereby (for the avoidance of doubt, (i)&nbsp;after giving effect to the MAAC Shareholder Redemption and
(ii)&nbsp;excluding the proceeds of the PIPE Financing). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Agreement</U>&#148; has the meaning set forth in the introductory paragraph to this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Ancillary Documents</U>&#148; means the Registration Rights Agreement, the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, the Sponsor Support Agreement, the PIPE Subscription Agreements, the Transaction Support Agreements, the Certificate of Merger and each other agreement, document, instrument and/or
certificate contemplated by this Agreement executed or to be executed in connection with the transactions contemplated hereby (including those entered into in connection with the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Anti-Corruption Laws</U>&#148; means, collectively, (a)&nbsp;the U.S. Foreign Corrupt Practices Act of 1977, (b) the UK Bribery
Act 2010 and (c)&nbsp;any other applicable anti-bribery or anti-corruption Laws or Orders related to combatting bribery, corruption and money laundering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Combination Proposal</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Day</U>&#148; means a day, other than a Saturday or Sunday, on which commercial banks in Hamilton, Bermuda, London, England,
New York, New York and San Francisco, California are open for the general transaction of business; <U>provided</U> that banks shall be deemed to be generally open for the general transaction of business in the event of a &#147;shelter in place&#148;
or similar closure of physical branch locations at the direction of any governmental authority if such banks&#146; electronic funds transfer system (including for wire transfers) are open for use by customers on such day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>CBA</U>&#148; means any collective bargaining agreement or other Contract with any labor union, labor organization, or works council.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Certificate of Merger</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1(b)(ii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Certificates</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1(b)(vii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Company Financial Statements</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.4(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Date</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Filing</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.4(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Press Release</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.4(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>COBRA</U>&#148; means Part 6 of Subtitle B of Title I of ERISA, Section&nbsp;4980B of the Code and any similar state Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Code</U>&#148; means the U.S. Internal Revenue Code of 1986. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Companies Act</U>&#148; means the Bermuda Companies Act, 1981. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company</U>&#148; has the meaning set forth in the introductory paragraph to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Acquisition Proposal</U>&#148; means any transaction or series of related
transactions under which any Person(s), directly or indirectly, acquires or otherwise purchases the Company or all or substantially all of the assets, Equity Securities or businesses of the Company and its controlled Affiliates on a consolidated
basis (whether by merger, consolidation, recapitalization, purchase or issuance of Equity Securities, purchase of assets, tender offer or otherwise). Notwithstanding the foregoing or anything to the contrary herein, (i)&nbsp;none of this Agreement,
the Ancillary Documents or the transactions contemplated hereby or thereby shall constitute a Company Acquisition Proposal and (ii)&nbsp;the Company&#146;s or one of its Affiliates&#146; acquisition of Equity Securities of a Public Group Company
that are not already owned by the Company or any issuance of Equity Securities of the Company in connection therewith shall not constitute a Company Acquisition Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Additional Capitalization Representations</U>&#148; means the representations and warranties set forth in the first two
sentences of <U>Section</U><U></U><U>&nbsp;3.2(a)</U> and <U>Section</U><U></U><U>&nbsp;3.2(c)</U> (Capitalization of the Group Companies). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Board</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company <FONT STYLE="white-space:nowrap">Bye-Laws</FONT></U>&#148; means the eighth amended and restated <FONT
STYLE="white-space:nowrap">bye-laws</FONT> of the Company, adopted on June&nbsp;17, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Common Shares</U>&#148; means
(a)&nbsp;prior to the consummation of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares, and (b)&nbsp;from and after the consummation of the Company <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, means the Company Post-Closing Common Shares. Any reference to the Company Common Shares in this Agreement or any Ancillary Document shall be deemed to refer to <U>clause (a)</U>&nbsp;and/or
<U>clause (b)</U>&nbsp;of this definition, as the context so requires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company CVAR Award</U>&#148; means, as of any
determination time, each capped value appreciation right with respect to Company Common Shares that is outstanding and granted under a Company Equity Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company D&amp;O Persons</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.15(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Designee</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.16(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Disclosure Schedules</U>&#148; means the disclosure schedules to this Agreement delivered to MAAC by the Company on the date
of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Equity Award</U>&#148; means, as of any determination time, each Company Option, each Company RSU
Award, each Company Restricted Common Share, each Company CVAR Award and each other award to any current or former director, manager, officer, employee, individual independent contractor or other service provider of any Group Company of rights of
any kind to receive any Equity Security of the Company under any Company Equity Plan or otherwise that is outstanding as of such time of determination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Equity Plan</U>&#148; means each of (a)&nbsp;the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan,
(b)&nbsp;the Roivant Sciences Ltd. Amended and Restated 2015 Restricted Stock Unit Plan and (c)&nbsp;each other plan that provides for the award to any current or former director, manager, officer, employee, individual independent contractor or
other service provider of any Group Company of rights of any kind to receive Equity Securities of the Company or benefits measured in whole or in part by reference to Equity Securities of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Equityholders</U>&#148; means, collectively, the Company Shareholders and
the holders of Company Equity Awards as of any determination time prior to the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Expenses</U>&#148; means,
as of any determination time and without duplication, the aggregate amount of fees, expenses, costs, disbursements, commissions or other amounts incurred by or on behalf of, and that are due and payable by (and not otherwise expressly allocated to
MAAC pursuant to the terms of this Agreement or any Ancillary Document) any Group Company in connection with the negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance of its covenants or agreements in
this Agreement or any Ancillary Document or the consummation of the transactions contemplated hereby or thereby, including (a)&nbsp;the fees and expenses of outside legal counsel, accountants, advisors, brokers, placement agents, investment bankers,
consultants, or other agents or service providers of any Group Company, (b)&nbsp;any other fees, expenses, commissions or other amounts that are expressly allocated to any Group Company pursuant to this Agreement or any Ancillary Document and
(c)&nbsp;fifty percent (50%) of the expenses incurred in connection with the filing of the Registration Statement / Proxy Statement with the SEC and the printing and mailing of the Registration Statement / Proxy Statement to holders of MAAC Shares.
Notwithstanding the foregoing or anything to the contrary herein, Company Expenses shall not include any MAAC Expenses or any fees, expenses, commissions or other amounts that are expressly contemplated to be allocated to and paid by MAAC pursuant
to this Agreement or any Ancillary Document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Financial Statements</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.4(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Fundamental Representations</U>&#148; means the representations and warranties
set forth in <U>Section</U><U></U><U>&nbsp;3.1(a)</U> and <U>Section</U><U></U><U>&nbsp;3.1(b)</U> (Organization and Qualification), <U>Section</U><U></U><U>&nbsp;3.2(a)</U> and <U>Section</U><U></U><U>&nbsp;3.2(d)</U> (Capitalization of the Group
Companies), <U>Section</U><U></U><U>&nbsp;3.3</U>&nbsp;(Authority), <U>Section</U><U></U><U>&nbsp;3.8(a)</U> (No Company Material Adverse Effect) and <U>Section</U><U></U><U>&nbsp;3.18</U> (Brokers). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company IT Systems</U>&#148; means all computer systems, Software and hardware, communication systems, servers, network equipment and
related documentation, in each case, owned, licensed or leased by a Private Group Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Licensed Intellectual
Property</U>&#148; means Intellectual Property Rights owned by any Person (other than a Group Company) that are licensed to any Group Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Material Adverse Effect</U>&#148; means any change, event, development, effect or occurrence that, individually or in the
aggregate with any other change, event, development, effect or occurrence, has had or would reasonably be expected to have a material adverse effect on (a)&nbsp;the business, results of operations, assets or financial condition of the Group
Companies, taken as a whole, or (b)&nbsp;the ability of the Company or Merger Sub to consummate the transactions contemplated by this Agreement to occur on the Closing Date (including the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT>
Steps and the Merger); <U>provided</U>, <U>however</U>, that, in the case of <U>clause (a)</U>, none of the following </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall be taken into account in determining whether a Company Material Adverse Effect has occurred or is reasonably likely to occur: any adverse change, event, development, effect or occurrence
arising after the date of this Agreement from or related to (i)&nbsp;general business or economic conditions in or affecting the United States, or changes therein, or the global economy generally, (ii)&nbsp;any national or international political or
social conditions in the United States or any other country, including the engagement by the United States or any other country in hostilities, whether or not pursuant to the declaration of a national emergency or war, or the occurrence in any place
of any military or terrorist attack, sabotage or cyberterrorism, (iii)&nbsp;changes in conditions of the financial, banking, capital or securities markets generally in the United States or any other country or region in the world, or changes
therein, including changes in interest rates in the United States or any other country and changes in exchange rates for the currencies of any countries, (iv)&nbsp;changes in any applicable Laws, (v)&nbsp;any change, event, development, effect or
occurrence that is generally applicable to the industries or markets in which any Group Company operates, (vi)&nbsp;the execution or public announcement of this Agreement or the pendency or consummation of the transactions contemplated by this
Agreement, including the impact thereof on the relationships, contractual or otherwise, of any Group Company with employees, customers, investors, contractors, lenders, suppliers, vendors, partners, licensors, licensees, payors or other third
parties related thereto (<U>provided</U> that the exception in this <U>clause</U><U></U><U>&nbsp;(vi)</U> shall not apply to the representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;3.5(b)</U> to the extent that its purpose is
to address the consequences resulting from the public announcement or pendency or consummation of the transactions contemplated by this Agreement or the condition set forth in <U>Section</U><U></U><U>&nbsp;6.2(a)</U> to the extent it relates to such
representations and warranties), (vii) any failure by any Group Company to meet, or changes to, any internal or published budgets, projections, forecasts, estimates or predictions (although the underlying facts and circumstances resulting in such
failure may be taken into account to the extent not otherwise excluded from this definition), (viii) any hurricane, tornado, flood, earthquake, tsunami, natural disaster, mudslides, wild fires, epidemics, pandemics (including <FONT
STYLE="white-space:nowrap">COVID-19)</FONT> or quarantines, acts of God or other natural disasters or comparable events in the United States or any other country or region in the world, or any escalation of the foregoing, or (ix)&nbsp;any
regulatory, preclinical, clinical, pricing or reimbursement changes, effects, developments or occurrences arising after the date hereof and relating to or affecting any Company Product (including (A)&nbsp;any suspension, rejection, refusal of,
request to refile or any delay in obtaining or making any regulatory application or filing relating to any Company Product, (B)&nbsp;any negative regulatory actions, requests, recommendations or decisions of any Governmental Entity relating to any
Company Product or the manufacture thereof, or any other regulatory or preclinical or clinical development relating to any Company Product, (C)&nbsp;any preclinical or clinical studies, trials, tests, results or adverse events, or announcements of
any of the foregoing, with respect to any Company Product, (D)&nbsp;any delay, hold or termination of any preclinical or clinical study, trial or test or any delay, hold or termination of any planned application for investigational new drug
application or application for marketing approval with respect to any Company Product, (E)&nbsp;any preclinical or clinical studies, trials, tests, results or adverse events, or announcements of any of the foregoing, with respect to any product or
product candidate competitive with or related to any Company Product, (F)&nbsp;FDA approval (or other preclinical or clinical or regulatory developments), market entry or threatened market entry of any product or product candidate competitive with
or related to any Company Product or (G)&nbsp;any recommendations, statements, decisions or other pronouncements made, published or proposed by professional medical organizations, payors, Governmental Entities or representatives of the foregoing, or
any panel or advisory body </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
empowered or appointed thereby, relating to any Company Product or any products or product candidates of any competitors of the Company), in each case, as applicable and solely to the extent not
resulting from or arising out of any fraud or intentional and material violation of any applicable Public Health Law or Order by any Group Company; <U>provided</U>, <U>however</U>, that (A)&nbsp;any change, event, development, effect or occurrence
resulting from a matter described in any of the foregoing <U>clauses</U><U></U><U>&nbsp;(i)</U> through <U>(v)</U>&nbsp;may be taken into account in determining whether a Company Material Adverse Effect has occurred or is reasonably likely to occur
to the extent such change, event, development, effect or occurrence has or has had a disproportionate adverse effect on the Group Companies, taken as a whole, relative to other participants operating in the industries or markets in which the Group
Companies operate and (B)&nbsp;in no event shall (x)&nbsp;any change, event, development, effect or occurrence to the extent relating to MAAC, (y)&nbsp;any MAAC Shareholder Redemption, in and of itself, or (z)&nbsp;any failure, in and of itself, by
a PIPE Investor to fulfill its obligations under a PIPE Subscription Agreement constitute a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates</U>&#148; means, collectively, each Company Related Party and
each former, current or future Affiliate, Representative, equityholder, successor, heir or permitted assign of any Company Related Party (other than, for the avoidance of doubt, the Company). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Shares</U>&#148; means
<FONT STYLE="white-space:nowrap">non-voting</FONT> common shares, par value $0.0000001 per share, of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company
Option</U>&#148; means, as of any determination time, each option to purchase Company Common Shares (including, for the avoidance of doubt, each option subject to any performance-based or liquidity-based vesting conditions) that is outstanding and
unexercised and granted under a Company Equity Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Owned Intellectual Property</U>&#148; means all Intellectual
Property Rights that are owned by any of the Group Companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Post-Closing
<FONT STYLE="white-space:nowrap">Bye-Laws</FONT></U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Post-Closing Common Shares</U>&#148; means common shares of the Company, with a par value equal to the par value of the
Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares<I> divided by</I> the Exchange Ratio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company
Post-Closing Employee Stock Purchase Plan</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.18</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company
Post-Closing Incentive Equity Plan</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.18</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares</U>&#148; means, collectively, the Company <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Shares and the Company Voting Common Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.1(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Product</U>&#148; means each product candidate, product or platform that is
being or has been researched, tested, developed, manufactured, distributed, sold, promoted, advertised or marketed by or on behalf of the Group Companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Registered Intellectual Property</U>&#148; means all Registered
Intellectual Property owned or purported to be owned by any Group Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Related Party</U>&#148; has the meaning set
forth in <U>Section</U><U></U><U>&nbsp;3.20</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Related Party Transactions</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.20</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Restricted Common Shares</U>&#148; means restricted Company Common Shares
outstanding and granted under a Company Equity Plan or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company RSU Award</U>&#148; means, as of any determination
time, each restricted stock unit award with respect to Company Common Shares outstanding and granted under a Company Equity Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Shareholder Written Consent</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.13</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Shareholders</U>&#148; means, collectively, the holders of Company Common Shares as of any determination time prior to the
Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Shareholders Agreements</U>&#148; means, collectively, (a)&nbsp;the Sixth Amended and Restated
Shareholders Agreement, dated June&nbsp;17, 2020, by and among the Company and the Company Shareholders party thereto, (b)&nbsp;the Second Amended and Restated Registration Rights Agreement, dated September&nbsp;6, 2017, by and among the Company and
the Company Shareholders party thereto, and (c)&nbsp;the Agreement Regarding 2018 Equity Raise, dated as of September&nbsp;26, 2018, by and among the Company and the Company Shareholders party thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Voting Common Shares</U>&#148; means common shares, par value $0.0000001 per share, of the Company (including, for the
avoidance of doubt, the Company Restricted Common Shares). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Warrant</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.1(b)(viii)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Confidentiality Agreement</U>&#148; means that certain Nondisclosure Agreement,
dated October&nbsp;26, 2020, between Roivant Sciences, Inc. and MAAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Consent</U>&#148; means any notice, authorization,
qualification, registration, filing, notification, waiver, order, consent, grant, clearance, permission or approval to be obtained from, filed with or delivered to, a Governmental Entity or other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Contract</U>&#148; or &#147;<U>Contracts</U>&#148; means any agreement, contract, license, lease, obligation, undertaking or other
commitment or arrangement that is legally binding upon a Person or any of his, her or its properties or assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Copyrights</U>&#148; has the meaning set forth in the definition of Intellectual Property Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">COVID-19</FONT></U>&#148; means
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> or <FONT STYLE="white-space:nowrap">COVID-19</FONT> and any evolutions thereof or related or associated epidemics, pandemics or disease outbreaks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Datavant</U>&#148; has the meaning set forth in the definition of
&#147;Subsidiary.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Designated Individuals</U>&#148; means the individuals listed on <U>Section</U><U></U><U>&nbsp;1.1</U>
of the Company Disclosure Schedules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>DGCL</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disclosed Subscription Agreements</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.20</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Effective Time</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1(b)(ii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Employee Benefit Plan</U>&#148; means each &#147;<U>employee benefit plan</U>&#148; (as such term is defined in Section&nbsp;3(3) of
ERISA, whether or not subject to ERISA), each equity or equity-based, deferred compensation, severance, retention, bonus, incentive, retirement, retiree or post-employment welfare, vacation, and other benefit or compensatory plan, program, policy or
Contract that any Private Group Company maintains, sponsors or contributes to, or under or with respect to which any Private Group Company has any Liability, other than (i)&nbsp;any plan, program, policy or Contract sponsored, maintained or entered
into by a Public Group Company or (ii)&nbsp;any plan sponsored or maintained by a Governmental Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Environmental
Laws</U>&#148; means all Laws and Orders concerning pollution, protection of the environment, or human health or safety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Equity
Securities</U>&#148; means any share, share capital, capital stock, partnership, membership, joint venture or similar interest in any Person (including any stock appreciation, phantom stock, profit participation or similar rights), and any option,
warrant, right or security (including debt securities) convertible, exchangeable or exercisable therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>ERISA</U>&#148; means
the Employee Retirement Income Security Act of 1974. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Ex-Im</FONT> Laws</U>&#148; means all
applicable Laws and Orders relating to export, <FONT STYLE="white-space:nowrap">re-export,</FONT> transfer and import controls, including the U.S. Export Administration Regulations, the International Traffic in Arms Regulations, and Laws
administered by the U.S. Customs and Border Protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Ratio</U>&#148; means 2.9262. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDA</U>&#148; means the U.S. Food and Drug Administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Federal Securities Laws</U>&#148; means the Exchange Act, the Securities Act and the other U.S. federal securities laws and the rules
and regulations of the SEC promulgated thereunder or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Foreign and Domestic Approval Laws</U>&#148; has the meaning set
forth in <U>Section</U><U></U><U>&nbsp;3.5(a)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Foreign Benefit Plan</U>&#148; means each Employee Benefit Plan maintained by any
of the Private Group Companies for its current or former employees, officers, directors or other individual service providers located outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fraud</U>&#148; means an act or omission by a Party, and requires: (a)&nbsp;a false or incorrect representation or warranty expressly
made by such Party in this Agreement, (b)&nbsp;with actual knowledge (as opposed to constructive, imputed or implied knowledge) by the Party making such representation or warranty that such representation or warranty expressly set forth in this
Agreement is false or incorrect, (c)&nbsp;an intention to deceive another Party to induce it to enter into this Agreement, (d)&nbsp;another Party, in justifiable or reasonable reliance upon such false or incorrect representation or warranty
expressly set forth in this Agreement, entering into this Agreement, and (e)&nbsp;another Party suffering damage by reason of such reliance. For the avoidance of doubt, &#147;Fraud&#148; does not include any equitable fraud, promissory fraud, unfair
dealings fraud or any torts (including a claim for fraud or alleged fraud) based on negligence or recklessness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148;
means United States generally accepted accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Governing Documents</U>&#148; means the legal document(s) by which
any Person (other than an individual) establishes its legal existence or which govern its internal affairs. For example, the &#147;Governing Documents&#148; of a U.S. corporation are its certificate or articles of incorporation and <FONT
STYLE="white-space:nowrap">by-laws,</FONT> the &#147;Governing Documents&#148; of a U.S. limited partnership are its limited partnership agreement and certificate of limited partnership, the &#147;Governing Documents&#148; of a U.S. limited
liability company are its operating or limited liability company agreement and certificate of formation and the &#147;Governing Documents&#148; of a Bermuda exempted company are its certificate of incorporation, memorandum of association and <FONT
STYLE="white-space:nowrap">bye-laws.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Governmental Entity</U>&#148; means any United States or <FONT
STYLE="white-space:nowrap">non-United</FONT> States (a)&nbsp;federal, state, local, municipal or other government, (b)&nbsp;governmental or quasi-governmental entity of any nature (including any governmental agency, branch, department, official, or
entity and any court or other tribunal) or (c)&nbsp;body exercising or entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature, including any arbitrator or arbitral
tribunal (public or private). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Group Companies</U>&#148; means, collectively, the Company and each of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Hazardous Substance</U>&#148; means any hazardous, toxic, explosive or radioactive material, substance or waste that is regulated by,
or may give rise to standards of conduct or Liability pursuant to, any Environmental Law, including any petroleum products or byproducts, asbestos, lead, polychlorinated biphenyls, <FONT STYLE="white-space:nowrap">per-</FONT> and poly-fluoroalkyl
substances, or radon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>HSR Act</U>&#148; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and
regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Incentive Stock Option</U>&#148; means a Company Option intended to be an &#147;incentive
stock option&#148; (as defined in Section&nbsp;422 of the Code). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property Rights</U>&#148; means all intellectual property rights
created or arising under the Laws of the United States or any other jurisdiction or under any international convention, including all (a)&nbsp;patents and patent applications, industrial designs and design patent rights, including any continuations,
divisionals, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part</FONT></FONT> and provisional applications and statutory invention registrations, and any patents issuing on any of the foregoing and any reissues,
reexaminations, substitutes, supplementary protection certificates, extensions of any of the foregoing (collectively, &#147;<U>Patents</U>&#148;); (b)&nbsp;trademarks, service marks, trade names, service names, brand names, trade dress rights,
logos, Internet domain names, corporate names and other source or business identifiers, together with the goodwill associated with any of the foregoing, and all applications, registrations, extensions and renewals of any of the foregoing
(collectively, &#147;<U>Marks</U>&#148;); (c) copyrights and works of authorship, database and design rights, mask work rights and moral rights, whether or not registered or published, and all registrations, applications, renewals, extensions and
reversions of any of the foregoing (collectively, &#147;<U>Copyrights</U>&#148;); (d) trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and confidential proprietary information, including inventions and formulae, whether patentable or
not; (e)&nbsp;intellectual property rights in or to Software; and (f)&nbsp;any other intellectual property or proprietary rights protectable or arising under any Law anywhere in the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intended Tax Treatment</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Investment Company Act</U>&#148; means the Investment Company Act of 1940. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>IPO</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.18</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>JOBS Act</U>&#148; means the Jumpstart Our Business Startups Act of 2012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Latest Balance Sheet</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.4(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Law</U>&#148; means any federal, state, local, foreign, national or supranational statute, law (including common law), act, statute,
ordinance, treaty, rule, code, Order, regulation or other legally binding directive or guidance issued, promulgated or enforced by a Governmental Entity having jurisdiction over a given matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Leased Real Property</U>&#148; has the meaning set forth in the definition of &#147;Real Property Leases.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Liability</U>&#148; or &#147;<U>liability</U>&#148; means any and all debts, liabilities and obligations, whether accrued or fixed,
absolute or contingent, known or unknown, matured or unmatured or determined or determinable, including those arising under any Law (including any Environmental Law), Proceeding or Order and those arising under any Contract, agreement, arrangement,
commitment or undertaking. Notwithstanding the foregoing or anything to the contrary herein, Liability shall not include any Company Expenses or MAAC Expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Lien</U>&#148; means any mortgage, pledge, security interest, encumbrance, lien, license or
<FONT STYLE="white-space:nowrap">sub-license,</FONT> charge, or other similar encumbrance or interest (including, in the case of any Equity Securities, any voting, transfer or similar restrictions). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC</U>&#148; has the meaning set forth in the introductory paragraph to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Acquisition Proposal</U>&#148; means any transaction or series of related
transactions constituting a &#147;Business Combination&#148; (as defined in MAAC&#146;s Governing Documents). Notwithstanding the foregoing or anything to the contrary herein, none of this Agreement, the Ancillary Documents or the transactions
contemplated hereby or thereby shall constitute a MAAC Acquisition Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Board</U>&#148; has the meaning set forth in
the recitals to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Board Recommendation</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;5.8</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Class</U><U></U><U>&nbsp;A Shares</U>&#148; means shares of Class&nbsp;A common
stock, par value $0.0001 per share, of MAAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Class</U><U></U><U>&nbsp;B Shares</U>&#148; means shares of Class&nbsp;B
common stock, par value $0.0001 per share, of MAAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC D&amp;O Persons</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;5.14(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Designee</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;5.16(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Disclosure Schedules</U>&#148; means the disclosure schedules to this Agreement
delivered to the Company by MAAC on the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Expenses</U>&#148; means, as of any determination time and
without duplication, the aggregate amount of fees, expenses, costs, disbursements, commissions or other amounts incurred by or on behalf of, and that are due and payable by (and not otherwise expressly allocated to the Company or any Company
Equityholder pursuant to the terms of this Agreement or any Ancillary Document) MAAC in connection with the negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance of its covenants or agreements in this
Agreement or any Ancillary Document or the consummation of the transactions contemplated hereby or thereby, including (a)&nbsp;the fees and expenses of outside legal counsel, accountants, advisors, brokers, placement agents, investment bankers,
consultants, or other agents or service providers of MAAC (including with respect to the PIPE Financing), (b)&nbsp;any other fees, expenses, commissions or other amounts that are expressly allocated to MAAC pursuant to this Agreement or any
Ancillary Document and (c)&nbsp;fifty percent (50%) of the expenses incurred in connection with the filing of the Registration Statement / Proxy Statement with the SEC and the printing and mailing of the Registration Statement / Proxy Statement to
holders of MAAC Shares. Notwithstanding the foregoing or anything to the contrary herein, MAAC Expenses shall not include any Company Expenses or any fees, expenses, commissions or other amounts that are expressly contemplated to be allocated to and
paid by the Company, Merger Sub or any Company Equityholder pursuant to this Agreement or any Ancillary Document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Financial
Statements</U>&#148; means all of the financial statements of MAAC included in the MAAC SEC Reports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Fundamental
Representations</U>&#148; means the representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;4.1</U> (Organization and Qualification), <U>Section</U><U></U><U>&nbsp;4.2</U> (Authority), <U>Section</U><U></U><U>&nbsp;4.4</U>
(Brokers), <U>Section</U><U></U><U>&nbsp;4.6</U> (Capitalization of MAAC), <U>Section</U><U></U><U>&nbsp;4.8</U> (Trust Account) and <U>Section</U><U></U><U>&nbsp;4.9</U> (No MAAC Material Adverse Effect). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Material Adverse Effect</U>&#148; means any change, event, development, effect
or occurrence that, individually or in the aggregate with any other change, event, development, effect or occurrence, has had or would reasonably be expected to have a material adverse effect on (a)&nbsp;the business, results of operations, assets
or financial condition of MAAC, taken as a whole, or (b)&nbsp;the ability of MAAC to consummate the transactions contemplated by this Agreement to occur on the Closing Date (including the Merger); <U>provided</U>, <U>however</U>, that, in the case
of <U>clause (a)</U>, none of the following shall be taken into account in determining whether a MAAC Material Adverse Effect has occurred or is reasonably likely to occur: any adverse change, event, development, effect or occurrence arising after
the date of this Agreement from or related to (i)&nbsp;general business or economic conditions in or affecting the United States, or changes therein, or the global economy generally, (ii)&nbsp;any national or international political or social
conditions in the United States or any other country, including the engagement by the United States or any other country in hostilities, whether or not pursuant to the declaration of a national emergency or war, or the occurrence in any place of any
military or terrorist attack, sabotage or cyberterrorism, (iii)&nbsp;changes in conditions of the financial, banking, capital or securities markets generally in the United States or any other country or region in the world, or changes therein,
including changes in interest rates in the United States or any other country and changes in exchange rates for the currencies of any countries, (iv)&nbsp;changes in any applicable Laws, (v)&nbsp;any change, event, development, effect or occurrence
that is generally applicable to the industries or markets in which MAAC operates, (vi)&nbsp;the execution or public announcement of this Agreement or the pendency or consummation of the transactions contemplated by this Agreement, including the
impact thereof on the relationships, contractual or otherwise, of MAAC with investors, contractors, lenders, suppliers, vendors, partners, licensors, licensees, payors or other third parties related thereto (<U>provided</U> that the exception in
this <U>clause</U><U></U><U>&nbsp;(vi)</U> shall not apply to the representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;4.3(b)</U> to the extent that its purpose is to address the consequences resulting from the public
announcement or pendency or consummation of the transactions contemplated by this Agreement or the condition set forth in <U>Section</U><U></U><U>&nbsp;6.3(a)</U> to the extent it relates to such representations and warranties), (vii) any failure by
MAAC to meet, or changes to, any internal or published budgets, projections, forecasts, estimates or predictions (although the underlying facts and circumstances resulting in such failure may be taken into account to the extent not otherwise
excluded from this definition), (viii) any hurricane, tornado, flood, earthquake, tsunami, natural disaster, mudslides, wild fires, epidemics, pandemics (including <FONT STYLE="white-space:nowrap">COVID-19)</FONT> or quarantines, acts of God or
other natural disasters or comparable events in the United States or any other country or region in the world, or any escalation of the foregoing or (ix)&nbsp;any change, event, development, effect or occurrence that is generally applicable to
&#147;SPACs&#148;; <U>provided</U>, <U>however</U>, that (A)&nbsp;any change, event, development, effect or occurrence resulting from a matter described in any of the foregoing <U>clauses</U><U></U><U>&nbsp;(i)</U> through <U>(v)</U>&nbsp;or
<U>clause (ix)</U>&nbsp;may be taken into account in determining whether a MAAC Material Adverse Effect has occurred or is reasonably likely to occur to the extent such change, event, development, effect or occurrence has or has had a
disproportionate adverse effect on MAAC relative to other &#147;SPACs,&#148; and (B)&nbsp;in no event shall (x)&nbsp;any change, event, development, effect or occurrence to the extent relating to any of the Group Companies, (y)&nbsp;any MAAC
Shareholder Redemption, in and of itself, or (z)&nbsp;any failure, in and of itself, by a PIPE Investor to fulfill its obligations under a PIPE Subscription Agreement constitute a MAAC Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates</U>&#148; means,
collectively, MAAC, the MAAC Sponsor and each of their respective former, current or future Affiliates and Representatives and any former, current or future equityholders, successors, heirs or permitted assigns of any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Related Party</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.11</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Related Party Transactions</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.11</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC SEC Reports</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.7</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Shareholder Approval</U>&#148; means, collectively, the Required MAAC Shareholder Approval and the Other MAAC Shareholder
Approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Shareholder Redemption</U>&#148; means the right of the holders of MAAC Class&nbsp;A Shares to redeem all or a
portion of their MAAC Class&nbsp;A Shares (in connection with the transactions contemplated by this Agreement or otherwise) as set forth in Governing Documents of MAAC, which shall be effected solely out of the Trust Account. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Shareholders Meeting</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Shares</U>&#148; means, collectively, the MAAC Class&nbsp;A Shares and the MAAC Class&nbsp;B Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Sponsor</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Sponsor Consent</U>&#148; means that certain letter agreement, dated as of the date hereof, by and between MAAC and the MAAC
Sponsor, pursuant to which the MAAC Sponsor consented to the entry by MAAC into this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Sponsor Specified
Provisions</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Warrant Agreement</U>&#148; means
the Warrant Agreement, dated as of October&nbsp;6, 2020, by and between MAAC and the Continental Stock Transfer&nbsp;&amp; Trust Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Warrants</U>&#148; means each warrant (or fraction of a warrant) to purchase one MAAC Class&nbsp;A Share at an exercise price of
$11.50 per share, subject to adjustment in accordance with the MAAC Warrant Agreement (including, for the avoidance of doubt, each such warrant held by the MAAC Sponsor). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Marks</U>&#148; has the meaning set forth in the definition of Intellectual Property Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Material Contracts</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.7(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Material Permits</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.6</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Sub</U>&#148; has the meaning set forth in the introductory paragraph to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Sub Shareholder Approval</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;5.9</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Sub Shareholder Approval Deadline</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;5.9</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Multiemployer Plan</U>&#148; has the meaning set forth in Section (3)37 or
Section&nbsp;4001(a)(3) of ERISA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Nasdaq</U>&#148; means the Nasdaq Capital Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Nasdaq Proposal</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;8.13</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Non-Voting</FONT> Share Conversion</U>&#148; has the
meaning set forth in the recitals to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Order</U>&#148; means any outstanding writ, order, judgment, injunction,
decision, determination, award, ruling, subpoena, verdict or decree entered, issued or rendered by any Governmental Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Other MAAC Shareholder Approval</U>&#148; means the approval of each Other Transaction Proposal by the affirmative vote of the
holders of the requisite number of MAAC Shares entitled to vote thereon, whether in person or by proxy at the MAAC Shareholders Meeting (or any adjournment or postponement thereof), in accordance with the Governing Documents of MAAC and applicable
Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Other Transaction Proposal</U>&#148; means each Transaction Proposal, other than the Required Transaction Proposals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parties</U>&#148; has the meaning set forth in the introductory paragraph to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Patents</U>&#148; has the meaning set forth in the definition of Intellectual Property Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>PCAOB</U>&#148; means the Public Company Accounting Oversight Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permits</U>&#148; means any approvals, authorizations, clearances, consents, exemptions, licenses, qualifications, registrations,
permits or certificates of a Governmental Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Liens</U>&#148; means (a)&nbsp;mechanic&#146;s, materialmen&#146;s,
carriers&#146;, repairers&#146; and other similar statutory Liens arising or incurred in the ordinary course of business for amounts that are not yet due and payable or are being contested in good faith by appropriate proceedings and for which
sufficient reserves have been established in accordance with GAAP; (b)&nbsp;Liens for Taxes, assessments or other governmental charges not yet due and payable as of the Closing Date or which are being contested in good faith by appropriate
proceedings and for which sufficient reserves have been established in accordance with GAAP; (c)&nbsp;encumbrances and restrictions on real property (including easements, covenants, conditions, rights of way and similar restrictions) that do not
prohibit or materially interfere with any of the Group Companies&#146; use or occupancy of such real property; (d)&nbsp;zoning, building codes and other land use Laws regulating the use or occupancy of real property or the activities conducted
thereon which are imposed by any Governmental Entity having jurisdiction over such real property and which are not violated by the current use or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
occupancy of such real property or the operation of the businesses of the Group Company and do not prohibit or materially interfere with any of the Group Companies&#146; use or occupancy of such
real property; (e)&nbsp;cash deposits or cash pledges to secure the payment of workers&#146; compensation, unemployment insurance, social security benefits or obligations arising under similar Laws or to secure the performance of public or statutory
obligations, surety or appeal bonds, and other obligations of a like nature, in each case in the ordinary course of business and which are not yet due and payable; (f)&nbsp;grants by any Group Company of
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> rights in Intellectual Property Rights in the ordinary course of business; (g)&nbsp;Liens arising under the Governing Documents of the Group Companies or the Company Shareholders Agreements;
(h)&nbsp;Liens in favor of any Group Company and (i)&nbsp;other Liens that do not materially and adversely affect the value, use or operation of the asset subject thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means an individual, partnership, corporation, limited liability company, joint stock company, unincorporated
organization or association, trust, joint venture or other similar entity (including a Governmental Entity), whether or not a legal entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Personal Data</U>&#148; means any data or information that (a)&nbsp;can, alone or when combined with other information, identify a
natural person, or (b)&nbsp;is otherwise considered &#147;personally identifiable information,&#148; &#147;personal information,&#148; or &#147;personal data&#148; as those terms are defined under applicable Laws relating to data privacy or data
protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>PIPE Financing</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>PIPE Investors</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>PIPE Subscription Agreements</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders</U>&#148; means the holders of MAAC Shares as of any
determination time prior to the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Privacy and Data Security Policies</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.21(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Privacy and Security Requirements</U>&#148; means any of the following to the extent
relating to the collection, processing, use, protection, security, transfer, distribution, or disposition of Personal Data or otherwise relating to data-related notifications: (a)&nbsp;all applicable Laws; (b)&nbsp;each Private Group Company&#146;s
own external-facing privacy policies; (c)&nbsp;any other industry standard to which any Private Group Company is bound; and (d)&nbsp;applicable provisions of Contracts to which any Private Group Company is a party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Private Group Companies</U>&#148; means, collectively, the Company and its Subsidiaries, other than the Public Group Companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Proceeding</U>&#148; means any lawsuit, litigation, action, audit, examination or investigation, claim, complaint (including a <I>qui
tam</I> complaint), charge, subpoena, civil investigative demand, inquiry, proceeding, suit or arbitration (in each case, whether civil, criminal or administrative and whether public or private) pending by or before or otherwise involving or on
behalf of any Governmental Entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Process</U>&#148; (or &#147;<U>Processing</U>&#148; or
&#147;<U>Processes</U>&#148;) means the collection, use, storage, processing, recording, distribution, transfer, import, export, protection (including security measures), disposal or disclosure or other activity regarding data (whether
electronically or in any other form or medium). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Prospectus</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;8.18(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Group Companies</U>&#148; means, collectively, each Subsidiary of the Company
whose common stock (or similar Equity Securities) is listed on a U.S. national securities exchange and each of their respective Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Group Company SEC Reports</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.26(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Health Laws</U>&#148; means all applicable Laws relating to the research, development,
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> testing, clinical testing, manufacture, production, analysis, distribution, importation, exportation, use, handling, quality, sale or promotion of any drug, biological product or medical device
(including any ingredient or component of the foregoing products), including (a)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167; 301 <I>et seq</I>.), (b) the Public Health Service Act (42 U.S.C. &#167; 201 et seq.), and the
regulations administered, issued, or promulgated by FDA thereunder, (c)&nbsp;the Medicare statute (Title XVIII of the Social Security Act), the Medicaid statute (Title XIX of the Social Security Act), and any other foreign, federal, and state Laws
relating to governmental healthcare programs, (d)&nbsp;foreign, federal, and state criminal or civil healthcare Laws related to fraud and abuse, false claims and anti-kickback Laws (including the federal Anti-Kickback Statute (42 U.S.C. &#167;1320a-
7(b)), the civil False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the criminal False Claims Law (42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;1320a-7b(a)),</FONT> criminal Laws relating to healthcare fraud and abuse, including 18 U.S.C.
&#167;&#167; 286, 287 and 1001, Physician Payment Sunshine Act (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7h),</FONT> the exclusion laws (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7),</FONT> and the civil monetary
penalties law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a)),</FONT> (e) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, (f) the Health Insurance
Portability and Accountability Act of 1996 (&#147;<U>HIPAA</U>&#148;) (42 U.S.C. &#167;1320d et seq.), as amended by the Health Information and Technology for Economic and Clinical Health Act of 2009, and any comparable foreign and state Laws
related to privacy, data protection and information security, and (g)&nbsp;each similar applicable federal, state or foreign Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Software</U>&#148; means any Software that contains, includes or incorporates any Software that is distributed as free
software, open source software (<I>e.g.</I>, Linux) or similar licensing or distribution models, including under any terms or conditions that impose any requirement that any Software using, linked with, incorporating, distributed with or derived
from such Public Software (a)&nbsp;be made available or distributed in source code form, (b)&nbsp;be licensed for purposes of making derivative works, or (c)&nbsp;be redistributable at no, or a nominal, charge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Real Property Leases</U>&#148; means all leases, <FONT STYLE="white-space:nowrap">sub-leases,</FONT> licenses, concessions or other
agreements, in each case, pursuant to which any Private Group Company leases, <FONT STYLE="white-space:nowrap">sub-leases</FONT> or otherwise occupies any real property leased, subleased, licensed, or similarly used or occupied by any of the Private
Group Companies (the &#147;<U>Leased Real Property</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registered Intellectual Property</U>&#148; means all issued Patents, pending Patent
applications, registered Marks, pending applications for registration of Marks, registered Copyrights, pending applications for registration of Copyrights and Internet domain name registrations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registration Rights Agreement</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registration Statement / Proxy Statement</U>&#148; means a registration statement of the Company on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> relating to the transactions contemplated by this Agreement and the Ancillary Documents and containing a prospectus of the Company to be used as a proxy statement of MAAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Representatives</U>&#148; means, with respect to any Person, such Person&#146;s Affiliates and its and such Affiliates&#146;
respective directors, officers, employees, accountants, consultants, advisors, attorneys, agents and other representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Required MAAC Shareholder Approval</U>&#148; means the approval of each Required Transaction Proposal by the affirmative vote of the
holders of the requisite number of MAAC Shares entitled to vote thereon, whether in person or by proxy at the MAAC Shareholders Meeting (or any adjournment or postponement thereof), in accordance with the Governing Documents of MAAC and applicable
Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Required Transaction Proposals</U>&#148; means, collectively, the Business Combination Proposal and the Nasdaq Proposal.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sanctioned Person</U>&#148; means a Person (a)&nbsp;named on any Sanctions- or <FONT STYLE="white-space:nowrap">Ex-Im</FONT>
Laws-related list of designated or blocked Persons maintained by a Governmental Entity, (b)&nbsp;located, organized or resident in a country or territory which is itself the subject of or target of any comprehensive Sanctions (at the time of this
Agreement, the Crimea region of Ukraine, Cuba, Iran, North Korea, and Syria), or (c)&nbsp;an entity owned, directly or indirectly, or controlled by one or more of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sanctions</U>&#148; means any Law or Order imposing or relating to economic sanctions administered by the Office of Foreign Assets
Control of the U.S. Department of the Treasury, the U.S. Department of State, the European Union, any European Union Member State, the United Nations, or Her Majesty&#146;s Treasury of the United Kingdom. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sarbanes-Oxley Act</U>&#148; means the Sarbanes-Oxley Act of 2002. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Schedules</U>&#148; means, collectively, the Company Disclosure Schedules and the MAAC Disclosure Schedules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>SEC</U>&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities Act</U>&#148; means the U.S. Securities Act of 1933. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities Laws</U>&#148; means Federal Securities Laws and other applicable foreign and domestic securities or similar Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Significant Company Shareholders</U>&#148; means the Large Lot Shareholders (as
defined in the Company <FONT STYLE="white-space:nowrap">Bye-Laws)</FONT> and Vivek Ramaswamy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Signing Filing</U>&#148; has the
meaning set forth in <U>Section</U><U></U><U>&nbsp;5.4(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Signing Press Release</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;5.4(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Software</U>&#148; shall mean any and all (a)&nbsp;computer programs, including any
and all software implementations of algorithms, models and methodologies, whether in source code or object code; and (b)&nbsp;documentation, including user manuals and other training documentation, related to any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sponsor Exchange Ratio</U>&#148; shall have the meaning set forth in the Sponsor Support Agreement.<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sponsor Support Agreement</U>&#148; has the meaning set forth in the recitals
to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary</U>&#148; means, with respect to any Person, any corporation, limited liability company,
partnership or other legal entity of which (a)&nbsp;if a corporation, a majority of the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees
thereof is at the time owned or controlled, directly or indirectly, by such Person or one or more of the other Subsidiaries of such Person or a combination thereof, or (b)&nbsp;if a limited liability company, partnership, association or other
business entity (other than a corporation), a majority of the partnership or other similar ownership interests thereof is at the time owned or controlled, directly or indirectly, by such Person or one or more Subsidiaries of such Person or a
combination thereof and, for this purpose, a Person or Persons own a majority ownership interest in such a business entity (other than a corporation) if such Person or Persons shall be allocated a majority of such business entity&#146;s gains or
losses or shall be a, or control any, managing director or general partner of such business entity (other than a corporation); <U>provided</U> that Datavant Holdings, Inc. and each of its Subsidiaries (collectively, &#147;<U>Datavant</U>&#148;)
shall not be deemed a Subsidiary of the Company. The term &#147;<U>Subsidiary</U>&#148; shall include all Subsidiaries of such Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Surviving Company</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1(b)(i)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax</U>&#148; means any federal, state, local or <FONT STYLE="white-space:nowrap">non-United</FONT> States income, gross receipts,
franchise, estimated, alternative minimum, sales, use, transfer, value added, excise, stamp, customs, duties, ad valorem, real property, personal property (tangible and intangible), capital stock, social security, unemployment, payroll, wage,
employment, severance, occupation, registration, environmental, communication, mortgage, profits, license, lease, service, goods and services, withholding, premium, unclaimed property, escheat, turnover, windfall profits or other taxes, charges,
imposts, fees, levies or assessments of any kind whatsoever, in each case in the nature of a tax, together with any interest, deficiencies, penalties, additions to tax, or additional amounts imposed by any Tax Authority with respect thereto, and
including any Liability for any of the aforementioned as transferee or successor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Authority</U>&#148; means any Governmental
Entity responsible for the collection or administration of Taxes or Tax Returns. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Return</U>&#148; means returns, information returns, statements, declarations,
claims for refund, schedules, attachments and reports relating to Taxes that are filed or required to be filed with any Governmental Entity, including any amendment of any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Termination Date</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;7.1(d)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transaction Payment</U>&#148; means (a)&nbsp;when used in reference to any Group Company, any success, change of control, retention,
transaction bonus or other similar payment or amount to any current or former officer, director or employee of any Group Company or any other Company Related Party that would (either alone or when combined with one or more additional circumstances,
matters or events) become payable as a result of or in connection with the transactions contemplated by this Agreement or the Ancillary Documents or (b)&nbsp;when used in reference to MAAC, any success, change of control, retention, transaction
bonus or other similar payment or amount to any current or former officer, director or employee of MAAC or any other MAAC Related Party that would (either alone or when combined with one or more additional circumstances, matters or events) become
payable as a result of or in connection with the transactions contemplated by this Agreement or the Ancillary Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transaction Proposals</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transaction Support Agreements</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transfer Agent</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.5</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transfer Agent Agreement</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.5</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Treasury Regulations</U>&#148; means the Treasury regulations promulgated under the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trust Account</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.18</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trust Account Released Claims</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.18</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trust Agreement</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trustee</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Unvested Company CVAR Award</U>&#148; means each Company CVAR Award outstanding as of immediately prior to the Company <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Steps that is not a Vested Company CVAR Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Unvested Company Option</U>&#148;
means each Company Option outstanding as of immediately prior to the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps that is not a Vested Company Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Unvested Company RSU Award</U>&#148; means each Company RSU Award outstanding as of immediately prior to the Company <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Steps that is not a Vested Company RSU Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Vested Company CVAR Award</U>&#148; means each Company CVAR Award outstanding as of
immediately prior to the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps that is vested as of such time or will vest in connection with the consummation of the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Vested Company Option</U>&#148; means each Company Option outstanding as of immediately prior to the Company <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Steps that is vested as of such time or will vest in connection with the consummation of the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Vested Company RSU Award</U>&#148; means each Company RSU Award outstanding as of immediately prior to the Company <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Steps that is vested as of such time or will vest in connection with the consummation of the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>WARN</U>&#148; means the Worker Adjustment Retraining and Notification Act of 1988 as well as similar foreign, state or local Laws.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Willful Breach</U>&#148; means a material breach of this Agreement by a Party that is a consequence of an act undertaken or a
failure to act by the breaching Party with the knowledge that the taking of such act or such failure to act would, or would reasonably be expected to, constitute or result in a breach of this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;2 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MERGER
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.1 </B><B><U>Closing Transactions</U></B>. On the terms and subject to the conditions set forth in
this Agreement,<B> </B>the following transactions shall occur in the order set forth in this <U>Section</U><U></U><U>&nbsp;2.1</U>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps and Share Conversion</U>. On the Closing Date prior to the Effective Time, the Company shall cause (i)&nbsp;a subdivision of the Company
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares to be consummated such that each Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Share shall be divided into a number of Company Post-Closing Common Shares equal to
the Exchange Ratio and the par value of each Company Post-Closing Common Share shall be equal to the then-current par value <I>divided by</I> the Exchange Ratio, (ii)&nbsp;the Company <FONT STYLE="white-space:nowrap">Bye-Laws</FONT> to be amended
and restated to be in substantially the form attached hereto as <U>Exhibit E</U> (the &#147;<U>Company Post-Closing <FONT STYLE="white-space:nowrap">Bye-Laws</FONT></U>&#148;) and (iii)&nbsp;the transactions set forth in
<U>Section</U><U></U><U>&nbsp;2.4</U> to occur (the transactions described in the foregoing <U>clauses</U><U></U><U>&nbsp;(i)</U> through <U>(iii)</U>, collectively, the &#147;<U>Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT>
Steps</U>&#148;). The Company shall also cause the <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Share Conversion to occur prior to the Effective Time, subject to the expiration or termination of any applicable waiting period under the HSR Act
with respect to the <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Share Conversion. In the event that any applicable waiting period under the HSR Act with respect to the <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Share Conversion has
not expired or been terminated as of the date of satisfaction (or, to the extent permitted by applicable Law, waiver) of the conditions set forth in <U>Article</U><U></U><U>&nbsp;6</U> (other than those conditions that by their nature are to be
satisfied at the Closing), then the Parties shall appropriately modify the Company Post-Closing <FONT STYLE="white-space:nowrap">Bye-Laws</FONT> that will become effective on the Closing Date immediately prior to the Effective Time in accordance
herewith to provide for a separate class of common shares of the Company that are identical to the Company Post-Closing Common Shares, except that they are not entitled to voting rights, with such modified Company Post-Closing <FONT
STYLE="white-space:nowrap">Bye-Laws</FONT> being in a form mutually agreed to by MAAC and the Company (such agreement not to be unreasonably withheld, conditioned or delayed). For the avoidance of doubt, the
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Share Conversion shall not be a condition to any Party&#146;s obligation to consummate the Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>The Merger</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) On the terms and subject to the conditions set forth in this Agreement and in accordance with the DGCL, on the Closing Date promptly
following the consummation of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, Merger Sub shall merge with and into MAAC (the &#147;<U>Merger</U>&#148;) at the Effective Time. Following the Effective Time, the separate
existence of Merger Sub shall cease and MAAC shall continue as the surviving corporation of the Merger (the &#147;<U>Surviving Company</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) On the terms and subject to the conditions set forth in this Agreement, at the Closing, the Parties shall cause a certificate of merger
relating to the Merger, in a form reasonably satisfactory to the Company and MAAC (the &#147;<U>Certificate of Merger</U>&#148;), to be executed and filed with the Secretary of State of the State of Delaware. The Merger shall become effective on the
date and time at which the Certificate of Merger is accepted for filing by the Secretary of State of the State of Delaware or at such later date and/or time as is agreed by the Company and MAAC and specified in the Certificate of Merger (the time
the Merger becomes effective being referred to herein as the &#147;<U>Effective Time</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) From and after the Effective
Time, the Merger shall have the effects set forth in this Agreement, in the Certificate of Merger and in Section&nbsp;251 of the DGCL. Without limiting the generality of the foregoing, and subject thereto, at the Effective Time, all of the assets,
properties, rights, privileges, powers and franchises of MAAC and Merger Sub shall vest in the Surviving Company and all debts, liabilities, obligations, restrictions, disabilities and duties of each of MAAC and Merger Sub shall become the debts,
liabilities, obligations and duties of the Surviving Company, in each case, in accordance with the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) At the Effective Time, by
virtue of the Merger, the certificate of incorporation of MAAC shall be amended and restated to be identical to the certificate of incorporation of Merger Sub as in effect immediately prior to the Effective Time and, as so amended and restated,
shall be the certificate of incorporation of the Surviving Company until thereafter amended in accordance with its terms as provided therein and by the DGCL, except that the name of the Surviving Company reflected therein shall be a name that is
determined by the Company prior to the Closing (which name does not reference &#147;Montes Archimedes&#148;). At the Effective Time, the bylaws of MAAC shall be amended to be identical to the bylaws of Merger Sub as in effect immediately prior to
the Effective Time and, as so amended, shall be the bylaws of the Surviving Company until thereafter amended in accordance with their terms as provided therein, the Governing Documents of the Surviving Company and the DGCL, except that the name of
the Surviving Company reflected therein shall be a name that is determined by the Company prior to the Closing (which name does not reference &#147;Montes Archimedes&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) At the Effective Time, the persons serving as the directors and officers of Merger Sub immediately prior to the Effective Time shall be
the initial directors and officers of the Surviving Company, each to hold office in accordance with the Governing Documents of the Surviving Company from and after the Effective Time until such director&#146;s or officer&#146;s successor is duly
elected or appointed and qualified, or until the earlier of their death, resignation or removal in accordance with the Governing Documents of the Surviving Company, or as otherwise provided by the DGCL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) At the Effective Time, by virtue of the Merger and without any action on the part of
any Party or any other Person, each share of capital stock of Merger Sub issued and outstanding immediately prior to the Effective Time shall be automatically canceled and extinguished and converted into one share of common stock, par value $0.0001,
of the Surviving Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) At the Effective Time, by virtue of the Merger and without any action on the part of any Party or any
other Person, (A)&nbsp;each (x) MAAC Class&nbsp;A Share and (y)&nbsp;each MAAC Class&nbsp;B Share that is not held by the MAAC Sponsor or any of its Affiliates (other than the MAAC Class&nbsp;A Shares and MAAC Class&nbsp;B Shares canceled and
extinguished pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)(ix)</U>) issued and outstanding as of immediately prior to the Effective Time shall be automatically canceled and extinguished and converted into one Company Post-Closing Common Share and
(B)&nbsp;each MAAC Class&nbsp;B Share issued and outstanding and held by the MAAC Sponsor or any of its Affiliates as of immediately prior to the Effective Time shall be automatically canceled and extinguished and converted into the number of
Company Post-Closing Common Shares equal to the Sponsor Exchange Ratio; <U>provided</U> that for the avoidance of doubt, a number of Company Post-Closing Common Shares owned by the MAAC Sponsor or any of its Affiliates, determined pursuant to the
Sponsor Support Agreement, shall become subject to the vesting and other terms and conditions set forth in the Sponsor Support Agreement at the Effective Time. As of the Effective Time, all MAAC Shares shall no longer be outstanding and shall
automatically be canceled and shall cease to exist, and shall thereafter represent the number of Company Post-Closing Common Shares into which such MAAC Shares were converted pursuant to this Agreement. From and after the Effective Time, each <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholder&#146;s certificate(s) (the &#147;<U>Certificates</U>&#148;), if any, evidencing ownership of MAAC Shares and MAAC Shares held in book-entry form issued and outstanding immediately prior
to the Effective Time shall each cease to have any rights with respect to such MAAC Shares, except as otherwise expressly provided for herein or under applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) At the Effective Time, each MAAC Warrant that is outstanding immediately prior to the Effective Time shall, by its terms, convert
automatically into the right to acquire Company Post-Closing Common Shares on the terms and subject conditions set forth in the MAAC Warrant Agreement as in effect immediately prior to the Effective Time (each, a &#147;<U>Company Warrant</U>&#148;);
<U>provided</U> that, for the avoidance of doubt, each Company Warrant shall, from and after the Effective Time, (x)&nbsp;represent the right to acquire the number of Company Post-Closing Common Shares equal to the number of MAAC Shares subject to
the underlying MAAC Warrant immediately prior to the Effective Time, and (y)&nbsp;have an exercise price of $11.50 per whole warrant to purchase one Company Post-Closing Common Share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) At the Effective Time, by virtue of the Merger and without any action on the part of any Party or any other Person, each MAAC Share held
immediately prior to the Effective Time by MAAC as treasury stock shall be automatically canceled and extinguished, and no consideration shall be paid with respect thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.2 </B><B><U>Closing of the Transactions Contemplated by this
Agreement</U></B>. On the terms and subject to the conditions set forth in this Agreement, the closing of the transactions contemplated by this Agreement (the &#147;<U>Closing</U>&#148;) shall take place electronically by exchange of the closing
deliverables by the means provided in <U>Section</U><U></U><U>&nbsp;8.11</U> as promptly as reasonably practicable, but in no event later than the third (3rd) Business Day, following the satisfaction (or, to the extent permitted by applicable Law,
waiver) of the conditions set forth in <U>Article</U><U></U><U>&nbsp;6</U> (other than those conditions that by their nature are to be satisfied at the Closing, but subject to satisfaction or waiver of such conditions) or at such other place, date
and/or time as MAAC and the Company may agree in writing (the date on which the Closing actually occurs is referred to in this Agreement as the &#147;<U>Closing Date</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.3 </B><B><U>Fractional Shares</U></B><U>. </U>Notwithstanding the foregoing or anything to the contrary
herein, no fractional Company Post-Closing Common Shares shall be issued in connection with the transactions contemplated hereby. Except with respect to Company Equity Awards, all fractional Company Post-Closing Common Shares that each Company
Equityholder will have a right to receive in connection with the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, as well as all fractional Company Post-Closing Common Shares that the MAAC Sponsor and its Affiliates as holders of
MAAC Class&nbsp;B Shares will have a right to receive in connection with the Merger, shall be aggregated and, if a fractional share results from such aggregation, such fractional share shall be rounded down to the nearest whole share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.4 </B><B><U>Treatment of Company </U></B><B><U>Equity Awards</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) On the Closing Date prior to the Closing (and as part of, for the avoidance of doubt, the Company
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps), each Company Option (whether a Vested Company Option or an Unvested Company Option) shall be adjusted in accordance with the applicable Company Equity Plan into an option to purchase
Company Post-Closing Common Shares (each, an &#147;<U>Adjusted Option</U>&#148;) in an amount and at an exercise price determined pursuant to this <U>Section</U><U></U><U>&nbsp;2.4(a)</U>. Each Adjusted Option shall: (i)&nbsp;be exercisable for, and
represent the right to purchase, a number of Company Post-Closing Common Shares (rounded down to the nearest whole share) equal to the product obtained by <I>multiplying</I> (A)&nbsp;the number of Company
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares subject to the corresponding Company Option immediately prior to the consummation of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, <I>by</I> (B)&nbsp;the
Exchange Ratio, and (ii)&nbsp;have an exercise price per Company Post-Closing Common Share (rounded up to the nearest whole cent) subject to such Adjusted Option equal to the quotient obtained by dividing (A)&nbsp;the exercise price per Company <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Common Share applicable to the corresponding Company Option immediately prior to the consummation of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, <I>by</I> (B)&nbsp;the Exchange
Ratio. Such conversion shall occur in a manner intended to comply with (x)&nbsp;the requirements of Section&nbsp;409A of the Code and (y)&nbsp;in the case of any Adjusted Option that is an Incentive Stock Option, the requirements of Section&nbsp;424
of the Code. Except as otherwise set forth in this <U>Section</U><U></U><U>&nbsp;2.4(a)</U>, each Adjusted Option shall continue to have, and be subject to, the same terms and conditions (including applicable vesting, expiration and forfeiture
provisions) as applied to the corresponding Company Option immediately prior to such adjustment. For the avoidance of doubt, the rounding of any shares pursuant to this <U>Section</U><U></U><U>&nbsp;2.4(a)</U> shall be determined on an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">award-by-award</FONT></FONT> basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) On the Closing Date prior to the Closing (and as part of, for the avoidance of doubt,
the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps), each Vested Company RSU Award shall be adjusted in accordance with the applicable Company Equity Plan into a number of Company Post-Closing Common Shares (rounded down to the
nearest whole share) equal to (i)&nbsp;the product obtained by <I>multiplying</I> (A)&nbsp;the number of Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares subject to the corresponding Vested Company RSU Award immediately
prior to the consummation of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, <I>by</I> (B)&nbsp;the Exchange Ratio, <I>minus</I> (ii)&nbsp;that number of Company Post-Closing Common Shares with a fair market value equal to all
required withholding taxes due upon settlement of such Vested Company RSU Award, as determined in accordance with the applicable Company Equity Plan and award (or similar) agreement. For the avoidance of doubt, the rounding of any shares pursuant to
this <U>Section</U><U></U><U>&nbsp;2.4(b)</U> shall be determined on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">award-by-award</FONT></FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) On the Closing Date prior to the Closing (and as part of, for the avoidance of doubt, the Company
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps), each Unvested Company RSU Award shall be adjusted in accordance with the applicable Company Equity Plan into a restricted stock unit award (each, an &#147;<U>Adjusted RSU Award</U>&#148;)
with respect to a number of Company Post-Closing Common Shares (rounded down to the nearest whole share) equal to the product obtained by <I>multiplying</I> (A)&nbsp;the number of Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common
Shares subject to the corresponding Unvested Company RSU Award immediately prior to the consummation of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, <I>by</I> (B)&nbsp;the Exchange Ratio. Except as otherwise set forth in
this <U>Section</U><U></U><U>&nbsp;2.4(c)</U>, each Adjusted RSU Award shall continue to have, and be subject to, the same terms and conditions (including applicable vesting, expiration and forfeiture provisions) as applied to the corresponding
Unvested Company RSU Award immediately prior to such adjustment. For the avoidance of doubt, the rounding of any shares pursuant to this <U>Section</U><U></U><U>&nbsp;2.4(c)</U> shall be determined on an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">award-by-award</FONT></FONT> basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) On the Closing Date prior to the Closing (and as part of, for the
avoidance of doubt, the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps), each Company CVAR Award (whether a Vested Company CVAR Award or an Unvested Company CVAR Award) shall be adjusted in accordance with the applicable Company
Equity Plan into a capped value appreciation right with respect to Company Post-Closing Common Shares (each, an &#147;<U>Adjusted CVAR Award</U>&#148;) in an amount and at a hurdle price determined pursuant to this
<U>Section</U><U></U><U>&nbsp;2.4(d)</U>. Each Adjusted CVAR Award shall (i)&nbsp;be with respect to a number of Company Post-Closing Common Shares (rounded down to the nearest whole share) equal to the product obtained by <I>multiplying</I>
(A)&nbsp;the number of Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares subject to the corresponding Company CVAR Award immediately prior to the consummation of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT>
Steps, <I>by</I> (B)&nbsp;the Exchange Ratio, and (ii)&nbsp;have a (A)&nbsp;hurdle price per Company Post-Closing Common Share, (B)&nbsp;a <FONT STYLE="white-space:nowrap">&#147;knock-in&#148;</FONT> price per Company Post-Closing Common Share (if
applicable) and (C)&nbsp;value cap price per Company Post-Closing Common Share (in each case, rounded up to the nearest whole cent) subject to such Adjusted CVAR Award equal to the quotient obtained by <I>dividing</I> (A)&nbsp;the hurdle price per
Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Share, <FONT STYLE="white-space:nowrap">&#147;knock-in&#148;</FONT> price per Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Share (if&nbsp;applicable) and value
cap price per Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Share applicable to the corresponding Company CVAR Award immediately prior to the consummation of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps,
respectively, <I>by</I> (B)&nbsp;the Exchange Ratio. Except as otherwise set forth in this <U>Section</U><U></U><U>&nbsp;2.4(d)</U>, each Adjusted CVAR Award shall continue to have, and be subject to, the same terms and conditions (including
applicable vesting, expiration and forfeiture provisions) as applied to the corresponding Company CVAR Award immediately prior to such adjustment. For the avoidance of doubt, the rounding of any shares pursuant to this
<U>Section</U><U></U><U>&nbsp;2.4(d)</U> shall be determined on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">award-by-award</FONT></FONT> basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) After giving effect to this <U>Section</U><U></U><U>&nbsp;2.4</U>, and upon the approval
of the Company Post-Closing Incentive Equity Plan in accordance with <U>Section</U><U></U><U>&nbsp;5.18</U> of this Agreement, effective as of the Closing, no further grants or issuances shall be made under any of the Company Equity Plans (other
than, for the avoidance of doubt, (x)&nbsp;issuances pursuant to awards outstanding as of the Closing Date under the Company Equity Plans (as adjusted pursuant to this <U>Section</U><U></U><U>&nbsp;2.4</U>) and (y)&nbsp;grants or issuances pursuant
to the Company Post-Closing Incentive Equity Plan and the Company Post-Closing Employee Stock Purchase Plan). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Prior to the Closing,
the Company shall take, or cause to be taken, all necessary actions under the Company Equity Plans, under the underlying grant, award or similar agreement and otherwise to give effect to the provisions of this <U>Section</U><U></U><U>&nbsp;2.4</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.5 </B><B><U>Transfer Agent Matters</U></B>. At least three (3)&nbsp;Business Days prior to the
effectiveness of the Registration Statement / Proxy Statement, the Company shall appoint a transfer agent (the &#147;<U>Transfer Agent</U>&#148;) and, if required by the Transfer Agent, enter into a transfer agent agreement with the Transfer Agent
(the &#147;<U>Transfer Agent Agreement</U>&#148;) in a form and substance that is reasonably acceptable to MAAC (it being understood and agreed, for the avoidance of doubt, that Continental Stock Transfer<U></U>&nbsp;&amp; Trust Company (or any of
its Affiliates) shall be deemed to be acceptable to MAAC and any Transfer Agent Agreement in substantially the same form as the transfer agent agreement between MAAC and Continental Stock Transfer<U></U>&nbsp;&amp; Trust Company as of the date
hereof shall be deemed to be acceptable to MAAC). The Company and MAAC shall each take, or cause to be taken, all necessary or reasonably advisable actions in order to appropriately reflect the Company Post-Closing Common Shares issued pursuant to,
or as a result of, the transactions contemplated by this Agreement and the Ancillary Documents and outstanding immediately after the Effective Time, including taking any necessary or reasonably advisable actions
<FONT STYLE="white-space:nowrap">vis-&agrave;</FONT> <FONT STYLE="white-space:nowrap">-vis</FONT> MAAC&#146;s existing transfer agent or the Transfer Agent, and the Company and MAAC shall each reasonably cooperate with the other and the Transfer
Agent in connection with the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.6 </B><B><U>Withholding</U></B>. MAAC, the Company and the
Transfer Agent (and their respective Representatives) shall be entitled to deduct and withhold (or cause to be deducted and withheld) from any consideration payable pursuant to this Agreement such amounts as are required to be deducted and withheld
under applicable Tax Law. To the extent that amounts are so deducted and withheld and duly paid over to the appropriate Tax Authority, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the Person in
respect of which such deduction and withholding was made. The Parties shall cooperate in good faith to eliminate or reduce any such deduction or withholding (including through the request and provision of any statements, forms or other documents to
reduce or eliminate any such deduction or withholding), as reasonably requested by the relevant Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES RELATING </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO&nbsp;THE&nbsp;GROUP&nbsp;COMPANIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to <U>Section</U><U></U><U>&nbsp;8.8</U>, except (a)&nbsp;as set forth in the Company Disclosure Schedules, or (b)&nbsp;solely in the
case of the Public Group Companies, as set forth in any Public Group Company SEC Reports publicly available as of the date hereof (excluding any disclosures in any &#147;risk factors&#148; section that do not constitute statements of fact,
disclosures in any forward-looking statements disclaimers and other disclosures that are generally cautionary, predictive or forward-looking in nature), the Company and Merger Sub each hereby represents and warrants to MAAC as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.1 </B><B><U>Organization and Qualification</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company is an exempted limited company duly organized or formed, as applicable, validly existing and in good standing (or the
equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the Laws of Bermuda. The Company has the requisite exempted company or other applicable
business entity power and authority to own, lease and operate its properties and to carry on its businesses as presently conducted, except where the failure to have such power or authority would not have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) True and complete copies of the Governing Documents of the Company and the Company Shareholders Agreements have been made available to
MAAC, in each case, as amended and in effect as of the date of this Agreement. The Governing Documents of the Company and the Company Shareholders Agreements are in full force and effect, the Company is not in material breach or violation of any
provision set forth in its Governing Documents and the Company is not in material breach or violation of the Company Shareholders Agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each Group Company (other than the Company) is a corporation, limited liability company or other applicable business entity duly organized
or formed, as applicable, validly existing and in good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the Laws of its
jurisdiction of formation or organization (as applicable). Each Group Company (other than the Company) has the requisite corporate, limited liability company or other applicable business entity power and authority to own, lease and operate its
properties and to carry on its businesses as presently conducted, except where the failure to have such power or authority would not have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) True and complete copies of the Governing Documents of each Private Group Company (other than the Company) have been made available to
MAAC, in each case, as amended and in effect as of the date of this Agreement. The Governing Documents of each Group Company (other than the Company) are in full force and effect and none of the Group Companies is in material breach or material
violation of any provision set forth in its Governing Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Each Group Company is duly qualified or licensed to transact business and is in good
standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) in each jurisdiction in which the property and assets owned, leased or
operated by it, or the nature of the business conducted by it, makes such qualification or licensing necessary, except where the failure to be so duly qualified or licensed and in good standing would not have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.2 </B><B><U>Capitalization of the Group Companies</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Section</U><U></U><U>&nbsp;3.2(a)</U> of the Company Disclosure Schedules sets forth a true and complete statement as of April&nbsp;30,
2021 (the &#147;<U>Designated Capitalization Date</U>&#148;) of (i)&nbsp;the aggregate number and class, series or type (as applicable) of all of the Equity Securities of the Company issued and outstanding and (ii)&nbsp;the identity of the Persons
that are the owners of one percent (1.0%) or more of the issued and outstanding Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares. Except for (x)&nbsp;the aggregate number of Equity Securities of the Company and the Company
Equity Awards outstanding as set forth on <U>Section</U><U></U><U>&nbsp;3.2(a)</U> of the Company Disclosure Schedules, (y)&nbsp;those Equity Securities of the Company issued or granted during the period beginning on the day after the Designated
Capitalization Date and ending on the date of this Agreement that would, assuming such issuance or grant occurred during the period from the date of this Agreement until the Closing, be permitted by <U>Section</U><U></U><U>&nbsp;5.1(b)(v)</U> or
<U>Section</U><U></U><U>&nbsp;5.1(b)(vi)</U> (provided that, for purposes of <U>clause (3)</U>&nbsp;and <U>(4)</U> of Section&nbsp;5.1(b)(vi), no such issuances or grants are to any Designated Individual or Affiliated Shareholder), and (z)&nbsp;the
exercise, vesting, settlement or forfeiture of any Company Equity Awards outstanding as of the Designated Capitalization Date during the period beginning on the day after Designated Capitalization Date and ending on the date of this Agreement, the
Company has no outstanding Equity Securities as of the date hereof. All of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares have been duly authorized and validly issued and are fully paid and non-assessable. The Equity
Securities of the Company (1)&nbsp;were not issued in violation of the Governing Documents of the Company, the Company Shareholders Agreements or any other Contract to which any Group Company is party or by which any Group Company is otherwise bound
and (2)&nbsp;were not issued in violation of any preemptive rights, call option, right of first refusal or first offer, subscription rights, transfer restrictions or similar rights of any Person. Other than (A)&nbsp;as set forth above and pursuant
to the Governing Documents of the Company or the Company Shareholders Agreement and (B)&nbsp;pursuant to offer letters or similar Contracts with service providers who are not Designated Individuals or Affiliated Shareholders entered into in the
ordinary course of business providing for the grant or issuance of Equity Securities, as of the date hereof, the Company has no outstanding purchase rights, subscription rights, conversion rights, exchange rights, calls, puts or rights of first
refusal or first offer or other Contracts that could require the Company to issue, sell or otherwise cause to become outstanding or to acquire, repurchase or redeem any Equity Securities or securities convertible into or exchangeable for Equity
Securities of the Company. Except for the Governing Documents of the Company and the Company Shareholders Agreements, there are no voting trusts, proxies or other Contracts to which the Company is a party or otherwise bound with respect to the
voting or transfer of the Equity Securities of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Section</U><U></U><U>&nbsp;3.2(b)</U> of the Company Disclosure Schedules sets forth
a true and complete statement as of the Designated Capitalization Date of (i)&nbsp;the aggregate number and class, series or type (as applicable) of all of the Equity Securities (other than equity incentive awards) of each Private Group Company
(other than the Company) and Datavant issued and outstanding, (ii)&nbsp;the aggregate pool of allocated and unallocated equity incentive awards of each Private Group Company (other than the Company) and Datavant and (iii)&nbsp;the aggregate number
and class, series or type (as applicable) of all of the Equity Securities of each Private Group Company (other than the Company) that are owned by another Group Company and the aggregate number and class, series or type (as applicable) of all of the
Equity Securities of Datavant that are owned by a Group Company. Except for (x)&nbsp;the aggregate number of Equity Securities of each Private Company Vant (other than the Company) and Datavant outstanding as set forth on
<U>Section</U><U></U><U>&nbsp;3.2(b)</U> of the Company Disclosure Schedules, (y)&nbsp;those Equity Securities of a Private Group Company or Datavant issued or granted during the period beginning on the day after the Designated Capitalization Date
and ending on the date of this Agreement that would, assuming such issuance or grant occurred during the period from the date of this Agreement until the Closing, either be permitted by <U>Section</U><U></U><U>&nbsp;5.1(b)(v)</U> or
<U>Section</U><U></U><U>&nbsp;5.1(b)(vi)</U> (provided that, for purposes of <U>clause (3)</U>&nbsp;and <U>(4)</U> of <U>Section</U><U></U><U>&nbsp;5.1(b)(vi)</U>, no such issuances or grants are to any Designated Individual or Affiliated
Shareholder), and (z)&nbsp;the exercise, vesting, settlement or forfeiture of any equity incentive awards outstanding as of the Designated Capitalization Date during the period beginning on the day after Designated Capitalization Date and ending on
the date of this Agreement, each Private Group Company (other than the Company) and Datavant has no outstanding Equity Securities as of the date hereof. Other than (A)&nbsp;as set forth above and pursuant to the Governing Documents of the Private
Group Companies (other than the Company) and (B)&nbsp;pursuant to offer letters or similar Contracts with service providers who are not Designated Individuals or Affiliated Shareholders entered into in the ordinary course of business providing for
the grant or issuance of Equity Securities of a Private Group Company, as of the date hereof, no Private Group Company has any outstanding purchase rights, subscription rights, conversion rights, exchange rights, calls, puts or rights of first
refusal or first offer or other Contracts that could require any Private Group Company (other than the Company) to issue, sell or otherwise cause to become outstanding or to acquire, repurchase or redeem any Equity Securities or securities
convertible into or exchangeable for Equity Securities of any Private Group Company (other than the Company), in each case other than to another Group Company. Except for the Governing Documents of the applicable Private Group Company or
shareholders agreements or similar Contracts to which the applicable Private Group Company is a party and that has, in the case of each such material agreement or Contract, been made available to MAAC, there are no voting trusts, proxies or other
Contracts to which a Private Group Company is a party with respect to the voting or transfer of any Equity Securities of any Private Group Company (other than the Company), in each case other than in favor of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Section</U><U></U><U>&nbsp;3.2(c)</U> of the Company Disclosure Schedules sets forth a true and complete statement as of the date
hereof of the number and class or series (as applicable) of all of the capital stock of each Public Group Company owned by the Company (whether <U>of record, beneficially, legally or otherwise).</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Immediately after the Effective Time, (i)&nbsp;the authorized share capital of the Company will consist of 7,000,000,000 Company
Post-Closing Common Shares and (ii)&nbsp;all of the issued and outstanding Company Post-Closing Common Shares (A)&nbsp;will be duly authorized, validly issued, fully paid and nonassessable and (B)&nbsp;will not have been issued in breach or
violation of any preemptive rights, call option, right of first refusal or first offer, subscription rights, transfer restrictions or similar rights of any Person or any Contract to which the Company is a party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Equity Securities of the Company have been offered, sold and issued by the Company
in compliance with applicable Law, including Securities Laws, in all material respects. Immediately after the Effective Time, all of the issued and outstanding Company Post-Closing Common Shares will have been offered, sold and issued in compliance
with applicable Law, including Securities Laws, in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Except as set forth on <U>Section 3.2(b)</U> and
<U>Section&nbsp;3.2(c)</U> of the Company Disclosure Schedules or for any changes to the extent permitted by <U>Section</U><U></U><U>&nbsp;5.1(b)</U> or resulting from the acquisition of Equity Securities of any Person permitted by
<U>Section</U><U></U><U>&nbsp;5.1(b)(ii)</U>, none of the Private Group Companies owns or holds (of record, beneficially, legally or otherwise), directly or indirectly, any Equity Securities in any other Person (other than Merger Sub) or the right
to acquire any such Equity Securities, and none of the Private Group Companies are a partner, member or similar participant of or in any partnership, limited liability company or similar business entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Section</U><U></U><U>&nbsp;3.2(g)</U> of the Company Disclosure Schedules sets forth any agreements evidencing indebtedness to third
parties for borrowed money of the Private Group Companies as of the date of this Agreement<U>. </U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)
<U>Section</U><U></U><U>&nbsp;3.2(h)</U> of the Company Disclosure Schedules sets forth a list of all Transaction Payments of the Private Group Companies as of the date of this Agreement and, to the knowledge of the Company, of the Public Group
Companies and Datavant as of the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Company has made available to MAAC a schedule that sets forth, with
respect to each Company Equity Award outstanding as of the Designated Capitalization Date (i)&nbsp;the date of grant and (ii)&nbsp;any applicable exercise, hurdle cap, <FONT STYLE="white-space:nowrap">&#147;knock-in&#148;</FONT> or similar price (in
the case of Company Options and Company CVAR Awards). Each Company Option and Company CVAR Award was granted with an exercise price equal to or greater than the fair market value of the underlying Company
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Share on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.3
</B><B><U>Authority</U></B>. The Company and Merger Sub each have the requisite corporate, limited liability company or other similar power and authority to execute and deliver this Agreement and each Ancillary Document to which it is or will be a
party, to perform its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery of this Agreement, the Ancillary Documents to which the Company or Merger Sub is or will be a
party and the consummation of the transactions contemplated hereby and thereby have been (or, in the case of any Ancillary Document entered into after the date of this Agreement, will be upon execution thereof) duly authorized by all necessary
corporate (or other similar) action on the part of the Company or Merger Sub. This Agreement and each Ancillary Document to which the Company or Merger Sub is or will be a party has been or will be, upon execution thereof, as applicable, duly and
validly executed and delivered by the Company and/or Merger Sub, as applicable, and constitutes or will constitute, upon execution and delivery thereof, as applicable, a valid, legal and binding agreement of the Company and/or Merger Sub, as
applicable (assuming that this Agreement and the Ancillary Documents to which the Company and/or Merger Sub is or will be a party are or will be upon execution thereof, as applicable, duly authorized, executed and delivered by the other Persons
party thereto), enforceable against the Company and/or Merger Sub, as applicable, in accordance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with its terms (subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors&#146; rights and subject to general
principles of equity). The Company Shareholder Written Consent and the approval to be obtained by Merger Sub pursuant to <U>Section</U><U></U><U>&nbsp;5.9</U> are the only votes or consents of the holders of any class or series of Equity Securities
of the Company or Merger Sub required to approve and adopt this Agreement, the Ancillary Documents to which the Company or Merger Sub is or is contemplated to be a party, the performance of the obligations of the Company and Merger Sub hereunder and
thereunder and the consummation of the transactions contemplated hereby (including the Merger and the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.4 </B><B><U>Financial Statements; Undisclosed Liabilities</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company has made available to MAAC a true and complete copy of (i)&nbsp;the audited consolidated balance sheet of the Company as of
March&nbsp;31, 2019 and March&nbsp;31, 2020 and the related audited consolidated statements of operations, comprehensive income (loss), shareholders&#146; equity and redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest and
cash flows of the Company for the years then ended and (ii)&nbsp;the unaudited consolidated balance sheet of the Company as of December&nbsp;31, 2020 (the &#147;<U>Latest Balance Sheet</U>&#148;) and the related unaudited consolidated statements of
operations, comprehensive income (loss), shareholders&#146; equity and redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest and cash flows of the Company for the period then ended (<U>clauses (i)</U>&nbsp;and <U>(ii)</U>,
collectively, the &#147;<U>Company Financial Statements</U>&#148;). Each of the Company Financial Statements (including the notes thereto)&nbsp;(A) were prepared in accordance with GAAP applied on a consistent basis throughout the periods indicated
(except as may be indicated in the notes thereto), (B) fairly presents, in all material respects in accordance with GAAP, the consolidated financial position, results of operations and cash flows of the Company as at the date thereof and for the
period indicated therein (except as may be indicated therein and subject to, in the case of any unaudited financial statements, normal year end audit adjustments (none of which are, individually or in the aggregate, material)), and (C)&nbsp;in the
case of the Company Financial Statements described in <U>clause</U><U></U><U>&nbsp;(i)</U> of the preceding sentence, contain an unqualified report of the Company&#146;s auditors and comply in all material respects with the applicable accounting
requirements and with the rules and regulations of the SEC, the Exchange Act and the Securities Act (including Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> or Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> as applicable) in effect
as of the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The financial statements or similar reports required to be included in the Registration Statement /
Proxy Statement (including (i)&nbsp;the audited consolidated balance sheet of the Company as of March&nbsp;31, 2019 and March&nbsp;31, 2020 and the related audited consolidated statements of operations, comprehensive income (loss),
shareholders&#146; equity and redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest and cash flows of the Company for the years then ended, audited in accordance with the standards of the PCAOB, (ii)&nbsp;the audited
consolidated balance sheet of the Company as of March&nbsp;31, 2021 and the related audited consolidated statements of operations, comprehensive income (loss), shareholders&#146; equity and redeemable
<FONT STYLE="white-space:nowrap">non-controlling</FONT> interest and cash flows of the Company for the years then ended, audited in accordance with the standards of the PCAOB, and (iii)&nbsp;customary pro forma financial statements) or any other
filings to be made by the Company or MAAC with the SEC in connection with the transactions contemplated in this Agreement or any other Ancillary Document (the &#147;<U>Closing Company Financial Statements</U>&#148;), when delivered following the
date of this Agreement in accordance with <U>Section</U><U></U><U>&nbsp;5.17</U>, (i) will be prepared in accordance with GAAP applied on a consistent basis throughout the periods indicated (except as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be indicated in the notes thereto and subject to, in the case of any unaudited financial statements, normal year end audit adjustments (none of which are, individually or in the aggregate,
material) and the absence of notes thereto), (ii) will fairly present, in all material respects in accordance with GAAP, the consolidated financial position, results of operations and cash flows of the Company as at the date thereof and for the
period indicated therein (except as may be indicated therein and subject to, in the case of any unaudited financial statements, normal year end audit adjustments (none of which are, individually or in the aggregate, material)), (iii) in the case of
any audited financial statements, will be audited in accordance with the standards of the PCAOB and will contain an unqualified report of the Company&#146;s auditors and (iv)&nbsp;will comply in all material respects with the applicable accounting
requirements and with the rules and regulations of the SEC, the Exchange Act and the Securities Act (including Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> or Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> as applicable) in effect
as of their respective dates of delivery, at the time of filing of the Registration Statement / Proxy Statement (in the case of the Closing Company Financial Statements included in the initial filing of the Registration Statement / Proxy Statement)
and at the time of effectiveness of the Registration Statement / Proxy Statement (in the case of all Closing Company Financial Statements). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except (i)&nbsp;as set forth on or provided for in the Company Financial Statements (and in the notes thereto), (ii) for Liabilities
incurred in the ordinary course of business since the date of the Latest Balance Sheet (none of which are Liabilities for a breach of Contract, breach of warranty, tort, infringement, Proceeding or violation of, or
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with, Law), (iii) for Liabilities incurred in connection with the negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance by any of the Company of its
covenants or agreements in this Agreement or any Ancillary Document to which it is or will be a party or the consummation of the transactions contemplated hereby or thereby (including, for the avoidance of doubt, the Company Expenses), (iv)
executory obligations under Contracts (excluding any Liabilities for a breach of Contract), (v) that are expressly permitted pursuant to or incurred in accordance with <U>Section</U><U></U><U>&nbsp;5.1(b)</U> (including as expressly set forth in
<U>Section</U><U></U><U>&nbsp;5.1(b)</U> of the Company Disclosure Schedules) and (vi)&nbsp;for Liabilities that would not have a Company Material Adverse Effect, no Group Company has any Liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To the knowledge of the Company, the Company has established and maintains a system of internal accounting controls that are designed to
provide, in all material respects, reasonable assurance that (i)&nbsp;all transactions are executed in accordance with management&#146;s authorization and (ii)&nbsp;all transactions are recorded as necessary to permit preparation of proper and
accurate financial statements in accordance with GAAP and to maintain accountability for the Company&#146;s consolidated assets. The Company maintains and, for all periods covered by the Company Financial Statements and the Closing Company Financial
Statements, has maintained books and records of the Company in the ordinary course of business that are accurate and complete and reflect the consolidated revenues, expenses, assets and liabilities of the Company in all material respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Since January&nbsp;1, 2019, the Company has not received any written complaint, allegation, assertion or claim that there is (i)
&#147;significant deficiency&#148; in the internal controls over financial reporting of the Company or, to the knowledge of the Company, any other Group Company as it pertains to the Company&#146;s consolidated financial reporting, (ii)&nbsp;a
&#147;material weakness&#148; in the internal controls over financial reporting of the Company or, to the knowledge </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Company, any other Group Company as it pertains to the Company&#146;s consolidated financial reporting or (iii)&nbsp;fraud, whether or not material, that involves management or other
employees of the Group Companies who have a significant role in the internal controls over financial reporting of the Company or, to the knowledge of the Company, any other Group Company as it pertains to the Company&#146;s consolidated financial
reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.5 </B><B><U>Consents and Requisite Governmental Approvals;
No</U></B><B><U></U></B><B><U>&nbsp;Violations</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) No Consent, approval or authorization of, or designation, declaration or
filing with, any Governmental Entity is required on the part of the Company or Merger Sub with respect to the Company or Merger Sub&#146;s execution, delivery or performance of its obligations under this Agreement or the Ancillary Documents to which
the Company or Merger Sub is or will be party or the consummation of the transactions contemplated hereby or thereby, except for (i)&nbsp;compliance with and filings under the HSR Act, if applicable, or under any applicable antitrust or other
competition Laws of any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions or any other merger control or investment laws or laws that provide for review of national security or defense matters (collectively, &#147;<U>Foreign and
Domestic Approval Laws</U>&#148;), (ii) the filing with the SEC of (A)&nbsp;the Registration Statement / Proxy Statement and the declaration of the effectiveness thereof by the SEC and (B)&nbsp;such reports under Section&nbsp;13(a) or 15(d) of the
Exchange Act as may be required in connection with this Agreement, the Ancillary Documents or the transactions contemplated hereby or thereby, (iii)&nbsp;the filing of (A)&nbsp;the Certificate of Merger and (B)&nbsp;any filings required under the
Companies Act in connection with the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps or the Merger, (iv)&nbsp;such filings with and approvals of Nasdaq to permit the Company Post-Closing Common Shares to be issued in connection
with the transactions contemplated by this Agreement and the other Ancillary Documents to be listed on Nasdaq, (v)&nbsp;the approval to be obtained by Merger Sub pursuant to <U>Section</U><U></U><U>&nbsp;5.9</U><I> </I>or (vi)&nbsp;any other
consents, approvals, authorizations, designations, declarations, waivers or filings, the absence of which would not have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) None of the execution or delivery by the Company or Merger Sub of this Agreement or any Ancillary Documents to which it is or will be a
party, the performance by the Company or Merger Sub of its obligations hereunder or thereunder or the consummation of the transactions contemplated hereby or thereby will, directly or indirectly (with or without due notice or lapse of time or
both)&nbsp;(i) result in a violation or breach of any provision of any Group Company&#146;s Governing Documents, (ii)&nbsp;result in a violation or breach of, or constitute a default or give rise to any right of termination, Consent, cancellation,
amendment, modification, suspension, revocation or acceleration under, any of the terms, conditions or provisions of (A)&nbsp;any Material Contract or (B)&nbsp;any Material Permits, (iii)&nbsp;violate, or constitute a breach under, any Order or
applicable Law to which any Group Company or any of its properties or assets are subject or bound or (iv)&nbsp;result in the creation of any Lien upon any of the assets or properties (other than any Permitted Liens) or Equity Securities of any Group
Company, except, in the case of any of <U>clauses</U><U></U><U>&nbsp;(ii)</U> through <U>(iv)</U>&nbsp;above, as would not have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.6 </B><B><U>Permits</U></B>. Except as would not have a Company Material Adverse Effect, each of the
<U>Private </U>Group Companies has all Permits (the &#147;<U>Material Permits</U>&#148;) that are required to own, lease or operate its properties and assets and to conduct its business as currently conducted. Except as would not have a Company
Material Adverse Effect, (i)&nbsp;each Material Permit is in full force and effect in accordance with its terms and (ii)&nbsp;no written notice of revocation, cancellation or termination of any Material Permit has been received by any Private Group
Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.7 </B><B><U>Material Contracts</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Section</U><U></U><U>&nbsp;3.7(a)</U> of the Company Disclosure Schedules sets forth a list of the following Contracts to which a
Private Group Company or, in the case of <U>Section</U><U></U><U>&nbsp;3.7(a)(viii)(B)</U>, Datavant is, as of the date of this Agreement, a party (each Contract required to be set forth on <U>Section</U><U></U><U>&nbsp;3.7(a)</U> of the Company
Disclosure Schedules, together with each Contract entered into after the date of this Agreement that would be required to be set forth on <U>Section</U><U></U><U>&nbsp;3.7(a)</U> of the Company Disclosure Schedules if entered into prior to the
execution and delivery of this Agreement, collectively, the &#147;<U>Material Contracts</U>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) any Contract relating to
indebtedness for borrowed money to a third party of any Private Group Company in excess of $25&nbsp;million or to the placing of a Lien (other than a Permitted Lien) on any assets or properties of any Private Group Company that are material to the
business of all of the Private Group Companies, taken as a whole; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) any Contract under which any Private Group Company is lessee of
or holds or operates, in each case, any tangible property (other than real property) that is material to the business of all of the Private Group Companies, taken as a whole, owned by any other Person; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any joint venture, profit-sharing, partnership, <FONT STYLE="white-space:nowrap">co-promotion,</FONT> commercialization or other
similar Contract, in each case, material to the business all of the Private Group Companies, taken as a whole; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) any Contract that is
material to the business of all of the Private Group Companies, taken as a whole, and (A)&nbsp;limits or purports to limit the freedom of any Private Group Company to engage or compete in any line of business or with any Person or in any area,
(B)&nbsp;contains any exclusivity, &#147;most favored nation&#148; or similar provisions, obligations or restrictions that are binding on a Private Group Company or (C)&nbsp;contains any other provisions restricting or purporting to restrict the
ability of any Private Group Company to sell, manufacture, develop, commercialize, test or research products, directly or indirectly through third parties, or to solicit any potential employee or customer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) any Contract requiring any Private Group Company to guarantee the Liabilities of any Person (other than the Company or a Subsidiary of
the Company) in excess of $10&nbsp;million; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) any Contract entered into under which any Private Group Company has, directly or
indirectly, made or agreed to make any loan, advance or assignment of payment to any Person (other than the Company or a Subsidiary of the Company), individually or in the aggregate, in an amount in excess of $10&nbsp;million; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) any Contract required to be disclosed on <U>Section</U><U></U><U>&nbsp;3.20</U> of the Company Disclosure Schedules; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) any Contract with any Person (A)&nbsp;pursuant to which any Private Group Company
may be required to pay milestones, royalties or other contingent payments based on any research, testing, development, regulatory filings or approval, sale, distribution, commercial manufacture or other similar occurrences, developments, activities
or events, in each case, that are material to the business of, or that are material in amount to all of, the Private Group Companies, taken as a whole, or (B)<B></B>&nbsp;under which any Private Group Company or Datavant grants to any Person any
right of first refusal, right of first negotiation, option to purchase, option to license or any other similar preferential rights with respect to any Company Product or any Company Owned Intellectual Property that is material to the business of all
of the Private Group Companies, taken as a whole; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) any Contract governing the terms of, or otherwise related to, the employment,
engagement or services of any Designated Individual; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) any Contract for the disposition of all or a material portion of the assets or
business of any Private Group Company or for the acquisition by any Private Group Company of all or a material portion of the assets or business of any other Person (in each case, whether by merger, consolidation, recapitalization, purchase or
issuance of Equity Securities, purchase of assets, tender offer or otherwise), in each case under which any Private Group Company has any continuing Liabilities (including any obligation with respect to an &#147;earn out,&#148; purchase price or
other contingent or deferred payment obligation) that are material to the business of, or material in amount to, all of the Group Companies, taken as a whole; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) any settlement, conciliation or similar Contract (A)&nbsp;the performance of which would be reasonably likely to involve any material
payments by any Private Group Company after the date of this Agreement or (B)&nbsp;that imposes or is reasonably likely to impose, at any time in the future, any material, <FONT STYLE="white-space:nowrap">non-monetary</FONT> obligations on any
Private Group Company (or MAAC or any of its Affiliates (other than the Group Companies) after the Closing); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xii) any other
Contract the performance of which requires <FONT STYLE="white-space:nowrap">non-contingent</FONT> payments either (A)&nbsp;on an annual basis, to or from any Private Group Company in excess of $10&nbsp;million, or (B)&nbsp;in the aggregate, to or
from any Private Group Company in excess of $25&nbsp;million over the life of the agreement and, in each case, that is not terminable by the applicable Private Group Company without penalty upon less than sixty (60)&nbsp;days&#146; prior written
notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as would not have a Company Material Adverse Effect, (i)&nbsp;each Material Contract is valid and binding on the
applicable Group Company and, to the Company&#146;s knowledge, the counterparties thereto, and is in full force and effect and enforceable in accordance with its terms against such Group Company and, to the Company&#146;s knowledge, the
counterparties thereto (subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors&#146; rights and subject to general principles of equity), (ii) the applicable Group
Company and, to the Company&#146;s knowledge, the counterparties thereto are not in breach of, or default under, any Material Contract and (iii)&nbsp;no event has occurred that (with or without due notice or lapse of time or both) would result in a
breach of, or default under, any Material Contract by the applicable Group Company or, to the Company&#146;s knowledge, the counterparties thereto. The Company has made available to MAAC true and complete copies of all Material Contracts in effect
as of the date hereof (other than purchase orders, invoices, and similar confirmatory or administrative documents that are ancillary to the main contractual relationship between the parties to a particular Contract or group of Contracts and that, in
each case, do not contain any material executory or continuing terms, conditions, obligations or rights). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.8 </B><B><U>Absence of Changes</U></B>. During the period
beginning on April&nbsp;1, 2020 and ending on the date of this Agreement, (a)&nbsp;no Company Material Adverse Effect has occurred and (b)&nbsp;except (x) as expressly contemplated by this Agreement, any Ancillary Document or in connection with the
transactions contemplated hereby and thereby, (y)&nbsp;for any action taken, or omitted to be taken, by any Group Company to the extent determined to be reasonable and advisable in response to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> or
(z)&nbsp;as would not reasonably be expected to be, individually or in the aggregate, material to the Company and its Subsidiaries, taken as a whole, (i)&nbsp;the Group Companies have conducted their businesses in the ordinary course, and
(ii)&nbsp;no Private Group Company has taken any action that would require the consent of MAAC if taken during the period from the date of this Agreement until the Closing pursuant to <U>Section</U><U></U><U>&nbsp;5.1(b)(i)</U>,
<U>Section</U><U></U><U>&nbsp;5.1(b)(iv)(A)</U>, <U>Section</U><U></U><U>&nbsp;5.1(b)(xii)</U> or <U>Section</U><U></U><U>&nbsp;5.1(b)(xv)</U> (to the extent related to any of the foregoing). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.9 </B><B><U>Litigation</U></B>. There is, and since January&nbsp;1, 2019 there has been, no Proceeding pending
or, to the Company&#146;s knowledge, threatened against any Private Group Company that, if adversely decided or resolved, has been or would reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a
whole. Except as would not have a Company Material Adverse Effect, neither the Private Group Companies nor any of their respective properties or assets is subject to any Order. Except as would not have a Company Material Adverse Effect, as of the
date of this Agreement, there are no Proceedings by a Private Group Company against any other Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.10
</B><B><U>Compliance with Applicable Law</U></B>. Each Private Group Company (a)&nbsp;conducts (and since January&nbsp;1, 2019 has conducted) its business in accordance with all Laws and Orders applicable to such Private Group Company and
(b)&nbsp;as of the date hereof, has not received any written communications or, to the Company&#146;s knowledge, any other communications from or on behalf of a Governmental Entity that alleges that such Private Group Company is not in compliance
with any such Law or Order, except in each case of <U>clauses (a)</U>&nbsp;and <U>(b)</U>, as is not, and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.11 </B><B><U>Merger Sub Activities</U></B>. Merger Sub was organized solely for the purpose of entering into
this Agreement, the Ancillary Documents, the performance of its covenants and agreements in this Agreement and the Ancillary Documents and consummating the transactions contemplated hereby and thereby and has not engaged in any activities or
business, other than those incident or related to, or incurred in connection with, its organization, incorporation or formation, as applicable, its continuing corporate (or similar) existence or the negotiation, preparation or execution of this
Agreement or any Ancillary Document, the performance of its covenants or agreements in this Agreement or any Ancillary Document or the consummation of the transactions contemplated hereby or thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.12 </B><B><U>Employee Plans</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) No Group Company maintains, contributes to, or has any material Liability with respect to or under: (i)&nbsp;a Multiemployer Plan;
(ii)&nbsp;a &#147;defined benefit plan&#148; (as defined in Section&nbsp;3(35) of ERISA, whether or not subject to ERISA) or a plan that is or was subject to Title IV of ERISA or Section&nbsp;412 of the Code; or (iii)&nbsp;a &#147;multiple employer
plan&#148; within the meaning of Section of 413(c) of the Code or Section&nbsp;210 of ERISA. No Private Group Company maintains, contributes to, or has any material Liability with respect to or under a &#147;multiple employer welfare
arrangement&#148; as defined in Section&nbsp;3(40) of ERISA. No Group Company has any material Liabilities to provide any retiree or post-termination health or life insurance or other welfare-type benefits to any Person other than health
continuation coverage pursuant to COBRA or similar law. No Group Company has any material Liabilities under Title IV of ERISA by reason of at any time being considered a single employer under Section&nbsp;414 of the Code with any other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a
whole, each Employee Benefit Plan has been established, maintained, funded and administered in accordance with its terms and in compliance with all applicable Laws, including ERISA and the Code. Each Employee Benefit Plan that is intended to be
qualified under Section&nbsp;401(a) of the Code is so qualified and has timely received a favorable determination or opinion or advisory letter from the Internal Revenue Service. Since January&nbsp;1, 2019, none of the Private Group Companies has
incurred (whether or not assessed) any material penalty or Tax under Section&nbsp;4980H, 4980B, 4980D, 6721 or 6722 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
There are no pending or, to the Company&#146;s knowledge, threatened in writing, material claims or Proceedings with respect to any Employee Benefit Plan (other than routine claims for benefits). With respect to each Employee Benefit Plan,
(i)&nbsp;there have been no &#147;prohibited transactions&#148; within the meaning of Section&nbsp;4975 of the Code or Sections 406 or 407 of ERISA and no breaches of fiduciary duty (as determined under ERISA), and (ii)&nbsp;all contributions,
distributions, reimbursements and premium payments that are due have been timely made, except, in each case of each of <U>clauses (i)</U>&nbsp;and <U>(ii)</U>, as is not and would not reasonably be expected to be, individually or in the aggregate,
material to the Group Companies, taken as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The execution and delivery of this Agreement and the consummation of the
transactions contemplated by this Agreement will not (alone or in combination with any other event)&nbsp;(i) result in any payment or benefit becoming due to or result in the forgiveness of any indebtedness of any current or former director,
manager, officer, employee, individual independent contractor or other service providers of any of the Private Group Companies under any Employee Benefit Plan or (ii)&nbsp;accelerate the time of payment, funding or vesting or increase the amount or
value of, or result in the forfeiture of, any compensation or benefit under any Employee Benefit Plan to any current or former director, manager, officer, employee, individual independent contractor or other service providers of any of the Private
Group Companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Private Group Companies have no material obligations to indemnify, reimburse, make-whole or <FONT
STYLE="white-space:nowrap">&#147;gross-up&#148;</FONT> any person for any Tax or related interest or penalties incurred by such person imposed under Section&nbsp;4999 or 409A of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Each Foreign Benefit Plan that is required to be registered or intended to be tax exempt
has been registered (and, where applicable, accepted for registration) and is tax exempt and has been maintained in good standing in all material respects, to the extent applicable, with each Governmental Entity. No Foreign Benefit Plan is a
&#147;defined benefit plan&#148; (as defined in ERISA, whether or not subject to ERISA) or has any material unfunded or underfunded Liabilities. All material contributions required to have been made by or on behalf of any of the Private Group
Companies with respect to plans or arrangements maintained or sponsored a Governmental Entity (including severance, termination indemnities or other similar benefits maintained for employees outside of the U.S.) have been timely made or fully
accrued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.13 </B><B><U>Environmental Matters</U></B>. Except as would not have a Company Material Adverse
Effect: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) None of the Private Group Companies have received any written communication or, to the Company&#146;s knowledge, other
communication from any Governmental Entity or any other Person regarding any actual, alleged, or potential violation of, or Liability under, any Environmental Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) There is no Proceeding pending or, to the Company&#146;s knowledge, threatened against any Private Group Company in respect to any
Environmental Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) There has been no manufacture, release, treatment, storage, disposal, arrangement for disposal, transport or
handling of, contamination by, or exposure of any Person to, any Hazardous Substances that has given rise to any Liability pursuant to Environmental Laws for any Private Group Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.14 </B><B><U>Intellectual Property</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as would not have a Company Material Adverse Effect, (i)&nbsp;all necessary fees and filings with respect to any Company Registered
Intellectual Property have been timely submitted to the relevant intellectual property office or Governmental Entity and Internet domain name registrars to maintain such Company Registered Intellectual Property in full force and effect and
(ii)&nbsp;there are no Proceedings pending, including litigations, interference, <FONT STYLE="white-space:nowrap">re-examination,</FONT> <I>inter </I><I>partes</I> review, reissue, opposition, nullity, or cancellation proceedings, that relate to any
of the Company Registered Intellectual Property and, to the Company&#146;s knowledge, no such Proceedings are threatened in writing by any Governmental Entity or any other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as would not have a Company Material Adverse Effect, (i)&nbsp;a Group Company exclusively owns all right, title and interest in and
to all Company Owned Intellectual Property, free and clear of all Liens (other than Permitted Liens) and (ii)&nbsp;for all issued Patents owned by the Group Companies, each named inventor on the Patent has assigned their rights to a Group Company.
Except as would not have a Company Material Adverse Effect, (x)&nbsp;the applicable Group Company has rights under all Contracts for Company Licensed Intellectual Property to use, sell, license and otherwise exploit, as the case may be, all Company
Licensed Intellectual Property licensed pursuant to such Contracts as the same is currently used, sold, licensed and otherwise exploited by such Group Company, (y)&nbsp;the Company Owned Intellectual Property and the Company Licensed Intellectual
Property, to the Company&#146;s knowledge, constitute all of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Intellectual Property Rights used or held for use by the Group Companies in the operation of their respective businesses, and all Intellectual Property Rights necessary and sufficient to enable
the Group Companies to conduct their respective businesses as currently conducted (it being understood that this <U>Section</U><U></U><U>&nbsp;3.14(b)(y)</U> is not a representation or warranty with respect to any infringement, misappropriation or
other violations of third-party Intellectual Property Rights) and (z)&nbsp;the Company Registered Intellectual Property, to the Company&#146;s knowledge, is valid, subsisting and enforceable (in each case, subject to applicable bankruptcy,
insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors&#146; rights and subject to general principles of equity). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as would not have a Company Material Adverse Effect, each Group Company&#146;s employees, consultants, advisors and independent
contractors who independently or jointly contributed to or otherwise participated in the authorship, invention, creation, improvement, modification or development of any Company Owned Intellectual Property have assigned or have agreed to a present
assignment to such Group Company of all Intellectual Property Rights authored, invented, created, improved, modified or developed by such person in the course of such person&#146;s employment or other engagement with such Group Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as would not have a Company Material Adverse Effect, (i)&nbsp;each Group Company has taken reasonable steps to safeguard and
maintain the secrecy of any trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and other confidential information owned by each Group Company, (ii)&nbsp;without limiting the foregoing, to the knowledge of the Company, each Group Company
has not disclosed any trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> or confidential information to any other Person unless, such disclosure was under a written <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement
containing reasonably appropriate limitations on use, reproduction and disclosure and (iii)&nbsp;to the Company&#146;s knowledge, there has been no violation or unauthorized access to or disclosure of any trade secrets, <FONT
STYLE="white-space:nowrap">know-how</FONT> or confidential information owned by a Group Company, or of any written obligations with respect to such. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) None of the Company Owned Intellectual Property and, to the Company&#146;s knowledge, none of the Company Licensed Intellectual Property
is subject to any outstanding Order that restricts in any manner the use, sale, transfer, licensing or exploitation thereof by the Group Companies or affects the validity, use or enforceability of any such Company Owned Intellectual Property, except
as would not have a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) To the Company&#146;s knowledge, since January&nbsp;1, 2019, neither the conduct
of the business of the Group Companies nor any of the Company Products offered, marketed, licensed, provided, sold, distributed or otherwise exploited by the Group Companies nor the design, development, manufacturing, reproduction, use, marketing,
offer for sale, sale, importation, exportation, distribution, maintenance or other exploitation of any Company Product infringes, misappropriates or otherwise violates any Intellectual Property Rights of any other Person, except as would not have a
Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Except as would not have a Company Material Adverse Effect, there is no Proceeding pending nor has
any Group Company received any written communications (i)&nbsp;alleging that a Group Company has infringed, misappropriated or otherwise violated any Intellectual Property Rights of any other Person or (ii)&nbsp;challenging the validity,
enforceability, use or exclusive ownership of any Company Owned Intellectual Property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Except as would not have a Company Material Adverse Effect, (i)&nbsp;to the
Company&#146;s knowledge, no Person is infringing, misappropriating, misusing, diluting or violating any Company Owned Intellectual Property and (ii)&nbsp;since January&nbsp;1, 2019, no Group Company has made any written claim against any Person
alleging any infringement, misappropriation or other violation of any Company Owned Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Except as would not have a
Company Material Adverse Effect, to the Company&#146;s knowledge, no event has occurred, and no circumstance or condition exists, that (with or without notice or lapse of time or both) will, or could reasonably be expected to, result in the
delivery, license or disclosure of any source code that constitutes Company Owned Intellectual Property to any Person who is not, as of the date the event occurs or circumstance or condition comes into existence, a current employee or contractor of
a Group Company subject to confidentiality obligations with respect thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) No Group Company has accessed, used, modified, linked
to, created derivative works from or incorporated into any proprietary Software included in the Company Owned Intellectual Property any Public Software, in each case in a manner that (i)&nbsp;requires such Company Owned Intellectual Property to be
licensed, sold, disclosed, distributed, hosted or otherwise made available, including in source code form and/or for the purpose of making derivative works, for any reason, (ii)&nbsp;grants, or requires any Group Company to grant, the right to
decompile, disassemble, reverse engineer or otherwise derive the source code or underlying structure of any Company Owned Intellectual Property, (iii)&nbsp;limits in any manner the ability to charge license fees or otherwise seek compensation in
connection with marketing, licensing or distribution of any Company Owned Intellectual Property or (iv)&nbsp;otherwise imposes any limitation, restriction or condition on the right or ability of any Group Company to use, hold for use, license, host,
distribute or otherwise dispose of any Company Owned Intellectual Property, other than compliance with notice and attribution requirements, in each case, except as would not have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.15 </B><B><U>Labor Matters</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Since January&nbsp;1, 2019, except as has not and would not reasonably be expected to result in, individually or in the aggregate,
material Liability to the Group Companies, taken as a whole, (i)&nbsp;none of the Private Group Companies (A)&nbsp;has or has had any Liability for any failure to pay or delinquency in paying any wages or other compensation for services (including
salaries, wage premiums, commissions, fees or bonuses), or any penalties, fines, interest, or other sums, or (B)&nbsp;has or has had any Liability for any payment to any trust or other fund governed by or maintained by or on behalf of any
Governmental Entity with respect to unemployment compensation benefits, social security, social insurances or other benefits or obligations for any employees of any Private Group Company (other than routine payments to be made in the normal course
of business and consistent with past practice); and (ii)&nbsp;the Private Group Companies have withheld all amounts required by applicable Law or by agreement to be withheld from wages, salaries and other payments to employees or independent
contractors or other service providers of each Private Group Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Since January&nbsp;1, 2019, there has been no &#147;mass layoff&#148; or &#147;plant
closing&#148; as defined by WARN related to any Private Group Company, and the Private Group Companies have not incurred any material Liability under WARN. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) No Private Group Company is a party to or bound by any CBA and no employees of any Private Group Company are represented by any labor
union, labor organization, works council, employee delegate, representative or other employee collective group with respect to their employment. There is no duty on the part of any Private Group Company or, to the knowledge of the Company, any
Public Group Company or Datavant, to bargain with any labor union, labor organization, works council, employee delegate, representative or other employee collective group as a result of the execution and delivery of this Agreement, the Ancillary
Documents or the consummation of the transactions contemplated hereby or thereby. Since January&nbsp;1, 2019, there has been no actual or, to the Company&#146;s knowledge, threatened in writing material unfair labor practice charges, material labor
grievances, material labor arbitrations, material strikes, lockouts, work stoppages, slowdowns, picketing, handbilling or other material labor disputes against any Private Group Company. To the Company&#146;s knowledge, since January&nbsp;1, 2019,
there have been no actual, pending or threated labor organizing activities with respect to any employees of any Private Group Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To the Company&#146;s knowledge, as of the date of this Agreement, there are no unresolved allegations of sexual harassment, or other
discrimination or retaliation, against any executive officer or director of the Company (in his or her capacity as such) that, if known to the public, would bring the Company into material disrepute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) No material employee layoff, facility closure or shutdown (whether voluntary or by Order), <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">reduction-in-force,</FONT></FONT> furlough, temporary layoff, work schedule change or reduction in hours, or material reduction in salary or wages, or other material workforce changes affecting employees of the Private
Group Companies has occurred since the date of the Latest Balance Sheet or is currently contemplated, planned or announced, including as a result of <FONT STYLE="white-space:nowrap">COVID-19</FONT> or any Law, Order, directive, guideline or
recommendation by any Governmental Entity in connection with or in response to <FONT STYLE="white-space:nowrap">COVID-19.</FONT> As of the date of this Agreement, the Private Group Companies have not otherwise experienced any material
employment-related Liability with respect to or arising out of <FONT STYLE="white-space:nowrap">COVID-19</FONT> or any Law, Order, directive, guideline or recommendation by any Governmental Entity in connection with or in response to <FONT
STYLE="white-space:nowrap">COVID-19.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.16 </B><B><U>Insurance</U></B>. Except as would not have a
Company Material Adverse Effect, all policies of fire, liability, workers&#146; compensation, property, casualty and other forms of insurance owned or held by any Private Group Company as of the date of this Agreement, are in full force and effect,
all premiums due and payable thereon as of the date of this Agreement have been paid in full as of the date of this Agreement, and true and complete copies of all such policies have been made available to MAAC. As of the date of this Agreement, no
claim by any Private Group Company is pending under any such policies as to which coverage has been denied or disputed, or rights reserved to do so, by the underwriters thereof, except as would not have a Company Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.17 </B><B><U>Tax Matters</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Group Companies have prepared and filed all material Tax Returns required to have been filed by or with respect to such entities, all
such Tax Returns are true and complete in all material respects, and the Group Companies have paid all material Taxes required to have been paid by or with respect to such entities regardless of whether shown on any Tax Return. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Group Companies have timely withheld and paid to the appropriate Tax Authority all material amounts required to have been withheld and
paid in connection with amounts paid or owing to any employee, independent contractor, other service provider, equity interest holder, creditor or other <FONT STYLE="white-space:nowrap">third-party.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) No Group Company is currently the subject of a Tax audit or examination or has been informed in writing of the commencement or anticipated
commencement of any Tax audit or examination that has not been resolved or completed, in each case, with respect to material Taxes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) No
Group Company has consented to extend or waive the time in which any material Tax may be assessed or collected by any Tax Authority, other than any such extensions or waivers that are no longer in effect or that were extensions of time to file Tax
Returns obtained in the ordinary course of business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) No &#147;closing agreement&#148; as described in Section&nbsp;7121 of the Code
(or any corresponding or similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income Tax Law), private letter rulings, technical advice memoranda or similar agreements or rulings have been entered into or issued by
any Tax Authority to a Group Company, which agreement or ruling would be effective after the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) No Group Company is or has
been a party to any &#147;listed transaction&#148; as defined in Section&nbsp;6707A of the Code and Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4</FONT> (or any corresponding or similar provision of state, local or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> Tax Law). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) There are no Liens for material Taxes on any assets of the Group Companies other
than Liens described in <U>clause (b)</U>&nbsp;of the definition of Permitted Liens. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) During the two (2)-year period ending on the date
of this Agreement, no Group Company was a distributing corporation or a controlled corporation in a transaction purported or intended to be governed by Section&nbsp;355 of the Code (or so much of Section&nbsp;356 of the Code as relates to
Section&nbsp;355 of the Code). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) No Group Company (i)&nbsp;has been a member of an affiliated group filing a consolidated U.S. federal
income Tax Return (other than a group the common parent of which was a Group Company) or (ii)&nbsp;has any material Liability for the Taxes of any Person (other than a Group Company) under Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or any corresponding or similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax Law), as a transferee or successor or by Contract (other than any
customary indemnification provisions contained in any commercial Contract entered into in the ordinary course of business and the principal purpose of which does not relate to Taxes). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) No written claims have ever been made by any Tax Authority in a jurisdiction where a
Group Company does not file Tax Returns that such Group Company is or may be subject to taxation by, or required to file a Tax Return with, that jurisdiction, which claims have not been resolved or withdrawn. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) No Group Company is a party to any Tax allocation, Tax sharing or Tax indemnity or similar agreements (other than any (i)&nbsp;such
agreement with another Group Company or (ii)&nbsp;customary commercial Contract entered into in the ordinary course of business and the principal purpose of which does not relate to Taxes). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) No Group Company has taken or agreed to take any action not contemplated by this Agreement and/or any Ancillary Document that could
reasonably be expected to prevent, impair or impede the Merger from qualifying for the Intended Tax Treatment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) The Company believes
that it is not, and does not expect to become, a &#147;passive foreign investment company&#148; within the meaning of Section&nbsp;1297(a) of the Code (&#147;<U>PFIC</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) Notwithstanding anything to the contrary in this Agreement, Section&nbsp;3.4 (Financial Statements; Undisclosed Liabilities),
Section&nbsp;3.12 (Employee Plans), Section&nbsp;5.5(a)(i) and this <U>Section</U><U></U><U>&nbsp;3.17</U> (Tax Matters) contain the sole representations and warranties of the Group Companies concerning Taxes. Notwithstanding any representation or
warranty in this Agreement (including the representations and warranties set forth in this <U>Section</U><U></U><U>&nbsp;3.17</U> (Tax Matters)), no representation or warranty is being made as to the use or availability of any Tax attribute or
credit of any Group Company in any taxable period (or portion thereof) beginning on the day immediately after the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.18 </B><B><U>Brokers</U></B>. Except for J.P. Morgan Securities LLC, SVB Leerink LLC and Goldman
Sachs&nbsp;&amp; Co. LLC, no broker, finder, investment banker or other Person is entitled to any brokerage fee, finders&#146; fee or other commission in connection with the transactions contemplated by this Agreement based upon arrangements made by
or on behalf of the Company or any of its Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.19 </B><B><U>Real and Personal Property</U></B>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Owned Real Property</U>. No Private Group Company owns any real property. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Leased Real Property</U>. Each Real Property Lease is in full force and effect and is a valid, legal and binding obligation of the
applicable Private Group Company party thereto, enforceable in accordance with its terms against such Private Group Company and, to the Company&#146;s knowledge, each other party thereto (subject to applicable bankruptcy, insolvency, reorganization,
moratorium or other Laws affecting generally the enforcement of creditors&#146; rights and subject to general principles of equity). There is no material breach or default by any Private Group Company or, to the Company&#146;s knowledge, any
counterparty under any Real Property Lease, and, to the Company&#146;s knowledge, no event has occurred which (with or without notice or lapse of time or both) would constitute a material breach or default under any Real Property Lease or would
permit termination of, or a material modification or acceleration thereof, by any counterparty to any Real Property Lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Personal Property</U>. Each <U>Private </U>Group Company has good, marketable and
indefeasible title to, or a valid leasehold interest in or license or right to use, all of the material tangible assets and tangible properties of the <U>Private </U>Group Companies reflected in the Financial Statements or thereafter acquired by the
<U>Private </U>Group Companies, except for assets disposed of in the ordinary course of business or otherwise as permitted by <U>Section</U><U></U><U>&nbsp;5.1(b)</U> (including as set forth in <U>Section</U><U></U><U>&nbsp;5.1(b)</U> of the Company
Disclosure Schedules) or in accordance with <U>Section</U><U></U><U>&nbsp;5.1(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.20
</B><B><U>Transactions with Affiliates</U></B>. <U>Section</U><U></U><U>&nbsp;3.20</U> of the Company Disclosure Schedules sets forth all material Contracts between (a)&nbsp;any Private Group Company or, to the knowledge of the Company, Datavant or
any Public Group Company, on the one hand, and (b)&nbsp;any officer, director, executive (including, for the avoidance of doubt, the Designated Individuals), manager, direct or, to the Company&#146;s knowledge, indirect, equityholder of more than
one percent (1.0%) of the Company Common Shares (each such direct or indirect equityholder, an &#147;<U>Affiliated Shareholder</U>&#148;), or Affiliate, in each case, of the Company, on the other hand (each Person identified in this
<U>clause</U><U></U><U>&nbsp;(b)</U>, a &#147;<U>Company Related Party</U>&#148;), other than (i)&nbsp;Contracts solely between or among the Group Company(ies) and/or Datavant, (ii)&nbsp;with respect to or otherwise related to a Company Related
Party&#146;s (A)&nbsp;employment with (including benefit plans and other ordinary course compensation from) any of the Group Companies, (B)&nbsp;service to any of the Group Companies as a director (or member of a similar governing body) or
(C)&nbsp;in the case of an individual, service to any of the Group Companies as an independent third-party consultant or other <FONT STYLE="white-space:nowrap">non-employee</FONT> service provider (in the case of this <U>clause (C)</U>, on an
arms&#146; length basis and terms), and any ordinary course compensation in connection with any of the foregoing in the preceding <U>clauses</U><U></U><U>&nbsp;(A)</U> through <U>(C)</U>, (iii) Contracts entered into after the date of this Agreement
that are either permitted pursuant to <U>Section</U><U></U><U>&nbsp;5.1(b)</U> (including as set forth in <U>Section</U><U></U><U>&nbsp;5.1(b)</U> of the Company Disclosure Schedules) or entered into in accordance with
<U>Section</U><U></U><U>&nbsp;5.1(b)</U>, (iv) Contracts relating to or entered into in connection with a Company Related Party&#146;s status as an equityholder of such Private Group Company (including the Company Shareholders Agreements and similar
Contracts), (v)&nbsp;commercial agreements entered into in the ordinary course of business on an arms&#146; length basis and terms that are not individually material to the business of the Group Companies, taken as a whole, or (vi)&nbsp;customary
director and officer indemnification agreements that have been made available to MAAC. No Company Related Party (A)&nbsp;owns any material interest in any material asset or property used in any Private Group Company&#146;s business,
(B)&nbsp;possesses, directly or indirectly, any material financial interest in, or is a director or executive officer of, any Person which is a material supplier, vendor, partner, customer or lessor, or other material business relation, of any
Private Group Company or (C)&nbsp;is a material supplier, vendor, partner, customer or lessor, or other material business relation, of any Private Group Company. All Contracts, arrangements, understandings, interests and other matters that are
required to be disclosed pursuant to this <U>Section</U><U></U><U>&nbsp;3.20</U> (including, for the avoidance of doubt, pursuant to the second sentence of this <U>Section</U><U></U><U>&nbsp;3.20</U>) are referred to herein as &#147;<U>Company
Related Party Transactions</U>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.21 </B><B><U>Data Privacy and Security</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as would not have a Company Material Adverse Effect, each Private Group Company has implemented adequate written policies relating
to the Processing of Personal Data as and to the extent required by applicable Law (&#147;<U>Privacy and Data Security Policies</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as would not have a Company Material Adverse Effect, there is no Proceeding
pending or, to the Company&#146;s knowledge, threatened in writing, against any Private Group Company initiated by any Person (including (i)&nbsp;the United States Federal Trade Commission, any state attorney general or similar state official,
(ii)&nbsp;any other Governmental Entity, foreign or domestic or (iii)&nbsp;any regulatory or self-regulatory entity) alleging that any Processing of Personal Data by or on behalf of a Private Group Company is or was in violation of any Privacy and
Security Requirements, nor, to the Company&#146;s knowledge, is there any basis for the foregoing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Since January&nbsp;1, 2019, to the
Company&#146;s knowledge, (i)&nbsp;there has been no unauthorized access to, or use, disclosure, or Processing of Personal Data in the possession or control of any <U>Private </U>Group Company or any of its contractors with regard to any Personal
Data obtained from or on behalf of a <U>Private </U>Group Company, (ii)&nbsp;there have been no unauthorized intrusions or breaches of security into any Company IT Systems, and (iii)&nbsp;none of the <U>Private </U>Group Companies has notified or
been required to notify any Person of any (A)&nbsp;loss, theft or damage of, or (B)&nbsp;other unauthorized or unlawful access to, or use, disclosure or other Processing of, Personal Data, except, in each case of <U>clauses (i)</U>, <U>(ii)</U> and
<U>(iii)</U>, as would not have a Company Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as would not have a Company Material Adverse Effect,
(i)&nbsp;each Private Group Company owns or has licenses to use the Company IT Systems as necessary to operate the business of each Private Group Company as currently conducted, (ii)&nbsp;to the Company&#146;s knowledge, all Company IT Systems are
free from any defect, bug, virus or programming, design or documentation error and (iii)&nbsp;since January&nbsp;1, 2019, there have not been any failures, breakdowns or continued substandard performance of any Company IT Systems that have caused a
failure or disruption of the Company IT Systems other than routine failures or disruptions that have been remediated in the ordinary course of business. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) To the knowledge of the Company, the consummation of this Agreement and any transfers of Personal Data necessary to give effect to the
Agreement will not violate any Privacy and Security Requirement, except as would not have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.22 </B><B><U>Certain Business Practices</U></B>. Except as would not have a Company Material Adverse Effect:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) None of the Private Group Companies, any of their respective officers, directors, or employees or, to the Company&#146;s knowledge,
any of their other Representatives, or any other Persons acting for or on behalf of any of the foregoing,&nbsp;since January&nbsp;1, 2019, (i) has been a Sanctioned Person, (ii)&nbsp;has transacted any business with or for the direct or knowing
indirect benefit of any Sanctioned Person in violation of applicable Sanctions or (iii)&nbsp;has otherwise violated any applicable Sanctions, <FONT STYLE="white-space:nowrap">Ex-Im</FONT> Laws, or anti-boycott Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) None of the Private Group Companies, any of their respective officers, directors or employees or, to the Company&#146;s knowledge, any of
their other Representatives, or any other Persons acting for or on behalf of any of the foregoing has, since January&nbsp;1, 2019, (i) made, offered, promised, paid or received any unlawful bribes, kickbacks, or other similar payments to or from any
Person, (ii)&nbsp;made or paid any contributions, directly or indirectly, to a domestic or foreign political party or candidate for any improper purpose or (iii)&nbsp;otherwise made, offered, received, authorized, promised or paid any improper
payment in violation of any Anti-Corruption Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Private Group Companies have instituted and maintained policies and procedures
designed to ensure compliance with the Anti-Corruption Laws, Sanctions, and <FONT STYLE="white-space:nowrap">Ex-Im</FONT> Laws in each jurisdiction in which any such entity operates. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To the Company&#146;s knowledge, no Private Group Company has, since January&nbsp;1, 2019, been the subject of any allegation, voluntary
disclosure, investigation, prosecution or enforcement action related to any Anti-Corruption Laws, Sanctions, or <FONT STYLE="white-space:nowrap">Ex-Im</FONT> Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.23 </B><B><U>Information Supplied</U></B>. None of the information of the Group Companies included or
incorporated by reference prior to the Closing in the Registration Statement / Proxy Statement will, when the Registration Statement / Proxy Statement is declared effective or when the Registration Statement / Proxy Statement is mailed to the <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders or at the time of the MAAC Shareholders Meeting, and in the case of any amendment thereto, at the time of such amendment, contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading; <U>provided</U> that, notwithstanding the foregoing provisions of
this <U>Section</U><U></U><U>&nbsp;3.23</U>, no representation or warranty is made by the Company or Merger Sub with respect to any information or statements included or incorporated by reference in the Registration Statement / Proxy Statement
supplied by or on behalf of MAAC for use therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.24 </B><B><U>Regulatory Compliance</U></B>. Except as
set forth in <U>Section</U><U></U><U>&nbsp;3.24</U> of the Company Disclosure Schedules: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Group Company conducts (and since
January&nbsp;1, 2019, has conducted) its business in accordance with all Public Health Laws applicable to such Group Company and is not in violation of any such Public Health Law or Order, except as is not and would not reasonably be expected to be,
individually or in the aggregate, material to the Group Companies, taken as a whole. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) No Group Company has received, as of the date
hereof, any written communication from the FDA or other Governmental Entity, including a warning, untitled or notice of violation letter or Form <FONT STYLE="white-space:nowrap">FDA-483,</FONT> that alleges that any Group Company or the research,
development, or manufacture of any Company Product is not in compliance with any Public Health Laws, except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a whole.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) There is (and since January&nbsp;1, 2019 there has been) no Proceeding pending or, to the Company&#146;s knowledge, threatened against
or involving any Group Company related to compliance with Public Health Laws, except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a whole. The Group Companies do
not have, and since January&nbsp;1, 2019 have not had, any Liabilities for failure to comply with any Public Health Laws, except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies,
taken as a whole. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) All preclinical studies, tests, and research being conducted by or on behalf of any
Group Company or with respect to any Company Product are being, and, in each case, at since January&nbsp;1, 2019 have been, to the extent applicable, conducted in compliance with all applicable Laws, including the good laboratory practice
regulations set forth at 21 C.F.R. Part 58, except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a whole. Except as is not and would not reasonably be expected to
be, individually or in the aggregate, material to the Group Companies, taken as a whole, all clinical studies, tests, and research being conducted by or on behalf of the Company or with respect to any Company Product are being and, in each case, at
all times have been, conducted in compliance with all applicable Laws and with good clinical practice, as defined or recognized by FDA, such as in the guidance document E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1), and applicable
provisions of the FDCA and implementing regulations at 21 C.F.R. Parts 50, 54, 56, and 312. Except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a whole, no
preclinical or clinical trial conducted by or on behalf of the Company or with respect to any Company Product has been terminated or suspended prior to completion for safety, data integrity, or <FONT STYLE="white-space:nowrap">non-compliance</FONT>
reasons, and neither the FDA nor any other Governmental Entity or regulatory authority, clinical investigator or institutional review board that has or had jurisdiction over or participated in any such clinical trial has initiated or threatened in
writing to initiate, any action to terminate, delay, suspend or modify any such ongoing preclinical or clinical trial, or, to the Company&#146;s knowledge, to disqualify, restrict or debar any preclinical or clinical investigator or other person
involved in any such preclinical or clinical trial. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) To the Company&#146;s knowledge, as of the date hereof, no information, condition
or circumstance exists that could reasonably be expected to materially adversely affect the acceptance, or the subsequent approval, of any filing, application or request for approval of any Company Product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a
whole, since January&nbsp;1, 2019, none of the Group Companies or, to the Company&#146;s knowledge, any of their respective officers, directors, employees, agents, or suppliers, with respect to any matter relating to the Group Companies or the
business of the Group Companies, has made an untrue statement of a material fact or fraudulent statement to the FDA or other Governmental Entity, failed to disclose a material fact required to be disclosed to the FDA or any other Governmental
Entity, or committed any act, made any statement, or failed to make any statement that, at the time such disclosure was made, could reasonably be expected to provide a basis for the FDA or any other Governmental Entity to invoke its policy
respecting &#147;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#148; set forth in 56 Fed. Reg. 46191 (September 10, 1991) or any similar policy. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a
whole, since January&nbsp;1, 2019, (i)&nbsp;none of the Group Companies or, to the Company&#146;s knowledge, any of their respective officers, directors or employees are or has been excluded, disqualified, debarred, or suspended, or threatened with
exclusion, debarment, or suspension under the FDA&#146;s debarment authority under 21 U.S.C. &#167; 335a or for the award of a contract by any Governmental Entity or for participation in governmental programs such as Medicare or Medicaid,
(ii)&nbsp;none of the Group Companies or, to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company&#146;s knowledge, any of their respective officers, directors or employees are or have been convicted of any crime or engaged in any conduct that could result in debarment or
exclusion under 21 U.S.C. &#167; 335a or any similar Public Health Laws, (iii)&nbsp;no claims, actions, proceedings or investigations that could reasonably be expected to result in such a debarment or exclusion are pending or, to the Company&#146;s
knowledge, threatened against the Group Companies or, to the Company&#146;s knowledge, any of their respective officers, directors or employees and (iv)&nbsp;no Group Company has undergone, or is currently undergoing, any inspection related to any
Company Product&nbsp;or any other Governmental Entity investigation under any Public Health Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.25
</B><B><U>Investment Company Act</U></B><U>. </U>The Company is not required to register as an &#147;investment company&#148; within the meaning of the Investment Company Act<U>.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.26 </B><B><U>SEC Filings and Matters</U></B><U>.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Public Group Company has timely filed or furnished all statements, forms, reports and documents required to be filed or furnished by
it prior to the date of this Agreement with the SEC pursuant to Federal Securities Laws since its initial public offering (collectively, and together with any exhibits and schedules thereto and other information incorporated therein, and as they
have been supplemented, modified or amended since the time of filing, the &#147;<U>Public Group Company SEC Reports</U>&#148;). Each of the Public Group Company SEC Reports, as of their respective dates of filing, and as of the date of any amendment
or filing that superseded the initial filing, complied in all material respects with the applicable requirements of the Federal Securities Laws (including, as applicable, the Sarbanes-Oxley Act and any rules and regulations promulgated thereunder)
applicable to the Public Group Company SEC Reports. As of their respective dates of filing, the Public Group Company SEC Reports did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances under which they were made or will be made, as applicable, not misleading. As of the date of this Agreement, there are no outstanding or unresolved comments in comment
letters received from the SEC with respect to the Public Group Company SEC Reports. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as is not required in reliance on
exemptions from certain reporting requirements by virtue of any Public Group Company&#146;s status as an &#147;emerging growth company&#148; within the meaning of the Securities Act, as modified by the JOBS Act, or as a &#147;smaller reporting
company&#148; within the meaning of the Exchange Act,&nbsp;since the later of January&nbsp;1, 2019 or its initial public offering, (i)&nbsp;each Public Group Company has established and maintained a system of internal controls over financial
reporting (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> and Rule <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act) sufficient to provide reasonable assurance regarding the reliability of its financial
reporting and the preparation of its financial statements for external purposes in accordance with GAAP and (ii)&nbsp;each Public Group Company has established and maintained disclosure controls and procedures (as defined in Rule <FONT
STYLE="white-space:nowrap">13a-15</FONT> and Rule <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act) designed to ensure that material information relating to it is made known to its principal executive officer and principal
financial officer by others within such Public Group Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Since the later of January&nbsp;1, 2019 or the first filing of a
registration statement in connection with its initial public offering, none of the Public Group Companies has taken any action prohibited by Section&nbsp;402 of the Sarbanes-Oxley Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Since the later of January&nbsp;1, 2019 or its initial public offering, each of the
Public Group Companies has complied in all material respects with all applicable listing and corporate governance rules and regulations of its stock exchange. As of the date of this Agreement, there is no material Proceeding pending or, to the
Company&#146;s knowledge, threatened against any Public Group Company by its stock exchange or the SEC with respect to any intention by such entity to deregister the Equity Securities of such Public Group Company or prohibit or terminate the listing
of Equity Securities of such Public Group Company on such stock exchange. None of the Public Group Companies has, as of the date hereof, taken any action that is designed to terminate the registration of any of its Equity Securities that are
registered under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.27 </B><B><U>No Other Representations</U></B>. In entering into this
Agreement and the Ancillary Documents to which it is or will be a party, each of the Company and Merger Sub has relied solely on its own investigation and analysis and the representations and warranties expressly set forth in
<U>Article</U><U></U><U>&nbsp;4</U> and in the Ancillary Documents to which it is or will be a party and no other representations or warranties of MAAC, any MAAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate or any other Person, either
express or implied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.28 </B><B><U>EXCLUSIVITY OF REPRESENTATIONS AND WARRANTIES</U></B>. NOTWITHSTANDING
THE DELIVERY OR DISCLOSURE TO THE COMPANY OR ANY OF ITS REPRESENTATIVES OF ANY DOCUMENTATION OR OTHER INFORMATION (INCLUDING ANY FINANCIAL PROJECTIONS OR OTHER SUPPLEMENTAL DATA), EACH OF THE COMPANY AND MERGER SUB, ON ITS OWN BEHALF AND ON BEHALF
OF ITS REPRESENTATIVES, ACKNOWLEDGES, REPRESENTS, WARRANTS AND AGREES THAT, EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN <U>ARTICLE</U><U></U><U>&nbsp;4</U> OR THE ANCILLARY DOCUMENTS TO WHICH IT OR MERGER SUB, AS APPLICABLE, IS OR WILL BE A PARTY,
NONE OF MAAC, ANY MAAC <FONT STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE OR ANY OTHER PERSON MAKES, AND EACH OF THE COMPANY AND MERGER SUB EXPRESSLY DISCLAIMS, ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND OR NATURE, EXPRESS OR IMPLIED, IN
CONNECTION WITH THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY, INCLUDING AS TO THE MATERIALS RELATING TO THE BUSINESS AND AFFAIRS OR HOLDINGS OF MAAC THAT HAVE BEEN MADE AVAILABLE TO THE COMPANY OR
ANY OF ITS REPRESENTATIVES OR IN ANY PRESENTATION OF THE BUSINESS AND AFFAIRS OF MAAC BY THE MANAGEMENT OR ON BEHALF OF MAAC OR OTHERS IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED HEREBY OR BY THE ANCILLARY DOCUMENTS, AND NO STATEMENT CONTAINED
IN ANY OF SUCH MATERIALS OR MADE IN ANY SUCH PRESENTATION SHALL BE DEEMED A REPRESENTATION OR WARRANTY HEREUNDER OR OTHERWISE OR DEEMED TO BE RELIED UPON BY THE COMPANY, MERGER SUB OR ANY COMPANY <FONT STYLE="white-space:nowrap">NON-PARTY</FONT>
AFFILIATE IN EXECUTING, DELIVERING OR PERFORMING THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. IT IS UNDERSTOOD THAT ANY COST ESTIMATES, PROJECTIONS OR OTHER PREDICTIONS, ANY DATA OR ANY MEMORANDA OR
OFFERING MATERIALS OR PRESENTATIONS, INCLUDING ANY OFFERING MEMORANDUM OR SIMILAR MATERIALS MADE AVAILABLE BY OR ON BEHALF OF MAAC ARE NOT AND SHALL </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
NOT BE DEEMED TO BE OR TO INCLUDE REPRESENTATIONS OR WARRANTIES OF MAAC, ANY MAAC <FONT STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE OR ANY OTHER PERSON, AND ARE NOT AND SHALL NOT BE
DEEMED TO BE RELIED UPON BY THE COMPANY, MERGER SUB OR ANY COMPANY <FONT STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE IN EXECUTING, DELIVERING OR PERFORMING THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR
THEREBY. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES RELATING TO MAAC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to <U>Section</U><U></U><U>&nbsp;8.8</U>, except (a)&nbsp;as set forth on the MAAC Disclosure Schedules, or (b)&nbsp;with respect to
any of the MAAC Fundamental Representations, as set forth in any publicly available MAAC SEC Reports as of the date hereof (excluding any disclosures in any &#147;risk factors&#148; section that do not constitute statements of fact, disclosures in
any forward-looking statements disclaimers and other disclosures that are generally cautionary, predictive or forward-looking in nature), MAAC hereby represents and warrants to the Company and Merger Sub as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.1 </B><B><U>Organization and Qualification</U></B>. MAAC is a corporation duly incorporated, validly existing
and in good standing under the Laws of its jurisdiction of incorporation. The Governing Documents of MAAC are in full force and effect and MAAC is not in material breach or violation of any provision set forth in its Governing Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.2 </B><B><U>Authority</U></B>. MAAC has the requisite corporate power and authority to execute and deliver
this Agreement and each Ancillary Document to which it is or will be a party, to perform its obligations hereunder and thereunder, and to consummate the transactions contemplated hereby and thereby. Subject to the receipt of the MAAC Shareholder
Approval, the execution and delivery of this Agreement, the Ancillary Documents to which MAAC is or will be a party and the consummation of the transactions contemplated hereby and thereby have been (or, in the case of any Ancillary Document entered
into after the date of this Agreement, will be upon execution thereof) duly authorized by all necessary corporate action on the part of MAAC. This Agreement has been and each Ancillary Document to which MAAC is or will be a party will be, upon
execution thereof, duly and validly executed and delivered by MAAC and constitutes or will constitute, upon execution thereof, as applicable, a valid, legal and binding agreement of MAAC (assuming this Agreement has been and the Ancillary Documents
to which MAAC is or will be a party are or will be, upon execution thereof, as applicable, duly authorized, executed and delivered by the other Persons party hereto or thereto), enforceable against MAAC in accordance with their terms (subject to
applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors&#146; rights and subject to general principles of equity). The MAAC Shareholder Approval and the MAAC Sponsor Consent are
the only votes or consents of the holders of any class or series of Equity Securities of MAAC required to approve and adopt this Agreement, the Ancillary Documents to which MAAC is or is contemplated to be a party, the performance of the MAAC&#146;s
obligations hereunder and thereunder and the consummation of the transactions contemplated hereby (including the Merger). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.3 </B><B><U>Consents and Requisite Governmental Approvals;
No Violations</U></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) No consent, approval or authorization of, or designation, declaration or filing with, any Governmental Entity
is required on the part of MAAC with respect to MAAC&#146;s execution, delivery or performance of its obligations under this Agreement or the Ancillary Documents to which it is or will be party or the consummation of the transactions contemplated
hereby or thereby, except for (i)&nbsp;compliance with and filings under the HSR Act and Foreign and Domestic Approval Laws, if applicable, (ii)&nbsp;the filing with the SEC of (A)&nbsp;the Registration Statement / Proxy Statement and the
declaration of the effectiveness thereof by the SEC and (B)&nbsp;such reports under Section&nbsp;13(a) or 15(d) of the Exchange Act as may be required in connection with this Agreement, the Ancillary Documents or the transactions contemplated hereby
or thereby, (iii)&nbsp;such filings with and approvals of Nasdaq to permit the Company Post-Closing Common Shares to be issued in connection with the transactions contemplated by this Agreement and the other Ancillary Documents to be listed on
Nasdaq or in order to deregister the MAAC Shares following the Closing, (iv)&nbsp;the filing of (A)&nbsp;the Certificate of Merger and (B)&nbsp;any filings required under the Companies Act in connection with the Company <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Steps and the Merger, (v)&nbsp;the MAAC Shareholder Approval, (vi)&nbsp;the MAAC Sponsor Consent or (vii)&nbsp;any other consents, approvals, authorizations, designations, declarations, waivers or
filings, the absence of which would not have a MAAC Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) None of the execution or delivery by MAAC of this
Agreement or any Ancillary Document to which it is or will be a party, the performance by MAAC of its obligations hereunder or thereunder or the consummation by MAAC of the transactions contemplated hereby or thereby will, directly or indirectly
(with or without due notice or lapse of time or both) (i)&nbsp;result in a violation or breach of any provision of the Governing Documents of MAAC, (ii)&nbsp;result in a violation or breach of, or constitute a default or give rise to any right of
termination, Consent, cancellation, amendment, modification, suspension, revocation or acceleration under, any of the terms, conditions or provisions of any material Contract to which MAAC is a party, (iii)&nbsp;violate, or constitute a breach
under, any Order or applicable Law to which MAAC or any of its properties or assets are subject or bound or (iv)&nbsp;result in the creation of any Lien upon any of the assets or properties (other than any Permitted Liens) of MAAC, except in the
case of any of <U>clauses</U><U></U><U>&nbsp;(ii)</U> through <U>(iv)</U>&nbsp;above, as would not have a MAAC Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.4 </B><B><U>Brokers</U></B>. Except for the Persons set forth on <U>Section</U><U></U><U>&nbsp;4.4</U> of the
MAAC Disclosure Schedules, no broker, finder, investment banker or other Person is entitled to any brokerage fee, finders&#146; fee or other commission in connection with the transactions contemplated by this Agreement based upon arrangements made
by or on behalf of MAAC or any of its Affiliates. True and complete copies of the engagement agreements in effect as of the date hereof with the Persons set forth on <U>Section</U><U></U><U>&nbsp;4.4</U> of the MAAC Disclosure Schedules have been
provided to the Company prior to the execution of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.5 </B><B><U>Information
Supplied</U></B>. None of the information supplied or to be supplied by or on behalf of MAAC expressly for inclusion or incorporation by reference&nbsp;prior to the Closing in the Registration Statement / Proxy Statement will, when the Registration
Statement / Proxy Statement is declared effective or when the Registration Statement / Proxy Statement is mailed to the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders or at the time of the MAAC Shareholders Meeting, and in the
case of any amendment thereto, at the time of such amendment, contain any untrue statement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made,
not misleading; <U>provided</U> that, notwithstanding the foregoing provisions of this <U>Section</U><U></U><U>&nbsp;4.5</U>, no representation or warranty is made by MAAC with respect to any other information or statements included or incorporated
by reference in the Registration Statement / Proxy Statement, including any such information or statements that were supplied by or on behalf of the Company or Merger Sub for use therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.6 <U>Capitalization of </U><U>MAAC</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Section</U><U></U><U>&nbsp;4.6(a)</U> of the MAAC Disclosure Schedules sets forth a true and complete statement of the number and class
or series (as applicable) of the issued and outstanding MAAC Shares and the number of issued and outstanding MAAC Warrants, in each case, prior to giving effect to the PIPE Financing, the MAAC Shareholder Redemption and the transactions contemplated
by the Sponsor Support Agreement. All issued and outstanding MAAC Shares have been duly authorized and validly issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> All outstanding Equity Securities of MAAC
(i)&nbsp;were not issued in violation of the Governing Documents of MAAC or in violation of any other Contracts to which MAAC is a party or by which it is otherwise bound, and (ii)&nbsp;are not subject to any preemptive rights, call option, right of
first refusal, subscription rights, transfer restrictions or similar rights of any Person (other than transfer restrictions under applicable Securities Laws or under the Governing Documents of MAAC) and were not issued in violation of any preemptive
rights, call option, right of first refusal, subscription rights, transfer restrictions or similar rights of any Person. Except for the MAAC Shares and MAAC Warrants set forth on <U>Section</U><U></U><U>&nbsp;4.6(a)</U> of the MAAC Disclosure
Schedules (assuming that no MAAC Shareholder Redemptions are effected), immediately prior to Closing and before giving effect to the PIPE Financing and the transactions contemplated by the Sponsor Support Agreement, there are no other Equity
Securities of MAAC issued and outstanding. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as expressly contemplated by the PIPE Subscription Agreements or as issued, granted
or entered into, as applicable, in accordance with <U>Section</U><U></U><U>&nbsp;5.10</U> there are no outstanding (A)&nbsp;equity appreciation, phantom equity or profit participation rights or (B)&nbsp;options, restricted stock, phantom stock,
warrants, purchase rights, subscription rights, conversion rights, exchange rights, calls, puts, rights of first refusal or first offer or other Contracts that could require MAAC to, and there is no obligation to MAAC to, issue, sell or otherwise
cause to become outstanding or to acquire, repurchase or redeem any Equity Securities or securities convertible into or exchangeable for Equity Securities of MAAC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Other than as set forth on <U>Section</U><U></U><U>&nbsp;4.6(c)</U> of the MAAC Disclosure Schedule and, except as permitted by
<U>Section</U><U></U><U>&nbsp;5.10(b)</U>, MAAC has no Subsidiaries and does not own or hold, directly or indirectly, any Equity Securities in any Person or the right to acquire any such Equity Security, and MAAC is not a partner, member or similar
participant of or in any partnership, limited liability company or similar business entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) There are no outstanding bonds, debentures, notes or other indebtedness of MAAC having
the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matter on which holders of MAAC Shares may vote. There are no voting trusts, proxies or other Contracts with respect to the voting or transfer
of any MAAC&#146;s Equity Securities between MAAC and any other Person. MAAC is not a party to any shareholders agreement or registration rights agreement relating to MAAC Shares or any other Equity Securities of MAAC. There are no securities issued
by or to which MAAC is a party containing anti-dilution or similar provisions that will be triggered by the consummation of the transactions contemplated by this Agreement or the Ancillary Documents, in each case, that have not been or will not be
waived on or prior to the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Section&nbsp;4.6(e)</U> of the MAAC Disclosure Schedules sets forth a list of all
indebtedness for borrowed money of MAAC as of the date of this Agreement, including the principal amount of such indebtedness, the outstanding balance as of the date of this Agreement, and the debtor and the creditor thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) All outstanding MAAC Equity Securities have been offered, sold and issued in compliance with applicable Law, including Securities Laws, in
all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.7 </B><B><U>SEC Filings</U></B>. MAAC has timely filed or furnished all
statements, forms, reports and documents required to be filed or furnished by it prior to the date of this Agreement with the SEC pursuant to Federal Securities Laws since its initial public offering (collectively, and together with any exhibits and
schedules thereto and other information incorporated therein, and as they have been supplemented, modified or amended since the time of filing, the &#147;<U>MAAC SEC Reports</U>&#148;) and, as of the Closing, will have filed or furnished all other
statements, forms, reports and other documents required to be filed or furnished by it subsequent to the date of this Agreement with the SEC pursuant to Federal Securities Laws through the Closing (collectively, and together with any exhibits and
schedules thereto and other information incorporated therein, and as they have been supplemented, modified or amended since the time of filing, the &#147;<U>Additional MAAC SEC Reports</U>&#148;). Each of the MAAC SEC Reports, as of their respective
dates of filing, and as of the date of any amendment or filing that superseded the initial filing, complied and each of the Additional MAAC SEC Reports, as of their respective dates of filing, and as of the date of any amendment or filing that
superseded the initial filing, will comply, in all material respects with the applicable requirements of the Federal Securities Laws (including, as applicable, the Sarbanes-Oxley Act and any rules and regulations promulgated thereunder) applicable
to the MAAC SEC Reports or the Additional MAAC SEC Reports (for purposes of the Additional MAAC SEC Reports, assuming that all information supplied by or on behalf of Group Companies or the Company Shareholders expressly for inclusion or
incorporation by reference therein, if any, is true and correct in all material respects). As of their respective dates of filing, and as of the date of any amendment or filing that superseded the initial filing, the MAAC SEC Reports and the
Additional MAAC SEC Reports did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made
or will be made, as applicable, not misleading (for purposes of the Additional MAAC SEC Reports, assuming that all information supplied by or on behalf of Group Companies or the Company Shareholders expressly for inclusion or incorporation by
reference therein, if any, is true and correct in all material respects). As of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC with respect to the MAAC SEC Reports. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.8 </B><B><U>Trust Account</U></B>. As of the date of this
Agreement, MAAC has an amount in cash in the Trust Account equal to at least $410,794,357.31. The funds held in the Trust Account are (a)&nbsp;invested in United States &#147;government securities&#148; within the meaning of Section&nbsp;2(a)(16) of
the Investment Company Act, having a maturity of one hundred eight-five (185)&nbsp;days or less or in money market funds meeting certain conditions under Rule <FONT STYLE="white-space:nowrap">2a-7</FONT> promulgated under the Investment Company Act
which invest only in direct U.S. government treasury obligations and (b)&nbsp;held in trust pursuant to that certain Investment Management Trust Agreement, dated October&nbsp;6, 2020 (the &#147;<U>Trust Agreement</U>&#148;), between MAAC and
Continental Stock Transfer&nbsp;&amp; Trust Company, as trustee (the &#147;<U>Trustee</U>&#148;). There are no separate agreements, side letters or other agreements or understandings (whether written or unwritten, express or implied) that would
cause the description of the Trust Agreement in the MAAC SEC Reports to be inaccurate in any material respect or, to MAAC&#146;s knowledge, that would entitle any Person to any portion of the funds in the Trust Account (other than (i)&nbsp;in
respect of deferred underwriting commissions or Taxes, (ii)&nbsp;the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders who shall have elected to redeem their MAAC Class&nbsp;A Shares pursuant to the Governing Documents of MAAC or
(iii)&nbsp;if MAAC fails to complete a business combination within the allotted time period set forth in the Governing Documents of MAAC and liquidates the Trust Account, subject to the terms of the Trust Agreement, MAAC (in limited amounts to
permit MAAC to pay the expenses of the Trust Account&#146;s liquidation, dissolution and winding up of MAAC) and then the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders). Prior to the Closing, none of the funds held in the
Trust Account are permitted to be released, except in the circumstances described in the Governing Documents of MAAC and the Trust Agreement. As of the date of this Agreement, MAAC is not in material default, or delinquent in performance in any
material respect in connection with the Trust Agreement, and, to MAAC&#146;s knowledge, as of the date hereof, no event has occurred which (with due notice or lapse of time or both) would constitute a material default under the Trust Agreement. As
of the date of this Agreement, there are no Proceedings pending with respect to the Trust Account. Since October&nbsp;6, 2020, MAAC has not released any money from the Trust Account (other than interest income earned on the funds held in the Trust
Account as permitted by the Trust Agreement). Upon the consummation of the transactions contemplated hereby (including the distribution of assets from the Trust Account (A)&nbsp;in respect of deferred underwriting commissions or Taxes or (B)&nbsp;to
the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders who have elected to redeem their MAAC Class&nbsp;A Shares pursuant to the Governing Documents of MAAC, each in accordance with the terms of and as set forth in the Trust
Agreement), MAAC shall have no further obligation under either the Trust Agreement or the Governing Documents of MAAC to liquidate or distribute any assets held in the Trust Account, and the Trust Agreement shall terminate in accordance with its
terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.9 </B><B><U>No MAAC Material Adverse Effect</U></B>. During the period beginning on July<U></U> 6,
2020 and ending on the date of this Agreement, no MAAC Material Adverse Effect has occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.10
</B><B><U>Material Contracts</U></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Section</U><U></U><U>&nbsp;4.10(a)</U> of the MAAC Disclosure Schedules sets forth a list of
all material Contracts (other than, for the avoidance of doubt, confidentiality, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> or other similar agreements) to which MAAC is a party or by which any of its assets is bound as of the date
hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as would not have a MAAC Material Adverse Effect, each Contract of a type
required to be listed on <U>Section</U><U></U><U>&nbsp;4.10(a)</U> of the MAAC Disclosure Schedules (together with (x)&nbsp;each Contract entered into after the date of this Agreement that would be required to be set forth on
<U>Section</U><U></U><U>&nbsp;4.10(a)</U> of the MAAC Disclosure Schedules if entered into prior to the execution and delivery of this Agreement and (y)&nbsp;each &#147;material contract&#148; (as such term is defined in Item 601(b)(10) of
Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> of the SEC), each, a &#147;<U>MAAC Material Contract</U>&#148;), (i) is valid and binding on MAAC and, to MAAC&#146;s knowledge, the counterparties thereto, and is in full force and effect and
enforceable in accordance with its terms against MAAC and, to MAAC&#146;s knowledge, the counterparties thereto (subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of
creditors&#146; rights and subject to general principles of equity), (ii) MAAC and, to MAAC&#146;s knowledge, the counterparties thereto are not in material breach of, or default under, any MAAC Material Contract and (iii)&nbsp;no event has occurred
that (with or without due notice or lapse of time or both) would result in a material breach of, or default under, any MAAC Material Contract by MAAC or, to MAAC&#146;s knowledge, the counterparties thereto. MAAC has made available to the Company
true and complete copies of all MAAC Material Contracts in effect as of the date hereof (it being understood and agreed, for the avoidance of doubt, that each MAAC Material Contract set forth in any MAAC SEC Report that is publicly available as of
the date hereof shall be deemed to have been made available to the Company pursuant to this sentence). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.11
</B><B><U>Transactions with Affiliates</U></B>. <U>Section</U><U></U><U>&nbsp;4.11</U> of the MAAC Disclosure Schedules sets forth all Contracts between (a)&nbsp;MAAC, on the one hand, and (b)&nbsp;any officer, director, employee, partner, member,
manager, direct or indirect equityholder (including the MAAC Sponsor) or Affiliate of MAAC<U> </U>or the MAAC Sponsor or any family member of the same household of the foregoing Persons, on the other hand (each Person identified in this
<U>clause</U><U></U><U>&nbsp;(b)</U>, a &#147;<U>MAAC Related Party</U>&#148;), other than (i)&nbsp;Contracts with respect to or otherwise related to a MAAC Related Party&#146;s employment with, or the provision of services to, MAAC (including
benefit plans, indemnification arrangements and other ordinary course compensation), (ii) Contracts entered into after the date of this Agreement that are either permitted pursuant to <U>Section</U><U></U><U>&nbsp;5.10</U> or entered into in
accordance with <U>Section</U><U></U><U>&nbsp;5.10</U>, (iii) Contracts with respect to a MAAC equityholder&#146;s status as an equityholder of MAAC and (iv)&nbsp;customary director and officer indemnification agreements that have been made
available to the Company. No MAAC<U> </U>Related Party (A)&nbsp;owns any interest in any material asset or property used in the business of MAAC or (B)&nbsp;possesses, directly or indirectly, any material financial interest in, or is a director or
executive officer of, any Person which is a material client, supplier, vendor, partner, customer or lessor, or other material business relation, of MAAC. All Contracts, arrangements, understandings, interests and other matters that are required to
be disclosed pursuant to this <U>Section</U><U></U><U>&nbsp;4.11</U> (including, for the avoidance of doubt, pursuant to the second sentence of this <U>Section</U><U></U><U>&nbsp;4.11</U>) are referred to herein as &#147;<U>MAAC Related Party
Transactions</U>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.12 </B><B><U>Litigation</U></B>. As of the date of this Agreement, there is (and
since its organization, incorporation or formation, as applicable, there has been) no Proceeding pending or, to MAAC&#146;s knowledge, threatened against MAAC that, if adversely decided or resolved, would be material to MAAC. As of the date of this
Agreement, neither MAAC nor any of its respective properties or assets is subject to any Order. As of the date of this Agreement, there are (and since July<U></U>&nbsp;6, 2020 through the date of this Agreement, there have been no) no material
Proceedings by MAAC pending against any other Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.13 </B><B><U>Compliance with Applicable Law</U></B>.
(a)&nbsp;MAAC is (and since its organization, incorporation or formation, as applicable, has been) in compliance with all applicable Laws and (b)&nbsp;as of the date hereof, has not received any written communications or, to MAAC&#146;s knowledge,
any other communications from or on behalf of a Governmental Entity that alleges that MAAC is not in compliance with any applicable Law or Order, except in each case of <U>clauses</U><U></U><U>&nbsp;(a)</U> and <U>(b)</U>, as has not had, and would
not reasonably be expected to have, a MAAC Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.14
</B><B><U>MAAC</U></B><B><U>&#146;</U></B><B><U>s Business Activities</U></B>. Since its incorporation, MAAC has not conducted any business activities other than activities (i)&nbsp;in connection with or incident or related to its incorporation or
continuing corporate (or similar) existence, (ii)&nbsp;directed toward the accomplishment of a business combination, including those incident or related to or incurred in connection with the negotiation, preparation or execution of this Agreement or
any Ancillary Documents, the performance of its covenants or agreements in this Agreement or any Ancillary Document or the consummation of the transactions contemplated hereby or thereby or (iii)&nbsp;those that are administrative, ministerial or
otherwise immaterial in nature. Except for this Agreement or the Ancillary Documents or as set forth in MAAC&#146;s Governing Documents, there is no Contract binding upon MAAC or to which MAAC is party which has or would reasonably be expected to
have the effect of prohibiting or materially impairing any business practice of it or its Affiliates, any acquisition of property by it or its Affiliates or the conduct of business by it or its Affiliates (including, in each case, following the
Closing). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.15 </B><B><U>Internal Controls; Listing; Financial Statements</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as is not required in reliance on exemptions from various reporting requirements by virtue of MAAC&#146;s status as an
&#147;emerging growth company&#148; within the meaning of the Securities Act, as modified by the JOBS Act, or &#147;smaller reporting company&#148; within the meaning of the Exchange Act,&nbsp;since its initial public offering, (i)&nbsp;MAAC has
established and maintained a system of internal controls over financial reporting (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> and Rule <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act) sufficient to
provide reasonable assurance regarding the reliability of MAAC&#146;s financial reporting and the preparation of MAAC&#146;s financial statements for external purposes in accordance with GAAP and (ii)&nbsp;MAAC has established and maintained
disclosure controls and procedures (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> and Rule <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act) designed to ensure that material information relating to MAAC is
made known to MAAC&#146;s principal executive officer and principal financial officer by others within MAAC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) MAAC has not taken any
action prohibited by Section&nbsp;402 of the Sarbanes-Oxley Act. There are no outstanding loans or other extensions of credit made by MAAC to any executive officer (as defined in Rule <FONT STYLE="white-space:nowrap">3b-7</FONT> under the Exchange
Act) or director of MAAC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Since its initial public offering, MAAC has complied in all material respects with all applicable listing
and corporate governance rules and regulations of Nasdaq. The classes of securities representing issued and outstanding MAAC Class&nbsp;A Shares are registered pursuant to Section&nbsp;12(b) of the Exchange Act and are listed for trading on Nasdaq.
As of the date of this Agreement, there is no Proceeding pending or, to MAAC&#146;s knowledge, threatened against MAAC by Nasdaq or the SEC with respect to any intention by such entity to deregister MAAC Class&nbsp;A Shares or prohibit or terminate
the listing of MAAC Class&nbsp;A Shares on Nasdaq. As of the date hereof, MAAC has not taken any action that is designed to terminate the registration of MAAC Class&nbsp;A Shares under the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The MAAC SEC Reports contain true and complete copies of the applicable MAAC Financial
Statements. The MAAC Financial Statements (i)&nbsp;fairly present in all material respects the financial position of MAAC as at the respective dates thereof, and the results of its operations, shareholders&#146; equity and cash flows for the
respective periods then ended (subject, in the case of any unaudited interim financial statements, to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments (none of which is expected to be material) and the absence of notes
thereto), (ii)&nbsp;were prepared in conformity with GAAP applied on a consistent basis during the periods indicated (except, in the case of any audited financial statements, as may be indicated in the notes thereto and subject, in the case of any
unaudited financial statements, to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments (none of which is expected to be material) and the absence of notes thereto), (iii) in the case of the audited MAAC Financial Statements,
were audited in accordance with the standards of the PCAOB and (iv)&nbsp;comply in all material respects with the applicable accounting requirements and with the rules and regulations of the SEC, the Exchange Act and the Securities Act in effect as
of the respective dates thereof (including Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> or Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> as applicable). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) MAAC has established and maintains systems of internal accounting controls that are designed to provide, in all material respects,
reasonable assurance that (i)&nbsp;all transactions are executed in accordance with management&#146;s authorization and (ii)&nbsp;all transactions are recorded as necessary to permit preparation of proper and accurate financial statements in
accordance with GAAP and to maintain accountability for MAAC&#146;s and its Subsidiaries&#146; assets. MAAC maintains and, for all periods covered by the MAAC Financial Statements, has maintained books and records of MAAC in the ordinary course of
business that are accurate and complete and reflect the revenues, expenses, assets and liabilities of MAAC in all material respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)
Since its incorporation, MAAC has not received any written complaint, allegation, assertion or claim that there is (i)&nbsp;a &#147;significant deficiency&#148; in the internal controls over financial reporting of MAAC, (ii)&nbsp;a &#147;material
weakness&#148; in the internal controls over financial reporting of MAAC or (iii)&nbsp;fraud, whether or not material, that involves management or other employees of MAAC who have a significant role in the internal controls over financial reporting
of MAAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.16 </B><B><U>No Undisclosed Liabilities</U></B>. Except for the Liabilities (a)&nbsp;set forth
in <U>Section</U><U></U><U>&nbsp;4.16</U> of the MAAC Disclosure Schedules, (b)&nbsp;incurred in connection with the negotiation, preparation or execution of this Agreement or any Ancillary Document, the performance of its covenants or agreements in
this Agreement or any Ancillary Document or the consummation of the transactions contemplated hereby or thereby (including, for the avoidance of doubt, the MAAC Expenses and any Liabilities arising out of, or related to, any Proceeding related to
this Agreement, the Ancillary Documents or the transactions contemplated hereby or thereby, including any shareholder demand or other shareholder Proceedings (including derivative claims) arising out of, or related to, any of the foregoing) (it
being understood and agreed that the expected third parties that are, as of the date hereof, entitled to fees, expenses or other payments in connection with the matters described in this <U>clause (b)</U><U></U>&nbsp;shall be set forth on
<U>Section</U><U></U><U>&nbsp;4.16</U> of the MAAC Disclosure Schedules), (c) set forth or disclosed in the MAAC Financial Statements included in the MAAC SEC Reports, (d)&nbsp;that have arisen since the date of the most recent balance sheet
included in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
MAAC SEC Reports and either are incurred in the ordinary course of business or immaterial and incurred in connection with activities that are administrative or ministerial in nature,
(e)&nbsp;that are either permitted pursuant to <U>Section</U><U></U><U>&nbsp;5.10</U> or incurred in accordance with <U>Section</U><U></U><U>&nbsp;5.10</U> or (f)&nbsp;that would not have a MAAC Material Adverse Effect, MAAC does not have any
Liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.17 </B><B><U>Employees</U></B>. Except as set forth on
<U>Section</U><U></U><U>&nbsp;4.17</U> of the MAAC Disclosure Schedules, and other than any executive officers or directors as described in the MAAC SEC Reports, as of the date of this Agreement, (a)<U></U> MAAC has never employed any employees or
retained any independent contractors, consultants or other individual service providers and (b)<U></U>&nbsp;MAAC has never maintained, sponsored, contributed to or had any direct or indirect Liability under, and does not currently maintain, sponsor,
contribute to or have any direct or indirect Liability under, any <U>&#147;</U>employee benefit plan<U>&#148;</U> (as such term is defined in Section<U></U>&nbsp;3(3) of ERISA, whether or not subject to ERISA), equity or equity-based, deferred
compensation, severance, retention, bonus, incentive, retirement, retiree or post-employment welfare, vacation, and other benefit or compensatory plan, program, policy or Contract. MAAC has no obligations to indemnify, reimburse, make-whole or <FONT
STYLE="white-space:nowrap">&#147;gross-up&#148;</FONT> any person for any Tax or related interest or penalties incurred by such person imposed under Section&nbsp;4999 or 409A of the Code. To MAAC&#146;s knowledge, as of the date of this Agreement,
there are no unresolved allegations of sexual harassment, or other discrimination or retaliation against any executive officer or director of MAAC (in his or her capacity as such) that, if known to the public, would bring MAAC into material
disrepute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.18 </B><B><U>Tax Matters</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) MAAC has prepared and filed all material Tax Returns required to have been filed by or with respect to it, all such Tax Returns are true
and complete in all material respects, and MAAC has paid all material Taxes required to have been paid by or with respect to it regardless of whether shown on any Tax Return. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) MAAC has timely withheld and paid to the appropriate Tax Authority all material amounts required to have been withheld and paid in
connection with amounts paid or owing to any employee, independent contractor, other service provider, equity interest holder, creditor or other <FONT STYLE="white-space:nowrap">third-party.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) MAAC is not currently the subject of a Tax audit or examination and has not been informed in writing of the commencement or anticipated
commencement of any Tax audit or examination that has not been resolved or completed, in each case, with respect to material Taxes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)
MAAC has not consented to extend or waive the time in which any material Tax may be assessed or collected by any Tax Authority, other than any such extensions or waivers that are no longer in effect or that were extensions of time to file Tax
Returns obtained in the ordinary course of business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) No &#147;closing agreement&#148; as described in Section&nbsp;7121 of the Code
(or any corresponding or similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income Tax Law), private letter rulings, technical advice memoranda or similar agreements or rulings have been entered into or issued by
any Tax Authority to MAAC, which agreement or ruling would be effective after the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) MAAC is not nor has it ever been a party to any &#147;listed transaction&#148; as
defined in Section&nbsp;6707A of the Code and Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4</FONT> (or any corresponding or similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax Law).
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) There are no Liens for material Taxes on any assets of MAAC other than Liens described in <U>clause (b)</U>&nbsp;of the definition of
Permitted Liens. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Beginning on the date of its incorporation and though the date of this Agreement, MAAC was not a distributing
corporation or a controlled corporation in a transaction purported or intended to be governed by Section&nbsp;355 of the Code (or so much of Section&nbsp;356 of the Code as relates to Section&nbsp;355 of the Code). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) MAAC (i)&nbsp;has not been a member of an affiliated group filing a consolidated U.S. federal income Tax Return (other than a group the
common parent of which was MAAC) and (ii)&nbsp;does not have any material Liability for the Taxes of any Person (other than MAAC) under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or any corresponding or
similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax Law), as a transferee or successor or by Contract (other than any customary indemnification provisions contained in any commercial Contract entered into in the
ordinary course of business and the principal purpose of which does not relate to Taxes). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) No written claims have ever been made by any
Tax Authority in a jurisdiction where MAAC does not file Tax Returns that MAAC is or may be subject to taxation by, or required to file a Tax Return with, that jurisdiction, which claims have not been resolved or withdrawn. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) MAAC is not a party to any Tax allocation, Tax sharing or Tax indemnity or similar agreements (other than any customary commercial Contract
entered into in the ordinary course of business and the principal purpose of which does not relate to Taxes). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) MAAC is not aware of any
fact or circumstance and has not taken or agreed to take any action not contemplated by this Agreement and/or any Ancillary Documents that could reasonably be expected to prevent, impair or impede the Merger from qualifying for the Intended Tax
Treatment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) Notwithstanding anything to the contrary in this Agreement, <U>Section</U><U></U><U>&nbsp;4.15(d)</U> (Internal Controls;
Listing; Financial Statements), <U>Section</U><U></U><U>&nbsp;4.16</U> (No Undisclosed Liabilities), Section<U></U>&nbsp;4.17 (Employees) and <U>Section</U><U></U><U>&nbsp;4.18</U> (Tax Matters) contains the sole representations and warranties of
MAAC concerning Taxes. Notwithstanding any representation or warranty in this Agreement (including the representations and warranties set forth in this <U>Section</U><U></U><U>&nbsp;4.18</U> (Tax Matters)), no representation or warranty is being
made as to the use or availability of any Tax attribute or credit of MAAC in any taxable period (or portion thereof) beginning on the day immediately after the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.19 </B><B><U>Certain Business Practices</U></B>. Except as
would not have a MAAC Material Adverse Effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) None of MAAC, any of its respective officers, directors or employees or, to MAAC&#146;s
knowledge, any of its other Representatives, or any other Persons acting for or on behalf of any of the foregoing,&nbsp;since July&nbsp;6, 2020, (i) has been a Sanctioned Person, (ii)&nbsp;has transacted any business with or for the direct or
knowing indirect benefit of any Sanctioned Person in violation of applicable Sanctions or (iii)&nbsp;has otherwise violated any applicable Sanctions, <FONT STYLE="white-space:nowrap">Ex-Im</FONT> Laws, or anti-boycott Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) None of MAAC, any of its respective officers, directors or employees or, to MAAC&#146;s knowledge, any of its other Representatives, or any
other Persons acting for or on behalf of any of the foregoing,&nbsp;since July&nbsp;6, 2020, (i) made, offered, promised, paid or received any unlawful bribes, kickbacks or other similar payments to or from any Person, (ii)&nbsp;made or paid any
contributions, directly or indirectly, to a domestic or foreign political party or candidate for any improper purpose or (iii)&nbsp;otherwise made, offered, received, authorized, promised or paid any improper payment in violation of any
Anti-Corruption Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To MAAC&#146;s knowledge, MAAC has not, since July&nbsp;6, 2020, been the subject of any allegation, voluntary
disclosure, investigation, prosecution or enforcement action related to any Anti-Corruption Laws, Sanctions, or <FONT STYLE="white-space:nowrap">Ex-Im</FONT> Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.20 </B><B><U>PIPE Financing</U></B>. MAAC has delivered to the Company a true and complete copy of the fully
executed PIPE Subscription Agreements as in effect as of the date hereof (the&nbsp;&#147;<U>Disclosed Subscription </U><U>Agreements</U>&#148;), each of which is substantially in the form attached hereto as <U>Exhibit A</U>, pursuant to which the
PIPE Investors have collectively committed, on the terms and subject to the conditions therein, to purchase an aggregate of 20,000,000 MAAC Shares for $10.00 per share. Each of the PIPE Subscription Agreements is, as of the date hereof, in full
force and effect (assuming, with respect to each PIPE Investor, that each such PIPE Subscription Agreement has been duly authorized, executed and delivered by each applicable PIPE Investor), and as of the date hereof, none of the PIPE Subscription
Agreements has been withdrawn, rescinded or terminated or otherwise amended or modified in any respect, and, to MAAC&#146;s knowledge, no such amendment or modification is contemplated as of the date hereof. Except as has not and would not
reasonably be expected to cause any of the conditions to a PIPE Investor&#146;s obligation to purchase MAAC Shares under the applicable PIPE Subscription Agreement to not be satisfied, as of the date hereof, MAAC is not in breach of any of the
representations or warranties of MAAC or terms or conditions set forth in any of the PIPE Subscription Agreements. As of the date hereof, no event has occurred which, with or without notice, lapse of time or both, would reasonably be expected to
constitute a material breach, default or failure to satisfy any condition precedent to a PIPE Investor&#146;s obligation to purchase MAAC Shares set forth therein (assuming the accuracy of the representations and warranties of the Company set forth
in this Agreement and, with respect to each PIPE Investor, the accuracy of the representations and warranties of such PIPE Investor set forth in the applicable PIPE Subscription Agreement). As of the date hereof, assuming the accuracy of the
representations and warranties contained in <U>Article</U><U></U><U>&nbsp;3</U> in all material respects and, with respect to each PIPE Investor, the representations and warranties of such PIPE Investor in the applicable PIPE Subscription Agreement
in all material respects, the performance by the Company of its covenants, agreements and obligations to be performed at or prior to the Closing hereunder in all material respects and, with respect to each PIPE Investor, the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
performance by such PIPE Investor of its covenants, agreements and obligations under the applicable PIPE Subscription Agreement in all material respects, MAAC (i)&nbsp;has no knowledge that any
event has occurred that (with or without notice or lapse of time, or both) would constitute a material breach or default under any of the PIPE Subscription Agreements, (ii)&nbsp;has no knowledge of any fact, event or other occurrence that makes any
of the representations or warranties of MAAC in any of the PIPE Subscription Agreements inaccurate in any material respect and (iii)&nbsp;has no knowledge that any of the conditions to the consummation of the transactions contemplated by the PIPE
Subscription Agreements will not be satisfied when required thereunder or that the transaction proceeds contemplated by the PIPE Subscription Agreements will not be made available when required thereunder. As of the date of this Agreement, no PIPE
Investor has notified MAAC in writing of its intention to terminate all or any portion of the Subscription Amount (as defined in the PIPE Subscription Agreements) or not provide the financing contemplated thereunder. Other than as set forth in the
PIPE Subscription Agreements delivered to the Company in connection with the execution of this Agreement, (A)&nbsp;there are no conditions precedent or contingencies to the obligations of the parties under the PIPE Subscription Agreements to make
the full amount of the PIPE Financing available to MAAC on the terms therein, and (B)&nbsp;to the knowledge of MAAC, there are no side letters or other agreements, understandings, contracts or arrangements (written, oral or otherwise) related to the
PIPE Subscription Agreements or the PIPE Financing, other than those entered into with the placement agents of the PIPE Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.21 </B><B><U>Investigation; No Other Representations</U></B>. In entering into this Agreement and the
Ancillary Documents to which it is or will be a party, MAAC has relied solely on its own investigation and analysis and the representations and warranties expressly set forth in <U>Article</U><U></U><U>&nbsp;3</U> and in the Ancillary Documents to
which it is or will be a party and no other representations or warranties of the Company, any Company <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate or any other Person, either express or implied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.22 </B><B><U>EXCLUSIVITY OF REPRESENTATIONS AND WARRANTIES</U></B>. NOTWITHSTANDING THE DELIVERY OR DISCLOSURE
TO MAAC, THE MAAC SPONSOR OR ANY OF THEIR RESPECTIVE REPRESENTATIVES OF ANY DOCUMENTATION OR OTHER INFORMATION (INCLUDING ANY FINANCIAL PROJECTIONS OR OTHER SUPPLEMENTAL DATA), EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN
<U>ARTICLE</U><U></U><U>&nbsp;3</U> OR THE ANCILLARY DOCUMENTS TO WHICH IT OR THE MAAC SPONSOR, AS APPLICABLE, IS OR WILL BE A PARTY, NONE OF THE COMPANY, MERGER SUB, ANY COMPANY <FONT STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE, ANY
COMPANY SHAREHOLDER OR ANY OTHER PERSON MAKES, AND MAAC EXPRESSLY DISCLAIMS, ON BEHALF OF ITSELF, THE MAAC SPONSOR AND THEIR RESPECTIVE REPRESENTATIVES, ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND OR NATURE, EXPRESS OR IMPLIED, IN CONNECTION WITH
THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY, INCLUDING AS TO THE MATERIALS RELATING TO THE BUSINESS AND AFFAIRS OR HOLDINGS OF THE GROUP COMPANIES THAT HAVE BEEN MADE AVAILABLE TO MAAC, THE MAAC
SPONSOR OR ANY OF THEIR RESPECTIVE REPRESENTATIVES OR IN ANY PRESENTATION OF THE BUSINESS AND AFFAIRS OF THE GROUP COMPANIES BY OR ON BEHALF OF THE MANAGEMENT OF THE GROUP COMPANIES OR OTHERS IN CONNECTION WITH THE TRANSACTIONS
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
CONTEMPLATED HEREBY OR BY THE ANCILLARY DOCUMENTS, AND NO STATEMENT CONTAINED IN ANY OF SUCH MATERIALS OR MADE IN ANY SUCH PRESENTATION SHALL BE DEEMED A REPRESENTATION OR WARRANTY HEREUNDER OR
OTHERWISE OR DEEMED TO BE RELIED UPON BY MAAC, THE MAAC SPONSOR, ANY MAAC <FONT STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE OR ANY OF THEIR RESPECTIVE REPRESENTATIVES IN EXECUTING, DELIVERING OR PERFORMING THIS AGREEMENT, THE ANCILLARY
DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. IT IS UNDERSTOOD THAT ANY COST ESTIMATES, PROJECTIONS OR OTHER PREDICTIONS, ANY DATA OR ANY MEMORANDA OR OFFERING MATERIALS OR PRESENTATIONS, INCLUDING ANY OFFERING MEMORANDUM OR SIMILAR
MATERIALS MADE AVAILABLE BY OR ON BEHALF OF ANY OF THE GROUP COMPANIES OR MERGER SUB ARE NOT AND SHALL NOT BE DEEMED TO BE OR TO INCLUDE REPRESENTATIONS OR WARRANTIES OF THE COMPANY, MERGER SUB OR ANY COMPANY
<FONT STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE, AND ARE NOT AND SHALL NOT BE DEEMED TO BE RELIED UPON BY MAAC, THE MAAC SPONSOR, ANY MAAC <FONT STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE OR ANY OF THEIR REPRESENTATIVES IN
EXECUTING, DELIVERING OR PERFORMING THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;5 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COVENANTS<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.1 </B><B><U>Conduct of Business of the Group Companies</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to <U>Section</U><U></U><U>&nbsp;5.1(c)</U>, from and after the date of this Agreement until the earlier of the Closing or the
termination of this Agreement in accordance with its terms, the Company shall, and the Company shall cause the other Private Group Companies to, except as expressly contemplated by this Agreement or any Ancillary Document, as required by applicable
Law, as set forth on <U>Section</U><U></U><U>&nbsp;5.1(a)</U> of the Company Disclosure Schedules, or as consented to in writing by MAAC (such consent not to be unreasonably withheld, conditioned or delayed), use commercially reasonable efforts to
(i)&nbsp;operate the Private Group Companies in the ordinary course of business in all material respects and (ii)&nbsp;maintain and preserve intact in all material respects the business organization, assets, properties and material business
relations of the Private Group Companies, taken as a whole; <U>provided</U> that taking any action that is permitted by an exception to <U>Section</U><U></U><U>&nbsp;5.1(b)</U> (including, for the avoidance of doubt, any exceptions in
<U>Section</U><U></U><U>&nbsp;5.1(b)</U> of the Company Disclosure Schedules) shall be deemed to not be a breach of this <U>Section</U><U></U><U>&nbsp;5.1(a)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Without limiting the generality of the foregoing, and subject to <U>Section</U><U></U><U>&nbsp;5.1(c)</U>, from and after the date of this
Agreement until the earlier of the Closing or the termination of this Agreement in accordance with its terms, the Company shall and shall cause the other Private Group Companies to, except as expressly contemplated by this Agreement or any Ancillary
Document, as required by applicable Law, as set forth on <U>Section</U><U></U><U>&nbsp;5.1(b)</U> of the Company Disclosure Schedules or as consented to in writing by MAAC (such consent not to be unreasonably withheld, conditioned or delayed), not
do any of the following: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) declare, set aside, make or pay a dividend on, or make any other distribution or
payment in respect of, any Equity Securities of the Company or repurchase, redeem or otherwise acquire any outstanding Equity Securities of the Company, other than repurchases, redemptions or other acquisitions of Equity Securities as required by
or, in the case of any employees of the Group Companies following termination of his or her employment, permitted by the terms of the Contracts and Company Equity Plans that have been made available to MAAC and that are in effect on the date of this
Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;(A) merge, consolidate, combine or amalgamate the Company with any Person, or (B)&nbsp;purchase or otherwise acquire
(whether by merging or consolidating with, purchasing any Equity Security in or a substantial portion of the assets of, or by any other manner) any corporation, partnership, association or other business entity or organization or division thereof,
except, in the case of this <U>clause (B)</U>&nbsp;for any such transaction that would not be material to the business of all of the Group Companies, taken as a whole; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) adopt any amendments, supplements, restatements or modifications to the Company&#146;s Governing Documents or the Company Shareholders
Agreements that are material and adverse to the holders of MAAC Shares or that would adversely affect the ability of the Company to perform, or otherwise comply with, any of its covenants, agreements or obligations under this Agreement or any
Ancillary Document or any Company Shareholder to perform, or otherwise comply with, any of its covenants, agreements or obligations under the Transaction Support Agreements; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) other than in the ordinary course of business or pursuant to a Contract that is in effect as of the date hereof, (A)&nbsp;sell, assign,
abandon, lease, exclusively license or otherwise dispose (other than through an issuance or sale of Equity Securities of a Private Group Company other than the Company) of any assets or properties of the Private Group Companies that are material to
the business of all of the Group Companies, taken as a whole or (B)&nbsp;create, subject or incur any Lien (other than any Permitted Liens) on any assets or properties of the Private Group Companies that are material to the business of all of the
Group Companies, taken as a whole; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) issue or grant any equity incentive awards of any Private Group Company, other than (1)&nbsp;the
grant or issuance of any such equity incentive awards by any Private Group Company to any employees, officers, directors or other services providers in the ordinary course of business and consistent with past valuation practices pursuant to any
equity incentive plan in effect as of the date hereof up to the maximum number of shares reserved for issuance thereunder as of the date hereof, (2)&nbsp;the issuance by any Private Group Company of any of its Equity Securities upon the exercise or
settlement of, as applicable, any equity incentive awards outstanding as of the date of this Agreement (or otherwise permitted to be granted or issued hereunder) in accordance with the terms of the applicable equity incentive plan and the underlying
grant, award or similar agreement, (3)&nbsp;the grant or issuance by any Private Group Company of any of its Equity Securities pursuant to offer letters or similar Contracts with service providers entered into in the ordinary course of business and
consistent with past valuation practices and (4)&nbsp;the grant or issuance by any Private Group Company of any of its Equity Securities to any employees, officers, directors or other services providers, which grant or issuance is approved by the
board of directors (or similar governing body) of such Private Group Company, is consistent with past valuation practices and is made pursuant to any equity incentive plan in effect as of the date hereof up to the maximum number of shares reserved
for issuance thereunder as of the date hereof; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) issue or grant any Equity Securities (other than as permitted by
<U>Section</U><U></U><U>&nbsp;5.1(b)(v)</U>) of any Private Group Company, other than (1)&nbsp;in the case of an issuance of Equity Securities of the Company, the issuance of Equity Securities consistent with past valuation practices that represent
less than one percent (1.0%) of the issued and outstanding Equity Securities of the Company as of the date hereof, (2)&nbsp;in the case of an issuance of Equity Securities of any Private Group Company other than the Company, if such issuance is to
any Person (other than a Company Related Party) and would not be material to the business of, or material in amount to, all of the Group Companies, taken as a whole, (3)&nbsp;Equity Securities issued pursuant to offer letters or similar Contracts in
effect as of the date hereof with service providers entered into in the ordinary course of business or pursuant to offer letters or similar Contracts entered into after the date hereof with service providers in the ordinary course of business that
are not Designated Individuals or Affiliated Shareholders, (4)&nbsp;Equity Securities granted or issued to any Person as required under any Contract to which the Private Group Companies are party as of the date of this Agreement (on the terms of
such Contract as they exist as of the date of this Agreement) and (5)&nbsp;Equity Securities issued to a Group Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) incur,
create or assume any indebtedness for borrowed money to a third party in excess of $200&nbsp;million in the aggregate; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;(A)
enter into, or amend or modify in any manner that would be adverse to the MAAC Shareholders in any material respect following the Closing (including, for the avoidance of doubt, by reason of any additional payments or consideration that occur prior
to the Closing) or that would adversely affect the ability of the Company to perform, or otherwise comply with, any of its covenants, agreements or obligations under this Agreement or any Ancillary Document, any Contract required to be or that, if
existing on the date hereof, would be required to be, disclosed on <U>Section</U><U></U><U>&nbsp;3.20</U> of the Company Disclosure Schedules or (B)&nbsp;consummate any other transaction or make any other payments that, if reflected in a Contract
and existing on the date hereof, would be required to be disclosed on disclosed on <U>Section</U><U></U><U>&nbsp;3.20</U> of the Company Disclosure Schedules; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) except (A)&nbsp;as set forth on <U>Section</U><U></U><U>&nbsp;5.1(b)(ix)</U> of the Company Disclosure Schedules or (B)&nbsp;as approved
by the board of directors (or similar governing body) of the applicable Private Group Company in an aggregate amount not to exceed $10&nbsp;million, enter into or provide for, or amend or modify in a manner that would result in material additional
payments or other amounts under (either individually or in the aggregate), any retention, transaction bonus or other similar payments or amounts (other than, for the avoidance of doubt, the grant or issuance of any Equity Securities of any Private
Company permitted by <U>Section</U><U></U><U>&nbsp;5.1(b)(v)</U> or <U>Section</U><U></U><U>&nbsp;5.1(b)(vi)</U>) to any Person that would (either alone or combined with one or more additional circumstances, matters or events) become payable as a
result of the transactions contemplated by this Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) other than in the ordinary course of business, make any loans, advances or
capital contributions to, or guarantees for the benefit of, any Person in an amount in excess of $25&nbsp;million in the aggregate, other than (A)&nbsp;between the Company and any of its Subsidiaries or between any Subsidiaries of the Company and
(B)&nbsp;the reimbursement of expenses of employees and other service providers in the ordinary course of business; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) enter into any settlement agreement or similar Contract the performance of which would
involve the payment by a Private Group Company in excess of $2&nbsp;million individually or $10&nbsp;million in the aggregate, or that imposes, or by its terms will impose at any point in the future, any material,
<FONT STYLE="white-space:nowrap">non-monetary</FONT> obligations on any Private Group Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xii) authorize, recommend, propose or
announce an intention to adopt, or otherwise effect, a plan of (A)&nbsp;complete or partial liquidation, dissolution or restructuring involving any Private Group Company (other than a Private Group Company with no material operations) or
(B)&nbsp;recapitalization, reorganization or similar transaction involving any Private Group Company (other than the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiii) change any Private Group Company&#146;s methods of accounting in any material respect, other than changes required by a change in GAAP
or Law or that are made in accordance with PCAOB standards; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiv) enter into Contract with any broker, finder, investment banker or other
Person under which such Person is or will be entitled to any brokerage fee, finders&#146; fee or other commission in connection with the transactions contemplated by this Agreement or any Ancillary Documents; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xv) enter into any Contract to take, or cause to be taken, any of the actions prohibited by this <U>Section</U><U></U><U>&nbsp;5.1</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything in this <U>Section</U><U></U><U>&nbsp;5.1</U> or this Agreement to the contrary, (i)&nbsp;nothing set forth in
this Agreement shall give MAAC, directly or indirectly, the right to control or direct the operations of the Group Companies prior to the Closing, (ii)&nbsp;any action taken, or omitted to be taken, by any Group Company to the extent such act or
omission is reasonably determined by the Company, based on the advice of outside legal counsel, to be necessary to comply with any Law, Order, directive, pronouncement or guideline issued by a Governmental Entity providing for business closures, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;sheltering-in-place&#148;</FONT></FONT> or other restrictions that relates to, or arises out of, <FONT STYLE="white-space:nowrap">COVID-19</FONT> shall in no event be deemed to
constitute a breach of this <U>Section</U><U></U><U>&nbsp;5.1</U>, (iii) any action taken, or omitted to be taken, by any Group Company to the extent determined by a Group Company to be reasonable and advisable in response to <FONT
STYLE="white-space:nowrap">COVID-19</FONT> shall not be deemed to constitute a breach of this <U>Section</U><U></U><U>&nbsp;5.1</U>; <U>provided</U>, <U>however</U>, that (x)&nbsp;in the case of each of <U>clauses (ii)</U>&nbsp;and <U>(iii)</U>, the
Company shall use reasonable best efforts to give MAAC prior written notice of any such act or omission, to the extent permitted by applicable Law and reasonably practicable, which notice shall describe in reasonable detail the act or omission and
the reason(s) that such act or omission is being taken, or omitted to be taken, pursuant to <U>clause (ii)</U>&nbsp;or <U>(iii)</U> and, in the event that it is permitted by applicable Law but not reasonably practicable for the Company to give the
prior written notice described in this <U>clause (x)</U>, the Company shall instead give such written notice to MAAC as promptly as practicable after such act or omission (<U>provided</U>, <U>further</U>, <U>however</U>, that any failure by the
Company to provide the prior written notice contemplated by this clause (x)&nbsp;that is not in made in bad faith shall not, in and of itself, constitute a breach or default of this <U>clause (x)</U>&nbsp;or a failure to satisfy the condition
precedent set forth in <U>Section</U><U></U><U>&nbsp;6.2(b)</U>) and (y)&nbsp;in no event shall <U>clause (ii)</U>&nbsp;or <U>(iii)</U> be applicable to any act or omission of the type described </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in <U>Sections 5.1(b)(i)</U> through <U>(vi)</U>, <U>Section</U><U></U><U>&nbsp;5.1(b)(viii)</U>, <U>Section</U><U></U><U>&nbsp;5.1(b)(ix)</U>, <U>Section</U><U></U><U>&nbsp;5.1(b)(xii)</U>,
<U>Section</U><U></U><U>&nbsp;5.1(b)(xiii)</U>, and <U>Section</U><U></U><U>&nbsp;5.1(b)(xv)</U> (such covenants or agreements, the &#147;<U>Company Specified Interim Operating Covenants</U>&#148;), and
(iv)<U>&nbsp;Section</U><U></U><U>&nbsp;5.21</U> (and not this <U>Section</U><U></U><U>&nbsp;5.1</U>) shall govern and control with respect Merger Sub&#146;s activities, businesses and other actions from and after the date of this Agreement until
the earlier of the Closing or the termination of this Agreement in accordance with its terms and, in the event that this <U>Section</U><U></U><U>&nbsp;5.1</U> conflicts with <U>Section</U><U></U><U>&nbsp;5.21</U>, then
<U>Section</U><U></U><U>&nbsp;5.21</U> shall govern and control to the extent of such conflict. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) From and after the date of this
Agreement until the earlier of the Closing or the termination of this Agreement in accordance with its terms, the Company shall not, and shall cause the other Private Group Companies that may hold Equity Securities of Datavant not to, take any
action in furtherance of, approve or consent to any dividend, distribution or other payment by Datavant to any Company Related Party (including, if applicable, by voting its Equity Securities of Datavant against any proposal to make any such
dividend, distribution or other payment), except for a dividend, distribution or other payment to the direct holders of Equity Securities of Datavant that is made in accordance with the Datavant Governing Documents and applicable Contracts governing
such Equity Securities (in each case, as in effect as of the date hereof) without the prior written consent of MAAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.2 </B><B><U>Efforts to Consummate</U></B><B><U>; Transaction Litigation</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms and conditions herein provided, each of the Parties shall use reasonable best efforts to take, or cause to be taken,
all actions and to do, or cause to be done, all things reasonably necessary or advisable to consummate and make effective as promptly as reasonably practicable the transactions contemplated by this Agreement (including (i)&nbsp;the satisfaction, but
not waiver, of the closing conditions set forth in <U>Article</U><U></U><U>&nbsp;6</U> and, in the case of any Ancillary Document to which such Party will be a party after the date of this Agreement, to execute and deliver such Ancillary Document
when required pursuant to this Agreement or otherwise, and (ii)&nbsp;using reasonable best efforts to obtain the PIPE Financing on the terms and subject to the conditions set forth in the PIPE Subscription Agreements). Without limiting the
generality of the foregoing, each of the Parties shall use reasonable best efforts to obtain, file with or deliver to, as applicable, any Consents of any Governmental Entities or other Persons necessary, proper or advisable to consummate the
transactions contemplated by this Agreement or the Ancillary Documents. Nothing in this <U>Section</U><U></U><U>&nbsp;5.2</U> obligates any Party or any of its Affiliates to agree to (A)&nbsp;sell, license or otherwise dispose of, or hold separate
and agree to sell, license or otherwise dispose of, any entities, assets or facilities of any Group Company or any entity, facility or asset of such Party or any of its Affiliates, (B)&nbsp;terminate, amend or assign existing relationships and
contractual rights or obligations, (C)&nbsp;amend, assign or terminate existing licenses or other agreements, or (D)&nbsp;enter into new licenses or other agreements. No Party shall agree to any of the foregoing measures, except with MAAC&#146;s and
the Company&#146;s prior written consent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) MAAC shall promptly inform the Company of any communication received by MAAC from any
Governmental Entity and the Company shall promptly inform MAAC of any communication received by the Company from any Governmental Entity, in either case, regarding any of the transactions contemplated by this Agreement or any Ancillary Document.
From and after the date of this Agreement until the earlier of the Closing or termination of this Agreement in accordance with its terms, MAAC, on the one hand, and the Company and Merger Sub, on the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other hand, shall give counsel for the Company (in the case of MAAC) or MAAC (in the case of the Company), a reasonable opportunity to review in advance, and consider in good faith the views of
the other in connection with, any proposed written communication to any Governmental Entity relating to the transactions contemplated by this Agreement or the Ancillary Documents. Each of the Parties agrees not to participate in any substantive
meeting or discussion, either in person or by telephone with any Governmental Entity in connection with the transactions contemplated by this Agreement, unless it consults with, in the case of MAAC, the Company, or, in the case of the Company or
Merger Sub, MAAC in advance and, to the extent not prohibited by such Governmental Entity, gives, in the case of MAAC, the Company, or, in the case of the Company or Merger Sub, MAAC, the opportunity to attend and participate in such meeting or
discussion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything to the contrary in the Agreement, in the event that this <U>Section</U><U></U><U>&nbsp;5.2</U>
conflicts with any other covenant or agreement in this <U>Article</U><U></U><U>&nbsp;5</U> that is intended to specifically address any subject matter, then such other covenant or agreement shall govern and control solely to the extent of such
conflict. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) From and after the date of this Agreement until the earlier of the Closing or termination of this Agreement in accordance
with its terms, MAAC, on the one hand, and the Company, on the other hand, shall each notify the other in writing promptly after learning of any shareholder demands or other shareholder Proceedings (including derivative claims) relating to this
Agreement, any Ancillary Document or any matters relating thereto (collectively, the &#147;<U>Transaction Litigation</U>&#148;) commenced against, in the case of MAAC, MAAC or any of its Representatives (in their capacity as a Representative of
MAAC) or, in the case of the Company, any Group Company or any of their respective Representatives (in their capacity as a Representative of a Group Company). MAAC and the Company shall each (i)&nbsp;keep the other reasonably informed regarding any
Transaction Litigation, (ii)&nbsp;give the other the opportunity to, at its own cost and expense, participate in the defense, settlement and compromise of any such Transaction Litigation and reasonably cooperate with the other in connection with the
defense, settlement and compromise of any such Transaction Litigation, (iii)&nbsp;consider in good faith the other&#146;s advice with respect to any such Transaction Litigation and (iv)&nbsp;reasonably cooperate with each other; <U>provided</U> that
in no event shall (x)&nbsp;MAAC or any of its Representatives settle or compromise any Transaction Litigation without the prior written consent of the Company (not to be unreasonably withheld, conditioned or delayed), or (y)&nbsp;any Group Company
or any of their respective Representatives settle or compromise any Transaction Litigation without the prior written consent of MAAC (not to be unreasonably withheld, conditioned or delayed). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.3 </B><B><U>Confidentiality and Access to Information</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Parties hereby acknowledge and agree that the information being provided in connection with this Agreement and the consummation of the
transactions contemplated hereby is subject to the terms of the Confidentiality Agreement, the terms of which are incorporated herein by reference. Notwithstanding the foregoing or anything to the contrary in this Agreement, in the event that this
<U>Section</U><U></U><U>&nbsp;5.3(a)</U> or the Confidentiality Agreement conflicts with any other covenant or agreement contained in this Agreement or any Ancillary Document that contemplates the disclosure, use or provision of information or
otherwise, then such other covenant or agreement contained in this Agreement or such Ancillary Document, as applicable, shall govern and control to the extent of such conflict. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) From and after the date of this Agreement until the earlier of the Closing Date or the
termination of this Agreement in accordance with its terms, upon reasonable advance written notice, the Company shall use reasonable best efforts to provide, or cause to be provided, to MAAC and its Representatives during normal business hours
reasonable access to the directors, officers, books and records and properties of the Private Group Companies (in a manner so as to not interfere with the normal business operations of the Private Group Companies). Notwithstanding the foregoing,
none of the Private Group Companies shall be required to provide, or cause to be provided to, MAAC or any of its Representatives any information (i)&nbsp;if and to the extent doing so would (A)&nbsp;violate any Law to which any Private Group Company
is subject, (B)&nbsp;result in the disclosure of any trade secrets of third parties in breach of any Contract with such third party, (C)&nbsp;violate any legally-binding obligation of any Private Group Company with respect to confidentiality, <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> or privacy, (D)&nbsp;jeopardize protections afforded to any Private Group Company under the attorney-client privilege or the attorney work product doctrine or (E)&nbsp;in the case of any <FONT
STYLE="white-space:nowrap">in-person</FONT> access, be contrary to, or would not be reasonably practicable in light of, any action taken, or omitted to be taken, by any Group Company to the extent determined to be reasonable and advisable in
response to <FONT STYLE="white-space:nowrap">COVID-19</FONT> (<U>provided</U> that, in case of each of <U>clauses</U><U></U><U>&nbsp;(A)</U> through <U>(D)</U>, the Company shall, and shall cause the other Private Group Companies to, use reasonable
best efforts to (x)&nbsp;provide such access as can be provided (or otherwise convey such information regarding the applicable matter as can be conveyed) without violating such privilege, doctrine, Contract, obligation or Law and (y)&nbsp;provide
such information in a manner without violating such privilege, doctrine, Contract, obligation or Law), or (ii)&nbsp;if any Group Company or any Company <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate, on the one hand, and MAAC, any MAAC <FONT
STYLE="white-space:nowrap">Non-Party</FONT> Affiliate or any of their respective Representatives, on the other hand, are adverse parties (or would, in light of then existing facts and circumstances, reasonably be expected to be potentially adverse
parties) in a litigation or dispute and such information is or would reasonably be expected to be pertinent thereto; <U>provided</U> that the Company shall, in the case of <U>clause (i)</U>&nbsp;or <U>(ii)</U>, provide prompt written notice of the
withholding of access or information on any such basis, unless such written notice is prohibited by applicable Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) From and after the
date of this Agreement until the earlier of the Closing Date or the termination of this Agreement in accordance with its terms, upon reasonable advance written notice, MAAC shall use reasonable best efforts to provide, or cause to be provided, to
the Company and its Representatives during normal business hours reasonable access to the directors, officers, books and records of MAAC (in a manner so as to not interfere with the normal business operations of MAAC). Notwithstanding the foregoing,
MAAC shall not be required to provide, or cause to be provided to, the Company or any of its Representatives any information (i)&nbsp;if and to the extent doing so would (A)&nbsp;violate any Law to which MAAC is subject, (B)&nbsp;result in the
disclosure of any trade secrets of third parties in breach of any Contract with such third party, (C)&nbsp;violate any legally-binding obligation of MAAC with respect to confidentiality, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> or
privacy, (D)&nbsp;jeopardize protections afforded to MAAC under the attorney-client privilege or the attorney work product doctrine or (E)&nbsp;in the case of any <FONT STYLE="white-space:nowrap">in-person</FONT> access, be contrary to, or would not
be reasonably practicable in light of, any action taken, or omitted to be taken, by MAAC to the extent determined to be reasonable and advisable in response to <FONT STYLE="white-space:nowrap">COVID-19</FONT> (<U>provided</U> that, in case of each
of <U>clauses (A)</U>&nbsp;through <U>(D)</U>, MAAC shall use, and shall cause the other MAAC to use, reasonable best efforts to (x)&nbsp;provide such access as can be provided (or otherwise convey such information regarding the applicable matter as
can be conveyed) without violating such privilege, doctrine, Contract, obligation or Law and (y)&nbsp;provide such information in a manner without </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
violating such privilege, doctrine, Contract, obligation or Law), or (ii)&nbsp;if MAAC or any MAAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate, on the one hand, and any Group
Company, any Company <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate or any of their respective Representatives, on the other hand, are adverse parties (or would, in light of then existing facts and circumstances, reasonably be expected
to be potentially adverse parties) in a litigation or dispute and such information is or would reasonably be expected to be pertinent thereto; <U>provided</U> that MAAC shall, in the case of <U>clause (i)</U>&nbsp;or <U>(ii)</U>, provide prompt
written notice of the withholding of access or information on any such basis, unless such written notice is prohibited by applicable Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Parties hereby acknowledge and agree that the Confidentiality Agreement shall be automatically terminated effective as of the Closing
without any further action by any Party or any other Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.4 </B><B><U>Public Announcements</U></B>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to <U>Section</U><U></U><U>&nbsp;5.4(b)</U>, <U>Section</U><U></U><U>&nbsp;5.7</U> and <U>Section</U><U></U><U>&nbsp;5.8</U>,
prior to the Closing, none of the Parties shall, and the Parties shall cause their respective controlled Affiliates and its and their respective officers and directors not to and shall use reasonable best efforts to cause their respective other
Representatives not to, issue any press releases or make any public announcements with respect to this Agreement or the transactions contemplated hereby without the prior written consent of the Company and MAAC; <U>provided</U>, <U>however</U>, that
each Party, the MAAC Sponsor and each of their respective Representatives may issue or make, as applicable, any such press release, public announcement or other communication (i)&nbsp;if such press release, public announcement or other communication
is required by applicable Law, in which case the disclosing Party or its applicable Representatives shall, to the extent reasonably practicable and, unless and to the extent prohibited by such applicable Law, (x)&nbsp;if the disclosing Person is
MAAC or a Representative of MAAC, reasonably consult with the Company in connection therewith and provide the Company with an opportunity to review and comment on such press release, public announcement or communication and shall consider any such
comments in good faith, or (y)&nbsp;if the disclosing Party is the Company, Merger Sub or a Representative of any of the foregoing, reasonably consult with MAAC in connection therewith and provide MAAC with an opportunity to review and comment on
such press release, public announcement or communication and shall consider any such comments in good faith, (ii)&nbsp;to the extent such press release, public announcements or other communications contain only information previously disclosed in a
press release, public announcement or other communication previously made in accordance with this <U>Section</U><U></U><U>&nbsp;5.4</U> and (iii)&nbsp;to Governmental Entities in connection with any Consents required to be made under this Agreement,
the Ancillary Documents or in connection with the transactions contemplated hereby or thereby. Notwithstanding anything to the contrary in this <U>Section</U><U></U><U>&nbsp;5.4</U> or otherwise in this Agreement, the Parties agree that the MAAC
Sponsor and its Representatives may provide general information about the subject matter of this Agreement and the transactions contemplated hereby to any direct or indirect former, current or prospective investor or in connection with normal fund
raising or related marketing or informational or reporting activities; <U>provided</U> that the recipients of such information are subject to customary confidentiality obligations prior to the receipt of such information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The initial press release concerning this Agreement and the transactions contemplated
hereby shall be a joint press release in the form agreed by the Company and MAAC prior to the execution of this Agreement and such initial press release (the &#147;<U>Signing Press Release</U>&#148;) shall be released as promptly as reasonably
practicable after the execution of this Agreement on the day thereof. Promptly after the execution of this Agreement, MAAC shall file a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (the &#147;<U>Signing Filing</U>&#148;) with
the Signing Press Release and a description of this Agreement as required by, and in compliance with, the Securities Laws, which Signing Filing shall be mutually agreed upon by the MAAC and the Company prior to such filing (such agreement not to be
unreasonably withheld, conditioned or delayed by either MAAC or the Company, as applicable). The Company, on the one hand, and MAAC, on the other hand, shall mutually agree upon (such agreement not to be unreasonably withheld, conditioned or delayed
by either the Company or MAAC, as applicable) a press release announcing the consummation of the transactions contemplated by this Agreement (the &#147;<U>Closing Press Release</U>&#148;) prior to the Closing, and, on the Closing Date (or such other
date as may be mutually agreed to in writing by MAAC and the Company prior to the Closing), the Parties shall cause the Closing Press Release to be released. Promptly after the Closing (but in any event within four (4)&nbsp;Business Days after the
Closing), the Company shall file a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (the &#147;<U>Closing Filing</U>&#148;) with the Closing Press Release and a description of the Closing as required by Securities Laws, which
Closing Filing shall be mutually agreed upon by the Company and MAAC prior to the Closing (such agreement not to be unreasonably withheld, conditioned or delayed by either the Company or MAAC, as applicable). In connection with the preparation of
each of the Signing Press Release, the Signing Filing, the Closing Press Release and the Closing Filing, each Party shall, upon written request by any other Party, furnish such other Party with all information concerning itself, its directors,
officers and equityholders, and such other matters, in each case, as may be reasonably necessary for such press release or filing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.5 </B><B><U>Tax Matters</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Tax Treatment</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)
The Parties intend that the Merger will qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code, and, for the period beginning on the date hereof until and including the Closing Date, each Party shall use
commercially reasonable efforts not to take any action that would reasonably be expected to cause the Merger to fail to so qualify; <U>provided</U> that, for the avoidance of doubt, the Parties shall not be required to restructure, or otherwise
alter the terms of, the transaction as provided for in this Agreement. The Parties have no plan or intention as of the date hereof and as of the Closing Date to take any action that would reasonably be expected to cause the Mergers to fail to
qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code. For two years following the Closing, (i)&nbsp;the Company shall use commercially reasonable efforts to cause MAAC not to liquidate (including a deemed
liquidation for U.S. federal income tax purposes), and (ii)&nbsp;the Company&#146;s &#147;qualified group&#148; (within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.368-1(d)(4)(ii))</FONT> shall use
commercially reasonable efforts to use at least fifty percent (50%) of the cash and cash equivalents in the Trust Account (but not taking into account any cash acquired in connection with the PIPE Financing) as of immediately prior to the Closing
(and prior to the MAAC Shareholder Redemption) (such cash and cash equivalents, the &#147;Relevant <FONT STYLE="white-space:nowrap">Pre-Redemption</FONT> Assets&#148;) in the Company&#146;s business within the meaning of Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.368-1(d)</FONT> (such business, the &#147;Roivant Business&#148;); provided that if, immediately following and as a result of the MAAC Shareholder Redemption, MAAC holds less than fifty percent (50%) but at
least <FONT STYLE="white-space:nowrap">one-third</FONT> of the Relevant <FONT STYLE="white-space:nowrap">Pre-Redemption</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Assets, then the Company&#146;s &#147;qualified group&#148; (within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.368-1(d)(4)(ii))</FONT> shall use
commercially reasonable efforts to use one hundred percent (100%) of the cash and cash equivalents in the Trust Account (but not taking into account any cash acquired in connection with the PIPE Financing) in the Roivant Business; <U>provided,
further, that </U>if, immediately following and as a result of the MAAC Shareholder Redemption, MAAC holds less than <FONT STYLE="white-space:nowrap">one-third</FONT> of the Relevant <FONT STYLE="white-space:nowrap">Pre-Redemption</FONT> Assets,
then there shall be no limitation or requirement imposed on the Company with respect to the use of MAAC&#146;s assets under this clause (ii)); <U>provided, further, that</U>, for purposes of this sentence, use in the Company&#146;s business or use
in the Roivant Business shall include, without limitation, retention of Relevant <FONT STYLE="white-space:nowrap">Pre-Redemption</FONT> Assets for future use in the business operations of members of the Company&#146;s &#147;qualified group&#148;,
loans of Relevant <FONT STYLE="white-space:nowrap">Pre-Redemption</FONT> Assets to other members of the Company&#146;s &#147;qualified group&#148; for current or future use of such Relevant <FONT STYLE="white-space:nowrap">Pre-Redemption</FONT>
Assets in the business operations of such members, and acquisitions of operating assets or controlling interests in operating entities in exchange for Relevant <FONT STYLE="white-space:nowrap">Pre-Redemption</FONT> Assets, in each case, by any
members of the Company&#146;s &#147;qualified group&#148; (including MAAC). Each Party shall file all Tax Returns consistent with, and take no position inconsistent with (whether in audits, Tax Returns or otherwise), such treatment unless
(x)&nbsp;such Party requests that each of Kirkland&nbsp;&amp; Ellis LLP and Davis Polk&nbsp;&amp; Wardwell LLP provides written confirmation to the effect that the Merger is more likely than not to qualify as a reorganization within the meaning of
Section&nbsp;368(a) of the Code and each such law firm fails to provide such confirmation prior to the later of (A)&nbsp;thirty (30) days following such request is made and (B)&nbsp;sixty (60) days prior to the date on which the relevant Tax Return
is due (taking into account applicable extensions); <U>provided</U> that the Parties shall provide customary factual representations to such law firm; <U>provided</U>, <U>further,</U> that, for the avoidance of doubt, the Parties shall not be
required to restructure, or otherwise alter the terms of, the transaction as provided for in this Agreement; or (y)&nbsp;otherwise required by a final &#147;determination&#148; within the meaning of Section&nbsp;1313(a) of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) MAAC and the Company hereby adopt this Agreement as a &#147;plan of reorganization&#148; within the meaning of Treasury Regulations
Sections <FONT STYLE="white-space:nowrap">1.368-2(g)</FONT> and <FONT STYLE="white-space:nowrap">1.368-3(a).</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) If, in
connection with the preparation and filing of the Registration Statement / Proxy Statement, the SEC requests or requires that a tax opinion be prepared and submitted, MAAC and the Company shall deliver to Kirkland&nbsp;&amp; Ellis LLP and/or Davis
Polk&nbsp;&amp; Wardwell LLP, as relevant, customary Tax representation letters reasonably satisfactory to such counsel and reasonably acceptable to the Company, dated and executed as of the date the Registration Statement / Proxy Statement shall
have been declared effective by the SEC and such other date(s) as determined reasonably necessary by such counsel in connection with the preparation and filing of the Registration Statement / Proxy Statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Tax Matters Cooperation</U>. Each of the Parties shall (and shall cause their respective Affiliates (other than in the case of the
Company, the Public Group Companies) to) cooperate fully, as and to the extent reasonably requested by another Party, in connection with the filing of relevant Tax Returns, and any audit or Tax proceeding. Such cooperation shall include the
retention and (upon the other Party&#146;s request) the provision (with the right to make copies) of records and information reasonably relevant to any Tax proceeding or audit, making employees available on a mutually convenient basis to provide
additional information and explanation of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material provided hereunder. Without limiting the generality of the foregoing, but subject to<U>&nbsp;Section</U><U></U><U>&nbsp;5.5(a)(i)</U>, following the Closing, MAAC shall, and the Company
shall cause MAAC to, (i)&nbsp;comply with the reporting requirements of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.367(a)-3(c)(6)</FONT> and the recordkeeping requirements of Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.368-3</FONT> and (ii)&nbsp;attach to its timely filed U.S. federal income Tax Return for the taxable year in which the Closing occurs, statements meeting the requirements specified in Treasury Regulations
Sections <FONT STYLE="white-space:nowrap">1.367(a)-3(c)(6)</FONT> and <FONT STYLE="white-space:nowrap">1.368-3(a).</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>QEF
Election</U>. If the Company provides to any Company Shareholders information that is reasonably required in order for such Company Shareholders to make an election as contemplated by Section&nbsp;1295 of the Code (and the Treasury Regulations
promulgated thereunder) with respect to the Company for any year that the Company is considered a PFIC, including through provision of the Annual Information Statement described in Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.1295-1(g),</FONT> the Company shall provide the same such information to the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.6 </B><B><U>Exclusive Dealing</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) From the date of this Agreement until the earlier of the Closing or the termination of this Agreement in accordance with its terms, the
Company shall not, and shall cause the Private Group Companies and its and their respective officers and directors not to and shall use reasonable best efforts to cause its other Representatives not to, directly or indirectly: (i)&nbsp;solicit,
initiate, knowingly encourage (including by means of furnishing or disclosing information), knowingly facilitate, discuss or negotiate, directly or indirectly, any inquiry, proposal or offer (written or oral) with respect to a Company Acquisition
Proposal; (ii)&nbsp;furnish or disclose any <FONT STYLE="white-space:nowrap">non-public</FONT> information to any Person in connection with, or that would reasonably be expected to lead to, a Company Acquisition Proposal; (iii)&nbsp;enter into any
Contract or other arrangement or understanding regarding a Company Acquisition Proposal; (iv)&nbsp;make any filings with the SEC in connection with a public offering of any Equity Securities or other securities of the Company (or any successor or
parent company of the Company), other than in connection with the transactions contemplated by, and in accordance with, this Agreement and the Ancillary Documents; or (v)&nbsp;otherwise cooperate in any way with, or assist or participate in, or
knowingly facilitate or knowingly encourage any effort or attempt by any Person to do or seek to do any of the foregoing. The Company agrees to (A)&nbsp;notify MAAC promptly upon receipt of any Company Acquisition Proposal by any Group Company, and
to describe the material terms and conditions of any such Company Acquisition Proposal in reasonable detail (excluding the identity of the Persons making such Company Acquisition Proposal) and (B)&nbsp;keep MAAC reasonably informed on a current
basis of any material modifications to such offer or information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) From the date of this Agreement until the earlier of the Closing or
the termination of this Agreement in accordance with its terms, MAAC shall not, and shall cause MAAC Sponsor and its and their respective officers and directors not to and shall use reasonable best efforts to cause its other Representatives not to,
directly or indirectly: (i)&nbsp;solicit, initiate, knowingly encourage (including by means of furnishing or disclosing information), knowingly facilitate, discuss or negotiate, directly or indirectly, any inquiry, proposal or offer (written or
oral) with respect to a MAAC Acquisition Proposal; (ii)&nbsp;furnish or disclose any <FONT STYLE="white-space:nowrap">non-public</FONT> information to any Person in connection with, or that would reasonably be expected to lead to, a MAAC
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Acquisition Proposal; (iii)&nbsp;enter into any Contract or other arrangement or understanding regarding a MAAC Acquisition Proposal; or (iv)&nbsp;otherwise cooperate in any way with, or assist
or participate in, or knowingly facilitate or knowingly encourage any effort or attempt by any Person to do or seek to do any of the foregoing. MAAC agrees to (A)&nbsp;notify the Company promptly upon receipt of any MAAC Acquisition Proposal by
MAAC, and to describe the material terms and conditions of any such MAAC Acquisition Proposal in reasonable detail (excluding the identity of any person or entity making such MAAC Acquisition Proposal) and (B)&nbsp;keep the Company reasonably
informed on a current basis of any material modifications to such offer or information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, it is understood and
agreed that the covenants and agreements contained in this <U>Section</U><U></U><U>&nbsp;5.6</U> shall not prohibit the Company, MAAC or any of their respective Representatives from taking any actions in the ordinary course that are not otherwise in
violation of this <U>Section</U><U></U><U>&nbsp;5.6</U> (such as answering phone calls) or informing any Person inquiring about a possible Company Acquisition Proposal or MAAC Acquisition Proposal, as applicable, of the existence of the covenants
and agreements contained in this <U>Section</U><U></U><U>&nbsp;5.6</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.7 </B><B><U>Preparation of
Registration Statement / Proxy Statement</U></B>. As promptly as reasonably practicable following the date of this Agreement, MAAC and the Company shall prepare and mutually agree upon (such agreement not to be unreasonably withheld, conditioned or
delayed by either of MAAC or the Company, as applicable), and the Company shall file with the SEC, the Registration Statement / Proxy Statement (it being understood that the Registration Statement / Proxy Statement shall include a proxy statement of
MAAC which will be included therein and which will be used for the MAAC Shareholders Meeting to solicit the adoption and approval of the Transaction Proposals, provide its applicable shareholders with the opportunity to elect to effect the MAAC
Shareholder Redemption, and other matters reasonably related to the Transaction Proposals, all in accordance with and as required by MAAC&#146;s Governing Documents, applicable Law, and any applicable rules and regulations of the SEC and Nasdaq).
Each of MAAC and the Company shall use its reasonable best efforts to (a)&nbsp;cause the Registration Statement / Proxy Statement to comply in all material respects with the applicable rules and regulations promulgated by the SEC (including, with
respect to the Company, the provision of financial statements and pro forma financial statements, and any other information with respect to the Group Companies for all periods and in the form, required to be included in the Registration Statement /
Proxy Statement under Securities Laws (after giving effect to any waivers received), or in response to any comments or requests from the SEC); (b)&nbsp;promptly notify the others of, reasonably cooperate with each other with respect to and respond
promptly to, any comments or requests of the SEC or its staff and, in the case of the Company, provide copies of any written correspondence with the SEC; (c)&nbsp;promptly prepare and mutually agree upon (such agreement not to be unreasonably
withheld, conditioned or delayed by either of MAAC or the Company, as applicable) any amendments or supplements to the Registration Statement / Proxy Statement in order to address comments or requests from the SEC or its staff (which amendments or
supplements shall be promptly filed by the Company); (d) have the Registration Statement / Proxy Statement declared effective under the Securities Act as promptly as reasonably practicable after it is filed with the SEC; and (e)&nbsp;keep the
Registration Statement / Proxy Statement effective through the Closing in order to permit the consummation of the transactions contemplated by this Agreement. MAAC, on the one hand, and the Company and Merger Sub, on the other hand, shall promptly
furnish, or cause to be furnished, to the other all information concerning such Party and its <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates and their respective Representatives and, in the case of the Company, the Company
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Equityholders, that may be required or reasonably requested in connection with any action contemplated by this <U>Section</U><U></U><U>&nbsp;5.7</U> or for inclusion in any other statement,
filing, notice or application made by or on behalf of MAAC or the Company to the SEC or Nasdaq in connection with the transactions contemplated by this Agreement or the Ancillary Documents, including delivering customary tax representation letters
to counsel to enable counsel to deliver any tax opinions requested or required by the SEC to be submitted in connection therewith as described in <U>Section</U><U></U><U>&nbsp;5.5(a)(iii)</U>. In the event there is any tax opinion, comfort letter or
other opinion required to be provided in connection with the Registration Statement / Proxy Statement, notwithstanding anything herein to the contrary, neither this provision nor any other provision in this Agreement shall require counsel to the
Company or MAAC or their respective tax advisors to provide any opinion regarding the qualification of the Merger as a reorganization within the meaning of Section&nbsp;368(a) of the Code or otherwise qualifies for the Intended Tax Treatment, unless
required by applicable Securities Laws or regulations, including SEC Staff Legal Bulletin No.&nbsp;19. If any Party becomes aware of any information that is, in the opinion of such Party, required or desirable to be disclosed in an amendment or
supplement to the Registration Statement / Proxy Statement, then (i)&nbsp;such Party shall promptly inform, in the case of MAAC, the Company, or, in the case of the Company or Merger Sub, MAAC, thereof, (ii)&nbsp;the Company and MAAC shall prepare
and mutually agree upon (such agreement not to be unreasonably withheld, conditioned or delayed in the case of either the Company or MAAC) an amendment or supplement to the Registration Statement / Proxy Statement, (iii)&nbsp;the Company shall file
such mutually agreed upon amendment or supplement with the SEC and (iv)&nbsp;if requested by MAAC, the Parties shall reasonably cooperate in mailing such amendment or supplement to the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC
Shareholders. The Company shall as promptly as reasonably practicable advise MAAC of effectiveness of the Registration Statement / Proxy Statement, of its becoming aware of the issuance of any stop order relating thereto or the suspension of the
qualification of the Company Common Shares for offering or sale in any jurisdiction, and MAAC and the Company shall each use its reasonable best efforts to have any such stop order or suspension lifted, reversed or otherwise terminated. Each of the
Parties shall use reasonable best efforts to ensure that none of the information related to him, her or it or any of his, her or its <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates or its or their respective Representatives or, in the
case of the Company, the Company Equityholders, supplied by or on his, her or its behalf for inclusion or incorporation by reference in the Registration Statement / Proxy Statement will, at the time the Registration Statement / Proxy Statement is
initially filed with the SEC, at each time at which it is amended, and at the time it becomes effective under the Securities Act contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances under which they are made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.8 </B><B><U>MAAC Shareholder Approval</U></B>. As promptly as reasonably practicable following the time at
which the Registration Statement / Proxy Statement is declared effective under the Securities Act, (A)&nbsp;MAAC shall duly give notice of, and use reasonable best efforts to duly convene and hold, a meeting of its shareholders (the &#147;<U>MAAC
Shareholders Meeting</U>&#148;) in accordance with the Governing Documents of MAAC (including by causing the Registration Statement / Proxy Statement to be mailed to the holders of MAAC Shares<U>)</U>, for the purposes of obtaining the MAAC
Shareholder Approval and, if applicable, any approvals related thereto and providing its applicable shareholders with the opportunity to elect to effect a MAAC Shareholder Redemption and (B)&nbsp;use reasonable best efforts to solicit proxies from
the holders of MAAC Shares to vote in favor of each of the Transaction Proposals. Except as otherwise required by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable Law, (i)&nbsp;MAAC shall, through unanimous approval of the MAAC Board, recommend (the &#147;<U>MAAC Board Recommendation</U>&#148;) to its shareholders that such shareholders approve
and adopt (A)&nbsp;this Agreement and the transactions contemplated hereby (including the Merger) (the &#147;<U>Business Combination Proposal</U>&#148;); (B) the issuance of MAAC Shares to the PIPE Investors as required by Nasdaq listing
requirements (the &#147;<U>Nasdaq Proposal</U>&#148;); (C) each other proposal that either the SEC or Nasdaq (or the respective staff members thereof) indicates is necessary in its comments to the Registration Statement / Proxy Statement or in
correspondence related thereto; (D)&nbsp;each other proposal reasonably agreed to by MAAC and the Company as necessary or appropriate in connection with the consummation of the transactions contemplated by this Agreement or the Ancillary Documents;
and (E)&nbsp;a proposal for the postponement or adjournment of the MAAC Shareholders Meeting, if necessary, to permit further solicitation of proxies because there are not sufficient votes to approve and adopt any of the foregoing (such proposals in
(A)&nbsp;through (E), collectively, the &#147;<U>Transaction Proposals</U>&#148;), and (ii)&nbsp;MAAC shall include the MAAC Board Recommendation in the Registration Statement / Proxy Statement. Notwithstanding the foregoing or anything to the
contrary herein, MAAC may postpone or adjourn the MAAC Shareholders Meeting (and MAAC shall adjourn the MAAC Shareholder Meeting if an adjournment is reasonably requested by the Company in writing)&nbsp;(1) to solicit additional proxies because
there are not sufficient votes to constitute the MAAC Shareholder Approval, (2)&nbsp;for the absence of a quorum, (3)&nbsp;to allow reasonable additional time for the filing or mailing of any supplemental or amended disclosures that MAAC (or the
Company) has reasonably determined, based on the advice of outside legal counsel, is reasonably likely to be required under applicable Law and for such supplemental or amended disclosure to be disseminated and reviewed by the <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders prior to the MAAC Shareholders Meeting or (4)&nbsp;if the holders of MAAC Class&nbsp;A Shares have elected to redeem a number of MAAC Class&nbsp;A Shares as of such time that would
reasonably be expected to result in the condition set forth in <U>Section</U><U></U><U>&nbsp;6.3(d)</U> not being satisfied; <U>provided</U> that, without the consent of the Company, in no event shall MAAC postpone or adjourn the MAAC Shareholders
Meeting for more than fifteen (15)&nbsp;Business Days later than the most recently postponed or adjourned meeting or to a date that is beyond the date that is five (5)&nbsp;Business Days prior to the Termination Date. Except as otherwise required by
applicable Law, MAAC covenants that none of the MAAC Board, MAAC or any committee of the MAAC Board shall (i)&nbsp;change, withdraw, withhold, qualify, amend or modify, or publicly propose to change, withdraw, withhold, qualify, amend or modify, in
a manner adverse to the Company, the MAAC Board Recommendation or any other recommendation by the MAAC Board or MAAC of the proposals set forth in the Registration Statement / Proxy Statement, (ii)&nbsp;adopt, approve, recommend or declare advisable
to the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholders, or publicly propose to adopt, approve, recommend or declare advisable, any MAAC Acquisition Proposal or (iii)&nbsp;fail to include the MAAC Board Recommendation in the
Registration Statement / Proxy Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.9 </B><B><U>Merger Sub</U></B><B><U> Shareholder
Approval</U></B>. As promptly as reasonably practicable (and in any event within one (1)<U></U>&nbsp;Business Day) following the date of this Agreement (the <U>&#147;</U><U>Merger Sub Shareholder Approval Deadline</U><U>&#148;</U>), the Company, as
the sole stockholder of Merger Sub, will approve and adopt this Agreement, the Ancillary Documents to which Merger Sub is or will be a party and the transactions contemplated hereby and thereby (including the Merger) (the &#147;<U>Merger Sub
Shareholder Approval</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.10 </B><B><U>Conduct of Business</U></B><B><U>
of</U></B><B><U> </U></B><B><U>MAAC</U></B>. From and after the date of this Agreement until the earlier of the Closing or the termination of this Agreement in accordance with its terms, MAAC shall not, and shall cause its Subsidiaries not to, as
applicable, except as expressly contemplated by this Agreement or any Ancillary Document (including, for the avoidance of doubt, in connection with the PIPE Financing or the transactions contemplated by the Sponsor Support Agreement), as required by
applicable Law, as set forth on <U>Section</U><U></U><U>&nbsp;5.10</U> of the MAAC Disclosure Schedules or as consented to in writing by the Company (such consent not to be unreasonably withheld, conditioned or delayed), do any of the following:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) adopt any amendments, supplements, restatements or modifications to the Trust Agreement, the MAAC Warrant Agreement or the Governing
Documents of MAAC; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) create or form any Subsidiary; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) acquire (including, without limitation, by merger, consolidation, or acquisition of stock or assets or any other business combination) any
corporation, partnership, other business organization or enter into any strategic joint ventures, partnerships or alliances with any other person, or make any loans, advances or capital contributions to, or guarantees for the benefit of, or any
investments in, any Person; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) declare, set aside, make or pay a dividend on, or make any other distribution or payment in respect of,
its Equity Securities, or repurchase, redeem or otherwise acquire, or offer to repurchase, redeem or otherwise acquire, any outstanding of its Equity Securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) split, combine or reclassify any of its capital stock or other Equity Securities or issue any other security in respect of, in lieu of or
in substitution for shares of its capital stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;(i) incur, create or assume any indebtedness for borrowed money (other than
working capital loans from the MAAC Sponsor in an amount not to exceed $3&nbsp;million (it being agreed that no loans from the MAAC Sponsor or any of its Affiliates shall be converted into warrants)) or (ii)&nbsp;guarantee any Liability of any
Person; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) make any loans or advances to, or capital contributions in, any other Person, other than to, or in, MAAC or any of its
Subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) issue any Equity Securities or&nbsp;grant any options, warrants or stock appreciation rights with respect to its Equity
Securities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;(i) amend, modify or renew any MAAC Related Party Transaction, other than (A)&nbsp;the entry into any Contract with
a MAAC Related Party with respect to the incurrence of indebtedness for borrowed money permitted by <U>Section</U><U></U><U>&nbsp;5.10(f)</U> or (B)&nbsp;for the avoidance of doubt, any expiration or automatic extension or renewal of any Contract
pursuant to its terms, (ii)&nbsp;enter into any Contract that would constitute a MAAC Related Party Transaction or (iii)&nbsp;make any material payment to any MAAC Related Party; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) engage in any activities or business, or incur any Liabilities, other than (i)&nbsp;any
activities, businesses or Liabilities that are contemplated by, incurred in connection with or that are otherwise incidental or attendant to this Agreement or any Ancillary Document, the performance of any covenants or agreements hereunder or
thereunder or the consummation of the transactions contemplated hereby or thereby or (ii)&nbsp;the engagement in any activities or businesses, or the incurrence of any Liabilities, permitted by another subsection of this
<U>Section</U><U></U><U>&nbsp;5.10</U> (as modified, for the avoidance of doubt, by <U>Section</U><U></U><U>&nbsp;5.10</U> of the MAAC Disclosure Schedules); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) enter into, or amend or modify any material term of (in a manner adverse to MAAC), terminate (excluding any expiration in accordance with
its terms), or waive or release any material rights, claims or benefits under, any Contract of a type required to be listed on <U>Section</U><U></U><U>&nbsp;4.10(a)</U> of the MAAC Disclosure Schedules (or any Contract, that if existing on the date
hereof, would have been required to be listed on <U>Section</U><U></U><U>&nbsp;4.10(a)</U> of the MAAC Disclosure Schedules); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) enter
into any collective bargaining agreement, except as required by Law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) authorize, recommend, propose or announce an intention to adopt
a plan of complete or partial liquidation, dissolution, restructuring, recapitalization, reorganization or similar transaction involving MAAC; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) make, change or revoke any material election concerning Taxes, enter into any material Tax closing agreement, settle any material Tax
claim or assessment, or consent to any extension or waiver of the limitation period applicable to or relating to any material Tax claim or assessment, other than any such extension or waiver that is obtained in the ordinary course of business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) change any methods of accounting in any material respect, other than changes required by a change in GAAP or Law or that are made in
accordance with PCAOB standards; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) enter into or amend any Contract with any broker, finder, investment banker or other Person under
which such Person is or will be entitled to any brokerage fee, finders&#146; fee or other commission in connection with the transactions contemplated by this Agreement or any Ancillary Document; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q)&nbsp;(i) establish, adopt, modify, amend or terminate any &#147;employee benefit plan&#148; (as such term is defined in Section&nbsp;3(3)
of ERISA, whether or not subject to ERISA), equity or equity-based, deferred compensation, severance, retention, bonus, incentive, retirement, retiree or post-employment welfare, vacation, and other benefit or compensatory plan, program, policy,
arrangement or Contract, (ii)&nbsp;grant or increase (or accelerate the timing of payment or funding of) any compensation or benefits (including, without limitation, any severance or change in control or retention payments) to any employee or
independent contractor or (iii)&nbsp;(A) hire any employee or (B)&nbsp;engage any individual independent contractor or consultant for fees (other than, in the case of this <U>clause (B)</U>, for purposes related, incidental or attendant to this
Agreement or any Ancillary Document, the performance or enforcement of, or compliance with, any covenants or agreements hereunder or thereunder or the consummation of the transactions contemplated hereby or thereby (including, for the avoidance of
doubt, purposes related, incidental or attendant to compliance with applicable Laws or applicable listing or corporate governance rules or regulations of Nasdaq or purposes related, incidental or attendant to its continuing (or similar) existence);
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) make any Transaction Payment; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) enter into any Contract to take, or cause to be taken, any of the actions set forth in this <U>Section</U><U></U><U>&nbsp;5.10</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in this <U>Section</U><U></U><U>&nbsp;5.10</U> or this Agreement to the contrary, (i)&nbsp;nothing set forth in this
Agreement shall give the Company, directly or indirectly, the right to control or direct the operations of MAAC, and (ii)&nbsp;nothing set forth in this Agreement shall prohibit, or otherwise restrict the ability of, MAAC from using the funds held
by MAAC outside the Trust Account to pay any MAAC Expenses or Liabilities of MAAC or from otherwise distributing or paying over any funds held by MAAC outside the Trust Account to the MAAC Sponsor or any of its Affiliates, in each case, prior to the
Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.11 </B><B><U>Nasdaq Listing</U></B><B><U>; MAAC Public Filings</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company shall use its reasonable best efforts (a)&nbsp;to cause the Company Post-Closing Common Shares issuable in accordance with
this Agreement (including, for the avoidance of doubt, the Company Post-Closing Common Shares issuable in respect of MAAC Shares converted into Company Post-Closing Common Shares in the Merger) to be approved for listing on Nasdaq, subject to
official notice of issuance thereof, and (b)&nbsp;to satisfy any applicable initial and continuing listing requirements of Nasdaq, in each case, as promptly as reasonably practicable after the date of this Agreement, and in any event prior to the
Effective Time. MAAC shall, and shall cause its Representatives to, reasonably cooperate with the Company and its Representatives in connection with the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) From and after the date hereof until the earlier of the Closing or termination of this Agreement in accordance with its terms, except as
set forth on <U>Section</U><U></U><U>&nbsp;5.11(b)</U> of the MAAC Disclosure Schedules, MAAC shall (except if, in the case of any reports to be filed or furnished in connection with the transactions contemplated by this Agreement or any Ancillary
Document, the Company&#146;s breach of its applicable covenants, agreements and obligations hereunder would result in the MAAC&#146;s inability to make such filings) use reasonable best efforts to keep current and timely file all reports required to
be filed or furnished with the SEC and otherwise comply in all material respects with its reporting obligations under applicable Securities Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.12 </B><B><U>Trust Account</U></B>. Upon satisfaction or, to the extent permitted by applicable Law, waiver of
the conditions set forth in <U>Article</U><U></U><U>&nbsp;6</U> and provision of notice thereof to the Trustee, (a)&nbsp;at the Closing, MAAC shall (i)&nbsp;cause the documents, certificates and notices required to be delivered to the Trustee
pursuant to the Trust Agreement to be so delivered, and (ii)&nbsp;make all appropriate arrangements to cause the Trustee to (A)&nbsp;pay as and when due all amounts, if any, payable to the holders of MAAC Class&nbsp;A Shares pursuant to the MAAC
Shareholder Redemption, (B)&nbsp;pay the amounts due to the underwriters of MAAC&#146;s initial public offering for their deferred underwriting commissions as set forth in the Trust Agreement and (C)&nbsp;immediately thereafter, pay all remaining
amounts then available in the Trust Account to MAAC in accordance with the Trust Agreement, and (b)&nbsp;thereafter, the Trust Account shall terminate, except as otherwise provided therein. From and after the date hereof until the earlier of the
Closing or termination of this Agreement in accordance with its terms, MAAC shall perform all material obligations required to be performed by it under the Trust Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.13 </B><B><U>Company Shareholder Approval</U></B>.
Substantially concurrently with the execution hereof, the Company has obtained and delivered to MAAC a true and correct copy of an irrevocable written consent (in the form attached hereto as <U>Exhibit F</U>) approving and adopting this Agreement,
the Ancillary Documents to which the Company is or will be a party and the transactions contemplated hereby and thereby (including the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps and the Merger) that is duly executed by the
Company Shareholders that hold at least the requisite number of issued and outstanding Company Common Shares required to approve and adopt such matters in accordance with the Companies Act, the Company&#146;s Governing Documents and the Company
Shareholders Agreements (the &#147;<U>Company Shareholder Written Consent</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.14 </B><B><U>MAAC
Indemnification; Directors</U></B><B><U>&#146;</U></B><B><U> and Officers</U></B><B><U>&#146;</U></B><B><U> Insurance</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each
Party agrees that, to the maximum extent permitted by applicable Law as if the Company were MAAC, (i)&nbsp;all rights to indemnification or exculpation now existing in favor of the directors and officers of MAAC, as provided in the applicable MAAC
Governing Documents or director and officer indemnification agreements, in substantially the form set forth in the MAAC SEC Reports, in either case, solely with respect to any matters occurring at or prior to the Effective Time, shall survive the
transactions contemplated by this Agreement and shall continue in full force and effect from and after the Effective Time for a period of six (6)&nbsp;years and (ii)&nbsp;the Company will perform and discharge, or cause to be performed and
discharged, all obligations to provide such indemnity and exculpation during such six (6)-year period. To the maximum extent permitted by applicable Law, during such six (6)-year period, the Company shall advance, or caused to be advanced, expenses
as provided in the applicable Governing Documents of MAAC as in effect immediately prior to the Effective Time or such indemnification agreements. The indemnification and liability limitation or exculpation provisions of the MAAC Governing Documents
shall not, during such six (6)-year period, be amended, repealed or otherwise modified following the Effective Time in any manner that would materially and adversely affect the rights thereunder of individuals who, as of immediately prior to the
Effective Time, or at any time prior to such time, were directors or officers of MAAC (the &#147;<U>MAAC D&amp;O Persons</U>&#148;) entitled to be so indemnified, have their liability limited or be exculpated with respect to any matters occurring at
or prior to the Effective Time and relating to the fact that such MAAC D&amp;O Person was a director or officer of MAAC or other person entitled to be so indemnified thereunder at or prior to the Effective Time, unless such amendment, repeal or
other modification is required by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company shall not have any obligation under this
<U>Section</U><U></U><U>&nbsp;5.14</U> to any MAAC D&amp;O Person when and if a court of competent jurisdiction shall ultimately determine (and such determination shall have become final and <FONT STYLE="white-space:nowrap">non-appealable)</FONT>
that the indemnification of such MAAC D&amp;O Person in the manner contemplated hereby is prohibited by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) MAAC shall
purchase, or cause to be purchased, at or prior to the Closing, and the Company shall maintain, or cause to be maintained, in effect for a period of six (6)&nbsp;years following the Effective Time, without any lapses in coverage, a &#147;tail&#148;
policy providing directors&#146; and officers&#146; liability insurance coverage for the benefit of those Persons who are currently covered (whether directly, via endorsement or otherwise) by any comparable insurance policies of MAAC in effect as of
the date of this Agreement with respect to matters occurring at or prior to the Effective Time. Such &#147;tail&#148; policy shall provide coverage on terms (with respect to coverage and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amount) that are substantially the same as (and no less favorable in the aggregate to the Persons covered thereby than) the coverage provided under MAAC&#146;s directors&#146; and officers&#146;
liability insurance policies in effect as of the date of this Agreement; <U>provided</U> that MAAC shall not pay a premium for such &#147;tail&#148; policy in excess of three-hundred percent (300%) of the most recent annual premium paid by MAAC
prior to the date of this Agreement and, in such event, MAAC shall purchase or cause to be purchased the maximum coverage available for three-hundred percent (300%) of the most recent annual premium paid by MAAC prior to the date of this Agreement.
Notwithstanding the foregoing or anything to the contrary in this Agreement, if the term of MAAC&#146;s directors&#146; and officers&#146; liability insurance policy in effect as of the date of this Agreement expires on or prior to the Closing Date,
then MAAC may renew such policy or obtain, or cause to be obtained, one or more directors&#146; and officers&#146; insurance policy(ies) that provides for coverage through October&nbsp;9, 2022 on terms (with respect to coverage and amount) that are
substantially the same as the coverage provided under such MAAC&#146;s directors&#146; and officers&#146; liability policy that so expired, and all references in this <U>clause (c)</U>&nbsp;to the directors&#146; and officers&#146; liability
insurance policies shall also be deemed to refer to such policy as renewed or such new policy(ies). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) If the Company or any of its
successors or assigns (i)&nbsp;shall merge or consolidate with or merge into any other corporation or entity and shall not be the surviving or continuing corporation or entity of such consolidation or merger or (ii)&nbsp;shall transfer all or
substantially all of their respective properties and assets as an entity in one or a series of related transactions to any Person, then in each such case, the Company shall use reasonable best efforts to cause the successors or assigns of the
Company shall assume all of the obligations set forth in this <U>Section</U><U></U><U>&nbsp;5.14</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Persons entitled to the
indemnification, liability limitation, exculpation or insurance coverage set forth in this <U>Section</U><U></U><U>&nbsp;5.14</U> are intended to be third-party beneficiaries of this <U>Section</U><U></U><U>&nbsp;5.14</U>. This
<U>Section</U><U></U><U>&nbsp;5.14</U> shall survive the consummation of the transactions contemplated by this Agreement and shall be binding on all successors and assigns of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.15 </B><B><U>Company Indemnification; Directors</U></B><B><U>&#146;</U></B><B><U> and
Officers</U></B><B><U>&#146;</U></B><B><U> Insurance</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Party agrees that (i)&nbsp;all rights to indemnification or
exculpation now existing in favor of the directors and officers of the Group Companies, as provided in the Group Companies&#146; Governing Documents or otherwise in effect as of immediately prior to the Effective Time, in either case, solely with
respect to any matters occurring at or prior to the Effective Time, shall survive the transactions contemplated by this Agreement and shall continue in full force and effect from and after the Effective Time for a period of six (6)&nbsp;years and
(ii)&nbsp;the Company will cause the applicable Group Companies to perform and discharge all obligations to provide such indemnity and exculpation during such six (6)-year period. To the maximum extent permitted by applicable Law, during such six
(6)-year period, the Company shall cause the applicable Group Companies to advance expenses as provided in the applicable Governing Documents of the Group Companies or such indemnification agreements. The indemnification and liability limitation or
exculpation provisions of the Group Companies&#146; Governing Documents shall not, during such six (6)-year period, be amended, repealed or otherwise modified following the Effective Time in any manner that would materially and adversely affect the
rights thereunder of individuals who, as of the Effective Time or at any time prior to the Effective Time, were directors or officers of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Group Companies (the &#147;<U>Company D&amp;O Persons</U>&#148;) entitled to be so indemnified, have their liability limited or be exculpated with respect to any matters occurring prior to
Closing and relating to the fact that such Company D&amp;O Person was a director or officer of any Group Company at or prior to the Effective Time, unless such amendment, repeal or other modification is required by applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) None of the Group Companies shall have any obligation under this <U>Section</U><U></U><U>&nbsp;5.15</U> to any Company D&amp;O Person when
and if a court of competent jurisdiction shall ultimately determine (and such determination shall have become final and <FONT STYLE="white-space:nowrap">non-appealable)</FONT> that the indemnification of such Company D&amp;O Person in the manner
contemplated hereby is prohibited by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company shall purchase, at or prior to the Closing, and the Company shall
maintain, or cause to be maintained, in effect for a period of six (6)&nbsp;years following the Effective Time, without lapses in coverage, a &#147;tail&#148; policy providing directors&#146; and officers&#146; liability insurance coverage for the
benefit of those Persons who are currently covered by any comparable insurance policies of the Group Companies in effect as of the date of this Agreement with respect to matters occurring at or prior to the Effective Time. Such &#147;tail&#148;
policy shall provide coverage on terms (with respect to coverage and amount) that are substantially the same as (and no less favorable in the aggregate to the Persons covered thereby) the coverage provided under the Group Companies&#146;
directors&#146; and officers&#146; liability insurance policies as of the date of this Agreement; <U>provided</U> that the Company shall not pay a premium for such &#147;tail&#148; policy in excess of three-hundred percent (300%) of the most recent
annual premium paid by the Group Companies prior to the date of this Agreement and, in such event, the Company shall purchase the maximum coverage available for three-hundred (300%) of the most recent annual premium paid by the Group Companies prior
to the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) If the Company or any of its successors or assigns (i)&nbsp;shall merge or consolidate with or merge
into any other corporation or entity and shall not be the surviving or continuing corporation or entity of such consolidation or merger or (ii)&nbsp;shall transfer all or substantially all of their respective properties and assets as an entity in
one or a series of related transactions to any Person, then in each such case, the Company shall use reasonable best efforts to cause the successors or assigns of the Company shall assume all of the obligations set forth in this
<U>Section</U><U></U><U>&nbsp;5.15</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Persons entitled to the indemnification, liability limitation, exculpation or insurance
coverage set forth in this <U>Section</U><U></U><U>&nbsp;5.15</U> are intended to be third-party beneficiaries of this <U>Section</U><U></U><U>&nbsp;5.15</U>. This <U>Section</U><U></U><U>&nbsp;5.15</U> shall survive the consummation of the
transactions contemplated by this Agreement and shall be binding on all successors and assigns of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.16 </B><B><U>Post-Closing Directors</U></B>.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company shall take, or cause to be taken, all actions within its power as may be necessary or appropriate such that effective
immediately after the Effective Time (i)&nbsp;the Company Board shall consist of a number of directors determined by the Company (upon reasonable prior consultation with MAAC) prior to the Effective Time, which shall be divided into
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
three (3)&nbsp;classes, designated Class&nbsp;I, II and III, with each class consisting of an approximately equal number of directors determined by the Company (upon reasonable prior consultation
with MAAC) prior to the Effective Time, and (ii)&nbsp;the members of the Company Board are the individuals determined in accordance with <U>Section</U><U></U><U>&nbsp;5.16(b)</U> and <U>Section</U><U></U><U>&nbsp;5.16(c)</U>; <U>provided</U> that,
in any event, (A)&nbsp;at least a majority of such directors that comprise the Company Board shall qualify as &#147;independent directors&#148; under the listing rules of Nasdaq immediately after the Effective Time and (B)&nbsp;no such determination
by the Company shall affect the ability of the MAAC Designee to serve on the Board in the class of directors set forth on <U>Section</U><U></U><U>&nbsp;5.16(b)</U> of the MAAC Disclosure Schedules immediately after the Effective Time or MAAC&#146;s
rights under <U>Section</U><U></U><U>&nbsp;5.16(b)</U> or the Company&#146;s obligations with respect thereto. At or prior to the Closing, the Company will provide the MAAC Designee with and, subject to the entry into the same by the MAAC Designee,
will enter into a director indemnification agreement with the MAAC Designee, in form and substance approved by the Company Board and to be offered to all directors serving on the Company Board as of immediately following the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The individual identified on <U>Section</U><U></U><U>&nbsp;5.16(b)</U> of the MAAC Disclosure Schedules shall be a director on the Company
Board immediately after the Effective Time (provided that such individual is willing to serve and is not prohibited by applicable Law or disability from so serving), with such individual being in the class of directors set forth opposite his or her
name on <U>Section</U><U></U><U>&nbsp;5.16(b)</U> of the MAAC Disclosure Schedules (the &#147;<U>MAAC Designee</U>&#148;). The MAAC Designee may be replaced by MAAC prior to the Effective Time with the prior written consent of the Company and, upon
such written consent to any such replacement individual, <U>Section</U><U></U><U>&nbsp;5.16(b)</U> of the MAAC Disclosure Schedules shall automatically be deemed amended to include such replacement individual as the MAAC Designee in lieu of, and to
serve in the same class of directors as, the individual so replaced; <U>provided</U>, <U>however</U>, that the Company shall not unreasonably withhold, condition or delay its consent to any individual proposed by MAAC prior to the Effective Time as
a replacement if the MAAC Designee (whether the initial or any subsequent MAAC Designee) is no longer able to serve on the Company Board as a result of death or disability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The individuals identified on <U>Section</U><U></U><U>&nbsp;5.16(c)</U> of the Company Disclosure Schedules shall be directors on the
Company Board immediately after the Effective Time, with each such individual being in the class of directors set forth opposite his or her name on <U>Section</U><U></U><U>&nbsp;5.16(c)</U> of the Company Disclosure Schedule (each, a
&#147;<U>Company Designee</U>&#148;). The Company may replace any Company Designee with any individual after reasonably consulting with MAAC with respect to such replacement Company Designee, by giving MAAC written notice, and, upon the Company so
giving written notice of the replacement of such Company Designee and after so reasonably consulting with MAAC with respect thereto, <U>Section</U><U></U><U>&nbsp;5.16(c)</U> of the Company Disclosure Schedules shall automatically be deemed amended
to include such replacement individual as a Company Designee in lieu of, and to serve in the same class of directors as, the individual so replaced. Notwithstanding the foregoing or anything to the contrary herein, unless otherwise agreed in writing
by MAAC, in no event shall less than at least a majority of the directors that comprise the Company Board qualify as &#147;independent directors&#148; under the listing rules of Nasdaq immediately after the Effective Time (whether as a result of the
replacement of any Company Designee as contemplated by this <U>Section</U><U></U><U>&nbsp;5.16(c)</U> or otherwise). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.17 </B><B><U>PCAOB Financial</U></B><B><U>s</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company shall deliver to MAAC, (i)&nbsp;as promptly as reasonably practicable following the date of this Agreement, subject to, in the
case of <U>clause (C)</U>, <U>Section</U><U></U><U>&nbsp;5.17(b)</U>, (A) the audited consolidated balance sheet of the Company as of March&nbsp;31, 2019 and March&nbsp;31, 2020 and the related audited consolidated statements of operations,
comprehensive income (loss), shareholders&#146; equity and redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest and cash flows of the Company for the years then ended, audited in accordance with the standards of the PCAOB,
(B)&nbsp;the audited consolidated balance sheet of the Company as of March&nbsp;31, 2021 and the related audited consolidated statements of operations, comprehensive income (loss), shareholders&#146; equity and redeemable <FONT
STYLE="white-space:nowrap">non-controlling</FONT> interest and cash flows of the Company for the year then ended and (C)&nbsp;customary pro forma financial statements (after giving effect to the transactions contemplated hereby), and (ii)&nbsp;as
promptly as reasonably practicable following the date of the relevant financial statement or other applicable period, the other Closing Company Financial Statements. The Company will use reasonable best efforts to promptly obtain the consents of its
auditors with respect to the Closing Company Financial Statements as may be required by applicable Law or requested by the SEC. The Closing Company Financial Statements (A)&nbsp;will be prepared in accordance with GAAP applied on a consistent basis
throughout the periods indicated (except, in the case of any audited financial statements, as may be specifically indicated in the notes thereto and subject, in the case of any unaudited financial statements, to normal
<FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments (none of which is expected to be individually or in the aggregate material) and the absence of notes thereto), (B) will fairly present in all material respects the financial
position, results of operation and cash flows of the Group Companies as at the date thereof and for the period indicated therein, (C)&nbsp;in the case of any audited financial statements, will be audited in accordance with the standards of the PCAOB
and will contain an unqualified report of the Company&#146;s auditor and (D)&nbsp;will comply in all material respects with the applicable accounting requirements and with the rules and regulations of the SEC, the Exchange Act and the Securities Act
in effect as their respective dates of delivery, at the time of filing of the Registration Statement / Proxy Statement and at the time of effectiveness of the Registration Statement / Proxy Statement (including Regulation <FONT
STYLE="white-space:nowrap">S-X</FONT> or Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> as applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) MAAC shall use its
reasonable best efforts to cooperate with the Company in connection with the preparation of customary pro forma financial statements that are required to be included in the Registration Statement / Proxy Statement. Without limiting the foregoing,
MAAC shall (i)&nbsp;reasonably assist the Company in causing to be prepared in a timely manner any financial information or statements (including customary pro forma financial statements) that involve financial information or statements of MAAC and
that are required to be included in the Registration Statement / Proxy Statement and any other filings to be made by the Company with the SEC in connection with the transactions contemplated by this Agreement or any Ancillary Document and
(ii)&nbsp;obtain the consents of its auditors with respect thereto as may be required by applicable Law or requested by the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.18 </B><B><U>Company Post-Closing Incentive Equity Plan</U></B><B><U>; Company Post-Closing Employee Stock
Purchase Plan</U></B>. Prior to the effectiveness of the Registration Statement / Proxy Statement, the Company Board (a)<U></U>&nbsp;shall approve and adopt the Roivant Sciences Ltd. Amended and Restated 2021 Equity Incentive Plan, substantially in
the form attached hereto as <U>Exhibit G</U>, with any changes or modifications to such form as the Company and MAAC may mutually agree </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(such agreement not to be unreasonably withheld, conditioned or delayed by either the Company or MAAC, as applicable) (the &#147;<U>Company Post-Closing Incentive Equity Plan</U>&#148;), in the
manner prescribed under applicable Laws, effective as of one day prior to the Closing Date, and (b)&nbsp;may approve and adopt an employee stock purchase plan, with such terms and conditions set forth on <U>Exhibit H</U> and with any changes or
modifications thereto as the Company and MAAC may mutually agree (such agreement not to be unreasonably withheld, conditioned or delayed by either the Company or MAAC, as applicable) (the &#147;<U>Company Post-Closing Employee Stock Purchase
Plan</U>&#148;), in the manner prescribed under applicable Laws, effective as of one day prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.19 </B><B><U>Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps</U></B>. The Company shall, and
shall cause its Representatives to, reasonably consult with and reasonably cooperate with MAAC and its Representatives in connection with the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps and otherwise keep MAAC and its
Representatives apprised, in reasonable detail, of the status of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps. Without limiting the generality of the foregoing, (a)&nbsp;within a reasonable time prior to the Closing (and in
any event ten (10)&nbsp;Business Days prior to the Closing Date), the Company shall provide, or cause to be provided, drafts of all agreements, documents and instruments related to the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT>
Steps, and give MAAC and its Representatives a reasonable amount of time to review all such agreements, documents and instruments and shall consider in good faith all comments provided by MAAC and its Representatives and (b)&nbsp;none of the Group
Companies shall enter into any agreement, document or instrument related to the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps that is not in a form and substance reasonably satisfactory to MAAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.20 </B><B><U>Company Related Party Transactions</U></B>. The Company shall use reasonable best efforts to
take, or cause to be taken, all actions necessary or advisable to terminate at or prior to the Closing all of the agreements set forth on <U>Section</U><U></U><U>&nbsp;5.20</U> of the Company Disclosure Schedules without any further Liabilities to
the Company or any of its Affiliates (including the other Group Companies and, from and after the Effective Time, MAAC and its Affiliates). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.21 </B><B><U>Conduct of Business of Merger Sub</U></B>. From and after the date of this Agreement until the
earlier of the Closing or the termination of this Agreement in accordance with its terms, Merger Sub shall not take any action, engage in any activities or business, or incur any Liabilities or obligations, other than (a)&nbsp;those that are
incident to its organization, (b)&nbsp;the execution of this Agreement or any Ancillary Document to which it is or will be a party, (c)&nbsp;those that are contemplated by this Agreement or any Ancillary Document (including the enforcement of any of
its rights or the performance of any of its obligations under this Agreement or any Ancillary Documents and the consummation of the transactions contemplated hereby or thereby) or (d)&nbsp;those that are consented to in writing by MAAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.22 </B><B><U>Notice of Certain Events</U></B>. From and after the date of this Agreement until the earlier of
the Closing or the termination of this Agreement in accordance with its terms, each Party shall use reasonable best efforts to promptly (after having knowledge thereof) notify the other Parties of (i)&nbsp;any written notice or other communication
received by such Party or any of its Representatives (in their capacity as such) from any Governmental Entity of the type that would, if received prior to the execution and delivery of this Agreement, have been required to have been disclosed
pursuant to any section or subsection of <U>Article</U><U></U><U>&nbsp;3</U> or <U>Article</U><U></U><U>&nbsp;4</U>, as applicable, and (ii)&nbsp;the occurrence or <FONT STYLE="white-space:nowrap">non-occurrence</FONT> of any event the occurrence or
<FONT STYLE="white-space:nowrap">non-occurrence</FONT> of which, as the case </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be, would reasonably be expected to cause any condition to the other Parties&#146; obligations to consummate the transactions contemplated hereby set forth in
<U>Article</U><U></U><U>&nbsp;6</U> not to be satisfied at any time from the date of this Agreement to the Effective Time; <U>provided</U>, <U>however</U>, that any failure by a Party to provide such notice that is not in made in bad faith shall
not, in and of itself, constitute a breach or default of this <U>Section</U><U></U><U>&nbsp;5.22</U> or a failure to satisfy the condition precedent set forth in <U>Section</U><U></U><U>&nbsp;6.2(b)</U> or <U>Section</U><U></U><U>&nbsp;6.3(b)</U>,
as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.23 </B><B><U>PIPE Subscription Agreements</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) MAAC shall use its reasonable best efforts to (i)&nbsp;obtain the PIPE Financing, enforce the obligations of the PIPE Investors under the
PIPE Subscription Agreements, and consummate the purchases contemplated by the PIPE Subscription Agreements, in each case, on the terms and subject to the conditions set forth in the PIPE Subscription Agreements, (ii)&nbsp;satisfy all conditions to
the PIPE Financing set forth in the PIPE Subscription Agreements that are within its control, and (iii)&nbsp;satisfy and comply with its obligations under the PIPE Subscription Agreements; <U>provided</U>, <U>however</U>, that (a)&nbsp;MAAC shall be
deemed to have satisfied its obligations under this sentence if the PIPE Financing contemplated by any underlying PIPE Subscription Agreement has been funded or will be funded on its terms substantially concurrently with the occurrence of the
Closing and (b)&nbsp;for the avoidance of doubt, any breach, or failure to perform or comply with, any provision of a PIPE Subscription Agreement by a PIPE Investor shall not, in and of itself, be deemed to be a breach of, or failure to perform or
comply with, this sentence. The Company shall use its reasonable best efforts to, and shall use its reasonable best efforts to cause its Representatives to, cooperate with MAAC and its Representatives in connection with the matters specified in this
<U>Section</U><U></U><U>&nbsp;5.23</U>. If reasonably requested by the Company, MAAC shall, to the extent it has such rights under the applicable PIPE Subscription Agreement, waive any breach of any representation, warranty, covenant or agreement
under a PIPE Subscription Agreement by a PIPE Investor to the extent necessary to cause the satisfaction of the conditions to closing of the PIPE Financing set forth in the PIPE Subscription Agreements and solely for the purpose of consummating the
Closing, provided that (i)&nbsp;any such waiver may (in MAAC&#146;s sole discretion) be subject to, and conditioned upon, the Closing occurring and the substantially concurrent funding of such PIPE Financing, (ii)&nbsp;subject to, and condition
upon, the Closing occurring substantially concurrent funding of the PIPE Financing, the Company also waives any such breach to the extent the Company is a third party beneficiary of the provision that was so breached and (iii)&nbsp;any such waiver
shall be subject to the rights of the placement agent, as applicable, under such PIPE Subscription Agreement with respect to such waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) MAAC shall not amend, modify or waive any provisions of any PIPE Subscription Agreement without the prior written consent of the Company;
<U>provided</U> that any amendment, modification or waiver that is solely ministerial in nature or otherwise immaterial, and, in each case, that does not affect any economic or any other material term, shall not require the prior written consent of
the Company, so long as MAAC has provided to the Company no less than two (2)&nbsp;Business Days written notice of such amendment, modification or waiver, it being understood, but without limiting the foregoing, that it shall be deemed material if
any amendment, modification or waiver (i)&nbsp;reduces the amount of the PIPE Financing available under such PIPE Subscription Agreement or (ii)&nbsp;imposes new or additional conditions or otherwise expands, amends or modifies any of the conditions
to the receipt of the PIPE Financing under such PIPE Subscription Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) MAAC shall (i)&nbsp;promptly notify the Company upon having knowledge of any material
breach or default under, or termination of, any PIPE Subscription Agreement (including any refusal or repudiation by any PIPE Investor with respect to its obligation and/or ability to provide the full financing contemplated by the applicable PIPE
Subscription Agreement), (ii) prior to delivering any written notice to a PIPE Investor with respect to any PIPE Subscription Agreement, deliver such written notice to the Company for its prior review and consent (which consent shall not be
unreasonably withheld, conditioned or delayed), and (iii)&nbsp;promptly, and in any event, within two (2)&nbsp;Business Days following the Company&#146;s reasonable request, deliver the Closing Notice (as defined in the PIPE Subscription Agreements)
to the PIPE Investors if conditions to the delivery of such notice under the PIPE Subscription Agreement have been satisfied and all of the conditions to the Closing set forth in <U>Article</U><U></U><U>&nbsp;6</U> have been satisfied or waived
(other than those conditions that, by their nature, are to be satisfied at the Closing, but that would, as of such date, reasonably be expected to be satisfied if the Closing were to occur). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;6 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDITIONS TO CONSUMMATION OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.1 </B><B><U>Conditions to the Obligations of the Parties</U></B>. The obligations of the Parties to consummate
the transactions contemplated by this Agreement are subject to the satisfaction or, if permitted by applicable Law, waiver by MAAC and the Company of the following conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) no Order or Law issued by any court of competent jurisdiction or other Governmental Entity, in each case (x)&nbsp;in the United States or
any other jurisdiction in which the Group Companies conduct material operations or (y)&nbsp;that is otherwise material, in each case, preventing the consummation of the transactions contemplated by this Agreement, shall be in effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) the Registration Statement / Proxy Statement shall have become effective in accordance with the provisions of the Securities Act, no stop
order shall have been issued by the SEC and shall remain in effect with respect to the Registration Statement / Proxy Statement, and no Proceeding seeking such a stop order shall have been threatened or initiated by the SEC and remain pending; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) the Required MAAC Shareholder Approval shall have been duly obtained; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) the Company&#146;s initial listing application with Nasdaq in connection with the transactions contemplated by this Agreement shall have
been conditionally approved and, immediately following the Effective Time, the Company shall satisfy any applicable initial and continuing listing requirements of Nasdaq, and the Company shall not have received any notice of <FONT
STYLE="white-space:nowrap">non-compliance</FONT> therewith that has not been cured prior to, or would not be cured at or immediately following, the Effective Time, and the Company Post-Closing Common Shares (including the Company Post-Closing Common
Shares to be issued hereunder and under the Ancillary Documents) shall have been approved for listing on Nasdaq; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) after giving effect to the transactions contemplated hereby (including the PIPE
Financing), the Company shall have at least $5,000,001 of net tangible assets (as determined in accordance with Rule <FONT STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the Exchange Act) immediately after the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.2 </B><B><U>Other Conditions to the Obligations of </U></B><B><U>MAAC</U></B>. The obligations of MAAC to
consummate the transactions contemplated by this Agreement are subject to the satisfaction or, if permitted by applicable Law, waiver by MAAC of the following further conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;(i) the Company Fundamental Representations (other than the representations and warranties set forth in
<U>Section</U><U></U><U>&nbsp;3.8(a)</U>) shall be true and correct (without giving effect to any limitation as to &#147;materiality&#148; or &#147;Company Material Adverse Effect&#148; or any similar limitation set forth herein) in all material
respects as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct
(without giving effect to any limitation as to &#147;materiality&#148; or &#147;Company Material Adverse Effect&#148; or any similar limitation set forth herein) in all material respects as of such earlier date), (ii) the representation and warranty
set forth in <U>Section</U><U></U><U>&nbsp;3.8(a)</U> shall be true and correct in all respects as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an
earlier date, in which case such representation and warranty shall be true and correct in all respects as of such earlier date) (<U>provided</U>, <U>however</U>, that this <U>clause (ii)</U>&nbsp;shall be deemed to be satisfied if no Company
Material Adverse Effect is continuing as of the Closing Date), (iii) the Company Additional Capitalization Representations shall be true and correct (without giving effect to any limitation as to &#147;materiality&#148; or &#147;Company Material
Adverse Effect&#148; or any similar limitation set forth herein) as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such
representation and warranty shall be true and correct (without giving effect to any limitation as to &#147;materiality&#148; or &#147;Company Material Adverse Effect&#148; or any similar limitation set forth herein) as of such earlier date), except
where the failure of such representations and warranties to be true and correct would not be material to the Group Companies, taken as a whole, and (iv)&nbsp;the representations and warranties of the Company and Merger Sub set forth in
<U>Article</U><U></U><U>&nbsp;3</U> (other than the Company Fundamental Representations and the Company Additional Capitalization Representations) shall be true and correct (without giving effect to any limitation as to &#147;materiality&#148; or
&#147;Company Material Adverse Effect&#148; or any similar limitation set forth herein) in all respects as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as
of an earlier date, in which case such representation and warranty shall be true and correct (without giving effect to any limitation as to &#147;materiality&#148; or &#147;Company Material Adverse Effect&#148; or any similar limitation set forth
herein) in all respects as of such earlier date), except where the failure of such representations and warranties to be true and correct would not have a Company Material Adverse Effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) the Company and Merger Sub shall have performed and complied in all material respects with the covenants and agreements required to be
performed or complied with by the Company and Merger Sub under this Agreement at or prior to the Closing; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) since the date of this Agreement, no Company Material Adverse Effect has occurred that
is continuing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) as of immediately after the Effective Time, the Company Board shall include the MAAC Designee, as determined pursuant
to <U>Section</U><U></U><U>&nbsp;5.16(b)</U>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps shall have been
consummated on the Closing Date prior to the Effective Time in accordance with the applicable terms of this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) the waiting
period under the HSR Act with respect to the Notification and Report Form to be filed by the MAAC Sponsor as an acquiring person (as that term is defined by 16 C.F.R. 801.2) in connection with the transactions contemplated by this Agreement shall
have expired or been terminated; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) at or prior to the Closing, the Company shall have delivered, or caused to be delivered, to MAAC
a certificate duly executed by an authorized officer of the Company, dated as of the Closing Date, to the effect that the conditions specified in <U>Section</U><U></U><U>&nbsp;6.2(a)</U>, <U>Section</U><U></U><U>&nbsp;6.2(b)</U> and
<U>Section</U><U></U><U>&nbsp;6.2(c)</U> are satisfied, in a form and substance reasonably satisfactory to MAAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.3 </B><B><U>Other Conditions to the Obligations of </U></B><B><U>the Company</U></B>. The obligations of the
Company to consummate the transactions contemplated by this Agreement are subject to the satisfaction or, if permitted by applicable Law, waiver by the Company of the following further conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;(i) the MAAC Fundamental Representations shall be true and correct in all material respects as of the Closing Date, as though made on
and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct in all material respects as of such earlier date)
(<U>provided</U>, <U>however</U>, that the representation and warranty set forth in <U>Section</U><U></U><U>&nbsp;4.9</U> shall be deemed to be true and correct in all material respects as of the Closing Date for purposes of this <U>clause
(i)</U>&nbsp;if no MAAC Material Adverse Effect is continuing as of the Closing Date), and (ii)&nbsp;the representations and warranties of MAAC (other than the MAAC Fundamental Representations) contained in <U>Article</U><U></U><U>&nbsp;4</U> of
this Agreement shall be true and correct (without giving effect to any limitation as to &#147;materiality&#148; or &#147;MAAC Material Adverse Effect&#148; or any similar limitation set forth herein) in all respects as of the Closing Date, as though
made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct (without giving effect to any limitation as to
&#147;materiality&#148; or &#147;MAAC Material Adverse Effect&#148; or any similar limitation set forth herein) in all respects as of such earlier date), except where the failure of such representations and warranties to be true and correct would
not have a MAAC Material Adverse Effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) MAAC shall have performed and complied in all material respects with the covenants and
agreements required to be performed or complied with by it under this Agreement at or prior to the Closing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) since the date of this
Agreement, no MAAC Material Adverse Effect has occurred that is continuing; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) the Aggregate Trust Account Proceeds shall be equal to or greater than $210,000,000;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) the MAAC Sponsor shall have complied in all material respects with its covenants and agreements required to be performed or complied
with by it under the Sponsor Support Agreement at or prior to the Closing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) at or prior to the Closing, MAAC shall have delivered, or
caused to be delivered, the following documents to the Company: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) a certificate duly executed by an authorized officer of MAAC, dated
as of the Closing Date, to the effect that the conditions specified in <U>Section</U><U></U><U>&nbsp;6.3(a)</U>, <U>Section</U><U></U><U>&nbsp;6.3(b)</U> and <U>Section</U><U></U><U>&nbsp;6.3(c)</U> are satisfied, in a form and substance reasonably
satisfactory to the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) a certificate prepared in a manner consistent and in accordance with the requirements of Treasury
Regulations Sections <FONT STYLE="white-space:nowrap">1.897-2(g),</FONT> (h) and <FONT STYLE="white-space:nowrap">1.1445-2(c)(3),</FONT> certifying that no interest in MAAC is, or has been during the relevant period specified in
Section&nbsp;897(c)(1)(A)(ii) of the Code, a &#147;United States real property interest&#148; within the meaning of Section&nbsp;897(c) of the Code, and a form of notice to the Internal Revenue Service prepared in accordance with the provisions of
Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.897-2(h)(2).</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMINATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.1 </B><B><U>Termination</U></B>. This Agreement may be terminated and the transactions contemplated by this
Agreement may be abandoned at any time prior to the Closing: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) by mutual written consent of MAAC and the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) by MAAC, if any of the representations or warranties set forth in <U>Article</U><U></U><U>&nbsp;3</U> shall not be true and correct or if
the Company or Merger Sub has failed to perform any covenant or agreement on the part of the Company or Merger Sub set forth in this Agreement (including an obligation to consummate the Closing) such that the condition to Closing set forth in either
<U>Section</U><U></U><U>&nbsp;6.2(a)</U> or <U>Section</U><U></U><U>&nbsp;6.2(b)</U> would not (assuming that the Closing occurred as of such date) be satisfied and the breach or breaches causing such representations or warranties not to be true and
correct, or the failures to perform any covenant or agreement, as applicable, is (or are) not cured or cannot be cured within the earlier of (i)&nbsp;thirty (30)&nbsp;days after written notice thereof is delivered to the Company by MAAC and
(ii)&nbsp;the Termination Date; <U>provided</U>, <U>however</U>, that MAAC is not then in breach of this Agreement so as to prevent the condition to Closing set forth in either <U>Section</U><U></U><U>&nbsp;6.3(a)</U> or
<U>Section</U><U></U><U>&nbsp;6.3(b)</U> from being satisfied (assuming that the Closing occurred as of such date); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) by the Company,
if any of the representations or warranties set forth in <U>Article</U><U></U><U>&nbsp;4</U> shall not be true and correct or if MAAC has failed to perform any covenant or agreement on the part of MAAC set forth in this Agreement (including an
obligation to consummate the Closing) such that the condition to Closing set forth in either <U>Section</U><U></U><U>&nbsp;6.3(a)</U> or <U>Section</U><U></U><U>&nbsp;6.3(b)</U> would not (assuming that the Closing occurred as of such date) be
satisfied and the breach or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
breaches causing such representations or warranties not to be true and correct, or the failures to perform any covenant or agreement, as applicable, is (or are) not cured or cannot be cured
within the earlier of (i)&nbsp;thirty (30) days after written notice thereof is delivered to MAAC by the Company and (ii)&nbsp;the Termination Date; <U>provided</U>, <U>however</U>, that none of the Company or Merger Sub is then in breach of this
Agreement so as to prevent the condition to Closing set forth in <U>Section</U><U></U><U>&nbsp;6.2(a)</U> or <U>Section</U><U></U><U>&nbsp;6.2(b)</U> from being satisfied (assuming that the Closing occurred as of such date); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) by either MAAC or the Company, if the transactions contemplated by this Agreement shall not have been consummated on or prior to
November&nbsp;30, 2021 (the &#147;<U>Termination Date</U>&#148;); <U>provided</U>, that (i)&nbsp;the right to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(d)</U> shall not be available to MAAC if MAAC&#146;s breach
under this Agreement or any Ancillary Document to which it is a party shall have proximately caused the failure to consummate the transactions contemplated by this Agreement on or before the Termination Date, and (ii)&nbsp;the right to terminate
this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(d)</U> shall not be available to the Company if the Company&#146;s or Merger Sub&#146;s breach under this Agreement or any Ancillary Document to which such Person is a party shall
have proximately caused the failure to consummate the transactions contemplated by this Agreement on or before the Termination Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)
by either MAAC or the Company, if any Governmental Entity of competent jurisdiction shall have issued an Order or taken any other action permanently enjoining, restraining or otherwise prohibiting the transactions contemplated by this Agreement and
such Order or other action shall have become final and nonappealable; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) by either MAAC or the Company if the MAAC Shareholders Meeting
has been held (including following any adjournment or postponement thereof), has concluded, MAAC&#146;s shareholders have duly voted and the Required MAAC Shareholder Approval was not obtained; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) by MAAC, if the Company does not deliver, or cause to be delivered to MAAC, the Merger Sub Shareholder Approval in accordance with
<U>Section</U><U></U><U>&nbsp;5.9</U> on or prior to the Merger Sub Shareholder Approval Deadline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.2
</B><B><U>Effect of Termination</U></B>. Except for a termination pursuant to <U>Section</U><U></U><U>&nbsp;7.1(a)</U>, any termination of this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U> will be effective (subject to the cure
periods (if any) provided above) immediately upon the delivery of a valid written notice of the terminating Party to the Company (if the terminating Party is MAAC) or MAAC (if the terminating Party is the Company). In the event of the termination of
this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U>, this entire Agreement shall forthwith become void (and there shall be no Liability or obligation on the part of the Parties and their respective
<FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates) with the exception of (a)<U>&nbsp;Section</U><U></U><U>&nbsp;5.3(a)</U>, this <U>Section</U><U></U><U>&nbsp;7.2</U>, <U>Article</U><U></U><U>&nbsp;8</U> and
<U>Article</U><U></U><U>&nbsp;1</U> (to the extent, with respect to <U>Article</U><U></U><U>&nbsp;1</U>, related to the foregoing), each of which shall survive such termination and remain valid and binding obligations of the Parties and (b)&nbsp;the
Confidentiality Agreement, which shall survive such termination and remain valid and binding obligations of the parties thereto in accordance with its terms. Notwithstanding the foregoing or anything to the contrary herein, the termination of this
Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U> shall not affect (i)&nbsp;any Liability on the part of any Party for any Willful Breach of any covenant or agreement set forth in this Agreement prior to such termination or Fraud or
(ii)&nbsp;any Person&#146;s Liability under any PIPE Subscription Agreement, the Confidentiality Agreement, any Transaction Support Agreement or the Sponsor Support Agreement to which such Person is a party to the extent arising from a claim against
such Person by another Person party to such agreement on the terms and subject to the conditions thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE&nbsp;8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.1 </B><B><U><FONT STYLE="white-space:nowrap">Non-Survival</FONT></U></B>. The representations, warranties,
agreements and covenants in this Agreement shall terminate at the earlier of (a)&nbsp;the Effective Time and (b)&nbsp;the termination of this Agreement in accordance with its terms, except for (i)&nbsp;in the case of <U>clause (a)</U>, those
covenants and agreements that, by their terms, expressly contemplate performance after the Effective Time, which covenants and agreements shall so survive the Effective Time in accordance with their terms, and (ii)&nbsp;in the case of <U>clause
(b)</U>, those covenants and agreements that expressly survive termination of this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.2 </B><B><U>Entire Agreement; Assignment</U></B>. This Agreement (together with the Ancillary Documents)
constitutes the entire agreement among the Parties with respect to the subject matter hereof and supersedes all other prior agreements and understandings, both written and oral, among the Parties with respect to the subject matter hereof. This
Agreement&nbsp;may not be assigned by any Party (whether by operation of law or otherwise) without the prior written consent of MAAC and the Company; <U>provided</U>, <U>however</U>, that to the extent any such assignment following the Closing
relates to any of the Company&#146;s obligations under <U>Section</U><U></U><U>&nbsp;5.14</U>, such assignment shall, unless otherwise agreed to in writing by the MAAC Sponsor (not to be unreasonably withheld, conditioned or delayed), and except for
an assignment of the type described in <U>clause (d)</U>&nbsp;thereof in connection with a sale of all or substantially all of the Company&#146;s assets or businesses, only be effective to the extent such obligations are actually performed or
discharged. Any attempted assignment of this Agreement not in accordance with the terms of this <U>Section</U><U></U><U>&nbsp;8.2</U> shall be void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.3 </B><B><U>Amendment</U></B>. This Agreement may be amended or modified only by a written agreement executed
and delivered by MAAC and the Company; <U>provided</U>, <U>however</U>, that any such amendment or modification prior to the Closing with respect to <U>Section</U><U></U><U>&nbsp;6.2(f)</U> or following the Closing with respect to
<U>Section</U><U></U><U>&nbsp;5.14</U>, the proviso in the first sentence of <U>Section</U><U></U><U>&nbsp;8.2</U>, this <U>Section</U><U></U><U>&nbsp;8.3</U>, <U>Section</U><U></U><U>&nbsp;8.9</U>, <U>Section</U><U></U><U>&nbsp;8.13</U> or
<U>Section</U><U></U><U>&nbsp;8.14</U>, in each case, solely as and to the extent related to the MAAC Sponsor or any of the MAAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates (collectively, the &#147;<U>MAAC Sponsor Specified
Provisions</U>&#148;) shall also require the written consent of the MAAC Sponsor. This Agreement may not be modified or amended except as provided in the immediately preceding sentence and any purported amendment by any Party or Parties effected in
a manner which does not comply with this <U>Section</U><U></U><U>&nbsp;8.3</U> shall be void, <I>ab initio</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.4 </B><B><U>Notices</U></B>. All notices, requests, claims, demands and other communications hereunder shall
be in writing and shall be given (and shall be deemed to have been duly given) by delivery in person, by <FONT STYLE="white-space:nowrap">e-mail</FONT> (having obtained electronic delivery confirmation thereof (<I>i.e.,</I> an electronic record of
the sender that the <FONT STYLE="white-space:nowrap">e-mail</FONT> was sent to the intended recipient thereof without an &#147;error&#148; or similar message that such <FONT STYLE="white-space:nowrap">e-mail</FONT> was not received by such intended
recipient)), or by registered or certified mail (postage prepaid, return receipt requested) (upon receipt thereof) to the other Parties as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If to MAAC, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Montes Archimedes Acquisition Corp. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">724 Oak Grove, Suite 130 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Menlo Park, CA 94025 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Maria Walker </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> maria@patientsquarecapital.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>with a copy (which shall not constitute notice) to</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Kirkland&nbsp;&amp; Ellis LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">601 Lexington Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Michael E. Weisser, P.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ryan Brissette </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> michael.weisser@kirkland.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;ryan.brissette@kirkland.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If to the Company or Merger Sub, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant Sciences Ltd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Suite 1, 3rd Floor, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">11-12</FONT> St. James&#146;s Square, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">London SW1Y 4LB, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">United Kingdom </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Matthew Gline </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> matthew.gline@roivant.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;legalnotices@roivant.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>with a copy (which shall not constitute notice) to</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant Sciences, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">151 West 42nd Street, 15th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10036 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> jo.chen@roivant.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">-and-</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Davis Polk&nbsp;&amp; Wardwell LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">450 Lexington Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Derek Dostal </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;Brian Wolfe </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;Lee Hochbaum </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> derek.dostal@davispolk.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;brian.wolfe@davispolk.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;lee.hochbaum@davispolk.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as the Party to whom notice is given may have previously furnished to the others in
writing in the manner set forth above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.5 </B><B><U>Governing Law</U></B>. This Agreement shall be
governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the
application of the law of any jurisdiction other than the State of Delaware (except that the Bermuda Companies Act 1981 shall also apply to the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.6 </B><B><U>Fees and Expenses</U></B>. All fees and expenses incurred in connection with this Agreement, the
Ancillary Documents and the transactions contemplated hereby and thereby, including the fees and disbursements of counsel, financial advisors and accountants, shall be paid by the Party incurring such fees or expenses; <U>provided, </U>that the
Parties intend for all unpaid fees and expenses at the Closing required to be paid by MAAC pursuant to this <U>Section</U><U></U><U>&nbsp;8.6</U> to be paid by MAAC from a bank account opened by MAAC LLC (as defined in
<U>Section</U><U></U><U>&nbsp;4.6(c)</U> of the MAAC Disclosure Schedules), assuming that MAAC LLC is formed prior to Closing and such a bank account is opened, and otherwise from a bank account specified by MAAC (it being understood and agreed that
in no event shall this proviso result in a failure of any condition to Closing set forth in <U>Article</U><U></U><U>&nbsp;6</U>); <U>provided</U> <U>further</U> that, for the avoidance of doubt, if this Agreement is terminated in accordance with its
terms, the Company shall pay, or cause to be paid, all Company Expenses and MAAC shall pay, or cause to be paid, all MAAC Expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.7 </B><B><U>Construction; Interpretation</U></B>. The term &#147;this Agreement&#148; means this Business
Combination Agreement together with the Schedules and Exhibits hereto, as the same may from time to time be amended, modified, supplemented or restated in accordance with the terms hereof. The headings set forth in this Agreement are inserted for
convenience only and shall not affect in any way the meaning or interpretation of this Agreement. The language used in this Agreement shall be deemed to be the language chosen by the Parties to express their mutual intent and the Parties acknowledge
that each Party and its counsel has reviewed and participated in the drafting of this Agreement. No Party, nor its respective counsel, shall be deemed the drafter of this Agreement for purposes of construing the provisions hereof, and all provisions
of this Agreement shall be construed according to their fair meaning and no rule of strict construction, presumption or burden of proof favoring or disfavoring a Party shall be applied against any Party. Unless otherwise indicated to the contrary
herein by the context or use thereof: (a)&nbsp;the words, &#147;hereof,&#148; &#147;herein,&#148; &#147;hereby,&#148; &#147;hereto,&#148; &#147;herewith,&#148; &#147;hereunder&#148; and words of similar import refer to this Agreement as a whole,
including the Schedules and Exhibits hereto, and not to any particular provision, section, subsection, paragraph, subparagraph or clause set forth in this Agreement; (b)&nbsp;masculine gender shall also include the feminine and neutral genders, and
vice versa; (c)&nbsp;words importing the singular shall also include the plural, and vice versa; (d)&nbsp;the words &#147;include,&#148; &#147;includes&#148; or &#147;including&#148; shall be deemed to be followed by the words &#147;without
limitation&#148;; (e) all monetary figures used herein, including references to &#147;$&#148; or &#147;dollar&#148; or &#147;US$,&#148; shall be references to United States dollars; (f)&nbsp;the word &#147;or&#148; is disjunctive but not necessarily
exclusive; (g)&nbsp;the words &#147;writing,&#148; &#147;written&#148; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form; (h)&nbsp;the word &#147;day&#148; means
calendar day unless Business Day is expressly specified; (i)&nbsp;any reference to a date or time shall be deemed to be such date or time in New York, New York; (j)&nbsp;references from or through any date mean from and including or through and
including such date, respectively; (k)&nbsp;the word </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;extent&#148; in the phrase &#147;to the extent&#148; means the degree to which a subject or other thing extends, and such phrase shall not mean simply &#147;if&#148;; (l) all references to
Articles, Sections, Exhibits or Schedules are to Articles, Sections, Exhibits and Schedules of this Agreement; (m)&nbsp;the words &#147;provided,&#148; &#147;made available,&#148; &#147;delivered&#148; or words of similar import (regardless of
whether capitalized or not) shall mean, when used with reference to documents or other materials required to be provided or made available to MAAC, any documents or other materials posted to the electronic data room located at
https://wwwna.dfsvenue.com/cardhub.aspx under the project name &#147;Project Rhine&#148; as of 8:00 p.m., Eastern Time, at least one (1)&nbsp;day prior to the date of this Agreement; (n)&nbsp;all references to any Law will be to such Law as amended,
supplemented, consolidated, replaced or otherwise modified or <FONT STYLE="white-space:nowrap">re-enacted</FONT> from time to time and shall include all regulations and rules promulgated thereunder; (o)&nbsp;all references to any Contract are to
that Contract as amended or modified from time to time in accordance with the terms thereof (subject to any restrictions on amendments or modifications set forth in this Agreement); (p) any reference to &#147;MAAC&#148; in this Agreement shall mean
and refer to the &#147;Surviving Company&#148; from and after the Effective Time; (q)&nbsp;whenever any other word derived from a defined term shall be used in this Agreement, such derived word shall have the meaning correlative to such defined term
(e.g., &#147;controlled&#148; or &#147;controlling&#148; shall have the meaning correlative to &#147;control&#148;); (r) the phrase &#147;ordinary course of business&#148; means an action taken, or omitted to be taken, by any Person in the ordinary
course of such Person&#146;s business consistent with past practice, subject to, other than in the case of any action taken, or omitted to be taken, of the type that would, if taken during the period from the date of this Agreement until the Closing
(and regardless of whether taken prior to, at or after the date hereof), require the consent of MAAC pursuant to any Company Specified Interim Operating Covenants, any action taken, or omitted to be taken, by any Group Company to the extent
determined by a Group Company to be reasonable and advisable in response to <FONT STYLE="white-space:nowrap">COVID-19;</FONT> and (s)&nbsp;the phrase &#147;consistent with past valuation practices&#148; shall mean (i)&nbsp;with respect to any equity
incentive awards of any Private Group Company (other than any Company CVAR Award) that has an exercise price, an exercise price at or above fair market value and (ii)&nbsp;with respect to all Equity Securities of the Company or any other Private
Group Company (other than equity incentive awards described in the preceding <U>clause (i)</U>), an issuance or grant with a value at or above fair market value (with such fair market value, in the case of each of <U>clause (i)</U>&nbsp;and
<U>(ii)</U>, determined by reference to, among other things, the Company&#146;s most recent equity financing or third-party valuations). If any action under this Agreement is required to be done or taken on a day that is not a Business Day, then
such action shall be required to be done or taken not on such day but on the first succeeding Business Day thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.8 </B><B><U>Exhibits and Schedules</U></B>. All Exhibits and Schedules (including the Company Disclosure
Schedules and the MAAC Disclosure Schedules), or documents expressly incorporated into this Agreement, are hereby incorporated into this Agreement and are hereby made a part hereof as if set out in full in this Agreement. Any capitalized term(s)
used in any Exhibits and Schedules (including the Company Disclosure Schedules and the MAAC Disclosure Schedules) annexed hereto or referred to herein but not otherwise defined therein shall have the meaning ascribed to such term(s) in this
Agreement. The Schedules shall be arranged in sections and subsections corresponding to the numbered and lettered Sections and subsections set forth in this Agreement. Any item disclosed in the Company Disclosure Schedules or in the MAAC Disclosure
Schedules corresponding to any Section or subsection of <U>Article</U><U></U><U>&nbsp;3</U> (in the case of the Company Disclosure Schedules) or <U>Article</U><U></U><U>&nbsp;4</U> (in the case of the MAAC Disclosure Schedules) shall be deemed to
have been disclosed with respect to every other section and subsection of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Article</U><U></U><U>&nbsp;3</U> (in the case of the Company Disclosure Schedules) or <U>Article</U><U></U><U>&nbsp;4</U> (in the case of the MAAC Disclosure Schedules), as applicable, where
the relevance of such disclosure to such other Section or subsection is reasonably apparent. The information and disclosures set forth in the Schedules that correspond to the section or subsections of <U>Article</U><U></U><U>&nbsp;3</U> or
<U>Article</U><U></U><U>&nbsp;4</U> may not be limited to matters required to be disclosed in the Schedules, and any such additional information or disclosure is for informational purposes only and does not necessarily include other matters of a
similar nature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.9 </B><B><U>Parties in Interest</U></B>. This Agreement shall be binding upon and inure
solely to the benefit of each Party and its successors and permitted assigns and, except as provided in <U>Section</U><U></U><U>&nbsp;5.14</U>, <U>Section</U><U></U><U>&nbsp;5.15</U><U>,</U> the two subsequent sentences of this
<U>Section</U><U></U><U>&nbsp;8.9</U> and <U>Section</U><U></U><U>&nbsp;8.13</U>, nothing in this Agreement, express or implied, is intended to or shall confer upon any other Person any rights, benefits or remedies of any nature whatsoever under or
by reason of this Agreement. The MAAC Sponsor shall be an express third-party beneficiary of <U>Section</U><U></U><U>&nbsp;5.14</U>, <U>Section</U><U></U><U>&nbsp;6.2(f)</U>, <U>Section</U><U></U><U>&nbsp;8.2</U>,
<U>Section</U><U></U><U>&nbsp;8.3</U>, <U>Section</U><U></U><U>&nbsp;8.13</U>, this <U>Section</U><U></U><U>&nbsp;8.9</U> and the last sentence of <U>Section</U><U></U><U>&nbsp;5.4(a)</U>. Each of the
<FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates shall be an express third-party beneficiary of <U>Section</U><U></U><U>&nbsp;8.13</U> and this <U>Section</U><U></U><U>&nbsp;8.9</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.10 </B><B><U>Severability</U></B>. Whenever possible, each provision of this Agreement will be interpreted in
such a manner as to be effective and valid under applicable Law, but if any term or other provision of this Agreement is held to be invalid, illegal or unenforceable under applicable Law, all other provisions of this Agreement shall remain in full
force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any Party. Upon such determination that any term or other provision of this Agreement is invalid,
illegal or unenforceable under applicable Law, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner in order that the transactions
contemplated hereby are consummated as originally contemplated to the greatest extent possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.11
</B><B><U>Counterparts; Electronic Signatures</U></B>. This Agreement and each Ancillary Document (including any of the closing deliverables contemplated hereby) may be executed in one or more counterparts, each of which shall be deemed to be an
original, but all of which shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement or any Ancillary Document (including any of the closing deliverables contemplated hereby) by <FONT
STYLE="white-space:nowrap">e-mail,</FONT> or scanned pages shall be effective as delivery of a manually executed counterpart to this Agreement or any such Ancillary Document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.12 </B><B><U>Knowledge of </U></B><B><U>Company; Knowledge of </U></B><B><U>MAAC</U></B>. For all purposes of
this Agreement, the phrase &#147;to the Company&#146;s knowledge&#148; and &#147;known by the Company&#148; and any derivations thereof shall mean as of the date hereof (in the case of the representations and warranties of the Company and Merger Sub
set forth in <U>Article</U><U></U><U>&nbsp;3</U>) or as of the applicable determination date (in the case of any covenants or agreements set forth herein), the actual knowledge of the individuals set forth on
<U>Section</U><U></U><U>&nbsp;8.12</U><U>(a)</U> of the Company Disclosure Schedules. For all purposes of this Agreement, the phrase &#147;to MAAC&#146;s knowledge&#148; and &#147;to the knowledge of MAAC&#148; and any derivations thereof shall mean
as of the date hereof (in the case of the representations and warranties of MAAC set forth in <U>Article</U><U></U><U>&nbsp;4</U>) or as of the applicable determination date (in the case of any covenants or agreements set forth herein), the actual
knowledge of the individuals set forth on <U>Section</U><U></U><U>&nbsp;8.12</U><U>(b)</U> of the MAAC Disclosure Schedules. <U>For </U>the avoidance of doubt, none of the individuals set forth on <U>Section</U><U></U><U>&nbsp;8.12(a)</U> of the
Company Disclosure Schedules or <U>Section</U><U></U><U>&nbsp;8.12(b)</U> of the MAAC Disclosure Schedules shall have any personal Liability or obligations regarding such knowledge. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.13 </B><B><U>No Recourse</U></B>. Except for claims pursuant
to any Ancillary Document by any party(ies) thereto against any Company <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate or any MAAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate (each, a &#147;<U><FONT
STYLE="white-space:nowrap">Non-Party</FONT> Affiliate</U>&#148;) party thereto on the terms and subject to the conditions thereunder, each Party agrees on behalf of itself and on behalf of the Company
<FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates, in the case of the Company, and the MAAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates, in the case of MAAC, that (a)&nbsp;this Agreement may only be enforced against, and
any action for breach of this Agreement may only be made against, the Parties, and no claims of any nature whatsoever arising under or relating to this Agreement, the negotiation hereof or its subject matter, or the transactions contemplated hereby
shall be asserted against any <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate, and (b)&nbsp;without limiting the generality of the foregoing, none of the <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates shall have any
Liability arising out of or relating to this Agreement, the negotiation hereof or its subject matter, or the transactions contemplated hereby, including with respect to any claim (whether in tort, contract or otherwise) for breach of this Agreement
or in respect of any written or oral representations made or alleged to be made in connection herewith, except as expressly provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.14 </B><B><U>Extension; Waiver</U></B>. The Company may (a)&nbsp;extend the time for the performance of any of
the obligations or other acts of MAAC set forth herein, (b)&nbsp;waive any inaccuracies in the representations and warranties of MAAC set forth herein or (c)&nbsp;waive compliance by MAAC with any of the agreements or conditions set forth herein.
MAAC may (i)&nbsp;extend the time for the performance of any of the obligations or other acts of the Company or Merger Sub set forth herein, (ii)&nbsp;waive any inaccuracies in the representations and warranties of the Company or Merger Sub set
forth herein or (iii)&nbsp;waive compliance by the Company or Merger Sub with any of the agreements or conditions set forth herein. Any agreement on the part of any such Party to any such extension or waiver shall be valid only if set forth in a
written instrument signed on behalf of such Party. Any waiver of any term or condition shall not be construed as a waiver of any subsequent breach or a subsequent waiver of the same term or condition, or a waiver of any other term or condition of
this Agreement. The failure of any Party to assert any of its rights hereunder shall not constitute a waiver of such rights. Notwithstanding the foregoing or anything to the contrary in this Agreement, any extension or waiver following the Closing
with respect to any MAAC Sponsor Specified Provision or, prior to the Closing, Section&nbsp;6.2(f) shall also require the prior written consent of the MAAC Sponsor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.15 </B><B><U>Waiver of Jury Trial</U></B>. THE PARTIES EACH HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY
LAW, ANY RIGHT TO TRIAL BY JURY OF ANY PROCEEDING, CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (I)&nbsp;ARISING UNDER THIS AGREEMENT OR UNDER ANY ANCILLARY DOCUMENT OR (II)&nbsp;IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE
PARTIES IN RESPECT OF THIS AGREEMENT OR ANY ANCILLARY DOCUMENT OR ANY OF THE TRANSACTIONS RELATED HERETO OR THERETO OR ANY FINANCING IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED HEREBY OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREBY, IN EACH
CASE, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY, OR OTHERWISE. THE PARTIES EACH HEREBY AGREES AND CONSENTS THAT ANY </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
SUCH PROCEEDING, CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS AGREEMENT WITH ANY
COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A)&nbsp;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR
OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B)&nbsp;EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C)&nbsp;EACH SUCH PARTY MAKES THIS WAIVER
VOLUNTARILY AND (D)&nbsp;EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <U>SECTION</U><U></U><U>&nbsp;8.15</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.16 </B><B><U>Submission to Jurisdiction</U></B>. Each of the Parties irrevocably and unconditionally submits
to the exclusive jurisdiction of the Chancery Court of the State of Delaware (or, if the Chancery Court of the State of Delaware declines to accept jurisdiction, any state or federal court within State of New York, New York County), for the purposes
of any Proceeding, claim, demand, action or cause of action (a)&nbsp;arising under this Agreement or under any Ancillary Document or (b)&nbsp;in any way connected with or related or incidental to the dealings of the Parties in respect of this
Agreement or any Ancillary Document or any of the transactions contemplated hereby or any of the transactions contemplated thereby, and irrevocably and unconditionally waives any objection to the laying of venue of any such Proceeding in any such
court, and further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such Proceeding has been brought in an inconvenient forum. Each Party hereby irrevocably and unconditionally waives, and agrees not
to assert, by way of motion or as a defense, counterclaim or otherwise, in any Proceeding claim, demand, action or cause of action against such Party (i)&nbsp;arising under this Agreement or under any Ancillary Document or (ii)&nbsp;in any way
connected with or related or incidental to the dealings of the Parties in respect of this Agreement or any Ancillary Document or any of the transactions contemplated hereby or any of the transactions contemplated thereby, (A)&nbsp;any claim that
such Party is not personally subject to the jurisdiction of the courts as described in this <U>Section</U><U></U><U>&nbsp;8.16</U> for any reason, (B)&nbsp;that such Party or such Party&#146;s property is exempt or immune from the jurisdiction of
any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (C)&nbsp;that (x)&nbsp;the
Proceeding, claim, demand, action or cause of action in any such court is brought against such Party in an inconvenient forum, (y)&nbsp;the venue of such Proceeding, claim, demand, action or cause of action against such Party is improper or
(z)&nbsp;this Agreement, or the subject matter hereof, may not be enforced against such Party in or by such courts. Each Party agrees that service of any process, summons, notice or document by registered mail to such party&#146;s respective address
set forth in <U>Section</U><U></U><U>&nbsp;8.4</U> shall be effective service of process for any such Proceeding, claim, demand, action or cause of action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.17 </B><B><U>Remedies</U></B>. Except as otherwise expressly provided herein, any and all remedies provided
herein will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree
that irreparable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that the Parties do not perform their respective obligations under the provisions
of this Agreement (including failing to take such actions as are required of them hereunder to consummate the transactions contemplated by this Agreement) in accordance with their specific terms or otherwise breach such provisions. It is accordingly
agreed that the Parties shall be entitled to seek an injunction or injunctions, specific performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, in each
case, without posting a bond or undertaking and without proof of damages and this being in addition to any other remedy to which they are entitled at law or in equity. Each of the Parties agrees that it will not oppose the granting of an injunction,
specific performance and other equitable relief when expressly available pursuant to the terms of this Agreement on the basis that the other parties have an adequate remedy at law or an award of specific performance is not an appropriate remedy for
any reason at law or equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.18 </B><B><U>Trust Account Waiver</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Reference is made to the final prospectus of MAAC, filed with the SEC (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-248802)</FONT>
on October&nbsp;9, 2020 (the &#147;<U>Prospectus</U>&#148;). The Company and Merger Sub each acknowledges and agrees and understands that MAAC has established one or more trust accounts (collectively, the &#147;<U>Trust Account</U>&#148;) containing
the proceeds of its initial public offering (the &#147;<U>IPO</U>&#148;) and from certain private placements occurring simultaneously with the IPO (including interest accrued from time to time thereon) for the benefit of the holders of MAAC
Class&nbsp;A Shares, and MAAC may disburse monies from the Trust Account only in the express circumstances described in the Prospectus. For and in consideration of MAAC entering into this Agreement, and for other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the Company and Merger Sub each hereby agrees on behalf of itself and its Representatives that, notwithstanding the foregoing or anything to the contrary in this Agreement, none of the
Company, Merger Sub or any of their respective Representatives does now or shall at any time hereafter have any right, title, interest or claim of any kind in or to any monies in the Trust Account or distributions therefrom, or make any claim
against the Trust Account (including any distributions therefrom), regardless of whether such claim arises as a result of, in connection with or relating in any way to, this Agreement or any proposed or actual business relationship between MAAC or
any of its Representatives, on the one hand, and the Company, Merger Sub or any of their respective Representatives, on the other hand, or any other matter, and regardless of whether such claim arises based on contract, tort, equity or any other
theory of legal liability (any and all such claims are collectively referred to hereafter as the &#147;<U>Trust Account Released Claims</U>&#148;). The Company and Merger Sub each, on its own behalf and on behalf of its Representatives, hereby
irrevocably waives any Trust Account Released Claims that it or any of its Representatives may have against the Trust Account (including any distributions therefrom to the holders of MAAC Class&nbsp;A Shares or in respect of deferred underwriting
commissions from the IPO) now or in the future as a result of, or arising out of, any negotiations, or Contracts with MAAC or its Representatives and will not seek recourse against the Trust Account (including any distributions therefrom to the
holders of MAAC Class&nbsp;A Shares or in respect of deferred underwriting commissions from the IPO) for any reason whatsoever (including for an alleged breach of any agreement with MAAC or its Affiliates). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding <U>Section</U><U></U><U>&nbsp;8.18(a)</U>,
<U>Section</U><U></U><U>&nbsp;8.18(a)</U> shall not serve to limit or prohibit (and the Trust Account Released Claims shall not include) the Company&#146;s right to pursue a claim against (i)&nbsp;MAAC under, and on the terms and subject to the
conditions in, this Agreement or under, and on the terms and subject to the conditions in, any Ancillary Document to which it and MAAC is a party or (ii)&nbsp;any other party to an Ancillary Document to which it is a party under, and on the terms
and subject to the conditions in, such Ancillary Document, in the case of either the foregoing <U>clause (i)</U>&nbsp;or <U>(ii)</U>, for legal relief against monies or other assets held outside the Trust Account or for specific performance or other
equitable relief to the extent not prohibited by this Agreement or such Ancillary Document (including a claim for MAAC to specifically perform its obligations under this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;8.17</U>). If the terms of
the Confidentiality Agreement or any Ancillary Document conflicts with the terms of this <U>Section</U><U></U><U>&nbsp;8.18(b)</U>, the terms of this <U>Section</U><U></U><U>&nbsp;8.18(b)</U> shall govern and control to the extent of such conflict.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, each of the Parties has caused this Business Combination
Agreement to be duly executed on its behalf as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MONTES ARCHIMEDES ACQUISITION CORP.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Maria C. Walker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Maria C. Walker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:<B> </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROIVANT SCIENCES LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marianne Romeo</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Marianne Romeo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:<B> </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Head, Global Transactions &amp; Risk Management</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RHINE MERGER SUB, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Gline</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Matthew Gline</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:<B> </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Business Combination Agreement] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.9
<SEQUENCE>3
<FILENAME>d307489dex29.htm
<DESCRIPTION>EX-2.9
<TEXT>
<HTML><HEAD>
<TITLE>EX-2.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 2.9 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDMENT NO. 1 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">to </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BUSINESS COMBINATION AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment No.&nbsp;1 to the Business Combination Agreement (this &#147;<U>Amendment</U>&#148;) is made as of June&nbsp;9, 2021, by and
among Montes Archimedes Acquisition Corp., a Delaware corporation (&#147;<U>MAAC</U>&#148;), and Roivant Sciences Ltd., a Bermuda exempted limited company (the &#147;<U>Company</U>&#148;). Capitalized terms used, but not otherwise defined herein,
shall have the meaning given to them in the BCA (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on May&nbsp;1, 2021 (a) MAAC, the Company and Rhine Merger
Sub, Inc., a Delaware corporation and a direct wholly owned Subsidiary of the Company, entered into that certain Business Combination Agreement (as amended, amended and restated, supplemented or otherwise modified from time to time in accordance
with its terms, the &#147;<U>BCA</U>&#148;) and (b)&nbsp;the Company, MAAC, Patient Square Capital LLC, a Delaware limited liability company (the &#147;<U>MAAC Sponsor</U>&#148;), and, solely for purposes of certain provisions therein, each of James
C. Momtazee, George Barrett, Maria C. Walker and Steve Oesterle entered into that certain Sponsor Support Agreement (as amended, amended and restated, supplemented or otherwise modified from time to time in accordance with its terms, the
&#147;<U>Sponsor Support Agreement</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to Section&nbsp;8.3 of the BCA, the BCA may be amended or modified only
by a written agreement executed and delivered by MAAC and the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the date hereof (a)&nbsp;MAAC, the Company, the MAAC
Sponsor, James C. Momtazee, George Barrett, Maria C. Walker and Steve Oesterle are entering into Amendment No.&nbsp;1 to the Sponsor Support Agreement in order to provide that, among other things, (i)&nbsp;each MAAC Class&nbsp;B Share held by a MAAC
Independent Director or a MAAC Independent Director Transferee (each as defined in Section&nbsp;1 below) issued and outstanding immediately prior to the Effective Time be converted as of the Effective Time into the number of Company Post-Closing
Common Shares equal to the Sponsor Exchange Ratio, on the terms and subject to the conditions set forth in the BCA and the Sponsor Support Agreement, and (ii)&nbsp;a portion of the Company Post-Closing Common Shares that are issued to the MAAC
Independent Directors or any MAAC Independent Director Transferee upon conversion of the MAAC Class&nbsp;B Shares in the Merger be subject to the vesting provisions set forth in the Sponsor Support Agreement, and (b)&nbsp;each MAAC Independent
Director, on the one hand, and the Company, on the other hand, is entering into a <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, each of MAAC and the Company desire to amend the BCA in connection with agreements described in the preceding recital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration for the mutual promises made herein and other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, MAAC and the Company hereby agree to amend the BCA as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Amendments to the BCA</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Section&nbsp;1.1 of the BCA is hereby amended by adding the following new definitions in the appropriate alphabetical
order: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Independent Directors</U>&#148; means, collectively, George Barrett and Steve Oesterle. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>MAAC Independent Director Transferee</U>&#148; means any transferee of MAAC Class&nbsp;B Shares originally held by a MAAC Independent
Director, prior to the Effective Time. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Section&nbsp;2.1(b)(vii) of the BCA is hereby amended and restated in
its entirety and replaced with the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">&#147;(vii) At the Effective Time, by virtue of the Merger and without any action on the
part of any Party or any other Person, (A)&nbsp;each (x) MAAC Class&nbsp;A Share and (y)&nbsp;each MAAC Class&nbsp;B Share that is not held by the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent Director or any MAAC Independent
Director Transferee (other than the MAAC Class&nbsp;A Shares and MAAC Class&nbsp;B Shares canceled and extinguished pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)(ix)</U>) issued and outstanding as of immediately prior to the Effective Time shall
be automatically canceled and extinguished and converted into one Company Post-Closing Common Share and (B)&nbsp;each MAAC Class&nbsp;B Share issued and outstanding and held by the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC
Independent Director or any MAAC Independent Director Transferee as of immediately prior to the Effective Time shall be automatically canceled and extinguished and converted into the number of Company Post-Closing Common Shares equal to the Sponsor
Exchange Ratio; <U>provided</U> that for the avoidance of doubt, a number of Company Post-Closing Common Shares owned by the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent Director or any MAAC Independent Director Transferee,
determined pursuant to the Sponsor Support Agreement, shall become subject to the vesting and other terms and conditions set forth in the Sponsor Support Agreement at the Effective Time. As of the Effective Time, all MAAC Shares shall no longer be
outstanding and shall automatically be canceled and shall cease to exist, and shall thereafter represent the number of Company Post-Closing Common Shares into which such MAAC Shares were converted pursuant to this Agreement. From and after the
Effective Time, each <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> MAAC Shareholder&#146;s certificate(s) (the &#147;<U>Certificates</U>&#148;), if any, evidencing ownership of MAAC Shares and MAAC Shares held in book-entry form issued and
outstanding immediately prior to the Effective Time shall each cease to have any rights with respect to such MAAC Shares, except as otherwise expressly provided for herein or under applicable Law.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Section&nbsp;2.3 of the BCA is hereby amended and restated in its entirety and replaced with the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Section</B><B></B><B>&nbsp;2.3 </B><B><U>Fractional Shares</U></B>. Notwithstanding the foregoing or anything to the contrary herein,
no fractional Company Post-Closing Common Shares shall be issued in connection with the transactions contemplated hereby. Except with respect to Company Equity Awards, all fractional Company Post-Closing Common Shares that each Company Equityholder
will have a right to receive in connection with the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, as well as (a)&nbsp;all fractional Company Post-Closing Common Shares that the MAAC Sponsor and its Affiliates as holders of MAAC
Class&nbsp;B Shares will have a right to receive in connection with the Merger and (b)&nbsp;all fractional Company Post-Closing Common Shares that each MAAC Independent Director and the applicable MAAC Independent Director Transferee(s) as holders
of MAAC Class&nbsp;B Shares will have a right to receive in connection with the Merger, shall, in each case be aggregated and, if a fractional share results from such aggregation, such fractional share shall be rounded down to the nearest whole
share.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Effect of Amendments and Modifications</U>. Except as expressly amended hereby, the BCA shall remain unaltered and in
full force and effect and the respective terms, conditions or covenants thereof are hereby in all respects confirmed. Whenever the BCA is referred to in any agreement, document or other instrument, such reference will be to the BCA as amended by
this Amendment. For the avoidance of doubt, each reference in the BCA, as amended hereby, to &#147;the date hereof&#148;, the &#147;date of this Agreement&#148; and derivations thereof and other similar phrases shall continue to refer to May&nbsp;1,
2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Miscellaneous</U>. Sections 8.5, 8.7, 8.10, 8.11, 8.15 and 8.16 of the BCA are incorporated herein by reference, <I>mutatis
mutandis</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Amendment to be signed as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MONTES ARCHIMEDES ACQUISITION CORP.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Maria C. Walker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Maria C. Walker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROIVANT SCIENCES LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marianne Romeo</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Marianne Romeo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Head, Global Transactions &amp; Risk Management</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Amendment No.&nbsp;1 to the Business Combination Agreement] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>d307489dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ROIVANT SCIENCES LTD. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIRD AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS THIRD AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this &#147;<B>Agreement</B>&#148;) is made and entered into as of May&nbsp;1,
2021, by and among (i)&nbsp;Roivant Sciences Ltd., a Bermuda exempted limited company (the &#147;<B>Company</B>&#148;), (ii) the Dexxon Investors (as defined herein), (iii) the QVT Investors (as defined herein), (iv) the Viking Investors (as defined
herein), (v) SVF Investments (UK) Limited (&#147;<B>Softbank</B>&#148;), (vi) Sumitomo Dainippon Pharma Co., Ltd. (&#147;<B>Sumitomo</B>&#148;), (vii) Vivek Ramaswamy (the &#147;<B>Founder</B>&#148;), (viii) the parties listed on<B> Exhibit <FONT
STYLE="white-space:nowrap">A-1</FONT></B> hereto who signed joinder agreements in connection with the Original Registration Rights Agreement, the First Amended and Restated Registration Rights Agreement or the Second Amended and Restated
Registration Rights Agreement (each, as defined below), as the case may be (the &#147;<B>Joinder Parties</B>&#148; and together with the Dexxon Investors, the QVT Investors, the Viking Investors, Softbank, Sumitomo, the Founder and each of their
respective Permitted Transferees who, at any time, acquire securities of the Company and execute a counterpart of this Agreement or who otherwise agree to be bound by this Agreement, the &#147;<B>Investors</B>&#148;) and (ix)&nbsp;each of the other
Persons who, at any time, acquire securities of the Company or shares or rights, convertible into, exchangeable for or exercisable for, equity securities of the Company in accordance with the terms hereof, execute a counterpart of this Agreement or
otherwise agree to be bound by this Agreement and shall be listed on Exhibit <FONT STYLE="white-space:nowrap">A-2</FONT> hereto at such time as such Person entered into a joinder agreement (the &#147;<B>Other Shareholders</B>&#148;). The Other
Shareholders and the Investors are collectively referred to herein as the &#147;Shareholders.&#148; The Company, the Investors and the Other Shareholders are sometimes collectively referred to herein as the &#147;Parties&#148; and individually as a
&#147;<B>Party</B>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company, Dexxon, the QVT Investors, the Founder and the Joinder Parties were parties to that
certain Registration Rights Agreement, dated May&nbsp;5, 2014 (the &#147;<B>Original Registration Rights Agreement</B>&#148;) pursuant to which the Company undertook to grant certain registration rights to Dexxon, the QVT Investors, the Founder and
the Joinder Parties in connection with certain securities of the Company and BVC Ltd., a Bermuda exempted limited liability company (&#147;<B>BVC</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as of December&nbsp;4, 2015, the Company and BVC completed a statutory merger under Bermuda law, as a result of which BVC merged with
and into the Company, with the Company as the surviving entity and in connection with which the Company, Dexxon, the QVT Investors, the Viking Investors, the Founder and the Joinder Parties entered into that certain Amended and Restated Registration
Rights Agreement, dated December&nbsp;8, 2015 (the &#147;<B>First Amended and Restated Registration Rights Agreement</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
the Company, the Dexxon Investors, the QVT Investors, the Viking Investors, Softbank, the Founder and the Joinder Parties entered into that certain Second Amended and Restated Registration Rights Agreement, dated September&nbsp;6, 2017 (the
&#147;<B>Second Amended and Restated Registration Rights Agreement</B>&#148;) for the purpose, among others, of providing certain registration rights to the Dexxon Investors, the QVT Investors, the Viking Investors, Softbank, the Founder and the
Joinder Parties; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company, Rhine Merger Sub, Inc., a Delaware corporation and direct wholly owned
subsidiary of the Company (the &#147;<B>Merger Sub</B>&#148;), and Montes Archimedes Acquisition Corp., a Delaware corporation (&#147;<B>SPAC</B>&#148;), have entered into a Business Combination Agreement, dated as of May&nbsp;1, 2021 (as it may be
amended, supplemented or otherwise modified from time to time, the &#147;<B>Merger Agreement</B>&#148;), pursuant to which, among other things, Merger Sub will merge with and into SPAC (the &#147;<B>Merger</B>&#148;), with SPAC as the surviving
corporation in the Merger and, after giving effect to the Merger, SPAC will become a subsidiary of the Company and the Company shall become subject to the reporting requirements of the Exchange Act and certain of the Company&#146;s Common Shares,
par value $0.0000001 per share (the &#147;<B>Common Shares</B>&#148;), shall be registered under the Securities Act (together with the Merger, the &#147;<B>Go Public Transaction</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the parties executing this Agreement constitute the holders of the requisite number of shares necessary pursuant to Section&nbsp;13D
of the Second Amended and Restated Registration Rights Agreement in order to effect the amendment and restatement of such agreement effected hereby; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with the Go Public Transaction, the Company and the Investors desire to enter into this Agreement for the purpose,
among others, to provide the registration rights set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants,
agreements and understandings contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1. <I>Demand Registrations</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Requests for Registration</I>. Subject to Section&nbsp;1(e) below and the other terms and conditions of this Agreement, at any time
beginning one hundred eighty (180)&nbsp;days following the date on which the Company completes the Go Public Transaction, each Major Holder and each Person, if any, holding at least five percent (5.0%) of the then-outstanding number of Registrable
Securities (&#147;<B>Other Demand Holders</B>&#148;) may (i)&nbsp;request registration under the Securities Act on Form <FONT STYLE="white-space:nowrap">S-1</FONT> or any similar long-form registration statement (a &#147;<B>Long-Form
Registration</B>&#148;) of all or any portion of its Investor Registrable Securities or Other Registrable Securities, as the case may be, in accordance with Section&nbsp;1(b) or (ii)&nbsp;if available, request registration under the Securities Act
on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (including a Shelf Registration) or any similar short-form registration statement (a &#147;<B>Short-Form Registration</B>&#148;) of all or any portion of its Investor Registrable Securities or
Other Registrable Securities, as the case may be, in accordance with Section&nbsp;1(c) (each such request, a &#147;<B>Demand Notice</B>&#148;). Subject to Section&nbsp;1(e) below and the other terms and conditions of this Agreement, at any time
beginning one hundred eighty (180)&nbsp;days following the date on which the Company completes the Go Public Transaction, any Other Shareholder may, if available, request Short-Form Registrations of all or any portion of its Registrable Securities
in accordance with Section&nbsp;1(c). All registrations requested pursuant to this Section&nbsp;1(a) by the holders of Registrable Securities are referred to herein as &#147;<B>Demand Registrations</B>.&#148; Each request for a Demand Registration
shall specify the intended method of distribution and the approximate number of Registrable Securities requested to be registered. No Demand Registration will be consummated (and no registration statement with respect thereto filed) if the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number of Registrable Securities requested to be registered (including pursuant to the following sentence) is fewer than (A)&nbsp;in the case of Long-Form Registrations, such number of Common
Shares with a value (based on the closing price on the trading day immediately prior to the filing of the registration statement or prospectus supplement, as applicable, for any Long-Form Registration) of $100,000,000 and (B)&nbsp;in the case of
Short-Form Registrations, such number of Common Shares with a value (based on the closing price on the trading day immediately prior to the filing of the registration statement or prospectus supplement, as applicable, for any Short-Form
Registration) of $50,000,000. Within ten (10)&nbsp;days after receipt of any such request, the Company shall give written notice of such requested registration to all other Shareholders and, subject to the terms of Section&nbsp;1(d), shall include
in such registration (and in all related registrations and qualifications under state blue sky laws and in compliance with other registration requirements and in any related underwriting) all Registrable Securities with respect to which the Company
has received written requests for inclusion therein within twenty (20)&nbsp;days after the delivery of the Company&#146;s notice; <I>provided, however</I>, that no Investor shall be required to be named an &#147;underwriter&#148; without such
Investor&#146;s express prior written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Long-Form Registrations</I>. The Major Holders shall be entitled to Long-Form
Registrations under this Agreement as follows: (i)&nbsp;the QVT Investors (acting by action of the holders of a majority of the Common Shares held by them), the Viking Investors (acting by action of the holders of a majority of the Common Shares
held by them), the Dexxon Investors, Softbank and Sumitomo shall each be entitled to three (3)&nbsp;Long-Form Registrations, and (ii)&nbsp;the Founder shall be entitled to one (1)&nbsp;Long-Form Registration. Other Shareholders shall have the right
to demand Long-Form Registrations or Short-Form Registrations only to the extent such Other Shareholders are designated as Other Demand Holders pursuant to the terms of this Agreement, provided however, that the Other Shareholders will be entitled
to a maximum of two (2)&nbsp;Long-Form Registrations if so designated. The Company shall pay all Registration Expenses with respect to such Long-Form Registrations. All Long-Form Registrations shall only be made if the method of distribution to be
used in connection with such registration is an underwritten offering unless otherwise approved by the board of directors of the Company (the &#147;<B>Board</B>&#148;). The Company shall file a registration statement on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> under the Securities Act covering all Registrable Securities requested to be included in such Long-Form Registration (subject to the limitations set forth herein) promptly following the Company&#146;s receipt of
a Demand Notice therefor and, in any event, within sixty (60)&nbsp;days after the date the Demand Notice is duly delivered to the Company in accordance with this Agreement. The Company shall use commercially reasonable efforts to cause such Long
Form Registration to be declared effective under the Securities Act as soon as practicable after the filing thereof, but no later than the earlier of (i)&nbsp;sixty (60) calendar days after the filing date thereof (or ninety (90)&nbsp;calendar days
after the filing thereof if the SEC notifies the Company that it will &#147;review&#148; the Long Form Registration) and (ii)&nbsp;ten (10) business days after the Company is notified (orally or in writing, whichever is earlier) by the SEC that the
Long Form Registration will not be &#147;reviewed&#148; or will not be subject to any further review. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Short-Form
Registrations</I>. In addition to the Long-Form Registrations provided pursuant to Section&nbsp;1(b), each of the Major Holders and the Other Demand Holders shall be entitled to request an unlimited number of Short-Form Registrations in which the
Company shall pay all Registration Expenses, whether or not any registration statement for such a registration has become effective. Demand Registrations shall be Short-Form Registrations whenever the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company is permitted to use any applicable short form registration statement. After the Go Public Transaction, the Company shall use its reasonable best efforts to make Short-Form Registrations
available for the sale of Registrable Securities. If the Shareholder initially requesting a Short-Form Registration requests that such Short-Form Registration be filed pursuant to Rule 415 (a &#147;<B>Shelf Registration</B>&#148;), and the Company
is qualified to do so, then the Company shall use its reasonable best efforts to promptly file and cause the Shelf Registration to be declared effective under the Securities Act as soon as reasonably practicable after the filing thereof and the
Company shall use its reasonable best efforts to keep such shelf registration continuously effective following such registration; provided that any request for an underwritten offering using such Shelf Registration (an &#147;<B>Underwritten
Takedown</B>&#148;) shall be deemed a Demand Registration. The provisions of Section&nbsp;1(a) shall apply <I>mutatis</I> <I>mutandis</I> to each Underwritten Takedown, with references to &#147;filing of the registration statement&#148; or
&#147;effective date&#148; being deemed references to filing of a prospectus or supplement for such offering and references to &#147;registration&#148; being deemed references to the offering; <I>provided</I> that Shareholders participating in the
Underwritten Takedown shall only include Shareholders whose Registrable Securities are included in such Shelf Registration or may be included therein without the need for a post-effective amendment to such Shelf Registration (other than an
automatically effective amendment). If for any reason the Company ceases to be a WKSI or becomes ineligible to utilize Form <FONT STYLE="white-space:nowrap">S-3</FONT> or any similar applicable short form registration statement, then the Company
shall prepare and file with the U.S. Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) one or more registration statements on such form that is available for the sale of Registrable Securities. The Company shall file a
registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act covering all Registrable Securities requested to be included in such Short Form-Registration (subject to the limitations set forth herein) promptly
following the Company&#146;s receipt of a Demand Notice therefor and, in any event, within thirty (30)&nbsp;days after the date the Demand Notice is duly delivered to the Company in accordance with this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Priority on Demand Registrations</I>. If a Demand Registration is for an underwritten offering and the managing underwriters advise the
Company in writing that in their opinion the number of securities requested to be included in such offering exceeds the number of securities which marketing factors permit to be sold in such offering, then the Company shall include in such
registration only that number of Registrable Securities that in the opinion of such underwriters marketing factors permit to be sold in such offering, and the Registrable Securities that are included in such offering shall be allocated pro rata
among the respective holders thereof on the basis of the number of Registrable Securities owned by each such holder; provided, however, that the number of Registrable Securities held by such holders to be included in such registration shall not be
reduced unless all other securities are first entirely excluded from the registration. A registration shall not be counted as &#147;effected&#148; if, as a result of an exercise of the underwriter&#146;s cutback provisions in this Section&nbsp;1(d),
fewer than fifty percent (50%) of the total number of Registrable Securities that holders have requested to be included in such registration statement are actually included. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Restrictions on Demand Registrations</I>. The Company shall not be obligated to effect any Demand Registration within one hundred
eighty (180)&nbsp;days after the effective date of the Go Public Transaction or within ninety (90)&nbsp;days after the effective date of a previous Long-Form Registration. The Company may postpone the filing or the effectiveness of a registration
statement or prospectus supplement, as applicable, for a Demand Registration or suspend the use </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of a prospectus included in any registration statement for a Demand Registration, if the Board determines in its good faith judgment that such Demand Registration would reasonably be expected to
(i)&nbsp;materially interfere with any proposal or plan that is material to the Company related to any financing, acquisition of assets or securities, recapitalization, merger, consolidation, tender offer, reorganization or similar transaction,
(ii)&nbsp;require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential or (iii)&nbsp;render the Company unable to comply with requirements under the Securities Act or Exchange
Act; <I>provided</I> that in such event, the Shareholder initially requesting such Demand Registration shall be entitled to withdraw such request and, if such request is withdrawn with respect to a Long-Form Registration, such Demand Registration
shall not count against the total number of Long-Form Registrations provided for in Section&nbsp;1(b), and the Company shall pay nonetheless all Registration Expenses in connection with such registration; <I>provided, further</I>, that the Company
shall not register any securities for its own account or that of any other stockholder during such postponement or suspension period other than pursuant to: (a)&nbsp;a Resale Shelf (including any amendments, supplements or any other filings related
thereto); (b) a registration relating to the sale or grant of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan; (c)&nbsp;a registration on any form that does not
include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (d)&nbsp;a registration in which the only Common Shares being registered are Common Shares
issuable upon conversion of debt securities that are also being registered. The Company may not delay a Demand Registration or suspend the use of a prospectus pursuant to this Section&nbsp;1(e): (i) more than two (2)&nbsp;times in any period of
twelve (12)&nbsp;consecutive months, (ii)&nbsp;the duration of any one suspension or postponement may not exceed sixty (60)&nbsp;days and (iii)&nbsp;the total duration of any suspension or postponement period may not be more than ninety
(90)&nbsp;days in any period of twelve (12)&nbsp;consecutive months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Resale Registration Statement</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company shall file within 30 days of the consummation of the Go Public Transaction, and use commercially reasonable
efforts to cause to be declared effective as soon as practicable thereafter, a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (the &#147;<B>Resale <FONT STYLE="white-space:nowrap">S-1</FONT> Shelf</B>&#148;) or, if the
Company is eligible to use a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (the &#147;<B>Resale <FONT STYLE="white-space:nowrap">S-3</FONT>
Shelf</B>&#148; and together with the Resale <FONT STYLE="white-space:nowrap">S-1</FONT> Shelf, each a &#147;<B>Resale Shelf</B>&#148;), in each case, covering the resale of all the Registrable Securities (determined as of two business days prior to
such filing) and any other Common Shares or other securities of the Company issued in connection with the Go Public Transaction that have not been registered under the Securities Act; provided, that the Parties acknowledge and agree that the sale of
any Registrable Securities registered under such Resale Shelf may be subject to restrictions imposed by <FONT STYLE="white-space:nowrap">lock-up</FONT> or holdback restrictions and/or applicable securities laws. Such Resale Shelf shall provide for
the resale of the Registrable Securities included therein pursuant to any method or combination of methods legally available to, and requested by, any of the Investors named therein. Notwithstanding anything to the contrary herein, to the extent
there is an active Resale Shelf under this Section&nbsp;1(f) covering Registrable Securities of any Major Holder and/or the Other Demand Holders, and such Major Holder and/or the Other Demand Holder wishes to request a Demand Registration, such
Demand Registration shall reduce the number of Demand Registrations that may be made pursuant to Section&nbsp;1(b). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Company agrees to use commercially reasonable efforts to cause such
Resale Shelf, or another shelf registration statement that includes all Registrable Securities, including, without limitation, the PIPE Shares, to remain effective until the earliest of (i)&nbsp;the second anniversary of the consummation of the Go
Public Transaction and, (ii)&nbsp;the date on which Investors cease to hold any Registrable Securities (the &#147;<B>End Date</B>&#148;). Prior to the End Date, the Company will use commercially reasonable efforts to&nbsp;(1) qualify the Registrable
Securities for listing on one or more of the New York Stock Exchange, NYSE American, LLC and/or the Nasdaq Stock Market and (2)&nbsp;update or amend the Registration Statement as necessary to include the Registrable Securities. The Company shall use
its commercially reasonable efforts to provide a draft of the Resale Shelf to the Investors holding Registrable Securities for review (but not comment) at least two (2)&nbsp;Business Days in advance of filing the Resale Shelf; provided that, for the
avoidance of doubt, in no event shall the Company be required to delay or postpone the filing of such Resale Shelf as a result of or in connection with any Investor&#146;s review. Notwithstanding the foregoing, if the Securities and Exchange
Commission prevents the Company from including any or all of the Registrable Securities proposed to be registered under the Resale Shelf due to limitations on the use of Rule 415 of the Securities Act for the resale of Registrable Securities by the
applicable stockholders or otherwise, such Resale Shelf shall register for resale the maximum number of Registrable Securities as is permitted. In such event, the number of Registrable Securities to be registered for each selling stockholder named
in the Resale Shelf shall be reduced pro rata among all such selling stockholders, in each case, giving priority first to the PIPE Shares and then to the remainder of Registrable Securities, and as promptly as practicable after being permitted to
register additional Registrable Securities under Rule 415 under the Securities Act, the Company shall amend the Resale Shelf or file a new Resale Shelf to register such Registrable Securities not included in the initial Resale Shelf and use its
commercially reasonable efforts to cause such amendment or Resale Shelf to become effective as promptly as practicable. The Registration Expenses of the holders of Registrable Securities shall be paid by the Company in the Resale Shelf, whether or
not any such offering is completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Selection of Underwriters</I>. If any Demand Registration is for an underwritten offering,
then the holders of a majority of the Registrable Securities being sold in such Demand Registration shall have the right to select the investment banker(s) and manager(s) to administer such offering, subject to the prior written approval of the
Board, which approval shall not be unreasonably withheld, conditioned or delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Other Registration Rights</I>. Except as
provided to the holders of Registrable Securities in this Agreement and except in connection with the Go Public Transaction (including the filing of the Resale Shelf contemplated thereby), the Company shall not grant to any Persons the right to
request the Company to register any equity securities of the Company, or any securities, options or rights convertible or exchangeable into or exercisable for such securities, without the prior written consent of the Board; <I>provided </I>that the
Company may (i)&nbsp;grant rights to participate in any registration pursuant to Section&nbsp;2 below (a &#147;<B>Piggyback Registration</B>&#148;) so long </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as such rights are subordinate in priority to the rights of Parties hereto with respect to Piggyback Registrations, as provided in Section&nbsp;2(c) and Section&nbsp;2(d), and not otherwise
inconsistent with the terms and conditions hereof, and (ii)&nbsp;enter into an agreement with any holder or prospective holder of any securities of the Company related to the filing of a Resale Shelf to register shares issued to such holder as
consideration in an acquisition of a third party, if and only if such Resale Shelf does not permit underwritten offerings (provided that nothing in this clause (ii)&nbsp;shall be interpreted to limit the rights of a holder of securities of the
Company in connection with the Go Public Transaction and the Resale Shelf contemplated thereby). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Termination of Registration
Rights</I>. The rights of any holder of Registrable Securities to request inclusion of such Registrable Securities pursuant to this Section&nbsp;1 shall terminate upon the earlier to occur of (i)&nbsp;the seventh anniversary of the date of this
Agreement and (ii)&nbsp;the date as of which (A)&nbsp;all of the Registrable Securities have been sold pursuant to a Registration Statement (but in no event prior to the applicable period referred to in Section&nbsp;4(a)(3) of the Securities Act and
Rule 174 thereunder (or any successor rule promulgated thereafter by the Commission)) or (B)&nbsp;all Registrable Securities have been sold under Rule 144 under the Securities Act. The provisions of Section&nbsp;7 and Section&nbsp;9 shall survive
any termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2. <I>Piggyback Registrations</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Right to Piggyback</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Other than in connection with a Resale Shelf or a request for a Demand Registration or a Shelf Registration pursuant to
Sections 1(a), 1(b) and 1(c) of this Agreement, if at any time the Company, including if the Company qualifies as a WKSI, proposes to file (A)&nbsp;a prospectus supplement to an effective shelf registration statement (a &#147;<B>Shelf Registration
Statement</B>&#148;), or (B)&nbsp;a registration statement other than a Shelf Registration Statement, in either case, for the sale of Common Shares for its own account, or for the benefit of the holders of any of its Common Shares other than the
Shareholders, to an underwriter on a firm commitment basis for reoffering to the public or in a &#147;bought deal&#148; or &#147;registered direct offering&#148; with one or more investment banks (collectively, a &#147;<B>Piggyback Underwritten
Offering</B>&#148;), then the Company shall give prompt written notice, to be delivered not less than five (5)&nbsp;business days prior to the filing of (1)&nbsp;any preliminary prospectus supplement relating to such Piggyback Underwritten Offering
pursuant to Rule 424(b) under the Securities Act, (2)&nbsp;any prospectus supplement relating to such Piggyback Underwritten Offering pursuant to Rule 424(b) under the Securities Act (if no preliminary prospectus supplement is used) or (3)&nbsp;such
registration statement, as the case may be, to all holders of Registrable Securities of the Company and such notice (a &#147;<B>Piggyback Notice</B>&#148;) shall offer the Shareholders the opportunity to include in such Piggy-Back Underwritten
Offering such number of Registrable Securities as each such Shareholder may request in writing. Each such Shareholder shall then have three (3)&nbsp;business days after receiving such notice to request in writing to the Company inclusion of
Registrable Securities in the Piggy-Back Underwritten Offering, except that such Shareholders shall have two (2)&nbsp;business days after such Shareholder confirms receipt of the notice to request inclusion of Registrable Securities in the Piggy
Back Underwritten Offering in the case of a &#147;bought deal&#148;, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
&#147;registered direct offering&#148; or &#147;overnight transaction&#148; where no preliminary prospectus is used. Upon receipt of any such request for inclusion from a Shareholder received
within the specified time, the Company shall use reasonable best efforts to effect the registration in any registration statement of any of the Shareholder&#146;s Registrable Securities requested to be included on the terms set forth in this
Agreement. Prior to the commencement of any &#147;road show,&#148; any Shareholder shall have the right to withdraw its request for inclusion of its Registrable Securities in any registration by giving written notice to the Company of its request to
withdraw and such withdrawal shall be irrevocable and, after making such withdrawal, such Shareholder shall no longer have any right to include Registrable Securities in the Piggyback Underwritten Offering as to which such withdrawal was made. The
Company may postpone or withdraw the filing or the effectiveness of a Shelf Registration Statement or a proposed Piggyback Underwritten Offering at any time in its sole discretion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) If the Company does not qualify as a WKSI, (A)&nbsp;the Company shall give each Shareholder five (5)&nbsp;business
days&#146; notice prior to filing a Shelf Registration Statement and, upon the written request of any Shareholder, received by the Company within three (3)&nbsp;business days of such notice to the Shareholder, the Company shall include in such Shelf
Registration Statement a number of Common Shares equal to the aggregate number of Registrable Securities requested to be included without naming any requesting Shareholder as a selling shareholder and including only a generic description of the
holder of such securities (the &#147;<B>Undesignated Registrable Securities</B>&#148;), (B) the Company shall not be required to give notice to any Shareholder in connection with a filing pursuant to Section&nbsp;2(a)(i) unless such Shareholder
provided such notice to the Company pursuant to this Section&nbsp;2(a)(ii) and included Undesignated Registrable Securities in the Shelf Registration Statement related to such filing, and (C)&nbsp;at the written request of a Shareholder given to the
Company more than two (2)&nbsp;business days before the date specified in writing by the Company as the Company&#146;s good faith estimate of a launch of a Piggyback Registration (or such shorter period to which the Company in its sole discretion
consents), the Company shall use reasonable best efforts to effect the registration of any of the Shareholders&#146; Undesignated Registrable Securities so requested to be included and shall file a post-effective amendment or, if available, a
prospectus supplement to a Shelf Registration Statement to include such Undesignated Registrable Securities as any Shareholder may request, <I>provided</I> that (1)&nbsp;the Company is actively employing its reasonable best efforts to effect such
Piggyback Registration; and (2)&nbsp;the Company shall not be required to effect a post-effective amendment more than two (2)&nbsp;times in any twelve (12)&nbsp;month period. In lieu of providing the notice set forth in Section&nbsp;2(a)(i), the
Company may determine to include in a Shelf Registration Statement a number of Undesignated Registrable Securities equal to the Registrable Securities held by all Shareholders. The Company shall have the right to terminate or withdraw any
registration or offering initiated by it under this Section&nbsp;2(a) before the effective date of such registration, whether or not any Shareholder has elected to include Registrable Securities in such registration or offering. The expenses of such
withdrawn registration or offering shall be borne by the Company in accordance with Section&nbsp;2(b). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Piggy Back Expenses</I>. The Registration Expenses of the holders of Registrable
Securities shall be paid by the Company in all Piggyback Underwritten Offerings, whether or not any such offering is completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
<I>Priority on Primary Piggyback Registrations</I>. If a Piggyback Registration is an underwritten primary offering on behalf of the Company and the managing underwriters advise the Company in writing that in their reasonable opinion the number of
securities requested to be included in such offering exceeds the number of Registrable Securities which marketing factors permit to be sold in such offering, then the Company shall include in such offering only that number of securities that in the
opinion of such underwriters marketing factors permit to be sold in such offering, with priority for inclusion to be determined as follows: (i)&nbsp;first, the securities the Company proposes to sell, (ii)&nbsp;second, a number of Registrable
Securities requested to be included in such registration allocated pro rata among the respective holders thereof on the basis of the number of Registrable Securities owned by each such holder, and (iii)&nbsp;third, any securities entitled to
registration rights pursuant to a private placement expected to be consummated in connection with the Merger, <I>provided, however</I>, that (i)&nbsp;the number of Registrable Securities held by such holders to be included in such offering shall not
be reduced unless securities held by persons other than the Company and Major Holders are first entirely excluded from the offering and (ii)&nbsp;the number of Registrable Securities included in the offering shall not be reduced below thirty percent
(30%) of the total number of securities included in such offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Priority on Secondary Piggyback Registrations</I>. If a
Piggyback Registration is an underwritten secondary offering on behalf of holders of the Company&#146;s securities (other than holders of Registrable Securities) and the managing underwriters advise the Company in writing that in their reasonable
opinion the number of securities requested to be included in such offering exceeds the number of securities which marketing factors permit to be sold in such offering, then the Company shall include in such offering only that number of securities
which in the opinion of such underwriters marketing factors permit to be sold in such offering, and the Registrable Securities that are included in such offering shall be allocated pro rata among the respective holders thereof on the basis of the
number of Registrable Securities owned by each such Shareholder; <I>provided, however</I>, that the number of Registrable Securities held by such holders to be included in such offering shall not be reduced unless all other securities are first
entirely excluded from the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Selection of Underwriters</I>. If any Piggyback Registration is an underwritten offering, the
Board shall select the investment banker(s) and manager(s) for such offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Other Registrations</I>. If the Company has
previously filed a registration statement with respect to Registrable Securities pursuant to Section&nbsp;1 or Section&nbsp;2, and if such previous registration has not been withdrawn or abandoned, then the Company shall not file or cause to be
effected any other registration of any of its equity securities or securities convertible or exchangeable into or exercisable for its equity securities under the Securities Act (except on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or any
successor form), whether on its own behalf or at the request of any holder or holders of such securities, until a period of at least ninety (90)&nbsp;days has elapsed from the effective date of such previous registration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Termination of Registration Rights</I>. The rights of any holder of Registrable
Securities to request inclusion of such Registrable Securities pursuant to this Section&nbsp;2 shall terminate upon the earlier of (i)&nbsp;the seventh anniversary of the date of this Agreement and (ii)&nbsp;the date as of which (A)&nbsp;all of the
Registrable Securities have been sold pursuant to a Registration Statement (but in no event prior to the applicable period referred to in Section&nbsp;4(a)(3) of the Securities Act and Rule 174 thereunder (or any successor rule promulgated
thereafter by the Commission)) or (B)&nbsp;all Registrable Securities have been sold under Rule 144 under the Securities Act. The provisions of Section&nbsp;7 and Section&nbsp;9 shall survive any termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3. <I>Holdback Agreements</I>. Each Shareholder hereby agrees that such Shareholder shall not (i)&nbsp;lend, offer, pledge, sell,
contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, (a)&nbsp;any Common Shares that are held
by or on behalf of such Shareholder immediately prior to the consummation of the Go Public Transaction or (b)&nbsp;any securities that are held by or on behalf of such Shareholder immediately prior to the consummation of the Go Public Transaction
that are convertible into or exercisable or exchangeable (directly or indirectly) for Common Shares (including without limitation, Common Shares or other securities that may be issued after the consummation of the Go Public Transaction upon
exercise, vesting or settlement, as applicable, of any stock option, restricted stock unit, capped value appreciation right or other equity or equity-based award or interest (the securities described in this clause (b), the &#147;<B>Other
Securities</B>&#148;)) or (ii)&nbsp;enter into any swap, hedge or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Common Shares or Other Securities, whether any such transaction
described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Common Shares or Other Securities, in cash, or otherwise, and whether any such transaction is made or executed by or on behalf of someone other than the Shareholder (each, a
&#147;<B>Sale Transaction</B>&#148;) for a period of <FONT STYLE="white-space:nowrap">one-hundred</FONT> eighty (180)&nbsp;days following the consummation of the Go Public Transaction (a &#147;<B>Holdback Period</B>&#148;), <I>provided</I> that all
officers and directors of the Company and holders of at least one percent (1%) of the Company&#146;s voting securities (calculated on a fully diluted basis) are bound by and have entered into agreements that are no less restrictive than such
agreements entered into by the Shareholders (including, without limitation, any provisions relating to early release from such obligations); <I>provided</I>, further, that the term &#147;Sale Transaction&#148; shall not include a sale or other
transfer by an Upstream Equity Holder of its direct or indirect common stock or membership, partnership or other equity ownership interest in a Shareholder (whether or not for consideration). The foregoing provisions of this Section&nbsp;3 shall not
apply to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(1) the sale of any Common Shares to an underwriter pursuant to an underwriting agreement to which the Company is a party in
connection with a Shareholder&#146;s exercise of piggyback registration rights set forth in, and in accordance with the terms and conditions of, Section&nbsp;2 hereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) a transfer of any or all of Common Shares or Other Securities (I)&nbsp;by gift, will, intestate succession or charitable contribution,
(II)&nbsp;to any Permitted Transferee, (III)&nbsp;by operation of law or pursuant to a court order or an order of a regulatory agency, such as a qualified domestic relations order, divorce decree or separation agreement, (IV)&nbsp;to the Company
pursuant to the exercise, in each case on a &#147;cashless&#148; or &#147;net exercise&#148; basis, of any Other Securities (provided that any Common Shares received upon any such exercise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
will be subject to the restrictions set forth above), (V) for purposes of satisfying any withholding taxes and/or estimated taxes due as a result of the exercise, vesting or settlement, as
applicable, of any Other Securities, (VI)&nbsp;in connection with the Company&#146;s consummation of a liquidation, merger, amalgamation, share exchange, reorganization, tender offer or other similar transaction that results in all of the
Company&#146;s shareholders having the right to exchange their equity holdings in the Company for cash, securities or other property or (VII)&nbsp;by pledging, hypothecating or otherwise granting a security interest in Common Shares or Other
Securities in a bona fide transaction to one or more unaffiliated lending institutions as&nbsp;collateral&nbsp;or security for any margin loan and any transfer in the event of foreclosure upon such Common Shares or Other Securities as a result of a
default on such margin loan (so long as any such pledge, hypothecation or grant of security interest shall be on terms consistent with customary margin loans, and the applicable Shareholder shall provide the Company with written notice prior to
entering into such margin loan); provided, however, that in the case of any of the foregoing clauses (I), (II) or (III), the transferee in such transfer shall agree in a writing delivered to the Company that the Common Shares or Other Securities so
transferred will thereafter continue be subject to the terms set forth above; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(3) the establishment or modification of a written plan
meeting the requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> of the Exchange Act that does not provide for the sale or transfer of Common Shares during the Holdback Period; provided that, to the extent a public announcement or
filing under the Exchange Act is required regarding the establishment or modification of such plan, such announcement or filing shall include a statement to the effect that no sales or transfers of Common Shares may be made under such plan during
the Holdback Period; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(4) any Common Shares or Other Securities issued in connection with the private placement consummated in
connection with the Go Public Transaction, including any Common Shares or other securities received in exchange for, or converted for, securities acquired in such private placement (the &#147;<B>PIPE Shares</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Shareholder agrees to execute and deliver such other customary agreements as may be reasonably requested by the Company or the managing underwriter in an
underwritten transaction that are consistent with the foregoing or which are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions by the Company or the underwriters of any or all of such restrictions
with respect to any officer or director of the Company or a holder of 1% or more of the Company&#146;s total outstanding Common Shares (including a release of such restrictions set forth in Section&nbsp;5 of the
<FONT STYLE="white-space:nowrap">Bye-Laws,</FONT> a &#147;<B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Release</B>&#148;) shall apply pro rata to all Major Holders, based on the number of shares subject to such restrictions (the
&#147;<B>Shareholder Pro Rata Release</B>&#148;); <I>provided</I> that the prior sentence shall not apply to (a)&nbsp;waivers or terminations granted in an amount less than or equal to 1% of the Company&#146;s total outstanding Common Shares
(calculated on a fully-diluted basis immediately after the consummation of the Go Public Transaction) or (b)&nbsp;any primary or secondary public offering or sale that is underwritten and in which each holder of Registerable Securities is offered
the opportunity to participate pursuant to Section&nbsp;2 hereof. The Company may impose stop-transfer instructions with respect to the Common Shares (or other securities) subject to the foregoing restriction until the end of said <FONT
STYLE="white-space:nowrap">one-hundred</FONT> eighty <FONT STYLE="white-space:nowrap">(180)-day</FONT> period. At least two </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business days&#146; prior to the effective date of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Release, the Company shall provide written notice to the Major Holders stating the
percentage of Common Shares held by such Major Holder to be released. The Company acknowledges that the approval of this Agreement by the Board and the approval of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Release triggering such
Shareholder Pro Rata Release shall together constitute Board approval under Section&nbsp;5 of the <FONT STYLE="white-space:nowrap">Bye-Laws</FONT> of any Shareholder Pro Rata Release. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4. <I>Registration Procedures</I>. Whenever the holders of Registrable Securities have requested that any Registrable Securities
be registered pursuant to this Agreement (including pursuant to a Resale Shelf), the Company shall use its reasonable best efforts to effect the registration and the sale of such Registrable Securities hereunder in accordance with the intended
method of disposition thereof, and pursuant thereto the Company shall as expeditiously as reasonably possible: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) in accordance with the
Securities Act and all applicable rules and regulations promulgated thereunder, prepare and file with the Commission a registration statement, and all amendments and supplements thereto and related prospectuses as may be necessary to comply with
applicable securities laws, with respect to such Registrable Securities and use its reasonable best efforts to cause such registration statement to become effective; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) notify each holder of Registrable Securities of (i)&nbsp;the issuance by the Commission of any stop order suspending the effectiveness of
any registration statement or the initiation of any proceedings for that purpose, (ii)&nbsp;the receipt by the Company or its counsel of any notification with respect to the suspension of the qualification of the Registrable Securities for sale in
any jurisdiction or the initiation or threatening of any proceeding for such purpose, and (iii)&nbsp;the effectiveness of each registration statement filed hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) prepare and file with the Commission such amendments and supplements to such registration statement and the prospectus used in connection
therewith as may be necessary to keep such registration statement effective for a period ending when all of the securities covered by such registration statement have been disposed of in accordance with the intended methods of disposition by the
sellers thereof as set forth in such registration statement or, in the case of a Shelf Registration, if earlier, the date as of which all of the Registrable Securities included in such registration are able to be sold within a ninety (90)&nbsp;day
period in compliance with Rule 144 (but in any event not before the expiration of any longer period required under the Securities Act or, if such registration statement relates to an underwritten offering, such longer period as in the opinion of
counsel for the underwriters a prospectus is required by law to be delivered in connection with sales of securities thereunder by any underwriter or dealer) and comply with the provisions of the Securities Act with respect to the disposition of all
securities covered by such registration statement during such period in accordance with the intended methods of disposition by the sellers thereof set forth in such registration statement; <I>provided</I>, that any such period shall be extended for
a period of time equal to the period the holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration statement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) furnish to each seller of Registrable Securities thereunder such number of copies of such registration statement, each amendment and
supplement thereto, the prospectus included in such registration statement (including each preliminary prospectus and any summary prospectus), each Free-Writing Prospectus and such other documents as such seller may reasonably request in order to
facilitate the disposition of the Registrable Securities owned by such seller; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) use its reasonable best efforts to register or qualify such Registrable Securities under
such other securities or blue sky laws of such jurisdictions as any seller reasonably requests and do any and all other acts and things which may be reasonably necessary or advisable to enable such seller to consummate the disposition in such
jurisdictions of the Registrable Securities owned by such seller (<I>provided</I> that the Company shall not be required to (i)&nbsp;qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify but for
this Section&nbsp;4(e), (ii) subject itself to taxation in any such jurisdiction, or (iii)&nbsp;consent to general service of process in any such jurisdiction); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) promptly notify in writing each seller of such Registrable Securities at any time when a prospectus relating thereto is required to be
delivered under the Securities Act, of the happening of any event as a result of which the prospectus included in such registration statement contains an untrue statement of a material fact or omits any fact necessary to make the statements therein
not misleading, and, at the request of any such seller, the Company promptly shall prepare, file with the Commission and furnish to each such seller a reasonable number of copies of a supplement or amendment to such prospectus so that, as thereafter
delivered to the purchasers of such Registrable Securities, such prospectus shall not contain an untrue statement of a material fact or omit to state any fact necessary to make the statements therein not misleading; <I>provided</I>, that each
selling holder of the Registrable Securities, upon receipt of any notice from the Company of any event of the kind described in this Section&nbsp;4(f), shall forthwith discontinue disposition of the Registrable Securities pursuant to the
registration statement covering such Registrable Securities until such holder is advised in writing by the Company that the use of the prospectus may be resumed and is furnished with a supplemented or amended prospectus as contemplated by this
Section&nbsp;4(f), and if so directed by the Company, such holder shall deliver to the Company (at the Company&#146;s expense) all copies, other than permanent file copies then in such holder&#146;s possession, of the prospectus covering such
Registrable Securities at the time of receipt of such notice; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) prepare and file promptly with the Commission, and notify such holders
of Registrable Securities prior to the filing of, such amendments or supplements to such registration statement or prospectus as may be necessary to correct any statements or omissions if, at the time when a prospectus relating to such securities is
required to be delivered under the Securities Act, when any event has occurred as the result of which any such prospectus or any other prospectus as then in effect would include an untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein not misleading, and, if any such holders of Registrable Securities or any underwriter for any such holders is required to deliver a prospectus at a time when the
prospectus then in circulation is not in compliance with the Securities Act or the rules and regulations promulgated thereunder, the Company shall use its best efforts to prepare promptly upon request of any such holder or underwriter such
amendments or supplements to such registration statement and prospectus as may be necessary in order for such prospectus to comply with the requirements of the Securities Act and such rules and regulations; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) cause all such Registrable Securities to be listed on each securities exchange on which
similar securities issued by the Company are then listed; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) provide a transfer agent and registrar for all such Registrable Securities
not later than the effective date of such registration statement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) enter into and perform such customary agreements (including
underwriting agreements in customary form) and take all such other actions as the holders of a majority of the Investor Registrable Securities included in such registration, the holders of a majority of the Other Registrable Securities included in
such registration or the underwriters, if any, reasonably request in order to expedite or facilitate the disposition of such Registrable Securities (including effecting a split or combination of equity, recapitalization or reorganization and
preparing for and participating in such number of &#147;road shows,&#148; investor presentations and marketing events as the underwriters managing such offering may reasonably request); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) make available upon reasonable notice and during normal business hours for inspection by any seller of Registrable Securities, any
underwriter participating in any disposition pursuant to such registration statement and any attorney, accountant or other agent retained by any such seller or underwriter, all financial and other records, pertinent corporate and business documents
and properties of the Company, as shall be reasonably necessary to enable them to exercise their due diligence responsibility, and cause the Company&#146;s officers, managers, directors and employees to supply all information reasonably requested by
any such seller, underwriter, attorney, accountant or agent in connection with such registration statement; provided, that, unless the disclosure of such records is necessary to avoid or correct a misstatement or omission in the registration
statement or the release of such records is ordered pursuant to a subpoena or other order from a court of competent jurisdiction, the Company shall not be required to provide any information under this Section&nbsp;4(k) if the Company believes,
after consultation with counsel for the Company, that to do so would cause the Company to forfeit an attorney-client privilege that was applicable to such information; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) take all reasonable actions to ensure that any Free-Writing Prospectus prepared by or on behalf of the Company in connection with any
Demand Registration or Piggyback Registration hereunder complies in all material respects with the Securities Act, is filed in accordance with the Securities Act to the extent required thereby, is retained in accordance with the Securities Act to
the extent required thereby and, when taken together with the related prospectus, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) otherwise use its reasonable best efforts to comply with all applicable rules and regulations
of the Commission and make available to its security holders, as soon as reasonably practicable, an earnings statement covering the period of at least twelve (12)&nbsp;months beginning with the first day of the Company&#146;s first full calendar
quarter after the effective date of the registration statement, which earnings statement shall satisfy the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) permit any holder of Registrable Securities which holder, in its good faith judgment
(based on the advice of counsel), could reasonably be expected to be deemed to be an underwriter or a controlling Person of the Company, to participate in the preparation of such registration or comparable statement and to require the insertion
therein of material, furnished to the Company in writing, which in the reasonable judgment of such holder and its counsel should be included; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) in the event of the issuance of any stop order suspending the effectiveness of a registration statement, or the issuance of any order
suspending or preventing the use of any related prospectus or suspending the qualification of any equity securities included in such registration statement for sale in any jurisdiction, the Company shall use its reasonable best efforts promptly to
obtain the withdrawal of such order; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) obtain (i)&nbsp;a cold comfort letter from the Company&#146;s independent public accountants in
customary form and covering such matters of the type customarily covered by cold comfort letters and (ii)&nbsp;opinions of counsel from the Company&#146;s counsel in customary form and covering such matters of the type customarily covered in a
public issuance of securities, in each case, in form and substance reasonably satisfactory to the underwriters and addressed to the managing underwriters; in each case as the holders of a majority of the Registrable Securities included in such
registration reasonably request; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) otherwise use its reasonable best efforts to take all other steps necessary to effect the
registration of such Registrable Securities contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5. <I>Certain Obligations of Holders of Registrable
Securities</I>. Each holder of Registrable Securities that sells such securities pursuant to a registration under this Agreement agrees as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Such holder (if such holder is an employee or independent contractor of the Company or any of its Affiliates) shall cooperate with the
Company (as reasonably requested by the Company) in connection with the preparation of the registration statement, and, for so long as the Company is obligated to file and keep effective such registration statement, each holder of Registrable
Securities that is participating in such registration shall provide to the Company, in writing, for use in the applicable registration statement, all such information regarding such holder and its plan of distribution of such securities as may be
reasonably necessary to enable the Company to prepare the registration statement and prospectus covering such securities, to maintain the currency and effectiveness thereof and otherwise to comply with all applicable requirements of law in
connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) During such time as a holder of Registrable Securities may be engaged in a distribution of such securities,
such holder shall distribute such securities under the registration statement solely in the manner described in the registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each Person that is participating in any registration under this Agreement, upon receipt of any notice from the Company of the happening
of any event of the kind described in Section&nbsp;4(f), shall immediately discontinue the disposition of its securities of the Company pursuant to the registration statement until such Person&#146;s receipt of the copies of a supplemented
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or amended prospectus as contemplated by Section&nbsp;4(f). In the event the Company has given any such notice, the applicable time period set forth in Section&nbsp;4(c) during which a
registration statement is to remain effective shall be extended by the number of days during the period from and including the date of the giving of such notice pursuant to this Section&nbsp;5(c) to and including the date when each seller of
Registrable Securities covered by such registration statement shall have received the copies of the supplemented or amended prospectus contemplated by Section&nbsp;4(f). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6. <I>Registration Expenses</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All expenses incident to the Company&#146;s performance of or compliance with this Agreement, including all registration, qualification
and filing fees, fees and expenses of compliance with securities or blue sky laws, filing expenses, printing expenses, messenger and delivery expenses, fees and disbursements of custodians and fees and disbursements of counsel for the Company and
all independent certified public accountants, underwriters (excluding underwriting discounts and commissions) and other Persons retained by the Company (all such expenses being herein called &#147;<B>Registration Expenses</B>&#148;), shall be borne
by the Company as provided in this Agreement, and the Company also shall pay all of its internal expenses (including all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit or
quarterly review, the expense of any liability insurance and the expenses and fees for listing the securities to be registered on each securities exchange on which similar securities issued by the Company are then listed. Notwithstanding anything to
the contrary contained herein, each seller of securities pursuant to a registration under this Agreement shall bear and pay all underwriting discounts and commissions applicable to the securities sold for such seller&#146;s account. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In connection with each Demand Registration and each Piggyback Registration, the Company shall reimburse the holders of Registrable
Securities included in such registration for the reasonable and documented fees and disbursements of one (1)&nbsp;counsel chosen by the holders of a majority of the Registrable Securities requesting inclusion in such registration, subject to the
approval of the Company of such counsel (which approval shall not be unreasonably withheld, conditioned or delayed) and for the reasonable and documented fees and disbursements of each additional counsel retained by any holder of Registrable
Securities for the purpose of rendering a legal opinion on behalf of such holder in connection with any underwritten Demand Registration or Piggyback Registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) To the extent any expenses relating to a registration hereunder are not required to be paid by the Company, each holder of securities
included (or requested to be included) in any registration hereunder shall pay those expenses allocable to the registration (or proposed registration) of such holder&#146;s securities so included (or requested to be included), and any expenses not
so allocable shall be borne by all sellers of securities requested to be included in such registration in proportion to the aggregate selling price of the securities to be so registered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7. <I>Indemnification</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company shall indemnify and hold harmless, to the fullest extent permitted by law, each holder of Registrable Securities, its
officers, directors, members, managers, partners, agents, Affiliates and employees and each Person who controls such holder (within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act) against all losses,
claims, actions, damages, liabilities and expenses (including with respect to actions or proceedings, whether commenced or threatened, and including reasonable attorney fees and expenses) caused by, resulting from, arising out of or based upon any
of the following statements, omissions or violations by the Company: (i)&nbsp;any untrue or alleged untrue statement of material fact contained in any registration statement, prospectus, preliminary prospectus or Free-Writing Prospectus, or any
amendment thereof or supplement thereto, (ii)&nbsp;any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading, or (iii)&nbsp;any violation or alleged violation by the
Company of the Securities Act, the Exchange Act or any other similar federal or state securities laws or any rule or regulation promulgated thereunder applicable to the Company and relating to action or inaction required of the Company in connection
with any such registration, qualification or compliance, and to pay to each holder of Registrable Securities, its officers, directors, members, managers, partners, agents, Affiliates and employees and each Person who controls such holder (within the
meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act), as incurred, any legal and any other expenses reasonably incurred in connection with investigating, preparing or defending any such claim, loss, damage,
liability or action, except to the extent that the same are caused by or based upon any information furnished in writing to the Company or any managing underwriter by such holder expressly for use therein. In connection with an underwritten
offering, the Company shall indemnify any underwriters or deemed underwriters, their officers and directors and each Person who controls such underwriters (within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the
Exchange Act) to the same extent as provided above with respect to the indemnification of the holders of Registrable Securities (or to such lesser extent that may be agreed to between the underwriters and the Company). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In connection with any registration in which a holder of Registrable Securities is participating, each such holder shall furnish to the
Company and the managing underwriter in writing such information and affidavits as the Company or the managing underwriter reasonably requests for use in connection with any such registration statement or prospectus relating to the Registrable
Securities, or any amendment or supplement thereto, or any preliminary prospectus or Free Writing Prospectus and, to the fullest extent permitted by law, shall indemnify the Company, its directors, officers, agents and each Person who controls the
Company (within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act) against any losses, claims, damages, liabilities and expenses resulting from any untrue or alleged untrue statement of material fact
contained in the registration statement, prospectus or preliminary prospectus or any amendment thereof or supplement thereto and any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements
therein not misleading, but only to the extent that such untrue statement or omission is contained in any information or affidavit so furnished in writing by such holder expressly for use therein and has not been corrected in a subsequent writing
prior to or concurrently with the sale of Registrable Securities to the Person asserting the claim; <I>provided</I> that, in the event that a court of competent jurisdiction decides against any such allegations of untrue statements or omissions of a
material fact, such holders shall be reimbursed for any amounts previously paid hereunder with respect to such allegations; <I>provided</I> <I>further</I> that the obligation to indemnify shall be individual, not joint and several, for each holder
and shall be limited to the net amount of proceeds received by such holder from the sale of Registrable Securities pursuant to such registration statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Any Person entitled to indemnification hereunder shall (i)&nbsp;give prompt written
notice to the indemnifying party of any claim with respect to which it seeks indemnification (provided that the failure to give prompt notice shall not impair any Person&#146;s right to indemnification hereunder to the extent such failure has not
prejudiced the indemnifying party) and (ii)&nbsp;unless in such indemnified party&#146;s reasonable judgment a conflict of interest between such indemnified and indemnifying parties may exist with respect to such claim, permit such indemnifying
party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party. The indemnifying party shall not be subject to any liability for any settlement made by the indemnified party without the consent of the
indemnifying party. An indemnifying party who is not entitled to, or elects not to, assume the defense of a claim shall not be obligated to pay the fees and expenses of more than one (1)&nbsp;counsel for all parties indemnified by such indemnifying
party with respect to such claim, unless in the reasonable judgment of any indemnified party a conflict of interest may exist between such indemnified party and any other of such indemnified parties with respect to such claim. In such instance, the
conflicting indemnified parties shall have a right to retain one (1)&nbsp;separate counsel, chosen by the holders of a majority of the Registrable Securities included in the registration by such conflicting indemnified parties, at the expense of the
indemnifying party. No indemnifying party, in the defense of such claim or litigation, shall, except with the consent of each indemnified party, consent to the entry of any judgment or enter into any settlement which does not include as an
unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Each party hereto agrees that, if for any reason the indemnification provisions contemplated by Section&nbsp;7(a) or Section&nbsp;7(b) are
unavailable to or insufficient to hold harmless an indemnified party in respect of or is otherwise unenforceable with respect to any losses, claims, damages, liabilities or expenses (or actions in respect thereof) referred to therein, then each
indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages, liabilities or expenses (or actions in respect thereof) in such proportion as is appropriate to reflect the
relative fault of the indemnifying party and the indemnified party as well as any other relevant equitable considerations. The relative fault of such indemnifying party and indemnified party shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by such indemnifying party or indemnified party, and the parties&#146; relative intent,
knowledge, access to information and opportunity to correct or prevent such statement or omission. The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;7(d) were determined by pro rata
allocation (even if the holders or any underwriters or all of them were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this Section&nbsp;7(d).
The amount paid or payable by an indemnified party as a result of the losses, claims, damages, liabilities or expenses (or actions in respect thereof) referred to above shall be deemed to include any legal or other fees or expenses reasonably
incurred by such indemnified party in connection with investigating or, except as provided in Section&nbsp;7(c), defending any such action or claim. No Person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the
Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. The sellers&#146; obligations in this Section&nbsp;7(d) to contribute shall be several in proportion to the amount of
securities registered by them and not joint and shall be limited for each seller to an amount </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
equal to the net proceeds actually received by such seller from the sale of Registrable Securities effected pursuant to such registration; provided that in no event shall the aggregate amounts
payable by any such seller by way of indemnity or contribution under this Section&nbsp;7(d) and when combined with any amounts payable under Section&nbsp;7(b) exceed the net proceeds from the offering actually received by such seller from the sale
of Registrable Securities effected pursuant to such registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The indemnification and contribution provided for under this
Agreement shall be in addition to any other rights to indemnification and contribution that any indemnified party may have pursuant to law or contract and shall remain in full force and effect regardless of any investigation made by or on behalf of
the indemnified party or any officer, director or controlling Person of such indemnified party and shall survive the transfer of securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8. <I>Participation in Underwritten Registrations</I>. No Person may participate in any registration hereunder which is
underwritten unless such Person (i)&nbsp;agrees to sell such Person&#146;s Registrable Securities on the basis provided in any underwriting arrangements in form customary for transactions of this type approved by the holders of a majority of the
Registrable Securities to be sold in the contemplated offering (including pursuant to any over-allotment or &#147;green shoe&#148; option requested by the underwriters, provided that no holder of Registrable Securities shall be required to sell more
than the number of Registrable Securities such holder has requested to include) and (ii)&nbsp;completes and executes all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents required under the terms of such
underwriting arrangements; <I>provided</I> that no holder of Registrable Securities included in any underwritten registration shall be required to make any representations or warranties to the Company or the underwriters in connection with an
underwritten registration (other than representations and warranties regarding such holder, such holder&#146;s title to the securities and such holder&#146;s intended method of distribution) or to undertake any indemnification obligations to the
Company or the underwriters with respect thereto, except as otherwise specifically provided in Section&nbsp;7, or to agree to any <FONT STYLE="white-space:nowrap">lock-up</FONT> or holdback restrictions, except as otherwise specifically provided in
Section&nbsp;3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9. <I>Other Agreements.</I> At all times after the Company has filed a registration statement with the
Commission pursuant to the requirements of either the Securities Act or the Exchange Act, the Company shall use its reasonable best efforts to file all reports required to be filed by it under the Securities Act and the Exchange Act and the rules
and regulations adopted by the Commission thereunder and shall take such further action as the Investors or the Other Shareholders may reasonably request, all to the extent required to enable such Persons to sell securities pursuant to (i)&nbsp;Rule
144 or any similar rule or regulation hereafter adopted by the Commission or (ii)&nbsp;a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> or any similar registration form hereafter adopted by the Commission. Upon reasonable
request, the Company shall deliver to the Investors and the Other Shareholders a written statement as to whether it has complied with such requirements. The Company shall at all times after it has consummated the Go Public Transaction use its
reasonable best efforts to cause the securities so registered to be listed on one or more of the New York Stock Exchange, NYSE American, LLC and/or the Nasdaq Stock Market. The foregoing agreements in this Section&nbsp;9 shall not apply to a
&#147;take private&#148; or other transaction in which the Common Shares cease to be registered under the Exchange Act, so long as such transaction is approved by the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10. <I>Subsidiary Public Offering</I>. If, after an initial public offering of
the capital stock or other equity securities of one of its subsidiaries, the Company distributes securities of such subsidiary to its equity holders, then the rights of holders hereunder and the obligations of the Company pursuant to this Agreement
shall apply, <I>mutatis</I> <I>mutandis</I>, to such subsidiary, and the Company shall cause such subsidiary to comply with such subsidiary&#146;s obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11. <I>Term</I>. This Agreement shall become effective upon consummation of the Go Public Transaction and shall terminate upon
the earlier to occur of (i)&nbsp;the seventh anniversary of the date of this Agreement and (ii)&nbsp;the date as of which (A)&nbsp;all of the Registrable Securities have been sold pursuant to a Registration Statement (but in no event prior to the
applicable period referred to in Section&nbsp;4(a)(3) of the Securities Act and Rule 174 thereunder (or any successor rule promulgated thereafter by the Commission)) or (B)&nbsp;all Registrable Securities have been sold under Rule 144 under the
Securities Act. The provisions of Section&nbsp;7 and Section&nbsp;9 shall survive any termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12. <I>Definitions</I>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; means, as applied to any Person, means any other Person that, directly or indirectly through one or more
intermediaries, controls, is controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, officer or director of such Person or any venture capital, private equity or other
investment fund or account now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company or investment advisor with, such Person, and the term &#147;<B>Affiliated</B>&#148;
shall have the correlative meaning. The term &#147;control&#148; means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting
securities, by contract or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Certificate of Incorporation</B>&#148; means the Memorandum of Association of the Company,
as issued by the Registrar of Companies in Bermuda, and as amended from time to time in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Dexcel</B>&#148; means Dexcel Pharma Technologies Ltd., an Israeli limited liability company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Dexxon</B>&#148; means Dexxon Holdings Ltd., an Israeli limited liability company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Dexxon Investors</B>&#148; means (i)&nbsp;Dexxon and (ii)&nbsp;Dexcel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Family Member</B>&#148; means
a spouse, civil partner, child (natural, step or adopted) parent, sibling or grandchild. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>FINRA</B>&#148; means the Financial
Industry Regulatory Authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Free-Writing Prospectus</B>&#148; means a free-writing prospectus, as defined in
Rule 405 promulgated under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Investor Registrable Securities</B>&#148; means (i)&nbsp;Common Shares issued,
distributed, issuable or distributable to the Major Holders as of the date of this Agreement or hereafter, (ii)&nbsp;any other securities issued or issuable directly or indirectly with respect to the securities described in clause (i)&nbsp;of this
definition by way of a dividend, distribution or equity split or in connection with an exchange or a combination of equity interests, recapitalization, reclassification, merger, consolidation or other reorganization (including any common shares
issued or issuable to the Investors in anticipation of a registered offering), and (iii)&nbsp;any other equity securities of the Company or its corporate successor held at any time by Persons holding securities described in clause (i)&nbsp;or (ii)
of this definition. As to any particular Investor Registrable Securities, such securities shall cease to be an Investor Registrable Security upon the earlier to occur of (x)&nbsp;a registration statement covering such Investor Registrable Security
having been declared effective by the Commission and such Investor Registrable Security having been disposed of pursuant to such effective registration statement or (y)&nbsp;such Investor Registrable Securities being able to be disposed of pursuant
to Rule 144 under the Securities Act in a single transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Major Holder</B>&#148; means each of the Founder, the Dexxon
Investors, the QVT Investors, the Viking Investors, Softbank and Sumitomo, and any of their Permitted Transferees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>MNPI</B>&#148; means material <FONT STYLE="white-space:nowrap">non-public</FONT> information within the meaning of Regulation FD
promulgated under the Exchange Act, which shall in any case include the receipt of any notice delivered by the Company under this Agreement, including pursuant to Section&nbsp;1 or Section&nbsp;2 hereof and the information contained in any such
notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Other Registrable Securities</B>&#148; means (i)&nbsp;the Common Shares issued, distributed, issuable or distributable
to the Other Shareholders, (ii)&nbsp;any other securities issued or issuable directly or indirectly with respect to the securities described in clause (i)&nbsp;of this definition by way of a dividend, distribution or equity split or in connection
with an exchange or a combination of equity interests, recapitalization, reclassification, merger, consolidation or other reorganization (including any common share issued or issuable in anticipation of a registered offering), and (iii)&nbsp;any
other equity securities of the Company or its corporate successor held at any time by Persons holding securities described in clause (i)&nbsp;or (ii) of this definition. As to any particular Other Registrable Securities, such securities shall cease
to be Other Registrable Securities upon the earlier to occur of (x)&nbsp;a registration statement covering such Other Registrable Securities having been declared effective by the Commission and such Other Registrable Securities having been disposed
of pursuant to such effective registration statement or (y)&nbsp;such Other Registrable Securities being able to be disposed of pursuant to paragraph (b)(1) of Rule 144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Permitted Transferee</B>&#148; means (i)&nbsp;with respect to any Person, an Affiliate of such Person, (ii)&nbsp;with respect to the
Founder, a transfer for bona fide estate planning purposes, either during his or her lifetime or on death by will or intestacy to a Family Member or any custodian or trustee of any trust, executor or other fiduciary all of the beneficial interest in
is held for the benefit of, him or her or his or her Family Members, or to a trust for the himself or herself, or a charitable remainder trust, (iii)&nbsp;with respect to any QVT Investor, (a)&nbsp;any investor in such QVT Investor and (b)&nbsp;any
entity in which one or more investors in such QVT Investor have the power to control the decisions of such entity or at least 90% of the beneficial interest in which is held, by any such investors and any Family Member thereof, and (iv)&nbsp;with
respect to Softbank, each of SVF Holdings (UK) LLP and SoftBank Vision Fund L.P., and any investor in SoftBank Vision Fund L.P. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; means an individual, a partnership, a corporation, a limited
liability company, an association, a joint stock company, a trust, a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Public Subsidiary</B>&#148; means any subsidiary of the Company that has a class of securities registered under the Exchange Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>QVT Investors</B>&#148; means, collectively, QVT Roiv Hldgs Offshore Ltd., a Cayman Islands limited company, QVT Roiv Hldgs
Onshore Ltd., a Cayman Islands limited company, QVT Financial Investment Cayman Ltd., a Cayman Islands limited company, QVT Deferred Compensation Holdings Ltd., a Cayman Islands limited company, QVT P&amp;E Roiv Hldgs Ltd., a Cayman Islands limited
company, Fourth Avenue Capital Partners LP, a Delaware limited partnership, and any Permitted Transferee of any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registrable Securities</B>&#148; means, collectively, the Investor Registrable Securities and the Other Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Rule 144</B>,&#148; &#147;<B>Rule 158</B>,&#148; &#147;<B>Rule 405</B>&#148; and &#147;<B>Rule 415</B>&#148; mean, in each case, such
rule promulgated under the Securities Act (or any successor provision) by the Commission, as the same shall be amended from time to time, or any successor rule then in force. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended, and the rules and regulations promulgated from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Upstream Equity
Holder</B>&#148; means, with respect to a Shareholder, its direct or indirect stockholders, partners, members or other equity holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Viking Investors</B>&#148; means, collectively, Viking Global Opportunities Illiquid Investments
<FONT STYLE="white-space:nowrap">Sub-Master</FONT> LP, Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Long Master Fund Ltd. and Viking Global Equities Master Ltd. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>WKSI</B>&#148; means a well-known seasoned issuer, as defined under Rule 405. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;13. <I>Miscellaneou</I>s. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>No Inconsistent Agreements</I>. The Company shall not hereafter enter into any agreement with respect to its securities which is
inconsistent with or violates the rights granted to the holders of Registrable Securities in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Adjustments Affecting
Registrable Securities</I>. The Company shall not take any action, or permit any change to occur, with respect to its securities that would materially and adversely affect the ability of the holders of Registrable Securities to include such
Registrable Securities in a registration undertaken pursuant to this Agreement or that would materially and adversely affect the marketability of such Registrable Securities in any such registration (including effecting a split or a combination of
securities). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Remedies</I>. Any Person having any rights under any provision of this Agreement
shall be entitled to enforce such rights specifically (without posting a bond or other security), to recover damages by reason of any breach of any provision of this Agreement and to exercise all other rights granted by law. The Parties agree and
acknowledge that the Investors and the other holders of Registrable Securities would be irreparably harmed by, and money damages would not be an adequate remedy for, any breach of the provisions of this Agreement and that, in addition to any other
rights and remedies existing in its favor, any Party shall be entitled to specific performance and/or other injunctive relief from any court of law or equity of competent jurisdiction (without posting any bond or other security) in order to enforce
or prevent violation of the provisions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Amendments and Waivers</I>. The provisions of this Agreement may be
amended, and any provision of this Agreement may be waived, only upon the prior written consent of (i)&nbsp;the Company, (ii)&nbsp;the holders of a majority of the Registrable Securities, and (iii)&nbsp;the holders of at least 60% of the Investor
Registrable Securities; <I>provided</I> that to the extent any such amendment alters or waives any rights of the Other Shareholders in this Agreement in a manner disproportionately adverse to the Other Shareholders (as compared to the Investors),
such amendment or waiver will also require the prior written consent of the Other Shareholders holding a majority of the Registrable Securities held by the Other Shareholders; <I>provided</I><B> </B><I>further</I><B> </B>that this Agreement may not
be amended, modified or supplemented and the observance of any term hereof may not be waived with respect to any Investor (each an &#147;<B>Amendment</B>&#148;) without the written consent of such Investor, if such Amendment would
(A)&nbsp;disproportionately and materially adversely affect such Investor&#146;s rights hereunder, or (B)&nbsp;grant any rights to any Investor that are not similarly granted or offered to all other Investors. No course of dealing between or among
the Parties (including the failure of any Party to enforce any of the provisions of this Agreement) shall be deemed effective to modify, amend, waive or discharge any part of this Agreement or any rights or obligations of any Party under or by
reason of this Agreement, and the failure of any Party to enforce any of the provisions of this Agreement shall in no way be construed as a waiver of such provisions and shall not affect the right of such Party thereafter to enforce each and every
provision of this Agreement in accordance with its terms. The waiver by any Party hereto of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any preceding or succeeding breach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Successors and Assigns</I>. This Agreement and all of the covenants and agreements contained herein and rights, interests or
obligations hereunder, by or on behalf of any of the Parties, shall bind and inure to the benefit of the respective successors and assigns of the Parties whether so expressed or not, provided that neither this Agreement nor any of the covenants and
agreements herein or rights, interests or obligations hereunder may be assigned or delegated by the Company except in connection with a Business Combination (as defined in the Amended and Restated <FONT STYLE="white-space:nowrap">Bye-laws</FONT> of
the Company (the &#147;<B><FONT STYLE="white-space:nowrap">Bye-Laws</FONT></B>&#148;)) in accordance with the terms and conditions set forth in the <FONT STYLE="white-space:nowrap">Bye-Laws.</FONT> Without limiting the foregoing, whether or not any
express assignment has been made, the provisions of this Agreement which are for the benefit of holders of Investor Registrable Securities or Other Registrable Securities are also for the benefit of, and enforceable by, any subsequent holder of
Investor Registrable Securities and Other Registrable Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Severability</I>. Whenever possible, each provision of this Agreement shall be
interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement or the application of any such provision to any Person or circumstance shall be held to be prohibited by or illegal or unenforceable
under applicable law in any respect by a court of competent jurisdiction, such provision shall be ineffective only in such jurisdiction and to the extent of such prohibition or illegality or unenforceability, without invalidating the remainder of
such provision or the remaining provisions of this Agreement in such jurisdiction or any provisions of this Agreement in any other jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Counterparts</I>. This Agreement and any amendments hereto or thereto, to the extent signed and delivered in counterparts (any one of
which need not contain the signatures of more than one Party hereto or thereto, but all such counterparts together shall constitute one and the same Agreement) by means of a facsimile machine or electronic transmission in portable document format
(pdf), shall be treated in all manner and respects as an original thereof and shall be considered to have the same binding legal effects as if it were the original signed version thereof delivered in person. At the request of any Party hereto or
thereto, each other Party hereto or thereto shall <FONT STYLE="white-space:nowrap">re-execute</FONT> original forms thereof and deliver them to all other Parties hereto or thereto. No Party hereto shall raise the use of a facsimile machine or
electronic transmission in pdf to deliver a signature or the fact that any signature or document was transmitted or communicated through the use of facsimile machine or electronic transmission as a defense to the formation of a contract, and each
such Party forever waives any such defense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Descriptive Headings; Interpretation</I>. The headings and captions used in this
Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. The use of the word &#147;including&#148; herein shall mean &#147;including without limitation.&#148; Any reference to the
masculine, feminine or neuter gender shall be deemed to include any gender or all three as appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Governing Law;
Jurisdiction; Agreement for Service</I>. All issues and questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by, and construed in accordance with, the laws of the State of New York,
without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of New York or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of New York. The
Parties agree that all disputes, legal actions, suits and proceedings arising out of or relating to this Agreement must be brought exclusively in a federal district court or a state court in New York County, New York. Each Party hereby consents and
submits to the exclusive jurisdiction of such courts. Each Party hereby irrevocably waives all claims of immunity from jurisdiction and any right to object on the basis that any dispute, action, suit or proceeding brought in such court has been
brought in an improper or inconvenient forum or venue. No legal action, suit or proceeding with respect to this Agreement may be brought in any other forum except to enforce a judgment entered in a court described in the preceding sentence. Each
Party hereby irrevocably waives all claims of immunity from jurisdiction and any right to object on the basis that any dispute, action, suit or proceeding brought in such court has been brought in an improper or inconvenient forum or venue. Each of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company, Softbank and the Dexxon Investors (A)&nbsp;acknowledges that it has, by separate written instrument, irrevocably designated and appointed Corporation Service Company
(&#147;<B>CSC</B>&#148;), 1180 Avenue of the Americas, Suite 210, New York, NY 10036-8401 as its authorized agent upon which process may be served in any suit or proceeding arising out of or relating to this Agreement and acknowledges that CSC has
accepted such designation and (B)&nbsp;agrees that service of process upon CSC, and written notice of said service to any such Party, in the manner provided in Section&nbsp;13(k) shall be deemed in every respect effective service of process upon
such Party, as the case may be, in any such suit or proceeding. Each of the Company, Softbank and the Dexxon Investors further agrees to take any and all action, including the execution and filing of any and all such documents and instruments, as
may be necessary to continue such designation and appointment of CSC in full force and effect so long as this Agreement shall be in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>WAIVER OF TRIAL BY JURY</I>. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW THAT CANNOT BE WAIVED, THE PARTIES HEREBY WAIVE, AND
COVENANT THAT THEY WILL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR OTHERWISE), ANY RIGHT TO TRIAL BY JURY IN ANY ACTION ARISING IN WHOLE OR IN PART UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY, WHETHER NOW
EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE. THE PARTIES AGREE THAT ANY OF THEM MAY FILE A COPY OF THIS PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY AND
<FONT STYLE="white-space:nowrap">BARGAINED-FOR</FONT> AGREEMENT AMONG THE PARTIES IRREVOCABLY TO WAIVE ITS RIGHT TO TRIAL BY JURY IN ANY PROCEEDING WHATSOEVER BETWEEN THEM RELATING TO THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Notice</I>. All notices, demands or other communications to be given or delivered under or by reason of the provisions of this
Agreement will be in writing and will be deemed to have been given when (i)&nbsp;delivered personally to the recipient, (ii)&nbsp;received, if sent by confirmed electronic mail or facsimile during normal business hours of the recipient (or, if sent
outside of normal business hours, then on the next business day) or (iii)&nbsp;one (1) business day after it is sent to the recipient by reputable overnight courier service (charges prepaid). Such notices, demands and other communications will be
sent to the Company at the address set forth below and to any other Party to this Agreement at such address as indicated by the Company&#146;s records, or at such other Party&#146;s principal place of business with copies (which shall not constitute
notice) to such address or to the attention of such other person as the recipient Party has specified by prior written notice to the sending Party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>To the Company: </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Roivant
Sciences Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Suite 1, 3rd Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">11-12</FONT> St. James&#146;s Square </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">London </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">SW1Y 4LB </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">United Kingdom </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
Attention: Marianne Romeo </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: marianne.romeo@roivant.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>with copies (which shall not constitute notice to the Company) to: </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Davis Polk&nbsp;&amp; Wardwell LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">450 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York,
New York 10017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Derek J. Dostal; Lee Hochbaum </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Telephone: (212) <FONT STYLE="white-space:nowrap">450-4322;</FONT> (212) <FONT STYLE="white-space:nowrap">450-4736</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: derek.dostal@davispolk.com; lee.hochbaum@davispolk.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>If to any of the Dexxon Investors at: </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">c/o Dexxon Holdings Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1
Dexcel Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Or Akiva, 30600000, Israel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Dan Oren, President&nbsp;&amp; CEO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Telephone: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+972-4-6364040</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Facsimile: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+972-4-6364004</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: Dan@Dexcel.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>with a
copy (which shall not constitute notice to the Dexxon Investors) to: </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Greenberg Traurig, P.A. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">333 S.E. 2nd Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Miami, FL
33131 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Robert L. Grossman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Telephone:
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-305-579-7970</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Facsimile:
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-305-579-0717</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: grossmanb@gtlaw.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>If to any of the QVT Investors at: </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">c/o QVT Financial LP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">888
Seventh Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, NY 10106 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: legalnotices@qvt.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Facsimile: (212) <FONT STYLE="white-space:nowrap">705-8820</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>with a copy (which shall not constitute notice to the QVT Investors) to: </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Davis Graham&nbsp;&amp; Stubbs LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1550 17th Street, Suite 500 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Denver, CO 80202 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: John
Elofson </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
Telephone: (303) <FONT STYLE="white-space:nowrap">892-7335</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Facsimile: (303) <FONT
STYLE="white-space:nowrap">893-1379</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: John.Elofson@dgslaw.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>If to any of the Viking Investors at: </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">c/o Viking Global Investors LP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">55 Railroad Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Greenwich, CT
06830 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> legalnotices@vikingglobal.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>with a copy (which shall not constitute notice to the Viking Investors) to: </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Gunderson Dettmer Stough Villeneuve Franklin&nbsp;&amp; Hachigian, LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1250 Broadway, 23rd Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New
York, New York 10001 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Greg Volkmar </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Phone: (212) <FONT STYLE="white-space:nowrap">430-3170</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: gvolkmar@gunder.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>If to Softbank at: </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">c/o
SB Investment Advisers (US) Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1 Circle Star Way </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">San Carlos, CA 94070 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn:
Akshay Naheta </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: akshay@softbank.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>with copies (which shall not constitute notice to Softbank) to: </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">SB Investment Advisers (US) Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1 Circle Star Way </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">San Carlos, CA
94070 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn: Brian Wheeler, General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: bwheeler@softbank.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">-and- </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">3175 Hanover Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Palo Alto,
CA 94304 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn: Matthew S. Bartus </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: mbartus@cooley.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Telephone: (650) <FONT STYLE="white-space:nowrap">843-5756</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>If to Sumitomo at: </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">c/o Sumitomo Dainippon Pharma Co., Ltd </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">6-8,</FONT> Doshomachi <FONT STYLE="white-space:nowrap">2-Chome,</FONT>
<FONT STYLE="white-space:nowrap">Chuo-ku</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Osaka <FONT STYLE="white-space:nowrap">541-0045</FONT> Japan </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Shigeyuki Nishinaka, Senior Executive Officer, Global Corporate Strategy </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: <FONT STYLE="white-space:nowrap">shigeyuki-nishinaka@ds-pharma.co.jp</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>with a copy (which shall not constitute notice to Sumitomo) to: </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Jones Day </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">3161 Michelson Drive
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Irvine, CA 92612-4412 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Jonn R. Beeson, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: jbeeson@jonesday.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)
<I>Rights Cumulative</I>. The rights and remedies of each of the Parties under this Agreement shall be cumulative and not exclusive of any rights or remedies which a Party would otherwise have hereunder at law or in equity or by statute, and no
failure or delay by either Party in exercising any right or remedy shall not impair any such right or remedy or operate as a waiver of such right or remedy, and neither shall any single or partial exercise of any power or right preclude a
Party&#146;s other or further exercise thereof or the exercise of any other power or right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>No Strict Construction</I>. The
Parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties, and no presumption
or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Complete Agreement.</I> This Agreement and the other agreements and instruments referred to herein contain the complete agreement
between the Parties with respect to the subject matter hereof and thereof and supersede any prior understandings, agreements and representations by or between the parties hereto (whether written or oral) that may have related to the subject matter
hereof or thereof in any way. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>Aggregation of Stock</I>. All shares of Registrable Securities held or acquired by Affiliates shall
be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14. <I>MNPI Provisions</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each Shareholder acknowledges that (i)&nbsp;the provisions of Section&nbsp;1, 2 and 4 of this Agreement may require certain communications
to be made by the Company or other Shareholders to such Shareholder that may result in such Shareholder and its Representatives (as defined below) acquiring MNPI (which may include, solely by way of illustration, the fact that an offering of the
Company&#146;s securities is pending or the number of Company securities or the identity of the selling Shareholders) (such communications, &#147;<B>RRA Communications</B>&#148;), and (ii)&nbsp;subject to the time limitations set forth in
Section&nbsp;1(e) and the qualifications in Section&nbsp;14(b), there is no limitation on the duration of time that such Shareholder and its Representatives may be in possession of MNPI included in such RRA Communications and no requirement that the
Company or other Shareholders make any public disclosure to cause information in such RRA Communications to cease to be MNPI; provided that the Company will notify each Shareholder entitled to notice or who received an RRA Communication if any
proposed registration or offering for which an RRA Communication has been delivered pursuant to this Agreement has been terminated or aborted to the extent the knowledge of such registration or offering constitutes MNPI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each Shareholder agrees that it will maintain the confidentiality of MNPI in RRA Communications delivered to it and, to the extent such
Shareholder is not a natural person, such confidential treatment shall be in accordance with procedures adopted by it in good faith to protect confidential information of third parties delivered to such Shareholder (&#147;<B>Policies</B>&#148;);
provided that the obligation to maintain confidentiality of MNPI in RRA Communications shall cease when the information in the RRA Communications (i)&nbsp;is known or becomes known to the public in general (other than as a result of a breach of this
Section&nbsp;14(b) by such Shareholder or its Representatives), or (ii)&nbsp;is or has been made known or disclosed to the Shareholder by a third party not known by such Shareholder to be in breach of any obligation of confidentiality such third
party may have to the Company; provided further that a Shareholder may deliver or disclose MNPI in such RRA Communications to (1)&nbsp;to its affiliates, its and its affiliates&#146; respective directors, officers, employees, partners, members,
agents, attorneys, consultants and financial and other advisors, and potential sources of capital (including potential limited partners) (collectively, the &#147;<B>Representatives</B>&#148;), but solely to the extent such disclosure reasonably
relates to its evaluation of exercise of its rights under this Agreement and the sale of any Registrable Securities in connection with the subject of the notice, (2)&nbsp;to any federal, state, national, foreign or other regulatory or
self-regulatory authority having jurisdiction over such Shareholder, or (3)&nbsp;to any Person if necessary to effect compliance with any law, rule, regulation, investigation, audit, request or order applicable to such Shareholder, including in
response to any subpoena or other legal process, audit or examinations; provided further, that in the case of clause (1), the recipients of such MNPI in such RRA Communications are subject to the Policies or agree to or are otherwise obligated to
hold confidential the MNPI in a manner substantially consistent with the terms of this Section&nbsp;14 and that in the case of clauses (2)&nbsp;and (3), such Shareholder promptly notifies the Company of such disclosure to the extent such Shareholder
is legally permitted to give such notice and it is reasonably practicable; provided further, no such notice shall be required where disclosure is made (x)&nbsp;in response to a general request by a regulatory or self-regulatory authority or
(y)&nbsp;in connection with a routine audit or examination by a bank examiner or auditor and such audit or examination does not reference the Company or this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each Shareholder, by its execution of this Agreement, hereby (i)&nbsp;acknowledges that
it is aware that the U.S. securities laws prohibit any Person who has MNPI about a company from purchasing or selling, directly or indirectly, securities of such company (including entering into hedge transactions involving such securities), or from
communicating such information to any other Person in certain circumstances, and (ii)&nbsp;agrees that it will not use or permit any third party to use, and that it will use its commercially reasonable efforts to assure that none of its
Representatives will use or permit any third party to use, any MNPI the Company provides in contravention of the U.S. securities laws and such Shareholder will cease trading in the Company&#146;s securities while in possession of such MNPI to the
extent prohibited by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Each Shareholder shall have the right, at any time and from time to time (including after receiving
information regarding any potential underwritten offering), to elect not to receive RRA Communications that the Company or any other Shareholders otherwise are required to deliver pursuant to this Agreement by delivering to the Company a written
statement signed by such Shareholder that it does not want to receive any RRA Communications (an &#147;<B><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Request</B>&#148;); in which case, and notwithstanding anything to the contrary in this
Agreement, the Company and other Shareholders shall not be required to, and shall not, deliver any RRA Communications for which the Shareholder has indicated in the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Request that it does not want to
receive hereunder to the extent that such RRA Communications would result in a Shareholder acquiring MNPI. An <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Request may state a date on which it expires or, if no such date is specified, shall remain
in effect until the Shareholder notifies the Company that it withdraws the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Request, and the Shareholder may, in its sole discretion, determine the scope and applicability of the <FONT
STYLE="white-space:nowrap">Opt-Out</FONT> Request as set forth in the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Request. A Shareholder who previously has given the Company an <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Request may update
or revoke such request at any time, and there shall be no limit on the ability of a Shareholder to issue, update and revoke subsequent <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Requests; provided that each Shareholder shall use commercially
reasonable efforts to minimize the administrative burden on the Company arising in connection with any such <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Requests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed or caused to be executed on their behalf this
Third Amended and Restated Registration Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">COMPANY:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">ROIVANT SCIENCES LTD.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marianne Romeo</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Marianne Romeo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Head, Global Transactions &amp; Risk Management</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed or caused to be executed on their behalf this
Third Amended and Restated Registration Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SVF Investments (UK) Limited</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ [authorized officer]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[authorized signatory]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[authorized signatory]</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed or caused to be executed on their behalf this
Third Amended and Restated Registration Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">DEXXON HOLDINGS LTD</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dan Oren</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dan Oren</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">DEXCEL PHARMA TECHNOLOGIES LTD</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dan Oren</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dan Oren</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chairman of the Board</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed or caused to be executed on their behalf this
Third Amended and Restated Registration Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">QVT INVESTORS:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">QVT FINANCIAL INVESTMENT CAYMAN LTD.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ian Pilgrim</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ian Pilgrim</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">QVT ROIV HLDGS OFFSHORE LTD.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ian Pilgrim</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ian Pilgrim</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">QVT ROIV HLDGS ONSHORE LTD.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ian Pilgrim</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ian Pilgrim</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">QVT DEFERRED COMPENSATION HOLDINGS LTD.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dan Gold</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dan Gold</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">QVT P&amp;E ROIV HLDGS LTD.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dan Gold</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dan Gold</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fourth Avenue Capital Partners LP</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By its general partner Fourth Avenue Capital Partners GP LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dan Gold</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dan Gold</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed or caused to be executed on their behalf this
Third Amended and Restated Registration Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VIKING INVESTORS:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS <FONT STYLE="white-space:nowrap">SUB-MASTER</FONT> LP</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By: Viking Global Opportunities Portfolio GP LLC, its general partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Bloom</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Matthew Bloom</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VIKING GLOBAL EQUITIES II LP</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By:
Viking Global Performance LLC, its general partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Bloom</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Matthew Bloom</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PURCHASERS (CONTINUED):</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VIKING
GLOBAL EQUITIES MASTER LTD.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By: Viking Global Performance LLC, its investment manager</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Bloom</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael Bloom</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VIKING LONG FUND MASTER LTD.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By:
Viking Long Fund GP LLC, its investment manager</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Bloom</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael Bloom</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed or caused to be executed on their behalf this
Third Amended and Restated Registration Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SUMITOMO DAINIPPON PHARMA CO., LTD.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Hiroshi Nomura</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hiroshi Nomura</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Representative Director, President and CEO</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed or caused to be executed on their behalf this
Third Amended and Restated Registration Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">VIVEK RAMASWAMY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Vivek Ramaswamy</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Third Amended and Restated Registration Rights Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT <FONT STYLE="white-space:nowrap">A-1</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adam Cutler </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alan S. Roemer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alexander Rafael </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">American Home Assurance Company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anchorage Illiquid Opportunities Offshore Master V, L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anchorage Illiquid Opportunities Offshore Master VI (A), L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Astellas Pharma Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beatriz Toporowicz </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ben Silver </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian Symonds </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chidambar Kulkarni </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christiana Trust as trustee of the Alan S.
Roemer 2015 Family Trust </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CRS Capital, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Daniel Michalow
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David F. Roemer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Shankman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elaine S. Roemer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMEDRA 841 Family Limited Partnership </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jeffrey Strong </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jonathan Fassberg </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jorge Goti </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Justin Ryan </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Keith Nunziata </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kevin Gan </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lawrence Friedhoff </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LBV Partners </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Le Zhang </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Malcolm Levine </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew Spiro </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Navroz Udwadia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nicholas Green </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novaquest Pharma Opportunities Fund V, L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novaquest Pharma Opportunities Fund V (Delaware), L.P. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Omar Musa
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parvinder Thiara </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perea Capital Partners, LP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phase One Development LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Randolph Street Investment Partners,
L.P.&#151;2014 DIF </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ray Cahnman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Raymond Schinazi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RFS Partners, LP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Richard Kim </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RMG Holdings LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RPY Investments, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RTW Innovation Master Fund, Ltd. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RTW Master Fund, Ltd.Sahsen Foundation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Travis May </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Viju Kulkarni </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vikram Modi </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Waqas Khatri </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">William Symonds </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Xiaotong Zhou </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT <FONT STYLE="white-space:nowrap">A-2</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JOINDER AGREEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS JOINDER AGREEMENT (this &#147;<B>Joinder</B>&#148;) is being delivered to Roivant Sciences Ltd., a Bermuda exempted limited company (the
&#147;<B>Company</B>&#148;). Reference is made to the Third Amended and Restated Registration Rights Agreement, dated as of May&nbsp;1, 2021, by and among the Company and certain shareholders of the Company from time to time Party thereto (as
amended, modified or restated from time to time, the &#147;<B>Agreement</B>&#148;). Capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby acknowledges and agrees that its signature below constitutes an executed counterpart signature page to the Agreement
and hereby agrees to become a Party to the Agreement and to be subject to, and bound by, all of the terms and conditions of the Agreement as an &#147;Other Shareholder.&#148; The undersigned hereby acknowledges that it has received a copy of the
Agreement and has had an opportunity to consult with independent legal counsel regarding the terms and conditions therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS
WHEREOF, the undersigned has executed this Joinder as of the date set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>5
<FILENAME>d307489dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SUBSCRIPTION AGREEMENT </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Montes
Archimedes Acquisition Corp. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">724 Oak Grove, Suite 130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Menlo
Park, CA 94025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
Subscription Agreement (this &#147;<U>Subscription Agreement</U>&#148;) is being entered into as of the date set forth on the signature page hereto, by and among Montes Archimedes Acquisition Corp., a Delaware corporation (&#147;<U>SPAC</U>&#148;),
the undersigned subscriber (the &#147;<U>Investor</U>&#148;) and, solely for the purposes of Sections 6, 8 and 11, Roivant Sciences Ltd., a Bermuda exempted limited company (the &#147;<U>Company</U>&#148;), in connection with the Business
Combination Agreement, dated as of the date hereof (as may be amended, supplemented or otherwise modified from time to time, the &#147;<U>BCA</U>&#148;), by and among SPAC, the Company, Rhine Merger Sub, Inc., a Delaware corporation and a direct
wholly-owned subsidiary of the Company (&#147;<U>Merger Sub</U>&#148;) and the other parties thereto, pursuant to which, among other things, Merger Sub will merge with and into SPAC (the &#147;<U>Merger</U>&#148;), with SPAC as the surviving company
in the Merger and, after giving effect to the Merger, will become a subsidiary of the Company, on the terms and subject to the conditions therein (the transactions contemplated by the BCA, including the Merger, the &#147;<U>Transaction</U>&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Transaction, SPAC is seeking commitments from interested investors to purchase, contingent upon, and immediately
prior to the closing of the Transaction, shares of SPAC&#146;s Class&nbsp;A common stock, par value $0.0001 per share (the &#147;<U>Shares</U>&#148;), in a private placement for a purchase price of $10.00 per share (the &#147;<U>Per Share Purchase
Price</U>&#148;). On or about the date of this Subscription Agreement, SPAC is entering into subscription agreements (the &#147;<U>Other Subscription Agreements</U>&#148; and, together with the Subscription Agreement, the &#147;<U>Subscription
Agreements</U>&#148;) substantially similar to this Subscription Agreement with certain other investors (the &#147;<U>Other Investors</U>&#148; and, together with the Investor, the &#147;<U>Investors</U>&#148;), pursuant to which the Investors,
severally and not jointly, have agreed to purchase on the closing date of the Transaction, inclusive of the Shares subscribed for by the Investor, an aggregate amount of up to 20,000,000 Shares, at the Per Share Purchase Price. The aggregate
purchase price to be paid by the Investor for the subscribed Shares (as set forth on the signature page hereto) is referred to herein as the &#147;<U>Subscription Amount</U>.&#148; Pursuant to the BCA, on the Closing Date (as defined herein), the
Shares so purchased will be exchanged for shares of the Company on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, as described more fully in the BCA. For the avoidance of doubt, with respect to
any obligations existing in this Subscription Agreement, following consummation of the Transaction, (i)&nbsp;the Company shall be the public issuer and (ii)&nbsp;the term &#147;Shares&#148; as defined above shall refer to the <FONT
STYLE="white-space:nowrap">as-converted</FONT> shares in the Company. Notwithstanding anything to the contrary herein, nothing in this Subscription Agreement shall be interpreted to limit the consummation of the Transaction in accordance with the
terms of the BCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection therewith, and in consideration of the foregoing and the mutual representations, warranties and
covenants, and subject to the conditions, set forth herein, and intending to be legally bound hereby, each of the Investor, the Company and SPAC acknowledges and agrees as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Subscription</U>. The Investor hereby irrevocably subscribes for and agrees to purchase from SPAC the number of Shares set forth on the
signature page of this Subscription Agreement on the terms and subject to the conditions provided for herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Closing</U>. The
closing of the sale of the Shares contemplated hereby (the &#147;<U>Closing</U>&#148;) is contingent upon the substantially concurrent consummation of the Transaction. The Closing shall occur on the date of, and substantially concurrently with and
conditioned upon the effectiveness of, the Transaction. Upon (a)&nbsp;satisfaction or waiver of the conditions set forth in Section&nbsp;3 below and (b)&nbsp;delivery of written notice from (or on behalf of) SPAC to the Investor (the
&#147;<U>Closing Notice</U>&#148;), that SPAC reasonably expects all conditions to the closing of the Transaction to be satisfied or waived on a date that is not less than five (5)&nbsp;business days from the date on which the Closing Notice is
delivered to the Investor, the Investor shall deliver to SPAC (i)&nbsp;at least one (1)&nbsp;business day prior to the closing date specified in the Closing Notice (the &#147;<U>Closing Date</U>&#148;), the Subscription Amount by wire transfer of
United States dollars in immediately available funds to the account(s) specified by SPAC in the Closing Notice to be held in escrow until the Closing, or (ii)&nbsp;on the Closing Date, the Subscription Amount to an account specified by SPAC
otherwise mutually agreed by the Investor and SPAC due to legal reasons that apply to such Investor (the&nbsp;&#147;<U>Alternative Settlement Procedures</U>&#148;) by wire transfer of United States dollars in immediately available funds. The
Investor shall also deliver </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to SPAC, at least one (1)&nbsp;business day prior to the Closing Date, any other information that is reasonably requested in the Closing Notice in order for SPAC to issue the Shares to the
Investor in accordance with the Subscription Agreement, including, without limitation, the legal name of the person in whose name such Shares are to be issued and a duly executed Internal Revenue Service Form
<FONT STYLE="white-space:nowrap">W-9</FONT> or <FONT STYLE="white-space:nowrap">W-8,</FONT> as applicable. On the Closing Date, SPAC shall (1)&nbsp;issue a number of Shares to the Investor set forth on the signature page to this Subscription
Agreement and subsequently cause such Shares to be registered in book entry form in the name of the Investor (or its nominee in accordance with its delivery instructions) on SPAC&#146;s share register, free and clear of any liens or other
restrictions (other than those arising under this Subscription Agreement or applicable securities laws), and (2)&nbsp;provide evidence from the Company&#146;s transfer agent of such issuance on and as of the Closing Date. If the Closing does not
occur within three (3)&nbsp;business days following the Closing Date specified in the Closing Notice, SPAC shall promptly (but not later than one (1)&nbsp;business day thereafter) return the Subscription Amount in full to the Investor, in
immediately available funds to the account specified by the Investor in writing, and any book entries for the Shares shall be deemed cancelled. For purposes of this Subscription Agreement, &#147;business day&#148; shall mean a day other than a
Saturday, Sunday or other day on which commercial banks in New York, New York are authorized or required by law to close. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Closing
Conditions</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The obligation of the parties hereto to consummate the purchase and sale of the Shares pursuant to this Subscription
Agreement is subject to the following conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) no applicable governmental authority shall have enacted, issued,
promulgated, enforced or entered any injunction, judgment, order, law, rule or regulation (whether temporary, preliminary or permanent) which is then in effect and has the effect of making the consummation of the transactions contemplated hereby
illegal or otherwise enjoining, restraining or prohibiting consummation of the transactions contemplated hereby; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)
all conditions precedent to the closing of the Transaction under the BCA shall have been satisfied (as determined by the parties to the BCA and other than those conditions under the BCA which, by their nature, are to be fulfilled at the closing of
the Transaction, including to the extent that any such condition is dependent upon the consummation of the purchase and sale of the Shares pursuant to this Subscription Agreement or Other Subscription Agreements) or waived and the closing of the
Transaction shall be scheduled to occur concurrently with or on the same date as the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The obligation of SPAC to
consummate the issuance and sale of the Shares pursuant to this Subscription Agreement shall be subject to the satisfaction or waiver of the following conditions: (i)&nbsp;all representations and warranties of the Investor contained in this
Subscription Agreement are true and correct in all material respects (other than representations and warranties that are qualified as to materiality, which representations and warranties shall be true in all respects) at and as of the Closing Date
(except for those representations and warranties that speak as of a specified earlier date, which shall be true and correct in all material respects as of such specified earlier date&nbsp;(other than representations and warranties that are qualified
as to materiality&nbsp;as of such specified earlier date, which representations and warranties shall be true in all respects)), and consummation of the Closing shall constitute a reaffirmation by the Investor that each of the representations and
warranties of the Investor contained in this Subscription Agreement as of the Closing Date are true and correct in all material respects (or, in the case of representations and warranties that are qualified as to materiality, in all respects as of
the Closing Date) and (ii)&nbsp;all obligations, covenants and agreements of the Investor required to be performed by it at or prior to the Closing Date shall have been performed in all material respects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The obligation of the Investor to consummate the purchase of the Shares pursuant to this Subscription Agreement shall be subject to the
satisfaction or waiver of the following conditions: (i)&nbsp;all representations and warranties of SPAC and the Company contained in this Subscription Agreement shall be true and correct in all material respects (other than representations and
warranties that are qualified as to materiality or Material Adverse Effect (as defined herein), which representations and warranties shall be true in all respects) at and as of the Closing Date, and consummation of the Closing shall constitute a
reaffirmation by SPAC and the Company that each of the representations and warranties of SPAC and the Company contained in this Subscription Agreement as of the Closing Date are true and correct in all material respects (or, in the case of
representations and warranties that are qualified as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to materiality or Material Adverse Effect, in all respects) as of the Closing Date (except for those representations and warranties that speak as of a specified earlier date, which shall be true
and correct in all material respects as of such specified earlier date&nbsp;(other than representations and warranties that are qualified as to materiality&nbsp;as of such specified earlier date, which representations and warranties shall be true in
all respects)); (ii) all obligations, covenants and agreements of SPAC and the Company required by the Subscription Agreement to be performed by them at or prior to the Closing Date shall have been performed in all material respects; and
(iii)&nbsp;the BCA shall not have been amended or waived in a manner that materially and adversely affects the economic benefits that the Investor (in its capacity as such) would reasonably expect to receive under this Subscription Agreement;
provided, that, the SEC&#146;s (as defined herein) issuance of the Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (the &#147;<U>Statement</U>&#148;), made on April&nbsp;12, 2021, and
any consequences thereof or actions taken by SPAC directly in response thereto, shall not cause either of the conditions in this clause (c)&nbsp;to be deemed to not have been satisfied so long as any such consequences or actions shall not have
caused a material adverse effect on the business, financial condition or results of operations of SPAC (a &#147;<U>Material Adverse Effect</U>&#148;). For the avoidance of doubt, any restatement of the financial statements of SPAC and any amendments
to previously filed SEC reports or delays in filing SEC reports, in connection with the Statement or any subsequent related agreements or other guidance from the SEC with respect to the Statement, shall not be considered to result in a Material
Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Further Assurances</U><U>.</U> At or prior to the Closing Date, the parties hereto shall execute and deliver or
cause to be executed and delivered such additional documents and take such additional actions as the parties reasonably may deem to be practical and necessary in order to consummate the subscription as contemplated by this Subscription Agreement.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>SPAC Representations and Warranties</U>. SPAC represents and warrants to the Investor that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) SPAC is duly incorporated, validly existing and in good standing under the laws of the State of Delaware. SPAC has all power (corporate or
otherwise) and authority to own, lease and operate its properties and conduct its business as presently conducted and to enter into, deliver and perform its obligations under this Subscription Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) As of the Closing Date, the Shares will be duly authorized and, when issued and delivered to the Investor against full payment therefor in
accordance with the terms of this Subscription Agreement, the Shares will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and will not have been issued in violation of or subject to any preemptive or similar
rights created under SPAC&#146;s certificate of incorporation and bylaws (each as amended on the Closing Date) by contract or under the General Corporation Law of the State of Delaware. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) This Subscription Agreement has been duly authorized, executed and delivered by SPAC and, assuming that this Subscription Agreement
constitutes the valid and binding agreement of the Investor, this Subscription Agreement constitutes the valid and binding agreement of SPAC and is enforceable against SPAC in accordance with its terms, except as may be limited or otherwise affected
by (i)&nbsp;bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally, or (ii)&nbsp;principles of equity, whether considered at law or equity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The execution and delivery of, and the performance of the transactions contemplated hereby, including the issuance and sale of the Shares
and the compliance by SPAC with all of the provisions of this Subscription Agreement and the consummation of the transactions contemplated herein will be done in accordance with the Nasdaq marketplace rules (&#147;<U>Nasdaq</U>&#148;) and will not
conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any of the property or assets of SPAC or any of its
subsidiaries pursuant to the terms of (i)&nbsp;any indenture, mortgage, deed of trust, loan agreement, lease, license or other agreement or instrument to which SPAC or any of its subsidiaries is a party or by which SPAC or any of its subsidiaries is
bound or to which any of the property or assets of SPAC is subject that would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect or materially affect the validity of the Shares or the legal authority of SPAC
to comply in all material respects with the terms of this Subscription Agreement; (ii)&nbsp;result in any violation of the provisions of the organizational documents of SPAC; or (iii)&nbsp;result in any violation of any statute or any judgment,
order, rule or regulation of any court or governmental agency or body, domestic or foreign, having jurisdiction over SPAC or any of its properties that would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect
or materially affect the validity of the Shares or the legal authority of SPAC to comply in all material respects with this Subscription Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) As of their respective dates, all reports (the &#147;<U>SEC Reports</U>&#148;) required
to be filed by SPAC with the SEC complied in all material respects with the applicable requirements of the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), and the Securities Exchange Act of 1934, as amended (the
&#147;<U>Exchange Act</U>&#148;), and the rules and regulations of the SEC promulgated thereunder, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated
therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements of SPAC included in the SEC Reports comply in all material respects with applicable
accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing and fairly present in all material respects the financial position of SPAC as of and for the dates thereof and the results of
operations and cash flows for the periods then ended, subject, in the case of unaudited financial statements, to normal, <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments. A copy of each SEC Report is available to the Investor via
the SEC&#146;s EDGAR system. There are no material outstanding or unresolved comments in comment letters from the staff of the Division of Corporation Finance of the SEC with respect to any of the SEC Reports. SPAC has timely filed each report,
statement, schedule, prospectus, and registration statement that SPAC was required to file with the SEC since its inception. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Other
than the Other Subscription Agreements, including any subscription agreement entered into consistent with Section&nbsp;7(b) of this Subscription Agreement, the BCA and any other agreement contemplated by the BCA, including any Ancillary Documents as
defined therein, or described in the SEC Reports, SPAC has not entered into any side letter or similar agreement with any investor in connection with such investor&#146;s direct or indirect investment in SPAC (other than any side letter or similar
agreement to the extent relating to the transfer to any investor of (i)&nbsp;securities of SPAC by existing securityholders of SPAC, which may be effectuated as a forfeiture to SPAC and reissuance, or (ii)&nbsp;securities to be issued to the direct
or indirect securityholders of the Company pursuant to the BCA). Except for any Alternative Settlement Procedures, no Other Subscription Agreement includes a lesser Per Share Purchase Price or other terms and conditions that are materially more
advantageous to any such Other Investor than Investor hereunder, and such Other Subscription Agreements have not been amended, modified or waived in any material respect, or in any respect that materially benefits the Other Investors thereunder
unless the Investor has been offered substantially similar benefits in writing, following the date of this Subscription Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) As
of the date of this Subscription Agreement, the authorized capital stock of SPAC consists of (i)&nbsp;400,000,000 shares of Class&nbsp;A common stock, (ii) 40,000,000 shares of Class&nbsp;B common stock and (iii)&nbsp;1,000,000 shares of preferred
stock, each with a par value of $0.0001 per share. As of the date of this Subscription Agreement, (A) 41,071,823 shares of Class&nbsp;A common stock of SPAC are issued and outstanding, (B) 10,267,956 shares of Class&nbsp;B common stock of SPAC are
issued and outstanding, (C) 30,750,267 warrants to purchase shares of Class&nbsp;A common stock of SPAC are issued and outstanding, and (D)&nbsp;no shares of preferred stock are issued and outstanding. All (1)&nbsp;issued and outstanding shares of
Class&nbsp;A common stock and Class&nbsp;B common stock of SPAC have been duly authorized and validly issued, are fully paid and <FONT STYLE="white-space:nowrap">are&nbsp;non-assessable&nbsp;and</FONT> (2)&nbsp;outstanding warrants have been duly
authorized and validly issued. Except as set forth above and pursuant to the Other Subscription Agreements, the BCA and the other agreements and arrangements referred to therein or in the SEC Reports, as of the date hereof, there are no outstanding
options, warrants or other rights to subscribe for, purchase or acquire from SPAC any Class&nbsp;A common shares, Class&nbsp;B common shares or other equity interests in SPAC, or securities convertible into or exchangeable or exercisable for such
equity interests. As of the date hereof, SPAC has no subsidiaries and does not own, directly or indirectly, interests or investments (whether equity or debt) in any person, whether incorporated or unincorporated. There are no shareholder agreements,
voting trusts or other agreements or understandings to which SPAC is a party or by which it is bound relating to the voting of any securities of SPAC, other than (1)&nbsp;as set forth in the SEC Reports and (2)&nbsp;as contemplated by the BCA. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Assuming the accuracy of the Investor&#146;s representations and warranties set forth in Section&nbsp;7, no registration under the
Securities Act is required for the offer and sale of the Shares by SPAC to the Investor hereunder. The Shares (i)&nbsp;were not offered by any form of general solicitation or general advertising (as those terms are used in Regulation D under the
Securities Act) and (ii)&nbsp;are not being offered in a manner involving a public offering under, or in a distribution in violation of, the Securities Act, or any state securities laws, or in a manner that would otherwise adversely affect reliance
by SPAC on Section&nbsp;4(a)(2) of the Securities Act for the exemption from registration for the transactions contemplated hereby or would require registration of the Shares under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Except for such matters as have not had and would not be reasonably likely to have,
individually or in the aggregate, a Material Adverse Effect, there is no (i)&nbsp;action, suit, claim or other proceeding, in each case by or before any governmental authority pending, or, to the knowledge of SPAC, threatened against SPAC or
(ii)&nbsp;judgment, decree, injunction, ruling or order of any governmental entity or arbitrator outstanding against SPAC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) SPAC is in
compliance with all applicable laws, except where such noncompliance would not reasonably be expected to have a Material Adverse Effect. As of the date hereof, SPAC has not received any written communication from a governmental authority that
alleges that SPAC is not in compliance with or is in default or violation of any applicable law, except where such <FONT STYLE="white-space:nowrap">non-compliance,</FONT> default or violation would not reasonably be expected to have, individually or
in the aggregate, a Material Adverse Effect. As of the date hereof, the issued and outstanding Shares of SPAC are registered pursuant to Section&nbsp;12(b) of the Exchange Act, and are listed for trading on Nasdaq, under the symbol &#147;MAAC&#148;
(it being understood that the trading symbol will be different for the Company upon completion of the Transaction). There is no suit, action, proceeding or investigation pending or, to the knowledge of SPAC, threatened against SPAC by Nasdaq or the
SEC, respectively, to prohibit or terminate the listing of SPAC&#146;s Shares on Nasdaq or to deregister the Shares under the Exchange Act. Except as described in or contemplated by the BCA, SPAC has taken no action as of the date hereof that is
designed to terminate the registration of the Shares under the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) Other than the Placement Agents (as defined below), SPAC
has not engaged any broker, finder, commission agent, placement agent or arranger in connection with the sale of the Shares, and SPAC is not under any obligation to pay any broker&#146;s fee or commission in connection with the sale of the Shares
other than to the Placement Agents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) SPAC is not required to obtain any consent, waiver, authorization or order of, give any notice to,
or make any filing or registration with, any court or other federal, state, local or other governmental authority, self-regulatory organization or other person in connection with the execution, delivery and performance by SPAC of this Subscription
Agreement (including, without limitation, the issuance of the Shares), other than (i)&nbsp;filings with the SEC, (ii)&nbsp;filings required by applicable state securities laws, (iii)&nbsp;filings required in accordance with Section&nbsp;13 of this
Subscription Agreement, (iv)&nbsp;filings required by Nasdaq, or such other applicable stock exchange on which SPAC&#146;s common stock is then listed, and (v)&nbsp;the failure of which to obtain would not be reasonably likely to have, individually
or in the aggregate, a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) SPAC is not, and immediately after receipt of payment for the Shares will not be, an
&#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) SPAC acknowledges and agrees
that, notwithstanding anything herein to the contrary, the Shares may be pledged by the Investor in connection with a bona fide margin agreement, provided such pledge shall be (i)&nbsp;pursuant to an available exemption from the registration
requirements of the Securities Act or (ii)&nbsp;pursuant to, and in accordance with, a registration statement that is effective under the Securities Act at the time of such pledge, and the Investor effecting a pledge of Shares shall not be required
to provide SPAC with any notice thereof; provided, however, that neither SPAC, the Company or their respective counsels shall be required to take any action (or refrain from taking any action) in connection with any such pledge, other than providing
any such lender of such margin agreement, upon the prior written request of the Investor, with an acknowledgment that the Shares are not subject to a contractual prohibition on pledging or lock up pursuant to this Subscription Agreement, the form of
such acknowledgment to be subject to review and comment by SPAC in all respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Company Representations and Warranties</U>. The
Company represents and warrants to the Investor that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company is an exempted limited company duly organized, validly existing and
in good standing (or the equivalent thereto with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the laws of the Bermuda. The Company has all power (corporate or otherwise) and authority to
own, lease and operate its properties and conduct its business as presently conducted and to enter into, deliver and perform its obligations under this Subscription Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) This Subscription Agreement has been duly authorized, executed and delivered by the
Company and, assuming that this Subscription Agreement constitutes the valid and binding agreement of the Investor, this Subscription Agreement is enforceable against the Company in accordance with its terms, except as may be limited or otherwise
affected by (i)&nbsp;bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally, or (ii)&nbsp;principles of equity, whether considered at law or equity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The execution and delivery of, and the performance of the transactions contemplated hereby, and the compliance by the Company with all of
the provisions of this Subscription Agreement and the consummation of the transactions contemplated herein will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in
the creation or imposition of any lien, charge or encumbrance upon any of the property or assets of the Company or any of its subsidiaries pursuant to the terms of (i)&nbsp;any indenture, mortgage, deed of trust, loan agreement, lease, license or
other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject that
would reasonably be expected to have a material adverse effect on the business, financial condition or results of operations of the Company and its subsidiaries, taken as a whole (a &#147;Company Material Adverse Effect&#148;) or materially affect
the legal authority of the Company to comply in all material respects with the terms of this Subscription Agreement; (ii)&nbsp;result in any violation of the provisions of the organizational documents of the Company; or (iii)&nbsp;result in any
violation of any statute or any judgment, order, rule or regulation of any court or governmental agency or body, domestic or foreign, having jurisdiction over the Company or any of its properties that would reasonably be expected to have a Company
Material Adverse Effect or materially affect the legal authority of the Company to comply in all material respects with this Subscription Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except for such matters as have not had and would not be reasonably expected to have, individually or in the aggregate, a Company Material
Adverse Effect, as of the date hereof, there is no (i)&nbsp;action, suit, claim or other proceeding, in each case by or before any governmental authority pending, or, to the knowledge of the Company, threatened against the Company or
(ii)&nbsp;judgment, decree, injunction, ruling or order of any governmental entity or arbitrator outstanding against the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) As
of the Closing Date, the issued and outstanding Company Shares will be registered pursuant to Section&nbsp;12(b) of the Exchange Act, and will be listed for trading on Nasdaq or another national stock exchange. There is no suit, action, proceeding
or investigation pending or, to the knowledge of the Company, threatened against the Company by Nasdaq or the SEC, respectively, to prohibit the listing of the Company Shares on Nasdaq or to deregister the Company Shares under the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Company is in compliance with all applicable laws, except where such <FONT STYLE="white-space:nowrap">non-compliance</FONT> would not
reasonably be expected to have a Company Material Adverse Effect. The Company has not received any written communication from a governmental authority that alleges that the Company is not in compliance with or is in default or violation of any
applicable law, except where such <FONT STYLE="white-space:nowrap">non-compliance,</FONT> default or violation would not reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Investor Representations and Warranties</U>. The Investor represents and warrants to SPAC that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Investor, or each of the funds managed by or affiliated with the Investor for which the Investor is acting as nominee, as applicable,
(i)&nbsp;is a &#147;qualified institutional buyer&#148; (as defined in Rule 144A under the Securities Act), or an institutional &#147;accredited investor&#148; (within the meaning of Rule 501(a) under the Securities Act), in each case, satisfying
the applicable requirements set forth on <U>Schedule A</U>, (ii)&nbsp;is an &#147;institutional account&#148; (as defined in FINRA Rule 4512(c)), (iii) is acquiring the Shares only for his, her or its own account and not for the account of others,
or if the Investor is subscribing for the Shares as a fiduciary or agent for one or more investor accounts, the Investor has full investment discretion with respect to each such account, and the full power and authority to make the acknowledgements,
representations and agreements herein on behalf of each owner of each such account, and (iv)&nbsp;is not acquiring the Shares with a view to, or for offer or sale in connection with, any distribution thereof in violation of the Securities Act (and
shall provide the requested information set forth on <U>Schedule A</U>). The Investor is not an entity formed for the specific purpose of acquiring the Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything to the contrary set&nbsp;forth herein, the Investor
acknowledges and agrees that, subsequent to the date of this Subscription Agreement and prior to the Closing, SPAC may enter into one or more additional subscription agreements with additional investors with terms and conditions that are not
materially more advantageous to the investor thereunder than this Subscription Agreement, and entry into such agreements may increase the aggregate amount of Shares being subscribed for in the private placement contemplated by this Subscription
Agreement. For the avoidance of doubt, such additional agreements shall reflect not less than the same Per Share Purchase Price and shall constitute Other Subscription Agreements for purposes of this Agreement,<I>&nbsp;mutatis mutandis</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Investor acknowledges and agrees that the Shares are being offered in a transaction not involving any public offering within the
meaning of the Securities Act and that the Shares have not been registered under the Securities Act. The Investor acknowledges and agrees that, other than with respect to any actions taken to consummate the Transaction pursuant to the BCA, the
Shares may not be offered, resold, transferred, pledged or otherwise disposed of by the Investor absent an effective registration statement under the Securities Act except (i)&nbsp;to SPAC or an affiliate thereof, (ii)&nbsp;to <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> persons pursuant to offers and sales that occur outside the United States within the meaning of Regulation S under the Securities Act or (iii)&nbsp;pursuant to another applicable exemption from the
registration requirements of the Securities Act, and in each of clauses (i)&nbsp;and (iii) in accordance with any applicable securities laws of the states and other jurisdictions of the United States, and that any certificates representing the
Shares shall contain a restrictive legend to such effect. The Investor acknowledges and agrees that the Shares will be subject to the foregoing transfer restrictions and, as a result of these transfer restrictions, other than with respect to any
actions taken to consummate the Transaction pursuant to the BCA, the Investor may not be able to readily offer, resell, transfer, pledge or otherwise dispose of the Shares and may be required to bear the financial risk of an investment in the Shares
for an indefinite period of time. The Investor acknowledges and agrees that, other than with respect to any actions taken to consummate the Transaction pursuant to the BCA, the Shares will not immediately be eligible for offer, resale, transfer,
pledge or disposition pursuant to Rule 144 promulgated under the Securities Act. The Investor acknowledges and agrees that it has been advised to consult legal counsel and tax and accounting advisors prior to making any offer, resale, transfer,
pledge or disposition of any of the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Investor acknowledges and agrees that the Investor is purchasing the Shares directly
from SPAC. The Investor further acknowledges that there have been no representations, warranties, covenants and agreements made to the Investor by or on behalf of SPAC, the Company, the Placement Agents or any of their respective affiliates or any
control persons, officers, directors, employees, partners, agents or representatives of any of the foregoing or any other person or entity, expressly or by implication, other than those representations, warranties, covenants and agreements of SPAC
and the Company expressly set forth in Section&nbsp;5 and Section&nbsp;6 of this Subscription Agreement, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The
Investor&#146;s acquisition and holding of the Shares will not constitute or result in a <FONT STYLE="white-space:nowrap">non-exempt</FONT> prohibited transaction under section 406 of the Employee Retirement Income Security Act of 1974, as amended,
section 4975 of the Internal Revenue Code of 1986, as amended, or any applicable similar law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Investor acknowledges and agrees
that the Investor has received such information as the Investor deems necessary in order to make an investment decision with respect to the Shares, including, with respect to SPAC, the Transaction and the business of the Company and its
subsidiaries. Without limiting the generality of the foregoing, the Investor acknowledges that he, she or it has reviewed SPAC&#146;s filings with the SEC. The Investor acknowledges and agrees that the Investor and the Investor&#146;s professional
advisor(s), if any, have had the full opportunity to ask such questions, receive such answers and obtain such information as the Investor and such Investor&#146;s professional advisor(s), if any, have deemed necessary to make an investment decision
with respect to the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The Investor became aware of this offering of the Shares solely by means of direct contact between the
Investor and SPAC, the Company or a representative of SPAC or the Company, or by means of contact from any of the Placement Agents in their capacity as such, and the Shares were offered to the Investor solely by direct contact between the Investor
and SPAC, the Company or a representative of SPAC or the Company, or by contact </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
between the Investor and one or more Placement Agents in their capacity as such. The Investor did not become aware of this offering of the Shares, nor were the Shares offered to the Investor, by
any other means. The Investor acknowledges that the Shares (i)&nbsp;were not offered to it by any form of general solicitation or general advertising, including methods described in section 502(c) of Regulation D under the Securities Act and
(ii)&nbsp;to its knowledge, are not being offered in a manner involving a public offering under, or in a distribution in violation of, the Securities Act, or any state securities laws. The Investor acknowledges that it is not relying upon, and has
not relied upon, any statement, representation or warranty made by any person, firm or corporation (including, without limitation, SPAC, the Company, the Placement Agents, any of their respective affiliates or any control persons, officers,
directors, employees, partners, agents or representatives of any of the foregoing), other than the representations and warranties of SPAC and the Company contained in Section&nbsp;5 and Section&nbsp;6 of this Subscription Agreement, respectively, in
making its investment or decision to invest in SPAC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The Investor acknowledges that it is aware that there are substantial risks
incident to the purchase and ownership of the Shares, including those set forth in SPAC&#146;s filings with the SEC. The Investor has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks
of an investment in the Shares, and the Investor has sought such accounting, legal and tax advice as the Investor has considered necessary to make an informed investment decision and the Investor has made its own assessment and has satisfied itself
concerning relevant tax and other economic considerations relative to its purchase of the Shares.. The Investor is able to sustain a complete loss on its investment in the Shares, has no immediate need for liquidity with respect to its investment in
the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Alone, or together with any professional advisor(s), the Investor has adequately analyzed and fully considered the risks
of an investment in the Shares and determined that the Shares are a suitable investment for the Investor and that the Investor is able at this time and in the foreseeable future to bear the economic risk of a total loss of the Investor&#146;s
investment in SPAC. The Investor acknowledges specifically that a possibility of total loss exists. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) In making its decision to purchase
the Shares, the Investor has relied solely upon independent investigation made by the Investor and SPAC&#146;s and the Company&#146;s representations and warranties expressly set forth in Section&nbsp;5 and Section&nbsp;6 of this Subscription
Agreement, respectively, and no other representations and warranties of any kind, whether express or implied, of SPAC or any other person. Without limiting the generality of the foregoing, the Investor has not relied on any statements or other
information provided by or on behalf of the Placement Agents or any of their respective affiliates or any control persons, officers, directors, employees, partners, agents or representatives of any of the foregoing concerning SPAC, the Company, the
Transaction, the BCA, this Subscription Agreement or the transactions contemplated hereby or thereby, the Shares or the offer and sale of the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) The Investor acknowledges that the Placement Agents: (i)&nbsp;are each acting solely as the SPAC&#146;s Placement Agent in connection with
the transactions contemplated by the Subscription Agreements and is not acting as an underwriter or in any other capacity and is not and shall not be construed as a fiduciary for the Investor, (ii)&nbsp;have not made or make any representation or
warranty, express or implied, of any kind or character and have not provided any advice or recommendation in connection with the transactions contemplated by the Subscription Agreements, (iii)&nbsp;will have no responsibility with respect to
(a)&nbsp;any representations, warranties or agreements made by any person or entity under or in connection with the Transaction or any of the documents furnished pursuant thereto or in connection therewith, or the execution, legality, validity or
enforceability (with respect to any person) of any thereof, or (b)&nbsp;the business, affairs, financial condition, operations, properties or prospects of, or any other matter concerning the SPAC, the Company or the Transaction, (iv)&nbsp;have not
acted as the Investor&#146;s financial advisor or fiduciary in connection with the issue and purchase of Shares, (v)&nbsp;may have acquired, or during the term of the Shares may acquire, <FONT STYLE="white-space:nowrap">non-public</FONT> information
with respect to the Company, which, subject to the requirements of applicable law, the Investor agrees need not be provided to it, (vi)&nbsp;may have existing or future business relationships with SPAC and the Company (including, but not limited to,
lending, depository, risk management, advisory and banking relationships) and will pursue actions and take steps that it deems or they deem necessary or appropriate to protect its or their interests arising therefrom without regard to the
consequences for a holder of Shares, and that certain of these actions may have material and adverse consequences for a holder of Shares; and (vii)&nbsp;shall have no liability or obligation (including without limitation, for or with respect to any
losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses or disbursements incurred by the Investor, the Company or any other person or entity), whether in contract, tort or otherwise, to the Investor, or to
any person claiming through the Investor, in respect of the Transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) The Investor acknowledges that it has not relied on the Placement Agents in connection
with its determination as to the legality of its acquisition of the Shares or as to the other matters referred to herein and the Investor has not relied on any investigation that the Placement Agents, any of their affiliates or any person acting on
their behalf have conducted with respect to the Shares, SPAC or the Company. The Investor further acknowledges that it has not relied on any information contained in any research reports prepared by the Placement Agents or any of their affiliates.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) The Investor acknowledges that J.P. Morgan Securities LLC and SVB Leerink LLC are each acting as financial advisors to the Company
(i)&nbsp;in connection with the Transaction and (ii)&nbsp;in connection with the Company&#146;s contemplated acquisition of all issued and outstanding shares of common stock of Immunovant, Inc. not currently owned by the Company (the
&#147;<U>Immunovant Acquisition</U>&#148;), as disclosed on Schedule 13D filed on March&nbsp;8, 2021 by the Company (it being understood and agreed by the Investor that the purchase of the Shares pursuant to this Subscription Agreement on the
Closing Date and the closing of the Transaction shall not be contingent on the consummation of the contemplated Immunovant Acquisition). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) The Investor acknowledges and agrees that no federal or state agency has passed upon or endorsed the merits of the offering of the Shares
or made any findings or determination as to the fairness of this investment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) The Investor, if not an individual, has been duly formed
or incorporated and is validly existing and is in good standing under the laws of its jurisdiction of formation or incorporation, with power and authority to enter into, deliver and perform its obligations under this Subscription Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) The execution, delivery and performance by the Investor of this Subscription Agreement are within the powers of the Investor, have been
duly authorized and will not constitute or result in a breach or default under or conflict with any order, ruling or regulation of any court or other tribunal or of any governmental commission or agency, or any agreement or other undertaking, to
which the Investor is a party or by which the Investor is bound, and, if the Investor is not an individual, will not violate any provisions of the Investor&#146;s organizational documents, including, without limitation, its incorporation or
formation papers, bylaws, indenture of trust or partnership or operating agreement, as may be applicable. The signature of the Investor on this Subscription Agreement is genuine, and the signatory, if the Investor is an individual, has legal
competence and capacity to execute the same or, if the Investor is not an individual, the signatory has been duly authorized to execute the same, and, assuming that this Subscription Agreement constitutes the valid and binding obligation of SPAC,
this Subscription Agreement constitutes a legal, valid and binding obligation of the Investor, enforceable against the Investor in accordance with its terms except as may be limited or otherwise affected by (i)&nbsp;bankruptcy, insolvency,
fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally, and (ii)&nbsp;principles of equity, whether considered at law or equity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) The Investor is not (i)&nbsp;a person or entity named on the List of Specially Designated Nationals and Blocked Persons administered by the
U.S. Treasury Department&#146;s Office of Foreign Assets Control (&#147;<U>OFAC</U>&#148;) or in any Executive Order issued by the President of the United States and administered by OFAC (&#147;<U>OFAC List</U>&#148;), or a person or entity
prohibited by any OFAC sanctions program; (ii)&nbsp;owned, directly or indirectly, or controlled by, or acting on behalf of, one or more persons that are named on the OFAC List; (iii)&nbsp;organized, incorporated, established, located, resident or
born in, or a citizen, national or the government, including any political subdivision, agency or instrumentality thereof, of, Cuba, Iran, North Korea, Syria, the Crimea region of Ukraine or any other country or territory embargoed or subject to
substantial trade restrictions by the United States; (iv)&nbsp;a Designated National as defined in the Cuban Assets Control Regulations, 31 C.F.R. Part 515; or (v)&nbsp;a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> shell bank or providing
banking services indirectly to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> shell bank (each, a &#147;<U>Prohibited Investor</U>&#148;). The Investor agrees to provide law enforcement agencies, if requested thereby, such records as required by
applicable law, provided that the Investor is permitted to do so under applicable law. If the Investor is a financial institution subject to the Bank Secrecy Act (31 U.S.C. Section&nbsp;5311 et seq.) (the &#147;<U>BSA</U>&#148;), as amended by the
USA PATRIOT Act of 2001 (the &#147;<U>PATRIOT Act</U>&#148;), and its implementing regulations (collectively, the &#147;<U>BSA/PATRIOT Act</U>&#148;), the Investor maintains policies and procedures reasonably designed to comply with applicable
obligations under the BSA/PATRIOT Act. To the extent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required, it maintains policies and procedures reasonably designed to ensure compliance with OFAC-administered sanctions programs, including for the screening of its investors against the OFAC
sanctions programs, including the OFAC List. To the extent required by applicable law, the Investor maintains policies and procedures reasonably designed to ensure that the funds held by the Investor and used to purchase the Shares were legally
derived and were not obtained, directly or indirectly, from a Prohibited Investor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) The Investor acknowledges that no disclosure or
offering document has been prepared by J.P. Morgan Securities LLC, SVB Leerink LLC, Citigroup Global Markets Inc., any additional placement agent that may be engaged by SPAC, or any of their respective affiliates (collectively, the
&#147;<U>Placement Agents</U>&#148;) in connection with the offer and sale of the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) The Investor acknowledges that neither
Placement Agents, nor any of their respective affiliates nor any control persons, officers, directors, employees, partners, agents or representatives of any of the foregoing have made any independent investigation with respect to SPAC, the Company
or its subsidiaries or any of their respective businesses, or the Shares or the accuracy, completeness or adequacy of any information supplied to the Investor by SPAC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t) The Investor, when required to deliver payment to SPAC pursuant to Section&nbsp;2 above, will have, sufficient funds to pay the
Subscription Amount and consummate the purchase and sale of the Shares pursuant to this Subscription Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(u) The Investor agrees
that, from the date of this Subscription Agreement until the Closing or the earlier termination of this Subscription Agreement, none of Investor, its controlled affiliates, or any person or entity acting on behalf of the Investor or any of its
controlled affiliates or pursuant to any understanding with the Investor or any of its controlled affiliates will engage in any Short Sales with respect to securities of the SPAC. For the purposes hereof, &#147;Short Sales&#148; shall include,
without limitation, all &#147;short sales&#148; as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act, and all types of direct and indirect stock pledges (other than pledges in the ordinary course of business as part of
prime brokerage arrangements), forward sale contracts, options, puts, calls, swaps and similar arrangements (including on a total return basis), including through <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker dealers or foreign regulated
brokers. Notwithstanding the foregoing, (A)&nbsp;nothing herein shall prohibit (x)&nbsp;other entities under common management with the Investor with whom the Investor is not acting in concert with respect to any trading in securities of the SPAC,
this Subscription Agreement or the Investor&#146;s participation in this offering of the Shares including the Investor&#146;s controlled affiliates and/or affiliates, or (y)&nbsp;in the case of an Investor that is externally managed, advised or <FONT
STYLE="white-space:nowrap">sub-advised</FONT> by another person, any other person that is not directly controlled or managed by such manager, adviser or <FONT STYLE="white-space:nowrap">sub-adviser,</FONT> in each case from entering into any Short
Sale and (B)&nbsp;in the case of an Investor that is a multi-managed investment bank or vehicle whereby separate portfolio managers manage separate portions of such Investor&#146;s assets and the portfolio managers have no knowledge of the
investment decisions made by the portfolio managers managing other portions of such Investor&#146;s assets, this Section (u)&nbsp;shall apply only with respect to the portion of assets managed by the portfolio manager that made the investment
decision to purchase the Shares covered by this Subscription Agreement. For the avoidance of doubt, nothing in this Section (u)&nbsp;shall restrict any transactions with respect to securities of SPAC other than transactions that are Short Sales
including the exercise of any redemption with respect to securities of the SPAC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) Except as expressly disclosed in a Schedule 13D or
Schedule 13G (or amendments thereto) filed by such Investor with the SEC with respect to the beneficial ownership of the SPAC&#146;s common stock, the Investor is not currently (and at all times through Closing will refrain from being or becoming) a
member of a &#147;group&#148; (within the meaning of section 13(d)(3) or section 14(d)(2) of the Exchange Act) acting for the purpose of acquiring, holding or disposing of equity securities of the SPAC (within the meaning of Rule <FONT
STYLE="white-space:nowrap">13d-5(b)(1)</FONT> under the Exchange Act). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(w) No broker, finder or other financial consultant has acted on
behalf of the Investor in connection with this Subscription Agreement or the transactions contemplated hereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) The Investor
acknowledges the SEC&#146;s issuance of the Statement, and the Investor agrees that any actions taken by SPAC in connection with, or as may be necessary or advisable to address the potential implications of, such Statement or review shall not be
deemed to constitute a breach of any of the representations, warranties or covenants in this Subscription Agreement; provided, however, that any such actions may not materially </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and adversely affect the rights of the Investor (in its capacity as such) under this Subscription Agreement. For the avoidance of doubt, any restatement or the financial statements of SPAC and
any amendments to previously filed SEC reports or delays in filing SEC reports, in connection with the Statement or any subsequent related agreements or other guidance from the SEC with respect to the Statement shall not be considered to materially
and adversely affect the rights of the Investor (in its capacity as such) under this Subscription agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Registration
Rights</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In the event that the Shares are not registered in connection with the consummation of the Transaction, the Company agrees
that, within thirty (30)&nbsp;calendar days after the Closing Date (the &#147;<U>Filing Deadline</U>&#148;), it will file with the SEC (at its sole cost and expense) a registration statement (the &#147;Registration Statement&#148;) registering the
resale of the Shares, and it shall use its commercially reasonable efforts to have the Registration Statement declared effective as soon as practicable after the filing thereof, but no later than the earlier of (i)&nbsp;sixty (60) calendar days
after the filing thereof (or ninety (90)&nbsp;calendar days after the filing thereof if the SEC notifies the Company that it will &#147;review&#148; the Registration Statement) and (ii)&nbsp;five (5) business days after the Company is notified
(orally or in writing, whichever is earlier) by the SEC that the Registration Statement will not be &#147;reviewed&#148; or will not be subject to further review ((i) and (ii)&nbsp;collectively, the &#147;<U>Effectiveness Deadline</U>&#148;). In
connection with the foregoing and with all transactions contemplated by this Subscription Agreement, Investor shall not be required to execute any <FONT STYLE="white-space:nowrap">lock-up</FONT> or similar agreement or otherwise be subject to any
contractual restriction on the ability to transfer the Shares. The Company agrees to use commercially reasonable efforts to cause such Registration Statement, or another shelf registration statement that includes the Shares to be sold pursuant to
this Subscription Agreement, to remain effective until the earliest of (i)&nbsp;the second anniversary of the Closing, (ii)&nbsp;the date on which the Investor ceases to hold any Shares issued pursuant to this Subscription Agreement, or
(iii)&nbsp;on the first date on which the Investor is able to sell all of its Shares issued pursuant to this Subscription Agreement (or shares received in exchange therefor) under Rule 144 promulgated under the Securities Act (&#147;<U>Rule
144</U>&#148;) within ninety (90)&nbsp;calendar days without the public information, volume or manner of sale limitations of such rule (such date, the &#147;<U>End Date</U>&#148;). Prior to the End Date, the Company will use commercially reasonable
efforts to&nbsp;(1) qualify the Shares for listing on Nasdaq or another applicable national stock exchange and (2)&nbsp;update or amend the Registration Statement as necessary to include the Shares. Subject to receipt from the Investor by the
Company and its transfer agent of customary representations and other documentation reasonably acceptable to the Company and the transfer agent in connection therewith, including, if required by the transfer agent, an opinion of the Company&#146;s
counsel in a form reasonably acceptable to the transfer agent, the Investor may request that the Company remove any legend from the book-entry position evidencing the Shares following the earliest of such time as the Shares (A)&nbsp;have been or are
being sold or transferred pursuant to an effective registration statement or (B)&nbsp;have been or are being sold pursuant to Rule 144 promulgated under the Securities Act (&#147;<U>Rule 144</U>&#148;). To the extent required by the Company&#146;s
transfer agent, the Company shall use commercially reasonable efforts to cause its legal counsel to deliver a customary opinion within two business days of the delivery of all reasonably necessary representations and other documentation from the
Investor as reasonably requested by the Company&#146;s transfer agent. If restrictive legends are no longer required for the Shares pursuant to the foregoing, the Company shall, reasonably promptly following any request therefor from the Investor as
described above (and no later than five (5)&nbsp;business days after such request), deliver to the transfer agent instructions to remove such restrictive legends from the Shares of the Investor. The Company may amend the Registration Statement so as
to convert the Registration Statement to a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> at such time after the Company becomes eligible to use such Form <FONT STYLE="white-space:nowrap">S-3.</FONT> For as long as the
Investor holds the Shares, the Company will use commercially reasonable efforts to file all reports, and provide all customary and reasonable cooperation, necessary to enable the Investor to resell the Shares pursuant to the Registration Statement
or Rule 144 of the Securities Act (when Rule 144 of the Securities Act becomes available to the Investor), as applicable. In no event shall the undersigned be identified as a statutory underwriter in the Registration Statement unless in response to
a comment or request from the staff of the SEC or another regulatory agency; provided, however, that if the SEC requests that the undersigned be identified as a statutory underwriter in the Registration Statement, the undersigned will have an
opportunity to withdraw from the Registration Statement. For purposes of clarification, any failure by the Company to file the Registration Statement by the Filing Deadline or to effect such Registration Statement by the Effectiveness Deadline shall
not otherwise relieve the Company of its obligations to file the Registration Statement or effect the registration of the Shares set forth in this Section&nbsp;8. The Investor acknowledges and agrees that the Company may suspend the use of any such
registration statement if it determines in good faith, upon advice of legal counsel (internal counsel being sufficient), that in order for such registration statement not to contain a material misstatement or omission, an amendment thereto would be
needed to include information that would at that time not otherwise be required in a current, quarterly, or annual report under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Exchange Act, provided, that, (I)&nbsp;the Company shall not so delay filing or so suspend the use of the Registration Statement on more than three (3)&nbsp;occasions for a period of more
than sixty (60)&nbsp;consecutive days or more than a total of ninety (90)&nbsp;calendar days, in each case in any three hundred sixty (360)&nbsp;day period and (II)&nbsp;the Company shall use commercially reasonable efforts to make such Registration
Statement available for the sale by the Investor of such securities as soon as practicable thereafter. The Company&#146;s obligations to include the Shares issued pursuant to this Subscription Agreement (or shares issued in exchange therefor) for
resale in the Registration Statement are contingent upon the Investor furnishing in writing to the Company such information regarding the Investor, the securities of the Company held by the Investor and the intended method of disposition of such
Shares, as shall be reasonably requested by the Company to effect the registration of such Shares, and shall execute such documents in connection with such registration as the Company may reasonably request that are customary of a selling
stockholder in similar situations. The Company shall use its commercially reasonable efforts to provide a draft of the Registration Statement to the Investor for review at least two (2)&nbsp;business days in advance of filing the Registration
Statement; provided that, for the avoidance of doubt, in no event shall the Company be required to delay or postpone the filing of such Registration Statement as a result of or in connection with the Investor&#146;s review. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding the foregoing, if the SEC prevents the Company from including any or all of the Shares proposed to be registered under the
Registration Statement due to limitations on the use of Rule 415 of the Securities Act for the resale of Shares by the applicable stockholders or otherwise, such Registration Statement shall register for resale such number of Shares which is equal
to the maximum number of Shares as is permitted by the SEC. In such event, the number of Shares to be registered for each selling stockholder named in the Registration Statement shall be reduced pro rata among all such selling stockholders and as
promptly as practicable after being permitted to register additional Shares under Rule 415 under the Securities Act, the Company shall amend the Registration Statement or file a new Registration Statement to register such Shares not included in the
initial Registration Statement and use its commercially reasonable efforts to cause such amendment or Registration Statement to become effective as promptly as practicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the case of the registration, qualification, exemption or compliance effected by the Company pursuant to this Agreement, the Company
shall, upon reasonable request, inform Investor as to the status of such registration, qualification, exemption and compliance. At its expense, the Company shall use its commercially reasonable efforts to advise Investor reasonably promptly (but
within no later than 5 business days): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) when a Registration Statement or any amendment thereto has been filed with the
SEC and when a Registration Statement or any post-effective amendment thereto has become effective; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) after it shall
receive notice or obtain knowledge thereof, of the issuance by the SEC of any stop order suspending the effectiveness of any Registration Statement or the initiation of any proceedings for such purpose; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) of the receipt by the Company of any notification with respect to the suspension of the qualification of the Shares
included therein for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) subject to the provisions in this Subscription Agreement, of the occurrence of any event that requires the making of any
changes in any Registration Statement or prospectus included therein so that, as of such date, the statements therein are not misleading and do not omit to state a material fact required to be stated therein or necessary to make the statements
therein (in the case of a prospectus, in the light of the circumstances under which they were made) not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon receipt of any written notice
from the Company (which notice shall not contain any material <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company) of the happening any event contemplated in clauses (ii)&nbsp;through (iv) above during the period
that the Registration Statement is effective or if as a result of the occurrence of such event the Registration Statement or related prospectus contains any untrue statement of a material fact or omits to state any material fact required to be
stated therein or necessary to make the statements therein, in light of the circumstances under which they were made (in the case of the prospectus) not misleading, the undersigned Investor agrees that (1)&nbsp;it will immediately discontinue offers
and sales of the Shares under the Registration Statement (excluding, for the avoidance of doubt, sales conducted pursuant to Rule 144) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
until the undersigned Investor receives copies of a supplemental or amended prospectus (which Company agrees to promptly prepare) that corrects the misstatement(s) or omission(s) referred to
above and receives notice that any post-effective amendment has become effective or unless otherwise notified by Company that it may resume such offers and sales, and (2)&nbsp;it will maintain the confidentiality of any information included in such
written notice delivered by Company except (A)&nbsp;for disclosure to the Investor&#146;s employees, agents and professional advisers who need to know such information and are obligated to keep it confidential, (B)&nbsp;for disclosures to the extent
required in order to comply with reporting obligations to its limited partners who have agreed to keep such information confidential and (C)&nbsp;as required by law or subpoena. The Company shall use its commercially reasonable efforts to obtain the
withdrawal of any order suspending the effectiveness of any Registration Statement as soon as reasonably practicable. Upon the occurrence of any event contemplated in clauses (ii)&nbsp;through (iv) above, except for such times as the Company is
permitted hereunder to suspend, and has suspended, the use of a prospectus forming part of a Registration Statement, the Company shall use its commercially reasonable efforts to as soon as reasonably practicable prepare a post-effective amendment to
such Registration Statement or a supplement to the related prospectus, or file any other required document so that, as thereafter delivered to purchasers of the Shares included therein, such prospectus will not include any untrue statement of a
material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Indemnification</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company shall indemnify Investor (to the extent a seller under the Registration Statement), its officers, directors,
advisers and agents, and each person who controls Investor (within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act) to the fullest extent permitted by applicable law, from and against any and all losses,
claims, damages, liabilities, costs (including reasonably incurred and documented attorneys&#146; fees) and reasonably incurred and documented expenses (collectively, &#147;<U>Losses</U>&#148;) that arise out of or are based upon any untrue or
alleged untrue statement of a material fact contained or incorporated by reference in the Registration Statement pursuant to which Investor&#146;s Shares are registered, any prospectus included in the Registration Statement or any form of prospectus
or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein (in the
case of any prospectus or form of prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading, except to the extent that such untrue statements or alleged untrue statements, omissions or alleged
omissions are based upon information regarding Investor furnished in writing to the Company by Investor expressly for use therein or Investor has omitted a material fact from such information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Investor shall indemnify and hold harmless the Company, its directors, officers, agents and employees, and each person
who controls the Company (within the meaning of Section&nbsp;15 of the Securities Act and Section&nbsp;20 of the Exchange Act), to the fullest extent permitted by applicable law, from and against all Losses arising out of or are based upon any
untrue or alleged untrue statement of a material fact contained or incorporated by reference in any Registration Statement pursuant to which Investor&#146;s Shares are registered, any prospectus included in the Registration Statement, or any form of
prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein
(in the case of any prospectus, or any form of prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading to the extent, but only to the extent, that such untrue statements or omissions are based upon
information regarding Investor furnished in writing to the Company by the Investor expressly for use therein. In no event shall the liability of Investor be greater in amount than the dollar amount of the net proceeds received by Investor upon the
sale of the subscribed Shares giving rise to such indemnification obligation. The Investor shall notify the Company promptly of the institution, threat or assertion of any proceeding arising from or in connection with the transactions contemplated
by this Section&nbsp;8 of which the Investor is aware. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Any person entitled to indemnification herein shall (1)&nbsp;give
prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification (provided that the failure to give prompt notice shall not impair any person&#146;s right to indemnification hereunder to the extent such
failure has not prejudiced the indemnifying party) and (2)&nbsp;permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party. If such defense is assumed, the indemnifying party
shall not be subject to any liability for any settlement made by the indemnified party without its written consent. An indemnifying party who elects not to assume the defense of a claim shall not be obligated to pay the fees and expenses of more
than one counsel for all parties indemnified by such indemnifying party with respect to such claim, unless in the reasonable judgment of legal counsel to any indemnified party a conflict of interest exists between such indemnified party and any
other of such indemnified parties with respect to such claim. No indemnifying party shall, without the consent of the indemnified party (which consent shall not be unreasonably withheld, conditioned or delayed), consent to the entry of any judgment
or enter into any settlement which cannot be settled in all respects by the payment of money (and such money is so paid by the indemnifying party pursuant to the terms of such settlement) or which settlement does not include as an unconditional term
thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) The indemnification provided for under this Subscription Agreement shall remain in full force and effect regardless of any
investigation made by or on behalf of the indemnified party or any officer, director, employee, agent, affiliate or controlling person of such indemnified party and shall survive the transfer of the Shares purchased pursuant to this Subscription
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) If the indemnification provided under this Section&nbsp;8(d) from the indemnifying party is unavailable or
insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities and expenses referred to herein, then the indemnifying party, in lieu of indemnifying the indemnified party, shall contribute to the amount
paid or payable by the indemnified party as a result of such losses, claims, damages, liabilities and expenses in such proportion as is appropriate to reflect the relative fault of the indemnifying party and the indemnified party, as well as any
other relevant equitable considerations. The relative fault of the indemnifying party and indemnified party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of
a material fact or omission or alleged omission to state a material fact, was made by, or relates to information supplied by, such indemnifying party or indemnified party, and the indemnifying party&#146;s and indemnified party&#146;s relative
intent, knowledge, access to information and opportunity to correct or prevent such action. The amount paid or payable by a party as a result of the losses or other liabilities referred to above shall be deemed to include, subject to the limitations
set forth in this Section&nbsp;8(d), any legal or other fees, charges or expenses reasonably incurred by such party in connection with any investigation or proceeding. No person guilty of fraudulent misrepresentation (within the meaning of
Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution pursuant to this Section (8(d)(v) from any person who was not guilty of such fraudulent misrepresentation. Each indemnifying party&#146;s obligation to make a contribution
pursuant to this Section&nbsp;8(d)(v) shall be individual, not joint and several, and in no event shall the liability of any Investor hereunder be greater in amount than the dollar amount of the net proceeds received by such Investor upon the sale
of the subscribed Shares giving rise to such indemnification obligation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Company shall not hereafter enter into, and is not
currently a party to, any Other Subscription Agreements with respect to the Shares that is inconsistent in any material respect with, or superior to, the registration rights granted to Investor by this Subscription Agreement. Notwithstanding any
other rights and remedies Investor may have in respect of the Company or such Other Investors pursuant to this Subscription Agreement, if the Company enters into any other registration rights or similar agreement with respect to the Shares that
contains provisions that violate the preceding sentence, the terms and conditions of this Subscription Agreement shall be deemed to have been amended without further action by the Company or Investor so that Investor shall be entitled to the benefit
of any such more favorable or less restrictive terms or conditions, as the case may be. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Termination</U>. This Subscription Agreement shall terminate and be void and of no
further force and effect, and all rights and obligations of the parties hereunder shall terminate without any further liability on the part of any party in respect thereof, upon the earlier to occur of (a)&nbsp;such date and time as the BCA is
terminated in accordance with its terms without being consummated, (b)&nbsp;upon the mutual written agreement of each of the parties hereto to terminate this Subscription Agreement, (c)&nbsp;December&nbsp;30, 2021, if the Closing has not occurred by
such date, or (d)&nbsp;if any of the conditions to Closing set forth in Section&nbsp;3 of this Subscription Agreement are (i)&nbsp;not satisfied or waived or (ii)&nbsp;not capable of being satisfied and, in each case of (i)&nbsp;and (ii), as a
result thereof, the transactions contemplated by this Subscription Agreement will not be and are not consummated at the Closing (the termination events described in clauses (a)&#150;(d) above, collectively, the &#147;<U>Termination
Events</U>&#148;); provided that in the case of clause (d), to the extent such failure to satisfy the conditions to Closing set forth in Section&nbsp;3 of this Subscription Agreement is caused by the Investor&#146;s failure to satisfy such
conditions, termination shall instead be at the election of SPAC; provided, further, that nothing herein will relieve any party from liability for any willful breach hereof prior to the time of termination, and each party will be entitled to any
remedies at law or in equity to recover losses, liabilities or damages arising from any such willful breach. SPAC shall notify the Investor in writing of the termination of the BCA promptly after the termination of such agreement. Upon the
occurrence of any Termination Event and subject to the provisions of this Section&nbsp;9, this Subscription Agreement shall be void and of no further effect and any monies paid by the Investor to SPAC in connection herewith shall promptly (and in
any event within one (1)&nbsp;business day) following the Termination Event be returned to the Investor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Trust Account Waiver</U>.
The Investor acknowledges that SPAC is a blank check company with the powers and privileges to effect a merger, asset acquisition, reorganization or similar business combination involving SPAC and one or more businesses or assets. The Investor
further acknowledges that, as described in SPAC&#146;s prospectus relating to its initial public offering dated October&nbsp;6, 2020 (the &#147;<U>Prospectus</U>&#148;) available at www.sec.gov, substantially all of SPAC&#146;s assets consist of the
cash proceeds of SPAC&#146;s initial public offering and private placement of its securities, and substantially all of those proceeds have been deposited in a trust account (the &#147;<U>Trust Account</U>&#148;) for the benefit of SPAC, its public
shareholders and the underwriters of SPAC&#146;s initial public offering. Except with respect to interest earned on the funds held in the Trust Account that may be released to SPAC to pay its tax obligations and to fund certain of its working
capital requirements, the cash in the Trust Account may be disbursed only for the purposes set forth in the Prospectus. For and in consideration of SPAC entering into this Subscription Agreement, the receipt and sufficiency of which are hereby
acknowledged, the Investor hereby irrevocably waives any and all right, title and interest, or any claim of any kind it has or may have in the future, in or to any monies held in the Trust Account, and agrees not to seek recourse against the Trust
Account as a result of, or arising out of, this Subscription Agreement; provided, however, that nothing in this Section&nbsp;10 shall be deemed to limit the Investor&#146;s right, title, interest or claim to any monies held in the Trust Account by
virtue of its record or beneficial ownership of Shares (x)&nbsp;acquired by any means other than pursuant to this Subscription Agreement or (y)&nbsp;currently outstanding on the date hereof, pursuant to a validly exercised redemption right with
respect to any such Shares, except to the extent that the Investor has otherwise agreed in writing with SPAC to not exercise such redemption right. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
Neither this Subscription Agreement nor any rights that may accrue to the parties hereunder (other than the Shares acquired hereunder, if any) may be transferred or assigned without the prior written consent of each of the other parties hereto;
provided that (i)&nbsp;this Subscription Agreement and any of the Investor&#146;s rights and obligations hereunder may be assigned to an affiliate or any fund or account advised or managed by the Investor or the same investment manager or investment
advisor as the Investor or by an affiliate (as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act) of such investment manager or investment advisor without the prior consent of SPAC or the Company; provided, however,
the Investor shall provide notice of any such assignment to SPAC and the Company and (ii)&nbsp;the Investor&#146;s rights under Section&nbsp;8&nbsp;may be assigned to an assignee or transferee of the Shares; provided further that prior to such
assignment any such assignee shall agree in writing to be bound by the terms hereof. Upon such assignment by the Investor in accordance with this Section (a), the assignee shall become an Investor hereunder and have the rights and obligations
provided for herein to the extent of such assignment; provided, that no assignment pursuant to clause (i)&nbsp;of this Section&nbsp;11(a) shall relieve the Investor of its obligations hereunder, except to the extent actually performed in accordance
with the terms hereof, unless consented to in writing by SPAC and the Company (such consent not to be unreasonably conditioned, delayed or withheld). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) SPAC and/or the Company may request from the Investor such additional information as
they may reasonably deem necessary to register the resale of the Shares and evaluate the eligibility of the Investor to acquire the Shares, and the Investor shall promptly provide such information as may reasonably be requested to the extent readily
available; provided, that, each of SPAC and the Company agrees to keep any such information provided by Investor confidential except (i)&nbsp;as necessary to include in any registration statement required to be filed hereunder, (ii)&nbsp;as required
by the federal securities law or pursuant to other routine proceedings of regulatory authorities or (iii)&nbsp;to the extent such disclosure is required by law, at the request of the staff of the SEC or regulatory agency or under the regulations of
any national securities exchange on which SPAC&#146;s or the Company&#146;s securities, as the case may be, are listed for trading. The Investor acknowledges and agrees that if it does not provide SPAC and/or the Company with such requested
information, the Investor&#146;s Shares may not be registered for resale pursuant to Section&nbsp;8 hereof. The Investor acknowledges that SPAC and/or the Company may file a copy of this Subscription Agreement (or a form of this Subscription
Agreement) with the SEC as an exhibit to a periodic report or a registration statement of SPAC or the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Investor
acknowledges that (i)&nbsp;SPAC and the Company will rely on the acknowledgments, understandings, agreements, representations and warranties of the Investor contained in this Subscription Agreement, including Schedule A hereto and (ii)&nbsp;the
Placement Agents will rely on the acknowledgments, understandings, agreements, representations and warranties of the Investor contained in Section&nbsp;7 of this Subscription Agreement, including Schedule A hereto. Each of SPAC and the Company
acknowledges that the Investor will rely on the acknowledgments, understandings, agreements, representations and warranties of each of SPAC and the Company contained in this Subscription Agreement. Prior to the Closing, the Investor agrees to
promptly notify SPAC and the Company if any of the acknowledgments, understandings, agreements, representations and warranties set forth in Section&nbsp;7 above are no longer accurate in any material respect (other than those acknowledgments,
understandings, agreements, representations and warranties qualified by materiality, in which case the Investor shall notify SPAC if they are no longer accurate in any respect). Investor further acknowledges and agrees that each of the Placement
Agents is a third-party beneficiary of the representations and warranties of the Investor contained in this Subscription Agreement. The Investor acknowledges and agrees that the purchase by the Investor of Shares from SPAC will constitute a
reaffirmation of the acknowledgments, understandings, agreements, representations and warranties herein (as modified by any such notice) by the Investor as of the time of such purchase. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Each of SPAC, the Company, the Investor and the Placement Agents is each entitled to rely upon this Subscription Agreement and each is
irrevocably authorized to produce this Subscription Agreement or a copy hereof to any interested party in any administrative or legal proceeding or official inquiry with respect to the matters covered hereby; provided, however, that the foregoing
clause of this Section&nbsp;11(d) shall not give the Company or the Placement Agents any rights other than those expressly set forth in this Section&nbsp;11(d) and, without limiting the generality of the foregoing and for the avoidance of doubt, in
no event shall the Company be entitled to rely on any of the representations and warranties of SPAC set forth in this Subscription Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) All of the agreements, representations and warranties made by each party hereto in this Subscription Agreement shall survive the Closing.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) This Subscription Agreement may not be amended, modified, waived or terminated (other than pursuant to the terms of Section&nbsp;9
above) except by an instrument in writing, signed by each of the parties hereto. No failure or delay of either party in exercising any right or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such
right or power, or any abandonment or discontinuance of steps to enforce such right or power, or any course of conduct, preclude any other or further exercise thereof or the exercise of any other right or power. The rights and remedies of the
parties hereunder are cumulative and are not exclusive of any rights or remedies that they would otherwise have hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) This
Subscription Agreement (including the schedule hereto) constitutes the entire agreement, and supersedes all other prior agreements, understandings, representations and warranties, both written and oral, among the parties, with respect to the subject
matter hereof. Except as expressly otherwise provided herein, this Subscription Agreement shall not confer any rights or remedies upon any person other than the parties hereto, and their respective successors and assigns, and the parties hereto
acknowledge that such persons so referenced are third party beneficiaries of this Subscription Agreement with right of enforcement for the purposes of, and to the extent of, the rights granted to them, if any, pursuant to the applicable provisions.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Except as otherwise provided herein, this Subscription Agreement shall be binding upon,
and inure to the benefit of the parties hereto and their heirs, executors, administrators, successors, legal representatives, and permitted assigns, and the agreements, representations, warranties, covenants and acknowledgments contained herein
shall be deemed to be made by, and be binding upon, such heirs, executors, administrators, successors, legal representatives and permitted assigns. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) If any provision of this Subscription Agreement shall be adjudicated by a court of competent jurisdiction to be invalid, illegal or
unenforceable, the validity, legality or enforceability of the remaining provisions of this Subscription Agreement shall not in any way be affected or impaired thereby and shall continue in full force and effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) This Subscription Agreement may be executed in one or more counterparts (including by facsimile or electronic mail or in .pdf) and by
different parties in separate counterparts, with the same effect as if all parties hereto had signed the same document. All counterparts so executed and delivered shall be construed together and shall constitute one and the same agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) The parties hereto acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this Subscription
Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Subscription Agreement, without
posting a bond or undertaking and without proof of damages, to enforce specifically the terms and provisions of this Subscription Agreement, this being in addition to any other remedy to which such party is entitled at law, in equity, in contract,
in tort or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) If any change in the number, type or classes of authorized shares of SPAC (including the Shares), other than as
contemplated by the BCA or any agreement contemplated by the BCA, shall occur between the date hereof and immediately prior to the Closing by reason of reclassification, recapitalization, stock split (including reverse stock split) or combination,
exchange or readjustment of shares, or any stock dividend, the number of Shares issued to the Investor and the Per Share Purchase Price shall be appropriately adjusted to reflect such change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) This Subscription Agreement shall be governed by and construed in accordance with the laws of the State of Delaware (regardless of the laws
that might otherwise govern under applicable principles of conflicts of laws thereof) as to all matters (including any action, suit, litigation, arbitration, mediation, claim, charge, complaint, inquiry, proceeding, hearing, audit, investigation or
reviews by or before any governmental entity related hereto), including matters of validity, construction, effect, performance and remedies. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) Each party hereto hereby, and any person asserting rights as a third party beneficiary may do so only if he, she or it, irrevocably agrees
that any action, suit or proceeding between or among the parties hereto, whether arising in contract, tort or otherwise, arising in connection with any disagreement, dispute, controversy or claim arising out of or relating to this Subscription
Agreement or any related document or any of the transactions contemplated hereby or thereby (&#147;<U>Legal Dispute</U>&#148;) shall be brought only to the exclusive jurisdiction of the courts of the State of Delaware or the federal courts located
in the State of Delaware, and each party hereto hereby consents to the jurisdiction of such courts (and of the appropriate appellate courts therefrom) in any such suit, action or proceeding and irrevocably waives, to the fullest extent permitted by
law, any objection that it may now or hereafter have to the laying of the venue of any such suit, action or proceeding in any such court or that any such suit, action or proceeding that is brought in any such court has been brought in an
inconvenient forum. During the period a Legal Dispute that is filed in accordance with this Section&nbsp;11(n) is pending before a court, all actions, suits or proceedings with respect to such Legal Dispute or any other Legal Dispute, including any
counterclaim, cross-claim or interpleader, shall be subject to the exclusive jurisdiction of such court. Each party hereto and any person asserting rights as a third party beneficiary may do so only if he, she or it hereby waives, and shall not
assert as a defense in any Legal Dispute, that (i)&nbsp;such party is not personally subject to the jurisdiction of the above named courts for any reason, (ii)&nbsp;such action, suit or proceeding may not be brought or is not maintainable in such
court, (iii)&nbsp;such party&#146;s property is exempt or immune from execution, (iv)&nbsp;such action, suit or proceeding is brought in an inconvenient forum, or (v)&nbsp;the venue of such action, suit or proceeding is improper. A final judgment in
any action, suit or proceeding described in this Section&nbsp;11(n) following the expiration of any period permitted for appeal and subject to any stay during appeal shall be conclusive and may be enforced in other jurisdictions by suit on the
judgment or in any other manner provided by applicable laws. EACH OF THE PARTIES HERETO AND ANY PERSON ASSERTING RIGHTS AS A THIRD PARTY BENEFICIARY MAY DO SO ONLY IF HE, SHE OR IT IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT TO TRIAL BY JURY ON
ANY CLAIMS OR COUNTERCLAIMS ASSERTED IN ANY </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
LEGAL DISPUTE RELATING TO THIS SUBSCRIPTION AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY AND FOR ANY COUNTERCLAIM RELATING THERETO. IF THE SUBJECT MATTER OF ANY SUCH LEGAL DISPUTE IS ONE IN
WHICH THE WAIVER OF JURY TRIAL IS PROHIBITED, NO PARTY HERETO NOR ANY PERSON ASSERTING RIGHTS AS A THIRD PARTY BENEFICIARY SHALL ASSERT IN SUCH LEGAL DISPUTE A NONCOMPULSORY COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS SUBSCRIPTION AGREEMENT OR
THE TRANSACTIONS CONTEMPLATED HEREBY. FURTHERMORE, NO PARTY HERETO NOR ANY PERSON ASSERTING RIGHTS AS A THIRD PARTY BENEFICIARY SHALL SEEK TO CONSOLIDATE ANY SUCH LEGAL DISPUTE WITH A SEPARATE ACTION OR OTHER LEGAL PROCEEDING IN WHICH A JURY TRIAL
CANNOT BE WAIVED. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) Any notice or communication required or permitted hereunder to be given to a party hereto shall be in writing and
either delivered personally, emailed or sent by overnight mail via a reputable overnight carrier, or sent by certified or registered mail, postage prepaid, to such address(es) or email address(es) set forth on the signature page hereto, and shall be
deemed to be given and received (i)&nbsp;when so delivered personally, (ii)&nbsp;when sent, with no mail undeliverable or other rejection notice, if sent by email, or (iii)&nbsp;three (3) business days after the date of mailing to the address below
or to such other address or addresses as the party may hereafter designate by notice given hereunder: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) if to Investor,
to such address(es) or email address(es) as set forth herein; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) if to SPAC, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Montes Archimedes Acquisition Corp. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">724 Oak Grove, Suite 130 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Menlo Park, CA 94025 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;Maria Walker </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;maria@patientsquarecapital.com
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>with a copy (which shall not constitute notice) to:</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Kirkland&nbsp;&amp; Ellis LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">601 Lexington Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Michael E. Weisser, P.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:15%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;Ryan Brissette </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:&nbsp;&nbsp;&nbsp;&nbsp;</FONT> michael.weisser@kirkland.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:15%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;ryan.brissette@kirkland.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) if to the Company, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant Sciences Ltd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Suite 1, 3rd Floor, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">11-12</FONT> St. James&#146;s Square, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">London SW1Y 4LB </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">United Kingdom </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;Matthew Gline </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;matthew.gline@roivant.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:15%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;legalnotices@roivant.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>with a copy (which shall not constitute notice) to:</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roivant Sciences, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">151 West 42nd Street, 15th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10036 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;jo.chen@roivant.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">-and- </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Davis Polk&nbsp;&amp; Wardwell LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">450 Lexington Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Derek Dostal </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:15%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;Brian Wolfe </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:15%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;Lee Hochbaum </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> &nbsp;&nbsp;&nbsp;&nbsp;derek.dostal@davispolk.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:15%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;brian.wolfe@davispolk.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:15%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;lee.hochbaum@davispolk.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U><FONT STYLE="white-space:nowrap">Non-Reliance</FONT> and Exculpation</U>. The Investor acknowledges that it is not relying upon, and has
not relied upon, any statement, representation or warranty made by any person, firm or corporation (including, without limitation, the Placement Agents, any of their respective affiliates or any control persons, officers, directors, employees,
partners, agents or representatives of any of the foregoing), other than the statements, representations and warranties of SPAC and the Company expressly contained in Section&nbsp;5 and Section&nbsp;6 of this Subscription Agreement, respectively, in
making its investment or decision to invest in SPAC. The Investor acknowledges and agrees that none of (i)&nbsp;any other investor pursuant to this Subscription Agreement or any other subscription agreement related to the private placement of the
Shares (including the investor&#146;s respective affiliates or any control persons, officers, directors, employees, partners, agents or representatives of any of the foregoing), (ii) the Placement Agents, their respective affiliates or any control
persons, officers, directors, employees, partners, agents or representatives of any of the foregoing, or (iii)&nbsp;any other party to the BCA or any <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate (other than SPAC or the Company with
respect to the previous sentence), shall have any liability to the Investor, or to any other investor, pursuant to, arising out of or relating to this Subscription Agreement or any other subscription agreement related to the private placement of the
Shares, the negotiation hereof or thereof or its subject matter, or the transactions contemplated hereby or thereby, including, without limitation, with respect to any action heretofore or hereafter taken or omitted to be taken by any of them in
connection with the purchase of the Shares or with respect to any claim (whether in tort, contract or otherwise) for breach of this Subscription Agreement or in respect of any written or oral representations made or alleged to be made in connection
herewith, as expressly provided herein, or for any actual or alleged inaccuracies, misstatements or omissions with respect to any information or materials of any kind furnished by SPAC, the Company, the Placement Agents or any <FONT
STYLE="white-space:nowrap">Non-Party</FONT> Affiliate concerning SPAC, the Company, the Placement Agents, any of their controlled affiliates, this Subscription Agreement or the transactions contemplated hereby. For purposes of this Subscription
Agreement, <FONT STYLE="white-space:nowrap">&#147;Non-Party</FONT> Affiliates&#148; means each former, current or future officer, director, employee, partner, member, manager, direct or indirect equityholder or affiliate of SPAC, the Company, the
Placement Agents or any of SPAC&#146;s, the Company&#146;s or the Placement Agents&#146; controlled affiliates or any family member of the foregoing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Disclosure</U>. SPAC shall, by 9:00 a.m., New York City time, on the first (1st) business day immediately following the date of this
Subscription Agreement, issue one or more press releases or file with the SEC a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (collectively, the &#147;Disclosure Document&#148;) disclosing all material terms of the transactions
contemplated hereby and by the Other Subscription Agreements, the Transaction and any other material, nonpublic information that SPAC has provided to the Investor at any time prior to the filing of the Disclosure Document. Upon the issuance of the
Disclosure Document, to the actual knowledge of SPAC, the Investor shall not be in possession of any material, <FONT STYLE="white-space:nowrap">non-public</FONT> information received from SPAC or any of its officers, directors, or employees or
agents (including the Placement Agents), and the Investor shall no longer be subject to any confidentiality or similar obligations under any current agreement, whether written or oral, with SPAC or any of its affiliates, relating to the transactions
contemplated by this Subscription Agreement. Notwithstanding anything in this Subscription Agreement to the contrary, neither SPAC nor the Company shall publicly disclose the name of the Investor or any of its affiliates or advisers, or include the
name of the Investor or any of its affiliates or advisers without the prior written consent of the Investor (a)&nbsp;in any press release or marketing materials or (b)&nbsp;in any filing with the SEC or any regulatory agency or trading market except
(i)&nbsp;as required by the federal securities law or pursuant to other routine proceedings of regulatory authorities, (ii)&nbsp;to the extent such disclosure is required by law, at the request of the staff of the SEC or regulatory agency or under
the regulations of any national securities exchange on which SPAC&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities are listed for trading or (iii)&nbsp;to the extent such announcements or other communications contain only information previously disclosed in a public statement, press release or
other communication previously approved in accordance with this&nbsp;Section 13; provided that, in each case of (i), (ii), or (iii), SPAC will provide the Investor with written notice (including by <FONT STYLE="white-space:nowrap">e-mail)</FONT> of
any such disclosure and shall reasonably consult with Investor regarding such disclosure. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Separate Obligations</U>. For the
avoidance of doubt, all obligations of the Investor hereunder are separate and several from the obligations of any Other Investor. The decision of Investor to purchase the Shares pursuant to this Subscription Agreement has been made by Investor
independently of any Other Investor or any other investor and independently of any information, materials, statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations, condition (financial
or otherwise) or prospects of SPAC, the Company, or any of their respective subsidiaries which may have been made or given by any Other Investor or investor or by any agent or employee of any Other Investor or investor, and neither Investor nor any
of its agents or employees shall have any liability to any Other Investor or investor (or any other person) relating to or arising from any such information, materials, statements or opinions. Nothing contained herein or in any Other Subscription
Agreement, and no action taken by Investor or Other Investors pursuant hereto or thereto, shall be deemed to constitute Investor and Other Investor or other investors as a partnership, an association, a joint venture or any other kind of entity, or
create a presumption that Investor and Other Investors or other investors are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this Subscription Agreement and the Other Subscription
Agreements. The Investor acknowledges that no Other Investor has acted as agent for Investor in connection with making its investment hereunder and no Other Investor will be acting as agent of Investor in connection with monitoring its investment in
the Shares or enforcing its rights under this Subscription Agreement. The Investor shall be entitled to independently protect and enforce its rights, including without limitation the rights arising out of this Subscription Agreement, and it shall
not be necessary for any Other Investor or investor to be joined as an additional party in any proceeding for such purpose. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.
<U>Massachusetts Business Trust</U>. If Investor is a Massachusetts Business Trust, a copy of the Declaration of Trust of Investor or any affiliate thereof is on file with the Secretary of State of the Commonwealth of Massachusetts and notice is
hereby given that the Subscription Agreement is executed on behalf of the trustees of Investor or any affiliate thereof as trustees and not individually and that the obligations of the Subscription Agreement are not binding on any of the trustees,
officers or stockholders of Investor or any affiliate thereof individually but are binding only upon Investor or any affiliate thereof and its assets and property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>SIGNATURE PAGES FOLLOW</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Investor has executed or caused this Subscription Agreement
to be executed by its duly authorized representative as of the date set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name&nbsp;of&nbsp;Investor:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">State/Country of Formation or Domicile:</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name in which Shares are to be registered (if different):</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date: ________, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor&#146;s EIN:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Business Address-Street:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mailing Address-Street (if different):</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">City, State, Zip:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">City, State, Zip:</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone No.:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Telephone No.:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Facsimile No.:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile No.:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of Shares subscribed for:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Aggregate Subscription Amount: $</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Price Per Share: $10.00</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You must pay the Subscription Amount by wire transfer of United States dollars in immediately available funds
to the account specified by SPAC in the Closing Notice. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned has accepted this Subscription Agreement as of the date
set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MONTES ARCHIMEDES ACQUISITION CORP.</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ROIVANT SCIENCES LTD.</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR></TABLE></DIV>
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELIGIBILITY REPRESENTATIONS OF THE INVESTOR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">QUALIFIED INSTITUTIONAL BUYER STATUS </P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">(Please check the applicable subparagraphs):</P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;We are a &#147;qualified institutional buyer&#148; (as defined in Rule 144A under the Securities
Act (a &#147;<U>QIB</U>&#148;)). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#9744; We are subscribing for the Shares as a fiduciary or agent with full investment discretion for one
or more investor accounts, and each owner of such account is a QIB. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">** OR ** </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">INSTITUTIONAL ACCREDITED INVESTOR STATUS </P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">(Please check the applicable subparagraphs):</P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="97%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="97%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#9744;&nbsp;We are an &#147;accredited investor&#148; (within the meaning of Rule 501(a) under the Securities Act or an entity in which all of the equity holders are accredited investors within the meaning of Rule 501(a) under the
Securities Act), and have marked and initialed the appropriate box on the following page indicating the provision under which we qualify as an &#147;accredited investor.&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;We are not a natural person.</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rule 501(a), in relevant part, states that an &#147;accredited investor&#148; shall mean any person who comes within any
of the below listed categories, or who the issuer reasonably believes comes within any of the below listed categories, at the time of the sale of the securities to that person. The Investor has indicated, by marking and initialing the appropriate
box below, the provision(s) below which apply to the Investor and under which the Investor accordingly qualifies as an &#147;accredited investor.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;Any bank, registered broker or dealer, insurance company, registered investment company, business development company, or small
business investment company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;Any plan established and maintained by a state, its political subdivisions, or any agency or
instrumentality of a state or its political subdivisions for the benefit of its employees, if such plan has total assets in excess of $5,000,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;Any employee benefit plan, within the meaning of the Employee Retirement Income Security Act of 1974, if a bank, insurance
company, or registered investment adviser makes the investment decisions, or if the plan has total assets in excess of $5,000,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;Any organization described in section&nbsp;501(c)(3) of the Internal Revenue Code, corporation, similar business trust, or
partnership, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;Any trust with assets in excess of $5,000,000, not formed to acquire the securities offered, whose purchase is directed by a
sophisticated person; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;Any entity in which all of the equity owners are accredited investors meeting one or more of the
above tests. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">** AND ** </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">C.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">AFFILIATE STATUS</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">(Please check the applicable subparagraphs):</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">&#9744;&nbsp;We are:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">&#9744;&nbsp;We are not:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">an &#147;affiliate&#148; (as defined in Rule 144 under the Securities Act) of the SPAC or acting on behalf of an affiliate of the SPAC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">** AND **</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">QUALIFIED PURCHASER STATUS</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Please check the applicable subparagraphs):</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">FOR INDIVIDUALS:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#9744;&nbsp;A natural person who owns not less than U.S.$5,000,000 in investments.&nbsp;For this purpose, investments owned by the Investor include all investments that are the Investor&#146;s separate property and any investments
held jointly with the Investor&#146;s spouse, as community property or otherwise, but do not include investments that are the separate property of the Investor&#146;s spouse unless the interest will be a joint investment of the Investor and the
Investor&#146;s spouse.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#9744;&nbsp;A natural person who has discretionary investment authority with regard to at least U.S.$25,000,000 of investments, including for this purpose solely the Investor&#146;s own investments and investments of third parties
that are themselves accurately described by one or more paragraphs of this Section D.</TD></TR>
</TABLE></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="97%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="97%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Please check the applicable subparagraphs):</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">FOR ENTITIES:</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="97%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#9744;&nbsp;A corporation, partnership, limited liability company, trust or other organization that:&nbsp;(i) was not organized or reorganized and is not operated for the specific purpose of acquiring the interest or any other
interest in SPAC, and less than 40% of the assets of which will consist of interests in SPAC (calculated as of the time of the Investor&#146;s execution of this Subscription Agreement); (ii) owns not less than U.S.$5,000,000 in investments; and
(iii)&nbsp;is owned directly or indirectly solely by or for two or more natural persons who are related as siblings or spouses (including former spouses), or direct lineal descendants by birth or adoption, spouses of such persons, the estates of
such persons, or foundations, charitable organizations, or trusts established by or for the benefit of such persons.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#9744;&nbsp;A trust:&nbsp;(i) that is not described in paragraph (3)&nbsp;of this Section D; (ii)&nbsp;that was not organized or reorganized and is not operated for the specific purpose of acquiring the interest or any other
interest in SPAC, and less than 40% of the assets of which will consist of interests in SPAC (calculated as of the time of the Investor&#146;s execution of this Subscription Agreement); and (iii)&nbsp;with respect to which each of the settlors and
other contributors of assets, trustees, and other authorized decision makers is a person described in paragraph&nbsp;(1), (2), (3) or (4)&nbsp;of this Section D.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">5.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#9744;&nbsp;An entity that:&nbsp;(i) was not organized or reorganized and is not operated for the specific purpose of acquiring the interest or any other interest in SPAC, and less than 40% of the assets of which will consist of
interests in SPAC (calculated as of the time of the Investor&#146;s execution of this Subscription Agreement); and (ii)&nbsp;has discretionary investment authority with regard to at least U.S.$25,000,000 of investments, whether for its own account
or for the account of other persons that are themselves accurately described by one or more other paragraphs of this Section D.</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An entity, each and every beneficial owner of which is a person accurately described by one or more of the
foregoing paragraphs of this Section D or is itself an entity each and every beneficial owner of which is a person accurately described by one or more of the foregoing paragraphs of this Section D.&nbsp;<I>If the Investor is a qualified purchaser
solely for the reason described in this paragraph 6, the Investor shall, at the request of SPAC, submit to SPAC a separate qualified purchaser questionnaire for each beneficial owner of the Investor&#146;s securities.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>This page should be completed by the Investor </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>and constitutes a part of the Subscription Agreement. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>6
<FILENAME>d307489dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPONSOR SUPPORT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>SPONSOR SUPPORT AGREEMENT</B> (this &#147;<U>Agreement</U>&#148;) is entered into as of May 1, 2021, by and among Roivant Sciences
Ltd., a Bermuda exempted limited company (the&nbsp;&#147;<U>Company</U>&#148;), Montes Archimedes Acquisition Corp., a Delaware corporation (&#147;<U>MAAC</U>&#148;), Patient Square Capital LLC, a Delaware limited liability company (the
&#147;<U>MAAC Sponsor</U>&#148;), and solely for purposes of <U>Sections 1(b)</U>, <U>1(d)</U>, <U>4</U>, <U>5</U>, <U>8(a)</U> and <U>(b)</U>, <U>9</U> (solely for purposes of his or her representations or warranties therein), <U>10</U> through
<U>13</U> and <U>14</U> through <U>23</U> (to the extent related to the foregoing sections) the Insiders (as defined below). Each of the Company, MAAC, the MAAC Sponsor and each of the Insiders are sometimes referred to herein individually as a
&#147;<U>Party</U>&#148; and collectively as the &#147;<U>Parties</U>.&#148; Each of the MAAC Sponsor and each of the Insiders are sometimes referred to herein individually as a &#147;<U>Shareholder</U>.&#148; Except as otherwise specified herein,
capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Business Combination Agreement (as defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, concurrently with the execution of this Agreement, MAAC, the Company and Rhine Merger Sub, Inc., a Delaware corporation and a
wholly owned subsidiary of the Company (&#147;<U>Merger Sub</U>&#148;), entered into that certain Business Combination Agreement (as amended, supplemented or otherwise modified from time to time in accordance with its terms, the &#147;<U>Business
Combination Agreement</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Business Combination Agreement contemplates that, on the terms and subject to the
conditions therein, (a)&nbsp;on the Closing Date prior to the Closing, the Company will consummate the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, and (b)&nbsp;on the Closing Date promptly following consummation of the Company
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, Merger Sub will merge with and into MAAC (the &#147;<U>Merger</U>&#148;), with MAAC as the surviving corporation in the Merger and, after giving effect to such Merger, becoming a
wholly-owned Subsidiary of the Company (collectively, and together with the other transactions contemplated by the Business Combination Agreement and the Ancillary Documents, the &#147;<U>Transactions</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, reference is hereby made to the following Contracts (collectively, the &#147;<U>Affected Agreements</U>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(A) that certain Letter Agreement dated October&nbsp;6, 2020 and delivered by the MAAC Sponsor to MAAC (the &#147;<U>Sponsor Letter</U>&#148;);
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(B) those certain Letter Agreements, dated October&nbsp;6, 2020, and delivered by each of George Barrett, James Momtazee, Maria Walker and
Stephen Oesterle (each, an &#147;<U>Insider</U>&#148; and, collectively, the &#147;<U>Insiders</U>&#148;) to MAAC (each, an &#147;<U>Insider Letter</U>&#148; and, collectively, the &#147;<U>Insider Letters</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(C) that certain Warrant Agreement dated October&nbsp;6, 2020 between MAAC and Continental Stock Transfer&nbsp;&amp; Trust Company, a New York
corporation, as warrant agent (the &#147;<U>Warrant Agent</U>&#148;) (the &#147;<U>Warrant Agreement</U>&#148;); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(D) that certain
Registration and Stockholder Rights Agreement dated October&nbsp;6, 2020 (the &#147;<U>MAAC Registration Rights Agreement</U>&#148;) by and among MAAC, the MAAC Sponsor and each of the other Holders (as such term is defined therein). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, as of the date hereof, each Shareholder, in its respective capacity as such,
is the holder of record and the &#147;beneficial owner&#148; (within the meaning of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of (i)&nbsp;the number of MAAC Class&nbsp;A Shares, (ii)&nbsp;private placement warrants
(the &#147;<U>Warrants</U>&#148;) to purchase an aggregate number of MAAC Class&nbsp;A Shares and/or (iii)&nbsp;the number of MAAC Class&nbsp;B Shares, in each case, set forth on <U>Exhibit</U><U></U><U>&nbsp;A</U> attached hereto opposite such
person&#146;s name on such Exhibit (collectively, with respect to each Shareholder, the &#147;<U>Subject Company Securities</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, as part of the Transactions, each of the MAAC Class&nbsp;A Shares and the MAAC Class&nbsp;B Shares will be converted into
Company Post-Closing Common Shares on the terms and conditions set forth in the Business Combination Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in
connection with the Transactions, and concurrently with the execution of this Agreement and the Business Combination Agreement, (a)&nbsp;the Company and the MAAC Sponsor entered into that certain <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement (as amended, supplemented or otherwise modified from time to time in accordance with its terms, the &#147;<U>Sponsor <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</U>&#148;), and (b)&nbsp;the Company, on the one hand, and
certain Company Shareholders, on the other hand, entered into those certain <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements (as amended, supplemented or otherwise modified from time to time in accordance with their applicable terms,
collectively, the &#147;<U>Significant Company Shareholder <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</U>&#148; and, together with the Sponsor <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, collectively, the &#147;<U><FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in consideration for the benefits to be received by the
MAAC Sponsor and each of the Insiders under the terms of the Business Combination Agreement and as a material inducement to the Company and MAAC agreeing to enter into and consummate the transactions contemplated by the Business Combination
Agreement, the MAAC Sponsor and each of the Insiders agrees to enter into this Agreement and to be bound by the applicable agreements, covenants and obligations contained in this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Parties acknowledge and agree that the Company and MAAC would not have entered into and agreed to consummate the
transactions contemplated by the Business Combination Agreement without each of the Shareholders entering into this Agreement and agreeing to be bound by the applicable agreements, covenants and obligations contained in this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW,
THEREFORE</B>, in consideration of the premises and the mutual promises set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound,
hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Sponsor Letter and Insider Letters</U>. The Company, MAAC, the MAAC Sponsor (in the case of clauses (a),
(b), (c) and (e)) and each Insider (in the case of clauses (b)&nbsp;and (d), as it relates to the Insider Letter to which he or she is a party) hereby agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Sponsor Letter provides in Section&nbsp;1 thereof that MAAC shall not enter into a definitive agreement regarding a Business
Combination (as defined therein) without the prior written consent of the MAAC Sponsor. The Transactions constitute a Business Combination for purposes of the Sponsor Letter and the MAAC Sponsor hereby consents to entry into the Business Combination
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Sponsor Letter provides in Section&nbsp;2 thereof, and each Insider Letter provides
in Section&nbsp;1 thereof, for certain requirements of the MAAC Sponsor and the Insiders in respect of a Business Combination (in each case, as defined therein), including in respect of voting all MAAC Shares beneficially owned by the MAAC Sponsor
and by the Insiders, as applicable, in favor of such Business Combinations and forgoing redemption rights in respect thereof. The Transactions constitute a Business Combination for purposes of the Sponsor Letter and each Insider Letter and the MAAC
Sponsor and each Insider will comply with its, his or her respective obligations under Section&nbsp;2 of the Sponsor Letter or Section&nbsp;1 of its, his or her Insider Letter, as applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Subject to, and conditioned upon the occurrence and effective as of, the Effective Time,&nbsp;Section 6 of the Sponsor Letter shall be
amended and restated to provide in its entirety as follows: &#147;[Reserved].&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Subject to, and conditioned upon the occurrence
and effective as of, the Effective Time,&nbsp;Section 5 of each Insider Letter shall be amended and restated to provide in its entirety as follows: &#147;[Reserved].&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Section 7 of the Sponsor Letter is hereby amended and restated to provide in its entirety as follows: &#147;[Reserved].&#148; For the
avoidance of doubt, if the Business Combination Agreement is terminated in accordance with its terms, then this clause (e) (and the amendment and restatement contemplated by this clause (e)) shall be of no further force and effect and Section&nbsp;7
shall be reinstated and effective from and after such time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U><FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to, and conditioned upon the occurrence of and effective immediately after the Effective Time, (i) 20% of the number of Company
Post-Closing Common Shares issued to the MAAC Sponsor upon the conversion of MAAC Class&nbsp;B Shares (rounded up to the nearest whole share) shall be subject to the provisions set forth below in this<U>&nbsp;Section</U><U></U><U>&nbsp;2</U> (such
Company Post-Closing Common Shares, the &#147;<U>20% Earn</U><U><FONT STYLE="white-space:nowrap">-Out</FONT> Shares</U>&#148;), (ii) 10% of the number of Company Post-Closing Common Shares issued to the MAAC Sponsor upon the conversion of MAAC
Class&nbsp;B Shares (rounded up to the nearest whole share) shall be subject to the provisions set forth below in this<U>&nbsp;Section</U><U></U><U>&nbsp;2</U> (such Company Post-Closing Common Shares, the &#147;<U>10% Earn</U><U><FONT
STYLE="white-space:nowrap">-Out</FONT> Shares</U>&#148; and, together with the 20% <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares, the &#147;<U><FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares</U>&#148;) and (iii)&nbsp;the remaining
70% of the number of Company Post-Closing Common Shares issued to the MAAC Sponsor upon the conversion of MAAC Class&nbsp;B Shares (rounded down to the nearest whole share) shall not be subject to the provisions set forth below in
this<U>&nbsp;Section</U><U></U><U>&nbsp;2</U> (such Company Post-Closing Common Shares, the &#147;<U>Retained Shares</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Subject to, and conditioned upon the occurrence of and effective immediately after the
Effective Time, the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares shall be unvested and subject to the restrictions and forfeiture provisions set forth in this <U>Section</U><U></U><U>&nbsp;2</U>. The
<FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares shall vest and become free of the provisions set forth in this <U>Section</U><U></U><U>&nbsp;2</U> at such time as the Stock Price (as defined below) of Company Post-Closing Common Shares
equals or exceeds (x)&nbsp;with respect to the 20% <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares, $15.00 per share (the &#147;<U>20% Trigger Price</U>&#148;), and (y)&nbsp;with respect to the 10%
<FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares, $20.00 per share (the &#147;<U>10% Trigger Price</U>&#148; and, together with the 20% Trigger Price, the &#147;<U>Trigger Price</U>&#148;), in each case, for any 20 Trading Days within any 30
Trading Day period commencing no earlier than the Closing Date and ending no later than the fifth (5th) anniversary of the Closing Date (the &#147;<U><FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date</U>&#148;); <U>provided</U>,
<U>however</U>, that (i)&nbsp;if the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date occurs on a day that is not a Trading Day, then the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date shall be deemed to occur on the next
following Trading Day, and (ii)&nbsp;if the Company or any of its Affiliates enters into a definitive agreement with respect to a Sale (as defined below) on or prior to the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date, then the <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> End Date shall be automatically extended and shall be deemed to occur on the earlier of (A)&nbsp;the day after such Sale is consummated and (B)&nbsp;the termination of such definitive agreement with respect
to such Sale in accordance with its terms. Any <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares that have not vested in accordance with this <U>Section</U><U></U><U>&nbsp;2(b)</U> or <U>Section</U><U></U><U>&nbsp;2(c</U>) on or before the <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> End Date will be immediately forfeited at 11:59 p.m., New York, New York time on the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event of a Sale (as defined below) on or prior to the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date, any unvested <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Shares will fully vest and become free of the restrictions set forth in this <U>Section</U><U></U><U>&nbsp;2</U> as of immediately prior to the closing of such Sale. For purposes of this Agreement,
&#147;<U>Sale</U>&#148; means (A)&nbsp;a purchase, sale, exchange, merger, business combination or other transaction or series of related transactions in which substantially all of the Company Post-Closing Common Shares are, directly or indirectly,
converted into cash, securities or other property or <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration (other than, in the case of this clause (A), any transaction in which the holders of Company Post-Closing Common Shares as of
immediately prior to the consummation of such transaction continue to own all or substantially all of the equity securities of the Company (or any successor or parent entity of the Company) immediately following the consummation of such
transaction), (B) a direct or indirect sale, lease, exchange or other transfer (regardless of the form of the transaction) in one transaction or a series of related transactions of a majority of the Company&#146;s assets, as determined on a
consolidated basis, to a third party or third parties acting as a &#147;group&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act) or (C)&nbsp;any transaction or series of transactions that results, directly or indirectly, in the
shareholders of the Company as of immediately prior to such transactions holding, in the aggregate, less than fifty percent (50%) of the voting Equity Securities of the Company (or any successor or parent company of the Company) immediately after
the consummation thereof (excluding, for the avoidance of doubt, any <FONT STYLE="white-space:nowrap">Earn-out</FONT> Shares) (in the case of each of clause (A), (B) or (C), whether by amalgamation, merger, consolidation, arrangement, tender offer,
recapitalization, purchase, issuance, sale or transfer of Equity Securities or assets or otherwise). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The MAAC Sponsor agrees that it
shall not engage in any Sale Transaction (as defined in the Sponsor <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement) with respect to any <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares until such time as the <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Shares have vested pursuant to <U>Section</U><U></U><U>&nbsp;2(b)</U> or <U>Section</U><U></U><U>&nbsp;2(c)</U>. Notwithstanding the foregoing or anything to the contrary herein, (i)&nbsp;the MAAC Sponsor
(and, for the avoidance of doubt, any permitted transferees pursuant to this clause (i)) may transfer all or any of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares in any transfer of the type described in Sections 1(b)(iv)(A) through
(C)&nbsp;or (F) of the Sponsor <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, <U>provided</U> that, in the case of a transfer of the type described in clauses (A)&nbsp;through (C), the transferee shall, in addition to any requirements in
the Sponsor <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, agree in writing that he, she or it is receiving and holding such <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to the provisions of this <U>Section</U><U></U><U>&nbsp;2</U> and (ii)&nbsp;from and after a transfer pursuant to clause (i)&nbsp;of this sentence, all references to the MAAC Sponsor in
this <U>Section</U><U></U><U>&nbsp;2</U> and <U>Section</U><U></U><U>&nbsp;7</U> shall include such transferee and shall collectively mean the MAAC Sponsor (to the extent that it then holds <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares)
and each permitted transferee of <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares pursuant to clause (i)&nbsp;of this sentence (in each case, to the extent he, she or it then holds <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares).
Each transferee of <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares pursuant to clause (i)&nbsp;of the preceding sentence shall be a third party beneficiary of this <U>Section</U><U></U><U>&nbsp;2</U> and <U>Section</U><U></U><U>&nbsp;7</U>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) As used herein, &#147;<U>Stock Price</U>&#148; means, on any date on or after the Closing and on or prior to the <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> End Date, the closing sale price per share of Company Post-Closing Common Shares reported as of 4:00 p.m., New York, New York time on such date by Bloomberg, or if not available on Bloomberg, as reported by
or an authoritative source generally used for such purposes and selected by the Company, and &#147;<U>Trading Day</U>&#148; means any day on which trading is generally conducted on Nasdaq or any other exchange on which the Company Post-Closing
Common Shares are traded on or after the Closing and on or prior to the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date. The <FONT STYLE="white-space:nowrap">Earn-out</FONT> Shares and the applicable Trigger Price (and all references to
Company Post-Closing Common Shares and each of the foregoing in this Agreement) shall each be adjusted appropriately to reflect the effect of any stock split, reverse stock split, stock dividend (including any dividend or other distribution of
securities convertible into Company Post-Closing Common Shares), reorganization, recapitalization, reclassification, combination, exchange of shares or other like change with respect to the Company Post-Closing Common Shares (or any other Equity
Securities into which they are adjusted pursuant to this <U>Section</U><U></U><U>&nbsp;2(e)</U>) at any time prior to the vesting of the <FONT STYLE="white-space:nowrap">Earn-out</FONT> Shares pursuant to this <U>Section</U><U></U><U>&nbsp;2</U> so
as to provide the holders of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares with the same economic effect as contemplated by this <U>Section</U><U></U><U>&nbsp;2</U> prior to such event and as so adjusted shall, from and after the date
of such event, be the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares and the 20% Trigger Price or the 10% Trigger Price, as applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Company shall use reasonable best efforts to remain listed as a public company on, and for the
<FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares to be tradable over, Nasdaq or any other nationally recognized U.S. stock exchange; <U>provided</U>, <U>however</U>, the foregoing shall not limit the Company or any of its Affiliates from
consummating a Sale or entering into a definitive agreement that contemplates a Sale. Subject to <U>Section</U><U></U><U>&nbsp;2(c)</U> and the other applicable provisions of this <U>Section</U><U></U><U>&nbsp;2</U>, upon the consummation of Sale
the Company shall have no further obligations under this <U>Section</U><U></U><U>&nbsp;2(f)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) At the time that the <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Shares become vested pursuant to this <U>Section</U><U></U><U>&nbsp;2</U>, the Company shall remove any legends, stock transfer restrictions, stop transfer orders or similar restrictions with respect to the
<FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares related to such vesting or this <U>Section</U><U></U><U>&nbsp;2</U> (other than, for the avoidance of doubt, those that relate to any applicable and then-existing
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period (as defined in the Sponsor <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement) with respect to such <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) For the avoidance of doubt, (i)&nbsp;the MAAC Sponsor shall retain all of its rights as a stockholder of the Company with respect to the <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Shares owned by it during any period of time that such shares are subject to restriction on transfer or sale hereunder, including the right to vote any such shares and the right to receive dividends and
other distributions with respect to such <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares prior to vesting (<U>provided</U> that dividends and other distributions with respect to <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares that
are subject to vesting and are unvested at the time of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dividend or distribution shall be set aside by the Company and shall only be paid to such holders upon the vesting of such <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares (and, if any
dividends or other distributions with respect to <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares are set aside and such <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares are subsequently forfeited pursuant to this
<U>Section</U><U></U><U>&nbsp;2</U>, such set aside dividends or distributions shall become the property of the Company)), (ii) any <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares that vest in accordance with the terms of this
<U>Section</U><U></U><U>&nbsp;2</U> shall remain subject to any applicable <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period set forth in the Sponsor <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and (iii)&nbsp;notwithstanding the
expiration of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period with respect to any <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares, such shares shall remain subject to any applicable restrictions set forth this
<U>Section</U><U></U><U>&nbsp;2</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The MAAC Sponsor intends to make a protective election under Section&nbsp;83(b) of the Code with
respect to the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) The Parties agree and acknowledge that the <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Shares are intended to constitute &#147;voting stock&#148; within the meaning of Section&nbsp;368(a)(1) of the Code and the Treasury Regulations promulgated thereunder received by MAAC Sponsor in connection
with the Merger, and shall file all Tax Returns consistent with, and take no position inconsistent with (whether in audits, Tax Returns or otherwise), such treatment unless (i)&nbsp;such Party requests that each of Kirkland&nbsp;&amp; Ellis LLP and
Davis Polk&nbsp;&amp; Wardwell LLP provides written confirmation to the effect that such treatment is more likely than not correct, and each such law firm fails to provide such confirmation prior to the later of (A)&nbsp;thirty (30) days following
such request is made and (B)&nbsp;sixty (60) days prior to the date on which the relevant Tax Return is due (taking into account applicable extensions); <U>provided</U> that the Parties shall provide customary factual representations to such law
firm; <U>provided</U>, <U>further</U>, that, for the avoidance of doubt, the Parties shall not be required to restructure, or otherwise alter the terms of, the transaction as provided for in this Agreement or the Business Combination Agreement, or
(ii)&nbsp;otherwise required by a final &#147;determination&#148; within the meaning of Section&nbsp;1313(a) of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Sponsor
Exchange Ratio</U>. For purposes of the Business Combination Agreement, the term &#147;<U>Sponsor Exchange Ratio</U>&#148; shall mean: (i)&nbsp;one <I>minus</I> (ii)&nbsp;a number equal to (A) 0.5 <I>multiplied by</I> (B)&nbsp;a fraction equal to
(x)&nbsp;the number of MAAC Class&nbsp;A Shares with respect to which a MAAC Shareholder Redemption has been exercised <I>divided by</I> (y)&nbsp;the total number of MAAC Class&nbsp;A Shares outstanding as of the date hereof; <U>provided</U> that
the number referenced in the foregoing clause (ii)&nbsp;shall not in any event be greater than 0.25. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Working Capital Loans; Related
Party Agreements</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) With respect to any loan of funds made by the MAAC Sponsor or an Affiliate of the MAAC Sponsor or any of
MAAC&#146;s officers or directors (each, a &#147;<U>Lender</U>&#148;) to MAAC or any of its Subsidiaries, in each case, prior to the Closing (a &#147;<U>Working Capital Loan</U>&#148;) that is or may be convertible into warrants or other securities
(derivative or otherwise) of MAAC or the Company, MAAC, the MAAC Sponsor and the Insiders hereby agrees, and shall take such reasonably necessary or appropriate actions within its power so as to ensure, that each and any Working Capital Loan shall
be repaid solely in cash, and that no Working Capital Loan will be converted into warrants or other securities (derivative or otherwise) of MAAC or the Company, notwithstanding any applicable provisions of the Insider Letter, the Warrant Agreement,
the MAAC Registration Rights Agreement or any other Contract. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) MAAC and the MAAC Sponsor agree that, notwithstanding anything to the contrary in any
such agreement, (i)&nbsp;each of the agreements set forth on <U>Schedule</U><U></U><U>&nbsp;A</U> attached hereto shall be automatically terminated and of no further force and effect (including any provisions of any such agreement that, by its
terms, survive such termination), effective as of, and subject to and conditioned upon the occurrence of, the Closing and (ii)&nbsp;upon such termination, MAAC shall not have any further Liabilities under each such agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>MAAC Registration Rights Agreement</U>. Subject to, and conditioned upon the occurrence and effective as of the Effective Time, MAAC, the
MAAC Sponsor and each of the other Shareholders who are party to the MAAC Registration Rights Agreement agree that the MAAC Registration Rights Agreement is hereby terminated in its entirety, and shall be of no further force or effect from and after
such time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Anti-Dilution Adjustment Waiver</U>. Subject to, and conditioned upon the occurrence of and effective as of immediately
prior to the Effective Time, the MAAC Sponsor, which is the holder of at least a majority of the outstanding MAAC Class&nbsp;B Shares as of the date hereof, hereby waives on behalf of the holders of all MAAC Class&nbsp;B Shares, pursuant to and in
compliance with the provisions of the Amended and Restated Certificate of Incorporation of MAAC (the &#147;<U>MAAC Charter</U>&#148;), any adjustment to the conversion ratio set forth in Article Eighth of the MAAC Charter, and any rights to other
anti-dilution protections with respect to the MAAC Class&nbsp;B Shares, that may result from the PIPE Financing and/or the consummation of the Transactions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Registration Rights</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Capitalized terms used in this <U>Section</U><U></U><U>&nbsp;7</U> but not otherwise defined herein shall have the meanings ascribed to
them in the Registration Rights Agreement (as in effect as of the date hereof); <U>provided</U> that, for purposes of <U>Section</U><U></U><U>&nbsp;7</U>, (i) the term &#147;Registrable Securities&#148; shall be deemed to include the Common Shares
(including any Common Shares underlying any other securities of the Company or into which other securities of the Company are convertible into, exercisable or exchangeable for) held by or on behalf of the Shareholders as of immediately following the
Effective Time and (ii)&nbsp;the term &#147;Investor&#148; shall be deemed to include the MAAC Sponsor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company shall file within
thirty (30)&nbsp;days of the consummation of the Go Public Transaction, and use commercially reasonable efforts to cause to be declared effective as soon as practicable thereafter, a Resale <FONT STYLE="white-space:nowrap">S-1</FONT> Shelf or, if
the Company is eligible to use a Resale <FONT STYLE="white-space:nowrap">S-3</FONT> Shelf, in each case, covering the resale of all the Registrable Securities (determined as of two business days prior to such filing) and any other Common Shares or
other securities of the Company issued in connection with the Go Public Transaction (including any Common Shares underlying any other securities of the Company or into which other securities of the Company are convertible into, exercisable or
exchangeable for) the transfer or sale of which has not been registered under the Securities Act; <U>provided</U>, that the Company and the Shareholders acknowledge and agree that the sale of any Registrable Securities registered under such Resale
Shelf may be subject to restrictions imposed by the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements and/or applicable securities laws. Such Resale Shelf shall provide for the resale of the Registrable Securities included therein pursuant
to any method or combination of methods legally available to, and requested by, the MAAC Sponsor and any other Investor named therein. The MAAC Sponsor shall be entitled to the benefits of Section&nbsp;4 and the first, second and third sentences of
Section&nbsp;1(f)(ii), <U>mutatis</U> <U>mutandis</U>, under the Registration Rights Agreement with respect to its Common Shares or other securities of the Company and it shall not be subject to any &#147;cutback&#148; or other restriction in
connection with the inclusion of its Common Shares or other securities in any Resale Shelf. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The MAAC Sponsor will be offered an opportunity to participate in (x)&nbsp;an offering
and/or sale of Common Shares by any holder that is conducted as a block trade or underwritten basis (whether firm commitment or otherwise) without substantial marketing efforts prior to pricing, including, without limitation, a same day trade,
overnight trade or similar transaction or (y)&nbsp;an &#147;at the market&#148; or similar registered offering of the Covered Securities through a broker, sales agent or distribution agent, whether as agent or principal. The rights of the MAAC
Sponsor set forth in this <U>Section</U><U></U><U>&nbsp;7(c)</U> shall be substantially the same as those investors who are party to the Registration Rights Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Other Covenants and Agreements</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Shareholder shall not, and each Shareholder shall cause its controlled Affiliates and its and their respective officers and directors
not to, and shall use reasonable best efforts to cause its other Representatives not to, at or at any time prior to the Effective Time, issue any press releases or make any public announcements with respect to this Agreement, the Business
Combination Agreement or the transactions contemplated hereby or thereby that contain any information that is not, at the applicable time, already publicly available (other than as a result of disclosure by the Shareholder in violation of any
applicable confidentiality obligations) without the prior written consent of the Company and MAAC, <U>provided</U>, <U>however</U>, that the Shareholder and its Representatives may issue or make, as applicable, any such press release, public
announcement or other communication to the extent such press release, public announcement or other communication is required by applicable Law or applicable rule of a stock exchange on which its or any of its Affiliates&#146; securities are listed,
in which case the Shareholder or its applicable Affiliates shall, to the extent reasonably practicable and unless and to the extent prohibited by such applicable Law, reasonably consult with the Company and MAAC in connection therewith and provide
the Company and MAAC with an opportunity to review and comment on such press release, public announcement or communication and shall consider any such comments in good faith. Notwithstanding anything to the contrary in this Section&nbsp;8(a) or
otherwise in this Agreement, each Shareholder and its Representatives may provide general information about the subject matter of this Agreement, the Business Combination Agreement and the transactions contemplated hereby and thereby (1)&nbsp;to
their respective affiliates, their and their affiliates&#146; respective directors, officers, employees, partners, members, agents, attorneys and consultants, financial and other advisors, (2)&nbsp;to the extent required by any federal, state,
national, foreign or other regulatory or self-regulatory authority having jurisdiction over the Shareholder or its Representatives, (3)&nbsp;to any Person if necessary to effect compliance with any law, rule, regulation, investigation, audit,
request or order of a Governmental Entity of competent jurisdiction that is applicable to the Shareholder or its Representatives, including in response to any subpoena or other legal process, audit or examinations or (4)&nbsp;to any direct or
indirect former, current or prospective investor or in connection with normal fund raising or related marketing or informational or reporting activities (so long as, in the case of this clause (4), the recipients of such information are subject to
customary confidentiality obligations prior to the receipt of such information); provided further that in the case of the foregoing clause (2)&nbsp;and (3), each Shareholder </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or its Representatives promptly notifies the Company of such disclosure to the extent the Shareholder or its Representatives are legally permitted to give such notice and it is reasonably
practicable; provided further that no such notice shall be required where disclosure is made (x)&nbsp;in response to and required by a general request by a regulatory or self-regulatory authority of competent jurisdiction or (y)&nbsp;in connection
with and required by a routine audit or examination by a bank examiner or auditor and such audit or examination does not reference the Company, this Agreement or the Business Combination Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If applicable, prior to the Effective Time, each Shareholder hereby agrees to as promptly as practicable execute and deliver all additional
agreements, documents or instruments, take, or cause to be taken, all actions and provide, or cause to be provided, all additional information or other materials as may be necessary or reasonably advisable, in each case, as mutually reasonably
determined and agreed to by MAAC and the Company (such determination and agreement not to be unreasonably withheld, conditioned or delayed by either MAAC or the Company), in connection with, or otherwise in furtherance of, the transactions and the
other covenants and agreements contemplated by the Business Combination Agreement or this Agreement (<U>provided</U>, <U>however</U>, that in no event shall any Shareholder be obligated to take, approve or consent to any action that would result in
any adverse economic or other material change to the Business Combination Agreement, this Agreement or any other Ancillary Document to which he, she or it is or will be a party). If applicable, from and after the Effective Time, MAAC Sponsor and the
Company each hereby agrees to as promptly as practicable execute and deliver execute and deliver all additional agreements, documents or instruments, take, or cause to be taken, all actions and provide, or cause to be provided, all additional
information or other materials as may be reasonably necessary to effectuate the purpose of the covenants and agreements of this Agreement that survive the Effective Time. Notwithstanding the foregoing, no Shareholder or the Company shall be required
to provide any information which is, based on the advice of outside counsel, subject to legal privilege. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Without limiting
<U>Section</U><U></U><U>&nbsp;8(b)</U>, the MAAC Sponsor and the Company shall each (i)&nbsp;make any appropriate filings pursuant to the HSR Act with respect to the Company Post-Closing Common Shares to be received by the MAAC Sponsor pursuant to
the terms of the Business Combination Agreement as promptly as reasonably practicable (and in any event within ten (10)&nbsp;Business Days) following the date of this Agreement, (ii)&nbsp;use reasonable best efforts to obtain any other approvals of
any Governmental Entity as may be required to be obtained by the MAAC Sponsor or the Company in connection with the receipt by the MAAC Sponsor of the Company Post-Closing Common Shares to be received by the MAAC Sponsor pursuant to the terms of the
Business Combination Agreement and (iii)&nbsp;respond as promptly as reasonably practicable to any requests by any Governmental Entity for additional information and documentary material that may be requested pursuant to the HSR Act or in connection
with such other required approvals of any Governmental Entity described in clause (ii). The MAAC Sponsor and the Company shall each pay fifty percent (50%) of the HSR Act filing fee. Without limiting the foregoing, the MAAC Sponsor and its
applicable Affiliates and the Company and its applicable Affiliates shall not (A)&nbsp;extend any waiting period, review period or comparable period under the HSR Act or in connection with such other required approvals of any Governmental Entity,
(B)&nbsp;request early termination of any waiting period, review period or comparable period under the HSR Act without the prior written consent of the MAAC Sponsor (in the case of the Company or any of its applicable Affiliates) or the Company (in
the case of the MAAC Sponsor or any of its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable Affiliates) or (C)&nbsp;enter into any agreement with any Governmental Entity not to consummate the transactions contemplated by the Business Combination Agreement except with the
prior written consent of the Company and MAAC (in the case of MAAC Sponsor or any of its applicable Affiliates) or MAAC Sponsor (in the case of the Company or any of its applicable Affiliates). The MAAC Sponsor shall promptly inform the Company and
MAAC of any communication received by the MAAC Sponsor from any Governmental Entity relating to the matters contemplated by this <U>Section</U><U></U><U>&nbsp;8(c)</U>, and the Company shall promptly inform the MAAC Sponsor and MAAC of any
communication received by any Group Company from any Governmental Entity relating to the matters contemplated by this <U>Section</U><U></U><U>&nbsp;8(c)</U>. The MAAC Sponsor shall give the Company and its counsel, and MAAC and its counsel, a
reasonable opportunity to review in advance, and consider in good faith the views thereof in connection with, any proposed written communication to any Governmental Entity relating to the matters contemplated by this
<U>Section</U><U></U><U>&nbsp;8(c)</U>, and the Company shall give MAAC Sponsor and its counsel and MAAC and its counsel a reasonable opportunity to review in advance, and consider in good faith the views thereof in connection with, any proposed
written communication to any Governmental Entity relating to the matters contemplated by this <U>Section</U><U></U><U>&nbsp;8(c)</U>. The MAAC Sponsor and the Company each agrees not to, and to cause its Representatives not to, participate in any
substantive meeting or discussion, either in person or by telephone with any Governmental Entity in connection with the matters contemplated by this <U>Section</U><U></U><U>&nbsp;8(c)</U> unless it consults with the Company and MAAC (in the case of
the MAAC Sponsor or its Representatives) or the MAAC Sponsor and MAAC (in the case of the Company or its Representatives) in advance and, to the extent not prohibited by such Governmental Entity, gives the Company and MAAC (in the case of the MAAC
Sponsor or its Representatives) or the MAAC Sponsor and MAAC (in the case of the Company or its Representatives) the opportunity to attend and participate in such meeting or discussion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Each Shareholder acknowledges and agrees that MAAC and the Company are entering into the Business Combination Agreement in reliance upon
such Shareholder entering into this Agreement and agreeing to be bound by, and perform, or otherwise comply with, as applicable, the applicable agreements, covenants and obligations contained in this Agreement and, but for each Shareholder entering
into this Agreement and agreeing to be bound by, and perform, or otherwise comply with, as applicable, the applicable agreements, covenants and obligations contained in this Agreement, MAAC and the Company would not have entered into or agreed to
consummate the transactions contemplated by the Business Combination Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Shareholder Representations and Warranties</U>. Each
Shareholder represents and warrants, as of the date hereof, solely with respect to himself, herself or itself, and not on behalf of any other Shareholder, to the Company and MAAC as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If the Shareholder is not an individual, the Shareholder is a corporation, limited liability company or other applicable business entity
duly organized or formed, as applicable, validly existing and in good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under
the Laws of its jurisdiction of formation or organization (as applicable). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Shareholder (if not an individual) has the requisite corporate, limited liability
company or other similar power and authority and, if the Shareholder is an individual, legal capacity to execute and deliver this Agreement, to perform his, her or its covenants, agreements and obligations hereunder (including, for the avoidance of
doubt, those covenants, agreements and obligations hereunder that relate to the provisions of the Business Combination Agreement), and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement has been duly
authorized by all necessary corporate or other action on the part of the Shareholder. This Agreement has been duly and validly executed and delivered by the Shareholder and constitutes a valid, legal and binding agreement of the Shareholder
(assuming that this Agreement is duly authorized, executed and delivered by the other parties hereto), enforceable against the Shareholder in accordance with its terms (subject to applicable bankruptcy, insolvency, reorganization, moratorium or
other Laws affecting generally the enforcement of creditors&#146; rights and subject to general principles of equity). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) No consent,
approval or authorization of, or designation, declaration or filing with, any Governmental Entity is required on the part of the Shareholder with respect to the Shareholder&#146;s execution, delivery or performance of his, her or its covenants,
agreements or obligations under this Agreement (including, for the avoidance of doubt, those covenants, agreements and obligations under this Agreement that relate to the provisions of the Business Combination Agreement) or the consummation of the
transactions contemplated hereby, except for (A)&nbsp;compliance with and filings under the HSR Act, if applicable, or under any applicable Foreign and Domestic Approval Laws, (B)&nbsp;any filings with the SEC related to his, her or its ownership of
Equity Securities of MAAC or Company Post-Closing Common Shares or the transactions contemplated by the Business Combination Agreement, this Agreement or any other Ancillary Documents to which he, she or it is a party, or (C)&nbsp;any other
consents, approvals, authorizations, designations, declarations, waivers or filings, the absence of which would not reasonably be expected to adversely affect the ability of the Shareholder to perform, or otherwise comply with, any of his, her or
its covenants, agreements or obligations hereunder in any material respect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) None of the execution or delivery of this Agreement by the
Shareholder, the performance by the Shareholder of any of his, her or its covenants, agreements or obligations under this Agreement (including, for the avoidance of doubt, those covenants, agreements and obligations under this Agreement that relate
to the provisions of the Business Combination Agreement) or the consummation of the transactions contemplated hereby will, directly or indirectly (with or without due notice or lapse of time or both)&nbsp;(i) if the Shareholder is not an individual,
result in any breach of any provision of the Shareholder&#146;s Governing Documents, (ii)&nbsp;result in a violation or breach of, or constitute a default or give rise to any right of termination, Consent, cancellation, amendment, modification,
suspension, revocation or acceleration under, any of the terms, conditions or provisions of any Contract to which the Shareholder is a party, (iii)&nbsp;violate, or constitute a breach under, any Order or applicable Law to which the Shareholder or
any of his, her or its properties or assets are bound or (iv)&nbsp;other than the restrictions contemplated by this Agreement, the Business Combination Agreement or any other Ancillary Document, result in the creation of any Lien upon the Subject
Company Securities (other than as expressly provided under this Agreement), except, in the case of any of <U>clauses</U><U></U><U>&nbsp;(ii)</U> and <U>(iii)</U>&nbsp;above, as would not reasonably be expected to adversely affect the ability of the
Shareholder to perform, or otherwise comply with, any of his, her or its covenants, agreements or obligations hereunder in any material respect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Shareholder is, as of the date hereof, the record and beneficial owner of the
Subject Company Securities as set forth on <U>Exhibit A</U> hereto. The Shareholder has the sole right to vote (and provide consent in respect of, as applicable) the Subject Company Securities set forth on <U>Exhibit A</U> hereto as of the date
hereof. Except for this Agreement, the Business Combination Agreement, the other Ancillary Documents to which he, she or it is or will be a party, the Affected Agreements and the Governing Documents of MAAC, the Shareholder is not party to or bound
by (i)&nbsp;any option, warrant, purchase right or other Contract that would reasonably be expected (either alone or in connection with one or more events, developments or events (including the satisfaction or waiver of any conditions precedent)) to
require the Shareholder to Transfer any of the Subject Company Securities or (ii)&nbsp;any voting trust, proxy or other Contract with respect to the voting or Transfer of any of the Subject Company Securities, in the case of either clause
(i)&nbsp;or (ii), that would reasonably be expected to adversely affect the ability of the Shareholder to perform, or otherwise comply with, any of his, her or its covenants, agreements or obligations hereunder in any material respect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) There is no Proceeding pending or, to the Shareholder&#146;s knowledge, threatened against or involving the Shareholder or any of his, her
or its Affiliates that, if adversely decided or resolved, would reasonably be expected to adversely affect the ability of the Shareholder to perform, or otherwise comply with, any of its covenants, agreements or obligations under this Agreement in
any material respect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The Shareholder, on his, her or its own behalf and on behalf of his, her or its Representatives, acknowledges,
represents, warrants and agrees that he, she or it has conducted his, her or its own independent review and analysis of, and, based thereon, has formed an independent judgment concerning, the business, assets, condition, operations and prospects of,
the Company and the transactions contemplated by this Agreement, the Business Combination Agreement and the other applicable Ancillary Documents to which he, she or it is or will be a party as he, she or it and his, her or its Representatives have
deemed necessary to enable him, her or it to make an informed decision with respect to the execution, delivery and performance of this Agreement or the other Ancillary Documents to which he, she or it is or will be a party and the transactions
contemplated hereby and thereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) In entering into this Agreement and the other Ancillary Documents to which he, she or it is or will
be a party, the Shareholder has relied solely on his, her or its own investigation and analysis and the representations and warranties expressly set forth in the Ancillary Documents to which he, she or it is or will be a party and no other
representations or warranties of MAAC, the Company or any other Person, either express or implied, and the Shareholder, on his, her or its own behalf and on behalf of his, her or its Representatives, acknowledges, represents, warrants and agrees
that, except for the representations and warranties expressly set forth in this Agreement or in the other Ancillary Documents to which he, she or it is or will be a party, none of MAAC, the Company or any other Person makes or has made any
representation or warranty, either express or implied, to the Shareholder in connection with or related to this Agreement, the Business Combination Agreement or the other Ancillary Documents or the transactions contemplated hereby or thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Company and MAAC Acknowledgement</U>. In entering into this Agreement, the Business
Combination Agreement and the other Ancillary Documents to it is or will be a party, each of the Company and MAAC have not relied on any representations or warranties of the Shareholder, either express or implied, except for the representations and
warranties of the Shareholder expressly set forth in this Agreement or in the other Ancillary Documents to which he, she or it is or will be a party and to which MAAC or the Company, as applicable, is or will be a party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Transfer of Subject Company Securities</U>. From and after the date hereof and until the earlier of (A)&nbsp;the termination of this
Agreement in accordance with its terms and (B)&nbsp;the Effective Time, each Shareholder agrees not to (a)&nbsp;Transfer any of the Subject Company Securities, (b)&nbsp;enter into (i)&nbsp;any option, warrant, purchase right, or other Contract that
would reasonably be expected (either alone or in connection with one or more events, developments or events (including the satisfaction or waiver of any conditions precedent)) to require the Shareholder to Transfer the Subject Company Securities or
(ii)&nbsp;any voting trust, proxy or other Contract with respect to the voting or Transfer of the Subject Company Securities, or (c)&nbsp;take any actions in furtherance of any of the matters described in the foregoing clauses (a)&nbsp;or (b),
unless, in the case of clauses (a)&nbsp;through (c), the Shareholder causes any transferee of any such Transfer to enter into a written agreement in form and substance reasonably satisfactory to MAAC and the Company agreeing to be bound by this
Agreement (which will include, for the avoidance of doubt, all of the covenants, agreements and obligations of the Shareholder hereunder and the making of all the representations and warranties of the Shareholder set forth in
<U>Section</U><U></U><U>&nbsp;9</U> with respect to such transferee and his, her or its Subject Company Securities received upon such Transfer, as applicable) prior and as a condition to the occurrence of such Transfer; <U>provided</U> that, if the
Shareholder is not an individual, a Transfer of securities in the Shareholder by an equityholder of the Shareholder shall not require the transferee to enter into such written agreement so long as (x)&nbsp;following such Transfer, the Shareholder
continues to hold the Subject Company Securities and to have the exclusive right to vote and to take all other actions related to the ownership of the Subject Company Securities without restriction and (y)&nbsp;such Transfer would otherwise be
permitted under the Shareholders Agreement. For purposes of this Agreement, &#147;<U>Transfer</U>&#148; means any direct or indirect sale, transfer, assignment, pledge, mortgage, exchange, hypothecation, grant of a security interest in or
disposition or encumbrance of an interest (whether with or without consideration, whether voluntarily or involuntarily or by operation of law or otherwise). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Termination</U>. This Agreement shall automatically terminate, without any notice or other action by any Party, and be void <I>ab
initio</I> upon the termination of the Business Combination Agreement in accordance with its terms. Upon termination of this Agreement as provided in the immediately preceding sentence, none of the Parties shall have any further obligations or
Liabilities under, or with respect to, this Agreement. Notwithstanding the foregoing or anything to the contrary in this Agreement, (i)&nbsp;the termination of this Agreement shall not affect any Liability on the part of any Party for a Willful
Breach of any covenant or agreement set forth in this Agreement prior to such termination or Fraud, (ii)<U>&nbsp;Section</U><U></U><U>&nbsp;10</U>, this <U>Section</U><U></U><U>&nbsp;12</U> and the representations and warranties set forth in
<U>Sections 9(g)</U> and <U>(h)</U>&nbsp;shall each survive any termination of this Agreement, and (iii)<U>&nbsp;Sections 13</U> through <U>21</U> shall survive any termination of this Agreement. For purposes of this
<U>Section</U><U></U><U>&nbsp;12</U>, (x) &#147;<U>Willful Breach</U>&#148; means a material breach of this Agreement that is a consequence of an act or a failure to act by the breaching Party with the knowledge that the taking of such act or such
failure to act would, or would reasonably be expected to, constitute or result in a breach of this Agreement and (y) &#147;<U>Fraud</U>&#148; means an act or omission by a Party, and requires: (A)&nbsp;a false or incorrect representation or warranty
expressly made by such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Party in this Agreement, (B)&nbsp;with actual knowledge (as opposed to constructive, imputed or implied knowledge) by the Party making such representation or warranty that such representation or
warranty expressly set forth in this Agreement is false or incorrect, (C)&nbsp;an intention to deceive another Party, to induce him, her or it to enter into this Agreement, (D)&nbsp;another Party, in justifiable or reasonable reliance upon such
false or incorrect representation or warranty expressly set forth in this Agreement, entering into this Agreement, and (E)&nbsp;another Party suffering damage by reason of such reliance. For the avoidance of doubt, &#147;Fraud&#148; does not include
any claim for equitable fraud, promissory fraud, unfair dealings fraud or any torts (including a claim for fraud or alleged fraud) based on negligence or recklessness. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Fiduciary Duties</U>. Notwithstanding anything in this Agreement to the contrary, (a)&nbsp;the Shareholder makes no agreement or
understanding herein in any capacity other than in such Shareholder&#146;s capacity as a record holder and beneficial owner of the Subject Company Securities and, (i.e., if such Shareholder is an individual, not in such Shareholder&#146;s capacity
as a director, officer or employee of MAAC), and (b)&nbsp;nothing herein will be construed to limit or affect any action or inaction by such Shareholder if such Shareholder is an individual, or, if such Shareholder is not an individual, any
representative of such Shareholder serving as a member of the board of directors of MAAC or as an officer, employee or fiduciary of MAAC, in each case, acting in such person&#146;s capacity as a director, officer, employee or fiduciary of MAAC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Notices</U>. All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given (and shall
be deemed to have been duly given) by delivery in person, by <FONT STYLE="white-space:nowrap">e-mail</FONT> (having obtained electronic delivery confirmation thereof (i.e., an electronic record of the sender that the email was sent to the intended
recipient thereof without an &#147;error&#148; or similar message that such email was not received by such intended recipient)), or by registered or certified mail (postage prepaid, return receipt requested) (upon receipt thereof) to the other
Parties as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to MAAC or the MAAC Sponsor, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">c/o Patient Square Capital </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">724
Oak Grove Ave, Suite 130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Menlo Park, California 94025 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;Maria Walker </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;maria@patientsquarecapital.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Kirkland&nbsp;&amp; Ellis LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">601 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York,
NY 10022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;Michael Weisser, P.C.; Ryan Brissette; Sharon Freiman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;michael.weisser@kirkland.com; ryan.brissette@kirkland.com; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
sharon.freiman@kirkland.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the Company, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Roivant Sciences Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Suite 1,
3rd Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">11-12</FONT> St. James&#146;s Square </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">London SW1Y 4LB </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">United Kingdom
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;Matthew Gline </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;matthew.gline@roivant.com;
legalnotices@roivant.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Roivant Sciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">151 West
42nd Street, 15th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, NY 10036 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; jo.chen@roivant.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Davis Polk&nbsp;&amp; Wardwell LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">450 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York,
NY 10017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;Derek Dostal; Lee Hochbaum; Brian Wolfe </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;derek.dostal@davispolk.com; lee.hochbaum@davispolk.com; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;brian.wolfe@davispolk.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">if to a Shareholder other than the MAAC Sponsor, to the address on the Shareholder&#146;s signature page hereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as the Party to whom notice is given may have previously furnished to the others in writing in the manner set forth above. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Entire Agreement</U>. This Agreement, the Business Combination Agreement and documents referred to herein and therein (including the
Ancillary Documents) constitute the entire agreement of the Parties with respect to the subject matter of this Agreement, and supersede all prior agreements and undertakings, both written and oral, among the Parties with respect to the subject
matter of this Agreement, except as otherwise expressly provided in this Agreement. In the event and to the extent that there shall be a conflict between the provisions of this Agreement and the provisions of any Affected Agreement, this Agreement
shall control with respect to the subject matter thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Amendments and Waivers; Assignment</U>. Any provision of this Agreement
may be amended or waived if, and only if, such amendment or waiver is in writing and signed by the Shareholders, the Company and MAAC. Notwithstanding the foregoing, no failure or delay by any Party in exercising any right hereunder shall operate as
a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise of any other right hereunder. Subject to <U>Section</U><U></U><U>&nbsp;2(d)</U>, neither this Agreement nor any of the rights, interests or
obligations hereunder shall be assignable by a Shareholder or the Company without MAAC&#146;s prior written consent (to be withheld or given in its sole discretion) or by MAAC without the Company&#146;s prior written consent (to be withheld or given
in its sole discretion). Any attempted assignment of this Agreement not in accordance with the terms of this <U>Section</U><U></U><U>&nbsp;16</U> shall be null and void <I>ab initio</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Fees and Expenses</U>. Except, in the case of MAAC and the Company, as otherwise
expressly set forth in the Business Combination Agreement, all fees and expenses incurred in connection with this Agreement and the transactions contemplated hereby, including the fees and disbursements of counsel, financial advisors and
accountants, shall be paid by the Party incurring such fees or expenses; <U>provided</U>, that, any such reasonable and documented fees and expenses incurred by the Shareholders in connection with this Agreement and the transactions contemplated
hereby on or prior to the Closing shall be deemed to be fees and expenses of MAAC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>No Third Party Beneficiaries</U>. Except as set
forth in <U>Section</U><U></U><U>&nbsp;2(d)</U>, this Agreement shall be for the sole benefit of the Parties and their respective successors and permitted assigns and is not intended, nor shall be construed, to give any Person, other than the
Parties and their respective successors and permitted assigns, any legal or equitable right, benefit or remedy of any nature whatsoever by reason this Agreement. Nothing in this Agreement, expressed or implied, is intended to, or shall be deemed to,
create a joint venture. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Miscellaneous</U>. <U>Sections 8.5</U> (Governing Law), <U>8.7</U> (Construction; Interpretation),
<U>8.10</U> (Severability), <U>8.11</U> (Counterparts; Electronic Signatures), <U>8.15</U> (Waiver of Jury Trial), <U>8.16</U> (Submission to Jurisdiction) and <U>8.17</U> (Remedies) of the Business Combination Agreement are incorporated herein by
reference and shall apply to this Agreement, <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>No Ownership Interest</U>. Nothing contained in this
Agreement will be deemed to vest in the Company, any Company <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate, or any MAAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate any direct or indirect ownership or incidents of
ownership of or with respect to the Subject Company Securities. All rights, ownership and economic benefits of and relating to the Subject Company Securities shall remain vested in and belong to each Shareholder, and the Company and MAAC (and each
other Company <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate and MAAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate) shall have no authority to manage, direct, superintend, restrict, regulate, govern or administer any of
the policies or operations of Company or exercise any power or authority to direct any Shareholder in the voting of any of the Subject Company Securities, except as otherwise expressly provided herein with respect to the Subject Company Securities.
Except as otherwise set forth in Section&nbsp;1, no Shareholder shall not be restricted from voting in favor of, against or abstaining with respect to any other matters presented to the stockholders of MAAC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Spouses and Community Property Matters</U>. Each Shareholder&#146;s spouse (if applicable) hereby represents, warrants and covenants to
MAAC and the Company that such spouse shall not assert or enforce, and does hereby waive, any rights granted under any community property statue with respect to the Subject Company Securities that would adversely affect (x)&nbsp;the covenants made
by the applicable Shareholder pursuant to this Agreement or (y)&nbsp;the transactions contemplated by the Business Combination Agreement and the Ancillary Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>No Recourse</U>. Except for claims pursuant to the Business Combination Agreement or
any Ancillary Document by any party(ies) thereto against any other party(ies) on the terms and subject to the conditions therein, each Party agrees that (a)&nbsp;this Agreement may only be enforced against, and any action for breach of this
Agreement may only be made against, the Parties, and no claims of any nature whatsoever arising under or relating to this Agreement, the negotiation hereof or its subject matter, or the transactions contemplated hereby shall be asserted against any
Person that is not a Party, and (b)&nbsp;without limiting the generality of the foregoing, no Person that is not a Party shall have any Liability arising out of or relating to this Agreement, the negotiation hereof or its subject matter, or the
transactions contemplated hereby, including with respect to any claim (whether in tort, contract or otherwise) for breach of this Agreement or in respect of any written or oral representations made or alleged to be made in connection herewith,
except as expressly provided herein. Notwithstanding anything to the contrary in this Agreement, (i)&nbsp;in no event shall any Shareholder have any obligations or Liabilities related to or arising out of the covenants, agreements, obligations,
representations or warranties of any other Shareholder under this Agreement (including related to or arising out of the breach of any such covenant, agreement, obligation, representation or warranty by any other Shareholder), and (ii)&nbsp;in no
event shall MAAC have any obligations or Liabilities related to or arising out of the covenants, agreements, obligations, representations or warrants of any Shareholder under this Agreement (including related to or arising out of any breach of any
such covenant, agreement, obligation, representation or warranty by any such Shareholder). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.
<U><FONT STYLE="white-space:nowrap">Non-Survival</FONT></U>. The representations, warranties, agreements and covenants in this Agreement shall terminate at the Effective Time, except for those covenants and agreements in this Agreement that, by
their terms, expressly contemplate performance or survival after the Effective Time, which covenants and agreements shall so survive the Effective Time in accordance with their terms; <I>provided </I>that the foregoing shall not limit any
Party&#146;s rights in the event of another Party&#146;s Willful Breach of any agreement and covenant set forth in Section&nbsp;4(a) or Section&nbsp;11 prior to the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page(s) follow(s).] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed and delivered this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROIVANT SCIENCES LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matt Maisak</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Matt Maisak</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Sponsor Support Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">N WITNESS WHEREOF, the Parties have executed and delivered this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MONTES ARCHIMEDES ACQUISITION CORP.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Maria C. Walker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Maria C. Walker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Sponsor Support Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed and delivered this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PATIENT SQUARE CAPITAL LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Maria C. Walker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Maria C. Walker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Sponsor Support Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed and delivered this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INSIDERS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ George Barrett</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">George Barrett</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom" BGCOLOR="#000000">&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#000000"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#000000">&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#000000"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Sponsor Support Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed and delivered this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INSIDERS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James C. Momtazee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">James C. Momtazee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom" BGCOLOR="#000000">&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#000000"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#000000">&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#000000"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Sponsor Support Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed and delivered this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INSIDERS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Maria C. Walker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Maria C. Walker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom" BGCOLOR="#000000">&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#000000"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#000000">&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#000000"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Sponsor Support Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed and delivered this Agreement as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INSIDERS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Steve Oesterle</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Steve Oesterle</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom" BGCOLOR="#000000">&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#000000"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#000000">&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#000000"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Sponsor Support Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A &#151; MAAC Security Ownership </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A common stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B common stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Private Placement Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owners</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Approximate<BR>Percentage<BR>of Class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Approximate<BR>Percentage<BR>of Class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Approximate<BR>Percentage<BR>of Class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patient Square Capital LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,167,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,214,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James C. Momtazee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,167,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maria C. Walker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George Barrett</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">**&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Stephen Oesterle</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">**&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1% </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Exhibit A to Sponsor
Support Agreement] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE A </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The letter, dated as of October&nbsp;6, 2020, regarding &#147;administrative support agreement&#148; by and
between MAAC and the MAAC Sponsor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Securities Subscription Agreement, dated as of July&nbsp;23, 2020, by and between MAAC and the MAAC
Sponsor. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Exhibit B to Sponsor
Support Agreement]</I> </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>7
<FILENAME>d307489dex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[FORM OF] TRANSACTION SUPPORT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>TRANSACTION SUPPORT AGREEMENT</B> (this &#147;<U>Agreement</U>&#148;) is entered into as of May&nbsp;1, 2021, by and among Montes
Archimedes Acquisition Corp., a Delaware corporation (&#147;<U>MAAC</U>&#148;), Roivant Sciences Ltd., a Bermuda exempted limited company (the &#147;<U>Company</U>&#148;), and [&#149;], a [&#149;] ([collectively,] the
&#147;<U>Shareholder</U>&#148;).<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> Each of MAAC, the Company and the Shareholder are sometimes referred to herein individually as a &#147;<U>Party</U>&#148; and collectively as the
&#147;<U>Parties</U>&#148;. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Business Combination Agreement (as defined below). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
concurrently with the execution of this Agreement, MAAC, the Company and Rhine Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#147;<U>Merger Sub</U>&#148;), entered into that certain Business Combination
Agreement (as amended, supplemented or otherwise modified from time to time in accordance with its terms, the &#147;<U>Business Combination Agreement</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Business Combination Agreement contemplates that, on the terms and subject to the conditions therein, (a)&nbsp;on the
Closing Date prior to the Closing, the Company will consummate the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, and (b)&nbsp;on the Closing Date promptly following consummation of the Company
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps, Merger Sub will merge with and into MAAC, with MAAC as the surviving corporation in the merger and, after giving effect to such merger, becoming a wholly-owned Subsidiary of the Company;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Shareholder is, as of the date hereof, the record and beneficial owner of the number and class or series (as
applicable) of the Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares set forth on <U>Schedule A</U> hereto (together with any other Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares that the
Shareholder acquires record or beneficial ownership of after the date hereof and prior to the Effective Time, collectively, the &#147;<U>Subject Company Shares</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in consideration for the benefits to be received by the Shareholder under the terms of the Business Combination Agreement and
as a material inducement to the Company and MAAC agreeing to enter into and consummate the transactions contemplated by the Business Combination Agreement, the Shareholder agrees to enter into this Agreement and to be bound by the agreements,
covenants and obligations contained in this Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Parties acknowledge and agree that the Company and MAAC
would not have entered into and agreed to consummate the transactions contemplated by the Business Combination Agreement without the Shareholder entering into this Agreement and agreeing to be bound by the agreements, covenants and obligations
contained in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the premises and the mutual promises set forth herein and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows: </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to institutional investors, this Agreement is to be executed by all entities that hold Company
Pre-Closing Common Shares. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Company Shareholder Consent and Related Matters.</U> Prior to the earlier of (A)&nbsp;the termination of this Agreement in accordance
with its terms and (B)&nbsp;the Effective Time, (i)&nbsp;to the extent that it is necessary or reasonably advisable, in each case, as mutually reasonably determined and agreed by MAAC and the Company (such determination and agreement not to be
unreasonably withheld, conditioned or delayed by either MAAC or the Company, as applicable) for matters, actions or proposals to be approved by the Shareholder in connection with, or otherwise in furtherance of, the transactions contemplated by the
Business Combination Agreement and/or the Ancillary Documents, if any, the Shareholder shall vote (or cause to be voted) the Subject Company Shares in favor of and/or consent to any such matters, actions or proposals promptly following written
request thereof from MAAC and the Company, as applicable (<I>provided</I>, <I>however</I>, that the Shareholder shall not be required to vote for, or consent to, any action that would result in any adverse economic or other material changes to the
form of the Business Combination Agreement and/or the Ancillary Documents as approved by the Board of Directors of the Company on or prior to the date hereof (any such action, an &#147;<U>Adverse Action</U>&#148;)), and (ii)&nbsp;the Shareholder
shall vote (or cause to be voted) the Subject Company Shares against and withhold consent with respect to (A)&nbsp;any Company Acquisition Proposal or (B)&nbsp;any other matter, action or proposal that would reasonably be expected to result in
(x)&nbsp;a breach of any of the Company&#146;s covenants, agreements or obligations under the Business Combination Agreement or (y)&nbsp;any of the conditions to the Closing set forth in Article VI of the Business Combination Agreement not being
satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Other Covenants and Agreements</U>.<U> </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Shareholder and the Company hereby agrees that, notwithstanding anything to the contrary in any such agreement, (i)&nbsp;each of the
agreements set forth on <U>Schedule B</U> hereto shall be automatically terminated and of no further force and effect (including any provisions of any such agreement that, by its terms, survive such termination, effective as of, and subject to and
conditioned upon the occurrence of, the Closing and (ii)&nbsp;upon such termination neither the Company nor any of its Affiliates (including the other Group Companies and, from and after the Effective Time, MAAC and its Affiliates) shall have any
further Liabilities under each such agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Shareholder acknowledges and agrees that the Shareholder is, and during the term
of this Agreement shall continue to be, bound by the confidentiality obligations set forth in the Sixth Amended and Restated Shareholders Agreement, dated June&nbsp;17, 2020, by and among the Company and the Company Shareholders party thereto (the
&#147;<U>Shareholders Agreement</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Shareholder shall not, and the Shareholder shall cause its controlled Affiliates and
its and their respective officers and directors not to, and shall use reasonable best efforts to cause its other Representatives not to, at or at any time prior to the Effective Time, issue any press releases or make any public announcements with
respect to this Agreement, the Business Combination Agreement or the transactions contemplated hereby or thereby that contain any information that is not, at the applicable time, already publicly available (other than as a result of disclosure by
the Shareholder in violation of any applicable confidentiality obligations) without the prior written consent of the Company and MAAC; <I>provided</I>, <I>however</I>, that the Shareholder and its Representatives may issue or make, as applicable,
any such press release, public announcement or other communication if such press release, public announcement or other communication is required by applicable Law or applicable rule of a stock exchange on which its or any of its Affiliates&#146;
securities are listed, in which case the Shareholder or its applicable Representatives shall, to the extent reasonably practicable and unless and to the extent prohibited by such applicable Law, reasonably consult with the Company and MAAC in
connection therewith and provide the Company and MAAC with an opportunity to review and comment on such press release, public announcement or communication and shall consider any such comments in good faith. Notwithstanding anything to the contrary
in this <U>Section</U><U></U><U>&nbsp;2(c)</U> or otherwise in this Agreement, the Shareholder and its Representatives may provide general information about the subject matter of this Agreement, the Business Combination Agreement and the
transactions contemplated hereby and thereby (1)&nbsp;to their respective affiliates, their and their affiliates&#146; respective directors, officers, employees, partners, members, agents, attorneys, consultants and financial and other advisors, and
potential sources of capital (including potential limited partners), (2) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the extent required by any federal, state, national, foreign or other regulatory or self-regulatory authority having jurisdiction over the Shareholder or its Representatives, (3)&nbsp;to any
Person if necessary to effect compliance with any law, rule, regulation, investigation, audit, request or order of a Governmental Entity of competent jurisdiction that is applicable to the Shareholder or its Representatives, including in response to
any subpoena or other legal process, audit or examinations or (4)&nbsp;to any direct or indirect former, current or prospective investor or in connection with normal fund raising or related marketing or informational or reporting activities (so long
as, in the case of this clause (4), the recipients of such information are subject to customary confidentiality obligations prior to the receipt of such information); <I>provided</I> <I>further</I> that in the case of the foregoing clause (1), the
recipients of such information are subject to policies to protect such confidential information or agree to hold confidential the information in a manner substantially consistent with the terms of the confidentiality provisions of the Shareholders
Agreement and that, in the case of the foregoing clauses (2)&nbsp;and (3), the Shareholder or its Representatives promptly notifies the Company of such disclosure to the extent the Shareholder or its Representatives are legally permitted to give
such notice and it is reasonably practicable; <I>provided</I> <I>further</I> that no such notice shall be required where disclosure is made (x)&nbsp;in response to and required by a general request by a regulatory or self-regulatory authority of
competent jurisdiction or (y)&nbsp;in connection with and required by a routine audit or examination by a bank examiner or auditor and such audit or examination does not reference the Company, this Agreement or the Business Combination Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Shareholder (i)&nbsp;shall be bound by and subject to <U>Section</U><U></U><U>&nbsp;8.18</U> (Trust Account Waiver) of the
Business Combination Agreement to the same extent as such provisions apply to the Company, as if the Shareholder is directly party thereto, and (ii)&nbsp;shall vote its Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares,
exercise its director appointment and termination rights, execute any documents and otherwise use its reasonable best efforts to take, or cause to be taken, all actions, in each case, as may be necessary or appropriate so that, immediately after the
Effective Time, the Company Board consists of the number of directors, and is comprised of the individuals, determined pursuant to <U>Section</U><U></U><U>&nbsp;5.16(a)</U> (Post-Closing Directors) of the Business Combination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) [Except with respect to the transactions contemplated by the PIPE Subscription Agreement entered into by and among the Shareholder, the
Company and MAAC on the date hereof (the &#147;<U>Shareholder PIPE Subscription</U>&#148;),]<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> if applicable, the Shareholder hereby agrees to promptly execute and deliver all additional
agreements, documents or instruments, take, or cause to be taken, all actions and provide, or cause to be provided, all additional information or other materials as may be necessary or reasonably advisable, in each case, as mutually reasonably
determined and agreed to by MAAC and the Company (such determination and agreement not to be unreasonably withheld, conditioned or delayed by either MAAC or the Company), in connection with, or otherwise in furtherance of, the transactions and the
other covenants and agreements contemplated by the Business Combination Agreement or this Agreement (<I>provided</I>, <I>however</I>, that in no event shall the Shareholder be obligated to take, approve or consent to an Adverse Action).
Notwithstanding the foregoing, the Shareholder shall not be required to provide any information which is, based on the advice of outside counsel, subject to legal privilege. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) [The Shareholder hereby acknowledges and agrees that, in connection with the consummation of the Company
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Steps on the Closing Date, all of the <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Shares held by the Shareholder as of immediately prior to such consummation of the Company <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Steps will be converted on a one for one basis into voting Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares (the &#147;<U>Share Conversion</U>&#148;), subject to the prior
expiration or termination of the applicable waiting period under the HSR Act with respect to such Share Conversion. Without limiting <U>Section</U><U></U><U>&nbsp;2(e)</U>, the Shareholder shall use reasonable best efforts to take any actions
reasonably necessary or appropriate to cause the Share Conversion to be consummated, including by (A)&nbsp;making any appropriate filings pursuant to the HSR Act </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Note to Draft:</B> To be included for Company shareholders that are also PIPE investors.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with respect to the Share Conversion as promptly as reasonably practicable (and in any event within ten (10)&nbsp;Business Days) following the date of this Agreement, (B)&nbsp;obtaining any other
approvals of any Governmental Entity as may be required in connection with the Share Conversion and (C)&nbsp;responding as promptly as reasonably practicable to any requests by any Governmental Entity for additional information and documentary
material that may be requested pursuant to the HSR Act or in connection with such other required approvals of any Governmental Entity. Without limiting the foregoing, the Shareholder and its applicable Affiliates shall not extend any waiting period,
review period or comparable period under the HSR Act or in connection with such other required approvals of any Governmental Entity or enter into any agreement with any Governmental Entity not to consummate the Share Conversion except with the prior
written consent of the Company and MAAC. The Shareholder shall promptly inform the Company and MAAC of any communication received by the Shareholder from any Governmental Entity regarding the Share Conversion. The Shareholder shall give the Company
and its counsel, and MAAC and its counsel, a reasonable opportunity to review in advance, and consider in good faith the views thereof in connection with, any proposed written communication to any Governmental Entity relating to the Share
Conversion. The Shareholder agrees not to participate in any substantive meeting or discussion, either in person or by telephone with any Governmental Entity in connection with the Share Conversion unless it consults with the Company and MAAC in
advance and, to the extent not prohibited by such Governmental Entity, gives the Company and MAAC the opportunity to attend and participate in such meeting or discussion.]<SUP STYLE="font-size:85%; vertical-align:top">3</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) [Without limiting Section&nbsp;2(e), the Shareholder shall use reasonable best efforts to consummate the Shareholder PIPE Subscription,
including by (A)&nbsp;making any appropriate filings pursuant to the HSR Act with respect to the Shareholder PIPE Subscription as promptly as reasonably practicable (and in any event within ten (10)&nbsp;Business Days) following the date of this
Agreement, (B)&nbsp;obtaining any other approvals of any Governmental Entity as may be required in connection with the Shareholder PIPE Subscription and (C)&nbsp;responding as promptly as reasonably practicable to any requests by any Governmental
Entity for additional information and documentary material that may be requested pursuant to the HSR Act or in connection with such other required approvals of any Governmental Entity. Without limiting the foregoing, the Shareholder and its
applicable Affiliates shall not extend any waiting period, review period or comparable period under the HSR Act or in connection with such other required approvals of any Governmental Entity except with the prior written consent of the Company and
MAAC. Notwithstanding anything to the contrary contained herein, it is expressly understood and agreed that: (i)&nbsp;the Shareholder shall have no obligation to litigate or contest any Proceeding in respect of such filings and approvals and
(ii)&nbsp;the Shareholder shall be under no obligation to proffer, make proposals, negotiate, execute, carry out or submit to agreements or Orders providing for (A)&nbsp;the sale, transfer, license, divestiture, encumbrance or other disposition or
holding separate (through the establishment of a trust or otherwise) of any assets, categories of assets, operations or categories of operations of the Shareholder or any of its Affiliates, (B)&nbsp;the discontinuation of any product or service of
the Shareholder or any of its Affiliates, or (C)&nbsp;the imposition of any limitation or regulation on the ability of the Shareholder or any of its Affiliates to freely conduct their business or own their respective assets. The Shareholder shall
promptly inform the Company and MAAC of any communication received by the Shareholder from any Governmental Entity regarding the Shareholder PIPE Subscription. The Shareholder shall give the Company and its counsel, and MAAC and its counsel, a
reasonable opportunity to review in advance, and consider in good faith the views thereof in connection with, any proposed written communication to any Governmental Entity relating to the Shareholder PIPE Subscription. The Shareholder agrees not to
participate in any substantive meeting or discussion, either in person or by telephone with any Governmental Entity in connection with the Shareholder PIPE Subscription unless it consults with the Company and MAAC in advance and, to the extent not
prohibited by such Governmental Entity, gives the Company and MAAC the opportunity to attend and participate in such meeting or discussion. For the avoidance of doubt, it is hereby acknowledged and agreed that nothing in this Agreement shall limit
the conditions set forth in Section&nbsp;3(a) and 3(c) of the PIPE Subscription Agreement entered into in connection with the Shareholder PIPE Subscription.]<SUP STYLE="font-size:85%; vertical-align:top">4</SUP> </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Note to Draft</B>: To be included for the Founder. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Note to Draft</B>: To be included for Shareholders whose participation in the PIPE Financing requires an HSR
filing or other governmental approvals. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) [The Shareholder agrees not to participate in any Piggyback Registration (as defined in
the Registration Rights Agreement) pursuant to Section&nbsp;2 of the Registration Rights Agreement during the Holdback Period (as defined in the Registration Rights Agreement).]<SUP STYLE="font-size:85%; vertical-align:top">5</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Shareholder acknowledges and agrees that MAAC and the Company are entering into the Business Combination Agreement in reliance upon
the Shareholder entering into this Agreement and agreeing to be bound by, and perform, or otherwise comply with, as applicable, the agreements, covenants and obligations contained in this Agreement and, but for the Shareholder entering into this
Agreement and agreeing to be bound by, and perform, or otherwise comply with, as applicable, the agreements, covenants and obligations contained in this Agreement, MAAC and the Company would not have entered into or agreed to consummate the
transactions contemplated by the Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Shareholder Representations and Warranties</U>. The Shareholder
represents and warrants to MAAC as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If the Shareholder is not an individual, the Shareholder is a corporation, limited
liability company or other applicable business entity duly organized or formed, as applicable, validly existing and in good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the
concept of good standing or any equivalent thereof) under the Laws of its jurisdiction of formation or organization (as applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
The Shareholder (if not an individual) has the requisite corporate, limited liability company or other similar power and authority and, if the Shareholder is an individual, legal capacity to execute and deliver this Agreement, to perform his, her or
its covenants, agreements and obligations hereunder (including, for the avoidance of doubt, those covenants, agreements and obligations hereunder that relate to the provisions of the Business Combination Agreement), and to consummate the
transactions contemplated hereby. The execution and delivery of this Agreement has been duly authorized by all necessary corporate or other action on the part of the Shareholder. This Agreement has been duly and validly executed and delivered by the
Shareholder and constitutes a valid, legal and binding agreement of the Shareholder (assuming that this Agreement is duly authorized, executed and delivered by MAAC and the Company), enforceable against the Shareholder in accordance with its terms
(subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors&#146; rights and subject to general principles of equity). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) No consent, approval or authorization of, or designation, declaration or filing with, any Governmental Entity is required on the part of
the Shareholder with respect to the Shareholder&#146;s execution, delivery or performance of his, her or its covenants, agreements or obligations under this Agreement (including, for the avoidance of doubt, those covenants, agreements and
obligations under this Agreement that relate to the provisions of the Business Combination Agreement) or the consummation of the transactions contemplated hereby, except for any consents, approvals, authorizations, designations, declarations,
waivers or filings, the absence of which would not reasonably be expected to adversely affect the ability of the Shareholder to perform, or otherwise comply with, any of his, her or its covenants, agreements or obligations hereunder in any material
respect. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Note to Draft</B>: To be included for the Founder and Matthew Gline.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Subject to the due execution and delivery of the Company Shareholder Written Consent and
that certain Large Lot Shareholders&#146; Consent and Waiver and Founder&#146;s Waiver relating to the transactions contemplated by the Business Combination Agreement on or prior to the date hereof, none of the execution or delivery of this
Agreement by the Shareholder, the performance by the Shareholder of any of his, her or its covenants, agreements or obligations under this Agreement (including, for the avoidance of doubt, those covenants, agreements and obligations under this
Agreement that relate to the provisions of the Business Combination Agreement) or the consummation of the transactions contemplated hereby will, directly or indirectly (with or without due notice or lapse of time or both)&nbsp;(i) if the Shareholder
is not an individual, result in any breach of any provision of the Shareholder&#146;s Governing Documents, (ii)&nbsp;result in a violation or breach of, or constitute a default or give rise to any right of termination, Consent, cancellation,
amendment, modification, suspension, revocation or acceleration under, any of the terms, conditions or provisions of any Contract to which the Shareholder is a party, (iii)&nbsp;violate, or constitute a breach under, any Order or applicable Law to
which the Shareholder or any of his, her or its properties or assets are bound or (iv)&nbsp;result in the creation of any Lien upon the Subject Company Shares (other than as expressly provided under this Agreement), except, in the case of any of
<U>clauses</U><U></U><U>&nbsp;(ii)</U> and <U>(iii)</U>&nbsp;above, as would not reasonably be expected to adversely affect the ability of the Shareholder to perform, or otherwise comply with, any of his, her or its covenants, agreements or
obligations hereunder in any material respect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Shareholder is, as of the date hereof, the record and beneficial owner of the
Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Common Shares set forth on <U>Schedule A</U> hereto. The Shareholder has the sole right to vote (and provide consent in respect of, as applicable) the Subject Company Shares and, except for
this Agreement, the Business Combination Agreement and the Company Shareholders Agreement, the Shareholder is not party to or bound by (i)&nbsp;any option, warrant, purchase right or other Contract that would reasonably be expected (either alone or
in connection with one or more events, developments or events (including the satisfaction or waiver of any conditions precedent)) to require the Shareholder to Transfer any of the Subject Company Shares or (ii)&nbsp;any voting trust, proxy or other
Contract with respect to the voting or Transfer of any of the Subject Company Shares (other than the Company Shareholders Agreement and the other Governing Documents of the Company) that would reasonably be expected to adversely affect the ability
of the Shareholder to perform, or otherwise comply with, any of his, her or its covenants, agreements or obligations hereunder in any material respect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) There is no Proceeding pending or, to the Shareholder&#146;s knowledge, threatened against or involving the Shareholder or any of his, her
or its Affiliates that, if adversely decided or resolved, would reasonably be expected to adversely affect the ability of the Shareholder to perform, or otherwise comply with, any of its covenants, agreements or obligations under this Agreement in
any material respect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The Shareholder, on his, her or its own behalf and on behalf of his, her or its Representatives, acknowledges,
represents, warrants and agrees that he, she or it has conducted his, her or its own independent review and analysis of, and, based thereon, has formed an independent judgment concerning, the business, assets, condition, operations and prospects of,
MAAC and the transactions contemplated by this Agreement, the Business Combination Agreement and the other applicable Ancillary Documents to which he, she or it is or will be a party as he, she or it and his, her or its Representatives have deemed
necessary to enable him, her or it to make an informed decision with respect to the execution, delivery and performance of this Agreement or the other Ancillary Documents to which he, she or it is or will be a party and the transactions contemplated
hereby and thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) In entering into this Agreement and the other Ancillary Documents to which he, she or it
is or will be a party, the Shareholder has relied solely on his, her or its own investigation and analysis and the representations and warranties expressly set forth in the Ancillary Documents to which he, she or it is or will be a party (including
the PIPE Subscription Agreement entered into by and among the Shareholder, the Company and MAAC on the date hereof, if applicable) and no other representations or warranties of MAAC, the Company or any other Person, either express or implied, and
the Shareholder, on his, her or its own behalf and on behalf of his, her or its Representatives, acknowledges, represents, warrants and agrees that, except for the representations and warranties expressly set forth in this Agreement or in the other
Ancillary Documents to which he, she or it is or will be a party (including the PIPE Subscription Agreement entered into by and among the Shareholder, the Company and MAAC on the date hereof, if applicable), none of MAAC, the Company or any other
Person makes or has made any representation or warranty, either express or implied, to the Shareholder in connection with or related to this Agreement, the Business Combination Agreement or the other Ancillary Documents or the transactions
contemplated hereby or thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Company and MAAC Acknowledgement</U>. In entering into this Agreement, the Business Combination
Agreement and the other Ancillary Documents to it is or will be a party, each of the Company and MAAC have not relied on any representations or warranties of the Shareholder, either express or implied, except for the representations and warranties
of the Shareholder expressly set forth in this Agreement or in the other Ancillary Documents to which he, she or it is or will be a party (including the PIPE Subscription Agreement entered into by and among the Shareholder, the Company and MAAC on
the date hereof, if applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Transfer of Subject Securities</U>. From and after the date hereof and until the earlier of
(A)&nbsp;the termination of this Agreement in accordance with its terms and (B)&nbsp;the Effective Time, the Shareholder agrees not to (a)&nbsp;Transfer any of the Subject Company Shares, (b)&nbsp;enter into (i)&nbsp;any option, warrant, purchase
right, or other Contract that would reasonably be expected (either alone or in connection with one or more events, developments or events (including the satisfaction or waiver of any conditions precedent)) to require the Shareholder to Transfer the
Subject Company Shares or (ii)&nbsp;any voting trust, proxy or other Contract with respect to the voting or Transfer of the Subject Company Shares, or (c)&nbsp;take any actions in furtherance of any of the matters described in the foregoing
<U>clauses (a)</U>&nbsp;or <U>(b),</U> unless, in the case of clauses (a)&nbsp;through (c), the Shareholder causes any transferee of any such Transfer to enter into a written agreement in form and substance reasonably satisfactory to MAAC and the
Company agreeing to be bound by this Agreement (which will include, for the avoidance of doubt, all of the covenants, agreements and obligations of the Shareholder hereunder and the making of all the representations and warranties of the Shareholder
set forth in <U>Section&nbsp;3</U> with respect to such transferee and his, her or its Subject Company Shares received upon such Transfer, as applicable) prior and as a condition to the occurrence of such Transfer; <I>provided</I> that, if the
Shareholder is not an individual, a Transfer of securities in the Shareholder by an equityholder of the Shareholder shall not require the transferee to enter into such written agreement so long as (x)&nbsp;following such Transfer, the Shareholder
continues to hold the Subject Company Shares and to have the exclusive right to vote and to take all other actions related to the ownership of the Subject Company Shares without restriction and (y)&nbsp;such Transfer would otherwise be permitted
under the Shareholders Agreement. For purposes of this Agreement, &#147;<U>Transfer</U>&#148; means any direct or indirect sale, transfer, assignment, pledge, mortgage, exchange, hypothecation, grant of a security interest in or disposition or
encumbrance of an interest (whether with or without consideration, whether voluntarily or involuntarily or by operation of law or otherwise). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Termination</U>. This Agreement shall automatically terminate, without any notice or other action by any Party, and be void <I>ab
initio</I> upon the earlier of (a)&nbsp;the Effective Time and (b)&nbsp;the termination of the Business Combination Agreement in accordance with its terms. Upon termination of this Agreement as provided in the immediately preceding sentence, none of
the Parties shall have any further obligations or Liabilities under, or with respect to, this Agreement. Notwithstanding the foregoing or anything to the contrary in this Agreement, (i)&nbsp;the termination of this Agreement pursuant to <U>clause
(b)</U>&nbsp;of this <U>Section&nbsp;6</U> shall not affect any Liability on the part of any Party for a Willful Breach of any covenant or agreement set forth in this Agreement prior to such termination or Fraud, (ii)&nbsp;<U>Section&nbsp;2(b)</U>,
<U>Section&nbsp;2(c)</U> and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
representations and warranties set forth in <U>Sections 3(g)</U> and <U>(h)</U>&nbsp;shall each survive any termination of this Agreement, (iii)&nbsp;<U>Section&nbsp;2(d)</U> (solely to the
extent that it relates to <U>Section&nbsp;8.18</U> (Trust Account Waiver) of the Business Combination Agreement) shall survive any termination of this Agreement pursuant to <U>Section&nbsp;6(b)</U> and (iv)&nbsp;this <U>Section&nbsp;6</U> and
<U>Sections 8</U>, <U>9</U>, <U>10</U>, <U>11</U>, <U>12</U>, <U>13</U>, <U>14</U> and <U>15</U> shall survive any termination of this Agreement. For purposes of this <U>Section&nbsp;6</U>, (x) &#147;<U>Willful Breach</U>&#148; means a material
breach of this Agreement that is a consequence of an act or a failure to act by the breaching Party with the knowledge that the taking of such act or such failure to act would, or would reasonably be expected to, constitute or result in a breach of
this Agreement and (y) &#147;<U>Fraud</U>&#148; means an act or omission by a Party, and requires: (A)&nbsp;a false or incorrect representation or warranty expressly set made by such Party in this Agreement, (B)&nbsp;with actual knowledge (as
opposed to constructive, imputed or implied knowledge) by the Party making such representation or warranty that such representation or warranty expressly set forth in this Agreement is false or incorrect, (C)&nbsp;an intention to deceive another
Party, to induce him, her or it to enter into this Agreement, (D)&nbsp;another Party, in justifiable or reasonable reliance upon such false or incorrect representation or warranty expressly set forth in this Agreement, causing such Party entering
into this Agreement, and (E)&nbsp;another Party suffering damage by reason of such reliance. For the avoidance of doubt, &#147;Fraud&#148; does not include any claim for equitable fraud, promissory fraud, unfair dealings fraud or any torts
(including a claim for fraud or alleged fraud) based on negligence or recklessness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Fiduciary Duties</U>. Notwithstanding anything
in this Agreement to the contrary, (a)&nbsp;the Shareholder makes no agreement or understanding herein in any capacity other than in such Shareholder&#146;s capacity as a record holder and beneficial owner of the Subject Company Shares and, (i.e.,
if such Shareholder is an individual, not in such Shareholder&#146;s capacity as a director, officer or employee of any Group Company or in such Shareholder&#146;s capacity as a trustee or fiduciary of any Company Equity Plan, as applicable), and
(b)&nbsp;nothing herein will be construed to limit or affect any action or inaction by such Shareholder if such Shareholder is an individual, or, if such Shareholder is not an individual, any representative of such Shareholder serving as a member of
the board of directors of any Group Company or as an officer, employee or fiduciary of any Group Company or any Company Equity Plan, in each case, acting in such person&#146;s capacity as a director, officer, employee or fiduciary of such Group
Company or any Company Equity Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Notices</U>. All notices, requests, claims, demands and other communications hereunder shall be
in writing and shall be given (and shall be deemed to have been duly given) by delivery in person, by <FONT STYLE="white-space:nowrap">e-mail</FONT> (having obtained electronic delivery confirmation thereof (i.e., an electronic record of the sender
that the email was sent to the intended recipient thereof without an &#147;error&#148; or similar message that such email was not received by such intended recipient)), or by registered or certified mail (postage prepaid, return receipt requested)
(upon receipt thereof) to the other Parties as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to MAAC, to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">c/o Patient Square Capital </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">724 Oak Grove, Suite 130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Menlo
Park, California 94025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maria Walker </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
maria@patientsquarecapital.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Kirkland&nbsp;&amp; Ellis LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">601 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York,
NY 10022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Michael Weisser, P.C.; Ryan Brissette </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
michael.weisser@kirkland.com; ryan.brissette@kirkland.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to the Company, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Roivant Sciences Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Suite 1,
3rd Floor, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">11-12</FONT> St. James&#146;s Square, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">London SW1Y 4LB, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">United
Kingdom </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;Matthew Gline </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;matthew.gline@roivant.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
legalnotices@roivant.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Davis Polk&nbsp;&amp; Wardwell LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">450 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York,
NY 10017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention:&nbsp;&nbsp;&nbsp;&nbsp;Derek Dostal; Lee Hochbaum; Brian Wolfe </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;derek.dostal@davispolk.com; lee.hochbaum@davispolk.com; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
brian.wolfe@davispolk.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to the Shareholder, to the address on the Shareholder&#146;s signature page hereto or to an address of such
Shareholder in the books and records of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as the Party to whom notice is given may have previously furnished to the
others in writing in the manner set forth above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Entire Agreement</U>. This Agreement, the Business Combination Agreement and
documents referred to herein and therein (including the Ancillary Documents) constitute the entire agreement of the Parties with respect to the subject matter of this Agreement, and supersede all prior agreements and undertakings, both written and
oral, among the Parties with respect to the subject matter of this Agreement, except as otherwise expressly provided in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Amendments and Waivers; Assignment</U>. Any provision of this Agreement may be amended or waived if, and only if, such amendment or
waiver is in writing and signed by the Shareholder, the Company and MAAC. Notwithstanding the foregoing, no failure or delay by any Party in exercising any right hereunder shall operate as a waiver thereof nor shall any single or partial exercise
thereof preclude any other or further exercise of any other right hereunder. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assignable by the Shareholder or the Company without MAAC&#146;s prior written
consent (to be withheld or given in its sole discretion) or by MAAC without the Company&#146;s prior written consent (to be withheld or given in its sole discretion). Any attempted assignment of this Agreement not in accordance with the terms of
this <U>Section&nbsp;10</U> shall be null and void <I>ab initio</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Fees and Expenses</U>. Except, in the case of MAAC and the
Company, as otherwise expressly set forth in the Business Combination Agreement, all fees and expenses incurred in connection with this Agreement and the transactions contemplated hereby, including the fees and disbursements of counsel, financial
advisors and accountants, shall be paid by the Party incurring such fees or expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>No Third Party Beneficiaries</U>. This
Agreement shall be for the sole benefit of the Parties and their respective successors and permitted assigns and is not intended, nor shall be construed, to give any Person, other than the Parties and their respective successors and permitted
assigns, any legal or equitable right, benefit or remedy of any nature whatsoever by reason this Agreement. Nothing in this Agreement, expressed or implied, is intended to, or shall be deemed to, create a joint venture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Miscellaneous</U>. <U>Sections 8.5</U> (Governing Law), <U>8.7</U> (Construction;
Interpretation), <U>8.10</U> (Severability), <U>8.11</U> (Counterparts; Electronic Signatures), <U>8.15</U> (Waiver of Jury Trial), <U>8.16</U> (Submission to Jurisdiction) and <U>8.17</U> (Remedies) of the Business Combination Agreement are
incorporated herein by reference and shall apply to this Agreement, <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>No Ownership Interest</U>. Nothing
contained in this Agreement will be deemed to vest in MAAC or any MAAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate any direct or indirect ownership or incidents of ownership of or with respect to the Subject Company Shares. All
rights, ownership and economic benefits of and relating to the Subject Company Shares shall remain vested in and belong to the Shareholder, and MAAC (and each MAAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate) shall have no authority
to manage, direct, superintend, restrict, regulate, govern or administer any of the policies or operations of Company or exercise any power or authority to direct Shareholder in the voting of any of the Subject Company Shares, except as otherwise
expressly provided herein with respect to the Subject Company Shares. Except as otherwise set forth in Section&nbsp;1, the Shareholder shall not be restricted from voting in favor of, against or abstaining with respect to any other matters presented
to the stockholders of the Company. Without limiting the foregoing, nothing in this Agreement shall obligate or require the Shareholder to exercise an option to purchase any Company Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page follows] </I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed and delivered this Transaction Support
Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MONTES ARCHIMEDES ACQUISITION CORP.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROIVANT SCIENCES LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Transaction Support Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed and delivered this Transaction Support
Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>[SHAREHOLDER(S)]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Transaction Support Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE A</U><SUP STYLE="font-size:85%; vertical-align:top">6</SUP> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Class/Series of Securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of Shares</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Company <FONT STYLE="white-space:nowrap">Pre-Closing</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Common Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[&#149;]</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Note to Draft</B>: Company to complete for each Company Shareholder. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company Shareholders Agreements. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>8
<FILENAME>d307489dex1028.htm
<DESCRIPTION>EX-10.28
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.28</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.28 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Version </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDMENT NO. 1 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">to </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SPONSOR SUPPORT AGREEMENT </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
Amendment No.&nbsp;1 to the Sponsor Support Agreement (this &#147;<U>Amendment</U>&#148;) is made as of June&nbsp;9, 2021, by and among Roivant Sciences Ltd., a Bermuda exempted limited company (the &#147;<U>Company</U>&#148;), Montes Archimedes
Acquisition Corp., a Delaware corporation (&#147;<U>MAAC</U>&#148;), Patient Square Capital LLC, a Delaware limited liability company (the &#147;<U>MAAC Sponsor</U>&#148;), and each of James C. Momtazee, George Barrett, Maria C. Walker and Steve
Oesterle (collectively, the &#147;<U>Insiders</U>&#148; and, together with the MAAC Sponsor, the &#147;<U>Shareholders</U>&#148;). Capitalized terms used, but not otherwise defined herein, shall have the meaning given to them in the Sponsor Support
Agreement (as defined below) or the Business Combination Agreement (as defined below), as the context so requires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on
May&nbsp;1, 2021 (a) the Company, MAAC, the MAAC Sponsor and, solely for purposes of certain provisions therein, the Insiders entered into that certain Sponsor Support Agreement (as amended, amended and restated, supplemented or otherwise modified
from time to time in accordance with its terms, the &#147;<U>Sponsor Support Agreement</U>&#148;), and (b)&nbsp;MAAC, the Company and Rhine Merger Sub, Inc., a Delaware corporation and a direct wholly owned Subsidiary of the Company, entered into
that certain Business Combination Agreement (as amended, amended and restated, supplemented or otherwise modified from time to time in accordance with its terms, including, for the avoidance of doubt, as amended by Amendment No.&nbsp;1 to the
Business Combination Agreement, the &#147;<U>Business Combination Agreement</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to Section&nbsp;16 of the
Sponsor Support Agreement, the Sponsor Support Agreement may be amended if, and only if, such amendment is in writing and signed by the Company, MAAC and the Shareholders; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company, MAAC and each Shareholder desires to amend the Sponsor Support Agreement to provide that, among other things,
(a)&nbsp;each MAAC Class&nbsp;B Share held by George Barrett or Steve Oesterle (each, a &#147;<U>MAAC Independent Director</U>&#148;) issued and outstanding immediately prior to the Effective Time be converted as of the Effective Time into the
number of Company Post-Closing Common Shares equal to the Sponsor Exchange Ratio, on the terms and subject to the conditions set forth in the Business Combination Agreement and the Sponsor Support Agreement, and (b)&nbsp;a portion of the Company
Post-Closing Common Shares issued upon conversion of the MAAC Class&nbsp;B Shares held by a MAAC Independent Director in the Merger be subject to the vesting provisions set forth in the Sponsor Support Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the date hereof (a)&nbsp;the Company and MAAC are entering into Amendment No.&nbsp;1 to the Business Combination Agreement
(&#147;<U>Amendment No.</U><U></U><U>&nbsp;1 to the Business Combination Agreement</U>&#148;) in connection with the amendments contemplated hereby and (b)&nbsp;each MAAC Independent Director, on the one hand, and the Company, on the other hand, are
entering into a <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement (each, a &#147;<U>MAAC Independent Director <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration for the mutual promises made herein and other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the Company, MAAC and each Shareholder hereby agree to amend the Sponsor Support Agreement as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>Amendments to the Sponsor Support Agreement</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Section&nbsp;2 of the Sponsor Support Agreement is hereby amended
and restated in its entirety and replaced with the following: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;2. <U><FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to, and conditioned upon the occurrence of and effective immediately after the Effective Time, (i) 20% of the number of Company
Post-Closing Common Shares issued to the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent Director (as defined in the BCA) or any MAAC Independent Director Transferee (as defined in the BCA) upon the conversion of MAAC
Class&nbsp;B Shares held by him, her or it immediately prior to the Effective Time (rounded up to the nearest whole share) shall be subject to the provisions set forth below in this<U>&nbsp;Section</U><U></U><U>&nbsp;2</U> (such Company Post-Closing
Common Shares, the &#147;<U>20% Earn</U><U><FONT STYLE="white-space:nowrap">-Out</FONT> Shares</U>&#148;), (ii) 10% of the number of Company Post-Closing Common Shares issued to the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC
Independent Director or any MAAC Independent Director Transferee upon the conversion of MAAC Class&nbsp;B Shares held by him, her or it immediately prior to the Effective Time (rounded up to the nearest whole share) shall be subject to the
provisions set forth below in this<U>&nbsp;Section</U><U></U><U>&nbsp;2</U> (such Company Post-Closing Common Shares, the &#147;<U>10% Earn</U><U><FONT STYLE="white-space:nowrap">-Out</FONT> Shares</U>&#148; and, together with the 20% <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Shares, the &#147;<U><FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares</U>&#148;) and (iii)&nbsp;the remaining 70% of the number of Company Post-Closing Common Shares issued to the MAAC Sponsor, any
Affiliate of the MAAC Sponsor, any MAAC Independent Director or any MAAC Independent Director Transferee upon the conversion of MAAC Class&nbsp;B Shares held by him, her or it immediately prior to the Effective Time (rounded down to the nearest
whole share) shall not be subject to the provisions set forth below in this<U>&nbsp;Section</U><U></U><U>&nbsp;2</U> (such Company Post-Closing Common Shares, the &#147;<U>Retained Shares</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Subject to, and conditioned upon the occurrence of and effective immediately after the Effective Time, the
<FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares shall be unvested and subject to the restrictions and forfeiture provisions set forth in this <U>Section</U><U></U><U>&nbsp;2</U>. The <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares
shall vest and become free of the provisions set forth in this <U>Section</U><U></U><U>&nbsp;2</U> at such time as the Stock Price (as defined below) of Company Post-Closing Common Shares equals or exceeds (x)&nbsp;with respect to the 20% <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Shares, $15.00 per share (the &#147;<U>20% Trigger Price</U>&#148;), and (y)&nbsp;with respect to the 10% <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares, $20.00 per share (the &#147;<U>10% Trigger
Price</U>&#148; and, together with the 20% Trigger Price, the &#147;<U>Trigger Price</U>&#148;), in each case, for any 20 Trading Days within any 30 Trading Day period commencing no earlier than the Closing Date and ending no later than the fifth
(5th) anniversary of the Closing Date (the &#147;<U><FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date</U>&#148;); <U>provided</U>, <U>however</U>, that (i)&nbsp;if the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date occurs on a day
that is not a Trading Day, then the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date shall be deemed to occur on the next following Trading Day, and (ii)&nbsp;if the Company or any of its Affiliates enters into a definitive agreement with
respect to a Sale (as defined below) on or prior to the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date, then the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date shall be automatically extended and shall be deemed to occur on the
earlier of (A)&nbsp;the day after such Sale is consummated and (B)&nbsp;the termination of such definitive agreement with respect to such Sale in accordance with its terms. Any <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares that have not
vested in accordance with this <U>Section</U><U></U><U>&nbsp;2(b)</U> or <U>Section</U><U></U><U>&nbsp;2(c</U>) on or before the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date will be immediately forfeited at 11:59&nbsp;p.m., New York,
New York time on the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event of a Sale (as defined below) on or prior
to the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date, any unvested <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares will fully vest and become free of the restrictions set forth in this <U>Section</U><U></U><U>&nbsp;2</U> as of
immediately prior to the closing of such Sale. For purposes of this Agreement, &#147;<U>Sale</U>&#148; means (A)&nbsp;a purchase, sale, exchange, merger, business combination or other transaction or series of related transactions in which
substantially all of the Company Post-Closing Common Shares are, directly or indirectly, converted into cash, securities or other property or <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration (other than, in the case of this clause (A),
any transaction in which the holders of Company Post-Closing Common Shares as of immediately prior to the consummation of such transaction continue to own all or substantially all of the equity securities of the Company (or any successor or parent
entity of the Company) immediately following the consummation of such transaction), (B) a direct or indirect sale, lease, exchange or other transfer (regardless of the form of the transaction) in one transaction or a series of related transactions
of a majority of the Company&#146;s assets, as determined on a consolidated basis, to a third party or third parties acting as a &#147;group&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act) or (C)&nbsp;any transaction or series of
transactions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that results, directly or indirectly, in the shareholders of the Company as of immediately prior to such transactions holding, in the aggregate, less than fifty percent (50%) of the voting Equity
Securities of the Company (or any successor or parent company of the Company) immediately after the consummation thereof (excluding, for the avoidance of doubt, any <FONT STYLE="white-space:nowrap">Earn-out</FONT> Shares) (in the case of each of
clause (A), (B) or (C), whether by amalgamation, merger, consolidation, arrangement, tender offer, recapitalization, purchase, issuance, sale or transfer of Equity Securities or assets or otherwise). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Each Shareholder agrees that he, she or it shall not engage in any Sale Transaction (as defined in the applicable <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement) with respect to any of his, her or its <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares until such time as the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares have vested pursuant
to <U>Section</U><U></U><U>&nbsp;2(b)</U> or <U>Section</U><U></U><U>&nbsp;2(c)</U>. Notwithstanding the foregoing or anything to the contrary herein, (i)&nbsp;the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent Director or any
MAAC Independent Director Transferee (and, for the avoidance of doubt, any permitted transferees pursuant to this clause (i)) may transfer all or any of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares held by him, her or it in any
transfer of the type described in Sections 1(b)(iii)(A) through (C)&nbsp;or (F) of the applicable <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, <U>provided</U> that, in the case of a transfer of the type described in clauses
(A)&nbsp;through (C), the transferee shall, in addition to any requirements in the applicable <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, agree in writing that he, she or it is receiving and holding such
<FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares subject to the provisions of this <U>Section</U><U></U><U>&nbsp;2</U> and (ii)&nbsp;from and after a transfer pursuant to clause (i)&nbsp;of this sentence, all references to any of the MAAC
Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent Director or any MAAC Independent Director Transferee in this <U>Section</U><U></U><U>&nbsp;2</U> and <U>Section</U><U></U><U>&nbsp;7</U> shall include such transferee and shall
collectively mean the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent Director or any MAAC Independent Director Transferee (to the extent that he, she or it then holds <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares)
and each permitted transferee of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares originally held by the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent Director or any MAAC Independent Director Transferee pursuant
to clause (i)&nbsp;of this sentence (in each case, to the extent he, she or it then holds <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares). Each transferee of <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares pursuant to clause
(i)&nbsp;of the preceding sentence shall be a third party beneficiary of this <U>Section</U><U></U><U>&nbsp;2</U> and <U>Section</U><U></U><U>&nbsp;7</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) As used herein, &#147;<U>Stock Price</U>&#148; means, on any date on or after the Closing and on or prior to the <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> End Date, the closing sale price per share of Company Post-Closing Common Shares reported as of 4:00 p.m., New York, New York time on such date by Bloomberg, or if not available on Bloomberg, as reported by
or an authoritative source generally used for such purposes and selected by the Company, and &#147;<U>Trading Day</U>&#148; means any day on which trading is generally conducted on Nasdaq or any other exchange on which the Company Post-Closing
Common Shares are traded on or after the Closing and on or prior to the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> End Date. The <FONT STYLE="white-space:nowrap">Earn-out</FONT> Shares and the applicable Trigger Price (and all references to
Company Post-Closing Common Shares and each of the foregoing in this Agreement) shall each be adjusted appropriately to reflect the effect of any stock split, reverse stock split, stock dividend (including any dividend or other distribution of
securities convertible into Company Post-Closing Common Shares), reorganization, recapitalization, reclassification, combination, exchange of shares or other like change with respect to the Company Post-Closing Common Shares (or any other Equity
Securities into which they are adjusted pursuant to this <U>Section</U><U></U><U>&nbsp;2(e)</U>) at any time prior to the vesting of the <FONT STYLE="white-space:nowrap">Earn-out</FONT> Shares pursuant to this <U>Section</U><U></U><U>&nbsp;2</U> so
as to provide the holders of the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares with the same economic effect as contemplated by this <U>Section</U><U></U><U>&nbsp;2</U> prior to such event and as so adjusted shall, from and after the date
of such event, be the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares and the 20% Trigger Price or the 10% Trigger Price, as applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Company shall use reasonable best efforts to remain listed as a public company on, and for the
<FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares to be tradable over, Nasdaq or any other nationally recognized U.S. stock exchange; <U>provided</U>, <U>however</U>, the foregoing shall not limit the Company or any of its Affiliates from
consummating a Sale or entering into a definitive agreement that contemplates a Sale. Subject to <U>Section</U><U></U><U>&nbsp;2(c)</U> and the other applicable provisions of this <U>Section</U><U></U><U>&nbsp;2</U>, upon the consummation of Sale
the Company shall have no further obligations under this <U>Section</U><U></U><U>&nbsp;2(f)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) At the time that the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares become
vested pursuant to this <U>Section</U><U></U><U>&nbsp;2</U>, the Company shall remove any legends, stock transfer restrictions, stop transfer orders or similar restrictions with respect to the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares
related to such vesting or this <U>Section</U><U></U><U>&nbsp;2</U> (other than, for the avoidance of doubt, those that relate to any applicable and then-existing <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period (as defined in the applicable <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement) with respect to such <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)
For the avoidance of doubt, (i)&nbsp;the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent Director or any MAAC Independent Director Transferee shall retain all of his, her or its rights as a stockholder of the Company with
respect to the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares owned by him, her or it during any period of time that such shares are subject to restriction on transfer or sale hereunder, including the right to vote any such shares and the
right to receive dividends and other distributions with respect to such <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares prior to vesting (<U>provided</U> that dividends and other distributions with respect to
<FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares that are subject to vesting and are unvested at the time of such dividend or distribution shall be set aside by the Company and shall only be paid to such holders upon the vesting of such <FONT
STYLE="white-space:nowrap">Earn-Out</FONT> Shares (and, if any dividends or other distributions with respect to <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares are set aside and such <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares
are subsequently forfeited pursuant to this <U>Section</U><U></U><U>&nbsp;2</U>, such set aside dividends or distributions shall become the property of the Company)), (ii) any <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares that vest in
accordance with the terms of this <U>Section</U><U></U><U>&nbsp;2</U> shall remain subject to any applicable <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period set forth in the applicable <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement
and (iii)&nbsp;notwithstanding the expiration of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period with respect to any <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares, such shares shall remain subject to any applicable restrictions
set forth this <U>Section</U><U></U><U>&nbsp;2</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent Director
or any MAAC Independent Director Transferee shall determine, based on advice from its own tax advisors, whether to make an election under Section&nbsp;83(b) of the Code with respect to its <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) The Parties agree and acknowledge that the <FONT STYLE="white-space:nowrap">Earn-Out</FONT> Shares are intended to constitute
&#147;voting stock&#148; within the meaning of Section&nbsp;368(a)(1) of the Code and the Treasury Regulations promulgated thereunder received by of the MAAC Sponsor, any Affiliate of the MAAC Sponsor, any MAAC Independent Director or any MAAC
Independent Director Transferee in connection with the Merger, and shall file all Tax Returns consistent with, and take no position inconsistent with (whether in audits, Tax Returns or otherwise), such treatment unless (i)&nbsp;such Party requests
that each of Kirkland&nbsp;&amp; Ellis LLP and Davis Polk&nbsp;&amp; Wardwell LLP provides written confirmation to the effect that such treatment is more likely than not correct, and each such law firm fails to provide such confirmation prior to the
later of (A)&nbsp;thirty (30) days following such request is made and (B)&nbsp;sixty (60) days prior to the date on which the relevant Tax Return is due (taking into account applicable extensions); <U>provided</U> that the Parties shall provide
customary factual representations to such law firm; <U>provided</U>, <U>further</U>, that, for the avoidance of doubt, the Parties shall not be required to restructure, or otherwise alter the terms of, the transaction as provided for in this
Agreement or the Business Combination Agreement, or (ii)&nbsp;otherwise required by a final &#147;determination&#148; within the meaning of Section&nbsp;1313(a) of the Code.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) The definition <FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Agreements&#148; is hereby amended, and deemed, to include the MAAC
Independent Director <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything in the
Sponsor Support Agreement to the contrary, the Insiders acknowledge and agree that Section&nbsp;2 of the Sponsor Support Agreement shall apply to the Insiders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Effect of Amendments and Modifications</U>. Except as expressly amended hereby, the
Sponsor Support Agreement shall remain unaltered and in full force and effect and the respective terms, conditions or covenants thereof are hereby in all respects confirmed. Whenever the Sponsor Support Agreement is referred to in any agreement,
document or other instrument, such reference will be to the Sponsor Support as amended by this Amendment. For the avoidance of doubt, each reference in the Sponsor Support Agreement, as amended hereby, to &#147;the date hereof&#148;, the &#147;date
of this Agreement&#148; and derivations thereof and other similar phrases shall continue to refer to May&nbsp;1, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.
<U>Miscellaneous</U>. Sections 8.5, 8.7, 8.10, 8.11, 8.15 and 8.16 of the Business Combination Agreement are incorporated herein by reference, <I>mutatis mutandis</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[The remainder of this page intentionally left blank.] </I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Amendment to be signed as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROIVANT SCIENCES LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matt Maisak</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Matt Maisak</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Amendment No.&nbsp;1 to the Sponsor Support Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Amendment to be signed as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MONTES ARCHIMEDES ACQUISITION CORP.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Maria C. Walker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Maria C. Walker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Amendment No.&nbsp;1 to the Sponsor Support Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Amendment to be signed as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PATIENT SQUARE CAPITAL LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Maria C. Walker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Maria C. Walker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Amendment No.&nbsp;1 to the Sponsor Support Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Amendment to be signed as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INSIDERS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ George Barrett</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">George Barrett</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="background-color:#000000">6724 Perimeter Loop Road, #311</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="background-color:#000000">Dublin, Ohio 43017</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Amendment No.&nbsp;1 to the Sponsor Support Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Amendment to be signed as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INSIDERS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James C. Momtazee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">James C. Momtazee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="background-color:#000000">724 Oak Grove Ave, Suite 130</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="background-color:#000000">Menlo Park, California 94025</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Amendment No.&nbsp;1 to the Sponsor Support Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Amendment to be signed as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INSIDERS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Maria C. Walker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Maria C. Walker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="background-color:#000000">8240 McDaniel Road</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="background-color:#000000">Fort Worth, Texas 76126</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Amendment No.&nbsp;1 to the Sponsor Support Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Amendment to be signed as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INSIDERS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Steve Oesterle</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Steve Oesterle</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="background-color:#000000">240 Oliver Ave S.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="background-color:#000000">Minneapolis, Minnesota 55405</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Amendment No.&nbsp;1 to the Sponsor Support Agreement] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>9
<FILENAME>d307489dex1036.htm
<DESCRIPTION>EX-10.36
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.36</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.36 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BY [***], HAS BEEN OMITTED BECAUSE ROIVANT SCIENCES LTD. (THE &#147;COMPANY&#148;) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HAS DETERMINED THAT THE INFORMATION (I)&nbsp;IS NOT MATERIAL AND (II)&nbsp;WOULD </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INVESTOR RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS INVESTOR RIGHTS AGREEMENT</B> (this &#147;<B>Agreement</B>&#148;) is made as of September&nbsp;13, 2021, by and among Priovant
Holdings, Inc., a Delaware corporation with offices at [***] (the &#147;<B>Company</B>&#148;), Roivant Sciences Ltd., an exempted limited company incorporated under the laws of Bermuda with its registered office at [***]
(&#147;<B>Roivant</B>&#148;), Pfizer Inc., a Delaware corporation with offices at [***] (&#147;<B>Pfizer</B>&#148;) and each other Person that becomes an &#147;<B>Investor</B>&#148; hereunder after the date hereof in accordance with this Agreement.
Each of the Company and the Investors shall be referred to herein as a &#147;<B>Party</B>&#148; and collectively as the &#147;<B>Parties</B>&#148;. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
the Company, Roivant, and Pfizer are parties to that certain Stock Purchase Agreement dated as of the date hereof (as it may be amended from time to time, the &#147;<B>Stock Purchase Agreement</B>&#148;) and Priovant, Inc., a wholly-owned Subsidiary
of the Company, and Pfizer are parties to that certain License Agreement dated as of the date hereof (as it may be amended from time to time, the &#147;<B>License Agreement</B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in order to induce the Company, Roivant, and Pfizer to enter into the Stock Purchase Agreement and to induce Priovant, Inc.
and Pfizer to enter into the License Agreement, and to perform the transactions contemplated thereby and hereby, the Investors and the Company hereby agree that this Agreement shall govern the rights of the Investors to cause the Company to register
certain of their Equity Securities, to receive certain information from the Company, and certain other matters as set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the foregoing premises and the mutual covenants contained herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; means, with respect to any specified Person, any other Person who directly or indirectly controls, is controlled
by, or is under common control with such Person, including any direct or indirect parent or Subsidiary of such Person (it being understood, for the avoidance of doubt, that a Person is only deemed an Affiliate of another Person at such times that
the criteria set forth in this definition apply). &#147;<B>Affiliated</B>&#148; has a correlative meaning. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Beneficially
Own</B>&#148; or &#147;<B>Beneficial Ownership</B>&#148; has the meaning assigned to such term in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act, and a Person&#146;s Beneficial Ownership of securities shall be calculated
in accordance with the provisions of such Rule, in each case irrespective of whether or not such Rule is actually applicable in such circumstance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Board</B>&#148; means the Board of Directors of the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; means a day other than a Saturday, Sunday or a national or
public holiday, on which commercial banks in the State of New York, United States, and London, England are open for the transaction of commercial banking business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Change of Control</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Certificate of Incorporation</B>&#148; means the Company&#146;s Certificate of Incorporation, as amended or restated from time to
time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Common Stock</B>&#148; means shares of the Company&#146;s common stock, par value $0.01 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Contract</B>&#148; means any contract, lease, license, sublicense, indenture, loan, note, agreement or other legally binding
commitment, arrangement or undertaking (whether written or oral and whether express or implied). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>control</B>&#148; (including,
with correlative meanings, the terms &#147;controlled by&#148; and &#147;under common control with&#148;), as used with respect to any Person or group of Persons, means (a)&nbsp;possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of the Person, whether through the Beneficial Ownership of voting securities, by Contract or otherwise or (b)&nbsp;Beneficial Ownership of at least fifty percent (50%) of the aggregate voting rights of issued
and outstanding equity securities that are entitled to vote at a general meeting of such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Corporate Strategic
Relationship</B>&#148; means one or more agreements, arrangements or transactions that establishes, effects, amends or modifies any of the following; [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Damages</B>&#148; means any loss, damage, claim or liability (joint or several) to which a Person is subject or may become subject
under the Securities Act, the Exchange Act, or other applicable Laws or Orders, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (a)&nbsp;any untrue statement or alleged untrue
statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (b)&nbsp;an omission or alleged omission to
state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (c)&nbsp;any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities
Act, the Exchange Act, any other applicable securities Law or Order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Designated Affiliate</B>&#148; means (a)&nbsp;with respect
to the Company, Roivant Sciences Ltd. and any Person controlled by Roivant Sciences Ltd., (b) with respect to Pfizer, any Person controlled by Pfizer and (c)&nbsp;with respect to any other Person that becomes an Investor hereunder, the ultimate
parent entity of such Person, and each other Person controlled by such ultimate parent entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Equity Securities</B>&#148;
means, without duplication, (a)&nbsp;the Shares, (b)&nbsp;any other class or series of equity security or equity-linked security issued by the Company and (c)&nbsp;any other securities or rights (including options and warrants) convertible into or
exchangeable or exercisable for (in each case, directly or indirectly) Shares or any other class or series of equity or equity-linked securities issued by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Excluded Registration</B>&#148; means: (a)&nbsp;a registration relating to the sale of securities to employees of the Company or a
Subsidiary of the Company pursuant to an equity option, equity purchase, or similar plan; (b)&nbsp;a registration relating to an SEC Rule 145 transaction; (c)&nbsp;a registration in connection with an exchange offer; (d)&nbsp;a registration in which
the only securities being registered are securities issuable upon </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conversion of other securities that are also being registered; (e)&nbsp;a registration relating to the acquisition of, or combination with, another Person, including any registration on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> or <FONT STYLE="white-space:nowrap">F-4</FONT> (or any successor thereto) or its foreign equivalent; or (f)&nbsp;a registration on any form that does not include substantially the same information as would be
required to be included in a registration statement covering the sale of the Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exempted
Securities</B>&#148; means: (a)&nbsp;Equity Securities issued by reason of a dividend, share split, <FONT STYLE="white-space:nowrap">split-up</FONT> or other dividend or distribution on Equity Securities, in each case, <U>provided</U> that such
Equity Securities are issued to all Holders, pro rata to the number of Equity Securities held or otherwise in accordance with the terms of such Equity Securities; (b)&nbsp;Equity Securities issued to officers, employees or directors of, or
consultants or advisors to, the Company or any of its Subsidiaries pursuant to a plan, agreement or arrangement approved by the Board; (c)&nbsp;Equity Securities issued pursuant to an employee stock option plan, management incentive plan, restricted
stock plan, stock purchase plan or stock ownership or similar benefit plan, program or agreement as approved by the Board; (d)&nbsp;Equity Securities issued upon the exercise or conversion of other Equity Securities, in each case provided such
issuance is pursuant to the terms of such Equity Security; (e)&nbsp;Equity Securities issued to banks, equipment lessors, other financial institutions, or to real property lessors or other Persons, pursuant to debt financing, equipment leasing or
real property leasing transactions approved by the Board; (f)&nbsp;Equity Securities issued to suppliers or third party service providers in connection with the provision of goods or services pursuant to transactions approved by the Board;
(g)&nbsp;Equity Securities issued pursuant to the acquisition of, or combination with or into, another Person, business or assets by the Company or any of its Subsidiaries approved by the Board; (h)&nbsp;Equity Securities issued in connection with
sponsored research, collaboration, technology license, development, marketing or other similar agreements or strategic partnerships approved by the Board; or (i)&nbsp;Equity Securities issued in connection with a bona fide strategic partnership or
commercial arrangement with a Person approved by the Board; or (j) [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>FINRA</B>&#148; means the Financial Industry
Regulatory Authority, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Form <FONT STYLE="white-space:nowrap">S-3</FONT></B>&#148; means such form under the Securities Act
as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Free Writing Prospectus</B>&#148; means a free writing prospectus, as defined by Rule 405 promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Global Trade Control Laws</B>&#148; means the U.S. Export Administration Regulations; the U.S. International Traffic in Arms
Regulations; the U.S. economic sanctions rules and regulations implemented under statutory authority or the President&#146;s Executive Orders and administered by the U.S. Department of the Treasury Office of Foreign Assets Control; E.U. Council
Regulations on export controls, including Nos. 428/2009, 267/2012; other E.U. Council sanctions regulations, as implemented in E.U. Member States; United Nations sanctions policies; all relevant regulations and legislative instruments made under any
of the above; other applicable economic sanctions, export and import control laws, and other applicable laws, regulations, legislation, Orders and requirements imposed by a relevant Governmental Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Authority</B>&#148; means any U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> federal, state, local or other
governmental, administrative or regulatory (including self-regulatory) authority, body, agency, court, tribunal or similar entity, including any taxing authority, any work council or similar labor entity or any department, bureau, division or
instrumentality of any of the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Healthcare Laws</B>&#148; means the federal Anti-kickback Statute (42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7b(b)),</FONT> the Anti-Inducement Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a(a)(5)),</FONT> the Civil Monetary Penalty Statute (42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7a),</FONT> the civil False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the administrative False Claims Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(a)),</FONT> the Health Insurance
Portability and Accountability Act of 1996 (42 U.S.C. &#167; 1320d et seq.), the exclusion laws (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7),</FONT> the FD&amp;C Act (21 U.S.C. &#167;&#167; 301 et. seq,), the Controlled Substances Act
(21 U.S.C. &#167;&#167; 801 et seq.), Section&nbsp;1128G of the Social Security Act (the Physician Payment Sunshine Law), The Foreign Corrupt Practices Act (15 U.S.C. &#167; <FONT STYLE="white-space:nowrap">78dd-1,</FONT> et seq.), the Medicare
Program (Title XVIII of the Social Security Act), the Medicaid Program (Title XIX of the Social Security Act), the regulations promulgated pursuant to such laws, requirements of the Medicaid Drug Rebate Program (42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1396r-8)</FONT> and any state supplemental rebate program, requirements of Medicare average sales price reporting (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1395w-3a),</FONT> the Public Health Service Act (42
U.S.C. &#167; 256b), the VA Federal Supply Schedule (38 U.S.C. &#167; 8126), state pharmaceutical assistance programs and regulations under such laws, and the U.S. FDA Good Clinical Practices (GCP) (21 C.F.R. Parts 50, 54, 56, 58 and 312), Good
Laboratory Practices (GLP) (21 C.F.R. Part 58), and Good Manufacturing Practices (GMP) (21 C.F.R. Parts <FONT STYLE="white-space:nowrap">210-211</FONT> and 820). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Holders</B>&#148; means, collectively, the Investors and their respective valid transferees that are holders of Registrable
Securities and Party to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Immediate Family Member</B>&#148; means a child, stepchild, grandchild, parent,
stepparent, grandparent, spouse, sibling, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law,</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sister-in-law,</FONT></FONT> including adoptive relationships, of a natural person
referred to herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Investors</B>&#148; means the Persons named on Schedule 1 hereto and each Person to whom the rights of such
parties are assigned pursuant to Section&nbsp;6.1 <I>(Successors and Assigns; Third Party Beneficiaries)</I> each Person who hereafter becomes a signatory to this Agreement pursuant to Section&nbsp;6.14 <I>(Additional Investors)</I> and any one of
them, as the context may require; provided, however, that any such Person shall cease to be considered an Investor for purposes of this Agreement if, together with its Designated Affiliates, it ceases to Beneficially Own [***] of the aggregate
voting rights of issued and outstanding Equity Securities that are entitled to vote at a meeting of stockholders of the Company; provided, however, that [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Law</B>&#148; means any international, supranational, national, federal, state or local law, constitution, treaty, convention,
statute, ordinance, code, rule, regulation, common law or other similar requirement enacted, adopted, promulgated or applied by any Governmental Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Listing Event</B>&#148; means (a)&nbsp;the Company&#146;s first underwritten public offering of its Shares or any other Equity
Securities of the Company pursuant to an effective registration statement filed under the Securities Act or its foreign equivalent, (b)&nbsp;any transaction (including a &#147;direct listing&#148; or &#147;reverse merger IPO&#148; transaction)
pursuant to which the Company or any successor entity first becomes subject to the periodic reporting requirements of Section&nbsp;13 or 15(d) of the Exchange Act or any foreign equivalent, or (c)&nbsp;an acquisition of the Company by, or
consolidation, amalgamation, merger, reorganization or other business combination involving the Company with or into, a special purpose acquisition company that is publicly listed on a national or foreign securities exchange and that does not
conduct any material business or maintain any material assets other than cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>New Securities</B>&#148; means Equity Securities,
whether or not currently authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Order</B>&#148; means any judgment, order, injunction, decision ruling, writ or decree of
any Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; means any individual, general or limited partnership, corporation, limited
liability company, business trust, joint stock company, trust, unincorporated organization, joint venture, firm, association or other entity or organization (whether or not a legal entity), including any Governmental Authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Preferred Director</B>&#148; means any Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Director or Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Preferred Stock</B>&#148; means Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock and Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Qualified Listing Event</B>&#148; means (a)&nbsp;the Company&#146;s first
underwritten public offering of its capital stock pursuant to an effective registration statement filed under the Securities Act of 1933, as amended, or its foreign equivalent, (b)&nbsp;any transaction (including a &#147;direct listing&#148; or
&#147;reverse merger IPO&#148; transaction) pursuant to which the Company or any successor entity first becomes subject to the periodic reporting requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, as amended, or any
foreign equivalent, or (c)&nbsp;an acquisition of the Company by, or consolidation, amalgamation, merger, reorganization or other business combination involving the Company with or into, a special purpose acquisition company that is publicly listed
on a national or foreign securities exchange and that does not conduct any material business or maintain any material assets other than cash, in each case of clauses (a)&#150;(c), which results [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registrable Securities</B>&#148; means (a)&nbsp;the Common Stock held by the Investors, including Common Stock issued or issuable
(directly or indirectly) upon conversion, exchange or exercise of any other securities of the Company, acquired by the Investors on or after the date hereof; and (b)&nbsp;Common Stock issued as (or issuable upon the conversion or exercise of any
warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the securities referenced in clause (a); excluding in all cases, any Registrable Securities Transferred
by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Section&nbsp;6.1 <I>(Successors and Assigns; Third Party Beneficiaries)</I> and excluding for purposes of Article II <I>(Registration
Rights)</I> any securities for which registration rights have terminated pursuant to Section&nbsp;2.13 <I>(Termination of Registration Rights)</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Related Party</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Related Party Transaction</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Relatives</B>&#148; means, with respect to any individual, collectively, the spouse, parents, siblings and descendants of such
individual and their respective issue (whether by blood or adoption and including stepchildren) and the spouses of such persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Requisite Preferred Director Vote</B>&#148; means the vote of a majority of the Series <FONT STYLE="white-space:nowrap">A-2</FONT>
Preferred Directors then seated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Restricted Market</B>&#148; means, as applicable under Global Trade Control Laws, the Crimean
Peninsula, Cuba, Iran, North Korea, and Syria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Restricted Party</B>&#148; means any individual or entity on any of the following
&#147;<B>Restricted Party Lists</B>&#148;: the list of sanctioned entities maintained by the United Nations; the Specially Designated Nationals List and the Sectoral Sanctions Identifications List, as administered by the U.S. Department of the
Treasury Office of Foreign Assets Control; the U.S. Denied Persons List, the U.S. Entity List, and the U.S. Unverified List, all administered by the U.S. Department of Commerce; the entities subject to restrictive measures and the Consolidated List
of Persons, Groups and Entities Subject to E.U. Financial Sanctions, as implemented by the E.U. Common Foreign&nbsp;&amp; Security Policy; the List of Excluded Individuals / Entities, as published by the U.S. Health and Human Services &#150; Office
of Inspector General; any lists of prohibited or debarred parties established under the FD&amp;C Act; the list of persons and entities suspended or debarred from contracting with the U.S. government; and similar lists of restricted parties
maintained by the Governmental Authorities of the countries that have jurisdiction over the activities conducted by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Restricted Securities</B>&#148; means the securities of the Company required to
bear the legend set forth in Section&nbsp;2.12(b) <I>(Restrictions on Transfer)</I> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sale Transaction</B>&#148; means
[***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>SEC</B>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>SEC Rule 144</B>&#148; means Rule 144 promulgated by the SEC under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>SEC Rule 145</B>&#148; means Rule 145 promulgated by the SEC under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Act</B>&#148; means the Securities Act of 1933. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Selling Expenses</B>&#148; means all underwriting discounts, selling commissions, and share transfer taxes applicable to the sale of
Registrable Securities, and fees and disbursements of counsel for any Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Series <FONT STYLE="white-space:nowrap">A-1</FONT>
Preferred Director</B>&#148; means any director of the Company that the holders of record of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock are entitled to elect, exclusively and as a separate class, pursuant to the Certificate
of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</B>&#148; means shares of the
Company&#146;s Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, par value $0.01 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred Director</B>&#148; means any director of the Company that the holders of record of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock are entitled to elect, exclusively and as a
separate class, pursuant to the Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred
Stock</B>&#148; means shares of the Company&#146;s Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, par value $0.01 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Shares</B>&#148; means shares of the Common Stock and the Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Standoff Period</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Subsidiary</B>&#148; means, with respect to any Person, any other Person with respect to which such first Person (a)&nbsp;possesses,
directly or indirectly, the power to direct or cause the direction of the management and policies of such Person, whether through the Beneficial Ownership of voting securities, by Contract or otherwise or (b)&nbsp;Beneficially Owns at least fifty
percent (50%) of the aggregate voting rights of issued and outstanding Equity Securities that are entitled to vote at a general meeting of such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transaction Documents</B>&#148; has the meaning given to such term in the Stock Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transfer</B>&#148; by any Person means to, directly or indirectly, sell, transfer, assign, pledge, encumber, mortgage, hypothecate or
otherwise dispose of or transfer (by the operation of Law or otherwise), either voluntarily or involuntarily. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.1 </B><B>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand Registration</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) From and after a Listing Event, if at any time when it is eligible to use a Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration
statement, the Company receives a request from any Holder (the &#147;<B>Initiating Holder</B>&#148;) that the Company file a Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement with respect to outstanding Registrable Securities
of such Initiating Holder having an anticipated aggregate offering price, net of Selling Expenses, of at least [***], then the Company shall, (i)&nbsp;within [***] after the date such request is given, give notice of such demand (a &#147;<B>Demand
Notice</B>&#148;) to all Holders other than the Initiating Holder; and (ii)&nbsp;as soon as practicable, and in any event within [***] after the date such request is given by the Initiating Holder, file a Form
<FONT STYLE="white-space:nowrap">S-3</FONT> registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by the Initiating Holder and by any other Holder, as specified by notice
given by each such Holder to the Company within [***] of the date the Demand Notice is given, and in each case, subject to the limitations of Section&nbsp;2.1(b) <I>(Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand Registration)</I> and
Section&nbsp;2.3 <I>(Underwriting Requirements)</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding the foregoing obligations, if the Company furnishes to the
Initiating Holder a certificate signed by any of the Company&#146;s authorized officers stating that in the good faith judgment of the Board it would or would reasonably be expected to be materially detrimental to the Company and its stockholders
for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i)&nbsp;materially interfere with a significant
acquisition, corporate reorganization, or other similar transaction involving the Company; (ii)&nbsp;require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or
(iii)&nbsp;render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing or suspend the use of such registration statement (a
&#147;<B>Suspension Period</B>&#148;); <U>provided</U> that the Company shall not be permitted to exercise a Suspension Period for more than a total of [***] consecutive calendar days or more than [***] total calendar days in any [***] period; and
provided further that the Company shall not register any securities for its own account or that of any other stockholder during any such Suspension Period other than an Excluded Registration. Each Holder agrees that, upon receipt of notice from the
Company of the occurrence of a Suspension Period, such Holder shall cease offering, selling or distributing the Registrable Securities owned by such Holder until the Company notifies such Holder that such Suspension Period has ended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section&nbsp;2.1(a) <I>(Form <FONT
STYLE="white-space:nowrap">S-3</FONT> Demand Registration)</I>: (i) during the period that is [***] before the Company&#146;s good faith estimate of the date of filing of, and ending on a date that is [***] after the effective date of, a
Company-initiated registration, <U>provided</U> that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii)&nbsp;if the Company has effected [***]
registrations pursuant to Section&nbsp;2.1(a) <I>(Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand Registration)</I> within the [***] period immediately preceding the date of such request. A registration shall not be counted as
&#147;effected&#148; for purposes of this Section&nbsp;2.1(c) <I>(Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand Registration)</I> until such time as the applicable registration statement has been declared effective by the SEC, unless the
Initiating Holder withdraws its request for such registration, elects not to pay the registration expenses therefor, and forfeits its right to one demand registration statement pursuant to Section&nbsp;2.6 <I>(Expenses of Registration)</I>, in which
case such withdrawn registration statement shall be counted as &#147;effected&#148; for purposes of this Section&nbsp;2.1(c) <I>(Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand Registration)</I>; <U>provided</U>, that if such withdrawal is
during a period the Company has deferred taking action pursuant to Section&nbsp;2.1(b) <I>(Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand Registration)</I>, then the Initiating Holders may withdraw their request for registration and such
registration will not be counted as &#147;effected&#148; for purposes of this Section&nbsp;2.1(c) <I>(Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand Registration)</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.2 </B><B>Company Registration</B>. If the Company proposes
to register (including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its Shares or other Equity Securities under the Securities Act in connection with the public offering of such securities
solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration, which notice shall describe the amount and type of securities to be included in such offer, the
proposed manner of distribution and the name of the managing underwriter (if any and if known at such time). Upon the request of each Holder given within [***] after such notice is given by the Company, the Company shall, subject to the provisions
of Section&nbsp;2.3 <I>(Underwriting Requirements)</I> cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any
registration initiated by it under this Section&nbsp;2.2 <I>(Company Registration)</I>, before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other
than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Section&nbsp;2.6 <I>(Expenses of Registration)</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.3 </B><B>Underwriting Requirements</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If, pursuant to Section&nbsp;2.1 <I>(Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand Registration)</I>, the Initiating Holder
intends to distribute the Registrable Securities covered by its request by means of an underwriting, it shall so advise the Company as a part of their request made pursuant to Section&nbsp;2.1 <I>(Form <FONT STYLE="white-space:nowrap">S-3</FONT>
Demand Registration)</I>, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and shall be reasonably acceptable to the Initiating Holder. In such event, the right of any Holder to
include such Holder&#146;s Registrable Securities in such registration shall be conditioned upon such Holder&#146;s participation in such underwriting and the inclusion of such Holder&#146;s Registrable Securities in the underwriting to the extent
provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in Section&nbsp;2.4(e) <I>(Obligations of the Company)</I>) enter into an underwriting agreement in
customary form with the underwriter(s) selected for such underwriting; [***]. Notwithstanding any other provision of this Section&nbsp;2.3 <I>(Underwriting Requirements)</I>, if the managing underwriter(s) advise(s) the Initiating Holder in writing
that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holder shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of
Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holder, in proportion (as nearly as practicable) to the number of Registrable Securities owned
by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; <U>provided</U> that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all
other securities (held by <FONT STYLE="white-space:nowrap">non-Holders)</FONT> are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may
round the number of shares allocated to any Holder to the nearest one hundred (100)&nbsp;shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In connection with any offering
involving an underwriting of Shares or other Equity Securities pursuant to Section&nbsp;2.2 <I>(Company Registration)</I>, the Company shall not be required to include any of the Holders&#146; Registrable Securities in such underwriting unless the
Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the
Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their sole
discretion determine is compatible with the success of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole
discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that
are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by
all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100)&nbsp;shares.
Notwithstanding the foregoing, in no event shall (i)&nbsp;the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the
offering, or (ii)&nbsp;the number of Registrable Securities included in the offering be reduced below [***] of the total number of securities included in such offering, unless such offering is a Qualified Listing Event, in which case the selling
Holders may be excluded further if the Company (and, if applicable, the underwriters) makes the determination described above and no other securities of the Company held by others are included in such offering. For purposes of the provision in this
Section&nbsp;2.3(b) <I>(Underwriting Requirements)</I> concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and
Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single &#147;selling
Holder,&#148; and any pro rata reduction with respect to such &#147;selling Holder&#148; shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such &#147;selling Holder,&#148; as defined in this
sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) For purposes of Section&nbsp;2.1 (<I>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand Registration</I>), a
registration shall not be counted as &#147;effected&#148; if, as a result of an exercise of the underwriter&#146;s cutback provisions in Section&nbsp;2.3(a) <I>(Underwriting Requirements)</I>, fewer than [***] of the total number of Registrable
Securities that Holders have requested to be included in such registration statement are actually included. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.4 Obligations of the Company</B>. Whenever required under this Article II <I>(Registration Rights)</I> to
effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) prepare and file
with the SEC a registration statement with respect to such Registrable Securities and use commercially reasonable efforts to cause such registration statement to become effective and, upon the request of any Holder, keep such registration statement
effective for a period of up to [***] or, if earlier, until the distribution contemplated in the registration statement has been completed; <U>provided</U> that: (i)&nbsp;such [***] period shall be extended for a period of time equal to the period
the Holder refrains, at the request of an underwriter of Shares or other Equity Securities, as applicable, from selling any securities included in such registration, and (ii)&nbsp;in the case of any registration of Registrable Securities on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such [***] period shall be extended for up to [***], if necessary, to keep the registration
statement effective until all such Registrable Securities are sold; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) prepare and file with the SEC such amendments and supplements to
such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement
and provide the selling Holders and their counsel a reasonable opportunity to review and comment on such amendments and supplements prior to filing them with the SEC; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) furnish to the selling Holders such numbers of copies of a prospectus, including a
preliminary prospectus, as required by the Securities Act, and such other documents as such Holders may reasonably request in order to facilitate the disposition of their Registrable Securities and provide such Holders and their counsel a reasonable
opportunity to review and comment on such prospectus prior to filing it with the SEC; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) use its commercially reasonable efforts to
register and qualify the securities covered by such registration statement under such other securities or <FONT STYLE="white-space:nowrap">blue-sky</FONT> laws of such jurisdictions as shall be reasonably requested by the selling Holders;
<U>provided</U> that the Company shall not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except
as may be required by the Securities Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) in the event of any underwritten public offering, enter into and perform its obligations
under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) use its commercially
reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities
issued by the Company are then listed; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to
this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) notify each selling Holder of such Registrable Securities, at any time when a prospectus or Free Writing Prospectus relating thereto is
required to be delivered under the Securities Act, of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state any
material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading (which, for the avoidance of doubt, will commence a Suspension Period) and, at
the request of any such Holder, the Company will, as soon as reasonably practicable, file and furnish to all such Holders a supplement or amendment to such prospectus or Free Writing Prospectus so that, as thereafter delivered to the purchasers of
such Registrable Securities, such prospectus will not contain an untrue statement of a material fact or omit to state any material fact necessary to make the statements therein not misleading in light of the circumstances under which they were made;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant
to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and
cause the Company&#146;s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify
the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) use
its commercially reasonable efforts to furnish, at the request of any selling Holder requesting registration of Registrable Securities pursuant to this Article II, if such securities are being sold through underwriters, (i)&nbsp;an opinion, dated
such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
underwritten public offering, addressed to the underwriters, (ii)&nbsp;a &#147;negative assurances letter&#148;, dated such date, of the legal counsel representing the Company for the purposes of
such registration, in form and substance as is customarily given to underwriters in an underwritten public offering and (iii)&nbsp;a letter dated such date, from the independent certified public accountants of the Company, in form and substance as
is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) in connection with an underwritten offering, the Company shall cause its officers to use their commercially reasonable efforts to support
the marketing of the Registrable Securities covered by such offering (including participation in &#147;road shows&#148; or other similar marketing efforts); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) cooperate with the selling Holder and each underwriter or agent participating in the disposition of Registrable Securities and their
respective counsel in connection with any filings required to be made with FINRA, including the use of commercially reasonable efforts to obtain FINRA&#146;s <FONT STYLE="white-space:nowrap">pre-clearance</FONT> or
<FONT STYLE="white-space:nowrap">pre-approval</FONT> of the registration statement and applicable prospectus upon filing with the SEC; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) after such
registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the
Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company&#146;s directors may implement a trading program under Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> of the Exchange Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.5 Furnish Information</B>. It shall be a condition precedent to the obligations of the Company to take
any action pursuant to this Article II <I>(Registration Rights)</I> with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by
it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder&#146;s Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.6 </B><B>Expenses of Registration</B>. All expenses (other than Selling Expenses) incurred in connection with
registrations, filings, or qualifications pursuant to Article II <I>(Registration Rights)</I>, including all registration, filing, and qualification fees; printers&#146; and accounting fees; fees and disbursements of counsel for the Company; [***],
shall be borne and paid by the Company; <U>provided</U> that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section&nbsp;2.1 <I>(Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand
Registration)</I>, if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the
number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Section&nbsp;2.1(a) <I>(Form <FONT
STYLE="white-space:nowrap">S-3</FONT> Demand Registration)</I>; provided further that if, at the time of such withdrawal, (i)&nbsp;the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company
from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such material adverse change or (ii)&nbsp;if the Holders have withdrawn the request in connection with the
deferral of a registration by the Company pursuant to Section&nbsp;2.1(b) <I>(Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand Registration)</I>, then the Holders shall not be required to pay any of such expenses and shall not forfeit their
right to one registration pursuant to Section&nbsp;2.1(a) <I>(Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand Registration)</I>. All Selling Expenses relating to Registrable Securities registered pursuant to this Article II <I>(Registration
Rights)</I> [***] shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.7 Delay of Registration</B>. No Holder shall have any right
to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Article II <I>(Registration
Rights)</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.8 </B><B>Indemnification</B>. If any Registrable Securities are included in a registration
statement under this Article II <I>(Registration Rights)</I>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To the extent permitted by applicable Law or Order, the Company will
indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each
such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other
aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; <U>provided</U> that the indemnity
agreement contained in this Section&nbsp;2.8(a) <I>(Indemnification)</I> shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be
unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such
Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To
the extent permitted by applicable Law or Order, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if
any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any
controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information
furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred
thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; <U>provided</U> that the indemnity agreement contained in this Section&nbsp;2.8(b) <I>(Indemnification)</I>
shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the
aggregate amounts payable by any Holder by way of indemnity or contribution under Section&nbsp;2.8(b) <I>(Indemnification)</I> and Section&nbsp;2.8(d) <I>(Indemnification)</I> exceed the proceeds from the offering received by such Holder (net of any
Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an
indemnified party under this Section&nbsp;2.8 <I>(Indemnification)</I> of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a
claim in respect thereof is to be made against any indemnifying party under this Section&nbsp;2.8 <I>(Indemnification)</I>, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in
such action and, to the extent the indemnifying party so desires, participate jointly with any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the Parties; <U>provided</U> that an indemnified party (together
with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified
party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice
to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section&nbsp;2.8 <I>(Indemnification)</I>, to the extent that such
failure materially prejudices the indemnifying party&#146;s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this
Section&nbsp;2.8 <I>(Indemnification)</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To provide for just and equitable contribution to joint liability under the Securities Act
in any case in which either: (i)&nbsp;any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section&nbsp;2.8 <I>(Indemnification)</I> but it is judicially determined (by the entry of a final
judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Section&nbsp;2.8
<I>(Indemnification)</I> provides for indemnification in such case, or (ii)&nbsp;contribution under the Securities Act may be required on the part of any Party hereto for which indemnification is provided under this Section&nbsp;2.8
<I>(Indemnification)</I>, then, and in each such case, such Parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate
to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any
other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the
omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties&#146; relative intent, knowledge, access to information, and opportunity to correct or prevent
such statement or omission; <U>provided</U> that, in any such case (x)&nbsp;no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to
such registration statement (net of any Selling Expenses paid by such Holder), and (y)&nbsp;no Person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) will be entitled to contribution from any
Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder&#146;s liability pursuant to this Section&nbsp;2.8(d) <I>(Indemnification)</I>, when combined with the amounts paid or payable by
such Holder pursuant to Section&nbsp;2.8(b) <I>(Indemnification)</I>, exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations
of the Company and the Holders under this Section&nbsp;2.8 <I>(Indemnification)</I> shall survive the completion of any offering of Registrable Securities in a registration under this Article II <I>(Registration Rights)</I>, and otherwise shall
survive the termination of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.9 Reports Under Exchange Act</B>. With a view to making
available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> the Company shall use commercially reasonable efforts to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) make and keep available adequate
current public information, as those terms are understood and defined in SEC Rule 144, at all times after the date of consummation of a Listing Event and for so long as the Company remains subject to the periodic reporting requirements under
Sections 13 or 15(d) of the Exchange Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) file with the SEC in a timely manner all reports and other documents required of the
Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) furnish to any Holder, so long as such Holder owns any Registrable Securities, forthwith upon request (i)&nbsp;to the extent accurate, a
written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after 90 days after the applicable Listing Event), the Securities Act, and the Exchange Act (at any time after the Company has become
subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form <FONT STYLE="white-space:nowrap">S-3</FONT> (at any time after the Company so qualifies) and (ii)&nbsp;such other
information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting
requirements under the Exchange Act) or pursuant to Form <FONT STYLE="white-space:nowrap">S-3</FONT> (at any time after the Company so qualifies to use such form). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.10 Limitations on Subsequent Registration Rights</B>. From and after the date of this Agreement, the Company
shall not, without the prior written consent of the Holders, enter into any agreement with any holder or prospective holder of any securities of the Company that: (a)&nbsp;would provide to such holder the right to include securities in any
registration on other than either (i)&nbsp;a pro rata basis with respect to the Registrable Securities or (ii)&nbsp;on a subordinate basis after all of the Holders have had the opportunity to include in the registration and offering all Registrable
Securities that they wish to so include or (b)&nbsp;allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.11 </B><B>&#147;</B><B>Market <FONT STYLE="white-space:nowrap">Stand-off</FONT></B><B>&#148;</B><B>
Agreement</B>. Each Holder agrees that it will not, without the prior written consent of the Company and, if applicable, the managing underwriter, during the Standoff Period: (a)&nbsp;lend; offer; pledge; sell; contract to sell; sell any option or
contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise Transfer or dispose of, directly or indirectly, any Shares or any securities convertible into or exercisable or exchangeable
(directly or indirectly) for Shares or (b)&nbsp;enter into any swap or other arrangement that Transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in
clause (a)&nbsp;or (b) above is to be settled by delivery of Shares or other securities, in cash, or otherwise. The foregoing provisions of this Section&nbsp;2.11 <I>(</I><I>&#147;</I><I>Market
<FONT STYLE="white-space:nowrap">Stand-off</FONT></I><I>&#148;</I><I> Agreement)</I> shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement or the Transfer of any shares to any Designated Affiliate of the
Holder; <U>provided</U> that such Designated Affiliate shall agree to be bound by the provisions of this Section&nbsp;2.11 <I>(</I><I>&#147;</I><I>Market <FONT STYLE="white-space:nowrap">Stand-off</FONT></I><I>&#148;</I><I> Agreement)</I> with
respect to future Transfers; provided further that this Section&nbsp;2.11 <I>(</I><I>&#147;</I><I>Market <FONT STYLE="white-space:nowrap">Stand-off</FONT></I><I>&#148;</I><I> Agreement)</I> shall be applicable to each Holder and transferee only if
all officers and directors of the Company and stockholders with at least a [***] ownership of the issued and outstanding Common Stock (after giving effect to the conversion into Common Stock of all outstanding Preferred Stock) immediately prior to
(x)&nbsp;in respect of a QLE Standoff Period, the Company entering into an underwriting, business combination or similar agreement in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with a Qualified Listing Event and (y)&nbsp;in respect of a <FONT STYLE="white-space:nowrap">non-QLE</FONT> Standoff Period, the Company entering into an underwriting agreement in
respect of the applicable underwritten public offering, are subject to the same restrictions and the Company obtains a substantially identical agreement from all other Investors. Any discretionary waiver or termination of the restrictions of any or
all of such agreements by the Company or the underwriters shall apply pro rata to all Company stockholders that are subject to such agreements, based on the number of shares subject to such agreements. The underwriters, if any, in connection with
such Qualified Listing Event or other underwritten public offering of the Company&#146;s Equity Securities under the Securities Act are intended third party beneficiaries of this Section&nbsp;2.11 <I>(&#147;Market
<FONT STYLE="white-space:nowrap">Stand-off&#148;</FONT> Agreement)</I> and shall have the right, power, and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may
be reasonably requested by the Company or the underwriters in connection with such registration or other transaction that are consistent with this Section&nbsp;2.11 <I>(&#147;Market <FONT STYLE="white-space:nowrap">Stand-off&#148;</FONT>
Agreement)</I> or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to the Registrable Securities (and the Equity Securities of every other
Person subject to the foregoing restriction) until the end of such restricted period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.12
</B><B>Restrictions on Transfer</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Preferred Stock and the Registrable Securities shall not be Transferred, and the Company
shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such Transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of
the Securities Act. Each Holder, if effecting a Transfer, will cause any proposed transferee of the Preferred Stock and the Registrable Securities to agree to take and hold such securities subject to the provisions and upon the conditions specified
in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each certificate or instrument representing the Preferred Stock, the Registrable Securities, and any other
securities issued in respect of such Preferred Stock or Registrable Securities, upon any split, dividend, recapitalization, merger, amalgamation, consolidation, or similar event, shall (unless otherwise permitted by the provisions of
Section&nbsp;2.12(c) <I>(Restrictions on Transfer)</I> be stamped or otherwise imprinted with a legend substantially in the following form: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED BY THIS CERTIFICATE WERE ORIGINALLY ISSUED ON __________ ____, 20__, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE &#147;SECURITIES ACT&#148;), OR APPLICABLE STATE SECURITIES LAWS (&#147;STATE ACTS&#148;) AND MAY NOT BE TRANSFERRED, SOLD, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF (&#147;TRANSFERRED&#148;) IN THE
ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR STATE ACTS OR AN EXEMPTION FROM REGISTRATION THEREUNDER. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">THE
SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF THE BYLAWS OF THE COMPANY, A CERTAIN INVESTOR RIGHTS AGREEMENT BY AND AMONG THE COMPANY AND CERTAIN STOCKHOLDERS OF THE COMPANY AND A
CERTAIN RIGHT OF FIRST REFUSAL AND <FONT STYLE="white-space:nowrap">CO-SALE</FONT> AGREEMENT BY AND AMONG THE COMPANY AND CERTAIN STOCKHOLDERS OF THE COMPANY. ANY TRANSFEREE OF THESE SECURITIES TAKES SUBJECT TO THE TERMS THEREOF. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Holders consent to the Company&#146;s making a notation in its records and giving
instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on Transfer set forth in this Section&nbsp;2.12 <I>(Restrictions on Transfer)</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each Holder, as a holder of Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the
provisions of this Article II <I>(Registration Rights)</I>. Before any Transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder shall give notice
to the Company of its intention to effect such Transfer. Each such notice shall describe the manner and circumstances of the Transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder&#146;s
expense by either: (i)&nbsp;a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without
registration under the Securities Act; (ii)&nbsp;a &#147;no action&#148; letter from the SEC to the effect that the proposed Transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that
action be taken with respect thereto; or (iii)&nbsp;any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed Transfer of the Restricted Securities may be effected without registration under the Securities
Act, whereupon the Holder of such Restricted Securities shall be entitled to Transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or
&#147;no action&#148; letter (x)&nbsp;in any transaction in compliance with SEC Rule 144 or (y)&nbsp;in any transaction in which such Holder distributes Restricted Securities to a Designated Affiliate of such Holder for no consideration;
<U>provided</U> that, in the case of clause (y), each transferee agrees in writing to be subject to the terms of this Section&nbsp;2.12 <I>(Restrictions on Transfer)</I>. Each certificate or instrument evidencing the Restricted Securities
transferred as above provided shall bear, except if such Transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Section&nbsp;2.12(b) <I>(Restrictions on Transfer)</I>, except that such certificate shall not bear
such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding the provisions of Sections Section&nbsp;2.12(a) <I>(Restrictions on Transfer)</I> and 2.12(c) <I>(Restrictions on
Transfer)</I> above, no such registration statement or opinion of counsel or &#147;no action&#148; letter shall be necessary for: (a)&nbsp;a transfer by a Holder to any of its Affiliates, (b)&nbsp;a transfer by a Holder that is a partnership,
limited liability company or corporation to a partner, limited partner, retired partner, member, retired member or stockholder of a Holder; (c)&nbsp;a transfer to a Charity; (d)&nbsp;a transfer by gift, will or intestate succession of any partner to
his or her spouse or to the siblings, lineal descendants or ancestors of such partner or his or her spouse; or (e)&nbsp;the transfer by a Holder exercising its <FONT STYLE="white-space:nowrap">co-sale</FONT> rights under the Right of First Refusal
and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement by and among the Company and the Investors and Common Holders named therein of even date herewith, as amended, if in each transfer under clauses (a), (b), (c) or (d)&nbsp;the prospective
transferee agrees in all such instances in writing to be subject to the terms hereof to the same extent as if he or she were an original Holder hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The rights to cause the Company to register Registrable Securities pursuant to this Section&nbsp;2.12(e) <I>(Restrictions on Transfer)</I>
may be assigned by a Holder to a transferee or assignee of Registrable Securities (for so long as such shares remain Registrable Securities) that (a)&nbsp;is a subsidiary, parent, general partner, limited partner, retired partner, member or retired
member, of a Holder that is a corporation, partnership or limited liability company, (b)&nbsp;is a Holder&#146;s family member or trust for the benefit of an individual Holder, (c)&nbsp;acquires at least [***] of the then-outstanding Registrable
Securities or (d)&nbsp;is an Affiliate of such Holder; provided, however, that (i)&nbsp;the transferor shall, within [***] after such transfer, furnish to the Company written notice of the name and address of such transferee or assignee and the
securities with respect to which such registration rights are being assigned and (ii)&nbsp;such transferee shall agree to be subject to all restrictions set forth in this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.13 </B><B>Termination of Registration Rights</B>. The right
of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Section&nbsp;2.1 <I>(Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand Registration)</I> or Section&nbsp;2.2 <I>(Company
Registration)</I> shall terminate upon the earliest to occur of: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the consummation of a Change of Control of the Company or the
liquidation, winding up or other dissolution of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) such time as Rule 144 or another similar exemption under the Securities
Act is available for the sale of all of such Holder&#146;s shares without limitation during a three-month period without registration; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) the [***] of a Qualified Listing Event. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION
RIGHTS. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.1 </B><B>Delivery of Financial Statements</B>. The Company shall deliver to each Investor:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) within ninety (90)&nbsp;days after the end of each fiscal year of the Company beginning with the fiscal year ended March&nbsp;31,
2022: (i) a balance sheet as of the end of such year, (ii)&nbsp;statements of income and of cash flows for such year, and (iii)&nbsp;a statement of stockholders&#146; equity as of the end of such year, all such financial statements to be to be
(x)&nbsp;prepared in accordance with applicable Accounting Standards (as such term is defined in the License Agreement) and (y)&nbsp;audited commencing in the year in which the Company or any of its Affiliates achieves its first commercial sale of a
Licensed Product (as defined in the License Agreement), with the audit to be conducted by an independent registered public accounting firm selected by the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) within sixty (60)&nbsp;days after the end of each of the first three quarters of each fiscal year of the Company beginning with the fiscal
quarter ending December&nbsp;31, 2021, unaudited statements of income and a balance sheet for such fiscal quarter and as of the end of such fiscal quarter (respectively) to be prepared in accordance with applicable Accounting Standards (as such term
is defined in the License Agreement) (except that such financial statements (i)&nbsp;may be subject to income tax or normal year end audit adjustments; and (ii)&nbsp;may not contain all notes thereto that may be required in accordance with
applicable Accounting Standards). [***]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, for any period, the Company has any Subsidiary whose accounts are consolidated with those of the Company, then in respect of such period
the financial statements delivered pursuant to clauses (a)&nbsp;through (b) shall be the consolidated financial statements of the Company and all such consolidated Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything else in this Section&nbsp;3.1 <I>(Delivery of Financial Statements)</I> to the contrary and subject to applicable Law
and Order, the Company may cease providing the information set forth in this Section&nbsp;3.1 <I>(Delivery of Financial Statements)</I> during the period starting with the date thirty (30)&nbsp;days before the Company&#146;s good-faith estimate of
the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; <U>provided</U> that the Company&#146;s covenants under this
Section&nbsp;3.1 <I>(Delivery of Financial Statements)</I> shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.2 </B><B>Access</B>. Except in connection with any dispute
involving the Company or any other Investor or any of their respective Affiliates, the Company shall, and shall cause each of its Subsidiaries to, provide each Investor (for the purpose of monitoring its investment in the Company) reasonable access
to the Company&#146;s and each of its Subsidiaries&#146; properties, books of account and records, and officers to discuss the Company&#146;s and such Subsidiaries&#146; affairs, finances and accounts. All access pursuant to this Section&nbsp;3.2
<I>(Access)</I> shall be conducted (i)&nbsp;during normal business hours of the Company or its Subsidiaries, as applicable, upon reasonable advance written notice to the Company, (ii)&nbsp;in such a manner as not to unreasonably interfere with the
normal operations of the Company and its Subsidiaries, as applicable and (iii)&nbsp;at the Investor&#146;s sole cost and expense; provided, however, that the Company shall not be obligated pursuant to this Section&nbsp;3.2 <I>(Access)</I> to provide
access to any information, books, accounts, records or other material if (a)&nbsp;the Company reasonably determines in good faith that providing access to any such information is reasonably likely to result in a material competitive disadvantage or
(b)&nbsp;providing access to any such information would reasonably be expected to (x)&nbsp;violate any applicable Law or Order, (y)&nbsp;jeopardize an attorney-client privilege or cause a loss of attorney work product protection or other privilege
or protection, (z)&nbsp;violate a confidentiality obligation to a third party (<U>provided</U> that, the Company shall use reasonable efforts to provide an alternative means of providing access to such information to the maximum extent that would
not reasonably be expected to result in a material competitive disadvantage or a loss of such legal privilege or protection or violate any such confidentiality obligations or contravene any applicable Law or Order). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.3 Termination of Information Rights</B>. The covenants set forth in Section&nbsp;3.1 <I>(Delivery of Financial
Statements)</I> and Section&nbsp;3.2 <I>(Access)</I> shall terminate and be of no further force or effect upon the earliest of: (i)&nbsp;immediately before the consummation of a Qualified Listing Event, (ii)&nbsp;the consummation of a Change of
Control of the Company or (iii)&nbsp;the liquidation, winding up or other dissolution of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.4
</B><B>Confidentiality</B>. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor or make decisions with respect to its investment in the Company) any information
obtained from or on behalf of the Company or its Subsidiaries pursuant to the terms of this Agreement unless such information: (a)&nbsp;is known or available or becomes known or available to the public (other than as a result of a breach of this
Section&nbsp;3.4 <I>(Confidentiality)</I> by such Investor), (b) is or has been independently developed or conceived by such Investor without use of the Company&#146;s information or (c)&nbsp;is or has been made known or disclosed to such Investor
by a third party without a known or reasonably expected breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information: (i)&nbsp;to its attorneys,
accountants, consultants, and other professionals to the extent necessary or useful to obtain their services in connection with monitoring its investment in the Company; (ii)&nbsp;to any prospective purchaser of any Registrable Securities from such
Investor, if such prospective purchaser agrees to be bound by the provisions of this Section&nbsp;3.4 <I>(Confidentiality)</I>; (iii) to any existing Affiliate, partner, member, stockholder, or wholly owned Subsidiary of such Investor in the
ordinary course of business, <U>provided</U> that such Investor informs such Person that such information is confidential and causes such Person to maintain the confidentiality of such information, or (iv)&nbsp;in the event that the Investor or
anyone to whom it discloses information receives a request, or is legally required, to disclose all or any part of the information under the terms of a subpoena or other Order, <U>provided</U> that the Investor shall (a)&nbsp;promptly notify the
Company of the existence, terms and circumstances surrounding such a request or requirement so that the Company may seek, at the Company&#146;s sole cost and expense, an appropriate protective order, other reasonable assurance that confidential
treatment will be accorded to such information or other remedy, (b)&nbsp;cooperate with the Company in its efforts to obtain such an order, assurance or other remedy or to take steps to resist or narrow the scope of such request or requirement and
(c)&nbsp;not oppose any action to obtain such protective order, assurance or other remedy. If, a protective order, other reasonable assurance or other remedy is not obtained and subject to such Investor&#146;s compliance with the preceding sentence,
such Investor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(1) may disclose such information only to the extent legally required based on the advice of such Investor&#146;s counsel, (2)&nbsp;will use reasonable best efforts, at such Investor&#146;s sole
cost and expense, to obtain assurance that confidential treatment will be accorded to such information, (3)&nbsp;will give advance notice to the Company of the information to be disclosed, or the proposed disclosure itself (as applicable, as far in
advance as practicable and (4)&nbsp;in the case of any required public disclosure, will give the Company a reasonable opportunity to comment on such disclosure prior to it being made public. Each Investor agrees that it will be liable for any breach
of this Section&nbsp;3.4 <I>(Confidentiality)</I> by any Person to whom it discloses confidential information pursuant to the foregoing clauses (i), (ii), and (iii). The obligations under this Section&nbsp;3.4 <I>(Confidentiality)</I> shall survive
the termination of this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RIGHT TO FUTURE SHARE ISSUANCES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.1 </B><B>Right of First Offer</B>. Subject to the terms and conditions of this Section&nbsp;4.1 <I>(Right of
First Offer)</I> and applicable Laws and Orders, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Investor. An Investor shall be entitled to apportion the right of first offer
hereby granted to it in such proportions as it deems appropriate, among (i)&nbsp;itself and (ii)&nbsp;its Affiliates; <U>provided</U> that each such Affiliate agrees to enter into this Agreement and the Voting Agreement of even date herewith among
the Company, the Investors and the other parties named therein, as an &#147;<B>Investor</B>&#148; in each such agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company
shall give notice (the &#147;<B>Offer Notice</B>&#148;) to each Investor, stating (i)&nbsp;its bona fide intention to offer such New Securities, (ii)&nbsp;the number of such New Securities to be offered, and (iii)&nbsp;the price and terms, if any,
upon which it proposes to offer such New Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) By notification to the Company within [***] after the Offer Notice is given,
each Investor may irrevocably elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Equity Securities then Beneficially
Owned by such Investor and its Designated Affiliates (including all Equity Securities then issuable (directly or indirectly) upon conversion or exercise, as applicable, of any other Equity Securities then held by such Investor) bears to the total
Equity Securities of the Company then outstanding (assuming full conversion or exercise, as applicable, of all other Equity Securities then outstanding) (with respect to each Investor, the &#147;<B>Proportionate Percentage</B>&#148;); provided,
however, that an Investor&#146;s election to purchase or acquire New Securities may be revoked in the event (i)&nbsp;any of the terms set forth in the Offer Notice are changed or (ii)&nbsp;any material term that had not been set forth in the Offer
Notice is required or included in connection with such Investor&#146;s purchase or acquisition of such New Securities. The closing of any sale pursuant to this Section&nbsp;4.1(b) <I>(Right of First Offer)</I> shall occur within the later of [***]
of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Section&nbsp;4.1(c) <I>(Right of First Offer)</I>; provided, however, that if such sale pursuant to this Section&nbsp;4.1(b) would require the
approval of any Governmental Authority prior to consummating such sale, such closing shall be extended to the date that is [***] after such approval has been obtained or finally denied, but in no event later than [***] after the Offer Notice is
given. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in
Section&nbsp;4.1(b) <I>(Right of First Offer)</I>, the Company may, during the [***] period following the expiration of the periods provided in Section&nbsp;4.1(b) <I>(Right of First Offer)</I>, offer and sell the remaining unsubscribed portion of
such New Securities to any Person or Persons at a price not less than, and upon terms not materially more favorable in the aggregate to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the
sale of the New Securities within such period, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Investors in accordance with this Section&nbsp;4.1 <I>(Right of
First Offer)</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The right of first offer in this Section&nbsp;4.1 <I>(Right of First Offer)</I> shall
not be applicable to issuances of: (i)&nbsp;Exempted Securities; and (ii)&nbsp;securities issued in a Qualified Listing Event or to a new holding company solely for the purposes of a forthcoming Qualified Listing Event. In addition to the foregoing,
the right of first offer in this Section&nbsp;4.1 <I>(Right of First Offer)</I> shall not be applicable with respect to any particular Investor in any subsequent offering or sale of New Securities if (x)&nbsp;at the time of such offering or sale,
such Investor is neither a &#147;qualified institutional buyer&#148; as that term is defined in Rule 144A under the Securities Actor nor an &#147;accredited investor&#148; as that term is defined in Rule 501(a) of the Securities Act and
(y)&nbsp;such offering or sale of Shares is otherwise being offered or made only to qualified institutional buyers or accredited investors, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding anything to the contrary contained herein, in lieu of complying with the provisions of this Section&nbsp;4.1 <I>(Right of
First Offer)</I>, the Company may consummate the offering and sale of New Securities without first providing an Offer Notice pursuant to Section&nbsp;4.1(b) <I>(Right of First Offer)</I>, <U>provided</U> that the Company complies with the terms and
conditions of this Section&nbsp;4.1(e) <I>(Right of First Offer</I><B><I>)</I></B>. In the event that an offering or sale of New Securities is consummated without prior delivery of an Offer Notice to one or more Investors, the Company shall, within
[***] from the closing of such offer and sale of New Securities, provide each <FONT STYLE="white-space:nowrap">non-participating</FONT> Investor with written notice of such offering (including the material terms and conditions thereof) and thereupon
provide each such Investor with the right, which shall be exercisable for a period of [***] from delivery of such notice, to subscribe for a number of New Securities equal to such Investor&#146;s Proportionate Percentage (calculated pursuant to
Section&nbsp;4.1(b) <I>(Right of First Offer)</I> before giving effect to the issuance of the New Securities) of the shares offered and sold in such offering, at the same price and on the same terms and conditions as which such securities were first
sold. The closing of such sale shall occur within [***] of the date the notice is given to the Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.2 Termination</B>. The covenants set forth in Section&nbsp;4.1 <I>(Right of First Offer)</I> shall terminate
and be of no further force or effect upon the earliest of: (i)&nbsp;immediately before the consummation of a Qualified Listing Event (ii)&nbsp;the consummation of a Change of Control of the Company or (iii)&nbsp;the liquidation, winding up or other
dissolution of the Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADDITIONAL COVENANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.1 </B>[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.2 </B><B>Indemnification Matters</B>. The Company hereby acknowledges that one (1)&nbsp;or more of the
Preferred Directors nominated to serve on the Board by one (1)&nbsp;or more Investors may have certain rights to indemnification, advancement of expenses or insurance provided by one (1)&nbsp;or more of the Investors and certain of their Affiliates
(collectively, the &#147;<B>Investor Indemnitors</B>&#148;). The Company hereby agrees (a)&nbsp;that it is the indemnitor of first resort (<I>i.e.</I>, its obligations to any such Preferred Director are primary and any obligation of the Investor
Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Preferred Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Preferred
Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Preferred Director to the extent legally permitted and as required by the Certificate of
Incorporation or bylaws of the Company (or any agreement between the Company and such Preferred Director), without regard to any rights such Preferred Director may have against the Investor Indemnitors, and, (c)&nbsp;that it irrevocably waives,
relinquishes and releases the Investor Indemnitors from any and all claims against the Investor Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment
by the Investor Indemnitors on behalf of any such Preferred Director with respect to any claim for which such Preferred Director has sought indemnification from the Company shall affect the foregoing and the Investor Indemnitors shall
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have a right of contribution or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Preferred Director against the Company. The Preferred Directors
and the Investor Indemnitors are intended third-party beneficiaries of this Section&nbsp;5.2 <I>(Indemnification Matters)</I> and shall have the right, power and authority to enforce the provisions of this Section&nbsp;5.2 <I>(Indemnification
Matters)</I> as though they were a party to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.3 </B>[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.4 Termination</B>. The covenants set forth in Section&nbsp;5.1 <I>(Protective Provisions)</I>, [***],
Section&nbsp;5.9 (Board Matters), and [***] shall terminate and be of no further force or effect upon the earliest of: (i)&nbsp;immediately before the consummation of a Qualified Listing Event, (ii)&nbsp;the consummation of a Change of Control or
(iii)&nbsp;the liquidation, winding up or other dissolution of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.5 </B><B>Legal
Compliance</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Compliance with Law</U>. The Company shall, and shall cause its Subsidiaries to, comply in all material respects
with all applicable Laws, including applicable Healthcare Laws and accepted pharmaceutical industry business practices governing product research and development, marketing, promotion, and sale, including with respect to product claims and
restrictions on <FONT STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> promotion, interactions with healthcare professionals, and product pricing and price-reporting obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Foreign Corrupt Practices Act</U>. The Company shall not, and shall not permit any of its subsidiaries and affiliates or any of its or
their respective directors, officers, managers, employees, independent contractors, representatives or agents (collectively, &#147;<B>Representatives</B>&#148;) to, promise, authorize or make any payment to, or otherwise contribute any item of value
to, directly or indirectly, any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government official, in each case, in violation of the U.S. Foreign Corrupt Practices Act (&#147;<B>FCPA</B>&#148;) or any other applicable anti-bribery or
anti-corruption law. If applicable at any time, the Company shall, and shall cause each of its subsidiaries and affiliates to, cease all of its or their respective activities, as well as remediate any actions taken by the Company, its subsidiaries
or affiliates or any of its or their respective Representatives in violation of the FCPA or any other applicable anti-bribery or anti-corruption law. Within a reasonable period of time following the Closing (but in no event greater than six months
post-Closing), the Company shall, and shall cause each of its affiliates to, institute and maintain a customary code of conduct and anti-corruption policy and commence devising applicable systems of internal controls (including, but not limited to,
appropriate accounting systems, purchasing systems and billing systems, if reasonably necessary) to provide reasonable assurance that the Company and its affiliates will comply with the FCPA or any other applicable anti-bribery or anti-corruption
law to the extent required by such laws. The Company will monitor its operations and the operations of each of its affiliates with the purpose of ensuring the systems and controls are effective at the reasonable assurance level and make necessary
changes from time to time, in particular as its business activities expand. Solely for purposes of this Section&nbsp;5.5(b) <I>(Foreign Corrupt Practices Act)</I>, the term &#147;affiliate&#148; shall mean, with respect to a Person, any wholly or
partially-owned subsidiary of such Person that the Person has the power to control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Global Trade Controls Compliance Program</U>.
For so long as the holders of record of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock are entitled to elect, exclusively and as a separate class, pursuant to the Certificate of Incorporation, the Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred Director, the Company shall, and shall cause its Subsidiaries to, comply with Global Trade Control Laws, and will engage in activities involving Restricted Parties and Restricted Markets only as
authorized by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.6 </B><B>D&amp;O Insurance</B>. The Company shall use its best efforts to
obtain and maintain in full force and effect directors and officers insurance in the amount of at least [***] for so long as human trials are not being conducted by the Company and its subsidiaries, and at least [***] once human trials are to be
conducted by the Company or any of its subsidiaries, on such other terms as reasonably determined by the Board and covering such risks as are adequate and customary for its size and business, each with financially sound and reputable insurance
companies or associations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.7 </B>[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.8 </B>[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.9 Board Matters</B>. The Company shall reimburse its nonemployee directors for all reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> travel expenses incurred (consistent with the Company&#146;s travel policy) in connection with attending meetings of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.10 </B><B>Successor Indemnification</B>. If the Company or any of its successors or assignees consolidates
with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company
assume the obligations of the Company with respect to indemnification of members of the Board as in effect immediately before such transaction, whether such obligations are contained in the Company&#146;s bylaws, the Certificate of Incorporation, or
elsewhere, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.11 </B>[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.12 </B>[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.13 </B><B>Publicity</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to Pfizer&#146;s rights pursuant to Section&nbsp;15.4.3(c)(iv) of the License Agreement, no Party (nor any of its Affiliates or
agents) shall use the registered or unregistered trademarks of the other Party or its Affiliates in any press release, publication or other form of promotional disclosure without the prior written consent of the other Party in each instance;
provided, however, that the Company and any of its Affiliates or sublicensees may state publicly that Licensee (as defined in the License Agreement) has received, or been sublicensed under, a license from Pfizer to Exploit the Compounds and Products
(each as defined in the License Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Parties acknowledge that one or more Parties, either singly or jointly, may desire to
publish one or more press releases relating to the Transaction Documents, the rights granted thereunder, and developments made thereto. However, each Party agrees not to issue any press release or other public statement, whether written, electronic,
oral or otherwise, disclosing the existence of the Transaction Documents, the terms hereof or thereof or any information relating to the Transaction Documents without the prior written consent of the other Parties, such consent not to be
unreasonably withheld, conditioned or delayed; <U>provided</U> that a Party desiring to make such public disclosure may issue such press release or public announcement without such prior written consent by the other Party if (a)&nbsp;the entire
contents of such press release or public announcement have previously been made public other than through a breach of the Transaction Documents by such Party, and (b)&nbsp;such press release or public announcement does not materially differ from a
previously issued press release or other publicly available information. No Party will be prevented from complying with any duty of disclosure it may have pursuant to applicable Law or the rules of any recognized stock exchange so long as the
disclosing Party provides the other Parties at least [***] prior written notice to the extent practicable and only discloses information to the extent required by applicable Law or the rules of any recognized stock exchange. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Parties acknowledge that nothing herein shall restrict disclosure and publication
explicitly permitted pursuant to Section&nbsp;16.3 of the License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.14 </B>[***] </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.1 </B><B>Successors and Assigns; Third Party Beneficiaries</B>. No Investor shall assign its rights under this
Agreement without the Company&#146;s prior written consent, except by a Holder to a transferee of Registrable Securities in accordance with this Agreement, or as otherwise expressly permitted by the terms hereof: (x)&nbsp;that is a Designated
Affiliate of such Holder or (y)&nbsp;in connection with the Transfer of all Registrable Securities held by such Holder to such transferee; <U>provided</U> that: (i)&nbsp;such Transfer or assignment may otherwise be effected in accordance with
applicable Laws and Orders, (ii)&nbsp;the Company is, within two (2)&nbsp;Business Days after such Transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights
are being transferred; and (iii)&nbsp;such transferee agrees in a written instrument, in form and substance satisfactory to the Company, delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the
provisions of Section&nbsp;2.11 <I>(</I><I>&#147;</I><I>Market <FONT STYLE="white-space:nowrap">Stand-off</FONT></I><I>&#148;</I><I> Agreement)</I>; and provided further that, for the avoidance of doubt, in no case shall any Investor assign its
rights under Section&nbsp;5.1 <I>(Protective Provisions)</I> of this Agreement pursuant to the preceding clause (y)&nbsp;without the Company&#146;s prior written consent. The terms and conditions of this Agreement inure to the benefit of and are
binding upon the respective successors and permitted assignees of the Parties. Nothing in this Agreement, express or implied, is intended to confer upon any Party other than the Parties hereto or their respective successors and permitted assignees
any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.2 </B><B>Governing Law; Dispute Resolution</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) This Agreement shall be governed and construed in all respects in accordance with the internal law of the State of Delaware, as such laws
are applied to agreements among Delaware residents entered into and performed entirely within the state of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of
Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Parties shall negotiate in good faith and use reasonable efforts to settle any dispute, controversy or action arising
from or related to this Agreement or the breach thereof. In the event that the Parties cannot resolve such dispute, controversy or action within a period of [***] from when the dispute, controversy or action is first identified in writing by the
Party raising or asserting such dispute, controversy or action, then the matter shall be referred to designated representatives of the Parties for resolution by the sending of a notice of dispute(s) (a &#147;<B>Notice of Dispute(s)</B>&#148;). The
designated representatives shall endeavor to meet in person or by means of telephone conference, video conference or similar communications equipment by means of which all Persons participating in the meeting can hear and speak to each other, and
where such participation by the Parties&#146; designated representatives shall constitute presence in person at the meeting, within [***] following transmittal of the Notice of Dispute(s). Each Party shall be entitled to name representatives upon
written notice to the other Party. The foregoing duties may be delegated to the extent the person delegated with such duties is duly authorized to enter into the foregoing resolution without seeking any additional approval within the respective
Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If the Parties do not fully settle any dispute, controversy or action referred to the representatives of the Parties within
[***] of it being referred to them, and a Party wishes to pursue the matter, then such dispute, controversy or action shall be finally resolved by binding arbitration administered by the American Arbitration Association (&#147;<B>AAA</B>&#148;)
pursuant to AAA&#146;s Commercial Arbitration Rules then in effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The arbitration shall be conducted by a panel of three (3)&nbsp;neutral arbitrators,
each of whom shall have significant legal or business experience in the pharmaceutical industry, and none of whom shall be a current or former employee or director, or a current significant shareholder, of either Party or any of their respective
Affiliates or sublicensees; and within [***] after initiation of arbitration, each Party shall select one (1)&nbsp;person to act as arbitrator and the two (2)&nbsp;Party-selected arbitrators shall select a third (3rd) arbitrator within [***] of
their appointment. If the arbitrators selected by the Parties are unable or fail to agree upon the third (3rd) arbitrator, then on the [***] after the initiation of arbitration, the two (2)&nbsp;Party-selected arbitrators shall make a written
request to AAA to appoint a third (3rd) arbitrator. AAA shall appoint such third (3rd) arbitrator within [***] of being notified by the two (2)&nbsp;Party-selected arbitrators. The place of arbitration shall be New York, New York, and all
proceedings and communications shall be in English. The award rendered by the arbitrators shall be final, binding and <FONT STYLE="white-space:nowrap">non-appealable,</FONT> and judgment may be entered upon it in any court of competent jurisdiction.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the controversy is
otherwise resolved. Either Party has the right to file an early dispositive motion seeking a determination on the issue of whether a material breach has occurred, and the arbitrators will promptly rule on such motion. Each Party shall bear its own
costs and expenses and attorneys&#146; fees and an equal share of the arbitrators&#146; fees and any administrative fees of arbitration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Except to the extent necessary to confirm or enforce an award or as may be required by applicable Law, neither Party nor an arbitrator may
disclose the existence, content or results of an arbitration without the prior written consent of the other Party. In no event shall an arbitration be initiated after the date when commencement of a legal or equitable action based on the dispute,
controversy or action would be barred by the applicable statute of limitations in the state of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.3 </B><B>Specific Performance</B>. Each Party agrees that irreparable damage for which monetary relief, even
if available, would not be an adequate remedy, would occur in the event that any provision of this Agreement is not performed in accordance with its specific terms or is otherwise breached. Each Party acknowledges and agrees that, notwithstanding
Section&nbsp;6.2 <I>(Governing Law; Dispute Resolution)</I>, and without waiving any other remedy under this Agreement, the Parties shall be entitled to an injunction or injunctions, specific performance or other equitable relief from any court of
competent jurisdiction to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof. The Parties agree not to assert that a remedy of specific enforcement or other equitable relief is unenforceable, invalid,
contrary to Law or inequitable for any reason, and agree not to assert that a remedy of monetary damages would provide an adequate remedy or that the Parties otherwise have an adequate remedy at Law. The Parties acknowledge and agree that any Party
seeking an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in accordance with this Section&nbsp;6.3 <I>(Specific Performance)</I> shall not be required to provide
any bond or other security in connection with any such injunction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.4 Counterparts</B>. This Agreement may
be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, <I>e.g.</I>, www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all
purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.5 Titles and Subtitles</B>. The titles and subtitles used in
this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.6 </B><B>Interpretation</B>. Unless the context requires otherwise, (i) &#147;include,&#148;
&#147;includes&#148; or &#147;including&#148; shall be deemed to be followed by &#147;without limitation&#148;; (ii) &#147;hereof,&#148; &#147;herein&#148;, &#147;hereby&#148;, &#147;hereto&#148; and &#147;hereunder&#148; shall refer to this
Agreement as a whole and not to any particular provision of this Agreement; (iii) &#147;extent&#148; in the phrase &#147;to the extent&#148; shall mean the degree to which a subject or other item extends and shall not simply mean &#147;if&#148;;
(iv) the singular includes the plural and vice versa; (v) &#147;any&#148; shall mean &#147;any and all&#148;; (vi) &#147;or&#148; is used in the inclusive sense of &#147;and/or&#148;; (vii) any reference to any Contract, Law or Order is a reference
to it as amended, modified and supplemented from time to time (and, in the case of a Law, to (x)&nbsp;any successor provision and (y)&nbsp;the rules and regulations promulgated thereunder); (viii) the words &#147;date hereof&#148; shall refer to the
date of this Agreement; (ix)&nbsp;any provision that requires action by a Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Director shall be applicable only so long as the Board includes a Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Director; and (x)&nbsp;all references to &#147;$&#148; mean the lawful currency of the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.7 </B><B>Notices</B>. All notices and other communications given or made pursuant to this Agreement shall be
in writing and shall be deemed effectively given upon the earlier of actual receipt or: (a)&nbsp;personal delivery to the Party to be notified; (b)&nbsp;when sent, if sent by electronic mail during the recipient&#146;s normal business hours, and if
not sent during normal business hours, then on the recipient&#146;s next Business Day; (c) [***] after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (d) [***] after the Business Day of deposit with a
nationally recognized overnight courier, freight prepaid, specifying <FONT STYLE="white-space:nowrap">next-day</FONT> delivery, with written verification of receipt. All communications shall be sent to the Investors at their respective addresses set
forth on Schedule 1 and to the Company at the address set forth on the signature pages hereto, or at such other address as the Company or the Investors may designate by [***] advance written notice to each other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.8 </B><B>Amendments and Waivers</B>. Subject to the terms of this Section&nbsp;6.8 <I>(Amendments and
Waivers)</I>, any term of this Agreement may be amended, modified or terminated and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the
written consent of the Company and the holders of at least a majority of the Registrable Securities then outstanding; provided, however, that the Company may in its sole discretion: (a)&nbsp;add any holder of Shares or New Securities as an
&#147;<B>Investor</B>&#148; and include such shares and securities as Registrable Securities, and (b)&nbsp;waive compliance with any obligation owed to the Company under Section&nbsp;2.12(c) <I>(Restrictions on Transfer)</I> (and the Company&#146;s
failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Section&nbsp;2.12(c) <I>(Restrictions on Transfer)</I> shall be deemed to be a waiver); and provided further that any provision hereof may be
waived by any waiving Party on such Party&#146;s own behalf, without the consent of any other Party. Notwithstanding the foregoing: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1) this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any
Investor without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment,
termination, or waiver effected in accordance with this Section&nbsp;6.8 <I>(Amendments and Waivers)</I> shall be binding on all Parties hereto, regardless of whether any such Party has consented thereto. No waivers of or exceptions to any term,
condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.9 Severability</B>. In case any one or more of the
provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal,
or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.10 Aggregation of Securities</B>. All Registrable Securities held or acquired by Designated Affiliates of a
Person shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Designated Affiliates may apportion such rights as among themselves in any manner they deem appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.11 Entire Agreement</B>. This Agreement (including any Schedules and Exhibits hereto), along with the Stock
Purchase Agreement and other Transaction Documents, constitute the full and entire understanding and agreement among the Parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof
existing between the Parties is expressly canceled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.12 WAIVER OF JURY TRIAL</B>. EACH PARTY HEREBY WAIVES
ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE <FONT
STYLE="white-space:nowrap">ALL-ENCOMPASSING</FONT> OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY
CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH
PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.13 Delays or Omissions</B>. No delay or omission to exercise any right, power or remedy accruing to any Party
under this Agreement, upon any breach or default of any other Party under this Agreement, shall impair any such right, power or remedy of such <FONT STYLE="white-space:nowrap">non-breaching</FONT> or
<FONT STYLE="white-space:nowrap">non-defaulting</FONT> Party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of
any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any Party of any breach or default under this
Agreement must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by Law or otherwise afforded to any Party, shall be cumulative and not alternative </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.14 </B><B>Additional Investors</B>. Notwithstanding anything to the contrary contained herein, if the Company
issues additional Equity Securities after the date hereof, then, at the Company&#146;s election, any purchaser of such securities may become a Party to this Agreement by executing and delivering an additional counterpart signature page to this
Agreement and thereafter shall be deemed an &#147;<B>Investor</B>&#148; for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional
Investor has agreed in writing to be bound by all of the obligations as an &#147;<B>Investor</B>&#148; hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.15 Business Day Requirements</B>. If any notice or other
action or omission is required to be taken by a Party under this Agreement on a day that is not a Business Day, then such notice or other action or omission shall be deemed to be required to be taken on the next occurring Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signatures Follow] </I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed this Investor Rights Agreement as of the date
first set forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PRIOVANT HOLDINGS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Benjamin Zimmer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Benjamin Zimmer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROIVANT SCIENCES LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matt Maisak</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Matt Maisak</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PFIZER INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Young</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John Young</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Business Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Investor Rights Agreement] </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>10
<FILENAME>d307489dex1037.htm
<DESCRIPTION>EX-10.37
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.37</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.37 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE ROIVANT SCIENCES LTD. (THE &#147;COMPANY&#148;) HAS
DETERMINED THAT THE INFORMATION (I)&nbsp;IS NOT MATERIAL AND (II)&nbsp;WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AND COLLABORATION
AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>by and between </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PFIZER INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRIOVANT, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DATED AS OF SEPTEMBER&nbsp;13, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B><U>Page </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1. DEFINITIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2. LICENSE GRANT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>License Grant to Licensee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Sublicense Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>License Grant to Pfizer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Retained Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Residuals</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Additional Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3. CLOSING</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing Deliverables</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4. TRANSFER ACTIVITIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5. DEVELOPMENT; REGULATORY; MANUFACTURING</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>General</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Alliance Management</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Diligence</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regulatory Filings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Progress Reporting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Permitted Contractors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Development Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Safety Reporting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Ongoing Clinical Trials</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6. COMMERCIALIZATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>General</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Diligence</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Territory Integrity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7. PAYMENT TERMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Inventory Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Sales Milestone Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Royalty Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Royalty Deduction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Blended Royalty</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Other Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Late Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Currency</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Method of Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8. RECORDS; AUDIT RIGHTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Relevant Records</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Audit Request</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Audit Fees and Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Payment of Deficiency</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9. INTELLECTUAL PROPERTY RIGHTS.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Pre-existing</FONT> IP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Patent Prosecution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Trademarks</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10. INFRINGEMENT; MISAPPROPRIATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Infringement Action</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11. CONFIDENTIALITY [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exceptions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Ongoing Obligation for Confidentiality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12. REPRESENTATIONS, WARRANTIES AND COVENANTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Representations and Warranties by Each Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Representations and Warranties and Covenants by Pfizer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Representations, Warranties and Covenants by Licensee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Representations, Warranties and Covenants Related to Anti-Corruption Laws and Healthcare Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Representations, Warranties and Covenants Related to Global Trade Control Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Action Required Which Would Violate Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Other Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Disclaimer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Other Government Approvals</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13. INDEMNIFICATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification by Licensee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification by Pfizer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification Procedure for Third Party Claims</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification Procedure for Direct Claims</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14. LIMITATION OF LIABILITY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Damages Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Survival</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exclusive Remedy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Insurance Recovery</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No <FONT STYLE="white-space:nowrap">Set-Off</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15. TERM; TERMINATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination for Cause</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effects of Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Survival</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>365(n) Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16. PUBLICITY; PUBLICATIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Use of Names</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Press Releases</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Publications</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17. INSURANCE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Licensee Insurance Requirements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Licensee Policy Notification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Pfizer Insurance Requirements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Pfizer Policy Notification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18. GENERAL PROVISIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Assignment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Governing Law; Dispute Resolution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Equitable Relief</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Force Majeure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waivers and Amendments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Relationship of the Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Successors and Assigns</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Further Assurances</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Third Party Beneficiary Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Entire Agreement; Confidentiality Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cumulative Remedies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Performance by Affiliates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver of Rule of Construction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AND COLLABORATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS LICENSE AND COLLABORATION AGREEMENT (&#147;<B>Agreement</B>&#148;) is dated as of the
13<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of September, 2021 (the &#147;<B>Effective Date</B>&#148;), by and between Pfizer Inc., a corporation organized and existing under the laws of Delaware with offices at [***]
(&#147;<B>Pfizer</B>&#148;), Priovant, Inc., a corporation organized and existing under the laws of Delaware with offices at [***] (&#147;<B>Licensee</B>&#148;), and solely with respect to <U>Section</U><U></U><U>&nbsp;11.4</U>, Roivant Sciences
Ltd., a corporation organized and existing under the laws of Bermuda with offices at [***] (&#147;<B>Roivant</B>&#148;). Licensee and Pfizer (and, solely with respect to <U>Section</U><U></U><U>&nbsp;11.4</U>, Roivant) may, from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time,</FONT></FONT> be individually referred to as a &#147;<B>Party</B>&#148; and collectively referred to as the &#147;<B>Parties</B>&#148;. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Pfizer
Controls the Licensed Technology (hereinafter defined); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Licensee wishes to obtain, and Pfizer wishes to grant, certain
licenses under the Licensed Technology on the terms and conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual
agreements and covenants set forth herein and other good and valuable consideration, the receipt and sufficiency of which the Parties hereby acknowledge, the Parties, intending to be legally bound hereby, agree to the foregoing and as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B> &#147;<B>[***]</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B> &#147;<B>[***]</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3</B> &#147;<B>AAA</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;18.3.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4</B> &#147;<B>Accounting Standard</B>&#148; means International Financial Reporting Standards (IFRS) or U.S. Generally Accepted
Accounting Principles (GAAP), as generally and consistently applied by the applicable entity in accordance with Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.5</B> &#147;<B>Affiliate</B>&#148; means, with respect to a Party, as of the applicable point in time and for so long as the applicable
relationship exists, any Person that controls, is controlled by, or is under common control with that Party. For the purpose of this definition, the definition of Excluded Affiliate, and <U>Sections 12.4</U> and <U>12.5</U>, &#147;control&#148; and,
with correlative meanings, the terms &#147;controlled by&#148; and &#147;under common control with&#148; shall refer to: (a)&nbsp;the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of
an entity, whether through the ownership of voting securities or other ownership interest, by contract or otherwise, or (b)&nbsp;the ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities or other ownership
interest of such entity (or, with respect to a limited partnership or other similar entity, its general partner or controlling entity). The Parties acknowledge that in the case of certain entities organized under the laws of certain countries
outside of the United States, the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and that in such case such lower percentage shall be substituted in the preceding sentence, <I>provided</I>
that such foreign investor has the power to direct the management or policies of such entity. Notwithstanding the foregoing, an Excluded Affiliate will not be deemed an Affiliate of Licensee for any purpose under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.6</B> &#147;<B>Agreement</B>&#148; is defined in the introduction to this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.7</B> &#147;<B>Alliance Manager</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;5.2.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.8</B> &#147;<B>Anti-Corruption Laws</B>&#148; means applicable international, national, state and local laws, statutes, rules and
regulations regarding corruption and bribery, including laws that prohibit the corrupt payment, offer, promise, or authorization of the payment or transfer of anything of value (including gifts or entertainment), directly or indirectly, to any
Government Official, commercial entity, or any other Person to obtain an improper business advantage, including the Foreign Corrupt Practices Act (15 U.S.C.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#167;78-dd-1,</FONT></FONT> et seq.), the UK Bribery Act of 2010, and laws implementing the Convention on Combating Bribery of Foreign Public Officials in International Business
Transactions; each as may be amended or supplemented from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.9</B> &#147;<B>Applicable Law</B>&#148; means any applicable
United States federal, state or local law, or foreign or multinational law, statute, standard, ordinance, code, rule, regulation, resolution, or promulgation, or any order, writ, judgment, injunction, decree, stipulation, ruling, determination, or
award entered by or with any Governmental Authority, or any license, franchise, permit, or similar right granted under any of the foregoing, or any similar provision having the force or effect of law, including the Federal Food, Drug, and Cosmetic
Act (21 U.S.C. &#167; 301, et seq.), the Anti-Kickback Statute (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b),</FONT> the Civil Monetary Penalty Statute (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a),</FONT> the False
Claims Act (31 U.S.C. &#167; 3729 et seq.), comparable state statutes, the regulations promulgated under all such statutes, and the regulations issued by the FDA, and all applicable Anti-Corruption Laws, accounting and recordkeeping laws, and laws
relating to interactions with Healthcare Professionals and Government Officials. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof shall be deemed to include all then-current amendments thereto or any
replacement or successor law, statute, standard, ordinance, code, rule, regulation, resolution, promulgation, order, writ, judgment, injunction, decree, stipulation, ruling, or determination thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.10</B> &#147;<B>Bankruptcy Code</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;15.6</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.11</B> &#147;<B>Brepo</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;1.12</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.12</B> &#147;<B>Brepo</B> <B>Compounds</B>&#148; means brepocitinib [***] (&#147;<B>Brepo</B>&#148;), [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.13</B> &#147;<B>Brepo</B><B> </B><B>Product</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.14</B> &#147;<B>Business</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;12.2.17</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.15</B> &#147;<B>Business Day</B>&#148; means any day other than a Saturday, a Sunday or a day on which commercial banks located in New
York, New York or London, United Kingdom are authorized or required by Applicable Law to remain closed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.16</B> &#147;<B>Calendar Quarter</B>&#148; means the respective periods of three
(3)&nbsp;consecutive calendar months ending on March&nbsp;31, June&nbsp;30, September&nbsp;30 and December&nbsp;31, except that the first Calendar Quarter of the Term commences on the Effective Date and ends on the first to occur of March&nbsp;31,
June&nbsp;30, September&nbsp;30 and December&nbsp;31 after the Effective Date, and the last Calendar Quarter of the Term ends on the last day of the Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.17</B> &#147;<B>Calendar Year</B>&#148; means the period of twelve (12)&nbsp;consecutive calendar months ending on December&nbsp;31,
except that the first Calendar Quarter of the Term commences on the Effective Date and ends on December&nbsp;31 of the year in which the Effective Date occurs, and the last Calendar Year of the Term commences on January&nbsp;1 of the year in which
the Term ends and ends on the last day of the Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.18</B> &#147;<B>Cap</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.19</B> [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.20</B>
&#147;<B>CDA</B>&#148; means that certain Confidential Disclosure Agreement, dated [***], entered into between the Parties or any of their respective Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.21</B> &#147;<B>Change of Control</B>&#148; means, with respect to a Party, whether effected in a single transaction or a series of
related transactions, [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.22</B> &#147;<B>Clinical Trial</B>&#148; means those studies in human subjects that are required by
Applicable Law, or otherwise recommended or required by the Regulatory Authorities or reasonably useful, to obtain or maintain any Regulatory Approval for a Product for one (1)&nbsp;or more indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.23</B> &#147;<B>Closing</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;3.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.24</B> &#147;<B>CMO</B>&#148; means a contract manufacturing organization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.25</B> &#147;<B>[***]</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;6.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.26</B> &#147;<B>[***]</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;6.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.27</B> &#147;<B>Code</B>&#148; means the U.S. Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.28</B> [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.29</B>
&#147;<B>Commercialize</B>&#148; or &#147;<B>Commercialization</B>&#148; means to market, promote, distribute, offer for sale, sell, have sold, import, have imported, export, have exported or otherwise commercialize a compound or product. When used
as a noun, &#147;<B>Commercialization</B>&#148; means any and all activities involved in Commercializing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.30</B>
&#147;<B>Commercially Reasonable Efforts</B>&#148; means, with respect to the Development or Commercialization of a Compound or Product in or for a particular country, [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.31</B> &#147;<B>Compound Product</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;1.97</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.32</B> &#147;<B>Compounds</B>&#148; means Brepo Compounds and TYK2 Compounds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.33</B> &#147;<B>Confidential Information</B>&#148; means the existence, terms and provisions of this Agreement and all other proprietary
information and data of a financial, commercial or technical nature that the disclosing Party or any of its Affiliates has supplied or otherwise made available to the other Party or its Affiliates. [***]<B> </B>Confidential Information shall not
include information that: (a)&nbsp;is, at the time of disclosure or becomes, after the time of disclosure, known to the public or part of the public domain through no breach of this Agreement by the receiving Party or any Recipients to whom it
disclosed such information; (b)&nbsp;was known to, or was otherwise in the possession of, the receiving Party prior to the time of disclosure by the disclosing Party to the receiving Party; (c)&nbsp;is disclosed to the receiving Party on a <FONT
STYLE="white-space:nowrap">non-confidential</FONT> basis by a Third Party who is entitled to disclose it without breaching any confidentiality obligation to the disclosing Party; or (d)&nbsp;is independently developed by or on behalf of the
receiving Party or any of its Affiliates, as evidenced by its written records, without use of or access to the Confidential Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.34</B> &#147;<B>Control</B>&#148; or &#147;<B>Controlled</B>&#148; means, with respect to any Intellectual Property Rights or other
rights to provide data or other information, the legal authority or right (whether by ownership, license or otherwise, other than any license granted pursuant to this Agreement) of a Party to grant a license or a sublicense of or under such
Intellectual Property Rights to the other Party or provide such data or other information to such other Party without breaching the terms of any agreement with a Third Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.35</B> &#147;<B>Covered</B>&#148; means, with respect to a given Compound or Product and a given Valid Claim of a Licensed Patent Right,
that the Exploitation of such Compound or Product would, but for the licenses granted by Pfizer to Licensee under this Agreement, infringe such Valid Claim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.36</B> &#147;<B>CRO</B>&#148; means a contract research organization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.37</B> &#147;<B>CSO</B>&#148; means a contract sales organization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.38</B> [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.39</B>
[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.40</B> &#147;<B>Develop</B>&#148; or &#147;<B>Developing</B>&#148; means to discover, research or otherwise develop a process,
compound or product, including conducting <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical research and development activities directed to, necessary, reasonably useful or otherwise requested or required by a Regulatory Authority as
a condition or in support of obtaining or maintaining a Regulatory Approval, including fulfilling post-approval regulatory obligations. When used as a noun, &#147;<B>Development</B>&#148; means any and all activities involved in Developing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.41</B> &#147;<B>Developed IP</B>&#148; means any Intellectual Property Rights that are: (a)&nbsp;both (i) related to the Compounds or
Products, and (ii)&nbsp;conceived or reduced to practice by Licensee, its Affiliates or sublicensees alone or together with one or more Third Parties during the Term in connection with the Development, Manufacture or use of any Compound or Product
under this Agreement or (b)&nbsp;both (i) related to the Compounds or Products, and (ii)&nbsp;Controlled by Licensee pursuant to a Licensee Third Party License. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.42</B> &#147;<B>Development Plan</B>&#148; is defined in
<U>Section</U><U></U><U>&nbsp;5.7</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.43</B> &#147;<B>Effective Date</B>&#148; is defined in the introduction to this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.44</B> &#147;<B>Election Notice</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;9.2.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.45</B> &#147;<B>EMA</B>&#148; means the European Medicines Agency or any successor agency thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.46</B> &#147;<B>E.U.</B>&#148; means any of the 27 countries comprising the European Union as of the Effective Date, and any additional
member countries from time to time, and the United Kingdom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.47</B> &#147;<B>Excluded Action</B>&#148; is defined in
<U>Section</U><U></U><U>&nbsp;18.3.7</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.48</B> &#147;<B>Excluded Affiliate</B>&#148; means [***]. For clarity, a Person may cease
to be or may become an Excluded Affiliate from time to time if its status changes such that it ceases to satisfy or satisfies the requirements of an Excluded Affiliate hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.49</B> &#147;<B>Existing Pfizer Affiliates</B>&#148; means the Affiliates of Pfizer existing as of the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.50</B> &#147;<B>Exploit</B>&#148; or &#147;<B>Exploitation</B>&#148; means to Develop, Manufacture or Commercialize, or to otherwise
make, use, offer to sell, sell or import, a compound or product. When used as a noun, &#147;<B>Exploitation</B>&#148; means any and all activities involved in Exploiting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.51</B> &#147;<B>FD&amp;C Act</B>&#148; means the United States Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.),
as amended, and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.52</B> &#147;<B>FDA</B>&#148; means the United States Food and
Drug Administration or any successor federal agency thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.53</B> &#147;<B>Fees</B>&#148; means (a)&nbsp;in the case of Pfizer,
collectively, the Inventory Payment and any and all U.S. Sales Milestone Payment and Licensee Royalties, and (b)&nbsp;in the case of Licensee, collectively, ROW Sales Milestone Payment and Pfizer Royalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.54</B> &#147;<B>Field</B>&#148; means the treatment, prevention, diagnosis, control and maintenance of all indications in humans and
animals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.55</B> &#147;<B>First Commercial Sale</B>&#148; means the first sale of a Product by Licensee or Licensee&#146;s Affiliate
or sublicensee to a Third Party in a country in the Territory following receipt of Regulatory Approval for such Product in such country. Dispositions of Product, or use of Product in, clinical trials or other scientific testing, as free samples, or
under expanded access programs or for charitable purposes shall not be considered a First Commercial Sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.56</B> &#147;<B>First
Reporting Window</B>&#148; is defined in <U>Section</U><U></U>&nbsp;5.5.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.57</B> &#147;<B>Fraud</B>&#148; means, with respect to
any Person, a deliberately fraudulent misrepresentation with respect to the making of the representations and warranties specifically set forth in <U>Section</U><U></U><U>&nbsp;12</U>, as applicable, with the actual knowledge by such Person that
such representations and warranties made pursuant to <U>Section</U><U></U><U>&nbsp;12</U> (each as qualified by the Disclosure Schedules), as applicable, were untrue when made, with the specific intention that a Party to this Agreement rely thereon
to its detriment and such Party did in fact rely thereon to such Party&#146;s detriment; <I>provided</I>, <I>however</I>, that in no event shall the knowledge of any Person be imputed to any other Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.58</B> &#147;<B>FTE</B>&#148; means the efforts of one or more employees of Pfizer (or
its Affiliate) equivalent to the efforts of one full-time employee for one year, or in the case of less than a full-time dedicated person, a full-time equivalent person-year based upon a total of eighteen hundred (1800)&nbsp;hours per year of work.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.59</B> &#147;<B>Generic Competition</B>&#148; means, with respect to a Product (the &#147;<B>Reference Product</B>&#148;) in a
particular country in the Territory, [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.60</B> &#147;<B>Generic Product</B>&#148; means, with respect to the Reference Product
in a particular country in the Territory, any pharmaceutical product that (a)&nbsp;is marketed for sale by a Third Party not authorized by Licensee, (b)&nbsp;receives Regulatory Approval (with or without Pricing and Reimbursement Approval) in such
country in full or partial reliance on the Regulatory Approval (but not necessarily Pricing and Reimbursement Approval) of the Reference Product, and (c)&nbsp;is determined by a Regulatory Authority to be therapeutically equivalent (as defined in
FDA regulations at 21 CFR 314.3(b)) to and substitutable with the Reference Product, it being acknowledged that the foregoing standard is intended to be consistent with the standard set forth in the introduction to the &#147;Orange Book,&#148; as
amended from time to time, or any analogous or comparable standard in any country outside of the United States. For the avoidance of doubt, in the United States, a &#147;Generic Product&#148; as defined herein includes one approved under
Section&nbsp;505(j) of the FD&amp;C Act, as supplemented or amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.61</B> &#147;<B>Global Regulatory Filings</B>&#148; means
[***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.62</B> &#147;<B>Global Trade Control Laws</B>&#148; means the U.S. Export Administration Regulations; the U.S. International
Traffic in Arms Regulations; the U.S. economic sanctions rules and regulations implemented under statutory authority or the President&#146;s Executive Orders and administered by the U.S. Department of the Treasury Office of Foreign Assets Control;
E.U. Council Regulations on export controls, including Nos. 428/2009, 267/2012; other E.U. Council sanctions regulations, as implemented in E.U. Member States; United Nations sanctions policies; all relevant regulations and legislative instruments
made under any of the above; other applicable economic sanctions, export and import control laws, and other applicable laws, regulations, legislation, Orders and requirements imposed by a relevant Governmental Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.63</B> &#147;<B>GMP</B>&#148; means all applicable requirements, standards, practices, and procedures for current good manufacturing
practices for pharmaceuticals promulgated by FDA, including those included in the FD&amp;C Act and 21 C.F.R. Parts 210, 211 and 820, as the same may be amended from time to time, and such standards of good manufacturing practice as are required by
the Regulatory Authorities of the E.U. and other organizations and Governmental Authorities in countries in which the applicable Product is intended to be manufactured or sold, to the extent such standards are not less stringent than United States
GMP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.64</B> &#147;<B>Good Clinical Practices</B>&#148; means the FDA&#146;s standards for
the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials contained in 21 C.F.R. Parts 50, 54, 56, 58 and 312, or those equivalent standards applicable in the relevant jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.65</B> &#147;<B>Government</B>&#148; or &#147;<B>Governmental Authority</B>&#148; is broadly interpreted and includes: (a)&nbsp;any
national, federal, state, local, regional, or foreign government, or level, branch, or subdivision thereof; (b)&nbsp;any multinational or public international organization or authority; (c)&nbsp;any ministry, department, bureau, division, authority,
agency, commission, or body entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power; (d)&nbsp;any court, tribunal, or governmental arbitrator or arbitral body; (e)&nbsp;any
government-owned or -controlled institution or entity; (f)&nbsp;any enterprise or instrumentality performing a governmental function; and (g)&nbsp;any political party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.66</B> &#147;<B>Government Official</B>&#148; is broadly interpreted and includes: (a)&nbsp;any elected or appointed Government official
(e.g., a legislator or a member of a ministry of health); (b) any employee or person acting for or on behalf of a Government, a Government department or agency, an institution or entity owned or controlled by a Government (e.g., a Healthcare
Professional employed by a Government-owned or -controlled hospital, or a person serving on a healthcare committee that advises a Government), or an enterprise or instrumentality performing a governmental function; (c)&nbsp;any candidate for public
office, or officer, employee, or person acting for or on behalf of a political party or candidate for public office; (d)&nbsp;an employee or person acting for or on behalf of a public international organization (e.g., the United Nations, the Red
Cross, or the World Bank); (e) any member of a military or a royal or ruling family; and (f)&nbsp;any person otherwise categorized as a Government official under Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.67</B> &#147;<B>HCP</B>&#148; or &#147;<B>Healthcare Professional</B>&#148; includes any physician, nurse, pharmacist, or other person
who may administer, prescribe, purchase, or recommend pharmaceutical products or other healthcare products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.68</B>
&#147;<B>Healthcare Laws</B>&#148; means the federal Anti-kickback Statute (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(b)),</FONT> the Anti-Inducement Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a(a)(5)),</FONT> the
Civil Monetary Penalty Statute (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a),</FONT> the civil False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the administrative False Claims Law (42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1320a-7b(a)),</FONT> the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &#167; 1320d et seq.), the exclusion laws (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7),</FONT> the FD&amp;C
Act, the Controlled Substances Act (21 U.S.C. &#167;&#167; 801 et seq.), Section&nbsp;1128G of the Social Security Act (the Physician Payment Sunshine Law), The Foreign Corrupt Practices Act (15 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">78dd-1,</FONT> et seq.), the Medicare Program (Title XVIII of the Social Security Act), the Medicaid Program (Title XIX of the Social Security Act), the regulations promulgated pursuant to such laws, requirements of
the Medicaid Drug Rebate Program (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1396r-8)</FONT> and any state supplemental rebate program, requirements of Medicare average sales price reporting (42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1395w-3a),</FONT> the Public Health Service Act (42 U.S.C. &#167; 256b), the VA Federal Supply Schedule (38 U.S.C. &#167; 8126), state pharmaceutical assistance programs and regulations under such laws, and Good
Clinical Practices, Good Laboratory Practices (GLP) (21 C.F.R. Part 58), and Good Manufacturing Practices (GMP) (21 C.F.R. Parts <FONT STYLE="white-space:nowrap">210-211</FONT> and 820). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.69</B> [***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.70</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.71</B> &#147;<B>IND</B>&#148; means: (a)&nbsp;an investigational new drug application filed with the FDA for authorization for the
investigation of a Compound or a Product pursuant to 21 C.F.R. Part 312, and (b)&nbsp;any of its foreign equivalents as filed with the applicable Regulatory Authorities in other countries or regulatory jurisdictions in the Territory, as applicable.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.72</B> &#147;<B>Indemnified Party</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;13.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.73</B> &#147;<B>Indemnifying Party</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;13.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.74</B> &#147;<B>Intellectual Property Rights</B>&#148; means all trade secrets, copyrights, Patent Rights, Trademarks, moral rights, <FONT
STYLE="white-space:nowrap">Know-How</FONT> and any and all other intellectual property or proprietary rights now known or hereafter recognized in any jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.75</B> &#147;<B>Intended Tax Treatment</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;7.10.5</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.76</B> [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.77</B>
&#147;<B>Inventory Payment</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;7.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.78</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.79</B> [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.80</B>
&#147;<B><FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means any proprietary invention, discovery, development, data, information, process, method, technique or other <FONT STYLE="white-space:nowrap">know-how,</FONT> whether or not
patentable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.81</B> &#147;<B>Knowledge</B>&#148; means actual knowledge of the individuals listed on <U>Schedule </U><U>1.81</U> and
is not meant to require or imply that any particular inquiry or investigation has been undertaken, including obtaining any type of search (independent of that performed by the actual Governmental Authority during the normal course of patent
prosecution, as applicable, in a jurisdiction) or opinion of counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.82</B> &#147;<B>Licensed
<FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means <FONT STYLE="white-space:nowrap">Know-How</FONT> Controlled by Pfizer or any of the Existing Pfizer Affiliates [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.83</B> &#147;<B>Licensed</B> <B>Patent Rights</B>&#148; means all Patent Rights [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.84</B> &#147;<B>Licensed Technology</B>&#148; means, collectively, the Licensed Patent Rights and Licensed
<FONT STYLE="white-space:nowrap">Know-How.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.85</B> &#147;<B>Licensee</B>&#148; is defined in the introduction to this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.86</B> &#147;<B>Licensee Indemnitees</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;13.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.87</B> &#147;<B>Licensee Marginal Royalty Rates</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;7.3.1</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.88</B> &#147;<B>Licensee Product Trademarks</B>&#148; is defined in
<U>Section</U><U></U><U>&nbsp;9.3.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.89</B> &#147;<B>Licensee Quarter</B>&#148; means each of the four (4)&nbsp;thirteen (13)
week periods commencing on April&nbsp;1 of any Licensee Year, consistently applied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.90</B> &#147;<B>Licensee Royalties</B>&#148; is
defined in <U>Section</U><U></U><U>&nbsp;7.3.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.91</B> &#147;<B>Licensee Third Party License</B>&#148; is defined in
<U>Section</U><U></U><U>&nbsp;7.4.2(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.92</B> &#147;<B>Licensee Year</B>&#148; means the twelve-month fiscal periods observed
by Licensee commencing on April&nbsp;1 and ending March&nbsp;31, consistently applied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.93</B> &#147;<B>Losses</B>&#148; means,
subject to <U>Section</U><U></U><U>&nbsp;14.1</U>, losses, damages, liabilities, payments, fines, fees, penalties, charges, judgments, settlement payments and costs and expenses including interest penalties and reasonable attorneys&#146; fees and
expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.94</B> &#147;<B>Major European Market Country</B>&#148; means [***]. The &#147;<B>Major European Market
Countries</B>&#148; means [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.95</B> &#147;<B>Manufacture</B>&#148; or &#147;<B>Manufacturing</B>&#148; means to make, have made,
produce, manufacture, process, fill, finish, package, label, perform quality assurance testing, release, ship or store a compound or product or any component thereof. When used as a noun, &#147;<B>Manufacture</B>&#148; or
&#147;<B>Manufacturing</B>&#148; means any and all activities involved in Manufacturing a compound or product or any component thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.96</B> &#147;<B>NDA</B>&#148; means, with respect to a pharmaceutical product, a New Drug Application submitted to the FDA in accordance
with the FD&amp;C Act or any analogous application or submission with any Regulatory Authority outside of the United States for the purpose of obtaining Regulatory Approval to market and sell the product, including, an application with the EMA for
the purpose of obtaining Regulatory Approval to market and sell the product, using the EMA&#146;s centralized procedure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.97</B>
&#147;<B>Net Sales</B>&#148; means [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.98</B> &#147;<B>Notice of Dispute(s) for Executive Resolution</B>&#148; is defined in
<U>Section</U><U></U><U>&nbsp;18.3.2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.99</B> &#147;<B>Occurrence</B>&#148; is defined in
<U>Section</U><U></U><U>&nbsp;12.4.6</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.100</B> &#147;<B>Ongoing Clinical Trial Costs</B>&#148; is defined in
<U>Section</U><U></U><U>&nbsp;5.9.2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.101</B> &#147;<B>Ongoing Clinical Trials</B>&#148; mean those Clinical Trials of the
Products that are ongoing as of the Effective Date and set forth on <U>Schedule </U><U>1.101</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.102</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.103</B> [***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.104</B> &#147;<B>Order</B>&#148; means any writ, judgment, order, decree, injunction,
decision, verdict, award or ruling or other binding obligation of, or settlement or other similar agreement with, any Governmental Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.105</B> &#147;<B>Other Active Ingredient(s)</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;1.97</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.106</B> &#147;<B>Other Product</B>&#148; means any Product other than a Brepo Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.107</B> &#147;<B>Party</B>&#148; and &#147;<B>Parties</B>&#148; is defined in the introduction to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.108</B> &#147;<B>Patent Rights</B>&#148; means any and all (a)&nbsp;issued patents, (b)&nbsp;pending patent applications, including all
provisional applications, divisions, continuations, substitutions, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part</FONT></FONT> and renewals, and all patents granted thereon, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">(c)&nbsp;patents-of-addition,</FONT></FONT> <FONT STYLE="white-space:nowrap">re-examinations,</FONT> reissues and extensions or restorations by existing or future extension or restoration mechanisms, including patent term
adjustments, pediatric exclusivity, Patent Term Extensions or the equivalent thereof, (d)&nbsp;inventor&#146;s certificates, (e)&nbsp;other forms of government-issued rights substantially similar to any of the foregoing and (f)&nbsp;United States
and foreign counterparts of any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.109</B> &#147;<B>Patent Term Extension</B>&#148; is defined in
<U>Section</U><U></U><U>&nbsp;9.2.3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.110</B> &#147;<B>Permitted Contractor</B>&#148; means a CMO, CRO, CSO, distributor or
wholesaler, in each case, that is providing services on behalf of Licensee on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fee-for-service</FONT></FONT> basis in connection with the Development, Commercialization or
Manufacture of the Compounds or Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.111</B> &#147;<B>Person</B>&#148; means an individual, corporation, partnership, limited
liability company, trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, Governmental Authority or any other form of entity not specifically listed herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.112</B> &#147;<B>Pfizer</B>&#148; is defined in the introduction to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.113</B> &#147;<B>Pfizer Indemnitees</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;13.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.114</B> &#147;<B>Pfizer Marginal Royalty Rate</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;7.3.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.115</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.116</B> &#147;<B>Pfizer Product Trademarks</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;9.3.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.117</B> &#147;<B>Pfizer Quarter</B>&#148; means each of the four (4)&nbsp;thirteen (13) week periods commencing on December&nbsp;1 of any
Pfizer Year, consistently applied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.118</B> &#147;<B>Pfizer Royalties</B>&#148; is defined in
<U>Section</U><U></U><U>&nbsp;7.3.2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.119</B> &#147;<B>Pfizer Third Party License</B>&#148; is defined in
<U>Section</U><U></U><U>&nbsp;7.4.2(b)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.120</B> &#147;<B>Pfizer Year</B>&#148; means the twelve-month fiscal periods observed
by Pfizer commencing on December&nbsp;1 with respect to any country in the ROW and Japan, consistently applied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.121</B>
&#147;<B>Pharmacovigilance Agreement</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;5.8</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.122</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.123</B> &#147;<B>Pricing and Reimbursement Approval</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.124</B> &#147;<B>Priority Review Voucher</B>&#148; means a &#147;Section&nbsp;529&#148; US priority review voucher issued by the United
States Department of Health and Human Services that entitles the holder of such voucher to Priority Review of a single human drug application submitted under Section&nbsp;505(b)(1) of the Act or Section&nbsp;351(a) of the United States Public Health
Service Act, as further defined in Section&nbsp;529(a)(2) of the Act (21 U.S.C. &#167; 360ff(a)(2)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.125</B>
&#147;<B>Product</B>&#148; means each (a)&nbsp;Brepo Product, (b)&nbsp;TYK2 Product and (c)&nbsp;each other product, dosage, substance or formulation, for use in the Field, that is Covered by a Valid Claim under the Licensed Patent Rights, in each
case of clauses (a), (b) and (c), other than [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.126</B> &#147;<B>Purchase Agreement</B>&#148; means the Stock Purchase Agreement
entered into by Priovant Holdings, Inc., Roivant and Pfizer and dated as of the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.127</B> &#147;<B>Recipients</B>&#148;
is defined in <U>Section</U><U></U><U>&nbsp;11.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.128</B> &#147;<B>Reference Product</B>&#148; is defined in
<U>Section</U><U></U><U>&nbsp;1.59</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.129</B> &#147;<B>Regulatory Approval</B>&#148; means, with respect to a Product in any
country or jurisdiction, any approval, registration, license or authorization that is required by the applicable Regulatory Authority to market and sell such Product in such country or jurisdiction, including any Pricing and Reimbursement Approvals.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.130</B> &#147;<B>Regulatory Authority</B>&#148; means, with respect to a particular country or jurisdiction, any Governmental
Authority responsible for granting Regulatory Approvals for a Product in such country or jurisdiction in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.131</B>
&#147;<B>Regulatory Exclusivity</B>&#148; means exclusive marketing rights conferred by any Regulatory Authority with respect to a Product that prevents the Regulatory Authority from accepting or approving an application pursuant to [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.132</B> &#147;<B>Regulatory Filings</B>&#148; means, with respect to a Product, any submission to a Regulatory Authority of any
appropriate regulatory application, including any IND, NDA, exclusivity requests, any submission to a regulatory advisory board, any marketing authorization application, any documentation for customs authorities, and any supplement or amendment
thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.133</B> &#147;<B>Regulatory Transfer Activities</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;2</U> of <U>Schedule
4</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.134</B> &#147;<B>Relevant Records</B>&#148; is defined in
<U>Section</U><U></U><U>&nbsp;8.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.135</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.136</B> &#147;<B>Report</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;5.5.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.137</B> &#147;<B>Reporting Category</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;5.5.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.138</B> &#147;<B>Residuals</B>&#148; means information in <FONT STYLE="white-space:nowrap">non-tangible</FONT> form that is retained in
the unaided memory of persons who have had access to the Compounds, Products or Licensed Technology prior to the Effective Date, including ideas, concepts, <FONT STYLE="white-space:nowrap">know-how</FONT> or techniques contained therein, but not
including any ideas, concepts, <FONT STYLE="white-space:nowrap">know-how,</FONT> or techniques to the extent Covered by a Valid Claim in any Licensed Patent Right. A person&#146;s memory will be considered to be unaided if the person has not
intentionally memorized the information for the purpose of retaining and subsequently using or disclosing it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.139</B>
&#147;<B>Restricted Market</B>&#148; means, as applicable under Global Trade Control Laws, the Crimean Peninsula, Cuba, Iran, North Korea, and Syria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.140</B> &#147;<B>Restricted Party</B>&#148; means any individual or entity on any of the following &#147;<B>Restricted Party
Lists</B>&#148;: the list of sanctioned entities maintained by the United Nations; the Specially Designated Nationals List and the Sectoral Sanctions Identifications List, as administered by the U.S. Department of the Treasury Office of Foreign
Assets Control; the U.S. Denied Persons List, the U.S. Entity List, and the U.S. Unverified List, all administered by the U.S. Department of Commerce; the entities subject to restrictive measures and the Consolidated List of Persons, Groups and
Entities Subject to E.U. Financial Sanctions, as implemented by the E.U. Common Foreign&nbsp;&amp; Security Policy; the List of Excluded Individuals / Entities, as published by the U.S. Health and Human Services &#150; Office of Inspector General;
any lists of prohibited or debarred parties established under the FD&amp;C Act; the list of persons and entities suspended or debarred from contracting with the U.S. government; and similar lists of restricted parties maintained by the Governmental
Authorities of the countries that have jurisdiction over the activities conducted under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.141</B> &#147;<B>Review
Period</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;16.3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.142</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.143</B> &#147;<B>Roivant</B>&#148; is defined in the introduction to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.144</B> &#147;<B>ROW</B>&#148; means the Territory, excluding the United States and Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.145</B> &#147;<B>ROW Sales Milestone</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;7.2.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.146</B> &#147;<B>ROW Sales Milestone Payment</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;7.2.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.147</B> &#147;<B>Royalty Term</B>&#148; means, with respect to each Product in each country in the Territory or ROW, as applicable, the
period commencing on the First Commercial Sale of such Product in such country and expiring upon the later of: (a) [***] years following the date of First Commercial Sale of such Product in such country, (b)&nbsp;the expiration of all Regulatory
Exclusivity provided by an applicable Governmental Authority for such Product in such country and (c)&nbsp;the date upon which the use, sale, offer for sale or importation of such Product in such country would no longer infringe, but for the license
granted herein, a Valid Claim of a Licensed Patent Right. Notwithstanding anything herein to the contrary, the term &#147;Royalty Term&#148; will not apply to any Valid Claim that constitutes a [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.148</B> &#147;<B>SDNY</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;18.3.8</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.149</B> &#147;<B>SEC</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;12.2.17</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.150</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.151</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.152</B> &#147;<B>Significant Violation</B>&#148; means conduct that a reasonable person would consider a probable violation of applicable
policies or procedures designed to ensure compliance with Applicable Laws, which may result in significant or substantial liability if a Governmental Authority determined such conduct to be a violation of Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.153</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.154</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.155</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.156</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.157</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.158</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.159</B> &#147;<B>Specified Compound</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.160</B> &#147;<B>Subsidiary</B>&#148; means, with respect to any Person, any other Person with respect to which such first Person
(a)&nbsp;possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of such Person, whether through the beneficial ownership of voting securities, by contract or otherwise or (b)&nbsp;beneficially
owns at least fifty percent (50%) of the aggregate ordinary voting power of such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.161</B> &#147;<B>Tax Action</B>&#148; is
defined in <U>Section</U><U></U><U>&nbsp;7.10.2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.162</B> &#147;<B>Tax Credit</B>&#148; is defined in
<U>Section</U><U></U><U>&nbsp;7.10.3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.163</B> &#147;<B>Tax Payment</B>&#148; is defined in
<U>Section</U><U></U><U>&nbsp;7.10.3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.164</B> &#147;<B>Term</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;15.1</U>. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.165</B> &#147;<B>Terminated Products</B>&#148; means all [***], as applicable, with
respect to which this Agreement is terminated by either Party pursuant to <U>Section</U><U></U><U>&nbsp;15.2</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.166</B><B>
</B>&#147;<B>Terminated Territory</B>&#148; means each country with respect to which this Agreement is terminated by either Party pursuant to <U>Section</U><U></U><U>&nbsp;15.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.167</B> &#147;<B>Territory</B>&#148; means worldwide, other than any Terminated Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.168</B> &#147;<B>Third Party</B>&#148; means any Person other than a Party or an Affiliate of a Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.169</B> &#147;<B>Third Party Infringement</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;10.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.170</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.171</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.172</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.173</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.174</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.175</B> &#147;<B>Trademark</B>&#148; means trademarks, service marks, certification marks, trade dress, internet domain names, trade
names, identifying symbols, designs, product names, company names, slogans, logos or insignia, whether registered or unregistered, and all common law rights, applications and registrations therefor, and all goodwill associated therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.176</B> &#147;<B>Transaction Agreements</B>&#148; means (a)&nbsp;this Agreement, [***] and (e)&nbsp;each other agreement or certificate
to be delivered by any Party hereto at the Closing contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.177</B> &#147;<B>Transfer Tax</B>&#148; is defined in
<U>Section</U><U></U><U>&nbsp;7.10.1(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.178</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.179</B> [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.180</B> &#147;<B>TYK2</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;1.181</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.181</B> &#147;<B>TYK2 C</B><B>ompounds</B>&#148; means [***] (&#147;<B>TYK2</B>&#148;), [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.182</B> &#147;<B>TYK2 Product</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.183</B> &#147;<B>U.S. Sales Milestone</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;7.2.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.184</B> &#147;<B>U.S. Sales Milestone Payment</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;7.2.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.185</B> &#147;<B>United States</B>&#148; or &#147;<B>U.S.</B>&#148; means the United States of America and its territories and
possessions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.186</B> &#147;<B>Valid Claim</B>&#148; means with respect to a particular country, a
claim of a Patent Right within the Licensed Patent Rights that [***] (i) has not been held permanently revoked, unenforceable or invalid by a decision of a court or other Governmental Authority of competent jurisdiction, which decision is unappealed
or unappealable within the time allowed for appeal and (ii)&nbsp;has not expired or been cancelled, withdrawn, abandoned, disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise and [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.187</B> &#147;<B>VAT</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;7.10.1(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.188</B> &#147;<B>Working Group</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;6.4.6</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.189</B> <B>Interpretation</B>. Except where the context expressly requires otherwise, (a)&nbsp;the use of any gender herein shall be
deemed to encompass references to all genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b)&nbsp;the words &#147;include&#148;, &#147;includes&#148; and &#147;including&#148; shall be deemed to be followed
by the phrase &#147;without limitation&#148;, (c)&nbsp;the word &#147;will&#148; shall be construed to have the same meaning and effect as the word &#147;shall&#148;, (d)&nbsp;any definition of or reference to any agreement, instrument or other
document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth
herein), (e) any reference herein to any Person shall be construed to include the Person&#146;s successors and assigns, (f)&nbsp;the words &#147;herein&#148;, &#147;hereof&#148; and &#147;hereunder&#148;, and words of similar import, shall be
construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g)&nbsp;all references herein to Sections, Exhibits or Schedules shall be construed to refer to Sections, Exhibits or Schedules of this Agreement, and
references to this Agreement include all Exhibits and Schedules hereto, (h)&nbsp;the word &#147;notice&#148; means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications
contemplated under this Agreement, (i)&nbsp;provisions that require that a Party, the Parties or any committee hereunder &#147;agree,&#148; &#147;consent&#148; or &#147;approve&#148; or the like shall require that such agreement, consent or approval
be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding instant messaging), (j) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed
to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, and (k)&nbsp;the term &#147;or&#148; shall be interpreted in the inclusive sense commonly associated with the term &#147;and/or.&#148;
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LICENSE GRANT. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>License Grant to Licensee.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.1.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Licensed Patent Rights</B>. Subject to the terms and conditions of this Agreement, including
Pfizer&#146;s retained rights set forth in <U>Section</U><U></U><U>&nbsp;2.4</U>, Pfizer hereby grants to Licensee an exclusive (even as to Pfizer and its Affiliates, except as otherwise provided in <U>Section</U><U></U><U>&nbsp;2.4</U>),
sublicensable, through multiple tiers (subject to <U>Section</U><U></U><U>&nbsp;2.2</U>), milestone- and royalty-bearing right and license under the Licensed Patent Rights to use, have used, Develop, have Developed, Manufacture, have Manufactured,
Commercialize, and have Commercialized Compounds and Products in the Field within the Territory. The [***] shall be deemed to be included in the Licensed Patent Rights for the purpose of this <U>Section</U><U></U><U>&nbsp;2.1.1</U> only, but only on
a fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> <FONT STYLE="white-space:nowrap">non-royalty</FONT> bearing basis. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.1.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT></B>. Subject to the terms and conditions of
this Agreement, Pfizer hereby grants to Licensee a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable, through multiple tiers (subject to <U>Section</U><U></U><U>&nbsp;2.2</U>), milestone- and royalty-bearing right and license to
use the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize, and have Commercialized and otherwise Exploit Compounds and Products in the Field within the
Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.1.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Affiliates</B>. To the extent any of the Licensed Technology is Controlled by an Existing Pfizer Affiliate,
then promptly following the Effective Date, Pfizer shall cause such Existing Pfizer Affiliate to take all necessary actions to give effect to the licenses granted under this <U>Section</U><U></U><U>&nbsp;2.1</U>, and carry out the other obligations
of Pfizer hereunder (including under <U>Section</U><U></U><U>&nbsp;9.2</U> and <U>Section</U><U></U><U>&nbsp;10.2</U>). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.1.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Wrong Pockets.</B> [***] </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sublicense Rights.</B> [***] Licensee may sublicense the rights granted to it by Pfizer under <U>Sections
2.1.1</U> and <U>2.1.2</U>, through multiple tiers, without Pfizer&#146;s approval. Any and all sublicenses shall be subject to the following requirements: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.2.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>All sublicenses shall be subject to and consistent with the terms and conditions of this Agreement and
shall (a) [***] and (b)&nbsp;preclude the granting of further sublicenses in contravention with the terms and conditions of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.2.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In no event shall any sublicense relieve Licensee of any of its obligations under this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.2.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Except with respect to a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> sublicense by Licensee to
an Affiliate or Permitted Contractor of less than all or substantially all of the rights granted to Licensee by Pfizer under <U>Sections 2.1.1</U> and <U>2.1.2</U> and which does not specifically reference this Agreement or the Licensed Technology,
Licensee shall [***]. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">In addition, <U>Sections</U><U> </U><U>2.2.1</U>, <U>2.2.2</U>, and <U>2.2.3</U> shall apply to
sublicenses granted by Pfizer under the rights granted by Licensee to Pfizer hereunder, <I>mutatis mutandis</I>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>License Grant to Pfizer.</B> Subject to the terms and conditions of this Agreement, Licensee hereby
grants to Pfizer (a)&nbsp;an exclusive (even as to Licensee and its Affiliates), sublicensable, through multiple tiers, milestone- and royalty-bearing right and license under the Licensed Patent Rights to Commercialize and have Commercialized
(i)&nbsp;Compounds and Products in the Field in the ROW and (ii)&nbsp;TYK2 Compounds and Other Products in the Field in Japan, and (b)<B></B>&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable, through multiple tiers,
milestone- and royalty-bearing right and license under the Developed IP to Commercialize and have Commercialized (i)&nbsp;Compounds and Products in the Field in the ROW and (ii)&nbsp;TYK2 Compounds and Other Products in the Field in Japan. Licensee
shall use reasonable best efforts to promptly disclose to Pfizer all Developed IP during the Term. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Retained Rights. [***]</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.5</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Residuals. </B>Pfizer may use for any purpose the Residuals resulting from access to or work with the
Compounds, Products or Licensed Technology; <I>provided</I> that, for the avoidance of doubt, this <U>Section</U><U></U><U>&nbsp;2.5</U> shall not constitute a grant back of the license and rights granted to Licensee under the Licensed Patent Rights
pursuant to <U>Section</U><U></U><U>&nbsp;2.1.1</U> or a license or other rights under any Patent Right Controlled by Licensee. Any use made by the Pfizer of any such Residuals is on an &#147;as is, where is&#148; basis, with all faults and all
representations and warranties disclaimed and at Pfizer&#146;s sole risk. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.6</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>No Additional Rights.</B> Nothing in this Agreement shall be construed to confer any rights upon
Licensee by implication, estoppel, or otherwise as to any technology or Intellectual Property Rights of Pfizer or its Affiliates other than the rights in Licensed Technology expressly granted herein, regardless of whether such technology or
Intellectual Property Rights shall be dominant or subordinate to any Licensed Technology. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CLOSING. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Closing. </B>The closing of the transactions contemplated by this Agreement (the
&#147;<B>Closing</B>&#148;) shall take place remotely via the exchange of documents and signature pages on the date hereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Closing Deliverables.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Closing Deliverables and Actions by Pfizer</B>. At the Closing, Pfizer shall deliver, or cause to be
delivered, to Licensee each of the Transaction Agreements duly executed by Pfizer or the applicable Pfizer Affiliate that is a party thereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.2.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Closing Deliverables and Actions by Licensee</B>. At the Closing, Licensee shall deliver, or cause to
be delivered, to Pfizer the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a duly executed certificate by the Secretary of Licensee certifying as to: (i)&nbsp;the full force and effect
of the articles of incorporation and bylaws (or equivalent governing documents) of Licensee attached to such certificate as an exhibit, (ii)&nbsp;the accuracy and full force and effect of resolutions adopted by the board of directors of Licensee
approving the transactions contemplated by the Transaction Agreements, attached to such certificate as an exhibit, and (iii)&nbsp;the good standing of the Licensee in its jurisdiction of formation, with a certificate of good standing from such
jurisdiction dated no more than [***] prior to the Effective Date, attached to such certificate as an exhibit; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each of the Transaction Agreements duly executed by Licensee or the applicable Licensee Affiliate that is a
party thereto; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Inventory Payment pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TRANSFER ACTIVITIES.</B> <U>Schedule 4</U> sets forth the documentation, materials and Licensed <FONT
STYLE="white-space:nowrap">Know-How</FONT> that Pfizer will transfer to Licensee or its designee and related activities and services to be performed by the Parties. If there is an inconsistency between <U>Schedule 4</U> and this Agreement, the terms
of this Agreement shall prevail.<B> </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEVELOPMENT; REGULATORY; MANUFACTURING. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>General</B>. Except as set forth on <U>Schedule 4</U> or as otherwise expressly set forth in this
<U>Section</U><U></U><U>&nbsp;5</U>, as between the Parties, Licensee shall have sole responsibility for [***] and the sole authority over and control of, the Development, Manufacture and Regulatory Approval of Compounds and Products in the Field in
the Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Alliance Management.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.2.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>A</B><B>lliance Managers</B>. Within [***] following the Effective Date, each Party will designate
(by written notice to the other Party) a single individual to act as its alliance manager under this Agreement to conduct the activities described below in <U>Section</U><U></U><U>&nbsp;5.2.2</U> (each, an &#147;<B>Alliance Manager</B>&#148;). Each
Party may change the person designated as its Alliance Manager upon written notice (including via email notification) to the other Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.2.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>R</B><B>oles and Responsibilities</B>. The Alliance Managers will serve as the primary contact point
between the Parties for the activities under this Agreement for the purpose of providing each Party with information on the progress of Development and Commercialization of the Products and shall have the following responsibilities:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">perform such other functions as agreed by the Parties. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.3</B><B><U></U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U></U></B><B>Diligence.</B> Licensee shall itself, or through its Affiliates or sublicensees, use
Commercially Reasonable Efforts to [***] (collectively, the &#147;<B>Development Commitments</B>&#148;). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.4<U></U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U></U>Regulatory Filings. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.4.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>General</B>. In connection with its efforts to Develop the Products, as between the Parties, Licensee
shall bear all responsibility [***] for submitting Regulatory Filings and obtaining and, subject to <U>Section</U><U></U><U>&nbsp;5.4.6</U>, maintaining Regulatory Approval for the Products in the Territory, subject to such Regulatory Transfer
Activities to be performed by Pfizer as set forth in <U>Section</U><U></U><U>&nbsp;2</U> of <U>Schedule</U><U></U><U>&nbsp;4</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.4.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>U.S. Review Rights</B>. Licensee will own all Regulatory Filings, Regulatory Approvals, and related
regulatory documents for the Products for the U.S. and Brepo Products in Japan. Licensee shall provide Pfizer with a reasonable opportunity to review and comment on all material Regulatory Filings relating to all Products submitted to the FDA, as
well as all Global Regulatory Filings, by or on behalf of Licensee during the Term. Licensee shall promptly provide Pfizer with access to key correspondence with the FDA relating to Products. For clarity, [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.4.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>ROW Review Rights</B>. Notwithstanding <U>Section</U><U></U><U>&nbsp;5.4.1</U>, and except with
respect to Global Regulatory Filings which are covered by <U>Section</U><U></U><U>&nbsp;5.4.2</U>, Licensee shall provide Pfizer with an opportunity to review and comment on all material Regulatory Filings (i)&nbsp;in the ROW and (ii)&nbsp;other
than with respect to Brepo Compounds or Brepo Products, in Japan, prior to submission to the applicable Regulatory Authority. Licensee shall provide access to interim drafts of such material Regulatory Filings to Pfizer, and Pfizer shall provide its
comments on the near final drafts of such material Regulatory Filings or of proposed material actions within [***], or such other longer period of time mutually agreed to by the Parties. In the event that a Regulatory Authority establishes a
response deadline for any such material Regulatory Filing or material action shorter than such [***] period, the Parties shall work cooperatively to ensure that Pfizer has a reasonable opportunity for review and comment within such deadlines.
Licensee shall, [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.4.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>ROW Information Rights</B>. Subject to the immediately following sentence, Licensee shall provide
Pfizer with (a)&nbsp;access to or copies of all material written or electronic correspondence (other than Regulatory Filings) relating to the Development or Commercialization of (i)&nbsp;Compounds or Products received by Licensee or its Affiliates
or sublicensees from, or forwarded by Licensee or its Affiliates or sublicensees to, the Regulatory Authorities in the ROW and (ii)&nbsp;TYK2 Compounds or Other Products received by Licensee or its Affiliates or sublicensees from, or forwarded by
Licensee or its Affiliates or sublicensees to, the Regulatory Authorities in Japan, and (b)&nbsp;copies of all meeting minutes and summaries of all meetings, conferences, and discussions held by Licensee or its Affiliates or sublicensees with the
Regulatory Authorities (i)&nbsp;in the ROW and (ii)&nbsp;solely with respect to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
TYK2 Compounds or Other Products, in Japan, including copies of all contact reports produced by Licensee or its Affiliates or sublicensees, in each case ((a) and (b)) within [***] following the
end of each Calendar Quarter (which Licensee may provide to Pfizer through upload to a mutually acceptable data room). If such written or electronic correspondence received from any such Regulatory Authority relates to the withdrawal, suspension, or
revocation of any Regulatory Approval for a Product, the prohibition or suspension of the supply of a Compound or Product, or the initiation of any investigation, review, or inquiry by such Regulatory Authority concerning the safety of a Compound or
Product, Licensee shall notify Pfizer and provide Pfizer with copies of such written or electronic correspondence as soon as practicable, but not later than [***] after receipt of such correspondence. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.4.5</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>ROW Meeting Rights</B>. Licensee shall provide Pfizer with prior written notice of any scheduled
meeting, conference, or discussion (including any advisory committee meeting) with a Regulatory Authority (i)&nbsp;in the ROW relating to a Product and (ii)&nbsp;in Japan relating to a Other Product, within [***] after Licensee or its Affiliate or
sublicensee first receives notice of the scheduling of such meeting, conference, or discussion (or within such shorter period as may be necessary in order to give Pfizer a reasonable opportunity to attend such meeting, conference, or discussion).
[***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.4.6</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Transfer of Regulatory Approvals in the ROW and Japan</B>. As soon as practicable and in any event
within [***] following receipt of Regulatory Approval for (a)&nbsp;a Product in a country in the ROW or (b)&nbsp;a Other Product in Japan, Licensee shall execute and provide to Pfizer all documents (in a form reasonably acceptable to Pfizer)
required to transfer such Regulatory Approval to Pfizer,<I> provided</I> that if the provision of any such documents is delayed by a Regulatory Authority for reasons outside of Licensee&#146;s reasonable control, then such period will be extended
for the period of delay by such Regulatory Authority. Licensee shall provide Pfizer with the status of the progress of each such Regulatory Approval transfer [***]. Licensee shall also provide a copy of each certificate of registration of the
transfer of each such Regulatory Approval to Pfizer promptly after receiving such certificate from the respective Regulatory Authority. Licensee shall use Commercially Reasonable Efforts to keep the transition of Regulatory Approvals for Products in
the ROW and Other Products in Japan as short as possible. Pfizer shall use Commercially Reasonable Efforts to assist, or to cause its Affiliates to assist, Licensee and its Affiliates in the transfer of Regulatory Approvals for Products in the ROW
and Other Products in Japan to Pfizer, including by providing Licensee and its Affiliates with any information reasonably requested by Licensee and necessary for the transfer of such Regulatory Approvals or requested by any Regulatory Authority and,
in each case, reasonably available to Pfizer or its Affiliates. Following the transfer of a Regulatory Approval for a Product in a country in the ROW to Pfizer or a Other Product in Japan to Pfizer, Pfizer shall bear all responsibility and expense
for maintaining such Regulatory Approval. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.4.7</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Priority Review Voucher.</B> If Licensee elects to transfer to a Third Party or otherwise monetize a
Priority Review Voucher, all proceeds thereof shall be allocated to Licensee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Progress Reporting. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.5.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Semi-Annual Reports</B>. During the First Reporting Window, [***]. <B><I></I></B>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.5.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Annual Reports</B>. For each Reporting Category, after the end of the applicable First Reporting
Window, Licensee&#146;s reporting obligations will be limited as follows: [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.5.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Conclusion of Reports</B>. Notwithstanding the foregoing, Licensee&#146;s reporting obligations to
Pfizer under <U>Section</U><U></U><U>&nbsp;5.5.1</U> or <U>5.5.2</U> with respect to any and all Products described therein shall end on [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.5.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Cooperation</B>. Licensee shall promptly respond to Pfizer&#146;s reasonable inquiries regarding the
Development activities related to the Compounds and Products, and regarding clinical recruitment progress, occurred adverse events, and the status of any applications for Regulatory Approvals related to the Compounds and Products in Development by
Licensee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.6</B><B><U></U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U></U></B><B>Permitted Contractors</B>. Licensee may subcontract with Permitted Contractors to handle
certain clinical Development or Manufacture activities in the Territory and Commercialization activities in the U.S. and Japan, in Licensee&#146;s reasonable discretion, consistent with the then-current Development Plan. As between the Parties, all
costs of Permitted Contractors will be borne solely by Licensee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.7</B><B><U></U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U></U></B><B>Development Plan</B>. Licensee&#146;s plan for conducting Development activities with respect
to the Compounds and Products is set forth in the development plan set forth in <U>Schedule </U><U>5.7</U>, as amended by Licensee pursuant to this <U>Section</U><U></U><U>&nbsp;5.7</U> (the &#147;<B>Development Plan</B>&#148;). For clarity, the
Development Plan shall not cover the Ongoing Clinical Trials, and the Development Plan is provided for informational purposes only and is not intended to expand or diminish the scope of Licensee&#146;s diligence obligations in
<U>Section</U><U></U><U>&nbsp;5.3</U>. [***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.8</B><B><U></U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U></U></B><B>Safety Reporting</B>. The safety units from each of the Parties shall agree upon a
pharmacovigilance agreement (the &#147;<B>Pharmacovigilance Agreement</B>&#148;) for exchanging adverse event and other safety information relating to Compounds and Products prior to both Parties&#146; initiation of any clinical or marketing
activity implicating pharmacovigilance obligations for the Compounds and Products in the Territory. Such Pharmacovigilance Agreement shall ensure that adverse event and other safety information is exchanged according to a schedule that will permit
each Party to comply with Applicable Laws, including any local regulatory requirements as a Regulatory Approval holder. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.9<U></U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U></U>Ongoing Clinical Trials. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.9.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>General</B>. From and after the Effective Date, Pfizer shall remain as sponsor of, and have sole
decision making authority and responsibility for directing the activities and conduct of, the Ongoing Clinical Trials; <I>provided,</I> that [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.9.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Ongoing Clinical Trial Costs</B>. Pfizer shall bear [***] of all costs (external and internal)
invoiced to or incurred by Pfizer after the Effective Date in connection with the performance of the Ongoing Clinical Trials (&#147;<B>Ongoing Clinical Trial Costs</B>&#148;), except [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within [***] after the end of each Calendar Quarter, Pfizer shall deliver to Licensee an invoice setting forth
the Ongoing Clinical Trial Costs reimbursable by Licensee pursuant to this <U>Section</U><U></U><U>&nbsp;5.9.2</U>, together with reasonable supporting documentation. Licensee shall pay to Pfizer its allocation of such Ongoing Clinical Trial Costs
within [***] of Pfizer&#146;s delivery of the applicable undisputed invoice. In addition, (a)&nbsp;within [***] days after the end of each month, Pfizer shall deliver to Licensee a good faith estimate of the amount for which it anticipates invoicing
Licensee for reimbursable Ongoing Clinical Trial Costs pursuant to this <U>Section</U><U></U><U>&nbsp;5.9.2</U> in the preceding month [***], (b) between [***] of each year, Pfizer shall deliver to Licensee a quarterly forecast of the amount for
which Pfizer anticipates that it will invoice Licensee through the conclusion of the Ongoing Clinical Trials, together with reasonable supporting documentation for such amount, and (c)&nbsp;if, at any time, Pfizer forecasts an aggregate increase or
decrease of more than [***] for any Ongoing Clinical Trial during any remaining [***] period compared to last forecast provided, Pfizer shall promptly provide Licensee updated an quarterly forecast through until completion of the applicable Ongoing
Clinical Trial within [***] of determining such increase or decrease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>[***] </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>[***] </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.12</B><B><U></U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U></U></B><B>Compliance</B>. Licensee shall, and shall cause its Affiliates, to comply with all Applicable
Laws with respect to the Development and Manufacture of the Products. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMMERCIALIZATION. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>6.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>General. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.1.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>U.S. and Japan.</B> Subject to [***], Licensee shall have sole responsibility for [***], and the sole
authority over and control of, the Commercialization of Compounds and Products in the Field in the U.S. and Brepo Compounds and Brepo Products in the Field in Japan. Licensee shall have the sole right to invoice and book sales, establish all terms
of sale (including pricing and discounts) and warehousing, and distribute the Products in the U.S. and the Brepo Products in Japan and to perform or cause to be performed all related services. Licensee shall handle all returns, recalls, or
withdrawals, order processing, invoicing, collection, distribution, and inventory management with respect to the Products in the U.S. and Brepo Products in Japan. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.1.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ROW</B>. As between the Parties, Pfizer shall have sole responsibility for [***], and the sole authority
over and control of, the Commercialization of Compounds and Products in the Field in the ROW and TYK2 Compounds and Other Products in the Field in Japan. Pfizer shall have the sole right to invoice and book sales, establish all terms of sale
(including pricing and discounts) and warehousing, and distribute the Products in the ROW and the Other Products in Japan and to perform or cause to be performed all related services. Pfizer shall handle all returns, recalls, or withdrawals, order
processing, invoicing, collection, distribution, and inventory management with respect to the Products in the ROW and the Other Products in Japan. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>6.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Diligence. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Licensee</B>. Licensee shall itself, or through its Affiliates or sublicensees, use Commercially Reasonable
Efforts to Commercialize [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.2.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Pfizer</B>. Pfizer shall itself, or through its Affiliates or sublicensees, use Commercially
Reasonable Efforts to Commercialize [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>6.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>[***] </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>6.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>[***] </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>6.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Territory Integrity. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.5.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Subject to its rights pursuant to <U>Section</U><U></U><U>&nbsp;6.3</U>, Pfizer hereby covenants and
agrees that during the Term it shall not (and shall cause its Affiliates not to), either itself or through a Third Party, Commercialize any (i)&nbsp;Products for use in the Field in the United States or (ii)&nbsp;Brepo Products for use in the Field
in Japan. Without limiting the generality of the foregoing, Pfizer shall not (a)&nbsp;engage in any </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
advertising activities relating to (i)&nbsp;Products for use in the Field directed primarily to customers located in the United States or (ii)&nbsp;Brepo Products for use in the Field directed
primarily to customers located in Japan or (b)&nbsp;actively or intentionally solicit orders from any prospective purchaser of a (i)&nbsp;Product for use in the Field located in the United States or (ii)&nbsp;Brepo Product for use in the Field
located in Japan. To the extent permitted by Applicable Law, if Pfizer receives any order from a prospective purchaser for a (i)&nbsp;Product in the Field located in the United States or (ii)&nbsp;Brepo Product in the Field located in Japan, Pfizer
shall promptly refer that order to Licensee and shall not accept any such order or deliver or tender (or cause to be delivered or tendered) the Product under such order. If Pfizer should reasonably know that its customer or distributor is actively
engaged itself or through a Third Party in the sale or distribution of any Product inside the United States in the Field, then Pfizer shall (i)&nbsp;within [***] of becoming aware of such activities, notify Licensee regarding such activities and
provide all information reasonably available to Pfizer that Licensee may reasonably request concerning such activities and (ii)&nbsp;use Commercially Reasonable Efforts (including cessation of sales to such customer) necessary to limit such sale or
distribution inside the United States in the Field, unless otherwise agreed in writing by the Parties. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.5.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Licensee hereby covenants and agrees that during the Term it shall not (and shall cause its Affiliates
not to), either itself or through a Third Party, Commercialize any (i)&nbsp;Products for use in the Field in the ROW or (ii)&nbsp;Other Products for use in the Field in Japan. Without limiting the generality of the foregoing, with respect to
countries within the ROW and Japan, Licensee shall not (a)&nbsp;engage in any advertising activities relating to (i)&nbsp;Products for use in the Field directed primarily to customers located in such countries within the ROW or (ii)&nbsp;Other
Products for use in the Field directed primarily to customers located in Japan or (b)&nbsp;actively or intentionally solicit orders from any prospective purchaser of a (i)&nbsp;Product for use in the Field located in such countries within the ROW or
(ii)&nbsp;Other Product for use in the Field located in Japan. To the extent permitted by Applicable Laws, if Licensee receives any order from a prospective purchaser for a (i)&nbsp;Product in the Field located in a country inside of the ROW or
(ii)&nbsp;Other Product in the Field located in Japan, Licensee shall promptly refer that order to Pfizer and shall not accept any such order or deliver or tender (or cause to be delivered or tendered) the Product under such order. If Licensee
should reasonably know that its customer or distributor is actively engaged itself or through a Third Party in the sale or distribution of any (i)&nbsp;Product inside the ROW in the Field or (ii)&nbsp;Other Product inside Japan in the Field, then
Licensee shall (i)&nbsp;within [***] of becoming aware of such activities, notify Pfizer regarding such activities and provide all information reasonably available to Licensee that Pfizer may reasonably request concerning such activities and
(ii)&nbsp;use Commercially Reasonable Efforts (including cessation of sales to such customer) necessary to limit such sale or distribution inside the ROW in the Field, unless otherwise agreed in writing by the Parties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>6.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>[***] </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>6.7</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Compliance</B>. Each Party shall, and shall cause its Affiliates, to comply with all Applicable Laws,
Anti-Corruption Laws, and Healthcare Laws with respect to the Commercialization of the Products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PAYMENT TERMS. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Inventory Payment</B>. In consideration of the inventory set forth on <U>Schedule 7.1</U>, Licensee
shall pay to Pfizer a <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> and <FONT STYLE="white-space:nowrap">non-creditable</FONT> payment of $10,000,000 (the &#147;<B>Inventory
Payment</B>&#148;) within [***] of the Effective Date. The inventory set forth on <U>Schedule 7.1</U> shall be transferred to Licensee as soon as reasonably practicable, and in any event within [***] from the Effective Date, and the Parties shall
negotiate in good faith and execute a quality agreement with respect to such inventory prior to such transfer, and in any event within [***] from the Effective Date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sales Milestone Payments. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.2.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>U.S. </B>Licensee shall pay to Pfizer the following <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT
STYLE="white-space:nowrap">non-creditable,</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> payment when the milestone indicated below is achieved (such event, the &#147;<B>U.S. Sales Milestone</B>&#148; and such payment, the
&#147;<B>U.S. Sales Milestone Payment</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>U.S. SALES MILESTONE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>U.S. SALES MILESTONE PAYMENT</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Licensee shall notify Pfizer, via email notification to the Alliance Manger, [***] and to a finance contact provided by Pfizer, of the
achievement of the U.S. Sales Milestone Payment within [***] after the end of the applicable Licensee Quarter in which the U.S. Sales Milestone is achieved, following which Pfizer shall provide a written acknowledgement (which may be via email
notification) of Licensee&#146;s notice and changes to Pfizer&#146;s bank account information, if any. Licensee shall pay to Pfizer the U.S. Sales Milestone Payment within [***] following receipt of Pfizer&#146;s written acknowledgement. For the
avoidance of doubt: (i)&nbsp;the U.S. Sales Milestone Payment shall be payable only once upon first achievement of the U.S. Sales Milestone; and (ii)&nbsp;satisfaction of the U.S. Sales Milestone by a sublicensee or assignee of, or Third Party
retained by, Licensee or its Affiliates shall be deemed to have been satisfied by Licensee for purposes of this <U>Section</U><U></U><U>&nbsp;7.2.1</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.2.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>ROW</B>. Pfizer shall pay to Licensee the following <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT
STYLE="white-space:nowrap">non-creditable,</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> payment when the milestone indicated below is achieved (such event, the &#147;<B>ROW Sales Milestone</B>&#148; and such payment, the
&#147;<B>ROW Sales Milestone Payment</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>ROW SALES MILESTONE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>ROW SALES MILESTONE PAYMENT</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Pfizer shall pay to Licensee the ROW Sales Milestone Payment within [***] after the end of the applicable
Pfizer Quarter in which the ROW Sales Milestone is achieved. For the avoidance of doubt: (i)&nbsp;the ROW Sales Milestone Payment shall be payable only once upon first achievement of the ROW Sales Milestone; and (ii) satisfaction of the ROW Sales
Milestone by a sublicensee or assignee of, or Third Party retained by, Pfizer or its Affiliates shall be deemed to have been satisfied by Pfizer for purposes of this <U>Section</U><U></U><U>&nbsp;7.2.2</U>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Royalty Payments. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.3.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Licensee.</B> Licensee shall pay to Pfizer <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT
STYLE="white-space:nowrap">non-creditable</FONT> royalties in the amount of the marginal royalty rates (set forth below) (&#147;<B>Licensee Marginal Royalty Rates</B>&#148;) on the aggregate Net Sales resulting from the sale of (i)&nbsp;Products, on
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis, in the U.S. and (ii)&nbsp;Brepo Products, on a Brepo <FONT STYLE="white-space:nowrap">Product-by-Brepo</FONT> Product basis, in Japan, during
each Licensee Year (collectively, &#147;<B>Licensee Royalties</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>U.S. AND JAPAN NET SALES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>LICENSEE MARGINAL ROYALTY RATE</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Each Licensee Marginal Royalty Rate set forth in the table above shall apply only to that portion of the Net Sales of each Product in the U.S.
and each Brepo Product in Japan during a given Licensee Year that falls within the indicated range. Within [***] following the expiration of each Licensee Quarter (or [***] if such Licensee Quarter is the last Licensee Quarter of a Licensee Year)
after the date of the First Commercial Sale in the U.S., Licensee will provide Pfizer, via email notification to the Alliance Manger, [***] and to a finance contact provided by Pfizer, a report that includes reasonably detailed information regarding
a total monthly sales </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
calculation of Net Sales of Product in the U.S., Net Sales of Brepo Product in Japan and all Licensee Royalties payable to Pfizer for the applicable Licensee Quarter, following which Pfizer shall
provide a written acknowledgement (which may be via email notification) of Licensee&#146;s report and changes to Pfizer&#146;s bank account information, if any. Licensee shall pay to Pfizer the Licensee Royalties within [***] following receipt of
Pfizer&#146;s written acknowledgement. Licensee Royalties will be payable on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(i)&nbsp;Product-by-Product</FONT></FONT> basis during the Royalty Term for such Product until the
expiration of the Royalty Term for such Product in the U.S. and (ii)&nbsp;Brepo <FONT STYLE="white-space:nowrap">Product-by-Brepo</FONT> Product basis during the Royalty Term for such Product until the expiration of the Royalty Term for such Brepo
Product in Japan. For purposes hereof, Net Sales during the Royalty Term for each Product in the U.S. and each Brepo Product in Japan include sales of such Products that occur after the expiration of the Royalty Term or termination of this Agreement
where the Manufacture, use or other Exploitation of such Products was Covered by a Valid Claim of a Licensed Patent Right during the Royalty Term. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.3.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Pfizer</B>. Pfizer shall pay to Licensee <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT
STYLE="white-space:nowrap">non-creditable</FONT> royalties in the amount of the marginal royalty rates (set forth below) (&#147;<B>Pfizer Marginal Royalty Rates</B>&#148;) on the aggregate Net Sales resulting from the sale of (i)&nbsp;Products, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis, in the ROW and (ii)&nbsp;Other Products, on an Other
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Other</FONT></FONT> Product basis, in Japan, during each Pfizer Year (collectively, &#147;<B>Pfizer Royalties</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>ROW AND JAPAN NET SALES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>PFIZER MARGINAL ROYALTY RATE</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Each Pfizer Marginal Royalty Rate set forth in the table above shall apply only to that portion of the Net
Sales of each Product in the ROW and each Other Product in Japan during a given Pfizer Year that falls within the indicated range. Pfizer shall pay to Licensee the applicable Pfizer Royalties within [***] following the expiration of each Pfizer
Quarter after the date of the First Commercial Sale in the ROW or Japan, as applicable. All ROW Royalty payments shall be accompanied by a report that includes reasonably detailed information regarding a total monthly sales calculation of Net Sales
of Product in the ROW, Net Sales of Other Product in Japan, and all Pfizer Royalties payable to Licensee for the applicable Pfizer Quarter (including any foreign exchange rates employed). Pfizer Royalties will be payable on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(i)&nbsp;Product-by-Product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis during the Royalty Term for such
Product in each country until the expiration of the Royalty Term for such Product in such country in the ROW and (ii)&nbsp;Other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Other</FONT></FONT> Product basis during
the Royalty Term for such Product in Japan until the expiration of the Royalty Term for such Product in Japan. For purposes hereof, Net Sales during the Royalty Term for each Product in the ROW and each Other Product in Japan include sales of such
Products that occur after the expiration of the Royalty Term or termination of this Agreement where the Manufacture, use or other Exploitation of such Products was Covered by a Valid Claim of a Licensed Patent Right during the Royalty Term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Royalty Deduction. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.4.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Expiration of Valid Claims</B><B> and Regulatory Exclusivity</B>. If, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis, the Royalty Term for such Product in such
country is only being calculated under [***], then the Licensee Marginal Royalty Rates or Pfizer Marginal Royalty Rates used to calculate the Licensee Royalties or Pfizer Royalties, as applicable, with respect to such Product in such country shall
by reduced by [***]. If, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis, the
Royalty Term for such Product in such country is only being calculated under [***], then the Licensee Marginal Royalty Rates or Pfizer Marginal Royalty Rates used to calculate the Licensee Royalties or Pfizer Royalties, as applicable, with respect
to such Product in such country shall by reduced by [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.4.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Third Party Licenses</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Licensee, its Affiliates and sublicensees shall have the first right to obtain a license under any Third Party
Patent Rights that is [***] for the Exploitation of any Compound in any Product in the Field in the Territory (each such license, a &#147;<B>Licensee Third Party License</B>&#148;). Licensee, or its applicable Affiliate or sublicensee, shall pay all
amounts due under any such Licensee Third Party License; <I>provided</I>, that Licensee shall be entitled to reduce the Licensee Royalties due to Pfizer upon Net Sales of a Product by up to [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Licensee does not, with respect to its first right under <U>Section</U><U></U><U>&nbsp;7.4.2(a)</U>, obtain
a license under any Third Party Patent Rights that is necessary or reasonably useful for the Commercialization of any Compound in any Product in the Field in the ROW or any TYK2 Compound in any Other Product in the Field in Japan (&#147;<B>Pfizer
Third Party License</B>&#148;), then Pfizer, its Affiliates and sublicensees shall have the right to obtain such Pfizer Third Party License. Pfizer, or its applicable Affiliate or sublicensee, shall pay all amounts due under Pfizer Third Party
Licenses; <I>provided</I>, that Pfizer shall be entitled to reduce the Pfizer Royalties due to Licensee upon Net Sales of a Product by up to [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.4.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Generic Competition</B>. If, at any time during the Royalty Term, Generic Competition exists in a
given country with respect to a Reference Product, then the Pfizer Marginal Royalty Rates and Licensee Marginal Royalty Rates used to calculate royalties for such Reference Product in such country shall be reduced by [***] for so long as such
Generic Competition exists. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.4.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Maximum Deductions</B>. Notwithstanding anything in Sections 7.4.1, 7.4.2, or 7.4.3 to the contrary,
under no circumstances shall the reductions set forth in this Section&nbsp;7.4 cause (a)&nbsp;the total Licensee Royalties payable to Pfizer in any Licensee Quarter or Pfizer Royalties payable to Licensee in any Pfizer Quarter to be reduced by more
than [***] of the amount that would otherwise be due without giving effect to this Section&nbsp;7.4, or (b)&nbsp;the Licensee Marginal Royalty Rates or Pfizer Marginal Royalty Rates used to calculate Licensee Royalties in any Licensee Quarter or
Pfizer Royalties in any Pfizer Quarter to be reduced by more than [***] of the rates set forth in Section&nbsp;7.3. Notwithstanding the foregoing, [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.5</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Blended Royalty</B>. Licensee acknowledges that (a)&nbsp;the Licensed
<FONT STYLE="white-space:nowrap">Know-How</FONT> and the documentation and materials transferred to Licensee pursuant to <U>Schedule 4</U> is proprietary and valuable and that, without the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT>
and such documentation and materials Licensee would not be able to Develop, obtain and maintain Regulatory Approvals for, Manufacture or Commercialize the Compounds and Products, (b)&nbsp;access to Licensed
<FONT STYLE="white-space:nowrap">Know-How</FONT> and such documentation and materials has provided Licensee with a competitive advantage in the marketplace beyond the exclusivity afforded by the Licensed Patent Rights and any Regulatory Exclusivity
and (c)&nbsp;the U.S. Sales Milestone Payment and Licensee Royalties, respectively, are, in part, intended to compensate Pfizer for such exclusivity and such competitive advantage. The Parties agree that the Licensee Marginal Royalty Rates set forth
in <U>Section</U><U></U><U>&nbsp;7.3.1</U> reflect an efficient and reasonable blended allocation of the value provided by Pfizer to Licensee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.6</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Other Payments</B>. Licensee shall pay to Pfizer any other amounts due under this Agreement within
[***] following receipt of an undisputed invoice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.7</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Late Payments</B>. Any undisputed amount required to be paid by a Party hereunder which is not paid
on the date due shall bear simple interest thereafter accrued on the sum due to until the date of payment, to the extent permitted by law, at [***] over the prime rate effective for the date such payment was due, as reported by the [***]. Such
interest shall be computed on the basis of a year of three hundred sixty (360)&nbsp;days for the actual number of days payment is delinquent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.8</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Currency</B>. All amounts payable and calculations under this Agreement shall be in United States
dollars. Notwithstanding anything to the contrary in this Agreement, conversion of sales recorded in local currencies shall be translated into United States dollars in a manner consistent with Pfizer&#146;s normal practices used to prepare its
audited financial statements for external reporting purposes, provided that such practices use a widely accepted source of published exchange rates. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.9</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Method of Payment</B>. All payments from one Party to the other Party shall be made by wire transfer
via immediately available funds in U.S. dollars to credit the bank account as designated by such Party in writing to the other Party at least [***] before payment is due. Any payment which falls due on a date which is not a Business Day may be made
on the next succeeding Business Day. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Taxes. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.10.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>General</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary in <U>Section</U><U></U><U>&nbsp;7.10</U>, each Party shall solely
bear and pay all taxes imposed on such Party&#146;s net income or gain (in each case, however denominated) arising directly or indirectly from the activities of the Parties under this Agreement. Each Party shall comply with Applicable Laws and
regulations regarding filing and reporting for income tax purposes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to <U>Section</U><U></U><U>&nbsp;7.10.1(a)</U>, each Party shall bear and pay [***] of any transfer,
stamp or similar taxes or obligations (&#147;<B>Transfer Tax</B>&#148;) imposed on amounts payable by the paying Party to the receiving Party in connection with this Agreement. Each Party shall cooperate with the other Party to file any tax returns
(as required to be filed under Applicable Law) with respect to such Transfer Taxes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">It is understood and agreed between the Parties that any payments made under this Agreement are exclusive of
any value added or similar tax (&#147;<B>VAT</B>&#148;), which shall be added thereon as applicable. In the event any payments made by a Party pursuant to this Agreement become subject to withholding taxes under the laws or regulation of any
jurisdiction, such Party (and its representatives) shall [***]. To the extent that a Party is required to deduct and withhold taxes on any payments under this Agreement, such Party shall [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.10.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Tax Actions</B>. Notwithstanding anything in this Agreement to the contrary, if as a result of any
assignment or sublicense by the paying Party of its rights or obligations under this Agreement, any change in the paying Party&#146;s tax residency, any change in the entity that originates the payment, or any failure on the part of the paying Party
to comply with Applicable Laws (other than any failure resulting from reliance on any certification or other information provided by the receiving Party with respect to the amount of withholding tax required to be withheld or deducted) with respect
to withholding taxes (including filing or record retention requirements) (a &#147;<B>Tax Action</B>&#148;) leads to the imposition of withholding tax liability or VAT on the other Party that would not have been imposed in the absence of a Tax Action
or in an increase in such liability above the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
liability that would have been imposed in the absence of such Tax Action, then (i)&nbsp;the sum payable by the Party that caused the Tax Action (in respect of which such deduction or withholding
is required to be made) shall be increased to the extent necessary to ensure that the other Party receives a sum equal to the sum which it would have received had no Tax Action occurred and (ii)&nbsp;the sum payable by the Party that caused a Tax
Action (in respect of which such deduction or withholding is required to be made) shall be made to the other Party after deduction of the amount required to be so deducted or withheld, which deducted or withheld amount shall be remitted in
accordance with Applicable Law. For the avoidance of doubt, a Party shall only be liable for increased payments pursuant to this <U>Section</U><U></U><U>&nbsp;7.10.2</U> to the extent such Party engaged in a Tax Action that created or increased a
withholding tax or VAT on the other Party. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.10.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>T</B><B>ax Credit</B>. If a Party makes a payment in accordance with
<U>Section</U><U></U><U>&nbsp;7.10.2</U> (a &#147;<B>Tax Payment</B>&#148;) and (a)&nbsp;a credit against, relief or remission for, or repayment of any Tax (&#147;<B>Tax Credit</B>&#148;) is attributable to that Tax Payment and (b)&nbsp;the
receiving Party determines in good faith that it has obtained and utilized that Tax Credit on an affiliated group basis, the receiving Party shall pay to the paying Party an amount equal to such Tax Credit, net of all
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including Taxes) of such receiving Party and without interest (other than interest paid by the relevant taxing authority with respect to such Tax
Credit). Notwithstanding anything else in this <U>Section</U><U></U><U>&nbsp;7.10.3</U>, in no event will the receiving Party be required to pay any amount to the paying Party pursuant to this <U>Section</U><U></U><U>&nbsp;7.10.3</U>, the payment of
which would place the receiving Party in a less favorable net <FONT STYLE="white-space:nowrap">after-tax</FONT> position than the receiving Party would have been in if the tax giving rise to such Tax Credit had not been deducted, withheld or
otherwise imposed and the applicable Tax Payment had never been paid. This <U>Section</U><U></U><U>&nbsp;7.10.3</U> shall not be construed to require the receiving Party to make available its tax returns (or any other information relating to its
taxes that it deems confidential) to the paying Party or any other Person. The receiving Party shall use its commercially reasonable efforts to obtain and utilize that Tax Credit on an affiliated group basis. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.10.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Cooperation</B>. The Parties agree to cooperate and produce on a timely basis any tax forms or
reports, including an IRS Form <FONT STYLE="white-space:nowrap">W-9</FONT> or an IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> reasonably requested by the other Party in connection with any
payment made under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.10.5</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>[***] </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RECORDS; AUDIT RIGHTS. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Relevant Records</B>. Each Party shall, and shall cause its Affiliates to, maintain complete and
accurate patent prosecution and maintenance records and financial books and records pertaining to sale of the Products by such Party, its Affiliates or sublicensees, including any and all calculations of the applicable amounts payable hereunder
(collectively, &#147;<B>Relevant Records</B>&#148;). Each Party shall maintain the Relevant Records for the longer of: (a)&nbsp;the period of time required by Applicable Law, or (b) [***] from the creation of such records. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Audit Request</B>. Each Party shall have the right during the Term and for [***] thereafter to
engage, [***], an independent public accounting firm of nationally recognized standing reasonably acceptable to the other Party and subject to confidentiality restrictions no less stringent than those set forth in
<U>Section</U><U></U><U>&nbsp;11</U>, to examine the Relevant Records from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> as may be necessary to verify compliance with the terms of this Agreement. Such
examinations may not (a)&nbsp;be conducted for any Pfizer Quarter or Licensee Quarter, as applicable, more than [***] after the end of such Pfizer Quarter or Licensee Quarter, as applicable, (b)&nbsp;be conducted more than once in any [***] period
or (c)&nbsp;be repeated for the records for any Pfizer Quarter or Licensee Quarter, as applicable. Such audit shall be requested in writing at least [***] in advance and shall be conducted during the audited Party&#146;s normal business hours and
otherwise in a manner that minimizes any interference to the audited Party&#146;s business operations. The accounting firm shall disclose only whether the reports are correct or not, and the specific details concerning any discrepancies. No other
information shall be shared. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Audit Fees and Expenses</B>. The auditing Party shall bear [***] it may incur in connection with any
such audit of the Relevant Records; <I>provided</I>, <I>however</I>, in the event an audit reveals an underpayment by the other Party of more than [***] as to the period subject to the audit, the other Party shall reimburse the auditing Party for
any reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses of the audit within [***] after receiving invoices thereof, and notwithstanding the provisions of
<U>Section</U><U></U><U>&nbsp;8.2</U>, the auditing Party shall have the right to have the accounting firm examine the Relevant Records of the other Party up to [***] every [***] for the [***] period following the audit revealing such underpayment.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Payment of Deficiency</B>. If any audit establishes that (a)&nbsp;additional amounts were owed by the
audited Party, the audited Party shall pay the additional amounts, with interest from the date originally due as provided in <U>Section</U><U></U><U>&nbsp;7.7</U> or (b)&nbsp;excess payments were made by the audited Party, the auditing Party shall
reimburse such excess payments, in either case ((i) or (ii)), within [***] after the date on which such audit is completed by the auditing Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INTELLECTUAL PROPERTY RIGHTS. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>9.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B><FONT STYLE="white-space:nowrap">Pre-existing</FONT> IP</B>. Subject only to the rights expressly
granted to Licensee under this Agreement, each Party shall retain all rights, title and interests in and to any Intellectual Property Rights that are owned, licensed or sublicensed by such Party prior to or independent of this Agreement.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>9.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Patent Prosecution. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.2.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Patent Prosecution and Maintenance</B>. Subject to Pfizer&#146;s rights set forth in <U>Sections
9.2.4</U> and <U>9.2.5</U> below, Licensee will be responsible for filing, prosecuting (including in connection with any reexaminations, revocation proceedings, <I>inter </I><I>partes</I> reviews, oppositions and the like) and maintaining the
Licensed Patent Rights in the Territory and in Pfizer&#146;s name [***] using, as of the Effective Date, Licensee to identify (a)&nbsp;lead patent counsel acceptable to Pfizer as its lead patent counsel in the U.S., Europe and Japan, respectively,
and (b)&nbsp;an annuity service acceptable to Pfizer as its annuity service provider to prepare, file, prosecute and maintain the Licensed Patent Rights. Licensee will select additional qualified patent counsel and foreign agents as necessary, in
each case reasonably acceptable to Pfizer, within [***] after the Effective Date. During the Term, Licensee will provide notice of any substitution of such counsel, foreign agents or annuity service providers within [***] after such substitution.
Before each submission is filed, Licensee will provide Pfizer a reasonable opportunity to review and comment on proposed, substantive submissions to any patent office and reasonably consider any comments provided by Pfizer to Licensee. Licensee will
keep Pfizer reasonably informed of the status of the Licensed Patent Rights by timely providing Pfizer copies of significant communications relating to such Licensed Patent Rights that are received from any patent office or patent counsel of record
or foreign associate. Licensee will provide Pfizer with a written update of the Licensed Patent Rights listed on <U>Schedule </U><U>1.83</U> [***] or upon reasonable written request by Pfizer. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.2.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Cooperation</B>. The Parties agree to cooperate fully in the preparation, filing, prosecution, and
maintenance of the Licensed Patent Rights in the Territory under this Agreement. Cooperation shall include (a)&nbsp;executing all papers and instruments or requiring its employees or contractors to execute such papers to effectuate the ownership and
rights, including Patent Right extensions, supplementary protection certificates and the like, under this Agreement; (b)&nbsp;assisting in any license registration processes applicable to a particular Governmental Authority; and (c)&nbsp;promptly
informing the other Party of any matters coming to such Party&#146;s attention that may materially affect the preparation, filing, prosecution, or maintenance of any such Licensed Patent Rights in the Territory. [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.2.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Patent Term Extensions</B>. Licensee shall provide Pfizer with notice of each marketing application
and approval within [***] of such application and approval. Licensee shall have the first right with respect to making decisions regarding patent term extensions, including supplementary protection certificates, patent term linkages and any other
extensions that are now or in the future become available, wherever applicable (each, a &#147;<B>Patent Term Extension</B>&#148;), for Licensed Patent Rights in any country or other jurisdiction in connection with the Products. Prior to selecting
any </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
such Patent Rights for a Patent Term Extension, Licensee shall notify Pfizer of any such selection and, at Pfizer&#146;s request, discuss in good faith any issues or comments Pfizer may have with
respect to the selection of such Patent Rights and Licensee shall take into consideration Pfizer&#146;s reasonable comments. Licensee shall have the responsibility of applying for any Patent Term Extension with respect to such Patent Rights and the
Products in the Territory. Licensee shall consult with Pfizer and keep Pfizer fully informed of its efforts to obtain such Patent Term Extension. As reasonably requested by Licensee in writing, Pfizer shall cooperate, [***], in obtaining such Patent
Term Extension. Licensee agrees to execute and deliver such further authorizations and instruments in advance of submission to provide Pfizer with reasonable comment rights and Licensee agrees to take into consideration such further actions as may
be requested by Pfizer to implement the foregoing. If Licensee does not exercise its rights to file Patent Term Extensions on any Licensed Patent Right in the Territory, Pfizer shall have the right, on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis to file a Patent Term Extension for such Licensed Patent Rights [***]; <I>provided</I>, <I>however</I>, that Pfizer shall not have such right in a country if such filing by Pfizer
would preclude Licensee from filing a Patent Term Extension for another Patent Right of Licensee&#146;s choosing in such country. [***] For clarity, Pfizer will not seek, and will cause its Affiliates to not seek, to apply a Patent Term Extension to
(a) [***] without the prior written consent of Licensee or (b)&nbsp;any foreign counterpart for any Pfizer drug product, [***], without the prior written consent of Licensee, which shall not be unreasonably withheld, conditioned or delayed.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.2.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Failure to Prosecute or Maintain</B>. Unless otherwise agreed in writing by Pfizer, Licensee shall
file, prosecute (including in connection with any reexaminations, revocation proceedings, <I>inter </I><I>partes</I> reviews, oppositions and the like) and maintain each of the Licensed Patent Rights for at least [***] after the Effective Date.
After the [***] of the Effective Date, in the event Licensee elects to forego filing, prosecution or maintenance of the Licensed Patent Rights, Licensee shall notify Pfizer of such election at least [***] prior to any filing or payment due date, or
any other due date that requires action (&#147;<B>Election Notice</B>&#148;). Upon receipt of an Election Notice, Pfizer shall be entitled, upon written notice to Licensee, at its sole discretion [***], to file or to continue the prosecution or
maintenance of such Patent Right in such country in Pfizer&#146;s name using counsel of its own choice [***]. As of the date Licensee provides Pfizer such Election Notice, Pfizer shall have the right, at its discretion, to either (a)&nbsp;terminate
the applicable license to such specific Licensed Patent Right or (b)&nbsp;convert the license granted in <U>Section</U><U></U><U>&nbsp;2.1.1</U> under such Patent Right to a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> and non-sublicensable
license. In each case, Licensee shall promptly take all necessary steps to allow Pfizer to take over prosecution and maintenance and will have no further rights in respect of the filing, maintenance or enforcement of such Patent Right.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.2.5</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>R</B><B>etained Patent Prosecution and Maintenance. </B>Pfizer<B> </B>will be responsible for
prosecuting (including in connection with any reexaminations, revocation proceedings, <I>inter </I><I>partes</I> reviews, oppositions and the like) and maintaining only the [***] and any continuations and divisionals therefrom [***]. Before each
submission is filed, Pfizer will provide Licensee a reasonable opportunity to review and comment on proposed, substantive submissions to the United States Patent Office and reasonably consider any comments provided by Licensee to Pfizer. Pfizer will
keep Licensee reasonably informed of the status of the [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>9.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Trademarks. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.3.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Determination and Ownership of Product Trademarks. </B>Licensee shall determine, in consultation with
Pfizer, and exclusively own all right, title and interest in and to the Trademarks for Products Commercialized in the United States and Brepo Products Commercialized in Japan (the &#147;<B>Licensee Product Trademarks</B>&#148;), provided that if a
Trademark cannot be registered or used under Applicable Law (for regulatory, trademark law or other legal reasons), such Trademark will not be used and an alternate Trademark will be selected by Licensee in consultation with Pfizer. Pfizer shall
determine and select, in its sole discretion, the Trademarks for Products Commercialized in the ROW and Other Products Commercialized in Japan (the <B>&#147;Pfizer Product Trademarks</B>&#148;), including that Pfizer may elect, in its sole
discretion, to use a Trademark which is identical to a Licensee Product Trademark as a Pfizer Product Trademark, and Pfizer shall exclusively own all right, title and interest in and to the Pfizer Product Trademarks. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.3.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Registration, Prosecution, Maintenance, Enforcement and Defense of Product Trademarks.</B> Licensee shall
have the right, using counsel of its own choice, to conduct clearance activities (including searches), register, prosecute, maintain and enforce the Licensee Product Trademarks [***]. Pfizer shall have the right, using counsel of its own choice, to
conduct clearance activities (including searches), register, prosecute, maintain and enforce the Pfizer Product Trademarks [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.3.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Corporate Names. </B>Each Party and its Affiliates will retain all right, title and interest in and to its
and their respective house marks, corporate names and corporate logos. Each Party shall not, and shall cause its Affiliates and its or their respective Sublicensees not to (a)&nbsp;do any act in connection with this Agreement that endangers,
destroys or similarly affects, in any material respect, the value of the goodwill pertaining to the corporate names of the other Party or (b)&nbsp;attack, dispute or contest the validity of or ownership of the corporate names of the other Party
anywhere in the world or any registrations issued or issuing with respect thereto. Each Party shall, and shall cause its Affiliates and its and their respective Sublicensees to, conform (y)&nbsp;to the customary industry standards for the protection
of the corporate names of the other Party and (z)&nbsp;to maintain the quality standards of the other Party with respect to the goods sold and services provided in connection with the corporate names of such other Party. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>INFRINGEMENT; MISAPPROPRIATION</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>10.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Notification</B>. Each Party will promptly notify the other Party in writing of any actual or
threatened infringement, misappropriation or other violation by a Third Party of any Licensed Technology in the Field and in the Territory of which it becomes aware, including (i)&nbsp;the filing of an Abbreviated New Drug Application under
Section&nbsp;505(j) of the FD&amp;C Act or an application under Section&nbsp;505(b)(2) of the FD&amp;C Act naming a Product as a reference listed drug and including a certification under Section&nbsp;505(j)(2)(A)(vii)(IV) or 505(b)(2)(A)(IV),
respectively or (ii)&nbsp;declaratory judgment action against any Licensed Patent Right in the Territory in connection with any infringement described in clause (i) (any of (i)&nbsp;or (ii) constituting a (&#147;<B>Third Party
Infringement</B>&#148;)). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>10.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Infringement Action. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.2.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Right of First Enforcement</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Pfizer&#146;s rights set forth in <U>Section</U><U></U><U>&nbsp;10.2.1(c)</U> below, Licensee shall
have the first right (but not the obligation), [***], to control enforcement of the Licensed Technology against any Third Party Infringement within the scope of its exclusive license. Prior to commencing any such action, Licensee shall consult with
Pfizer and shall give due consideration to Pfizer&#146;s timely and reasonable recommendations regarding the proposed action. In order to establish standing, Pfizer, upon the request of Licensee, agrees to timely commence or to join any such
litigation, [***], and to cooperate with Licensee in such litigation [***]. Licensee shall give Pfizer timely notice of any proposed settlement of any such action instituted by Licensee and shall not, without the prior written consent of Pfizer,
which in the case of (i), (iii) and (iv)&nbsp;below shall not be unreasonably withheld, conditioned or delayed, enter into any settlement that would: (i)&nbsp;adversely affect the validity, enforceability or scope of any of the Licensed Patent
Rights, (ii)&nbsp;give rise to liability of Pfizer or its Affiliates, (iii)&nbsp;admit <FONT STYLE="white-space:nowrap">non-infringement</FONT> of any Licensed Patent Rights, or (iv)&nbsp;otherwise impair Pfizer&#146;s rights in any Licensed
Technology or this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Licensee does not, with respect to its first right of enforcement under
<U>Section</U><U></U><U>&nbsp;10.2.1(a)</U>, obtain agreement from the alleged infringer to desist or fails or refuses to initiate an infringement action by the earlier of (i) [***] following Licensee&#146;s receipt of notice of the alleged
infringement, or (ii) [***] before the expiration date for filing such actions, then Pfizer shall have the right, at its sole discretion, to control such enforcement of the Licensed Technology [***]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pfizer shall have the right (but not the obligation), [***], to control enforcement only of a patent issuing
from the [***] or any continuation or divisional thereof [***] against any Third Party Infringement. Prior to commencing any such action, Pfizer shall consult with Licensee and shall give due consideration to Licensee&#146;s timely and reasonable
recommendations regarding the proposed action. Pfizer shall give Licensee timely notice of any proposed settlement of any such action instituted by Pfizer and shall not, without the prior written consent of Licensee, which shall not be unreasonably
withheld, conditioned or delayed, enter into any settlement that would adversely affect the validity, enforceability or scope of the [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.2.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Recoveries</B>. Any recoveries resulting from an action instituted by Licensee relating to a claim of Third
Party Infringement pursuant to <U>Section</U><U></U><U>&nbsp;10.2.1(a)</U> shall first be applied to reimburse each Party&#146;s costs and expenses incurred in connection therewith. Any remaining recoveries shall be retained by (or if received by
Pfizer, paid to) Licensee; [***]. If Licensee fails to institute an action or proceeding and Pfizer exercises its right to prosecute such infringement pursuant to <U>Section</U><U></U><U>&nbsp;10.2.1(b)</U>, any remaining recoveries shall be
retained by Pfizer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>CONFIDENTIALITY </B><B>[***]</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>11.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Obligations</B>. The receiving Party will protect all Confidential Information against unauthorized
disclosure to Third Parties with the same degree of care as the receiving Party uses for its own similar information, but in no event less than a reasonable degree of care. The receiving Party may only use the Confidential Information for exercising
its rights and performing its obligations under this Agreement, and may only disclose the Confidential Information to [***] (collectively, &#147;<B>Recipients</B>&#148;) who have a need to know such information for exercising its rights and
performing its obligations under this Agreement, <I>provided</I> that the receiving Party shall hold such Recipients to written obligations of confidentiality with terms and conditions at least as restrictive as those set forth in this Agreement.
All obligations of confidentiality under this Agreement shall survive expiration or termination of this Agreement for a period of [***]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>11.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exceptions. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.2.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Disclosure Required by Law</B>. The restrictions set forth in this
<U>Section</U><U></U><U>&nbsp;11</U> shall not apply to any Confidential Information that the receiving Party is required to disclose under Applicable Laws, the rules of any recognized stock exchange or any Order, <I>provided</I> that the receiving
Party: (a)&nbsp;provides the disclosing Party with prompt notice of such disclosure requirement if legally permitted, (b)&nbsp;affords the disclosing Party an opportunity to oppose, limit or secure confidential treatment for such required disclosure
and (c)&nbsp;if the disclosing Party is unsuccessful in its efforts pursuant to subsection (b), discloses only that portion of the Confidential Information that the receiving Party is required to disclose under Applicable Laws or the rules of any
recognized stock exchange or such Order as advised by the receiving Party&#146;s legal counsel; <I>provided</I> that before disclosing this Agreement or any of the terms hereof pursuant to this <U>Section</U><U></U><U>&nbsp;11.2.1</U>, the Parties
will consult with one another on the terms of this Agreement to be redacted in making any such disclosure, with the disclosing Party providing as much advanced notice as is feasible under the circumstances, and giving consideration to the comments
of the other Party. For the avoidance of doubt, Licensee shall be permitted to file this Agreement with the Securities and Exchange Commission in connection with an initial public offering of Licensee&#146;s stock or as otherwise required by
Applicable Law; <I>provided</I> that Licensee shall, [***], seek such confidential treatment of confidential portions of this Agreement as may be reasonably requested by Pfizer. Notwithstanding the foregoing or anything else to the contrary in this
Agreement, each Party (and each employee, representative or other agent of any Party) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of, and tax strategies relating to, the transactions in
which such Party participates pursuant to this Agreement. For this purpose, &#147;tax structure&#148; is limited to any facts relevant to the United States federal income tax treatment of such transactions and does not include information relating
to the specific identity of the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.2.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Disclosure to Assignee of Payments</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that Pfizer wishes to assign, pledge or otherwise transfer its rights to receive some or all of
the U.S. Sales Milestone Payment and Licensee Royalties payable hereunder, Pfizer may disclose to a Third Party Confidential Information of Licensee reasonably relevant to such U.S. Sales Milestone or Licensee Royalties (as applicable) in connection
with any such proposed assignment, <I>provided</I> that Pfizer shall hold such Third Parties to written obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> with terms and conditions at least as restrictive as those set
forth in this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that Licensee wishes to assign, pledge or otherwise transfer its rights to receive some or all of
the ROW Sales Milestone Payment and Pfizer Royalties payable hereunder, Licensee may disclose to a Third Party Confidential Information of Pfizer reasonably relevant to such ROW Sales Milestone or Pfizer Royalties (as applicable) in connection with
any such proposed assignment, <I>provided</I> that Licensee shall hold such Third Parties to written obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> with terms and conditions at least as restrictive as those set
forth in this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.2.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Use of Residuals</B>. The restrictions set forth in this <U>Section</U><U></U><U>&nbsp;11</U> shall not
apply to the use of Residuals in accordance with <U>Section</U><U></U><U>&nbsp;2.5</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>11.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Ongoing Obligation for Confidentiality</B>. Upon expiration or termination of this Agreement, the
receiving Party shall, and shall cause its Recipients to, destroy or return (as requested by the disclosing Party) any Confidential Information of the disclosing Party, except that the receiving Party (a)&nbsp;may retain a single copy of
Confidential Information for the sole purpose of (i)&nbsp;ascertaining its rights and responsibilities in respect of such information and (ii)&nbsp;exercising its rights that expressly survive the expiration or termination of this Agreement and
(b)&nbsp;shall not be required to destroy any computer files stored securely by the receiving Party that are created by automatic system back up. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>11.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>[***] </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>REPRESENTATIONS, WARRANTIES AND COVENANTS</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>12.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Representations and Warranties by Each Party</B>. Each Party represents and warrants to the other
Party as of the Effective Date that: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.1.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>it is a corporation duly organized, validly existing, and in good standing under the laws of its
jurisdiction of formation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.1.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>it has full corporate power and authority to execute, deliver, and perform under the Transaction
Agreements to which it will be a party, and has taken all corporate action required by Applicable Law and its organizational documents to authorize the execution and delivery of the Transaction Agreements to which it will be a party and the
consummation of the transactions contemplated by the Transaction Agreements to which it will be a party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.1.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>the Transaction Agreements to which it will be a party will, at and after the Closing, constitute a
valid and binding agreement enforceable against it in accordance with their terms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.1.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>all consents, approvals and authorizations from all Governmental Authorities or other Third Parties
required to be obtained by such Party in connection with the Transaction Agreements to which it will be a party have been obtained; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.1.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>the execution and delivery of the Transaction Agreements to which it will be a party and all other
instruments and documents required to be executed pursuant to the Transaction Agreements to which it will be a party, and the consummation of the transactions contemplated thereby do not and shall not: (i)&nbsp;conflict with or result in a breach of
any provision of its organizational documents, (ii)&nbsp;result in a breach of any agreement to which it is a party that would impair the performance of its obligations thereunder; or (iii)&nbsp;violate any Applicable Law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>12.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Representations and Warranties and Covenants by Pfizer</B>. Pfizer represents and warrants to
Licensee as of the Effective Date that: [***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>12.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Representations, Warranties and Covenants by Licensee. [***] </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>12.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Representations, Warranties and Covenants Related to Anti-Corruption Laws and Healthcare Laws</B>. Without
limiting the generality of <U>Section</U><U></U><U>&nbsp;12.3.2</U>, Licensee represents, warrants and covenants to Pfizer as of the Effective Date as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.4.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Licensee shall comply with all applicable Anti-Corruption Laws and Healthcare Laws. [***]
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>12.5</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Representations, Warranties and Covenants Related to Global Trade Control Laws</B>. Without limiting the
generality of <U>Section</U><U></U><U>&nbsp;12.3.2</U>, Licensee represents, warrants and covenants to Pfizer as follows: [***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>12.6</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>No Action Required Which Would Violate Law</B>. In no event shall either Party be obligated under
this Agreement to take any action or omit to take any action that such Party believes, in good faith, would cause such Party to violate any Applicable Law, including the Anti-Corruption Laws and Global Trade Control Laws. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>12.7</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>No Other Warranties</B>. EXCEPT AS EXPRESSLY STATED IN THIS <U>SECTION 12</U>, NEITHER PARTY MAKES
ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING WARRANTIES OF TITLE, <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT,</FONT> VALIDITY, ENFORCEABILITY, MERCHANTABILITY AND
FITNESS FOR A PARTICULAR PURPOSE. EXCEPT AS EXPRESSLY STATED IN THIS <U>SECTION</U><U></U><U>&nbsp;12</U>, ANY INFORMATION OR MATERIALS PROVIDED BY PFIZER OR ITS AFFILIATES IS MADE AVAILABLE ON AN &#147;AS IS&#148; BASIS WITHOUT WARRANTY WITH
RESPECT TO COMPLETENESS, COMPLIANCE WITH REGULATORY STANDARDS OR REGULATIONS OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER KIND OF WARRANTY WHETHER EXPRESS OR IMPLIED. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>12.8</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Disclaimer</B>. Licensee hereby expressly acknowledges and agrees that Pfizer makes no representation
or warranty with respect to any estimates, projections, forecasts, plans or budgets that may have been provided to Licensee. Licensee (a)&nbsp;specifically disclaims that it is relying upon or has relied upon any representations or warranties other
than as set forth in <U>Sections 12.1</U> and <U>12.2</U>, that may have been made by any </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Person, and acknowledges and agrees that Pfizer and its Affiliates specifically disclaimed and do hereby specifically disclaim any such other representation or warranty made by any Person,
(b)&nbsp;specifically disclaims any obligation or duty by Pfizer and its Affiliates to make any disclosures of fact not required to be disclosed pursuant to the specific representations and warranties set forth in <U>Sections 12.1</U> and
<U>12.2</U> and (c)&nbsp;is entering into the transactions contemplated hereby and acquiring the Licensed Technology in connection with the transactions contemplated hereby subject only to the specific representations and warranties of Pfizer set
forth in <U>Sections 12.1</U> and <U>12.2</U>. Licensee hereby further acknowledges that (i)&nbsp;it has conducted, to its satisfaction, an independent investigation, due diligence review and verification of the Licensed Technology and (ii)&nbsp;it
is an informed and sophisticated Person and has engaged advisors experienced in the evaluation and consummation of transactions of the type contemplated hereunder. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>12.9</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Other Government Approvals</B>. Each of Licensee and Pfizer shall cooperate with the other Party and
shall use reasonable efforts to make all registrations, filings and applications, to give all notices and to obtain as soon as practicable all governmental or other consents, transfers, approvals, orders, qualifications authorizations, permits and
waivers required in connection with this Agreement, if any, and to do all other things necessary or desirable for the consummation of the transactions as contemplated hereby. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>13.</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>INDEMNIFICATION</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>13.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification by Licensee</B>. From and after the Closing, Licensee agrees to indemnify, hold harmless and
defend Pfizer and its Affiliates, and its and their respective officers, directors, employees, contractors, agents and successors and assigns (collectively, &#147;<B>Pfizer Indemnitees</B>&#148;), from and against any Losses to the extent arising or
resulting from: (a) [***], (e)&nbsp;the negligence, recklessness or wrongful intentional acts or omissions of Licensee or its Affiliates, contractors, subcontractors or sublicensees in the exercise of their rights or performance of their obligations
hereunder, (f)&nbsp;breach by Licensee of any representation, warranty or covenant as set forth in this Agreement or (g)&nbsp;breach by Licensee of the scope of the license set forth in <U>Section</U><U></U><U>&nbsp;2.1</U>. Notwithstanding the
foregoing, Licensee shall not be liable and have no obligation to indemnify Pfizer to the extent such losses arise out of or result from (a)&nbsp;the breach by Pfizer of any representation, warranty or covenant set forth in this Agreement, or
(b)&nbsp;the negligence, recklessness, wrongful intentional act or omission, or violation of Applicable Law by any Pfizer Indemnitee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>13.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Indemnification by Pfizer</B>. From and after the Closing, Pfizer agrees to indemnify, hold harmless
and defend Licensee and its Affiliates, and its and their respective officers, directors, employees, agents and successors and assigns (collectively, &#147;<B>Licensee Indemnitees</B>&#148;), from and against any Losses to the extent arising or
resulting from: (a)&nbsp;the negligence, recklessness or wrongful intentional acts or omissions of Pfizer or its Affiliates, contractors, subcontractors or sublicensees in the exercise of their rights or performance of their obligations hereunder
[***], or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
(e)&nbsp;breach by Pfizer of any representation, warranty or covenant as set forth in this Agreement. Pfizer shall not be liable and have no obligation to indemnify Licensee to the extent such
losses arise out of or result from (a)&nbsp;the breach by Licensee of any representation, warranty or covenant set forth in this Agreement, or (b)&nbsp;the negligence, recklessness, wrongful intentional act or omission, or violation of Applicable
Law by any Licensee Indemnitee. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>13.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Indemnification Procedure for Third Party Claims</B>. In connection with any claim of a Third Party
for which a Pfizer Indemnitee or Licensee Indemnitee (either of the foregoing, the &#147;<B>Indemnified Party</B>&#148;) seeks indemnification from the other Party (the &#147;<B>Indemnifying Party</B>&#148;) pursuant to this Agreement, the
Indemnified Party shall: (a)&nbsp;give the Indemnifying Party prompt written notice of the claim, the amount or the estimated amount of damages sought under such claim to the extent then ascertainable and, to the extent practicable, any other
material details pertaining thereto; <I>provided</I>, <I>however</I>, that failure to provide such notice or to include the foregoing information shall not relieve the Indemnifying Party from its liability or obligation hereunder, except to the
extent of any material prejudice as a direct result of such failure; (b)&nbsp;cooperate with the Indemnifying Party, [***], in connection with the defense and settlement of the claim; and (c)&nbsp;permit the Indemnifying Party to assume control of
the defense and settlement of the claim, [***]; <I>provided</I>, <I>however</I>, that the Indemnifying Party may not settle the claim without the Indemnified Party&#146;s prior written consent, which shall not be unreasonably withheld, conditioned
or delayed, unless such settlement (x)&nbsp;provides for the payment by the Indemnifying Party of money as sole relief for the claimant (other than as contemplated by the Deductible), (y) results in the full and general release of the Indemnified
Party from all liabilities arising or resulting from such claim, and (z)&nbsp;involves no finding or admission of any violation of Applicable Law or the rights of any Person and does not have an effect on any other claims that may be made against
the Indemnified Party. If the Indemnifying Party does not assume control of the defense and settlement of such claim, then the Indemnified Party shall control the defense and settlement of such claim with counsel of its selection, [***]. Either the
Indemnified Party (if such claim is controlled by the Indemnifying Party) or the Indemnifying Party (if such claim is controlled by the Indemnified Party) shall have the right to participate (but not control) and be represented in any suit or action
by advisory counsel of its selection [***]. Notwithstanding the foregoing, if the Indemnifying Party assumes control of the defense and settlement of such claim, the Indemnified Party will have the right to employ separate counsel [***], in
connection with the defense and settlement of the claim if: (i)&nbsp;there are or may be legal defenses available to the Indemnified Party that are different from or additional to those available to the Indemnifying Party; or (ii)&nbsp;in the
reasonable opinion of counsel to the Indemnified Party, a conflict or potential conflict exists between the Indemnified Party and Indemnifying Party that would make such separate representation advisable. In the event that the Indemnified Party
controls the defense and settlement of such claim, the Indemnified Party may not settle such claim without the Indemnifying Party&#146;s prior written consent, which shall not be unreasonably withheld, conditioned or delayed. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>13.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Indemnification Procedure for Direct Claims.</B> In connection with any claim for indemnification
that an Indemnified Party wishes to make pursuant to this Agreement that does not arise or result from a claim by a Third Party, the Indemnified Party shall give the Indemnifying Party prompt written notice of such claim, the section(s) of this
Agreement that form the basis of the claim for indemnification, the amount or the estimated amount of damages sought under such claim to the extent then ascertainable and, to the extent practicable, any other material details pertaining thereto;
<I>provided</I>, <I>however</I>, that failure to provide such notice or to include the foregoing information shall not relieve the Indemnifying Party from its liability or obligation hereunder, except to the extent of any material prejudice as a
direct result of such failure. Upon receipt of any such notice, the Indemnified Party and the Indemnifying Party shall use commercially reasonable efforts to cooperate and arrive at a mutually acceptable resolution of such claim within [***] of the
Indemnified Party&#146;s receipt of such notice. If a mutually acceptable resolution cannot be reached between the Indemnified Party and the Indemnifying Party within such [***], the Indemnified Party shall be free to seek enforcement of its rights
to indemnification under this Agreement with respect to such claim. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LIMITATION OF LIABILITY. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>14.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Damages Waiver.</B> EXCEPT FOR [***], NEITHER PARTY SHALL BE LIABLE TO ANY PERSON HEREUNDER FOR ANY
SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES, OR ANY DAMAGES THAT ARE SPECULATIVE OR NOT REASONABLY FORESEEABLE AS A PROXIMATE RESULT OF THE BREACH BY A PARTY OF ANY OF ITS REPRESENTATIONS, WARRANTIES, COVENANTS OR AGREEMENTS UNDER THIS AGREEMENT,
REGARDLESS OF WHETHER IT HAS BEEN INFORMED OF THE POSSIBILITY OR LIKELIHOOD OF SUCH DAMAGES OR THE TYPE OF CLAIM, CONTRACT OR TORT (INCLUDING NEGLIGENCE). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>14.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>[***] </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>14.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>[***] </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>14.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Survival.</B> The representations and warranties contained in this Agreement shall survive the
Closing until the [***] of the Effective Date, except that (a)&nbsp;the representations and warranties contained in <U>Section</U><U></U><U>&nbsp;12.1</U> shall survive the Closing until [***] after expiration of the relevant statute of limitations
period, and (b)&nbsp;the representations and warranties contained in <U>Section</U><U></U><U>&nbsp;12.2.4</U> shall survive the Closing until the [***] of the Effective Date and, in each case, all rights to indemnification hereunder for any breach
of or inaccuracy in any representation or warranty shall terminate and expire on, and no action or proceedings seeking damages or other relief for breach of any representation or warranty or for misrepresentation or inaccuracy shall be commenced
after, such date. All covenants and agreements of the Parties requiring performance in full prior to the Effective Date shall survive until the Effective Date and all other covenants and agreements contained herein shall survive until the expiration
of the relevant statute of limitations period, and, in each case, all rights to indemnification </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
hereunder for any breach of any covenant or agreement shall terminate and expire on, and no action or proceedings seeking damages or other relief for breach of any covenant or agreement shall be
commenced after, such date. In the event that notice of any claim for indemnification under <U>Section</U><U></U><U>&nbsp;13</U> has been given pursuant to <U>Section</U><U></U><U>&nbsp;13.3</U> or <U>Section</U><U></U><U>&nbsp;13.4</U>, as the case
may be, within the applicable survival period, the representations, warranties, covenants or agreements that are the subject of such indemnification claim (and the right to pursue such claim) shall survive with respect to such claim until such time
as such claim is finally resolved. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>14.5</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Exclusive Remedy</B>. Except for any claim for Fraud, gross negligence or willful misconduct, the
provisions of <U>Section</U><U></U><U>&nbsp;13</U> and this <U>Section</U><U></U><U>&nbsp;14</U> shall be the exclusive monetary remedy of the Parties for any matter subject to indemnification pursuant to <U>Section</U><U></U><U>&nbsp;13</U>, except
(a)&nbsp;as set forth in <U>Section</U><U></U><U>&nbsp;18.4</U> and (b)&nbsp;to the extent the procedures of <U>Section</U><U></U><U>&nbsp;2.1.4</U> would fully mitigate Losses with respect to a breach of any representation or warranty in this
Agreement, the procedures of <U>Section</U><U></U><U>&nbsp;2.1.4</U> will be the sole and exclusive remedy of the Licensee Indemnitees for any such breach. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>14.6</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Insurance Recovery</B>. Notwithstanding the foregoing, the indemnifiable Losses shall be net of
(a)&nbsp;the amount of any insurance proceeds actually received by the Indemnified Party (offset by any increase in premium resulting therefrom and after deducting therefrom the full amount of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees, costs and expenses incurred by it in procuring such recovery and any taxes payable or expected to be payable thereon), and each Indemnified Party agrees to file claims under each
applicable insurance policy and to use commercially reasonable efforts to pursue all such insurance claims (but, shall not include an obligation to commence litigation), (b) any indemnity or contribution amounts actually recovered by such
Indemnified Party from a Third Party in respect of such indemnifiable Losses (after deducting therefrom the full amount of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees, costs and expenses
incurred by it in procuring such recovery and any taxes payable or expected to be payable thereon), and (c)&nbsp;the amount of any actual reduction in net taxes as a result of such indemnifiable Losses, solely for the taxable year of the incurrence,
accrual or payment of such indemnifiable Losses (treating any such benefit as the last item of deduction for the applicable tax year). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>14.7</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>No <FONT STYLE="white-space:nowrap">Set-Off.</FONT></B> Notwithstanding anything to the contrary,
neither Party shall set off any indemnifiable Losses against the U.S. Sales Milestone Payment, ROW Sales Milestone Payment, Licensee Royalties, or Pfizer Royalties, as applicable, that would otherwise be payable to the other Party pursuant to
<U>Section</U><U></U><U>&nbsp;7</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERM; TERMINATION. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>15.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Term</B>. The term of this Agreement (&#147;<B>Term</B>&#148;) shall commence as of the Effective
Date and shall expire, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, on the
expiration of the applicable Royalty Term, unless earlier terminated, as provided in this <U>Section</U><U></U><U>&nbsp;15</U>. Upon expiration of the Term for any Product, the licenses granted to Licensee under this Agreement shall become fully <FONT
STYLE="white-space:nowrap">paid-up,</FONT> royalty-free, transferable, perpetual and irrevocable, with the right to grant sublicenses, through multiple tiers, with respect to such Product in the Field in the Territory. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>15.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Termination for Cause.</B><SUP STYLE="font-size:85%; vertical-align:top"> </SUP>Each Party shall have
the right, without prejudice to any other remedies available to it at law or in equity, to terminate this Agreement in its entirety in the event the other Party materially breaches any of its obligations hereunder and fails to cure such breach
within [***] of receiving notice thereof; <I>provided</I>, <I>however</I>, if such breach is capable of being cured, but cannot be cured within such [***] period, and breaching Party initiates actions to cure such breach within such period and
thereafter diligently pursues such actions, the breaching Party shall have such additional period as is reasonable to cure such breach, but in no event will such additional period exceed [***]; and <I>provided, further</I>, that in the event that
any such material breach by the breaching Party is limited to the [***] or one or more (but not all) countries, then the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party shall have right to terminate solely with respect to all [***] or
such countries, as applicable. Any termination by a Party under this <U>Section</U><U></U><U>&nbsp;15.2</U> shall be without prejudice to any damages or other legal or equitable remedies to which it may be entitled from the breaching Party.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>15.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Termination for Convenience.</B> At any time, Licensee shall have the right to terminate [***].
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>15.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Effects of Termination.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>15.4.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination in its Entirety by Licensee for Cause</B>. In the event that Licensee terminates this Agreement
in its entirety pursuant to <U>Section</U><U></U><U>&nbsp;15.2</U>, the following shall apply: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Rights and Obligations</B>. Except as otherwise provided herein, including pursuant to
<U>Section</U><U></U><U>&nbsp;15.5</U>, all rights and obligations of each Party hereunder shall cease, including, for clarity, all licenses granted to Pfizer hereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Licenses</B>. All rights and licenses granted to Licensee hereunder shall become fully <FONT
STYLE="white-space:nowrap">paid-up,</FONT> irrevocable and perpetual. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Transition</B>. During the notice period provided in <U>Section</U><U></U><U>&nbsp;15.2</U>, at
Licensee&#146;s sole option, Licensee shall prepare and the Parties shall negotiate a transition plan that will include, at a minimum, a plan for accomplishing the activities described in this <U>Section</U><U></U><U>&nbsp;15.4.1(c)</U>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Continued </B><B>Exploitation</B>. At Licensee&#146;s request [***], Pfizer shall continue <FONT
STYLE="white-space:nowrap">on-going</FONT> Exploitation for a mutually agreed-upon period following the termination of this Agreement, which period shall not be [***] unless otherwise agreed to by the Parties. For avoidance of doubt, if Licensee
chooses not to continue a Clinical Trial initiated by Pfizer, [***] of winding down such Clinical Trial, including compliance with any ethical or other requirements imposed by an applicable Regulatory Authority. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Technology Transfer</B>. At Licensee&#146;s request, Pfizer shall make available to Licensee all currently
available records and data which exist and are Controlled by Pfizer as of the effective date of termination and are necessary or useful for Licensee to continue Commercializing and Exploiting Compounds and Products in the Field in the Territory.<B>
</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulatory Matters</B>. At Licensee&#146;s request, Pfizer shall transfer and assign to Licensee (or its
designee) all Regulatory Approvals and Regulatory Filings held by Pfizer with respect to Compounds and Products, <I>provided</I> that if such transfer and assignment is not permitted by the applicable Regulatory Authority, Pfizer shall permit
Licensee to cross-reference and rely upon such Regulatory Approvals and Regulatory Filings. Pfizer shall make available to Licensee copies of all regulatory documentation and records related to Compounds and Products, including information contained
in the regulatory and safety databases. The Parties shall cooperate to ensure the prompt transition of regulatory responsibilities for Compounds and Products from Pfizer to Licensee. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Trademarks</B>. Licensee shall have, and Pfizer does hereby grant to Licensee, a fully <FONT
STYLE="white-space:nowrap">paid-up,</FONT> royalty-free, worldwide, transferable, sublicensable, perpetual and irrevocable license to use the Pfizer Product Trademarks, if any, solely for the purpose of using, Developing, Commercializing and
Manufacturing the Products in the ROW and Japan. Licensee shall have a transitional license to use Pfizer&#146;s Trademarks and promotional materials solely for the purpose of using, Developing, Commercializing and Manufacturing the Products.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Inventory and Supply</B>. At Licensee&#146;s request, Pfizer shall transfer to Licensee (or its designee)
all Compound and Product, components and <FONT STYLE="white-space:nowrap">in-process</FONT> inventory held by Pfizer with respect to the Manufacture of Compounds and Products as of such date of termination, if any. At Licensee&#146;s request, if
Pfizer has licensed to a CMO to Manufacture the Compounds or Products, Pfizer shall </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="33%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
promptly assign such license to Licensee (to the extent allowed under such license), or if not, Pfizer shall continue to Manufacture or have Manufactured the Products for a period of not less
than [***], including, at Licensee&#146;s request, a reasonable stock build. Licensee shall pay to Pfizer [***] of manufacturing associated with inventory and Compound and Product received by Licensee pursuant to this
<U>Section</U><U></U><U>&nbsp;15.4.1(c)(v)</U>. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Agreements</B>. At Licensee&#146;s request, to the extent Pfizer is able to do so, Pfizer shall
assign to Licensee (or its designee) any agreements with Third Parties with respect to the Development, Commercialization and Manufacture of the Compounds and Products. With respect to Third Party agreements that Pfizer is not able to assign to
Licensee, Pfizer shall cooperate to give Licensee the benefit of such contracts for a reasonable transitional period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>15.4.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Termination of Terminated Products or Terminated Territory by Licensee for Cause</B>. In the event
that Licensee terminates this Agreement with respect to [***] or a Terminated Territory, as applicable, pursuant to <U>Section</U><U></U><U>&nbsp;15.2</U> (but not in the case of any termination of this Agreement in its entirety), the following
shall apply: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Rights and Obligations</B>. Except as otherwise provided herein, including pursuant to
<U>Section</U><U></U><U>&nbsp;15.5</U>, this Agreement shall automatically be deemed to be amended to exclude the rights and obligations of Pfizer hereunder with respect to such Terminated Products or Terminated Territory, as applicable, including,
for clarity, all licenses granted to Pfizer hereunder with respect to such Terminated Products or Terminated Territory, as applicable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Licenses</B>. All rights and licenses granted to Licensee hereunder shall become fully <FONT
STYLE="white-space:nowrap">paid-up,</FONT> irrevocable and perpetual with respect to such Terminated Products or Terminated Territory, as applicable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Transition</B>. During the notice period provided in <U>Section</U><U></U><U>&nbsp;15.2</U>, at
Licensee&#146;s sole option, Licensee shall prepare and the Parties shall negotiate a transition plan that will include, at a minimum, a plan for accomplishing the activities described in this <U>Section</U><U></U><U>&nbsp;15.4.2(c)</U>.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Continued </B><B>Exploitation</B>. At Licensee&#146;s request [***], Pfizer shall continue <FONT
STYLE="white-space:nowrap">on-going</FONT> Exploitation with respect to such Terminated Products or Terminated Territory, as applicable, for a mutually agreed-upon period following the termination of this Agreement with respect to the Terminated
Products or Terminated Territory, as applicable, which period shall not be less than [***] unless otherwise agreed to by the Parties. For avoidance of doubt, if Licensee chooses not to continue a Clinical Trial initiated by Pfizer, [***] of winding
down such Clinical Trial, including compliance with any ethical or other requirements imposed by an applicable Regulatory Authority. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Technology Transfer</B>. At Licensee&#146;s request, Pfizer shall make available to Licensee all currently
available records and data which exist and are Controlled by Pfizer with respect to such Terminated Products or Terminated Territory, as applicable, as of the effective date of termination and are necessary or useful for Licensee to continue
Commercializing and Exploiting such Terminated Products in the Field in the Territory or the Products in the such Terminated Territory, as applicable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulatory Matters</B>. At Licensee&#146;s request, Pfizer shall transfer and assign to Licensee (or its
designee) all Regulatory Approvals and Regulatory Filings held by Pfizer with respect to such Terminated Products or Terminated Territory, as applicable, <I>provided</I> that if such transfer and assignment is not permitted by the applicable
Regulatory Authority, Pfizer shall permit Licensee to cross-reference and rely upon such Regulatory Approvals and Regulatory Filings. Pfizer shall make available to Licensee copies of all regulatory documentation and records related to such
Terminated Products or Terminated Territory, as applicable, including information contained in the regulatory and safety databases. The Parties shall cooperate to ensure the prompt transition of regulatory responsibilities with respect to such
Terminated Products or Terminated Territory, as applicable, from Pfizer to Licensee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Trademarks</B>. Licensee shall have, and Pfizer does hereby grant to Licensee, a fully <FONT
STYLE="white-space:nowrap">paid-up,</FONT> royalty-free, worldwide (except in the event that Licensee terminates this Agreement with respect to a Terminated Territory, and such Terminated Territory is in the ROW or Japan, in which case, such license
shall be solely for the Terminated Territory), transferable, sublicensable, perpetual and irrevocable license to use the Pfizer Product Trademarks </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="33%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
associated with the Terminated Products, or all Products with respect to the Terminated Territory, as applicable, if any, solely for the purpose of using, Developing, Commercializing and
Manufacturing with respect to the Terminated Products or Terminated Territory, as applicable. Licensee shall have a transitional license to use Pfizer&#146;s Trademarks and promotional materials solely for the purpose of using, Developing,
Commercializing and Manufacturing the Terminated Products, or all Products with respect to the Terminated Territory, as applicable. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Inventory and Supply</B>. At Licensee&#146;s request, Pfizer shall transfer to Licensee (or its designee)
all Compound and Product, components and <FONT STYLE="white-space:nowrap">in-process</FONT> inventory held by Pfizer with respect to the Terminated Products or Terminated Territory, as applicable, as of such date of termination, if any. At
Licensee&#146;s request, if Pfizer has licensed to a CMO to Manufacture a Terminated Product, or any Products with respect to the Terminated Territory, as applicable, and if Pfizer is able to do so, Pfizer shall promptly assign such license to
Licensee, or if not, Pfizer shall continue to Manufacture or have Manufactured such Terminated Product or any Products with respect to the Terminated Territory, as applicable, for a period of not less than [***], including, at Licensee&#146;s
request, a reasonable stock build. Licensee shall pay to Pfizer [***] of manufacturing associated with inventory and Compound and Product received by Licensee pursuant to this <U>Section</U><U></U><U>&nbsp;15.4.2(c)(v)</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Agreements</B>. At Licensee&#146;s request, to the extent Pfizer is able to do so, Pfizer shall
assign to Licensee (or its designee) any agreements with Third Parties with respect to such Terminated Products or Terminated Territory, as applicable. With respect to Third Party agreements that Pfizer is not able to assign to Licensee, Pfizer
shall cooperate to give Licensee the benefit of such contracts for a reasonable transitional period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>15.4.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination in its Entirety by Pfizer for Cause; Termination in its Entirety for Convenience by
Licensee</B>. In the event that (i)&nbsp;Pfizer terminates this Agreement in its entirety pursuant to <U>Section</U><U></U><U>&nbsp;15.2</U>, or (ii)&nbsp;Licensee terminates this Agreement in its entirety pursuant to
<U>Section</U><U></U><U>&nbsp;15.3</U>, the following shall apply: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Rights and Obligations</B>. Except as otherwise provided herein, including pursuant to
<U>Section</U><U></U><U>&nbsp;15.5</U>, all rights and obligations of each Party hereunder shall cease, including, for clarity all licenses granted to Licensee hereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Licenses</B>. Licensee hereby grants to Pfizer and its Affiliates, an exclusive, sublicensable,
royalty-free, full <FONT STYLE="white-space:nowrap">paid-up,</FONT> irrevocable, worldwide and perpetual right and license, with the right to assign and grant sublicenses, under the Developed IP, as it exists as of the effective date of termination,
to Exploit the Products in the Field in the Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Transition</B>. During the notice period provided in <U>Section</U><U></U><U>&nbsp;15.2</U> and
<U>Section</U><U></U><U>&nbsp;15.3</U>, as applicable to such termination, at Pfizer&#146;s sole option, Pfizer shall prepare and the Parties shall negotiate a transition plan that will include, at a minimum, a plan for accomplishing the activities
described in this <U>Section</U><U></U><U>&nbsp;15.4.3(c)</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Continued Exploitation</B>. At Pfizer&#146;s request [***], Licensee shall continue <FONT
STYLE="white-space:nowrap">on-going</FONT> Exploitation for a mutually agreed-upon period following the termination of this Agreement, which period shall not be less than [***] unless otherwise agreed to by the Parties. For avoidance of doubt, if
Pfizer chooses not to continue a Clinical Trial initiated by Licensee, [***] of winding down such Clinical Trial, including compliance with any ethical or other requirements imposed by an applicable Regulatory Authority. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Technology Transfer</B>. At Pfizer&#146;s request, Licensee shall make available to Pfizer all currently
available records and data which exist and are Controlled by Licensee as of the effective date of termination and are necessary or useful for Pfizer to continue Exploiting Compounds and Products in the Field in the Territory. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulatory Matters</B>. At Pfizer&#146;s request, Licensee shall transfer and assign to Pfizer (or its
designee) all Regulatory Approvals and Regulatory Filings held by Licensee with respect to Compounds and Products, <I>provided</I> that if such transfer and assignment is not permitted by the applicable Regulatory Authority, Licensee shall permit
Pfizer to cross-reference and rely upon such Regulatory Approvals and Regulatory Filings. Licensee shall make available to Pfizer copies of all regulatory documentation and records related to Compounds and Products, including information contained
in the regulatory and safety databases. The Parties shall cooperate to ensure the prompt transition of regulatory responsibilities for Compounds and Products from Licensee to Pfizer. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Trademarks</B>. Pfizer shall have, and Licensee does hereby grant to Pfizer, a fully <FONT
STYLE="white-space:nowrap">paid-up,</FONT> royalty-free, worldwide, transferable, sublicensable, perpetual and irrevocable license to use the Licensee Product Trademarks solely for the purpose of using, Developing, Commercializing and Manufacturing
the Products in the U.S. and Japan. Pfizer shall have a transitional license to use Licensee&#146;s Trademarks and promotional materials solely for the purpose of using, Developing, Commercializing and Manufacturing the Products.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Inventory and Supply</B>. At Pfizer&#146;s request, Licensee shall transfer to Pfizer (or its designee) all
Compound and Product, components and <FONT STYLE="white-space:nowrap">in-process</FONT> inventory held by Licensee with respect to the Manufacture of Compounds and Products as of such date of termination. At Pfizer&#146;s request, if Licensee has
sublicensed to a CMO to Manufacture the Compounds or Products, Licensee shall promptly assign such sublicense to Pfizer, or if not, Licensee shall continue to Manufacture or have Manufactured the Products for a period of not less than [***],
including, at Pfizer&#146;s request, a reasonable stock build. Pfizer shall pay to Licensee [***] of manufacturing associated with inventory and Compound and Product received by Pfizer pursuant to this <U>Section</U><U></U><U>&nbsp;15.4.3(c)(v)</U>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Agreements</B>. At Pfizer&#146;s request, to the extent Licensee is able to do so, Licensee
shall assign to Pfizer (or its designee) any agreements with Third Parties with respect to the Development, Commercialization and Manufacture of the Compounds and Products. With respect to Third Party agreements that Licensee is not able to assign
to Pfizer, Licensee shall cooperate to give Pfizer the benefit of such contracts for a reasonable transitional period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>15.4.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination Terminated Products or a Terminated Territory by Pfizer for Cause</B>. In the event that Pfizer
terminates this Agreement with respect to all [***] or a Terminated Territory, as applicable, pursuant to <U>Section</U><U></U><U>&nbsp;15.2</U> (but not in the case of any termination of this Agreement in its entirety), the following shall apply:
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Rights and Obligations</B>. Except as otherwise provided herein, including pursuant to
<U>Section</U><U></U><U>&nbsp;15.5</U>, this Agreement shall automatically be deemed to be amended to exclude the rights and obligations of Licensee hereunder with respect to such Terminated Products or Terminated Territory, as applicable, including
for clarity, all licenses granted to Licensee hereunder with respect to such Terminated Products or Terminated Territory, as applicable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Licenses</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All rights and licenses granted to Pfizer hereunder shall become fully
<FONT STYLE="white-space:nowrap">paid-up,</FONT> irrevocable and perpetual with respect to such Terminated Products or Terminated Territory, as applicable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Pfizer terminates this Agreement with respect to Terminated Products, Licensee hereby grants to Pfizer and
its Affiliates, an exclusive, sublicensable, royalty-free, full <FONT STYLE="white-space:nowrap">paid-up,</FONT> irrevocable, and perpetual right and license, with the right to assign and grant sublicenses, under the Developed IP, as it exists as of
the effective date of termination, to Exploit the Terminated Products in the Field in the Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Pfizer terminates this Agreement with respect to a Terminated Territory, Licensee hereby grants to Pfizer
and its Affiliates, an exclusive, sublicensable, royalty-free, full <FONT STYLE="white-space:nowrap">paid-up,</FONT> irrevocable, and perpetual right and license, with the right to assign and grant sublicenses, under the Developed IP, as it exists
as of the effective date of termination, to Exploit the Terminated Products in the Field in the Terminated Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Transition</B>. During the notice period provided in <U>Section</U><U></U><U>&nbsp;15.2</U>, at
Pfizer&#146;s sole option, Pfizer shall prepare and the Parties shall negotiate a transition plan that will include, at a minimum, a plan for accomplishing the activities described in this <U>Section</U><U></U><U>&nbsp;15.4.4(c)</U>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Continued Exploitation</B>. At Pfizer&#146;s request [***], Licensee shall continue <FONT
STYLE="white-space:nowrap">on-going</FONT> Exploitation with respect to such Terminated Products or Terminated Territory, as applicable, for a mutually agreed-upon period following the termination of this Agreement with respect to the Terminated
Products or Terminated Territory, as applicable, which period shall not be less than [***] unless otherwise agreed to by the Parties. For avoidance of doubt, if Pfizer chooses not to continue a Clinical Trial initiated by Licensee pursuant to this
<U>Section</U><U></U><U>&nbsp;15.4.4(c)(</U><U>i</U><U>)</U>, [***] of winding down such Clinical Trial, including compliance with any ethical or other requirements imposed by an applicable Regulatory Authority. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Technology Transfer</B>. At Pfizer&#146;s request, Licensee shall make available to Pfizer all currently
available records and data which exist and are Controlled by Licensee with respect to such Terminated Products or Terminated Territory, as applicable, as of the effective date of termination, and are necessary or useful for Pfizer to continue
Exploiting such Terminated Products in the Field in the Territory or the Products in the such Terminated Territory, as applicable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulatory Matters</B>. At Pfizer&#146;s request, Licensee shall transfer and assign to Pfizer (or its
designee) all Regulatory Approvals and Regulatory Filings held by Licensee with respect to such Terminated Products or Terminated Territory, as applicable, <I>provided</I> that if such transfer and assignment is not permitted by the applicable
Regulatory Authority, Licensee shall permit Pfizer to cross-reference and rely upon such Regulatory Approvals and Regulatory Filings. Licensee shall make available to Pfizer copies of all regulatory documentation and records related to such
Terminated Products or Terminated Territory, as applicable, including information contained in the regulatory and safety databases. The Parties shall cooperate to ensure the prompt transition of regulatory responsibilities with respect to such
Terminated Products or Terminated Territory, as applicable, from Licensee to Pfizer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Trademarks</B>. Pfizer shall have, and Licensee does hereby grant to Pfizer, a fully <FONT
STYLE="white-space:nowrap">paid-up,</FONT> royalty-free, worldwide (except in the event that Pfizer terminates this Agreement with respect to a Terminated Territory, and such Terminated Territory is in the U.S. or Japan, in which case, such license
shall be solely for the Terminated Territory) transferable, sublicensable, perpetual and irrevocable license to use the Licensee Product Trademarks associated with the Terminated Products, or all Products with respect to the Terminated Territory, as
applicable, solely for the purpose of using, Developing, Commercializing and Manufacturing with respect to the Terminated Products or Terminated Territory, as applicable. Pfizer shall have a transitional license to use Licensee&#146;s Trademarks and
promotional materials solely for the purpose of using, Developing, Commercializing and Manufacturing the Terminated Products, or all Products with respect to a Terminated Territory, as applicable. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Inventory and Supply</B>. At Pfizer&#146;s request, Licensee shall transfer to Pfizer (or its designee) all
Compound and Product, components and <FONT STYLE="white-space:nowrap">in-process</FONT> inventory held by Licensee with respect to the Terminated Products or Terminated Territory, as applicable, as of such date of termination. At Pfizer&#146;s
request, if Licensee has sublicensed to a CMO to Manufacture a Terminated Product, or any Products with respect to the Terminated Territory, as applicable, Licensee shall promptly assign such sublicense to Pfizer, or if not, Licensee shall continue
to Manufacture or have Manufactured with respect to such Terminated Product or any Products with respect to the Terminated Territory, for a period of not less than [***], including, at Pfizer&#146;s request, a reasonable stock build. Pfizer shall
pay to Licensee [***] of manufacturing associated with inventory and Compound and Product received by Pfizer pursuant to this <U>Section</U><U></U><U>&nbsp;15.4.4(c)(v)</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Agreements</B>. At Pfizer&#146;s request, to the extent Licensee is able to do so, Licensee
shall assign to Pfizer (or its designee) any agreements with Third Parties with respect to the Development, Commercialization and Manufacture of the Terminated Products or Terminated Territory, as applicable. With respect to Third Party agreements
that Licensee is not able to assign to Pfizer, Licensee shall cooperate to give Pfizer the benefit of such contracts for a reasonable transitional period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>15.5</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Survival</B>. Expiration or termination of this Agreement shall not relieve the Parties of any
obligation accruing hereunder prior to such expiration or termination. Without limiting the foregoing, (a)&nbsp;the provisions of <U>Sections 1</U> (Definitions), <U>8</U> (Records; Audit Rights), <U>9.1</U>
<FONT STYLE="white-space:nowrap">(Pre-existing</FONT> IP), <U>11</U> (Confidentiality), <U>13</U> (Indemnification), <U>14</U> (Limitation of Liability) <U>15.4</U> (Effects of Termination), <U>15.5</U> (Survival), <U>17</U> (Licensee Insurance) and
<U>18</U> (General Provisions) shall survive expiration or termination of this Agreement and [***]. If this Agreement is terminated with respect to a Terminated Product or Terminated Territory, as applicable, but not in its entirety, then following
such termination the foregoing provisions of this Agreement shall remain in effect with respect to such Terminated Product or Terminated Territory (to the extent they would survive and apply in the event the Agreement expires or is terminated in its
entirety or as otherwise necessary for any of Pfizer and its Affiliates and its and their sublicensees to exercise their rights to such Terminated Product or Terminated Territory) and all provisions not surviving in accordance with the foregoing
shall terminate upon termination of this Agreement with respect to the Terminated Product or Terminated Territory and be of no further force and effect. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>15.6</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>365(n) Rights.</B> All rights and licenses now or hereafter granted to Licensee under or pursuant to
this Agreement, including <U>Sections 2.1.1</U> and <U>2.1.2</U>, are rights to &#147;intellectual property&#148; as defined in Section&nbsp;101(35A) of Title 11 of the United States Bankruptcy Code (the &#147;<B>Bankruptcy Code</B>&#148;). Pfizer
hereby grants to Licensee a right of access and to obtain possession of and to benefit from the Licensed <FONT STYLE="white-space:nowrap">Know-How,</FONT> which constitute &#147;embodiments&#148; of intellectual property pursuant to
Section&nbsp;365(n) of the Bankruptcy Code. Pfizer agrees not to interfere with Licensee&#146;s exercise of rights and licenses to intellectual property licensed hereunder and embodiments thereof in accordance with this Agreement and agrees to use
commercially reasonable efforts to assist Licensee to obtain such intellectual property and embodiments thereof in the possession or control of Affiliates or Third Parties as reasonably necessary or desirable for Licensee to exercise such rights and
licenses in accordance with this Agreement. The Parties acknowledge and agree that all payments by Licensee to Pfizer under this Agreement, other than U.S. Sales Milestone Payments and Licensee Royalties, do not constitute &#147;royalties&#148;
within the meaning of Bankruptcy Code &#167; 365(n) or relate to licenses of intellectual property hereunder. Conditioned upon satisfaction of the requirements of Section&nbsp;365(b) of the Bankruptcy Code, Pfizer hereby consents to assumption of
this Agreement in a case filed by or against Licensee under the Bankruptcy Code. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>16.</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>PUBLICITY; PUBLICATIONS</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>16.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Use of Names.</B> Subject to Pfizer&#146;s rights pursuant to
<U>Section</U><U></U><U>&nbsp;15.4.3(c)(iv)</U>, neither Party (nor any of its Affiliates or agents) shall use the registered or unregistered Trademarks of the other Party or its Affiliates in any press release, publication or other form of
promotional disclosure without the prior written consent of the other Party in each instance; <I>provided</I>, <I>however</I>, that Licensee and any of its Affiliates or sublicensees may state publicly that Licensee has received, or been sublicensed
under, a license from Pfizer to Exploit the Compounds and Products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>16.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Press Releases.</B> The Parties acknowledge that one or both Parties, either singly or jointly, may
desire to publish one or more press releases relating to this Agreement, the rights granted hereunder, and developments made thereto. However, each Party agrees not to issue any press release or other public statement, whether written, electronic,
oral or otherwise, disclosing the existence of this Agreement, the terms hereof or any information relating to this Agreement without the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed;
<I>provided</I> that a Party desiring to make such public disclosure may issue such press release or public announcement without such prior written consent by the other Party if (a)&nbsp;the entire contents of such press release or public
announcement have previously been made public other than through a breach of this Agreement by such Party, and (b)&nbsp;such press release or public </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
announcement does not materially differ from a previously issued press release or other publicly available information. Neither Party will be prevented from complying with any duty of disclosure
it may have pursuant to Applicable Law or the rules of any recognized stock exchange so long as the disclosing Party provides the other Party at least [***] prior written notice to the extent practicable and only discloses information to the extent
required by Applicable Law or the rules of any recognized stock exchange. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>16.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Publications.</B> During the Term, subject to the final sentence of this
<U>Section</U><U></U><U>&nbsp;16.3</U>, Licensee shall have the sole right to make any academic, scientific or medical publication or public presentation related to the Compounds and Products; <I>provided</I> that written copies of such proposed
publication or presentation shall be submitted to Pfizer for review no later than [***] before submission for publication or presentation (the &#147;<B>Review Period</B>&#148;). [***] </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>17.</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>INSURANCE</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>17.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Licensee Insurance Requirements.</B> Licensee will maintain during the Term and until the later of
(a) [***] after termination or expiration of this Agreement, or (b)&nbsp;the date that all statutes of limitation covering claims or suits that may be instituted for personal injury based on the sale or use of the Products have expired, commercial
general liability insurance from a minimum <FONT STYLE="white-space:nowrap">&#147;A-&#148;</FONT> AM Best rated insurance company, including contractual liability and product liability or clinical trials, if applicable, with coverage limits of not
less than [***] U.S. Dollars per occurrence and [***] U.S. Dollars in the aggregate. Licensee has the right to provide the total limits required by any combination of primary and umbrella/excess coverage. The minimum level of insurance set forth
herein shall not be construed to create a limit on Licensee&#146;s liability hereunder. Such policies shall name Pfizer and its Affiliates as additional insured via form CG20101185 or its equivalent (usually for US, Canada and Puerto Rico exposures)
or indemnify Pfizer and its Affiliates, as principal (usually for rest of world exposures) and provide a waiver of subrogation in favor of Pfizer and its Affiliates. Licensee shall also maintain statutory workers&#146; compensation and employers
liability with a minimum of [***] U.S. Dollars per occurrence. Such insurance policies shall be primary and <FONT STYLE="white-space:nowrap">non-contributing</FONT> with respect to any other similar insurance policies available to Pfizer or its
Affiliates. Any deductibles or retentions for such insurance shall be assumed by Licensee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>17.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Licensee Policy Notification</B>. Licensee shall provide Pfizer with certified copies of such policies or
original (electronic is acceptable) certificates of insurance evidencing such insurance (a)&nbsp;prior to execution by both Parties of this Agreement, and (b)&nbsp;the earlier of annually thereafter or prior to expiration of any one coverage.
Licensee shall provide that Pfizer shall be given at least [***] written notice prior to cancellation, termination or any material change to restrict the coverage or reduce the limits afforded. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>17.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pfizer Insurance Requirements</B>.<B> </B>Pfizer, as sponsor of the <B>[***]</B> and <B>[***]</B>, will
maintain during the Term and until the later of (a) <B>[***]</B> after termination or expiration of this Agreement, or (b)&nbsp;the date that all statutes of limitation covering claims or suits that may be instituted for personal injury based on the
sale or use of the Products have expired, commercial general liability insurance from a minimum <FONT STYLE="white-space:nowrap">&#147;A-&#148;</FONT> AM Best rated insurance company, including contractual liability and product liability or clinical
trials, if applicable, with coverage limits of not less than <B>[***]</B> U.S. Dollars per occurrence and <B>[***] </B>U.S. Dollars in the aggregate. Pfizer has the right to provide the total limits required by any combination of primary and
umbrella/excess coverage. The minimum level of insurance set forth herein shall not be construed to create a limit on Pfizer&#146;s liability hereunder. Such policies shall name Licensee and its Affiliates as additional insured via form CG20101185
or its equivalent (usually for US, Canada and Puerto Rico exposures) or indemnify Licensee and its Affiliates, as principal (usually for rest of world exposures) and provide a waiver of subrogation in favor of Licensee and its Affiliates. Pfizer
shall also maintain statutory workers&#146; compensation and employers liability with a minimum of [***] U.S. Dollars per occurrence. Such insurance policies shall be primary and <FONT STYLE="white-space:nowrap">non-contributing</FONT> with respect
to any other similar insurance policies available to Licensee or its Affiliates. Any deductibles or retentions for such insurance shall be assumed by Pfizer.<B> </B>Pfizer&#146;s insurance obligations can be met through a combination of insurance
and/or self-insurance. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>17.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pfizer Policy Notification</B>.<B> </B>Pfizer shall provide Licensee with original (electronic is
acceptable) certificates of insurance evidencing such insurance (a)&nbsp;prior to execution by both Parties of this Agreement, and (b)&nbsp;the earlier of annually thereafter or prior to expiration of any one coverage. Pfizer shall provide that
Licensee shall be given at least [***] written notice prior to cancellation, termination or any material change to restrict the coverage or reduce the limits afforded. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>GENERAL PROVISIONS</B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Assignment.</B> For purposes of this <U>Section</U><U></U><U>&nbsp;18.1</U>, any Change of Control
shall be deemed an assignment. Neither Party may assign its rights and obligations under this Agreement without the other Party&#146;s prior written consent, except that: (a)&nbsp;either Party may assign to a Third Party such Party&#146;s rights to
receive some or all of the Fees payable hereunder, (b)&nbsp;either Party may assign its rights and obligations under this Agreement or any part hereof to one or more of its Affiliates without the consent of other Party, <I>provided</I> that Licensee
shall not assign all or substantially all of its rights and obligations hereunder to one or more of its Affiliates (other than Priovant Holdings, Inc. or any direct or indirect wholly owned subsidiary of Priovant Holdings, Inc.) without the prior
written consent of Pfizer; and (c)&nbsp;either Party may assign this Agreement in connection with a Change of Control of such Party. The assigning Party shall provide the other Party with prompt written notice of any such assignment. Any permitted
assignee pursuant to clauses (b)&nbsp;and (c) above shall assume all obligations of its assignor under this Agreement, and no permitted assignment shall relieve the assignor of liability for its obligations hereunder. Any attempted assignment in
contravention of the foregoing shall be void. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Severability.</B> Should one or more of the provisions of this Agreement become void or unenforceable
as a matter of law, then such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement, and the Parties agree to substitute a valid and enforceable provision therefor
which, as nearly as possible, achieves the desired economic effect and mutual understanding of the Parties under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Governing Law; Dispute Resolution</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.3.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>This Agreement shall be governed by and construed in all respects in accordance with the internal laws
of the State of New York, as such laws are applied to agreements among New York residents entered into and performed entirely within New York, without giving effect to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">conflict-of-law</FONT></FONT> principles thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.3.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>With support from the Alliance Managers, the Parties shall negotiate in good faith and use reasonable
efforts to settle any dispute, controversy or action arising from or related to this Agreement or the breach thereof. Subject to <U>Section</U><U></U><U>&nbsp;18.3.8</U>, in the event that the Parties cannot resolve such dispute, controversy or
action within a period of [***] from when the dispute, controversy or action is first identified in writing by the Party raising or asserting such dispute, controversy or action, then the matter shall be referred to designated senior executives of
the Parties for resolution by the sending of a notice of dispute(s) for executive resolution (a &#147;<B>Notice of Dispute(s) for Executive Resolution</B>&#148;). The designated senior executives shall endeavor to meet in person or by means of
telephone conference, video conference or similar communications equipment by means of which all Persons participating in the meeting can hear and speak to each other, and where such participation by the Parties&#146; designated senior executives
shall constitute presence in person at the meeting, within [***] following transmittal of the Notice of Dispute(s) for Executive Resolution. Each Party shall be entitled to name substitute senior executives upon written notice to the other Party.
The foregoing duties may be delegated to the extent the person delegated with such duties is duly authorized to enter into the foregoing resolution without seeking any additional approval within the respective Party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.3.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Except as expressly set forth in <U>Section</U><U></U><U>&nbsp;18.3.8</U>, if the Parties do not fully
settle any dispute, controversy or action referred to the senior executives of the Parties within [***] of it being referred to them, and a Party wishes to pursue the matter, then such dispute, controversy or action that is not an Excluded Action
shall be finally resolved by binding arbitration administered by the American Arbitration Association (&#147;<B>AAA</B>&#148;) pursuant to AAA&#146;s Commercial Arbitration Rules then in effect. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.3.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The arbitration shall be conducted by a panel of three (3)&nbsp;neutral arbitrators, each of whom shall
have significant legal or business experience in the pharmaceutical industry, and none of whom shall be a current or former employee or director, or a current significant shareholder, of either Party or any of their respective Affiliates or
sublicensees; and within [***] after initiation of arbitration, each Party shall select one (1)&nbsp;person to act as arbitrator and the two (2)&nbsp;Party-selected arbitrators shall select a third (3rd) arbitrator within [***] of their appointment.
If the arbitrators selected by the Parties are unable or fail to agree upon the third (3rd) arbitrator, then on the [***] after the initiation of arbitration, the two (2)&nbsp;Party-selected arbitrators shall make a written request to AAA to appoint
a third (3rd) arbitrator. AAA shall appoint such third (3rd) arbitrator within [***] of being notified by the two (2)&nbsp;Party-selected arbitrators. The place of arbitration shall be New York, New York, and all proceedings and communications shall
be in English. The award rendered by the arbitrators shall be final, binding and <FONT STYLE="white-space:nowrap">non-appealable,</FONT> and judgment may be entered upon it in any court of competent jurisdiction. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.3.5</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is
rendered or the controversy is otherwise resolved. Either Party has the right to file an early dispositive motion seeking a determination on the issue of whether a material breach has occurred under <U>Section</U><U></U><U>&nbsp;15.2</U>, and the
arbitrators will promptly rule on such motion. The arbitrators&#146; authority to award punitive or any other type of damages not measured by a Party&#146;s compensatory damages shall be subject to the limitation set forth in
<U>Section</U><U></U><U>&nbsp;14.1</U>. [***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.3.6</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Except to the extent necessary to confirm or enforce an award or as may be required by Applicable Law,
neither Party nor an arbitrator may disclose the existence, content or results of an arbitration without the prior written consent of the other Party. In no event shall an arbitration be initiated after the date when commencement of a legal or
equitable action based on the dispute, controversy or action would be barred by the applicable statute of limitations in New York. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.3.7</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The term &#147;<B>Excluded Action</B>&#148; means a dispute, controversy or action that concerns
(i)&nbsp;the construction, scope, validity, enforceability, inventorship or infringement, misappropriation or other violation of any Intellectual Property Rights; or (ii)&nbsp;any antitrust, anti-monopoly or competition law or regulation, whether or
not statutory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.3.8</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Either Party may bring an action in any court of competent jurisdiction to resolve any Excluded Action,
and no Excluded Action shall be subject to arbitration pursuant to <U>Sections 18.3.3</U> or <U>18.3.4</U>. Any Excluded Action brought by either Party pursuant to this <U>Section</U><U></U><U>&nbsp;18.3.8</U> shall be venued exclusively in the
United States District Court for the Southern District of New York (&#147;<B>SDNY</B>&#148;), or if the SDNY does not have the jurisdiction to hear such Excluded Action, in a state court located in New York county, and each Party expressly and
irrevocably consents and submits to the jurisdiction of such courts having appropriate jurisdiction in connection with any such legal action. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.3.9</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION ARISING FROM OR
RELATED TO THIS AGREEMENT OR THE BREACH THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE <FONT STYLE="white-space:nowrap">ALL-ENCOMPASSING</FONT> OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT ARISE FROM OR RELATE TO THIS
AGREEMENT OR THE BREACH THEREOF, INCLUDING CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE
PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS
FOLLOWING CONSULTATION WITH LEGAL COUNSEL. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Equitable Relief</B>. The Parties agree that irreparable damage would occur in the event that any of
the provisions of <U>Section</U><U></U><U>&nbsp;3</U> or <U>Section</U><U></U><U>&nbsp;11</U>, in each case, is not performed in accordance with its specific terms of this Agreement or is otherwise breached. It is accordingly agreed that either
Party shall be entitled to an injunction or injunctions to prevent breaches of <U>Section</U><U></U><U>&nbsp;3</U> or <U>Section</U><U></U><U>&nbsp;11</U> and to enforce specifically the terms and provisions of such section of this Agreement in any
court of the United States or any state having jurisdiction, this being in addition to any other remedy to which such Party is entitled at law or in equity. Each Party hereby waives (a)&nbsp;any requirement that the other Party post a bond or other
security as a condition for obtaining any such relief and (b)&nbsp;any defenses in any action for specific performance, including the defense that a remedy at law would be adequate. The Parties acknowledge and agree that damages, to the extent
incurred by and awarded to, a Party are an appropriate remedy for any breach or violation of any other provision of this Agreement and that the Parties do not intend for any other provision of this Agreement to be specifically enforceable.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.5</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>Force Majeure</B>. Except with respect to delays or nonperformance caused by the negligent or
intentional act or omission of a Party, any delay or nonperformance by such Party (other than payment obligations under this Agreement) will not be considered a breach of this Agreement to the extent such delay or nonperformance is caused by acts of
God, natural disasters, acts of any Governmental Authority or civil or military authority, fire, floods, epidemics, quarantine, energy crises, war or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
riots or any other cause outside of the reasonable control of such Party (each, a &#147;<B>Force Majeure Event</B>&#148;), provided that the Party affected by such Force Majeure Event will
promptly begin or resume performance as soon as reasonably practicable after the event has abated. If the Force Majeure Event prevents a Party from performing any of its obligations under this Agreement for three hundred sixty five (365)&nbsp;days
or more, then the other Party may terminate this Agreement immediately upon written notice to the <FONT STYLE="white-space:nowrap">non-performing</FONT> Party. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.6</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Waivers and Amendments</B>. The failure of any Party to assert a right hereunder or to insist upon
compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. No waiver shall be effective unless it has been
given in writing and signed by the Party giving such waiver. No provision of this Agreement may be amended or modified other than by a written document signed by authorized representatives of each Party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.7</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Relationship of the Parties</B>. Nothing contained in this Agreement shall be deemed to constitute a
partnership, joint venture, or legal entity of any type between Pfizer and Licensee, or to constitute one Party as the agent of the other. Moreover, each Party agrees not to construe this Agreement, or any of the transactions contemplated hereby, as
a partnership, joint venture, employment, franchise, agency or fiduciary or similar relationship for any tax purposes. Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give any Party the
power or authority to act for, bind, or commit the other Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.8</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Successors and Assigns</B>. This Agreement shall be binding upon and inure to the benefit of the Parties
hereto and their respective successors and permitted assigns. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.9</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notices</B>.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>All notices, consents, waivers, and other
communications required or permitted to be given hereunder shall in all cases be delivered by email (with receipt of such email acknowledged by a <FONT STYLE="white-space:nowrap">non-automated</FONT> response by the applicable recipient within two
(2)&nbsp;Business Days of receipt, or, in the event that receipt is not so acknowledged by the applicable recipient, with delivery by an internationally recognized courier service of a confirmatory hardcopy without undue delay) and shall be deemed
given when sent, <I>provided</I> that (a)&nbsp;there is no &#147;bounce back&#148; message and (b)&nbsp;such email is sent on a Business Day prior to 6:00 pm local time of the recipient, and on the next Business Day if sent at any other time, but
may, as a second method of delivery, also be delivered (i)&nbsp;by personal delivery or (ii)&nbsp;by an internationally recognized overnight courier service, to the applicable address set forth below, unless another address has been previously
specified in writing by such Party in the manner set forth above. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to Pfizer: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Pfizer Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to Licensee: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Priovant, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to Roivant: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Roivant
Sciences Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.10</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Further Assurances</B>. Licensee and Pfizer hereby covenant and agree without the necessity of any further
consideration, to execute, acknowledge and deliver any and all such other documents and take any such other action as may be reasonably necessary or appropriate to carry out the intent and purposes of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.11</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Third Party Beneficiary Rights</B>. This Agreement is not intended to and shall not be construed to give
any Third Party any interest or rights (including any third party beneficiary rights) with respect to or in connection with any agreement or provision contained herein or contemplated hereby, except for (a)&nbsp;the provisions of
<U>Section</U><U></U><U>&nbsp;13</U>, which shall be for the benefit of the Licensee Indemnitees and the Pfizer Indemnitees, (b)&nbsp;the provisions of <U>Section</U><U></U><U>&nbsp;18.1</U>, which shall be for the benefit of the Persons
contemplated thereby, and (c)&nbsp;this <U>Section</U><U></U><U>&nbsp;18.11</U> in respect of the sections set forth under the foregoing clauses (a)&nbsp;and (b). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.12</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entire Agreement; Confidentiality Agreement. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.12.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>This Agreement, together with its Schedules, sets forth the entire agreement and understanding of the
Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter, including the CDA. The Parties acknowledge and agree that, as of the
Effective Date, all Confidential Information (as defined in the CDA) disclosed by Pfizer or its Affiliates pursuant to the CDA shall be considered Pfizer&#146;s Confidential Information and subject to the terms set forth in this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>18.12.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event of any conflict between a material provision of this Agreement and any Schedule hereto, the
Agreement shall control. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.13</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Counterparts</B>. This Agreement may be executed in two or more counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same instrument. The Parties agree that execution of this Agreement by industry standard electronic signature software or by exchanging executed signature pages in .pdf format via <FONT
STYLE="white-space:nowrap">e-mail</FONT> shall have the same legal force and effect as the exchange of original signatures, and that in any proceeding arising under or related to this Agreement, each Party hereby waives any right to raise any
defense or waiver based upon execution of this Agreement by means of such electronic signatures or maintenance of the executed agreement electronically. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.14</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cumulative Remedies</B>. No remedy referred to in this Agreement is intended to be exclusive, but each shall
be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.15</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Performance by Affiliates</B>. Any obligation of either Party under or pursuant to this Agreement may be
satisfied, met or fulfilled, in whole or in part, at such Party&#146;s sole and exclusive option, by any Affiliate of such Party that it causes to satisfy, meet or fulfill such obligation, in whole or in part, <I>provided</I> that such Party shall
remain liable hereunder for the performance by its Affiliates of any such obligations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.16</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Waiver of Rule of Construction</B>. Each Party has had the opportunity to consult with counsel in connection
with the review, drafting and negotiation of this Agreement. Accordingly, any rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Signature pages to follow] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties intending to be bound have caused this Agreement to be
executed by their duly authorized representatives as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PFIZER INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Young</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">J<SMALL>OHN</SMALL> Young</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Business Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to License and Collaboration Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties intending to be bound have caused this Agreement to be
executed by their duly authorized representatives as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PRIOVANT, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Benjamin Zimmer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Benjamin Zimmer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">And solely with respect to Section&nbsp;11.4:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROIVANT SCIENCES LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matt Maisak</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Matt Maisak</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Operating Officer, Roivant Platforms</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to License and Collaboration Agreement</I>] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.38
<SEQUENCE>11
<FILENAME>d307489dex1038.htm
<DESCRIPTION>EX-10.38
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.38</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.38 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE ROIVANT SCIENCES LTD. (THE
&#147;COMPANY&#148;) HAS DETERMINED THAT THE INFORMATION (I)&nbsp;IS NOT MATERIAL AND (II)&nbsp;WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>FIRST AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">THIS FIRST AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT (the &#147;<B>First Amendment</B>&#148;) is dated as of the 10th day of June, 2022
(the &#147;<B>First Amendment Effective Date</B>&#148;), by and between Pfizer Inc., a corporation organized and existing under the laws of Delaware with offices at [***] (&#147;<B>Pfizer</B>&#148;), and Priovant Therapeutics, Inc., formerly known
as Priovant, Inc., a corporation organized and existing under the laws of Delaware with offices at [***] (&#147;<B>Licensee</B>&#148;). Licensee and Pfizer may be individually referred to as a &#147;<B>Party</B>&#148; and collectively referred to as
the &#147;<B>Parties</B>&#148;. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Original Agreement (as defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties entered into a License and Collaboration Agreement dated September&nbsp;13, 2021 (the &#147;<B>Original
Agreement</B>,&#148; as amended by this First Amendment, the &#147;<B>Agreement</B>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties have agreed to amend
the[***] to [***]; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties desire to amend certain portions of Section&nbsp;5.9.2 of the Original Agreement relating to
the [***], and certain related definitional provisions, in light of the planned amendment to the [***]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration
of the mutual agreements, provisions and covenants contained in this First Amendment, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby
agree as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The first sentence of the first paragraph of Section&nbsp;5.9.2 of the Original Agreement is hereby amended by
deleting the text beginning with &#147;(a)&#148; and ending before &#147;(b)&#148; and inserting in lieu thereof the following: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;[***]&#148;. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Original Agreement is hereby further amended by deleting Section&nbsp;5.9.2(b) in its entirety. In
addition, Section&nbsp;1.76, Section&nbsp;1.153 and Section&nbsp;1.154 of the Original Agreement are each hereby deleted in their entirety and replaced with the following text: &#147;Intentionally Left Blank.&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as set forth in this First Amendment, all terms and conditions of the Original Agreement are hereby
ratified and shall remain in full force and effect. Amendments made pursuant to this First Amendment shall be effective as of the First Amendment Effective Date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of a conflict between a provision of the Original Agreement and a provision of this First
Amendment, the provisions of this First Amendment will control to the extent of such conflict. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This First Amendment may be executed in counterparts (including by facsimile or other electronic transmission),
all of which together shall constitute an agreement binding on the Parties. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have duly
executed this First Amendment as of the First Amendment Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PFIZER INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Vincent</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael Vincent</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">SVP&nbsp;&amp; CSO - I&amp;I</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PRIOVANT THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Benjamin Zimmer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Benjamin Zimmer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>12
<FILENAME>d307489dex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 21.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>List of Subsidiaries of Roivant Sciences Ltd. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">* The names of certain other subsidiaries of Roivant Sciences Ltd. are omitted because, considered in the aggregate, they would not constitute a
&#147;significant subsidiary.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Jurisdiction&nbsp;of&nbsp;Incorporation
or<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Formation&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Affivant Sciences GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Switzerland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Affivant Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Bermuda</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Affivant Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alyvant GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Switzerland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alyvant Holdings, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alyvant Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Bermuda</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alyvant, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aruvant Sciences GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Switzerland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aruvant Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Bermuda</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aruvant Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dermavant Sciences GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Switzerland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dermavant Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Bermuda</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dermavant Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DSL Treasury Holdings Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DSL Treasury Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Genevant Sciences BioVentures GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Switzerland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Genevant Sciences Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Canada</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Genevant Sciences GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Switzerland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Genevant Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Bermuda</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Genevant Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hemavant Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Bermuda</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hemavant Sciences GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Switzerland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hemavant Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Immunovant Sciences GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Switzerland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Immunovant Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Bermuda</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Immunovant, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IMVT Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Izana Bioscience Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">United Kingdom</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kinevant Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Bermuda</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kinevant Sciences GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Switzerland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kinevant Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Bermuda</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kinevant Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lokavant Holdings, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lokavant, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oncopia Therapeutics, Inc. d/b/a/ Proteovant Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pharmavant 3 GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Switzerland</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Priovant Holdings, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Priovant Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proteovant Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roivant Discovery, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roivant Rhine Holdings, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roivant Sciences GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Switzerland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roivant Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roivant Treasury Holdings, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roivant Treasury, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VantAI Holdings, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">United States &#150; Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VantAI, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">United States &#150; Delaware</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>13
<FILENAME>d307489dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in the following Registration Statement of Roivant Sciences Ltd.: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Registration Statement (Form <FONT STYLE="white-space:nowrap">S-8</FONT>
<FONT STYLE="white-space:nowrap">No.&nbsp;333-260173)</FONT> pertaining to the Roivant Sciences Ltd. 2021 Equity Incentive Plan, the Roivant Sciences Ltd. Employee Stock Purchase Plan and the Roivant Sciences Ltd. Amended and Restated 2015 Equity
Incentive Plan; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of our report dated June&nbsp;28, 2022, with respect to the consolidated financial statements of Roivant Sciences Ltd.
included in this Annual Report (Form <FONT STYLE="white-space:nowrap">10-K)</FONT> of Roivant Sciences Ltd. for the year ended March&nbsp;31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/
Ernst&nbsp;&amp; Young LLP&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Iselin, New Jersey </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;28, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>14
<FILENAME>d307489dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CERTIFICATION </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Matthew Gline,
certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Roivant Sciences
Ltd.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> for the registrant and have: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[Reserved]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: June&nbsp;28, 2022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Gline</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Matthew Gline</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Principal Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>15
<FILENAME>d307489dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CERTIFICATION </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Richard Pulik,
certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Roivant Sciences
Ltd.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> for the registrant and have: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[Reserved]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: June&nbsp;28, 2022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Richard Pulik</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Richard Pulik</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Principal Financial Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>16
<FILENAME>d307489dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the
requirement set forth in Rule <FONT STYLE="white-space:nowrap">13a-14(b)</FONT> of the Securities Exchange Act of 1934, as amended, (the &#147;Exchange Act&#148;) and Section&nbsp;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C.
&#167;1350), Matthew Gline, Principal Executive Officer of Roivant Sciences Ltd. (the &#147;Company&#148;), hereby certifies that, to the best of his knowledge: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
March&nbsp;31, 2022, to which this Certification is attached as Exhibit 32.1 (the &#147;Annual Report&#148;), fully complies with the requirements of Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The information contained in the Annual Report fairly presents, in all material respects, the financial
condition and results of operations of the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June&nbsp;28, 2022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Gline</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Matthew Gline</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Principal Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A signed original of this written statement required by Section&nbsp;906 of 18 U.S.C. &#167;&nbsp;1350 has been provided
to the Company, and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This certification
accompanies the Form <FONT STYLE="white-space:nowrap">10-K</FONT> to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act
of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form <FONT STYLE="white-space:nowrap">10-K),</FONT> irrespective of any general incorporation language contained in such filing. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>17
<FILENAME>d307489dex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the
requirement set forth in Rule <FONT STYLE="white-space:nowrap">13a-14(b)</FONT> of the Securities Exchange Act of 1934, as amended, (the &#147;Exchange Act&#148;) and Section&nbsp;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C.
&#167;1350), Richard Pulik, Principal Financial Officer of Roivant Sciences Ltd. (the &#147;Company&#148;), hereby certifies that, to the best of his knowledge: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
March&nbsp;31, 2022, to which this Certification is attached as Exhibit 32.2 (the &#147;Annual Report&#148;), fully complies with the requirements of Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information contained in the Annual Report fairly presents, in all material respects, the financial
condition and results of operations of the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June&nbsp;28, 2022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Richard Pulik</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Richard Pulik</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Principal Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A signed original of this written statement required by Section&nbsp;906 of 18 U.S.C. &#167;&nbsp;1350 has been provided
to the Company, and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This certification
accompanies the Form <FONT STYLE="white-space:nowrap">10-K</FONT> to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act
of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form <FONT STYLE="white-space:nowrap">10-K),</FONT> irrespective of any general incorporation language contained in such filing. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>roiv-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 28-June-2022 [03:58:35] {PM}-->
<schema targetNamespace="http://roivant.com/20220331" elementFormDefault="qualified" xmlns:roiv="http://roivant.com/20220331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://roivant.com/role/Cover" id="Cover">
<link:definition>1001 - Document - Cover</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
<link:definition>1004 - Statement - Consolidated Statements of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ConsolidatedStatementsOfOperationsParenthetical" id="ConsolidatedStatementsOfOperationsParenthetical">
<link:definition>1005 - Statement - Consolidated Statements of Operations (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss" id="ConsolidatedStatementsOfComprehensiveLoss">
<link:definition>1006 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest" id="ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest">
<link:definition>1007 - Statement - Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1008 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/DescriptionOfBusinessAndLiquidity" id="DescriptionOfBusinessAndLiquidity">
<link:definition>1009 - Disclosure - Description of Business and Liquidity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/BusinessCombinationWithMaac" id="BusinessCombinationWithMaac">
<link:definition>1011 - Disclosure - Business Combination with MAAC</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/Investments" id="Investments">
<link:definition>1012 - Disclosure - Investments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/AssetAcquisitionsAndLicenseAgreements" id="AssetAcquisitionsAndLicenseAgreements">
<link:definition>1013 - Disclosure - Asset Acquisitions and License Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/AccruedExpenses" id="AccruedExpenses">
<link:definition>1014 - Disclosure - Accrued Expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitment" id="LongTermDebtAndLoanCommitment">
<link:definition>1015 - Disclosure - Long-Term Debt and Loan Commitment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1016 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareholdersEquity" id="ShareholdersEquity">
<link:definition>1017 - Disclosure - Shareholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensation" id="ShareBasedCompensation">
<link:definition>1018 - Disclosure - Share-Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1019 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/Leases" id="Leases">
<link:definition>1020 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/CommitmentsContingencies" id="CommitmentsContingencies">
<link:definition>1021 - Disclosure - Commitments &amp; Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1022 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/OtherExpenseNet" id="OtherExpenseNet">
<link:definition>1023 - Disclosure - Other Expense, Net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/NetLossPerCommonShare" id="NetLossPerCommonShare">
<link:definition>1024 - Disclosure - Net Loss per Common Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1025 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1026 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1027 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
<link:definition>1028 - Disclosure - Accrued Expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentTables" id="LongTermDebtAndLoanCommitmentTables">
<link:definition>1029 - Disclosure - Long-Term Debt and Loan Commitment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensationTables" id="ShareBasedCompensationTables">
<link:definition>1030 - Disclosure - Share-Based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1031 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/LeasesTables" id="LeasesTables">
<link:definition>1032 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1033 - Disclosure - Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/OtherExpenseNetTables" id="OtherExpenseNetTables">
<link:definition>1034 - Disclosure - Other Expense, Net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/NetLossPerCommonShareTables" id="NetLossPerCommonShareTables">
<link:definition>1035 - Disclosure - Net Loss per Common Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail" id="DescriptionOfBusinessAndLiquidityAdditionalInformationDetail">
<link:definition>1036 - Disclosure - Description of Business and Liquidity - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition>1037 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail" id="SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail">
<link:definition>1038 - Disclosure - Summary of Significant Accounting Policies - Schedule of Aggregate Amounts of Cash, Cash Equivalents, and Restricted Cash (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail" id="SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail">
<link:definition>1039 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail" id="BusinessCombinationWithMaacAdditionalInformationDetail">
<link:definition>1040 - Disclosure - Business Combination with MAAC -  Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/InvestmentsAdditionalInformationDetail" id="InvestmentsAdditionalInformationDetail">
<link:definition>1041 - Disclosure - Investments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail" id="AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail">
<link:definition>1042 - Disclosure - Asset Acquisitions and License Agreements -Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail" id="AccruedExpensesScheduleOfAccruedExpensesDetail">
<link:definition>1043 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail" id="LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail">
<link:definition>1044 - Disclosure - Long-Term Debt and Loan Commitment - Summary of Long-Term Debt (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail" id="LongTermDebtAndLoanCommitmentAdditionalInformationDetail">
<link:definition>1045 - Disclosure - Long-Term Debt and Loan Commitment  - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail" id="LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail">
<link:definition>1046 - Disclosure - Long-Term Debt and Loan Commitment - Schedule of Company's Annual Payments (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail" id="RelatedPartyTransactionsAdditionalInformationDetail">
<link:definition>1047 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail" id="ShareholdersEquityAdditionalInformationDetail">
<link:definition>1048 - Disclosure - Shareholders' Equity - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail" id="ShareBasedCompensationAdditionalInformationDetail">
<link:definition>1049 - Disclosure - Share-Based Compensation - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail" id="ShareBasedCompensationScheduleOfFairValueAssumptionsDetail">
<link:definition>1050 - Disclosure - Share-Based Compensation - Schedule of Fair Value Assumptions (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail" id="ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail">
<link:definition>1051 - Disclosure - Share-Based Compensation - Summary of Fair Value of Vested Stock Option (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail" id="ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail">
<link:definition>1052 - Disclosure - Share-Based Compensation - Summary of Restricted Stock Units (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail" id="ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail">
<link:definition>1053 - Disclosure - Share-Based Compensation - Summary of Performance Options Activity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail" id="ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail">
<link:definition>1054 - Disclosure - Share-Based Compensation - Summary of Capped Value Appreciation Rights (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" id="ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail">
<link:definition>1055 - Disclosure - Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail" id="IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail">
<link:definition>1056 - Disclosure - Income Taxes - Schedule of Loss Before Income Taxes by Geographic Region (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail" id="IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail">
<link:definition>1057 - Disclosure - Income Taxes - Schedule Components of Income Tax Expense (Benefit) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
<link:definition>1058 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail" id="IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail">
<link:definition>1059 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" id="IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail">
<link:definition>1060 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail" id="LeasesScheduleOfOperatingLeaseCostsDetail">
<link:definition>1061 - Disclosure - Leases - Schedule of Operating Lease Costs (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail" id="LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail">
<link:definition>1062 - Disclosure - Leases - Summary of Operating Lease ROU Assets and Operating Lease Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" id="LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail">
<link:definition>1063 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesAdditionalInformationDetail">
<link:definition>1064 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" id="FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail">
<link:definition>1065 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail" id="FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail">
<link:definition>1066 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail" id="FairValueMeasurementsAdditionalInformationDetail">
<link:definition>1067 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail" id="FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail">
<link:definition>1068 - Disclosure - Fair Value Measurements - Change in the Fair Value of the Derivative Warrant Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfChangeInFairValueOfTheLevel3AssetsDetail" id="FairValueMeasurementsScheduleOfChangeInFairValueOfTheLevel3AssetsDetail">
<link:definition>1069 - Disclosure -  Fair Value Measurements - Schedule of Change IN Fair Value of the Level 3 Assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail" id="FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail">
<link:definition>1070 - Disclosure -  Fair Value Measurements - Schedule of Fair Value of Significant Unobservable Inputs Using Valuation Techniques (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail" id="FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail">
<link:definition>1071 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Unobservable Input Related To Options to Acquire Under Sumitomo Transaction Agreement (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail" id="OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail">
<link:definition>1072 - Disclosure - Other Expense, Net - Summary of Other Expense, Net From Continuing Operations (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail" id="NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail">
<link:definition>1073 - Disclosure - Net Loss per Common Share - Summary Of Potentially Dilutive Securities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/SubsequentEventsAdditionalInformationDetail" id="SubsequentEventsAdditionalInformationDetail">
<link:definition>1074 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="roiv-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="roiv-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="roiv-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="roiv-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
<import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
<import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="DeferredConsiderationLiabilityCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_DeferredConsiderationLiabilityCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SubscriptionsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_SubscriptionsReceivable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LiabilityInstrumentsMeasuredAtFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_LiabilityInstrumentsMeasuredAtFairValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_OperatingCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AcquiredInProcessResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_AcquiredInProcessResearchAndDevelopmentExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="GainLossOnFairValueOfDebtAndLiabilityInstruments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EquityInterestOptionToThirdPartyPurchaserGainOnTermination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConsolidationOfUnconsolidatedEntity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ConsolidationOfUnconsolidatedEntity" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeconsolidationOfSubsidiary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_DeconsolidationOfSubsidiary" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CapitalContributionsToSubsidiaries" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_CapitalContributionsToSubsidiaries" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfSubsidiaryCommonSharesNetValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_IssuanceOfSubsidiaryCommonSharesNetValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfSubsidiaryWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_IssuanceOfSubsidiaryWarrants" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RepurchaseOfEquityAwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_RepurchaseOfEquityAwards" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedDuringPeriodValueSubsidiaryPreferredShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_StockIssuedDuringPeriodValueSubsidiaryPreferredShares" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfStockUponWarrantsExerciseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_IssuanceOfStockUponWarrantsExerciseShares" substitutionGroup="xbrli:item" />
<element name="StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled" substitutionGroup="xbrli:item" />
<element name="IssuanceOfStockUponWarrantsExerciseValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_IssuanceOfStockUponWarrantsExerciseValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SubscriptionsReceivablesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SubscriptionsReceivablesMember" substitutionGroup="xbrli:item" />
<element name="RedeemableNoncontrollingInterestMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_RedeemableNoncontrollingInterestMember" substitutionGroup="xbrli:item" />
<element name="ProceedsFromSubsidiaryDebtFinancingsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ProceedsFromSubsidiaryDebtFinancingsNet" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentForOfferingAndLoanCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_PaymentForOfferingAndLoanCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromBusinessCombinationAndPipeFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ProceedsFromBusinessCombinationAndPipeFinancing" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromPaymentOfSubscriptionReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ProceedsFromPaymentOfSubscriptionReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromAndPaymentForOtherFinancingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ProceedsFromAndPaymentForOtherFinancingActivities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherNonCashTransactions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_OtherNonCashTransactions" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseInOtherInvestingNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_IncreaseDecreaseInOtherInvestingNet" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_IncreaseDecreaseInOperatingLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="GainOnTerminationOfEquityInterestOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_GainOnTerminationOfEquityInterestOptions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NonCashAcquiredInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_NonCashAcquiredInProcessResearchAndDevelopment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="RoivantSciencesLtd.Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_RoivantSciencesLtd.Member" substitutionGroup="xbrli:item" />
<element name="GeneralAndAdministrativeExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_GeneralAndAdministrativeExpensesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="WarrantliabilitiesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_WarrantliabilitiesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock" substitutionGroup="xbrli:item" />
<element name="CappedValueAppreciationRightsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_CappedValueAppreciationRightsMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandFifteenEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_TwoThousandFifteenEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_TwoThousandTwentyOneEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="DatavantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_DatavantMember" substitutionGroup="xbrli:item" />
<element name="SumitomoOptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SumitomoOptionsMember" substitutionGroup="xbrli:item" />
<element name="EarnoutSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_EarnoutSharesMember" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_PrivatePlacementWarrantsMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_ScheduleOfAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_ScheduleOfAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="ProceedsFromReleaseOfEscrowDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_ProceedsFromReleaseOfEscrowDeposit" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CashPaidToSettleDeferredConsiderationLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_CashPaidToSettleDeferredConsiderationLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability" substitutionGroup="xbrli:item" />
<element name="CashAndCashEquivalentsAndRestrictedCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_CashAndCashEquivalentsAndRestrictedCash" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LaboratoryandotherequipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_LaboratoryandotherequipmentMember" substitutionGroup="xbrli:item" />
<element name="BusinesscombinationwithmaacTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_BusinesscombinationwithmaacTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="MaacClassASharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_MaacClassASharesMember" substitutionGroup="xbrli:item" />
<element name="MaacClassBSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_MaacClassBSharesMember" substitutionGroup="xbrli:item" />
<element name="MontesArchimedesAcquisitionCorpMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_MontesArchimedesAcquisitionCorpMember" substitutionGroup="xbrli:item" />
<element name="RoivantWarrantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_RoivantWarrantMember" substitutionGroup="xbrli:item" />
<element name="PublicWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_PublicWarrantsMember" substitutionGroup="xbrli:item" />
<element name="RedemptionOfRoivantWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_RedemptionOfRoivantWarrantsMember" substitutionGroup="xbrli:item" />
<element name="MaacIndependentDirectorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_MaacIndependentDirectorMember" substitutionGroup="xbrli:item" />
<element name="LockUpAgreementsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_LockUpAgreementsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="LockUpAgreementsDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_LockUpAgreementsDomain" substitutionGroup="xbrli:item" />
<element name="LockUpPeriodNineMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_LockUpPeriodNineMember" substitutionGroup="xbrli:item" />
<element name="LockUpPeriodOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_LockUpPeriodOneMember" substitutionGroup="xbrli:item" />
<element name="LockUpPeriodTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_LockUpPeriodTwoMember" substitutionGroup="xbrli:item" />
<element name="LockUpPeriodSevenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_LockUpPeriodSevenMember" substitutionGroup="xbrli:item" />
<element name="LockUpPeriodEightMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_LockUpPeriodEightMember" substitutionGroup="xbrli:item" />
<element name="LockUpPeriodThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_LockUpPeriodThreeMember" substitutionGroup="xbrli:item" />
<element name="LockUpPeriodFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_LockUpPeriodFourMember" substitutionGroup="xbrli:item" />
<element name="LockUpPeriodFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_LockUpPeriodFiveMember" substitutionGroup="xbrli:item" />
<element name="LockUpPeriodSixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_LockUpPeriodSixMember" substitutionGroup="xbrli:item" />
<element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_AgreementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AgreementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_AgreementDomain" substitutionGroup="xbrli:item" />
<element name="PipeFinancingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_PipeFinancingMember" substitutionGroup="xbrli:item" />
<element name="MaacSponsorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_MaacSponsorMember" substitutionGroup="xbrli:item" />
<element name="RoivantCommonSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_RoivantCommonSharesMember" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_BusinessCombinationAgreementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="BusinessCombinationAgreementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_BusinessCombinationAgreementDomain" substitutionGroup="xbrli:item" />
<element name="SponsorSupportAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SponsorSupportAgreementMember" substitutionGroup="xbrli:item" />
<element name="TriggeringEventAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_TriggeringEventAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TriggeringEventDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_TriggeringEventDomain" substitutionGroup="xbrli:item" />
<element name="SharePriceEqualOrExceedsTwentyDollarMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SharePriceEqualOrExceedsTwentyDollarMember" substitutionGroup="xbrli:item" />
<element name="SharePriceEqualOrExceedsEighteenDollarMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SharePriceEqualOrExceedsEighteenDollarMember" substitutionGroup="xbrli:item" />
<element name="SharePriceEqualOrExceedsEighteenPerDollarMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SharePriceEqualOrExceedsEighteenPerDollarMember" substitutionGroup="xbrli:item" />
<element name="SharePriceEqualOrExceedsTenDollarMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SharePriceEqualOrExceedsTenDollarMember" substitutionGroup="xbrli:item" />
<element name="SharePriceEqualOrExceedsFifteenDollarMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SharePriceEqualOrExceedsFifteenDollarMember" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationWithMAACLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_BusinessCombinationWithMAACLineItems" substitutionGroup="xbrli:item" />
<element name="ExchangeRatioOfMAACClassBToRoivantCommonShares" type="xbrli:pureItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_ExchangeRatioOfMAACClassBToRoivantCommonShares" substitutionGroup="xbrli:item" />
<element name="StockholdersEquityNoteStockSplitExchangeRatio1" type="xbrli:pureItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_StockholdersEquityNoteStockSplitExchangeRatio1" substitutionGroup="xbrli:item" />
<element name="Costsincurredrelatedtofinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_Costsincurredrelatedtofinancing" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Allocationoftransactioncostsincurredtowarrantsandearnoutshares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_Allocationoftransactioncostsincurredtowarrantsandearnoutshares" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Portionofsharesubjecttoearnout" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_Portionofsharesubjecttoearnout" substitutionGroup="xbrli:item" />
<element name="Numberoftradingdaystomeetwarrantredemptionthreshold" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_Numberoftradingdaystomeetwarrantredemptionthreshold" substitutionGroup="xbrli:item" />
<element name="Percentageofsharessubjecttolockupfordefinedperiodoftime" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime" substitutionGroup="xbrli:item" />
<element name="Stockpricetriggerforredemptionofwarrants" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_Stockpricetriggerforredemptionofwarrants" substitutionGroup="xbrli:item" />
<element name="Numberoftradingdaystomeetearnoutpricethreshold" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_Numberoftradingdaystomeetearnoutpricethreshold" substitutionGroup="xbrli:item" />
<element name="Tradingdayperiodforwarrantredemption" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_Tradingdayperiodforwarrantredemption" substitutionGroup="xbrli:item" />
<element name="Tradingdayperiodforearnoutshares" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_Tradingdayperiodforearnoutshares" substitutionGroup="xbrli:item" />
<element name="PeriodForFairMarketValueDetermination" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_PeriodForFairMarketValueDetermination" substitutionGroup="xbrli:item" />
<element name="EarnOutSharePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_EarnOutSharePrice" substitutionGroup="xbrli:item" />
<element name="Lockupperiodofcommonshares" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_Lockupperiodofcommonshares" substitutionGroup="xbrli:item" />
<element name="Percentageofwarrantssubjecttolockupfordefinedperiodoftime" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_Percentageofwarrantssubjecttolockupfordefinedperiodoftime" substitutionGroup="xbrli:item" />
<element name="Lockupperiodwarrants" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_Lockupperiodwarrants" substitutionGroup="xbrli:item" />
<element name="Timetowarrantexercisability" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_Timetowarrantexercisability" substitutionGroup="xbrli:item" />
<element name="Shareredemptiontriggerprice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_Shareredemptiontriggerprice" substitutionGroup="xbrli:item" />
<element name="Classofwarrantsredemptionpriceperunit" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_Classofwarrantsredemptionpriceperunit" substitutionGroup="xbrli:item" />
<element name="Classofwarrantsredemptionnoticeperiod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_Classofwarrantsredemptionnoticeperiod" substitutionGroup="xbrli:item" />
<element name="MaximumRedemptionFeaturePerWarrant" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_MaximumRedemptionFeaturePerWarrant" substitutionGroup="xbrli:item" />
<element name="CommonStockWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_CommonStockWarrants" substitutionGroup="xbrli:item" />
<element name="UncategorizedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_UncategorizedAbstract" substitutionGroup="xbrli:item" />
<element name="InvestmentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_InvestmentsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ArbutusBiopharmaCorporationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_ArbutusBiopharmaCorporationMember" substitutionGroup="xbrli:item" />
<element name="DatavantHoldingsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_DatavantHoldingsIncMember" substitutionGroup="xbrli:item" />
<element name="SioGeneTherapiesIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SioGeneTherapiesIncMember" substitutionGroup="xbrli:item" />
<element name="InvestmentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_InvestmentsLineItems" substitutionGroup="xbrli:item" />
<element name="PreferredStockOwnedBalanceSharesOfArbutus" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_PreferredStockOwnedBalanceSharesOfArbutus" substitutionGroup="xbrli:item" />
<element name="InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock" substitutionGroup="xbrli:item" />
<element name="GainOnMeasurementOfInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_GainOnMeasurementOfInvestment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromSaleOfInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ProceedsFromSaleOfInvestment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DatavantMergerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_DatavantMergerMember" substitutionGroup="xbrli:item" />
<element name="CombinedCompanyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_CombinedCompanyMember" substitutionGroup="xbrli:item" />
<element name="SiliconTherapeuticsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SiliconTherapeuticsMember" substitutionGroup="xbrli:item" />
<element name="PriovantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_PriovantMember" substitutionGroup="xbrli:item" />
<element name="FutureDevelopmentAndCommercialMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_FutureDevelopmentAndCommercialMilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessAcquisitionConsiderationTransferred" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_BusinessAcquisitionConsiderationTransferred" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NonRefundableUpfrontPaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_NonRefundableUpfrontPaymentReceived" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentForUpfrontPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_PaymentForUpfrontPayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueOfRestrictedStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_FairValueOfRestrictedStock" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueOfCommonShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_FairValueOfCommonShares" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfControllingInterestHeld" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_PercentageOfControllingInterestHeld" substitutionGroup="xbrli:item" />
<element name="PaymentUnderSponsoredResearchAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_PaymentUnderSponsoredResearchAgreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedDuringPeriodValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_StockIssuedDuringPeriodValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PotentialMilestonePaymentReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_PotentialMilestonePaymentReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UpfrontCashPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_UpfrontCashPayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MilestonePaymentPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_MilestonePaymentPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PayableForEachAdditionalProductIndication" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_PayableForEachAdditionalProductIndication" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MilestoneEventsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_MilestoneEventsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="MilestoneEventsDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_MilestoneEventsDomain" substitutionGroup="xbrli:item" />
<element name="FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" substitutionGroup="xbrli:item" />
<element name="FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" substitutionGroup="xbrli:item" />
<element name="FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" substitutionGroup="xbrli:item" />
<element name="AffivantSciencesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_AffivantSciencesMember" substitutionGroup="xbrli:item" />
<element name="GenevantSciencesLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_GenevantSciencesLtdMember" substitutionGroup="xbrli:item" />
<element name="ProteovantSciencesIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_ProteovantSciencesIncMember" substitutionGroup="xbrli:item" />
<element name="FirstTrancheMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_FirstTrancheMember" substitutionGroup="xbrli:item" />
<element name="SecondTrancheMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SecondTrancheMember" substitutionGroup="xbrli:item" />
<element name="CommercialMilestoneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_CommercialMilestoneMember" substitutionGroup="xbrli:item" />
<element name="DevelopmentAndRegulatoryMilestoneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_DevelopmentAndRegulatoryMilestoneMember" substitutionGroup="xbrli:item" />
<element name="PharmanvanthSevenGmbhMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_PharmanvanthSevenGmbhMember" substitutionGroup="xbrli:item" />
<element name="HemavantSciencesGmbhMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_HemavantSciencesGmbhMember" substitutionGroup="xbrli:item" />
<element name="CollaborationAgreementWithBlueprintMedicinesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_CollaborationAgreementWithBlueprintMedicinesMember" substitutionGroup="xbrli:item" />
<element name="BalanceSheetComponentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_BalanceSheetComponentsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="EmployeeRelatedExpensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_EmployeeRelatedExpensesMember" substitutionGroup="xbrli:item" />
<element name="OtherGeneralAndAdministrativeExpensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_OtherGeneralAndAdministrativeExpensesMember" substitutionGroup="xbrli:item" />
<element name="AccruedLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_AccruedLiabilitiesLineItems" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentExitFeeAndEndOfTermCharge" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_DebtInstrumentExitFeeAndEndOfTermCharge" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DebtInstrumentValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_DebtInstrumentValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RegulatoryMilestoneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_RegulatoryMilestoneMember" substitutionGroup="xbrli:item" />
<element name="MaximumMilestonePaymentObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_MaximumMilestonePaymentObligation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MaximumMilestonePaymentOffsetAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_MaximumMilestonePaymentOffsetAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CommittedFundingUnderRIPSA" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_CommittedFundingUnderRIPSA" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MilestonePaymentDueOverSixYearPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_MilestonePaymentDueOverSixYearPeriod" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NovaquestMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_NovaquestMember" substitutionGroup="xbrli:item" />
<element name="RevenueInterestPurchaseAndSaleAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_RevenueInterestPurchaseAndSaleAgreementMember" substitutionGroup="xbrli:item" />
<element name="LongTermDebtExcludingDebtWithFairValueOption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_LongTermDebtExcludingDebtWithFairValueOption" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccessFeePaidToRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_AccessFeePaidToRelatedParty" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AssetPurchaseTransactionConsiderationReceivedInCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_AssetPurchaseTransactionConsiderationReceivedInCash" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SumitomoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SumitomoMember" substitutionGroup="xbrli:item" />
<element name="AssetPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_AssetPurchaseAgreementMember" substitutionGroup="xbrli:item" />
<element name="TransitionServicesAndStrategicCooperationAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_TransitionServicesAndStrategicCooperationAgreementMember" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_ClassOfWarrantOrRightExercisable" substitutionGroup="xbrli:item" />
<element name="StockHoldersEquityNoteStockSplitExchangeRatio1" type="xbrli:pureItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_StockHoldersEquityNoteStockSplitExchangeRatio1" substitutionGroup="xbrli:item" />
<element name="SubscriptionReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_SubscriptionReceived" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfCommonSharesVolumeWeightedAveragePrice" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_PercentageOfCommonSharesVolumeWeightedAveragePrice" substitutionGroup="xbrli:item" />
<element name="UpfrontCommitmentFeeNumberOfSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_UpfrontCommitmentFeeNumberOfSharesIssued" substitutionGroup="xbrli:item" />
<element name="CommonSharesValueAvailableForSale" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_CommonSharesValueAvailableForSale" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ClassOfWarrantOrRightCanceled" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ClassOfWarrantOrRightCanceled" substitutionGroup="xbrli:item" />
<element name="ImmunovantSciencesLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_ImmunovantSciencesLtdMember" substitutionGroup="xbrli:item" />
<element name="UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_UnderwrittenPublicOfferingMember" substitutionGroup="xbrli:item" />
<element name="ImmunovantINCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_ImmunovantINCMember" substitutionGroup="xbrli:item" />
<element name="SkMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SkMember" substitutionGroup="xbrli:item" />
<element name="CantorFitzgeraldCo.Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_CantorFitzgeraldCo.Member" substitutionGroup="xbrli:item" />
<element name="SubsidiaryEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SubsidiaryEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="StockOptionsAndPerformanceStockOptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_StockOptionsAndPerformanceStockOptionsMember" substitutionGroup="xbrli:item" />
<element name="RestrictedStockUnitsAndPerformanceStockUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember" substitutionGroup="xbrli:item" />
<element name="SubsidiaryEquityIncentivePlansMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SubsidiaryEquityIncentivePlansMember" substitutionGroup="xbrli:item" />
<element name="March2020CappedValueAppreciationRightsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_March2020CappedValueAppreciationRightsMember" substitutionGroup="xbrli:item" />
<element name="OneTimeCatchUpExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_OneTimeCatchUpExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares" substitutionGroup="xbrli:item" />
<element name="IncrementOfEmployeeStockPurchasePlan" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_IncrementOfEmployeeStockPurchasePlan" substitutionGroup="xbrli:item" />
<element name="EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable" substitutionGroup="xbrli:item" />
<element name="IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EventAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_EventAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="EventDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_EventDomain" substitutionGroup="xbrli:item" />
<element name="AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMember" substitutionGroup="xbrli:item" />
<element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" substitutionGroup="xbrli:item" />
<element name="IntrinsicValueOfOptionsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_IntrinsicValueOfOptionsExercised" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RestrictedStockAndPerformanceStockUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_RestrictedStockAndPerformanceStockUnitsMember" substitutionGroup="xbrli:item" />
<element name="RSLEquityPlansMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_RSLEquityPlansMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_IncomeTaxDisclosureTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_IncomeTaxDisclosureLineItems" substitutionGroup="xbrli:item" />
<element name="OtherMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_OtherMember" substitutionGroup="xbrli:item" />
<element name="ComponentsOfIncomeTaxExpenseTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_ComponentsOfIncomeTaxExpenseTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ComponentsOfIncomeTaxExpenseLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_ComponentsOfIncomeTaxExpenseLineItems" substitutionGroup="xbrli:item" />
<element name="AnnualNOLUtilizationLimitationPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_AnnualNOLUtilizationLimitationPercentage" substitutionGroup="xbrli:item" />
<element name="TaxAuthorityInOtherJurisdictionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_TaxAuthorityInOtherJurisdictionsMember" substitutionGroup="xbrli:item" />
<element name="UnitedStatesAndCanadaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_UnitedStatesAndCanadaMember" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_DeferredTaxAssetsLiabilitiesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DeferredTaxAssetsLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_DeferredTaxAssetsLiabilitiesLineItems" substitutionGroup="xbrli:item" />
<element name="DeferredTaxLiabilitiesDepreciation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_DeferredTaxLiabilitiesDepreciation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_DeferredTaxLiabilitiesRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_DeferredTaxAssetsLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TaxRatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_TaxRatesAbstract" substitutionGroup="xbrli:item" />
<element name="EffectiveTaxRateReconcilingItemsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_EffectiveTaxRateReconcilingItemsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="EffectiveTaxRateReconcilingItemsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_EffectiveTaxRateReconcilingItemsLineItems" substitutionGroup="xbrli:item" />
<element name="LesseeOperatingLeaseLiabilityTenantImprovementAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingLeaseLiabilityPresentValueAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_OperatingLeaseLiabilityPresentValueAdjustments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MasterSubscriptionAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_MasterSubscriptionAgreementMember" substitutionGroup="xbrli:item" />
<element name="ProductServiceAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_ProductServiceAgreementMember" substitutionGroup="xbrli:item" />
<element name="RoivPublicWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_RoivPublicWarrantsMember" substitutionGroup="xbrli:item" />
<element name="RoivPrivatePlacementWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_RoivPrivatePlacementWarrantsMember" substitutionGroup="xbrli:item" />
<element name="RoivLiabilityInstrumentsMeasuredAtFairValueMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_RoivLiabilityInstrumentsMeasuredAtFairValueMember" substitutionGroup="xbrli:item" />
<element name="RoivEarnoutSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_RoivEarnoutSharesMember" substitutionGroup="xbrli:item" />
<element name="FairValueDisclosuresTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_FairValueDisclosuresTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="FairValueDisclosuresLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_FairValueDisclosuresLineItems" substitutionGroup="xbrli:item" />
<element name="EquityInterestOptionToThirdPartyPurchase" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_EquityInterestOptionToThirdPartyPurchase" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LiabilityInstrumentsMeasuredAtFairValueMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_LiabilityInstrumentsMeasuredAtFairValueMember" substitutionGroup="xbrli:item" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueAssetMeasurementInput" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_FairValueAssetMeasurementInput" substitutionGroup="xbrli:item" />
<element name="AlternativeInvestmentExpectedTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_AlternativeInvestmentExpectedTerm" substitutionGroup="xbrli:item" />
<element name="OtherIncomeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_OtherIncomeExpense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherOperatingIncomeExpensesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_OtherOperatingIncomeExpensesNet" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NovemberTwoThousandAndTwentyOneCvarsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_NovemberTwoThousandAndTwentyOneCvarsMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndTwentyCvarsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_TwoThousandAndTwentyCvarsMember" substitutionGroup="xbrli:item" />
<element name="EarnOutSharesNonvestedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_EarnOutSharesNonvestedMember" substitutionGroup="xbrli:item" />
<element name="OtherInstrumentsIssuedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_OtherInstrumentsIssuedMember" substitutionGroup="xbrli:item" />
<element name="MilestonePaymentPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_MilestonePaymentPeriod" substitutionGroup="xbrli:item" />
<element name="GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RoivrevenueInterestPurchaseAndSaleAgreementMemberMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_RoivrevenueInterestPurchaseAndSaleAgreementMemberMember" substitutionGroup="xbrli:item" />
<element name="GSKMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_GSKMember" substitutionGroup="xbrli:item" />
<element name="WelichemBiotechIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_WelichemBiotechIncMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>roiv-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 28-June-2022 [03:58:35] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ConsolidatedBalanceSheets" roleURI="http://roivant.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ConsolidatedStatementsOfOperations" roleURI="http://roivant.com/role/ConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://roivant.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail" roleURI="http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail" roleURI="http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LeasesScheduleOfOperatingLeaseCostsDetail" roleURI="http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" roleURI="http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail" roleURI="http://roivant.com/role/OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail" />
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_RestrictedCashCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_RestrictedCashNoncurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_LongTermInvestments" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="10" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SubscriptionsReceivable" xlink:label="loc_ROIV_SubscriptionsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_ROIV_SubscriptionsReceivable" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_MinorityInterest" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredConsiderationLiabilityCurrent" xlink:label="loc_ROIV_DeferredConsiderationLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_ROIV_DeferredConsiderationLiabilityCurrent" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DeferredRevenueCurrent" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LongTermDebtNoncurrent" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValue" xlink:label="loc_ROIV_LiabilityInstrumentsMeasuredAtFairValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_ROIV_LiabilityInstrumentsMeasuredAtFairValue" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent" use="optional" order="32" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OperatingCosts" xlink:label="loc_ROIV_OperatingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_ROIV_OperatingCosts" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AcquiredInProcessResearchAndDevelopmentExpense" xlink:label="loc_ROIV_AcquiredInProcessResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_ROIV_AcquiredInProcessResearchAndDevelopmentExpense" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_GainLossOnInvestments" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="loc_us-gaap_GainOnSaleOfInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_GainOnSaleOfInvestments" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_ROIV_GainLossOnFairValueOfDebtAndLiabilityInstruments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_ROIV_GainLossOnFairValueOfDebtAndLiabilityInstruments" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xlink:label="loc_ROIV_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_ROIV_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" xlink:label="loc_ROIV_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_ROIV_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="17" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" use="optional" order="5" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncreaseDecreaseInOtherInvestingNet" xlink:label="loc_ROIV_IncreaseDecreaseInOtherInvestingNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ROIV_IncreaseDecreaseInOtherInvestingNet" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromBusinessCombinationAndPipeFinancing" xlink:label="loc_ROIV_ProceedsFromBusinessCombinationAndPipeFinancing" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ROIV_ProceedsFromBusinessCombinationAndPipeFinancing" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:label="loc_ROIV_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ROIV_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromPaymentOfSubscriptionReceivable" xlink:label="loc_ROIV_ProceedsFromPaymentOfSubscriptionReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ROIV_ProceedsFromPaymentOfSubscriptionReceivable" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromSubsidiaryDebtFinancingsNet" xlink:label="loc_ROIV_ProceedsFromSubsidiaryDebtFinancingsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ROIV_ProceedsFromSubsidiaryDebtFinancingsNet" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:label="loc_ROIV_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ROIV_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PaymentForOfferingAndLoanCosts" xlink:label="loc_ROIV_PaymentForOfferingAndLoanCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ROIV_PaymentForOfferingAndLoanCosts" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromAndPaymentForOtherFinancingActivities" xlink:label="loc_ROIV_ProceedsFromAndPaymentForOtherFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ROIV_ProceedsFromAndPaymentForOtherFinancingActivities" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnInvestments" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="loc_us-gaap_GainOnSaleOfInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainOnSaleOfInvestments" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_ROIV_GainLossOnFairValueOfDebtAndLiabilityInstruments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ROIV_GainLossOnFairValueOfDebtAndLiabilityInstruments" use="optional" order="18" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity" xlink:label="loc_ROIV_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ROIV_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GainOnTerminationOfEquityInterestOptions" xlink:label="loc_ROIV_GainOnTerminationOfEquityInterestOptions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ROIV_GainOnTerminationOfEquityInterestOptions" use="optional" order="20" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense" use="optional" order="21" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments" use="optional" order="22" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_ROIV_IncreaseDecreaseInOperatingLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ROIV_IncreaseDecreaseInOperatingLeaseLiabilities" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" use="optional" order="28" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_NonCashAcquiredInProcessResearchAndDevelopment" xlink:label="loc_ROIV_NonCashAcquiredInProcessResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ROIV_NonCashAcquiredInProcessResearchAndDevelopment" use="optional" order="29" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail">
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CashAndCashEquivalentsAndRestrictedCash" xlink:label="loc_ROIV_CashAndCashEquivalentsAndRestrictedCash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ROIV_CashAndCashEquivalentsAndRestrictedCash" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ROIV_CashAndCashEquivalentsAndRestrictedCash" xlink:to="loc_us-gaap_RestrictedCash" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="loc_us-gaap_LongTermDebtCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="loc_us-gaap_LongTermDebt" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xlink:label="loc_ROIV_DebtInstrumentExitFeeAndEndOfTermCharge" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="loc_ROIV_DebtInstrumentExitFeeAndEndOfTermCharge" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DebtInstrumentValue" xlink:label="loc_ROIV_DebtInstrumentValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="loc_ROIV_DebtInstrumentValue" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_OperatingLeaseCost" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_ShortTermLeaseCost" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_VariableLeaseCost" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OperatingLeaseLiabilityPresentValueAdjustments" xlink:label="loc_ROIV_OperatingLeaseLiabilityPresentValueAdjustments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_ROIV_OperatingLeaseLiabilityPresentValueAdjustments" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:label="loc_ROIV_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_ROIV_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_OperatingLeaseLiability" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_ROIV_DeferredTaxAssetsLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_ROIV_DeferredTaxAssetsLeaseLiabilities" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_ROIV_DeferredTaxLiabilitiesDepreciation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_ROIV_DeferredTaxLiabilitiesDepreciation" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="loc_ROIV_DeferredTaxLiabilitiesRightOfUseAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_ROIV_DeferredTaxLiabilitiesRightOfUseAssets" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther" use="optional" order="11" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail">
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LongTermDebtExcludingDebtWithFairValueOption" xlink:label="loc_ROIV_LongTermDebtExcludingDebtWithFairValueOption" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ROIV_LongTermDebtExcludingDebtWithFairValueOption" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ROIV_LongTermDebtExcludingDebtWithFairValueOption" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ROIV_LongTermDebtExcludingDebtWithFairValueOption" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ROIV_LongTermDebtExcludingDebtWithFairValueOption" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ROIV_LongTermDebtExcludingDebtWithFairValueOption" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ROIV_LongTermDebtExcludingDebtWithFairValueOption" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail">
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OtherOperatingIncomeExpensesNet" xlink:label="loc_ROIV_OtherOperatingIncomeExpensesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ROIV_OtherOperatingIncomeExpensesNet" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ROIV_OtherOperatingIncomeExpensesNet" xlink:to="loc_us-gaap_InterestIncomeOther" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ROIV_OtherOperatingIncomeExpensesNet" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OtherIncomeExpense" xlink:label="loc_ROIV_OtherIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ROIV_OtherOperatingIncomeExpensesNet" xlink:to="loc_ROIV_OtherIncomeExpense" use="optional" order="4" weight="-1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>roiv-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 28-June-2022 [03:58:35] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#Cover" roleURI="http://roivant.com/role/Cover" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ConsolidatedBalanceSheets" roleURI="http://roivant.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://roivant.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ConsolidatedStatementsOfOperations" roleURI="http://roivant.com/role/ConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ConsolidatedStatementsOfOperationsParenthetical" roleURI="http://roivant.com/role/ConsolidatedStatementsOfOperationsParenthetical" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest" roleURI="http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://roivant.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#FairValueMeasurements" roleURI="http://roivant.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareBasedCompensationTables" roleURI="http://roivant.com/role/ShareBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#FairValueMeasurementsTables" roleURI="http://roivant.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#BusinessCombinationWithMaacAdditionalInformationDetail" roleURI="http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#InvestmentsAdditionalInformationDetail" roleURI="http://roivant.com/role/InvestmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail" roleURI="http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#AccruedExpensesScheduleOfAccruedExpensesDetail" roleURI="http://roivant.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LongTermDebtAndLoanCommitmentAdditionalInformationDetail" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareholdersEquityAdditionalInformationDetail" roleURI="http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareBasedCompensationAdditionalInformationDetail" roleURI="http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareBasedCompensationScheduleOfFairValueAssumptionsDetail" roleURI="http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail" roleURI="http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail" roleURI="http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://roivant.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail" roleURI="http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" roleURI="http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://roivant.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail" roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#FairValueMeasurementsAdditionalInformationDetail" roleURI="http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail" roleURI="http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#FairValueMeasurementsScheduleOfChangeInFairValueOfTheLevel3AssetsDetail" roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfChangeInFairValueOfTheLevel3AssetsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail" roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail" roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail" roleURI="http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#SubsequentEventsAdditionalInformationDetail" roleURI="http://roivant.com/role/SubsequentEventsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#DescriptionOfBusinessAndLiquidityAdditionalInformationDetail" roleURI="http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LeasesScheduleOfOperatingLeaseCostsDetail" roleURI="http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail" roleURI="http://roivant.com/role/LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#RelatedPartyTransactions" roleURI="http://roivant.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#CommitmentsContingencies" roleURI="http://roivant.com/role/CommitmentsContingencies" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareholdersEquity" roleURI="http://roivant.com/role/ShareholdersEquity" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#IncomeTaxes" roleURI="http://roivant.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#IncomeTaxesTables" roleURI="http://roivant.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#SubsequentEvents" roleURI="http://roivant.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#DescriptionOfBusinessAndLiquidity" roleURI="http://roivant.com/role/DescriptionOfBusinessAndLiquidity" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#OtherExpenseNet" roleURI="http://roivant.com/role/OtherExpenseNet" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#OtherExpenseNetTables" roleURI="http://roivant.com/role/OtherExpenseNetTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#NetLossPerCommonShare" roleURI="http://roivant.com/role/NetLossPerCommonShare" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#Investments" roleURI="http://roivant.com/role/Investments" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#AssetAcquisitionsAndLicenseAgreements" roleURI="http://roivant.com/role/AssetAcquisitionsAndLicenseAgreements" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LongTermDebtAndLoanCommitment" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitment" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LongTermDebtAndLoanCommitmentTables" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareBasedCompensation" roleURI="http://roivant.com/role/ShareBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#Leases" roleURI="http://roivant.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LeasesTables" roleURI="http://roivant.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#AccruedExpensesTables" roleURI="http://roivant.com/role/AccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail" roleURI="http://roivant.com/role/OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" roleURI="http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#BusinessCombinationWithMaac" roleURI="http://roivant.com/role/BusinessCombinationWithMaac" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#NetLossPerCommonShareTables" roleURI="http://roivant.com/role/NetLossPerCommonShareTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#AccruedExpenses" roleURI="http://roivant.com/role/AccruedExpenses" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/Cover">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1475343" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_1096081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_DocumentPeriodEndDate_1096081" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_1096083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_DocumentFiscalYearFocus_1096083" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_AmendmentFlag_4" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_DocumentType_3" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_1096076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_DocumentTransitionReport_1096076" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityCentralIndexKey_6" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityEmergingGrowthCompany_9" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityExTransitionPeriod_10" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityFilerCategory_7" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityRegistrantName_5" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntitySmallBusiness_8" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_1096107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityCurrentReportingStatus_1096107" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_1096111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityInteractiveDataCurrent_1096111" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_1096096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityTaxIdentificationNumber_1096096" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_1096099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityAddressAddressLine1_1096099" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_1096100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityAddressAddressLine2_1096100" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_1096102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityAddressCityOrTown_1096102" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1096086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1096086" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1096113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1096113" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_1096133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityShellCompany_1096133" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_1096103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityAddressPostalZipCode_1096103" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_1096104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_CityAreaCode_1096104" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_1096106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_LocalPhoneNumber_1096106" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_1096141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_Security12bTitle_1096141" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_1096142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_TradingSymbol_1096142" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_1096143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_SecurityExchangeName_1096143" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_1096807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityAddressCountry_1096807" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_dei_CountryRegion_1105052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_CountryRegion_1105052" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_1096091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_CurrentFiscalYearEndDate_1096091" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_1096094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityFileNumber_1096094" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1096095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1096095" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_1475335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_DocumentAnnualReport_1475335" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1475340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_us-gaap_StatementTable_1475340" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1475341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1475340" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1475341" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1475342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1475341" xlink:to="loc_us-gaap_ClassOfStockDomain_1475342" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1475342_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1475341" xlink:to="loc_us-gaap_ClassOfStockDomain_1475342_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1475344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1475342" xlink:to="loc_us-gaap_WarrantMember_1475344" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1475345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1475342" xlink:to="loc_us-gaap_CommonStockMember_1475345" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_1475347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_1475347" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_1475348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityVoluntaryFilers_1475348" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_1475349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_IcfrAuditorAttestationFlag_1475349" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_1476439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityPublicFloat_1476439" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_1514483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_AuditorName_1514483" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_1514484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_AuditorFirmId_1514484" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_1514485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_AuditorLocation_1514485" use="optional" order="45" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_AssetsAbstract_13" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_Assets_31" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_AssetsCurrentAbstract_14" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_AssetsCurrent_38" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_OtherAssetsCurrent_36" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_RestrictedCashCurrent_34" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_LongTermInvestments_29" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_26" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_30" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_24" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_28" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_27" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_StatementTable_22" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_22" xlink:to="loc_dei_LegalEntityAxis_17" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_17" xlink:to="loc_dei_EntityDomain_16" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_16_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_17" xlink:to="loc_dei_EntityDomain_16_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_22" xlink:to="loc_us-gaap_StatementClassOfStockAxis_20" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_20" xlink:to="loc_us-gaap_ClassOfStockDomain_15" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_15_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_20" xlink:to="loc_us-gaap_ClassOfStockDomain_15_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_44" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_19" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_55" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_AccountsPayableCurrent_55" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_57" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_LiabilitiesCurrent_62" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_56" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_61" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_61" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredConsiderationLiabilityCurrent" xlink:label="loc_roiv_DeferredConsiderationLiabilityCurrent_1106509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_roiv_DeferredConsiderationLiabilityCurrent_1106509" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_1475354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_DeferredRevenueCurrent_1475354" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_46" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_MinorityInterest_52" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_StockholdersEquityAbstract_23" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_68" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_68" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_65" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_AdditionalPaidInCapital_65" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_64" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_CommonStockValue_64" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SubscriptionsReceivable" xlink:label="loc_roiv_SubscriptionsReceivable_66" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_roiv_SubscriptionsReceivable_66" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_69" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_StockholdersEquity_69" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_67" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_67" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValue" xlink:label="loc_roiv_LiabilityInstrumentsMeasuredAtFairValue_1106513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_roiv_LiabilityInstrumentsMeasuredAtFairValue_1106513" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_47" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_CommitmentsAndContingencies_49" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_Liabilities_48" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_54" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_50" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_1475356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_1475356" use="optional" order="47" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_76" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_90" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_90" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_91" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_CommonStockSharesIssued_91" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_92" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_92" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_82" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_LongTermDebtFairValue_82" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_77" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_StatementTable_77" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_74" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_77" xlink:to="loc_dei_LegalEntityAxis_74" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_73" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_74" xlink:to="loc_dei_EntityDomain_73" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_73_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_74" xlink:to="loc_dei_EntityDomain_73_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_75" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_77" xlink:to="loc_us-gaap_StatementClassOfStockAxis_75" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_72" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_75" xlink:to="loc_us-gaap_ClassOfStockDomain_72" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_72_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_75" xlink:to="loc_us-gaap_ClassOfStockDomain_72_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_89" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_89" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_103" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_NetIncomeLoss_139" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_138" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_OperatingExpensesAbstract_101" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_101" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_118" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_101" xlink:to="loc_us-gaap_OperatingExpenses_119" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_101" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_117" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OperatingCosts" xlink:label="loc_roiv_OperatingCosts_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_101" xlink:to="loc_roiv_OperatingCosts_116" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AcquiredInProcessResearchAndDevelopmentExpense" xlink:label="loc_roiv_AcquiredInProcessResearchAndDevelopmentExpense_1476506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_101" xlink:to="loc_roiv_AcquiredInProcessResearchAndDevelopmentExpense_1476506" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_OperatingIncomeLoss_131" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_96" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_96" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_96" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_107" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_97" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_97" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_97" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_112" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_130" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_StatementTable_104" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_104" xlink:to="loc_dei_LegalEntityAxis_100" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_98" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_100" xlink:to="loc_dei_EntityDomain_98" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_98_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_100" xlink:to="loc_dei_EntityDomain_98_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_134" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_128" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_124" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_us-gaap_GainLossOnInvestments_122" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" xlink:label="loc_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity_126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity_126" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xlink:label="loc_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination_1106522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination_1106522" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="loc_us-gaap_GainOnSaleOfInvestments_1294532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_us-gaap_GainOnSaleOfInvestments_1294532" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1294542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1294542" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_ProfitLoss_137" use="optional" order="28" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ConsolidatedStatementsOfOperationsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1475381" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1475375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1475381" xlink:to="loc_us-gaap_StatementTable_1475375" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1475376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1475375" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1475376" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1475377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1475376" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1475377" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1475377_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1475376" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1475377_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1475380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1475377" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1475380" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1475378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1475377" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1475378" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1475383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1475381" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1475383" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_149" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_198" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ConsolidationOfUnconsolidatedEntity" xlink:label="loc_roiv_ConsolidationOfUnconsolidatedEntity_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_ConsolidationOfUnconsolidatedEntity_195" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeconsolidationOfSubsidiary" xlink:label="loc_roiv_DeconsolidationOfSubsidiary_194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_DeconsolidationOfSubsidiary_194" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CapitalContributionsToSubsidiaries" xlink:label="loc_roiv_CapitalContributionsToSubsidiaries_197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_CapitalContributionsToSubsidiaries_197" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IssuanceOfSubsidiaryCommonSharesNetValue" xlink:label="loc_roiv_IssuanceOfSubsidiaryCommonSharesNetValue_168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfSubsidiaryCommonSharesNetValue_168" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" xlink:label="loc_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue_169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue_169" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" xlink:label="loc_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits_178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits_178" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StatementTable_150" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_150" xlink:to="loc_us-gaap_StatementClassOfStockAxis_147" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_147" xlink:to="loc_us-gaap_ClassOfStockDomain_143" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_143_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_147" xlink:to="loc_us-gaap_ClassOfStockDomain_143_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_150" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_148" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_148" xlink:to="loc_us-gaap_EquityComponentDomain_145" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_145_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_148" xlink:to="loc_us-gaap_EquityComponentDomain_145_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_159" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_us-gaap_NoncontrollingInterestMember_160" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_156" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_us-gaap_CommonStockMember_155" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SubscriptionsReceivablesMember" xlink:label="loc_roiv_SubscriptionsReceivablesMember_158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_roiv_SubscriptionsReceivablesMember_158" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_us-gaap_RetainedEarningsMember_157" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RedeemableNoncontrollingInterestMember" xlink:label="loc_roiv_RedeemableNoncontrollingInterestMember_1295290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_roiv_RedeemableNoncontrollingInterestMember_1295290" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_SharesOutstanding_167" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IssuanceOfSubsidiaryWarrants" xlink:label="loc_roiv_IssuanceOfSubsidiaryWarrants_172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfSubsidiaryWarrants_172" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_200" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_175" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_174" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_ProfitLoss_201" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RepurchaseOfEquityAwards" xlink:label="loc_roiv_RepurchaseOfEquityAwards_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_RepurchaseOfEquityAwards_196" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_173" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_161" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_166" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" xlink:label="loc_roiv_StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing_1294590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing_1294590" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:label="loc_roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration_1294691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration_1294691" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" xlink:label="loc_roiv_StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing_1294651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing_1294651" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodValueSubsidiaryPreferredShares" xlink:label="loc_roiv_StockIssuedDuringPeriodValueSubsidiaryPreferredShares_1294701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_StockIssuedDuringPeriodValueSubsidiaryPreferredShares_1294701" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany" xlink:label="loc_roiv_StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany_1294706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany_1294706" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent" xlink:label="loc_roiv_AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent_1294713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent_1294713" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IssuanceOfStockUponWarrantsExerciseShares" xlink:label="loc_roiv_IssuanceOfStockUponWarrantsExerciseShares_1475452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfStockUponWarrantsExerciseShares_1475452" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled" xlink:label="loc_roiv_StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled_1475454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled_1475454" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IssuanceOfStockUponWarrantsExerciseValue" xlink:label="loc_roiv_IssuanceOfStockUponWarrantsExerciseValue_1475457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfStockUponWarrantsExerciseValue_1475457" use="optional" order="40" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_215" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_264" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromSubsidiaryDebtFinancingsNet" xlink:label="loc_roiv_ProceedsFromSubsidiaryDebtFinancingsNet_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_ProceedsFromSubsidiaryDebtFinancingsNet_258" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:label="loc_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_252" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:label="loc_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_259" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PaymentForOfferingAndLoanCosts" xlink:label="loc_roiv_PaymentForOfferingAndLoanCosts_1294816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_PaymentForOfferingAndLoanCosts_1294816" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromBusinessCombinationAndPipeFinancing" xlink:label="loc_roiv_ProceedsFromBusinessCombinationAndPipeFinancing_1294788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_ProceedsFromBusinessCombinationAndPipeFinancing_1294788" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromPaymentOfSubscriptionReceivable" xlink:label="loc_roiv_ProceedsFromPaymentOfSubscriptionReceivable_1294799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_ProceedsFromPaymentOfSubscriptionReceivable_1294799" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromAndPaymentForOtherFinancingActivities" xlink:label="loc_roiv_ProceedsFromAndPaymentForOtherFinancingActivities_1475482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_ProceedsFromAndPaymentForOtherFinancingActivities_1475482" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_283" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OtherNonCashTransactions" xlink:label="loc_roiv_OtherNonCashTransactions_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" xlink:to="loc_roiv_OtherNonCashTransactions_235" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_217" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_217" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_285" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_217" xlink:to="loc_us-gaap_InterestPaidNet_286" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" xlink:label="loc_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares_1139677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" xlink:to="loc_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares_1139677" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_282" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_274" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_273" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1294753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1294753" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncreaseDecreaseInOtherInvestingNet" xlink:label="loc_roiv_IncreaseDecreaseInOtherInvestingNet_1475505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_roiv_IncreaseDecreaseInOtherInvestingNet_1475505" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_240" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_241" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_237" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_245" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_roiv_IncreaseDecreaseInOperatingLeaseLiabilities_243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_roiv_IncreaseDecreaseInOperatingLeaseLiabilities_243" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_1475475" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_1475475" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_227" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_229" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_GainLossOnInvestments_226" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_230" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GainOnTerminationOfEquityInterestOptions" xlink:label="loc_roiv_GainOnTerminationOfEquityInterestOptions_1106544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_roiv_GainOnTerminationOfEquityInterestOptions_1106544" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_ShareBasedCompensation_222" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="loc_us-gaap_GainOnSaleOfInvestments_1294717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_GainOnSaleOfInvestments_1294717" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity" xlink:label="loc_roiv_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity_1294751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_roiv_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity_1294751" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_NonCashAcquiredInProcessResearchAndDevelopment" xlink:label="loc_roiv_NonCashAcquiredInProcessResearchAndDevelopment_1476505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_roiv_NonCashAcquiredInProcessResearchAndDevelopment_1476505" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_276" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" xlink:to="loc_us-gaap_ProfitLoss_275" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_StatementTable_216" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_216" xlink:to="loc_dei_LegalEntityAxis_210" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_210" xlink:to="loc_dei_EntityDomain_208" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_208_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_210" xlink:to="loc_dei_EntityDomain_208_default" use="optional" order="46" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1574" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1574" xlink:to="loc_us-gaap_StatementTable_1575" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1575" xlink:to="loc_dei_LegalEntityAxis_1573" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573" xlink:to="loc_dei_EntityDomain_1572" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1572_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573" xlink:to="loc_dei_EntityDomain_1572_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1574" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1577" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1630" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1630" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1633" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1630" xlink:to="loc_us-gaap_StatementTable_1631" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1631" xlink:to="loc_dei_LegalEntityAxis_1629" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1629" xlink:to="loc_dei_EntityDomain_1628" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1628_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1629" xlink:to="loc_dei_EntityDomain_1628_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivantSciencesLtd.Member" xlink:label="loc_roiv_RoivantSciencesLtd.Member_1484083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1628" xlink:to="loc_roiv_RoivantSciencesLtd.Member_1484083" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1526" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1542" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1544" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1540" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_1533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_1533" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1545" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1529" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1549" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_StatementTable_1527" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1527" xlink:to="loc_dei_LegalEntityAxis_1525" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1525" xlink:to="loc_dei_EntityDomain_1524" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1524_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1525" xlink:to="loc_dei_EntityDomain_1524_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_UseOfEstimates_1531" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1538" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_1546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_1546" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1552" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock_1548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock_1548" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1551" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1550" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1547" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_WarrantliabilitiesPolicyTextBlock" xlink:label="loc_roiv_WarrantliabilitiesPolicyTextBlock_1294682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_roiv_WarrantliabilitiesPolicyTextBlock_1294682" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_1475352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_1475352" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_1475355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_1475355" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1727" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1733" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_us-gaap_StatementTable_1728" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1728" xlink:to="loc_us-gaap_AwardTypeAxis_1725" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1725" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1725" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CappedValueAppreciationRightsMember" xlink:label="loc_roiv_CappedValueAppreciationRightsMember_1730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726" xlink:to="loc_roiv_CappedValueAppreciationRightsMember_1730" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1475855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1728" xlink:to="loc_us-gaap_PlanNameAxis_1475855" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1475856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1475855" xlink:to="loc_us-gaap_PlanNameDomain_1475856" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1475856_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1475855" xlink:to="loc_us-gaap_PlanNameDomain_1475856_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1475857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1475856" xlink:to="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1475857" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandTwentyOneEquityIncentivePlanMember_1475858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1475856" xlink:to="loc_roiv_TwoThousandTwentyOneEquityIncentivePlanMember_1475858" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock" xlink:label="loc_roiv_ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock_1735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_roiv_ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock_1735" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_1510985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_1510985" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1734" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1737" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock" xlink:label="loc_roiv_ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock_1515540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_roiv_ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock_1515540" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1638" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1638" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1642" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1638" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1643" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1638" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1641" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1638" xlink:to="loc_us-gaap_StatementTable_1639" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1639" xlink:to="loc_dei_LegalEntityAxis_1637" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1637" xlink:to="loc_dei_EntityDomain_1636" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1636_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1637" xlink:to="loc_dei_EntityDomain_1636_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DatavantMember" xlink:label="loc_roiv_DatavantMember_1294766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1636" xlink:to="loc_roiv_DatavantMember_1294766" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SumitomoOptionsMember" xlink:label="loc_roiv_SumitomoOptionsMember_1485653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1636" xlink:to="loc_roiv_SumitomoOptionsMember_1485653" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1294768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1639" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1294768" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1294769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1294768" xlink:to="loc_us-gaap_EquityComponentDomain_1294769" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1294769_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1294768" xlink:to="loc_us-gaap_EquityComponentDomain_1294769_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EarnoutSharesMember" xlink:label="loc_roiv_EarnoutSharesMember_1294774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1294769" xlink:to="loc_roiv_EarnoutSharesMember_1294774" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1294777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1639" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1294777" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1294779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1294777" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1294779" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1294779_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1294777" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1294779_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="loc_roiv_PrivatePlacementWarrantsMember_1294781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1294779" xlink:to="loc_roiv_PrivatePlacementWarrantsMember_1294781" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1294746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1638" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1294746" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ScheduleOfAccountingPoliciesLineItems" xlink:label="loc_roiv_ScheduleOfAccountingPoliciesLineItems_453" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaap_EscrowDeposit_1097060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesLineItems_453" xlink:to="loc_us-gaap_EscrowDeposit_1097060" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromReleaseOfEscrowDeposit" xlink:label="loc_roiv_ProceedsFromReleaseOfEscrowDeposit_1105109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesLineItems_453" xlink:to="loc_roiv_ProceedsFromReleaseOfEscrowDeposit_1105109" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ScheduleOfAccountingPoliciesTable" xlink:label="loc_roiv_ScheduleOfAccountingPoliciesTable_454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesLineItems_453" xlink:to="loc_roiv_ScheduleOfAccountingPoliciesTable_454" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesTable_454" xlink:to="loc_dei_LegalEntityAxis_451" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_451" xlink:to="loc_dei_EntityDomain_450" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_450_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_451" xlink:to="loc_dei_EntityDomain_450_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesTable_454" xlink:to="loc_us-gaap_StatementClassOfStockAxis_455" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_455" xlink:to="loc_us-gaap_ClassOfStockDomain_449" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_449_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_455" xlink:to="loc_us-gaap_ClassOfStockDomain_449_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesTable_454" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_456" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_456" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_452" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_452_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_456" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_452_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1294739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesTable_454" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1294739" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1294740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1294739" xlink:to="loc_us-gaap_EquityComponentDomain_1294740" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1294740_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1294739" xlink:to="loc_us-gaap_EquityComponentDomain_1294740_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1294742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1294740" xlink:to="loc_us-gaap_CommonStockMember_1294742" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CashPaidToSettleDeferredConsiderationLiability" xlink:label="loc_roiv_CashPaidToSettleDeferredConsiderationLiability_1294727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesLineItems_453" xlink:to="loc_roiv_CashPaidToSettleDeferredConsiderationLiability_1294727" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability" xlink:label="loc_roiv_StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability_1294737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesLineItems_453" xlink:to="loc_roiv_StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability_1294737" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_904" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_904" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_908" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_904" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_907" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_904" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_906" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_906" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_913" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_911" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_912" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" xlink:to="loc_us-gaap_ComputerEquipmentMember_909" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LaboratoryandotherequipmentMember" xlink:label="loc_roiv_LaboratoryandotherequipmentMember_1475379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" xlink:to="loc_roiv_LaboratoryandotherequipmentMember_1475379" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1475367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_906" xlink:to="loc_srt_RangeAxis_1475367" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1475368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1475367" xlink:to="loc_srt_RangeMember_1475368" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1475368_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1475367" xlink:to="loc_srt_RangeMember_1475368_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1475369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1475368" xlink:to="loc_srt_MaximumMember_1475369" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1475370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1475368" xlink:to="loc_srt_MinimumMember_1475370" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BusinessCombinationWithMAACLineItems" xlink:label="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BusinesscombinationwithmaacTable" xlink:label="loc_roiv_BusinesscombinationwithmaacTable_1294796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_BusinesscombinationwithmaacTable_1294796" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1294842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1294842" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1294843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1294842" xlink:to="loc_us-gaap_ClassOfStockDomain_1294843" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1294843_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1294842" xlink:to="loc_us-gaap_ClassOfStockDomain_1294843_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaacClassASharesMember" xlink:label="loc_roiv_MaacClassASharesMember_1294845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1294843" xlink:to="loc_roiv_MaacClassASharesMember_1294845" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1294855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1294843" xlink:to="loc_us-gaap_CommonClassAMember_1294855" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaacClassBSharesMember" xlink:label="loc_roiv_MaacClassBSharesMember_1294844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1294843" xlink:to="loc_roiv_MaacClassBSharesMember_1294844" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1294839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1294839" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1294840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1294839" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1294840" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1294840_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1294839" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1294840_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MontesArchimedesAcquisitionCorpMember" xlink:label="loc_roiv_MontesArchimedesAcquisitionCorpMember_1294841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1294840" xlink:to="loc_roiv_MontesArchimedesAcquisitionCorpMember_1294841" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1294859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1294859" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1294861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1294859" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1294861" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1294861_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1294859" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1294861_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivantWarrantMember" xlink:label="loc_roiv_RoivantWarrantMember_1294862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1294861" xlink:to="loc_roiv_RoivantWarrantMember_1294862" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="loc_roiv_PrivatePlacementWarrantsMember_1294867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1294861" xlink:to="loc_roiv_PrivatePlacementWarrantsMember_1294867" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PublicWarrantsMember" xlink:label="loc_roiv_PublicWarrantsMember_1294873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1294861" xlink:to="loc_roiv_PublicWarrantsMember_1294873" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RedemptionOfRoivantWarrantsMember" xlink:label="loc_roiv_RedemptionOfRoivantWarrantsMember_1294875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1294861" xlink:to="loc_roiv_RedemptionOfRoivantWarrantsMember_1294875" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1294897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_srt_TitleOfIndividualAxis_1294897" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1294898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1294897" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1294898" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1294898_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1294897" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1294898_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaacIndependentDirectorMember" xlink:label="loc_roiv_MaacIndependentDirectorMember_1294900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1294898" xlink:to="loc_roiv_MaacIndependentDirectorMember_1294900" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpAgreementsAxis" xlink:label="loc_roiv_LockUpAgreementsAxis_1294925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_roiv_LockUpAgreementsAxis_1294925" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpAgreementsDomain" xlink:label="loc_roiv_LockUpAgreementsDomain_1294926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_roiv_LockUpAgreementsAxis_1294925" xlink:to="loc_roiv_LockUpAgreementsDomain_1294926" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpAgreementsDomain" xlink:label="loc_roiv_LockUpAgreementsDomain_1294926_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_roiv_LockUpAgreementsAxis_1294925" xlink:to="loc_roiv_LockUpAgreementsDomain_1294926_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodNineMember" xlink:label="loc_roiv_LockUpPeriodNineMember_1294941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_LockUpAgreementsDomain_1294926" xlink:to="loc_roiv_LockUpPeriodNineMember_1294941" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodOneMember" xlink:label="loc_roiv_LockUpPeriodOneMember_1294930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_LockUpAgreementsDomain_1294926" xlink:to="loc_roiv_LockUpPeriodOneMember_1294930" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodTwoMember" xlink:label="loc_roiv_LockUpPeriodTwoMember_1294932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_LockUpAgreementsDomain_1294926" xlink:to="loc_roiv_LockUpPeriodTwoMember_1294932" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodSevenMember" xlink:label="loc_roiv_LockUpPeriodSevenMember_1294939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_LockUpAgreementsDomain_1294926" xlink:to="loc_roiv_LockUpPeriodSevenMember_1294939" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodEightMember" xlink:label="loc_roiv_LockUpPeriodEightMember_1294940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_LockUpAgreementsDomain_1294926" xlink:to="loc_roiv_LockUpPeriodEightMember_1294940" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodThreeMember" xlink:label="loc_roiv_LockUpPeriodThreeMember_1294933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_LockUpAgreementsDomain_1294926" xlink:to="loc_roiv_LockUpPeriodThreeMember_1294933" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodFourMember" xlink:label="loc_roiv_LockUpPeriodFourMember_1294935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_LockUpAgreementsDomain_1294926" xlink:to="loc_roiv_LockUpPeriodFourMember_1294935" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodFiveMember" xlink:label="loc_roiv_LockUpPeriodFiveMember_1294936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_LockUpAgreementsDomain_1294926" xlink:to="loc_roiv_LockUpPeriodFiveMember_1294936" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodSixMember" xlink:label="loc_roiv_LockUpPeriodSixMember_1294938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_LockUpAgreementsDomain_1294926" xlink:to="loc_roiv_LockUpPeriodSixMember_1294938" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementAxis" xlink:label="loc_roiv_AgreementAxis_1294881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_roiv_AgreementAxis_1294881" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementDomain" xlink:label="loc_roiv_AgreementDomain_1294882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_roiv_AgreementAxis_1294881" xlink:to="loc_roiv_AgreementDomain_1294882" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementDomain" xlink:label="loc_roiv_AgreementDomain_1294882_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_roiv_AgreementAxis_1294881" xlink:to="loc_roiv_AgreementDomain_1294882_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PipeFinancingMember" xlink:label="loc_roiv_PipeFinancingMember_1294885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_AgreementDomain_1294882" xlink:to="loc_roiv_PipeFinancingMember_1294885" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1294886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1294886" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1294894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1294886" xlink:to="loc_us-gaap_RelatedPartyDomain_1294894" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1294894_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1294886" xlink:to="loc_us-gaap_RelatedPartyDomain_1294894_default" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaacSponsorMember" xlink:label="loc_roiv_MaacSponsorMember_1294896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1294894" xlink:to="loc_roiv_MaacSponsorMember_1294896" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1294902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1294902" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1294904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1294902" xlink:to="loc_us-gaap_EquityComponentDomain_1294904" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1294904_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1294902" xlink:to="loc_us-gaap_EquityComponentDomain_1294904_default" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivantCommonSharesMember" xlink:label="loc_roiv_RoivantCommonSharesMember_1294906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1294904" xlink:to="loc_roiv_RoivantCommonSharesMember_1294906" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1294942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_srt_RangeAxis_1294942" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1294943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1294942" xlink:to="loc_srt_RangeMember_1294943" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1294943_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1294942" xlink:to="loc_srt_RangeMember_1294943_default" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1294944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1294943" xlink:to="loc_srt_MaximumMember_1294944" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1294945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1294943" xlink:to="loc_srt_MinimumMember_1294945" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BusinessCombinationAgreementAxis" xlink:label="loc_roiv_BusinessCombinationAgreementAxis_1294909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_roiv_BusinessCombinationAgreementAxis_1294909" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BusinessCombinationAgreementDomain" xlink:label="loc_roiv_BusinessCombinationAgreementDomain_1294910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_roiv_BusinessCombinationAgreementAxis_1294909" xlink:to="loc_roiv_BusinessCombinationAgreementDomain_1294910" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BusinessCombinationAgreementDomain" xlink:label="loc_roiv_BusinessCombinationAgreementDomain_1294910_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_roiv_BusinessCombinationAgreementAxis_1294909" xlink:to="loc_roiv_BusinessCombinationAgreementDomain_1294910_default" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SponsorSupportAgreementMember" xlink:label="loc_roiv_SponsorSupportAgreementMember_1294911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationAgreementDomain_1294910" xlink:to="loc_roiv_SponsorSupportAgreementMember_1294911" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TriggeringEventAxis" xlink:label="loc_roiv_TriggeringEventAxis_1294914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_roiv_TriggeringEventAxis_1294914" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TriggeringEventDomain" xlink:label="loc_roiv_TriggeringEventDomain_1294915" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_roiv_TriggeringEventAxis_1294914" xlink:to="loc_roiv_TriggeringEventDomain_1294915" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TriggeringEventDomain" xlink:label="loc_roiv_TriggeringEventDomain_1294915_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_roiv_TriggeringEventAxis_1294914" xlink:to="loc_roiv_TriggeringEventDomain_1294915_default" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SharePriceEqualOrExceedsTwentyDollarMember" xlink:label="loc_roiv_SharePriceEqualOrExceedsTwentyDollarMember_1294919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TriggeringEventDomain_1294915" xlink:to="loc_roiv_SharePriceEqualOrExceedsTwentyDollarMember_1294919" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SharePriceEqualOrExceedsEighteenDollarMember" xlink:label="loc_roiv_SharePriceEqualOrExceedsEighteenDollarMember_1294920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TriggeringEventDomain_1294915" xlink:to="loc_roiv_SharePriceEqualOrExceedsEighteenDollarMember_1294920" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SharePriceEqualOrExceedsEighteenPerDollarMember" xlink:label="loc_roiv_SharePriceEqualOrExceedsEighteenPerDollarMember_1294921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TriggeringEventDomain_1294915" xlink:to="loc_roiv_SharePriceEqualOrExceedsEighteenPerDollarMember_1294921" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SharePriceEqualOrExceedsTenDollarMember" xlink:label="loc_roiv_SharePriceEqualOrExceedsTenDollarMember_1294924" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TriggeringEventDomain_1294915" xlink:to="loc_roiv_SharePriceEqualOrExceedsTenDollarMember_1294924" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SharePriceEqualOrExceedsFifteenDollarMember" xlink:label="loc_roiv_SharePriceEqualOrExceedsFifteenDollarMember_1294916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TriggeringEventDomain_1294915" xlink:to="loc_roiv_SharePriceEqualOrExceedsFifteenDollarMember_1294916" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ExchangeRatioOfMAACClassBToRoivantCommonShares" xlink:label="loc_roiv_ExchangeRatioOfMAACClassBToRoivantCommonShares_1294972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_ExchangeRatioOfMAACClassBToRoivantCommonShares_1294972" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockholdersEquityNoteStockSplitExchangeRatio1" xlink:label="loc_roiv_StockholdersEquityNoteStockSplitExchangeRatio1_1294962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_StockholdersEquityNoteStockSplitExchangeRatio1_1294962" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Costsincurredrelatedtofinancing" xlink:label="loc_roiv_Costsincurredrelatedtofinancing_1294984" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Costsincurredrelatedtofinancing_1294984" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Allocationoftransactioncostsincurredtowarrantsandearnoutshares" xlink:label="loc_roiv_Allocationoftransactioncostsincurredtowarrantsandearnoutshares_1294985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Allocationoftransactioncostsincurredtowarrantsandearnoutshares_1294985" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Portionofsharesubjecttoearnout" xlink:label="loc_roiv_Portionofsharesubjecttoearnout_1294988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Portionofsharesubjecttoearnout_1294988" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Numberoftradingdaystomeetwarrantredemptionthreshold" xlink:label="loc_roiv_Numberoftradingdaystomeetwarrantredemptionthreshold_1294989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Numberoftradingdaystomeetwarrantredemptionthreshold_1294989" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1294974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1294974" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime" xlink:label="loc_roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime_1295012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime_1295012" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1294977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1294977" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1294978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_us-gaap_SharePrice_1294978" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Stockpricetriggerforredemptionofwarrants" xlink:label="loc_roiv_Stockpricetriggerforredemptionofwarrants_1294980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Stockpricetriggerforredemptionofwarrants_1294980" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1294982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1294982" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1294983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_us-gaap_Cash_1294983" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Numberoftradingdaystomeetearnoutpricethreshold" xlink:label="loc_roiv_Numberoftradingdaystomeetearnoutpricethreshold_1294994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Numberoftradingdaystomeetearnoutpricethreshold_1294994" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1295025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1295025" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Tradingdayperiodforwarrantredemption" xlink:label="loc_roiv_Tradingdayperiodforwarrantredemption_1295000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Tradingdayperiodforwarrantredemption_1295000" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Tradingdayperiodforearnoutshares" xlink:label="loc_roiv_Tradingdayperiodforearnoutshares_1295001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Tradingdayperiodforearnoutshares_1295001" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PeriodForFairMarketValueDetermination" xlink:label="loc_roiv_PeriodForFairMarketValueDetermination_1295034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_PeriodForFairMarketValueDetermination_1295034" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EarnOutSharePrice" xlink:label="loc_roiv_EarnOutSharePrice_1295035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_EarnOutSharePrice_1295035" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Lockupperiodofcommonshares" xlink:label="loc_roiv_Lockupperiodofcommonshares_1295015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Lockupperiodofcommonshares_1295015" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Percentageofwarrantssubjecttolockupfordefinedperiodoftime" xlink:label="loc_roiv_Percentageofwarrantssubjecttolockupfordefinedperiodoftime_1295018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Percentageofwarrantssubjecttolockupfordefinedperiodoftime_1295018" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Lockupperiodwarrants" xlink:label="loc_roiv_Lockupperiodwarrants_1295023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Lockupperiodwarrants_1295023" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Timetowarrantexercisability" xlink:label="loc_roiv_Timetowarrantexercisability_1295028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Timetowarrantexercisability_1295028" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1295029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1295029" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Shareredemptiontriggerprice" xlink:label="loc_roiv_Shareredemptiontriggerprice_1295030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Shareredemptiontriggerprice_1295030" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Classofwarrantsredemptionpriceperunit" xlink:label="loc_roiv_Classofwarrantsredemptionpriceperunit_1295032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Classofwarrantsredemptionpriceperunit_1295032" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Classofwarrantsredemptionnoticeperiod" xlink:label="loc_roiv_Classofwarrantsredemptionnoticeperiod_1295033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Classofwarrantsredemptionnoticeperiod_1295033" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaximumRedemptionFeaturePerWarrant" xlink:label="loc_roiv_MaximumRedemptionFeaturePerWarrant_1295036" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_MaximumRedemptionFeaturePerWarrant_1295036" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CommonStockWarrants" xlink:label="loc_roiv_CommonStockWarrants_1510974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_CommonStockWarrants_1510974" use="optional" order="92" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/InvestmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_InvestmentsLineItems" xlink:label="loc_roiv_InvestmentsLineItems_918" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_937" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_InvestmentsTable" xlink:label="loc_roiv_InvestmentsTable_919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_InvestmentsTable_919" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_InvestmentsTable_919" xlink:to="loc_us-gaap_StatementClassOfStockAxis_923" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_923" xlink:to="loc_us-gaap_ClassOfStockDomain_916" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_916_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_923" xlink:to="loc_us-gaap_ClassOfStockDomain_916_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_InvestmentsTable_919" xlink:to="loc_dei_LegalEntityAxis_922" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_922" xlink:to="loc_dei_EntityDomain_917" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_917_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_922" xlink:to="loc_dei_EntityDomain_917_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ArbutusBiopharmaCorporationMember" xlink:label="loc_roiv_ArbutusBiopharmaCorporationMember_925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_917" xlink:to="loc_roiv_ArbutusBiopharmaCorporationMember_925" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DatavantHoldingsIncMember" xlink:label="loc_roiv_DatavantHoldingsIncMember_927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_917" xlink:to="loc_roiv_DatavantHoldingsIncMember_927" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SioGeneTherapiesIncMember" xlink:label="loc_roiv_SioGeneTherapiesIncMember_926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_917" xlink:to="loc_roiv_SioGeneTherapiesIncMember_926" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_InvestmentsTable_919" xlink:to="loc_us-gaap_InvestmentTypeAxis_920" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_920" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_921" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_921_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_920" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_921_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentCompaniesMember" xlink:label="loc_us-gaap_OtherInvestmentCompaniesMember_946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_921" xlink:to="loc_us-gaap_OtherInvestmentCompaniesMember_946" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1294810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_InvestmentsTable_919" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1294810" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1294811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1294810" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1294811" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1294811_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1294810" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1294811_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DatavantMergerMember" xlink:label="loc_roiv_DatavantMergerMember_1294812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1294811" xlink:to="loc_roiv_DatavantMergerMember_1294812" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_1295110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_InvestmentsTable_919" xlink:to="loc_srt_OwnershipAxis_1295110" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1295111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_1295110" xlink:to="loc_srt_OwnershipDomain_1295111" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1295111_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_1295110" xlink:to="loc_srt_OwnershipDomain_1295111_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CombinedCompanyMember" xlink:label="loc_roiv_CombinedCompanyMember_1295113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1295111" xlink:to="loc_roiv_CombinedCompanyMember_1295113" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1105159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1105159" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_939" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_LongTermInvestments_945" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1139348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1139348" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_SharePrice_938" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_936" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PreferredStockOwnedBalanceSharesOfArbutus" xlink:label="loc_roiv_PreferredStockOwnedBalanceSharesOfArbutus_929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_PreferredStockOwnedBalanceSharesOfArbutus_929" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock" xlink:label="loc_roiv_InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock_1294729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock_1294729" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GainOnMeasurementOfInvestment" xlink:label="loc_roiv_GainOnMeasurementOfInvestment_1294818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_GainOnMeasurementOfInvestment_1294818" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromSaleOfInvestment" xlink:label="loc_roiv_ProceedsFromSaleOfInvestment_1294808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_ProceedsFromSaleOfInvestment_1294808" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_951" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_976" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FutureDevelopmentAndCommercialMilestonePayments" xlink:label="loc_roiv_FutureDevelopmentAndCommercialMilestonePayments_966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_FutureDevelopmentAndCommercialMilestonePayments_966" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_993" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_988" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_997" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BusinessAcquisitionConsiderationTransferred" xlink:label="loc_roiv_BusinessAcquisitionConsiderationTransferred_983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_BusinessAcquisitionConsiderationTransferred_983" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_NonRefundableUpfrontPaymentReceived" xlink:label="loc_roiv_NonRefundableUpfrontPaymentReceived_969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_NonRefundableUpfrontPaymentReceived_969" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PaymentForUpfrontPayments" xlink:label="loc_roiv_PaymentForUpfrontPayments_985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_PaymentForUpfrontPayments_985" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_us-gaap_AssetAcquisitionAxis_950" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_950" xlink:to="loc_us-gaap_AssetAcquisitionDomain_949" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_949_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_950" xlink:to="loc_us-gaap_AssetAcquisitionDomain_949_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SiliconTherapeuticsMember" xlink:label="loc_roiv_SiliconTherapeuticsMember_963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_949" xlink:to="loc_roiv_SiliconTherapeuticsMember_963" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SiliconTherapeuticsMember" xlink:label="loc_roiv_SiliconTherapeuticsMember_1515550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1515549" xlink:to="loc_roiv_SiliconTherapeuticsMember_1515550" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PriovantMember" xlink:label="loc_roiv_PriovantMember_1294550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_949" xlink:to="loc_roiv_PriovantMember_1294550" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PriovantMember" xlink:label="loc_roiv_PriovantMember_1515551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1515549" xlink:to="loc_roiv_PriovantMember_1515551" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MilestoneEventsAxis" xlink:label="loc_roiv_MilestoneEventsAxis_954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_roiv_MilestoneEventsAxis_954" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MilestoneEventsDomain" xlink:label="loc_roiv_MilestoneEventsDomain_955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_roiv_MilestoneEventsAxis_954" xlink:to="loc_roiv_MilestoneEventsDomain_955" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MilestoneEventsDomain" xlink:label="loc_roiv_MilestoneEventsDomain_955_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_roiv_MilestoneEventsAxis_954" xlink:to="loc_roiv_MilestoneEventsDomain_955_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" xlink:label="loc_roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember_1003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_MilestoneEventsDomain_955" xlink:to="loc_roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember_1003" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" xlink:label="loc_roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember_1005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_MilestoneEventsDomain_955" xlink:to="loc_roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember_1005" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" xlink:label="loc_roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember_1004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_MilestoneEventsDomain_955" xlink:to="loc_roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember_1004" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_srt_RangeAxis_956" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_956" xlink:to="loc_srt_RangeMember_957" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_957_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_956" xlink:to="loc_srt_RangeMember_957_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_957" xlink:to="loc_srt_MaximumMember_1006" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_dei_LegalEntityAxis_953" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_953" xlink:to="loc_dei_EntityDomain_952" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_952_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_953" xlink:to="loc_dei_EntityDomain_952_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ArbutusBiopharmaCorporationMember" xlink:label="loc_roiv_ArbutusBiopharmaCorporationMember_1002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_952" xlink:to="loc_roiv_ArbutusBiopharmaCorporationMember_1002" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_959" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_959" xlink:to="loc_us-gaap_RelatedPartyDomain_958" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_958_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_959" xlink:to="loc_us-gaap_RelatedPartyDomain_958_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AffivantSciencesMember" xlink:label="loc_roiv_AffivantSciencesMember_1010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_958" xlink:to="loc_roiv_AffivantSciencesMember_1010" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GenevantSciencesLtdMember" xlink:label="loc_roiv_GenevantSciencesLtdMember_1008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_958" xlink:to="loc_roiv_GenevantSciencesLtdMember_1008" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProteovantSciencesIncMember" xlink:label="loc_roiv_ProteovantSciencesIncMember_1009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_958" xlink:to="loc_roiv_ProteovantSciencesIncMember_1009" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_us-gaap_RestructuringPlanAxis_960" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_960" xlink:to="loc_us-gaap_RestructuringPlanDomain_961" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_961_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_960" xlink:to="loc_us-gaap_RestructuringPlanDomain_961_default" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FirstTrancheMember" xlink:label="loc_roiv_FirstTrancheMember_1011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_961" xlink:to="loc_roiv_FirstTrancheMember_1011" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SecondTrancheMember" xlink:label="loc_roiv_SecondTrancheMember_1012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_961" xlink:to="loc_roiv_SecondTrancheMember_1012" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaap_TransactionTypeAxis_1294568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_us-gaap_TransactionTypeAxis_1294568" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_1294569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TransactionTypeAxis_1294568" xlink:to="loc_us-gaap_TransactionDomain_1294569" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_1294569_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TransactionTypeAxis_1294568" xlink:to="loc_us-gaap_TransactionDomain_1294569_default" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CommercialMilestoneMember" xlink:label="loc_roiv_CommercialMilestoneMember_1294570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransactionDomain_1294569" xlink:to="loc_roiv_CommercialMilestoneMember_1294570" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_roiv_DevelopmentAndRegulatoryMilestoneMember_1294578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransactionDomain_1294569" xlink:to="loc_roiv_DevelopmentAndRegulatoryMilestoneMember_1294578" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1294565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1294565" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1294566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1294565" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1294566" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1294566_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1294565" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1294566_default" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PharmanvanthSevenGmbhMember" xlink:label="loc_roiv_PharmanvanthSevenGmbhMember_1294567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1294566" xlink:to="loc_roiv_PharmanvanthSevenGmbhMember_1294567" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_HemavantSciencesGmbhMember" xlink:label="loc_roiv_HemavantSciencesGmbhMember_1476361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1294566" xlink:to="loc_roiv_HemavantSciencesGmbhMember_1476361" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementAxis" xlink:label="loc_roiv_AgreementAxis_1476354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_roiv_AgreementAxis_1476354" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementDomain" xlink:label="loc_roiv_AgreementDomain_1476355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_roiv_AgreementAxis_1476354" xlink:to="loc_roiv_AgreementDomain_1476355" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementDomain" xlink:label="loc_roiv_AgreementDomain_1476355_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_roiv_AgreementAxis_1476354" xlink:to="loc_roiv_AgreementDomain_1476355_default" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CollaborationAgreementWithBlueprintMedicinesMember" xlink:label="loc_roiv_CollaborationAgreementWithBlueprintMedicinesMember_1476356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_AgreementDomain_1476355" xlink:to="loc_roiv_CollaborationAgreementWithBlueprintMedicinesMember_1476356" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1515548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1515548" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1515549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1515548" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1515549" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1515549_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1515548" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1515549_default" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueOfRestrictedStock" xlink:label="loc_roiv_FairValueOfRestrictedStock_1001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_FairValueOfRestrictedStock_1001" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_981" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_989" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueOfCommonShares" xlink:label="loc_roiv_FairValueOfCommonShares_1000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_FairValueOfCommonShares_1000" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_995" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_roiv_BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_996" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_977" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_994" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_GainLossOnInvestments_980" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_972" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_982" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_ShareBasedCompensation_999" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PercentageOfControllingInterestHeld" xlink:label="loc_roiv_PercentageOfControllingInterestHeld_978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_PercentageOfControllingInterestHeld_978" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PaymentUnderSponsoredResearchAgreement" xlink:label="loc_roiv_PaymentUnderSponsoredResearchAgreement_986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_PaymentUnderSponsoredResearchAgreement_986" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_979" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="loc_us-gaap_StockholdersEquityNoteSubscriptionsReceivable_991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_StockholdersEquityNoteSubscriptionsReceivable_991" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_990" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_974" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodValue" xlink:label="loc_roiv_StockIssuedDuringPeriodValue_992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_StockIssuedDuringPeriodValue_992" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_975" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PotentialMilestonePaymentReceivable" xlink:label="loc_roiv_PotentialMilestonePaymentReceivable_970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_PotentialMilestonePaymentReceivable_970" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_UpfrontCashPayments" xlink:label="loc_roiv_UpfrontCashPayments_964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_UpfrontCashPayments_964" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_987" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_987" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_1294549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_1294549" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1294552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1294552" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1294572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1294572" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MilestonePaymentPayable" xlink:label="loc_roiv_MilestonePaymentPayable_1294561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_MilestonePaymentPayable_1294561" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1294556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1294556" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PayableForEachAdditionalProductIndication" xlink:label="loc_roiv_PayableForEachAdditionalProductIndication_1294559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_PayableForEachAdditionalProductIndication_1294559" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_1476357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_DeferredRevenue_1476357" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1476358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1476358" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AcquiredInProcessResearchAndDevelopmentExpense" xlink:label="loc_roiv_AcquiredInProcessResearchAndDevelopmentExpense_1510975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_AcquiredInProcessResearchAndDevelopmentExpense_1510975" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedParties" xlink:label="loc_us-gaap_NotesReceivableRelatedParties_1510978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_NotesReceivableRelatedParties_1510978" use="optional" order="91" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AccruedLiabilitiesLineItems" xlink:label="loc_roiv_AccruedLiabilitiesLineItems_1070" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_AccruedLiabilitiesLineItems_1070" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1074" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BalanceSheetComponentsTable" xlink:label="loc_roiv_BalanceSheetComponentsTable_1071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_roiv_AccruedLiabilitiesLineItems_1070" xlink:to="loc_roiv_BalanceSheetComponentsTable_1071" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_BalanceSheetComponentsTable_1071" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1072" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1072" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1073" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1073_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1072" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1073_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EmployeeRelatedExpensesMember" xlink:label="loc_roiv_EmployeeRelatedExpensesMember_1076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1073" xlink:to="loc_roiv_EmployeeRelatedExpensesMember_1076" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OtherGeneralAndAdministrativeExpensesMember" xlink:label="loc_roiv_OtherGeneralAndAdministrativeExpensesMember_1078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1073" xlink:to="loc_roiv_OtherGeneralAndAdministrativeExpensesMember_1078" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1073" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1075" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1095" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaximumMilestonePaymentObligation" xlink:label="loc_roiv_MaximumMilestonePaymentObligation_1111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_MaximumMilestonePaymentObligation_1111" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaximumMilestonePaymentOffsetAmount" xlink:label="loc_roiv_MaximumMilestonePaymentOffsetAmount_1112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_MaximumMilestonePaymentOffsetAmount_1112" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentTable_1096" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaap_TransactionTypeAxis_1100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_TransactionTypeAxis_1100" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_1099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TransactionTypeAxis_1100" xlink:to="loc_us-gaap_TransactionDomain_1099" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_1099_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TransactionTypeAxis_1100" xlink:to="loc_us-gaap_TransactionDomain_1099_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CommercialMilestoneMember" xlink:label="loc_roiv_CommercialMilestoneMember_1116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransactionDomain_1099" xlink:to="loc_roiv_CommercialMilestoneMember_1116" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RegulatoryMilestoneMember" xlink:label="loc_roiv_RegulatoryMilestoneMember_1115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransactionDomain_1099" xlink:to="loc_roiv_RegulatoryMilestoneMember_1115" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1098" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1098" xlink:to="loc_us-gaap_RelatedPartyDomain_1097" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1097_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1098" xlink:to="loc_us-gaap_RelatedPartyDomain_1097_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1101" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1101" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1094" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1094_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1101" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1094_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_NovaquestMember" xlink:label="loc_roiv_NovaquestMember_1104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1094" xlink:to="loc_roiv_NovaquestMember_1104" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_1102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_VariableRateAxis_1102" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_1103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_1102" xlink:to="loc_us-gaap_VariableRateDomain_1103" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_1103_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_1102" xlink:to="loc_us-gaap_VariableRateDomain_1103_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_1117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_1103" xlink:to="loc_us-gaap_PrimeRateMember_1117" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1097057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_srt_RangeAxis_1097057" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1097058" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1097057" xlink:to="loc_srt_RangeMember_1097058" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1097058_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1097057" xlink:to="loc_srt_RangeMember_1097058_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1097323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1097323" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1097324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1097323" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1097324" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1097324_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1097323" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1097324_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementMember" xlink:label="loc_roiv_RevenueInterestPurchaseAndSaleAgreementMember_1097325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1097324" xlink:to="loc_roiv_RevenueInterestPurchaseAndSaleAgreementMember_1097325" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_1113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentFairValue_1113" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_1110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_1110" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_1108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_1108" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1097053" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1097053" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1097048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1097048" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_1097050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentTerm_1097050" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1105" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_1106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_1106" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xlink:label="loc_roiv_DebtInstrumentExitFeeAndEndOfTermCharge_1105123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_DebtInstrumentExitFeeAndEndOfTermCharge_1105123" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" xlink:label="loc_roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement_1097321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement_1097321" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1097054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1097054" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CommittedFundingUnderRIPSA" xlink:label="loc_roiv_CommittedFundingUnderRIPSA_1515522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_CommittedFundingUnderRIPSA_1515522" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MilestonePaymentDueOverSixYearPeriod" xlink:label="loc_roiv_MilestonePaymentDueOverSixYearPeriod_1515571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_MilestonePaymentDueOverSixYearPeriod_1515571" use="optional" order="39" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1130" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" xlink:label="loc_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary_1135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1130" xlink:to="loc_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary_1135" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AccessFeePaidToRelatedParty" xlink:label="loc_roiv_AccessFeePaidToRelatedParty_1136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1130" xlink:to="loc_roiv_AccessFeePaidToRelatedParty_1136" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1130" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1132" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1132" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1131" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1131" xlink:to="loc_us-gaap_RelatedPartyDomain_1129" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1129_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1131" xlink:to="loc_us-gaap_RelatedPartyDomain_1129_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SumitomoMember" xlink:label="loc_roiv_SumitomoMember_1134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1129" xlink:to="loc_roiv_SumitomoMember_1134" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementAxis" xlink:label="loc_roiv_AgreementAxis_1475622" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1132" xlink:to="loc_roiv_AgreementAxis_1475622" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementDomain" xlink:label="loc_roiv_AgreementDomain_1475623" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_roiv_AgreementAxis_1475622" xlink:to="loc_roiv_AgreementDomain_1475623" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementDomain" xlink:label="loc_roiv_AgreementDomain_1475623_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_roiv_AgreementAxis_1475622" xlink:to="loc_roiv_AgreementDomain_1475623_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AssetPurchaseAgreementMember" xlink:label="loc_roiv_AssetPurchaseAgreementMember_1475624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_AgreementDomain_1475623" xlink:to="loc_roiv_AssetPurchaseAgreementMember_1475624" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TransitionServicesAndStrategicCooperationAgreementMember" xlink:label="loc_roiv_TransitionServicesAndStrategicCooperationAgreementMember_1475627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_AgreementDomain_1475623" xlink:to="loc_roiv_TransitionServicesAndStrategicCooperationAgreementMember_1475627" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AssetPurchaseTransactionConsiderationReceivedInCash" xlink:label="loc_roiv_AssetPurchaseTransactionConsiderationReceivedInCash_1475620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1130" xlink:to="loc_roiv_AssetPurchaseTransactionConsiderationReceivedInCash_1475620" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xlink:label="loc_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination_1475621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1130" xlink:to="loc_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination_1475621" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary" xlink:label="loc_roiv_AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary_1475631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1130" xlink:to="loc_roiv_AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary_1475631" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1144" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ClassOfWarrantOrRightExercisable" xlink:label="loc_roiv_ClassOfWarrantOrRightExercisable_1185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_roiv_ClassOfWarrantOrRightExercisable_1185" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1174" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1173" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_CommonStockSharesIssued_1179" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1184" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1186" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1183" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1169" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1151" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1157" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1157" xlink:to="loc_us-gaap_ClassOfStockDomain_1143" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1143_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1157" xlink:to="loc_us-gaap_ClassOfStockDomain_1143_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_srt_RangeAxis_1146" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1146" xlink:to="loc_srt_RangeMember_1147" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1147_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1146" xlink:to="loc_srt_RangeMember_1147_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1149" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1149" xlink:to="loc_us-gaap_RelatedPartyDomain_1148" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1148_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1149" xlink:to="loc_us-gaap_RelatedPartyDomain_1148_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ImmunovantSciencesLtdMember" xlink:label="loc_roiv_ImmunovantSciencesLtdMember_1198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1148" xlink:to="loc_roiv_ImmunovantSciencesLtdMember_1198" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_AwardTypeAxis_1140" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1140" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1152" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1152_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1140" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1152_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1158" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1158" xlink:to="loc_us-gaap_EquityComponentDomain_1145" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1145_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1158" xlink:to="loc_us-gaap_EquityComponentDomain_1145_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1145" xlink:to="loc_us-gaap_CommonStockMember_1192" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1145" xlink:to="loc_us-gaap_WarrantMember_1193" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivantCommonSharesMember" xlink:label="loc_roiv_RoivantCommonSharesMember_1294676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1145" xlink:to="loc_roiv_RoivantCommonSharesMember_1294676" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1159" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1159" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1150" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1150_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1159" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1150_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_UnderwrittenPublicOfferingMember" xlink:label="loc_roiv_UnderwrittenPublicOfferingMember_1200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1150" xlink:to="loc_roiv_UnderwrittenPublicOfferingMember_1200" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1142" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1142" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1141" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1141_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1142" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1141_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ImmunovantINCMember" xlink:label="loc_roiv_ImmunovantINCMember_1162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1141" xlink:to="loc_roiv_ImmunovantINCMember_1162" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1160" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1160" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1139" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1139_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1160" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1139_default" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_1153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_1153" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_1154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_1153" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_1154" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_1154_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_1153" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_1154_default" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1155" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1155" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1156" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1156_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1155" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1156_default" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1294665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1294665" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1294666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1294665" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1294666" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1294666_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1294665" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1294666_default" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SkMember" xlink:label="loc_roiv_SkMember_1294669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1294666" xlink:to="loc_roiv_SkMember_1294669" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1475822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1475822" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1475823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1475822" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1475823" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1475823_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1475822" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1475823_default" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CantorFitzgeraldCo.Member" xlink:label="loc_roiv_CantorFitzgeraldCo.Member_1475824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1475823" xlink:to="loc_roiv_CantorFitzgeraldCo.Member_1475824" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_1294671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_EquityMethodInvestments_1294671" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1294674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1294674" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1294658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1294658" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_1294660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_CommonStockVotingRights_1294660" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockHoldersEquityNoteStockSplitExchangeRatio1" xlink:label="loc_roiv_StockHoldersEquityNoteStockSplitExchangeRatio1_1294661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_roiv_StockHoldersEquityNoteStockSplitExchangeRatio1_1294661" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SubscriptionReceived" xlink:label="loc_roiv_SubscriptionReceived_1294662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_roiv_SubscriptionReceived_1294662" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1294657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1294657" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_1475814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_PurchaseObligation_1475814" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PercentageOfCommonSharesVolumeWeightedAveragePrice" xlink:label="loc_roiv_PercentageOfCommonSharesVolumeWeightedAveragePrice_1475820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_roiv_PercentageOfCommonSharesVolumeWeightedAveragePrice_1475820" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_UpfrontCommitmentFeeNumberOfSharesIssued" xlink:label="loc_roiv_UpfrontCommitmentFeeNumberOfSharesIssued_1475821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_roiv_UpfrontCommitmentFeeNumberOfSharesIssued_1475821" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CommonSharesValueAvailableForSale" xlink:label="loc_roiv_CommonSharesValueAvailableForSale_1487110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_roiv_CommonSharesValueAvailableForSale_1487110" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ClassOfWarrantOrRightCanceled" xlink:label="loc_roiv_ClassOfWarrantOrRightCanceled_1510994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_roiv_ClassOfWarrantOrRightCanceled_1510994" use="optional" order="65" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1222" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" xlink:to="loc_us-gaap_PlanNameAxis_1212" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1212" xlink:to="loc_us-gaap_PlanNameDomain_1213" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1213_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1212" xlink:to="loc_us-gaap_PlanNameDomain_1213_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SubsidiaryEquityIncentivePlanMember" xlink:label="loc_roiv_SubsidiaryEquityIncentivePlanMember_1218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1213" xlink:to="loc_roiv_SubsidiaryEquityIncentivePlanMember_1218" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1213" xlink:to="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1217" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandTwentyOneEquityIncentivePlanMember_1294736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1213" xlink:to="loc_roiv_TwoThousandTwentyOneEquityIncentivePlanMember_1294736" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" xlink:to="loc_us-gaap_AwardTypeAxis_1211" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1211" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1211" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CappedValueAppreciationRightsMember" xlink:label="loc_roiv_CappedValueAppreciationRightsMember_1239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_roiv_CappedValueAppreciationRightsMember_1239" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockOptionsAndPerformanceStockOptionsMember" xlink:label="loc_roiv_StockOptionsAndPerformanceStockOptionsMember_1475929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_roiv_StockOptionsAndPerformanceStockOptionsMember_1475929" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:label="loc_roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember_1475963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember_1475963" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SubsidiaryEquityIncentivePlansMember" xlink:label="loc_roiv_SubsidiaryEquityIncentivePlansMember_1475988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_roiv_SubsidiaryEquityIncentivePlansMember_1475988" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_March2020CappedValueAppreciationRightsMember" xlink:label="loc_roiv_March2020CappedValueAppreciationRightsMember_1490707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_roiv_March2020CappedValueAppreciationRightsMember_1490707" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EventAxis" xlink:label="loc_roiv_EventAxis_1294731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" xlink:to="loc_roiv_EventAxis_1294731" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EventDomain" xlink:label="loc_roiv_EventDomain_1294732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_roiv_EventAxis_1294731" xlink:to="loc_roiv_EventDomain_1294732" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EventDomain" xlink:label="loc_roiv_EventDomain_1294732_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_roiv_EventAxis_1294731" xlink:to="loc_roiv_EventDomain_1294732_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMember" xlink:label="loc_roiv_AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMember_1294733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_EventDomain_1294732" xlink:to="loc_roiv_AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMember_1294733" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1475984" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1475984" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1475985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1475984" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1475985" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1475985_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1475984" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1475985_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_1475986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1475985" xlink:to="loc_us-gaap_EmployeeStockMember_1475986" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1220" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1230" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1224" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1221" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OneTimeCatchUpExpense" xlink:label="loc_roiv_OneTimeCatchUpExpense_1294728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_roiv_OneTimeCatchUpExpense_1294728" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares" xlink:label="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares_1294776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares_1294776" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_1475920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_1475920" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1475937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1475937" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1475962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1475962" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1475968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1475968" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1475969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1475969" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncrementOfEmployeeStockPurchasePlan" xlink:label="loc_roiv_IncrementOfEmployeeStockPurchasePlan_1475978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_roiv_IncrementOfEmployeeStockPurchasePlan_1475978" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable" xlink:label="loc_roiv_EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable_1475980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_roiv_EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable_1475980" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment" xlink:label="loc_roiv_IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment_1492261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_roiv_IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment_1492261" use="optional" order="38" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_1248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_1248" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1251" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1249" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1250" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1245" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1245" xlink:to="loc_us-gaap_AwardTypeAxis_1244" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1244" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1247" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1247_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1244" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1247_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1247" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1252" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1290" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1290" xlink:to="loc_us-gaap_AwardTypeAxis_1287" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1287" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1292" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1292_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1287" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1292_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RestrictedStockAndPerformanceStockUnitsMember" xlink:label="loc_roiv_RestrictedStockAndPerformanceStockUnitsMember_1294754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1292" xlink:to="loc_roiv_RestrictedStockAndPerformanceStockUnitsMember_1294754" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1290" xlink:to="loc_us-gaap_PlanNameAxis_1288" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1288" xlink:to="loc_us-gaap_PlanNameDomain_1289" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1289_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1288" xlink:to="loc_us-gaap_PlanNameDomain_1289_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RSLEquityPlansMember" xlink:label="loc_roiv_RSLEquityPlansMember_1294755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1289" xlink:to="loc_roiv_RSLEquityPlansMember_1294755" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1296" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1295" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1294" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1294756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1294756" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1475894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1475894" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1475895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1475895" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1475896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1475896" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1475897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1475897" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1312" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1317" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1314" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1313" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1316" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1324" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1308" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1308" xlink:to="loc_us-gaap_AwardTypeAxis_1305" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1305" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1310" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1310_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1305" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1310_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockOptionsAndPerformanceStockOptionsMember" xlink:label="loc_roiv_StockOptionsAndPerformanceStockOptionsMember_1325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1310" xlink:to="loc_roiv_StockOptionsAndPerformanceStockOptionsMember_1325" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1308" xlink:to="loc_us-gaap_PlanNameAxis_1306" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1306" xlink:to="loc_us-gaap_PlanNameDomain_1307" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1307_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1306" xlink:to="loc_us-gaap_PlanNameDomain_1307_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RSLEquityPlansMember" xlink:label="loc_roiv_RSLEquityPlansMember_1294738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1307" xlink:to="loc_roiv_RSLEquityPlansMember_1294738" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1475865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1475865" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1475866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1475866" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1475867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1475867" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1475873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1475873" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1475876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1475876" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1475880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1475880" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1475883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1475883" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1475884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1475884" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1335" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1337" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1336" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1340" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1341" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1339" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1331" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1331" xlink:to="loc_us-gaap_AwardTypeAxis_1328" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1328" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1333" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1333_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1328" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1333_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CappedValueAppreciationRightsMember" xlink:label="loc_roiv_CappedValueAppreciationRightsMember_1343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1333" xlink:to="loc_roiv_CappedValueAppreciationRightsMember_1343" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1331" xlink:to="loc_us-gaap_PlanNameAxis_1329" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1329" xlink:to="loc_us-gaap_PlanNameDomain_1330" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1330_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1329" xlink:to="loc_us-gaap_PlanNameDomain_1330_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1330" xlink:to="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1334" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandTwentyOneEquityIncentivePlanMember_1475902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1330" xlink:to="loc_roiv_TwoThousandTwentyOneEquityIncentivePlanMember_1475902" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1475900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1475900" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1475901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1475901" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1384" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1384" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1387" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1384" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1383" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1383" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1381" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1381" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1382" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1382_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1381" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1382_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1382" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1386" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1382" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1385" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail">
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncomeTaxDisclosureLineItems" xlink:label="loc_roiv_IncomeTaxDisclosureLineItems_1391" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_1391" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1390" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1390" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1395" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncomeTaxDisclosureTable" xlink:label="loc_roiv_IncomeTaxDisclosureTable_1392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_1391" xlink:to="loc_roiv_IncomeTaxDisclosureTable_1392" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_IncomeTaxDisclosureTable_1392" xlink:to="loc_srt_StatementGeographicalAxis_1394" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1394" xlink:to="loc_srt_SegmentGeographicalDomain_1393" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1393_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1394" xlink:to="loc_srt_SegmentGeographicalDomain_1393_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="loc_country_CH_1397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1393" xlink:to="loc_country_CH_1397" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OtherMember" xlink:label="loc_roiv_OtherMember_1399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1393" xlink:to="loc_roiv_OtherMember_1399" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BM" xlink:label="loc_country_BM_1398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1393" xlink:to="loc_country_BM_1398" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="loc_country_US_1396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1393" xlink:to="loc_country_US_1396" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail">
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ComponentsOfIncomeTaxExpenseLineItems" xlink:label="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems_772" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems_772" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_774" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_774" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_782" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems_772" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_775" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_775" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_786" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ComponentsOfIncomeTaxExpenseTable" xlink:label="loc_roiv_ComponentsOfIncomeTaxExpenseTable_773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems_772" xlink:to="loc_roiv_ComponentsOfIncomeTaxExpenseTable_773" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseTable_773" xlink:to="loc_srt_StatementGeographicalAxis_779" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_779" xlink:to="loc_srt_SegmentGeographicalDomain_778" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_778_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_779" xlink:to="loc_srt_SegmentGeographicalDomain_778_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="loc_country_US_789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_778" xlink:to="loc_country_US_789" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OtherMember" xlink:label="loc_roiv_OtherMember_792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_778" xlink:to="loc_roiv_OtherMember_792" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BM" xlink:label="loc_country_BM_791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_778" xlink:to="loc_country_BM_791" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="loc_country_CH_790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_778" xlink:to="loc_country_CH_790" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseTable_773" xlink:to="loc_dei_LegalEntityAxis_777" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_777" xlink:to="loc_dei_EntityDomain_776" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_776_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_777" xlink:to="loc_dei_EntityDomain_776_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems_772" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_781" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncomeTaxDisclosureLineItems" xlink:label="loc_roiv_IncomeTaxDisclosureLineItems_857" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_OperatingLossCarryforwards_864" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_867" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncomeTaxDisclosureTable" xlink:label="loc_roiv_IncomeTaxDisclosureTable_858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_roiv_IncomeTaxDisclosureTable_858" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_IncomeTaxDisclosureTable_858" xlink:to="loc_dei_LegalEntityAxis_859" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_859" xlink:to="loc_dei_EntityDomain_854" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_854_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_859" xlink:to="loc_dei_EntityDomain_854_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_IncomeTaxDisclosureTable_858" xlink:to="loc_srt_StatementGeographicalAxis_863" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_863" xlink:to="loc_srt_SegmentGeographicalDomain_862" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_862_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_863" xlink:to="loc_srt_SegmentGeographicalDomain_862_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB" xlink:label="loc_country_GB_879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_862" xlink:to="loc_country_GB_879" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TaxAuthorityInOtherJurisdictionsMember" xlink:label="loc_roiv_TaxAuthorityInOtherJurisdictionsMember_880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_862" xlink:to="loc_roiv_TaxAuthorityInOtherJurisdictionsMember_880" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="loc_country_US_878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_862" xlink:to="loc_country_US_878" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="loc_country_CH_877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_862" xlink:to="loc_country_CH_877" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_UnitedStatesAndCanadaMember" xlink:label="loc_roiv_UnitedStatesAndCanadaMember_1475806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_862" xlink:to="loc_roiv_UnitedStatesAndCanadaMember_1475806" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_IncomeTaxDisclosureTable_858" xlink:to="loc_srt_RangeAxis_860" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_860" xlink:to="loc_srt_RangeMember_861" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_861_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_860" xlink:to="loc_srt_RangeMember_861_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_861" xlink:to="loc_srt_MinimumMember_875" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_861" xlink:to="loc_srt_MaximumMember_876" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_IncomeTaxDisclosureTable_858" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_855" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_855" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_856" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_856_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_855" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_856_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_856" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_873" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_866" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="loc_us-gaap_TaxCreditCarryforwardExpirationDate_868" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_TaxCreditCarryforwardExpirationDate_868" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_853" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_874" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_870" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_869" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AnnualNOLUtilizationLimitationPercentage" xlink:label="loc_roiv_AnnualNOLUtilizationLimitationPercentage_865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_roiv_AnnualNOLUtilizationLimitationPercentage_865" use="optional" order="30" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredTaxAssetsLiabilitiesLineItems" xlink:label="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems_796" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredTaxAssetsLiabilitiesTable" xlink:label="loc_roiv_DeferredTaxAssetsLiabilitiesTable_797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems_796" xlink:to="loc_roiv_DeferredTaxAssetsLiabilitiesTable_797" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesTable_797" xlink:to="loc_dei_LegalEntityAxis_800" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_800" xlink:to="loc_dei_EntityDomain_799" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_799_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_800" xlink:to="loc_dei_EntityDomain_799_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems_796" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_809" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems_796" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_816" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_roiv_DeferredTaxLiabilitiesDepreciation_811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" xlink:to="loc_roiv_DeferredTaxLiabilitiesDepreciation_811" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_815" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="loc_roiv_DeferredTaxLiabilitiesRightOfUseAssets_813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" xlink:to="loc_roiv_DeferredTaxLiabilitiesRightOfUseAssets_813" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems_796" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_804" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_803" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_808" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_807" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_801" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_805" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_roiv_DeferredTaxAssetsLeaseLiabilities_806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_roiv_DeferredTaxAssetsLeaseLiabilities_806" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail">
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EffectiveTaxRateReconcilingItemsLineItems" xlink:label="loc_roiv_EffectiveTaxRateReconcilingItemsLineItems_821" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_EffectiveTaxRateReconcilingItemsLineItems_821" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_836" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_838" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_826" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_827" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_835" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_832" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_829" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_837" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_834" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_1475778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_1475778" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_1475780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_1475780" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_1475782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_1475782" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_1475784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_1475784" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_1475786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_1475786" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EffectiveTaxRateReconcilingItemsTable" xlink:label="loc_roiv_EffectiveTaxRateReconcilingItemsTable_822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_roiv_EffectiveTaxRateReconcilingItemsLineItems_821" xlink:to="loc_roiv_EffectiveTaxRateReconcilingItemsTable_822" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_EffectiveTaxRateReconcilingItemsTable_822" xlink:to="loc_dei_LegalEntityAxis_825" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_825" xlink:to="loc_dei_EntityDomain_823" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_823_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_825" xlink:to="loc_dei_EntityDomain_823_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_EffectiveTaxRateReconcilingItemsLineItems_821" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_842" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_849" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_846" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_848" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_847" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_844" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_841" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_840" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_850" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:label="loc_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_1475777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_1475777" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets_1475779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets_1475779" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1475781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1475781" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_1475783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_1475783" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDeductionsOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationDeductionsOther_1475785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationDeductionsOther_1475785" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_599" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_599" xlink:to="loc_us-gaap_StatementTable_600" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_600" xlink:to="loc_dei_LegalEntityAxis_597" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_597" xlink:to="loc_dei_EntityDomain_596" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_596_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_597" xlink:to="loc_dei_EntityDomain_596_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_600" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_601" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_601" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_598" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_598_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_601" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_598_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementAxis" xlink:label="loc_roiv_AgreementAxis_1510958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_600" xlink:to="loc_roiv_AgreementAxis_1510958" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementDomain" xlink:label="loc_roiv_AgreementDomain_1510959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_roiv_AgreementAxis_1510958" xlink:to="loc_roiv_AgreementDomain_1510959" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementDomain" xlink:label="loc_roiv_AgreementDomain_1510959_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_roiv_AgreementAxis_1510958" xlink:to="loc_roiv_AgreementDomain_1510959_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MasterSubscriptionAgreementMember" xlink:label="loc_roiv_MasterSubscriptionAgreementMember_1510960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_AgreementDomain_1510959" xlink:to="loc_roiv_MasterSubscriptionAgreementMember_1510960" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProductServiceAgreementMember" xlink:label="loc_roiv_ProductServiceAgreementMember_1510961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_AgreementDomain_1510959" xlink:to="loc_roiv_ProductServiceAgreementMember_1510961" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_1510957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_599" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_1510957" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_DebtInstrumentFairValue_702" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_704" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_701" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_699" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_706" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_682" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_682" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_683" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_683_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_682" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_683_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_715" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_715" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_716" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_714" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_714" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_688" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_688" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_688" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" xlink:to="loc_us-gaap_CommonStockMember_710" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" xlink:to="loc_us-gaap_MoneyMarketFundsMember_709" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentCompaniesMember" xlink:label="loc_us-gaap_OtherInvestmentCompaniesMember_712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" xlink:to="loc_us-gaap_OtherInvestmentCompaniesMember_712" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_dei_LegalEntityAxis_693" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_693" xlink:to="loc_dei_EntityDomain_684" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_684_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_693" xlink:to="loc_dei_EntityDomain_684_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ArbutusBiopharmaCorporationMember" xlink:label="loc_roiv_ArbutusBiopharmaCorporationMember_698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_684" xlink:to="loc_roiv_ArbutusBiopharmaCorporationMember_698" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SioGeneTherapiesIncMember" xlink:label="loc_roiv_SioGeneTherapiesIncMember_697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_684" xlink:to="loc_roiv_SioGeneTherapiesIncMember_697" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DatavantMember" xlink:label="loc_roiv_DatavantMember_1294913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_684" xlink:to="loc_roiv_DatavantMember_1294913" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_690" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_690" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_691" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_691_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_690" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_691_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_691" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_713" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_700" use="optional" order="32" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1294931" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1294929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1294931" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1294929" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1294953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1294929" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1294953" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1294954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1294953" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1294954" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1294954_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1294953" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1294954_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1295014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1294954" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1295014" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1294959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1294954" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1294959" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1294950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1294929" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1294950" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1294952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1294950" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1294952" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1294952_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1294950" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1294952_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivPublicWarrantsMember" xlink:label="loc_roiv_RoivPublicWarrantsMember_1294957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1294952" xlink:to="loc_roiv_RoivPublicWarrantsMember_1294957" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivPrivatePlacementWarrantsMember" xlink:label="loc_roiv_RoivPrivatePlacementWarrantsMember_1295022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1294952" xlink:to="loc_roiv_RoivPrivatePlacementWarrantsMember_1295022" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1294948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1294929" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1294948" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1294949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1294948" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1294949" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1294949_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1294948" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1294949_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1294955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1294949" xlink:to="loc_us-gaap_WarrantMember_1294955" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivLiabilityInstrumentsMeasuredAtFairValueMember" xlink:label="loc_roiv_RoivLiabilityInstrumentsMeasuredAtFairValueMember_1295024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1294949" xlink:to="loc_roiv_RoivLiabilityInstrumentsMeasuredAtFairValueMember_1295024" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SumitomoOptionsMember" xlink:label="loc_roiv_SumitomoOptionsMember_1295026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1294949" xlink:to="loc_roiv_SumitomoOptionsMember_1295026" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivEarnoutSharesMember" xlink:label="loc_roiv_RoivEarnoutSharesMember_1294960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1294949" xlink:to="loc_roiv_RoivEarnoutSharesMember_1294960" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_NonfinancialLiabilitiesFairValueDisclosure_1294937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1294931" xlink:to="loc_us-gaap_NonfinancialLiabilitiesFairValueDisclosure_1294937" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_1294934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1294931" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_1294934" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueDisclosuresLineItems" xlink:label="loc_roiv_FairValueDisclosuresLineItems_722" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueDisclosuresTable" xlink:label="loc_roiv_FairValueDisclosuresTable_723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_roiv_FairValueDisclosuresLineItems_722" xlink:to="loc_roiv_FairValueDisclosuresTable_723" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_dei_LegalEntityAxis_724" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_724" xlink:to="loc_dei_EntityDomain_721" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_721_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_724" xlink:to="loc_dei_EntityDomain_721_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_srt_RangeAxis_727" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_727" xlink:to="loc_srt_RangeMember_728" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_728_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_727" xlink:to="loc_srt_RangeMember_728_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_728" xlink:to="loc_srt_MaximumMember_738" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_728" xlink:to="loc_srt_MinimumMember_737" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_725" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_725" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_726" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_726_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_725" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_726_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_726" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_736" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_719" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_719" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_720" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_720_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_719" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_720_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValueMember" xlink:label="loc_roiv_LiabilityInstrumentsMeasuredAtFairValueMember_729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_720" xlink:to="loc_roiv_LiabilityInstrumentsMeasuredAtFairValueMember_729" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1295125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1295125" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1295126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1295125" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1295126" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1295126_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1295125" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1295126_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="loc_roiv_PrivatePlacementWarrantsMember_1295127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1295126" xlink:to="loc_roiv_PrivatePlacementWarrantsMember_1295127" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1295121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1295121" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1295123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1295121" xlink:to="loc_us-gaap_EquityComponentDomain_1295123" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1295123_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1295121" xlink:to="loc_us-gaap_EquityComponentDomain_1295123_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EarnoutSharesMember" xlink:label="loc_roiv_EarnoutSharesMember_1295122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1295123" xlink:to="loc_roiv_EarnoutSharesMember_1295122" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_FairValueDisclosuresLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_734" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EquityInterestOptionToThirdPartyPurchase" xlink:label="loc_roiv_EquityInterestOptionToThirdPartyPurchase_1106618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_FairValueDisclosuresLineItems_722" xlink:to="loc_roiv_EquityInterestOptionToThirdPartyPurchase_1106618" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_1295124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_FairValueDisclosuresLineItems_722" xlink:to="loc_us-gaap_DerivativeLiabilities_1295124" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_1295119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_FairValueDisclosuresLineItems_722" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_1295119" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_763" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_767" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_768" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1096967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1096967" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" xlink:label="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary_1096985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary_1096985" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_us-gaap_StatementTable_764" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_764" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_760" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_760" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_761" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_761_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_760" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_761_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_761" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_766" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_764" xlink:to="loc_dei_LegalEntityAxis_762" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_762" xlink:to="loc_dei_EntityDomain_759" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_759_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_762" xlink:to="loc_dei_EntityDomain_759_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_1291490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_1291490" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne" xlink:label="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne_1476403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne_1476403" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsScheduleOfChangeInFairValueOfTheLevel3AssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1295047" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1295045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1295047" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1295045" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1295052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1295045" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1295052" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1295053" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1295052" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1295053" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1295053_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1295052" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1295053_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1295054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1295053" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1295054" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_1295048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1295047" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_1295048" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment" xlink:label="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment_1295049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1295047" xlink:to="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment_1295049" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_1295050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1295047" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_1295050" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1295075" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueAssetMeasurementInput" xlink:label="loc_roiv_FairValueAssetMeasurementInput_1295095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1295075" xlink:to="loc_roiv_FairValueAssetMeasurementInput_1295095" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_1295103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1295075" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_1295103" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1295073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1295075" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1295073" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1295092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1295073" xlink:to="loc_dei_LegalEntityAxis_1295092" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1295093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1295092" xlink:to="loc_dei_EntityDomain_1295093" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1295093_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1295092" xlink:to="loc_dei_EntityDomain_1295093_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DatavantMember" xlink:label="loc_roiv_DatavantMember_1295094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1295093" xlink:to="loc_roiv_DatavantMember_1295094" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1295076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1295073" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1295076" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1295078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1295076" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1295078" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1295078_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1295076" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1295078_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1295104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1295078" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1295104" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_1295105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1295078" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_1295105" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_1295080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1295078" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_1295080" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1295088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1295073" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1295088" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1295089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1295088" xlink:to="loc_us-gaap_EquityComponentDomain_1295089" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1295089_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1295088" xlink:to="loc_us-gaap_EquityComponentDomain_1295089_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EarnoutSharesMember" xlink:label="loc_roiv_EarnoutSharesMember_1295091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1295089" xlink:to="loc_roiv_EarnoutSharesMember_1295091" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1295082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1295073" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1295082" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1295083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1295082" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1295083" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1295083_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1295082" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1295083_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="loc_roiv_PrivatePlacementWarrantsMember_1295084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1295083" xlink:to="loc_roiv_PrivatePlacementWarrantsMember_1295084" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1443" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_1450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1443" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_1450" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AlternativeInvestmentExpectedTerm" xlink:label="loc_roiv_AlternativeInvestmentExpectedTerm_1449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1443" xlink:to="loc_roiv_AlternativeInvestmentExpectedTerm_1449" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1443" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1444" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1444" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1445" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1445" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1446" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1446_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1445" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1446_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_1453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1446" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_1453" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1446" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1452" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_1451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1446" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_1451" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1444" xlink:to="loc_srt_RangeAxis_1447" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1447" xlink:to="loc_srt_RangeMember_1448" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1448_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1447" xlink:to="loc_srt_RangeMember_1448_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1448" xlink:to="loc_srt_MinimumMember_1454" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1448" xlink:to="loc_srt_MaximumMember_1455" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1514284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1444" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1514284" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1514285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1514284" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1514285" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1514285_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1514284" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1514285_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SumitomoOptionsMember" xlink:label="loc_roiv_SumitomoOptionsMember_1514286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1514285" xlink:to="loc_roiv_SumitomoOptionsMember_1514286" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1294718" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1294670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1294718" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1294670" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1294672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1294670" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1294672" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1294672" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1294672" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_NovemberTwoThousandAndTwentyOneCvarsMember" xlink:label="loc_roiv_NovemberTwoThousandAndTwentyOneCvarsMember_1294693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" xlink:to="loc_roiv_NovemberTwoThousandAndTwentyOneCvarsMember_1294693" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockOptionsAndPerformanceStockOptionsMember" xlink:label="loc_roiv_StockOptionsAndPerformanceStockOptionsMember_1294679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" xlink:to="loc_roiv_StockOptionsAndPerformanceStockOptionsMember_1294679" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:label="loc_roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember_1294681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" xlink:to="loc_roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember_1294681" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TwoThousandAndTwentyCvarsMember" xlink:label="loc_roiv_TwoThousandAndTwentyCvarsMember_1294690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" xlink:to="loc_roiv_TwoThousandAndTwentyCvarsMember_1294690" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1294697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1294697" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EarnOutSharesNonvestedMember" xlink:label="loc_roiv_EarnOutSharesNonvestedMember_1294708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" xlink:to="loc_roiv_EarnOutSharesNonvestedMember_1294708" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="loc_roiv_PrivatePlacementWarrantsMember_1294710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" xlink:to="loc_roiv_PrivatePlacementWarrantsMember_1294710" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PublicWarrantsMember" xlink:label="loc_roiv_PublicWarrantsMember_1294711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" xlink:to="loc_roiv_PublicWarrantsMember_1294711" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OtherInstrumentsIssuedMember" xlink:label="loc_roiv_OtherInstrumentsIssuedMember_1294714" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" xlink:to="loc_roiv_OtherInstrumentsIssuedMember_1294714" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1294720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1294718" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1294720" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SubsequentEventsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1493" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_us-gaap_StatementTable_1494" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1486" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1486" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1485" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1485_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1486" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1485_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_1491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_srt_RestatementAxis_1491" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_1491" xlink:to="loc_srt_RestatementDomain_1492" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1492_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_1491" xlink:to="loc_srt_RestatementDomain_1492_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1490" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1489" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1490" xlink:to="loc_us-gaap_RelatedPartyDomain_1489" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1489_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1490" xlink:to="loc_us-gaap_RelatedPartyDomain_1489_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_DebtInstrumentAxis_1487" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1487" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1488" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1488_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1487" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1488_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1497" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1497" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1484" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1484_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1497" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1484_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1495" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1495" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1496" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1496_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1495" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1496_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1496" xlink:to="loc_us-gaap_SubsequentEventMember_1513" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1294964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1294964" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1294966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1294964" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1294966" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1294966_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1294964" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1294966_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1475389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1475389" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1475391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1475389" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1475391" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1475391_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1475389" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1475391_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivrevenueInterestPurchaseAndSaleAgreementMemberMember" xlink:label="loc_roiv_RoivrevenueInterestPurchaseAndSaleAgreementMemberMember_1475394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1475391" xlink:to="loc_roiv_RoivrevenueInterestPurchaseAndSaleAgreementMemberMember_1475394" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_1475410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_srt_CounterpartyNameAxis_1475410" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1475411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1475410" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1475411" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1475411_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1475410" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1475411_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GSKMember" xlink:label="loc_roiv_GSKMember_1475412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1475411" xlink:to="loc_roiv_GSKMember_1475412" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_WelichemBiotechIncMember" xlink:label="loc_roiv_WelichemBiotechIncMember_1475416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1475411" xlink:to="loc_roiv_WelichemBiotechIncMember_1475416" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaap_TransactionTypeAxis_1475413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_TransactionTypeAxis_1475413" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_1475414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TransactionTypeAxis_1475413" xlink:to="loc_us-gaap_TransactionDomain_1475414" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_1475414_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TransactionTypeAxis_1475413" xlink:to="loc_us-gaap_TransactionDomain_1475414_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RegulatoryMilestoneMember" xlink:label="loc_roiv_RegulatoryMilestoneMember_1475415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransactionDomain_1475414" xlink:to="loc_roiv_RegulatoryMilestoneMember_1475415" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MilestonePaymentPeriod" xlink:label="loc_roiv_MilestonePaymentPeriod_1475388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_roiv_MilestonePaymentPeriod_1475388" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MilestonePaymentPayable" xlink:label="loc_roiv_MilestonePaymentPayable_1475405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_roiv_MilestonePaymentPayable_1475405" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement" xlink:label="loc_roiv_GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement_1510956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_roiv_GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement_1510956" use="optional" order="39" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>roiv-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 28-June-2022 [03:58:35] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2" xml:lang="en-US">Entity Address, Address Line Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry" xml:lang="en-US">Entity Address, Country</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_dei_CountryRegion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CountryRegion" xml:lang="en-US">Country Region</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CountryRegion" xlink:to="lab_dei_CountryRegion" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport" xml:lang="en-US">Document Annual Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorName" xml:lang="en-US">Auditor Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorFirmId" xml:lang="en-US">Auditor Firm ID</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorLocation" xml:lang="en-US">Auditor Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted Cash, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermInvestments" xml:lang="en-US">Long-term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermInvestments" xml:lang="en-US">Long-term investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermInvestments" xml:lang="en-US">Carrying value of long-term investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Investments, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Investments measured at fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Aggregate fair value investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted Cash, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted cash, net of current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities, Redeemable Noncontrolling Interest and Shareholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating lease liabilities, noncurrent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Total accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredConsiderationLiabilityCurrent" xlink:label="loc_roiv_DeferredConsiderationLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DeferredConsiderationLiabilityCurrent" xml:lang="en-US">Deferred Consideration Liability Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DeferredConsiderationLiabilityCurrent" xml:lang="en-US">Deferred consideration liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DeferredConsiderationLiabilityCurrent" xlink:to="lab_roiv_DeferredConsiderationLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DeferredConsiderationLiabilityCurrent" xml:lang="en-US">Deferred consideration liability current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred Revenue, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Long-term debt (includes $177,400 and $150,100 accounted for under the fair value option at March 31, 2022 and 2021, respectively)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Total long term debt, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Noncontrolling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Shareholders' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 694,975,965 and 651,576,293 shares issued and outstanding at March 31, 2022 and 2021, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SubscriptionsReceivable" xlink:label="loc_roiv_SubscriptionsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SubscriptionsReceivable" xml:lang="en-US">Subscriptions Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SubscriptionsReceivable" xml:lang="en-US">Subscription receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SubscriptionsReceivable" xlink:to="lab_roiv_SubscriptionsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SubscriptionsReceivable" xml:lang="en-US">Subscriptions receivable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Shareholders' equity attributable to Roivant Sciences Ltd.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total shareholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValue" xlink:label="loc_roiv_LiabilityInstrumentsMeasuredAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_LiabilityInstrumentsMeasuredAtFairValue" xml:lang="en-US">Liability Instruments Measured At Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_LiabilityInstrumentsMeasuredAtFairValue" xml:lang="en-US">Liability instruments measured at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_LiabilityInstrumentsMeasuredAtFairValue" xlink:to="lab_roiv_LiabilityInstrumentsMeasuredAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_LiabilityInstrumentsMeasuredAtFairValue" xml:lang="en-US">Liability instruments measured at fair value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 13)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities, redeemable noncontrolling interest and shareholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xml:lang="en-US">Redeemable noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtFairValue" xml:lang="en-US">Long-term Debt, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtFairValue" xml:lang="en-US">Long term debt accounted under fair value option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par or stated value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss attributable to Roivant Sciences Ltd.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net loss attributable to noncontrolling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OperatingCosts" xlink:label="loc_roiv_OperatingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_OperatingCosts" xml:lang="en-US">Operating Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_OperatingCosts" xml:lang="en-US">Cost of revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_OperatingCosts" xlink:to="lab_roiv_OperatingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_OperatingCosts" xml:lang="en-US">Operating costs.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AcquiredInProcessResearchAndDevelopmentExpense" xlink:label="loc_roiv_AcquiredInProcessResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AcquiredInProcessResearchAndDevelopmentExpense" xml:lang="en-US">Acquired In Process Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_AcquiredInProcessResearchAndDevelopmentExpense" xml:lang="en-US">Acquired in-process research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_roiv_AcquiredInProcessResearchAndDevelopmentExpense" xml:lang="en-US">Acquired in process research and development expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AcquiredInProcessResearchAndDevelopmentExpense" xlink:to="lab_roiv_AcquiredInProcessResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AcquiredInProcessResearchAndDevelopmentExpense" xml:lang="en-US">Acquired in process research and development expense.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Basic and diluted net (loss) income per common share:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share&#8212;basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xml:lang="en-US">Basic and diluted weighted average shares outstanding:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average shares outstanding&#8212;basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax provision</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other expense, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xml:lang="en-US">Gain Loss on Fair Value of Debt and Liability Instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xml:lang="en-US">Change in fair value of debt and liability instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:to="lab_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xml:lang="en-US">Gain Loss on Fair Value of Debt and Liability Instruments</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnInvestments" xml:lang="en-US">Gain (Loss) on Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnInvestments" xml:lang="en-US">Change in fair value of investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainLossOnInvestments" xml:lang="en-US">Gain (loss) on remeasurement of investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" xlink:label="loc_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" xml:lang="en-US">Deconsolidation and Consolidation on Gain or Loss of Consolidated Entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" xml:lang="en-US">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" xlink:to="lab_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" xml:lang="en-US">Deconsolidation and consolidation on gain or loss of consolidated entity.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xlink:label="loc_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xml:lang="en-US">Equity Interest Option to Third Party Purchaser Gain on Termination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xml:lang="en-US">Gain on termination of Sumitomo Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xml:lang="en-US">Gain on termination of Sumitomo Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xlink:to="lab_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xml:lang="en-US">Equity interest option to third party purchaser gain on termination.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="loc_us-gaap_GainOnSaleOfInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainOnSaleOfInvestments" xml:lang="en-US">Gain on Sale of Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainOnSaleOfInvestments" xml:lang="en-US">Gain on sale of investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainOnSaleOfInvestments" xlink:to="lab_us-gaap_GainOnSaleOfInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">G&amp;A Expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">R&amp;D Expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive loss attributable to Roivant Sciences Ltd.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xml:lang="en-US">Other comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Total other comprehensive (loss) income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xml:lang="en-US">Foreign currency translation adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive loss attributable to noncontrolling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfPartnersCapitalAbstract" xlink:label="loc_us-gaap_StatementOfPartnersCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfPartnersCapitalAbstract" xml:lang="en-US">Statement of Partners' Capital [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfPartnersCapitalAbstract" xlink:to="lab_us-gaap_StatementOfPartnersCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ConsolidationOfUnconsolidatedEntity" xlink:label="loc_roiv_ConsolidationOfUnconsolidatedEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ConsolidationOfUnconsolidatedEntity" xml:lang="en-US">Consolidation of Unconsolidated Entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ConsolidationOfUnconsolidatedEntity" xml:lang="en-US">Consolidation of unconsolidated entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ConsolidationOfUnconsolidatedEntity" xlink:to="lab_roiv_ConsolidationOfUnconsolidatedEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ConsolidationOfUnconsolidatedEntity" xml:lang="en-US">Consolidation of Unconsolidated Entity</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeconsolidationOfSubsidiary" xlink:label="loc_roiv_DeconsolidationOfSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DeconsolidationOfSubsidiary" xml:lang="en-US">Deconsolidation Of Subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DeconsolidationOfSubsidiary" xml:lang="en-US">Deconsolidation of subsidiary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DeconsolidationOfSubsidiary" xlink:to="lab_roiv_DeconsolidationOfSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DeconsolidationOfSubsidiary" xml:lang="en-US">Deconsolidation Of Subsidiary</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CapitalContributionsToSubsidiaries" xlink:label="loc_roiv_CapitalContributionsToSubsidiaries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CapitalContributionsToSubsidiaries" xml:lang="en-US">Capital Contributions To Subsidiaries</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_CapitalContributionsToSubsidiaries" xml:lang="en-US">Cash contribution to majority-owned subsidiaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CapitalContributionsToSubsidiaries" xlink:to="lab_roiv_CapitalContributionsToSubsidiaries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_CapitalContributionsToSubsidiaries" xml:lang="en-US">Capital Contributions To Subsidiaries</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IssuanceOfSubsidiaryCommonSharesNetValue" xlink:label="loc_roiv_IssuanceOfSubsidiaryCommonSharesNetValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IssuanceOfSubsidiaryCommonSharesNetValue" xml:lang="en-US">Issuance of Subsidiary Common Shares Net Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IssuanceOfSubsidiaryCommonSharesNetValue" xml:lang="en-US">Issuance of subsidiary common shares, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IssuanceOfSubsidiaryCommonSharesNetValue" xlink:to="lab_roiv_IssuanceOfSubsidiaryCommonSharesNetValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IssuanceOfSubsidiaryCommonSharesNetValue" xml:lang="en-US">Issuance of Subsidiary Common Shares Net Value</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" xlink:label="loc_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" xml:lang="en-US">Issuance of Subsidiary Common Shares to the Company Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" xml:lang="en-US">Issuance of subsidiary common shares to the Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" xlink:to="lab_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" xml:lang="en-US">Issuance of Subsidiary Common Shares to the Company Value</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" xlink:label="loc_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" xml:lang="en-US">Exercise of Subsidiary Stock Options and Vesting of Subsidiary Restricted Stock Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" xml:lang="en-US">Exercise of subsidiary stock options and vesting of subsidiary restricted stock units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" xlink:to="lab_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" xml:lang="en-US">Exercise of Subsidiary Stock Options and Vesting of Subsidiary Restricted Stock Units</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IssuanceOfSubsidiaryWarrants" xlink:label="loc_roiv_IssuanceOfSubsidiaryWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IssuanceOfSubsidiaryWarrants" xml:lang="en-US">Issuance of Subsidiary Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IssuanceOfSubsidiaryWarrants" xml:lang="en-US">Issuance of subsidiary warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IssuanceOfSubsidiaryWarrants" xlink:to="lab_roiv_IssuanceOfSubsidiaryWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IssuanceOfSubsidiaryWarrants" xml:lang="en-US">Issuance of Subsidiary Warrants</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xml:lang="en-US">Foreign currency translation adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of the Company's common shares, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Public offering shares of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of the Company's common shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock issued, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RepurchaseOfEquityAwards" xlink:label="loc_roiv_RepurchaseOfEquityAwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RepurchaseOfEquityAwards" xml:lang="en-US">Repurchase of Equity Awards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_RepurchaseOfEquityAwards" xml:lang="en-US">Repurchase of equity awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RepurchaseOfEquityAwards" xlink:to="lab_roiv_RepurchaseOfEquityAwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RepurchaseOfEquityAwards" xml:lang="en-US">Repurchase of Equity Awards</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Exercise of subsidiary stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xml:lang="en-US">Balance, temporary equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xml:lang="en-US">Balance, temporary equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" xlink:label="loc_roiv_StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" xml:lang="en-US">Stock Issued During Period Shares Common Shares Upon Closing Of Business Combination And Pipe Financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" xml:lang="en-US">Issuance of the Company's common shares upon closing of Business Combination and PIPE Financing, net of issuance costs (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" xlink:to="lab_roiv_StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" xml:lang="en-US">Stock issued during period shares common shares upon closing of business combination and pipe financing.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:label="loc_roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" xml:lang="en-US">Stock Issued During Period Shares Common Shares Related To Settlement Of Transaction Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" xml:lang="en-US">Issuance of the Company's common shares related to settlement of transaction consideration (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:to="lab_roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" xml:lang="en-US">Stock issued during period shares common shares related to settlement of transaction consideration.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" xlink:label="loc_roiv_StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" xml:lang="en-US">Stock Issued During Period Value Common Shares Upon Closing Of Business Combination And Pipe Financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" xml:lang="en-US">Issuance of the Company's common shares upon closing of Business Combination and PIPE Financing, net of issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" xlink:to="lab_roiv_StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" xml:lang="en-US">Stock issued during period value common shares upon closing of business combination and pipe financing.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodValueSubsidiaryPreferredShares" xlink:label="loc_roiv_StockIssuedDuringPeriodValueSubsidiaryPreferredShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_StockIssuedDuringPeriodValueSubsidiaryPreferredShares" xml:lang="en-US">Stock Issued During Period Value Subsidiary Preferred Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_StockIssuedDuringPeriodValueSubsidiaryPreferredShares" xml:lang="en-US">Issuance of subsidiary preferred shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_StockIssuedDuringPeriodValueSubsidiaryPreferredShares" xlink:to="lab_roiv_StockIssuedDuringPeriodValueSubsidiaryPreferredShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_StockIssuedDuringPeriodValueSubsidiaryPreferredShares" xml:lang="en-US">Stock issued during period value subsidiary preferred shares.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany" xlink:label="loc_roiv_StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany" xml:lang="en-US">Stock Issued During Period Value Subsidiary Common And Preferred Shares To The Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany" xml:lang="en-US">Issuance of subsidiary common and preferred shares to the Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany" xlink:to="lab_roiv_StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany" xml:lang="en-US">Stock issued during period value subsidiary common and preferred shares to the company.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent" xlink:label="loc_roiv_AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent" xml:lang="en-US">Adjustments Of Payment Of Subscription Receivable Value Equity Component</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent" xml:lang="en-US">Payment of subscription receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent" xlink:to="lab_roiv_AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent" xml:lang="en-US">Adjustments of payment of subscription receivable value equity component.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IssuanceOfStockUponWarrantsExerciseShares" xlink:label="loc_roiv_IssuanceOfStockUponWarrantsExerciseShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IssuanceOfStockUponWarrantsExerciseShares" xml:lang="en-US">Issuance Of Stock Upon Warrants Exercise Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IssuanceOfStockUponWarrantsExerciseShares" xml:lang="en-US">Issuance of common stock upon warrants exercise, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IssuanceOfStockUponWarrantsExerciseShares" xlink:to="lab_roiv_IssuanceOfStockUponWarrantsExerciseShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IssuanceOfStockUponWarrantsExerciseShares" xml:lang="en-US">Issuance of stock upon warrants exercise shares.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled" xlink:label="loc_roiv_StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled" xml:lang="en-US">Stock Options Exercised And Restricted Stock Units Vested And Settled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled" xml:lang="en-US">Stock options exercised and restricted stock units vested and settled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled" xlink:to="lab_roiv_StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled" xml:lang="en-US">Stock options exercised and restricted stock units vested and settled.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IssuanceOfStockUponWarrantsExerciseValue" xlink:label="loc_roiv_IssuanceOfStockUponWarrantsExerciseValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IssuanceOfStockUponWarrantsExerciseValue" xml:lang="en-US">Issuance Of Stock Upon Warrants Exercise Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IssuanceOfStockUponWarrantsExerciseValue" xml:lang="en-US">Issuance of common stock upon warrants exercise</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IssuanceOfStockUponWarrantsExerciseValue" xlink:to="lab_roiv_IssuanceOfStockUponWarrantsExerciseValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IssuanceOfStockUponWarrantsExerciseValue" xml:lang="en-US">Issuance of stock upon warrants exercise value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Noncontrolling Interest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Noncontrolling Interest [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SubscriptionsReceivablesMember" xlink:label="loc_roiv_SubscriptionsReceivablesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SubscriptionsReceivablesMember" xml:lang="en-US">Subscriptions Receivables [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SubscriptionsReceivablesMember" xml:lang="en-US">Subscriptions Receivables [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SubscriptionsReceivablesMember" xlink:to="lab_roiv_SubscriptionsReceivablesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SubscriptionsReceivablesMember" xml:lang="en-US">Subscriptions Receivables [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RedeemableNoncontrollingInterestMember" xlink:label="loc_roiv_RedeemableNoncontrollingInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RedeemableNoncontrollingInterestMember" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_RedeemableNoncontrollingInterestMember" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RedeemableNoncontrollingInterestMember" xlink:to="lab_roiv_RedeemableNoncontrollingInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RedeemableNoncontrollingInterestMember" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromSubsidiaryDebtFinancingsNet" xlink:label="loc_roiv_ProceedsFromSubsidiaryDebtFinancingsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ProceedsFromSubsidiaryDebtFinancingsNet" xml:lang="en-US">Proceeds from Subsidiary Debt Financings Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ProceedsFromSubsidiaryDebtFinancingsNet" xml:lang="en-US">Proceeds from subsidiary debt financings, net of financing costs paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ProceedsFromSubsidiaryDebtFinancingsNet" xlink:to="lab_roiv_ProceedsFromSubsidiaryDebtFinancingsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ProceedsFromSubsidiaryDebtFinancingsNet" xml:lang="en-US">Proceeds from Subsidiary Debt Financings Net</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:label="loc_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xml:lang="en-US">Proceeds from Issuance of Subsidiary Common Shares Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xml:lang="en-US">Proceeds from issuance of subsidiary common shares, net of issuance costs paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:to="lab_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xml:lang="en-US">Proceeds from Issuance of Subsidiary Common Shares Net</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:label="loc_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xml:lang="en-US">Repayment of Long Term Debt and Convertible Debt by Subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xml:lang="en-US">Repayment of long-term debt by subsidiary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:to="lab_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xml:lang="en-US">Repayment of Long Term Debt and Convertible Debt by Subsidiary</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PaymentForOfferingAndLoanCosts" xlink:label="loc_roiv_PaymentForOfferingAndLoanCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PaymentForOfferingAndLoanCosts" xml:lang="en-US">Payment For Offering And Loan Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_PaymentForOfferingAndLoanCosts" xml:lang="en-US">Payment of offering and loan origination costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PaymentForOfferingAndLoanCosts" xlink:to="lab_roiv_PaymentForOfferingAndLoanCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PaymentForOfferingAndLoanCosts" xml:lang="en-US">Payment for offering and loan costs.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromBusinessCombinationAndPipeFinancing" xlink:label="loc_roiv_ProceedsFromBusinessCombinationAndPipeFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ProceedsFromBusinessCombinationAndPipeFinancing" xml:lang="en-US">Proceeds From Business Combination And Pipe Financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ProceedsFromBusinessCombinationAndPipeFinancing" xml:lang="en-US">Proceeds from business combination and PIPE financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ProceedsFromBusinessCombinationAndPipeFinancing" xlink:to="lab_roiv_ProceedsFromBusinessCombinationAndPipeFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ProceedsFromBusinessCombinationAndPipeFinancing" xml:lang="en-US">Proceeds from business combination and PIPE financing.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromPaymentOfSubscriptionReceivable" xlink:label="loc_roiv_ProceedsFromPaymentOfSubscriptionReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ProceedsFromPaymentOfSubscriptionReceivable" xml:lang="en-US">Proceeds From Payment Of Subscription Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ProceedsFromPaymentOfSubscriptionReceivable" xml:lang="en-US">Proceeds from payment of subscription receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ProceedsFromPaymentOfSubscriptionReceivable" xlink:to="lab_roiv_ProceedsFromPaymentOfSubscriptionReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ProceedsFromPaymentOfSubscriptionReceivable" xml:lang="en-US">Proceeds from payment of subscription receivable.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromAndPaymentForOtherFinancingActivities" xlink:label="loc_roiv_ProceedsFromAndPaymentForOtherFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ProceedsFromAndPaymentForOtherFinancingActivities" xml:lang="en-US">Proceeds From And Payment For Other Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_ProceedsFromAndPaymentForOtherFinancingActivities" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ProceedsFromAndPaymentForOtherFinancingActivities" xlink:to="lab_roiv_ProceedsFromAndPaymentForOtherFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ProceedsFromAndPaymentForOtherFinancingActivities" xml:lang="en-US">Proceeds from and payment for other financing activities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Non-cash investing and financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OtherNonCashTransactions" xlink:label="loc_roiv_OtherNonCashTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_OtherNonCashTransactions" xml:lang="en-US">Other Non Cash Transactions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_OtherNonCashTransactions" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_OtherNonCashTransactions" xlink:to="lab_roiv_OtherNonCashTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_OtherNonCashTransactions" xml:lang="en-US">Other Non Cash Transactions</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosure of cash paid:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xml:lang="en-US">Income Taxes Paid, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xml:lang="en-US">Income taxes paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" xlink:label="loc_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" xml:lang="en-US">Subscription Receivable Related To Issuance Of Subsidiary Common Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" xml:lang="en-US">Subscription receivable related to issuance of subsidiary common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" xlink:to="lab_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" xml:lang="en-US">Subscription Receivable Related To Issuance Of Subsidiary Common Shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash (used in) provided by investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xml:lang="en-US">Proceeds from sale of investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncreaseDecreaseInOtherInvestingNet" xlink:label="loc_roiv_IncreaseDecreaseInOtherInvestingNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IncreaseDecreaseInOtherInvestingNet" xml:lang="en-US">Increase Decrease In Other Investing Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_IncreaseDecreaseInOtherInvestingNet" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IncreaseDecreaseInOtherInvestingNet" xlink:to="lab_roiv_IncreaseDecreaseInOtherInvestingNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IncreaseDecreaseInOtherInvestingNet" xml:lang="en-US">Increase decrease in other investing net.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in assets and liabilities, net of effects from acquisition and divestiture:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" xml:lang="en-US">Increase (Decrease) in Deferred Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" xml:lang="en-US">Deferred consideration liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_roiv_IncreaseDecreaseInOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IncreaseDecreaseInOperatingLeaseLiabilities" xml:lang="en-US">Increase Decrease In Operating Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IncreaseDecreaseInOperatingLeaseLiabilities" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_roiv_IncreaseDecreaseInOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IncreaseDecreaseInOperatingLeaseLiabilities" xml:lang="en-US">Increase decrease in operating lease liabilities</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net (loss) income to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Loss from equity method investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xml:lang="en-US">Other Noncash Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GainOnTerminationOfEquityInterestOptions" xlink:label="loc_roiv_GainOnTerminationOfEquityInterestOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_GainOnTerminationOfEquityInterestOptions" xml:lang="en-US">Gain On Termination Of Equity Interest Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_GainOnTerminationOfEquityInterestOptions" xml:lang="en-US">Gain on termination of Sumitomo Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_GainOnTerminationOfEquityInterestOptions" xlink:to="lab_roiv_GainOnTerminationOfEquityInterestOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_GainOnTerminationOfEquityInterestOptions" xml:lang="en-US">Gain on termination of equity interest options.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity" xlink:label="loc_roiv_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity" xml:lang="en-US">Gain On Deconsolidation Of Subsidiary And Consolidation Of Unconsolidated Entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity" xml:lang="en-US">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity" xlink:to="lab_roiv_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity" xml:lang="en-US">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_NonCashAcquiredInProcessResearchAndDevelopment" xlink:label="loc_roiv_NonCashAcquiredInProcessResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_NonCashAcquiredInProcessResearchAndDevelopment" xml:lang="en-US">Non Cash Acquired in Process Research and Development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_NonCashAcquiredInProcessResearchAndDevelopment" xlink:to="lab_roiv_NonCashAcquiredInProcessResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_NonCashAcquiredInProcessResearchAndDevelopment" xml:lang="en-US">Non cash portion of acquired in process research and development.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Description of Business and Liquidity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xml:lang="en-US">Business Combination Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xml:lang="en-US">Business Combination with MAAC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xml:lang="en-US">Investments, All Other Investments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:label="loc_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xml:lang="en-US">Investments and Other Noncurrent Assets [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xml:lang="en-US">Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:to="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xml:lang="en-US">Business Combinations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" xlink:label="loc_roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" xml:lang="en-US">Asset Acquisitions and License Agreements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" xml:lang="en-US">Asset Acquisitions and License Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" xlink:to="lab_roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" xml:lang="en-US">Asset acquisitions and license agreements disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xml:lang="en-US">Accrued Liabilities and Other Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xml:lang="en-US">Long-term Debt [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xml:lang="en-US">Long-Term Debt and Loan Commitment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Shareholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments &amp; Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivantSciencesLtd.Member" xlink:label="loc_roiv_RoivantSciencesLtd.Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RoivantSciencesLtd.Member" xml:lang="en-US">Roivant Sciences Ltd. [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_RoivantSciencesLtd.Member" xml:lang="en-US">Roivant Sciences Ltd. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RoivantSciencesLtd.Member" xlink:to="lab_roiv_RoivantSciencesLtd.Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xml:lang="en-US">Other Expense, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xml:lang="en-US">Other Expense, Net [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:label="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xml:lang="en-US">Other Operating Income and Expense [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xml:lang="en-US">Other Expense, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:to="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Net Loss per Common Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash, Cash Equivalents, and Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xml:lang="en-US">Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentrations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xml:lang="en-US">Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock" xml:lang="en-US">General and Administrative Expenses [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock" xml:lang="en-US">General and Administrative Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock" xml:lang="en-US">General and Administrative Expenses, Policy [Text Block]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_WarrantliabilitiesPolicyTextBlock" xlink:label="loc_roiv_WarrantliabilitiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_WarrantliabilitiesPolicyTextBlock" xml:lang="en-US">WarrantLiabilities [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_WarrantliabilitiesPolicyTextBlock" xml:lang="en-US">Warrant Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_WarrantliabilitiesPolicyTextBlock" xlink:to="lab_roiv_WarrantliabilitiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_WarrantliabilitiesPolicyTextBlock" xml:lang="en-US">Warrant liabilities .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xml:lang="en-US">Acquired&#160;In-Process&#160;Research and Development Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="loc_roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xml:lang="en-US">Schedule Of Property Plant And Equipment Estimated Useful Lives [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xml:lang="en-US">Schedule of Estimated Useful Lives Used for Asset Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="lab_roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xml:lang="en-US">Schedule Of Property Plant And Equipment Estimated Useful Lives.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Schedule of Aggregate Amounts of Cash, Cash Equivalents, and Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US">Schedule of Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US">Schedule of Long Term Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xml:lang="en-US">Schedule of Company's Annual Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Fair Value Assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock" xlink:label="loc_roiv_ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock" xml:lang="en-US">Schedule Of Share based Payment Arrangement Fair Value Of Vested Stock Option And Performance Option [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock" xml:lang="en-US">Summary of Fair Value of Vested Stock Option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock" xlink:to="lab_roiv_ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock" xml:lang="en-US">Schedule&#8203; Of Share based &#8203;Payment &#8203;Arrangement&#8203; Fair&#8203; Value&#8203; Of Vested &#8203;Stock &#8203;Option &#8203;And Performance Option</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Summary of Restricted Stock Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of Stock Option Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Summary of Share-Based Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock" xlink:label="loc_roiv_ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock" xml:lang="en-US">Schedule Of Capped Value Appreciation Rights Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock" xml:lang="en-US">Summary of Capped Value Appreciation Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock" xlink:to="lab_roiv_ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock" xml:lang="en-US">Schedule of Capped Value Appreciation Rights Activity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CappedValueAppreciationRightsMember" xlink:label="loc_roiv_CappedValueAppreciationRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CappedValueAppreciationRightsMember" xml:lang="en-US">Capped Value Appreciation Rights [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_CappedValueAppreciationRightsMember" xml:lang="en-US">CVARs [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CappedValueAppreciationRightsMember" xlink:to="lab_roiv_CappedValueAppreciationRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_CappedValueAppreciationRightsMember" xml:lang="en-US">Capped Value Appreciation Rights [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_TwoThousandFifteenEquityIncentivePlanMember" xml:lang="en-US">Two Thousand Fifteen Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_TwoThousandFifteenEquityIncentivePlanMember" xml:lang="en-US">2015 EIP [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember" xlink:to="lab_roiv_TwoThousandFifteenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_TwoThousandFifteenEquityIncentivePlanMember" xml:lang="en-US">Two Thousand Fifteen Equity Incentive Plan [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandTwentyOneEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_TwoThousandTwentyOneEquityIncentivePlanMember" xml:lang="en-US">Two Thousand Twenty One Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_TwoThousandTwentyOneEquityIncentivePlanMember" xml:lang="en-US">2021 EIP [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:to="lab_roiv_TwoThousandTwentyOneEquityIncentivePlanMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Reconciliation of Federal Statutory Income Taxes Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Company's net deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Loss Before Income Taxes and Related Expense/(Benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xml:lang="en-US">Leases of Lessee Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xml:lang="en-US">Summary of Operating Lease ROU Assets and Operating Lease Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Schedule of Operating Lease Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DatavantMember" xlink:label="loc_roiv_DatavantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DatavantMember" xml:lang="en-US">Datavant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DatavantMember" xml:lang="en-US">Datavant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_roiv_DatavantMember" xml:lang="en-US">Datavant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DatavantMember" xlink:to="lab_roiv_DatavantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DatavantMember" xml:lang="en-US">Datavant [Member].</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SumitomoOptionsMember" xlink:label="loc_roiv_SumitomoOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SumitomoOptionsMember" xml:lang="en-US">Sumitomo Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SumitomoOptionsMember" xml:lang="en-US">Sumitomo Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SumitomoOptionsMember" xlink:to="lab_roiv_SumitomoOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SumitomoOptionsMember" xml:lang="en-US">Sumitomo options.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Schedule of Fair Value of Significant Unobservable Inputs Using Valuation Techniques</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Schedule of change in the fair value of the derivative warrant liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Schedule of Change IN Fair Value Of The Level 3 Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EarnoutSharesMember" xlink:label="loc_roiv_EarnoutSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_EarnoutSharesMember" xml:lang="en-US">Earnout Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_roiv_EarnoutSharesMember" xml:lang="en-US">Earnout Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_EarnoutSharesMember" xml:lang="en-US">Earnout Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_EarnoutSharesMember" xlink:to="lab_roiv_EarnoutSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_EarnoutSharesMember" xml:lang="en-US">Earnout shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="loc_roiv_PrivatePlacementWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PrivatePlacementWarrantsMember" xml:lang="en-US">Private Placement Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PrivatePlacementWarrantsMember" xml:lang="en-US">Private Placement Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_roiv_PrivatePlacementWarrantsMember" xml:lang="en-US">Private Placement Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_roiv_PrivatePlacementWarrantsMember" xml:lang="en-US">Private Placement Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PrivatePlacementWarrantsMember" xlink:to="lab_roiv_PrivatePlacementWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PrivatePlacementWarrantsMember" xml:lang="en-US">Private Placement Warrants [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xml:lang="en-US">Schedule of Other Operating Cost and Expense, by Component [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xml:lang="en-US">Summary of Other Expense, Net From Continuing Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Summary of potentially dilutive securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of Operating Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of operating and reporting segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ScheduleOfAccountingPoliciesTable" xlink:label="loc_roiv_ScheduleOfAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ScheduleOfAccountingPoliciesTable" xml:lang="en-US">Schedule Of Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ScheduleOfAccountingPoliciesTable" xml:lang="en-US">Schedule Of Accounting Policies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesTable" xlink:to="lab_roiv_ScheduleOfAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ScheduleOfAccountingPoliciesTable" xml:lang="en-US">Schedule Of Accounting Policies [Table]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ScheduleOfAccountingPoliciesLineItems" xlink:label="loc_roiv_ScheduleOfAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ScheduleOfAccountingPoliciesLineItems" xml:lang="en-US">Schedule Of Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ScheduleOfAccountingPoliciesLineItems" xml:lang="en-US">Schedule Of Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesLineItems" xlink:to="lab_roiv_ScheduleOfAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ScheduleOfAccountingPoliciesLineItems" xml:lang="en-US">Schedule Of Accounting Policies [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaap_EscrowDeposit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EscrowDeposit" xml:lang="en-US">Escrow Deposit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EscrowDeposit" xml:lang="en-US">Escrowed deposit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EscrowDeposit" xlink:to="lab_us-gaap_EscrowDeposit" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromReleaseOfEscrowDeposit" xlink:label="loc_roiv_ProceedsFromReleaseOfEscrowDeposit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ProceedsFromReleaseOfEscrowDeposit" xml:lang="en-US">Proceeds from Release of Escrow Deposit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ProceedsFromReleaseOfEscrowDeposit" xml:lang="en-US">Proceeds from release of escrow deposit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ProceedsFromReleaseOfEscrowDeposit" xlink:to="lab_roiv_ProceedsFromReleaseOfEscrowDeposit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ProceedsFromReleaseOfEscrowDeposit" xml:lang="en-US">Proceeds from Release of Escrow Deposit.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CashPaidToSettleDeferredConsiderationLiability" xlink:label="loc_roiv_CashPaidToSettleDeferredConsiderationLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CashPaidToSettleDeferredConsiderationLiability" xml:lang="en-US">Cash Paid To Settle Deferred Consideration Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_CashPaidToSettleDeferredConsiderationLiability" xml:lang="en-US">Cash paid to settle deferred consideration liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CashPaidToSettleDeferredConsiderationLiability" xlink:to="lab_roiv_CashPaidToSettleDeferredConsiderationLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_CashPaidToSettleDeferredConsiderationLiability" xml:lang="en-US">Cash paid to settle deferred consideration liability.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability" xlink:label="loc_roiv_StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability" xml:lang="en-US">Stock Issued During Period Shares To Settle Deferred Consideration Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability" xml:lang="en-US">Stock issued during period shares to settle deferred consideration liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability" xlink:to="lab_roiv_StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability" xml:lang="en-US">Stock issued during period Shares To settle deferred consideration liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CashAndCashEquivalentsAndRestrictedCash" xlink:label="loc_roiv_CashAndCashEquivalentsAndRestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CashAndCashEquivalentsAndRestrictedCash" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_roiv_CashAndCashEquivalentsAndRestrictedCash" xml:lang="en-US">Cash, cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CashAndCashEquivalentsAndRestrictedCash" xlink:to="lab_roiv_CashAndCashEquivalentsAndRestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_CashAndCashEquivalentsAndRestrictedCash" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xml:lang="en-US">Software Development [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xml:lang="en-US">Software [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LaboratoryandotherequipmentMember" xlink:label="loc_roiv_LaboratoryandotherequipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_LaboratoryandotherequipmentMember" xml:lang="en-US">Laboratoryandotherequipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_LaboratoryandotherequipmentMember" xml:lang="en-US">Laboratory&#160;and&#160;other&#160;equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_LaboratoryandotherequipmentMember" xlink:to="lab_roiv_LaboratoryandotherequipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_LaboratoryandotherequipmentMember" xml:lang="en-US">Laboratory&#160;and&#160;other&#160;equipment</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Estimated useful lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Estimated useful lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BusinesscombinationwithmaacTable" xlink:label="loc_roiv_BusinesscombinationwithmaacTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_BusinesscombinationwithmaacTable" xml:lang="en-US">BusinessCombinationWithMAAC [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_BusinesscombinationwithmaacTable" xml:lang="en-US">Business Combination with MAAC [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_BusinesscombinationwithmaacTable" xlink:to="lab_roiv_BusinesscombinationwithmaacTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_BusinesscombinationwithmaacTable" xml:lang="en-US">BusinessCombinationWithMAAC .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaacClassASharesMember" xlink:label="loc_roiv_MaacClassASharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MaacClassASharesMember" xml:lang="en-US">Maac Class A Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MaacClassASharesMember" xlink:to="lab_roiv_MaacClassASharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MaacClassASharesMember" xml:lang="en-US">Maac class a shares .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Common Class A [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaacClassBSharesMember" xlink:label="loc_roiv_MaacClassBSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MaacClassBSharesMember" xml:lang="en-US">Maac Class B Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MaacClassBSharesMember" xlink:to="lab_roiv_MaacClassBSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MaacClassBSharesMember" xml:lang="en-US">Maac class b shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MontesArchimedesAcquisitionCorpMember" xlink:label="loc_roiv_MontesArchimedesAcquisitionCorpMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MontesArchimedesAcquisitionCorpMember" xml:lang="en-US">Montes Archimedes Acquisition Corp. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MontesArchimedesAcquisitionCorpMember" xlink:to="lab_roiv_MontesArchimedesAcquisitionCorpMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MontesArchimedesAcquisitionCorpMember" xml:lang="en-US">Montes Archimedes Acquisition Corp. [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivantWarrantMember" xlink:label="loc_roiv_RoivantWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RoivantWarrantMember" xml:lang="en-US">Roivant Warrant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RoivantWarrantMember" xlink:to="lab_roiv_RoivantWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RoivantWarrantMember" xml:lang="en-US">Roivant Warrant .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PublicWarrantsMember" xlink:label="loc_roiv_PublicWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PublicWarrantsMember" xml:lang="en-US">Public Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_roiv_PublicWarrantsMember" xml:lang="en-US">Public Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PublicWarrantsMember" xlink:to="lab_roiv_PublicWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PublicWarrantsMember" xml:lang="en-US">Public Warrants [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RedemptionOfRoivantWarrantsMember" xlink:label="loc_roiv_RedemptionOfRoivantWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RedemptionOfRoivantWarrantsMember" xml:lang="en-US">Redemption of Roivant Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RedemptionOfRoivantWarrantsMember" xlink:to="lab_roiv_RedemptionOfRoivantWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RedemptionOfRoivantWarrantsMember" xml:lang="en-US">Redemption of Roivant Warrants .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaacIndependentDirectorMember" xlink:label="loc_roiv_MaacIndependentDirectorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MaacIndependentDirectorMember" xml:lang="en-US">MAAC Independent Director [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MaacIndependentDirectorMember" xlink:to="lab_roiv_MaacIndependentDirectorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MaacIndependentDirectorMember" xml:lang="en-US">MAAC Independent Director .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpAgreementsAxis" xlink:label="loc_roiv_LockUpAgreementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_LockUpAgreementsAxis" xml:lang="en-US">Lock Up Agreements [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_LockUpAgreementsAxis" xlink:to="lab_roiv_LockUpAgreementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_LockUpAgreementsAxis" xml:lang="en-US">Lock Up Agreements .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpAgreementsDomain" xlink:label="loc_roiv_LockUpAgreementsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_LockUpAgreementsDomain" xml:lang="en-US">Lock Up Agreements [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_LockUpAgreementsDomain" xlink:to="lab_roiv_LockUpAgreementsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_LockUpAgreementsDomain" xml:lang="en-US">Lock Up Agreements .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodNineMember" xlink:label="loc_roiv_LockUpPeriodNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_LockUpPeriodNineMember" xml:lang="en-US">Lock Up Period Nine [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_LockUpPeriodNineMember" xlink:to="lab_roiv_LockUpPeriodNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_LockUpPeriodNineMember" xml:lang="en-US">Lock Up Period Nine .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodOneMember" xlink:label="loc_roiv_LockUpPeriodOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_LockUpPeriodOneMember" xml:lang="en-US">Lock Up Period One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_LockUpPeriodOneMember" xlink:to="lab_roiv_LockUpPeriodOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_LockUpPeriodOneMember" xml:lang="en-US">Lock Up Period One .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodTwoMember" xlink:label="loc_roiv_LockUpPeriodTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_LockUpPeriodTwoMember" xml:lang="en-US">Lock Up Period Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_LockUpPeriodTwoMember" xlink:to="lab_roiv_LockUpPeriodTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_LockUpPeriodTwoMember" xml:lang="en-US">Lock Up Period Two .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodSevenMember" xlink:label="loc_roiv_LockUpPeriodSevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_LockUpPeriodSevenMember" xml:lang="en-US">Lock Up Period Seven [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_LockUpPeriodSevenMember" xlink:to="lab_roiv_LockUpPeriodSevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_LockUpPeriodSevenMember" xml:lang="en-US">Lock Up Period Seven .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodEightMember" xlink:label="loc_roiv_LockUpPeriodEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_LockUpPeriodEightMember" xml:lang="en-US">Lock Up Period Eight [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_LockUpPeriodEightMember" xlink:to="lab_roiv_LockUpPeriodEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_LockUpPeriodEightMember" xml:lang="en-US">Lock Up Period Eight .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodThreeMember" xlink:label="loc_roiv_LockUpPeriodThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_LockUpPeriodThreeMember" xml:lang="en-US">Lock Up Period Three [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_LockUpPeriodThreeMember" xlink:to="lab_roiv_LockUpPeriodThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_LockUpPeriodThreeMember" xml:lang="en-US">Lock Up Period Three .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodFourMember" xlink:label="loc_roiv_LockUpPeriodFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_LockUpPeriodFourMember" xml:lang="en-US">Lock Up Period Four [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_LockUpPeriodFourMember" xlink:to="lab_roiv_LockUpPeriodFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_LockUpPeriodFourMember" xml:lang="en-US">Lock Up Period Four .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodFiveMember" xlink:label="loc_roiv_LockUpPeriodFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_LockUpPeriodFiveMember" xml:lang="en-US">Lock Up Period Five [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_LockUpPeriodFiveMember" xlink:to="lab_roiv_LockUpPeriodFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_LockUpPeriodFiveMember" xml:lang="en-US">Lock Up Period Five .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodSixMember" xlink:label="loc_roiv_LockUpPeriodSixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_LockUpPeriodSixMember" xml:lang="en-US">Lock Up Period Six [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_LockUpPeriodSixMember" xlink:to="lab_roiv_LockUpPeriodSixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_LockUpPeriodSixMember" xml:lang="en-US">Lock Up Period Six .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementAxis" xlink:label="loc_roiv_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AgreementAxis" xlink:to="lab_roiv_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AgreementAxis" xml:lang="en-US">Agreement [Axis].</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementDomain" xlink:label="loc_roiv_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AgreementDomain" xlink:to="lab_roiv_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AgreementDomain" xml:lang="en-US">Agreement [Domain].</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PipeFinancingMember" xlink:label="loc_roiv_PipeFinancingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PipeFinancingMember" xml:lang="en-US">PIPE Financing [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PipeFinancingMember" xlink:to="lab_roiv_PipeFinancingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PipeFinancingMember" xml:lang="en-US">PIPE Financing .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaacSponsorMember" xlink:label="loc_roiv_MaacSponsorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MaacSponsorMember" xml:lang="en-US">MAAC Sponsor [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MaacSponsorMember" xlink:to="lab_roiv_MaacSponsorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MaacSponsorMember" xml:lang="en-US">MAAC sponsor .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivantCommonSharesMember" xlink:label="loc_roiv_RoivantCommonSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RoivantCommonSharesMember" xml:lang="en-US">Roivant Common Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_RoivantCommonSharesMember" xml:lang="en-US">Roivant Common Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RoivantCommonSharesMember" xlink:to="lab_roiv_RoivantCommonSharesMember" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BusinessCombinationAgreementAxis" xlink:label="loc_roiv_BusinessCombinationAgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_BusinessCombinationAgreementAxis" xml:lang="en-US">Business Combination Agreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_BusinessCombinationAgreementAxis" xlink:to="lab_roiv_BusinessCombinationAgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_BusinessCombinationAgreementAxis" xml:lang="en-US">Business Combination Agreement .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BusinessCombinationAgreementDomain" xlink:label="loc_roiv_BusinessCombinationAgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_BusinessCombinationAgreementDomain" xml:lang="en-US">Business Combination Agreement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_BusinessCombinationAgreementDomain" xlink:to="lab_roiv_BusinessCombinationAgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_BusinessCombinationAgreementDomain" xml:lang="en-US">Business Combination Agreement .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SponsorSupportAgreementMember" xlink:label="loc_roiv_SponsorSupportAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SponsorSupportAgreementMember" xml:lang="en-US">Sponsor Support Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SponsorSupportAgreementMember" xlink:to="lab_roiv_SponsorSupportAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SponsorSupportAgreementMember" xml:lang="en-US">Sponsor Support Agreement .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TriggeringEventAxis" xlink:label="loc_roiv_TriggeringEventAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_TriggeringEventAxis" xml:lang="en-US">Triggering Event [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_TriggeringEventAxis" xlink:to="lab_roiv_TriggeringEventAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_TriggeringEventAxis" xml:lang="en-US">Triggering Event .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TriggeringEventDomain" xlink:label="loc_roiv_TriggeringEventDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_TriggeringEventDomain" xml:lang="en-US">Triggering Event [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_TriggeringEventDomain" xlink:to="lab_roiv_TriggeringEventDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_TriggeringEventDomain" xml:lang="en-US">Triggering Event .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SharePriceEqualOrExceedsTwentyDollarMember" xlink:label="loc_roiv_SharePriceEqualOrExceedsTwentyDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SharePriceEqualOrExceedsTwentyDollarMember" xml:lang="en-US">Share Price Equal or Exceeds Twenty Dollar [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SharePriceEqualOrExceedsTwentyDollarMember" xlink:to="lab_roiv_SharePriceEqualOrExceedsTwentyDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SharePriceEqualOrExceedsTwentyDollarMember" xml:lang="en-US">Share Price Equal or Exceeds Twenty Dollar .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SharePriceEqualOrExceedsEighteenDollarMember" xlink:label="loc_roiv_SharePriceEqualOrExceedsEighteenDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SharePriceEqualOrExceedsEighteenDollarMember" xml:lang="en-US">Share Price Equal or Exceeds Eighteen Dollar [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SharePriceEqualOrExceedsEighteenDollarMember" xlink:to="lab_roiv_SharePriceEqualOrExceedsEighteenDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SharePriceEqualOrExceedsEighteenDollarMember" xml:lang="en-US">Share Price Equal or Exceeds Eighteen Dollar .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SharePriceEqualOrExceedsEighteenPerDollarMember" xlink:label="loc_roiv_SharePriceEqualOrExceedsEighteenPerDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SharePriceEqualOrExceedsEighteenPerDollarMember" xml:lang="en-US">Share Price Equal or Exceeds Eighteen Per Dollar [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SharePriceEqualOrExceedsEighteenPerDollarMember" xlink:to="lab_roiv_SharePriceEqualOrExceedsEighteenPerDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SharePriceEqualOrExceedsEighteenPerDollarMember" xml:lang="en-US">Share Price Equal or Exceeds Eighteen Per Dollar .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SharePriceEqualOrExceedsTenDollarMember" xlink:label="loc_roiv_SharePriceEqualOrExceedsTenDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SharePriceEqualOrExceedsTenDollarMember" xml:lang="en-US">Share Price Equal or Exceeds Ten Dollar [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SharePriceEqualOrExceedsTenDollarMember" xlink:to="lab_roiv_SharePriceEqualOrExceedsTenDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SharePriceEqualOrExceedsTenDollarMember" xml:lang="en-US">Share Price Equal or Exceeds Ten Dollar .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SharePriceEqualOrExceedsFifteenDollarMember" xlink:label="loc_roiv_SharePriceEqualOrExceedsFifteenDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SharePriceEqualOrExceedsFifteenDollarMember" xml:lang="en-US">Share Price Equal or Exceeds Fifteen Dollar [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SharePriceEqualOrExceedsFifteenDollarMember" xlink:to="lab_roiv_SharePriceEqualOrExceedsFifteenDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SharePriceEqualOrExceedsFifteenDollarMember" xml:lang="en-US">Share Price Equal or Exceeds Fifteen Dollar .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BusinessCombinationWithMAACLineItems" xlink:label="loc_roiv_BusinessCombinationWithMAACLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_BusinessCombinationWithMAACLineItems" xml:lang="en-US">Business Combination with M A A C [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems" xlink:to="lab_roiv_BusinessCombinationWithMAACLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_BusinessCombinationWithMAACLineItems" xml:lang="en-US">Business Combination with M A A C .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ExchangeRatioOfMAACClassBToRoivantCommonShares" xlink:label="loc_roiv_ExchangeRatioOfMAACClassBToRoivantCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ExchangeRatioOfMAACClassBToRoivantCommonShares" xml:lang="en-US">Exchange Ratio Of M A A C Class B To Roivant Common Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ExchangeRatioOfMAACClassBToRoivantCommonShares" xml:lang="en-US">Exchange Ratio Of MAAC Class B To Roivant Common Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ExchangeRatioOfMAACClassBToRoivantCommonShares" xlink:to="lab_roiv_ExchangeRatioOfMAACClassBToRoivantCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ExchangeRatioOfMAACClassBToRoivantCommonShares" xml:lang="en-US">Exchange Ratio Of M A A C Class B To Roivant Common Shares .</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockholdersEquityNoteStockSplitExchangeRatio1" xlink:label="loc_roiv_StockholdersEquityNoteStockSplitExchangeRatio1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_StockholdersEquityNoteStockSplitExchangeRatio1" xml:lang="en-US">Stockholders Equity Note Stock Split Exchange Ratio 1</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_StockholdersEquityNoteStockSplitExchangeRatio1" xlink:to="lab_roiv_StockholdersEquityNoteStockSplitExchangeRatio1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_StockholdersEquityNoteStockSplitExchangeRatio1" xml:lang="en-US">Stockholders equity note stock split exchange ratio 1.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Costsincurredrelatedtofinancing" xlink:label="loc_roiv_Costsincurredrelatedtofinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_Costsincurredrelatedtofinancing" xml:lang="en-US">CostsIncurredRelatedToFinancing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_Costsincurredrelatedtofinancing" xml:lang="en-US">Costs Incurred Related To Financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_Costsincurredrelatedtofinancing" xlink:to="lab_roiv_Costsincurredrelatedtofinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_Costsincurredrelatedtofinancing" xml:lang="en-US">Costs incurred related to financing.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Allocationoftransactioncostsincurredtowarrantsandearnoutshares" xlink:label="loc_roiv_Allocationoftransactioncostsincurredtowarrantsandearnoutshares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_Allocationoftransactioncostsincurredtowarrantsandearnoutshares" xml:lang="en-US">AllocationOfTransactionCostsIncurredToWarrantsAndEarnoutShares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_Allocationoftransactioncostsincurredtowarrantsandearnoutshares" xml:lang="en-US">Allocation of transaction costs incurred to warrants and earn-out shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_Allocationoftransactioncostsincurredtowarrantsandearnoutshares" xlink:to="lab_roiv_Allocationoftransactioncostsincurredtowarrantsandearnoutshares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_Allocationoftransactioncostsincurredtowarrantsandearnoutshares" xml:lang="en-US">Allocation of transaction costs incurred to warrants and earn-out shares.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Portionofsharesubjecttoearnout" xlink:label="loc_roiv_Portionofsharesubjecttoearnout" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_Portionofsharesubjecttoearnout" xml:lang="en-US">PortionOfShareSubjectToEarnout</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_Portionofsharesubjecttoearnout" xml:lang="en-US">Portion of Share Subject to Earnout</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_Portionofsharesubjecttoearnout" xlink:to="lab_roiv_Portionofsharesubjecttoearnout" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_Portionofsharesubjecttoearnout" xml:lang="en-US">Portion of share subject to earnout.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Numberoftradingdaystomeetwarrantredemptionthreshold" xlink:label="loc_roiv_Numberoftradingdaystomeetwarrantredemptionthreshold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_Numberoftradingdaystomeetwarrantredemptionthreshold" xml:lang="en-US">NumberOfTradingDaysToMeetWarrantRedemptionThreshold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_Numberoftradingdaystomeetwarrantredemptionthreshold" xml:lang="en-US">Number of trading days to meet warrant redemption threshold</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_Numberoftradingdaystomeetwarrantredemptionthreshold" xlink:to="lab_roiv_Numberoftradingdaystomeetwarrantredemptionthreshold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_Numberoftradingdaystomeetwarrantredemptionthreshold" xml:lang="en-US">Number of trading days to meet warrant redemption threshold.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price of warrants (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Warrant exercise price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime" xlink:label="loc_roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime" xml:lang="en-US">PercentageOfSharesSubjectToLockupForDefinedPeriodOfTime</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime" xml:lang="en-US">Percentage of shares subject to lock-up for defined period of time</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime" xlink:to="lab_roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime" xml:lang="en-US">Percentage of shares subject to lock-up for defined period of time.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Closing price of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Stockpricetriggerforredemptionofwarrants" xlink:label="loc_roiv_Stockpricetriggerforredemptionofwarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_Stockpricetriggerforredemptionofwarrants" xml:lang="en-US">StockPriceTriggerForRedemptionOfWarrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_Stockpricetriggerforredemptionofwarrants" xml:lang="en-US">Stock price trigger for redemption of warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_Stockpricetriggerforredemptionofwarrants" xlink:to="lab_roiv_Stockpricetriggerforredemptionofwarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_Stockpricetriggerforredemptionofwarrants" xml:lang="en-US">Stock price trigger for redemption of warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Numberoftradingdaystomeetearnoutpricethreshold" xlink:label="loc_roiv_Numberoftradingdaystomeetearnoutpricethreshold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_Numberoftradingdaystomeetearnoutpricethreshold" xml:lang="en-US">NumberOfTradingDaysToMeetEarnOutPriceThreshold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_Numberoftradingdaystomeetearnoutpricethreshold" xml:lang="en-US">Number of trading days to meet earn out price threshold</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_Numberoftradingdaystomeetearnoutpricethreshold" xlink:to="lab_roiv_Numberoftradingdaystomeetearnoutpricethreshold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_Numberoftradingdaystomeetearnoutpricethreshold" xml:lang="en-US">Number of trading days to meet earn out price threshold.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Number of outstanding warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Tradingdayperiodforwarrantredemption" xlink:label="loc_roiv_Tradingdayperiodforwarrantredemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_Tradingdayperiodforwarrantredemption" xml:lang="en-US">TradingDayPeriodForWarrantRedemption</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_Tradingdayperiodforwarrantredemption" xml:lang="en-US">Trading day period for warrant redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_Tradingdayperiodforwarrantredemption" xlink:to="lab_roiv_Tradingdayperiodforwarrantredemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_Tradingdayperiodforwarrantredemption" xml:lang="en-US">Trading day period for warrant redemption.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Tradingdayperiodforearnoutshares" xlink:label="loc_roiv_Tradingdayperiodforearnoutshares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_Tradingdayperiodforearnoutshares" xml:lang="en-US">TradingDayPeriodForEarnOutShares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_Tradingdayperiodforearnoutshares" xml:lang="en-US">Trading day period for earn out shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_Tradingdayperiodforearnoutshares" xlink:to="lab_roiv_Tradingdayperiodforearnoutshares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_Tradingdayperiodforearnoutshares" xml:lang="en-US">Trading day period for earn out shares.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PeriodForFairMarketValueDetermination" xlink:label="loc_roiv_PeriodForFairMarketValueDetermination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PeriodForFairMarketValueDetermination" xml:lang="en-US">Period For Fair Market Value Determination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PeriodForFairMarketValueDetermination" xml:lang="en-US">Period for fair market value determination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PeriodForFairMarketValueDetermination" xlink:to="lab_roiv_PeriodForFairMarketValueDetermination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PeriodForFairMarketValueDetermination" xml:lang="en-US">Period for fair market value determination.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EarnOutSharePrice" xlink:label="loc_roiv_EarnOutSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_EarnOutSharePrice" xml:lang="en-US">Earn Out Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_EarnOutSharePrice" xml:lang="en-US">Earn-Out share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_EarnOutSharePrice" xlink:to="lab_roiv_EarnOutSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_EarnOutSharePrice" xml:lang="en-US">Earn-Out share price.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Lockupperiodofcommonshares" xlink:label="loc_roiv_Lockupperiodofcommonshares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_Lockupperiodofcommonshares" xml:lang="en-US">LockUpPeriodOfCommonShares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_Lockupperiodofcommonshares" xml:lang="en-US">Lock Up Period of Common Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_Lockupperiodofcommonshares" xlink:to="lab_roiv_Lockupperiodofcommonshares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_Lockupperiodofcommonshares" xml:lang="en-US">Lock up period of common shares.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Percentageofwarrantssubjecttolockupfordefinedperiodoftime" xlink:label="loc_roiv_Percentageofwarrantssubjecttolockupfordefinedperiodoftime" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_Percentageofwarrantssubjecttolockupfordefinedperiodoftime" xml:lang="en-US">PercentageOfWarrantsSubjectToLockupForDefinedPeriodOfTime</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_Percentageofwarrantssubjecttolockupfordefinedperiodoftime" xml:lang="en-US">Percentage of warrants subject to lock-up for defined period of time</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_Percentageofwarrantssubjecttolockupfordefinedperiodoftime" xlink:to="lab_roiv_Percentageofwarrantssubjecttolockupfordefinedperiodoftime" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_Percentageofwarrantssubjecttolockupfordefinedperiodoftime" xml:lang="en-US">Percentage of warrants subject to lock-up for defined period of time.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Lockupperiodwarrants" xlink:label="loc_roiv_Lockupperiodwarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_Lockupperiodwarrants" xml:lang="en-US">LockUpPeriodwarrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_Lockupperiodwarrants" xml:lang="en-US">Lock up period ,warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_Lockupperiodwarrants" xlink:to="lab_roiv_Lockupperiodwarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_Lockupperiodwarrants" xml:lang="en-US">Lock up period ,warrants.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Timetowarrantexercisability" xlink:label="loc_roiv_Timetowarrantexercisability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_Timetowarrantexercisability" xml:lang="en-US">TimeToWarrantExercisability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_Timetowarrantexercisability" xml:lang="en-US">Time To Warrant Exercisability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_Timetowarrantexercisability" xlink:to="lab_roiv_Timetowarrantexercisability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_Timetowarrantexercisability" xml:lang="en-US">Time to warrant exercisability .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Shareredemptiontriggerprice" xlink:label="loc_roiv_Shareredemptiontriggerprice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_Shareredemptiontriggerprice" xml:lang="en-US">ShareRedemptionTriggerPrice</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_Shareredemptiontriggerprice" xml:lang="en-US">Share Redemption Trigger Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_Shareredemptiontriggerprice" xlink:to="lab_roiv_Shareredemptiontriggerprice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_Shareredemptiontriggerprice" xml:lang="en-US">Share redemption trigger price.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Classofwarrantsredemptionpriceperunit" xlink:label="loc_roiv_Classofwarrantsredemptionpriceperunit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_Classofwarrantsredemptionpriceperunit" xml:lang="en-US">ClassOfWarrantsRedemptionPricePerUnit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_Classofwarrantsredemptionpriceperunit" xml:lang="en-US">Class of warrants, redemption price per unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_Classofwarrantsredemptionpriceperunit" xlink:to="lab_roiv_Classofwarrantsredemptionpriceperunit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_Classofwarrantsredemptionpriceperunit" xml:lang="en-US">Class of warrants, redemption price per unit.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Classofwarrantsredemptionnoticeperiod" xlink:label="loc_roiv_Classofwarrantsredemptionnoticeperiod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_Classofwarrantsredemptionnoticeperiod" xml:lang="en-US">ClassOfWarrantsRedemptionNoticePeriod</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_Classofwarrantsredemptionnoticeperiod" xml:lang="en-US">Class of warrants, redemption notice period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_Classofwarrantsredemptionnoticeperiod" xlink:to="lab_roiv_Classofwarrantsredemptionnoticeperiod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_Classofwarrantsredemptionnoticeperiod" xml:lang="en-US">Class of warrants, redemption notice period.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaximumRedemptionFeaturePerWarrant" xlink:label="loc_roiv_MaximumRedemptionFeaturePerWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MaximumRedemptionFeaturePerWarrant" xml:lang="en-US">Maximum Redemption Feature Per Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_MaximumRedemptionFeaturePerWarrant" xml:lang="en-US">Maximum redemption feature per warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MaximumRedemptionFeaturePerWarrant" xlink:to="lab_roiv_MaximumRedemptionFeaturePerWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MaximumRedemptionFeaturePerWarrant" xml:lang="en-US">Maximum redemption feature per warrant.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CommonStockWarrants" xlink:label="loc_roiv_CommonStockWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CommonStockWarrants" xml:lang="en-US">Common Stock Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CommonStockWarrants" xlink:to="lab_roiv_CommonStockWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_CommonStockWarrants" xml:lang="en-US">Common Stock Warrants.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_UncategorizedAbstract" xlink:label="loc_roiv_UncategorizedAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_UncategorizedAbstract" xml:lang="en-US">Uncategorized [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_UncategorizedAbstract" xlink:to="lab_roiv_UncategorizedAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_UncategorizedAbstract" xml:lang="en-US">Uncategorized [Abstract]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_InvestmentsTable" xlink:label="loc_roiv_InvestmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_InvestmentsTable" xml:lang="en-US">Investments [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_InvestmentsTable" xml:lang="en-US">Investments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_InvestmentsTable" xlink:to="lab_roiv_InvestmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_InvestmentsTable" xml:lang="en-US">Investments [Table]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ArbutusBiopharmaCorporationMember" xlink:label="loc_roiv_ArbutusBiopharmaCorporationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ArbutusBiopharmaCorporationMember" xml:lang="en-US">Arbutus Biopharma Corporation [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ArbutusBiopharmaCorporationMember" xml:lang="en-US">Arbutus Biopharma Corporation [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ArbutusBiopharmaCorporationMember" xlink:to="lab_roiv_ArbutusBiopharmaCorporationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ArbutusBiopharmaCorporationMember" xml:lang="en-US">Arbutus Biopharma Corporation [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DatavantHoldingsIncMember" xlink:label="loc_roiv_DatavantHoldingsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DatavantHoldingsIncMember" xml:lang="en-US">Datavant Holdings, Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DatavantHoldingsIncMember" xml:lang="en-US">Datavant Holdings, Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DatavantHoldingsIncMember" xlink:to="lab_roiv_DatavantHoldingsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DatavantHoldingsIncMember" xml:lang="en-US">Datavant Holdings, Inc [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SioGeneTherapiesIncMember" xlink:label="loc_roiv_SioGeneTherapiesIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SioGeneTherapiesIncMember" xml:lang="en-US">Sio Gene Therapies Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SioGeneTherapiesIncMember" xml:lang="en-US">Sio Gene Therapies Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SioGeneTherapiesIncMember" xlink:to="lab_roiv_SioGeneTherapiesIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SioGeneTherapiesIncMember" xml:lang="en-US">Sio Gene Therapies Inc [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentCompaniesMember" xlink:label="loc_us-gaap_OtherInvestmentCompaniesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherInvestmentCompaniesMember" xml:lang="en-US">Other Investment Companies [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherInvestmentCompaniesMember" xml:lang="en-US">Other Investments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherInvestmentCompaniesMember" xml:lang="en-US">Other Investment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentCompaniesMember" xlink:to="lab_us-gaap_OtherInvestmentCompaniesMember" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_InvestmentsLineItems" xlink:label="loc_roiv_InvestmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_InvestmentsLineItems" xml:lang="en-US">Investments [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_InvestmentsLineItems" xml:lang="en-US">Investments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_InvestmentsLineItems" xlink:to="lab_roiv_InvestmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_InvestmentsLineItems" xml:lang="en-US">Investments [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US">Unrealized Gain (Loss) on Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US">Unrealized gain (loss) on investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity method investment ownership percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xml:lang="en-US">Gain on deconsolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PreferredStockOwnedBalanceSharesOfArbutus" xlink:label="loc_roiv_PreferredStockOwnedBalanceSharesOfArbutus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PreferredStockOwnedBalanceSharesOfArbutus" xml:lang="en-US">Preferred stock Owned, Balance, Shares of Arbutus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PreferredStockOwnedBalanceSharesOfArbutus" xml:lang="en-US">Preferred stock Owned, Balance, Shares of Arbutus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PreferredStockOwnedBalanceSharesOfArbutus" xlink:to="lab_roiv_PreferredStockOwnedBalanceSharesOfArbutus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PreferredStockOwnedBalanceSharesOfArbutus" xml:lang="en-US">Preferred stock Owned, Balance, Shares of Arbutus.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock" xlink:label="loc_roiv_InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock" xml:lang="en-US">Investment Owned Conversion Includes Both Preferred Stock and Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock" xml:lang="en-US">Investment owned conversion includes both preferred stock and common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock" xlink:to="lab_roiv_InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock" xml:lang="en-US">Investment owned conversion includes both preferred stock and common stock.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GainOnMeasurementOfInvestment" xlink:label="loc_roiv_GainOnMeasurementOfInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_GainOnMeasurementOfInvestment" xml:lang="en-US">Gain On Measurement Of Investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_GainOnMeasurementOfInvestment" xml:lang="en-US">Gain on measurement of investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_GainOnMeasurementOfInvestment" xlink:to="lab_roiv_GainOnMeasurementOfInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_GainOnMeasurementOfInvestment" xml:lang="en-US">Gain on measurement of investment.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromSaleOfInvestment" xlink:label="loc_roiv_ProceedsFromSaleOfInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ProceedsFromSaleOfInvestment" xml:lang="en-US">Proceeds From Sale Of Investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_roiv_ProceedsFromSaleOfInvestment" xml:lang="en-US">Proceeds from sale of investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ProceedsFromSaleOfInvestment" xlink:to="lab_roiv_ProceedsFromSaleOfInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ProceedsFromSaleOfInvestment" xml:lang="en-US">Proceeds from sale of investment.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DatavantMergerMember" xlink:label="loc_roiv_DatavantMergerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DatavantMergerMember" xml:lang="en-US">Datavant Merger [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DatavantMergerMember" xml:lang="en-US">Datavant Merger [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DatavantMergerMember" xlink:to="lab_roiv_DatavantMergerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DatavantMergerMember" xml:lang="en-US">Datavant Merger .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipAxis" xml:lang="en-US">Ownership [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipDomain" xml:lang="en-US">Ownership [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CombinedCompanyMember" xlink:label="loc_roiv_CombinedCompanyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CombinedCompanyMember" xml:lang="en-US">Combined Company [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CombinedCompanyMember" xlink:to="lab_roiv_CombinedCompanyMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xml:lang="en-US">Asset Acquisition [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xml:lang="en-US">Asset Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xml:lang="en-US">Asset Acquisition [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xml:lang="en-US">Asset Acquisition [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SiliconTherapeuticsMember" xlink:label="loc_roiv_SiliconTherapeuticsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SiliconTherapeuticsMember" xml:lang="en-US">Silicon Therapeutics [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SiliconTherapeuticsMember" xml:lang="en-US">Silicon Therapeutics [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SiliconTherapeuticsMember" xlink:to="lab_roiv_SiliconTherapeuticsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SiliconTherapeuticsMember" xml:lang="en-US">Silicon Therapeutics</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PriovantMember" xlink:label="loc_roiv_PriovantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PriovantMember" xml:lang="en-US">Priovant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PriovantMember" xml:lang="en-US">Priovant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PriovantMember" xlink:to="lab_roiv_PriovantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PriovantMember" xml:lang="en-US">Priovant.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xml:lang="en-US">Debt Conversion, Original Debt, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xml:lang="en-US">Aggregate principal amount of notes converted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="lab_us-gaap_DebtConversionOriginalDebtAmount1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FutureDevelopmentAndCommercialMilestonePayments" xlink:label="loc_roiv_FutureDevelopmentAndCommercialMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FutureDevelopmentAndCommercialMilestonePayments" xml:lang="en-US">Future Development And Commercial Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FutureDevelopmentAndCommercialMilestonePayments" xml:lang="en-US">Future development and commercial milestone payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FutureDevelopmentAndCommercialMilestonePayments" xlink:to="lab_roiv_FutureDevelopmentAndCommercialMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FutureDevelopmentAndCommercialMilestonePayments" xml:lang="en-US">Future Development And Commercial Milestone Payments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xml:lang="en-US">Asset acquisition, consideration transferred, liabilities incurred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Fair value of future contingent consideration payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xml:lang="en-US">Business combination, recognized identifiable assets acquired and liabilities assumed, current liabilities, accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BusinessAcquisitionConsiderationTransferred" xlink:label="loc_roiv_BusinessAcquisitionConsiderationTransferred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_BusinessAcquisitionConsiderationTransferred" xml:lang="en-US">Business Acquisition Consideration Transferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_roiv_BusinessAcquisitionConsiderationTransferred" xml:lang="en-US">Business acquisition, consideration transferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_BusinessAcquisitionConsiderationTransferred" xlink:to="lab_roiv_BusinessAcquisitionConsiderationTransferred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_BusinessAcquisitionConsiderationTransferred" xml:lang="en-US">Business Acquisition Consideration Transferred.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_NonRefundableUpfrontPaymentReceived" xlink:label="loc_roiv_NonRefundableUpfrontPaymentReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_NonRefundableUpfrontPaymentReceived" xml:lang="en-US">Non Refundable Upfront Payment Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_NonRefundableUpfrontPaymentReceived" xml:lang="en-US">Nonrefundable, upfront payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_NonRefundableUpfrontPaymentReceived" xlink:to="lab_roiv_NonRefundableUpfrontPaymentReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_NonRefundableUpfrontPaymentReceived" xml:lang="en-US">Non Refundable Upfront Payment Received</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PaymentForUpfrontPayments" xlink:label="loc_roiv_PaymentForUpfrontPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PaymentForUpfrontPayments" xml:lang="en-US">Payment For Upfront payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PaymentForUpfrontPayments" xml:lang="en-US">Upfront proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PaymentForUpfrontPayments" xlink:to="lab_roiv_PaymentForUpfrontPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PaymentForUpfrontPayments" xml:lang="en-US">Payment for upfront payments.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueOfRestrictedStock" xlink:label="loc_roiv_FairValueOfRestrictedStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FairValueOfRestrictedStock" xml:lang="en-US">Fair Value Of Restricted Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FairValueOfRestrictedStock" xml:lang="en-US">Fair value of restricted stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FairValueOfRestrictedStock" xlink:to="lab_roiv_FairValueOfRestrictedStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FairValueOfRestrictedStock" xml:lang="en-US">Fair Value Of Restricted Stock</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xml:lang="en-US">Fair value of noncontrolling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xml:lang="en-US">Equity Method Investment, Underlying Equity in Net Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xml:lang="en-US">Equity investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:to="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueOfCommonShares" xlink:label="loc_roiv_FairValueOfCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FairValueOfCommonShares" xml:lang="en-US">Fair Value Of Common Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FairValueOfCommonShares" xml:lang="en-US">Fair value of common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FairValueOfCommonShares" xlink:to="lab_roiv_FairValueOfCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FairValueOfCommonShares" xml:lang="en-US">Fair Value Of Common Shares</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Payment to acquire business, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_roiv_BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Business Acquisition Recognized Identifiable Assets Acquired And Liabilities Assumed Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Business Acquisition, recognized identifiable assets acquired and liabilities assumed, assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_roiv_BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Business Acquisition Recognized Identifiable Assets Acquired And Liabilities Assumed Net.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Notes converted, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Number of shares issued in business combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xml:lang="en-US">Payments to Acquire Equity Method Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xml:lang="en-US">Equity ownership interest, additional cash contribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xml:lang="en-US">Cash paid for common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PercentageOfControllingInterestHeld" xlink:label="loc_roiv_PercentageOfControllingInterestHeld" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PercentageOfControllingInterestHeld" xml:lang="en-US">Percentage Of Controlling Interest Held</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PercentageOfControllingInterestHeld" xml:lang="en-US">Percentage controlling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PercentageOfControllingInterestHeld" xlink:to="lab_roiv_PercentageOfControllingInterestHeld" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PercentageOfControllingInterestHeld" xml:lang="en-US">Percentage of controlling interest held.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PaymentUnderSponsoredResearchAgreement" xlink:label="loc_roiv_PaymentUnderSponsoredResearchAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PaymentUnderSponsoredResearchAgreement" xml:lang="en-US">Payment Under Sponsored Research Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PaymentUnderSponsoredResearchAgreement" xml:lang="en-US">Payment under SRA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PaymentUnderSponsoredResearchAgreement" xlink:to="lab_roiv_PaymentUnderSponsoredResearchAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PaymentUnderSponsoredResearchAgreement" xml:lang="en-US">Payment under sponsored research agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xml:lang="en-US">Investments in Affiliates, Subsidiaries, Associates, and Joint Ventures, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xml:lang="en-US">Investment, fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="loc_us-gaap_StockholdersEquityNoteSubscriptionsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xml:lang="en-US">Stockholders' Equity Note, Subscriptions Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xml:lang="en-US">Subscription receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="lab_us-gaap_StockholdersEquityNoteSubscriptionsReceivable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xml:lang="en-US">Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xml:lang="en-US">Ownership interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodValue" xlink:label="loc_roiv_StockIssuedDuringPeriodValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_StockIssuedDuringPeriodValue" xml:lang="en-US">Stock Issued During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_StockIssuedDuringPeriodValue" xml:lang="en-US">Newly issued shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_StockIssuedDuringPeriodValue" xlink:to="lab_roiv_StockIssuedDuringPeriodValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_StockIssuedDuringPeriodValue" xml:lang="en-US">Stock Issued During Period</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PotentialMilestonePaymentReceivable" xlink:label="loc_roiv_PotentialMilestonePaymentReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PotentialMilestonePaymentReceivable" xml:lang="en-US">Potential Milestone Payment Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PotentialMilestonePaymentReceivable" xml:lang="en-US">Collaboration Agreement Additional Contingent Milestone Payments Eligible To Receive</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PotentialMilestonePaymentReceivable" xlink:to="lab_roiv_PotentialMilestonePaymentReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PotentialMilestonePaymentReceivable" xml:lang="en-US">Potential milestone payment receivable.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_UpfrontCashPayments" xlink:label="loc_roiv_UpfrontCashPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_UpfrontCashPayments" xml:lang="en-US">Upfront Cash Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_UpfrontCashPayments" xml:lang="en-US">Payments to asset acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_UpfrontCashPayments" xlink:to="lab_roiv_UpfrontCashPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_UpfrontCashPayments" xml:lang="en-US">Upfront Cash Payments</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xml:lang="en-US">Repayment of Notes Receivable from Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xml:lang="en-US">Settlement of promissory notes receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:to="lab_us-gaap_RepaymentOfNotesReceivableFromRelatedParties" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xml:lang="en-US">Asset acquisition, Consideration Transferred, Equity Interests Issued and Issuable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Stock shares issued during the period asset acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MilestonePaymentPayable" xlink:label="loc_roiv_MilestonePaymentPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MilestonePaymentPayable" xml:lang="en-US">Milestone Payment Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_MilestonePaymentPayable" xml:lang="en-US">Milestone payment payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MilestonePaymentPayable" xlink:to="lab_roiv_MilestonePaymentPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MilestonePaymentPayable" xml:lang="en-US">Milestone payment payable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Stock shares issued value during the period asset acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PayableForEachAdditionalProductIndication" xlink:label="loc_roiv_PayableForEachAdditionalProductIndication" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PayableForEachAdditionalProductIndication" xml:lang="en-US">Payable For Each Additional Product Indication</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PayableForEachAdditionalProductIndication" xml:lang="en-US">Payable for each additional product indication</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PayableForEachAdditionalProductIndication" xlink:to="lab_roiv_PayableForEachAdditionalProductIndication" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PayableForEachAdditionalProductIndication" xml:lang="en-US">Payable for each additional product indication.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenue" xml:lang="en-US">Deferred Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenue" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue" xlink:to="lab_us-gaap_DeferredRevenue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Payments to Acquire Businesses, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Cash Payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedParties" xlink:label="loc_us-gaap_NotesReceivableRelatedParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesReceivableRelatedParties" xml:lang="en-US">Notes Receivable, Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesReceivableRelatedParties" xml:lang="en-US">Notes receivable, related parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableRelatedParties" xlink:to="lab_us-gaap_NotesReceivableRelatedParties" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MilestoneEventsAxis" xlink:label="loc_roiv_MilestoneEventsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MilestoneEventsAxis" xml:lang="en-US">Milestone Events [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_MilestoneEventsAxis" xml:lang="en-US">Milestone Events [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MilestoneEventsAxis" xlink:to="lab_roiv_MilestoneEventsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MilestoneEventsAxis" xml:lang="en-US">Milestone Events [Axis]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MilestoneEventsDomain" xlink:label="loc_roiv_MilestoneEventsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MilestoneEventsDomain" xml:lang="en-US">Milestone Events [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_MilestoneEventsDomain" xml:lang="en-US">Milestone Events [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MilestoneEventsDomain" xlink:to="lab_roiv_MilestoneEventsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MilestoneEventsDomain" xml:lang="en-US">Milestone Events [Domain]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" xlink:label="loc_roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" xml:lang="en-US">First Product First Product for Each Molecular Target Covered by Intellectual Property [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" xml:lang="en-US">First Product First Product for Each Molecular Target Covered by Intellectual Property [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" xlink:to="lab_roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" xml:lang="en-US">First Product First Product for Each Molecular Target Covered by Intellectual Property [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" xlink:label="loc_roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" xml:lang="en-US">First Product Targets Each of Certain Specified Additional MolecularTargets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" xml:lang="en-US">First Product Targets Each of Certain Specified Additional MolecularTargets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" xlink:to="lab_roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" xml:lang="en-US">First Product Targets Each of Certain Specified Additional MolecularTargets [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" xlink:label="loc_roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" xml:lang="en-US">First Product Targets Targeting Each of Two Specified Initial Targets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" xml:lang="en-US">First Product Targets Targeting Each of Two Specified Initial Targets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" xlink:to="lab_roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" xml:lang="en-US">First Product Targets Targeting Each of Two Specified Initial Targets [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AffivantSciencesMember" xlink:label="loc_roiv_AffivantSciencesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AffivantSciencesMember" xml:lang="en-US">Affivant Sciences [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_AffivantSciencesMember" xml:lang="en-US">Affivant Sciences [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AffivantSciencesMember" xlink:to="lab_roiv_AffivantSciencesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AffivantSciencesMember" xml:lang="en-US">Affivant Sciences [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GenevantSciencesLtdMember" xlink:label="loc_roiv_GenevantSciencesLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_GenevantSciencesLtdMember" xml:lang="en-US">Genevant Sciences Ltd [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_GenevantSciencesLtdMember" xml:lang="en-US">Genevant Sciences Ltd [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_GenevantSciencesLtdMember" xlink:to="lab_roiv_GenevantSciencesLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_GenevantSciencesLtdMember" xml:lang="en-US">Genevant Sciences Ltd [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProteovantSciencesIncMember" xlink:label="loc_roiv_ProteovantSciencesIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ProteovantSciencesIncMember" xml:lang="en-US">ProteoVant Sciences, Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ProteovantSciencesIncMember" xml:lang="en-US">ProteoVant Sciences, Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ProteovantSciencesIncMember" xlink:to="lab_roiv_ProteovantSciencesIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ProteovantSciencesIncMember" xml:lang="en-US">ProteoVant Sciences, Inc [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringPlanAxis" xml:lang="en-US">Restructuring Plan [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringPlanAxis" xml:lang="en-US">Restructuring Plan [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringPlanDomain" xml:lang="en-US">Restructuring Plan [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringPlanDomain" xml:lang="en-US">Restructuring Plan [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FirstTrancheMember" xlink:label="loc_roiv_FirstTrancheMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FirstTrancheMember" xml:lang="en-US">First Tranche [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FirstTrancheMember" xml:lang="en-US">First Tranche [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FirstTrancheMember" xlink:to="lab_roiv_FirstTrancheMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FirstTrancheMember" xml:lang="en-US">First Tranche [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SecondTrancheMember" xlink:label="loc_roiv_SecondTrancheMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SecondTrancheMember" xml:lang="en-US">Second Tranche [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SecondTrancheMember" xml:lang="en-US">Second Tranche [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SecondTrancheMember" xlink:to="lab_roiv_SecondTrancheMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SecondTrancheMember" xml:lang="en-US">Second Tranche [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaap_TransactionTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransactionTypeAxis" xml:lang="en-US">Transaction Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TransactionTypeAxis" xml:lang="en-US">Transaction Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionTypeAxis" xlink:to="lab_us-gaap_TransactionTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransactionDomain" xml:lang="en-US">Transaction [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TransactionDomain" xml:lang="en-US">Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionDomain" xlink:to="lab_us-gaap_TransactionDomain" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CommercialMilestoneMember" xlink:label="loc_roiv_CommercialMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CommercialMilestoneMember" xml:lang="en-US">Commercial Milestone [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_CommercialMilestoneMember" xml:lang="en-US">Commercial Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CommercialMilestoneMember" xlink:to="lab_roiv_CommercialMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_CommercialMilestoneMember" xml:lang="en-US">Commercial Milestone [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_roiv_DevelopmentAndRegulatoryMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DevelopmentAndRegulatoryMilestoneMember" xml:lang="en-US">Development And Regulatory Milestone [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DevelopmentAndRegulatoryMilestoneMember" xml:lang="en-US">Development And Regulatory Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DevelopmentAndRegulatoryMilestoneMember" xlink:to="lab_roiv_DevelopmentAndRegulatoryMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DevelopmentAndRegulatoryMilestoneMember" xml:lang="en-US">Development And Regulatory Milestone [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PharmanvanthSevenGmbhMember" xlink:label="loc_roiv_PharmanvanthSevenGmbhMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PharmanvanthSevenGmbhMember" xml:lang="en-US">Pharmanvanth Seven Gmbh [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PharmanvanthSevenGmbhMember" xml:lang="en-US">Pharmanvanth Seven Gmbh [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PharmanvanthSevenGmbhMember" xlink:to="lab_roiv_PharmanvanthSevenGmbhMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PharmanvanthSevenGmbhMember" xml:lang="en-US">Pharmanvanth Seven Gmbh [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_HemavantSciencesGmbhMember" xlink:label="loc_roiv_HemavantSciencesGmbhMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_HemavantSciencesGmbhMember" xml:lang="en-US">Hemavant Sciences GmbH [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_HemavantSciencesGmbhMember" xlink:to="lab_roiv_HemavantSciencesGmbhMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_HemavantSciencesGmbhMember" xml:lang="en-US">Hemavant Sciences GmbH.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CollaborationAgreementWithBlueprintMedicinesMember" xlink:label="loc_roiv_CollaborationAgreementWithBlueprintMedicinesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CollaborationAgreementWithBlueprintMedicinesMember" xml:lang="en-US">Collaboration Agreement With Blueprint Medicines [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CollaborationAgreementWithBlueprintMedicinesMember" xlink:to="lab_roiv_CollaborationAgreementWithBlueprintMedicinesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_CollaborationAgreementWithBlueprintMedicinesMember" xml:lang="en-US">Collaboration agreement with blueprint medicines.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BalanceSheetComponentsTable" xlink:label="loc_roiv_BalanceSheetComponentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_BalanceSheetComponentsTable" xml:lang="en-US">Balance Sheet Components [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_BalanceSheetComponentsTable" xml:lang="en-US">Balance Sheet Components [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_BalanceSheetComponentsTable" xlink:to="lab_roiv_BalanceSheetComponentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_BalanceSheetComponentsTable" xml:lang="en-US">Balance Sheet Components [Table]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EmployeeRelatedExpensesMember" xlink:label="loc_roiv_EmployeeRelatedExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_EmployeeRelatedExpensesMember" xml:lang="en-US">Employee Related Expenses [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_EmployeeRelatedExpensesMember" xml:lang="en-US">Employee Related Expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_EmployeeRelatedExpensesMember" xlink:to="lab_roiv_EmployeeRelatedExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_EmployeeRelatedExpensesMember" xml:lang="en-US">Employee Related Expenses [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OtherGeneralAndAdministrativeExpensesMember" xlink:label="loc_roiv_OtherGeneralAndAdministrativeExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_OtherGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Other General and Administrative Expenses [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_OtherGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Other General and Administrative Expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_OtherGeneralAndAdministrativeExpensesMember" xlink:to="lab_roiv_OtherGeneralAndAdministrativeExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_OtherGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Other General and Administrative Expenses [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AccruedLiabilitiesLineItems" xlink:label="loc_roiv_AccruedLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AccruedLiabilitiesLineItems" xml:lang="en-US">Accrued Liabilities [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AccruedLiabilitiesLineItems" xlink:to="lab_roiv_AccruedLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AccruedLiabilitiesLineItems" xml:lang="en-US">Accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAbstract" xlink:label="loc_us-gaap_LongTermDebtAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtAbstract" xml:lang="en-US">Long-term Debt, Unclassified [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAbstract" xlink:to="lab_us-gaap_LongTermDebtAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Long-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Total debt, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Long-term Debt, Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Less: current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xml:lang="en-US">Less: unamortized debt discount and issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xlink:label="loc_roiv_DebtInstrumentExitFeeAndEndOfTermCharge" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xml:lang="en-US">Debt Instrument Exit Fee and End of Term Charge</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xml:lang="en-US">Exit fee / end of term charge</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xlink:to="lab_roiv_DebtInstrumentExitFeeAndEndOfTermCharge" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xml:lang="en-US">Debt instrument exit fee and end of term charge.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DebtInstrumentValue" xlink:label="loc_roiv_DebtInstrumentValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DebtInstrumentValue" xml:lang="en-US">Debt Instrument Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DebtInstrumentValue" xml:lang="en-US">Principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DebtInstrumentValue" xlink:to="lab_roiv_DebtInstrumentValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DebtInstrumentValue" xml:lang="en-US">Debt Instrument Value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RegulatoryMilestoneMember" xlink:label="loc_roiv_RegulatoryMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RegulatoryMilestoneMember" xml:lang="en-US">Regulatory Milestone [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_RegulatoryMilestoneMember" xml:lang="en-US">Regulatory Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RegulatoryMilestoneMember" xlink:to="lab_roiv_RegulatoryMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RegulatoryMilestoneMember" xml:lang="en-US">Regulatory Milestone [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaximumMilestonePaymentObligation" xlink:label="loc_roiv_MaximumMilestonePaymentObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MaximumMilestonePaymentObligation" xml:lang="en-US">Maximum Milestone Payment Obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_MaximumMilestonePaymentObligation" xml:lang="en-US">Maximum amount required milestone payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MaximumMilestonePaymentObligation" xlink:to="lab_roiv_MaximumMilestonePaymentObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MaximumMilestonePaymentObligation" xml:lang="en-US">Maximum milestone payment obligation.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaximumMilestonePaymentOffsetAmount" xlink:label="loc_roiv_MaximumMilestonePaymentOffsetAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MaximumMilestonePaymentOffsetAmount" xml:lang="en-US">Maximum Milestone Payment Offset Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_MaximumMilestonePaymentOffsetAmount" xml:lang="en-US">Possible offset of regulatory milestone payments with commercial milestone</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MaximumMilestonePaymentOffsetAmount" xlink:to="lab_roiv_MaximumMilestonePaymentOffsetAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MaximumMilestonePaymentOffsetAmount" xml:lang="en-US">Maximum Milestone Payment Offset Amount</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xml:lang="en-US">Debt fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xml:lang="en-US">Debt issued by Dermavant to NovaQuest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Proceeds from Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Proceeds from credit facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xml:lang="en-US">Debt Instrument, Fee Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xml:lang="en-US">Debt Instrument, Fee Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US">Class of warrants or rights number of shares called by each warrant or right</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt Instrument, Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xml:lang="en-US">Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xml:lang="en-US">Debt interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" xlink:label="loc_roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" xml:lang="en-US">Committed Funding Under Revenue Interest Purchase And Sale Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" xml:lang="en-US">Securities Purchased under Agreements to Resell</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" xlink:to="lab_roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" xml:lang="en-US">Committed Funding Under Revenue Interest Purchase And Sale Agreement.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CommittedFundingUnderRIPSA" xlink:label="loc_roiv_CommittedFundingUnderRIPSA" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CommittedFundingUnderRIPSA" xml:lang="en-US">Committed Funding Under RIPSA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_CommittedFundingUnderRIPSA" xml:lang="en-US">Committed funding under RIPSA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CommittedFundingUnderRIPSA" xlink:to="lab_roiv_CommittedFundingUnderRIPSA" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_CommittedFundingUnderRIPSA" xml:lang="en-US">Committed Funding Under RIPSA.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MilestonePaymentDueOverSixYearPeriod" xlink:label="loc_roiv_MilestonePaymentDueOverSixYearPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MilestonePaymentDueOverSixYearPeriod" xml:lang="en-US">Milestone Payment Due Over Six Year Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_MilestonePaymentDueOverSixYearPeriod" xml:lang="en-US">Milestone payment due over six year period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MilestonePaymentDueOverSixYearPeriod" xlink:to="lab_roiv_MilestonePaymentDueOverSixYearPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MilestonePaymentDueOverSixYearPeriod" xml:lang="en-US">Milestone payment due over six year period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_NovaquestMember" xlink:label="loc_roiv_NovaquestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_NovaquestMember" xml:lang="en-US">Novaquest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_NovaquestMember" xml:lang="en-US">NovaQuest Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_NovaquestMember" xlink:to="lab_roiv_NovaquestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_NovaquestMember" xml:lang="en-US">Novaquest.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrimeRateMember" xml:lang="en-US">Prime Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrimeRateMember" xml:lang="en-US">Prime Rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementMember" xlink:label="loc_roiv_RevenueInterestPurchaseAndSaleAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RevenueInterestPurchaseAndSaleAgreementMember" xml:lang="en-US">Revenue Interest Purchase And Sale Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_RevenueInterestPurchaseAndSaleAgreementMember" xml:lang="en-US">Revenue Interest Purchase and Sale Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RevenueInterestPurchaseAndSaleAgreementMember" xlink:to="lab_roiv_RevenueInterestPurchaseAndSaleAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RevenueInterestPurchaseAndSaleAgreementMember" xml:lang="en-US">Revenue Interest Purchase And Sale Agreement [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LongTermDebtExcludingDebtWithFairValueOption" xlink:label="loc_roiv_LongTermDebtExcludingDebtWithFairValueOption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_LongTermDebtExcludingDebtWithFairValueOption" xml:lang="en-US">Long Term Debt Excluding Debt With Fair Value Option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_roiv_LongTermDebtExcludingDebtWithFairValueOption" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_LongTermDebtExcludingDebtWithFairValueOption" xlink:to="lab_roiv_LongTermDebtExcludingDebtWithFairValueOption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_LongTermDebtExcludingDebtWithFairValueOption" xml:lang="en-US">Long Term Debt Excluding Debt With Fair Value Option</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xml:lang="en-US">Long-Term Debt, Maturity, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xml:lang="en-US">2027</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" xlink:label="loc_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" xml:lang="en-US">Agreement Related Billed Amount For Costs Incurred On Behalf Of Subsidiary,Net Of Amounts Billed By Subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" xml:lang="en-US">Cost incurred and recorded as offsets to general and administrative expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" xlink:to="lab_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" xml:lang="en-US">Agreement related billed amount for costs incurred on behalf of subsidiary,net of amounts billed by subsidiary.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AccessFeePaidToRelatedParty" xlink:label="loc_roiv_AccessFeePaidToRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AccessFeePaidToRelatedParty" xml:lang="en-US">Access Fee Paid to Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_AccessFeePaidToRelatedParty" xml:lang="en-US">Access fee paid pursuant to strategic cooperation agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AccessFeePaidToRelatedParty" xlink:to="lab_roiv_AccessFeePaidToRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AccessFeePaidToRelatedParty" xml:lang="en-US">Access Fee Paid to Related Party.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AssetPurchaseTransactionConsiderationReceivedInCash" xlink:label="loc_roiv_AssetPurchaseTransactionConsiderationReceivedInCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AssetPurchaseTransactionConsiderationReceivedInCash" xml:lang="en-US">Asset Purchase Transaction Consideration Received In Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_roiv_AssetPurchaseTransactionConsiderationReceivedInCash" xml:lang="en-US">Consideration received in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AssetPurchaseTransactionConsiderationReceivedInCash" xlink:to="lab_roiv_AssetPurchaseTransactionConsiderationReceivedInCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AssetPurchaseTransactionConsiderationReceivedInCash" xml:lang="en-US">Asset Purchase Transaction Consideration Received In Cash.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary" xlink:label="loc_roiv_AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary" xml:lang="en-US">Agreement Related To Amendment Terms Additional Consideration Received By Subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary" xml:lang="en-US">Agreement related to amendment terms additional consideration received by subsidiary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary" xlink:to="lab_roiv_AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary" xml:lang="en-US">Agreement related to amendment terms additional consideration received by subsidiary.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SumitomoMember" xlink:label="loc_roiv_SumitomoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SumitomoMember" xml:lang="en-US">Sumitomo [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SumitomoMember" xml:lang="en-US">Sumitomo [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SumitomoMember" xlink:to="lab_roiv_SumitomoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SumitomoMember" xml:lang="en-US">Sumitomo [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AssetPurchaseAgreementMember" xlink:label="loc_roiv_AssetPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AssetPurchaseAgreementMember" xml:lang="en-US">Asset Purchase Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AssetPurchaseAgreementMember" xlink:to="lab_roiv_AssetPurchaseAgreementMember" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TransitionServicesAndStrategicCooperationAgreementMember" xlink:label="loc_roiv_TransitionServicesAndStrategicCooperationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_TransitionServicesAndStrategicCooperationAgreementMember" xml:lang="en-US">Transition Services And Strategic Cooperation Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_TransitionServicesAndStrategicCooperationAgreementMember" xlink:to="lab_roiv_TransitionServicesAndStrategicCooperationAgreementMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ClassOfWarrantOrRightExercisable" xlink:label="loc_roiv_ClassOfWarrantOrRightExercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ClassOfWarrantOrRightExercisable" xml:lang="en-US">Class of Warrant or Right, Exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ClassOfWarrantOrRightExercisable" xml:lang="en-US">Number of exercisable outstanding warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ClassOfWarrantOrRightExercisable" xlink:to="lab_roiv_ClassOfWarrantOrRightExercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ClassOfWarrantOrRightExercisable" xml:lang="en-US">Class of Warrant or Right, Exercisable</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Net proceeds of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Common stock per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestments" xml:lang="en-US">Equity Method Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestments" xml:lang="en-US">Equity Method Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockVotingRights" xml:lang="en-US">Common Stock, Voting Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockVotingRights" xml:lang="en-US">Common Stock, Voting Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockVotingRights" xlink:to="lab_us-gaap_CommonStockVotingRights" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockHoldersEquityNoteStockSplitExchangeRatio1" xlink:label="loc_roiv_StockHoldersEquityNoteStockSplitExchangeRatio1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_StockHoldersEquityNoteStockSplitExchangeRatio1" xml:lang="en-US">Stock holders Equity Note Stock Split Exchange Ratio1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_StockHoldersEquityNoteStockSplitExchangeRatio1" xml:lang="en-US">Stockholders Equity Note Stock Split Exchange Ratio 1</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_StockHoldersEquityNoteStockSplitExchangeRatio1" xlink:to="lab_roiv_StockHoldersEquityNoteStockSplitExchangeRatio1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_StockHoldersEquityNoteStockSplitExchangeRatio1" xml:lang="en-US">Stock holders Equity Note Stock Split Exchange Ratio1</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SubscriptionReceived" xlink:label="loc_roiv_SubscriptionReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SubscriptionReceived" xml:lang="en-US">Subscription Received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SubscriptionReceived" xlink:to="lab_roiv_SubscriptionReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SubscriptionReceived" xml:lang="en-US">Subscription Received</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PurchaseObligation" xml:lang="en-US">Purchase Obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PercentageOfCommonSharesVolumeWeightedAveragePrice" xlink:label="loc_roiv_PercentageOfCommonSharesVolumeWeightedAveragePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PercentageOfCommonSharesVolumeWeightedAveragePrice" xml:lang="en-US">Percentage Of Common Shares Volume weighted Average Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PercentageOfCommonSharesVolumeWeightedAveragePrice" xml:lang="en-US">Percentage of common shares volume-weighted average price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PercentageOfCommonSharesVolumeWeightedAveragePrice" xlink:to="lab_roiv_PercentageOfCommonSharesVolumeWeightedAveragePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PercentageOfCommonSharesVolumeWeightedAveragePrice" xml:lang="en-US">Percentage of common shares volume-weighted average price.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_UpfrontCommitmentFeeNumberOfSharesIssued" xlink:label="loc_roiv_UpfrontCommitmentFeeNumberOfSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_UpfrontCommitmentFeeNumberOfSharesIssued" xml:lang="en-US">Upfront Commitment Fee Number Of Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_UpfrontCommitmentFeeNumberOfSharesIssued" xml:lang="en-US">Upfront commitment fee number of shares issued | shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_UpfrontCommitmentFeeNumberOfSharesIssued" xlink:to="lab_roiv_UpfrontCommitmentFeeNumberOfSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_UpfrontCommitmentFeeNumberOfSharesIssued" xml:lang="en-US">Upfront commitment fee number of shares issued | shares.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CommonSharesValueAvailableForSale" xlink:label="loc_roiv_CommonSharesValueAvailableForSale" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CommonSharesValueAvailableForSale" xml:lang="en-US">Common Shares Value Available For Sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_CommonSharesValueAvailableForSale" xml:lang="en-US">Common Shares Value Available For Sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CommonSharesValueAvailableForSale" xlink:to="lab_roiv_CommonSharesValueAvailableForSale" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_CommonSharesValueAvailableForSale" xml:lang="en-US">Common Shares Value Available For Sale.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ClassOfWarrantOrRightCanceled" xlink:label="loc_roiv_ClassOfWarrantOrRightCanceled" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ClassOfWarrantOrRightCanceled" xml:lang="en-US">Class Of Warrant Or Right Canceled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ClassOfWarrantOrRightCanceled" xlink:to="lab_roiv_ClassOfWarrantOrRightCanceled" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ClassOfWarrantOrRightCanceled" xml:lang="en-US">Class Of Warrant Or Right Canceled.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ImmunovantSciencesLtdMember" xlink:label="loc_roiv_ImmunovantSciencesLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ImmunovantSciencesLtdMember" xml:lang="en-US">Immunovant Sciences Ltd [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ImmunovantSciencesLtdMember" xml:lang="en-US">Immunovant Sciences Ltd [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ImmunovantSciencesLtdMember" xlink:to="lab_roiv_ImmunovantSciencesLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ImmunovantSciencesLtdMember" xml:lang="en-US">Immunovant Sciences Ltd [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_UnderwrittenPublicOfferingMember" xlink:label="loc_roiv_UnderwrittenPublicOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_UnderwrittenPublicOfferingMember" xml:lang="en-US">Underwritten Public Offering [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_UnderwrittenPublicOfferingMember" xml:lang="en-US">Underwritten Public Offering [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_UnderwrittenPublicOfferingMember" xlink:to="lab_roiv_UnderwrittenPublicOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_UnderwrittenPublicOfferingMember" xml:lang="en-US">Underwritten Public Offering [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ImmunovantINCMember" xlink:label="loc_roiv_ImmunovantINCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ImmunovantINCMember" xml:lang="en-US">Immunovant INC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ImmunovantINCMember" xml:lang="en-US">Immunovant, Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ImmunovantINCMember" xlink:to="lab_roiv_ImmunovantINCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ImmunovantINCMember" xml:lang="en-US">Immunovant INC.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xml:lang="en-US">Share Repurchase Program [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xml:lang="en-US">Share Repurchase Program [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xml:lang="en-US">Share Repurchase Program [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xml:lang="en-US">Share Repurchase Program [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xml:lang="en-US">Investment, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xml:lang="en-US">Investment, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SkMember" xlink:label="loc_roiv_SkMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SkMember" xml:lang="en-US">Sk [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SkMember" xml:lang="en-US">Sk [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SkMember" xlink:to="lab_roiv_SkMember" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CantorFitzgeraldCo.Member" xlink:label="loc_roiv_CantorFitzgeraldCo.Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CantorFitzgeraldCo.Member" xml:lang="en-US">Cantor Fitzgerald Co. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CantorFitzgeraldCo.Member" xlink:to="lab_roiv_CantorFitzgeraldCo.Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SubsidiaryEquityIncentivePlanMember" xlink:label="loc_roiv_SubsidiaryEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SubsidiaryEquityIncentivePlanMember" xml:lang="en-US">Subsidiary Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SubsidiaryEquityIncentivePlanMember" xml:lang="en-US">Subsidiary EIPs [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SubsidiaryEquityIncentivePlanMember" xlink:to="lab_roiv_SubsidiaryEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SubsidiaryEquityIncentivePlanMember" xml:lang="en-US">Subsidiary Equity Incentive Plan [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockOptionsAndPerformanceStockOptionsMember" xlink:label="loc_roiv_StockOptionsAndPerformanceStockOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_StockOptionsAndPerformanceStockOptionsMember" xml:lang="en-US">Stock Options And Performance Stock Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_StockOptionsAndPerformanceStockOptionsMember" xml:lang="en-US">Stock options and performance stock options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_StockOptionsAndPerformanceStockOptionsMember" xlink:to="lab_roiv_StockOptionsAndPerformanceStockOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_StockOptionsAndPerformanceStockOptionsMember" xml:lang="en-US">Stock options and performance stock options.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:label="loc_roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember" xml:lang="en-US">Restricted Stock Units And Performance Stock Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember" xml:lang="en-US">Restricted stock units and performance stock units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:to="lab_roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember" xml:lang="en-US">Restricted stock units and performance stock units.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SubsidiaryEquityIncentivePlansMember" xlink:label="loc_roiv_SubsidiaryEquityIncentivePlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SubsidiaryEquityIncentivePlansMember" xml:lang="en-US">Subsidiary Equity Incentive Plans [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SubsidiaryEquityIncentivePlansMember" xlink:to="lab_roiv_SubsidiaryEquityIncentivePlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SubsidiaryEquityIncentivePlansMember" xml:lang="en-US">Subsidiary equity incentive plans.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_March2020CappedValueAppreciationRightsMember" xlink:label="loc_roiv_March2020CappedValueAppreciationRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_March2020CappedValueAppreciationRightsMember" xml:lang="en-US">March 2020 Capped Value Appreciation Rights [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_March2020CappedValueAppreciationRightsMember" xml:lang="en-US">March 2020 CVARs [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_March2020CappedValueAppreciationRightsMember" xlink:to="lab_roiv_March2020CappedValueAppreciationRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_March2020CappedValueAppreciationRightsMember" xml:lang="en-US">March 2020 Capped Value Appreciation Rights.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common shares reserved for future issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unrecognized compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Remaining weighted-average service period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Common shares available for grant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OneTimeCatchUpExpense" xlink:label="loc_roiv_OneTimeCatchUpExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_OneTimeCatchUpExpense" xml:lang="en-US">One Time Catch Up Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_OneTimeCatchUpExpense" xml:lang="en-US">One time catch up expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_OneTimeCatchUpExpense" xlink:to="lab_roiv_OneTimeCatchUpExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_OneTimeCatchUpExpense" xml:lang="en-US">One time catch up expense</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares" xlink:label="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Intrinsic Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares" xml:lang="en-US">Share based compensation by share based award weighted average intrinsic value of equity instruments other than options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares" xlink:to="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares" xml:lang="en-US">Share based compensation by share based award weighted average intrinsic value of equity instruments other than options granted</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xml:lang="en-US">Percentage of outstanding stock increase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Stock options exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Stock options outstanding , Options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Fair value of options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Grant date fair value of stock options vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Service-vested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xml:lang="en-US">Total fair value of CVARs that service-vested during the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncrementOfEmployeeStockPurchasePlan" xlink:label="loc_roiv_IncrementOfEmployeeStockPurchasePlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IncrementOfEmployeeStockPurchasePlan" xml:lang="en-US">Increment of Employee Stock Purchase Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IncrementOfEmployeeStockPurchasePlan" xml:lang="en-US">Increment of employee stock purchase plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IncrementOfEmployeeStockPurchasePlan" xlink:to="lab_roiv_IncrementOfEmployeeStockPurchasePlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IncrementOfEmployeeStockPurchasePlan" xml:lang="en-US">Increment of employee stock purchase plan.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable" xlink:label="loc_roiv_EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable" xml:lang="en-US">Employee Stock Purchase Plan Maximum Number Of Common Shares Issuable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable" xml:lang="en-US">Employee stock purchase plan maximum number of common shares issuable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable" xlink:to="lab_roiv_EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable" xml:lang="en-US">Employee stock purchase plan maximum number of common shares issuable.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment" xlink:label="loc_roiv_IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment" xml:lang="en-US">Incremental Fair Value After March Two Thousand And Twenty Capped Value Appreciation Rights Amendment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment" xml:lang="en-US">Incremental fair value after march two thousand and twenty capped value appreciation rights amendment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment" xlink:to="lab_roiv_IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment" xml:lang="en-US">Incremental fair value after march two thousand and twenty capped value appreciation rights amendment.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EventAxis" xlink:label="loc_roiv_EventAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_EventAxis" xml:lang="en-US">Event [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_EventAxis" xlink:to="lab_roiv_EventAxis" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EventDomain" xlink:label="loc_roiv_EventDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_EventDomain" xml:lang="en-US">Event [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_EventDomain" xlink:to="lab_roiv_EventDomain" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMember" xlink:label="loc_roiv_AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMember" xml:lang="en-US">Achievement Of Liquidity Event Vesting Condition Upon Closing Of Business Combination [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMember" xlink:to="lab_roiv_AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockMember" xml:lang="en-US">Employee Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Expected stock price volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Expected risk free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" xlink:label="loc_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" xml:lang="en-US">Sharebased Compensation Arrangement by Sharebased Payment Award, Options, Granted, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-average grant date fair value per share of stock options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" xlink:to="lab_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant-date fair value of options granted.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IntrinsicValueOfOptionsExercised" xlink:label="loc_roiv_IntrinsicValueOfOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IntrinsicValueOfOptionsExercised" xml:lang="en-US">Intrinsic Value Of Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IntrinsicValueOfOptionsExercised" xml:lang="en-US">Intrinsic value of options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IntrinsicValueOfOptionsExercised" xlink:to="lab_roiv_IntrinsicValueOfOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IntrinsicValueOfOptionsExercised" xml:lang="en-US">Intrinsic Value Of Options Exercised.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Non-vested balance, ending</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Non-vested balance, beginning</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, vested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value, Service-vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RestrictedStockAndPerformanceStockUnitsMember" xlink:label="loc_roiv_RestrictedStockAndPerformanceStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RestrictedStockAndPerformanceStockUnitsMember" xml:lang="en-US">Restricted Stock And Performance Stock Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_RestrictedStockAndPerformanceStockUnitsMember" xml:lang="en-US">Restricted Stock And Performance Stock Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RestrictedStockAndPerformanceStockUnitsMember" xlink:to="lab_roiv_RestrictedStockAndPerformanceStockUnitsMember" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RSLEquityPlansMember" xlink:label="loc_roiv_RSLEquityPlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RSLEquityPlansMember" xml:lang="en-US">R S L Equity Plans [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_RSLEquityPlansMember" xml:lang="en-US">R S L Equity Plans Member</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RSLEquityPlansMember" xlink:to="lab_roiv_RSLEquityPlansMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Stock options outstanding ,Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Stock options outstanding , Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Options Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Options Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Forfeited/Canceled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Contractual Life , Options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value , Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Aggregate Intrinsic Value , Options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value, forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Non-vested units, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Non-vested units , Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncomeTaxDisclosureTable" xlink:label="loc_roiv_IncomeTaxDisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IncomeTaxDisclosureTable" xml:lang="en-US">Income Tax Disclosure [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IncomeTaxDisclosureTable" xml:lang="en-US">Income Tax Disclosure [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IncomeTaxDisclosureTable" xlink:to="lab_roiv_IncomeTaxDisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IncomeTaxDisclosureTable" xml:lang="en-US">Income Tax Disclosure [Table]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncomeTaxDisclosureLineItems" xlink:label="loc_roiv_IncomeTaxDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems" xlink:to="lab_roiv_IncomeTaxDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xml:lang="en-US">Loss before income taxes:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Total loss before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="loc_country_CH" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_CH" xml:lang="en-US">SWITZERLAND</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_CH" xml:lang="en-US">Switzerland [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CH" xlink:to="lab_country_CH" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OtherMember" xlink:label="loc_roiv_OtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_OtherMember" xml:lang="en-US">Other [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_OtherMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_OtherMember" xlink:to="lab_roiv_OtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_OtherMember" xml:lang="en-US">Other [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BM" xlink:label="loc_country_BM" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_BM" xml:lang="en-US">BERMUDA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_BM" xml:lang="en-US">Bermuda [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BM" xlink:to="lab_country_BM" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="loc_country_US" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US" xml:lang="en-US">UNITED STATES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_US" xml:lang="en-US">United States [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ComponentsOfIncomeTaxExpenseTable" xlink:label="loc_roiv_ComponentsOfIncomeTaxExpenseTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ComponentsOfIncomeTaxExpenseTable" xml:lang="en-US">Components Of Income Tax Expense [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ComponentsOfIncomeTaxExpenseTable" xml:lang="en-US">Components Of Income Tax Expense [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseTable" xlink:to="lab_roiv_ComponentsOfIncomeTaxExpenseTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ComponentsOfIncomeTaxExpenseTable" xml:lang="en-US">Components Of Income Tax Expense [Table]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ComponentsOfIncomeTaxExpenseLineItems" xlink:label="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ComponentsOfIncomeTaxExpenseLineItems" xml:lang="en-US">Components Of Income Tax Expense [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ComponentsOfIncomeTaxExpenseLineItems" xml:lang="en-US">Components Of Income Tax Expense [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems" xlink:to="lab_roiv_ComponentsOfIncomeTaxExpenseLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ComponentsOfIncomeTaxExpenseLineItems" xml:lang="en-US">Components Of Income Tax Expense [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Current taxes:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Total current tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Deferred taxes:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Total deferred tax benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Research and development tax credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsExpirationDate" xml:lang="en-US">Operating Loss Carryforwards, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwardsExpirationDate" xml:lang="en-US">Net operating losses expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="lab_us-gaap_OperatingLossCarryforwardsExpirationDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="loc_us-gaap_TaxCreditCarryforwardExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardExpirationDate" xml:lang="en-US">Tax Credit Carryforward, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardExpirationDate" xml:lang="en-US">Research and development tax credit expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardExpirationDate" xlink:to="lab_us-gaap_TaxCreditCarryforwardExpirationDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Total income tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xml:lang="en-US">Interest and penalties related to unrecognized tax benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation allowance increase (decrease)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AnnualNOLUtilizationLimitationPercentage" xlink:label="loc_roiv_AnnualNOLUtilizationLimitationPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AnnualNOLUtilizationLimitationPercentage" xml:lang="en-US">Annual NOL Utilization Limitation Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_AnnualNOLUtilizationLimitationPercentage" xml:lang="en-US">Annual NOL utilization limitation percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AnnualNOLUtilizationLimitationPercentage" xlink:to="lab_roiv_AnnualNOLUtilizationLimitationPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AnnualNOLUtilizationLimitationPercentage" xml:lang="en-US">Annual NOL utilization limitation percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB" xlink:label="loc_country_GB" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_GB" xml:lang="en-US">UNITED KINGDOM</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_GB" xml:lang="en-US">United Kingdom [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TaxAuthorityInOtherJurisdictionsMember" xlink:label="loc_roiv_TaxAuthorityInOtherJurisdictionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_TaxAuthorityInOtherJurisdictionsMember" xml:lang="en-US">Tax Authority In Other Jurisdictions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_TaxAuthorityInOtherJurisdictionsMember" xml:lang="en-US">Other Jurisdictions [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_TaxAuthorityInOtherJurisdictionsMember" xlink:to="lab_roiv_TaxAuthorityInOtherJurisdictionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_TaxAuthorityInOtherJurisdictionsMember" xml:lang="en-US">Tax Authority In Other Jurisdictions [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_UnitedStatesAndCanadaMember" xlink:label="loc_roiv_UnitedStatesAndCanadaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_UnitedStatesAndCanadaMember" xml:lang="en-US">United States And Canada [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_UnitedStatesAndCanadaMember" xlink:to="lab_roiv_UnitedStatesAndCanadaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_UnitedStatesAndCanadaMember" xml:lang="en-US">United states&#160;and canada.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">United States and Local Jurisdiction [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredTaxAssetsLiabilitiesTable" xlink:label="loc_roiv_DeferredTaxAssetsLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DeferredTaxAssetsLiabilitiesTable" xml:lang="en-US">Deferred Tax Assets Liabilities [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DeferredTaxAssetsLiabilitiesTable" xml:lang="en-US">Deferred Tax Assets Liabilities [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesTable" xlink:to="lab_roiv_DeferredTaxAssetsLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DeferredTaxAssetsLiabilitiesTable" xml:lang="en-US">Deferred Tax Assets Liabilities [Table]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredTaxAssetsLiabilitiesLineItems" xlink:label="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DeferredTaxAssetsLiabilitiesLineItems" xml:lang="en-US">Deferred Tax Assets Liabilities [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DeferredTaxAssetsLiabilitiesLineItems" xml:lang="en-US">Deferred Tax Assets Liabilities [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems" xlink:to="lab_roiv_DeferredTaxAssetsLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DeferredTaxAssetsLiabilitiesLineItems" xml:lang="en-US">Deferred Tax Assets Liabilities [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xml:lang="en-US">Deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Net Deferred tax assets/(liabilities), net of valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_roiv_DeferredTaxLiabilitiesDepreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DeferredTaxLiabilitiesDepreciation" xml:lang="en-US">Deferred Tax Liabilities, Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_DeferredTaxLiabilitiesDepreciation" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DeferredTaxLiabilitiesDepreciation" xlink:to="lab_roiv_DeferredTaxLiabilitiesDepreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DeferredTaxLiabilitiesDepreciation" xml:lang="en-US">Deferred Tax Liabilities, Depreciation</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US">Deferred Tax Liabilities, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="loc_roiv_DeferredTaxLiabilitiesRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DeferredTaxLiabilitiesRightOfUseAssets" xml:lang="en-US">Deferred tax liabilities right of use assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_DeferredTaxLiabilitiesRightOfUseAssets" xml:lang="en-US">Right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="lab_roiv_DeferredTaxLiabilitiesRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DeferredTaxLiabilitiesRightOfUseAssets" xml:lang="en-US">Deferred tax liabilities right of use assets</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xml:lang="en-US">Deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Subtotal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Research tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_roiv_DeferredTaxAssetsLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DeferredTaxAssetsLeaseLiabilities" xml:lang="en-US">Deferred tax assets lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DeferredTaxAssetsLeaseLiabilities" xml:lang="en-US">Lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_roiv_DeferredTaxAssetsLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DeferredTaxAssetsLeaseLiabilities" xml:lang="en-US">Deferred tax assets lease liabilities</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TaxRatesAbstract" xlink:label="loc_roiv_TaxRatesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_TaxRatesAbstract" xml:lang="en-US">Tax Rates [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_TaxRatesAbstract" xlink:to="lab_roiv_TaxRatesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_TaxRatesAbstract" xml:lang="en-US">Tax Rates [Abstract]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EffectiveTaxRateReconcilingItemsTable" xlink:label="loc_roiv_EffectiveTaxRateReconcilingItemsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_EffectiveTaxRateReconcilingItemsTable" xml:lang="en-US">Effective Tax Rate Reconciling Items [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_EffectiveTaxRateReconcilingItemsTable" xml:lang="en-US">Effective Tax Rate Reconciling Items [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_EffectiveTaxRateReconcilingItemsTable" xlink:to="lab_roiv_EffectiveTaxRateReconcilingItemsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_EffectiveTaxRateReconcilingItemsTable" xml:lang="en-US">Effective Tax Rate Reconciling Items [Table]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EffectiveTaxRateReconcilingItemsLineItems" xlink:label="loc_roiv_EffectiveTaxRateReconcilingItemsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_EffectiveTaxRateReconcilingItemsLineItems" xml:lang="en-US">Effective Tax Rate Reconciling Items [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_EffectiveTaxRateReconcilingItemsLineItems" xml:lang="en-US">Effective Tax Rate Reconciling Items [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_EffectiveTaxRateReconcilingItemsLineItems" xlink:to="lab_roiv_EffectiveTaxRateReconcilingItemsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_EffectiveTaxRateReconcilingItemsLineItems" xml:lang="en-US">Effective Tax Rate Reconciling Items [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in Valuation Allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Income tax benefit at Bermuda statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Foreign rate differential(1)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Tax rate changes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xml:lang="en-US">Nontaxable gain on deconsolidation of business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xml:lang="en-US">Permanent disallowed IPR&amp;D</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xml:lang="en-US">Research&#160;tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xml:lang="en-US">Tax-effect of changes in the fair value of investments and loss from equity method investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xml:lang="en-US">Nontaxable gain on sale of investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Nondeductible executive compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xml:lang="en-US">Tax deficiencies (excess tax benefits) from share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Other, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xml:lang="en-US">Other permanent&#160;adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xml:lang="en-US">Permanent disallowed IPR&amp;D</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xml:lang="en-US">Research&#160;tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Tax rate changes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xml:lang="en-US">Nontaxable gain on deconsolidation of business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:to="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Foreign rate differential</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Income tax benefit at Bermuda statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:label="loc_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xml:lang="en-US">Tax-effect of changes in the fair value of investments and loss from equity method investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:to="lab_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xml:lang="en-US">Nontaxable gain on sale of investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:to="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Nondeductible executive compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xml:lang="en-US">Tax deficiencies (excess tax benefits) from stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDeductionsOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationDeductionsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationDeductionsOther" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Other, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationDeductionsOther" xml:lang="en-US">Other permanent&#160;adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationDeductionsOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationDeductionsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostAbstract" xml:lang="en-US">Lease, Cost [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Total operating lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermLeaseCost" xml:lang="en-US">Short-term Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermLeaseCost" xml:lang="en-US">Short-term lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Weighted average discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Weighted average remaining lease term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Cash paid for operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US">Maturities of operating lease liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">2027</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:label="loc_roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xml:lang="en-US">Lessee Operating Lease Liability Tenant Improvement Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xml:lang="en-US">Less: tenant improvement allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:to="lab_roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xml:lang="en-US">Lessee operating lease liability tenant improvement allowance..</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OperatingLeaseLiabilityPresentValueAdjustments" xlink:label="loc_roiv_OperatingLeaseLiabilityPresentValueAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_OperatingLeaseLiabilityPresentValueAdjustments" xml:lang="en-US">Operating Lease Liability Present Value Adjustments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_OperatingLeaseLiabilityPresentValueAdjustments" xml:lang="en-US">Less: present value adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_OperatingLeaseLiabilityPresentValueAdjustments" xlink:to="lab_roiv_OperatingLeaseLiabilityPresentValueAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_OperatingLeaseLiabilityPresentValueAdjustments" xml:lang="en-US">Operating Lease Liability Present Value Adjustments</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xml:lang="en-US">Purchase commitment, remaining minimum payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MasterSubscriptionAgreementMember" xlink:label="loc_roiv_MasterSubscriptionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MasterSubscriptionAgreementMember" xml:lang="en-US">Master Subscription Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MasterSubscriptionAgreementMember" xlink:to="lab_roiv_MasterSubscriptionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MasterSubscriptionAgreementMember" xml:lang="en-US">Master subscription agreement.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProductServiceAgreementMember" xlink:label="loc_roiv_ProductServiceAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ProductServiceAgreementMember" xml:lang="en-US">Product Service Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ProductServiceAgreementMember" xlink:to="lab_roiv_ProductServiceAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ProductServiceAgreementMember" xml:lang="en-US">Product service agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xml:lang="en-US">Liability instruments measured at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Money market funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Total liabilities at fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivPublicWarrantsMember" xlink:label="loc_roiv_RoivPublicWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RoivPublicWarrantsMember" xml:lang="en-US">Roiv Public Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_RoivPublicWarrantsMember" xml:lang="en-US">Roiv Public Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RoivPublicWarrantsMember" xlink:to="lab_roiv_RoivPublicWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RoivPublicWarrantsMember" xml:lang="en-US">Roiv public warrants.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivPrivatePlacementWarrantsMember" xlink:label="loc_roiv_RoivPrivatePlacementWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RoivPrivatePlacementWarrantsMember" xml:lang="en-US">Roiv Private Placement Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_RoivPrivatePlacementWarrantsMember" xml:lang="en-US">Roiv Private Placement Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RoivPrivatePlacementWarrantsMember" xlink:to="lab_roiv_RoivPrivatePlacementWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RoivPrivatePlacementWarrantsMember" xml:lang="en-US">Roiv private placement warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivLiabilityInstrumentsMeasuredAtFairValueMember" xlink:label="loc_roiv_RoivLiabilityInstrumentsMeasuredAtFairValueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RoivLiabilityInstrumentsMeasuredAtFairValueMember" xml:lang="en-US">Roiv Liability Instruments Measured At Fair Value [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_RoivLiabilityInstrumentsMeasuredAtFairValueMember" xml:lang="en-US">Roiv Liability Instruments Measured At Fair Value [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RoivLiabilityInstrumentsMeasuredAtFairValueMember" xlink:to="lab_roiv_RoivLiabilityInstrumentsMeasuredAtFairValueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RoivLiabilityInstrumentsMeasuredAtFairValueMember" xml:lang="en-US">Roiv liability instruments measured at fair value.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivEarnoutSharesMember" xlink:label="loc_roiv_RoivEarnoutSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RoivEarnoutSharesMember" xml:lang="en-US">Roiv Earnout Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_RoivEarnoutSharesMember" xml:lang="en-US">Roiv Earnout Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RoivEarnoutSharesMember" xlink:to="lab_roiv_RoivEarnoutSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RoivEarnoutSharesMember" xml:lang="en-US">Roiv earnout shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_NonfinancialLiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Nonfinancial Liabilities Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Non financial liabilities at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_NonfinancialLiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Financial liabilities at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueDisclosuresTable" xlink:label="loc_roiv_FairValueDisclosuresTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FairValueDisclosuresTable" xml:lang="en-US">Fair Value Disclosures [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FairValueDisclosuresTable" xml:lang="en-US">Fair Value Disclosures [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FairValueDisclosuresTable" xlink:to="lab_roiv_FairValueDisclosuresTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FairValueDisclosuresTable" xml:lang="en-US">Fair Value Disclosures [Table]</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueDisclosuresLineItems" xlink:label="loc_roiv_FairValueDisclosuresLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FairValueDisclosuresLineItems" xml:lang="en-US">Fair Value Disclosures [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FairValueDisclosuresLineItems" xml:lang="en-US">Fair Value Disclosures [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FairValueDisclosuresLineItems" xlink:to="lab_roiv_FairValueDisclosuresLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FairValueDisclosuresLineItems" xml:lang="en-US">Fair Value Disclosures [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xml:lang="en-US">Debt Instrument, Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xml:lang="en-US">Discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:to="lab_us-gaap_DebtInstrumentMeasurementInput" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EquityInterestOptionToThirdPartyPurchase" xlink:label="loc_roiv_EquityInterestOptionToThirdPartyPurchase" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_EquityInterestOptionToThirdPartyPurchase" xml:lang="en-US">Equity Interest Option to Third Party Purchase</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_EquityInterestOptionToThirdPartyPurchase" xml:lang="en-US">Fair value of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_EquityInterestOptionToThirdPartyPurchase" xlink:to="lab_roiv_EquityInterestOptionToThirdPartyPurchase" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_EquityInterestOptionToThirdPartyPurchase" xml:lang="en-US">Equity interest option to third-party purchase.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US">Measurement Input, Discount Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US">Measurement Input, Discount Rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValueMember" xlink:label="loc_roiv_LiabilityInstrumentsMeasuredAtFairValueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_LiabilityInstrumentsMeasuredAtFairValueMember" xml:lang="en-US">Liability Instruments Measured At Fair Value [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_LiabilityInstrumentsMeasuredAtFairValueMember" xml:lang="en-US">Liability Instruments Measured At Fair Value [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_LiabilityInstrumentsMeasuredAtFairValueMember" xlink:to="lab_roiv_LiabilityInstrumentsMeasuredAtFairValueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_LiabilityInstrumentsMeasuredAtFairValueMember" xml:lang="en-US">Liability Instruments Measured At Fair Value [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Balance at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Balance at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Changes in fair value of debt and liability instruments, included in net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Termination of DSP Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" xlink:label="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" xml:lang="en-US">Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Disposed Due to Deconsolidation of Subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" xml:lang="en-US">Liability instruments disposed due to deconsolidation of subsidiary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" xlink:to="lab_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, disposed due to deconsolidation of subsidiary.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xml:lang="en-US">Fair value of liability instrument issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne" xlink:label="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne" xml:lang="en-US">Settlements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne" xlink:to="lab_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis liability settlements one.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment" xlink:label="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment" xml:lang="en-US">Fair value of investment in Datavant at recognition date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment" xlink:to="lab_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis asset investment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xml:lang="en-US">Changes in fair value of investment in Datavant, included in net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueAssetMeasurementInput" xlink:label="loc_roiv_FairValueAssetMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FairValueAssetMeasurementInput" xml:lang="en-US">Fair Value Asset Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FairValueAssetMeasurementInput" xml:lang="en-US">Fair Value Asset Measurement Input</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FairValueAssetMeasurementInput" xlink:to="lab_roiv_FairValueAssetMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FairValueAssetMeasurementInput" xml:lang="en-US">Fair value asset measurement input.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xml:lang="en-US">Derivative Liability, Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xml:lang="en-US">Derivative Liability, Measurement Input</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="lab_us-gaap_DerivativeLiabilityMeasurementInput" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xml:lang="en-US">Risk-free rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xml:lang="en-US">Term (in years)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xml:lang="en-US">Volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xml:lang="en-US">Alternative Investment, Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xml:lang="en-US">Investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="lab_us-gaap_AlternativeInvestmentMeasurementInput" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AlternativeInvestmentExpectedTerm" xlink:label="loc_roiv_AlternativeInvestmentExpectedTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AlternativeInvestmentExpectedTerm" xml:lang="en-US">Alternative Investment Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_AlternativeInvestmentExpectedTerm" xml:lang="en-US">Time to expiration (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AlternativeInvestmentExpectedTerm" xlink:to="lab_roiv_AlternativeInvestmentExpectedTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AlternativeInvestmentExpectedTerm" xml:lang="en-US">Alternative investment expected term.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xml:lang="en-US">Measurement Input, Option Volatility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xml:lang="en-US">Measurement Input, Option Volatility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputOptionVolatilityMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="loc_us-gaap_OtherExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherExpensesAbstract" xml:lang="en-US">Other Expenses [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherExpensesAbstract" xlink:to="lab_us-gaap_OtherExpensesAbstract" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OtherIncomeExpense" xlink:label="loc_roiv_OtherIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_OtherIncomeExpense" xml:lang="en-US">Other Income Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_OtherIncomeExpense" xml:lang="en-US">Other (expense) income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_OtherIncomeExpense" xlink:to="lab_roiv_OtherIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_OtherIncomeExpense" xml:lang="en-US">Other Income Expense</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OtherOperatingIncomeExpensesNet" xlink:label="loc_roiv_OtherOperatingIncomeExpensesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_OtherOperatingIncomeExpensesNet" xml:lang="en-US">Other Operating Income Expenses Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_roiv_OtherOperatingIncomeExpensesNet" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_OtherOperatingIncomeExpensesNet" xlink:to="lab_roiv_OtherOperatingIncomeExpensesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_OtherOperatingIncomeExpensesNet" xml:lang="en-US">Other operating income expenses net.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest Income, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_NovemberTwoThousandAndTwentyOneCvarsMember" xlink:label="loc_roiv_NovemberTwoThousandAndTwentyOneCvarsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_NovemberTwoThousandAndTwentyOneCvarsMember" xml:lang="en-US">November Two Thousand And Twenty One Cvars [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_NovemberTwoThousandAndTwentyOneCvarsMember" xml:lang="en-US">November 2021 CVARs [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_NovemberTwoThousandAndTwentyOneCvarsMember" xlink:to="lab_roiv_NovemberTwoThousandAndTwentyOneCvarsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_NovemberTwoThousandAndTwentyOneCvarsMember" xml:lang="en-US">November two thousand and twenty one CVARS.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TwoThousandAndTwentyCvarsMember" xlink:label="loc_roiv_TwoThousandAndTwentyCvarsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_TwoThousandAndTwentyCvarsMember" xml:lang="en-US">Two Thousand And Twenty Cvars [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_TwoThousandAndTwentyCvarsMember" xml:lang="en-US">March 2020 CVARs [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_TwoThousandAndTwentyCvarsMember" xlink:to="lab_roiv_TwoThousandAndTwentyCvarsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_TwoThousandAndTwentyCvarsMember" xml:lang="en-US">Two thousand and CVARS.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted common stock (non-vested) [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EarnOutSharesNonvestedMember" xlink:label="loc_roiv_EarnOutSharesNonvestedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_EarnOutSharesNonvestedMember" xml:lang="en-US">Earn Out Shares Nonvested [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_EarnOutSharesNonvestedMember" xml:lang="en-US">Earn-Out Shares (non-vested) [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_EarnOutSharesNonvestedMember" xlink:to="lab_roiv_EarnOutSharesNonvestedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_EarnOutSharesNonvestedMember" xml:lang="en-US">Earn out shares nonvested.</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OtherInstrumentsIssuedMember" xlink:label="loc_roiv_OtherInstrumentsIssuedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_OtherInstrumentsIssuedMember" xml:lang="en-US">Other Instruments Issued [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_roiv_OtherInstrumentsIssuedMember" xml:lang="en-US">Other instruments issued [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_OtherInstrumentsIssuedMember" xlink:to="lab_roiv_OtherInstrumentsIssuedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_OtherInstrumentsIssuedMember" xml:lang="en-US">Other instruments issued.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementAxis" xml:lang="en-US">Revision of Prior Period [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RestatementAxis" xml:lang="en-US">Revision of Prior Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementDomain" xml:lang="en-US">Revision of Prior Period [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RestatementDomain" xml:lang="en-US">Revision of Prior Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MilestonePaymentPeriod" xlink:label="loc_roiv_MilestonePaymentPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MilestonePaymentPeriod" xml:lang="en-US">Milestone Payment Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MilestonePaymentPeriod" xlink:to="lab_roiv_MilestonePaymentPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MilestonePaymentPeriod" xml:lang="en-US">Milestone Payment Period</label>
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement" xlink:label="loc_roiv_GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement" xml:lang="en-US">Gross Proceeds From Revenue Interest Purchase And Sale Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement" xml:lang="en-US">Gross proceeds from revenue interest purchase and sale agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement" xlink:to="lab_roiv_GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement" xml:lang="en-US">Gross proceeds from revenue interest purchase and sale agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivrevenueInterestPurchaseAndSaleAgreementMemberMember" xlink:label="loc_roiv_RoivrevenueInterestPurchaseAndSaleAgreementMemberMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RoivrevenueInterestPurchaseAndSaleAgreementMemberMember" xml:lang="en-US">ROIVRevenue Interest Purchase And Sale Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RoivrevenueInterestPurchaseAndSaleAgreementMemberMember" xlink:to="lab_roiv_RoivrevenueInterestPurchaseAndSaleAgreementMemberMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GSKMember" xlink:label="loc_roiv_GSKMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_GSKMember" xml:lang="en-US">G S K [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_GSKMember" xml:lang="en-US">G S K</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_GSKMember" xlink:to="lab_roiv_GSKMember" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_WelichemBiotechIncMember" xlink:label="loc_roiv_WelichemBiotechIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_WelichemBiotechIncMember" xml:lang="en-US">Welichem Biotech Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_WelichemBiotechIncMember" xlink:to="lab_roiv_WelichemBiotechIncMember" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>roiv-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 28-June-2022 [03:58:35] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#Cover" roleURI="http://roivant.com/role/Cover" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ConsolidatedBalanceSheets" roleURI="http://roivant.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://roivant.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ConsolidatedStatementsOfOperations" roleURI="http://roivant.com/role/ConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ConsolidatedStatementsOfOperationsParenthetical" roleURI="http://roivant.com/role/ConsolidatedStatementsOfOperationsParenthetical" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest" roleURI="http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://roivant.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#DescriptionOfBusinessAndLiquidity" roleURI="http://roivant.com/role/DescriptionOfBusinessAndLiquidity" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#BusinessCombinationWithMaac" roleURI="http://roivant.com/role/BusinessCombinationWithMaac" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#Investments" roleURI="http://roivant.com/role/Investments" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#AssetAcquisitionsAndLicenseAgreements" roleURI="http://roivant.com/role/AssetAcquisitionsAndLicenseAgreements" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#AccruedExpenses" roleURI="http://roivant.com/role/AccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LongTermDebtAndLoanCommitment" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitment" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#RelatedPartyTransactions" roleURI="http://roivant.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareholdersEquity" roleURI="http://roivant.com/role/ShareholdersEquity" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareBasedCompensation" roleURI="http://roivant.com/role/ShareBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#IncomeTaxes" roleURI="http://roivant.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#Leases" roleURI="http://roivant.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#CommitmentsContingencies" roleURI="http://roivant.com/role/CommitmentsContingencies" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#FairValueMeasurements" roleURI="http://roivant.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#OtherExpenseNet" roleURI="http://roivant.com/role/OtherExpenseNet" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#NetLossPerCommonShare" roleURI="http://roivant.com/role/NetLossPerCommonShare" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#SubsequentEvents" roleURI="http://roivant.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#AccruedExpensesTables" roleURI="http://roivant.com/role/AccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LongTermDebtAndLoanCommitmentTables" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareBasedCompensationTables" roleURI="http://roivant.com/role/ShareBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#IncomeTaxesTables" roleURI="http://roivant.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LeasesTables" roleURI="http://roivant.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#FairValueMeasurementsTables" roleURI="http://roivant.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#OtherExpenseNetTables" roleURI="http://roivant.com/role/OtherExpenseNetTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#NetLossPerCommonShareTables" roleURI="http://roivant.com/role/NetLossPerCommonShareTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#DescriptionOfBusinessAndLiquidityAdditionalInformationDetail" roleURI="http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#BusinessCombinationWithMaacAdditionalInformationDetail" roleURI="http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#InvestmentsAdditionalInformationDetail" roleURI="http://roivant.com/role/InvestmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail" roleURI="http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#AccruedExpensesScheduleOfAccruedExpensesDetail" roleURI="http://roivant.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LongTermDebtAndLoanCommitmentAdditionalInformationDetail" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareholdersEquityAdditionalInformationDetail" roleURI="http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareBasedCompensationAdditionalInformationDetail" roleURI="http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareBasedCompensationScheduleOfFairValueAssumptionsDetail" roleURI="http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail" roleURI="http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail" roleURI="http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://roivant.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail" roleURI="http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" roleURI="http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LeasesScheduleOfOperatingLeaseCostsDetail" roleURI="http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail" roleURI="http://roivant.com/role/LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" roleURI="http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://roivant.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail" roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#FairValueMeasurementsAdditionalInformationDetail" roleURI="http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail" roleURI="http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#FairValueMeasurementsScheduleOfChangeInFairValueOfTheLevel3AssetsDetail" roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfChangeInFairValueOfTheLevel3AssetsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail" roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail" roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail" roleURI="http://roivant.com/role/OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail" roleURI="http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20220331.xsd#SubsequentEventsAdditionalInformationDetail" roleURI="http://roivant.com/role/SubsequentEventsAdditionalInformationDetail" />
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/Cover">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1475340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2" xlink:to="loc_us-gaap_StatementTable_1475340" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1475341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1475340" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1475341" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1475342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1475341" xlink:to="loc_us-gaap_ClassOfStockDomain_1475342" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1475344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1475342" xlink:to="loc_us-gaap_WarrantMember_1475344" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1475345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1475342" xlink:to="loc_us-gaap_CommonStockMember_1475345" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1475343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1475340" xlink:to="loc_us-gaap_StatementLineItems_1475343" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_DocumentType_3" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_AmendmentFlag_4" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityRegistrantName_5" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityCentralIndexKey_6" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityFilerCategory_7" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntitySmallBusiness_8" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityEmergingGrowthCompany_9" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityExTransitionPeriod_10" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_1096076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_DocumentTransitionReport_1096076" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_1096081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_DocumentPeriodEndDate_1096081" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_1096083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_DocumentFiscalYearFocus_1096083" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1096086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1096086" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_1096091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_CurrentFiscalYearEndDate_1096091" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_1096094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityFileNumber_1096094" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1096095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1096095" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_1096096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityTaxIdentificationNumber_1096096" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_1096099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityAddressAddressLine1_1096099" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_1096100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityAddressAddressLine2_1096100" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_1096102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityAddressCityOrTown_1096102" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_1096103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityAddressPostalZipCode_1096103" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_dei_CountryRegion_1105052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_CountryRegion_1105052" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_1096104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_CityAreaCode_1096104" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_1096106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_LocalPhoneNumber_1096106" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_1096107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityCurrentReportingStatus_1096107" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_1096111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityInteractiveDataCurrent_1096111" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_1096807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityAddressCountry_1096807" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_1096133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityShellCompany_1096133" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_1096141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_Security12bTitle_1096141" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_1096142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_TradingSymbol_1096142" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_1096143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_SecurityExchangeName_1096143" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1096113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1096113" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_1475335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_DocumentAnnualReport_1475335" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_1475347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_1475347" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_1475348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityVoluntaryFilers_1475348" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_1475349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_IcfrAuditorAttestationFlag_1475349" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_1476439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_EntityPublicFloat_1476439" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_1514483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_AuditorName_1514483" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_1514484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_AuditorFirmId_1514484" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_1514485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475343" xlink:to="loc_dei_AuditorLocation_1514485" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12" xlink:to="loc_us-gaap_StatementTable_22" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_22" xlink:to="loc_dei_LegalEntityAxis_17" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_17" xlink:to="loc_dei_EntityDomain_16" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_22" xlink:to="loc_us-gaap_StatementClassOfStockAxis_20" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_20" xlink:to="loc_us-gaap_ClassOfStockDomain_15" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_22" xlink:to="loc_us-gaap_StatementLineItems_21" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_AssetsAbstract_13" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_AssetsCurrentAbstract_14" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_RestrictedCashCurrent_34" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_OtherAssetsCurrent_36" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_AssetsCurrent_38" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_24" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_26" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_27" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_28" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_LongTermInvestments_29" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_30" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_Assets_31" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_19" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_AccountsPayableCurrent_55" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_56" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_57" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredConsiderationLiabilityCurrent" xlink:label="loc_roiv_DeferredConsiderationLiabilityCurrent_1106509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_roiv_DeferredConsiderationLiabilityCurrent_1106509" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_1475354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_DeferredRevenueCurrent_1475354" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_61" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_LiabilitiesCurrent_62" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValue" xlink:label="loc_roiv_LiabilityInstrumentsMeasuredAtFairValue_1106513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_roiv_LiabilityInstrumentsMeasuredAtFairValue_1106513" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_44" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_46" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_1475356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_1475356" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_47" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_Liabilities_48" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_CommitmentsAndContingencies_49" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_50" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_StockholdersEquityAbstract_23" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_CommonStockValue_64" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_AdditionalPaidInCapital_65" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SubscriptionsReceivable" xlink:label="loc_roiv_SubscriptionsReceivable_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_roiv_SubscriptionsReceivable_66" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_67" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_68" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_69" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_StockholdersEquity_69" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_MinorityInterest_52" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_54" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_71" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_71" xlink:to="loc_us-gaap_StatementTable_77" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_77" xlink:to="loc_us-gaap_StatementClassOfStockAxis_75" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_75" xlink:to="loc_us-gaap_ClassOfStockDomain_72" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_77" xlink:to="loc_dei_LegalEntityAxis_74" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_74" xlink:to="loc_dei_EntityDomain_73" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_77" xlink:to="loc_us-gaap_StatementLineItems_76" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_LongTermDebtFairValue_82" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_89" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_89" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_90" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_91" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_CommonStockSharesIssued_91" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_92" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_92" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_95" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95" xlink:to="loc_us-gaap_StatementTable_104" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_104" xlink:to="loc_dei_LegalEntityAxis_100" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_100" xlink:to="loc_dei_EntityDomain_98" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_104" xlink:to="loc_us-gaap_StatementLineItems_103" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_130" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_OperatingExpensesAbstract_101" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OperatingCosts" xlink:label="loc_roiv_OperatingCosts_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_101" xlink:to="loc_roiv_OperatingCosts_116" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_101" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_117" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AcquiredInProcessResearchAndDevelopmentExpense" xlink:label="loc_roiv_AcquiredInProcessResearchAndDevelopmentExpense_1476506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_101" xlink:to="loc_roiv_AcquiredInProcessResearchAndDevelopmentExpense_1476506" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_101" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_118" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_101" xlink:to="loc_us-gaap_OperatingExpenses_119" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_OperatingIncomeLoss_131" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_us-gaap_GainLossOnInvestments_122" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="loc_us-gaap_GainOnSaleOfInvestments_1294532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_us-gaap_GainOnSaleOfInvestments_1294532" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_124" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xlink:label="loc_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination_1106522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination_1106522" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" xlink:label="loc_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity_126" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_128" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1294542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1294542" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_134" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_ProfitLoss_137" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_138" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_NetIncomeLoss_139" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_96" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_96" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_96" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_107" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_97" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_97" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_97" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_112" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ConsolidatedStatementsOfOperationsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_1475374" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1475375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1475374" xlink:to="loc_us-gaap_StatementTable_1475375" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1475376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1475375" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1475376" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1475377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1475376" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1475377" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1475378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1475377" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1475378" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1475380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1475377" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1475380" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1475381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1475375" xlink:to="loc_us-gaap_StatementLineItems_1475381" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1475383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1475381" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1475383" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_882" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_882" xlink:to="loc_us-gaap_ProfitLoss_886" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_882" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_883" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_883" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_884" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_883" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_885" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_882" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_887" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_882" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_888" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_882" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_889" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfPartnersCapitalAbstract" xlink:label="loc_us-gaap_StatementOfPartnersCapitalAbstract_142" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfPartnersCapitalAbstract_142" xlink:to="loc_us-gaap_StatementTable_150" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_150" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_148" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_148" xlink:to="loc_us-gaap_EquityComponentDomain_145" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RedeemableNoncontrollingInterestMember" xlink:label="loc_roiv_RedeemableNoncontrollingInterestMember_1295290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_roiv_RedeemableNoncontrollingInterestMember_1295290" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_us-gaap_CommonStockMember_155" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_156" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SubscriptionsReceivablesMember" xlink:label="loc_roiv_SubscriptionsReceivablesMember_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_roiv_SubscriptionsReceivablesMember_158" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_159" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_us-gaap_RetainedEarningsMember_157" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_us-gaap_NoncontrollingInterestMember_160" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_150" xlink:to="loc_us-gaap_StatementClassOfStockAxis_147" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_147" xlink:to="loc_us-gaap_ClassOfStockDomain_143" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_150" xlink:to="loc_us-gaap_StatementLineItems_149" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_161" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_166" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_SharesOutstanding_167" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IssuanceOfSubsidiaryWarrants" xlink:label="loc_roiv_IssuanceOfSubsidiaryWarrants_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfSubsidiaryWarrants_172" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" xlink:label="loc_roiv_StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing_1294651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing_1294651" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing" xlink:label="loc_roiv_StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing_1294590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing_1294590" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration" xlink:label="loc_roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration_1294691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration_1294691" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IssuanceOfSubsidiaryCommonSharesNetValue" xlink:label="loc_roiv_IssuanceOfSubsidiaryCommonSharesNetValue_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfSubsidiaryCommonSharesNetValue_168" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodValueSubsidiaryPreferredShares" xlink:label="loc_roiv_StockIssuedDuringPeriodValueSubsidiaryPreferredShares_1294701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_StockIssuedDuringPeriodValueSubsidiaryPreferredShares_1294701" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" xlink:label="loc_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue_169" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" xlink:label="loc_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits_178" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany" xlink:label="loc_roiv_StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany_1294706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany_1294706" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent" xlink:label="loc_roiv_AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent_1294713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent_1294713" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IssuanceOfStockUponWarrantsExerciseValue" xlink:label="loc_roiv_IssuanceOfStockUponWarrantsExerciseValue_1475457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfStockUponWarrantsExerciseValue_1475457" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IssuanceOfStockUponWarrantsExerciseShares" xlink:label="loc_roiv_IssuanceOfStockUponWarrantsExerciseShares_1475452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfStockUponWarrantsExerciseShares_1475452" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled" xlink:label="loc_roiv_StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled_1475454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled_1475454" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeconsolidationOfSubsidiary" xlink:label="loc_roiv_DeconsolidationOfSubsidiary_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_DeconsolidationOfSubsidiary_194" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ConsolidationOfUnconsolidatedEntity" xlink:label="loc_roiv_ConsolidationOfUnconsolidatedEntity_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_ConsolidationOfUnconsolidatedEntity_195" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RepurchaseOfEquityAwards" xlink:label="loc_roiv_RepurchaseOfEquityAwards_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_RepurchaseOfEquityAwards_196" use="optional" order="32" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CapitalContributionsToSubsidiaries" xlink:label="loc_roiv_CapitalContributionsToSubsidiaries_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_CapitalContributionsToSubsidiaries_197" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_173" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_174" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_175" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_198" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_200" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_ProfitLoss_201" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_165" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_202" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_SharesOutstanding_203" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_205" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_205" xlink:to="loc_us-gaap_StatementTable_216" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_216" xlink:to="loc_dei_LegalEntityAxis_210" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_210" xlink:to="loc_dei_EntityDomain_208" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_216" xlink:to="loc_us-gaap_StatementLineItems_215" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" xlink:to="loc_us-gaap_ProfitLoss_275" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_NonCashAcquiredInProcessResearchAndDevelopment" xlink:label="loc_roiv_NonCashAcquiredInProcessResearchAndDevelopment_1476505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_roiv_NonCashAcquiredInProcessResearchAndDevelopment_1476505" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_ShareBasedCompensation_222" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_GainLossOnInvestments_226" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="loc_us-gaap_GainOnSaleOfInvestments_1294717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_GainOnSaleOfInvestments_1294717" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_227" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity" xlink:label="loc_roiv_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity_1294751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_roiv_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity_1294751" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GainOnTerminationOfEquityInterestOptions" xlink:label="loc_roiv_GainOnTerminationOfEquityInterestOptions_1106544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_roiv_GainOnTerminationOfEquityInterestOptions_1106544" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_229" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_230" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_237" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_240" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_241" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_roiv_IncreaseDecreaseInOperatingLeaseLiabilities_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_roiv_IncreaseDecreaseInOperatingLeaseLiabilities_243" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_1475475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_1475475" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_245" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_276" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1294753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1294753" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_273" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncreaseDecreaseInOtherInvestingNet" xlink:label="loc_roiv_IncreaseDecreaseInOtherInvestingNet_1475505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_roiv_IncreaseDecreaseInOtherInvestingNet_1475505" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_274" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromBusinessCombinationAndPipeFinancing" xlink:label="loc_roiv_ProceedsFromBusinessCombinationAndPipeFinancing_1294788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_ProceedsFromBusinessCombinationAndPipeFinancing_1294788" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:label="loc_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_252" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromPaymentOfSubscriptionReceivable" xlink:label="loc_roiv_ProceedsFromPaymentOfSubscriptionReceivable_1294799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_ProceedsFromPaymentOfSubscriptionReceivable_1294799" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromSubsidiaryDebtFinancingsNet" xlink:label="loc_roiv_ProceedsFromSubsidiaryDebtFinancingsNet_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_ProceedsFromSubsidiaryDebtFinancingsNet_258" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:label="loc_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_259" use="optional" order="35" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PaymentForOfferingAndLoanCosts" xlink:label="loc_roiv_PaymentForOfferingAndLoanCosts_1294816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_PaymentForOfferingAndLoanCosts_1294816" use="optional" order="36" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromAndPaymentForOtherFinancingActivities" xlink:label="loc_roiv_ProceedsFromAndPaymentForOtherFinancingActivities_1475482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_ProceedsFromAndPaymentForOtherFinancingActivities_1475482" use="optional" order="37" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_264" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_282" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_283" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_284" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" xlink:label="loc_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares_1139677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" xlink:to="loc_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares_1139677" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OtherNonCashTransactions" xlink:label="loc_roiv_OtherNonCashTransactions_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" xlink:to="loc_roiv_OtherNonCashTransactions_235" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_217" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_217" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_285" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_217" xlink:to="loc_us-gaap_InterestPaidNet_286" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/DescriptionOfBusinessAndLiquidity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1680" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1680" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1681" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1571" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1571" xlink:to="loc_us-gaap_StatementTable_1575" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1575" xlink:to="loc_dei_LegalEntityAxis_1573" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573" xlink:to="loc_dei_EntityDomain_1572" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1575" xlink:to="loc_us-gaap_StatementLineItems_1574" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1574" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1577" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/BusinessCombinationWithMaac">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1294772" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1294775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1294772" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1294775" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/Investments">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1687" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:label="loc_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_1688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1687" xlink:to="loc_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_1688" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/AssetAcquisitionsAndLicenseAgreements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_1690" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" xlink:label="loc_roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock_1691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1690" xlink:to="loc_roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock_1691" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/AccruedExpenses">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_1510991" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1510992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_1510991" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1510992" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongTermDebtAndLoanCommitment">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1711" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock_1712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1711" xlink:to="loc_us-gaap_LongTermDebtTextBlock_1712" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1595" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1595" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1601" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1619" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1619" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1625" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1721" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1721" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1722" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1645" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1645" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1651" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/Leases">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1739" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1739" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1740" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CommitmentsContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1603" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1603" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1609" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1627" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1627" xlink:to="loc_us-gaap_StatementTable_1631" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1631" xlink:to="loc_dei_LegalEntityAxis_1629" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1629" xlink:to="loc_dei_EntityDomain_1628" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivantSciencesLtd.Member" xlink:label="loc_roiv_RoivantSciencesLtd.Member_1484083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1628" xlink:to="loc_roiv_RoivantSciencesLtd.Member_1484083" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1631" xlink:to="loc_us-gaap_StatementLineItems_1630" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1630" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1633" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/OtherExpenseNet">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_1750" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:label="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_1751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1750" xlink:to="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_1751" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/NetLossPerCommonShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1756" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1756" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1757" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1664" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1664" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1670" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1523" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1523" xlink:to="loc_us-gaap_StatementTable_1527" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1527" xlink:to="loc_dei_LegalEntityAxis_1525" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1525" xlink:to="loc_dei_EntityDomain_1524" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1527" xlink:to="loc_us-gaap_StatementLineItems_1526" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1529" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_UseOfEstimates_1531" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_1533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_1533" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1542" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1544" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1545" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_1546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_1546" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1547" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_1475355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_1475355" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock_1548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock_1548" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_1475352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_1475352" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1538" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1549" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1550" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1551" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1552" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_WarrantliabilitiesPolicyTextBlock" xlink:label="loc_roiv_WarrantliabilitiesPolicyTextBlock_1294682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_roiv_WarrantliabilitiesPolicyTextBlock_1294682" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1540" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1683" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1683" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1684" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="loc_roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_1685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1683" xlink:to="loc_roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_1685" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/AccruedExpensesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_1706" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_1706" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1708" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongTermDebtAndLoanCommitmentTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1714" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_1715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1714" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_1715" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_1716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1714" xlink:to="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_1716" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1724" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1724" xlink:to="loc_us-gaap_StatementTable_1728" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1728" xlink:to="loc_us-gaap_AwardTypeAxis_1725" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1725" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CappedValueAppreciationRightsMember" xlink:label="loc_roiv_CappedValueAppreciationRightsMember_1730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726" xlink:to="loc_roiv_CappedValueAppreciationRightsMember_1730" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1475855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1728" xlink:to="loc_us-gaap_PlanNameAxis_1475855" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1475856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1475855" xlink:to="loc_us-gaap_PlanNameDomain_1475856" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1475857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1475856" xlink:to="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1475857" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandTwentyOneEquityIncentivePlanMember_1475858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1475856" xlink:to="loc_roiv_TwoThousandTwentyOneEquityIncentivePlanMember_1475858" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1728" xlink:to="loc_us-gaap_StatementLineItems_1727" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1733" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1734" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_1510985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_1510985" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock" xlink:label="loc_roiv_ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock_1735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_roiv_ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock_1735" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1737" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock" xlink:label="loc_roiv_ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock_1515540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_roiv_ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock_1515540" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1653" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1653" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1662" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1653" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1661" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1653" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1660" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1742" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_1743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1742" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_1743" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_1744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1742" xlink:to="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_1744" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1742" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1745" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1635" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1635" xlink:to="loc_us-gaap_StatementTable_1639" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1639" xlink:to="loc_dei_LegalEntityAxis_1637" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1637" xlink:to="loc_dei_EntityDomain_1636" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DatavantMember" xlink:label="loc_roiv_DatavantMember_1294766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1636" xlink:to="loc_roiv_DatavantMember_1294766" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SumitomoOptionsMember" xlink:label="loc_roiv_SumitomoOptionsMember_1485653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1636" xlink:to="loc_roiv_SumitomoOptionsMember_1485653" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1294768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1639" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1294768" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1294769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1294768" xlink:to="loc_us-gaap_EquityComponentDomain_1294769" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EarnoutSharesMember" xlink:label="loc_roiv_EarnoutSharesMember_1294774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1294769" xlink:to="loc_roiv_EarnoutSharesMember_1294774" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1294777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1639" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1294777" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1294779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1294777" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1294779" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="loc_roiv_PrivatePlacementWarrantsMember_1294781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1294779" xlink:to="loc_roiv_PrivatePlacementWarrantsMember_1294781" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1639" xlink:to="loc_us-gaap_StatementLineItems_1638" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1638" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1641" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1294746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1638" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1294746" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1638" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1643" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1638" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1642" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/OtherExpenseNetTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_1753" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_1754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1753" xlink:to="loc_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_1754" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/NetLossPerCommonShareTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1579" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1294981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1579" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1294981" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_891" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_891" xlink:to="loc_us-gaap_NumberOfOperatingSegments_892" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_891" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_893" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_891" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_894" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_891" xlink:to="loc_us-gaap_ProfitLoss_895" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_448" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ScheduleOfAccountingPoliciesTable" xlink:label="loc_roiv_ScheduleOfAccountingPoliciesTable_454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448" xlink:to="loc_roiv_ScheduleOfAccountingPoliciesTable_454" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesTable_454" xlink:to="loc_dei_LegalEntityAxis_451" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_451" xlink:to="loc_dei_EntityDomain_450" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesTable_454" xlink:to="loc_us-gaap_StatementClassOfStockAxis_455" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_455" xlink:to="loc_us-gaap_ClassOfStockDomain_449" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1294739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesTable_454" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1294739" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1294740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1294739" xlink:to="loc_us-gaap_EquityComponentDomain_1294740" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1294742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1294740" xlink:to="loc_us-gaap_CommonStockMember_1294742" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesTable_454" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_456" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_456" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_452" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ScheduleOfAccountingPoliciesLineItems" xlink:label="loc_roiv_ScheduleOfAccountingPoliciesLineItems_453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesTable_454" xlink:to="loc_roiv_ScheduleOfAccountingPoliciesLineItems_453" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaap_EscrowDeposit_1097060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesLineItems_453" xlink:to="loc_us-gaap_EscrowDeposit_1097060" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromReleaseOfEscrowDeposit" xlink:label="loc_roiv_ProceedsFromReleaseOfEscrowDeposit_1105109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesLineItems_453" xlink:to="loc_roiv_ProceedsFromReleaseOfEscrowDeposit_1105109" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CashPaidToSettleDeferredConsiderationLiability" xlink:label="loc_roiv_CashPaidToSettleDeferredConsiderationLiability_1294727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesLineItems_453" xlink:to="loc_roiv_CashPaidToSettleDeferredConsiderationLiability_1294727" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability" xlink:label="loc_roiv_StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability_1294737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesLineItems_453" xlink:to="loc_roiv_StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability_1294737" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_897" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_897" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_898" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_897" xlink:to="loc_us-gaap_RestrictedCash_899" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CashAndCashEquivalentsAndRestrictedCash" xlink:label="loc_roiv_CashAndCashEquivalentsAndRestrictedCash_900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_897" xlink:to="loc_roiv_CashAndCashEquivalentsAndRestrictedCash_900" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_902" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_902" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_906" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_906" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" xlink:to="loc_us-gaap_ComputerEquipmentMember_909" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LaboratoryandotherequipmentMember" xlink:label="loc_roiv_LaboratoryandotherequipmentMember_1475379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" xlink:to="loc_roiv_LaboratoryandotherequipmentMember_1475379" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_911" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_912" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_913" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1475367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_906" xlink:to="loc_srt_RangeAxis_1475367" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1475368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1475367" xlink:to="loc_srt_RangeMember_1475368" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1475369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1475368" xlink:to="loc_srt_MaximumMember_1475369" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1475370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1475368" xlink:to="loc_srt_MinimumMember_1475370" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_906" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_904" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_904" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_907" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_904" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_908" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1294792" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BusinesscombinationwithmaacTable" xlink:label="loc_roiv_BusinesscombinationwithmaacTable_1294796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1294792" xlink:to="loc_roiv_BusinesscombinationwithmaacTable_1294796" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1294839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1294839" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1294840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1294839" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1294840" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MontesArchimedesAcquisitionCorpMember" xlink:label="loc_roiv_MontesArchimedesAcquisitionCorpMember_1294841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1294840" xlink:to="loc_roiv_MontesArchimedesAcquisitionCorpMember_1294841" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1294842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1294842" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1294843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1294842" xlink:to="loc_us-gaap_ClassOfStockDomain_1294843" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaacClassASharesMember" xlink:label="loc_roiv_MaacClassASharesMember_1294845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1294843" xlink:to="loc_roiv_MaacClassASharesMember_1294845" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaacClassBSharesMember" xlink:label="loc_roiv_MaacClassBSharesMember_1294844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1294843" xlink:to="loc_roiv_MaacClassBSharesMember_1294844" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1294855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1294843" xlink:to="loc_us-gaap_CommonClassAMember_1294855" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1294859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1294859" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1294861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1294859" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1294861" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivantWarrantMember" xlink:label="loc_roiv_RoivantWarrantMember_1294862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1294861" xlink:to="loc_roiv_RoivantWarrantMember_1294862" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="loc_roiv_PrivatePlacementWarrantsMember_1294867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1294861" xlink:to="loc_roiv_PrivatePlacementWarrantsMember_1294867" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PublicWarrantsMember" xlink:label="loc_roiv_PublicWarrantsMember_1294873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1294861" xlink:to="loc_roiv_PublicWarrantsMember_1294873" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RedemptionOfRoivantWarrantsMember" xlink:label="loc_roiv_RedemptionOfRoivantWarrantsMember_1294875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1294861" xlink:to="loc_roiv_RedemptionOfRoivantWarrantsMember_1294875" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementAxis" xlink:label="loc_roiv_AgreementAxis_1294881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_roiv_AgreementAxis_1294881" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementDomain" xlink:label="loc_roiv_AgreementDomain_1294882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_AgreementAxis_1294881" xlink:to="loc_roiv_AgreementDomain_1294882" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PipeFinancingMember" xlink:label="loc_roiv_PipeFinancingMember_1294885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_AgreementDomain_1294882" xlink:to="loc_roiv_PipeFinancingMember_1294885" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1294886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1294886" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1294894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1294886" xlink:to="loc_us-gaap_RelatedPartyDomain_1294894" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaacSponsorMember" xlink:label="loc_roiv_MaacSponsorMember_1294896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1294894" xlink:to="loc_roiv_MaacSponsorMember_1294896" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1294897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_srt_TitleOfIndividualAxis_1294897" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1294898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1294897" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1294898" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaacIndependentDirectorMember" xlink:label="loc_roiv_MaacIndependentDirectorMember_1294900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1294898" xlink:to="loc_roiv_MaacIndependentDirectorMember_1294900" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1294902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1294902" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1294904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1294902" xlink:to="loc_us-gaap_EquityComponentDomain_1294904" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivantCommonSharesMember" xlink:label="loc_roiv_RoivantCommonSharesMember_1294906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1294904" xlink:to="loc_roiv_RoivantCommonSharesMember_1294906" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BusinessCombinationAgreementAxis" xlink:label="loc_roiv_BusinessCombinationAgreementAxis_1294909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_roiv_BusinessCombinationAgreementAxis_1294909" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BusinessCombinationAgreementDomain" xlink:label="loc_roiv_BusinessCombinationAgreementDomain_1294910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationAgreementAxis_1294909" xlink:to="loc_roiv_BusinessCombinationAgreementDomain_1294910" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SponsorSupportAgreementMember" xlink:label="loc_roiv_SponsorSupportAgreementMember_1294911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationAgreementDomain_1294910" xlink:to="loc_roiv_SponsorSupportAgreementMember_1294911" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TriggeringEventAxis" xlink:label="loc_roiv_TriggeringEventAxis_1294914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_roiv_TriggeringEventAxis_1294914" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TriggeringEventDomain" xlink:label="loc_roiv_TriggeringEventDomain_1294915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TriggeringEventAxis_1294914" xlink:to="loc_roiv_TriggeringEventDomain_1294915" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SharePriceEqualOrExceedsFifteenDollarMember" xlink:label="loc_roiv_SharePriceEqualOrExceedsFifteenDollarMember_1294916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TriggeringEventDomain_1294915" xlink:to="loc_roiv_SharePriceEqualOrExceedsFifteenDollarMember_1294916" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SharePriceEqualOrExceedsTwentyDollarMember" xlink:label="loc_roiv_SharePriceEqualOrExceedsTwentyDollarMember_1294919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TriggeringEventDomain_1294915" xlink:to="loc_roiv_SharePriceEqualOrExceedsTwentyDollarMember_1294919" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SharePriceEqualOrExceedsEighteenDollarMember" xlink:label="loc_roiv_SharePriceEqualOrExceedsEighteenDollarMember_1294920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TriggeringEventDomain_1294915" xlink:to="loc_roiv_SharePriceEqualOrExceedsEighteenDollarMember_1294920" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SharePriceEqualOrExceedsEighteenPerDollarMember" xlink:label="loc_roiv_SharePriceEqualOrExceedsEighteenPerDollarMember_1294921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TriggeringEventDomain_1294915" xlink:to="loc_roiv_SharePriceEqualOrExceedsEighteenPerDollarMember_1294921" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SharePriceEqualOrExceedsTenDollarMember" xlink:label="loc_roiv_SharePriceEqualOrExceedsTenDollarMember_1294924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TriggeringEventDomain_1294915" xlink:to="loc_roiv_SharePriceEqualOrExceedsTenDollarMember_1294924" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpAgreementsAxis" xlink:label="loc_roiv_LockUpAgreementsAxis_1294925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_roiv_LockUpAgreementsAxis_1294925" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpAgreementsDomain" xlink:label="loc_roiv_LockUpAgreementsDomain_1294926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_LockUpAgreementsAxis_1294925" xlink:to="loc_roiv_LockUpAgreementsDomain_1294926" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodOneMember" xlink:label="loc_roiv_LockUpPeriodOneMember_1294930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_LockUpAgreementsDomain_1294926" xlink:to="loc_roiv_LockUpPeriodOneMember_1294930" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodTwoMember" xlink:label="loc_roiv_LockUpPeriodTwoMember_1294932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_LockUpAgreementsDomain_1294926" xlink:to="loc_roiv_LockUpPeriodTwoMember_1294932" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodThreeMember" xlink:label="loc_roiv_LockUpPeriodThreeMember_1294933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_LockUpAgreementsDomain_1294926" xlink:to="loc_roiv_LockUpPeriodThreeMember_1294933" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodFourMember" xlink:label="loc_roiv_LockUpPeriodFourMember_1294935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_LockUpAgreementsDomain_1294926" xlink:to="loc_roiv_LockUpPeriodFourMember_1294935" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodFiveMember" xlink:label="loc_roiv_LockUpPeriodFiveMember_1294936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_LockUpAgreementsDomain_1294926" xlink:to="loc_roiv_LockUpPeriodFiveMember_1294936" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodSixMember" xlink:label="loc_roiv_LockUpPeriodSixMember_1294938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_LockUpAgreementsDomain_1294926" xlink:to="loc_roiv_LockUpPeriodSixMember_1294938" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodSevenMember" xlink:label="loc_roiv_LockUpPeriodSevenMember_1294939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_LockUpAgreementsDomain_1294926" xlink:to="loc_roiv_LockUpPeriodSevenMember_1294939" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodEightMember" xlink:label="loc_roiv_LockUpPeriodEightMember_1294940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_LockUpAgreementsDomain_1294926" xlink:to="loc_roiv_LockUpPeriodEightMember_1294940" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LockUpPeriodNineMember" xlink:label="loc_roiv_LockUpPeriodNineMember_1294941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_LockUpAgreementsDomain_1294926" xlink:to="loc_roiv_LockUpPeriodNineMember_1294941" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1294942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_srt_RangeAxis_1294942" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1294943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1294942" xlink:to="loc_srt_RangeMember_1294943" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1294945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1294943" xlink:to="loc_srt_MinimumMember_1294945" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1294944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1294943" xlink:to="loc_srt_MaximumMember_1294944" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BusinessCombinationWithMAACLineItems" xlink:label="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinesscombinationwithmaacTable_1294796" xlink:to="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockholdersEquityNoteStockSplitExchangeRatio1" xlink:label="loc_roiv_StockholdersEquityNoteStockSplitExchangeRatio1_1294962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_StockholdersEquityNoteStockSplitExchangeRatio1_1294962" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ExchangeRatioOfMAACClassBToRoivantCommonShares" xlink:label="loc_roiv_ExchangeRatioOfMAACClassBToRoivantCommonShares_1294972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_ExchangeRatioOfMAACClassBToRoivantCommonShares_1294972" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1294974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1294974" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1294977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1294977" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1294978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_us-gaap_SharePrice_1294978" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Stockpricetriggerforredemptionofwarrants" xlink:label="loc_roiv_Stockpricetriggerforredemptionofwarrants_1294980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Stockpricetriggerforredemptionofwarrants_1294980" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1294982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1294982" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1294983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_us-gaap_Cash_1294983" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Costsincurredrelatedtofinancing" xlink:label="loc_roiv_Costsincurredrelatedtofinancing_1294984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Costsincurredrelatedtofinancing_1294984" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Allocationoftransactioncostsincurredtowarrantsandearnoutshares" xlink:label="loc_roiv_Allocationoftransactioncostsincurredtowarrantsandearnoutshares_1294985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Allocationoftransactioncostsincurredtowarrantsandearnoutshares_1294985" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Portionofsharesubjecttoearnout" xlink:label="loc_roiv_Portionofsharesubjecttoearnout_1294988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Portionofsharesubjecttoearnout_1294988" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Numberoftradingdaystomeetwarrantredemptionthreshold" xlink:label="loc_roiv_Numberoftradingdaystomeetwarrantredemptionthreshold_1294989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Numberoftradingdaystomeetwarrantredemptionthreshold_1294989" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Numberoftradingdaystomeetearnoutpricethreshold" xlink:label="loc_roiv_Numberoftradingdaystomeetearnoutpricethreshold_1294994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Numberoftradingdaystomeetearnoutpricethreshold_1294994" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Tradingdayperiodforwarrantredemption" xlink:label="loc_roiv_Tradingdayperiodforwarrantredemption_1295000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Tradingdayperiodforwarrantredemption_1295000" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Tradingdayperiodforearnoutshares" xlink:label="loc_roiv_Tradingdayperiodforearnoutshares_1295001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Tradingdayperiodforearnoutshares_1295001" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime" xlink:label="loc_roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime_1295012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime_1295012" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Lockupperiodofcommonshares" xlink:label="loc_roiv_Lockupperiodofcommonshares_1295015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Lockupperiodofcommonshares_1295015" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Percentageofwarrantssubjecttolockupfordefinedperiodoftime" xlink:label="loc_roiv_Percentageofwarrantssubjecttolockupfordefinedperiodoftime_1295018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Percentageofwarrantssubjecttolockupfordefinedperiodoftime_1295018" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Lockupperiodwarrants" xlink:label="loc_roiv_Lockupperiodwarrants_1295023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Lockupperiodwarrants_1295023" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1295025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1295025" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Timetowarrantexercisability" xlink:label="loc_roiv_Timetowarrantexercisability_1295028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Timetowarrantexercisability_1295028" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1295029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1295029" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Shareredemptiontriggerprice" xlink:label="loc_roiv_Shareredemptiontriggerprice_1295030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Shareredemptiontriggerprice_1295030" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Classofwarrantsredemptionpriceperunit" xlink:label="loc_roiv_Classofwarrantsredemptionpriceperunit_1295032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Classofwarrantsredemptionpriceperunit_1295032" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_Classofwarrantsredemptionnoticeperiod" xlink:label="loc_roiv_Classofwarrantsredemptionnoticeperiod_1295033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_Classofwarrantsredemptionnoticeperiod_1295033" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PeriodForFairMarketValueDetermination" xlink:label="loc_roiv_PeriodForFairMarketValueDetermination_1295034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_PeriodForFairMarketValueDetermination_1295034" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EarnOutSharePrice" xlink:label="loc_roiv_EarnOutSharePrice_1295035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_EarnOutSharePrice_1295035" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaximumRedemptionFeaturePerWarrant" xlink:label="loc_roiv_MaximumRedemptionFeaturePerWarrant_1295036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_MaximumRedemptionFeaturePerWarrant_1295036" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CommonStockWarrants" xlink:label="loc_roiv_CommonStockWarrants_1510974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BusinessCombinationWithMAACLineItems_1294961" xlink:to="loc_roiv_CommonStockWarrants_1510974" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/InvestmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_UncategorizedAbstract" xlink:label="loc_roiv_UncategorizedAbstract_915" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_InvestmentsTable" xlink:label="loc_roiv_InvestmentsTable_919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_UncategorizedAbstract_915" xlink:to="loc_roiv_InvestmentsTable_919" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsTable_919" xlink:to="loc_dei_LegalEntityAxis_922" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_922" xlink:to="loc_dei_EntityDomain_917" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ArbutusBiopharmaCorporationMember" xlink:label="loc_roiv_ArbutusBiopharmaCorporationMember_925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_917" xlink:to="loc_roiv_ArbutusBiopharmaCorporationMember_925" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SioGeneTherapiesIncMember" xlink:label="loc_roiv_SioGeneTherapiesIncMember_926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_917" xlink:to="loc_roiv_SioGeneTherapiesIncMember_926" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DatavantHoldingsIncMember" xlink:label="loc_roiv_DatavantHoldingsIncMember_927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_917" xlink:to="loc_roiv_DatavantHoldingsIncMember_927" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsTable_919" xlink:to="loc_us-gaap_InvestmentTypeAxis_920" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_920" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_921" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentCompaniesMember" xlink:label="loc_us-gaap_OtherInvestmentCompaniesMember_946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_921" xlink:to="loc_us-gaap_OtherInvestmentCompaniesMember_946" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsTable_919" xlink:to="loc_us-gaap_StatementClassOfStockAxis_923" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_923" xlink:to="loc_us-gaap_ClassOfStockDomain_916" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1294810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsTable_919" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1294810" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1294811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1294810" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1294811" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DatavantMergerMember" xlink:label="loc_roiv_DatavantMergerMember_1294812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1294811" xlink:to="loc_roiv_DatavantMergerMember_1294812" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_1295110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsTable_919" xlink:to="loc_srt_OwnershipAxis_1295110" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1295111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_1295110" xlink:to="loc_srt_OwnershipDomain_1295111" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CombinedCompanyMember" xlink:label="loc_roiv_CombinedCompanyMember_1295113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1295111" xlink:to="loc_roiv_CombinedCompanyMember_1295113" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_InvestmentsLineItems" xlink:label="loc_roiv_InvestmentsLineItems_918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsTable_919" xlink:to="loc_roiv_InvestmentsLineItems_918" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PreferredStockOwnedBalanceSharesOfArbutus" xlink:label="loc_roiv_PreferredStockOwnedBalanceSharesOfArbutus_929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_PreferredStockOwnedBalanceSharesOfArbutus_929" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_936" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_937" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_SharePrice_938" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_939" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_LongTermInvestments_945" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1105159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1105159" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1139348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1139348" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock" xlink:label="loc_roiv_InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock_1294729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock_1294729" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProceedsFromSaleOfInvestment" xlink:label="loc_roiv_ProceedsFromSaleOfInvestment_1294808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_ProceedsFromSaleOfInvestment_1294808" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GainOnMeasurementOfInvestment" xlink:label="loc_roiv_GainOnMeasurementOfInvestment_1294818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_GainOnMeasurementOfInvestment_1294818" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_948" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_948" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_959" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_959" xlink:to="loc_us-gaap_RelatedPartyDomain_958" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GenevantSciencesLtdMember" xlink:label="loc_roiv_GenevantSciencesLtdMember_1008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_958" xlink:to="loc_roiv_GenevantSciencesLtdMember_1008" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProteovantSciencesIncMember" xlink:label="loc_roiv_ProteovantSciencesIncMember_1009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_958" xlink:to="loc_roiv_ProteovantSciencesIncMember_1009" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AffivantSciencesMember" xlink:label="loc_roiv_AffivantSciencesMember_1010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_958" xlink:to="loc_roiv_AffivantSciencesMember_1010" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_dei_LegalEntityAxis_953" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_953" xlink:to="loc_dei_EntityDomain_952" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ArbutusBiopharmaCorporationMember" xlink:label="loc_roiv_ArbutusBiopharmaCorporationMember_1002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_952" xlink:to="loc_roiv_ArbutusBiopharmaCorporationMember_1002" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_us-gaap_AssetAcquisitionAxis_950" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_950" xlink:to="loc_us-gaap_AssetAcquisitionDomain_949" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SiliconTherapeuticsMember" xlink:label="loc_roiv_SiliconTherapeuticsMember_963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_949" xlink:to="loc_roiv_SiliconTherapeuticsMember_963" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PriovantMember" xlink:label="loc_roiv_PriovantMember_1294550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_949" xlink:to="loc_roiv_PriovantMember_1294550" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1515548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1515548" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1515549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1515548" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1515549" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SiliconTherapeuticsMember" xlink:label="loc_roiv_SiliconTherapeuticsMember_1515550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1515549" xlink:to="loc_roiv_SiliconTherapeuticsMember_1515550" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PriovantMember" xlink:label="loc_roiv_PriovantMember_1515551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1515549" xlink:to="loc_roiv_PriovantMember_1515551" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_us-gaap_RestructuringPlanAxis_960" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_960" xlink:to="loc_us-gaap_RestructuringPlanDomain_961" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FirstTrancheMember" xlink:label="loc_roiv_FirstTrancheMember_1011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_961" xlink:to="loc_roiv_FirstTrancheMember_1011" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SecondTrancheMember" xlink:label="loc_roiv_SecondTrancheMember_1012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_961" xlink:to="loc_roiv_SecondTrancheMember_1012" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MilestoneEventsAxis" xlink:label="loc_roiv_MilestoneEventsAxis_954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_roiv_MilestoneEventsAxis_954" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MilestoneEventsDomain" xlink:label="loc_roiv_MilestoneEventsDomain_955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_MilestoneEventsAxis_954" xlink:to="loc_roiv_MilestoneEventsDomain_955" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" xlink:label="loc_roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember_1003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_MilestoneEventsDomain_955" xlink:to="loc_roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember_1003" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" xlink:label="loc_roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember_1004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_MilestoneEventsDomain_955" xlink:to="loc_roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember_1004" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" xlink:label="loc_roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember_1005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_MilestoneEventsDomain_955" xlink:to="loc_roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember_1005" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_srt_RangeAxis_956" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_956" xlink:to="loc_srt_RangeMember_957" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_957" xlink:to="loc_srt_MaximumMember_1006" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1294565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1294565" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1294566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1294565" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1294566" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PharmanvanthSevenGmbhMember" xlink:label="loc_roiv_PharmanvanthSevenGmbhMember_1294567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1294566" xlink:to="loc_roiv_PharmanvanthSevenGmbhMember_1294567" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_HemavantSciencesGmbhMember" xlink:label="loc_roiv_HemavantSciencesGmbhMember_1476361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1294566" xlink:to="loc_roiv_HemavantSciencesGmbhMember_1476361" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaap_TransactionTypeAxis_1294568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_us-gaap_TransactionTypeAxis_1294568" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_1294569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionTypeAxis_1294568" xlink:to="loc_us-gaap_TransactionDomain_1294569" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CommercialMilestoneMember" xlink:label="loc_roiv_CommercialMilestoneMember_1294570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionDomain_1294569" xlink:to="loc_roiv_CommercialMilestoneMember_1294570" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_roiv_DevelopmentAndRegulatoryMilestoneMember_1294578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionDomain_1294569" xlink:to="loc_roiv_DevelopmentAndRegulatoryMilestoneMember_1294578" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementAxis" xlink:label="loc_roiv_AgreementAxis_1476354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_roiv_AgreementAxis_1476354" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementDomain" xlink:label="loc_roiv_AgreementDomain_1476355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_AgreementAxis_1476354" xlink:to="loc_roiv_AgreementDomain_1476355" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CollaborationAgreementWithBlueprintMedicinesMember" xlink:label="loc_roiv_CollaborationAgreementWithBlueprintMedicinesMember_1476356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_AgreementDomain_1476355" xlink:to="loc_roiv_CollaborationAgreementWithBlueprintMedicinesMember_1476356" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_951" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_UpfrontCashPayments" xlink:label="loc_roiv_UpfrontCashPayments_964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_UpfrontCashPayments_964" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FutureDevelopmentAndCommercialMilestonePayments" xlink:label="loc_roiv_FutureDevelopmentAndCommercialMilestonePayments_966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_FutureDevelopmentAndCommercialMilestonePayments_966" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_NonRefundableUpfrontPaymentReceived" xlink:label="loc_roiv_NonRefundableUpfrontPaymentReceived_969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_NonRefundableUpfrontPaymentReceived_969" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PotentialMilestonePaymentReceivable" xlink:label="loc_roiv_PotentialMilestonePaymentReceivable_970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_PotentialMilestonePaymentReceivable_970" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_972" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedParties" xlink:label="loc_us-gaap_NotesReceivableRelatedParties_1510978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_NotesReceivableRelatedParties_1510978" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_974" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_975" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_976" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_977" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PercentageOfControllingInterestHeld" xlink:label="loc_roiv_PercentageOfControllingInterestHeld_978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_PercentageOfControllingInterestHeld_978" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_979" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_GainLossOnInvestments_980" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_981" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_982" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BusinessAcquisitionConsiderationTransferred" xlink:label="loc_roiv_BusinessAcquisitionConsiderationTransferred_983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_BusinessAcquisitionConsiderationTransferred_983" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AcquiredInProcessResearchAndDevelopmentExpense" xlink:label="loc_roiv_AcquiredInProcessResearchAndDevelopmentExpense_1510975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_AcquiredInProcessResearchAndDevelopmentExpense_1510975" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PaymentForUpfrontPayments" xlink:label="loc_roiv_PaymentForUpfrontPayments_985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_PaymentForUpfrontPayments_985" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PaymentUnderSponsoredResearchAgreement" xlink:label="loc_roiv_PaymentUnderSponsoredResearchAgreement_986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_PaymentUnderSponsoredResearchAgreement_986" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_987" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_988" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_989" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_990" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="loc_us-gaap_StockholdersEquityNoteSubscriptionsReceivable_991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_StockholdersEquityNoteSubscriptionsReceivable_991" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockIssuedDuringPeriodValue" xlink:label="loc_roiv_StockIssuedDuringPeriodValue_992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_StockIssuedDuringPeriodValue_992" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_993" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_994" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_995" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_roiv_BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_996" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_997" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1515544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1515544" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_ShareBasedCompensation_999" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueOfCommonShares" xlink:label="loc_roiv_FairValueOfCommonShares_1000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_FairValueOfCommonShares_1000" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueOfRestrictedStock" xlink:label="loc_roiv_FairValueOfRestrictedStock_1001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_FairValueOfRestrictedStock_1001" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_1294549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_1294549" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1294552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1294552" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1294556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1294556" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PayableForEachAdditionalProductIndication" xlink:label="loc_roiv_PayableForEachAdditionalProductIndication_1294559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_PayableForEachAdditionalProductIndication_1294559" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MilestonePaymentPayable" xlink:label="loc_roiv_MilestonePaymentPayable_1294561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_MilestonePaymentPayable_1294561" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1294572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1294572" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_1476357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_DeferredRevenue_1476357" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1476358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1476358" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1069" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_BalanceSheetComponentsTable" xlink:label="loc_roiv_BalanceSheetComponentsTable_1071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1069" xlink:to="loc_roiv_BalanceSheetComponentsTable_1071" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BalanceSheetComponentsTable_1071" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1072" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1072" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1073" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1073" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1075" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EmployeeRelatedExpensesMember" xlink:label="loc_roiv_EmployeeRelatedExpensesMember_1076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1073" xlink:to="loc_roiv_EmployeeRelatedExpensesMember_1076" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OtherGeneralAndAdministrativeExpensesMember" xlink:label="loc_roiv_OtherGeneralAndAdministrativeExpensesMember_1078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1073" xlink:to="loc_roiv_OtherGeneralAndAdministrativeExpensesMember_1078" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AccruedLiabilitiesLineItems" xlink:label="loc_roiv_AccruedLiabilitiesLineItems_1070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BalanceSheetComponentsTable_1071" xlink:to="loc_roiv_AccruedLiabilitiesLineItems_1070" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_AccruedLiabilitiesLineItems_1070" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1074" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAbstract" xlink:label="loc_us-gaap_LongTermDebtAbstract_1086" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DebtInstrumentValue" xlink:label="loc_roiv_DebtInstrumentValue_1295130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAbstract_1086" xlink:to="loc_roiv_DebtInstrumentValue_1295130" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xlink:label="loc_roiv_DebtInstrumentExitFeeAndEndOfTermCharge_1294759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAbstract_1086" xlink:to="loc_roiv_DebtInstrumentExitFeeAndEndOfTermCharge_1294759" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAbstract_1086" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1088" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_1089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAbstract_1086" xlink:to="loc_us-gaap_LongTermDebt_1089" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_1090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAbstract_1086" xlink:to="loc_us-gaap_LongTermDebtCurrent_1090" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAbstract_1086" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1091" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1093" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1093" xlink:to="loc_us-gaap_DebtInstrumentTable_1096" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1101" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1101" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1094" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_NovaquestMember" xlink:label="loc_roiv_NovaquestMember_1104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1094" xlink:to="loc_roiv_NovaquestMember_1104" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1098" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1098" xlink:to="loc_us-gaap_RelatedPartyDomain_1097" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_1102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_VariableRateAxis_1102" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_1103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_1102" xlink:to="loc_us-gaap_VariableRateDomain_1103" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_1117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_1103" xlink:to="loc_us-gaap_PrimeRateMember_1117" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaap_TransactionTypeAxis_1100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_TransactionTypeAxis_1100" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_1099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionTypeAxis_1100" xlink:to="loc_us-gaap_TransactionDomain_1099" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RegulatoryMilestoneMember" xlink:label="loc_roiv_RegulatoryMilestoneMember_1115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionDomain_1099" xlink:to="loc_roiv_RegulatoryMilestoneMember_1115" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CommercialMilestoneMember" xlink:label="loc_roiv_CommercialMilestoneMember_1116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionDomain_1099" xlink:to="loc_roiv_CommercialMilestoneMember_1116" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1097057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_srt_RangeAxis_1097057" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1097058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1097057" xlink:to="loc_srt_RangeMember_1097058" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1097323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1097323" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1097324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1097323" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1097324" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementMember" xlink:label="loc_roiv_RevenueInterestPurchaseAndSaleAgreementMember_1097325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1097324" xlink:to="loc_roiv_RevenueInterestPurchaseAndSaleAgreementMember_1097325" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1095" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1105" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_1106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_1106" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_1108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_1108" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xlink:label="loc_roiv_DebtInstrumentExitFeeAndEndOfTermCharge_1105123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_DebtInstrumentExitFeeAndEndOfTermCharge_1105123" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_1110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_1110" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaximumMilestonePaymentObligation" xlink:label="loc_roiv_MaximumMilestonePaymentObligation_1111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_MaximumMilestonePaymentObligation_1111" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MaximumMilestonePaymentOffsetAmount" xlink:label="loc_roiv_MaximumMilestonePaymentOffsetAmount_1112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_MaximumMilestonePaymentOffsetAmount_1112" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_1113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentFairValue_1113" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1097048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1097048" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_1097050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentTerm_1097050" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1097053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1097053" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1097054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1097054" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement" xlink:label="loc_roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement_1097321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement_1097321" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CommittedFundingUnderRIPSA" xlink:label="loc_roiv_CommittedFundingUnderRIPSA_1515522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_CommittedFundingUnderRIPSA_1515522" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MilestonePaymentDueOverSixYearPeriod" xlink:label="loc_roiv_MilestonePaymentDueOverSixYearPeriod_1515571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_MilestonePaymentDueOverSixYearPeriod_1515571" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_1119" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1119" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1120" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1119" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1121" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1119" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1122" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1119" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1123" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_1124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1119" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_1124" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_1125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1119" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_1125" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LongTermDebtExcludingDebtWithFairValueOption" xlink:label="loc_roiv_LongTermDebtExcludingDebtWithFairValueOption_1126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1119" xlink:to="loc_roiv_LongTermDebtExcludingDebtWithFairValueOption_1126" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1128" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1128" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1132" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1132" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1131" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1131" xlink:to="loc_us-gaap_RelatedPartyDomain_1129" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SumitomoMember" xlink:label="loc_roiv_SumitomoMember_1134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1129" xlink:to="loc_roiv_SumitomoMember_1134" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementAxis" xlink:label="loc_roiv_AgreementAxis_1475622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1132" xlink:to="loc_roiv_AgreementAxis_1475622" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementDomain" xlink:label="loc_roiv_AgreementDomain_1475623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_AgreementAxis_1475622" xlink:to="loc_roiv_AgreementDomain_1475623" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AssetPurchaseAgreementMember" xlink:label="loc_roiv_AssetPurchaseAgreementMember_1475624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_AgreementDomain_1475623" xlink:to="loc_roiv_AssetPurchaseAgreementMember_1475624" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TransitionServicesAndStrategicCooperationAgreementMember" xlink:label="loc_roiv_TransitionServicesAndStrategicCooperationAgreementMember_1475627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_AgreementDomain_1475623" xlink:to="loc_roiv_TransitionServicesAndStrategicCooperationAgreementMember_1475627" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1132" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_1130" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" xlink:label="loc_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary_1135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1130" xlink:to="loc_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary_1135" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AccessFeePaidToRelatedParty" xlink:label="loc_roiv_AccessFeePaidToRelatedParty_1136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1130" xlink:to="loc_roiv_AccessFeePaidToRelatedParty_1136" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AssetPurchaseTransactionConsiderationReceivedInCash" xlink:label="loc_roiv_AssetPurchaseTransactionConsiderationReceivedInCash_1475620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1130" xlink:to="loc_roiv_AssetPurchaseTransactionConsiderationReceivedInCash_1475620" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xlink:label="loc_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination_1475621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1130" xlink:to="loc_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination_1475621" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary" xlink:label="loc_roiv_AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary_1475631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1130" xlink:to="loc_roiv_AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary_1475631" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1138" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1138" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1151" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1149" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1149" xlink:to="loc_us-gaap_RelatedPartyDomain_1148" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ImmunovantSciencesLtdMember" xlink:label="loc_roiv_ImmunovantSciencesLtdMember_1198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1148" xlink:to="loc_roiv_ImmunovantSciencesLtdMember_1198" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1142" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1142" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1141" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ImmunovantINCMember" xlink:label="loc_roiv_ImmunovantINCMember_1162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1141" xlink:to="loc_roiv_ImmunovantINCMember_1162" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_srt_RangeAxis_1146" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1146" xlink:to="loc_srt_RangeMember_1147" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1160" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1160" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1139" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1159" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1159" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1150" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_UnderwrittenPublicOfferingMember" xlink:label="loc_roiv_UnderwrittenPublicOfferingMember_1200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1150" xlink:to="loc_roiv_UnderwrittenPublicOfferingMember_1200" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_1153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_1153" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_1154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_1153" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_1154" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1157" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1157" xlink:to="loc_us-gaap_ClassOfStockDomain_1143" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1158" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1158" xlink:to="loc_us-gaap_EquityComponentDomain_1145" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1145" xlink:to="loc_us-gaap_CommonStockMember_1192" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1145" xlink:to="loc_us-gaap_WarrantMember_1193" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivantCommonSharesMember" xlink:label="loc_roiv_RoivantCommonSharesMember_1294676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1145" xlink:to="loc_roiv_RoivantCommonSharesMember_1294676" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1155" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1155" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1156" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_AwardTypeAxis_1140" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1140" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1152" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1294665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1294665" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1294666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1294665" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1294666" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SkMember" xlink:label="loc_roiv_SkMember_1294669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1294666" xlink:to="loc_roiv_SkMember_1294669" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1475822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1475822" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1475823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1475822" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1475823" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CantorFitzgeraldCo.Member" xlink:label="loc_roiv_CantorFitzgeraldCo.Member_1475824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1475823" xlink:to="loc_roiv_CantorFitzgeraldCo.Member_1475824" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_ClassOfStockLineItems_1144" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1169" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1173" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1174" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_CommonStockSharesIssued_1179" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1183" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1184" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ClassOfWarrantOrRightExercisable" xlink:label="loc_roiv_ClassOfWarrantOrRightExercisable_1185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_roiv_ClassOfWarrantOrRightExercisable_1185" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1186" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1294657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1294657" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1294658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1294658" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_1294660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_CommonStockVotingRights_1294660" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockHoldersEquityNoteStockSplitExchangeRatio1" xlink:label="loc_roiv_StockHoldersEquityNoteStockSplitExchangeRatio1_1294661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_roiv_StockHoldersEquityNoteStockSplitExchangeRatio1_1294661" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SubscriptionReceived" xlink:label="loc_roiv_SubscriptionReceived_1294662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_roiv_SubscriptionReceived_1294662" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_1294671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_EquityMethodInvestments_1294671" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1294674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1294674" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_1475814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_PurchaseObligation_1475814" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PercentageOfCommonSharesVolumeWeightedAveragePrice" xlink:label="loc_roiv_PercentageOfCommonSharesVolumeWeightedAveragePrice_1475820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_roiv_PercentageOfCommonSharesVolumeWeightedAveragePrice_1475820" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_UpfrontCommitmentFeeNumberOfSharesIssued" xlink:label="loc_roiv_UpfrontCommitmentFeeNumberOfSharesIssued_1475821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_roiv_UpfrontCommitmentFeeNumberOfSharesIssued_1475821" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CommonSharesValueAvailableForSale" xlink:label="loc_roiv_CommonSharesValueAvailableForSale_1487110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_roiv_CommonSharesValueAvailableForSale_1487110" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ClassOfWarrantOrRightCanceled" xlink:label="loc_roiv_ClassOfWarrantOrRightCanceled_1510994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_roiv_ClassOfWarrantOrRightCanceled_1510994" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1210" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1210" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" xlink:to="loc_us-gaap_PlanNameAxis_1212" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1212" xlink:to="loc_us-gaap_PlanNameDomain_1213" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1213" xlink:to="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1217" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SubsidiaryEquityIncentivePlanMember" xlink:label="loc_roiv_SubsidiaryEquityIncentivePlanMember_1218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1213" xlink:to="loc_roiv_SubsidiaryEquityIncentivePlanMember_1218" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandTwentyOneEquityIncentivePlanMember_1294736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1213" xlink:to="loc_roiv_TwoThousandTwentyOneEquityIncentivePlanMember_1294736" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" xlink:to="loc_us-gaap_AwardTypeAxis_1211" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1211" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CappedValueAppreciationRightsMember" xlink:label="loc_roiv_CappedValueAppreciationRightsMember_1239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_roiv_CappedValueAppreciationRightsMember_1239" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockOptionsAndPerformanceStockOptionsMember" xlink:label="loc_roiv_StockOptionsAndPerformanceStockOptionsMember_1475929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_roiv_StockOptionsAndPerformanceStockOptionsMember_1475929" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:label="loc_roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember_1475963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember_1475963" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SubsidiaryEquityIncentivePlansMember" xlink:label="loc_roiv_SubsidiaryEquityIncentivePlansMember_1475988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_roiv_SubsidiaryEquityIncentivePlansMember_1475988" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_March2020CappedValueAppreciationRightsMember" xlink:label="loc_roiv_March2020CappedValueAppreciationRightsMember_1490707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_roiv_March2020CappedValueAppreciationRightsMember_1490707" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EventAxis" xlink:label="loc_roiv_EventAxis_1294731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" xlink:to="loc_roiv_EventAxis_1294731" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EventDomain" xlink:label="loc_roiv_EventDomain_1294732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_EventAxis_1294731" xlink:to="loc_roiv_EventDomain_1294732" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMember" xlink:label="loc_roiv_AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMember_1294733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_EventDomain_1294732" xlink:to="loc_roiv_AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMember_1294733" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1475984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1475984" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1475985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1475984" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1475985" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_1475986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1475985" xlink:to="loc_us-gaap_EmployeeStockMember_1475986" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1220" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1221" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1222" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1224" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1230" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OneTimeCatchUpExpense" xlink:label="loc_roiv_OneTimeCatchUpExpense_1294728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_roiv_OneTimeCatchUpExpense_1294728" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares" xlink:label="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares_1294776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares_1294776" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_1475920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_1475920" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1475937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1475937" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1475962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1475962" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1475968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1475968" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1475969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1475969" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncrementOfEmployeeStockPurchasePlan" xlink:label="loc_roiv_IncrementOfEmployeeStockPurchasePlan_1475978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_roiv_IncrementOfEmployeeStockPurchasePlan_1475978" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable" xlink:label="loc_roiv_EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable_1475980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_roiv_EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable_1475980" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment" xlink:label="loc_roiv_IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment_1492261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_roiv_IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment_1492261" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1243" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1243" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1245" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1245" xlink:to="loc_us-gaap_AwardTypeAxis_1244" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1244" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1247" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1247" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1252" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1245" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_1248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_1248" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1249" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1250" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1251" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1282" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IntrinsicValueOfOptionsExercised" xlink:label="loc_roiv_IntrinsicValueOfOptionsExercised_1510995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1282" xlink:to="loc_roiv_IntrinsicValueOfOptionsExercised_1510995" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1282" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1283" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" xlink:label="loc_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_1284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1282" xlink:to="loc_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_1284" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1286" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1286" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1290" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1290" xlink:to="loc_us-gaap_AwardTypeAxis_1287" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1287" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1292" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RestrictedStockAndPerformanceStockUnitsMember" xlink:label="loc_roiv_RestrictedStockAndPerformanceStockUnitsMember_1294754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1292" xlink:to="loc_roiv_RestrictedStockAndPerformanceStockUnitsMember_1294754" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1290" xlink:to="loc_us-gaap_PlanNameAxis_1288" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1288" xlink:to="loc_us-gaap_PlanNameDomain_1289" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RSLEquityPlansMember" xlink:label="loc_roiv_RSLEquityPlansMember_1294755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1289" xlink:to="loc_roiv_RSLEquityPlansMember_1294755" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1290" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1294" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1295" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1294756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1294756" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1296" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1297" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1475894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1475894" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1475895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1475895" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1475896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1475896" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1475897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1475897" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1475898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1475898" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1304" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1304" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1308" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1308" xlink:to="loc_us-gaap_AwardTypeAxis_1305" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1305" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1310" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockOptionsAndPerformanceStockOptionsMember" xlink:label="loc_roiv_StockOptionsAndPerformanceStockOptionsMember_1325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1310" xlink:to="loc_roiv_StockOptionsAndPerformanceStockOptionsMember_1325" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1308" xlink:to="loc_us-gaap_PlanNameAxis_1306" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1306" xlink:to="loc_us-gaap_PlanNameDomain_1307" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RSLEquityPlansMember" xlink:label="loc_roiv_RSLEquityPlansMember_1294738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1307" xlink:to="loc_roiv_RSLEquityPlansMember_1294738" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1308" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1312" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1313" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1475866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1475866" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1314" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1315" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1475867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1475867" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1316" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1317" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1475865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1475865" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1475873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1475873" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1319" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1475876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1475876" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1324" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1475880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1475880" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1475883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1475883" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1475884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1475884" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1327" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1327" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1331" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1331" xlink:to="loc_us-gaap_AwardTypeAxis_1328" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1328" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1333" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_CappedValueAppreciationRightsMember" xlink:label="loc_roiv_CappedValueAppreciationRightsMember_1343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1333" xlink:to="loc_roiv_CappedValueAppreciationRightsMember_1343" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1331" xlink:to="loc_us-gaap_PlanNameAxis_1329" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1329" xlink:to="loc_us-gaap_PlanNameDomain_1330" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1330" xlink:to="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1334" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandTwentyOneEquityIncentivePlanMember_1475902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1330" xlink:to="loc_roiv_TwoThousandTwentyOneEquityIncentivePlanMember_1475902" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1331" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1335" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1336" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1337" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1475900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1475900" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1338" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1339" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1340" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1341" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1342" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1475901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1475901" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1380" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1380" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1383" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1383" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1381" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1381" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1382" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1382" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1385" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1382" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1386" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1384" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1384" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1387" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1389" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncomeTaxDisclosureTable" xlink:label="loc_roiv_IncomeTaxDisclosureTable_1392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1389" xlink:to="loc_roiv_IncomeTaxDisclosureTable_1392" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureTable_1392" xlink:to="loc_srt_StatementGeographicalAxis_1394" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1394" xlink:to="loc_srt_SegmentGeographicalDomain_1393" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BM" xlink:label="loc_country_BM_1398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1393" xlink:to="loc_country_BM_1398" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="loc_country_US_1396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1393" xlink:to="loc_country_US_1396" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="loc_country_CH_1397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1393" xlink:to="loc_country_CH_1397" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OtherMember" xlink:label="loc_roiv_OtherMember_1399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1393" xlink:to="loc_roiv_OtherMember_1399" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncomeTaxDisclosureLineItems" xlink:label="loc_roiv_IncomeTaxDisclosureLineItems_1391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureTable_1392" xlink:to="loc_roiv_IncomeTaxDisclosureLineItems_1391" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_1391" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1390" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1390" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1395" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_771" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ComponentsOfIncomeTaxExpenseTable" xlink:label="loc_roiv_ComponentsOfIncomeTaxExpenseTable_773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_771" xlink:to="loc_roiv_ComponentsOfIncomeTaxExpenseTable_773" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseTable_773" xlink:to="loc_dei_LegalEntityAxis_777" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_777" xlink:to="loc_dei_EntityDomain_776" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseTable_773" xlink:to="loc_srt_StatementGeographicalAxis_779" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_779" xlink:to="loc_srt_SegmentGeographicalDomain_778" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="loc_country_US_789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_778" xlink:to="loc_country_US_789" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="loc_country_CH_790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_778" xlink:to="loc_country_CH_790" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BM" xlink:label="loc_country_BM_791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_778" xlink:to="loc_country_BM_791" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OtherMember" xlink:label="loc_roiv_OtherMember_792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_778" xlink:to="loc_roiv_OtherMember_792" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ComponentsOfIncomeTaxExpenseLineItems" xlink:label="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems_772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseTable_773" xlink:to="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems_772" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems_772" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_774" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_774" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_782" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems_772" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_775" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_775" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_786" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems_772" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_781" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_852" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncomeTaxDisclosureTable" xlink:label="loc_roiv_IncomeTaxDisclosureTable_858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_852" xlink:to="loc_roiv_IncomeTaxDisclosureTable_858" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureTable_858" xlink:to="loc_dei_LegalEntityAxis_859" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_859" xlink:to="loc_dei_EntityDomain_854" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureTable_858" xlink:to="loc_srt_StatementGeographicalAxis_863" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_863" xlink:to="loc_srt_SegmentGeographicalDomain_862" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="loc_country_CH_877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_862" xlink:to="loc_country_CH_877" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="loc_country_US_878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_862" xlink:to="loc_country_US_878" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB" xlink:label="loc_country_GB_879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_862" xlink:to="loc_country_GB_879" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TaxAuthorityInOtherJurisdictionsMember" xlink:label="loc_roiv_TaxAuthorityInOtherJurisdictionsMember_880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_862" xlink:to="loc_roiv_TaxAuthorityInOtherJurisdictionsMember_880" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_UnitedStatesAndCanadaMember" xlink:label="loc_roiv_UnitedStatesAndCanadaMember_1475806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_862" xlink:to="loc_roiv_UnitedStatesAndCanadaMember_1475806" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureTable_858" xlink:to="loc_srt_RangeAxis_860" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_860" xlink:to="loc_srt_RangeMember_861" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_861" xlink:to="loc_srt_MinimumMember_875" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_861" xlink:to="loc_srt_MaximumMember_876" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureTable_858" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_855" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_855" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_856" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_856" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_873" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_IncomeTaxDisclosureLineItems" xlink:label="loc_roiv_IncomeTaxDisclosureLineItems_857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureTable_858" xlink:to="loc_roiv_IncomeTaxDisclosureLineItems_857" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_874" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_853" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_OperatingLossCarryforwards_864" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AnnualNOLUtilizationLimitationPercentage" xlink:label="loc_roiv_AnnualNOLUtilizationLimitationPercentage_865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_roiv_AnnualNOLUtilizationLimitationPercentage_865" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_866" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_867" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="loc_us-gaap_TaxCreditCarryforwardExpirationDate_868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_TaxCreditCarryforwardExpirationDate_868" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_869" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_870" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_794" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredTaxAssetsLiabilitiesTable" xlink:label="loc_roiv_DeferredTaxAssetsLiabilitiesTable_797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_794" xlink:to="loc_roiv_DeferredTaxAssetsLiabilitiesTable_797" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesTable_797" xlink:to="loc_dei_LegalEntityAxis_800" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_800" xlink:to="loc_dei_EntityDomain_799" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredTaxAssetsLiabilitiesLineItems" xlink:label="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems_796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesTable_797" xlink:to="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems_796" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems_796" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_801" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_803" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_804" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_805" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_roiv_DeferredTaxAssetsLeaseLiabilities_806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_roiv_DeferredTaxAssetsLeaseLiabilities_806" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_807" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_808" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems_796" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_809" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems_796" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_roiv_DeferredTaxLiabilitiesDepreciation_811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" xlink:to="loc_roiv_DeferredTaxLiabilitiesDepreciation_811" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="loc_roiv_DeferredTaxLiabilitiesRightOfUseAssets_813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" xlink:to="loc_roiv_DeferredTaxLiabilitiesRightOfUseAssets_813" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_815" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_816" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail">
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TaxRatesAbstract" xlink:label="loc_roiv_TaxRatesAbstract_819" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EffectiveTaxRateReconcilingItemsTable" xlink:label="loc_roiv_EffectiveTaxRateReconcilingItemsTable_822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TaxRatesAbstract_819" xlink:to="loc_roiv_EffectiveTaxRateReconcilingItemsTable_822" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_EffectiveTaxRateReconcilingItemsTable_822" xlink:to="loc_dei_LegalEntityAxis_825" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_825" xlink:to="loc_dei_EntityDomain_823" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EffectiveTaxRateReconcilingItemsLineItems" xlink:label="loc_roiv_EffectiveTaxRateReconcilingItemsLineItems_821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_EffectiveTaxRateReconcilingItemsTable_822" xlink:to="loc_roiv_EffectiveTaxRateReconcilingItemsLineItems_821" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_EffectiveTaxRateReconcilingItemsLineItems_821" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_840" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_841" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_842" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:label="loc_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_1475777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_1475777" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets_1475779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets_1475779" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_844" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1475781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1475781" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_1475783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_1475783" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDeductionsOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationDeductionsOther_1475785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationDeductionsOther_1475785" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_846" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_848" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_847" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_849" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_850" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_EffectiveTaxRateReconcilingItemsLineItems_821" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_826" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_827" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_829" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_1475778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_1475778" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_1475780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_1475780" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_832" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_1475782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_1475782" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_1475784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_1475784" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_1475786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_1475786" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_834" use="optional" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_836" use="optional" order="31" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_835" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_837" use="optional" order="33" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_838" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract_1401" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_1402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_1401" xlink:to="loc_us-gaap_OperatingLeaseCost_1402" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_1403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_1401" xlink:to="loc_us-gaap_ShortTermLeaseCost_1403" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_1404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_1401" xlink:to="loc_us-gaap_VariableLeaseCost_1404" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_1405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_1401" xlink:to="loc_us-gaap_LeaseCost_1405" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1407" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1407" xlink:to="loc_us-gaap_OperatingLeasePayments_1408" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1407" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1409" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1407" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1410" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1407" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1411" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1413" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1413" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1415" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1416" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1417" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1418" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1419" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1420" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1421" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OperatingLeaseLiabilityPresentValueAdjustments" xlink:label="loc_roiv_OperatingLeaseLiabilityPresentValueAdjustments_1423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" xlink:to="loc_roiv_OperatingLeaseLiabilityPresentValueAdjustments_1423" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:label="loc_roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_1424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" xlink:to="loc_roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_1424" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" xlink:to="loc_us-gaap_OperatingLeaseLiability_1425" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_595" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_595" xlink:to="loc_us-gaap_StatementTable_600" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_600" xlink:to="loc_dei_LegalEntityAxis_597" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_597" xlink:to="loc_dei_EntityDomain_596" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_600" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_601" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_601" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_598" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementAxis" xlink:label="loc_roiv_AgreementAxis_1510958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_600" xlink:to="loc_roiv_AgreementAxis_1510958" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AgreementDomain" xlink:label="loc_roiv_AgreementDomain_1510959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_AgreementAxis_1510958" xlink:to="loc_roiv_AgreementDomain_1510959" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MasterSubscriptionAgreementMember" xlink:label="loc_roiv_MasterSubscriptionAgreementMember_1510960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_AgreementDomain_1510959" xlink:to="loc_roiv_MasterSubscriptionAgreementMember_1510960" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ProductServiceAgreementMember" xlink:label="loc_roiv_ProductServiceAgreementMember_1510961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_AgreementDomain_1510959" xlink:to="loc_roiv_ProductServiceAgreementMember_1510961" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_600" xlink:to="loc_us-gaap_StatementLineItems_599" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_1510957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_599" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_1510957" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_681" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_681" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_dei_LegalEntityAxis_693" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_693" xlink:to="loc_dei_EntityDomain_684" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SioGeneTherapiesIncMember" xlink:label="loc_roiv_SioGeneTherapiesIncMember_697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_684" xlink:to="loc_roiv_SioGeneTherapiesIncMember_697" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_ArbutusBiopharmaCorporationMember" xlink:label="loc_roiv_ArbutusBiopharmaCorporationMember_698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_684" xlink:to="loc_roiv_ArbutusBiopharmaCorporationMember_698" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DatavantMember" xlink:label="loc_roiv_DatavantMember_1294913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_684" xlink:to="loc_roiv_DatavantMember_1294913" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_688" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_688" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" xlink:to="loc_us-gaap_MoneyMarketFundsMember_709" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" xlink:to="loc_us-gaap_CommonStockMember_710" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentCompaniesMember" xlink:label="loc_us-gaap_OtherInvestmentCompaniesMember_712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" xlink:to="loc_us-gaap_OtherInvestmentCompaniesMember_712" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_690" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_690" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_691" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_691" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_713" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_682" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_682" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_683" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_714" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_715" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_716" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_699" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_700" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_701" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_DebtInstrumentFairValue_702" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_704" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_706" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1294927" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1294929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1294927" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1294929" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1294948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1294929" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1294948" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1294949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1294948" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1294949" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1294955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1294949" xlink:to="loc_us-gaap_WarrantMember_1294955" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivEarnoutSharesMember" xlink:label="loc_roiv_RoivEarnoutSharesMember_1294960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1294949" xlink:to="loc_roiv_RoivEarnoutSharesMember_1294960" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivLiabilityInstrumentsMeasuredAtFairValueMember" xlink:label="loc_roiv_RoivLiabilityInstrumentsMeasuredAtFairValueMember_1295024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1294949" xlink:to="loc_roiv_RoivLiabilityInstrumentsMeasuredAtFairValueMember_1295024" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SumitomoOptionsMember" xlink:label="loc_roiv_SumitomoOptionsMember_1295026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1294949" xlink:to="loc_roiv_SumitomoOptionsMember_1295026" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1294950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1294929" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1294950" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1294952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1294950" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1294952" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivPublicWarrantsMember" xlink:label="loc_roiv_RoivPublicWarrantsMember_1294957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1294952" xlink:to="loc_roiv_RoivPublicWarrantsMember_1294957" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivPrivatePlacementWarrantsMember" xlink:label="loc_roiv_RoivPrivatePlacementWarrantsMember_1295022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1294952" xlink:to="loc_roiv_RoivPrivatePlacementWarrantsMember_1295022" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1294953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1294929" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1294953" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1294954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1294953" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1294954" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1294959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1294954" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1294959" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1295014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1294954" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1295014" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1294931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1294929" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1294931" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_1294934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1294931" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_1294934" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_NonfinancialLiabilitiesFairValueDisclosure_1294937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1294931" xlink:to="loc_us-gaap_NonfinancialLiabilitiesFairValueDisclosure_1294937" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_718" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueDisclosuresTable" xlink:label="loc_roiv_FairValueDisclosuresTable_723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_718" xlink:to="loc_roiv_FairValueDisclosuresTable_723" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_srt_RangeAxis_727" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_727" xlink:to="loc_srt_RangeMember_728" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_728" xlink:to="loc_srt_MinimumMember_737" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_728" xlink:to="loc_srt_MaximumMember_738" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_725" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_725" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_726" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_726" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_736" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_719" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_719" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_720" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValueMember" xlink:label="loc_roiv_LiabilityInstrumentsMeasuredAtFairValueMember_729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_720" xlink:to="loc_roiv_LiabilityInstrumentsMeasuredAtFairValueMember_729" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_dei_LegalEntityAxis_724" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_724" xlink:to="loc_dei_EntityDomain_721" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1295121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1295121" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1295123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1295121" xlink:to="loc_us-gaap_EquityComponentDomain_1295123" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EarnoutSharesMember" xlink:label="loc_roiv_EarnoutSharesMember_1295122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1295123" xlink:to="loc_roiv_EarnoutSharesMember_1295122" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1295125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1295125" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1295126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1295125" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1295126" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="loc_roiv_PrivatePlacementWarrantsMember_1295127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1295126" xlink:to="loc_roiv_PrivatePlacementWarrantsMember_1295127" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueDisclosuresLineItems" xlink:label="loc_roiv_FairValueDisclosuresLineItems_722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_roiv_FairValueDisclosuresLineItems_722" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_FairValueDisclosuresLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_734" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EquityInterestOptionToThirdPartyPurchase" xlink:label="loc_roiv_EquityInterestOptionToThirdPartyPurchase_1106618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_FairValueDisclosuresLineItems_722" xlink:to="loc_roiv_EquityInterestOptionToThirdPartyPurchase_1106618" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_1295119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_FairValueDisclosuresLineItems_722" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_1295119" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_1295124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_FairValueDisclosuresLineItems_722" xlink:to="loc_us-gaap_DerivativeLiabilities_1295124" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_758" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_758" xlink:to="loc_us-gaap_StatementTable_764" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_764" xlink:to="loc_dei_LegalEntityAxis_762" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_762" xlink:to="loc_dei_EntityDomain_759" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_764" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_760" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_760" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_761" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_761" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_766" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_764" xlink:to="loc_us-gaap_StatementLineItems_763" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_767" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_1291490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_1291490" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_768" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne" xlink:label="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne_1476403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne_1476403" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1096967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1096967" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" xlink:label="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary_1096985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary_1096985" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_769" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsScheduleOfChangeInFairValueOfTheLevel3AssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1295044" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1295045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1295044" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1295045" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1295052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1295045" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1295052" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1295053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1295052" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1295053" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1295054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1295053" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1295054" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1295047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1295045" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1295047" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_1295048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1295047" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_1295048" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment" xlink:label="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment_1295049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1295047" xlink:to="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment_1295049" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_1295050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1295047" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_1295050" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_1295051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1295047" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_1295051" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1295072" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1295073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1295072" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1295073" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1295076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1295073" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1295076" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1295078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1295076" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1295078" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_1295080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1295078" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_1295080" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1295104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1295078" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1295104" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_1295105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1295078" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_1295105" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1295082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1295073" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1295082" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1295083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1295082" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1295083" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="loc_roiv_PrivatePlacementWarrantsMember_1295084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1295083" xlink:to="loc_roiv_PrivatePlacementWarrantsMember_1295084" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1295088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1295073" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1295088" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1295089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1295088" xlink:to="loc_us-gaap_EquityComponentDomain_1295089" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EarnoutSharesMember" xlink:label="loc_roiv_EarnoutSharesMember_1295091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1295089" xlink:to="loc_roiv_EarnoutSharesMember_1295091" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1295092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1295073" xlink:to="loc_dei_LegalEntityAxis_1295092" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1295093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1295092" xlink:to="loc_dei_EntityDomain_1295093" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_DatavantMember" xlink:label="loc_roiv_DatavantMember_1295094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1295093" xlink:to="loc_roiv_DatavantMember_1295094" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1295075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1295073" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1295075" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_FairValueAssetMeasurementInput" xlink:label="loc_roiv_FairValueAssetMeasurementInput_1295095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1295075" xlink:to="loc_roiv_FairValueAssetMeasurementInput_1295095" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_1295103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1295075" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_1295103" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1442" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1442" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1444" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1444" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1445" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1445" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1446" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_1451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1446" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_1451" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1446" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1452" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_1453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1446" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_1453" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1444" xlink:to="loc_srt_RangeAxis_1447" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1447" xlink:to="loc_srt_RangeMember_1448" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1448" xlink:to="loc_srt_MinimumMember_1454" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1448" xlink:to="loc_srt_MaximumMember_1455" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1514284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1444" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1514284" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1514285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1514284" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1514285" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_SumitomoOptionsMember" xlink:label="loc_roiv_SumitomoOptionsMember_1514286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1514285" xlink:to="loc_roiv_SumitomoOptionsMember_1514286" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1444" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1443" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_AlternativeInvestmentExpectedTerm" xlink:label="loc_roiv_AlternativeInvestmentExpectedTerm_1449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1443" xlink:to="loc_roiv_AlternativeInvestmentExpectedTerm_1449" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_1450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1443" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_1450" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="loc_us-gaap_OtherExpensesAbstract_1460" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_1461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherExpensesAbstract_1460" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_1461" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1461" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1462" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_1463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1461" xlink:to="loc_us-gaap_InterestIncomeOther_1463" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_1464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1461" xlink:to="loc_us-gaap_InterestExpense_1464" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OtherIncomeExpense" xlink:label="loc_roiv_OtherIncomeExpense_1465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1461" xlink:to="loc_roiv_OtherIncomeExpense_1465" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OtherOperatingIncomeExpensesNet" xlink:label="loc_roiv_OtherOperatingIncomeExpensesNet_1466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1461" xlink:to="loc_roiv_OtherOperatingIncomeExpensesNet_1466" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1294668" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1294670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1294668" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1294670" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1294672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1294670" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1294672" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1294672" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_StockOptionsAndPerformanceStockOptionsMember" xlink:label="loc_roiv_StockOptionsAndPerformanceStockOptionsMember_1294679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" xlink:to="loc_roiv_StockOptionsAndPerformanceStockOptionsMember_1294679" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:label="loc_roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember_1294681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" xlink:to="loc_roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember_1294681" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_TwoThousandAndTwentyCvarsMember" xlink:label="loc_roiv_TwoThousandAndTwentyCvarsMember_1294690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" xlink:to="loc_roiv_TwoThousandAndTwentyCvarsMember_1294690" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_NovemberTwoThousandAndTwentyOneCvarsMember" xlink:label="loc_roiv_NovemberTwoThousandAndTwentyOneCvarsMember_1294693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" xlink:to="loc_roiv_NovemberTwoThousandAndTwentyOneCvarsMember_1294693" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1294697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1294697" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_EarnOutSharesNonvestedMember" xlink:label="loc_roiv_EarnOutSharesNonvestedMember_1294708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" xlink:to="loc_roiv_EarnOutSharesNonvestedMember_1294708" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PrivatePlacementWarrantsMember" xlink:label="loc_roiv_PrivatePlacementWarrantsMember_1294710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" xlink:to="loc_roiv_PrivatePlacementWarrantsMember_1294710" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_PublicWarrantsMember" xlink:label="loc_roiv_PublicWarrantsMember_1294711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" xlink:to="loc_roiv_PublicWarrantsMember_1294711" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_OtherInstrumentsIssuedMember" xlink:label="loc_roiv_OtherInstrumentsIssuedMember_1294714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1294673" xlink:to="loc_roiv_OtherInstrumentsIssuedMember_1294714" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1294718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1294670" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1294718" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1294720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1294718" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1294720" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SubsequentEventsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1483" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1483" xlink:to="loc_us-gaap_StatementTable_1494" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1486" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1486" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1485" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1490" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1490" xlink:to="loc_us-gaap_RelatedPartyDomain_1489" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1495" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1495" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1496" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1496" xlink:to="loc_us-gaap_SubsequentEventMember_1513" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_1491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_srt_RestatementAxis_1491" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_1491" xlink:to="loc_srt_RestatementDomain_1492" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1497" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1497" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1484" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_DebtInstrumentAxis_1487" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1487" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1488" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1294964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1294964" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1294966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1294964" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1294966" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1475389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1475389" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1475391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1475389" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1475391" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RoivrevenueInterestPurchaseAndSaleAgreementMemberMember" xlink:label="loc_roiv_RoivrevenueInterestPurchaseAndSaleAgreementMemberMember_1475394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1475391" xlink:to="loc_roiv_RoivrevenueInterestPurchaseAndSaleAgreementMemberMember_1475394" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_1475410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_srt_CounterpartyNameAxis_1475410" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1475411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1475410" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1475411" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GSKMember" xlink:label="loc_roiv_GSKMember_1475412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1475411" xlink:to="loc_roiv_GSKMember_1475412" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_WelichemBiotechIncMember" xlink:label="loc_roiv_WelichemBiotechIncMember_1475416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1475411" xlink:to="loc_roiv_WelichemBiotechIncMember_1475416" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaap_TransactionTypeAxis_1475413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_TransactionTypeAxis_1475413" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_1475414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionTypeAxis_1475413" xlink:to="loc_us-gaap_TransactionDomain_1475414" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_RegulatoryMilestoneMember" xlink:label="loc_roiv_RegulatoryMilestoneMember_1475415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionDomain_1475414" xlink:to="loc_roiv_RegulatoryMilestoneMember_1475415" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_StatementLineItems_1493" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MilestonePaymentPeriod" xlink:label="loc_roiv_MilestonePaymentPeriod_1475388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_roiv_MilestonePaymentPeriod_1475388" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_MilestonePaymentPayable" xlink:label="loc_roiv_MilestonePaymentPayable_1475405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_roiv_MilestonePaymentPayable_1475405" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20220331.xsd#roiv_GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement" xlink:label="loc_roiv_GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement_1510956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_roiv_GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement_1510956" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g307489g11i11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g11i11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2>>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )X*^$!%#A"24T$!       #QP!6@ #&R5'' (   +[LP X0DE-!"4
M   ! 3<.Y/DV<0P3$H*B%M/Z%U.$))300Z      #E    $     $
MMP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $
MEN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&
M5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4
M!R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0F
MQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M   BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W
M!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;V
MP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $
M5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D
M="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M       $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M      0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'#M<*
M         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M  4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'
M0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E
M!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F
M]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !#M<*  $  @$.UP
MH  0 ".$))300F       .             #^    X0DE-! T       0
M >.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "
MT    &       !.$))30/X      !P  #___________________________
M__ ^@     _____________________________P/H     /____________
M________________\#Z     #_____________________________ ^@  #
MA"24T$"       $     $   )    "0      X0DE-!!X       0     .$
M))300:      ,U    !@             #RP  !IP          0
M                 !              :<   #RP
M !                         !     !        ;G5L;     (    &8F
M]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M  3&5F=&QO;F<          $)T;VUL;VYG   #RP    !29VAT;&]N9P  !I
MP    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M=S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F
M5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP96
M5N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M      4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M    !"=&]M;&]N9P   \L     4F=H=&QO;F<   :<     W5R;%1%6%0
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MEC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M  "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M  .$))3001       ! 0 X0DE-!!0       0    ).$))300,     !T;
M   0   *    !<   !X   K(   !S_ !@  ?_8_^(,6$E#0U]04D]&24Q%
M$!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E
M0     245#('-21T(               $  /;6  $     TRU(4" @
M                                                         18W
M!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0
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M(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M
M   %A96B        #S40 !     1;,6%E:(                     !865
MH@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M   "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V
M@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                              9&5S8P
M N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D
M="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7
M(@<W!A8V4@+2!S4D="                             &1E<V,
M  +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C
M$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@24
M5#-C$Y-C8M,BXQ                                  !V:65W
M 3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %
M<?YVUE87,          0                        */     G-I9R
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M$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-=
MV.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^
MP0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!
M*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7
M@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA &&48BA
MBO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:'
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M6PZK%@L=:R2[+"LSBSKK0EM)RU$[6
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(_QZ\\5U(4#,'_\ (=/RR9^5O+'P5IQ)'[W(SJ.M0_(G(VSM_P *6018$;7
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M;;B@X1V8XM5BL9H'U4QI:2I?9-0TFMK%"FI4+:$!0=><2W*B$(*LZR$).+E
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ML#!A<RE6AP.GL,?;[_K_ $X8K+MZF=?O[G$9G*2HB8M:_EM&\B-\.[76  K
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MD R-9(  UN>4XDO_ -''-V @+NVN\D+"QCK1>7B$Y,09C.<G+]+I]ZU2KM*
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MX\WAH7L-X@#YV$X4QYZ'07$E(R3E)[#0X&00!C;&V<Y]0I.AT'*Q]09UPQ2
M" )!C0ZD6W3RB+^AT!7B6I"1\F1C!P<$Z[ :YQZ]M_3B,@3^:W.Y/R$'WP=V
M2/RC2VECY'KK:^^ )[1&%=2?90('<9VUT'H?Y<&FAFVL>>]X]/E&#N5GJ.FO
M.+$:$SI8],(WILQISSX(1)1CI<::<'F*1N1Y:NE2M0<!/4=-.$ 2=51U(L/V
MW],6D-@ 9A?[Z3^NWGX9EO27?,A2%(?20'J?+*DJSD AM:P% [82YE.F H
M<*J /$F1>%)((TB^H(\@#J3A^0 R"=[&#SD"8UTN3M&%Z@Q+7Y<UIZ#(&!YK
M8(23L"ILX01WZAT$C91!XC,@2DYAR]]]?K^F')RFQL;P8BYVMIS$^*/.<'I;
MK%&!=9Z9\(ZKZ"5H+9&H6A6>@XWZATG/RJ)U$9*'+'PJ$B#J#M'/T/H<2@%
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M6G>ELE7AE-35;OXK<>55T/#&U<.IF*3,T5BO6EI "A7H<7_3K*-\]TI!9!0
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MF?KZX5H02<GMM_?Y?4[>G#%* M8D_K<^]]YWQ&/$N;@3)WC?6-3M;7"YIE1
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MG&%* RTUDZX&J$D'0+7D^A2#CB)0D%2H:1.X\2HL)&I\AZ@WQ.E !%LY-XM
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MQ"4LL( SDJ??<1MZE"<8['40HXSWJLK-.3, 9E$J\@A(T'(*B^L#&K3]DVQ
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M"T.-J%]%)*A(-E))S(4"%"04XK+;4A12XDI(,*"A!'H==#!T.&1M@ CJ [
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M.H]*^EQU?PZR-O*EJ4DXPKN+#C"%I"E(2M4"4EU0;DQ8D 9@"-T'D8-L*,A
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M)N6='4MEB<Y4G&F*A29,]_--I2T1H='<D2*E*E\/5@=H34A\OJX5WM70TK2
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MN03:TR8,=CVFFF&FV66VV666T----(2VTTTVD(;;;;0 A#:$ )0A("4I 2D
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M(3H+@!:90>EQC/(P<'OG.^A&#_?W''1&?2-=P9^F_IBGGO,A(F-!]=_X(\C
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M#(BTDP.NQJR7<=X7@^XS36I"FP?G#(3Y;2",)+\ASHC1P,_+YA2?\J%+..-
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M25J5VC5!3H>0E#-0XI(2E* MP4].E(D96\Z6&R(!&1!4%7$&!B%*5$22D3L
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M&%*2$$^NG41]-CJ- =L]RM.;*VM:D;*(RZ:P)-@-X!OH(@U%/MIF#,7FX/E
MF-+>^F"45Q*'6P7 ?G1@X[A0[C30_F/TC'$'$S*C?J![ 'G.G7K+/B$R)\K1
M>=#%R !RVQ_8#X^&<</@<&# X,&$LZ;"IL*74*E+C4^GP8STN=.F/M18D.)'
M;4[(DR9+RD,QV&&DJ<=>=6EMM"5+6H)!/#5*2A*EK4$H2"I2E$!*4@22HFP
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M?3%152;R2 +W/GR)@SS.(W(K;CA.,[[DZ9^Y],'^6,\4U51)U!$>777:U["
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M3]GN"4]F>'4K0*U.JR,H3F=4HJ4M4) *U*.<K(S%4JF;X4UKZS=Q4D 7*B0
M( $DPF!>#I:V(9!ES;IN"DPKEN:3$AU&JP(4^MU%<F>U28<N6RQ*J;L8.)<D
M-P6'')3C#:D+=0T6T+"E@C16ANE8=734R%K;;<6AA 2@NK0@E+84$PDK4 E*
MB#!5)%KQ%PN* 6X8*AF49( )N8&L3-B/EB3\V>65:Y.\S[YY85YQF35;'N6J
M6^[4(R5)AU:/#D*33ZY3DJ4I1IM=IJHM8IJRH^;!FQW"H]635X5Q%CC'#*+B
M3 *&JVG:?#:B,[2EI!<8<( _JLN9F7!:%H4FT1@<9++SC:OS-** 1,$:A0WA
M0.8="//$,8Z@1I[ G&HR.W\_3&N_%M0 /(?0\O7;3I88 L@ 0+?>O\8DD&2E
MK!4<9[=CC?[_ %QGMQ"M,@ "UQOO^GE[6P9]9UMIMRM%Q?\ 0[XNBC6E=$VT
M'KX8CT=FV&)-4AIEU*ZK4H\R9+HL:!,JD>DT6JUJ%7*T]#8JE/4XW2:=-4I<
MQEEL+>5Y?&.]5TJ*Q-"I3QJBEM65NEJ74MH>4M#:G7VF5L-)4IMR"ZX@#(5&
M!?#DH<*5.I*<LD$J6@$E(&8!)6%$@$62F=M[-,6MA6,+&VV>W;7.AT^@XE4P
M0-#Y_P "WH+_ #PS.3^=(('+;VO?UVTC$NK4.J4"H*I59C"+.1%ILU3 D,2
MF/5J;$JT!SS(SKS&7Z?-C/%(<*VRX6G4H=2XA-1I352T5M*#C:E.-G,E0!+:
MUM.)*5"2 M"DF1!@D2#>6 VJ#*5B#8DD3=)D6N((Y>8PHF7#5*NW3FJE4),U
M%+B"#3TR7"OX:)YSCP80I8*BD+=6$E1*O+2VT%>6TVA/"]B_PR[&?A[5=J*S
MLEP2DX,]VOXP.-<:%(A+;3E6EA##;;+:0$T],W#KZ*9L!INHJJI;:4)=R)ZS
MM)VV[2=KZ;@M-Q_B3G$4=GZ)=!P]3L%WNW' XMZJ< S5%6M*&&%U3I4ZXQ24
MR7"M:%.*\(6%C.Q[CW_J..\QRX<!\*K:S,S$?=_;GA\H= JMR5)BD4:-\94)
M3<IUECSH\?K1"AR)\DEZ4ZRPGRXD5YT]3@4HHZ&PIQ2$J@?J&J9I3KRLC:5)
M2595&,ZTH3X4I43*E)%@=9, &(BG.HI0#,G*"1< 28)-@(, Q$&^V&@ @GJ&
M$[=SD?IW&^@_K*3,003MTZWGGI<_40J@:B9%R)D#6+<_8;WM@P%)]\GOKL/?
M^]>&@&;C;8QJ?^W[L).%22;I5"4_F_,9DCU]N0PX4^9/I$^%5:3.E4ZI4Z2Q
M.IU0I\EZ'/@S8KJ7H\N'+CN-O1I$=]*'67FG$.M.(2IM:5 'A'&T.MK:=0EQ
MMU*FW&W$A;:T*$*0I"TD+2I$I4""%3!!&CLRDY5@J2H&0H$I@V@@S,]=^N-;
M5^!!\5-MUB]J#!AT[Q'VC2WJM?\ ;E,C,Q8W.NVZ>SYE3YA6[38Z6V6N8=#C
MMJG7W183:47'3TOW12HZ9T:KQ7.3IUN=EJAFB?<4YV=JW4M4-0XI2E\&J7##
M7#ZAU4J_T]Y1#="\N33.%%*ZHH4PH6W(K4*=;"15MI)<2 !\0@?F=0!8N)F7
M /S"5 2#.,TI6#J<$$ @CN<_IVVV[<=@2(Y@@GT'^<9@F9T,QO<GGI;G%^F%
M3:.K<:'0$^^!C0Z^YQVQKOPV)%[1>QO,R29 C68ZFVD.FXWF1H -K"YL-S<<
MMSA4AG90'V.G?WUR/L#ZG'"B!-Q%O0>?+EYG6<.*"19,F+WGTG61.T=28C"M
M#((^;VTU/OOMG;;..$*XT&NYMITUUG6.F'!M2OS&!L(Y&XM D=9YC?!PC9&4
M]L:YW]AKO[9S_,('+WTZ:CS^>V$6T$@$&\^5HV&LSS./895@'I23D9TR?3.2
M<;?Z8X4+3U'2/I'Z_OAA0K, ;E5S[Q?;_./01J0!@@ZX SG0>Q/]!MDGB):Y
M$C:>?,Z\K ^9'D,3MH*=YD S G06G7GTC2#CWY:.MM#P 25IT4#G&1KJ1C/J
M!ID<1%:A)%H2=/>?EY#%A*9B;S:/,CJ.?409PWU=$9M;CD7+C[G2D)/_ *8Z
M0CI; &1G3*B.M6>E) SE6W%$ *@)$WYW)O)N /2")Z6$,WDCG _D>HO&D3K,
M/J27Z:@1VVU+J4\H04C^)/4H)#:"-, GIRD]/F=:L]+(Q.A:79450VB==P-S
MYZWO$ S,8DR%&@)4HB#!( D:1H1RL-^6&R5/_"XXID=>7EX<G2 ?XW<8Z$JQ
MD(;.4-YQD=3A^97"!'>*[U8L)"$\A.I M)MF@1H#UNLCNQEW-U$"(Z"18GS@
M=3API<)AJ**M7 6H@^:-$)*79Y R%K&JVXI/<8<>_P#3(20I5=UQ:E=RR05G
M\R@)2B\1R) 'DG?&@VTF,RK)&Q.IYF\[1 N9C0X?'V7:LTBH5U]5(HB$@PX#
M1#,B4RG^ -M:)88P$A*UIP1@H2H8<XA!2P2A@=Z^9"UD2E))N"1=2@3%CJ;\
ML2=V7CX_ T#)2+$BQ)43MR&EDP) .$K,FHUL.TJUHC-(HT;_ .[GJRU':21_
MU93[GSR'U)&4(45O+QHA* I:54A#4.U2RZZH>%$ G6P T2 9T@ Z&;8F2$B$
M-)RIF,T?( [Z23XIY8.#E)MJ=3J3!J4*%5ZP^U&E7=7FY#D>DQW^KJG+990M
M^-&*$N&.RGRY$Y00VIU$4.SFZSSKBVG'7$+6VV"6Z5@I"G%"/""3XE21F600
M@20G-X%;'"^$N\1>R-I)2F[BR9MOS!4= D7D29@QI.K77RQ\-%LU>51GT7SS
M"E4-NMUFKS)C"Y;L!Y(5 FURHQT/(H-N2'U)30+>I3#TRJ.J*J;3Y[B*G5F.
M00QQ+M'4M!\?"40?+++:$'('+!Q##9*>_?0F._?<4E+*8#KB 6FE=TQ3L432
MFF6\N02JT&1HI9UDW 3!)_M  )'(GG1SGJ_-BK*N6HR:]7:G$B+<FS9DD4F@
M4%AQ*E"D6S0H4A3-*I;2\%Z14*C/JU;?8:>=6PZ)!E>I\(X0UPMH4R PPVM<
M-MH27GWR(EVI?6D%UTC\J6FFV64J4 % I*(5'O3("E1$DDI _P"T)$Z$[G,H
MBV\9-<O]-,J3\^2Y\0\XEY2I+[8FRQ(4H*+[)DN^3\6M6<29"'E()4H)"E9/
M3FB2IH)G(@91E!"$%('Y2$C,4#_:@IFPF,2-H*)4<I,F"H[_ .[0R;<IWUG%
M$W;=WXE/DS4I4V7B5$+>=?=6<G+CKKJBI;J\@$C" E*4H2E*0>(7ZU%(T&FU
M D")3"8M,!(B$_,V))-\5GJPI!2E68F9( &I.EYUOSYGE4=3KBU*5A>-R3G.
M.V=R-2/4CMKD\<Q4URG"94;\S<SK(FTSKK<F<9+E0HDF0->7RTO[[>6(3-K"
M$'1:BK4GYMCN<@8]\?73TXR':H"2%1UF;0(VDW&_IBBX^F3!).MA$GEK8#_=
MO;KB*2JJI62%'N!DGL?K_P 8TQMQ074&X$D^PO,\].LW/GBL5E4@6D;0?W$&
M#%]R"1:6=<MQTDE2@/7L,@XQKD[:$::Z$<5BM1)OKY?7[Z8 B;DDVW,>?(1,
M R3ZP<>$N*.2%:YP<:G)P,[@#'T]3KPPW^_OH/+$B1 ! !N 8Y[G?SD$;:7P
MK;>4G&BE$;*(3J>_L/KOOP#,DRD@6@@Z1T_:V':V(WUU'/?VL/;#HW)4I."H
M@ZZ:D=AW^X!(_D.+*'U*$3!CF9VZP-=-O+#@!)!D==;^IFV_RP:EQT'(6LDC
M. 3J!I@ZZ[]SC7MKPA69NHR9W(PY.8&1) M:;\K3_B??VE3CG\0(P"=,YT]B
M<#)WTQ[=7#29%B=HBY]1;KK;UMB0%1G,-#;Y7CISG;"N.PA3C1 4I9=0<8('
M\8T)SN<C3!]CDC@-A(41 $1'*!>-_8SB0(28A1!M()B3((*;QJ.@'M/]E_CY
M)QRN!P8,#@P8PQXY;DY84&T;1C\Q.B8W6*I5:0]2/W?FR;1J<!$*Z*@VM3@=
MC2J'*<MZLT=Z%'FU!^NP*9!:BI@RJG.@<UVC:;>30!%&JNX@U4K?H6$,EXIR
M-*14/.>%:6F6VW %+=26ENJ:84E9>2D][^'U%QFMXL\GA)#8:I^^J77$]XRD
M,K#K+;C?=NAT/+06>[*""E:E$C+.'+P.V+8MH<LJH_:DI%3JLVO/PJY5"AD*
M=@4]/Q-J-QG65N(?@R[=J<*O!\+!7/K4]I;,(QQ38#.ROPKM$_6,I*:FJJG1
M6H4TAE;#S"BVFD+;;;82FG1"1*$J*E*4I*"HH37[>5G$*KCKJ:YE-,EI"134
M[82EMMI7YK)2A.?.E2%G*">[2#( )VKQU&.*P.#!@F3)C0HTB9,D,1(D1AV3
M*E276V(T:,PVIU^1(?=4AIEAEI"G'77%);;;2I:U!()!@QQ=\/-.E_M,_$S!
M\<=ZMO2/!?X:[MN.W? !84]E8I'-_F5179EL7QXY:]3WD);J$!N4*U8GAJ;G
MMNFEV_&K_,R%'I]2NFE24&#':C@P8'!@P5(>;CL/R'5EMIAEQYQ82I90VTA2
MUK"$A2E%*4D]*4J4K& "3CACBTM-N.+)2AM"UJ4$E12E"2I1"4A2E$ $A*02
M= ";84"2 -20!) %^9, >9,#?'%?FU59$^%<KSLB3'N&M5:7+<8>=$F([/F*
M<;>J=)367HE ;AU>,PAQ3D5A^4^W*##I;BI\MOR_L"X'N".<:>K1Q-[B==5U
M;E?\&:9Y]E+A+*UM-4C#B4J2&EP:9I21&=&@&QQ$0\AA*0VEEI"$I"PH D1$
ME2_$E14D0H]-,27E[2Z9$M:'\53%1EN04ORT38K;;R7E(2IX20E"$+:7E+D<
MO>:XTR8\<K<5&0X.7[.=F5=NN+/<9XI5*JF7>)5=/1,LU 734M)2K4TZRFG"
MU-AV4A+Z4(2EU96Z6T+4M*K594?Z<T&&4A!2A"G"4D%:U0<V: 8()(,RF(E0
M@XJSF9>;41IU+:O*"4*4LM/-JV2$DDIP25I2G(PHX2G!T/'U?V%[!<'X8PA=
M-0,AXDM(<<8"E(;;5X4I*IRP3*<L 6@ #'(5]>^\N%.*R@38P"3S UY'GT(Q
MS>YGW\[*>DJ\]1 ZDH)4/F0 >D* V60< =SDZ@GCW_A7#&F$-H;0$I$"!I)@
M*-M)\C;RMA/N*5()F2?6+@3\_.^,6716'GEOK*CU+*L:@X*LZ#<X ]_]^QIV
M@ E(T3MY?Y]!Z116L"V:U[<R9.GWIBDJLXI]Q?4<@'&^N?0G/<Z^VVF--=I(
M M[:>L?+I<8C*K &1H01< _336UQ8:WB;V4JTT R.^I]?0XSH,GZ8!XM(T_Q
M;2WK$_SB Y@=B 3,0/E: -K^<8\!PG^+TW[_ '_,Y_+'#H VZ_?MA09%M/IT
M/(^XZX+<(.3V ]^VN>W^N1POW[X10M-[21_GESCTPV+0A9R=SG!&A'VV^^OY
MYXD*3:-M.>_]WKI/I:2\0;&V_,VVMYWVT]4CB.DX2K7&3D#3&<]_]>_"@2(!
M@'F!IZ=-9OY8823^7>\BXCE>!,VU._*2!D  X5IV.OIIZ:GMGTSIHL$0!?SV
MY1>==-8],+M?6 /6>5QO%NG+'M#B@0.W<9S^7?<_E]"2@@VT,F-==3K!,S<'
M^<+!&L\M(^7IYV,G7#FTH%.<C)P-]SDC]=]M,Z\1D1;W&P\O2.MO+"28)(T$
MZ1S^H@\[WP84Y.<Z_< 8QCU/Z@]QPEN5OO[T],,SSTTZ^>W\\ACTDGOIKVSV
M/O\ IKKP&X]/ORPN:XB(W)F/?3_(P:E/5J>^3C;^_;U_F: #E PX&>E_<>O/
M[O@]*#II@>G?[#W_ -_JD[CWV^Q[<SR6(^_KO-M[\\+68_6-L[C&>^=?MV.^
M3G;&L2E7,=+^6YY="(M//"D 1NJQC].<_IA0NG!0) &=\8R,^Y&?7&<X[;\-
M2X.?+4W Y $Q(CEOA2WT!M  .GOY;>F$BJ:XG8 ]_P ]\Y(T]-,:\2!U)^_T
MU\]?7$9;N9!'E?K:!YVVC&S?$C"5?W+KPW<_$A3U1N_ETOE/?TCIZW'K_P"1
M*X5IQYTV3DK=F5KEI+Y=U!Y3X\YV0)CI4M"@4\=V<7\#Q'M%P(PENDXA_JM"
MG0)H..=Y5*0@1"4,\23Q!M.4P$Y$ZB,7JD=XU35']RVRTX3NMB$ DZDJ;+<[
MR#)&V3TP,#'2,X[@ZZ#?&/\ 7/J-#U1<'4_Q_&GZ8I03N;7,0+>5[#_.QP4J
M*XV<I'3Z])R,#4Y2=#Z#77WT(<%@W.\W(U]?YUPT[3SMFM%IL4Z?K]=#T'FA
M;<?D:YRSJ4VI4ZMQ:]?-:BJ9Y5<N+QC547-2+/BTZ*B\[GJL&\+%,>9;+J9L
MFU8TA:F)C<I")$B,&%<^_P ,J5<;'$FT-.LK8H659N*<1HU-_#.U:G%FCIFE
MT==F14@H35* S(*92E14+(>1\.&B5@A3BA_1:=2<X0!_44K.W!0<Q1>"+&(Q
M:$OQ,4*NUNO5";$N:@R)MQ<U7K2NNC0:))N3EQ:UX5&P*C:E,M>&:A1V&E4)
MFU[IHST")6:/$@Q+XK,^D31-D3&Y6:GLX_3L,(0NF?2ECA8JZ5Y;R:;B%52-
MUS=4Y4K[MU1#ZJFF>#BV7EK71-(=3D2@I>NL0I15XTDJ>*% #.TAPM%"4"4C
MPA"T_F&4.**3?$IJ/B4LVM*NR0*3<C2:TU<33E%<@6V:;?)K7+:@610WKV>C
MNQVZ<NP:U1Y5VVZU2J55(R)LXIHK5H5 .UARLWV<K&12#OJ<]R:<]\'*GO*(
M,\1?K'Q1)5F+@KV7DTE0776E9$?UC5MPSA55;:N\,+&8+!3"/ZF9H(25WL&E
M)S@)2J9L$'Q"62/$58L^H1)T:/>%#J/X1;$6?<]#H](:FK9H-7KLZ=95/MVJ
M7758-*M*XH56AQ:L:=6(='ZZ+!CQ+"C4-3U$<JI[/US:%H4:1]HO5*D4SSSI
M1+[3*&ZQRH:I6ENU=.MI:FN\94]#SBEURWX>#C5M%4I*TJRIE24@&$%9[M*2
MX4I;4% *(4!"1#03*3YI/B<I]+3;D2EV[*HE&I+M"=D4"F-4LT](8YIW7=]P
MQXJW4H=D-U:RZ_!L=]^9A^ITF *-5.NB(9C\#O9MQWXE;E0EYYY+X2^Z7 N5
M<+I:1A2@"4I+58PNM2E'A;=<+S</DJPY-<@90$E(3'A3$$AY2U $ZA3:@@[J
M'A/AU=J!S\L&D63;EO1K=K[M1I-7%4\R2M3S-+\R@\P*/4H](D2+DDP&X=:?
MNNCS'X]/MFW%L)H2&:G,N60W!FQ8W^!5SM;4U"JBG2VZR6H3 +L/T+K:G4)I
MTN%;":9Y"5+J:F2^5-HIDE:%I\6VAM*<BR0J1: GPN(,'/E@A:9&5$1<JL1F
M!#:5C3()U&,D8U]_N<8^_;IX"@9OM,0>O7WZ6.IH%1,"X)N(@R+]+Z6'D!CZ
MJ,M.A&/IIZ #3 [;@G;\U !OKZS[C0:Z1;Z%T6@#J4JB3$#EH#>^\B1@UM'2
M,*(4/7OC^7^_L .% BP^_O\ S?"%0(()\,S UGI,VVO.^@P_6U<E>LJXJ+=M
MJU.71+AMVI1:M1JK#<\N3"GPG4NLO(.J5I"@4/,N!3,ADN,/M.,NN(5!54M/
M6T[U+5-(>8J&U-/-K$I6VL%*@=Y@^$@@I4 I)! .%0XIM25H*@I)S)/5)GK:
M-18&(W.+XYYVQ0+RMVC>(OEY3(M+H-YU-VA\S;1IK?EP^7/-A+"ILR-!C@YC
MVE?4-+US6CTE3,-:*Y;WF(-%:0OGN"U%315+O9[B#JW7Z)H/\.K'52OB7"9"
M$*<5_=5T*R*6KD!2Y8J8_KJ(MU+:'4IJF@$H=5E>0D69?-Y&X;='C1'_ ')F
M$XRZE10<[@X!SG&0?389VSMKMWXZ8:P)\N4[2=2+F(];1BF % D$$@208\03
MJ8V,=-)]75EU*DI2K4@#!]L#MIVQV['?/"%)F4V)G:=9T,6]]]L6$D%)(@"V
MFHF;&+CITC#DA*%I2<ZG.-,=]\C?OIIZ9XC-IFT8,Q)&42#O?IMJ/7VPJ#6-
MS]P"?3V QIW/\^&%8BT_L>OUZ^\!2I1DD0"+#EYQ,F(^8(P<$]@!D^Q/IZ]O
M;/8\-)L=;FTS8:SK[>6%@3H+=-SMZ"_GIOCTD(0L!*4J<).<_P (&I.<9/R@
M>@)VT!X:2<I))@<]^G4]#IB0"\$3/7ZD3$1L >9 U9JB\%25])!#>4YR2,]P
M/T'?4:9[O1^22)*@#!&NE_*3^HQ*A)SD1 !B09C>)U'/ST.LD,>7$0:G)0%M
MM]28Z-BX\,@+&2,^6< ' '5G4% /$2I*LB;$_F,DB-3U^QK.+Z)  N=YM8:S
M;?>/F(,)(2>MNJ7#+ 6&08T<$#I,AU/[SISMY+10TC3'[[.<IR$<-VV$6)@J
M\M1>VIDFP)(TC%QM G,0(BV^HG?2QUB;[$1AMIUM1>@UVLM*#+B^N'#P>N<\
MH_NU*:(*BP5J"6FTIZI!Z4IRW@.([5+!#+1\0&5:[0A('B@Z"!^91,)N-9(N
M(80?&01,F-+^0 UTMT',!TET]B H5BO+3(J!'53J,KI6Q T);<E)0>AV0 !T
MM=):8UZBI6K==#JE?T6 0B?ZCH)"EBT@$W2F9N#F5RU!N!F86HP ?"GEOM;-
MU(@'3#1'H-2NE;M:KLT0:#'6H+?45 R%)U,:$@I <<2G <> 4TP#@#K)1Q*:
MANF :905O* C0Y9T)^9"=3J8%\ 96XK8)%X!.ATDP=KDZ:QO%V<J+'J',I55
M_ 82(=KVN6H[ 2A71*GO(6YU?.DIDS$MMI<ZG2ZEKS \]UJ#(E8'&N*,\*0S
MWZBY5U69803=*1"03!\*))! $G+E3_<4[O!>"O<5?*4'NZ9H@/5 %@-2VU*;
MK4#K8"2I5LJ5U[S,YGV-RZ9N'EU)M6D7[=:%)1Y3L]F*Q;-8J2T1V6IDMII;
MU0J$I12XY /F.PF6%3JHZRW&BL/1<.H.(<4+'$%U+M%2JE06$**JAIL$J4V@
MPEMM   <$)6I0;:"E*6I/>BEIZ#*S1@)+>5*DH,YEDP@.*)DN$^(S)2D$D!.
M6>95_<Q'J>Q7+:I%4<F-U2<N3=-?[UJ<A/D*@TDN R(=N0VDIAQ0XKXVHLH+
MDCX>&ZFFM>D\/X>EPL53K.0M(":2G(/]!'YN\>B$JJ'"2M4#(V3"<RP7#2><
M4I2VDF<RE*><MXU:*2DG1(B!)S*B=(!RG<U[S/@OPMN24PFW%N^0CI0A;RE$
MEY_HZ5/.?PI27"ORTI0E 24C'2M4S+2B^L J( SFY  T2#H#<D)UF3.AD"0V
MB5F F2 ( F;DZ D[$S$1,3B@ZW<!RY^\*E'(SG))[XU&F^,YP!N.,WB'$T@%
M#<VV^6HL;VD[B]\9%55E2LJ 0F\ 3UTY=?."+'%>RYCSW4XLE*<: YSC^]^Y
M&=^.4?J5+S$W-C)V)MY0+Z:D=<4N[61G48!FY&W3KYP3.NN(!5J@4J4E)QJ=
MCC<YU(W[Z;:'. >,EYZ"0"9O/M&^Y^9VC&94+@D D01>3(D\A/G&PG2#B).2
MNLDJ4=-@,ZX_3\S^7% J*C))&L>WIKIB 7!$>8\^9))Y=1UC"+K.3C7)TSJ=
M>V=/OMGOL,-/7SPX:P()\A%K1Z3OI.^#0VH[GJ.FF3C7!],'Z?D. Z'?$H3_
M +C,<C8#G?06V]\&I0!C8D;C<8[>AV_OT/OF/T_3#P($1;EYZ@Z_?S4I)P #
MKC48QD'VUT&PQH/73'"6M(\I_3VG$B9/]H(YZ3Z^X&GRPM;'V]>VN.YV.N-"
M<GU]5!C2VW+Z>6'903!F;:3%AM-N5];1AQ:;4,:@@@DY*M^WOCW.Y.1P3(YZ
MW^^L^<XD";6C>PU'72/+7RPY,,=6B4DY.VNQ[?S.<Z;Y'#@2!(-OUZR+V\XM
MRQ(D$@""0#$@01<6-@).IOI,F!A\B0QYC(./^JC0;CYA]0=-OOZ<.3<1!M<;
M@]+V^F\1B8,@3(D*((FT1L(D&]CT^?\ 8^X^2\<9@<&# X,&.+'[3R@W'*O:
MVZNER2+<CV72^E#1EMI#D.OW&*K-"HC*G'6J8NIT+\0)4IN$*G39+P0%MK'&
M\4K6Z7M+14U0A'_Q#A3R>'.N4RJA*ZFD?+E92-P^SDJ':9YIYM("U.HIW18(
MO[K^$2J<T7%V_P"F:@5+*G$K#Y4IE31#1 86%Y0M+N8E"D@ZE,^+1/[-2EW!
M'Y27%5:P9*8,NM0*716Y+OGJ7&ID-ZH+EMO*::==:>;K\:.A;I44)AB.G"6
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M(=B7'"J=09:6Z1"9#+DE*HL=9:07.ASA^S9-+V0X,M^K;A'#JBK?K&F6F4M
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M#C(E>7YCR_G"L!6NN3W/T).N<G[:#CJV1!!N!,1\A)OH#<>QQGN@A$ >(P3
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MA^Y.#KWR3J3QU7*_\XS5" #Z29GF#]1?T$1!BX86#@$'&N,D;=_]<D#!^G#
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M3 D;Q: (YP3B>"53[)H72\[U..GKDE("7:A*QHRV-TQ8^2A.1\V5NK!4L(%
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M!QTD8]1V^OU]P/7B(B+$&=N1_D:ZF^V'YCI-MM.4>>\;]</#!4H=6"1]M<'
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M@G733 TV]AFFYDG[^_O3"%8)*0;_ &;6D^F\1KA-H,I&I.?MI^1(^WVXB<(
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MUD,7F''D,RK@ET H4/+3TMP4OI6T3A3Q<6);+X"@AL(2V0I2UA&JQ4)56FB
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M;AY3RUTTUQIZEL-/.+32MKKVBAY-,D(6MHO$*99[U#U,5+B5(A"D-Y52( 6
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MK<('FY5Y;CB4J)<* ,HL'(BA!X?3U"D4=.RIJB=J74--5"GWJMP!R%O! 2V
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M[C[W"$4+HIE'O^"4U'E4IZLI&U(>J*-#K:VJCB#O]2A#LDEE*EX593M\0I7
MM(2ZP*A3PS 97EK)@(61E2X0H9&TP'"-ED)X;<SN6U2Y77Y7K-JK*FW:;,>3
M%<4,!^'UD-.(43A:<8 4%8(QJ>_Z!<(XM3\9X;2<1I'4/,5++;J7&EI<0M+B
M<Z5)6@J"T*2904D@@@BU\>:5E.JF>6VH%)2H@YI!!(,I ) !&AN((ZQB'ML
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M2H:/"^&M\/9[[Q.57PC;3JRJ<Y:1&5(M 4L7@P8!\.-  (1FU)C7\WD?<3J
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MU2XXF1OB4+Z?,_\ ,/) <PX,E2B2>I)ZP"%)4#@\8G&'\E"\EM80HMJ (F/
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MDQ( ,0-.<_J=.9O?"5#2D*!&=-?ET&/<X[C^SQ(I<B(UUG]/OTQ&$@&Y (D
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M0)U.@ @@#SG%.U]YI$EU#))0-!\Q(Z@/F&=21GU&?;TYVH6H) )VOJ-S:T:
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M$O %,,7)4!IG]Y%M:L*:.,8REPI4#V*1L=>.6[:K4CLWQ"/[S3-?_E4LR/4
M],:?"A-<ST#BO.&U?J1C)/[1"2+G\77/);$XL5.VZA;K,%*G.E3XB6K:-.4P
MS\IZ51_)<E@I( )=)WR-?L.GX;LQP8%O,W4H?+ECX<U34N2>84%!%^0O,C'H
M+"0IM,$@I$V-Y)FUB9L+"P$'RQ9S%Y:3':?1JD[6A+N"KVNFYIS;\A*T-!Q5
M9=?AMI)\PO%4:.\'"M74W)4\XEQSJ4OJ^'\30EQUH,E-.S4FF00F"J R LV
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MPNR2H>+,3*P"M(D$1C-',9O2JCR% H<"OWKF'&_WA *D9'4K7!^4:GJX^O\
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MB'$D.MK>8(?6TMQQ:ZHS*_3&OZG!T*3E !ILSBP2I:P'!E*25_TF5 I!E*5
M) 0=H!4&V:KR@MAY$B9*D6QS;YGPJXY(8>B2DS+NHEE5>F*J,5U"5,3)L:E3
MG9K23T];#CR5.?$!U7SWVC8=;0TVML)13<7JVT,4K:4\.ITUO">$N-TM M+#
M!6TR]25AJ4+;2INH[] RMA"4^K?AE5)(XHVEPK4NGI'5+6!G)9?JT+6860!#
MS24%*B"%I*_$"55P%%/2GY04DDC.4DM+2%-+4'24,@ *9=PHDX!))R.2"C)
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M"RM90E.0 !TI00E("0D#('IN22"2<\X^ @+@1!/G<JDWF_J1,#08RJ@%;M[
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M/4LI*$MH2ZD.(37+[I17WJ\U\!?"P<B%%NN_M4$N(2I-LX_N2;DF"!+8S>$
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M!3"?$0)5<R'C4IT(!7!D9<TI*B)L"8,F8-QURCXMZW>M*M"D(HU,IE1MF?\
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ML?G/087:YDV\K"/G;;;7$BI22[8ESN+*EDR$MZJ&P1%)QKV)V_(<4:@Y:VG
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M*@3>!S]+SU@@$8@,MI25A2=.D'..V<?3.I/\_0<8#Z;J%Q.GF-9WY;?OBA$
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MM_.>GK>&\7-)1TC-8VZMU-4[P]UU()0#35 I@^M1DPI*FEGGF49M>ZT<T_\
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MB&4I"W5+>6V20A2%DJ]"_&);%+14:6<P4W'Y52K\^4 3(\-SX8&OK)3I'?(
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M,K (^^>WWU'20**("H(.XB1KK'R\^>OK!)R1C!R-R.V0#G'I_L.$($1SM/\
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MXU(NHZ"WN8!&^A.WEAMJ3!>BO(&JT$+2,'/;J'H!U  ?_(D'.O %95"-#OZ
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MQ^8G/"BR:G&3(H]H=%?GI/2ME3D=Q)BL.*(Z5*<>"<#48/\ F&,>,_B]VB/
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MQ>)#E*4>!82%H65!(SH*U)DFR2#, P=;$D'%BG_ZX!F"E8C<"0.GSY&,(><
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MU%:Q\14JX<AJBK525!5,\ER'EW-#*E*4XR^HM5W#N<E2$%;R,X$ E">^47$
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M: QMWM4X%4XH^!4:'$^$U-=6UR@D_P#8Q24J"9%@'T^,:B0<3%*0<X*Y!N!
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MT5&&RL^7YR$NN.)(*4A;JD%Q:FVO+9^5) 7T%)&G/5J"A2%9U$2 )2F0)O)
M!(%P23%A;#P00; '4:QU'[1Z1A1%:ITII2T'\/EM(42PL+<BR D#Y6G.E3C#
MJM@AT*1DC]XG.N:_WB3E)#B2;$0%)F-4DD*3&L$:V&X>DS/,6\P-#YF>9Q*:
M7$S$=E=82&7F$)01JXM[K4,8V"$,DDGVP>,:I("D@[I4=8  UGJ23]8,8E1;
M0;ZC:9FPYB>FDXNGE9)GP+I@56),D06*0XFJ5-V/),4NPH;K;BX2G04Y-0<Z
M(+:3U$*?#G3TH61RO'&&:BB=IG&D/*J 6&0ML.95N I[V(,!A)4ZK20B-2!B
M9,YK6%][3-IT/M,R>A,NJ];G5B:XJ9*>E.!74^ZXXXHN2 E*5@A80 E"TJ*0
ME"4E14H#7C-;I6:9M+;+2&D)3"4H  2D3%ATL3^QQ/;01:UO?]>GEB14>:Q'
M=04PD!I3?ER2I:W'7 <8*2L*;;*5I#B 6B I(!*AGC.J$D@RHZRFUATM<R)!
MYC$Z;IY;3(GE-SI)W%O+%BTU<6<5L"4Z"XA08:E=/4'DIZFPVZV.D**P$%!Z
M H*(&H &.]+8NGS($P.:@8-KP1)%M=,3(M(\H&P%[CH>F+BH5+;JEN)J,AUU
MZ=2W 6TNN+=E_%,F2LL8Q\0VWA45Q2!UA:4M%)2H%"L*I6$+($!*HF!X<L )
M5H$V@P1I)OA9\46@R#$3RZSN#:PUL!A^LR97JW6H%OT)AA4^M3D,AN:X&(T5
MX?,_)7,4M B0(["7I,QQX>5$9;<DJ_Z(6,RKR-I4I<D) (R@E1), !(29*B0
ME(!)58"YQ.AO,0!<DV%R22  #%SI$?/&VKVKEEVS;D./8?3<5T7"IJE7[>4Q
ME$&BQIB(H=G1+7HKJ$U)R+5GF7O-JU=0B7/CMSFX,-J,E]XYW%&7UM<'I*Y=
M5W5$T*JFIG%DLYV5]VPE>5;C>>C:6RM;25I*7W65NMI(0TCH:M_CC5$RQ7]P
MW3K:++3+:BY4I2G+F55I3#33[K<62DK"2L.+2M2D)S&Y%74VGU/!*ZBP$=*G
MP$.O!4A,F6_D@1E+4E;'DB&I2 P]A9R%+734HA6NM[;6@::3>00)B +B,<6
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M(3(2H 6(S9CFG&<+\@$M2$D.'H<6D9 #8"@1H--20,_;VX^M>'N0X+@9T),
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M2[5M<1 F@KU*4\$ID&F?<3\4A($#O*9V'T)&H#0-EF>PX54A;:9_,V VX/\
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M0M(RA:BZHQ5*,U!1K"",JWF"1=!$E2?[1E62%P,RSM*83BJ;^IY\R<CHR?\
MJ#RU@MIP1G&N%C3"3C)WT[_67!ZI+M/1/)7F2ZT#)20I69(5-PDI)(G83ICB
MZAOQ+&D&9FP_P"!KZ6,8\NF&4O/  D*)5V]PH#7&=@,_KQW-.N0DR+1K-YB/
M.#.@L)Z8HK28(T)'O%P.HUWMBJ);:D$G&",CMC!U&/S^W&F@ZCF-_E.\&_GB
M $'RF.7GY]2 =!Y%E=;SG(."#J,Y[9^A21D?0@9TQ(#>+WN-9  WGRZ_J7QH
M;$BQ BX)Z<_GZ88WVEMJZL9.N2,GWSV.NX.N,DGB5)M!T.GZ_O&FV^%)2J(
MD3:#:VWEH()B2>N$ZDY220?F&#IH#@]_T]N^F>  YK7@GI;V^GH,-6)$V!4
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M;GQE/6/AUAPK;4ELU-$E3;+W>-O--)"ZIW*ZX4A0UJFLX57N4[]+3T2ZQZN
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M4V9!C>=B#)%M--09@ZXN[PZ<[*WRRYNV[7Y=<DQK?K51@T6\T..9ARJ%*?\
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M" H:C (.QQCL-=3QE/).\B8^=P+D&=O/UQ,DW TMOJ#8:#;?3RY8E\(*6I
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MZZ]P1Q9"M"K2_OU Z=-^N&I5FS)&H\A(\]9G8["^XPU.(P"DCY?X3V&#_7T
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M\H((T.]X%XWWVT&UP$6T*=A!T$P>D;<M+8B-<@I1+?4A #@6?,;2,D+!R'$
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M. %0ZM02"..^_"[B_P 91\&J2ZPOX[A33:_].6'>'_$TH+3Q04J6$95MN)"
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M'33 UP.W#^X1\/\ #-J4T@,]PA25'.V@-E"2E9DYD #*3))@F;X152LU!J'
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MP?;Z[ZC^O"$9;^@Z\]N1U]X-L.SE4"T""8$::&9Y@2/*)%\-SY5DC.<;:X(
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MOI;UTT\X%(@2FX!B+R>L<C[CKLW.(!.@ /? P#_/\^_IPJP)MKO]9^>VT[#
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M9\S;>.7EAZ52(,S?2=.?WY 8DD*9\[>5?YD9SIZ#.Y]AVR-P1CC(J&DG0@D
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M97#6;Y%N2N8T.G/P85!K3<9%P4M,AL@II3S[:%5*'YG[UEYGS6F',.AJ%+2
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M3%:$@?\ 1=$KS&0K*H2"D7_-"A>^(W6D&>[*@D"Z% 2";6()!'F=-SH#1!6
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M(I^Y/<TP*UY,H<(A:SFW4N!AQ0,BH'B[[(/(@P.6H&.J#_C-\/\ 58_AVIM
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MDP"DUEZ+/=C-2)D* N8@"9N8YW OO;H+BV)'N&OM/FG;A\%OO8"VPH !&<E
M<,05@ 6*Q=((G%AW'XN>0EJ"EBX;MJ](%3I%*N!Q4ZPN8335"HM<>7'I-0O!
MS_"Q;LMB:\TXVR;I72',MK*TM@:S!:01)U'46/Z]#ZZXI#AU4YF[IL* 6I(
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MC^O;T._%I*XZB+>N(UI@R(Z3MIKTG_-\-#D10)R,YSCM^6F,Z@[YR1VXF#L
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M7(L)B8@"0,N+JVG6WPEA&9GNFE*3GA*,R$E2\ZU "22;D"^@M&@9W.;DE?\
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M:A0@& H&<1/-'O"Y3PC246$D:P1;Q$"1 2+QKBUT7) J/1$NVD*A2]$&I06
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M 7%,MKI!'^8)!&A&"09%_&%*D.LMO(((4)3!!Z>$GZCG;#F75,.)=:*F76U
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M"8F?6/TQ)E&L+1(;5*DSX3)2V_(C&0]#PC"DE3O0A/3J,]80<D=0(QQB/T8
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M*'W*RD4EVD##OQ!2O.5/)".Y*EQE6YF2V!(W_4X>ZD)<STKJ74E)$=V[(4"
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M8![Q!%P-)%@H1:)!G%UI4 9#:TH,VZ [6TUFQ,X2N4IUY*A$0_$?5GJB.!:
MZ, _(I)\I[<_P$_+T]385NTJ"?SPM/\ N$6@G61F$'F+G2!BTE05$2@G94V(
MU@B 1'(ZG37$3E4F6API=BO-KRK=I0!QW22 -,Z^A [\2I6DB01[CI8\_(R,
M6$K4B 01R)@"-ARC73Y[3*A52KM-? SA(E1" A#J@OXIC30I="@M:4C&,J\Q
M'^1P8Z>*;S*"<S<)4+D >$Q8F^EN5O*3-I%1E@*DI.I$DC:9N;R=/%&EKX3U
M?XN*L*G4R-6*:Z<IDE'E2 "2D!3S39:44GY27(ZG H?O%=1ZN&H"5&$K4RZG
M43X=SN<W6,T:V(Q<0H%.J7$$:D C2#-@%1UN)N#J4$2+0U.ID4VHU"@2TXP7
M4NMMI)SHF3'\QL)SC^(,#&^,'#U+>RY7$H?3R@$[7@P3OL8D3? EML72%MG4
M%"B+WBQD 7YCKKB6I1<KS6'(]+N>*  7>E"I/3C&$R8:@H+QD9>0XH'4\4S\
M//\ ZE.KI) Y^%5XY%)_7%E*W$_WI6.9LH&UY!C>\]+7NT2*10Y"L3*#7*0\
M<A2F&?CXX/KU,^7(P#J/W*C@?;B1+KR?^F\VX-@3E) Y!4C_ /;Y##L^I4GE
MN+"XN9N=/[>?080FT:4X28UP1V<_PMU%+U/5G_X3&8Y.FG\9SVSP]-2\)EF=
M9*"%'?7*I0](\Q)PA=18%4&+; 7ZB=-YZ'"V/8E65K%?@34*_A6Q)97G48.4
M.N9TUT'?.FO$:ZE%BI*TZZ@Q\P+VV_P]#J2;$'E)!VW)M[#KKK8EL,\T;7=6
M[0)3T5;J64N!:(TYI:(Y46$%F='EM%+74OH 0, J WXR*QCA56?^890N"?$"
MIM5X!)6VI"C,7!),><8UJ;BE?2I*&*I;:3 "#"T 01X4.)6E,ZV"=,3^CUSF
M)%G5>IUJB,UB?7'V'IL[SDT]XI8:+:&DMLQ%1DM)!4M+:&&P%J4>^.,=_A'#
MBE":9]=.AM,);COD:V_,H+G225*MIOC?H^U56R FH89J$I(!6E187X?]T)6V
M8%I"4 :F3)+=<]&LFX6G)-T6G06Y. 5R*BS1TR@-U)34FW6IA ).".A6=DCO
M$B@KVR$TKZW4;);+H&T'(I.0=;GVQOL=L.$F/B>]I;7S .)&HL6U9H'_ +!,
M[#%<TCE=R-J<CH;JTJVG5.84]2J_)@!L]> 6I-;9FLI [%E?21G!*>(*NEXR
MA!*Z%;VL LAT&9_,EDF=?[A(O80<:K7:3L[4?DXI2@Q/]5PLB=;=^E /,C8]
M+BWE>'#E/663"@7W/DL+:1U2&YMFU:HJ6$I!<755TAR:A6< EMYD8/3@ XXX
MM]SBK.9Q_ARV2"KPK8JFD 3IW?>)1<&Q(/GOBY35='4@J9JZ5Z9LW4-+T@3"
M5F-N>NAM"6'X,;<;\TQKM35$.'+"JO1*A(>80H (2':'=]"9=(U5UKBGJ))
M"<)3C/\ %G23-+W9F^1:4@^CK+IL3 &8VC>^+J0#'C29,FXN!)N9N/,;6TPX
MT_P9?A,MJHQ>9$ZF2&W%.,O4^W'(JHW4".F/(=N-V0E(22G+CSJRG1:U:E68
M]Q?.%-JH4N))N%O3F\TAH"]M  ;Q Q+W21'B2)&IVY&9%MYMIB13_#U2W4(_
MQ7SAKU8C1%I6N/+=IT4_*L%(4],GSO)UQDJ;7NG!!X@8?<=<2BFX4&\ULR&W
>5P(G1*1.F JID27*IEL"9*G&TP!OXE@"]S^N/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g307489g22i22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g22i22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[15Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %5Z^5' X0DE-! 0      "(< 5H  QLE1QP"   "^[,< @4 #G-L:61E
M,S%G<F%P:&EC.$))300E       0?> 0K (VB)^JO=NE4AG (SA"24T$.@
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M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _
M@   .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          CA"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8              >8
M  =3          $                          0             '4P
M >8                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M >8     4F=H=&QO;F<   =3    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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MML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ YQME[WA@L=+C @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M !\  0 !! ,! 0$            '!08("0,$"@(+ ?_$ %80  $$ @(  0H
M!@H." 8#  4#! 8' 0( " D1$A,4%1886)?6"A<9(5?5(C$W45-5D96VTR,E
M-&%S=G>2DZ*SU-?A-4%C=):AM-$D)C,V5&(R15;_Q  = 0$  @(# 0$
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MO\=%OYQ>?UW'AZ_YA/\ 5!^SCQUW^.6OK#?V\>WSO\=%OYQ>?UW'AZ_YA/\
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M.)QU;@5W)KO75L-IV"KPF\M%AJU..FQXK(QDI@2B9G#P9Q&<UA#7P;;3%*%
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MINA2JC81;KV+3?1:MH^&5;-9#JA)49\A?$=T %JRF& .9]IPALM7K:>Q*56
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M.CKJ]BMJ5C1$'5E6+5=\S;?XF8NL2FN-1) FF,+,VN![N1QL*^/X1<?L4Z8
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M'.3&)I]+L-'K^)F7.T\=)%'<H%#S9+VQ;T5VF*"8F#8'B;3H6+8CFH&B9],
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MNJ:O9:I%E^BX:M[1[%@U&NO;7=:S6WBL+&PN$BA5FU/AVN5*B")88"/5DD>
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MQN\Q'HF1B8\T_P"%"_NN=2O\G-G?TFBW.]/W//\ !O$O].U__M[&=*?N@/\
M7.&/Z-M/[VCGEIYZ*SSQCC&.,8XQCC&.,8XQCC&.,9>PVR['#1Q6'![!G F(
MKK/W"T5&2P^PC:K@JR5&%%U0;0@B+47)#5UQS]79KE1XQ669N=E&ZNZ>T-FN
MU[GQ:=1IMM# #%EE9!O@5G#%C#B"61"V1!A$%R X@AY%$3DU6RV**\U$["\F
MJ4G,UE7+"Z\RP9!DRD&"KFP)D#GIYF,R)<XF8GM)VS:B6T2W2LVPDMX"BHW@
MFZ<TDFF\);K(>K+(1';4GC:-(JMO_AU$@N62:B']BVURG^QYQG6:V8LQ.OHS
M%V8*Y$U*\Q;*"ZHFSS7^'F"^-$MZY@O/V^>??2FSCPO+9;"/!#(TN5VS'@QD
M.B1J<FQX89#XDPGHB1^+/EY9;:LHDSC0FDO(CRZ9MB+&&DUC!!70N-!^I>Q!
MY33=QMJ08A_9H[V4T=X60'>H,O4TT?54/1R(K5AE<C70,I-C$S"5Q*F.ZNZQ
M4P/X,V]9]PPY$SK/KF>HN> [5H^[UV;!]\%K?UN:7>6GI[(-YE/<!/0':$^H
M5] =$#TQRDBNKTG=>2T+*]G6LYT!R0=-6\4L E)SD+>S6/C%AL1EAJ/M) *2
M-F(?YZ#D%DFLY8YU9HB2K(G''! *]K[^EI7ZK:T#X*75SJ%9HKKIMA3<R&6J
MJGDADI5:Y$+NW G\<FK-;X!H6.NWE[7VU6Y+QW9>-L:VP;9?4.XE<KK6W(&P
MN'/J<@)!-DACH%9B:9)9124*$39,B:,/7)(L7?O"A0B\5V7>$")!PH[?/7:^
M^<[K.7;I95==7?.=E%5-]]LYSMG/+-2UI6M*@%:E "U+"($ 6L8$ $8\H$1B
M!&(\HB(B,JW-:]K7N,FN<PVM8<\S8UA2;#*9]I&1213^69F<Z/.>8\<8QQC'
M&,<8QQC'&,<8QQC/4_\ @N_[J';S_$*IOZ0S7GG/]T/_  ?PQ_3-E_<5,]"?
MN?\ ^$.*/Z'JO[^_GHLGZ0A+J3W?]DH5>AKN([7*D,5:4=%&JA12*2+9ZM-]
MW:26S&R5-O,S,1B/I&C)WZ%-HIE#.FNO3$2^>)^">^6Y*81PF*O3200<)%R(
M6.MA9%#-/'GZ/<7)C%]4G'5SF>XEQ7CAWC/PXZ4(FWQ43O0KS>!/E;I8>RDQ
M&5;DO*=BF.8+;TP!2'+/S,_+C]_'\N.>\\\,<X^6/UQCRX_?Q_+CC'./EC]<
M8\N/W\?RXXQSCY8_7&/+C]_'\N.,<X^6/UQCRX_?Q_+CC'./EC]<9<&)=*,$
M&!;$G/X*BFNC$62P:(X(#6*::B2;-@\PY]99M4TE54]&[=1-'1-13373&N^V
M,X/"U>@U>&1VV%)L7V5]##F8F3,.GI,IF(F2*)GG$3S\LD>,L]P&^+?W5CT+
M9WV=Q8<ICH6?7U '*9CI&8'E,QR\YSHHF22"R"^I!WG=N[7?)8V>.<8P[=X3
MU>KXSHMIOJL]T123>+)[Z+.$]--5%,XTU\G,DJ(2&5A$$ A/(!_%#G(#YQ,<
M@F9D(F)@9F9B//.(V6@0G#CY@PVQS8?[XSE#3\BB>IL#$,*)@CB(@IGE'*0I
M[=$^L.8%YH3,8"$# R&@U!T0PI&0+,#7<;!Q"#!& H:OHDF.BT=C80<*PXW<
MN4_4$W:[E=^HLZ4@4=11H5%4UJ[RTLM-AEN8LO-UZPZU<<;61)2RP][6-F.D
M9ZY&!@(@8GWMW?OW7WS?%=M@:JR72F:B 520JM42I2CB!760E2U1,D0]/5)2
M<D4W80[+6*^JU2I4$(8$C[X+&HT?*QV(!P<HE,=AY(:9CH>0&&"26'230N$C
MY-^^:M61B2$(\">RDD<=#&JND9?#U!>RC9R5MS@;8>A5BTUU:L^TLTO:A3)F
M1DE->L (S4@'N"NM(L*,FMXIV3-5&HCP::\I17<VO66FU9168#4J>T)B"@6)
M09F"UN>2%%88Z0B<A]Q+I2[>^T7<G/NB'E<;>ON#1%9[YSQFF.=[>M*.=E_*
MZ'HHL7&?2>5=FDFU5\Y!/73%H-2J(] UJXA\7X@I7 _$.3#XL#$?%.9,?+XI
MS)1RF9G*:;]LCAA7+),'JZ3FPV3CK"%GR*3ZHZUC %RGXP1 SS&(C.B\-ER+
M4>Q(%R+]B)1V;BF;Q^Y=-1C??.-MT![==7=%DCOG77.R3;1+3;.N,YUSG&.9
M 2I9&:U+ VSU,, $287RF0Q$G/Z2F9S&=AK06MCV,6J.E0&TC!0SRB86)%(A
M$Q$1R&(CRCY(PJ;+KC&P1<N16#,EU'3,0J_<J#&CI;SL+.6S#=7+1!=7&^^%
M%DDM%-_.V\[;/G9\J$J%A.A2X<<0)-@!AA#'L$CB.J8CE'*)F8CEB;#24*">
MPDA,D"984J IY\R%<ET#,]1<YB(GXT_+.?(LP4!O-"(4H_$$$M%$TWPM\X'O
M$]%M,IJZ:.FBJ*^FBJ>V=%-==\8WTSG7;&=<YQPQ2G!*W+6T)F)D& + F8GG
M$R)1,3,3YQ/+RGSC/BGL0<,0XTLB)B#4PEG$3Y3$$!07*8\ICGY_ESJJ.EUD
MTT57*RJ2.ZRB22BV^Z:2CC.NR^Z>FVV==-U]M-,K;:XQLIG37.^=LZX\G.!&
M)F8$8F8B)F(B)F!\AB9CSF(B9B.?LY^6<981"(DR9$9*1&3F1&3Y=4C$SRB2
MY1U3$<RY1SY\HSNJG"[@6U!KER2P5BX5=L@ZI!TH+9NG&,X7<M1^ZVS1NX6Q
MG.%5D4=%%,9SC?;;RYYPA*A83A4L7&,";8 888C^*)'$=1#'Y(F9B/R1G,K#
M24"">PDKF2!)-*5 4\^9 N2Z!*><\R@8F><\Y\YSX%F"@-YH0"E2 =^GHHFF
M^%OG ]XFFMIE-;31RT516UT53VV34UUWQKOIMG7;&=<YQPU2GA*W*6Y<S$R#
M0%@3,3SB9$XF)F)\XGEY3[,^*>Q!PQ#C2R(F(-3"6<1/E,00%!<ICRF.?G^7
M/K!LOJ,6":ER6H9P[U?KB,/W6!B[[77&FKU9AA7U51WKIC&NKG=+9;&N,:XW
MQC&,<=E/<AW:7W1'H%O0/<@/^Y!\NJ!_\,3R_1B+#842(>R$$?<),,*%$?E\
M<E]71)^4?&F.?E'GY9>L3MN?PPMN;#R4@H_S#)I D-R;MP338QN>061UR<:C
MTG:RFK%9.+RHRU$N&WHU!+A=-VR]&JCIGD.UJJ-M4);77 1;J79A8BN3L4KB
M+R29(C'6,V*ZB:)<X:,2)<XG)]3<["DPFIMLDBIW*,=QALA:+M-U%W:@C_!F
M-=[(28<I4720^SEEF.#QIVY</'1DHY>.WR)-TZ<$7:SER2;84PW(N%U%ME5G
MS?"RV$7:FVSA+"JF-%-<;[>66*4B(B*5"(A*Q$5A BLN74 Q$1$ 7*.8Q$#/
M*.<>60BM.(B(K#2(F TB)IR1-7$BMA3)3,L7!% ',]0P4P,Q$SG:VE<FW)O#
M6\D.[&"#=5H_+;&"&Q-\T61U;K-7C_+G+IRW50TT05165W341UU2VUSIKC7'
M'PU;MBKPZ.T!00*[2^V!1/5!"'3TB43YQ,1$Q/GSYY]\99[IN\4_O&';-O?9
MW3#E$=!LZNL@Y1$=,S,<HB.7*(RC+N5G2ZSITNHY<N5E'#APNKLLNX76WV46
M7664VV45654VV444WVVW4WVVVVVSMG.<YA$1$1$8$1B!$1B($1B.4",1RB(B
M(B(B(Y1'E&8C9)D1F<F9E)&9EU$1%,R1$4S,D13,S,S,S,S,S//.+RX_?Q_+
MCGW././EC]<8\N/W\?RXXQSCY8_7&=X7G'M(=^?']W-/^O'_ .0GS&[]Z;_Y
M9_\ IG,]68\37\X_?T_EC\X.?I[YZ#]&<YSG/3;JUG.<YSG.:"JSRYSG\^<Y
M_P#E;]O.>?GQZY\7Q_\ JGB'WSL/O&>^IX3X7F9F>&]#,S/.9G44)F9GVS,^
M'\YG/Y\ W1GY-NK7T"JS[5X]<^+_ *4\0^^=A]XQZI\+?1O0^Z-?]WQ\ W1G
MY-NK7T"JS[5X]<^+_I3Q#[YV'WC'JGPM]&]#[HU_W?'P#=&?DVZM?0*K/M7C
MUSXO^E/$/OG8?>,>J?"WT;T/NC7_ '?'P#=&?DVZM?0*K/M7CUSXO^E/$/OG
M8?>,>J?"WT;T/NC7_=\? -T9^3;JU] JL^U>/7/B_P"E/$/OG8?>,>J?"WT;
MT/NC7_=\? -T9^3;JU] JL^U>/7/B_Z4\0^^=A]XQZI\+?1O0^Z-?]WQ\ W1
MGY-NK7T"JS[5X]<^+_I3Q#[YV'WC'JGPM]&]#[HU_P!WQ\ W1GY-NK7T"JS[
M5X]<^+_I3Q#[YV'WC'JGPM]&]#[HU_W?'P#=&?DVZM?0*K/M7CUSXO\ I3Q#
M[YV'WC'JGPM]&]#[HU_W?'P#=&?DVZM?0*K/M7CUSXO^E/$/OG8?>,>J?"WT
M;T/NC7_=\? -T9^3;JU] JL^U>/7/B_Z4\0^^=A]XQZI\+?1O0^Z-?\ =\?
M-T9^3;JU] JL^U>/7/B_Z4\0^^=A]XQZI\+?1O0^Z-?]WQ\ W1GY-NK7T"JS
M[5X]<^+_ *4\0^^=A]XQZI\+?1O0^Z-?]WQ\ W1GY-NK7T"JS[5X]<^+_I3Q
M#[YV'WC'JGPM]&]#[HU_W?'P#=&?DVZM?0*K/M7CUSXO^E/$/OG8?>,>J?"W
MT;T/NC7_ '?'P#=&?DVZM?0*K/M7CUSXO^E/$/OG8?>,>J?"WT;T/NC7_=\?
M -T9^3;JU] JL^U>/7/B_P"E/$/OG8?>,>J?"WT;T/NC7_=\? -T9^3;JU]
MJL^U>/7/B_Z4\0^^=A]XQZI\+?1O0^Z-?]WQ\ W1GY-NK7T"JS[5X]<^+_I3
MQ#[YV'WC'JGPM]&]#[HU_P!WQ\ W1GY-NK7T"JS[5X]<^+_I3Q#[YV'WC'JG
MPM]&]#[HU_W?'P#=&?DVZM?0*K/M7CUSXO\ I3Q#[YV'WC'JGPM]&]#[HU_W
M?'P#=&?DVZM?0*K/M7CUSXO^E/$/OG8?>,>J?"WT;T/NC7_=\? -T9^3;JU]
M JL^U>/7/B_Z4\0^^=A]XQZI\+?1O0^Z-?\ =\OFW0\6$@J?"X%5"/#!;<JU
MC&1=@N-P @0H,=[MPC6M&@QOZ':P1[='5O!0F$VP[?*:R"NR;5+*>S0-ML?O
M&@W>&UV@W)6F:E8V6M6Q<$^=L33B1U)S/5LGQ)-&)$AB3GG&+B%=44Z-;5Z.
M%KXAT\5@W#2KK6T&E"(U,*"8/<!RY:Y$P*SGK$I@(F)K-H==Z!NYV)?W-2-2
MVR^ -G3,&\LFNXC-W09H]526>-1;B2B"2K!N[6015<HM=TDUU$DMU-=MM-<X
MKM?O-UJ1:&JVVRUH.(2<%"]9J"T@B8 F"AJX,A@I@9*)F(F8B>4Y:7M1J=I*
MRV6LU^P),%"INTZ]J50<Q)PN7K9(04B,E \HF8CGSY1D6_ -T9^3;JU] JL^
MU>6/KGQ?]*>(??.P^\9 ]4^%OHWH?=&O^[X^ ;HS\FW5KZ!59]J\>N?%_P!*
M>(??.P^\8]4^%OHWH?=&O^[X^ ;HS\FW5KZ!59]J\>N?%_TIXA]\[#[QCU3X
M6^C>A]T:_P"[X^ ;HS\FW5KZ!59]J\>N?%_TIXA]\[#[QCU3X6^C>A]T:_[O
MCX!NC/R;=6OH%5GVKQZY\7_2GB'WSL/O&/5/A;Z-Z'W1K_N^/@&Z,_)MU:^@
M56?:O'KGQ?\ 2GB'WSL/O&/5/A;Z-Z'W1K_N^/@&Z,_)MU:^@56?:O'KGQ?]
M*>(??.P^\8]4^%OHWH?=&O\ N^/@&Z,_)MU:^@56?:O'KGQ?]*>(??.P^\8]
M4^%OHWH?=&O^[X^ ;HS\FW5KZ!59]J\>N?%_TIXA]\[#[QCU3X6^C>A]T:_[
MOCX!NC/R;=6OH%5GVKQZY\7_ $IXA]\[#[QCU3X6^C>A]T:_[OCX!NC/R;=6
MOH%5GVKQZY\7_2GB'WSL/O&/5/A;Z-Z'W1K_ +OCX!NC/R;=6OH%5GVKQZY\
M7_2GB'WSL/O&/5/A;Z-Z'W1K_N^/@&Z,_)MU:^@56?:O'KGQ?]*>(??.P^\8
M]4^%OHWH?=&O^[X^ ;HS\FW5KZ!59]J\>N?%_P!*>(??.P^\8]4^%OHWH?=&
MO^[X^ ;HS\FW5KZ!59]J\>N?%_TIXA]\[#[QCU3X6^C>A]T:_P"[X^ ;HS\F
MW5KZ!59]J\>N?%_TIXA]\[#[QCU3X6^C>A]T:_[OCX!NC/R;=6OH%5GVKQZY
M\7_2GB'WSL/O&/5/A;Z-Z'W1K_N^/@&Z,_)MU:^@56?:O'KGQ?\ 2GB'WSL/
MO&/5/A;Z-Z'W1K_N^/@&Z,_)MU:^@56?:O'KGQ?]*>(??.P^\8]4^%OHWH?=
M&O\ N^/@&Z,_)MU:^@56?:O'KGQ?]*>(??.P^\8]4^%OHWH?=&O^[X^ ;HS\
MFW5KZ!59]J\>N?%_TIXA]\[#[QCU3X6^C>A]T:_[OCX!NC/R;=6OH%5GVKQZ
MY\7_ $IXA]\[#[QCU3X6^C>A]T:_[OCX!NC/R;=6OH%5GVKQZY\7_2GB'WSL
M/O&/5/A;Z-Z'W1K_ +ODIU?UXH*D71=]3-)5-4SV0-VC0\[K:NXE"')IJP46
M68MRJ\:$C52"#-5RX5:I.]E=&ZBZVZ6NFRN^=J[8;O<[<5!M=MLMD*)(DC?O
M6;8J(XB#)</8R DH$8*1B)F(B)]F3Z.GU.KEA:W6:_7DZ!AQ4J=>K+8"2D(9
M*%KDX"2*1@N<#)3RY<YS@J95C( UE,W985+F&]J64%?-]:X6@S)HCJ5W;/8P
M2'D,*)3-5CJHJS(S;739G+LJ*./,W\U7.TS>@==VH(:[J1SH]0\"+;#LS;,H
M@@N*8KE- &\H-6MF>NC$0'.(F.4#1&-A.W$K*;H1O-N@H#4GK!3 V)$J;5LY
MQL#3SD&;,8A=_GW(B?.9[GP_4+^A*HOIM#?U+R%Z:W/SML_K]K[7)_H?4_->
MN^I5OLL?#]0OZ$JB^FT-_4O'IK<_.VS^OVOM<>A]3\UZ[ZE6^RQ\/U"_H2J+
MZ;0W]2\>FMS\[;/Z_:^UQZ'U/S7KOJ5;[+'P_4+^A*HOIM#?U+QZ:W/SML_K
M]K[7'H?4_->N^I5OLL?#]0OZ$JB^FT-_4O'IK<_.VS^OVOM<>A]3\UZ[ZE6^
MRQ\/U"_H2J+Z;0W]2\>FMS\[;/Z_:^UQZ'U/S7KOJ5;[+'P_4+^A*HOIM#?U
M+QZ:W/SML_K]K[7'H?4_->N^I5OLL?#]0OZ$JB^FT-_4O'IK<_.VS^OVOM<>
MA]3\UZ[ZE6^RQ\/U"_H2J+Z;0W]2\>FMS\[;/Z_:^UQZ'U/S7KOJ5;[+/C>@
MJ"3USNI2M/IZ8\F,[;UQ"]-<9S^;&,[;!L8_/G\V/S_GX]-;GYVV?U^U]KB-
M/J9GE&JUTS\D4:TS_=9P_B*Z]?H<IGZ>PC]4<>FMS\[;/Z_:^USEZ%U?S30^
MH5_LL_N*)Z]YSC&*;IK.<YQC&,5Y",YSG/YL8QC CRYSG/YL8Q^WQZ:W/SML
M_K]K[7'H75Q[=30^H5_LL['P_4+^A*HOIM#?U+QZ:W/SML_K]K[7./H?4_->
MN^I5OLL?#]0OZ$JB^FT-_4O'IK<_.VS^OVOM<>A]3\UZ[ZE6^RQ\/U"_H2J+
MZ;0W]2\>FMS\[;/Z_:^UQZ'U/S7KOJ5;[+'P_4+^A*HOIM#?U+QZ:W/SML_K
M]K[7'H?4_->N^I5OLL?#]0OZ$JB^FT-_4O'IK<_.VS^OVOM<>A]3\UZ[ZE6^
MRQ\/U"_H2J+Z;0W]2\>FMS\[;/Z_:^UQZ'U/S7KOJ5;[+'P_4+^A*HOIM#?U
M+QZ:W/SML_K]K[7'H?4_->N^I5OLL?#]0OZ$JB^FT-_4O'IK<_.VS^OVOM<>
MA]3\UZ[ZE6^RQ\/U"_H2J+Z;0W]2\>FMS\[;/Z_:^UQZ'U/S7KOJ5;[+'P_4
M+^A*HOIM#?U+QZ:W/SML_K]K[7'H?4_->N^I5OLL?#]0OZ$JB^FT-_4O'IK<
M_.VS^OVOM<>A]3\UZ[ZE6^RS^Z]?Z'USC;6DZCUVUSC.NVM;PW&<9Q^?&<9P
M&\N,XS^?&<?GQQZ:W,^W;;/Z_:^UQ&HU,3SC5ZZ)CSB8I5N<3\O[UDN<K,L<
M<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQ
MC(>N,AH/:USMO(&L?P[M^OF&-W5>NK#P8W=$U-- ""+;_P"SW13?&$D+ <8R
MWBVVGK._DW63VUOM J6GMN54[7;T.U;,!M0U7AX!,3-HI/\ A $1/46K#D=V
M)Z8YB)1-!OVPH-3SM!5[F^U2HD]2>V\1)NF(JB(?P>;ICD.U/XE*8ZY\R&<F
M'E#E_CC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8X
MQCC&.,8XQD550J259SG)-:RUMT[0G23/-FC@HYTF.3*^1FC#=0J:>CNN4T_+
MB&D"7GEW@_SE'N^?['KK=[L4BS6PD=0,3IM:3/0[;#@)THYL+838F9#;3/\
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M3Z3J3,IG39/4^8,D%#Z,G;)[^;LB,DPHJ..!FF,>8-$/F0I/&FK#"2=V40<
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M#JX*;173#M&*VNZ>\M6:-Y6<\JJJNX@<NF!:;-K=)7IC!N$+%F8\R(>I:O\
MPJ$HY1R]DLD8,OR=(ST1YI^$CX9>(..+1UJ+K6DX=44C7UM=Y+=:&)F(?LW)
MD9<PXY3%42*JCR@8:P9>>EK\(EEOAKU\>%QROPH]'NSH5'*30?3:04?&0\67
MRHJ]VNQHR3U#:S-R@HFXC[%DDWG"J"C1Y)'"$=6#^N;)6^":WQ<AUZE"=3(K
M.467*(*]]T1/2OM+B"Z)..EET /H\X@+!!VQNO@K_=/\0?!?;1J]^^_Q5PJY
M@"_6ML]_9ZA1$,%:U-FT<],+")*-6]RZEB8F%G3,RL1YU)69.W*)JS%LS.UY
M17 1)LG$&[R4&W:8V$H''#60,*^:RK<E'Q6<.&Q<>DHT';L69E!5)VBKALX:
M[:KH^+N+_@IVUO37:@,!93XG5W(&1+K#\#9I7E03!441!!VS958/7$JAW,U^
MN.+O@@^!W]TEPPOB[A&[4U^UMAUUN)-(J$,BW$0;*'$^DYI%ED9*!L>)57VJ
M8E;56CKR ._08\,^!^&;,NJ8Z/=-ZZK<K6RPQL&LF-S",@#=GN3:[?.SYI>:
M1I D4,''BFJ^Z:Q%9]&7C;3R1!3:.H,DTMK5QE?W]B-NK:VHM@?4/9>RLVB7
M.9$% HQFO$<IZ"7/(^4E##+J*?SUXX^#3B#X-MHSASB;414F8.:M@1E^MVU:
M)Z?%4;9! 6U%S'N"<#8010JTE+8E<:=O$I\!J304R2[.^''[:#$ BZDF+T1&
M2A,?* +UME5RZ.T:;;O-">RJ?YW"4"]93)(;ZK(PYZ[RH-BR/I#@+X9:]Q*^
M'N/(2Y;8BNK<V%+97<$Q BG;ID)7RG\6;G3*YCE-H!Y,L3T+O^"F+86RX=(J
M[QYF=-1RHN?GS*F8R/07+_L9F!GS[<Q/("C?PW/P@.>5P='43X@3LO)(NV=^
M[[&\G0M?-@01ZT5T89'VD':M-'\I%LU4E$B$@29[S8:NFJH7;R7=155C/X\^
M!.G>2S<\$"M#R"'GIQ8/@K@%'7W-:XSZ*["B8($2?A&1,0HJ\1 G'X?XZ:I@
MT-_U1(EVHO$$@Q1Q\7HN*@8]A1,$V!$AG]\"?,X]B46E48G,<"3"%R$++(G)
M!K4Q'I+'";(T"-BGJ>JS0B**CEG#%^R<I;:[HN6JZJ2FN?+KOGGERQ7L5'MJ
MVD-K64,)3Z[UFIR6A/(UM4R!,#&8Y$)1$Q/MC.T@8#0%BS%BS&" P*" Q*.8
MD)#,P0S'G$Q,Q,>S*_S#G/'&,B"X".PYM7>=3^T?]=MR #L[ZUXZL3VOAT25
MU]@[(M4E?<[4IMKA+\8+CT;:*[:ZN=UD]UD\YO="KNGM?]%BUV]%M&\IVH:K
ML="8GQ,$9#Z0E//J]%AU'=B9"!F!G*'?M[0:F?%35[F^U2N<:EFV\1UNF/"R
M*Q+T?#IY1Z5/I"C,0<E$E'.7^467V.,8XQCC&.,8XQCC&.,9KC\2+L]8G7BN
MJ^!U*Y9 Y_<,R?Q=I-R YB:3@<= 1PE)9%(!@0HDX%%Y(X]4&@0+8PV=!V2Y
ME8Z18E$0_L<CLG#>LJWWVG71)M>B@7>&$R7XES7 E2C8$B8)CJ-K960L*%PH
M"7+.X$RFD&F9,B2!8P71$S'7,E Q$E'F(QSF9F//RB(\YYYI=SV@[6;9SMOV
MVO';?;.<[;8_%*EC;;.?+MG":-5)HIXSGRYQHDFFGIC]CIIKKC&N-M\'J_F3
M7?JN3_;-^9G_ 'S,_+.3^TK\PC]1S_S*9Q\3_:KYM+R_TE4_\+>/!ZOYEUWZ
MKGW[':7^81^H_P!K'Q/]JOFTO+_253_PMX\'J_F77?JN??L=I?YA'ZC_ &L?
M$_VJ^;2\O])5/_"WCP>K^9==^JY]^QVE_F$?J/\ :Q\3_:KYM+R_TE4_\+>/
M!ZOYEUWZKGW[':7^81^H_P!K'Q/]JOFTO+_253_PMX\'J_F77?JN??L=I?YA
M'ZC_ &L?$_VJ^;2\O])5/_"WCP>K^9==^JY]^QVE_F$?J/\ :Q\3_:KYM+R_
MTE4_\+>/!ZOYEUWZKGW[':7^81^H_P!K+]K#OMV4I^?0V23&Z9;;M:NY?%8_
M84)GXB!NELQF3R$;'7\CB)V+Q"+&Q4EB^A/!YJR=/20(^@/<@W0UJ[(M#8S$
M[2ZS8)<A6O12L]A[*UBL=@>3DJ-H*<MMAZS4Z0[1% @Q4E#(,H"5G\*JIHD,
M* #Z2D#7)1$$(R408S,Q(ST\IGR(>?..?+E/J!YUGE+CC&.,8XQCC&.,8XQD
M5U1N1W9SCVEFR\[ZVA.]6GXS40Z+KV?J6SAIB&8#9SHI7&$__LU4A_;50=YV
M7F,?V/'+K=PF&:WL^B.4Z;62?H<K!!W91^$](>(\XVW/^$!5^ AO+M\_C3E+
MI);*]EW?3'.-ULX7Z8&N)]J+$]OT?X?RG4<OX.)WX>4^;>4\HB5.4N76.,8X
MQCC&0'V/[1]>^H=:%+?[)VU#JAK\5JKKDU+">K=P6?)-U76H6+@VVCD_+I&X
M016491N+C"YU[JDIEH/6PGOG5[<9IQ^(3Q*_%,VR-Z=Q.0^'/TM*[^A<]O;R
MBJ3CL];L=70URH[H"D7^^J$&"&4%]-@]ARQ_JJY&.6T@C!1H69N >K^W^S_/
M^?Y,9L3Z6^&QU7Z+,BY*IHB1DUO3'*KFSNQEKEW%AW[:!5WE%0F0EEC'-52:
M;<DZ03>.0('4-'=G>N'NPK=_NL[68S/?C&.,8XQF)'9?M2WH$C$8R%A[>P)I
M*FI0TH"<2K,19A8L)W;LU3A$JG')2KA1^7>MAH<?@7KDCE PYU=):!W&BDE"
M(:)&9RM8R(]4!UR1ESGI@9,/8,3)3U>7Q8G\:,VWAKA;T\JY;L73UU&H:40\
M*GC&/M.@CA"TS9J#,+2!-<SO?@^I(R$RX9C&3\HK/OEWC/UT>_\ !?F;PM?^
M,M^K#]YS9?\ [/M5])+G_P#KZ_\ ^]SB6\2*6C4MR!CKP-U$,L>M%MP=QN#)
ME(8AG"I!84'7J<2D6(H--5EF8O8FP]H.-$VFKM#=;537[%1!3 C9/J*>0]=<
M1'JGRCJ*'ETCSY<RZ9Y1Y\IY9R'X.]<TH4CB1TN9/0F+&D!"):7DL7/'<NE*
MB.1@VPIG;&9/H*!Y3,B/0_KQ+9+8-KQ^8WLV$=ABA*Q)Y&8=V-MX+3UA/9S!
MA$.(G'U:B)8VA#Y _#!@1HKGV1E)RBR8N/)E5%/?6!,2,R,QRF)F)B?;$Q/*
M8G^2<ZO<EM=S:[UDIR&&ERCB1-;5%(,68SYP0&,B43YQ,3&8B$_"01,]B0,D
M=RZ.,.L\>L]A:.:J"F;N;.I3L/ZW.^N>D7E,(<VDZIK:1/A+O4A(+P$Q%A.S
MX1@UC"X=H7=FYR5^?_7_ *YCS*J!>&7U=K^2167M&]KRB30IE30F,%Y_=%D3
M54,!Z^'W\DIV.CFAT^Z', 4*)%2F[<>Q9MDS&23]Q(LF'[QR\58SKV9X7O4J
MU1TP&'05D VUCM;O$67F!W'9<$6LB*]AK)DUO6=")RI%Y(-S(H<1L67R*0B
M3W&S>/:F"X0-LTCAT\(*/9C)V[%4!1%M06+YNQ58%#:2E#6WA\E1G12O&L97
MB\1E,6,OY+)1Y40DK#R%>2V:1F;#I [4 $XH?,HE4\:;:N4&,@6!^&+U1K\C
M#Y$Q1M61/8 &I<##'LYNZR9DVC<0Z\3\/:%,1D0U.R)V-8QZ"RD*W>M$6[9-
M4RW=DTY,Z-[$7*V[&8W9\*ME8?9AS:=H2N&2[KLXL#LG:3.I016Y%8Y.]^T]
M;SZM9@&D%<'+/.4I%TWL9M"3D9?.J[BP\]:$C42DRK>(/CTUVE3&9:#O#LZ_
M,FX)1^9O64R6+616%H1>?S3L#;4MG\=.4\)DT=@8H1*3DI>/FT581N;S<"7C
MO[-C*V<RDKJ5X-%R:A+5C*K7GA[=7*M@ RLH;##+"'B#_5N3,1[F92@BNF7Z
M;YKW-"+;OGI-9VJE&<U=#O:C=579&3^H.,']'_M!YZ9C,9.C_AM2SJ]>36WI
MA8D>.L8-1,GZ\5C#880N5>*C(?*["B,^($145M.S9\!J$.R4@P,5'JHK!!**
M@F[@BFD;=!F<5C\9?YY_EQFW/C&.,8XQCC&8E=H>]/5+IQ'W9WL'<\0A3M%G
MEV/AFI!(S8L@QMC/H$H_ A.SN3DL.%/-2P^U')B6F=]5B)%DUQNXTA6MA4IC
M,O< ER\E#/4TODY+'F7*?9U3$#'Y9B,VOAG@CBGC"P*.']-<NC)]#+?;E6OK
M^?QIL7F]%973'.>B62THB86LRY#/C>[P>*+W(\7&9.^LO2ZJ+2$T>]<ZMG4%
MAK%P1GECL\N-TD"]OG0F=P\5B&V,Z*JQ=4SI$F6^N7,D/'-V[-8?I][9VML<
MUJZF0F9\JZXDV,CV03Y#R@/R]$SVAGS,BF!D?7_!7P8\'?!-3#B7C7:ZMV\6
M/6%JVP0HZX^43*M37=R=;N1[(M0GQ)<^FNA,$?7N!\*?P&(5U66"]ANX&L8L
M.]A>J9J+P751 M6U.N6^,N$B[UVXQAA,IN.UUPNF651S&XN[TV< ]29!FPDJ
M5SJM#"2%]R(8Z)B5HCD2U%S\B*8\F,Y^R/-83RD>HH@XZB^%3X=[O%(OT/"A
M6=9H#@EV[I<T[#;!/D2^0SU4Z)QSB4P7?L#/)\K CKSDMWT\>WI'TT$&0$.F
M(KLM>"#==(96]3'F!:/C"6OG)ZXGMDL-2<9C+=LMKMH^&#]Y!+4=\:)[QQ))
M7+M'M71\$;G<&!M2>NI3,=5JT$@1#/G^ 1/2QLS'L(NA7MGN<XY3YAM;2K5B
M8DX:WV0I<]4]7Y((HYB'G[>?G'Y!GV9Y/1U$^*OX^U\,[5EH8R+J_9TJW#3V
M5CS$-ZZU-$EWFNRXJN6;K13>6D$D\I:NT8SI(Y6<=)M7,K,(M4\$6?:,WN%^
M!:15DF#+?*.XE1 Z]:; _C6"B8[(<X\NYT*7$S"ER4R)4,IV&W:+&#*DQ,2,
MG$PH!^50S,2PY]G5^7\I1'EGM$Z/^$MU(Z2T(=I8-!0=I$[(!ZB+OL.P0 XF
M;M;5333+@8]9.O7FX&&M7&FJP.'#%]F(U5)$DZ<DY#ER<<],<2;VYQ0TYV,#
M-2>H4T(^-62N9GE'3,1W&\OQGE'7,Q'3T# B.Y:)UKANW5V&EMV=?LJ3@LU]
MA5::+:K"^72U;ER)!,>SIB>GIF1F)@BB="7?WP&K;IJ3O+LZ&YD$UAC$AI(D
M*O&EG2=MUL^:+ZO$%X(4V=)D)J.'N$]5A6K5WI.Q^VK5!%O(UTU2F.G-MPM9
MJG-C6P;T1/7V1F9LHF)YQ"XY]3AB?Q9'\-'E$@?*3S]$?@H_=3:#B&BOAGX5
M/"Z[8-3-0MXZN!:'<*,)60;6O"R5KG-"9%Y&N=6Z),B*F,PF9>Z,>/7)ZL5:
MT)XB\:F3$Q'-T@R=R;1DBWF8G1'5%%%G;<!V8M#;QTV2PILO)P3)8ZZQJCJ2
MC1)\H[,J9]5Q6=?_ $7:BP^W/1XB!YN#E_LV%>1',>?,XYMG_: RF2S7OA/_
M '*]+=@SBKX'KNN?5N05B>'8NI/7.DI(B/0;6&G6!9SR@*-IHUP^-V;BEPNN
M.YOL357A_P#BF]?W[8_858SV-!![HQ';>A,PC>);4+]=OYNQ;!;=QEQ'4M=L
MHY.QB6MD11#"2*1D7ZRV9KM.W^#./KW#%V-IH-DDU3 ^-IFR"J6DQ,3V[B)(
M264<_P &WDMZ9*>@H$C$O#?&'P=;NHV=%Q5PUM]9=-DKK+MZ^PBQ+O9!T&$K
MILQ/+R*N3E.'RYF,YX8CTLL+PN^WA)7JIVRK^SR$36UU:6%3YK!Z#S&/+NU/
M/B$_";;/(T67VU;Z>WHRW*R@>+>Y;NA9WVHT;/FGJ76?"/\ !=\*NN]!;BWK
MZM]@CU:S96 K-7:F)&&Z;:'VD66B7. \*V+4AS%]6%D0EUQLO@?^%W@2L'$U
M?A;?LTC)+_34ZYSB% =)\]KJUP=VG7F"B1M6:ZJI3SE5F"\HM\I.K3\4'MZ$
M(]L.TT&J[66O-F6]@VFY?!:TK&,H+X6]V(<"9:9"!$DT=U<B6!$G'1QDGJHZ
MD\L2*/7!1UYWX\_<[\9ZR^V[HV^L^G.9(&KB VM)/.9A3=:'/Q/1$P('KI9+
MYB6M15YSR];?!7^ZG^"_0<&#JV<-6>&^):P##: &#J&]NR/*;T[UW2U,%,=3
MD[!/747(HI3< (Y>YGK+ O#>\*OK:PVC=Q4U#8>:9(EI1=TQL"'*22XB[-OG
M&Q'4RW?;*2+73.5=(_$(@BY8#=%E$1 M1\[>N7NCZWAF[586OK:R\=V)B+ E
M5=%GK^5PD$2D(_()="PCG,^<D4]6\;?"!N..MD>XWE]<H'KBC34R!U]"O)3,
M*K!)2,E,<NZ\Y)[RB)8<P( &A[Q"/PBV9W8N^ZT>%C#;$-R&4Y6".+Q9P\R[
MGI9!?"J#AG2M<MQSV1CW+M'=+T$RD(]I(6/I%]1,6%$4F)]'MG0\ )IP.QXG
M?64I?(XI$X!4,QRF)N/DA60Q,3S2HI HCXS9CFN>L[6W)O-.N VG/,9<(%,#
M^3\&/+F4\Y_&F(&/R<_+(5\-/\''N"Y)<.OWQ&DS<)@SLCM)]J6?FG:MO6<0
M>.=WZZUF&&SS9_!1)%PILX+-MR6]A$U%739XG%7.=7ZLWB'X0:E-)4.'8!K8
M'M>,A<15K#$=/*LN8Z7%$1R">F$!RB1[L?%C#2TQF7>O3,]4]4JDI(S*?;+2
MYSRB?RB,S,_EF(\I]8793P\NK/9ZB@]!2ZM0,7BT*$:C*H)0,6-C1BI,MVF&
MC+:$;L6NC1D-2TT1P^CB[=< 7T12P1'K+(MG#?HC;T$[L63>DVV#(CBV125@
M6GSF3[A<Y/JGS,#F1/RF8ZH$A[D^#OX2>*/@QW*]OPS<[2R[:]AJGQ)ZS:50
M+GX>Y6B1CG$<X393*[5:2F4-"",3\E%B] _$J\)NX\73UYWE,_AXE=75I9M3
M!7\C$FHUA;"J@*WZQ;^TGX\:NEJGL20*M"L8;NO0.@\H]JMFSEKUP_5[G0V/
M$U^X8!,]-FL)$!!S\QL*CJD!GRDA;!+Y\NEA$/./T%U'PK? S\/7#OJWQ?%'
M4;%X1)Z;?654WUKO3(Q:X?W9]E+7#,S"22:+IAU!8HR@S ]XG3'Q]NLEWLAD
M0[);(]:K9TSHP?/#F[IQ4IM^GC5-5PPENZ>RT.]*KJLHN.FZ;%B,QC5MI*"J
MV<;9V?6\6T[,"N[_ *(Z>4=R.9UCGVQ,'$22N?MY,CH&.7X4IG/,OPC?N5.-
MN&&/V'!T%QIH)YM4%00'?5E%S(0;KA+EL.D>F!=K):QTS)S20/EGWXB'A&=;
M_$A#/;VZX3:O(E?KEKASBP(@2&GZUMCS4=]FC:?[11=^EH47\FB3>?B$'QE-
MMKJB682)JV8(,?0_P<?#!=X7A="VR=UP[SB(2MP-LZ^"GS.@TBD97RB9FDPP
M3)<Y4:"DR/QKQE\'[7N8%ZA;T>[7$C,7J3ZC&2,SS7;K.6IO.)GEW.F&!SY3
MU1R'-"]!WOXG'@@SA[$+:IJ;2#KRL644/0L[Z^4J0INX5_9R&KK6#M#@"*'G
M>NVJZZ+955%[Z75.51;8DFV48=Y;K3?![\+M0+6LVM2OO87$)M*Z%;-?*.<(
MV.M:276DC/.(*8YARF:UGMR4'UU0N<2\'-[%RDZSK.J9(!ZFUQCGYLK60$X2
M4_C=MD#!>?4L"GJCTAT]X]WAAV=%VI>5]CXM0DGRU;KE:^O%?6&2,=LOY^F-
MVCWSGL<D##9=%PFB^!&7OYD<^N-V*V?5]?,'%_!NVX+V(Z[:E38;E]^LVI96
MZ'5Y8:Q;*)D;2((EF,=]"Q(@,5DSH*8[1U&XI[JM-JGWH 3[;!<DUDML")RN
M9F) Y@3&9[9G$04<^7.,EO\ +0>%+\_/6GZBC.:GEKD6VGXSOA<;MX)[,[]5
MCC;6SX3L]_%M8\0U7R-U?J>N8FOMS?37-<YT\WWNU%><:RS]%ZCIMCTV.76E
ME/5L^]Z(\]+L85Z7\3T][M#V_1WAHG_XMSY^ [_*OW.KN3$].4F[ATCJ^S.X
MB?36MEGH?PW5VN[/<C9>)_\ R?ER](=C_2.WT]ORZLE+\M!X4OS\]:?J*,Y2
MY=X_+0>%+\_/6GZBC.,8_+0>%+\_/6GZBC.,8_+0>%+\_/6GZBC.,8_+0>%+
M\_/6GZBC.,8_+0>%+\_/6GZBC.,8_+0>%+\_/6GZBC.,8_+0>%+\_/6GZBC.
M,9K \2+OOTZ[4.>O(#K3V0JFZY!$I3/S<E$5]*69U^%#/8;@>V)/T&_[-!HL
M]SJUT6VQYN5MM=/+C.V.;OP:/4.X_H]2><_DY6H_M\\M-9'.;'_EA[?/_M!]
MOL^3->?O#C^$S_G8YMO;_3_9_CEET_S?^'_''O#C^$S_ )V..W^G^S_''3_-
M_P"'_''O#C^$S_G8X[?Z?[/\<=/\W_A_QQ[PX_A,_P"=CCM_I_L_QQT_S?\
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M=/25%[O*_P 5J;EAPXTZQ-H.M6\ADUA60[EEBLYR,+O YQE$T<N<?)SCG_\
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M_9C,_P!8/+R_+Y_+FD+WC_O_ .O_ ,^;QV_T_P!G^.6_1/RQ_P ,8]X_[_\
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MC-ML*-Z^=><TE.^_JZNF^Z">N;_0-E1[;E9.MW-#M%3(:I>V[XFD8FL0LB?
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$8S__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g307489g22s22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g22s22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[3)R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ,E:^$HACA"24T$!       %QP!6@ #&R5'' (   *  !P"!0 #5V5B #
MA"24T$)0      $'=20>Z\EP^<=O6Y=853JF<X0DE-!#H      .4    0
M   0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT96
M5N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M  "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8F
MIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M   0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #
MA"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M  %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M!#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F
M]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M$       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W
M5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'
M0               !";&0@56YT1B-2;'0               !2<VQT56YT1B
M-0>&Q >0            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M  4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"
M!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&
M-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M      #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;V
MYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ &0
M   0 " 9     !  (X0DE-!"8       X             /X   #A"24T$#0
M      !    !XX0DE-!!D       0    >.$))30/S       )
M ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&
M9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M$ -0    $ +0    8       $X0DE- _@      '   /________________
M____________\#Z     #_____________________________ ^@     __
M___________________________P/H     /________________________
M____\#Z   .$))300(       0     0   D    )      #A"24T$'@
M  !      X0DE-!!H      S4    &              5I   )V@
M !                          $             "=H   5I
M            $                         $     $       !N=6QL
M   @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;V
MYG          !,969T;&]N9P          0G1O;6QO;F<   5I     %)G:'
M1L;VYG   )V@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V
M4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M    !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V
M)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&
MQO;F<          $)T;VUL;VYG   %:0    !29VAT;&]N9P  "=H    #=7
M)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M$       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O;
M$    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15
M-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6
MT    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;V
MYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&
M]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M "/_         X0DE-!!$       $! #A"24T$%       !     ,X0DE-!
MP     )^@    !    H    %@   '@  "E    )\P &  !_]C_X@Q824-#7U
M!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q
M!A8W-P35-&5     !)14,@<U)'0@               0  ]M8  0    #3+4
MA0("
M       !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W
M!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !
M1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U
M   "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#
M $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6
M=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M     2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.3
M8V+3(N,0
M              6%E:(        /-1  $    !%LQ865H@
M       %A96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-
MI865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W
M=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                                        !D97
M-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&
M%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D
M="(&-O;&]U<B!S<&%C92 M('-21T(                             9&
M5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S
M8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&
MEO;B!I;B!)14,V,3DV-BTR+C$                                  '
M9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $
MP)5@!0    5Q_G;65A<P         !                         H\
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M]M____[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)"
MP)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,#
MP,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,#
MP,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( %@ H ,!(@
M "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)"@
ML!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@% P
MPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6
M-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>
M7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!
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MC*F%Q<TNK:^F@5B?IP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! ?_  !$( 4P"70,!$0 "$0$#$0'_Q  ?  $  00" P$
M" 8'"0H!!0,$"P+_Q !J$   !@(! 00$"0<$"!$)! L" P0%!@<!"  )$1(3
M%!4A6)<*%A<8&E>6U-49(C%6F-;7(SA!420R-SEA=X&W)28S-39"4G5XE:&Q
MM+6VX_!%2&)T=I'%X?$T.FAQ1&-F9X2'I+.XP=/_Q  < 0$   <!
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MRJ\(;7.HDK_",<L^];A&<X?;=A@'KTR$XQ8LBG4Y6#BPRZY-N7I7IV+]C8^
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M.Q_[QR'Q3\'_ (/=_/I?\^[ZM/69?XOT?XZ?27^J5^NE/>YV/_>.1^*?@_\
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MQ\4_!_X/>_/I?JT]9E_B_1_CI])?ZI7ZZ4][G8_]YX^*C@_\&N_GTVGK,O\
M%^C_ !T^DO\ 5*_72GO<['_O/(?%/P?^#WOSZ7ZO\X^?3UF7^+]'^.GTE_JE
M?KI3WN=C_P!YY'XJ.#_P:[^?3:>LR_Q?H_QT^DO]4K]=*>]SL?\ O''Q4<'_
M (-=_/IO\_Y'OR]9E_B_1_CI])?ZI7ZZ4][G8_\ ^_\ ^T?_ "_P<?%1P?\
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M9Y'98XU9V53$%(T6#MIW7:4CD=6:V*>Z-D@Z4Y2P6-<[<(7>"\3AP3B*<8;
M'0CN^CHFVG)WY^0&C6/2Y&E/1)>=(DL;-Z.\UMO%+?\ CB,XM;K(J6]EX8G
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M1@"$)![CCIWXU$)6E/0JE*)47X2E&H.2J"N\ ?AGIS!%'%]\L0RQ]PP @]X
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MRA0Q8*<X!!R<KLB<R@$Y P03G/S$'WZM=MV(O>;H96-;6T%3(JWGZ_5"3;
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M?_\ B.L,W7[_ +[;MO\ [Y5/_F*K'F]^C?\ V+V3_L[?_K[6J%C]V?\ \/\
MRKK#GS>-4=?0>^"RB,!TW[($2' S@[666(H&?T#,Q6--9 '/K#ZA"QC&?SL>
MK/Z<?IYYE],&/LKK9Z#X'IY^;UJ]G5_5_<V_WS_RKK&!U.]T>MG/=++J@6W>
MBU3TSKQ+#(,U32R&!JD"=[9,I+*B3U%@H#U5[3!*6:[2AI9&H[)\:7@$E7*
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M9R,P?>,,$(8A"SIE^]:W.[;W"],]BY=L2VK,\AR\L\[M)(Y/O9C@# 4850
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M(SLE( XKTI'7;RA2DA7A0%+R3?1;X*](,NYO"TD?PE+NE<GHMJG?:4SI&Y!
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MD0<Y",(@YR$60Y[.W&<X]?.O@A@&!R& (/F",@_C&K3NU]!CX++DT/3?L@1
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M9CD<#/<2#WC46GD=2IY<'OP.O>#Y^[5!JNL9NFKTY#HJ<]UWF@@5FDJ7#>&
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MG,B41-IGJ=BB%8361NYT&?@EC8ID4W-#(L5F15[ :4)HD(2<M+G@TKR2L_Q
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M/2E^ET'F+ZMN-*W +$-JN\?J\=IRL\+B."4.4ED9'95C)BE4.2%+12 'V&Q
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M ZYU*8R&"AE8DXZ9Z'..N0/ZO#56L'3VN"0;NM>B1<PJEOL1]/-/8K)<9#(
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M[O@AD6)BNO+*D>) VOSHN;Y)-C,LDGF#ZS5LWD-*U+(WN'5]"I=8DL1JG!I
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M=N<8[R@\LO)"8K&<X[YR@PHH&,]HQAQZ^4I9H81S32I&/X[!<_,"<D^X D^
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M:)J9"QC- 47D6)=SVB2GP1N.T54EM6%V2Y !$C236[<L$C32*B N\MJR\DA
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MFM!S6F-?%8G6?46^J<MU?3Y<+.,K'R,K2P&8KR?+"@^&8Z)B#(Z]J )AO[>
M8#UYG1:/$^U;]1K;%QRD[K4C%?9^+*D?;;QM$0Z1U;\1(.\[/$V6$#L+U53(
M*<Q!6%>.;IP/OW"FZ7.*?1:]2)K\_KG$7 .X2^K<.<0SG';W]IG4%>&^(IXQ
MRM;B0[9>E6%MQK*5EL/759[&0&Q'0R'KL.==6DB!C+M55A)@1^8IAA#G)A[2
M2<8)#*V@60C&F>XRK<T)Z? #C!)Q#\(.)WW@K=]EKC<X3!O6P2G_ $;B#9G-
MS;7!/LI995$NW60,"2K?C@F1\JH<#F.?X6])G#W$MMMDL"WPUQ; H]<X1XCB
M&W;U$0"3)321C7W>FW*7BO;5-:@>+E=S$6Y!?WFH:Z)IQIIQIIQIKQG'$IB3
M5"@TH@@@L9IQYQ@2B22BPY$88:8/(0%E@#C(AC&+ 0AQG(LXQC.>3*K.RHBL
M[LP554%F9F.%55&26)(  !))P.NI))$B1Y)72..-6>221@B(B@LSN[$*JJH)
M9F(  )) &L+'4"ZW>K.F+"ZLT=DC7:ELY2GA:(['U ')H3K.P8"C%*E(H)]+
M%EFX_.\@J3,^1%FI5DD;E@0)C>S<)^AW==Q[#<>*FEX?VEN5UJ,J_#M^/H0M
M>E(#ZE&XR/6KZIR]&CKSJ<CC^Y^E&7>;5C8O1;M\7%V[Q.8+?$,K21<#;!)W
M,^X;Q'UW>S#S*XVK8S9GE',LEBJ48C0+W:WUOC>JR5\[MR2+3FWS0AL45+59
MRU-*<O)H4F,E%%IDQIZ8DXPI. A(E0(0G*<-R%(-8O,5^A:M:CME&#:=GIQ;
M;M54EH:D)8EY&&'LVYF)DMVY !VD\S,V %0*@ U?\)<#1;!:M[_O&XS\3<:;
MM&D>[<37XTCE[!#SIM>T4TS!LVRP2$M%M]3 D?$MJ2Q*J,D)N3ZWS3C33C33
MC33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33
MC33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33
MC33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C34L]8=%=MMR
M7XECUQHN=6.4)6!&NE"-LRU0)C,%G'>S()^^C;8>S9+!G)N2%SR4L."$0$J9
M0=D!0L+N_$6R[%$9=TW&M5]GF6$OSV9!_P#DJT?-/)GNRJ$#Q(&3J=8W?[E2
M??W#Z3TUN#].[X,?5M2K6&T]ZY$T7?-T0DKD@I.*B6E4^QKB\A/+!,'A62@>
M[)/3&!+R8U!1QZ)"- I1.2.7-AP1BX?Q1Z6KEU9*?#L4FWUV+*VX3<OKLB]1
M]HC4M'5!\'+2S8PR]@_07<=95ZN0Q\OWH^G[K\>![CK:N:&AJ8&MN8V)L;V5
MD9T*5L:&=I1)FYK:VU"0!,B;VYO1EDI$2%&F++3I4B8DHA.26 HHL  A#CC;
MN\KO)([22.Q=W=B[N['+,[,2S,Q))8DDDY)SJZUV')=-.--.--.--.--6ZL>
MHZUMUI+9;'AK)*T:<>34!K@F[KFT*,]W/FV-Z2B3N[&MQD(>Q8TKD:G\W&/%
M[OJYFMDXCWSARPUK9-SM;?*X"S+#)F"R@S]KMU9 ]:W%U/VJQ%*G4^SG6L\3
M\&\+\9TUH\3[)1W>",EZ[V8L6Z<AP3-0O0F.[0GRJ_;J=B"7H!SXZ:LABB;D
M@8<XI?8F0@:B>P::$7>S%6RQ%X!C(2T"*5871^P6QO #N%E@/D#V(@ >P !8
MP (-J^RWAG=R/LGX+I&PV5DW7A6TW#UML]6FEV_LKFS3S$Y8E:=4,3U/>3HG
MV <;</ _8/Z2=Q%1,-%L/'E(<8;>O*"$KP;OZSMW$=2J!RH%?<;YC4>P.X+[
M&)7N2P=H'2GZ1L(. X[%4,MB1PHP>>SL%GT9+X,\E@SG/9GP_3 PAQ^;XP_[
M;DGP?Z,[F#!Q+Q3LQ)/VO<^':6Z*!X?;]MW:JQQW9%8$Y!Y%ZC53X7]-NW#%
MO@O@/B3H/MNQ\8;GL3$]Q_T;>>'[J GO"^ND* 1SL<:_6;5VF'C 2M36HLS.
M<8[ZS82(EIL>OLSD1B2)K5/=Q^G'=2#%G&,_FXSV8S#['^ 1U;TAV"O7I'P;
MN+/W$@ 2;C$F3W=9  3Y9.HGB[TLD 1^A^GSD@9F](^SQQ#) )+Q;/8EP 2<
M"%B0,=Y UXAJ-U9/C)9+;KW4J0\6 "5*G.;VR_H"LX[!&ITB=!7K$H4AS^<7
MA0K&1VX[HRQ8_.Y,$]%] Y:?C+B*1!D)'!M7#M25AW*\CR[S;1#W,4C#8.00
M>FI6D].>ZY6.MZ-^#X)"%,LUG?N,-QKJ0,R111U^&]OED!R5220(>YLXR8I;
M*=.6Y]H6L3+-=_[NC+0H( 6O:(#"8+'FA2;C':(PEK'YU"DR6+.<HU0"!O*7
M&?6\'#_E.9G:O2A3X<8GAG@C8=I;#!;DDUO<MWY6[P=TMDS(" ,K62M&3DA!
MT D/HCBWMTG](?%G$/'CJZ2?!=J2+8^$U>,\T;#AC9O5ZMDJV<G=;&Y%AA6R
M,\V*-T^"C:]/C@K=GK;W81W=5YPU*YR<V2#KUZU0//:,]4L5)C5"@X>?[8PT
MP8Q?TYSR];TU;T[%WVG;W=B2S/-;9F)[R6:0DGYSKIU/:*.WU8*5"O!1IUHQ
M%7J4X(:U:")?N8X8(42*)!X(B*H\!KT/HF.LWM67K]F(!]RY+\=&\?(^V_E+
M7Z^KGU5/OF_1]6GT3'6;VK+U^S$ ^Y<?'1O'R/MOY2U^OIZJGWS?H^K3Z)CK
M-[5EZ_9B ?<N/CHWCY'VW\I:_7T]53[YOT?5I]$QUF]JR]?LQ /N7'QT;Q\C
M[;^4M?KZ>JI]\WZ/JT^B8ZS>U9>OV8@'W+CXZ-X^1]M_*6OU]/54^^;]'U:?
M1,=9O:LO7[,0#[EQ\=&\?(^V_E+7Z^GJJ??-^CZM/HF.LWM67K]F(!]RX^.C
M>/D?;?REK]?3U5/OF_1]6GT3'6;VK+U^S$ ^Y<?'1O'R/MOY2U^OIZJGWS?H
M^K3Z)CK-[5EZ_9B ?<N/CHWCY'VW\I:_7T]53[YOT?5I]$QUF]JR]?LQ /N7
M'QT;Q\C[;^4M?KZ>JI]\WZ/JT^B8ZS>U9>OV8@'W+CXZ-X^1]M_*6OU]/54^
M^;]'U:?1,=9O:LO7[,0#[EQ\=&\?(^V_E+7Z^GJJ??-^CZM/HF.LWM67K]F(
M!]RX^.C>/D?;?REK]?3U5/OF_1]6GT3'6;VK+U^S$ ^Y<?'1O'R/MOY2U^OI
MZJGWS?H^K3Z)CK-[5EZ_9B ?<N/CHWCY'VW\I:_7T]53[YOT?5I]$QUF]JR]
M?LQ /N7'QT;Q\C[;^4M?KZ>JI]\WZ/JT^B8ZS>U9>OV8@'W+CXZ-X^1]M_*6
MOU]/54^^;]'U:?1,=9O:LO7[,0#[EQ\=&\?(^V_E+7Z^GJJ??-^CZM/HF.LW
MM67K]F(!]RX^.C>/D?;?REK]?3U5/OF_1]6GT3'6;VK+U^S$ ^Y<?'1O'R/M
MOY2U^OIZJGWS?H^K3Z)CK-[5EZ_9B ?<N/CHWCY'VW\I:_7T]53[YOT?5I]$
MQUF]JR]?LQ /N7'QT;Q\C[;^4M?KZ>JI]\WZ/JT^B8ZS>U9>OV8@'W+CXZ-X
M^1]M_*6OU]/54^^;]'U:?1,=9O:LO7[,0#[EQ\=&\?(^V_E+7Z^GJJ??-^CZ
MM/HF.LWM67K]F(!]RX^.C>/D?;?REK]?3U5/OF_1]6GT3'6;VK+U^S$ ^Y<?
M'1O'R/MOY2U^OIZJGWS?H^K3Z)CK-[5EZ_9B ?<N/CHWCY'VW\I:_7T]53[Y
MOT?5I]$QUF]JR]?LQ /N7'QT;Q\C[;^4M?KZ>JI]\WZ/JT^B8ZS>U9>OV8@'
MW+CXZ-X^1]M_*6OU]/54^^;]'U:?1,=9O:LO7[,0#[EQ\=&\?(^V_E+7Z^GJ
MJ??-^CZM/HF.LWM67K]F(!]RX^.C>/D?;?REK]?3U5/OF_1]6GT3'6;VK+U^
MS$ ^Y<?'1O'R/MOY2U^OIZJGWS?H^K3Z)CK-[5EZ_9B ?<N/CHWCY'VW\I:_
M7T]53[YOT?5I]$QUF]JR]?LQ /N7'QT;Q\C[;^4M?KZ>JI]\WZ/JT^B8ZS>U
M9>OV8@'W+CXZ-X^1]M_*6OU]/54^^;]'U:?1,=9O:LO7[,0#[EQ\=&\?(^V_
ME+7Z^GJJ??-^CZM/HF.LWM67K]F(!]RX^.C>/D?;?REK]?3U5/OF_1]6GT3'
M6;VK+U^S$ ^Y<?'1O'R/MOY2U^OIZJGWS?H^K3Z)CK-[5EZ_9B ?<N/CHWCY
M'VW\I:_7T]53[YOT?5I]$QUF]JR]?LQ /N7'QT;Q\C[;^4M?KZ>JI]\WZ/JT
M^B8ZS>U9>OV8@'W+CXZ-X^1]M_*6OU]/54^^;]'U:?1,=9O:LO7[,0#[EQ\=
M&\?(^V_E+7Z^GJJ??-^CZM/HF.LWM67K]F(!]RX^.C>/D?;?REK]?3U5/OF_
M1]6GT3'6;VK+U^S$ ^Y<?'1O'R/MOY2U^OIZJGWS?H^K3Z)CK-[5EZ_9B ?<
MN/CHWCY'VW\I:_7T]53[YOT?5I]$QUF]JR]?LQ /N7'QT;Q\C[;^4M?KZ>JI
M]\WZ/JT^B8ZS>U9>OV8@'W+CXZ-X^1]M_*6OU]/54^^;]'U:?1,=9O:LO7[,
M0#[EQ\=&\?(^V_E+7Z^GJJ??-^CZM/HF.LWM67K]F(!]RX^.C>/D?;?REK]?
M3U5/OF_1]6GT3'6;VK+U^S$ ^Y<?'1O'R/MOY2U^OIZJGWS?H^K3Z)CK-[5E
MZ_9B ?<N/CHWCY'VW\I:_7T]53[YOT?5I]$QUF]JR]?LQ /N7'QT;Q\C[;^4
MM?KZ>JI]\WZ/JT^B8ZS>U9>OV8@'W+CXZ-X^1]M_*6OU]/54^^;]'U:?1,=9
MO:LO7[,0#[EQ\=&\?(^V_E+7Z^GJJ??-^CZM/HF.LWM67K]F(!]RX^.C>/D?
M;?REK]?3U5/OF_1]6GT3'6;VK+U^S$ ^Y<?'1O'R/MOY2U^OIZJGWS?H^K3Z
M)CK-[5EZ_9B ?<N/CHWCY'VW\I:_7T]53[YOT?5I]$QUF]JR]?LQ /N7'QT;
MQ\C[;^4M?KZ>JI]\WZ/JUR'X)CK+WL=[:N]LA[<=[ 8U7X19#V^O&!90"P'.
M<>K&<A%C&?7D.?T<?'1O'R/MOY2U^O\ 7\QT]53[YOT?5JY\,^"HZ&,R@M3,
M;AV?FOAB +*$F35Q&&P_N]OB 4@0UHM=<EC]79A*\)#0=F?Y47;ZK2?TQ\1R
M B"CM,&<^TT5J9QW=Q-I$SW]2A'7NSUU$58QWEC^, ?H&?TZR+4CT/>E[0ZE
M,Y1S52&3-[3""8%XN%:^VZ,1P.[D!X66>N3U%$QP! ",!B&/I,ECQWR^Z+.<
M\U?</2#Q=N(*2[S/!&?WE%8Z6,YZ=I72.8CJ1@RGITU46&)>Y!^/VOZ\X_%C
M64]G9FB/-B%D8&IM8V9L3EI&UH9T*5L;&](5CNE)4*!$40D2)R@_FEDD%%E@
MQZ@AQCFGR2/*[22N\DCDL[R,7=F/>69B68GQ)).JNNRY)IIQIIQIIQIIQIIQ
MIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQ
MIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQ
MIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQ
MIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIJW<]M
MVKJN3 56)8$1AA9H>\G*D#ZWMRQ7_@1(#SPKEP\Y]6 )$YX\Y[,8#G.>9K:.
M'-_W]S'LNS[CN94X=J=2::./Q^VS(ABB& 3F1U& >NM:X@XRX4X4B67B7B/9
MMD5P3&FX[A6K338.,5Z\D@L6&STY8(I&STQG5E0[CU4Z"QB$QVYK+*SWL><@
M=*V.Z-N>Z+N]I;HX,#2W* 9S_:FIE1Q(L8[V#.[G&<[0?1IQ! #\*7>&-C8?
M]5N_%&R03CH3[5>&Y8F0X'59(T89QC.<:,/39PE:(&Q;9QQQ2AYOM_#W W$U
MJK[) RMNSMU.K(I)Z/%-(G0Y8=,^<6TZ4O&1GZ_[2DE8]8C?D6=3\!QV_IR4
MD<5"G/J]><!($+'KQV=OJS(. )&P$XPX!9CW+]D]=#G_ 'I88X_=DOCWXZZJ
M-Z68T!:3T<^EA$'[\<$6I3\_9PVI)??T0GPQGIKA+N?0 5!2*4R.0UFO-%W/
M*6K 9Q7H "[W=[!NLE8$+%^G].0.H\8QZ\YQCMY&3T8\8%&EV^C3WV%1GM>'
M]WVK>21C/2O1N2V^F#WUQU&/+4(?3?Z.PZ0[ON>Y<+6&)!@XNX=W[AP(0W+A
M[>Y[=!MXZXZBX0,C)&KL9N^EL%ISA6]6 2E9(%*4P4^B@0*$YG;X9Y(A.V,&
ME#[,]TP&1 %V9QC/JSS49]FW>K*T%G:MRKS(>5X9Z-F*5&\FC>)64^X@'73=
MOW/;=VJQWMKW"CN5*89BMT+<%RM(!T)CGKR21/@]#RL<'H=?CY<Z3^N&K/Z_
M[H,2_1_7_KORC\';A^ 7//\ U6?N\_N-7N1YCZ1I\N=)_7%5GO!B7XOQ\';A
M^ W/S6?]33(\Q](T^7.D_KBJSW@Q+\7X^#MP_ ;GYK/^IID>8^D:?+G2?UQ5
M9[P8E^+\?!VX?@-S\UG_ %-,CS'TC3Y<Z3^N&K/>#$OQ?CX.W#\!N?FL_P"I
MID>8^D:?+G2?UPU9[P8E^+\?!VX?@-S\UG_4TR/,?2-<_+E2?UPU9[P8E^+\
MC\';A^ 7?S6?]GID>8^D:X^7.D_KBJSW@Q+\7Y#X.W#\!N?FL_ZFF1YCZ1I\
MN=)?7%5GO!B7XOQ\';A^ W/S:?\ 4TR/,?2-/ESI/ZX:L]X,2_%^/@[</P&Y
M^:S_ *FF1YCZ1I\N=)_7%5GO!B7XOQ\';A^ W/S6?]33(\Q](T^7.D_KAJSW
M@Q+\7X^#MP_ ;GYK/^IID>8^D:?+G2?UQ59[P8E^+\?!VX?@-S\UG_4TR/,?
M2-/ESI/ZX:L]X,2_I_1_Y7_IX^#MP_ +GYK/X]W[SQTR/,?2-/ESI/ZX:L]X
M,2_%^/@[</P"Y^:S_J:9'F/I&GRYTE]<56>\&)?B_'P=N'X#<_-I_P!33(\Q
M](T^7.D_KAJS^O\ N@Q+]']?^N_'P=N'X!<\_P#59^[S^XTR/,?2-/ESI/ZX
M:L]X,2_%^/@[</P&Y^:S_J:9'F/I&GRYTG]<56>\&)?B_'P=N'X#<_-9_P!3
M3(\Q](T^7.D_KBJSW@Q+\7X^#MP_ ;GYK/\ J:9'F/I&GRYTG]<-6>\&)?B_
M'P=N'X#<_-9_U-,CS'TC3Y<Z3^N&K/>#$OQ?CX.W#\!N?FL_ZFF1YCZ1I\N=
M)_7#5GO!B7XOQ\';A^ W/S6?]33(\Q](T^7.D_KBJSW@Q+\7X^#MP_ ;GYK/
M^IID>8^D:?+G2?UQ59[P8E^+\?!VX?@-S\UG_4TR/,?2-/ESI/ZXJL]X,2_%
M^/@[</P&Y^:S_J:9'F/I&GRYTG]<56>\&)?B_'P=N'X#<_-9_P!33(\Q](T^
M7.D_KAJSW@Q+\7X^#MP_ ;GYK/\ J:9'F/I&GRYTE]<56>\&)?B_'P=N'X#<
M_-I_U-,CS'TC3Y<Z2^N*K/>#$OQ?CX.W#\!N?FT_ZFF1YCZ1I\N=)?7%5GO!
MB7XOQ\';A^ W/S:?]33(\Q](T^7.D_KAJSW@Q+\7X^#MP_ ;GYK/^IID>8^D
M:?+G27UQ59[P8E^+\?!VX?@-S\VG_4TR/,?2-/ESI/ZXJL]X,2_%^/@[</P&
MY^:S_J:9'F/I&GRYTE]<56>\&)?B_'P=N'X#<_-I_P!33(\Q](T^7.D_KAJS
MW@Q+\7X^#MP_ ;GYK/\ J:9'F/I&GRYTG]<56>\&)?B_'P=N'X#<_-9_U-,C
MS'TC3Y<Z3^N*K/>#$OQ?CX.W#\!N?FL_ZFF1YCZ1I\N=)_7%5GO!B7XOQ\';
MA^ W/S6?]33(\Q](T^7.D_KAJSW@Q+\7X^#MP_ ;GYK/^IID>8^D:?+G27UQ
M59[P8E^+\?!VX?@-S\VG_4TR/,?2-/ESI/ZXJL]X,2_%^/@[</P&Y^:S_J:9
M'F/I&GRYTG]<-6>\&)?B_'P=N'X#<_-9_P!33(\Q](T^7.D_KBJSW@Q+\7X^
M#MP_ ;GYK/\ J:9'F/I&N?ERI/ZX:M]X,2_%^1^#=Q_ +OYK/^STR/,?2-<?
M+G2?UPU9[P8E^+\A\';A^ W/S6?]33(\Q](T^7.D_KAJSW@Q+\7X^#MP_ ;G
MYK/^IID>8^D:?+G2?UPU9[P8E^+\?!VX?@%S\UG_ %-,CS'TC3Y<Z3^N*K/>
M#$OQ?CX.W#\!N?FL_P"IID>8^D:?+G2>?T7#5GO!B7XOQ\';@>ZA<_-9_P!3
M3(\Q](T^7.D_KAJSW@Q+\7X^#MP_ ;GYK/\ J:9'F/I&GRYTG]<56>\&)?B_
M'P=N'X#<_-9_U-,CS'TC3Y<Z3^N*K/>#$OQ?CX.W#\!N?FL_ZFF1YCZ1I\N=
M)_7#5G]7]T&)?I_J_P!=^/@[</P"YY?ZK/W^7W&F1YCZ1KGY<J3^N&K/>#$O
MQ?D?@[</P"[^:S_L],CS'TC7'RYTE]<56>\&)?B_(?!VX?@-S\VG_4TR/,?2
M-/ESI/ZX:L]X,2_%^/@[</P&Y^:S_J:9'F/I&GRYTG]<56>\&)?B_'P=N'X#
M<_-9_P!33(\Q](T^7.D_KBJSW@Q+\7X^#MP_ ;GYK/\ J:9'F/I&F+SI/.>S
M%PU9G.?5C&+!B7;G/]7^N_'P=N'X#<_-I_U-,CS'TC58,TQB,CSV1Z4QQ]SZ
M_4S/C8Z9]7Z?4A5'Y]7]/*$E>>(9EAEC'G)&Z#KW=64:CJH^4M-.--.--.--
M.--.--.--.--6LM2Y()3K2C<9@XJ!.#RI]'16)L:(Y[F<S>!=S!3-$XTAP-Q
M>%YIAA)8LE%@1H_&*-<%:-.+QL9_A_AG=N);$L.VP((:L?;[AN-J1:NV;96&
M>:SN-Z7$-:%55F 9C+($988Y''+K4N+N-^'N"JD%C>K4AM7I36VC9J$#W]\W
MRZ<!*.S[7!S6;MAW:-"458(3(C69H(VY]61*C>Q]Y8RKFD@6:VUTJ[<IH/ E
MR%RN1X1#[,EBE-@Y*5-4),-!@!@FN&)%;HFP::E42(!Q6<YVIKO!/"GVO:Z<
M7'&]1XY]UW>*:#AFM*/NA0V;FCL;JJG*BQN<D=>3E$B4BK#6B)MGI-X^';;Y
MN,_HPX:E),>P\/SU[/&UZNWW)W;B,K-4V%F 60U=CAEN1"1H9=R5XSS73K[7
M&E*Q4^DXK7[+\8QCR<JF3\ Z53A<I%W<F*%DPDIKI(33#1AP8, 7 !&#,YR6
M27CLQC ;SQMQ3OJ=AN&\6O4@.6/;*97;]JB09Y4CVVBM>FJJ#R@F$N5P&=CU
MUMG#?HQX%X5E];VCARC\)LW:2[WN*ON^_3RG'-)+O.Z/;W$L[#F95L+&&R51
M=7NYJNM\TXTUX%25*N3G)%J8A8D4%B*4)51):A.>4/'8,LXDT(RS2Q8]0@#"
M((L>K.,XY/'))$ZR1.\<B,&22-F1T8=0RNI#*P/<001X:IRQ13QO#/%'-%(I
M22*5%DCD1A@JZ."K*1T*L"".A&L?NRG2YTJVC9EK=/Z8C#6XJ2S_  'V)-B!
MD5)%)^,]Y86W%)1LF58QYP(U>!M*=LX[V"').,7B8Z/L7I9XSV81P3;A\.T%
M(!H[\K;@H3 4K#;=A?K87H@AM+&AP3&P&-<MW/T.<'3V9-SX=BN\";XXS\+<
M%6CL9D8-SXO;7"K;)N4;R8:9+VW3-*H*F1<YUJ"=1/X.9<.O2)^LW6Q>;:%<
M-X5"]6QYP,+TS(0=XP63 J3U"M$4G*#G(CERIU:P% &I<),WC&2B'WCA;C[A
MKC!HJE=SL>^2$*NT;C.C5[<A'W.U[D1&DKL<!*MI(++L2L7;8YM8"?B/C?T?
M$_9]4BXEX5C)SQYPU1EBM;;""<3<5\+PFQ+7A506GW79'LTH5 :>I65B5UGG
MEF=XZZKV-^;%S,\M:DQ&XM;FE.1+T*HK/880J2J %G$F!]6<A&#&<AS@6.T.
M<9SN#H\;M'(C)(A*NCJ592/ @@'^P^&NI4-PH[K2K;CMMNM?H7(EGJW*DT=B
MM8A?[F2&:)FC=3U&58X((.""!UG)=7>G&FG&FG&FG&FG&FG&FG&FG&FG&FG&
MFG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&
MFG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&
MFG&FG&FG&FG&FG&FG&FG&FO82+%:!04K0JE*)6G,":0J2'FIE!)H!8$ PHXD
M0#"S "Q@01@$$018QG&<9QR!56!5E#*0000""#W@@]"#DYSWYTU-^D^IGO\
M:\*D1U3[;W>QH6\81IHV\S9SG$+#W<XSW1P>=CDL0&$6,=T7>9<BR#.0][&,
M\U_<.$N&MT#"[LNWR,V<RI72O8.<_P#XBN(IQC.1B3H=5%ED7N<_C]K_ )LZ
MS[:E?"K+EBZIKCNY=+QRTH[@1:=;8]0!+A,_2D_F]]P<(:YJSX3)U6<][M2M
M*RO4P0""(/?&7D!W-=Z]#E&97EV*_+3EZE:MTFQ6/DBSHHL0C^,XM,<=W7I7
M2T>YP"/->A_&.X_BQK;5U!WZU0WJB0Y5K;;;%-%"!*2HDD)5Y&PV-#LG"P7W
M)3!W7"=\;T_F<B2D/)*=7''(\HST.\N)0?%SQ??.&]ZX=F['=:4E<,Q$5A<2
M59\=<PV$S&QQAC&2LJ CM(T/35TCHXRK ^8\1\X[Q_G&IC<P6I].--.--.--
M6.NRY U@B8V..,ADVM>>K#F:MJ_2'A(.>G$DK!BUW>%6>W#/#XX0(*^2/IV,
M$HTN $%YRJ4D!YM?"_#)WZ6W;NVAM?#VT1+:WS>)$+K5@9N6*M6CZ>L[E=<=
MC1J*>:20EVQ&CG6@\=\;CA2"AM^V46WWB_B*=Z/"_#L,@C>]:5.>:Y=ES_H6
MR[;'_I&YWW')#$ BYED0:Z:H*)S$'559EEO)=CWI(DN"GV;J4^0-L<0&9$:&
M%UNUG=H(Q#VT1HR08( 4Z/QOBN;X>:>H"F2W/$G%HW*O'L6Q53LG"=*3FJ;5
M&^9[TRX!W3>["X-_<I^56)<M!44+!4140O)9\&>C\[-;EXIXIO+Q-Q_N4/)N
M&_2Q\M;:ZS%G&Q\,5'&-JV6L79!R*EO<'+6K\C/(L,,BN:7KI6G&FG&FG&FG
M&FG&FN!!",(@##@018R$018P((@BQV9"+&>W&<9QG.,XSC.,XSV9Y$$@@@D$
M'((Z$$=Q!\"-0(!!! (((((R"#T((/0@CO&M:7K&]#V![+Q5^O/76/H(E<C$
MB5.3I'V=#X2&2IB"S%!^4"!&#M'G&0B&H9$Q!A@,",7QHH"X*QADWH;T=^E#
MUOU;AKB^UDGD@V?B*PV9('R%BH;Q*V6FJ2$A8;\A,U1\"=GKL7@X9OG"VY^C
MBY;XN]'].:YP]/*UOB[T>51F*5#[5GB#@Z GDH[S @,MO9H1'2WJ)2L2PWXX
M#+H"RZ)2*"25YB$L:E++(F!<:WNC:K!W34Z@KLSC(18SDLY.>6(M0D5$B,3J
MTII*E.880:68+MLL4D$CPS(4DC/*ZGK@]_0CHRD$%6&0RD,"00=='V3>]KXC
MVFAOFRW(K^V;E72S4M0DE9(WR"K*0'CEB<-%/#(JRP3))#*B2(RBG.4]973C
M33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C
M33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C
M33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C35P*NM
M:RJ2G4?LVHIS)ZYG\66 7,$MB+NK97IN/#G'? !4C,+R<D4E]J=>WJ<'('%(
M,U&O3*4IQI([:Y2J;A7DJ7:\5JM,O+)!.@DC<>]6'0@]58896 92& (B&*G*
MD@CQ'^?T:WP>COU_HSMFMC>M>WRAB@&QZO!+5"+%3@3,L"NQ:' 2R&M2EQDI
M%#+*78[/ :2O#C4K68,)COH=U5-L64><^.?1K-LHEW78UDL[4N7L523)9H+U
M)=6ZM8JJ![3G,T*X,O:('F6^AG#X5NC>!\&^H^[N/AY:V=^<DU<Z<::I*>S>
M/5M#)-/96LP@CL49UCTZ*.S C,ITA61A3I2LB#E0N6G9*1H$H,^(K6J$Z8K&
M3#08SD=HVJ[OFYT=HVZ(S7=PLQ5:Z=0O/(V"\C8/)%$O-+-(1RQQ(\C852=8
M;B'?MMX7V/=>(=XG]7VS9Z4]ZW+@%^SA4D11(2.TL3OR05X0>::>2.),LX&K
M$:]0"0*U+S?]JH<$VU::--E,T']IOR75N$>%<7K5KR9CM3GDE#+=YB>2!/EU
MDZD_*@L04"87-MXSWBG''5X.X?EYN'>'Y9!)93V?A_?".SO[[8"G#HS UML5
MB_J^WQH$8&:0:Y_Z-N'=RFEO>D7BZ#DXQXM@B,5*3+_8GPP")MJX6J%NL;HI
M6[O4B+$;>ZRR&5#ZM&QE)S0==9TXTU8:8;1:\5_-<UQ-KC@48G836L@44>'Y
M*C>\'/928]H+RB,%@S W$E8E,2X[/Y4!Y>0^H6.9*#9]TLU_6Z]"S-6PY[:.
M,M'B,D.>8?>E6!\B#K8:7"?$NY4?A.ALFX6]O(F87(:[/ 5@++,0XZ$1LCAS
MX%2/#5^>8W6O:<::H"46I7$*<0-$MFD>CSF:D*7EH75Q)2*1HSC3R2E(2C,X
M%DDPU*H+"/&.S(B3,8]8<\N8:=JPI>"O+*@8J61"P#  D9 [P"#CWC60J[5N
M5Z,S4Z5BQ$KF,R11LZAU"L5)'3(5E)'D1JO0B",(1@%@0!AP((L9[<""+&,A
M%C/].,XSC.,_TXY;:L"""0>A!P1Y$:_7&H:<::TU?A''2];LM9FZ=,Q\"500
M,95FLK4E"$L61>97*7$!) 0X 4J#A6[$B$'L(<BW9!@PX;ZQ(4/J3T5\8-Q'
MM3<.;E(9-[V.L9-ML.V9-RV6' >JY8@R6]K!4Q-GGEHGEY&:M)(W"+U4>B[C
M2*[6^U< ^D+=4K;A6  K\+\<7!BMN$'* (-JXI9/5KJ,O9UMZ$-CM8X[AB&E
MCSIFNOZ<::R3=(2B*HV:ZB^MM'7A$RYQ5L\=+!32N*FN[\Q =B66HY_)6P G
M:,.C*^H_*O;,VKL"0.:41N4V"#A&)C3B3-5XVW&YM/"^[;AM\QKW*T==H9@D
M<A0O=K1,>25)(VS'(Z^TC 9R!D BI" TJ*PR"6R//",?ZP-;@UP].CX/%1E]
M59J];M/,L"N:\D*!36,?<K'VM"AD?IE^6Q9H2ES!'/%419W-T?T*AJ;$3V]M
MJE6NRF)(+&8L2!/X=0XG])VX[;<WBC?DLT=N=A;D6KLW-%V<0F=C U99I$2-
M@[F.-P!G/0-B\,< 8*5 +=PRPS^//NQW]3T\1K7KZ\72-KCIUR6K;1U]<Y"9
M1UR+Y!'1Q"4N>7QSKR;L*9*Z%MK<_G@+<'>-2%F4J5#4%VRN>6Q6QNA;@[N!
M2U!X'3?1SQM:XHBN4]S2,;A16*43PIV:6J\I9"S1@E4FB=0'Y.6-UD4HB\K#
M5O/"(R&7[DY&"<X/N]V//)Z=_76P,T]*KHE4WI34.SNT=%,40C2ZH*5?[ L!
MSLS9$Y**3V#'8L3YHYIB4_6&DB>I.^%E@(:V@M$E,5A" E*D+_D^9'C'T@;A
MOMS:=HW*6>9;EZ.M62IM0/8UI93@/-54$1Q1YR[EB!WECUN!'"$#,H Y5))S
MXX]_B3K76ZH%2]+NR[7TSJ;I&&153(K6FLEKRQP-;W=S@E^,LQD=61NI NAM
MPJ5QB-,):ZRW^4CH<8R5A0-S"9DIOQCJ/"%WB^I3WZYQJ)Q%3KQ6JADBH*>R
M@BN2W>0454,0J0])3WX"$9;5O*(F9!%C+$@XSXD =_SG6PM->F_T-^E;0%>J
MMUHJTS1YEZLB(J[/L%OM&:R:=S(+;Y]]41^&U\)P31!B;B@'*$^&MH2Y:D D
M"5R?7=Z4%JW#F=?BKTA<8[E:&P3/7C@!G%.JU2"*O!S\L8EGL\K3R,<!N=R'
M;F98HXP56X,<$2CG \LMDDGYAG] Z:U;NK_'NFE';YKENZ:X1+($\5^@E5B.
M;+-)+*(&%_DJWQ66.QU%-/-RV//;.S)A+)<W.+P82B5O;>S%,[&XLKJG-Z]P
M1+Q7+MEM^*CRV8[+PU5D@ABL]G"F'EE:#$$L;R'E@9$',L;2<\BR(1:S",,.
MS[B,G!R.O<.O4$>(]XZ#&LUO7FZ6^B.G6BL4N#7"ADM;V*Y7=7L26R,F?VI)
MAG1Y[B4Z<G1O]&3*<2)F+PJ6L[<?E24W 5E938 0H*+-. 9H7HXXOXCWWB*>
MCNNY-;JIMUJ=8C6IQ 2QSUD1N>"O%(<+(XP6*G.2"0-5IXHTCRJX/,!G)/GY
MDZA=\'.T,U.WDE&V#=M-4R>U$=<,-.K862?+Y]$_0JF3N%CD/IH1P651@U=Y
M\IC:@B Y#6 3^4QE*$@1I^3=@]*/$6\\/5]F?9[K4VM37$G(AK3=HL25S&"+
M$,P7E+L<H%)SU)Z8DK(KF3F&<!,=_3)?/=\P_P YU[FG.@^I=H]=K9K3Z=U(
MG?=<X YW\GB5<"E\_;R6@F&.36GC0 R5JE2&8K/1A2@X&!.$A5B5=_O+1*18
M#G%'?.)-[J>CK:-\KWFCW2R-O[>UV%9C)VZRF7,3P- O,5'W$2\N/9QHD:&=
MD(RHYL#)\",>.?IU#CKOZL4-IYO<HI[7*!%5Q7(*>KN3AC9,@E<E!A\?#I"%
MT7>DYD^R%YSE4%$EQDC+CE*5X6/ (*[P^]G_ $<[QN6^<."]NMDV[7K]J'M3
M%#$>SC$11>2".*/V>9NO)S'/4GIJ6PBHX"C *@XZ]^6'C\PUFGZ4>J?09VPI
MK7>IIM$(O8F[+_6ZQVLN) FVS+"\*7]B Y.;^>=EHDS% 4PT3,G*4&E,ZDA*
M,(.ZG+,/$(.=!XSWGTC;-?W2[7L3U=@CMK'4F]7VF2,1R<JQ@=I#)9(9R0"X
M)\R!C5:)8&51@%\=1[6<^/NU=?J/:9_!^M/*[NBLWN"16L-J%&ODWFE,1I7/
M-I'QS42ARCLL05JYI18EC]#S1*IHR>73I7Y1E#DY)G#JFP@,SDRSX6WWTE[Y
M:H6X[,]O9QN4$%Z45]GC00I+"UI6^T1SCE@?),8#=?8;F'2:1(%!!"ABI(ZG
MWX\<=XU;[I7]'C12OM#6S?SJ$LJ&=%2N!+;C&BE;C)R:]JJI2@'JV%9F.1%2
MF7S*2R)E+(?587 EZ!C#JU1^/L '-*I7O%UQCQQQ%:XC?AOAB1JYAL+1YH%A
M-FY</211+,"M>*)R8P5,9!C>627D*I'+%#&(P\@SD<W7. .\=/'(Z]?F'O@7
MU4A]!:3:FEV?H.V(DFPSQ8;/$F2/P=VL^%C9FPO!KO)I#.ZOLU,-..*EM"(;
M2SN$<:V8U7(WML\%Z4I6MV0 V/@[XQH=Z-/B1RVV1U7FDEL)4L<[G"115[=-
M@1,7;GD6=I L4;_:U9XW,DO8<F4 YB<#!((\22I\/#N^8ZUF^=9U:ZWV-$M%
M_@]FYL<C$+JNNHK:MU1FHHA+K89FZP=J&18V.(D#"TR=Q5"<9BPL&<8ECEE*
M8G93C" FGXRC(PC!@0/-_$/$/I.V*26Q=M3TZ$MV:"G(U79Y%8<TCQ(.6O))
MUA0L#( 2%]H\V=7Z)7?HH!(&3U;^T^>H6]7C7#H2ZR43LI4-)1J+P;>^!HX
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MP>QN6XR'A'AYR,/ UNOV_$&XP]S+)7VMDH13QG,4NY'J&QCC/&BGC#T@<(\
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M5WDGB595$:1,>0D$JLB%ERH=<Y&Y54<]#:E55I9P&L3&"Q8#$)R%E$LPXB:
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M,^U;U1XTDD<WD-:%NWIR,*L]>6&P%:H65#E\CM!G)!&1G5G*T8=&BQ[/4X!
MR"".A ULP5!UFND]U08S#-?-L8 TQ&9S)U9V]%6>P$-326""L)P+$U)AP.TF
MY.N;F)<8<N/;622/8ZZ?#,+LH2,$GJ_!-Y->X$XSX1EL;GLUEYZ\".S6MMG,
M5@UE]L^L4V*M*H #O$@LQCEYST7(NA-%)[+="?WKCQ]Q[OF[CK"+U^.D-1>A
MB&J-B-9L/$6K"RIZ=7,GK!Z>U\C1Q.6C9'&4,3C$'I[4K9$-C=FM@D);DVOC
MB[&MBY$D,1..$;@! AW_ -&_&^X\1F[M>[<DURK5]:AMQQK$TT(=8I5G2,+$
M)$>2+D:-$YU9@R97F-O8B5 &7H"<$> .,C&>O@<ZS=_"=4QR[I@Q!8D!E0F1
M[#U$M4'%8$866D/AMB(RE A@P((2AJ5B4D)@\A (P\H&!9&8 (M ]$C!.+IU
M;HS;7=0 ]#S"Q48C!\0%8X[^FJ]G]R_\0_MUCS^"-MJW,BWK=\$#]'%LNO+:
M)3G&<%Y6G+KD5 ("+L[!#P00,P>,9SD <@R+&,##V[1Z:Y%[#AZ+/MF7<9 /
MXJI34GZ6 U2J#K(?,(/HY_K&OST]C"S?A-VY8RA@,!A[VI!W@"P(/?*>V<HP
M/:'.<=XLP RQX_2$81!SV9QG').)01Z)=A!&#R[0<'R,<S _C!!'F"#J,?\
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MCD QS32PQLA=  0I8%?N2!U/3N[LXQCKWZT6N>A]6.MJ7X)U_/%V1_X- O\
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M'7 B(Z +GBVUJ=D]+_&NT*O+5XKX<V#C6LJCEC6_1EGX8WK S@RS1UMEGE8
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M9A&3S!FSS88]V21FWC=%F+$X3+8Z$X!SCPS^C7AZ[NY-!;R[H1RY-<92Y2^
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MC<&G% 'MOI)X?W3B/9J=/:H4GGBW*.RZO+'"!$M:S$6YI&520\J#E!R020,
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M,<9-H7YI><],L#YX P!\^ /+KY:SN]?_ *J&EV^NNM*U[K/8C],I3#+J%,Y
MA=J^FT0)2Q_,&D[)A44MD[(UI%1OI%S1D^53FF*.Z8(WP_#+&(/.?1KP=OW#
MFZW[6[5HX(9]O]7B9+$,Q:7UF"3E*QNS <B,<D 9&/'5:Q*CJH5LD-D]".F/
M>!K5"YV;5KIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQ
MIIQIIQIIQIIQIIQIIQIIQIIQIIQIK?+^"R[/$274JZ=?):_I4XZ#M%M?HKZ3
M5E)2TD-N5"\.I32BRH-"$8$\SA\X=S@EXQX9C]VCQ_*!SGSGZ8-G:+>J&YP1
M%OA*H\<W("Q,]%D3G8 =,P3P1CS$7GG5_5;*%?O3^ALG^L'6P#I&#(M8ZT<A
MYP)1(0RZ5*S,8[,FJY1.9,_'C'_3D7><.YVY]?8'']&,<USTIG''>^P#(2D=
MNV^)2<\L=#::-- /=B'/X_/7*_00.;T5\+VB0TFY?#6[3, 5YY=UX@W7<'+
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M?F.0/NNG3&I6<Y]KKNH'[]_W.H5_[;?_  %VYLG#/^MV/^[_ /Z1-;]Z/O\
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M;!JN*Y#D4M1!Q^D3;) X_P#SS&7C&.6US_5V_P!^'_SH]8_=/]2D_P"TK?\
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M;+N-NBU>UN-2#G6MVD4C0DE%,]B 31R=C#SAI "&((P#G&K>.,LR\P8*?'!
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M)TH%0";V;>5FX?L;UMR-+C;[-N".10CK)#%(3'-&[(%>&5&2:,N""CJ&)P3
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M/>H56^H6R*E1"4Q-W.556>U)SG$;@)^B3PXM#Y#$+G'D+L8D6N;RTJ&(AY+
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MTV7.2WPEPS(^TV YQCF>HFWSC))*S GOUS/T7 ;1O'I.X/D 239^.+N_TT4
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M7W+9$N57@M2K-"TL7KT4ANU7,JK9BGBC>*5D:J&"OJ/;#F+<K D+U5\$%1C
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MP;.?(,,8_P#%WYU-2R.H15&P:JRFC8K6^52JOY+>AFP5>L]=7FDK^7P&6/$
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MN\<9U;O8WIYW5K13S%?LDF-%V-3\IM)?4$8GE)6TQ6@Q/TO:6!8_.P$:AD*
M),C;,-SDU+/2H&YQ YH1Y W&-BIN<EMWM7$]#=KLFW10;A4O0U%NS5MPI2U)
M8H9).SC+"3H2X*N.S9UY6 +<ZNJP>)D',2I!/*"IR,XSY>XCKUSK)#J+T\J
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M,L]0>L+!S99^+-IK0;M-.TZ'9;D%&["8&,YFLM&M8P1#)FCL]JK0LGW2Y.
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M@0JW!.:,&!3;=QCL^YV8Z\(NQ"Q'9FH6;-*>"KN4-/)LR49F7$PB4%V4A'*
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M;T^,K52=;V)%LP@B:6=$GN.NQ4SEV94VQ%R21R RJ.H&.'F3)P4.#K,<L3.
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M::<::<::<::KNLZOL6YIQ'ZUJ>$R6PY]*EQ;='XE$FA8]/;HJ'Z\X(1(BC3
MD$%X$>L6'>&C0I2S5:T\A*2:<"VMW*M"O);NV(JM:%2TL\[K'&@'FS$#)[E
MR6)"J"2 8A2QPH))\!_G].M[KHZ_!_8]JHNC.R^XR5BG.Q2'*9X@E8IC4SY!
M:67]T!R9W<U@/%;YG9;>+./++4V5$7B2T E3 <^.I#9)$/G;CGTER[RLVT[$
M9*^UL&CLVV!CL7U[C&BG#05&_?*<33J>601H7B:^A@">T^"W@.\+]9]_</#S
MUM!\Y#JYTXTTXTTXTU:JUJ9@MQ-2)#+4*LAU95.7"*3&/K36.;0MWQC'AN\5
MDB3&%K6L ()8S"NTYO6^$64XHEA ?"YL'#_$^[<-6)9=NEC>O:3L=PVVY$MK
M:]TK?OJVX4I/M4\9!(5O9FBYBT$L3^UK4>+N"-@XUJ05]X@FCMT9?6=HWO;9
MWH;[L=P8Y;FT;I#B>I,K*K,F7K3\BI9@GC')JR94JV-H['DYW&5NQM?)L]U-
M8-=H$+?;34B#G. !E];Y.3-TM.)#D !O$(5IUAY98E"B-^.,8L[2VW\%<5GM
M=HO1<%;S)U?9MZFEFX=L2],G;=\Y7FVY7.2*VZQO$C$(EX(%&M$3=_29P".P
MX@VJQZ3>'(L"+B/AJO7K\8U( 2 N\\,&2*MO#IE%-W8IXYY(T::7;#(6)NQ7
MVQ-+6>:)#$;!8CWTH6"UD3=SC8U,V\_'9@:=?$)$4UR)*:4//A&9&W>'XF,A
M 8/&<9SKV\<&<4;"HFW+9K:5''-%N-95O;9,AZJ\.Y4FL4I%9?:7$_-R]2HP
M<;CPYZ2>!^*V,&S<14)+Z,4FVBX[[7O=:0='CL;-N25=RB=&]ABU;DY@0K-J
M]/-7UO&G&FO I4ID9!JI6H(2IB09,.4*32R""@!QVB&:::()98 X]>1#%C&,
M?ISR=(WE=8XT>1V("HBEW8GN"JH))/@ "=4Y98H(WEFDCABC4M)+*ZQQHHZE
MG=R%50.I+$ >)U G9/J<Z8:M,JURL2YHNN<$N#0E,,6=&YZ7*510,Y$CPM+5
MELI*L(^Z Q"8YX<^W(L$(% RQEXZ+L/HIXRWP),^W? E!L$[AOK-MT7(?WT5
M>13>L\P!*&O5D1L &10RD\PW;TP<'4[3[7L<USC??ERHV7@NL=]GC8=#Z[?@
M9=HVQ$8J)7W#<*[1@D\C<K :@W44^$<6W?J)^K'61O,K*NW M2WJY$(1PGIX
M1FX$4/(QJ4Z56L*/+SW@$+$;2UY*,-2.D=>>Z2L!W?A;@#AGA!HK<2_#V^1E
M77=MPA1*E.1<GFVS;&,BI(IP4MW'FG1U$D*PY(UKL_#_ !QZ0C__ 'U:7A/A
M63[K@3AR^TVX;G$<9AXIXIK]BTE=P'2?:MC6"M-')R3WI^3KK(O;V\21V7OL
M@=%ST].BDQ6XNCFJ.6+EJDS/:,Y2I/&,TT>>S <9$+. @"$ <8 $(<;G)*TK
MM))(9)')9W=N9F)[R222==1V_;J&TTJVV[73K;?M].)8*M.G#'7K5XD^YCBA
MC541>\G R6)8DL23U?),CS'TC5YIQD>8^D::<9'F/I&FG&1YCZ1IIQD>8^D:
M:<9'F/I&FG&1YCZ1IIQD>8^D::<9'F/I&FG&1YCZ1IIQD>8^D::<9'F/I&FG
M&1YCZ1IIQD>8^D::<9'F/I&FG&1YCZ1IIQD>8^D::<9'F/I&FG&1YCZ1IIQD
M>8^D::<9'F/I&FG&1YCZ1IIQD>8^D::<9'F/I&FG&1YCZ1IIQD>8^D::<9'F
M/I&FG&1YCZ1IIQD>8^D::<9'F/I&FG&1YCZ1IIQD>8^D::<9'F/I&FG&1YCZ
M1IIQD>8^D::<9'F/I&FG&1YCZ1IIQD>8^D::<9'F/I&FG&1YCZ1IIQD>8^D:
M:<9'F/I&FG&1YCZ1IIQD>8^D::<9'F/I&FG&1YCZ1IIQD>8^D::<9'F/I&FG
M&1YCZ1IIQD>8^D::<9'F/I&FG&1YCZ1IIQD>8^D::<9'F/I&FG&1YCZ1IIQD
M>8^D::<9'F/I&FG&1YCZ1IKV$J14N/+3(DRA8I-%@!2=*28H/,&+/8$!9101
MF#$+/JP$(<YSGU8QR!90,EE '>20 /QDXTP3W#.IHTITW=\]AST@*BU-O"3(
MEHBP)Y$M@SK$H:+)HNX'(YO,RH]$"@XSZS!&O8,%@_/,R$'YW,%N'%7#FU@F
M]O.WPLN<Q+82:?I_^SP&2<_BCZGH.O34XBD;N1NOB1@?2<#6?C4OX*K>$O4M
MDBW(N2.5#',F$*%M=U1E//;$5ILAP)0WK):L*)@D56!$+N@7-I%BILY +M3=
M@@#YS7>O3'M\ >+8Z$MV7J%M7,UJH.>C+",V9E(Z\KFJW4=>A!N$JGH78 >0
MZGYL]P_%G6VQIWT^]3=$8H*,ZWU.S1->N1DI)+/G+M?[*F/@^&/(I--7()CL
MI3&*"_-@8T VV,H5(QF-;(@"+(.<6WSB;>N(INVW6[),JL6BK)]KJ09S^XUU
M/(I /+VC<\K#H\C:NDC1!A5 \SWD_.3U_%W:F?S ZGTXTTXTTXTTXTTXTTXT
MU;2?TU4]J$X)L:NH=,A +\(A6_,+>M<T@.WM[$#L,CTHWBQG] T*M./'] L<
MSFS\3<0\/L6V7>MSVP%N9XZER:*"4_\ Y:N'["8>8EC<'N(UJW$7!'!_%R<G
M$W#6R[V0G9I-N&WUI[<*9R!7NF,6ZQ!ZAJ\\;#K@]=6>QI[6;8#!4)EMX5LG
M"+(BT4&O"R4#85D6<YS@II=7]Y:RP8SZPE 1X*#C& A!@.,!YLOQE;[.<[IM
MW"N^.>^7=N%=DFL-W=6LUZE:PQP,%C*6.222>NM+7T+<+5%$>Q;QQYPO$K%E
MK[!QYQ/7J*3G(6E;W&[3523GE6 *,  !1C7/S5PC_,/V,VJ/)]>,D9N$Q-C(
M<_I#E2@84B[U_P"ZPJP,/^U%CLQV#Z0#WIP5Z/D;.0XX:#D$?Q)KDD7XC&1[
MM2CT1#ND])OI>E3!!C;C9H@0QR1VE;;H+ /@&6964= 1@8\A6FE#*E!"V8,L
MKM!:G$$19]K6-/K#(R((L#[QC3)9$M8S.\/'>$$37D';G.,!P'.<9E;TF<6Q
MH\6VVMOV&)\@KP]LFS[,X!&,+9HTHK8P#@$6.;S)P-55]"7H^FDCGWJCN_%<
M\1!63B[B;B+B1"58-EJFY[G/0;+ %E-3E)[Q@D&XIFN^OYP20'493QP4Y($Y
M 3:SA9F"4Y?^ID%=]D%X90.W/<+#V #VY[,8[>:M8W[?;4K3VMZW:S,YRTT^
MXW)I6/7JTDDS,>\]Y\3KI6V;1M6RU(Z&S;9M^TT8L]E3VRE6H58\]Y2O5CBA
M0G'4J@SXZ\7S<->?J&ICW70?\#Y1^%MU^4]P_/;/[360T^;AKS]0U,>ZZ#_@
M?'PMNORGN'Y[9_::A@>0^C3YN&O/U#4Q[KH/^!\?"VZ_*>X?GMG]IJ.!Y:?-
MPUY^H:F/==!_P/CX6W7Y3W#\]L_M--/FX:\_4-3'NN@_X'Q\+;K\I[A^>V?V
MFFGS<->?J&ICW70?\#X^%MU^4]P_/;/[34,#R&GS<=>?T?(-3'9_5\ET'_ ^
M/A;=?E/</SVS^TTP/(?1I\W#7GZAJ8]UT'_ ^/A;=?E/</SVS^TU' \O\]W]
M733YN&O/U#4Q[KH/^!\?"VZ_*>X?GMG]IJ&!Y#3YN&O/U#4Q[KH/^!\?"VZ_
M*>X?GMG]II@>0_R,?U=/FT^;AKS]0U,>ZZ#_ ('Q\+;K\I[A^>V?VFF!Y#3Y
MN&O'U#4Q[KH/^!\?"VZ_*>X?GMG]II@9S@9\_'3YN&O/U#4Q[KH/^!\?"VZ_
M*>X?GMG]II@>0^C\7]733YN&O/U#4Q[KH/\ @?'PMNORGN'Y[9_::8 [@!I\
MW#7CZAJ8]UT'_ ^/A;=?E/</SVS^TTP/(:?-PUX^H:F/==!_P/CX6W7Y3W#\
M]L_M-1P/+3YN&O'U#4Q[KH/^!\?"VZ_*>X?GMG]III\W#7CZAJ8]UT'_  /C
MX6W7Y3W#\]L_M--/FX:\?4-3'NN@_P"!\?"VZ_*>X?GMG]III\W#7GZAJ8]U
MT'_ ^/A;=?E/</SVS^TU# \A]&GS<->?J&ICW70?\#X^%MU^4]P_/;/[33 \
MAI\W#7GZAJ8]UT'_  /CX6W7Y3W#\\L_M-,#R'GW>/GI\W#7CZAJ8]UT'_ ^
M/A;=?E/</SVS^TTP/(?1I\W#7CZAJ8]UT'_ ^/A;=?E/</SVS^TTP/(=^?Q^
M?SZ?-QUY^H:F/==!_P #X^%MU^4]P_/;/[33 />!]&GS<->/J&ICW70?\#X^
M%MU^4]P_/;/[34=/FX:\_4-3'NN@_P"!\?"VZ_*>X?GMG]IJ&!Y#Z-/FXZ\_
MI^0:F.W^OY+H/^!\?"VZ_*>X?GMG]II@>0^C3YN&O/U#4Q[KH/\ @?'PMNOR
MGN'Y[9_::8'D-/FX:\_4-3'NN@_X'Q\+;K\I[A^>V?VFF!Y#3YN&O/U#4Q[K
MH/\ @?'PMNORGN'Y[9_::C@>7=W:?-PUY^H:F/==!_P/CX6W7Y3W#\]L_M-0
MP/(=>_II\W#7GZAJ8]UT'_ ^/A;=?E/</SVS^TTP/(?Y.?Z^OSZ?-PUX^H:F
M/==!_P #X^%MU^4]P_/;/[34<#NQT\M/FX:\?4-3'NN@_P"!\?"VZ_*>X?GM
MG]IJ&!Y#Z-/FX:\_4-3'NN@_X'Q\+;K\I[A^>V?VFF!Y#3YN&O'U#4Q[KH/^
M!\?"VZ_*>X?GMG]IJ.!W8Z>6GS<->/J&ICW70?\  ^/A;=?E/</SVS^TU# \
MAI\W#7GZAJ8]UT'_  /CX6W7Y3W#\]L_M-,#R'T:?-PUY^H:F/==!_P/CX6W
M7Y3W#\]L_M-,#R'EW>'EI\W#7CZAJ8]UT'_ ^/A;=?E/</SVS^TTP,8P,>7A
MI\W#7GZAJ8]UT'_ ^/A;=?E/</SVS^TTP/(=.[W:?-PUX^H:F/==!_P/CX6W
M7Y3W#\]L_M-1P/+_ #W?U=-/FX:\_4-3'NN@_P"!\?"VZ_*>X?GMG]IJ&!Y#
M3YN&O/U#4Q[KH/\ @?'PMNORGN'Y[9_::8'D/HT^;AKQ]0U,>ZZ#_@?'PMNO
MRGN'Y[9_::8'D/\ )S_7U^?3YN&O'U#4Q[KH/^!\?"VZ_*>X?GMG]II@>0^C
M3YN&O'U#4Q[KH/\ @?'PMNORGN'Y[9_::C@>6GS<->?J&ICW70?\#X^%MU^4
M]P_/;/[34,#R'3N]VGS<->?J&ICW70?\#X^%MU^4]P_/;/[34=/FX:\?4-3'
MNN@_X'Q\+;K\I[A^>V?VFH8'D//N\?/3YN&O'U#4Q[KH/^!\?"VZ_*>X?GMG
M]IJ.!Y?Y'=]&GS<->?J&ICW70?\  ^/A;=?E/</SVS^TTT^;AKQ]0U,>ZZ#_
M ('Q\+;K\I[A^>V?VFF!Y:?-PUY^H:F/==!_P/CX6W7Y3W#\]L_M-,#RT^;A
MKQ]0U,>ZZ#_@?'PMNORGN'Y[9_::A@>0^@:?-QUY^H:F/==!_P #X^%MU^4]
MP_/;/[33 \A]&GS<->?J&ICW70?\#X^%MU^4]P_/;/[33 \AI\W#7GZAJ8]U
MT'_ ^/A;=?E/</SVS^TU' />-/FX:\?4-3'NN@_X'Q\+;K\I[A^>V?VFFJXC
M]?0*)&>+%81$(R;V=GB1^-,S,9V=W(>SOMJ),+L[HLA[.W^USG'Z,YQRVEM6
M9AB:Q/*/*6620=X/<S$=X!^<#357\H::<::<::<::<::<::<::<::<::<::?
MH_3QIJU\BNZFHB<<FE-LUM'52<60')'F;QIN6%##^D TBIR*48'C^D'A=[_!
MS/4N%N)MQ57H</;W<C< I)6VJ]-&P/<1)' R$'SYL>_6J;EQWP1L\DD.Z\8<
M,;;-$<207=^VNM.A'7E:"6TDH;^+R9]VJ))VVU@4'> 5?]1Y-SG >P4\CI8>
MW/Z/Y0Q> OL_KSWNP/\ 3G',JWHZX\1>=N#^(PH!.?@FX3@=_01$_BQG6"3T
MP^BJ1^S7TB<'%\@8/$&VJ,GNRS6 H]Y)P/'&KIQFQZ]FN<XAT[ALL%@'B9#&
MI.R/HL S_MQ!;%RH6 _^EG&,?X>8"_LF\[6,[GM&Y[<">4&]0M5 6\@;$48)
M]PZZVS:N)^&]])79.(=CWAE7F9=JW:AN#*OWQ%2Q,0/>0!JL^8O6<TXTTXTT
MXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTT
MXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTT
MXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTT
MXTTXTTXTTXTTXTTXTTXTUT[_ "%BBC,XR*3/#9'V%H3&+71X>%J=N;4"4K':
M8>K6*C"B""P_H[PQX[19P$/:(6,9N:=.WN%F&E1K3W+=F18H*U:)YIYI&. D
M<489V8^0!P,D] 3JRW'<MOVBC9W/=;M7;MNI1-/;NW9XZU6M"@RTDT\K)'&H
M[LLPR2 ,D@&*Y=UVW= A$:Y0=*S0TT>2\7G;Z!T;(XO([V0B5U_7Q0D$JF)8
MP9\5"\.QT:8!F R'Q%Q>>S/0#PMPYPP _&NZR6=S4 _8IPW+7GNPOT/9[QO#
M=KM^V,I]F6M76]< .>6(]1R5>.N,>.#R>C/88J6R.2OV>\:5[=3;+$>2#+P[
MPXC5]WWI64AZ]VV^U[<64J6G&1KW2]3VR5]BJ][0LR[UAF.\H9G60*8/7!9N
M>]VY05Y SF1L\+ 19+P!]6R X1>.Z8H,QD7;2/I#GVX=GPEL.Q<*Q*?8M5Z<
M>Z[VRCN$V\[NMN?FR.;-2*FH;JJ# Q77T05=WY9O2!Q7Q3QY.5^V4KFXR;#P
MRLG7VJ_#?#ST*H&#RXOS[BY7HTA!(-U8WK]1</( GC%.UDR@+QC&!H81'"U(
M\AQV8$<LRW"5J#.SU9-//,,%_MA9YK][C'BS<G+W^)=]M$YZ2[K=,8R<X2(3
M"-!GKRHBCW:VW;/1SP!LT:Q;7P5PK15  &@V';%E.!@%YS6,TC8Z<TDC,?$Z
MK<Z$PQ03A,HB,8/3AQV!3G,#4:3C&?TXP4-((&,9[,>K >8I=UW-'+IN-]'/
M>ZW+"N?G82 GZ=9V38=BEC6&79=IDA3(6*3;J;QJ#WA8VA*C/C@#.K62C5O7
M28B":^TQ7HU@!8&6ZM4<0QQ\)&'^U&0_1PMJ>2!@S^< 9*X @"_.#G L8SS/
MT./N-=LRM3B?>1&00:]B[-=J,#WAJEUK%5@?$-"0?'.M3W;T3>C3>L-N' _#
M9F!!6W4VNOME]"OW)3<-L6G=0K^]*6%*^!&H [/=*?-OMBM13NVVV%&R$)&0
M-R=@O^U0QU/@HONIDJ8A')R#$A?J 6)6[)97DHD 2R$6,!#C&Z;/Z4J!98^*
MN"^'=U0D!]QVS;*.U[F"6R\TD:5WV^VYR3R>KU"QR6F!.=:\_HXXGX>':^C[
MT@;U3BC):/AOC26?B[AUD ^UU*]NS-%Q)M4 /[^#=K2QC')6('*=1_>S53K*
MZ1K5KL[[/;:3ZN0''913&,7S;RTK*8&!F=\P"26G%J<E$AR,THG)+N @LU>N
M8&M&'(P]GV.'@7BBLUKAVMLNX&).TL[?+M=*MN]-?$V*#1,TD:DA39J-8K%N
M@D[P*=+TE6]JOUMB](VSV."MUM2K7H;J;1W#@[>YVPJKMG$*)%'4LSD%H]MW
MF*A< Y8U[=V4MB+^?;O!C.<9W'VIQG'JSC.P=M]N,X]6<>N7=N,XYD/L?V'Y
M$VC^;:?[#74NUD.")'((&#SL<CPP<]V.[3Y]V[_MC[4?M!VU^]W'V/[#\B;1
M_-M+]CIVDG\(_P#+;Z]/GW;O^V/M1^T';7[W<?8_L/R)M'\VTOV.G:2?PC_R
MV^O3Y]V[_MD;4?M!VU^]W_U_IX^Q_8?D3:/YMI?L=.TD_A'_ )3?7I\^[=_V
MR-J/V@[:_>[C[']A^1-H_FVE^QT[67^$D_EM]>GS[MW_ &Q]J/V@[:_>[C['
M]A^1-H_FVE^QT[23^$?^4WUZX^?;N_[9&U/[0EM8_P":7<?8_L/R)M'\VTOV
M.G:R?PC_ ,MOKUS\^[=_VR-J/V@[:_>[C[']A^1-H_FVE^QT[23^$?\ EM]>
MN/GV[O\ MD;4_M"6U^]W'V/[#\B;1_-M+]CIVLG\(_\ +;Z]<_/NW?\ ;'VH
M_:#MK][>/L?V'Y$VC^;:7['3M)/X1_Y;?7KCY]V[_MD;4_M"6U^]W'V/[#\B
M;1_-M+]CIVLG\(_\MOKT^?;N_P"V1M3^T);7[W?X?_'9CC[']A^1-H_FVE^Q
MT[23^$?^4WUZ?/MW?]LC:G]H2V_WNX^Q_8?D3:/YMI?L=.TD_A'_ );?7I\^
M[=_VR-J?VA+:_>[C[']A^1-H_FVE^QT[23^$?^4WUZ?/NW?]LC:G]H2VOWNX
M^Q_8?D3:/YMI?L=.UD[^T?/GSM]>GS[=W_;(VI_:$MK][N/L?V'Y$VC^;:7[
M'3M9/X1_Y;?7KGY]V[_MC[4?M!VS^]O'V/[#\B;1_-M+]CIVLO\ "2?RV^O7
M'S[MW_;(VI_:$MK][N/L?V'Y$VC^;:7['3M9/X1_Y;?7I\^W=_VR-J?VA+:_
M>[C[']A^1-H_FVE^QT[23^$?^6WUZY^?=N_[9&U'[0=M?O=Q]C^P_(FT?S;2
M_8Z=I)_"/_+;Z]/GW;O^V1M1_7_.#MK][O\ D_1Q]C^P_(FT?S;2_8Z=I)_"
M/_+;Z]/GW;O^V/M1^T';7[W<?8_L/R)M'\VTOV.G:R?PC_RV^O3Y]V[_ +9&
MU'K_ /Q!VU^]WJ_R<?8_L/R)M'\VTOV.G:R?PC_RV^O7'S[MW_;(VI_:$MK]
M[N/L?V'Y$VC^;:7['3M9/X1_Y;?7KGY]V[_Z?GD;4?M!VU_S?&[LX^Q_8?D3
M:/YMI?L=.TD_A'_E-]>GS[MW_;'VH_:#MK][N/L?V'Y$VC^;:7['3M9/X1_Y
M;?7KCY]V[_MD;4_M"6U^]W'V/[#\B;1_-M+]CIVLG\(_\MOKUS\^[=_VR-J/
M7_\ B#MK][O5_DX^Q_8?D3:/YMI?L=.TD_A'_E-]>GS[MW_;'VH_:#MK][N/
ML?V'Y$VC^;:7['3M9?X23^6WUZ?/NW?_ $_/(VH_:#MK_F^-W9Q]C^P_(FT?
MS;2_8Z=I)_"/_+;Z]<?/NW?]LC:G]H2VOWNX^Q_8?D3:/YMI?L=.TD_A'_E-
M]>N?GW;O^V1M1^T';7[W<?8_L/R)M'\VTOV.G:R?PC_RV^O3Y]V[_MD;4?M!
MVU^]WK_R\?8_L/R)M'\VTOV.G:2?PC_RF^O7'S[MW_;(VI_:$MK][N/L?V'Y
M$VC^;:7['3M9/X1_Y;?7KGY]V[_MC[4?M!VU^]W'V/[#\B;1_-M+]CIVLG\(
M_P#+;Z]<?/NW?[.SYY&U/[0EM=O_ +_C=V\?8_L/R)M'\VTOV.G:R?PC_P M
MOKUS\^[=_P!L?:C]H.V?WMX^Q_8?D3:/YMI?L=.UD_A'_EM]?N&N/GW;O^V1
MM3^T);7[W<?8_L/R)M'\VTOV.G:2?PC_ ,MOKT^?=N_[9&U/[0EM?O=Q]C^P
M_(FT?S;2_8Z=I)_"/_+;Z]<_/NW?]LC:C]H.VOWNX^Q_8?D3:/YMI?L=.TD_
MA'_E-]>N/GW;O^V1M3^T);7[W<?8_L/R)M'\VTOV.G:2?PC_ ,MOKT^?=N_G
M_P \C:G]H2VL?\TNX^Q_8?D3:/YMI?L=.UD_A'_EM]>N?GW;O^V/M1^T';7[
MW<?8_L/R)M'\VTOV.G:2?PC_ ,MOKUQ\^W=_VR-J?ZOYPEM?O=_R_IX^Q_8?
MD3:/YMI?L=.UE_A).O?[;=?TZY^?=N_[9&U'[0=M?O=Q]C^P_(FT?S;2_8Z=
MK)_"/_+;Z]<?/NW?]LC:G]H2VOWN_P '_/\ UYX^Q_8?D3:/YMI?L=.TD_A'
M_E-]>N?GW;O^V1M1^T';7[W<?8_L/R)M'\VTOV.G:2?PC_RV^O3Y]V[_ .GY
MY&U'[0=M?\WQN[./L?V'Y$VC^;:7['3M)/X1_P"4WUZX^?;N_P"V1M3_ %_S
MA+:_>[_D_1Q]C^P_(FT?S;2_8Z=I)_"/_*;Z]/GW;O\ MD;4_M"6U^]W'V/[
M#\B;1_-M+]CIVLG\(_\ +;Z]/GW;O^V1M3^T);7[W<?8_L/R)M'\VTOV.G:R
M?PC_ ,MOKUS\^[=_VQ]J/V@[:_>[C[']A^1-H_FVE^QT[23^$?\ EM]>GS[M
MW_;'VH_:#MK][N/L?V'Y$VC^;:7['3M)/X1_Y;?7I\^[=_VQ]J/V@[:_>[C[
M']A^1-H_FVE^QT[63^$?^6WUZ?/NW?\ ;(VH_:#MK][O5_DX^Q_8?D3:/YMI
M?L=.TD_A'_EM]>N/GV[O^V1M3^T);7[W<?8_L/R)M'\VTOV.G:R?PC_RV^O7
M/S[MW_;(VH_K_G!VU^]W_)^CC[']A^1-H_FVE^QT[63^$?\ EM]>GS[MW_;'
MVH_:#MK][N/L?V'Y$VC^;:7['3M)/X1_Y3?7KCY]N[_MD;4_M"6U^]W'V/[#
M\B;1_-M+]CIVDG\(_P#*;Z]5A&NI5U#(B<4<P[O[5IL$CP8!*JOBRG9NR/&<
M9[36IXD:]M/QZL8R$](8'..T.<9#G.,V\W"O#,^>UX?V9B1@L-NJ*^/<Z1*X
M[_!AJ(ED'[]OQL3_ %YU.VF_A%/5+J96G$\7)&+I9R,A[6&X*ZC#H0: ..S(
M3'Z&IH1,AB%CU]\R2F9P+LSG L=H<ZY?]%_!]U2$HRT)#_UM&U,A'S13-/7'
MXH1J=;$H[R&_WA]6#K/1J?\ "J:(G"ILC6WM+R*D7%0(A,HL>MU:JQZ_P<,6
M,'+W:+F(T4[C: O&>T)#."PU><8SG.<8YSC>O0YN-=7EV2_'N"C)%6TJU;.
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M%J@O&1\W[;]QH[K5CN[=:AN59,\LT+AER/ND8?=)(IZ/&X5U/1E!U0964\K
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M1>$+UJO2K;H\EFW/%7@C-#<4#S3.(XTYY*JHO,[!>9V51G+$#)U$P2*"2!@
MD]1W#J=4'K9T;NH9MQ3T9OFA*1;9E5TO4/Z6/R%1:=3QDU:?&7]RC#T 3-*)
MHSO:7"1Z:%Z0(E;>0%0$G"A/DU,:4:.XW7COA?9;TVW;EN+5[D C,L0I7I@H
MEC26,]I!6DC;FC=6]ER1G!P00(+#(ZAE (.<=0.XD?UC2_>C+U+-:86X6+:6
MKDK!"69,<N?)!!W^$V@0P($X!FJG)^15Q)90ZL[2C)+&<M>'! G:D1(<FJUA
M(,X%F.V\=\)[M86K3WB V'8+'%8BL4S*Q("I&UN&%)'8G"HC%V/0*=&AD49*
MDCS&#CY\=?[-8O\ FW:I:<::<::<::<::<::<::<::<::<::<::<::<::<::
M<::<::DUJON)L;I;8Z2T-<;/?Z^D!9B<+PW)#_.1.8-R<P0_0LUB:SQ6.3M(
M\#-P AS1FGH#3,K6I2WN)9"PK$;SL6U;_5:GNE2.S$0>S<CEF@<C]TKS+B2%
MQ@=4(##V7#(2IG1V0Y4X]W@?G'^3Y:^@MTF^MK3746;$E939*U4_M:UMIJET
MKDQ</,9L1*WD>*X2.J')>:)4M 42 Q>[0IP-.DC E H4$J)"S(5;Z7YHXTX
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M$=ZE,BA$AL]#-ZY>H"9!4L$3MR6!/=DOB$0%9D"9&1":M,D,>=A9 N)/5E$
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M1)W-T<EJ8M6$_*8]>L$0(O"@W J.T[)M>QP2UMJJ+3@FE,TD2/*RM*46,O\
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MW2[7HU@.TG?',?N8T4%I)7_BQH&8CO..5<L0#FN'MBN\2;Q1V:@!V]R7E,C
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M!8XJWH1()!A@=5 QJ+"/C.S;WK8TJ4I1LNX[)-NLTDIK)-&JNBRS2EIBPBH
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MY33K3/+4'KNY^N>JI2@7MLJ"I[9[,W9Q(J3)[3H \37(8+SJ6[R,'HOBWT]
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M%1M6L5_A!P)^*_LH+^KJ>23M8Y/4P.U]I/M>.VR&Z_N>JG;=<\O_ %79=_\
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MJ3<BLI7.6YLABO7R.,Y'N^GPQ<R=]7D%B(MST\AUO0!6;0WI =F:^=6ZVGM
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MJ5R]MV L^-4U9CK/@NV#)E>FM!)3I!;+E[.-Y5G)'-*[Q,I2H"F4') 'IB3
M9+>.!!O%IGEW,+1>2LZP/MM26_42L8\0;=NIY+%2%Q& RE)B 2H;E)!D2?E'
MW/M=>O,P!)\67N)[^N1W],:IZF.KFTUY$-;G&Q=0Z[N;8W3*(+X-JW?CO8DV
MBJ>'1P*AQ6Q-%8-8,1(V*S,0!8Z*S(GG+Q%@HB\$Y&$2_"AQ55;W!+V9]T6K
MO5FAM6^SK8WG;8ZT$QGDPJS&K<D/:U/640"?V)N8YQRKA%+, %R@9D&%8DC
M\,CN./#R\.NHR65U )E:E:::P250Y&L>=2[6O&W%<S&_FY6VK(KTN)GN-_\
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M7<Y[KK^G&FL*/7-_FV5/_CV;?\WEA<Z!Z.O^EKW_  U__5U==T] ?^TV\_\
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M=O46X6;%,T[]&S!!!:$5^&.)IJMAY8X[$78S3KR&2%T:.5HYT8 20KG4K(5
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MT6:-/(^NF\L8'>0J'ENW72;8N5E/N6=G;V\A/(2BU[3F+-P#,,3BX )(=W1
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MN:EQ@D@A!L7@X51@X44F6F&KAT)N![+;16HK]C\TJ7;=VW5GV@IML[VD6)1
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M.)U#,<.,MS=".HP!@@Y'AWC!\B.N<4R7<XMDW]5[OQ.H8E%VT^[WJTR*39E
MFZ+I(W(%ZX+Q!TKF@0I?)&+X^Y.#>8^H6E,6G=59CPD9B2PEMH=R;83+PTO#
M\]Z>9QM\50[A(.:9IH50QV&5V;FY941NS9V)1>1G)RVJ(DQ)V@ 'M<W*.['B
M,^\>.._KCPU)*GM[M;M67&N6C7FJ;D<80EV=K_96TU=KRZ&*)BZ8JJ+6#%J\
MK"(?%9C2,J=J8B;0F#B\S)U"%RE3@>V"!'HVD;QI%>+M\/;KNJV9-SNT!8^"
M+>TTUIP3K @NRUI;-N<S2/(7D-.NJ0Q^S$BN#+*7RLZRJA'*K8YN8Y(ST!
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M1BK(P$_9.2  "6R 0RD9 R1D$@$>6K2I=7K8=MBX_JQ%BX-.K=E<IC$,C*:
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M%-\5=%_"O2KQDG(_"^VS!G8J=WFC;HB@ADH!AWNS /: .%4)"22\R)>5HO\
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MYVR5-TV<;3;CW)YD-5HV=H[4(AAE$Z<KD/6<Q\[ 9D"ME*Z2)R!7YAR/SJ5
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MV6//S)#M4Z*0W*8EC8C&01GNST(Z_P"'AKM8_P!5?56J#JUINLX]>SW0FO\
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MR'M_0'&/5SID_HBX!KPO.-FED*IS".3=-U[/)!/_ %=R.3 QT^V?/G7&8?\
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MUM/R$_2;]C>&_;>W?XA<?&)QG\NV/R%+^[:>KP_>?TF^O3\A/TF_8WAOK_\
MVXM[^(?J_P G'QB<9_+MC\A2_NVG81?>=WO;Z^OX]/R$_2;]C>&_;BWOXA\?
M&)QG\NV/R%+^[:=A%]Y^EOKT_(3])OV-X;]N+>_B%Q\8G&?R[8_(4O[MIV$7
MWG])OKT_(3])OV-X;]N+>_B'Q\8G&?R[8_(4O[MIV$7WGZ6^O3\A/TG/8WAO
MVWMW^(7'QB<9_+MC\A2_NVGJ\/WG])OUM/R$_2;]C>&_;BWOXA<?&)QG\NV/
MR%+^[:=A%]Y_2;Z]/R$_2;]C>&_;>W?XA<?&)QG\NV/R%+^[:>KP_>?TF^O3
M\A/TF_8WAOVWMW^(7'QB<9_+MC\A2_NVGJ\/WG])OKT_(3])OV-X;]M[=_B%
MQ\8G&?R[8_(4O[MIZO#]Y_2;Z]/R$_2;]C>&_;>W?XA<?&)QG\NV/R%+^[:>
MKP_>?TF^O3\A/TG/8WAOVWMW^(7'QB<9_+MC\A2_NVGJ\/WG])OUM/R$_2;]
MC>&_;BWOXA<?&)QG\NV/R%+^[:=A%]Y_2;Z]/R$_2;]C>&_;>W?XA<?&)QG\
MNV/R%+^[:>KP_>?TF^O3\A/TF_8WAOVWMW^(7'QB<9_+MC\A2_NVGJ\/WG])
MOKT_(3])SV-X;]M[=_B%Q\8G&?R[8_(4O[MIZO#]Y_2;];3\A/TG/8WAOVWM
MW^(7'QB<9_+MC\A2_NVGJ\/WG])OUM/R$_2<]C>&_;>W?XA<?&)QG\NV/R%+
M^[:>KP_>?TF_6T_(3])OV-X;]N+>_B'Q\8G&?R[8_(4O[MIV$7WGZ6^O3\A/
MTF_8WAOVWMW^(7'QB<9_+MC\A2_NVGJ\/WG])OKT_(3])OV-X;]M[=_B%Q\8
MG&?R[8_(4O[MIZO#]Y_2;Z]/R$_2;]C>&_;>W?XA<?&)QG\NV/R%+^[:>KP_
M>?TF^O3\A/TG/8WAOVWMW^(7'QB<9_+MC\A2_NVGJ\/WG])OUM/R$_2;]C>&
M_;>W?XA<?&)QG\NV/R%+^[:>KP_>?TF^O3\A/TG/8WAOVWMW^(7'QB<9_+MC
M\A2_NVGJ\/WG])OUM51'^BOTL8TH+4MVEE2J3"A]\(9!B42Q/G./Z#$DID;R
ME.!_^K.)&#/](>4I>/N,)AA]^NCH!]J$$!Z>(,,49!]XP3UR>IU,(8A^\7\8
MSW?/_D^.IOU=KGK[2!(2*9HVH*G*" 1?97%;PZ%"$$6.P>##(XSMQAN1X_U0
M1@AB,_V^19SS7[FZ[GN!S?W&]=[O]:MSV!T[L"61P / #H/#4X55[E ^8 ?U
1:O+RPU'3C33C33C33C37_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g307489g23s23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g23s23.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2+(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (JR^B'8X0DE-! 0      "4< 5H  QLE1QP"   "@  < @4 $4EM;75N
M;W9A;G1-1U1R:6%L #A"24T$)0      $#)*<=:,9V1*XGP50235B!4X0DE-
M!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W13
M8F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX
M=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q >0            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M    /X   #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  0/   '=          !                          $
M!W0   0/                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   0/     %)G:'1L;VYG   '=     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   $#P    !29VAT
M;&]N9P  !W0    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     &#     !    H    %<   '@  "C(   &!0
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M/8K_ -BZ^7%XP-3RX%AF1L]SOM'O]J@_IO7; )P2!#@-AK'TFNKD.]8_O_\
M4)>YC/Z<1_A02,4P/DD=>L9M%^/@M):VT/\ T;7->&!K2\OVV,A_N]M7O_ZO
M_1JO%<<-^X+7/3^OEX>< N(WR'&MP)L.Y[]K[W>[^JI?8^OD:8#8/) IU@M\
M+OWF(C+C_>B?\**#BR']&8_P9./L9^Z/N"W?J>YS>H9%;216ZD.+!]'<';=V
MW][:Y5+>C];L?O."]N@$!U<?^?5H_5K SL3J=ARZ'4BR@[-Q:9VO;N_FWO\
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M3G=O]W\E+AEV516Z**FX(937;36US]M=[0UXEQ+O:T#V
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( /D!R@,!$0 "$0$#$0'_Q  ?   ! P0# 0
M    !P@)! 4&"@$#"P+_Q !S$   !@$" 08$"PX0" D)"0 " P0%!@<!  @1
M"1(3%"$Q%19!> H7-C<X45=A<;:W&"(Y5G5V=X&1F+&TM=8C)"8R,S0U=)66
MH;C!U-7P&24G6')SL]<:0D-$1EEE9K)49X:4EZ71X?%%1U-C@Z.DIL/_Q  <
M 0$  04! 0               0(#!08'! C_Q !F$0 ! P,!! ,'#0D,!0D(
M @,! @,$  41(082,4$346$4<8&1H;'P!Q46(C(S<G-TLK/!T2,T-395=973
MX21"4E-45H.2D[34\25$1932%S=B8V1VM<+#)D-&98*%HL2$HZ3%XO_:  P#
M 0 "$0,1 #\ W^-*4:4HTI1I2C2E&E*UE>4:W)6%:=_V)3:24/C'3]1.;;#_
M !087=<S(9U*A1]G?Y)()OEK4I3Y$A0+'LN.,L6=3%,?1"8SWTQN4.C@0>W?
M1/J0; 6:ZVUS:.]Q6K@5RGHL"'( <BMHCA(=??95E#[BW%*0A#J5-H0V5E*E
M+24?./JQ^J#>K3<VMF['+=MH1$:E3YD<A$MQ<@K+4=EX?=([;;:4N+<:*'7%
MN!(6E#:@Y&OXFQ+AGC&6'CQQV^"D/O<,9ST/=V9X_:UW#V&[(9&-EMGL8X>L
MMOY=0[F[VF?!PKA7LTVP_G5M'^F[E_B:XQ#HEV?J98O;[&I#Y./#LZ#'#A\/
M'A[6I]AFR.#_ .R^SO+&;-;QYX_'P:'36GLSVP_G5M'^F[E_B:YQ#8EG.,>+
M#!GR?N4ASC^0CCW\?>[?:X9U2=C=D?YK[/@#C_H6W9U.G&/C3Q^'.'LSVP_G
M5M'^F[E_B:/$V(\,_J98>_A^Y*'/_P#CCO\ ?QCM[N';PGV&;):#V+;/'OV>
MW#/#/^K<NPZ<\Z9>S3;#A[*]I,?GRY_XFCQ-B7TL,7E[FE#G[OZ!WXX\,]W9
M\.GL-V0X^Q?9WEQLUO'?_P!7X$:CCSI[,]L,Y]E6TG+_ &Y<^7#'[IT\%<8A
ML2SV>+3#W>5I0\,>7/\ R/=W]O\ )J3L;L@-3LML]QY6>WY/_P#C<>SRT]F>
MV'\ZMH_TW<O\31XG1/CP\66+[32BX]W^H\G=GWL?;T]AFR!_^%]GN7^QK=_A
M^!'GI[,]L/YU;1_INY?XFCQ-B7TLL6._'[DH?M\?T#[O#R=GEXZCV&;(\]E]
MG>]ZS6[P8S'SD\-3C7LU>S/;#^=6T?Z;N7^)H\38GV_J98O>QX)0\<]O#_\
M ][MX>7'=V=CV&[(Z?\ LOLZ>LBS6['#G^YSW^0[W-[--L/YU;1_INY?XFN<
M0V)\,\(RP^__ (I1=G?_ /D\.'#V_?\ AT.QNR&<>Q?9[]#6[7/_ /&U/'0#
M'FI[,]L/YU;1_INY?XFN?$R)8[XRP\>/#AX)0XQ[??DCM\G9QQQ[>&>';J/8
M=LB3ILOL[C&?P-;R?$(YQSUP<:9&=*>S3;#^=6T?Z;N7^)HQ#8EGOC+#V_\
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M#UXTU''.?"!QU.G#)H= 3U5>9%'7J)O"^.2-O/:7MK."2X-RG(.G2FC)+/
MSHAF%YR(HTL>,A&+'-$'RYSJQ$EQIS#,R&\F1&?25-/(]RM(4I)(W@%8"D*'
M '(/(8KT2XLB#(=B3&E1Y+"@EYES=WVU%(6 K=)&=T@Z$Z&N&5@>)(K4(&)
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M 1TA*$A@(C+"8S(#L9++P"2.DPMP*2_/'/?GAW</:\O#V^[NXY[?;\NLWH.
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M:WL8P$)<(1DD9.< X.)WT;X;WAOE)5N\]T'&>P9/.L<8(P^R@3N!A0"<!,+
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M3!P!VT]8[W^1KM^C9OZBN/'F$^28Q;^,+3W?^MX_HU/KY93QN]KX:_Z0B<?
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MK&-Y01O$[B FG>9WM_>1O8W=[>&<#7''AGP'3LJQ<<>WC[N-73=K4.-SM_\
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MQ_\ L_2E'I6UE[G4$_BC'_[/TI1Z5M9>YU!/XHQ_^S]*4>E;67N=03^*,?\
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M2Y[2M,O45;$#)F%1!97*89$WASBLJ:S$)39(G2",ZI$X&N+>N8PJVA24-C4
M'C_EKQ_RIGCV>G/'V=M(>_\ *+RF&S#Q'EVWL]/)(LUP![M5ABLUE,Z>V)!9
MKTX!CB" %1ZGSF:>2-DA1#=-)LVOK[7;>A\)9C\2>9JX(SS<L>#CC3C@:\_
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M<^L>&D.2<%MCDB*&8 <5./\ +S^/G5G^9"H#QS/G.(<Z8<E+DK?SF,,\L$$
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M\)CCP:EP/!.7)H2R)_1I%8@"-*1O3B0'. *1ZYMZI[#2K'$D*0DO-7%IMMS
MWTMNL2"X@'CNK+;:B.!*$GB*W'8UQSNZ2WOJZ-44K4C.05(=;"5$'F M0!&.
M)%;[VN$5T>N!=V?@S^#2E-<V/>PQVG>;C2WR=1W4JXGOGSTITFHI1I2C2E&E
M*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2M!K=M[*O<UYP=S
M_*/)-7 #@>U' ?O1_P 56B$Y.O,\S_PFM<F4>J:1?5UW_*"C7UPS[TU\6CYH
MKAR_=J^$KSFK%JY5-&E*D+Y)OZ)3LH\X. _E,.M>VL_%N]?('_,*S%@_#$#X
M[_R+ZO3KTKU+=?,%=@HTI38-LO[-N*\Y^S_Q&*Z4IS^E*TKY[Z)"WGQ6P)I$
MT%1[93V^-S&1QU$>KC%HC6'(V=[6-J<U2,FVB"1*3"$X!G"*()*$;D60%%@S
M@&/H*)ZDVS\B)&?7.O 6_'9>4$O0MT*<;2LA(, G=!4< DG'$DZUFTVQDH"B
MX[DH"N*<9(S_  >%3;\L5RB]R<GG"*/DM/Q.M96MLR3R]D>R;(;).Y)4:6/M
M#,X)#&L$9ED5-*/-.<3@*1*SEA8BP%8++*%@0A\[V"V4@;52;BS/?F,)B,,.
MMF(ME"E*=<6A067F'P0 D8"0DY)R3PKPPHR)*EI6I2=U((W<<SC7(-8YR-?*
M779RBA.XDVXX?5T3S41M4 CN*U:I6V87XG8+'$ZY>?&>82O)V4V8>W>#^I=0
MZ/IUO6.L](1U>]M]LA;ME#:A D37^[Q.Z7NQ;"]WN7N/<Z/H8[&-[NA>_O;^
M<)QNX.4V,B,I"4*4K>22=['(XTP!4,\F]$B;T&6=R"+)JCVR&(6F6NK G//C
M%I"5C2('E0W%&G"+MLLD2@1)01F" 2 O)F<Y"4$/ &-_8]279]R,T\J?>-];
M"'%!+T+=WE-A1 !@$@9/ DD#3).M>SUM9Z+I-]S.YO8RG&=W./<5-ERQG*.W
M-R>,4HA]I^)5G*U=HOTY:GTJR&R4.2=$GC#;&EB$;2&,RR*F$FG&/2D*O*PU
M: 8"R,$@)$$P1G/-@MD[?M4_<FI[\QA,-J,MLQ%L(*B\MY*@OIF'P0 V-T)"
M>)R3H*\<*,B2I:5J4G=2"-TCF2#G*3V=7AY6_D;>4HNKE$FW<&MN*(5A$S*F
M75BECX:V:Y4V 7 FJ>>&N8GC$GETK$<-.*+H,(<HA(<%X.5]/A1D9.2*]OMD
M;?LJNUI@/S7Q.1,4[W8MA928YC!'1]#'8P#TRM[>WLX3C&N9FQ41BV$*4K?"
ML[V--W=QC '74,)WHD+>>7/S8F&H]LO4 3$R/8/S&+1RLZF%ZRVX-R/TV\$]
M9Z''/R+H,%=+V]%S/G-;^/4FV?,0/]W7C?,</8Z:%N[W1[^,=P9W<\LYQSSK
M7M];&=S>WW?<[V,HZLX]Q4T7+(\I+=/)W,] N-.Q"L96=:SG8Z)_!9+7*7(I
M"5#TL+/;A-&(S+HH,DQ0.1K<+<K!K0C"2FP0$C(3<F\_V!V2M^U3ET1/?F,"
M$B(IKN-;""HR%2 OI.FCO@@!E.[NA.,JSG3'BA1422X%J4G<"<;N-=[>SG(/
M57;R.?*171RAT:OYYN&(UC%%-5/$ ;V NMVN4MI"TF5M\N5KQ.X9-+I48<80
M8P) H\HS$(0 -48. >(18BHV]V3M^RS]L:@/S'DS6Y*G3,6PLI+*F$IZ/H6&
M  0ZK>W@HD@8(US$V,B,I 05JW@HG>QRQC& .O6H5VKT2'O/73YMBIM1[9 H
M%DP1QXP\N,6EA6%&H>BVT9H!BMH1.%."1Y&$0B!%X-X9R5D/$&N@K]2;9],5
M;XGWC?3'4Z!TT+=WDME8!'< .[D:C>SC3/.O:;:R&RO?=R$%6,IQPS_ J9KE
MDN4KNOD[4>WY33L0J^6#MA399$@#9+5*G,*$,,*@QC9EG\6)?%,DB49DR["[
MKF5V#,$I>@PGYAN3M!V!V1M^U2KH)\B:P((AEKN-;""KN@R=_I.FCOYQT*=W
M=W>*LDZ8\4*,B27 M2D[@21ND<R<YR#U5=^1\Y1RYN4(@M\2BWHE6<575;((
MBTL1-<MDH;4BU._L[\X*S'8$EELI...*.:R )\HSD0 EC.P8 T0@#!:V\V4@
M;+2;:S ?F/HF,ON.&6ME:DJ:<;0 CH6&  0LYW@HYQ@@<4V,B,M"4*4H*22=
M[&00<:8 J%B&^B/-YLBLN*PM94FV<IM?9TQQA4H31BT0+BD+F_I6H\Y.,VV3
M2 JP)SQ&%",3F%!.P'(R1@QD&>A2?4GL#,.1(3.O!<:C.O)!>A;A6AI2P"!
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M39&0,C.&AII3H-UVXJ940K@Y$4:8TYADR>0&KLR!*Z*!$B:3&<"?"7+<[-F
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MSCEDIQX\&M=E1R6G*%CM4]Y#M*M[+6*P37,*[#(FZ#*#,C$JPJP+KW[#E/\
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M/+PE),YAN0:=ZIOXO,?G2-U_R>9U UL&QOX1?T_U-?A^[,>;ZZW2_FL=[/\
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M D+,RJ<FA4G>$Q(VLXM6*,'JJ<^GIQK$I3O?H"OMQ#QMMLJ9,]<3%'%JODC
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M)QKUTE"'>=0#BX(FQ))W0:QP6)T"4L47D!81J51X$Y(,F#08 # C3 AR,0L
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M#3KK/*][5\ ^;TY5)%RCG[!4?^NFO^SB_P#)W>]W:T;8GW=R^#%\\BL%8O\
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M_&::3<?(1TO;]V5I8*V]=P3;!X"R&!7L3I:4VL*PWZ28><N216S6584@D*F
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M 99(U 4Y8,&B* 88$&1XSD(1BQCLSG42)<J44JDR'GU(!""ZXI92"<D)*B<
MD G%0X\Z]CI7%N;N=W?458SC.,DXS@9K$2J$I4A04K)JV#%*B3P*2E!<=;0&
MEJ"QX-+. ,)&!!, 9C PBQGC@6,9QVXUZ3=[HI)2JX2RD@I(+[A!21@@^VU!
M&AJ[W9+P1W2]@@@CI%8P>6,XK*I97L&G>4.9G$V"3Y;.L8;_  VV)7'J76^A
MZUU;K)8^BZ?JY'2\SAS^A+YW'FXX>>/,EQ-_N62]'Z3=W^B<4C>W<[N]ND9Q
MO'&>&35MMYYG/1.N-[V-[<6I.<9QG!&<9.,]9KMB\#A<)3+440B['&TCB8$Y
M>F9FY,@)5F@+R2 Q06G  )HPE9R7@0L9S@.<X[LZB1+DRE)5)D.OJ0-U"G7%
M+*03G"2HG SKISJ''G72"ZXMPI&$E:BH@9SH22>-8@GH2E4B@A6FJV#$*DQY
M2E.H*CK< TE028$THXL>"," 868$(P"QG&0BQC..W7I5=[HI*DJN$M25 I4D
MON$%)&""-[4$'!%73,ED8,AX@C!'2*P0=,$9QPK*977<$G8T(YG$8_)QM@5
M&\3VV)7$2(*O).5(4V5)8^BP?E.1DW .'/R47SN/-QKSQYLN)O\ <LEZ/TF[
MO]$XI&_NYW=[=(SN[RL9X9-6VWGF<]$ZXWO8WMQ:DYQG&<$9QDXSUFJB*P:'
M09.K20Z,LD92KC@*%B=D;T[>4J/+!T0#CP)P "88 OYP(Q8SG >S&>&HD2Y,
MM2527W7U(!2E3JU+*03D@%1) SKCKJ''G72"ZXMP@8!6HJ(!Y DG K*M>>K=
M-EH'UQ=X_G--7\UC;'I2G-:4I@_*G?0X-[WFSVU\4G'6=V7_ !BLGYSB?3(]
M!VUCKO\ @NX?)'_HU5Y7^OJ.N,5+KR9L&ETY@U^D4\P,^+I:9)5*IOFCYL]E
M.[M V5VJ:+.(EL9$VM=56NQ5VH?74$;<RWA8RE.\C31Y:VHE!+>WNHAZGM(\
MPR_ ,UU8A+;E!3"+LU:5*D)5&+3H4N7$7(Z-)<24!90V7$K4"I2*SUI0XMB0
MF.C]TA;12\82YH2R0Z'&RD1Y"6MX[IWE)RL I&@53 ]T$8E,,O\ M*+38IC(
MEC))1(GXB-5>"EF0APPA1&&DHJJ!%H1B#8*P8$M0Q"B;$:0K">:>@+..,$//
M6QQIZ!%=8*RRMH*;+DKNU93DX*I73/\ 3YY+#S@(P H@"L5,0MN2ZAW=Z0+(
M6$M=  KF UT;71XX%/1H(.F-*FT]#!?1');YK5F?'VI-:3ZIOXNL_G2-_=Y=
M;-L;^$'_ )(Y]+'KT"]<#KI-<"[L_!G\&E*:YL>]ACM.\W&EODZCNI5Q/?/G
MI3H\XQG&<9QC.,XSC.,]V<9[,XS[V<:BE)*10E*IE!2M/5L&)5$'EJ25!<=;
M0&E*"AA-*.+'@C @F ,"$818SC.!8QG';K(F[W122E5PEE)!24E]P@@C!!&]
M@@C0CJKT]V2SH9+Q&,8+BB"#U@G!\-%HT)2MVB916]5L&LD4;PX!8!3*.MK]
MEG"ZY1Y<L-^7 @[JN%V6Y#E5@KF]-E(GY_'H@\,=7FJKK.DJAIAO=FFIJVAM
M=-CZJ*6O*"'L+>Q)71601E,2I7$H"20*#BDXA$@&9@0@EYR#&>&>&G#A2J5-
M0M+(U)"Q+5L&3JDIY2E,H)CC: XA008$TDXHP)&! ,*,"$8!AS@01!P+&>.-
M9%5WNBDE*KA+4E0*5)+[A!!&"""K!!&A!XBO29DH@@R'B",$=(O!!Y8SC'9P
MKKM&@:2NPUE.MZJX+9)L<+7E,)DRCC:_#:"W020;B!O$X$'92A6B0(A*<%<W
M!V4I&1\>C#PQU>:J^M*4J.FVIU8ZHKB'5XSOJO"]Y;(BPH&-$YK0I@HPJEJ=
M"226H/PE %/@PP(A8)#@''FXQC0$@Y!P1J".(/72J5)0U+H%25<BJZ#I5B)0
M0K2*2(ZVEG)E*8T)R<\DP)&!%FDF@ 86,.<9",.!8SQQK(JNUT6E2%3Y:DJ2
M4J27W"%)4,$$%6"""01S%>DS)1!!D/$$$$%Q9!!&"""<$$5T6AM^I"[%#,JM
MVJ('9"F/$K4[$?,HVV/QK20Y#3&+RD UY!PDQ:PQ&E&H"5D.#1)R<CQG( \,
M=7FJYUM2]2TZS.D=JJN8?7K$]K1.+PTQ)B0,B!R7C2%(1+%J9"224H4"1D$I
M<FF!$/)!0"^/-#C&I!(((T(.0>HB@T.1H<Y\-4:*B*8;E:1>@J^$)%J!2G6(
ME:>/-Q2A*K2F@/3*"#0$8&6<0<6 TH8<X$ 8<"QGCCCKWKNUS<0I"Y\M2%I4
MA:5/N%*DJ!"DD%6H()!',&O29DI0(5(>((((+BL$'(((S@@@D53VAM\HZZU+
M0LMVIX%9"N/D*TK(HF4:;'XYJ3KS"#5I* Q>0<),4J-3)S#P%Y"$P9)8A8SD
M&.&/KS5=:XIBIJ@8G2+U;74/K^.O:XYS=V6)L2!D;7)P4(T[<<M6)$))12A2
M:A2)D@S3 B&).045G/-!C&)!*2% X((((X@@Y!'>-2"001H0<@]1%4B&BJ:;
M%R-R;JPA*)P;E2=<A6)H\W$J4BQ(<!0E5)S0$8&4>G/+ :48#.! , $0<XSC
M&=>]=VN;B%-KGRUH6E2%I4^X4J2H$*2H%6"""00>(-7S+E*!2J0\4D$$%Q9!
M!X@C.H-4=G[>:,NM8TN%N5- ;'7,290C9E<QC38_'MB16:6>J3HC%Z<X2<E0
M<46:: O(0C& (A8SD.-8^O/5XKNFJHJ..N<1K"O(A 8P\KU+H[,$48T+*U.+
MBL0I&Q6N6(D1)1!ZE0WH4:,XXP&1F)DI!0LY 6'&)!*2%))!!!!&A!!R"#R(
M.HJ02""#@@@@CB"-0?!5*WT93;2O0NC964)0.3:K3+V]<EC[<2J1K49P%"54
MG. 1@91Z<\LLXHT&<" 8 (@YQG&,Z]Z[K<W$+;<GRUH6E2%H4^X4J2H$*2H%
M6"""00>(J^J7*4%)5(>4E0(4DN+(((P01G!!!P1PQ5OL_;O15U+FMSMNI(!8
M[@R)#T#0MF,9;'Y2VHE)V%"A*B-7ISAIR#CPA-,++R$(C,8%G&<]NL?7GK(:
MTJ2L*:8U<9JB!16NX\O=3GQ:RQ!F1,;:J>%"1$A/<STB$HDDQ:<C;D"4Q0(.
M3!D)$Y>19"4#&%*432E:#6[;V5>YKS@[G^4>2:NC=P,[O =56%<3WSYZUR91
MZII%]77?\H*-?6[/O37Q:/FBN(+]VKX2O.:?/R;34G>;VE:1M0,RFS 5#)U=
M*.<AJ.W[Q98W9J.20U0!]7UQ2<(L27NV"X.";MJ5Q411R8XZO<TLA7$GJFQ
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MWXH#(2YN+C$+L:-Q+[MWEC]6#&J3*E")_BL9B.=S66-"WC/0)L'LY2 )23'
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M0.C$(;:X.B@C(<!9/8>/'M].]V4QYL5(P246G**()!@LDDL!118?UH"RPX
M >_L"$. X][&HJ:[-*4:4HTI1I2C2E-FH'&?3$WC"X9YHMS39D.?(+ =K>V8
ML60Y[LX"8 98N''@, @YX"#G&%*<SI2L:F</C-AQ"4P&:LR.10Z;1UZB4JC[
MB#)B![CDB;E+0]-*T 1 $)*X-RM2D/P 8!]&:+F#"+@+%UEYV.\U(86IMYAQ
M#K3B3A2'&U!:%I/6E0!'>JAQM#K:VG$A3;B%(6D\%(6"E23V$$BM5*P?0HU2
M/,M>7.M-WLY@<.6+#U#/%)-4K/8+HRICC1F%-XI4EG\'PYDI0""00<H82E8B
MBPB4GJ#LC-%U./ZJDI#*$R;0R^\E("W6IBXZ%D#!4&C&?W">) <(SP & -+>
MV+94XI3,Y3:"20AR/TJADYQOI?9!QP]P*PO_ ()FP_Y]KQ][@A_WW:O?\JZ_
MR$G])'_ 5;]A(_*0_P!R/^,H_P""9L/^?:\?>X(?]]VG_*NO\A)_21_P%/82
M/RD/]R/^,J9GDR.2"HWDT03&2Q>6R*V+?GK6GCT@LN3-B!@ BBJ98G<LQB*Q
MEN4N &-L<'1(B<WD:QY>E[DK;FSG+"4R A/C3=IMKINTO0MN,MQ(D=1<;C-K
M4X5.D%/2NNJ"-]24$I1NMH2D*7H2HFM@M%CCV@.*0M3SSH"5NJ2$ (!SNH0"
MHI!.JLK420.&*EMUJ=9NN!=V?@S^#2E-<V/>PRVGX\N-N5+XSCRXSBNX]C.,
M^UG&<9QG'?C.,XSJ5<3WSYZ4Z344HTI1I2C2E&E*02N-N->5>RV^R1P3V<5=
MED6C:,P7.BEM4.:>06XK&MDZ-D5IFE'E(R)CAB\"HEA;B>D#PPJ6+A<199SY
MJ4S)GY(W;*RRZN):GDMO*\UHVT<VM3$YO<"<6IV*H"'B@4-\,KU-;CE9:-TB
MQRQ#+(_'I,P11W6KE+^F8&Z183.R>K>)!&FN>OF<]?7UU &.OT&,^+P=F:N:
MCDK:/<*[:ZP?+6W&R>+0IRKY?3J&63Z+RALH]/6&)$GB#37L1?8 O@#@@2L\
MH=XVX'V9$;#>7F-#1LKJ[*T;<A GC.N=.WEGOX_R\M,?LYX\?UUT.O)/[>75
M,B:Q3R^4$</K""4].HJV3:,HV&UX#!+!E%HE,]@$X@HUQIDEF<N=G"2K8FOB
M:L2,>69A-8&9:[H7)GO<_!GJ^JF.?>\F?MI7J]V"TW6]Q--NLTCM)Q(B4QM6
MPZWJE]E3:NJ:KIY=GA#%FRJ$,1$=1R(E?(PO+\ I#()7(&-@#('GQ9:682T0
M@LGQ\3S./3R4P-.S/E_S/C[U)/N3Y*^E-Q[[9#^;:FX.I VRM _V'$JGGK0S
MUY-)F3#38"7+9-$GR*2#K:Q=%LIF:3MC6YLK),D*%*&3-[BI+PKU(5C&@..&
M1X:8\'>QKW^O'*LEEG)C;:YV\[BI/+"Y:MD^Z*HX#4%G.S<LCK,6E:J];XZD
M:9%"&Q'&>H1B2*U<0B;PM,$4YM&'&,LHT;0D(2F$'QDZ=G#PTQQ[>)YGT[*7
M66;4*\DM"5UM[:Y!8E>QJHDE;DUG+*XE((S/H<LJI$B;H@ZM[MAL6LRU40B1
M83.2%[CSHP.Q*E46N9C0#+"4SKGT]/+4^2D#1\F;332T-2AAL_<!';=:K0L&
MW_FCV6<1E+=KC,[58V6,V$-S6&00ZNU#'*(]&8RTKHX771#,45'6E6B1I7-.
M-<:SV#'5RT\O,\Z>GIXJ>+2E01:AJQBU4PU7)7)ABJ=: IWF4@6RF6/:]U=%
MKV\O<BD#AG*ES=G=X<ES@K-P!.D)&HZJW(T+<G2HR()S2E3TI1I2C2E&E*-*
M5H/[M"3A[JMS P$FB"+<%<P@B"6,01!%8TDS@0<XQG&<9QG&<9QG.,XSQQJX
M,8&B. XD9\.E62#DZ'B>1ZZWX-6ZO4:4HTI1I2C2E&E*:B_-=ATC9<TL2#PI
MWM2L+76M+_84(BJMF)L&%6 TL+3$3)Y#VV1.3&SRR,22*L$<22Z+$/;=(VAT
MC@)!%FZ6KI.[M:.>/4.W7ZL^G@I58+=?$0"R =4;H@C#G(1A#M>N\T(1!SP%
MC!I$+-(-QC.,XP82:84/'SQ9@P9P+,4KCYK&'^Y3NC^]:O3\Q]*4?-8P_P!R
MG=']ZU>GYCZ4H^:QA_N4[H_O6KT_,?2E'S6,/]RG=']ZU>GYCZ4H^:QA_N4[
MH_O6KT_,?2E'S6,/]RG=']ZU>GYCZ4H^:QA_N4[H_O6KT_,?2E'S6,/]RG='
M]ZU>GYCZ4H^:QA_N4[H_O6KT_,?2E'S6,/\ <IW1_>M7I^8^E*/FL8?[E.Z/
M[UJ]/S'TI1\UC#_<IW1_>M7I^8^E*/FL8?[E.Z/[UJ]/S'TI1\UC#_<IW1_>
MM7I^8^E*/FL8?[E.Z/[UJ]/S'TI1\UC#_<IW1_>M7I^8^E*/FL8?[E.Z/[UJ
M]/S'TI1\UC#_ '*=T?WK5Z?F/I2NA5N6>W].-OJK;[>TLEBGB0@(G=?OU(PQ
MN/,#G!#C*YC9R!D,21].9S1.0X>PSF4EI\#$UQ)W4]&E,4I3*2K1?6$,.;Y"
M]DRB=2F1R">V-*$J,UN1/DXEJX2]V&T-QZA8H;HVR)\((M$&U2L6K&V(L#$@
M6KERQ.>L/4I7M*4:4HTI1I2C2E&E*-*4:4IF<86SO:\%= %E:S2RJ-3.CLY5
ME+JO;4\IDU>1]V<%3MZ6DVKXI8FE3BUQ-2M.:J_DL";98-5$B6QEE#0R.;#A
M]E4^?TU^WR=CT].]64_-8P_W*=T?WK5Z?F/J*4?-8P_W*=T?WK5Z?F/I2CYK
M&'^Y3NC^]:O3\Q]*4?-8P_W*=T?WK5Z?F/I2CYK&'^Y3NC^]:O3\Q]*4?-8P
M_P!RG=']ZU>GYCZ4H^:QA_N4[H_O6KT_,?2E'S6,/]RG=']ZU>GYCZ4H^:QA
M_N4[H_O6KT_,?2E'S6,/]RG=']ZU>GYCZ4H^:QA_N4[H_O6KT_,?2E'S6,/]
MRG=']ZU>GYCZ4H^:QA_N4[H_O6KT_,?2E'S6,/\ <IW1_>M7I^8^E*/FL8?[
ME.Z/[UJ]/S'TI1\UC#_<IW1_>M7I^8^E*/FL8?[E.Z/[UJ]/S'TI1\UC#_<I
MW1_>M7I^8^E*/FL8?[E.Z/[UJ]/S'TI5 ZW[8,Y0FL%%4G9P94Y@&C(FMTP1
M[JBMH*,W& 9D,D13(3!.I>6WEB$K11F"QQS.?UI)+0XOT10JU$C;%*LS'L+V
MVHF5H1R2"H)Q(DC6WIG^:2(L(I!+WHA(24ZRA\$EZ%,)XD"X![LYB3DE$96J
MS\DEEE\T.%*>7I2C2E&E*-*4:4HTI1I2C2E4_7$G6\(.M)^O93Y681=.5UO*
M3!N"<JL)N=TV4^#A!*R?S.BP;G!>1<_.,:KZ-SH^EW%]%O\ 1])NJZ/I-W>W
M-_&[O[H*MW.]NZXQ5'2-](&ND1TI07 UO)Z0M@[I6$9WMP*(258W<G&<UP2L
M2*#E28A4F/4(AEEK""3RC#D@SB\'% 5% $(:<9I0@FEA-"#(R\X&'&0YQG13
M;B$H6I"TH<!+:E)4$N!)*5%"B % *!22DD @@ZT2XVM3B$.(4MHA+J$K2I3:
ME)"DAQ()*"I)"@% $I((T.:J=457724H3GB/ 0>2<-*=U=2 HT!@DZCHBC^@
M/" 6<DG="<2=T1F CZ(THSF\PP&<U*0M(25)4D+3OH*DD!:-Y2=Y)(&\G>2I
M.\,C>2H9R"!2E:%%02I*BA6XL)4"4+W4JW5 $[JMU25;IP=U23C!!(H4)TA0
MCU1Y*8@&08&<H- 24#)@PE@P(PP00!R,P8"P8R+'.&((<<1"QC)"%N*"4)4M
M1SA*$E2C@$G  ). "3IH 2=!1:T-I*W%I0D8!4M02D$D) )40!E1 &NI( U-
M=VJ:JHTI1W=^E*QDB:PU2-,!-+8RH&MZQU,!#\U&C5]4/"E5]6"6K%D_JJD0
M4ZCHL#Z$\023.:9G =>Q5NN" LK@3$!O<Z0JBOI#?2)*T;Y*!N[Z 5HWL;R0
M5#(UKQ)N5N64!%PA++N_T83*847.C6&W-P!PE>XLA"]W.ZLA*L$XK)M>.O;1
MI2C2E<9$$/-P(00Y$+FAQG.,<X7#.>:'CWBX8SGACCGAC.>[&=,'73AJ>P9Q
MD^$@=\U!(&,D#)P,\SU#K.AKJ3J$ZL@I2D/)4ICP!,)4)S0'$'%BQQ"84:6(
M19@!8[0B +(<X[LZJ6A;:E(6E2%I.%)6DI4DCB%)(!!'41FH0M#B4K;4E:%
M%*T*"DJ!X%*@2"#R()%=VJ:JHTI72H4IT9!JI6>2E3$ $:>H4&@(()+#CB(P
MTXT02RP!QVB&,6 XQVYSC52$+<4E#:5+6H@)0A)4I1/ )2 22>0 )JE:T-H4
MXXM+:$ J6M:@E"4CBI2E$!(',D@"N[5-54:4HTI1I2C2E&E*-*4:4HTI1I2C
M2E&E*HB7-M4+EK60X(3W-N*2'N#<2K(-7("5^#LH3EJ0!@E"4I;A,HRD,/+
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M!#"W7'F',,])NBV9=6TR6>F8E=ETBI-0O=4T9>88[IXI84]>HVPUNTL 6:"
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MCL,MM7*._<&+=:YDQZ+OSI"UR79DEJ)&8DL0H1+KSR6FR=QIBLM(]KE./;D
M84DK"6RH@[QR23NC(2./M<G2G,2G=#*J*006QH?N'FV[ZI''<3,Z-);S(+!R
M'Z93]TH"0.4#KR.6)"H;&8I.T3E?<8;HNUS&),[>SQY_F3G"Y"[NV(DN"UXA
MFS,W%<F(_:X]BFHM4>Y%0DR5-1XJ+HTB3*=BR)#S\93=L>6^N.^XIQYJ.B0T
MVCIT;] ;"RI)0&E! 6=3A(WP"2"="$')3Q.-,$XIPNX*T+BVJ[0(':]BSI5+
M)O ;#HQPO=VC499CL2AAFMMQF/V)$8@Q%-80$M*9/+C&&'8()+DIK8TM&%3J
MI?%*QP4XNUPX%ZOLF%$C)8CR8ER3;6WGG!T+D: \[%>?=*]7"6 [()/0A:W-
MU"6@E*:6TH==4D#=2I*]S)Q@I22DG74Z:C.,D\M*C_+W%[PY[!+=K2P) WHY
M="[ ;:2L0@4'A#W&7JT-XL_KF'5;2C>A>(TO9Y#%J$KZ>RM]F*E<WJ5<C;1U
M\XR4YQ0JI @6;.;58HTF!,BM*4P_%7<8JNZ9+;R(=ABRWYEQ6IMU+C3USE1F
M&V$I6E+"Q*0RE!2TI/HZ-E*D*2/:J25CVR@0EH**EY"AA3BD@)U&[[;0:&K?
M5<?/MBU8B8Q[@Y6UM[ONAWP[J9L]M154.3E6,.VP$#V>UJVMI>("<QQMU<X)
M.8>O3H9:R/N6ED9DJ]E:T#DB&ZG5371"A2 Y:V5K;LVSMECM+,U"9DB\*%^E
MK61)#KJ$28TA)4PZV'''"E:UH5T8E1W$+RD$AIAH9R-XNGIEDG.2-X'7(R3J
M<4^7&XNRX=R:M5W;.)<XH[:L:OZ?1HYVL8H(0I:9)=CY'6.)224D2!3#JQCX
MVU)*FM3(GU^"WQ)I<"E#B='G4K!,6<==]:H;^ULVW1V4*@Q),]2HZ7))2XS;
MFG77VF"T)$QT+4PL--M%;ZTD(#R#EY'G+:3(6A(&ZE2M,JP=T:@8RHY(. ,G
ME37*7W$[C;=ES?3,4W N0VY]W=.\#26FC74W:\I05)5FU]MM"XRVF5L51Q"N
MG\E58TWKZ-QF0C@+B6PNKT>68MD[&F2)E&9N%JM4%A=P?M: MJQ-RE0E)GPF
M%SIMY7"@E;+L^1+:*8D:4\\UW2@N(;20EIQ2E"M2&TI"BD;P;WBDDI!4I>ZC
M0J)T2"2,Z@9.#QM\;W4V6]QF/L=H[OY#2$7!4]TVQ7=K)8A5[Y:MYX<-R]E5
MK0;(BBJRO'-KL5QB];1R#O4D@U5PMJE]@OMB0]&68DZ\$AUK=LL1MUUV%86K
MD\9UO@RH*GYK4*W%%HB2[FXI],MM<1#\QV0VS*FR%QXK420HA03O(%M()*6P
MOVR4J&5;J?:)4HZ'(R2H)420 DXS5WCTHN=GM9_OJ-6G)'![N[?J@H=!7,<B
M4+1Q:RH'MBIQWC5N'+T[XP228I#W)91]PN$301^8M*>*OSH5@\Y[4'GB%:<8
M@+A-VUZ$RANW;,JN:Y;K\E3T25>)[;T'=+3K4=24)N,!#ZG8[A>:0=T-)2*@
MA!2$D ;K.\5$G13BP1C!P<!:0<C)W2._B0MY]T)ZRC-AP+<:3<MD6;M4LBQ;
M.KMH:*U7P;;;;LV3PF/;>HTV$L$2(E45=VJWIKZ6@(C:$@D3].D\>E+JY-8'
M6.K\)KXV?@&8]%E6HP(D.]1(D.6MR8F3=H,<R';H\LNOJ8>0N!',POPFFFHR
MG64(<+;J-ZX&D;Q"D;J4NI""=[+B 5%PDDX(*4YRD#!( T-3;5/#9A!H>E9Y
MY:$EMV5''B<7B6R5KB3(+KJM,EPK;&)HAL>CK<VQA&K)4&,B%<6[O:5,IR2Z
M2%X.!A5GGLU]B0^7(T-J"R!N-L-+?<]JDJW5N.2'75K>4D@.*26VU*&4--@[
MM>-1!)*4A(Y 9.G+)).3CB>?4*4K7DJFC2E&E*-*4:4HTI1I2C2E&E*Z,IDV
M<X%E.1D6#^LX%DHOCA3S.BZQC/-XX/Z/.2^E_9.9\YSN;V:JWUXQOJQN[F-X
MXW,[VYQ]SO:[O#.N,U3N(SG<3G>W\[HSOXW=_A[K=TWN.-,XKI&VMQO5^E0(
MC.J&F'I>>E('U8XWGX-.3\XO/0FF8,,P887S1CYX^=G/.%QJ#SHW\.N#I$A*
M\+4-]*<;J5X/MDC P#D# QP%4EEE6YO--JZ-16WEM)W%JSE2,CVJCDY4G!.3
MDZFOL*%$ O)0$:4!63"C<EA3E!+R:1@O!!F08!@.3"<$DX*'G'.+P47@&<<P
M/""XX3O%Q9.%)R5J)W59WAG.<*WE;PX'>.<Y- TT!NAML))2HI"$@%2-T(.,
M8RD)2$GBG=3C&!@PB1!!DL*1*$L0"2L@P05@ BT^<Y3E9#@& Y 1D0LD@SCF
ME9SG(,!SG.G2.$[Q<7D%2@=]6=Y?NSG.<J_?'BKGFI#;8& V@#"4X"$XW4'*
M!C'!!)*1P23IBK8^+&=E0*'5S1F')PGI2CL(696\K33G(Y,S%9PA;$:Q<>$?
M624ZHX! RTZ'!ARL92$@XPN]&;D2'4L,N!*]QQ2>DD-QVTI92N2K[J\XVTG&
MXI:$E0*W<)0%.J2#8E.1XS2WWFU*0%H"@U&<DN*6\I$9)#3#;CJ\](E"U!!"
M&MY3A2TE1%:6TM1):@DIL;RB51?1*BBT:8!:@K.!8R6H+"7@)Q><"'CF&8$'
M@(6.'#.=6R^^I25%YTJ0=Y"BXLJ0K^$DE64G0:C!TJXF/'2%I2PRE*QNK2EM
M "TZZ+ 3A0U.A!'&JLDDE,44G3E%)R"0!+)()+ 4446#&,!+**!@(   '&,!
M  . AQC&,8QC5"E*6HK6I2E*)*E*)4I1.I))R22>))R:N)2E"4H0E*$) 2E*
M0$I2D: )2   !H !@5T%-S>2$X!*%&4%0HZXH 4F(+">KZ0)N%1P0 Q@Q1TH
M &=./ C>D $?.YP<9Q4IUU125.N**4=&DJ6HE*,%.XDDZ(W24[HP,$C&#5*6
M6D!02TVD+7TBPE"0%.9"M]0 &\O> 5O'*L@'.17;A,F"/!@4Y 3 F&&X,P47
M@>#3@X":9@6 \[!AH<8"8/&><,.,8%G..S5)6LC!6H@A*2"HX*4ZI3C.,).J
M1P'*J@A .0A((*E A(R%*T4K.,Y4-%'B>=4V6EJRF4H\MK?E&L,,/5I<HTW5
ME1QHL#-.4D='T1YA@PX&88:$0ABQ@0LYSC&=5].]OH<Z9WI&TA+:^D7OH2D$
M)2A6=Y*4@D )( !( JCH&"A;?0M%MQ2E.(Z-&XXI1!4I:<;JU$@%14"20,\*
M%"!K$GR!4B0"2E&X6Y >F3B(+.(QSPJ^8,&2PFDX!@83^&!@YN!8%CAQT0Z\
M%@H<="U)+8*5J"BE6A1D')2K."G@<XQ1;3)3A;;10E0=PI""E*D:AS!& I.,
MA7$8R#2;5RR0IY5*;HC;J]R4VSF)D6M+V^GK!!1PTP)KNS,\;;5J1":Q,1YK
MD<[#2B2A6K5"DHUP4* )&\M)E[M)N,="-GIC$>&+-)DMOQHR6P7+@DICR)$Q
MYMQT292$LI8"PLM-H0I+*$%QU3F%L\6VR''-I(3\F:J]Q8KC$J4MPANVD*D1
MH\)EUMHQ8JU/JD%LMAQU:TJ>6O<:#:H'HT:@8#%"5,>84 8"S#B"C1E@,R')
M@0"& 0@!,R6#(PASC \@!D6,Y#CAADN.(!"%K2%$$A*E)!(S@D @$C)QGADX
MXUG%-MK(4M"%%((!4E*BD*QD D$@'=&<:' SPJW,J]KD#8V2% E/"F=DR5T1
MB<VA:SN82STV<)QJVUV2(G5O5A3'"*$F7I4RQ. 9A!I1><C!J[(:>BO/1'5H
M*V%N,+#,AN0SE*_;AMYAQQAULK3D+:6MM9 4E1T-68SS$MAB6TA81(0A]LOQ
MW8[^%(]J7&9#;;[+@0HI*'4(<0"4J2-15,R.L9D*EV<6,U"O5L[HOBKJX$)<
MA.(<F<T(7%IRM,(+$HPWJC,DJ D&G)B5H%"80\*DZ@LNN2Q,B(89DAUIN0RU
M.8:4OVJF9"267^C"B$=*@;R"I*5J;*5@;BT$T1GX4M;[T533KD=]V"^\A&%)
M>CJ >C](4@K#2SNK"%*0EP+1G?0L"GD<,99*P.T>.PM9D[N ?2N$96G1YZ2J
M1*R5^%R!U;,D*DZS"Y,0J&/G#*5#+Z-<4J3F'$F5Q+A(ARF):>CD*8(W6IK:
M9<9: VIKHG6'@I"V^C6I & 4 Y;4A82H43;;&FQ'X:NEC(D [ST%U<.4VLN)
M>Z5J0P4N(<Z5"'"<E+A3NNI<0I256>!UE':_)=LMQKH\.K^[@?'V12-64Y/C
MHY$-B9E1FFGE)DB-&0@9TB=M0H6M"@0I4P3<EIL'JEARCT72\R[JICIDLQV(
MK!C18D1"F8S#*WER7$I2I;CCBG9#BWG77G'75KW0I>ZVVE'GM5EAVE+_ $*G
MY,B5($J5,F+2]*?>2RB,VI2TMMMMH:CMH9::8:::;0%;J-YQQ2U +++*#D)1
M8"PY&,S(2P! '(S1B,,'G <8QD9A@A&#%PXC&(0A9R+.<YQ1)4<DDG &223@
M  #)Y   #D  -!66"4I&$@)&2<  #*B23@<R223Q)))UK[U%31I2C2E&E*-*
M4:4HTI1I2C2E&E*-*51A;F\&2L@0(PY(RJ$3D*4@.21+A9&MR5G ,='E8,61
MJL@X94"SD1W/SG.=5;RM?;*UQG4Z[ON<ZZ[O+JY5.3UG7CVU2'1]@4#2C4,;
M0>-"B.;40SFU$:-&W*2PDJ$"40R!93HCR@ *.2E9 0:6 (!EB"'&,2'7!O .
M+ 4H+4 M0WE@DA2L'50))"CD@DD'6F3UFJLMO0%&9.*0HRSLX58R:6F) 9G"
MTPLY9C(P@P+.%9Q)1JKCG],&%%C-YX@!SB"I1&"I1&FA)Q[4$)TS^]!('4"0
M.-16 *Y36H+$;*C5 ;#9T]5P_P H1L/@$U06*N8^^1^..V%;@!O,:439EYDC
M0C2LBU808Z"ZX<WH51#4Y&I/2EF7W*N<G?$9N6TRIWI0#W6ZVZZWNHWPXI?1
MM.*4XE)"/:A:DEQ 55A6[O<M[&<_OB">&<\!J<::9.HK-2V)B))"22S-)*<)
M/5PE%MZ,LG"?*,#?T 2PDX!@G* LM#T6,<S*, $W-Z$(08\Y<<))+BR2=XDK
M425;V]DDGCO$JSQWCGC49/6:KP)DQ9N3RTY!9XB2DV3@%%A-$G($8,E/DP(<
M#R22(TT117'HRQ&F" '&1BSFDDD8))&2<$G&3C)QUG R>)P.JHJG\%->' ;O
MX-;\.IB0* QTZFGPX&(0CR8%&-;T?61) F"$8%.(W).!BR+ .=G.=3OKW.CW
MU;@.\$;QW HC!5NYQG&F<9Q2CP4UX+"5X-;\%!3)T0"^II^C"D3&8,2I @Z/
MFX3)S>!B<C&,%%&<!%@"+MTWU\=Y622HG>/NE:%7'B1H3Q/.F3UUA-A3&O*G
M9EUE3@Q"QHL+8G%%;^4S*'%U5*Y?+&>'1-DP%I0K'A;ASE<B:6Q&E+*.)*4K
MPG&!**"<<#T18\J:XF)&"G5;K[Z6BX$H"6&''WW/;J2VG<896M2B02E&!DX%
M2 5' ZB<9_@@D^3-4JV2UA%9G#ZF-(:6V56.P3EVC,;11X>2'6.0DU@'-E"D
MU"W":T*!$KFC"!06Z'I0."Q[*+3 5*!G!#4EF8_'?F@K6Q$=C-O.J=&4.R0[
MW. %+WU*4F,[C<"MU+9)W0!4X4059T20,YUR<XQXC5DD%#0>46)6UA/!S^<7
M4A2A1 Z_(= (ZQ9I.<B=FE/.\P](D)3+)BTL;\\LC(XJU)R-H1.)QR!N)<RT
MS@1<:N4EF++BMAH&<0F3**-Z8XR%-N*C=.I1*6%NM-N.)2 IQ2 %K*"4F0M0
M2I(Q[;W1P-XC^#O<=TD D<\"ED/3IU16251!*@G(BS,E'E@-*R,DT!Q(\@,"
M(.1%'%EFEBSCB6: !@<X$$.<> $I.02#J,@D'!!!&1U@D'K!(JBNKJ"#.1"Z
MDDSDQ4!>,75R>(UQ8"P%K19YGSRHL!10 *<YR<$!980CQ@ <8G>5I[96B=T:
MG1.OM1_T=3IPU-*IP-;,BPJ.*;6Q)A1A68L-+1I2.GPK'TZX:D8"P]+UHP/3
M*Q&Y%TXP](=D0L<=25K5@%2U8W0D%1.-T82 ,Z8&B0. T%,GKX<*Q& S&!7+
M6D4G,.,322N+#B[8_P :/6LRI$B>XL\HRU36I$R/:%(J*1+4!A)Y*9<@)$).
M86+). "#J_)CR;?,?C/@LRXKRVG@EQ*E-O-J*5IZ1M2@5)4""4J.% C.:J4%
M)4I*M%))2H9!P0<$9!(/,'6LQ3-34D& :1M;TIA01!+$F1IB1E!&2F3"" 11
M8<@"-.C2$"P'.,")2IBL\2R"@@\Y6M6=Y:CGCE1.=2K7)UU4H]\D\2:IR>OT
M]":ZQLC*;EM$8T-9@F8S)K.(:!(/+4;D&21&-N1%9RA,R7Q*R-+T0N9Q!G/-
M[-2''!O@+6 X ' %*]N <@+U]L =0%9UUJ<G74Z\>WOU5 0(2^@YB-(#JQZA
M2FYB<D/5U*K)V52@C@#'1'J<J5&5!I?-,.R>=T@A=*/G4[RM?;'VP 5J=0,8
M!ZP-T8!X8&. J*I2&-E2]<ZLSM:?PBM"XN'0-Z0KK[@ 99H%ZSHR0]:6@,)*
M,"J/YYX1E%CP9@0 YQ47'%;N\M:MQ.XG*E'=1K[5.3HG4^U&!J=-:5=-44HT
MI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4J.*W6-PMFSK^:&N"2222)LC4#I^K
M)<ER$,7K^<9:%,[>YJJ<0N! HZ\1,%C1MV+>@IA.:HAH.8V T]:-:@.ZW89+
M5BLVRS[]SB0XCTRYW^]P%ZS;I;>G1;(UN0R6EB7'GFT3&#&4H,H4^F5*"6@T
MZGCFT,5V_P![VLCL6N9,F,PK5L[8K@WI"M%T,==TDW-;P=08DB +S"D)DA!>
M<3&7$BJ4Z7659&LJB2'.J6P5T->G28R'</*)6\K31#-<FBLJR2O"Z!M2,@2C
M)#:CFSM6-:&Y1(RP#<53XG$X9,"G"$CRMWR&EARU-W".Q B[)PH,=L82S(O-
MY7':NC[B@V5/+MS%ZO(#CA(:1&4&<%9*O:Y8IBI#=V<MTE^X3-L)T^2XH%3T
M:R61$EZUL-)*REENYR+'9%=&V$J>7*;+V>C 3@@=N+FABPSU]>K)))VK:V[G
MO!:LU2L)GMZ3Q<-R+:W8)ZL0'D$$=F4\UE1K@FMT8)DB=6V@*5%DFI\F=KF'
M)P2U=6X<-_;:.F.IM*&U6O9FV-AE3[!2V#'-S8DH$EQHI>F*A*;>*D$A6+&Q
MSS4$EVT.3)K&P\E<@.*6XFZ;475WITL/[SI$D6N1&68S;N\S"3,0XR$K"%(J
M7JLK(76#&4AL.=Q+HI8]-L:2;A8'%V<$E9PG$6.<Y0ALAVFRA.U"D^$3L@?X
MU#HFW'C&X+390!?@Y8Z*J(]YM#5JFN"XL='.M&T,ERVF4TPTY>;CW:EF$[:&
M+:A3XA=(P[%F7">ZD=$VF$6BEIA%<BRWEV[0FU6Z078%YV<C(N?<C[[S=EMA
M@K?G-7F1<UH8[MZ.0U*@VZWLKRZZJ:ETJ<?74NT/?ZYBU,V6S1S ]Q$WMB0.
M2YJ?5PLNRM9;#!:PR(PZ!$H,,)B=>+98@D#RVM8 IFYNBSLZ )PK$I4&6V+A
M%N\W:*T2)9&REML41EIZ,W]P;;L4JQA4U@A"0J?=FX+L6,\^>D>>G,,%71A"
M!7(M\NSP=F[S&A[VUUSO\IYR/*<P^X[?HE^*8+X*R4P+0[/9E266 $,LP9#X
M3OE:RN-J5K*X_0;) 8*K?7PU+(XH=8+@F3&.DHEC"ID9;O8KF)N(=V)0ZJI(
MN.5+W]F;7AN4KV96[M+2,(S4J4>N62\096U$FZ7-$:,E<.<FU-+6&84&4B&8
M]I9#JF)26$0VDH;BR'F'D-2&V'WP0%K&S7VRSXFRD6TVMR5**)D!5W>0A3\Z
MX15S!(O#Y:1(BKD.375..RXS,EE;L9R1'CD%3;92>#TM(G9WA35*(LZ(*P/G
M5BVBMB&&4J(QMN3M4(8J[BL>,A[=(7PMF0S54]2.:J88>Y*B%1Y;F<]H4AZY
M:U SERVBB,,7%^%-8=O2;7:;(W<.Z%3YCRW[E*NTZ6+@]$C&0[;FXT.VHN*&
MD+0DLIC.N);:?K VS9N9(DVUB=!?:LB[K>+Z[;^YDP(3*(]KAV>!#-N9F2A&
M:N3DF;<UVU;SB'%)?5):;4Z['"9*:ML,BM1L$DJF9REY4T&G)I]F;AEF-%6V
M5,)#.GN3X5'B=$Q<8?H.2\0=$QN8,X/31Z-C8HL>$\:Y&HS*+U:5W@2H=\M\
M*.C:A:K_ "'@H/WNSP(ELC0MQ 949L6Y*CW)V2RKVJY<SNJ:DI#3B<(NQ7=-
ME[DF6*Y3I+FR:$[/1FRE4>QWNX3+I*FAQ?3)3"E6Q,FUM17A[9$2$8T%8676
MU7V)P,^3R![)BL'D(W]EO6$L$%M [&"HM#*OH(V(PF4 :' "\.$*M\5P.:1I
MPCR)&!9)<OZ(QR+51Y/UA%Y9]S3"BQ53KE$$63LQ<95SLJ<JG7&];4BX7&&7
MVBU]U1&;NENF-2G7"W#[E=#)1+5N.>NWVI4R7)3 MDQ4N-M1;(EKOBM(%ML>
MR:K?:YR8[P>'1N2G+5<H;\1IL.33+;+R5PT;S7V.!VEB+HE\9KB6M=T-4&M/
M%L3MT"00;/9U+XPZQYG86IR+<339;'29B[(I@Q'$E^ XC&XLW($IC8I-PV8C
MUSLIFN-3+O ?V=?N=D]8K8P5*3:[9 FL2Y$I]E3(3 EJM[#EODI)[IGS)SSJ
MP\A)>,FU7SN!MV%9[@QM(Q:[YZ_W1_=2;K=;A"?B1XD=X/*,^&BY/M7"*H),
M6WP8+++9:<5T(SXJC74;HF>!QEW,>@[AJ[;XV[*CC3%,,J:GV:/I0NC6(Q3D
MMJ23D,#7(7-:F"6J?$TQ2H%^3DO0A+Q:MI6 RN.)D<1CLG=G9C"$I"+C?;_(
ME+++P2V"^NV^NC;C+:RI$9=O<=9W7"HG+#9E_IFY'<,@R1M;:&H<A:E%=ML&
MST:&CIV"5D,(N@M3K3SB %R6[BAETJ0$@+CM<AH(9434G4P\R%2-\>)/)9>T
MJ6U.VK/&-ZD+DM5=.!.(9:A.D(-3-C6J ,1)K2A0Y2\$N"=:WMK<#<;\^I%P
M%QB1H\.';WT/+>;[CC166V]TK *%N*2MY]! 4E]QW?\ ;[U;-L/;A;=GV$KM
MYMLR5(FS;A'6PAASNR3,>=<WDHRE:6TJ0PPX"4JCM-=']S"13B-:G6WT:4HT
MI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2F[;MF^TG7;5=+72V'D5FN$
M$=T48#&ER9LE(QJ0@)=BXBY+#TJ5!,#&(;F")K3U28M-(Q-AV5!',Z4&5LBH
M:+O;UW#H^XT26U/=,E2V<).4=.A(4I4?I CITA*BIG?&Z<X-QK=#B"K&[O#.
M>'82.:<XR.8R*B04;;UGC].;#KS:_;=>[;5LNVOP&:U0D:CVN=673419K<F=
MJ21'!02$V0+4,MM"24BV6='.F+E5@1ZOY,=(FQZ/=G1$MW<79(C1XLJ\0I5V
M2Q>),>:5AR-$GOK@QX32I/1!I*F(;-Q7#=P68KTID-+;#:%)]/29"4J=2IP!
MQ063E*5DI"1O$8]JD*(TW4D@)(Y=%CT3:AU?GIF[;M.&>OG*Y;?NBA:0501C
MN&L8JA,@L1K^)4[==$H)*SJ8BTVHX^/ENQF01>8M2&C9'(34[B)F=>>@TB7*
M$)0*[I'<E)@0;?<KBF2[ F/K[I?E/S[?<E,N)?<A([F@/-O1W#<66@I'2(PJ
MJDN)WLEQ)4$(0MP**%G!*M]#A!!* $H*2G*P,:CA4!VU;AWJY4#/)8',FMW1
M2?;.FJ28&,RRSDE$T]7T%JYREX(IN8DEN)5S"]-\Z:;+9YJT*(7()O;QZY)X
M64/\0?TZF.QZ[VMN M;,EA;:F;NJ<P'$PS<Y\J3-0QT]H9@E+C:HSD-<=:9#
M4> $J+:6GV5!UTK81D$'1W>&\$=(M14 2T$$'*2DIU"4<@"-7@[_ &+V-/)-
M5T8;*7,M*O$$6LB3""*OG*WVIUM0DMA:89#'^!*+2KBNV5,O:7"0NK78EHH9
M>PQ]Q1=&UE1US,RN78+9EZ)&9F/+N'<4M;\1G24B"M$(EUR1(:DIA2Y3A2XA
MI"XL-<=QU"O;EU'M$V6"E(42O<42E.0K<(0<DJ"@A2C@@92D@D=8IE9.SNXY
MWM\ER6RH!-I)9L?VE[/=MU2!D2E8>IBT_?TQDAM^WV)&>Y"*3R"HWNU\-[9+
M5&?#L3(JUV2-"X&#%@U>PF_0(UT8,23':ANWR_7:=T02E+\5M0:@0'5! ):G
M-P=]; ^YOF:A3B?<[M[ID!P$%(07G7%[NF4@@(0=."@G)' [P)'4IIM 3*Q-
MP,)!85$62OL5!ORDMF3S<&[A)S"4&W.L,S2<;=89'9!A]&>]0QS'%:<2GP1$
MV&-#'9"1YE$I1M\O,:USEX_7-B+:Y/<MRB(B*V:9AQK6@_NA=UF=S1[M(=:Z
M+#<A/37!0DJ6''(A;884J.%)11OA+9PM.[T( ;'NND5@+)&[@$$J(42#NX )
M ("O;Q:LN2PKM?Y<R0R<O%902KZ'@KN1"5.$<MG=?63N'%,-UD8@1A3DVKU"
M\-<5-6#=(D+6L0O3W''QX8X\H.?%")/GP6&; BV]IAR1&;F29MSDH,A.\Q&D
MQ+5W/97I/M%I"3+G3%-*6%-M.M(==2&@I54-*2E(!*0HJ6H%7!)2WALJ&"/=
MG(SD9 )P!FD D%!;ADIS=,]L]526D(M--U2F/5I7PD[?'C:0J&P]JLFIB>[@
M'.")G(QJA9::RQ([+00(DLM<L6-K*ZO3,BDLE=TA.4:N=K5OQ[O-9N+L>RAZ
M9*RIWURGQ;TS<(UK1*4@.2,P]Z&J23NI"W6VW%,LMJ-S?0='5A9#0*E YWU)
M<"TMYQ[;VOM<Y  X*( %)PEVK;G4%-PLV21F;!BE?V\AH8ZO,,RZTY&MV>UJ
MKM!Y1R-X@B.:Q)WGY%MW0JK)=.(\FD@7.05/ X<I<D+JV"D4<6^HWJT+GO\
M1/1^GDP%W(2RM,)M%]EIA-EIN2J/(;C&#;TS$QW2SNMS9+Z4%"PTZFH.M;ZL
M$94DN;Q.Z.E5NY 44G=W4;P22DA*E*P1HH.+HO:%*9C*:@8+S@#R12<29MQ%
ML)*Q>&Y+&((R2.T9S7['5U>'P)@F$K96UMC<2BLXL<%='OTE:80^SU"WE'EG
ML2$I-BKC?66&)[EODMFX2'+7"5,0M3TEUJ''E.398DNQV'%K>??C1.Z@TRN0
MU&6L@AQ1-+CR4I66U#?46T;P.5$(2HJ5O$ Y)*4[P W@D]N;WOUKNPYO-;C
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g307489g24s24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g24s24.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2J&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *FJ^$(6#A"24T$!       %QP!6@ #&R5'' (   *  !P"!0 #5V5B #
MA"24T$)0      $'=20>Z\EP^<=O6Y=853JF<X0DE-!#H      .4    0
M   0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT96
M5N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M  "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8F
MIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M   0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #
MA"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M  %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M!#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F
M]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M$       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W
M5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'
M0               !";&0@56YT1B-2;'0               !2<VQT56YT1B
M-0>&Q =WC$H         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M  4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"
M!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&
M-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M      #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;V
MYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ %WC$
MH  0 " 7>,2@ !  (X0DE-!"8       X             /X   #A"24T$#0
M      !    !XX0DE-!!D       0    >.$))30/S       )
M ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&
M9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M$ -0    $ +0    8       $X0DE- _@      '   /________________
M____________\#Z     #_____________________________ ^@     __
M___________________________P/H     /________________________
M____\#Z   .$))300(       0     0   D    )      #A"24T$'@
M  !      X0DE-!!H      S4    &              10   &(@
M !                          $             !B(   10
M            $                         $     $       !N=6QL
M   @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;V
MYG          !,969T;&]N9P          0G1O;6QO;F<   10     %)G:'
M1L;VYG   &(@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V
M4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M    !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V
M)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&
MQO;F<          $)T;VUL;VYG   $4     !29VAT;&]N9P  !B(    #=7
M)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M$       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O;
M$    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15
M-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6
MT    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;V
MYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&
M]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M "/_         X0DE-!!$       $! #A"24T$%       !     ,X0DE-!
MP     '_L    !    H    '$   '@  #3X   ']\ &  !_]C_X@Q824-#7U
M!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q
M!A8W-P35-&5     !)14,@<U)'0@               0  ]M8  0    #3+4
MA0("
M       !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W
M!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !
M1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U
M   "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#
M $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6
M=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M     2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.3
M8V+3(N,0
M              6%E:(        /-1  $    !%LQ865H@
M       %A96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-
MI865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W
M=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                                        !D97
M-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&
M%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D
M="(&-O;&]U<B!S<&%C92 M('-21T(                             9&
M5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S
M8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&
MEO;B!I;B!)14,V,3DV-BTR+C$                                  '
M9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $
MP)5@!0    5Q_G;65A<P         !                         H\
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M]M____[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)"
MP)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MRIVD^/;I];I[76O>WI!(;T[>WV,!.OQ?^Q6_)UJ?8ELIH?8QL]W@66VX[_\
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M)!BLEEDHWLT?)MGK>DOW@WV2OD!Z(FSV^V22A71YUMA,PGX[V/<.*$9#*)"
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MP83,Z#T);C:#*5'F28;(8$EY"Y"E-K>;0V'6XZV6<HWD(2I2RJV< G)S6TQ
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M_!/5Y3X:?P N7Z9:OX]BL$_;[_;W]_7KV>_:]^[M_<Z_%:OLK (Y:9\G?ID
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M_3@D:D8&.0&-!RU(UZH5R/D/HKL[^# ^\5T/^PY]]:DYK\^]I/PBO_ZZNO\
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M/M-ND+]^]N25_P#]QTC_ ''4]N+;_P!]V/BNV?5:>TUX/?>9_P"-KM]=J7/
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M6U0VK\"*6M^/$2O*'9,PL1&2P4(D,*&U(&O<2!KG0G7JZQRUZ^KGB">>#U9
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M)VC;97T3ER YC!P=W7'/4:Z]>O5ISY\Z:GNYCR'.//R_XR15WYURAWE$%Y3
M-<<I(+O1%["..LX:[>7;Z:AC^.F=G;'-1HWKB*21K&7>E!)?8D9"*&--I;<!
M$<A#E-XSE,@D>!8$^:QC3.#G.,:^3/;ST.NA(\A9UZB/^,Y\QR/4U:\YSRY
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M;$![]HK@NT>L7B.#EH[:KIWR36;N6ZB:R*J>66"B>>.>-[XY6O7D2DJ0I2%
MI4E12I)&"E23@@@Z@@@@CJ-;T"% *204J ((.001D$'K!&H-;RN-349=V>[/
MPX^>C8/]&3>M2.2O)\XI4FJBE*4I2E*4I2E*4I2E*4I2E*4I2E<-(HY'I>#)
MQF6 0TGC9MHHP,Q^0C&1H(68K=/*LR8HD@Y8OVJO2WE&[I!5+/I;QL+]+4I7
M'0R"PG7$?:1/7L/B\$BS#-=1C&X< %1D"S4<JY+.5&H@*T9#T%'"V62R^:3?
M')97+)12^6=[WNI554I2E*4I2E*4I2E*4I2E*4I49>'_ +@P+\>-U_7?L6I/
M/S)] I4FJBE*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME>.F0O>Y!_>]^M[OG=[WOWWO=PI>][_+7V!RKP8?:I_,1^Z*V=*FE*5IEW7^
M2]*E/,>45ZXW&"][\:>/%[WZWOHS4M[WOWWO[ 8_VWKY-N?WRN'Z=+_B'*]M
M@_<4/]%C_P"4BKYU@UE5&7=GNS\./GHV#_1DWK4CDKR?.*5)JHI2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*C+P_]P8%[_LXW7]=
M^Q:D\_,GT"E2:J*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*5XZ1#]?O_V:[_G"E?8%>##[5'YB/W14U?!SE%A?+C7UV;.7*DR4:VV"
M#&H#'XC))G!#)W4<W%#-G1YI/Y5"80.=ZR>.TIVZDDJE0$+%A@!_(79<78=B
M2:4NT* NTR-XM;J7(JUH?<>;9?0B6PI<5Q4=I]]0E)!CI;::<<=6XEM*%[^Z
M;&V**9;92%DD.I!;2A3B"IEU(>0''&FP62>*5+<0E"4%96G=R+S>$C![/$IZ
M<=3OE#NWE*$)VG=XK+=BN]0R>!BUV*D61/CH'/-*<H>3L.,';9J#?9J 6,QL
MU'DL(PX>,7C<VS50Q-GG(J^EICVR#;%IX'%:BHE,O+R'2A3[$RU6MY#?VW <
MX;J'#Q0%)*"#V7)+PX"G)<F6A0<W%ON,NH204[R6G&)TYM2OM2ZG?0I X>\#
MO#&+C+NO\E_R5LM5B>8\H]->N-Q?^]IX\?,9J7\P8_7R;=/OE<?TZ7_$.5[;
M!^XH?Z+'_P E%7SK!K*J,N[/=GX<?/1L'^C)O6I')7D^<4J3512E*4I2E*4I
M2E*5TSOLB;?N]=5\T]6Q_6&ZMM:X O>+T-,O D#V/,8@(=EW&U]TLERKD;'C
M(YDN279#V#19\JCFZ4:L6;?-7))LCAA[[X*K9;9NS\UV9;X,MU-X?;2Y)B,/
MN);$*WJ" MUM:@@*4I02#@%2B!E1S=6UMM;*RMM"R'2 5(2H@;B-,D$X[JR.
M> %VCLW9O!3?$DV3L6=[!D(W=D['#3\XET@EAH>P;:IUV];L614\0?OFK-N\
M=.7:+5!=-!)TY7<)X8JK*9Y:IX3H4.'M);6HD2-%:7;HREMQV&F&UJ,Z6DJ4
MAM*4J44I2DJ()*0 3@"L:X(0B0@(2E(*$Y2E(2/ME:X '/YJZAD=YB<N59 "
M25Y3<C54E3 Q-1-3=^S,TU$\WJ&.>&>&4GOCGAGC>^.6.5KXY8WO:]KVO7N;
MEAL?!619K5D-J(/B^(#G=.N0SY_+5R6&<'["UR/_ ):/HKMM_9&^U=H:IX^\
M?"FKMD3W6Q,IN,NP)D8#,)##GQ%BG"2;C!D^=QTB.<.VF#C#!?!LX441Q6PQ
M5MA;/&V5O$/!1"AS;I=$3(D:6A$!"D(E,-2$H49" 5)2ZA82HC3( .-,XJGM
MB$+=<"T)6 WD!20H [PU&0:AU]CC[SW9M;D!R$&;1W#M/9(T7IT,_&#Y]L&6
MS%B.?*34<W4>,&DB+D6[-VHWSS0S<MTTULD<LDLL[X7OC>]\+%MMT*V6I<.!
M"B+7.<2M<6*PPI:1'40E1:0@J2#K@DC.#U5W7-MM#;10A""5D'=2$YP.O %8
MM?"7\I>3<1Y\\KXS$^1F]XQ&PFY)0P#1^/;>V %""&**J5D60P4-D+9@P:)6
MO>R39JW213M>]L<+5N>R%EL[^S%D>?M5M>=<@,K<==@QG'%K.<J6M;2E*4>L
MDDGKK+B,M*C,E33:B4#)*$DG4\R1DUV'MS[2V</^QWP^TV&QIVRV<IHW0Q)3
M8S27R!M/,R)/<VNF!%_G+T2&$@R>D&#MTR>NKD;KNVCEPV744164PR\MM\*&
MOPJ.0E1(RH8N-S0(BF&C&"46^6M"0P4<()0M*5)&[A*@%#! -5J$(-R*"E)1
MQ'!NE(W<!"L#=QC ZABL%'@?>37)&=^$@XQQ.<<@]WS*+&#L[3+1J5[7GDAC
MY1-MJ>>O6R9$,7/O!SW!N];-G:&#ELKBDZ;H.$[8JI)YX^C[>6>TQMD[P_'M
M=NCO-MQ2V\Q"C-.H*IT5)W7&VDK3E*BDX(RDD'0FK":TTF,ZI+3:2 G!2A((
M]VGD0,BI6?9"O(#?&KN<4,CFLMV[=UU'U^-\#++@H)LF91$,N5<S[:S5P36%
MQ\T/9*D'#9DS;KO%$,G"J#1JEFIE@@ECA2>"RUVR9L[)=F6^#+=%VD(#DF)'
M?<"!%A$("W6UJ"05*(2#@$D@9)KHMK;:V5E;:%D.D J0E1 W$:9()QW<AYS6
M6O['GV3L7:7":=2'9L^FNQ3[;D9-!3<Y.Y2<EQA 6W@6KW+<:B3D#\@]28(.
M7CMPBSP7Q;I+NG*N">*BZN66D^%.)$A;11FH<6/$:5:8ZRW&9;8;*S*F)*RA
MI*$E1"4@J(R0D G %8EQ0E$@!"4I'#2<) 2,[RNH =E9WJ\UK I2E*4I2E*4
MI2E1EX?^X,"_'C=?UW[%J3S\R?0*5)JHI2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I7CI$/U^^_9KO^<*5]@5X,G[5'YB/E2#61?P;>
MH9=/]J/)1$([*YT/CHB>Q7;L,#:9V1LT ZTM.]+[08S:YTKKLP!*B"<A',7D
M2B @.78S(B?*-RT2P*/P>09]KVT4MEB*&WG6F%.+8=B/.3(T58FL38JF VF0
MAQ*TMK4EUY2T*92V@H>*$N;Z;:ULN+>WFT+< 2XEY"&7'AP%L/AW>X2DJ!4E
M)0@!25E2@IO>4C=-UO"1:I#:>U/Q^C.L=<3#5.EWL]W.6'QS8^O-KP2?&]D9
M M1-Y7)2B^Y"#>1'@V,<3A@0%G'8;&HF,N.(HW>'Y$Y-.&F+L[*7+E3W),AF
M5,2Q#2IR-(BOL(C[\LM-I$-);;7Q"\M?$><=7O).ZVVE /9=&DLLQT--.-,%
MQ]0#S3S;BGBECB*/'(4L;O#2DH0A P0=Y941B&R[K_)?\E;75.GF/*/37KC<
M7_O:>/'S&:E_,&/U\FW3[Y7'].E_Q#E>VP?N*'^BQ_\ )15\ZP:RJC+NSW9^
M''ST;!_HR;UJ1R5Y/G%*DU44I2E*4I2E*4I2E='3[)B^_JU)^U,@_P!<.]:^
MB_!#^#D[]=R/X&W5>VO^I<_O3^XBLG?V.=_L^N0OS\;!^I_6E:?X5_PHM7ZL
MB_Q\RL6Y?=*/[M/[RJZ749_UCC__ +[%?S]O7T Y_4.?W2OW#5XKD?(?17<K
M^R=?O;^-WSW&OS#*UX'X'OOM=OU<W_$MU26K^M=_NQ^\*A+]C$_?&\D_F3!_
MGV,K8?##]ZK1^L'?X95=]U_JVOSU?NUB0\*C_M%>87;U_P#3?+/_ (J/9^YW
M5O&Q7X*6']7L_P#^JS(?W*S^8/2:[+6\O_5HPGS <>/KQUG7DEM_^KKGZSNO
M_P ;,JK;^^A_O7/W%5U]/ I?[3_BE^,&P?J=V)7I_A#_  .O7]W$_P#D(E64
M[[D>\B?WTU+_ .R4/O\ J#?M8->_6+MZJ'P1_@S*_7$G^$@]?KCSUT6O^H7_
M 'ROW$=?KCSUF2^QK/O#M@?MFYU]7>IZT/PN?A+%_4\;^+G5A7/[I3_=)_>7
M783KRVJZE*4I2E*4I2E*5&3A_P"X*"_'?=??W^[?L6I//S)] IY:DW44I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4KQTB'Z_?\ [-=_
MSA2OL <AU=W97@R?M4?F(_<%2_X'FV(7D CF3=7P9KZNWIYJ/)')V @Q>1-]
M+3Y:*#]I/==$A$DQUBN?LR1F_4BQ!>Q]5_C+7K2(9GE\*>^(*X!W1J),+*DH
M8<?0V9L<.JBB0E;72@WO%CW*G.($\%*GN&#86Y24ODJ)W>$_IO.(0I0CO%"7
M2TI*^$58#F%)3N$\0AK?J3OA''>H)5KG1>QM5@])A1LJFFTL@/M-E).?=JP1
MS"='RD."VFYDLDE+J+;(@DEE$NB9.'.'HHC=@U821>.M&1D><D=;L\);4B;&
ME.37%M,QN)TQ+:$\</S6EN10VTT'8[[;33J70E:=XJ;#I4A2&\FZ<%3<=UE+
M"$K6]NI84XH[A1'6E+W$6LH=:4M:"C>2K=PHH 4E:\2^7=?Y+_DK:JJ$\QY1
MZ:]<;B_][3QX^8S4OY@Q^ODVZ??*X_ITO^(<KVV#]Q0_T6/_ )**OG6#6549
M=V>[/PX^>C8/]&3>M2.2O)\XIV>O4:DU44I2E*4I2E*4I2E=7SPV/@O^7O-?
ME-K[:>@(;&I%#H_H"+P F],SJ,QATE)1>Q=IR)XU38&GS9TLA@+E(=7%VFG=
MNHHNJCCG=1NKCC[%X/=L;'L[9I4.YOO-2';F])0EN.\ZDLKBPVDJ*VTJ2#OL
MK&Z3G !Y$5:P93+#2TN*()<*@ DG3=2.8':#4X/ X\+M]\.>(VWM1[UCP8!-
MY?M672L&Q$28-)&JX8OKN%1UBLL1$.7#1LKF4"$$LFZRF*J::>"V>-DU<,KZ
M[M[M#;+_ 'R!.MKCCD=B$PPXIQIQI0<;ER75 )<"5$!#B#D#!)(ZJQYKS;SR
M7&R2D(2#D$8(42=#CF"*ZUH7P _A*F1D2]<:P@F*#0FP=+96VW \KXHMW22J
ME[8XEKY97MAAE>V-K7O>_9:U[WKUI?A.V3+:TB5))*%)']"DC)*2!_Y>FM6A
MN,7!&^KD?^A7T5V/_#?<)>0/-[3.F(9Q\CH61GH9LXE)SS<U)PL71;B',5?B
MDED7)IRU1<JW>.$L+H(Y9*XXWNI?'Q+7O7E'@[VBMFSEPN$BZ.N--R(:&6BV
MRX\2L/I600VE1 W0=2,=55D!]MAQ:G"0%(W1@$Z[P/5Y*C)X$#P;'*_A#N3=
M$RY!Q&.1P#--9"XR <!9M')0LX+M94R*K(K-@KUTLV2Q9H*9V76QQ3RSM9.U
M[Y7M:K?PB;767:.!;V+6\ZZY'EK>=#D=UD!"F5(!!<2D$[Q P->NNV?*9?0V
M&U$E*B3E)&A&.NL?G.[P*_/O>_,3D5N+7.O(:3@NQ=GGY/%G[[9L-%/'8@@H
MGDV6<#7Q)%VR5SMCEXR#A/!7#_>MUO6S[->$+9JV6&U0)<E],F)#;9>2F)(6
ME*TYR M*"E0&>8..RLF-.CML-H6I04E." E1U\H%9JMH\*]^RCP*8SA4'CP9
M;?S;4NH(DM'E9,&0#8FXAM"$R@XA:3JN<0V23<.$(+(N+.?).54\$$<LE5<,
M;^?PMH;8SX0E[0N.N"V*FSWPZ&7"YPY$*0PV>"!Q-7'$@C=R 22-*P$/MB<7
MR3P^(M6<'.%)4!ISYD5B,\&?X'+G7QHYQ:%WCMJ Q$/KR!%Y<[DA(;LB(&WK
M5 OKJ81UCD@+&D5WKNZA0PQ1SQ02SNFFIFMGT33SRMO&U^WNSEXV<N=MA2'U
MRI*(X:2N*^VDEN7'>5E:T!*?<-J(R1DX',UFRIL=UAQM"E%2@G *5 :*2>9'
M8#4A_#1^"VYA\T>647VQH2%QF0PH7HZ(0=X^,SN,1EUA(1$QV&8?-\1YE\V=
MJ(8,9$+4P=8IW04S543PROFBI:U5X/\ ;.Q;/61^%<GWFY#EQ?DI2W'>=3PE
MQXK:3O-H4D$J:7D9S@ GG75!E,L-*2XHA2G"H ))TW4CF!V@Z5D>\"SQ$W?P
MMXJ2[56_ 0F/3(ONZ4S=DR#2(3)FJD?*P^ !V;G-^&<.6J:V;X 23R:YJ673
MP234RQM@LG>^J^$"^V[:&],3;8XXXPW;F8RE.-+:(=1(E.* 2X$J("74'>Q@
MDD#D:QISR'W@MLDI"$IR01J"HG0^6LO%:+6'2E*4I2E*4I2E*C+P_P#<&!?C
MQNOZ[]BU)Y^9/H%*DU44I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4KQTB'Z_?\ [-=_SA2OL <AU]_;7@R?M4?F(_<%3=X#$SD-W4*G
M,+VC$-?;!=@]L:P@RA1Y.D)&&E&R-%[, 1V>M&T-UY/'#P%'CS@<R=M6C-Z7
M?%R8@=@&4%.R14927U"'H2V'HSLB.%Q)+X2(_#6U&G1G'&"7Y$<!;C8402H(
M2A*U;^^$H78VY7#?2XEU+;FZ\VDD/90IV-(;2YEIITD)44Y !62I.$[I4I,A
MO",# L7U'Q^C=XOKR,[ ,;'WGLC9_M0#-J1_5AV4R2,Z,C64CB4/V?J35V<#
MN;;PC$@<AD64D$5&&UWKR/81<$2%Q43@;/*<=E7!WBR'8Z8\&/%Z6N([*0TT
M[/<X;ST69*X^X7]U#SH;>4@)#G&<2MY>3=-Q+45 #:7"Y*==X*'VVE*6F*G>
M0V_'8+>]P\J;;WVTJR4<-"DM)Q(7[K_)>MJJG',>4>FO7&XO_>T\>/F,U+^8
M,?KY-NGWRN/Z=+_B'*]M@_<4/]%C_P"2BKYU@UE5&7=GNS\./GHV#_1DWK4C
MDKR?.*5)JHI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*C+P_]P8%^/&Z_KOV+4GGYD^@4]?7-2:J*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*5XZ1#]?O_ -FN_P"<*5]@#D.KN[*\&3]J
MC\Q'[@J>?@R,7JW+J-LQV$I=/B6J^1@IL&@QMG$IO)E27'W9;+&+0V>$/&9:
M[E,BNMZ* SQTDZ;1DDY;D'+ DWP5'.J':0@6EPJX02F5;E%;Z%.L-!%PC*XK
MS"<*D--XWW& 4EU *0I!PH6EI"C,2$[Y4IJ2E*6U!#BR8SP"$.$$-*7JE+N#
MPR0K=4,I.[YVQ261BVL_9/JSEUK6SS*6^97Y3<@P.],3'F]H[Y>T)L$U9K6\
M:NQ\LE<_=S<QZ6L[#^2LQ]'J>=Q8W67>D\*5:9.[P0KQ7 7!W,\7'&WY<GB;
MV#P\;FYA>=[>TXW!"D%K?;GMD\3 FO)>SC<W@UNQV C&F^/=[V4XW0G7'KEW
M7^2_Y*OZKT\QY1Z:]+;0P3PK"FC=,J0[8/ YM$<]4:[SBK:1:ZWNZD#>.91
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MFG,"8[(BFG2S&S)L&%W#PLDT30?MWV6N<\%+I163%(FD,+.9.,8SDY&O5@)
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M'#LM0<:<6(_"@+<R'MXA;B6$J7[D!(4E9.JD^XRI.!D[H*M1RW;0&=,<<HW
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MZ**RGE,;*)J8\J$U)CJ8"G(V4%M#T4I9?82<!7 <W%<(J2-PE*?M"1CECBI
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M"KH/"Y[*HL+<E%]L[K9K$G \&68-%GZS1BR:JO%$<G"C=FU0S4NDW1QP]_\
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ME^BM::7QT]?7FEQFHO9%E.;%?1T.W5$_3OHNT4NRLK[;W);D-9]8;Y^Y\GZ
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M%^AZ+*X).F#QB\<#GD<]O//GJ!CJ'R8Y>NE2)0BT8:J@%VL< MEHH.7#Q99
M0/15C0AT@R:NA8!1-OCF&'.6HT<V78CKMFRR#!DBHEDFU0Q3BIK@)IJO6&R%
M0Z^Q-<0*>KQY?-T 6FD/CTI5!NE,DLU'(=0X.?9C%U,VZ&6:S*Z"F>2*6665
M[IX7Q4K62ZMUE-#0"1S'74$EDABBN"\6/26(Q\Z:C2Z:^+E-8 4*#W3X,JFY
MPP<8*#EVV>*^&*N-[*8VRLI5=TI2E*4I2E*C+P_]P8%^/&Z_KOV+4GGYD^@4
MJ3512E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2O'LFD
M=-P^92V)24:Z#2.+R<_'3XA\ED@]%&@I9V-*CG:.=K9I.63YLNV73RM;+!5+
M/&]K7M7UZTXAYIMYI06VZVAQM8U"T+2%(4#UA22".XUX2I"FE%M8W5MX;6D\
MTK0-U23WA0(/DKAFA!^PQ=X,7SQG@_:J,7V+1RLWQ>LE<L,U6;O%'/"SAJIF
MFGDHW6MFCGEAAEEA>^.-[<BE*L9 ."%#(!PH<B,\B,G!&M<02.1(\E?N3-F3
M7H_TR7*%_1(QH%%>E"#LAZ,#,,<L6 @?YVLKYD,98YYXM&#;R;5MCGE9%+"V
M676$H0C>W$)1OJ*U[J0G>6K[9:L ;RE8&5').-37)2E*(*B3@!(R<X Y =@'
M9R'57'I(K.54V[=)5=PNI@B@@BGDJLLLKE;!)))+"V6:BJF>6.":>&.66>>5
ML<;7O>UJY$@ DD  9).@ ',D]0%0GF/*/37KK\?096,Z%TC&SK)8:<CVH=:@
MS(YSCXCA@5$PP*P(LE\/]U9J[;K(*X_[N:>5O57R7<%H=GSG$*"D.3)*T*')
M2%O+4E0[B""*]OB)4B)%0H$*1'92H'((4EI(((.H((QKK5WJPZR*C+NSW9^'
M'ST;!_HR;UJ1R5Y/G%*DU44I2E*4I2E*4I2E*4J%>V.,1?;/)J.;+?R^?0Z#
M!M"2/7[A[K#9DDUS*GLE+; CT@09/',878D7 /T0/>*^5P((Y-R.#?-&V"UL
M%L%*B9L;@U/ ,M<B]0Z_A;O2+>4ZIN'CBA"&&IL'!P/1LMUXV)!<=WQ39&OG
M!-*3'L/9&:F\=ETG=A'Q8V"44DRF63GD#\.O<.H@:=^3IC7%1COQZ]6=!\%4
M_J7A+N^"QZ%QJ8:QU+/9:G!./$4CNX#,MQ<D>-RNEBY+TO["$FL="R!VT014
MPF>NF\/5C@PU)RSN/ST, C#-2Q%O>7KY8&<]O/N[=.\:@"!C3JQGJQCX>WJ^
MBVD.\'=NP! QH4S (U+WT6'\9PLMB<HG6IVL&WBMI_=\6V/,"JC6 :"A9,FS
M?AP1[..2#=Q673<B2FQT-)VMVKHI(# GRXUZN61C',Z?!3&/DUZSWGOY^7SU
M<4EPAVUFTG+UQHW3\O#;.A^^(SK_ $Z9EPQK&>*1K:<QL?#2.-NO8LY%8(E$
M_('9^]UPP:R"-R48S9PK"2LUE3*,9SY-//C3Y.KEISUH1Y#H>??Z]G\YN[+U
M#M@2:XR;6@EA6U)YQ_BTQ@LHCDH/91=?88'8D4B@B224-('+(HS939A(H-'S
M+)L;LT&%Q+Z2B7)P0Y>-G^#//O\ I]>[NY$3Z_\ /.HG1#4',>^U6?(N>:7A
M"FSTM\L)N<@L4V<&&PE[!D.)!W1@MU'Y*13+%U96WE!ET0E;$\&9M6;!08%C
MIJ5,@OLA(#C3'9\N3Y.KK^0=4:_+_+3L[>OK'7FIS<;-9SV%J;LGNSVT=#SC
M?6X%MHE(A$C#N1 (4-'Z\U]JR,QY.1/1 !4^8RC>N!AF2E$@HYED?+D&(Y)P
M/8-B#T>KN'\_GJ?7U]>=2;J*4I2E*4I2E*4I2E*5&7A_[@P+\>-U_7?L6I//
MS)] I4FJBE*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M8R^2/@>O!X\KMBD=L[BX_,'NQ3>6*LBE$2ELXU^[DSG%--+$A(VD+D0069+>
M32PP4,O6*I9SCCABZ>KXIIVPV6W;7[0VJ,F)#N"DQT:-MNLL2 T,D[K:GVUJ
M0C71 5N#_I2*IY5AM<QU3[\8%U>JUMN.-;YY$J#:TI*CIE6-X]9.M1]^YX?!
M1_@!D_TV[E_^^/CJP]L':K^WM?X*'_L5C>Q:S8QP'/\ $/Z\N?N^ZGW/#X*/
MKU]H&3]>_P!VW<W_ -\?X[Z>V#M5_;VO\%#_ -BGL7LW+H[A'+'2'_\ 7GUQ
MRJ\.C/ H^#6X\;$ [5UWQU9JS>*O6Y2,$YI-M@3]D +LU<5V1D<!F$G, ,##
M!Q@FY&DUAB[P8[21>CU6KM%)?#$G;:;27".Y%D7%08=24.I88CQU.((PI"G&
M6D.;BAD+2%A*TDI4"DD'OC[/6F,ZAYN+O.((4@NN..A*@00H)6HI*DD I)!*
M3JG!Q656M5JZI2E1DWAE9+<7#=93]0CEO&=,[*Y=B=G3GC#OQ1NA?._2UE%[
M-EK(XWOU4RPOAC:^5[6O(Z^\?.#\U*DW44I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E1DX>98J\?HH[3RQ4;$Y+M<R/7PRMFD\%&
M]O3LN)?M\[?J5&I 8]:/6JN/ZE5NX24Q_4Y6J3S\P'P  TJ3=12E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2K6[A
MU<QVY#%(TJ9)18V.+AI9"9H$Q;YFH3.8N^3*1F4#47>"C-[YB^1L@5#/TU1<
MD NRT;,(KB"[Y!1Z_#2K4--G\F(L@D'FW&AUL<NVP\DI,=&[#UJVB9RR7BX6
M)91S<LTUS)HF[?=KA2.)N9LT$WRNT3F)NR>+Q93U]?7^6Z]O+<_P,-Y_2!Q8
M_2#I2GMY;G^!AO/Z0.+'Z0=*4]O+<_P,-Y_2!Q8_2#I2GMY;G^!AO/Z0.+'Z
M0=*4]O+<_P "_>?T@<6/T@Z4I[>6Y_@7[S^D#BQ^D'3S^GZ*C/<3\'SFGMY;
MG^!AO/Z0.+'Z0=*GS>CX.?\ +OI[>6Y_@8;S^D#BQ^D'2E/;RW/\##>?T@<6
M/T@Z4I[>6Y_@8;S^D#BQ^D'2E/;RW/\  PWG]('%C](.GGS\/S@5'F/R?33V
M\MS_  ,-Y_2!Q8_2#I4T]O+<_P ##>?T@<6/T@Z4I[>6Y_@8;S^D#BQ^D'2E
M/;RW/\##>?T@<6/T@Z>?T_13S>CZ:>WEN?X&&\_I XL?I!TI3V\MS_ PWG](
M'%C](.E*>WEN?X&&\_I XL?I!TI3V\MS_ PWG]('%C](.E*>WEN?X&&\_I X
ML?I!TIYO1]-<$?)<E]T#G$,%:]?<98N9QS'2S8<LFD(D^U68-?HF2;:OB^N"
MLWB+"1$F62[0;-95-,,8@Z42,(PF3KH)L\9T\O\ QV]QZL>>E2<B45C\%BT;
MA43&(!8O$ (B,QP0U\?S86#!,&XP4/0NIEFIDDS8M4&^&2N>:F6*=LE,\\[Y
M97CG2J@I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2OG//!/#-13/%--/'+////*V.&&&-KY99YY97MCCCC
MC:]\LKWM:UK7O>]K6J0"2  220  ,DDZ  #4DG0 <Z@D $D@  DDG  &I))T
M  U)/*N.N;#8A[2'(N,Q 7'X%K'+OVM@]Q2B%G6!.Q.ZOF5Q^;7+%S@]LOYM
MDAE9:RET[VRKMZ-(,CH@8>,KBECHW"7TCCA106>#N\3BA8*"WN[X4"G&=*Z3
M)C"/TLR&!$X(D=*+K8C\ HX@?XV]P^"4$+#F]N%!WM[&M;<A)8X)>"QY60!!
MC\XK=$*Q(%6#-X86MXO5$6V<KIK$%;>/AU3:8+9_JL>S]5;KS:ARWVWG6(LE
MYJ,G>D.M,.N-L).<*>6A*DM).#JLI&A[#7%Z;#CN,,ORXS#LI13&:>?:;<D*
M&,I80M:5/*&1D-A1U':*YNL:LFE*4I2OA11-+#)17/!-/&W7+-3+'##&W7IU
MRRRO;&UNM[6ZWO;MO4@%1 2"HGD "2?(!J:@D)!*B$@<R2 !Y2=!7W45-*4I
M2E*4KXP435QODGG@IC;-1.^6&6.>-E$5,DE<+WQO>ULTE<,TU,?_ !8*8989
M6MEC>UI((.""#@'!!!PH!23KU%)!!Y$$$:&H!"AE)!&2,@@C*24J&1U@@@CJ
M((.HK:OB0X6@LZ)$&0YLV0S<N'+YT@T00;89889N%EG"B::2&&:F&&:N>6*>
M.6>&-\K7RM:_-MEYY24,M..K6H(0AM"G%*602$)2D$J40"0D D@$@:&NMUYE
MA*EO.M,H0DK6MUQ+:4(! *U*60$I!(!42 "0"=16]KKKMI2E;1@_8E&;<@,>
MM"+!VG99J^8.47;-RE>][65;N6^:B*R=[VO:V:>>6-[VOTOV5V.M.LN+:>;<
M9=0=U;;J%-N(5_[5H6 I)[B :ZVG6GVT/,.-O-.)"FW6EI<;6D\E(6@E*DGJ
M*216[KKKLK:,7[$FV3>C7K0@S6NIBD[8N$7;97)%7-!:R:Z&:B6=TETE$5+8
MYWNFJGFGETSPRM;FXTXRLMO-K:<3@J;<0I"TA20I)*5 *&\E04,C5)!&A!KK
M:=:>0'67&W6U;P2XTM+B%%*BE0"T$I.ZI*DJP=% @Z@BMW7"NRE*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2J8FL2&3N)R"'F,W*0V1#'(QRX9>;6?,_+X?Y)\PS>-GC9(@P7L
MD\8+K-7&"#M!%;R6=T[6K-MTYZV3HMPCA!>B/(>0ES?X;FZ?=-.AM;:U-.IW
MFW4I6@J;4I.\,YK!N5O8NL"7;I)6EF8PME:V]P.M[P]RZT7$.(2ZTH)<:4IM
M82XE*MTXK'5RBA;S7FD#^F8I#-A.--Q354VE+N0B;"'R1.47Q,.(J%E!10J(
M)IQZ&+I(R4P[Q8D29Q9E&D7JI'% [8IZUL5<6[KM)$VAG7"U)VAG7RW0FXKY
M?;4Q"S'3.DPF$L2&3+N*5*A1VRXRQ&2Y,4TEHJBECR#;BVN6G9F7LY!MUV7L
MY;[%<ISDMC@.I?G$2508TY\R([Z8=M4E,V2YPWGI2FX:7%/;DH/<IL<C$BK'
ME"0G@](/)B''W7J^N!4L3'MY>S1SCLNN";1A#%R[4Q,);0O?'#&/N7"]I'<3
M;)7)QZ/K'L[,]AW8IJV.JD0FMJKJB[OP5.J@.*$N!TI<U2D-I,<V7!)EH0GH
MG'PD)XM9%Y>@/M[</75E$>8]LG:%6>//#2+BTE42X&,W#1ON$2$WL@ 1%K5T
MP,>Z*^":Y=W)MSOW4H*VV]*(\L%Y(ZUTLVC[ '!G(ED!E\9UCC)':MBL6($'
MIU!]-7[\,[>/UF8Y\Q:^78/V:CQHXZ40MG6D0F/$,*6B3L?>-HERG9-R1(<E
M6^9>C$;26)K33493=M::DMMM)<=:<<W7&W$MN)R')NTCKDY_V0S8:HVV5FV;
M1%:BVMR.W%N$*RB8XH2(+KKDI+MR==C../*;9<;1O,NME;:OL;L:;9S"VKI=
MN4Y$8D(V1N4#?:;S&"#9(9RA@771N(0IZ9*QC.*-G:K.828NX<I@6Y(P.A^"
M&*EL,"N;CB]:+<+?XZ@;/1I\Z1:-GY7B1LW-Z''\82;O&GW%J.Q-$Y;8<M\.
M.A!E*9CO7 JW<E@(,WBYFX"QS]HY-OM\>\[1Q3?7!:V9DGQ;&M$FWVUV4_",
M%#JF[A-D+6(J'I#-NW K=#^_<Z%;;,I\0R^V)#.5BQ06#V:\PV SC(DHLZ1!
MRZ5" )YI%V;@ %>WLQ9#EFS'-X-'*VQPN_>IM[N'%4UQL4=6WK%BB6U,=AZ3
M9FS:G)C["6S)@09$J*Y-<1*D-_9''DK<#;SP)(:;*]Q%7=MO\@>#]^_R[HJ0
M^S%O3@NS<)A]3B8UPGQXDMN"VJ+&<^Q-,*0TIQEE0 +SB4;ZZBM-YS.#X?:\
M$/[ E&(8$,XZ3C%8Q)-32.1 7I3=+06;R)F(-&<8P-9*#VXR07"J+%<1:S!F
M]P?8A2*XU?=[;;;;%D6.YQK5",B4]M;;=UB'?(D24TSLZM^.&8]RF=,><#JG
MX@DI2P7TNN-%HR64/)T:Y72YRV+]:I=UG"/%8V0N85)FV"9,BN/[2-L22](M
MD(06&E-(8EF,I<C@*:;<2X(SQ85>=;:<Q06+2IOMUX^DP7D*%U0)T[DA#,F$
MAA;B:!8NBLNQ0 X2IV?DL-?+[1;R<>5;#F[=5!5JP3C;5TV6UU-DMZDLPEV!
MMN'(V4D7Q[: +N(=B7%%OD35)0XN48*(L2XM)LBX;S#CREA25NJF+0L;&J^W
M!*GYR-H'')L;:V-86-GBBW%J9;5W&-"0I;28@GKES;:ZJ^)G,OMLH2I)0T(2
M%H5^839.Q8+K^,<AIULN2R>%KSZ6!=C1=P'B: *-PZTEF,,C!<%81&F1Y-V,
M.,XC<RL0-/D72+LFX\1JCAAAARD6>TW.ZS-D[99X<.XIM4&3:)J)$Y4F9<.A
MV^XS&))D3'(I;>BN3^CI9C-*0I#*<K))/&->;Q:[3!VNNEYFSK:JZSXUY@JC
MV],6';NF7&VPI$7H\)J4'&)3=O,E3LEU+B7'UX;2 !1VPML[<!1A=(K/I6!G
MT?TBGMJ1C&*FJ8@ BYR8F)B4 C2I2:#2AF:)!41;>%L(K%HQAXUPJBITZ]-2
M1AZ/L+58[#)F)+%J@RK7+VD-AAONB^3Y<V-;X]O9E/1V+<\Q'MRI*GE7%V=-
MFG'2=V+&;CPW>-77>_W^)!4F1=9\2ZQ-FDW^8PT;#;XL&3<9-Q>BM2'KDR_)
MN28J646UJ!!A#>Z*I4N4[)F-<+GUMT[ 3V!'C)2=O%(F0D&D0MQ$'>Z^>)@E
MI^ A=WX"9Z[DPH;.B'LD,2-8B,F4)DQVP@2]'+H@\DPAUJ\Q$;.VHVN7'9MB
M!.:B;22>/<F[JV9*;5*N/"E6Z[0WWK:T(<:&EE^W7&'&,B0V\A4G,F*XUE*V
MDNPNT.2_=7#!>E[,QC&MCEI<3$5=HMMXL2XVB:PS='NFR9BGF;C;)TGH\=UE
M2(Q3%E-N4=$)F5C<5C4""[6FZQ%[-.3Q\XDQ)Z?C2S!O%MND!EW!V=RX6F/
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M)+J4X#AU4#6_R$"/%RMD,&^)<CB8SMDR:^+<LDI@M@5RM=+I<BFJDFKB^O\
MYS@HGAG96V6&-[=72'\@AY[(:,<'B+R&""DL#W7]44DI+?VA!(W<$UVF/'P0
M6&<%X2""VC''2H*#Y]SCC)4E*@[]N% $*R :XQPPB,Z$#G+ME')@!<W:F!*[
MEL-D E>]\/*,2@Y17!VS4O=-3RC1\VOEUPS\=%7Q<NM^U#L^VOO(;<EV^2D.
M1WTH6]%?2,X=8>2DMN 9&'&E@:C"DY%=*VK?=([*W&X=PBKW)$=:T,RXZ],M
MOLE0<;5[E66W49T.4JP:XJ2"M=,6@)Q*@L3P9#3 D7&\RX88LB--GB;04':A
M[+M%,6#TB6=,F;7S2R.:CI5''QK7Z7MWPW[LZY)3"D3BX]'D/S Q(>2IZ-%8
M<?D+D;JP76V6$..+XF\ A*M*Z)D>T-MQ53HT -LR([$,R(["DLR93[;$=N/O
MMD-./2%M-HX>Z2LIUSBN6?QZ)XD\9>1 Q_(V*:*W3DKH2/4,,&2*2F2UD2RC
M?)^W0P2NK?+!)?'#Q+YV\7I>]K]#<N=P3 :E2A&>6,PT/NB.ZXI0"=Y@+#2E
M%6[@E).0-=*[W8<#CBX/18ADL-G$UR.R9#3:0HJW9!074("2K(2L#!.FIJFT
M)3JI 4B6:E(<D+("HM9-=MZ-QQ6";"**-HCBHBBG9;$9*R[QQ@)P72Q:DGJK
MO)*V:MG.5LQ4*]K?4PMFX*>:?F[R5\8E,FU,A<\A2CNEZ#';07RE16RTEO>P
MG<SAHG6)#"9#;]N2PZQ!PM'! 5&NSY1;]Y*1O!F?(<6& I(0\ZIPC*M\U0,X
MX[ 9Y(%")26RIO&W>()(C!6Z$3<@<V@'S6R8L,0*1@A*(@%+)LFJ4@$Q$^%9
M%<<5\[IH.'Y!9U:6W:R5;(H:8@PE2VS*4U<U+GHE!R5O[S\AIB:U"GR&"XLQ
M7Y\62XP2D J2TTE%5<]D(MUEJ>?N$]$-P14O6M"8"XI;B\,!B,Z_">G6^-(#
M2!+CV^5&;?PM1"5NNJ7>0?+(R6?-1HLZ+)/7H7&1LT6#Q%Y9V"R=^8X%FRK?
M)1%=CF\_S?!PDIEADIV8WO;MK7G8,QAM;K\9YEMN1T1Q3K:FRW)#?%+"TK 4
MET-^Z*% $#G6Q,SX4AU#+$IAYQV,)C:6G$N<2*7.$)"%()2IHN>X"TD@GE50
MUBUETI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*5!SE+*)H%D1)C%Y1(([93C[.BC=4,]70\T/(;.U&,8&44<
M;^0R)LF!0DW;+*89Y6;NW:%[7066PS])V*A6Z3$9<FPHLLC:JULK3(;2OB15
M6:_/NQU*(W@RXZPRI:00"MMM7VR4D>8[<SKC&F/-09TN&#LE='D*C.K1N2TW
MO9]AJ0E(.Z7VVGWT(4H$A#CB2"A2@>$D"DE@.R3L""S6?OXW:=\32B&,@EQ^
M0DVV4\GLX!39D@<*/')5,.;91H:J[#XN[#&BJCF[%JS;N+HVR8J85TL\:YR;
M=:VIGBS;IE1BP(L5E?BNUVV1;751F6T,&1&<F/)1(+9><2$!U;BD;QQ99F6J
M]2K3&N5V=A>--@GTB7<)<M]!NUUNL6YM)E/N+?$:2W"84Y'XG ;4I8:;;0L(
M%CXC-,]=1/)A'93L!9F A7,A:7B@LH>ECP.6B-R:[8"%\O97<\S $P\;-IG+
MO'HUPF.:FS$KR9.795^N]V2?;A=YX=EPK4ER5<O!ZF _)@ML1I,"1L_=W9"!
MT+HKDIB1,C&-PVWD%Y<:/!#B&V6DMZW;[D;/;RU#G793<6V>$15P8C3G9$J+
M<&-HK*U&6>G&4W%>CPY0E%QQE09;DR9Y;6X^ZMSC24@]/#-I!B\V>N]>1@YQ
M.G:3R-[TV/LX&&\YW:Y%STPRVD<:1LR[9CP;)J2,H#LE8[%"XYL68J,#8NZS
M'N9B"*]9)#%N;;NTV+MU;%-S-F;199,C=V;0_:X[EDC.3([;CTEUQF.MT)ES
MH[RH[H=CO;KN._+Z4S?(S]R<<M,*5L#=$N0]J+S>XL8+VF6Q=I+5\E-PY+C;
M,9MMZ0EDJB0)#*)#1:DL9:K@-L#9+S;>*=IR-9S#V]W,>%Q)]L[83\F3U"F<
M52$((Z580@A$W,<-:]3;R)'::IJZZ1)Q<T3E;/%-P&1K9%KL[=ASXL><@>QE
M$MZ>U9K2TRS?E14JD*7M&[<FIS<R/=2N&JR)C;JF4='9@N%2))LX]UO+FT&Z
M+JRW<?92N(Q =O5W=>?V?3)4(Z$;-M6QV N')M"4S$WPR-X/+Z4_/;"7(Z>4
MU09&2#:7&<F5V!+)#N!;/:"VX(<:/E2#6'RK.#'$7[%6*.U<QNO?1I!%T'CP
MT4R"H'PK?,CD@5NTL0PZ;Y'>B63;)EBUP8FSZ194V"X1HK#2[A"%SC*:=3.0
ME+UVXS2D2);S[DA<20H,[S 7P3WV&2S+OFQ;TB[3Y>T*C?%;0V^3*?=1;IQM
MDI+K2H#BE,VC@NI7'B,L-1D2XR.,4OEOBB2/).'QX@MJ29.Q>+R2 MW:2&AR
M*RSI:PEF0VG&LB.;!EFMDP:.GB6/F[LDBUP(*LNK)1W=G?)"^H;'SY;2;];V
MWRW#D[-[2/2&4I0GCN-628&0ZX$AUQ#9.^AE2RTES[(&^)A5;EMG;HCJMG[B
MXP')L7:;9EF.\I3BNCMNWR&7BTT5%EMQQ(W''DMAY366U.<+*:L7NAKM+/=F
MNYC(M:.RK$/O&+1W5;IE+(OB.:1C("?6,+^8KOL"#61S,DEY^5?/FR#5B$CH
M (AXKG%\Y*[+L\NR#9N[6^)>4,.R-FYLN]MN0)A=<FB7$3'0'4-EI<2W,GAL
M-MJ4MR1+ER5906T,ZQM&B^'::T7&995OM1]IH,.Q.-W"$&6X1B2U2%<);H=1
M,N3R>*^ZZA*&HT2)&3[H.K?OQR$-MQDBU.PE\O-0+4I8A+L9M)P\D)PG#$\R
M"M5X,%,3,.[&D0 DFOF==>,D4'(DRHH4+<.%<'5F3O6=E(RWHE\=@0(]TOS#
M4 VV%(ALW(F*Y(6FYR6+=(;>9E/LH$9&%,O*98??>2A)1Q&]HVMDH9F6!JX7
M"3:K ^[</&4V/,>M@Z6U';5:XTBY1W&7HC#RS*6-U]E+\AAAA:U!8:<A&$F;
M=IK^#Q5I+I*V9NT^0,D"F3NW9/IIE)7.>])4S$OF2L'BY&9[#V5DE=-XC!\<
MV C)$I9PY'.'CQLFCZ-)MRW+K<ISD"&MQ!V6AR8T:P0MH7(:$[-0G'VG$7*:
MS;K39P<MJN)#SX4QN(=2VTLJ\UBW%+=HMD%JX34-K&ULR-)E[03=G&YBSM1/
M;CNMJMD%ZXW>\XW7$VS+,8H?WUL+<=0E%SP\]VV_!:8C]Y')B#_E5J+3V362
MH.72:\(EL>&BUMWEF"S6Z>,?=E=?/+G!:32S'!.7BR#I&Z;EPKXM-(M=A:E;
M0RA$AM-;$7[: +AJ0@IN4"6\\G9IAU+@493;%U;$9\N<4J@/M(4%(2,W<>ZW
M]V+LW#Z9->>VZV?V>*)B5K"[9/AL,*VGD-*00(CC]H<,IE+?"W;BPZM.ZM:L
M<[K.<%D.1B(![-C4W<GIKM8:Z:"=A27!]&1(G$Z_$C=FZ(E(5<3#X^"19L!,
M5GD)*B,Y*\6!O']B;:1*X.,6\6UA6R2I3=NCVU$6W61YM;]JA%J:^^8K3[UE
MVG@R$/W"5)4X[(FVNY,R!#;3*;:X+D,%&39;E(1M@F*[<Y-S7*N5^8<1'N\T
M.PH[ E/1V+WLM.C+CVZ)%2TU'@76V/QC-<5%<=XZ):@O>;XF0<=MW:(F1[9F
ML)=AM#0J1ZLCT=EQL"B3V&[.[5;X.1@48X3;S"1N%QL?'MHB^:E61]#/+!V$
M)69HJ,>.S%O?>L%E?B6*W7)$C:BY1+W+EP(\I3%I;C6-90](>0I5OAH2]*=7
M/:6PY%4,HDL\10<[-JKC'9V@OD>9?KE;'(VRMMF6*)#GR8J7[NY*OR MF,PM
M*+C,6MB(TBW.H?;EI.%QGN&E35-O7NQG0_<T]D,RGPR6Q?9G'2(M(R/E!=A%
M .$G!<<"4Y:M8\T738+9ORLC/(+J+X+XMDU7F#2S>[XG=WELM6A#NSUKBVZU
MOP)UFVNGN3'H4=V=*,*3M>S;%KE.)4ZGA,PXJDA!25E+?$W^$SN8;CEX<:VC
MNLRXW9BX0KUL=;T069TAJ!%$V)L:_=$(B-K#*BZ_-E(6I04$)4X&]SBO%S=
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92E*4I2E*4I2E*4I2E*4I2E*4I2E*4K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g307489g25s25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g25s25.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1L$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &NB^:(@X0DE-! 0       \< 5H  QLE1QP"   "@   .$))300E
M   0RUD-THD(ZPQ<1'O!%[K[*#A"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!UZ!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              \P   :0          $
M                 0             &D    \P
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   \P     4F=H=&QO;F<   :0
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   /,     %)G:'1L;VYG   &D     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      0@0
M  $   "@    70   >   *Y@   090 8  '_V/_M  Q!9&]B95]#30 "_^X
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M<R^RZPO>2255="U.7P^U#ANR3Q$^)892LNUB=<P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MH;$))$+!T? S4N'Q%R5B-#5#<I(F-E-CA:)%57-U@J34_\0 '0$   <! 0$
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MQA:T@,3Y3>Q*O_PW@ =L'MCOQZR\.X$!1.J&,WT@7&I_"]=@*(]/7?+Y#D:
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M!'5J2\&-R3;V&#__ +'J?(>N?3AIN78I'_P\%'32*/YV;73\?;A0E<'[[C0
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M1P=+NZU%]R0;^GMWM21S&U*,9U!<G;M^+3B,X]WOS]-QV X1]@Q=?^E@T_\
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M# _/OQ$?ET&H\B+38>6IK7UH_IMOPX)'.I<@'7[Q/M[;6?4V>'-&UM=. ?\
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M?@]'U$\TH'Q,C;;(&VP&_MCUX0T((-K5?0^]=M/QX, _Z237JPK3;8C<#O\
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MUTPIR^2O+S "!(SR](I,F4K05'5)!-"8F9P\;XBQNZA)A+AQA;$4)X3_ -0
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M*-#X:U]=+U][U^6WOI9C@!CU:#VK3;V)('II^/&25KR3XA2<YP0%>?8X/O\
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M/Y:1XLKM!.R1Y@1,W(QL7K.(TRQO,TJ1N5D;&RPGV:6?AM&)(GD("*W59+@
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M<$I=DVPO"W% #LVTGK<(VQU*4E03D;$ *&#LI/!*&<FJ.VYH>E?G_3N;>\D
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M^-1S/-\E7;R>68;12Y:R+\:L(85;)A,?3#.(P#CN?>,,3!CFQ.2O%S/FN02
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MQRD @ DMU6*(LJT?00&!;I>A74O$RL2W(B*A#Z2PZU5J;D1UNL27F7427W7
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M'._<9'EY=R#CV[9]N%_O]_3@[O\ K_?777];^7&0!)P/][?[_IP.!PH,)P<
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M.:XD:9\<\< :%1E3^7BO<.+'A\T\_P"QO #"98H<C7XG.</(4!I/LDQH-?\
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M!@D@+LCPX3A9P8HGC@Q!DQPKDRPPR28T71%K'! S2!LKS'GIR%^SXP$4 L
M$=0T-DEG(LJ"0':S74S]((Y@%HO.*=<<*W'%J<<6H]2UK4<J45$]1)4<DD[D
MYWX] @4 %&@  &P &@_"JT]N* V;U_+7\]]?WWXV>!TG'?'V\O;;MN>_D.W
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M+9^K(Q\/*D>-S*D >58\N R)!)&\V.\F.JJ&!GAEEGCZ%QGMA88R6/F+0+J
M="Q )4T2" P#7?W2 -R#PR.;&@:_EAJ6#05VKZK634JE:LI,^G6P['@SA:6U
M3*JW'(\B4T\I#E29\60A:6Y=;8P9; <COM27IO*L]^98[SR8LN&RS&-$E!#.
MABBE60!E4K8EZ&4@]$L;JU,I"IE41, '612!JM:&V! (T-58/<$5IJ8\2YU
M'=7E[>_?[_?VVQQ8UN*K6S]-O36QK55KWHE!842#^EW\C_;;Z<*$8I*AOTC.
M1VP/]G8]]\<-M\M=;%DWZ;^U>G>ZX2K4=_0&]^^H.U"]R?7;3BQN@]9]-;'I
M+&2S&->A7X39/,)=9C0VQ8SIL&3';3F3)GOO,Q8DI]#I\)3<"2ZU$:AOP.5^
M)/!F-+S.3G./B-EIG P<TP8Y DDD^4_+\6/F,+,#1PH<=IGCCEB:*029F*&R
MGG3*N8,X^4(6D"]!ZHW(+#I4.3$=0.ERU D'J%(_PA>B38FB:_Q/&0B31//N
M1'O =#L^L;;\)E2GXTIAMV6IJ1$7)G*=*7:]Z0XRPPN*VD1T9'FOB_F>'C)%
MB'DWB5+E5(\Z=>6<QZ9$S'3#R?-O#$^/T0PS>8D.7#CQRG)Q9Y7;(8TY;#(_
M6WGXSJ0X>-3*BLE+YL3+\85NHLE=498BI%%KQ'UIR)CSBN5%NI=6Q(2@2ZZN
MM*9ALNR(8G);C,R?FW8K:EID)\-++J0@,/,MQV)#+:>;Q>'^1<YYU%YGAOQ%
MR**:8/)'AB'F'+D#RNH:":;"22!),<Q3&)HBD9ER,>,1#&03:I?$/-<?",<F
M1AYKH*66<O%.0 /\U(I.F1P; <,"1TN>LL2K/Y#L"LYBW5#.0N0%PXM16,-N
M!5G/1!8C0ZV"N2PE$E"%%+#,80U,XD+6MDM%2U(ZNGAV'DN-S/&Y4(,"2#&K
M-YSFA&R8L%3(PR8YGZ8RT<!,LKR=,$:HIDC+(J\57,<].9XW*Y)>MBIEC.-$
MI6)I5"GI918-2$F,BY2'(ZQ9JWFH-01($=34-<=V>M"VD(C!*J^''4J8EM]I
MQN2W*9NHBRV?%=0ZIY:U2G5(62W)A^&/#^=D=2Y*RX_)FD1BDX!S^9$?9W*<
MS@S.6&.3'FC'EN<7(C@CBACQ,59(P9HZ[*R(XP#'TM.H(M21'#9(N)HYM&!-
M@LI<L2[FSTF$I3KCKA4H%2E$DJ.2=R<DD;[DY))))R=N.M*JHJHH 4 !: H
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M$L$Z++$ZW11AU E2 5(NB&IE(Z6 *FH<L;1.013*U,M&Q7Y:Z:KH0;L@\/\
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M>AQE*&Z"D[;8SD[^7V[[9_492[ $ZWKH.W]0-M.U#M1HK]O[?U_MVWX/J@N
MY2DCRVR0-NP&3@^OIPCK'K]2-_P';Y#@R+&Y^G[]_P >-:'I4=6#XA .V.P
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MD9E5[5:A/S B%U5E,C0A';F$*3$D20^8\20H -RW6#E)PH9+QU*T7A7FJH9
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M//EVD@I6D#&P.V,[;]L^H_IMP?63ZD>M$]C\_;;;O1V*@!=D7[T?<:=P>WJ
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M[G@?\_O^WX\2%C&AU)'[^?#EB0>GI40%$9.,$)SV_,>XVS^O"RYJAM0%]_\
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M,0*:CA:6TI7*5^&4,$K=45KV7.M)[I^9M+%U.$E^22EE/4AA"5.2'7^S^!?
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MH-J:\>6RXZV<,)<\(.E0'6L E24#NHX(*E   $#N<<;0%,:,NQV%U[[#V[$
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M,YYEI(E/*@9V-R[ Q9<QL)9!!BH)$4=1;&QHYD7X&;I<PX\^0+(,AC9D#'X
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M3FL7)N3^&)LKF47VCF&+RC+R\^>:+$8XLW)9N5<TGQ^A623%YWBY^(Q8O!+
MDB2#J[ WJ" /+!%&^K;S -="C=)V(^[< .Q LD@YW_7.^P[[#&^?U XZF'KM
MH!\OK];UX'6XO6_4[D^]$']?[<$U1"E7;_(G\B"=\>I]CPL,"/3YZ@7MJ*T^
M=?UX,2#<@ @F]:_'][\>>#@[A0VR?I"A^H)]?(_?@7KOIM6H()]=1Z'M?IPO
MKTV%_E^_UUUXV(24G'=)^WMY;GV&,_;OP>U;: ]O]P /8Z>^QX03>M:W^_K[
M_E?#@J69$V3%BQF'I4J0ZEAB/';4\^^ZM0"&V6FPM;KBU$)0A"2I2B$@$G!A
MY,\.+#-D9$L<$$,;RRS3.L4442 L\DDCE51$0%W=F 506)%'AR"";)FCQ\:*
M7(GGD2.&"%&DEEED8*D<<: O)([,%5%5F9C2@V.);@Z$UK\@BV:TCJGY#!4F
MS:H;4P^D=:"H36XJF.DJ"T*4'/\ "H'L1QDY?%OA-LI^7/XE\.G-#!6P'YSR
MW[4&(5E#8K97G=5,K % :*D58XLEY/SQ(DRQRGFBX[(6CR5P<H0E;9&=)1%T
M$$JZ,>JNI64[,.#,?45O!80S9+584+DAHR:*6HB%->IT,%MEQII3;\1Q*C&6
M\\CH\=82N4B8E*VE%/RGEN1)+]A5<;F4,;!,^!1Y^+%S$R%I(WD5XIU*^=Y<
M1ZA$/AB,!*N)GV[F$?D9/,7>3"RA(\<<O2Z94V >E5=(W5XRV0$6:1U5G+-(
MZS#J1TVYK-%WY7.IY[E/-4YXSM39&,PM)=>?<EAB>1'@SF&FOEV:]M3D.6"A
M0=8?4ZIUMO"R/$7*63&S<5>88H7HCS\3SI5(5(E@\W%_FY>-([^<^0ZKE0$,
MO1+$$$;/SKR/FP>7SGY?E*E^4T<*AW7S&D_F 1PR QB&*$@Q2,ZLTJN96D2.
MIM<J)(\+ZBEQ"7T)407FFG%*\)N1TI#8>\/I6XEI2T J "R00-;BS^?%UFK#
M%"5!".RZ,T0)+F/JL*7"L>EC737&=S,=<:8)&S&-HHI4ZBK2JLJ+(B2]"A.L
M*P9E3J"=706)!XS9C$IR.K., GN3[8R0/7/;SQMAQG WO4:Z@ :7Z7>X]_0@
M:1*^'<ZC6[T.GKV]:]=38XW)4ZR1DG QN 3D9^WL,8/OP1"LON--A9)]O4?C
MZC:SZ2="1H-+&G??:J&U&_7>N%R+)4L +!'8'.?/<$=\?;)\_3B,Z#77736M
M]]_;3:SMN."LJ:.M[:_E^O\ ZC7>^%Z,ZK&"3@' /EVW!._L?3AEEH7WV(T'
MKJ!IZ:::C7UX4-/?YW^M_P!M]-;/"\RMM] 2L)*@,$*[GRR,^^^=SY>7#.H/
MH/4:#ZUK5$BCI8L[G@>NOR-_E\P?UKMQXNN:<.4)((\@,C]3V[_]0,\+!8"K
MOZU\MOSV^7!%;["_?;4]Z^O8Z\$'H[\?!0G('; QZGRW'EY??/!BB=;_ -_K
MPEM-_2A[>Q(W]OG\0X,1)KB" X% C;M@@YV VW&>YV)QN,'@$ '0WMP5U\CV
MTK?8;BOUUL<.B'=RF$+C-2I,>+*+*)K3+[C+<AMLJ #P0E25I0EQPI\1IT(Z
MU=+9R08LV+C3/%++CP2S0%FQY)8D=X7< ,868=4;-TJ&*,I:A9T%.QY4\*2Q
MQ3RQ13*J31QR.B2HK=2K*%/3(JD=0#A@&U"W1%J')7P^TE3JJLB3X5Y(L94B
M)1.S*M$U^OBR]'7DF*B9:NTKDD-P]6.4M=:W%),BS5NQ?G:1R-4/2HLC-!?$
M$\N)(\;PK&BM.J3&-9&3,@5RD0G"V^()I(H9T9.E^B<-,%=9?5B*KK:L6)"V
M+JXWJWZ;^\55W78@E:6P3%E+^&!_4-K:M"-"I[>^U_3,U$.EMIIH6KVPTS04
M>IX"7W:QM=#6T$/5&L*1HOR)VG[NWB5WX%:-5B&Y28T\2KCPQGJ>:*# F:5Y
MHD\]H(\F:;&DH2'SY)WQL2<]*)/!"\IGB:0E4'[%ULU@*7D3H"DE>MD57&WP
M! TB_P#:S5TGI%P_R4=6W-YGPU*2MAWD[S$\9;946G?PR"S;PW$%24DI-A60
MW6NM()4E&4I.PM^<:IRQJHKSCEU [CS)#$X]CY<C@T?4#?B/C&C..J_Y$HNJ
MLJ PT(U^)16@[=Q?#*@6_5TA?L HC.?0$C;;]3VR>+"2'0D;421^_P#CV'!)
M)1[U[[:_+0$_K8X<J'D/I\MP,8.V<C*AGL3OZ=^V#Q$*E=0=OQW_ #]^)"D-
ML/8BO:NWMZ?3;C8N*I/2E&%%P9 !P=SL.V.QWSL#GTX1U7OVWV';N=MJ_#A]
M1J0 =36IL:6-+.FM[>MGC/YN33JC/P'W8\V-(9E-2F%%#C,J.XEUEUI8&4J8
M<0A2%#!"AU YX:<+(KAU#HRE64T0RL"&!&Q4BQ6N@-<3(P4JM"=;O8#?Y75
M^WUX5OB#:CG7\[44".TQ5\PJNEYC5S$< 1XQUM7,7%Q6Q@DX2U1:E?NZ!*!C
MI55J2E(2$@0>1%CA1X\C,9,&2;!=FOJ;[%(T,4C7NTV,(<@__BC74\2W'QWJ
M ]."-!9 L@$[!B1ZFJ'%>I$=R7(9@QQEQQ;;"$^1<=4$E1QO_$HDGL$@X'%V
M'"AW;8 M[T-0!IZ4/GQ*C4DA0;)(7>Z)WNM!J?\ ?:E35D5]<K3^A*-"I$F2
M_"C)8:P%S;.P?1'B,J ."MYYT$9'_$?&-@.(N,RA<C-FH*H=V).@CC7J<@WL
MJCI!O15.]D<39 08X$O4@ ;%K-*#KNYU-C=O;6Q7QP<S]/\ PI<A]/?"3H)B
M _K'F#IC\6YK7\5:FIC,.2IIE<KQ0"M<K4]K"EQ([<A15!TK5+AH;:590YC&
M6\*8&1XHYWD>*,UG7$P<GR^60,+0LMD* = N/&RNQ7[^3(')(1U.UY9B) BT
M .FK-#XI&!ZF+=QV!T%4-P1QP@U;;S]1LW&IK:=%8-3"I*F'%;;2V'&H42/4
M5-;!CI4.AF!5UZ5.OK+KRPR'I"WY$AY\]AQ8H\=H<:)&82O-*[&S19C+-)(Q
MNV>5Z"@!;("A54+Q;HA9JT!)(U/;<:?B?F?>A5/4$QQ3COB]25$E1"@0H#ND
M84 =Q@]NV_8[6.;,(HND'2K)NA0^1]?U^7#N0>E.@&@!KZ[Z#][]SOQ"VH+%
M25A">I165;YV2D$9.,')SVWQYD^N#SIR2;LW>WKN?0[C:^*/(E/4H N]+T^$
M:6=^WO[^W#KY3<^8G* 7,6PTG)U1!NM2Z+U&37ZJG:0M:^;HAC5@JWJNU@5]
M@['FLS]2,6L>0\S(AHD5+,>?76E?,EQ#D.9XQS&0B7RRL<T8#1B56$S1=09&
M*AA494T0U.>E@RAA!D]>JCJ-@11[&]  -/3786.+,UGQTZ,O)G-F?JK0TK1M
M3>4/,Z1HG1>CYM?(KI6H.8%U\0^H&M/:B2WIFJK9NBW++G1I1G4D)J/22);?
M*70U]72VW]+4VEE4$G)Y47'$<HE9'QQ--*&#".!,%.N,F1F$O3B2=!MP/M,R
M,/YC2\,M&PZ=18JR;L!>G4;BSTFCJ+9KW)#!UU\?5_JB[TY=T6B7-/-Z.YU\
MM.=VEM+RM40Y^BH=QR^FZELD4-M14FD-)2+RE+UQ4TVF9$FU:NM*Z.H6-)MV
M=K5-42=.'%R94#HTOF>;BY&++)Y73*5G5$ZU9I).AP%9I %*R2OYG2KE^LEC
M !LV2"I-4:/O9KWWLF].ZEHCXWM \N8M17:+^':!"@5;VAY%F];:HT5;7.OE
M:2UIJO5$F)S+GL\EZR!JZ)+KM1P*2IG+IX.J*>3INIU+,U)>W;,-ZO1-RB:<
MEI<XLQ$P4)'*J0^;#'&# IRF,95D+LH=HF$C1A$0D%P0EMW)LG0 @ D  K\>
MGK>H(-4!8+/UG\6<SF+R;MN6-EH.+$U!?NZ9=U#S#:M:V79ZL>T]6\OZYF7J
MF+.TF_83K*&GE^PK3=G5Z@I;"B8U/K"M?DV]9J&PB/N1\N&/E+D+.Q1!)T0%
M&"QAVF8^6PD "DSDNI1PYCC-*R B5'!T.KAK(L!2#\-V?A(( &NH-V0#I7"I
M\&?/)GD-KC58LG7X&G>9VBOV NKV(N6B?I-QG5VE=;4&K(287]Y>=J-1:0JT
M3$MH?6FHF63K,6=);8A2*#Q?R9>=8_+YD03Y')\]N81XY",,N.7!S.69F(3)
M\ :7"SYVALHIR(X5,D2L94U/AOF(Y5S%<J4L(G0PRM'8DC1R")4H7U1LH8 :
MZ73&E-H_CIY&BNT9R>^)" Q E(YQWW,C3M]>:87#M=,W4S0U=RVMZ[4JKJF5
M*J95I<IY@3J>5.$UR5<G2Z;"S5(U*O4,AS,^#.<JV;S7DJ.5P,*# FY=#E*^
M-EP3RR<PBYCA+AY BR((,88V#EQX[0QC#_Q%L=(TQTQT6S\41\NER8<KESI(
M)XO.RF@%P*\C$1L2HI)9&28=#$.1$&=?-,A//B'$6, )'8#MDX/FHG;'H.^V
MWKQNGF6SJ#[=5 5^]ZXR_<:$G\A?O_3OZ   />JA1TNA,QA3S+B>@J2I25QU
M$C#S8!Z%J0<#H<2I"T=:1T+(6F)+.Q'P-3#6JM6T^[9H@&[L&[K0C3AT*=S0
M:Q[;#V^E4=!??AZQ::T2J151V7'6FY.7E(;"62IO*$NO/%*0&DH/6GQG/";Z
ME+3TE2B839,5+*S ,5 4,;(NR0HO5C0&@)TK:K7TEMC0 NJ&A%GZ=AZ']95T
M]61IE5'7(C-..,ER/U>)&9!2TLXZ0[T%8.2HN)ZDE14.K*5)373Y)25NAB :
M;:1C9'<K8&V@-&J-41PL 5V%6-*UUN]2#9OTX_4QXY7QS;@<#@<#@<#@<#@<
M#@<#@<#@<#@<#@<#@<4!^*B6X=:M,MR'6D1M),!]+#DE?6')%L^AJ97,,..+
M2E*7'*^Q84%!:[*.O*HK*3A)"TGCG.U<C'\,82*HQ5CZ6R.8Y9)7-D 60,(Q
M2AF$1652 SB[%=.7IM\66Y/Q7HL2#50= "=30/W3J-J.73BT:0(>6^2M5@XC
MYJQ#Y5F0EOK89: 7&^E'2Y%EX=9Z3UH#G4!O?X4IYOB/Q#D"V9O$.2CO]D,4
MW3B<OBQXTR#* ,A8[Z<;+QAT%#]GD+R1N[5_.2%QL5=*&+$1\74MO(68K5U>
M[HQU(Z@ K <<X^:RPNSEYWP0!]?B# 2D8ZMC@^F-NW<<>M^6"HTKT[ C30U7
M;?4ZWN:N^,A*3U[:^FGOIN._H2-*OBJ]M';6M:0E)!5G!W&W],G<>A/KQI$.
MQL@U7YGWUK45_3>N8DDW^_;8<,J?!<1U=&2,8/MDC(R-\'MOMOZ@<248,1?S
M]C6NE_IW_1MAK8%WOH#M\_T%;:[Z(D>O5*GPHKJTM-2I<:.MYUUB.AI+[R&B
MXY)DN-1F4("BI3LAUIEL#K=<0@*4%963]GQ,K(12[8V-/.D:1S2O(T,32!%A
M@26>5FZ0!'!%)*YI(T9R%*@U @5=$6=!M>U:>_IJ*T!XD'G@_I>/JM%!I&KJ
MXE=I:KAT;MG71J]B1>38[23(GV;U/>WE+8RPM7A+LZYZ,B84K6_&;='2C _P
MKBY_-X=?G/B/.YAD9OB#.RN;18&;/ES0\IQ9Y7\G#P(N9\FY-S7"Q>D>8G+\
M^&:3%!5(YV3XF2Q#$ =-#04%LC?[R*JN-33%58@TPL7Q")'GW.<X_I]MAW/F
M-O,'IW"_W^_PX"4A9&<85MN,XSW!]@>W8Y[$#@<)8@#47>GZ\;TP4*/<]R-L
MC?R[D_H!PD,2+ K:B=KL"M-?KPD4=EKWZB-?^+VO\.-GX6#D@$]L$_41@Y]N
M )!577RNC[_\\&".YK7_ +B?37V^M<'('S53.AV4*0J-,@2&9D1]M*"MB1&<
M2ZRZ@+"D]3;B$J3U)4G(P01MQ'RL?&S\;(PLJ(3XV7!+CY$3=062"9#'+&Q4
MJX#HQ4])4ZZ,#J)>)EY'+\G&S<.5X,K#GBRL:9*+13P2++#*@8%>J.1%8=0(
ML $$6.)'TUS6U?I&1"?HY_X>W!BQ8;#5>5P'$QXLZ7:(2)413<T+78SI<IY8
MD$NJ>\$XCH:9;Q?//X=>&O$./E0<VQOMTF7/-D32YG3EAII\.#ES$XLXDQ"%
MPL:#'1!CT@B$H_GL\CZO#\?<[Y>^,,1L7'P\2D@P8(%CBCA^WMS-H!.G_6&-
M\UY)6#Y#Z2/&*B(02C%^(>MU!8)E<VM 5/,D,:9A43#LB>_0W8EQICLM^Y-Y
M5M)D*L9H=;:D2)<><ZEN*PVVI+2I3<G&_P#^(\WD6&,7P#XOSO!ZOSS)YK-%
M'B1<SY8<6;&BQXN61\KS96@BQ,4HTD46-)BJ[S2NZF589(ITOCCE_,LPY7/?
M#V/S'R\"'&QP,F2')&1%DM.V7+E]'FRR3(ZQ.9!(U11D-TF99&QS(NN4FK(K
MUKI")K+3FH7+2RLW:>VK=/VM?)-Q(AO.0T:FKI]/-;B5BFY;M>)6FI;RTRC&
M<=:"?&-_X,Y-XY\/2I@<\S.1\WY3'@X&#%G8F9S;#R<?_#8LJ-,D\HS(.8X[
M3YZRX\>68>;X\:''$J1O8C$3Q-SSD//D7)P\#(Y=S+[5F9$Z+BX9ARERQB 0
MODX\F-(J8A@GEA=\2:25LJ3S&5K<Q)$@.2"M*6EJ4VG*@E))2$]]N^1O]('5
M@$XP#QT.6=(^DLZJK'I4L=#U'2O;4?%]W7?C'PP2SNRQ1M(ZJ[,H&M1JSOW!
M)"HYZ1;&B "=.#@AEM12H$*!*2""DH4#A22D[A0(P1@'.<@9QPGKZ@"&!%6"
M"""#J""-P11%:55<,,&ZNEEZ2#1&U$;@V.H'L;UU.]5QO5#2X-D95YX&=_7;
MS'^\C X2'%[D'U.GY^_OP5$  &J]>Y^9.GL!W[';CQB*IM8P@C?/D>YP/UQY
M[C&_N9:[-WO^7ST_IP-;'<#V%C?6^]^@'IML73&CI4@=AC8[G/8$[9]?7S)Q
M[QR3>UD]]:^M#Y_UWX7H-P+-43[[:=_[]M.#28Q0H*2H@;'_ $]?/MVSV[<%
M9HV =P:.GYD5O7>N#LE?N@ ?B+/;6M?W7"E'*NM!/L"<9[^?MY=SY?J0V(-Z
MW?M[#2CWV'R]D@U=C:MSZ;V-?<;^IX<:8+4I."E.0D'JQ@]MCL<X]CD???AC
MS&4G4G4[_.B/?YZ=];X=**R[5J!I1 L6._T&F^VG!1^BZ05(&1COC.Y\^P[G
M'W/Y<.+,#H1K^_\ G?\ K3#1T>UU1&F^M'0_+2NYTX1G:]Q!  .>VWK^?IY[
M#W/#H(.QX;*Z@#Y:GZDCV'!B)$<ZLE).!V]=M_\ /;(_EC@$@;G]_3@ ;Z70
MNCOZ?/UV[Z[@#A:,%"D94-P/08/Y$>1\L??AOK-Z5]=Z]]?W7"^COL>^Q%GV
M(V]![<2MRTKQ7:0YW:D6 TF/R]@:6@K4<!VWUEK;2\7Y1)V'B.Z7KM622G(*
MFX;I"2E*CQ4\R<29G),<:EN8294@K:'#PLINK3L,J3$6_P#SBS9HO1+29+UM
M$$76K:1T'MKTJY(W[]KXBIB $=!.V,;Y^YR!_%Y>Q]<CBU:0Z@#<;=Z_3]Z<
M,A:WW]1=_C?YBC^)X=,)I/4E*E#IR,YVR.X]#Y'&/MY@\0Y"2"?4_P"X_3TU
MXDQ ZT+.W:O0^M[_ "[Z]G#@=/4UNXZH)!)_A0#T@)R3C&^3OOD^6\4T#[*/
MPTWN[/:J([;$<3H5&EG7;;V_3;T/OKJ@V0PHI'\#:2.^Y"!E6?\ YCD9\R1C
MTX4NH^>OM6P&U;  C\>)2BCK^.E:]Z'L!^?#@ULX+[DWRNU 0%/Z0U#K;EQ/
M6"26JQV1"Y@:9\0G/_M4W56M6FD[$(K5#=( 1 PQY/-N9P__ &O'Q,^/WD"O
M@9/30/W(\7#))V,OT,O0JA/^@LI.E ?>[; DD&M1^1B[1<)J393+61M&JH[L
MA:SN$N+2L(S[AI+RO4*"3MQ-S'I%B ^*1@*&]*1I6_WBOY\3<1.IV-_"M 'W
M((8_(*&/T&I[V!^#71L/6?.FXYG:C4PUI?E=63=73IDLI$.-/6U)9IU2"H$(
M;KX[%C=)=R/ <J&U>8SG?&.8^%R:'ET%G)YG(N*BI?4T8*-/0[EV,<)'<2G3
M32TY;%]HS#,18B%@7IU,2$%C8J.IO8J*[<<F?BLYQ/<]^9&J.;,R>SXNH]37
MD*BHFF^B14:)HDPXFE7[,]:E)ES*YQN'X82V2[42Y+C8$IM2]_X<Y6O)<#'Y
M8J-4&/"\\Q-K+F3]39"QZ5THXZ[^+255!'20-S&O1&JUL+^9!O\ ,G0>W%&]
M16"H,T>.R%JB/H4Y%=[*6TXE:VG!OCJQT*!!(P0I)RH<;&",/&2#0=33 70(
M(%;?,"^VG$R!.JS=?"1=;:;UH-]*)%G3MQ!6J+9<N1,F2%(2[(4I:L !"0=@
M$^?2D )'?9/W/%3S"9(U9+KX J_H230K37Y^_$+*DHD@@*M G;;<_/M\^(7N
M9&0M8.4E.4]\')P#Z^IS[Y^V+RG)O7?733U%_P!?H=N*>1OR%W_ZOGI_6_IQ
M%S[RGGW"M!/3GI))\O/!V'H1OD9XHG8LQ-'OH>P_IK^>FW$<639%]Z_KN >V
MGZ\)CN5K'2M0P22$]CC;!/IODX_Q# \SPRX+$ $"B"???3YUK^QP#OO?:_E^
M)^=>_P!=R4@^7IY=_8?8Y&WKPB^FP-]B??L=]=/78C@U0FB?I[_/VJ_UVX5(
M<13J@3D-CN<;D_\ *#W[>?;.W#,CA>_Q'U.@]S>GSO76]AI,5:T&I_76]OZ\
M7#^%C06F-97?-N!J>FC6L>F^&WGYJ^D3(\4?AFI=&\NK?4M#;L%I;?\ >84Z
MM06O%*VE%PI6VYU!)I>8Y+HN.8W(+YF+&Y'=99E1U[_"5/8"M[X5)<:H01;3
M1(1ZJS $'38V1=WZ5VA*'#!(^DGT3CR[;CMD;^WN>#>2MCON=;O^OO7]SQ+4
M7J1>IUK;W[=6O:]/KQUP^#/FC*N^54;X>GG(YEU^K-<ZDTW12E1I,?F#6:YI
M]&0-4:-_!IZ366TAAS1\&;%K)R91MEV66HWR]1-4OE_BN#&QN8OS?)UQ<B#
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M@;4#6I[]^VNNUP6%'?9CIIM6_:KL;#VX096$J4%8';8]B,>Y()_/)\\<+4Z
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M<%RH@0)S,)MSY\H5*JT2T-RWROQ3B/$7B7EWA'D+P<KS$FYIR;#;FN%RG,R
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M0LB5;IO4@D&EH$D>OQK5 "B5<2#0C2^(6+* ,C;ZACS\B2,'<CU'G]@>.F\
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M@ GB56/AGU6E4,-ZGT:CYZ/4.(C-6=E/LX3VI*^);4-?;5]/3V,NM<LZJ8)
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M0VH"@DC<GOOZZ]]+XJUKJ)^$]4*7-$RS9=CN!UIYUY@PGH;3K09ZQTA".I"
M?I)Z< )0D#B@R\CSF+!2L?Q"BH#!U<W8]]3[:77%3D-H39LGZZ=J]/0;^O$
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M 52UT/F3VV_'T[\;4QG$GMZ8[_F?(CR[ 9P/OP9=:WK0[[Z?0CY^G!:[@-]
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M#3"+"EFO)6UI[5T>+&A6G3\E/C5-VARM,3$S9TF&!S#HCS.EF@FCZEQ^8QJ
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M?W/KZ]^$,"38%V.WUK3Y ?\ .G!-9V)JK]039]+]-+] #Q@HY/W]OTW^W?\
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M;1R+:0%J'6'(,LM3HJE)44]06TXR5)44D[I4H$$[Y6$^&7A?2:$-%(/_ +Q
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MX)!\44T9U1U]U8,C,K+CF>)K4@T""-U=3NK BBIVK3MW X=VN-+T\BI8YCZ
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M@U\<\$LK>T[)02I]+$^R92XF"U*CX4TV\6XMHVVRJ8E*E%3CSS*'6%K7E.Y
MUG@">.#QAXBA#0!FYAX?S61.8NDJG,Y>^,7DP*$:&1H&)F6_M,BS([*0AXA\
MS4O@XS:G^3D)_EW?E2]0J34T :Z;I1T^I/%/>8\50=0HA1ZF2C*EI604.+&
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M "<8O<=)(L;'2:0RRQPQ1R2DDM(ZH%DDLFRTA!8WKK9-Z".Y!=U44K,QZ:%
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MGQ H-/1U!Q'TE(_A_P#];X3RL)7Z)HLS,QQKTLCLD,\+#N%5Y;V^\#H=0=]
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M;[\R2J0D.E+B8F9B<OY7C<LABZTYIFX^1E\PC?I83RH<4R9,91Y J1MDIC@
MA0D<87X%4'5\YQ((,7";'4GR5\CS KKU@JTWQ=5JQZB]%#80])V6D&DEO5T-
M41AV0TTU(=2EN,7VD(QTA25A)6I2PH$%QU16M'0H'PRWQ5$J22X4GW%_TTUO
M0[&^,TX+&QK8'?\ ?[WUOC[!..V<<#X' X' X' X' X' X' X' X' X' X'
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M<C()&,>7ECOMMOL/L.'4 K?7O[?\_G7!<9(^K? V 'N,?KWSC[\&QH=]]AW
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M-I>Z)+3SRUNN-O)6A;BU+4DJ))LSCP$H3!"3&0T9,:6C*  R'IM2   5H@
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MJ1(677WWWW5+=>?==4IQUUQ2G''%J6M:E$D[!T5H0J!55%"!5'2JJ!2@!0
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MY_Q'BFRDH4:T[C:]!^^^E\/H-==[_&[/>ZHZ5OW[\23#R_#B.) Z(^8JP/\
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MAAUYJ,RPAU]&F]+L29-=IF'(> D6-S-MKJQBXF#+YC<PY@R2Y[HR(D9+8^!
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M)LB%4CA CFR9H2>I75R"3=9N3]@C'+<*?KA\MAD-2LWFN[AT1QH 4JZ!<%F
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ME;CL(/QU(>:9D+668BV4I6ILMN*TG\,9Q@<SYARL="#!Y]S*'RH\23#"P<S
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MV]^]_0>_?;8>G&KQ ?U'GG[]L?H<CA?2-=]11]?WZ^OXVFQ9%G;?4&A_7<Z
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MW7-(*6@E.48[NCY\D_,W*]1&:RMCJR[%,*)(<)64GX9#CF5=+D)'49ZS4C
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M.VVNM'77T ^5<&/,+$$ ](%T*/H"?72MKT]Z'$@U<S"@"0!D'I[@[CML=SW
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MH?$=ZZ>INH4* I6-_$&NZ)90%&4[X@)UDY+,C3KT5,QU99?JM0NP+"A8%OS
MMV6-*3OPJ0G3YQKLUTI34:0U)KJL1T1XZ)I3%)/#Z1A LZMTJ+67'$D>0WD\
MOA9LI/-4Y _Z$.MLI624L68H.HFR@2WPG4]FHJ.J1J0U\-"4@Z40*%7PR=<\
MT++73*X\RH@549%E'L:^#7*=16T_3 <ASH5/#6GH@PK%WP);[+2AE<6.EQ3Y
M:0X)V#RN/!8,DTDK&)HY'DHR36X9))G&KR1KU*K$:!VKI!*\(?(\PUTA1=@6
M:734*+T#5L--!N>(]8(Z@>KI.!C;8CS'<8V\L_F>)[[UIKK="^X_WU[\))K]
M]_Z<*" GJRH=0.<XWP2?3OC_ +[]N$;\&*W.EU\_EK]?[<&$I0H'H*?3?\_S
M'?\ Z$\%MM5^_P">U:[GA9"G:R-;'?VH5>_>CP0D15J)4!GR"1G/W[D?T^VY
MX4K=/;3V'^WY?VX25(W&A_KPDNL%(((Q@'((P=L;X/IOOOZGUX>!!V/T[\-L
MI(W)KMI]>POMZ5^7"-);&2"D*R2<GMOCO]/<?].'T)K?;3WK^W]OP:H'<7PM
MU6M;FB9=:K6*Z.I3<=MN0U70!(;#"%)<<\?Y<NK>D*Z5N.E05MA)!RI6-YMX
M$Y;SS*7(YCG\TR(Q-D3/BRY^8V,PF=6CC2'[0(HX\<&1(D"L@# ]%+1V_+O&
M_P#AF%]EQ_#O)O.6'%B3-&/&)S)CQ/'+),RQ]<GVEA%++T/#+UB:YB)5\M7D
M<Y^9CN$MZE=B!)3THBP:YI*2@ )5DQ%.!6!U=7625GJ.X21#Q?X2> ,92#R)
M,HL3;Y>7F3LUL6((.0J$7H 4("@**73B)E^/?$V7)YBYL>"1=)@XN/BHI*])
M((C,@M 0:>F8DD FRS=2:RUMJU"&M2:JOKJ.T<M1;&SER(C1!!RU$4Z8K2@<
M9+;23L,' XU')O"GAGP[UGD7(.4<I>05)+@8&-CS2#N))XXUFD'_ *W;C/\
M,.<<VYH1_B/,\S-4&U7)RI9437M&S%%(_P#*H]MN#O+]K2#-R^YK@2'JEFO<
M=CQHTF5$7*L/FH:&F%R(<26^VT(RY;RU)0D+#(;#J'%)/%ES#[885&"5$K2
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M+]H$@8E<5HYG3&5KGZV<SHK1(22$*@H2_P +E0M*;-@$CVHGIO7U%CB5H?\
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MTX>A)(U)V/Z\$=OJOZCA%6E)4<@'\AY@9X>X/C86T#LA W'9('F/;A/^K_\
M+_7@<%GFT=7\"/\ Z1Z#VX5PM #=@';?Z\:?#1_R(_\ I'^G X(_=7Z_KP92
MA'6GZ$]E?X1[>W"3N?\ \O\ _4>"['YC^O"LPA'[OZ4]T_X1Z_;AEB:.IV/?
M@U_U?^D\.%AM!0,H0< 8RD>_MPPVY^9_7A2:[Z[[^W37X<$)[372#X;>>D;]
M"<]OMPJ-FLZG_5W/_=PI?]7_ *CPE+0@8PA(SG.$@9[>W#UGU/XGA-"VT&Z]
MO4Z\8*0CH)Z4YR=^D9_A]<<&";&IW'<^O#?!-24Y3]*=SOL-]QWVX79Z+LWZ
M]]^!Q@XE.?X4]T^0]N%\&-_H?T/&\(1@_0GN/\(]#[>P_3A()ZFUVJO;3@N
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M=^_KQ7Y&5E0,#!DSPG36*:2,[>J,.'YRJU!?R&XC,B\MWV2^ 6GK*:ZT0%8
M+:WU(V&PV[;=N,MSW"PU$SKB8JN.JF&/$&&AV8)8^AXV'AWF&?-+CB7.S)00
MMB3)F>]8_P#N<^I_$\7,H7''$I\1:W-C_&I2NRAC^(GMQQW*51))2@?>[#WX
MZC"S&K9C]W<D_KPX[A2FHKBFE%M0;V4V2A7\/JG!XI553( 5!!8@@@$$>FO#
MTC,!HQ&C;$C]/F>*^ZAMK1NPZ6[*P0GP4'")DE(SU.#. X!G  SZ <:_EN/
C<;6"$_S'_P##3T7_ ,O%'DY.2K@+D3J.@&EED NVUH-Q_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g307489g26b78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g26b78.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1_<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '\"^@2@X0DE-! 0       \< @   @  ' (%  -796( .$))300E
M   04Q0N@(LOPZY94@"A0'MCCSA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #00    8             !&4   8:    !@!G #( -@!B #<
M.     $                          0             &&@  !&4
M                 0                         0     0       &YU
M;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !&4
M4F=H=&QO;F<   8:    !G-L:6-E<U9L3',    !3V)J8P    $       5S
M;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M      9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A
M=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   1E     %)G:'1L;VYG   &&@
M  -U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB
M;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M  ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E
M96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E
M=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S
M971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M#     (_\        #A"24T$$0       0$ .$))3004       $     SA"
M24T$#      53     $   "@    <P   >   ->@   5,  8  '_V/_M  Q!
M9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1
M%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ <P"@ P$B  (1 0,1 ?_=
M  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$!
M 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A
M$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$
MDU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:V
MQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%1
M87$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4
MHQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G
M-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]522224I))))34?U*BNU]3VO#FF!
M#29TW?FSM_MIOVKB1/O@F!^C?J9<W]W^0Y7%!\ES6 P#))',#M_TD[T]C]JP
MB?[P_P 7_P!"6HO9?7ZC 0)(AP@Z';PJF;T>C+R!DNMNIL#&LW4O],PUSK/Y
MQK?4]V]V]F_TOY'J5UO38.59?7?8X%KL>UU9!^D0SGU*P7['._P>W^19_P &
MK%YMMI>QE9]S2!N($Z?-+Y9::=$Q-@7KHYIZ3C$AU=^<&&7 LO.HC9O:USO5
M_1[_ ,QO_;BL8G2,:NZO+9D9%Q:YSV"RTO;[PYNW8[\UGJ.V++R\WJ7[9)J9
M8-KZQ0[8XTFCV?:/5NV^G0ZMWK_:6W[+/T=7I_I/26]0ZP-)],[7N<YNH!@F
M?<U^W;N^DI,@E$#U?,%L)<1EI7":7S<RO"QW9%K7N8TM!%8W.]SFUSM'[N]9
MX^M'2_SQ?6(U+J;  3^9]'Z:#G]5=BFK(R*;+*,@$4%CRR+3/H8WIM<QVZQC
M?YS](M' LR(%62TML-;;-A.XLW;@ZIUGYVS;^]_VY_.*.@!9'XLC4/UHZ6UK
MG.%S=@W.!ILTT<_:?;^Y6]6L#JN-U!]K*&V#T0TEUC"P$/W[=F^'_P"#_=5U
M) F/0'[5*22204I))))2DDDDE/\ _]#U5#KOILK%M=C7UNT:]I!:3.S1P_E>
MU3(!$'@K+/U7Z%M:T8H:UH  :Y[> UK3[7?2_1_2_P"N?31%=;^BM750K;@P
M0P!]A<&!L_G$;O<==OL]ZSO^:W0]I;]G,&/\)8- 6.;J+/\ @O\ 7>BGHV!1
MBOIHH8*C9ZSZGDECB&BLSOW;?T;4:CW/V?\ H2#?8?:VG'*K;O)9:!JYC6EI
MC^1[W^Y.TONVV-.QG+#$ET_O?NL_D_3_ *BHCI^ 6@X^ UEL2QSV!H:?WG?2
M_P"@M"DL],-;(V -+3R('#DC70_A2!9^8 >1XO\ O4;:FTAE;6M943!#1&OT
MFS_)5A1L9O86\$\'P(U:[_.35/WL#H@GD>!&CA_G)MK@ &+F,.0PD G:XS'<
M%D(J&[^?9_5=^5BD]P8TO=PT2?DDIS\OIE>6[TG-;933:V]C'[AMM]QW,=4^
MO_2;_3?_ *16FTW5.=;N]6Q_TP1&@^BVK]S;^Z]$I:6UC=])WN=\3JE=;L$#
MZ1!()U _E.^CX_11U.BB5AD4P27AD?2#O:1V]VY$!!$C4%8?4&Y;K678ECJW
M,(@07-?N_1V_:-@<[?Z>RVE[6?X#T?\ "+3P!MJ<T2&[I8TZ$-(^EM_,]1X?
M9M1,:0) AE=<:FW6O?LJI;O=[=Q #7.>8:7/=_F(;<_%=K]KJ \# TW;?SG?
M1=M=M<C[&O-K'B6. !!F""-5R'2?K'@]5K>T=+H+[V4O8RJ[U&;[WV'[+F/=
M13]ES&-]3(]/9=^A_P )_-)T1$[@]-N%:1/<57C;TYSJ [:[):" "7%L-@BL
MA^^=NQWJ?2_E^FG&=C.L%;<NLO<8:!&I)<QK>?I[OS%A=1Z]CTV6LR>F"Q]%
M#K,O8^=M./?C-LV?HV^JRK&SGYVS]'_-?9T)OUGZ._JF+ANQ*Q7D9#ZJK_5;
M)96\8>'E-H^E:S*ZC3=C4>GZGIU4_:G_ **U&H]C_P U59-Q5?X3T3<_&<YS
M?M+&ECRPM<-IEKG-/TB/W=F]29DBVI]F/>RXUB2&C=K ,'T][O=M?^:N:Q_K
M)C]1N&+1TQAS7G)L--UNQA;2_;7?ZC*;768^9NR/?Z/Z/*HLQK?](MCI&0<W
MH8ZA9BUXGVV@7-K99ZH]-[/6JP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MW"O^XL;0L5;ZN=NUY^,,'#'G*L/#33T0&64.W+R9\;!V(..8;J\ ^T+%P$?
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MF#<I>NH"P=4K6YZK0)_;LW?5ET%K;<?;5*G],9K ;=5C-2SE;C2S@9UF58(
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M<8SYRE*LIRI*593GNG.<8SE.?IW3G..^,]O;OCMSWDCG@D<^_P"_\\\X!X)
M)'L>/;^7VSG*4YSA64XRI/?PYSC&<I[X[9[9^N.^/;/;ZX^O/,< D$@$CV/
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M4>'$>PI:([8V\7H&SCI[)\M!X&O]5;8K31"LY7XT W&29;PE&<$N96I+?K)
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M+7XNU[L77,-EK"LXRMU^T76 !2EO"E>$M6>V$X4K%UJ.&@WM<']6QI7]%?\
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MI'6D<+Z7KM(XM ]W?ZGIJ?';V^><E6CU5^<5A23I\]/\1?&-:DV(W /+^O\
M#)%$:1 'I^EZKJ2>_OX';G$6K:V;E)8FFM>IU[C!?R=R+?LBKDI7=KT'S)DL
M=$(G&4^?ZO(KR\XSY6&<9QE><>SC0?EL)K-N#M_T_B!.E(:T>&]7T6C<VCY[
M?3[U'CN[OIBJ>JOSFR+J=/CI_B;X1JLFR.Y)Y3T/B4FB6D 5[_6]*0\'L[.0
M3Q3(!6[\@6K\4,ZJ3*8 5^",0!%N< 7)^6;X,6K,B*V0V!YOR[Q9B$ND>7DW
MMCQ)8\6ZV.F/6H? MOC!ZH_,_BTUXF$'=%S\!Z,C(TO;ZW L=J=WI<G@OQ%H
M'K<U]K^9ITJ+8KG\D^ EV[5VM=L_ VIL0K(E?O\ AN34#R=IG\<B/GX85O/\
M&&Y)9U/C87S5OY<VP3<,TS,)_)/-R:ZX)B;3*_\ 7WEI894)GL)XE8[O=O7'
M2WYE$(VW_P"4>@?6+QZ[\R%K]3CTE63X4P?T7/>PD_I./ZN>(>N?R:<RQ]*?
MY0?%+\,J2[<Z8TOT>\SNT(NBU_RCM$<9A\0\GR_',NK>6*S7\P+.IU7'.2/Q
M4B7)MZ*RE/=7I/P^X&*N47GMX/4?,6F\=_%Y?MVXKCI;XZW\6V_&MX3X$UTU
MQO$\#U/BUED$ '//9Z+'QP&^X6SUQ^64#13I0[CF3\T6W+MUU@')]'X!X86M
M,>.WU/B$7SR5\  ^^;5M[$[7,5QK6ZJSEJ,_%RIM^SHG4/\ K%?.?PX@ =R/
M<:Q'^',9\S<;7DSQ8*[,9QG&FJ.GOA+GQK;D7NZ;\O%5*)J%/3'P_P 89768
M-ZW/K>@&'I\=GS9(NGJ[X_7#7+TX=65J_FS77V8OJ_K'XS\N6"-J[+\/Q\+\
M2Z$S<B7A.#G:VK;'X\<2ZUKS]&/=7E.-OV3\>=OE6/!YC*A_P_W^=]\*RDC_
M &J[*QCU>?#CQAH/RH%6W'YYX[E9*7Y5_3^>'#_%_P#)?(Y3^G\']/SF2GJO
M\]8.G3W^3/GL99-E^>\?"#CN0QC7C_/N>2)#_FG! ];QGE@5;ES(63%H:UDF
M*P*?^$,P)%J7(+-\]7RO%D3(C-C-BY&\.3\QBG7</^+ ^,MXQG.=L=-^C3^!
M;=FQZD7Y@+:4!"(NP>O\&89&<R=_/I"<*O9QWGG-5 ]8FQL?S1.F5J"*Q^4&
MA)M&L--ZA^%_,18B2-8C%Q\1\,782<B/E0"?-&JWCFISN9AG5*;S@AC\,HC2
M;>JIJ$\0OJ<SKI0B)A!'@];Y&(]EQOQ8%\S/;+O;9..E_CZOPS[\ZOL?XXSQ
MZX7Q)Q)Z?PJQR&N4Y]+O]9E;CU./ZN:JQZX_*KQMITH-WZL?Y:M:7;G5&'F+
MU?CGEA%M9>/6],5T9>1%W'@OQP:K>7X-B<Q[.J,[!S(NXG6S2;?BFIB.\AY&
M8EY@14VJ1\.(KS4F,(&QG,AX%9PD;Q(QTO\ F5@3-O\ \H]%?A3&FN.R-C]'
MO^(5I!5$//K]IC8O_0\C^/CV8];_ )/4->/I4]0?$O\ '+--MQIQ3YL>F:CI
M";IL\?"=XFC6+DV.UO$7/=/JW5A%7_"[.KE+R$/^-?GY-L0A$C_)O58J_P N
M%<RX%C^6>G5+>4_GL-YB<=W>V-0=-<WOCFWH'JO^6?")0),/ZGI_'>M(O;+_
M $7?\/W)_2=O]7,[YZTXU?Y8G3!)@C_.OCY=JH6S^EZHU?P\+=\']-Z9M]DG
MB+N'EN/:8K;/XX%Q'M:[SK;NQZUPQ^RIO&,>E5ZKTK+ RH'.<&^'#'FOIQD7
MQ9<[/8QC.J,:#\KD,S;C\Z^?TEC6E^5_T@]/U&9_B_Z+GO[4_I. OR\G-TQZ
ML_.XA73IX].<Q^LTTFR&[ ](^KZ4:1&@3Z_ C[I!S%R6X?QG,*K;&;;,XL36
MO$T3")#\/N0K]D7;5.>J8^5?.6CAVX=",@^IS(>B><5@K#&!N[.7,X61H/R^
MM\&VX.UYB^,%E:0UX'IMZ_PS1.UDGU>P1>JH!C[B_#<#%(]6?FUP;%.GAHNV
MQ\ U*39';%_5C^%^,2>)::J8/5^(,+L1*(Q&"A8BEP2MXY@K-FS,ZH39<#-?
M@U,$3;UP2R_ 3Y_XF7("MR#8WF^D\K,4VZ[X,DY7CQ8:QG?:'2_Q5'X)M^:7
M>WYD;2:X6A'RG;\"(I&A9^/4[A8*KSV '@L1&HGK?X'9_F:=*C9B)?R<49=N
MU%INV3O_ #,V(EL+%W>CV_"AW[?4Y\A>8:M75MKS19HE0ZE+K5JQL(X!%A%C
MJ37MAST*Y6C"S(^-+];BOF*08X;%2C3X[CB%(2RTO#>$.H6OHJ/0&WZHCDV'
M1>MO7M1%*:CS;.YIZED78XXYIH_2^,C!C6*> HX!!+,.[D$#D]C^*6CZ+EBU
M7XB[C5ZW?S0B_%7TFOZAOTCK9998*\IG_+YB)FFK6EDC9E*A$/;VL&;+SGS[
M/JV.,8XQCC&.,8XQCC&.,8XQCC&.,9%NT[+.184#5:<\@:\;"FOPU7I)T1L\
M:LBM ERUENAP3N?)('K$  :1'#E)R!*6HFM5\UQAF:R\B=1AC=I9[ [JM2/U
MID#%#,Q98X:RL/*F>5E5V7YHX!-,O)BX,2W*Z".*$\3V7]*-B.X1J%+RS,/M
M%&K%0?E:4Q(W ?G+HIE+@*% L5^NC.M"H?).-,,(=/F)R8/=R1*V"P2Q*EFS
M,_,%J<,E98YUTLPEQ2W%^'"$(T6+$MJ4RRD%N JJH"QQ1H.$BBC7A8XHUX5$
M4!5 ^_).Z&%($"1CQR69B>7D<_Q22,?+R.?+,Q))_8#+JYHS;G4^PP4P\,2R
MT0,0TXP0.^VAYA]AY&6W67FG,*;=:=;4I#C:TJ0M"LI5C*<YQST$@@@D$$$$
M'@@CR""/((/D$>V>$ @@@$$$$$<@@^""#X((]QF-L?+NZ+LK.M6(R>L--M(!
M9^F(B,9]<;"RL5Y.)[5+1A;K H$ $$^/9J25-GL1\)7V;5!K-C:_48 55E8(
MNUC>\"U#(L5X#P9Q+W&&Z0/'J,RM#:(X#2>A*>Z6Q(<A1<UIQ5_YB5&DJ_\
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M],\\]O?,O?VSGC&.,8XQCC&6AL)FTD4&[CT9[T]V?J-D9I[^5"(PQ:'88U$
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MSLF Y?\ <49-V-%8)&[B2.J-9U))=3GY\2A2PY4/+3-OM/R^ES#9=(C\VM^
ME(:H^[C8-M+*['8P5X[\T$7Q"T8A5-V4!C^97EYDABMVE:-IEK00K9[39>.*
M69II^AZ>Z8UG2>GCI?'[*Y7DDDL:C4RVH9VU.MFC4U:OY@\4D\>OA<=^NH6E
MNWO@W9&N4Z0UH>4"J5OB'94=6MUQMHDT(\:H/9>O8%-=.4G*W,B"2.OL5"=K
MRR,Y0.B5+_&+<>UCSUP4J[C+;E2)*S<!ZY0>W?#*W?\ ^LRR]Z.?V7T@>. 5
MYYRZ^(UTG8DNN,"HJIZM*U,)G^9R9IUN&U%++VL@[*XHQ,(P (V=G%X:YV)B
M[-345+PI%0OM/,'C;M2S2D'.1)!C*R(J6AY9ID8>R4^R"-N&UBSB#CMG-LGQ
M,H#"6N"LM;A,)8O3[65A)%("T<@''/!X967R4E0^'C)/'*NI>)XY'U7*?PQB
MDBF2S4LH7K64';W=O EAGB[F:M;KL0EBNY) :.>%YZ=BK:GDKFG(6.,98VSX
MAR?UKL*"9FQJT]-4>V1+5C-(4(' .2,">&B;+*0ZRL8:*4]@Y\A#S*F6F%.)
M=;RG"\6FDL+4W6HM-6>ZM;::^PU.)!));6&W%(:T:%6#O.%,2(58,S@%3SQE
M'U-4:_TWU!12[%K7N:3:U5V,TABAH-8HSQ"Y-*&0QQ52XFDD#J41"P8<<BZ(
M=C(L1%C*(06H>.!846VK*VR<M#--Y(0O.596A[*?,2K*LY4E6,]\]^_(-EQ)
M8G<(8P\TKB,C@QAG8A".!P4Y[2.!QQQP,LZ:&.I5C,@F,=:!#,I[EE*1*ID5
MB26#\=P))Y!YY/OFO_KRJ$/?;+TE4VQQV92NV;?(\'.A=G,8>BY2#*#,3EUK
MLX.OR75J:(0I#C#J4/-+0XA*L?6?PKV%G54>O]C2F]"Y2Z6:U5E^4E9X+*R1
MGM;D,.Y0&4@AE)5@0Q!^&_C7JZNZVGX7:F_ ;%#8]8_!78OF'?6LUA%, Z<-
M&WILQ212&C8!U(901@]0*?OC7G4K:M,+>-D[=J;I;W#4-&6M+;K)=@KI_KIW
M7!;1*^PZC8\^6S",9:6D>.)C,0_O\I4\[].V^QZ5V_1=#J15C@U^_P"N.G=A
MU10)5XZER+T:NYC9!RXCFBK?%,&#/,DQL_\ SCM7XWH]5UKH.O\ :=(F2:SM
M^F/PXZKU?1FQ"LDEVA,MF[T]-'(>$+P3VS3C["(ZTE?X($_"EVL[I+J\-8]F
MZ%@(DRMBVUN(OT3N>O5G7^S6;=)5Z4!) MT'OR<L4RY6GLG.O.N0Q347@1$C
M@9G#89:H<55EU]>LT])U7;L177UYL:FQTU;N[?2OKX;D$J2ZZWTI5IUQ=3TE
M119C:P9##WGF1!9<4WX8:VGL.I.B*%677Q[05=W5ZKHZW1]1IM)M=9AEAVU'
MK>Y?MG6N+'?(:<J55A6P(4(BL&G&;9''V[29<2:>C9 V/^&[- PN6/"K#MKC
M[AN>6;>6$[E'A;%-H7H1EX:[81%QC1+F<,K;;5.=^G]I!)56:.*7\9JTUD."
M.VC-KNFJY19!SRTD>U]5QW^]B=HUY8$B!%%U5I[4-QZTDT'_  ?K4%,H00^P
M@VO5]E7>%^WB.*QIA$C]GA:E5)6 0JAW&=#&OCJ'TY4\R>84U<=DDRVV;J^\
MWEHLR?OQ>9=ITU*L87@QB!S"@$87CQ8<#5A6,*[\_.OXH[>+:]8[&.J_.NTJ
M5^G]:BMW1Q5-3&*[+$1X])[8LS)QXXD'&?K'\%M#-H_P_P!5+=C[-MU#):ZH
MW#LO9+->W<OQ*/./?UDH"E!)W?-W0GGSSFM;9.M+>!U)7#HJB(PL;4_4)NVB
M[U<(#PXT,-1V0)F;V/'-X;_8LM+EX(=@#S%(2.Y4 6_+<4>QX?L^FW6OFZ,U
MWXEV9HWW_2/3.TZ6"R%6>3:/-7K::9N[YF85[3M-P.Z1=C*W($3D_GSJ#IW:
M0?B!MOP@J02Q],]<]8Z3K-FA#(D>F2"Y;W\2]OR(OQ=.)*Y;A8FTU=>UC/&H
M]?7493IK=&X:?(4>F0=CK^EH@*EV"[0^R[M9+TEV'<D 8K2M>AI,:G4YV&D'
ME1YMA="):!,'EY(H4QEN9:8U_A;'L:W3?3NQAV>RM4[?4MB394]98TNLI:HK
M86*6QU+;LP/L-B+$*>M%465&EC>M DD3&L7R_&F;4V^K^K-7/IM/2OT.DJ<&
MHO;FMU'N-CN@U1IX:O2%"I9CU&H-6P_P\MYX)(H)DMVI8IQ\:D5R:NU]4MW;
MXZ4(O9<1^-H#^\#K!L@)+NFO!R,Q%6B3CTLS&4NMY/6 2\X1@4Q;F&I,,0W*
M/4AL.-P]YMMATQTIU]/I+'Y9;'XM7HH9*ZQ+)#6L4()>ZN"K"(2HJIZD8!:"
M22('TY74V73>BU/676OX85NH*@W%(?@AK9IH[33-'/:J;"Q7"6B&5IC#+(TG
MIRL0MF**8CU(D88]-5J@B].O299]HP^"*)4.J2ZTJU'R@DQ(L1>M"[&?+2,&
M2R$V^;F,)6$67D89E1;[R'$BI6XK+>>N>[MGZQZ^I:.QV;78]#ZW9T(8)*\3
MS[J.G'7BM(\I2(3H)8T]1V$:J0SD <YP<6OT4?0'X9;+J6J'TFL_$;;:?936
M([<\=;IV:X]RU1=(@\QKRF&Q+Z4:-,[*PB!8E<^MX8I]=W/MF>A@*MLB8DME
M5J7B=6;3I&Q:WN>0P^Y$J@<Z2O5"-Q)%5-+&1_DBR)J%1\G!8;77RW, *E'3
M'YC<Z;T%6S->TU:'2W:\^^T.ST]SIN$HLXM_Y3:K;1&!-@6$GQ(6M9)LRN1<
MB4R_#X]8C3T>K.J;U6OK=]:FZBU]JKTUU+INH-?U=9#O7-#_ "0W&CG%F35B
M,PFD9+E(&E%$K:^8_#?%;=NMJ C+?TA[6>L$!AXR*H[UJC(\S*B"86R1X?FA
MOH6ROLZ=&.$/M8<[N-K7XU92O&<<_/?X:6Y]?^(6A2I;[8Y]JE">:,!$LTII
M@LJD,/EBG5%8KX(' Y'&?JS\8*-;:_A9U+)?H]TU33MM*T$I+R4MC7A[HI R
M-PTU8R2+W?,I/<>"#F!\-T\:IM.[^C/7<W21W:))=*A%LL%;9>DP8^7L4D*3
M.'$2CHA3!>5D6 O,XXP@IE&9,<=WP>!ORE?5;/5^^H=+_B/N*NS==I#UZM"I
M=9899J].!XJL20"1'CX2G&*JN48^@[KSRW</B57H/I?9=;?A-H;>FC;2V?PS
M.SNT$:Q#!:O6$MWIY++Q2)*?4V$WQC(LJ+\2L;<=J]ABG:,3J&'F>L.O;]K4
M^]U#R=F,$Z94#0MO*(?JC #8>I!-</Q++L6.'%%MA-'L^-E+@+2(]."BQS1&
M[[16.H;-?\.[G25RHO2$%)).MB]G71JFP>5I>H)-RL[+.SSQM(T1[6(E8S'L
MC>*0\QU)5Z3IV_Q7U_7&MO-UY9V4L7X>+'3VDC2:J.%8>EHM"]96K)#5D2%9
MU)56KJM=%EECG@6_LZE>V%NBW =0->S:;?6/A[0,[*,3*BGE,;&CPQA$RQ3@
M[S:"K%%J+D48?RM_RI$@HP?L0EIY%4=^NHZ:UTO2-SX'77OQ<MU8&K!%633S
M2RR&NBR(2E.<1P'L 7F%(XW^4LIN5Z7?>]8[>OUS0.RVNN_ JE?L);,K/'OZ
M]>O"MF5XY!ZM^N9K*EV9^VP\LJ?.JN*1I37-=J>/AK;%@H9^/O-UM5_!NEF0
M_(*E9N,88>BH^.E'G7E]XZ.AFT1$:'X6Q18O"A&FL-+5C.[J7<7;_P#X:-/:
ML++J]90U,NNHE(A!5G9EGFF@55'$TUIC9GD/=(]@B1F[@,U]']/Z[6#_ (/V
M_I5&K[K<;7>0[;8*\YLW*\8>K7AG=G;]"O105((@%CCJ\Q*OIDC-\?/ROG[6
MS6!UH;^OFK=JP]=K'3/6-QQY5$B9=VT35$FK,4&63.641R#1(1P9##3 K0+!
MJ!%+PZVY(NNJ3A+Z,Y^X?AMTGJ-[H;-R]UO=Z<F3:V*XH5MI6I))&E6E(MHQ
M32H[/(TK1&0#M(A50>5('YL_&#KC>=-]3U*&M_#G6=6UY-)5M-L[NAO[26*6
M2[L8FI+8K021K'$L*3"$MWJUAG( D7G9_P ^'Y^D\<8QQC(\U_JG7VK%WE=!
MK8]=5LK8-AVI=\L&29?SZ_VM #=@L;V)(TS I$DB,!2X)'X$C6?3IR,$SE;F
M5R[=^W>%46YC,*52&C6Y5%]*I!W&*$=BKW!.]N&?N<\_,Q\9&K4ZU0V#7B$7
MQ5F2W/PSMZEB;M]24]S-P6[5Y5>U1QX4><C&6Z0^F^=UI:=02^JH20UW<[]-
M;3GZ\2=/.9=V+8)Q=DE+E&3'S;$]7I]V;<=/&/KTI%NQJW76HW(C#BVE38^H
M-Q%=@V,=Z5+E>K'1BF"Q?\DBB$*5I(_3]*:(1 (R3)(' '?W$ Y&DT^MEJRT
MI*B/6FL26GC+2?\ *9)3,\Z2=_J1RF5BX>-T*,3V%1XRW!.A;I1 J=#I(&H(
ML"!UIL=W;U/R#8+D'.@[+(2IHVY25L'L;5KLLS)CY2)+/6>:F&Y8%D4&2:*$
M$%99WMU1OFL6K+;!VENTQK[ :&LT3TE/*5DKM":\,<;?-&((HS&Y9T*LS$Z1
MH-0L,%=:2K'6LM<A[99UD6TP*O.TZRB:61U)60RR/ZB\*_<  .NI]!W2)2)*
MZ2E<T94AG-@5FSTNRQY[TY/5Y50ND@J5MM6@JK/R\G6JA7K')*R=,0]0B8./
M.)PEUX=2D)\*?JGJ"RE:.;9V"*DT%F!T$44PL5D].O/+/%&D]B6% %CDL22N
MB^ 1GD/3VFKO8>+7P@V8I8)E8R21M#.Q>:)89'>**.5SW.D2(K-Y(/ RIZZZ
M*.ES5%1V/1J-J&$C:UMR 55-D"R4I9K0?;*KF)+@F:Q(SUJG)N?1708@XP&+
MA Y,:,B6B7LQ@HCBU+SA<ZEWE^Q3M6MA*\VOE^(ILB00)!/ZBRF=(H(HHC,T
MBJTDK(SR$#O9AF5;1:FI#:KP4HUBNQ>C:#O+,TT(0QB%I)I))/25&94C5PB
MGL"D\YX[-T-=*=NJ>JJ/.Z>AWJOI.#D:OK.- F[;"*KM9F@6(R>K;LA!V".D
MY^ L0(S+%CAK*9,1UA[+<FACG7GG',H.I]]7GOVHMC()]G*D]YWBKR^M/$YD
MBF"2PND4L+L3#)"L;Q>T950 /)>G]/-%3@>C&8J$30U%5YD]*%U"21=R2*TD
M<B@"1)6=9/=PQ\YZ!NB3I<$JMAI+&IHY-7M>IJOHNP1*[!<7D2.IZ47)&U:F
M+)>L3AK $,1+2"A2Q26)7+;^&'CW1V1VFO#U+O&GALF^_KU[\VTAD$5<%+]A
M42>R%$(4O(L:!E92G(Y"@EB??R+4^C)7^#0PS4H]=(ADF(:E"S-%7Y,A8(A=
MN."&X/!;@ "0JAT]Z>H6T;ON>GTUJ"V1LB(@X.[V 29L2F+$!6P(V+A,F5\B
M7>K2) &.AXP'$P+#L2[XHC;!)SS:G$KAV-ML;=*KKK%DRTZ4DLE6)HX>86G=
MY)>V41B8HSR._IM(8PS$JH.28-;2K6K%V" 1V;2QI8D5Y.)1$BQQEHRYB[E1
M$7O"!RJ@,Q&>;:+[=*M="VZ1X&X& 1.42^FNN8;8A*9>R((EJUDJRGPX$KEQ
MK%63+EON,!0E5F+18#7VQ8IWOE2!LU[5 <F64Q6JJ@$F2Q5$JF  >[35YY_3
M #,\T<,2#NDQ:_1FKVR/DC]2O.Q]D@L&,^J?VCFBA[R2 D32.WA<G#E9D['&
M,<8R#;$ZW>=PTRL!>-^-U&\3L6VFLJ2H5BT3%=F:I1JD5G"LI=,?B;)9+H<'
MC'JHE$13CB4-C6&,<(LX0:NOL3MX>^!4KJ>0Q@CFCGM3C_5$D,596_A<R6%'
M+1-Q!D_7N01+Y2H38F;W E:)XH(3].XI*\Y ^9 D+'@2+W3ERLR=CC&.,8XQ
MCC&1AL'.*^?5]B(RTTS6C7(6T/.?JXQ2+2\$)*D+<RI+0[,#-BURT&F/YR@6
M%A9E"?#DI:N,9)_&,<8QQC'&,C;;J<KU_-8QGMGU5>5__"S0Z\X_KPGM_7QC
M))XQCC&.,8XQD8['3\]S7->H0AY%SDU+L+2E=\)HM>\B2M&'V<IS@@&:=5#T
MHQKQ(SAJW8>QG.&58XQDG<8QQC'&,<8QQC(2G9:!W*O8>I8.<ML6S7EPD3=[
M?5,C@AM%&D-GSFO(ZR+6X2Q8WJ\AIBR.PHZ#JW'6,)8\O'SRVD"]-5KV^FQI
M^H+577SM<%JQJ]=?[Y96CB0Q5=Q-2 "-26X6:DMES%=FI2AZ\U0,9.+O6J/6
M!Z@Z4HWMK52@:53=;?5>G#"DLTBSWNGZ^Q+-*FQ?7A4V+4XQ-KJ^QA:.W7OE
M1%:&Z;_C7&K[9%ZY"88(I="FU1(D>UV&!_#M?*7$P<<RTE><*1Z,<3.&D+RP
MWV8:PI_Q>5(UNLGO32[;9M),\\LEG]4]TEJ:5C(]B8D$D,[%_(YD8]Q'9QW+
MNTJTGH=/:F(1UXFIT&2I^F*]5&CKK1IE5?LD6("(,J/Z(X15:0$)J+ZP.D+6
M.HK=H'J3(E;?%Z7E]94CITV9>Z[=+?%$Z N!;0(^B^KJ/&AYN.@R0P+B^%5M
MK)G!"H4@6PPMN>!]:).'DR=-M;,\-N@JQ/;6>:_7AEAA<7X_+7M8Y>,OW21!
MI*_I]KAD>,$!E4=S='Q4MCO0PNTTKJ@"H86+'B-0B(J>C[*H144+VJBCA<FB
MM3<;M3;.OA]P"*SOY^5E>FK>^MX:PV($N'OU8K!%JI_4-18:,F(YL[7=AJ38
M<Y(NE(^38AIR,PVVN6B3TF9?/3IV32;B@%3:4++QQ,KUY91#/K;#O&Y6RDP:
M-.T^IWQMY".O'%[+7U[MVN;,;226.ZA/&DL\;12+&TD%^%(I4#1HO],KGL[&
M'@LI#; HFF ZSV_HR%A2#3G2M1;.IUA-*>><*FP*],4*R1<W+Y\2TO.0T]*3
MC$4EY2F8K%[F!@L-H.6E7*V++VUM2NBJ'L12J%'"1$I(GIKX\!T5.?(+^BI/
M/;XZ_5UORW0+J8TEGK5;-5UN3=TCQSO#;$J&1@P1MAXE>,.H<4(@J,E=?3RF
MY QCC&6#M82O2&KMD 6V3(A*J;0K>)9ID1E1!<37R:_(LS,F*P@8Q;Y $<LD
MIEE 92G'&DH2,_E6&E6NADMQ;S32Z^!+-^/:ZZ2E6D8(EBVER%JT#N7C"I+,
M$C9C)&%#$EUX[A0]4PZ^QTQU%!M;,E+5S:+;1;*Y$ADEJ4)*%A+=F.,1S%W@
MKF25$$4I9E $;\]INN%;%:AHEH%Y1 3<8 V&0M.4K?%0*TD=Y:<I1E*G6L(6
MI.4(SC*LXRE/;MB#:,C6;#2J$E:>4RH#R$D,C%U!!((5N0#R?;W.6M)8DIU%
M@<R0K6@6&1APTD0B01NP(4@L@#$=J\$\<#VRI\T9)QQC.,)3C.583C&5=O%G
M&,8RKM].^<>^>WV[_3GO)X Y/ ]A]!S[\?SSS@<D\#D^Y^IX]N?Y9SSS/<<8
MQQC./"G.<*SC&58QG&%=L=\8SV[XQGZXQGMCOC'U[8[_ $X_Q_C^\XX'OQY'
ML?MS[YSQC.,I2K'96,*Q[9[9QC..^,XSC/;/M[9QC./RSC&> 2/8\?RP0#[C
MG^>,I3E6%92G*DXSC"LXQXL8S]<8S]<8S]^WUY[R>..3Q]OI_=GG YYX'(]C
MQY']N<\\SW'&,XRE.<XSE.,Y3W\.<XQG*>_MGMGZX[X]L]OKQR?/GW]_W_GG
MG Y!X'(]C]1S[\?SSGC/<<8QQC-<G5Q)=>X>RXEKI? <*U[FEQBY-Q FKG\8
MMN9FPID497=5IEL9Q$I@\^%G'H,85C+.?/R3S[)^'T/X4R:6PW7$J)M_S*<0
MAI-ZA_+_ (:F82!K!\/Q\0;7EOU>>0WR!,_/GXJS?CC'U'57\-DG;0_D]8V#
M%#TK(OYJ;=_XCEMVIM\_"BER$/PX'!0>H9<V-\^-Y^@\<8QQC'&,<8QQC'&,
M<8QQC'&,<8SH*%%.%)"-&8,#,8>%+$*9;(%*%(;4R^,2.\E;3[#[2UM/,NH4
MVZVI2%I4E6<9]5F5@RDJRD,K*2&5@>001Y!!\@CR#Y&>$!@58!E8$,I (((X
M((/@@CP0?!&8XG.W'00@@\*(3LW6CIX,+6J;B4'9VK72Y%]L6,J]//GBA(2]
MP(Z.ZPP[5.UR9K$,&<4;:9V*#:'BK-I*=\AK#BC</])8$;/3L-Y)EFCA5YJT
MS'^-J\4T4C<'T(3WN\$)8J>(4-JN/X8>]$L0K]$B:0I'-$H_A662-T X]20=
MJK>.-XU=K"6Y"J;DC3NW9\#.BMP3&1G<8QE3*I6L4N>KI.4Y_5\^/F3 UYQG
M+1*T=E9P_+)SY2?7.ON'_--?'R/OZ<]F*9?Y/&K?=<].PA'AH;RL/=1KKTGG
M[>I#!)$?YK(1]>>/.>$BV;3O/CCZ+33M=13KF&G]@[+' 1()"6GNHRGZY!D#
M9<V1RGQ-,YV$Y2F(PG+1ST)91FG(LK(5Z-7A[-E+D@'(J4F<IW#V6S;9%C5/
MJ14^)+KRHEA8AU&6U8Y6"%JR'Q\19"ANTC^*&NKF0L/I\3Z 4\$I( 5/T!J[
M.M&<3>M/6GS*U.%W:.FY+U!>U2GE^<=.S,J2I@=G8><^),3/N)%BU@H%J)[
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MVEV=2%VCFM:^.A8>Y6BD66!DDGKB2)'6:(JS B1".X77"K%=AHET%E8X3D8
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M/D92.2,AJOS[F(K$=(5]C+MKMBB[3%,S$0ZZL=U;X[S!([P<A'GB.J'/BY0
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MK6M:LJ6M:L]U+6K.<Y4I6>^5*SG.<YSG.<]\YYU:JJ*%4!5           X
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M10PU]?Z0M2M?,3"0,UBK'6C6 22M93UDK1QV'AE24ZEJ\' 4"QAUR9/C]IT
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M9 EXPQY9!)"\N.O+SW4M6<8QCZ>V$I3C"4(3C"4(2E",82G&,=3##%7B2&%
MD:+PBK[ >_//N23R23R22222<^'3SS69I)YW:261BSNWN3[<?8 #@*H "@
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MD?(:[M-,S-4DAFT*5A#*<]LX\%IN?GAK2+]5-:*/G]N^!890/_5D7_:><?2
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MS[8[<B)#*Z2RHC-'"%,K@<K&';L0L?IW,>T?<YM+JK*I8!GY"@GRW Y/ ^O
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MXF(>(LD-*0$[' 3<#/1AL1,1,D,R=&2T1*"NAR$<>&0AP<P$\-]X8H9Y#C)
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MO4CAE((#*00>#GBQ,9A"WRL6[3SYX/W_ '_O\YBY9OB+]4DOT_\ 2=OKIO\
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MJ=1.S;W3A^F:Q;UV;JCI7,Z?H?5^Q*=?I2W[4AX@FX[%DDHVC.1TFB5_&<7
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M5DH4*^JL;":9 $::BGI^L*MP08MZ)_\ S&O6S]__ +">M.__ +5T-SZO9_\
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M\Y3<_P#E78__ &R?_P#J-D&7^E?_ -8YKO\ [FM__!-O?_UXMX?YGZE_Z?\
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M[CCV(/D_7@XQGO\ EG'?/T[9_?[?E]^WT[_7Z?=YX^O/OP!^Y'GZ?M['P..
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M,?0BLSNDD4,JFC];.P[AJ7I)ZAMF:_E\P%VH^J[58ZO-)"CI',9,QH"W@C,
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M">29IY#))PC,WR<&-87)4QOP"2.#VCGG8+,_$NI$)$:Z%)Z=NJ5>W-KGV?\
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M*5WL-5K]O@2B-8^2WCF9#_"&(LJ6KGO0SS1LH$((52"6F<(7,:<#CN"@>_\
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MC9$DC:X\T4:O/')%+$\=>!I[ BE 1YXH4</&SHV*W2)UP]1,@Y 5+J0J>@Z
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MKQUB6:.MBU\$CSF6$?%2_#>DT9EF#*5E+'DE$+)PI!["#SR1Q2YC9YFW*?\
M#-VGU>Z^N%ET+HJ>V_ISJJK<S2;#9HF(VQ7ZP#7=:VW8%.$C#29\"8$3"3BC
M/ELB"I]ZQQ"&GG37(Z0V14$UUGKK7]-W:U?;[:'6;/I^>.U#!+)KIIY)K]:G
M9:11"\3>M#V]\;\""4D=JNGJ1"&3:PT9HTL6%AFILLBJQA:3NECCDY 1E^92
M.Y3QVGCCRL-F:XD)'0/6J1JG4&S(3I[&Z\]+["MFKQJK8ZS8Y;I=!C[/(G!
M54QL6:1#,^MJTRU$Y0ER CAQ"C6@&HA]8EDMU$W'2Z['949=RW26TI5]@;$$
M\$>^9JZ*SV$+1&4A+$1DY(FD9E0N95[MPE7XJCZT\+V?RZ>-9N]'1;9*A27'
M*AO#J6X/<>0 >X9*1$3IFR;UZ^+7TH:EGZ9I.V?"EVR%65@ZRLM JUOM?SRJ
MA21M(KDM"Q#J!B70<1#K0D:+F5L4'8)%A@OSW3RZ\2;2OJ>D*_4.QBL[6O\
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M&G,O#U.:^8&F$GN.5H<A\>#$=)6!%L/.LAB,MN+3F/!HM175$AH01A+,-Q2
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M*KZ)-N)@!)14?(!0;NOZ?H:_J7=['4R;:S4ZZNZN!9]E>C,D!B$H2U*)7EF
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M81+!++;J=N0LL+#EVH7ZKZ9'8M.;RG""F6T/;$@&,N9[^K%;2P/>8T)E6>Q
M*!;DD8=MK,=<Y8ATQ3&=DMN"GB0\9(03Y%TE)\TN)K55JR1RK+-S4>C#DG%^
MB/(CV8)V$3E.;(59R82/K'=*9\J.=<::<UR2B,#PSNQX2-."[GZ\<D  #RS,
M551Y9AXR?0U\M]I65XJ]:L@DMW;)=:U6-F[4,C1I)(\DC?+#!!'+8G8$11/V
MMVTM%>W+:&UOV&_1VM&75J6/"ZRAXBP3 +?T0U(738L)-Q$NM2>ZW, :X@?3
MN9\ELHQ#?J'M798<<O*L//LL*J[*/WDF5E8_RA4 ^/F'DSC9T=0A:VNEVK
M-/MIYZT$A^K14-78KSP#GPIDVECN #%(R2BT6PZDV0?7IR%C.H"YG+FXPR)?
M3>:EK>6CVQ#QW!BO(Q0JGK"=&*<8<<;9,;GU9$6OSVV%N(1C 0S+Y6U(Y\^)
MHX67_P#%1P-__/\ V9X=CJIN$GZ?JUT^LFJO;.O9]_\ 3V5O<5B/N/A 3]'7
MWRYZK?3AI@"@W^O#4RV/C.8KKD86N2H]S'CQE/DMTV;>$CGT2D>$RX6?4)J/
MC9X,,<TV+:GH"-*GL9),W<(IE$<A_@(;NCEX'+>FQ /< "3&P#A067O52PU6
MM;%\.]_66&NT8RHL+)&(;U NP2/XVNKR+Z+N1'%=KR2UG=HXY36LRI6R6>;\
MJ,<8QQC'&,CS;N>VI]GY^O;7EUSV_/M6Y//&,OX?/=AC/YLMY_\ @3QC.WC&
M.,8XQCC&1A)W&9FY.1K6O(L"6)C'W +#:IU;[=-@#4>#!$2E ?8^UV$=+N%%
MPD6X%'@Y0^).66%DDL $U$M^Q/-+5U<4<TD+&.S=L%A1JRCCNA C(EN6DY!>
MO"T<<?E9[4$O;&U[#K*M:O#=W4\L$=A!+4U]4(VRN1$$I.WJ_HZ^E)QQ':L+
M+-,"LE6C:@+RI1(#55KA8*)A,;IO8K$."Q'!L04)K@6/8"%1AD,9E%EI5PFE
M-B#):%94?8) A3+*,D$/OY<>7Y^7[!R7EWMZ-B/*4ZNKAKK_ .HEJC?L#_\
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M^'*1G/H)TPEI82OHNJ_##X*K#M^OMD.E];,>*VN"^MU%L7/';%6H+',\+L6
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M-4JM%W%]/0_XSA4^M5CYG"#DV:2%GFA*C^D>-2\U7^LLP,:LL<\ZO(,M>Z1
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M-XX[F@^S1<\]B^W#0\]G9](O38$\MVW^T4[&"/>0_.[B&ON4''?!L53TUMN
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M'((()5E8>S*RD,K#Z,I!'T.2Z=VS0F]>K($<H\4BNB2PS0R#B2"Q!*KPV()
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M$ ',%Q9Q36(TJP@O/Q\H*]E\60;+:"D6*UBV;4TE*7L>QKI4@=HS(T<*ND_
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EQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g307489g26s26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g26s26.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2*T4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (IB^B%8X0DE-! 0      "(< 5H  QLE1QP"   "@  < @4 #G-L:61E
M,CAG<F%P:&EC.$))300E       01T[-Y9#1HR\&KXAM0<D9D3A"24T$.@
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M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!QU0Y0        "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _
M@   .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          CA"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8             !1\
M  ;Z          $                          0             &^@
M!1\                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M!1\     4F=H=&QO;F<   ;Z    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M:P==A>0UKWM#FO=;[*WK9^K[\7,QL7I^1@!XHZ=@W?:K6L<UY+;/3K&[<_\
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M*OS?\R;[Q_Z2V>SFU5Y-S6OLR'8UMK=[,=@K(8T_FV-M8^S(>R?T[]]=>_\
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M^>K$?IQEEG];^"!]9_\ Q-=6_P#"61_YZL6C@_FHL&7YR__1[;ZK_P WC_\
MIIZ=_P"[:O=2P^IWWM?AY0IJ%-M;ZB
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 1$  A$! Q$!_\0 'P   @(" P$! 0            0("0,'!08+ @H!_\0
M>A    4" P0%!08-#@@("P 3 0($!08#!P ($2$Q0? )46%QL1*!D:'A$Q05
M&3G!"A87(E98EYBVT=;7\1@:55=S=GB4E9:WN-+3(R0W0F)UM=0E)S(X9:.F
MM"8S149'9')T=X>DQC0UHD-$4K)C9X*%AI*3I[/$XO_$ !T! 0 # 0 # 0$
M           ! @,$!08'" G_Q !F$0 ! @,&! (&! 8+# 0+" ,!  (#!!$%
M(3%!4? 287&Q!N$'$X&1H<$4(M'Q%2,R-I33"!874E5R='6SM+4D,S5"5'.2
MDZ.RTM0T15-6)28W0V)D@H25HL,81$9C98.%I':EPO_:  P# 0 "$0,1 #\
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MY$E7NLK>Y=5J.1#"Z//>_@BE P],%G]NU2R:6IM'EDLC%,QV92Z>;RSSY6S
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M[E@B^"P"WIC'(6$PTQZ?D^Z$"-L@F)Y8>43RR@B$2^47ZXNH!J&T,$7W]3R
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MH?\ S99?]RP1'U/(!]@T/_FRR_[E@B/J>0#[!H?_ #99?]RP1'U/(!]@T/\
MYLLO^Y8(CZGD ^P:'_S99?\ <L$1]3R ?8-#_P";++_N6"+X- +>E.0AH5#"
MGJ>5[F08VR 8_DAY1O(**+4WDE#4V@#H&T<$7W]3R ?8-#_YLLO^Y8(CZGD
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MB<%4L2.-)>X4#M[V$6]''-]FWG*W,DW90;EY=YE:_(992S3\^W)O-'7V?O\
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M1]'WB3P=9?ACP_;5D^)K9?;4K:K9FR)F#:$M94I+RTU"BO?/RYB2[9B:,PR
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M(P1&"(P1&"(P1&"(P1=$BMK+8P5U>WV$6Y@<.>Y-4&M(WF*Q"/QYUD%4:QE
MU7MQ:&]&K=:@USGKB=?64&&L<U37RS"82)ELMS;YEE#Y-V>"PYIFDFH%3227
MML894,HD"8@TS$3OC^E14G5VH$-1I"2BO5J*91I4Q*4!(71O>ZHN41Q6,-Q&
M.FWQQA0TXQ24IXV1&SMZ8D>H+*/O9718RT4Y"M-)4G_P"FF@!.2O1_P54IB?
M6X(HX37)O9:X%\[?WNE,=;'?ZGMIKL6D0VT<8Y$W*V;LV7?N!;&Y4@D+Q'7%
MB5>[R1%*+6M*YM645-!/[X=7A<M2JW"JF5IB+?,AMO;N6U8W7E<"A<GK0U73
M7Q"M(8LQO56*+Z04 I+8W4<D*D[&LI@F3 12V&2UB GH 4X>Y$\E3[.7NP1<
MJVQ2+LM6G79XVP-->BE6HJ59M9VY!5I(G%Q.\."2G42IJ1R)5[M5JNBU.40I
M*G&H=;7)44G-5$BB[<#)[&[DWXL-=>0SZ6TK;Y<:PRJVN6EH:H,T6>1WA3MD
MOCS/>%Q.ABM*;KY%'8U-7AL88^>5$AC8MIM\A2L--[355:EO?;HBE:],C+)&
MQ6R2)H:WYF7D)37M#TWI'1L6TZ=4E>G35H%U&ND4D)6I4JQ"UJ1REJTR5"@!
MR%$"+AHO 8)!P6!"X5$H@#@-(5X1>.,\?!<*?R_<!6 THT@*1H^ZU/<O=O+]
MS]T/Y'D^6;4B[;@B,$1@B,$71'>UMLG^6M$^?;=01ZG4?"D##-':(Q]REC(%
M QST0:)&L;ZSPVA1/4J'I B64/<SG,8N@F$1(FY';R 3%TCSY+H-#I2]1%8+
MC$WB1QEE?'2,. GI5!71YP<T2I6RK!J)Z%053;635_+HTC>7Y5,@E(N25Q:,
M.!7PJ^.,*TLFHIDTD*K:&]260IT=$4Z2@^!63G!VHI4YC4$U)>"@E"B(TJ12
MD$2X(M%9GLKUOLT]K7JULQK+XXD?I'9J0+Y/%4K)0E-2E9"\42O5%6$S@Z-3
MG2JL5>31.FD6H*R>H6DW/#R9M,A<%95M,BVHAM/:UMA[E;UNMM 6^ O)UE1W
M@Z*'1U)$'6HX5"5E]1RC2=NILJXZVK3IU5AE**J*JH0IZ_NABE$"+*V6OMHR
MHT3<S6[@K2WMM!F3-R%LB3 @1H$T=7UW2/IT29*WTJ"6@Q.:I2XLU*@2G3:U
MZBNL1%H**M2H8BT]F?RW'S&6KF5KV*ZLWL"-R_>K/<J=6C:H$2>3*!5&ESC[
M]!E3W,HE*BMJ9Z8750WIY&U)TDKC8DH*(X\-QRUB5R+>D*AL9MU#8G;^%M"2
M/PZ#1IBA\484!!IH66-QIK2LS&THR")C%2MS8B2I*!3&,8*5$H&,8=1$+D7$
MMUJK7M#[]-#3;> M<F%2I6#(FZ'QY$^BK6#4%8J^%TS=2</?*H:U45-?WQ[K
M7&K4&J8XG-J1=]P1&"(P1&"*ICHY/^<[TP'\/ED_JG9=<$5L^"(P1&"(P1&"
M(P1&"*NCI>/DO,_'\%:\GX'.>"+R;L$7I8?0ROR/]@_W\7W_ *8IA@BH Z8?
M*UTNM^>F4L9=&WT":8B^KI,^M/1]HCW<MT0?I:RJHDMT9!*G<22,J2-KI(O7
MKYTL;9(=(J5IGM-$3BM%H"B#XJ,Z^SV;HOW=VM=YS(+;0)[N?$J,"N0ZQ"/+
MY]"DSNVOZ2*S%2U):LD8D3XT*US:[H6UW,K2H7)&JK4EB2G14:E-4,0I2N^8
M(C!%5ITJ^8BXF7VV^7H(+<:2VI:+M9H(#:JY\VM?#8_="_;3;A[CLR=7$+%6
MJ?X[-?IXFBU^98\WNI&> SY[C4+5264H(DO,TG5("+E>BOS$7#S"Y<;@RVY,
MX=;DA LQ=\[7P>;S&+,-O[P2*V$ D-)'#U]\K:1YLCJ6WEV!1U5%%YC:R'05
MU4LU&/2-QA[(H?S4CQ[=[NU]J*#EC\U&;3Z5.C[SMSR_;K,K;Y^LRR:T$LRP
M*81;9LMS:6 WJ27/46(<+7R=DA[?=()? J\,B"2<+II-)<W38DAD]8C;'S)&
MBJDE%'[)/FOJWX@]JG^\?2J9^XW>R:W!D;"\VO@F5RWZ^TB9R2W>D<2C,:03
MBED"EK85@7LR!DH.SU5NHJI(*BMPJJY"UG35A0D5DMVNF.RI6FSBPO+$^3YG
MHL]6*WW"ZTLK1FY]5RM_<^U<LM9&8U!4S<@A*M,_T)3]-TVK+'QK4+6QMJ1!
M,45GN;JG/5;ON119NKFJS:H(/FVS\QZ^SPQ6MRGYVE5@V'*DEAEL5EL[D6,M
M5=N"V3NZ\2^4ND-4W92W0E;R]SB5Q-[8YTT,D;*Q1=G/%G=*J<ZRN*8\^OV]
MJ(M41+I%KNW4OP_7(#,I>*T5O8_G[<LKK)#5V5QM>LCM*#1"[)K1A KN7\&!
MJ[AM=];T@E426(S5@N"C@$$D<F@43D34GIJ7!.J8?'=^79%^FT:U$IPI&K4@
MJ#H 4QJ% XB;_DZ$$WE?7< TV\-<2BRX(C!$8(C!$8(C!$8(C!$8(C!$8(C!
M$8(C!$8(C!$8(D71M2/#8XM"^F:JA=4*MM6TBG/2-42+D]1*IIEJTS%J4S'H
MU3E ],Q3D$?**8#  X(JA(_T%^1*),C9&HHLS91B-LB2DWLL?CN=[-<R,;.@
MH!Y-!"UM+;=E,@;T= OUM%*D3T:%(OUI"%#9@BYCXE')E]E.<O[_ "S>?G@P
M1'Q*.3+[*<Y?W^6;S\\&"(^)1R9?93G+^_RS>?G@P1'Q*.3+[*<Y?W^6;S\\
M&"(^)1R9?93G+^_RS>?G@P1'Q*.3+[*<Y?W^6;S\\&"(^)1R9?93G+^_RS>?
MG@P1'Q*.3+[*<Y?W^6;S\\&"(^)1R9?93G+^_P LWGYX,$1\2CDR^RG.7]_E
MF\_/!@B/B4<F7V4YR_O\LWGYX,$1\2CDR^RG.7]_EF\_/!@B/B4<F7V4YR_O
M\LWGYX,$1\2CDR^RG.7]_EF\_/!@B/B4<F7V4YR_O\LWGYX,$1\2CDR^RG.7
M]_EF\_/!@B/B4<F7V4YR_O\ +-Y^>#!$?$HY,OLISE_?Y9O/SP8(CXE')E]E
M.<O[_+-Y^>#!$?$HY,OLISE_?Y9O/SP8(CXE')E]E.<O[_+-Y^>#!$?$HY,O
MLISE_?Y9O/SP8(CXE')E]E.<O[_+-Y^>#!$?$HY,OLISE_?Y9O/SP8(CXE')
ME]E.<O[_ "S>?G@P1'Q*.3+[*<Y?W^6;S\\&"(^)1R9?93G+^_RS>?G@P1'Q
M*.3+[*<Y?W^6;S\\&"(^)1R9?93G+^_RS>?G@P1'Q*.3+[*<Y?W^6;S\\&"(
M^)1R9?93G+^_RS>?G@P1'Q*.3+[*<Y?W^6;S\\&"(^)1R9?93G+^_P LWGYX
M,$1\2CDR^RG.7]_EF\_/!@BE_E+R4V'R41Z>QNQ3=-DR:YTV^J).72X%RY[=
M632&6A'F2*E=%THN(_R-^J"1BCS0@IT!7^X$II""6F!A,(D4LL$1@B,$1@B,
M$1@B,$5='2\?)>9^/X*UY/P.<\$7DW8(O2P^AE?D?[!_OXOO_3%,,$4B,XGR
MJ?0W?NG2$_U;H[@BMPP1&"(P10IS>Y5)5?Y\R^75M1=%NM%?C*[<9\N':J42
MB#C<RW[B28PE[MS.XE/8)1DT*<W5EDL1?UJ5.YQ^81R0Q]QHIG%M<1TKI5!%
MTVP&4:]MCBOTA-F%B\CN/>_-&YYC<UCS0LQ09HE<%K<+:,=L4MK[616K.7==
M:QJ962#6Y!)*':1W!D+E68'M4\5%2J35:C?%^]C/EY-[HM'6BZ,N>6^DV7J#
MRG,0TS3*'E"O%++WY<K+I[35(_<=OD[DCG2&W<?N;=WZH3JV3*(6637'DA(2
MD8[<0YT=*J.,5I.Y. ,9J;@Q!KGI\L/BBZA8'(ATD>6.V<:LI:3/_E\26MAC
MI*E,:;)/DA=7^2)VV5S5_FRQ"X2*EF:;*:]1272)=0I+2M28 HEHC[V#R-!E
M%::^62@,BO5;G, ZH5U6Y=JX%<RVT0<J3FKHMR2+7<=;>/,U2JVDAP1KE*U?
M:Z(5$:U00U=O(D54TQBE7* ,15O7!Z,:;S&37@MZV9AFAER7YB,RT=S57FL4
MIM/6=+EN,Y02.&SB:0>'WE+<- V1VV-TI[ V63RUM76S>Y&C^$90U,4B0I'L
MIT48X[Y[P/O1(/\ T7$W=%DWL\VYBF5KR/7.S4)<W$WL<:SWOJ[)YD-TF>^,
M@MO';VEN$E:&FUDKN\QI)8XTU%K'&;H&Y4Z1AKEM!$JH+$DF_P!N**8V<Z%0
MT]D[@SPT2C(SEM3106Z9BPM0RMO&A,(_0HBAD0I/A=(-&C5JT:0T%E,:=*I4
MID\DAS /@/%3G0_"_B1['.8]E@VP]KVN+7-<VSY@M<UP-6EI (((((J*%<L\
M2)*<()!$K,$$&A!$%Y!!%X(.!50))3*0V?3+(!$>'PRXC_\ [/K^;'\]OPM:
MO\)VA^FS/ZQ?*6QY@_\ GXP&9]:_W#ZV*8+*90 ;9(_B([]7APV?_48?A:U?
MX3M#]-F?UBT]?'P]=%K_ )Q]PU/UOOPR)7T642@1V2-^[_AAPV?_ %&)_"]K
M?PI:/Z;,_K5(CQQ_YZ+_ *Q_VIJG)Y2.@!)'_3_7+CM_^IYW!V1^%[5.-IV@
M?_?9G]:K"/,'_P _&.@]:^__ .;#O@,R'"R:3[OIC?A'CJ[N&S_ZC=SV8L+5
MM4_6=:=H4_ELS4\A^-WVU$:.,8\4G/\ &/\ A>F"R:3[ "1/P]OPNX?[QL#L
MQ!M>UG'_  G:'(?39F@'^L]Y^2U;%CFA,:+3(&(__BP[],6Z<DDI0VR)]U[7
M=P]?^,>@.'?BS;5M4_\ 6=H4S/TV9OY?WS#OVT]?'/\ YZ+_ *Q__$LY9+)1
M'7Z87P _ULO 1[O\8QH;5M,7FTI_],F/UBU;%C 7Q8I/.(XT^*9)))*80_\
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MA7]_#:+X\=@?":W9_P!?ZN'A'X6M7^$[0_39G]8G&_\ ?._TC]JRE?G\P_\
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MYX8::],7R*E@; 5J1'B/N]7^WN\?1B!:MJ&\VE/C0?3)CWG\9CRRZJWJX?\
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M2\I9+3]/EW9CUCF]1!B$'W@4SS5@%"A3HTR4Z90*2F0I*90W%(0 *0 ["E
M . !UX]$H7DN.9))_?$FIZ"N].2\\R?B5#O/<LGB&PRVM!SN=&B>0ME&8J&D
M:I%=&(G2.?OLQZB<044D)W4K11<#TA HI*E6FH-[S.I ?UA^PWE/!LYZ996'
MXN99\6*RP[0B^%H%IB$Z6B^)F3-G_1A#AQOQ,2<99IM.+),B D3#&/@#Z2R
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M6 )-VHRJ!U^S-.4Z8B/;X=@=O6/#QC>^N0Q6@%U,OB[GTTSNQIB^0FF@!O\
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MX@8],#>^^CF&(7B!]MQA64\,69:5O3#B:#CE95\.1A@F@]9%M"/*L8VM7&M
M:&GD)%H;&]:140&1(KCE5K2& '4Q"T5IJ.0L#0HJ"%(E0)*844B)-02)J1=?
M)I)TU(M&C3#7:($ID*4-1UT#;CT=Q=$>^+$O<]SGNRXG./$3H!4DU^Y<Y-22
M<3>5R-.GKH !L]8CSO'D*%U?GSZ<AEGF;\+M;6\X=][Y.%*!0[>=@=F( )-
MMFMKTW=O#W LTZ8Z@8P;.H0'S=7;UZ<<22 .%OM=KR^[YW[ 4%$Z4FFT?,'5
MVCV\[]U5*S%*)A[.=@=N+M;2\XXCES/R&=_4:M;2\X]M[YNTZ>F[JV]@?./C
MZ<6) %3K4#,G4Z=,O<!H 2>YT312\ W<1YX\[L2!?4X]N0WY[  "@6< W  8
MLM&MK><.^]\F:=, #4?T^SQP6JSXLUM;\JWHL].GKM']'8';SWZX#I[5(%<<
M,S\AS3Q2 4.=G=^/CBKC0T%Y.'*[[_??=CNUM]![.6\SLLTZ8B.H_H[1[>H.
M0@"O3,Z\ARU.:V %+L,S^^\N_3%XA---FW@'SCV^'A/Y6%S1U%>73?2R:*33
MM'PQ)-+AB<!O)6 KC<!B4P4NFT=_AV>W "E^)S/R'+?2X'%R;D!G0^]9"E$P
M]GCW8LKIZE2TT$0YZOQCY@XC@32\K1K:],SKR'+4YX"ZI+92Z[]W#GJQBYU>
MF0^U:X4^ Y;P&>=U*YREU[ #G9@!05.> UYGERSZ*[6G$XG"N7,\^7WADA.
M!NZN'=_I>&\=NZS6U^L[[_+>&.F";(330 #;X<\1XXT1-%+P#?Q'GASOP6C6
MUO.&0^W=_1,$)U><>>0Q!/M.^V\5LUI/35-$)Z/'GB/( *==_#0+0#(7 8G
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MJIC5D7D(+DYD5#8J"DH1HI:A3EA=M::VD137AM-R?*J%!4>J!JWT.W1"\)6
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MXQ9< M>:8N@N(:"<26$5O)"[']77I!5I?@Y!D"AC*Y5-:--^D6;V%*HBEJ:
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MJ0MI9=SW75=(!;UPN]=&(W7D3[D9J2A$^Q.-H(Q0;&B27"8W>BQ*T;6K4H7
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MYY#$$^T[[;Q6S6D]-4T0GH\>>(\@ IUW\- M!2E!AJ+B2/=I>?8.3)2<1W<
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MYQ[/'Q_G43Q7Y9#,G>)R7H36YGV#7F>6] 6RETV!O\<2!7IF<*_^B-&C/5:
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MC3C(49KI"/$]?+2Q:0^5B/OBL:ZO#ZDF]K0 6W"A))=+PY]X!NXCSPYW;_7
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M!6X)LA-PB&S@'/(^):M;3YGY#YGYX9@ 1'Q'JQ8#,\Z"M*T[#'/SNF:=/70
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M=\A\_L'ONQSE+KV '.@8 4O/L&O,\N_17:W,XXWY<SST'F0R0FX UV>D/_\
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MYE: 9"X:C/EYUY#DR4G$=W .>'.[?4DD\+<<SIO=ZLF2EUVCNX!U^SQ[M]@
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M5V,K>;Z_'D.73O4I8Y]>P ]?/ ,6 ]N@U^P#X^PD=C&4I=?ERW[AE<ECG]'
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MJCN51N7 EK5.8@PQ5!"'0)6H6Q)U;'DC6#I6;"+1-3HX[CPQ^G]DX5DS7!F
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M9TWNY.4Z8B/;X=@=O6/#Q+4 4I2X'_2YGEWNP&+Y":: &_P]GCB.9]@T\^V
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M*KMVY*Z,NKL*=)1!P<)W3(2,MGN@I%5<*U%0:DE;"^EV'$M6#'F8LX+7@65
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M8T0W2T>"X0V")$B/XV/<VXA@]:\--22*-:*8WT!M9K5M-=O/.X/..S9CYJ
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M&"(P1&"(P1&"(P11XS6?Y")E_P"_P;^D&*X\#XJ_-CQ'_,-L?V?,*#>"-05
MRG3$1U']':/;U!R'\^0,;[LSKJ =-3FH %+L,S^^\N_3%XA---FW@'SCV^'A
M/Y5V#1\:'+EOI9-%+IWCZN>>V2:7#$X#>2L&UOP Q*8*73OYW8 >TYGY#EK[
MNEP.*EU&C :\S?[MURE*)NO3Q'%E?HG:5+3:(<]0?./F#B.!-+RM&MKTS.O(
M<M3G@+JDME+KO#9X]W9C%SJ],A]JUP^0^W[/E2N<I=>P YT# "EY]@UYGEWZ
M*[6YG'&_+F>>@\R&2$W &SAW=G_M>'';NLUM?K.^_P MX8Z8)LA-- #?Z@#G
M?VXT1-%+P#?Q'GASOP6C6UO(NR&O,[OZ)@A. ><>?4&()TQ.'VGEJMFBI[[U
M31">8 ]?//8 IU.)6E,A<!CSU ^9]@Y<16E<4225NAJN31Y++W=N5.[3$U#T
MVT)*Z-*$XTUKHWL5125T6MR.H D5+4R6JFH' 2UJI!#3&XE9N)+1)N'*S#I.
M#$;!C3C8$5TK!C/%60HDP&&$R*\7M8YX<X?D@Y35H(;4 D5 J*T&) Q("6C]
MP8)*9)+X?')?''V56_4-B2;QUJ=T*YXBBIY2&7--"0-Z>M44M=5P1TZBA(17
M3I#7ITZ@DU&F< UC6;/2DM*3<Q)S,"5GVQ'R4S%@O9!FVP7!D5T"(YH;%$-Q
M#7<!/"2*XBLM<TEPJ"6TJT$7$WCB&(Y:^PKH&8QCL<\VQ</U0CQ'XU;U&XM=
M0\FD+ZGC*=C>EBHK4T*4CXIK4*:-<I5+P;Z)#G/35@K.EK4*]*J>F/78K;6B
M3\.%8LO,34\]D3AEI:"^8?%A,88D4&$QKBYK6,+S<"WAX@00"O5O&/@[P]XY
ML:)8OB:4$U(F-#F(;VQ'0)B4FH8<R%,RL=A#H45K8CX9_*8^'$?"BL?#>YAZ
MW#[;9=,ED!E<_JNE")1<*;97EMP9>Z&7'(BK+J#>T4*ZVBG)03H:CBY)Z2>B
M@1TB*%2ND>M[L<M(Y.@Q+:\3STO(08+YN;>8C9:2EH8:7.9#=$BD,<:E[8<-
M[G%SC1K78"X>+\!^C'P?Z-)>='AZ5CLC3YA_3K1GY@S4['APB[U,$Q."'#A0
M(;GN<(<"%":][N.)QN:TMD7)YO"8/'S2V<2^+PV+4S)"5)'+']JCC%2.O.2F
MAIUG9Y5HD%*HLJ5"4TM,Z@IZ]0Y24RF,( /BY:1G9V8^B24G-3DT>.DM*0(L
MS'(A@F(1"@M>\A@!+B&D- )) 7T4EH%7.#6W5<X@ 5PO-!>LD'N!;^Y+?6=[
M>3J'3UJ3U_>JATA<G9)2W)U/D@;WM66L:Y<FI*!*/E>Y5*I:GD_7>3IM&9RS
MY^SH@A6A(SDC%<WB;"G):-+1'-PX@R/#8\BMU0"/:M&EKQ]1S7,%Q+7!U3S(
M-WO^"V"0FF@!O\/9XXX^9]@T\^V S)T3)"< \X\^H/:.)5VMS(Z#7F>0W7 L
MD)P#<&\>>//5@M *;W0#(?-?1S@0- [MG/I'AWXD D]SHM6MK><,AKY=^F*9
MS\1WCN#GASUXW:W(;YE;-;7IF4A6K::[>_OYW!YQV:8W  '<ZKK8SA&%^7+S
MU7'G/O,8>X.?6/L#&K6T-3CIH-3UT\Z=#6TO..0TZ[\DCG$X]G5SSXXT5U@.
M?34 'O'J]O._==K:WG#(:^7?ICHUM;SAD-?+OTQ3J5/8'SCS\XXU72UM+SCD
M-//MUP6,;3M$>?1BX :*G'(;V.JZ&MI><<AIY]NN"YC:=HCSZ,7:TD\3L?@!
MO=2M "30)4Y]-=NT>?T< WCLQ?&X??S.[O>3NUN0QS.\MXI*I4[=1'A\_7IX
MB'#AJUM.N972QGNS.N_AW3.?74 'O'K]G.[?< D]SHML+A[!OXGYE+'-KL#=
MQW;?9C8  4"NQE;S]_(<MXU*6.?7L /7SP#%@,+JUP%]_/ISY=2.QC*4NOR&
MB6.?T< Z^?5XZM;3J<3\AR70UM.N92QC;Q'GL#%E<"O(#'>J4J5!,.@;N=@?
M./'NQHUM+SCD-//MUPU PK@,!\SS[=4K4J>2&@;QU\W/'\>[1;-;6\X9#7R[
M],5!'7:.) )/<Z+4#W;^.\*K$<^\ '9Q'GD?'8  4W5:-;F?8-.?7?1<Q@ /
M*-N_S2]?:/S!\VHXE;L96^E=!\SRZW)4QA,.H^P YYTP76T4'/-(5ZVNI"CL
MXCM#79W_ #>O&K6TO./9;-;2\X^PT\U7OF]55Z-^,AU.A7K4J=:_#[3KDI5:
ME,E8GTE+ \BJ4ABEJ$ #&^M.!B_7&V:".ONGAM@-D>+R0"6V/"I4 D$S3+P<
MC=E>O4?$W&VVO!='.;Q6U&!:"1Q#Z(\T<,^A'Q6G<Q-U'&TN9?,),8C&XB29
M0S(=1G#3*W% YK':NL2705H:+.O(5XHME=A*">@J%/2;TZ\ZFC3$[D9.4$^/
M*V)9[+0L&QI6:CS/T::\7&4B2T-\-L,-=(-<8K3ZLQ&QJN+:E[F!I-(8=4G@
MMRT8EE>(;>FY66E1.2?@D3T*9B,B.BE[;1>P0H@$40W0:-:[A$-L0N K$X?J
MK4L[S)WX^ KDV_O>DL_.(]=7)/.;]1=LB35(4:*-F3,ZFI2BS_6JO97![:5:
M,3%KN=%0W*JZX*8M]='2IU"'\E)V'9/KI*<LIUIRD>S_ !1*V1,1)F) <^/6
M( 9B"!!]7"B-<+H9#P&UXVN)"X9[Q#;8@VC(VPVR9V7M/P;/6Y+0I6%':R7X
M8)(E9ASHW'&@O82#%#F.<^GJW, (/49??.]<]M#*;0VQ+:Z#V_MED"@TVG[8
M]-+TL5R-#.K0)JZZ/PQ05VJUF)$Q1Q69.PJ%HN54KRF2IWA0M2KO+3=4K9%E
MR=IR]IS_ .$)N=G_ !A-RLG$A1(360'2EI.#(TTWU8$5T6.T&,UG /5.>Z&&
M.90X3-LVS/65-659HLR2D;-\"24_/0X\*.Y\Q#G[)#GP)-PBDP&0)=W#!<_U
MI$9K6Q7/:^K=\R"X$NMET4T9F4$6*6Z4M67BUJ5M<T7E M:ROM.*1]Q=$=0@
M>6G6-C6ZK5R5600,CKIZ:LIBC1 Q?$P9.7G_ $@QY:;:U\N^V9]T1CJ<,3U)
MF(L.&\&YS7Q(;&.:?RFDMS7LD:>G++]%,O/R#W0YN%X=LIL**RO'";'$I+Q(
MK"+VOAPHKXC7B]CFAX(X:K<.6++-96V#7 KFP-6_+)?*K>H*C[*%,YD;O0N(
M9_;VMW7/KLTN#JK:5:H%0>^T2A$B2F04U)Z6T@ACQEO6[:EH1)N0FV06RT"<
M<(4!LK AF2]4]\-D&'%9#;$:WA)8YKWNXR.+%>Q>%?"]B65!L^U)!\P^<FK.
MAF/-/GYF,VT?I$.%&B1XT&)%?!>X/^O#<QC?5AY%]5OJ\MQQM9!'"54D)'):
M10E;VU)5,8B8ZY:<Q:514:F(5 34:9*M:H6F):E7R"T2GIC4"H3UP-X>IST\
MN_;U#T^>E@^ACT:VMXV@V:RUK0A3,E9=DR,=[X4I$M*T8IAP(D]$AN;%;*2\
M-D:8C,@N;%C^J;+LB03%]?#CW87,M(KC2TT0EC6TTE"Y&L6-3@S4528I*B*F
M*BLC5IU*M64U,R8M4]%13J4S$J4@I5:=;W8*E*R_,?[%W]E]XI]+?CQ_@#QQ
M8EAR\U:4A/S]A6GX>EYV48R-9L'Z7,R%H2TY/3X?"B24.8C2\W#C070XL 2\
M6%',RR+ F#6K 0! !^N\/;X8LUM=X<S\AGB;L?Z*,9A==WWF?8%QYC:ZB(]N
MWASZ\; 9#S)U*V2M2IP#]':/;V<CHUONS.O(<M3FM6MI><<AIY]NN%MF4+_(
MFS?ZYD/^TJF/NG@7\WH'\HFOZ4K\<>F?\^YW^0V;_5FJ3N/<%\I1@B,$1@BK
MHZ7CY+S/Q_!6O)^!SG@B\F[!%Z6'T,K\C_8/]_%]_P"F*88(I$9Q/E4^AN_=
M.D)_JW1W!%85F"O?'<N-HI;>65QBXLR88>#**Z-VGA3K<2?.0OLA:8TE*PQ!
ME 7%V%.L>$ZMQ&AY)4+507.-<Q:"2H."+\D$$N7>3+UFEN/:VR6<[I$;;VLE
M>=6Y,S=+/,W1"-TDM6E=KA7G6.$P9&.Z<I<'=R005W6*%)/II:2MS931JE,J
M;F=!55U:(D7[1<$1@B,$1@B,$1@B,$1@BCSFJVV)F(?](07^D**8\#XJ_-CQ
M'_,-L?V?,(H,D)IILV\ ^<>WP\/Y]?E78-'QH<N6^A-%+IWCZN>>V2:7#$X#
M>2L&UOP Q*8*73O'?SXX 4OQ)Q/R'NWE>G%3)HP%XK=CYK(4OE=W9U]6+*_1
M8VUU9W)0O2-[JVKU;56][.:5"N2JE#<H$3A[W74:%6I41UQ&G4 :2@M.IJ0X
M 7ZTVFD2#&A,AQ(L*+#9%;QPGQ(;V-BMN^M#<X /;>+VDB\:K0,U]OV?:?9K
M5I"[L[BK7H$#JVK5K2<E)T1(UR52K;:M7R_<J2]/0JGK(SU/<ZGD$4$IF/[F
M?R0'R3:9184=C842)!BPX<8%T%[X;V,B@4JZ&YP#8@%14L) J-;]<!V%V6H[
M#97;9;$W@[K3:91'7,["8Y'PC<]-JT[,>F!QJ$=")E-4S>8@4S^656%$2@0_
ME 'DCC1\C.0!!=&E)F$)BGT?UL"*P1ZTH89<P"(#44X*UJ,BK- Q-YQY#F?L
MQ[AIEE<6D#=5=V"2,#XTIZQT]=T9WAN<VY/7I@0:E&JN1J:R:E6)[H03TZE4
MIR <HF+]<7$Q)*;@11"F968@1G .;"C08D*(YIK1PAO:UQ::&A H:'(+04R-
M>?-?4+FL0N RIY#"9$TR9E4G64J#BT*Z2M,<Z!S7LZP/*(/E%]P=&MQ0G$Y0
M 5*)20HF&F;&T[(SEG1W2T[+1I:.T,)A1F%C@(D*'&8;[J&%%A1+B:->W-P!
MD$.%0;M=Y[P7="EX!OXCSPYWXY5HUM;R+LAKS.[^B8(3@'G'GU8@G3$X?:>6
MJV:WB/(8IHA/, >OGGL 4ZG$K2F0N K7GR'QK[@F2DXCNX!SPYW;ZDDGA;CF
M=-[OPLJH+]2Z)P?I4<K[_-I1'8>PT<M5UT]9[E+VV1]II*%3JY4DU"HY.RE(
MCIUE%0?(H4CU@/5/];3*8=F/K-@24U.^BSQ/+R4K,SD<^)+*<(,K!B3$8M;#
MA%SA#@M<\M:+W$-H!C<N6(YK9J"74 ,*(*D@#*E2?>/ABHDY@<S]TK<2#I"I
MA:FX,?B@QN]^3)'%IJSQ:#K* QB;1+WR[*G1WH,IJ\R:%Z,*5<BEY<',]-L$
M]!I6HTR@WE>WV!X9LNT9?T?R=JR$>:$Q8GC!\U)QIJ>81,R4WPPFPX+HX;)Q
MH;Z@M@PX58M\5CW-6<2(]OTES'!O#%EPTT;@]HXJFGU@:@WDT%:473+RYB+Q
M1^#9Y[74\P#?F?AEKU>4J3PNZ[[$[9R9$WN]QI]%0D\;&@@8'&$N":L"A2=K
M3&2JCL)FHYFXR5=35'I=MC^'K(C3W@FU#8$3PS.6DSQ7+3EE0)JT99\2#9\A
M-?19DE\>'.L<.%HBO#F".(H$0/AEE42(]K9A@BB*UAERV(6PW!OK'CB;<WAI
M2\#+&M;UQ&?6\%Q[HQ?I"&^6YEJ$#8+.70@%I8/E@,VPZBFN#%A?(ZO!_P#\
M>HTY>K=5RU*:6(79HKUO>:1E<D5<!95!*2;?P+9%G69,^ 8DIX<,],6O9<_:
ML[XE$2;+I":]1,0S ^H3*-A,8_Z*^%% XWQH;VTC-JZ9A[GMFN*-PMAO9#;!
MX6_7%6GBK^54F\4-P!RN5F?2N46\^2Z(D>"(SM52\N7LCH1Q"@9N,WGE3>"T
MBX%.J8R,R8:H*@K@- : G"K_ (,3:_./1<8G[<9PPN,1?P/;YA&&7")ZSZ,_
M@+.'ZW'Q4X>&_BH1?1=D[3Z.VM.$QH-:WU^NVIY"XCICBM76Z0619NE@@3?D
MW)!4D,5Y;I?7S(MEEA9BVTI5:#A7+ ZSLEB8C%4LH^%SLH5 3$IKP3U4M2L4
M#K%AZWE9]]M1O1=/O\7F=?.,\12@\.Q+8]<;2(=#;]-$-TW_ '4Z6]5Z\CB)
M94. /"R&!#!#$\T2W &>I<8XA\(8*&C"0VX.)H+K_>5>40G /.//J#VCCXPO
M*M;F?8->9Y;T!9(3@&X-X\\>>K!: 4WN@&0^:^CG @:!W;.?2/#OQ(!)[G1:
MM;6\X9#7R[],4SGXCO'<'/#GKQNUN0WS*V:VO3,I"M6TUV\\[@\XXW  '<ZK
MK8P-'/MYZG9X\Y^)A[@UY\X^P,;-;2\B\_ ?;\?BNAC:7G'L/MWJDCG$P[]G
M#GGTZXNKK <^FH />/5[>=^Z[6UO.&0U\N_3'1K:WG#(:^7?IBG4J>P/G'GY
MQQJNEK:7G'(:>?;K@L8VG:(\^C%P T5..0WL=5T-;2\XY#3S[=<%S&T[1'GT
M8NUI)XG8_ #>ZE: $F@2ISZ:\1'GG@ ;1V8OC</OYG=WO)W:W(8YG>6\4D>I
MZ1X<\/$0]&K6TZYE=+&>[,Z[^'=,Y]=0 >\>OV<[M]P"3W.BVPN'L&_B?F4L
M8_ -VW4>OV8V  % KL96\_?R'+>-2ECGU[ #U\\ Q8#VUP&O/I]G4CL8RE+K
M\AHECG]' .OGU>.K6TZG$_(<ET-;3KF4L8V\1Y[ Q97 KR QWJE*E03#H&[G
M8'SCQ[L:-;2\XY#3S[=<-0,*X# ?,\^W5*U*GDAH&\=?-SQ_'NT6S6UO.&0U
M\N_3%01UVCB0"3W.BU ]V_CO"JQ'/O !V<1YY'QV  %-U6C6YGV#3GUWT7,8
M #RC;O\ -+U]H_,'S:CB5NQG$17V#YGEW[JF,(B(C^@,,5U@ #N=4A6KZ_6E
MW<1V@.[OY[>&K6TO./9;-;2\X^PT\TB8VNP-W$>OV>/=OOAUW\>W5=#6TO..
M0T\^W7#1=Z\OMHLP*&.MUUXPIDB>)N:AXCPHY-*XNI;7)4E]Y*%-);$GQC65
M!J)O\'Y%>O5I!_RB$*</*QYFR;8M*Q71XEGQVP'3,-L*,'0)>8:^&UW&UI9,
M0HK11U]P!R)R7C[5\/V7;C(#+5EG3#9:(Z-+\$S-2SH41S>!S@^5C0'DEMU"
MX@8TJM&7&R76U6VMN!%K7,]*,3:363=+(,4DD4HFS^G01-9(%LMH-SD9V=WV
MNJHTI&X*UYW.HF5O1:=4J(BHR"A124_+R7BB>9:$G,6A%,Q*P+5AVK%@0)>4
M@N?,-@MEW/A^KA00TF QK/5AS851Q\/&2X^+M#P?9T2S)^5LV$):<F;&BV+
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MB"D0>MA.:^CQ<\<5#@:XG1S6O!:]K7M.+7-#A=>+B"%@MM9RT]GV]6TVGMI
M[:MKA6(H<4<%B;%%4R^O3 Q:===29$*(JRM2*8Q*513[J>F01(0Q2B(8TM"U
MK4M:(V+:EHSUHQ& M8^=FH\RYC3>6L,9[^ $WD-H";S>KPX3&#ZC&,!->%K6
MMJ=30"X;Q%=GD)P#<&\>>//5CQZV IO= ,A\U]'.! T#NV<^D>'?B0"3W.BU
M:VMYPR&OEWZ8IG/IM'?X!^+GK'&[6Y#?,K9K2X\MW#FD*U;37;W]_.X/..S3
M&X  [G5=;&<(PORY>>JX\Y]XCVZ!SZQ]@8V:VE"<?@-[U70UE+SCV\]\TD<X
MG'4=W .>?7K?!76 Y]-0 >\>KV\[]UVMK><,AKY=^F.C6UO.&0U\N_3%.I4]
M@?.//SCC5=+6TO..0T\^W7!8QM.T1Y]&+@!HJ<<AO8ZKH:VEYQR&GGVZX+F-
MIVB//HQ=K23Q.Q^ &]U*T )- E3GTUXB///  VCLQ?&X??S.[O>3NUN0QS.\
MMXI(]3TCPYX>(AZ-6MIUS*Z6,]V9UW\.Z9SZZ@ ]X]?LYW;[@$GN=%MA</8-
M_$_,I8QM=0#=Q'N^;&P  H%=C*WG[^0Y;QJ4L<^O8 >OG@&+ >VN UY]/LZD
M=C&4I=?D-$L<_HX!U\^KQU:VG4XGY#DNAK:=<REC&WB//8&+*X%>0&.]4I4J
M"8= W<[ ^<>/=C1K:7G'(:>?;KAJ!A7 8#YGGVZI6I4 NP-_9SZ>KPT6S6UO
M.&0U\N_3%41U$1Z\2 2>YT6H'NW\=X56$Y]^@[.(]?/KQL  *;JM&MS(Z#3G
MU.^2YC  >4;=_FEZ^T?F#YM1Q*Z&,K3WCS^&[DJ8PB(B8?9@!6X+J#0.N92%
M:OY7UI=0#B/7V8V:VE^)[;U6S6TO..FG/JD#GW@&[B//#G=OMWPI3=_9=#69
MG'(;SWC@K4J!N#]/;W>/FQJUM+SCV70UM+SCV2ASZ:B.\>=1[,75TH<XFX[.
MWC^(.SD- *7?XWP:/M.[L=FMIU[>>^J=2IK]:7=Q'GD._=< "[XGN5T,9AJ?
MAO,[*AC:[ W<1Z_9X]V^V-!LG>\5TM%!SS6(1  \ Z\:M;3KF58 D]SHECG'
M7M\.P,670UN0PS.\]X)*M6 @" #]=X>WPQ9K:[PYGY#/$W8]+&877=]YGV!<
M>8VNHB/;MX<^O&P&0\R=2MDK4J< _1VCV]G(Z-;[LSKR'+4YK5K:7G'(:>?;
MK@J<^\ W\1YX\[]VBW:VMYPR&OEWZ8X1'@&_B/  _'U!@M%;QD]T^H@S:;OA
MJ1;^/_"53;Y\?</ WYOP/Y1-?TI7XP]-8IX]G@?\ALS^JL4H<>X+Y,C!$8(C
M!%71TO'R7F?C^"M>3\#G/!%Y-V"+TL/H97Y'^P?[^+[_ -,4PP12(SB?*I]#
M=^Z=(3_5NCN"*P;,9?ZW.5FQUS,PUVUCFWVVM+&%<NEZME:E#V[4FE'4HT3@
MWM*40KKE52NHHTJ5$IB%\H_EU:E*D4]0I%^0Z07L>\]UQ8DGN+G7Z3RYV4N>
M9AH)=2*6DBW1&EAL63-;%=1MG%LF%)F,8OA9U11^(K4C(D53VFDK*%;6VUW%
M73IC7K 4B_:W@BAMG1MZ[SJ#Q9<[9GWO*W8>W\C<;@9DY1$Y!4MY*Y9;"/Q1
M^/1BB&\M!X:EUI&$LGKLS_+Y&T"5[<F!F41YO=&0'.NMP1:-Z+.570E5@+FR
M^6R*[4TLTZW[N0YY/97?=2N6WBE>54&Z-?2/(98XOB9)+'-L?9/3G#G;ITG*
M<LS<K9JH<O?*B@5">O5(JY;"W2OPS6YZ,S/N\Y@KSS*79ZLU;/;:^%G9'-5K
MI8RA;7,,BN\IA$;M[:VN6JRV_<+&J8U"#,LBC'O)\>TC;*1FBY\I/5;WDWO>
M-Z*/60B1H[RVZL[)[KFZ<R;W*EMR)2@?+EV\G68.OEF55TUZI3'FAQ3.[?-Z
M,<IV_8VA$V(I/6IH/>".BVO)*]"H6A5 Q%:G>#I4RVQSQVURV4+!YHGB!.4!
MS&JYVY,^3+,E)I6^S2UDRLQ'8<]V:7,4;.USVT@I)E,:TSG,=9)/'TU17;Q0
M61LU!^0TWTBA==^ZU^?J49VND70Y@;PL<PRL9^76TEL+)-$Z<&RPJJP]E+X6
MYLA+K<3BTH$%CD3_ '<1*IM)W&7.U&K,VI]>XN>+NS,@::*)3',:885Z[NO]
MA:BBN;:[MQ;KR_-'/I=GKM9;>)=(T\Y?$UYXN^0-?DKMK!(;?VA9&,68F^7)
M9<..S&<1NZJ1,C07*S!&@[@LMS<J>M9FA_*FBC@V46\K]TWD7Z"\U\UAJ2UD
MGB:N6QA+*E;C #)8RH?FJC(%(59_%JU(4[-45$<:P5*5.I5IC33& ],ASEU*
M4PAX+Q3?X8\1_P PVQ_9\RBB>4H &O$0#'\^P,<R<3\A\S[K\-@*XB@!N&O,
M[\\I2B/=X]GMQ96739]:>W%V&BBQW*A4>FC4F4>^TB1^;:"X$2KR?(%0AK'+
M[X15C$_P=2JEJT3U*?\ @SB8FH8]F\+>-/%?@B>B6EX2\0VKX>G8L+U$>/9D
MW$E_I$&O$(4Q#:?53$,.^LUD9D1K7_6: Z]28,.*.&(QKV@UHX5%?_1^9SP%
MUZ[1$H=%X*PH(O#8^T1>-M=,U)O96- G;6Y*4YAJ5!I)DM.G3 ]6J8U:O6,!
MJM>L<]6J<]0YC#XBW+>MGQ+:<U;-OVI/VQ:LX\/F;0M*9BS<W'<T!K..-&<]
MW"Q@#(; 0R'#:UC&M8T ;,8R&T-8UK6C!K0 !?F,/9GB>>M''+'8)ZC+Q#7:
MT\.<8K(+AJKL/3&L;04-[C<==4]T62]11JU#>4\JA$Q:]<HE)4HGJ4#4QH53
MTS]4+Q3XA@34">A6O.0YN7LUED2\=D3AB0[,ABC),. %(#* M;CQ .!J 5H(
M8(H0+S6E+@3_ (QY_$D7YT[P%H+95))-I;6@\=4R.Y+$W1>>N:MNI+*DLCS2
MEK(6]E?**H*R5<WIT:BLE!-5H#2/0J#2K%J% I2\C;7M7Z-(RGT^9;*V9,1)
MJSX+(A8)29BN#XD> YG"^'$<\!W$'5XA44STX14FEY%"<R!]YPU6H(]D4RA1
ME%+FUCR]VV1(IZV? LL3? A5-)U:/A) \%;/\;JUS($--V:VMSI)6TR.C2<&
MU LID*H2)ZE/SLQXZ\7S423B1_$-I1(DA%]?*.]?P&#&]6^ 8OU T/?ZF+%A
M.=$XR8<2(PU:]P-1#9?]5H!QNQSH>I"VG9S+M9++^A=6ZS-M(O;^@_5Z"A[J
M,2(Q5SM52A4*E^$G-755.2RDD"O7]Z)U"NI02C7KBGITQK5!/XVV/$-M^((D
M*);-IS5HN@-<V ([QP0@\@O]7"8UD)A?PMXW-8'/X6\1/"*:LAM%X:&@FM!G
MUKEOKNXA. ><>?5CPI.F)P^T\M5T-;Q'D,4T0F[J#U\_H[ %.IQ*T R& J#S
MY#XUYW#DR4G$=W .>'.[?4DD\+<<SIO=ZLF2EUVCNX!U^SQ[M]@*"BM<+S[!
MKS/+OT6<A!,/9SZOT!MQ*B]QU)7(4Z8% .OGD X=^"V  '<ZIDI-=H^8.OGU
M]V\K 5^9T3E.F(CV^'8';UCP\2U KT^+N9Y=\[KD^0FF@!O\/9XXCF?8-//M
M@,R;)DA. ><>?4'M'$J[6X$^P:\SH-YBK)"< W!O'GCSU8+0"F]T R'S7T<X
M$#0.[9SZ1X=^) )/<Z+5K:WG#(:^7?IBF<_$=X[@YX<]>-VMR&^96S6UZ9E(
M5JVFNWGG<'G'&[6TN&/==;&<-+K\AIY[Z\><^\QA[@Y]8^P,:M;2\XY<N>_N
MZ&MI><<AIO?)(YQ,(]75SSY]N-%=8#GTU ![QZO;SOW7:VMYPR&OEWZ8Z-;6
M\X9#7R[],4ZE3V!\X\_..-5TM;2\XY#3S[=<%C&T[1'GT8N &BIQR&]CJNAK
M:7G'(:>?;K@N8VG:(\^C%VM)/$['X ;W4K0 DT"5.?37B(\\\ #:.S%\30??
MOX?%;M;D,<SO+>*2/4](\.>'B(>C5K:=<RNEC/=F==_#NF<^NH />/7[.=V^
MX!)[G1;87#V#?Q/S*6,;74 W<1[OFQL  *!78RMY^_D.6\:E+'/KV 'KYX!B
MP'MK@->?3[.I'8QE*77Y#1+'/Z. =?/J\=6MIU.)^0Y+H:VG7,I8QMXCSV!B
MRN!7&X#$I2I4$PZ!NYV!\X\>[&C6TO..0T\^W7#4#"N P'S//MU2M2IY(:!O
M'U<\]FBV:VMYPR&OEWZ8JB.HB/7B0"3<M-[ZK"<^\ '9Q'GD?'8  4"U:W,^
MP:<SSWH N8P::FW?YI>OM'YOQ:CB5T,96GO'G\-W)8QA,(B(^S!=0  [G5<?
M6K"(B4NX..T-X>;KYVXV:V@YG'[%LUM+SCIHD3&UV!NXCU^SQ[M]L.M^]X+H
M:VEYQR&GGVZX*5*FFP/T]H]@>OPU:VEYQ[;\ET-;2\X]M^24.?341WCSJ/9B
MZNE#G\K7;LXCU^SGNT I_&S.31]N\,=FMIU[>>^J=2IK]:7=Q'GD._=< "[X
MGN5T,9AJ?AO,[*AC:[ W<1Z_9X]V^UYH!]^_A[UTM%!SS6(1  \ Z\:M;3KF
M58 D]SHECG'7M\.P,670UN0PS.\]X)*M6 @" ?\ *\/;X8LUM=X<S\AGB;L>
MEC!=IW.\_8.7'F-KJ(CSSYQQL!D/,G4K8"F]T')*U*G /T=H]O9R.C6^[,Z\
MARU.:U:VEYQR&GGVZX*G/O -_$>>/._=HMVMK><,AKY=^F.$1X!OXCP /Q]0
M8+1+U:H$#0/,'$P]8]G/==K:WG#(:^7?ICO#AYG[N0Y\]FWS)P(FL:RB.\7J
M1_[3JX^W^"/\ 0?Y1,_TB_%GIO%/2!: '^0V7_4X:E+CVY?(T8(C!$8(JZ.E
MX^2\S\?P5KR?@<YX(O)NP1>EA]#*_(_V#_?Q??\ IBF&"*1&<3Y5/H;OW3I"
M?ZMT=P13/SKWHM[EWRFY@+V77MXINU;BW-LY%(9E;-*SLS^><,=),"95&ZS1
M(=6-8@<P4E3N976G70TFXRJNH3*B4A3U2+\+^5C,Q8*XN;RVMV\O^:2TO0U0
M&2S^.?#66'+\7.'?&0WI<W61(*22-W%@PP*.Y2XI\-%/18:2N)-XHX^+DK5U
MJ"_WG1K58YW??OVHO1!Q** F?W(K^KQA]L(0NOS<.R[';:Y+9=*LW0R,VUF;
M%/)%' )6B*6?Q&ZD3F4/E;!&'0#OJ&//K$XLBEZ*A<5Z!2I:FVHG(NYVSRXW
MXAK%"6N<YX+T7=<XK=SZH+M()#;S+[$54T@P1&K'263?6VW%K(FRIX21YJ_3
ME\,M#<AFYGBG20FDAF,A&XL7ZZ^6F"+0]J^C$BELKAVI6UKZW6F5@,NUSIW>
M7+?EBD*"!E@UIKASQ-+T?OWZ;F^+IK@S)@@">X$VHVJCLED"BA#"/E+W54\B
MRL@H)1:[M-T8^8:PL,9[868Z4G,] ;61ISD*Z,0)-97)L_H6-+)I2\2]T:Z+
M[++ /TJ6IJKP^N50M=S>UJRG3K^Y4ZY*5*C3ID5HKG:V /5R8?>!UC*%;<N
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MTA/]6Z.X(K;Q # )3  @(:" @ @(#O 0'8(#U#@BQ@GH ("%"B @.H"%,@"
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M[WD[M;D,<SO+>*2J5/2/#Y^=_AJUM.N972QGNS.N_AW3.?74 'O'K]G.[?<
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M*X@PF71'0?7U;#@S-'AS RH]J\$3LDRV)*:GO5PH?#%:U\4CU<":+2R&YY-
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M#>/FUF^"_$4.:DC*^';1D+:E?%<>T_VP3%I2YLJ%9<2:B/>UL@9R.V)$B0"
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M/.?>8P]P<^L?8&-FMI?G\!ORPJ5T-;2\X]M[YI'.)QU'=P#GGUZW5U@.?34
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MR\66G,RX@171)"2MJ#.0I*9>UL,PW<+YF&][(+XCV /+6$M:#=TO%(B- !K
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M&M!SI@24:SH9$"59#9*3 X8\)D!D$0(?K!^7$9#;$)#2'_5!'E8'AZRH,O\
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MI<.*S[>FYRWO#\O9L>TH<G%#X-IV-'LGU$&S&RTAPPVF:?+!Y#X["12,6B@
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MAO3"O0:GG3 >TT76UM>0&_>E#GUU ![QZ_9SNWZ >[+GS/R&76@&P%+@ESG
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MY'1K?=F=>0Y:G-:M;2\XY#3S[=<%3GW@&_B//'G?NT6[6UO.&0U\N_3'"(\
M\X]0?CZO2.S!:)>K5 H:!Y@XF'K'LY[KM;6\X9#7R[],=X</,_=R'/GL\><X
MZB([3#SZ,;AM?=7H-3\A[[EUM;7D!OWI0Y]=0 >\>OV<[M^@'NRY\S\AEUH!
ML!2X)<YP -^SQ]G7U[@V:CBX&9N W0<^RNUM?NW[,1KD"F<_$?,'//J#%\*$
MC^*W>>I^= .EC*7GV#3F>>\<%#G$1[>/9W<[._=8"^IQ[<AOST2YC:=_ASSV
MV6C6YG?GVZ_DJF-KW>///86K6UN&'9+G.  /5Q'K[ Y]6-&MI><<AIY]NN&[
M6Y#?,I4QN([N <\>=V-%T-;D,<SO+>*O R,CKEZ8!_Z>E'^UZV/K/A#_  +"
M_P _,?[Z_ ?[((4])=HC_P#3K(_J3%+_ ![.OB:,$1@B,$5='2\?)>9^/X*U
MY/P.<\$7DW8(O2P^AE?D?[!_OXOO_3%,,$4B,XGRJ?0W?NG2$_U;H[@BMPP1
M&"(P15*](L^,EO<SW177@N6\-D7L9 ,S]UVV>S*3+T[7"8=,KA98;L0VT+S+
M'5>>DULJ=;+E]6,,SVZUDR)(_P B;4HJJ"A?0$Q%P'1\7<M71D>>.=(+@PQG
MMKF:Z2JX;/EB>E4C:TC!>22ME@+-1B:UK4*ZM:DDFOPU<RVEV'"C7C7PC2>*
MK!(7))67T4RE89L(JU\O$U@\ERT]"IEEA,ECR[-A9K/;07WEM:UN2$+H6R46
M<:<R%#-7(+AQ4E:E(XLW+3/+DB=WA^1(4<A5SQAJ):SD$A0 M>>]X]R2Z,+,
M+1@V6FQC2]],ODFL?&F&<7$J/65^X<5L)0N4P,Q+]SQ:Z0MXELES"1V5H'24
M(SJ%:!X6P=.L;4SZBKIFQ?234#JF]^Y%8!?++QTATAZ2VP%R8/F%MLW6]:[*
M9Q&^-S!3DZD$FC=H8Y++@99W!FM5/7*AF594DXF\U;& E:-S0M2"%H4K?2M1
M2A+D1Z.6.MZHH!WHF4%;<I_29Y4G*1,*+.9<KI7E*ZW-J%;P@27;G$BN?F/L
M;/LN]P(;%*J@9(OCJ2U:2,N[?)FY.H:6AC@;\-5R3TV%>1-&[COWW%%JF'RR
M>V>9KSTW?,ZPRC,0U],+(&8G1KS*"V.D;9>5LNEF]:) QR]RC,DB#K?-RFM6
MV\@:KUVKO<PRU%%[?1VWD;^#VTZ6./+B:=[^:+],6:5?<6K WED88,R.K"L>
MK;T:<@63<6I4"]1<.*A23&8PC"\?<!6^]TQE0.8B6E6.J!.;W'W"IX^UI)UI
M65:5G-B"$Z?L^<DFQ7-XA#=-2T2 (CF@@N##$XBT$5 H"*U5F.X7-=CPN#J:
MT-5KD+=Y@ _]'$('3A]5.L ?@'C\XGT 6D1=XDDAS_!\?_F%Y3\(L_[)W^D/
ML60+?Y@ ';;>$"'_ ,5*WY!;>[ ?L?[0 H/$<E^@1_\ F%(M)@_\TX_^T/C=
M?T64(%?_ (VWA(__ #4K!_\ 8'A^X!:7_>.1_0)C]>GX2::DPG5_C#[%G)";
M_$#_ "9PD1Z_JJU?R!_1Z=7[@%I9^))+V2$?X_CQOV4LVU&"[U+N9XQ]GP64
M(;?\!VVSA(]GU5JWY XG]P"T?^\DE^@1_P#F%;\*P_\ LG_Z35F+$K_!M&V4
M*$?_ (K5?5_X ^O#]P"TO^\DE3+^X(_M_P#O"M^%X>'J'TTXFWG4FF^ER9+&
M;^%#9;"%_=7J_D#^G$?N 6C7\Y)+E_X/CW?_ -C'>M;?AF'_ -@__2;]BX25
MGO7"XM(I<\6MBAFJ,,CH_N0([I&KJS(6A%67*@343P6B2K7&A0.%*F:K3*<_
MDE$Y0$3!/[@%H_\ >22_0(__ #"D6S"&,!Y'\=N=VGV+LH,-^PV?4NAFG_Q7
MJ;?^P.'[@%H_]Y)+] C_ /,*PMR'_D[R?X[?LRWBOL66_NFA;6PL/_FQ4]7_
M ( >O#]P"T?^\DE^@1_^85A;L(&^7>1_G&_\-_18!8+_ (B(_4NA79_QL5?#
MZG_SXN/0': %!XBDOT"/^O6G[8(7^3Q/]-OV+ >-9@#?^C&%!_\ ->J/_P!@
M ;O1Z,:-] UH"[]L,EU^@Q[_ /;A:M\206__ '2)R_&-N_\ E2QHE?\ ,.HV
MSA7W5:OY!8T;Z")\7_MADR?Y#'_7K5OBB"+_ *'$)_SK?^!8#PS,"<=1MK">
M[ZJM;\@N?3B?W"[0R\027/\ N&./_K%7_;5 _P DB_ZQG_"L8PG, (;+:PD.
MWZJE;\@L2/07: O/B"3/+Z%'_7?!2/%< &^3BGEZUG_"NOR9BOG%XZ_R=SMM
M$!;8XRNK\X%370J55(HFA#7<%8)Z1H-2+5KBG3U HTS5*93U/)*-0@")@T_<
M.M#^'Y/]"C_KEJWQ? !J9**?_P!UEW_R)M%"K^N"-(OH6XA845J6@KH^Z72J
ME.%)32)6I^64((8"F AR^44#" #J "(!KB1Z#Y\&OX?DSI_<4?\ 7+0>,I<&
MOT&,=/QK/^%9!MYF#'_T<P?7MNG7_((,3^XA:%:FWY,G+^XH]!_MM]5?]NLO
M_D,;_7,_X%C&W&8,=?\ BZ@^H\?JIU_R#Q;]Q*T/X>D_T./C_KO=I[ZW;XWE
MA=^#XW,^N9_P?!836RS!F_\ 1Y!_NHUQ_P#L$]/7Z-+M]"D^T?X=DR<_[CC?
M#\<M6^.I4?\ 5\?G^.AW_P#R)<UK<PIM?^+Z#;=__&C7U'_L)LQ;]Q6?_AV4
M_0HWZY:CQ_*BX6;'_P!?#_X%C-:C,((:?4_@P?\ S0K_ )"XN/0Q/ 4%N2GZ
M'&_7(/'\J,;-CG7\?#'_ /Q<-XWK$:TF80=GT@08 _\ B?7_ "%Q/[C,]_#D
MH?\ W2-^N^SJMF^D25;_ -5QSI_=$.[_ &254VFS"4:%:N> P;R*%*I6,!;G
MJ!'R:9!.;0/I&#4P@4= U ->._%QZ&YX7FW)0DXGZ)&^'XU:M])$HW_JN8)U
M^D0_U:X.-V[OS+(ZP2EL@$+*VR1D:G]N*JN96I*2H7A!0<4A5%(D(JDI5P3J
M:85J9:M0I*GE%"H< \H9_<<GOX;E/T2-^M5OW2I3^"IC])A?JURQ[,9B#_\
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M$$BX2[',EX$"0BP9>"'D&(60Q&<2^(6MXWO>]Y#6MXN%H TB>EJ5BD%]D31
MP:)F" *Y_P![O]M5L UA<Q9A$1A$![/^,U5^0N/7/W(YW^&97]%B_K59OI:D
M /\  TW7/^Z8/ZM8:E@,QAPT"%P$H?\ Q,5#_P#8,'Z,6;Z)9P?]<2O,_18O
MZWYJP]+D@+_P+-G3^ZH-W^S75XS9J_DOCS/)6F%P@K<^(:#BC!7<=114A04%
M\H@5J1(55*2H ?\ **6H<-=QA#?;]R>=_AB5_18WZW>BT;Z8) 4/X$FSI_=4
M$?\ TES)LN>8TVP(;  _^92L?_L'#%F^BB=%_P"%Y4G^31?UBU;Z9) 7_@.;
M)_E<']4L(Y;LQHZC])\ U[;DJ_R(Q;]RN=_A>5_1HOZQ6_=FD?X#F_TR#^I6
M$V6G,<;_ ,T+?_=)5[>K_P Q^?-BP]%DX*_^%Y:N1^BQ;O\ :JS?3/( U_ 4
MV?\ WR#=_L5@/EES(&#0(E;XO_S)6#_]A <^G%AZ+9L?];2WZ-%OYG\8M6^F
MNSQ_U#.$_P L@?#\2L(Y7\QXAI]*=O@Z_P#C(6?D1BQ]%TWE:TMS_N:+C_K/
M=]]=1Z;[/ _P!.<S]-@7_P"Q6/\ 4N9C_L3M[]TA9^1&);Z,)MM?_"LL?_=H
MOZQ6_=QL[^ )W],@?JEC-E9S(F_\U;>@/_Q'6; [/_ CGOQ;]S*;SM66_1HI
M_P#J!7'ISLT"@\/SOZ; _4KK$7R]W_F+,#XT16#$1G<GYJ#WY<%52K^^HZ_.
M4=<!&F2'52^Y&<&I4*<_EB-1.-*J8E,QQIEG]S*:_A67_1HGZV_?1:-].]FB
MG_B[.TJ:_P!W0*FAH?\ S&^2Y<<IF9(PZC&;>?=%6_D5BX]&DT/^M)?]'B7\
MS^,6W[O=F?\ =V>_39?]2L9\I.9,VZ,V[#ON*MW_ ,RMO/GN/1M,@7VI YTE
MHEXTKZT4&NNJD>GRS0:_M<G3UGX _P#H%8!RAYDQ_P#-NW8:\?JBK1'\"L7_
M '.)G*U('Z-$_6JX]/\ 9H-_AN=/_P#(0/\ E[_@L8Y0,RG"-VZ#M^J*N\/I
M*^?$?N<S?\)R_P"CQ/\ C6G_ -H*S?\ NW/?I\O^H7R;)]F3$- CENP[[B+=
MH]8C])>WN]F)'HYF0;[3ER/Y/$_6*S?V0EE@U/AJ?/2?E_U'Q2QLF^94PB(Q
M^W0B/_ZPUWY%\.K&@]'LR/\ K.!^CQ+N?]\6X_9$V6+OVLS]/YPE_P#EU@-D
MQS*F_P#(%N=N\?JA+M1_[%[,7'H^F1=^$8%!_P#D1,=3]>_EI[J:#]D998N'
MAB?_ /B$O_RZZU',J>825)'!8V1^!%HML@D4:4@JGJRD<7&,/2UB<AI@2(5
M,F,N05Q35!$IZM#R#FITC&$A9_:!,YVC _U$3_C*#]D;9?\ W8G_ /XA+_\
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M;6_U-F4O+M8BXZ($LC,E;:)*KNOB,D;@41>:M"$!/5&H@7(I!314SKW.,M5
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M )/2?W."(^ V7]AVO^3TG]S@B/@-E_8=K_D])_<X(CX#9?V':_Y/2?W."(^
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M[<='E.>C?:#*[JV[,99:.>JR+'.9./N48I :X:2K3 J%4F!/'2DU"O'ZXZ&
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D1@B,$1@B,$1@B,$1@B,$1@B,$1@B,$7\-N'N'PP1;9P1?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g307489g27s27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g27s27.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2B 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *&2^$#0#A"24T$!       )QP!6@ #&R5'' (   *  !P"!0 31V5N97
M9A;G1#;&EN:6-486)L90 X0DE-!"4      ! <3*8=![N$8RL8OMQ\2Q_C.$
M))300Z      #E    $     $       MP<FEN=$]U='!U=     4     4'
M-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%
M-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<'
M)I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M     *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V
M]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6
MYT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M    !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8F
MQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M      0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M      0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M          4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;V
MP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'
M0               !4;W @56YT1B-2;'0               !38VP@56YT1B
M-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%
M)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
MUC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M X0DE- ^T      ! !D     $  @&0     0 ".$))300F       .
M       #^    X0DE-! T       0    >.$))3009       $    'CA"24
MT#\P      "0           0 X0DE-)Q        H  0         ".$))30
M/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #
M(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M!P  #_____________________________ ^@     __________________
M___________P/H     /____________________________\#Z     #___
M__________________________ ^@  #A"24T$"       $     $   )
M "0      X0DE-!!X       0     .$))300:      ,U    !@
M     $F   "=H          0                         !
M    G:   $F                      !                         !
M     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W
M0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;V
MUL;VYG   $F     !29VAT;&]N9P  "=H    &<VQI8V5S5FQ,<P    %/8F
MIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W
M)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M  #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M!);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&
MQO;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !)@     4F
M=H=&QO;F<   G:     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M      37-G951%6%0    !       &86QT5&%G5$585     $       YC96
MQL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W
M)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "7
M9E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F
M4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M  #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M  .$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!
M0       0    #.$))300,     !WF     0   *    !+   !X   C*   !
MW* !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B
M!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M    $  /;6  $     TRU(4" @
M                             18W!R=    5     S9&5S8P   80
M!L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   B
MP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9
M   TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&
M5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P
M@,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($
M-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M     2<U)'0B!)14,V,3DV-BTR+C$
M                                   %A96B        #S40 !     1
M;,6%E:(                     !865H@        ;Z(  #CU   #D%A96B
M        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M   !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#
MHO+W=W=RYI96,N8V@
M                  9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6
MQT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.3
M8V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                   &1E<V,         +%)E9F5R96YC92!6:65W:6YG($
M-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V
M4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                    !V:65W       3I/X %%\N !#/%  #[<P !!,+
M-<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                */     G-I9R      0U)4(&-U<G8        $
M4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@
M!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .
M4 ZP#P /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@
M%U 7P!@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B
M8"+P(X D$"2P)4 ET"9P)Q GH"A *. I@"H@*L K8"P0++ M4"X +K O4#
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M$:D0&,H%+Q>*PYEF;Y0SX<]]:12_2C&(#36;+Z=;S <6W-(5>$I2G50DD")
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MRM#",6.<BPRU#+< A;0P2O=BJG'$')E!I?YG1UD_'^DXY\^M:_'_ /6/\_\
M[<XZZZ/S.CK)]SJ_GUK7XO\ ZQ_+'[?Q9::/S.CK)]SCGSZUK_?+_P!>--'Y
MG1UD^YQSY]:U_OCQIJ>;Z$.NEF:*)-ZR((G X+8P3*Q?=9^+ @,HD-M18^?;
M#L2TA$J0E*<XSV8=7CM^/'8TU8XO1Y]4*AQAT./12:8@V(B Q%7=]5O1WH3,
M1L?$BDV7[2XV:9'0&6((ELNF>D1#CQXHS$1B.RA#^S_IS_S_ .NFLQWI,^J,
M/]W#]/,R,8)SRSOF+SJI_P Y-)YL7G\D<NVA>2D24BVVEET<1\T/S'L9N,F)
MA@I-;>::JEAZ%.NRV.1'K)K2<8>@XGHB/S;WK)U]ELD4FFIC*7L6[#O@.E2,
M^<AA2LLL/RY&6$-)=6E335=_,Z.LG[>G'/GUK7^+[,?N?\/YN--'YG1UD^YQ
MSY]:U_OCQIH_,Z.LGW.N?/K6O]\?_+C31^9S]9/N=7\^=:_%_P#67\?9QIJT
MW+H8ZIKT;;/5;5KA,2S7J=6')7M?08?=.4:G@J1:(669]IBR,^F6>NEQGF$M
M9BS,P_-P7Y4!^-)>[3P2TT@BF3!S%!,!DK7CJ88ZB%KJ6'?AEC>U[KEBP#!E
M'*&>*H0R0MF@DFB)Q9?.4\TD$JV8 ]V6-UO:S6R4E2":M^9T=9/V]..?/K6G
M]\N<==='YG1UD^YUSY]:U_C^S'_W_:XTU:X/1!U[#8@J! UX4BPPDZ$2$QV;
M_K1+8^>.GS"D&5'QFW=J7(Q$C.EM9SV]CTEU79G"L8XTU-8Z0OJB.$#4)IAI
MO AKP8*F[]J]IQ"/'KLA:I#K=L2[.>>74JRF3(G+DOR8X,=$D.NQ8S;/&FLS
M'2C]4:PIE::<6;7&<&JBK:NVIVG(;(<L..B!\)QNS(7#"B2XD>0& HRF@P^3
M&2N' 9PMW"VFL)OI!^J'M1VHK5*,-,L/#'X^&KWJUM<;T98IX9%C/(M27HPZ
M)(!!9:!3"VQBYPH=.=BKEQ&'T--4B?\ 4^>M<FXP[/U-)EN184$;'6]>]:*4
MU &16H,"*C/MCCL:BQ&&8[2<_&EMM..W/9V\::POS.CK)]SCGSZUK_?+C31^
M9T=9/N=<_>]NM:_WQ_GS^]QIJW5?H>ZHJ?!NH^Q:O<'S+]4'*14V?:ZARO5;
M.[8ZW:&QGB0[1(:A=X'5CLWSA!<2#C,'RV96)4F(P_VAIYJA9WB3):6$U,YR
M5<(1)'"7 9@6\Y-$N*AFL]\;!B.,L\4+0+*^+5$P@A&+'.4QR2A.Z"%\W#(V
M367NVO<@&H_F='63[G'/GUK7^^/..NVC\SGZR?<XOY]:U^+_ .L?YNWC31^9
MS]9/V].KQ_\ /6M?[XY_\_M?M\::/S.?K)[/]#CGQ=GZ^M:?WQ[/B^+_ ,L?
M<::/S.CK)]SCG[?^76M?XL?Y8_\ //W/V^--'YG1UD^YUSY]:T_Y?Y8_S_\
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M_P#AV=G\;31^9T=9/N=<^?6M?C_:^S'_ -.--'YG1UD^YUSY]:U^Y_#'\O\
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M.N6M%E".I)&T[MM_T^T!X6*-K )OW<6L*M'JZ$#%M[$L$$/J6RS);*E5;$V
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MQ#DPYLW3K8*CI+$&#HN17W?/#\1)<&9.31I=#%CTW=T5@SFY4KZ0=5((#*>
M0;\&X($TM1+A**G,30Q1RNC)$ME=7(*&*212&:.11DP92O(L035Q_6\58PV4
MN>E9U5JD5O7)"P&HU]%6(B("[:J)&UTF2P"B XBRA*.D5+&7,:V0C, Y*X;P
M G<8[LA<.33#P63)KN "A4$QL%:Y)N ;W4V-^00I&N:[BWI24Y1 (6=A*'*K
M.A>,A @+$ $2"X"FV)<7(E\=8%I2<I5(?TB[&V)LE>OB%*K[VQA2PSU7V14=
MO6L46L5GB5Z2D*3!)TW8(-J"01)YJ.J<.DUDO:T9?:;=G%F;J=Q,PYP-PR-&
MI !(N#U 5-P>#<+;5NWOE'&:>TLW2,:&9;%)HZAU+L$.++V=PZJK@7!1GY&E
M@YUA;FM5OI[5&UW76 %FF]/N!P$O:&8YR4_LP5O?VL#'3"0A(<+@BS&M6<,&
M0\<G,0. O2X@\E(LK8H5?L\:JV3MDO5N0+CN&+$@7!-PYN#87-KV4D\37U#R
M1B.) KM2V1GLQZRU.:,V+* &A])0>ZA(R+@!JU/K0CV6Z:RJTW6A.J0-A1Q\
M-5ALM@0.&MVR28MU<(5BIE7P3=/NDT(?J:H4T:BX [I-C&@Q %2BS,E2&^;4
MY57;,,5N0%%^[96#,+Y*"K7!Q*@@@L-=TW#.2%#"4$MER=P 'R=&1&QZ<A5D
ML1U%D(92D;7MJ4N74K9:KMVS:NK5&D; /+,,P00^=8@]-"#&!FIV-E%W7C>1
M!<@\F;&P]%B(='S'<&7XL=2H0A<@A!A8 T8D+!5M<D LW,A0<7 X(YL1Q[3P
M;25;I.\*1F5LK*"ZQJH6 3,<L6)N. +$Y>Q;D2^Q^JABEZAU3N )K\U8P6T@
MHBR(<F29PH330IBEKN<21=#H6O6]FO8DM> $BE"D.%4634IAH[:@,-UJ8Y"0
M92/&7"E"18"Y8AL3B"5R]M@<K>"GFTS5HC@AG6)G695?DE5C5H^H#(RJX2X(
M4,P$88V9U%CJ@V_KF%U*KV'9"M;SRVK!KVT (&UC+B F$+)=-5:DN&VS0MH)
M 9G08U8*0*%:J\"N,2Q%FYQF!'FY#-5LG .OW6E+,$S <X%E*FRJ\BQ@W-CD
M"ZDK8<'QR!&N4FY+&K2F$F$&9%D61"7DAIY*AEQ%P$81.BR!F!8 XA"&.(>Z
MXYM DVE_:&F2-6KM'LMBIUI,!;P*MDR+8P_3>4ZI8448';#B'"<27K49Z<2F
MN3(/IEUF1@\)@X%3*LL<*;.V$@8LH8 J5[IF$%R;FQS-P/Z/)(-AHVXF+,S4
MY18W>-RL@D.:TC5@"C%2085LQXQD(4!UN^FQKSJ5DW"B[6MQ_65FITW50%RR
MRQDYH\@98ABJS-L;#8$Y9*G4'Y)&*L;/#'HR0BXPDBRR[&G%ADZ!/DT:'%XU
M5U;J-C<6NIR"\@,W'((-^1Z@1KM#5F2*:1H7C,*YE3EBXP+C!G1"2+%6[ME-
MK%@02NB?6<2"-(#G-51 U_FL:_-B*K+V/#FQ9]5V56KU8:],8E *L;M9FS,/
M:ZLP(S4*30[E*'$&(Y;U!^G+DVB)<4U^0]T&8+!"+,C*K Y$*!WU(9G4$&WI
M=W7$[@5[K0!93TF5#*""DJ2NINB,[/YIU:...0@@&Y2[A19Z^R3>86QSU9D@
MM.2&J?:Q483F(5NA"MF>C7</4H;"V4?-C-QHD^')HT:*/D BC2WI\6##D.('
M2B;KG3LGY@:\G>4D\*"*F*$%>;GTB2"/ DVN!;AY3:XE9"("(Y%5;&0HU!45
M;*X(L"#& ,3XJ 3B3IM".L:W'I(RMBM G\7HL:(#H8PY8"]2J3PZ#0YU]<)Q
MK9:M?AR4UUA@60KA$?"J$CR%D3!3B9)KY!FPIY&G478RC$ $D ,URX2UE<@#
MD$$L 1?U\:[IN#O95I6ZK,0%9V1"!$9+]1XE)(Q*$!#9[<E6#:7 KKVM4D7;
M[UG4N2FO7S6JE48@T5+PO9ZK; Z<:GO-^?M8F*JMLC5AW#]DA@AYER.U46BA
M:&+/G0,2!FQ%KFE%U3.S@/F+ Y,DS16C!89>%R/2L"0I)Q')=S<J\H@+1%H>
MF<F&"2TD=3>=E20)^,50WH9,%9E"YM]'P!F'8@06P#W&78!T2.,PG8TV 2CN
MPR<-F;&<CD14J:+GLK9?0IJ:-FRX$I&4OPY4B.XVZOR$6)!\02.00>#;D'D?
ML/(UK(P=5<>#JK"Q!%F (Y4E3P?$$@^()&I;D:MHXTT<::.--'&FCC31QII9
M:S^38'WS;9_/!YK[O^C/HBB_Z2:R]K_2/TI5_P#;TS>9&M31QIHXTT<::.--
M'&FCC36EG6+U-;*Z<JT)L^MM,1-P#AI43(VI*G7EJCL46HDS8@'"DC%2@11F
MW6T_/*8@@:E EQB:G4M3'F'(;[/B:VU;?3U\C1U%6:0LCBFM"9NM*B,Y#6=3
M%$@6[RD%?S1R#;SSRO$H9(Q)9ESNV.*DVOX'(W(LHY/_ %W$*%!@0=,+FB,$
M0*'1W)1 F3EQX ^#%:QWG9,R9*<:CQF&T_&MUYQ#:,?&I6,<RU5G8*BLS,;*
MJ@LQ)\  +DD^P#7H) Y)L/:==UD(#4^,*<G0VRDV'.(0QJY+*)\N ,>'QB4Z
M-#4O$A^&/D%Q4>=):;6S$>)CVI"VUS8R78Q;$M8X@A2UCB&8,5!/@"P5B >2
M%8CP.G_G_G]XUF<C36&P1'RI<Z!%GPI,X6N.V3AL2F'I8YR6PF5%1.CMN*>B
M+DQ5HDQTR$-J>86EYO"FU85F2K !BI :^)((#6-C8^!L>#;P/&FLSD::.--+
M*]_99IC[XI?^B39W-?;?R+?_ **@_?FS:RZ_\LV3Z2G_ '/NNF;S(UJ:.--)
M_;.TIVOW:/7:Q5T7;86S+)*K-*K4HZW5@RW10 M:3QNS658TX\$K@,&%EO3)
M0ZOV$M(GR!8T<$F/SN\STC0/D6;%$7)F R/)"@*MP"Q)%@646N21;7GGG,1C
M1$ZDLS%(T+8+W5+LSO9BJ*H-R%8DE5"DD:UV+=;HJDVFMTK9^O"-1L'PDS-<
M;.DC+%&LU8USXM4K=IK%]0;P)#RK!KBQ-W*LPI-@E!JS-JJI):;9PXZ%7RCS
M744Q8,T;AEPS2XQ9^\5*VN0'&)[MV#<!221KRG<1&ZQS1&-A,8IBKYI",%=)
M<L5+Q/F@R*H4NQ90$8C#-]:TN.9EAPE&H;.1:MYNDIFR-V0=:0W86D=RV+3\
MST25*HQZ&1)6"37G#S$&=*#Q!<24B-+*.X9<FYD4QL"68WZ5L(RY'5C$@N,@
M0!?'B]SZM0=Q.3*D<7=[3<S5 A!%-.T!Q/2<$L5R )4*#8GB^KX$ZNZN?O6D
M:E$J5BB#=RZ[IUV<L15<:"BB%]FUJRVS65(M(]*9'A';6*H=\8<6W.2T+,!P
MHM2)CUK%K34T[!)&R!,;LN(_."%5=E/L4NGJY!)_-.NJUR-)3H(V"SQ1R9D@
M")ID=X8G O9G6*7D&RLJKR9%UYUK=_4!9[KLRB0M&:O9,:O>K,8N])Z@+$D?
M.DVP)&L0I,!YO0+C^64"WU>==?C-+8FMXC,LR65^:3#1QJJ.9'L^6-HA?NMB
M;^=_M'S>P\:)453R31BFARA*!B:I['-0XM:E)\#S<#G@7'.EI$ZT[IFE:DN1
MW6&IZ;%W24-0Z@_<NHB17Z]"A5X&:,$I%HL<W3:611!]8C$(.,A0BZ2+DK"W
M9T'+7A.].S#*10[MTL<L8LCWB ,0'Y'/))%M<1N,G3@D:&",5#.(S)5%$ 0,
M6S<T]E-ULH ;*_B+6-SIO5E8=J1*P+U1JT19;V8@7TV:B&=F-A-;!ZU0M@$=
M;^T0C9(>EVV9;Q=Z/#)LG7,H-2,1C86%/(FY%9\NTQ*HT 3(R.54% "$NY9T
M#XE"RA2@(#@M<$V4-S:\=<TX18(5>1A*S!I@L*I%*8<UF6.0R+(P)B*QV902
MQ2P!V+U+LJ#MFDQ+?#$D:]*08M-6L5;+KB/$JU<*-9R],N->ER1[\F!-R(LP
M(I"8)0)#L$I%:8(Q%YCRF^<I$,;%20>%8$7LRLH92+@'E2#R./#7K@F$\8D"
ME#DZ.C6)22-VCD0D<'%U8 C@BQ'CIE<IKMHXTTMM4?8E*_AWM;^E.Y<UMZ_+
MD^C=E_<U!K+V?\C?Z0WC][UVF3S)UJ:.--'&FCC31QIHXTT<::.--'&FE9LG
M]6-0_?3C?]"7SFUM'Y/OWT*_[RVS63NGX_9?I9?W?N.FGS%UK:/E^7C36O$7
MI.Z=H3)>-&U8 ;BF1LH.N'E\NY"#BII@?89,"H0G"2XM%BNGQ @WEJEL@$H+
M"!1!&$RQL)UCKUY>.^>"#X#D@%06X[Y )'?RX)'@3KRBAI & A4!E*VNUE4L
M'(C%[1@LJMYL+WE4^(%IB!TVZ-'0"XUG6X&3#L$:X1#S9;SYQPXUL"%5!]V4
M8DFID^43DVF-1ZIZW-G//S)\D)%FOOJFJ?D/#-*2#F05*D6L+8%BM@  ,2S6
M]E]2*.F 8=%"&$@8-=LA*$$F61.1<1ID3<DJ"3<DF%-=-&O<5"R@**/@TJPV
M,';Z^[>)4!V\GTP=A-52!=W2+MO($'K+-.A*760_F+'+)IBQ  *,EIT<*9&K
MD3ODI<EE4J< <%NF16V(&(!9CW0+DD^)OJK4<.#K&HC=TD3J$&1K3",29=0G
M,LL:+WRU@BCT5MJ^(T[KKX+@.FI%;BS->5H%5J\&!O./M^0A4I(S-6DPYT1V
M-/@E@<H.,(BS$"3%)#RD*,2A2F)C+;R:=1\S)D<R6);VEKY7'@002"#P02"+
M:Z]GBZ*TY0&)%154WX$=L""+$,I565@0P8!@00#JFHZ6>G]$0'!3K$%B)7W2
M;L./XY;+<W!FTO7@I'LB<D<^V$&=<I$FU/CK9ZU 78),@OY;$Y]U]=NM+<G,
MW-KGCBRX"W'=(7N@K8VX]6N?8J6RCHK9;V!+&^3F0A[MWP9"7L^0R.5KZ]E]
M,6AUY/*5K@1E5BD8E2U>;,X6-DIL[5VP]4UX)X51W,7)B/:^]2\@,^TD:,;S
M_C*.S);=:7COG@6]7(Q*=[CO=TE>]?N\>&I['3=[S2]_D\MQ=^KW.]YOSEG\
MWC9P&'(!UYRNEO0$R.!BR-9 EQZXEK$!I+Y9E,I3%ID7F.]8?!(MYMLF/=YD
MZYQY5JR9DQ[9/(61EU!F?,FONM+SWSSSZN.Z$XX[O= 7NV[H"^ MJ#14I"@P
MK9/"Q87[YD[]B#(>H3)=\CF2_I$DWZWZLU]?<SU7"JC#KA,1!!2WY:7DR<C1
M9V/9Q3<>5'>9D09(FQQ(AX21@NQR(PO$BD8$N/+C,NHJKNEL6(L20/5<C$W!
MX-U)!!X()!XUUDABEOU$5B5"W/C8,'%B+$%7 92+$, 001KPI>H];Z\>;E4R
MIC0<UL=.%+(,*ER2<N(4/3+0442)3I,J>5FE;&0G&RA0G(EDR).6_+FS'WG5
M*R:1W])B1<&W@!8!18"P%E       &D<$,1O&@4V*W%R2&8NV1))8LY+%F)8
MDDDG2KV;TDZ7V4-V5A^KP@MIV76KN (6V'B7*DBY.P*C(I5E/# LJ;D#&+&
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MQ(E5]%45A9@T0(%'HT>M(0!'07I;D(4*2F$,CQ&,81R&ED:X9B018C@"U\O
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M4^W<*^7P<4SIX\GWNWM[/#SI94SN=GUO=\_W^[_^IWOKN.HG]1'_ /:FO_\
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M6XY"N2Z-34=/.:62D5R(-SE:226=90]$]>T"625(PKK2QQR@QEG1V*-'(5<
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M6D!NW4OP&"\8V' OZP=:A>66>F:*JD6&IB>8*J0$ (L) !>)F[V9+78D'@6
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M]NAHJ]'!N655@UF<,PQ%2-.0O4F"9,!*03J9AV.@4K#67<XU) 1.MT8QB<
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M6W;#7D(=+3[+-8DQU.22AJ'%4%!8AV">-G1^$408R=QY"CHH56Q-F+ MZ+>
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M(BN X#%7F%F3CLPRB;#6*BMP5/D$RXRHB'L/M97T$4I7,1R% "2X1BH O<Y
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M.--'&FCC31QII97O[+-,??%+_P!$FSN:^V_D6_\ T5!^_-FUEU_Y9LGTE/\
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M7^P%I5=,7DY7[O82-AA !4491(3R42CBQ\1CN[1&28F962>0<*'NJ]57+D%
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MJ%;]GIVS<?=$GUVD_CT>UFP?=1.^>-5_"N.P[9[[B^H5OV>G;-Q]T2?7:/\
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M*P:W!MTT5KTM"M:&+;JR&1>OKES:Q7GZAN%L59$RAB:=F9&L8]^?73S91T=
M>:*5TW';XRP8A#&')8N"MUD(PPYRCN.2UL2 PMSP1KU4U;F\J3O"@C$3*]I(
M,C+U.YTZBS77"X=24;(@6*MJY.=1LVOWG?@6_P!+>JM;U+7=7F*BXP4'G;5L
ME[9%CV15 L<8)&2G844E;+'2AX:B5A4QPX0?,P,F,"R))0013HW6(JV32,X/
M!"I@$)N2+V4,2[6L #:X%ST-64EJ5ECP2".%XR&#/-U7EC4!1P&=XPL27+'(
M98LV*ZUD>N^XQ0%'>DT^J5NSR*??MA;'BDXFR;;5:P"IFU3.MFQLBT4"K'&Z
MF)7D 9GV;;-PB,5"HH@PI,H-/AF5K#=Q2K=^\S ,J)8HK,6C#DA789'D8QK=
MFY -QSY#N;A(B8T1S'++*&$TB(L4S18EXD?!>ZQ>=QTTL"4(;N[.5/8^XRG4
M/9=7DH.LR-"JU4]K#I^NXM#)T#FT%IT76M8F+(27Q!"QF!(@T=L#4-MAH..A
MBY7=\*S">W@R1B%7!<,QQ .-C8=]K#D*"0%)\23_ $3KUQS5#53PL(3$D?49
MTSR7-B(4-[J7959FM8* #^<NMG^<=>W1QIHXTTMM4?8E*_AWM;^E.Y<UMZ_+
MD^C=E_<U!K+V?\C?Z0WC][UVF3S)UJ:.--'&FCC31QIHXTT<::.--'&FE9LG
M]6-0_?3C?]"7SFUM'Y/OWT*_[RVS63N?X_9OI9?W?N&H(;LG9,SJ"L>JIFE3
M8[58C7(RW"-\NV$:\!L%KF%F8,JAQZVW&P0BS8<-R1/S/<GN*PD>_B0/C1IH
MF7.RBB=(2=0%RY4Q6-PH%\[WM:_%K#YB;$:]HFF-4\)IV$*Q!UJ<P59RUC'A
M:X(%S?*_!NH!4EU275LQWWFF5R7&F776X[>4I<?6VA2T,MJ7G",+=5C"$Y5G
M"<*5C*LXQV\Y#Q\;?/[/GUZ#P";7L/#V_-KYLUO=]II>B]=]55^WS-LLB\ZN
MM&PS&AI02@0:X6,1-;'=ARM>ZY)#0(BVTXEK1\-,%';!;CUR8R*#'TVL:@T_
M (!_8T:M*\"16"R*@E!<D#,)FXN0P>X("A>2,3:X.0E1)'30UDM47,L3RM3%
M8@K,(GE,,+!5>-H2N+.[R+BK9C(AELEKZN-N5:RF]:N:IUP0V-6HEB.F78FT
M;#FC>S@;6*=F150BWP;*.*L$IMJ;7Y :8"B-14J$6=,]Z"62,C0M/&RA^HX1
MB +QKE<OAX=2UA<&]S<W%N+ZZ/75".T/0A,JAF8B=NG@(>L+-T2Q?@J5P%AB
M][,!KJ#ZO-L66QU:B#-4ZXAW&Z$ LL.LMM0\S68-5L>F".XAKY(@SK9PH_88
ML<3-KQ$>/$.0,+4R<8(JBMR834&!%5G+N54&]D%R1*(S8%P O.5R;^JU[:+7
MS.Z1"&(/(5*Y3M@$>G,ZDL(KENZ4("V\&#$7&E('^J 7*6\2F@=?%+<_>WF[
MY2:W,A6J5$I-""=-/2_L:P5R00UGKBZFB$XC<=TNN0+(9$- HD&24*2S#,""
M# S>K4@ 4%@N(P9N!DYGJ$!M(Z"P6(< Y$VL#R1YDW24EL8BYD;J1(0YZ<2T
M=%,R7AAD8DR5'#NH506+, %0RT;KEVC#-VF!C6\>RO6?8$]S6H=IJ[$)-8H(
M'I[T1M,J)M+&M]:7<RZ>D$ML#NY.3 GBA[Y"S*E&<BJL$CV"#2I927QQCNY[
MO><RRQC'-U%K1GUW-EL+L<;#<IP\B]'/.4]%;2'"-:2GF97Z,,K%BTR\@%1>
M2[6C7-AU?JJV%M>[Z(FU>LBJ1JZV[FCT&QLF+$Q,V,2D2NE&X;L<#$:Q[-2!
M(P1%+R@'A$A%MR8D*K3!!MMVO61;#5# D:RAFS=8RRD X"TZQW#9 DD!N"MA
M<_G :[1ULL\E,4010O4")PS!I23125&#)@5502AR5\B4!]%[:KEONW4W8=];
MTK&JBFW9J:'LO4(&IPA@_IW;T6&!%M>ZKM]SC;*F7.$SN.2J2R>LQ!YVDRI1
M!N/-&Q0*T3&\QVI581%$9 @S20L29C*2'D52@4].PQ4=ZPN#?QU1Y*QZJJ2!
MJ@]*:G1 HI!3*K0P22";J6J"2'=B8^;%0IR%AATWK#VI6:6,7L>M5,^4M0N_
M&-=G(]@L3A*P+K7476-,M S]3I^KRA3UA]G8E:F5D-0Q%O,'L"I0EUA)28B?
MF7IT+' E0I0.+"RY0M+=69Q<=Q@2Y4"X-[:B/<)DC7K(CLZRO$X=[OA5QT^+
MI' Q#>>0HL0D9K8D F^I0#UW6LHY1GB>J1H,'/N!NF[!LLXML#(VJSP^Z"VH
M$+FP86K9QZC)(($2+!"D[=$T,"X8PY07K#&*PR1:#!I5 >TA9@JLB@("P:,2
M<7DLUK@'IEVMW\2.#9=RD/2)@"JSLDKEI2J%:AH+D+"6COB7!G6),O-%PP+!
MG],_5L5Z@;(T.F:R*T\#8Z).V/234J-<H_F ,"QC0*AAERTTBIB)QF0P:$E&
MY=$+7&OL.^LB9)1M0P:1L5)J<0B^88A\& *GFQ-QBS$"X([P4^! Y('>CKFJ
MGL86C1XS+&QS%U#JN+9QHI8AE:\32H.\I;NJ72ELVKOX')M)O7.UW=HU@1?]
M440M9+4 H]'UN[L^W=4NL:;-UWK$L)J)$X]4P- ,7"C[.LA27L)\58) .+6#
MCM\"7* .Z*D1Q#QX,4D8!2S/TU@D8.X+ 9%PKQ@874$L,&0GRR3U2EVAJ#,B
MRPQ,[I''%UGK(D,4)6-FZ:Q-)%/(3+BV.+&5) 'C;-\[,E:!M%SK(2I@]F5'
M= ;4A>&L[*,TU^9#W97-=G)H@VY6<S7H18426KNRJZB=7Y\F:/>1*GA?&E<E
MB02A6+%&B,@-K-8Q,ZW&5@01_2((%_ Z]3U,W97D146:.H6!AD6C)%0L3%6*
M7L0?6EU-QR5N51.ZR;\/*1K(;IE?#5N6/ZF!5-#0KT6*M68OI[J+U'T^BY-L
M&C]/%K8P<.6.UR'Z>$U_*L,N8P6=!/@++8B0+(3IV=/1#,6\R6.(%A)#),<2
M9 +!5[Q8"UKW4 Y<#7S AVC14(JUC42,V;054%,I<"!G#,S^;6(N3D5*LS+C
M?M!]2-SW-MP>$*C,50<,I.YX5BJ[<4HVQ*ME!V-K (*/H1;JM5KN%<4"M$UF
M57#(T>\.FRI<:;'FNPHD[-)85C0D'(DQ$-QZ+HY([K,IY46()N+>%R-=:6KD
MJ)PK+TPL=0&2S<O%+"JMYQ$D4XN048"Q)!O8'52JG5[?WY+3":(+-U8)<M25
MVW60_>DQ[?GX>.J"_=/==] !@M<CZ_.8J,JNP#D[$^:&>E!'$BT/3RS+YF59
MJ=1^>0Q61E4)W?-0),UR7)&61 L#8B_@;#G'72^'2#HCP+([RVD/::R6F7!5
MB"GIX!CD5R7N@EKL6+M#<VVZANS:%2IU&L.PZZ%Z=->W>'$!E-<A$4VS&;;O
M480/S7[F7!SRR2T&I 6T#XCI:+%Q7G%X@17B#BI]4CC:)&9E1C,ZW8.<U"Q$
M*, UK%CR0/2\3;CK-43I4S1QQM*BT<4@56B7!VDJ5+DR,A;(1H  3;$\"]SI
MG7>HKJ0D)7L&=;=D2JC5[?T?BK078A: 1J4;7=EZAZ;+1LM%FKLBOL[P+6,T
M1V3:)PQVA26X \B<K[,+#(X43'M^@Q0CN8H&=9RHO+U,DDF5"IOTPJA%!#7)
M -^3?7@6JJR>J9)BB/0JY_FO0"304CS9H5%0SL97*F(V!90+!2!MIK+;&SK/
ML.F:))65;]XU-<=IR=^G,"PK<FPT"L,(B:;\Y':%M#PI';HC8FN]@/N@H4!M
M"JA=P@UZ,RP]C/!TC56E"]V14Z0N;*['SEN;D1E'07_I*UO#7MAGG>6.F9[R
M023&J>R@O$@M3W  "M.)893B .Y(HMSKVO'5T>H%MOGKM*IC.LZ5LPSJ=5D?
MV-)A65P^*Z>/\('UTJ#>IZQ(>KMCV9($B[@_/)P(V%VM4)P;#>ANPM.'5;,V
M;(),<.[8S=&P.5R;\CBQ/=O<ZF2O:*23..,0QS-!F92'R6D-5DRX8JE@5/>)
M []L0=(TCUJ;?/DA(>!315,D [O8Q=W0ZNZ@R):LO]+6V-Q@O11NT]15^Q@R
MX\M3')+<HQ4FH158D"\AM\'9"L0;U[-&M[L6N@*VQ(#">.,W,;LI!#6L&XN>
M<E%_.=PJ'(41",K(RN#U%9D-'-.N*S0(ZL#&2+I9BJ?FNV.6_P#5#+ (#6TT
MC3Y<U6Z95-DI0;GR;8/EEK?JG11O;Y+U4\G64'6[0ZP2JT2KC#%>L9"QQ6Y(
MNUJJC(>60@ 0HP2HZ@!9DN!CPKRB,6'4+W&0;E0IL5RO:[RHRK(W09DC2;O'
MJ EX*9ISDW16&S%"MD<N 0^&)(6XV_JGWC7K?#"RZ#KV'*IEEV$Q=P0[8CK@
M^V"Q738K==2&BK7:*."C ):ITM8DR2)-CAT>4'A3U3<B2I"&-HL$1!.;G()B
M2G*WFZ3757.7 N #?DBUP">DE;4K(%Z40,;2]11+<2 4@J(P'>- ANV+$V%U
M!O8D#9KIVW*5W-6+-/L5>C5.S5&W.U0[6T,7<>1&OYKE<LL7U@+L*D4.Q")C
M\.QLJCH2,)AR@U,$^%/$(!9IN+QEC$94 Y*RY!N[8\D<%'<&UN>00;@@$<^R
MDJ&J$=G01NDA1D\X".XCC)98XF4D/QPRL+.K$-8; \Y:]6CC31QIHXTT<::.
M--'&FCC31QIHXTT<::.--++6?R; ^^;;/YX/-?=_';/HBA_Z2:R]K_2/TI5_
M]O3-YD:U-'&FCC31QIHXTT<::.--'&FCC31QIHXTT<::.--'&FEE>_LLTQ]\
M4O\ T2[.YK[;^1;_ /14'[\V;677_EFR?24_[GW73-YD:U-'&FNJE)0E2UJ2
MA"$Y4M:LX2E*4XSE2E*SG&$I3C&<YSG.,8QC.<Y[.--:-N0.B"<]&JF-M:A5
M=2VW!VVH!1G:M#QLZ9L(U>H^P1.(!!)+UMZ&5ES8M>'U]AA<.?2)C-6CQGA<
ME#;GIO4CO&.3$1],@QMA@$P-Q:UP!D3ZF[WCK-_!I(3KT_4:<3J>M%UC*TG5
M6Q)R(8D(% L8S@!8ZS[?IKI1=UAK:KV"^!*[3JST_P!KUE4+-C980+)L/3_9
M*('I%HCR[!)E)AV2H.BWZ>==-)2[!'V2'5CT>7&=6TF662?-V"%F:5788$XS
M*Y=38<JP.0MZU+ CV3)3T1AB5I52-*9XHW$RJ6I7C6-[N39XR"C9> ?!@1<7
M8M2TOJ&HW)]X[:)^R=BW6M0HP[.V;8.MU@D4RDS)$IMFJUZ2S$@Q@@8G;G91
M0D&")>5+-P\%B#J5#&FJ-)(RV"A$5C?IJ5&3?TB.22%X!/ !L/'76.GIXY.]
M(9I9$ 7KR"1S'&2>XIL,59[LRKXL,CZ(%@LM#T58"VS+1>X]%M,0B-H%*V2,
MN[M</U$3F@RCEMIT,Z&.HDBPYEA6SU&&O4T-RWHQ6OS66T-KA//0'E 15R4@
MNR%<@QSLK6(Y([F/''##VZN\5*[322B)P5BBE$I1HUZ9:2,,K756\]EWN;,I
M'%KZSM:4Z&D0C6M*IL6A4YJHA-I"-GU&@[0I=<ESJ"?L*[%M&J;3#BI"'XU6
M'SHJH).5*C!C%3#,RPD8X)'2RD>7VZE5<2,CL6*%&9&:S@6C9"1RQ!X'(8V)
M!(!'C[/MMFB2:*/IK,LZ1S1H3$SYS1SJ.1&",6N%*("@95)!VW%C=:ZTL=L*
MJ/B@QW<=G&VN:T<L$%ATN2&US7NJAS-=B2WF%X&,1AU*%-PH*7FL'CS&>WSI
M]AI[SDNZJ I(C4J,5)L"7<W(OSRQY]0]@U[@(87=LU5JAPYR<#)@L4"X GP
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MR%1FKV98V.=@21U#(+'@!3TN#:]SXZD56XR*Y"/%E$]0EX02@![.L!!4Y.9
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MEGI;DU&MVP5)UF55) %[ 7V=!L)]==$D<SZ4)IC5PKTO#$:=8QQ,P[J,V07
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MV$>-(RXA6$\J*7;B 3NEB5@)'89SBTCD3K?*Q[.MGN.);XK8C5C45X) VX$
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M<LY[5CO#\>0IQ"\8Q44NW$"^Z$$I 2.PS&S2.5G2^?/9T ?+PEOB@!&K&HW
M$@;<",IP#VR(76- 86L4N.NQ*8^,5LFN"-<H/WA3K25Z_2AM;X=#KOM8*5X+
M,V*ITN_W,1L*<]%DX3%PTG.%$N]X\?+:,=W,&EVX*Q&Z$D+4%5[#,,FC<+ M
M\[#M"7?(\0VQ>YYT%17W .W  M ">V1&RNEYVMAST'[@4<R^DI4<:Q_:._\
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M>1^W5>A!9!T8K1G*,=-+(WM06LIX'*V/&O;.L=:Y>M4C.O*-E^]-Y:NS^:F
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M^[ACEX<^C\^G?SEKTZ^,'2U0K73=018=(I\2E;]":/94*0YT-7W45G=N=:R
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M$QZLE.PC(DL7+ /3J&M&]!.S"D2D2]I1(\>E:SEZ8%4:@HM-&NVR)]^M$+9
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MU?4LC?I5&O6V]B$0-]N%4H06W5:C*K%A"3.C(SL8/8"4H71*[E^/_A*I$UF
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M8ZJKJX)1@P#.A(Y&4;LCK^U75E/L((U,94G&>S*L8S];\6<XQGZ[/=3_ /\
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MB/;"#S:+ 1CZZ@U"2*(U.M0ALV9*L-JLK/19T&-Y)6*LK.2H)G4#F)KM? >
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MT=298P%U)VRG+,QEW"[-.QMNVZ* :A CA0*P!54"\"* M,]Y*<1.S,8:75Z
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MM4X5C?OLMFD(!<L0"+MS/U[]'&FCC31QIHXTT<::.--'&FEE>_LLTQ]\4O\
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M"DW!OE<Z]-.M5'#6*T61DFDDD9I&5D:2EIV81+@_4579U #J 5Q'-[:^5&O
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M,0B#";J]DH5@SOWL0XJ 3(>F)!:;NVT]M75[J7A;'U];;^;V#+E&-LW>M;&
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M\96A)B MTUEDR"DFR%U/!(!(M?'B^O;3)5+'4LP;M#T\73:154M*L3A<@&=
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M!8]/,@VQRM<VN=G9G491 E+U1;K..O :7N"NPS]7IL&A7&X7-M;E29N9421
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M7HY?R"HTG758CW/$0O:3]AL<6$Y<XA:4X.GRH\5!*20F#(J(TW*W/-*ZNL1
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M(0BBF3%<#S(APB/@&Y4N Q$)O9;P]73R14]*15#VL#;@,N8#$J"4!S )! )
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M$#'/!;KPQ558V!!!N3R;:J9FE)+6E,K%0D(*M,V3,).D96LURJR.Z#(@JR@
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M0[1F0AF62)E-^JUE ")9,%7$:9&J='KUO<,$\%9A&O5+3NMM(:^25*/&;#(
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MJTFV9/U J9'%*U4+Q*K4HE6HZ98?%AMN KY%:AQ#EDJ5257PNN-.I)N''11
MP6S $,Z V8V(5;VY&N4VW22P/&)L'ZE>Z* IB8U<DK)U,HV92D<A0E!=<WQ)
M.)TX>HG2%ZV5%T4\"R%NQ'5=L(';(S:=F7;2$JUMS]9VND+(1K?J*H6 J')*
M+'XYJ4,'!X >7';E#\9CQ5HCYYQ2(ADN2@=0!C&LH'?5K8R.H(LM@22?7KT5
M5/)*M-AC(8'+-U)9*<N##)%<20(S*UW#$*H4BZ\ VTBK;TD[-NEB06D4_30/
M)C5FK-<8/S]H;$V=>].3==[HV-L25;-<W"XZOA'[:4*A[179,-PP3I4P=:P\
M5EV=,$ H<DGV6H15L&D-GD>V"(L@>)$Q=5<A0"IO8/=3X DV\KT,\CY&.G7*
M&&'(SS320&*IFF,D3R0!G9@Z$9-&5D4<E5!.#"Z*MCHG4O'9J8#\']AJ4J=;
MP4\^NU;QC"NK72G4"1M6SX^:</0.ML*O:M/M#HBS=Y:)7F^&9*;!6P[LQR:[
M2EF'G&S# *0,8KP2Q!4.1)6[K<V2R(!BQM8NWS91D]!>D\9+HSEZD+7051>8
M&,8N$A;$92AI96.2+XWWI2Z8MIZ9V(3NE\F:[6T3U="I!%%&?@QFR=@'VV58
MDFXX(-J36D 0#?;*%?)##!&[V<4_(?20N=F<(R9S%9YTD0*H?B0L,KFP*@6+
M&1R3P+D!0?Z(M;72BHYJ>5I)>E9H1&>F1RRR%@V*T\*JIR8J&,CJ2;R/D2%R
M/Z,=KB(554*C::'G-80*JQ"-035DA$.H8Q6.HG5&[F;5N:?'U^A^KGW(>M#,
M1J7&;VG(C6G9]P,-2L0<.PS5S4H2U^H1(6X(!Z(:*2(K$,^\OG!P3'=453\W
M$;?.JIB*<-"J ,&<-5-'505*R3L(O-MYIQ<"8B2:1@0.&C#W1/ML\W++% F@
MCQZRG+8?LHDV;M$@#'8+=9HKJ<@5!LF[K*9/L@ G5TF*18I,T4!PF>XB6P&G
MCR4J/"D5,8X!E 4*%("Y'&F,&1&=E(-F%BW''%A>&VZ=KDK3,SN[N&9RH#;@
ME:([F$EU9 T;W5>3>Q#$:FI?0>?LH_9DHQC6%5.76@;M"4H=76)QT+IP_M:S
M"2B(-/E$*P!<]#EP!<IVV%QPBMSYI2SV1F"#1!F+6_7M0!2V;!6B+$V#2+&I
M!RLQYY 4$M8*O>N-6.VNPG)Z$;2Q5"QA 66!YG##"Z)W2 3(55"6=[+8G5.*
M]"VXR-;F"HWP2PH]A.7T@8K$DT#*PQ*[)K>BT(,7%V%[IF8#I5E-;-^U(:I:
MPUL:+C)5?C-[":DCS$@W85,88&TG 0 V(N%=W(($U_SABQ=@"#W.1CS;;:AD
M*^84.TK,F2L%+PQQ*RN:,*?0;-4AA9E*CJW#%G3T^=)FQM/[><VH?LE4M&;"
M-AU^PAY) N315H0_3>G:FBR:ZESZU$?'V,Y<]<&(%XBOKA1[C39M.*S2D8K2
MXE;E<YITDC$:JRA>0;"['J2'%[-RH5P5/.+!E LV0]%+0RT\_69XWR 5E)9L
M *>GCSB)4$.TD3"0=T21F-B0T80_0CGDUJZ.--'&FCC31QIHXTT<::.--'&F
MCC31QII9:S^38'WS;9_/!YK[O^C/HBB_Z2:R]K_2/TI5_P#;TS>9&M31QIHX
MTT<::.--'&FEH^%VTM]Y4?8-(9CJ=<4PR[K L^ZTSE><M-N/IV<PEYQM&4I6
MZEAG#BL97AIO"NYC76HV0*H;;-Q9@H#,-X@4,UN2%.SL5!-R%R:PXR/CK,:'
M>"S%=PH%4DE0=JG8A;FP+#=E#$"P+!5!-SB ;#R]#W![QJ+]%9?\:?)[1L7N
MK<OC5/\ <NJ]#>?>.W?"*C[XT>A[@]XU%^BLO^-/CM&Q>ZMR^-4_W+IT-Y]X
M[=\(J/OC1Z'N#WC47Z*R_P"-/CM&Q>ZMR^-4_P!RZ=#>O>6W?"*C[XT>A[@]
MXU%^BLO^-/CM&Q>ZMR^-4_W+J>AO/O';_A,_WOH]#W![QJ+]%9?\:?':-B]U
M;E\:I_N74=#>O>6W?"*C[XT>A[@]XU%^BLO^-/CM&Q>ZMR^-4_W+IT-Z]Y;=
M\(J/OC1Z'N#WC47Z*R_XT^.T;%[JW+XU3_<NG0WKWEMWPBH^^-+NZ!MK)L^H
MTR+]2WGG+Z53"<:UF58;BR<:NV,M;\AI6RWLRV50T2HZ8Z'8BD/OLRLOK1&7
M%DZNWS[*:/?"NV;@JC;(#(#N\#%T\L[2 J,-H41L)"CEBL@*JR8@N'3-KH=W
M%5LV6X4!8[A,$*[7,H5O)6Y$LRG=6+@QAT"AD(9E?(A,&8GH>X/>-1?HK+_C
M3YE=HV+W5N7QJG^Y=:70WGWCMWPBH^^-'H>X/>-1?HK+_C3X[1L7NK<OC5/]
MRZ=#>O>6W?"*C[XT>A[@]XU%^BLO^-/CM&Q>ZMR^-4_W+IT-Y]X[=\)G^]]'
MH>X/>-1?HK+_ (T^.T;%[JW+XU3_ '+IT-Y]X[=\)G^]]'H>X/>-1?HK+_C3
MX[1L7NK<OC5/]RZ=#>?7N.W?"*@?_K!T>A[@]XU%^BLO^-/CM&Q>ZMR^-4_W
M+IT-Y]X[=\WX(J/OCG_EH]#W![QJ+]%9?\:?':-B]U;E\:I_N74]#>?>.W_"
M9_#XO_S_ .6CT/<'O&HOT5E_QI\=HV+W5N7QJG^Y=1T-Z]Y;=\(J/OC1Z'N#
MWC47Z*R_XT^.T;%[JW+XU3_<NG0WKWEMWPBH^^-'H>X/>-1?HK+_ (T^.T;%
M[JW+XU3_ '+IT-Y]X[=?Z(J/^GEC_P"='H>X/>-1?HK+_C3X[1L7NK<OC5/]
MRZ=#>O>6W?"*C[XT>A[@]XU%^BLO^-/CM&Q>ZMR^-4_W+IT-Y]X[=?Z(J/\
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MXU%^BLO^-/CM&Q>ZMR^-4_W+IT-Y]X[=\(J/[?TQ_P"?/H]#W![QJ+]%9?\
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MX)G_ +?TQS_\:[>D[;[.]\)=![/$\'M^"XKV>-W_  _"[?A4[/$[_P!9W/\
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M$]]]EE]#2\<X5V\;?0+.LM72]JAIY:A:(U,*5,HCB>4(D;-G>14.'<-Q<@$
MZT_DU\@OE1\II=KEI-DWH;)N.[46U2?*&/9ZZIVFC:KK8**2>:KCB%,4I7G4
MS@SH%.,;O&SKJ8,[EU=5$UMJ[[ I5))VD=#)"1%HM00-/E,3$M)2N.P1EQ'7
MV$2740_-):PPJ4I#&%X><0WGK+NFWTP@%764M+)4(KQ15%1%$[!K 8J[*6&1
M"Y 6+66]R!KQT?R,^5.ZG<GV3Y/[WO=+M53-35=9M>TUU;3Q/"7)$CTT,R1R
M&-#-TBQD$0:0C!2PEBNSM< CC-8-7VFB;)(BKG,@"-E#PS*X*(,PFN=@8_,1
M-Q"2/'3IBIBF<1L1XDAW+O<:5G'62NHH95@EK*6.=E+K"\\22E CR%Q&SA\
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M7*Y;NI =7+EO8([?'@FM;MU>62Y$]@[1''M;WJC:U,[T#U*DUC6D1\B<K\V
M?!T:,V49Q4%PQ==*O9FDVYZ1\_LRPEDB(2[K JA$*NCN(BS,YX8$%S;GDCP
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M6&.0E^.;Y&]BN(&1+$D E?* ]NG:*2S+(SF6825U13JL1+  J(QC</DQ$=D
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M.>QIK-XTTBS5&E$^HZ@WY\$U,#5G3VS@#)M]$1U(FQ62W:Q?BQXR'5YE,S2
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M[#*H;;0G"$(0C4>SDH0A"<82E*4XPE*4XQA.,8QC&,8Y^B[: *'?P!8#:J<
M#P \N;-QK^<MQ9FK=E9B69MSG9F8DLS'9]U)))Y))Y)/)/)TS^9&M/2[N6Q]
M3ZHPW/V!>=?ZXQ993LAN9;K)7JEZ_-@L"AC\A#Y>9 R4DPHB@L%]["GW(L7(
MV.ZIMC$9.+JDDGH([X\=U6:P-S;@&U^\?[S[=<I)8(.99(H<S>\CI'D1BM[L
M1E8%03S86!XMI!']L=/#0\95]=:^K&^XNT+S9@Y&L:9CZ:L(J;<ZJ$1<+$_<
MW+#;ZK5?680YJ(0=]2(R3;CCL!Y,=6'6'L]52:Y9G:(HH.4AD4A6.("V5FL3
MP+"W!]FO*\]( $AB2JZTCJR4XIW!D1>HYDSD1,@MCWF+<@VY&N^O^JW19B\T
M37 P(:HMPV2C9 D:-,UD0':B6G35I)5BV:\-DPA(D+3:8).-99H./ FDP1B
M*-S QJ2M;34P\$H5W)#*F!)!)[LBAE< @'$@J"2 02+CUA%6TS2QQ!6CDF$H
M ** '@=D>)F4D9@ARH!*L Q5N0#)0.I[2LN-H@&@27BCNIH><)54>_7!V!0Z
M#*7!\T]?T1YKX\.BUV.T"ZW QCU/U^U6%F'GQ/&F268,,GG3<7@(#=XW)%P
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M((!!UP6I@=<ED#*)N@2 WX[+'"UKWN18^B00P)4@E@G+ %K4%DD?)Q!,"06
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M+#BLNR)#JLX2VTVI2LXQC@ D@ 7)(  \23P!_;HS*JLS$*J@LS$V 4"Y)/J
M N3K)AS(I")%G0GD2(DV,Q,BOH[>Z]%DM)>8>1A6,*[CK2TK3WDXSV9^/&,]
MN.1X: @@$<@@$'YCX:7>L_DV!]\VV?SP>:^[^.V?1%#_ -)-9FU_I'Z4J_\
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M;[-(K?JK%:?F,LMCQZ;%)$2[",&SR H3.BCS9B+.C_SU?_/_ ,<ZY@%@0,;
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M5'J-F0S#H89!1<L7(N2-5)KH(N3.([C.V(L%BJ6VGVFCU<'(VU7ZTU*K$/:
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MBJ*P\.54A&;O%?4>L.WO#)"RRJ%CP+A1+WRJN""KS.A!+W61U:9%!0.01C]
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M,5NP(8+:6VZ1%/1CA!;M2R+?$/%)6PRPI;'%A'2I(B(]XU8A"K1LX,75.B'
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M=.S;S[TH_A3_ 'EH] VU[R:I]&4K\8'':MD]T5GQ=?NW3LV\^]*/X4_WEH]
MVU[R:I]&4K\8'':MD]T5GQ=?NW3LV\^]*/X4_P!Y:/0-M>\FJ?1E*_&!QVK9
M/=%9\77[MT[-O/O2C^%/]Y:/0-M>\FJ?1E*_&!QVK9/=%9\77[MT[-O/O2C^
M%/\ >6CT#;/O)JGT92?[_P#':MD]T5GQ=?NW3LV\^]*/X4_WEH] VU[R:I]&
M4K\8'':MD]T5GQ=?NW3LV\^]*/X4_P!Y:/0-M>\FJ?1E*_&!QVK9/=%9\77[
MMT[-O/O2C^%/]Y:/0-M>\FJ?1E*_&!QVK9/=%9\77[MT[-O/O2C^%/\ >6CT
M#;7O)JGT92OQ@<=JV3W16?%U^[=.S;S[TH_A3_>6CT#;7O)JGT92OQ@<=JV3
MW16?%U^[=.S;S[TH_A3_ 'EH] VU[R:I]&4K\8'':MD]T5GQ=?NW3LV\^]*/
MX4_WEH] VS[R:I]&4G^__':MD]T5GQ=?NW3LV\^]*/X4_P!Y:/0-M>\FJ?1E
M*_&!QVK9/=%9\77[MT[-O/O2C^%/]Y:/0-M>\FJ?1E*_&!QVK9/=%9\77[MT
M[-O/O2C^%/\ >6CT#;7O)JGT92OQ@<=JV3W16?%U^[=.S;S[TH_A3_>6CT#;
M/O)JGT92?[_\=JV3W16?%U^[=.S;S[TH_A3_ 'EH] VU[R:I]&4K\8'':MD]
MT5GQ=?NW3LV\^]*/X4_WEH] VU[R:I]&4K\8'':MD]T5GQ=?NW3LV\^]*/X4
M_P!Y:/0-M>\FJ?1E*_&!QVK9/=%9\77[MT[-O/O2C^%/]Y:/0-M>\FJ?1E*_
M&!QVK9/=%9\77[MT[-O/O2C^%/\ >6CT#;7O)JGT92OQ@<=JV3W16?%U^[=.
MS;S[TH_A3_>6CT#;7O)JGT92OQ@<=JV3W16?%U^[=.S;S[TH_A3_ 'EH] VU
M[R:I]&4K\8'':MD]T5GQ=?NW3LV\^]*/X4_WEH] VU[R:I]&4K\8'':MD]T5
MGQ=?NW3LV\^]*/X4_P!Y:/0-M>\FJ?1E*_&!QVK9/=%9\77[MT[-O/O2C^%/
M]Y:/0-M>\FJ?1E*_&!QVK9/=%9\77[MT[-O/O2C^%/\ >6EUKL'M!?MSY;8-
M8C]S8MG1(\374F1XTE.87BR&^R\L^ VYVI[D?/BY:[,]K[G;\6KNE3LX\G9[
M75M?:J,K;=56RD/BI_!QR(];=V_]$:S=NI]V/;\-RI%MN54&OMC-DXPNP_""
MX@\67O6MZ1OPQ?0-M>\FJ?1E*_&!S*[5LGNBL^+K]VZTNS;S[TH_A3_>6CT#
M;7O)JGT92OQ@<=JV3W16?%U^[=.S;S[TH_A3_>6CT#;/O)JGT9R?[_\ ':MD
M]T5GQ=?NW3LV\^]*/X4_WCH] VU[R:I]&4K\8'':MD]T5GQ=?NW3LV\^]*/X
M4_WEH] VS[R:I]&4G^__ !VK9/=%9\77[MT[-O/O2C^%/]Y:EA8G8$?Q_5[H
M!)]_PO+^4I#POP.[XGC>)W[:1\?Q>\UW.SP?"\-7_:>)]9QFGVQL>AMU3%:^
M6>XB;*]L;6HHL;6-_2O<>%N>T,.Y+EUZZFEO;'"@:'&U\KWK9<KW%O1M8^-^
M+SS-UH:.--'&FCC31QIHXTT<::.--+*]_99IC[XI?^B79W-?;?R+?_HJ#]^;
M-K+K_P LV3Z2G_<^ZZ9O,C6IHXTT<::.--'&FCC31QIHXTT<::.--'&FCC32
MVU1]B4K^'>UOZ4[ES6WK\N3Z-V7]S4&LO9_R-_I#>/WO7:9/,G6IHXTT<::.
M--'&FCC31QIHXTT<::5FR?U8U#]].-_T)?.;6T?D^_?0K_O+;-9.Z?C]F^EE
M_=^X:@AHCJ ;Z@K(:*VR@/\ 38_KD9!J],B")[>QH.S&RK#I,T3,+CX@/5]X
M3B8PVRW/=6MUT>VV+@N09A ME$Q=( *_6S)9KC#"W  \;WMZO[3>P]P6I[4S
M&2(TAB 2,*>J)LA=BUK%2M_7[!B+$EX<Y:]&OB+J[3^^M2=.6N-\T4!3:-=
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M<?%@0;K_ /OX^&N]=!+-4%HX8)BE(2JU",ZEQ(Q C(9 DA'K)YNHNHNVM1C
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M]2GR@(T316:R:@+J)BCPZB .-7DD\:J3D.)$EDB?%K)8QIU&S(,06FB*XC(
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M/+46ZK6M:R#ND,!:-00"+@@'B_S:U-O#"DCR+$EIC=U*,UYY"&*$#'($'&P
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MR424B.RE%TD>.Y1F6]KV-O#D']H/@?$>K7&6"&>PFC23&X&0O8-8,/\ VL
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M)4#L@G1@@47N5\O'NTBLPAD,M#+PE0Q-J)6*,X27LV-77KK*E"T!-& !U!U
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MVN3#=L.36&+AJB] ! R(+%234LM690*TPPHWT\K)-+$^+-)<JK7!0W)>!([
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MP*@< )X-(&?O,,2;J@)),BDK,XKQD".2)D83!FCB%6\K0LSR\%:=A&1%&PD
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M&IVUT567DA$F*VE53&9,71FE=@-B:QTB[9-2GXUI V@7KY-;W)Z-1CFPPD'
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MBK EF4)BV7<4,Q/%@H!\2>;'BPOKEY0IC+TQ(F(B24S&2,1VD<HBB[Y,[$>
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MK*<A$[#7KDQ$AQ7)E7(V&3*+W(U;FK9H=BR2KDS9M1LV^<)8 S;4T9IK=DF
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M*6TEAQUIQM"U+0I.,?M-5:_:*BU[7ZLEK^-KY6O;U:U>E3WQZ4.0%RN"7 /
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M1/\ )T/^IX[54_[1/_C2?Q:="#^IB_PT_P M'H +]A1/\G0_ZGCM53_M$_\
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M3_VC7THY\_KII97O[+-,??%+_P!$FSN:^V_D6_\ T5!^_-FUEU_Y9LGTE/\
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M5:+*!(P5*D)*Z3=2[V%[&[%6LQ60A[&Q!O2NF*TYZ;!VHW'*(NTP-LVO:C2
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MLD6#;^P+&U=G<72$2<LU^U-,UQ,%O:L"&A&O8E;8?(RD/Y3-)19=%C#:9%K
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MC31QIHXTT<::.--'&FCC31QIHXTT<::.--'&FCC31QIHXTT<::.--++6?R;
M^^;;/YX/-?=_';/HBA_Z2:R]K_2/TI5_]O2(V]T4Z<W[O4/MO=50I&T:Z$TZ
M3U;!U[>:?"L0QN65N4.SRK#E\C)>A.M/PHJPLH/(#O-2F'U..RLM85%<R-:O
M%O7>YN;\6XMQ;@CFYN;W' MRI+YT KLC6QT4[9P_7+USZD2F_JY)#ZX$D&Z*
MU(Z$F.BT)5AP>860#)(KBHS&P(+TT<D*]#:32GZ[F&IPLJ0;>WY[&WK_ &<?
M\^>=61PC*P#6!7,!K9A7#V'=( X7Q#V90W/"C6Y?U*K9K\.QDIO4&!(78V5U
M\3&6 A#ZF)AZHOTW6.PM:RYE9VD_U8KW<*F$DW2.:],%[%&4EX7$*T G39U<
M+,2!:_C[2;WL./F M;Y^0?5:PTS\3BN18L6L+ $$%50 ( 2Q)[IMBF&%FR;.
MG?J;)G5>]*ELXGO(IL&MU;8SFYUC['G:K%@);/(:)<TF;))KP[=+/3X&8(YG
MFK*T9$Z'8N$$8450&3N0;*I\@3R?4#ZA^WP_8.-&?)I&4"-9"Q*(2%"EL@@%
M^54@6!OZ(/B-;UV/4#A_J&U)O7!]$5K5^I][:R76,C%/+-+W/:-!V-LRDOB>
MTD>FNXTDY$7 R-FY*YLB'TS!^!*FB,:IIV<::.--'&FOAY]4:^I=[JZP^I>K
M;WU?M^E:_&B^GW.BS@4]FX0C!2#/N=N/GU1C%696]%&F EE]!D(9>8F>&N:I
M+J$J:RK['8/E'1[5M\M%4TLT[-7=L1X^DR*1#$B720B[(\8D%[KP+@\ZXR1%
MV#!K64KZ_7^PCU<:U@/_ %'WKVLLR7/*]6VLW9Y*#?HA(PB"=:L<OX0*MM*F
MDX6+(W0TF&*RBO[ "Q,U)$G(;#]023'M"BY=L@&TD^5>R1@!=LJ  82J^;Z8
M,$M/*K=/KX=3.%B);9>=Q.2KBU.@_P#3 \>0.;$$6O[+&W_[ZG9?U)+KID2"
MSK74UIYE!:W-7A__ "?<\Y[4C7JX@!94E8^K8A*):Q8>%:P+]M#R1%C)"+&'
M%O$6@U(!BEU_E1LO=OMU6<8^B.\ !$P<O'CVDJ8V<Q.(V#(IC8A<YG?00N.
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M'?=[R'X8W7Q]X5?](_KM<JW;N;L5^FYL[Y<?K^M7_A_=;D#Y._)^_P#H/9_
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;E7S8&GPZM9428Y&HRQSD;&^*WM:]A?P&O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g307489g28b91.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g28b91.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1H44&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M    /X   #A"24T#\@      "@  ________   X0DE-! T       0    >
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M      H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      -!    !@             #<P  !V,    & &< ,@ X &( .0 Q
M     0                         !              =C   #<P
M               !                         !     !        ;G5L
M;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #<P    !2
M9VAT;&]N9P  !V,    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L
M:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M    !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T
M960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   W,     4F=H=&QO;F<   =C
M W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0
M   !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O
M;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M#T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T
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M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !+ * # 2(  A$! Q$!_]T
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M?2&N []P?^_-*]&^H?USR,HGH_5'NOR6L+L/(/TK&L&ZRFYWYU]3/TC;?\,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( 1L"70,!$0 "$0$#$0'_Q  ?  $   8# 0$             !08'" D*
M 0($ PO_Q !Q$   !@(  @4&! \'"PT-"0$! @,$!08 !P@1"1(3(3$4%19!
M4? *&6%Q&"(C4E976(&1E:&QT=36%S*2DY3!TQHD,S0V.$)#4W+Q)D9C9G=X
MEI>CLK.XX24G1$5B9':%AK6VPM4U-U5E@H2BM,3%_\0 '0$!  $% 0$!
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M2'/EUC"^J4H>RJD(//GU*?UQ  $$Q$1 -!,]&&/, JBO09H%[)2XMAT_^%Y
M;ST_G>.=A<U4'D'6X[K_ #?567K0''WP9\48-4=%\1NL;S,//[!4RSQ*[>S#
MR 1$:%:TX.Y%('/EVHP?8F, @50W+/&XA@&,X5<S\-E1T)U=+96Q^O:WV;]6
M_?JJX%)5H0?G\-:N^S4553%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3P\<4JSOBIX\>&;@ZB?*=R; :(69RV%S"ZXK1"6#8<X0Q3BBHVKK58AHQ@N
M*9R)3EB<PL"*I#(><_*!*D;-AX?*G*LPV=P&RG5^RTGG=1&9%Q[*0I5C?=MG
M6._)9CB[BP#P0,UFYM?=X"_XQL!SK6<XG^GKXD=HJ2-?X?8.*T!35RJ-DYPQ
M6EOV@^0,)R&6-,R#7T<K?E"(E'R:&@74K&K@*C.UJF AR^JB;.Q6K*DJ5(7J
M4BZ&AIEN@[Z[&^:EA*AJ@5IG\5=42EI(;3F"38N>)ND9<A>^BA6$V];"ONSK
M YMFR;K;+_9W8=5S8;G8I:S32J?7,<$CR<R[>._)R&,84VX+ BD ]5-,I0 ,
MWS;3;*0AIMMI T2VE*4Z?DI %^NVO96L6XMQ14I942;[RE$DZ<R3EJ-+9V T
MJ3^7M]H\OD#V?+[1^7Y@RX;<,OX"^N>MZI/S&Q -O<1U$',YYZ:O5[_?]OY.
M?L#(\^;U'.V5_P"-OFS^87KGW]_?UXJ1EGF!?+6WG0\S;A4(Z1'^^:/_ +W[
M@V_ZGFB<Z3L?_@&/P_NO%/\ JDRO2H_FF?\ 0,_^VGSPJQ[/3U-,4KL0YTCD
M53.9-1,Y5$U"&$ATU"& Q#D.40,0Y# !BF*(&*8 $! 0 <@@$$$ @Y$$7!'(
M@ZTK*OPI]-#Q_<)ZS&.@MPO]LT)H**9M<[R4D=B01&B0@4K6'FWLBWNU9111
M$Y&C2OVAA$I',0[B+=E2*EGD<6V'V>Q8*4J&F%(-[2( 3'7O&YWEMA)8=-]2
MMLJMD%"KB75IXW'(Y^'$?-U5M=<$'P@GA$XH'$12-Q";A=VQ(G29MV-XF49#
M5\\_.4H G";-\CBV$4JN?K=DSNT?62F5,DQ82$NZ.GVO)<=]'N,X2%OQ!\*0
MTW)7'01);3_E(UU*4!D"IE3G%2DH&E]#J59'V3UG+QR]]JSTHK(N$4G#=5-=
MNNF19!=%0JJ*R*I0.DJDJ03$434(8IR*$,)3E$#%$0$!SP)!!((((-B#D01J
M".!%7:^F12F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5*DU=ZM =<LC,-2KDY\VC8P
MNW?,/\$R#8%3I"(]P&6!(G/Q,&1<#CIKU7J0"=!Y%4BG]ZHMFL@[C6;"+C(Q
MFZDI2Q6F0:QT3#Q;)(RSZ5E5U7#9A&1K- IEW,@_DTFS9(HF7Y /() 4I02A
M)4I1"0E(NHJ)L !Q)OEQSTJ5 (25+4$@ DD\+7.9T&G.M</CCZ;:P.%9G6G"
M?.*/5 [:/FMZOV/9,0^E,FNCJBI/6J3=,$C_ $B-\MC%R^5#M5*_ QIR,+$K
MZS#MGA[+T_,Y*3&!R''\*H:\]P:<5:IK1S,4S4W&RL""Z1>^7X@.0N;>T0=;
M) R56NI8;%8+=.2MGM<Y,6:R3KU61FK!8)-[,S<Q(+B KOI.5D5G#Y\[5$ [
M1PZ755/R#K''D !ZI*$(2E"$I0E(LE*0$I2.  &0 Z@-36C4I145*)4J^:B2
M23UF_4>1[J@V54)N;D',#*_V9^<Q7'\WS_F_TX[_ #Y[:6&6>1TUTO;/099Z
M<>JG+V=W?S_3^'_MQ0G+P'"U\[9CJ ZSF+USCSV5!L="3H #R[N[WZZTQ4VR
MOI<YCD.!MGERY==ZA'2(_P!\T?\ WOW!M_U/-$YTC8[_  !'_P!:Q3_J<RO2
MH_FF/] S_P"VFK'L]14TQ2F*4Q2F*5F)Z.SIH>)W@0>PU+DI!WNSAU152;O-
M17"7<F=U>/'F!EM5VEP5XZIJS<W)8L JA(TYX NRF@V,D]"<:>*VDV'PO'DK
M?;2F!B1!*93*!N/*UM*:%@Z#_2 I=3E[2DC<-Q#BD9:IY'AV'R*WQ^#_ (UN
M'OCCU@VVAH*YH3K-'R=M:JG(@E'7B@S*Z/:C"7&NBNLO'.?I509R#=1Y!S*:
M*KJ#E9)J0RP<"QC!,1P*4J)B#!;5F6G4W4Q(0#;I&7; +3I=)LM%P%I2<JRD
MJ"A=)O\ 1VU=AFIJJF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5+DS;JY  8)66:-U2_^#%.+AX/
M<(A_6C<%7  /+EUC)@3GR 3!SQ4V)T!/=5)9K>"!.NE 1!UC=X$>29^R2 0_
MP@9MS&44*/JZ[IN8/67U"\^<QY\14$'B;>^J23-]M<[URO9=PFW/S 6;$?(F
MO4'_  #)MQ*98GL\I46-X<S#R#(Y_5YOK[JK" .L\S]6E4WLEDK-*K5@NUVL
M$94J74HQ::M%HFEC(1<)%H&*05US$*==PX<+J(LHV-9HN)*6DW+2,C&KI\Z0
M04N-M./+2TR@K=60E"$ZDGPL  22;  $DV%ZI<<0TA2UD)2D7))L /.0 !))
M  N:U4N/?I&[CQ3R+[76O32M%X=XQ^4S.N&6\EG]DNF"_79V?8RC54Q%DP63
M(^@:6FLXA*X<$'"II6>1&9SWF%X0U 2'' ER4H>TNUTMW&:6KC++)2_E*&0W
M4G=KRLZ>Y))2FZ&0<A>Q78Y$]7$)%P#G<G.L8F;FM?<6':+\LCKK>^?SVH/O
M_P!G/'+AYUH>&A)Y<^O*_5J#J=2:J31-/[.V<TFGU I4W:6E?\G3DUHMN0X%
M>/&[]XQB&1554CR]@?LXN4>Q]<B"OIZ09QDD[9QR[=@[41M./M,E(<<2@JN1
M<G0$ J-ODI!(!6;)!4 3F*N-M.. E""K=O<CA<$@"^I%C9(N=2!E<0V>UIL&
MKQT7+6.F6.$CYIYY!%+R<4[9B\>^:*]/IMTT5DRN"J.(6V5N49@JDF#QG,,U
MV@KD.822EYI94E+B%%(NJR@; J4GL^4A:3GD4D&UJ%IQ-BI)"57 N#8G="AD
M0+Y*21?4$6J4W$?(-"=H[8O&J?;JM@4<-ED2"Y;G.FNW RA"AVZ"B:B:R7/M
M$SD.4Y0,4P!<!!T-^.6>1T/?5!21D;ZZ<+@=O'/KL-,\O)BJ>7 ZY$==M+6U
MYY<M*?)]_)]W _;X>ZIZC?/+(Z:<,R>&75;490CI$?[YH_\ O?N#;_J>:)SI
M&Q_^ 6/];Q3_ *I,KTJ/YIG_ $#/_MI\*L>ST]33%*8I3%*8I3%*N&X8>*?=
M_![MB#W+H6Z/:A;H@P(/6X&4<UVV0:BJ:KVK7*"%5)I8:Y(BDF+A@[Y*-G*3
M:4BW,?,,8^1::S%L(@8U$7"Q!E+K2\TJT=9< .ZZRY\I"TW.8R()2H*2HI,I
M44FXUX\B.1YCYN&=?HD=&CTF^G^D8U::9KWDM*W34&;4NUM/NY CF1@7"@E;
MDLM;75*@O/T66<B 1\N1 J\:Y4"'FDF[\J!WOSCM-LQ-V;E]&[=Z$\HF),2D
MA#@%ST;@%PV^@?*1>R@-]!*;A.8A86.1&H\\*R99YBJZ8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I4#E[+ P)!
M/+2K-F(!S!$ZH'<G ?#LVB0*.5/G(D8 #O$0#OQ4V)T!-4FFMWQR'72@8Q=\
M?D(%=OS>2-@'D/(Y6Y.NY6+SY<RJ&:&[_$.61?PY_1;JXWM500>) ]YJDDUL
M:W3G6*O*JLVYN?\ 6L7UF*/(?$ICI'\I5*/K*NX5#E@Y]FA!^PY7\VJH( X$
M]I^;YL_XR/S$1$1'F)AYB/B(B/>(B/K$1]?W^??@=F60'&_;[AW'A5=N'S94
MR>_3S>GD===5%&S=!T\?/649'1[-Y)2DI)ND6$9%1<<V5>R4I)OW!B-V4=',
MD%WCUVN<B+=LBHJH8"D'"0I1"4 J4H@) %]Y1R2 !J3D,M2<N-J5*"4E2B
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M,8>9C',81,8PCSYB81$1[Q'%N1^KZ^P7L*K  TKK[_-BW/GEYXY<[FGGZZ8
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M7E)!FP2Y"('=.$T>OR\03*<P&4-[")E,81[@ 1Q>U*I9-;IK[+K)Q#5U,J@
M\E1YL&?/P_LBZ9W)A >_D#0"F .Y3O <@^?.?S?1500H]7;5(YK:MOE^NFD\
M)$-C"( C%D%!3J]_+K.U#*N^L #R,**J)#"'/LR^&#?+.W.P/?8\-<OXU6$
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MKL?0CF1><U5ZVJZ37OVO6(+"':#"R+P;K",D3+.31\E<%>HG'PB14^*>D[
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MY4+<3;+S:J@+6-Q?49^!N<K@Y6ZN6=<?/^C\W+'5X_/[N/94:$WY6YZ::\B
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M4VE#8_Y4@^)-9R8$1/\ B4JZUE2^K\8D5.>P^C$X -K/E)6_<*.HIV74B:]
MFF @E8F8"&J=>C*G68TDM".XV13:0=:A8F$C4DW)2M8Z.:-T^1$2@&5$VFQ^
M"A+47%9;+:%+6EL+"D!3BU.+.XM*D^VM2E*N+$J).M9/1MV W$V    M8
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M'XUN9LG0@+%:T6T]P[1W;9U+CMF]6.^V,Y#((O[!(*.DXUF)S*%C(2/("49
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M4[=U:4J"7$^P7I24!2=PD>PRU[=K .I4JY("@CL*((>"+)NH;R22O<9*B#O
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M0V5+=@NDV#A6PO\ !OE;?8_1+Z1_O3G'!L7=5][6)O@N+7OJ^!YRPA",0;0
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M5U&2\<N[BI9BHB_C'KMDNBN?KD.;$Q".W+A2&Y,=T70ZTH*2>!!XI4DW"D*
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M*B056KUNBZ;*"FH55,5$%R*)'%-4A%""8H]50A3EY&* @I7I  * %*  4
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MJ^VV0W3=ZFNVJ]QH*I]JFEJ3:VO-@S AXF37JE<L;VX,'!0Y"9I)UYF[3YE
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MB[N!LWCN)J"8>%RW ?\ &K:+# ZR^_T;67$!9/('*J5+2G4CLX^'=XY5K/\
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MIBE,4IBE,4IBE,4IBE:IWPI&NK.-*\/%J*01;P^V%X590.\"K6NF6AVD!O6
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M85Y%Y2,:MG+UU(L&[-DH9)X[7>-T6K10ABD.FZ<*J%2;G(<Y2F*L<ABF.4#
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MZW6%!FT;-DG#Z1D' )J&0CXYJZ>*))+N.Q!LV<KHYV#8)BF/SF\.PB&[,EN
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M05(WY(3#)P!Q*]8%=RO&<,0<YL<I#A;6M+S90VH,/2+K5O 6Z-AT^SO$%)!
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M=4Y$TR&444,4B:9"B<YSG$"D(0I0$QC&,(%*4H")A$  !$<@D $D@  DDFP
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M^9M'V,/WLK"#\@J/@_\ \0XSY"W;]G.G2#EGYX_97R-I&TA^]D((?G</P_\
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MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2I$V/J[6NXJH_HNV*!3ME4R4ZHR%6O5;B+5
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MO6)C#3\:C,1AP?PSQW&),I=H55>-<.DT%C)P @\3V9<3EP\]522L<!V\O?\
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MVG2(_*%/CHNB^^Z^H'XCV#^Q^#L7M0-<&E#M4S^]J.E;&JTCOI\=%T7WW7U
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M:.E*$I2EAH)2$@  -I   %@ -!6 K4]I^>I/Y![ _ &7[#D/ 5%.0>P/P9!
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M]=6X../KPK&,1EQX[B<*,LH=A%PQIJ8L8/N^KJ=!40V[TD53@WFU+:4I!(N
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M1T-L+E*4RTV/57Y14]NI4K>*&%(2A.96H'>W4DU0$YD&_LZVM<F]LOGZ@#<
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M)64JL01<&QUK%+*R3\G,WU/$]E2G_4XG26_8]IG_ (V6/_TC+WQE[-?E3?\
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ML\?#O!E4Q#O^4+9[CW8^(O:8:XK@0/(NXC?_ *=0?=+;&'3!=IO]WPOA;_\
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MO^TJM_RGI?Z%Q_\ CSG]D5S\:3+_ &E(WQ /[OG7R_[3_'WY#ZGQ"QOTH?\
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ME.\I*=XV&\I(OG7T;])_879C$:Z,:.3$#F8K>\O5C% 1Y 8P)TXP@41[N8@
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M\=F.<YAZI"D*6GB)C&-R I2@(F'N#ORX?0-%2"5;4/)"022<(;  %R22<2L
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M==2[!M<B[!<.C,(F&N< _?(,XI2 739FBHZ84+<E(<1M,9"(\F2^K$H6ZV]
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M32)Z_#7%JQ#%T *2R#AKY;7D6)TF'O2X^Z%+#92RB%(<;2HI#TEQS>472H^
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M%@0A)0;Q5-C%A,!?5!M'7-[BY/<^ZK E9&T2ZM_IQ'4.[\GJ#2%<N[*R4C9
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MD?\ H_\ F7P_\5!C67=]1]7^56]H_P"R8$ATD#?U(_%3^S5(BL6)Z/A^4O\
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/U S3UOZ8I3%*8I3%*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g307489g28s28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g28s28.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1P.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &_*^<50X0DE-! 0      "(< 5H  QLE1QP"   "@  < @4 #G-L:61E
M,S!G<F%P:&EC.$))300E       0G,: +LDP583J+6Z(\:,29#A"24T$.@
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M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!Q0_O@        "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _
M@   .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          CA"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8              S@
M  4-          $                          0             %#0
M S@                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M S@     4F=H=&QO;F<   4-    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
M 04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!
M  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]522224I)1<]K&[GD-:.
M23 46WTOT98UW/!!XY_*DI(LCJ[;<S/PND^JZC&R&77Y)K<6/L90:&-Q66LV
MV5-M?E>I=Z7Z3TJ?2_PBU1962X!P)9JX2-.?I?YJJ=3Z97U!E9]1^/DX[_4Q
MLJJ-];XVF-X<RRNQCO3NIM;Z=K$@@O/NQZZ,3JV=A4U=-S>B6/%3L9Q-=M==
M-.;Z><S]$V_UV7>G=O9OH_P-OJU^JNJJ?ZE;+(+=[0[:>1(F"L.GZKEUCOMM
MU#L>QPLR*,3&;C#(>T^HQW4'^ID69+?4<ZSTF^C79_A=]?Z-;K[&5C=8X,'$
MN,#\42H,DDDR"5TDE7R,_"Q2X9%[*BQH>X.< 0PN])MCOW6.L.S<DIL))@YI
M):""6_2'<3XJ+K:FDASVM+8F2!$Z-G^LDIFLCJC;,WJF+TEUCZL5]-N3D>FX
ML=:*W4TLQO5K+;&4[LCU,CT_^"J_FK;5K2/$*CU' HZBVNRN\X^5BN)Q\JHM
M+JW.$.8YKP^NRJYCF^K19_.?\9Z5B047FL<;.EYO6L.JC NZ6][J;L-SAC9=
M5+0^^FVMXK^T5N=ZV)]JV?S]?VC&L79C4+G\?ZMTLL95EWXPQFV,>["P\=F)
M7;:SW8[LS;9?9D>GM]2NG?55[/YNQ;[+*[!NK<'CB6F1/R1* "R22202_P#_
MT/55CV_5]S[+7MSKV-N>UY;N)V[;GY>VMQ/M;NLV,_T:V$DE.<_%9U&CJ?3\
MISK*+7FF#M):Q]-+R&;FEOL?:]]>_>J[OJITHY!R0'LM/JZLVM'Z87,M]K6?
M]V7;'N_2>RO_ (7U+N%_2>H?^&&_^>,97$E/)=3Z-T?HF,]Y=>YM[/18P>D=
MK&>E:[U+;&TNL;LPZ:MV5?;^?_A+;[56.)TAN7<VC(ZA330YXL++18P"JJRV
M6M<Y]U=UGIVV,_1VV/9_HZ<NM=H6-<6EP!+#+21P8+9;_9<I)*>!W] IJ<VC
M,ZDVV)(?JYCGEM7VNZK;79;]F?=3D;V?0]7]%_VH6KT?IO1,^O,JQKLJVI[J
MK"+W->UKFVV7-?0Q[;&->[(KM=;ZC-ZZ84TBXWBMOK%H8;8&XM!+FLW_ $MC
M7.^BHT8V-C-V8]3*6G4MK:&C[FPDIPO^9M.Y
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M7HYQE%ZE:C/94HU5]*$UZ8RW26W8\TI>Y;&1& , 8 P!@# & , 8 P!@# &
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M'EVFNS@L,TFH.DM6AC-*K&M!;(JXHIS^,2_6D]7/OU9O/YV2O[S#&V# & ,
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MN%+8\GE43W9%\V8<VH8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MZE4G6J?'WUW/XV[KO;K3>;4(-Y/4AK/+=K-MY):L8V.98F9& , 8 P!@# &
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M"WRS&D,<!*#HPX(VA0ZM"M\ WM"HQS( G9;]]L532RFH$)G7R>:W9+7UBC;
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M<<87A: D3D426Y>._P"?\.3E!DB>6W?$>Q(35THL2*S&KK8J/HVRF5@25O\
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M,>(JNDJE<U<UC%319A:U"9T5NEL/]?5K++"E\]>%@W1ZVMB[7'8T@:F-IC:
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M<M=XDDBEAP>9*)?J&3I(VN6E:T"3<_XC@TYC;)&$5E6] 4-=2NHIKS^9"'.
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MI%"Z/QIVE)D3CBY4E3*EC PMBA2G)/,,* !*C & , 8 P!@# & , 8 P!@#
M(0SG_:+\S_J>]E?Q>XFP";V , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8!A5E?)U/O8J5?82_ -'\-%F$\4<>DF@&4:5RUSZ4:68'8!EF
MJ:(A& 81:UL(@"UL(@[UK>A:WK?PZW@$I< 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P"'\K*+'WS0YHBP",*Y#ZQT49L =C+T9<O&.C-
M'O6Q T/00Z'H.]>EH.M"\]:\L F!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 \];_FWYX P!@# ,*LKY.I][%2K["7X!J;CKYHO+'ZN-'_PRC&
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M_P#TTZ_7C\%>.Y="ZCI<$C /V7^,+_MA_P 6L$2W/H?47BI/Z(E_-R?V8<%
MY& , 8 P!@# & , 8!\^+J#YRW0_Z<[:_?Z09Z0Z*=RVC7D#!_NZV.B.DG=%
MC_EK%?;JY'UU_P!5N7Y@L^KF9E+_ +!O?%+GU,S'679EIXS0]; ZV(_%2,>S
MS+]FILL='.Y[ ?(V%^PT"]Q_M[C7E;$?;*QD.9DQ)]&6!_$>&>RD=^R$>>9>
M(]L+[QRZ]?,] +3L2U\7H^KB97EF7 P"KKQ5+ZBW/].0F2/5N=3UK(GR9F1V
M",G*R&O=2"?R18V&[+:YW*+1JJSX9!H$RE!V\/,J<P,AB DL>V\,B<A)(\N
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M-AIMKCY_8J.%JE-ON$D7<6,-QN]B$3QIK1:*E=R151[(\RU)#R9RLTY*43H
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M!]0^DO/U,K8P5A@# )@<<?'25^RX?M9#@IU.3S^XL0P4Q@$;.LOD6?/I6/\
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MC_8"\/3^S,W?0#M[/Q"X]9;EI>:4<TC & , 8 P!@# & 53RNA:[=>QK-D4
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M?]L/^+6");GT/J+Q4G]$2_FY/[,."@<C & , 8 P!@# & , ^?%U!\Y;H?\
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M#1@# )6\<_*TH]DGCZVU9A,?[ 7AZ?V9F[Z =O9^(7'K+<M+S2CFD8 P!@#
M& , 8 P#R]<%%^"V9SGS"9.J'K-?>8H7!!/[^]<GV5*9(HL7TDWK'-?8#73I
MK$[NFWOT5!DE1N8FXT_7NT"WU.O7:C9_QL[_ "$\+HW</G[YZA<D@8 P!@#
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MY_<6(8*8P"-G67R+/GTK'_M5/F8P+MA3\'5^PS4=..YVZ\-:^T0*FLW@X-&
M, E;QS\K2CV2>/K;5F$Q_L!>'I_9F;OH!V]GXA<>LMRTO-*.:1@# & , 8 P
M!@# & , 8!JNV[NJFBF%MDELS5IAC6^/:>-,&EP5BQSD<B4HUSD4Q1MA:4K@
M^R)W]ZVQT=C6YE;5ZM.T-;FZGE%-[<L4D =0]='T5'ZD8KW<K2B'WH94GC*B
M*3QO<@O+++-3,]*EB2:*;9@+U<F<I(J6I4K(U,:5>YN2DW2=*D-.", 0,^@D
M\AEGP^/6!7DF9IC"I8V$/$<DS M)<&EW;C_2T!0D5$B$'>RS &)U) _04(U9
M)Z1642J(-) !&@[_ &@#?^IV\?QJ8\ F)@%),D^,3_\ 33K]>/P5X[ET+J.E
MP2, _9?XPO\ MA_Q:P1+<^A]1>*D_HB7\W)_9AP4#D8 P!@# & , 8 P!@'S
MXNH/G+=#_ISMK]_I!GI#HIW+:->0,'^[K8Z(Z2=T6/\ EK%?;JYHS,^848 P
M#Z,L#^(\,]E([]D(\\R\1[87WCEUZ^9Z 6G8EKXO1]7$RO+,N!@# & , TTY
M4!5CH\V5(C&5Z;W^WEM;N%A/<>G<^BSJ_*:D.2G0/12^-2=I4LB9K"C*2.2&
M/&M2&4MABQIEB=\;'!>D4@8?6?(E!5#9TAMZ!1!U:YK(2YN2$:^>6!(XU%4]
MFS!+8-DI*Y@LDE#M"*Q1V#.4*&63-)7T>C:>1/:)&K<BS_<B8!3CCCW@Y78/
MS2>I/U=+M_AI)L VU7?R?P7V.C'V(AP#0_7WR8-7MJU_8TAP?4/I+S]3*V,%
M88 P"8'''QTE?LN'[60X*=3D\_N+$,%,8!&SK+Y%GSZ5C_VJGS,8%VPI^#J_
M89J.G'<[=>&M?:(%36;P<&C & 2MXY^5I1[)/'UMJS"8_P!@+P]/[,S=] .W
ML_$+CUEN6EYI1S2, 8 P!@# & , 8 P!@# ()][+^D$-?0?7+%*&69:"V<;;
M3+";2:@7S#GR(.L<>VJ6V=6[-<DV@,:>K&5,RY1#HPC42(AG3BD*QUE**0Q]
MN61&1N.D$>7:HK!C%*\;,%0<JVJA8.-+(J"VPU=-K!I9UL>P64^"7O4DWCB-
M_!9JZ&N]P0H<W:;C>'"22N.Q&6.C@C3QV6"?O?!*SN.-O*"8'$E:3BJ>>6>/
M6.Q)8I,I%9O1-NNT-2.2%X+@Y=^=%6M>;5!#G1J4+&A>N@[-8K?$W%2S+5S*
M8O9E.V=<M;?<JHX#K3O]H W_ *G;Q_&ICP"8F 4DR3XQ/_TTZ_7C\%>.Y="Z
MCI<$C /V7^,+_MA_Q:P1+<^A]1>*D_HB7\W)_9AP4#D8 P!@# & , 8 P!@'
MSXNH/G+=#_ISMK]_I!GI#HIW+:->0,'^[K8Z(Z2=T6/^6L5]NKFC,SYA1@#
M/HRP/XCPSV4COV0CSS+Q'MA?>.77KYGH!:=B6OB]'U<3*\LRX& , 8 P!@#
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M_G^53[/6?_#J29Q1\-W]76,>,X3]YVIR3\$?=QAWBV(^PUCVEYT8.WHP!@#
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MW@H8;)VFTF:G:;15"H"8> \1KTFV24:6!0,F#[,H_# =OR/^S/\ E?"_\S\
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17A5!0)SC=ZV$!90$T< __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g307489g30c61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g30c61.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1@24&AO=&]S:&]P(#,N,  X0DE-! 0
M    %_:^830X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! #O_XU  (  0.__C4  @ !.$))300F       .             #^    X
M0DE- _(       H  /_______P  .$))300-       $    6CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M00    8              NT   =D    !@!G #, , !C #8 ,0    $
M                     0             '9    NT
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   NT     4F=H=&QO;F<
M  =D    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   +M     %)G:'1L;VYG   '9     -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
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M# P,# P,# P,# P,# P,_\  $0@ /P"? P$B  (1 0,1 ?_=  0 "O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M[8;:L=@!]-YK]-V.
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$!_\  $0@ \ )= P$1  (1 0,1 ?_$ !\  0 !!0$! 0$!
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MK1)J#H'=6<$Q@L6=BRZE;!<M;F W496!'5%3*/IK82RFQ-UR[_2MD@KOJL2
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MGQG<S'2&8$+7HWW*\]E<O#S"2)&HF+ 29YF15B@.P(+O>GFFQD!.E@'>N?\
M^:V]48")ON+:],:GEV34<>R@2 L*6$CY&OK/3M]ZXT7.N%\KY'=TVXR==G8U
MP.;/B2+%7]0"@8 *-&^?ED!%I&PQG;_JUR<YLS%=W(2Y,;JSJ[">.6SGNQ%#
M(MFL0G0Q);D(]RSN[,(4=>8;#W:O%%SKMXBT.I&564&)X[B*W+R*;C68F#M*
M"1$%50O.,"76VUSZI/U%6#J:UBJRAZR#UM?J5KZF7JX-FAUHT;1L.=3F^-9B
M]K#PE%V5<6HI_=LBMTO6@/$?8]JKE+M!%"C]IL0<-!P?M/R!8)R?<<V\CW$$
ML\L,15H[R?')]G.UN6FMX\QVFN:X?,$<DT:XCC1W)2(^5+MKN$,BK%*B1R2Z
M@]M%_M,\2S!8Y7Z=P5CB3$CI&QZ;$ !MFUUZH[NO<@B83.YJ "\:KZA>D=;5
M7U*]ZY5:RT??>\9N@;32[#:0>S]EA;FE@&>G'P\:R#M57B!9J]%.E=4@T"8D
ME.,_(5I:N%3G9(;FQY2S)<C3+'-9V:WL<J1O;P/%TT".8S<PM$Y1;ERQS>/E
M2YG!+!$DAN;3H0DLDB3W#6SH76219!@EE#".0.H<Q+@8_H$Y\77TM.*4XI3B
ME.*4XI3BE.*4XI3BE.*5A[$717J^</N1WI;8,.3+N18^/"D24#83\U4=A/;/
M=YY+&6VL=L]UJ3CMGVN7C3G)$0$ NZH"> U$#)\@SO57;0CN02$5FP.)T@G
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M4Y9I8;NWC$AT 3V][:/<0LJQS3QCFS!)TDE;6LJ$X(P.ZTOS=3( %"26\SZ
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M)(Y-,MO$8+?)CU;K$2@5MI!G4&.35%L^3B7 MHU+I*&#QO'J25Q+-@.%R#(
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M"+I5"&('3<9TLQ)/1U '"C"YP,L"1D8)V0N=3.-(+=!=B0H &6(R-3')P"0
M0,YS6Q<SK2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*UBWW:F:^"/V6^VVL4BN1G6&)-@MYX56@D=^
M2OQ<9E\J9EPH#3LAS^=L-N2$K=7](WA2O1S2*&6=Q'#%)-(02$B1I'(&Y(5
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M]>$*NPZ*$.#:M+J;M=$NA0CXP9#?#C'8LMW0]QS64?)[27#6\#:XOO%X)HY
M6;G$F4"59#K<%E;)#,IR"11>1.ZI;N2^5;83S+S<GWZWYMTP%T-$<H4Z*D*1
M@$ [8VF$[$]6'LQ^=:RQ9A^U%2-8.$;+YG].V#KEII@%^JU6YC2:Z0Y)JMT
MUB1@ ,M=,77#<0;'B(9F)?CH?YYZ7_<*BJBRWP0<Z-(%\H*3:3+$Y &N)V74
M5D+ DD<,*.Y[3NP8EC'8DD(2VJV)#QZ@DBAB=$B X5E&P ;&<FN/8?J:'6(0
MF,Q_8\95(FR4I<E3;8%?6IZ2[W=E3'\SY$M]:EK4])>\%^0XK*UY2ZZKLKWT
M[MNYJ&-8XYYE2- J(EG/LJ+A54% !L !J(WXGB:\%^Y'E^61Y)8X2\C%W=KF
M(Y9CEF."23DY.!GC7^A=T9:^*:GZ5M ZR-/LRBU U11:<1EQT.M1I<VMUH:'
ME2HS;R4O(CR'X;CS"7DI=PTM&'$I7WQC\<O[E;R]N[M%*K<W-Q<*K8U*LTSR
M*K8V+!6 )!(SG&U?J=G";>UMX&(+0P0Q,PX,8XT0D9WP2IQY,5T*7;R[$4C"
MLMJSZ4.)_HFG$YPMIU/?T>$VXE*\=_=Q[6<=^<HW/^.*W)QO['&<^7@3Y >S
MK]!,_!&"U(SA*'DY6Q+:3GOAF6PK+4AO'NY1AQ.5-*SV\8RIMS'TJ\9S%6!S
MN*R/%*<4KY4I*$J6M6$H0G*E*5G&$I2G&<J4K.?1C&,8SG.<^C&,=\\?MV'G
M/ ?#2HG-W>6^ZXP(5Y+%3GP<2O QF2_VSG&5)PXE6&&EX_H4^!A_MV7EQM6<
MMIZTA5/# 9NL'P5/9MX1'63E<[ $ ,<"[-PZ*]74Q';Y >H;-C<D':M4R:,Y
MSG.2Q/TYSGT3Y6,>GWL8=QC&/M8QC&/<YKA?$C^3C^S4;^,WQF^NJ>O1CZ[E
M/QA+_P"^XZ/B1_)Q_9IOXS?&;ZZ>O)CZ[E/QA+_[[CH^)'\G']FF_C-\9OKJ
MOKT9^NY3\82_^^XZ/B1_)Q_9IOXS?&;ZZ\GCY2.RZ^^;(LL,-N//.N$I2&VF
MFDY6XXXM3V,(0VA.5+4K.,)3C.<YQCOR0 2 (XR20 !%'DD[ >#UU!. 268
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M<<0>O'H$Y!)[,Y('ESU[;[Y!X9^&ITK^DJCK"[QB@P]3*X=,ZMU_K6JV,O!
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M9F?)S(BJJL<DZ5;Y3NN[JH.Y.PAO);62\DN;@6T,$<BP@MS;R.\DK))H553
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M(> \H_2&^JM YTUG3BE.*4XI3BE:];ZU!N=2M-.)O2XXVVUL[6",B MEN<Q
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MLT:,('<SR8%@&EB\:E;B1E@9^4==U!>S-?ZH2LS7%W;1SS%%BRYD"Z4D9:S
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MPA^][W.BW\)_S?IZ:5E)U><?0]:#SHJE.*5P_<][5?6/6M&JNS=O5W7M(/\
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M6T9;[!3PM+=@ZPV0BRVLY6Z24L;P\BY6(8@22JLJ606BQQ,M6+XR0,X4,3V
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M8RDZ="*$4DA JA< "K/R;W6-*TBRVJ Z0J!HL*$D:1=A&!G4Q+, -623N35
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MS#-;1W(:-HF.D)S@1DD"L5Z0CP0Y_H<>ZDG&>H.WZ+CTE@]BJ5.O6.0:K5Y
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M2(9]Z%(?$3P(J8+>D#5-*'/NCY$1R(X\/5'85!=4SE<13+.8ZF\MHRE\ [>
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M-'_I;E^((_RKQ]R[NF\;DWYW)^[T^ZUW*>+RI\SC_>:?1T:0_2W+\01_1_\
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MQZWXSG'?M_RL>UG'?&?3B>^%/"-M_P"E]:?XTYL^^#XH^NMC%:QZAMMN(B;
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MH-__ ,5\^O\ N>M_/5M\W/[S7S7^NJ=7)-Y\8<?DZ?\ RE^-_6&[-_90;_\
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M9((X+N0.&U2]S"R.BQN><4:G8]+4B@1G!9B<$=;Y )&3U["6TYOI^_6HW"V
MB;3BUA45#5Z?M/:(64/\<Q8VHDIK-6&CH0T-6,SQ.6-=1$2A]R?9E2[/<6,0
M $0=+03EW82=%FRHUNI&Q )(&,*",*!@D;YVJ%G@"1J8^DJX9@B'.#DC<\6W
MZ7$9V R:UU'3]U!R :(TS<Q:(6'U[R-E8[:&RG&K#:\/ZT9,VLB1D0FGZZU=
M@H#80YNL0AMAKVJ)UNBV&DPRIJ/Y5%IWO<X/W[< XZ;X)Z())QD:@&V_%)R!
MV6[XM\C[R,9W^]H"%PV  ",E25WV+!<$CKD"?J?<\BN:G%1]DS$DJM"EQ;:2
M?O5L9EN3)-MIYF :P0%!!SFRW:[6 UDI[(>[P@T"RHL23IU]!&.ZF1HT,Q6(
M<X>B,-EFSDL#JR -1"Y7! V/PUF)H0TIYL8<@J B\ "-."3HRV'RI.",;C K
M5A/3&:!BNG@-!F5F0QJ:FZTK1B<0FFY,\22HUZU_?+ 9I#DP<0E3%7]=0(U8
MZ@B1KKS08C!E*?(,P7 $B.]6',!2N(U5223J4JX<LAQQ?!!X;;9W-6[Z!,Y;
M43(SL!@:65E**K@'@H((\(9';N<=>]$;:NCFVQ0\S%&B[JYL88E\C<K2 'D,
MW$!5H82V20E1:EL6]D36(Z]5NUVY9@Q@[=:Q9A<8DV1\FGP\$KM)@X#-)DEB
M 0P72< $'"_>\-L,9J5GB58]0U%0AV121I+93+;KEOOFI=SG?J!PY;075*_
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MOCI=0I[P(>,"5@6(9'R&#DZ2@?@R2L4\B4E,Q)MXVC5@P4,S:CH/1X   8&
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MJF%YO[WJ.,MTR1C9@5SCHDAAQSL17GPVJ2P%\OSAUZ1P7H '(RN&'C=)2-L
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M&@WE^>%.V&YV JR8=8('I!Z#.>%/J5&5MZ3^GBUWR6!'[3A#+=9S%AIT\2(
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MLD# 56(9MLA20,D @G.-M^HU!M)02.C@<264:1E@"P!. 2I QG?;B15I9NJ
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M].9.#W@CU>_8BP U:2 <D'.3J   !W) W)Q@]HQ5N\IM).VH$[9&,#3DELC
M&HC&"<J< @YJ4:/U):AV'<?,&KV5<JW(&K(2P<H;/'SQSK$$:4F"24:8PR_"
M+0AQ<=+D1WFDLJ0^XU&D2),*>S%U2YBD8*I.2NK=2. R0>P@?!V$UD]M+&NM
M@,9 V8'.=@?,3MGT]56%'ZE=?[/L::SKU!:R2_6B]3W9ODF1PV$1I#&JIJP1
M"1+[/12!<;N"J3HR<QG%C<9G#CC(XU"DC&:I=)(VE Q.')R,#H!3CRYU#!'T
M[59[9XUU2%0-2#8ZCA]6XQMMI.1D9WWJ+1G7+K2;A$^<)+!JXY%J1UJPSY</
M$5ZH6\6H9%LC;*,>&A _<F8VDB<*6Y%\BM$Q@Q+EQPGC'49B]3K4@;;C?(*Y
MV&,YU='':1PK0V,@X,"<D8Q@!@=@23L"G3SU#;!R"<J6ZZNG(=#FS8UV9(MB
M6Z7,->!$(1E"1MR*T""W(E1W869V9HZ#LRIE<BT0\R2N)ZQ8?,XK +Q!MFO8
M!UM^+G*D8#$>3B 02/+@;[5 L9SQ 'A8&H$DJ#CKX$J0#U8)(Q4W6W9<RM'Z
MO7H=%L)V1; -J+#YC,^MBH392N!'#4>J2,ES$64R:--M.M,278K5>')9>=*F
MHB\QF)6KRZ2JZ&;4K,#D*,JI;2<\#MOG  WR3M6*1:PY+JNAE!!!)(9M)(P#
ML#C'6<UF-9W?&Q:</MJ1[(YJ?-.Q8^(1')D22C!CQ()&/UXTJ *4:K%C8'(.
MUDUZV04%P1" 18CXCRFG%VBDYQ ^,9)''(.#C(.V5/$' R-^&":RIS;E,YP
M>&",C.",G##@1G8[<:WW/S[8^?S]';&/:TK.G;[^?;^[[_W?N^UZ,^WQ2J<4
MIQ2G%*K]OV^V?3GV\?MX_=]OBE4^?S_V^CBE/N\4ICV\=N*57TX[9^_]W[OW
M?3WXI43[T_J0;"]/_HU.[>WZ>^$8]'W^93_@)_S$WZIZWM?X3!^=3^\*Z/U#
M_4VJ'ZBP_O?SI/\ M^_SY2OJ>WVZA4D<4KBGU2+_ ( /69_S:]P_]2#'/7Y
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M)699H$.SO#B98.DC!LTEH(X6,>5)(4;97)Z1;I9.^YW)SOQ&U42Z,LRJX#J
M7SP;H] +T2 2NR^",;9P:TB3LWI["#8#\3I^)-T*Y5=NUQSTH76&QSM?DV74
MC>MRK@I!^>3ATBSGC6OFZT.AQ?."I+#CVB-  B1,V0+S:2V7/WCH%"V6["5*
M$C).D[  >">H#AH([D[\^-:MC /6 VO?&G6!JSD8.YU$XQE0V[>E')TS%CZ]
MFH*1;Q :@R4U.(1@&]G58W=RPH72\I(OJ'6C%\J]X4'B2H-6D&+@]*.MM/\
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MJ>M[7^$P?G4_O"NCM0_U-J?^HL/_ #2>?*5]0.OS_L''VX8J2.*FN*?5(O\
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M*\;EU&::.4H9)W)2_6E)^RR=&FPI*US1IJM4^YU^M6^Z$;?'/M4:] !HX>+
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,K&,>C&,?:QCBE?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g307489g32c36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g32c36.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1W.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ';*^=@(X0DE-! 0       << @   @   #A"24T$)0      $.CQ7/,O
MP1BAHGMGK<5DU;HX0DE-!#H      /,    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     @ 2P!Y &\ 8P!E '( 80      #W!R:6YT4')O;V93971U<$]B:F,
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M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!QU"CP        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "
M  $#O_XU  (  3A"24T$)@      #@             _@   .$))30/R
M   *  #_______\  #A"24T$#0      !    %HX0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M          22   &@@    8 9P S #( 8P S #8    !
M          $             !H(   22                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   22     %)G:'1L;VYG   &@@    9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   $D@    !29VAT;&]N9P  !H(    #=7)L5$585     $
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M!!$       $! #A"24T$%       !     0X0DE-! P     $R(    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
M A$#$0 _ +7UW^L'7,+KS\?#SK<>EM8(K9$3N=K[FN6!_P [/K/_ .6E_P![
M?_(+I/KE]5?K!U/KK\K Q/7IV-;O]2MFLN=&VU['?G+$_P"8?UN_\K__  :G
M_P!*JSC,.$7PWXTP3X^(UQ5X6UO^=GUG_P#+2_[V_P#D$O\ G9]9_P#RTO\
MO;_Y!6?^8?UN_P#*_P#\&I_]*I?\P_K=_P"5_P#X-3_Z53[Q_P!7_FK?UG];
M\6M_SL^L_P#Y:7_>W_R"T<3ZP=1NHJ^T?6*_&O>VQSP[:6-AUE&.UVVISVN?
M;]FM?_.?JGVFW]#Z5?JU_P#F'];O_*__ ,&I_P#2J7_,/ZW?^5__ (-3_P"E
M4#[?>(_Q4CW!^\?\9LV_6#J55(L_;V0]YJ#C6RR@N%FQ^AV5O;L^T"MFQMGJ
M>A^E?_HDUG7>I^IDL9]8KF>G94W'>[TWM<Q[?TKK'4CZ=-CV>KZ'JTU^G=[[
MU7_YA_6[_P K_P#P:G_TJE_S#^MW_E?_ .#4_P#I5#]7WC_S4\4^Q_YR6_KG
M6ZJRYOUD?<]I;-;0R8+VUN_2--C/4J:_U+-GJ4_H[/3OMK_2*QD=7ZF+K1C_
M %I(J88K%CZG.=#'O^E5M9M<]K&?]=_ZVJM/U$^M8M8;.G2P&7#UJ3H/+U59
M'U2^MO Z8&,VV#2S%<07EH:_5PW>E4SV?\._U$CP=X_\U0XNQ'^.P/6NK-;!
M^L[B^1+V["V"UC_:QP:_Z;OW_P"QZGZ)-7UGK1RS39]9XI8RNQU[=L.+W!ME
M5+;/3W/J9^D_\_>A^87'^J'UBKIKJ?T9I>UNQ]WK8[B1N?=NV.?]/=9LW?Z*
MJBM4C]1/K<23^S@)),"^G2>W\ZEZ.\?^8H\6FA_Y[:Q>N=2OQF.M^LMN/DN<
M6FM^PM;%GH[W.#?SVNJN9[_YOU_TJ#D]>ZY3ANNK^L;LF\;'-IKV@EKMS;(W
MLW;Z?9N_\]_X5#_YA_6[_P K_P#P:G_TJE_S#^MW_E?_ .#4_P#I5']7WC_S
M47/L?^<SS?K%UJFH68W6\B[=<YC07TEWIAC'^K;36USZ'>H_T_\ "5V?I?\
M1_IZ?_.SZS_^6E_WM_\ (*S_ ,P_K=_Y7C_MZG_TJE_S#^MW_E?_ .#4_P#I
M5(>WWC_S4'W"?TA_C-;_ )V?6?\ \M+_ +V_^02_YV?6?_RTO^]O_D%9_P"8
M?UN_\K__  :G_P!*I?\ ,/ZW?^5__@U/_I5&\?\ 5_YJOUG];_G-;_G9]9__
M "TO^]O_ )!=#]5^O];RL#K3\G-MM?CXC[*7.B6.%=KFO9#?W@L?_F'];O\
MRO\ _!J?_2JW?JU]5NOX.'UBG+Q?2MR\5]>.WU*W;G&NQC6[F/<UGO>WZ:CR
M\' :X;TVI=CX^(7=>+__T/4F?SC_ )?D0\L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M  #_X4>F:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 W+C M8S P," W.2XQ,S4W8SEE+" R,#(Q+S W+S$T
M+3 P.C,Y.C4V(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT
M=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @
M(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O
M,2XS+R(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N
M=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X
M;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B @
M(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR
M,#(Q+3 Q+3$R5#(S.C$X.C,T6CPO>&UP.D-R96%T941A=&4^"B @(" @(" @
M(#QX;7 Z36]D:69Y1&%T93XR,#(R+3 V+3(T5#$P.C,R.C,P*S U.C,P/"]X
M;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R
M,BTP-BTR-%0Q,#HS,CHS,"LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @
M(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!0:&]T;W-H;W @,C(N,2 H
M36%C:6YT;W-H*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \<&1F.E!R
M;V1U8V5R/FUA8T]3(%9E<G-I;VX@,3 N,34N-R H0G5I;&0@,3E(,34I(%%U
M87)T>B!01$9#;VYT97AT/"]P9&8Z4')O9'5C97(^"B @(" @(" @(#QX;7!-
M33I);G-T86YC94E$/GAM<"YI:60Z93DT.3(T,S,M-61C-RUF,S1F+6$W834M
M-C4S-C,T-C5D8C(S/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP
M34TZ1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H;W Z.&)A-C0T9C4M
M,#(R,BTV9C0P+6(T8C@M8F9B,C$Q-3<U-C$V/"]X;7!-33I$;V-U;65N=$E$
M/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z
M8F0R-C(P,34M,S<U8RTT,#)C+6)D9# M,#0X-#(V-30Y-#=F/"]X;7!-33I/
M<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#IB9#(V,C Q-2TS-S5C
M+30P,F,M8F1D,"TP-#@T,C8U-#DT-V8\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#$M,3)4,3@Z,C,Z
M,C4M,#8Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,BXQ("A-86-I;G1O
M<V@I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V
M;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+VIP96<\+W-T179T.G!A<F%M
M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C-A
M.38Y965B+3,Q8F8M-#8U-"TY8C8V+3=D9#9E,#%A,S4T-#PO<W1%=G0Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP
M,2TQ,E0Q.#HR,SHR-2TP-CHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(R
M+C$@*$UA8VEN=&]S:"D\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C W,#@W-F,V+6(X
M,6,M.#,T.2TX-F4Y+68R-3EC8S4T83DV83PO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTP-BTR-%0Q,#HS
M,CHR,"LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(R+C4@*%=I;F1O
M=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IP87)A;65T97)S/F9R;VT@:6UA9V4O:G!E9R!T;R!A<'!L:6-A
M=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A;65T97)S/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!I
M;6%G92]J<&5G('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W \
M+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C8T.&4X-35B+3 W8C8M-3 T,RUA-F(X+3 U.3)D968W.34W
M93PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C R,BTP-BTR-%0Q,#HS,CHR,"LP-3HS,#PO<W1%=G0Z=VAE;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@
M4&AO=&]S:&]P(#(R+C4@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#IB
M96,U8S=C9"TY-#DP+3DU-#,M8C,Y8BTS.#4U.#,S,#@Y83<\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C(M
M,#8M,C14,3 Z,S(Z,S K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R
M,BXU("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N
M+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R
M86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R
M=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I
M;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.FEN<W1A;F-E240^>&UP+FEI9#IE.30Y,C0S,RTU9&,W+68S-&8M83=A-2TV
M-3,V,S0V-61B,C,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,C(M,#8M,C14,3 Z,S(Z,S K,#4Z,S \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E(%!H;W1O<VAO<" R,BXU("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y
M/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N
M:6ED.F)E8S5C-V-D+3DT.3 M.34T,RUB,SEB+3,X-34X,S,P.#EA-SPO<W12
M968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^
M>&UP+F1I9#HV-#AE.#4U8BTP-V(V+34P-#,M839B."TP-3DR9&5F-SDU-V4\
M+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA
M;$1O8W5M96YT240^>&UP+F1I9#IB9#(V,C Q-2TS-S5C+30P,F,M8F1D,"TP
M-#@T,C8U-#DT-V8\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @
M(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/&1C.F9O<FUA=#YI
M;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(" @(#QP:&]T;W-H;W Z3&5G
M86-Y25!40T1I9V5S=#Y%.$8Q-4-&,S)&0S$Q.$$Q03(W0C8W041#-38T1#5"
M03PO<&AO=&]S:&]P.DQE9V%C>4E05$-$:6=E<W0^"B @(" @(" @(#QP:&]T
M;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @
M(" @(#QP:&]T;W-H;W Z24-#4')O9FEL93YS4D="($E%0S8Q.38V+3(N,3PO
M<&AO=&]S:&]P.DE#0U!R;V9I;&4^"B @(" @(" @(#QP:&]T;W-H;W Z2&ES
M=&]R>3XR,#(Q+3 Q+3$R5#$W.C,Y.C0T+3 V.C P)B-X.3M&:6QE($1-5E0@
M4S$@4F]U;F0@,B!);6%G97,@=&\@0V]N=F5R="!T;R!(:6=H(%)E<U]"2'8Q
M7S$N,3(N,C R,2TQ."YP9&8@;W!E;F5D)B-X03LR,#(Q+3 Q+3$R5#$X.C(S
M.C(U+3 V.C P)B-X.3M&:6QE(%!A9V5?,3@N:G!G('-A=F5D)B-X03L\+W!H
M;W1O<VAO<#I(:7-T;W)Y/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 8H",0,!
M$0 "$0$#$0'_Q  ?  $  0,% 0$              08'" ($!0D* PO_Q !\
M$   ! 4" @(&#!$3$04( 04! P0%  (&!Q$A,0A!46$)$A,4<9$5%A<8&1HT
M4E>!H;$*)S(V-W-U=I*7LK7!T=+6\"(C)"4F-3A'4U155F9R=Y.5M-4S0D-$
M149E9W2&AY26MM/A\5B"F*6F*&)C9(.BI-2$>(6CL\7_Q  < 0$  04! 0
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M+QS_ (KKM]&=,4'T:P[B.4W@T?+*#ZTAY7<G;_C%P_W:MXVS^Y^.6J#\$%\
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M(JI:.JCIG $5#H)6Q$.]J6R.;L%KK]ZX:WR.=SR=+\*/%%6R1 XT=PWWXJI
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MM?'&VX:21=Q<-D7< X K8/P+#JBDK:G"\8[,?00&HFAEHY:?V(7VBV20@;0
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MN218I2$MQ92(HN8XP#<#D_AS9,/Y0U5/3L&*FOQB&BJGL:)XW& MA$,CP'1
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M("(@ :8T#ESV\(YT*DYWUX6! N3G?,[]VO4+9Y-<'&?/(VR#_P"?=^G<:;>
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MH8]H-H*DW!MPS) )M<:YDWWW/6=4EFGD$)I1FEFEQ-+-*(A-+-H(3!, @("
M@&! 0 !#(:A!3EU6.G43D,M=_'.VA7T-..4&3G'G&'G&8$PTZ>8PR; !* S&
M3S33S8"7M R(XE ,:!+D !D!8< A-SGNTU)-M-VMB"+]6\V^?, R/C#7.1'7
M.=1  WT'(9VR4;B;#R'*U@,K6R!)TS%C;6T /(!WZ!V$1$--],<L\\AT@4D;
MR-.(U  .>F=]]MUCP/UF4*)R9$\QQLQ!0B861-//,5)/-\5.64(]SDFF ?Q0
MA+D0W$=1A87O87X[_*G#,V+G97-A?+B<R1J+7\@7RV';E@0'P9#4-,CC<1W'
M0-()N\=Q;H.X'.POH!H-<T[8 Y!OT^#GICK'7..B";).\Z;QU[L[] RM?BN:
M8:=?JK<R62F&-WJ-Y4$KE!#4R-RQU<34[8B4.3@>6B0DG*9B$#<E5KUILI8E
MI4:90I.FD(),GDI?(R)I?(]L;!8%SW!K07$-:"20+N<0T"^9( N2 I8R1[@V
M-KGN(VMAC=IS@ 2X@#:)V6MN3N:"XVS)J!EMA<JI36 BF[>5R_J*K1NCC2Y#
M+2+\ZFU(WLBDQ&]+6 I"@43O"-H6DG)7)2W I)0*BC4ZHPDTN>26V^HIXQ(9
M)X6"(M;*7RL:(W/ +&R$N&P7 @M#K%P((N"JV4]1(6!D$TG. NC#(Y'&0-NU
MSF;+;O:VQ:]S186SS58.?#SQ%,[0N7/%CKTM;"T)U;NY+G.VE<H6EL2(TLZA
M<YKE"IE*1(TR1*48<K6J#"RB$Y<\YILA4DTP6FUU ]P:RLI'O<0QH940N<\D
MV:UH#]IQ+C8- )).0NKSJ*N8USW4=6UC6ESBZGF:QK6ZN)+ &@-S)R  )*WQ
M/#7Q.$ 8*:P5^"0/D$LP2+5W!* TF8!_$3]S8I.Z%S!C,LXS2#S#&])Q'#KB
M]=17U%ZF"]^([]2*#$ !:BK+$"X%/-GU]X>)R ZK[K0.S14%(O2MF?6IYIFH
MF=3.F<&EW1+69Y:UDDLO;IUJ%84F7(5$DLP#,6>44;++, S2ZB$9;7,E8'L<
MR2-XNUS2'L<#O#@2UPZ02%BO8]CG,>UT;V$!S7-<Q[3G:[2 0<_:D#@ !8G[
M>5FJ3J=.K;RO/YM)%O,K"IJ[R)<#*=DJ$U*#B#*<_ G%L!Z,1CW]*VF*P73I
M1[Y[B)0]T".<C$@AYQ@EV.<$6VWG.;OL[89?:V-KO=JVS?*]U7S<AC,NQ(8M
MOFS)LO,>V02&EY%@[9-RV^U:Q MK#72U4/S>^NS'3C^]-5+HBE]3N32SN+BW
MTZWJ#9B4ZU]6HTQR9I1G'2S$E*EYJ<DTR68N0P9\@!TL;',8^1C'2$MC:Y[6
MND<!<AC207$"Q(:";*(XGO:]S(W.;&-MSVM+FL:;#:<0"& G3:L+Y;ER'F?5
MYWF<XC1-7 @(I(FOCUHTV[R)"J%/=TU/D5I.HF1]QEI4Y^5I64JH>V%H,=5)
M#=(L%6=(2-//PWV>>CVC*8-GG&W,P89##:]^=#&EYC]L&@NM8757,S6)YF2P
MCYXN+'D<T7B,2WV0#&7D,#R0W:L+FPO3$B@^4B=/*><!!DX&&)Y3IP(,,EP,
MLQA7;=SFG#M0[6::49@&4!"8,!%VPO>POQW^567$Z:-RRMIG:XXVR\MK:KXY
MYX'<1P/5KGJ$,;"/@P P2VZXT N-<\K=(-]0.NY"^AQQQ\X3G&FJ#9999!,-
MGG,G"4N4)9)0GG&8>UDEE"6274 E#  $  -!;J4W)N2; Z7.HZKWT/$6RW:)
MSCYBBB9CS9R2>W$DJ<R<2R>Z_BC!++&;M"Q,FQ--VLH=L(!,(C@1!8:VS.IX
MVT2^UD0<B<M1D?6]M<Q:Y%_ERR(\^D>K&P;^#&@8#78F^P&[@.F^ITZ[YFYR
MU!GEG?(;@'1H.@CC0!T#H 0SJ0VWVTL=">.8S OF1F>)!ME]R5*A,)O<#C4X
MG%B2:)1DY7=2YQ_%ES]K,';ES;S2S ,HX )@'2! -KB]LQ?.QXC@@ON<=""
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MP( W;L[*0V$/;QH&NFFF1TZL#ICF$%!U!\5\SEGGG89]-QG?<5(CC3(;<\B
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MGH&G0!OU(RO:QSR3GJ =KSVZM=,9W#4 U#$%.[(G:W:].6=[:'(G(W0=<:Y
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M(6XZW\1O8[[63 [=(CC.V@@'3D,AH !J/3C&"7&O "]M<[GA8V.9)R!W7O>
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MN=J6+GF,J12D?DU=W1<KA5Y554R-!2QY+/<YG21N5$4TC,72MK4F! 6:MFE
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MU/1JH[7.PAL. \6PCJ.O@#?;,$VK:@BQ%S](&6G7NULIQ@!R.X &F-M@$=0
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M]OONAW[]URG:^A_(*+7\FAT^+^GJ3T.[A/TQ8>SGMVRHSW<,@>UB(.)XF?\
M&>(_+*CQY<[;Q&^7!.U]#G_!]%\F@S__ )^FR>AW<)_L#V<^EE1FO_D>W(=
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M+H*BI-%(V6I#(7V<3&+M8;6E< V,DC+X7VLC?_BE6\=O&;;[A_O6STN]WNX
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M&6Y2\6)5ZO-K*&RQ'%&NXT";1!08!6,M^G&VY-N5$LUS9JHF33V_$LKR>D8
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M$2")!$@B016QO%\CJJ/F2N_FIT5,]NWX3?2%0_0_ ?X\@OR:%8A*J4CKZH.
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MU&=AP  R\1RS L4V'&-QQR'3K  '.@ZX'PX$0$2:B]]!?>,^@DBV8RN.JX!
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M"^6=K:#2RCJ#33(Z:@&N^@:[;XUQ@1SF"=)SSL,\B<M,SEKI?*]P+63'(!$
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MM=(/ ^.RVW(!SU8#'CWY#KOKH.G*4WD6Z;F_DTWC+3+,9[V P&N!$>L>@0P
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M0^=5H@]1)?E!?U(10JENX(M,_P 3-^]'WA@BMK;OU77'ST#]:T$5GVC.M_\
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M(.>OH4!IMSQG<!QIUZ:Y\>F@Y I/3;*_ B^9.[/=Y#?,9SSZ<CD,9'7&<_9
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M4Q504\-:W&=J),5U UHEYEHZGN4T)2VE16[DB.(LCN'FFKLTI;LIJO*_$O\
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M:\+Z>.1#IY!G.O,1ZNGEH.X:[P47R-M]Q:VEAT'APN-#EHOU#NQQ_H)^&+^
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M3N!K@2C-FD6=V53F%$2A,=VDI81@XAB5?BM2ZLQ&JFJZEX#3+,ZY#6^U8QH
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MLTLU1,099YYYWR332OLT.DD>YUFM:"&M %4Q@+8I!$@B016_N=\:*GYJ4_\
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M8:1//)*?*0I(-F+$0F LXN80Q,&=578=7X9*V#$*.HHIGQB5D=3$^)[HRYS
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M!%;&\7R.JH^9*[^:G14SV[?A-](5+M">#7?,OR:%6BM2(9QWP<(\O[),&-<
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MH?7 =_V+.%+_ ,/EI_O3AV[QGPMB?R^J_:IVGPGP7AWR*FX6][X)Z'UP'?\
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M>F_Z-_#?>'=/RD\/XU_[I6_MT[EN3/\ D[@?_M5#^P0+%64#:T=M _S'IO\
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M1VO;48BYF&H[)?5Q,IC%/,^GC<)7EMSS\;HBRVWM6LTAP)GM_06 V:HR\]+
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M!&9IJAY-RXE\DT\LCW7L7/L UH:T5TU'%2OJY(]HR5M2:J=SR"3(((:9C18
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MX#007;.T0,R+"ZQ8.4F%S2LC:^H8R=_-P5,M+-%2SO.09%.]@8XDY,VMD'(
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MI(<UP.8((((.A"VC7-D:Q["',>T/:X$$.:X7:YI!-P0;@C<<B!D>3$,\N8X
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MB01<>ZX\C5V=N]C0TZY1Z-8*'7L;:_O]>I68I+(T^WAU*M>D>^U(#H(]?M:
M/5 T'TW\^]"!Z/,1;^[I.]5$(XY^$!W$0'7/AU#<0P&(E0-;$#+2P\WBRX'H
M U:ZZ8YB&!V$1'EOID-1#QA!3EET'>!U>+.QZ=V5DZ UU'EISUQMUZ"&F<:#
MG)1X]!H>.Z^IMTWSZ0<HSOUAH ;:]7/&H<]8*2+VZ#T;O+KEP^93RQC&1#I
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MM D) E=C7-E0E.3.8B+7+DKVSR(6L@'AP1G)\..OI.U> 817/9V#BE/712R
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MJTOG77NRKW0[TTY:@&N1#>"BQ\0T -CIQ^8]=[9)YZ3A\'/PU:6U# ?CRL
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M;WJNUM]YBUO;W_UUT3TRIV._]B.(?Z6]._?]#[7>.>_X=\?/]63N[P?WFO\
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M^QWZ_E1Q#Z?XMZ=QX_+]B'VN\<]_P[X^?ZLG=Y@WO5=G_F8K^3G[H'P2GV/
M=FCB''_1O3ON_F^_#GRA]KO'/?\ #OCY_JR'EY@PUBKA_L8OV_2GIE/L=^GY
M4<0^NWPMJ>Y?Y^P^UWCGO^'?'S_5D[N\&S]BKLM?8HM_^W3TRGV.\=FCB''_
M $;T[]_WX>V$/M=XY[_AWQ\_U9.[O!AK%7#_ &,7[?U\13TRIV._]B.(?I^1
MO3O@_;]^&^T/M=XY[_AWQ\_U9.[O!_>J[A]YBZ_?_735/3*?8[^;1Q#AX;;T
M[IX?S?:=73RS#[7>.>_X=\?/]63N[P;WJN^)B\WL^?3;3>GIE/L> _W(XA]?
M\6].^_Y?L?\ 0>B'VN\<]_P[X^?ZLG=Y@PO[%79?YF+T<_?^\<4],J=CO#/Y
M4<0^G^+>G?O^A]KO'/?\.^/G^K)W=X.;>Q5V?^9B_;IZ93['?OY$<0_TMZ=\
M7Q_;]6X\H?:[QSW_  [X^?ZLG=W@VG-5WQ,7E^_Z=.@WIZ93['@/]R.(?Z6]
M.A[]?<^73RA]KO'/?\.^/G^K(>7F##_!5WQ,1]$^[?PWIZ93['>.S1Q#C_HV
MI[E_G[_UA]KO'/?\.^/G^K)W>8,-8JX?[&+?_M_[D],I]CO_ &(XA^CY&U/;
M]'Q^]</M=XY[_AWQ\_U9.[O!O>J[C]YBTX_?^A/3*?8[_P!B.(?Z6].].-?S
M?:?@.T/M=XY[_AWQ\_U9.[O!O>J[XF+A?W_/U&J>F4^QW_L1Q#_2VI[J_=[U
MA#[7>.>_X=\?/]60<N\&.7-5WQ,73_G^@^1/3*?8[_V(XA]/\6]._?\ ?@.F
M\/M=XY[_ (=\?/\ 5D[N\']ZK\_\S%^W]1GH@_!*G8[P_N1Q#_2WIT?>KZ'V
MN\<]_P .^/G^K(.7>#G_  5=\3$/3.H],J=CO_8CB'^EO3O7^[WJA]KO'/?\
M.^/G^K*>[O!_>J[XF+B!NG/%3Z93['A^Q'$/TZ6WIT=.G2OH?:[QSW_#OCY_
MJRCN\P;WJNX9PQ#/AG.H],J=CO\ V(XA_I;4]]_NN\/M=XY[_AWQ\_U93W=X
M/[U7?$Q>?V?+T*?3*?8[]O(CB'UU^1O3H;_Y_0^UWCGO^'?'S_5E'=W@VO-5
MV67WF(Z?[=/3*?8\/V'XB/I;4]]_L/M=XY[_ (=\?/\ 5D[N\&][K?%%%Y/O
M^JCTRIV._P#8CB(ZOA;4]KX/S>_AB'VN\<]_P[X^?ZLI[N\']ZKA_LHOVZGT
MRGV._P#8CB'Z?D;T[]_WN;P^UWCGO^'?'S_5E'=W@WO5=P^\Q?M_/HGIE/L=
MX?W(XA_I;4]GQ>7V'VN\<]_P[X^?ZLG=W@Q_P5=\3%Z>?3TRGV.\-VCB'^EM
M3WW^^,.7.'VN\<]_P[X^?ZLG=W@QTBKOB8OV_D._<GIE3L=_[$<0^HX^1O3N
M_P#M]#[7>.>_X=\?/]64]W>#9^Q5PL+_ 'F+YIT],I]COU_*CB'TW^%M3WW^
MP^UWCGO^'?'S_5E'=W@V7L5=GI[%%^W0?@E/L=X!GR(XA^CY&].[]'Q_0^UW
MCGO^'?'S_5D[N\&)MS5=Q^\Q:<?OZ>F4^QW\FCB''P6WIT?>KZ'VN\<]_P .
M^/G^K)W=X-OBKAUPQ#_]_+Y-;!/3*?8[_P!B.(?I^1M3WA_;[#[7>.>_X=\?
M/]63N[P;WJNX?>HNKW]/3*?8[_V(XA]/\6U/=7[O>L(?:[QSW_#OCY_JR=W>
M#>]5W1[#%GKOY^VY1Z94['?^Q'$/]+:GO=_-[I#[7>.>_P"'?'S_ %93W=X/
M[U7?$Q?M\U(?!*?8[Q_N1Q#_ $MJ>Z<?M]Z8?:[QSW_#OCY_JR@\N\&'^"KO
MB8N%_?\ @@_!*?8[PW:.(?H^1M3O+_/V'VN\<]_P[X^?ZL@Y=X,=(J[C]YBW
M_P"W0?@E/L=X;M'$/]+>G?L5]#[7>.>_X=\?/]60<N\&.D5=\3%\\Z>F4^QW
M_L1Q#Z_XMZ=Y;_W_ &GMP^UWCGO^'?'S_5D[N\&S]BKLO\S%XO\ #YWZ./!7
M M3V;_@SXO;BTCP^6I;KRD5Y7KK+Y!FU71+,T,4OE<3J*J<._G!)5SFH(RV,
MBP$_:(3NZ*1)*F[G*8)DN%B/(W%<(HJBOJ9:-\,+&AXAEE=)[+(R)I#70,![
MY[;]\+"Y%[6690<J\-Q.L@HJ>.K;+*YQ:98HVL]CC>]UW-E<1WK3:P-SEQMW
M>H/427Y07]2$<>NI6[@B"&0$.D,01=/_ !L]C^H3B/KA-6536QHNKWU(VE,Z
M1[?Z;;79R3M)*I6N);25:M,<>6B*6."U26G"<"I#E1YH2]N;,(Y]+BN)4#'1
MT==5TL3WF1T=//)&TO+0TO+6N +MEK03F2 !N6!48=A]8YLE714M1(Q@C#YX
M8Y7-8TN<&ASFD[(+G.L,@2[?=8*^@ZVUS\A"VXZ_M-9O#^L/=^S&2>4>/;L7
MQ'QU4_'/W7S=.BL=I,$\%X?\F@_54!V':VN ^$C;?7]QC-U9W0;=>VT3W18]
MX7Q'Y7/^MKT)VCP7P7A^6OW+#E_\.M3Z#M;;V$;<:X'XS6;/M_D#E[FD1W18
M]G_"^(WSUJI[7_XO[]RCM'@G@O#LO]%@W_\ HWIZ#M;7;S$;;\_[S68-L9_M
M#;;P^U#NCQ[PQB)_WJ?I_IG]WC"GM'@I_P 5X?P_!8/%[GK\Z>@[6VT^$C;C
MI#\QK-R#_(.C;W(=T6/>&,1U_*IQY.^-_1T[U':/!/!>'WWCL6"_2/:IZ#M;
M;E9*V_+^\UFZ=-.\--1TSX8=T6/>&,1^53_K^OC4]H\$U[5X>=?Y+!GQ]SPU
M\Z>@[6V]A&V^W[36;8!V'\@: '/;VH=T6/>&,1Z^RI\]=.^XCIX)VCP3P5A^
MH/X+!F3O]KKZA/0=K;9^0C;CEC\QK-UCOWAC[7MP[H\>M^.,1^53^C;OXM_G
M4=H\$S_@O#^G[E@WVO[GTIZ#M;;3%D;;\M0HUF$---P08T]R Y18]X8Q&WYU
M.#YW_,I[1X)OPO#_ )+#OU]QO3T':VW.R-N!V_O,9AZ?_D-=^77TP[HL>\,8
MB-?Y5/\ KBWC\73':/!!IA>'C_=8/U5 ]AVMJ/Z2-N!_S,9A''^H=8:>Y#NB
MQZ_XXQ&WYU.,_P#CTX;NGC/:/!!_BO#P/S6#]7H\RGT':VWL(VX_V-9L;8_6
M&-M,\MA@.4>/>&,1W_RJ?<?A]5M_S1VCP3P7A]_S6#C?^;QS_>GH.UM=?A)6
MWZ/C-9>H!_M#P!#NCQ[*^,8CXJFH\7NS;?>_D4]H\%\%8?Q_!8.DW]IUGRIZ
M#M;7;S$;;[[>4UF\?J#W8'E'CWAC$?E4_HV_W[[63M'@FO:O#_DL'D]JH#L.
MUM?80MQU_F,9M==O4&O7C:'=%CWAC$=_\KG_ %_/?/@G:/!/!>'_ ":']53Z
M#M;4?TD;;]&M&LOV4&L#RCQ[PQB/RFH/]OAN\?0G:/!-V%X?;\U@R_\ CTIZ
M#K;7V$;;_P"QK+T_Y!_UY0[H\>\,8C\IJ/U^OJROTNTF"^"\/^30?J[D]!VM
MJ'Z2-N-^5&,VX>!!XO<AW18]?\<8C;+^53W\[O-GTV0X)@G@O#_DT&AU]ST9
MJ/0=K;;^8C;??'QF,V<_ZATY]OKAW1X]NQ?$M/RJ?YWCR7"CM'@NG:O#\QIV
M+!P&O>\/,.I3Z#M;;;S$;<?[&,V _P#P,=?BAW18]X8Q'Y5/Z-N^GG\B=H\$
MU[5X?U]BP9ZC^;Z^5 [#M;8-K(VW\(4:S!OT?D >KGCQ0[H\>\+XE\JG_6_>
M5)P/!-#A>'^.E@_54>@[VUR/PD;<9Y_F,9O:_N?XHGNBQ_PQB/RJ<>7O^/T=
M*=H\$M^*\/MN^Y8+=/N$]!VMJ&<V1MOT?&:S=?\ \AT!MR#I 0AW18]X8Q'Y
M5..D:OX%1VCP7+^"L//"U+!QUS;Q\ZGT':VWL(VX'/11C,.>C9 ,0.46/9_P
MQB/1]U3CTN^;+I3M'@@_Q7A^5_Y+!E_\5'H.UMM@LC;?.N &C68.C/\ :'0/
MMA$=T>/[\8Q'Q550?[8MY/393VCP77M7A_R6#CE[GCI]*GT':VOL(VWT#.M&
MLH"'//J#;[,3W1X]X7Q+Y5/^MZ]-T[1X+X+P\W-OP6#/_P"/!3Z#M;;'R$;<
M=7YC68<8Z@0?AIB Y18]X7Q+Y5./2[Q]6:CM'@G@K#SK_)8/U=_]ZT^@ZVUY
M61MOH/[367_]#IY^$.0P[H\>\+XEO_E4_P"L/)Y%)P3!?!>'V/\ HT%O^7I4
MCV':VVXV1MQG;XS681Z?UAGKAW1X\?\ '&(^.JGX]+AN]<LW:/!/!>'V/^BP
M6X7]KXD]!VMM["-N/]C6;_\ 0Z--/!#NCQ[+^&,1Z?NJH].UQXC3-1VCP3P7
MAWR6#]1/0=K;#^DC;?7]QK-K_P#@:P[H\>\,8E\JG_6Z_75VCP3P5A^5_P"2
MP?JY>;5 [#O;;&0LE;?&^E&LWM:=X9VY^WM#NBQZ]NW&(_*I^'';L,[\>&JG
MM%@AM?"L/\=+!Y/:*/0=[:^PE;?;/QFLVW^H:;![G5#NBQ[PQB-M/PJ?]?SV
MM\SM%@O@K#\_]%A\GM-]SYU/H.UM>=D;<=/QFLW/7]8;Z>&'='CU_P ;XC;\
M[GO?_BTS]=SM'@G@O#\O]%@T_P"'3-/0=K:B/R$;;B/SFLH^/\@=7.'='CWA
M?$OE4_HVL_F3M'@@_P 5X>/]UA_4Z4]!VMKRLC;C.NU&LV1P.N?R!_UAW18]
MG_#&([K?=4^__P!0].6_@AP/!+?BO#[9?R6#Q>YX>;1/0=K:^PC;?F ?F-9O
M;_M#;W->L(=T>/>%\1^55'1_2/KE;4AVCP3P7A^OY+!XO<]&2>@[6V'3S$;;
MCT_F-9L9$,Y]08]V'='CV?\ #&(]'W5/IU;=]?*!XT[1X(/\5X>-WX+#IP]H
MGH.UMA'6R-N!_P S6;W^\/<AW1X]X8Q'Y5/Z-NZCM)@@R&%X?\F@M_RIZ#M;
M;V$;;[8'%&LW1_D&V.6O(.B'=%CWAC$?E4_ZWS#)3VCP3?A>'C?G2P:_\.M[
M^-0'8=K:^PC;?3]QK-N'7Y'XT\,.Z+'K$]N,1Z/NJ?3I&W>_]]MR=H\%WX7A
M^8WTL&_=[7]Q4CV':VVOPDK;]?YC68=NG\@=7VH#E%CV_%\1W?RJ??UNXW\2
M# \$R_@K#QP^Y8-_"S=_1Q3T'>VWL(VXTS_>:S:=/]H?]8=T6/>&,1ME_*I[
M_P#/EX^HJ.T>">"L/S_T6#,7L/<Z?W:Y*/0=K:AGX2-MP_S,9MM/_D-=_:YA
MI#NBQ[PQB/RJ?7_CT];J>T>"G_%>'G/\E@/]E3Z#O;;V$;<::X\IK-IOTH--
MAQ#NBQ[PQB/RJ?\ 7MJ>K7@5':/!/!>'YY?@L&?_ ,<_WIZ#M;4-/,1MOUXH
MUFUWY=X=0P[H\>W8QB/CJI_UA\V\[E/:/!->U>'Y;^Q8?U.I/0=K;;!9&V^G
M[C&;'6&>\,!#NCQZU^V^(_*I_1M7\RCM'@F=\+P_.W\E@SX>Y]=R>@[6U'])
M&VX]?E-9N>OZPQKG,.Z+'O#&)?*I_'?OKC+Z<]!/:/!1_BO#_DL Z/YO190/
M8=[:\[(VWZ?C-9N6@_VAOTATZ=$3W18]X7Q'(V/W5/?_ )O/ZAVCP7=A5!U"
ME@Z2/<^/U*>@[6U]A&W&G[C&;GC3U!N.?^41W18]X8Q&WYU/Z=OYD[1X+X+P
M_/._8L&[_P!/7Y"I#L.UM<_(1MOI^XUF# ^'O#&NGX;.Z+'LCVXQ+Y5/^MEZ
M^-VCP0_XKP_3\E@SM?\ H[O7>H]!WMK["-N-/W&,V>K'Y ZO<ZH=T6/>&,1U
M_*Y^G^F>CU(3M'@G@O#^G[EA_4Z?/TJ?0=K;!M9&VX;?WFLW_P"AOC,.Z/'O
M#&)?*:C]?J\_B@X'@AUPO#SE>YI8.-OYO[D]!VMM["-N-,_WFLW_ .AL/B&'
M=%CWAC$=!_*I_P!?S:C>I[1X)KVKP_Y+!G;_ -.Y![#M;;G9&V^_.C6;G_\
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M#+MOB/RJ?];+QZ=*=H\%/^*\/^2P=8]SPN1T74AV':VP[61MQKG^\UF]O/Y
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E#@/(G:2>ME^A#[4$L. \@4A+*&H2@ ](  04V T%E,$2"+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g307489g32c71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g32c71.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1[B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'L:^>'@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! #O_XU  (  0.__C4  @ !.$))300F       .             #^    X
M0DE- _(       H  /_______P  .$))300-       $    6CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M00    8             !(8   :"    !@!G #, ,@!C #< ,0    $
M                     0             &@@  !(8
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P  !(8     4F=H=&QO;F<
M  :"    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   2&     %)G:'1L;VYG   &@@    -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
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M# P,# P,# P,# P,# P,_\  $0@ ;P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MF&?S32/T6Q]GT?T]E3+?\$A_\P_K=_Y7_P#@U/\ Z52_YA_6[_RO_P#!J?\
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MC6V^[:YE5M9LL;^CW_\ &+3^I'U@ZYF]=&/F9UL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MLK/2U.$D)39"0T25M/%%5F)C9(.$PW6"%Z.DXJ+"Q/_:  P# 0 "$0,1 #\
M[X,XF:.&MAB]4-(4TT55:B/  ]S3W?%ANUZ;#IY_D'>/-NJ#>]MVE[Z=.FOV
M<.G363?GI<<LF6QT8VJ\$Z,BJR2D.*IE*3Q.9R8%A#6<F)75U&12.O9:,2#%
MB>D"UM:8PT*QJ)H,IH,&C;X9@6*XREY>'10^EA2$NG;L-92X%% &W=;*KA)-
MTY@-Q(TOJ\1QG#<*4RB?)4RIX+4T-D^YF""D*N6&U@6*DCMB"2=+U83U01D
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MI[+^3US_ #@HZ_!9M@?)_H.[F%Z>J",@'TY5G#Z5EX??]8/^C#L)Y3=S1Y9
M_>JCLOY.ZCK@=?\ IIM^]K'_ (_13U01D ^G,K\EEX/@#AV$\INYH\L@?O5.
MR_D[;\(*\FFWUW:=3W[PM]=0]4$Y !X7E5^Y:R\'P!UP[">4W<T>60/WKUM\
ML]EW)WCB"M-/O:;KQO\ >_#UW:1]4$9 /IRK/)9>'X X=A'*;N:/+('[U4=E
M_)WN@KR:=QZ=AZ^&GJ@C(!].59Y*[P_ '#L)Y3=S1Q_OL#]Z]>/"G9?R=O\
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M(4M*02E)"E  WK*=P^<P%J>@RV@TE*W%.QW4)0AQ12E2U+0$A*U I2HV257
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MI5LL94AI+ZLVJ;,E8<)(U ";D:BKB8<Q;"Y2(DA4=-[R$L.J9&715W0G( +
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MIL0 RXDB.%GM"\RZR%$"Y"2M(O:PTX:$V %OA_R]7ZBMO6B[<GLI=>/6L?\
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M,NL.CME-OH4VM(MH5(6,VO VL;WX"JGM9E_OO?*MVHLO9BZ=VJF&D@Q]"V\
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MKHH(U8:R\"AS5FD:(K<Z-P5L@-W6EW:5UY)'?2+N#VT*Y*POQ14F=$[>M:I
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M<Z-0M00,I(371%;IY38ZPPX4.2<$"FD)<#>TEI9CAI0[9(VJ$J5E7H4I4HW
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M/-PMIPO8_)IQIYM9QYIIYQE05&&G55&FF#P$:S*QJJJJX (B(CJ   Z8  :
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MOT&JU:@VH\]4I//KH&BLXX\PTRJBJ@2AHJ-KKJ,JH$L:BJJ1J$!H$0T$-A@
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M$0#JUWXX4YB--;@\][WXFV\ GGMINIIKL(B.NH\M^&VVNG7QT -!TZE1>VH
M%K#CIOUUM?FW7)N+\\1#KU$>&^H!XAW[-=-0XZAJ&@84!YK ;]+$]\:=-KV.
MZQL;FF@:[Z<1TU'@&H;:;<.K7GPY84N;:7W"]AO-CK?7?SVX;^--.O3Q<-=
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M>J--;VL]W%(@J=3F])42D-<A0(Q6UDBIJ2$"8)5'5H"@A 6H+6$I"UA.0*4
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MHO7P:RIZR$98(4VG2N.60M*R/K :D<FQV9[=Q%M=$"HA8G&A0B7HF<A4E/I
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MV_Q:/FI^RG@QM_6Y#_!$_P#5X;9W\:Y\]7VTV;?XM'S4_93P8V_K<A_@B?\
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M 4T@-==55=0@&M5=550ZB(CB5*4HYE**E&P)4238  "YN=  !S  #05  2+
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M(G7*$S#>F)Q;#<+ALR&2C9,NPV4Q7NJ5+4E32,HVJ%%)!%DBYS9-EN:[+3-
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MCYO95CDK-"'2R<I:8TI;ZY;4%#X[$+%S(Z+D#LO;P!G5+&Q2BK5-0 C4=]*
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M.LR602UVD#LF;DA:L$Y:E95X4IA2F%*84IA2F%*84IA2F%*H6Y\V,MK;F<7
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MO_MJKL8-95,*4PI3"E,*4PI3"E,*4PI3"E,*5+W5?0V-ZM<8&M*8FLP0Z^Y
M1TPJ"3PWG3O:'7Z*\M+,;>BZ]>86_-2.Y]Q$J2J\UT!2ID\VDI)"9.,W?:B2
M""2G2DLHDDON2RBRZ::"Z*::**0II ,?2F'18IP^ 3&8),.*22RV226$$DDI
MN23O-?/V(2) GS0)#P'5DFP#BP+;=21;72P.[7Z:LR-YKP;Z75N2/BG<HX<N
M#L//JTV#MVS.I(GP:/XEO]FL3JF1I>2^.^XO?QWD<.>^IZ-9LLNQ=,AK:%J>
MY=P"EBZMPI7*RYG(RU*P$IY124%1]#E2:I!-16860!U1G>2ZJJ2^YIJ'751(
ML8XIBR3'8(2G#\H+39 NR[>PRV%^-M_&MG*D2.M>%$OO JZO)(<5<V>1O.8G
M0$6O8"^@J4_%GO!P^*M<D! 1XSJ4Z<A_73?CV@ !KPQM>I(GP:/XEO\ 9K5]
M4R-_5$@@@;G57XCWVF[H))MOK<CT#5WK@K>DAM>CDT\F;^U*89= DYL>I0]N
MJ PZN&K^\&F(UZY0GKK),^/+K$L:BZZ0KI$! !#D.7,=AOD])4VPRA6WBC,A
MI"5 %Y-]4@$7W&NJY&//+QQD*>=<269-DK<6H&S:MX4JQ.@(TT.O UZ"-(A5
M334'"H $/$(:ACPZO9-]1PI3"E,*4PI3"E,*4PI3"E,*4PI3"E4;1^F I[8>
MC^L\K?N_6QGG\&)^/K_R[?KX*Q1]^J^*I_6KJLL8%95,*4PI3"E,*4PI5$W'
M]9$A]IT?SI/BXWJI6E_8GM/^RYZGZJH<]J/RVOUB*G[!\IFWM2%?:@']&+9^
MSS>O?JH<>@G[?K^KA4WPJ:84JV<-]=\^_;&'^2<^O%P^Y(_.._HLU;'M_P#Z
M#?\ E*]1PMNK!6^UUCLO%]IT_P!OKLV9;7>YK/#%]P;<7GCMU*"VUXCC.:PL
M<SBLUMPP2+^XND;(;FQYB+LS'DU'LJ1T;GQG.5.:5=;[U7*R9REMS)7:Y=.6
MNYT2O"XW<G$JN7+)[ DE+9"'"4.2A,P*V>+-%3J^*VEKA[?&VN'"B=G9<_5+
M6%8LD!A;TJ7D$J5D[A2F%*84IA2F%*84IA2F%*84IA2F%*84K"O/M 8+*LNL
MY>91"XG)'AA(CA3&[/T<9WAR9BW"<Q4M>6U+G!&H5-U"TNFDM70C-)I4T4A0
M<%=( &%*RXC<7C4-9DD<B$=8HK'D J!0L4;:4#&S(A5J3EJL4C6UITJ%,*E8
MH4*U DD4"<I/./,[HTVNNI2IYA2F%*84IA2F%*84IA2F%*84IA2F%*84IA2J
M1K]?A';$5?UGE%]W&</P:KX\C7AJPO[*Q3]^CXJK]:FJNQ@UE4PI3"E,*4PI
M3"E,*4PI3"E,*4PI5*S;UKO'M,[[2H,*@\._\EO7H^JO*9S !K?J]G(0N[<G
MAQT&9/.G+D&PZ_7U#7Z;PW\'0/B47]0W7SQB)MB&(<09DK?NN'W+\>)U%OHL
M;6C[1#CQ !TUT_1;CPU\77J&VN,VL06N.8$=)L=0!8'=K8ZVN+'4BJD7O+8K
M;DZ$EFK3"E[^*4\7,PX2JE!E!IU51=26@#@'O>E("-/<]USX8TT7#IS$QV4[
MB27Q(V0?:$)#6<,H4AO*L/K*+9KFR3FM;3?6UDSX3T5N*WAZV3'#@8<ZM4[D
M+[B5N;1!90%W(L 5IR[[FPO3>NH< W';?CIV["&VVXCU   .-S6IM8[SH-=-
MU^<:@ZZZ <Y)(K<'T% _[(_:8==/S,W%$-QX#$5^NO/J\?+GCC>7G]&Y/QB'
M_F$5U?(O3'F+7]QE [A>S2K6X;[FW [^%>C*3\B*_:Z/M0QX2=Y^O?X:]H&X
M=X5R85-,*4PI3"E,*4PI3"E,*4PI3"E,*51U/Z8!O6,.(\6SVH^[C//X,'Q]
M7TQT?9ZZ6Q!]_*Z8J?UJAZ[OKJL<8%9=,*4PI3"E,*4PI5$W']9$B]IT?SDC
M%QKVROS3_P"I<W]'/T7JVY[4;O=&M_YU'T\W3:I^P?*9M]J%?8Q;/V>;6JA?
MMK^^^BPM]%3?"JJ84JV4-]=\^_9L'B^1.>+A]R1^<=_19JV/=#P[0?I*^GGZ
M>)K%_,+F4NC:J:RUHBBS*<$;A-OFVXDE"ZEXKF1B=,; N=:(^4YNL6A5F)\E
M3H7F0FE,D.(H=S'J7N8*$+*U*5:4XFBW5RJSR6ITZNU4BG8S"*3!\NQ=6X%Q
M9?5!VF21^*Q>6+W$A@=H2W,,T2-LR:EL7\[A#?)BI:SL,A72VE^=W-@9#W$6
MQ*I676%*84IA2F%*84IA2F%*84IA2F%*T/\ 3B=(C?[(/#[!NF7M9#4[S<&4
M35LE 2^,4R8D6]D:6)6V^8BA7(O,AH*5ZGOQFIG?:1+I  [G4>TY&X% QQZ<
MW.#Q3':86WLG-F;N+<"LQRJN+)%MUJY'E9C4W!VH:X9:!><>2O:MA=PA"%#*
M"4@>V-S?7HM779]4=]))Q\*V3TW_ .*PH>'+9]X\1ZM-^0X[[L Y/^]F>4__
M -*XGLWQS=GBWT_NUM_'5S=N'/?3B*I^5=/AG]O PN%N9BYVB,C<C!.#E0W6
MU+0+:@:EB=[2"0J!Z-$H 7-J43![V/=E 86&G=ZAK\4Y$8'$@2)#*96T;#>7
M-()3VSK:#<9!_54;:[[&L[#>6&,RIK##RHN1PKS96+'M6G%@7S:',D7L#III
MOJH1_)'722!_PK93W+5E#J'+_A[CP#@(;AXL;#L Y/\ O9GE/_\ 2L <N,</
M]:)X8X%CQ_K[MYW@Z'OU ?R1UTDFWY;63#;G:LKCU!J_!PYAR[<.P#D_[V9Y
M3_\ TJ1RXQRY[:*=>$;ATV63KP(W]%=T+(#?.6YDLG>7^]=P#FL^=W"MXU2&
M65LJ &MJ%X5&J:% H6\#CP2$:%4=R2!QG<CK\<.N/(L;ALP,6GPXX4&8\A;3
M>=6965-K9E6%SKJ;5ZEA$IV;AL.4_EVK["7%Y!E25&^H3<V&FZYW5F)C55LJ
M84IA2F%*84IA2F%*84IA2F%*84JD:P_-XF'_ -T5H:?_ *R@_'W\9H_!ROCK
M?ZARL8_?@W?>RN_[JCZ#?Z*J[&%633"E,*4PI3"E,*4PI3"E,*4PI3"E4K-O
M6N\>TS?M*L*5Y3.8 0IOS>P=!_3=N2 \O\LGD0]W7;Q!KIH(8^F\-_!T#XE%
M_4-U\\8B"K$)XN/OV21Q_MW ?!;7=O-KW!JT0ZB.O#4!ZN&FH[\@'8 $>&HA
MMIIC-K"%@+;[$<^^]AIQ(U) WV!UO>FFM7+3CSX"//GKOKN/NZ85-[)XWW<-
MX'#A;2V@\%ZCOQU$-Q#3CO[F@#N/N#H&%1INL#H#?=IX;D:#PBYK<'T$XZ](
M]:?B(^=JXNX#R\Z*_0.([[[#IK[NN.-Y>_T;D_&(?^8175\BQ;'H^X#82M".
M.Q5<[AIIJ+V\%C7HRD_(BOVNC[4,>$G>?JW>"O:$[AWAYJY,*FF%*84IA2F%
M*84IA2F%*84IA2F%*HX/TP3/^IQ7BV>SONXS_P#9@^/J_P NFL;^^'XL/UI]
M?4U6.,"LFF%*84IA2F%*84JB;C^LB0^TZ/YR1BXU[95M/8G]1^9<]>BK;GM1
M^<:_6HJ?L'RF;?:A7V,4'ZAYAS^O-I52?ZWY1^KU[^_6IOB*JIA2K90WUWS[
M]FP?R3GBX?<D?G'?T6:H'NA_(3^DKAPK'*X>5*33:]"F8D7!8T=J95/K,75N
M) 5L16K92^S.P%-*NW[:U3(J2I6YNA*F1,\)D;^RKHJZJZET75EH%Y),F7@E
MMU75X\OUKI-;&,RLV=/S)(9_<BXLJNA-U<7;EK3$T;W)!0(DK)&$#DK7.-+0
MPQYE8VD%S@H\W/B](N?U:=">Z&(4RE7O%8D!32C%4F!753W=*43R@4U4:"/=
MTD#5WT:= $>Z"G30!'70!PI7Z,*4PI3"E,*4PI3"E,*4PI3"E=0W\E%5U5,^
M6"@1$::91<80#;;\IXT B #KOISZ@Y<0]-^YK]\XMNT8B=_5Q_[*\[^Z!][X
M=;0[>1WK[-JU[6M?3P\]]>H* ZZZ!QUT#;4>'=!QTWV'KX\-0''K=>7D6M<[
MMYUL-^4[KZ:CFO;?8BJBC9C:E7EKG%?YD!-W?<E4I#E%1P&D'$U"%17QI?<#
M53J%?Z+40H'80QI\:;F/Q%Q8D3J@O!.99?:92T6W6U@$+U7G"2 4[B-=];?!
MUPV92),J46 RI65&P==+FT:<3<%%PG*5 F^I!O;3-4D5%D$GUEIE0+" [CN5
M $UIPK&JBD:_[F9\?3W-6M&HZA5W(U  @.-FPMUQI"WF>IW59LS)<0Z4640F
MZT=H<R0%Z;LUCJ*US[;*'5)9=#[:0,KNS6WGND$C9N=L,I)2;V)L%"P(K@#7
M7?4 '3W1$/%H/'?;Q#L 8NU9-K:6)%_  >_<;M->^-2:])SH9JZZNCPRS@(B
M---M6L*0WT  4JP .(Z>+'SKRH_I!B_QQSS)KWGDY^ \+Y^I$><WX#ZN]6U#
M&AK=TPI3"E,*4PI3"E,*4PI3"E,*4PI5(F>OQ(/7$EX>\[MXXS1^#EBW]];U
M_P"P[I6,;=6)/$QE@>!U!^OSU5V,*LFF%*84IA2F%*84IA2F%*84IA2F%*I6
M;>M=X]IG?:584KRF<P&U^;W#IH/Q7;D\P#A,GGQ#H.O(-1ZQUQ]-X;^#H'Q*
M+^H;KYXQ'7$9PO<=62N!.]]SOBXMQ-AS"U6BZO&&O 1$>L-]N6^PCJ ZCKC-
MK#Y^\;;P .8Z:\=-0+$6%J ( .HAH'+7?EMXPTU !TYZ:X4()%@;GC;3CKWC
M>Q(OPO:@"(=8[:AR$=>'(=]AVUW  X@&@J$ \PUL>(%M_$::C6VA)W$W&X3H
M)Q#TQZTP::#YVKBZ[=417@.WC$=-NSECC>7G]')/QB'_ )A%=5R,!Z_,&]QL
M)5M>=E1&O> X]/&O1E)^1%?M='VH8\).\_7O\->T)W#O#S5R85-,*4PI3"E,
M*4PI3"E,*4PI3"E,*51W_& /;#J?K/=?W<9_^S!T3S],<?96+_??_%_]M5CC
M K*IA2F%*84IA2F%*HFX_K(D/M.C^=)\5M[U?FG_ -2Y?Z-]4.>U'Y;7ZQ%3
M]@^4S;[4*^QBD[_ /,*E/];\HU-\155,*5;*&^N^?:_JV#^2<\7#[DC\X[^B
MS5L>Z&WO!^DK=T<W1:L.7IFS#H,RF8)W@5YK.VCB3XGM'4W)[MVM>+@GR%6V
MPHU(Y+XZL;;XVN+;4",_N42U(8U.%9JVD3_-P />:;=7*R8:R[IGV0FA,@E4
M/O-<8V.S0IE66E(<+(M3ZN,:%=+!'FMW5SJY:R&O1JP2D(S&B1J!:%2@EW*0
M)A1=[K4K57"4<&=9E$8O>7H\\J%CI?*96RM*I\O#=:747=7NKBY)B#ET,NZ\
MY70;+JW' *C%;/3%;YKWUX>"B2_/ A4&U+B5*W9QI@2Q9A:XZA6/2]$SI:$2
M15(GQUDSV:F*&KO(.4@?5:]Z>%!18TDBX.R]:XJ:2Z3%JM2H$PZM2M9LSOQ?
M*#7"46[JN8+XWW5-LP-O;D&Q>VHL*1#<2_\ #;:3I_LZGBWA\DV/P6.W$C#(
MW)[VJ']Z<9\X,[LGID43%S35J5,#+RYFVI&AE29Q-FL1MI=6Y]J7Y64EMVS5
M70<HQ=1SA$912M$8UHW8J6RI";'(G%3K2I&:/EW0!]<I>UM$.K2-;?&OKZ[M
MW3OI68^76ZK/=BVS6ZH9<9-7IF3,C=+W^N-.$23N3Z\12/S5.ZL[(Y-S:H)B
M[]'Y4R2")G@2<)T<=&SS4K4.-"ZH)I5]\*4PI3"E,*4PI74+_)1'RHRQ;_Y4
M7%$.O4&B-:::=H[\=N !CTW[FOWUBWQ>)^L?^S3P]%>=_= /\GPW3^WD \UM
MFT23>W/\O'GZ@NO4.G(-/K#UAQ[1'?ACUNO,+<XOQ-_I',=W0!IOKZXAJ&^@
M:"/,>'B'K#KTZQX*C<;'2YN!P&_OCF/-?F&\/+B.P:\]. #MQUV'4! ==]AW
MT4Y]PU-N%]Y&NZVHL01;34:7@''7D _<U'8 #QZZ;" 85)W6XD?;8:DGO6OJ
M":])OH9/[WAEIXZ_$W;./'_;*O7MZO=UX:X^=>5'](,7^..>9->\<G/P'A?-
MU(C=NWFUN X_QM6U+&AK=TPI3"E,*4PI3"E,*4PI3"E,*4PI5('>OQ#VQ-Q#
MWG9NUU^MIC. OASG1-:^EAT?5_K6*;=6HZ8RQ\CB#]M5?C!K*IA2F%*84IA2
MF%*84IA2F%*84IA2J5FWK7>/:9OVE6%*\IG,!^GS>[7Z;ER1WW$0\^3R/5PT
M =-^S4!T''TWAOX.@?$HOZANOGC$OPA.M\-DC3<#MW!S[[D7TZ;$7%6B\>FN
M_(1'7B(B//3F&_'<-M,9M8?>O;3B +;@ .%^!TW:'6].'+34=-/L:AH(CMU#
MV\1 14W\;V%[^>QN -><=&X$!IIIKPY\0UWYZB [<M@W$/=4O>]M_#<;:<+
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M84(N"1I8'33<+CAX>?OUZ3?0R?WO#+2/#\[=KU#?CYI6=?5PQ\Z\J/Z08O\
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MDPJ:84IA2F%*84IA2F%*84IA2F%*84JCC/TP4O;#E_UGMM^^W]S&</P8L?\
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M8Y5)4@#52F)*IJJ 5*K["E,*4PI3"E,*4PI3"E,*4PI3"E=0O\E$;M.6(/\
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MMH?#47!) ()&\7%QWQPKZ$0 !$1T -Q$> !UCB*FO@#**J.^4UT54:"/=A4
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MPJ =""#Q! W:\-!IOY[Z>"H:!J&N_+J'D&VFXB&O ?%RUPJ;G6VG'GYSK?0
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M8GY$5^UT?:ACPFO9T[AWAYJY,*FF%*84IA2F%*84IA2F%*LAF+DJF,6=GJY
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MN/$ ]P-0TXCCUNO,+Z\=#:YOKO &@W$^$V-]PIQTWX:@.H!MMMKKKML/8'(
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M&TX_0DX!IUZAIP#41#Q!CC>7G]')/QB'_F$5U?(RW7]BQ_L)/-?W%1OS:WZ
M#?G->C,3\B*_:Z/M0QX3Z\U>SIW#O#S5R85-,*4PI3"E,*4PI3"E,*5BUF^_
M29E'_1ZCJ_4#[OO>[CI.1_\ 2G /_E(GZT5RW+;^B?*+_P"(F?JCT6^GP:UH
MLQ]>5\84PI3"E,*5L/Z/_P!<LMY_&->W7\:NQX3]V3[YP#\QB'ZR)7T#]Q/[
MTY1</9\,U_\ I,K;3CQ6O=Z84IA2F%*HFX_K(D/M.C^<D8N->V5Q]B?Z/[%R
M_KQJVY[4?G&OUJ*G[!\IFWVH5]J'X_Z<4'ZA] %5)X_E'U^2W^E3?$553"E6
MSAWKPG_+^Z,/\DYXN'W)'YQW]%FK:?;_ /;3KSZGP].[C5S,6ZN4PI3"E,*5
M;>Z=LVNZL:2Q]P=GJ.K&B31::1N2QRMMI>X[*8:^(I Q.J&AY;7EG54T+$0)
M7!O=6IP;W-K5+F]4FJ*55#2I5$-67J--D(C4",D,G=V=LN2[77EBIT.:Z76X
MLQ>I/(;@+%LE.:&QH1(DX7)?$DV3((VWLJ!(JCS*RIDI4>*4-9ZE?LL!8>/Y
M>X:JAL=>G=]2JUS.K,6O!#.D.I*CD%AUMV-.4D8FUK;BJRXK!& 7526EH,=W
M^MW>S:2*G+S(F4J^>%*84IA2F%*84JS]TLO5A+Y4-A=Z;*6GNX6R&J3V:BY=
MO8G.:&DY9046K.;:9,TN8(3519)-"@Q,!51U!1=)@U4T4@&5&FS(16J'+DQ5
M. )6J,^ZP5A.J0HM*25!))*;WM<VM>L:1#B2PE,J+'DI024!]EMX)*K9BD.)
M4 387(M>PO5G/2\\A'L*,J'_ (>[4?!3&7U]QSNSBO\ B$OTU8O63!NY.&[K
M?>,7=XKHIZ7GD(]A1E0_\/=J/@IAU]QONSBO^(R_34ZRX-W)PSR"+Z*GI>>0
MCV%&5#_P]VH^"F'7W&^[.*_XC+]-3K+@_<G#/((O'?\ V7&GI>>0C77T%&5#
M4/\ \O=J/@IAU]QONSBO^(2[?)MK>"IZS8/W*PWR&+Z*LF(7!(1;>.MD0M[#
MXQ!8HRIJ4;/&8>PM<;8&I)0(U4)6YH9TJ-O1)Z*JJAI)3)RRZ1$1"D!$<:YU
MUU]Q;S[CCSKBBIQUU:G'%J.]2UK)4HGG))K.::;9;2TRVAII "4-MI"$(2-R
M4H2 E(Z  *JO%NKE,*4PI3"E,*4PI3"E,*4$ $! 0 0$-! =P$!X@(<P'"E6
M[=K16J?EIKD]VV@KNXG]R)Z]RBC&M6'=S2%-/?5*A"8<9W-(!33W=8Z   &P
M8VD7',:@LICPL7Q.&PDJ4EB+.E1VDJ6HJ60VTZA *E$J40+DFYN:U,O <#GO
MJDSL&PJ9(6$I4_*P^)(>4E "4)4ZZTM9"4@)2"JP L+"I;\0FRGTI+;_ %%1
MW\'XR>RCE+_O#C?^*SO3UC=BG)?_ '<P+_"8'[O3XA-E/I26W^HJ._@_#LHY
M2_[PXW_BL[T].Q3DO_NY@7^$P/W>GQ";*?2DMO\ 45'?P?AV4<I?]X<;_P 5
MG>GIV*<E_P#=S O\)@?N]<A-C[,IS2SR+46Z*.)KH-*-+AD>H,+,HJ"J@RBL
M&\*J:Z*@"JFJD0$! ! <4.<I.43J%MNX]C+C;B5(6A>)S5(6A0*5)4E3Q"DJ
M22% @@@D$6-5(Y+\FFEH<;Y/X(VXVI*VW$87!0M"T$*0M"DL!25)4 I*DD%)
M (((JYI!!"4J@A,24G(*I"@LDDN@HHND T"F@N@*::0  T    QI:WM<N%*8
M4IA2F%*84IA2F%*84KA/3D*BJTZDDI00;2-)A)Q=)I1E([#3716%5-0#S 0$
M!PI6)[ED$R,/#@N=G;)KE:<G1S5J7!Q<5]@[6JUR]>L.K4JUJU4?%JSU2I4H
M,,/4*#JZS3CC*S#*ZJZZJAV:<;QE"4H1BV)H0@!*$HG2DI2E("0E(2Z E(
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M#>7$+$8.&.MA#<Z6[@S<J)(1/CH9Z[K6TE41Y4%8FA+K3K;:T98RUMJ#DEH
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M% 52% 8ZEK4LN*6I3BE%:EE1*RLG,5E1-RHJU*B;DZWO5\(0E ;2E(0$A 0
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MIWQ[6XYKU .K;W "K7;W0Z^ \1TT#?"I/R\.8BYYQK;=?H%]:B':(CPX:::
M&P#KH ;]>X[[!KA3=X;WY^^+:_Z\+6J&N@CISUYZ<1VWUWY#KU#QTPI:X'/Q
M^L6/ \WAWU'30!\>^G(>6N@\AY<-P'37;"ES?=PYQZZ]/$<-] #@'6(\*MN(
M;@ ?8Y<?$J#Q._3FWC6XY]?DW;];F%T/+EM+32(^9S&@M74&H:=]%4H*$=O^
M273H/8&^'/T"_>UI;4$FQOPXC@#S[K_+WZF\V>#6ZME1E_H7-PH3&Z\!H&FN
MH0TZP&@!#7 Z6/.;?Z]%-YZ /#J3]0\QWZU* #3XX=./7OS 1 =0#7;4.OEI
MA4[[CO[[:^?07'#Y=:B(?H1UXB(_HAT#GIKXPX\=>OCA4 ZD<;;[:G6USJ-.
MCFXZVJ&VN@[#[@ '/;4-NS?????45-0/K(N3PU U)XWTMIIOLZ^K3CMH&_8'
M#7W!TJ$-QTPJ>GG\%_XVY^;7=HT'B <-M!'741U#LV =@TZO'HIPW]-QH!N/
M3OWZ[[GA2K@/N".X<>KKT'CPTVU#;@J!OW<UM^[PBVE^>]M^HU;#MIRW#B.V
MPZ:B.G+B(:Z &@\,*=X\=-=->\-?I/3<Z.&F^FX_':ZZ[CJ.P\=]-]?<TPIH
M=PN1H1;Z-1N&_2W/:L9LT.;.TF4&)1"97>KEU;;/)\TVQBJ"$Q%WFK^[S)\:
MGMX:VE(Q,A9R]08L2L+@60!))M9RL$Z0LNHU26 [+#,*EXLZ\S$#69B.N2ZI
M]Y#+:&6U(2M:G%V2 DK23<Z)N3H#6!B.(QL-::=E;7*\^B.V&FU/+6ZM*U(2
ME"+J*E);(%M;D 7-A5F(ETG63B5P.\5P%%Q'J$(+!-["ZW:CMQ[?SF#3B)HI
M4I*0Q<T8<_L*5[>*I&Y*$S4T%,"5U-4NBM B&@LYP04J<QWDUC#3\..(Z'E3
MU.(B.1Y##[#JF@5.C;-N%"-FD%2RX4 )2HZA*K8C?*#"W&I3VW6T(24&2V^P
M\R\VEP@-DM.(#CF=7:HR!1*E ;U"]66#S]6 S"S=]ME'Z[B6^N4PQ,)^? ;V
M6UEEII,XP$55"*J;LB*6H49#M&RE=99!ZQ*IK-3Z@:I3E$:FXM3\!Q##V427
M!'?C..F.'X<EJ4VF0!?8++2E%+A%R$D:VL#?2KL'&8,UYR,@R&9"&]L69D=V
M*ZIBY&U0'4ISMA5[J!N+Z@;ZM$DZ7')4KDA#?3+YV3 U,J\XZ2_:JU,_39>E
M4L\V"V@T%7;-8PC=%(N-(H_#!QA,?[JD58NX-X@L'+/)/&4MD[)@OAK;F )3
M!Q -9<V;J0+VA.7ML@NY_5RYNUK%3RFPC:%(=>#1=V*9AC/"$7,V3()11LM%
M7 42&_\ BMK61.:'.;E\R>,D!D-]IE7&FNY<P2PN*G(FU8\F*5ZA+6L4N:DE
MOI-,2QYI3=Y-=WFL*DJ(%B&FL:JU9-%>OPS!Y^+K?;@LAU<9DO.A2DHLD'*$
M@JL"XHW"$7NJQX UGXABL'"T,+FNEM,AT--V25W5:Y4<HT0D6)7N&9(M<@5^
M;,]G0LQE)IMO1=.F=+UMV'9Z98*T6[@S[<%Z>E[ @2.CD02TQXA2MJ[V@6$J
M:*BR3>^%TG5@'<%F5!.&8-,Q;JCJ78)$5*%OKD/HCH0EQ12DE;A"?;)(-R+&
MW/48ABD7#2QU075*DE:64,,K?6M2$A1LANZB+*N-#>YUTTMQ#NDJRJS:WE[[
MAMLCF347ERC*687@A<OMM,X9<>)QU>B.6MKG5#90T-3BYI5Z=.;4E/:A6D#6
M!5)QI0JDG?\ )>Y-XJQ(A1U-LKZX.%F(\S)9>C.N).5:=LTM24E)-B%6XVO8
MVL-8]ASS,QY+CR>H4!V4TZP\T^TA0*@K9.)2I0(!MDO;H)%Z[MWGERZ70O6U
M9?(Q+%Q=TG^S\3ODPL+RRK6@M[@4P96N1-9[6N5!YD6/1+,[I'!Q8BZQ<D:2
MA:HJ),(;UQA./(P3$8L-<]UI)BMRW8+CB%I7D?96IM04D:A!6@I2X1E4<HO=
M20;K&,09$M$%#I$E<5N8A"T*2%L.I2M!2HV!6$K"E(MF !.6R21*W'I <KK'
M9)_S 2*=JV"W3!<J46> YQCSU7(GZY$4?ET:7Q*)Q1N2KGZ3.BQU;E=#80U(
MC_-*1.>XFBG;DRI236G <3<FMX>VP')#D9J79+B-FW'=;#B7775$-MI"5#,5
M*%E$)U40#2O&L.1$7.6\4,(D.1>V0O:.2&EELMM-@%:UE84$Y$JNFZKA(N.3
M+OGSL#F6F[_:^(G3^%76CK"3*UUK[PVZE-K)PHB"A04C*E;4SRA"E!X8Q5G%
M$&J&]0I.25'$5+"$Y1Y%9D8A@4_#6427@P]%<<+29420U*8#H%RTM;2CD78$
M@* O8V)(($P,8A3WEQFR\U);0'3'EL.1WRW< .H0ZE.9&J02FY!(S 7N?W9C
M\\^7C*Q(&:(W2?96?+GJ,NDZIBD!M],[C/[1;UE55HWNX<D00YE=AC\,:519
MJ=6].E28JNLA52CH5"B5]XC#L#Q#%&UNQ4-!I#B6-J_(9CMKD+ *([:GEHVC
MRP00A%R!8JM=-YGXS!PY:6I"W2ZMLO;)EAY]:6$&RWEI:0K(TFQ!4JPO<"Y"
MK9)0.=1&YT*BUQ("_(91"IJQ-DFBTA:ZZZT+NR/"4I:WKR!,+*.HI.3F4C60
MH*)5)C0K3JB"5!1A=&N?8>BO.QWT*:>8<4VZVK>A:"0H&UP;$;P2"-02#>L]
MEYN0TT^RH.-.H#C:QN6A8NDB^NXC0@$7MIJFJN'Q<Q#3?MU'3733Q#QXU;8L
MU=[WT]X6N=]^_<\_"H!K[X:!MJ.VH;!IL&^^NFOC'"H/#GON)\.N_=OTO;3A
M4 #7ZV@!U]>_NC[^X;:JDW'A.\_P[UK][?30.WW..N^F_ >8;::Z<-@U4Z?/
MIIQ^W7O:7T:]@;AON/C'?CP'00\0[[84UMIIS:<WAX^#3FWU'AKJ&PZARY#O
MMN&O -MM?%KA0#=S].I^G7GW](TIL(Z"&^^NG'GKH [".N^W !VX:X5%K7UT
MX='\-W'A>^IK\JP^I(D5*:?T29.<H#LJ**KK > AL-(;[\M!#794]/@&[7G&
M_H/-TC2OU2-R,<[6."\T/CU+:FJJUVWK5)0'AU=UMXN//%QK>K=[D]S$>XN<
M]AYJH7[4 \'&_#9Q%C]OJ*KY@^4S;V)"OM0'^G%!^H>856./23]GU5-\14TP
MI5L(9Z\9_P"./?R;KBX?<D?G'?T6:MCW4_FT_I+JY^+=7*84IA2F%*84IA2F
M%*_.K_VJH_:3/M!Q(WCOCUX><5!W'O'UX^8U8N):^"3-.'A9\$>S\ME@#U[Z
M#U<!#;7%(^L_230V/\-_.-?,;C72^^JGUW'MU#3MX .X\=]]=A#7CB:#ZN&O
M?MT<WFH',=@UTV =..H[CJ&G/;?80#CH(*<=WAMTC3^/.*CJ&FG6.FO/7F(:
M:AIN.VN^HZ=JHMN-]UM-0+=)M?=S^$6-J@&P"/(0$.KWM@#??3JZA'0!4(O:
MXU!N/XZ][CJ1S4Y#KMJ(;;!MKS$=.77UZB'/"FF\:Z&QWV\'3K?CPYJB/4(\
M@T';?781W[=.8;;\L*"_TW/1S#>.'003KNWPYCUCL #KH #MH&P:#U#PT'?3
M"I&[S]//Q.[OWTMWX!Q[.(<-?L#N/(/%OMKA0VU[UCP]>_PUZ:ZRN4K(=>7-
MC8:^=O)SF<EEL\LDISAWM43/+\S69B!,AEB=BNBCD/FM-=Y\552=H1/JU WJ
M":4;&H2$@C * 6ISCR1]*Q7'8>%3X4AC#&I.)-81"#,]<QTMM%R*INQB(&S4
M4)4H&ZTDYKFQ ->?89@\K$H4QA_$'8^'NXI++L),1O.Z$20YF$E9SI2LA)T0
M0+ W()!_%G,=;5VKS.9G'ALN-FCR&WQ.AT'2Q)7#8F]WOL#G9:6.#"R1.M9;
M4F".T97O+,GH26_<&Z02&E"GK4+SU9)BRF3&U3@Z)4K#,,2J/A>.P0Z^IX/.
MHA3\&6X_G=RR2^EQ"5$JD)6VWF("0DY2U=BIC1L0Q!27\2P>8660VIEM4N%B
MP;9R-%4?8K;4M RLJ2M8 )43KM#556RNC/,M&93+AG0SM6L?X%"+OY!HQ9]U
ME40M<_KV&Q5T&F;5R=3'I%"86T.SE;]/.F&E(]5H$K,52A>G98R%H4R9H>:6
MJW)C,8GAN(X-@TIM]^)CSLM+3TIM+DZ,IG9;5MYY2$2-@L%)45ZH0%W.=LKN
M1Y#^'SH&*XO'6RS)P5J*IUF,XI$.0EXN%MQII*E,!Y!2;!(RK44V 2O+*%U\
M)LD7=*+GRL; 9\V0K,8P6&R]Y7:W&'2&-O=X;K$QY3;\^Z#1%G-"WO:=HC:E
MU-<&]X<F]/2O3(U19QA#@D=426H0F"GDQ@4Y]A;^'+G3\4"7D.(AQ=IU0(RW
M4%2,S@2$K0E1RJ((NA2%&%3'TGE%C,-E]#4Y$*%AV9E;:Y4D(+)DI;6$KRMY
M@I*R %!*@;+2H"394;3YC^CWS5Y2'*YUAXG:^TMVK7,^3:X[W;FX)US4LJN8
MD,>)K#+LS=*DC3&7&'^02TQ0SG+#S7-N1,BYTH%RI!/36IKQ67AV/X5BR8TY
MZ5*B2EXQ&1)8ZG+48Y67HC)4ZLNMMM=O8!!*P@Y=3EHPV-/P3$L,7(AM1XLJ
M,G"GUQWR^'7P5O,RGDA" VM;A*"25 )6L$Z7.+K%9+,ZBZ.E)-UEPKR2W*2?
MF(N8FS.91X/$81&YO5:.B]+L8Z3" S=;"W:<K1H=DJ)[D3 I-$A:SJU)J5U9
M69$L5$;-R;AIY0J83'AM8KUNC'#<5?=?=8ZJ,-.5F0PE]#"04$H;<2+I6!="
MUE(.O$/$1@@>,B4[AW5T@3\,::8;>$7JM14XR\65O*.<!;B";*0JP4A *A?3
M-.U))')^EN>;9L;JX6^E&1')_P#$U4-K*\5)'9@!+$CFA*T4*$H*CSDS1YF
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M6Z3OL#H=U^/>OTBW'C\@&W"G7M$0';77GS]P.(#PV4.O$VZ+$<]R+'UM;>:
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MDV4O 5T5#36 0V5#N [@ TM AQZA'<.([XBIMN_U\_GX\:X_1NY=PW\];SL
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M_CH.)\(^G[/6W>NN?>GZ/M[_ -'/3T!,'_4E]?Z$/N?6XXCP^?Y-W\.FIO\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g307489g33i33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g33i33.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1;B4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M    /X   #A"24T#\@      "@  ________   X0DE-! T       0    >
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M      H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      ,U    !@             "Z0  !U,          0
M               !              =3   "Z0                     !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   "Z0    !29VAT;&]N9P  !U,
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    3.$))300,      PS
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
M# ,!  (1 Q$ /P#U#(QJ<JEU%[=];HD21P=P]S8<L[)QZNFY&#=C[F45[L9]
M>YY'IN#K0[:YSMUE;Z_ZZ-T$N/2ZR]Y>XOMDEV\@^K9[/4EV[T_YM0?7U(X=
M;<VRHY'K-(?2US6#]P[;"]WL?[TBKS=($$2-0>"G6?@YC!:W#+'M#JQ=0\M.
MS:Z?U7U?H?:,?:_]#_W']):")%?74>2OV:%2222"G/R.A=*R<G[7=@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MEM38(S=WU3)!M@H8)%%Q&2<S0F$E)C5%4E6'I<C_Q  = 0$  @(# 0$
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MQRN8/#FE!2C2V0$. :DGU_,R*<0\PAL<TJ/;0^H7ET(<% TFUH"5ANB5A&M
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MQ;T$(0AUO8A"$+>@A"'6M[WO>]:UK6][WK6"0 23L!S)/8!XE<@$D  DD@
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M!D_C%9#U:U$UW+I60!'.@-2F*64W@^ 6RTH"ZKX+9C: .]!$$E%.8Z_DIM#
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M/\EFU?-P-:T DF"[3!V+P-[RYZN(O1Z>U$T\;LUA*T-YV^Y&7P7_ $+<X_\
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M#(&#"9=K1VG>T[ 2D#D&1RN(Y$JGWML;K+#7B2V#4&/MZ>G\'7\>)\WB"[N
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M;/M#1'JK%T\^XL_1-^<25,X!X;9ZEDRUO:(S&3^EN:?HG_"XJQ@23QZ6R=O
MM:[])N/@ZNW@@2?TCZ@N8L.>.3I!(  06BVV4U7!,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(HVMVWZVH:O)':UN2UMA$
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M]B0 UC1N22.X=I 49E\UBL!1DR69O5\=0B?''):LOX(F/F>(XFEVQ.[WN#0
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M)0SPIME!,$ 80;%H6PBUK>MY-*L;ERI4:\,-JS!6#R"X,,\K(@\M!!<&EVY
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M"RL.ILM;FCK4,)IH.SF:R%F8D15Z6-QXFL3/>1SD+600M_.6)H8@7BG>YES
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MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(HL:/YVV#_2RG?\
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MOV-F0'C\TF>-7'.>S*RV'81$)$/*MELQG)[N^]HHIEOU5;K>2EW\ [3)24X
M@UH!.RM=>MB-7&,_ZIJ*W3V_1:S,QVHF^ $60-QO"/ ;>'8H1O3WI6R.'.0=
M#6>W&SI)JF"P-E_(-XG6M&Y#3,[Y-A_F2/D)=[3^(H=.[6C0@[B?.[BG8*(H
M.M:07%$HRB?%'36M:V;+JIM>&-! A=.HC 5P>'6^HM$B_P .#9NP_P"3J/"V
MFCL9>AB9(?GGIW(F[_+Z/^Y<MZ3.@"_OZQJLPTKCOUVF.DK#RU(]R3[.-U%C
M\I9>!R :<XPD=KM^:^:WE]8#"F&DF4 XXV2WGDF)UQM,\MZX7*EJ8T(BCRS8
MK<[15#>6$\H0@C1;F+D4,)FB1J!ZV,6N6Y^]6<UTD&,G<PAS9L9G*P>'-((<
MV.XVFYCP1NWAG?L0#Q@]GR,IT"Y(.;2Z:<9B"\%O4:MQE-M<!P(+'7=,YS4D
MLK.>SG'%0[C<]7V--,GWE=2_'Y ZRJA9+,N.QQ*=<X*N.ECPI5:/'%^7@ :K
M.11E90S_ &2STB\N:G?AIW:%2M% Q*SAJWN#.BI0:N*V!1Z3]/:@GIX[7U6X
M^2Q/!59JB,0LSU,R/9"QV0R%<WJ&9JQ;CB&4(MMC $63KQLX%0LAHG#X.K?R
MG1GTM]#N2K4JUB[+IN+I$T_3PUR*O')/(W%X/4EW3>=Q-R5K3U<>'IOKND)?
M)AK4[^-5BHKMO^5-@S!1%GSCI4,A5N467JXVACTG>Z["2_DK6PL@Q_DLS?I%
M'4364C/6".2N)D?+/4C1ECD;=W30F6[43N@RIC<E;T_K74>4M8C.P8BQ2AIX
MJW/D8Y:UJ7TO$^D2X*M)CC+6? <O)=]&A<SG7D;:HNL>>NAKIZM=*FILEI^?
M*=&>F*^-QEB_9S6J\_D-,8FNV"Y0JF6.7J-09#,.<ZX>IQF&Q5K(6.KDF:(J
ML,LXMJ49S$Y'>64WGSZH#BA"56]F+*\XTRZ)*; -2#WOHB7V(X2I>?&G8H'V
M1N$<EDG;3=Z\0* O8O#*H7PRQT)(P6&T[BV'D+^I\A7U?F1MVOBHM;C=+52_
MM$5K&9T1[?Y\F_+TIZVZ'J+3Z\Z4':\NM.XIZ;S&,Z--&;\O8FM'(9OI!S,(
M.XZ^IF-"32 [FK#P[&<:;X@]F93SMN7&R"J;>LDY6%Q7VA?%JQ.UIHN= ; ,
M#MLV1.9C$WNA8PZ,+<6=B;EH![T+S&]Z#O47D<T,UU(SVI)<ZVL[BJU\GDX)
M,=2/;_T?AX3!AL< >8;0Q]8 GYMLZMTMZ7PS+<&CLSH#0-:_$:]]NC;N*Q.2
MRE=VX=#G-3OOVM7:C8X'9PU#G\H".782#?T%[446  "[DJ8!8 A   +#AX0
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MG5V'"1PZU8,R)6,F3-@'YY(MT6$3")A%4#G3+)M N.$NF5;SJ<0F?M+G&&J
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@3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g307489g35c14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g35c14.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1C,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &+"^8R X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! #O_XU  (  0.__C4  @ !.$))300F       .             #^    X
M0DE- _(       H  /_______P  .$))300-       $    6CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M00    8              X<   =D    !@!G #, -0!C #$ -     $
M                     0             '9    X<
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   X<     4F=H=&QO;F<
M  =D    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   .'     %)G:'1L;VYG   '9     -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
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M# P,# P,# P,# P,# P,_\  $0@ 3 "? P$B  (1 0,1 ?_=  0 "O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MF_9N+MV^@W;!&W8R(,RW;M_E):*2#.) (8"#J"'=C\DXS3(FO_I?[$PQ0
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MY@!+0'.]SJ-K?:[\Y>@Y
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                 /_A1Z9H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP
M0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O
M8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#<N,"UC,# P
M(#<Y+C$S-3=C.64L(#(P,C$O,#<O,30M,# Z,SDZ-38@(" @(" @("(^"B @
M(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P
M,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H
M='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @(" @(" @("!X;6QN
M<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @
M(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z
M<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO
M<F<O9&,O96QE;65N=',O,2XQ+R(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S
M:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @
M(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C$M,#$M,3)4,C,Z,3@Z,S1:/"]X
M;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C(M
M,#8M,C14,3 Z,S8Z,C$K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @
M(" \>&UP.DUE=&%D871A1&%T93XR,#(R+3 V+3(T5#$P.C,V.C(Q*S U.C,P
M/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L
M/D%D;V)E(%!H;W1O<VAO<" R,BXQ("A-86-I;G1O<V@I/"]X;7 Z0W)E871O
M<E1O;VP^"B @(" @(" @(#QP9&8Z4')O9'5C97(^;6%C3U,@5F5R<VEO;B Q
M,"XQ-2XW("A"=6EL9" Q.4@Q-2D@475A<G1Z(%!$1D-O;G1E>'0\+W!D9CI0
M<F]D=6-E<CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HX
M839F-64V9"TR86)D+34R-&,M.&(R82TS8C,T.#,R-C0X-&$\+WAM<$U-.DEN
M<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/F%D;V)E.F1O
M8VED.G!H;W1O<VAO<#IC8S<X-&%D9BTU-F1D+6,W-#,M83EC."UD,6$R,#5C
M9#,W,F0\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG
M:6YA;$1O8W5M96YT240^>&UP+F1I9#IC.38Q,S=D,BUE,V8W+30X-F$M8C0V
M,"TU.6$P9F4T,64X.# \+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @
M(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.F,Y-C$S-V0R+64S9C<M-#@V82UB-#8P+34Y83!F930Q93@X
M,#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C R,2TP,2TQ,E0Q.#HR-#HP,RTP-CHP,#PO<W1%=G0Z=VAE;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@
M4&AO=&]S:&]P(#(R+C$@*$UA8VEN=&]S:"D\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E
M<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@
M:6UA9V4O:G!E9SPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#II;G-T86YC94E$/GAM<"YI:60Z,F1D-3=E964M,39B,2TT9#1B+6)C-3 M
M9#DP-6-A-64V9C4S/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 Q+3$R5#$X.C(T.C S+3 V.C P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N,2 H36%C:6YT;W-H*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z-V1C93$Y-&(M.#DX-BUE-S0S+6(T,34M8S@Y-6%F-38Y
M93<U/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(R+3 V+3(T5#$P.C,V.C$T*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @,C(N-2 H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O
M;2!I;6%G92]J<&5G('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H
M;W \+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A
M;65T97)S/F-O;G9E<G1E9"!F<F]M(&EM86=E+VIP96<@=&\@87!P;&EC871I
M;VXO=FYD+F%D;V)E+G!H;W1O<VAO<#PO<W1%=G0Z<&%R86UE=&5R<SX*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-38W868U.3<M-3=B
M-2TQ9#1D+6$P8S4M9&(W8S-B,61B-S1F/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(R+3 V+3(T5#$P.C,V
M.C$T*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N-2 H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F0R8V,T9&8T+39E9#4M-S8T,"UB938S
M+6)A83EC,S-C.#!D8CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.G=H96X^,C R,BTP-BTR-%0Q,#HS-CHR,2LP-3HS,#PO
M<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@4&AO=&]S:&]P(#(R+C4@*%=I;F1O=W,I/"]S=$5V=#IS
M;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E
M9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A
M;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T
M;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V
M;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M
M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.CAA
M-F8U939D+3)A8F0M-3(T8RTX8C)A+3-B,S0X,S(V-#@T83PO<W1%=G0Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTP
M-BTR-%0Q,#HS-CHR,2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(R
M+C4@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@
M(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I
M=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z9#)C8S1D9C0M-F5D-2TW-C0P
M+6)E-C,M8F%A.6,S,V,X,&1B/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @
M(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C4V-V%F-3DW+34W8C4M
M,60T9"UA,&,U+61B-V,S8C%D8C<T9CPO<W12968Z9&]C=6UE;G1)1#X*(" @
M(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.F,Y
M-C$S-V0R+64S9C<M-#@V82UB-#8P+34Y83!F930Q93@X,#PO<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M
M/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*
M(" @(" @(" @/'!H;W1O<VAO<#I,96=A8WE)4%1#1&EG97-T/D4X1C$U0T8S
M,D9#,3$X03%!,C="-C=!1$,U-C1$-4)!/"]P:&]T;W-H;W Z3&5G86-Y25!4
M0T1I9V5S=#X*(" @(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO
M=&]S:&]P.D-O;&]R36]D93X*(" @(" @(" @/'!H;W1O<VAO<#I)0T-0<F]F
M:6QE/G-21T(@245#-C$Y-C8M,BXQ/"]P:&]T;W-H;W Z24-#4')O9FEL93X*
M(" @(" @(" @/'!H;W1O<VAO<#I(:7-T;W)Y/C(P,C$M,#$M,3)4,3<Z,SDZ
M-#0M,#8Z,# F(W@Y.T9I;&4@1$U65"!3,2!2;W5N9" R($EM86=E<R!T;R!#
M;VYV97)T('1O($AI9V@@4F5S7T)(=C%?,2XQ,BXR,#(Q+3$Y+G!D9B!O<&5N
M960F(WA!.S(P,C$M,#$M,3)4,3@Z,C0Z,#,M,#8Z,# F(W@Y.T9I;&4@4&%G
M95\Q.2YJ<&<@<V%V960F(WA!.SPO<&AO=&]S:&]P.DAI<W1O<GD^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@
M96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$!_\  $0@!(0)= P$1  (1 0,1 ?_$ !\  0 !!0$! 0$!
M           & 00%!P@" PD*"__$ ' 0   &  ,"!P@)"PX)" D$ P$" P0%
M!@ '$2$Q"!,4%4%15!(687&1E-/4"20T4E-5@9*3(B,E,S5$8Y6AL=$*%QDR
M0T5D='5VM<'5\#96<X27I;;A\29"@Y:CI+.W&'*%M,/$Q=+C.$9EAEAB@O_$
M !P! 0$! 0$! 0$!           ! @,$!08'"/_$ %<1  $" P0'! 8( @<$
M!@D%  $  @,$$1(A,5$%06&1H='P$W&!L084(E+!X0<5%C)38I+Q(T(7)#1R
M@I2R,Y.BPC5#1%2STR4V<W1UA+2UTC=58V7#_]H # ,!  (1 Q$ /P#^_C!$
MP1,$3!$P1,$3!$P1,$3!$P1,$3!$P1,$3!$P1,$3!$P1,$3!%\UCBFDJH&\B
M9SAXRE$P?FP4-P)R!7\?6??LZUNR;X0EXRY)2KE*)9+<(S-PRZB=U108VIHF
MWO\ 1$*^Z:*L5^)K\8O.M;!%L%Q?-FK^!B^*:(KI(NVW]6DO14Z0T8([(DE!
M&D]!:,E65DPY\K$@S$A.OG8;@6UF9ALL^6C/]EYA3,4&(X$M=_/)OTEA2,^^
M ^%.172.E)R.ZDP&LC-B09F7$NX&I$&&8S8S&FH#X3*-&(YW;>S\WIO5H^N#
M7,QEEV.2LOE(:</?2<Y.I.4;1C=/,==0S<ZQK6P-'G6:NCN5) BCQP*<PB)C
MBI]=_HJ7SD2: T8UL33\#3?JXD6]DR#!=%<[10%0WU**(@:]@8(=&-K!-U/F
MM])H39=L"FD'%NBHNC.T=->T7Q T>O$VB[UEA;[+K5H5-(@4FE_U0S<I-[*.
MTJ!=V)9%]E*\3;-[VW*BQ)EC<4[5(-6Y21Z102OC8IJ[90(1(KF+.*;XDJ@'
M)!\D#T,?!9!88\A$[*%IN&7/D!:BG2\B9.$]_MGVM&N(F92\V8HJSL3[2]$7
MTM@O=%<(,\VV_1CP!,BC!HZ:;,/8VEUF=:#!F,+3'&U;H&KPT_5"US:SD5,&
MH=X<)1N9=GS /&*WMN+-\QL5,G:HC3G)#1YTS0,,[F4;''H'14:)2L6S41CV
MRQ2.T:_T->^6C0!&D&NBZ)D]&",V1 ?#B2L_+SKI]GMU$S,0X+I2*ZT'&#%?
M:B.!+29Z6P&1F13 G7AD_,3G9NF18<R/*Q)<2QU=E"?$$=C:$![&@- O6(9_
MJ@*[-8*%A3U+,)PK$Y4W'+5645OJ8O)&0M:M:5;7ET<S0ZAK'7^8'!(QP==5
MXD29?@A)M ,H5?M$]$G/F8\P':-8(VF9'2K8+9!O9PH4FV::_1[!:']6F?6&
M&,*!A,!A,)Q-6\V>E4!D*%"[.?=V>CIF0+S,BT]TP8)$VZ__ &T'LG"&:DTB
M.]L4H<G)?JA.YO\ G8$Z+>F02:N5:B?)[XB46!,MK(WGWR;82,4Q*6[H(FAK
M$*?$BYCU3)O><TM6X\X/H<Z%V!,60B=BW3(=:D6D13I65=+0B^KG5^KW.$>5
M!+@V(VK.S)M+43TL@/$4"#/-[4Z.((F0##$A&;%>&4I_:V@PXQN):XU+Q<O3
M?]4*W1"6A9,:->54XC-*SYCJL%+TW%M(Q]BI=LJ:-(=%,P.F>O0SNS-[''H*
M(K,TI6"C5$(QJNFB[:Q_H:Y\"/![60:Z-H>3T4V*)$!\*+*Z0DIUVD&$/!]:
MCPY1\I%<'->Z%,1;41[26/K?2R"V+"BB%/'L](QY\PS,@M>R/)S$KZHZM08$
M)\9LPQI%D183"UC2+0Q2?ZH"NY(6.B!J>81U&&76:%#4DC7U/E;MYF+)5B08
M6Y<XM14-.4DE><,Z\X.LH\00FI K.0C2*+).>Q]$W&8C1ZZ- BZ5T1I)L(2#
M;$.'HN%.0HLBT5 ]7T@9ID2:: UA?+PBZ'%(#F\F^E,)L*%#+)]W9R&D)(O,
MU[3W3T26B,F34FL:4$!S(#G%S@V,\![ 2'927_5"ESE'<FY3HEZ8$D4<H$B-
MVU\0*FR'*ZZOK;)'; 2/2 A[^T>$K5F$A4A<Q+5$CX91$ :$XP/0Y\%D!IC2
M$0P7:<<7.D16)];R$.3@AU7.!&C'L,U*6K0$9QL"%]Y=(OI9 BF*>QGF=H-&
M#V9H"Q]7S)F(A;2E#.-=V$>EFK ";52%Z3_5"MT3F6<L-%O)TVN:DEF0>.->
MV_)7#!_0):DIT=0HQXI][C-Y)I6M!L*)F034>V5+&)N>Y?)1WH:]T!\'MI %
M^AH6BA%$B+;(D+24&?.D1[1)FHD.$Z3<ZT']A%<.UH+!T/2V!VC(A@3ILZ0B
M3]@S+;):^5B2PE#=_L&N>(X;2G:,;[-Y*LT/U05=44&B(TV_*"UJ6;58,H>]
MHF,NYS.LU>L,?/JB9F(C)4-"#7A:TH8QUFT?+/4V+J*1.JV<='>A[G.B.[31
MX#Y[0DY9$B*-9HF4FI:+*M]JZ#I%TPV/-@4#HL&&7LBD-<S ]*H #!V<\;$K
MI*6J9D$N=I&8EX[([J&^))B 84#^9K(K[+F5<#60_5!EU?(2B)*9?6@R,7E1
M')J(7Q(IV*F6EE>3[]ZV$K-,Q5[T@Z)#642&2.Y8-DDWRLHEH@5"]$##=!<7
MZ.?V4;344M=(MI$;I:59+0H;JD^QHYS#'E,;$1[C#[(T<H_TJ@O;%;V<^WM(
M>C6!PFJN8='QG17.::B^;:1#CX6FCVK=ZNP_5"US":6EN\2\BDKFHEF26.&]
MH<D28IY>MJ,:CE)S?Q?>XH\0-;!;<2#$)Q8Z_-8N=7QN?V-?V @]M( C0KM%
M=IZB+9BG23I\:1K;KZT(;A)VK5LP&T[6AL+?VM@]IVG8SH_])#2 ;ZR+-CU,
M2OJ9%*=A:K,4(LB)0AEH!PLD_P!4%70D>R8]YE^,HSJ.:U7,[&^HBLX<9E3<
M%,1\^J(LA,:3HR4.O&UQ0ZAUV[25>$9NXQ,3I+=#Z(.,6)$MZ. ?/:&G!#$B
M UC-%2\Q BRS3;NA:1,=L6:  :7P6%S(IHX9'I7!#&,$*>]F6TC+E_K0+G&>
MB08C(SCB8DH(19 ))-F(:.8!1U9?]4%764"P@G3+\PY]J&5U61Y-?$B<TKY=
M62TS[^>8\6S2[B3NZ%C;0UA62Y.Y7CX./(\>221$6[9!]$'0C*VGZ.B>KSVF
M)QUN1;_';I64DY:%+1*DU@Z/?*OF)5IM,$28BV60[W/D3TJ@O[>D.?;VTIHZ
M6%)J^$9"/-1WQF&H/:3@F&PH[O9<60&5<^X-O3?JA:Z#874Z%$O ).,UFF91
M8D+VWY"C'M<IHW+,U%33"/!$*XXD&"E\50!N5F-E>KN#19WHFE%,#T-<)5LM
MVT@7-T-$T48WJ/\ $=%?IJ+I8:1)M5]:9"B-T<'6K7JL-K1%#?X0U]K(/;NC
M=E/4.DF:0$/UKV&L9HV'H_U("X>KN>QTX019[=Y-@N <ODS_ %0C<VIFAC4:
M]N :P^<,48%;XB8'"F:=PA;5&2"O=,3ZNLOFT4M7JP<PG5;Q<FZ39+12(F:J
MV)Z'.B=I2+H]EN/H.,+,@WV1HB1CR<:$VC@+&DWQFS4V+@Z-":7MBUM STL@
M-L5@SSK$+2<*IFA5_P!83,.8AO)H?:DFPW0(!J2&1'6;-*'&OOU0%=GD?.L2
MU+,)L>9RTR\R^2=HWU(J\8^HTI;)%Y<F8D:)F3G[8G9FS*;7241=K-X",*ZD
M'Y"))MNL/T2<R++Q2=&O$#2VE-).8Z1!;%A:1@R<*'(/!<1ZO)&4?$EP0YH?
M,12V'#Q.'>E,%S(S.SGVB+(R4G:;,BTQ\I$F'NF6FZD69$9K(M]2V"P%SA<,
MT;]4,W,9B4E0H-W!.1S2BLQTX_OZ;"U8L8V@5^DGI#<O-P)EKKU["+6MPW(B
MFR--2SU52,5<'4?+^<>ACQ @P>WD"86AXVBC%]1%N)%BZ3F=(#2+O;KZU#AQ
MVR3#4N$"##I% ]@=3Z70#%B1# G:/TA#G@P3(#6-AR<&4]4;_P#P.=",PX4H
M8KW58?O'Q%_JA:Z1R\0LI1;R^"+8YH,U$G%Z;F(_/F-:&%B8N70'8*@=6E-V
M1X2O"H"IF\>[739'C$3&;'U&]#716QP(LA#[:)H=X+9$5A#14I$EHK&$.!#=
M(.B"8F@" Z(QI>(I]I1GI9!88),&>>(3-(L]J8'\0ST=D9KGX@F4:WLX%:T:
MXT+* *.G]GYO)X12'[V\QP5/E?E_ET$D%_+RLC^D2,F_=W8#@W!0;#:RR"32
M;<<<#U=!DW*ZDWY *F3TCT5I,"/31A'UQI+2A@^H-##"GX4.'#T?2M!+2=AS
MY=H%AKGN+84,WGA]IH78B%9T@"-'2<AV@FJOMRKW/=-DDU,>/:#8A))(%"]P
MN,F4_5#5R//2,R% NQ$7^9T3F&2++>FW)&;*,RYAJ&I3$"A' F%??OHE6XN6
MY4$V9IZ1=K'C57)E)!;R#T+>):# ,>1+H6B(^BS&]1%N)%C:4F-(B?=[=?68
M<*.V18XN+Q A, B  0V^G[703&B1>PG:1-(0IX0_66EK&PI&#)F5:"*" ]\)
MTTX  &-$=[)O<?<3^J'+A&/X)X?+VZOB0TEFF_5:N;VW.C)IYD6QW96#-V!X
MY4ID*0U<D@*Z"J:Y6\:@F1FG&I:-BR-Z%OC0YF&)B1AF/!T/":YDB+4$Z*DV
M2L6)#]L$.T@]AF)JA%J(XVS$-7%#]+X#'07&7G7]C$T@\ATT"(@GIA\=C7W7
MB4:X0H&-&M!%DT AZ'L^=Z1JKFMFKV9*B[C)FB93A.'OY1D4I*FC.B\S$34X
M@5BVJT<])#+NRN2OU!BV7'RST")@C[CZ+UG&35G188S3VD-,^K^H-,)T&>$O
MV>BW5-#)RG8.[%I:8?\ %?2"PU)\Q])H1EW0::1!.BY31PBB:%L1)8Q2Z=U?
MUB/V@MFH-& 6SJERGZH;N:DK.2(4&[$3F,SJ[F(BR+>6W)XQC!4^IU9>F-"!
M'@0M?EW%9<V!\W3319&E)^255C7"YUG;KQ#T+>(,M"[>1)@:(FM%NB&1%N-$
MF9^>G6Z0?[7]J@-FV2L-Q+GB#*P@(C6T8ST'TM@F+&B=C.@1M(P)\,$S=#9!
ME):5,HV__8172[H[VW-[6/$-@GVC\H_]4+7-D[@'1Z)>71(2TYJ6-5NM>VXI
MRK?,F=L<RQ@WO=,#@>/HR,\A%ULBI5TFS.'8D9-HM,B2+>Q/0UT1DTP1I!AF
M)/0TJUS9$5@OT3+RD"+,0Z. $32+I9T::I0OB1XAB/C$ESHSTL@M=!)@SSNQ
MF-)1R#,_[1ND(TQ%;!??>R3$=L.7K4-9!AAC80 #=N07LN^9$UE_"-B*7Y%2
M1R-HF7W.9[6922)(0J)GJ]Z.N58BA[1-@\*E*/06!ZMQ)!6DW)0*4O[[1'T3
M/TM"@Z8;.Z)@0X^G=*Z6;)'1':PX<*)'B2S=&V_6&!\I ,"W!;V88VT0(334
MG\QI'Z0X<@^)H[U*?BF'HR2D?61I(,>]S(;(QF[(EW68\0/LQ"'FM/OD&@V(
M[]F-S!=/YYZ$/:4"S685-O*35.RI@C%LJI&5&.<U)F4I"$+"V%2L.GLJBF1%
MJLO8),7#%X8ZIW/2']!4PR'+0SI[1KNPT9/Z/<\Z$<718D[&G8K9U_\ 723,
M2K9MD."27%K9:%9B,%S>;_I6@NB1GC1$XT19V5FPP:5%(;99DNQTNS^J70HY
M@N=%H!4QG@M-*GXQ/LP^849,PDJI&VM\E#VK,RR*Q[FR%.VDF^8,O(R;&#=E
M4*JF:.IJ3]-A )J(KH(-F: -6T<4"IDU&^@N/&EYB -.:-ANCR>B)1L9NA7"
M)!=HR##A19B&1. B+/F&8DR06N<][K3H@O,A?2M"AQH,7ZIG'B%,S\P8;M*"
MQ$;./>YD%P]4([.5#PV""" &BC6G"(M?98,RVU--51>7]9T;(VL9.]\2EJ5&
M5"5KS24;+YF@J9R=<+=-'DB.)%V#OG)55BVX^9==R0R?M?\ 0O%=/^NC2>B&
ML'I#-Z<$J-!CLNPFGPG-T01ZR&F2@"$6PFV.S B/+8+"37RCZ3F"5]6^K](%
M_P!42^BS'.E?XABP \&?J98N]9BE]7FU4T <]P4TE/9C<P9%[//$X>U,2S5V
MR^MR+9O94RI1;:CNJPX>5QF4A$B$B+82O.&\T@D1!LLG-2'*F;X#JE<^"#]!
M4Q"ARS':=T=%,OH_2<BYS]"FL9^D&3;8<T\^ND]O)&::Z ZI</5X8:]@I9]<
M3Z5H,2)&>-$3C!%FY*:#6Z5%(8DW02Z"W^J?[*8$(B*V@:>T<2UU]?C'>S#Y
MA,)&NOSQ=L=D@;UF1<5FB]E(9"6:7YU:G#*LOBG*H12'IY+(V0@D5DW#=!."
MCN2,V $2*VU%^@N8BPIJ&-.Z-AF9T=HJ1:]NA'6X#]&MDVQ)N&1. B//&5>^
M9(+7.,Q%M/B8.,^E:"R)">=#SCA"FYZ9+7:5%E[9PQRV ZLF?X<L(S6PKB (
M32&MJ5%$?98LRTJ6G4A=7U1R3()KDH-C/:5!EC2[:(/&'S3,J+DS@;FY5.$@
MH\Y6,F#H@&&<,;ZZ'M=]"T0SYG!I/1 AGTE?I_U7ZD'8B7?&$4:&']: ]08T
M&$&%G9V3? N 7E'TG0Q*>K?5^D+7U*W1(C_6Q[3M6PC#=I&OJU?6G.(B%UJV
M'"Z+>IG,>S&Y@2DI,R24/:8\DM:<N[&DR:V4A6\<WHLI'2+R#;$(1),(ZV)L
M56,XFFDBBNW>KE=MI FJ9_! ^@F/!@P(1T]HV*8,GI65,1^A76XC](PHL*',
M/)G"3$DC$;$EB22UT-I:^&;QZHOTKP8D6)$&B)R&(DS(QPQNE:-8V3>Q[H+0
M)0#LYD,+(PI1S7FH=0!6T5[,-F'&S4++*QML?I1-WOUO5CG%E(+61:W9*43:
MUIV4X*IGB:N:234AD3I*MD!8-0:,V/<DXOI&^@N-%EX\$:<T9#=&T?HV1$5F
MA'!\-^CS"<^;81.@B-.]E9F#4.=VCR]\19A?2K"AQF13HF=B!DW.S79NTK[+
MFS8B!L!W]4([.7M@PJ#V2P!H:+E'$/9:,R4::PJAE;VJY99&2.3A[$>T'YU=
MRK^+C8Y/,U945S+C;V:T>H_0=F=GD0</7 EF2&$RA_0[Z%(IGGS@TKHEK'^D
M4+3OJHT(>Q9 AQHL4Z( ];IZB]L40W,#+%F&W^"0:#BWZ4(8E1+_ %;/EPT0
M_1?;'2HMF(^&U@GS_5:^LM+2\&U6KJ6Q0%2>8]F*S!E7,ZX3B;7'EF;7EE94
MD6ME(5.-;9>SE=F'T"T @)%)'7-&"7C)\B14$G#28?%>-I$AE$5_) ^@J/!9
M+-.G-&Q3+R6EY1Q?H1Q,9^DY>:@0IF)6<-8L@Z8;&EJEQ:^ RPZ$:.;Z(OTK
MPHCHI&B)Q@BS&CXX#=*BC&R,6!$?!;_5  R:$%S(UPJV*ZH=0 _"/]F$S$8R
M=?D#Q]M=)P>8E[O:S-:RE,A+,[HRM;1I4GQ3]VF>$JYK*@YAT%4EVB"L%&BU
M8,C)H*-M1?H,CQ(,S"&F]&,=,:+T;HYL1NA7!T%\C$DXD2=ATG 1,3?JKF1W
M5#W"8BVHD0%P?B']*D*'%A1#HJ=>(4].3A8[2H(>V;9'8V7=64(,*7[8&$""
MT&&TAC30MP!O9:<R35%E5Q5O7*&F3=URI-/A:5 DG,G;6\"BUS#65!;E!K37
M#PRJT4Z.[._24DWO)Y9GQJHK^K^A2*)Y\X-*Z)L/T[H_3/JWU)_!;!DG3!?H
ML#UJ@DYGU@",UK!#(A0[4%Y L\1])[!*MEOJZ?+FZ+G-'=M]:D/,2;$&S/$^
MK$F8ES")A&I<.T<&Q&@FLGF_9BLP9>3F9!.*M4<G+3N5<PDS:64A&\<CEO:6
MMCD(QJ5,B)",[PW;F@K"1-)%->.64(\1DDA% WC@?05'@P9>$=.Z-BN@2VF8
M#HC]"NM17:5E'RL*,^LZ3VFCWO\ 6):I=2(!9="(JO3%^E:%$B1GC1$XP18V
MCHH8W2HLL$C,-C1(;:2@HV;:WLH]* M))#B2#\&GLPN8;:5A9(T;;5TXC,ZU
M9B*L5;*0S>28V2K6NMH4MV4P&3- 0;BRMIV.;J)+,TY&!C3HQS98B3AK7_07
M'?!F(0TWHUIC:(D]&-B-T*ZW"BRLY)S3Y]A]=KZS,,E7R\4U#C#F(E8CA[+C
M?I6@MB0HAT3..$.?F)TL.E19B,CR\> V5=23_P!C!,9L6&*4#X3*-%Y6(_9<
M<Q^8B0P%NX*DRTO>7P27?./*Q?71Y&.VMR,85!4&?K!8XZ$.X%87B*3UP5K(
M,BG.13T'Z$HQF#'^M]%4.EM':2[+ZD-@0Y"'%8^1IZW3U:<,4.CMI8+H;2Z&
M^C2./]*,/LQ#^K)ZHT?.20?]:U=;FG0W-FC65OBR]@B%?4!Q >V^N5E_9@\Q
M)129.E'VZ."5F\II=(K:S  1R665IB+'(1K42BGW+2]MHM2"LA2 DFYCW[DK
M]&52.HV5XP/H-CP1 #M-:,B]C+Z;@.MZ$/\ %=I>4CRL**_^N&L31KHPF)4W
MEL2$SLW02 YNHOTIPHG:@:*G6=I&T7%%-*WL&CIB#'B0VGU4&S.MA=C,"X%D
M1]L1*D&J'LPF8B,S'RIH^VJ),<UIG,H\>>R%%J[CY:@6"E)T9<F@IFKD>\FT
M;4U;'148DFHIDLE%HN2)/V\=]!D=TO%@C3>C&NBZ%@:)$4:%-N'%@:2E9\Z1
M:3.5$U%AR[I-SFN#S C1 Z*YI,-VA]*L(1847ZJG2(>DHL^6'2OLQ(<62F)0
M2;AZJ08#'QQ,M:06B+"80QI <W$J>RX9C'KC2" MV*NURMS#RY&7"SFY<N_O
M2]<69790_& J-BJ(03A.$<F<&>(DF'P-I)B!E"K]Q]",;UI\P=+Z*LOTQHO2
M@@?4A$-D+1S9IL31X_K9'JL]ZPPQVAH96 RU#?<1S_I2A=@V#]63U6Z/G9$Q
M#I7VG/FS!+)L_P!5KVTOV3A")<32(ZCF@4.4GO9@<PIIU87",?;XLDX;*D44
M&=F J<27+2W+6=^5D"8H 0+RV5"OV0R14#.8Q,B;WG)$ :AQEOH-CR[95KM-
MZ,C&7^N;3GZ$-8YTK)-E(7:?UPU^KWM]9E0:AD5QL"&?:.XOTJ0HCI@C14ZP
M1VZ-: W2H_A"0F'1WV#ZH+YMKNRCFXEH%2\4"])^S"YB$L+6=&/MQD6V:K_,
MD\2-E)R%PP>Y5266Q*.HF("EWN-9"03O2+8R!V06-F@X)&)O2DDTH[Z#(YE7
MR_UWHRT_0T+10C?4I[1D6'IF%I4Z1!]<M>M/A0W:.<\.#_58CF]I8K"-_I5A
M=NR-]53E&:2B:0,/ZT%A['Z-BR E'#U2G8-B1!.!M"WMF-HP&CQ8$]EWS%)'
MHL11NAE$Z/F;3C/!LX@LHZS"G8698V8P]V)@EZ8E$KQD MQ@ND&DF[(T>1R8
MF05ZGZ$(QBNB_7&B@#I'1$\(?U)[(AZ,EYB!%E/[70P)]T9L69:19<^$PN9$
MO(PWZ4H0AB']5SQ(DY^4+SI6KBZ<C0HK)BIE21%EA#=#A&M0V(ZCFT 7N7]E
MZS&E!GS)M[G'C-US*Z"2!M9^Y+%.,N;+.S[Z79 F9+BWMU0F48>PF1XA1RPB
MV9'J\FD4C9&0/H/C03*UTSHN)ZO-Z8F76]"$]NS2DI+2T*!$K-DF'(.@/CRM
M2ZS$C/+!"(MN1/I2A/[?_P!%SK3&E]'P&ENE:&$Z1C1HKHK/ZI0/FA%;#CT
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M,;*[?^6=T_'1/ZF8?DTP]49[S]EXXW7[,D[=^3=QYKR>*DU"&(>Y7,2F*)3
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M$"T0R'#:Z(]P:"2&M-&@GN1?0CT7@0W18XBP83!5\6-/.APVBH%71'EK&BI
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MLL-O-EM2:DT%2<R::OBI4D 5-!<!4TIE3(ZQ@5BY+)?)R9;J,Y?*3+&5:*P
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M=2X5+020#> 3> ;P#0K;./*NZ8(F*.^G-$Q.KK]75<N"*WHO^#ZO\Z+_ /\
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M759/DSUD^<QK"6?+-XI_&2ZGV*F8=X_HG9BM1'BU:+0H\W<<<+^-RAD98?\
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M..-V=?R)^DP10JK#W4Q>!$HEUL:7U)M.Z#[#1N_01#R"."+[5;[MWG^<#?\
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M\E$.+97TF4'8JES#5@C['FWDM#960E17DJ]'/GKRT99S>:ALRVRTC+R]/LB
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MYV?:CN]R^J[_ -.W30<+ U5WCD4MG(<>:]<KD]/NL_\ !H+0?D]S;1T\(#U
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M1QNVZ?N8[=NS8.FS?A:V.W=8)3:-XZ^'C<J@\('[BZTT ?<CC=TC]K'8([_
M&F%K\KMR4[MXYJG+$O@G8?YHN(=6N@ICM$/ZM==-<+7Y7;DIW;QS44I;DA($
MH<4X$>>+.;4C=8Y?JK/,' .Z*F8/J0$ ,7>4P&*;00$,1KKL"<<!=C55P-?
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M:VBIN%IF;@RB>;AHE)$QSR,K#$ 3RL<S*J[CBZF=HHE#7"H/\W^GDE"/Y?\
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MC"2CY&.92S-RW/'&*M&R*(.63P$S,BJ)H.D# JB94B?=E 1T 0$"@0;PX_\
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MJN\7M]<X3U5?SJ[K];0%@F&<7PL,PS1HHBC&HO(6F.7,:[-&2@32C?>.[O\
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M6R141)3S5_#.V[ES%/E9&#@I&.C4[$#-VVJ:<H[9+6^1:N(JL)2TF@JT*1;
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MX(G+$O>.O,7OJ^")RQ+WCKS%[ZO@BTG?\GX>]/+S(FG)>,<9@4JF4"?9.*K
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M742Z:S.89Z4>6C+"Y8)P;9UGGF'EO!B$*XKKF:L%E<5.$K=FD(B)%P M''?
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M_-*$ZC<J<:'P;D=N@>U'0:AIIH BCMTW!IKTZZAIJM-S\T+2-7?KIWTP3C0
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MAKJ/N-T'1L#[3L'P=&O3KA:;GYI9.776M5%4 T^M.M?XH[WZ[-H(AT!L#0-
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M1\5+-C.DF[E11J=>*G(6223<%34482T:\*06[UNHH4\2;]F[#YJ2=PX^')]
M'I,$\3PY*G%N.T%^@#TF"J<6XT]T%\?$!Y/MF":\?#XIQ;CM!?H ])@B<6X[
M07Z /28(G%N.T%^@#_[\$3BW':"_0!_]^")Q;CM!?H ])@B<6X[07Q\0'I-/
MR8)X^%W*O%5[AQ\.3I_< ])T?\=<%/$\.6O7PHJ<6X[07Z /28*IQ;CM!?H
M\OVS_=X,$\?+=A\]JKW#CX<GT >DP4\3PY*G%N.T%^@#TF"JAM"(L-;()%@*
M7GNV!H*0&'4+9-@8=1.&\=1 --@" ;=-1(.^JF?<./AR?0?_ ),%*;3PY*G%
MN.T%^@#TF"JKW#C9]?+]"&WP?;/ZL%,[_*[;T53BW':"^+B ])K^7!7Q\;N5
M."C$K<JQ!3]?JTS;H&,LMJ*]/6H!\\9MI>=)&F:DD#Q4>HX*Z>ILCOF1'2B"
M9R('=MRJ&*99,#$6*;6++R'L;F#:62FQ=KM]N=1SF*1<Q32<LMWBZ/'3KYH9
MD5R1Y+6&.R\C(F4>)@FN]:5=@Q<K@FP02,5\4\?+EU7N5HYNN6<U9E*@ZM],
ME+75+!%$<5]5Y&.Y2O6=Y&E?PB;IB+@ZD;,.(V21=1:;@B3I0CYHLT**CEJ8
MY%L?BW':"_0!Z3^^OBT)X^7+JG?6O<./AR?0!Z3!3Q/#DG<.-GM@OT ;?^T_
MOM\&A,[_ )=<MM:<6X[07Z /2='_ !UP5\?+EK_:B<6X[07Z /28)X^7)6,<
MFXY.I[8+[OE/W$/C-YK_ ,_I'R8(K[BW':"_0!Z3!$XMQV@OT ;/^T_/K@GC
MY7\/*B<6X[07Z /28(J]PX^')] 'I,%/$\.2B\W<JO6I:OP-AM]?A)JUN%FM
M9BI1\R8OYYPW78M5D8IJY=)K/3)NY2+9&X@A_;LI&,@'E4@S27*^/EOP^6Q8
M%6XY:5JSN(-:W4J$MMKL*+1W&'>Q3"9GK0C"U5H@BZ;"Y3</9I.!E*,Q3XXI
MW?(96HL0$22,(BN1'UURQF9QW3I"X4B2L%9FZXH_KCE_%.Y&%L#A]&N*L9Y&
MG='592AI-]!K0_'I$<)R3^$.V[AX]C15*4.9X<EL;N''PY/H/R_;/]W@P2FT
M\-V'SVIW#CX<GT'_ .3!*;3PY*G%N.T%^@#TF"J<6X[07Z .K?\ ;/EP3QZK
MA\$XMQV@OT >DP10N@%6&#?B54I0[]<R@$!2UU,&8UJ QM>[#3NA 3 &WN0'
M34=-1*'#&FV[KR4TXMQV@OT ?_?@JG%N.T%\7$!Z37\N">/C=RIP5>X<?#D^
M@_\ R8*4VGAR5.+<=H+X^(#TFGY,%?'PNY5XJ'6O,"F45>$;7.[UJJKV61;1
M%?2GI!E%FF95X_CXIG'1H/'27*WKN3EHN/;-D1,LN]D&;5(AUG"1#E*;3PY=
M5[EAY.\97T^RK,):Z4>MVJRR,7'N&CV0B(R6F94R47'Q#=RFJZ27=OQ2F*_'
M-.. R_<S%=8%'[)PZ+@JO<Q<\LI"8>4F=M])>SD))5AZ_K$B^BEY"-ECSM;7
MJ;AU%K.C*MGZ=BF*<XB3*HE6;RDS5UTN+7E8@[@IXGAR6QN+<=H+] 'I,%57
MN''PY/H-W_:?GUP4IM/"_AY45.+<=H+] 'I,%57N''PY/H ])@IXGAR5.+<=
MH+] '_WX*JPCB..)6T7*'M^2U^L@.H\O<ZC^WZ>KHP17_%N.T%^@#TF")Q;C
MM!?H ])@BKW#CX<GT >DP4\3PY)W#CX<GT'_ .3!*;3PY*+6&ZU6HO(&/M-Q
MKE=?6B03BJZSFI!C&N)R26=,F"+*,1=NTE'CA20DXN/330 PGD)2,8%U=R+)
M%<E-IX<M?[+ R=URRJ%E.QE[C2:[:[/(PD0HV?/XF,EIN6<%;,8!BJFLZ16>
M2*H24:P8)' [@PR<*R( C(Q2*Y54G+GEB^EW=(L-OI#N;AY"K2+VKR;Z)6?Q
M\IWQUA6HNG$6NY,L@^2M$Q2UHHYTBKMY29JRZ?%K2L2=P1;'XMQV@OT >DP3
MQ\N2KW#CX<GT'_Y,%*;3PY*G%N.T%^@#TF"OCY<E7N''PY/H/R_;/]W@P4IM
M/#=A\]JIQ;CM!?%Q >DU_+@KX^-W*G!0NK 8)B\ 80,;OC2U$ [D!^PT;T:C
MIY1P0=]>MBK6ED4IR\@HJF01GVX@!SE*(AS/'[0U'!!N4SY6U[0C](3]."+C
MR<X-]CEXJ;J7ZZ=-<9?GN5BO-:IMBRF;V-HI+6S-=OFS-QN9KQ>]M#Y@UE*5
M/,1<1"PZ&7X QD63RS.[7+PC&0$BUB7@$5QK$Q*;#,IHI:8LE1UNM@H<18YN
M2=4IYD0O7I*5%Y-I!(R$(AD[.!7SO%5VL,^S'F7B;-PW;R,?8R*'-O8Z&1*?
M::?(9I4698VN!MT*4DMDLA)1]&/9:^XCQ?Y514CF4\0H2DG./'4O?$&BKY.X
M1Q6,%'&J1F"4L8BW'GQP0&>>%L5LRV8D/6A6A"Q_'-Z0+^SME4J1=Z4: 86M
M*Y13ICE7+I7)63M.72#$JLZ[1?@G:HTTN==F10T/8_LOG--[VIBSP4G)ECYE
MDTGEZ8+P\,#^F7NN0[: 3G[=/R\7"TR=O![7388;"Z3KCF%BF44Y:':,Y!D1
M8V6X $2^MTC/-,R:HT@@>R:]9J2N4T>I'P$,OF3'YGPM)=FC;I#LY^C5Z?AX
MSFZ$=Q;9VT3263AY:&9\WLHPBBSKV-N.%DBVC\Y(ILX:K4E\U?/LLRR1B3E0
MR?H65![(_COUP6<)8YAWWC]\C)&UQ<] ,W4J9I*P5B/'MI Q%^IG*VO:$?I"
M?IP1.5M>T(_2$_3@B<K:]H1^D)^G!$Y6U[0C](3].")RMKVA'Z0GZ<$3E;7M
M"/TA/TX(G*VO:$?I"?IP1.5M>T(_2$_3@B<K:]H1^D)^G!$Y6U[0C](3].")
MRMKVA'Z0GZ<$3E;7M"/TA/TX(G*VO:$?I"?IP1.5M>T(_2$_3@BAE!<MRUL@
M&72*//=M'03E =#6V;,4=!'<)1 0ZP$!#!%,^5M>T(_2$_3@B<K:]H1^D)^G
M!$Y6U[0C](3].")RMKVA'Z0GZ<$6A<P<GDKOF?0,QFUJB()2G&C =G3KIW5P
M79Q,^E80BJQ<V]DC"UB)LYTU("_QS^OVIO:*HX7B&A8%PJI)G(L'%Y)@2>K,
MX]EH)O)9<YZ9MYJ5*;!@24DIR'S9J>8K)U S"AUXYU$(PLYF@X0!NS?/T)2)
MH-<,<62TB!80BALAP<)=2]2=P;W2L@2RW6A62;9P5:=U-1X>KYBY>9ER<S;G
M0VNPMKO--'.7!:CETJG$UIS3:Y=+"WE']I4.=VH1=D<K:]H1^D)^G!$Y6U[0
MC](3].")RMKVA'Z0GZ<$3E;7M"/TA/TX(G*VO:$?I"?IP16$<Z; W4U<(A[?
ME!VJ%W#)O! =_2&T/!@BO^5M>T(_2$_3@B<K:]H1^D)^G!$Y6U[0C](3].")
MRMKVA'Z0GZ<$6A<SLG4LQ+O2;8C<6T&SKYH5*QQ)H<9-S8(^LYD47-2 0B)8
MLY&EK+M&ST-BVE'BT;84I.!D7[%-DP?D82S,BU@]X-3V7S!F;0XN\7&Q+O,W
MOP70YI5EYFQU\MER7S*C8U:5YZB"5V7@[YE2$ D]%C8VKK+=2/B4FK&5:M)&
M,(K26X,\\]DG<FXS%A),SRPLY5D@QK;BL'@E;5FME%FKFW*#(*VBS*RQWTWE
M.U4RXC2-(U>H)2JL;,S=K*BWE6I%VIRMKVA'Z0GZ<$3E;7M"/TA/TX(G*VO:
M$?I"?IP1.5M>T(_2$_3@B<K:]H1^D)^G!%"J"Y;E@GX&72*(W7,DP )R@/<G
MS%M1B&T$=QB&*8H])1 0V#@.?FBFO*VO:$?I"?IP1.5M>T(_2$_3@B<K:]H1
M^D)^G!$Y6U[0C](3]."* W"H,KC.Y=2;R<!",H-L<7%6"!)-9K8I1.LST!!D
MD5#N"$*V@'LZ-F8IF;.>YL$3"2*0MG,8W7*1<_V;(2Y6&_2TLUS#J,=1)/.*
M*S8G*M/4Z0M:ER+&T_*F!BJ\]D8Z\4IW!-ZQ.9:*V-@D;OA@YA\]K"DY"/FM
M66BY<BPMIX,D_-/[I-*9AP$D^N[8S=PV0K+FO$A)BZ+Y&L,RK;&R"MIL:QRL
MH_)EE.Y<UT[8KN G7RS65M<XW(P=QI%VQRMKVA'Z0GZ<$3E;7M"/TA/TX(G*
MVO:$?I"?IP1.5M>T(_2$_3@B<K:]H1^D)^G!%81SIL"*VJZ(:OY(?MA=POW(
M@._I#!%?\K:]H1^D)^G!$Y6U[0C](3].")RMKVA'Z0GZ<$3E;7M"/TA/TX(M
M!YR9.)YL3--DT;DUKK: 3<Q-@9J0A9I6>K#^\997U\PB7@3<3WMS:DME7!,V
M\\JVGD&L:_EP+"GDC1DE&$6MKAP;7UQOMML)KTQAHBRVT)5^F>*&<?2-1F8O
M(%.R5E@J,M#]Z\\E,<'J!4AK3I8&C.'LDF@6O'EFK"49$5E;>#5/SDAF!-#F
M!79)YF#$2<2X8IUES )P4KF VR4K68%P821K18%7!8> R@8S]"K*K--Q'V1P
MLC)VN0;C&N8<B[2Y6U[0C](3].")RMKVA'Z0GZ<$3E;7M"/TA/TX(G*VO:$?
MI"?IP1.5M>T(_2$_3@BA56,4\Q>#$,!BC8TM#%$! ?L/&AL$-@[<$7WJ_P!V
M[S_.!M_0\?@IU3Q-_BIM@JN-GO#?RA@Y5Y&VE.Q5I*,D\VX:0DY2 GFD2$IE
M?G17,DVK.+F7\0Q@9X]MG;*SD6RT1+NFE>8).#6)RQ217<HD4@8\,_("6EFT
M#!6:8GIN3@Z_88"'B*C9W<M98VRL*K*QJD'%EBRR+HX15UKLDY*JU;@@R<OU
MQ,8L#8 BR+#5;APY&V<D-'MWEF[])B#K<NA08VHV6?M*Z\_67]L6BXV.B8I=
MS)NX>'AYI\\XMNB+IC%JOXLCUJY8J.7777<BJIPX<B8@SQK<Y2<I,HULUD@4
MXZ=K4^DJ_CJ[=+K25+5&J<VD*_@%Y&ASHF.U!5ZW523:@T7.Y8*/2+L'!$P1
M,$3!$P1,$3!$P1,$3!$P1,$3!$P1,$3!$P10O+__  :)_+EN_P!KIS!%-,$3
M!$P1,$6L[CF06H7C*2F*5J8DD\U[/8:NC9&R\8C#5M]!9?7#,!).43</"2KM
MQ,,J;(M(]*-CG#9(Q%W$B^8B1DWD2+4JW"AC._Y:I,:?)/82-M\74YNV#*LF
MY&AY_,C]96"?,(8R!W<F5;-^/M-5DVYG#$\7%5I>S H];R4:Q7(LK,\(7O:S
M0D<NK)1I6(;(KT8T/8U)1JJC.1-YN\7EHTE6C(&J:"P,;O8*ZUD&$9*RSR&@
MI9M,VM.LNI"NPU@(ND<$3!$P1,$3!%81ON=3^/RO]*/,$5_@B8(F")@BT=F3
MG8TR[N=-J:M==S"-B/#J3DL@_;M"UMC9,P:5E?77";%9!16;7?VV\QO*6J"S
M,L?"1TQ)*.%G:<;%2A%"YWA0Q$3>C5)I4Y&4C6-U1I\U92239J@TX^U94Y?!
M)1L>HV47ERMLP,UF=>?-"KLS-6]4MDD"ZJB$+'39%1]PH8J+MTS!R=2D&M?8
MS[Z"B[2$JS6"4[V<P\N,KKU(N(8J .8EE6[;FC7DVG'.G"\[%,9^3229%9QR
M$N1=38(F")@B8(F"*$9??<%__/?,S_S(M>"*;X(F")@B8(M/YJYIO,LW=$22
MJ+BS-+E;(BIJ*LYR,8R;9[-34-$M4(2 7!:4M4D@RDI6VR31BDU81%*IMOGY
M:88A&LVLD1:XNW"CAZC<Y&JMZI(336NV-*#M4RE*-61(ILFYR892TBQ8JMUE
M9<\6ZSZH@\@(NT4=MFEL.DL1Y$1;"?(L=)\+FLQN869])/5IHS'*D4>?[(KR
MQFU<IL'.6![F]BBO(A&+EF=-ALTXB7DDH>=DYI(L8_1E86%0E*B]LQ%UQ@B8
M(F")@B8(L?&_:%_Y0D_Z0<X(LA@B8(F")@BT;FYG8WRHEZA&+5E[/HV CB4F
M7K61:,0KU98W++JBOY=-NX354F7K69S0KKOFA 6AEX5G/.47II)I&1$P10V\
M\)Z+I]PDZNUJ,C/-:U,&86V91EF3$D1'QWZSW?'),F"R*JTNK"$SUH+DD<FL
MT5DFR5J!NLF_AXMA8"*MCX3L;6KC>JZ\ITHK"4-*56DK,C)LQ!1"H)90RN8+
MT8<4!<HL*Q6,XHB<9JD<.'<\>N6>-28L%4X-><(NH\$3!$P1,$3!%!*Q]VKS
M_.-+^AHW!.NNY64'+,8^>NZ;HZY3'G6YR\4R>N2]SS0P+J)VK=8A1U ?J3&
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M7CZRL(ESR+]<>0:S+:7D\LDUB5B3+EFG'-'=(K>8<I:[8\N;FM1<E'Y>V-O
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MNF@[P#3< :!H [AV; WCU; P1-F\=GC#:.H#U:=(>#9MZ<.M>WK=L14V;]=
M'I'34=VW377?KJ("/Y\.M6_K<B"([.O38'5T;]^NSPCL !$=NA%4==@CM$==
M^P TZMH!MV;0_*.FA$TZPTZ=1$/#H&T-X[O!L'HP14'Y=!'37334-^OA'J$0
MV[>K!%41U =O4 : &FW;I\@;PU'00#?T$5!'=KMV>'7;IIJ(Z]&W9N'4 TWX
M(@AIKKU]>_\ W[M=F[3=TNNJHFFSKVZ!T:Z; WB Z:CINW=.P-"( ](]&H](
M]?CTVZ;_ -.KK5U\;MY5'>([-=?%ILV[/R:[!UTZ=F")MZ@UU\FNFP.K=IL'
M4--FF@ZD5-VFX!Z-.D==X;-VWHV"(;.C!$TU\0:ZZ;M@;!TUWCUZ[>K8.I$W
M!T:CLVZ;-!#>&G7U]&S!%79IY=FFFG1M'KVAN#3<&")X=P:B.\-NT>O74=-G
MRAT:ZD0--H[@\8: ;>.FFW39H&FHZ?D==9CO_8O5#]TV[^<!/Z+8^$?S^7'G
M/WG?WCY!=VX#N'DO,/#IR,_=E3NWC<4YUN0"MN2=R8.:6!NZ-RAHX,!M1T^I
M,4---FNW%!(P*%H-*C##%2;O70'?)R@^#6-T_)&ABVW9\!R4L-RXE:44SCR0
M*K'H!F<JNZE;KF+EVP8-(YR]D7%TRF-,_KAP(1S2LKODW%9+!22KI=9N1D[0
M(S<1SEZA)Q:CQ;=GP')+#<N)YK(P;[)/,N<I3V&LL+;K*G4_UQZ.Z%A"/I^$
MJUFBX9(U@C5GD ,E5^?H6SPZ2J2AHN1DHR3(FHW6:@N5.6B2#K&%PNPV; ED
M9<3S6VN]=#XSE/']C-?Z,V:=&F[%MNSX#DEAN7$IWKH;/LG*!H&FP8WQ_%O7
MMPMNSX#DEAN7$\T&KH#I]DY39_)G]F_FV;NK"V[/@.26&Y<3S5.]9#XSE/+&
M_P!FX6W9\!R2PW+B>:KWK(?&<I_JS^J-Z.CH#"V[/@.26&Y<3S7@*FT!0ZH2
M$B"JA2$.H!8L%#D2$XIE.<(SNC%3%102 (B!!4.)=!,816G9\!R2RW+B>:MW
M='B7_)^7+.7@,W2#YH#IM#.0:OFPB+9ZVXZ)/Q#MN)C"@Y2[E=(3&%,Y=1PM
M$Z^ U)9;EQ/->75%B'RL>N]5</%XEZ:2BEW36%<+1DB=B]C#/X]5:).=D]-&
MR4C'&=-C)+BQD'S05.3NW":BT[/#8.266Y8[3S5[WK-_C.4W:;XWI_\ 9O\
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MR'QG*=6^,\?Q9U[<+;L^ Y)8;EQ/-4&KMB@)C2DF!2@(B)AC   #:(B/-H:
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MF+616=UQE;:Y)V!&+C)E@[<+;L^ Y)8;EQ*VGWKH?&<IU;XW=KK\6]&%IV?
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M&,0V:N+)"=PX3*25=LP5;$"":*N2*QJV132"RPN>6,S?;9;$,PHF[,;G;92
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-W)@H?O-_Q>28+2__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g307489g35d33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g35d33.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1CL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &-"^8U(X0DE-! 0      !\< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @   #A"24T$)0      $-/)GTL]C>HHA4@U:H05G"LX0DE-!#H
M /,    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
M    26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I
M=&)O;VP     "W!R:6YT97).86UE5$585     @ 2P!Y &\ 8P!E '( 80
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@
M#@             _@   .$))300-       $    6CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !H    !
M   "0    D     "  !FP $   T= 3A"24T$'@      !      X0DE-!!H
M     T$    &              /"   '9     8 9P S #4 9  S #,    !
M                          $             !V0   /"
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   /"     %)G:'1L
M;VYG   '9     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   #P@    !29VAT;&]N9P  !V0    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !    !0X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MDT^A9O>T,W!_L:]S:;-S?]+2&6[/\']!&@+SRS,SFP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^%7O6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $T ET# 1$  A$! Q$!_\0
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M]CB_#JOKU;^T<'O)>D/\O3_+P=!]:?[<O^>#V.'\.J^O5O[1P>\EZ0_R]/\
M+P='_=/]IX/8XOPZKZ]6_M'![R7I#_+T_P O!T'UI_MO!['%^'5?7JW]HX/>
M2](?Y>G^7@Z#ZT_VW@]CB_#JOKU;^T<'O)>D/\O3_+P=!]:?[;P>QQ?AU7UZ
MM_:.#WDO2'^7I_EX.@^M/]N7_/!['#^'5?7JW]HX/>2](?Y>G^7@Z#ZT_P!I
MX/8XOPZKZ]6_M'![R7I#_+T_R\'0?6G^V\'L<7XRK^O5GZ_@]Y+TA_EZ?Y>#
MH/6?[<O^>#V.+\.J^O5O[1P>\EZ0_P O3_+P=!]:?[<O^>#V.+\.J_1[=6_K
M[_T\'O)>D/\ +T_R\'0>L_MZY?\ -?NX/8XOPZKZ]6_M'![R7I#_ "]/\O!T
M'UI_MO!['%^'5?H]NK?U]_Z>#WDO2'^7I_EX.@]9_;UR_P":_=P>QP_AU7UZ
MM_:.#WDO2'^7I_EX.@^M/]IX/8XOPZKZ]6_M'![R7I#_ "]/\O!T'UI_MO![
M'%^'5?7JW]HX/>2](?Y>G^7@Z#ZT_P!MX/8XOPZKZ]6_M'![R7I#_+T_R\'0
M?6G^V\'L</X=5]>K?VC@]Y+TA_EZ?Y>#H_[I_M/!['%^'5?7JW]HX/>2](?Y
M>G^7@Z#ZT_VW@]CB_#JOKU;^T<'O)>D/\O3_ "\'0?6G^W+_ )X/8XOPZH_^
MW5O^B<<'O)>D/\O3_+P=!ZS/\<O]UX/8XOPZKZ]6_M'![R7I#_+T_P O!T'U
MI_MR_P">#V.+\.J^O5O[1P>\EZ0_R]/\O!T'UI_MR_YX/8XOPZKZ]6_M'![R
M7I#_ "]/\O!T'UI_MO!['%^'5^M_OZM_T5 [?IX/>2](?Y>G^7@Z#ZT]J^)_
MW7/V<'L<7X=5]>K?VC@]Y+TA_EZ?Y>#H/K3_ &W@]CB_#JOKU;^T<'O)>D/\
MO3_+P=!]:?[;P>QQ?AU7UZM_:.#WDO2'^7I_EX.@^M/]MX/8XOPZKZ]6_M'!
M[R7I#_+T_P O!T'UI_MO!['#^'5?7JW]HX/>2](?Y>G^7@Z#ZT_VG@]CB_#J
MOKU;^T<'O)>D/\O3_+P=!]:?[;P&CB_&58_]NK/],YX/>2](?Y>G^7@Z#UF_
M;.7^R<'L<7X=5]>K?VC@]Y+TA_EZ?Y>#H/K3_;E_SP>QQ?C*OZ]6?K^#WDO2
M'^7I_EX.@]9_MR_YX/8XOPZKZ]6_M'![R7I#_+T_R\'0?6G^W+_G@]CB_#JO
MKU;^T<'O)>D/\O3_ "\'0?6G^W+_ )X/8XOPZKZ]6_M'![R7I#_+T_R\'0?6
MG^W+_G@]CB_#JOKU;^T<'O)>D/\ +T_R\'0?6G^V\'L<7X=5]>K?VC@]Y+TA
M_EZ?Y>#H/K3_ &W@]CB_#JOKU;^T<'O)>D/\O3_+P=!]:?[;P>QQ?AU7UZM_
M:.#WDO2'^7I_EX.@^M/]MX/8X?PZKZ]6_M'![R7I#_+T_P O!T'UI_MO!['%
M^'5?7JW]HX/>2](?Y>G^7@Z#ZT_VW@]CB_#JOKU;^T<'O)>D/\O3_+P=!]:?
M[<O^>#V.+\.J^O5O[1P>\EZ0_P O3_+P=!]:?[;P>QQ?AU7UZM_7\'O)>D/\
MO3_+P=!ZS_;E_P \'L<7X=5]>K?VC@]Y+TA_EZ?Y>#H/K3_;>#V.+\.J/_MU
M;_HG'![R7I#_ "]/\O!T'K,_QR_W7B1Z>:(%Z6>3-;MT:B5YXIK?O&DE,DT6
M7HLD;V0D,T<JKTV.J+?7$KZT8D91^81HD&[%,Y"45O@Z4^%<7A;'[;R*]QQZ
M.W%>GG2IA29+@..ZL+,CJ<9(W%SC)&X9'6YQ=2+]N&RBQ6+E,6;/S-L.YPX2
M0)L_S3\S9XQ7:U9)65F[C(233;E>E2_NBCTG2G51] #2.;?22??PK\,/\7\>
M&QWE\Z>_<^?_ +<9APWA_!P<'!P<'!P<'!P<'!P<'!P<'!P<'!P<'&@^??B?
MY&^&+3=IZMSOWM)LZDWUN"7:NT4IMK;SW?7Z]N"#2ZS6I=,H-)V1MW<FJO/'
MI=!65K,]$D(AIY/E<@%.;R7AW.>(RU8\GH^]=#3-7574TM*.GILXP)2GK3TX
M@SE&.]VF.,;F.;Y?E/=_K&J:?O9NGI'3.<M29%DQA&$92DD8LD#87MQ:=J^+
M[PV;UY-;Z\0.VN;&@5_*3EA%N-^8NZ9:37--GV/-M+3H]6W#IVZ=LZII5%NW
M1-:T[39Z:L;0M0T*#6JB"LHFHZ"H]MI!,[5\+\0T>;T>1U.6G'FN9=,Y?3&$
MC6-671IRTM2,I:6I"4A"<9L+&Y%--CSW*2T-7F37T_<:#,UYJQ]RZ9>I'5C(
M)Z<HB+&420(UDX1?=F^&9_#_ *3XHZ?FKI59R.W!40T&W=Y46D;GK*G<6L5.
MY*C9]+MW0=HTVAR[VUC=%7N>EJ=$I-KZ=MRHW!4U\$L4.FN(W8*^%>('.S\.
M>6D<YIC+4T92TXD(QT_?2G/59^YAIQTJG+5EJ&F1RRX3]?Y/]5CSAKPERTT(
M:D24NN4I^[C"$(Q=2>HZGD-.,6;+RD;XUY)\(_X-:;EI'S8U#F[/I>U#S/H^
M2U72:GRYYJT6^-'YKZAHM=N*@V%K_+&;8Z\R- W!6Z)IU7J5'3ZQM2BBJZ6-
M'III?:*833G@/BKS#RQRI+5_5GG!CS'+.C/E8SCIRU]/F36_5]33)R(K#5E4
ML)8U$>*^'NG[TY@Z??G+,73UC5CS#%F:,]!TS6AJ,!D1EIBQR83C,MG>.#PQ
M;\BV;-MWF+7$<P>9L7)S9D>N\N^:&T:G7^8\VV*[>46W*.DW=LO0ZI2^V]-K
MM1&K5$,.A#V:2C.IBO I3%J^$>(:+JD]"/\ 4<O^MZW1K\OJFGR_O8Z/O).E
MK3/[248](L\CTUGB>'.\M/W=:B>]U71TC4T]729ZI"6IT1-2$%>B,I6%5%S8
MG&<<V?$WR,Y&:M%H?-;?]%M#59N7/,7FU%1U6D[BU!GY><IJ*AU'F%N42:-H
M^I0B#;='J=#//1&0:I6BH5=+H:Z1)$2+EO#^<YR+/EM"6K$YCE^54E"/_B.;
ME*/+Z=3E%O4E"02KIC7FE$KA=?G.6Y9K7UH:3[K6UZE=^YT EK:F!\NF2&7?
M)0WQC^K^,;PT:'MC8N]-0YLZ&-J\S.5>^>=FQ=<HM/W#JM!N+E?RUVWIN[M\
M[KI9-*T>M:"#;VWM7T^OJ].K5I=9F:=J*CTVIU"GJ:6%\?"_$)ZNMHG+3][R
M_,Z/)ZT),(RT^9YC4EI:.D]4BV>I"41+B5;(BBM>?Y.,-/5>8T_=ZVAJ<SIS
MM8ST-*,9ZFJ(/EA&<67<LQ?%IY'>-WPT>)#<4>UN36_-:W9J\^W9=V4WM/*[
MFWM/2JO;T,FG1'4J/<.]-B[=V_61RG5:!Z6&EU26JK()S4TD$]/#/+$[G/".
M?Y"'O.;T8:434]TUS'+:LC4J3TRT]'6U)QKIE:Q 2E%!7E^=Y;FFM"<IW'K%
MTM:$6+5,9ZFG&,KL2E4R8MX==Q6\97!P<'!P<'!P<'!P<'!P<'!P<'!P<'!P
M<'!P<'!P<'!P<'!P<'!P<'!P<'&MN8/-[ESRKU#EUI>_]S0;;K>;._=.Y7\O
MDJJ'5:F'<6_=7TS5M7TO;4=7I]!5TFG5NH:?H>JS4<NKSZ?1U$E(U+%4M52P
M02SZ'*Z_,FO+0TW4.6T)<SKTQ'3T(RC"6HDD9$93B2(DD&TJWB+4U]+1=*.K
M,@ZVH:.D-^?58RD0$*ZF,9)=73QIN/QP^%2?1N:NX*?G%H=5I7)'FSI7(SF?
M/2:3NFJGVQS7US<VG;.TC9OL%/H4NH:S7ZCN;5*/1Z2KV_2ZMI4M2U05K^C0
MUTM-EOA'B1/EH/*S)<WRLN=Y<9:8:G*PTY:LM:V9&,8Z<)32;&0!Y;2X#Q#D
MI&M*/,Z<CE^8CRNM2ON^8G..G'1D!?7*<XQ NU#C$MA_"*^#[F?O'3-A[!YI
M:MN;<>L;FK=G:<M!RFYT+H<^X]-U&JTC4-/;=M3R\@VG3BBU.BJZ*JK*G6X:
M""HIY4DJEQXDU_ _%.6T9:^OR\-/3CI1UI=7,\IUFG*).,O=&NZOFC(D1(=2
M(AGANEXER6O(CHZKJ+.4!CHZ[!G"3"4?>>[Z+C*+&7FPB.SQ0Y:?"/>#?G%K
M6C:#RVYK:MNBLW =4^)ZNFY2<ZJ+0*U=$I-1K=4=-TZKRZH-L114D&E:@'FG
MU>*)ZBF:CB>2K>*!UYGP'Q7DX3GS/+0TC3Z>L>:Y26I'K8D3W4->6HJSC@@H
M-M%O":/B?)<QT^YUG4)=73..CK^[2-]2:CIFG0B7U596_&PM'\9WAFW#%R&?
M0.:>GZW/XG*>KKN1FEZ3H&[M1U[?NE:? ]3J>O4VW:3;\VO:)MO2*>-YM9W)
MN;3M%T'1XQEJ>HT@*WAGX3XAIO.^\Y:4#PYC'G)3GI1AH3DU'3=1F0GJ3<0T
M].4]2;\,6N'QY_DY_JW1S$)O.1E+EB-REK0B7*<8@RZ(_2FA&-EI?&R^<'.[
ME3R"VK2[VYP[VTC8FV:_<FW=GZ=J6K"KF;4MT;LU.'2-OZ%IE!IU-6ZEJ6I:
MC6S#&FH:.H>GHX:S4JOV?3:"MJZ?'Y7E.9YW4='E=&6MJ1T]36E&-'3I:46>
MI.3)(QC&)E4M2)<D&77YG0Y6!J<QJPTH2G#3C*;75J:DB,(1-V4I( "]]A>-
MJ<8W$_!P<'!P<'!P<'!P<'!P<'!P<'!P<'!P<'!P<'!P<'!P<'!P<'!P<'!P
M<'!P<'!P<'#4=\^.+PJ<M-H\T-][[YPZ+MC:O)?FA2<F.9NJ:EHVZT.UN9==
M3:16T6V)Z"+0)=2U&2KH==TNOI]4T>CU'1)J&HDK8]2:EI*R6GLM'P?Q+F-7
MEM'0Y2>IJ\YR\N;Y:,9:;[WEXRU(RU!ZR($M.<6,F,^HKIMB.%J^(\CH:>MJ
MZW,Z6GI\OK1Y?6G-0T]:1%CIRQA2<9':D;K/"'FWX\O"=R,W'K>T>9_-JGT#
M<NW=7Y?Z!J^CT.S^8.ZZRFUSFGHNZ=Q\O](C39^T]?6LU'<VA[+W-JE%24+5
M,\5)IO4K4IO;-/%6[E?!O$^<TX:O+\JST]2&OJ0FZNAIQ8<M/2T]>:ZNK#IC
MISUM*,F5%S*NFC6\1Y+E]26EJ\Q&.I&6E!@1G*?7KQU)Z42,(R66I#2U)1"U
M(/&,:A\)#X-M)V;HV_=5YJZQINVMQ[XJN6^@35W*#G;2:MK.]*+;Z;IJM%TS
M;$_+A-T5IAT&0:@:^GT:32RJ30)7-54\\$<D? ?%9ZL]&'+1EJ:>B<QJ=/-<
MHPAHNI[HG+5-=THW/R]+,EL]-(K9>)\E",)RUF)J:CI:9+1UR<]0@S8PTW3-
M23T#+$4H6\-9_L;QH^&SF-7<M],VKS"JYM2YN[HWMLWESIVM["YD[1K]S[CY
M<[2I]\[SH*:CW=M#0JBCBT7:M5#JK:CJ<=#I=<IDI-,K:VO@GI8X-;PKG] Y
MB6IH!'E=/1U>8E#6Y?5CI:>OJNCHR9:6K,6>H,2,5D;R"-/$L.=Y;4EI1CJU
M+7EJ0THSAJ:<M26E U-0C'4A%>F"26J394>-B\GN??*/G_I6Y=>Y.;RIM^[=
MVINS6=CZKN72-,UR/;-1N7;T_LVM4>W=QZAIE'H>\*73JD&FJ-9VE7ZWH@J
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M_EIS$Y@^$_6-<Y,[7K]Y<[>2G,CE%S\Y0[>TFGDJM5U3>/*SF%H.MSZ;I]/
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MD6UEC5YU:+\DC]9% ,I2^9-JXSRK\;/BP2ARI^;NX3/(@53[)H#/$]NS$-I
M5NY&0N "+VL K11]L_:94_IGF"^[#ERLUM[K[&B^[QDZ?Z-/T=NH$_9ODF%N
M35YPZBS ',V=J?1K&XB^[1\7JT76FYS;ACD9E#1&BVZ)53L[M$!HI#,55NG=
MF#7 "GU"S]M?:0DAXQS'[&A3L-#I#N-;=_EQ!K?HV_1]UII^S7)] *3][SAE
ML"5\SV:9&$+SQKG6?'=XO:&@>JCY^;M0A))2DNG;7C>,6;%1;0R75.SY7Q9
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MX%39.FA7)7ESQY]\^=.F3FC+51+=GH-+E<L!ET3)54S(Y"QA\RHS(-B J,S
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M2CI3YC6(0AK:DY1862('7-4U'W*3J$8H:,XJ:C&*YSE)S 7<&B4=!7R-1&G
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MC\XBY!)] >(6+&K,;^K;C8QB\UGOZK)"F][6EMMJNJ)\EH$]4;..Q7X,0*/
MYR.P%E]FWR0._OYE[R/O ^GZ/T7'?BNU_P"UG;?PY=_A-^-IY'_RNCVQ+?\
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MS\;\7U(L4GXCSDJKJH>:U#LG52)5F;+L#C<\+)T5D&:MB/E/.K>9UC$)0Y9
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M9SU["QNXDI*5ZMN#*F&PZ=>*KC>^$@^_F_P2/^NDX?\ ],_OO^F/#?I_X?\
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MGNXV*8>D;^Q=OF?+C5>9ZCF.8QAUM0NES[S!]PWC;%M;-VC#!LPI%F52" ;
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M2"CAC*2@Y\P+]E@24$B(6[(Q44;)P$ZA8BP5L(T939C?&.\=TNJ-\H6[,>H
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M^'_?A7PSAW'-3\(&I?Q<<S@2&5*?9!*XC)<]C;<#>=@P48$Y&P8H95!]XO\
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M#90DYCD"6 8-6=-'4.+*0'IL5:2BJ!E*R2!6N&-BH[@JBAU,@LIZ@"D*;!D
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M):J5II@TSL>)>=\1YKQ+7-?G-1U-0A'3BQC$B1C)0A&!&(=4I(U:R7BF\/\
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M582TM/*CQ$391S&K^)K-A;O%ZE"7F'$@BJQ0F,C1W<E;V!+9"-\EO<D+V\N
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M'8@"_E[$ANX(/">\P1,T;XM%!!R;Y],4 XX=T]]KR CTIZ[7^'?OOP=-2S*
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M5NG#.A,R7%2"0*Q0)56_V*(GF5%9(1U+LTL=@&9""H9ABLA01W=38M<+&2&
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M)!+>4K07LY+SZG_%7PR4GI"I6WM@K-;[?(>WX<(&&4A)=@['L06:S*I)/<*
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M-LF^:5B ;@T-->6SS5W=A<K&\LJ,7"J*3JD.S*L1$VS:41,E<*E?JMZ87C8
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M;&-5G==QJHKQS7VA0\6Y@\ML=%R%V:$$PW=X-@0<W+AEDC91+BC !0KLJ#(
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MI3%'9\>]_P!-TN8&ER,H]HU#VW4*J-D"R=>I=) '4#-"0@5@4BNQ(8%E(X]
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M$:B2E:4MZ_\ #A+[)S3WA3232QG4-,H]0C!4.+"HKHW4-D51DF 6"-V1F <
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MC&6R*2JLVEMHBFZ7=2<;JUQ[O?!P_P#B_:AB2RCF/N,>90K C1]L *0+V*@
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MS;B6(T2HKN]BA,C=5==F_4XQ$% D[6/=MS;ZM+>3&<H"[/!8[ "X\^1(ZA+
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M.-_X2B_MK"_<TJ]_T2D?3Z_G!]?Y.)/^E_\ I'_2?S]_#?I_X?\ ?A4+^_\
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MFU =*TW$+"Z>'$\RD2+/B4!N@KT;J42BE:4+&>0F7)(Y JL6-S& ?*50JR%
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MW?SQG;MD!HWJ^,4(_2<+Y2LFV2FKW=Q+,<5S5+D8T 5;$+Y1WM<@$$%<CW[
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M<,_I#JK"[7)LN5JEE-](74=TJKXC5:O/FI\AO5$<WU=^ZV@DK1JB,"2QLAC
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M ZA?,VJM)U1B6O21.DM9:!W5"98JB.8X]6G<*BD]2)5#6;YK#$X1DL6L[M(
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MV7O*DO=JU%#&#CWI^#>:;[GS43!##C]LK<HQEF>,V^)=JE2!'!+F3Y@22+
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M(%_.K^[AX5W7[5?XJ_@\5!?W^O?W^G?L+?3Z]_Y;\)PO ;GT:P]/3Z?>/3]
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M7Y991ZE,+WZFV5N+/EYBVSCGZ(CA*"SRY /HM.1[_1<-WPN6(]!"'5C8%B&
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MS_B7+"_U^ARS$M^*.KJ0:^PU,_;7HOL!L>AHM)V[I-((U4TE- KC$7$G0:-
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MM71EHR@:@B2';U$<I5XQ9?5;?'G_ ,T^4FN:93MI6OTD\]/I\COHF[J2'*>
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MDBXM<^4%1<CUL2>Q'?L%A"[H^XJ\;@=L7OW;WX2>HB%W6;JJMWQ=9.^0"JK
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MO(7/8=S:]K=O3C!U?[27W?Z3C9.1;Y72?E/-W=:DR[HWX?IQ'QE\'!P<,/\
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MK$<X!*WNA*+E*)/>E"J'-MIO;2FEE89*D8 .01R+"-F# BT@%K]BK8AD2:Q
M)(?&,>JKGU %VX:3>E;QM=W60>&2E,A)Z(4R:@].UW]:L.&V+AR6)<*:MF!4
MM"(^KT^XQ5%*KEDSEO+V]$5B<A)D<6)$,]**/3),MY%L\P1-KW5D%&PBW)#5
ME%!A%N-V%!V;D.V2@N\BXKA?U%22H1F8EFC3)@+,Z^:T:EB?,&4+=F&'3-[
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M/W/SW6^-1YJ0<SKBU_7:F:NWKEOWVJJVWO'#>8FC0*Q8Y.++9I,U((Q':P8
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MDBL?D"Y;K*%VYS@##:[5Q3&-1ZO2VO*8<'PU\)TYN5(D9UE60+'8 AK.S&Z
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M.>NY0U(LA7N,FJNZ+$R?*LO&=Z"ID 8M:5 86"Y,1&S+:2UCZ W  N+$+8
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MF$92DGO8,JC'S-%K7IQSA1>'_GY9E^T;S>R=@ 3RRWH0%(#!LI-'L "Q=E9
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M1=73=23.6J,].X,J8D^PM2^"S?2\@N?"-)?DIS9*K:Q/+C>)8L N-F71R&=
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MO?:BJ_('GQB6;DMS="A2HCCY;;P)+.1A<#1_WJ!LB%QR*]U0=I3F-$0-32I
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M53J2A9=\*-8^$<Y":?X<^1/B.T30N9N]M'\2&Z-(V%RCY;;/VSH]7S3W#O\
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M#@X.#@X.#@X.#@X.,%V1\_=G^.&O6_1[9)_IOPL\IFO+#:OJ1]1X9#O]LO\
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M\W!]WUR&_%<P1_[DU_Z[@Z3Z\?PG^7@M^K+\8_FX/N^>0WXOF#ZV_P"\FO\
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M#[OGD-^*Y@_S)K_U_!TGUX_A/\O!;]67XQ_-Q'[OGD->W3Y@_I^PFOM_7?\
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M)\LOX*:9W]?['B[_ *1T[?QVOPE?;^+P4?\ 'R^STX/M)\LOX*:;^GH17O\
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%'"\?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g307489g38e50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g38e50.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1O\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &^"^<38X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      \P   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4    " !+ 'D ;P!C &4 <@!A       /<')I;G10<F]O9E-E
M='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93
M971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F
M0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T
M:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O
M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! #O_XU  (  0.__C4  @ !.$))300F       .             #^    X
M0DE- _(       H  /_______P  .$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M00    8             ! @   =C    !@!G #, . !E #4 ,     $
M                     0             '8P  ! @
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P  ! @     4F=H=&QO;F<
M  =C    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   0(     %)G:'1L;VYG   '8P    -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
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M# P,# P,# P,# P,# P,_\  $0@ 5P"? P$B  (1 0,1 ?_=  0 "O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MI_5W-&SJ1:_67>BV#J-OLW?N
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ME9;1T]35X24T4U1B-41'56-R@I*4TA@W9'.#AJ*C\?_:  P# 0 "$0,1 #\
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M%3*.'SQPKT(4P$*10MRR_;>*_P#%UJS^X+YA%;K")A$PBKQ+<5])SDK)S4E
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MZ\L3JPCK>GLT6Q@BR,E)+&UK6OCZX9&67N$\SVD>9OJ,9_"?\)#_ /G6(_\
MS7#[_P#HS<\WP4_[)_\ \O)?_N7CT>(W\N+^G$__ &JQ?$Z.\<Y'?VO5.2\G
M4U-&%DU_Y14Y57C\L*D'Z%UU)%EUFW^E830NO3?"SH&(P*Y[?BAO0>>4T-R!
M_A2[#W1A([ RWECT)B&9&INMO>0WW>G\KIWY@<"\MWY>G])4ABF\Y%^L<D^
MT>L^I#O0;,?2[ZOIV^;U]6BWI(;U =9Z=@WGF_\ XTW6X]!Z?4*V_P"_[O\
MX?\ 3/M_9USD:O?S^[M_?O\ N6JI_P GKHXYL45_7=O6N->//$$=Z1ME"MO*
M"R2-T2UHK99[7YZ_,\,*_36NK=9:F7>!"A0-E6N>7V#:7TA59LL@]EK2"34G
MY_M_(6%:2W]8)35NF;%JWE5N7<.^K;K7EHIRTHEAVE9[JSUOK^HZCVO(TFX2
M=*D'3MCIY_6=@0^K(C7]NCF5?D]A(V%TLM)64DDJX1(LXF[-N&2U)RFWX7D'
MOV+MG'#6_!6SZK@H7:-FC:*TGK3H72MGO3NSTU!V$)>6UU?2;TD]#VQK+0YC
M/9)^U8-Y:3>OU2+\O7)ZYDYL0CNO;?M<,^C?$0J&C;)2K7R?LOTI)JQY=8K7
M,S%GX95NF):QJ6D)0LF@O3MRWVPFN5FD):N3+635E;#&,$B?S?G[/S__ -[&
M@3%FB=0<2]E;WY6<B:UI_DGM[=49R5VC-;SN-8KM.;Z[?;9CM%4>,NJ,FQ#1
MM5M4E',(VR62"E:Z^MTI7X2*EK 3XJ=%R19UQD8S>U^5/$NZV?8VX+S5:TOS
MXA]"7Z=OMS8N=F:+UQL33A-5VNP)-GT8QNS2=;6&9B']IE(PZFUJO7ZA+V0\
MXFTBW8$5RO%@U+0;CQJ5V598(TQ<-4WK3*NOWCF3EQCZX_M?(+3T+-3+:OIO
MR0#F>5A?4Q#*=?QCN7B(R2F642\9-YB3(Z(L<YMZ%.VV?3MF:YV+88K<NX]E
M:WKVLM;DC(%]7'6ZZ=0]FU6"W3+R"L<M:&U;TGJ:WWO8]HK;)\A"V1S1:['K
MG;NI1PTFR+L_#@Y#!=4)'C[#TVHUZFZ<UM NJ^WK%@E9^T4,$-E;0UBMK?>J
MDF43I;K6+K@M]LSD?A[J1=6B2%W$B9FG.SI%$<9R:T)P?V_ST?\ +QX-6NVS
M]\P=XITI*5Y62DMP\?9^BZRHE*BM>"NGW7V/U>_:VN-ME$K:LG.PGDS$DC6W
M9Y9('Q%3[A[OK1^E-A<--E[)V91=4:6LFD?$52U,I<;5#QL?4J/;.7NKK/JO
M6;UVH].VCK%#41-%,:HLHG)0#=DI"NF;9Q%+H)$_/Y_K6T/P^!C;)<^;.W==
M1#R'X_;BY&QEITRLK"/ZW$7(8O4.O:SLG9=4B9!E'J'K-UOT1*K,9Q!J5K9'
M4:_FD%%TW8+*$5*];(6V]:YX.4YUL79NNYCD'SEYLAR8<ZTNL[0;=8[% -.4
MLW-U*6GX%RRF8YO&2=$KE?:^D692,1"P<62%7B7+./<-"++:C5>5VR-51D1K
MV6W=LY'4N].7&G36LO-:3T+:7=8UMR&N-/U\C=7JFG=HO=F3C*J0K2.&TR;V
M-D2)LA]860</E71<?S'\_/OK\_U% ?B*T#EO(\39JM[0TK<[!I35''S8=VFY
M-WR4I.SY;^7*2F;8U@;-LJSV!GKBV;#K>I*:LUGJC"0]"*16V6*/>'!R^UQ!
M.7645Y^7.NZ]8[EX>'(&VZ\>57=!N4N@*.JQE[.-E6HD#(P^R;#-UF/3AYB0
MHR3]W+E:DGK+7&WK)Y"+B6;F6>1D9'MT"*<8-9:.\378<9 G4+$V3A5KBQ[&
M:("8686N$W/?('7$H\(4?*3EI"M.KQ' L8H.'49 ,TC&,C'H 1^?S_4BOMA$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8151WMS8XX\;]F:8T[M
M:]&B-D[\L4=6M;52,A9BP24@\E9R.K4<]EB0[-V2O0KR<DT(YK,31V3%RX1D
M"MU50C) 6Q%A7*_Q'N'?"F7@*WR$VVWJ]KLK(LI%U&%KUFN=F"%.NNU3G)&(
MJ<3+N(:(7<M739D]EO1$DEVKM*,!X=F[*@19+-\\^)\)QC4YA&W!!2N@ 3;%
M;7&#;2DH[?RSV02B6M7:UE!C])BVX\HL1@XK#N):S$:J"RLJT8M6KMP@1<_C
MYS6X]\EM>W_9.O+6_CH;4TI,0VUHJ_U^7H%IUI(P+ \K)HW.OV9LQ>Q"3>,2
M6>>M,"K Q&SY '7K(V1;-"*0N.V_J+R?U#5=X:R0LI*#=BR2]8=6N!<5J3E8
M^,E7D.:62B7BAW:4:]=L')XUPX*B9\S*D]13%JX054(IMPB81,(F$3")A$PB
M81,(F$6";.GK-6=?7&>I;"MRMOB:[+/ZW&W"<5K-6>2[1FJLS2L-@09R"T1#
M^:0II!^FS7,W;%4.! Z=Y=JC'7FN5HK;YXZTD\;)WUH1/8;$YX#C#"7,$LNC
MIC"YH<X@;^2\++Y8J\TD#8WS,B>Z)LTABB<]K26B20-<6,V/C<&GI;LZ[+3U
MX=O/_??)?>&Q:-<J?66M.DI^R[3AI29O[<9B#U([9H5"J,-00C.@5U39]!1V
M36YQ)SL-\]1.FVL#5!T1)RE'H2'2>:<1PV"Q5&Y5M3.LLB@QLT<5-WERY-CG
M6K)R<KKLXQ]WT,\)%%K#LP.>TEI>8Z?QWD%_)WK,$\,0A<^2W&]]D%S*;@V"
M$4XVUHO55A:CD!M.<#^L < 0P.W@9RQ7=,(F$3")A$PB81,(F$3")A%47EE^
MV\5_XNM6?W!?,(K=81,(F$3")A%^   (B   CTZB !U'I[!U']_0/8.ORPB_
M<(F$7CVE[N_M+W@42@?H'<!1$!$O=TZ]HB "(=>@B #TZAA%Z0:-0557!LW!
M=?RO.6!%,%EO(_J/-5 O>IY/_!=QA\O_ 'G;A%&NFM.4?1&MZQJO7[)TVJM2
MCU8N*"3=?$I0[-5^^DA3?R2B::SP2.9%UY0JEZ)I'!,A0*'N12=Y270Q?*3[
M3@4#E["]# 4 *4#!TZ& I0 "@/7H   >P!A%Z_2-/.4<>F;^>L5(JR_DI^<J
M5 >Y$JBG;WJ%1,(BD!C""8^Y.@X1?JK5LN@=JLW06;*%$JC=5)-1!0HCW"4Z
M)RBF8HF]Q Q1 1]Q#KA%[ 33+V=I"!Y91(GT*4.P@@4!*3H'V2B!2@)2] Z%
M*'3V#"+],4IP$IRE,4>@B4P 8!$! 0$0$!#V$ $/[! !#W#"+T*LV:[AJ\6:
MMEG;+S_1.E4$E'#3U) 2<^E7.056_J$R@FOY1B>:0 (IW%  PB\&L='L5'BS
M)BS9JR#@7C]5JV1;J/G8ID2%T\.D0AG+@4DTTQ76$ZHID(3N[2E "+VK-6SD
M41<-T' MU060%9%-445B@(%61%0IA35* B *$[3@ CT'WPBZ]A7X&*260BX2
M(C4'+]]*.$6$:S9I.).3<&=R4BLFW13(J_D'9SNGSM0#.';@YEG"BBAA,)%V
M_P OEA%&="U+3]:S.R)BIHOF)=I7IQLFQQ"KL'$*TN<C"1,)/3$ R.D!H<]E
M)"M)6?;(+F:/I]:2FP01?R\FL[(I+*4I0$"E H")C"!0  $QA$QC#T^8F,(B
M8?F(B(C[CA%^&*4Y1(<I3E, @8I@ Q3 /S 2B @(#^\!#IA$,4ING<4INTP&
M+W  ]I@Z]#!U#V,'4>@A[AU'H.$4<5'5-4IEUV=L.-+(O+?MJ5K\A:YB6> ]
M6(QJ< VKM9K,,4$44XJKP;9.0D&,0B4Q?CE@L<RX67?3+M4Q%).$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3"*(=^[NHO&[36Q=Y[+>KL:3K2M.[
M'-G:(BX?NP2,DUCHF-;]2E7E9R6<L86*144225D7[5-99%(QU2$7PX7;:4=N
M3D_PHY\;LWQK!QL?=/,.LS4_JZ(V;5I=AQ?X[ZYO&O!U_&7A!.2%:D>8V<V:
M6?*3R<6B+)B>=DR(3\E8TFV-]CKN?[_L3\_G\_VK:QN&8C.-/BR;4YA;HT)>
M>4_%SE+QTKT7HR\ZHU\SWC7TG,E4M;,6\5'%.JI72?2!C4K"T:"RD/-DJ_=8
M^39 ZAIB:.GG\_G_ )Z_K14@\.OB_M3F9PFYJ:#UTI'Z]L^KN7FI]UZTIU^4
MDFE7CKI"M;5&6&B651NR>2$;T@HIC'.%2QBYB2\7&D>MT$3N'"!%:/:^I-_T
M6=W'QYVE:M?4#?/BM;H':V]V.L9V6L%3XY\+].1TY.[.M4I992.AQ-(61JI-
M0('<-1B9B+C):)^('DY06[0BW-\)_$(X;[OEJKQKX_Q]^HJ-:U>WE=.PM\US
M,4& V!J2DNOH6G8-6OI,YRV*#BEXM5B?SR,)108V64]$H>&FQ8$6S;")A$PB
M81,(F$3")A$PB8189>&#N0A7"+01!0Q#%Z%^?N'[_< $!#V'K[?/V]^F/P]_
MYQ_9[?C\E\GW[^Q!'_+6O<_CW^_05!=-VS5K+:*%1AI>%:3B9W%+ASLJU(1D
M*Z& .Y<KTJOVP(=K5Y->&.1VJ-8AIIRHR5([$C$BR3H$[%9P'(V4'Y&U6L&H
M0V_.U]J&2Q&RR&-9>LT?/=<ACGVQK;=BNQLFV#S.ES.JH5>:\0L99N&J9*!V
M0=-+CX'-IVXJ=BU4ZS/CJ65?5;C+5JOTR&2E5MRRQN;(#$',D#=E9 $I"E$>
MH@4H"/\ :(  "/\ G'*ZK@/8;_._EW^SV7EA93")A$PB81,(F$3")A$PBJ+R
MR_;>*_\ %UJS_5^^?]_^_7"*W6$3")A%32Q\]>.]5L$Y6)A;<9):NS$E!R96
M7&SD/*,BR$2\68/ 9R<;K!U'230'""GII".=.F#U'L=,G*[95)4]WK>'G)K=
M:O:@;A3#9ABL1%_)^-Q/,<S&R,ZXI<JR2)_2X=<<C&R1NVQ[6N! J4_-^/5Y
MYJ\LN3;+7FE@E#<!GGM$D+W1O#9&8UT<C>IIZ9(W.CD;I['.8X./3?SB?&;_
M (_=@_\ X7N2G_;JG/?][3E7\C!C_P#M?&/^+KR_3WC?_;93_1[D'_#%7F@>
M*%&2%L82>R**6!T]LXMT7TXZH:LMM'<L,AKF9)79\-W:BHS&P6>HJ3K\_J8H
M\1'2*-:6[*]:C(R!_6$LV2\)Y8J<D6+R!L9K%>A&;9D6PXG"3NR<!LP' YG(
M/K5+HK1CIF$TL;K3=V:H+ (S7L?XE1RVV/R-)M?$Y'U9Q+Z3I,EEH&T)A7F^
MF<72%BQ6,\FW1&"*05W:@L;=N46&_G$^,W_E&[/_ -+W)3\J<K/[VG*OY&#_
M -*N,?\ %U8?T]XW_P!ME/\ 1[D'_#%)NIN6VFMUVH]-H:FR5)PD6[F#!:=)
M;EH44#%BJV1<&-/W>B5^"*X[W: (LSR)7;GJ?TR*OEG[8K,<-SF"J"]D6XP5
MS,R >DSN$R$QDD#W-U6H9"Q8+=,=U/$18SMUN;L;D,9RG#YBSZ2B^\^?RWRZ
MGQ&6IQAC"T.)GN4H( =N :TR!SB?A:='5#K)HRX+\\Z]I)+EMS&84&U<:=D[
MM>QS#=IVZ[.W0FWM?U:-9Q:WT<.1G76\/:Y- L4**H]Q&9@= #<Q5*LK$LLE
M_$EDH+E)!:)D:/I]Q7YSD(GQZ%O7-_L[CO"OOGZ,DG [$N&MJI1Y>FU&KS<H
MP3;IUFP;38;"CXY^S?2E;9R .X-J185#^(KMJR:JI&PMF:!BM9:SY'4K>T?I
M^S43=SFP[#C;GK'6FP[XT1M$:\U="QE2;7* US;'].L<+*W%U"/V4,%@@$U)
M$Z+(BXY?$7V_5Z?<;+"Z A;=J3CI1.+TUMN]6W>CQ#9DS%[PUCKJWN%JO7FV
MIW,5:K754;<X>3[F<L-/C[ #-):.,V>RBK&+(L^M_B2R5/Y0P^C7U'U ZKTI
MR%J?'M5K#[_9V?>L8YN:S2,@]E3^KJG1YZJU&GN9U\V:$K]MV="WT(TY))W7
MF3M4D.!%T>N_$*Y%[/BM4*5WB]KIE-\D+ML&KZ"93F_)ALP7@M,GNJ>U[QM-
MXRTX^<U*,CU*M&DIT/6V-REK.:RM!>!!),G*QR+!F_)#?_)GE+Q0H3.'6T_7
M*;<N1\=R$H]7WE8HEQ(;/XXVW74/.1@S$!K,H;%UJWA;?!V.K0CU]5F>P$+?
M)1ES955>JLQF"*P7()SL_;O*R;T#6MV;%TA5==<2%-Z,I36+Z'AYB=V;:MA6
M2FUE_8GTK#RX3%2I+&F/';FH&*C#3KRP$&?3>H-&:*9%U5AW+R.W9X7>K=OZ
MBAK2[Y$;HU5QVEQ2UB$&PL#"0O\ .4 NR)^KJ61RSKT45A6I"U2\:XF':$7'
M)E;G>.4FR*C@A%7,)[D/<*!;=4T,_-!?:.G-[P@<D]=SFY]0OMU)T&Y:1NLG
MJ=]I[;<$\H-+>T.4V&MKNRV-NG-1,^+*$N4/(M7#%%Y$2Q/S^?R%,'%7EH6Q
M;3@X[?VWU$;N\HNN]%TNJP;.Q.]<WO8L$:2A-N;ID)F @S4&#/M7>E4O>L-)
MA9I2)/:(74TN[UZD]1M[MJ8BY_B*WJ[P.Z.'=)KTORE3J][)R&7M]7XD2<='
M[/LJM3JU%?UQ;MEG\;'N(J"=OWKM\"SHITFSAP*1%#'[<(J[Z4Y'[IEHGCC6
MYG9.UDY!GXHEJT;/5C;#-K ;UC-,DT+M*\4W7G(%M%147#3%A=^1"7%M)PYY
M>-EZ\M479YZ2E6\B*3O^?L^?]Z+'HMYOB$X&[2YYPG+'?A=KZLG^2%\3I-PN
M$1:=)6:OZ=WCL:"0UW)469KRRK2,L%,JK>MM7L1-L)F,E7+>2C7B:J96YB+9
MAR[VI:8O4&I:W1Y24H]PY0;@U!HV(L[!4$)RAQNQU7$]>YZ*7%/JWL\+K6NW
M0M:=E!,[&T#$OP$HMNT2*$W/.O;<5L.W-2:!JJN@]:\O*-PZLNPG&Y9-39#F
MQWV3U_78*YP^OU]<KQTA Q4SLBL-["G);!;S*Y%WSB/2>>A546(N@J'B<1]A
MW)&ZQDI+@RQCG-U<5=^]@_$&J-EOK-DTD'#5VZ:ZS+IV*<2%@;(-U%EJL-C:
M*)N2*LCR@"D*XDV/M42<>^:]NY/<U[(WJ.]J+6M3[,XN;*5XU:^3EH&PR#&=
MK&PJY%5[;%\IQ9IA)/;W;H[Z37>-UXY7C)*'U*QB"R18V3=V8[(BD#0[K;+'
ME+N/B-L'<'(]Y79KB^,Q&7#;KR)AK?L'9;*WKT[86ZN-UAHJ2J%-HD4UGJT<
MU3<3T7*5J:EZT]A:E'QOJI)^178X5;;M6[>,^MKS?C-E=@MRVN@["=LD$VK*
M3ONI[M9-6W*;9-$@!%FSGK%3I&;:LD>J+-"03:I&.1$IA?G_ %(K3X1,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PBCS:^I]=[RU]9-5;8JS"ZZ]N#=HTL
MM7DU'B+&6;L))E,-$G"D>Y9O"%0DHYD[(*#E(PJ-R 81()BF(M*G)KP'^-NQ
M;WQQFN/^OM7Z@I] V0G8-[5MX>\OU-L4,LK5G)ZFT5"6D09K&CHRQ,O.%>/^
MU-$'U(=@F2(L$Y-ZOVC7N6M/;\ .>=9X_I0'&\E)E-7;,L3RT<<J34]>66N:
M7])4W$JZN]0K^QV$F2H0ZM3<U9A84IF(6E5;"=[,S$>XFF\>R[\?])-IS&'U
M455L/E2FVXS5)+L<[*XC+W575HWO%@?JR.X)'=1QRM 6O2&Q'YGE/E+^MGDM
M\NPVJ^-TO5TMF$[VQF(D/ZCK6^RV6>'/P0@. FCG^N4;>ZV/?[O;'^PMJ;$=
ML31HV:W235HR%./8JNG[EI"Q3)FD@S3=OG3IV\6DY=P9%>44:-X52*B6C\#;
MW>MI<\]T\F)^MJW;E%3;)QSU,G2924L#;47&)>ON(B+C6[B7AJT9&U6&3=DL
MMMCF2"L8$U&D<-)9?XF[\LBK=P4\,WDYIGD+HC:?(R[Z5?U7B1H"SZ!TJRU&
MK<7,Y=F-AL-J?%M.P2VB%B6<.NSA+=(LAC8=>137>H,%>Y+TSIU)$6^C")A$
MPB81,(F$3")A$PB815VNV\CJSS[6VFZ^3:.RVH@A,)HO#,Z%K\R@F+ZG8=N0
M3<(1SA("G52J\85[:'XI>41BS(H5V6UX_C0%6/+Y^T<+AW_% 2P293* :)9B
M:#W,=,UVPTW9C'2BZNHRR.'EGGV9YNYU^;CO#Z+>3<DB/EW R8PX+ %Q+?,Y
M!E6-D97D;ISVXRLV?)V.@M;!$US91%% XW[5A(G5FO[=<M?/]=:JML3>X]Y7
M*U,Q]SG)>'>/IF.A'AG\D[BHV*93,DL9Q+MC.I>9C6R;5TDT5?/ES3.3Y5@I
MY\WE*&.RD66S=&?&R1VK=>3'UH+$<=>:PP10QSRS/KQ ,@>&05Y7E['2-CC:
M*S@O#_E5.IQC 9;,X&?CW%\M4SD$V/QUR#,7;=.6:W7IS>?9EJ5ZL5NPXR6X
MO-M7*\38Y&1/GFD5X,YVNSIA$PB81,(F$3"+259?%#V"MXA-HX<4IIQ=B:S3
M]HZMUVYE=L[1M52V/<CVN"K<W<D=>PK&!D*W+V*#4E)*#@H:2E8I2;GT(Z+;
M"Y<.UB($71:U\6;:]PVC3I"4T%6!XW[TOG)C5_'J=KELFGVVYNV\<H:2EDG%
MQKZL2: ;QVS%X=W#UUE!.'4A%2BHIO#OF[1-Q)D7&XR>*SMSD75*Q7(B@ZJ?
M;KV5NC4]"H3FJ+VN5UFQI]BU+4MW[UF+.BYE4)E6;XVU:5EZ1=VS*=8HN]EN
M*K#J-H4\FLP(1;V_G\L(JA\LCD^(<5T^XOF?6YU8;L[@[^SX!? [NWKW=O7V
MZ].G7]^$5O,(F$3")A$PBC&KZ7U12KY>-GU.@5B V#LD6(WFVQD8BVF;)\.(
M!&WKW)0]@,)2+O ;E1"1=D(]D =/"$7+*V\YF+^/H8FYD;=G&XOS/H^G+*YT
M%7S#MWEM/OH$MCZR[RHR8XNB,EIC*V&Q=*]=R=6C7@OY$L-VU&P"6?H&AU'N
M&[.G2= ;YKP))>MX#E)V12DTPBB=SIJH.]XPW()4\O\ 3V#U98-/LDRO4@@1
MJ5EM=<N4D=:.%H*ZDL$O5XPK=Z5\1))F+E S50ZI54R*K[?P[=/-+?#V1M>M
MU(0%8Y!N>4%2UBE=HQ/7-;W%*VE_;K#/M8LM8^-2K*P24Q.HNHBRV"<8Q+&>
ME4ZNG N%&KIH10SQ>\,^#HNH-<U_>]UV%=;73J7M6MQ-/"_C-:OU?*;@;6>O
M76Q:Q9*UR+D$YN4J5DD8UH[LJ\ZTKA)J<:5N/BV;Y5(Y%9 _!+2!]=;AU>9>
M[?1K=]=U/5[H<)]D$F2,TU2:K0:@,,[^#>6P<G@J?$FEU5FSLKU\9VX13:$6
M(@D18LZ\.[3[FYFM*=\W6QA4N1C;EA%ZV87>,;Z]A][%M[>[2EP1C35A29E4
M)Z8(]*_KMEGIRNL&\Q)GKL9"/@C7L:19.XX+:C3UEJ'7-;L>S:0^T+:;5<=2
M;-J5I8L-E4^9N[NS+VPB4F[@G]?EX>?:6Z8B)6!GJS*0[V,,S*NS.]8-'J1%
MD>K.&VGM0SNNK/5CW%U9==H[E5"P6.R*3TS=K#OR<K%CV=<]@23UH+RP6J<F
M*G%N47J2T>SCD?-8,X]*.28M&1%[=\\1Z'ONRQMT?7+:NL[BUI%AU=+6C45Q
M)4)BU:OM3MM(3=!L:KF*F4'$.K(M22,=(Q[>-L]??*NW-?GXM1Z[%8BXUQX:
MZHN-1+K]27V16J)$4[4E3U_3Z=>']?@]2/-'SJEAUS>=8(-T5%JU?HEZ2+;O
M)]1Q()S$5 0T5*L7;!!T@\(NRU_Q8K6M:?N.'K^PMI/=@[U.]>[ WK8YZ'F=
MM/9HU51IL!,1[\:\UJD0:E035HWIT/&U)K78=1N+CX.NX=OU79%@IN!6E&UV
MU9:J\\N54@=5P&FJ^UUK R40E1;6AQXE;'/Z2>VE)]!/K(I(4&?M4O,H+P=C
M@R6!\9F-K2G$62*($6?[]XMU??\ 9-7W.0V'MS6-PU$-U"G6C4-JBZM,HH;
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M /-=.EC"=R_?N1*!W<@^6</7:O55RX54$3#5,ADKV6M27<C:EMVI3\4LSMD
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MS^H2,:3H9.JW 5'9>I;O%U1\+[4-F[8M0WH7S,BEC>RQ)(R*8M?U0RPAA;(
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M 'LU(O5TR""*)TT"$2+QS+9O*YVR;>5NSW)N_3YCM11-)V600M#88&?^")C
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M+19[OM3;4_#$7)$3&T]JVR6O5V5AO5)-W1X",EYM2 K1W39JZ&MP\2#AJV6
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MJMBJ/@Z,S#<!\.V-GS-@9O.-:'LKF*.:5CRT%IAQQ>ZO5;L$LL7I'/\ VH9
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MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(@B  (B(
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ML+W:/2P$N=K0!*@8W(YQ;Q,VT=JV[;5,< \BUO&PZ]UD)1_66+=+8@@XEDB
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M3*JO3ONC0B!"]14.N()E+U$P@'7/:OZCSHQ5\[U!<!$*_7YQ>>P$8C^,N)[
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MV-%0Z^9)[JXE=K-;J,2U@:G7X2L0;$@)LH:O13"%BFB8 !0(UCHU!LT0(
M 5)$@   '3H&4JS:M79GV+EFQ;L2';Y[,TD\SS]KY97/>X_>7%6ZO6KU(FP5
M8(:T+!ID,$3(8F#[&QQM:UH_ !=WFNO9,(F$6"6[5VMKZDHC=:%4+450HE$\
M]78J3<$Z@(=R3IVU5<H*%[A$BB*J:A!'J4P#[Y)T,WF,6X.QV4R%'1V!5MSP
ML/W.8QX8X?:'-(/S"C+^$P^4!&1Q="]L:ZK52"9X_P#=>]A>T_,%K@0>X.U6
M*I\>=EPJ&MM:OI77A-0:DV UOE:FXQM-%V/,IP\G*2\%!2D<JT2K\2J5U)BV
MGK PE7KB98-U$PCVIY-X*=SO<KPUEV8S$4&6.?SN*DQERM,^L<17=8A@@M6H
M)6O=:G:60]=6I+!&VM*\'SGB"/=,H\4S-=N'P\DV)& P65CR=.U"RP,O8%>:
M:Q6K30E@JP.ZYC':M13R.L1,(\IAFD"NQG.5T9,(F$3")A$PB81,(F$3")A%
M47EE^V\5_P"+K5G^K]\PBMUA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3"**]T[LUCQZUS8=K;>MD=3J36FPK/I)^IU
M6=N3%/Z2(AV"?<\F)R35)Z>+AXY%=\^<"":")NAS%D,7B[^9O0X[&UWV;4[M
M,C8.S6C75+*\Z;%#&#U22O+6,'<GV6I=NU<=6DMW)F001#;GN/N3]5C![OD>
M>S&-!<X^P7R[6.V<K/'2W4I3J,C,:6X4Z]GTE)*0D$#+L4C-C =&3LGI%DV5
MUVK),'";B(IK204@::U<IJJO0(=S8ISO4%?CWA1BA:M&+*<HN0GH8PZ>[J!#
MHX.H%]7'1O:6RVG1B:TYI 8?A@BY=++EN=7?)@ZZ6$KO'6YP^%I&B'2])U8M
MN!VR%K_+A:0=C9E?],7&[C1J'BCK"'U/IJL(0%>C0*XDGZOEN;#:YLZ1$WMD
MM<N"22TQ-OA3*!UE"IMF;8B$;%M6$4S9L6_#<YG<ER&_+D<G.9IG_"Q@VV&O
M$"2R"O%LB.)F^P&W/<722.?(Y[W=,QN,IXFJRI2B$<;>[W'1EFD(^*69^@7R
M.^9T&M&FL:UC6M$]Y#J03")A%^"(  B(@   B(B/0  /<1$1]@  ]Q$?ECW]
MD) !).@.Y)]@/M*@*R<E]4PDFM78*4DMF6]$1(>G:HBG-]GD5 $0$D@,**D1
M!]HAT.I8)6*13$0\Q0H" Y9ZG$,W9A;;LPPX>@[N,AFYV8NJX=N\7J-3V??8
M%2"=Q'L"J'DO$CBU*R_'TK5CDF7:2#A^+59<]?8X;V+'HNNI1T0079"U48/F
MX+H/BO)[8GV8B J&@:\OU[):VN$MD[(,B(@9-1&J0RS&EPJZI!$IR2-GL)FI
MP#S&2HB)";7D\.Q7\?:O\HM-]X:+'8C$AWL0;UALF1L-:>X,5*J'CL)&]B='
MU7B7R#8J4<1P/'OWTV\K(WDG(BTZ+7-Q5-\&%I/<.SA/E,B8S[PN.PWF1_&"
MBOGK::VE*VK=UA;*$<)N]F2YI*O-7!1[^Z+H,>G'46/2*?H9(@0"ZR8E*87!
MU %0?.7F.2CCDKX:"EQVH\%KH\/7$-I[==.ILI*9<G*XC8<3::T[(Z .R]8/
M#3!SS1W>3VLIS3(1N$C9>26O4X^*0'>ZN!KLK8.NP'1:T4'O:0#YCG;<;#LF
M+*,:(,(UFUCV+5,$FS)DW1:-&Z1?U4T&Z!$T44R_N(F0I0_<&562229[I99'
MRR//4^21[GO>[[7/<2YQ^\DE= A@AK1,@KPQ001-#8X88V111M'LUD; UC&C
MY!H 'V+E9\+U6)7>]U+7%=>VNZSC* @F/:51V\./>NX5Z@W8,&J15'<E)/#@
M*3*-8(N'KM7HFW04/[9OXW&7\O;CHXZM):LR[+8XP--8W77+*]Q#(88P=R32
MN9'&WN]P"T<EDZ&(J27LC9CJUHM R2$[<]V^B*)C09)II"-1PQ-?)([LQI*K
MJ6M; Y('![L%K-ZRT>H<IX_6'GJQ=]V.V >Y)YLIZR5(YJU=7#M,G1HQV,@^
M((C87Z2921Y[8;F*XB#%BGULSR0-U+FNEL^+Q#SV='AXY 67;;/8Y.:,11'M
M5B<=RBI"GE>7$295EG#<;)W%ANIT.4R[.^I,Q)&X/I5'#1&-B?YLH)]5(T!L
M9M/%1,7!1K&&A(YC$1$8V29QT9&M4&+!BT1*!$6S1HV(F@W03*  1-),I"A\
M@RDSSS69I+%F:2>>9[I)9IGNDEED<=N?)(\ESW$]RYQ)*NT$$-:&.O6AC@@A
M8V.*&%C8XHHVC361QL :QH'8-:  NPSR7JF$3")A$PB811?L[=FG]+199G;6
MSJ-KF.4*<S9:X6:)@E'PD^:4:U?ND7<FX$>A2MH]!RX.80*1(QA !EL5@<UG
M93!AL5D,G*".IM*K-8$>_8ROC861-^UTCF- [DZ49DLSB</%YV5R5+'QD$M-
MNS%"7Z]Q&Q[@^5WR#8VN<20 "2%67ZZDIL#N;\9N-^Z]Y><7N876;A T=IUP
M3N OJ"7_ &DE%2LHTZ""J:]2I=H!PC]MN"H&3[[7^@D6-T[E?)\%Q_1U+0@G
M^G\VP_R#C<29H8G[^$MMWZO0[L_6CJM_IE)?VWC?'LQFM@^7<FA^A<0[1UU>
MOR8BED8?K!U:G9ZF]V[V-_@ZWYS;5 5-B;WU]QS@%^I%*AQUJ87NXJ-%! PD
M>;<VS'E8,) A!,B92OZO;@F8 4;/S"4#GQ]*< Q';&<>R7)K+3L7>2W#CZ0>
M-@%F&P\IDDB/9P%G*N)]GQ#V&?H_FN4[Y#-T./P.V#4P%7UUPL.OK97*1B..
M0#8W!C0 >[7G7?**EP1XW5^;0MUJJ<KNR^(&\PM[Y 6><W+8DUOF"T>E=WDG
M P1R")A2"NPD01$#&!(A"CTS5N>(7*+,#J5.Y#@<>[M]'\<J08.J1\Q(:#(K
M,X.AOU-B8NT-DZ6S5X1QZ"9MNU5ES-YO?UV=LS9>QU :#F"X^2"$@$Z\B&+6
MSI6];-FS-NBT:-T&K5NF5%NV;))H-T$B !2)(HI%*FDF0H !2$*4I0    #*
M6][Y'.>]SGO<2YSWN+G.<?<N<222?F222K6UK6-#&-:UK0 UK0&M:!V  &@
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M9K[1NDVR586"[[,%O:IJ2:.2'(ZCFC5Z@,-7H18BBB7P*O1L;&BW$J"R*X$
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ME4,;49Y%"A#OM'6@:2 3[R32%\\SOBED>=:FL-@:.$CE\CS;%RV_S;^2MO\
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MM#ICL.GEUYFX)99MH8YI=S&-'!&0W#SL5P_;:;JN<Y.T:?> 98P^#D^;:+7
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MM_2QX,+F@-LFFFFDF1)(A$DDB%3333*4B::9"@4A"$* %(0A0 I2E "E*
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MXYLG<:DRMYU2B&@C3G0RSEO\DD$#T_"_$ VS]J3L>EN(]<6[5"LJFR=\B-L
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MK)NX 5D7)NC\4\.<GGQ'=OE^+Q!T_P Z1FK5IFNK=6%X $;AK5F;46B'Q,G
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M.<XZ#6@;)))   )).@OE[V1L?)(]L<<;7/>][@UC&-!<Y[W.(:UK6@ESB0
M22 % MLY5\;J1".;#9-W:T9QR%;;6]$$+=#2+^4KCUX[CV$K Q4<[=25@:R,
M@Q=L&!H5H^%X]04;( =4HER;J\9Y!<F;!7P^1>]UAU0EU66-D5AC&2/BGED:
MV.!T<;V2/\YS.AC@YV@=JK7^<\.QM9]NYR7#1PMI,R+0S(5YI9Z4LDD,5BK!
M#))/;CFFBDAB-:.7S)6.8S;@0M+FS^;/*/GO;Y+1W"FIV&E:].;TEDV LH:)
MGG,2X$Q#/[-:F_G,]=0+DI%1;Q<.Z=6N830.BB\<"Z<U\G7<;P_C?":D>9Y?
M:KW+X'77H "6 2MT1'6JN#77YV$CJDF:VK$7 EK>ELY_.F;\2.;^*60FXUX<
M4+>.Q)(CN90N->T^N[>Y;M^/JBP]60 ]$%>22]9:PM9+(9)*;;Z<._#-U#QH
M".NEO!KM7<Z8%=&MDNS[H&K/5"E,J2EPCH52(N$5.XI+-)E6GEOTBK,85!TM
M'!2>5^(F5Y#YE.IU8S$';/2Q/U/:8.P-R9FNIKAK=:,B =@_SG-$AZEX?>#6
M X;Y.1R CSG(AI_K[$0]+1D< 7#'5G]0:]I["[,'6G'J=%Z5DCH!LOSGB[(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBJ+RR_;>*_\76K
M/[@OF$5NL(F$3")A$PB81,(F$3")A$PB81,(F$48[6W+K+2-7=W#:-QAJA!M
M45U06DW1".7@MTQ451CF)1,[?K$)]I0C5%0$2?I5S)(E,H66P^"RN?M"GB:4
MUN7X>LL&H8&N.A)8G<6Q01[_ &I'M!/9NW:!@>0<GP?%Z@NYO(14XWDLKP_%
M+<NS:V*]&E"'VKDY[:BKQ2. ^)P:T%P^;OEGXY4[<Y5;5W$BKSCQQ+O"PD;,
M,$5W-FL#QT84&[6,&)([>I*.EC$21CJD"THZ Q%&%Q8KF,U#O7'?"K%8B-M_
MD4\&0LQ-,KXWGIQ50-'47O$A9ZOH )<^UY59OL^K*T!YXGE^;<LY8]U7&1VN
M)865P8SRC'+RS)L<=!O7'YU?!,D!T&5O5Y+8 ;9J.<6C -"^$%RYY=R,;L3F
MM?IG3VOG#H99MKIJ"+G8L@*YC&46&OJ M7Z4]>(+'(YL5K&PWA<4@1FX-813
M=DQG_%'"8;KK<>@CRUYC?)%QVV8^%C0 V-CF!CYXF$ MKTVUZ8V70RM[M,WQ
MGPU?'"WSXAB:<CC/)"W<N1MS.)+I[4LSI9'6) X]=F[+8MN&F/9H CZ/^.'$
M7CSQ.K 5C1FMH2HE7133F;$9,TI<[*<@$$5K%;9$7$W)@*A?.28G=IQ3$YC$
MC8]DB()!PS-\DS/(I_/RUZ6QHDQ0#4=6#>^T-:,-BC.CHOZ3(\=Y'O/===QN
M(QV)B\JC69#L /E/QSRG[99G;D?W[AI/0WV:UHT%9+(-228111MS=-!TE!LI
MV]R#ING*/31\3'1C%:3EI1TFB9RY!HR0Z=K=DV(9P^?.E6S%FF*8.'*:BZ!%
M9&AB[619=F@$;*^.K&W=LSR"."O%U!C YVG.?+-(6Q5X(F2332.#8XW:.HW(
M96KCGTHIS))8R-EM2E5@C,L]B8M+WEK=M:R*&-KI;%B5\<$$8ZI9&[;N(3\T
M=,2$3'NJ4O8=@6&30.LC2ZS"J!/Q@D55;F&U+RZL9!U%L1PF)3O)^79H*H'3
M=L1>MED%%9^/A.5:/47[&-Q6,+8Y(\O>NQMI6HIHV31NH"+S;-]SXGAPCJP2
M/:=LE$;VO:V!DYMBG$U\?!D<KE&OEBDQ%&G(Z[5EAD?#(V^9?*K4&LE86.DL
MSL:X%LD7FQN:XX+)7ZR7WN-LOD#J_0%54$?-I&M+_6IO8CMN8 ,9O.;(D#IM
MH-P';T,E2X+U )G,"-@[P X>GK^*83MC:$G);[1VR&;C=6Q<;Q^U6PT4AELM
M[C1R-GIV/BJZ.EY^AY7F^^3OQ\;H.]\?A)!9RDC#[ML9F:)L=9P(]L?6ZNDD
M"R#W65T&]\0=6$<I4";K:DH^,)I.:B&M@O-NGES=!.I+V5)G.V"864,3O[7<
M@N0INODIIE$"Y!Y7/Y?-.9](WI9HHNT%5@9!2K-&]-KTJ[8ZL  .OU<37$:Z
MB3W4WBN/XC"A_P!'4HH99>\]MY?8O6"=;=8NSNDM3DD ZDE<!^R %A5\YP-9
MN!G&7%.@SG(384;)# /6[2.GHRF4B4-T*9>^R+>*>3S<68"=;X!%0R\J_%NH
MU.M%%.1Z7:Q^'JQ6().4R9/"8V6+U$;V8JS+=R,0&PW&MG;7J/Z^S?4S6601
M];7@3=V+SO92Q+!,SCK,?E[\<GD2-=DJ\=6C(=CJOF%TUEO0=DUX8'3/Z7-W
M%V<HKUUK*<DK=%[@Y!:RW?R2W9'*"[KCJSUBF4G4&JU5"@;TFIM93=Z&/@UV
MO=Y 76PMYB]R/E$<KR[(5#-$YC)\S<VG-A.*TAQK!2CHLMAE,N8R[03^LS.6
MZ63S-?\ 6]!7\FA%U%C89  XQF/XH#;CR_([AS^9C/7 98_+Q6+)'U,5C=NA
MB<WV]9/YMV3I#S+&26BZ [ WJ[]X[C\W9D, ]A[)M>ML#@ A]D5$(.*LABB
M_KD!01#I["/7**K@OSXCR??>Z-6TA7R"'RD+?=K"L01Z=!%-A4X1$_;[@8H.
M2 8?D< PB\C5[DG)!_2MEZLK0"/02P&LYV:4('M[E6G;T@F8WS#[30"_(>@>
MX81>/\F6XW8=LGR.L*9#"(F+7==:]A^G4/8$U)&,L"Y #W_654'W^?7H.$7D
M&BW;DO\ CG=N])4Q@'O!&YQ]<3$3" F[252OP9R%]NA2@H/: B!1PB\?JTZP
M<=1F#7^QF']8U@VKLJ1 W4>H]R)K2FW$##[B7R>WKUZ  >V$7-9\:="LE 5+
MJNI/50$1\R:8#8#B(].O4TZK(F-U$ 'H81#K[_,1PBSJ.UEK>'[?A.OZ3&=O
MZHQ]5@F8E^7ZHMV"8A\@^7]F$7G<=>4Z^U=_3+1"I/JU)BT]=&-7+V(*N#%V
M@_:E%Q#.6#LA$G;9!7RTURD.*8%4*<@B42+&]9:/UCIX\N?7=</7S3Q69)4!
MF[!*D=!'BX%H/E3,K()HF2%VX^VW(D<X*=JACE*4"D4L81,(F$3")A$PB81,
M(F$7K56202.LNJFBBD43J*JG*FDF0/F8ZAQ*4A0_>8P@ ?O',@%Q :"2>P !
M))^P =RL.<UH+G$-:!LN<0  /<DGL!]Y58MA<UN*.K@=%N.^=<MGC/O*XB8:
M>0M<XDH3KU24A*J$U*IJ]0$O8HT(/=[#TRQT.(<GR1;Z3"9!S'ZZ99H'582#
MKN)K7DQ%NCO8>0J7EO$?@N$#_I'E&(9)'OK@KVFW[32.W2:M 6; =OMHQA42
MV'XUO&JND<H4"G[*V._3 ?2N#Q\;3:ZY$!Z *DA,/G,^W*/N/4U34-T_WGOE
MTH>$'(;!:;UO'8]A^NT227+#?PCA8V!Y_"T/Q]]<PRW[H[AM02-Q6/S&7E:#
MY;W108ZH\C^5+9E?;C!^TT''[M=U"\'SIWCR[L-1H5RXAS33B]=[?5(?8TO%
MQ.V;(K\$>V"/08&7N-:;UB+6B G319YV-/$/6<O#D?1<BV<1SITF>7FX9AN+
M06KM/E4+N24JEJ;'QR2XNN/.9!(Z3IJ6'69!-Y'F""03-?%,62QN$C6$5NMX
MG<EY_:HXK)>']EO"<G?H5\O/!7SUT^FDMPMB+\E2;2@=7]48'6H36DCL5A+!
M*Q\,D@5H.8,3IW<6F;KK]MJZF2]HK.SM>:=T5\#;$7>NYVWLZY(>=75*XC%J
M0,3%UN8L[URW]>XKR+*N+S#U)<6:;,E.X1D<M3STEAUZW7JPU[MW-/FD)8^"
MM"9";#; >))7V36A9\)L.?*UC'M\PN72_%+"\=R7$X*3<5CKE^Q<QF+XQ'7@
M DCM7K+8&MIR4C$Z&O%2;=LOV\4XXJKYI(Y/)#5L5UCJG7>F:C'435]1AZ;5
M8PO]'BXAOY?G+B4I57TB\5,J^EI1R!"B[E)-R[D'9P [ARH8 $*?D<G?R]J2
M[DK4MNS)]:25V]-V2&1L #(HV[/3%&UL;?V6A='PN"Q''<?#B\)0KXZC"/@@
MKLUU.( =+-(XNEL3O 'F3SODFD(!>]Q"D'-%2R81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB815]LG*71E5W_KOB]*WM@.\MGQ%CGZQ1(]%U)R*4-5X
M=W.2$C856"*[6L-G4='R"D,:=68C-G8/$HPKD[94"D4457Q%.'ESW3;- P.X
M8Y;8M-/=V\FD[A++&U9](:S9_$=C1%;O$A#MJA9YBC, 4?6:,@9E^\C6;=VZ
M.D9NT<J)$7!I/B,\5]B:UD=HU*VV:0AF&P=;:P;P#J@W"%O<Y;MQI5U]JII7
M*3.1,;8)UEL""M,/::S)Q[-5B_JRCN=\]-E'2"C8BO/A%47EE^V\5_XNM6?W
M!?,(K=81,(F$3")A$PB81,(F$3")A$PBZR9FH>NQ;Z<GY6.A(6+;J.Y*6EGK
M>/C6#5(.JCAX]=J)-FR) _6464(0.H=1ZB&>T%>>U-'7K0RV+$S@R*""-\LL
MCS[-CC8'/>X_8T$K7MVZE"M-<O6:].I789)[5J:."O#&/=\LTKFQQM';XG.
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MNA&E;2SN;(4C91LX6*=$R"8BZ, H^8"BRW@Z1SVQM(:!&PL:6M:TD%[G[>X
M%[@7EH<XEP8UC >EC0/=K QTC@7;D<'N!<YP!#&LTP$D,:0WJ+6@ O<]Y'4]
MQ.1;:V%QLXT0T?(VV'J,+*3CCX=3*14:;'2VPKY,B)"(PE&I<#'J3MCDE%5$
M4C%8M1:,O-35D7;)L(KEF\%QO+\CGDBQE8.BKM\R[?L/;6QN.@[DSW[TO37J
MQ!H<X>8_K?TD1,>X=*B<SG\7@88Y,A8+99W>74I0,=8OWIM@"&E3B#IK$A<Y
MK?@;T,+FF1[&G:@Y'6W(?E>4'&Y%I;C)Q[>=IFVAJ+-$9[GV'$G$#II;DV-
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M.ND$>[58!HS:1[9!DP:MV3-JF5%LT:()-FS=$@=I$D$$2D223(4  J:9"E*
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MI5[==<1N,FIRHC0M&ZWA7: E,E+K5IC-V$IB_JC]))\DI/&[1]P TB( /N
M.4N_RGD>3V+N:R$S'=C$+#X:YW[_ ,'@,4'_ /K73\1P'A>" ^B^,X>M(T[%
MAU.*S;[>V[EL3VB!\@9B![#2L24I2%*0A2D(4 *4A0 I2E .@%*4     ]@
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MF !*(?V" ]0$/\@X1?AB$.0R9R%.F<HD.F8H&(8A@$IB&*("4Q3%$2B40$!
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M94/(;MZS6)ALD<0 B92B(!.8?E$5PNBX+P.Q8CA:6S7G0TL/0K #9?;O,9-
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MKYII''W=)+(YSWN/VN<2KA!7@JQ,@K0Q5X(QTQPP1LBBC;[Z9'&UK&C??30
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M0?24E(O'3U\[<.5U53$4BX1,(F$3")A%Z/5-?+(KZEOY2I_+34\Y/RU%!$0
MA#]W:<XB4P=I1$W4!#IU <(O855(RATBJ)F53 HJ)E.45$P.'4@G( ]Q0,'N
M43 '<'N'7"+J)^M5VUL"Q5H@(6R19'L?)%C9^*8S# LC$O$9&*?E9R*#AN#V
M,D&S=]'N@3!=F\01<MU$UDB'+[UK5JG(9JEF>K,8Y(C+6FD@D,4S'131E\3F
MN,<L;G1R,WTO8YS' M)!\+%:M;C\JU7@LQ!\<@BL11S1B2)XDBDZ)&N;UQR-
M:^-^NICVAS2' %=N*B8* D*A 5,43@D)R^8) $ $X$Z]PE 1 !, = $0 1ZC
MG@O=>>$7@15-7O%)0B@$.9(_8<I^Q0@]#IG[1'M.0?8Q!Z&*/L( .$7GA$PB
M81,(F$3")A$PB](N6X%5,+A$"H&[5S"JF!43>WV51$W1,WN'L<0'W#V]\(OT
M%T1.1,%DA.J3S$B H3O43 .HG(7KU.0 $![B@)>G[\(O!VT:OVKAD^;-WC)X
M@JV=M':*;AJZ;+D,FLW<-UBG27063,9-5)4ADU"&,0Y1*(AA%Y%].U(@@7R6
MZ8 1NV1+V(D "$Z)H()AVE "D+T(FF'V2%Z%* ![$7NPB\"*)J"<I%"',F;L
M4*0Y3"F?H!NPX (B0W:(#VFZ#T$!Z=!#"+SPB81,(F$3")A$PB81>OSDO,,E
MYJ?FE)YAD^\OF%3$>@*&)U[@)U]NX0 O7VZX1> .FQB)*%<("18X)HG!9,2*
MJ"(@":1@-T4.(E, %*(FZ@(=.H#A%[\(N"U:1L,R(V9-F,5'-Q.*;=JBW8LD
M!76,JH)$DBI()"LX5.H<2E+YBRICFZG.(B1<["+UF52(=-,ZB9%%A,"29CE*
M=42%[C@F01 QQ(7[1NT![2^X] PB]F$3")A$PB81,(F$3"+P,JF0Y$S*$*HK
MW>6F8Y0.IV!W'["B(&/VA[F[0'M#W'H&$7K%TV BIQ<( 1 PD6.*R?8B<! !
M(J;NZ)F 1 !*<0$!$ Z=1PB]_P _EA%PV[%@P,]7:LV;,[YP9](K-VZ+<SQW
MY*2!GCU1,A!<./3MT$3.%Q.KY*"28G[$B%*1<HAR*$*HF<JA#@!B'(8#$,4?
MD8IBB(& ?W" B X1?AE$RG(F90A5%.[RR&.4#J=H=3=A1$#&[0]S=H#T#W'H
M&$7GA$PB81,(F$3")A$PB](N&X>=U71#TX *_54@>0 AW *W4WZ,!+]H._MZ
MA[A[81?H.$!%(H+)"*Y1,@ *$$5BE+W&,D &ZJ% OVA$G4 +[B/3WPB]N$7!
M,TC$'QI,S9BC).4$8TT@9%NF^7;)JJK-V!G8E!=5 BRRZR+45#)E5554(F!S
MG$2+G81> *IBH9$%""J4A5#) <HJ%(83%*<Q.O<!#"4P%,(  B4P (B X1"*
MIJ]WEJ$4[#BF?L.4_8<OZQ#=HCVG+U#J4>@A^\,(O/")A$PBX+F+C'BOGNXY
MBZ6!,J0+.6C==4$B&.<B?F*IF/Y9#JJ&*3KVE,H<P  G,(D7.PB81,(F$3")
MA$PB81,(OALVW0-QVZ6WWX>.NWE@BFOA^;4YI\SZ\NU!43KT:*C*7:=#5^-)
MVF*:47?W&S.$VQ2AWA/@9H(@<IR$5LZ#S:V[%:^W=SIU)"K1-V\0/GQJSC53
MK1(5)K=7E&UCKK6";!G+52ESEBJL%8[._?I2T)7X&>L43#/I9NX)(/$5T043
M(I>D/%(YNR-8T=I]&/;U[:UWW]R*U?-[BJVJM?WZVSM5T96*O9(06FDC;B1H
M-7V9/*6L([8-0DMC":JIU^0<0R+A9TW0$BK+NKQ#>3,+?^+/+EIKRNNMW3?
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M5V$+5[/"P)];4PT+$62:D2(S-ABXLT*+%A.2R+EPE)RS1!)^_2763=.%2JG
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MD[U'(P]#JL8DPNRC.?CU+BR3912!&MJ48(HL3V% $Y<[-)-L9X**92!@>P_
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6<[AJV6,F*B"1BY1;?<(F$3")A%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g307489g44i44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g44i44.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2'T4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (=B^AF0X0DE-! 0      !<< 5H  QLE1QP"   "^[,< @4  U=E8@ X
M0DE-!"4      ! WC$S9VXU-N8]Q]Y_]2H:9.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE-! T
M      0    >.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             ";   !U,
M 0                         !              =3   ";
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   ";     !29VAT
M;&]N9P  !U,    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M C_P        .$))3001       ! 0 X0DE-!!0       0    6.$))300,
M     !=J     0   *     U   !X   8V   !=. !@  ?_8_^(,6$E#0U]0
M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(               $  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M-4TUAS7"-?TV-S9R-JXVZ3<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  $0@ Q@)8 P$1  (1 0,1 ?_$ !\  0 !! (# 0
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M P$  A$#$0 _ /OXT T T T T T T T T T T T T T T T T T T T T T
MT T T T!$F9<^8.VZ19G.,_9@QGA.&$3C6,L)7E6<1N QU[(WS(@19 FAF4$
MA@]P7=CQ)1ZW').+W:S0<^<)I7)-5[[ //'^>,)97D^0X5C#+N-LAS#$9NV-
M92B\*FL=DT@QY(+EGS6@:9B Y%X^CA'RP658U:%D&JUI 45876T>#'R#<"6-
M 8U*IG$H.R&DIE) D7'F)-%H8*>GB346V(RV;GQ\4AT;9+/%4DW!N428L+
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M&ZZOY54>6D](C.2=<?XSO./6.[*O:@;7/O?\3_[):;KJ_E51Y:3TAG).N/\
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M?%6[/&$"BS78[OC20Q8#SF:WAN,>1F(JL\9-W3>%1(%N3@(N1QY)\T$D+\*
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MNFX9^%2\OH><#-N^AY2/N\+9I'KO,1?R%N*^\ZW>?J-TW#/PJ7E]#S@G-/\
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M*^\ZW>?J-TW#/PJ7E]#S@9I_T?*1^D/7>8B_D+<5]YUN\_4;IN&?A4O+Z'G
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MLD'_ #K3WO6,'9W!/D:S[<WQ[!T[,7.QF&?)T7/!\=&[=?:QYI^V6#=_9_\
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M5UE_$GG&0_@J/95/!Q>W0V_?= $_])IN.JZR_B3SC(?P5_@3I@[=UMBW+/Y
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MWM'AMJNG:WTN#[?/\%[_ ()6X+Z8J[OY_P#-I!^_7Y'_ -(3_O+@3_!-M_\
MSU5OZU/TS[B?]P843_W7_I8?,=WFYOY(MI_TU44_%=E[7PF#X-1]77\6(^U,
M_;[Q?M0VJUG*&JN?LTX6QA*H@-R#"[9;.7,>ELG@?C1R.OGB=T::ID%QP$S(
MW+*],R5>M62"32/7/W0^MK<W(DQ %O4PD!'(G=UM^K*F;5#'AEKEEE"84S'@
M146B#R:6,):5@P=E QKUJ92=#&8J29"B@Y;T\6CD1=U=K&@9$D$%E";$"VK;
MN=NI5Y&I,.QPY.Q!A"C<F'9(>PT*(:!'9P9C$NO$0J\CM'W#"A@?F*.*S!\5
M?1B,":NB-ADVXH'EMT> M9S>#MO.0]_+HWB$[DI2) BTKCS9#'(-=M863QU?
MD<^T8EE[WB0YT,BC9!>4%12#Y-2V]BQ"724D0"#20+H122"V9]K2#Q6-CHI$
MIXJX*>)-T('%8A*PL1E>1#[+'Z8V>O$;T6;"2SF8.F4-?-7%K@K>O6KZ7(BX
MTQ?&&@&&PG/&#\HPG![XC"N9P21BF6W.%\1DZ3%_C=(,'CSF/'LB XFJ"L)C
MX2(D4&?CA!0"0(-BE8^]B<9(.X^S=, *N]ZFU,XJ=EA*.OR[F+ I:VD4@7@P
M,Z_ X]"BAAPX_+/FKTB]&QQ\@;9-UXF\O0E29EQ4,=AX\M=:TO OT\W:XP:X
MKB><8[CYQD=$S()]$F:=*Q=,E&RT"QIE>:G+7YNQR;'J"[64%.B+R45?GV+L
M<>O*!E#3!S1!^!8U=UNTL?,@$?/0U"-Y'J;\F7"&H#'&LJB!DRB*B05P[I1:
M]VX5ES+TB#,',3O.N&P*QK65V1\*'(*# /8QW<;9!Y]O<ACTV%F$CCL4DS-K
M3'L;:30X@Z5CXV#-*"6A*^3JNE@TL OXZ\>,T@C4>06!HF&LF&&8V/ D3&F6
M-O$I/I0&'P)J!DQ1])092)JX_"A7;% 6K(DIL[-H,K%&5\>&SB''X$;*(+OA
M;^>C+63-8FS=#R[D#9):'1%PS3'+Q6.+CT2)$PBQ6!C%6:1<QZ8^FQ1-K>UN
M0L(E/3<MZ8OK;*.7WIH1\I55\M<^B@<5: 01P!&15Q"HDO& J[9R'CBT;#J@
M1+EG<I>T<# ][*X>P7:WJJWME6K=)1"Y52Y*ZVM]U:@<YO%(LT240:1H U06
M?)E%46X8<BDJ32'HB4B*B:;:VR]\F+;MQJ;NZVKBP>@BSM4HW2L3M LS3&.-
M6'I-Y#CV#L_4Y8LG'O)(F ;^D2;A]:3<)AO01]GI78N2LL(+6L?0+57UEKN^
MER]M%* 7 )"(7&:,J1R(1>/T'-'[ ?0( $BJ,&!5XB0*,F5&#1O1JT)/VS=\
M_;(>AHO'B"+EQ8HLE9?:!07!H4#:H,0L/BP=DU5N6;,Q<?$CVK=:XFW-7*H-
MVC1%)%6XRT:EKE$[+;JDVS=_6OE2*:MH'/!QN.QANZ:1H %CS1Z_<E7C8&*8
MB6[LF]K;<\).D6"#=-P_=W667.7BMM[A>MMM55+ZVTX O6@&@&@-7-\7\"K>
M!]*YN _%/+=:*3XW2_6(?Q&EX^J1]^W[R'YKL2Y]2D7]R. NO_\ %M..>E*5
MZTKQTI2E:]M.Y6?&ZKZQ/^*X2=4?W[OO*9!V]]/J<UKUKQW<^_[G7KSQK.4'
M%/?ISV]>/-QW]*4IUXYKYNE*UT [J\]W=V5ZTIW\<]>O;SSV=O%:@.*4XY]V
ME>SGW*].>SFM.G3FE.>*Z =O=S7KW>[7OYK3X?-_Y7.@%>*]/J\=>>.>..O9
M2G;SQQWUY[0*<UI3KSUZ^;K2G2O6G%>>_OKT^$#:S9/NKD6R[<KCO/@6A%\#
M".E8[D^-#;:*.)CB:1+,TYH";MK[D['15DDT'RZ*M[EVMBLQC$?1<.4QRSVQ
M71 YJJZ&1R-CFLW*=JBD15S<O:1JJK7K9;1/DLBNL7:J:6K:SDM==Y=YW@U+
MVE4_1<BTHCTWC,=F<1,,)#%):"$R:,GQ:]KD8; '6#<H'+CW-G[E=D1'NF[Q
MJM;T406LOITKKBYKF.<QR*US7*US5T*CFK945-J*BHI14LJHNM-"E^U4#0$?
MY7E!2$XRR!, B;!4S&(?(3HI,JW<.AEY$8+<NV="#5H\'.G+*KA)/RE!L08K
MK(^.FD[;WW6K6 :6Y[QQOH*Y)C$I@>>\31S#0''$Z;Y7C3K&1M9.7JN+4EQ[
M(?&G<U..K2B;%%_8C*&,YB5PFJR5BPR2M[UF5FFC^-TNW=,&G_>MWOZG.;J4
MNC1FY/NKHU:?;0?F7VTZ4\_3N]SFE/>X^#GM[:TK_2UJ:$VZ-[M71.Y;P7UZ
MU1?P/-U67]X_[RCS4ZU[O/[_ #STKW4[*5[>-3L32N]M[M[Z%WDU(NNQS%*4
M[N..>>.O-*]O/N=W3BG^K4(B;UK7O;3=%UW[6]HLG\@/-7X:<=>ZO'/6GGY[
MJ=W/?6=B^%+:=Y;7TIMOO)O7WU%.E:]GFZ<<?#6E:=G'2E??I3CGG5="KJV:
M+6\*HJ:K:$7NHEKW!Y4I3K6G?_V^;OY^IU[>NK(B:53?_P ]F_?BTZ](';YZ
M?4_^?2NFO:G%_70H*=.^G;WTZ]W/FZ\]:\<4ISW=:<QHWTU[Z:=Z^S3?2MK(
ME][2EPK6O%.E>[N[/-7CKV=O%.M._C156R:%WM[5L6VG5KLFE-^P*4Z<<4K6
MG=V^YV\^?FM>:<4Z>_HFBUD54WM?:UWVW5;I9-'=!7I7OI2O;7BM.:].WGWJ
M]]/>\^FA=]$76ME2ZZ-=^XN^G<V@I2O/=S7IUXITI7KYNRM/?KUKSQ7IJ$6^
M]==&FR:$73LU*G=72M[+H!7K6M?>K3MXK2O3I\'2G-.>SKVZG2JKW%379471
MH\&A+I?5IU@E7&^;,G8B1((8]DML?M)%X_(%5:@XX7=,I%%+"Z<8DH-Z=$$G
MD;DP"T\8])Y#'EQ9H=>0<*-7R=];;K?&X0P-@[":Q+74ZS9N*:G3]=/$U]/4
MK$L]/,R&6)L\$ZPQ9R"9LD3\E,IJIK\I@_#6$L%L>RAJ$A:^6.?3#!*YD\37
MMCGB=-'(Z&9C7N1LL2M>EULI= FX7+H%.]NA+7#QDLF 069$V LA9:UC<4&P
M-BW'O'+.\D!HZ@H@?##+J//Q) [&6U@@P[>M.4Z\)L 8*F5KGTB-D:M0YKHW
MR,1'5%3)6/<]J/2*9&U<CZJ%D[9&0SKG8F,<:H,9L-T^6C:U[F2) DC9&1/R
MFT\,=,QK7N8LD6531,IY70OC?+$F0]SD53)9/NRSQ*BDI(NIO>Q0E52]JX82
M' L0X5$VXF:Y"D69V#*TC#]Y3(<Y2?R )>QDA>R62*\P8?K&R:KOA38KX$IX
MZ=C*1)'4V:M+)+,^:984I4CW2]9+5$;%H:58X)4=3QK3P9J)C8F(FBHQOP_4
M2U4JUJQ-JLXBQ110LC@;(Z97)3)FU=!(Y*B9KYXW)42MEDSLKU>Y5E_#DQW4
M[@97:-"9?#@%RDFC,/<')G:-#1PC,,IOY8!;*FKQ$2+6.Y&6927)$QD$M+#E
M2BS43(Y(\,NI6T!INO%85H\6<!T^7+@J6=(X*BJ;#2J^6>.EP:RFF?FL[4QH
MR")]/0TL%+$](T=)# V)M.Z;(\Q@>NQKP_,^*#"L4*/EIZ5SZF...&:IKEG@
M8UV9I9,JHDCEJZB29[4<N;DF=(LS8U6WF'^\?'D\ "%I5(&&39\_3,4"-70^
MP\V/X5E<G@8RPLHZ9-QB)&//X.36$JL'SQBZ%48O+':RCFJ2=HH\4J^BGDW-
M"[!U"S-YYS9%@6+"U-3ULBQ(QSGJR9E7&DJ/8Q[9$>W(3)NJ6;'3!]?#$VLE
M3"6$T>Y88\TDM\%S55&ULBRQLC3(2&9T:L<K7Q.1V4JN1#AX]99RF^=GL8/9
M1@V,,BCHDZCJZ&20#M>!)PP>,4DI@"\CD&QG/X**B84,@_G9V\]'AD4&U8D)
M6]>6'$;W5TUS\"T>!&3PX-J\)4$E4V=K\'S-;6;JDE2GBF;/65]'62U,LKFT
M<20S25#T<RG:W,KDI7!S</5N'IHJK"U)@K"D%)F<W709=,ZE;$L\D*04E'4T
M4<,42+4R9UD<377ENLN4J9'ES'.YLK HDGD7)*$N8S.%&,_A1) //TC4B'M(
M\METB\=3R0XS" 9J:$P_*$PR!08VG\F;15J0FS:MP>0FD0Q[A@NOQ=BK:EU!
M@Y](^EJXL#2RLEHEA@>^9,&,:E%#7RS4<4M3@^FHW2NHH'3N92N_6PQNDB[X
M7P=C'-@^F96X7AK6S4T^%XZ=8JE)I$BB2O<BU;Z*..IE93UD]5'#NJ1L3%FR
M6L<Y&NA&*[G\L1Z:)3,H;K,U+ZR.TR$DM7/I-(6TM*2\_(61E,*X$NG3(F>G
MDI,O6%77I:17+.F!9D2!+N@Z_FZG%O!512+2Q0K29*0+%/!DK+ ZFBI8H71+
M*DK6O9!1T\;7HW+:C$?$]DS6R-\#2XV88@JFU,T^[$O,LD%0B)%+GW5+Y$?F
MLVY4=)5SO5MU8Y7JU[7,NQ:D-T.75,N2O,\>,LX=*9=Z4MR+$$,:/(VF,CMP
M)2,BZ Y-9(&C]O&W,7C9 *X,4)$&!H(-.H/+#+1%]8CQ:P4F"Z;!,\3ZNGI5
MD5DDLCF5&<FSVZ),]3K"]KITJ)HYFQ*QCXI9(G-S;G,7F_&?"O\ K6JPO3R1
MTE169"2Q11,DIE9%F\TQ8*ALT;LVZ*.1CG-5S)&H]BM<>J4;I\\S)G(F4BGB
MC^DM4/7R$@G'(B//$$Y;=8I+&E9*- ,Y$U&RI6RY:3B691L,D*[E\L79O%2#
MV]Q--BU@6D?3OIZ+)W-F$A8ZHJ7PL6G1R4S]SR3.A=)3(J-IY'QNDA:C&Q.:
MC&9-:G&C#=4V=LU9?=*2-G>R"GCF>V=K6SLST<396LJ,E%FC8]K)%5RN:N4M
M]?>WZG/%:_TTKTIQV?Z^>NO.Z^*]E7[470EM7\[Z3P I7W:\4K7ZO7GGCN\W
M/G\_&I1>VMD5>/3>]M[9?;ML"M?Z>WOI7IQQ_17NZ<U\^B_;KWT71:WV+O:+
MKM!3W>:<?5K6G;W]:>?CNZ:CMW2W&JIKW]*;;;V@%+NO;7L[:4[:]O%.OF_T
M^:G34.TZUU:T36NNR:=G\=B: 5K2G%:<4ZTXIY_]/FZ<=?J<:E42RI9-*63;
M_'9HMIXK <TXI2M.WNXIV]O%>O2M>VE*Z72R(J:]ZR:]=ETZ%76B*"G7GLI7
MFO;QS3CQ>VO''/?QW=>[FFHTWU(MUUVNELG6MK7W[;VG>N@*TXZ].M.E>>^G
M;V4\_6O9UU*6TZ-*:%OOIKU)MTKJT@<4YI6OG[*T]_BGO\UYK7KS7KTTLET5
M=NI4[MD[MUNJZ;KIT 5\U>E.RG9Q[E._WZ4[Z=*TU*[%T)J35;M)O]U$WTT*
M@'O5ZUYKS3CCK3MXK6M>G3L\].[4=Q=*W6Z6MI37955=&C5M3> IUI7IQU[^
M?J^Y\'9W:)I1=%M._?C[7@U;P/M\_P %[X]:5N"XK_RBK_Q:0?K7W:UYY]WM
MU^1_](3_ +RX$V?ZDU]O=U5>_;V]M3],>XG_ '#A7_%/^FB.[S<W\D6T_P"F
MJBGXKLO:^$P?!J?JZ_BQ'VMG[?>+]J&U6LY0C>98AQOD$N).3.*L9 1"IV(L
MKGJ[^C-9%%ZD39H%1:#M$6>0&E442PE XS(I""Z=A498T(6T<T P^.[8\%Q4
MH.,@\?LFQ(11OZ5.7!:1$_2V]N9CLCJLP1*F'K=HX>2*)QZ0%G*"2;@T<&)%
MRZKXBJY<K!J.%3:EM\3N2O;8U%L+FPX&-8U%DY"*H+LC?J-](R >@TPUH'D(
MZF.X%:C*1=&DENLAD8L5+*6 QUK<#VK;6-OR\5<0F[&(-*,.R2Y9R,:N"[+T
M9X[C2T,?^.\9DD"%6A2(N747+C?*O2XO'W3H.3:.Q[A9O>%M%M[49S(\18WE
MIZ.2>11,>3.12@ZT(]44>H^A)ABS.0!$'[9LZ09FVP&0CV,B M3;<BW!R%FV
M.B4F99%-Y:!PC6$<52$##HN7A8QW'X"/:AXH*HJ_;-1@)HT8,+8XI:T=H7$X
MRZ9BA;<I&R]S\$93&CZ%Q[VK-O5,#& FU[ 4>'$1(O&0&P86B;J"/V+U4H7;
MKPMV.8![HK1,N0?40 -PXH4''"V_H3,2(%C18M)FQ8-&Z(&1/\%XI*PYC BL
M1;E8N/+$SS=D4)FR3Q0T<0-M#A5Z<>DUSQ-^<9260,#;DD3=JEQQHF/(W.63
MU="\#BDMOV'"TA5E;^!BE3[I\F1($$ER;6IAVA:,\BO/-FCY!F?2%K!A;\,U
M--W[4*59(&!*+,I;5Y4#")CM!P-,F[E-Q#[@SITXC+A1_'RQ4<LG6,-HF*;U
M;-?+%A;5V1C,(C$2+EV[!(V]CP82TJ2L7#!W(\/;B,NAN <?0.?J9#CS-=L4
M2@2..0S)2C%1J"CRLI)3:0WH$*LJ20N5F,L)72"4%9.=.NWY9"C]*]LZ>EEB
M($V: : : : : : : : : : U<WQ?P*MX'TKFX#\4\MUHI/C=+]8A_$:7CZI'
MW[?O(?FNQ/Y%(OYJ1P%TXIT_WK:^?WNGGYK2G?I5_&ZKZQ/^*X2=4D[]WWE+
M_P!/AI7KSW\=:]E.>WGK]6O9K.4*_P#[N.RM*5YXK3NK3CS=O9V]:T[> '/=
M2E?=I[M.?<X]^E:4ZTI7KVZ 5^#CCLISQ6G7MY]ROOUK7IQS2N@*5]ZE/AKW
M<=.O']'N=M- //QSQ3KV^]QV5XYIT_T]E>. *\\TKTIQQ[O?7LI\/9TXIQ6G
M?SH"E>.[IU[:UZTK[E.:5XIT[N?/YM ?6A_@^^]+U4PJ1;)9V4N4D.,V1"=X
M17=W6TN(XN>DT/53"45KU*J+N<?2@PF0%(76V^)$)4Q%#4:#H<XN2TR7FB;/
MK>Q6Q3[56RYJ5>_:W(<NE5>S*<MY$0N[])J/WT_1=X$_1=X42R[52ZZSZ5M9
MB@T!#VX3]XK+_P#FXF']1/= 9K/?D%FG^2<C_J=YK31?'*3ZS!^*PY3=1E_=
M2?<7:?DDTK^Y[*]U.//V4[*].ON=NOZ6HOZ.I=Y+;=2:ET:>UK/P1-U67]X_
M[RE?<IW<4_Z]./-V>?NXU/:3>LGMHMLU;=ZQS/&OOUYK7I[G7BE:]_'Y>RG2
ME*KW5NJZ.UILBKOV\^I-"(%.ZG;\'/'/N\UIYO@]SKHF\FOP7M?MW5-G@[6D
M%>E*U[.O3MKV4IYN:\UXX[O/7GKQJ="*NK3HUKJ1-EUNMK;VU;Z; 5[.>.WC
MI\/97W^:\_#SHNJ]M=M'AU+W;K?PW K2E?<[^_OZ5K6E:=.G-*<]W/'9HJ(O
M:W]_?T*JHJ:-%T2^]>VH"O7KVTY_T=E:]G7IST[Z=:5U*Z=.M+_PU*NK3HOH
MWTTHH*\=.*\]/=YY]_S]O6GP:6T66^CMWOW=NO2G@!3LKV=.SGGKQ7NKV5YY
M_I[>>M8U+JT:KWTV7>74M[_;KOI4*=M:UI3W^G/OUKV4I2G3CMZ?5)K551.[
MHOW574B(FBVO1QBO3WNWGCS].:\]G3W:?T5U.CN:[VVZ+K?5H[:?8H*4[.>*
MTIQW>[W4I3K[M:]*]GO4A-5[*B6WNWO(B:>VJZ%U=Q YYXY\_3BM.WN[_-[O
M7K3S4JO>U]NBRIKWM_9V].E-B*'P=.ONTZ\>:G7ISU[.O%>M:TH\&C3VTTVV
M)IT7TZM-ETJJ(%/=I7K6G/-*4Y\WP4Z=*=>?/7G1.VBZ52]T1+[/ FC0FF^U
M;@FO$N:S.)&1E,.Q0=/U)/ 9]&W:]]*H!YMCMT=;!R#]G<DI:7#K1N:3,8Y%
MV*L%KGY 42L?42%K#R'AL*X'BPH^%99',C;35U%4,1+K+1US(72MB>BIFY&S
MTU+(R14>B,9+'FU61',\_@7#TN!F3YJ)LDKIZ*LIGN7]&*JHI'Y"R-_\2%\,
M\[',1S'9:QN1R9*E9%N'RU)'>)RKF5NQLBPQ!6^.H+*@'C@Y0VC3$@>>#DB!
MP<HB\(OQS&0.(XS(JJ6NTXRR%!K[U$&*=;E/@'!5.S"<3:9LE/A>L6OJJ:=,
M]3K.YD+7K'$]%9&Q[X6SNC31GWR2)9S[)SGQBPM/)@R=:IT=3@FDW%2545V5
M&91TJIG)$55>]&2K$CE1%6-K46ZHJKCB&7)[Z=3>3$CSN0RC($5(Q"12:2+N
MC1]806L&M"-[<J\<7NDGSL.-I'5G5]ZM;@+XB,]#]!<\V:%P50K#1T\<+8*:
MAJHZRGIZ=$B@SD2O?'E1M3)<ULLF?R41OZYK'VNU+\&X9K\_75,DRSU.$*22
MBJ*B>\DJPRMC8_(?=,ESHHTBOI_5JYMK*I)@K<J>81BD9I%(H-:,H7,HZPK&
M!MH"PK(9MC=##!6:S-#E\D7+(8M6-"VJ(2R,M%I*_MEY1(B8<'53GCI,787U
M"U.Z:E[GU=-/)NF19EBIZ2O=A6.DI76:L4;\(-BE>Z;/O; Q::)8XDB2+R\>
M-50VFW.ZDIF9NAJ*:%U+'F,Y4U-&W!CJNK:JO;(]F#UDB:R%L$;I%;*]KG9:
MNUJ\_F]SK2G9W<=*]].WO[N->Q;=G:THFK>MH7?37O[UCU0IS2O/->:4]SI7
MN[:].*U_H[>*5K5=%O=;HG:T+O:UT65?LUV1545YITI6G'96E/A\W';ST^'I
M72Z:$5+:E1/#LMKOH\.A0.G?UX[:].RO/2M/]7'7I[NFC?TVUKHU+?0J?RMI
MT=L%?A[^O/PUXXX]WN_U<5GP[^F_A6UK=O>_E90^#S5]RG9T]RM*=:4XX_IT
M\&Q>TFK1VE1-*):WV@<=O;6GFK_\_J4[N.O72VO6J;%_KQ)O6TZ04Z^?FO=6
MG9W\=.:\_4K\/'.HT[;KO*FK?MHNM^)?#:X%:]_=2E>^G->SKSUKQYZ]O/'.
MBKO[R(N^EUU:;Z5MM77>UP*=G%.WFM*\=W7CLYY][BOY-$U637=46V]IMJO?
MN67S =U.SMI\%>>O;7MYYZ]OFYKVMY-6M/ M].M==[Z=>RZZPKU\_N\]...*
M\^:G';S2G%?/UIHNG;V[Z+6LM]B6UW1++MTH!S3GW>RO3K_1U^IQ[O3JNE^W
MJ71I^S3Q6[>C2'3IUK7CO]^G;[O2G;]7SZ:-&E5MO]U-?;T)KX]H'9SUKV<]
M>ON\UIQS2G=_H[>*U:KZ5U7TZ>W=4M=$WOX:[*H4Z\TKWTY[^>*\T[_-T\_7
MGX":;HN^E]^]ENF_LT;=-_ /M[_P7NO.TK<'7_\ 45=^+2#Z_(_^D(M\9,"+
M_P"R?]=5'Z9]Q/\ N#"G^*_]+"=WNYOY(MI_TU44_%=E[7PF#X-3]77\6(^U
M,U/[Q?M:;5:SE!H!H!H!H!H!H#2/=AOF@.T8_#PDTATJD])5%99-+W,;,X^&
M+,04-.0T"41'C9O,HF^E\E<NIL,4"PZ'IFI.:2;/Z#1CA1O6RH%S<;\=N;>2
M.@M)426$CO50/(2E&+2F]A;+8MDJ#8E=0P,(H%]4\O,.IW/1,=;.X<$/!+3*
M#L.N42*6V-+P/<WW][2'44K.$,NMU(I83"BEC7J-R'8V:WR$10Z()/;+XE:X
M8QIT+\=Q66O$4(LVO0=-79A!XT<H) 9&%WG;:9"7> A.3$5RK.0I16QJM%9P
MQH5/J9$#8EO'QMP0C+5K*KFF1Y (B))Q&EBS045>4M)+M$$7"R($6G?"!8JB
M^?,GX.DHES'T<.MB1*>SLO-,9,V@X*&PZQS67/"\?7S*N79,'&Q=_8V=O8W
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MOB_@5;P/I7-P'XIY;K12?&Z7ZQ#^(TO'U2/OV_>0_->B?R*1?M^1P%V=M/\
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M>P>>"U]JF&^Z1F7]8FG3<]T/YQS<AP7S(=+3$CL%#RFNYT/8//!:^U3#>?\
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MR)1!-F3],Z6,Z6T;>.XSE#5C<UN!RCAO+..@\0!IR>+2W'\\'N@M@F]PYIE
MN3CD=PN[6+(WT59!RD_)"8"1;5M\G\>=M#+M9LV"*JT UJQ[X1?(-T0%MYGC
M4.N<&8HQ.4+2\Q+A$4M.3691W"CEZ>?0AFV(%XI"RYG+#AH(+.44(LT?!$&I
M>4A1Y,D1B0&QFW7=[,,Y&HQZ8XO#Q2+R-QZGO+6\Q>'#C*7ML10_*I&R]E9&
M&89>-HTD!./-B3<\H\7?#VR]6-B3A:Q ##RVX+)^'7>55Y1+&4[9 <X/\4QE
MYDQS%\:0X2(#;>(UG"\F9D<,QVX>N)')##\K!@#?R2@U==P*M2;+EF2C4X!$
MDE\(;D<$,-!UH3$DY8NXRPF@VM/.FDJ@J#<[DT1C),_#BP5%L6,L;(>&6DPT
M.7*N%4"S4@_:1\<3"+F@-@\Z;GLF8DR5ZGHY$ DU'O\ &<.D+,<7)/HTV8E[
MHANHR%*GRID7'Y&\<W/A&"@D?&"JL;$&Y$RF]O<66W7HN (\+;_)?'3TFC1O
M&$'L/PYL-</H\RR285D,KH>*OFK53'PIS 6BYUC%1%&4CGKUUZ7^E AF<=MF
M[A!N@K<!D-^^"7Q\D<;S;&449MX:@B6GC*+S@_(9/$X0,&8TE<QR>[C[B B7
M;F!"(?/R3D2^0IY<>-0YR*9M*N#"B,? L C?;EDO,'D#5V\C8Y)K5<9B$Q\C
MR:P1>!#N03^% RJLH"#PKZ4M8^*IF%6B9AC'W(\B\B"J#9_6TZI?'0+2KX0K
M(HYO /37 (NY[.A<<EB%H[)S%H-2C\D#0D@/B[,G,@40L*9.>+RI_0=&6**]
M'[<"XN:W+4N>K"P32B+M).Q9NNR9D/(N%8Z<A4*A #)4;3F3BZV3&3)!P)DL
M.E9J(@6*K^-1]!*7MGT(/OC@JRQVWO">A*L'RU[!_54/Z6T_Y[W;(K"[QY\
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MI*17_BPE_P"H//\ X=376#JT/[V/[Z'*?J,W[J3[CCH*L<./$M_W=;_%M_\
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M&@&@&@&@&@&@&@&@&@)1QS,Q$3L=^F=CRZ^Z01@RA5HT5=5JD$3.INDK:)2
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M+5K_ &>M@S3XF(RJ=50.B;45+DJ5R9DD>E5,U(ID6IC1&2.16S,A77GSUT:
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M+-$5GH$D8!NET$7=B+A<06)C5%DU+F1!XVJFX4 S70#0#0#0#0&KF^+^!5O
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M= @/LPFQ5@+^YNHT*N82U.1\S5^&?/V($9%LB[D482WEQ=^5LAQZUV('R5P
MC-/1*E4SC FB(+VB:%1CHN-4+QTLZ&N&;LM%FZ,3(KN8R/'B6P$TX]%9N"9
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M6 16KY[$ MS&X/%G;JHKT=Q'15PP94<&5OO',O2T?1NW3HR;42 \G^#<*%#
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M(+186X0Y9$0D=7&QTHPO<,R0=TB^(6N@,3NSH25!*AZQ2+B+48O*Q(RL79N
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M_#G]D- /9"/H2_AS^R&@'LA'T)?PY_9#0#V0CZ$OX<_LAH![(1]"7\.?V0T
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M+E =4*F;5#S./#JE#ZC.QR'0JSN%-;%?1$S-1=[M1&ZT=1Y2Y*Y0".M - -
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MX(23&K0^*R/C64@!(*<7Q2ULPM+%A-J2SE-1Y'U!&]Y]'\OY:]!=Y[X0#<S
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MYN _%/+=:*/XW2_6(-6OJK2\?5(^_;]Y#:/6<H- - - - - - - - - - -
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M+6?(UC8EV3CE3K@0Y46=29..))32H$BOQ^\!/!^.7P,2799B<YERO(Y8@N^
MDKX[&Y+&<SKQQ5%H7-/ CD4QD!>%M! )54FU'(7L4*L4D&-RK0# )PGX0..2
M"1N(6ZR!*6[BWTF8$5K<-*V*#(K-]R[6)%&P-R,8 6QF6A*X,=3ETU$!?31F
M80IY5%F0TB[B &7%W_A!!\N%JCZ/2P0O*9L[4:H!L3+B 0M',4K!B@KQBY4
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M_;]Y#:/6<H- - - - - - - - - - - - - - - - - - - - - - - - -
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M0&A>V%!!/=EX2"Y-%).ZF:L$VTNL3LMNI;?M+PJI?;2MM*5I2]3]W?3LNO\
MW5>;NNO)5GQ'!/U>I_YZH.LG4X>\=^*\DK<W\D6T_P"FJBGXKLO:RP?!J?JZ
M_BPE6_M=XN]VTXN[X-\VJUG*#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0
M#0#0#0&KF^+^!5O ^E<W ?BGENM%)\;I?K$/XC2\?5(^_;]Y#:/6<H- - -
M- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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MLOL?M*_NJZC/L^2T_'4<X(RDX#>-_ICUM>2_;P[LOL?M+_NJZ9]GR6GXZCG
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M5@V0=9*G7D+9FT5'MT \/MV_9.X8H!\ -MS#PF3P1YE'(4B%FQ67HX,>R,:
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+@&@&@&@&@&@/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g307489g55i55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g55i55.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1@V4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &!J^87 X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+4>N         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             "W0
M!UL          0                         !              =;   "
MW0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
MW0    !29VAT;&]N9P  !UL    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   MT     4F=H=&QO;F<
M  =;     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
M   &.$))300,      X@     0   *     ^   !X   =$    X$ !@  ?_8
M_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,
M$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,
M# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  ^ * # 2(  A$!
M Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !
M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M/]W_ *WX,?N>#[]ZMW^@=][?_)*A9_SF.[T788!<\L]1EFC#_,M=LN]UC?\
M"_\ 07B'KM_TQ_[</_DD2O+Q6MBW?8Z2=S<AS-(]K=L6(?=_'\$^X.S[6_\
MYS[CZ;L,,D[0YEDQ^;NVW)?]D^FN' &IV6:NG_C?:W9_TUXV+^F;F#U0 0'/
M<<BX@:.FMVVOZ>K?YM"?E83=S6ESG %HL^T/+=T_SK&PWV[?\&Y+V/'\%>X.
MS[M59EBI@OJW7!H]1U9 87Q[S6U[W/;7N^AO4O5N_P! [[V_^27@/VAO^F/_
M &X?_))?:&_Z8_\ ;A_\DC]W_K?@CW/!]^]6[_0.
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ Z@)8 P$1  (1 0,1 ?_$ !\  0 " @(# 0$            &!P4( P0!
M"0H+ O_$ &P0  (" @(!  ((# \("A & P0% P8"!P !" D1$A,4%1885Y87
M&2%55EAWE[?1U-<:,34V05%3D9*5MM+5UM@X87%X@9BU\ HC,C0W2'-VH;$B
M)"4F)RA%969G<K*SP>'Q,SE"=,;'4H7(_\0 ' $!  ,  P$!
M  $" P0%!P8(_\0 6A$  0,! @4+$ <&! 4#! ,   $" P0%$1(A,9/3!A,6
M%U%25%64TO 4%2(R05-6<G.1DK&RL]'487&!E:&DP0<C-6)TX3,T0O$D=8*T
MPR4V0T1&8V6#H\3_V@ , P$  A$#$0 _ /OXX X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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M5%141<2DHJJMRX-V"_(UJ9&JJ8T;?B7'B5#9?F!0< < < < < < < < < <
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MUFI?NN^/WX>M;<TB[9?)S>Z>6;E7Q7^PXMWF94< < < < < < < < < < <
M< < ITY%OR0TR1;LW5 BZ0HC, 0W2MK8&#!Y2YY##E'0[U70FDPP]X1SEQ+P
M8R),<IL QL<^H<-D=3W)?%,JW)>J5$:(J]U41:951+\B7K=NKE+WQ]UK_3;H
MU.K\'_(GY5=/_>*M_P#:!Y.%3=YGY1'\J+X]Z_.-T8^#_D3\JNG_ +Q5O_M
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M-1UI)3D$1EW%1>GVD_I>W-&WV]5O%=KVP",'D;G5@S9LK38U=/;#TTVT;-K
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MZC&)6K$Z731LZXV56:=@H)<*Y@F2L$@H)J&Q & VD"!"6BQ!+@Q0 H.LNH!
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M[Z/]YV6!V'9=EV?8XK^R['+B+8,R85^N=CVV-<5Z*['CQ=BBK]2*I5GM<?\
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MIN._\UO+EZ(.R$%<^2N[VHPKE6P1MQAV&R;(7# T2MAQ&BAC%'+C&:L9"C'
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M1AVQM+6)DIMMI5,13KJVL#BT3!F MH9A??<BU6$:?&'+#&)>U( &Z@'ZAPB
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M._I<[)H1^A@?2 ?L[,\4OG]M+O\ _I?KC;%L+@]IYBF^<&QBT=_2YR30C]#
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MT@'RF>*7S^VE^9?C;%L+@]IYBF^<&QBT=_2YV30C]# ^D _9V9XH_/[:7?\
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MQ@]MD]IQSFP(SQB]GE[7UG/'"/A/EUA['K*;""#"7OUYXPQ8Y=88@<7 ' '
M' -QO ?Q<M_F!Y5:LTW4RF28:5T/;[K;U?<T1='H=0,#9V"S"FP]=Y+W&&70
M2:JE]_\ 8X6]Q7\<^\8\I),-H4N<LJWHV*YRW=UU]S&7_P RY?Y$<O<+LQ*K
M\=S,>);KU7$C;_I[OT(I]_I'BC7<!I\NMS^4W?>$$O?7LO)':>77?>,>7?7L
MNNWWJ[]?J^KUW]3OF)0G7C"% N\;]"A#>V>T#:>US''W-++/+EUU4E/?><L\
MV6<LLF>7?>><DF>6>>7?>67???? +SX X X X X X X X X X X X X X X
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M-FPG8Z%.HZ>=5E_=HU4C=*^1V'@WPHUJN:^]Y0O/I3YQ,B=P< < < < < <
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MX8(8_8QX_I6@_P C1?TE-[EA^<*W_.UG]74^_D,1SEG&' ' ' ' ' ' ' '
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MI+JMQL=C;"2)IX-P%PW1PWCI!*S*!(7%8\6T\K#7]_DP)7JL>HLZ[9UQ8PT
MLJ:>("&UNG>,M>NS4Y-6+?3D^E[HT,L%O-?LJUI]+;U$-DM.9+TAE9A%A>*6
M+;5@'73FKI%0N#B #'/N%*IZ7"//^']\OG([M15X-IU#>RW+8"\E+LX2[GX
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M3RS<J^*_V''YWWI&_P"[V\PO\8K;/\LFW$O;)Y.'W3 [*GBL]AII;S,J. .
M. . . . . >^+T#?A#WY#>1V?D'>$^16I_&]@N<*_=,?78%DW/E[2?4%?6.7
M_8DPTP;U75EAUZ_<[+JG8RXYP'RX=[-_=QK(O;/O9'NHF21_T8NP;NJYRIC8
M73L6J[NNO:WZ$_U.R?\ 2BW]UW=3%]QW,2@X!P%?[V(_Y"7_ .'EP"MM(_\
M SJ7[FM'_DRLX!ZB+=^NNS_\X77^DB>?I6@_R-%_24WN6'YPK?\ .UG]74^_
M>1[G+.,. . .!>F[]/V;HX X X X X X X X X%Z;O3)Z\0X X!D5K0M5*1*
M)GUCV2).%/CEUEWCG#/UCWUWW['+#+J0>>. P;/K+KN(L:";KU^U^Q[REACF
M1B/2_ D9(U4NO1S57%C1>Q>U71O3_5&][>[>:13/A5ZL5.S8Z-R+>J*UWU*G
M9,<C7L6_L9&-=<MUR_R4T9&Q=0&'%E08FFL<89YY)8\3V7M'O@9CAGEWCB0;
M[F']TR]==9S>T1>V=Y>PQ]1D$,;E='%&QRQQQ*YK4:JQ0X>M1JJ)>K(]<?@-
MR-PG7(EZA\LLC<&21[VH^25&N<KDUR7!UU]RJJ8<F W#=E=@I>JW(?RO8GJ2
M.BUI<X)/4<D7MPTF46?<4V'>$L67L>^NLXI<.^\9(\NN\,^O]UUW]3DRQ1SL
M5DS&R,54=@O1%3":MZ.2_(J+C14QHO=$4LD+]<B>Z-]SFX3%5JX+DN<BJF5%
M3$J+B4RX]NL0\L$N30LKL:<@P? R>4F.(XC$SOW=CC)GWZRX)V!9@TN?>74)
MD\Q'6/>4TWMF#Z&E>CDUEC,-K(WK&UK%=$Q8_P!TJM1/W;VQ1QO:EV%&UK+T
M1K<'5M;4M5JK.]^ Y\C4D>YZ-D>DE\J(YW;M=+)(QRWX,CW/NO<Z^-\Y9QAP
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P#='PK_7=<O\ FX)_I./GG?[1?X?9_P#6
M/]PX] _9[_$+0_HXO?GL7YY&>L%'[Y_4&A?=PTE^$JN\VARR>1E]A2[,KO$?
MZE)F;J^@,=DHMP&U=>1LNLU-Y1D5OS[(]\UM3LC%8V=I(<<9\1,A3V*=<5GG
M,-(1%F/EB/-%'.3A-B4(;NX"I!KJW?K'L3#4Y])>1C(+W-VES%#+N_M50S1G
MB6 0Q4:(_(9 #Q0S11R1-!UAD4\>(LF$H%.V+PSK5C9]'G[2V)/+B0K=9^^$
MU:9G&WA=5J=4L+@T9%HLCC32UM#K\TZG&0=-[JP8]CA0#E1#B 8 /P-HO75\
ME;[)V)8R[U3['263%L4A*8!KK#6;;59S8C)%$D\K<5;<#\H2"LY!8LQ@AAP1
ME0\:W #*!^$5#58-.T5SL*@TX]T0O:0**24S7IK&!L!8\2$F'UPJ9^/,!LJQ
MQ F.LBR%L_0AL?<ID[R9V!63[Q?T0OK[8G#=5G55M197M-KD2[!"T;4VT,;3
M8;-84M59 H"+M-<HG#]W-">L.SL"Q7!)!G+*GB>QL0-D6^H*YM7MI:TFS&1=
M.VIIU#K.QP*\:\Y!N%'&PN<@#0%],',:$R/AO[CVYD%-E%+ET'GB/')%)[8!
M44OA.*RN;1K9MH/GU8L8*PNXA2K:J XL;]/;45F5]=D@UZ&-$C7E59%EC@DE
M%--DC-'.EFBF@D@ R%$\7:&':$S57M^V.;-0K2GLC/J+"KI'W0BVJTB@HZZV
MR3)%+8>K,4^I0,3UIWMZNT9YLFF$'4O2DU<!E3_&'7%GN&ZXHK@'D=L!O[ZW
MY>/4J)+;DTME1(APUT%QF29V4=46+6P3A5I914,D?M\7?60^>&$8B[HF(BQG
MB;1[C:-QJ7]UD5/K7=#+YU6ZP<&?E5M>7BE;'UV*IDA=I\<((+=9;9N78)'<
M0GL!;C8VH(Q;$%9U,8)Z=/P\W=,]8/!K6=AL%ML$UA?QRW:.UXV&"8&K,\,<
M;$ZO3\.5+*T1F9HIT#38%@S"+"]1,V& /4TV) N1,H'B[>)FMQQK#;#=GVJC
M@^VVFPOFV#-"M3PK'95+9/(6\LP$$<J.**B 82CE%="S#SEP,^C@9,PY%W3I
MZOMRC(8*L^%VN*NI5=+]C7V:O"Y49"P$-65XF=V#1L]4IU*TG*6K=G ]$V#4
M5<9',5L ?><1SCK&6-9DM(5@=JN>&]"85RLSU[;5M:5F=@FL0TJW*H,JZYK8
M%NUOL)"CKPLR9@I0U/WZUPF-B"J\8:F0-R['6"@+RUT"X#@14?2]3HJK4JK?
M9L11&PZMLFJN),TQP-?9UQNMFKB-.O[625*O5IP?3R,$M;QZ7@MBIVN-.&A$
MR$"% Z-M\>M*$JZI:G6[G2@O:SVCAU^^8L*TM:W&XNF^T;@G*IC:!2-.C?6N
M79[[I=%7)A!.TRY:GR!-5Y,A&(%;O?&GQI<!7774&^F]?B<-R*TT&6=58 HP
M-K8WM'^"$SW.N8Y7K-!>MIPI<(SCGPU9N9:.-VNCLA9,[$/[[O3ZOP)S:/$[
M2<=NSK5BVVV@MUMFM&P$-,/BJ)@$B,%>X57X]9KXI(2A+E/@NT65D=0J,2VQ
M02PMI$S)DL<KL#?]&0K+2J"D98IZ4E8!.H.!D@E",62BQ9@E"2B]8C2#3BY1
M2P9CXXP9198]Q8]1]X]= 93@%1;M_6:E^Z[X_?AZUMS2+ME\G-[IY9N5?%?[
M#C\[[TC?]WMYA?XQ6V?Y9-N)>V3R</NF!V5/%9[#32WF94< < < < < < E%
M(I5IV1<JKKZCIBK#<KM8%-6JZ,/'UD-'KPZ%<M#QR[_["'"0HB/V\F7O$<,?
MJ4LG.,>&63&\;%D<C45$OO57+D:U$57.7Z&HBJO=Q8L99J82HE]R=U>XB)C5
M5^I#])OPF\5ZIX9^-FM]"UCL8TFM*_=]TL<(^(\MPV Z]B=;[.1U['J7O YI
MGF,JAGRDD7( U"G'/N%?%UU,CT>Z]J*C&HC6-7*C$R7W8KUQN<J97*Y>Z'.P
MEQ9$1$:FXB9//E7Z55<JFUO,RHX!PD_[V(_Y"7_X>7[7U> 5KI'_ (&=2_<U
MH_\ )E9P"4R4FF329RRU&L2RRYY2222(%6<DDF>7>6>>>>0G>6>>>7?>6667
M?>667????????.<VT[2:U&MM"N:UJ(C6MJZA&M1,2(B)(B(B)B1$Q(<);-LY
MRJYU!1.<Y55SEI8%555;U556.]55<:JN-5/X^ M(^PZJ_-Y1^1\GKK:?&-?R
MRHTA'6RS>+J'DE/HQ\!:1]AU5^;RC\CXZZVIQE7\LJ-(.MEF\74/)*?1CX"T
MC[#JK\WE'Y'QUUM/C*OY94:0=;+-XNH>24^C'P%I'V'57YO*/R/CKK:?&5?R
MRHT@ZV6;Q=0\DI]&/@+2/L.JOS>4?D?'76T^,:_EE1I!ULLWBZAY)3Z,? 6D
M?8=5?F\H_(^.NMI\95_+*C2#K99O%U#R2GT8^ M(^PZJ_-Y1^1\==;3XRK^6
M5&D'6RS>+J'DE/HQ\!:1]AU5^;RC\CXZZVIQE7\LJ-(.MEF\74/)*?1CX"TC
M[#JK\WE'Y'QUUM/C*OY94:0=;+-XNH>24^C'P%I'V'57YO*/R/CKK:G&5?RR
MHT@ZV6;Q=0\DI]&/@+2/L.JOS>4?D?'76T^,J_EE1I!ULLWBZAY)3Z,? 6D?
M8=5?F\H_(^.NMI\8U_+*C2#K99O%U#R2GT8^ M(^PZJ_-Y1^1\==;3XQK^65
M&D'6RS>+J'DE/HQ\!:1]AU5^;RC\CXZZVGQC7\LJ-(.MEF\74/)*?1CX"TC[
M#JK\WE'Y'QUUM3C*OY94:0=;+-XNH>24^C'P%I'V'57YO*/R/CKK:G&5?RRH
MT@ZV6;Q=0\DI]&/@+2/L.JOS>4?D?'76U.,J_EE1I!ULLWBZAY)3Z,? 6D?8
M=5?F\H_(^.NMJ<95_+*C2#K99O%U#R2GT8^ M(^PZJ_-Y1^1\==;3XQK^65&
MD'6RS>+J'DE/HQ\!:1]AU5^;RC\CXZZVGQE7\LJ-(.MEF\74/)*?1CX"TC[#
MJK\WE'Y'QUUM/C&OY94:0=;+-XNH>24^C'P%I'V'57YO*/R/CKK:G&5?RRHT
M@ZV6;Q=0\DI]&/@+2/L.JOS>4?D?'76T^,J_EE1I!ULLWBZAY)3Z,? 6D?8=
M5?F\H_(^.NMJ<95_+*C2#K99O%U#R2GT8^ M(^PZJ_-Y1^1\==;3XRK^65&D
M'6RS>+J'DE/HQ\!:1]AU5^;RC\CXZZVIQE7\LJ-(.MEF\74/)*?1CX"TC[#J
MK\WE'Y'QUUM/C*OY94:0=;+-XNH>24^C'P%I'V'57YO*/R/CKK:?&5?RRHT@
MZV6;Q=0\DI]&/@+2/L.JOS>4?D?'76T^,:_EE1I!ULLWBZAY)3Z,? 6D?8=5
M?F\H_(^.NMJ<95_+*C2#K99O%U#R2GT8^ M(^PZJ_-Y1^1\==;3XRK^65&D'
M6RS>+J'DE/HQ\!:1]AU5^;RC\CXZZVIQE7\LJ-(.MEF\74/)*?1CX"TC[#JK
M\WE'Y'QUUM3C*OY94:0=;+-XNH>24^C'P%I'V'57YO*/R/CKK:?&-?RRHT@Z
MV6;Q=0\DI]&/@+2/L.JOS>4?D?'76T^,J_EE1I!ULLWBZAY)3Z,R2VO($TDD
MJ=&G52S8=1S2K5@0,DL?67LNHY,Q8(LL\.LNNLNL<N^\>LNO7UUZ_J\PGK*N
MI1K:FJJ*AK5O:D\\LJ-6ZZ]J2.<B+=BO3'<;0TE)3JYU/34\#G)<YT,,<2N2
M^^YRL:U52_'<N*\S'..<@H_?/Z@T'[N&DOPDU[FT.63Z(9?85/U+LRN\1_J4
MO#F)0H3>FC^MZC5JNN+<SKM,5YV<Q\M1KDA36P'N:NQJ*V/(RQKGJ@56N5V*
MQDD#Y(23IFLB1@O8JYE'>10&KTO@BV82H75DV0KL]PA?8.[982ZY8$TMC8QU
M35]=$LW4M:NRAR+:TA.OFIZ$WISD.LCN[X4*,3*4@@X"8T3Q*N=.JV_4T^R:
MNP9[H7(A8RX-:K!48)ZHBQ]MFKFI3'%UEL1:5[H5:S@P4C0=0+H96.+XK*<@
M@.FX5Q4_1\'5VNFKY=GKN[!-G8Q5EC74\L8I#6[ %OT?X(K)2;04QBKT$NY$
MG1(,+$:)B+1AHLL!I2P)DH?;TW>FZ7"F\53%6HB==]EZW[-GW!8-L##J:;9*
MM4T.;UFP.A44^*LW=7;::<EP8=X 62OV80K/J,H.0'!2V.7< K\3P8<8N&;Q
MKMQ@_?%4I:I5W)Q#:RK;7[2AJJ5/73 R.[QBO:UE)9T(&P!U-D$=,2;/U,R.
M:DO9<;#$'X=.GG,5EZ/S&1Q,8;?PW([$:C9NBW*:PDMFI*"6ED7%47 /<QJZ
M;5;XVKCVTL$[9*R@%LUL.8]1$%#PF< Z4W@LP2W10S1.%TP%CV$"?=V*A&!7
MB(M:P6'9-HL%#<2Y.I"W2"P"OZ;5EH2\&3-<0BE.E]RJIL!10+GV]XE8;5N5
MQMTUJ7 S/ZXQ7H(2ZUVSEJMFEJJVO)+<"1DV&_[J5\H#)JN(&B#-&EFZZ$-%
MFC]T9 4BZ]'PT=-'#$O8-8EB.]Y1I18ZC9%4ML]Z"]Q$Q6S8S1%?%K2Q[ C[
MVF+-!8@2E'<1==F)@C%F:@RUUTR].F.\%S5'Q4L%.K_D J7WY%*PW8.;FN-,
MI6342C$%%6#V20!;8G[Z!I29X6D;PZNL?;<2[Z\V%:R)YH;?&F4 4\'X -XJ
M';J(SN.M[&):ZM?*Z$=9-8'N2Z!%:GFRWX 5!S)N?6*E1&1?P@["++C+BY$K
M<.4,0,A8O2<"9@^#Q([(,R?9&.2Z)P!;"ZW!79XT1-U@W(#>BK)T/(]E]C++
MK0"+4@XN6.44*[.5G+W/%GTKP R_CAXM/-.NK  :P%AJ:#6-2UY0NE 0:@?W
M_FJU?2;+O"A2$S9>\HEE'H^N?:@3,X&$=F4W)G[7F"[$** S6M/'_9=.J2^N
M VVM5H!XHUT+L(,BL=61O(WUO3ZWKZ>2HMI'<:D)#=$E)13]X-4AKQ!@<U*!
M*$=DBR) , Z\2;[>*/1J7<=O#)(=6ZQ(I5#,U[4A!<\+9BLK:Y-L-W'=)[?Z
MFM=QK4<B:.N2(&07ONZP@?QXEX^U@<\GB/:#7AC4G825) =<:]=VRNGH+.KK
MUE?J]PZZVL6Z:4UK>7=046//JBEI^[!5DZ<QX=9&-BL^+0G*<(D"3/?&6RG[
M%"V_+MRT.[G4G]%,J4!R"CQPDU"HC6.!S5WD@"-')*XM0>PMEJ<6Z(^I)AQG
M%5D<HW!-7F-:@7GI2FM-?:IHE-=S0S.$2 49G[FDRF#&.FRD+)7@2Y]=92+U
MDI&2Y?GWCA[((6#OJ./KOK#$"T. 5%NW]9J7[KOC]^'K6W-(NV7R<WNGEFY5
M\5_L.-&-H>AK]'KN/8MUVKL'3+QQ>-A61M;K8U&V[N!/ Q?O"Y#F9L2I/>05
M0&))4TDON5>&,+%WGWC##'AZL>K),ZY$5D3KD1+W1M5;FHC42^Z];D1"<-<6
M)JW(B7JU%7$ER8_J()](B]&-\A%C^_AO+\X?&O+WN'-,^ PUWK/00?2(O1C?
M(18_OX;R_.'QKR][AS3/@,-=ZST4'TB+T8WR$6/[^&\OSA\:\O>X<TWX##_E
M9Z*#Z1%Z,;Y"+']_#>7YP^->7O<.:9\!AKO6>B@^D1>C&^0BQ_?PWE^</C7E
M[W#FF? 8:[UGH(/I$7HQOD(L?W\-Y?G#XUY>]PYIGP&&N]9Z*#Z1%Z,;Y"+'
M]_#>7YP^->7O<.:9\!AKO6>@A<N@O1.^"'C+M%!N74&FBTFQ*M"TBKKQSL79
M5QB3R.%Q"@\P)3;K:Z41,<UAA@4+#W#V8+ 63B+-#W-GWW"RN5'(B,:CDN7
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M7?'[\/6MN:1=LODYO=/+-RKXK_8<6[S,J. . . . . . . . . . . <)/\
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MVR^3F]T\LW*OBO\ 8<6[S,J. . . . . . . . . . . . . >@*X_KOM?\
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M(AA[QRZDSQ]CWZ@,>/N/5A3UY6XK_5??:N'(%+F&1T#".(ZLY#H1(@]WRS8
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M/$1$=E&0V-!F@)"7X9YF$"2Q300YPR89=@=/Z+>L,G**O0W^HF.[*^.JZ18
M^7,"SK"M1FV0]/C$"01W">*C7%L9AR/:<\8(\?J>SF@PD R+/8.OE>3F!S=Z
M:NRK\@<%AA9V5()DDE8Q9SKX7,91L?:V0^".28.,[J'(J*/.2#K/#'++H#EA
MO]#(S C'NU1GS:L6*=9A#9$TN;)NH]E[[*P,<#<NS&*OV.7OB"/U(2%['+W3
M%%ZN^ =,?9^M"^\>A=AT8GO-8:ZPZ'MJ";O-,MR+Q8ML>HV&7>2Q?DO/Q-/Z
M]8HN01?4\L?8TW6 &/>;DU-6TY[]WLFD J5M6-NY965F43=]5!<%(Q,L<$ Y
M<I)BB(*+,CHT.&>&7#KKJ'*3+/#'(#D=[9U]7;3K^EM[&./8]I1NYJ*!&.:7
M&\AKRGIVTFQ.$&G7@PQK<L9196)0D;"7+$5?D25EC#V!B:IO#7-OKX5L#:GH
MZNUC1RI+!=T3NA*;!C9(Y)DF*$RX@)(V\K"*/VR$<+N8CO&6#V477<\760$A
MO.QZKKJ!)+926'4]E;Y(:\K3)'-C=.VT:ID\F"6)T(+%B7*.F3M&<_<8_>$0
M@,^>677?6&.8$(;>1^G$9+$-G;)!BU6HI=ZG#95^RY$0ZRAREPD>=PXI^Y,C
M<>X)<NZUCCW9^H\.Y,D_6'JRX!-$^RZFUQ7=$%F5DMRQD5(U=X5L*0Y?'1#P
ME20HD]I'5,7'6,,^&7>:X8G#K+K/#U^RCSZQ GO *BW;^LU+]UWQ^_#UK;FD
M7;+Y.;W3RS<J^*_V'%N\S*C@#@#@#@#@#@#@#@#@#@#@#@#@&LI_B-I=D<:Q
M*5.\BCS"3B<L+ PPPR(+FD(F[QPQR]CACW))EWCAU]3'KU==?I=< ZGQ.=(?
M6E[\XV/\_@#XG.D/K2]^<;'^?P/MN\WZH/B<Z0^M+WYQL?Y_ 'Q.=(?6E[\X
MV/\ /X ^)SI#ZTO?G&Q_G\ ?$YTA]:7OSC8_S^!]OJ^'=_V'Q.=(?6E[\XV/
M\_@#XG.D/K2]^<;'^?P!\3G2'UI>_.-C_/X'V^KSY/[?0/B<Z0^M+WYQL?Y_
M!'VK^'P'Q.=(?6E[\XV/\_@G[?5\!\3G2'UI>_.-C_/X ^)SI#ZTO?G&Q_G\
M#[?5\!\3G2'UI>_.-C_/X ^)SI#ZTO?G&Q_G\ ?$YTA]:7OSC8_S^ /B<Z0^
MM+WYQL?Y_ 'Q.=(?6E[\XV/\_@#XG.D/K2]^<;'^?P/M]7FR?W^D?$YTA]:7
MOSC8_P _@B[Z5_#X#XG.D/K2]^<;'^?P2/B<Z0^M+WYQL?Y_!'VK^'P[O=_"
MX?$YTA]:7OSC8_S^"1\3G2'UI>_.-C_/X ^)SI#ZTO?G&Q_G\ ?$YTA]:7OS
MC8_S^ /B<Z0^M+WYQL?YW 'Q.=(>OU^]+[YQL?5_[_\ K^_P!\3G2'UI>_.-
MC_/X'V^KX=+_ *KGQ.M(?6E[\XV/\_@#XG.D/K2]^<;'^?P!\3G2'UI>_.-C
M_/X(^U5^N[]$0?$YTA]:7OSC8_S^"1\3G2'UI>_.-C_/X'V^KX?;_;$/B<Z0
M^M+WYQL?Y_\ K^]P1]J_A\"2T'7>E].7F&MUIJ.LO=UK3AHNK+2R>ZG3FLU5
MBCA?-E:@J;HH@!(QL=?&9G#Q9Q"2N%T4^>&1<765D8]6.D1KE8US6N>B+@M<
M]'*UJNR(KD:Y41<:HU;LA:Y;E=<MR*B*MV*]<EZ[N);C8#E2"C]\_J#0ONX:
M2_"57>;0Y7^1E]A?-T3NEV97>(_U*2T[5-"9;0K^YS4.,VR:O3W]!1V3WP:1
MY!5.SLU+AVJ[61'8)B>C&*-81B86OG/&]HRB$*@A((CEQ*$"\AM1U#;5:4A7
M6U=5).I.<0^[9LU40A9%UJSS7<2\F1OEB+WF3E:^L01O9=YG,O<@6.$ONCVK
M-TZ=/J!01/CAK ZT["I"G=R2!QL%E8S[71LAZ.WMR\AG<-C;-"&KXQ!.3FLP
M*NMHM?=D4*^29BH%7D^W+XRFN;,#ID^C\JYF.&!>P6QD(2)1258I%>!B%QH:
MA59DV"M[$L8+<K582 ;)GT39'4DXQ<@GL6%?.#/8AD@2Q%XH4W H5Y0MD19-
M*R>X4YD=):O:TL+25]N@RR!O4G>?0)3J"/=C];E&?GT0M*5+I31RH2&RT\#/
M5+P]J-6JVX*EC97!@.V:^=5IF78^&#U.D*:V]V/#F>44P':2@L+DRRCAZ!6I
MB(</46FG+/;F, .XC\7ZTE'VX&XNA1[K?M);TJRSPKE".'"5BQV(Z8L*HDPS
M)C!]IAOI/72SJ0Z+KI1$T.F*.-8E3 5U-X::^P(K4I.R/8-::YL+"R22!JHH
MC"]@;0#V@NSS4=L\0%#,>R#"A5Z=T-8(2P8P\>UY3,!6>$!CJ[X%UQ"V6'-=
MJO[ ?G;U=J+A<K1"O?G)&5I-ED##BT:,RX>BI]%5@AAG%.0)!&U>C+%RM;DG
M"4 =TSP!HI$B'.&X.<,$U4$I,P!"Z#-.Q0]$,2&LA"I><J%E<,>RPXXRS^F*
MV"$#N Q,T'*DAP F2'P]IU5=TIF%='HDE='6*XAQ/:D);?%<LW; 7(*T1%*F
MZUT?!N%L9(R5EXEC_!T.;'K/&4O/%TZ=/[#"]>%VO$#]M<&-T8]*HK39KG#G
M9<NF9*V2VF/FS\9M9+&U.P* Z<OLSP2,!%1<>(8>+DMX9#$PB CJKP:ULH9H
M+<%L,Z9<#C10NXRXP9$!8].3ZPKU>][(@60"D5H4WUNM.R,*&<13'-Y(! (F
M "4\)T\P(LU\$6K2S)JS%8%*G4"&O(<H&@Q/<M^.N-:U%7-3IR,%X]:5C(Z[
MB+6U[9HG"MQ0[,B,[KJ(3)S)[V@3);X6ZSL56L B;8.+'"RC-!V+RMAI2Q\"
M+#KS<55+R&FR-;DYQSC;U9V>*-DW9&$%"+"C#SNV)AA(%L;$\;:Q?+8!<['>
MK&LND,.M5E(*5-RDJQ0?K6P%WWK$*K1,\%-BDL+",\AV$W@99](A?<D.<< /
M9'3] 5A+X7)UNIUNNY;Z@K*:I=HCP+E6Z !2[0%C6:V_KF3QQ8U]HB]UNO>A
MX7)(TFZ&52>S8B/4SNO.&J0@"Y+71P-Y5#X(-;?KFQ'52X'DN5N=9JVRZWWB
M R=C5D"SU]QGV8MLB87!>QZ8JF5<9!6]-+.-)FLP)63@4L^\!*<]K!:DG9^S
M)[&2 4A^%K1Z8XRDJI6G9])Y5]A6BS<:VSPRK$^3,EH2![[%V7V3>4OK/+VK
M$1=NX\=_U=/]B9Y^+,!YE =A6^MI#=>68QVNEUS1!J*,QZZ95DLY(?[UV1C#
M..>PJ P+^%I Y6DC]89](QGZ5,Y7B3;1-BVP3JL7\@,SW%:#BZE5X31+)6V(
ML73&1=&3ED1&#F9U-D)A/EE-@/W'C+EWGUEWP"M-V_K-2_==\?OP]:VYI%VR
M^3F]T\LW*OBO]AQ;O,RHX X X X X X X X X X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X!ZM
MMO: JEC]++XB;G,L=_%M2'Q7\HBEP"ZU3B56.*E7GQX0"+YJ]B-F(0 Z!W1;
M\[)#/WG*U,%K!G<\$U95=P]M#4O98]93HV)6/JZ5%56(K^SCJ'*J.OOO:L#,
M%?\ 2BN3&CU.2QZI32LN;=KD?<Q]DCU7']& ER]S&G=/:3SJ3C%(;X_4"A?=
MOTE^$JN\UARO\E+[MQ=F5WB/]2EW\R*&MGDEI.P;]25VBP6!/7:9B6\;6V<U
M:2Z9''XU\Y/41ERK A:+[%2U=36^)M*W&*3V.KU@L$0S/N:0,"DJKH3R( 5[
M,$M%E3DNME0QLF;ZD[/-IV,-HFUA2*HV9*QY=&O'24@VR5=@4,='8V(X:MC!
M)(D*DBF7R@2BRZ1WTYT_KRGBWQ>/<ZZGN:MPR"OFPT0PSIU 6+1+[%8@QSK#
M;FNN,<H"Y:JZ@3UBVL2"INL:T&"H7C 8XOQLV>ETY5Z+1+9 KMJ3;^Q]BD,X
M[W<$%?/%N5^N]K6PV"):D/?V008&PK(F5; ;4[O%E!,4LM</N6/,\"GUGC;Y
M1V55[X&[&M%.A+?.IV-2'W;<AG;N3%UMG%9;YK,XI-]%IQ$2ZT4F,.CHDC5'
M[EJRXWIP*8O6C0.G3IYATZ7EH.] ^0I ["-3=%F;65Y;S#K$VVSM7KX:J; 7
M:>TP9E95*@%5",K*5X G"EJQ9@))"T,XP"<):&GS X-8>-6]*CK[8">P;(!.
MO-MLNN#E]GCMEF9L8*[2-E'6"50VLLE=1LC9\Z).-5HLH%D 9G<4@4PX2S/K
MU"-WZ=WS?H0-KX=;YDBITZ_;$V;:N50)84W*V=L+)[VZ:5W6X>R)U+QPDLV8
M8]Z.HS-=[HF7SQI1[+-8Q$^;& A2<))&V\5][%I8,!=NW#$^-JBZD"^CA:!C
MYJNOJ5L6YH^[C]# M3 0OM+M(^@9#:OC.;P5X&!D7&6+"7F!E O'S=-<V %L
M5BZ^B"LI-_9;#05Y]M*WN+.TS(HFW:V2"$3C44%558SDW.LXJD&=?*Q@'$.!
M/MA:Q:A$A L/>^CMD;1<6_I4U63UZT:Z"JR45O?;K7!:0[APN'3L_.GU]0SK
MEX@M>+NOCE3/I@YTW5?A*$B-E@"PC K59XQ^0@,BEAGN.>1S%<JB4WGDOVPR
MUY%%1J:-VS2#*28.UG1QUDKCAEEG[A@S,':2PF,>HF3$7@=.F/X?6=,KQU\E
MI,=6#KKJK3R4^R4]S=;!AN[;[9I>#4%FUTQL[N=2YKAJ,(&]H:W:0&%##B%$
M6FN!^AK9(I861<S Z6CO&W<NH+OJFN36>66E"K\GFT.JZU?15DTFBT"EU'7Z
ML'HJ)7CTP;6G*S-[!#"%E[[UQ!7AG,GM,(X/ .SL[0GDADVOMEJVPF<5<GN;
M.ZBH1-BWQM;6Z>2H[;4S515&M2UY96U1)=PJF*U,M&=O4G2G-@#:71E;J"K$
M")I/''R4M=&;MQ[T_P!=V9N):U=41/\ ;.T6O=41M;5Y,2#1%23X2RE9SH-B
MZA[6,&JS"QKA:2'#,&C-KJ@'H"55#Q1W/2+(P,#MZ]U3#K%;'V5%PVOM*GC=
MM[/L3;UN'L^3E*K.-C8*%UVK<$Z:*'WO>,1"YRS()$*0PT##@^*WE"5\+9G>
MX< I6"=Z=6A$NV-K2+5.PC:R<K6.X^I5@3.&O!N_>MQ"D;M+=-!)!,046T*]
MAUD'3IT[INIHC73+5>O,*:UE#()'N&R7D1 +-HUBF7V_8EHMRS*4AP..9$9&
MN>#0'"=>WCC&13X#%EP^PGS N+@%1;M_6:E^Z[X_?AZUMS2+ME\G-[IY9N5?
M%?[#BSFK1:C6,G;D\-4G3@&-&K1@1$( M6KQY"SCSBY\L(!0PQ892"2)L\(H
M88\Y),L<,>^^LRIH%K#TD.EKS3NK=9%5II&3?:337U*K<2EE>+1:TT>MJ_N>
MOW;!'3UC%@K$;ZELZBY,D)(\KFM]9&)3XIFP!$&(%N[T\SM)^/S*U5^Y&6IE
M:*AJIEN-O7ZE3;'9)Q::&KO+)<2:Q7KY$RB2QYZXMJM'FX8@!D.0!5<Y0QKA
M+"Q ZN7FSHT$*IQO&5C66RXLG]:34."FVUM:V5TIY=(472HIE@"20ARTJUDO
MZ&N-) XNQ86<;GJ66*"O/IEH&.T)YQZ8WY&L$0D.$]G>['NU!0U%BD?>_;$2
MJ0/WR^YR02)Q<E]4?T=0OL^3DW")4C/L*BF-&.%M*'6$ <TOGIXP1DL@<+VS
M*8*5Z)@8M7T>[L676-A&V@<"$.O!KY!AC:%?IV^,6*D6&9BL! 6$&C0X6)![
MX@92H^:_C_>;73J16[!8S[5=,WD0B?&B7+HA%)7KB_U\R^%^727*&L#X7:L.
MZU&Q:RP*\V0D6/9V,#!9,8!R6GS3\>Z8Y?);!:'PTJ)@T21GAT.\.%%FLJ"V
MU.AV*IT9FGKYXMXM=>NEWK54<5VK9M&HMA-*3XC2,$KP=:!#"/2)>*H0,;1E
M<[*L4QV%Y3'3<[6NPXU53O-:[N>;ZC6]CA6I!*[;U8.O;@W)1L)8R_>15"VB
MQD!=UZ9L!WB_//0(;X2M3M+2/8\FN5::4@K7>RH]EJ[>8UUTLKM:DHD%,*8^
M[G\>SJRX@[+) ZBKQ?PACP*2 OV"(#/ZV\VO'O;EAH-<H-CLKPC9N1PU.:]:
M]O8598ME%)[V&]K\]G.KPZ):_057N URK8G"D!%E0*,NLF_MP,(&#?>=6F%]
MY6ZR0"WFW7]GM"HZR'KJNDV0+*62QV&VHVMN$/;+0@F-0J,.O[VT=-E\I&$H
M=;SF7]$ALEII '5LOG;J"H;(V)KRR#6=/EK.WIJ2W;35BUM.K(\;H]7G^XZ
MMJ]=L)-H*">;RTU52 \I%A$[>\11@8%R!Q#L ,;CZ1[Q1[@]GG;[7 ;*)@P!
M2DZRV$,^;@1%;'!;GIE$U<P,: 5LS46QA; <''*&O(K,T/4\TC%-BQ M^X^5
MFD*/C4IFUH--"N-717H!I7*U9+,J4T2T-5:.M76UL$:LX:IU=^X<!KT[>P2
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M,"[.!&FE&ECDRAP]E['H"=\ < < < < < < < < < < < < < < < < < <
M< < < < < < < < TJOW_P"85XN_XI?FI^Q_ZU/![]G]_P"I_?YS8_X?4_U=
M'[JM-6_X,OCP^J7N=+OM-U><(R*/WS^H-"_O;PTE^$JN\VARO\C+["EV97>(
M_P!2EX<Q*%$[S7;H,"J.>EVL8)Q%CCKMPB(R281+Z=9X?>]E>0.W A'1%BU_
M-@.]3*\.Y!F^';!>6O893"XP :-24KSJK$)/51@M'OLVL=3>D306'4,U4"!3
M5/7RDVLCUL\Y5VL7,SU]X(9D)IXQ12R!S!TCPQWV>A NH6G>2M2U[XQUVJ^_
M?1U;@"5[:1P'T.=:2)FS28%$O+0^;%,NL5BKWZEA$K:2S]/<)2 ))J^PR4O@
MHQ],?PQ],87(MV7N%"TH_P P'=XIFK\K%?49=<K:,7;Y*)=JH"C(! [-I(<,
M6GDSUX@L%_E2<MFP-\<H\U;<[IHPH$9BP)*0#(Z=WIYS974 7EH+9VO6QBC3
MEY.GE& 93V37PM?5;6%KU6&F@%%IYC1U8!F#S&QL6K4@2GA+).RUX:ZR DHS
ME('%I5#Y2R;!K)VT'=R!UXLKURG8JG[#5!3AM<9T^F0U4;R2CA$]2UO%Y]&1
MI5(%18DXX>875E[B]2%6.!K TUAYN9+E='&67**AK8*_BP$46_4TQ)G:RUU"
MY>^M;;.' 3)98@S%SU=$L=C-U1G>?1!C[-4<,A5 ;!;3#\R>M'4T+7'3Z;:W
M;&[3GL.FFK>G*Y7'(])UB#>!6DBJIN6,B[*OJKL94'<8 +V,UF&#:U?J%F K
MY+KOS*7"FHJ\\O=408VG9K@GMB\TZR/F+9Y[^L53QIY7N5[,+2C7+73@IH5C
M[CL,)<)$/<0BF%^::([O^_\ M]GV]TF R+S6:OP8F3NP(5TED9E7(H$_5/:>
M99'E<BZ2)K:/H1B\"3QJO@DIV5A:(('!=HZCGJLLJ3%NSE$D<BK'G4BK\DF5
MCN5O:'+5@)HLCG3 IRZ8FK:.-;-D_>*A(O(. NQ.[A<5TS%= Q1 !JP6R/W1
M7+#"'3IT_4KI1I_S7.R"<VS%M[_%,:$WM!:M]K<0Y\SK_P! !0RZ*QC8D!PH
MCPZM>6C^N F0J&W0>>68AYTZB H.G3^Q-8*UYXBU>Q036*S#.15J6%*DJU7T
MCTFD]RYKL5H->?L]EJYP?:E<,X5RE,JB@<5K-,97(+*L!% :/MOZ=.F('LCK
MF3C.O(L[#!@*_P TRO)X-&9"PC'<9!0=LX,#Q@5@YV$)O<\>)D"U?"3CCU-$
M")AGC!&!F> . . . . . 5%NW]9J7[KOC]^'K6W-(NV7R<WNGEFY5\5_L..U
MNRJZZNFJKO7MO&P@:L)23F;#E-=YUY/-34\D;BP@V5IC.-CA4F2P D"VB$3Q
M@LZV2T6,.\@#"<,LRIJRX\4O#+9!O5M#F6+55^=TNWF5VHWCNL4JV-9%=3BI
MA\M'$*'3#OB@J#6YZ\]5K%=U7SJS9*\Z6RL'G1H$EW?XK^,N\K0VN&TWC QB
ML S5%08[-*6+*J6[1M*)F<&)[X>JND.DQYJ4])A(-5K(= *Q<UUK8E8+(4#$
ML/#/QBZMS>Z%V*U W*I/G5W =8[;; GZC8WNXV'8MK95V+IC&/4H;T]M-A(?
MDGCRR.U!@ZG(GM2CKPR@# >/.F/&?1VX+TYIMY0O+15M9ZQT.O6C3-6>.H=6
MZ_J>=Q3K+?9F3ZT926^YJ&JFS7>^V%DAGN:]9KF$L#W0N6DM ,L5X+>'S)BT
M[Z5=>_\ ?U[2:(B*^'$M#8'&UBM[8LD@A; N J,"W^SS4=]!'+1*6'C2\1I*
M=B0IE AQN@/#3Q5L^G#C8]FQ.JNUV1>]951/#M[;A$;TMU<[3LB_1U>EH[@X
M5QX'[J>169G% HK!L3ZLJGL!_::IP+@,?3*?X!;1N^5VJUUSMF%(V"7L.O'D
M6BX1ZCJEXMEXJ?D!:/@0_90AT(PVX;&GJ6P[0F7/7!?OXOP7QCK 535*.!B2
MO1ZZ.87AE,[V;#+I53T7:3].@.K L)(O5MU-+J6+:&P+O-LH_%I92JNT?F*'
M@52JK*9H6F;=-BSTLIC6+NG3'_L@+Q"\1/%VH7N+:S PS+9'1OP\8WFS[&,D
M>.F^".^5J.Z.)2CX R)1$NPVJT F$090J"34L)8*&'3:Z.!((/ICQ#UKX_[@
M7W<+;2D6CTBG6M%JC3L!!Z9%3 +L+K%0[MCDE_L.S0V6R2IZ'6U0UA6H:A!Z
M[+8C2Q365J(*D RM+\+/$K4.R5^TZQ@]AOE.LU'P&DAM[BPS(B85VVJ=3T[-
M '[M[Q68J_(+8F)31X'*PF$:16&POI8Z_"T" F,_BUXQ.-D0;.).E96X_9Y]
MU6]?1%*S7RW[WTUI9V(02L=CA";G"\T_KE[*BFZ,]Q3U99C' .O&B%P JN_^
M%_@Q2DF#>^D15(76^NJVB)?-]E,@G"76%:"L-<B!).+8R,Q5CTJYO)6CD+H9
M\QMS;!RM<"V?H,S "]=E>.WCWL5F!9K<3F$+#7:A3VP"V\%UZMVRN:XN<M@U
MZCMH(Y\,#<*C7YJ4<E%DDAQR;M2E#G%H"=(JD R.JZ-X]6JE>-=EUF0&^HNJ
M*9T#H.:%LQF715XFDBTJ!E&"RSC);GP4OK-<*R:#RGC!-F,W6>/OI-)(!';Q
MXY>,FQIVS"T$B%DOMF,KCF8+?IP<QMLYU&FZX%;*<A&<<8=KK"&GU=97Q(,>
MY4I6&>48?<[(G$@"(LO"WQ$99.FEB'S=-0ZSN*D7*S.]EN9G)!&[XC2=CO+8
MQ]^H<8KN0K9.UR!U/@&91JF[;UJG1(:N3[UQ@=&J^$GB#1L[].%WE*3:)E-O
MV"2VV%+EU-%W:*#=,F1X<!@:Q$ALS'5U'A;!@@K*\U05\5#$)&EZR#[ M>J>
M-?CNB7:9JB10H-)T?DB?:_ED:BEV>0.MU)S3:U-8V _<;2WJ$J&X9]K??[(\
M7!ETB>9Y2MP@3N@.KMCPVTIN1O9[#:QK@%8+6#$N8/*I>+%5V8@D&O[MK >-
M,0J,A]Y\AZ9LF_+1Y ,89()K:Y8198'D8D1@11OX!>.]@F7DNU=G-(7T-?KG
MVT:QRU_W76T2FUH:M 1!5A40L6523W1V#7QU\ *L?K%(46N-/K-<+5 ;E@A"
MK0@UP4. X0 HX0@\?7JP@%%AP@'APZ_8PBBCPPQZ_8ZQZZX!VN . . . . .
M . . . . . . . . . . . . . . . . . . . . . 1XJI5DVU)KP6B6$7"
MNH[#645DF$BS<*:_;3JXRLR8 W+'N8=>]/I]7,9C1Y=1ED(%<DO660D7>-D>
MY&.8CE1CG-<YM_8JYB.1KE3(JM1[D1>XCEW2;UN5+\2JBJG<54O1%^R]?.I(
M>5(*/WS^H-!^[AI+_+_X2J]S:'+)Y&7V%Z8O5>79E=XC_L[%2\.8E!P!P!P!
MP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P"HMV_K-2_==\?OP]:VYI%VR^3F]
MT\LW*OBO]AQT_(W5AF\="[>TV"R7J)MHZ^L]#E/;!RGKHP+0L(3M(C!8)(YL
MH2UI98>4L664@W9'1.$,^4/4$F94]<^R?1AO+>L0+*Y?Z!5NR;ML^W7IC!KN
M+%D;AL/>*C8F(*-B,1$XAP1ZM3B:6K>';=</5 0U5E60E=+(Z]*Z=-T&+NGH
MMK"_60Y*-@ZZ"LAM:JV%D=S4 ^&9GM'IUO.Y[ VU/%&Z+364VRW?<44\M,V+
M7;M66M03'5@_H,QH'84P''#Z,C9T&X,=MD;>UU8,$S1P6%K]UKDL>B7\9I?#
M+4$+LY2E:K\#UU:"%U[E74V.+CW'9=8+'.;:2"QE@I0Z(9N+T8[8&T*;@'9]
M1YE5BTD6(6GBZQ,KVN[R'/+H(4:K7&N!/F$BZLUVOZ"K"BIJ S'HB>6& J>)
MB)F8JFC'CR?1_?IB^D=.GG)'1_1^V74[BC[($=TO9FQZ#LQ+<0,O@OA1\2JP
MMU3=:6IUFC92-'D]&UQ6-G[BVGM5:C7RM\%R"=)31PW12_(YA(-L=C^+:+;F
M]%^UKW8[3)7JYIUEJZL5"HW38&O9HY[E;1[#LAA86]%ME=DL:>S+ZOKQ3%7&
M<1"\?W@8$$8D]L(L!@-%)_1>OERHRII7NES]=VQ[[;L2A&:[(K@#NF';AWMN
M*S4=$S5R-\JZLMAFSZ+1'Q4"R9A/K#6N=-7EJL+'BQ2 2FG^C$C4;2EMUKO%
M?ME-DVS9+T?53Z^V(EL]:>;:8;K4U9_'.[]X9!*5:DNI$%7 *3N 5E8U^<,G
MS1J;'%5D@%D>1_@43O.XN]AAVNNJK/U>=3-*T.8B*Z QUUJRAW=.KUT\*$)S
MGE61[)V*]VK#$*'VMG;(ZJ$6N]TK172X"CR?1+JR*XR1$7BH-#3:%L.E0V5U
M0SF[P/)UH[6?CYK8X4]U:'#.$'6U+KVRWBQ+*U+APN.P VP90T]?]TG@1PST
M5FU#K/=7WT?:JM@LR]P / MH)(Q&3!DL\A.\+>QR!;+1LG0]LVQKJYKP^ARL
MDS35.6 [LOJU$RK@+; ]&QW7]V5W8=4L&N:]3$>VUNP0*>NH4\ ]>KB(74J0
M6EK$4S0VD'1M:WH_7&4-C@KM:N%'O*HN[UVS'#LSZJ2'1#([K]'S9=P;\LNW
M#+?KK!#8++JMPRK+:DGO)[(GUS?],6B)*T*<M&OP;+SKNMK-4SSZ9*IKMT6V
MI-G;*1,WJ(KXT.G3^Y79'HV]O$SJ'9FU=2N'=3J;ZH5=-8]<6)W19F%R@WDT
MNFU;.AFM</OM>'FQMO+M@^\V&4"0?NG+*_$?B=@'< 0+=\-?"Y_H=UM)Z<9*
MF5KA ]<^-%2;P*6HVM:B'KC6]8O=Z+7H'Q84[C<&P*"-:2UT;Z,P2GIJV#/*
MB>-[2'@!K'6?1<[)#M#:LN'^K\=<%ZVLM87O(:C(U;U G:,^M4EN*H+)JWEN
M)FP*57M,1$:^O&Q"GS:JA;4#KT=IM8.M8QG(%MH_1JV45A5CWE[UFUPIE7!3
M8*\M:3D+=FW2H5/<HE/W1N*-BZ)[M^Q6NQ-OR;(MN96),<#FLBY*&,IK8QC
MZ=/]OM!&JGZ+FTT.T)7B&_:X;I*5\ QE%+M-+=MT>QE.O:U7*76%VQS6KQS8
M%@RNMTVBF-4];;%TFWW[7]1V#G2ZRXA90'@;C^'/A\I\54MOP-?+K[=;:SK^
M1%XZKD2(X2M5V@4NI 4U2)V:TS1U )M6W#Y)5P3\U:2-]TOB[*D#[.( W1X
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M_H/'O_Y(_)1I/[_]Y_LV<G!I^^S9AGS!-T>^?Z#=(/?_ ,D/DHTG]_\ O/\
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M]GFN+FCO->I-GVZWCMXQ<'!)R$7L=<1+7U@'T \ < < < < < < < < < <
M< < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M< < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
MX"A13A203AAS C!YA3 RH8R!2A2(\H2!B1YL<XIQYXL\XIH9<,HY8\LL,\<L
M<N^NP/X!!"5A!K5H8JY<N%'!7KP1X1 @0A(<!Q0PQ1\(X!A1H(XX1QX(\(88
M<,(X\,<,<<>@.UP#'E*51QJQD:L7F,4LI)"8\H(8@U3.:)* 9,L*EBSG E+!
MGG")D%DBSG$FE&ERSADSP[ R' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
,' ' ' ' ' ' /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g307489g66i66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g66i66.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1Q.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '#*^<A@X0DE-! 0      !<< 5H  QLE1QP"   "^[,< @4  U=E8@ X
M0DE-!"4      ! WC$S9VXU-N8]Q]Y_]2H:9.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE-! T
M      0    >.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             "\0  !KT
M 0                         !              :]   "\0
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "\0    !29VAT
M;&]N9P  !KT    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M C_P        .$))3001       ! 0 X0DE-!!0       0    (.$))300,
M     !'$     0   *    !&   !X   @T   !&H !@  ?_8_^T #$%D;V)E
M7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,
M#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,
M# P,# P,# P,# P,# P,# P,# S_P  1" !& * # 2(  A$! Q$!_]T !  *
M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M<^HWTLAS&OJV_P Y^XL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$!_\  $0@ \0(H P$1  (1 0,1 ?_$ !\  0 !! ,! 0$
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MG!20CVTBD),@6(MH?")PB<(G")PB<(H B?V4R?\ X -0_P"T5=_-Z[_)T?\
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M-#,%N$5E6I178*U+W[#;5IH0JT@I)@>(1V,(3"4CW,:%N.K3&,.H[#82B/\
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M*1XM+JY.QP=N5/*/"Q5%@G&#;K50OE0C\($7Y!XY<%9(>=N] D&^]LK"PL+
MC<1QVRW>H+7WN\"[;!Y+M(Z;C<%S"W,W<;!I.=SI$DF[B3;\+ZH=I8>G,I,U
MF:I&SXZJ*D4-+2*R47$.M.?"IX0+NS<F!A*_%F@[235Z5D$&=/I.=EI4&UE:
M@9JT)B(=&2>^HOC-@1XNPV N!;<23L=8Y6O:^^RTM@G;I.TB7MLYI=)=LCP\
MFY:& C282V[G.+0[1L0UI53/=)K45%V7'&<I<GQR576B'J4T:GTE:&4K1(T)
MUE@M=V 8W:;8V8'FEC5I9<L6+IJ.U@A0VE(F">Q(HKEK!(+M)\H%V5Q;2>2
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M'!QK2/[G S9%C,#$,0 )N;VN,B;>*'6< TB^=KDML1>QW5M4\O:W18<V@D.
MUFE*^/2CTGM.B T/ #9+@Z-QDXY3<=I+1BG3ZK.T\PC4,,_'$#"9U*HU#V<A
M;X#1:T(5EW"08/8B7(NBLD1L,_!HX3(K:(L'PQ^4=M10]9-#9.: ,CF D6)
M)WEISO8<0)'LS637O;3QSN:TZ0:XM;?)LC?$ N<W:98TG($$Y!1GD_="\I*&
M"FV7Q:IQZ+SM%I01*MGI6+LY3!;IZ=U[?#EXS*D1:*L8B<JLZTJ_;F5WK!\,
M&Q(^1T(M7;]N2&:A&V]LW Y[@0"V0LSXRUH=;?<>W":F1S0X6CL2UQ-RV[)*
M=DISMDUSY&:5Q8-<0;V(O.+]MKJB ^.1^8D:V?)3\G(%8Q9<G:G6@FM R-^2
M*M\D;74UD ]E(F&&OP(S ["7<!03,OA,9?OU\.,R'88VFY%[BUVY9W:"-'BY
MB?;DM0J)&G1)80XNT7NO9@USH[O.D X'("VA8D DWNKV =Y31QLR!K?)B-F\
M@E%716%))DGSUE/F$QMZS*M+V7!Q*Y9@6D<%(CX VGL/58K+)? )MJD_,/M=
MDGRL,5L\[ .)Y+-:[1)M8.%[$\>[CU-JBXAO\V'%T;6YDZ8<][#(T7!+"&AS
M;'8<W':KF@W8*W7_ %XZ1R(61A$\GM[1T K.)*Z$O5VCA031\KM24ZB 49-#
MV^\S(/(:XBBC?5^R$#I$^>/<B4&S'6.\A8W3D&8#2;#ET@T9F]AG?.YL+7)S
M6ILLABIR"U[I0-)UC;*-SW6:T_J.B6VN '&]@!HJ.+7Q&[:>5XG+=XM40Q5R
MXAA90JYE4'?C0PB502Q)@0A^X1G?2:AF51E:%#D7;QY*8A+B@(R1.#J5V?1Y
M2/$=>I%[7<=MA8B_C !U]'80=P(!L-*QN, K'E@=:(7+?&TFEHTFN<6VUF;F
MZ(_SFN()(BN-%9OSW=+:/W1AT8ID9'-;%B\1=P0J[E(ZT(3$'=S5171>T)MN
M069,1,6*Q6?NIN&S)0$)P$&/8:Y=.Y+H4*-AVG5<CB=$F^5B;.-A:YR(L;7N
M;[,B<O?6=R8P--K2PDA[6ZV-A>Z^0;HOTQI!N6B<P3:V6W?J8F;,B<:C<4@Y
M>)&ITL!;%D9)&$%9]&B?:>U: $F8 \-V4 >OE@,7K\7.B68Q#[+1D[XZD&T2
MA ]R--N6J :2;WMRY'0:_P :S3:Y-@"6VVW-BM/?3B]H:&%I< #I-N\&=\5V
M$O;FUK XAK7Z1-O%R*VF<PK?)PB<(G")PB<(G")PB@")_93)_P#@ U#_ +15
MW\WKO\G1_P!MF_W$"R_Z ?O3_L-4_N;)8DX1.$6L4?9 #HIV"O(7>9#2%]<.
MSUFMKMK"^#G_ '%6< M201")PVR:7M*4[Y^"J\5/&88WLFNY9+EP\6E3J:22
M'I%DI&!',CG(&,UD$)A&G44[##)",Y9(P]SXY8F;9 UK]7(U@+F!C7D:));F
M(UC6Z.;V M<T;2T7+7-&TV!(<!<BP.PY371[%=?7"2:Z%ZTXNBMIJHDLC9T)
M4253WQC;3=-30WMIOIMC.,Z[:YSKMC.,XSG'-F89AD8I >(QNZECT'^0[HGJ
M7)ZPE!_OX5!]9<,^VN-3+YJ3H.ZDT'^2[HGJ3UA*#_?PJ#ZRX9]M<:F7S4G0
M=U)H/\EW1/4GK"4'^_A4'UEPS[:XU,OFI.@[J30?Y+NB>I/6$H/]_"H/K+AG
MVUQJ9?-2=!W4F@_R7=$]2_&_8#K^IC&JEVTZIKC?13&-[)A6^,*);ZJ);XQL
M:SC&Z:FNJFFV/U6F^NNVN<;8QG#4R^:DZ#NI-!_DNZ)ZEUTKTZZ(;JJ(7'2J
M*BSK9\MNE84&3W5?;I80W>*[:%\94=;H8PCLXWSE;9+&$\[YTQY<:F7S4G0=
MU)H/\EW1/4N+>[>MJJ3I!2W*/40>NM7SU'>?0/=)V]TV1VT>.D]BV='#K39N
MWVU<*XW5UV01SC?&4M/1:F7S4G0=U)H/\EW1/4N?Y=^N_OK+[Y9:7]^Y331R
M\^42#^^LHI97RDEEQ\,>[>YIY<N<II^GZ.F7"^=<8]U4])J9?-2=!W4F@_R7
M=$]2Y-K]Z^[9SMM=5-[;;;)[[;;6/"<YVW1VQLCOG.3/GG9+;&-D]L_2GMC&
M=<XSCC4R^:DZ#NI-!_DNZ)ZETM;KZUZ[Y4UMNCM5-D<-]M]9[ L;[(:JKK:H
M9VP5]+*.%G3E7"><^AA5PNIC7TUE,[-3+YJ3H.ZDT'^2[HGJ7:6OCKPYV;;N
M+FIA?9FOARTV6L2#J[-7.J:B.KAMMN8VR@OA)55+"J6=5,)J*:8V]'?;&6IE
M\U)T'=2:#_)=T3U*S9'..H\M<1EU(;)HX@K$)0XF@#SLF(M4FLF> I'&G9-T
MW92!LW+>^PLND31TS+I/V#A0EN]6:[OD&CE!J9?-2=!W4F@_R'=$]2N_:].N
MFSKW]M<=*[/?<TD??FUA0;+KW%!115!+WQDOE7W-%5951)/T_13454WTQKMO
MMG+4R^:DZ#NI-!_DNZ)ZEQZ7=UO30]ZIV]2&C;.JVN6^D_@>J'HN5_?3C7W'
M4MA/T5W/_="V/1\E5_\ ?M_24_5<:F7S4G0=U)H/\EW1/4K7@D_ZK5Q&]XK%
M;BJU(2N1-&'ZANYQ,L,F"TB(N2AHF>D<KEAJ0GGY!X[6RJZ,$WJVC;#=@CLD
MP:-6R+4R^:DZ#NI-!_DNYCU*R8\WZ/16*S&%!)[3C:.3Z/IQ25,U;E'/7!&-
M(P<)6K<(@4>S%P6$CV\&C8&/((AGH_*;<4S=XV^$M-GN[4R^:DZ#NI-!_DNY
MCU++@V[>MX=FS'C+AI=DS8)[),T4;&A6N$-=\^:N==LFL[Y47VSE1PMOMLJY
M5VW57W44WVWRU,OFI.@[J30?Y+NB>I=[/8#K_E3"N;LIW*NNFR>JF;(A7NFJ
M>^VNV^F-_AGTL:;;::;;:XSZ.VVFN<XSG7'DU,OFI.@[J30?Y+NB>I6G*['Z
MJS:/22*R2U:6?@9DVPQEC!.S(BQUD@[.$TG PVL//-7)$809I["RC!TLHU)A
MUW8A\DN.=N&RK4R^:DZ#NI-!_DNZ)ZE=_K"4'^_A4'UEPO[:XU,OFI.@[J30
M?Y+NB>I/6$H/]_"H/K+AGVUQJ9?-2=!W4F@_R7=$]2>L)0?[^%0?67#/MKC4
MR^:DZ#NI-!_DNZ)ZD]82@_W\*@^LN&?;7&IE\U)T'=2:#_)=T3U)ZPE!_OX5
M!]9<,^VN-3+YJ3H.ZDT'^2[HGJ5N2SMGU:@@)_)YEV/HN-1\8CLN^*F+7@S)
MHCIKCZ-,;K'-<K+J[>2;=JAJHY<K;Z(-TE5E-$]M3*:HD<&L@F>XY -C>3S
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MZC_3_P!FJF?Q" ?F?")ZC_3_ -FJF?Q" ?F?")ZC_3_V:J9_$(!^9\(GJ/\
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M3]0:8SMO5U;::X\O/;:$Q?7&/2SC77SSD9C&//;.,8_=SG&,?3PI8'<+^H+
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MG41\+^\A<MC%;RBH0QQ5#KN5=HUK,[+Q<4AA[O4QV@((%A+FS?=)BSU+HOG
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MA$X1.$3A$X1.$3A$X1.$3A$X1.$4=+W_ ..'5K\(O3^@N\^$6@#Q0^YGA?\
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MG9NM0\AEA'?4@5*D61JV\.Y."QN^HCBQW+839P%D&AN!K+;<!"BY FC*)Q+
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M$X1.$3A$X1.$3A$X1.$3A$X11:M'[Z+JG_B;L'_->&\(M?O=MVS2[9 VGO\
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M=PY6TQR-'B."PTN(15&"]\35$4;*1YJG@TTK2\F82Z(D;HZ328V MFL&R$-
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M?;LOMR.95YV-X276=!D^;,K=B]1BKJDSF.M!C&#UV%%3MW-9A%9X"A(;+5^
M*$RS-"%N_B+F(EALB9^^7;YHH\ :R".GZF6V_P SEGR[!?U#DRM5H=X3=5&
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M<[.%R!MZYW5(IB\(G")PB<(G")PB<(G")PB<(G")PB<(G")PBBU:/WT75/\
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MPF1N*4X+B(B&P5K&C.VK<[5SD"P_FGB1Y_3 -B^@W<T_;:X!\)N]\.X>4<O
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M0OD86N.;.<4N]IPB<(G")PB<(G")PB<(G")PB<(G")PBBU:/WT75/_$W8/\
MFO#>$6M9;L76$K\2,_%IGV.@]#JH9(5@"@(VU^OCX]*I515D0W:/C;!KBYJ6
ME4@B,EO,C>TEU@[JJYS')5*(E"$5-%7Q5J.?QHBV40K[\[L7^#KU(_I [A<(
MI3<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG"*+Q1K2>_=*#/7KXYKV-;]8+2;QH8GH^^+:M*N[5J!2;/G2FK/89\.(3EI
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M=+0W!? LE(K(P45;X_!.2NW(D*08-AC!L"/.7/N[M)QHD+75]RRGC3W3E:+
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M4?IK>L0RTH>=7IA9K>YML,LR$: &VO!XJ[K%';(/8CJ&-$2K*5.,:21%EN^
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M,;@@<*87<:GU#N-L\M343L@BFFEECIF&*G8][G-AC+B\LC!)#6Z3B;#+=L
MXRAP7",,JL3K<.PRAH:O&:IM;BU32TT4$^(U;(60-J*R2-K73RB*-K ^0N/Z
MG?J>]SI,>N7XA7\#_;O\7K?=.?ZR?+_V\P+DT]<OQ"OX'^W?RONG/]9/_/\
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M#!%XB9'M#"CYVX7*I_""KC;;7//-4S25%1*^::5Q?)+(XO>]QVESB23Q#<
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MG")PB<(G")PB<(G")PB\</C*_L_7A5?XGH;_ &EIKPBT^]4OUP>BO^56CO\
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(O_PUK\(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g307489g77i77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g307489g77i77.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1G44&AO=&]S:&]P(#,N,  X0DE-! 0
M    &;B^980X0DE-! 0      !<< 5H  QLE1QP"   "^[,< @4  U=E8@ X
M0DE-!"4      ! WC$S9VXU-N8]Q]Y_]2H:9.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE-! T
M      0    >.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             "5   !U,
M 0                         !              =3   "5
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "5     !29VAT
M;&]N9P  !U,    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
M       !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!
M46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%
MPJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V
M-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3
M!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%
M539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G
M=X>7I[?'_]H # ,!  (1 Q$ /P#T&JD9H^U9?Z5EONHH=K6RL_S1-7T'WO9^
MDLLL_F_YJI$_9^!_W%I_[:9_Y%0Q+JZ>G8SK"0!CUN) )  ;6TR1[?\ "-41
MUCISBYK;'.+ 7. JMX'_ %OS31$4-+7RE(2(!( - !+^S\#_ +BT_P#;3/\
MR*7[/P/^XM/_ &TS_P BLSJ/46VFJW"S[L6:WP&XSK6.&X[GOKM:SWM]'8S\
M]"-N:+MAZZ\6&(9]BTUAO@YG[O\ ;1X1V"..7[Q^UV/V?@?]Q:?^VF?^12/3
M\ B/LU0\VL:TC^J]@:]O]E"QNIX=PJK;<ZRQY%>XU/8'/#0]WTF!K-_T_P!Q
M7$N$=@KCE^\?M:U>6["-E%Y?<UH8[&/TK'![O1]%Q=MWOJL_PS_\#97ZWO\
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MU7?N):?O_C%52_S?
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         /_A1NYH='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ
M<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E
M<'-F/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @
M(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<]
M(G@M9&5F875L="(^5V5B/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L
M=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+R(^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@26QL=7-T<F%T
M;W(@,C8N,R H36%C:6YT;W-H*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @
M(" \>&UP.D-R96%T941A=&4^,C R,BTP-BTR,E0Q,SHU,#HS-"TP-#HP,#PO
M>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(R
M+3 V+3(T5#$Q.C$R.C(Y*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @
M(" @/'AM<#I-971A9&%T841A=&4^,C R,BTP-BTR-%0Q,3HQ,CHR.2LP-3HS
M,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @
M>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C945V96YT(R(^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#
M;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @
M/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C8U138S.3 V.#9#1C$Q
M1$)!-D4R1#@X-T-%04-"-# W/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^
M"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z1#%%140Q-#8W
M148S14,Q,3E%,#!$-$(U045&1C$Q0S@\+WAM<$U-.D1O8W5M96YT240^"B @
M(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z,D(X0T$P-D8X,$8S
M14,Q,3E%,#!$-$(U045&1C$Q0S@\+WAM<$U-.DEN<W1A;F-E240^"B @(" @
M(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z1#)%
M140Q-#8W148S14,Q,3E%,#!$-$(U045&1C$Q0S@\+W-T4F5F.FEN<W1A;F-E
M240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z1#%%
M140Q-#8W148S14,Q,3E%,#!$-$(U045&1C$Q0S@\+W-T4F5F.F1O8W5M96YT
M240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I
M9#HV-44V,SDP-C@V0T8Q,41"039%,D0X.#=#14%#0C0P-SPO<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N
M0VQA<W,^9&5F875L=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @
M(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y
M/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#ID.3-C9F%C-"UD
M8S)E+30U,V(M8F)B-2TR,S8Y,#ED-&)F8C \+W-T179T.FEN<W1A;F-E240^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C(M,#8M,C)4,3(Z
M,#4Z,S<M,#0Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R(#(V+C,@*$UA
M8VEN=&]S:"D\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D0P145$,30V-T5&,T5#,3$Y
M13 P1#1"-4%%1D8Q,4,X/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(R+3 V+3(T5#$Q.C$R.C(S*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R
M86UE=&5R<SYF<F]M(&EM86=E+VIP96<@=&\@87!P;&EC871I;VXO=FYD+F%D
M;V)E+G!H;W1O<VAO<#PO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@:6UA9V4O:G!E9R!T
M;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A
M;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I$
M,45%1#$T-C=%1C-%0S$Q.44P,$0T0C5!149&,3%#.#PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTP-BTR
M-%0Q,3HQ,CHR,RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D0R145$,30V-T5&,T5#,3$Y
M13 P1#1"-4%%1D8Q,4,X/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(R+3 V+3(T5#$Q.C$R.C(Y*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R
M86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @
M=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO
M=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A
M;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HR
M0CA#03 V1C@P1C-%0S$Q.44P,$0T0C5!149&,3%#.#PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTP-BTR
M-%0Q,3HQ,CHR.2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL
M;'5S=')A=&]R+S$N,"\B/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z4W1A<G1U
M<%!R;V9I;&4^5V5B/"]I;&QU<W1R871O<CI3=&%R='5P4')O9FEL93X*(" @
M(" @(" @/&EL;'5S=')A=&]R.D-R96%T;W)3=6)4;V]L/D%D;V)E($EL;'5S
M=')A=&]R/"]I;&QU<W1R871O<CI#<F5A=&]R4W5B5&]O;#X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@
M4$1&(&QI8G)A<GD@,34N,# \+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.G!D9G@](FAT=' Z+R]N<RYA9&]B92YC
M;VTO<&1F>"\Q+C,O(CX*(" @(" @(" @/'!D9G@Z0W)E871O<E9E<G-I;VX^
M,C$N,"XP/"]P9&9X.D-R96%T;W)697)S:6]N/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N
M8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'!H;W1O<VAO<#I#;VQO
M<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_
MVP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0'_P  1" "_ E@# 1$  A$! Q$!_\0 '@   04! 0$! 0            $&
M!P@)!00# @K_Q !M$  ! P," @4%"@@&# D(!PD% P0& 0('  @1(0DQ05'P
M$F%Q@9$3%!46&!FAL<'1%SE869C6X?$B5G66M]<C)28G-3='>'F7N-4D*3(V
M.$95=X8H15=E9F=VIC-"2$F%B,928FB5I:>VQ<?_Q  < 0$!  (# 0$
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M/#_HS1KLZY9DOC__ )K[=3Q+V73]:K-6K>+X./[YS'85>@A[)[IX]T3$O>[
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MCWQFVB!)(4R1E"?SL,D_B&0HUN;=GA96 *21\997B1,0MQ4[ $R!]D4K7-=
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MSS,TKMDZ0K&>0!=M&&,=\8MQAG)S).^Y$:US[ 0KR18DFJB=W]B^%9=%&)R
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MRY]G56G5U\^?"G+AQ[>%*Z0/Q%<T(1\SHK!^,5;WD[HH_LXP')<\26+E):*
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M!/F=7@8=25XPHXA<N22G$"I+ IDD!=AP"Y4G2Y!/&:^V 1)C,LXE( +*OE.
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MJ]4S9:HH9H0OCQX].JZHZ-H2KAR5%00 SN L(SPZ3^VX-M9ORJT\JP[@/-&
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M-X&,M![Y9%-L^<BB:#5115@[L1;P4RJ-X $A7 *@%*H2# "A0HNZ%#$UW51
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M'PEP4U5PH7*K%:63#\9?L2Y?Y,MVGJ_N5@_HZJ\O3U]NO-MJ_KNV2^Y,>_\
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M1/\ YUM9JOM8^=S"UW39R_-X;R^KE_:?$O+J_P#>GQ[._3QXM?:MM#_)7/\
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MM,F(#%6;L91/"Y3!#U^R AM^&22,<AX+-<UD64L?E263\7O5)I;3'!X(-8M
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M*5V+)#P[ZU@U?4G@!D075$JJHI?+-23#<'$U^9D_+R,62=;N\[;@^BPF&[7
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MF/PQ]E*";E"(^7:E:9\1GZ#%$P0*7S;M%/1%D-WF LT926%711I2>U3P/D6
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ME:*J(3QXD51F+FJH.-.OOX?LZNOK[.6@4 +0ZGDW +7@$.A1GETKWXOG<?\
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MK[O:G?<EY5MMW"BE11*N15B0"G]ZE*GA%0Z%J_#'Z3D<?71$.$3P99N?5N0
MK)%&-Z)M>U)9>Y$2K8O=825M0076N3956OM2054K3R$[ZVES9PZ(,W8HN>JM
MF-Z"'0M5J0WY)DS'\08*$Y'+P(MBC((=%7"RI!!7WK()_)AD.APQVDWN66:+
MGY*9&BF=SFQ)"U1Q5PX51:(.7",8D+P!?STY[U'=7@A.6O7W0P^?HK7VTKJA
M"@"N25*U2HY%'4FJE*SS]^J#QX\>S0NK ^4<P*D"@?K*:OFA/-QY_3X]/?J.
M@.BN_4,F*^?G#X8756HKD P?S($94!*HC($)QI3M[/;W=7KX4IU\^%-2E:U2
MK%  X+LI8:)H@I7CPX=7T=W#N^NG+T5T &A"YD<*BH'6350B0C/'I7OQ?.X_
M^18/U_\ >K!/OX>..M8VS^MG%6+6=U<LWJV[9 -Z6CW?Z&7[.G1_]VXO][>-
M0O11?B^MN'\BSC^E2=Z;&?6SA1?^YWEZ![]>15#\-59S#Z)K[.G2!]VX1][>
M"QH2K?>FBHI8E>O?8G??:@E5.BBUUMM;J))W+*)(VWJ5IY%E5E4TZ75I6]2R
MSC=3:%#D*6=BAIS05KD4'#PA.7<]Z1#>WO)<WR_B.*Y"R-AJ58!F!ZIRA?$\
MU)#C$CC%!<A*B&%[\@+21:+VFAS!H>:4M;H*)M":*5]EUR?NJIT)1$50@IR.
M@*(@JJN1%(0L5XCYB8S*FN>=Q;#<!DQJ+F>8@\3#[X\08'BQYZRVZ_):CD5/
M0+ 4LD$,R7<YCA'<*T/3&R7S #$I /N'A'F0IACJ+M)D(=//<+,"KN2]<EX?
M!PCD "#ZF@9 9J=S2(F:[OMTN-XR;R07DD^E*,HQKO2*PX=D-M@4_ 7TUPL2
MD)N#N(7%L/@0>: H")PV*24C+%\BE;V)ED+3!I76RB01Y_84C.NO?OG4P(E+
M !B%J!4*%#$Y)&IV(+WT=R$3AKG=81SXZ*XLCD\:166@,<4/#4'1=^,3R*+E
M6*HS#0K6$3=2EK,=&B<?*W5>!WA*+&[1Z!5AK( *\V3/4FJE,W57RTC AE1'
M\W(Y\D$4HQ;OJW"+XI%2*8P?%,A)#<7X9D\AD",KGZ1&0SC<%F_)>*8%$XCC
M^ X9EQDQ>-;P2UV[9C&ZA@P5?L@ ]I7B\D:$WBF557/XD<LB/&1D"UJK<D8*
M:]\H[<2Z1')TM')&VN$H<T$1*@NN5J$LA288<8U=;O<D;47C>&@G..*K.2"=
M^/G4\J/ECF-KL%5OB6^K1Q6^1-2D]3KJ5[*E4YHBPW!K4MV*_9#+*[WL\9:?
M1."18'&,-'C&;<8M5U!TJ)G3Q[#9]UEQ9R3BLG+X</8ME(@[7&#!HWG..3LR
M&N;RQJ/7UBQ :U+D8O )HZ>G/,UXPW !GIUDHJ-G$BG^D2F2D8QJ1@.'04M/
MY PQM@RV\#LYF8,OH\GN @>>9T5&CXG$H<?GT_NAZ&&F#?WE!XT6DSH')R4U
M<1UL$AY%)[50E@5&E%?S'5:(T!)J34^GOWJV1_2(2I]7+Y6#Q>'3(1#H;+-P
MJA.:96K'8<OB&&[?-K>2WD=Q6;&X@9D"+DRZS6Y>,GLY8>6)NJF5-DVPZ4AX
MO$@)>F=<U1N*IZ2L-P-71O25)B:XCO9EQ"87W2S$"R&,S)?<H#A;C':TZR9F
M%\[VZ9<CN+WJIW$P''=KE&LE^'W!6X?&34G=1Q$&JN0O<LWKE4$4L2-4YL53
MTY%<BL3=J%<)4(->/?G$$9IZ0C(\))BLGBX6):87BLMW$@G\*=2%^*S+-W^'
ML$R>5H#Y]"#V/*O,5!%Y?8/+.7K8H0D,:CC( 8/AGJ4M5CPLIKKR6B*R:M%$
ME0:LXIQ0J_Y##@1Z0C,#A.2B:X0QX EF/8[GZ:35"?Y0D\#%N(U@R%8+GEU@
M5H3QD[E0<])!F;&[%8?,@ 9$"U +S"QR<CQ058[*25*+V(13N56AAN 5-2!S
M?GU]5#'(*])Y+TW>0B ;;P\5B81]E>-P=U)Y$?B!4Q+,2%1H<DVE%[^".08P
M:<=WF;K*1(G-C<:9VQ1\8$.$9._LBT5.JCT[$Z]<Q#P>I\T<_/&^O/PO'&YV
M&Q2&XR@V9<&8JW%2>2S9;(K]Q&6*>-(WC]_'S>+&D@QHK=+Y5:GE,(3<QN6B
MA01J=$L(VZ?OVLQ'E&%)-&8E]>/$\:Z(ZA*&)<%$ZPKZ=768=1GI'IVVDV2F
M C #=8$"F>2X#CPD?ELDBU)#),7;AX?M\+4D+Q[CUR/;BRY:1OSE7,,5FS^'
M(,@PN1BU7\@K<++FE.X5$I3++(.W.->'?AIYXE/#.Y;,^2MSP_%LF!02,QV-
MP7<,PGHL =)'OA&?8JRMC*+A9#&"A.*!"=0SF-3)DHH*>_!_O=\6/(.:%* @
MA(B"GR60<EKE5454%0J5@90)5#T0\,E'=3&B&LCP+9)JR4<FM7!1=3QP:I!-
M*BN7(!&Y*X\EX0>.W]WL]>H-$=4)1 H(HC4&F0)$(/'GT1E (.F;FO"C$Z<
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MWMJ[G+BI+#;G/I6<7WC9$R0C6;&6!@[<B[1'R]VW=9NSNN8C9]@53$GX15U
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MT0 U6I1W%"I?(%66HTA!X\??SU"K*'YU1D';6JE0T._?N(*^.KQSZOJU55:
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M=(E^DJI^J7GKIXKS^V3:CWVG_!Q?7SL37H9Z"C_W E^4X7YM%.O7OLZ1.O\
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MAS1* 9O"$]/U\/9Y^/*G/UZ*45ZH<DID6&>@"Y4A"^/'T]?'GW:BJBA6;3-
M->*E:@/"$\_KY>OERISISKJIR95568KJ"C."30&'?NM.^4+HH9$3RFZT"JF1
M8'D"[(./#C^SQ[=":!RU'.00H"&8L3QX0A*<?-ZO'?[/5SBIH]12@"C0**AB
MO4J%T?2O8AU12I4!*D(2Z$(3QZ?;PX5\5T<<P^\I<.$=4-45"R(L._>L+JY#
MLXF@31$0$JF]G0P@]/W?5]]?3HA<KFZYHA" 9NB+V&COKVQGCTKWXOG<?QXT
M_M+!N[_TJP/S_OZN%=:OMF/TLXK5?!W:O&^W8OQ.8)JJ!#'N_P!#+]G3H_\
MNW%_O;QJ$Z*+\7SMP_D6<=O#_*K._'GZNW5V,;9G"C_\.\T?]NWI&YT.H1EA
M]$U]G3I ^[<(^]O!EC0[JZZ^GN_9X[>-:[,>OX"X<C2C2J$(2C^$0OT_L_;J
MG75048(%<OF:E:%*HJ/'<P87KT=7LF=SFEUBE'%S9&Y>BEG"EE]%KD_=/+L\
MFVEMWE>5;Y-O#APIIF @',(C+]4*H/,1FXJFBE-%A4V+%-1=9-DT35<K6.'"
MMC=*Q1PX2XT377OMLI<JLG3_ )"M];K[>-?)NI3KFJD<:.XT"D9U!5F(6"\3
MIU:5Y]S'VN11OJI6])*^JJ=$5JW)V7552IY?!)3C2OEIT]T4X)W<;:>Z7\OX
M=W&ZH&4&E$+Y+FH4'R>L"/\ "/C\WFC\7-6UZ]KJ]LA<YM1N;VN*I)U7M;J5
MI<HA1:MONE$;KZ4NN3MN\BZZE+JVUK2G B*KBK#3J"*Z(6K1X=?=>YC\JL62
MR=45FC95*Y1%6Y)1!*].Y5#W/W!2MEUE;:J(T12HE?6GE)T33I96GD6\(4R5
MR*HYT(#IKQH*0Z]>_7"T9M+5+%K6K:BR22C=-6B"5%+$%;Z**HV*4M\JQ%12
MVEZB=M:67WVTNNMK6E*Z:4 J&3,@%RY;,LKLIA'XM'L+*UK8R9V5JUL8UK:V
M0MK5DG6ZJ;2M:64K5K96Z[R&]?[#;6M?)LIQKQJL@>:I8$/5^*C44'&$-$)C
M>(Q^;S7(XYB_NF60&L<'R,P2/R W_:F)MWJ  &"8&2;X9$@#)4F6*7@HJS#"
M7AXR9D#]FY-E7[]Q$<*024S"C/B-.U (I+)E6B9=_AA\U[.?#KY\N7+KZ^-/
M5QY<>/?JGC* 7R0:#-0N2H')10L2#Z/3P[_-]'VZC,#Q"TR* U(RX(Q'DPA?
MHU49:OR-:"A,P*N<J!R(0=_#Q]?U:C<2Q-74AU%&0K55%8<X2O?RZNOEQX=?
MLKZ::.<V/G<EE8N@5!R180NKIH0#DR?5)\SATS$(3Q]O/U</OKQUCJ:LBB@7
MB:L0$+@')(0OM^WZ-9(A(?,KFS@L7.@:H)$(/K]'+QYN.B@EQJ63CQ0E6%%9
M2Z0A.SC7NIQZNSGV=U>?77KKJ!F4U- #DA8*-=42CPA:^GAH2E @+L =01I\
MW%50GBM.OU5X\_'/CH7T5*,3FHYNM!H T.XR/ ]_G@KQ\?N^RO=Y]4.P*]8)
MY.'J70 JBPBA\3_&WE?]'@P_VCG6M35=MK0_Z,2:'_"DV8;OV^^G]C'=OX\[
MU]X=A&I.MHCPJ#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@T
MA!I"#2$&D(-(0:0@TA!I",MK?QL&5J=^Q7$']-F3J>CU=NM;L/KMOW^HKEV^
MK+W3C3S1[GB?[&S9EE_W8]INSQ1P%7[^:+X<>'7XY>CS5KK:*G77]RFK9$J2
MZ*QUCP3E^7S]7&%TYLH/]Z&=U(15H""%6BD0@U0&0@Y)0ZERB)P*\J0A/7QX
M>OSUZJ<>/#J[/-K%4"*I&63*V62@U54 8&'?3EP[N8YAPR-C@4Q(3+CWH' B
MR!DJZ]R67]ZC1;19\^<>X-TU7"WN+5!53W)!)193R?(23OOK;;=24"<!H40T
M9,ZU09/ 9)56BF>WS?YA?<,'5D@\%DG%43=,(,5B<TS0"CT2A&06.23U(O"[
M(7,P\NE$7>'SDB58!$((8+@\BI$BPIHYB"*SY*RN((1*<7^///E0Y9&0CCR^
M'N?0KID^^7:["\N"<.RW+L&C9<U'90992PY-8.(Q_<<AN066,C^-U)*1D[6Z
MF4&$L=+LUX98/4?-K1)FQXJU>CU6=2Y,E37)6"E#4G0G6A;LR+^5"/0\2*6W
M.[;0$KDD$.;@<*!IM#6)0G+H<5RE"!\HBXT''7TO-$)" =G$2H9D'B8PE)BC
MHBT;H#P#!X7=WHCVRSBS)@Z@H$&=*9GS %5-%B(2Z$\8^8O='MG-E82""[A\
M'EC62E7Z&.A W*T%?$YXL+,$(\12AK%L>5<R91B?$E ;JT,D]N1,#7XV^E'K
M-PBF;7,L'4Y$$$D955UU@AT/88Z+K<5M^9"D3KS.6(&81R%>2- RZR3#FXI:
M/#YBQQV_/)$%C-C2\.QGY,;"'A.U:K)M+G[*.+KV%W*#.^!"')5$+DLW-%+9
MMDCP0Z9IU_D^:'/#\K8PR'"J9)@.18/-\>51)N*3J(2H')8C5 +<M875I(@K
MY\)N3%WMG%I"MKNOO.Y!6UQ1.ZRZE*7\I>:4"4&:N!J!5'6"%41S\,5LPIT@
M.US-F ;-RS7(HO%V*Z2QY"7I7.!*/8O7$R1&UN\&#BM39V\6V6DX!^'ED82L
M*+."L8-BR-$$5%EVS> AN1!5%5"<\B3GF'@92"E65GB;FNXC +^7Q?'S#.&(
MGL\G !E*X7"VF2(>YE4NC!(<N8&R*,@$#-Y4\#("6KDJQ*BVKIB\&MW#YNNJ
MU145MK%%.FG!0Y85*(FF0)#H=*'E#;OW=;4TX<]R&IN8P!; 1DG^))&;5S#C
MZD28S*K55]2*.I#\8/@E"1W,45GUH15W:2JR25=T;U;IWJ4BAP@!(+J@*OIV
M \B1#=.AUH_9WUCNN-R6W=K*E(*ZSQAMO-$XJI.KXBMDV%IR6V%(@+Y4K+K@
M=YJA*D:3BZ:DEO-^]O@VV/67FKG-!MM7-#(]6S4YGB#HB/FBA"$9'L,<F*[L
M=K4ZD(B(PG<E@:82L^2*!P49B^78 ?/FBP1DD2,#!0<5('9 @_%CUDGQ!HT;
MJN&;12UPNFFE7R]50M1553-5+G(IEP"T4AT/88^7RM]JOQ5>SKY2^ JPD=)'
M,-?R_P##!C[XKLI<S%/3SJ+.CU)!\%H2% (.(&% RCJTC:+9.G]6_O5!56V
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MVXO][>-0O11?B^MN'\BSC^E2=Z;&']+&%9CP=Z4-^_;T-5 U- @A]$U]G3I
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M-P&6GL#$#(;CV'%)_CK&+IB*<VQ5Z4)$,G;9&.8WN6H6-,Y]CV3SL-A4S($
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MF&VK=-;MEW1X/>0P@,G&[?(\UG>2<C0ESB^,1T"RR,TB$6FD8@..U<LEG(5
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M(SY9EG)T*Z+X1"\/'&OCQYJ:I9W1 RY:L6H$+AZJT%[H._?B8JDIN[P>'+9
M"3TXR@KF%Y%DL.>4+(N2*;QE# &/CI[(Q:X,/?)Q.! KY]'!QB:RV\5&P#V]
ME:6-LJO6%M^)2B@!BCFN?8>&0C+=* A:<DX!UUCN6[K-MK0Q.!-,D F96&+2
MFDMLJ(/M:*$H-,QV,I:.&/;@B;28R".3PL"A)()%W)TXVD1V.AJL??9T,B]H
M( (*'S$\\CY\ZAX;LS,>Z=G6E.R&81N.V[X[<X_P[B<2T1@]S$6U'$R)!_'4
MXX_IDY7%Y&-GA\Z:HS%I+8X;2=5=B9&BT+)6-J,[J-_)2OI&8!P=5"$MYOCB
MF68J2QT' -GF?CTATA-[FV\[(I"U9GZJ"XT-QH[CDC0BLJ>$)F6R\VRD8'A<
M?Q)K&5)I)5;HGBXI.;R<:#%!1J%OK)4P=N0#%\2LI(1 F50%"L13)%5.M46;
MLU-591DCUXPXWF]':HQ=#A">6 )51^A&E@B48!RF7,RRDGAS3(L.'Q]U%8^9
M'F#<C@ZR<NB\?$+NCAD$S)$Q YTW"E5&4! 3FA!%0<\TH&>BPW9J\].M7YN_
M9$-SC<WM1C[F<;C"QI"1$X%C:1AX(O'9=*I6+E6/2N*<>;AS\C 0X'<0BD*;
MG1$XA-DERD2",/<@SR'W2:9-010*/H)"DKKQ55K0=G!E6*!,$&IX,GS(U6HE
M9TQ%D;;DW;1?;UCHD$97Q2*"8R'@MS<P^9-V<+BT?M4B2,I+-' 662N'1U4%
M?)A",A-2P4U]P(R)NCQO<5H( #YJ0_#1N*9)4JD0B9R7"5X'31>5"8LK[W0\
MOW2J*-5/+M4I?[G;Y7NEB?N5JGE<.-%+4JU2MNX^51.OD4KY/&FH$?AR92E5
M (>J@T(8&(IUCYV,F2:J*Z;1K8NW0JU06L02M50;5K;=5NBI2WRTF];K+;JH
MV76IUNMMK6WC2E=4)4+V"CJN0ZU8AQ DO6N9]/&/"_ C" H@&O059,R31VR6
M4#.W8(BWL>LE!ZCD87"KL"@<DBU5NL9%A3QF4'WVI+L7;=PBDI92CL."A$<5
M1"X(3/+4F:<*>F.'"\>0['L- 8_B8- ?$XR'M!"AKIP],JT'\KG'PB4-.")8
MV_)K^6^-%C3X@5.$EG),N\?$'+ARI"@#4<4!<@H5U* E*:Y156IK6'31@RI[
MGP9M:>Y7>4CP;I4]QNXHW>4EPM_L=WE-T+O*L\FO%%*O6G9P)3)SUH2:U*LC
MG(A2J2&'D;%,*RH ;1N5M3*3)B0'EACV)2V68_D(D@,3=HLW(F400W')&.I:
MU?OV*Z#,HBV>#W[U@\1<-'2Z%ZNA(6@J "CC(E E41$5\A,0K]NO?YXZL.Q_
M#8!"X]CN)@6@R&Q48R$! JE[DFFV9CZVW(7.7A99^0)O[U[:O'A4J[>E2)&]
M8D0>N7ZZ[F^A!0$]9JBA$ R+J*+6,5)7C6&*;V\8HD.2P^62X4TYEH-X,*,&
MUDXG;6%7G C5ZS"R(CC5G)$,=&)*(;OUK1LA+19Z9:*-Q;E%[:Y"!EF$,O5Z
M!J35@6.B!:K&6\41>V)B39,T*W50:-DJW.5'EU4D$DZW/%K+K%G5U;+*<7"M
ME]]BJ]>*M]EUUMUUU+JTK: .&+,H[<@2J\B@2N,?)08,63]S6'L5D_(02\A1
MHWOL]R;*56:I>3<G6WR&REU5$+.'DI*5K>G2VZZM=2I"#@<PAH-5<#*A%%0^
M??N5CT+MF[JVRQTW1<6IK)N$[5TK%K4W"-U;DE[**6W>0JE=3RDU;:4OLNKY
M5EU*\]5*+5D(T'$<E)*H*/"/I9999Y7D66V>5=6^_P FVEOE7W</*ONX4IY5
MUW#^%=7C6M:<Z\N1$)(3-"R9*C94T"HJU:=\SV1^N?#S_7Z?7H@*.>13B$ *
MNM%-,X0<.[KY^;TUY<.?HY\^SCJ(M$7K4U("-EF@!8"$4/BGXV\K_H\&'^T:
MZUJ@?;6T/^C%F-#^NDV2\O@2D>^G]C'=OX\[S]X=A&I.MHCPJ#2$&D(-(0:0
M@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I",M[
M/QL&5O\ ,5Q!_39D[6MV'UW7X_\ ,5R3F+Y>L\N:=E1[GBG[&O9G^./:;[T<
M"B]].-*4I2E/II]E>//CK9^:,$=N",10 ZJAX >"1S["XF\JN"L*#KSC5@W*
MN0UCYM<5;BWCARU:$EQ]%:O$F#ITS=MV[Q1&UNNX:N44U+U$%;;:REU925R0
M5:G!'S"(8KZ5X>CYHZ'=Q]'+]E*<.KT5^C4<H=5!)H@U( R#NI31%D5-S+O
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MR0K%FI*I0=9R0=:!_2S0W^!S3S(OG^>'GB;H\T,97B[G646\EM&8_>P>RQ>
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MR&(!1M3"$\W'[Z\:>;AP[>5.?571J)VBJ,'#AD9';5W?O\\+J([555"@H58
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M$HH9SR$0 G(]7?\ +')IGW!59))8=3-.)JRV%A#4EF,7_"-#_C%$X['+K+9
M>DH6ACX1!!@-54J&B91LT9"_=4O?RZ'EV5NE07&J!E1:AAQH2@Y*0Z'+N^L?
M'#V=\99Z:SPGBJ2#Y@ Q_/+\=D92"(B#47-'$H5"IRX<1<Z#)DV)@6U&SL4-
M=.J*MUFYYD9&J-;?>%JZ]#@59:J&8-4)JXY@0(0]A_*L3!]?U=7'L]G'Z..H
M H)<<7(8OJ5<GM<!8D+X\<-4JQ)&H?-5=30\"0,J+"$XUX]7K]7BG/AZ] ]%
M]*&H4Z D\VJ04=^_?YU]O+S_ +?KU"@("HC$N^;5 =:T*/"#QX\=NK3=05 5
ME4\JM51",\.DP\J3X%A.#6E/=3.Y/<7M_P ,BT;:\Z)/LE!)D=>JVTKY=&(^
M.PTJY?+6\*-T:4OONI3AQU7; ^%PNQP\$&TQ7$\/N$DM%WKU);SS$!]T2V$V
M\6 "DE%7WKZ'63U%MSBNU]HDMTV!V$VVVKO,\TJC>LL O>$7*RE)\GPUM?\
M%KM)8R3+OSM*"7"S+_R4>D#OD1'RF&$]^XX "4*7UML%1G=9CP5>,"#W:EU;
M$1]F6<>MDV8[A6YP:E\?HA2R^Z^JEG'O?2?:0SSG=N&T4ME9[Y_N=CB]WE,L
M@)I+ZKL&ESGMY R!1]]G8GI*Z$I;K=P+?:[H6M[]??4\H)O.(=&V-WB6\7RW
MLY0LUL=F<;M#:V[;MUPN^F<S 2B4Z':VX.0H% "-T^>G#(@-2I_.T'=X\>SN
MU&!UKJ'(R"(]94(75@80:JA05'-*$@#5&[  A4E80GG[_3]6@R\EM0>"J<J%
MUJK!&A"\>_QW>.VNFI)R*$,K$GE71B'>J#GS\??Z*^CJU "*4/(E'+(2ZKHX
M'%$)7U<^-._[O735(3LYU4(A3()J$*ZPA=$*&C[R9DT8+KJCMPA"=G?Z?V^.
M.HRGM*H%S9N2#@A!AW[I!3JY]OV]W#O]->?56NLB 44J,G=UX/1EY*8?!W=8
M//QISIZ.7#T]_/CV<>'GU 0[HH)T[%+$L1PJM80O?V>.OS<]0(<F)09E%)5R
M:E-0QZT'CK\?MU2 %IDJ!:5 4I4%D*,31D'CO^KOIU>*:E>+<U(!JAJAU4)1
MQ"#QX[]5RF0H&(1-5:H1-ZJ+2$'?I6K9 EPJ$T5"R.@<TA"<J<N[L\<^S2J4
M&KNY=M4J44T2$+XZ^SQ^_LU%/QJ4)!%2F2$('.F<.X@^WL\<M5-,Z@%PA5EY
MA0SO2$''M\>?QVZ@RJ3H<P55&*@HI*4S6$)3JIV>.S0$'AYAD"45S7@0*/#O
MW[B#J[:U]//QZ?;WZ/DQ6J%URSZMY\U#"$1/G3,L-V^8DGF9)\[]ZQB!@'9E
MVDG?9:\*O+?);AX^*L4K2U<S(BZ[$&';UK2BY)^V3NNMLNNOM^+$<0L,,N5Y
MO]Y(EL[O933S!@9YP=VSLI :SVLQ%G)59IP"P)&T;%[)8OMWM1@NR>!V7A<1
MQJ^V=ULYIA,;*ZV+VE[OUY,H)DNEPNLEM?+U/_>6%C:$*4!8W1Z8:F>*\!J2
MK++6YIG'<+-I-N%S,U4MK8H&E^1UD';&(6IW<;FJ,)BC6/Q>H^VZYNR?#7]K
M;@E?3CU6SERM[K<)K>^!+_B=XM<2OH(0R6UZ(FEL4+R^!LA9V9D5))A,)?)2
M-]Z:=I\)Q_:^SPO9JT%ILAL/@^'[$;*VDI!EO6%X#)/96V)F8-:3XOB-I?<1
M\.1X2VLKQ8FT)F!B]6N_CR*#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$
M&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I",]^D:QG,SV(XGG7$XI4UF+:3/QF>H
M6":V*7/)G'P;1V-RACI.Y"Q5U5.9X^?FF]C5FBL[?DF MDV3JLM96FN;2W:W
MFNECB-SDW[[@UXDQ"PD )-M9R RWJ[,#-NVUW,P(E!FF,HEE"F/:.A#',*N^
MT6*;&[2WF6Z;+=)F"7G8S%;Y:32BRPJ^WRTLK?9['9A.9;,383C=C=+0VEK/
M)96-A;7BUM)MR68&<<69-AN9\<PO*N/2R1N&3V/CI)'R*?DVWJ,2"-%*MGB-
MMRE69,>O[L.+#E;J.!I-J\8.;4W#96RWOKG>[OB%TL+W=9Q/8WFREM;.:DQ$
MP),LXRGE(,EI(7DG$TI0RD'RO:79W%MDL?Q?9G';M-<\6P2_7C#[]=YE,HMK
M"?=\)93L+6[V]GN7B[6\BV=XN]I96UF9K.TE)X8_!.)1>;)!N+'PM@VS3*8&
M,QB?G=CPM5^1@P<K::'@E!][^\(E8B2L07O?-Q:)-S8U9MG+U9JS;(I?2X)+
M%5E"KD0QYC7K-8Z12B9"):IV>RGH^SJ^KMU'5JM0,.=2R41:+1!.YB(9]BJZ
M;Y&P3/J'*#+<*S"8RNHKX-J\K)*2O%DVQK[PH^]_M:":L;IA0U5U5J2]]4'U
M'^]V]77OYO$S +$U5^>39T:*"$(U3DQ[ZQ11+HT6:9-T\KENZX>Z-FIO<"^(
MJ=HRW)Y'<=)LOL,DTX2FJU9*.Q9+3.!E5/+X/@2C<[=>A8V1C]H!<V9*NZ>9
M7.1;.,C.JM4$<:?'GIDL?!IT<C]C#<Z09H;VS#[,W1;<]%".4Q>U5ZPW -&.
MXM;(+]*I7**><+D)%9%"$T'H/&ZT78)24#'4!5OP$X<(DF RG@@J:=H+]@Y+
M#?!U1LQ5N&5:N:AS$QXZV2-,>YO99B0R#>33!Y%R3)(I&E(LDSMC./I\+G+U
MEBX>41.*4^#8KD;*V3I>,*?!MGE!I"*AZ8MHUC;,FO=T@ZHZ<%0*BUT=@8&=
M00B*G?S"&_DWH_ .3L<KQ-YE><1Z3-Y'N!,Q^2QRZYF$',,_[@36=#;!_#5G
MSEL3(#+" V)V'D"@P@[;"U':=&+(F[":B,E4;2JG,=I:CA'AONJ5J_5PII\R
M24&V\Y>A<ED+#'V>6$=Q++\OM<P2 (^QM4[E)N^?% \AR##P&1G$T0C32,Y*
MD T@_-.R^,C,A#,Y9*AP(FW4<1XA&3T!H_)*EM2&SY*\4$.' 9*'(-P.G'(0
MW]P.R"-;CI9D.8S/(4Z#%S&*P6-L5*0F2S&(-\6O0ALI-[)F_&1^7C@F2#%^
M2*PR8(C9:+O!ME<;Q%K[Q550=OEQ'%>:<]:J:=?" F0  9J5^#J])CGJ[3<L
MR[)HG(&7<[1R<MX^HR'"!@;$?Q.>+1%//$)W .(X=?)3TR-)ILCF-8-! ;AL
M"&770$833E5DJDAMV<LJ$ER%5,LDX-D SK1(N]*A !SSS+>COG':C^VS-\,'
M78]@&Y!C!,0C99DN6Q5H"Q(P?Y4$63]W,3PJ'$)K*9A(869B4(F,PJ;%\<6L
MCA<1'8]&#!55-,V5.Q#3@#0/RUK5:<DAO!5,KT*T9-17T=<>6W:1*S^"]X&-
ML@Y1 &9]O$;3.R6S>-8[>1V*QAW),!PK  U</!24\DI!ZB/ P07("39U-4OA
M0N^)-FJHEC5K8@1O^DB'(>9%JKK7KF\%! * ( 3^7N(:&3-C$BR1GI7++G,]
MXN)IY$2GPN"-H]+TTQ:=<!$\%.H_8R&94#XP(+5M+D)@WGAO%)7(R-Z[>&62
M=.(C&;'0A2P8N&H%3)?G'&*)T "%AU9==%Y:&&E']@>0XJN4DH?-T%7G4@@Q
M_&)IV>PF6,PKXG2K!6V[#)AP,AZF8$7B,E27VW )(S>/Y*1$.&$C.Q,H%>-Z
MM3"(2DZ+IP#$]K<8N^&J');N&JO4\2-N0V6'LUX_@.,XGF0G 8U$,-3K##[W
MXRF3XF;'2^.1&-L),]-8^R9B<Z4? V<56O>PZ1ECF-YDY,^_9?$BJP(/:F+H
MR%E/4$)T0 ]3A0\03(I2I_+Z8:\TZ/=O,X6O%5\G("W;B?9BR"J7:0-%Q8L4
MRA"F\88,GXUQ)_(*BP#\:&?EV+QU<G+0PZD<6^"$U$R+9,#F')):A\[ 5IGP
M@)T+#( *4HM>V+28&Q)*<7*9C,326QN72?,N7W&6"RT0A;R"QX(JKC3&6.$0
M;$21ELT?O+DVV-T"CPV\,T<$WQ9RHHR;U3K<K1F"<THVA+$#15&C%8Q)5. S
MS>O?2L3[QX>CG]'?RKSIS\W+STX9 E3G50!FR,BG12FF06?-W]';!]/U<:<?
MW=OUZQ7CGFN:YY$U)!=5")"#[^%/9V<O-^WCRT:;S*SZU45H&1@U%0OF^KL^
MSEJE004H10_.Y*DZH75T0G?3K^[V?1S^G6.2$_"F99:AQS8 EPC/.%_^5;T@
M5)(/\M_A/80.D,>0)V5LO$R;=9D,6F-/LFBEM;TB-N)\?.%&!'C6BX>72"Y*
MMEEZ=JE^IB;Z<[2"TD)FP_9Z2ULQ.'DML6O,HDM)932<72P66:DTEO,]03^B
M;:Q];7H2-TO %AM=TT6]ROTUVF!EO.']&^!W@WBXVUI*0)K [38W(+>P";EZ
MPRY"<3$3&66^^XK ,!W-XAEN',C-7%X*3-D5&18:I1J?B<C&K6OH[,(P0I2J
M@V0QPJBW(CG2=?)ON249N[%V#IVV6[O$L.N^*7.VN5Y!W+4 RSRH+2QM9#O6
M5M93$'=M+.<":4YO+,LLTP/E6P^V>,[ [38;M1@=I9B^7"TFEM;M>)?"7+$K
MC;R&QOV%XA8KNV]QO]VGM+"WLYG F%K9F2VL[.TEH5@K<9.<73D;M$WGNVH/
M.#6R]GBC,2Z=@O'FZ>+M%$6PP[&2*ON;$7E.U)5NWF6.%EOA*A.M2(6UZS()
MHM^HPS%[>[6TN"X[,+/$)5ENE]/DW;%[($"6TLYR@DOB&66VNY)F,[RJ)R!Z
M1MWT=83CN$WCI0Z)[&TOFQUK,+;:396SF-XQSHXQ"TEFM+Q<\0L)=ZVO&S9F
MEGM,*QZ63P NY%A?/ VMA-//H5QY<?7]_P"^GIIQUM+JK5I4*- %US%4*O'@
MAJ_?3\G4T+U4]'CM^W0ESDH=%85?0U5LU0YR$^SEVT_?YOHU:9H0P:KG*BZ'
M0D.A,._9!VU\=]?MIXZXG!0&T=$?@"%KG6L(.[U\>7BOHZZ</5JNH4%E;1'%
M$&0*5**&(5"^.OQXYZ%#R5:!BC_ "#G4C-"4KXI[:?1V]7'46GF9<Q4+4H*
M*34(3"#S\O-7S5X?7]VCJ=:%E&FA.5$R54:$+W_1Y_%?OT"H@!J34(.9XABI
M#&E%0G5Q[>[V=7'[:Z*?W2TJ:$.KH3R /:!#N?F#=D'C]_=W]G9Z- I.;%60
M/D4HNJJW5"#G]-?9Q^OAPIXYTA=:D4S0E$S=P4H:K"#GS^CCZ/O]/W&J?B0Y
M%$92$-0JUH$+7MX=?#]VATR4,Q.G&@2@6M:PA.%>%>WT^/HX]U.-.O4 HRJ
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M"*--(GL-NE;[9[$>_&,=GUN_-Q@^?+V=_P 4L_\ .G/^XJ#<NOM_"=QT]<;
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MP>K47-2*]D/8;=*XIB>P_5C&,_V=$-0[TR6PR3G8A)I#B_-1H] 7Y$K"R9&
M0-TYC14L,5#$"8BJN3KK&A!P*<.1]7MEGOE)HY<HHJIV.%J*3UQL"_Y#%&"#
M\[W9N/ZMKWR$/8;=*]/IGL.__.^,<?\ 1WT:\X=?SY>SS^*6?_YE0?\ K.\>
MO3UQ<!5? 8I4E/4]V1?Y[R76'L-NE;[9[$'_ &OC'P[.\^Z0?/E[._XI9_\
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MVFZ0;O8W#9JXVX"6=YP[8RY6]N<0,I_-++Z>7U+&TW9Q83&26+_83P1B3;I
MQV-<,0<-!8@.NN7]XBTE%'9,BK;9:Z,R N\4<EY"=>^YV>_#)IZ^).:6)V*.
M:I))66=Y<,/N>&7>6[7&PDL+&5R)5,T\V<]I/,3/:3G.>>::9$"H !Y+M9MA
MM+MQC%OCVU6+7K%\3MP)/#7B:66RN]A(3X.ZW*ZV4MG=KC<[)3X*ZW2QL;"S
/68RV8FFF)ES7VQK4?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724307890400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 21, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Roivant Sciences Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001635088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">D0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1173944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Suite 1, 3rd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">11-12 St. James&#8217;s Square<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">SW1Y 4LB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">+44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400 3347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,765,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,115,587,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Iselin, New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Redeemable Warrants, each whole warrant exercisable for one Common Share at an exercise price of $11.50 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ROIVW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, $0.0000000341740141 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ROIV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724306290192">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,060,400<span></span>
</td>
<td class="nump">$ 2,055,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,903<span></span>
</td>
<td class="nump">77,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">82,220<span></span>
</td>
<td class="nump">54,250<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,146,523<span></span>
</td>
<td class="nump">2,186,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,905<span></span>
</td>
<td class="nump">14,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61,044<span></span>
</td>
<td class="nump">62,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,731<span></span>
</td>
<td class="nump">8,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments measured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">325,834<span></span>
</td>
<td class="nump">188,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,092<span></span>
</td>
<td class="nump">27,197<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,585,129<span></span>
</td>
<td class="nump">2,589,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,583<span></span>
</td>
<td class="nump">20,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">127,531<span></span>
</td>
<td class="nump">76,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,398<span></span>
</td>
<td class="nump">12,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DeferredConsiderationLiabilityCurrent', window );">Deferred consideration liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,147<span></span>
</td>
<td class="nump">5,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">708<span></span>
</td>
<td class="nump">3,244<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">184,367<span></span>
</td>
<td class="nump">218,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_LiabilityInstrumentsMeasuredAtFairValue', window );">Liability instruments measured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,912<span></span>
</td>
<td class="nump">67,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">62,468<span></span>
</td>
<td class="nump">62,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt (includes $177,400 and $150,100 accounted for under the fair value option at March 31, 2022 and 2021, respectively)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">210,025<span></span>
</td>
<td class="nump">170,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred Revenue, Noncurrent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,740<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,183<span></span>
</td>
<td class="nump">8,169<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">523,695<span></span>
</td>
<td class="nump">527,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,491<span></span>
</td>
<td class="nump">22,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 694,975,965 and 651,576,293 shares issued and outstanding at March 31, 2022 and 2021, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,421,614<span></span>
</td>
<td class="nump">3,814,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_SubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(2,763,724)<span></span>
</td>
<td class="num">(1,918,462)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(946)<span></span>
</td>
<td class="nump">1,445<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' equity attributable to Roivant Sciences Ltd.</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,656,944<span></span>
</td>
<td class="nump">1,797,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">381,999<span></span>
</td>
<td class="nump">241,726<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,038,943<span></span>
</td>
<td class="nump">2,039,514<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable noncontrolling interest and shareholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,585,129<span></span>
</td>
<td class="nump">$ 2,589,692<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for the stock subdivision as described in Note 3.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DeferredConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred consideration liability current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DeferredConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_LiabilityInstrumentsMeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability instruments measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_LiabilityInstrumentsMeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_SubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subscriptions receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_SubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724310912992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long term debt accounted under fair value option</a></td>
<td class="nump">$ 177,400<span></span>
</td>
<td class="nump">$ 150,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share</a></td>
<td class="nump">$ 0.00000003<span></span>
</td>
<td class="nump">$ 0.00000003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">7,000,000,000<span></span>
</td>
<td class="nump">7,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">694,975,965<span></span>
</td>
<td class="nump">651,576,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">694,975,965<span></span>
</td>
<td class="nump">651,576,293<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724310943264">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 55,286<span></span>
</td>
<td class="nump">$ 23,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_OperatingCosts', window );">Cost of revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,966<span></span>
</td>
<td class="nump">2,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">483,035<span></span>
</td>
<td class="nump">236,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AcquiredInProcessResearchAndDevelopmentExpense', window );">Acquired in-process research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">139,894<span></span>
</td>
<td class="nump">596,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">775,033<span></span>
</td>
<td class="nump">259,878<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,406,928<span></span>
</td>
<td class="nump">1,094,693<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,351,642)<span></span>
</td>
<td class="num">(1,070,898)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Change in fair value of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">87,291<span></span>
</td>
<td class="num">(95,533)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOnSaleOfInvestments', window );">Gain on sale of investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(443,754)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments', window );">Change in fair value of debt and liability instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,354)<span></span>
</td>
<td class="nump">29,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination', window );">Gain on termination of Sumitomo Options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(66,472)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity', window );">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,041)<span></span>
</td>
<td class="num">(115,364)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,435<span></span>
</td>
<td class="nump">8,701<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(923,747)<span></span>
</td>
<td class="num">(898,547)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">369<span></span>
</td>
<td class="nump">1,686<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(924,116)<span></span>
</td>
<td class="num">(900,233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(78,854)<span></span>
</td>
<td class="num">(90,999)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Roivant Sciences Ltd.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (845,262)<span></span>
</td>
<td class="num">$ (809,234)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Basic and diluted net (loss) income per common share:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share&#8212;basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1.26)<span></span>
</td>
<td class="num">$ (1.28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Basic and diluted weighted average shares outstanding:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding&#8212;basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">669,753,458<span></span>
</td>
<td class="nump">630,046,720<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for the stock subdivision as described in Note 3.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AcquiredInProcessResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquired in process research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AcquiredInProcessResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation and consolidation on gain or loss of consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity interest option to third party purchaser gain on termination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Loss on Fair Value of Debt and Liability Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_OperatingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_OperatingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of an investment.  A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment.  This element refers to the Gain included in earnings and not to the cash proceeds of the sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724307861664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">$ 564,956<span></span>
</td>
<td class="nump">$ 84,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">63,735<span></span>
</td>
<td class="nump">22,637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">$ 501,221<span></span>
</td>
<td class="nump">$ 62,321<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724307730672">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (924,116)<span></span>
</td>
<td class="num">$ (900,233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,271)<span></span>
</td>
<td class="nump">3,826<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive (loss) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,271)<span></span>
</td>
<td class="nump">3,826<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(926,387)<span></span>
</td>
<td class="num">(896,407)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(78,734)<span></span>
</td>
<td class="num">(90,967)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Roivant Sciences Ltd.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (847,653)<span></span>
</td>
<td class="num">$ (805,440)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for the stock subdivision as described in Note 3.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724301908608">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Redeemable Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Subscriptions Receivables [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Balance, temporary equity at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2,086,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,143,739<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (2,349)<span></span>
</td>
<td class="num">$ (1,109,228)<span></span>
</td>
<td class="nump">$ 54,042<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">628,779,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IssuanceOfSubsidiaryCommonSharesNetValue', window );">Issuance of subsidiary common shares, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">456,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324,995<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue', window );">Issuance of subsidiary common shares to the Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,692)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits', window );">Exercise of subsidiary stock options and vesting of subsidiary restricted stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DeconsolidationOfSubsidiary', window );">Deconsolidation of subsidiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(3,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ConsolidationOfUnconsolidatedEntity', window );">Consolidation of unconsolidated entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_RepurchaseOfEquityAwards', window );">Repurchase of equity awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_CapitalContributionsToSubsidiaries', window );">Cash contribution to majority-owned subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of the Company's common shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">301,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of the Company's common shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,077,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">84,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,720,090<span></span>
</td>
<td class="nump">57,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(900,233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(809,234)<span></span>
</td>
<td class="num">(90,999)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Balance, temporary equity at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,039,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,814,805<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">1,445<span></span>
</td>
<td class="num">(1,918,462)<span></span>
</td>
<td class="nump">241,726<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651,576,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IssuanceOfSubsidiaryWarrants', window );">Issuance of subsidiary warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing', window );">Issuance of the Company's common shares upon closing of Business Combination and PIPE Financing, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">129,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing', window );">Issuance of the Company's common shares upon closing of Business Combination and PIPE Financing, net of issuance costs (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,372,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration', window );">Issuance of the Company's common shares related to settlement of transaction consideration (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">840,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodValueSubsidiaryPreferredShares', window );">Issuance of subsidiary preferred shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany', window );">Issuance of subsidiary common and preferred shares to the Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent', window );">Payment of subscription receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,000)<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IssuanceOfStockUponWarrantsExerciseValue', window );">Issuance of common stock upon warrants exercise</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IssuanceOfStockUponWarrantsExerciseShares', window );">Issuance of common stock upon warrants exercise, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled', window );">Stock options exercised and restricted stock units vested and settled</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,757,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DeconsolidationOfSubsidiary', window );">Deconsolidation of subsidiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_RepurchaseOfEquityAwards', window );">Repurchase of equity awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(2,247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_CapitalContributionsToSubsidiaries', window );">Cash contribution to majority-owned subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,219)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of subsidiary stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of the Company's common shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">57,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of the Company's common shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,369,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">564,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(2,271)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(924,116)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(845,262)<span></span>
</td>
<td class="num">(78,854)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Balance, temporary equity at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2,038,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,421,614<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (946)<span></span>
</td>
<td class="num">$ (2,763,724)<span></span>
</td>
<td class="nump">$ 381,999<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,975,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for the stock subdivision as described in Note 3.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments of payment of subscription receivable value equity component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CapitalContributionsToSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Contributions To Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CapitalContributionsToSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ConsolidationOfUnconsolidatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidation of Unconsolidated Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ConsolidationOfUnconsolidatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DeconsolidationOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation Of Subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DeconsolidationOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of Subsidiary Stock Options and Vesting of Subsidiary Restricted Stock Units</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IssuanceOfStockUponWarrantsExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of stock upon warrants exercise shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IssuanceOfStockUponWarrantsExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IssuanceOfStockUponWarrantsExerciseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of stock upon warrants exercise value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IssuanceOfStockUponWarrantsExerciseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IssuanceOfSubsidiaryCommonSharesNetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Subsidiary Common Shares Net Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IssuanceOfSubsidiaryCommonSharesNetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Subsidiary Common Shares to the Company Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IssuanceOfSubsidiaryWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Subsidiary Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IssuanceOfSubsidiaryWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_RepurchaseOfEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repurchase of Equity Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_RepurchaseOfEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares common shares related to settlement of transaction consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares common shares upon closing of business combination and pipe financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value common shares upon closing of business combination and pipe financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value subsidiary common and preferred shares to the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodValueSubsidiaryPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value subsidiary preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodValueSubsidiaryPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock options exercised and restricted stock units vested and settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724310995488">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (924,116)<span></span>
</td>
<td class="num">$ (900,233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_NonCashAcquiredInProcessResearchAndDevelopment', window );">Non Cash Acquired in Process Research and Development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78,223<span></span>
</td>
<td class="nump">351,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">564,956<span></span>
</td>
<td class="nump">84,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Change in fair value of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">87,291<span></span>
</td>
<td class="num">(95,533)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOnSaleOfInvestments', window );">Gain on sale of investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(443,754)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments', window );">Change in fair value of debt and liability instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,354)<span></span>
</td>
<td class="nump">29,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity', window );">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,041)<span></span>
</td>
<td class="num">(115,364)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_GainOnTerminationOfEquityInterestOptions', window );">Gain on termination of Sumitomo Options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(61,472)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,819<span></span>
</td>
<td class="nump">16,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of effects from acquisition and divestiture:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,403<span></span>
</td>
<td class="nump">3,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50,595<span></span>
</td>
<td class="nump">9,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred consideration liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(50,000)<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,865)<span></span>
</td>
<td class="num">(5,497)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,969<span></span>
</td>
<td class="nump">2,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,383)<span></span>
</td>
<td class="num">(37,839)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(677,729)<span></span>
</td>
<td class="num">(552,138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sale of investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">320,170<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(17,436)<span></span>
</td>
<td class="num">(5,806)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncreaseDecreaseInOtherInvestingNet', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">561<span></span>
</td>
<td class="num">(25,896)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">303,295<span></span>
</td>
<td class="num">(31,702)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ProceedsFromBusinessCombinationAndPipeFinancing', window );">Proceeds from business combination and PIPE financing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">213,424<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet', window );">Proceeds from issuance of subsidiary common shares, net of issuance costs paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">455,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ProceedsFromPaymentOfSubscriptionReceivable', window );">Proceeds from payment of subscription receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ProceedsFromSubsidiaryDebtFinancingsNet', window );">Proceeds from subsidiary debt financings, net of financing costs paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary', window );">Repayment of long-term debt by subsidiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,590)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PaymentForOfferingAndLoanCosts', window );">Payment of offering and loan origination costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(20,297)<span></span>
</td>
<td class="num">(286)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ProceedsFromAndPaymentForOtherFinancingActivities', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,145)<span></span>
</td>
<td class="nump">794<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">306,792<span></span>
</td>
<td class="nump">456,264<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(67,642)<span></span>
</td>
<td class="num">(127,576)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,141,676<span></span>
</td>
<td class="nump">2,269,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,074,034<span></span>
</td>
<td class="nump">2,141,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares', window );">Subscription receivable related to issuance of subsidiary common shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_OtherNonCashTransactions', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,035<span></span>
</td>
<td class="nump">4,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash paid:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">916<span></span>
</td>
<td class="nump">4,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,535<span></span>
</td>
<td class="nump">$ 2,017<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for the stock subdivision as described in Note 3.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Loss on Fair Value of Debt and Liability Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_GainOnTerminationOfEquityInterestOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on termination of equity interest options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_GainOnTerminationOfEquityInterestOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IncreaseDecreaseInOtherInvestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in other investing net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IncreaseDecreaseInOtherInvestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_NonCashAcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash portion of acquired in process research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_NonCashAcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_OtherNonCashTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Non Cash Transactions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_OtherNonCashTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PaymentForOfferingAndLoanCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for offering and loan costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PaymentForOfferingAndLoanCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ProceedsFromAndPaymentForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from and payment for other financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ProceedsFromAndPaymentForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ProceedsFromBusinessCombinationAndPipeFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from business combination and PIPE financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ProceedsFromBusinessCombinationAndPipeFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Subsidiary Common Shares Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ProceedsFromPaymentOfSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from payment of subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ProceedsFromPaymentOfSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ProceedsFromSubsidiaryDebtFinancingsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Subsidiary Debt Financings Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ProceedsFromSubsidiaryDebtFinancingsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment of Long Term Debt and Convertible Debt by Subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subscription Receivable Related To Issuance Of Subsidiary Common Shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of an investment.  A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment.  This element refers to the Gain included in earnings and not to the cash proceeds of the sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724309048176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Liquidity</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1&#8212;Description of Business and Liquidity </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Description of Business </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roivant Sciences Ltd. (inclusive of its consolidated subsidiaries, the &#8220;Company&#8221; or &#8220;RSL&#8221;) aims to improve health by rapidly delivering innovative medicines and technologies to patients. The Company does this by building biotech and healthcare technology companies (&#8220;Vants&#8221;) and deploying technology to drive greater efficiency in research and development and commercialization.&#160;In addition to biopharmaceutical subsidiaries, the Company also builds technology Vants focused on improving the process of developing and commercializing medicines. The Company was founded on April&#160;7, 2014 as a Bermuda exempted limited company. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">VTAMA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (tapinarof) cream was approved by the United States Food and Drug Administration (&#8220;FDA&#8221;) in May 2022 as the first and only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> steroid-free topical medication in its class for the treatment of plaque psoriasis in adult patients. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has determined that it has one operating and reporting segment as it allocates resources and assesses financial performance on a consolidated basis. The Company&#8217;s subsidiaries are wholly owned subsidiaries and majority-owned or controlled subsidiaries. Refer to Note 4, &#8220;Investments&#8221; for further discussion of the Company&#8217;s investments in unconsolidated entities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;30, 2021, RSL completed its business combination with Montes Archimedes Acquisition Corp. (&#8220;MAAC&#8221;), a special purpose acquisition company, and began trading on Nasdaq under the ticker symbol &#8220;ROIV.&#8221; Refer to Note 3, &#8220;Business Combination with MAAC&#8221; for additional details. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Liquidity </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has incurred significant losses and negative cash flows from operations since its inception. As of March&#160;31, 2022, the Company had cash and cash equivalents of approximately $2.1&#160;billion and its accumulated deficit was approximately $2.8&#160;billion. For the years ended March&#160;31, 2022 and 2021, the Company incurred net losses of $924.1&#160;million and $900.2&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million, respectively. The Company has historically financed its operations primarily through the sale of equity securities, sale of subsidiary interests, debt financings and revenue generated from licensing and collaboration arrangements. Through March&#160;31, 2022, the Company had not generated any revenue from the sale of its product candidates. Through its subsidiary Dermavant Sciences Ltd., the Company has launched its first commercial product, VTAMA cream, following approval by the FDA in May 2022. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals to market its product candidates, dependence on key products, dependence on third-party service providers, such as contract research organizations, and protection of intellectual property rights. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company intends to raise such additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates or take other steps to conserve capital. The Company expects its existing cash and cash equivalents will be sufficient to fund its committed operating expenses and capital expenditure requirements for at least the next </div>12<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months from the date of issuance of these consolidated financial statements.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724308923952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2&#8212;Summary of Significant Accounting Policies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Basis of Presentation and Principles of Consolidation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s fiscal year ends on March&#160;31, and its fiscal quarters end on June&#160;30, September&#160;30, and December 31. </div></div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying audited consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).&#160;&#160;&#160;&#160; </div></div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the accounts of RSL and the subsidiaries in which it has a controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of common stock ownership interest retained in the respective operations by the noncontrolling parties. The Company presents noncontrolling interests as a component of shareholders&#8217; equity on its consolidated balance sheets. </div></div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for changes in its ownership interest in its subsidiaries while control is retained as equity transactions. The carrying amount of the noncontrolling interest is adjusted to reflect the change in RSL&#8217;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received or paid and the amount by which the noncontrolling interest is adjusted is recognized within shareholders&#8217; equity attributable to RSL. </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Use of Estimates </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </div></div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Additionally, the Company assessed the impact that the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> pandemic has had on its operations and financial results as of March&#160;31, 2022 and through the issuance of these consolidated financial statements. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Concentrations</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">T</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">he Company has long-lived assets in different geographic locations. As of March 31, 2022 and 2021, a majority of the Company&#8217;s long-lived assets were located in the United States. </div></div></div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"/> <div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">(D) Cash, Cash Equivalents, and Restricted Cash </div></div></div></div> <div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company considers all highly liquid investments purchased with original maturities of three months or less to</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> be cash equivalents. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash classified as a current asset consists of legally restricted </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> bearing deposit accounts relating to the Company&#8217;s corporate credit card programs. Restricted cash classified as a long-term asset consists of restricted deposit accounts related to irrevocable standby letters of credit. As of March&#160;31, 2021, restricted cash classified as a current asset included $</div>75.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million held in escrow for the purpose of fulfilling certain indemnification obligations. The full escrow amount of $</div>75.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was disbursed to the Company in June 2021.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash as reported in the accompanying consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the accompanying consolidated balance sheets as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,060,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,055,044</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,634</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,632</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,074,034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,141,676</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(E) Contingencies </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible. </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(F) Property and Equipment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, consisting primarily of computers, laboratory and other equipment, furniture and fixtures, software, and leasehold improvements, is recorded at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement or sale, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation of property and equipment is recorded using the straight-line method over the estimated useful lives of the related assets once the asset has been placed in service. Leasehold improvements are amortized using the straight-line method over the estimated useful life or remaining lease term, whichever is shorter. The following table provides the range of estimated useful lives used for each asset type: </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 39%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 59%; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated Useful Life</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computers</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">3 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory&#160;and&#160;other&#160;equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">5 - 10 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">7 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Software</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">3 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Lesser of estimated useful life or remaining lease term</td> </tr> </table>   <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company reviews the recoverability of all long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable. Recoverability is measured by comparison of the book values of the assets to the future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets.</div>   <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(G<div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">)</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> Investments </div></div></div></div> <div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Investments in equity securities may be accounted for using (i)&#160;the fair value option if elected, (ii)&#160;fair value through earnings if fair value is readily determinable or (iii)&#160;for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the measurement alternative is made for each eligible investment. </div></div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company has elected the fair value option to account for certain investments over which the Company has significant influence. The Company believes the fair value option best reflects the underlying economics of the investment. See Note 4, &#8220;Investments.&#8221; </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(H) Research and Development Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. Preclinical and clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. R&amp;D costs primarily consist of costs associated with preclinical studies and clinical trials, including amounts paid to contract research organizations, contract manufacturing organizations, and other third parties that conduct R&amp;D activities on behalf of the Company, as well as employee-related expenses, such as salaries, share-based compensation, and benefits, for employees engaged in R&amp;D activities. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">(I) Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Process</div> Research and Development Expenses </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">For the year ended March&#160;31, 2022, the Company began reporting acquired </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in-process</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> research and development (&#8220;IPR&amp;D&#8221;) expense as a separate line item in its consolidated statements of operations. Acquired IPR&amp;D expenses include consideration for the purchase of IPR&amp;D through asset acquisitions and license agreements as well as payments made in connection with asset acquisitions and license agreements upon the achievement of development milestones. These expenses were previously recorded in &#8220;Research and development&#8221; on the consolidated statements of operations. Prior periods have been revised to conform to the current period presentation. </div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> agreements for </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in-process</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> research and development projects (&#8220;IPR&amp;D&#8221;) to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> agreement for IPR&amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as acquired </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in-process</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> research and development expense in its consolidated statements of operations. Payments for milestones achieved and payments for a product license prior to regulatory approval of the product are expensed in the period incurred. Milestone payments made in connection with regulatory approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(J) General and Administrative Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">General and administrative (&#8220;G&amp;A&#8221;) expenses consist primarily of employee-related expenses for G&amp;A personnel, including those responsible for the identification and acquisition or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> of new drug candidates as well as for overseeing Vant operations and facilitating the use of the Company&#8217;s platform and technologies at Vants. G&amp;A expenses also consist of legal and accounting fees, consulting services and other operating costs </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">relating to corporate matters and daily operations. G&amp;A expenses include costs incurred relating to the identification, acquisition or </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in-license</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> and technology transfer of promising drug candidates along with costs incurred relating to the integration of new technologies.</div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div>  <div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">(K) Leases </div></div></div></div> <div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company determines if an arrangement includes a lease at the inception of the agreement. For each of the Company&#8217;s lease arrangements, the Company records a </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> asset representing the Company&#8217;s right to use an underlying asset for the lease term and a lease liability representing the Company&#8217;s obligation to make lease payments. Operating lease </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> assets and operating lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the expected lease term. If the interest rate implicit in the Company&#8217;s leases is not readily determinable, in determining the weighted-average discount rate used to</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> calculate the net present value of lease payments, the Company utilizes an estimate of its incremental borrowing rate. The Company&#8217;s incremental borrowing rates are determined based on the term of the lease, the economic environment of the lease, and the effect of collateralization. Lease expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term and variable lease costs are expensed as incurred. </div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company elected the practical expedient not to apply the recognition and measurement requirements to short-term leases, which is any lease with a term of one year or less as of the lease commencement date. Leases may require the Company to pay additional amounts for taxes, insurance, maintenance, and other expenses, which are generally referred to as </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> components. The Company has elected the practical expedient to combine lease and </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> components. If a lease includes options to extend the lease term, the Company does not assume the option will be exercised in its initial lease term assessment unless there is reasonable certainty that the Company will renew based on an assessment of economic factors present as of the lease commencement date. </div></div></div> <div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">(L) Income Taxes </div></div></div></div> <div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded when, after consideration of all positive and negative evidence, it is not more likely than not that the Company&#8217;s deferred tax assets will be realizable. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </div></div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(M) Share-Based Compensation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based awards to employees, directors, and consultants, including stock options, restricted stock units, performance options and capped value appreciation rights, are measured at fair value on the date of the grant and that fair value is recognized as share-based compensation expense in the Company&#8217;s consolidated statements of operations over the requisite service period of the respective award. The estimated fair value of awards that contain performance conditions is expensed when the Company concludes that it is probable that the </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/>  <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">performance condition will be achieved. The Company may grant awards with graded-vesting features. When such awards have only service vesting requirements, the Company elected to record share-based compensation expense on a straight-line basis. If awards with graded-vesting features contain performance or market conditions, then the Company records share-based compensation expense using the accelerated attribution method. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">The Company measures the fair value of its stock options that only have service vesting requirements or performance-based options without market conditions using the Black-Scholes option pricing model. For performance-based awards with market conditions, the Company determines the fair value of the awards as of the grant date using a Monte Carlo simulation model. When determining the grant-date fair value of stock-based awards, management further considers whether an adjustment is required to the observable market price or volatility of the Company&#8217;s common stock that is used in the valuation as a result of material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-public</div> information, if that information is expected to result in a material increase in share price. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Certain assumptions need to be made with respect to utilizing the Black-Scholes option pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate and the fair value of the Company&#8217;s shares of common stock. Since the Company has limited option exercise history, it has generally elected to estimate the expected life of an award based upon the &#8220;simplified method&#8221; with the continued use of this method extended until such time the Company has sufficient exercise history. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. The expected share price volatility for the Company&#8217;s common shares is estimated by taking the average historical price volatility for industry peers. The Company accounts for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-vesting</div> award forfeitures when they occur. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">One of the inputs to the Black-Scholes option pricing model is the fair value of the Company&#8217;s common shares. Prior to the closing of its business combination with MAAC, as a privately held company, the Company estimated the fair value of the shares of common stock underlying its share-based awards on each grant date. Given the absence of a public trading market, and in accordance with the American Institute of Certified Public Accountants&#8217; Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, the Company exercised reasonable judgment and considered numerous objective and subjective factors to determine its best estimate of the fair value of its common shares. The estimation of the fair value of the common shares considered factors including the following: the prices of the Company&#8217;s common shares sold to investors in arm&#8217;s length transactions; the estimated present value of the Company&#8217;s future cash flows; the Company&#8217;s business, financial condition and results of operations; the Company&#8217;s forecasted operating performance; the illiquid nature of the Company&#8217;s common shares; industry information such as market size and growth; market capitalization of comparable companies and the estimated value of transactions such companies have engaged in; and macroeconomic conditions. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies a similar methodology to estimate the fair value of the shares of common stock underlying share-based awards issued by its privately held Vants. Following the closing of the Company&#8217;s business combination with MAAC, RSL&#8217;s common shares became publicly traded and the Company began determining the fair value of each common share underlying share-based awards based on the closing price of its common shares as reported by Nasdaq on the date of grant. Therefore, it will not be necessary to determine the fair value of the new stock-based award pursuant to the methodology described above. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="background: none; letter-spacing: 0px; top: 0px; text-decoration: none;;display:inline;"> </div></div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">(N) Fair Value Measurements </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs</div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>   <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a three-tier fair value hierarchy that distinguishes among the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-Valuations</div> are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-Valuations</div> are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-Valuations</div> are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s financial instruments include shares of common stock of Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;); shares of common stock of Sio Gene Therapies Inc. (&#8220;Sio&#8221;); shares of common stock of Heracles Parent, L.L.C., the parent entity of Datavant (as defined and discussed in Note 4, &#8220;Investments&#8221;); liability instruments issued, including the Roivant Warrants and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares (each as defined in Note 3, &#8220;Business Combination with MAAC&#8221;) liabilities issued in connection with the Company&#8217;s business combination with MAAC (as discussed in Note 3, &#8220;Business Combination with MAAC&#8221;); the deferred consideration liability; its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and long-term debt. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The shares of Arbutus and Sio common stock and investments in common stock with a readily determinable fair value are classified as Level&#160;1, and their fair value is determined based upon quoted market prices in an active market. In October 2021, shares of Arbutus&#8217; Series A participating convertible preferred shares (&#8220;Arbutus Preferred Shares&#8221;) held by the Company were converted into shares of common stock of Arbutus pursuant to mandatory conversion provisions. Prior to conversion, the Arbutus Preferred Shares held by the Company were classified as Level&#160;2 as the fair value of such preferred shares was determined based upon the quoted market price of Arbutus common stock into which such preferred shares were convertible. The shares of common stock of Heracles Parent, L.L.C., the parent entity of Datavant (as defined and discussed in Note 4, &#8220;Investments&#8221;), and liability instruments issued, excluding the Public Warrants (as defined and discussed in Note 3, &#8220;Business Combination with MAAC&#8221;), are classified as Level&#160;3 within the fair value hierarchy as the assumptions and estimates used in the valuations are unobservable in the market. The Public Warrants are publicly traded and therefore are classified as Level&#160;1 as the Public Warrants have a readily determinable fair value. Cash, accounts payable, and the deferred consideration liability are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature. The deferred consideration liability was based on a fixed monetary amount, and payment was based solely on the passage of time. The deferred consideration liability was settled in November 2021 by payment of $50.0&#160;million in cash as well as the issuance of 6,348,057 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the Company&#8217;s <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares. Money market funds are included in Level&#160;1 of the fair value hierarchy and are valued at the closing price reported by an actively traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly owned subsidiaries, &#8220;Dermavant&#8221;), which is stated at amortized cost, approximates fair value based on current interest rates for similar types of borrowings and therefore is included in Level&#160;2 of the fair value hierarchy. Long-term debt issued by Dermavant for which the </div></div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fair value option has been elected is included in Level&#160;3 of the fair value hierarchy as the assumptions and estimates used in the valuation are unobservable in the market. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(O) Foreign Currency </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and liabilities of foreign operations are translated using exchange rates in effect at the balance sheet date and their results of operations are translated using average exchange rates for the year. Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Adjustments resulting from the translation of the financial statements of the Company&#8217;s foreign functional currency subsidiaries into U.S. dollars are excluded from the determination of net loss and are accumulated in a separate component of shareholders&#8217; equity. Foreign exchange transaction gains and losses are included in &#8220;Other expense, net&#8221; in the Company&#8217;s statements of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(P) Revenue Recognition </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes revenue when its customer <div style="letter-spacing: 0px; top: 0px;;display:inline;">obtains </div>control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for its arrangements, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when or as the Company satisfies a performance obligation. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, assessing the recognition and future reversal of variable consideration, and determining and applying appropriate methods of measuring progress for performance obligations satisfied over time. These judgments are discussed in more detail below. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licenses of intellectual property:</div></div> If the licenses to intellectual property are determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are not distinct from other promises, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition accordingly. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Milestone payments: </div></div>At the inception of each arrangement that includes research, development or regulatory milestone payments, the Company<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis in earnings in the period of the adjustment. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalties and commercial milestone payments: </div></div>For arrangements that include sales-based royalties, including commercial milestone payments<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>based on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-specified</div> level of sales, the Company </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon performance of the licensee. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue is also generated by certain technology-focused Vants from subscription and service-based fees recognized for the use of certain technology developed by these Vants. Subscription revenue is recognized ratably over the contract period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade Receivables, Net </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in customer credit profiles. The Company reserves against trade receivables for estimated losses that may arise from a customer&#8217;s inability to pay, and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated losses was de minimis as of March&#160;31, 2022 and 2021. Trade receivables, net is included in &#8220;Other current assets&#8221; on the accompanying consolidated balance sheets. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Q) Warrant Liabilities </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company classifies the Roivant Warrants as liabilities. At the end of each reporting period, changes in fair value during the period are recognized within the consolidated statements of operations. The Company will continue to adjust the carrying value of the liability associated with the Roivant Warrants for changes in the fair value until the earlier of a) the exercise or expiration of the Roivant Warrants or b) the redemption of the Roivant Warrants. Issuance costs incurred that were attributable to the Roivant Warrants were expensed as incurred. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(R) Recently Adopted Accounting Pronouncements </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06,</div> &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06&#8221;).</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current U.S. GAAP. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> also removes certain settlement conditions that are required for equity contracts to qualify for the derivatives scope exception, which will permit more equity contracts to qualify for it. Either a modified retrospective transition method or a fully retrospective transition method is permissible for the adoption of this standard. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> is effective for fiscal years beginning after December&#160;15, 2021, including interim periods within those fiscal years. The early-adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> on April&#160;1, 2021 did not have a material impact on the Company&#8217;s consolidated financial statements. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724308975728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination with MAAC<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination with MAAC</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3&#8212;Business Combination with MAAC </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;30, 2021 (the &#8220;Closing Date&#8221;), in <div style="letter-spacing: 0px; top: 0px;;display:inline;">accordance </div>with the Business Combination Agreement, as amended (the &#8220;Business Combination Agreement&#8221;), RSL completed its previously announced business combination (the &#8220;Business Combination&#8221;) with MAAC, through the merger of RSL&#8217;s wholly owned subsidiary, Rhine Merger Sub, Inc., with MAAC (the &#8220;Merger&#8221;), with MAAC surviving the Merger as a wholly owned subsidiary of RSL. As MAAC does not represent a business for accounting purposes and its primary asset represents cash and cash equivalents, the Business Combination was treated as an equity contribution in exchange for the issuance of RSL shares. The net assets of MAAC were stated at historical cost, with no goodwill or other intangible assets recorded. Reported amounts from operations included herein prior to the Business Combination are those of RSL. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On the Closing Date prior to the effective time of the Merger (the &#8220;Effective Time&#8221;), RSL effected a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.9262-for-1</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">stock subdivision based on the fixed exchange ratio established in the Business Combination. The shares, equity awards and net loss per share available to holders of the Company&#8217;s <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px;;display:inline;">stock</div></div> prior to the Business Combination, have been retroactively restated to reflect the fixed exchange ratio.</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the terms of the Business Combination Agreement, at the Effective Time: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">a.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each share of MAAC Class&#160;A common stock (the &#8220;MAAC Class&#160;A Shares&#8221;) and each share of MAAC Class&#160;B common stock (the &#8220;MAAC Class&#160;B Shares&#8221;) that were outstanding immediately before the Effective Time (other than treasury shares and any shares held by Patient Square Capital LLC (the &#8220;MAAC Sponsor&#8221;), any affiliate of the MAAC Sponsor or any of MAAC&#8217;s independent directors (the &#8220;MAAC Independent Directors&#8221;) or its transferee) were automatically canceled and extinguished and converted into one <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div>hare of RSL (the &#8220;Roivant Common Share&#8221;), </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">b.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each MAAC Class&#160;B Share that was outstanding immediately before the Effective Time and held by the MAAC Sponsor, any affiliate of the MAAC Sponsor or any of the MAAC Independent Directors or its transferee were automatically canceled and extinguished and converted into a number of Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares based on an exchange ratio of 0.75, with a portion of such Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares issued to the MAAC Sponsor, any affiliate of the MAAC Sponsor, any MAAC Independent Director or its transferee by virtue of the Merger being subject to the vesting and other terms and conditions set forth in the Sponsor Support Agreement (as more fully described below), </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">c.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each warrant to purchase MAAC Class&#160;A Shares that was outstanding immediately before the Effective Time was converted automatically into a right to acquire a Roivant Common Share (a &#8220;Roivant Warrant&#8221;) at an exercise price of $11.50 per share, subject to certain adjustments. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the Merger, the Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div>hares and the Roivant Warrants began trading on the Nasdaq Global Market under the ticker symbols &#8220;ROIV&#8221; and &#8220;ROIVW,&#8221; respectively, on October&#160;1, 2021. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="background: none; letter-spacing: 0px; top: 0px; text-decoration: none;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Business Combination, RSL entered into subscription agreements with certain investors, whereby it issued </div>22,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">hares at $</div>10.00<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share for an aggregate purchase price of $</div>220.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;PIPE Financing&#8221;). The PIPE Financing closed simultaneously with the consummation of the Business Combination.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the Business Combination and PIPE Financing, the Company received $213.4&#160;million in cash at closing (the &#8220;Closing&#8221;), net of deferred underwriting expenses and unpaid expenses incurred by MAAC in connection with the transaction. The Company incurred $24.4&#160;million in costs directly related to the Business Combination and PIPE Financing, such as banker fees and costs associated with third-party legal, accounting and other professional services. Upon Closing, these costs, which had been capitalized on the Company&#8217;s balance sheet were recorded as a reduction of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital with the exception of $7.4&#160;million, which were expensed as they represent the allocation of the transaction costs associated with the Roivant Warrants and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares liabilities. Transaction costs were allocated to the Roivant Warrants and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares liabilities based on the fair value of such instruments out of the total consideration. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sponsor Support Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the execution of the Business Combination Agreement, MAAC, the MAAC Sponsor, Roivant and each of the MAAC Independent Directors, entered into the Sponsor Support Agreement, which was subsequently amended on June&#160;9, 2021, to reflect the MAAC Independent Directors and Roivant entering into respective </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> Agreements, and further amended on September&#160;30, 2021. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Sponsor Support Agreement, among other things: </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">a.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">2,033,591 Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares issued to the MAAC Sponsor and 10,000 Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares issued to each MAAC Independent Director (collectively, the &#8220;20% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares&#8221;), each in respect </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">of its MAAC Class&#160;B Shares, will vest if the closing price of Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares is greater than or equal to $15.00 over any <span style="-sec-ix-hidden:hidden50659038">twenty</span> out of <span style="-sec-ix-hidden:hidden50659044">thirty</span> trading day period during the Vesting Period (defined below). </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">b</div>.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">1,016,796 Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares issued to the MAAC Sponsor and 5,000 Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares issued to each MAAC Independent Director (collectively, the &#8220;10% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares&#8221; and, together with the 20% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Earn-Out</div> Shares&#8221;), each in respect of its MAAC Class&#160;B Shares, will vest if the closing price of Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares is greater than or equal to $20.00 over any <span style="-sec-ix-hidden:hidden50659039">twenty</span> out of <span style="-sec-ix-hidden:hidden50659043">thirty</span> trading day period during the Vesting Period (as defined below). </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The remaining number of Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares issued to the MAAC Sponsor and each MAAC Independent Director are not subject to the vesting conditions described above (the &#8220;Retained Shares&#8221;). </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">The Vesting Period represents the period commencing on November&#160;9, 2021, the date on which the registration statement on Form </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">S-1</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> required to be filed by the Company in connection with the PIPE Financing was declared effective, and ending no later than September&#160;30, 2026 (the &#8220;Vesting Period&#8221;). The Vesting Period will, if a definitive purchase agreement with respect to a Sale (as defined in the Sponsor Support Agreement) is entered into on or prior to the end of such period, be extended to the earlier of one day after the consummation of such Sale and the termination of such definitive transaction agreement, and if a Sale occurs during such Vesting Period, then all of the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> Shares unvested as of such time will automatically vest immediately prior to the consummation of such Sale. If any </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> Shares have not vested on or prior to the end of such Vesting Period, then such </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> Shares will be forfeited. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">The </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> Shares require liability classification and are classified as &#8220;Liability instruments measured at fair value&#8221; on the consolidated balance sheets. The </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> Shares liability is subject to remeasurement at each balance sheet date with changes in fair value recognized in the Company&#8217;s statement of operations. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> Agreements </div></div></div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;1, 2021 and June&#160;9, 2021, RSL, on the one hand, and the MAAC Sponsor, the MAAC Independent Directors and certain Roivant equityholders, on the other hand, entered into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> agreements, pursuant to which, among other things, the MAAC Sponsor, the MAAC Independent Directors and such Roivant equityholders have agreed not to effect any sale or distribution of the Roivant Common Shares (including those underlying incentive equity awards or Roivant Warrants) held by the MAAC Sponsor, the MAAC Independent Directors or such equityholders as of immediately following the Closing during the applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period, subject to customary exceptions. </div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="background: none; letter-spacing: 0px; top: 0px; text-decoration: none;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period applicable to Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares held by the MAAC Sponsor and MAAC Independent Directors as of immediately following the Closing will be (i)&#160;with respect to 25% of the Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares held by the MAAC Sponsor and MAAC Independent Directors, six months following the Closing, which expired on March&#160;30, 2022, (ii) with respect to an additional 25% of the Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares held by the MAAC Sponsor and MAAC Independent Directors, the earlier of twelve months following the achievement of certain price-based vesting restrictions or six years from the Closing and (iii)&#160;with respect to 50% of the Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares held by the MAAC Sponsor and MAAC Independent Directors, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden50659060">thirty</span>-six</div> months following the Closing. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares underlying warrants held by the MAAC Sponsor as of immediately following the Closing will be subject to a corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period for (a)&#160;with respect to 25% of such warrants held by the MAAC Sponsor, six months from the Closing, which expired on March&#160;30, 2022, (b) with respect to an additional 25% of such warrants held by the MAAC Sponsor, twelve months from Closing and (c)&#160;with respect to 50% of such warrants held by the MAAC Sponsor, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden50659065">thirty-</span>six</div> months from the Closing. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period applicable to Roivant Common Shares held by certain Roivant equityholders as of immediately following the Closing (including those underlying incentive equity awards) will be (x)&#160;with respect </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">to 25% of the Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares held by such Roivant equityholders (including those underlying incentive equity awards), six months following the Closing, which expired on March&#160;30, 2022, (y) with respect to an additional 25% of the Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares held by such Roivant equityholders (including those underlying incentive equity awards), twelve months following the Closing and (z)&#160;with respect to 50% of the Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares (including those underlying incentive equity awards) held by such Roivant equityholders, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden50659059">thirty</span>-six</div> months following the Closing. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Common Stock Warrants </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the effective time of the Merger, 10,214,365 Roivant Warrants that were held by the MAAC Sponsor at an exercise price of $11.50 (the &#8220;Private Placement Warrants&#8221;) and 20,535,896 Roivant Warrants held by MAAC&#8217;s shareholders at an exercise price of $11.50 (the &#8220;Public Warrants&#8221;) were converted into the right to acquire Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares. Pursuant to the agreement governing the Roivant Warrants, the Roivant Warrants became exercisable 30 days following the completion of the Business Combination. The Roivant Warrants will expire five years after the completion of the Business Combination, or earlier upon redemption or liquidation. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Private Placement Warrants are generally identical to the Public Warrants, except that (i)&#160;the Private Placement Warrants (including the <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">c</div></div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">stock</div></div></div>&#160;issuable upon exercise of the Private Placement Warrants) were not transferable, assignable or salable until</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;30 days after the completion of the Business Combination (ii)&#160;they will not be redeemable by the Company when the price per share of Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares equals or exceeds $18.00, and (iii)&#160;the Private Placement Warrants may be exercised by holders on a cashless basis. If the Private Placement Warrants are held by holders other than our sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by Roivant in all redemption scenarios and exercisable by the holders on the same basis as the Public Warrants. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Roivant Warrants require liability classification and are classified as &#8220;Liability instruments measured at fair value&#8221; on the consolidated balance sheets. The Private Placement Warrants liability and Public Warrants liability are subject to remeasurement at each balance sheet date with changes in fair value recognized in the Company&#8217;s statement of operations. As of March&#160;31, 2022, 60,021 Roivant Warrants have been exercised and none redeemed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of Roivant Warrants when the price per share of Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div>hares equals or exceeds $18.00. </div></div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may redeem the outstanding Roivant Warrants for cash (except with respect to the Private Placement Warrants): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $0.01 per Roivant Warrant; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon a minimum of 30 days&#8217; prior written notice of redemption; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">if, and only if, the last reported sale price of&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div></div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">stock</div></div></div> for any</div>&#160;20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-trading</div> day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrantholders (the &#8220;Reference Value&#8221;) equals or exceeds $18.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like). </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">However, in this case, the Company will not redeem the Roivant Warrants unless an effective registration statement under the Securities Act covering the Roivant Common Shares issuable upon exercise of the Roivant Warrants is effective and a current prospectus relating to those Roivant Common Shares is available throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> redemption period. Any such exercise would not be on a &#8220;cashless&#8221; basis and would require the exercising warrantholder to pay the exercise price for each Roivant Warrant being exercised. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of Roivant Warrants when the price per share of Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div>hares equals or exceeds $10.00. </div></div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may redeem the outstanding Roivant Warrants (except as described herein with respect to the Private Placement Warrants): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at $0.10 per Roivant Warrant upon a minimum of 30 days&#8217; prior written notice of redemption provided that holders will be able to exercise their Roivant Warrants on a cashless basis prior to redemption and receive that number of Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares determined by reference to an agreed table based on the redemption date and the &#8220;fair market value&#8221; of the Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares;</div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted for stock splits, stock dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like); and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if the Reference Value is less than $18.00 per share (as adjusted for stock splits, stock dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like), the Private Placement Warrants must also concurrently be called for redemption on the same terms (except as described herein with respect to a holder&#8217;s ability to cashless exercise its warrants) as the outstanding Public Warrants, as described above. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For these purposes, &#8220;fair market value&#8221; of Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div></div>hares shall mean the volume-weighted average price of&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares for the</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;10 trading days immediately following the date on which the notice of redemption is sent to warrantholders. In no event will the Roivant Warrants be exercisable in connection with this redemption feature for more than 0.361 Roivant <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Common Shares</div></div> per Roivant Warrant (subject to adjustment). </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724308800624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock', window );">Investments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 4&#8212;Investments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investment in Arbutus </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2017, pursuant to a subscription agreement entered into by RSL and Arbutus, RSL acquired 16,013,540 shares of common stock of Arbutus and 1,164,000 Arbutus Preferred Shares, which converted into 22,833,922 shares of Arbutus common stock in October 2021. The Company accounts for its investment in Arbutus as an equity method investment accounted for using the fair value option. Due to the Company&#8217;s significant influence over operating and financial policies, Arbutus is considered a related party of the Company. At March&#160;31, 2022, RSL held approximately 26% of issued and outstanding shares of Arbutus. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2022 and 2021, the aggregate fair value of the Company&#8217;s investment in Arbutus was $115.8&#160;million and $129.4&#160;million, respectively, with the Company recognizing an unrealized loss on its investment in Arbutus of $13.6&#160;million and an unrealized gain of $90.2&#160;million in the accompanying consolidated statements of operations for the years ended March&#160;31, 2022 and 2021. The fair value of the Company&#8217;s investment was determined using the closing price of Arbutus&#8217;s common stock on March&#160;31, 2022 and 2021 of $2.98 and $3.33, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investment in Sio </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2020, RSL&#8217;s ownership interest in Sio fell below 50.0%, and as a result, the Company deconsolidated Sio. The Company accounts for its investment in Sio as an equity method investment accounted for using the fair value option. Due to the Company&#8217;s significant influence over operating and financial policies, Sio is considered a related party of the Company. At March&#160;31, 2022, RSL held approximately 25% of Sio&#8217;s issued and outstanding common shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At March&#160;31, 2022 and 2021, the fair value of the Company&#8217;s investment in Sio was $12.4&#160;million<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>and<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>$48.5&#160;million, respectively, with the Company recognizing an unrealized loss on its investment in Sio of $36.1&#160;million and an unrealized gain of $3.2&#160;million in the accompanying consolidated statements of operations for the years ended March&#160;31, 2022 and 2021, respectively. The fair value of common shares held by the Company was determined using the closing price of Sio&#8217;s common stock on March&#160;31, 2022 and 2021 of $0.67 and $2.61, respectively. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investment in Datavant </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2020, following an equity raise completed by Datavant Holdings, Inc. (&#8220;Datavant&#8221;) along with a restructuring of Datavant&#8217;s equity classes, it was determined that RSL no longer controlled Datavant. As such, the Company deconsolidated Datavant as of April 2020. Due to the Company&#8217;s significant influence over operating and financial policies, Datavant is considered a related party of the Company. Upon deconsolidation, the Company recorded its investment in Datavant based on the fair value of Datavant preferred shares held of $99.0&#160;million. Prior to the Datavant Merger (defined below), the Company accounted for its investment in Datavant using the measurement alternative to fair value. Under the measurement alternative, the investment is remeasured upon observable price changes in orderly transactions or upon impairment, if any. The Company recognized a gain on deconsolidation of $86.5&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. In July 2020, Datavant issued and sold additional preferred shares to RSL at a price consistent with that of the initial round of Datavant&#8217;s Series B equity raise, which resulted in an increase in the carrying value of the Company&#8217;s investment to $100.6&#160;million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, Datavant and Heracles Parent, L.L.C. (referred to herein as &#8220;Ciox Parent&#8221; and, after the closing of the Datavant Merger (as defined below), &#8220;Datavant&#8221;), a provider of healthcare information services and technology solutions to hospitals, health systems, physician practices and authorized recipients of protected health records in the United States, primarily through its wholly owned subsidiary CIOX Health, LLC, entered into a definitive agreement to merge Datavant with and into a newly formed wholly owned subsidiary of Ciox Parent (the &#8220;Datavant Merger&#8221;). The merger closed on July&#160;27, 2021. At closing, the Company received approximately $320&#160;million in cash and a minority equity stake in Ciox Parent. As a result of the transaction, the Company recognized a gain on remeasurement of $443.8&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2022. As of March&#160;31, 2022, the Company&#8217;s minority equity interest represented approximately 17% of the outstanding Class&#160;A units in Ciox Parent. Ciox Parent&#8217;s capital structure includes several classes of preferred units that, among other features, have liquidation preferences and conversion features. Upon conversion of such preferred units into Class&#160;A units, the Company&#8217;s ownership interest would be diluted. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the completion of the Datavant Merger, the Company&#8217;s minority equity interest became subject to the equity method of accounting. At such time, the fair value option was elected to continuously remeasure the investment to fair value each reporting period with changes in fair value reflected in earnings. As of March&#160;31, 2022 and July&#160;27, 2021, the fair value of the Company&#8217;s investment was $193.9&#160;million and $224.1&#160;million, respectively, with the Company recognizing an unrealized loss on its investment of $30.2&#160;million for the year ended March&#160;31, 2022. The fair value of the Company&#8217;s investment was determined using valuation models that incorporate significant unobservable inputs and is classified as a Level&#160;3 measurement within the fair value hierarchy. Refer to Note 14, &#8220;Fair Value Measurements&#8221; for more information. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Investment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company holds an additional equity investment that is measured using the fair value option. The fair value of this investment was $3.7&#160;million and $11.1&#160;million as of March&#160;31, 2022 and 2021, respectively. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire  disclosure for investments and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724308826384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisitions and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock', window );">Asset Acquisitions and License Agreements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 5&#8212;Asset Acquisitions and License Agreements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the years ended March&#160;31, 2022 and 2021, the Company, directly or indirectly through Vants, completed the following key asset acquisitions and license agreements. The Company evaluated the below agreements, except the collaboration agreement entered into between Proteovant Therapeutics, Inc. and Blueprint Medicines Corporation (&#8220;Blueprint Medicines&#8221;) that is evaluated separately below, and determined that the acquired assets did not meet the definition of a business as substantially all the fair value of the assets acquired were concentrated in a single asset or group of similar assets and/or the acquired assets were not capable of producing outputs due to the lack of an assembled workforce and early stage of development and thus, each transaction was accounted for as an asset acquisition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company then evaluated whether each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development asset had an alternative future use and concluded it did not. As a result, the Company recorded the consideration attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development under the below agreements as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development expense in the accompanying consolidated statements of operations for the years ended March&#160;31, 2022 and 2021. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Genevant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In July 2020, RSL increased its investment in Genevant Sciences Ltd. (&#8220;Genevant&#8221;) as part of a recapitalization transaction (the &#8220;Recapitalization&#8221;). Genevant, an entity focused on the discovery, development, and commercialization of a broad range of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RNA-based</div> therapeutics enabled by Arbutus&#8217; proprietary lipid nanoparticle and ligand conjugate delivery technologies, was created in April 2018 as part of an agreement between RSL and Arbutus. As part of the initial transaction entered into in April 2018, RSL contributed $38.7&#160;million in cash, including transaction costs, for an equity ownership interest in Genevant. Prior to the Recapitalization, RSL accounted for its investment in Genevant under the equity method of accounting as it had determined that it was not the primary beneficiary of Genevant since it did not have the power to direct its most significant activities. Additionally, RSL made additional investments in the form of promissory notes issued by Genevant amounting to $20.1&#160;million aggregate principal amount outstanding (the &#8220;Genevant Outstanding Notes&#8221;) prior to the Recapitalization. RSL applied its share of losses relating to its equity method investment in Genevant against the Company&#8217;s carrying value of its investment in Genevant&#8217;s common shares and against the carrying value of the Genevant Outstanding Notes. The carrying value of RSL&#8217;s investment in Genevant was reduced to zero prior to the Recapitalization. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Recapitalization, the following transactions were completed: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant issued 74,272,043 common shares to RSL for an aggregated purchase price of $20.5&#160;million; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$15.1&#160;million aggregate principal amount of the Genevant Outstanding Notes were converted into 54,526,549 common shares; and </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant issued 9,057,566 common shares to Arbutus for an aggregated purchase price of $2.5&#160;million. </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the Recapitalization, RSL held an 82.9% controlling interest in Genevant. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrent with the Recapitalization, the composition of Genevant&#8217;s Board of Directors was restructured to include two directors designated by RSL and one director who is a senior officer of Genevant. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result of the Recapitalization and changes to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws,</div> RSL determined that it controls the most significant activities of Genevant and is the primary beneficiary of Genevant following the Recapitalization. As such, RSL began consolidating Genevant into the Company&#8217;s consolidated financial statements from the date of the Recapitalization. The Company evaluated the acquired set of assets and activities and determined that the acquired set did not meet the definition of a business and thus the transaction was not considered a business combination. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The transactions completed as part of the Recapitalization represent an acquisition achieved in stages, which required the remeasurement of RSL&#8217;s previously held interest in Genevant. As such, RSL&#8217;s investments in Genevant were remeasured to fair value of $28.8&#160;million, also resulting in a gain of $28.8&#160;million that was recognized in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. Along with the fair value of noncontrolling interests in Genevant of $9.2&#160;million and cash paid of $20.5&#160;million for common shares of Genevant as part of the Recapitalization, total consideration paid was $58.5&#160;million. Of this amount, $41.4&#160;million was attributed to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development, which was determined by the Company to have not reached technological feasibility and therefore have no alternative future use. Accordingly, the Company recorded $41.4&#160;million as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development expense in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. </div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proteovant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2020, Proteovant Sciences, Inc. (formerly known as Pharmavant 5, Inc.) (together with its wholly owned subsidiaries, &#8220;Proteovant&#8221;) entered into a stock purchase agreement to acquire Oncopia Therapeutics, Inc. (&#8220;Oncopia&#8221;), a preclinical biotechnology company developing small molecule protein degraders primarily against certain oncology targets. Upfront proceeds to Oncopia&#8217;s shareholders were $105.0&#160;million, prior to certain adjustments in accordance with the terms of the agreement. Proteovant is also obligated to make future development and commercial milestone payments of up to $100.0&#160;million for the first product targeting each of the two specified initial targets, and up to $51.0&#160;million for the first product targeting each of certain specified additional molecular targets. Additionally, the Company&#8217;s investments in promissory notes issued by Oncopia for an aggregate principal amount of $11.5&#160;million were settled through either conversion to equity or cancellation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Oncopia&#8217;s intellectual property was developed by the University of Michigan laboratory run by Oncopia&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-founder</div> (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Co-Founder&#8221;).</div> In connection with Proteovant&#8217;s acquisition, Oncopia amended and restated its existing license agreements with the University of Michigan. Under the new license agreement, Oncopia will be obligated to make future development and commercial milestone payments of up to $8.6&#160;million for the first product for each molecular target covered by intellectual property included in the agreement, in addition to paying tiered royalties on net sales ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-</div> to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single</div> digits, subject to certain adjustments. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Founder&#8217;s</div> lab at the University of Michigan had been providing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> discovery and optimization services to Oncopia under a sponsored research agreement (the &#8220;SRA&#8221;). Immediately after closing the acquisition, Oncopia extended the SRA through at least December&#160;31, 2023, and expanded the potential molecular targets to be pursued under the SRA. As revised, Oncopia is obligated to pay the University of Michigan approximately $15.5&#160;million under the SRA. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Lastly, in connection with the acquisition of Oncopia, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Founder</div> entered into an agreement with the Company to serve as a consultant. In exchange for these services, the Company has agreed to grant the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Founder</div> RSL restricted stock units for which the majority will vest upon achievement of development milestones for products directed to targets for which no milestones are payable to Oncopia shareholders and the remaining portion will be subject to time-based service requirements. These restricted stock units were also subject to a liquidity requirement to vest, which was achieved upon the closing of the Business Combination. The Company will also make a cash payment to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Founder</div> upon achievement of development milestones for each such product. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the year ended March&#160;31, 2021, the Company recorded $116.5&#160;million, relating to the net upfront cash payment of $101.2&#160;million, settlement of promissory notes receivable, including accrued interest, of $11.9&#160;million, and fair value of future contingent consideration payments of $3.4&#160;million, as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development expense in the accompanying consolidated statements of operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2020, RSL, Proteovant and SK, Inc. (formerly known as SK Holdings Co., Ltd.) (&#8220;SK&#8221;) entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) pursuant to which SK agreed to make a $200.0&#160;million equity investment in Proteovant, representing an ownership interest of 40.0% on the closing date. In January 2021, in accordance with the terms of the Subscription Agreement, SK made the first payment of $100.0&#160;million to Proteovant. SK made the second payment of $100.0&#160;million to Proteovant in July 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2022, Proteovant entered into a collaboration agreement with Blueprint Medicines pursuant to which the parties will jointly research and advance up to two novel protein degrader compounds into development candidates, as well as up to two additional novel protein degrader target programs as may be mutually agreed to by the Blueprint Medicines and Proteovant (each a target program). Under the terms of the collaboration agreement, Proteovant received a nonrefundable, upfront payment of $20.0&#160;million in March 2022 and will be eligible to receive up to an additional $632.0&#160;million in contingent milestone payments including</div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">specified research, development, regulatory and commercialization milestones and tiered percentage royalties on a licensed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-licensed</div></div> product basis ranging from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-</div> to high-single digits on net sales on the first two target programs, subject to adjustment in specified circumstances. If Proteovant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opts-in</div> to the second target program (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Opt-In</div> Right&#8221;), the parties will jointly develop and commercialize such compounds and will split profits and losses of that program equally in the United States along with global development costs. Additionally, development and regulatory milestone payments for the second target or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-in</div> target program will be reduced, and Proteovant will only be eligible to receive commercialization milestone payments and royalties on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ex-United</div> States sales of products relating to such target program. In addition, the parties may jointly extend the collaboration, with the same structure and financial terms, for up to two additional target programs through additional funding by Blueprint Medicines and Proteovant&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Opt-In</div> Right would extend to the second of such additional target programs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Proteovant will be performing research and development activities throughout the period until Blueprint Medicines can exercise its option to obtain a worldwide, exclusive license to develop and commercialize any licensed compound, subject to Proteovant&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Opt-In</div> Right. Proteovant initially recorded the $20.0&#160;million upfront payment as deferred revenue on the accompanying consolidated financial statements and will recognize it as revenue as the services are provided. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Affivant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2020, RSL and its indirect subsidiary Affivant Sciences GmbH (&#8220;Affivant&#8221;) entered into a licensing and strategic collaboration agreement with Affimed N.V. (&#8220;Affimed&#8221;) to develop and commercialize novel innate cell engagers for multiple cancer targets in exchange for consideration that includes $40.0&#160;million in upfront cash and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-paid</div> R&amp;D funding and $20.0&#160;million of newly issued shares in RSL. Affimed could receive further short-term proceeds in the form of option fees contingent on the commencement of additional programs contemplated under the agreement. Affimed is eligible to receive up to an additional approximately $2.0&#160;billion in milestones over time upon achievement of specified development, regulatory and commercial milestones, as well as tiered royalties on net sales. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquisition of Silicon Therapeutics </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">In March 2021, the Company completed the acquisition of the business of Silicon Therapeutics, LLC (&#8220;Silicon Therapeutics&#8221;), a physics-driven computational drug discovery company, for total consideration of approximately $450.0&#160;million, with additional cash payments payable subject to the satisfaction of certain regulatory and commercial milestones. This acquisition did not include one of Silicon Therapeutics&#8217; subsidiaries, Silicon SWAT, Inc. Approximately $350.0&#160;million of the consideration was payable primarily in the <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ompany&#8217;s </div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px;;display:inline;">stock</div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"> at or near closing of the acquisition (the &#8220;First Tranche&#8221;). At closing of the acquisition, the Company issued 21,409,764 </div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"> and paid approximately $14.0&#160;million in cash, net of cash received, to Silicon Therapeutics after giving effect to certain transaction adjustments and holdbacks. The remainder of the First Tranche was paid in a combination of </div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"> and cash as certain holdbacks were released. In November 2021, the Company transferred the remaining $100.0&#160;million (the &#8220;Second Tranche Consideration&#8221;) to Silicon Therapeutics through a $50.0&#160;million cash payment and the issuance of 6,348,057 of the Company&#8217;s <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The transaction was accounted for as an asset acquisition as substantially all of the fair value of the assets acquired were concentrated in a single asset, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">in-process</div> research and development related to the computational drug discovery platform that designs and develops small molecule therapeutics. For accounting purposes, the fair value of consideration transferred was $402.4&#160;million, consisting of $281.7&#160;million relating to the fair value of <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares</div> issued upfront and expected to be issued shortly thereafter; $105.1&#160;million relating to the fair value of liabilities due to the sellers, including the Second Tranche Consideration, future contingent consideration payments, and closing consideration to be paid in cash; and cash of $15.6&#160;million paid at closing. Of this amount, $399.6&#160;million was attributed to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">in-process</div> research and development, which was determined to </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">have no alternative future use. Accordingly, the Company recorded $399.6&#160;million as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development expense in the accompanying consolidated statement of operations for the year ended March&#160;31, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the transaction, the vesting of certain outstanding Silicon Therapeutics share-based compensation awards held by employees of Silicon Therapeutics was discretionarily accelerated at closing. As a result, the Company recorded share-based compensation expense of $23.5&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">In addition, certain share-based compensation awards of Silicon Therapeutics were exchanged with restricted </div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px;;display:inline;">stock</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"> of the Company, subject to certain service-based vesting requirements, with a fair value of $22.6&#160;million. Of this amount, $15.6&#160;million was attributed to precombination service and therefore included in the total fair value of consideration transferred. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Priovant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In September 2021, Priovant Therapeutics, Inc. (&#8220;Priovant&#8221;) entered into a license and collaboration agreement with Pfizer, Inc. (&#8220;Pfizer&#8221;) (the &#8220;Pfizer License Agreement&#8221;). The transaction was accounted for as an asset acquisition as the acquired assets did not meet the definition of a business. The fair value of consideration transferred was $82.1&#160;million, consisting of $70.0&#160;million of preferred stock issued to Pfizer, representing a dilution-protected minority ownership interest in Priovant; a $10.0&#160;million upfront cash payment; and $2.1&#160;million relating to other obligations. The acquired rights, which included the licensed rights, starting materials and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> inventory for each drug candidate, represent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development assets, which were determined to have no alternative future use. Accordingly, the Company recorded $82.1&#160;million as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development expense in the accompanying consolidated statements of operations for the year ended March&#160;31, 2022. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Priovant is obligated to pay Pfizer a mid tens-of-millions sales milestone payment if aggregate net sales of its licensed products in Priovant&#8217;s territory in a given year exceed a mid hundreds-of-millions amount. Pfizer is obligated to pay Priovant a low tens-of-millions sales milestone payment if aggregate net sales of its licensed products outside of Priovant&#8217;s territory in a given year exceed a mid hundreds-of-millions amount. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Priovant is obligated to pay Pfizer a tiered, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-teens</div> royalty, on aggregate net sales of its licensed products in Priovant&#8217;s territory. Pfizer is obligated to pay Priovant a tiered high single-digit to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-teens</div> royalty, on aggregate net sales of its licensed products outside of Priovant&#8217;s territory. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Hemavant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2021, Hemavant Sciences GmbH (&#8220;Hemavant&#8221;), a wholly owned subsidiary of the Company, entered into a license agreement with Eisai Co., Ltd. (&#8220;Eisai&#8221;) (the &#8220;Eisai License Agreement&#8221;). Pursuant to the Eisai License Agreement, Eisai granted Hemavant (i)&#160;an exclusive, worldwide, sublicensable, royalty-bearing license under certain patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">know-how</div> and (ii)&#160;a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">non-exclusive,</div> worldwide, sublicensable, royalty-bearing license under certain additional patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">know-how</div> and inventions, in each case, to develop, manufacture and commercialize the compound known as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">RVT-2001</div> and products incorporating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">RVT-2001</div> for all human and animal uses. In exchange for the rights, the Company made an upfront payment to Eisai consisting of $8.0&#160;million in cash and the issuance of $7.0&#160;million in shares of the Company&#8217;s <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px;;display:inline;">stock</div></div></div> at an agreed price of $8.00 per share. Hemavant may also be obligated to pay up to a maximum of $65.0&#160;million in development and regulatory milestone payments (with respect the product for the first indication) and up to a maximum of $18.0&#160;million in payments (with respect to the product for each additional indication) and up to a maximum of $295.0&#160;million in commercial milestone payments. Hemavant may also be obligated to pay a tiered high single-digit to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">sub-teens</div> royalty, subject to certain customary reductions, on net sales of licensed products. </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"/> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The transaction was accounted for as an asset acquisition as the acquired assets did not meet the definition of a business. The acquired rights, which include the licensed rights and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">in-process</div> inventory of the drug candidate, represent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">in-process</div> research and development assets that were determined to have no alternative future use. The fair value of the 874,957 shares of the Company&#8217;s <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px;;display:inline;">stock</div></div></div> issued to Eisai based on the closing price as of the effective date of the Eisai License Agreement was $6.1&#160;million. Accordingly, the Company recorded $14.1&#160;million as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">in-process</div> research and development expense in the accompanying consolidated statements of operations for the year ended March&#160;31, 2022. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisitions and license agreements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724308838400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 6&#8212;Accrued Expenses </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses at March&#160;31, 2022 and 2021 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">66,188</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,755</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation-related expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,262</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,552</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other general and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,081</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,629</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">127,531</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,936</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724308835968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt and Loan Commitment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt and Loan Commitment</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 7&#8212;Long-Term Debt and Loan Commitment </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Long-Term Debt </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt, net consists of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal amount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">217,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exit fee / end of term charge</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,390</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: unamortized debt discount and issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,375</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total debt, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">210,025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170,280</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total long-term debt, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">210,025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170,280</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>   <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2019, Dermavant entered into a loan and security agreement (the &#8220;Hercules Loan Agreement&#8221;) with Hercules Capital, Inc. (&#8220;Hercules&#8221;), pursuant to which Dermavant borrowed an aggregate of $20.0&#160;million, which </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">bore interest at a variable per annum rate at the greater of (i) 9.95% or (ii)&#160;the prime rate plus 4.45%. Dermavant was also obligated to pay an end of term charge of $1.4&#160;million. Following the achievement of certain milestones, the term loan maturity was extended to June&#160;1, 2023 with interest-only monthly payments through December 2021. All amounts outstanding under the Hercules Loan Agreement were repaid in May 2021 using the proceeds from a $40.0&#160;million senior secured credit facility (the &#8220;Credit Facility&#8221;) entered into by Dermavant and certain of its subsidiaries in May 2021 with XYQ Luxco S.A.R.L (&#8220;XYQ Luxco&#8221;), as lender, and U.S. Bank National Association, as collateral agent. The Credit Facility has a five-year maturity and bears an interest rate of 10.0% per annum. Interest is payable quarterly in arrears on the last day of each calendar quarter through the maturity date. A lump sum principal payment is due on the maturity date. Dermavant is also obligated to pay an exit fee of $5.0&#160;million. The exit fee can be reduced to $4.0&#160;million upon achievement of certain equity milestones defined in the agreement, which are not deemed likely as of March&#160;31, 2022. In connection with the funding of the Credit Facility, Dermavant issued a warrant to XYQ Luxco to purchase 1,199,072 common shares of Dermavant at an exercise price of $0.01 per common share.</div></div>  <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with Dermavant&#8217;s acquisition of tapinarof from GlaxoSmithKline Intellectual Property Development Ltd. and Glaxo Group Limited (collectively &#8220;GSK&#8221;) pursuant to an asset purchase agreement (the &#8220;GSK Agreement&#8221;), Dermavant and NovaQuest </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Fund VIII, L.P. (&#8220;NovaQuest&#8221;) entered into a funding agreement (the &#8220;NovaQuest Agreement&#8221;). Pursuant to the NovaQuest Agreement, Dermavant borrowed $</div>100.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in </div>August 2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and $</div>17.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in </div>October 2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> in exchange for an obligation to make certain variable future payments calculated as a function of the achievement of regulatory and commercial milestones or events of termination. The aggregate maximum amount of regulatory milestone payments that Dermavant could be required to make under the NovaQuest Agreement is $</div>440.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, with $176.3 million due over a six-year period paid quarterly following the U.S. regulatory approval of VTAMA in May 2022. The maximum aggregate amount of commercial milestone payments is $</div>141.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. In some circumstances, Dermavant may be able to offset certain of the regulatory milestone payments with up to $</div>88.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of the commercial milestone payments. At issuance, the Company concluded that certain features of the long-term debt would be considered derivatives that would require bifurcation. In lieu of bifurcating various features in the agreement, the Company has elected the fair value option for this financial instrument and will record the changes in the fair value within the statements of operations at the end of each reporting period. Direct costs and fees related to the debt issued under the NovaQuest Agreement were recognized in earnings. As of March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the fair value of the debt was $</div>177.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>150.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively. Refer to Note </div>14<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, &#8220;Fair Value Measurements&#8221; for additional details regarding the fair value measurement.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Debt Maturities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Annual maturities, including the exit fee, of debt outstanding as of&#160;March&#160;31, 2022&#160;are as follows (in thousands). Long term debt issued by Dermavant for which the fair value option has been elected is excluded from the below as the repayment terms are variable. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ending March&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Loan Commitment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In May 2021, Dermavant, as seller, entered into a $160.0&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million revenue interest purchase and sale agreement (the &#8220;RIPSA&#8221;) for its investigational product tapinarof with XYQ Luxco, NovaQuest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Fund XVII, L.P., an affiliate of NovaQuest Capital Management, LLC, and MAM Tapir Lender, LLC, an affiliate of Marathon Asset Management, L.P. (collectively, the &#8220;Purchasers&#8221;), together with U.S. Bank National Association, as collateral agent. Under the terms of the RIPSA, the Purchasers procured a capped single-digit revenue interest in net sales of tapinarof for all dermatological indications in the United States, up to a cap of $344.0&#160;million, in exchange for </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$160.0&#160;million in committed funding to be paid to Dermavant, conditional based on the approval of tapinarof by the FDA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VTAMA (tapinarof) cream was approved by the FDA in May 2022. Refer to Note 17, &#8220;Subsequent Events&#8221; for more information.</div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724308879456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 8&#8212;Related Party Transactions</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sumitomo Dainippon Pharma Co., Ltd. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In May 2021, the Company entered into an Asset Purchase Agreement with Sumitomo Dainippon Pharma Co., Ltd. (&#8220;Sumitomo&#8221;) and its subsidiary Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (&#8220;SPC&#8221;) (the &#8220;Asset Purchase Agreement&#8221;). The transactions contemplated by the Asset Purchase Agreement closed in June 2021. Pursuant to the Asset Purchase Agreement: (i)&#160;Sumitomo terminated all of its existing options to acquire the Company&#8217;s equity interests in certain of its subsidiaries (the &#8220;Sumitomo Options&#8221;); (ii) the Company transferred and assigned to SPC all of its intellectual property, development and commercialization rights for (a)&#160;lefamulin in Mainland China, Taiwan, Hong Kong, and Macau (collectively &#8220;Greater China&#8221;), (b) vibegron in Mainland China, (c)&#160;rodatristat ethyl in Greater China and South Korea and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(d)&#160;RVT-802</div> in Greater China and South Korea; (iii)&#160;Sumitomo agreed to pay the Company $5.0&#160;million in cash; and (iv)&#160;Sumitomo entered into an agreement with the Company to pursue future collaborations with Genevant. The Company received the cash payment, net of certain withholding taxes, in August 2021. The Company recorded a gain on the termination of the Sumitomo Options of $66.5&#160;million, consisting of the fair value of the Sumitomo Options on the date of termination and the cash payment, in the accompanying consolidated statements of operations for the year ended March&#160;31, 2022. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transition Services Agreement and Strategic Cooperation Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">In December 2019, RSL and Sumitomo completed the transactions contemplated by the transaction agreement by and between RSL and Sumitomo, dated as of October 31, 2019 (the &#8220;Sumitomo Transaction Agreement&#8221;). Concurrent with entry into the Sumitomo Transaction Agreement, RSL and Sumitomo entered into the following agreements: (i)&#160;a transition services agreement (the &#8220;TSA&#8221;), pursuant to which the parties agreed to provide certain transitional services to one another at cost for a specified period of time following the closing date and (ii)&#160;a strategic cooperation agreement (the &#8220;SCA&#8221;), providing for certain technology-related collaborations. Pursuant to the terms of the TSA and the SCA, RSL billed Sumitomo </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$1.0&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">million and</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $1.4&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">million, net of amounts billed by Sumitomo to RSL, during the years ended March&#160;31, 2022 and 2021, respectively. Additionally, during each of the years ended March&#160;31, 2022 and 2021, the Company paid Sumitomo a </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$1.0&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million DrugOme access fee pursuant to the SCA. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;1, 2022, RSL and Sumitomo amended the SCA. In connection with the amendment, RSL agreed to pay Sumitomo an aggregate of </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$4.5&#160;million. This consideration was expensed during the year ended March&#160;31, 2022. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724308799392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 9&#8212;Shareholders&#8217; Equity </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) RSL Common <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Stock</div> </div></div></div></div> <div style="letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;30, 2021 in connection with the closing of the Business Combination, the Company effected a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.9262-for-1</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> stock subdivision based on the fixed exchange ratio established in the Business Combination. All per share amounts and number of shares in the consolidated financial statements and related notes have been retroactively restated to reflect the stock split.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, in connection with the closing of the Business Combination, the Company adjusted its authorized share capital to equal 7,000,000,000 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">c</div></div></div></div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">s</div></div></div></div>hares, par value $<span style="-sec-ix-hidden:hidden50658913">0.00000003</span>41740141 per share. Each <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">c</div></div></div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div>hare has the right to one vote. The holders of <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">s</div></div>hares are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared by the board of directors since the Company&#8217;s inception.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Committed Equity Facility</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;14, 2022, the Company entered into a committed equity facility (the &#8220;Facility&#8221;) with an affiliate of Cantor Fitzgerald&#160;&amp; Co. (&#8220;Cantor&#8221;). Under the terms of the Facility, Cantor has committed to purchase up to an aggregate of $250.0&#160;million in the Company&#8217;s </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div>hares<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from time to time at the request of the Company, subject to certain limitations and the satisfaction of certain conditions. Any sales of the <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div></div>ompany&#8217;s </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div>hares<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to Cantor under the Facility will be made at 99% of the volume-weighted average price of the Company&#8217;s </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div>hares<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> on Nasdaq on a given trading day. In consideration for entry into the Facility, the <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div></div>ompany paid Cantor an upfront commitment fee in the form of 145,986 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div>hares<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. As of March&#160;31, 2022, $250.0&#160;million of the Company&#8217;s </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div>hares<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> remained available for sale under the Facility. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Consolidated Vant Equity Transactions </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Immunovant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2020 and September 2020, Immunovant, Inc. achieved the first and second earnout milestones as defined in the share exchange agreement with Health Sciences Acquisitions Corporation. As a result, all of the 20,000,000 earnout shares of Immunovant, Inc.&#8217;s common stock were issued, including 17,547,938 shares of common stock issued to RSL. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2020, Immunovant, Inc. completed an underwritten public offering of 9,613,365 shares of its common stock, including 1,034,483 shares of common stock purchased by RSL, at a price of $14.50 per share for net proceeds to Immunovant, Inc. of approximately $131.0&#160;million, after deducting underwriting discounts and commissions and offering expenses. The proceeds included $15.0&#160;million received from RSL. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2020, Immunovant, Inc.&#8217;s 11,500,000 outstanding warrants became exercisable for an aggregate of 5,750,000 shares of Immunovant, Inc.&#8217;s common stock at a price of $11.50 per share. An aggregate of 11,438,290 outstanding warrants were exercised for an aggregate of 5,719,145 shares of Immunovant, Inc.&#8217;s common stock at a price of $11.50 per share, for net proceeds of approximately $65.8&#160;million. The remaining 61,710 warrants were cancelled. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2020, Immunovant, Inc. completed an underwritten public offering of 6,060,606 shares of its common stock, including 380,000 shares of common stock purchased by RSL, at a price of $33.00 per share for net proceeds to Immunovant, Inc. of approximately $188.1&#160;million, after deducting underwriting discounts and commissions and offering expenses. The proceeds included $12.5&#160;million received from RSL. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proteovant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2021, Proteovant collected the subscription receivable relating to the second $100.0&#160;million payment due under a subscription agreement entered into with SK, Inc. (&#8220;SK&#8221;) in December 2020 pursuant to which SK agreed to make a $200.0&#160;million equity investment in Proteovant, representing an ownership interest of 40.0% on the closing date. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724312040512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 10&#8212;Share-Based Compensation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Share-Based Compensation Expense </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense was as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense recognized as:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63,735</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,637</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">501,221</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,321</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">564,956</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84,958</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The achievement of the liquidity event vesting condition for certain equity instruments upon the closing of the Business Combination resulted in the recognition of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> expense of $372.9&#160;million in September 2021 relating to cumulative service rendered between the grant date of the respective awards and completion of the Business Combination. This <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> expense is reflected in the accompanying consolidated statements of operations for the year ended March&#160;31, 2022. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) RSL Equity Incentive Plans </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">RSL has three equity incentives plans: the Roivant Sciences Ltd. 2021 Equity Incentive Plan (the &#8220;RSL 2021 EIP&#8221;), the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan (the &#8220;RSL 2015 EIP&#8221;), and the Roivant Sciences Ltd. Amended and Restated 2015 Restricted Stock Unit Plan (the &#8220;2015R Plan&#8221;) (collectively, the &#8220;RSL Equity Plans&#8221;). The RSL 2021 EIP was approved and adopted in connection with the Business Combination and became effective immediately prior to closing. Since the effective date of the RSL 2021 EIP, no further stock awards have been or will be made under the RSL 2015 EIP. Additionally, no further stock awards will be made under the 2015R Plan. As of March&#160;31, 2022,</div></div>&#160;69,300,000 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">of the Company&#8217;s <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares were reserved for issuance under the RSL 2021 EIP. The number of <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares reserved for issuance under the RSL 2021 EIP will automatically increase on April&#160;1 of each year by an amount equal to the lesser of (i)</div></div>&#160;5%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">of the <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares outstanding as of the last day of the immediately preceding fiscal year and (ii)&#160;such number of <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares as determined by our board of directors in its discretion. The RSL 2021 EIP has a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ten-year</div> term. The Company&#8217;s employees, directors, and consultants are eligible to receive incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock awards under the RSL 2021 EIP. At March&#160;31, 2022, a total of</div>&#160;59,373,756 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div></div>ommon <div style="display:inline;">s</div>hares were available for future grants under the RSL 2021 EIP. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">All RSL <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares issuable on exercise of vested options or settlement of other equity instruments that were issued and outstanding as of the closing of the Business Combination were subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period expired on March&#160;30, 2022. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options and Performance Stock Options </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Activity for stock options and performance stock options under the RSL Equity Plans for the year ended March&#160;31, 2022 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual&#160;Life<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic&#160;Value<br/> (in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options outstanding at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69,687,308</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.64</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,181,127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(101,436</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Canceled</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,402,095</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options outstanding at March&#160;31, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80,364,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.37</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,899</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options exercisable at March&#160;31, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39,236,351</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,456</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr> </table>  <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate intrinsic value is calculated as the difference between the exercise price of all outstanding and exercisable options and the fair value of the Company&#8217;s <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">stock</div></div> at March&#160;31, 2022. At March&#160;31, 2022, total unrecognized compensation expense related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> stock options and performance stock options was approximately </div>$149.7&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">million and is expected to be recognized over a weighted-average period of approximately</div></div></div>&#160;2.63 years.<br/></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2022 and 2021, there were 39,236,351 and 16,193,146 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">vested stock options and performance stock options, respectively. Vesting for performance stock options was subject to a liquidity event vesting requirement in addition to time-based service requirements. The liquidity event vesting requirement was met upon closing of the Business Combination on September 30, 2021. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company estimated the fair value of each stock option on the date of grant using the Black-Scholes closed form option-pricing model applying the weighted average assumptions in the following table. No performance stock options were granted during the years ended March&#160;31, 2022 and 2021. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assumptions</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock price volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">81.70</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74.84</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected risk free interest rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.13</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.43</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term, in years</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional information regarding stock options and performance stock options is set forth below (in thousands, except per share data). </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intrinsic value of options exercised</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Grant date fair value of options vested</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">210,487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,711</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average grant date fair value per share of stock options granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.85</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.67</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units and Performance Stock Units </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Activity for restricted stock units and performance stock units under the RSL Equity Plans for the year ended March&#160;31, 2022 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;Restricted<br/> Stock Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/> Grant Date Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,294,028</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,948,227</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.44</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,111,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,173,956</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.79</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2022</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,956,749</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total fair value of restricted stock units and performance stock units vested during the year ended March&#160;31, 2022 was $59.3&#160;million. Vesting for both restricted stock units and performance stocks units was subject to a liquidity event vesting requirement. There were no vested restricted stock units or performance stock units at March&#160;31, 2021 as the liquidity event vesting requirement was not met until the closing of the Business Combination on September&#160;30, 2021. Restricted stock units vest upon the achievement of time-based service requirements. The vesting of performance stock units requires that certain performance conditions are achieved during the performance period and is subject to continued service requirements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At March&#160;31, 2022, total unrecognized compensation expense related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> restricted stock units and performance stock units was approximately $155.8&#160;million. Unrecognized compensation expense relating to restricted stock units and performance stock units that are deemed probable of vesting is expected to be recognized over a weighted-average period of approximately 2.97 years.</div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Capped Value Appreciation Rights </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">March 2020 CVAR Grants </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2020, the Company granted capped value appreciation rights (&#8220;CVARs&#8221;) that will pay at settlement the excess in shares of (a)&#160;the lesser of (i)&#160;the fair market value of a <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;"><div style="display:inline;">c</div></div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;"><div style="display:inline;">s</div></div></div>hare as of the settlement date or (ii)&#160;the cap of $12.68, over (b)&#160;the hurdle price of either $6.40 or $11.50, as applicable to each grant. On March&#160;30, 2022, the Company amended the outstanding CVARs that were granted in March 2020. Pursuant to the amendment, in the event any CVARs have satisfied the time-based service and liquidity event vesting requirements (&#8220;service-vested CVARs&#8221;) but have not satisfied the applicable hurdle price on an applicable measurement date, then such CVARs will be deemed to remain outstanding and the applicable award holder will be provided the right to earn such CVARs if the hurdle price is satisfied on subsequent annual &#8220;hurdle measurement dates&#8221; prior to the original expiration date of the CVARs, being March&#160;31, 2026. The &#8220;hurdle measurement dates&#8221; are March&#160;30 of each of years 2023 through 2026. If the hurdle price is not satisfied on any such subsequent annual hurdle measurement date prior to the expiration date of the CVARs, then the CVARs will be forfeited in their entirety on the expiration date. This amendment was accounted for as a modification and resulted in an aggregate of approximately $16.9&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million of incremental fair value. Incremental fair value associated with CVARs that do not require further service for vesting was recognized in full on March&#160;30, 2022. The Company will recognize the incremental fair value for CVARs that require future service for vesting over the remaining requisite service </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">period.</div></div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/>  <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Activity</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">for CVARs under the RSL 2015 EIP for the year ended March&#160;31, 2022 is as follows:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;CVARs</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-service-vested</div> CVARs balance at March&#160;31, 2021</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,447,626</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.72</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service-vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,213,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(435,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-service-vested</div> CVARs balance at March&#160;31, 2022</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,798,086</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">At March&#160;31, 2022, there were 18,213,910 service-vested CVARs. The hurdle price was not satisfied for these service-vested CVARs and as such they remain outstanding. The total fair value of CVARs that service-vested during the year ended March&#160;31, 2022 was</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;$22.3&#160;million. There were no service-vested CVARs at March&#160;31, 2021 as the liquidity event vesting requirement was not met until the closing of the Business Combination on September&#160;30, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At March&#160;31, 2022, total unrecognized compensation expense related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-service-vested</div> CVARs was approximately $10.1&#160;million and is expected to be recognized over a weighted-average period of approximately 1.74 years. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">November 2021 CVAR Grants </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2021, the Company made <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> grants of 6,317,350 CVARs in the aggregate under the RSL 2021 EIP to eligible participants. The CVARs are eligible to vest based on the satisfaction of service-based and performance-based vesting requirements. The performance-based vesting requirement was achieved in December 2021. Vested CVARs will be settled in <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">c</div></div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div>hares, up to a specified cap price.</div>  <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Activity for CVARs under the RSL 2021 EIP for the year ended March&#160;31, 2022 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;CVARs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,317,350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(32,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.71</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2022</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,285,250</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At March&#160;31, 2022, total unrecognized compensation expense related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> CVARs was approximately $19.3&#160;million and is expected to be recognized over a weighted-average period of approximately 3.13 years. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Employee Stock Purchase Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">In September 2021, the Company adopted the Roivant Sciences Ltd. Employee Stock Purchase Plan (the &#8220;RSL ESPP&#8221;), which provides for the granting of an option to purchase <div style="display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares of RSL to eligible employees, as defined by the RSL ESPP. As of March&#160;31, 2022, the maximum number of <div style="display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares reserved and available for purchase under the RSL ESPP was</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;13,900,000. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">The total number of <div style="display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares available for purchase under the RSL ESPP will be increased annually on April&#160;1 of each year during the term of the plan in an amount equal to the least of (i)</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> 13,900,000 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"><div style="display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares, (ii)</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden50659171">one</span> </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">percent of the aggregate number of <div style="display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares outstanding (on a fully diluted basis) on the last day of the immediately preceding Company fiscal year and (iii)&#160;such lesser number of <div style="display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares as determined by the board of directors; provided that the maximum number of <div style="display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares that may be issued under the RSL ESPP during the term of the plan is</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;147,447,650 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares.</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 8pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(D) Subsidiary Equity Incentive Plans</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Certain wholly owned and majority-owned or controlled subsidiaries of RSL adopt their own equity incentive plan (&#8220;EIP&#8221;). Each EIP is generally structured so that the applicable subsidiary, and its affiliates&#8217; employees, directors, officers and consultants are eligible to receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> and incentive stock options, stock appreciation rights, restricted share awards, restricted stock unit awards, and other share awards under their respective EIP. The Company recorded share-based compensation expense of $47.4&#160;million and $29.1&#160;million for the years ended March&#160;31, 2022 and 2021, respectively, related to subsidiary EIPs. At March&#160;31, 2022, total unrecognized compensation expense related to subsidiary EIPs was approximately $134.5&#160;million. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724310054432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 11&#8212;Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The loss before income taxes and the related expense/(benefit) are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bermuda<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">390,831</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(227,471</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(747,953</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(212,921</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Switzerland</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(544,870</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(424,494</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21,755</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(33,661</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total loss before income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(923,747</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(898,547</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily entities which are centrally managed and controlled in the United Kingdom </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily Greater China and United Kingdom activity </div></div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current taxes:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bermuda</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(223</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,365</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Switzerland</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">592</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">321</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">369</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred taxes:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bermuda</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Switzerland</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total income tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">369</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily Greater China and United Kingdom activity </div></div></div></td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of income tax provision/(benefit) computed at the Bermuda statutory rate to income tax expense reflected in the consolidated financial statements is as follows (in thousands, except percentages): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit at Bermuda statutory rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign rate differential<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(179,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.38</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(150,778</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.78</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Permanent disallowed IPR&amp;D</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,347</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.66</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">111,432</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Tax-effect</div> of changes in the fair value of investments and loss from equity method investment</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,169</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.64</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nontaxable gain on sale of investment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(84,313</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.13</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nontaxable gain on deconsolidation of business</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(958</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.83</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nondeductible executive compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,973</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2.81</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">905</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Tax deficiencies (excess tax benefits) from share-based compensation</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,918</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(439</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.05</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other permanent adjustments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,912</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.18</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,457</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research tax credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,113</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.09</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,555</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">205,811</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85,046</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9.46</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax rate changes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,444</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,443</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,933</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.97</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total income tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">369</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily related to operations in the United States, Switzerland, the United Kingdom, and other jurisdictions with statutory tax rates different than the Bermuda rate. </div></div></div></td></tr></table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s effective tax rates for the years ended March&#160;31, 2022 and 2021 was (0.04)% and (0.19)%, respectively, driven by the Company&#8217;s jurisdictional earnings by location and a valuation allowance that eliminates the Company&#8217;s global net deferred tax assets.</div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred taxes reflect the tax effects of the differences between the amounts recorded as assets and liabilities for financial reporting purposes and the comparable amounts recorded for income tax purposes. </div>Significant components of the deferred tax assets (liabilities) at March&#160;31, 2022 and 2021 are as follows (in thousands):&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;</div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research tax credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,155</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,063</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61,544</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,564</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">312,749</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">202,906</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93,177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,623</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,406</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,638</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,651</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,303</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subtotal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">530,682</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">323,097</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(512,736</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(303,287</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,397</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,214</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,661</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,908</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,888</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,688</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets/(liabilities)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has Federal net operating losses in Switzerland, the <div style="letter-spacing: 0px; top: 0px;;display:inline;">United </div>States, the United Kingdom and other jurisdictions in the amount of $1,749.2&#160;million, $244.1&#160;million, $40.1&#160;million, and $98.4&#160;million, respectively. The Switzerland net operating losses will expire in varying amounts between March 31, 2025 and March 31, 2029. The United States net operating losses can be carried forward indefinitely with utilization limited to 80% of future taxable income for tax years beginning on or after January&#160;1, 2021, while the United Kingdom and other net operating losses can be carried forward indefinitely as well, with an annual limitation on utilization. The Company has generated net operating losses from United States state and local jurisdictions in the amount of $94.8&#160;million which will expire in varying amounts between March 31, 2035 and March 31, 2042. The Company has generated $27.2&#160;million of research tax credit carryforwards primarily in the United States and Canada, which will expire in varying amounts between March 31, 2035 and March 31, 2042. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company assesses the realizability of the deferred tax assets at each balance sheet date based on available positive and negative evidence in order to determine the amount which is more likely than not to be realized and record a valuation allowance as necessary. Due to the Company&#8217;s cumulative loss position which provides significant negative evidence difficult to overcome, the Company has recorded a valuation allowance of $512.7&#160;million as of March&#160;31, 2022, representing the portion of the deferred tax asset that is not more likely than not to be realized. For the period April&#160;1, 2021 through March&#160;31, 2022, the valuation allowance increased by $209.4&#160;million, primarily as a result of corresponding increases in our global net operating losses, as well as increased costs related to share-based compensation. The amount of the deferred tax asset considered realizable could be adjusted for future factors that would impact the assessment of the objective and subjective evidence of the Company. The Company will continue to assess the realizability of deferred tax assets at each balance sheet date in order to determine the amount, if any, required for a valuation allowance. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are outside basis differences related to the Company&#8217;s investment in subsidiaries for which no deferred taxes have been recorded as these would not be subject to tax on repatriation as Bermuda has no tax regime for Bermuda exempted limited companies, and the United Kingdom tax regime relating to company distributions and sales generally provides for exemption from tax for most overseas profits, subject to certain exceptions. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to tax and is required to file United States, United Kingdom, and Switzerland federal income tax returns, as well as income tax returns in various state, local, and foreign jurisdictions. The</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Company<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">is subject to tax examinations for tax years ended March&#160;31, 2018 and forward in major taxing jurisdictions. Tax audits and examinations can involve complex issues, interpretations and judgments. The resolution of matters may span multiple years particularly if subject to litigation or negotiation. The Company believes it has appropriately recorded its tax position using reasonable estimates and assumptions, however, the potential tax benefits may impact the results of operations or cash flows in the period of resolution, settlement or when the statutes of limitations expire. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s unrecognized tax benefit activity during the year ended March&#160;31, 2022 was not material to the Company&#8217;s consolidated financial statements. There were no unrecognized tax benefits recorded as of March&#160;31, 2021. No interest and penalties related to unrecognized tax benefits were recorded as of March&#160;31, 2022 or March&#160;31, 2021. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724308832544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 12&#8212;Leases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s operating leases consist primarily of real estate leases, including those entered into by certain wholly owned and majority-owned or controlled subsidiaries of RSL. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of operating lease expense for the Company were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,649</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,931</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">326</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">237</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,227</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">704</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,202</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px;;display:inline;">Information related to the Company&#8217;s operating lease right-of-use assets and operating lease liabilities was as follows (in thousands, except periods and percentages):&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">During&#160;the&#160;Year&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,830</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,035</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;202<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, maturities of operating lease liabilities were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ending March&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,714</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,672</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,455</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,363</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,680</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46,783</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100,667</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: present value adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(24,996</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: tenant improvement allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,805</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73,866</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724308767920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments &amp; Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments &amp; Contingencies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 13&#8212;Commitments and Contingencies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Commitments </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Long-Term Debt </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is obligated to make contractual payments related to its long-term debt. Refer to Note 7, &#8220;Long-Term Debt and Loan Commitment&#8221; for further information. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lease Commitments </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has operating leases, consisting primarily of real estate leases. Refer to Note 12, &#8220;Leases&#8221; for further information. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Commitments </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2021, the Company entered into a master subscription agreement with Palantir Technologies Inc. (&#8220;Palantir&#8221;) for access to Palantir&#8217;s proprietary software for a five-year period. As of March&#160;31, 2022, the remaining minimum payments for this software subscription are $30.0&#160;million. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2021, the Company&#8217;s subsidiary, Immunovant, Inc. (&#8220;Immunovant&#8221;), entered into a Product Service Agreement with Samsung Biologics Co., Ltd. (&#8220;Samsung&#8221;) by which Samsung will manufacture and supply Immunovant with batoclimab drug substance for commercial sale and perform other manufacturing-related services with respect to batoclimab. As of March&#160;31, 2022, the minimum purchase commitment related to this agreement is estimated to be approximately $36.0&#160;million. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company, primarily through its subsidiaries, has entered into commitments under various asset acquisition and license agreements. Additionally, the Company through its subsidiaries enters into agreements with contract service providers to assist in the performance of its R&amp;D activities. Expenditures to contract research organizations and contract manufacturing organizations represent significant costs in the clinical development of its product candidates. Subject to required notice periods and certain obligations under binding purchase orders, the Company can elect to discontinue the work under these agreements at any time. The Company expects to enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require upfront payments and long-term commitments of capital resources. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Loss Contingencies </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company accrues for loss contingencies when available information indicates that it is probable that a liability has been incurred and the amount of such loss can be reasonably estimated, and if the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation or claim, including an estimable range, if possible. The Company is currently not involved in any legal proceedings with a probable and estimable material loss. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Immunovant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the Company&#8217;s subsidiary, Immunovant, has previously disclosed, in February 2021, a putative securities class action complaint was filed against Immunovant and certain of its current and former officers in the U.S. District Court for the Eastern District of New York on behalf of a class consisting of those who acquired Immunovant&#8217;s securities from October&#160;2, 2019 and February&#160;1, 2021. The complaint alleged that Immunovant and certain of its officers violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, by making false and misleading statements regarding the safety of batoclimab and seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;29, 2021, the U.S. District Court appointed a lead plaintiff. On February&#160;1, 2022, the lead plaintiff filed an amended complaint adding both (i)&#160;the Company and (ii)&#160;Immunovant&#8217;s directors and underwriters as defendants, and asserting additional claims under Section&#160;11, 12(a)(2), and 15 of the Securities Act of 1933, which was further amended by an amended complaint filed on March&#160;15, 2022. On May&#160;27, 2022, defendants, including the Company, filed motions to dismiss that amended complaint. The Company intends to vigorously defend the case and has not recorded a liability related to this lawsuit because, at this time, the Company is unable to reasonably estimate possible losses or determine whether an unfavorable outcome is either probable or remote. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In March 2022, Acuitas Therapeutics Inc. filed a lawsuit in the U.S. District Court for the Southern District of New York against two of the Company&#8217;s affiliates, Genevant and Arbutus, seeking a declaratory judgment that U.S. Patents 8,058,069, 8,492,359, 8,822,668, 9,006,417, 9,364,435, 9,404,127, 9,504,651, 9,518,272, and 11,141,378 are not infringed by the manufacture, use, offer for sale, sale or importation into the United States of COMIRNATY, Pfizer&#8217;s and BioNTech&#8217;s vaccine for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and are otherwise invalid. Each of Genevant and Arbutus intend to vigorously defend the case and neither they nor the Company have recorded a liability related to this lawsuit. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Indemnification Agreements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. The Company also indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits. The maximum amount of potential future indemnification is unlimited; however, the Company currently maintain director and officer liability insurance, which may cover certain liabilities arising from our obligation to indemnify our directors. The Company has not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. To date, the Company has not incurred any material costs and have not accrued any liabilities related to such obligations in the consolidated financial statements as of March&#160;31, 2022 and 2021. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724308802624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_RoivantSciencesLtd.Member', window );">Roivant Sciences Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 14&#8212;Fair Value Measurements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recurring Fair Value Measurements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of&#160;March&#160;31, 2022 and 2021, by level, within the fair value hierarchy (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 33%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;as&#160;of<br/> March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;as&#160;of<br/> March&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,297,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,297,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,420,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,420,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Datavant Class&#160;A units</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193,963</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193,963</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Sio common shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,447</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,447</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Arbutus common shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115,765</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115,765</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Arbutus convertible preferred shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other investments</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,659</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,659</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,429,715</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193,963</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,623,678</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,533,538</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,609,575</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt issued by Dermavant to NovaQuest</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments measured at fair value<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,893</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,912</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,893</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,893</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">204,293</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">222,312</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">217,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">217,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">At March&#160;31, 2022, Level&#160;1 includes the fair value of the Public Warrants of $18.0&#160;million, and Level&#160;3 includes the fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares of $9.2&#160;million, Private Placement Warrants of $9.1&#160;million, and other liability instruments issued of $8.6&#160;million. At March&#160;31, 2021, Level&#160;3 includes the fair value of the Sumitomo Options of $62.4&#160;million and other liability instrument issued of $5.5&#160;million. </div></td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no transfers of assets between Level&#160;1 and Level&#160;2 of the fair value measurement hierarchy that occurred during the years ended March&#160;31, 2022 and 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Level&#160;3 Disclosures </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures its Level&#160;3 assets and liabilities at fair value based on significant inputs not observable in the market, which causes them to be classified as a Level&#160;3 measurement within the fair value hierarchy. The valuation of the Level&#160;3 assets and liabilities uses assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions and estimates on an ongoing basis as additional data impacting the assumptions and estimates are obtained. Changes in the fair value related to updated assumptions and estimates are recorded within the statements of operations at the end of each reporting period. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of Level&#160;3 assets and liabilities may change significantly as additional data are obtained, impacting the Company&#8217;s assumptions regarding probabilities of potential scenarios used to estimate fair value. In evaluating this information, considerable judgment is required to interpret the data used to develop the </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">assumptions and estimates. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company&#8217;s results of operations in future periods. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in fair value of the Level&#160;3 assets during the&#160;year ended March&#160;31, 2022&#160;were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of investment in Datavant at recognition date</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">224,147</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of investment in Datavant, included in net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,184</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193,963</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no Level&#160;3 assets held during the year ended March&#160;31, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in fair value of the Level&#160;3 liabilities during the&#160;years ended March&#160;31, 2022 and 2021 were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">191,473</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of debt and liability instruments, included in net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments disposed due to deconsolidation of subsidiary</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">217,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of liability instrument issued</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,634</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of debt and liability instruments, included in net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,226</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Settlements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(88</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Termination of DSP Options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(61,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">204,293</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Datavant </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company elected the fair value option to account for the investment in Datavant. The estimate of fair value for this investment was determined using the income approach and implementation of the option pricing method (&#8220;OPM&#8221;). The OPM allows for the allocation of a company&#8217;s equity value among the various equity capital owners (preferred and common shareholders). The OPM uses the preferred shareholders&#8217; liquidation preferences, participation rights, dividend policy, and conversion rights to determine how proceeds from a liquidity event shall be distributed among the various ownership classes at a future date. The fair value was calculated using significant unobservable inputs including the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 23%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Point Estimate Used</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Input</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.62</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt issued by Dermavant to NovaQuest </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the debt instrument as of&#160;March&#160;31, 2022 and 2021 represents the fair value of amounts payable to NovaQuest using the Monte Carlo simulation method under the income approach determined by using probability assessments of the expected future payments through 2032 and applying discount rates ranging from <span style="-sec-ix-hidden:hidden50658326">10</span>% to <span style="-sec-ix-hidden:hidden50658327">12</span>%. The future payments are based on significant inputs that are not observable in the market which are subject to remeasurement at each reporting date. The estimates of fair value may not be indicative of the amounts that could ultimately be paid by Dermavant to NovaQuest. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares issued as part of the Business Combination was calculated using the Monte Carlo simulation method under the income approach. The model was structured to include the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> periods to which the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares are subject. Refer to Note 3, &#8220;Business Combination with MAAC&#8221; for additional details. Significant unobservable inputs used to calculate the fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares included the following: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 25%; vertical-align: bottom;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Point&#160;Estimate&#160;Used</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Input</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;31,&#160;2022</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">82.3%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2.43%</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of March&#160;31, 2022, the fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares was $9.2&#160;million. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares are included in &#8220;Liability instruments measured at fair value&#8221; in the accompanying consolidated balance sheets. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private Placement Warrants </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Private Placement Warrants issued as part of the Business Combination was calculated using the Monte Carlo simulation method under the income approach. The model was structured to incorporate the redemption features as discussed in Note 3, &#8220;Business Combination with MAAC&#8221; and the added restriction by which the Company cannot redeem the Private Warrants if the Reference Value is greater than $18.00. Significant unobservable inputs used to calculate the fair value of the Private Placement Warrants included the following: </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 25%; vertical-align: bottom;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Point&#160;Estimate&#160;Used</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Input</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;31,&#160;2022</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">56.5%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2.43%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term (in years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">4.50</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, the fair value of the Private Placement Warrants was $9.1&#160;million. The Private Placement Warrants are included in &#8220;Liability instruments measured at fair value&#8221; in the accompanying consolidated balance sheets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sumitomo Options </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to termination in June 2021, the fair value of the options to acquire the Company&#8217;s interest in certain of its subsidiaries, which were granted to Sumitomo under the Sumitomo Transaction Agreement, was calculated using significant unobservable inputs including the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Range&#160;or&#160;Point<br/> Estimate Used</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Input</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time to expiration (in years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: center;">3.59</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: center;">0.52%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">89.0%&#160;-&#160;95.0</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, the Company completed a transaction with Sumitomo pursuant to which Sumitomo terminated all of its existing options to acquire the Company&#8217;s equity interests in certain subsidiaries. As of March&#160;31, 2021, the fair value of the Sumitomo Options was $62.4&#160;million, which is included in &#8220;Liability instruments measured at fair value&#8221; in the accompanying consolidated balance sheets. See Note 8, &#8220;Related Party Transactions&#8221; for additional information. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=roiv_RoivantSciencesLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=roiv_RoivantSciencesLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724309547824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expense, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeAndExpenseTextBlock', window );">Other Expense, Net</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 15&#8212;Other Expense, Net </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense, net was as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from equity method investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,750</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(369</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,418</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,041</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,809</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,237</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,560</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,435</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,701</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other operating income and other operating expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724312055632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 16&#8212;Net Loss per Common Share </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">Basic net loss per common share is computed by dividing net loss attributable to Roivant Sciences Ltd. by the weighted-average number of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to Roivant Sciences Ltd. by the diluted weighted-average number of common stock outstanding during the period.</div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">For periods of loss, diluted loss per share is calculated similar to basic loss per share as the effect of including all potentially dilutive common stock equivalents is anti-dilutive. All outstanding common stock equivalents have been excluded from the computation of diluted loss per share because their effect was anti-dilutive due to the net loss.</div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022 and 2021, potentially dilutive securities were as follows: </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options and performance stock options</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80,364,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69,687,308</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Restricted stock units and performance stock units <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(non-vested)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,956,749</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,294,028</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">March 2020 CVARs<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,011,996</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,447,626</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">November 2021 CVARs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,285,250</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Restricted <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">stock</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(non-vested)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">741,405</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,720,090</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(non-vested)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,080,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private Placement Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,214,365</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,475,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other instruments issued</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,103,577</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,458,543</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Refer to Note 10, &#8220;Share-Based Compensation&#8221; for details regarding settlement of CVARs. </div></div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724312028352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 17&#8212;Subsequent Events </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In May 2022, VTAMA (tapinarof) cream was approved by the FDA as the first and only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> steroid-free topical medication in its class for the treatment of plaque psoriasis in adult patients. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the approval of VTAMA cream by the FDA in May 2022, Dermavant received $160.0&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million in June 2022 pursuant to the terms of the RIPSA as described in Note 7, &#8220;Long-Term Debt and Loan Commitment.&#8221; </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Also, as a result of FDA approval, Dermavant achieved a regulatory milestone to GSK of &#163;100.0&#160;million (approximately $126 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million on the date of achievement), which will be paid within</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;70 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">calendar days of FDA approval. Additionally, the first sale of VTAMA cream in May 2022 resulted in the achievement of a milestone to Welichem Biotech Inc. of CAD$</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">25.0&#160;million (approximately $20 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">million on the date of achievement), which will be paid within</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> 60 calendar days of the invoice date. Dermavant intends to primarily use the RIPSA proceeds for the payment of these obligations. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724307351040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Basis of Presentation and Principles of Consolidation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s fiscal year ends on March&#160;31, and its fiscal quarters end on June&#160;30, September&#160;30, and December 31. </div></div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying audited consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).&#160;&#160;&#160;&#160; </div></div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the accounts of RSL and the subsidiaries in which it has a controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of common stock ownership interest retained in the respective operations by the noncontrolling parties. The Company presents noncontrolling interests as a component of shareholders&#8217; equity on its consolidated balance sheets. </div></div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for changes in its ownership interest in its subsidiaries while control is retained as equity transactions. The carrying amount of the noncontrolling interest is adjusted to reflect the change in RSL&#8217;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received or paid and the amount by which the noncontrolling interest is adjusted is recognized within shareholders&#8217; equity attributable to RSL. </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Use of Estimates </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </div></div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Additionally, the Company assessed the impact that the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> pandemic has had on its operations and financial results as of March&#160;31, 2022 and through the issuance of these consolidated financial statements. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses. </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Concentrations</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">T</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">he Company has long-lived assets in different geographic locations. As of March 31, 2022 and 2021, a majority of the Company&#8217;s long-lived assets were located in the United States. </div></div></div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">(D) Cash, Cash Equivalents, and Restricted Cash </div></div></div></div> <div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company considers all highly liquid investments purchased with original maturities of three months or less to</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> be cash equivalents. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash classified as a current asset consists of legally restricted </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> bearing deposit accounts relating to the Company&#8217;s corporate credit card programs. Restricted cash classified as a long-term asset consists of restricted deposit accounts related to irrevocable standby letters of credit. As of March&#160;31, 2021, restricted cash classified as a current asset included $</div>75.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million held in escrow for the purpose of fulfilling certain indemnification obligations. The full escrow amount of $</div>75.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was disbursed to the Company in June 2021.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash as reported in the accompanying consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the accompanying consolidated balance sheets as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,060,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,055,044</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,634</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,632</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,074,034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,141,676</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(E) Contingencies </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible. </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(F) Property and Equipment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, consisting primarily of computers, laboratory and other equipment, furniture and fixtures, software, and leasehold improvements, is recorded at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement or sale, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation of property and equipment is recorded using the straight-line method over the estimated useful lives of the related assets once the asset has been placed in service. Leasehold improvements are amortized using the straight-line method over the estimated useful life or remaining lease term, whichever is shorter. The following table provides the range of estimated useful lives used for each asset type: </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 39%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 59%; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated Useful Life</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computers</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">3 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory&#160;and&#160;other&#160;equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">5 - 10 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">7 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Software</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">3 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Lesser of estimated useful life or remaining lease term</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company reviews the recoverability of all long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable. Recoverability is measured by comparison of the book values of the assets to the future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets.</div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(G<div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">)</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> Investments </div></div></div></div> <div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Investments in equity securities may be accounted for using (i)&#160;the fair value option if elected, (ii)&#160;fair value through earnings if fair value is readily determinable or (iii)&#160;for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the measurement alternative is made for each eligible investment. </div></div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company has elected the fair value option to account for certain investments over which the Company has significant influence. The Company believes the fair value option best reflects the underlying economics of the investment. See Note 4, &#8220;Investments.&#8221; </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(H) Research and Development Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. Preclinical and clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. R&amp;D costs primarily consist of costs associated with preclinical studies and clinical trials, including amounts paid to contract research organizations, contract manufacturing organizations, and other third parties that conduct R&amp;D activities on behalf of the Company, as well as employee-related expenses, such as salaries, share-based compensation, and benefits, for employees engaged in R&amp;D activities. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired&#160;In-Process&#160;Research and Development Expenses</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">(I) Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Process</div> Research and Development Expenses </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">For the year ended March&#160;31, 2022, the Company began reporting acquired </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in-process</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> research and development (&#8220;IPR&amp;D&#8221;) expense as a separate line item in its consolidated statements of operations. Acquired IPR&amp;D expenses include consideration for the purchase of IPR&amp;D through asset acquisitions and license agreements as well as payments made in connection with asset acquisitions and license agreements upon the achievement of development milestones. These expenses were previously recorded in &#8220;Research and development&#8221; on the consolidated statements of operations. Prior periods have been revised to conform to the current period presentation. </div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> agreements for </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in-process</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> research and development projects (&#8220;IPR&amp;D&#8221;) to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> agreement for IPR&amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as acquired </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in-process</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> research and development expense in its consolidated statements of operations. Payments for milestones achieved and payments for a product license prior to regulatory approval of the product are expensed in the period incurred. Milestone payments made in connection with regulatory approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset. </div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(J) General and Administrative Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">General and administrative (&#8220;G&amp;A&#8221;) expenses consist primarily of employee-related expenses for G&amp;A personnel, including those responsible for the identification and acquisition or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> of new drug candidates as well as for overseeing Vant operations and facilitating the use of the Company&#8217;s platform and technologies at Vants. G&amp;A expenses also consist of legal and accounting fees, consulting services and other operating costs </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">relating to corporate matters and daily operations. G&amp;A expenses include costs incurred relating to the identification, acquisition or </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in-license</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> and technology transfer of promising drug candidates along with costs incurred relating to the integration of new technologies.</div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">(K) Leases </div></div></div></div> <div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company determines if an arrangement includes a lease at the inception of the agreement. For each of the Company&#8217;s lease arrangements, the Company records a </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> asset representing the Company&#8217;s right to use an underlying asset for the lease term and a lease liability representing the Company&#8217;s obligation to make lease payments. Operating lease </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> assets and operating lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the expected lease term. If the interest rate implicit in the Company&#8217;s leases is not readily determinable, in determining the weighted-average discount rate used to</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> calculate the net present value of lease payments, the Company utilizes an estimate of its incremental borrowing rate. The Company&#8217;s incremental borrowing rates are determined based on the term of the lease, the economic environment of the lease, and the effect of collateralization. Lease expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term and variable lease costs are expensed as incurred. </div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company elected the practical expedient not to apply the recognition and measurement requirements to short-term leases, which is any lease with a term of one year or less as of the lease commencement date. Leases may require the Company to pay additional amounts for taxes, insurance, maintenance, and other expenses, which are generally referred to as </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> components. The Company has elected the practical expedient to combine lease and </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> components. If a lease includes options to extend the lease term, the Company does not assume the option will be exercised in its initial lease term assessment unless there is reasonable certainty that the Company will renew based on an assessment of economic factors present as of the lease commencement date. </div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">(L) Income Taxes </div></div></div></div> <div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded when, after consideration of all positive and negative evidence, it is not more likely than not that the Company&#8217;s deferred tax assets will be realizable. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </div></div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(M) Share-Based Compensation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based awards to employees, directors, and consultants, including stock options, restricted stock units, performance options and capped value appreciation rights, are measured at fair value on the date of the grant and that fair value is recognized as share-based compensation expense in the Company&#8217;s consolidated statements of operations over the requisite service period of the respective award. The estimated fair value of awards that contain performance conditions is expensed when the Company concludes that it is probable that the </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">performance condition will be achieved. The Company may grant awards with graded-vesting features. When such awards have only service vesting requirements, the Company elected to record share-based compensation expense on a straight-line basis. If awards with graded-vesting features contain performance or market conditions, then the Company records share-based compensation expense using the accelerated attribution method. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">The Company measures the fair value of its stock options that only have service vesting requirements or performance-based options without market conditions using the Black-Scholes option pricing model. For performance-based awards with market conditions, the Company determines the fair value of the awards as of the grant date using a Monte Carlo simulation model. When determining the grant-date fair value of stock-based awards, management further considers whether an adjustment is required to the observable market price or volatility of the Company&#8217;s common stock that is used in the valuation as a result of material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-public</div> information, if that information is expected to result in a material increase in share price. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Certain assumptions need to be made with respect to utilizing the Black-Scholes option pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate and the fair value of the Company&#8217;s shares of common stock. Since the Company has limited option exercise history, it has generally elected to estimate the expected life of an award based upon the &#8220;simplified method&#8221; with the continued use of this method extended until such time the Company has sufficient exercise history. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. The expected share price volatility for the Company&#8217;s common shares is estimated by taking the average historical price volatility for industry peers. The Company accounts for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-vesting</div> award forfeitures when they occur. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">One of the inputs to the Black-Scholes option pricing model is the fair value of the Company&#8217;s common shares. Prior to the closing of its business combination with MAAC, as a privately held company, the Company estimated the fair value of the shares of common stock underlying its share-based awards on each grant date. Given the absence of a public trading market, and in accordance with the American Institute of Certified Public Accountants&#8217; Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, the Company exercised reasonable judgment and considered numerous objective and subjective factors to determine its best estimate of the fair value of its common shares. The estimation of the fair value of the common shares considered factors including the following: the prices of the Company&#8217;s common shares sold to investors in arm&#8217;s length transactions; the estimated present value of the Company&#8217;s future cash flows; the Company&#8217;s business, financial condition and results of operations; the Company&#8217;s forecasted operating performance; the illiquid nature of the Company&#8217;s common shares; industry information such as market size and growth; market capitalization of comparable companies and the estimated value of transactions such companies have engaged in; and macroeconomic conditions. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies a similar methodology to estimate the fair value of the shares of common stock underlying share-based awards issued by its privately held Vants. Following the closing of the Company&#8217;s business combination with MAAC, RSL&#8217;s common shares became publicly traded and the Company began determining the fair value of each common share underlying share-based awards based on the closing price of its common shares as reported by Nasdaq on the date of grant. Therefore, it will not be necessary to determine the fair value of the new stock-based award pursuant to the methodology described above. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="background: none; letter-spacing: 0px; top: 0px; text-decoration: none;;display:inline;"> </div></div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">(N) Fair Value Measurements </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs</div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a three-tier fair value hierarchy that distinguishes among the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-Valuations</div> are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-Valuations</div> are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-Valuations</div> are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s financial instruments include shares of common stock of Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;); shares of common stock of Sio Gene Therapies Inc. (&#8220;Sio&#8221;); shares of common stock of Heracles Parent, L.L.C., the parent entity of Datavant (as defined and discussed in Note 4, &#8220;Investments&#8221;); liability instruments issued, including the Roivant Warrants and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares (each as defined in Note 3, &#8220;Business Combination with MAAC&#8221;) liabilities issued in connection with the Company&#8217;s business combination with MAAC (as discussed in Note 3, &#8220;Business Combination with MAAC&#8221;); the deferred consideration liability; its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and long-term debt. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The shares of Arbutus and Sio common stock and investments in common stock with a readily determinable fair value are classified as Level&#160;1, and their fair value is determined based upon quoted market prices in an active market. In October 2021, shares of Arbutus&#8217; Series A participating convertible preferred shares (&#8220;Arbutus Preferred Shares&#8221;) held by the Company were converted into shares of common stock of Arbutus pursuant to mandatory conversion provisions. Prior to conversion, the Arbutus Preferred Shares held by the Company were classified as Level&#160;2 as the fair value of such preferred shares was determined based upon the quoted market price of Arbutus common stock into which such preferred shares were convertible. The shares of common stock of Heracles Parent, L.L.C., the parent entity of Datavant (as defined and discussed in Note 4, &#8220;Investments&#8221;), and liability instruments issued, excluding the Public Warrants (as defined and discussed in Note 3, &#8220;Business Combination with MAAC&#8221;), are classified as Level&#160;3 within the fair value hierarchy as the assumptions and estimates used in the valuations are unobservable in the market. The Public Warrants are publicly traded and therefore are classified as Level&#160;1 as the Public Warrants have a readily determinable fair value. Cash, accounts payable, and the deferred consideration liability are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature. The deferred consideration liability was based on a fixed monetary amount, and payment was based solely on the passage of time. The deferred consideration liability was settled in November 2021 by payment of $50.0&#160;million in cash as well as the issuance of 6,348,057 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the Company&#8217;s <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>hares. Money market funds are included in Level&#160;1 of the fair value hierarchy and are valued at the closing price reported by an actively traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly owned subsidiaries, &#8220;Dermavant&#8221;), which is stated at amortized cost, approximates fair value based on current interest rates for similar types of borrowings and therefore is included in Level&#160;2 of the fair value hierarchy. Long-term debt issued by Dermavant for which the </div></div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fair value option has been elected is included in Level&#160;3 of the fair value hierarchy as the assumptions and estimates used in the valuation are unobservable in the market. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(O) Foreign Currency </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and liabilities of foreign operations are translated using exchange rates in effect at the balance sheet date and their results of operations are translated using average exchange rates for the year. Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Adjustments resulting from the translation of the financial statements of the Company&#8217;s foreign functional currency subsidiaries into U.S. dollars are excluded from the determination of net loss and are accumulated in a separate component of shareholders&#8217; equity. Foreign exchange transaction gains and losses are included in &#8220;Other expense, net&#8221; in the Company&#8217;s statements of operations. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(P) Revenue Recognition </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes revenue when its customer <div style="letter-spacing: 0px; top: 0px;;display:inline;">obtains </div>control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for its arrangements, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when or as the Company satisfies a performance obligation. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, assessing the recognition and future reversal of variable consideration, and determining and applying appropriate methods of measuring progress for performance obligations satisfied over time. These judgments are discussed in more detail below. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licenses of intellectual property:</div></div> If the licenses to intellectual property are determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are not distinct from other promises, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition accordingly. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Milestone payments: </div></div>At the inception of each arrangement that includes research, development or regulatory milestone payments, the Company<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis in earnings in the period of the adjustment. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalties and commercial milestone payments: </div></div>For arrangements that include sales-based royalties, including commercial milestone payments<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>based on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-specified</div> level of sales, the Company </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon performance of the licensee. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue is also generated by certain technology-focused Vants from subscription and service-based fees recognized for the use of certain technology developed by these Vants. Subscription revenue is recognized ratably over the contract period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade Receivables, Net </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in customer credit profiles. The Company reserves against trade receivables for estimated losses that may arise from a customer&#8217;s inability to pay, and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated losses was de minimis as of March&#160;31, 2022 and 2021. Trade receivables, net is included in &#8220;Other current assets&#8221; on the accompanying consolidated balance sheets. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_WarrantliabilitiesPolicyTextBlock', window );">Warrant Liabilities</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Q) Warrant Liabilities </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company classifies the Roivant Warrants as liabilities. At the end of each reporting period, changes in fair value during the period are recognized within the consolidated statements of operations. The Company will continue to adjust the carrying value of the liability associated with the Roivant Warrants for changes in the fair value until the earlier of a) the exercise or expiration of the Roivant Warrants or b) the redemption of the Roivant Warrants. Issuance costs incurred that were attributable to the Roivant Warrants were expensed as incurred. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(R) Recently Adopted Accounting Pronouncements </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06,</div> &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06&#8221;).</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current U.S. GAAP. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> also removes certain settlement conditions that are required for equity contracts to qualify for the derivatives scope exception, which will permit more equity contracts to qualify for it. Either a modified retrospective transition method or a fully retrospective transition method is permissible for the adoption of this standard. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> is effective for fiscal years beginning after December&#160;15, 2021, including interim periods within those fiscal years. The early-adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> on April&#160;1, 2021 did not have a material impact on the Company&#8217;s consolidated financial statements. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General and Administrative Expenses, Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_GeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_WarrantliabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant liabilities .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_WarrantliabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724309629696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Aggregate Amounts of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash as reported in the accompanying consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the accompanying consolidated balance sheets as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,060,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,055,044</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,634</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,632</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,074,034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,141,676</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Schedule of Estimated Useful Lives Used for Asset Type</a></td>
<td class="text">The following table provides the range of estimated useful lives used for each asset type: <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 39%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 59%; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated Useful Life</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computers</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">3 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory&#160;and&#160;other&#160;equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">5 - 10 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">7 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Software</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">3 years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Lesser of estimated useful life or remaining lease term</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Property Plant And Equipment Estimated Useful Lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724315398288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses at March&#160;31, 2022 and 2021 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">66,188</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,755</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation-related expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,262</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,552</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other general and administrative expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,081</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,629</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">127,531</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,936</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724301852448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt and Loan Commitment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Long Term Debt</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt, net consists of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal amount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">217,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exit fee / end of term charge</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,390</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: unamortized debt discount and issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,375</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total debt, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">210,025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170,280</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total long-term debt, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">210,025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170,280</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of Company's Annual Payments</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Annual maturities, including the exit fee, of debt outstanding as of&#160;March&#160;31, 2022&#160;are as follows (in thousands). Long term debt issued by Dermavant for which the fair value option has been elected is excluded from the below as the repayment terms are variable. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ending March&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph (a)<br> -Subparagraph (5)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724307326432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company estimated the fair value of each stock option on the date of grant using the Black-Scholes closed form option-pricing model applying the weighted average assumptions in the following table. No performance stock options were granted during the years ended March&#160;31, 2022 and 2021. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assumptions</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock price volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">81.70</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74.84</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected risk free interest rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.13</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.43</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term, in years</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Activity for stock options and performance stock options under the RSL Equity Plans for the year ended March&#160;31, 2022 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual&#160;Life<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic&#160;Value<br/> (in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options outstanding at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69,687,308</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.64</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,181,127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(101,436</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Canceled</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,402,095</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options outstanding at March&#160;31, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80,364,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.37</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,899</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options exercisable at March&#160;31, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39,236,351</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,456</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Units</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Activity for restricted stock units and performance stock units under the RSL Equity Plans for the year ended March&#160;31, 2022 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;Restricted<br/> Stock Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/> Grant Date Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,294,028</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,948,227</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.44</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,111,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,173,956</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.79</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2022</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,956,749</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock', window );">Summary of Fair Value of Vested Stock Option</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional information regarding stock options and performance stock options is set forth below (in thousands, except per share data). </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intrinsic value of options exercised</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Grant date fair value of options vested</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">210,487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,711</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average grant date fair value per share of stock options granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.85</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.67</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Share-Based Compensation Expense</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense was as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense recognized as:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63,735</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,637</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">501,221</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,321</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">564,956</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84,958</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember', window );">CVARs [Member] | 2015 EIP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock', window );">Summary of Capped Value Appreciation Rights</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Activity</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">for CVARs under the RSL 2015 EIP for the year ended March&#160;31, 2022 is as follows:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;CVARs</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-service-vested</div> CVARs balance at March&#160;31, 2021</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,447,626</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.72</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service-vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,213,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(435,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-service-vested</div> CVARs balance at March&#160;31, 2022</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,798,086</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember', window );">CVARs [Member] | 2021 EIP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock', window );">Summary of Capped Value Appreciation Rights</a></td>
<td class="text"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Activity for CVARs under the RSL 2021 EIP for the year ended March&#160;31, 2022 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;CVARs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,317,350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(32,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.71</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2022</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,285,250</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Capped Value Appreciation Rights Activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule&#8203; Of Share based &#8203;Payment &#8203;Arrangement&#8203; Fair&#8203; Value&#8203; Of Vested &#8203;Stock &#8203;Option &#8203;And Performance Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_TwoThousandTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_TwoThousandTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724301885200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss Before Income Taxes and Related Expense/(Benefit)</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The loss before income taxes and the related expense/(benefit) are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bermuda<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">390,831</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(227,471</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(747,953</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(212,921</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Switzerland</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(544,870</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(424,494</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21,755</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(33,661</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total loss before income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(923,747</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(898,547</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily entities which are centrally managed and controlled in the United Kingdom </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily Greater China and United Kingdom activity </div></div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current taxes:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bermuda</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(223</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,365</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Switzerland</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">592</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">321</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">369</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred taxes:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bermuda</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Switzerland</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total income tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">369</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Federal Statutory Income Taxes Rate</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of income tax provision/(benefit) computed at the Bermuda statutory rate to income tax expense reflected in the consolidated financial statements is as follows (in thousands, except percentages): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit at Bermuda statutory rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign rate differential<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(179,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.38</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(150,778</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.78</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Permanent disallowed IPR&amp;D</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,347</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.66</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">111,432</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Tax-effect</div> of changes in the fair value of investments and loss from equity method investment</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,169</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.64</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nontaxable gain on sale of investment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(84,313</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.13</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nontaxable gain on deconsolidation of business</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(958</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.83</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nondeductible executive compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,973</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2.81</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">905</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Tax deficiencies (excess tax benefits) from share-based compensation</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,918</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(439</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.05</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other permanent adjustments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,912</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.18</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,457</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research tax credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,113</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.09</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,555</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">205,811</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85,046</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9.46</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax rate changes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,444</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,443</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,933</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.97</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total income tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">369</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily related to operations in the United States, Switzerland, the United Kingdom, and other jurisdictions with statutory tax rates different than the Bermuda rate. </div></div></div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Company's net deferred tax assets</a></td>
<td class="text">Significant components of the deferred tax assets (liabilities) at March&#160;31, 2022 and 2021 are as follows (in thousands):<div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research tax credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,155</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,063</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61,544</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,564</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">312,749</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">202,906</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93,177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,623</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,406</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,638</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,651</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,303</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subtotal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">530,682</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">323,097</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(512,736</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(303,287</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,397</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,214</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,661</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,908</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,888</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,688</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets/(liabilities)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724307807664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Operating Lease Costs</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of operating lease expense for the Company were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,649</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,931</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">326</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">237</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,227</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">704</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,202</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Summary of Operating Lease ROU Assets and Operating Lease Liabilities</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px;;display:inline;">Information related to the Company&#8217;s operating lease right-of-use assets and operating lease liabilities was as follows (in thousands, except periods and percentages):&#160;</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">During&#160;the&#160;Year&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,830</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,035</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;202<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, maturities of operating lease liabilities were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ending March&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,714</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,672</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,455</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,363</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,680</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46,783</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100,667</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: present value adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(24,996</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: tenant improvement allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,805</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73,866</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724311058064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of&#160;March&#160;31, 2022 and 2021, by level, within the fair value hierarchy (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 33%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;as&#160;of<br/> March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;as&#160;of<br/> March&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,297,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,297,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,420,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,420,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Datavant Class&#160;A units</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193,963</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193,963</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Sio common shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,447</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,447</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Arbutus common shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115,765</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115,765</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Arbutus convertible preferred shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other investments</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,659</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,659</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,429,715</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193,963</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,623,678</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,533,538</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,609,575</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt issued by Dermavant to NovaQuest</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments measured at fair value<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,893</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,912</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,893</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,893</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">204,293</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">222,312</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">217,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">217,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">At March&#160;31, 2022, Level&#160;1 includes the fair value of the Public Warrants of $18.0&#160;million, and Level&#160;3 includes the fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares of $9.2&#160;million, Private Placement Warrants of $9.1&#160;million, and other liability instruments issued of $8.6&#160;million. At March&#160;31, 2021, Level&#160;3 includes the fair value of the Sumitomo Options of $62.4&#160;million and other liability instrument issued of $5.5&#160;million. </div></td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Change IN Fair Value Of The Level 3 Assets</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in fair value of the Level&#160;3 assets during the&#160;year ended March&#160;31, 2022&#160;were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of investment in Datavant at recognition date</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">224,147</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of investment in Datavant, included in net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,184</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193,963</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of change in the fair value of the derivative warrant liabilities</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no Level&#160;3 assets held during the year ended March&#160;31, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in fair value of the Level&#160;3 liabilities during the&#160;years ended March&#160;31, 2022 and 2021 were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">191,473</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of debt and liability instruments, included in net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments disposed due to deconsolidation of subsidiary</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">217,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of liability instrument issued</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,634</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of debt and liability instruments, included in net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,226</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Settlements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(88</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Termination of DSP Options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(61,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">204,293</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value of Significant Unobservable Inputs Using Valuation Techniques</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Private Placement Warrants issued as part of the Business Combination was calculated using the Monte Carlo simulation method under the income approach. The model was structured to incorporate the redemption features as discussed in Note 3, &#8220;Business Combination with MAAC&#8221; and the added restriction by which the Company cannot redeem the Private Warrants if the Reference Value is greater than $18.00. Significant unobservable inputs used to calculate the fair value of the Private Placement Warrants included the following: </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 25%; vertical-align: bottom;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Point&#160;Estimate&#160;Used</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Input</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;31,&#160;2022</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">56.5%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2.43%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term (in years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">4.50</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=roiv_EarnoutSharesMember', window );">Earnout Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value of Significant Unobservable Inputs Using Valuation Techniques</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares issued as part of the Business Combination was calculated using the Monte Carlo simulation method under the income approach. The model was structured to include the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> periods to which the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares are subject. Refer to Note 3, &#8220;Business Combination with MAAC&#8221; for additional details. Significant unobservable inputs used to calculate the fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares included the following: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 25%; vertical-align: bottom;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Point&#160;Estimate&#160;Used</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Input</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;31,&#160;2022</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">82.3%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2.43%</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_DatavantMember', window );">Datavant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value of Significant Unobservable Inputs Using Valuation Techniques</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company elected the fair value option to account for the investment in Datavant. The estimate of fair value for this investment was determined using the income approach and implementation of the option pricing method (&#8220;OPM&#8221;). The OPM allows for the allocation of a company&#8217;s equity value among the various equity capital owners (preferred and common shareholders). The OPM uses the preferred shareholders&#8217; liquidation preferences, participation rights, dividend policy, and conversion rights to determine how proceeds from a liquidity event shall be distributed among the various ownership classes at a future date. The fair value was calculated using significant unobservable inputs including the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 23%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Point Estimate Used</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Input</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.62</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_SumitomoOptionsMember', window );">Sumitomo Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value of Significant Unobservable Inputs Using Valuation Techniques</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to termination in June 2021, the fair value of the options to acquire the Company&#8217;s interest in certain of its subsidiaries, which were granted to Sumitomo under the Sumitomo Transaction Agreement, was calculated using significant unobservable inputs including the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Range&#160;or&#160;Point<br/> Estimate Used</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Input</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time to expiration (in years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: center;">3.59</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: center;">0.52%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">89.0%&#160;-&#160;95.0</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=roiv_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=roiv_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=roiv_DatavantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=roiv_DatavantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=roiv_SumitomoOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=roiv_SumitomoOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724307744976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expense, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock', window );">Summary of Other Expense, Net From Continuing Operations</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense, net was as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from equity method investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,750</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(369</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,418</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,041</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,809</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,237</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,560</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,435</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,701</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724309037440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of potentially dilutive securities</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022 and 2021, potentially dilutive securities were as follows: </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options and performance stock options</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80,364,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69,687,308</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Restricted stock units and performance stock units <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(non-vested)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,956,749</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,294,028</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">March 2020 CVARs<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,011,996</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,447,626</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">November 2021 CVARs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,285,250</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Restricted <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ommon <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">stock</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(non-vested)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">741,405</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,720,090</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(non-vested)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,080,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private Placement Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,214,365</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,475,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other instruments issued</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,103,577</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,458,543</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Refer to Note 10, &#8220;Share-Based Compensation&#8221; for details regarding settlement of CVARs. </div></div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724302328320">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Liquidity - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating and reporting segments | Segment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,060,400<span></span>
</td>
<td class="nump">$ 2,055,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(2,763,724)<span></span>
</td>
<td class="num">(1,918,462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (924,116)<span></span>
</td>
<td class="num">$ (900,233)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for the stock subdivision as described in Note 3.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724307302656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Nov. 01, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ScheduleOfAccountingPoliciesLineItems', window );"><strong>Schedule Of Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrowed deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ProceedsFromReleaseOfEscrowDeposit', window );">Proceeds from release of escrow deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_CashPaidToSettleDeferredConsiderationLiability', window );">Cash paid to settle deferred consideration liability</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ScheduleOfAccountingPoliciesLineItems', window );"><strong>Schedule Of Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability', window );">Stock issued during period shares to settle deferred consideration liability</a></td>
<td class="nump">6,348,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CashPaidToSettleDeferredConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid to settle deferred consideration liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CashPaidToSettleDeferredConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ProceedsFromReleaseOfEscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Release of Escrow Deposit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ProceedsFromReleaseOfEscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ScheduleOfAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ScheduleOfAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period Shares To settle deferred consideration liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724307858592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Aggregate Amounts of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,060,400<span></span>
</td>
<td class="nump">$ 2,055,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">13,634<span></span>
</td>
<td class="nump">86,632<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_CashAndCashEquivalentsAndRestrictedCash', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 2,074,034<span></span>
</td>
<td class="nump">$ 2,141,676<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CashAndCashEquivalentsAndRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CashAndCashEquivalentsAndRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724311028096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=roiv_LaboratoryandotherequipmentMember', window );">Laboratory&#160;and&#160;other&#160;equipment | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=roiv_LaboratoryandotherequipmentMember', window );">Laboratory&#160;and&#160;other&#160;equipment | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful lives</a></td>
<td class="text">Lesser of estimated useful life or remaining lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=roiv_LaboratoryandotherequipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=roiv_LaboratoryandotherequipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724300248192">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Business Combination with MAAC -  Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 57,167<span></span>
</td>
<td class="nump">$ 301,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_CommonStockWarrants', window );">Common Stock Warrants | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=roiv_RoivantCommonSharesMember', window );">Roivant Common Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_StockholdersEquityNoteStockSplitExchangeRatio1', window );">Stockholders Equity Note Stock Split Exchange Ratio 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.9262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=roiv_RoivantCommonSharesMember', window );">Roivant Common Shares [Member] | Sponsor Support Agreement [Member] | Share Price Equal or Exceeds Fifteen Dollar [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Numberoftradingdaystomeetearnoutpricethreshold', window );">Number of trading days to meet earn out price threshold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Tradingdayperiodforearnoutshares', window );">Trading day period for earn out shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_EarnOutSharePrice', window );">Earn-Out share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=roiv_RoivantCommonSharesMember', window );">Roivant Common Shares [Member] | Sponsor Support Agreement [Member] | Share Price Equal or Exceeds Twenty Dollar [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Tradingdayperiodforearnoutshares', window );">Trading day period for earn out shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_EarnOutSharePrice', window );">Earn-Out share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=roiv_MaacIndependentDirectorMember', window );">MAAC Independent Director [Member] | Sponsor Support Agreement [Member] | Share Price Equal or Exceeds Fifteen Dollar [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=roiv_MaacIndependentDirectorMember', window );">MAAC Independent Director [Member] | Sponsor Support Agreement [Member] | Share Price Equal or Exceeds Twenty Dollar [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_MaacSponsorMember', window );">MAAC Sponsor [Member] | Sponsor Support Agreement [Member] | Share Price Equal or Exceeds Fifteen Dollar [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,033,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_MaacSponsorMember', window );">MAAC Sponsor [Member] | Sponsor Support Agreement [Member] | Share Price Equal or Exceeds Twenty Dollar [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,016,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_MaacSponsorMember', window );">MAAC Sponsor [Member] | Roivant Common Shares [Member] | Sponsor Support Agreement [Member] | Share Price Equal or Exceeds Fifteen Dollar [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Portionofsharesubjecttoearnout', window );">Portion of Share Subject to Earnout</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_MaacSponsorMember', window );">MAAC Sponsor [Member] | MAAC Independent Director [Member] | Sponsor Support Agreement [Member] | Share Price Equal or Exceeds Twenty Dollar [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Portionofsharesubjecttoearnout', window );">Portion of Share Subject to Earnout</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_MaacSponsorMember', window );">MAAC Sponsor [Member] | MAAC Independent Director [Member] | Sponsor Support Agreement [Member] | Share Price Equal or Exceeds Ten Dollar [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Portionofsharesubjecttoearnout', window );">Portion of Share Subject to Earnout</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_MaacSponsorMember', window );">MAAC Sponsor [Member] | MAAC Independent Director [Member] | Roivant Common Shares [Member] | Lock Up Period One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime', window );">Percentage of shares subject to lock-up for defined period of time</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Lockupperiodofcommonshares', window );">Lock Up Period of Common Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_MaacSponsorMember', window );">MAAC Sponsor [Member] | MAAC Independent Director [Member] | Roivant Common Shares [Member] | Lock Up Period Two [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime', window );">Percentage of shares subject to lock-up for defined period of time</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_MaacSponsorMember', window );">MAAC Sponsor [Member] | MAAC Independent Director [Member] | Roivant Common Shares [Member] | Lock Up Period Two [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Lockupperiodofcommonshares', window );">Lock Up Period of Common Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_MaacSponsorMember', window );">MAAC Sponsor [Member] | MAAC Independent Director [Member] | Roivant Common Shares [Member] | Lock Up Period Two [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Lockupperiodofcommonshares', window );">Lock Up Period of Common Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_MaacSponsorMember', window );">MAAC Sponsor [Member] | MAAC Independent Director [Member] | Roivant Common Shares [Member] | Lock Up Period Three [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime', window );">Percentage of shares subject to lock-up for defined period of time</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Lockupperiodofcommonshares', window );">Lock Up Period of Common Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_MaacSponsorMember', window );">MAAC Sponsor [Member] | MAAC Independent Director [Member] | Roivant Common Shares [Member] | Lock Up Period Four [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Percentageofwarrantssubjecttolockupfordefinedperiodoftime', window );">Percentage of warrants subject to lock-up for defined period of time</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Lockupperiodwarrants', window );">Lock up period ,warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_MaacSponsorMember', window );">MAAC Sponsor [Member] | MAAC Independent Director [Member] | Roivant Common Shares [Member] | Lock Up Period Five [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Percentageofwarrantssubjecttolockupfordefinedperiodoftime', window );">Percentage of warrants subject to lock-up for defined period of time</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Lockupperiodwarrants', window );">Lock up period ,warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_MaacSponsorMember', window );">MAAC Sponsor [Member] | MAAC Independent Director [Member] | Roivant Common Shares [Member] | Lock Up Period Six [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Percentageofwarrantssubjecttolockupfordefinedperiodoftime', window );">Percentage of warrants subject to lock-up for defined period of time</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Lockupperiodwarrants', window );">Lock up period ,warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_MaacSponsorMember', window );">MAAC Sponsor [Member] | MAAC Independent Director [Member] | Roivant Common Shares [Member] | Lock Up Period Seven [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime', window );">Percentage of shares subject to lock-up for defined period of time</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Lockupperiodofcommonshares', window );">Lock Up Period of Common Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_MaacSponsorMember', window );">MAAC Sponsor [Member] | MAAC Independent Director [Member] | Roivant Common Shares [Member] | Lock Up Period Eight [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime', window );">Percentage of shares subject to lock-up for defined period of time</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Lockupperiodofcommonshares', window );">Lock Up Period of Common Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_MaacSponsorMember', window );">MAAC Sponsor [Member] | MAAC Independent Director [Member] | Roivant Common Shares [Member] | Lock Up Period Nine [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime', window );">Percentage of shares subject to lock-up for defined period of time</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Lockupperiodofcommonshares', window );">Lock Up Period of Common Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_RoivantWarrantMember', window );">Roivant Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Timetowarrantexercisability', window );">Time To Warrant Exercisability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,214,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member] | Share Price Equal or Exceeds Eighteen Per Dollar [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Stockpricetriggerforredemptionofwarrants', window );">Stock price trigger for redemption of warrant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,535,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_RedemptionOfRoivantWarrantsMember', window );">Redemption of Roivant Warrants [Member] | Share Price Equal or Exceeds Eighteen Per Dollar [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Stockpricetriggerforredemptionofwarrants', window );">Stock price trigger for redemption of warrant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Numberoftradingdaystomeetwarrantredemptionthreshold', window );">Number of trading days to meet warrant redemption threshold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Tradingdayperiodforwarrantredemption', window );">Trading day period for warrant redemption</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Classofwarrantsredemptionpriceperunit', window );">Class of warrants, redemption price per unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Classofwarrantsredemptionnoticeperiod', window );">Class of warrants, redemption notice period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_RedemptionOfRoivantWarrantsMember', window );">Redemption of Roivant Warrants [Member] | Share Price Equal or Exceeds Ten Dollar [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Stockpricetriggerforredemptionofwarrants', window );">Stock price trigger for redemption of warrant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Classofwarrantsredemptionpriceperunit', window );">Class of warrants, redemption price per unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Classofwarrantsredemptionnoticeperiod', window );">Class of warrants, redemption notice period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_RedemptionOfRoivantWarrantsMember', window );">Redemption of Roivant Warrants [Member] | Roivant Common Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PeriodForFairMarketValueDetermination', window );">Period for fair market value determination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_MaximumRedemptionFeaturePerWarrant', window );">Maximum redemption feature per warrant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=roiv_MaacClassASharesMember', window );">Maac Class A Shares [Member] | Roivant Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Share Price Equal or Exceeds Eighteen Dollar [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Shareredemptiontriggerprice', window );">Share Redemption Trigger Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Roivant Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Timetowarrantexercisability', window );">Time To Warrant Exercisability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_MontesArchimedesAcquisitionCorpMember', window );">Montes Archimedes Acquisition Corp. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_StockholdersEquityNoteStockSplitExchangeRatio1', window );">Stockholders Equity Note Stock Split Exchange Ratio 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.9262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Allocationoftransactioncostsincurredtowarrantsandearnoutshares', window );">Allocation of transaction costs incurred to warrants and earn-out shares | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_MontesArchimedesAcquisitionCorpMember', window );">Montes Archimedes Acquisition Corp. [Member] | PIPE Financing [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash received | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">213,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_Costsincurredrelatedtofinancing', window );">Costs Incurred Related To Financing | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 24,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_MontesArchimedesAcquisitionCorpMember', window );">Montes Archimedes Acquisition Corp. [Member] | Maac Class B Shares [Member] | Roivant Common Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCombinationWithMAACLineItems', window );"><strong>Business Combination with M A A C [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ExchangeRatioOfMAACClassBToRoivantCommonShares', window );">Exchange Ratio Of MAAC Class B To Roivant Common Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for the stock subdivision as described in Note 3.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_Allocationoftransactioncostsincurredtowarrantsandearnoutshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allocation of transaction costs incurred to warrants and earn-out shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_Allocationoftransactioncostsincurredtowarrantsandearnoutshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_BusinessCombinationWithMAACLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination with M A A C .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_BusinessCombinationWithMAACLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_Classofwarrantsredemptionnoticeperiod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrants, redemption notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_Classofwarrantsredemptionnoticeperiod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_Classofwarrantsredemptionpriceperunit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrants, redemption price per unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_Classofwarrantsredemptionpriceperunit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_Costsincurredrelatedtofinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred related to financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_Costsincurredrelatedtofinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_EarnOutSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earn-Out share price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_EarnOutSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ExchangeRatioOfMAACClassBToRoivantCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exchange Ratio Of M A A C Class B To Roivant Common Shares .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ExchangeRatioOfMAACClassBToRoivantCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_Lockupperiodofcommonshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lock up period of common shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_Lockupperiodofcommonshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_Lockupperiodwarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lock up period ,warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_Lockupperiodwarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MaximumRedemptionFeaturePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum redemption feature per warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MaximumRedemptionFeaturePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_Numberoftradingdaystomeetearnoutpricethreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of trading days to meet earn out price threshold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_Numberoftradingdaystomeetearnoutpricethreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_Numberoftradingdaystomeetwarrantredemptionthreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of trading days to meet warrant redemption threshold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_Numberoftradingdaystomeetwarrantredemptionthreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares subject to lock-up for defined period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_Percentageofwarrantssubjecttolockupfordefinedperiodoftime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of warrants subject to lock-up for defined period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_Percentageofwarrantssubjecttolockupfordefinedperiodoftime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PeriodForFairMarketValueDetermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for fair market value determination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PeriodForFairMarketValueDetermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_Portionofsharesubjecttoearnout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of share subject to earnout.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_Portionofsharesubjecttoearnout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_Shareredemptiontriggerprice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share redemption trigger price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_Shareredemptiontriggerprice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockholdersEquityNoteStockSplitExchangeRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders equity note stock split exchange ratio 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockholdersEquityNoteStockSplitExchangeRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_Stockpricetriggerforredemptionofwarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock price trigger for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_Stockpricetriggerforredemptionofwarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_Timetowarrantexercisability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Time to warrant exercisability .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_Timetowarrantexercisability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_Tradingdayperiodforearnoutshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading day period for earn out shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_Tradingdayperiodforearnoutshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_Tradingdayperiodforwarrantredemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading day period for warrant redemption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_Tradingdayperiodforwarrantredemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=roiv_RoivantCommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=roiv_RoivantCommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_BusinessCombinationAgreementAxis=roiv_SponsorSupportAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_BusinessCombinationAgreementAxis=roiv_SponsorSupportAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_TriggeringEventAxis=roiv_SharePriceEqualOrExceedsFifteenDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_TriggeringEventAxis=roiv_SharePriceEqualOrExceedsFifteenDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_TriggeringEventAxis=roiv_SharePriceEqualOrExceedsTwentyDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_TriggeringEventAxis=roiv_SharePriceEqualOrExceedsTwentyDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=roiv_MaacIndependentDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=roiv_MaacIndependentDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_MaacSponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_MaacSponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_TriggeringEventAxis=roiv_SharePriceEqualOrExceedsTenDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_TriggeringEventAxis=roiv_SharePriceEqualOrExceedsTenDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_LockUpAgreementsAxis=roiv_LockUpPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_LockUpAgreementsAxis=roiv_LockUpPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_LockUpAgreementsAxis=roiv_LockUpPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_LockUpAgreementsAxis=roiv_LockUpPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_LockUpAgreementsAxis=roiv_LockUpPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_LockUpAgreementsAxis=roiv_LockUpPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_LockUpAgreementsAxis=roiv_LockUpPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_LockUpAgreementsAxis=roiv_LockUpPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_LockUpAgreementsAxis=roiv_LockUpPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_LockUpAgreementsAxis=roiv_LockUpPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_LockUpAgreementsAxis=roiv_LockUpPeriodSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_LockUpAgreementsAxis=roiv_LockUpPeriodSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_LockUpAgreementsAxis=roiv_LockUpPeriodSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_LockUpAgreementsAxis=roiv_LockUpPeriodSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_LockUpAgreementsAxis=roiv_LockUpPeriodEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_LockUpAgreementsAxis=roiv_LockUpPeriodEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_LockUpAgreementsAxis=roiv_LockUpPeriodNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_LockUpAgreementsAxis=roiv_LockUpPeriodNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_RoivantWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=roiv_RoivantWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_TriggeringEventAxis=roiv_SharePriceEqualOrExceedsEighteenPerDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_TriggeringEventAxis=roiv_SharePriceEqualOrExceedsEighteenPerDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=roiv_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_RedemptionOfRoivantWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=roiv_RedemptionOfRoivantWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=roiv_MaacClassASharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=roiv_MaacClassASharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_TriggeringEventAxis=roiv_SharePriceEqualOrExceedsEighteenDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_TriggeringEventAxis=roiv_SharePriceEqualOrExceedsEighteenDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=roiv_MontesArchimedesAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=roiv_MontesArchimedesAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AgreementAxis=roiv_PipeFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AgreementAxis=roiv_PipeFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=roiv_MaacClassBSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=roiv_MaacClassBSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724307952720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 27, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Aggregate fair value investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325,834<span></span>
</td>
<td class="nump">$ 188,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Carrying value of long-term investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,975,965<span></span>
</td>
<td class="nump">651,576,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_DatavantMergerMember', window );">Datavant Merger [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ProceedsFromSaleOfInvestment', window );">Proceeds from sale of investment</a></td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_GainOnMeasurementOfInvestment', window );">Gain on measurement of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 443,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_DatavantMergerMember', window );">Datavant Merger [Member] | Combined Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentCompaniesMember', window );">Other Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Aggregate fair value investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember', window );">Arbutus Biopharma Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PreferredStockOwnedBalanceSharesOfArbutus', window );">Preferred stock Owned, Balance, Shares of Arbutus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Aggregate fair value investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,800<span></span>
</td>
<td class="nump">129,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (13,600)<span></span>
</td>
<td class="nump">$ 90,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.98<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,013,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock', window );">Investment owned conversion includes both preferred stock and common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,833,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_SioGeneTherapiesIncMember', window );">Sio Gene Therapies Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Aggregate fair value investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,400<span></span>
</td>
<td class="nump">$ 48,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (36,100)<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.67<span></span>
</td>
<td class="nump">$ 2.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_DatavantHoldingsIncMember', window );">Datavant Holdings, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Aggregate fair value investment</a></td>
<td class="nump">$ 224,100<span></span>
</td>
<td class="nump">$ 193,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (30,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Carrying value of long-term investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_GainOnMeasurementOfInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on measurement of investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_GainOnMeasurementOfInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment owned conversion includes both preferred stock and common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_InvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_InvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PreferredStockOwnedBalanceSharesOfArbutus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock Owned, Balance, Shares of Arbutus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PreferredStockOwnedBalanceSharesOfArbutus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ProceedsFromSaleOfInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ProceedsFromSaleOfInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=roiv_DatavantMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=roiv_DatavantMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=roiv_CombinedCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=roiv_CombinedCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=roiv_SioGeneTherapiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=roiv_SioGeneTherapiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=roiv_DatavantHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=roiv_DatavantHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724296838816">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisitions and License Agreements -Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued, value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,167<span></span>
</td>
<td class="nump">$ 301,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) on remeasurement of investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87,291)<span></span>
</td>
<td class="nump">95,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AcquiredInProcessResearchAndDevelopmentExpense', window );">Acquired in process research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,894<span></span>
</td>
<td class="nump">596,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">564,956<span></span>
</td>
<td class="nump">84,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=roiv_PharmanvanthSevenGmbhMember', window );">Pharmanvanth Seven Gmbh [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AcquiredInProcessResearchAndDevelopmentExpense', window );">Acquired in process research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock Issued During Period, Value, Acquisitions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock shares issued during the period asset acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">874,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock shares issued value during the period asset acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PayableForEachAdditionalProductIndication', window );">Payable for each additional product indication</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=roiv_PharmanvanthSevenGmbhMember', window );">Pharmanvanth Seven Gmbh [Member] | Commercial Milestone [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_MilestonePaymentPayable', window );">Milestone payment payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=roiv_PharmanvanthSevenGmbhMember', window );">Pharmanvanth Seven Gmbh [Member] | Development And Regulatory Milestone [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_MilestonePaymentPayable', window );">Milestone payment payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=roiv_HemavantSciencesGmbhMember', window );">Hemavant Sciences GmbH [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_UpfrontCashPayments', window );">Payments to asset acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Asset acquisition, Consideration Transferred, Equity Interests Issued and Issuable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_SiliconTherapeuticsMember', window );">Silicon Therapeutics [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares issued in business combination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,409,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Business combination, recognized identifiable assets acquired and liabilities assumed, current liabilities, accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 281,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_SiliconTherapeuticsMember', window );">Silicon Therapeutics [Member] | First Tranche [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Asset acquisition, consideration transferred, liabilities incurred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_SiliconTherapeuticsMember', window );">Silicon Therapeutics [Member] | Second Tranche [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares issued in business combination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,348,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_PriovantMember', window );">Priovant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Asset acquisition, consideration transferred, liabilities incurred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=roiv_SiliconTherapeuticsMember', window );">Silicon Therapeutics [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessAcquisitionConsiderationTransferred', window );">Business acquisition, consideration transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AcquiredInProcessResearchAndDevelopmentExpense', window );">Acquired in process research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payment to acquire business, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Business Acquisition, recognized identifiable assets acquired and liabilities assumed, assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock Issued During Period, Value, Acquisitions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueOfCommonShares', window );">Fair value of common shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueOfRestrictedStock', window );">Fair value of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock shares issued value during the period asset acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=roiv_SiliconTherapeuticsMember', window );">Silicon Therapeutics [Member] | Second Tranche [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessAcquisitionConsiderationTransferred', window );">Business acquisition, consideration transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash Payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=roiv_PriovantMember', window );">Priovant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_UpfrontCashPayments', window );">Payments to asset acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AcquiredInProcessResearchAndDevelopmentExpense', window );">Acquired in process research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock Issued During Period, Value, Acquisitions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock shares issued value during the period asset acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_GenevantSciencesLtdMember', window );">Genevant Sciences Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Equity ownership interest, additional cash contribution</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedParties', window );">Notes receivable, related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">74,272,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued, value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 20,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Aggregate principal amount of notes converted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Notes converted, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">54,526,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PercentageOfControllingInterestHeld', window );">Percentage controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">82.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure', window );">Investment, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) on remeasurement of investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Fair value of noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Cash paid for common shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessAcquisitionConsiderationTransferred', window );">Business acquisition, consideration transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AcquiredInProcessResearchAndDevelopmentExpense', window );">Acquired in process research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_GenevantSciencesLtdMember', window );">Genevant Sciences Ltd [Member] | Arbutus Biopharma Corporation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,057,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued, value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ProteovantSciencesIncMember', window );">ProteoVant Sciences, Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_UpfrontCashPayments', window );">Payments to asset acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FutureDevelopmentAndCommercialMilestonePayments', window );">Future development and commercial milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Aggregate principal amount of notes converted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AcquiredInProcessResearchAndDevelopmentExpense', window );">Acquired in process research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PaymentForUpfrontPayments', window );">Upfront proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PaymentUnderSponsoredResearchAgreement', window );">Payment under SRA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentOfNotesReceivableFromRelatedParties', window );">Settlement of promissory notes receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of future contingent consideration payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets', window );">Equity investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions', window );">Ownership interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ProteovantSciencesIncMember', window );">ProteoVant Sciences, Inc [Member] | Collaboration Agreement With Blueprint Medicines [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_NonRefundableUpfrontPaymentReceived', window );">Nonrefundable, upfront payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PotentialMilestonePaymentReceivable', window );">Collaboration Agreement Additional Contingent Milestone Payments Eligible To Receive</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ProteovantSciencesIncMember', window );">ProteoVant Sciences, Inc [Member] | First Product First Product for Each Molecular Target Covered by Intellectual Property [Member] | Maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FutureDevelopmentAndCommercialMilestonePayments', window );">Future development and commercial milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ProteovantSciencesIncMember', window );">ProteoVant Sciences, Inc [Member] | First Product Targets Targeting Each of Two Specified Initial Targets [Member] | Maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FutureDevelopmentAndCommercialMilestonePayments', window );">Future development and commercial milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ProteovantSciencesIncMember', window );">ProteoVant Sciences, Inc [Member] | First Product Targets Each of Certain Specified Additional MolecularTargets [Member] | Maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FutureDevelopmentAndCommercialMilestonePayments', window );">Future development and commercial milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_AffivantSciencesMember', window );">Affivant Sciences [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_UpfrontCashPayments', window );">Payments to asset acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodValue', window );">Newly issued shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_AffivantSciencesMember', window );">Affivant Sciences [Member] | Maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FutureDevelopmentAndCommercialMilestonePayments', window );">Future development and commercial milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="13"></td></tr>
<tr><td colspan="13"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for the stock subdivision as described in Note 3.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AcquiredInProcessResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquired in process research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AcquiredInProcessResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_BusinessAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Consideration Transferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_BusinessAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Recognized Identifiable Assets Acquired And Liabilities Assumed Net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_FairValueOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Common Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_FairValueOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_FairValueOfRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Restricted Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_FairValueOfRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_FutureDevelopmentAndCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future Development And Commercial Milestone Payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_FutureDevelopmentAndCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MilestonePaymentPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MilestonePaymentPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_NonRefundableUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Refundable Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_NonRefundableUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PayableForEachAdditionalProductIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payable for each additional product indication.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PayableForEachAdditionalProductIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PaymentForUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for upfront payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PaymentForUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PaymentUnderSponsoredResearchAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment under sponsored research agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PaymentUnderSponsoredResearchAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PercentageOfControllingInterestHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of controlling interest held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PercentageOfControllingInterestHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PotentialMilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential milestone payment receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PotentialMilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_UpfrontCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Cash Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_UpfrontCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125513658&amp;loc=d3e32014-111567<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments in an entity not consolidated. Includes, but is not limited to, investments in an entity that is affiliated with the reporting entity by means of direct or indirect ownership, an entity in which the reporting entity shares control of the entity with another party or group, an entity which the company has significant influence, but does not have control and subsidiaries that are not required to be consolidated and are accounted for using the equity or cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from parties associated with the reporting entity as evidenced by a written promise to pay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentOfNotesReceivableFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentOfNotesReceivableFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity method investee's stock owned by parent immediately after all stock transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=roiv_PharmanvanthSevenGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=roiv_PharmanvanthSevenGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=roiv_CommercialMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=roiv_CommercialMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=roiv_DevelopmentAndRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=roiv_DevelopmentAndRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=roiv_HemavantSciencesGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=roiv_HemavantSciencesGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=roiv_SiliconTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=roiv_SiliconTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=roiv_FirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=roiv_FirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=roiv_SecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=roiv_SecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=roiv_PriovantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=roiv_PriovantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=roiv_SiliconTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=roiv_SiliconTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=roiv_PriovantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=roiv_PriovantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_GenevantSciencesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_GenevantSciencesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ProteovantSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ProteovantSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AgreementAxis=roiv_CollaborationAgreementWithBlueprintMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AgreementAxis=roiv_CollaborationAgreementWithBlueprintMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MilestoneEventsAxis=roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MilestoneEventsAxis=roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MilestoneEventsAxis=roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MilestoneEventsAxis=roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MilestoneEventsAxis=roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MilestoneEventsAxis=roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_AffivantSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_AffivantSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724311122688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AccruedLiabilitiesLineItems', window );"><strong>Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 127,531<span></span>
</td>
<td class="nump">$ 76,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AccruedLiabilitiesLineItems', window );"><strong>Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">66,188<span></span>
</td>
<td class="nump">20,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=roiv_EmployeeRelatedExpensesMember', window );">Employee Related Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AccruedLiabilitiesLineItems', window );"><strong>Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">44,262<span></span>
</td>
<td class="nump">38,552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=roiv_OtherGeneralAndAdministrativeExpensesMember', window );">Other General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AccruedLiabilitiesLineItems', window );"><strong>Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 17,081<span></span>
</td>
<td class="nump">$ 17,629<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AccruedLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AccruedLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=roiv_EmployeeRelatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=roiv_EmployeeRelatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=roiv_OtherGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=roiv_OtherGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724311121072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt and Loan Commitment - Summary of Long-Term Debt (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAbstract', window );"><strong>Long-term Debt, Unclassified [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DebtInstrumentValue', window );">Principal amount</a></td>
<td class="nump">$ 217,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DebtInstrumentExitFeeAndEndOfTermCharge', window );">Exit fee / end of term charge</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized debt discount and issuance costs</a></td>
<td class="num">(12,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,210)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">210,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long term debt, net</a></td>
<td class="nump">$ 210,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DebtInstrumentExitFeeAndEndOfTermCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument exit fee and end of term charge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DebtInstrumentExitFeeAndEndOfTermCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DebtInstrumentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DebtInstrumentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724303229120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt and Loan Commitment  - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 01, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt Instrument, Fee Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DebtInstrumentExitFeeAndEndOfTermCharge', window );">Debt Instrument Exit Fee and End of Term Charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 1,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from credit facility</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrants or rights number of shares called by each warrant or right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,199,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=roiv_RevenueInterestPurchaseAndSaleAgreementMember', window );">Revenue Interest Purchase and Sale Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement', window );">Securities Purchased under Agreements to Resell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_CommittedFundingUnderRIPSA', window );">Committed funding under RIPSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember', window );">Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=roiv_NovaquestMember', window );">NovaQuest Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,400<span></span>
</td>
<td class="nump">$ 150,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=roiv_NovaquestMember', window );">NovaQuest Agreement [Member] | Regulatory Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_MaximumMilestonePaymentObligation', window );">Maximum amount required milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_MaximumMilestonePaymentOffsetAmount', window );">Possible offset of regulatory milestone payments with commercial milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_MilestonePaymentDueOverSixYearPeriod', window );">Milestone payment due over six year period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=roiv_NovaquestMember', window );">NovaQuest Agreement [Member] | Commercial Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_MaximumMilestonePaymentObligation', window );">Maximum amount required milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CommittedFundingUnderRIPSA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Committed Funding Under RIPSA.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CommittedFundingUnderRIPSA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Committed Funding Under Revenue Interest Purchase And Sale Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DebtInstrumentExitFeeAndEndOfTermCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument exit fee and end of term charge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DebtInstrumentExitFeeAndEndOfTermCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MaximumMilestonePaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum milestone payment obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MaximumMilestonePaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MaximumMilestonePaymentOffsetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Milestone Payment Offset Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MaximumMilestonePaymentOffsetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MilestonePaymentDueOverSixYearPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment due over six year period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MilestonePaymentDueOverSixYearPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=roiv_RevenueInterestPurchaseAndSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=roiv_RevenueInterestPurchaseAndSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=roiv_NovaquestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=roiv_NovaquestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=roiv_RegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=roiv_RegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=roiv_CommercialMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=roiv_CommercialMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724302488032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt and Loan Commitment - Schedule of Company's Annual Payments (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_LongTermDebtExcludingDebtWithFairValueOption', window );">Total</a></td>
<td class="nump">$ 45,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_LongTermDebtExcludingDebtWithFairValueOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt Excluding Debt With Fair Value Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_LongTermDebtExcludingDebtWithFairValueOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724300093056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 01, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination', window );">Gain on termination of Sumitomo Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,472<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AgreementAxis=roiv_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AssetPurchaseTransactionConsiderationReceivedInCash', window );">Consideration received in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination', window );">Gain on termination of Sumitomo Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AgreementAxis=roiv_TransitionServicesAndStrategicCooperationAgreementMember', window );">Transition Services And Strategic Cooperation Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary', window );">Cost incurred and recorded as offsets to general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SumitomoMember', window );">Sumitomo [Member] | Transition Services And Strategic Cooperation Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AccessFeePaidToRelatedParty', window );">Access fee paid pursuant to strategic cooperation agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary', window );">Agreement related to amendment terms additional consideration received by subsidiary</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AccessFeePaidToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Access Fee Paid to Related Party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AccessFeePaidToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement related billed amount for costs incurred on behalf of subsidiary,net of amounts billed by subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement related to amendment terms additional consideration received by subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AssetPurchaseTransactionConsiderationReceivedInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Purchase Transaction Consideration Received In Cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AssetPurchaseTransactionConsiderationReceivedInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity interest option to third party purchaser gain on termination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AgreementAxis=roiv_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AgreementAxis=roiv_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AgreementAxis=roiv_TransitionServicesAndStrategicCooperationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AgreementAxis=roiv_TransitionServicesAndStrategicCooperationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SumitomoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SumitomoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724301668608">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Additional Information (Detail)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 14, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,975,965<span></span>
</td>
<td class="nump">651,576,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000,000<span></span>
</td>
<td class="nump">7,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00000003<span></span>
</td>
<td class="nump">$ 0.00000003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=roiv_CantorFitzgeraldCo.Member', window );">Cantor Fitzgerald Co. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase Obligation | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PercentageOfCommonSharesVolumeWeightedAveragePrice', window );">Percentage of common shares volume-weighted average price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_UpfrontCommitmentFeeNumberOfSharesIssued', window );">Upfront commitment fee number of shares issued | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">145,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_CommonSharesValueAvailableForSale', window );">Common Shares Value Available For Sale | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_SkMember', window );">Sk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_SubscriptionReceived', window );">Subscription Received | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering shares of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,369,000<span></span>
</td>
<td class="nump">21,077,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=roiv_RoivantCommonSharesMember', window );">Roivant Common Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00000003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common Stock, Voting Rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one vote<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_StockHoldersEquityNoteStockSplitExchangeRatio1', window );">Stockholders Equity Note Stock Split Exchange Ratio 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.9262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=roiv_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering [Member] | Common Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering shares of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,034,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds of common stock | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_ImmunovantINCMember', window );">Immunovant, Inc [Member] | Warrant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,719,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ClassOfWarrantOrRightExercisable', window );">Number of exercisable outstanding warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,438,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds of warrants | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ClassOfWarrantOrRightCanceled', window );">Class Of Warrant Or Right Canceled</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_ImmunovantINCMember', window );">Immunovant, Inc [Member] | Underwritten Public Offering [Member] | Common Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering shares of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,060,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,613,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds of common stock | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ImmunovantSciencesLtdMember', window );">Immunovant Sciences Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,547,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively restated for the stock subdivision as described in Note 3.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ClassOfWarrantOrRightCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Canceled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ClassOfWarrantOrRightCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CommonSharesValueAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Shares Value Available For Sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CommonSharesValueAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PercentageOfCommonSharesVolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of common shares volume-weighted average price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PercentageOfCommonSharesVolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockHoldersEquityNoteStockSplitExchangeRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock holders Equity Note Stock Split Exchange Ratio1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockHoldersEquityNoteStockSplitExchangeRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_SubscriptionReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subscription Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_SubscriptionReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_UpfrontCommitmentFeeNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront commitment fee number of shares issued | shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_UpfrontCommitmentFeeNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=roiv_CantorFitzgeraldCo.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=roiv_CantorFitzgeraldCo.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_SkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=roiv_SkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=roiv_RoivantCommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=roiv_RoivantCommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=roiv_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=roiv_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=roiv_ImmunovantINCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=roiv_ImmunovantINCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ImmunovantSciencesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ImmunovantSciencesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724296646320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 564,956,000<span></span>
</td>
<td class="nump">$ 84,958,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,487,000<span></span>
</td>
<td class="nump">$ 25,711,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding stock increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncrementOfEmployeeStockPurchasePlan', window );">Increment of employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable', window );">Employee stock purchase plan maximum number of common shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,447,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_EventAxis=roiv_AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMember', window );">Achievement Of Liquidity Event Vesting Condition Upon Closing Of Business Combination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_OneTimeCatchUpExpense', window );">One time catch up expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 372,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_StockOptionsAndPerformanceStockOptionsMember', window );">Stock Options And Performance Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining weighted-average service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,236,351<span></span>
</td>
<td class="nump">16,193,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember', window );">Restricted Stock Units And Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining weighted-average service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_SubsidiaryEquityIncentivePlansMember', window );">Subsidiary Equity Incentive Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,400,000<span></span>
</td>
<td class="nump">$ 29,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_March2020CappedValueAppreciationRightsMember', window );">March 2020 CVARs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment', window );">Incremental fair value after march two thousand and twenty capped value appreciation rights amendment.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 EIP [Member] | CVARs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining weighted-average service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Service-vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,213,910<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of CVARs that service-vested during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=roiv_SubsidiaryEquityIncentivePlanMember', window );">Subsidiary EIPs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=roiv_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 EIP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,373,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding stock increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=roiv_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 EIP [Member] | CVARs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares', window );">Share based compensation by share based award weighted average intrinsic value of equity instruments other than options granted</a></td>
<td class="nump">6,317,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan maximum number of common shares issuable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IncrementOfEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increment of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IncrementOfEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental fair value after march two thousand and twenty capped value appreciation rights amendment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_OneTimeCatchUpExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>One time catch up expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_OneTimeCatchUpExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation by share based award weighted average intrinsic value of equity instruments other than options granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_EventAxis=roiv_AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_EventAxis=roiv_AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_StockOptionsAndPerformanceStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_StockOptionsAndPerformanceStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_SubsidiaryEquityIncentivePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_SubsidiaryEquityIncentivePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_March2020CappedValueAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_March2020CappedValueAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_SubsidiaryEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_SubsidiaryEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_TwoThousandTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_TwoThousandTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724310954544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Fair Value Assumptions (Detail) - Stock Option [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">81.70%<span></span>
</td>
<td class="nump">74.84%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Expected risk free interest rate</a></td>
<td class="nump">1.13%<span></span>
</td>
<td class="nump">0.43%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724307797040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Fair Value of Vested Stock Option (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IntrinsicValueOfOptionsExercised', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Grant date fair value of stock options vested</a></td>
<td class="nump">$ 210,487<span></span>
</td>
<td class="nump">$ 25,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share of stock options granted</a></td>
<td class="nump">$ 6.85<span></span>
</td>
<td class="nump">$ 8.67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IntrinsicValueOfOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic Value Of Options Exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IntrinsicValueOfOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724302421232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Restricted Stock Units (Detail) - Restricted Stock And Performance Stock Units [Member] - R S L Equity Plans Member<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested balance, beginning | shares</a></td>
<td class="nump">7,294,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">20,948,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="num">(5,111,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(1,173,956)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested balance, ending | shares</a></td>
<td class="nump">21,956,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning balance | $ / shares</a></td>
<td class="nump">$ 11.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">10.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, vested | $ / shares</a></td>
<td class="nump">11.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">10.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending Balance | $ / shares</a></td>
<td class="nump">$ 10.63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_RestrictedStockAndPerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_RestrictedStockAndPerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_RSLEquityPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_RSLEquityPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724307368272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Performance Options Activity (Detail) - Stock options and performance stock options [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options outstanding , Options exercisable</a></td>
<td class="nump">39,236,351<span></span>
</td>
<td class="nump">16,193,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_StockOptionsAndPerformanceStockOptionsMember', window );">R S L Equity Plans Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding ,Beginning balance</a></td>
<td class="nump">69,687,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">12,181,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(101,436)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited</a></td>
<td class="num">(1,402,095)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding , Ending balance</a></td>
<td class="nump">80,364,904<span></span>
</td>
<td class="nump">69,687,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options outstanding , Options exercisable</a></td>
<td class="nump">39,236,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Beginning balance</a></td>
<td class="nump">$ 11.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">9.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">4.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited/Canceled</a></td>
<td class="nump">11.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending balance</a></td>
<td class="nump">11.37<span></span>
</td>
<td class="nump">$ 11.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable</a></td>
<td class="nump">$ 11.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 10 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life , Options exercisable</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value , Ending balance</a></td>
<td class="nump">$ 1,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value , Options exercisable</a></td>
<td class="nump">$ 1,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_StockOptionsAndPerformanceStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_StockOptionsAndPerformanceStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_RSLEquityPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_RSLEquityPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724311098720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Capped Value Appreciation Rights (Detail) - CVARs [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember', window );">2015 EIP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested balance, beginning</a></td>
<td class="nump">32,447,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="num">(435,630)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(18,213,910)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested balance, ending</a></td>
<td class="nump">13,798,086<span></span>
</td>
<td class="nump">32,447,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units, Beginning balance</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, forfeited</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units , Ending balance</a></td>
<td class="nump">1.25<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Service-vested</a></td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember', window );">2021 EIP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested balance, beginning</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">6,317,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="num">(32,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested balance, ending</a></td>
<td class="nump">6,285,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units, Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Granted</a></td>
<td class="nump">4.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, forfeited</a></td>
<td class="nump">4.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units , Ending balance</a></td>
<td class="nump">$ 4.95<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_TwoThousandTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_TwoThousandTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724296793696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 564,956<span></span>
</td>
<td class="nump">$ 84,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">63,735<span></span>
</td>
<td class="nump">22,637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">G&amp;A Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 501,221<span></span>
</td>
<td class="nump">$ 62,321<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724303226960">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Loss Before Income Taxes by Geographic Region (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Loss before income taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Total loss before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (923,747)<span></span>
</td>
<td class="num">$ (898,547)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BM', window );">Bermuda [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Loss before income taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Total loss before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">390,831<span></span>
</td>
<td class="num">(227,471)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Loss before income taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Total loss before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(747,953)<span></span>
</td>
<td class="num">(212,921)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CH', window );">Switzerland [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Loss before income taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Total loss before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(544,870)<span></span>
</td>
<td class="num">(424,494)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=roiv_OtherMember', window );">Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Loss before income taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Total loss before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">$ (21,755)<span></span>
</td>
<td class="num">$ (33,661)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Primarily entities which are centrally managed and controlled in the United Kingdom</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Primarily Greater China and United Kingdom activity</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=roiv_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=roiv_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724311040896">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule Components of Income Tax Expense (Benefit) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 369<span></span>
</td>
<td class="nump">$ 1,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">369<span></span>
</td>
<td class="nump">1,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(223)<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CH', window );">Switzerland [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BM', window );">Bermuda [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=roiv_OtherMember', window );">Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">592<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Primarily Greater China and United Kingdom activity</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=roiv_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=roiv_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724310892048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest and penalties related to unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(0.04%)<span></span>
</td>
<td class="num">(0.19%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 512,736<span></span>
</td>
<td class="nump">$ 303,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increase (decrease)</a></td>
<td class="nump">209,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">United States and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 94,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | United States and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Net operating losses expiration date</a></td>
<td class="text">Mar. 31,  2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | United States and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Net operating losses expiration date</a></td>
<td class="text">Mar. 31,  2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CH', window );">Switzerland [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 1,749,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CH', window );">Switzerland [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Net operating losses expiration date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CH', window );">Switzerland [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Net operating losses expiration date</a></td>
<td class="text">Mar. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 244,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AnnualNOLUtilizationLimitationPercentage', window );">Annual NOL utilization limitation percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 40,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=roiv_TaxAuthorityInOtherJurisdictionsMember', window );">Other Jurisdictions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">98,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=roiv_UnitedStatesAndCanadaMember', window );">United States And Canada [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">$ 27,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=roiv_UnitedStatesAndCanadaMember', window );">United States And Canada [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Research and development tax credit expiration date</a></td>
<td class="text">Mar. 31,  2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=roiv_UnitedStatesAndCanadaMember', window );">United States And Canada [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Research and development tax credit expiration date</a></td>
<td class="text">Mar. 31,  2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AnnualNOLUtilizationLimitationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual NOL utilization limitation percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AnnualNOLUtilizationLimitationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the tax credit carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=roiv_TaxAuthorityInOtherJurisdictionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=roiv_TaxAuthorityInOtherJurisdictionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=roiv_UnitedStatesAndCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=roiv_UnitedStatesAndCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724306511488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research tax credits</a></td>
<td class="nump">$ 27,155<span></span>
</td>
<td class="nump">$ 19,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">61,544<span></span>
</td>
<td class="nump">50,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">312,749<span></span>
</td>
<td class="nump">202,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">93,177<span></span>
</td>
<td class="nump">26,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">15,406<span></span>
</td>
<td class="nump">16,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other assets</a></td>
<td class="nump">20,651<span></span>
</td>
<td class="nump">7,303<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Subtotal</a></td>
<td class="nump">530,682<span></span>
</td>
<td class="nump">323,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(512,736)<span></span>
</td>
<td class="num">(303,287)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DeferredTaxLiabilitiesDepreciation', window );">Depreciation</a></td>
<td class="num">(1,397)<span></span>
</td>
<td class="num">(1,214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="num">(12,661)<span></span>
</td>
<td class="num">(13,908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other liabilities</a></td>
<td class="num">(3,888)<span></span>
</td>
<td class="num">(4,688)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net Deferred tax assets/(liabilities), net of valuation allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DeferredTaxLiabilitiesDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Depreciation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DeferredTaxLiabilitiesDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724303341952">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at Bermuda statutory rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(179,000)<span></span>
</td>
<td class="num">(150,778)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Permanent disallowed IPR&amp;D</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,347<span></span>
</td>
<td class="nump">111,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary', window );">Tax-effect of changes in the fair value of investments and loss from equity method investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,169<span></span>
</td>
<td class="num">(22,472)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDispositionOfAssets', window );">Nontaxable gain on sale of investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(84,313)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDispositionOfBusiness', window );">Nontaxable gain on deconsolidation of business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(958)<span></span>
</td>
<td class="num">(16,438)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Nondeductible executive compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,973<span></span>
</td>
<td class="nump">905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Tax deficiencies (excess tax benefits) from stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,918<span></span>
</td>
<td class="num">(439)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDeductionsOther', window );">Other permanent&#160;adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,912<span></span>
</td>
<td class="nump">2,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research&#160;tax credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,113)<span></span>
</td>
<td class="num">(10,555)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">205,811<span></span>
</td>
<td class="nump">85,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Tax rate changes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,444)<span></span>
</td>
<td class="nump">2,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,933)<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 369<span></span>
</td>
<td class="nump">$ 1,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at Bermuda statutory rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential(1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">19.38%<span></span>
</td>
<td class="nump">16.78%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Permanent disallowed IPR&amp;D</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1.66%)<span></span>
</td>
<td class="num">(12.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary', window );">Tax-effect of changes in the fair value of investments and loss from equity method investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1.64%)<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets', window );">Nontaxable gain on sale of investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9.13%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness', window );">Nontaxable gain on deconsolidation of business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">1.83%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Nondeductible executive compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2.81%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Tax deficiencies (excess tax benefits) from share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="nump">0.05%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther', window );">Other permanent&#160;adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1.18%)<span></span>
</td>
<td class="num">(0.28%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research&#160;tax credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.09%<span></span>
</td>
<td class="nump">1.17%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in Valuation Allowance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(22.28%)<span></span>
</td>
<td class="num">(9.46%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Tax rate changes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.26%<span></span>
</td>
<td class="num">(0.27%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.97%<span></span>
</td>
<td class="num">(0.01%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.04%)<span></span>
</td>
<td class="num">(0.19%)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Primarily related to operations in the United States, Switzerland, the United Kingdom, and other jurisdictions with statutory tax rates different than the Bermuda rate.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDeductionsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDeductionsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724311098000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Operating Lease Costs (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 13,649<span></span>
</td>
<td class="nump">$ 11,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,227<span></span>
</td>
<td class="nump">704<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">$ 15,202<span></span>
</td>
<td class="nump">$ 12,872<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724310839392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Operating Lease ROU Assets and Operating Lease Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">$ 14,403<span></span>
</td>
<td class="nump">$ 8,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">$ 6,035<span></span>
</td>
<td class="nump">$ 5,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724314353728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Operating Lease Liabilities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturities of operating lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 12,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">12,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">10,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">9,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">8,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">46,783<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">100,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_OperatingLeaseLiabilityPresentValueAdjustments', window );">Less: present value adjustment</a></td>
<td class="num">(24,996)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance', window );">Less: tenant improvement allowance</a></td>
<td class="num">(1,805)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 73,866<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability tenant improvement allowance..</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_OperatingLeaseLiabilityPresentValueAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability Present Value Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_OperatingLeaseLiabilityPresentValueAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724307705184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AgreementAxis=roiv_MasterSubscriptionAgreementMember', window );">Master Subscription Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitment, remaining minimum payment</a></td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AgreementAxis=roiv_ProductServiceAgreementMember', window );">Product Service Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitment, remaining minimum payment</a></td>
<td class="nump">$ 36,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AgreementAxis=roiv_MasterSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AgreementAxis=roiv_MasterSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AgreementAxis=roiv_ProductServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AgreementAxis=roiv_ProductServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724303119040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">$ 325,834<span></span>
</td>
<td class="nump">$ 188,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets held in Trust Account</a></td>
<td class="nump">1,623,678<span></span>
</td>
<td class="nump">1,609,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt issued by Dermavant to NovaQuest</a></td>
<td class="nump">177,400<span></span>
</td>
<td class="nump">150,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Liability instruments measured at fair value</a></td>
<td class="nump">44,912<span></span>
</td>
<td class="nump">67,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">222,312<span></span>
</td>
<td class="nump">217,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets held in Trust Account</a></td>
<td class="nump">1,429,715<span></span>
</td>
<td class="nump">1,533,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Liability instruments measured at fair value</a></td>
<td class="nump">18,019<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">18,019<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets held in Trust Account</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">76,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets held in Trust Account</a></td>
<td class="nump">193,963<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt issued by Dermavant to NovaQuest</a></td>
<td class="nump">177,400<span></span>
</td>
<td class="nump">150,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Liability instruments measured at fair value</a></td>
<td class="nump">26,893<span></span>
</td>
<td class="nump">67,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">204,293<span></span>
</td>
<td class="nump">217,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">1,297,844<span></span>
</td>
<td class="nump">1,420,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">1,297,844<span></span>
</td>
<td class="nump">1,420,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_OtherInvestmentCompaniesMember', window );">Other Investment [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">3,659<span></span>
</td>
<td class="nump">11,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_OtherInvestmentCompaniesMember', window );">Other Investment [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">3,659<span></span>
</td>
<td class="nump">11,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_SioGeneTherapiesIncMember', window );">Sio Gene Therapies Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">12,400<span></span>
</td>
<td class="nump">48,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_SioGeneTherapiesIncMember', window );">Sio Gene Therapies Inc [Member] | Common Shares [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">12,447<span></span>
</td>
<td class="nump">48,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_SioGeneTherapiesIncMember', window );">Sio Gene Therapies Inc [Member] | Common Shares [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">12,447<span></span>
</td>
<td class="nump">48,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember', window );">Arbutus Biopharma Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">115,800<span></span>
</td>
<td class="nump">129,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember', window );">Arbutus Biopharma Corporation [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">76,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember', window );">Arbutus Biopharma Corporation [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">76,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember', window );">Arbutus Biopharma Corporation [Member] | Common Shares [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">115,765<span></span>
</td>
<td class="nump">53,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember', window );">Arbutus Biopharma Corporation [Member] | Common Shares [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">115,765<span></span>
</td>
<td class="nump">53,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_DatavantMember', window );">Datavant [Member] | Common Shares [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">193,963<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_DatavantMember', window );">Datavant [Member] | Common Shares [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">$ 193,963<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_OtherInvestmentCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_OtherInvestmentCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=roiv_SioGeneTherapiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=roiv_SioGeneTherapiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=roiv_DatavantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=roiv_DatavantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724302419808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Parenthetical) (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrant | Roiv Public Warrants [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities at fair value</a></td>
<td class="nump">$ 18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrant | Roiv Private Placement Warrants [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities at fair value</a></td>
<td class="nump">9.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=roiv_RoivEarnoutSharesMember', window );">Roiv Earnout Shares [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosure', window );">Non financial liabilities at fair value</a></td>
<td class="nump">9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=roiv_RoivLiabilityInstrumentsMeasuredAtFairValueMember', window );">Roiv Liability Instruments Measured At Fair Value [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities at fair value</a></td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=roiv_SumitomoOptionsMember', window );">Sumitomo Options [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of obligations not classified as financial liabilities. Includes, but is not limited to, accounts payable and accrued liabilities, commitments, obligations, and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonfinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_RoivPublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=roiv_RoivPublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_RoivPrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=roiv_RoivPrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=roiv_RoivEarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=roiv_RoivEarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=roiv_RoivLiabilityInstrumentsMeasuredAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=roiv_RoivLiabilityInstrumentsMeasuredAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=roiv_SumitomoOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=roiv_SumitomoOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724306318720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=roiv_LiabilityInstrumentsMeasuredAtFairValueMember', window );">Liability Instruments Measured At Fair Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueDisclosuresLineItems', window );"><strong>Fair Value Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_EquityInterestOptionToThirdPartyPurchase', window );">Fair value of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=roiv_LiabilityInstrumentsMeasuredAtFairValueMember', window );">Liability Instruments Measured At Fair Value [Member] | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueDisclosuresLineItems', window );"><strong>Fair Value Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability</a></td>
<td class="nump">$ 9.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=roiv_LiabilityInstrumentsMeasuredAtFairValueMember', window );">Liability Instruments Measured At Fair Value [Member] | Earnout Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueDisclosuresLineItems', window );"><strong>Fair Value Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and Nonfinancial Liabilities, Fair Value Disclosure</a></td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Measurement Input, Discount Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueDisclosuresLineItems', window );"><strong>Fair Value Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Measurement Input, Discount Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueDisclosuresLineItems', window );"><strong>Fair Value Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_EquityInterestOptionToThirdPartyPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity interest option to third-party purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_EquityInterestOptionToThirdPartyPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_FairValueDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Disclosures [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_FairValueDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=roiv_LiabilityInstrumentsMeasuredAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=roiv_LiabilityInstrumentsMeasuredAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=roiv_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=roiv_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724302991376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Change in the Fair Value of the Derivative Warrant Liabilities (Detail) - Fair Value, Inputs, Level 3 [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at beginning of period</a></td>
<td class="nump">$ 217,993<span></span>
</td>
<td class="nump">$ 191,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value of liability instrument issued</a></td>
<td class="nump">38,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value of debt and liability instruments, included in net loss</a></td>
<td class="nump">9,226<span></span>
</td>
<td class="nump">29,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne', window );">Settlements</a></td>
<td class="num">(88)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Termination of DSP Options</a></td>
<td class="num">(61,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary', window );">Liability instruments disposed due to deconsolidation of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,325)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at end of period</a></td>
<td class="nump">$ 204,293<span></span>
</td>
<td class="nump">$ 217,993<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, disposed due to deconsolidation of subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability settlements one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724302465888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Change IN Fair Value of the Level 3 Assets (Detail) - Fair Value, Inputs, Level 3 [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment', window );">Fair value of investment in Datavant at recognition date</a></td>
<td class="nump">224,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Changes in fair value of investment in Datavant, included in net loss</a></td>
<td class="num">(30,184)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending Balance</a></td>
<td class="nump">$ 193,963<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis asset investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724302569824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value of Significant Unobservable Inputs Using Valuation Techniques (Detail)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>yr</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility | Datavant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueAssetMeasurementInput', window );">Fair Value Asset Measurement Input</a></td>
<td class="nump">110.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility | Earnout Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueAssetMeasurementInput', window );">Fair Value Asset Measurement Input</a></td>
<td class="nump">82.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility | Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueAssetMeasurementInput', window );">Fair Value Asset Measurement Input</a></td>
<td class="nump">56.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free rate | Datavant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueAssetMeasurementInput', window );">Fair Value Asset Measurement Input</a></td>
<td class="nump">1.62%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free rate | Earnout Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueAssetMeasurementInput', window );">Fair Value Asset Measurement Input</a></td>
<td class="nump">2.43%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free rate | Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueAssetMeasurementInput', window );">Fair Value Asset Measurement Input</a></td>
<td class="nump">2.43%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Term (in years) | Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative Liability, Measurement Input</a></td>
<td class="nump">4.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_FairValueAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value asset measurement input.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_FairValueAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=roiv_DatavantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=roiv_DatavantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=roiv_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=roiv_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=roiv_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724314367136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value of Unobservable Input Related To Options to Acquire Under Sumitomo Transaction Agreement (Detail) - Sumitomo Options [Member]<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AlternativeInvestmentExpectedTerm', window );">Time to expiration (in years)</a></td>
<td class="text">3 years 7 months 2 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Investment</a></td>
<td class="nump">0.52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Measurement Input, Option Volatility [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Investment</a></td>
<td class="nump">89,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Measurement Input, Option Volatility [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Investment</a></td>
<td class="nump">95,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AlternativeInvestmentExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Alternative investment expected term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AlternativeInvestmentExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=roiv_SumitomoOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=roiv_SumitomoOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724307348064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expense, Net - Summary of Other Expense, Net From Continuing Operations (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Expense, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="num">(369)<span></span>
</td>
<td class="num">(1,418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">7,041<span></span>
</td>
<td class="nump">2,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_OtherIncomeExpense', window );">Other (expense) income</a></td>
<td class="num">(3,237)<span></span>
</td>
<td class="nump">3,560<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_OtherOperatingIncomeExpensesNet', window );">Total</a></td>
<td class="nump">$ 3,435<span></span>
</td>
<td class="nump">$ 8,701<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_OtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Income Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_OtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_OtherOperatingIncomeExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other operating income expenses net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_OtherOperatingIncomeExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724296809632">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share - Summary Of Potentially Dilutive Securities (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_StockOptionsAndPerformanceStockOptionsMember', window );">Stock options and performance stock options [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">80,364,904<span></span>
</td>
<td class="nump">69,687,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember', window );">Restricted stock units and performance stock units [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,956,749<span></span>
</td>
<td class="nump">7,294,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_TwoThousandAndTwentyCvarsMember', window );">March 2020 CVARs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">32,011,996<span></span>
</td>
<td class="nump">32,447,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_NovemberTwoThousandAndTwentyOneCvarsMember', window );">November 2021 CVARs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,285,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted common stock (non-vested) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">741,405<span></span>
</td>
<td class="nump">1,720,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_EarnOutSharesNonvestedMember', window );">Earn-Out Shares (non-vested) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,080,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,214,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,475,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_OtherInstrumentsIssuedMember', window );">Other instruments issued [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,103,577<span></span>
</td>
<td class="nump">5,458,543<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Refer to Note 10, &#8220;Share-Based Compensation&#8221; for details regarding settlement of CVARs.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_StockOptionsAndPerformanceStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_StockOptionsAndPerformanceStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_TwoThousandAndTwentyCvarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_TwoThousandAndTwentyCvarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_NovemberTwoThousandAndTwentyOneCvarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_NovemberTwoThousandAndTwentyOneCvarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_EarnOutSharesNonvestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_EarnOutSharesNonvestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_OtherInstrumentsIssuedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=roiv_OtherInstrumentsIssuedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139724301493920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) - Subsequent Event [Member]<br> &#8364; in Millions, $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">G S K | Regulatory Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_MilestonePaymentPeriod', window );">Milestone Payment Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">70 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_MilestonePaymentPayable', window );">Milestone Payment Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126.0<span></span>
</td>
<td class="nump">&#8364; 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Welichem Biotech Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_MilestonePaymentPeriod', window );">Milestone Payment Period</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_MilestonePaymentPayable', window );">Milestone Payment Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">ROIVRevenue Interest Purchase And Sale Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement', window );">Gross proceeds from revenue interest purchase and sale agreement.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from revenue interest purchase and sale agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MilestonePaymentPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MilestonePaymentPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MilestonePaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MilestonePaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=roiv_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=roiv_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=roiv_RegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=roiv_RegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=roiv_WelichemBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=roiv_WelichemBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=roiv_RoivrevenueInterestPurchaseAndSaleAgreementMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=roiv_RoivrevenueInterestPurchaseAndSaleAgreementMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>d307489d10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:roiv="http://roivant.com/20220331"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="roiv-20220331.xsd" xlink:type="simple"/>
    <context id="P04_01_2021To03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn05_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="PAsOn05_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="P05_01_2021To05_01_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="P09_01_2021To09_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn05_01_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2021-05-01</instant>
        </period>
    </context>
    <context id="PAsOn06_21_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2022-06-21</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="P11_01_2021To11_01_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="PAsOn10_01_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommonStockMemberusgaapFairValueByAssetClassAxis_DatavantMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:DatavantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommonStockMemberusgaapFairValueByAssetClassAxis_DatavantMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:DatavantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_TaxAuthorityInOtherJurisdictionsMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">roiv:TaxAuthorityInOtherJurisdictionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_GBsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CHsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">roiv:EmployeeRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">roiv:OtherGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RSLEquityPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_UnitedStatesAndCanadaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">roiv:UnitedStatesAndCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ImmunovantINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_DatavantHoldingsIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:SubsidiaryEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_NovaquestMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:NovaquestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CombinedCompanyMembersrtOwnershipAxis_DatavantMergerMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">roiv:CombinedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DatavantMergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivPublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:RoivPublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivPrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:RoivPrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivLiabilityInstrumentsMeasuredAtFairValueMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">roiv:RoivLiabilityInstrumentsMeasuredAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivEarnoutSharesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">roiv:RoivEarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:MontesArchimedesAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_MaacClassBSharesMemberusgaapStatementClassOfStockAxis_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:MontesArchimedesAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">roiv:MaacClassBSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_MaacClassASharesMemberusgaapStatementClassOfStockAxis_RoivantWarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:RoivantWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">roiv:MaacClassASharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis_PipeFinancingMemberROIVAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:MontesArchimedesAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:AgreementAxis">roiv:PipeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsEighteenPerDollarMemberROIVTriggeringEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:RedemptionOfRoivantWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis">roiv:SharePriceEqualOrExceedsEighteenPerDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsTenDollarMemberROIVTriggeringEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:RedemptionOfRoivantWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis">roiv:SharePriceEqualOrExceedsTenDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsEighteenPerDollarMemberROIVTriggeringEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis">roiv:SharePriceEqualOrExceedsEighteenPerDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LockUpPeriodOneMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis">roiv:LockUpPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LockUpPeriodTwoMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis">roiv:LockUpPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LockUpPeriodThreeMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis">roiv:LockUpPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LockUpPeriodSevenMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis">roiv:LockUpPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LockUpPeriodEightMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis">roiv:LockUpPeriodEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LockUpPeriodNineMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis">roiv:LockUpPeriodNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LockUpPeriodFourMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis">roiv:LockUpPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LockUpPeriodFiveMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis">roiv:LockUpPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LockUpPeriodSixMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis">roiv:LockUpPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RoivantWarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:RoivantWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsTwentyDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis">roiv:SponsorSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis">roiv:SharePriceEqualOrExceedsTwentyDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis">roiv:SponsorSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis">roiv:SharePriceEqualOrExceedsFifteenDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_EarnoutSharesMemberusgaapStatementEquityComponentsAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_EarnoutSharesMemberusgaapStatementEquityComponentsAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_DatavantMemberdeiLegalEntityAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:DatavantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_DatavantMemberdeiLegalEntityAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:DatavantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_EarnoutSharesMemberusgaapStatementEquityComponentsAxis_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">roiv:LiabilityInstrumentsMeasuredAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">roiv:LiabilityInstrumentsMeasuredAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">roiv:PharmanvanthSevenGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommercialMilestoneMemberusgaapTransactionTypeAxis_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">roiv:PharmanvanthSevenGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">roiv:CommercialMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_DevelopmentAndRegulatoryMilestoneMemberusgaapTransactionTypeAxis_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">roiv:PharmanvanthSevenGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">roiv:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CantorFitzgeraldCo.MemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">roiv:CantorFitzgeraldCo.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_MasterSubscriptionAgreementMemberROIVAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="roiv:AgreementAxis">roiv:MasterSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ProductServiceAgreementMemberROIVAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="roiv:AgreementAxis">roiv:ProductServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CollaborationAgreementWithBlueprintMedicinesMemberROIVAgreementAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:AgreementAxis">roiv:CollaborationAgreementWithBlueprintMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">roiv:RegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:NovaquestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">roiv:SumitomoOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">roiv:SumitomoOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_MaximumMembersrtRangeAxis_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">roiv:SumitomoOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_DatavantMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:DatavantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_DatavantMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:DatavantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">roiv:EmployeeRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">roiv:OtherGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ImmunovantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:GenevantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">roiv:SiliconTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:SiliconTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">roiv:LiabilityInstrumentsMeasuredAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_NovaquestMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:NovaquestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">roiv:SumitomoOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivLiabilityInstrumentsMeasuredAtFairValueMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">roiv:RoivLiabilityInstrumentsMeasuredAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LaboratoryandotherequipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">roiv:LaboratoryandotherequipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LaboratoryandotherequipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">roiv:LaboratoryandotherequipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="roiv:AgreementAxis">roiv:TransitionServicesAndStrategicCooperationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RoivantSciencesLtd.MemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:RoivantSciencesLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:RestrictedStockAndPerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RSLEquityPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RSLEquityPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SumitomoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:AgreementAxis">roiv:TransitionServicesAndStrategicCooperationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_SubsidiaryEquityIncentivePlansMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:SubsidiaryEquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OtherMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">roiv:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CHsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_BMsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BM</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CollaborationAgreementWithBlueprintMedicinesMemberROIVAgreementAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:AgreementAxis">roiv:CollaborationAgreementWithBlueprintMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_MaximumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_MinimumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CHsrtStatementGeographicalAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CHsrtStatementGeographicalAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_MaximumMembersrtRangeAxis_UnitedStatesAndCanadaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">roiv:UnitedStatesAndCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_MinimumMembersrtRangeAxis_UnitedStatesAndCanadaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">roiv:UnitedStatesAndCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DatavantHoldingsIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">roiv:PharmanvanthSevenGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CommonStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_WarrantMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_StockOptionsAndPerformanceStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_TwoThousandAndTwentyCvarsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:TwoThousandAndTwentyCvarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_NovemberTwoThousandAndTwentyOneCvarsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:NovemberTwoThousandAndTwentyOneCvarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_EarnOutSharesNonvestedMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:EarnOutSharesNonvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_PrivatePlacementWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_PublicWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OtherInstrumentsIssuedMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:OtherInstrumentsIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_SumitomoOptionsMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SumitomoOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_EarnoutSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DatavantMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:DatavantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DatavantMergerMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DatavantMergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis_PipeFinancingMemberROIVAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:MontesArchimedesAcquisitionCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:AgreementAxis">roiv:PipeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis">roiv:SponsorSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis">roiv:SharePriceEqualOrExceedsFifteenDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis">roiv:SponsorSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis">roiv:SharePriceEqualOrExceedsFifteenDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SharePriceEqualOrExceedsTwentyDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis">roiv:SponsorSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis">roiv:SharePriceEqualOrExceedsTwentyDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_SharePriceEqualOrExceedsTwentyDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis">roiv:SponsorSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis">roiv:SharePriceEqualOrExceedsTwentyDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis">roiv:SponsorSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis">roiv:SharePriceEqualOrExceedsFifteenDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SharePriceEqualOrExceedsTenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis">roiv:SponsorSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis">roiv:SharePriceEqualOrExceedsTenDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SharePriceEqualOrExceedsTwentyDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis">roiv:SponsorSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis">roiv:SharePriceEqualOrExceedsTwentyDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsEighteenPerDollarMemberROIVTriggeringEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:RedemptionOfRoivantWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis">roiv:SharePriceEqualOrExceedsEighteenPerDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis">roiv:SponsorSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis">roiv:SharePriceEqualOrExceedsFifteenDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsTwentyDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:BusinessCombinationAgreementAxis">roiv:SponsorSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis">roiv:SharePriceEqualOrExceedsTwentyDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LockUpPeriodOneMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis">roiv:LockUpPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LockUpPeriodTwoMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MinimumMembersrtRangeAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis">roiv:LockUpPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LockUpPeriodTwoMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis">roiv:LockUpPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LockUpPeriodSevenMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis">roiv:LockUpPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LockUpPeriodEightMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis">roiv:LockUpPeriodEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LockUpPeriodNineMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis">roiv:LockUpPeriodNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LockUpPeriodThreeMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis">roiv:LockUpPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LockUpPeriodSixMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis">roiv:LockUpPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LockUpPeriodFiveMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis">roiv:LockUpPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LockUpPeriodFourMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:MaacIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:MaacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:LockUpAgreementsAxis">roiv:LockUpPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_RoivantWarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:RoivantWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RoivantWarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:RoivantWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsEighteenDollarMemberROIVTriggeringEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis">roiv:SharePriceEqualOrExceedsEighteenDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsTenDollarMemberROIVTriggeringEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:RedemptionOfRoivantWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:TriggeringEventAxis">roiv:SharePriceEqualOrExceedsTenDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">roiv:RedemptionOfRoivantWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RoivantCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AssetPurchaseAgreementMemberROIVAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="roiv:AgreementAxis">roiv:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_March2020CappedValueAppreciationRightsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:March2020CappedValueAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="roiv:AgreementAxis">roiv:TransitionServicesAndStrategicCooperationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SumitomoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:AgreementAxis">roiv:TransitionServicesAndStrategicCooperationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_SubsidiaryEquityIncentivePlansMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:SubsidiaryEquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OtherMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">roiv:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CHsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_BMsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BM</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:GenevantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">roiv:SiliconTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OtherInstrumentsIssuedMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:OtherInstrumentsIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_StockOptionsAndPerformanceStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_TwoThousandAndTwentyCvarsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">roiv:TwoThousandAndTwentyCvarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RSLEquityPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:RestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P11_01_2021To11_01_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="PAsOn10_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="PAsOn04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ImmunovantINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="PAsOn04_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="PAsOn07_27_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-27</instant>
        </period>
    </context>
    <context id="P07_27_2021To07_27_2021_DatavantMergerMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DatavantMergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-27</startDate>
            <endDate>2021-07-27</endDate>
        </period>
    </context>
    <context id="P11_01_2021To11_30_2021_HemavantSciencesGmbhMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">roiv:HemavantSciencesGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P11_01_2021To11_30_2021_SecondTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">roiv:SiliconTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">roiv:SecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P11_01_2021To11_30_2021_SecondTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:SiliconTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">roiv:SecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P11_01_2021To11_30_2021_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">roiv:PharmanvanthSevenGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P11_01_2021To11_30_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="PAsOn11_30_2021_HemavantSciencesGmbhMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">roiv:HemavantSciencesGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn05_31_2019_PrimeRateMemberusgaapVariableRateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="PAsOn05_31_2021_AssetPurchaseAgreementMemberROIVAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="roiv:AgreementAxis">roiv:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="PAsOn05_31_2021_RevenueInterestPurchaseAndSaleAgreementMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">roiv:RevenueInterestPurchaseAndSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:NovaquestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">roiv:RegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:NovaquestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="PAsOn08_31_2018_CommercialMilestoneMemberusgaapTransactionTypeAxis_NovaquestMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">roiv:CommercialMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:NovaquestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="PAsOn10_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:NovaquestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="P05_01_2021To05_31_2021_RevenueInterestPurchaseAndSaleAgreementMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">roiv:RevenueInterestPurchaseAndSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_GSKMembersrtCounterpartyNameAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">roiv:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">roiv:RegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_RoivrevenueInterestPurchaseAndSaleAgreementMemberMemberusgaapFinancialInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">roiv:RoivrevenueInterestPurchaseAndSaleAgreementMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WelichemBiotechIncMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">roiv:WelichemBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_GSKMembersrtCounterpartyNameAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">roiv:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">roiv:RegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="P05_31_2022To05_31_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WelichemBiotechIncMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">roiv:WelichemBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="PAsOn10_31_2017_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="P03_01_2022To03_01_2022_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SumitomoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:AgreementAxis">roiv:TransitionServicesAndStrategicCooperationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <context id="PAsOn02_14_2022_CantorFitzgeraldCo.MemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">roiv:CantorFitzgeraldCo.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-14</instant>
        </period>
    </context>
    <context id="P02_14_2022To02_14_2022_CantorFitzgeraldCo.MemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">roiv:CantorFitzgeraldCo.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-14</startDate>
            <endDate>2022-02-14</endDate>
        </period>
    </context>
    <context id="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ImmunovantINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ImmunovantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ImmunovantINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="P05_01_2020To05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ImmunovantINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="PAsOn05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ImmunovantINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="P09_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P09_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ImmunovantINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn07_01_2021_SkMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:SkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SkMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">roiv:SkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="P04_01_2018To04_30_2018_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:GenevantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="P07_31_2020To07_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:GenevantSciencesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-31</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="P07_31_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:GenevantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-31</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="PAsOn07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:GenevantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="PAsOn07_31_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="P01_01_2021To01_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="P11_01_2020To11_30_2020_AffivantSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:AffivantSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="P11_01_2020To11_30_2020_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:MilestoneEventsAxis">roiv:FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="P11_01_2020To11_30_2020_AffivantSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:AffivantSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="P11_01_2020To11_30_2020_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:MilestoneEventsAxis">roiv:FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="P11_01_2020To11_30_2020_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:MilestoneEventsAxis">roiv:FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="P11_01_2020To11_30_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="P12_01_2020To12_31_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn01_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="P03_01_2021To03_31_2021_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">roiv:SumitomoOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P03_01_2021To03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">roiv:SiliconTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P03_01_2021To03_31_2021_FirstTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:SiliconTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">roiv:FirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P03_01_2021To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:SiliconTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P07_01_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:GenevantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="P09_01_2021To09_30_2021_PriovantMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">roiv:PriovantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P09_01_2021To09_30_2021_PriovantMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:PriovantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P09_01_2021To09_30_2021_AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMemberROIVEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="roiv:EventAxis">roiv:AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:GenevantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:StockOptionsAndPerformanceStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RSLEquityPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:RestrictedStockAndPerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RSLEquityPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:RestrictedStockAndPerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:RSLEquityPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RedeemableNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_RedeemableNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RedeemableNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Day">
        <measure>utr:Day</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_CAD">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="Unit_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Segment">
        <measure>roiv:Segment</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Y">
        <measure>utr:Y</measure>
    </unit>
    <dei:AmendmentFlag contextRef="P04_01_2021To03_31_2022">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="P04_01_2021To03_31_2022" id="hidden50657982">Roivant Sciences Ltd.</dei:EntityRegistrantName>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="PAsOn03_31_2022_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      id="hidden50658326"
      unitRef="Unit_pure">0.10</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="PAsOn03_31_2022_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      id="hidden50658327"
      unitRef="Unit_pure">0.12</us-gaap:DebtInstrumentMeasurementInput>
    <dei:EntityCentralIndexKey contextRef="P04_01_2021To03_31_2022">0001635088</dei:EntityCentralIndexKey>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2022"
      decimals="8"
      id="hidden50658054"
      unitRef="Unit_USD_per_Share">0.00000003</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2021"
      decimals="8"
      id="hidden50658055"
      unitRef="Unit_USD_per_Share">0.00000003</us-gaap:CommonStockParOrStatedValuePerShare>
    <dei:DocumentFiscalPeriodFocus contextRef="P04_01_2021To03_31_2022">FY</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="P04_01_2021To03_31_2022">--03-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="8"
      id="hidden50658913"
      unitRef="Unit_USD_per_Share">0.00000003</us-gaap:CommonStockParOrStatedValuePerShare>
    <roiv:Numberoftradingdaystomeetearnoutpricethreshold
      contextRef="P04_01_2021To03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis"
      id="hidden50659038">P20D</roiv:Numberoftradingdaystomeetearnoutpricethreshold>
    <roiv:Numberoftradingdaystomeetearnoutpricethreshold
      contextRef="P04_01_2021To03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis"
      id="hidden50659039">P20D</roiv:Numberoftradingdaystomeetearnoutpricethreshold>
    <roiv:Tradingdayperiodforearnoutshares
      contextRef="P04_01_2021To03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis"
      id="hidden50659043">P30D</roiv:Tradingdayperiodforearnoutshares>
    <roiv:Tradingdayperiodforearnoutshares
      contextRef="P04_01_2021To03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsTwentyDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis"
      id="hidden50659044">P30D</roiv:Tradingdayperiodforearnoutshares>
    <roiv:Lockupperiodofcommonshares
      contextRef="P04_01_2021To03_31_2022_LockUpPeriodNineMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis"
      id="hidden50659059">P36M</roiv:Lockupperiodofcommonshares>
    <roiv:Lockupperiodofcommonshares
      contextRef="P04_01_2021To03_31_2022_LockUpPeriodThreeMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis"
      id="hidden50659060">P36M</roiv:Lockupperiodofcommonshares>
    <roiv:Lockupperiodwarrants
      contextRef="P04_01_2021To03_31_2022_LockUpPeriodSixMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis"
      id="hidden50659065">P36M</roiv:Lockupperiodwarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="P04_01_2021To03_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="hidden50659171"
      unitRef="Unit_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <dei:DocumentType contextRef="P04_01_2021To03_31_2022">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="P04_01_2021To03_31_2022">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="P04_01_2021To03_31_2022">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="P04_01_2021To03_31_2022">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="P04_01_2021To03_31_2022">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="P04_01_2021To03_31_2022">001-40782</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="P04_01_2021To03_31_2022">D0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="P04_01_2021To03_31_2022">98-1173944</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P04_01_2021To03_31_2022">Suite 1, 3rd Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="P04_01_2021To03_31_2022">11-12 St. James&#x2019;s Square</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="P04_01_2021To03_31_2022">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P04_01_2021To03_31_2022">SW1Y 4LB</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="P04_01_2021To03_31_2022">GB</dei:EntityAddressCountry>
    <dei:CountryRegion contextRef="P04_01_2021To03_31_2022">+44</dei:CountryRegion>
    <dei:CityAreaCode contextRef="P04_01_2021To03_31_2022">207</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P04_01_2021To03_31_2022">400 3347</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="P04_01_2021To03_31_2022_CommonStockMemberusgaapStatementClassOfStockAxis">Common Shares, $0.0000000341740141 per share</dei:Security12bTitle>
    <dei:Security12bTitle contextRef="P04_01_2021To03_31_2022_WarrantMemberusgaapStatementClassOfStockAxis">Redeemable Warrants, each whole warrant exercisable for one Common Share at an exercise price of $11.50 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P04_01_2021To03_31_2022_CommonStockMemberusgaapStatementClassOfStockAxis">ROIV</dei:TradingSymbol>
    <dei:TradingSymbol contextRef="P04_01_2021To03_31_2022_WarrantMemberusgaapStatementClassOfStockAxis">ROIVW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P04_01_2021To03_31_2022_CommonStockMemberusgaapStatementClassOfStockAxis">NASDAQ</dei:SecurityExchangeName>
    <dei:SecurityExchangeName contextRef="P04_01_2021To03_31_2022_WarrantMemberusgaapStatementClassOfStockAxis">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="P04_01_2021To03_31_2022">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="P04_01_2021To03_31_2022">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="P04_01_2021To03_31_2022">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P04_01_2021To03_31_2022">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P04_01_2021To03_31_2022">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P04_01_2021To03_31_2022">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P04_01_2021To03_31_2022">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P04_01_2021To03_31_2022">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="P04_01_2021To03_31_2022">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="P04_01_2021To03_31_2022">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="PAsOn10_01_2021"
      decimals="0"
      unitRef="Unit_USD">1115587985</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn06_21_2022"
      decimals="INF"
      unitRef="Unit_shares">700765918</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="P04_01_2021To03_31_2022">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="P04_01_2021To03_31_2022">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="P04_01_2021To03_31_2022">Iselin, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2060400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2055044000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3903000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">77701000</us-gaap:RestrictedCashCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">82220000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">54250000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2146523000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2186995000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">25905000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14749000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">61044000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">62279000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">9731000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8931000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">325834000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">188978000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">100563000</us-gaap:LongTermInvestments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">16092000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">27197000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2585129000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2589692000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">34583000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">20550000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">127531000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">76936000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">11398000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">12313000</us-gaap:OperatingLeaseLiabilityCurrent>
    <roiv:DeferredConsiderationLiabilityCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:DeferredConsiderationLiabilityCurrent>
    <roiv:DeferredConsiderationLiabilityCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">100000000</roiv:DeferredConsiderationLiabilityCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">10147000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5918000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">708000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3244000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">184367000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">218961000</us-gaap:LiabilitiesCurrent>
    <roiv:LiabilityInstrumentsMeasuredAtFairValue
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">44912000</roiv:LiabilityInstrumentsMeasuredAtFairValue>
    <roiv:LiabilityInstrumentsMeasuredAtFairValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">67893000</roiv:LiabilityInstrumentsMeasuredAtFairValue>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">62468000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">62384000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtFairValue
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">177400000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">150100000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">210025000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">170280000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">13740000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">8183000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8169000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">523695000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">527687000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn03_31_2022"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn03_31_2021"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">22491000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">22491000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2021"
      decimals="INF"
      unitRef="Unit_shares">7000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2022"
      decimals="INF"
      unitRef="Unit_shares">7000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2022"
      decimals="INF"
      unitRef="Unit_shares">694975965</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2022"
      decimals="INF"
      unitRef="Unit_shares">694975965</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2021"
      decimals="INF"
      unitRef="Unit_shares">651576293</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2021"
      decimals="INF"
      unitRef="Unit_shares">651576293</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      id="Fact_50658038"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      id="Fact_50658039"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      id="Fact_50658041"
      unitRef="Unit_USD">4421614000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      id="Fact_50658040"
      unitRef="Unit_USD">3814805000</us-gaap:AdditionalPaidInCapital>
    <roiv:SubscriptionsReceivable
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      id="Fact_50658043"
      unitRef="Unit_USD">0</roiv:SubscriptionsReceivable>
    <roiv:SubscriptionsReceivable
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      id="Fact_50658042"
      unitRef="Unit_USD">-100000000</roiv:SubscriptionsReceivable>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      id="Fact_50658045"
      unitRef="Unit_USD">-2763724000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      id="Fact_50658044"
      unitRef="Unit_USD">-1918462000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      id="Fact_50658047"
      unitRef="Unit_USD">-946000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      id="Fact_50658046"
      unitRef="Unit_USD">1445000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      id="Fact_50658049"
      unitRef="Unit_USD">1656944000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      id="Fact_50658048"
      unitRef="Unit_USD">1797788000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      id="Fact_50658022"
      unitRef="Unit_USD">381999000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      id="Fact_50658023"
      unitRef="Unit_USD">241726000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      id="Fact_50658024"
      unitRef="Unit_USD">2038943000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      id="Fact_50658025"
      unitRef="Unit_USD">2039514000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2585129000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2589692000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">55286000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">23795000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <roiv:OperatingCosts
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">8966000</roiv:OperatingCosts>
    <roiv:OperatingCosts
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2057000</roiv:OperatingCosts>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2021To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">63735000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">22637000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">483035000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">236626000</us-gaap:ResearchAndDevelopmentExpense>
    <roiv:AcquiredInProcessResearchAndDevelopmentExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">139894000</roiv:AcquiredInProcessResearchAndDevelopmentExpense>
    <roiv:AcquiredInProcessResearchAndDevelopmentExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">596132000</roiv:AcquiredInProcessResearchAndDevelopmentExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2021To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">501221000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">62321000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">775033000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">259878000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1406928000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1094693000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-1351642000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-1070898000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnInvestments
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-87291000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">95533000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainOnSaleOfInvestments
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">443754000</us-gaap:GainOnSaleOfInvestments>
    <us-gaap:GainOnSaleOfInvestments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:GainOnSaleOfInvestments>
    <roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3354000</roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments>
    <roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-29845000</roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments>
    <roiv:EquityInterestOptionToThirdPartyPurchaserGainOnTermination
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">66472000</roiv:EquityInterestOptionToThirdPartyPurchaserGainOnTermination>
    <roiv:EquityInterestOptionToThirdPartyPurchaserGainOnTermination
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:EquityInterestOptionToThirdPartyPurchaserGainOnTermination>
    <roiv:DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5041000</roiv:DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity>
    <roiv:DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">115364000</roiv:DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-3435000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-8701000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-923747000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-898547000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">369000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1686000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-924116000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-900233000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-78854000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-90999000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-845262000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-809234000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P04_01_2021To03_31_2022"
      decimals="2"
      id="Fact_50658157"
      unitRef="Unit_USD_per_Share">-1.26</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P04_01_2020To03_31_2021"
      decimals="2"
      id="Fact_50658156"
      unitRef="Unit_USD_per_Share">-1.28</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P04_01_2021To03_31_2022"
      decimals="0"
      id="Fact_50658155"
      unitRef="Unit_shares">669753458</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P04_01_2020To03_31_2021"
      decimals="0"
      id="Fact_50658154"
      unitRef="Unit_shares">630046720</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-924116000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-900233000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-2271000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3826000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-2271000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3826000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-926387000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-896407000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-78734000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-90967000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-847653000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-805440000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="PAsOn03_31_2020_RedeemableNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658125"
      unitRef="Unit_USD">22491000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="Fact_50658115"
      unitRef="Unit_shares">628779048</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658121"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658116"
      unitRef="Unit_USD">3143739000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658122"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658117"
      unitRef="Unit_USD">-2349000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658118"
      unitRef="Unit_USD">-1109228000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658119"
      unitRef="Unit_USD">54042000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      id="Fact_50658120"
      unitRef="Unit_USD">2086204000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_01_2020To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="Fact_50658092"
      unitRef="Unit_shares">21077155</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658095"
      unitRef="Unit_USD">301744000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      id="Fact_50658096"
      unitRef="Unit_USD">301744000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <roiv:IssuanceOfSubsidiaryCommonSharesNetValue
      contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658111"
      unitRef="Unit_USD">324995000</roiv:IssuanceOfSubsidiaryCommonSharesNetValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesNetValue
      contextRef="P04_01_2020To03_31_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658112"
      unitRef="Unit_USD">-100000000</roiv:IssuanceOfSubsidiaryCommonSharesNetValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesNetValue
      contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658113"
      unitRef="Unit_USD">231102000</roiv:IssuanceOfSubsidiaryCommonSharesNetValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesNetValue
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      id="Fact_50658114"
      unitRef="Unit_USD">456097000</roiv:IssuanceOfSubsidiaryCommonSharesNetValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue
      contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658109"
      unitRef="Unit_USD">-11692000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue
      contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658110"
      unitRef="Unit_USD">11692000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue>
    <roiv:ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits
      contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658285"
      unitRef="Unit_USD">522000</roiv:ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits>
    <roiv:ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits
      contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658286"
      unitRef="Unit_USD">385000</roiv:ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits>
    <roiv:ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      id="Fact_50658287"
      unitRef="Unit_USD">907000</roiv:ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits>
    <roiv:DeconsolidationOfSubsidiary
      contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658281"
      unitRef="Unit_USD">-3054000</roiv:DeconsolidationOfSubsidiary>
    <roiv:DeconsolidationOfSubsidiary
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      id="Fact_50658282"
      unitRef="Unit_USD">-3054000</roiv:DeconsolidationOfSubsidiary>
    <roiv:ConsolidationOfUnconsolidatedEntity
      contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658279"
      unitRef="Unit_USD">9178000</roiv:ConsolidationOfUnconsolidatedEntity>
    <roiv:ConsolidationOfUnconsolidatedEntity
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      id="Fact_50658280"
      unitRef="Unit_USD">9178000</roiv:ConsolidationOfUnconsolidatedEntity>
    <roiv:RepurchaseOfEquityAwards
      contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658273"
      unitRef="Unit_USD">113000</roiv:RepurchaseOfEquityAwards>
    <roiv:RepurchaseOfEquityAwards
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      id="Fact_50658274"
      unitRef="Unit_USD">113000</roiv:RepurchaseOfEquityAwards>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658266"
      unitRef="Unit_USD">-1642000</roiv:CapitalContributionsToSubsidiaries>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658267"
      unitRef="Unit_USD">1642000</roiv:CapitalContributionsToSubsidiaries>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2020To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658253"
      unitRef="Unit_USD">1720090000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658254"
      unitRef="Unit_USD">57252000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658255"
      unitRef="Unit_USD">27706000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      id="Fact_50658256"
      unitRef="Unit_USD">84958000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P04_01_2020To03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658241"
      unitRef="Unit_USD">3794000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658242"
      unitRef="Unit_USD">32000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      id="Fact_50658243"
      unitRef="Unit_USD">3826000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658229"
      unitRef="Unit_USD">-809234000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658230"
      unitRef="Unit_USD">-90999000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      id="Fact_50658231"
      unitRef="Unit_USD">-900233000</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="PAsOn03_31_2021_RedeemableNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658123"
      unitRef="Unit_USD">22491000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="Fact_50658198"
      unitRef="Unit_shares">651576293</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658213"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658202"
      unitRef="Unit_USD">3814805000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658203"
      unitRef="Unit_USD">-100000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658204"
      unitRef="Unit_USD">1445000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658205"
      unitRef="Unit_USD">-1918462000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658206"
      unitRef="Unit_USD">241726000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      id="Fact_50658207"
      unitRef="Unit_USD">2039514000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <roiv:IssuanceOfSubsidiaryWarrants
      contextRef="P04_01_2021To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658103"
      unitRef="Unit_USD">2051000</roiv:IssuanceOfSubsidiaryWarrants>
    <roiv:IssuanceOfSubsidiaryWarrants
      contextRef="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658104"
      unitRef="Unit_USD">24000</roiv:IssuanceOfSubsidiaryWarrants>
    <roiv:IssuanceOfSubsidiaryWarrants
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      id="Fact_50658105"
      unitRef="Unit_USD">2075000</roiv:IssuanceOfSubsidiaryWarrants>
    <roiv:StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing
      contextRef="P04_01_2021To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="Fact_50658903"
      unitRef="Unit_shares">32372478</roiv:StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing>
    <roiv:StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing
      contextRef="P04_01_2021To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658909"
      unitRef="Unit_USD">129097000</roiv:StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing>
    <roiv:StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      id="Fact_50658910"
      unitRef="Unit_USD">129097000</roiv:StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing>
    <roiv:StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration
      contextRef="P04_01_2021To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="Fact_50658921"
      unitRef="Unit_shares">840398</roiv:StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryPreferredShares
      contextRef="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658924"
      unitRef="Unit_USD">70000000</roiv:StockIssuedDuringPeriodValueSubsidiaryPreferredShares>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryPreferredShares
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      id="Fact_50658925"
      unitRef="Unit_USD">70000000</roiv:StockIssuedDuringPeriodValueSubsidiaryPreferredShares>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany
      contextRef="P04_01_2021To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658929"
      unitRef="Unit_USD">-52189000</roiv:StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany>
    <roiv:StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany
      contextRef="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658930"
      unitRef="Unit_USD">52189000</roiv:StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany>
    <roiv:AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent
      contextRef="P04_01_2021To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658935"
      unitRef="Unit_USD">-40000000</roiv:AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent>
    <roiv:AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent
      contextRef="P04_01_2021To03_31_2022_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658936"
      unitRef="Unit_USD">100000000</roiv:AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent>
    <roiv:AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent
      contextRef="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658937"
      unitRef="Unit_USD">40000000</roiv:AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent>
    <roiv:AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      id="Fact_50658938"
      unitRef="Unit_USD">100000000</roiv:AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent>
    <roiv:RepurchaseOfEquityAwards
      contextRef="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658275"
      unitRef="Unit_USD">2247000</roiv:RepurchaseOfEquityAwards>
    <roiv:RepurchaseOfEquityAwards
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      id="Fact_50658276"
      unitRef="Unit_USD">2247000</roiv:RepurchaseOfEquityAwards>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_01_2021To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="Fact_50658093"
      unitRef="Unit_shares">7369000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P04_01_2021To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658097"
      unitRef="Unit_USD">57167000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      id="Fact_50658098"
      unitRef="Unit_USD">57167000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <roiv:IssuanceOfStockUponWarrantsExerciseShares
      contextRef="P04_01_2021To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="Fact_50659118"
      unitRef="Unit_shares">60021</roiv:IssuanceOfStockUponWarrantsExerciseShares>
    <roiv:IssuanceOfStockUponWarrantsExerciseValue
      contextRef="P04_01_2021To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50659121"
      unitRef="Unit_USD">778000</roiv:IssuanceOfStockUponWarrantsExerciseValue>
    <roiv:IssuanceOfStockUponWarrantsExerciseValue
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      id="Fact_50659120"
      unitRef="Unit_USD">778000</roiv:IssuanceOfStockUponWarrantsExerciseValue>
    <roiv:StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled
      contextRef="P04_01_2021To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="Fact_50659119"
      unitRef="Unit_shares">2757775</roiv:StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P04_01_2021To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658101"
      unitRef="Unit_USD">412000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      id="Fact_50658102"
      unitRef="Unit_USD">412000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <roiv:DeconsolidationOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658283"
      unitRef="Unit_USD">3578000</roiv:DeconsolidationOfSubsidiary>
    <roiv:DeconsolidationOfSubsidiary
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      id="Fact_50658284"
      unitRef="Unit_USD">3578000</roiv:DeconsolidationOfSubsidiary>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="P04_01_2021To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658268"
      unitRef="Unit_USD">-10219000</roiv:CapitalContributionsToSubsidiaries>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658269"
      unitRef="Unit_USD">10219000</roiv:CapitalContributionsToSubsidiaries>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2021To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658257"
      unitRef="Unit_USD">519712000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658258"
      unitRef="Unit_USD">45244000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      id="Fact_50658259"
      unitRef="Unit_USD">564956000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P04_01_2021To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658244"
      unitRef="Unit_USD">-2391000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658245"
      unitRef="Unit_USD">120000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      id="Fact_50658246"
      unitRef="Unit_USD">-2271000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2021To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658232"
      unitRef="Unit_USD">-845262000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2021To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658233"
      unitRef="Unit_USD">-78854000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      id="Fact_50658234"
      unitRef="Unit_USD">-924116000</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="PAsOn03_31_2022_RedeemableNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658124"
      unitRef="Unit_USD">22491000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="Fact_50658199"
      unitRef="Unit_shares">694975965</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658214"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658208"
      unitRef="Unit_USD">4421614000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658215"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658209"
      unitRef="Unit_USD">-946000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658210"
      unitRef="Unit_USD">-2763724000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_50658211"
      unitRef="Unit_USD">381999000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      id="Fact_50658212"
      unitRef="Unit_USD">2038943000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-924116000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-900233000</us-gaap:ProfitLoss>
    <roiv:NonCashAcquiredInProcessResearchAndDevelopment
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">78223000</roiv:NonCashAcquiredInProcessResearchAndDevelopment>
    <roiv:NonCashAcquiredInProcessResearchAndDevelopment
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">351523000</roiv:NonCashAcquiredInProcessResearchAndDevelopment>
    <us-gaap:ShareBasedCompensation
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">564956000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">84958000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnInvestments
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-87291000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">95533000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainOnSaleOfInvestments
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">443754000</us-gaap:GainOnSaleOfInvestments>
    <us-gaap:GainOnSaleOfInvestments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:GainOnSaleOfInvestments>
    <roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3354000</roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments>
    <roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-29845000</roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments>
    <roiv:GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5041000</roiv:GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity>
    <roiv:GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">115364000</roiv:GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity>
    <roiv:GainOnTerminationOfEquityInterestOptions
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">61472000</roiv:GainOnTerminationOfEquityInterestOptions>
    <roiv:GainOnTerminationOfEquityInterestOptions
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:GainOnTerminationOfEquityInterestOptions>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-3750000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-13819000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-16978000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">15403000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3752000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">50595000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9225000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-50000000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">100000000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <roiv:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-6865000</roiv:IncreaseDecreaseInOperatingLeaseLiabilities>
    <roiv:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-5497000</roiv:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">17969000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2297000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">11383000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">37839000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-677729000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-552138000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">320170000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">17436000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5806000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <roiv:IncreaseDecreaseInOtherInvestingNet
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-561000</roiv:IncreaseDecreaseInOtherInvestingNet>
    <roiv:IncreaseDecreaseInOtherInvestingNet
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">25896000</roiv:IncreaseDecreaseInOtherInvestingNet>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">303295000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-31702000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <roiv:ProceedsFromBusinessCombinationAndPipeFinancing
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">213424000</roiv:ProceedsFromBusinessCombinationAndPipeFinancing>
    <roiv:ProceedsFromBusinessCombinationAndPipeFinancing
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:ProceedsFromBusinessCombinationAndPipeFinancing>
    <roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet>
    <roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">455756000</roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet>
    <roiv:ProceedsFromPaymentOfSubscriptionReceivable
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">100000000</roiv:ProceedsFromPaymentOfSubscriptionReceivable>
    <roiv:ProceedsFromPaymentOfSubscriptionReceivable
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:ProceedsFromPaymentOfSubscriptionReceivable>
    <roiv:ProceedsFromSubsidiaryDebtFinancingsNet
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">36400000</roiv:ProceedsFromSubsidiaryDebtFinancingsNet>
    <roiv:ProceedsFromSubsidiaryDebtFinancingsNet
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:ProceedsFromSubsidiaryDebtFinancingsNet>
    <roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">21590000</roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary>
    <roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary>
    <roiv:PaymentForOfferingAndLoanCosts
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20297000</roiv:PaymentForOfferingAndLoanCosts>
    <roiv:PaymentForOfferingAndLoanCosts
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">286000</roiv:PaymentForOfferingAndLoanCosts>
    <roiv:ProceedsFromAndPaymentForOtherFinancingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1145000</roiv:ProceedsFromAndPaymentForOtherFinancingActivities>
    <roiv:ProceedsFromAndPaymentForOtherFinancingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-794000</roiv:ProceedsFromAndPaymentForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">306792000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">456264000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-67642000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-127576000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2141676000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2269252000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2074034000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2141676000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <roiv:SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares>
    <roiv:SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">100000000</roiv:SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares>
    <roiv:OtherNonCashTransactions
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6035000</roiv:OtherNonCashTransactions>
    <roiv:OtherNonCashTransactions
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4531000</roiv:OtherNonCashTransactions>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">916000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4076000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5535000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2017000</us-gaap:InterestPaidNet>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 1&#x2014;Description of Business and Liquidity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Description of Business &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Roivant Sciences Ltd. (inclusive of its consolidated subsidiaries, the &#x201c;Company&#x201d; or &#x201c;RSL&#x201d;) aims to improve health by rapidly delivering innovative medicines and technologies to patients. The Company does this by building biotech and healthcare technology companies (&#x201c;Vants&#x201d;) and deploying technology to drive greater efficiency in research and development and commercialization.&#160;In addition to biopharmaceutical subsidiaries, the Company also builds technology Vants focused on improving the process of developing and commercializing medicines. The Company was founded on April&#160;7, 2014 as a Bermuda exempted limited company. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;VTAMA&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; (tapinarof) cream was approved by the United States Food and Drug Administration (&#x201c;FDA&#x201d;) in May 2022 as the first and only &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FDA-approved&lt;/div&gt; steroid-free topical medication in its class for the treatment of plaque psoriasis in adult patients. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has determined that it has one operating and reporting segment as it allocates resources and assesses financial performance on a consolidated basis. The Company&#x2019;s subsidiaries are wholly owned subsidiaries and majority-owned or controlled subsidiaries. Refer to Note 4, &#x201c;Investments&#x201d; for further discussion of the Company&#x2019;s investments in unconsolidated entities. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&#160;30, 2021, RSL completed its business combination with Montes Archimedes Acquisition Corp. (&#x201c;MAAC&#x201d;), a special purpose acquisition company, and began trading on Nasdaq under the ticker symbol &#x201c;ROIV.&#x201d; Refer to Note 3, &#x201c;Business Combination with MAAC&#x201d; for additional details. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) Liquidity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has incurred significant losses and negative cash flows from operations since its inception. As of March&#160;31, 2022, the Company had cash and cash equivalents of approximately $2.1&#160;billion and its accumulated deficit was approximately $2.8&#160;billion. For the years ended March&#160;31, 2022 and 2021, the Company incurred net losses of $924.1&#160;million and $900.2&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, respectively. The Company has historically financed its operations primarily through the sale of equity securities, sale of subsidiary interests, debt financings and revenue generated from licensing and collaboration arrangements. Through March&#160;31, 2022, the Company had not generated any revenue from the sale of its product candidates. Through its subsidiary Dermavant Sciences Ltd., the Company has launched its first commercial product, VTAMA cream, following approval by the FDA in May 2022. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals to market its product candidates, dependence on key products, dependence on third-party service providers, such as contract research organizations, and protection of intellectual property rights. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company intends to raise such additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates or take other steps to conserve capital. The Company expects its existing cash and cash equivalents will be sufficient to fund its committed operating expenses and capital expenditure requirements for at least the next &lt;/div&gt;12&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; months from the date of issuance of these consolidated financial statements.&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="P04_01_2021To03_31_2022"
      decimals="INF"
      unitRef="Unit_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2022"
      decimals="-8"
      unitRef="Unit_USD">2100000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2022"
      decimals="-8"
      unitRef="Unit_USD">-2800000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-5"
      unitRef="Unit_USD">-924100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-5"
      unitRef="Unit_USD">-900200000</us-gaap:ProfitLoss>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 2&#x2014;Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Basis of Presentation and Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s fiscal year ends on March&#160;31, and its fiscal quarters end on June&#160;30, September&#160;30, and December 31. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying audited consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;).&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The consolidated financial statements include the accounts of RSL and the subsidiaries in which it has a controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of common stock ownership interest retained in the respective operations by the noncontrolling parties. The Company presents noncontrolling interests as a component of shareholders&#x2019; equity on its consolidated balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for changes in its ownership interest in its subsidiaries while control is retained as equity transactions. The carrying amount of the noncontrolling interest is adjusted to reflect the change in RSL&#x2019;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received or paid and the amount by which the noncontrolling interest is adjusted is recognized within shareholders&#x2019; equity attributable to RSL. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additionally, the Company assessed the impact that the &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; pandemic has had on its operations and financial results as of March&#160;31, 2022 and through the issuance of these consolidated financial statements. The Company&#x2019;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(C) Concentrations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;T&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;he Company has long-lived assets in different geographic locations. As of March 31, 2022 and 2021, a majority of the Company&#x2019;s long-lived assets were located in the United States. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"/&gt; &lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt;&lt;div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(D) Cash, Cash Equivalents, and Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company considers all highly liquid investments purchased with original maturities of three months or less to&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; be cash equivalents. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash classified as a current asset consists of legally restricted &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; bearing deposit accounts relating to the Company&#x2019;s corporate credit card programs. Restricted cash classified as a long-term asset consists of restricted deposit accounts related to irrevocable standby letters of credit. As of March&#160;31, 2021, restricted cash classified as a current asset included $&lt;/div&gt;75.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million held in escrow for the purpose of fulfilling certain indemnification obligations. The full escrow amount of $&lt;/div&gt;75.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million was disbursed to the Company in June 2021.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash as reported in the accompanying consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the accompanying consolidated balance sheets as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,060,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,055,044&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,634&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86,632&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, cash equivalents and restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,074,034&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,141,676&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(E) Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(F) Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, consisting primarily of computers, laboratory and other equipment, furniture and fixtures, software, and leasehold improvements, is recorded at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement or sale, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation of property and equipment is recorded using the straight-line method over the estimated useful lives of the related assets once the asset has been placed in service. Leasehold improvements are amortized using the straight-line method over the estimated useful life or remaining lease term, whichever is shorter. The following table provides the range of estimated useful lives used for each asset type: &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 39%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 59%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated Useful Life&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computers&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;3 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory&#160;and&#160;other&#160;equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;5 - 10 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;7 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Software&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;3 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;Lesser of estimated useful life or remaining lease term&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;   &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The Company reviews the recoverability of all long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable. Recoverability is measured by comparison of the book values of the assets to the future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets.&lt;/div&gt;   &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(G&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; Investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments in equity securities may be accounted for using (i)&#160;the fair value option if elected, (ii)&#160;fair value through earnings if fair value is readily determinable or (iii)&#160;for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the measurement alternative is made for each eligible investment. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has elected the fair value option to account for certain investments over which the Company has significant influence. The Company believes the fair value option best reflects the underlying economics of the investment. See Note 4, &#x201c;Investments.&#x201d; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(H) Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs are expensed as incurred. Preclinical and clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. R&amp;amp;D costs primarily consist of costs associated with preclinical studies and clinical trials, including amounts paid to contract research organizations, contract manufacturing organizations, and other third parties that conduct R&amp;amp;D activities on behalf of the Company, as well as employee-related expenses, such as salaries, share-based compensation, and benefits, for employees engaged in R&amp;amp;D activities. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(I) Acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In-Process&lt;/div&gt; Research and Development Expenses &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the year ended March&#160;31, 2022, the Company began reporting acquired &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; research and development (&#x201c;IPR&amp;amp;D&#x201d;) expense as a separate line item in its consolidated statements of operations. Acquired IPR&amp;amp;D expenses include consideration for the purchase of IPR&amp;amp;D through asset acquisitions and license agreements as well as payments made in connection with asset acquisitions and license agreements upon the achievement of development milestones. These expenses were previously recorded in &#x201c;Research and development&#x201d; on the consolidated statements of operations. Prior periods have been revised to conform to the current period presentation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluates &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; agreements for &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; research and development projects (&#x201c;IPR&amp;amp;D&#x201d;) to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; agreement for IPR&amp;amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as acquired &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; research and development expense in its consolidated statements of operations. Payments for milestones achieved and payments for a product license prior to regulatory approval of the product are expensed in the period incurred. Milestone payments made in connection with regulatory approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(J) General and Administrative Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;General and administrative (&#x201c;G&amp;amp;A&#x201d;) expenses consist primarily of employee-related expenses for G&amp;amp;A personnel, including those responsible for the identification and acquisition or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-license&lt;/div&gt; of new drug candidates as well as for overseeing Vant operations and facilitating the use of the Company&#x2019;s platform and technologies at Vants. G&amp;amp;A expenses also consist of legal and accounting fees, consulting services and other operating costs &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;relating to corporate matters and daily operations. G&amp;amp;A expenses include costs incurred relating to the identification, acquisition or &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-license&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; and technology transfer of promising drug candidates along with costs incurred relating to the integration of new technologies.&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;  &lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(K) Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company determines if an arrangement includes a lease at the inception of the agreement. For each of the Company&#x2019;s lease arrangements, the Company records a &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; asset representing the Company&#x2019;s right to use an underlying asset for the lease term and a lease liability representing the Company&#x2019;s obligation to make lease payments. Operating lease &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; assets and operating lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the expected lease term. If the interest rate implicit in the Company&#x2019;s leases is not readily determinable, in determining the weighted-average discount rate used to&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; calculate the net present value of lease payments, the Company utilizes an estimate of its incremental borrowing rate. The Company&#x2019;s incremental borrowing rates are determined based on the term of the lease, the economic environment of the lease, and the effect of collateralization. Lease expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term and variable lease costs are expensed as incurred. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company elected the practical expedient not to apply the recognition and measurement requirements to short-term leases, which is any lease with a term of one year or less as of the lease commencement date. Leases may require the Company to pay additional amounts for taxes, insurance, maintenance, and other expenses, which are generally referred to as &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; components. The Company has elected the practical expedient to combine lease and &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; components. If a lease includes options to extend the lease term, the Company does not assume the option will be exercised in its initial lease term assessment unless there is reasonable certainty that the Company will renew based on an assessment of economic factors present as of the lease commencement date. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(L) Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded when, after consideration of all positive and negative evidence, it is not more likely than not that the Company&#x2019;s deferred tax assets will be realizable. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(M) Share-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based awards to employees, directors, and consultants, including stock options, restricted stock units, performance options and capped value appreciation rights, are measured at fair value on the date of the grant and that fair value is recognized as share-based compensation expense in the Company&#x2019;s consolidated statements of operations over the requisite service period of the respective award. The estimated fair value of awards that contain performance conditions is expensed when the Company concludes that it is probable that the &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;  &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;performance condition will be achieved. The Company may grant awards with graded-vesting features. When such awards have only service vesting requirements, the Company elected to record share-based compensation expense on a straight-line basis. If awards with graded-vesting features contain performance or market conditions, then the Company records share-based compensation expense using the accelerated attribution method. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;The Company measures the fair value of its stock options that only have service vesting requirements or performance-based options without market conditions using the Black-Scholes option pricing model. For performance-based awards with market conditions, the Company determines the fair value of the awards as of the grant date using a Monte Carlo simulation model. When determining the grant-date fair value of stock-based awards, management further considers whether an adjustment is required to the observable market price or volatility of the Company&#x2019;s common stock that is used in the valuation as a result of material &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-public&lt;/div&gt; information, if that information is expected to result in a material increase in share price. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;Certain assumptions need to be made with respect to utilizing the Black-Scholes option pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate and the fair value of the Company&#x2019;s shares of common stock. Since the Company has limited option exercise history, it has generally elected to estimate the expected life of an award based upon the &#x201c;simplified method&#x201d; with the continued use of this method extended until such time the Company has sufficient exercise history. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. The expected share price volatility for the Company&#x2019;s common shares is estimated by taking the average historical price volatility for industry peers. The Company accounts for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-vesting&lt;/div&gt; award forfeitures when they occur. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;One of the inputs to the Black-Scholes option pricing model is the fair value of the Company&#x2019;s common shares. Prior to the closing of its business combination with MAAC, as a privately held company, the Company estimated the fair value of the shares of common stock underlying its share-based awards on each grant date. Given the absence of a public trading market, and in accordance with the American Institute of Certified Public Accountants&#x2019; Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, the Company exercised reasonable judgment and considered numerous objective and subjective factors to determine its best estimate of the fair value of its common shares. The estimation of the fair value of the common shares considered factors including the following: the prices of the Company&#x2019;s common shares sold to investors in arm&#x2019;s length transactions; the estimated present value of the Company&#x2019;s future cash flows; the Company&#x2019;s business, financial condition and results of operations; the Company&#x2019;s forecasted operating performance; the illiquid nature of the Company&#x2019;s common shares; industry information such as market size and growth; market capitalization of comparable companies and the estimated value of transactions such companies have engaged in; and macroeconomic conditions. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company applies a similar methodology to estimate the fair value of the shares of common stock underlying share-based awards issued by its privately held Vants. Following the closing of the Company&#x2019;s business combination with MAAC, RSL&#x2019;s common shares became publicly traded and the Company began determining the fair value of each common share underlying share-based awards based on the closing price of its common shares as reported by Nasdaq on the date of grant. Therefore, it will not be necessary to determine the fair value of the new stock-based award pursuant to the methodology described above. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(N) Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;   &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a three-tier fair value hierarchy that distinguishes among the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Level &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1-Valuations&lt;/div&gt; are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Level &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2-Valuations&lt;/div&gt; are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Level &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-Valuations&lt;/div&gt; are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company&#x2019;s financial instruments include shares of common stock of Arbutus Biopharma Corporation (&#x201c;Arbutus&#x201d;); shares of common stock of Sio Gene Therapies Inc. (&#x201c;Sio&#x201d;); shares of common stock of Heracles Parent, L.L.C., the parent entity of Datavant (as defined and discussed in Note 4, &#x201c;Investments&#x201d;); liability instruments issued, including the Roivant Warrants and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares (each as defined in Note 3, &#x201c;Business Combination with MAAC&#x201d;) liabilities issued in connection with the Company&#x2019;s business combination with MAAC (as discussed in Note 3, &#x201c;Business Combination with MAAC&#x201d;); the deferred consideration liability; its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and long-term debt. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The shares of Arbutus and Sio common stock and investments in common stock with a readily determinable fair value are classified as Level&#160;1, and their fair value is determined based upon quoted market prices in an active market. In October 2021, shares of Arbutus&#x2019; Series A participating convertible preferred shares (&#x201c;Arbutus Preferred Shares&#x201d;) held by the Company were converted into shares of common stock of Arbutus pursuant to mandatory conversion provisions. Prior to conversion, the Arbutus Preferred Shares held by the Company were classified as Level&#160;2 as the fair value of such preferred shares was determined based upon the quoted market price of Arbutus common stock into which such preferred shares were convertible. The shares of common stock of Heracles Parent, L.L.C., the parent entity of Datavant (as defined and discussed in Note 4, &#x201c;Investments&#x201d;), and liability instruments issued, excluding the Public Warrants (as defined and discussed in Note 3, &#x201c;Business Combination with MAAC&#x201d;), are classified as Level&#160;3 within the fair value hierarchy as the assumptions and estimates used in the valuations are unobservable in the market. The Public Warrants are publicly traded and therefore are classified as Level&#160;1 as the Public Warrants have a readily determinable fair value. Cash, accounts payable, and the deferred consideration liability are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature. The deferred consideration liability was based on a fixed monetary amount, and payment was based solely on the passage of time. The deferred consideration liability was settled in November 2021 by payment of $50.0&#160;million in cash as well as the issuance of 6,348,057 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of the Company&#x2019;s &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;hares. Money market funds are included in Level&#160;1 of the fair value hierarchy and are valued at the closing price reported by an actively traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly owned subsidiaries, &#x201c;Dermavant&#x201d;), which is stated at amortized cost, approximates fair value based on current interest rates for similar types of borrowings and therefore is included in Level&#160;2 of the fair value hierarchy. Long-term debt issued by Dermavant for which the &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;fair value option has been elected is included in Level&#160;3 of the fair value hierarchy as the assumptions and estimates used in the valuation are unobservable in the market. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(O) Foreign Currency &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets and liabilities of foreign operations are translated using exchange rates in effect at the balance sheet date and their results of operations are translated using average exchange rates for the year. Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Adjustments resulting from the translation of the financial statements of the Company&#x2019;s foreign functional currency subsidiaries into U.S. dollars are excluded from the determination of net loss and are accumulated in a separate component of shareholders&#x2019; equity. Foreign exchange transaction gains and losses are included in &#x201c;Other expense, net&#x201d; in the Company&#x2019;s statements of operations. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(P) Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes revenue when its customer &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;obtains &lt;/div&gt;control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for its arrangements, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when or as the Company satisfies a performance obligation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, assessing the recognition and future reversal of variable consideration, and determining and applying appropriate methods of measuring progress for performance obligations satisfied over time. These judgments are discussed in more detail below. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licenses of intellectual property:&lt;/div&gt;&lt;/div&gt; If the licenses to intellectual property are determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable,&lt;/div&gt; upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are not distinct from other promises, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable,&lt;/div&gt; upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition accordingly. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Milestone payments: &lt;/div&gt;&lt;/div&gt;At the inception of each arrangement that includes research, development or regulatory milestone payments, the Company&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis in earnings in the period of the adjustment. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Royalties and commercial milestone payments: &lt;/div&gt;&lt;/div&gt;For arrangements that include sales-based royalties, including commercial milestone payments&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;based on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-specified&lt;/div&gt; level of sales, the Company &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon performance of the licensee. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue is also generated by certain technology-focused Vants from subscription and service-based fees recognized for the use of certain technology developed by these Vants. Subscription revenue is recognized ratably over the contract period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Trade Receivables, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in customer credit profiles. The Company reserves against trade receivables for estimated losses that may arise from a customer&#x2019;s inability to pay, and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated losses was de minimis as of March&#160;31, 2022 and 2021. Trade receivables, net is included in &#x201c;Other current assets&#x201d; on the accompanying consolidated balance sheets. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Q) Warrant Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company classifies the Roivant Warrants as liabilities. At the end of each reporting period, changes in fair value during the period are recognized within the consolidated statements of operations. The Company will continue to adjust the carrying value of the liability associated with the Roivant Warrants for changes in the fair value until the earlier of a) the exercise or expiration of the Roivant Warrants or b) the redemption of the Roivant Warrants. Issuance costs incurred that were attributable to the Roivant Warrants were expensed as incurred. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(R) Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06,&lt;/div&gt; &#x201c;Debt&#x2014;Debt with Conversion and Other Options (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20)&lt;/div&gt; and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40):&lt;/div&gt; Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&#x201d;).&lt;/div&gt; ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current U.S. GAAP. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; also removes certain settlement conditions that are required for equity contracts to qualify for the derivatives scope exception, which will permit more equity contracts to qualify for it. Either a modified retrospective transition method or a fully retrospective transition method is permissible for the adoption of this standard. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; is effective for fiscal years beginning after December&#160;15, 2021, including interim periods within those fiscal years. The early-adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; on April&#160;1, 2021 did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Basis of Presentation and Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s fiscal year ends on March&#160;31, and its fiscal quarters end on June&#160;30, September&#160;30, and December 31. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying audited consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;).&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The consolidated financial statements include the accounts of RSL and the subsidiaries in which it has a controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of common stock ownership interest retained in the respective operations by the noncontrolling parties. The Company presents noncontrolling interests as a component of shareholders&#x2019; equity on its consolidated balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for changes in its ownership interest in its subsidiaries while control is retained as equity transactions. The carrying amount of the noncontrolling interest is adjusted to reflect the change in RSL&#x2019;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received or paid and the amount by which the noncontrolling interest is adjusted is recognized within shareholders&#x2019; equity attributable to RSL. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additionally, the Company assessed the impact that the &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; pandemic has had on its operations and financial results as of March&#160;31, 2022 and through the issuance of these consolidated financial statements. The Company&#x2019;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(C) Concentrations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments. &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;T&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;he Company has long-lived assets in different geographic locations. As of March 31, 2022 and 2021, a majority of the Company&#x2019;s long-lived assets were located in the United States. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(D) Cash, Cash Equivalents, and Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company considers all highly liquid investments purchased with original maturities of three months or less to&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; be cash equivalents. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash classified as a current asset consists of legally restricted &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; bearing deposit accounts relating to the Company&#x2019;s corporate credit card programs. Restricted cash classified as a long-term asset consists of restricted deposit accounts related to irrevocable standby letters of credit. As of March&#160;31, 2021, restricted cash classified as a current asset included $&lt;/div&gt;75.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million held in escrow for the purpose of fulfilling certain indemnification obligations. The full escrow amount of $&lt;/div&gt;75.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million was disbursed to the Company in June 2021.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash as reported in the accompanying consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the accompanying consolidated balance sheets as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,060,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,055,044&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,634&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86,632&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, cash equivalents and restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,074,034&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,141,676&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:EscrowDeposit
      contextRef="PAsOn03_31_2021"
      decimals="-5"
      unitRef="Unit_USD">75000000</us-gaap:EscrowDeposit>
    <roiv:ProceedsFromReleaseOfEscrowDeposit
      contextRef="PAsOn06_30_2021"
      decimals="-5"
      unitRef="Unit_USD">75000000</roiv:ProceedsFromReleaseOfEscrowDeposit>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash as reported in the accompanying consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the accompanying consolidated balance sheets as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,060,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,055,044&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,634&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86,632&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, cash equivalents and restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,074,034&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,141,676&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2060400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2055044000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">13634000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">86632000</us-gaap:RestrictedCash>
    <roiv:CashAndCashEquivalentsAndRestrictedCash
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2074034000</roiv:CashAndCashEquivalentsAndRestrictedCash>
    <roiv:CashAndCashEquivalentsAndRestrictedCash
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2141676000</roiv:CashAndCashEquivalentsAndRestrictedCash>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(E) Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(F) Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, consisting primarily of computers, laboratory and other equipment, furniture and fixtures, software, and leasehold improvements, is recorded at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement or sale, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation of property and equipment is recorded using the straight-line method over the estimated useful lives of the related assets once the asset has been placed in service. Leasehold improvements are amortized using the straight-line method over the estimated useful life or remaining lease term, whichever is shorter. The following table provides the range of estimated useful lives used for each asset type: &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 39%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 59%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated Useful Life&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computers&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;3 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory&#160;and&#160;other&#160;equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;5 - 10 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;7 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Software&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;3 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;Lesser of estimated useful life or remaining lease term&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The Company reviews the recoverability of all long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable. Recoverability is measured by comparison of the book values of the assets to the future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets.&lt;/div&gt; </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <roiv:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock contextRef="P04_01_2021To03_31_2022">The following table provides the range of estimated useful lives used for each asset type: &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 39%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 59%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated Useful Life&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computers&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;3 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory&#160;and&#160;other&#160;equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;5 - 10 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;7 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Software&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;3 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;Lesser of estimated useful life or remaining lease term&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </roiv:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P04_01_2021To03_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P04_01_2021To03_31_2022_LaboratoryandotherequipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P04_01_2021To03_31_2022_LaboratoryandotherequipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P04_01_2021To03_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P04_01_2021To03_31_2022_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P04_01_2021To03_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">Lesser of estimated useful life or remaining lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:InvestmentPolicyTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(G&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; Investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments in equity securities may be accounted for using (i)&#160;the fair value option if elected, (ii)&#160;fair value through earnings if fair value is readily determinable or (iii)&#160;for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the measurement alternative is made for each eligible investment. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has elected the fair value option to account for certain investments over which the Company has significant influence. The Company believes the fair value option best reflects the underlying economics of the investment. See Note 4, &#x201c;Investments.&#x201d; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(H) Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs are expensed as incurred. Preclinical and clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. R&amp;amp;D costs primarily consist of costs associated with preclinical studies and clinical trials, including amounts paid to contract research organizations, contract manufacturing organizations, and other third parties that conduct R&amp;amp;D activities on behalf of the Company, as well as employee-related expenses, such as salaries, share-based compensation, and benefits, for employees engaged in R&amp;amp;D activities. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(I) Acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In-Process&lt;/div&gt; Research and Development Expenses &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the year ended March&#160;31, 2022, the Company began reporting acquired &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; research and development (&#x201c;IPR&amp;amp;D&#x201d;) expense as a separate line item in its consolidated statements of operations. Acquired IPR&amp;amp;D expenses include consideration for the purchase of IPR&amp;amp;D through asset acquisitions and license agreements as well as payments made in connection with asset acquisitions and license agreements upon the achievement of development milestones. These expenses were previously recorded in &#x201c;Research and development&#x201d; on the consolidated statements of operations. Prior periods have been revised to conform to the current period presentation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluates &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; agreements for &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; research and development projects (&#x201c;IPR&amp;amp;D&#x201d;) to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; agreement for IPR&amp;amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as acquired &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; research and development expense in its consolidated statements of operations. Payments for milestones achieved and payments for a product license prior to regulatory approval of the product are expensed in the period incurred. Milestone payments made in connection with regulatory approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <roiv:GeneralAndAdministrativeExpensesPolicyTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(J) General and Administrative Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;General and administrative (&#x201c;G&amp;amp;A&#x201d;) expenses consist primarily of employee-related expenses for G&amp;amp;A personnel, including those responsible for the identification and acquisition or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-license&lt;/div&gt; of new drug candidates as well as for overseeing Vant operations and facilitating the use of the Company&#x2019;s platform and technologies at Vants. G&amp;amp;A expenses also consist of legal and accounting fees, consulting services and other operating costs &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;relating to corporate matters and daily operations. G&amp;amp;A expenses include costs incurred relating to the identification, acquisition or &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-license&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; and technology transfer of promising drug candidates along with costs incurred relating to the integration of new technologies.&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; </roiv:GeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(K) Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company determines if an arrangement includes a lease at the inception of the agreement. For each of the Company&#x2019;s lease arrangements, the Company records a &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; asset representing the Company&#x2019;s right to use an underlying asset for the lease term and a lease liability representing the Company&#x2019;s obligation to make lease payments. Operating lease &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; assets and operating lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the expected lease term. If the interest rate implicit in the Company&#x2019;s leases is not readily determinable, in determining the weighted-average discount rate used to&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; calculate the net present value of lease payments, the Company utilizes an estimate of its incremental borrowing rate. The Company&#x2019;s incremental borrowing rates are determined based on the term of the lease, the economic environment of the lease, and the effect of collateralization. Lease expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term and variable lease costs are expensed as incurred. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company elected the practical expedient not to apply the recognition and measurement requirements to short-term leases, which is any lease with a term of one year or less as of the lease commencement date. Leases may require the Company to pay additional amounts for taxes, insurance, maintenance, and other expenses, which are generally referred to as &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; components. The Company has elected the practical expedient to combine lease and &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; components. If a lease includes options to extend the lease term, the Company does not assume the option will be exercised in its initial lease term assessment unless there is reasonable certainty that the Company will renew based on an assessment of economic factors present as of the lease commencement date. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(L) Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded when, after consideration of all positive and negative evidence, it is not more likely than not that the Company&#x2019;s deferred tax assets will be realizable. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(M) Share-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based awards to employees, directors, and consultants, including stock options, restricted stock units, performance options and capped value appreciation rights, are measured at fair value on the date of the grant and that fair value is recognized as share-based compensation expense in the Company&#x2019;s consolidated statements of operations over the requisite service period of the respective award. The estimated fair value of awards that contain performance conditions is expensed when the Company concludes that it is probable that the &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;performance condition will be achieved. The Company may grant awards with graded-vesting features. When such awards have only service vesting requirements, the Company elected to record share-based compensation expense on a straight-line basis. If awards with graded-vesting features contain performance or market conditions, then the Company records share-based compensation expense using the accelerated attribution method. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;The Company measures the fair value of its stock options that only have service vesting requirements or performance-based options without market conditions using the Black-Scholes option pricing model. For performance-based awards with market conditions, the Company determines the fair value of the awards as of the grant date using a Monte Carlo simulation model. When determining the grant-date fair value of stock-based awards, management further considers whether an adjustment is required to the observable market price or volatility of the Company&#x2019;s common stock that is used in the valuation as a result of material &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-public&lt;/div&gt; information, if that information is expected to result in a material increase in share price. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;Certain assumptions need to be made with respect to utilizing the Black-Scholes option pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate and the fair value of the Company&#x2019;s shares of common stock. Since the Company has limited option exercise history, it has generally elected to estimate the expected life of an award based upon the &#x201c;simplified method&#x201d; with the continued use of this method extended until such time the Company has sufficient exercise history. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. The expected share price volatility for the Company&#x2019;s common shares is estimated by taking the average historical price volatility for industry peers. The Company accounts for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-vesting&lt;/div&gt; award forfeitures when they occur. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;One of the inputs to the Black-Scholes option pricing model is the fair value of the Company&#x2019;s common shares. Prior to the closing of its business combination with MAAC, as a privately held company, the Company estimated the fair value of the shares of common stock underlying its share-based awards on each grant date. Given the absence of a public trading market, and in accordance with the American Institute of Certified Public Accountants&#x2019; Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, the Company exercised reasonable judgment and considered numerous objective and subjective factors to determine its best estimate of the fair value of its common shares. The estimation of the fair value of the common shares considered factors including the following: the prices of the Company&#x2019;s common shares sold to investors in arm&#x2019;s length transactions; the estimated present value of the Company&#x2019;s future cash flows; the Company&#x2019;s business, financial condition and results of operations; the Company&#x2019;s forecasted operating performance; the illiquid nature of the Company&#x2019;s common shares; industry information such as market size and growth; market capitalization of comparable companies and the estimated value of transactions such companies have engaged in; and macroeconomic conditions. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company applies a similar methodology to estimate the fair value of the shares of common stock underlying share-based awards issued by its privately held Vants. Following the closing of the Company&#x2019;s business combination with MAAC, RSL&#x2019;s common shares became publicly traded and the Company began determining the fair value of each common share underlying share-based awards based on the closing price of its common shares as reported by Nasdaq on the date of grant. Therefore, it will not be necessary to determine the fair value of the new stock-based award pursuant to the methodology described above. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(N) Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a three-tier fair value hierarchy that distinguishes among the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Level &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1-Valuations&lt;/div&gt; are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Level &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2-Valuations&lt;/div&gt; are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Level &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-Valuations&lt;/div&gt; are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company&#x2019;s financial instruments include shares of common stock of Arbutus Biopharma Corporation (&#x201c;Arbutus&#x201d;); shares of common stock of Sio Gene Therapies Inc. (&#x201c;Sio&#x201d;); shares of common stock of Heracles Parent, L.L.C., the parent entity of Datavant (as defined and discussed in Note 4, &#x201c;Investments&#x201d;); liability instruments issued, including the Roivant Warrants and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares (each as defined in Note 3, &#x201c;Business Combination with MAAC&#x201d;) liabilities issued in connection with the Company&#x2019;s business combination with MAAC (as discussed in Note 3, &#x201c;Business Combination with MAAC&#x201d;); the deferred consideration liability; its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and long-term debt. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The shares of Arbutus and Sio common stock and investments in common stock with a readily determinable fair value are classified as Level&#160;1, and their fair value is determined based upon quoted market prices in an active market. In October 2021, shares of Arbutus&#x2019; Series A participating convertible preferred shares (&#x201c;Arbutus Preferred Shares&#x201d;) held by the Company were converted into shares of common stock of Arbutus pursuant to mandatory conversion provisions. Prior to conversion, the Arbutus Preferred Shares held by the Company were classified as Level&#160;2 as the fair value of such preferred shares was determined based upon the quoted market price of Arbutus common stock into which such preferred shares were convertible. The shares of common stock of Heracles Parent, L.L.C., the parent entity of Datavant (as defined and discussed in Note 4, &#x201c;Investments&#x201d;), and liability instruments issued, excluding the Public Warrants (as defined and discussed in Note 3, &#x201c;Business Combination with MAAC&#x201d;), are classified as Level&#160;3 within the fair value hierarchy as the assumptions and estimates used in the valuations are unobservable in the market. The Public Warrants are publicly traded and therefore are classified as Level&#160;1 as the Public Warrants have a readily determinable fair value. Cash, accounts payable, and the deferred consideration liability are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature. The deferred consideration liability was based on a fixed monetary amount, and payment was based solely on the passage of time. The deferred consideration liability was settled in November 2021 by payment of $50.0&#160;million in cash as well as the issuance of 6,348,057 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of the Company&#x2019;s &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;hares. Money market funds are included in Level&#160;1 of the fair value hierarchy and are valued at the closing price reported by an actively traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly owned subsidiaries, &#x201c;Dermavant&#x201d;), which is stated at amortized cost, approximates fair value based on current interest rates for similar types of borrowings and therefore is included in Level&#160;2 of the fair value hierarchy. Long-term debt issued by Dermavant for which the &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;fair value option has been elected is included in Level&#160;3 of the fair value hierarchy as the assumptions and estimates used in the valuation are unobservable in the market. &lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <roiv:CashPaidToSettleDeferredConsiderationLiability
      contextRef="P11_01_2021To11_01_2021"
      decimals="-5"
      unitRef="Unit_USD">50000000</roiv:CashPaidToSettleDeferredConsiderationLiability>
    <roiv:StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability
      contextRef="P11_01_2021To11_01_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">6348057</roiv:StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(O) Foreign Currency &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets and liabilities of foreign operations are translated using exchange rates in effect at the balance sheet date and their results of operations are translated using average exchange rates for the year. Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Adjustments resulting from the translation of the financial statements of the Company&#x2019;s foreign functional currency subsidiaries into U.S. dollars are excluded from the determination of net loss and are accumulated in a separate component of shareholders&#x2019; equity. Foreign exchange transaction gains and losses are included in &#x201c;Other expense, net&#x201d; in the Company&#x2019;s statements of operations. &lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(P) Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes revenue when its customer &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;obtains &lt;/div&gt;control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for its arrangements, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when or as the Company satisfies a performance obligation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, assessing the recognition and future reversal of variable consideration, and determining and applying appropriate methods of measuring progress for performance obligations satisfied over time. These judgments are discussed in more detail below. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licenses of intellectual property:&lt;/div&gt;&lt;/div&gt; If the licenses to intellectual property are determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable,&lt;/div&gt; upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are not distinct from other promises, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable,&lt;/div&gt; upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition accordingly. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Milestone payments: &lt;/div&gt;&lt;/div&gt;At the inception of each arrangement that includes research, development or regulatory milestone payments, the Company&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis in earnings in the period of the adjustment. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Royalties and commercial milestone payments: &lt;/div&gt;&lt;/div&gt;For arrangements that include sales-based royalties, including commercial milestone payments&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;based on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-specified&lt;/div&gt; level of sales, the Company &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon performance of the licensee. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue is also generated by certain technology-focused Vants from subscription and service-based fees recognized for the use of certain technology developed by these Vants. Subscription revenue is recognized ratably over the contract period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Trade Receivables, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in customer credit profiles. The Company reserves against trade receivables for estimated losses that may arise from a customer&#x2019;s inability to pay, and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated losses was de minimis as of March&#160;31, 2022 and 2021. Trade receivables, net is included in &#x201c;Other current assets&#x201d; on the accompanying consolidated balance sheets. &lt;/div&gt;&lt;/div&gt; </us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <roiv:WarrantliabilitiesPolicyTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Q) Warrant Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company classifies the Roivant Warrants as liabilities. At the end of each reporting period, changes in fair value during the period are recognized within the consolidated statements of operations. The Company will continue to adjust the carrying value of the liability associated with the Roivant Warrants for changes in the fair value until the earlier of a) the exercise or expiration of the Roivant Warrants or b) the redemption of the Roivant Warrants. Issuance costs incurred that were attributable to the Roivant Warrants were expensed as incurred. &lt;/div&gt;&lt;/div&gt;</roiv:WarrantliabilitiesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(R) Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06,&lt;/div&gt; &#x201c;Debt&#x2014;Debt with Conversion and Other Options (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20)&lt;/div&gt; and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40):&lt;/div&gt; Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&#x201d;).&lt;/div&gt; ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current U.S. GAAP. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; also removes certain settlement conditions that are required for equity contracts to qualify for the derivatives scope exception, which will permit more equity contracts to qualify for it. Either a modified retrospective transition method or a fully retrospective transition method is permissible for the adoption of this standard. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; is effective for fiscal years beginning after December&#160;15, 2021, including interim periods within those fiscal years. The early-adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; on April&#160;1, 2021 did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 3&#x2014;Business Combination with MAAC &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&#160;30, 2021 (the &#x201c;Closing Date&#x201d;), in &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;accordance &lt;/div&gt;with the Business Combination Agreement, as amended (the &#x201c;Business Combination Agreement&#x201d;), RSL completed its previously announced business combination (the &#x201c;Business Combination&#x201d;) with MAAC, through the merger of RSL&#x2019;s wholly owned subsidiary, Rhine Merger Sub, Inc., with MAAC (the &#x201c;Merger&#x201d;), with MAAC surviving the Merger as a wholly owned subsidiary of RSL. As MAAC does not represent a business for accounting purposes and its primary asset represents cash and cash equivalents, the Business Combination was treated as an equity contribution in exchange for the issuance of RSL shares. The net assets of MAAC were stated at historical cost, with no goodwill or other intangible assets recorded. Reported amounts from operations included herein prior to the Business Combination are those of RSL. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On the Closing Date prior to the effective time of the Merger (the &#x201c;Effective Time&#x201d;), RSL effected a &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.9262-for-1&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;stock subdivision based on the fixed exchange ratio established in the Business Combination. The shares, equity awards and net loss per share available to holders of the Company&#x2019;s &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px;;display:inline;"&gt;stock&lt;/div&gt;&lt;/div&gt; prior to the Business Combination, have been retroactively restated to reflect the fixed exchange ratio.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In accordance with the terms of the Business Combination Agreement, at the Effective Time: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;a.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;each share of MAAC Class&#160;A common stock (the &#x201c;MAAC Class&#160;A Shares&#x201d;) and each share of MAAC Class&#160;B common stock (the &#x201c;MAAC Class&#160;B Shares&#x201d;) that were outstanding immediately before the Effective Time (other than treasury shares and any shares held by Patient Square Capital LLC (the &#x201c;MAAC Sponsor&#x201d;), any affiliate of the MAAC Sponsor or any of MAAC&#x2019;s independent directors (the &#x201c;MAAC Independent Directors&#x201d;) or its transferee) were automatically canceled and extinguished and converted into one &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;hare of RSL (the &#x201c;Roivant Common Share&#x201d;), &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;b.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;each MAAC Class&#160;B Share that was outstanding immediately before the Effective Time and held by the MAAC Sponsor, any affiliate of the MAAC Sponsor or any of the MAAC Independent Directors or its transferee were automatically canceled and extinguished and converted into a number of Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares based on an exchange ratio of 0.75, with a portion of such Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares issued to the MAAC Sponsor, any affiliate of the MAAC Sponsor, any MAAC Independent Director or its transferee by virtue of the Merger being subject to the vesting and other terms and conditions set forth in the Sponsor Support Agreement (as more fully described below), &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;c.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;each warrant to purchase MAAC Class&#160;A Shares that was outstanding immediately before the Effective Time was converted automatically into a right to acquire a Roivant Common Share (a &#x201c;Roivant Warrant&#x201d;) at an exercise price of $11.50 per share, subject to certain adjustments. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Following the Merger, the Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;hares and the Roivant Warrants began trading on the Nasdaq Global Market under the ticker symbols &#x201c;ROIV&#x201d; and &#x201c;ROIVW,&#x201d; respectively, on October&#160;1, 2021. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with the Business Combination, RSL entered into subscription agreements with certain investors, whereby it issued &lt;/div&gt;22,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;hares at $&lt;/div&gt;10.00&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; per share for an aggregate purchase price of $&lt;/div&gt;220.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million (the &#x201c;PIPE Financing&#x201d;). The PIPE Financing closed simultaneously with the consummation of the Business Combination.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In connection with the Business Combination and PIPE Financing, the Company received $213.4&#160;million in cash at closing (the &#x201c;Closing&#x201d;), net of deferred underwriting expenses and unpaid expenses incurred by MAAC in connection with the transaction. The Company incurred $24.4&#160;million in costs directly related to the Business Combination and PIPE Financing, such as banker fees and costs associated with third-party legal, accounting and other professional services. Upon Closing, these costs, which had been capitalized on the Company&#x2019;s balance sheet were recorded as a reduction of additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital with the exception of $7.4&#160;million, which were expensed as they represent the allocation of the transaction costs associated with the Roivant Warrants and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares liabilities. Transaction costs were allocated to the Roivant Warrants and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares liabilities based on the fair value of such instruments out of the total consideration. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sponsor Support Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concurrently with the execution of the Business Combination Agreement, MAAC, the MAAC Sponsor, Roivant and each of the MAAC Independent Directors, entered into the Sponsor Support Agreement, which was subsequently amended on June&#160;9, 2021, to reflect the MAAC Independent Directors and Roivant entering into respective &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lock-Up&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; Agreements, and further amended on September&#160;30, 2021. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the Sponsor Support Agreement, among other things: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;a.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;2,033,591 Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares issued to the MAAC Sponsor and 10,000 Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares issued to each MAAC Independent Director (collectively, the &#x201c;20% &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares&#x201d;), each in respect &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;of its MAAC Class&#160;B Shares, will vest if the closing price of Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares is greater than or equal to $15.00 over any &lt;span style="-sec-ix-hidden:hidden50659038"&gt;twenty&lt;/span&gt; out of &lt;span style="-sec-ix-hidden:hidden50659044"&gt;thirty&lt;/span&gt; trading day period during the Vesting Period (defined below). &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;b&lt;/div&gt;.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;1,016,796 Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares issued to the MAAC Sponsor and 5,000 Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares issued to each MAAC Independent Director (collectively, the &#x201c;10% &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares&#x201d; and, together with the 20% &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;Earn-Out&lt;/div&gt; Shares&#x201d;), each in respect of its MAAC Class&#160;B Shares, will vest if the closing price of Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares is greater than or equal to $20.00 over any &lt;span style="-sec-ix-hidden:hidden50659039"&gt;twenty&lt;/span&gt; out of &lt;span style="-sec-ix-hidden:hidden50659043"&gt;thirty&lt;/span&gt; trading day period during the Vesting Period (as defined below). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The remaining number of Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares issued to the MAAC Sponsor and each MAAC Independent Director are not subject to the vesting conditions described above (the &#x201c;Retained Shares&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Vesting Period represents the period commencing on November&#160;9, 2021, the date on which the registration statement on Form &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-1&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; required to be filed by the Company in connection with the PIPE Financing was declared effective, and ending no later than September&#160;30, 2026 (the &#x201c;Vesting Period&#x201d;). The Vesting Period will, if a definitive purchase agreement with respect to a Sale (as defined in the Sponsor Support Agreement) is entered into on or prior to the end of such period, be extended to the earlier of one day after the consummation of such Sale and the termination of such definitive transaction agreement, and if a Sale occurs during such Vesting Period, then all of the &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; Shares unvested as of such time will automatically vest immediately prior to the consummation of such Sale. If any &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; Shares have not vested on or prior to the end of such Vesting Period, then such &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; Shares will be forfeited. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; Shares require liability classification and are classified as &#x201c;Liability instruments measured at fair value&#x201d; on the consolidated balance sheets. The &lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; Shares liability is subject to remeasurement at each balance sheet date with changes in fair value recognized in the Company&#x2019;s statement of operations. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lock-Up&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On May&#160;1, 2021 and June&#160;9, 2021, RSL, on the one hand, and the MAAC Sponsor, the MAAC Independent Directors and certain Roivant equityholders, on the other hand, entered into &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lock-up&lt;/div&gt; agreements, pursuant to which, among other things, the MAAC Sponsor, the MAAC Independent Directors and such Roivant equityholders have agreed not to effect any sale or distribution of the Roivant Common Shares (including those underlying incentive equity awards or Roivant Warrants) held by the MAAC Sponsor, the MAAC Independent Directors or such equityholders as of immediately following the Closing during the applicable &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lock-up&lt;/div&gt; period, subject to customary exceptions. &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lock-up&lt;/div&gt; period applicable to Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares held by the MAAC Sponsor and MAAC Independent Directors as of immediately following the Closing will be (i)&#160;with respect to 25% of the Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares held by the MAAC Sponsor and MAAC Independent Directors, six months following the Closing, which expired on March&#160;30, 2022, (ii) with respect to an additional 25% of the Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares held by the MAAC Sponsor and MAAC Independent Directors, the earlier of twelve months following the achievement of certain price-based vesting restrictions or six years from the Closing and (iii)&#160;with respect to 50% of the Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares held by the MAAC Sponsor and MAAC Independent Directors, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden50659060"&gt;thirty&lt;/span&gt;-six&lt;/div&gt; months following the Closing. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares underlying warrants held by the MAAC Sponsor as of immediately following the Closing will be subject to a corresponding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lock-up&lt;/div&gt; period for (a)&#160;with respect to 25% of such warrants held by the MAAC Sponsor, six months from the Closing, which expired on March&#160;30, 2022, (b) with respect to an additional 25% of such warrants held by the MAAC Sponsor, twelve months from Closing and (c)&#160;with respect to 50% of such warrants held by the MAAC Sponsor, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden50659065"&gt;thirty-&lt;/span&gt;six&lt;/div&gt; months from the Closing. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lock-up&lt;/div&gt; period applicable to Roivant Common Shares held by certain Roivant equityholders as of immediately following the Closing (including those underlying incentive equity awards) will be (x)&#160;with respect &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;to 25% of the Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares held by such Roivant equityholders (including those underlying incentive equity awards), six months following the Closing, which expired on March&#160;30, 2022, (y) with respect to an additional 25% of the Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares held by such Roivant equityholders (including those underlying incentive equity awards), twelve months following the Closing and (z)&#160;with respect to 50% of the Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares (including those underlying incentive equity awards) held by such Roivant equityholders, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden50659059"&gt;thirty&lt;/span&gt;-six&lt;/div&gt; months following the Closing. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Common Stock Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At the effective time of the Merger, 10,214,365 Roivant Warrants that were held by the MAAC Sponsor at an exercise price of $11.50 (the &#x201c;Private Placement Warrants&#x201d;) and 20,535,896 Roivant Warrants held by MAAC&#x2019;s shareholders at an exercise price of $11.50 (the &#x201c;Public Warrants&#x201d;) were converted into the right to acquire Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares. Pursuant to the agreement governing the Roivant Warrants, the Roivant Warrants became exercisable 30 days following the completion of the Business Combination. The Roivant Warrants will expire five years after the completion of the Business Combination, or earlier upon redemption or liquidation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Private Placement Warrants are generally identical to the Public Warrants, except that (i)&#160;the Private Placement Warrants (including the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;c&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#160;issuable upon exercise of the Private Placement Warrants) were not transferable, assignable or salable until&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;30 days after the completion of the Business Combination (ii)&#160;they will not be redeemable by the Company when the price per share of Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares equals or exceeds $18.00, and (iii)&#160;the Private Placement Warrants may be exercised by holders on a cashless basis. If the Private Placement Warrants are held by holders other than our sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by Roivant in all redemption scenarios and exercisable by the holders on the same basis as the Public Warrants. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Roivant Warrants require liability classification and are classified as &#x201c;Liability instruments measured at fair value&#x201d; on the consolidated balance sheets. The Private Placement Warrants liability and Public Warrants liability are subject to remeasurement at each balance sheet date with changes in fair value recognized in the Company&#x2019;s statement of operations. As of March&#160;31, 2022, 60,021 Roivant Warrants have been exercised and none redeemed. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Redemption of Roivant Warrants when the price per share of Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;hares equals or exceeds $18.00. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may redeem the outstanding Roivant Warrants for cash (except with respect to the Private Placement Warrants): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in whole and not in part; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at a price of $0.01 per Roivant Warrant; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;upon a minimum of 30 days&#x2019; prior written notice of redemption; and &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;if, and only if, the last reported sale price of&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; for any&lt;/div&gt;&#160;20 trading days within a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;-trading&lt;/div&gt; day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrantholders (the &#x201c;Reference Value&#x201d;) equals or exceeds $18.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;However, in this case, the Company will not redeem the Roivant Warrants unless an effective registration statement under the Securities Act covering the Roivant Common Shares issuable upon exercise of the Roivant Warrants is effective and a current prospectus relating to those Roivant Common Shares is available throughout the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-day&lt;/div&gt; redemption period. Any such exercise would not be on a &#x201c;cashless&#x201d; basis and would require the exercising warrantholder to pay the exercise price for each Roivant Warrant being exercised. &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Redemption of Roivant Warrants when the price per share of Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;hares equals or exceeds $10.00. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may redeem the outstanding Roivant Warrants (except as described herein with respect to the Private Placement Warrants): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in whole and not in part; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at $0.10 per Roivant Warrant upon a minimum of 30 days&#x2019; prior written notice of redemption provided that holders will be able to exercise their Roivant Warrants on a cashless basis prior to redemption and receive that number of Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares determined by reference to an agreed table based on the redemption date and the &#x201c;fair market value&#x201d; of the Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted for stock splits, stock dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like); and &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;if the Reference Value is less than $18.00 per share (as adjusted for stock splits, stock dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like), the Private Placement Warrants must also concurrently be called for redemption on the same terms (except as described herein with respect to a holder&#x2019;s ability to cashless exercise its warrants) as the outstanding Public Warrants, as described above. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For these purposes, &#x201c;fair market value&#x201d; of Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;hares shall mean the volume-weighted average price of&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;hares for the&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;10 trading days immediately following the date on which the notice of redemption is sent to warrantholders. In no event will the Roivant Warrants be exercisable in connection with this redemption feature for more than 0.361 Roivant &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common Shares&lt;/div&gt;&lt;/div&gt; per Roivant Warrant (subject to adjustment). &lt;/div&gt;&lt;/div&gt; </us-gaap:BusinessCombinationDisclosureTextBlock>
    <roiv:StockholdersEquityNoteStockSplitExchangeRatio1
      contextRef="PAsOn03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="4"
      unitRef="Unit_pure">2.9262</roiv:StockholdersEquityNoteStockSplitExchangeRatio1>
    <roiv:StockholdersEquityNoteStockSplitExchangeRatio1
      contextRef="PAsOn03_31_2022_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis"
      decimals="4"
      unitRef="Unit_pure">2.9262</roiv:StockholdersEquityNoteStockSplitExchangeRatio1>
    <roiv:ExchangeRatioOfMAACClassBToRoivantCommonShares
      contextRef="PAsOn03_31_2022_MaacClassBSharesMemberusgaapStatementClassOfStockAxis_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      unitRef="Unit_pure">0.75</roiv:ExchangeRatioOfMAACClassBToRoivantCommonShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn03_31_2022_MaacClassASharesMemberusgaapStatementClassOfStockAxis_RoivantWarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_01_2021To03_31_2022_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis_PipeFinancingMemberROIVAgreementAxis"
      decimals="INF"
      unitRef="Unit_shares">22000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="PAsOn03_31_2022_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis_PipeFinancingMemberROIVAgreementAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P04_01_2021To03_31_2022_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis_PipeFinancingMemberROIVAgreementAxis"
      decimals="-5"
      unitRef="Unit_USD">220000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:Cash
      contextRef="PAsOn03_31_2022_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis_PipeFinancingMemberROIVAgreementAxis"
      decimals="-5"
      unitRef="Unit_USD">213400000</us-gaap:Cash>
    <roiv:Costsincurredrelatedtofinancing
      contextRef="P04_01_2021To03_31_2022_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis_PipeFinancingMemberROIVAgreementAxis"
      decimals="-5"
      unitRef="Unit_USD">24400000</roiv:Costsincurredrelatedtofinancing>
    <roiv:Allocationoftransactioncostsincurredtowarrantsandearnoutshares
      contextRef="PAsOn03_31_2022_MontesArchimedesAcquisitionCorpMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">7400000</roiv:Allocationoftransactioncostsincurredtowarrantsandearnoutshares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_01_2021To03_31_2022_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis"
      decimals="INF"
      unitRef="Unit_shares">2033591</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_01_2021To03_31_2022_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis"
      decimals="INF"
      unitRef="Unit_shares">10000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <roiv:Portionofsharesubjecttoearnout
      contextRef="P04_01_2021To03_31_2022_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</roiv:Portionofsharesubjecttoearnout>
    <roiv:EarnOutSharePrice
      contextRef="PAsOn03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsFifteenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">15</roiv:EarnOutSharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_01_2021To03_31_2022_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SharePriceEqualOrExceedsTwentyDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis"
      decimals="INF"
      unitRef="Unit_shares">1016796</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_01_2021To03_31_2022_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_SharePriceEqualOrExceedsTwentyDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis"
      decimals="INF"
      unitRef="Unit_shares">5000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <roiv:Portionofsharesubjecttoearnout
      contextRef="P04_01_2021To03_31_2022_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SharePriceEqualOrExceedsTenDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</roiv:Portionofsharesubjecttoearnout>
    <roiv:Portionofsharesubjecttoearnout
      contextRef="P04_01_2021To03_31_2022_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SharePriceEqualOrExceedsTwentyDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</roiv:Portionofsharesubjecttoearnout>
    <roiv:EarnOutSharePrice
      contextRef="PAsOn03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis_SharePriceEqualOrExceedsTwentyDollarMemberROIVTriggeringEventAxis_SponsorSupportAgreementMemberROIVBusinessCombinationAgreementAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">20</roiv:EarnOutSharePrice>
    <roiv:Percentageofsharessubjecttolockupfordefinedperiodoftime
      contextRef="PAsOn03_31_2022_LockUpPeriodOneMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</roiv:Percentageofsharessubjecttolockupfordefinedperiodoftime>
    <roiv:Lockupperiodofcommonshares contextRef="P04_01_2021To03_31_2022_LockUpPeriodOneMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">P6M</roiv:Lockupperiodofcommonshares>
    <roiv:Percentageofsharessubjecttolockupfordefinedperiodoftime
      contextRef="PAsOn03_31_2022_LockUpPeriodTwoMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</roiv:Percentageofsharessubjecttolockupfordefinedperiodoftime>
    <roiv:Lockupperiodofcommonshares contextRef="P04_01_2021To03_31_2022_LockUpPeriodTwoMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MinimumMembersrtRangeAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">P12M</roiv:Lockupperiodofcommonshares>
    <roiv:Lockupperiodofcommonshares contextRef="P04_01_2021To03_31_2022_LockUpPeriodTwoMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">P6Y</roiv:Lockupperiodofcommonshares>
    <roiv:Percentageofsharessubjecttolockupfordefinedperiodoftime
      contextRef="PAsOn03_31_2022_LockUpPeriodThreeMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</roiv:Percentageofsharessubjecttolockupfordefinedperiodoftime>
    <roiv:Percentageofwarrantssubjecttolockupfordefinedperiodoftime
      contextRef="PAsOn03_31_2022_LockUpPeriodFourMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</roiv:Percentageofwarrantssubjecttolockupfordefinedperiodoftime>
    <roiv:Lockupperiodwarrants contextRef="P04_01_2021To03_31_2022_LockUpPeriodFourMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">P6M</roiv:Lockupperiodwarrants>
    <roiv:Percentageofwarrantssubjecttolockupfordefinedperiodoftime
      contextRef="PAsOn03_31_2022_LockUpPeriodFiveMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</roiv:Percentageofwarrantssubjecttolockupfordefinedperiodoftime>
    <roiv:Lockupperiodwarrants contextRef="P04_01_2021To03_31_2022_LockUpPeriodFiveMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">P12M</roiv:Lockupperiodwarrants>
    <roiv:Percentageofwarrantssubjecttolockupfordefinedperiodoftime
      contextRef="PAsOn03_31_2022_LockUpPeriodSixMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</roiv:Percentageofwarrantssubjecttolockupfordefinedperiodoftime>
    <roiv:Percentageofsharessubjecttolockupfordefinedperiodoftime
      contextRef="PAsOn03_31_2022_LockUpPeriodSevenMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</roiv:Percentageofsharessubjecttolockupfordefinedperiodoftime>
    <roiv:Lockupperiodofcommonshares contextRef="P04_01_2021To03_31_2022_LockUpPeriodSevenMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">P6M</roiv:Lockupperiodofcommonshares>
    <roiv:Percentageofsharessubjecttolockupfordefinedperiodoftime
      contextRef="PAsOn03_31_2022_LockUpPeriodEightMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</roiv:Percentageofsharessubjecttolockupfordefinedperiodoftime>
    <roiv:Lockupperiodofcommonshares contextRef="P04_01_2021To03_31_2022_LockUpPeriodEightMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">P12M</roiv:Lockupperiodofcommonshares>
    <roiv:Percentageofsharessubjecttolockupfordefinedperiodoftime
      contextRef="PAsOn03_31_2022_LockUpPeriodNineMemberROIVLockUpAgreementsAxis_MaacIndependentDirectorMembersrtTitleOfIndividualAxis_MaacSponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</roiv:Percentageofsharessubjecttolockupfordefinedperiodoftime>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">10214365</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn03_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">20535896</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn03_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <roiv:Timetowarrantexercisability contextRef="P04_01_2021To03_31_2022_RoivantWarrantMemberusgaapClassOfWarrantOrRightAxis">P30D</roiv:Timetowarrantexercisability>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="PAsOn03_31_2022_RoivantWarrantMemberusgaapClassOfWarrantOrRightAxis">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <roiv:Timetowarrantexercisability contextRef="P04_01_2021To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_RoivantWarrantMemberusgaapClassOfWarrantOrRightAxis">P30D</roiv:Timetowarrantexercisability>
    <roiv:Shareredemptiontriggerprice
      contextRef="P04_01_2021To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsEighteenDollarMemberROIVTriggeringEventAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">18</roiv:Shareredemptiontriggerprice>
    <roiv:CommonStockWarrants
      contextRef="P04_01_2021To03_31_2022"
      decimals="INF"
      unitRef="Unit_shares">60021</roiv:CommonStockWarrants>
    <roiv:Classofwarrantsredemptionpriceperunit
      contextRef="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsEighteenPerDollarMemberROIVTriggeringEventAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.01</roiv:Classofwarrantsredemptionpriceperunit>
    <roiv:Classofwarrantsredemptionnoticeperiod contextRef="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsEighteenPerDollarMemberROIVTriggeringEventAxis">P30D</roiv:Classofwarrantsredemptionnoticeperiod>
    <roiv:Numberoftradingdaystomeetwarrantredemptionthreshold contextRef="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsEighteenPerDollarMemberROIVTriggeringEventAxis">P20D</roiv:Numberoftradingdaystomeetwarrantredemptionthreshold>
    <roiv:Tradingdayperiodforwarrantredemption contextRef="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsEighteenPerDollarMemberROIVTriggeringEventAxis">P30D</roiv:Tradingdayperiodforwarrantredemption>
    <roiv:Stockpricetriggerforredemptionofwarrants
      contextRef="PAsOn03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsEighteenPerDollarMemberROIVTriggeringEventAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">18</roiv:Stockpricetriggerforredemptionofwarrants>
    <roiv:Classofwarrantsredemptionpriceperunit
      contextRef="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsTenDollarMemberROIVTriggeringEventAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.1</roiv:Classofwarrantsredemptionpriceperunit>
    <roiv:Classofwarrantsredemptionnoticeperiod contextRef="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsTenDollarMemberROIVTriggeringEventAxis">P30D</roiv:Classofwarrantsredemptionnoticeperiod>
    <roiv:Stockpricetriggerforredemptionofwarrants
      contextRef="PAsOn03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsTenDollarMemberROIVTriggeringEventAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</roiv:Stockpricetriggerforredemptionofwarrants>
    <roiv:Stockpricetriggerforredemptionofwarrants
      contextRef="PAsOn03_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis_SharePriceEqualOrExceedsEighteenPerDollarMemberROIVTriggeringEventAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">18</roiv:Stockpricetriggerforredemptionofwarrants>
    <roiv:PeriodForFairMarketValueDetermination contextRef="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">P10D</roiv:PeriodForFairMarketValueDetermination>
    <roiv:MaximumRedemptionFeaturePerWarrant
      contextRef="P04_01_2021To03_31_2022_RedemptionOfRoivantWarrantsMemberusgaapClassOfWarrantOrRightAxis_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="3"
      unitRef="Unit_USD_per_Share">0.361</roiv:MaximumRedemptionFeaturePerWarrant>
    <us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 4&#x2014;Investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Investment in Arbutus &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October 2017, pursuant to a subscription agreement entered into by RSL and Arbutus, RSL acquired 16,013,540 shares of common stock of Arbutus and 1,164,000 Arbutus Preferred Shares, which converted into 22,833,922 shares of Arbutus common stock in October 2021. The Company accounts for its investment in Arbutus as an equity method investment accounted for using the fair value option. Due to the Company&#x2019;s significant influence over operating and financial policies, Arbutus is considered a related party of the Company. At March&#160;31, 2022, RSL held approximately 26% of issued and outstanding shares of Arbutus. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At March&#160;31, 2022 and 2021, the aggregate fair value of the Company&#x2019;s investment in Arbutus was $115.8&#160;million and $129.4&#160;million, respectively, with the Company recognizing an unrealized loss on its investment in Arbutus of $13.6&#160;million and an unrealized gain of $90.2&#160;million in the accompanying consolidated statements of operations for the years ended March&#160;31, 2022 and 2021. The fair value of the Company&#x2019;s investment was determined using the closing price of Arbutus&#x2019;s common stock on March&#160;31, 2022 and 2021 of $2.98 and $3.33, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Investment in Sio &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2020, RSL&#x2019;s ownership interest in Sio fell below 50.0%, and as a result, the Company deconsolidated Sio. The Company accounts for its investment in Sio as an equity method investment accounted for using the fair value option. Due to the Company&#x2019;s significant influence over operating and financial policies, Sio is considered a related party of the Company. At March&#160;31, 2022, RSL held approximately 25% of Sio&#x2019;s issued and outstanding common shares. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;At March&#160;31, 2022 and 2021, the fair value of the Company&#x2019;s investment in Sio was $12.4&#160;million&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;and&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;$48.5&#160;million, respectively, with the Company recognizing an unrealized loss on its investment in Sio of $36.1&#160;million and an unrealized gain of $3.2&#160;million in the accompanying consolidated statements of operations for the years ended March&#160;31, 2022 and 2021, respectively. The fair value of common shares held by the Company was determined using the closing price of Sio&#x2019;s common stock on March&#160;31, 2022 and 2021 of $0.67 and $2.61, respectively. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Investment in Datavant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In April 2020, following an equity raise completed by Datavant Holdings, Inc. (&#x201c;Datavant&#x201d;) along with a restructuring of Datavant&#x2019;s equity classes, it was determined that RSL no longer controlled Datavant. As such, the Company deconsolidated Datavant as of April 2020. Due to the Company&#x2019;s significant influence over operating and financial policies, Datavant is considered a related party of the Company. Upon deconsolidation, the Company recorded its investment in Datavant based on the fair value of Datavant preferred shares held of $99.0&#160;million. Prior to the Datavant Merger (defined below), the Company accounted for its investment in Datavant using the measurement alternative to fair value. Under the measurement alternative, the investment is remeasured upon observable price changes in orderly transactions or upon impairment, if any. The Company recognized a gain on deconsolidation of $86.5&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. In July 2020, Datavant issued and sold additional preferred shares to RSL at a price consistent with that of the initial round of Datavant&#x2019;s Series B equity raise, which resulted in an increase in the carrying value of the Company&#x2019;s investment to $100.6&#160;million. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2021, Datavant and Heracles Parent, L.L.C. (referred to herein as &#x201c;Ciox Parent&#x201d; and, after the closing of the Datavant Merger (as defined below), &#x201c;Datavant&#x201d;), a provider of healthcare information services and technology solutions to hospitals, health systems, physician practices and authorized recipients of protected health records in the United States, primarily through its wholly owned subsidiary CIOX Health, LLC, entered into a definitive agreement to merge Datavant with and into a newly formed wholly owned subsidiary of Ciox Parent (the &#x201c;Datavant Merger&#x201d;). The merger closed on July&#160;27, 2021. At closing, the Company received approximately $320&#160;million in cash and a minority equity stake in Ciox Parent. As a result of the transaction, the Company recognized a gain on remeasurement of $443.8&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2022. As of March&#160;31, 2022, the Company&#x2019;s minority equity interest represented approximately 17% of the outstanding Class&#160;A units in Ciox Parent. Ciox Parent&#x2019;s capital structure includes several classes of preferred units that, among other features, have liquidation preferences and conversion features. Upon conversion of such preferred units into Class&#160;A units, the Company&#x2019;s ownership interest would be diluted. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Following the completion of the Datavant Merger, the Company&#x2019;s minority equity interest became subject to the equity method of accounting. At such time, the fair value option was elected to continuously remeasure the investment to fair value each reporting period with changes in fair value reflected in earnings. As of March&#160;31, 2022 and July&#160;27, 2021, the fair value of the Company&#x2019;s investment was $193.9&#160;million and $224.1&#160;million, respectively, with the Company recognizing an unrealized loss on its investment of $30.2&#160;million for the year ended March&#160;31, 2022. The fair value of the Company&#x2019;s investment was determined using valuation models that incorporate significant unobservable inputs and is classified as a Level&#160;3 measurement within the fair value hierarchy. Refer to Note 14, &#x201c;Fair Value Measurements&#x201d; for more information. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other Investment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company holds an additional equity investment that is measured using the fair value option. The fair value of this investment was $3.7&#160;million and $11.1&#160;million as of March&#160;31, 2022 and 2021, respectively. &lt;/div&gt;&lt;/div&gt; </us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn10_31_2017_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">16013540</us-gaap:CommonStockSharesOutstanding>
    <roiv:PreferredStockOwnedBalanceSharesOfArbutus
      contextRef="PAsOn10_31_2017_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">1164000</roiv:PreferredStockOwnedBalanceSharesOfArbutus>
    <roiv:InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock
      contextRef="PAsOn10_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">22833922</roiv:InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.26</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">115800000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">129400000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P04_01_2021To03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">-13600000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P04_01_2020To03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">90200000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:SharePrice
      contextRef="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.98</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.33</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn03_31_2022_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2022_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">12400000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">48500000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P04_01_2021To03_31_2022_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">-36100000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P04_01_2020To03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">3200000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:SharePrice
      contextRef="PAsOn03_31_2022_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.67</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="PAsOn03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.61</us-gaap:SharePrice>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn04_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">99000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="P04_01_2020To03_31_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">86500000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn07_31_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">100600000</us-gaap:LongTermInvestments>
    <roiv:ProceedsFromSaleOfInvestment
      contextRef="P07_27_2021To07_27_2021_DatavantMergerMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">320000000</roiv:ProceedsFromSaleOfInvestment>
    <roiv:GainOnMeasurementOfInvestment
      contextRef="P04_01_2021To03_31_2022_DatavantMergerMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">443800000</roiv:GainOnMeasurementOfInvestment>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn03_31_2022_CombinedCompanyMembersrtOwnershipAxis_DatavantMergerMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">0.17</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2022_DatavantHoldingsIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">193900000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn07_27_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">224100000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P04_01_2021To03_31_2022_DatavantHoldingsIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">-30200000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2022_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">3700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">11100000</us-gaap:InvestmentsFairValueDisclosure>
    <roiv:AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 5&#x2014;Asset Acquisitions and License Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the years ended March&#160;31, 2022 and 2021, the Company, directly or indirectly through Vants, completed the following key asset acquisitions and license agreements. The Company evaluated the below agreements, except the collaboration agreement entered into between Proteovant Therapeutics, Inc. and Blueprint Medicines Corporation (&#x201c;Blueprint Medicines&#x201d;) that is evaluated separately below, and determined that the acquired assets did not meet the definition of a business as substantially all the fair value of the assets acquired were concentrated in a single asset or group of similar assets and/or the acquired assets were not capable of producing outputs due to the lack of an assembled workforce and early stage of development and thus, each transaction was accounted for as an asset acquisition. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The Company then evaluated whether each &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development asset had an alternative future use and concluded it did not. As a result, the Company recorded the consideration attributable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development under the below agreements as acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development expense in the accompanying consolidated statements of operations for the years ended March&#160;31, 2022 and 2021. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Genevant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In July 2020, RSL increased its investment in Genevant Sciences Ltd. (&#x201c;Genevant&#x201d;) as part of a recapitalization transaction (the &#x201c;Recapitalization&#x201d;). Genevant, an entity focused on the discovery, development, and commercialization of a broad range of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RNA-based&lt;/div&gt; therapeutics enabled by Arbutus&#x2019; proprietary lipid nanoparticle and ligand conjugate delivery technologies, was created in April 2018 as part of an agreement between RSL and Arbutus. As part of the initial transaction entered into in April 2018, RSL contributed $38.7&#160;million in cash, including transaction costs, for an equity ownership interest in Genevant. Prior to the Recapitalization, RSL accounted for its investment in Genevant under the equity method of accounting as it had determined that it was not the primary beneficiary of Genevant since it did not have the power to direct its most significant activities. Additionally, RSL made additional investments in the form of promissory notes issued by Genevant amounting to $20.1&#160;million aggregate principal amount outstanding (the &#x201c;Genevant Outstanding Notes&#x201d;) prior to the Recapitalization. RSL applied its share of losses relating to its equity method investment in Genevant against the Company&#x2019;s carrying value of its investment in Genevant&#x2019;s common shares and against the carrying value of the Genevant Outstanding Notes. The carrying value of RSL&#x2019;s investment in Genevant was reduced to zero prior to the Recapitalization. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the Recapitalization, the following transactions were completed: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Genevant issued 74,272,043 common shares to RSL for an aggregated purchase price of $20.5&#160;million; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$15.1&#160;million aggregate principal amount of the Genevant Outstanding Notes were converted into 54,526,549 common shares; and &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Genevant issued 9,057,566 common shares to Arbutus for an aggregated purchase price of $2.5&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Following the Recapitalization, RSL held an 82.9% controlling interest in Genevant. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concurrent with the Recapitalization, the composition of Genevant&#x2019;s Board of Directors was restructured to include two directors designated by RSL and one director who is a senior officer of Genevant. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As a result of the Recapitalization and changes to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;bye-laws,&lt;/div&gt; RSL determined that it controls the most significant activities of Genevant and is the primary beneficiary of Genevant following the Recapitalization. As such, RSL began consolidating Genevant into the Company&#x2019;s consolidated financial statements from the date of the Recapitalization. The Company evaluated the acquired set of assets and activities and determined that the acquired set did not meet the definition of a business and thus the transaction was not considered a business combination. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The transactions completed as part of the Recapitalization represent an acquisition achieved in stages, which required the remeasurement of RSL&#x2019;s previously held interest in Genevant. As such, RSL&#x2019;s investments in Genevant were remeasured to fair value of $28.8&#160;million, also resulting in a gain of $28.8&#160;million that was recognized in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. Along with the fair value of noncontrolling interests in Genevant of $9.2&#160;million and cash paid of $20.5&#160;million for common shares of Genevant as part of the Recapitalization, total consideration paid was $58.5&#160;million. Of this amount, $41.4&#160;million was attributed to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development, which was determined by the Company to have not reached technological feasibility and therefore have no alternative future use. Accordingly, the Company recorded $41.4&#160;million as acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development expense in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. &lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Proteovant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In November 2020, Proteovant Sciences, Inc. (formerly known as Pharmavant 5, Inc.) (together with its wholly owned subsidiaries, &#x201c;Proteovant&#x201d;) entered into a stock purchase agreement to acquire Oncopia Therapeutics, Inc. (&#x201c;Oncopia&#x201d;), a preclinical biotechnology company developing small molecule protein degraders primarily against certain oncology targets. Upfront proceeds to Oncopia&#x2019;s shareholders were $105.0&#160;million, prior to certain adjustments in accordance with the terms of the agreement. Proteovant is also obligated to make future development and commercial milestone payments of up to $100.0&#160;million for the first product targeting each of the two specified initial targets, and up to $51.0&#160;million for the first product targeting each of certain specified additional molecular targets. Additionally, the Company&#x2019;s investments in promissory notes issued by Oncopia for an aggregate principal amount of $11.5&#160;million were settled through either conversion to equity or cancellation. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Oncopia&#x2019;s intellectual property was developed by the University of Michigan laboratory run by Oncopia&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-founder&lt;/div&gt; (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;Co-Founder&#x201d;).&lt;/div&gt; In connection with Proteovant&#x2019;s acquisition, Oncopia amended and restated its existing license agreements with the University of Michigan. Under the new license agreement, Oncopia will be obligated to make future development and commercial milestone payments of up to $8.6&#160;million for the first product for each molecular target covered by intellectual property included in the agreement, in addition to paying tiered royalties on net sales ranging from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-&lt;/div&gt; to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-single&lt;/div&gt; digits, subject to certain adjustments. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Co-Founder&#x2019;s&lt;/div&gt; lab at the University of Michigan had been providing &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on-going&lt;/div&gt; discovery and optimization services to Oncopia under a sponsored research agreement (the &#x201c;SRA&#x201d;). Immediately after closing the acquisition, Oncopia extended the SRA through at least December&#160;31, 2023, and expanded the potential molecular targets to be pursued under the SRA. As revised, Oncopia is obligated to pay the University of Michigan approximately $15.5&#160;million under the SRA. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Lastly, in connection with the acquisition of Oncopia, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Co-Founder&lt;/div&gt; entered into an agreement with the Company to serve as a consultant. In exchange for these services, the Company has agreed to grant the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Co-Founder&lt;/div&gt; RSL restricted stock units for which the majority will vest upon achievement of development milestones for products directed to targets for which no milestones are payable to Oncopia shareholders and the remaining portion will be subject to time-based service requirements. These restricted stock units were also subject to a liquidity requirement to vest, which was achieved upon the closing of the Business Combination. The Company will also make a cash payment to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Co-Founder&lt;/div&gt; upon achievement of development milestones for each such product. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;During the year ended March&#160;31, 2021, the Company recorded $116.5&#160;million, relating to the net upfront cash payment of $101.2&#160;million, settlement of promissory notes receivable, including accrued interest, of $11.9&#160;million, and fair value of future contingent consideration payments of $3.4&#160;million, as acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development expense in the accompanying consolidated statements of operations. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2020, RSL, Proteovant and SK, Inc. (formerly known as SK Holdings Co., Ltd.) (&#x201c;SK&#x201d;) entered into a subscription agreement (the &#x201c;Subscription Agreement&#x201d;) pursuant to which SK agreed to make a $200.0&#160;million equity investment in Proteovant, representing an ownership interest of 40.0% on the closing date. In January 2021, in accordance with the terms of the Subscription Agreement, SK made the first payment of $100.0&#160;million to Proteovant. SK made the second payment of $100.0&#160;million to Proteovant in July 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2022, Proteovant entered into a collaboration agreement with Blueprint Medicines pursuant to which the parties will jointly research and advance up to two novel protein degrader compounds into development candidates, as well as up to two additional novel protein degrader target programs as may be mutually agreed to by the Blueprint Medicines and Proteovant (each a target program). Under the terms of the collaboration agreement, Proteovant received a nonrefundable, upfront payment of $20.0&#160;million in March 2022 and will be eligible to receive up to an additional $632.0&#160;million in contingent milestone payments including&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;specified research, development, regulatory and commercialization milestones and tiered percentage royalties on a licensed &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;product-by-licensed&lt;/div&gt;&lt;/div&gt; product basis ranging from the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-&lt;/div&gt; to high-single digits on net sales on the first two target programs, subject to adjustment in specified circumstances. If Proteovant &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;opts-in&lt;/div&gt; to the second target program (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;Opt-In&lt;/div&gt; Right&#x201d;), the parties will jointly develop and commercialize such compounds and will split profits and losses of that program equally in the United States along with global development costs. Additionally, development and regulatory milestone payments for the second target or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;opt-in&lt;/div&gt; target program will be reduced, and Proteovant will only be eligible to receive commercialization milestone payments and royalties on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ex-United&lt;/div&gt; States sales of products relating to such target program. In addition, the parties may jointly extend the collaboration, with the same structure and financial terms, for up to two additional target programs through additional funding by Blueprint Medicines and Proteovant&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Opt-In&lt;/div&gt; Right would extend to the second of such additional target programs. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Proteovant will be performing research and development activities throughout the period until Blueprint Medicines can exercise its option to obtain a worldwide, exclusive license to develop and commercialize any licensed compound, subject to Proteovant&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Opt-In&lt;/div&gt; Right. Proteovant initially recorded the $20.0&#160;million upfront payment as deferred revenue on the accompanying consolidated financial statements and will recognize it as revenue as the services are provided. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Affivant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In November 2020, RSL and its indirect subsidiary Affivant Sciences GmbH (&#x201c;Affivant&#x201d;) entered into a licensing and strategic collaboration agreement with Affimed N.V. (&#x201c;Affimed&#x201d;) to develop and commercialize novel innate cell engagers for multiple cancer targets in exchange for consideration that includes $40.0&#160;million in upfront cash and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-paid&lt;/div&gt; R&amp;amp;D funding and $20.0&#160;million of newly issued shares in RSL. Affimed could receive further short-term proceeds in the form of option fees contingent on the commencement of additional programs contemplated under the agreement. Affimed is eligible to receive up to an additional approximately $2.0&#160;billion in milestones over time upon achievement of specified development, regulatory and commercial milestones, as well as tiered royalties on net sales. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Acquisition of Silicon Therapeutics &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;In March 2021, the Company completed the acquisition of the business of Silicon Therapeutics, LLC (&#x201c;Silicon Therapeutics&#x201d;), a physics-driven computational drug discovery company, for total consideration of approximately $450.0&#160;million, with additional cash payments payable subject to the satisfaction of certain regulatory and commercial milestones. This acquisition did not include one of Silicon Therapeutics&#x2019; subsidiaries, Silicon SWAT, Inc. Approximately $350.0&#160;million of the consideration was payable primarily in the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ompany&#x2019;s &lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px;;display:inline;"&gt;stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; at or near closing of the acquisition (the &#x201c;First Tranche&#x201d;). At closing of the acquisition, the Company issued 21,409,764 &lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;hares&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; and paid approximately $14.0&#160;million in cash, net of cash received, to Silicon Therapeutics after giving effect to certain transaction adjustments and holdbacks. The remainder of the First Tranche was paid in a combination of &lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;hares&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; and cash as certain holdbacks were released. In November 2021, the Company transferred the remaining $100.0&#160;million (the &#x201c;Second Tranche Consideration&#x201d;) to Silicon Therapeutics through a $50.0&#160;million cash payment and the issuance of 6,348,057 of the Company&#x2019;s &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;hares&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The transaction was accounted for as an asset acquisition as substantially all of the fair value of the assets acquired were concentrated in a single asset, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development related to the computational drug discovery platform that designs and develops small molecule therapeutics. For accounting purposes, the fair value of consideration transferred was $402.4&#160;million, consisting of $281.7&#160;million relating to the fair value of &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;hares&lt;/div&gt; issued upfront and expected to be issued shortly thereafter; $105.1&#160;million relating to the fair value of liabilities due to the sellers, including the Second Tranche Consideration, future contingent consideration payments, and closing consideration to be paid in cash; and cash of $15.6&#160;million paid at closing. Of this amount, $399.6&#160;million was attributed to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development, which was determined to &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;have no alternative future use. Accordingly, the Company recorded $399.6&#160;million as acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development expense in the accompanying consolidated statement of operations for the year ended March&#160;31, 2021. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with the transaction, the vesting of certain outstanding Silicon Therapeutics share-based compensation awards held by employees of Silicon Therapeutics was discretionarily accelerated at closing. As a result, the Company recorded share-based compensation expense of $23.5&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;In addition, certain share-based compensation awards of Silicon Therapeutics were exchanged with restricted &lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px;;display:inline;"&gt;stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; of the Company, subject to certain service-based vesting requirements, with a fair value of $22.6&#160;million. Of this amount, $15.6&#160;million was attributed to precombination service and therefore included in the total fair value of consideration transferred. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Priovant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In September 2021, Priovant Therapeutics, Inc. (&#x201c;Priovant&#x201d;) entered into a license and collaboration agreement with Pfizer, Inc. (&#x201c;Pfizer&#x201d;) (the &#x201c;Pfizer License Agreement&#x201d;). The transaction was accounted for as an asset acquisition as the acquired assets did not meet the definition of a business. The fair value of consideration transferred was $82.1&#160;million, consisting of $70.0&#160;million of preferred stock issued to Pfizer, representing a dilution-protected minority ownership interest in Priovant; a $10.0&#160;million upfront cash payment; and $2.1&#160;million relating to other obligations. The acquired rights, which included the licensed rights, starting materials and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; inventory for each drug candidate, represent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development assets, which were determined to have no alternative future use. Accordingly, the Company recorded $82.1&#160;million as acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development expense in the accompanying consolidated statements of operations for the year ended March&#160;31, 2022. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Priovant is obligated to pay Pfizer a mid tens-of-millions sales milestone payment if aggregate net sales of its licensed products in Priovant&#x2019;s territory in a given year exceed a mid hundreds-of-millions amount. Pfizer is obligated to pay Priovant a low tens-of-millions sales milestone payment if aggregate net sales of its licensed products outside of Priovant&#x2019;s territory in a given year exceed a mid hundreds-of-millions amount. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Priovant is obligated to pay Pfizer a tiered, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-teens&lt;/div&gt; royalty, on aggregate net sales of its licensed products in Priovant&#x2019;s territory. Pfizer is obligated to pay Priovant a tiered high single-digit to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-teens&lt;/div&gt; royalty, on aggregate net sales of its licensed products outside of Priovant&#x2019;s territory. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Hemavant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In November 2021, Hemavant Sciences GmbH (&#x201c;Hemavant&#x201d;), a wholly owned subsidiary of the Company, entered into a license agreement with Eisai Co., Ltd. (&#x201c;Eisai&#x201d;) (the &#x201c;Eisai License Agreement&#x201d;). Pursuant to the Eisai License Agreement, Eisai granted Hemavant (i)&#160;an exclusive, worldwide, sublicensable, royalty-bearing license under certain patents and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and (ii)&#160;a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;non-exclusive,&lt;/div&gt; worldwide, sublicensable, royalty-bearing license under certain additional patents, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and inventions, in each case, to develop, manufacture and commercialize the compound known as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;RVT-2001&lt;/div&gt; and products incorporating &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;RVT-2001&lt;/div&gt; for all human and animal uses. In exchange for the rights, the Company made an upfront payment to Eisai consisting of $8.0&#160;million in cash and the issuance of $7.0&#160;million in shares of the Company&#x2019;s &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px;;display:inline;"&gt;stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; at an agreed price of $8.00 per share. Hemavant may also be obligated to pay up to a maximum of $65.0&#160;million in development and regulatory milestone payments (with respect the product for the first indication) and up to a maximum of $18.0&#160;million in payments (with respect to the product for each additional indication) and up to a maximum of $295.0&#160;million in commercial milestone payments. Hemavant may also be obligated to pay a tiered high single-digit to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;sub-teens&lt;/div&gt; royalty, subject to certain customary reductions, on net sales of licensed products. &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"/&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The transaction was accounted for as an asset acquisition as the acquired assets did not meet the definition of a business. The acquired rights, which include the licensed rights and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;in-process&lt;/div&gt; inventory of the drug candidate, represent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development assets that were determined to have no alternative future use. The fair value of the 874,957 shares of the Company&#x2019;s &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px;;display:inline;"&gt;stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; issued to Eisai based on the closing price as of the effective date of the Eisai License Agreement was $6.1&#160;million. Accordingly, the Company recorded $14.1&#160;million as acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development expense in the accompanying consolidated statements of operations for the year ended March&#160;31, 2022. &lt;/div&gt; </roiv:AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="P04_01_2018To04_30_2018_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">38700000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:NotesReceivableRelatedParties
      contextRef="PAsOn06_30_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">20100000</us-gaap:NotesReceivableRelatedParties>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_31_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">74272043</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P07_31_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">20500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="P07_31_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">15100000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P07_31_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">54526549</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_31_2020To07_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">9057566</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P07_31_2020To07_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">2500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <roiv:PercentageOfControllingInterestHeld
      contextRef="PAsOn07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="3"
      unitRef="Unit_pure">0.829</roiv:PercentageOfControllingInterestHeld>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure
      contextRef="PAsOn03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">28800000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure>
    <us-gaap:GainLossOnInvestments
      contextRef="P04_01_2020To03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">28800000</us-gaap:GainLossOnInvestments>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">9200000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="P04_01_2020To03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">20500000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <roiv:BusinessAcquisitionConsiderationTransferred
      contextRef="P07_01_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">58500000</roiv:BusinessAcquisitionConsiderationTransferred>
    <roiv:AcquiredInProcessResearchAndDevelopmentExpense
      contextRef="P04_01_2020To03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">41400000</roiv:AcquiredInProcessResearchAndDevelopmentExpense>
    <roiv:AcquiredInProcessResearchAndDevelopmentExpense
      contextRef="P04_01_2020To03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">41400000</roiv:AcquiredInProcessResearchAndDevelopmentExpense>
    <roiv:PaymentForUpfrontPayments
      contextRef="PAsOn11_30_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">105000000</roiv:PaymentForUpfrontPayments>
    <roiv:FutureDevelopmentAndCommercialMilestonePayments
      contextRef="P01_01_2021To01_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000</roiv:FutureDevelopmentAndCommercialMilestonePayments>
    <roiv:FutureDevelopmentAndCommercialMilestonePayments
      contextRef="P11_01_2020To11_30_2020_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">51000000</roiv:FutureDevelopmentAndCommercialMilestonePayments>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="P11_01_2020To11_30_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">11500000</us-gaap:DebtConversionOriginalDebtAmount1>
    <roiv:FutureDevelopmentAndCommercialMilestonePayments
      contextRef="P11_01_2020To11_30_2020_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">8600000</roiv:FutureDevelopmentAndCommercialMilestonePayments>
    <roiv:PaymentUnderSponsoredResearchAgreement
      contextRef="P11_01_2020To11_30_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">15500000</roiv:PaymentUnderSponsoredResearchAgreement>
    <roiv:AcquiredInProcessResearchAndDevelopmentExpense
      contextRef="P04_01_2020To03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">116500000</roiv:AcquiredInProcessResearchAndDevelopmentExpense>
    <roiv:UpfrontCashPayments
      contextRef="P04_01_2020To03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">101200000</roiv:UpfrontCashPayments>
    <us-gaap:RepaymentOfNotesReceivableFromRelatedParties
      contextRef="P04_01_2020To03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">11900000</us-gaap:RepaymentOfNotesReceivableFromRelatedParties>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">3400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets
      contextRef="PAsOn12_31_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">200000000</us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets>
    <us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions
      contextRef="P12_01_2020To12_31_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="3"
      unitRef="Unit_pure">0.40</us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="PAsOn01_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <roiv:FutureDevelopmentAndCommercialMilestonePayments
      contextRef="P11_01_2020To11_30_2020_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000</roiv:FutureDevelopmentAndCommercialMilestonePayments>
    <roiv:NonRefundableUpfrontPaymentReceived
      contextRef="P04_01_2021To03_31_2022_CollaborationAgreementWithBlueprintMedicinesMemberROIVAgreementAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</roiv:NonRefundableUpfrontPaymentReceived>
    <roiv:PotentialMilestonePaymentReceivable
      contextRef="P04_01_2021To03_31_2022_CollaborationAgreementWithBlueprintMedicinesMemberROIVAgreementAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">632000000</roiv:PotentialMilestonePaymentReceivable>
    <us-gaap:DeferredRevenue
      contextRef="PAsOn03_31_2022_CollaborationAgreementWithBlueprintMedicinesMemberROIVAgreementAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:DeferredRevenue>
    <roiv:UpfrontCashPayments
      contextRef="P11_01_2020To11_30_2020_AffivantSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">40000000</roiv:UpfrontCashPayments>
    <roiv:StockIssuedDuringPeriodValue
      contextRef="P11_01_2020To11_30_2020_AffivantSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</roiv:StockIssuedDuringPeriodValue>
    <roiv:FutureDevelopmentAndCommercialMilestonePayments
      contextRef="P11_01_2020To11_30_2020_AffivantSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis"
      decimals="-8"
      unitRef="Unit_USD">2000000000</roiv:FutureDevelopmentAndCommercialMilestonePayments>
    <roiv:BusinessAcquisitionConsiderationTransferred
      contextRef="P03_01_2021To03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">450000000</roiv:BusinessAcquisitionConsiderationTransferred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="P03_01_2021To03_31_2021_FirstTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">350000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="P03_01_2021To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_shares">21409764</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P03_01_2021To03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">14000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <roiv:BusinessAcquisitionConsiderationTransferred
      contextRef="P11_01_2021To11_30_2021_SecondTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000</roiv:BusinessAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="P11_01_2021To11_30_2021_SecondTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">50000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="P11_01_2021To11_30_2021_SecondTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_shares">6348057</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <roiv:BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="PAsOn03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">402400000</roiv:BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
      contextRef="PAsOn03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">281700000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">105100000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">15600000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <roiv:AcquiredInProcessResearchAndDevelopmentExpense
      contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">399600000</roiv:AcquiredInProcessResearchAndDevelopmentExpense>
    <roiv:AcquiredInProcessResearchAndDevelopmentExpense
      contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">399600000</roiv:AcquiredInProcessResearchAndDevelopmentExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">23500000</us-gaap:ShareBasedCompensation>
    <roiv:FairValueOfCommonShares
      contextRef="PAsOn03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">22600000</roiv:FairValueOfCommonShares>
    <roiv:FairValueOfRestrictedStock
      contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">15600000</roiv:FairValueOfRestrictedStock>
    <roiv:AcquiredInProcessResearchAndDevelopmentExpense
      contextRef="P09_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">82100000</roiv:AcquiredInProcessResearchAndDevelopmentExpense>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P09_01_2021To09_30_2021_PriovantMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">70000000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <roiv:UpfrontCashPayments
      contextRef="P09_01_2021To09_30_2021_PriovantMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</roiv:UpfrontCashPayments>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="P09_01_2021To09_30_2021_PriovantMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">2100000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <roiv:AcquiredInProcessResearchAndDevelopmentExpense
      contextRef="P09_01_2021To09_30_2021_PriovantMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">82100000</roiv:AcquiredInProcessResearchAndDevelopmentExpense>
    <roiv:UpfrontCashPayments
      contextRef="P11_01_2021To11_30_2021_HemavantSciencesGmbhMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">8000000</roiv:UpfrontCashPayments>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="P11_01_2021To11_30_2021_HemavantSciencesGmbhMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">7000000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn11_30_2021_HemavantSciencesGmbhMemberusgaapRelatedPartyTransactionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">8</us-gaap:SharesIssuedPricePerShare>
    <roiv:MilestonePaymentPayable
      contextRef="PAsOn03_31_2022_DevelopmentAndRegulatoryMilestoneMemberusgaapTransactionTypeAxis_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">65000000</roiv:MilestonePaymentPayable>
    <roiv:PayableForEachAdditionalProductIndication
      contextRef="PAsOn03_31_2022_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">18000000</roiv:PayableForEachAdditionalProductIndication>
    <roiv:MilestonePaymentPayable
      contextRef="PAsOn03_31_2022_CommercialMilestoneMemberusgaapTransactionTypeAxis_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">295000000</roiv:MilestonePaymentPayable>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="P11_01_2021To11_30_2021_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis"
      decimals="INF"
      unitRef="Unit_shares">874957</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P11_01_2021To11_30_2021_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">6100000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <roiv:AcquiredInProcessResearchAndDevelopmentExpense
      contextRef="P04_01_2021To03_31_2022_PharmanvanthSevenGmbhMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">14100000</roiv:AcquiredInProcessResearchAndDevelopmentExpense>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 6&#x2014;Accrued Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses at March&#160;31, 2022 and 2021 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;66,188&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,755&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation-related expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,262&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,552&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other general and administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,081&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,629&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;127,531&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,936&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses at March&#160;31, 2022 and 2021 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;66,188&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,755&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation-related expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,262&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,552&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other general and administrative expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,081&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,629&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;127,531&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,936&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">66188000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">20755000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2022_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">44262000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2021_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">38552000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2022_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">17081000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2021_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">17629000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">127531000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">76936000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 7&#x2014;Long-Term Debt and Loan Commitment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Long-Term Debt &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term debt, net consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principal amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;217,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;170,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exit fee / end of term charge&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,390&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: unamortized debt discount and issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,375&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total debt, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;210,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;170,280&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: current portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total long-term debt, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;210,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;170,280&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;   &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dermavant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2019, Dermavant entered into a loan and security agreement (the &#x201c;Hercules Loan Agreement&#x201d;) with Hercules Capital, Inc. (&#x201c;Hercules&#x201d;), pursuant to which Dermavant borrowed an aggregate of $20.0&#160;million, which &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;bore interest at a variable per annum rate at the greater of (i) 9.95% or (ii)&#160;the prime rate plus 4.45%. Dermavant was also obligated to pay an end of term charge of $1.4&#160;million. Following the achievement of certain milestones, the term loan maturity was extended to June&#160;1, 2023 with interest-only monthly payments through December 2021. All amounts outstanding under the Hercules Loan Agreement were repaid in May 2021 using the proceeds from a $40.0&#160;million senior secured credit facility (the &#x201c;Credit Facility&#x201d;) entered into by Dermavant and certain of its subsidiaries in May 2021 with XYQ Luxco S.A.R.L (&#x201c;XYQ Luxco&#x201d;), as lender, and U.S. Bank National Association, as collateral agent. The Credit Facility has a five-year maturity and bears an interest rate of 10.0% per annum. Interest is payable quarterly in arrears on the last day of each calendar quarter through the maturity date. A lump sum principal payment is due on the maturity date. Dermavant is also obligated to pay an exit fee of $5.0&#160;million. The exit fee can be reduced to $4.0&#160;million upon achievement of certain equity milestones defined in the agreement, which are not deemed likely as of March&#160;31, 2022. In connection with the funding of the Credit Facility, Dermavant issued a warrant to XYQ Luxco to purchase 1,199,072 common shares of Dermavant at an exercise price of $0.01 per common share.&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with Dermavant&#x2019;s acquisition of tapinarof from GlaxoSmithKline Intellectual Property Development Ltd. and Glaxo Group Limited (collectively &#x201c;GSK&#x201d;) pursuant to an asset purchase agreement (the &#x201c;GSK Agreement&#x201d;), Dermavant and NovaQuest &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Co-Investment&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Fund VIII, L.P. (&#x201c;NovaQuest&#x201d;) entered into a funding agreement (the &#x201c;NovaQuest Agreement&#x201d;). Pursuant to the NovaQuest Agreement, Dermavant borrowed $&lt;/div&gt;100.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in &lt;/div&gt;August 2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and $&lt;/div&gt;17.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in &lt;/div&gt;October 2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; in exchange for an obligation to make certain variable future payments calculated as a function of the achievement of regulatory and commercial milestones or events of termination. The aggregate maximum amount of regulatory milestone payments that Dermavant could be required to make under the NovaQuest Agreement is $&lt;/div&gt;440.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, with $176.3 million due over a six-year period paid quarterly following the U.S. regulatory approval of VTAMA in May 2022. The maximum aggregate amount of commercial milestone payments is $&lt;/div&gt;141.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. In some circumstances, Dermavant may be able to offset certain of the regulatory milestone payments with up to $&lt;/div&gt;88.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of the commercial milestone payments. At issuance, the Company concluded that certain features of the long-term debt would be considered derivatives that would require bifurcation. In lieu of bifurcating various features in the agreement, the Company has elected the fair value option for this financial instrument and will record the changes in the fair value within the statements of operations at the end of each reporting period. Direct costs and fees related to the debt issued under the NovaQuest Agreement were recognized in earnings. As of March&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the fair value of the debt was $&lt;/div&gt;177.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;150.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively. Refer to Note &lt;/div&gt;14&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &#x201c;Fair Value Measurements&#x201d; for additional details regarding the fair value measurement.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) Debt Maturities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Annual maturities, including the exit fee, of debt outstanding as of&#160;March&#160;31, 2022&#160;are as follows (in thousands). Long term debt issued by Dermavant for which the fair value option has been elected is excluded from the below as the repayment terms are variable. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Years Ending March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2027&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;45,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;45,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(C) Loan Commitment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In May 2021, Dermavant, as seller, entered into a $160.0&#160;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million revenue interest purchase and sale agreement (the &#x201c;RIPSA&#x201d;) for its investigational product tapinarof with XYQ Luxco, NovaQuest &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Co-Investment&lt;/div&gt; Fund XVII, L.P., an affiliate of NovaQuest Capital Management, LLC, and MAM Tapir Lender, LLC, an affiliate of Marathon Asset Management, L.P. (collectively, the &#x201c;Purchasers&#x201d;), together with U.S. Bank National Association, as collateral agent. Under the terms of the RIPSA, the Purchasers procured a capped single-digit revenue interest in net sales of tapinarof for all dermatological indications in the United States, up to a cap of $344.0&#160;million, in exchange for &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$160.0&#160;million in committed funding to be paid to Dermavant, conditional based on the approval of tapinarof by the FDA. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;VTAMA (tapinarof) cream was approved by the FDA in May 2022. Refer to Note 17, &#x201c;Subsequent Events&#x201d; for more information.&lt;/div&gt;&lt;/div&gt; </us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term debt, net consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principal amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;217,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;170,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exit fee / end of term charge&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,390&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: unamortized debt discount and issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,375&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total debt, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;210,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;170,280&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: current portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total long-term debt, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;210,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;170,280&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfDebtTableTextBlock>
    <roiv:DebtInstrumentValue
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">217400000</roiv:DebtInstrumentValue>
    <roiv:DebtInstrumentValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">170100000</roiv:DebtInstrumentValue>
    <roiv:DebtInstrumentExitFeeAndEndOfTermCharge
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5000000</roiv:DebtInstrumentExitFeeAndEndOfTermCharge>
    <roiv:DebtInstrumentExitFeeAndEndOfTermCharge
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1390000</roiv:DebtInstrumentExitFeeAndEndOfTermCharge>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">12375000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1210000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">210025000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">170280000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">210025000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">170280000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn05_31_2019"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="PAsOn05_31_2019"
      decimals="4"
      unitRef="Unit_pure">0.0995</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="PAsOn05_31_2019_PrimeRateMemberusgaapVariableRateAxis"
      decimals="4"
      unitRef="Unit_pure">0.0445</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="PAsOn05_31_2019"
      decimals="-5"
      unitRef="Unit_USD">1400000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P05_01_2021To05_01_2021"
      decimals="-5"
      unitRef="Unit_USD">40000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentTerm contextRef="P05_01_2021To05_01_2021">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn05_01_2021"
      decimals="3"
      unitRef="Unit_pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <roiv:DebtInstrumentExitFeeAndEndOfTermCharge
      contextRef="PAsOn05_31_2021"
      decimals="-5"
      unitRef="Unit_USD">5000000</roiv:DebtInstrumentExitFeeAndEndOfTermCharge>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="PAsOn05_31_2021"
      decimals="-5"
      unitRef="Unit_USD">4000000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="PAsOn05_31_2021"
      decimals="INF"
      unitRef="Unit_shares">1199072</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn05_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">17500000</us-gaap:DebtInstrumentFaceAmount>
    <roiv:MaximumMilestonePaymentObligation
      contextRef="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">440600000</roiv:MaximumMilestonePaymentObligation>
    <roiv:MilestonePaymentDueOverSixYearPeriod
      contextRef="PAsOn03_31_2022_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">176300000</roiv:MilestonePaymentDueOverSixYearPeriod>
    <roiv:MaximumMilestonePaymentObligation
      contextRef="PAsOn08_31_2018_CommercialMilestoneMemberusgaapTransactionTypeAxis_NovaquestMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">141000000</roiv:MaximumMilestonePaymentObligation>
    <roiv:MaximumMilestonePaymentOffsetAmount
      contextRef="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">88100000</roiv:MaximumMilestonePaymentOffsetAmount>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2022_NovaquestMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">177400000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2021_NovaquestMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">150100000</us-gaap:DebtInstrumentFairValue>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Annual maturities, including the exit fee, of debt outstanding as of&#160;March&#160;31, 2022&#160;are as follows (in thousands). Long term debt issued by Dermavant for which the fair value option has been elected is excluded from the below as the repayment terms are variable. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Years Ending March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2027&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;45,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;45,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">45000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <roiv:LongTermDebtExcludingDebtWithFairValueOption
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">45000000</roiv:LongTermDebtExcludingDebtWithFairValueOption>
    <roiv:CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement
      contextRef="P05_01_2021To05_31_2021_RevenueInterestPurchaseAndSaleAgreementMemberusgaapFinancialInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">160000000</roiv:CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement>
    <roiv:CommittedFundingUnderRIPSA
      contextRef="PAsOn05_31_2021_RevenueInterestPurchaseAndSaleAgreementMemberusgaapFinancialInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">344000000</roiv:CommittedFundingUnderRIPSA>
    <roiv:CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement
      contextRef="P05_01_2021To05_31_2021_RevenueInterestPurchaseAndSaleAgreementMemberusgaapFinancialInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">160000000</roiv:CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 8&#x2014;Related Party Transactions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sumitomo Dainippon Pharma Co., Ltd. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In May 2021, the Company entered into an Asset Purchase Agreement with Sumitomo Dainippon Pharma Co., Ltd. (&#x201c;Sumitomo&#x201d;) and its subsidiary Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (&#x201c;SPC&#x201d;) (the &#x201c;Asset Purchase Agreement&#x201d;). The transactions contemplated by the Asset Purchase Agreement closed in June 2021. Pursuant to the Asset Purchase Agreement: (i)&#160;Sumitomo terminated all of its existing options to acquire the Company&#x2019;s equity interests in certain of its subsidiaries (the &#x201c;Sumitomo Options&#x201d;); (ii) the Company transferred and assigned to SPC all of its intellectual property, development and commercialization rights for (a)&#160;lefamulin in Mainland China, Taiwan, Hong Kong, and Macau (collectively &#x201c;Greater China&#x201d;), (b) vibegron in Mainland China, (c)&#160;rodatristat ethyl in Greater China and South Korea and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(d)&#160;RVT-802&lt;/div&gt; in Greater China and South Korea; (iii)&#160;Sumitomo agreed to pay the Company $5.0&#160;million in cash; and (iv)&#160;Sumitomo entered into an agreement with the Company to pursue future collaborations with Genevant. The Company received the cash payment, net of certain withholding taxes, in August 2021. The Company recorded a gain on the termination of the Sumitomo Options of $66.5&#160;million, consisting of the fair value of the Sumitomo Options on the date of termination and the cash payment, in the accompanying consolidated statements of operations for the year ended March&#160;31, 2022. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Transition Services Agreement and Strategic Cooperation Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;In December 2019, RSL and Sumitomo completed the transactions contemplated by the transaction agreement by and between RSL and Sumitomo, dated as of October 31, 2019 (the &#x201c;Sumitomo Transaction Agreement&#x201d;). Concurrent with entry into the Sumitomo Transaction Agreement, RSL and Sumitomo entered into the following agreements: (i)&#160;a transition services agreement (the &#x201c;TSA&#x201d;), pursuant to which the parties agreed to provide certain transitional services to one another at cost for a specified period of time following the closing date and (ii)&#160;a strategic cooperation agreement (the &#x201c;SCA&#x201d;), providing for certain technology-related collaborations. Pursuant to the terms of the TSA and the SCA, RSL billed Sumitomo &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$1.0&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;million and&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; $1.4&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;million, net of amounts billed by Sumitomo to RSL, during the years ended March&#160;31, 2022 and 2021, respectively. Additionally, during each of the years ended March&#160;31, 2022 and 2021, the Company paid Sumitomo a &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$1.0&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million DrugOme access fee pursuant to the SCA. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;1, 2022, RSL and Sumitomo amended the SCA. In connection with the amendment, RSL agreed to pay Sumitomo an aggregate of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$4.5&#160;million. This consideration was expensed during the year ended March&#160;31, 2022. &lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <roiv:AssetPurchaseTransactionConsiderationReceivedInCash
      contextRef="PAsOn05_31_2021_AssetPurchaseAgreementMemberROIVAgreementAxis"
      decimals="-5"
      unitRef="Unit_USD">5000000</roiv:AssetPurchaseTransactionConsiderationReceivedInCash>
    <roiv:EquityInterestOptionToThirdPartyPurchaserGainOnTermination
      contextRef="P04_01_2021To03_31_2022_AssetPurchaseAgreementMemberROIVAgreementAxis"
      decimals="-5"
      unitRef="Unit_USD">66500000</roiv:EquityInterestOptionToThirdPartyPurchaserGainOnTermination>
    <roiv:AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary
      contextRef="P04_01_2021To03_31_2022_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis"
      decimals="-5"
      unitRef="Unit_USD">1000000</roiv:AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary>
    <roiv:AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary
      contextRef="P04_01_2020To03_31_2021_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis"
      decimals="-5"
      unitRef="Unit_USD">1400000</roiv:AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary>
    <roiv:AccessFeePaidToRelatedParty
      contextRef="P04_01_2021To03_31_2022_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis"
      decimals="-5"
      unitRef="Unit_USD">1000000</roiv:AccessFeePaidToRelatedParty>
    <roiv:AccessFeePaidToRelatedParty
      contextRef="P04_01_2020To03_31_2021_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis"
      decimals="-5"
      unitRef="Unit_USD">1000000</roiv:AccessFeePaidToRelatedParty>
    <roiv:AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary
      contextRef="P03_01_2022To03_01_2022_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis"
      decimals="-5"
      unitRef="Unit_USD">4500000</roiv:AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 9&#x2014;Shareholders&#x2019; Equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) RSL Common &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&#160;30, 2021 in connection with the closing of the Business Combination, the Company effected a &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.9262-for-1&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; stock subdivision based on the fixed exchange ratio established in the Business Combination. All per share amounts and number of shares in the consolidated financial statements and related notes have been retroactively restated to reflect the stock split.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additionally, in connection with the closing of the Business Combination, the Company adjusted its authorized share capital to equal 7,000,000,000 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;c&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;hares, par value $&lt;span style="-sec-ix-hidden:hidden50658913"&gt;0.00000003&lt;/span&gt;41740141 per share. Each &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;c&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;hare has the right to one vote. The holders of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;hares are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared by the board of directors since the Company&#x2019;s inception.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) Committed Equity Facility&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February&#160;14, 2022, the Company entered into a committed equity facility (the &#x201c;Facility&#x201d;) with an affiliate of Cantor Fitzgerald&#160;&amp;amp; Co. (&#x201c;Cantor&#x201d;). Under the terms of the Facility, Cantor has committed to purchase up to an aggregate of $250.0&#160;million in the Company&#x2019;s &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;hares&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; from time to time at the request of the Company, subject to certain limitations and the satisfaction of certain conditions. Any sales of the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;ompany&#x2019;s &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;hares&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; to Cantor under the Facility will be made at 99% of the volume-weighted average price of the Company&#x2019;s &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;hares&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; on Nasdaq on a given trading day. In consideration for entry into the Facility, the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&lt;/div&gt;ompany paid Cantor an upfront commitment fee in the form of 145,986 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;hares&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. As of March&#160;31, 2022, $250.0&#160;million of the Company&#x2019;s &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;hares&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; remained available for sale under the Facility. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(C) Consolidated Vant Equity Transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Immunovant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2020 and September 2020, Immunovant, Inc. achieved the first and second earnout milestones as defined in the share exchange agreement with Health Sciences Acquisitions Corporation. As a result, all of the 20,000,000 earnout shares of Immunovant, Inc.&#x2019;s common stock were issued, including 17,547,938 shares of common stock issued to RSL. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In April 2020, Immunovant, Inc. completed an underwritten public offering of 9,613,365 shares of its common stock, including 1,034,483 shares of common stock purchased by RSL, at a price of $14.50 per share for net proceeds to Immunovant, Inc. of approximately $131.0&#160;million, after deducting underwriting discounts and commissions and offering expenses. The proceeds included $15.0&#160;million received from RSL. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2020, Immunovant, Inc.&#x2019;s 11,500,000 outstanding warrants became exercisable for an aggregate of 5,750,000 shares of Immunovant, Inc.&#x2019;s common stock at a price of $11.50 per share. An aggregate of 11,438,290 outstanding warrants were exercised for an aggregate of 5,719,145 shares of Immunovant, Inc.&#x2019;s common stock at a price of $11.50 per share, for net proceeds of approximately $65.8&#160;million. The remaining 61,710 warrants were cancelled. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In September 2020, Immunovant, Inc. completed an underwritten public offering of 6,060,606 shares of its common stock, including 380,000 shares of common stock purchased by RSL, at a price of $33.00 per share for net proceeds to Immunovant, Inc. of approximately $188.1&#160;million, after deducting underwriting discounts and commissions and offering expenses. The proceeds included $12.5&#160;million received from RSL. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Proteovant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July 2021, Proteovant collected the subscription receivable relating to the second $100.0&#160;million payment due under a subscription agreement entered into with SK, Inc. (&#x201c;SK&#x201d;) in December 2020 pursuant to which SK agreed to make a $200.0&#160;million equity investment in Proteovant, representing an ownership interest of 40.0% on the closing date. &lt;/div&gt;&lt;/div&gt; </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <roiv:StockHoldersEquityNoteStockSplitExchangeRatio1
      contextRef="PAsOn03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="4"
      unitRef="Unit_pure">2.9262</roiv:StockHoldersEquityNoteStockSplitExchangeRatio1>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">7000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockVotingRights contextRef="P04_01_2021To03_31_2022_RoivantCommonSharesMemberusgaapStatementEquityComponentsAxis">one vote</us-gaap:CommonStockVotingRights>
    <us-gaap:PurchaseObligation
      contextRef="PAsOn02_14_2022_CantorFitzgeraldCo.MemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">250000000</us-gaap:PurchaseObligation>
    <roiv:PercentageOfCommonSharesVolumeWeightedAveragePrice
      contextRef="P02_14_2022To02_14_2022_CantorFitzgeraldCo.MemberusgaapRelatedPartyTransactionAxis"
      decimals="2"
      unitRef="Unit_pure">0.99</roiv:PercentageOfCommonSharesVolumeWeightedAveragePrice>
    <roiv:UpfrontCommitmentFeeNumberOfSharesIssued
      contextRef="P02_14_2022To02_14_2022_CantorFitzgeraldCo.MemberusgaapRelatedPartyTransactionAxis"
      decimals="INF"
      unitRef="Unit_shares">145986</roiv:UpfrontCommitmentFeeNumberOfSharesIssued>
    <roiv:CommonSharesValueAvailableForSale
      contextRef="PAsOn03_31_2022_CantorFitzgeraldCo.MemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">250000000</roiv:CommonSharesValueAvailableForSale>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_30_2020_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">20000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2021_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">17547938</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2021_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">17547938</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">9613365</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">1034483</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">14.5</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">131000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <roiv:ClassOfWarrantOrRightExercisable
      contextRef="PAsOn05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">11500000</roiv:ClassOfWarrantOrRightExercisable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">5750000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <roiv:ClassOfWarrantOrRightExercisable
      contextRef="PAsOn03_31_2022_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">11438290</roiv:ClassOfWarrantOrRightExercisable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2022_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">5719145</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P05_01_2020To05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="-5"
      unitRef="Unit_USD">65800000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <roiv:ClassOfWarrantOrRightCanceled
      contextRef="P05_01_2020To05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">61710</roiv:ClassOfWarrantOrRightCanceled>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P09_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">6060606</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P09_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">380000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">33</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P09_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">188100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P09_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">12500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <roiv:SubscriptionReceived
      contextRef="PAsOn07_01_2021_SkMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000</roiv:SubscriptionReceived>
    <us-gaap:EquityMethodInvestments
      contextRef="PAsOn12_31_2020_SkMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="-5"
      unitRef="Unit_USD">200000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2020_SkMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="3"
      unitRef="Unit_pure">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 10&#x2014;Share-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Share-Based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expense was as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expense recognized as:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;63,735&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22,637&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;501,221&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;62,321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;564,956&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;84,958&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The achievement of the liquidity event vesting condition for certain equity instruments upon the closing of the Business Combination resulted in the recognition of a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; expense of $372.9&#160;million in September 2021 relating to cumulative service rendered between the grant date of the respective awards and completion of the Business Combination. This &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; expense is reflected in the accompanying consolidated statements of operations for the year ended March&#160;31, 2022. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) RSL Equity Incentive Plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;RSL has three equity incentives plans: the Roivant Sciences Ltd. 2021 Equity Incentive Plan (the &#x201c;RSL 2021 EIP&#x201d;), the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan (the &#x201c;RSL 2015 EIP&#x201d;), and the Roivant Sciences Ltd. Amended and Restated 2015 Restricted Stock Unit Plan (the &#x201c;2015R Plan&#x201d;) (collectively, the &#x201c;RSL Equity Plans&#x201d;). The RSL 2021 EIP was approved and adopted in connection with the Business Combination and became effective immediately prior to closing. Since the effective date of the RSL 2021 EIP, no further stock awards have been or will be made under the RSL 2015 EIP. Additionally, no further stock awards will be made under the 2015R Plan. As of March&#160;31, 2022,&lt;/div&gt;&lt;/div&gt;&#160;69,300,000 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;of the Company&#x2019;s &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;hares were reserved for issuance under the RSL 2021 EIP. The number of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;hares reserved for issuance under the RSL 2021 EIP will automatically increase on April&#160;1 of each year by an amount equal to the lesser of (i)&lt;/div&gt;&lt;/div&gt;&#160;5%&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;hares outstanding as of the last day of the immediately preceding fiscal year and (ii)&#160;such number of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;hares as determined by our board of directors in its discretion. The RSL 2021 EIP has a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ten-year&lt;/div&gt; term. The Company&#x2019;s employees, directors, and consultants are eligible to receive incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock awards under the RSL 2021 EIP. At March&#160;31, 2022, a total of&lt;/div&gt;&#160;59,373,756 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="display:inline;"&gt;s&lt;/div&gt;hares were available for future grants under the RSL 2021 EIP. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;All RSL &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;hares issuable on exercise of vested options or settlement of other equity instruments that were issued and outstanding as of the closing of the Business Combination were subject to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;six-month&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lock-up&lt;/div&gt; period. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lock-up&lt;/div&gt; period expired on March&#160;30, 2022. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Options and Performance Stock Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Activity for stock options and performance stock options under the RSL Equity Plans for the year ended March&#160;31, 2022 is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&#160;Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&#160;Life&lt;br/&gt; (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; Intrinsic&#160;Value&lt;br/&gt; (in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options outstanding at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69,687,308&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.89&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,181,127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(101,436&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.06&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited/Canceled&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,402,095&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options outstanding at March&#160;31, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;80,364,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,899&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options exercisable at March&#160;31, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;39,236,351&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,456&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of all outstanding and exercisable options and the fair value of the Company&#x2019;s &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;stock&lt;/div&gt;&lt;/div&gt; at March&#160;31, 2022. At March&#160;31, 2022, total unrecognized compensation expense related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; stock options and performance stock options was approximately &lt;/div&gt;$149.7&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million and is expected to be recognized over a weighted-average period of approximately&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#160;2.63 years.&lt;br/&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At March&#160;31, 2022 and 2021, there were 39,236,351 and 16,193,146 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;vested stock options and performance stock options, respectively. Vesting for performance stock options was subject to a liquidity event vesting requirement in addition to time-based service requirements. The liquidity event vesting requirement was met upon closing of the Business Combination on September 30, 2021. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company estimated the fair value of each stock option on the date of grant using the Black-Scholes closed form option-pricing model applying the weighted average assumptions in the following table. No performance stock options were granted during the years ended March&#160;31, 2022 and 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected stock price volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;81.70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74.84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected risk free interest rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.43&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term, in years&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additional information regarding stock options and performance stock options is set forth below (in thousands, except per share data). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intrinsic value of options exercised&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grant date fair value of options vested&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;210,487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,711&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average grant date fair value per share of stock options granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.85&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.67&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Stock Units and Performance Stock Units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Activity for restricted stock units and performance stock units under the RSL Equity Plans for the year ended March&#160;31, 2022 is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 58%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;Restricted&lt;br/&gt; Stock Units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;Average&lt;br/&gt; Grant Date Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,294,028&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,948,227&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.44&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,111,550&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,173,956&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.79&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,956,749&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total fair value of restricted stock units and performance stock units vested during the year ended March&#160;31, 2022 was $59.3&#160;million. Vesting for both restricted stock units and performance stocks units was subject to a liquidity event vesting requirement. There were no vested restricted stock units or performance stock units at March&#160;31, 2021 as the liquidity event vesting requirement was not met until the closing of the Business Combination on September&#160;30, 2021. Restricted stock units vest upon the achievement of time-based service requirements. The vesting of performance stock units requires that certain performance conditions are achieved during the performance period and is subject to continued service requirements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;At March&#160;31, 2022, total unrecognized compensation expense related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; restricted stock units and performance stock units was approximately $155.8&#160;million. Unrecognized compensation expense relating to restricted stock units and performance stock units that are deemed probable of vesting is expected to be recognized over a weighted-average period of approximately 2.97 years.&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Capped Value Appreciation Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March 2020 CVAR Grants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March 2020, the Company granted capped value appreciation rights (&#x201c;CVARs&#x201d;) that will pay at settlement the excess in shares of (a)&#160;the lesser of (i)&#160;the fair market value of a &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;c&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;hare as of the settlement date or (ii)&#160;the cap of $12.68, over (b)&#160;the hurdle price of either $6.40 or $11.50, as applicable to each grant. On March&#160;30, 2022, the Company amended the outstanding CVARs that were granted in March 2020. Pursuant to the amendment, in the event any CVARs have satisfied the time-based service and liquidity event vesting requirements (&#x201c;service-vested CVARs&#x201d;) but have not satisfied the applicable hurdle price on an applicable measurement date, then such CVARs will be deemed to remain outstanding and the applicable award holder will be provided the right to earn such CVARs if the hurdle price is satisfied on subsequent annual &#x201c;hurdle measurement dates&#x201d; prior to the original expiration date of the CVARs, being March&#160;31, 2026. The &#x201c;hurdle measurement dates&#x201d; are March&#160;30 of each of years 2023 through 2026. If the hurdle price is not satisfied on any such subsequent annual hurdle measurement date prior to the expiration date of the CVARs, then the CVARs will be forfeited in their entirety on the expiration date. This amendment was accounted for as a modification and resulted in an aggregate of approximately $16.9&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million of incremental fair value. Incremental fair value associated with CVARs that do not require further service for vesting was recognized in full on March&#160;30, 2022. The Company will recognize the incremental fair value for CVARs that require future service for vesting over the remaining requisite service &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;period.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;  &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Activity&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;for CVARs under the RSL 2015 EIP for the year ended March&#160;31, 2022 is as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;CVARs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-service-vested&lt;/div&gt; CVARs balance at March&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,447,626&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service-vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(18,213,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(435,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-service-vested&lt;/div&gt; CVARs balance at March&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,798,086&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;At March&#160;31, 2022, there were 18,213,910 service-vested CVARs. The hurdle price was not satisfied for these service-vested CVARs and as such they remain outstanding. The total fair value of CVARs that service-vested during the year ended March&#160;31, 2022 was&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;$22.3&#160;million. There were no service-vested CVARs at March&#160;31, 2021 as the liquidity event vesting requirement was not met until the closing of the Business Combination on September&#160;30, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;At March&#160;31, 2022, total unrecognized compensation expense related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-service-vested&lt;/div&gt; CVARs was approximately $10.1&#160;million and is expected to be recognized over a weighted-average period of approximately 1.74 years. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;November 2021 CVAR Grants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In November 2021, the Company made &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; grants of 6,317,350 CVARs in the aggregate under the RSL 2021 EIP to eligible participants. The CVARs are eligible to vest based on the satisfaction of service-based and performance-based vesting requirements. The performance-based vesting requirement was achieved in December 2021. Vested CVARs will be settled in &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;c&lt;/div&gt;&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;hares, up to a specified cap price.&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Activity for CVARs under the RSL 2021 EIP for the year ended March&#160;31, 2022 is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;CVARs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,317,350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(32,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,285,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;At March&#160;31, 2022, total unrecognized compensation expense related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; CVARs was approximately $19.3&#160;million and is expected to be recognized over a weighted-average period of approximately 3.13 years. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(C) Employee Stock Purchase Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;In September 2021, the Company adopted the Roivant Sciences Ltd. Employee Stock Purchase Plan (the &#x201c;RSL ESPP&#x201d;), which provides for the granting of an option to purchase &lt;div style="display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;hares of RSL to eligible employees, as defined by the RSL ESPP. As of March&#160;31, 2022, the maximum number of &lt;div style="display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;hares reserved and available for purchase under the RSL ESPP was&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;13,900,000. &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;The total number of &lt;div style="display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;hares available for purchase under the RSL ESPP will be increased annually on April&#160;1 of each year during the term of the plan in an amount equal to the least of (i)&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; 13,900,000 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;hares, (ii)&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden50659171"&gt;one&lt;/span&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;percent of the aggregate number of &lt;div style="display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;hares outstanding (on a fully diluted basis) on the last day of the immediately preceding Company fiscal year and (iii)&#160;such lesser number of &lt;div style="display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;hares as determined by the board of directors; provided that the maximum number of &lt;div style="display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;hares that may be issued under the RSL ESPP during the term of the plan is&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;147,447,650 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;hares.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-size: 8pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(D) Subsidiary Equity Incentive Plans&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Certain wholly owned and majority-owned or controlled subsidiaries of RSL adopt their own equity incentive plan (&#x201c;EIP&#x201d;). Each EIP is generally structured so that the applicable subsidiary, and its affiliates&#x2019; employees, directors, officers and consultants are eligible to receive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-qualified&lt;/div&gt; and incentive stock options, stock appreciation rights, restricted share awards, restricted stock unit awards, and other share awards under their respective EIP. The Company recorded share-based compensation expense of $47.4&#160;million and $29.1&#160;million for the years ended March&#160;31, 2022 and 2021, respectively, related to subsidiary EIPs. At March&#160;31, 2022, total unrecognized compensation expense related to subsidiary EIPs was approximately $134.5&#160;million. &lt;/div&gt; </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expense was as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expense recognized as:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;63,735&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22,637&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;501,221&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;62,321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;564,956&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;84,958&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2021To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">63735000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">22637000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2021To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">501221000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">62321000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">564956000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">84958000</us-gaap:AllocatedShareBasedCompensationExpense>
    <roiv:OneTimeCatchUpExpense
      contextRef="P09_01_2021To09_30_2021_AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMemberROIVEventAxis"
      decimals="-5"
      unitRef="Unit_USD">372900000</roiv:OneTimeCatchUpExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn03_31_2022_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">69300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="P04_01_2021To03_31_2022_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn03_31_2022_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">59373756</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Activity for stock options and performance stock options under the RSL Equity Plans for the year ended March&#160;31, 2022 is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&#160;Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&#160;Life&lt;br/&gt; (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; Intrinsic&#160;Value&lt;br/&gt; (in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options outstanding at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69,687,308&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.89&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,181,127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(101,436&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.06&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited/Canceled&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,402,095&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options outstanding at March&#160;31, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;80,364,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,899&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options exercisable at March&#160;31, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;39,236,351&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,456&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn03_31_2021_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">69687308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2021_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P04_01_2020To03_31_2021_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis">P5Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P04_01_2021To03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">12181127</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P04_01_2021To03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P04_01_2021To03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">101436</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P04_01_2021To03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">4.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P04_01_2021To03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">1402095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P04_01_2021To03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">80364904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P04_01_2021To03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1899000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">39236351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P04_01_2021To03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1456000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn03_31_2022_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">149700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P04_01_2021To03_31_2022_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis">P2Y7M17D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn03_31_2022_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">39236351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn03_31_2021_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">16193146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company estimated the fair value of each stock option on the date of grant using the Black-Scholes closed form option-pricing model applying the weighted average assumptions in the following table. No performance stock options were granted during the years ended March&#160;31, 2022 and 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected stock price volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;81.70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74.84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected risk free interest rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.43&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term, in years&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P04_01_2021To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.817</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.7484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P04_01_2021To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P04_01_2021To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P04_01_2021To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <roiv:ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additional information regarding stock options and performance stock options is set forth below (in thousands, except per share data). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intrinsic value of options exercised&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grant date fair value of options vested&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;210,487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,711&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average grant date fair value per share of stock options granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.85&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.67&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </roiv:ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock>
    <roiv:IntrinsicValueOfOptionsExercised
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">89000</roiv:IntrinsicValueOfOptionsExercised>
    <roiv:IntrinsicValueOfOptionsExercised
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:IntrinsicValueOfOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">210487000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">25711000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <roiv:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue
      contextRef="P04_01_2021To03_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">6.85</roiv:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue>
    <roiv:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue
      contextRef="P04_01_2020To03_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">8.67</roiv:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Activity for restricted stock units and performance stock units under the RSL Equity Plans for the year ended March&#160;31, 2022 is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 58%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;Restricted&lt;br/&gt; Stock Units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;Average&lt;br/&gt; Grant Date Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,294,028&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,948,227&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.44&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,111,550&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,173,956&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.79&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,956,749&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2021_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">7294028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2021_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P04_01_2021To03_31_2022_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">20948227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P04_01_2021To03_31_2022_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P04_01_2021To03_31_2022_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">5111550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P04_01_2021To03_31_2022_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P04_01_2021To03_31_2022_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">1173956</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P04_01_2021To03_31_2022_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2022_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">21956749</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2022_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P04_01_2021To03_31_2022_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">59300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P04_01_2020To03_31_2021_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn03_31_2022_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">155800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P04_01_2021To03_31_2022_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAwardTypeAxis">P2Y11M19D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <roiv:IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment
      contextRef="P04_01_2021To03_31_2022_March2020CappedValueAppreciationRightsMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">16900000</roiv:IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment>
    <roiv:ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Activity&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;for CVARs under the RSL 2015 EIP for the year ended March&#160;31, 2022 is as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;CVARs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-service-vested&lt;/div&gt; CVARs balance at March&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,447,626&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Service-vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(18,213,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(435,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-service-vested&lt;/div&gt; CVARs balance at March&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,798,086&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </roiv:ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">32447626</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.72</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">18213910</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">435630</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.4</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">13798086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">22300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">10100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">P1Y8M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares
      contextRef="P11_01_2021To11_30_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">6317350</roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares>
    <roiv:ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis">&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Activity for CVARs under the RSL 2021 EIP for the year ended March&#160;31, 2022 is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;CVARs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,317,350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(32,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,285,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </roiv:ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">6317350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">4.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">32100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">4.71</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">6285250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandTwentyOneEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">4.95</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn03_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">13900000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <roiv:IncrementOfEmployeeStockPurchasePlan
      contextRef="PAsOn03_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">13900000</roiv:IncrementOfEmployeeStockPurchasePlan>
    <roiv:EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable
      contextRef="P04_01_2021To03_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">147447650</roiv:EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2021To03_31_2022_SubsidiaryEquityIncentivePlansMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">47400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To03_31_2021_SubsidiaryEquityIncentivePlansMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">29100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn03_31_2022_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">134500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 11&#x2014;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The loss before income taxes and the related expense/(benefit) are as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ended March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss before income taxes:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bermuda&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;390,831&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(227,471&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United States&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(747,953&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(212,921&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Switzerland&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(544,870&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(424,494&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(21,755&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(33,661&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total loss before income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(923,747&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(898,547&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Primarily entities which are centrally managed and controlled in the United Kingdom &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Primarily Greater China and United Kingdom activity &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current taxes:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bermuda&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United States&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(223&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,365&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Switzerland&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;369&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred taxes:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bermuda&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United States&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Switzerland&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;369&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Primarily Greater China and United Kingdom activity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation of income tax provision/(benefit) computed at the Bermuda statutory rate to income tax expense reflected in the consolidated financial statements is as follows (in thousands, except percentages): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt;March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt;March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax benefit at Bermuda statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign rate differential&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(179,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19.38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(150,778&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16.78&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Permanent disallowed IPR&amp;amp;D&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,347&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;111,432&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax-effect&lt;/div&gt; of changes in the fair value of investments and loss from equity method investment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,169&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(22,472&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nontaxable gain on sale of investment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(84,313&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nontaxable gain on deconsolidation of business&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(958&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(16,438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nondeductible executive compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,973&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2.81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;905&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Tax deficiencies (excess tax benefits) from share-based compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,918&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(439&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other permanent adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,912&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,457&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research tax credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.09&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;205,811&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(22.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;85,046&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9.46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax rate changes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,444&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,443&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;85&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;369&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Primarily related to operations in the United States, Switzerland, the United Kingdom, and other jurisdictions with statutory tax rates different than the Bermuda rate. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s effective tax rates for the years ended March&#160;31, 2022 and 2021 was (0.04)% and (0.19)%, respectively, driven by the Company&#x2019;s jurisdictional earnings by location and a valuation allowance that eliminates the Company&#x2019;s global net deferred tax assets.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred taxes reflect the tax effects of the differences between the amounts recorded as assets and liabilities for financial reporting purposes and the comparable amounts recorded for income tax purposes. &lt;/div&gt;Significant components of the deferred tax assets (liabilities) at March&#160;31, 2022 and 2021 are as follows (in thousands):&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research tax credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27,155&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,063&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;61,544&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;50,564&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;312,749&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;202,906&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;93,177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,623&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,406&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,638&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,651&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subtotal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;530,682&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;323,097&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(512,736&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(303,287&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,397&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,214&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,661&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,908&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,888&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,688&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax assets/(liabilities)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has Federal net operating losses in Switzerland, the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;United &lt;/div&gt;States, the United Kingdom and other jurisdictions in the amount of $1,749.2&#160;million, $244.1&#160;million, $40.1&#160;million, and $98.4&#160;million, respectively. The Switzerland net operating losses will expire in varying amounts between March 31, 2025 and March 31, 2029. The United States net operating losses can be carried forward indefinitely with utilization limited to 80% of future taxable income for tax years beginning on or after January&#160;1, 2021, while the United Kingdom and other net operating losses can be carried forward indefinitely as well, with an annual limitation on utilization. The Company has generated net operating losses from United States state and local jurisdictions in the amount of $94.8&#160;million which will expire in varying amounts between March 31, 2035 and March 31, 2042. The Company has generated $27.2&#160;million of research tax credit carryforwards primarily in the United States and Canada, which will expire in varying amounts between March 31, 2035 and March 31, 2042. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company assesses the realizability of the deferred tax assets at each balance sheet date based on available positive and negative evidence in order to determine the amount which is more likely than not to be realized and record a valuation allowance as necessary. Due to the Company&#x2019;s cumulative loss position which provides significant negative evidence difficult to overcome, the Company has recorded a valuation allowance of $512.7&#160;million as of March&#160;31, 2022, representing the portion of the deferred tax asset that is not more likely than not to be realized. For the period April&#160;1, 2021 through March&#160;31, 2022, the valuation allowance increased by $209.4&#160;million, primarily as a result of corresponding increases in our global net operating losses, as well as increased costs related to share-based compensation. The amount of the deferred tax asset considered realizable could be adjusted for future factors that would impact the assessment of the objective and subjective evidence of the Company. The Company will continue to assess the realizability of deferred tax assets at each balance sheet date in order to determine the amount, if any, required for a valuation allowance. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There are outside basis differences related to the Company&#x2019;s investment in subsidiaries for which no deferred taxes have been recorded as these would not be subject to tax on repatriation as Bermuda has no tax regime for Bermuda exempted limited companies, and the United Kingdom tax regime relating to company distributions and sales generally provides for exemption from tax for most overseas profits, subject to certain exceptions. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is subject to tax and is required to file United States, United Kingdom, and Switzerland federal income tax returns, as well as income tax returns in various state, local, and foreign jurisdictions. The&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;is subject to tax examinations for tax years ended March&#160;31, 2018 and forward in major taxing jurisdictions. Tax audits and examinations can involve complex issues, interpretations and judgments. The resolution of matters may span multiple years particularly if subject to litigation or negotiation. The Company believes it has appropriately recorded its tax position using reasonable estimates and assumptions, however, the potential tax benefits may impact the results of operations or cash flows in the period of resolution, settlement or when the statutes of limitations expire. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s unrecognized tax benefit activity during the year ended March&#160;31, 2022 was not material to the Company&#x2019;s consolidated financial statements. There were no unrecognized tax benefits recorded as of March&#160;31, 2021. No interest and penalties related to unrecognized tax benefits were recorded as of March&#160;31, 2022 or March&#160;31, 2021. &lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The loss before income taxes and the related expense/(benefit) are as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ended March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss before income taxes:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bermuda&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;390,831&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(227,471&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United States&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(747,953&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(212,921&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Switzerland&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(544,870&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(424,494&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(21,755&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(33,661&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total loss before income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(923,747&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(898,547&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Primarily entities which are centrally managed and controlled in the United Kingdom &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Primarily Greater China and United Kingdom activity &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current taxes:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bermuda&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United States&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(223&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,365&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Switzerland&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;369&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred taxes:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bermuda&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United States&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Switzerland&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;369&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2021To03_31_2022_BMsrtStatementGeographicalAxis"
      decimals="-3"
      id="Fact_50658687"
      unitRef="Unit_USD">390831000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2020To03_31_2021_BMsrtStatementGeographicalAxis"
      decimals="-3"
      id="Fact_50658688"
      unitRef="Unit_USD">-227471000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2021To03_31_2022_USsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">-747953000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2020To03_31_2021_USsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">-212921000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2021To03_31_2022_CHsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">-544870000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2020To03_31_2021_CHsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">-424494000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2021To03_31_2022_OtherMembersrtStatementGeographicalAxis"
      decimals="-3"
      id="Fact_50658692"
      unitRef="Unit_USD">-21755000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2020To03_31_2021_OtherMembersrtStatementGeographicalAxis"
      decimals="-3"
      id="Fact_50658691"
      unitRef="Unit_USD">-33661000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-923747000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-898547000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P04_01_2021To03_31_2022_BMsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021_BMsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P04_01_2021To03_31_2022_USsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">-223000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021_USsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">1365000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P04_01_2021To03_31_2022_CHsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021_CHsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P04_01_2021To03_31_2022_OtherMembersrtStatementGeographicalAxis"
      decimals="-3"
      id="Fact_50658338"
      unitRef="Unit_USD">592000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021_OtherMembersrtStatementGeographicalAxis"
      decimals="-3"
      id="Fact_50658337"
      unitRef="Unit_USD">321000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">369000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1686000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P04_01_2021To03_31_2022_BMsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021_BMsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P04_01_2021To03_31_2022_USsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021_USsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P04_01_2021To03_31_2022_CHsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021_CHsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P04_01_2021To03_31_2022_OtherMembersrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021_OtherMembersrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">369000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1686000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation of income tax provision/(benefit) computed at the Bermuda statutory rate to income tax expense reflected in the consolidated financial statements is as follows (in thousands, except percentages): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt;March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt;March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax benefit at Bermuda statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign rate differential&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(179,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19.38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(150,778&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16.78&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Permanent disallowed IPR&amp;amp;D&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,347&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;111,432&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax-effect&lt;/div&gt; of changes in the fair value of investments and loss from equity method investment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,169&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(22,472&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nontaxable gain on sale of investment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(84,313&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nontaxable gain on deconsolidation of business&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(958&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(16,438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nondeductible executive compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,973&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2.81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;905&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Tax deficiencies (excess tax benefits) from share-based compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,918&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(439&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other permanent adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,912&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,457&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research tax credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.09&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;205,811&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(22.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;85,046&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9.46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax rate changes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,444&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,443&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;85&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;369&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Primarily related to operations in the United States, Switzerland, the United Kingdom, and other jurisdictions with statutory tax rates different than the Bermuda rate. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P04_01_2021To03_31_2022"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P04_01_2020To03_31_2021"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      id="Fact_50658400"
      unitRef="Unit_USD">-179000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P04_01_2021To03_31_2022"
      decimals="4"
      id="Fact_50658382"
      unitRef="Unit_pure">0.1938</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      id="Fact_50658399"
      unitRef="Unit_USD">-150778000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      id="Fact_50658381"
      unitRef="Unit_pure">0.1678</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">15347000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="P04_01_2021To03_31_2022"
      decimals="4"
      unitRef="Unit_pure">-0.0166</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">111432000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.124</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-15169000</us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="P04_01_2021To03_31_2022"
      decimals="4"
      unitRef="Unit_pure">-0.0164</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">22472000</us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:IncomeTaxReconciliationDispositionOfAssets
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-84313000</us-gaap:IncomeTaxReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="P04_01_2021To03_31_2022"
      decimals="4"
      unitRef="Unit_pure">0.0913</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <us-gaap:IncomeTaxReconciliationDispositionOfAssets
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="P04_01_2020To03_31_2021"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-958000</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="P04_01_2021To03_31_2022"
      decimals="4"
      unitRef="Unit_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-16438000</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.0183</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">25973000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P04_01_2021To03_31_2022"
      decimals="4"
      unitRef="Unit_pure">-0.0281</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">905000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">12918000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="P04_01_2021To03_31_2022"
      decimals="4"
      unitRef="Unit_pure">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-439000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">0.0005</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:IncomeTaxReconciliationDeductionsOther
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">10912000</us-gaap:IncomeTaxReconciliationDeductionsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther
      contextRef="P04_01_2021To03_31_2022"
      decimals="4"
      unitRef="Unit_pure">-0.0118</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:IncomeTaxReconciliationDeductionsOther
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2457000</us-gaap:IncomeTaxReconciliationDeductionsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.0028</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">10113000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="P04_01_2021To03_31_2022"
      decimals="4"
      unitRef="Unit_pure">-0.0109</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">10555000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.0117</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">205811000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P04_01_2021To03_31_2022"
      decimals="4"
      unitRef="Unit_pure">0.2228</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">85046000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">0.0946</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-2444000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="P04_01_2021To03_31_2022"
      decimals="4"
      unitRef="Unit_pure">0.0026</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2443000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.0027</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-8933000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P04_01_2021To03_31_2022"
      decimals="4"
      unitRef="Unit_pure">-0.0097</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">85000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">0.0001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">369000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P04_01_2021To03_31_2022"
      decimals="4"
      unitRef="Unit_pure">-0.0004</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1686000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.0019</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P04_01_2021To03_31_2022"
      decimals="4"
      unitRef="Unit_pure">-0.0004</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.0019</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P04_01_2021To03_31_2022">Significant components of the deferred tax assets (liabilities) at March&#160;31, 2022 and 2021 are as follows (in thousands):&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research tax credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27,155&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,063&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;61,544&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;50,564&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;312,749&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;202,906&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;93,177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,623&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,406&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,638&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,651&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subtotal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;530,682&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;323,097&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(512,736&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(303,287&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,397&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,214&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,661&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,908&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,888&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,688&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax assets/(liabilities)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">27155000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">19063000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">61544000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">50564000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">312749000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">202906000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">93177000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">26623000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <roiv:DeferredTaxAssetsLeaseLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">15406000</roiv:DeferredTaxAssetsLeaseLiabilities>
    <roiv:DeferredTaxAssetsLeaseLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16638000</roiv:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20651000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">7303000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">530682000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">323097000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">512736000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">303287000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <roiv:DeferredTaxLiabilitiesDepreciation
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1397000</roiv:DeferredTaxLiabilitiesDepreciation>
    <roiv:DeferredTaxLiabilitiesDepreciation
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1214000</roiv:DeferredTaxLiabilitiesDepreciation>
    <roiv:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">12661000</roiv:DeferredTaxLiabilitiesRightOfUseAssets>
    <roiv:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13908000</roiv:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3888000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4688000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn03_31_2022_CHsrtStatementGeographicalAxis"
      decimals="-5"
      unitRef="Unit_USD">1749200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn03_31_2022_USsrtStatementGeographicalAxis"
      decimals="-5"
      unitRef="Unit_USD">244100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn03_31_2022_GBsrtStatementGeographicalAxis"
      decimals="-5"
      unitRef="Unit_USD">40100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn03_31_2022_TaxAuthorityInOtherJurisdictionsMembersrtStatementGeographicalAxis"
      decimals="-5"
      unitRef="Unit_USD">98400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="P04_01_2021To03_31_2022_CHsrtStatementGeographicalAxis_MinimumMembersrtRangeAxis">2025-03-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="P04_01_2021To03_31_2022_CHsrtStatementGeographicalAxis_MaximumMembersrtRangeAxis">2029-03-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <roiv:AnnualNOLUtilizationLimitationPercentage
      contextRef="P04_01_2021To03_31_2022_USsrtStatementGeographicalAxis"
      decimals="2"
      unitRef="Unit_pure">0.80</roiv:AnnualNOLUtilizationLimitationPercentage>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn03_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">94800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="P04_01_2021To03_31_2022_MinimumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">2035-03-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="P04_01_2021To03_31_2022_MaximumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">2042-03-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn03_31_2022_UnitedStatesAndCanadaMembersrtStatementGeographicalAxis"
      decimals="-5"
      unitRef="Unit_USD">27200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardExpirationDate contextRef="P04_01_2021To03_31_2022_MinimumMembersrtRangeAxis_UnitedStatesAndCanadaMembersrtStatementGeographicalAxis">2035-03-31</us-gaap:TaxCreditCarryforwardExpirationDate>
    <us-gaap:TaxCreditCarryforwardExpirationDate contextRef="P04_01_2021To03_31_2022_MaximumMembersrtRangeAxis_UnitedStatesAndCanadaMembersrtStatementGeographicalAxis">2042-03-31</us-gaap:TaxCreditCarryforwardExpirationDate>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn03_31_2022"
      decimals="-5"
      unitRef="Unit_USD">512700000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P04_01_2021To03_31_2022"
      decimals="-5"
      unitRef="Unit_USD">209400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 12&#x2014;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s operating leases consist primarily of real estate leases, including those entered into by certain wholly owned and majority-owned or controlled subsidiaries of RSL. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of operating lease expense for the Company were as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,649&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,931&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term lease cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;326&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;237&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable lease cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,227&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;704&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,202&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px;;display:inline;"&gt;Information related to the Company&#x2019;s operating lease right-of-use assets and operating lease liabilities was as follows (in thousands, except periods and percentages):&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;During&#160;the&#160;Year&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid for operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,830&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Operating lease right-of-use assets obtained in exchange for operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,035&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,491&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining lease term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average discount rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March&#160;31, 2022, maturities of operating lease liabilities were as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Years Ending March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,714&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,672&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,455&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,363&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2027&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,680&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46,783&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100,667&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: present value adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(24,996&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: tenant improvement allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,805&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;73,866&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of operating lease expense for the Company were as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,649&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,931&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term lease cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;326&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;237&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable lease cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,227&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;704&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,202&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">13649000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11931000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">326000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">237000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1227000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">704000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">15202000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">12872000</us-gaap:LeaseCost>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px;;display:inline;"&gt;Information related to the Company&#x2019;s operating lease right-of-use assets and operating lease liabilities was as follows (in thousands, except periods and percentages):&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;During&#160;the&#160;Year&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid for operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,830&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Operating lease right-of-use assets obtained in exchange for operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,035&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,491&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining lease term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average discount rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">14403000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8830000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6035000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5491000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn03_31_2022">P9Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn03_31_2021">P9Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn03_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn03_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.071</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March&#160;31, 2022, maturities of operating lease liabilities were as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Years Ending March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,714&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,672&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,455&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,363&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2027&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,680&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46,783&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100,667&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: present value adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(24,996&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: tenant improvement allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,805&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;73,866&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">12714000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">12672000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">10455000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">9363000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">8680000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">46783000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">100667000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <roiv:OperatingLeaseLiabilityPresentValueAdjustments
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">24996000</roiv:OperatingLeaseLiabilityPresentValueAdjustments>
    <roiv:LesseeOperatingLeaseLiabilityTenantImprovementAllowance
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1805000</roiv:LesseeOperatingLeaseLiabilityTenantImprovementAllowance>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">73866000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 13&#x2014;Commitments and Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Commitments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Long-Term Debt &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is obligated to make contractual payments related to its long-term debt. Refer to Note 7, &#x201c;Long-Term Debt and Loan Commitment&#x201d; for further information. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Lease Commitments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has operating leases, consisting primarily of real estate leases. Refer to Note 12, &#x201c;Leases&#x201d; for further information. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other Commitments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2021, the Company entered into a master subscription agreement with Palantir Technologies Inc. (&#x201c;Palantir&#x201d;) for access to Palantir&#x2019;s proprietary software for a five-year period. As of March&#160;31, 2022, the remaining minimum payments for this software subscription are $30.0&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In November 2021, the Company&#x2019;s subsidiary, Immunovant, Inc. (&#x201c;Immunovant&#x201d;), entered into a Product Service Agreement with Samsung Biologics Co., Ltd. (&#x201c;Samsung&#x201d;) by which Samsung will manufacture and supply Immunovant with batoclimab drug substance for commercial sale and perform other manufacturing-related services with respect to batoclimab. As of March&#160;31, 2022, the minimum purchase commitment related to this agreement is estimated to be approximately $36.0&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company, primarily through its subsidiaries, has entered into commitments under various asset acquisition and license agreements. Additionally, the Company through its subsidiaries enters into agreements with contract service providers to assist in the performance of its R&amp;amp;D activities. Expenditures to contract research organizations and contract manufacturing organizations represent significant costs in the clinical development of its product candidates. Subject to required notice periods and certain obligations under binding purchase orders, the Company can elect to discontinue the work under these agreements at any time. The Company expects to enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require upfront payments and long-term commitments of capital resources. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) Loss Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company accrues for loss contingencies when available information indicates that it is probable that a liability has been incurred and the amount of such loss can be reasonably estimated, and if the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation or claim, including an estimable range, if possible. The Company is currently not involved in any legal proceedings with a probable and estimable material loss. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Immunovant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As the Company&#x2019;s subsidiary, Immunovant, has previously disclosed, in February 2021, a putative securities class action complaint was filed against Immunovant and certain of its current and former officers in the U.S. District Court for the Eastern District of New York on behalf of a class consisting of those who acquired Immunovant&#x2019;s securities from October&#160;2, 2019 and February&#160;1, 2021. The complaint alleged that Immunovant and certain of its officers violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, by making false and misleading statements regarding the safety of batoclimab and seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#x2019; fees. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&#160;29, 2021, the U.S. District Court appointed a lead plaintiff. On February&#160;1, 2022, the lead plaintiff filed an amended complaint adding both (i)&#160;the Company and (ii)&#160;Immunovant&#x2019;s directors and underwriters as defendants, and asserting additional claims under Section&#160;11, 12(a)(2), and 15 of the Securities Act of 1933, which was further amended by an amended complaint filed on March&#160;15, 2022. On May&#160;27, 2022, defendants, including the Company, filed motions to dismiss that amended complaint. The Company intends to vigorously defend the case and has not recorded a liability related to this lawsuit because, at this time, the Company is unable to reasonably estimate possible losses or determine whether an unfavorable outcome is either probable or remote. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March 2022, Acuitas Therapeutics Inc. filed a lawsuit in the U.S. District Court for the Southern District of New York against two of the Company&#x2019;s affiliates, Genevant and Arbutus, seeking a declaratory judgment that U.S. Patents 8,058,069, 8,492,359, 8,822,668, 9,006,417, 9,364,435, 9,404,127, 9,504,651, 9,518,272, and 11,141,378 are not infringed by the manufacture, use, offer for sale, sale or importation into the United States of COMIRNATY, Pfizer&#x2019;s and BioNTech&#x2019;s vaccine for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; and are otherwise invalid. Each of Genevant and Arbutus intend to vigorously defend the case and neither they nor the Company have recorded a liability related to this lawsuit. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(C) Indemnification Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. The Company also indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits. The maximum amount of potential future indemnification is unlimited; however, the Company currently maintain director and officer liability insurance, which may cover certain liabilities arising from our obligation to indemnify our directors. The Company has not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. To date, the Company has not incurred any material costs and have not accrued any liabilities related to such obligations in the consolidated financial statements as of March&#160;31, 2022 and 2021. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="PAsOn03_31_2022_MasterSubscriptionAgreementMemberROIVAgreementAxis"
      decimals="-2"
      unitRef="Unit_USD">30000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="PAsOn03_31_2022_ProductServiceAgreementMemberROIVAgreementAxis"
      decimals="-2"
      unitRef="Unit_USD">36000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P04_01_2021To03_31_2022_RoivantSciencesLtd.MemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 14&#x2014;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recurring Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of&#160;March&#160;31, 2022 and 2021, by level, within the fair value hierarchy (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 33%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&#160;as&#160;of&lt;br/&gt; March&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&#160;as&#160;of&lt;br/&gt; March&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,297,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,297,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,420,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,420,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Datavant Class&#160;A units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;193,963&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;193,963&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Sio common shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,447&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,447&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Arbutus common shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;115,765&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;115,765&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Arbutus convertible preferred shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other investments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,429,715&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;193,963&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,623,678&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,533,538&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,609,575&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt issued by Dermavant to NovaQuest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;177,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;177,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability instruments measured at fair value&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,019&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,912&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,019&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;204,293&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;222,312&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;217,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;217,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;At March&#160;31, 2022, Level&#160;1 includes the fair value of the Public Warrants of $18.0&#160;million, and Level&#160;3 includes the fair value of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares of $9.2&#160;million, Private Placement Warrants of $9.1&#160;million, and other liability instruments issued of $8.6&#160;million. At March&#160;31, 2021, Level&#160;3 includes the fair value of the Sumitomo Options of $62.4&#160;million and other liability instrument issued of $5.5&#160;million. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no transfers of assets between Level&#160;1 and Level&#160;2 of the fair value measurement hierarchy that occurred during the years ended March&#160;31, 2022 and 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Level&#160;3 Disclosures &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures its Level&#160;3 assets and liabilities at fair value based on significant inputs not observable in the market, which causes them to be classified as a Level&#160;3 measurement within the fair value hierarchy. The valuation of the Level&#160;3 assets and liabilities uses assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions and estimates on an ongoing basis as additional data impacting the assumptions and estimates are obtained. Changes in the fair value related to updated assumptions and estimates are recorded within the statements of operations at the end of each reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of Level&#160;3 assets and liabilities may change significantly as additional data are obtained, impacting the Company&#x2019;s assumptions regarding probabilities of potential scenarios used to estimate fair value. In evaluating this information, considerable judgment is required to interpret the data used to develop the &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;assumptions and estimates. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company&#x2019;s results of operations in future periods. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The changes in fair value of the Level&#160;3 assets during the&#160;year ended March&#160;31, 2022&#160;were as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of investment in Datavant at recognition date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;224,147&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in fair value of investment in Datavant, included in net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30,184&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;193,963&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no Level&#160;3 assets held during the year ended March&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The changes in fair value of the Level&#160;3 liabilities during the&#160;years ended March&#160;31, 2022 and 2021 were as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;191,473&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in fair value of debt and liability instruments, included in net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability instruments disposed due to deconsolidation of subsidiary&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;217,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of liability instrument issued&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,634&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in fair value of debt and liability instruments, included in net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,226&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Settlements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Termination of DSP Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(61,472&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;204,293&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Datavant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company elected the fair value option to account for the investment in Datavant. The estimate of fair value for this investment was determined using the income approach and implementation of the option pricing method (&#x201c;OPM&#x201d;). The OPM allows for the allocation of a company&#x2019;s equity value among the various equity capital owners (preferred and common shareholders). The OPM uses the preferred shareholders&#x2019; liquidation preferences, participation rights, dividend policy, and conversion rights to determine how proceeds from a liquidity event shall be distributed among the various ownership classes at a future date. The fair value was calculated using significant unobservable inputs including the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 23%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Point Estimate Used&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Input&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;March&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;110.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt issued by Dermavant to NovaQuest &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the debt instrument as of&#160;March&#160;31, 2022 and 2021 represents the fair value of amounts payable to NovaQuest using the Monte Carlo simulation method under the income approach determined by using probability assessments of the expected future payments through 2032 and applying discount rates ranging from &lt;span style="-sec-ix-hidden:hidden50658326"&gt;10&lt;/span&gt;% to &lt;span style="-sec-ix-hidden:hidden50658327"&gt;12&lt;/span&gt;%. The future payments are based on significant inputs that are not observable in the market which are subject to remeasurement at each reporting date. The estimates of fair value may not be indicative of the amounts that could ultimately be paid by Dermavant to NovaQuest. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The fair value of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares issued as part of the Business Combination was calculated using the Monte Carlo simulation method under the income approach. The model was structured to include the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lock-up&lt;/div&gt; periods to which the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares are subject. Refer to Note 3, &#x201c;Business Combination with MAAC&#x201d; for additional details. Significant unobservable inputs used to calculate the fair value of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares included the following: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 25%; vertical-align: bottom;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Point&#160;Estimate&#160;Used&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Input&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;March&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;82.3%&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;2.43%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As of March&#160;31, 2022, the fair value of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares was $9.2&#160;million. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares are included in &#x201c;Liability instruments measured at fair value&#x201d; in the accompanying consolidated balance sheets. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Private Placement Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Private Placement Warrants issued as part of the Business Combination was calculated using the Monte Carlo simulation method under the income approach. The model was structured to incorporate the redemption features as discussed in Note 3, &#x201c;Business Combination with MAAC&#x201d; and the added restriction by which the Company cannot redeem the Private Warrants if the Reference Value is greater than $18.00. Significant unobservable inputs used to calculate the fair value of the Private Placement Warrants included the following: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 25%; vertical-align: bottom;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Point&#160;Estimate&#160;Used&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Input&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;March&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;56.5%&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;2.43%&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term (in years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;4.50&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March&#160;31, 2022, the fair value of the Private Placement Warrants was $9.1&#160;million. The Private Placement Warrants are included in &#x201c;Liability instruments measured at fair value&#x201d; in the accompanying consolidated balance sheets. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sumitomo Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior to termination in June 2021, the fair value of the options to acquire the Company&#x2019;s interest in certain of its subsidiaries, which were granted to Sumitomo under the Sumitomo Transaction Agreement, was calculated using significant unobservable inputs including the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Range&#160;or&#160;Point&lt;br/&gt; Estimate Used&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Input&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Time to expiration (in years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;3.59&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;0.52%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;89.0%&#160;-&#160;95.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2021, the Company completed a transaction with Sumitomo pursuant to which Sumitomo terminated all of its existing options to acquire the Company&#x2019;s equity interests in certain subsidiaries. As of March&#160;31, 2021, the fair value of the Sumitomo Options was $62.4&#160;million, which is included in &#x201c;Liability instruments measured at fair value&#x201d; in the accompanying consolidated balance sheets. See Note 8, &#x201c;Related Party Transactions&#x201d; for additional information. &lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of&#160;March&#160;31, 2022 and 2021, by level, within the fair value hierarchy (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 33%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&#160;as&#160;of&lt;br/&gt; March&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&#160;as&#160;of&lt;br/&gt; March&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,297,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,297,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,420,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,420,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Datavant Class&#160;A units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;193,963&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;193,963&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Sio common shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,447&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,447&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Arbutus common shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;115,765&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;115,765&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Arbutus convertible preferred shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other investments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,429,715&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;193,963&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,623,678&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,533,538&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,609,575&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt issued by Dermavant to NovaQuest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;177,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;177,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability instruments measured at fair value&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,019&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,912&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,019&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;204,293&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;222,312&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;217,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;217,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;At March&#160;31, 2022, Level&#160;1 includes the fair value of the Public Warrants of $18.0&#160;million, and Level&#160;3 includes the fair value of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares of $9.2&#160;million, Private Placement Warrants of $9.1&#160;million, and other liability instruments issued of $8.6&#160;million. At March&#160;31, 2021, Level&#160;3 includes the fair value of the Sumitomo Options of $62.4&#160;million and other liability instrument issued of $5.5&#160;million. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1297844000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1297844000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1420597000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1420597000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapFairValueByAssetClassAxis_DatavantMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">193963000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapFairValueByAssetClassAxis_DatavantMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">193963000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_DatavantMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_DatavantMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">12447000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">12447000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">48487000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">48487000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">115765000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">115765000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">53325000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">53325000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2022_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">76037000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">76037000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3659000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3659000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">11129000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">11129000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1429715000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">193963000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1623678000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1533538000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">76037000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1609575000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">177400000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">177400000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">150100000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">150100000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">18019000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">26893000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="PAsOn03_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">44912000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">67893000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">67893000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">18019000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">204293000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">222312000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">217993000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">217993000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivPublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-5"
      unitRef="Unit_USD">18000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:NonfinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivEarnoutSharesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-5"
      unitRef="Unit_USD">9200000</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivPrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-5"
      unitRef="Unit_USD">9100000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivLiabilityInstrumentsMeasuredAtFairValueMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-5"
      unitRef="Unit_USD">8600000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-5"
      unitRef="Unit_USD">62400000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivLiabilityInstrumentsMeasuredAtFairValueMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-5"
      unitRef="Unit_USD">5500000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The changes in fair value of the Level&#160;3 assets during the&#160;year ended March&#160;31, 2022&#160;were as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of investment in Datavant at recognition date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;224,147&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in fair value of investment in Datavant, included in net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30,184&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;193,963&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <roiv:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment
      contextRef="P04_01_2021To03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">224147000</roiv:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="P04_01_2021To03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">-30184000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">193963000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no Level&#160;3 assets held during the year ended March&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The changes in fair value of the Level&#160;3 liabilities during the&#160;years ended March&#160;31, 2022 and 2021 were as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;191,473&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in fair value of debt and liability instruments, included in net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability instruments disposed due to deconsolidation of subsidiary&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;217,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of liability instrument issued&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,634&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in fair value of debt and liability instruments, included in net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,226&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Settlements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Termination of DSP Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(61,472&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;204,293&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">191473000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P04_01_2020To03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">29845000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <roiv:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary
      contextRef="P04_01_2020To03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">-3325000</roiv:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">217993000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P04_01_2021To03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">38634000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P04_01_2021To03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">9226000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <roiv:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne
      contextRef="P04_01_2021To03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">-88000</roiv:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P04_01_2021To03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">-61472000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn03_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">204293000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="P04_01_2021To03_31_2022_DatavantMemberdeiLegalEntityAxis">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company elected the fair value option to account for the investment in Datavant. The estimate of fair value for this investment was determined using the income approach and implementation of the option pricing method (&#x201c;OPM&#x201d;). The OPM allows for the allocation of a company&#x2019;s equity value among the various equity capital owners (preferred and common shareholders). The OPM uses the preferred shareholders&#x2019; liquidation preferences, participation rights, dividend policy, and conversion rights to determine how proceeds from a liquidity event shall be distributed among the various ownership classes at a future date. The fair value was calculated using significant unobservable inputs including the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 23%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Point Estimate Used&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Input&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;March&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;110.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <roiv:FairValueAssetMeasurementInput
      contextRef="PAsOn03_31_2022_DatavantMemberdeiLegalEntityAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis"
      decimals="3"
      unitRef="Unit_pure">1.10</roiv:FairValueAssetMeasurementInput>
    <roiv:FairValueAssetMeasurementInput
      contextRef="PAsOn03_31_2022_DatavantMemberdeiLegalEntityAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0162</roiv:FairValueAssetMeasurementInput>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="P04_01_2021To03_31_2022_EarnoutSharesMemberusgaapStatementEquityComponentsAxis">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The fair value of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares issued as part of the Business Combination was calculated using the Monte Carlo simulation method under the income approach. The model was structured to include the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lock-up&lt;/div&gt; periods to which the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares are subject. Refer to Note 3, &#x201c;Business Combination with MAAC&#x201d; for additional details. Significant unobservable inputs used to calculate the fair value of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares included the following: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 25%; vertical-align: bottom;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Point&#160;Estimate&#160;Used&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Input&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;March&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;82.3%&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;2.43%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <roiv:FairValueAssetMeasurementInput
      contextRef="PAsOn03_31_2022_EarnoutSharesMemberusgaapStatementEquityComponentsAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.823</roiv:FairValueAssetMeasurementInput>
    <roiv:FairValueAssetMeasurementInput
      contextRef="PAsOn03_31_2022_EarnoutSharesMemberusgaapStatementEquityComponentsAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0243</roiv:FairValueAssetMeasurementInput>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2022_EarnoutSharesMemberusgaapStatementEquityComponentsAxis_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">9200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="P04_01_2021To03_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Private Placement Warrants issued as part of the Business Combination was calculated using the Monte Carlo simulation method under the income approach. The model was structured to incorporate the redemption features as discussed in Note 3, &#x201c;Business Combination with MAAC&#x201d; and the added restriction by which the Company cannot redeem the Private Warrants if the Reference Value is greater than $18.00. Significant unobservable inputs used to calculate the fair value of the Private Placement Warrants included the following: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 25%; vertical-align: bottom;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Point&#160;Estimate&#160;Used&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Input&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;March&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;56.5%&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;2.43%&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term (in years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;4.50&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <roiv:FairValueAssetMeasurementInput
      contextRef="PAsOn03_31_2022_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="3"
      unitRef="Unit_pure">0.565</roiv:FairValueAssetMeasurementInput>
    <roiv:FairValueAssetMeasurementInput
      contextRef="PAsOn03_31_2022_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="4"
      unitRef="Unit_pure">0.0243</roiv:FairValueAssetMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn03_31_2022_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_Y">4.5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn03_31_2022_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-5"
      unitRef="Unit_USD">9100000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="P04_01_2021To03_31_2022_SumitomoOptionsMemberdeiLegalEntityAxis">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior to termination in June 2021, the fair value of the options to acquire the Company&#x2019;s interest in certain of its subsidiaries, which were granted to Sumitomo under the Sumitomo Transaction Agreement, was calculated using significant unobservable inputs including the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Range&#160;or&#160;Point&lt;br/&gt; Estimate Used&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Input&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Time to expiration (in years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;3.59&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;0.52%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;89.0%&#160;-&#160;95.0&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <roiv:AlternativeInvestmentExpectedTerm contextRef="P03_01_2021To03_31_2021_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis">P3Y7M2D</roiv:AlternativeInvestmentExpectedTerm>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="PAsOn03_31_2021_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="2"
      unitRef="Unit_pure">0.52</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="PAsOn03_31_2021_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-2"
      unitRef="Unit_pure">89000</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="PAsOn03_31_2021_MaximumMembersrtRangeAxis_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-2"
      unitRef="Unit_pure">95000</us-gaap:AlternativeInvestmentMeasurementInput>
    <roiv:EquityInterestOptionToThirdPartyPurchase
      contextRef="PAsOn03_31_2021_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">62400000</roiv:EquityInterestOptionToThirdPartyPurchase>
    <us-gaap:OtherOperatingIncomeAndExpenseTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 15&#x2014;Other Expense, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other expense, net was as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from equity method investment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,750&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(369&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,418&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,041&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,809&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other (income) expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,237&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,560&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,435&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,701&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:OtherOperatingIncomeAndExpenseTextBlock>
    <us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other expense, net was as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from equity method investment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,750&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(369&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,418&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,041&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,809&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other (income) expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,237&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,560&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,435&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,701&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-3750000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:InterestIncomeOther
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">369000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1418000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">7041000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2809000</us-gaap:InterestExpense>
    <roiv:OtherIncomeExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3237000</roiv:OtherIncomeExpense>
    <roiv:OtherIncomeExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-3560000</roiv:OtherIncomeExpense>
    <roiv:OtherOperatingIncomeExpensesNet
      contextRef="P04_01_2021To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3435000</roiv:OtherOperatingIncomeExpensesNet>
    <roiv:OtherOperatingIncomeExpensesNet
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8701000</roiv:OtherOperatingIncomeExpensesNet>
    <us-gaap:EarningsPerShareTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 16&#x2014;Net Loss per Common Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;Basic net loss per common share is computed by dividing net loss attributable to Roivant Sciences Ltd. by the weighted-average number of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to Roivant Sciences Ltd. by the diluted weighted-average number of common stock outstanding during the period.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;For periods of loss, diluted loss per share is calculated similar to basic loss per share as the effect of including all potentially dilutive common stock equivalents is anti-dilutive. All outstanding common stock equivalents have been excluded from the computation of diluted loss per share because their effect was anti-dilutive due to the net loss.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March&#160;31, 2022 and 2021, potentially dilutive securities were as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options and performance stock options&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;80,364,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69,687,308&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Restricted stock units and performance stock units &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(non-vested)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,956,749&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,294,028&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;March 2020 CVARs&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,011,996&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,447,626&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;November 2021 CVARs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,285,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Restricted &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;stock&lt;/div&gt;&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(non-vested)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;741,405&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,720,090&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(non-vested)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,080,387&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Private Placement Warrants&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,214,365&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Public Warrants&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,475,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other instruments issued&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,103,577&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,458,543&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Refer to Note 10, &#x201c;Share-Based Compensation&#x201d; for details regarding settlement of CVARs. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March&#160;31, 2022 and 2021, potentially dilutive securities were as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options and performance stock options&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;80,364,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69,687,308&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Restricted stock units and performance stock units &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(non-vested)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,956,749&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,294,028&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;March 2020 CVARs&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,011,996&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,447,626&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;November 2021 CVARs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,285,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Restricted &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c&lt;/div&gt;ommon &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;stock&lt;/div&gt;&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(non-vested)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;741,405&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,720,090&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(non-vested)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,080,387&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Private Placement Warrants&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,214,365&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Public Warrants&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,475,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other instruments issued&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,103,577&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,458,543&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Refer to Note 10, &#x201c;Share-Based Compensation&#x201d; for details regarding settlement of CVARs. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_01_2021To03_31_2022_StockOptionsAndPerformanceStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">80364904</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_01_2020To03_31_2021_StockOptionsAndPerformanceStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">69687308</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_01_2021To03_31_2022_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">21956749</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_01_2020To03_31_2021_RestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">7294028</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_01_2021To03_31_2022_TwoThousandAndTwentyCvarsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      id="Fact_50658972"
      unitRef="Unit_shares">32011996</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_01_2020To03_31_2021_TwoThousandAndTwentyCvarsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      id="Fact_50658973"
      unitRef="Unit_shares">32447626</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_01_2021To03_31_2022_NovemberTwoThousandAndTwentyOneCvarsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">6285250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_01_2021To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">741405</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">1720090</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_01_2021To03_31_2022_EarnOutSharesNonvestedMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">3080387</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_01_2021To03_31_2022_PrivatePlacementWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">10214365</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_01_2021To03_31_2022_PublicWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">20475875</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_01_2021To03_31_2022_OtherInstrumentsIssuedMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">5103577</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_01_2020To03_31_2021_OtherInstrumentsIssuedMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">5458543</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 17&#x2014;Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In May 2022, VTAMA (tapinarof) cream was approved by the FDA as the first and only &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FDA-approved&lt;/div&gt; steroid-free topical medication in its class for the treatment of plaque psoriasis in adult patients. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Following the approval of VTAMA cream by the FDA in May 2022, Dermavant received $160.0&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million in June 2022 pursuant to the terms of the RIPSA as described in Note 7, &#x201c;Long-Term Debt and Loan Commitment.&#x201d; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Also, as a result of FDA approval, Dermavant achieved a regulatory milestone to GSK of &#xa3;100.0&#160;million (approximately $126 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million on the date of achievement), which will be paid within&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;70 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;calendar days of FDA approval. Additionally, the first sale of VTAMA cream in May 2022 resulted in the achievement of a milestone to Welichem Biotech Inc. of CAD$&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;25.0&#160;million (approximately $20 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;million on the date of achievement), which will be paid within&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; 60 calendar days of the invoice date. Dermavant intends to primarily use the RIPSA proceeds for the payment of these obligations. &lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <roiv:GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement
      contextRef="P04_01_2022To06_30_2022_RoivrevenueInterestPurchaseAndSaleAgreementMemberMemberusgaapFinancialInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">160000000</roiv:GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement>
    <roiv:MilestonePaymentPayable
      contextRef="PAsOn06_30_2022_GSKMembersrtCounterpartyNameAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_EUR">100000000</roiv:MilestonePaymentPayable>
    <roiv:MilestonePaymentPayable
      contextRef="PAsOn06_30_2022_GSKMembersrtCounterpartyNameAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">126000000</roiv:MilestonePaymentPayable>
    <roiv:MilestonePaymentPeriod contextRef="P04_01_2022To06_30_2022_GSKMembersrtCounterpartyNameAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">P70D</roiv:MilestonePaymentPeriod>
    <roiv:MilestonePaymentPayable
      contextRef="PAsOn06_30_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WelichemBiotechIncMembersrtCounterpartyNameAxis"
      decimals="-5"
      unitRef="Unit_CAD">25000000</roiv:MilestonePaymentPayable>
    <roiv:MilestonePaymentPayable
      contextRef="PAsOn06_30_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WelichemBiotechIncMembersrtCounterpartyNameAxis"
      decimals="-6"
      unitRef="Unit_USD">20000000</roiv:MilestonePaymentPayable>
    <roiv:MilestonePaymentPeriod contextRef="P05_31_2022To05_31_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WelichemBiotechIncMembersrtCounterpartyNameAxis">P60D</roiv:MilestonePaymentPeriod>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_50658022"
          xlink:label="Fact_50658022"
          xlink:type="locator"/>
        <link:footnote id="FN_162816" xlink:label="FN_162816" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Retroactively restated for the stock subdivision as described in Note 3.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658022"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658023"
          xlink:label="Fact_50658023"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658023"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658024"
          xlink:label="Fact_50658024"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658024"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658025"
          xlink:label="Fact_50658025"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658025"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658038"
          xlink:label="Fact_50658038"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658038"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658039"
          xlink:label="Fact_50658039"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658039"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658040"
          xlink:label="Fact_50658040"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658040"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658041"
          xlink:label="Fact_50658041"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658041"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658042"
          xlink:label="Fact_50658042"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658042"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658043"
          xlink:label="Fact_50658043"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658043"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658044"
          xlink:label="Fact_50658044"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658044"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658045"
          xlink:label="Fact_50658045"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658045"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658046"
          xlink:label="Fact_50658046"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658046"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658047"
          xlink:label="Fact_50658047"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658047"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658048"
          xlink:label="Fact_50658048"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658048"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658049"
          xlink:label="Fact_50658049"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658049"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658092"
          xlink:label="Fact_50658092"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658092"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658093"
          xlink:label="Fact_50658093"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658093"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658095"
          xlink:label="Fact_50658095"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658095"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658096"
          xlink:label="Fact_50658096"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658096"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658097"
          xlink:label="Fact_50658097"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658097"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658098"
          xlink:label="Fact_50658098"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658098"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658101"
          xlink:label="Fact_50658101"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658101"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658102"
          xlink:label="Fact_50658102"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658102"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658103"
          xlink:label="Fact_50658103"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658103"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658104"
          xlink:label="Fact_50658104"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658104"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658105"
          xlink:label="Fact_50658105"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658105"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658109"
          xlink:label="Fact_50658109"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658109"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658110"
          xlink:label="Fact_50658110"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658110"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658111"
          xlink:label="Fact_50658111"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658111"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658112"
          xlink:label="Fact_50658112"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658112"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658113"
          xlink:label="Fact_50658113"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658113"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658114"
          xlink:label="Fact_50658114"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658114"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658115"
          xlink:label="Fact_50658115"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658115"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658116"
          xlink:label="Fact_50658116"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658116"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658117"
          xlink:label="Fact_50658117"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658117"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658118"
          xlink:label="Fact_50658118"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658118"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658119"
          xlink:label="Fact_50658119"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658119"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658120"
          xlink:label="Fact_50658120"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658120"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658121"
          xlink:label="Fact_50658121"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658121"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658122"
          xlink:label="Fact_50658122"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658122"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658123"
          xlink:label="Fact_50658123"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658123"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658124"
          xlink:label="Fact_50658124"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658124"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658125"
          xlink:label="Fact_50658125"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658125"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658154"
          xlink:label="Fact_50658154"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658154"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658155"
          xlink:label="Fact_50658155"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658155"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658156"
          xlink:label="Fact_50658156"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658156"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658157"
          xlink:label="Fact_50658157"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658157"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658198"
          xlink:label="Fact_50658198"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658198"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658199"
          xlink:label="Fact_50658199"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658199"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658202"
          xlink:label="Fact_50658202"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658202"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658203"
          xlink:label="Fact_50658203"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658203"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658204"
          xlink:label="Fact_50658204"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658204"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658205"
          xlink:label="Fact_50658205"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658205"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658206"
          xlink:label="Fact_50658206"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658206"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658207"
          xlink:label="Fact_50658207"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658207"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658208"
          xlink:label="Fact_50658208"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658208"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658209"
          xlink:label="Fact_50658209"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658209"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658210"
          xlink:label="Fact_50658210"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658210"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658211"
          xlink:label="Fact_50658211"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658211"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658212"
          xlink:label="Fact_50658212"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658212"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658213"
          xlink:label="Fact_50658213"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658213"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658214"
          xlink:label="Fact_50658214"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658214"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658215"
          xlink:label="Fact_50658215"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658215"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658229"
          xlink:label="Fact_50658229"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658229"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658230"
          xlink:label="Fact_50658230"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658230"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658231"
          xlink:label="Fact_50658231"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658231"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658232"
          xlink:label="Fact_50658232"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658232"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658233"
          xlink:label="Fact_50658233"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658233"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658234"
          xlink:label="Fact_50658234"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658234"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658241"
          xlink:label="Fact_50658241"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658241"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658242"
          xlink:label="Fact_50658242"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658242"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658243"
          xlink:label="Fact_50658243"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658243"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658244"
          xlink:label="Fact_50658244"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658244"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658245"
          xlink:label="Fact_50658245"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658245"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658246"
          xlink:label="Fact_50658246"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658246"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658253"
          xlink:label="Fact_50658253"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658253"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658254"
          xlink:label="Fact_50658254"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658254"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658255"
          xlink:label="Fact_50658255"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658255"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658256"
          xlink:label="Fact_50658256"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658256"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658257"
          xlink:label="Fact_50658257"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658257"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658258"
          xlink:label="Fact_50658258"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658258"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658259"
          xlink:label="Fact_50658259"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658259"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658266"
          xlink:label="Fact_50658266"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658266"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658267"
          xlink:label="Fact_50658267"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658267"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658268"
          xlink:label="Fact_50658268"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658268"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658269"
          xlink:label="Fact_50658269"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658269"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658273"
          xlink:label="Fact_50658273"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658273"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658274"
          xlink:label="Fact_50658274"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658274"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658275"
          xlink:label="Fact_50658275"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658275"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658276"
          xlink:label="Fact_50658276"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658276"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658279"
          xlink:label="Fact_50658279"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658279"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658280"
          xlink:label="Fact_50658280"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658280"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658281"
          xlink:label="Fact_50658281"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658281"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658282"
          xlink:label="Fact_50658282"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658282"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658283"
          xlink:label="Fact_50658283"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658283"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658284"
          xlink:label="Fact_50658284"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658284"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658285"
          xlink:label="Fact_50658285"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658285"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658286"
          xlink:label="Fact_50658286"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658286"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658287"
          xlink:label="Fact_50658287"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658287"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658337"
          xlink:label="Fact_50658337"
          xlink:type="locator"/>
        <link:footnote id="FN_162812" xlink:label="FN_162812" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Primarily Greater China and United Kingdom activity</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658337"
          xlink:to="FN_162812"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658338"
          xlink:label="Fact_50658338"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658338"
          xlink:to="FN_162812"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658381"
          xlink:label="Fact_50658381"
          xlink:type="locator"/>
        <link:footnote id="FN_162813" xlink:label="FN_162813" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Primarily related to operations in the United States, Switzerland, the United Kingdom, and other jurisdictions with statutory tax rates different than the Bermuda rate.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658381"
          xlink:to="FN_162813"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658382"
          xlink:label="Fact_50658382"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658382"
          xlink:to="FN_162813"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658399"
          xlink:label="Fact_50658399"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658399"
          xlink:to="FN_162813"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658400"
          xlink:label="Fact_50658400"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658400"
          xlink:to="FN_162813"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658687"
          xlink:label="Fact_50658687"
          xlink:type="locator"/>
        <link:footnote id="FN_162811" xlink:label="FN_162811" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Primarily entities which are centrally managed and controlled in the United Kingdom</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658687"
          xlink:to="FN_162811"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658688"
          xlink:label="Fact_50658688"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658688"
          xlink:to="FN_162811"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658691"
          xlink:label="Fact_50658691"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658691"
          xlink:to="FN_162812"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658692"
          xlink:label="Fact_50658692"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658692"
          xlink:to="FN_162812"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658903"
          xlink:label="Fact_50658903"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658903"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658909"
          xlink:label="Fact_50658909"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658909"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658910"
          xlink:label="Fact_50658910"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658910"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658921"
          xlink:label="Fact_50658921"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658921"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658924"
          xlink:label="Fact_50658924"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658924"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658925"
          xlink:label="Fact_50658925"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658925"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658929"
          xlink:label="Fact_50658929"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658929"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658930"
          xlink:label="Fact_50658930"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658930"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658935"
          xlink:label="Fact_50658935"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658935"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658936"
          xlink:label="Fact_50658936"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658936"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658937"
          xlink:label="Fact_50658937"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658937"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658938"
          xlink:label="Fact_50658938"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658938"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658972"
          xlink:label="Fact_50658972"
          xlink:type="locator"/>
        <link:footnote id="FN_162815" xlink:label="FN_162815" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Refer to Note 10, &#x201c;Share-Based Compensation&#x201d; for details regarding settlement of CVARs.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658972"
          xlink:to="FN_162815"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50658973"
          xlink:label="Fact_50658973"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50658973"
          xlink:to="FN_162815"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50659118"
          xlink:label="Fact_50659118"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50659118"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50659119"
          xlink:label="Fact_50659119"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50659119"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50659120"
          xlink:label="Fact_50659120"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50659120"
          xlink:to="FN_162816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50659121"
          xlink:label="Fact_50659121"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50659121"
          xlink:to="FN_162816"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>120
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M^S9O!%T5"]Z>J1 T*5XN"0X)RW>0G\\I%;LW^1?L%UE>_!]02P,$%     @
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MOIR]P>?7)#$.C<7?G-VKHVMD4ED)\=W<O,\O9YY!Q J6:1."PM^.7;&B,)$
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M?W\;EQ0'SZO@HY>WQU5(]7N22T@EIZ4D"[PW:OID94)-0DD9SLU^&?PCRQI
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MI)[*!NQ^63QZ=5)\[@GD-_W@=J0E$=]L=QAT>'A$H^$>T2G&^<DD18WN<5D
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M=:^J'F0,^&IPXL;@Q#FKJ+;I[YBY _.P)8M,K@M@<0/<4J<\2CCU%J)9SN&
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M5;_>YDX21?D5WOV-_5 0!"]CMH+/2W%G9C. 2;%,4+WEYSMJG@!W8P0OG%R
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M.?SZ="]40/KB3<,_N)D;[TW%'U=*PDFT /<7QOCTA3;H?H%U\1]02P,$%
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MO6&&5H,;77A3/364DQ4%Y<X9O)6@<]=OJGMA';SL[.7,@2$]GF4M\<M G#Y
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M3I?^$L,-!B]:@/<KC4"V-R2@_T9U_5]02P,$%     @ 43_<5$(\=2&>#P
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M0-\#0X,&QUQ,7XR>7R^(&^_CY-]'%IXMCG(.3#KBXIY,1?:-29'&/L/A(%>
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M8_8=YCVQBZT(;6P!%O+V47#=19]VF>.-(=B%%-!-MB1PZYLN!6*D9#-#&@*
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M%@\HV*Y3M]TSS6)VTS.2UFR9'&WKM<.0$]+3@HT7E X/\%.Y)'Y&%:5-2IJ
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MVWZ8: ?>U.%CP,IX;\IP61!.;I8GX/G:P-ANP!L,7X<N_@M02P,$%     @
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M0?.PW&RDV&#5![7*:/20'$ [8!<O^ZP!JPLGG,^<P)T#2CUO'$[8=#Q?#'Y
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MMX^U4R))?OQAFB;IR[8 \76E!%QBQ5RAOI70_J'CA[(JA,,!HTKI5"'4'9#
MJD%OKBJUT.Y:2)!(*Q9UB=JVHJ<K$-2-!:6]?M'YCY(F9(9 7/,5!;9#@:7H
M)IV?+TA^T7FKS+HII.@EU^*9R&9Q-,T27/72=!(-)XFX[OQ::5+JBX-N$#T9
M3J+9*!/7.).DT2RE,U^VVOVA3$F6]$;#832=Q'1BF ZCX6R($_^"@08D3!9-
M1B-ZG&71>$ST7VLGR\L.@CZS-(L@6I":O>EL&HWH1X?T_F0T8$Z7]T)53CL-
M@NU*PPGDM1SWC"SQ<"TK@%_!WLY12P;.Q$]VI1+!RG_J:EG4ZPXI>N#[=Z"P
M@_KO5KJ2S.#XN(<\[>Z?C,2[QAAH=.K^9R(DS>'JU.]I2CY/HFP\.G+WCG!'
M%AP-OXQFJ<@@TSLW/TC>)1A%?#S#_TDTGHX[[]5"X4SQUY4[U>%I_4[O>AV+
ME@8B)/]9\?[X(4<N6'2<'7\ZBN(-2A$IDNM22VYI]:(M;&/J6TW-LE6A>+AI
MB)ETG$\[YUEXJ'&UN1<&PH6KSVF-_DC-\Y"-$&[K4A<,!PNH"UU@,#%3:-3.
M"FTO D($OKG:.+%1AM(?6;\#B9"9A\O.AX,V.X?#@@O:/SN-F[@Z=Z^#-HXF
M77FB0B\052I-6$ 1Z263613'!!#)K)]-P:27C.)H,IG2K7$??Z\ZGZ""K"AC
M"VTEF0G%/WSZ_*-<;UZ^%\DHRH  O:0_'HOK*\!N$@VS%#?2_A"LKSH WN<*
MHG-'AQ.D!1T>TF$4$\ MA;2T/XHA["/P0-[)>:G$$O.50,@A4_FXWRKKR.G
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MN]@]\ [/#.29ZZL(OK ;S[F\CT1A<%&)^3TS/E6B;2#B +$5O&#I>%GG(4'
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M^L#HY\9BAA<=X?H[AB#13%"($6>D(4" @Y4KM8,'>)9)6HZ@S%#-F 19(/_
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M=28-Y+ABJ'\R&CB@ZS%1;TAMJM9<*N)&K\R4)RMJ&\#G*\4%;#;V@G96S_\
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M6X2YO 83Y=_P"14" #QSU$/>@-TOLQD[X;&W$Q[/V@F?6]KQF[8S.Q2R8R;
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M*8LVQ]XA&.UEG>@19MCUZ'&2_*\USRARV,OEU(+'-=HH<A(?Z,%JT1H ?38
MOZRKS7%)5I-P#>S<V5\=>+KUQJH&9#J\R2A#"3DEJ. /=/>#0R1VVE#V'*Y*
M H66F'"F9QGVJ6?8I_,,"R2ZR/#?[$T@5 XU? +J :6)*^(+8]P\/_F#UT?9
M-RS _TPP3L24GL< *RM5?1&1"(XE,Y<0)SP&O=U%H@'5I%.1( . [CLCABE.
MG)*RD]+M+3,WH%:W9,F0R0>GO %J+F,>HC.W6H.O3-$WT/WL<I))<2A?(KS0
MP[P$F@#29G<%'*W>$BT2I3"@+<OY4F](+M@P YCUQ]Z67X%EA6:%H#"X5BP1
MX$FJO#Q]@L\+6@7(SK%6CJ&)QB(S[.X ,M$W +$; 3H"=APN9EX#F[ZN.0"$
MVK< S5SJCN)F7H:/LB+\:[\)I4)N1?;W;&? '4(34I?$AKK-D<70?B//O+<H
MA$@J]^7:L.^4 V6AP#1H]U1!MM8@BS<J\C!A3.FF#$YF6!4MD<*TJ]ZV7H)Y
M"C42*,0=+H5Y#GV#Q 68B3T06M9E?>.YK>7QFPUX"7CRD3V1$U</*7?A[/<$
MU0"3!! T67[S0*6! ([1E035 ]H06.JP2'OTXMY VJ8G?F]:EOP].UN</#U9
M/#XYX;^?/%F</'Y\;TC"IX\63Q\]SIX_A?_.[EV,[GATPS3IL\>+$QB-?Y\^
M/ET\??9T1EH_\]+ZV6WF%?M3F  8D\>SPR>LJS=D785Y!^8-.%EZ(8Z!V9&P
MQ/]1J6&PB PJYT(!J3:]LU&!Q<P._@0E3+%#G*'"'$Z9K?H6[9"6TT'F,.+$
MCF//$67V,5I2\FBX;H29K'@VLA"(#806?7!;LWM=:!0YL%1FP :NP&5;JVL0
M8RA"P-4"&M39#?D_):@%,B10IJWH!0KNP2+>Y=N#;0E"PS]CQX[]IU5PF(J#
MZ)5%%PXE!FJ2/,&UN$H@EL&\ 0%=$*-U45C&S5-HS9OT +).\P8]FR\4+P4&
M1GEV$._!N%P/\X8A8"TE;NT^WL8["83*-^1(#/"#GDUF*;C%&06WE,2&R"'A
MV%<+Z@]-&O-%EWL.MZJ*3G#@4PK"\#LX.[/K=\YJHID KDJ<Y'8TR!M<=D;0
MY 'JKX8"%@F:39O#0UE_RNL3> (U+D1H4K2P$I3A0@3R NG/K3UKMSWWDN#Y
MK"2XM.@\BS&.AA6%2,9$PNP\XR(A>_#V*!M?(?U:NZ\73J%+7F@'7%_N)5B-
M(L%BK$BMT(2H+0]FYHVF6/<6[%OP9R0:\!7_QFA1O>YNP'9C]0*<VE*T$1UG
M6U^S!ENXT*1%M:TX6+1@,PL(JM_U;$> @0%O&4D=?$#/1E?*18,PRF=<\*>H
MR?&055 2Z*^=%H9"4]V3011@=XXV;$(<:Q(K<:2C]>RYS#XW=452LVY5B59*
M9RP'!V$Y^$J[:!)#CYMR<;W1+3$6=C7Z$1++B1(_-)*B?AA>H>P96BEHC@HO
M>\,GI Y<&"ML89F]CI>$9\TH421'TI,2H-@V.-Z8I3]&6LQV&G0Z$,.UQ-*\
M^($1&LRC(:9YSX)F].-YBV2V>?G7E"KG32!%FQQX[OTHV=!!@<0"1^#?_QF0
M:\VZ IUEG(3(-$/ULV!AKG$P8*3=HGEFQ?XCVX86)6F!D!EG>;'<A)U/X*1'
MXD*UHA5&2PD%W;[1+^Y-\.X;/\]GGN<]@'WOPG%H]HC2U>V]][.,FCW)CK/3
M$WGW[2C39L_D\97P;IA[_!S>HXJW$YN=QNT@F'V-Y2)"*#F>EE-SJ+E ]QYX
MV;'8CNDKQC.>GZ[H^. ?,H"3-%2J&<#D1VM?AS#H2!9)'4 "F@ZH32(= 7K4
M%I_2K: >A?U3V&>U)_F*)A8S(@68Z_I+%#?V[-$Z_V'=TWEA K.O4-\A6,YX
M90_  S^09[GX8ISO[S39"&121"_&\4WR<#'""7*M6/AXI[$N R*[E8S28'-3
MJ:JPQ<$.,4;&855CH^S8PB6UX^G)9Q=_!"CQ3]Y<A(\(3Q%J$GLV++V<4>H_
M>*7^PZQ2?Q?""F.:?';PA''_2W:41=,F?Z,WRVFZ5N<N5L$&O],9(F!8+CXP
M1P=9QX:U#K!M2?A;P%OP6O2*"]4#]R/SMOAR])AT!(=DG+7.YKG%F7"JVCHP
MX[ +VI>8+1D='.87ZTY.G8A.E?!FY>.?\LC9#"'7208[NMF!7DD:KA"W(JU!
MM3A1L*! @J]18?GNZ]Y@H;[5L[ @<:I"!XD.9NR&C-6P[Y$(;RE,.7HPZ-'P
M27+RW,<E B))J1VZ&SAW'%$UU1KFK7(]2, %6WML_177(U BG-^AK%E)\M 7
M6#@FCO=YI77V6PUR]/$BDP*8B':74@@S9TJ?GH3JNY-9OOL49QQ?1QG'-Y(;
M&2VUFYUS@AU_/<IN72Q](TZ NDJ@3_]0N^;E:U]-1(G1U.9,K,Q+D+  '^4_
MV3.7#VW7%_MH.+M>D:$CYA,6H)BZ (H %<!1,S$0J6+ .TF>=S -H#%=@56-
M+&G[AI(+('$W-9X^:VOO2>$V2?VO@5"9TP0N2E=2KL/M1_8O+P1W0WP0=CNX
M+*6MT4QUP=DF0@3NW?A0A7S96:/*Q"IP02\JG^#<$6TXI*EKNU&@O=@V7H07
M=JKJT7_L*>(Z>"O85> F8R25ZVY8\<(410\SN'V&*$E&/+55Y7J02"#I<Z/!
MQD&9L&O*>J_UL3-G0D9>=#7Z%E09,YV+9QA7H.C7!@TE$DLR,18J;M2&R> 0
MRED/]S0JBCV=9<OSG&HFBG_\[?0I<O\QF+5(4_SY^YAV=L4)IGUWE#E0L@ %
MU9WA";@23WB:AB33P,)* P%(=)8(RTUIJN-&IIPL?7"<_^YRR/MRM!S%;KE*
M!=U3C'EU>O=-16?+:)]N(4\[(0>3E!A%@7!*@^",8;"O""0;E[;<FI#Q!UW)
MP&^L=@Y9(.-&[?D[4HM<7E.)/N5:U#O/2L*'?>$MZJN=5*G%.-Z9$M1+74DL
MLM5AZY2+:U!BU7U;[H-7"T YF3QQ=$Y1U5Y>WN4<+D'<6B]U0R$D@B A!:DU
M<D:]2V#P&!=QESA'K+%#H0\0GJ"JB'&%)WH7FA2;N9TASF$(%D.T%-9'B L0
M+)5Q(005!84IQM*3JRRQU=0<)5KWKX/06F%Q*.WTG;,D1K9&8P-M^M0R@G07
MB+R70><A]38YIM8[G6^KNJPWI$368. 9\=9D))A &/N4@8G9)UX&6(>IO/#$
ME[(!5QU)%'>,>[Y)KCCI\6U2XM)!1%5,GFT<<W'8N8E?HK QZ30'=$,43F62
M6(+&P88&(P*J=+K-C4DL&S$\A,Z#4?#!P7&[W!A94CQ7U9A.E>2*DCWC(T/$
M<&Q:6(P"H(GKC*00F$@B%I%C.J\0SX)"/)M5B+]PE3V7G!<8&V^IB 6H:%;I
MS<XZH?3^>93=8;GD'96^X\3"+\1OYT.-U7IS+8D73]HN1$<R%YY^BX=:I@$<
MS,1B,!8G)C]0E!.HJZI+2UPBK9&QP'.4&:?"0]I[ISC33!RD"-B((QQ<(\J2
M*[\E'S-,LZ> +6:@(D'BQ(P4*Z\Y8@84O..81&'[#:9T"L.M!PK#3$SSMP$"
MPG43"J(JL,R#4+O-H@O=/:?S[3T4_!NGT>]IV/GO(P[KIBE+KW%:R?HI2Y%4
M#DF[U+:2**+$N>![W;C=<]I;A"HW&)!#/E6[PQ.%528Z!E1F*:1<KX_[UL6L
MK195[4*0P]EIC(L?4 [3.] \@R/R*"I*!"Y?A%S?K4N%\@1?F\QS.(FZS#XR
MT?L@[.&.F$7JP7M)U:%-8GYR OP>]C9@E($.BY*A29PN!(=E*R$*N#9?=3&
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M4EG1F9+V'NCM[Y%;(S(K*$'#!:6Q^/Q#4?#_;6C52<7R' U-B>GX%K"4&U9
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M-Y+CTAW*WFK<Y>AGU_OV,(C*R9X7DN><46G)AC'52,ME079*<,;!D#</]"#
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MO) &KX(3*SS#H*P#OB^E-%O%)N@/>_X/4$L#!!0    ( %$_W%1OI_RSK0,
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M4%VM- JXMAE_<NJ8F%H&">^2:3]BZVG$\@\6#26/<[P$@J1E]>KZ5W3Q;6E
M+DL&0P:JI7LWVP6@JT94ZFCP<5G= AAD];758G<QF<TDGP$W@T_-S-!+E(;@
MC*J8WH8F*$IQE,38]Q*TAP@910$*1TDZ>-?(D5!,$H()C6$\'<41<,AE5I@-
MLT\\@@,_0@<P%HR\: "5?LH+\!N?FS4HK1$./(J]-+1F,$42/2LVBA(/^U&
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M@AY^*(T"K2^$T(\#XZ![2L[^!U!+ P04    " !1/]Q4:XB]U"H)  !T'0
M&0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6S-65MOVSH2?O>O('Q.#Q)
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MEB:\FY1! "1 \02<C%5@3#4#_$P<;S(;7!_:5;<LIW9NC*TYI)E4 .$?!1!
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M<((@A4.YLA#_)&!PX)A\Y+NGW;N ,Q2YN;R\-H.\4Q,^N "-,5! K);<7E!
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M J^/F[,>QQBTA:$YT3YAC65+M,;-FZ*W:7J$88K:RO(2"D'#;<XO#H)[<_L
M)C+1<!C_WN"19^94R[X77%H[MFJV8!0N=N/!'87^FZV,OQBY;\A;L@@Q?#H#
M9=SZ(2QC\LG\W(?7SI!=[&]B36OSD^*E_2%M,]S^'@GZ/\'AEJ1L!5/=T2P<
M6DZK/[0HS,]J2Z'!X.8U813\@ .@?R7@>%!]X +-#ZT7_P502P,$%     @
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M4AHJ^WJ:49]%90WH?"6EV2ZL@ZYSQ_\ 4$L#!!0    ( %$_W%02#3S;@ ,
M &,'   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;(55WX_:.!!^YZ^P
M4JGJ2MZ-X_QD%Y!@K]6==-TBZ+4/IWLPB2'6)C9G.]#^]S=.LEFH6.X%['CF
MF^\;SXPG1Z6?3<FY13_J2IJI5UJ[O_=]DY>\9N9.[;F$DZW2-;.PU3O?[#5G
M1>M45SXE)/%K)J0WF[3?EGHV48VMA.1+C4Q3UTS_7/!*':=>X+U\6(E=:=T'
M?S;9LQU?<_O7?JEAYP\HA:BY-$))I/EVZLV#^T7D[%N#;X(?S<D:.24;I9[=
MYH]BZA%'B%<\MPZ!P=^!/_*J<D! X]\>TQM".L?3]0OZIU8[:-DPPQ]5]5T4
MMIQZF8<*OF5-95?J^#OO]<0.+U>5:7_1L;.-0@_EC;&J[IV!02UD]\]^]'DX
M<<C(&PZT=Z M[RY0R_(W9MELHM41:6<-:&[12FV]@9R0[E+65L.I #\[>X)[
M_U,9@_9<HT=5UY"I=<DT1Q^^LDW%S<W$MQ#'6?MYC[GH,.D;F %%GY6TI4$?
M9<&+<P ?" XLZ0O+!;V*^)GI.Q0&&%%"Z16\<% =MGC)&W@?F99"[@Q:@NI.
M[M_SC;$:BN2?2X([N/ RG&N<>[-G.9]ZT!F&ZP/W9N_?!0EYN$(V&LA&U]!G
MZZY?D-JBO;)<6L&JZB<J1-6XBD:&YXT65G!SB?E5[,O,Y\;%@ISGY9!TQ&3A
M%K#]'Q+HR"&=S*"MJJ#ES?WH%Z2S;3!:6Y4_([5W36K:,%"*[;21.>">G68$
MATF$QR1"R1@G68I#DHU6'&Y.Y)87O7DCA7T+JCO[()6\/8 ?+VX0B!K'"4ZC
M,4HQ'4>8T*PG#0P)>OPV7X%+<(-"BDD UN/$+:,HQ0E-1D_JP.L-5)+3TULG
MF&8QIC%![]]E-* /IRSSGLL9BS0*<$1B%."4$DS&9.2J]/9+8\_M0DQ<&K)T
M0%YJ<6"6HV4%%PD#TZ+O3&LF06= , TB2%K\:MUL*I&_FD"P*(UQEKZ:?+$E
MJ!$2"#<.SR!A3 /$8QR0$,=I"JLHSG <A2.7EQ7?@H-5Z EJPP5MH2AY:'OK
M=@%CLW#3!9X2P]Q5ML?! ]2(AAEJF:@,C/@=TP6T)123M56G! JQ3>@=NM1)
M_LG@J[G>M>/=H%PUTG8S</@ZO"#S;G"^FG?/#]SW#A2CBF_!E=REL8=T-]*[
MC57[=HQNE(6AW"Y+> 6Y=@9POE6@O=^X ,.[.OL/4$L#!!0    ( %$_W%3R
MLZG)?0,  *L)   9    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;*U6VX[;
M-A#]%4(-B@3(KJZ6+[4%V'*#!$C2Q;II'X(^T!)M$4N1"DG9V2 ?GR$EJUY'
M5H*B+S8YFCD\9X;D<'X4\D$5A&CTN61<+9Q"ZVKFNBHK2(G5K:@(AR\[(4NL
M82KWKJHDP;D-*ID;>%[LEIAR)YE;VYU,YJ+6C')R)Y&JRQ++QQ5AXKAP?.=D
MN*?[0AN#F\PKO"<;HC]4=Q)F;H>2TY)P105'DNP6SM*?K:?&WSK\1<E1G8V1
M4;(5XL%,WN0+QS.$"".9-@@8_@XD)8P9(*#QJ<5TNB5-X/GXA/[*:@<M6ZQ(
M*MC?--?%PIDX*"<[7#-]+XZO2:MG9/ RP93]1<?6UW-05BLMRC88&)24-__X
M<YN'LP _O!(0M '!14!X;86P#0@O H+@2D#4!D0V,XT4FX<UUCB92W%$TG@#
MFAG89-IHD$^Y*?M&2_A*(4XG:Z(R22M; [%#JUJ!@U((\QR]I9]JFE/]B&[0
M,H<!.&&&WO!FMYF0YVNB,64OT#-$.?JS$+6"2#5W-7 S*[A9RR-M> 17>/@!
M>B>X+A3ZG><D?PK@@JA.67!2E@:#B.^PO$6A_Q(%7A"@#YLU>O[L!=J0/6Q:
MW4-P_?-P_@EN@&;8%2"TN/$5W#_D'G/ZQ:;S)4H%5X+1O,FN*<*=) H(XU.%
M7E&.>4:A#ALP$B-&H8_+K=(2SM _?9EO"(3]!,R],E,5SLC"J<Q:\D"<Y-=?
M_-C[K2]+_Q/8DUQ%7:ZB(?3D?5UNB319@&M/0DKXWN9(DDI(.U-->17Z.E#I
MM%DELJN8>_&0^'/W<*YRD,=_5#GJ5(X&5:98%5969@8$SN !,R.J3TH#-3J3
M$GBQ%WG>A: ^O]'(BZ+.[PG7N.,:#W)=9EE=U@PV8FYN6YK1OH2OAD$^^KW;
M-OZN2C?!. ['072AK<?1G_J3* [ZQ8T[<>/A[09=EPG5E_?5<.051>/OBG S
M#2+?CR\$]?EY7A"&_7HFSH5AV@F<_HCF/=%2-,V7/<)!4MK6$FYXI N"H/]D
M#_ FV.;T0&VKQPH*;7K&%MS@SG\O-$'A;=^^=\_:4DGDWK9WA3)1<]T<^L[:
MO2!6MG%>V%-X6?@]]N5DED[Z[--9:E\B[K_+-L\8N,7WE"O$R XH>+=C2+)L
MG@;-1(O*-LNMT-!Z[;" UQ21Q@&^[P3H;2=F@>Y]EGP#4$L#!!0    ( %$_
MW%00%)J,*@,  *@,   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;+67
M76^;,!2&_XK%JJF3MD#(I[H$J0V;UFG=HD;=+JI=.' (5@UFMDG:?[]CH"C9
M"&HT=I-@[/?U.0_VP<QV0CZH&$"3QX2G:F[%6F<7MJV"&!*J>B*#%'LB(1.J
ML2DWMLHDT+ 0)=QV'6=L)Y2EEC<K[BVE-Q.YYBR%I20J3Q(JGZZ B]W<ZEO/
M-V[9)M;FANW-,KJ!%>B[;"FQ9=<N(4L@54RD1$(TMR[[%_[4C"\&?&>P4WO7
MQ&2R%N+!-*[#N>68@(!#H(T#Q;\M+(!S8X1A_*H\K7I*(]R_?G;_6.2.N:RI
M@H7@/UBHX[DUM4@($<VYOA6[3U#E,S)^@>"J^"6[:JQCD2!76B25&"-(6%K^
MT\>*PYZ@/SPB<"N!^U+!H!(,7BH85H)A0:9,I>#@4TV]F10[(LUH=#,7!<Q"
MC>FSU#SVE9;8RU"GO57YN(F(R(IM4A:Q@*::7 :!R%/-T@U9"LX"!HJ\(Y=A
MR,S3HIQ<I^62,\_NW =-&7^#(^Y6/CD_>T/."$O)#>,<^]7,UABIF<\.JJBN
MRJC<(U%]%=L><?IOB>NX_0;YHEW^.4][9. <E?OM\ALJ4=XXNXUX:\9NS=@M
M_,;'&.->#7,.Y%O4"/;^"PK(M89$_6QB5;H/FMU-7;A0&0U@;N'&5R"W8'FO
M7_7'SOLF<EV:^1V9'5 =U%0';>[>!Q6@ D+<Y9E03#>1:W4XE5R79GYI-BK,
M3&G>>I/1S-XV\!C6/(:M/)92! "A(I$4"59D#E@.S;Z& E0;IE;C4S$-VS(K
MD^]HO@-,HQK3J!73@JJ89)2%1 NB0&O<E_B> "EQ*058K5@(LJQKG-$UXTP_
M-3$;_97FR#E,<]$:R*D+IB.S V;CFMFXG9E($N2QTB)X(/<WD*Q!-E:J5IM3
M%U*79GY'9@?X)C6^R7^M_Y,NJ79IYG=D=D!U6E.=MB[*<C4RI7+S#LBE09J!
M9"(D*J8XWS]N\'+VX=X&'P^&4V<T^6.7MT9Y*M".S$J@]MZQT)SA\5RS8:DB
M'"*T=WH3K"FR/!>7#2VRXJ2X%AK/G<5EC)\2(,T [(^$T,\-<_BL/TZ\WU!+
M P04    " !1/]Q4+].1"IP"  #0!@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S."YX;6RM5<MNG# 4_16+1E4B3<.;1"F#-)FT2A>51IFF751=>. "5HP]
ML<U,^O>U#2$D(8]%-^#'/8=S#OB2[KFXD36 0G<-97+NU$IMSUQ7YC4T6![S
M+3"]4W+18*6GHG+E5@ N+*BA;N!YB=M@PIPLM6LKD:6\590P6 DDVZ;!XN\Y
M4+Z?.[YSOW!%JEJ9!3=+M[B"-:CK[4KHF3NP%*0!)@EG2$ Y=Q;^V3(V];;@
M)X&]'(V1<;+A_,9,OA5SQS."@$*N# /6MQTL@5)#I&7<]IS.\$@#'(_OV;]:
M[]K+!DM8<OJ+%*J>.Z<.*J#$+557?'\)O1\K,.=4VBO:][6>@_)6*M[T8*V@
M(:R[X[L^AQ' CUX !#T@>"\@[ &A-=HIL[8NL,)9*O@>"5.MV<S 9F/1V@UA
MYBVNE="[1.-4MN[>'N(E6I.*D9+DF"FTR'/>,D58A5:<DIR 1)_06G]#14O!
M5"^J2D"%%:!%8TJE65QB6<_L%7VY;<D.4] [,X19@:Y *D%R!457<'@!"A-Z
MI'FOUQ?H\. ('2#"T(^:MU(#9.HJ;=#(=//>S'EG)GC!S'<LCE'HSU#@!<$$
M?/E^N/\8[NI8AVR#(=O \B4O\%F;QOK30-#OQ4:'H3_A/U,F.]9PFM4<ZS.Y
MQ3G,'7UN)8@=.-G'#W[B?9ZR_)_('@40#@&$K[$_!)"; 3P$,.6ZHXHME>D]
MNRSP$B_RO-3=C0U-U<6Q%T5#W2.MT: U>E7KZ/,T:J<4=@31Z,E^F(31$WW/
MJTZ3) RFU<6#NOC-)&?/8K39BK>%QQ.1G43>,^D3=7[D)R?)$_'NJ-^87J\/
M3D681!1*C?2.3S2%Z/IG-U%\:UO0ABO=T.RPUK\<$*9 [Y><J_N)Z6K#3RS[
M!U!+ P04    " !1/]Q4K>^7YGX#  #]#P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6RU5UUKXS@4_2O""\LLS-:6TR1M)PFTG98MI! FS,[#, ^*
M?9V(T8='DIL6]L?OE9W:6;95:*A?$LG6/3KWZB@W9[+5YJ?= #CR*(6RTVCC
M7'D1QS;;@&3V1)>@\$VAC60.IV8=V]( R^L@*>(T24:Q9%Q%LTG];&%F$UTY
MP14L#+&5E,P\78'0VVE$H^<'7_AZX_R#>#8IV1J6X+Z6"X.SN$7)N01EN5;$
M0#&-+NG%59KX@'K%WQRV=F],?"HKK7_ZR5T^C1+/" 1DSD,P_'J :Q#"(R&/
M7SO0J-W3!^Z/G]%OZ^0QF16S<*W%-YZ[S30ZBT@.!:N$^Z*W?\$NH:''R[2P
M]2?9[M8F$<DJZ[3<!2,#R57SS1YWA=@+&(Y>"4AW 6G-N]FH9OF9.3:;&+TE
MQJ]&-#^H4ZVCD1Q7_E26SN!;CG%NMFQ.@^B"+/E:\8)G3#ERF66Z4HZK-5EH
MP3,.EOQ)EJB)O!+@5]]8Q[$HD).O%HI*D#E6UY(/G\$Q+OZ8Q [9^3WB;,?D
MJF&2OL*$IN1>*[>QY$;ED/\7(,:TVMS2Y]RNTB#B/3,G9$ _DC1)TP#>H*W5
MH,8;O()WK659.3#D^SW(%9@?+R49A/!W[,*6+(-IA)?(@GF :/;[;W24? H0
M/&T)GM;HHU<(+@S>5N.>/I*%\*?(5$YN?E6\Q&ODR/<Y+B=W#J1]D?EI#\R'
M+?-AL+2=FJI&3<*KZ26689P!>0)F;(#1J&4T"B+-V4H;YK1Y:I+$6C8#[39@
MFB&TM?V'W+-'+BL9U$9PQR,K/&[S&?>HC7$/S,]:YF?OI(TP#DT.BN.\I73^
MON+@ZJ X@CL>66*:=&T@Z5$>._!W)K_7P^@[*>0 T/"@0FC:D4J#6+>54=Q5
M!NI:WO)'/[9!"801CRUCU][HH$\-]-'Y:-?Z:+ _O44#8:#Q80UT78V&V]%2
M%V[+4 +!4P]B'%NXKL_149^GWD=/HUU3H\'.\Y93#P,=_N- NWY%PXUF#F@3
M-EKDY$Z61C^ K^2!FQ]$/+:,73NCYWUJH(_6E7:M*PUVES=HX #0'"RR\^8&
M_@]9H.LQZ$.]T_6V2/A#)N@&Y$M)Q'N.3()9U[[3DMI4->:L?=IZV\O&T77+
M&V.,+F;-E<4-"PQ-3L;X<V$:K]E,G"YK?[?2#MUB/=R@/P?C%^#[0FOW//$;
MM(Y_]B]02P,$%     @ 43_<5)&HH-<V$0  'KD  !D   !X;"]W;W)K<VAE
M971S+W-H965T-# N>&ULS9UK;]LX%H;_"N$M%K- 6NMFR>ZF =*$Q0:8MD&2
MSGPH]H-B,[&VLN31)6F ^?%+R9))RO*1F1RV[0 3W_B2>D4=\=&AQ./'-/N6
M+QDKR/=5G.3O1LNB6+\=C_/YDJW"_$VZ9@G_YB[-5F'!WV;WXWR=L7!1%UK%
M8\>R_/$JC)+1R7']V65V<IR611PE[#(C>;E:A=G3>Q:GC^]&]JC]X"JZ7Q;5
M!^.3XW5XSZY9\65]F?%WXZW*(EJQ)(_2A&3L[MWHU'Y+;=>O2M0_^2-BC[GT
MFE3;<INFWZHW%XMW(ZMJ$HO9O*@T0O[G@9VQ.*ZD>$/^:E1'VTJK@O+K5OU#
MO?5\:V[#G)VE\9_1HEB^&TU'9,'NPC(NKM+'_[!FBR:5WCR-\_K_Y+'YK34B
M\S(OTE53F+=@%26;O^'WQ@FI@.WN*> T!9Q. 6]?#6Y3P.T4<)P]!;RF@-<M
MX.TI,&D*U)L^WFQ[;=QY6(0GQUGZ2++JUURM>E&[7Y?F?D5)U5.NBXQ_&_%R
MQ<G[,N>?Y#DY2U>W41+6>^\Q*I;DX^GI&7E-R.EB$56?AC&Y2#9=L_K-;^>L
M"*/X7^05&9-\&68L)U%"OB11D1_Q#_GKFV5:YF&RR(_'!6]J5>%XWC3K;-,L
M9T^S;(=\3)-BF1.:+-A"%1CS;=QNJ--NZ)D#*GX,LS?$M8^(8SD.^7)]3GY[
MI31^\Z>GJ>>'"]NM<(\,'9)Y$BJB6<"6N]M=[-;*OOXN)J?\OS/R]7?^ W)1
ML%7^W[Y]M=%W^_6K6/8V7X=S]F[$@U7.L@<V.OGG/VS?^G>?FYAB%$E,\=7;
M^NI!ZB?T.\OF4<[(.HOFC*1WY#',LC I<O(;[_V+-([#+"=KEFWV95^G. .K
MT+464XQNQ():K#K?/)Q8;RS[>/S08]ED:]D$M.RZ2.??R$6>EVQ!SLLL2N[)
M)<NB='%$_@CCDAV13_S<4O\@)W^35ST->P]7\=7N[<*;0A-I:R:![0?;S=D8
MN/LKU[(#SU-_1L$6/+/7^5L+?7#[^$&\XL?OQLD_VP[W]_[P=;;1\Z2-\BT>
M9#J;#M:JVW>0Q!2#@JU! 6C051H]<$](:]0FNG_]R%:W+.OM&Z">[C&(*4:1
MQ!0?IUL?IX9/&U-,7S'%*)*8XNMLZ^ML. 8NTWC!^,F!_E5&Q1/YE!:L.:2O
MUW%4$/I]O@R3>T:N*M^)W6?OIIJI=%P[;V:.[W0.;+ UNL8AB2G&V988JUHO
M.+1Y$+Q>ITF>9N2Z7*_3K""G]QECG&L*Y4=5,7)9G[2Y_WQ<RTMPPQE;Y.1#
M=%<PEI#S^NP-A@VXL;K]&U6-8JFI.TJ""MMP[&@JP#(74XUBJ:GF.L)<!SP*
M/I55EZS&FT46+JHAU")\RDF1DE5U:8&%64+2LFB&I<62MZ$*-[TNPS4Y5BW=
MZRA84MM1)#7540%(-L@))S?"QVJXSH>CA(.N<'+_V&I V 4,1.4@+#750$%"
M]@ *<:=>?VZ=VO2\7KN\G0&V/>F<K^"JM(U!4E.-$;QCPS3R \Y8-X_\UT\'
MG;"0N*793YAJ%$M-W4\"JFS?] D+$Z#.4=4HEIIJK@ R&R:R%X176!@*KZ@<
MAJ6F&BA(S :!Y/#P.MT)KX[5#:^H((6EIAHC4,J&6:J^1GV1+-B:\?_QH'D>
M96Q>I-G/@P),W#I'5:-8:NKU=T%OCF4XQCJHQ(6J1K'45',%<3D@=(!75C>C
MCLZEU?U!MZE)OF!H6_Q?)Y# #=*VSP13.8*I')AT?E @.7RL!K=7NZNCTAJ6
MFKJO!*TYIO-9#FI""U6-8JFIY@J2<V"2PXPCWDX<F?2$$53<PU)3W1.XY\"X
M5X>1-DS\K"$(W$;MWHV*>5AJZOX1F.>8QCP'%?-0U2B6FFJNP#P'IC',T!'L
MA ['<MW)K)NUA)ND;: )S',$YCDPYIF+'AKC#M2D':H:Q5)3=X^ 36=F.GB@
MPB&J&L524Z<H"3ATX=0>8O!H:E+YQ?:#F=\)'G"3M*<BF0! 5P"@"P/@ON#Q
M:^5,X8W0GDJ&BJ!8:NH.% CJ.J:GZ:$R(ZH:Q5)3S96F0,*)N$O>LRL_T[NF
M*U^7M__C@%]E3:NKJVE9]#JZ49TID^"Z$RS@JK6-,L%_KN _%^:_?6'DE[M
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M[K(\C:M@.8(X3/8__3^J7\11@#%Z)8!6 ?0TP'HEP*P"S'-[&%4!HW,#QE7
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M[KVAM^\_YQMY[U4N>+I[+=2ZA])L*,V!TEPHS8/2&(JF"K"N!AACW+T66@&
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M2G.@-!=*\Z T5M&49-,:&N9X]%K"7;OT5#]I_TZ]:@7ROB?WB/+]S#!91KM
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MP$710'Z_2M/\Y4/1P6%!YOG_ %!+ P04    " !1/]Q4ZFJ]Q>,;  !HP $
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MUM5LW]65&E2M_":J-M-'U?07GQI_&N_SVUVY*XP?DVQ;[>9O(N-#EF^SXYZ
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M"_T*=?_=NO=:5V'KD;Z%C6H6JMFHYJ":>]06)X4]^&Y\5M7HD!ZJ^:@F42U
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MY7R6DRP7L%R(<6>]87C2&_Z>=0)?&*=_NT"SD2QGLYS#<B[+B2=.76FD?;;
M8\?U64ZR7,!R(<:=-8+122/09JK^PMSD:4;R(<[+*$E/9B4G68KGDR9]9RAD
MKNR&Y2R6LUG.83F7Y03+>2SGLYQDN8#E0HP[:S[CD^8S?HT9"AJZ9#F+Y6R6
M<UC.93G!<A[+^2PG62Y@N1#CSGK#Y*0WZ(.:W P%36*RG,5R-LLY+.>RG'CB
M3F<H$[-K@H(F+5E.LES <B'&G?6!Z4D?T*<RW]_=)>K]RW57:KZ@]:]V-*')
M<C;+.2SGLIQ@.8_E?):3+!>P7(AQ9TUA=M(49J\Q<4"3EBQGL9S-<@[+N2PG
M6,YC.9_E),L%+!=BW%EOF)_T!OWBB[UO<_8"V+\OH*%+EK-9SF$YE^7$$W<Z
M0QAWGL) ,Y4L)UDN8+D0X\X*?G%2\/ID91A_7G\YWLO<*!ZB:I3N,D>3DRQG
ML9S-<@[+N2PGGK@7+F3VV&%]EI,L%[!<B'%JF9LG*4I3GZ+\^H& %\XEZMW>
M=8]R%LO9+.>PG,MR@N4\EO-93K)<P'(AQIVUAY.TH_D::4>333NBG,5R-LLY
M+.>RG& YC^5\EI,L%[!<B'%GO>$D[6C^36E'_3C]VP6;=D0YF^4<EG-93CQQ
M[47C6Y,(=&"?Y23+!2P78MQ9)ZCCCF<_.@DAF?I5WWXS_^>GN,RS:%DF57_X
M4M]!M8S*>+5?^J%\B(VJ,2Q_-XK=[2IYK/8LJOV*J*B:2;W"].WAYJMA5L;&
MZ+NN%WE=/,1Q>1.5T;NW5;>YCS_$ZW5])^9=6M;_WDY^6HU\5[_@[W\<OKEN
M_?S&_-XW.WXNS>^#KI]7O_BH>J3ZXW0^-JX?&]>/73<OZ]W;;70?!U%^GZ2%
ML8[OJI<X^&Y6546>W#\\?U-FV^IO_,:XS<HRV^R_?(BC59S73Z@>O\NJO\?Q
MFWJ SUG^^_[/\.[_ %!+ P04    " !1/]Q4!1/RVAD#   8#0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970T,RYX;6RM5UUOFS 4_2L6JZI.VLI7(*1-D-JD
MVRJU6I6TVT.U!R?<)%8-9K:3M/]^-E :$LH:B1>P\3V'>ZX/<.EO&'\22P")
MGF.:B(&QE#(],TTQ6T*,Q2E+(5$K<\9C+-64+TR1<L!1!HJIZ5B6;\:8)$;8
MSZ[=\;#/5I*2!.XX$JLXQOSE$BC;# S;>+TP)HNEU!?,L)_B!4Q /J1W7,W,
MDB4B,22"L 1QF ^,"_ML:#L:D$7\(K 16V.DI4P9>]*3ZVA@6#HCH#"3F@*K
MTQJ&0*EF4GG\+4B-\IX:N#U^9?^6B5=BIEC D-'?))++@1$8*((Y7E$Y9IL?
M4 CR--^,49$=T::(M0PT6PG)X@*L,HA)DI_Q<U&(+8#=>0?@% #GHP"W +B9
MT#RS3-8(2QSV.=L@KJ,5FQYDM<G02@U)]#9.)%>K1.%D>#&;\15$Z.I9&4.
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MM93#1%U$@>L%ZGW,F-Q.]-6EN=KZ_P!02P,$%     @ 43_<5 ;>@R4$"
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MR-?762;>'Y0=-#<76_X?4$L#!!0    ( %$_W%2MW<&QAP(  -0&   9
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MN<ZA/7'>J7)4P(;X,8KF&T4+3*$U*3KJ(-U7ZH>06"W"@G,D"OL_54,8C]1
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M:]P +\_SRX%DN3ZP7C*)Y4U?;H BN4H [Z\8D_N!6J#^JC+Y'U!+ P04
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ME2B_1A%9+(2P;86%V+TH:4X#)CU-B8C@QI)]9GS2%31O $H+6IIVJSPV/FL
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M])+W[\).\+G)G/\$=F!5J[:J=0P]N7DIZ;*3?NW.5JEXBK"2@OP2W&R:M%>
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MD+=L8?(5(]A/C*+01);EF!$.8F/83YY-V+!/UR(,8C)A@*^C"+/M+0GI9F!
M8_?@*5@LA7I@#OLKO"!3(IY7$R;OS-R+'T0DY@&- 2/S@3&"-V.$E$$RXEM
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M.1KEP*/K6*1'6_G3_/AUE!PZ5I[?PIMQ>HA:N$G/=!\QDUJ*@Y#,I4NKU96
M+#TF36\$724GC3,J!(V2RR7!/F%J@/Q]3JG8W:@)\L/JX7]02P,$%     @
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M<B<DB_-@Q2 .D^R;?L\+<1* _0L!) \@U0#O0H";![BIT(Q9*NL#E70RXNR
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M1C3[D"<S]T;Z(K/[OC *5P7ZF>GG;"53('?\"32Y( O45;1+@,@U^5UJ36:
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MD.O?V<;0(-<+99P6?]&ZO'>$>RC,4BV336'3@H2+\C]]V 1BJX _?*8 WA3
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M<:895=?HZIYJPO@U./Y8WJ.K#]?H V(E^IZ+O2+E6LU<#8QF)#=K>#[7//X
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MPC@=8CSU*OQZL[*<<=RK,^SKCZ@T/6V##F_<NU&O[WO=>,9,ZEC<LT.M^:*
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M=]]]W]F^ZZ^D>M(9@"'/12[TP,N,*2]\7T\S*)@^E24(W)E)53"#4S7W=:F
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M!J;,<-KCSQ0 KBT*<Y)K]P6X]AJNO=9-NJ.+R D:=P77S OW#9?PB$R;MZ?
MMKOK5)8P %&),X&,/9H6H/T&:+_5\YR;AW=+.E) ,/$4LE;[9Z9QT* ;O"K)
M#%Z ZT7#]:)U)Z[E!HUUQ_H4LLHVKHS=R[D91^>]9!AN3H2\;$)>_M>KI+I
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MDLYIJ)!X7<;JAF2EJ013)E5=,:^9JOS =8 :GS$F5PT]0?M?(OX'4$L#!!0
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MBQ@5^2\ZEG,="T69D"PIP2J"A*3%/_Y1"G$!</T; *\$>%< S[L!\$N _ZN
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MF>*5B,T4SS4@]KR!1QC:5QN+ Q[8*F"U _'M<:"F[#Z^#ZN*:<-V,(Z$(89
M+=IK- B0[ 3PL:\/MDM\/PSM"&!V!;Z/(; ;<013 !HPQ/>+Y^#6\\BKGE->
M\__I\6]02P,$%     @ 43_<5)>*NQS     $P(   L   !?<F5L<R\N<F5L
M<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\
M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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M-/\GC'JQD+DXUWE3"^6Z.!I1!4!E2[FR Z9X+::#,_TH3+@??X'+HKLWYZ%
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M4];?SFV_.7YZEKUMA]=\-OVA]>894$L! A0#%     @ 43_<5 =!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " !1/]Q40<BRQ^\    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " !1/]Q4F5R<(Q &  "<)P  $P
M        @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( %$_
MW%3U, 9R90@  ' Y   8              " @0X(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " !1/]Q4]B&SM18(  !?(@  &
M        @(&I$   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ 43_<5 L@T(.6 @  #0<  !@              ("!]1@  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( %$_W%3(SG_:+08  .\7   8
M              " @<$;  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    " !1/]Q4MM'+@]H"  !5"   &               @($D(@  >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 43_<5$$B8:6X P
MF L  !@              ("!-"4  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( %$_W%10O9<@E P  +9T   8              " @2(I
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !1/]Q4BC*\
M=J,(  !O)@  &               @('L-0  >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ 43_<5/X\W( %"   )!,  !@
M ("!Q3X  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( %$_
MW%3U%#?)VB(  ,YN   9              " @0!'  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ 43_<5$),8A8K#   C24  !D
M         ("!$6H  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    " !1/]Q4[)@8K@L)  "O&@  &0              @(%S=@  >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( %$_W%1"/'4AG@\  'HN
M   9              " @;5_  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ 43_<5"*66N*P @  [04  !D              ("!BH\
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !1/]Q4.Z7^
M6;,)  ";%P  &0              @(%QD@  >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( %$_W%3L<XX,A 4  *8-   9
M  " @5N<  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
M43_<5/J2_D =!P  *1(  !D              ("!%J(  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    " !1/]Q416&]1B$+  !M(   &0
M            @(%JJ0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( %$_W%0E- G-1 L  ((<   9              " @<*T  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ 43_<5*ZI BD^!
MB D  !D              ("!/<   'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    " !1/]Q4EN^2<%(+   ''   &0              @(&R
MQ   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( %$_W%1N
M;>QF/ L  (TA   9              " @3O0  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ 43_<5/ @+JNE @  MP4  !D
M     ("!KML  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %$_W%2TO">OLP(  .0%   9              "
M@68/ 0!X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ 43_<
M5&^G_+.M P  (P@  !D              ("!4!(! 'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    " !1/]Q4>\0:=6 &  "T$@  &0
M        @($T%@$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( %$_W%1[T4?)% <  !$1   9              " @<L< 0!X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ 43_<5 62[64D!   5@H
M !D              ("!%B0! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    " !1/]Q4:XB]U"H)  !T'0  &0              @(%Q* $
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( %$_W%21H()7
MNP(  ,4%   9              " @=(Q 0!X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ 43_<5!(-/-N  P  8P<  !D
M ("!Q#0! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !1
M/]Q4\K.IR7T#  "K"0  &0              @(%[. $ >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( %$_W%00%)J,*@,  *@,   9
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M 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ 43_<5,:
MF2+("   G%D  !D              ("!A5<! 'AL+W=O<FMS:&5E=',O<VAE
M970T,2YX;6Q02P$"% ,4    " !1/]Q4ZFJ]Q>,;  !HP $ &0
M    @(&$8 $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (
M %$_W%0%$_+:&0,  !@-   9              " @9Y\ 0!X;"]W;W)K<VAE
M971S+W-H965T-#,N>&UL4$L! A0#%     @ 43_<5&>S*?TQ P  Y@H  !D
M             ("![G\! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"
M% ,4    " !1/]Q4!MZ#)00(  !H3   &0              @(%6@P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( %$_W%2MW<&QAP(
M -0&   9              " @9&+ 0!X;"]W;W)K<VAE971S+W-H965T-#8N
M>&UL4$L! A0#%     @ 43_<5&JJ\W^#!   81D  !D              ("!
M3XX! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " !1/]Q4
M@G:S/AP,   &C@  &0              @($)DP$ >&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;%!+ 0(4 Q0    ( %$_W%2=?(F:.@D  "5-   9
M      " @5R? 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%
M  @ 43_<5#69%NSP @  /@@  !D              ("!S:@! 'AL+W=O<FMS
M:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " !1/]Q4@K6V<?,"  "6!P
M&0              @('TJP$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+
M 0(4 Q0    ( %$_W%2M 9P?? ,  ,(*   9              " @1ZO 0!X
M;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ 43_<5!8'Y^KI
M!   N!8  !D              ("!T;(! 'AL+W=O<FMS:&5E=',O<VAE970U
M,RYX;6Q02P$"% ,4    " !1/]Q4+6()!Y0$  "\%@  &0
M@('QMP$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( %$_
MW%2;C$)Q"P,  +L+   9              " @;R\ 0!X;"]W;W)K<VAE971S
M+W-H965T-34N>&UL4$L! A0#%     @ 43_<5'W.,VT3!   "!(  !D
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M=#8P+GAM;%!+ 0(4 Q0    ( %$_W%1"@>PXO0(  )P'   9
M  " @5W: 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @
M43_<5,3Z=@4/ P  BP@  !D              ("!4=T! 'AL+W=O<FMS:&5E
M=',O<VAE970V,BYX;6Q02P$"% ,4    " !1/]Q4L)1EP/ "  !Z"   &0
M            @(&7X $ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4
M Q0    ( %$_W%1T+7LM1P(  )H%   9              " @;[C 0!X;"]W
M;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ 43_<5.YBU"/@!P
M^D(  !D              ("!/.8! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX
M;6Q02P$"% ,4    " !1/]Q4G 2TS](#  #]$P  &0              @(%3
M[@$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( %$_W%3"
MDQ.!G0,  $<2   9              " @5SR 0!X;"]W;W)K<VAE971S+W-H
M965T-C<N>&UL4$L! A0#%     @ 43_<5-BB_\![ P  #@H  !D
M     ("!,/8! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4
M" !1/]Q4+(>W'?4"   .!P  &0              @('B^0$ >&PO=V]R:W-H
M965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( %$_W%3J 52TL0,  ,P2   9
M              " @0[] 0!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L!
M A0#%     @ 43_<5$%1^>IN P  G@P  !D              ("!]@ " 'AL
M+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " !1/]Q4E:)IE/$"
M  !7"   &0              @(&;! ( >&PO=V]R:W-H965T<R]S:&5E=#<R
M+GAM;%!+ 0(4 Q0    ( %$_W%2MTR3!<P4  "\B   9              "
M@<,' @!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ 43_<
M5)02P+R] P  -A$  !D              ("!;0T" 'AL+W=O<FMS:&5E=',O
M<VAE970W-"YX;6Q02P$"% ,4    " !1/]Q4U%GSX7$#  "L%@  #0
M        @ %A$0( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( %$_W%27BKL<
MP    !,"   +              "  ?T4 @!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( %$_W%1."5@H@04  /DP   /              "  >85 @!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " !1/]Q4Q]=S3T<"  #5*P  &@
M    @ &4&P( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" !1/]Q4'YV%;PD"  #8*@  $P              @ $3'@( 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     4@!2 '46  !-( (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>346</ContextCount>
  <ElementCount>479</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>142</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>Consolidated Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Description of Business and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/DescriptionOfBusinessAndLiquidity</Role>
      <ShortName>Description of Business and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Business Combination with MAAC</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/BusinessCombinationWithMaac</Role>
      <ShortName>Business Combination with MAAC</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Asset Acquisitions and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/AssetAcquisitionsAndLicenseAgreements</Role>
      <ShortName>Asset Acquisitions and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Long-Term Debt and Loan Commitment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LongTermDebtAndLoanCommitment</Role>
      <ShortName>Long-Term Debt and Loan Commitment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Commitments &amp; Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CommitmentsContingencies</Role>
      <ShortName>Commitments &amp; Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Other Expense, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/OtherExpenseNet</Role>
      <ShortName>Other Expense, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Net Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/NetLossPerCommonShare</Role>
      <ShortName>Net Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://roivant.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/AccruedExpenses</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Long-Term Debt and Loan Commitment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LongTermDebtAndLoanCommitmentTables</Role>
      <ShortName>Long-Term Debt and Loan Commitment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/LongTermDebtAndLoanCommitment</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/ShareBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/Leases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/FairValueMeasurements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Other Expense, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/OtherExpenseNetTables</Role>
      <ShortName>Other Expense, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/OtherExpenseNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Net Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/NetLossPerCommonShareTables</Role>
      <ShortName>Net Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/NetLossPerCommonShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Description of Business and Liquidity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail</Role>
      <ShortName>Description of Business and Liquidity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Summary of Significant Accounting Policies - Schedule of Aggregate Amounts of Cash, Cash Equivalents, and Restricted Cash (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Aggregate Amounts of Cash, Cash Equivalents, and Restricted Cash (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Business Combination with MAAC -  Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail</Role>
      <ShortName>Business Combination with MAAC -  Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/InvestmentsAdditionalInformationDetail</Role>
      <ShortName>Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Asset Acquisitions and License Agreements -Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>Asset Acquisitions and License Agreements -Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Long-Term Debt and Loan Commitment - Summary of Long-Term Debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail</Role>
      <ShortName>Long-Term Debt and Loan Commitment - Summary of Long-Term Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Long-Term Debt and Loan Commitment  - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail</Role>
      <ShortName>Long-Term Debt and Loan Commitment  - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Long-Term Debt and Loan Commitment - Schedule of Company's Annual Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail</Role>
      <ShortName>Long-Term Debt and Loan Commitment - Schedule of Company's Annual Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Shareholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Shareholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Share-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Share-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Share-Based Compensation - Schedule of Fair Value Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail</Role>
      <ShortName>Share-Based Compensation - Schedule of Fair Value Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Share-Based Compensation - Summary of Fair Value of Vested Stock Option (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Fair Value of Vested Stock Option (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Share-Based Compensation - Summary of Restricted Stock Units (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Restricted Stock Units (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Share-Based Compensation - Summary of Performance Options Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Performance Options Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Share-Based Compensation - Summary of Capped Value Appreciation Rights (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Capped Value Appreciation Rights (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Income Taxes - Schedule of Loss Before Income Taxes by Geographic Region (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail</Role>
      <ShortName>Income Taxes - Schedule of Loss Before Income Taxes by Geographic Region (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Income Taxes - Schedule Components of Income Tax Expense (Benefit) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail</Role>
      <ShortName>Income Taxes - Schedule Components of Income Tax Expense (Benefit) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Leases - Schedule of Operating Lease Costs (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail</Role>
      <ShortName>Leases - Schedule of Operating Lease Costs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Leases - Summary of Operating Lease ROU Assets and Operating Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Summary of Operating Lease ROU Assets and Operating Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Schedule of Maturities of Operating Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Fair Value Measurements - Change in the Fair Value of the Derivative Warrant Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail</Role>
      <ShortName>Fair Value Measurements - Change in the Fair Value of the Derivative Warrant Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure -  Fair Value Measurements - Schedule of Change IN Fair Value of the Level 3 Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurementsScheduleOfChangeInFairValueOfTheLevel3AssetsDetail</Role>
      <ShortName>Fair Value Measurements - Schedule of Change IN Fair Value of the Level 3 Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure -  Fair Value Measurements - Schedule of Fair Value of Significant Unobservable Inputs Using Valuation Techniques (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value of Significant Unobservable Inputs Using Valuation Techniques (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Unobservable Input Related To Options to Acquire Under Sumitomo Transaction Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value of Unobservable Input Related To Options to Acquire Under Sumitomo Transaction Agreement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure - Other Expense, Net - Summary of Other Expense, Net From Continuing Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail</Role>
      <ShortName>Other Expense, Net - Summary of Other Expense, Net From Continuing Operations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure - Net Loss per Common Share - Summary Of Potentially Dilutive Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail</Role>
      <ShortName>Net Loss per Common Share - Summary Of Potentially Dilutive Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="d307489d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="d307489d10k.htm">d307489d10k.htm</File>
    <File>d307489dex101.htm</File>
    <File>d307489dex102.htm</File>
    <File>d307489dex1028.htm</File>
    <File>d307489dex103.htm</File>
    <File>d307489dex1036.htm</File>
    <File>d307489dex1037.htm</File>
    <File>d307489dex1038.htm</File>
    <File>d307489dex104.htm</File>
    <File>d307489dex21.htm</File>
    <File>d307489dex211.htm</File>
    <File>d307489dex231.htm</File>
    <File>d307489dex29.htm</File>
    <File>d307489dex311.htm</File>
    <File>d307489dex312.htm</File>
    <File>d307489dex321.htm</File>
    <File>d307489dex322.htm</File>
    <File>roiv-20220331.xsd</File>
    <File>roiv-20220331_cal.xml</File>
    <File>roiv-20220331_def.xml</File>
    <File>roiv-20220331_lab.xml</File>
    <File>roiv-20220331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g307489g11i11.jpg</File>
    <File>g307489g22i22.jpg</File>
    <File>g307489g22s22.jpg</File>
    <File>g307489g23s23.jpg</File>
    <File>g307489g24s24.jpg</File>
    <File>g307489g25s25.jpg</File>
    <File>g307489g26b78.jpg</File>
    <File>g307489g26s26.jpg</File>
    <File>g307489g27s27.jpg</File>
    <File>g307489g28b91.jpg</File>
    <File>g307489g28s28.jpg</File>
    <File>g307489g30c61.jpg</File>
    <File>g307489g32c36.jpg</File>
    <File>g307489g32c71.jpg</File>
    <File>g307489g33i33.jpg</File>
    <File>g307489g35c14.jpg</File>
    <File>g307489g35d33.jpg</File>
    <File>g307489g38e50.jpg</File>
    <File>g307489g44i44.jpg</File>
    <File>g307489g55i55.jpg</File>
    <File>g307489g66i66.jpg</File>
    <File>g307489g77i77.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="742">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="42">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>126
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d307489d10k.htm": {
   "axisCustom": 6,
   "axisStandard": 34,
   "contextCount": 346,
   "dts": {
    "calculationLink": {
     "local": [
      "roiv-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "roiv-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d307489d10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "roiv-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "roiv-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "roiv-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 793,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 6,
    "http://roivant.com/20220331": 7,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 18
   },
   "keyCustom": 131,
   "keyStandard": 348,
   "memberCustom": 94,
   "memberStandard": 36,
   "nsprefix": "roiv",
   "nsuri": "http://roivant.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover",
     "role": "http://roivant.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://roivant.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Business Combination with MAAC",
     "role": "http://roivant.com/role/BusinessCombinationWithMaac",
     "shortName": "Business Combination with MAAC",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Investments",
     "role": "http://roivant.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "roiv:AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Asset Acquisitions and License Agreements",
     "role": "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreements",
     "shortName": "Asset Acquisitions and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "roiv:AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Accrued Expenses",
     "role": "http://roivant.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Long-Term Debt and Loan Commitment",
     "role": "http://roivant.com/role/LongTermDebtAndLoanCommitment",
     "shortName": "Long-Term Debt and Loan Commitment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Related Party Transactions",
     "role": "http://roivant.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Shareholders' Equity",
     "role": "http://roivant.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Share-Based Compensation",
     "role": "http://roivant.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Income Taxes",
     "role": "http://roivant.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Consolidated Balance Sheets",
     "role": "http://roivant.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Leases",
     "role": "http://roivant.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Commitments & Contingencies",
     "role": "http://roivant.com/role/CommitmentsContingencies",
     "shortName": "Commitments & Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022_RoivantSciencesLtd.MemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Fair Value Measurements",
     "role": "http://roivant.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022_RoivantSciencesLtd.MemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Other Expense, Net",
     "role": "http://roivant.com/role/OtherExpenseNet",
     "shortName": "Other Expense, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Net Loss per Common Share",
     "role": "http://roivant.com/role/NetLossPerCommonShare",
     "shortName": "Net Loss per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Subsequent Events",
     "role": "http://roivant.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://roivant.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Long-Term Debt and Loan Commitment (Tables)",
     "role": "http://roivant.com/role/LongTermDebtAndLoanCommitmentTables",
     "shortName": "Long-Term Debt and Loan Commitment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://roivant.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://roivant.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Income Taxes (Tables)",
     "role": "http://roivant.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Leases (Tables)",
     "role": "http://roivant.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://roivant.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Other Expense, Net (Tables)",
     "role": "http://roivant.com/role/OtherExpenseNetTables",
     "shortName": "Other Expense, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Net Loss per Common Share (Tables)",
     "role": "http://roivant.com/role/NetLossPerCommonShareTables",
     "shortName": "Net Loss per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Description of Business and Liquidity - Additional Information (Detail)",
     "role": "http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail",
     "shortName": "Description of Business and Liquidity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segment",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EscrowDeposit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EscrowDeposit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Summary of Significant Accounting Policies - Schedule of Aggregate Amounts of Cash, Cash Equivalents, and Restricted Cash (Detail)",
     "role": "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Aggregate Amounts of Cash, Cash Equivalents, and Restricted Cash (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Detail)",
     "role": "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Consolidated Statements of Operations",
     "role": "http://roivant.com/role/ConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn05_31_2021",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Business Combination with MAAC -  Additional Information (Detail)",
     "role": "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
     "shortName": "Business Combination with MAAC -  Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "INF",
      "lang": null,
      "name": "roiv:CommonStockWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Investments - Additional Information (Detail)",
     "role": "http://roivant.com/role/InvestmentsAdditionalInformationDetail",
     "shortName": "Investments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P07_27_2021To07_27_2021_DatavantMergerMemberusgaapBusinessAcquisitionAxis",
      "decimals": "-6",
      "lang": null,
      "name": "roiv:ProceedsFromSaleOfInvestment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Asset Acquisitions and License Agreements -Additional Information (Detail)",
     "role": "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
     "shortName": "Asset Acquisitions and License Agreements -Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P09_01_2021To09_30_2021",
      "decimals": "-5",
      "lang": null,
      "name": "roiv:AcquiredInProcessResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "role": "http://roivant.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "roiv:DebtInstrumentValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Long-Term Debt and Loan Commitment - Summary of Long-Term Debt (Detail)",
     "role": "http://roivant.com/role/LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail",
     "shortName": "Long-Term Debt and Loan Commitment - Summary of Long-Term Debt (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "roiv:DebtInstrumentValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn05_31_2019",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Long-Term Debt and Loan Commitment  - Additional Information (Detail)",
     "role": "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
     "shortName": "Long-Term Debt and Loan Commitment  - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn05_31_2019",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - Long-Term Debt and Loan Commitment - Schedule of Company's Annual Payments (Detail)",
     "role": "http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail",
     "shortName": "Long-Term Debt and Loan Commitment - Schedule of Company's Annual Payments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "roiv:EquityInterestOptionToThirdPartyPurchaserGainOnTermination",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - Related Party Transactions - Additional Information (Detail)",
     "role": "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
     "shortName": "Related Party Transactions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn05_31_2021_AssetPurchaseAgreementMemberROIVAgreementAxis",
      "decimals": "-5",
      "lang": null,
      "name": "roiv:AssetPurchaseTransactionConsiderationReceivedInCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn05_31_2021",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - Shareholders' Equity - Additional Information (Detail)",
     "role": "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail",
     "shortName": "Shareholders' Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn02_14_2022_CantorFitzgeraldCo.MemberusgaapRelatedPartyTransactionAxis",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - Share-Based Compensation - Additional Information (Detail)",
     "role": "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
     "shortName": "Share-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Consolidated Statements of Operations (Parenthetical)",
     "role": "http://roivant.com/role/ConsolidatedStatementsOfOperationsParenthetical",
     "shortName": "Consolidated Statements of Operations (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - Share-Based Compensation - Schedule of Fair Value Assumptions (Detail)",
     "role": "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail",
     "shortName": "Share-Based Compensation - Schedule of Fair Value Assumptions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "roiv:ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "roiv:IntrinsicValueOfOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure - Share-Based Compensation - Summary of Fair Value of Vested Stock Option (Detail)",
     "role": "http://roivant.com/role/ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail",
     "shortName": "Share-Based Compensation - Summary of Fair Value of Vested Stock Option (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "roiv:ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "roiv:IntrinsicValueOfOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2021_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure - Share-Based Compensation - Summary of Restricted Stock Units (Detail)",
     "role": "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail",
     "shortName": "Share-Based Compensation - Summary of Restricted Stock Units (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2021_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis_RSLEquityPlansMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure - Share-Based Compensation - Summary of Performance Options Activity (Detail)",
     "role": "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
     "shortName": "Share-Based Compensation - Summary of Performance Options Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022_RSLEquityPlansMemberusgaapPlanNameAxis_StockOptionsAndPerformanceStockOptionsMemberusgaapAwardTypeAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "roiv:ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure - Share-Based Compensation - Summary of Capped Value Appreciation Rights (Detail)",
     "role": "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
     "shortName": "Share-Based Compensation - Summary of Capped Value Appreciation Rights (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "roiv:ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure - Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail)",
     "role": "http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail",
     "shortName": "Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure - Income Taxes - Schedule of Loss Before Income Taxes by Geographic Region (Detail)",
     "role": "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail",
     "shortName": "Income Taxes - Schedule of Loss Before Income Taxes by Geographic Region (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure - Income Taxes - Schedule Components of Income Tax Expense (Benefit) (Detail)",
     "role": "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail",
     "shortName": "Income Taxes - Schedule Components of Income Tax Expense (Benefit) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Detail)",
     "role": "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)",
     "role": "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure - Leases - Schedule of Operating Lease Costs (Detail)",
     "role": "http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail",
     "shortName": "Leases - Schedule of Operating Lease Costs (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure - Leases - Summary of Operating Lease ROU Assets and Operating Lease Liabilities (Detail)",
     "role": "http://roivant.com/role/LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail",
     "shortName": "Leases - Summary of Operating Lease ROU Assets and Operating Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Detail)",
     "role": "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail",
     "shortName": "Leases - Schedule of Maturities of Operating Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022_MasterSubscriptionAgreementMemberROIVAgreementAxis",
      "decimals": "-2",
      "first": true,
      "lang": null,
      "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1064 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://roivant.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022_MasterSubscriptionAgreementMemberROIVAgreementAxis",
      "decimals": "-2",
      "first": true,
      "lang": null,
      "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1065 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)",
     "role": "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
     "shortName": "Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivPublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapFairValueByLiabilityClassAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1066 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Parenthetical) (Detail)",
     "role": "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail",
     "shortName": "Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_RoivPublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapFairValueByLiabilityClassAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2021_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "roiv:EquityInterestOptionToThirdPartyPurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1067 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2021_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "roiv:EquityInterestOptionToThirdPartyPurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1068 - Disclosure - Fair Value Measurements - Change in the Fair Value of the Derivative Warrant Liabilities (Detail)",
     "role": "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail",
     "shortName": "Fair Value Measurements - Change in the Fair Value of the Derivative Warrant Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1069 - Disclosure -  Fair Value Measurements - Schedule of Change IN Fair Value of the Level 3 Assets (Detail)",
     "role": "http://roivant.com/role/FairValueMeasurementsScheduleOfChangeInFairValueOfTheLevel3AssetsDetail",
     "shortName": "Fair Value Measurements - Schedule of Change IN Fair Value of the Level 3 Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2020_RedeemableNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007 - Statement - Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest",
     "role": "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
     "shortName": "Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2020_RedeemableNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022_DatavantMemberdeiLegalEntityAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "roiv:FairValueAssetMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1070 - Disclosure -  Fair Value Measurements - Schedule of Fair Value of Significant Unobservable Inputs Using Valuation Techniques (Detail)",
     "role": "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail",
     "shortName": "Fair Value Measurements - Schedule of Fair Value of Significant Unobservable Inputs Using Valuation Techniques (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "PAsOn03_31_2022_DatavantMemberdeiLegalEntityAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "roiv:FairValueAssetMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P03_01_2021To03_31_2021_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "roiv:AlternativeInvestmentExpectedTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1071 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Unobservable Input Related To Options to Acquire Under Sumitomo Transaction Agreement (Detail)",
     "role": "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail",
     "shortName": "Fair Value Measurements - Schedule of Fair Value of Unobservable Input Related To Options to Acquire Under Sumitomo Transaction Agreement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P03_01_2021To03_31_2021_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_SumitomoOptionsMemberusgaapFairValueByLiabilityClassAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "roiv:AlternativeInvestmentExpectedTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1072 - Disclosure - Other Expense, Net - Summary of Other Expense, Net From Continuing Operations (Detail)",
     "role": "http://roivant.com/role/OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail",
     "shortName": "Other Expense, Net - Summary of Other Expense, Net From Continuing Operations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
       "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InterestIncomeOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022_StockOptionsAndPerformanceStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1073 - Disclosure - Net Loss per Common Share - Summary Of Potentially Dilutive Securities (Detail)",
     "role": "http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail",
     "shortName": "Net Loss per Common Share - Summary Of Potentially Dilutive Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022_StockOptionsAndPerformanceStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2022To06_30_2022_GSKMembersrtCounterpartyNameAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "roiv:MilestonePaymentPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1074 - Disclosure - Subsequent Events - Additional Information (Detail)",
     "role": "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail",
     "shortName": "Subsequent Events - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2022To06_30_2022_GSKMembersrtCounterpartyNameAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "roiv:MilestonePaymentPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://roivant.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "roiv:NonCashAcquiredInProcessResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Description of Business and Liquidity",
     "role": "http://roivant.com/role/DescriptionOfBusinessAndLiquidity",
     "shortName": "Description of Business and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d307489d10k.htm",
      "contextRef": "P04_01_2021To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 142,
   "tag": {
    "country_BM": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BERMUDA",
        "terseLabel": "Bermuda [Member]"
       }
      }
     },
     "localname": "BM",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CH": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SWITZERLAND",
        "terseLabel": "Switzerland [Member]"
       }
      }
     },
     "localname": "CH",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_GB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "United Kingdom [Member]"
       }
      }
     },
     "localname": "GB",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r648",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r648",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r648",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r648",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://roivant.com/role/ConsolidatedBalanceSheets",
      "http://roivant.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/ConsolidatedStatementsOfOperations",
      "http://roivant.com/role/FairValueMeasurements",
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail",
      "http://roivant.com/role/FairValueMeasurementsTables",
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPolicies",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r648",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://roivant.com/role/ConsolidatedBalanceSheets",
      "http://roivant.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/ConsolidatedStatementsOfOperations",
      "http://roivant.com/role/FairValueMeasurements",
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail",
      "http://roivant.com/role/FairValueMeasurementsTables",
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPolicies",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "roiv_AccessFeePaidToRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Access Fee Paid to Related Party.",
        "label": "Access Fee Paid to Related Party",
        "terseLabel": "Access fee paid pursuant to strategic cooperation agreement"
       }
      }
     },
     "localname": "AccessFeePaidToRelatedParty",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_AccruedLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued liabilities.",
        "label": "Accrued Liabilities [Line Items]"
       }
      }
     },
     "localname": "AccruedLiabilitiesLineItems",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Achievement Of Liquidity Event Vesting Condition Upon Closing Of Business Combination [Member]"
       }
      }
     },
     "localname": "AchievementOfLiquidityEventVestingConditionUponClosingOfBusinessCombinationMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_AcquiredInProcessResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfOperations": {
       "order": 11.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired in process research and development expense.",
        "label": "Acquired In Process Research and Development Expense",
        "terseLabel": "Acquired in-process research and development",
        "verboseLabel": "Acquired in process research and development expense"
       }
      }
     },
     "localname": "AcquiredInProcessResearchAndDevelopmentExpense",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments of payment of subscription receivable value equity component.",
        "label": "Adjustments Of Payment Of Subscription Receivable Value Equity Component",
        "terseLabel": "Payment of subscription receivable"
       }
      }
     },
     "localname": "AdjustmentsOfPaymentOfSubscriptionReceivableValueEquityComponent",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_AffivantSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affivant Sciences [Member]",
        "label": "Affivant Sciences [Member]",
        "terseLabel": "Affivant Sciences [Member]"
       }
      }
     },
     "localname": "AffivantSciencesMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement [Axis].",
        "label": "Agreement [Axis]"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_AgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement [Domain].",
        "label": "Agreement [Domain]"
       }
      }
     },
     "localname": "AgreementDomain",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement related billed amount for costs incurred on behalf of subsidiary,net of amounts billed by subsidiary.",
        "label": "Agreement Related Billed Amount For Costs Incurred On Behalf Of Subsidiary,Net Of Amounts Billed By Subsidiary",
        "terseLabel": "Cost incurred and recorded as offsets to general and administrative expenses"
       }
      }
     },
     "localname": "AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement related to amendment terms additional consideration received by subsidiary.",
        "label": "Agreement Related To Amendment Terms Additional Consideration Received By Subsidiary",
        "terseLabel": "Agreement related to amendment terms additional consideration received by subsidiary"
       }
      }
     },
     "localname": "AgreementRelatedToAmendmentTermsAdditionalConsiderationReceivedBySubsidiary",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_Allocationoftransactioncostsincurredtowarrantsandearnoutshares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocation of transaction costs incurred to warrants and earn-out shares.",
        "label": "AllocationOfTransactionCostsIncurredToWarrantsAndEarnoutShares",
        "terseLabel": "Allocation of transaction costs incurred to warrants and earn-out shares"
       }
      }
     },
     "localname": "Allocationoftransactioncostsincurredtowarrantsandearnoutshares",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_AlternativeInvestmentExpectedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alternative investment expected term.",
        "label": "Alternative Investment Expected Term",
        "terseLabel": "Time to expiration (in years)"
       }
      }
     },
     "localname": "AlternativeInvestmentExpectedTerm",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "roiv_AnnualNOLUtilizationLimitationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual NOL utilization limitation percentage.",
        "label": "Annual NOL Utilization Limitation Percentage",
        "terseLabel": "Annual NOL utilization limitation percentage"
       }
      }
     },
     "localname": "AnnualNOLUtilizationLimitationPercentage",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "roiv_ArbutusBiopharmaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arbutus Biopharma Corporation [Member]",
        "label": "Arbutus Biopharma Corporation [Member]",
        "terseLabel": "Arbutus Biopharma Corporation [Member]"
       }
      }
     },
     "localname": "ArbutusBiopharmaCorporationMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisitions and license agreements disclosure.",
        "label": "Asset Acquisitions and License Agreements Disclosure [Text Block]",
        "terseLabel": "Asset Acquisitions and License Agreements"
       }
      }
     },
     "localname": "AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "roiv_AssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Purchase Agreement [Member]"
       }
      }
     },
     "localname": "AssetPurchaseAgreementMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_AssetPurchaseTransactionConsiderationReceivedInCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Transaction Consideration Received In Cash.",
        "label": "Asset Purchase Transaction Consideration Received In Cash",
        "presentationGuidance": "Consideration received in cash"
       }
      }
     },
     "localname": "AssetPurchaseTransactionConsiderationReceivedInCash",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_BalanceSheetComponentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance Sheet Components [Table]",
        "label": "Balance Sheet Components [Table]",
        "terseLabel": "Balance Sheet Components [Table]"
       }
      }
     },
     "localname": "BalanceSheetComponentsTable",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_BusinessAcquisitionConsiderationTransferred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition Consideration Transferred.",
        "label": "Business Acquisition Consideration Transferred",
        "verboseLabel": "Business acquisition, consideration transferred"
       }
      }
     },
     "localname": "BusinessAcquisitionConsiderationTransferred",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition Recognized Identifiable Assets Acquired And Liabilities Assumed Net.",
        "label": "Business Acquisition Recognized Identifiable Assets Acquired And Liabilities Assumed Net",
        "terseLabel": "Business Acquisition, recognized identifiable assets acquired and liabilities assumed, assets"
       }
      }
     },
     "localname": "BusinessAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_BusinessCombinationAgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination Agreement .",
        "label": "Business Combination Agreement [Axis]"
       }
      }
     },
     "localname": "BusinessCombinationAgreementAxis",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_BusinessCombinationAgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination Agreement .",
        "label": "Business Combination Agreement [Domain]"
       }
      }
     },
     "localname": "BusinessCombinationAgreementDomain",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_BusinessCombinationWithMAACLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination with M A A C .",
        "label": "Business Combination with M A A C [Line Items]"
       }
      }
     },
     "localname": "BusinessCombinationWithMAACLineItems",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_BusinesscombinationwithmaacTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BusinessCombinationWithMAAC .",
        "label": "BusinessCombinationWithMAAC [Table]",
        "terseLabel": "Business Combination with MAAC [Table]"
       }
      }
     },
     "localname": "BusinesscombinationwithmaacTable",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_CantorFitzgeraldCo.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cantor Fitzgerald Co. [Member]"
       }
      }
     },
     "localname": "CantorFitzgeraldCo.Member",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_CapitalContributionsToSubsidiaries": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital Contributions To Subsidiaries",
        "label": "Capital Contributions To Subsidiaries",
        "terseLabel": "Cash contribution to majority-owned subsidiaries"
       }
      }
     },
     "localname": "CapitalContributionsToSubsidiaries",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_CappedValueAppreciationRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capped Value Appreciation Rights [Member]",
        "label": "Capped Value Appreciation Rights [Member]",
        "terseLabel": "CVARs [Member]"
       }
      }
     },
     "localname": "CappedValueAppreciationRightsMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_CashAndCashEquivalentsAndRestrictedCash": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Cash Equivalents and Restricted Cash",
        "label": "Cash and Cash Equivalents and Restricted Cash",
        "totalLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndRestrictedCash",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_CashPaidToSettleDeferredConsiderationLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid to settle deferred consideration liability.",
        "label": "Cash Paid To Settle Deferred Consideration Liability",
        "terseLabel": "Cash paid to settle deferred consideration liability"
       }
      }
     },
     "localname": "CashPaidToSettleDeferredConsiderationLiability",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ClassOfWarrantOrRightCanceled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Canceled.",
        "label": "Class Of Warrant Or Right Canceled"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightCanceled",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_ClassOfWarrantOrRightExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercisable",
        "label": "Class of Warrant or Right, Exercisable",
        "terseLabel": "Number of exercisable outstanding warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisable",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_Classofwarrantsredemptionnoticeperiod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants, redemption notice period.",
        "label": "ClassOfWarrantsRedemptionNoticePeriod",
        "terseLabel": "Class of warrants, redemption notice period"
       }
      }
     },
     "localname": "Classofwarrantsredemptionnoticeperiod",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "roiv_Classofwarrantsredemptionpriceperunit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants, redemption price per unit.",
        "label": "ClassOfWarrantsRedemptionPricePerUnit",
        "terseLabel": "Class of warrants, redemption price per unit"
       }
      }
     },
     "localname": "Classofwarrantsredemptionpriceperunit",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "roiv_CollaborationAgreementWithBlueprintMedicinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement with blueprint medicines.",
        "label": "Collaboration Agreement With Blueprint Medicines [Member]"
       }
      }
     },
     "localname": "CollaborationAgreementWithBlueprintMedicinesMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_CombinedCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Company [Member]"
       }
      }
     },
     "localname": "CombinedCompanyMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_CommercialMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Milestone [Member]",
        "label": "Commercial Milestone [Member]",
        "terseLabel": "Commercial Milestone [Member]"
       }
      }
     },
     "localname": "CommercialMilestoneMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_CommittedFundingUnderRIPSA": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Committed Funding Under RIPSA.",
        "label": "Committed Funding Under RIPSA",
        "terseLabel": "Committed funding under RIPSA"
       }
      }
     },
     "localname": "CommittedFundingUnderRIPSA",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Committed Funding Under Revenue Interest Purchase And Sale Agreement.",
        "label": "Committed Funding Under Revenue Interest Purchase And Sale Agreement",
        "terseLabel": "Securities Purchased under Agreements to Resell"
       }
      }
     },
     "localname": "CommittedFundingUnderRevenueInterestPurchaseAndSaleAgreement",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_CommonSharesValueAvailableForSale": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Shares Value Available For Sale.",
        "label": "Common Shares Value Available For Sale",
        "terseLabel": "Common Shares Value Available For Sale"
       }
      }
     },
     "localname": "CommonSharesValueAvailableForSale",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_CommonStockWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants.",
        "label": "Common Stock Warrants"
       }
      }
     },
     "localname": "CommonStockWarrants",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_ComponentsOfIncomeTaxExpenseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components Of Income Tax Expense [Line Items]",
        "label": "Components Of Income Tax Expense [Line Items]",
        "terseLabel": "Components Of Income Tax Expense [Line Items]"
       }
      }
     },
     "localname": "ComponentsOfIncomeTaxExpenseLineItems",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_ComponentsOfIncomeTaxExpenseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components Of Income Tax Expense [Table]",
        "label": "Components Of Income Tax Expense [Table]",
        "terseLabel": "Components Of Income Tax Expense [Table]"
       }
      }
     },
     "localname": "ComponentsOfIncomeTaxExpenseTable",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_ConsolidationOfUnconsolidatedEntity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidation of Unconsolidated Entity",
        "label": "Consolidation of Unconsolidated Entity",
        "terseLabel": "Consolidation of unconsolidated entity"
       }
      }
     },
     "localname": "ConsolidationOfUnconsolidatedEntity",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_Costsincurredrelatedtofinancing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred related to financing.",
        "label": "CostsIncurredRelatedToFinancing",
        "terseLabel": "Costs Incurred Related To Financing"
       }
      }
     },
     "localname": "Costsincurredrelatedtofinancing",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DatavantHoldingsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Datavant Holdings, Inc [Member]",
        "label": "Datavant Holdings, Inc [Member]",
        "terseLabel": "Datavant Holdings, Inc [Member]"
       }
      }
     },
     "localname": "DatavantHoldingsIncMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_DatavantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Datavant [Member].",
        "label": "Datavant [Member]",
        "terseLabel": "Datavant [Member]",
        "verboseLabel": "Datavant [Member]"
       }
      }
     },
     "localname": "DatavantMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail",
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_DatavantMergerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Datavant Merger .",
        "label": "Datavant Merger [Member]",
        "terseLabel": "Datavant Merger [Member]"
       }
      }
     },
     "localname": "DatavantMergerMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_DebtInstrumentExitFeeAndEndOfTermCharge": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument exit fee and end of term charge.",
        "label": "Debt Instrument Exit Fee and End of Term Charge",
        "terseLabel": "Exit fee / end of term charge"
       }
      }
     },
     "localname": "DebtInstrumentExitFeeAndEndOfTermCharge",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DebtInstrumentValue": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Value.",
        "label": "Debt Instrument Value",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentValue",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfOperations": {
       "order": 16.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deconsolidation and consolidation on gain or loss of consolidated entity.",
        "label": "Deconsolidation and Consolidation on Gain or Loss of Consolidated Entity",
        "negatedLabel": "Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity"
       }
      }
     },
     "localname": "DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DeconsolidationOfSubsidiary": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deconsolidation Of Subsidiary",
        "label": "Deconsolidation Of Subsidiary",
        "terseLabel": "Deconsolidation of subsidiary"
       }
      }
     },
     "localname": "DeconsolidationOfSubsidiary",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DeferredConsiderationLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 26.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred consideration liability current.",
        "label": "Deferred Consideration Liability Current",
        "terseLabel": "Deferred consideration liability"
       }
      }
     },
     "localname": "DeferredConsiderationLiabilityCurrent",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease liabilities",
        "label": "Deferred tax assets lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DeferredTaxAssetsLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Liabilities [Line Items]",
        "label": "Deferred Tax Assets Liabilities [Line Items]",
        "terseLabel": "Deferred Tax Assets Liabilities [Line Items]"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesLineItems",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_DeferredTaxAssetsLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Liabilities [Table]",
        "label": "Deferred Tax Assets Liabilities [Table]",
        "terseLabel": "Deferred Tax Assets Liabilities [Table]"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesTable",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_DeferredTaxLiabilitiesDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Depreciation",
        "label": "Deferred Tax Liabilities, Depreciation",
        "negatedLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDepreciation",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right of use assets",
        "label": "Deferred tax liabilities right of use assets",
        "negatedLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DevelopmentAndRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development And Regulatory Milestone [Member]",
        "label": "Development And Regulatory Milestone [Member]",
        "terseLabel": "Development And Regulatory Milestone [Member]"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestoneMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_EarnOutSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earn-Out share price.",
        "label": "Earn Out Share Price",
        "terseLabel": "Earn-Out share price"
       }
      }
     },
     "localname": "EarnOutSharePrice",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "roiv_EarnOutSharesNonvestedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earn out shares nonvested.",
        "label": "Earn Out Shares Nonvested [Member]",
        "terseLabel": "Earn-Out Shares (non-vested) [Member]"
       }
      }
     },
     "localname": "EarnOutSharesNonvestedMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_EarnoutSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout shares.",
        "label": "Earnout Shares [Member]",
        "terseLabel": "Earnout Shares [Member]",
        "verboseLabel": "Earnout Shares [Member]"
       }
      }
     },
     "localname": "EarnoutSharesMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail",
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_EffectiveTaxRateReconcilingItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciling Items [Line Items]",
        "label": "Effective Tax Rate Reconciling Items [Line Items]",
        "terseLabel": "Effective Tax Rate Reconciling Items [Line Items]"
       }
      }
     },
     "localname": "EffectiveTaxRateReconcilingItemsLineItems",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_EffectiveTaxRateReconcilingItemsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciling Items [Table]",
        "label": "Effective Tax Rate Reconciling Items [Table]",
        "terseLabel": "Effective Tax Rate Reconciling Items [Table]"
       }
      }
     },
     "localname": "EffectiveTaxRateReconcilingItemsTable",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_EmployeeRelatedExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Related Expenses [Member]",
        "label": "Employee Related Expenses [Member]",
        "terseLabel": "Employee Related Expenses [Member]"
       }
      }
     },
     "localname": "EmployeeRelatedExpensesMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan maximum number of common shares issuable.",
        "label": "Employee Stock Purchase Plan Maximum Number Of Common Shares Issuable",
        "terseLabel": "Employee stock purchase plan maximum number of common shares issuable"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumNumberOfCommonSharesIssuable",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_EquityInterestOptionToThirdPartyPurchase": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity interest option to third-party purchase.",
        "label": "Equity Interest Option to Third Party Purchase",
        "terseLabel": "Fair value of options"
       }
      }
     },
     "localname": "EquityInterestOptionToThirdPartyPurchase",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfOperations": {
       "order": 15.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity interest option to third party purchaser gain on termination.",
        "label": "Equity Interest Option to Third Party Purchaser Gain on Termination",
        "negatedLabel": "Gain on termination of Sumitomo Options",
        "presentationGuidance": "Gain on termination of Sumitomo Options"
       }
      }
     },
     "localname": "EquityInterestOptionToThirdPartyPurchaserGainOnTermination",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperations",
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_EventAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Event [Axis]"
       }
      }
     },
     "localname": "EventAxis",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_EventDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Event [Domain]"
       }
      }
     },
     "localname": "EventDomain",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_ExchangeRatioOfMAACClassBToRoivantCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Ratio Of M A A C Class B To Roivant Common Shares .",
        "label": "Exchange Ratio Of M A A C Class B To Roivant Common Shares",
        "terseLabel": "Exchange Ratio Of MAAC Class B To Roivant Common Shares"
       }
      }
     },
     "localname": "ExchangeRatioOfMAACClassBToRoivantCommonShares",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of Subsidiary Stock Options and Vesting of Subsidiary Restricted Stock Units",
        "label": "Exercise of Subsidiary Stock Options and Vesting of Subsidiary Restricted Stock Units",
        "terseLabel": "Exercise of subsidiary stock options and vesting of subsidiary restricted stock units"
       }
      }
     },
     "localname": "ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_FairValueAssetMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value asset measurement input.",
        "label": "Fair Value Asset Measurement Input",
        "terseLabel": "Fair Value Asset Measurement Input"
       }
      }
     },
     "localname": "FairValueAssetMeasurementInput",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "roiv_FairValueDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Disclosures [Line Items]",
        "label": "Fair Value Disclosures [Line Items]",
        "terseLabel": "Fair Value Disclosures [Line Items]"
       }
      }
     },
     "localname": "FairValueDisclosuresLineItems",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_FairValueDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Disclosures [Table]",
        "label": "Fair Value Disclosures [Table]",
        "terseLabel": "Fair Value Disclosures [Table]"
       }
      }
     },
     "localname": "FairValueDisclosuresTable",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis asset investment.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Investment",
        "terseLabel": "Fair value of investment in Datavant at recognition date"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInvestment",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfChangeInFairValueOfTheLevel3AssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, disposed due to deconsolidation of subsidiary.",
        "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Disposed Due to Deconsolidation of Subsidiary",
        "terseLabel": "Liability instruments disposed due to deconsolidation of subsidiary"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability settlements one.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements One",
        "terseLabel": "Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsOne",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_FairValueOfCommonShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Of Common Shares",
        "label": "Fair Value Of Common Shares",
        "terseLabel": "Fair value of common shares"
       }
      }
     },
     "localname": "FairValueOfCommonShares",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_FairValueOfRestrictedStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Of Restricted Stock",
        "label": "Fair Value Of Restricted Stock",
        "terseLabel": "Fair value of restricted stock"
       }
      }
     },
     "localname": "FairValueOfRestrictedStock",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Product First Product for Each Molecular Target Covered by Intellectual Property [Member]",
        "label": "First Product First Product for Each Molecular Target Covered by Intellectual Property [Member]",
        "terseLabel": "First Product First Product for Each Molecular Target Covered by Intellectual Property [Member]"
       }
      }
     },
     "localname": "FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Product Targets Each of Certain Specified Additional MolecularTargets [Member]",
        "label": "First Product Targets Each of Certain Specified Additional MolecularTargets [Member]",
        "terseLabel": "First Product Targets Each of Certain Specified Additional MolecularTargets [Member]"
       }
      }
     },
     "localname": "FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Product Targets Targeting Each of Two Specified Initial Targets [Member]",
        "label": "First Product Targets Targeting Each of Two Specified Initial Targets [Member]",
        "terseLabel": "First Product Targets Targeting Each of Two Specified Initial Targets [Member]"
       }
      }
     },
     "localname": "FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_FirstTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Tranche [Member]",
        "label": "First Tranche [Member]",
        "terseLabel": "First Tranche [Member]"
       }
      }
     },
     "localname": "FirstTrancheMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_FutureDevelopmentAndCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Development And Commercial Milestone Payments.",
        "label": "Future Development And Commercial Milestone Payments",
        "terseLabel": "Future development and commercial milestone payments"
       }
      }
     },
     "localname": "FutureDevelopmentAndCommercialMilestonePayments",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_GSKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "G S K [Member]",
        "terseLabel": "G S K"
       }
      }
     },
     "localname": "GSKMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://roivant.com/role/ConsolidatedStatementsOfOperations": {
       "order": 14.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Loss on Fair Value of Debt and Liability Instruments",
        "label": "Gain Loss on Fair Value of Debt and Liability Instruments",
        "negatedLabel": "Change in fair value of debt and liability instruments"
       }
      }
     },
     "localname": "GainLossOnFairValueOfDebtAndLiabilityInstruments",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity.",
        "label": "Gain On Deconsolidation Of Subsidiary And Consolidation Of Unconsolidated Entity",
        "negatedLabel": "Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity"
       }
      }
     },
     "localname": "GainOnDeconsolidationOfSubsidiaryAndConsolidationOfUnconsolidatedEntity",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_GainOnMeasurementOfInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on measurement of investment.",
        "label": "Gain On Measurement Of Investment",
        "terseLabel": "Gain on measurement of investment"
       }
      }
     },
     "localname": "GainOnMeasurementOfInvestment",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_GainOnTerminationOfEquityInterestOptions": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on termination of equity interest options.",
        "label": "Gain On Termination Of Equity Interest Options",
        "negatedLabel": "Gain on termination of Sumitomo Options"
       }
      }
     },
     "localname": "GainOnTerminationOfEquityInterestOptions",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_GeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General and Administrative Expenses, Policy [Text Block]",
        "label": "General and Administrative Expenses [Policy Text Block]",
        "terseLabel": "General and Administrative Expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "roiv_GenevantSciencesLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genevant Sciences Ltd [Member]",
        "label": "Genevant Sciences Ltd [Member]",
        "terseLabel": "Genevant Sciences Ltd [Member]"
       }
      }
     },
     "localname": "GenevantSciencesLtdMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from revenue interest purchase and sale agreement.",
        "label": "Gross Proceeds From Revenue Interest Purchase And Sale Agreement",
        "terseLabel": "Gross proceeds from revenue interest purchase and sale agreement."
       }
      }
     },
     "localname": "GrossProceedsFromRevenueInterestPurchaseAndSaleAgreement",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_HemavantSciencesGmbhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hemavant Sciences GmbH.",
        "label": "Hemavant Sciences GmbH [Member]"
       }
      }
     },
     "localname": "HemavantSciencesGmbhMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_ImmunovantINCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunovant INC.",
        "label": "Immunovant INC [Member]",
        "terseLabel": "Immunovant, Inc [Member]"
       }
      }
     },
     "localname": "ImmunovantINCMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_ImmunovantSciencesLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunovant Sciences Ltd [Member]",
        "label": "Immunovant Sciences Ltd [Member]",
        "terseLabel": "Immunovant Sciences Ltd [Member]"
       }
      }
     },
     "localname": "ImmunovantSciencesLtdMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Disclosure [Line Items]",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Disclosure [Table]",
        "label": "Income Tax Disclosure [Table]",
        "terseLabel": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_IncreaseDecreaseInOtherInvestingNet": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in other investing net.",
        "label": "Increase Decrease In Other Investing Net",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherInvestingNet",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_IncrementOfEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increment of employee stock purchase plan.",
        "label": "Increment of Employee Stock Purchase Plan",
        "terseLabel": "Increment of employee stock purchase plan"
       }
      }
     },
     "localname": "IncrementOfEmployeeStockPurchasePlan",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental fair value after march two thousand and twenty capped value appreciation rights amendment.",
        "label": "Incremental Fair Value After March Two Thousand And Twenty Capped Value Appreciation Rights Amendment",
        "terseLabel": "Incremental fair value after march two thousand and twenty capped value appreciation rights amendment."
       }
      }
     },
     "localname": "IncrementalFairValueAfterMarchTwoThousandAndTwentyCappedValueAppreciationRightsAmendment",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_IntrinsicValueOfOptionsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic Value Of Options Exercised.",
        "label": "Intrinsic Value Of Options Exercised",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "IntrinsicValueOfOptionsExercised",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment owned conversion includes both preferred stock and common stock.",
        "label": "Investment Owned Conversion Includes Both Preferred Stock and Common Stock",
        "terseLabel": "Investment owned conversion includes both preferred stock and common stock"
       }
      }
     },
     "localname": "InvestmentOwnedConversionIncludesBothPreferredStockAndCommonStock",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_InvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments [Line Items]",
        "label": "Investments [Line Items]",
        "terseLabel": "Investments [Line Items]"
       }
      }
     },
     "localname": "InvestmentsLineItems",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_InvestmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments [Table]",
        "label": "Investments [Table]",
        "terseLabel": "Investments [Table]"
       }
      }
     },
     "localname": "InvestmentsTable",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_IssuanceOfStockUponWarrantsExerciseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of stock upon warrants exercise shares.",
        "label": "Issuance Of Stock Upon Warrants Exercise Shares",
        "terseLabel": "Issuance of common stock upon warrants exercise, Shares"
       }
      }
     },
     "localname": "IssuanceOfStockUponWarrantsExerciseShares",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_IssuanceOfStockUponWarrantsExerciseValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of stock upon warrants exercise value.",
        "label": "Issuance Of Stock Upon Warrants Exercise Value",
        "terseLabel": "Issuance of common stock upon warrants exercise"
       }
      }
     },
     "localname": "IssuanceOfStockUponWarrantsExerciseValue",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_IssuanceOfSubsidiaryCommonSharesNetValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Subsidiary Common Shares Net Value",
        "label": "Issuance of Subsidiary Common Shares Net Value",
        "terseLabel": "Issuance of subsidiary common shares, net"
       }
      }
     },
     "localname": "IssuanceOfSubsidiaryCommonSharesNetValue",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Subsidiary Common Shares to the Company Value",
        "label": "Issuance of Subsidiary Common Shares to the Company Value",
        "terseLabel": "Issuance of subsidiary common shares to the Company"
       }
      }
     },
     "localname": "IssuanceOfSubsidiaryCommonSharesToTheCompanyValue",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_IssuanceOfSubsidiaryWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Subsidiary Warrants",
        "label": "Issuance of Subsidiary Warrants",
        "terseLabel": "Issuance of subsidiary warrants"
       }
      }
     },
     "localname": "IssuanceOfSubsidiaryWarrants",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_LaboratoryandotherequipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory\u00a0and\u00a0other\u00a0equipment",
        "label": "Laboratoryandotherequipment [Member]",
        "terseLabel": "Laboratory\u00a0and\u00a0other\u00a0equipment"
       }
      }
     },
     "localname": "LaboratoryandotherequipmentMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability tenant improvement allowance..",
        "label": "Lessee Operating Lease Liability Tenant Improvement Allowance",
        "negatedLabel": "Less: tenant improvement allowance"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementAllowance",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_LiabilityInstrumentsMeasuredAtFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 31.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability instruments measured at fair value.",
        "label": "Liability Instruments Measured At Fair Value",
        "terseLabel": "Liability instruments measured at fair value"
       }
      }
     },
     "localname": "LiabilityInstrumentsMeasuredAtFairValue",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_LiabilityInstrumentsMeasuredAtFairValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Instruments Measured At Fair Value [Member]",
        "label": "Liability Instruments Measured At Fair Value [Member]",
        "terseLabel": "Liability Instruments Measured At Fair Value [Member]"
       }
      }
     },
     "localname": "LiabilityInstrumentsMeasuredAtFairValueMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_LockUpAgreementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lock Up Agreements .",
        "label": "Lock Up Agreements [Axis]"
       }
      }
     },
     "localname": "LockUpAgreementsAxis",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_LockUpAgreementsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lock Up Agreements .",
        "label": "Lock Up Agreements [Domain]"
       }
      }
     },
     "localname": "LockUpAgreementsDomain",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_LockUpPeriodEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lock Up Period Eight .",
        "label": "Lock Up Period Eight [Member]"
       }
      }
     },
     "localname": "LockUpPeriodEightMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_LockUpPeriodFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lock Up Period Five .",
        "label": "Lock Up Period Five [Member]"
       }
      }
     },
     "localname": "LockUpPeriodFiveMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_LockUpPeriodFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lock Up Period Four .",
        "label": "Lock Up Period Four [Member]"
       }
      }
     },
     "localname": "LockUpPeriodFourMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_LockUpPeriodNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lock Up Period Nine .",
        "label": "Lock Up Period Nine [Member]"
       }
      }
     },
     "localname": "LockUpPeriodNineMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_LockUpPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lock Up Period One .",
        "label": "Lock Up Period One [Member]"
       }
      }
     },
     "localname": "LockUpPeriodOneMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_LockUpPeriodSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lock Up Period Seven .",
        "label": "Lock Up Period Seven [Member]"
       }
      }
     },
     "localname": "LockUpPeriodSevenMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_LockUpPeriodSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lock Up Period Six .",
        "label": "Lock Up Period Six [Member]"
       }
      }
     },
     "localname": "LockUpPeriodSixMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_LockUpPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lock Up Period Three .",
        "label": "Lock Up Period Three [Member]"
       }
      }
     },
     "localname": "LockUpPeriodThreeMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_LockUpPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lock Up Period Two .",
        "label": "Lock Up Period Two [Member]"
       }
      }
     },
     "localname": "LockUpPeriodTwoMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_Lockupperiodofcommonshares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lock up period of common shares.",
        "label": "LockUpPeriodOfCommonShares",
        "terseLabel": "Lock Up Period of Common Shares"
       }
      }
     },
     "localname": "Lockupperiodofcommonshares",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "roiv_Lockupperiodwarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lock up period ,warrants.",
        "label": "LockUpPeriodwarrants",
        "terseLabel": "Lock up period ,warrants"
       }
      }
     },
     "localname": "Lockupperiodwarrants",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "roiv_LongTermDebtExcludingDebtWithFairValueOption": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Debt Excluding Debt With Fair Value Option",
        "label": "Long Term Debt Excluding Debt With Fair Value Option",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtExcludingDebtWithFairValueOption",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_MaacClassASharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maac class a shares .",
        "label": "Maac Class A Shares [Member]"
       }
      }
     },
     "localname": "MaacClassASharesMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_MaacClassBSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maac class b shares.",
        "label": "Maac Class B Shares [Member]"
       }
      }
     },
     "localname": "MaacClassBSharesMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_MaacIndependentDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MAAC Independent Director .",
        "label": "MAAC Independent Director [Member]"
       }
      }
     },
     "localname": "MaacIndependentDirectorMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_MaacSponsorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MAAC sponsor .",
        "label": "MAAC Sponsor [Member]"
       }
      }
     },
     "localname": "MaacSponsorMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_March2020CappedValueAppreciationRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2020 Capped Value Appreciation Rights.",
        "label": "March 2020 Capped Value Appreciation Rights [Member]",
        "terseLabel": "March 2020 CVARs [Member]"
       }
      }
     },
     "localname": "March2020CappedValueAppreciationRightsMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_MasterSubscriptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master subscription agreement.",
        "label": "Master Subscription Agreement [Member]"
       }
      }
     },
     "localname": "MasterSubscriptionAgreementMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_MaximumMilestonePaymentObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum milestone payment obligation.",
        "label": "Maximum Milestone Payment Obligation",
        "terseLabel": "Maximum amount required milestone payments"
       }
      }
     },
     "localname": "MaximumMilestonePaymentObligation",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_MaximumMilestonePaymentOffsetAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Milestone Payment Offset Amount",
        "label": "Maximum Milestone Payment Offset Amount",
        "terseLabel": "Possible offset of regulatory milestone payments with commercial milestone"
       }
      }
     },
     "localname": "MaximumMilestonePaymentOffsetAmount",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_MaximumRedemptionFeaturePerWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum redemption feature per warrant.",
        "label": "Maximum Redemption Feature Per Warrant",
        "terseLabel": "Maximum redemption feature per warrant"
       }
      }
     },
     "localname": "MaximumRedemptionFeaturePerWarrant",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "roiv_MilestoneEventsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Events [Axis]",
        "label": "Milestone Events [Axis]",
        "terseLabel": "Milestone Events [Axis]"
       }
      }
     },
     "localname": "MilestoneEventsAxis",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_MilestoneEventsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Events [Domain]",
        "label": "Milestone Events [Domain]",
        "terseLabel": "Milestone Events [Domain]"
       }
      }
     },
     "localname": "MilestoneEventsDomain",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_MilestonePaymentDueOverSixYearPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment due over six year period.",
        "label": "Milestone Payment Due Over Six Year Period",
        "terseLabel": "Milestone payment due over six year period"
       }
      }
     },
     "localname": "MilestonePaymentDueOverSixYearPeriod",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_MilestonePaymentPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment payable.",
        "label": "Milestone Payment Payable",
        "terseLabel": "Milestone payment payable"
       }
      }
     },
     "localname": "MilestonePaymentPayable",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_MilestonePaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Period",
        "label": "Milestone Payment Period"
       }
      }
     },
     "localname": "MilestonePaymentPeriod",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "roiv_MontesArchimedesAcquisitionCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Montes Archimedes Acquisition Corp. [Member]",
        "label": "Montes Archimedes Acquisition Corp. [Member]"
       }
      }
     },
     "localname": "MontesArchimedesAcquisitionCorpMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_NonCashAcquiredInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash portion of acquired in process research and development.",
        "label": "Non Cash Acquired in Process Research and Development"
       }
      }
     },
     "localname": "NonCashAcquiredInProcessResearchAndDevelopment",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_NonRefundableUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Refundable Upfront Payment Received",
        "label": "Non Refundable Upfront Payment Received",
        "terseLabel": "Nonrefundable, upfront payment"
       }
      }
     },
     "localname": "NonRefundableUpfrontPaymentReceived",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_NovaquestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novaquest.",
        "label": "Novaquest [Member]",
        "terseLabel": "NovaQuest Agreement [Member]"
       }
      }
     },
     "localname": "NovaquestMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_NovemberTwoThousandAndTwentyOneCvarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "November two thousand and twenty one CVARS.",
        "label": "November Two Thousand And Twenty One Cvars [Member]",
        "terseLabel": "November 2021 CVARs [Member]"
       }
      }
     },
     "localname": "NovemberTwoThousandAndTwentyOneCvarsMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_Numberoftradingdaystomeetearnoutpricethreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of trading days to meet earn out price threshold.",
        "label": "NumberOfTradingDaysToMeetEarnOutPriceThreshold",
        "terseLabel": "Number of trading days to meet earn out price threshold"
       }
      }
     },
     "localname": "Numberoftradingdaystomeetearnoutpricethreshold",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "roiv_Numberoftradingdaystomeetwarrantredemptionthreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of trading days to meet warrant redemption threshold.",
        "label": "NumberOfTradingDaysToMeetWarrantRedemptionThreshold",
        "terseLabel": "Number of trading days to meet warrant redemption threshold"
       }
      }
     },
     "localname": "Numberoftradingdaystomeetwarrantredemptionthreshold",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "roiv_OneTimeCatchUpExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One time catch up expense",
        "label": "One Time Catch Up Expense",
        "terseLabel": "One time catch up expense"
       }
      }
     },
     "localname": "OneTimeCatchUpExpense",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_OperatingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfOperations": {
       "order": 8.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating costs.",
        "label": "Operating Costs",
        "terseLabel": "Cost of revenues"
       }
      }
     },
     "localname": "OperatingCosts",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_OperatingLeaseLiabilityPresentValueAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liability Present Value Adjustments",
        "label": "Operating Lease Liability Present Value Adjustments",
        "negatedLabel": "Less: present value adjustment"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityPresentValueAdjustments",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_OtherGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other General and Administrative Expenses [Member]",
        "label": "Other General and Administrative Expenses [Member]",
        "terseLabel": "Other General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_OtherIncomeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail": {
       "order": 4.0,
       "parentTag": "roiv_OtherOperatingIncomeExpensesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income Expense",
        "label": "Other Income Expense",
        "negatedLabel": "Other (expense) income"
       }
      }
     },
     "localname": "OtherIncomeExpense",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_OtherInstrumentsIssuedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other instruments issued.",
        "label": "Other Instruments Issued [Member]",
        "verboseLabel": "Other instruments issued [Member]"
       }
      }
     },
     "localname": "OtherInstrumentsIssuedMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other [Member]",
        "label": "Other [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_OtherNonCashTransactions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Non Cash Transactions",
        "label": "Other Non Cash Transactions",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherNonCashTransactions",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_OtherOperatingIncomeExpensesNet": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other operating income expenses net.",
        "label": "Other Operating Income Expenses Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpensesNet",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_PayableForEachAdditionalProductIndication": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payable for each additional product indication.",
        "label": "Payable For Each Additional Product Indication",
        "terseLabel": "Payable for each additional product indication"
       }
      }
     },
     "localname": "PayableForEachAdditionalProductIndication",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_PaymentForOfferingAndLoanCosts": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for offering and loan costs.",
        "label": "Payment For Offering And Loan Costs",
        "negatedLabel": "Payment of offering and loan origination costs"
       }
      }
     },
     "localname": "PaymentForOfferingAndLoanCosts",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_PaymentForUpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for upfront payments.",
        "label": "Payment For Upfront payments",
        "terseLabel": "Upfront proceeds"
       }
      }
     },
     "localname": "PaymentForUpfrontPayments",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_PaymentUnderSponsoredResearchAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment under sponsored research agreement.",
        "label": "Payment Under Sponsored Research Agreement",
        "terseLabel": "Payment under SRA"
       }
      }
     },
     "localname": "PaymentUnderSponsoredResearchAgreement",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_PercentageOfCommonSharesVolumeWeightedAveragePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of common shares volume-weighted average price.",
        "label": "Percentage Of Common Shares Volume weighted Average Price",
        "terseLabel": "Percentage of common shares volume-weighted average price"
       }
      }
     },
     "localname": "PercentageOfCommonSharesVolumeWeightedAveragePrice",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "roiv_PercentageOfControllingInterestHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of controlling interest held.",
        "label": "Percentage Of Controlling Interest Held",
        "terseLabel": "Percentage controlling interest"
       }
      }
     },
     "localname": "PercentageOfControllingInterestHeld",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "roiv_Percentageofsharessubjecttolockupfordefinedperiodoftime": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of shares subject to lock-up for defined period of time.",
        "label": "PercentageOfSharesSubjectToLockupForDefinedPeriodOfTime",
        "terseLabel": "Percentage of shares subject to lock-up for defined period of time"
       }
      }
     },
     "localname": "Percentageofsharessubjecttolockupfordefinedperiodoftime",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "roiv_Percentageofwarrantssubjecttolockupfordefinedperiodoftime": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of warrants subject to lock-up for defined period of time.",
        "label": "PercentageOfWarrantsSubjectToLockupForDefinedPeriodOfTime",
        "terseLabel": "Percentage of warrants subject to lock-up for defined period of time"
       }
      }
     },
     "localname": "Percentageofwarrantssubjecttolockupfordefinedperiodoftime",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "roiv_PeriodForFairMarketValueDetermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for fair market value determination.",
        "label": "Period For Fair Market Value Determination",
        "terseLabel": "Period for fair market value determination"
       }
      }
     },
     "localname": "PeriodForFairMarketValueDetermination",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "roiv_PharmanvanthSevenGmbhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmanvanth Seven Gmbh [Member]",
        "label": "Pharmanvanth Seven Gmbh [Member]",
        "terseLabel": "Pharmanvanth Seven Gmbh [Member]"
       }
      }
     },
     "localname": "PharmanvanthSevenGmbhMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_PipeFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PIPE Financing .",
        "label": "PIPE Financing [Member]"
       }
      }
     },
     "localname": "PipeFinancingMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_Portionofsharesubjecttoearnout": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of share subject to earnout.",
        "label": "PortionOfShareSubjectToEarnout",
        "terseLabel": "Portion of Share Subject to Earnout"
       }
      }
     },
     "localname": "Portionofsharesubjecttoearnout",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "roiv_PotentialMilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone payment receivable.",
        "label": "Potential Milestone Payment Receivable",
        "terseLabel": "Collaboration Agreement Additional Contingent Milestone Payments Eligible To Receive"
       }
      }
     },
     "localname": "PotentialMilestonePaymentReceivable",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_PreferredStockOwnedBalanceSharesOfArbutus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock Owned, Balance, Shares of Arbutus.",
        "label": "Preferred stock Owned, Balance, Shares of Arbutus",
        "terseLabel": "Preferred stock Owned, Balance, Shares of Arbutus"
       }
      }
     },
     "localname": "PreferredStockOwnedBalanceSharesOfArbutus",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_PriovantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Priovant.",
        "label": "Priovant [Member]",
        "terseLabel": "Priovant [Member]"
       }
      }
     },
     "localname": "PriovantMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_PrivatePlacementWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Private Placement Warrants [Member]",
        "documentation": "Private Placement Warrants [Member]",
        "label": "Private Placement Warrants [Member]",
        "terseLabel": "Private Placement Warrants",
        "verboseLabel": "Private Placement Warrants [Member]"
       }
      }
     },
     "localname": "PrivatePlacementWarrantsMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail",
      "http://roivant.com/role/FairValueMeasurementsTables",
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_ProceedsFromAndPaymentForOtherFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from and payment for other financing activities.",
        "label": "Proceeds From And Payment For Other Financing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromAndPaymentForOtherFinancingActivities",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ProceedsFromBusinessCombinationAndPipeFinancing": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from business combination and PIPE financing.",
        "label": "Proceeds From Business Combination And Pipe Financing",
        "terseLabel": "Proceeds from business combination and PIPE financing"
       }
      }
     },
     "localname": "ProceedsFromBusinessCombinationAndPipeFinancing",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance of Subsidiary Common Shares Net",
        "label": "Proceeds from Issuance of Subsidiary Common Shares Net",
        "verboseLabel": "Proceeds from issuance of subsidiary common shares, net of issuance costs paid"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSubsidiaryCommonSharesNet",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ProceedsFromPaymentOfSubscriptionReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from payment of subscription receivable.",
        "label": "Proceeds From Payment Of Subscription Receivable",
        "terseLabel": "Proceeds from payment of subscription receivable"
       }
      }
     },
     "localname": "ProceedsFromPaymentOfSubscriptionReceivable",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ProceedsFromReleaseOfEscrowDeposit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Release of Escrow Deposit.",
        "label": "Proceeds from Release of Escrow Deposit",
        "terseLabel": "Proceeds from release of escrow deposit"
       }
      }
     },
     "localname": "ProceedsFromReleaseOfEscrowDeposit",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ProceedsFromSaleOfInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of investment.",
        "label": "Proceeds From Sale Of Investment",
        "verboseLabel": "Proceeds from sale of investment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfInvestment",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ProceedsFromSubsidiaryDebtFinancingsNet": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Subsidiary Debt Financings Net",
        "label": "Proceeds from Subsidiary Debt Financings Net",
        "terseLabel": "Proceeds from subsidiary debt financings, net of financing costs paid"
       }
      }
     },
     "localname": "ProceedsFromSubsidiaryDebtFinancingsNet",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ProductServiceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product service agreement.",
        "label": "Product Service Agreement [Member]"
       }
      }
     },
     "localname": "ProductServiceAgreementMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_ProteovantSciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProteoVant Sciences, Inc [Member].",
        "label": "ProteoVant Sciences, Inc [Member]",
        "terseLabel": "ProteoVant Sciences, Inc [Member]"
       }
      }
     },
     "localname": "ProteovantSciencesIncMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_PublicWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Warrants [Member]",
        "label": "Public Warrants [Member]",
        "verboseLabel": "Public Warrants [Member]"
       }
      }
     },
     "localname": "PublicWarrantsMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_RSLEquityPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "R S L Equity Plans [Member]",
        "terseLabel": "R S L Equity Plans Member"
       }
      }
     },
     "localname": "RSLEquityPlansMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_RedeemableNoncontrollingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest [Member]",
        "label": "Redeemable Noncontrolling Interest [Member]",
        "terseLabel": "Redeemable Noncontrolling Interest [Member]"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_RedemptionOfRoivantWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption of Roivant Warrants .",
        "label": "Redemption of Roivant Warrants [Member]"
       }
      }
     },
     "localname": "RedemptionOfRoivantWarrantsMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_RegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestone [Member]",
        "label": "Regulatory Milestone [Member]",
        "terseLabel": "Regulatory Milestone [Member]"
       }
      }
     },
     "localname": "RegulatoryMilestoneMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment of Long Term Debt and Convertible Debt by Subsidiary",
        "label": "Repayment of Long Term Debt and Convertible Debt by Subsidiary",
        "negatedLabel": "Repayment of long-term debt by subsidiary"
       }
      }
     },
     "localname": "RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_RepurchaseOfEquityAwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchase of Equity Awards",
        "label": "Repurchase of Equity Awards",
        "negatedLabel": "Repurchase of equity awards"
       }
      }
     },
     "localname": "RepurchaseOfEquityAwards",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_RestrictedStockAndPerformanceStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock And Performance Stock Units [Member]",
        "terseLabel": "Restricted Stock And Performance Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockAndPerformanceStockUnitsMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_RestrictedStockUnitsAndPerformanceStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units and performance stock units.",
        "label": "Restricted Stock Units And Performance Stock Units [Member]",
        "terseLabel": "Restricted stock units and performance stock units [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsAndPerformanceStockUnitsMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail",
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_RevenueInterestPurchaseAndSaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Interest Purchase And Sale Agreement [Member].",
        "label": "Revenue Interest Purchase And Sale Agreement [Member]",
        "terseLabel": "Revenue Interest Purchase and Sale Agreement [Member]"
       }
      }
     },
     "localname": "RevenueInterestPurchaseAndSaleAgreementMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_RoivEarnoutSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roiv earnout shares.",
        "label": "Roiv Earnout Shares [Member]",
        "terseLabel": "Roiv Earnout Shares [Member]"
       }
      }
     },
     "localname": "RoivEarnoutSharesMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_RoivLiabilityInstrumentsMeasuredAtFairValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roiv liability instruments measured at fair value.",
        "label": "Roiv Liability Instruments Measured At Fair Value [Member]",
        "terseLabel": "Roiv Liability Instruments Measured At Fair Value [Member]"
       }
      }
     },
     "localname": "RoivLiabilityInstrumentsMeasuredAtFairValueMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_RoivPrivatePlacementWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roiv private placement warrants.",
        "label": "Roiv Private Placement Warrants [Member]",
        "terseLabel": "Roiv Private Placement Warrants [Member]"
       }
      }
     },
     "localname": "RoivPrivatePlacementWarrantsMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_RoivPublicWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roiv public warrants.",
        "label": "Roiv Public Warrants [Member]",
        "terseLabel": "Roiv Public Warrants [Member]"
       }
      }
     },
     "localname": "RoivPublicWarrantsMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_RoivantCommonSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Roivant Common Shares [Member]",
        "terseLabel": "Roivant Common Shares [Member]"
       }
      }
     },
     "localname": "RoivantCommonSharesMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_RoivantSciencesLtd.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Roivant Sciences Ltd. [Member]",
        "terseLabel": "Roivant Sciences Ltd. [Member]"
       }
      }
     },
     "localname": "RoivantSciencesLtd.Member",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurements"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_RoivantWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roivant Warrant .",
        "label": "Roivant Warrant [Member]"
       }
      }
     },
     "localname": "RoivantWarrantMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_RoivrevenueInterestPurchaseAndSaleAgreementMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ROIVRevenue Interest Purchase And Sale Agreement [Member]"
       }
      }
     },
     "localname": "RoivrevenueInterestPurchaseAndSaleAgreementMemberMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_ScheduleOfAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Accounting Policies [Line Items]",
        "label": "Schedule Of Accounting Policies [Line Items]",
        "terseLabel": "Schedule Of Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAccountingPoliciesLineItems",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_ScheduleOfAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Accounting Policies [Table]",
        "label": "Schedule Of Accounting Policies [Table]",
        "terseLabel": "Schedule Of Accounting Policies [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountingPoliciesTable",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Capped Value Appreciation Rights Activity.",
        "label": "Schedule Of Capped Value Appreciation Rights Activity [Table Text Block]",
        "terseLabel": "Summary of Capped Value Appreciation Rights"
       }
      }
     },
     "localname": "ScheduleOfCappedValueAppreciationRightsActivityTableTextBlock",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Property Plant And Equipment Estimated Useful Lives.",
        "label": "Schedule Of Property Plant And Equipment Estimated Useful Lives [Table Text Block]",
        "terseLabel": "Schedule of Estimated Useful Lives Used for Asset Type"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "roiv_ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule\u200b Of Share based \u200bPayment \u200bArrangement\u200b Fair\u200b Value\u200b Of Vested \u200bStock \u200bOption \u200bAnd Performance Option",
        "label": "Schedule Of Share based Payment Arrangement Fair Value Of Vested Stock Option And Performance Option [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Vested Stock Option"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentArrangementFairValueOfVestedStockOptionAndPerformanceOptionTableTextBlock",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "roiv_SecondTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Tranche [Member]",
        "label": "Second Tranche [Member]",
        "terseLabel": "Second Tranche [Member]"
       }
      }
     },
     "localname": "SecondTrancheMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation by share based award weighted average intrinsic value of equity instruments other than options granted",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Intrinsic Shares",
        "terseLabel": "Share based compensation by share based award weighted average intrinsic value of equity instruments other than options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicShares",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_SharePriceEqualOrExceedsEighteenDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Price Equal or Exceeds Eighteen Dollar .",
        "label": "Share Price Equal or Exceeds Eighteen Dollar [Member]"
       }
      }
     },
     "localname": "SharePriceEqualOrExceedsEighteenDollarMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SharePriceEqualOrExceedsEighteenPerDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Price Equal or Exceeds Eighteen Per Dollar .",
        "label": "Share Price Equal or Exceeds Eighteen Per Dollar [Member]"
       }
      }
     },
     "localname": "SharePriceEqualOrExceedsEighteenPerDollarMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SharePriceEqualOrExceedsFifteenDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Price Equal or Exceeds Fifteen Dollar .",
        "label": "Share Price Equal or Exceeds Fifteen Dollar [Member]"
       }
      }
     },
     "localname": "SharePriceEqualOrExceedsFifteenDollarMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SharePriceEqualOrExceedsTenDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Price Equal or Exceeds Ten Dollar .",
        "label": "Share Price Equal or Exceeds Ten Dollar [Member]"
       }
      }
     },
     "localname": "SharePriceEqualOrExceedsTenDollarMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SharePriceEqualOrExceedsTwentyDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Price Equal or Exceeds Twenty Dollar .",
        "label": "Share Price Equal or Exceeds Twenty Dollar [Member]"
       }
      }
     },
     "localname": "SharePriceEqualOrExceedsTwentyDollarMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options granted.",
        "label": "Sharebased Compensation Arrangement by Sharebased Payment Award, Options, Granted, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value per share of stock options granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "roiv_Shareredemptiontriggerprice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share redemption trigger price.",
        "label": "ShareRedemptionTriggerPrice",
        "terseLabel": "Share Redemption Trigger Price"
       }
      }
     },
     "localname": "Shareredemptiontriggerprice",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "roiv_SiliconTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon Therapeutics",
        "label": "Silicon Therapeutics [Member]",
        "terseLabel": "Silicon Therapeutics [Member]"
       }
      }
     },
     "localname": "SiliconTherapeuticsMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SioGeneTherapiesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sio Gene Therapies Inc [Member]",
        "label": "Sio Gene Therapies Inc [Member]",
        "terseLabel": "Sio Gene Therapies Inc [Member]"
       }
      }
     },
     "localname": "SioGeneTherapiesIncMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sk [Member]",
        "terseLabel": "Sk [Member]"
       }
      }
     },
     "localname": "SkMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SponsorSupportAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsor Support Agreement .",
        "label": "Sponsor Support Agreement [Member]"
       }
      }
     },
     "localname": "SponsorSupportAgreementMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_StockHoldersEquityNoteStockSplitExchangeRatio1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock holders Equity Note Stock Split Exchange Ratio1",
        "label": "Stock holders Equity Note Stock Split Exchange Ratio1",
        "terseLabel": "Stockholders Equity Note Stock Split Exchange Ratio 1"
       }
      }
     },
     "localname": "StockHoldersEquityNoteStockSplitExchangeRatio1",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "roiv_StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares common shares related to settlement of transaction consideration.",
        "label": "Stock Issued During Period Shares Common Shares Related To Settlement Of Transaction Consideration",
        "terseLabel": "Issuance of the Company's common shares related to settlement of transaction consideration (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCommonSharesRelatedToSettlementOfTransactionConsideration",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares common shares upon closing of business combination and pipe financing.",
        "label": "Stock Issued During Period Shares Common Shares Upon Closing Of Business Combination And Pipe Financing",
        "terseLabel": "Issuance of the Company's common shares upon closing of Business Combination and PIPE Financing, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period Shares To settle deferred consideration liability.",
        "label": "Stock Issued During Period Shares To Settle Deferred Consideration Liability",
        "terseLabel": "Stock issued during period shares to settle deferred consideration liability"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesToSettleDeferredConsiderationLiability",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_StockIssuedDuringPeriodValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period",
        "label": "Stock Issued During Period",
        "terseLabel": "Newly issued shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValue",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value common shares upon closing of business combination and pipe financing.",
        "label": "Stock Issued During Period Value Common Shares Upon Closing Of Business Combination And Pipe Financing",
        "terseLabel": "Issuance of the Company's common shares upon closing of Business Combination and PIPE Financing, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCommonSharesUponClosingOfBusinessCombinationAndPipeFinancing",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value subsidiary common and preferred shares to the company.",
        "label": "Stock Issued During Period Value Subsidiary Common And Preferred Shares To The Company",
        "terseLabel": "Issuance of subsidiary common and preferred shares to the Company"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSubsidiaryCommonAndPreferredSharesToTheCompany",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_StockIssuedDuringPeriodValueSubsidiaryPreferredShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value subsidiary preferred shares.",
        "label": "Stock Issued During Period Value Subsidiary Preferred Shares",
        "terseLabel": "Issuance of subsidiary preferred shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSubsidiaryPreferredShares",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_StockOptionsAndPerformanceStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options and performance stock options.",
        "label": "Stock Options And Performance Stock Options [Member]",
        "terseLabel": "Stock options and performance stock options [Member]"
       }
      }
     },
     "localname": "StockOptionsAndPerformanceStockOptionsMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail",
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options exercised and restricted stock units vested and settled.",
        "label": "Stock Options Exercised And Restricted Stock Units Vested And Settled",
        "terseLabel": "Stock options exercised and restricted stock units vested and settled"
       }
      }
     },
     "localname": "StockOptionsExercisedAndRestrictedStockUnitsVestedAndSettled",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_StockholdersEquityNoteStockSplitExchangeRatio1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders equity note stock split exchange ratio 1.",
        "label": "Stockholders Equity Note Stock Split Exchange Ratio 1"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitExchangeRatio1",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "roiv_Stockpricetriggerforredemptionofwarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock price trigger for redemption of warrants.",
        "label": "StockPriceTriggerForRedemptionOfWarrants",
        "terseLabel": "Stock price trigger for redemption of warrant"
       }
      }
     },
     "localname": "Stockpricetriggerforredemptionofwarrants",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscription Receivable Related To Issuance Of Subsidiary Common Shares.",
        "label": "Subscription Receivable Related To Issuance Of Subsidiary Common Shares",
        "terseLabel": "Subscription receivable related to issuance of subsidiary common shares"
       }
      }
     },
     "localname": "SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_SubscriptionReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscription Received",
        "label": "Subscription Received"
       }
      }
     },
     "localname": "SubscriptionReceived",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_SubscriptionsReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscriptions receivable.",
        "label": "Subscriptions Receivable",
        "terseLabel": "Subscription receivable"
       }
      }
     },
     "localname": "SubscriptionsReceivable",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_SubscriptionsReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscriptions Receivables [Member]",
        "label": "Subscriptions Receivables [Member]",
        "terseLabel": "Subscriptions Receivables [Member]"
       }
      }
     },
     "localname": "SubscriptionsReceivablesMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SubsidiaryEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Equity Incentive Plan [Member]",
        "label": "Subsidiary Equity Incentive Plan [Member]",
        "terseLabel": "Subsidiary EIPs [Member]"
       }
      }
     },
     "localname": "SubsidiaryEquityIncentivePlanMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SubsidiaryEquityIncentivePlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary equity incentive plans.",
        "label": "Subsidiary Equity Incentive Plans [Member]"
       }
      }
     },
     "localname": "SubsidiaryEquityIncentivePlansMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SumitomoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sumitomo [Member]",
        "label": "Sumitomo [Member]",
        "terseLabel": "Sumitomo [Member]"
       }
      }
     },
     "localname": "SumitomoMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SumitomoOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sumitomo options.",
        "label": "Sumitomo Options [Member]",
        "terseLabel": "Sumitomo Options [Member]"
       }
      }
     },
     "localname": "SumitomoOptionsMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail",
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_TaxAuthorityInOtherJurisdictionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Authority In Other Jurisdictions [Member]",
        "label": "Tax Authority In Other Jurisdictions [Member]",
        "terseLabel": "Other Jurisdictions [Member]"
       }
      }
     },
     "localname": "TaxAuthorityInOtherJurisdictionsMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_TaxRatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Rates [Abstract]",
        "label": "Tax Rates [Abstract]"
       }
      }
     },
     "localname": "TaxRatesAbstract",
     "nsuri": "http://roivant.com/20220331",
     "xbrltype": "stringItemType"
    },
    "roiv_Timetowarrantexercisability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time to warrant exercisability .",
        "label": "TimeToWarrantExercisability",
        "terseLabel": "Time To Warrant Exercisability"
       }
      }
     },
     "localname": "Timetowarrantexercisability",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "roiv_Tradingdayperiodforearnoutshares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading day period for earn out shares.",
        "label": "TradingDayPeriodForEarnOutShares",
        "terseLabel": "Trading day period for earn out shares"
       }
      }
     },
     "localname": "Tradingdayperiodforearnoutshares",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "roiv_Tradingdayperiodforwarrantredemption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading day period for warrant redemption.",
        "label": "TradingDayPeriodForWarrantRedemption",
        "terseLabel": "Trading day period for warrant redemption"
       }
      }
     },
     "localname": "Tradingdayperiodforwarrantredemption",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "roiv_TransitionServicesAndStrategicCooperationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transition Services And Strategic Cooperation Agreement [Member]"
       }
      }
     },
     "localname": "TransitionServicesAndStrategicCooperationAgreementMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_TriggeringEventAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Triggering Event .",
        "label": "Triggering Event [Axis]"
       }
      }
     },
     "localname": "TriggeringEventAxis",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_TriggeringEventDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Triggering Event .",
        "label": "Triggering Event [Domain]"
       }
      }
     },
     "localname": "TriggeringEventDomain",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_TwoThousandAndTwentyCvarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and CVARS.",
        "label": "Two Thousand And Twenty Cvars [Member]",
        "terseLabel": "March 2020 CVARs [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyCvarsMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_TwoThousandFifteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Fifteen Equity Incentive Plan [Member]",
        "label": "Two Thousand Fifteen Equity Incentive Plan [Member]",
        "terseLabel": "2015 EIP [Member]"
       }
      }
     },
     "localname": "TwoThousandFifteenEquityIncentivePlanMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_TwoThousandTwentyOneEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty One Equity Incentive Plan [Member]",
        "terseLabel": "2021 EIP [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyOneEquityIncentivePlanMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_UncategorizedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncategorized [Abstract]",
        "label": "Uncategorized [Abstract]"
       }
      }
     },
     "localname": "UncategorizedAbstract",
     "nsuri": "http://roivant.com/20220331",
     "xbrltype": "stringItemType"
    },
    "roiv_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten Public Offering [Member]",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering [Member]"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_UnitedStatesAndCanadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United states\u00a0and canada.",
        "label": "United States And Canada [Member]"
       }
      }
     },
     "localname": "UnitedStatesAndCanadaMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_UpfrontCashPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Cash Payments",
        "label": "Upfront Cash Payments",
        "terseLabel": "Payments to asset acquisition"
       }
      }
     },
     "localname": "UpfrontCashPayments",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_UpfrontCommitmentFeeNumberOfSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront commitment fee number of shares issued | shares.",
        "label": "Upfront Commitment Fee Number Of Shares Issued",
        "terseLabel": "Upfront commitment fee number of shares issued | shares"
       }
      }
     },
     "localname": "UpfrontCommitmentFeeNumberOfSharesIssued",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_WarrantliabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant liabilities .",
        "label": "WarrantLiabilities [Policy Text Block]",
        "terseLabel": "Warrant Liabilities"
       }
      }
     },
     "localname": "WarrantliabilitiesPolicyTextBlock",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "roiv_WelichemBiotechIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Welichem Biotech Inc [Member]"
       }
      }
     },
     "localname": "WelichemBiotechIncMember",
     "nsuri": "http://roivant.com/20220331",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Company's Annual Payments"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r55",
      "r57",
      "r119",
      "r120",
      "r239",
      "r270",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r238",
      "r269",
      "r316",
      "r318",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r536",
      "r596",
      "r598",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail",
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r238",
      "r269",
      "r316",
      "r318",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r536",
      "r596",
      "r598",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail",
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r238",
      "r269",
      "r305",
      "r316",
      "r318",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r536",
      "r596",
      "r598",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail",
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r238",
      "r269",
      "r305",
      "r316",
      "r318",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r536",
      "r596",
      "r598",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail",
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r56",
      "r57",
      "r119",
      "r120",
      "r239",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r1",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r149",
      "r201",
      "r202",
      "r356",
      "r387",
      "r438",
      "r439",
      "r440",
      "r441",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r674",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r1",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r149",
      "r201",
      "r202",
      "r356",
      "r387",
      "r438",
      "r439",
      "r440",
      "r441",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r674",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r183",
      "r184",
      "r302",
      "r303",
      "r597",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r661",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r183",
      "r184",
      "r302",
      "r303",
      "r597",
      "r626",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r661",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r186",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r34",
      "r502"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 23.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "verboseLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail",
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r60",
      "r61",
      "r62",
      "r579",
      "r604",
      "r608"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r59",
      "r62",
      "r70",
      "r71",
      "r72",
      "r123",
      "r124",
      "r125",
      "r427",
      "r599",
      "r600",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r356",
      "r502"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r353",
      "r354",
      "r355",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r319",
      "r321",
      "r359",
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net (loss) income to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r321",
      "r350",
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperationsParenthetical",
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure alternative investment.",
        "label": "Alternative Investment, Measurement Input",
        "terseLabel": "Investment"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "verboseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": {
     "auth_ref": [
      "r411",
      "r412",
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable",
        "terseLabel": "Asset acquisition, Consideration Transferred, Equity Interests Issued and Issuable"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "verboseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r114",
      "r170",
      "r174",
      "r180",
      "r199",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r421",
      "r429",
      "r455",
      "r500",
      "r502",
      "r553",
      "r575"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r52",
      "r114",
      "r199",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r421",
      "r429",
      "r455",
      "r500",
      "r502"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets held in Trust Account"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r322",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationTables",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r434",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r315",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r315",
      "r317",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned",
        "terseLabel": "Business combination, recognized identifiable assets acquired and liabilities assumed, current liabilities, accounts payable"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Number of shares issued in business combination"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r401",
      "r403",
      "r404",
      "r407"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Asset acquisition, consideration transferred, liabilities incurred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r402",
      "r405",
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Fair value of future contingent consideration payments"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combination with MAAC"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaac"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r3",
      "r122",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business and Liquidity"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r28",
      "r502",
      "r609",
      "r610"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "verboseLabel": "Cash received"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r28",
      "r103"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail": {
       "order": 1.0,
       "parentTag": "roiv_CashAndCashEquivalentsAndRestrictedCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets",
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r10",
      "r104",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r97",
      "r103",
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r97",
      "r458"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r111",
      "r114",
      "r139",
      "r140",
      "r141",
      "r143",
      "r145",
      "r152",
      "r153",
      "r154",
      "r199",
      "r224",
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r267",
      "r268",
      "r272",
      "r276",
      "r455",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/ConsolidatedBalanceSheets",
      "http://roivant.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/Cover",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r291",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail",
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail",
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "disclosureGuidance": "Class of Warrant or Right, Exercise Price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants (in dollars per share)",
        "verboseLabel": "Warrant exercise price per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "verboseLabel": "Class of warrants or rights number of shares called by each warrant or right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of outstanding warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r45",
      "r220",
      "r560",
      "r584"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 13)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r221",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments &amp; Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CommitmentsContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r222",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r123",
      "r124",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares [Member]",
        "verboseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/Cover",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par or stated value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock issued",
        "verboseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "positiveLabel": "Common stock, shares outstanding",
        "terseLabel": "Common stock acquired"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20",
      "r502"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 694,975,965 and 651,576,293 shares issued and outstanding at March 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common Stock, Voting Rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r65",
      "r67",
      "r68",
      "r81",
      "r568",
      "r591"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Roivant Sciences Ltd."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r67",
      "r80",
      "r419",
      "r420",
      "r433",
      "r567",
      "r590"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive loss attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r67",
      "r79",
      "r418",
      "r433",
      "r566",
      "r589"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r157",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r383",
      "r390",
      "r392"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Total current tax expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current taxes:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "verboseLabel": "Notes converted, shares issued"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "auth_ref": [
      "r106",
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Original Debt, Amount",
        "terseLabel": "Aggregate principal amount of notes converted"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r113",
      "r121",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r255",
      "r256",
      "r257",
      "r258",
      "r473",
      "r554",
      "r555",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r235",
      "r255",
      "r256",
      "r471",
      "r473",
      "r474"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r244",
      "r255",
      "r256",
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt fair value",
        "verboseLabel": "Debt issued by Dermavant to NovaQuest"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r41",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r43",
      "r113",
      "r121",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r255",
      "r256",
      "r257",
      "r258",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r43",
      "r113",
      "r121",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r284",
      "r287",
      "r288",
      "r289",
      "r470",
      "r471",
      "r473",
      "r474",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r242",
      "r253",
      "r255",
      "r256",
      "r472"
     ],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less: unamortized debt discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "terseLabel": "Gain on deconsolidation"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r101",
      "r115",
      "r384",
      "r390",
      "r391",
      "r392"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Total deferred tax benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred taxes:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 27.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 32.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net Deferred tax assets/(liabilities), net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r381",
      "r382"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r381",
      "r382"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r380",
      "r381",
      "r382"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r381",
      "r382"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r381",
      "r382"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": {
     "auth_ref": [
      "r435"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value",
        "terseLabel": "Liability instruments measured at fair value"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r53",
      "r54",
      "r57",
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative Liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure derivative liability.",
        "label": "Derivative Liability, Measurement Input",
        "verboseLabel": "Derivative Liability, Measurement Input"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Net loss per common share\u2014basic and diluted",
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Basic and diluted net (loss) income per common share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Basic and diluted weighted average shares outstanding:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate",
        "verboseLabel": "Total income tax expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r116",
      "r369",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax benefit at Bermuda statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r369",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "negatedLabel": "Change in Valuation Allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r369",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Tax rate changes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther": {
     "auth_ref": [
      "r369",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Other, Percent",
        "terseLabel": "Other permanent\u00a0adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets": {
     "auth_ref": [
      "r369",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent",
        "terseLabel": "Nontaxable gain on sale of investment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness": {
     "auth_ref": [
      "r369",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Percent",
        "negatedLabel": "Nontaxable gain on deconsolidation of business"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary": {
     "auth_ref": [
      "r369",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent",
        "terseLabel": "Tax-effect of changes in the fair value of investments and loss from equity method investment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r369",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign rate differential(1)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r369",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "Permanent disallowed IPR&amp;D"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r369",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "terseLabel": "Nondeductible executive compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r369",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r361",
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount",
        "terseLabel": "Tax deficiencies (excess tax benefits) from stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r361",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent",
        "terseLabel": "Tax deficiencies (excess tax benefits) from share-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r369",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedLabel": "Research\u00a0tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Remaining weighted-average service period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r70",
      "r71",
      "r72",
      "r123",
      "r124",
      "r125",
      "r127",
      "r134",
      "r137",
      "r151",
      "r200",
      "r283",
      "r290",
      "r353",
      "r354",
      "r355",
      "r386",
      "r387",
      "r439",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r466",
      "r599",
      "r600",
      "r601",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail",
      "http://roivant.com/role/FairValueMeasurementsTables",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity Method Investment, Ownership Percentage",
        "verboseLabel": "Equity method investment ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.",
        "label": "Equity Method Investment, Underlying Equity in Net Assets",
        "terseLabel": "Equity investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentUnderlyingEquityInNetAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r29",
      "r171",
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investments accounted under the equity method.",
        "label": "Equity Method Investments, Fair Value Disclosure",
        "terseLabel": "Fair value of noncontrolling interests"
       }
      }
     },
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EscrowDeposit": {
     "auth_ref": [
      "r559",
      "r629"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.",
        "label": "Escrow Deposit",
        "verboseLabel": "Escrowed deposit"
       }
      }
     },
     "localname": "EscrowDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r442",
      "r443",
      "r444",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value of Significant Unobservable Inputs Using Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfChangeInFairValueOfTheLevel3AssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r448",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfChangeInFairValueOfTheLevel3AssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r448",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Change IN Fair Value Of The Level 3 Assets"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r442",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r244",
      "r255",
      "r256",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r443",
      "r509",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfChangeInFairValueOfTheLevel3AssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r442",
      "r443",
      "r446",
      "r447",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r244",
      "r306",
      "r307",
      "r312",
      "r314",
      "r443",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r244",
      "r255",
      "r256",
      "r306",
      "r307",
      "r312",
      "r314",
      "r443",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r244",
      "r255",
      "r256",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r443",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfChangeInFairValueOfTheLevel3AssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r448",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of change in the fair value of the derivative warrant liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "terseLabel": "Changes in fair value of investment in Datavant, included in net loss"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfChangeInFairValueOfTheLevel3AssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "auth_ref": [
      "r448"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfChangeInFairValueOfTheLevel3AssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "verboseLabel": "Changes in fair value of debt and liability instruments, included in net loss"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r450"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "verboseLabel": "Fair value of liability instrument issued"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r450"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "terseLabel": "Termination of DSP Options"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r448"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r244",
      "r255",
      "r256",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r509",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfChangeInFairValueOfTheLevel3AssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r451",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r252",
      "r281",
      "r437",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Financial liabilities at fair value"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r87",
      "r101",
      "r188"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://roivant.com/role/ConsolidatedStatementsOfOperations": {
       "order": 12.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedLabel": "Change in fair value of investments",
        "terseLabel": "Gain (loss) on remeasurement of investment"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainOnSaleOfInvestments": {
     "auth_ref": [
      "r83",
      "r84",
      "r101",
      "r562",
      "r592"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://roivant.com/role/ConsolidatedStatementsOfOperations": {
       "order": 13.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the carrying value and the sale price of an investment.  A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment.  This element refers to the Gain included in earnings and not to the cash proceeds of the sale.",
        "label": "Gain on Sale of Investments",
        "negatedLabel": "Gain on sale of investment"
       }
      }
     },
     "localname": "GainOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "G&amp;A Expenses [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperationsParenthetical",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r32",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Acquired\u00a0In-Process\u00a0Research and Development Expenses"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r75",
      "r170",
      "r173",
      "r176",
      "r179",
      "r181",
      "r551",
      "r563",
      "r570",
      "r594"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r170",
      "r173",
      "r176",
      "r179",
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "terseLabel": "Total loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Loss before income taxes:"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r76",
      "r101",
      "r168",
      "r195",
      "r561",
      "r586"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://roivant.com/role/OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail": {
       "order": 1.0,
       "parentTag": "roiv_OtherOperatingIncomeExpensesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Loss from equity method investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail",
      "http://roivant.com/role/ConsolidatedStatementsOfOperationsParenthetical",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail",
      "http://roivant.com/role/ConsolidatedStatementsOfOperationsParenthetical",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r116",
      "r370",
      "r373",
      "r379",
      "r388",
      "r394",
      "r396",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r117",
      "r136",
      "r137",
      "r169",
      "r368",
      "r389",
      "r395",
      "r595"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "totalLabel": "Income tax provision",
        "verboseLabel": "Income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperations",
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r366",
      "r367",
      "r373",
      "r374",
      "r378",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r365",
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Tax rate changes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationDeductionsOther": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Other, Amount",
        "terseLabel": "Other permanent\u00a0adjustments"
       }
      }
     },
     "localname": "IncomeTaxReconciliationDeductionsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationDispositionOfAssets": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount",
        "terseLabel": "Nontaxable gain on sale of investment"
       }
      }
     },
     "localname": "IncomeTaxReconciliationDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationDispositionOfBusiness": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Amount",
        "terseLabel": "Nontaxable gain on deconsolidation of business"
       }
      }
     },
     "localname": "IncomeTaxReconciliationDispositionOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Amount",
        "negatedLabel": "Tax-effect of changes in the fair value of investments and loss from equity method investment"
       }
      }
     },
     "localname": "IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax benefit at Bermuda statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount",
        "terseLabel": "Permanent disallowed IPR&amp;D"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Nondeductible executive compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research\u00a0tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredLiabilities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.",
        "label": "Increase (Decrease) in Deferred Liabilities",
        "terseLabel": "Deferred consideration liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities, net of effects from acquisition and divestiture:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r74",
      "r167",
      "r469",
      "r472",
      "r569"
     ],
     "calculation": {
      "http://roivant.com/role/OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail": {
       "order": 3.0,
       "parentTag": "roiv_OtherOperatingIncomeExpensesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail": {
       "order": 2.0,
       "parentTag": "roiv_OtherOperatingIncomeExpensesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r95",
      "r98",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r197",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire  disclosure for investments and other noncurrent assets.",
        "label": "Investments and Other Noncurrent Assets [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsAndOtherNoncurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r442"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "positiveLabel": "Investments measured at fair value",
        "terseLabel": "Aggregate fair value investment",
        "verboseLabel": "Investment"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investments in an entity not consolidated. Includes, but is not limited to, investments in an entity that is affiliated with the reporting entity by means of direct or indirect ownership, an entity in which the reporting entity shares control of the entity with another party or group, an entity which the company has significant influence, but does not have control and subsidiaries that are not required to be consolidated and are accounted for using the equity or cost method.",
        "label": "Investments in Affiliates, Subsidiaries, Associates, and Joint Ventures, Fair Value Disclosure",
        "terseLabel": "Investment, fair value"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r487",
      "r489"
     ],
     "calculation": {
      "http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Leases of Lessee Disclosure [Text Block]",
        "terseLabel": "Summary of Operating Lease ROU Assets and Operating Lease Liabilities"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r488"
     ],
     "calculation": {
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r114",
      "r175",
      "r199",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r422",
      "r429",
      "r430",
      "r455",
      "r500",
      "r501"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r114",
      "r199",
      "r455",
      "r502",
      "r558",
      "r582"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, redeemable noncontrolling interest and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities, Redeemable Noncontrolling Interest and Shareholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r114",
      "r199",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r422",
      "r429",
      "r430",
      "r455",
      "r500",
      "r501",
      "r502"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "terseLabel": "Total liabilities at fair value",
        "verboseLabel": "Financial and Nonfinancial Liabilities, Fair Value Disclosure"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r16",
      "r243",
      "r254",
      "r255",
      "r256",
      "r555",
      "r576"
     ],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total debt, net"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Unclassified [Abstract]"
       }
      }
     },
     "localname": "LongTermDebtAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Less: current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Long term debt accounted under fair value option"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r121",
      "r223",
      "r247"
     ],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail": {
       "order": 6.0,
       "parentTag": "roiv_LongTermDebtExcludingDebtWithFairValueOption",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r121",
      "r223",
      "r247"
     ],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail": {
       "order": 1.0,
       "parentTag": "roiv_LongTermDebtExcludingDebtWithFairValueOption",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r121",
      "r223",
      "r247"
     ],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail": {
       "order": 5.0,
       "parentTag": "roiv_LongTermDebtExcludingDebtWithFairValueOption",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "verboseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r121",
      "r223",
      "r247"
     ],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail": {
       "order": 4.0,
       "parentTag": "roiv_LongTermDebtExcludingDebtWithFairValueOption",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r121",
      "r223",
      "r247"
     ],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail": {
       "order": 3.0,
       "parentTag": "roiv_LongTermDebtExcludingDebtWithFairValueOption",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r121",
      "r223",
      "r247"
     ],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail": {
       "order": 2.0,
       "parentTag": "roiv_LongTermDebtExcludingDebtWithFairValueOption",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentScheduleOfCompanysAnnualPaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 29.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "totalLabel": "Total long term debt, net",
        "verboseLabel": "Long-term debt (includes $177,400 and $150,100 accounted for under the fair value option at March 31, 2022 and 2021, respectively)"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets",
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentSummaryOfLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.",
        "label": "Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate",
        "terseLabel": "Debt interest rate"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingVariableInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Long-Term Debt and Loan Commitment"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Carrying value of long-term investment",
        "verboseLabel": "Long-term investment"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Measurement Input, Expected Term [Member]",
        "verboseLabel": "Term (in years)"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns.",
        "label": "Measurement Input, Option Volatility [Member]",
        "terseLabel": "Measurement Input, Option Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputOptionVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r50",
      "r114",
      "r199",
      "r224",
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r455",
      "r557",
      "r581"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r97",
      "r99",
      "r102"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r63",
      "r66",
      "r72",
      "r77",
      "r102",
      "r114",
      "r126",
      "r128",
      "r129",
      "r131",
      "r132",
      "r136",
      "r137",
      "r142",
      "r170",
      "r173",
      "r176",
      "r179",
      "r181",
      "r199",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r441",
      "r455",
      "r564",
      "r587"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to Roivant Sciences Ltd."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r63",
      "r66",
      "r72",
      "r136",
      "r137",
      "r424",
      "r432"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r290",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonfinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of obligations not classified as financial liabilities. Includes, but is not limited to, accounts payable and accrued liabilities, commitments, obligations, and other liabilities.",
        "label": "Nonfinancial Liabilities Fair Value Disclosure",
        "terseLabel": "Non financial liabilities at fair value"
       }
      }
     },
     "localname": "NonfinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableRelatedParties": {
     "auth_ref": [
      "r118",
      "r494",
      "r585"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from parties associated with the reporting entity as evidenced by a written promise to pay.",
        "label": "Notes Receivable, Related Parties",
        "terseLabel": "Notes receivable, related parties"
       }
      }
     },
     "localname": "NotesReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating and reporting segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r170",
      "r173",
      "r176",
      "r179",
      "r181"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r480",
      "r489"
     ],
     "calculation": {
      "http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Maturities of operating lease liabilities [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 24.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 28.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r478",
      "r483"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r486",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r485",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.",
        "label": "Operating Loss Carryforwards, Expiration Date",
        "terseLabel": "Net operating losses expiration date"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r51",
      "r502"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r418",
      "r419",
      "r426"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r58",
      "r60",
      "r456",
      "r457",
      "r459"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r64",
      "r67",
      "r70",
      "r71",
      "r73",
      "r78",
      "r283",
      "r460",
      "r465",
      "r466",
      "r565",
      "r588"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive (loss) income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Expense, Net [Abstract]",
        "verboseLabel": "Other Expense, Net [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/OtherExpenseNetSummaryOfOtherExpenseNetFromContinuingOperationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentCompaniesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in other investment companies (as defined).",
        "label": "Other Investment Companies [Member]",
        "terseLabel": "Other Investments [Member]",
        "verboseLabel": "Other Investment [Member]"
       }
      }
     },
     "localname": "OtherInvestmentCompaniesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r39",
      "r502"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 25.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfOperations": {
       "order": 17.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherOperatingIncomeAndExpenseTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other operating income and other operating expense items.",
        "label": "Other Operating Income and Expense [Text Block]",
        "verboseLabel": "Other Expense, Net"
       }
      }
     },
     "localname": "OtherOperatingIncomeAndExpenseTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/OtherExpenseNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r91",
      "r406"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash Payment"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "terseLabel": "Payment to acquire business, net"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Equity ownership interest, additional cash contribution"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "terseLabel": "Cash paid for common shares"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r322",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate [Member]"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "verboseLabel": "Proceeds of warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r94",
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from credit facility"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from sale of investment"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r63",
      "r66",
      "r72",
      "r96",
      "r114",
      "r126",
      "r136",
      "r137",
      "r170",
      "r173",
      "r176",
      "r179",
      "r181",
      "r199",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r418",
      "r423",
      "r425",
      "r432",
      "r433",
      "r441",
      "r455",
      "r570"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://roivant.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://roivant.com/role/ConsolidatedStatementsOfOperations",
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r31",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r214",
      "r502",
      "r571",
      "r583"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r214",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r17",
      "r556",
      "r577"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Purchase commitment, remaining minimum payment"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "terseLabel": "Redeemable noncontrolling interest"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r313",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r313",
      "r493",
      "r494",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r313",
      "r493",
      "r497",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r491",
      "r492",
      "r494",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentOfNotesReceivableFromRelatedParties": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.",
        "label": "Repayment of Notes Receivable from Related Parties",
        "terseLabel": "Settlement of promissory notes receivable"
       }
      }
     },
     "localname": "RepaymentOfNotesReceivableFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r363",
      "r537",
      "r644"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfOperations": {
       "order": 9.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "R&amp;D Expenses [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail",
      "http://roivant.com/role/ConsolidatedStatementsOfOperationsParenthetical",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r108",
      "r552",
      "r578"
     ],
     "calculation": {
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail": {
       "order": 2.0,
       "parentTag": "roiv_CashAndCashEquivalentsAndRestrictedCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r4",
      "r10",
      "r108"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r7",
      "r13",
      "r108",
      "r627"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash, net of current portion"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "Restricted common stock (non-vested) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r290",
      "r356",
      "r502",
      "r580",
      "r603",
      "r608"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets",
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r123",
      "r124",
      "r125",
      "r127",
      "r134",
      "r137",
      "r200",
      "r353",
      "r354",
      "r355",
      "r386",
      "r387",
      "r439",
      "r599",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r165",
      "r166",
      "r172",
      "r177",
      "r178",
      "r182",
      "r183",
      "r185",
      "r301",
      "r302",
      "r538"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r110",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r484",
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Operating lease right-of-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Common stock per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of potentially dilutive securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Aggregate Amounts of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Long Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Company's net deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Federal Statutory Income Taxes Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Loss Before Income Taxes and Related Expense/(Benefit)"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Units"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement.",
        "label": "Schedule of Other Operating Cost and Expense, by Component [Table Text Block]",
        "terseLabel": "Summary of Other Expense, Net From Continuing Operations"
       }
      }
     },
     "localname": "ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/OtherExpenseNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r31",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r495",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r322",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r326",
      "r338",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r47",
      "r111",
      "r152",
      "r153",
      "r260",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r276",
      "r281",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested balance, ending",
        "periodStartLabel": "Non-vested balance, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending Balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Service-vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of CVARs that service-vested during the year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, vested",
        "verboseLabel": "Weighted average grant date fair value, Service-vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Expected risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Stock options exercisable",
        "verboseLabel": "Stock options outstanding , Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Forfeited/Canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value , Ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r328",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Stock options outstanding , Ending balance",
        "periodStartLabel": "Stock options outstanding ,Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Ending balance",
        "periodStartLabel": "Weighted average exercise price, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of outstanding stock increase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r320",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationTables",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r322",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Closing price of common stock"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r344",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value , Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "presentationGuidance": "Weighted Average Remaining Contractual Life , Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value, forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Non-vested units , Ending balance",
        "periodStartLabel": "Non-vested units, Beginning balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of options",
        "verboseLabel": "Grant date fair value of stock options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "verboseLabel": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r481",
      "r489"
     ],
     "calculation": {
      "http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r109",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Software [Member]"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "United States and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r111",
      "r114",
      "r139",
      "r140",
      "r141",
      "r143",
      "r145",
      "r152",
      "r153",
      "r154",
      "r199",
      "r224",
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r267",
      "r268",
      "r272",
      "r276",
      "r283",
      "r455",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/ConsolidatedBalanceSheets",
      "http://roivant.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/Cover",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r49",
      "r70",
      "r71",
      "r72",
      "r123",
      "r124",
      "r125",
      "r127",
      "r134",
      "r137",
      "r151",
      "r200",
      "r283",
      "r290",
      "r353",
      "r354",
      "r355",
      "r386",
      "r387",
      "r439",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r466",
      "r599",
      "r600",
      "r601",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfSignificantUnobservableInputsUsingValuationTechniquesDetail",
      "http://roivant.com/role/FairValueMeasurementsTables",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://roivant.com/role/ConsolidatedBalanceSheets",
      "http://roivant.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/ConsolidatedStatementsOfOperations",
      "http://roivant.com/role/ConsolidatedStatementsOfOperationsParenthetical",
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/Cover",
      "http://roivant.com/role/FairValueMeasurements",
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail",
      "http://roivant.com/role/FairValueMeasurementsTables",
      "http://roivant.com/role/ShareBasedCompensationTables",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPolicies",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfPartnersCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Partners' Capital [Abstract]"
       }
      }
     },
     "localname": "StatementOfPartnersCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r151",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://roivant.com/role/ConsolidatedBalanceSheets",
      "http://roivant.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/ConsolidatedStatementsOfOperations",
      "http://roivant.com/role/ConsolidatedStatementsOfOperationsParenthetical",
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/Cover",
      "http://roivant.com/role/FairValueMeasurements",
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail",
      "http://roivant.com/role/FairValueMeasurementsTables",
      "http://roivant.com/role/ShareBasedCompensationTables",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPolicies",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r19",
      "r20",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Stock shares issued during the period asset acquisition"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r283",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "positiveLabel": "Public offering shares of common stock",
        "positiveTerseLabel": "Stock issued",
        "terseLabel": "Issuance of the Company's common shares, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r20",
      "r283",
      "r290",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r49",
      "r283",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Stock shares issued value during the period asset acquisition"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r283",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of the Company's common shares",
        "verboseLabel": "Stock issued, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail",
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r49",
      "r283",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of subsidiary stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r24",
      "r25",
      "r114",
      "r187",
      "r199",
      "r455",
      "r502"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Shareholders' equity attributable to Roivant Sciences Ltd."
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r71",
      "r114",
      "r123",
      "r124",
      "r125",
      "r127",
      "r134",
      "r199",
      "r200",
      "r290",
      "r353",
      "r354",
      "r355",
      "r386",
      "r387",
      "r416",
      "r417",
      "r431",
      "r439",
      "r455",
      "r460",
      "r461",
      "r466",
      "r600",
      "r601",
      "r675"
     ],
     "calculation": {
      "http://roivant.com/role/ConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedBalanceSheets",
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r112",
      "r268",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r290",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteSubscriptionsReceivable": {
     "auth_ref": [
      "r19",
      "r20",
      "r24",
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.",
        "label": "Stockholders' Equity Note, Subscriptions Receivable",
        "terseLabel": "Subscription receivable"
       }
      }
     },
     "localname": "StockholdersEquityNoteSubscriptionsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r467",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r467",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r467",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r503",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity method investee's stock owned by parent immediately after all stock transactions.",
        "label": "Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash paid:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Research and development tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardExpirationDate": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of the tax credit carryforward, in YYYY-MM-DD format.",
        "label": "Tax Credit Carryforward, Expiration Date",
        "terseLabel": "Research and development tax credit expiration date"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r46",
      "r114",
      "r199",
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodEndLabel": "Balance, temporary equity",
        "periodStartLabel": "Balance, temporary equity"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction [Domain]",
        "terseLabel": "Transaction [Domain]"
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]",
        "terseLabel": "Transaction Type [Axis]"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r252",
      "r281",
      "r437",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Interest and penalties related to unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance increase (decrease)"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r482",
      "r489"
     ],
     "calculation": {
      "http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/Cover",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisParentheticalDetail",
      "http://roivant.com/role/ShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants and Rights Outstanding, Term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BusinessCombinationWithMaacAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "Weighted average shares outstanding\u2014basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=125513658&loc=d3e32014-111567"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(d)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r645": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r646": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r647": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r648": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r649": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r650": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r651": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r652": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r653": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r654": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r655": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r656": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r657": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r658": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r659": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "303",
   "Subparagraph": "(5)"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r660": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r661": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r662": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r663": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r664": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r665": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r666": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r667": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r668": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r669": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r670": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r671": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08"
  },
  "r672": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r673": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>127
<FILENAME>0001193125-22-183362-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-183362-xbrl.zip
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MM([F MV\5ZOO98S\Z$^AUG]_R7%;'*DI1(*KZ8!5-#X"^+'DZ^)QTBOKR(C
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M,#I2G? VQX278!^4E<LH(\UZ,IDNB:][ L!BGK. >6R3@V13)KR>%+SJ]^-
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M*'6<^3=,>%?!.;!ZQ/Q\G"55?3K9!LO+R #^K'[!OJ=&GNZ-3%N$;>*&;S+
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M @K-T<Z$E#&89BZVVV+^M0)WCG,O-,V,/F-1*Y6Q[)T274 !H/G%O>&('V8
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MT\2RY'-9<AV5UO*X8UEZ\G52MRO&F#<4; A0:?1:_)X'6Z0MI\Q]FUA@\1T
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M<'4NXR!2PW/I/2/^B*KO/?>Z3 V4O'?UJS#V^(FK?NRQ<L,Q^>^388>4\(E
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M#ST)/S[H'S$BKEP1THT=3,(*N).?M<,BAP7);1QCZ2ZAPW_6Z_M'M<G3?[W
MND7^I<>IC:6D#8I5"1L>#++;M>M!W3G!""C[YVMMUEJ<>#E.2C3;A;$:T91<
M$5R,'[N ;R9I G<][GQCH<?^<G[S99OY#I;IXI&%E[5BBKE09F4,8??)J[L;
MTRWNQGQ#\W4=MV3LCN9"Q2>?](*?*2,OD],?>)C/SYWVT'%[W/V)@_OI",W7
M*CO++4*'.0_<]_=^!O(A<$+.0F!X#RZ$,6[PL]#Q>$<$^JCW;0P^W6'M*)&0
MG'2!L.Q/*C#R3\RTS?](19(FEB.9G@/X)XSV'SC8EAGK%0UUQC21;W(4G_.?
M=DP5QR?J;FP=CP0R@E_^B@6")X!#!XNL**J8%4X!TP,\@U7\B0HM9?CZ,BSS
MA_3C(&**ZK.H66OO659Y@E4>>IQ.-([PRYOZ6[U$/0 /Y!3/8;Z?LDN>C]K<
MW  O+F&= K?DL"8Q^Y"#\#*5Y?+@:M"E6P>*NYRRDNH-ATHWALX;>!]&H\+8
M[3EA3V*YBJ1>5=1CT>@L'E@XSO+TL)G(6P#'P'/>-'*S;8-E"#>U_P5SP8?H
M?G@2AV)>AH9F2".AD;(P<LYJCL>&X419>(*[SW6VA"Y@ATXWV+,S%Y@$.9O&
MY8;))XWLFQP7B<,7%HGYF!.I! 3JBPB3OKD/A%(R0.?>'SH<'/VA<X6V#7,I
MI_<SBY@N*37"MMD[\O"7UX^WO!OK#CC++T/5VKLSJ_L&E_[D@],X:.RGBAD0
M&P1D0 595BP6>AU21N?AV^>R<6[9<=4-5[\^&U>!@6]'+#8?WL,=YKK P(HA
M%^+:H[D6E/ZZ? Z$A=[+?<DL5?J]L \"!8-7"2@!&?L#%@QW$=<Q^@]$ZN+O
M724?HEYR>1]@GM.4R>JDJH*4<(\YJ(W:ATD3I\OU#\EM3]XP>7S)C8CMYN8)
M8TWN3.SBY1]9:[3WDB-K1@GF-=^^K<RS9MF!]<.55.8Y7LUKZR<K>6VC"F6$
MTG%^04#1+)L##?T#(<<J3WOEZ@7/^Y'Y/]5\[>DMHWC $DH"5/L5%1")URB:
MJLZ!+[ORV6<Z.;V).-HU;\(8_;>BE>(8EB\/T*]<$(Y?1,Y;VK31#Z;VC?[3
M6"ZKG>L3Y*;Q?8I#X(UP1B^UI-[Z#$U7+-ZL ][,,L-E\^CROCG_<Q?&F=!/
M:H^B.L*9C.XW&M>Y'M'JA71)FZ ;%''M3'&2\=CEC+%[#'=1D N4'P;Q(^G$
MH7:P@9ZZ@TY)_7[PT?%;_A __B#@T_!9)X!92O29[T5(RC1@@2N8C_XXGCK&
MF\,('&>FO-#!<I7"F[K9>O"&O2WU;.<(&UT\9CT\=*N?U;"KC?.7\98)[YLX
MB@,LA'$3!I\%1B"6 J)C@6@8)2@*#'ZGIXE9&((%@#\E/, ['4X!P,"46< G
M!<8% ^ RI*J2OB,!W'+,EX5PJ/5"D<4.:X>YXY4MIMH,WKUW_>CS(>T>O*D?
M.=_W6]BG]:1QC&<QW^+LLZF:?(&V#[R7X_..4'T=(!W  !C>!*)!NZ8>#9O%
MGHC,X&;CYRNWHYKXE%3-; $O?=9=45>:*L?I*<P9]KCO)ZCGO"GN12_=3<$@
M7I(%,A9X UZ9'-F>;[.R&&U^REK&)5A4#^?98"*RK9P!,&&*=;M 9.2"/B5+
M.??,CWFRR/>29 LA9"4!:_U^,UU7IZ3C7D8T=&"9:1=R-8'R#NX!PJS#(E/E
M^+W-4*7& T1,N.+Z,L2E2'/CB[>G&&HF$9K3! !$9D6GGBMPWN#K3'2[<"#!
MQ+3?[B*43\IPPVO7;B3;B9=9WW60#6ESB U \3\*X$#N#YW_-.Q]23L[\-PH
M?]\0LE[ZDHUN]33#ZZ!>2UA\!]!=Z"M8L.G']];G'4 #%S[DASIV#.8NIW_E
M!2"(^WN>I!8]>.O.Q_INO7ZT>W1ZLGMV>I2(0C*\C_LTZ0D&E#&>RJ:^:X[?
MX K@VM+6!2Q8I/.@G462EU['%L"VA^DV=0GG%=AFN;E9$XY#+G8\:A(S4XH3
MB1SSW63#EB;?YBY#>N,L^2"BC%$]V(.:87B2(Q_W\-LFH($[^5/DM2]#- HP
M?PZD@VQLCJP5<N!]+VEOB<4(:?.V9/.5(2;<:^DBT$IWS@H420'-'+DK%JE2
MA+&>@)%$4O^1W*J+5 -4A'2F3 )0#W'#&\_^H*D'%EZ"9B4PUF/W7&=!\$>L
M#,--,S"])PTCC;55H^7,@[FK/EARIA9V[M4A)3$8!A249#200 R3C!3 $H8A
M4R '#I:=P3(T(<ZO^,I.6G7;/!_NSV;SK#:M>9D?GT7WZMQ-<!J![5+W>>T0
MJ4DNP=_C@#L-#;L-9#]09P]<\:G0\2+C*]AS$Q5>[E2"EM3K."*G&;Y1H@%K
MQS\:B6%7U(!:Y^>5X-6WRYG5X$FMMGMR?+1[5C\=4X(%1*XXFXRS=GEWN P8
M9;;>^^-:YY4@P198FGVM/E^??_]Z\>VNY5Q].[^^O;F^;=Y=?'8^_=.YO;B\
MN,4.8#,E["_9O6FE/;$H'F'R5B;8 6@C#TG)44S$))4EX8, <>!?<: 1A.)O
M$]Y#(*B[V#M?.2?W";Y*\-(#FH$:3TQ3T)S\<9!:LFGJ):I3,'O(!0?M7F_4
MM/QC2B(HY&C,-T\_/MZ,F_IA&QO)0/0N5H9SLLX,.ME3\0Y@=N#B%1C,#=@[
M^K&KJZLTA\W,ZS:-+2W=.;L$B#1V?&WO'P8.,!3)!]3G#!8,*WZ"D3%Q KNS
MDACPVO=IM3-K2M.!H=\6O?JTIV<3'2Z<372X@H,MA0,H]9G/23[_E,KC"Y]2
MF337F9*[&NLUUXELF)]GG??':<K[A8W(-@?;!S<B_0< L9S%W4LW.0MI8]FB
MPJ!S*U0_.MAUDO^\_;#S;J)TU _V&Z?X=&&H^\<G):,U/W_(ZU>'%"P,E#D]
MA2;>?P""[Q0L@:+Y?D?Y=  9YV@Q!E'XRSOVO)-?9B5.]X]$4#SEI5N,F]$K
M/4Z=CF=^PQO,3\E+A0??'!WZ,HR8V9N6+V+%++.=\UWSTY<+[!I^?OWMCNR5
MV8\1UL?:N<X-M_5GM5U=N^S->A[05YN^>;:2?,C3X^6\]HE_OWZBQ]**?JW;
MBV9*V:E$A;.7J\-TPT8+@"V5:HMPNT:4I]D])>+!1")BH9"RJB")+M\C:V;%
M^K"HK>F+RRX)L4RUF9E 2O8/:B>'IV<_ZL PS=L[YRJS<O9'=J]7GKHUGC3V
MNL\^/[WQ.,T*?%Y[M!F3#U?RF<,5?>8E &,S0>)Y8YH[-2GB2<AB?T'!GT/T
MRJ(MY0C5V/F8Y#1KC%HY')6/;2FOR=L&Y/?A8;2E#LV"EP6OK02O9B71ZV#G
MXZT(?SJ7#/,!-A3!3AL6PBR$60A;%,(^51+"#K&3H^*A].^YY[0BUNE01E06
M&]\T/*L?'UE LX!F 6U!0&M4$L^.=C[>*#G ]W +8!; +(!9 )L 8 >5!+#C
MG8]?>)?Y#L"8RZGNF,4QBV,6QRR.3<"QPTKBV,G.QZ\P4J?%.CP:.I]%B(?S
M8F6MLJ6C6<F.NH4<FWWPVMD'ITGVP>NG'RS._)OQ%6LBK1M>;29&O;2)=%1)
M$^D,3"1=&0 /W-Y./"Q^0;46=N$.G\[1Y(XI.5^Q:(P*Z2RR[NC@W,3*[;&0
MTT$J_6RN"ORF6E_'UI>T0&F!<D&@/*XD4-9K.Q__WUL><G7/O?]O4Q'LQ"*8
M13"+8 LBV$DU$:R.MMY8+3^,BL5A*$P!P&; _&$HR'"[3"OUG<O TW4F\1Z
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MT.TY&-Y/_+,'"L(/=+O270U4E,%(4$5#<>6 QI5"6@9=Y;G@%M LH%E VQQ
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M/"3QPMM (/ E7$\'Z0_CI1/%^.! \U?A[?O.Q2.V@$8V,:5FR$ #IVT7ITU
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MZ$8M)N:8N:#U!9.2.N.E.F;MAD('S+L+Z--!!\S[OH%Y-VPLW7KCXJ\[QK
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M/8^MA U9F=BTETGJ2<6*D;;GY4GC=%)_ !V7132.^-Z"/0EWUR3D.>+X\B+
M0,_=]'E!0QS.>99&9";32H9?Z%2&9&>'V7(5%7ONI+/G*P<7 70DKLCB)\<=
M&0Q>=A9>M'T]38$(XC_V>!F4THD^P[*+\V4IC 0D2FC2DQ"?V,:PZP4!9#)%
M!GG'*<U0V55ZC4R7EVKTDJMRP#P>4(3_,T (:@SCP60]B44(8\@.<1";4$(1
MJ9-CSIVD8Y>IFY@9J0,35@7G*DC*@=/9$!?AE)Z 2YNG<:D)]&Q36;'T$OG=
M]Q)[" IJK#F,25>;,F,AQ.> A+G'G?RVQIT,0/54'DU?OI'(IX;$PUB%2;IR
MT^/[V@K>W)1<2N!,!Y[/=.[V;;S>#)E41V0<AY//9!E^"<[##-04$H]B0XXE
MM-1L:X3:G@L>#/U.S_);D@&_?!/[+ __87+/7B(]/?^:G6/8*1E= NF#1AL!
M!#\H3&"$HUFS)F+%+$3()5W9<+250G8+=.59]B0:S.<HC(@*DG<][\RPG13G
MJ83'O>-CSXU&<MB&H3GX0J<G12Q@([=0HV;%AM98^,$Y/37UR**UFUC$/\R#
M8+=\<_Y8?K$\MDEW+"5_ MSL&E(5A$<>TO6*82BQ/:P15&@P=QY("3AIAE0.
MR5YL#U=OB;%*=FF8L63X:YB4>4 :)&0=N2$J_WKRM]S)2AZ1Z!81%6Z;Z?=.
MO[-XV!0XF8G%BD;\MRZJY,BQ!LS2:4E6 9L,O@1SM-=64L+.4 N@^M3UQ.DC
MK/EX$[&,6*C"U_P6K74ZB7Q93W:+>EZRDD M9OP_OO#/JT/=:T00+[(Y5?PK
M3HC&F(,E;J9GTYX%DE<;;4Y4;>9<2)0;UMQ538F8ORUYZI;S$$>?C2;U8+G
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M7[3")T]C6B,?ON72,[<'824[\!+X:K=I]V[3_D5F_3)*9&E.Y7_^^-_C[(_
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M81J@I06]U+($"44#,VTJ7VXX)1%'9XSN,VZE)6<X>>VX&7H@2:J ZGR3#'R
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M'/(IRH ! 3Z2YO%[]:[P[D,CQJ<]MQ^JFJA617@P6KR:.+2,UD;A>?3%&YB
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MM)R@,H E,_BKV$JWUG]2DAW,?,K^<#=DE-UR&]5 @V@V@=ANKN?J[,$K5[#
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M2F9QN%Q*,U('F.5<N84N,59":^TY7\^TFZADSK*T3%RMK%DC*/&6TY9Q!5Y
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M6CVV0S??W#]L?=.C,>3D<FG?$=+;IQ?!US)>-"AL.C8EV*P+N9Z77>P0:_Y
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M?FU]]<3^3:HG[M^\>N*Z--'K-[>KT^CONU"S<7D]VGN!"8L-/RY5YT-QUBV
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MOAN]!M62!C-SNU&&\3C/,@E;0G8QUNJ+K1Z<%Y*QPEYFXUHV?>=LT0/;(?Q
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M6X*DP6BY2=C\,(R6)Q:W@%C!0+EUF!&DKT=GH&PEQD M&VA2/_6%2FLVZI%
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M:N!+S54&6QJ0WSU:SU5UXYO>@H6#[ED5E21.#?EVV.M%^']/7T7V6HL8&'<
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MODD?1C& ("]O'6X$>?G1R<O7%P-X\>*Z8@#&@-?4!+ ,:V*C>W$0B@)\AZ(
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M(;&>54]AEE=3(7')L[N(T/CIS?$.VYDN]-#$4?AV\%40A[D!.!52]8&V>#Z
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M78P4..:8TDVZS,NVXFOX67B*[2PUB^Z]7=:#4B-8G3D#\^@+K9+W53P3X#[
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MXFV;.J/%+7GO)IDRG!+X7#%D@=OM$V=]^3%ZTC=1>1S0#*L-7;W4.NVXSMD
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MELG'\/H[TR*1V0/,M#<%>'F*Y&U?:Z-/OJ>/<O<7 4' PRP:KN[X-WW[WW
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M!TU ,O [QP:6?8DF!]$"6&A5K\OZT/!]"VMS7W]UJ!0?*L6CU1@R,5<E7<F
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M'X%]^'#=_F(F]*;?IC[QE$$(F_.KKZ8@>^'/#[_ZK7LW >:%7-$[<'T:[WH
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MMF]V^C\24SQ-JTDM;PP><18E2%-F[]8?S)*>8]^#VVF1UHY:P,6:^<9'4(K
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M802,L\G_+6^._+IY;R>:]O] ]Z70/LG0+<SV%K,&U!F:'>%LM\?LD%.D*<(
M]'0T;TVF 0\OI03HI8ZX\P<34I.IM^%_[3_KK^$^/N]UR2\L7?K>2Q)H$Y<$
M8+U:'3$TU$H2NN<Q8'UM#KF3V"7_.CFKKN-=UXNW%D:$:6,TY\H+3;:C55I:
M44K>ACKR;;R.FO)+$'6ELZW79) 9@IXJB6VSO:_F4JQQ6Q1O4_2A]*5Y7<RR
MC360I2H0*/ TLJ+S/1;U-J0(XN.$\NTUEHO:)HX8:8C;OD&V98R2E&54):NG
MJ?.EN53N+8Z,)EWW/+\H;)%30'99^/;*:QBV=#U T*P/OM>SOJ%IH+^1!T1W
M$Y0"]R@J33D*BWR.+C#?HSI09%D[1%&_.8IZA45]6BS+'("1V5,]ZH8!U:D9
M;>TM^&=-9AX%DD-T%:.KYT^?G*3@53N\RPI);=H)OZJWL4RY@Z9$?$6THC#@
M.TQ5Y)XPX"R'6=OP^M0:!+HA,W#P"K##8D_^5 .\^3D1?@:;8U]8C;] TTB_
M:COU/820N$0\)\S!/M BKU.CDWG9= QMN_>MFG/+I]@ _D#(QUEE_?I4Y/<G
M1GO3-XONF#B,[PCKV.#ZJ&[ZH2V91M=.F1$\5-_I<HI3,;UZ# 55K,LSQ@?)
MAR]DRZO#P;IK@43&TKI#D!]_]= ->5M+1@_O'4J;GU WY$>^&G,OIR4,-...
M?%=OB)0J 9SLP@C.84S;-[YJB -&''A#&V:&[TXX=4]?_=.:55"#\X0@5@'9
M=VOG5R4JJ@%Z-T#*@^^-CK(D"W6=BX?TSUF?(T]5:,DDCU)"@DG1N'5&SS3K
MMP[$,G7KE[2I:PYZ\T22:'%>LV !;FCPP6[_ >,':A,F\40%/-!:**.N'%G'
M3?=)G!,+K"N!M=FE58W4WJ.<H*5#JT]?AH]R^%^N3"9GHB!VK;*DU3H,LVQ=
MD%1V=I*V9%HXMJ<WT>IJ8XX6RZ'$;CDF@F,6#6'.0C04X.J,I:3;!""I"@&]
M1B<%KB#GV8.[&7@\O\HB]CEF%W$BTS5,&8^3F'SIJR[U\%"G^MT1EO&%+A/"
M4"RNV*?-.JNW*99*C1J2'@(?5=X58/_4Y1M8BPDZC2 3*4_I>8+1!+0N A%P
M0B,:VZ[2S#/="*C6JT.FT*,7]NAS("!_R5%13SLB\MDJ;[LCVIL@O0D[*^<\
MCB]M%4;\BH:EB-_6'&; :D=P]97#%*CKN'!VG0 M"19P[2&C<MSNK,[-!7]Z
M#YL"T[/D3"S$W]HK4]PT9V#4DXGQ)IN-I"C0<5=S4M;24&X"2).FS,M6&:$$
M#[&4-R0O0^YYY!J(PFGMT^$&TZ0Y6P1DYP 3$-^(=FG4:^YG$D)G+RP=2(A2
MJ(Z#(9C F^Z,2+@T:^E@6?;KV-J9GN 21Z=C=+>)3\7-9*WMC&UWU;?TQ8^Q
MUF$PH<L./FSF7HV.GWGIJH#66;J64CYOQP\A11(=U,28TM@30:*=P?:$;$7T
MM28+A]L XT;4%&&@3=,W):<K7J![QS$7R_C=9<$U98K?'2??1T1'#/C_CVCB
MX:Q[$W])SRH_P,0!23,9O'TVA=V3L'8F22^$GDL=.P\L4]'&";.?3:8^!CR#
MXJWK839Y/B3)O0B)M\K8,+[@TRT<A$L'4CH=?#*6!3/+Y_^H3[JG+W/0DQDM
M38M.U%Q[4F<A)\1&:.$E6??XQIUO%M6NM*13.6EKCVW&J,UN U%A;(5%6.-K
MI?X%#">L7.D!XEV)WW)^)H>G] \HS))<9BY-!0V !!M8;OA3*E,^((IP$@;,
M3& A9<!Y2.V_+(8=-3FMW,U6^G/(#*?(03JYA3/#EG8JVI)7HXG.@]^11,Y7
M=^.* #@>@]F_ZZ&#8SV[%.E$M6W%Q\&KF+AD%H[BZZ]//7#_[7HE0[^O\P>%
MHY//G[" =!'* @[M]WN6X7AK34,G8@M;R[UY6 A?F@<51I;PU:@#8%0CJ -C
M):$E*!'!,$*3VT,2'3<@-SVA3CO* D^8J3^^'5-X6$2%.0<+EH^^LNK7#L3"
M['N*@1COLFSH&;>ZPEG<NXKE^;9OR)QCI9,I9];+X/Z' L#..GFX)Q@+H(N@
M!BU \F).*,G3ZVG.G!X%O6)+U@\HS3\IFP9H FG(W=3-O%SJ_MB 9YG7TAU-
M/[UX^3)RI5QKJ,F#T]=GX5@;/@1=T*H7XH76?:5N)<;'&)4FE__SGH<]LJ;G
MO6"9@'*7UR3Y$RP)'+X#CJ! -H\S82_K^K!WSO#F28J+BQ\C2QA]R,GEK(3P
ML;W0BT-WB!\0CX#?/1Z- ^@P<]";$8\C55[4=1COB%9^N,?>?X=ITE8Z;C2M
M5VI_Z)>;6L^@3<X&'PAWWV2B+-E"!IZK0GA7;EPGANO26.=]15\=@A+M#094
M><HY;"_/ZPE81X3Z<=,F21RD)."G::;X92.8-NFZ6]%RY),52UL!X[IG/#]6
MV."3B,K/R>5.V5KW<E0EAT:2.L!ZYQ*1)1S%7N\LN'8^H/G6PE)G("V1U+9&
M&4#&'/N;V#3)N;AAM=EUCZ1#K?*V5H<>WC_4*@^URMNR&E/7QHMJ1N?/W/Z)
M%D'O:/O<+0J@$-5@VGP7;+*G&]V'< 0&9W?& 7LTA$ZIPP>PYI ZG*Z_9=3Y
M,571>D[6\D*=5=;:B_UZ,<O!<:%Y.2'0W&?J0V6L8Z(R([IQU-\^F3)$2PF+
ME=%?C3*IBI]VQ)OGM%<8K"1)LS86Q<Q-'-!%=44LK1F1_ "O%:'\NT<.:\S4
M)@RS+\%Y5F?:V$9+*Q<:6#A$?14;/<&5[H<2]8[VW)5/W$@X$5:4_ZCCF3DS
M)CF$ZE5X=PFCZ$"@,8EF2W91(S<-IZ_P+ O8FD>J&,EI?#I I:61+*MBNJ*6
M5'AGM-96*P')Q1>>J9035$WGS*U^0;];-'7;'J']H:07S)M++O((=!]8U0SO
MGO@879A3".LB7X:4O,L?R!M.67BJ,0-/:(T<3ZVJ3?+F4+1[2!"05Y&7+0"V
MKLO:WWF0B'\DKT.+&=*7&<.A(4\$[R[EH(CWE"XJ/Z-Q(\1F<.:4Q'*0!D<S
M%O'!C= $J\IB*F&%1 [>-\X:DR%9/;)\RFDQH1?J54D2*3F^K%*2E**1I\;G
M>/9XRD'T;B18;74CN^*\ 8'QLTON)CT9D_T5OM;)_(6_NZ!$7FPH/0:&$@&.
M<T\J*S$[IM!*2CZ;()=A*[4..D@R?TF%*2W,L'C4%34BODZ^,RNB?X:K$.L]
MKA 6FUJ%D)>Y6R3[=],9JEM _<5IL;RJZIZMVCBI(>]@@O5+F*KW\G?%JG!,
MWUS#-6C%-QCFOW93)Z'$14C98,.M=P'\,1F0)5 EWX 0<D=#AFWW,'K86I+)
M]V!'TB!!15@M);HDL02<DCS:,GP=EK\4L'FRS7XF!$+\MKAW ;,(;]44;U!U
MW@5KRH>5^49)MJZ@;;UV'=XTX#LV3E,7II/XHM3<[U8E[P3@513ACT"*23%6
M?$)-;[N%,@'9XI!WM>[9C]1#.5UH$\[/.(?.7!!F'H]8Y<V5$0())F:W0&O3
MO ]NZ@2'G&7,X39H#C,+M-6A'J$<%>*"<GVN]41RHZ+QQ(Z)Q*"2N_3,AD(I
M=XNXY&[(-AF70@1YI]J"27:$ETQ;N"WG#;Y4RX?\"G99E-/KZ@P$'T6AQ15W
MQ.%>>N>TEXT]!RW86(71SD_G:+IV(NU*94A(W\!:8/29-PO)D3ZJ.TVE!+-I
M(\<PK)<G;P;UGU'U1TL][8!%X@"*^YV@N-AQY"6/N=,H_.66DC@X@OLPU%>F
MT?>,?&8:[HC?_M4S1V]O'F)*'\XGJ/Z%^T[U?!>VOB$#O@E9L!6. B5R2._5
M+TA:@1?KG*8D%<I ',:P8!7KB-A=LN';>HN6\,A+&ZN8R[JU[I=\B9B O19S
M'9C#?\^ETM:;JU54'-%YX*M8,GP;4<N$9QR1QTSW0LYNOY9C.F_8DU+*?[UP
M70O/H/!CI,_Q.L[J"W+_+N2WPQ=-8WO]PBL9;")R%^UA<GY.%JN HP9OZYJ\
M2TX .!SU- C#Z92D-(U2;->40PDD\;)D3&7%E?YE<!@8*5"W**9B%X9?".O1
M&2T/MN/X+=E-!=FG\V)CK (Y>=P6K]G).J4G"K7+T]>G<7;&G/.W'Z9E%/+T
M7H_JU1&S3<EO[B>&*7C C0$'0UL9^X_Z=TZ%2'(MS:WXD$Q#,8>Y,Y(K@+E%
M&_7+!^+3RE(.[^+UJ=B+P-5/E^@[/$NH9L5]R:^KCD+"HP 9B[-U'%=#(1?Z
M-CN>S*H@Y7<<JQFZ_T2FLLVB<8D>MXKX=:S'B/P43E@R&IF0Q$'*(SH6PHK:
M^5L+]8)1F7NI:),N3K2%@M%(C838T* VFN^Q%I$A(Z$D,\A0Y(E-9Y;Y;:/<
MDEK. 0F=8Y\=H#7Y+39L29.L@28*Z$7[5A21=)6="1/DCQ)1+#ABB*=?)UZE
M%GD,=G\"[B@^#!8!PX=C:SM'7@@DC0Z=)P'Y/!5=YND8DZ!ENO2WO(9'!%S"
MUS8 *DRDXZYH_3Z4[&ZP9/?@4++[N$MV[].CWK\\3\8X I<?DR2.MIM$*Z0L
M-YY:9%H0*[HC"=%.N;+T%U,BMA[/RO6G4A1N_0TDC%4!F)QIQ@&_A_EYWVX&
MA)W%?-"XCGA<ZG>XA]"%(MYSTU>.OH>UO%<AV>:>H:D[P^\W_BD"^#ED!<V8
MXWH7];JGB*,):LV!B6#H/TSH&W\P)XP.RB-API2?U<G\5P,TN!'4O)*CWS@1
M0NM];@[3(7[_[?$[\&\O0U3RRG.RW*)8/0I_IK R)XN0*<K=F%B+6 \.9?;0
MW"3L<)9:10Q>5KT&2Q;/>C*AX*)."VT[<7<I:V/;'+TMBFW*!PN?V9Q%CL 8
M>.?*JVGV(&C/E-7@X9SX0J:J#Z;]%1%_&L73/<@?'_+?AB2SQA->:6@F^C*X
M2A4:K"4N[ZL(VVN%I<,(N'Q6X<Y;L@@?H%DG;Q/[,*"RZA'!24RJ*Q4SP+VY
M>7@P6JL]I%"=?J8K^7*:@A[7A"$]EV_091']>59/@*DU'FJ46,^D@!NJ.&'R
MWOM4K*RC:#P)K1TH?C>T(36K)ZX4.>@E%V)&HVZMA2T*R3Y3-F')0]#C%8AS
M5 QNG5^VNNC/PNNGZYZ7\S+TD,0E^=ZGH5[MG06W!A /Q4$8U'I%'HEDU<L6
M$(,@[9>;R&K\*&M0=%J$XKH=[5F:B_?^0/I.ILG:W&,)BC*?>@B\]TH9O.>)
MI?,8HG6I)2@?_"?"J#"!JP*UN'6([ LC;Y<]D6B#&A_#&'#L=%PG.KRDR/[O
MOEI$-&C'G?W2IVB*M/R#D&=JD*UU!9>9$<'G'9GD9=2"L9L-W5/_Y!8FEYY;
MC<RDJ2B/>;ZC^DUL)&8C[^IY5> .",V9+A\8VZ]'XK)\M/WX].1+9(KI^O;/
MF%%.H2&1IWT -G(]2)8\O:8V\4WBHGU^F.,&VB0+PP6[<I5CDV@'G/,^K2/9
MHE?/7K[.G,J0)=EG)K_G,>$."2>,X9*0Q34X_5<4@1G,M2D,0":\[$/V-X!
M<)%WR#&YBV _ +^6.\R\/$JY"LL*22,>6RKI*3U.O*W.>O3@9/'T&H#8)">(
M++^O6,A,V2S%VK[Y"S26)9+(QLBY*6BP2]Q&W0*DG_'WPDL-<>E:(4?&35UC
MQ9U4NUC>')S<OC7+M6R84 8/9]BM$*Q1E@PSLT-[Z_@7MQ#8$,_,CFT8N*%P
MH.YG:W3X &=:.-JAJ!NEJ.1WN*_N2T?M&PN;-=-8!M>Q7BQZLD[!?[9$89C
MS[#[04K7T5U)"CG!8YLGT00K* 0RA+ /O>890T1',;-JGH6['<_^!=O$?1<*
MK4RBD$)*2_@[NRIELY2\M5.#VR:::"D:-*Y]548OI=TYX6&]UCC?\"8<^)!2
MLQS)S,7)])C#Z6C)6BJU#6NF*NZBZ Y[@T%9.,?-([GVI4E@I16)>M'#3*7X
M.%KUYKQTM?-F"IV<1OIR*T"&+DH=LJA&T(,<SUXF3^NTT6PF!2@;!37<],BP
MO#&L8T/R1#,+^RK>+1!3*45I<GZ"FKU8XP16F!29Q2U3-UT]V#3"E807+5R*
MWP+FS<N3.LWC_9?F]7<]33^9-00'#)>J&0N--3VYG.+"QW90X18.JXM0_T9U
M6N><'BYW5MK>_W!=,85V*>5U'F4<NAR^P!H#^\5'S@6]%D7J>DFZX%*@Q8R=
M!MZIW%F(?PZ6?S86;I)@23#OIE+KB#+C"+:)U&P$ FE7OD?8Q,L/X_8\YD.2
M7 B].0#HI>KE/8E$ZBD\+6T3BF0_6S06:YU[J2NH7%B6.0'7LBB6?\=RJW9*
M82?AM L B=5H2R64_8.-%0]Z54>T)5XLIX]^QZXW;J#-%^=*9"O^  C+V$0R
M8]M",=I8T"RE/,%&X,V=I 'D+/61)E<BF9VUA"G'V23[O,3:) OQ@R#6TLT0
MT*U])=FDX?ZX*IH[><:''LQ=1\[NEC%DUOG,\1H7DJO%+F@A[8ON,@GOPNX_
MM!;>VCKE5X<ZY<==I_R45J/WDO=8]&QTF%^H"*TFK,(I';)0P@/'V2'%!SK4
MR2-D)NLVD"PX=@,O5S>A>ZRP0W=9A.CM(SY3DFNF#JZA.A(WQ(B9.!^AT([C
MV4_\P<AH![B)V.#"4C>3 </?KF5Q'_YAB_OP/5G<__R/_V*BMAFDX[=(OU5G
M__V7NW_AG_7"_+,.84[.<='P#:PUE"W&HUEB4O[ RI4[''%;WK:E7]N_PI^2
MY_V+/$.P;,X.EHP0HKU[49=+^^!R8!*^_JN;F&XY_:$']$A<F:)U:(:#YOG1
M(V=)V)#@4M_>O__PBFO=VW.M*T9QS5OOM8EBX]Y3=7G?4IUAD1W96:(5X1NS
M9\-((WJ-D]GQ/1JNR"!*IBTA'E1L?V@K,=<Y^LL">3981%+#8C]:(A:R6 ,7
M *^>_MOP?[$OTY>Z6!=Y\S?07S[:Y+_89*NA.%B<@\4Y6)P;LSC0/ %0(6\8
M2.\B:Z0R!*8 #R>$U@/'YF +#K;@8 L^#5M ,6S?1F] 6UB#B**73F1<8-IW
M96&4_UPF'XS."/,!U-;UN)H4K9 :X,&P' S+P;!\&H9EM,O;HORU%RU1L+)7
M@A=@ZR F2.II@'1P3]>&&R>9I%#^I3)PG#LYV(F#G3C8B4_!3I0!H-@:)4*:
M&%V4%R5CDQ8-<\B!@9;^"]3 P10<3,'!%'PRIF!9S/-&<*72#XL,9$B"6D;4
MJ].EP)\AK.)#V()#S]-^J>38X\.%4"#]\</3,C^K:G2NWZK>I]?]@C6IZI5O
M#!JRC@D#*4 53,((Q&!F6?HA[6;$"!KZMEZ%G@<&\H>9 *QXZO=,*!DTJ("E
M V2O7D''(:]N^ 6;L/WLHNR:VK\^^8L-5_#S09W %5)#WP<0(%%O+P#&$S83
M@X_G@B\$&GP9#(#;]P)'%G3YDXDY;;E+5A325[M(O0A"$>#Y-E ICJ1R1F;.
M-B@7C*AH<@@I4M%WL0'WT<1U_:5F0CL"\0%P? *>S?V52K&-LRYPR3)-IA:M
MD8X)9+.&6WO'2)C&BAOF9C);;1%HO:]_G0B&[1N@ZJ77@1DF4"8/%V/U@_.R
ML+8=I(&TQ(V8S>N]['LMF/RH9J&U?&23VL$.\#A*U@X8M3$;>NR)X"Q!IE9N
M-%65]A\J2E JX>,N'-;5,M5KC[\] X2JVM.GF(Q623V4W\,I]OG^D+0OI&B%
MZX0^H14X/IL$G]NX0IZB_B,X=UWJ5Y,J86ROR>B)ZH;\JRQI613>P(#A%^GL
M(<XVL]";IY3C<9F\!/_0-Q=%2=X>PS]_KIBW%&RQOT"T1Q. 2"O2+\@VRH+R
MP#[ TYK"I O6#+5U!A%STR;+1(!P7ES"ILJQE[FIK&I'CJ+PL\"W\_6]NW?>
M?A&O88V.VL^CEPB5D&E-VI'A_PS!_V\"!\%P2K5+:'2H-8)[UK-WU%AF6Y^/
M#&X/#'+OPSMD3 'E4+G#_J#)I1#90Z6U*1+Z23>1[N8RX0!'FR8M0!9UZ92U
M-T(J>41Q@'H%623\P4 V8W_CVU[FK4HW6(]!@@92IJ.7^4Z)E+[-9O>^^^9A
M%G%"(LJ1B[@:IBT;\(89/RN@K3O8EYQU6J;U&/.II>^9M0);U<N3*/1,=GDC
MVCAYT%UTI[YZ3->=TN1QG$:,2(>UDZ_*J'@&W]:]G$Z0P/D9GE4P771G1."&
M[X^#E9L*?>QON85BU%IK10EJ>-SRU16+\XKI;C-_9-C)E#.(-U64$9[/?;IJ
M YKY">7+T9-=]1JN_9S9U,6UG<MV1*(V*&T"NDGV&>J\.[\$BUVP_*###PP>
MH([%&"^+]45AO"3!.B]-EVT@5FHXF*5PN,(O9))]AZH&]3;S>-X\2)]V5UJ!
MB]V^S(T%#I+=C%Y8F?3:F["".>+=;JL$Z$%6B16S6_C8Z%WU &]>E/AXXJYD
M:3-4BDB22PSHF&,;<J"D%89O1;^/B1B=/F DEB_A5#SG/L+4(X#)I_G)W-,%
M>C_NQXU* 7F5KW?=V.OBB5.2/@%QLJ 6W&-3:TZ)[N5^OKLTWEP)WSX -<,^
M*:K89F2=ZZL)-@MMI-NEO=1.(6'8)(%+_#_M^'F]:[MB,W.!O>=R_'^O7SFJ
M0N'8L066MB-!2H [)0/?7?!XM:DHLQXR;I"@MW3H [A]R.N'7Q_Z  Y] +=E
M-<+MEC[5T%.5I=VK/M(?-<)*)+B41JDW@Z,JVGW/VYH>Q]R[-@Q+^436' *?
M@>)=&',:I-J4[$;]5PY&XS$B/HXX(%D0$0G-7P4SZI,#GS>MEQM)/+](7<\G
M:9"@'X[?FB4G#PSNO*9;KO*+NA%]].3D4W50Z=/S'7WR&CEK$7Z+/2&_MX."
M&??EV$3TQY2\01S%\5"PZVIN#X1T2^03F& :ZC(+HYM8<6%PV M(3^QG)KS>
M5"/8YF8$M793H4V!^V:#_*W=9#>B7E>GR;%1N#E!+GCR#W)MHZ,5CTB4:!;2
M,CUR<5FN^9()6XPJ=YW)94*>\E)3L(G:[@;KU"T2'<CQC#LV0XNF^^MZ3-C@
MFITGNB]32&G:KN.91U9N$F,;S 0CPV2C9FAFQ.+59RXY_KB"J8$?TB*5D&^S
MGM3)/+U%.5B:^9)G'/B55/8TZ3+=RZ)BJNEA>9JM:L7]BEG(+%*;70@'B+*>
M90;3]^WXPD,>&76CJ-KD^ :<7L>S'\JWVAZ /SD)R[<L@C$Y+?+'89N\[XX7
M8J+8(>]9=9>R[]*L!2HB&GF;D\U&V2XQ:/R]TWX1+)NR386)=1MZJN6>)3@\
M"]--!X"6M,&IH'I'!HQ@PZC9909OKZ9?B*1/Z=2K%R4GU_E)*UK=ZZGL?VO*
M,&U1O)U.0L\LF0"M&]&]LOR"OV 8&U^J=:(0]E1@G:"P^U>F?\^%KZ! ECFO
M"A1'IN^^MZ1FY0T_"#41XE9B\E@_&MN:SV ;B2D0AH$PKT(X(/8.K/W2D22U
M+.!%IG@W.ZOQG"^JV4^+KL:A=O_NO6\S7<U@XP2WI@:_ZZ+I A0_/\-A*).I
MU2_'#,@\@6:FX'K$%^RTK"-!4*P!!8*5R%L$PI1S:'G9))R7J!2H'V+)^N7>
M5+V.5 7I8)GMC2]E3+SK[C^2\<F6AEF(G^)*@HA)"^\'30K8+(K9$PO1?XA7
M?^'D'D\B9;=E(I_\$&4%.*<L9C\.SX9#,XNWH1,OK'3(@G'+9(>_?3?[E[Z.
M'^08MF=] 5F#V=^+JMZ@?.4&U_9G9T6K.N;&8:"Z*Q!_8Y$'-Y&6](ZO,^6
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MP9G<SA!1VG :"/9 W,=]!RJS=.U5OTXN[&6! U=7D* >#A0F$QH#>#/B4V>
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MP'9&:Y0/W%QP$L:\A7>C?]-;T>=7D!?K^,Q)7SD;$#833#\&MX2?*R!2 T0
MEJ$)B1T8E?$TPJT:>S/<1GP-2_IGY4@2"@&^(FRGE'6=_?]L<PEP/6)2K(./
M&IU!FV1+#;B,F4;V,;?JWB1LWW3TGD('[(W$8%WC>/E;$L9;JHH)XU*?TO:S
MPZ'+B+!H9'E*ES-^#J"DBE>O6[RS0,ZWQ\,7:H<I8_K9KIY_%4-/@9$3;,6M
M^@C:#NF3B!6=!,K/V5>ILX:(Q=ZP\XH=3'4O;6N^K+D'5BM$;:A<A]J->?5P
M?*R =#P[Z9*[KM&;&4D__!T"7VXLM9)%.N]I5N%>%GG#>%F>#^MTM*45OJ57
MD$F"PBRO5SYOHH_-]3&I-/DRHGRD6(KRZ[0M#P.1E)@18W#BP-Z5OQ46MO^,
M _VT'"$,4]R*)[S&FTYX><5Y$FLR$QU,3T)A($ZK#J(!?5T;DBHF$=& Y(>K
M9L ]D7<I5L*0+!-B[OFQH@;8F1XI35@I0T;*&*>0LW1KG1\G$\H=7;???_]Z
M'S1!>#5V5HZGW=N05Q58A3)FJ&9[R"%]Z&)%"(#.?;'2FEOEJUN\SZ6AJ*OA
M@FZT@7?*_\8;3 ;)K^'=FU0ZJID;PH8;R36*PNA'IB@G:)[;GM&)7.19* ?!
M:!'MPT5( Q"*R.E,1(=,EH@@:ND'WV]O<^1) 7<67NV45S-4PVP;-G$6]FU)
MJ;MU')SC) ,2&U4E]H%7>=D$2R(O6>U(/J.XMT0Y_*P1S,Y</./D'>A^"F9%
MRL6R5T;4+5Y&-I/>8[I<Y%W@3B)\I#ICE^@\CXN"RVC"Z[B+WY*>//&:.0$D
M)S< D [8C]PIWERO[)J,.43:()*K%&B6!+3D>5ZN^Z8(S%6[X&A:,7PA1E.A
MHHR03L1@_)T75^S7S_;\/='-!)N8)4?8J2$Z9J?BQ;>SUSTP$-6X?=7_P7$\
MEO#:K+"878-I/3GM M-SDL,R6:\LLLFZPX97I1)',V;<,I)IH1G9NH!'E^#3
M<H%93 3J0?WDO%POFZ(*EDO15"\JHX8[5??Q#B]/&W?Q"^]N>K OE'F)AE?)
MZ4,K^LG+UXEI,+@X%KOI2]C$!TQY1S=L5SH/8"73:CGWVAKJ1%H\4T!.AQV)
M^3ZOVRT@EJ*[R'9=SR6%#5B933UAO!)P:" *YY 26TKZ+BO%,?#?//+)QC\"
MYY!Q6A5LGGD TP.S8V,X9^&JEW3< 8NC]AOV7&-2P>"W4L6DD_+W#.I0VKNU
MI;UO#Z6]0VEOM!HU/UV2^=K ]DO)"?>@HP <D72Z/PLB,?^@TR1O%!U[+P.!
MS7W#UP5^/ J;UIJS0\S8%,* '8!26D3;8XSI(^^]A*'62X9=U=51,&W&]ZQH
M3'W9!HT*'X.#73)WNQC8"AE_97W$<_(T)=XU>W<: '-%2D)I/17"3*VN=4QE
M?\!9E$PIVMLEKU((3U7D.Y4\G[BLEC''NQ:6</%=,6KOIJ@/NJ+P!C=^IR_Z
MV7F&1O245H\$'DP3#?F!(2!W"GL;47KV_:X\>FO97+Y:+ ]S34C1P #^LJ,D
M8C->#V ,T=5ODS-0KR_8FXCG^T2.^36&)*---(4T7F2JJ"))*5D-5A_B3#E5
M11='*@XA1CVAS9)N'UZ@UHDZG+60BZJ;V21H&>0?&)CNCT6]+<+2EUF2.'6M
M7/A<[LB&[18R#1*KAVJF5OZ6B1-<+AVT6AXX A5?(U+4X!03:"[[]CPG3W;!
MK&IYX.\JVHG@;?A9 $_)=XVI 7J)?<699+<30:(&DK4BD+C!92XN8"<FDGV#
M;ZKL"Z]-&? (K]LZIW./8QXL79R?B4-@['U/^9P*GD_6-3A:P&PK+-.?:4CZ
MPM5;')0^X#=BZ1HAZZ6V>OHUYI:G8B\LK"Q212QZ9>D*X,K;>4T["<7N</<Z
M!IX)N:WG4A%"2JFPA]RAH*\U\F@5S#^^97(C9/$XO'&7#@VIG*D"]4ZY$L,Z
MB(Z;]%IL>*H:_2;2"Q5:'EQPSE>EG:ULX=YF%:!I B^F<<_Q?C#RO<$^UIF)
M.C6I%:#(#%TK[;E;\&Z71DP/)RNE=[5<Z(YLH_70.68*ZO"I;4^77KB$+^>"
MM1,NW \XE7(AE=2$H<EOTXBB8(/QI9AEKC6HGRDG4I.R)&:^OB <2U*ZUUFR
MXV)D"T( ;BJF R!-=.$45#\W%16Q--=^!\B#X, I*R?@YN9&X^XP\#1BGOB*
MD8:S$LIZ;7 0!T-A6V=H+S0UQ-SW6$MO8:UP+H>)OTIFE!_$>-FPMS]; XF*
M:_0"?-X:G=[L3*^2CB%'1BG3[=HZD5=VO>J,P=!.L"*V!G*)*BY9H9_,9BQ5
M52JAVVR-6-#*ZVNX=T+.;OU;P.<52^LQ<Z[.<<CBQ\7@'VM>,[5:$'5CU:4H
MDZF;TA!&7.D!(ZDF\8T?SHT_[@G<<.I<-F0AJ@AK.?R]Y$ "ZY!>VY9!-_P3
M+>2+<A%K("V]X'6@=>?I\?ZINC\4?G%FTFBGY>R*+@VFQ[78<A\A\" *Z,S3
MDF3<F^PG(G+R1Z2]XSI R<P-S1(GE.OILI"<=WU%4UZ( =_1D\=""Q@P\$!6
M+P(ZKNXK*]XSPZ_#UVD$Z9:V-F?)'9.IFO2D0TS1M^(YB'?M<6K#@H%K".*'
M3+N!7).#UM(RZQNB;7M6-Q*DJ&Y1BK)EV%3?6=<N['CFF>:0ERS5U]1W5 C1
M-..1+5,[:%^*:%K+E,NYXESC5<^9C$D\[:BERD-C(Q:0E@]9D_5&EQ 7DWK3
MP:B'+S:;);&_BM.)-,':RFER="@E(F!H_/4B7=1\@/:^6U-QM;R<XOKP#OC4
MBDS\[W  \\X@]VN#M2%\B>R$UG$ #/Z(*U187$;* &Y_2$!+]]]-K#9;6ID6
MI["<TP76YI75Z&)!.KSCW_)NCV?/4+#@XF&83A]'>_/@'F"PCQ,WQZDLBYJ%
M&*[4.B)\]BB,:,,"RR: Z$=6EJ3WNRB.Q!DP9"L^MP2RK ML_C%<!,*QZ@*
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M2X-,\51+(*('(9_#W.'&J G^AA*+VO70[R90U9FHQ#)4BHUH\H<TQU&&\]7
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M"]S<.X&JV-?7Y:HP9P+4&T'/.QI1G$<(EP9EUJ!;!HJ;SG3$(R-5%Q-J$MK
M%ZB9@H(3B#'76#(>5+\/(A#@RMW9=_/1=PP8"A<PQ&8*YP$_?_KD1'-@T*$M
MZ!4.#W@]T/Q)'MB&XOFBCBU?3],E+9=C+XHC.'IVJ+]W]ZA63ZBJJR-9)?)S
MP"+K>_!3H;1;8^RCGLFKLFD[YU?0K\_T><,<J+\CZAA@4;-,L=([HJW8?(C)
M#R %;)XXNIFT#>$"#3SK771$H@HX+L*7=*JC_++RC33TD*^WJ<NBVP5,KO@!
MFWI=+!B#V,R$O@;BQFWBUN0+[X,(%9CD . W/8V10[*F^*5FX3DL898OV+$3
M9 #[=(AS?H2SPO/U]=VO[\R_N'/_"Y[#Z!FQGV>H;I9"5K]%?N=Z9=CAYU%>
M<G-?Z@@NZT(F% 0HQL*2:U6=;3*NP5%;H=E$U![YR?,N2-U(9&!OW:7S\F3M
MN\*+/H=TJJY@Y"3*H7===O;>6%\%Q(56('4&DLP-G2-+3?V]]]V"75)6*[Q,
MKHM:/^^;Q!:$#=S1X6D1)HUQ,VE8Y W-^.VF+Y:I^[;:ZJ .=JA=XP,T+;PS
MS JG\MI9Z*B$EG99)XJ];=<O&< 2N8$B%2!W_=,5F.5&Z7;BZ@".95D4F_@W
MK%TI Z-K3[)>:@O2"*9( YBDU1%/HBV),GI11>-T6=LU?.ZT:CK"+& ):WL]
M3[882S^]'..V%OP6L76F%8*78E2@P*>NF%:IO=D.V2H4),P#!^3RU S[I??D
MVCN'MJ>FW51:5S4VV1G'+L^#W9<@:?+)N'D*8]AW[B3V=@9 #5;-Y#ZDUZK;
M3Y@8[,.Q0RSL:>FMX0P3')&Y'&57F 6+RYHBS*BN/B6\T*J M&6MUT?&O@9]
MDH&#48%[KD6;(3<[;4"*U^#+FDOF"H9GQSST//R.G.JSOJFW!:T..MXU4->#
M_G_H=DM:X*(.X9+JMRB?>D,>^T_"P2CNT_T':#6]]U#.=B9&J1N1Y/5^DTWG
M1:W=CRM0BPFW8AX$U >OX\Z^O.GCANQB]P6[DA1XXA#-A/VB69SKN+BU^-XW
MF=I"M'[M(I$7.JZXS73BME #-ORY=6H9OBVA\#A!;Q>Y1E_?M:W_0]G.Z0MO
M %_8:68FG8 P FR9R;M7*?G#@\";=2*=<:5/),[)4^'O/"_FS8AK*TN38,]^
M'N+DP=<HZ=ABZ7-<DR\OV%,I?PHX?]1[',?[T^A/=VU8$RL#>V\P%=;CR$QI
MW%=#GWE21V#5R5E3* N9]989\PP0F?K'&8,=R3_I^"(^/]E=UH:C.)Z]#IQ#
M+N&]:LAI1JEYSX(.F67\C<P[?(YL8*1I4A>[*[H4LJ'U]QV2UNQ@S@+S"#7<
M'*M=-0J1N6YS!_KT$"_P^4U+XBF3 G W\  ME>E&&P,V%3WHT())C> ,^5=M
MT\>B*CRRKYU,^DXT"$].>&9UDY__)^F6)4>7HR,^@$.1'6<GX+#0G-7'=5\Z
MGKWH=/FWZM:U6!GH(-<G9]=#GW8?KIJK N@#-3AU?,IE(;U;TVNG- 9$+86(
MP7CY_2L)]+:]T44OBTXRUF<]S8U! :(B.9/ .FDSKODP"1+/"Z_TD>D ?ZM@
M#H1423O4^^V2/42;YF3(H>CBYF);ZW41X$Q/ _\:%1J=CH)3)7)_3M:K)6>/
M6[K '-NG]:W[S'9K^9K(_!N6@DWV_]Q\AN7F\ U\LCP[<0$^ N6F9"I@.:Q>
MLFFVE(;^<F""N;3S8]U<YF357BS(_ZZ$-^&'LEB<HRK0%<;D/MRHXTJMMOB-
M\8>^96QRD]'I-]Q%,NYL:LTA1S4WEO9""X+EBD4()^UJK"Z&1)WT#G+M1SY)
M]AR[DCF!)!@8*_-\-BOL=4EWR4-Q:O!*N)M;*6:VY]S'+I2[X9QCYG_[(7#T
MEV'=3KGB>9.L&0_ <ZM&8RK-,Y+!?V*W>2.153COR!>Y>^_+^W>_?/9D=@?W
M50Z2\(&@=-N"'85OBF.U)CLK?@)=?1BW3;D.:'>1>+/N.P4#*,^P9=6,Q(&W
M5[(RD48=W,.FZ>?,1I%N96&091:%R+;(Y_#2*NB6X=5='^=D6:XXJF7>L"K(
MP51&>"!=+!'WZHPM)R>P1;2VZE\05D-DLQI:'W49Z)W]K!EGKNGB=]E,BDI(
MA2738)M<V4R88SO44 ]=G[>UW//-@T/Q\5!\O"VK,11/0%L%NE3S@G[^DN*+
M2!@3:P=B>TJ+%U)5F<N: S&RCF2%:B3^_L9?"G0Q3X)3<1*<"G_T_/CD_[/W
M;LUM7,F6\/M$S'] =,2)L&.*;,MV^W(TYX'6I5O'K;;&\B7FZ8LBL$&6!52A
MJU"D,+_^RUR9N7?N0H&D;4JDJ'JQ11*HR[[DSLO*M4[LT"D4RA2D2XIN_XS,
MXKQ+1&'=[!/]VK,GQJ7UZ8@)16X2K91*!A]KG%V0,]JZ[)@R-@806[2464+8
MD"[(HC=S@4K'P'=@FN4 :B2;REP\<B!@*)[(V4Z/'&NKFIR)@[R3&[0?L7_U
MT[AWD84Y6I^5X*C,(CR!YQF8?0CQ09:<$_]#URC%_K-/GOW\*3G^L[]]\16Y
M2(^^S)9I^EQ:K3'.X'":ZY(FP& NDS'+<(FC7*^D-#!8.)GK0VX3\U]5RQV^
M*FOT2)I)9%D)B:-U%8&E3ZL14B/8,'=*=\"+DKX@X^!2/\=S3PG5M/$*?QF=
M+>-PXQ_32-@(@(U7,Y6 01U(Z'VNP&J:][E>S% *T1L[GKU6*&RBG.5YV[\K
MYW7P+:D(NSP>;_[</>1<9M-O]6I:O-QS(GG=F O)KA6<0>\&%C- *Z&$XZ9I
M.,-[F(!#SJS(''!K F<XQEXVU1NEFA[ODY*7:?GSDIA=5"5_CCG6('>(=$5E
M4EEH99;>:UQC$4KN1G-N.3=-=-W:VI<&BS5#-7RDANIYY-J6C%DA)X^;M$KJ
MAR/9Y>\3HW%:6,[";7JT&&"'H"EG'4O$6<QB:D-=VG18O5A?Z82^25YH*IC=
M2L$L(8NF<ME+=/%5;\1_-*J,$UJR1]]7\S>G3&_+-K</L<9^B'.MR,-WMDE*
M*0OP0&D2+Y)N/]]U+!=71Q$Q1\^QER[F9/(<OF;B4=1B=N1(+I*,@0&SZT6C
MS)!%Y"DLE$FCD,:I8BAP W0] IR1U%W516@)AB+MV_&LT'%6PI"4SC=?_/79
MDP&T*7TD]2:/W)X-_WG/W19H2&;R:$?!J4\2<X19#L-,&9NUS*1Q=Q3%J-4I
MRS$*7<QHKC4[?Y-I_$Z_R1TEY(=\EIG/#D "2];'BL"39B$YMU?<-9R4E9C6
MP:O!Q2<0,CKS#E_EU:,7<EG#,9PHC 1+YY-GSU^]./D4=_0W+" Z*T-.]E@&
M_?<LW[0@VW!9M@MQ[C9"JXTJ*@!G+QQ(:4#*,U?&_X.M:D:QVC*9'5!.[W0Q
M+97DUZ&F2E0N.>P9JYSP; 7U<=>-.I7T]AT//&J-4L)N;)>>A@BE DQFS>+2
ML[-JN45;WKRO*T:4N(&FC\<IH"%Z4VF+.M+SDC*D;8R4X$+["=>H(8 OAT;$
M'D?%%!"]B62T]-<FNF+=,QJ/;&QA)C. A]?"Y4[3B6FQQ-R[2VQ:@C)/3Z8@
M?F]+I>T2-]'L'YBAE_H,74870?M-_/2NB87",4>&"7DWK)S(X[@(7%)F]S-6
M%=B[_4@=Q#TB*S=^<=HD&1Y#@4$HXBUK5(Q)"&PLB*4R:U*4T2L+9W8&%NG?
M$0<G-6XK3C)42^B)#YV31=15R(_/]"@=<^:?D^.FHH3CRU#7C CPCM7@Z*2S
M3#:*P',.4H0DF7,B284R8APDJO-G?K/<AM14I)@Y$[F3SB(!P<Q3XV6,TQ3N
M&"\7Z[[:!T^WYMT)GZ)UI3*6ZXRR&'Z0S 49H"NLM%:EEV=D))G''@W82 RA
MDM.%O.BN'&-L2..YO%>DT--P+J=AFS_>W,Y(C1"*D9WMJH'Z*,^OZI?.Z=8&
MQP^%^OTV+OBJ>U/HY/)?VHKVW*(;*OMZ K9(S9:?6%,H\VY#F1\-ETZ.CVV/
M*:CQ"(,#!7@4W9$B-\ 2&%L%\BX%=$E<'JK)6W;[Y4E*;B>8""?;H=*UW6W"
M '6>8Z84+!/ETO>?5]T[U[6<><HK5FOC>BAD[*5BG5 */4!8>^2X#&M9"2%"
MSAT_,!+DQ;8Q4<9^7#"M9=3(I00T BK79N315[X9[>U7?Z(\XZYP"P70__D_
M_O=6V*C).]LP.45]]E]_^>PO^%DOC)_U$4X16.(&EC1% >_Q+*OP_8G]('<X
MXABFW'3T:_M7_%/VOG^1=XB%1E>6))>1ULU_SLJ+IEK8!Q>#"MW?_L,-S'8Q
M_J$OZ)68VI%7H-7Q:)P?/W:%/=3U^%*T8;ZZXEJ/#ESKBJ>XX:T/EBBEY'A+
MI]*AI3KC179DI5T]2>ZTBL.5V59MWTNHIJM@E/I8\1A"7:_+!/"V@^_'Q/9
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M><@*)7^=*P4WO03HR(5\B4%$(UYR!D*-";8A$+5ITP^J<>J2965FM0Z!BR7
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MZ((*"-L@N1V$OGQ[I72%&+HSBQW8JP[W=<>L/UHJH[9Q=/W$&KCM*W2+G;9
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M-JR9J4X83C;<W\Z]ONU.Z2,P+C@T\?!LO'=A*^L=Y!HW:36:$#!W@H#Y:D+
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MT^B40IMEQ1:7!^NH*YG9&E.AS6X-9(?Z6L%( ?:*>[->18J #%3@Q3]"K1G
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MKI(Y7(!?A3.AI9J'L "RU.-#:=:VU;:/T,8V=(844"64N[<3Q^_*1KRO[A9
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MYO,T^1W-!"XD/0*YPL!F9O^^LBJ2'3R>G:RVYTBU7/(9L:K"Q<&J6%9:<[D
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MSL-L]"7ETDL>=N*IO+SA)=BE02&!Y.]I#!BD)EVS;ZZE8*]C/+A$H10<#52
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M9&SC*_E!M59-&>!IVM+UU,_E<1U(47KA*^<RQNJE\&T 2;.>4#'X1/6Z$F.
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MX=VON@V=).48&&EG#X-R!3)(BAJOW+CXCJ&?%$,+$Z+,%#N+HDUH9VP%R[W
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M<M\_2KO?=.O.8*]-,1W(#PB@#J$9'1- _*EDO/RW%J]@$1F+R'@8(J-P&@'
M<,%!H -;A^TH%V^<.QIG8+GORWU?[OO'?=^CB&#M=@VQC8Z;ND(GEQ2_V*8,
M;FLZVWR\2(Q%8BP2XV%(C(AKNT4H+#BJ[II;4]Y%;A :04")QJIX(7@3=B.,
MDE24MRCR0[[C2O?5L$B319HLTN2!2!-;X)3[HD,#%<F].B/&X;S#/V'7"-P(
M;>>Q/?>AKU!8.EBF;*<-<%)+&2%5AIY&+NM+/=7@?H>'V6(_"I5@\_8M2OXL
M,,LV[_94B4G]:WY,_\2&!L];QC87<_DM9M8B&!?!^- $8Y5O"%@S%$.OX2_#
MT?2Q<8DQ@L1&;=0"4RZ'NSKY'M]"^ %!8G(C8B1 _8,7*;)(D46*/ PI$KI1
M;X;]:&R/; #U4QP+;+#T7:\=0[)K.4K$E^LAD1BL-F20L%]AG==O\'FAFW@,
MQ:!C2';)=V K]L)#ZM\^?0H"BQA&C/KDD76FQM<B[A9QMXB[AR'N$$L;18<(
M+24I".SN7'CC;:2U.S4"<2H]:5\Q]\@B$1:)L$B$!R 13 D,\CYA$^LMXC$<
M7@GL9(K9:.P?B4=-\'3_4-'QL#L?(PY:0JY1.Q16B;%V8UQ&!J/+&(H8&Y3;
MH?8<I4)'(YM_IBF5"QT2G:YGH+YO17H:<"D#I->4' :K.W?"$*R?M@XF646G
M4UN!F=X6HZ#II5H[L;.[DB,$-P%.G0CKC0..:JF7]:]#+7_EL62KSI7_HE;C
MONEYU2B10QBC<%- QG(-:\"8$KST\"&^_ZK9^'+7*%OT)]@$I#^.:).$1.O%
M2P*VXAZVF\E@%RB6N[O$CQ\]7J!8'A!_P_LW$#XRV&X!GIC!5S'U^2#3?-\]
MX34;D)>R'@)8ZQE6G#@WY1MY1Q3)7DX'#-;<P&PHZF$4E=%D%9,^W"NT[Z=5
MH+]2'#\#68C0=%YEW*1T">9F2BEO<=%S1+:.2;;<VY+Q-Q$\CEDUJMN2FV<,
M9B?8"DC@@#Q%77EE&?4NX:K[$#UAI6YAC-W>$2Y-FQ^)PC1 5RNHV78Z=DK_
M":8CAL#@^))I.B9-$GRT".8A06>'9=VLJ#V0T<SI''ITHZ8(@$I\9JO(=VB-
MC;'M!=/(^97<N *&%9WHN-+4(Q^CA5;10 (6K@\R^C0)@A^?NMX=E,F4D&L(
M/JGS;-B>$6L[)=E,['07;P;NP.7J9=/XB$%L\YA)(L&#&JXT!?RZ@=_$W^=8
M2B-WG\#J"($0=0*B*!)E0X#N1,(RR?_"GL<P/#>B+2&;GMC#'HI7[6.R)&?"
MPMF9[@&[XVQ]"E*IC!G[%A7Q,^#PH?&X1JQ0#4S7:*/Z".U[[VSZ%O3$Q7_^
M[8M,!-PO>5L+W\G/*'4JV-H?Z)E44\"W "_=4'O(!&)@^U5Q!-=*6Q:!-1V'
M=85\VXQ="N<$(8(5+EPEC<2CC64O+1<^L+UV9(&#M,!+#HLSQ&T8>L_WH"P9
MRY.L9GH=(53RA5(#'MVC\JI$9G98>1ZI^DVQ;1X\#))0XAYUB%\-Q@==<#7>
MLS,VO_@)PO\F?LSV!H\[T]M,(H!ANKSYOVE+O"9,?"1L[U010J??$A?&^$5T
M\3V<=[[=HH#VZS>2K+^-+>/NR,C_I-2[J+%(V"OM N*%.91!R$18-)LAB$V!
M1,8#0SD2Q;E,R'X+D->8. <YEBR7&1O/TP!::7">IMR^9N?J#7%9"/,U@\D;
MLRH(#J7:#/ZO7P""+&-(7F'$@*T?$2:H&#]&I.$1702!21/++C\0F4 4X)JI
M9D$A(I'VC".M=X;"34C+Q"3@9C86>T5U%94Y'1@:.)@=5B*K\4FD!+CJQQR!
M>M^_K 1KZT)G(2?<K'\*0Y @X=(J@;"K U NP3XG <UO=>'&%%)G^)@S*B9%
M:@%F=@7)R?TL/!4N.YT:\:=@?/JIC<S/6^%D"4Y>US6;DG*4XPV?6\=H\<*:
MBOU@R%I91W@$VYC5O2&)Q\8.@R%?.X53?(^ D_#H\^B2HSVRQJ3"^<60>>(O
M?<"SC:SJO3GAV=P)->#I\XC$@9L#I%3=,R2XT$$8+'(E%"!>\[ZLZ*1ZRMM.
M5KYM&>==-K^##[MM[HW'F0O 9-\H!S]!Y+S7\T*!$%S'D@'>B&R_)9.G^[T.
M/!9J\&=><DSOC0T G!7<GN^$ZE&-5$6Q3Q)*;$4:[^KFWMT1$SNB)DZ9DV<@
MP)IV]DE(HM=9OFTF<2&.D-2P2;PHMX>K'-%%)=6CI49 05"@X75P>4?FHD?6
M)VSN3@PX-'-HKQ";;#C0BI,#3.^/UAK])_42U7&41[+YS"(1)# 80&@;H26*
MU$LUU_Q:@S:?4$!-_' OZ&<>Z'FOR=L7#2-D*KB:TQ50FW\XDM4_I;^A$T#\
MW]<F(,6FK^+APK)Y^FX-_MP]$OU3SRA9L8@28Y69'6H#XQX5\I0=$2VVRJ2#
M4:XDJ"G",C/4I0"@KIVIG%3;,N?7<ARA.F/\;F&S,/I@?8O@VFX9H9.E.%MX
M*8O6T[/KF3>TFD+*PY<643_&T\:Z>#T*HR!0<+;(*+(5\7P<-WMA_GE3HO/E
M<4-^"\H^WT?PA/\Y.''= LLYJR:XW#MRS] B,!S<9$)[[JR31AU:%VYY8#J/
MG#YXR;Y<,V?2P/0?&5.$;N$L,+4'[(O,#XE2W[^U@-6V!@^I]0<O%,IFPJCC
M%\E;:S+4:)A)UH_0D6!WB4,_)AA9:TMEU'=@?P(:'TG)E/^3>5-A/Q2$N1L[
M(2'\I@C:0<E,F,1X6YF MIK1'(1K3D.C0Z\7D0<F71AY9^[B"&).$)U+>?-0
MG#(IU*E/HRMB[55ZH[(@6HV7BC-(]%,ZR<BNBO4B,J:4S=!5IY3YM"07[SRY
M^&1)+CZ@Y.)'?AR9+\9X:5)KH<7'*2N8[06A430Q N\RD\ L0Y%$[F7Y1BR<
M'5D_(:0Y*EM1GO=T:.),'<NTG$G#PO#)>BAVKA]32H8<Q:B6? M'+W!RI;[F
MA3@K(:^3NBZ@TJOEQ?:3LF,K[>FZ+0OJ"E9K:NWZ:R*EHUF5-A4H]J8FSA)D
M8L%C:+8)G8,>]2]&UX?B('Q>X0Y,Q-9KH7NLSRSWGX::YR89)H@#"3;C:+PC
MDN#.\[C'.V&YT<;T[5+%UJVJ\@UN.@5QU<K- \]CDB)]1#=M6-+OVMFXN_ #
MQ[,H3"LTDCF<.+1A*;D'GO5J#]*2^A)T^>T7>Q4-3 9M&NT3W)&V+0(%4==Q
M7L2;A2:%DR04O34E-/L[AP93A^4V4)YR%UI>5KY8(3;I+2,.^P7)WEOT_S!2
MUI 93'2=!]^&R]TH2(M;N3C5Q(@!<6 -7PDS)O\;5CA+7G1E: TDDB14J- 0
MN^DL 2>102X<][<MEOF)&"A^"KTY/X5#^E1C;'@6GJ5.(^:H7]K3*/]8/0LJ
M[%9U*^]I5]Z!H/X^;\J/E,*:ACE1P1$U9(FK'>I6D(RRWO7[4T9D]US+PO7.
MZ+Y3;G6HE6E4E'8HU9@S@NC>T:432F1"]G!UB+13B'0B)<Z4[J)N,L(CXMGR
MGO.-F>=4F50L5NYAT=0O)J=C+;H0O>;D@N3G*&R3IQ.7:#I1L :=7W>-FJ,N
M0D0N23=\&:[S*,5[]]1,:-#P 69^T!J\>CP5.*9,N(HPMMUQ>*T>8/F:H5/5
M;:LMK,4$H]FT[H8$#!-FZ](<FPKA&V*(35]^TY^.?*_R [*K$P!P4T<%"OK?
ML.2YR>HC83$Q:^F+\&I)U*A@TYKM2*3LB7,:?@=]P<V4H/ZTNL*W,*5L=*DL
MXRZ;+($0WI\T*:IG8V934DP=#RH&ZH0N*Z]M@8$AAJ5SZ'/N,W>>2M#@&#"?
M5#TFUHIN]S]>/WWQ%+:4$(6.#1A))%;(SN<.42'!([3EB ,XHIXV-&RQZ=]X
MZ9H8[91<32XMAC]%@/H@UVVHAYDXV257)LBNN;Z%.^73"FHH,*G_@0IIK(]X
MM^]()-VH^F8N*9WP0XC_IKBWEN;"I;EP:2Z\"X]?21=C=LX0"Q(]D[K7(.&P
M4)2$E*,P'LDTS/SW<*YZTL;*(=G#0KB>(E>%IBH\(A8I^KP[HP15**%AUZW6
M)5REG2U]Z[*0-YH=*=:W"JH5^\>2A\>Z9M"N76J0V;GJE5%?VGSA0+E@-"Q"
M<Q&:[UUHONLEC.IW3%SZ0Q3J:81_VMT3$]@JTH.)K\)S*O1CK)OC@]4+K]$B
M4A:1\K';81R+P<15E\B4>!N-,A3XW0I% 94U8E]$UT_"+:&/9&/*;$R@Z]8R
M<^OIKJV[N]@SB_!9A,_#$3[O;$;!4P@</91],.1Q1GGV';;1P9"R4 G0CCM@
M4QGA&&J/GR0Y4ZXL!LLJRM^#5,$0X;A?FNL?9H.AB_1:I-<BO1Z.]'KVTX^=
M+ZYJ'2<E&B][4N94G[]Q@AL4D $D "4]9IF7B-<E0Q1CW-NU;<-8HWCV-GNG
MS<%] ^=7(U&A:U>0F2C(E:C7,F5ODB:>&EL?4%XM5<%W4Q7\Q5(5_/%5!2\J
M=5&I#U6EOK-#@/&);2D9:ZKVH-8X4P^21=;[?$#4DH:DLE&1*@V8#&M7NVVI
MZ$33-! H>9(PE.L1C),6J_T6;V 178OH^H1%5QS+H"9Q>.D1'0F-5)! HU9;
M$U<E/! .VOYF62=5I?,=MHMT6J33(IT^8>F$AA7SI+$4VH&=TW(MS#BTL4)D
MIT5B+!)CD1@/1&*4"G*7K?[^ W>E>+@/"W!'@!O2^[ ^,9CN5=FA/.&X9>]<
M]F[)7X0:ZD)Q'O><90E@#!14W6;OBJ'R0+[C=U/JFH'94RVZ5'F?^!%91E0
MCJ%2[!CH^@GP6@3TUXY^Y#W&=Y&[Z9F+C98E8.%T2)DUX'Z#.2C%U0%7U/>P
M5/G:50+Z":<$OKX>/)#L0-B6 7]DT0"+!E@TP,/0 +^KR-&6#%)8# ->*_AY
M-008ZH/G[UAQF&UW6GU&N__HJY^^>?&*_O/Q5Y]3#A]\W="B?$X4+C)HD4&+
M#%IDD+6(CDW77X3\MMI!@I)X!!GD^)EDX(P9T9?RG46T+*)E$2VGD&<$K_.
MLN*4C7"9N(^?RG@Z#IO!(8O2B@HC/V+42#>@+1)GD3B+Q/F$)8ZRH(!'Q3)D
M4P9FFSF2H*8=@6O/<M1\A=]=1,PB8A81\\F*&$&_8?J8? S 0Z'_HCGVA#$2
MH18_!,+>;QODL,NQ0R2D*:I\J#&O@"AJQ$WWX[$O#P/)W2>/GCRFZ!-6:\ B
M,IXZX3^"TWC@*C3$PFOP-PK11M!)^-<.-D0H>?(V+\K=@:&X4)SL3HSA8H)G
MOD<7WEBT\*;:]-)Y'"(P.#>NK3M3IB;0//XEZ-".!L"^LH)6XH="J,4I%=8<
MAP:^#EN.W2X>IX")]TIG^."1?XU)%"LZ40AEZ%H$SEEQ);!?+=14Y14QX2H<
MYVM!MB:9!^*.U\PW^*S+9L0\!.=B8.L[W\![#V5NZO$Z++%'CB_F8!NMU:Z!
MWS,\!&'D^RTL&0^]N*(2F]QN"BS-!9K^:N!/]]>O,RV(.\!X\3!VHS7W7 UO
M\:<.\2M@/IN393Q6%C3T-&#Q%0B5$>L#!=5H^.'P:@C$(;'5$=Y)70/;,)T4
M0%+H69C.3:,E?TBW>D")IQA-0']ZK<!H"(FN1*"=1>DEV"F$S\>5W TE4S,J
M;9<@M&KKEUDJ0O7(6]/M%:-X^=087 X067#[SJ_>)\@70Y2(W.0FD%D>&"XF
MDFOJFZC!B29I4IVV;=I97+(SJ(8"7%6?(R 'Y=>E>O.88 3.T\Q8Y0#%K86S
M$Q@S7U@T8@)8@,<S40GVZ93M>)FTV"8 J2;8#P[82Q0[ 6CZ@QH2)>WQH['+
M9V8Y PV#944(_ PDNZR$2&>:S]4:(JL((DY+?;8'J6,.DP$Q* OF&TG+IL2O
M[)O3E]9S?*T0H7)''9LEJ ?LC^(LMQ)II<["L[B^2;#Z>%=))'5@0R%2-\'/
M@:9KX.P+@""K[ @@F H7CCFA_V#+EJA@!0W,D4W)LURZOB0@9%XV]NSX,<1#
M@E%L5:K7*/!B..ST>3IS(1)KKN.:\.'0)P8PP#/)?KK@U5]',(ZJ9@CC?2(G
M-%59CUN'ST!0$3:A1V?A,](A\E2'9Z9HKCW+[:CO8*S7@FEO8/X\9K:';O8$
M'DO#WGULV/O/I6'OXVO8>Z@T'K^ZYHB6M/!A&'US!FT5>96I2&X3I!;3PJ%
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MG&AN\4*+J1EYU!Y]VN]8 #3'LR)?S%;_>/WTQ5.=U1XI ;":TZ*FZT53XH6
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M786$QDS5LVD.ZU(D%]-6\$>'!BM"A9,2'T0:&JE>D-T('M\Y9H* [U;EUEW
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M% 5 :W81CU:WYG0V8'F^J<AUWZ^>E>UF*'LJNN@DX/$,/,'J!,;/2T:KI'M
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M?T*!>@'?2?J:7VB>=\"A8 N[!5._.3>5_][00O>>@@B+'ECTP*(''HH>>%J
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M 3@+A^*FGM[?VCB41067?KA@I@R]:C(TN'#$-,D]LT=N2[%2Y!R!!*JYX-]
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MPN?;'>/:#.F+//I98YO/;E#P3873I,BU(EC*('4/&: ]6 ?EX\T?Y6SV@[1
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MY(]><U5N5-);1G_<!QT7;<[>X6Z%# D#F@!(E5HX$+GJ 4HREYYT#):R_,(
M_]NX8TEO15-H(K%J!Q/C1WFD"&"?/)5%[VY9](^GLNAG5!;]G2]'$[4>LYC
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M(N68SNV3$7 83&FROU:98V.5S)84."\X_)IT =AL*8<)V$8XS\-]&H,D#PX
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M16<".PFERE! Y!,$'B:VA&.%G(>/-X!%9*_/_G8V)YLE:[YDEC/K/DZA*)H
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M\^0?P#Y\^'T2 ;X3K-L_7IT_.P>\HN:NL K(H0M.[&N*"KV0LUW7T-'+O/F
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MU"7-'_BRPYCUOBU5@&C/K\HFZB(9GI]R(D?]6_B$ V>P<Z]9A8=39WGECSV
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MQ_<%#1[%UG61HJ-N->1J[)NN?TA=/[B)#5/"*STOFG;7?OWAO\U>&K=S'^K
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MX%F[]M9'%Y&-M'LAY>/XH!P*M>D@GO@=%+""[?D<RRPD]*N_]OOVG?-?A'M
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M\,B'P'06%O9AL'WJ.Y1(I1AX@:RXR7U!?2&]\[ C!I*NF>+S;QV$L6$W8GG
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M5P4M6.D(%U5\EDO!7$@F"5?>O?$:_6P5$N;S1\:_:_R>;,Y21\L^P@B?[I*
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MI1N20F3;H[-!X4]7[>&./H)+ *."J%#;Y@K<KJEMO\,(ZV+H'^F,'#O]!-Y
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M3\,;# O\0LD)A<'U.9_O5_F;U8] ANIOZ1/D9.]H VY!&'VON>.VTKH;,]G
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MS=*TA_@KTMEZ4.=EB7LL^F31)Q^1/C&&!A;\Y'NH7/,#:0'CVCJF_<J[U7:
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ML:!V$6GE\JYK-A0ADM<V%6DPHN&@MA*P0GAW)2P>-G(D!.]"I#H5! VQV8F
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MF&]M8\QO'STAJ@P67F.3\I]R+>]5ONL.2>$9N17M'F_#Y"YC5<&M-G#<6<!
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M&WI6 WG6O"TK'#8 WY"*%F(4R)J=\ P0>>F.JSED'P7,Y\\O"97L&>8X=ZX
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M#*ZJ1:<]ZRF.<>W,M68NR-I?O^VDB0IOG3 U4B='+ \PX>)@LI=N!U)/]:,
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MG(($QN%EH_,TU_65LTQP_6XDH;.XZU.EIY(6,H;E&EM9C^:6\FE0HVUZ^0I
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MK7]*JJB$-XG;G4N<GQ9_(NW[.S&VO^HI"6%Y8A -A/P$N5)'2EL=L;A.O9_
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MDQ 5GA2$\)K<7K.TX(8]W,XCR:6. ;^?XMJ0 ,_/HUC')69Q"G/W)O,9.GU
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MKQ;6?8/T%N0AT VGI;0F%E$8M'+3*QJ"RD0,]4-M,I'Q4U40+6^/HM$O=5D
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MR&+I,;H+,"^!G3U763"M>+N/SW[?[1UV>[[W\?R/B]W> ?[SW2?XY[#;?X3
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M94H/@8<3"LC>)?X[GIK5DMNX.#VTJXQY9=HVJ-3)B8C#RCSTZ3<^UFJBI)R
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M_V"QST.L0.[C14='?2SB>!:$(0ST]U?=5_2W')C^K@A$>H$\JWQU\R?C,LM
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M^[1 L(5;"Y?;>L])NM7)QO<Q'\M)! RMN!D_BB,XJ6%4S#WX CZ^%KD\VL#
MA9(+8S#_ GBU@(?AT2C)BZS$87*OG*$.0F<FS?&7<N"?2_@+: ]:Y70$ KR0
MLZ^>?=^2T1&/DXEQ>I5HV1%4-<Q5H)6G8%L6L&<-&[V2\>'<CR>[Y4R.K[8%
M-[3?KXM=8GI</NS1N)R6^->U\'*174=CI 9P'0K7D2ANA& 2 0?#5H5P6!2U
M@8HSE&KPR^ FR$+F;^0.F+RD9.NN\*,@O9(27E2COYX]'!'Y*I;M9HYP@J,T
M!#GW:Y07:8:",Y[[>)N&40A4+-28_Q%W,Z\2 LRR\$$#SP5Y(^_2S#)F[TG
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M ^)J<LL,KP7<M(5W!2<WH_&#!*70M4A*H(X6!0HPDR5 K= K-R_"[RU1^4Z
M9H\2P;PM#D!43@0O[#+*0'*,T^E49.,(N%N.[7M_7!Q_.O:P9&WJ6YVT:,5
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MD<+U;UZ#"6I*09#>XIS?(8,*N%SS.@Z#3J,DFI93) G7.AGRVMI&,8ER2[F
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MMU,$LR@)LO3R#8?L3'3RVA1M8JP./L9_<MR/PIL)2*.58WG"JW;5ZQ6>)PP
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M78W36+TCC8+?>"23-A]@FNZ"5T\; ==@ G A2V*1$G/V9W"X!:5@HCQH<(@
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M/3GU(^G44Y$9H*7TM5(,%_6!RG95-E;=YJ2%(O0A'MQ=Y ?EV =U9HD)D^F
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M%-4^F;J0"J0C$IY P2X04:\DQW5>9"5# I!E,<7(%:>X*\9L.TH+Q5*>A %
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M:933T2BMI1KE$2,E,1F(^8$(1I1-/'E^(*9WT'G>=TI&P!QB!UV\M[+8BE)
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MK6>SV=)RE;[M6-G6]6:_Y/R04]"UVS.SR%#SAMZL'W"DN<*\.U3+G]F(^9B
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M%3WC8TR1] DO'B"NU1\>X$6S7=<[K1(.L(ZP)7QQ?-T>+:[+UUJWIO?Z)5@
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M.^$_#&WLHWGY7Z ,87T2 H"5A\5$>)L-(WL$NEQH9_8?,>G>9=L&D9W?C<1
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M_4E[O+Z]^7Y]\ZA]??J<MX6F>8#!"N%KL]9M]?I_CMIGBBD%,^4Z#7+B"*2
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MTM_[9:W2W0J15T+#/[ 4"G<\]_D";I]P_3Y\2ZG\(]?BR^+O8QK=C;X"A9Z
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M"PEV:L>$Z:Q+F'ZCM5 V)BG9>/=$-HKZV68BM=KE?.'-3 C&X7G&! =TQ/"
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MY&_VEGID]KMP;/O6!88OHO[T7T#;R3:;/JK1"%WM ?=UP+:4^-\]'RQ(,>:
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MR74<GI+>B"D #_DBYE_<7MM5B^-P%\>C\)Z?TG*0<_Z<].]2R%.M!D2>N<<
MA[PV\DX"UL1<DA:W*5)LNDZ HD' _ 7>_L6G(O.1?(O"_3)%FW,# %>4=:Y8
M.PK5?F(G[2=:JOW$^NTG%C29&/J_5+W3Q'P3B0TZ3C0VZCC16[:[EM9%(=LP
M]<5F/\0A*S/Q/%I&\V& GN/,%\U/1Z>E3]#3![)X0LU<.J"&'U32+M.'/!L
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M;*&1>?.L@('Z1]\\I:T!S2>H5[%-WY).-^G,OGC5QB^*57[2_T]XO[E_-M6
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M*%]7EKP2@<(S[\QC@[1W^-/@\DAT]**&4H%,,!*<)W-*E>%0^\/<6_X/5C"
M=EE0 V6.KUDT(D@SSQ_4D&+A*H,4,4]0)@R>N5T(--DAJ;4LKZ?UFKOLXT4L
M%6/L+N6+@!X-ND=D;V>'L=9C4>NDDN*Y;] <\Q1TA.5A;%.DYY0..IS3=W0D
M]F+8CJCFD]L&=]^=; M*SW[$E/5/2,#K5,+Z'9F. ]<"0(JG-R\,*^ &VR=K
MKQ$*75.'_GE6P;=SC7AT04S2TERJ1OSSG@CSF*JU8/PP\,P9726RJH(.X U4
M'+H7=%$!@V)U#3=;$30(P227SA;L/QH )C9YJ@9^$[E4L0&@%I5#1]PD/3/T
M5 "8S!+G)ICW$#<%I8,Y?'<:LH+B3)<DXOK*$N<G^/NS;XA"7Z1E9\N5)6=G
MP<)B$^G\DSS$M58^2CH1@P>LS18PR6O]BFP0 #@^KTO/=Q1S2I3FH*TJ35LL
MUR$V'3M(SCT0GF9V+[@NQKL<_MG!3'/X5$*<"KP^M<#K=P5/=W)"I57<](*X
MZ=S-!NEZ'!'5K4TBJMM%=';<<K4D'NGUXKEG.P0K8VJ.F@M5[Z'0J@2C9*T6
M*#FZ(/WZJM G%WC$WB>9>)L]*,53< '2.)2A W;XQ&+6!5:#Y-EA!C6@NM3(
M*N>%POCEE-SMN<Y;#*?D3>GS_9DD;R?V.G*'U&KLMRCVA)\UKAYY+CC#Q&3#
M_YN%*9A&(W7G/ OX_)6#3)K-&Z8)D_1Y9WOAE<8K>=OYE:$N>_ ]+8W[$'A_
MO@8I]RQF; X.5DDB2#:6B87&*^)(A@C:R@?)FL1S/$H1^I,#.O/BT1Q[3GS&
M3(6$\8*)9S&'AP#/OR4M-/E2D.^<G24 L9L_*SGNY2O*X@%Q=(*@?4/,H%T;
MON-I@3W!>#62"#Y&6E>SH7;TE MZ2O:=1/#,/# ,Q35$G/0H\LD!)1U!0>R2
MROIUR003=1.$2RQ5CED0A5=E!A*^>#ADV9HBWQ*;3&!*7!RX'1/P@$!ANJ7<
MQ1A1#1(%%BP^#4TK+*]8?-(NAD1,HZ%CFV*=V2[O T;92_9(GC;$'TH[+=%0
M-$@;%5 \3 KSX^$-7"UP,EUJE5[2U\*72C$58I&Y+#[^H4H(HO8!V< 4,DW!
MD>LOM]GN)$F\:KK> <JLGB-1J<AL(JM8B+X=_'TQ\MELB*L\@)M?D;.BR9_&
MHR,3(;W4'C%W(+/8,7+(L2=V&&NB.-)$&]L!%H2@TR&\+HGG2FUI<0AI[O1Q
M!>+L9YV\(K,^H*A=JJ+*]PI9;(SX(JNJ$GI/$L6I10A>+")K\#NXR.$;-8QF
M?H9!-!H!UWAYC^SL.#Y81/+8/2W&S0_VJ (J4C4IA&^#D"4=47Z_?(3G^K2/
MO&6"^*BXQBM2;*G(B)KU:9>,O"RU -,BM2C*50H EPA<[;%O!P=K_!UOXB+
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MIDKU\LN6R>YW3H W^2QQZXONC!ZI_KB>F0*:%J-DV+QQHQY@;J-X!:5^9E2
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M%R= LGMO.V-&V$#GYT[Z.-).R(HS2?3W5"OP"1 \9OD_$1DF9P6DH,"K2W[
M$]%?%R:-QFW&Q/%'H1,\D=!B<T'K+4Y%LI,73,?W0MX7*F&G'[JP/#? 8>%R
MC@TBSOL" YUHFFW+'.$VH*9/Z5^@S7D=H-5Y-L5M;69NKH6L3H[JG!PMV9NE
MYN: "AS^'D^D'U_C.<IM"B^#O]BVBP,CA\I>>Z Z2N9,6AT2NPHC+IH@OXP9
M24;EPJ8AHPO@=.Q"SGX'=@<,^S$E7&3"'P<*N(.]B1MD@>(8.G*G+#,(:)>:
M^DEA\C4$=@6BXQYD2KD/@WC4L2"F-?$HT(?K\@76[^9>GP+S]]ASA%\E$>5
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M4_%J]#*NCZAL."!$,4,_)-;?A%\=-?>U#FM4*JJBPT;WW H#5'H@0Y &0BB
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MQ;.*.BTZNPL:65/X0?T_5\-^D:.6G"@8 0EJU4#9 1MZLGMU)ZLTZ+$;A)&
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M;Y(\5\><CQLEZ0,W%J?/_5%$Z CQ$\0]2 -  ^U-8AQJEU R2<V;NA[WE"G
MAB8T:5[ZA_)\I:;-(39E;P?-P0GT;*,/5<6XRZDW:;YCRX_OSA6.\ZG45K00
M<PFF_UYGA>1>#&5$0.D+R T5+HA\!JS'@,;%;./ A8DOIQ([YUU"6'6/2IY4
M\QS*V%"8M-KU6J>SB^6*"J\XU.Q3CZ]LLI]S4YA"O03:7M_FJ]PNPTUQ;FYD
MB5:%-E[4.U&HF29(6_@,CF_7'^\*NI*08#F0,L,=:[V]-;R_,6&:*$:I@,0T
M<:WR,V$-(-V1B5&JW ,5WO+!?T?P S&GQ]BS@:[3\V(3N"]G7[@PN6K0T?WG
MY2T-?<>N32KP4I:X0N-I263?C/X8A&#A),D"+UD\VHT<.#7)O@CF .2)[[5(
MQ$UI46 M('*FR [=)>3,%G(BEKCT1D3>^4>:^D?^YDS-#?2/9$IWU"R+8:CD
MUSJ,PO.CCZG3:+#9.J)5UA%<YD1)NTP^NZ'I)FV@U)OI\T*G"?^BPF=RHW6,
MP-^5_* GOJ!>JS!/M17OW1W610B%4$ +]G3 05@U+X?;(X@KMSL"KH]ZD%PJ
M0^](+_C,C%3!W HRH[#=UNZC_RR(#=_ZWE4K6\4,0)?=3?9/S&/17=3QCGA#
M5Y)S7[";;*"A'*?>2F2A@<7N]#0(M1[<0R]&1 L)>9K&4Y-9^8A F31(6\%Z
M;G^_WQWN[0VT]6@R$.RN&;DX%V^2_HK)D%=S,@&5:8J>3>SEXJ&9A.9B6-A5
M65GKNOE('9;,/-0CG Y?_$8NO7EQY])%6)*G2.X*S/6Q 7)5R\9ETXKAPHJV
M&I=3UBXN\S<5E1J B2YK#;9H.X^;;*< A6M0MM:%M76=R(Q4MW7D2&XC&M2+
M(V_P-S=.0)\5-5Y<%C5]FSG!-_'6A*Z&C8L?X9;FZ0JADIF6^HE^@KC;U/U[
MY.3-$ '=!P\1T%T=9\NB\=TPQ$XU<' :VN]6@3.IP?1=U';N_F4FFK_!BH"W
MXVH>[Q 6=RT7^>BPR4V>#\3^O<QCF5$.Q*.CNC=(4<6-$A 2UB(>N4.CSGEL
MXI@N_ #[\R6H^Z*)WZ4:O?H@-^,<!HT$5-D6^[E=YM9HB9ZXX%Z_ZHH4X%UN
MQZ48GC:Z%440;.J(FO*JI7I*FBB>I;Z3@B0F*X9%3M'0I=800O%/MT(9Y]TJ
M_:Z^Y$>H+SGMZDM^@)9=+=:%5""WSNL=;+_]UX(8"RWD'57'ZHM"]:ORJU4$
MZH6UM[0P?;O@$.)@".[A%6'[?'88(7&^)B^*[;>*Q*@2=T";&M-BR#4GQP>]
MTR+<FLX/\#H_0))+QKXZ3AWWTXWNV3]@JNUET#HD5+QX\M,2]W]5RN*">7PK
M(-<%K-ZZ3)/-J#Q,=QG>C*T;'*PR2Z==;K_ZO)T">X>W[FL,IJ-K91W)K%V$
MPKP&8H%/@CB5J?C)#?'N@PQ"->WCI*+4(44_[PP'CGB&+ E&;,W$:!2V;KN5
MZH)!\-484U]]X+]').>&'\0Y&N+&-VR3@-B3#P$&QO#"P*@?-F2U1FYF?,0V
M,D>B=#GA?+%4>K55U^'.>G3L>.)<C_/7@ RI]F[ &VI(4=2V@XG/D<0'VFX!
MVR)^B9LFHX*.K8#A_,G$?T8^^9Z8IQ^'\'"X\W--*HR8]7!A;PX/T8([YS__
MXZ\1V>#8N6N&'E+O@71;_+<8F/Z=\E/0"X09/4+Q'_ GE#3N1>1@^& (H_SX
M:#'KE%^P2U4VLQ ^EG]37Z4VX-TON*:@8-.2;^V,W^!X\!-9V9%=^#4NX,D)
M(A=T NE7X&-*_:KVK^T/"W\$!>MM<E%).&D>)9>"M#\;YI/OVME]*IFF(2@F
M(=K^(9&MI+3LRE\W3FXTH  X<X]C:=4C"Q+A?^YJKJ^]GH'_V\D^(OUF&NF)
M;T2R&.E%'SYH3J9"E]1RA7B:7_UU%/SE%V)::0G:SO9WQ[CJ8QPL[1@78!C,
MC4LYAJ8#Z><SW#L <;I_ G\<'N[4\178V"J'P2ZYQI?LZ4P[ANF->%J[TH<N
MDD77IK[<UMASX:N(I_22UM!<D17[[I?_6FP _5:2*U>XYBMRCG(:\3GK(M4Q
MV4H_A.Y,N/3 .';NI"%\Y7/TN(DS85\Y$_;K_#!'O<')2<Z=L.AAS'FD/R(E
M##:,$H9[O>/#/,Q-BY2P/$'0L?B%6;P.R;0K$;LWB+VW,<K*>/QG <XE_,'2
MY;3R.WUPT!L>#=\6=]\B0AAL#"& ,GQXN%1"Z+3\K1<!UP18\.!X3H"=MK'B
MP9ZZGAMBGPF,9W;BX'7B@#;V5]Y7C"BE=G5M/&%PW-L[R4<2.^&P*N&PL61Q
M-#Q=@Z@0K"OO,2][T:M8(WOD5T.D[TKS+4M%A/ ;<C!W]IU=AAFO8[W06#Q*
M\V.ML:.'CA[*Z*'S6BB5=7_C5-9[0M4T,]'U#=!/M\,'.6Q1;1@>]P[WWY@Z
MN1VG6(M!V?P4CX]ZI_MY1-Q.^5NYL-\'06C[,>;)O%UIOR&+["BBHX@:!1#^
MP)PUD5"<Y$L6?5"54'GE>P_W3C#]Y(RBA7(G*_H(R4JQX6I3C+<I*?A8) 7C
M<>SB>1AX(.3SO/)-#TL-IFY$*0XU"<(M[>H<&:N;N*GOSW:,S%X6[5NS5&.Z
M&UUR<>/-IXW'HCG0^491CTK!1?YPV*4/O]'TX6%E^O#A<M*'6QBV2Q_N\DZ[
M].$W=XQ=^O#&>&DW+['@)G ]RYVAIY:@IG\D_RP5(Z-&>^F%H)>B24&%VRMR
MRPX'Q[V# DBWSBV[K,-KT1L[.-[K#99[>%UT:X/YYN?O;F2,'<?X"U:ZDRF'
M5I[U"--V-H")KC;;IN RX@9=.%BE_]FSK\?H?#BGS5D1=SWL[;TUWKJ=9]HF
MT^WMGVXIR^T4VE5YW)PP_!DH#M19V+Q_.S9YWJC;-NJW#,PNT:LM/XPV(25A
M63?[?75(.WV[?TOV[)/8K9O F;KQE*J@1H3)C=MVCKOVU5E=^D)O_[C]ZJ>=
M-\G+UW?BK?+YX:!]/K]3S^B[5(>-S/G[$=;8T4-'#UV>ZQ8JG)SGJL*[;UB;
MK%8M]/29E7E0]WI[PZ46QG>GMU07ZO"DL^<[]EIOSXM<$&.&YHKO=4P6KNE2
MBPC&[G?'WOVW$_BX5$K(*P&V7<MV_H!G^7K.N\:S[.SL;;(Y?H0U=O30T4-G
M9V^A(LAV]B2?4+T!RN#*BQ%UW>&K[UDKK2=]DV;W%ASAF["].]5O,\OJ?HA%
M=A31442+U:1S=,)<5X/"I."THBHUW<5P^&U0U<7P[7? H;\KVENHRYHVG@OJ
MJVOE'_\$.@"WPBWK>C-WO\=E%$TNO NKL1(N/>.+^6(,]P:G/2/96KJ$CFVX
M'C5VGF A,6:"A0[H76[TP@WEJ:CX/=9DHIMLN/?A;TY@Q=BXERJ/56<X^G;P
M8<>@1M/JH7-SAH?<,RX]JV^\SXPA?]0S9G& :374/)B[5B83!189^,_8%1.;
MW,,+'T2CNII&=.G$G@O0RLZHGJ-(GSQD?7)PVF)3Z+VZGM"R06=9R]L5T@CL
M,;8Y0XH((VSW8QI/9N!2Y>K,"6#K87U&@!MO<BM2. ?X5X#G\-[=J>EAJ2OV
M-W#X<![F@_/1,;$_X._B19?B];<P[EQG!,3CZ(=TH,YH=UAS2*?]T[S1]I/A
M![ H5V1'<:MTV'A>_VP2ARM=[K<;?#D^IJ,KRF'P\R)(Q04VY:!_4+ I?>U*
M4F=;[%">;T_N%23_SW]9G=7>U4'_H*Z_XX4J2>=6@(^N\\3<$18G^YVKMNXA
M]X"D/2#."N]FKHI;!^OA7H"P:7^//8=?Q5VU]IF#RKNXZWN3%V,*F_ (_Y7-
MXF'PP(\?D$M:1!-4U-@WSB:R:"TT_#@*(VRH"U..X6W<B+"$?7,SV\"9F2Y*
M!"$PA@,C#N62J6>B8X?&./"GP!]J#O1&/'X!3U]AD^+K\3F(&S=[I'"<"3J"
M^GM[1WM0RX9!XGDNW'@2?' H%DW3& /KG.")Z=*/EV!<B.^4U$L)T]&+=E50
MI$KR $IQX63">!2ZM@L7&,Y!WVPZ^?_]O_\QKN+OEF_<]<_ZM_TK)3;5-XG<
M!&*:("D%/7K1;_V[OO'1]/XPOI+R:TZ,LS#T+9?^18]3<7_$F,D/,&UN2IQ9
ME_&(%[P: 2-]8Y'=-3Q9[;AV8<]_MN/@&:P@.(5WOXS=)V<7FV7F+ MU@7"=
M(WB"6FDKD14(G6 >+J-S8(*IM1-F7<QX2J@SRVOWF_/:01%Y_I3(W+XA9VFX
M(=Y_$LE_QF8 GP)' /(Q@X"V0S3ZG9CPK&U29VT'^)2!,_%L,Y"_4LP#GU;;
MBHU,@8$8DW@Z PJ=HL@39;""Z^ $;.Q:[17],J%XMTHVR!JQ<HFP:)'-85/7
M8',><EC'0O@2J<59L-(1LE,[MGCYK4N_5EED+8>,9]BFMUCF.7_&2 6)Z.,N
M]<0,659*(2/U73-PJ*V]C1_;QL3]PP%*YI;4A=UQP8*!C?#8,F<N22@Q,4LW
MV2@\S<-Z*9*DSM@F2-\@$&9&PF>1/&-XK1G6]6(_A\L%@NR?/,IU<(LV-+ H
MD,#7XSLVG! %T9Q,'/OCRV?8LO2S<YWH8NW5![W!Z6EO[SC?1P'F0"W+DS[K
MFKB*^)H"(W1#1W0+KU??"C?FLQCE!@=17X;BVW P+WE_ Z[XC?K>ZWLR;+PC
MP&KSB)_$:O4-Z:<]# 4=F8LA@TZ:1A5;=B)H;V_#"]C$<[>(:V5%N[(:LWDX
M6&32>XW\6BEW(8:@LYOG3%-1]I$#EP"C[)-G\R7$O9&4K+WF,<CX70=[>S]]
M,*2/>1]GKN5P#@[W>X;\8^?#N[^4XF;M]X<G^./4K/M'QP43%Q^G6E0;Y(^$
M.9O&8X!W__^+?.M=H8N/?:*$O(8,ZAQ9B8>EBV:!*V5U[N<E[PNOK-;'7>>^
MKG:6MI])4;XQKW5I9A4")<(HG>_X RBA%F@FH4N/H(I@SES/#.!O9,#^.C&_
M^W=3^.D_<%!2LR>X>S%HO&"\@EB(T(Y+ND=>17:?K _ZJ?$K*-$SX\J%(4"U
M>(]V%<[G"7498;#]>O</92'J'DYT9(:A$R5J1[&O%7Z?][#V,L;E5__)_)\8
M#802#Z*^T44AZE<T7]N]])[@C3BM!B^==WSC A0[X_?+R\N><=6_2?S&:JG%
M=K>I-,+B[4QV*K>I?>-&.Q_\3<'#O2*G]'\E5[(=5_2)<&^=?,,I_(E3T/U^
M]R\S[&^/JM0#S:I)/Y4Y/&%[109IJ\>;-BW 2. =/(L?8MAM7'F[U(27I.U3
M&NRM]Y2.^P6Y1BLXI&LK\MG=V/8IH27Y'9@A[!>N'7FD<"#@!.!23LT_'&5T
MJN#$.(YB,">58Q3VSXJY'22YL( C6$H"Y!VW@?. 3_L!^Y70#D";!42 9L_"
M;. GGH G!18 <B125G\2DIJ:W]UI/!4>V,SP:CS=B0O65L)2+#^>V.PW ,$5
ML.. 5IVX;PNX$OI;*LF;'"I?>&Y?Y"QN>!+7:HO;8D7?;M6:U<M2/X*G0YX?
M_K[=>W%PL-<OZ >PM(O18]VCRI.5W?%/L7/]Y 1W[O?_<\S@Q@E<WZ[NQ[8E
M>S\X/NKOY\UKR4+(<_B$;DTC=+^3CQ=-;UB]04&'Q*4Y3D5:R*6M7]/9+( -
MF>#U^OW^[,N9YD$?\HU4]U#=S.1&%MWPY$:NXBJ=JQDT/:/UB)B#P4H5 ?+R
MA?X4>+P;6/$48U<6QM$2!CF%4P;V2'P?6*,_'J,.K057D%ZJ62Y=5U#;R27[
MVH.F][:KP*WUYIZ<] LZX2Q/FQ G57D5^\99I$").)B*/9]-[P5WW)K$%#Y%
M 2K/?^Q@0,)1&.+IM'CC64I7PAJWR6J /]TGZE\HA#$_).2O,7+'8)\)40_4
M.7&=&$=7GP.+0D7$C\/D[7FGMSYWC*N1C4ZS!_7%= ,88X+,<4;TA[I/] B,
M: Q:AD>[XRJ=E)249]A&F*/E!SP&*TWJS=J02.WBTU"V8:3]0>N6UA7*= X1
MM*> 4>!032FLCAETW_@$VV%%C U%<Q@[\$+9=UM83+3-PM->K;&(8+/E/W@$
M1X6ZGQEX\$8\]VP<@._I_J!5BNP)A98PG5LW-]38;4\Z2S/C9.<QL>!59HX;
MU$.\KLG*.2[(RU@B8WJUI=A@"P?KV<+#O97R]AY<ZW F_6!] ]: ?, WJ(\)
M;^W@H.5+(=P[> P&G8/QQ3%#X,;$[X2+AXU*VW9%7H3M@-28(!-[, -;:IO:
MW9HF8_1+G?-=EQINJ/)QA]NH?.&D $QL:=I1)0RBG]%YC\09FY-$C;YPD<C1
M2A*COLBF*UV[E>9'<^9YZ-&>JH/I@;A%_4F2O,Q:Z*$T(4FB9XY15)ZO>$%H
MGO^%\7QXCNVV,-.RI4^==HQ$$1,:0BI)"N\FYP84*T6H-HT<QU.ZDXM)=$(+
M)'<^_F[DP/MQ)FP'R+05?'5(20?2:]3OVLCDV\@<G6Q\&YF3PWFF6-%PYJB\
M,\QBXV_/C]?=V::X6')A)MDX"R/=M(0:F126WLO;:=#]V\7[UK@*?+FB^E4I
M'_]'J8*?F;EGNJ,49",L6A38O /-JTM3.U2KMP%F@+GO/SIN0:(^WTKU);P>
MJX8TE]Y7&/W^V9D\.5^P)"!\<TA7'=[(9E_1@PVXHNO')JN]IRAF[Y_][GIV
M<G8#+_%A=XD;7^+'P%E2?YXW>8V["]K&!3WJ+FC3"WKAQT%W/SLQNX&W^+B[
MQ8UOL?NTJBYX!TMO@]=)UPV^E_>/#FSL&'[3W<[ZVWF&&[7<"[IY8K;#8]Q(
M6.(?88V=$KB L-G?/&&# ,T;(&=6VX)<ER^?OXM<$_S'/]WH427+7<_*<N7?
MDM+7R9+-!#G](18Y#Y)KE]282VH\WV&4-*S8<:G8N3"I<>69A)<)9)A6'D/H
M7B'6L >];%UT58$:KRYR[ LNGOX-4_=OL> Q5AB%-Z)._<RS[X#?JDS^:L0O
MF?C<<# ]+?I"%C\D6=8M)T8?E>/"E9XH4<R\9"23RP/>A02R+"G^1]15F'5)
MV?KMY<W=F:IXQU1)!)%SJ0)?I,HB2%?@V[$5:3 ':32YG@X4H -?+ D1@(OX
M__=W6<3?(]2#\=B=N *J+9F/0(D%JO;,!U$U<W5USIAV7\Z^&/?P0&!<":0[
M\55ZM"]F8$:/L,]GA*R0&HHP!'2 !BZD$/LKZ3'0\&@C_\&!1P+>Q%?!ZOVF
M2F X 574:M!I\ON3%Q.X(H$/FH9ESF;P%\1=G#B[MOO@1GG:<3UL\T%4$V;
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ME_[Z!AFP>?9ZVI'.. %/WUG*U3++SB,5.;7;;*O-40ZMD*0J=Q#. 4I\Q)M
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M)M+SIIKA*(^:Z3.>&?C(7(^GY6'"IVF[KC)U[+G"_N-CIN><>3-;CSPGE;V
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MR]A#W56&LMVW'D6M&+?=PEP+\DX#S+%&HV:]4*NYP5M788''(')48+_3^;P
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ML ?;,Q+"5&-F&NP1[3^/=$UM =K: A51M-)#-1:WBD ,'2V^BW!!$]"VB(6
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MLC+M/L8HL@30C!Z1HYE+,M21GI1/;.SXZ+7A1BZ@O.]QI<!EDZ#(+9"?X&U
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M&)I9AC2Q[[;QR+<0[" ZR(VIN>[=5'QUYWQ' -)[XJ.4&<,[NS3 +@[D7NA
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M?$U1JGHRO)D8,[*@D-8:"FX3/]1(M @2W66+M"3XSI\+)0$?8*X'K-83FD4
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M,5[;3N29I5KFL<G,,O[C"Q$UTQX9J4ZP7I06#-Z8>*CDD#X@UJ%'!: VMWW
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M0M)56]V!;-DI^<L&_G*39L$ELQHUR/?0\5.+>8IINVZ-F<VKPI24WS7#^@S
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M/E==MGF@KTA%@D\!K4 ;A\D78'!,7E2Q$("^XRZ?X[F\X@B4F?V$!?0GC.D
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M ) [KAUJ!NMHU@-^3)[-W]!$"L[PRF63*^/Y:F;H@#EO^#_4<*_3[@.S .4
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MTO=7F<K6<RIY#L9(XKJ;)U4$DX3$QAP@R=GWGRTA!J,3D%A=;',^_=L](X'
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MM*,L&@3SF>A\P28C>$Y18]7@N:B(I5TKZEI%2UC:BY&EW<=Z:(]9TQ-&R)Q
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M&OW"X\JCQ_)./ 7 (DA\Q8V5@,3\D2 QORAU)7/['PL>"0+5'($@,+6-E8#
M-!9'V=;+6<O%;LX-!_H(Q%WURG2 :N*C]#*F*&V*TG[VU%'CO,?N*4P[[8V5
M /%4EE I%?,YS4@$",*_.N!XZ;Q?-BI&61>B<!0B>&E;W%F?B?F"6XG20YK,
MJU]Z$+CRQ72JHQ%F7)XL%;62IIIE,5;)@BCJ(G:YDBL> K'W&66XN!/U'%7!
M2F=C)7!;U7HH6BXJB%+#H(F>&QF]$6,? ?*OIA.:7JS#*$B!YP&.KZM=A<]\
M-3%U7M?MF9;E4D[]4PP<Q).QQ^XIJ7Z:&RL!W*J61=%R45V4&IQJ'!+5)>'
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M;WPH!XWR!@<-V'WG/;<_A1^'P7CTX?\#4$L#!!0    ( %$_W%2]?X:K_G\
M  [4 @ 1    9#,P-S0X.61E>#$P,2YH=&WLO7M7&\>V+_H_8_ =>N2<M0?<
MVQ P=NP\5D:PC6/6<@P'B+US_VM)+>A8ZM;J;H'9G_[,9]6L?DB"V"B^P_N<
MO6.D5G4]9LWW_,V?7E_\]N;GGUX?';[\>7/CIXOCBS='/Q_]]\[^WN[^3]_R
MG_#YM_) ]-/SDY=_1,]_?7'RYN3LG]^\?WU\<?3-S]'F!CST(LWKM/SYIY?'
M[Z+SBS_>'/WSFYML5%_]\&SW299_$R63[#+_YS>3=%Q_0V.=ZF/3I+S,\IVZ
MF/VP-ZM_C.3O05'7Q90_&A=YO5-E_Y/^L.__'B?3;'+[PT4V3:OH;7H3G173
M!-YT^.;XU[?__*;,+J_@53\]__GHXU4VR.H(EQ7]].WSGW_Z]A37U36#_4>?
M9PK_??3B]XOCD[?1NZ.S<_SODGD\>OP)YS&DLZ&)G)T<OSM\>Q&=OS@^>OOB
MZ#QZ<_%R]T$WQ4SFXO7QV<OH\+>CMR^/X+]O7T9G1^<7AQ='^(]?C\\OS@YI
MS\Z.?WU]<1X=_GIV= 0/7]Q[OG7ZL=[)\A%,X8?'_[C;_'&VY]&]I[Q57V55
M]%__:__QTQ]AZ8>799I.81ZX%/STV8_;$3PP349IE.2CB'8I'4597A=14D7%
M./HMN?VO?%#-?MR/-S<>[3W:CZ/!+3V<3(O\,MK*MOG[LR*[3O(Z.A]F:3Z$
M5;RI1[MQE$3/TW(Z'R51^C&=SFH8?9)-,_SOL)C.DOP69YGZ2;[@3\T48WA)
MMAWA4R_3CQ^+/#K.K].J+LHJVH)9CM)QEL-X5S#W+.?'Y?G_\^YB^</7_.R[
M[$,&"^I\?'/#/P^/G[][)<_A;L*3O_][.WHCR]IR2SDOQO4@R3^$:[F&N9W/
MX=EB6D0ODRS/9C-8T^E54DZ3Z$4!FX9;9\>1IYOCP$#OLNOT0W263)/J)IDV
M]_)5,0>Z*UN_D]V9)66=P4E-L@HG7N3PDT@9UT^O3H""-C>4KU[!XG:J63),
M?\B+FS*9??/SX0YP;'SL9WP#;2G0S<U5$57 =V'$/PND^S)*E/ J("TX]SQ/
MAW4&B[[)ZBN:R@FPK2Q/)M%9>@FS*1/Z^@QY614YNHWIV5=96=71(7PP@G<@
M*9[!222XA(6_CHJ2?G^>P@Q&G0-L;BP>82M-AE=Q9.AHD$Z*FVWZ",<>)E4*
M]^D6/F^<Q;]D+TYYT_V9T 3JXC*%QTN_(TU2C]L$'7?2;1PIW<6.SF3CF!SX
MJL-"\'[#YUFYN5&FU0S/Y#J-3N&^9C7NYD69Y-483A5H!$X5%EE'>&%KX%+P
MQ_ _\ZQ,HRH=SLN,"(G'B^0*\WL^PM<UL!<X]CFR%R0Z?C!KG T23H&;<)/!
M)A+-P+[@3@YPXLAWPA_QJMP.NQVP[ WGL)5]%"9E5LVOVMR Y59%?K\%PJ0K
MN+;X11F1X(7=!^*Z3N&,!Y.4&&D,>S"\2O++-,&/QO H_'_8EW*85?H1/ 0O
MJV\7O QN3C(<%N4H ?;JZ02V=%K1W2O&\1VV>W/C3GM-&PF+G4SP(<<Q&NQB
M(;-X),Q"&05L=C6'\\#=QOM#?_!Q-"11FY$T+M<)W9US/(NK8@)/6AK8C2Z0
MP_!QVV?XYL%WGN?#E[!SDPG?A<EM5*9P 7 F, ^6 7K5^>5VO%VYT!?^U.+F
M^/+&]H3IU54Q36O2 >XT">$IAI_ =F77V6@.YW6+SR:;&VZS\&F2KSI?U&JZ
M=>//H]2\?WUT=G1X'EORCH7A];(YR[SP[P8_C6Y@7YQ$@WVJKY)Z<V,(-Q%$
M[#*Q,B+IX72=)W'T:&__<9/(5I)1EOG,YF4U1Z6(Q&(VO HN-*VG+HH/^/5E
MB<_I=$O[!F8L^-#J6[2YT;5''<)7W[B8BS]_]V*Y/C?)DD$V02;F-#NW=S"
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M)@C,.MX^0C5UU!V68MV5IEMI3*\=3N.A\*+?HDR?SE'3)PFN?^8C^1L3I%
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MD%QU5R!EDG1[J^Q&BY+ P#9M9H'UQDI[\KF(XY/1&:^:4;A:/F$8,I!SO,L
M)-:" $,9NZHPDTX0Q%VJE?,B%P<!8IW%)QGMK^Z)#H 5-L&F]*"[WG>W)>TI
M:<VQ>184*:!GAR26 [%6IBK8\"(L\)IN.7--H820>X=I<UK3@P!*&#@BC853
M[KP>$\H]119:A'8*8J\[^[??<\,N-G2M,:=-<RM;^TP)ZV9UFJ9B1QA4"5X1
M(Z7J8[*-".=WVQ]H:DR!MBG0#"7<:@)+I76J95,TM\B9NY1@)J"-[<QG)EJ)
MNBUY/8,Q83'?%F'XTD\9ZWNP0+HY3PU6,K;)& /T(3DM(*56+#E0*E$AD5SP
M$GFI0[1":Y6^@%FEEPQGZJ*1"*[+07OUI YNN?!9YN*++[BD1MZ-%;(U$I-#
M8X#?$/B4:LZ8#%*BZLL_B,/2 5'#)>T\8?8=[)2I1VDH1" UW5WLBPBP4M$$
MH?A6W()=:8VQ8*1T8%<L^!E<J.J*;0%GN';[<#CTTV\4<Y2@$9CH3$6DNR,$
M3Z4 "],\=[]8'^23KS[(SZ;.-?0Y8LJ5:A=W2L?'9&5_;6,VOD4VM5/$O&XA
MSB5B:=6"-(,X<D9_[+)G?,:  !4=GQXI/!O?Q2FBN=DLNCIC.<T9YE4=9.N3
M)&(\L"3/,91?&?RY;F5V<Z-#@)+7JF%5!2 4GI]2L@TA*6 X=H'X"S6J(YCC
M2Q@R*)\YM57!^D28(4H)\*N=+L]]:W];4B)OFU(I -E!/Q&BF3-"1Y B(WN%
ME/='47X JP8]'>IUC*.W?YP?(0 ;R-0$3O+-FQ>6W;Y-JE'R'_G1;Q329GM2
M;;CYC/>V9$]0,,O0BD+5R\/#P3ZI.Z1?W/;4JFQNH$]LA1NB,CZ)1B78'EZV
M&QDG!^9I0O&0>B@!MYJK%*(M+D6I>2IYO>TQE +W@ .Y?*EV\>B:<E%@/CXK
M-)A6(RDSUI0ES XNLI'^>E3,!S4IR7G!WF'9)4MU#1<2NTJ,@1_$[,8=BETC
M2LT>UJ9"BV]JEO!J-4=33Z$7 G%>%L11M&:F.S^,C#!-$,/ )/D7[0(I.!^Z
M)9$>,<:_4)GCR$D7N(/7LH.-&,V)6=A<*4F6$*>22X,N6DM"=[_FG7E5LV=F
M7'D#AVT46^_A]:8'5@+&'2>FZHQXE9EFZ7M.!^(JS*71?L17-7GT5 #3#$0L
M3QEH;B[.AK-$T@D1G75>DX9+I?^MW3=UYIS,H7DM@KY*@#7S[G&KIB4IB*@S
M3<#BQ ]A!D:4:=C %?RP6!LM6C*KL>0 D?SSSN(V]FS:*@5-2T*55^J,DM[4
M/Z911W%]AF%7C8)EU6:#BU(K/G/44QI<TDU-R*US4L@-K8,:WR'AJ09/$8\3
M<'+$L+U+[:%/S"6HKG"6S5*B!<? TJ4[V-.N:>]9L"/*69*Y6ER33=?<9%LR
MM;FA-5-A"E=6>;C^-7A$+[D4+IVDKK[_=Y/9YG,2>W);EF0E,H!\WMS?-F9
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MO/09X2XLW!O>,)ED(8M-%FB/K%9+9$1+J^2-"2F#%K2;&$0K,0UE1#DB3B)
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M7&QEBX4EIC1 ^/+$A:I]635ZUID1CKN<F$&+"1M. 6K!5*,FT'^'?U]"'@W
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MW#M1_,RDAL'5<)CM4(J6L";KBBXE^"\(!7V$S-RZH<+P<R,G$[!6]G[R0U2
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MTE7D:-(*'5DTX*6E9"5$.^X.2ZS%G_9AF]4\UX1+50_O2F';G?S"'+O,X9J
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MS?QU>%4 +U<"O8\?6=Q4;-%IM^[N!.$0G9?@Z@RL9V##<7ZT3')+=$5]/,@
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MIK(5]$%G]27))@0B(.V,93XR#1\#S$#+R)BW-!(FJ99\X;I#L4172U\KHH"
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MU2>GIVXLK!:%)<!3X$D-(%N@+6!1([2.) 9'1N+CO2<!0^H+]*SQ)JE4Z;&
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M&6QHL)3W<44(%*2?AW66RS.0UYE8%+@XVLE%0TQC(>4-<S7PX;,BNXY>3T;
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MOO#<O#_ 3%/NT AQ',I;2C[ME5.+*UA1-LI4)4/AU'8_(1&TNL;IEU7,4DJ
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MGPBAPPB##(IP"6+#8^R,RF1<"Z)/$WOTF'_"W=2P>]UTD%TJI2GJ)>'&Y;6
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M#INIQKZA;O=>>(]DT_-P%?0TD$M\S]WJ/2HT4?BL?)).TW&I7NV.V7.ZCX^
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M5#3Y"&:SNJ5[!3<<V*ES5 -+F0N4!J'73;.>V]+BZ'+ASI#'P",'*)1!D!?
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M XCQ%$LB"I,J-4/W1<Y:/3KIT9PB/S;?%3Y68@D=J#BS7&P"RDIC3NPPEKT
M17POF#5%<&Q>&6;@>N;G07&&^0 D?AI YE2+L3B=.1(C\CJ8&/Q7E)6LZA=S
MR@T+# K[]?NWVO_TN<^8KVH2HUQ"E(D-,M.5Y+HK.ELB-# O[)N.M):'_+L)
M9QW]<JY%3^R?531>U)%!TQMDGC%G7:2"XH)*WO)S3570S<#Q.6H0[ ?2/^G7
MFNG4EC05;EC;?JV5JNN_[? 16[^Z[G8W,BQ<;YYU[G+GD<PON@QJEVMA#'B#
MBV@MP4#Z[CYV#OH\B T+PER%P4Q"Z"0I6V4<^IE*HEQJY&1]/>F78XE+O]WC
M[..?7N 55XU&='?,YG?%>#JFO.Z2] K2?J9>!5"'+:6GT8'E5FX;C)Z>&AR%
M&$?(^Y03>J;GC1X%-!!^]IGL#+BFI ^6JNT=[J<F$0%-+BJ38B L>HP GK0Z
M92S.]#+LTJ-G.[7C(]BMGG"[XF*/T[H*@MB'@'ZTAE=\.(WJ]! H;:"%,TWR
M3 3@%0,NTF$-]S!8X%H*5SCO^^;2'R5DEKB(V7O7OVCOG*UC4[9)P.6]5'+A
M?,P($QD%H;$J/Q(>:,'Z.?6!JFN.J)&\\PV2!&6S4C=+:^2(+EO#(N(+:WDJ
M[VC8683H+[LV$U,B&^4Y$X.;W=J?ECH:V;&R==/N_R#'O6 W;+2V[%/;(U>B
MBH? $"*I<PTZTT_UC12[J+$Z-%7<[U2RX3[R[R6A@?,!/:%KEPV3%,@;-LJQ
M9'><LLF%B:X#@Z?7(4JQ7\9X]$B2,$I" ?1)CT:[<PC%;:?HLL13GR)N"I""
M?.TV9[D%>]Q: T&Y4=9,E-,+O2NJ"O(^UD% /35VLO[=EKI;\-MV ];$%QH#
MM*2#AW+RB>Y"%U08CG^Y9'XJ,-5@$-^6G34ZK-5)Z.%1@T(>Z]M6H$<6T.*8
MOS0E]J.L&&-D%68N"4>.]-<T20(U1L*J-U!C[OO*3X(KWVB7)\T029>=47Z6
M%I)%P+FN1JM/F#6:#F="\0,/D_S3"X]CG!,8KH%^//*OJ/[B$N^>[MC$N_O?
MK6EO:5\<RAF94U9:>ZLE<?A''9>"<CH)^\]H\%9 XY@W94D?2!$XZ3"7%=O,
M?]=&AJX0#^N1-1S_L.HNYDBX/*C(C12K)(B]LSHC,Z@/\E]R?90B1I(2;%MW
M/A%67FG/E4ZW4YPZ9];O4S'=ON:NWBG332I'(2JTN_HFQ551P4V1CA%VK.6]
M2#RFQ45YE5]RDTZ8WE00&1K]7$4=#G-R,=<0Y)C!1;$">JX2513.+1*I(T23
ME9-C\%K_2*^5F#0!0G?*"!M>!H6:W&/C?"J^!?'IQ/3G$$NYFEX-8>ECT*S4
MDUF8*^;/W5P3]?O:<D]78XG-MAQV+@KX*2]'-(TQBH+%;%U,-3X9<7=CQ0Y6
MJD2S*R/(-81UR*\D#X53^TQ#% MC<^\ "#\P\K80VCI5\F=HF'FLG)M6RS\
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M]^G3O<[06D\2WZ,Q^8O9@!TT-)@OC,#OM =]Z7O/=G9Q-Y=\T:HSJ8"/7Y/
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M0*>!9-L2S]ZB:)3KS4QQ9P['^Y;POG?\<L+O1?Q5%SM5'5L:5"C]2!^/@79
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M1DKC_)(\JN+$%!1I>*2< *?6Z<I=Y9K!RSP10>#QK /G9#/=11WM]:*6F(4
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MRZGW#,/BMKWSJ0?V:62\V[S,)E2R^#%:>]!PJKTX\L+Z)50]%!@C&PXK;IV
M\@F]R!3F\A"L7-]'+,=-E+U*U!?'YLBBU"(T/X$M=DV9-:,M<#RMJ-ST4*[%
MTJRF%R[RA_?V*K_,J8I']DL 4WQI%-?5NJX;7VN(:'?G6XSHLV-$IB N;(KK
MTY&"2PC&+CL](ARXWCH9L,L4,*G<L->*3%;'3RWT@L>GXLHQJR)@C!WN8[E
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M!(PRN@B[Q>+H10CQS?TAK!YLZ>UU5X\Q?<_-L79W6*.I%O4\V1L,R++^'>5
M1:K-YD:0=1,U8 2JY\U$3U5_C!V/!Q?YX"/56O']DUR967FEJ?=P^RX+]!C6
M!O(M2R9YQ2V?L<DOMPUE9#G$("^K\VQ:_(_S JE!Y#8>/MC772ZFE^68K'AM
M[4:G50JVHK[#5Y!["F]'C2:]?1*M-^6N]D9<V%ZO)F?-)MX5A$C',$/2DL.U
M!A^2G#H>S$NG2/Q >L1.U&;KO1O;9L;[@ 3"KEY=;=?Y8/N\O"0'']K!<RY"
M$APP.UGIIBR&NS (RJ&^\ Z5Z)VN5>BYHNX$TGO@%"YJ\>5\:*GRAN;,0,&K
M<_]=;SH.<X(8%!41U 6DU$PH-=RB@(KM+FGMLYB(NBK.W>6U4,Y$E5M<+'S#
M@$2ONQG;VJLXMM%]?#^CNR_ZZFB!X/,$O2A:07@;I9NU .11F';HV)CD19"J
MG'T*# -:0DG#)X.\HA)!.9&KLOI(V(6@V15S<M%0FJ=DFHMF<M$^'YG*L*C[
MBXJZQT\E#9$NNN)91T[D//$$S,C7XBD,HB>ZQ5&;]N6-CBX\L@N3E\3D!M<^
MX0Z50VYC&W21'4;M0Z1'>P$B[K(<<+)"1D7#MK*&+#%X$W4!60:?K$MBE0 Y
M2TC8:NHQ1\GQH;.)SQ]D09YRK:KFBH@(ZZ0*,0NY;%H2:S 7BS0./!:7FNU>
MW=S0$PP#"RV9PTNE<3<N>T?G<W&K[[2YB"CNT*IJVDU._=U!/PUM[IH;1<;6
M95'-"4^!J!^WJ"(SIZN'MS9N^:1VS,"7[M)'\VQ:VR;LZ^+'HFEUK1"^SAT+
MF^Y<EL(4R&Q6,RGH!9-<9N-B.+YV?=S1H>DZN'.6''(>LK:4]3B=4A%4NVM3
MPON0V3)W*7\VBB:Q.&5$2(:NN;P K843NW4YY,WUFUW2;]X6]2 ?@X*2EXL'
M:_NYN?$N+S1:VTDB4V$AXNYQW!]$7K5PL?BFNV?+D*/Q!CO2=4^2?X*@:H23
MV[9#K!%IEP/328Q,IBCG+_:H\ Q"O\H+RCPUEJ_I-K?$3R&:?#GJY@U-5YC?
M#%F96PI=@3!SAMU@4UZR,D8J$1U*<[3LO&D(*TY7G4UR"4Y*WB0^7K$!J+^5
MFM.R4K^7'858B9G2%BF6(PKU%U/;WWY9=_O'_4>/7>_$MJI2GPVT?*Z)3K5Y
MZN:TZ:J702.9-G' >.V1RUYQC!75SGCI^9RT1-UI[38F$/;*7$(43 !A')/_
MIX,H^,?<-N#*HS:QQGNCE@'1LG,DL!/$+"-:6J[!>&*A49U'']N/(25J!S7R
M>3+S%]L[WJ68*EN\IV'L.>NQIA--1]!-8!M:@K$,FB!98NU7SESND;Q;3".I
MXOP);OJ69$1QL(NSXDX=8Z[S8YOW8'<7FRIKWI[O06(!Y>,F)(8=MLI";B<Z
MIB ]YGK$+FI&VFB<E\L/EDNC61?NO.'D6NF;FRSJ51.-+DZ<->FRJ2;+)G)G
M40/J?<5!JF??@E1W"":N-/9]R*R#_HC-/FU\3SV@<Y#FQ#B##9Q\U.7#*D"'
MO<R66;/K-KM708]=:"":FY"Y[)#88R=*C!G")WHUI8SB1[&X:>(-U?$2^@Y$
MV'OD7!_#; B;#+Q='2TQ\TJ="M0NMQRR%4$&M39K<#S45M$%6$**TU1X.*'6
MYJ.2>M'1#"@JYF2X7<,(O7PU<$52S(9U%VBECVW["'%Y6X8M>0R@06";* L.
M6XZ"'E\+4#,JYPDWS7U;XA\&DJIH "FE&E-0NM;<GI9F8XTF8TEI447DS^*G
M9J^O[QOKU^TZ?I3:=MCZA<(KI[\-O&"-[(*4/!38RU9$*9P>)[EU^U_C_E72
M>TIK"/0"=+$"VQ5#B#\H50U=(U%M-,[:M?X.P.SEPEN:B*H@5;-9Q[/<P<($
M WY0SJY7Q;2P94OFJHJ7Y:_WO+N:D*<IA3O_= &,24QO!N L!H(?QOA*70U9
M6[7E^[<[![W(M]W<:<=66CF81MQ<CH ?0/R%C PH'@P"/M#<,?3=-WND7F45
M)G>9!C26ZTF%_RJ@8)_)?#JXR#%),MG36'[#6-C<>.^\TGOGDM7V4,L*KL./
M*^AWZ4(E!;1#]K0==3"K+[T%2P7CNB<==11W7>B#E3@I:SI92(RT]>-AFL5=
M+KL[^OZC9&6'77HS#*BB&M25-1GZ=3!($D\7T30^>[X"8<[25#]>2-6(EM#5
MD3T5!*$Y D@[>;UB<;*FWG8 ?M",M,62S3J9W$5&SDTWF:*/0$'5\!&'ZYU;
MMW)'_(78T$W;2VI155O+,^TOCEHY[2E=3[0(";\@YP0:=!BIWO@%R%<1E5!)
M!DFGA.'45G;>])I-PMP>:CZ%(M/3>A\&!\\RQP"N,>8>PAT:,@*!M'$,F_=!
M_%*2S98[,.E53'.SX231>_]':IJK$IOVK(H9B*:C)9]:3LPA$5M;1A;'<%),
M12.YE)17+-,P !=$<!+X**:H33=KGG%#@,XH\$E)+&(K])<TYB4S05M6$?"<
M:ZK8XK,9]DSZ^GD1-XZMVL_$^,8;G-&CHJPH8>&O4_*:^CLI$J5)&_ IM'6,
M.>J614>[O,L9]L5=UN:L04X"7[<VK^),H.82.WC4O=\]8!![OO'8#=B/%LV:
MW"M1Z9:OL:6L512%;70GW:_&/>HM30@VII.DQ:>.UZ8F!],DQVYUAAI-A7F8
M4"7(USUU'7"X 2/"%8.Y>I]DFFB[[.LE";)4;J7Y?UJK3UI>X<(^Q(,D!*@U
MAAR1),-PD@^O&PG*W)2=2]UY]72UV)DZ=<H&22 8DY/X:6KD%Y%PHXDF@)34
M3U+6D0O*9WV@MG*J3-4C[>L%!EXZXZ2D*:=ALW7</IJ$V3%YDW'S4RJG<,"U
M@LK@-1PW5UF=<KAX#:9>Q7U5BDI;:E@T;:<9$.2>E9.%%*+:%%EJ"U"3=!@%
M#+7R RM#OY9NSCX,3#$!]YW[MVC/^7YM;G19_-YB(C^06DU,QSVC4K$;!MEQ
M9=B49BEA>5X^1$T.R92)G$P1R]!B76LY@TL3V(8+GYM.X4<JFZ-:7G/KTHX6
M1)162?C'Z&%55XID'&6U$8'^P)Q_T5>+K^*DDD@]RJLN^G"@JPH[$(:?0^;A
MW+5%I4M"ZH/[A4[,TC4B1$9D?+OA(($]FW@T-IX H7.X FFF=3(*DM@H<-=F
M66[YW%W\D;(#^DLCSPG9E*1:!4&OU(;-3#$;_':B(?BTP<T-TJ+/F549]C6&
M=7[X%M:Y*[YWT3/W_%:W&R/.!><;X35.N<4,2$+?\\&D2C9OHKG-^!_*)\(^
MS 2 :NP/^ME?\E0L$<LC+S66XP%'&VQ@B0*9!LP5[91IIJ"KD5ULC'J%I&Q)
M2.OG'J! 2K6"K6*6<P>K;E_T RCK!8&F" 0B<YRU:SVS(8&I:;E.1EK1G)6B
MR2PG5ABTN>,=+J:4Q 9L<*P0 NC$$CZ+W(^Y)SU%SBAZK&#4!_=8$"]DP!XJ
M@F\I-E@EZ\1VOI(4$6U5BJD5!$BGH*=]BZ+C&C5UH00]P&G^N=KXZ.?:-IT;
MI)C<>$J#RBN\[0$F/"Q[E THZYX>IO*=JIP6 VQ4,Y:ZE^W9<,3P>9AT"18-
M">.Y05\#HQ5^0'7??BGU@1?*J]*:@)K$I(%O<YT\AVJRN'<48'Z;+,]@': 7
MN/42%KWK5^'HF%3":D$LX%P15,PQJPL.]TJY$GTV>T K^R-'=F+6;'0DYX*4
M &%%+45(N^#2(]7MJ793TF=-HT7CE%AQJ4P8C8%V*0+9GCKC3AO$!ZJ""*S@
MJ[#I;2_=N/@I'VXG1U2?QL.@(7CMVO$X[ZKL1&N).%F_?RZFKMVF_TD:3_'"
MY8.K>(=S'('I5=;D.,I N>=\0C(*YMR8D@P \3'!)I84DG:H1];8E*V@K"-O
MV4MKI?4XF@A_KM+$39=<#@?_S+8E6^(.Q]/"L-1^T[BF+?45;:GDZ\^Q2TV*
MP6(8@\.@[L#NWQP<._DE07FA8^Z]#CMR/<LE;;P6M$CCA*W9ZZY.M<AV9)]\
M+[76#2;"-.M4N;1./0WN+G0\J"!;?/$4Z'$>)GYS:8'I#3AK"80Q+%0FP&_H
M@$!-PK>SAM]PC8=43Z7<_QVH#81GV/;C$NU=^^<>HR*XRBHX<I_Y0"VK0?Q+
M^BBZ3R0S1S:!!R+ &.K!Y,_$1#NP;W&S#,Y[Y#&5$Y],WFODY'WE 6/[N04!
M0XY $U+/*N.!<6(=S?H!F/1DN3QVZSA'%_M4HRU#(Y':>2=>3=]BB="VX(>#
M?$Q0TLE6B$^H+TCOT E;MH[)\L<E$28P08$^BIETGE2L4OJ!/B^>K)ZT6L^H
M;QV'#+9"I#$N\$:UN)BG!C82\U[ZA>O%SK1._Q2X54:32KE[&X)9IAJQ2$U$
M(X4KDU7TCPP^2@^%P%$8.[LL\JM:,!G9>J2Y\>KQ.-"CB-SOVK7($I^1C<+K
M"F$3O'XJQR6K5.@&$8!T<-9K]P!T.)5P6.!49XTV=>GVXLH1;'2"06*/HXNP
M-IPIG(\S+%'+HD(P4-DN$%_L@EO/XE'8\!<%1(4,8\((\;T<6RRKIGO,^94<
MX)T4,%D)U91.:?1< V]L6-3&#P@_S19SHCZ$V40&>>TKD)9W6UBJ(FF-AU"9
MZ[!65E;GZH9&$%.DK)Q5LN7;)Y%%=<!3MU60WO:G3GMQDP-U"8=MR16(8E'-
ME[ ;<8IIBJ \/BX'F625M;_7*+0/Z%*SH5U[QWAFDC)-W]J2JG!QHCE@2&S#
M/!Z+Q5%I/PH,LO?4Z&-H7F),F=,.;3L %,.-BL!U&J=L;G!^(AXI.6Y)%3.-
M0;$AIN3-<S$^Y]L+)E]V;8KY03E=A%432Z9L5R8F>>55^E5O*ZJ7TDES-.Z,
M"G<S>(1ZWI? >*>%N$H7D^WD(&Y@#;PDH%'W/4Y(75'+X *XP-'@M]K44ODY
M3S E6217AYE+'2ZR Q0[G)A>1^(PP9\B)$W4",GB5*E5E77]R,$D4ZA^ANU&
M4"%U]S "2>B^@G[GMUNX^)?DWGH5E>:]54R0<OPM_H+#IV=JB;8K3#0,+0ZQ
M%3$=&VV?:%O:^!%G4DTSM"WE7H\<3T5EV"8S&^C-5CEC K*.,U8Z+^W#2_J0
MZZTK1&:REOV*#!@ +$ILJD]8!\GNI,EB*CC;[)4H>+:7:\XVOI=)\\XQI-"E
MJ95RS&.-T8L)SWP[V8,;B9G/#ME>D3"6#!!@(W3=VQ A(_\T*WSYMU R\@G/
M2NEP@9-+6]VHHT$]1R)F-B-/6<^.WBI\4_U?;'.S_XMNMZ6RFN$C<6T">^*Q
M_5T;)GX-E*LIQ05]!G_8+ MTO<.]_=^2X]?)V6^'R?N]D[.CP]/DM\.3P[/C
M9._= ?S_/Y+WAR>GQ^^2O=/30_C[NU^3DZ-??SL[A5_ (9S]=G1R0&_^D;PZ
M?'?X^FC_:._DC^3MWA_)P7%R>IP<OWOS1W+T&D9-DU/XRO%)<G26')V<'/[]
M>'_O%?P1/_3AW?[QNX.CLZ/C=WMOX'>_[QW]'::"WZ?/)3"ALY.CO3?)JS^2
M__P 7SA^!TH+_'G_S=[1VU,<=O_X T9+Y!<\W\.#Y.@=#?/51JE^_!:E^NP.
M\6\.?P62.3@Z??_A[# Y.7RS1Q2,Q/3;T6ER^N'5Z?[)T7LDNV3OUY/#P[>P
M%*0EO ]G)WOO3O?V\8^G0%RPQK?O80 @*;PAKYAP7\/#1(:&^,R'^"YMXP7
M(>&#_WFX?P;7XPP>QHN'[YY^@$L83A4F=_P._@>(_/??CN#/^#9="GJ+;@#?
M!WCR_<GQ;T>OCF!F:?+N6&ZCW.)W,K_/NL6GO\%EE'?P'K5,= ^^ '?W[?L/
M;TZ/3Z)]V#LY.L5O'7\XPUG#5-8_@LV-=<Y@.WG]X01W^>WQR>$76?WIX>%_
MX6SAXZ?';XX.]G#1[8?V^]'9;S#>Z2&,18_1O''9QSA%>1I.:__P\ !G 5O*
MI[MG3G1S8W_OW;OC,Y@+G_C!_?LM2V[KI.70Y&D#W4!!AEV5$\K7]O;F?6K]
MD4^E.,7JA :RV96>@OS;W)!L+1\#\8H7]IK(2 7'K"LI,R;?"+F+*-!S6614
M\@)*'4,"NC\/LJHJ)#]*7T;8F4+1!4V=$ Z54EMSC$%0HW.,!JH2G@V'F,.R
MA4V%,=A$7[:_]*F/"NH,["Y#&!5BO4'2B>[$YD80Y.6-8Z>,8$8[[?0*FRF
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M4JI2#D:/#S\-%N-9T MR*:IE,=?,0D3^\67%#+9=(W30G$&LA^XOUQY6,BZ
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M\=U( 1%V2G7JCM<NQ[Y9\Q)Q=SJ#[[2TE"]=S3FY,J][,VHNT).N8D2]!)L
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MBF_2YINTZ<XZO.E%OPLGP,\_/I038%T?P.,.1U?L [A'DMO=7FU.KS"J6W6
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M@DI;)RR !4U4Q@UCHK,/:\CCLF'#UNZM5S((H_6UL]&N^18CF[.\F38=Y/G
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MM ][T&=)*G<?Q&F.3/4]/-B;91'LA#!<^<6EONL(3BD\-R^G4[S#_NWM+Y]
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M2>JBEH5B0!D5RN;59L6S]T=_?_?VF7CENAV/_O]VYN7%/ Y=Z15.:UN 7\V
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M.,\P3G$?XS#AD_PC[V9/4E' W>(\@!FDLQEH\D5(^]WMS.#DI@G.\.6;W$M
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M"S,3V&F&PL.DUH30O$1A###KH7Y0ZJTLD+@YVM>S2ZPMF1HD7[)R5HSF*-1
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MJ@F?LX2M#2<KV0]ZA,!9DU]1'@O_MKMC_@A;&@-_Z&N7R11U@H^.H7<&3^1
MI(3;@EN#@&(8?8 C"%-J%488P)VC+UK23('W#J\RO_,O7$C21Z<$)=G)?[N$
M69?M0!<NZB.OL, ,KV<%J67[Q>YW:#[1V-U+XN]N4 E)\NE2)M -B1:_RL>@
M^/&+X))9]IY#MFY&6O=H=#_AQ: I)[334+..S1K=%'4IT4L_5/]+T-#X8-Q?
MLZJ8WE%4$S-?3EA0E<+[0*9D<ES@HW5JV,OS[LZ 0/LPE9%HHX1!N)UL;U&G
M/LLQJD'+,1B9\YO 'N]@,M>].8HP%<PQ#6\&!);&4/881*]C2G""(AU^EB:;
MX'U.(OKLD9596\T=^!0M+^ZR! <!Y@:<30[TT=D91_C2@=QP.%"Z01^8!,_;
MHB1T$A]>#'9W3(065>5D22+-[I63#MH9Y*JD5GGHC(."9LNY!<W IE=HFY"I
MQ[]Z4!;5>Y@M]Q>V;G3[VGQWL/OY36:;H</')I(WC<&)YY.>+'NR!1:PMV&1
M;M"/Y/@5" N&%G+9U+1]<7A_H(??TH\8!MBS8;,AHW5?ID65[[KY&)H&O*IW
M(K9I:5BUU^NKF\/?7HO?>_C=XR=;'CN(!$SGF3F'XX^P1D!X8+-C!0(EFK#-
MRCP*S6(^%1S%^B[O./ D#;L[8;K _GV^;-HE:D=27$XXYKSMY,>Y)'OI%&W!
M+"C!0IJ7664/\.%APW//3T\XEGOXY*FUA(_,U@H?P(G"2CPLTK&$]QEKI&F:
M-W#W9/!N,B4Y&T$)#3-AG!\QD!]T5"+YI]V']AEK2XQCS@?BF!W12:RL?#M?
M@#30((?U[I^1DGND(_\[KGS/O4OY8M#3K3CW'8WOO-NL;.N..(%8YIMMYFP,
M&ZPM)(A VPNLA,NB\K"Q-$JYQ89Z\'SXO^>(EN!,$>S[X5S1^8,GFBF"MZY-
M+3WWEZL1"R8&VM,<IT9S?I].I$5+R7Q8*U(?-Z"OJ@7;T-/^6:G93Q&<!\SL
MI(8Y1B.</Y7</8PU+"C?)FIPE@<("7#8;NME":<6V$^1+R"/88]HR!]"?$%#
M:V.T+/Y;]38J!'_.;-.*$M CK&^/(=4Y4#I&ESG?83NW+.,9V!4W!8QLDG(P
M-VG!_@(G8ZUHT'4/EG,C3BRP^D#\S02GL+A<ZH+W0&!"*^>'=S]2&G&"N>!W
M/[)@H%6[N]/](!RN?!2>-V69("*5''IX2 )KG>F6JY:(:\4O[C[F.B\G84QM
M(,')84VURSL/,L?BX.2C[4> 4!RD.;X;L>\X29B2@8CH%;#E,W$6L\E-T3+T
M*.T<]MZ[=(<^OC4XY^GLC@+;-FH-WB1,O;< *7]ICNK!CXJM"?DL3AR(52$O
M-\%2V)[HF=SD\B?,GC3%F"2<[^3?R[\5>8:_)(.$'^[#G-Y&N:0PZ$+NAX^Z
M:C**W_A/Q\3-P.=.UGTNF0=XAUCL.2OP[M&Q1MH3E701<+(_4."*<.'6B=Z=
M.7E6"1[E*=FZF],DE*3'X5<\7 SQ5!0\+JH67$;:M2T=3X13X_C//,>0AMSJ
M=[V+N]N13_++A3ZVN@I?G;7D+S6HML,G\U^"P.G06DTW^&R*0!4Y#W9Q7303
M"<N <W2#D&]9AJ;MLSX#8 ,N ,+,U+>Z(61WL%;K1[V[LW=UGQVUH<7 ?B'J
MAMART$PQ[8"VS4%)1,[N"@TR-//7ZSZA.Y>PK6'G@-C 7V&SYQGLZ)2 X-FE
MRZ@N\O%U59?UU9W/UDWRF[RLYYQG@_/UO60/5/9TW_LX/"L(B>33<HN:&/P@
M<KCO_TV@52_K*@,A1WNE[XVBREW^WFI<>8*BJH9']ON^C?MOQ?QX/GI]=MSK
MA3]W>F-4398P"7>8.[E"M% -KN?Q<G%=HYIB3/ 6O\#;R"LM9,52=9/EJ'O)
M7AW*/^SN9*1%.*V3R#EA8>:RU0)K=.4CR0H&Q0G?CD"H24V%+R(BZ&"3B02Z
M<X9[M[#X!#XOG T=&,YD!8(SC;%1LDK8=JO'2]Y TZ+L!L6<1H3W;C.X\AQA
MM[_B'%$]DN8D>C _4[SR5J[TV0M**Q,D48+%&*1X\O I7C);EE=1_5"X(MO\
M\I_+^A)6\J+!JBT!W5 VJW=GOCLX/TA._P!Y6"3'DUE1>9F3#8KGU)&_=H2^
MN - P5O05D6!/@;SP^WJZ*8<=&(]@^M:4 -\\C4PGQP$;?PMA&L@Q><F%_VP
M)6F)3+5$(@BHMW!$H!^Q4#0*^#_C)=F+G+7C\+]\%<5S1%II4,]RU,$VY76!
M7L\27O6&*[W@U\_%8SWF4U'F\R@Y/7AW #\M0:N5P5?CCLYY/@T V'GFKVMP
M$)\\^O8?CQX^_"Y-'GW]#?SK\-&1VH/FL7:R_/-)+NTTP=337:^H+D\P9$<*
M*7LMH_+/4O3!$;E#35[FE 2QJX#35J+Z$>@&&GN-['HJ!I3RL<I7WL#Y?),?
M=9-.W95/=7KP+? A9J:H"H_3&)T'\9^"B7!#1*O K+@X^3Q>?$/+*Y_YK_V9
MRC?P"A!B=_QL==OVCJ@WA4[2NTELIJJK!WBQ.N#3'"L=RI2#&PAF&A.(D6=[
M=^?*C"%U&Z=A(2#TFCNR34*CS<OI _^G?;]1P;"L)UB2<H4%%&C(+1O,5Z*_
MS_!)9YAQ!BJ.82VR/^B?_H%TQM3->WP6;1+S##(276Z,3]&)V^1HY<+^7J84
M?I!\,B*55;:S4G)J :I"JD\.OMAH[^._H[V?>J^^ '=T<3W&X-+@P2I[+3D&
M<7SPOAB_O\S&[TD[+\'4VWORB+;Q"=4X?/T-N'P;@/@?/<P>?'.Y=[F_G^J6
MQE?1*T9474>G&6;W.R_8I$B GI_M9?M[3Z-7G,"6*9-7=94O,%?T-H?MB_[/
MQW].%KYH3"]ZGI4MO!1!-6SA[CT^#%\@'_7XFT??)3E8P/D_#_8YYA6IK>!1
M'S<SES SX6A9$, F JL!XS*[.V_A.%,$$)Y%QV-45.Y7+O7XW=<] \'W3*+/
MR3%+2-J*2M0_?/3AR)\_^_=L-C\ZX=E]-#"[#P]A- <XG'1?(XH.3'#.?L-8
M_9JAIWQ+3]%O.F?76/@##A]]^[/#M=3D(6K(BD=&=M[U78N0Q2IYF]V1A)\O
M$7)7T?:#9U[@!XFA=E(WS1)T[UO$018RN&3O\.E]I^V;;R>3!X=NTL)5>95/
M"MS_L. 2.]R[0#1C\C^_C$:C%5\4W%]@C7-X^^A_UM]L337KC=B0$&/4Q&8R
MYI \W+W_6;.\ DO_$OU/-Y8!&5N9-CI\_-W7S8-O]W6^%'G#V"R/\<K0YJ37
M2=2U.T"=W"1#_-\5)UWP4]$F;W*T& DS_2%;X;NGMP\>1SKG+5=PR&8^EY@?
MB<V31[L[X3L>/?WZ4M;AE^/DN6CY<_P^T(?CZWR"CN+>XV^CL7U[^.CK?;&\
MDOEU!E[V. =G!2TPK.[BK:23TO6,Q!ORRZI5L&0-/G]V##9M/0%%!\H/G^GE
M?^_GD[?[M,=/#IX?G!U0B6J;/'V8)D^?P/__&O[_M_2XQX>/8(CXG-V=EQQQ
M0UO//NIE]U%P]SX/AT;P*JN6B+M;-NQZ^WM?]0UC[9H].GSXX-'AH96K;Q\]
MW-^FK2XYI&X1J:6L&"@T+YK$5+?=@#4SX9 P1EIL!OF:7X(;PB0:;6J/R_$I
M4$U!X("C8WM!M-%L!AL8Q?PY72J>:4_H97Q=E)A57.1S^2?(?C61?S,V+<54
M3SZ7'_@"_:&=UTNJU2A@ V/V8*TPK;U@1JX03,(#V&6I"_.Q['W\XZ?9VL>O
MU++K<Z[@\OU9@Y]DRZOKQ=#P-S#YUEYPV:R:_DU<WO431*&@@3<8[Q.CJ+A#
M&P/Q;U-.B%=8%8@9*8K*8WHJIK?9YO93C=/KED@2#CX!B[BQZ$N/K,.$P1H>
M1:HH543?"\N$K_C@A*02J]!IK37*U@X)S+VO#PZ3'T8_[ITK0(15V#'=V!Z!
M'8>I-]9HKE %<TQ@58Q^# :%=?<X7J8P<AC:A '%==.C$E>.ZPD-['@R*22R
MZ::1WZWF#!5U3 D]-DN5E8@H1_Y@9A@Q9HY<ZC8%37Z+E0Q:4%_=!77Y7#\]
MQO(S0:4H)P57V3M0,"(^X1,PG"5V7/!UQ13)0JZDC$SIJ_H@UAB07/ ;"2-H
M:]:Q*DA8J.*JG]V=@;*?)*[ZZ6;'UE3]V&H?3-J;L\\D%X;G=.L5+^"'](;J
M"ALMQZ+".9Q?[D?_KS R1X4D%)M#'47RH,EVC)[EV8*":2 8%?V.*R"6"\)A
M3BC7AC4I]03^MZ'Z>F])IEI*5W(-0)@?-:8X+%6&4(M4,TIIX&S4$IV5T"I\
MZ^<74WT)NI[D\2:@78H+"WKJ6J=%TR[8YM:*3*GS)GRIR"JEPGO U2S_@:FV
M!EU+R4 ^;GHQ:)QK&TP #L+K(BR\K1DW$5PE8I-JQI*G+6:M:'##M5C(V5PA
MK]W;-W*%>>H^UL/[3^.JK1X<@8<(2KB6)USUN-9V";8!SMFB!I_0.'^QSQB&
M%1[C>PZ?[DU<T4P(_FX45]B9KK"B)T)5!%_"+"Z,P:+:?ZGWGF6P0V;R$\\5
M[K^ZN<JJXE^N.H@EQ0$O+%:CJ&[J\D81AT%FU2,XF)P&C1 ^$H*A*MDA*4?"
M"J'LEG>TM'SN!RP&;BH,E-4AJMEQ,>A+^N;)<LQGF2NVLB"26590[5=XA4!+
M#,/".&NOMV@KX>^&H9(]Z*S=G8B,!/[22-Z=-=Z_\LD6/XBR8+TGT>_+R=5,
M1)P*BXKJ]R6GY! ^,^:,")P6Y$BATB/(83[&]#A:/.M4_%:^EVVH@:.78*9+
M/%6UJI@*-)D/U.!OTB1@;) K=G=\+>=8J\R<C"^:90MSR;6J##1T%\G?EE7
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MDKPT>HK:NFN#^: /'X!MDI%2U8@^<JYN="=9AS=9Z6Z<K@*'D*/AX0$V+XV
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MW* 2?U]68S%?\'D%*V#;+9DJ<K3R:%!+Q'"S5E2OKQ6](WA'@YY_*^PD,U)
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M$6D2L5%M*=!=?6T;!_EJA2T9+F\Y'NG4=Y[H@GO=N/"&U:ZNW7 <6?/O3:6
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MRBP'A#B5(':T[S ;LU)N;7[7'<LB(13##@-, < :1>1NY>T<Q[*P\@FN$95
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M+_QA$RH1Z0O(^I&P9_0N^!0R-Z6BM2 6)XDBT,;+N.A BPL<::IYM,<%N6.
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M0Q8);KO[)([3A8(6,MR*OQ&3SE+8MI\D?C@5]3'?^P4'R![]'2#[A%FCE?8
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MFF@('GOI#A?4LN[ (:9G"MMH:;M2DF;>V,'YX&(P\26"/MKJ=S!BJR=D1$%
M3!5EC=6GIG >'*8E1QNI)%X4]% D\C.,7SLH]CGW)1IC6(1 1:ZF\K2#CN0D
M+\P)UM_B/$RR&9:E>L;!&9A-"Q1?5HTI+?#N#G;15,17*O.K'4 J7PQ(684[
MO8#9OHM.0% ZYDKU14\&IU7.%HD6]\2QJ1Y%OYPS0W43];8@14C*V$R$I>TE
M%>-G!A'?0;^(B'_K:V%=6YLQD%IVM65Q;R%MI@8LE*@2Y\KVO38Y%6OZ];?W
MK=PYQA$X_Q/".G5FYEXF/(C/;RXY_QPOIQ[S7'C9/>>9T8&74J:W+P5'IXUG
MM-/14 P@S-*:Q*OEY716+]FW@DOE4*QB2V7Z,!.N'ROOT^CTP,<6F->22UF<
MB^H&O,N)JA-1WH*X Y_+/4$[K7.4/?7RLVZ(;E?Q?FME@R@Y1G<+L:D1!<^]
M:#,_8_<NQ,QC]?<0YLL/V&U$VA:[.SZ@-BQ7?^;J]^5Q-V@L1GH0MF2?$NSI
M5F2)CF7R.2UZ65<3+S/2XN"NM_A/*5W]Q'QN^+6O#YXD)UC.GC<8TW;5F\'T
MDMG [3;&2X'"H)NDN/ZQ>4":^$A%T*M#VLQA[Q6P;<4S 6TG!$9\]:*^DF*T
M.$2.+KI:IL1T[8$C!\$7F+"S($-NB@R\X#%E$'*+U4=.@-+V,)E/'*[>7P4"
M3X'\)7UII[T/<4U-<]#,8(Z<GH]^?DW\4O!)CQX^?)BBR.4'5T(D?GM[>S"I
MQTM\X@$\;-\+DD3RB7PMF<$LU!-GUYH)1FRR_[2>)GZTWPE7SG%S> 2I+*K?
MU_N$[Y'^8"@0R&CF&EP*B1)7RQ<<V'SR=V#S+](B3Y,+M#=85Y\O+\GZ,+7@
M"__75O^*66AN9!J?"DVN--XWV!.6+))*66&:W%>?D(8H)@(=4'B#Y&/)B8=#
MB$MB>AAL/RLCW;&>C'38IM;Z725M2SFB ./0\ZFU949[Q;XD<Z6M<\H)CMV=
MX+>M,"3!'-G?PS0%U$EQ;U#..K*/Q/>IQ>K](G[ $8$?Y2(VUF0DYG>%7)R:
MWUW>=7^WJ+7Q':R^_S49P\%X*4^EZ .+P24B(21YRB7*W==S<(67<<2@1GDY
M>^_R9A=5;Q!$QQ<$7GZ'C(J]TIPM*P579@Z<Z,X#HE;D-LNMX1G"P;<%$0K1
MTV0!IS+Q2(=[L\^G)*PG?9FN.H^T7%)R 8\%S.:B/YS!!][HYPG +ARS^Y/&
M+]TZW[AY<0T*"[>S)6HLM$X(1F .,WW<Y!]Z$SVIV!>36?/^LDHG0H69JJ%-
M$%M&(+N+D7T2HY"XV#/"S*5@G4PXMLMZ!WQZ6D^M,+*\9LD>]3.0,1,DDL(,
M%%>!:WQ'23;JA!G!2PUA7^\,XI=K;YBN!A>"[6(,HBU+R8<[.=[G[R]XY6[!
MDFUEDB@$PEMH2-@1DB%!B*[<VF'[P9))[S2(QDTP*_51]%Z.?=WGCGP<A31X
MQ##&G 5.0/7UH)@_ZOV"1';?KO.54P-7F#2>V_\E,^JV99G=3I>E9+#&FI("
M[4M$B 3U(O=#$LV?X2GRC9XBC *1$_B8%0?QYU&%&6F8*./ /=3J1NL1H[;S
M76CA[HY!104M7.38<$8E+#P_/:(09[S_>+$DKN=Q7LQ1 7[O*RXY%X=UZ=K"
M3Y3K6V6FO\Q=!N?(5SQ2S)#+*8IIHK6=L>5O>I_#VXMY(?H:,_\5>H:ESZ3"
M.2=-3^")W".8'BO/&+C<9M.ZK\!CW.+^C["=2I!U V.>(&>Y? ZC:RU9P)A)
M-W(B."L1K N.2N5F4[)JJ R1O!0#>',,Z143.OXQ7QUG^>R(""N64\9!7%KX
M](P1-&504<AQKO^_O6OK;=M8PN\!\A\6*0Z0 FH2NVW:ICT&:(FVF$.3 DG9
MU3E/3"S':F6QL.PT^O=GKGNA*,>.6\,NG ='HLCE[NSL[.Q<OD&?!1J&9I2O
M@!".5'R<7JBF)CH^?=X/A:ODN%[I(E<&Z(7)#P@ZYF.BR+B9Y3>YU(B2:]7)
MV8+2@L_E)(HI8?0_?<(@_?"F$HV%5--731@7/IH!VV(T \/!^VOY1'N>_(,L
M/*SEL/O\P@=ATQ9$6GI0.V'7-?>>XLV01V1.I3[3>@"7BVTS7IS3O9)D/ZHD
MBW WE_!AH/41%A52F*FR*Z6C$UN4&DQVGH>M/7TBS5DS[(HA1==M3&)66-<M
MFG-72.'8VBB:=UBE3?,M/M\NU4J"/4L\.!^F"S0H*(RVU.(0557!-5@<R1/
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MZR2F1]@0R?DH9#1V?50C'O6'HS$)B7C:T987<M@: \_@AK=?- 23KT"[K<Z
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M9H</N#<,#OC+[ YP$&2S[<93G[-(=!_&8>GG@PE<'%8'Z<[_ 5!+ P04
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MZQS"S(OA]30=0;2I_YS 1[B1%53/8QXP%U3/+^P5>[7M7+3^)B@^Q%E<E5J
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MM,P&"CB$$7N\0'3_P",R'W)L-+W3Q._I,LTRS6/>Y8$0"1GQ)KP#D13Q9XW
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MPI0T!,BT^ D-=XF+M;OT>&5S9^]G2*?;JQQKBZ6*G#E#( VEJBCVCDPM/RP
M&6!QR !39"@.]X^40S70\=*72LQ;%6%<#I22.\3)26MY3"BXYP42:?33?#:N
M+DU-RQ2QU(/9N%&N 2!#4*T69$1S)V<JG=,$6LR[.@%,8(#HJR#6GQH.R#30
M7L8,#\MF. 5WC!$<M5&2I+TLI9OSA09A7]9D<L&-?/H;"IK,CWE_XR.;NRQM
MGJ_S\WPP=&H9H1:,6SQ!Q9[NC"U0MK&XU_@7VPK)0.S P\C(YW)MU\]=J.NX
M!:7:"R;Z%P,[QA]G!C=G7I!Y/BSL%J9,F(![FI,'&JFZ<WU)Z,?%D,F;[I@"
MB#KWH!Y,"S3UI/*6K7"XI1NM-'+#F_F^2&VI[T 2@:RBOC%2M(_:20<ODB[C
MF"V('A&I:>C=IWTG$!Q@0NT8S VYZX%NL+&'%X\R6RX4@;!U]9H[^&<2)^)
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M"&;8JS1J2GOPY*0;>7AMW@3_"[:XPV=BL4M'0)/T-D8*Z*1O?,:&ATT;9SH
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M/#/A'4.W%8]?H^RP2,M<23C 4G)S25K"53A0^@L:$M[_,5+C,'/@<O V)E6
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MANB[=+T78..C>R2+Z;,'8NI+-3F-PQVJI#@.T$KT0')J"Z7DW=N]K\NLU92
MY]]#]#B'(8&<C[%Q ]N'W!L9L39QUR*[@!HL,02TQ*T?)^9=V:>B.E]YBIY7
MEU\;F%I0+$Y%&2IU-$_WOK K(Y>RJI%/)=XQJ-=$B[*5*#J9J0IEY[GBS>[@
MUHM#2C(<D0M7:55L4WN12X]QF=*4<0]K3I)3I;2TR5V<$4J-K#C@8S95T!"W
ML 2-,_2B.-$<.;86B_@-+Y; ,+!O88Y%"Z.,%:\=#.(? 8Z!<J>GK#:A'G*;
M =<D4I]0S;$>\,J[N+N#>4>UN5VO/=1NL?(8+)3+K O K(ZS(GV7!:;R9B@=
M1T$X*I6 W.8C('9!?KUZ;8JZ9HG":7I*ZF P# (?#50^"1(^-GIP>'7/7)WA
M$);2FF.>@I"040RRG1S2\-L&O9F2#LV9S*B#YL9-5,6HJR-'N/02%]0</=74
MU?N^\T$/)$4"=[RA5M. _5K*%?L(S0@]K*WPW7MIAES.BMGKB../L6,P'@([
M?J;1J"VV(X5TI"H*1Q-.1J'.GK1K'J!(,1GCQA5,(WI0R9M+I!$W3MQD$FO>
M;">7D[8_?7GU!HC+-/<ZH/(P==FC,GAOGIG#T(G4M1<GD9VO7J\EUA&:,1!#
M6B8*:6F%A#M40,\A$X& D=F5@,)AKE5$3+$Y\@^_*35.T8X\/;-27C ,,YU4
MN.Y1<X9BHQ46W:@HHP D/A&"+((!;&?#&7,.U8VQ>IZ-C5!0TW)6I'75 WV'
M--](9C&_W(0UL\%&;M,G; 5N4NVI=V^53CPT- F?W6?J*2R&@YP%+*J</8T/
M2K4)?0KM^4TC2K*\,P_-&XZ&=6"J4+UFV^6-#"M$^($L)RS:^1@CMPO8["&Z
ML^W5J>P_\\II_-_>F@P!3DNIXN@J&L.*>9N=]#1M17^J;-S]RM7W:RBLK]9$
M8;U VQ;/IF11_!G",=1M[CI6(A"Y;N*, D;&X]6-%PVD<"W3V6 4!F!$88\R
M]">5OJ7AB'[25VH0,[H+\E;=- #^00]<MF%*%:-]_G3R@Y4EVPNMIG;)'VZ0
MXJNTL.?G:FN RR+CNU0C;ZL5!!-*6J' "1O9QVDZXR?R5!DR<O[R@D%XER:"
MP(,Z']!HQ#NK<M@7H:]UR5HN(RU,5B5-/B6I(Y!=UY2:SW8I)6=Q0"V7!Y<C
MQGI-4V/1D: ?;O=DUYX#WQMY@KW CJ'X;978](+TNRYILT=A0*ULM7/"(N-\
MZBSC!$1 QQG<]8?I$<'7IS1++T^&/4C;UL&WP@K@<Z&)?'"O.\2EKH(4 27A
M]E7:'8E'+:@.P L>@'7)[#O2V:9A,"T,R Y%B2:GKHX2CRZ'WC'DS5W33/)$
M!J0CK;O20)B2@U".BJ9+6/0#^[X7@+! GTH_FG#1LG':-IP0L=S10^X.;E44
M2Q*P/"7K[:4S-#:MZ=@M5^K*FFN@Z ZR)VHGN56G[OEM-1,:6X\*8.UW4)$4
M+5'749>Z!^2.(H9UXTFO+Q>P,"B]$2GT!HC2AT.'WGX7:-(<F%Q2:P:K,#V4
M^7+**:@ZQ3M,N9A)Y'HH^H,1Y$AQ]H[!KTW2H P&A;;H*,.W]L@O?*P\:TTI
M:J6.J?TPEN:0I6NDE<1>& 6,\^C?9QN]5H?UN0_KJ[4\K'DZS)Y33>5C^(5D
MB0#5<8.?4@EHJW7UV@SQ$N?14;%.)7TLO;90K:R!5T7/I)47P%1W1-'53,#'
MAEZ?HQ>T/(X:#)8CB^AE,I BF5K&@G9P09.P.DO?BKEX'I#B[1QI;G9%,-ZI
M7"\\Q8M-R)MVPPI\P>V"/8;533[S.(^R=*BDBI8%2V^^CUW.2!R 01EXL02,
M^Z TE46W!QKM)6,$8$1SUC+N<4EXE4GS,NSG]5JRGTM.4S7>D13(3Q)8,8>+
M"RXR;>VR5694-L?HD]B'X\:%0P'GS+OV?,("=#-M0]-3?5&XTB#ZV9U$\:A)
MKU!*[[/5<,:(H!BJC#@;C4Z3\:;P0%-,"6M\H^?%IZ\D2=AH/A1AC;XI=BD)
M_[7Z4L,[B^M@'V$=^7X8N-F":K[$(.X#*V8L\[2V[Q$K!:Q*MV/%-@+]4&PM
MC$/I1$Q^*.DZ8U*#ZC4+6I%@5$=C74_2LMJVN'>QG6& "XG1)S2XC&DD>4C2
M S:>$F*_"?V!BGZJN/5!%;?^!<3#FS61"U.4HBH2^%*.OC=K$PG,0$E]XOJ@
M@16.R2-^9_*8(@2BYI0[3&.BFG[6O$U#!>ROV^<LTI'[C02'G>!5UF^!FR5J
MWWJN&XX&^=9M%J:0^COG?>>#5O,;:6IKY>M^N2.P+L'*<A("G2[6,9]B\AX;
M9*8$$?U*&YB6'*$-R2GI_&$3,QAA@?ML.9*]*9YH"TYLRG%#!3*/[2;ISJ3T
M!6GIR)1SX&P8/7W6-$51;VA\EPI/Z)?%N?ZK6.%DA>9+:UW+NZUG>IY13S(Z
M"NB.(@9/+BG.ZWZ(/$%*>*/>)(K)$ODAO]0;C2J4A->*["CQM1D/-!:?2L@V
MTR2N& -S[ZT\8&E5857$4L+N0]/*E:J@8SH30I-%O"_)AP!;TXO'U&U3UI30
M;=S!P&/?N2EER;QB #;$E T= 7W<S+.+W-EWZ.*R8:WM2(H5:(0C3)4F*<ZE
MSQY:K(G7]\:2"(]C)6O;/) K1*S]?9 2GKKAVA8?8^T#&; T80TPM-';-($#
MLQNT+O? [N=:EG_S02!\$WB)&R?%58$=IV4Q!<+ITG#EC5CF^IR8Q^L:<7Q<
M/Y.<\* 3]-%$+GB>B-9%@Q;LC+XND$3U+B';'S&7S+KH&5/C0??Z&L.R)+[Z
M^$ZN@APH_6%8Z/:LX92F;+V [.$5K'+B)QLUB9P6KA1 ^;CT9@^,$EB M,KB
M\IFEGHRY*34,KF1+3;$^;)W/OA)EMY.PSJA,IE[+S29_Z <*6RU:2?[6LCEZ
MU2J=]1?L.E"Y_5^HG>+.RMHHF@2F^6TJ,E@@&30K,JC(8+NYNY910(Q!<=NN
MLHR]AM7?JJR4M9$/_>"%:?@']'7W+BZDF^8#[/@..W\HUV/KIPKY'%8AG_5@
M!@^?]\/5;;I]='YZVNX>=>#[_].ZZIR?50&<%Q$!A]NKJPA(O.8A2JAT@86%
M,8 25I@6LIFU7))LP>Z*:^O1K<ZMG'@*X,W1[+P4"'>^;N9E+26R=Q;;3&3N
M+^\Y87IX\E01T(R!T=FQAL_MA>$W)W9]5'X,X#?I/>B/00C>(?ULHY*-(W)?
M&NA7])'%#!5YYT;J)IS$5 8DOR>1UT/ G[+&-&;.^&%**PW^/=0!'X([)N4M
MWYJ&H[%<C8!M6F&.<<F:8 :X7 OZ61 CH$8?/L>,Z)BB/=(7 T:.09@/FI3Q
MWF)J-O>/0U>SF2=]XN 7YBIASL_(]"$OU1VGKLG4UB*5\'L)GK>[LCRO>_Z7
M@0,KS?3/>'D?R^S2Y 0X_<_%[#2"40[]MASCIXS5%:?X0XS.$3Y7KST/H]/S
MI4C%--2F'^)SN05YD,LY1297K[TLEYMC02IW__,K^:O+Y-+NL)6:_S(B;W>%
MU7RMQ946XCZM5? T^+MZS<*_L^6<JC+G7I 6UR5SCN5N28[< J@2.V*4H3)6
M5+D48;FWLK18A<9>C@KV*RJHJ&"%T>]2=().D*AK!BJN8B8OH[>L"?R=Y2%'
MG80\)MF\TH=32@^Y*-MXFA!2J7=/)>F!2W6/P:!>HVI9R>K,]0C&+,^TE'WC
MX;@\79.$F);OD:N 52M;L\I@C#9R"A+F3)IV&)E6SO2N,E]\0!!IEXG6T]+^
M&#FO;-E3"+!97!B81AY.$D9=TRMPS0$L+S%IS19Z5D:)Y-615ZO@&LA8(_W_
M1&D$KZHT@C5@CD]H;D9UVXD7DQ<U!VXE5=ES'DPNB%/8,\*#+?>X_VM_$L.N
MJRAV- CP0@ZP>1MZ16>]CIVWF5X8?>E02Y5.B-U#N!KP11R"M><E['*-TUYD
MXR@TG0: "_=OW%CCL^?7IWS 3YS^%/:5G]VV<\5>7.HZD4C1O&#79^OC&]@Y
M0UB8Z?"#4^10&L]XRGP9=KXPX85,=-I#!)")1URO%9#=AMQ1+$E[!64: *1<
MFKN2I#U"^'K*7N=*"916BH .-W*N?;E"#=)KU&#3=IL+0F+Z8.I^9R1%./$'
M=EN ;T%XIXLI8D.UTIR(/?A(FK&C*15[^*%L&<P2K7H=*29L/\^"EDB7G#J=
M%+?)W@MI<9(1>H8"\E4"/=4/1\1+,/YBZHM2SM+0W>?,)J7@>+E+644Q/4BH
MX*2T^T-9CP5:VPP&6;%=A-U(K^3=%J7.TXO#"DM1RPE38(4A+6ZAC@TB9*LW
MK<X46 V"RH<TQN*-J]<R.S?G5DT"G[J_&/QV:3,.5V'G,VFZ884BRYKK55;H
M0NV-M?"3FJ-29B@XB[(3ZK47-Q1T&RQSEG.QS&GW/MDZR,56$= /&[-HP+2R
MUF%E'3JG&15+4=BD*^>4>127U_0>_?%7KYKR-FLI,#^AE-1F/OFQBEQ,FIPE
M1Y]5E[,;#.G^://,>H9:-QVQMZC760UKEZK5Z3&C,OK#BIVS0+VN9#.-UH#[
ME-F+Z4Q1W\9'KZ@+6F71"U,'C4'R@#+H/%87M J384/D%4_2!6WZ7H(RZ$S3
M!?.[^D0-\*?Q4[VN_%1KH%3_:&CG<&55Z2K ]W)4L"[-V?(EC^T4R'(118^L
M"M9K+="#MX["*)J,24JPAHB/_J)</[GIHP2>6A]9FBX\5U5D1='SNP->K6X9
MWT7K[U,030X(I]/+*AS](CSLU7K$HN&?CLDBOW#O-6@R@3E1^X.!RK1_MI+.
M4TCW, OI_HI[!34RUE01L,IUWG\Z![+4RM&-EZBM>.SVU5NPM"(75B0,U!;B
M_+S_':_\,/N&( RVP+X$VP[YI[X-.>5<M_;!2O02^]8QKPG._O]I[C1V=NA_
M.01JLX3UFK6&&G@Z;SD58?88*WO^E4T;<.I6GU&V!2<A8DJO>LL@LMK6ZPJ"
MM&]]=IRF#7<>?U/7#62PN^NU0%V'B')-/A +H(L["DO7><0SXC[#!FXZ+[ $
M?TBOA,'5IN_U;)\X^*IXZP78WNH6-5R2@7[JP7\38"R:W56HQ"\4,'EEBAQ6
M7RA2'6@F>%(FP3@\H-N[/U&:U6MS"Z7&#\I!+<SN;J1H<60.@Q<,/';@]A3,
MA]V8-QXPUX&S0<R7^"P7(!K!1\N4.U>IZ&/C!^^5%TM?E0=O=XH2]%'V27/W
MR8<S?V;R9RKC\['.WJ(.-?K6\FXO="7Q<=4^(G/@#IIP'&E5S"_ZY/!,TQ'K
M"[,/V'^MOZ=E%:X@LYG"$YQ'S>;#E'&=G?_5;5T\^FSWR%&OOVIN[^"5&!D:
M./^Q0__W#MVI8]^]?TL'9JNO?#\WJ%DLP1S_R]9)^](Y[<!_K\[/VADA43XO
MH:HBB\S//[O)>@UF3^^W^1VNS2PSG#7Q N%-605'C,FBR$PI=6$D1%(NOX8D
M%4C/^Y&=L"64GG+Z4)E0":.Q%OUPBI=;OD*1\A9$YN/<WA;DHJU[//MKBU'J
M-'33<&X]UT'<4_E!&E-J!U/+9Q\8(F]=X^6"V\PEU:XS] +Z&>O8L4V@Z7[5
M2]_ =A'VP"&AHVTN@\DP14ID]?Y939S-) 4SFB(GA(<[]3V6'&Q8LCZ#HFOB
MFQS!HF!,HK 5(88,?360TNP-O@NC5&"ZF36ES FSJ)ME_;OP JFEY^XZ<;'?
M:<\-OE'/'83ZM4)H%$H&0VD&?/3C5CI="8I-CY,B>/245>!&:[S7R TTAOP@
MG/22MVF\<>9XC T,\Z#=I89I&.KC'E)#ZM@])SV]RV6%85@O1A YR_-1.AH@
M8=<N),2(GAO'WG6 ?W,%HA7JK=<BA<TOB?BM$'D8Y=/NS?0&:"D/N($F&+(]
M!)S@X7FY'GD8]D_;QPWG@:<6G1Q;O(DNM'Z!P3=58/#7,![7(MO.AHC)R@=F
MMU;BPB]N/&*"P]-MQY*[*].Q,AV7;CH27?[JEF/)(E2&XS-;<#.%S0,<\U%F
M5+TFKRJUHLK>8LD#H_X[,[7_A\;[9.6_Y*&I[N^4J?WFCGKMR6J_D]'Z9?E^
M1.=/VYX\1>/?337^*L"QP-C7ZF*4=,-[UT_NJYC7BYLM>VL3\]+"@G%\'W06
M/=*$:#S9:-$W1D2_7EH4)RVMA$?SFF K:*'SB/CI1II(08;)IM6-T,SO5-^K
MST@7[[43.$)YI6DK=0:/92$2J7CB<R<YG7/ >=W#8JD."(6@7ILCZV7F!?+$
MK=[]EOPIZZ27J^?&'C7+SH+:3JO#QI&!/.,O'_-VND._5)<8I"^70A N*Y,V
MWV;=_\8VEAL:X1+K)1I.<7>Z>N-_0:..&5YEU:V 54='J'5V[/Q/ZZ)UYIRU
MK]B^^?5,NY/.4?OLLMUV3EO=SYVSU@DHR'^W3J[^=KJMJ_8O8-U5DUG5R?Q2
M =MV1IB6*C%6'JEH L0#';<7WFJ]#LWZ>[:>*9KK)@[UY4SMWU39T1U)<_6?
MR!M!K\%$3_RU /W!M8:ZA:9S#;(^R*D!]-XA(F3;5;>I6SG"F"=7;)>$(+FF
M=NREB<I934/[*38TYCI&1,FW7 P(Q_0TZN!9^)&JBC,#WX1Y&V?)P.I#^XG\
M#VGE!:V@O6!6[(\:KNKH\<M%W%T'-RI*I*25BAI5)EUX@$X+GPH,[8),*>-$
M538)$Y@;-;+%&FVBDG6-(^[M_.1QQ$>MY(\QIWJM[_K]B6\.9(:)E/"/1O:*
M*3R$\"K@L!2M ^,'3&W4H?8S3L__>#BCPP*H>6Q*AS,SHT/.WG-G=)2LU,P\
M#NW?G9G(4?KPO%MVGC*/F1?D;>D9EJ\-9*(%(@&:F.;2*0@ =E&FR&)6@LR^
M=99QO1@[^@E3<>:=";W5X'E8.!6?;+<RHL:@1SL]H \-:9J"X,S2#T0 B1#1
M< (&:X3A(OK]262')QZ>*$$_8&-KZQ)8T98N/L%FZ"KBX(C5-)*AP.%F*K1W
MVM_'?N@E:9U_9EQW;@QBGJ$F*"CPIXNFV9'O>J.,PH"1 (+]Z%*'E"EK*&DX
ME0-VD0[8=<D;F8IFGX_F_03N5YG?BSI?'1?V_:6=KQH-:AI*%0\L< 1<::'C
MHV?F1C?#2RL,G'?G01>M7/,8!VUY9*GRT%8>VL7DW50.6CR7G\"P[%;NV6HR
M*S:9Y;AGVY8\>UXO*>A5#[E)M2) OQ6 ]$J=I+88GM-%.C,+S'*'Y"7X--?
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M(CK:24+P)&GY2UPN?0Q9@^[U-?"0KB\3U,OJM0&((C>*'_ ^Y5Q+QD5D'M_
MW^"(QCHE7FJ_^ZPHP_6HF?E.GV=C>I*:]JB<#P:',,R.SI'!D2<#5CD(8&K4
M\S9.3&O2+!1*@$5#ONZC:KE5QL  L FWE\"DW<F 7L,H3%CS%.,+N7B)RA:
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M>CQ9UOV("EJ6PBD$SR<C/E/WXT=)K='4CV:$@5*/2S7'KOUHJA5?9YH?L'%
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MT#M[T>N4M*Y%PX1R!G2E"0W:GEM-SI-"N$I3K$P/->G&ISF$>U'B;5IM/Y/
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M=*&IK22JE"VG(6-3\$^Z+\A9['I#YIU2!,*Q3@] ;=6'SRF<C&B[BQ3=7F3
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MQ4)1J:]9E%F4"7VYW;-&8D\OC]YQ48+P,4D#8FL_J6=)5M*\U093\C0FT+[
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M]3_VC[L<$6HJ39]".;S>_4K3/A@)\]B8/Q9&AW?)1^ZY5EMS852%;HH>R?U
MJA%AU;6?SJG;# G)()R&1JM4S?N._DSPI%&J0AW$C0L73D@R!R!B)WF"?RHF
MW:PC-+SR.?'G\HV$.1P-+IH),6]E*YO"R/!D:?(PM)O#=%07NL!I>WF:9-([
MF#&^U%_33YG?(DD1U6]WL2.N=\5T?!"*28D_C<,K,5&1&GCR%1<OQ@6DEH])
M?,7\YWA_!K02\2TGE8C8.7.4>$V#<6>5P VP_LW<X\C\3+_.M$TJC=U$Q>!;
M8;H.; 7G0EWY:POLVFY9Q&T'4]7RG5&V=M\^S:MO^QX=XV,FJ<[X5B)"51KS
M@ZNU3R)WQ^Y%*7->Y>O5<Q>]9(^FAC2:O")FC:XP>0L1"?:#GX7B&\#NCA/;
M&[;/DCHP[NXBSWS&^\ZG)O.8?(?I&( T;54=ML/?FM50'>COL.IKEKQ#FUQ[
M_.MV<F?E/K:W,;6_YFRFV#:E DH5;2@?UH9EY0GTVK[ I&O4FXV$7J?<E)+:
MJ-JXAX6H-L=[>E#E=G]]IL?TZ!KMH=68DE%_NQ(S 95V2[0V_.H9I1#>-BF$
M/9#;]T@A:./RNS3_>GNKU!G][O:-::->L7#:K?N;./<R+3<8.=X3V3CMEF7D
MU$CPNL!N8^(\H(FS+VR991/G EMS!]A> H.$#ATVI=TTM+':_6=INJ4[1-KD
MS$CUHU^UN!T*?NOC T%+BH=E.43X3VV>Z F$@:&R4JU8L0M0IB6%FB,=^G+\
M^:#VKDO-U6C?=G4C&B$(K0R*99MEY5PI7LKJDU1S-L7+;9JT4<P6UYC7P)\G
M!;NK)/4$Q1'HSZ=>X,]]S(=E28'=U)FRAKLBT:MR!2;\B6%PH>Q4XK=3NLH*
MDG,?=<%:X+-39 @-D$=TEJ%5I*@_J6(U3RHMG(B[_#JY#6_0INXKV 7VCY<.
M)W(U#UJM1,KRGQOJN#V6;,90HT]2AL*N6G#:$&@CHM*)&&QN&W V>;RB5$WX
M3<NBB(K0:P":XJ\BD$Y@OMCD2NDH=E.9YGNC%&IR)-7AZAY7*Y*WY$MDK#I!
M'>6S4+4HTOOGO9MAYE3$JM5A$O]B+HVJ$D/&O\639+#;OOD50T <#KY'?HBY
MN^Y69?].'SK5:FR11N0W\'&2]$U')))C=!2QQ>B/][X.9T''\-9C#V[*I,S\
M)>:1BYBBD_0VK04X^%;NQ*@R+@MI52 L2#53A<6;PX.6G)>:A;QWIR9G@_-&
MV7.@,CT,<:HC63H),>&-'>C 33M8'LH&U#X-T6!1"SJNLJ F!K[V<>P555Q_
MFIA$'95(C"MI<.:Z=9:L8?_UX#\J_QW?)+,;QJM-A60'6ST$JL&<G*AU,1S5
M&5'\L*F%'W%[;W$W[A@SB0Q:,'++L]%GTN6-X"CBS/)&KVPM4('356]0/[9R
M:C8<3WNQ2!;7/EJG4_FNV]Z2Y8,T>%2L O!G*.@'Z7G=BV17U6JQ@\BY992I
M8<S,IJNNR*%Z4S6+=9<[ZG$<JJ86OLATV@*D+GS=+PZD:L&('KGC(3,Z625!
MG&=EG!+W(E4L;F@Y,\IBN7+-U)*M;?I':=H5<^?]D=U[@]3L#6+6J"X+!X+@
M;K ^N#1J2EJ1$(O;?30)3,^BVB ]3X362:I.$W<6E5N!K+@!K4='6,R*ZB0T
M*W8080-)Z@*+PH3D PMB;.6(/T?"\95W-$NM>#*T\.$-;H$,D@58*BQEU.*L
M&E^'>"R%4P2C/TDNW.CZ4Z*PS&#V^6VX\ASCJM:I6T,)0G '42[RYDHH.MJD
M. &RR7.W&T_M8^E-XW;+OGNSE;1R2=:4U;*9XF/H9<^HY6?5'>;G)K+V(X0+
M=IYA8:MPP0F[.1PI('3+^D@!_J;DG!-F'U,(M<I--14CP;C:"V?Q9^PPCOVY
M03]?QH":WHY6K!)V+(_NY;:7):ET&#_(#E7O"8LV5CQ@9)BE<*2?19FK<6M6
M;??B =XVX0#8X\\K'N!M%0YHM];& Z0M#?4*6>A[61->M445BUK-C RPDCJ*
MIY.(T/3U*$L3A:"L7IH2@!+.D3<O\H)^Z$]PUO1#F$0R*Y2+5C("(K&290?7
M^!3*&+"F:TV5_*R-SYWXL6[/XD^NT7/8:'FM6"@9- U!K.-U\@ >.4TY\T =
MQX4=5ME0IC4-M7@N!R(5A72U"[M5H656M,$F/ 3L\LW1SBK9T_[G_DA*:3]Z
MIWVIZSUJB*Z>Q Q[L_N 2U4X*GK\3X*-LZ4E5=U8LBR"RRV*'W[JGIYZ'WJT
MK^!-C\ZIA/FB-QC"?H/K>I=G\+*XYOGL2[N%)=7][FD'[MS[?'':Y8KWB\NS
M_JC_1\\[Z7[N_MX;=E0MM/S;&WWJCKSN +82_)Z*JO^@>NFS\Y$WZ'7A8?#X
M+_B8WK#7HZ%TAUAE/3C_GSZ6C\-5P\O3$=7.?^IY'^!'QY^PBKPK,Y%*??@/
M5I.OZ9#3,>UQ:)2_#WI46C_T>*I4ZJX_[6 =^>_=P<DIU6Q_U&7<_9'W"8;X
MH=<[DW+WWHD:W<7Y<-B7\GMXQ&G_W[W3_J?S<[I@> D#5^MR/J ?C+Y<]/"[
MX]-N_S,.\&PTZ!Z/Z.OSP<@[,#P"9[W?X?7WSHY[AXWH?X+3_VIGCWW3_.L)
MM\'NDF4VV^ )M\&^A&2&U.32G[$5,+HNQX@K];<8_^6> %7H.WLU5M_,=DL@
MK>"LY!&GFVR/KL1$Z;8<=8!5=QG51IXWN[&PW>73'2P/E-&Y=O]/'KGNV)[!
MD+#S!WQ.Y'.J\@"+:Y- $I?CQYH*T:MN,9D-*\^A&7@@P=<F?H;1&*R4E,ZH
M5>]3!S$HHH0Q!L:^M5L,D8MB\+:+U)\L599L30D_CUZU5>7( 2TY+*M0$,2)
M16*VP,!A&%"5(GK..$\5G=*5EE;JV^557S.0A*<SC[+J1=:,M/M.\1"LH&ZW
M:*-TV.$.8!)'7I<2K8HG4-,F,*.]O ;IO"&EFS@/&PX,*T=9=LYU2)2H].;<
M-V_>=O4%6Q6>*X=E=A^^X"A>>7MS(NB-;W$D/.M$W&VO/:.,S"]-1F8/U/\]
ML,ZKY*$2.AKCFZ168X>G%7SKQC"F7FPBS;RJ,*LFB$V*8FU.1N*4&S39:])B
MR%-!9$F8*8F=',VFWQ_Q'9+-3V*-V<%@.J5%0  A_A#A!AT5P:6$B,$+96(E
M:1%6H\<[EA+O6 +67NO,H!,HE:-X4'3#<G?E>$T/5,#9X%1P7>R4^6%)3*^.
M HL$IP]R.'6@M[(2A&8*6Y'#^QF"K((&[?W(OL+.$S;+^'K?)K,BP_TU@-T<
MJ+:_;+(KJ6?DP,?4+^"H7*5)EEG%"F1O1;,9UB> G26\.@)]UAUTLBT(FU]K
MCA_R0S9<;=O)8]754DT(09,Y,EVD-+.R=:8F-_?SG'*>?&YK3)6[B"P60^SR
MM%O:W5G-.%=[FW?B ;A^1CD5RYHC4'Q5&XN+Y::,)$(;%"8?$9]1J*KS*F2
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MY,_*<^%Y*/UDIL%Q3SCBB?Q.X7FR[YZ7MWI:36CHL87'CLJ./N)%M(H;%I@
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M40KI_=W%$ 0PNGLUQ&M5#=&<QQ\<O5\+VW?W?PFT7XK'[A_[^*.@XC6WU/U
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MP63 'EOXW/:78[@2OJ'0=0TPEW.]##=U*\G6&\>V/;[.AGZI$<%D1$ZH_:&
M>0SJOZ8@ 8U'S#Q3 PIN$U8M;T.KV,X7<*P>\P7]7%A%X:;<MXU6*>!9LUL
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M\)\R-&QH\?.%A@8+EE.Y+07-+?YG;$4<W-^*P%@0N)<XJ/\([2]02P,$%
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M8/@N-J ;<GU*IT*@N!"&KUKC"-.T)FF7HGTZ,,R*T 7VS@1E*&1Y:?6S;CU
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MD)/56615.P3^''2O P <[.'$DUGL3P:[F/KUL4F(0IX"*@2K<(#$)"JHL:D
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M!IW,84W#^U9U+YX52*_?=J6T5U<J,E(E%6Y!!@%/:=DIRYIK@/6!E,DF^MU
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MYH#J><VN;LB'B$Z0G!YS:ZX8CQBUI5$R)EQ'E@1:N"%#+ZQ7"N<+35?RI,Z
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MFG>_MHT6Z-AB&./)P1_P\/W%AZ/=_P]02P,$%     @ 43_<5$UM:BM>?@$
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MPLY"KHRAZ1)X9X;IK5&?[4*:*;[SU3LO-"TK^R7&UE3LPLO'8.0/;1[<IT2
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MW\P37IQ189Q4J^L5LS9:<,?(R!,?QO;6$-^-:BA>'V89Z!$@IOVB\-'IF/O
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M'",7Q^WSHUK>(WWB#>"K;@!V3C(-0V^$]K+2X4\X/"P 0V&>F&C(183_4A5
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MKL,$G^+,]F[*+(@7\&0O &"G&]:YKFQKZ7E=;6_V.HN][:W56BLUM/NSQ)W
M]RULI]2YJHW6X-#80@[KEGF=/W_\? *^)Z"$ ==C>E?KO927/,)2*WVD!>'Q
M6 ;"IQ>.\I+/=" "'NF'MTAAOB]>87G6:G'5/3'1L\=2=:OI#7LT/BOLJ]!2
M96]I2[>WZO?TT:]=-"ZQ@O,MZBP:_,1Z!?VS(>UV414KJ%5N)^1%H]JM?< ;
M5F\7WM ?I=4N+J/7PG_Q)/WUKS?^^J;L#&#";:J5&'!AKU1[+&RB,?/ \TI^
M2='',RS]MR*+-0+:Q"Q=77U"Q9_7890;YTTV'VA94%D&]E;GB6)N8)F1H3+
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M#FR.UJ/!W[(@ +RP-V"4#&Y;XX4M6X<70+E&:ELV344/N_=,>TN5G&I\]K*
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MF)JB=(-H&+,Y1=PEF)@0WUSECAFE1#;:VG"D.0 N25%6[GJ[;9>R4)-7$#N
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MC2T&UV8916F*'7$YM%./Z?@@N!KD54.0T&;@.C*(+WR%5EG83!>AZOAB63B
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M]$@>=G=TR]6]6NW\V"O+4B4V8&RWA 83AV5">!!Q,'8<2)!W>YF,_$*60'
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M[%*J9H+IDDM1&1,[.:?*?V/!H5@X58F*RGV"[B.U&2[A<LUGS.1/N87$*D3
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MO-L%/G?'>3H<;+'W."U*\NPD<"E\@:AU*HYB5TN,M2^**0:;^Y78 8&@J!:
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MAABK[_3FQV9=#*R:2CAH=2SU-E(TL 4BE@2\%1&OTG8.83523$13]V"!NZ]
M>LW:[;X!_%< 6XUP[@2K(S50O8YG['O%\;ZONU&PPL'NL6XN!A.2O;2;*T<.
M+^2CI)HE_V:7"XLL5'#C<U$MA4<<>X+"5H!%4?'-FAFCLFV*7>/&'6BXC,Z\
M:SDD$P).X3DV"HV&3GP!EM"[!MIR5I!$9N3>Y7G%JK!3R69='*&W%(5'\,1S
MR,<3'\<CHQ2..T$.A@6"TK)DLO)WXW@_7:97#L)#8S3ST]-KM0KA>UGCBS7C
M$/3&=:"QJUB'3I]7L:_.JUAK\LI3Y<#$DH!NK;#LF=>0CD4RJ:37.*G(1MLN
M'.B3:;-8ZW7DW!^\RO@&$6>0'6:-#&.(T1T#)S7[5KVG/9 BND/_R[]JO.'V
M,'"=-N+^">$N0L/!EG3A@O\M5DOC"Z:6IKF,%LD5!2.67$IOMNEBY&XN5W2>
MZ/A=:<-Z]4B>\$.TAQ+U3;7^\;%X1ASMAK+W>0(_,G_'YGTE=#%BJ&G)967&
MO6(8)=H5>V(*36'/%@O^LVJ70 5"4_[ 47F \WE=.+8JX+Q:I*6J M<E[^3?
M*@(NZ5RIF 6]M@I[PN;1\+2LP*F[AEN8-9>$5FLX4 -"SO2(.+5T\W;_1877
MC9?:.2V9>\EXF^F2:!AL#Q>0CQ51P3F5[C81Q1K0Q"K(>YBE.<4IU#KQLVEQ
MY)U;JKDE7HUX6X+0PS.JD1,@MK'HC<.!#J@5NKUL*-%DN\PN+\IB=7Y!G6>O
M\6^L<R?%=1IN.;M>$3ZI^+1NC/"^++ZJXG1+2BD<,Q+N\9)MW3D[\P+5%6$X
MZ$C+Y<:RP '$4$2%4JK8 B#PDRK>/NGY5Q%2?.%Z^]!#H*'Q/$WE61+',7]R
MSYC:_NKW83M-$N#N(C&&+-4Y9\Z@(&DX:&N=X1\O"W*MMJ,SJ,BE0"627<)U
M<,4!'(I8 :,)F6TR".HMQ1F78)+13NV[-[,]Q>J"VLR9.G.D9F):>>7^ZGZN
M!Z^?&GKW]?:;<$<E8R7V;JED&ZK0$D"Q]+H6*P[J/<?K6ZA<BM)/TWFM7FC(
M/[H%DYGYH_9@>L0.3/[%<L\MF)YM)/+5STCDG=%FO8@7GG3;+>HV<:]]MZ(>
M;;>,8MZPZU8P[.B\Z<W;;.$M?^<^6U[O'&$@;A\$PFV0]Z+K[M!7;N%U%@OV
M['HDTU1V\"WL\5YRE2W-D;,!Z(CW&?8+_G-['4[MAX7,UTG@6_.E?A82^C;<
M+"%:-BP]CX@%GI2OD'04OP1)/@PV<I9ORTOEVH@H1P41K*582W0H3F)4_'0P
M0CM^]!>#K^I= :Q]87QM^#+;GT)H<O!Y/_I(=?7"4=,(?YVD,^8-L6/J"*E+
MY)C#8F!WF974-B/T]N@Q?P>^J",@-)9 /0B4'.";;J7%<8_^KT P#\ZL4;]F
M>[8M0-8,48^K-5$+_)J"5DQ+ZL[C(KX>8FI-6(6#M V0%>D["30$<KJ)RX!
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M[^#XV+L"^V%="N5H [U;IK8_R,A/1=E,U#K[&A@W4_",/0>/B)@ XT=1$7/
M9^DT8VHC >'%+IQ@3Q"_JQ<$*N?[ E^9%Q[AH0*[!JE%P0;UN4.0M70SA.$6
M^GVX%2I,[L-@-/:_^XE.A^<%;H<LRG"@<X3B^<@.R<(W2Q&?;0CSW<\0YD-I
M)K_EA%]Z-O9*SZRV&@X\+T244G0/.LEIHU EG+E _6JX&K2M!1;@$N$,ZX63
M(@@M2.VN<C:KJFYUQTT<ET+QJGZ'6>8ZGCH)-:R(!):=GDMOPQK8HMFQX;;.
MI&S>A.I*@T5LZ2N\>@T/,4=?D6;JR]^=IU/9Q;I(V)MD;!HM8&+TBAD$=D
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MZ\W.2ZN\&H7FV^TD6(LBR571#DAM;CF_*8?OLW5S#*BYRG<2N%<35^O5%!M
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M9U#31+:; &PSV0,B(<T<SESL_'AVYNC0%5<.!_3@LE)G=.X48MO+6,W'#VN
M(5ZG;<WT'H9XK<A(>H)7*;YE-)=66;U.+K/%1@#C&$?#EQ-8KA[."T@MMC:X
M F@@':.+[%MQL;E(EAN!*JQ))W$L;X:A*KNDJMZY31(]<9OB?M>YS*[S#11
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MP3O9NBF^*2=UV3*DVV?.FXV3M_<=R@+M@#WP+(C/X J[+..)Z3?9.KO,;$5
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MH <GNS 363)1*QNK%GUOEILEFNF&,/7'CT1,BR$H%>DQ?X+X.NK3159<U.-
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MEW7AF?GU+UM.A^0R(8]:<)D%%:;&%Q%^<UF2V3;/+M%@T!QZ\12B4<S? ,(
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MR@X')^95%TO;F?G*>(3,ENZ'Q6@U@YYJ6,8/3+7>X^LG@$D-V^>'TVZ[>15
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MY/-)&S.#6<-J@9]$01*(%*Q/3B;K#6=KLSVN4&>4U6:X5N%IL\OZNP$(PCB
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M&+G$ZSZ$0DXL0T^P'IF$!:Y6$-  ZWEBB]1%3,]4=ZE-F#;A&[*DSA;$=;5
M^BF?Y%*1\03KS#C'$+9G]B* 9"N73&1CQ:Z_V[C&>HN@K-U8\!M\FV[:& Z
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M\B9#L"75BRV&^2L?7L7N$=YZIGBKR&")GT6+@VJ_9V:ATA;\7^8]?_)[U#E
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M5'Z"O\7I&OD!6;E +HD['/A!VFUY7@B?6[_$A7O,:TI 2^&$12-*G*)=RL4
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MZL5^I:05P_OR&;*]G, 0"2B/@%_%C^;,YH?*0;2%<8\XCYU=4:C4/SES@6W
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M<,GG[IJ 2C ),"R9C]VQ?^V\_>^JU:ML1>\YU\+MW5^!?K&,B9V+B=(7L5<
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M0?YI 9KA^LG8PG773:>!^I?Q&ZI1"< \Q<T3>-C*.NWW_P502P,$%     @
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MJH"]?#SUS2=5>D/^:)\0)K_U]P]02P,$%     @ 43_<5,<D4^M& P  %PD
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MM=Z)+]3V]!:KSUE"=:B 0*:M/ASF<X_ULX)ZH(<GN1G.!S87^4#O EJV[BA
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M:0U\ SJ@Z)/?8K1=@D(V&'0V;)KBV9-\)CT9K?<@&V_*)J$*C-+;X0/**T^
M ^:@=QB#DXR@D$ZM&VIU*[& &52)P,T$=Y84]F!.4RYU:A#??L1_%Z+*+H4"
M'+ VUUI$$6C$M>0,+OG"O:]"D^Z32$!8C,#^0GOB =<F0@,N0D!/=&BOLAU.
M+9<RN^Z5KF#DBV\7Q.!-$V-F!-TF$&K@0XNX][6W:7@!,*M9"O+Y&E)/9DW0
M+#.4"KQUN80YG:VTC"+(83SSA2"ND]C?%1ZD.'0G7$W(P]4"R+^A191-MR[@
M@Q(U& &RFC7*O=1FW^ RY#3KZ:I%/'LMX#%X"?18$0CU#U7K_4$ 8 6DPAYP
M)<6I*RA^,"*PZA+B806V ? >R415"E]R3<?CQMC%-ILL4:ZE\,AU/%&]#T8/
M!5F>=2EE8RCIY'.V\^.IYH&9@X$%.Z+-"K4-H[H(QGI2[8!1F#C!D(HC".+
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M'WC\ M+&J/LK+-+_D/LO4$L#!!0    ( %$_W%2_XGYL#@<  +<E   1
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MK3K0[A2Y+ZUZ?J'*HZ9N;UZAT5W8^A=02P,$%     @ 43_<5.FAG4,,!P
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M.8GP;]G5AX.8;#S< A3.^C$,.4\03$L:(<\@Y' 9BLTS:-:J_YXS#!FJ8?-
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M\GG@5Q70&C00NA5)'$,?)X.T2@Y)J\H<R$'/HW^H71126O5XJX+^F55M4L/
M*^)F[;:DSMD>^G?N_:U#Q*-68U63Q#-6\ZV?Z5?=O\YNR>P^."#^[GXZAZ$#
M:L.5Q7]&Q$#Z\"H#U4-:!OJ'3+RLSSADH8-\UH+;HJ&2)#+/%'1@<VJA6KRZ
M@X8>)@SF@]8>=@P.<\[)[K+>&+YM 1[!LN$846VQH4B=%(;T[7MMN<D/K8ME
M'S&4;U<-UCY[_K QM-6C4Z='MI=W@&&$9(QD$F,68Q%C!>,KQA;)'LDAPPD$
MG0\DAVM#X$F<0E9 V4XSSP!DAK#K<GGR%@@.B0&E^.0\E0I4Y[4@>KHW"DSG
MK2"VG@[5+D /79]J?V"0;EAU-&F<9^)0&E]62B[PH6?QT&.YBO8:OH:"1DAK
M01?D34$_9*C@(]^G]EG=Q?E5SPW@3LH!W_$PNA?6E4LUA/ KF!0U-'"&*\P=
MU[VX^?EW10HEX7*,2KMJ-=KA!GHFC!:[\ Z'5!<O3WE?QD#,D-W(X=B:Q,*T
MU'OA>5Z%\#+X4[UJO0:]1KTVO6[X._B UVCX1.I,X6+'ZO#&[MZ5(P& /J8W
M;M'E3M(]2B9:?4@::R<7B$] V%NB5@X$4U!/TQFYP63F;3V"8'*.\!CQ%0A,
M"]V+MHWO3!'(+,HE*X@HW7OJ7;WWW+MIK\.[9Z\_8@0TGC;#M%C[16%S<3_B
MF!R]#MN. (NDF,* %@M2QV8')><?%8V45E3$4NW2CC0T,".W7D+4N41ZV=T6
M#":/6(KM2BK.2+_O4V!79E"A6"OXDKF5O)N\EWR(?(Q\FGR1^0OSEN WQ1-#
MX"W<*,(2LGKJ#PS8K"Q<2ORW1$ND/RAAJPOIWC*JM_ALQ^)TRZ/>]UN04D1&
M[.=DH<R,W,]%2H]+GF$WV#=U=PJ]+1F\^C%JZMNB_9?/V_8'RP $:!D?07)
M&4U'P5S**<SW410A@Z-4J@'3.S#)M(8A#EQ+?6X$XH2]OAN=!,O$R7U=%/WD
M1C7K\X.6U]V9?;XCL$^L\S@KRYL?OS6<EH&R\&-(_:@<Z!U8': .@@X2#O(.
MJGXZ,499EF7VSUW&O%<"<</98I63_;*R\GM*#BO8ZHP:LSIZWN$.*8_'S(ZM
M4&XZ?'L!N(1E3/"([-(U1\B+Z^R\=T5698QA;[1$#?_EP_:"+NB"+NB"+NB"
M+NB"+NB"+NB"+NB"+NB"+NB"_O^GTQEI=7M/3U<1+BYG#TY+&Q<K.*>UBQ/7
M+4M7+FY.*!= 3/*6JZ6U(]P3; 6W0SB+TZ^_:*('(VS$Z0WXU:!JKK)P>X22
MGSM<QT]=U]K/T5K8AEY2 E?LEL@M)U<GN*<E^);336</D5OB].?&15#W9VPN
M>O"YB*>C.+WTV0384$T3+.OB#@?S<_)R6$.YN<$" IS<?/P" MS7P3Q0;AXN
M*.J7  <WGPB_@ B/(/@/HI? 15W%W&UL1;3E%/Z 0XW$Z?_PR\?'A].'E]/%
MW8Z+6UA8^,P,#P\'2H+#P]?9T_(6A[,'PP\C/^W(P3VLW1&NG@@79_#9V-+*
MQ<M3G)X>%_P;_>&7DZN:VB^HOPVADQ/7WVEZ>,I[>_[;FAZZOJYP+FVXAXN7
MNS5<WAON[,GP]Z:TX;;_&5,H\7^X?.;UN1LB<B[67DXH$)B<!(K!:8.P$>$6
MY.-1X.83%I!7X)67Y>86EH="Y?AD^*7E%12XN66%Q+C^HOH7LS!G#T]+9VOX
M'V819V:%_V-F?U/]BUD-=P0J(2UO_@8M)P.55Q"2YN;CEN.6EI>3D>:1X^'A
MD1>2EN>3XX/*ROXT^S>J?S&OA/#P=''WE?A3O,_30P?N]F?NSXF;B/-T<;5T
M]X"?Q5N<_F? Z?^B<*9SG@(BEM9GB2;A8>D-MQ'C^A/O7RLA_B:F O]>3/^B
M^J_M^]C#G25XH*B#@CIR/'RZ4&$1?GX1J# [E%^$%_K3U+G4OS;BX6+KZ6/I
M#I>V0\58XL<Q_\=?!I;5$0"S&""<;5Q\/%A_6ORSRK\V;6UOZ6P'MY'@^JGX
MD_&7C>'ZL3/_"W;,VL79&^[N^9_8-12.):KZP=T])&S=79S ""=+.SB7@RO<
M#NSI K9T=;V)L+8\L\'E[6SSQREV_1FPGRB_&?G?Z*P-W!WQGTG0WU;Y*T[@
M_]N<_N^?R7^W?%Z<R?_#=DSH?_F.<0M>[-C_9!7]=TK(697Y47/@KAZV_Z]4
MT?^+G/[OG\E_]VWQXDS^F?OG5]2?K[U_?:7]^>+_(RT5SA+K/[;/8N<]QW^U
M@/Z3ZM]9MOFO]")_4?T[RR[_E;[A7ZK^-<J_!?-75\GU3VWE?[7=M+'^U>:Y
M>KG?/&]J;:RYX#?A9\OQ0+5ZW%Q_:NQLK$5L7=R=+#TE?J\&_^#^3R_P5P'Z
M^W;TU_1Y4_JGE?Z:$I%UN>GBKN9B Y?@$^/Z._;_]*)1^_9O=\__W"N+R+K#
M+3WA<JC/62GAYH#R<7#SZG+SBD"A(CQ"/TO)/TG^DPV4*PA;WY\V_E4Y^B?)
M?[8!][2TL?2T_ ]9^5WVWPSA#ZZVG(($+DKUY^_D_%W-^I^G"Y +D N0"Y +
MD N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0
M"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y#_81#<?_S;
M"'!G&W%Z'WI)B=-Q@"P [;])9T;^NS;03IL!1-AHANB&&&A$ '0B- PBM-/V
M\_\U .M\_M<_ 8$!Q 1A8>.@H^%>0@G " %H&!CH0" 0 X2)COK!1$,_DR"B
MXP9@$4MCDVA9DM*[!5])S,=AX*ELV2"3>3^SR:M-#I&U<K_*Q\AD'9+$S"_P
MH IEZAH:  WS3U" '[90:&=(1"@D=!0,$/,,#X1:%SH&$9 .0,PMC:EE"2)!
MP222YE=N8/&TO)]AD-F\HHT-X;4BXY-U9]1!P3P@9V+F#PVK.AT#X&&@H5S$
M( )( HZ_NUHT3[<$MX1BA(*P0'@$>%>IKT*%H!:N%NU^2R\X7G"F/%\8-2KN
M9UGK3KC2$Z<N8RWG=* .RI#Y9-X37TBL6V.)+Y!.XZ4$KR/+, _(LL&B]<*K
MU1^W=&9A9.S*5E&C5WLF-#L0AJ];".!T$^?G4+-^75Q@.98^0JK]AD4GGH6.
M4;DG+.0A#C #.$YD+)F=_601WP'^RL9<?W?8L'B0Q/ >022?K@1-5H-21":G
MDB5;#%K2G!-9Z,+,(AV\8FS@(=B0F04W"0>8;PG!SKBA!&/@@8-3 7E*@%CC
MQ]/?#2+Y(A]]"X!3J5^O'5LQ= NJ0_<@+7ZI#*,#W\..O>$O2E%_[J\EW^N;
M4M%,-PL/W/(KOF026"#'\>C4168PF OQ"U7T0=' 37PU6=V4]6&)Q[$Z/'/K
MG+A5? .7XMD D+!\1CF ZB7+US"CI+!H[2@E2A@3H(DW7L)L7S3U*&0QDV,9
MQ]M)WV;LE4">7)%A";CHWJ;N!\UW8U31FD6#[UFYFAQDKAHZ9659"=*H!"(^
M")J4%SR>J^%_I\]UUT!/'[?S\\F52P_M]SWS;X3(Z&PLVR#)8+%OD K\]4FR
MC@XYV#V4</P6+:VWE1EC6WD/\IOH9HGNAK:MX9=6,DX04-K4O#7ZI%J2."^P
M-=,IH8/7M,G5N+UJN5.?(LJFT_;&HXC%@4M%S,X;P;DIT>]VGW.%;7E0Q\C(
MJ6JZ)-^4'T>;(B!VB=><L*IB2]9).>IMV#?EQ<=T9=Z(%N4M03"2N*(F2/<*
M;C@A((&XP9;',B$WM:8SYKMG_6-&( NF@SJ.\#(8+=7B"PC$1QT@^3%&-:YN
M!DUYDXV+B5XN#D>R8IRZ;05361\)5A^GY9$>-&U7:\!Z>W@T1<&P_V@9IM^C
M3W![?;V1OS-K\\M+SAQH(IF2$B557!VZUY)0CYN.(/K\![\<IX7;04[U/36.
MJ3 WZ]X;0]E>U[BS/VN,BW=5B'GA513B*.&HSW]0S^74A_K./D@%32?YRC=:
M25KX6HF><.LX".LWC"X.3KA\%J4FN!XC<^>%J1C32;+8L0(#&X^T4K '6W1-
M]<ZBGS'!>ZZ"6'C;<HAG_VJYQXHH;1U169Q)4J"B_?[V7=7UB.X)VD2,7IY<
M\P#HYHG0S8=T:XJU[8ZQ2X/.#-_D->8/X@0I>XN.>FM;9M#;XU3EYU)[<W""
MHUYI[VNQH;7ZG ($/'8[Z[OJ]P>CQQ^*9% A@?=]$GUWIPS;=//X@/C1@@(+
M+@S^\C0OR&:CV81[FX/7ZR%[7P.\A&;["UP2)6Q.VM+O4V4YZ^:#;@)62T ^
M#:/XJ_7*?6\?>%2PT:ZN2#9N,885RQ4H;-[V"X!^5)]1<&%:,J\$[W2%WM"N
M7?LL/3INLC]SNQ)\E:2;XI# [!,4/5&"9'7Y:9V)+S\\L>@.5-(DUWRA=6'@
M%,"H(2XX:"Y1CT9\$PE*2_)U;WJ:V:KHX/BZM3&(.K<H$F-*ZW #F-PW-KE]
M:/EQYR#Q&A_H9/-5 [.>GI1=R;%7I^?$_!V=6&]J"KWNXU- @KD)'[H7]+Y<
M5XJ]R+(_4#_E\F;BGM!@HP_S]DE>CZ_+ZF'PTN@E;HO2J79?^2+![54&'Z51
MW B>A\6>V3Y#Z[&(]0/K,!V3+AXX0TDUSKU5]+;LF9@&9MB>J'J3["J/Z\:G
MYBL).<8^+4-VPJ-W^BK7VD3#W@6)HV&E.#))FAEJ5"8\>A2^.O)44TKB:/5@
M?5<$+BMUQY[H<>+CRVJ[.Y/O[GUU>AE:,6BNR="CCOO=P'Q6^/7HP6KN>A.N
M%B*L7;7Y!(K.K#-D)OR58W YDHRM%Q&)W?=T2JO\(=9H@*@CA1.3M%(3ZY3C
MN_F)C!'?MGS9=KQ@09  D5/L 78R>5L6^Z5.W(2M$U_FM835MDO8 G>=FM9H
M<J]CJE#UB<+J,O?(=Y,3BJKR*R5/ :-'IP!U0"MF9.Y^@-U"V-MG/7Y%'$M]
M;[#X38W<4JD#Y;R'[ 9WNK -05+,3O*OUN^\>HC#!@*OE@"Q[V8FKT7>VL<1
MPK1Q:OCB\3G@:.[FWBSCH*_T@L1[HJW1Q>D\B,++CB*E*;?JG/UL26Y3"-XC
MLP_[^[U>?>59WK.8?-(5H1Y%8Q]:EF[/-(>6YPAW/IAV[#_YJC;B?1 ?X+$S
M+GKD/:H6B?>UV$+<*J#)A-.QF_=5<V84=<.:V+Z0;DP_[:+DH,2+SP&G@'3\
MZZM/\VF7<.@Y:-J)YFTF1Q9$S7$3C<>76@9UID9%<GCWNU8&WH\%*-:E8<-4
MN^GW<4-W!!O'' 5;3@&QB<49>3S\RM7[O05[@QBF6 #[''Z,]<?J_8&W$*IR
MW2#5Y&+V19IG+NP6@9RN4KYVHM_GCQ8D!0,\AQ)SU72>*XDH9F LT=Y1-.,;
M=?/8K8D[!EK//.*B%*G*56]:SG;9^;XSHZ)IRW4[8Z$R8;N6$G97FL$*XN+R
MZGASD[\PX1B^H@0N-1O_/G;HF+#4&B%G!@Q,%L% 5SA:'N''J++E6.>1>E<4
M9A10\2IKJY^G+@5TFR7X,#L$Y"V28/;E>G0%[%6!R\#8$34.D]+;?/L)BAVQ
M@QRGJ[<3S,U$0GL89$-F!MU. 8$>=17@'+=V-@M$RD%GXWN&+[-R'%+![ER/
MD_SC0US(>9TV7@F2!"5,/;;XC!%#<>C_J7?:I;A$C'=FVSAG9X7OGM01Y4R/
MF?E;X)3UFY&YQT86+:WM$\[9)[M?[FQ# @-,:T?!),4WB]N"T*HQW!GZG*QN
M.BU%>81ZH/,)1\4_2QL=(B%K?6_JN4;7EGL*T#(]WAZ7:,K%^PJX9ZC!Q; ^
MSS&(K9LD+5S@S-"7NQ8Z7MYX^1A.#!M6T6]R4MSC;O6AYSO H)K\9.=23M*J
M7N GM3.:NAC ?"GSJ62._L-&[!L8GW5R%Q4^3IE1&E&AK4A:!NR-C(Y>0CHD
MX34+HN^O7'X59EZV,\$9"^_8$WD$<=P]\?U>;^<M.;[&X%2=P Y;5"#XDDP"
M#JW]7K.P!_6MSVFF<V36!FA=/0IWN)/K_$W]\YUJ9V>FN1O4>R2-5)]2NHF>
M,FP?O)LV'QHI5R1PGXW [C0!!\>CBN[1>JZJ]_3U./?+&N/?VI2Q>9@S1\2*
MWC<F<;VT=/2ACP_O6/U<)76(?!+5Z3,8L8_.)"&[=^]D[*TE@6/[48+:JYUM
M44[Y6^M++$CND-D(B?GLY/'U9-0^-%P3;ZP[WHCD)JL<BJ9"%'7.OWNR$*[T
MI"3(?P&M ?..1[GZ_293A9?,[EPV$XK?B&BOH_LL%$SZ" B.S*]_U8WYR*"W
MORM>W8G>-$49&\_P]<$^3?;!=N.'RD0ID]<B,/U(Q-M J[UJB_5.:I%(@LR6
M%;.V49WX+E6_ ((O<FA+CID,W_VV.[SHI-[2G@+H!K=>YZ:^K-S0SX;1ONKN
M??A$=HN9X>;:*0#W!M"0J*:Y]CDZ'\:BU3>Y#!%:5K7>]/[0HBV-<E)^DQNC
M[X36CMY.WQ04[O_J=>C4=@E+Z4#QK<=RM.ZC* C5,N\(IQ-E\]XG!W9'S18W
M\TPA$?R6WCFM VK7WD6!I57ZP-OV/D(VN]$B28K#S&92&931;;&4JW&/PUX^
M9D%7U [NCR4478^U4Z?WSF$#E(K R+?N33+O--*$DY8$V928 9+\@N0 S#?(
M1XEO#>^&7,[*<TN8?;W;6\PL3(D6_VFGI,QS(NX)(<$]C>+J3D;E-(V[CY7T
M&RV,[V=MM\U=Z2(E.1H,=PPJQ+]]4SW/;S6OBY U8Q@\Z2PVVS72JE#OJ_:5
MR;K#?I<R.5 VP"62;/42;?L,:^?E7MBX.P%(T3KGY+N"$>SDPWT9L>:Z;\NA
MUTD\L-SQ+I=?$;RQHM4ZO -YM/X@?BS@=CS%!(%<G)T&G27Y$O4^/2F:=5.&
MR Z4@]+1S<V?0]X&@K;$0NU8#O7LQI#(^^P6^QDTP5=Q>?E-^0-?W[4BO':,
M8G8TL;W*R7T&%:6N02-7FX.8#].IU$B"R*O]A!X-KZ_V3C"W8>0MB!CWOG^K
M\51,H5@**N-#C+E? ?18N&/B^QW1RKM(,J5G8W\;W7.O\RAVHXD = I8^M#Y
M7*VZ'0X3 "2/. 4J]%M]$H@-D+><U7XJ;(@ILILD2#&QOS<UV'^=60IS<6F9
MZ$WVNEN8$GDR>:*C!BM0?O;$ULYLRVW[1/3[;UW![\V"E&\^HM_%$7>ASOF&
M4K!2(L:<>>D3CE*^R))U?L-P VT:NG2J(K6@]M&,6Q$0GK;$J>.V<HQ[G4)>
M@F0S7A,B3Y2=[Y?EV!N7Z"M2,'1&CIMN";5%JSQY=*0?Y-T9B?NT="9;(?XY
M$E-7YV5J;0@C9U^P:BG]BFR)]CU-<CH%KJN+?5^.0]\8N7 +1_.$&WN-[1HA
MAW #6.<+07P*=OX!MB3Q(@^YA_GF'?S'>-V)3:'D^HH=0VK"NS(++QA-S>9"
M$F)9-_6'"?4N/=*)+IY-47:EW26%UM1?+35&%'Z+L7D<0:J<E!;Z"/[4X+NV
M&,S3G_Q5T5>$#,8Z\ROC,H<G>TG:8S'(#!EC-BEMY0&32S27L<5MYEYTQ?X(
M4LQVUO!#Z87=0>'JPH],J9Q\2F%A9?[1>$]H 0,]R+3)M-&L-YRIQ6_<8$9^
M*2GY)D^=ZO-FKF7,#EM59F$-JR(0;.8V0WQ98QVX#KH<^6C2H]DJ[@\(0QZO
MTN$(-4B-!NBWXBH/9K-:,K-B*T8[Y%05D" $*K+=NIYX*2,?R)<I(:;N.N?B
MCV?Q5CD0Y5>\QB,S>C3\59GMA"(M)8P)Z.#0@DW4WZ-?N-D3\_YC0MMA/-A=
M]SLMCA/=<^\L8TZA3?R"M#%$"<6G:],^0DKOZ&0TG4MIK[0GW2W@F"VDH(-A
M,RK@:-5'PU0I)![F?7]4Q)9NGV8#XZ&!1V2:1%+BE\G&UJ33&JC[=YEJRMQW
M38747QEX$)2M\<U'*DW(G("U0(_+G["P(OUNJ9,CYDH022J.BHJO[V!J;4NO
MLN:',."L^J+7X#V)&SWNB8B>1$P=,#8#-^1220LSY:V(4O9W&4GJ6.8><;"O
MW'G-#-+Q$@^_K$I+9R3;]"5"$JG7EDI&J6MDHM["AL9[IET>&YOB*8TC_?M*
M9P[LGNH)/?;^^D2Z-[+6J_.@N8NFKBUQ1HD\DPE/H>V-IL)(@M@H&I-%"]G2
M4E[F5E-F<B)[*D\Z>8@[3'CHVA8/_VA=_>[Z<&UL*0Y0:O1VQ]OX%])B->T0
M%RMOJ.+V3@[8BG@7%G"##8=R_:3IS7K(K6PFZ2 ]ZF#N7F!\8OFD=(6T0#)9
M%/I)YZ3=@*MA:3WW4<OZ\L&=)E 69$<0:W7_S4U6LHI)"T7.*O'(U=!P^(3U
MV_%ZR!U3T>62P;6VI-#N2:PHA0I?H@!^H&I+FWN?&OWH"IY4\!"!+(Y9J="T
ML);(89Q'D\?!\8Z8H;+V/23:@$:Q]%:NF)P.B:6XZM';M<>WMZ28'HG8Z:SE
M'#<-92\-N9X"FES&\7ONK*U@![L\.?@>-C?5F<2G=75*;7]7Y' YGIRS:(38
M"ZM@'!\\OA7B&>3GV;+6IY_'DA.@*R[8>W"$%YI'N3&0.>;UX2JMX<NU@(U*
MVBRE)4CTUFCN6GA4EA(% _/H'<N#PU/ ==?6NW'T8X8'7X'NUQ15"1-]L5#O
ME8BU'<)MQ2*]KSAQ4@6R@3?34]+&'40=W92UHZCHV$7O+]&JW;(NYU4/J=-/
M@<#>5@$&W2V<G)];X!C%0GR!]VWY*0]7;W7.+>0&.3N:O:<J&Z64;U!AN5R_
M,U]_3<7,Z!/;%N'8E+"L8S,^2RF,54%OX'+FWMU-XZI/N5)<>I'1=V:J!FK7
MC)*^/->XE:4K5MM_?Z&YSA3;J092J P#7V,+O*)[7-6,(1A5B(Y-._& >1L[
M!'8/SX'2_,O\PA"CM-7L(I\;4S[%:RA9ST=GR/2$/0GI.+&9;P%6.EGQE44J
MCS?&Q\J(BN+^HN0%KU/ )GG;/5_/H6S^_153)PW7VHG B!QJ>$&-ZHQW]-(*
M,H6!7]']BCYK47ZZ,2 [<U?KXZ@N[E UL"#L%9JC#ELJ.FE*P6*5!W6,>5@H
M%(_-X,O* K]E!E/PVZ3(,O<.$2%/:%4'S'DHT^%ZT5SCX4?.+.M5Q%:J@C%G
MY^U>67?C&Q&A)Y!Z/>,=V#=Y?WZ_M Y^;?,"+P+]VKDH[RCHL$JJ_!!=Q8$G
M#^)%,976+<RK'CE97JRFG;8#9 6M ^Z$V(;:2<32D(>LPB%)<E1J1 $GO<YP
M+09)B3>/FI]_L%S*U%4@TQ*^7#7(5=^6F)8B$HE\\Z5>NV"^<*3'/36T*]_[
M]N:C*C&/Z3'OO(V5GMG:L?SR&*/YEX.L)8$Y8XJDUV1WOM2GOOR 1:]N]0"<
M_3P>1[_3"[@D ]!RJ\RI2GJ +'@""4DE IP"GH]TXK]X?-396O)"]7E)*JY)
MFKYF/F.D$8P50DQ:4 R>3BQOOB_NG%2>U(#68S#NQD;6G5="4AB]7,>I_]K8
M47H3$G4<N-=NVO!)D8+YIH/'@>/3H6.WT(Y4\-UW=81<*][CTMVJ,TC/J<FE
M=0U5X1H.*738$+Y'"17>>K%'\+'0719FI0;*J]R\"SU=_9:P"K*!3<3.<O&*
MZW1T#,!_*F.MV.UDZJ;#0.C2R]!]2>%6_"_B3H?Q=WRZ"E6UJ!+>Y@2&'GW?
M;"96[PIXV+.TM(\#<@8=]2V#_.=PWG:@!]XDOHWG=PK8@AS?X;R6-@KP@+RF
MZ8=*31(D.O$E#BX%6F/Q:QLIM9XT]5&\IG0Z]-L(IUQ?**_=JL_,>5(P3:\0
M=)!Q@&JZ8UI@M,+ !).0P ;)_'%_@JM:(M$'U_ID,=2+84(W$TN"F=6DFDX!
MSD4#+MVH7L^@FY9;F"HTUSJQ5CVG=G"5.$L=]?8Z;R2<:T*L!*&Q5J+_9./R
M$H<HO^VNETGL%:+[Q\_BYPDEQ1+NZ*=%O"\&PT;XD4Z"0X=6? U,9-CW5)%\
MM9$Z@Y.NA?P8%8:[$Z&Y.J5]"PW4T+I771FTTK0>T<\NX6Q-'*TNW!*UZ-!-
M'U T'!]:FCBDS9^2;GP)MA5@>,T=SN3UTJ-I/43^1K/4RF##4/;)JZ.$-Y$^
MY%L#<WMU:R_'\7I!2?C5A&!$_39-X*I1Z1/%@ T8)(>_9=#$F^KHJ*(.Z_;5
MZ 0>;PFM(:\;$&(\M:\DE0(#S8$O9ES3=-%Z+]>Z>HDF'Z]XS>!B9^R\.E@.
M?.ABW^X;AEXH]R'VH;$SO166Q$.3JYEE5$D!6SXG?HX3>S.7?"JHCE]C'(QB
M*WMA(>I5 9XYX<]OFV"RW']RV2QZ5 U (43I(ZGIV>4?D>(9S3VRZ-^;_;(B
M7PZ'PG,>-(YV:Z$VR]*(6>C9$*SE"S:&="/J==VE8<AU(*RC>-08K;JC-T/W
M<;(KVE*U>CJ]W]8'LS?&V;/N?DW\)#GJH@5[?4[BWRR5@&C%:M8>!5+[+^\;
MXMJY^D>IIXL$'MX;)\ ?)A61%J%V3 P2G *>W/K@]#%G(M4P&5$;J3'Q;D]"
MC54L*O[YO>6"[>IVU9F/62'Z/BVBUEKK2027!\T_,[ ,,(_GBI\H!D _B]ZU
M5]]'YQ<8VZ,^L'S=\ A#1J/\9++ >EQ-*"K/J_9]8[&F[U2!4C/X7KO&43#3
MDC8P>6!,?N/AW AW"/<$7'&+@M*G92JL6T(K;_FMH\NL2SCERD+\Z.#]ID"W
M4'EY6#]1Q2@D./8P>'RU!:FQ3;,5F+C5#/OPZ!30[']R<@NJ*SAL[IR<HTXP
MU_3=WC7GX_QE*8UME\59!OQ4$U6:O(-W$75#?O?PKL8@F?W1LI?+7S5%)8R:
M'7[)F;B+[CLI-6H<&(K#?#+H"R7E&E![OEUW_;KS@U3:5!M"M$\P(>'. FO@
MRIUTHI2KW_/4JFF>WT[@-$3:@$/0?6A8@8<()QR)NM9*+4,,@NQIHFT'WJ)Y
M0 #_5-C7=L12^=B8>@;B-2^O!SJ#F8XE8FKD@_8G/=^#%/Y!R@#>[.PE"-%4
M(*4Q VR+83W]#3'DP4VI>T&*XI[OL+I#KYIDE44U@T,;*/8P5/<[\Y;7V^$0
MLS&_^,B KD;*@IP"9TG^=XOS[1T)VPD*>54^K%.2W-U7#T/')9UX\Z=[?&F?
M#N+C%]DDWAXO&4^+F#-7O>U<--VK*^ZNBR-BW9C[](XS7G'BB,A1P&J8-B$'
M42\HQ.+UZ'@/M$2?%"DHD<FPPR*2.ZKQMENIG] _ZNC8-5.J$LJ0*'*_;BF<
MPT 96Q@<'!HBW3>E.K>ZVJ9B<0I --XWZN(0B!-6P*NR(1WW6'HU?YF[=[]M
M7B4.,IU8])'!!.\40"C4>_15(ENF%FU +NZRN<L@+M>M"GIZKP5ZIZ+VONQH
M5='@0CQ,"SSGATT!50*'#MQ/KV07TV^ <T77BK<1'Q08^^Y<V?GL5+ 8O1VZ
M_**D/)L@76J08;&;68W@:#6O]_GMJRK4[>JUP4UFV4_7B3'O=7.+M Q^P CH
M6J$S8K<)\6_FZR0I]UZ_?YBP(]QVB;P_]''BR\X7':< -1"1"FB6H#UJ:>@J
MP-Q8O;:E],G2]T,' O7)C(/*B:756IY;ERA=UKY C)=KZRVUZ3<'<#('3=IT
M"A\N)-A6\^!H]96N7-UEP)*<<B;EX5\47NV^)M9NA4D$)7FCXRH6NU9W/"*T
MQ\[:C&;D=\5.=34.UC\G*1L[)\;L*@AX.]6JP3&7DI 33](?%Q:"59^X-39X
MDT7>O*2XT!<2Z^!1)'[LT[]D8H^%KP-6*P\H$B]898#5;NT$J;8$"R+MU*40
M!28YG9(*_O[#\4=_^5.9'_T7X5<KXP'GK^93 MF"VNTO[O<V//G\]/I.?B9_
MV?451X+'TS,<+QC9M5J:@7,QP[%E14EE.6S=93%V'Y6K>XJ-="QUJJ]H%%W7
M>LE:MNQ FOW:*C\RYLX$I1<[ZRY.@HGKG;;AY+?&*AWR0=7<>A'P3]&\UY#M
M8=&:QBES@GP8S)=P<U2+BRHIGVD@9QFE.)2=NI?CB5=?"H*>.)?>)TL9;%(S
M56LG4M&!I0#?OWSCPJ\_EHG)&#'2:J*CGD^@HUN+CMS*EI:12%C+<<$K_P)W
M["YQR,?,@@\N&)FBC::%\U2''BM[<5[)9$>[1(=PZBBMXCXDFNNOW%;X$8E(
M#_2/>@NVHVL%(A$F9:WX?'/W[95-X7N%_-M=1A">0J%6S>CK[+VQ-4RR,*-Q
MY2OA8\ZDIP"J:3&-<.VA.D6M&ZK&#OECGGI\8P/50J*=U!M/V%\C<]]..F_2
M\$&L.MA;[^>GIR15UU;H(A\7W U!&^NZ?0T_NHN$W9.YY$II6^D*W+3AJXH\
M?_H<FTR.2K<.]G7%^# 57PUYX_=@$(,HO8P#CAI/ME'R#6ISVS*$J/7'LOOD
M9A^#LN*OM&=^G2CRRHKQW'>\H?*X8LZ!#<>3_"H66]:ZART'LT()9\B3YQ%1
M]++OV*':NJD:89F:4$8F4D]A@AA1T43_X023!VHU;%N&SO/%K?!1_:A)75_5
M1E-+;+@]&Z*#I\B 8H&OAHZ8N)J<=,L$Y^&'E>2/@6Q3-K?&JY^PUO'L>>?K
M 1LZ6'FN1XQ.ENGIJ$=0*Q%^,*9#IO6TQA3,XL<4Q3GQZ&H^Y,=Y8VM"! 54
MZ>IB2]#QNH*M>6^%WRQ=OCW'WAL4>X7=BJ]3W9VO92JA_#9/=4JM-.AUU%"@
M!9/JP?H@=>@)=2M#S@XDA),@/83)PG<N_ON0;+2?$C L7#3N<EEE42004931
M,IA@,9-I^0Q#-T%<(S\C1S#;CM5 L+Y_TGM*]HT3_79L^ VC[POS^R*K'X+0
M(#D1/NM/;VX.TDL!8=R]6S9]6GMN. N'Q[V#-9OXR!DVH2F(WQ>O3N^3OF)R
M*@"$:LK<M'L5,3KF.HRN"QR#'*\?NK=>D2C(ID;B )?7/UR>%Z\14R6A;U=O
M*UY>#0_B9Q[*G:-YSR"Z7KRTVTSI&D94GZ"R&F#W70$]LS^7'D9[QRW<W@WB
MX#'%7-ME[A)P"T'9F591)\[$CVJ1VFS14H(\7Q5UN3EQU&YXXQ1*I"6G)&9[
M2TYFC--DN;0_0;?Q(BJ_1[)^AX.;,DPN_F'I<M]^FU"9?_N5N)VUB<_JN5-W
MC*]]/-X_D#J<O=Z6%@)ZO\KT_8F(Y>O,4C,>5XVBHVL@R6<';L2))5$#TPA)
MMTB<3) 7H2H%K7]$_0MAX1[11]D&8@Z8+UOO B+9KI 'R;$0Z23-;=&:JSC5
MAH6SRCLH2P&3!*G7[6]+MXGRRZS=(7EDE9DV8*E1GY:DBZ:OJ9N'&P4,@MQK
MKF4N+G8OM*P=9],2Q(%IC1SY[[SL[KIYG=/0_5X;/\UU 3"OIQEO1D3K5S^;
M++@:'V+02":T*DO;1-5[II))'%ZMZ&>3V:]%+T)?/<M8CM5QK>:[X9K&S4<:
M!--*3V:&$-^6J![/#$](%"7"TC]_3NV@[G[PQKGPIIN<CI8$NW;0&"T.L'K)
M3K&UU/[]I"XIJWOBI^>#I5JQ98;V:CU*.O(J&MY7H*I*>B:+<>]OE!0%&%5G
M>-C7D?2S[:@H93PH=M'*OG(CL:"U&.8M;\;KL9R:\?3YH(9<QH(,TH*N.)68
MYV5,O2L!:,5L+EN:GUH]/_*C#JGL\>4P-_FAYPYLXUIN5C&-SQO+*A@7WZSK
M#M7O^5!A<@G%,4WZ%3+RQ2);>5X;7N'D*XB-"B+)22D0<,]0UB26TL($ITLM
M%$/+=F*<9))[[@[4$-U-?11<HUX<Q:%'?+1WY-3FH">M6CU4&T[$CQN<]@:O
M2]-@_5HJXR)%6=<U>U:^B4N5UC,J3Y\I'=;S:[,B5DM">]RS*H8?A)/&,=<7
MX8_H/!DQ]7]2E*0;5E_((5)=V.6H-PE7MVV;42<;D>I%]GNI@/2P];5)O!9
M&.$J*=3=P;@JPQ+ZIH@"SF=D3XV258J$F72[/T>J.SX0>=A($XZ;G)6L#BOA
M) E&2W]0/7-IAGJ-/;RPH?T%IF:6UT!#>^A35SB8;YBGAYW(<)?X6]2#4GAV
M_.#3PP3=ZIZMVI""M E$6O(QVTY(")7RI0ZVMY4,;*8J ;/Z#[3S $J]F0*0
M@[JOXR.DD7/:CL_ >BNC=K/N"+U]6WXGK8F"YPXZFIOI\Y&7$@2BARE(]]L<
MB\=W3@%3Y/>=Z!"KMUG;VQZ[EM/O VYM4N)^77L>>G)_UU2*GX__"M^ZSQ6U
M.I,ZT6+9QP.E/;6DQ/JL27O4.H;O8;[(0UD5J;<IA0N"-O5AK!2M=[7 (7DI
M+.AH'IS7C0K*;VR?W!.97'1Z1D/=4_,&-]%IE#KVK36+B@.I3TZDA#*2[(LO
MCR1Q60U[?@:GLA50,7WS>AWM^]N"XXW#WF2UF84OV6[I^=#&F,WK&PR(2K>'
MKLOZRZ_44"IJZ<Z::CY:9QWA'=0JK!T:,.PKF=E)74L*2WD9XT5.G)<VDEH#
ML+,7X$4?4THQN>&LKD?2S45R0E*N+JMO4BISZ?$-#\B+C2OZE*[YU8QWV#7"
MF4L+\PCU(T5TD=K*4F(!CSX$3KKV?G1=7$'H5XNIQ F]61-5/C2%=U2MZ'?(
M4 94D85HDXTI([5GX>S2!B2F4KN4/?H0*=UP1HMP'!@N#!PEV+0(D8N%"^B+
M@/B;F3548P-J.L<"_;UC-.X.&<8]=?H^Z[_7@:_6\,'WB\ A(K0M[";VT+%$
M_>YN_^%J:R:E5/#^F_[N!:IP%C",8>G(HH]OKO\P<;>O]DY: S5%Y*?=K9?N
MW'>T.(Z.CK))-;2NCE(>:^Q/F=B9VPAD\O) 5M"&_!PPBRWMZ52#U).716E>
MC$]IA>@NP9:7*6\GQAWM=STMOT7,=)# :;=4%#):^PU72H3 FR+@ 9Z3?5=!
M4\)1Y!3#L:*_2VCKMTAZKIIU"=G2 =?$/9=](:/V#G!<-W.E^(N]0VO5.Q!-
M$*0EH9+R2/VDP!%]/+'XC>SH4J2W R"XO.':AD?N<IU;3GQD5(_ZK)P#7X(8
M)F]3?6+QJR\W_6;>-?C2LG45\77WCL5WJ9T"U D3N&D#/5:?BD'0@>]JHB5?
M+X>C*_=^.MJE_38UJF%&N#SZ9HG6#C.HI@\)^@1V6@6-Q9(57QE2&F1F'A6&
M?.:;NK:SMD)\N#W Q$74YW)D?:,UMH)!(()O$IRYX%&L;JC]MIA8JO?00>(D
M\MKFX5Q0D!?@<+5B04!TN[J7L  -<<U6\$.29Z9 ]9CKU[<U+-,E>)=-/8I
M;L?'/+>LDC#;)UX/KJ=/6/*'(1_>I@ I92:ONQ21^:Y2KE9,;3</6BF.4MF9
MT<.8W<JW1;8A:+7]S-)A1L0 1C9T^C:-)0OY79*P4T!4*21 '28$1GS N]PW
MBA']HM%N/'<J99:X5#(-&$V9,:9X@RJ9QZ*3^N&0- .SUOK 90NT_A#/0=J
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MKC)R50Y)%EYL?0 #+P+5.E\6OFRN-WK%X<VI\%"2@H1XFY-G4_:^;L8\X][
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M0$(ZW:%)1&>LRX$LG_Z44M$!'G[,I=V;%"\&/<;0KT3RX2/'+1TG)JX&80V
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M,.!Q*_0.3\&K!.[A[D>V88;Z5U;#X)]. ]A)8LYXV:05?-=.>-K2@+'?"V4
M8"PTA66[,&-;!O"4'S16-44!9IRL^FRP2S*)0F50V-H11Z;3* SG;ELP3_TW
M=\M_ $I:VZ$]9?E'<*U6Y,JWK0\0,=",(RWAF(^G>>D":Y1%^3TWC/KDD6>B
MRD#I G2J>Z136K6JGOG20.9D*YA%RF(3+CY"J/%[IJ2!?7RNY;#F<.4F6W@/
MU@O.54K+!)%HG-"E0I<<<1XXYNU\-:_EEY]1T15CV_$0TTA_(<(-S;#)$8 F
MSCV*T^S/BZGF."N+2LV;?V_LMF&O[&RQJ#9@QX)D0N1L!I3!)(CBU!O39(G?
M*XBRQ@]F[[H]JIQJ+)QJX]&QP@MJ[VL*3AAO?/":M@R$:UGXC=3&!U+;/[R(
MVCR$S",BMI1F=5LKTDF<* +[16)/B8@ DXK$6*\F?*[?8'CY_]R\-EAF'HK=
MB/MB:5!Z2Q[#Z.B^U\#4K"S0-F>MOZM=V01C<N542)U@O"?3]NUK;FBO]9XO
M GU^K0$S R$/*_5IHCAV( Q0[_"88=5<\K L.NL@1O!%P2T5YD=ZCF!XB8U
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M_[Y$HVW]FK"&M+G7(CB.&MPP')?E9(RO9Y)JQ\TB*?+KBJJ^CC0GONX$B<<
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M]G#%6>\6@DJY+2;DB+E'>WCZA+.'$[+$P*ADEJ8,A0=Q0H0K>5:"U VIS%!
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M#.KZZX%2-X2H;7E^'2E/LOKES]HD^>NI3O[,PX*Q^[JNEV]?!'^_RD0:2BP
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M-XY:!1;N>L<H651AJ(/O^S#/8NX7='XW_P#MO2*\<$JN2#E(NF.M5Q/GJBU
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MC>E09[8-/[P.=P&3*A?K;6,64AX$-;SS@N:/O-V$5MDAHE:R;VD\X[5\=*?
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M;CY0='Z;]:2.V471$&4Z]C5-2&A;$W!NWW6+_+;$NZU="%:NL=-/2.%9NU)
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M&Z_S>8S/'WC0[:\1W)?_Z0SAIOH1NU6X\^8FT;S]:\L2[W";N^2#<L1'H.1
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MZ2)=F1.A#=0@Y#H2/KFT?W+)G)DS5HANGS-62GN]BFX%1"M% [ "_$ 0$0@
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M4"=&<2Y%J-+G-@L5"F3V9$"='4MB7'=:4I!IUU!1\2IW*2NIT5%.X!F0X-%
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M9)).NA/3734"!<Z03@UR6Y4I/X?%7EEC*GGUJ/1\I'FOOK&0?FV _B6 A
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M-H\R.HY]1!G#?5T1FUN.1<N/N=*0D_\ ICI".EL 9&=,J(ZU9Z4D#.5;<40
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M'$,-DI[]]"8[]]Q24LI@.N(!::5W3%.Q1-*:9;RY!*K09&BEG63<!,$G^T
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MSG9 F.E2T*!3QW9Q?P/$>T7 C"6Z3B'^JT*= F@XYWE4I"!$)0SQ)/$&TY3
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M.)[,+C3(!PUAY.93T*PTY[&21:21_4=)F9,;5DL>E7D[SQ,!I)PVA!3J=[(
M>"?LG3:L\2!&".PE.# 9*H%%"D2E_P-DA^AR",3F:5@% "P-+<"F.5%E9<74
M5<*7>Y4&+AJO"2=HLD3]WDCI%N4JX^L^E\B&FF2KX=$ !77?2_18AMN1,'+5
M21H/(AN,X )5'5FAC[5D],N:FU<I0<E&?]]/>S=%D^BL(O@F3NDWG-E6A:0<
M&81E^$8>A\-7B'H?5OR-CR/]#@,)V(4K\<^FNFXU+ " #\T&*F;;'Y/G/$K
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MWSBY#^ZFS!\R@O)TVAFW,9[2\1G/>'9DDYUTCI2LF-,+>A47"KXD]UBYHO4
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MIJ]M#<JW?*5_MK0+P +DMJ?QBL+TM ]2YK'Q9$[;9SU?<<%F373,K]$?$.$
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MHIS9:AW:(T\9.6/L2Z!2,;M-F&IPJ!#:*4"@ MP/D([OJN%SH O--J[1>$W
M2TI7(JL=V5/9@NY_7:*G,.-'8$(ML3O-^OIRGO7FSUR LOPE'?"VY=OC'F03
M$))H]J[[MI[#P,]>0&^<&$HK5[BI<#Y)_ ZVF,*E2!.<H8<H@+N&G W%]!G.
M<&Z"T=A-3^V<")!M3I])('^Y"HV^T;&8ABVWX8+7+?-;/#4''6C6/#OC@E9B
MI@AY?#-N>;.\&>B@K4K+-3AT9">L@%I<ZQ*#6'RHH4W6B&6S1)U\5W--PML=
MZDT$2/^XW!,Z\)1=Q8MP)CH!9^CI]'B(B0JVYJ;JNEF=JP';0%G@A.9H/QDQ
MPKF2%Z\_<XD,0R,"8)O/$_RTGBI13OT#;,KY\!,Z2QD4W?BF)S._C&?;6U,Z
MZ]N '#,M[DE$^*"IU5)!)[4"3SU+RO]S-N,3XD5<]+O]L2NMV+\L$!FO.7)$
MB2#_*T3"2S?@3GK'1Y:"\,4=P)8',FI+0!Q HJ27D]S^:H1A2.,@2[MEQTV.
M&=&:$XU/__JQBPGLJ>DXBS-PI:,4]7*_N*TN9YN%A/ XM^K#KOZFB2HF1^"I
M96(3O)A4D%?#F0&J1M*HC6.@?M]2WLP#M8@#0]4WIJ+2WN;P(0;Q(3]O>RL6
M"LG:B=9I]F9!ZG?^W1.,CP0_NZ0S6F=)T8X6B2*G-W*:736HK;9S2/41%?OV
M0NA-=2%*_ ))A:;U/G5407'9 W>)V2=A1#,1_"J*1$M5YB3?W-HC!&.VV2/Z
MS33)/QD@8AD@@DJ(-D/"/;*,\/Q*(@Q0F5=&>A)ZL.TIV!.LO_;RDYEI9PMF
M;<YES_76R-\(OJE@F.EE+9:A5?!6Q^Y;QU/R> [ G;GH/.RYZJ?O"0JH*%%U
MO44#1;2IM6K:VH(SC0[X0.,E1D^[@"LK'S'Q6<!3PKA2*^7+,R_=9X_B1YL(
MLX_H@?E?6R^?BDV.2X6GI2>I6U7'&&Y9]3$1$!ND]-JE^?9Q&Z?OMKI\51OJ
MW-X?EPTJ; N&9U;O!C!@7V AN G&(7'SZJQ*6RF\,5+&7L#U;F9R*S9VUIBK
M@$8LK&-=)=@[/?2+)<%45%*%]+4%2 U^H6/_LMHWJ_!3@5?MS=%!*_+MH?BH
M*59@CK5<!625JD)+;.3C0 <;=JA#0 P[->\ZKRC@KWA[@X8YZ5P3GW)7TV46
M;F-E)O'X]L_7\1;B\_:;3ZX+GH'BAPB,ZVO< CWXS*6S\2G7';ZPYB;J1CO:
M\2>?RQ!SV(&7_Z,:Y'!DG78BC)GMC<8_0/ P6P$91-"8#I@>)M?[>.G^"^-B
M](/MLDQD8=M1[?S>Y?P.D=?0*Z? (7526H7+9-X@/\PR18(J78%(J9CH;O>G
MV>M"QD\.0-V%/:4B97A IPHI$9PK*),9YMQ^@UV!@ J(-FZ"O1C>OPYCG?JO
M:EHQ)U&#O)*'?>K@#1DA#768F*T)WMNN[HOM2<^5++JRP%4'[2Q^W\CYC# L
M1Z$<E<WCWW=WN_%IRT_S]#YLCX;DV?^*&]ADW#-0O..6@Z%S@T(CHZ<$N5]4
MX^# WZ]^S,?/#B'>0T \W%F3N=I!:J<#MP$K$0U]LL3=>:]=T9Y2AV^GJ/XD
MSJ>S),-+L#4Q37R(>%IM?#W.9PK:-OW'L6B'U(\Z>,,  JNWD_.'Q/;O=44'
M?.)ED_+H@.&$1V@4>&#F)Y=QB'#0KHBF-9^.!ONGH3/V/ >]RD6[&SCR4Y1P
M?"1;T!'[4F@L VTV/E[W[?T_0&A;>E]R;"X?\67<E2?558RN5P1J<YF/.^8Q
MD<G#W;H)=]+WVO.W,6S$1B5+6R!<T12R[;[[]EU3JL+__<? -##X#Q#;(1W7
M;9UHX66?\(V].'>N7>Q%;0.;>,9 0U&TL)K_:W RK>];/6TD]Y@565*0'[B_
M0OJ![V[@+31K#TG<WQDCF&/F%<OJ!AH3,42[,(LNB=RX&.F&J\[0L\(A7B3Z
M.\'B(TN_M^G=NYJ)\_B-))_QX[,Y>F6K1.0 '_"NC(:79=#+MJZ@/]I[<^2?
M9U_R7.I5::?KM;F55?+'L]WH5KF#Y%^N_3)8*!+2&<P]H'T%^PCGN1XJEXR?
MZ!)&@<6XFB_E-$TT1AA<2DZJ5/0'\A6::Z#^""P74I#Y30-8E5Y<A$!GCS@J
MPRC'YB.N(X5GI(V*(B2%SGA($+S&,T)F]0*Q;Q>3I5UOO *&)ORR_Q.[\"><
M34TFV&G$,95NY%F/ZR_O%HL_3:I_OCC/EL]XV++G'V[J10HZ:A3NY16!&]L;
M++V=%#[_)HI(0TS?*EK*S^97TLR4#P2*;CC3]$6RB:*%JA[EP"U_A-1H):JA
MX5 VWH56YVE+"I4R_0I][IE=^E$X><Q:+VHHE4'.KC F5]4'142N^+]]7TS;
M@[]4J*_>H*U"_M9,U'[7_SWJ<44G4)G\3#O5Q T9(NL89R(EL,QL]$1 V\ET
M2P Y7N0ZU4.S9+8R2Z_3HSSS]R/;JN^X>W/25'-L,C037!1G5U7>R@3;YRHC
MLGRK $HS;H;]*8O4;T'4J%2]_;B:1YO?_9RL6A5!O'E,K1KQ>/-\2**J71.^
M,"?&G2+'-O>UK G4+G0N<S/#G#L'M4JX\5Q/8Z$=D";U*95/%7!Q0TH_Q-&V
M^+LWQI<9F-0V?HKU/!Y88F*I<6Z;"M$>/U'XE5]I.+N6:T$[_O(]BT7&OJNR
MTE;&ZA$M"QS[(GQ,M;C\J?Y$H2<M/:FY]@,5HK*MP7,!0B:!@,JQAXJNBFJA
MY;1D"ZJ&^4\F,[RFTPJ(B#I#6/X&*B>$LAY:>,\8)D!?KBX=K\28NQ'EB]7M
M29ADJ0F89W'2IHE^\WI,5JA=D?/0((_4 O':4IU$Q*[WE'%+2018HS=J"![/
MM_$$<PQ"AE%ZTQ07Z\L[!J_#%A(MW G=X&R2&)\DOBP[I<4WN$@Y?#[WPH!)
M24WCAU&1E5@]APMLF J.+WDX7$2W'[LO#OCM%L+W0: Z8P4<E_KHCI,NM$.W
M.R"^9CG'?!@RORT#NG9@2549*LXB:>V^M\L\[;'BR.VEJ^:PKMN'=^!(;'9L
M#;\4B")QH>%VL/GM!>-Y-3S6^ ;LA=S] ;]49WS/TOW-.1\)_8RA2J^<ZU'F
M7N@_P.E ?Q;S?8],D2V2&JV1:R,,Z2?%(S/5 Q-8'23M5TR*^ ^3L((S',Q%
MW4,MEC=G5^OAG#C<SEL%)PHQ;BE:,)^J)F[>R6H=MS\8;T 8]/#^3O$@)F\T
M8MM+>ND':Q<\9JW?!RE:>W_7=7=\/D([MJFH\>,4$V9)%X,@J%2\OY[L#A!1
MW9NG:.Y=5BKT/3M?CMEF[;'%G6.(_?$6 P\5S62,Y@I'=L)F]Z]<<=8RVG=*
M_]^HC2?00'@T]5%%&K<9G:2"I\SF-_\:CNQPUD#I-3!RQU0&[X#Z9J]@+7=P
MF0" ,W=->+K/8[%W=TD_5ZN"M4A'F:_)BRJ5K%L/6IVA$]D11_M?;9]I V:S
M-#K.=D+OJ]29&B$C[K^47OEQN"4%;<NL%IPMJ'=U\9WM_\>?$71MA+B*HOE=
M5U:&#I<\R'!DV"I&!4=(UU.;N[NWLG%RIE1V%9(GS:62DVD?R#+!-&VQ$.RZ
M*IJG=XQ?JN!-O'E?=E"(W]32[;0<9G"SBGR+(_XSP6XZTLS_GA@^TG!Q4'<Z
M0D3/X@C*.ZK@:"=0!2N(K/2/F"*5.7S>*UFE_O:TE\#:]G0I98WIZA+E.KDS
M0W0.-8N3@T*6_/O#20" YRQGIXEY.(1'<O!*P1/6[:I*IW\ X13(WWBK1D]:
M+K[TCY=%<YEHLA _[A<C'#C51_W,$6ORKDU]TN+YQQW4F<Y+BPW>"5/\M'QM
M%;)O_@'.6!?6KMF./S"9ZPN8(CU%PS5B#W4INTYTRX[GO'M.D^9( ->0G"VJ
M6=MI-97$& 9*/&+F=2!\^<Y;N>_:L[<!.[6\(;6,I'_D6G'2O@M;GKW2YC9^
M!-P <GCEKU_?I/X&L_*]./L'4 HU,RR5;$@>1J7U3(5F7^#('I+V$1;HBB:'
MZ>C=>!:%A74S0L0@K,VG,\L*OOWE?7NZ91DJR]87..N0F_6HA[3<MCTSUWT+
MGE%CF=>%-LB!_,( )^^$ENI*SHM1#*'__"XJ#.4S6.D;6O]\QN[Z"A8U\ V4
ML4=/NH=AIDD*.4T]9REHHEUDC3CY[Z1Q$ZO*R^YAS8/W;7EJ">@9\=KY816.
M#Y_8[KH[C2V0 S^$Y=NS\T*OB:[9I));ZW>>8PO9:!<:*OBT:7Z+7\K=V#EA
MXOZD@R@D9CQ&M:]&NFD4/Q*U8SQI17LPRP?7GAN.V=RS_[ELQ19Z5\-\<HZ6
M;ZQ^*GB0/-QQ<R?>C=N.-F-(IN)V1U\LPT5@U[X$'WLPM/QB0>#9=4#A-;F[
MWS7[0'?>8%DT203FZ ,[O?I&I)V>Z'4!4M;*@]^I9()U6[9W,I9;IZ'(C?7N
M;U7)1V7B7>8]>'U<YXBV3G:%J^L-;+K(_'0X=_.4M..=_.G2A-EIF?G<PX?Y
M"*F&K.9L$Y.3DWVCX%4JHSJH?(Z +BA:((N_B$=FJRU"HJMDQ>0];>[P_E_Q
M[4+_6.KR0D=A U 4I,$WG$?S,?-' 4%+:2-'U QEVJ-?=1]*!B>W'ER]<6!%
M$3,>]&"/<,QO,2G9SVPM;56N0\Z'N$@9:(*S@>J_50HSO2*5#W8D%</?*DW%
MG<N77>V%AM62T]>8G/P#D #P=HN,]C,7C_*WFQ)2JW/D47:O3W91M4 H7GQG
MFO()Q@8)B@PIGN,>]R@CESF:Z"1'E"4WDLRS.E=GV=T<4P,_6SZD;#J_$\(R
M*(^#"@*ILF?L5#+1"A++:3/E;6GX5%K<+!V^9$J7//50])PUMZ<FC4SU"+_B
MNQZM OFRDZ$M&M(,^;'NTF<.!K,N\.ZGX[\_<@1J&0#S+XD)@%3:ZPU8/CZF
M*08S;;Y)JB>G2A41C#D:/BP'*$Q([U4VHPMJR$4MZA::8#^,=^4$#.P: &S8
M?;DE3.+GY(^<U; Y^>HLJYEL0T_A_=N4%<,FKXE8@_K?#*GV\(L%TG#A!J_G
M?9)83"JA-=IOY#U!]&4-3 AG1-(9CP# 7D#5EU@9L9&L&U =DS%.]O$J*>MI
M (U#9:8/OO9O!Q;(,371!V87;5*6H6*2;<*U !ZCW[F/M2;/97;W,PSQK2N@
MPTEH:6VS*WY=S6]9'?7&]1'*Y0LCJYQ1B:3?!1:S%_?>QC'C)=*R0#)IVF8+
MWJLC/7CA9<-?!@;4R;+&EPQ_+0E<]1IIQ\SAEQBCU^1QCL:?0=R*3L/]]IN<
MPBUO)\B5R\HJA<?L]<T<>Q,&XN4?NPCFK^6__-C$*FAM&AI3]9(4;Z&%D:(B
MD0A&;=SJ_W"RG-39X=-*\Z"42SX8F@\A!Z:.SHWGM^=X_@-XI9)0OW-B==RV
M32"6U_XEF8C+(_^BT_2[P\3X)\,#FI\\CYXF-#W9.KCV@U:D1;<PR[]^I^-?
M&LF&+9TIY\J?A<VA&%+U5^[RV J0+JG1:9O6#C7O''W&M%MTQPU=&&(FM@P1
MU4G2:WBZP#;C& WI\?Z32%].$A5Q0:D,O_0V?,"&Q-?.X2V+6A;:WF9NX\(B
M\VAHLHZH??>MA0([XBL\2MFKB:</]%EA]+=N]3=$>:E(-/NSEUP#"?TRNS)O
MR>G/S\\3X?R.[I6]Y>6"@=B$>&$"Q&L8'A0>!23_.8XH%X)RO?Z;D>Y)1^N!
M '!KC=7'R4'BDAR@MW-&/-]<BD?]M6 ""7@/4U1GBSGZ\* 0@$!:&<'I(R$!
M4UV0NN("$S0B@E9-)9N=B<Y.Y1OA;R*@URPZG<" 4[D=8_.A0$_7>,ZB5-FG
M4LW99[\V1$H6=TZ<HMM=HV70%;=9-G]:J/]*JK[;J#;[B:8A))TFY)5$D2M[
MV^>GCQ[1UF963F$)%-<YK/(+3D?$C2^W$H\.]K\:80/S'4&-$& !F #U'%O]
MBO:LT=BSY.J^>'WYW5&*.'TC9+_..J0%1\TKM>DCPGE-K7R5V<:H:_7P*JAI
M3W.[-C1O_:B'?* Q$K9T61CRX!SGH4K?2;E4>.._;+6.Q>"BV VV-[^Z0>QD
M =QZ)Q#%&UC4G:RL IK#I[OP'T ;5A> J)0ZNUK&CJNWOZ)5.Z-CW[BQ!<_\
M\MHAO^]!40QD9-*5O9>_?TGL[0%R?6OFVY[A\$52M(R1IBB567NC<36>76UX
MHXM!? 9?2V<,,<M4JV'OJI7:2FN47(:4&Z*I_#'=W/PR?"^CI:1ZC%*  L$S
M5$Z77=*X#[$(?\(SW!_W5'OBPZR^"6&Y2(9&3AP/9W;4*#2.: .81J[[N*18
MEYI2(08"."IH6D;[)#?TFM"(RI^)J?4Q\/Z0,V-3>XA'G>9+;%#>?CZ_:.NZ
M^@-HU'W%O<E\06Q45!>ZR.L%HBN?\)&/TKUWLH)FD-3/#":R.#M9ZEXR0QH&
M,R14P1B%9A!^,"V1'AJ ZY9Q^34N:YDUV0%)#:P?+.4LD."B!::WT17C;V36
M%7)D)R#2O&9]>PFT]XO9P_<O<#9//Z)>,'\[]%]:\%O<C47:0;#G/4N%V(&O
M-+/%E&3>RG.RM[$GHX>29ZE=4">=.EZ/$*&O$U<P+J<T_)/7B>!L-F[S'2_.
M6-:KZI3[5WAL<IL.RNF9[Y6/SN4H&5&#C)GP-P]:VXD\ZD_R5H?$.'V[1RQQ
MM@+W8;7;'%+KD__7:/R/3U*_2<<=/7PKS=U^YV1ENAGB7R<8.#<U3B6PDX_5
MJOE68IEY5*[S#T <EK#^7Z720+A,:;@LZ*BV,N1Y] 3J)D+3#5RR#!,5)@94
M!F6Z)/6(K%GP<].S.H;>O&&U5A>QR+>2*"?^;JJ=Q3$^WI^6<DY5'(UW9/6\
MU=B$+5]'7%L8E?#GGM9P$Z"A!IIC ;^6^6C";V'IQK,6DX'Z:C^X 5;[?/91
M.WQ.,$^O?,2R5E0GDI9 6+%Q?=^%U7\=W9K/^9C-D 6:;PZH=(0.=SJ7R-(B
M\,%0PQQI/GY\R&)VCU4 :/9ER[-PLMER:D* ,823(OJWK$-6_H6PSXN+K@#J
MS=+IV(HEUENIOY^/G8SL$#6D'4<"4H]C0FV_!69T$G,9>(2Z\A(D>&C:IJT[
MZFKNV\^[@P;^U_RC)&<<"WU6%1^IW&PF_K-<:'RC_=FLC=;DR"LM">Q/=R&=
M[,,G&*W*X4PIN40V >WAM:??()K0VR/T5=%:5V()08P0I=>(8+Y[P^N7!%K@
M-4OO^/H]_+S[CI]5@K 5@HDX")>?C&?,Y\58'HE>_/15I@]\TE&+C@^D&<BP
MK+_3A71^>:E4&>PF&(6^LD#JLUK2DMGQ?8-N?_W4Q#/N5MMX"?EL?-M_2F+I
MSDF<<3B'=K58,>;**>3\I0>#Y0?ED!U6Z7_C2GQ?E3,3:Q@)WE)G\LYR[UJ4
MBL7QP#N:-;_\18D+-":HIG7I&[<]$&3*,#;U*CWY),O/^8#L<9Y8MVE8\-QW
MID52.&%280L]CPRCRMXX)1$*(Q]B,A^#+^-LZA_UT=58-=>SKA/ZDOKC(R5$
M/PD79!RXV+OQV>2Y@+BLI4[<=)I.K<HLAWBM;'MP6JOM?%I3_5&!8F[FLKZW
M3]+Q[S-_?#S.]PJ@Y'7/!Y.929JD!OB]>!7L;Q0U2\[R]<^E(H0I"ZLCTZ]8
MBY#*\U2OQ&2PSGWL"\[R!^T%*][Y)CZ.>(%YVM=!.BV;[8,@M5>T$$:YWX!)
M3\E#*4!J"'IMS<0+J%*O($E0<_]RQC/>S'@S32\]<Y;Z.;Z;<. P$^N#!_P*
MD%X^ZS 1'_05XSFSEX1..X[J(4,&WY0-^MI%,BE01G\7Z.8_['/0<^.:'* G
MG+D9_5#E^PL*#PF( ?:4>!=YXX FZK[*$@R7#3WVUC,OPEI)I'U^<TS!.R.Q
MO<F!9-[PBYS16+;3:[N&U<I%+!YS<M[^ 3KR"K]EN&)BP+@;!?:+9]83'"0Y
MO"M<5@VF^C(#E@8F<SE]6.Q(A0P84_PFNCF-VVS#_.W[5@DY))G"6NW7U7GH
MN5/WM6&R8NOO%0+Y(:+ 75>.!6[K*_M7[) Y<V+LNZ#KUT7H@C9W1OWF/"L\
MYX8E8BUWIZF'N#2B#=]U;8)+YK=8H!T LBR[6J5]]0^0^N3Z1H-%O'JR#)R^
MOU^3Y-=_\8N8#>@PZW]]%])[OL;%-<B$2[_7Z,@[B-T"Z: QB, CEO.!@0=0
M-C-@2$M?+R.Q-H640O,R=8THG\.13)8@$>$2Z,;6MC#V(0)KZ,M(>,$,0RUW
M^TW?>(YQ0[+ETJ2P9VA\M32/QS/P']-43\2W8\P-$KR592;]%JGU=KOE@BX'
M1XTG%]?#D U>K5:BR@!A$'MA9'6F]+Q]9P4PW'_X'^!H^6J;95NS3\&O_BX&
M.\BC1L.IOB7LQG<QZ[/P]R)#C/0FK X3CO]&-F28-8,L^C?YKJLF9.G[?J1J
M_2?<],UOW^%V6?8>*[S^[(BI&>' ;YW='_LK7XBRY,5?4=R?;<;RVGSGW/$4
M"?WD@,+QG4SJD7.R</0\ ]P<@BS'-164X,&KOO<46L?<$\1ZF>S?_ZR&&C)E
MU-#F3DF\F6XWUTZ*SB<<"U+X99S62UBCRE).JD!F&,B.23E?FIRFHJVZ45<^
M)O@'R!R@_@>@]U(+:Q9,;_YL7V0>WZH#, $)?<CJ^P=8.A/C-DLK#:$4?Q9:
M(*(BJ_2!4O1@&7XW7" 8P3F"FKZ-QS"-B_D1:EZ=*,DDR103A'ME%D_-7BA-
MP"ZGJ-U#+ZYP#B@T4!N0#HJ_T\,^Q*5D.0 S:C(CZK">>)<' Q "5PK=_HN%
M#5L=4AF_UKO;@\NO7P>FL]IT)8Z69S.[19>U7:2G**'K+Z04\VM.EMT#DL'
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M&R5W<HDE)Y]=UM3Y?1G;1T[ZP7;W;1R%RQ[?$J==*R]NZ,Z3: )WV8\QSO\
M,H@^"Y'\?-]\-@4_6<:CUNZVM8XM8J$_<&;=AKIE'<J_Z5(Q"/P8A?-1#,L-
M%08K9_(2+JR9ABVC^G(0K94FEHZ,RN:S"<UOZ8=H2ZEP1I9,$L7:A75?K:E5
MJE+]/&78"DJ5EY;/!BCS/M_G//JAAU@3$N2'-C/34DHN<V/0(V[[M:*%0@_
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MQ[1&6C.$8]=M.^2<DXW.OM]PF9OIH+W^7SYSL1"@BYF8UT_3"YCK;((.=-0
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M<]LRWX[8QDE2TI2"I0'',=KI7PEJG!@U?&.!4J=_^KQBBS0-_ E1Y6)Q>X?
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MACQ^HIRG"1C"<9ZB>Y]@,X&<G SH!Q64O+8&5"9/\VL==YZ&29(4H@3!/6(
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M)TF<(Q\M"B%.E"G"<$   8!&F#@G!(W(T&G$.0JN;@3 TG]?, [:[8L-J*8
M@$P3)D1(F($Z#E,$],>!4PEAQ05DJ'E(.PV!4?OIC7V( R>(E-G-$:7OL1.O
M7H!RQ=;5RU('6 2#<6V /IRP=:T-JJ5UI3J0MJ&@RBDZ@K24I9Z@?_>H.#(.
MJ!V/$%2LM,F#"E^'E:#,1R @G<*W.+U,C,Y)T2)'_N)  ^9@=,6&PQ1[^%2I
MA8S_ (?JL AXX474!PK<*.E(4A,A#,ECI)((*%Y)^5.<5.TG=N3!?;786@$
M"1(D@E*@;QOH,:$)5*5&0",P.RA?:1M%]1(C7%9\UEO3ZR(L<%4:EM>0<?PF
M0K*WS@8U1U)9.QRV<>G%[AV5M!4H@%PS?9-X@]?,ZCUE.8I F;S[SS^_+&K>
M<5Q+Y ?LT2W3UJB7!S68B45ES/2ZZ]S">DU*JK2D!*NIFQJ?46 H]02F.APK
M"2D#C*!@<=_$,E<+I^&*6Z18@)H EIM-])K7$$\\Q@3CK>%,]VPR(@Y2Z1O*
M[SOH%).FQOR_/FN^(E!HEW4>BTQ*'+MMR@4"94Y3A7)81%E1:M<)80>M*4U6
MI168K0;4T&Z=&;"T*><</'M0HEOO4CSSLBEJ'ZA+: ,JLR5-4^8\VFU%9D&7
M%$ P!C:S 9@!)4$B;C_W6Z_ETTDQ)C%/7#;TR-9#%YAQY#,JX)= *%#RT]+<
M%+Z5M$X4\7%B6R^ H(;"$MD*4M81JL5"55IH@$DHIT/SK=2RF#K$2@I)N;FT
M";K"03FM(YR>1GY$^EML9RJK^>K7<G.#K[X]LX_3TUMUKF5,6 C;D!(][Z>4
M;XAK'(-A&P%A;]XF?KMBM:O("$J.<9UQ]CCWQN2=,:#TXXNM<E9Y F?.1.V]
MM_4C&.\O*F9-SY;1'0:6'OBNJ@Z@%6,#J.21H3J<$Z9/U^_IQAOK$J-A?;4C
MT/2_K/3.5<FWGIM OS^NVV(K+6,'.#W.==22._\ H??0'C+=5^I]]AY_M@3N
M2) &_P A]CTTPU[_ ,^_;7/V[_\ /%,W-[R(. "2 ??H.7M@Q"<Z_08WSMOG
M/?&^-2.W#!E!-C;K>1)MT(G>X%QN9FVY-C?RL+P=+"Y@#H;X=H<+S,+Q\J3D
M^A(Z=-<'!P==AIMQ XO+J"5: "Y YVL8T/GBVE(2(B"-Y-Y&QBYY"-=-(Q*(
ML3.JACN<#_-V &=O7(UU'N:2U6DG4B!?2\QUM8V/.!B=MO,=(M<ZGR)/I.L=
M;8D4>-U@:$(20-OXCIZ=OTU]=>*SBH%KFXY0.0\ITDR(@Q(Q.$ Z\C!3$ZQ8
M18:@6MSWQ)J; +S[+9&0XZV@>X4M*/J1@GUU[Z\47G<B5$&X!)O>PGK<6Y1S
MP?E\(]8DSJ(OT\_/2)Y)@+=J\J.V%++<CX1E(R5$-$,H;3C3'R_PCOMKG&8V
MX.Y2XJ$C)WBB9B3*B9&L@F1$GZ+!!N.7W8WF_P#&HOZE\I;JIEN2Y[,5:)LF
M/'+@#G2IB'(ZGRTA(&2XM#:/,6%#I#@0C7)/-5''*)VJ;;+H[MM2X"C,N#PY
MCM8DP" (%]8,P08-B0"!N;'GYP-H&AF;WEX<N9R.6M?52+C2Z+-YCMP:)>):
M9>>DTZJT"J"1;ESL-QW&97Q=#DONAUR"ZW4DTZI53X!9E/--+R^.4BJID5=(
ME+M9PP.5%(TH-*34M/M*344:DO%+9%0E*2C.M"$O-LJ6M 25IV>"<1'"JUM]
M0S,+E#[83F.69"D^)"PM"H4DMK;<2)R+2<;J\5/+NWZ5R;Y(78VJEU:I5GF%
MS%=MNY:6Y3ZC3)UJHIMBMH9<GT\BG3EKK<2H2(C;E,HSZY4JK*FT-BHKJ3\C
M@.S_ !M[B':[CK;2W44K/9O@**JD?4M-0CB7^H<=4M10\A%6VM%(\PT_\07G
MT);I6EU#J&V3CI^UM10UC'#:FE4VYF6^GOTY5$I*&E%#BTA)6YFO#S-._F[P
M.L]X''',;UV#5:\A,5IX-JF.0XJJ93HZD1S&:=>4AJ/"#V'7TH=(*4N E#26
M&6VDD =HAUMC^HJP0%D..*\140#*EQ %IT$3*B3<\23-DB\@0D<M@-=#SF/;
M"EVRWJ/!;BRV68SCBY9DN1NM##D%4=B1&1&6_P#$/J,E*0_+6VEMME ;C@..
M%TM1IKFWU%;:BH0G(%&%=X%%*BH)RIA)LF9)))L(!<4$0%;$@QY9@ -9C4B4
MWYE0P[-TYUQ,>-1%,M3E.%XL.8CRFXY+?2VTA;:&LJ#:2OJ6'/+"4E*=>(N\
M$E3V9200)!E!5SD$\S$" 9-['#@@P F,TDR0)B+#ESDZZ1:<?TF>,7'E.!P8
M,#@P8'!@P.#!@<&#'%_]E?\ M)(WC8Y]_M0.2U2K<>H5GPG^,R[;+L5A*VD%
MSDD(S=CVY(BM))5)8;O[EOS%E/34%32F*U2LE*GDE9@QV@X,&!P8,#@P8'!@
MQS'\1BT/<TKF\R)2J@B$S!0AR55(L"LT5Q-#:F*;6R]=]%=ETY8=368#C,.2
M&Q+>C>?3RRM8\RX6V@]N>VS@IZM"^XX4A3E6]GIG":&G(^'0'7N[IUIRY4E+
M,/!Y09DYU:SJB.'4*<R(*WE94IA4=XI)43E3*@1"C*CE A40,9?M]S_\)JB$
MJHZ4(FL!,2C.-R*K&"VDY,B6W5:RE_XH-@N)34))8,9H*2R7>CC>X$@)_$#C
MRBTNE4O@'#!WJG>]X96)4I5ZAH/'X>L@ )*V65&G"2%." FO4DGAM*)S_P!=
MZ1!2XV1%D*R^- ))LI?B4J0%:YBYI EJHJ/Q'_73N?ER"K_JZ?Q9R3_[M,8T
MX^R>$@!M@ -0&D?D(*?RI_(?]O+7PV'3AG/S+UN29.D"3!Y& #.O37&(+H:R
M\O'^;)3@8W)SD>N@Q_,<=G2G28M&OJ+1Z;>0Q2<("28)Z">0)$#2Y.XBXG%5
MRFPEPY!T41H<#?4$$'?7/IQI1R.M])VZ$6T_?%(GT&T6(.XTD'R-A%CALD(&
M2=2"D_-@GUTT.=,@8R<YT]Y$'PD&!ZQZS'KI(MZ-.Y!)'D;'D3O C%G\I>6E
M#OJ->M0KDYZ(S:E,I$QEANZK(LMN6]5:PS3.AVO7[/IU"9\E#BG414OJF2E8
M2RA00X1D\5XB_0JHT,H"S5.NH*C35M84AIE3DABB0MXSE"2HI"$W)-QBY3(2
MZ%E:HR0?S-HF3%U.%*?(2"=IPWIY'7Q58].J5O1:746J\J-)H5%9N:WYMQ/T
M6HWZ_P M:95Y,6),$9$%Z\DQZ"J876F77I<:H,)-'=,YJ3_6J)M3C=0MULL!
M27WC3/IITO-T*>(NM)4M.8K%$55&0 D)0IM1#HR$-.ZK*IN% P4I"DE1272R
M%$"T=Y"29U\0\/BQ.XG*>XK0IUI77:MTVDQ*JM!N%RMW;*N.V7[7I#DFXIMH
MTR-1JQ,C*73*]-5'D,L2&2FK0C'F5Z),I]#C.55JBOBE/5N5=+4TM44M/L!F
ME33U(J70FG15.*>9;5_481G22E0[I>9#"T./J#1E#+B4I4VM *D+*EYDE"?$
M4  D2%&X$#,(*P4I\0B<KP_<R(C-'=J%(@TPUBHW33PB=5H,4TTV5_B!5U3*
MJ^X[\%%B4)NU+B>JA3)=DPV*8'Y$9M%2HRJC;3Q[ARU/!MY;G<MTKA*&G%=[
M\9W'PR&D@9U+>-53AOPA*U.94K):>#4'P]0D)S)3XBM,*(\/=YLY4189,BBJ
MY( N/$)\P?#O?M5=EIAN6FIAI,)RGSY%V42)3Z\S4+=J-V19%%ERI+3,I@V[
M1JM493L@Q4TY=.D4JI_!UORJ8XCG'Z%H(SIJ@I16%MII7E.,J;?;I5)>2E)*
M5?$/--H"<Q<[P.M9V9=#TTSBI(*!$$**QE4"DKE,G0I"E2-(A1S2G$OE<I^?
MMY6_5:&W!IE6MNSXU J1=H<.WHL:Y/+L1BY+8G.5:B4R++NF?%Y>U5J;29=T
MRG9T"'511FG(U9JZ:5,JHXIP.CJ&GRXXU4U:GVX>4\M=--<:>I;#3SBTTK:Z
M]HH>33)"%K:+Q"F6>]0]3%2XE2(0I#>54B %@-9D&4)!60T04E9)"5 64H@Q
M+PY<G9_.;F72[;CQ7G:9$4FH5EQE"U@1F#U>22E! +NB1D;JU&,D0]M>T[79
M3@%9Q5UJIJ7$!#;-/2-*J*AQUYU#+80TV"J M:5.+@(::2MU?@0K$W#*(U=0
ME,H0 3XEJA-@5$R=X!2D1)5:9(QU-YG7DQ06&;%M)N?9E-MJE0YL(?X@8;HU
M==M[SC+><6A]ND.,H/Q3=+FI;F4BO+>53)T5+[JIC_P"]75'%ZWB7:WM$_QU
MNF9J*YIFAK:M=0GB%4*U];44U!2M*'#*)"RQ3K[HLGAS?QM7*D/5#GH3JA3-
MMT5(EE;BTHE2&@@LM%* 59G5$=\L@*(!S]X>[18A(-AT*A6?2(]RWY C55^M
MI=JUF\LA)4W'^#J<!,1-Q7<XW'CSJ70)#"ZFBCVQ#<BU.? J 8<<C0X<6>OR
MWM!VC5Q-USB%>ITMN]^CAE#1.\6X2JI;I^($M*XO3ON9:;A=0U0LBGI$*%5Q
M4./U&=ND?;GLNS'9-_B122HMTC?=EVK6VTX]G4C^HS0J \;Z5.0\\I/<T^5*
M84XDI$!NN_KJO!Q**W4NFGQ5*_#*!3VFZ5;%&;7GY*5087PU+AC3][(1'5+>
MR')DA]TEP\=5<1KN)2'75(:*RMN@:0W34%.IU1<!IZ-C(RE9>*PZX4E:U*SO
M+4HDGV/A_!^'<(;R4=,TV<L*J""Y4OY3![Y]04XL%("DIS! T0E*8&((Y/5'
MBR9B$H!CLAP*=4"E'[QLKZFQ^\2$I\P(6D*5U$9'3C-+N&*@=VXVIPK:=AA7
M>%MP+D%*NZ*)6RYF<1F)!4A(R!.)ZEU:&R0J$I4%%8RDIR@01GF I)2"!<23
MFS3$::53D-LSI<>2LST!Q3A<CQ"I;382IE&/+*W"!YN5>6XXE*B7"@#*+!R(
MH0>'T]0I%'3LJ:HG:EU#350I]ZK< <A;P0$M@)2I#H3!%I- $N@.]V\M#8<6
MX2M* I104(059!E2OQ*S%04)'_VW/:_.JM0J0JT[II=4??<[&P[T;BBU2NT]
M@@2Q:M<N,2JQ(S:M68*HW5)M[3TC]B8AL8K:'U5;C>(3LT;57E5*C6JK]W.?
M>Y_O<^\_<,[YZ7W?\SYGT-XT(G*6 V;_V6DP_+%X+T8Y<7[;12OCB-Q5"[PS
M*'I'( %5?<#ZTP>+.Y(?/&B6-QYB31,?0,Y)H-@>QI4CSQT>E<V\-1\0SUFJ
MZ1 ?X-M@66$#MT+>)U3;"PON=L0#UL_71[B\U\59&TL3JG4ZQR 9K"VS+32^
M;T982B$V%$H'UA2V\OL_!/78EN@'S(O'#FM09U4ZT=I_ :S+K?KVR8*U(NLH
M%N'Z]D_^N^XD=\%VL?-[@C7-)=AKEI/BD5N;I?LU'O&S'0NL7R^Y0QLX20<U
MGKD(8U$Z(B^,%U:%*G!N$,OEG.2'8T?8W9X1_=L9XQ9V>.UC'^A>DZXL%"73
MSBNP&JO*L1V8<>R!.6@F0\O"#1PTCL5FT R]TTT943P*:Q?[F0W'K(P5P17Y
M/\0C'G#9!13>EDP@UH[2H"QOB=,RDT1F#S9RN9:"-18$9>(XGZ@]RO\D/3T7
MPM/R(SO(4FKVY)OF);4>747^P_=?L+.AR.I:" ^"GU"I4U]?DP8\/A?3:8:Y
MBS]B<U<+AV;WML1T]1(L!F2X'MF-1L1F9DLSEF>V]/JEYD"?HR>^V2,['5]9
MURW5BJ.7?$:RV(;N4*V?9\PDF"O;^4>PLD7)$H^O*?N56Q]PK;<4Z6?.J@\9
M2G7E<MLY0$D;@7B8'6W4-"Y?&P:,HF[]OI.-/:@*11-8L83H FV*: @@@XR;
M)T&XSH5_&; )>"W)USOY%_"T;<43$ S*O[B8_G.<5 ,:Z@QC*2M\I,3X4I2V
MAY,W"B%WUP=]'*7XX\,4X0M0+_XO('U^:7AIN)*.(L^,.4A<4([L/RS+VDZO
M29+1S)\LNU7UY_S!4U,GIA?Y/X_+ND?$\F=-6/$/I:)BC$:3C^2G//=D'F?-
M1$;1@'@OAKM>:L FET-LJ.Q'UK)_HN+RR2F&=K1E0ULK;:/KAX;'/Z&$M60J
M_)#!(]/?Y DSHF?K;&JK0EN/7GL6?M:TN?W=G86H5!*16)CAXQ(\F_MAXGXY
MY[\JH]RE1J@JC: 9UR)_1[?!,\WEWK7'\]<N2"^RMOE&&:!!(4;822G*C2IF
M *UC\A?P^M&NZ/*,VL5&9[ U1VOKX?;E8>* 6V*>J#8'Q>"*_BHH<9EF-7'Z
MQ>[[LO.C_1]\-PUTM(G1@>B[X^C)/W[][(4.DSL;OZ*,VYI:)F_Y;-ZJYIP,
M[/S >:M]P7BXN,/V<R]]VUGTN4@HCYT<['[GS.^'^XG!30Y9OH9(0B-1OHNT
M&*+A4LR-YX*A!KL_G>) 6#'EB I[!+PI=EL%MO/KX:=K3=*_%6D-M4DDP6JU
M^=)U=?WJN%G!"3PPWL;L(Y89P9Y-43L(N*_V^U:JM1]MKA?!7'\SF_4;27T5
MS:?A+5$5!#AT;Y]NC#@(I[5PIX. 52) 7,J=8@AL.>*MYW\T;0?=KRTU#E!F
M+)LI?)X#4NZ,4G4=J^F8B!4W-JF5TKY.>1XI*9I)^%KJ10 \B[C8354V@\\9
MCC#I#)E]OZI)PK?D/L)K5]\%_S"/Y^9;!;-)0%PR@VGM1SHJCQZX*F?27^0V
M%6GF#W7D-WP]RU:7Q+,@SFH44 1'F6"O*[LG6E#4)Y_N4U(%8\8F>Y:G)3)^
MGR0ZP_'=3.@5BRT-0?^5GHF.\!?.FIG*MC/O>&XWO]_;??;Z.HI4G';Y40<S
M*3T+(0.QPNL=Q_2X>H&[9B<;15S2?@=+(?L0+W%-V6\T0P+^U3IQJ;LK>.]$
MW(S%K%GSSZL"7)FWU2M^/VE@+O_7$3XZ>V=2E]?V6UOXKE\-+3A'N?2NB4]K
MN%VG@WS,)9;K<,&H?3DIF,H2;1^>5#N>'%)3]&^#F;2OPWCMDN5S[4YCHV*&
M<AA1KZK>!X)NMY#P?'@:%?7HST;>*/KBTUD#Z97ZR>WBKR^R6R%?5IY&O!+R
MNV%:ZF&S<\ %I$4GG'R[-["V\4$/81<:+O'/LXWH0P-)\J5'8^P#Z7YL&H7U
M9<0-!46C@?J9[AA6J?:,ZKQ@YNG@V([Q)#IM+0MO.PZ*LLSRK&[I1VRB8CDK
MHGL71ZKIE-5>K36_3B-J5[)UVX7J:ARX'<2+3=RX[<42'WJ%;309!1C1^"C*
M(OZ%5!V?K%U%?O6X4[ZAT71TE^E9SQ&?_5_ E7<THO'P/.7"/K;C7(#V%9&&
MPIP?8OE]Q2AWS*JM)O_;] :W3Q%\268\97H7:K5$%I2!Q&ONT?G%M+%6Q(#
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M:(X57KW=7CMT-IN<'+H\IN^SP,^8Q[E920W'+/?NF=TUD8W2IZ9Z^<OIJ%T
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MZQ5UYU?N5A.T?D&;J)1?1E+R\$MM)?3PLF\[N:XMR^, =[[A!3[YA8(Y-A;
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MXS&=UJ-D8^O[0/ZJ+WNJ? S_ "???_9*"82I M2?CO*2THZ_O,;^#";P O^
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M:^-,BBZY&%OO6BV\U#BUL#,VRM'"<WEG0@(Z\P6]FO.*C7W(#NCPX92W5?\
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MO'S7B(5&*P&KGJ<=- L28PURBO[:IMSP>E@USL>K$P^#_0>K1+""H(6XR<H
M<XV19!!ZEAH/ U%2&EENNPU(?AT/XXZ6N.>85RB,'V<*R#W\B/USNP!IEXXL
M2V@4J<!U;^E=&8WA?[G5:G)3Y4(.^XM$O$U4MI0ZOR=F??UA)F5"4;UN2E#8
M87GD :,@VR+X"3BHKR>B;'2QR)X"*>S7#'HP6,8S #V/O/,$D=N)4B!B9=IK
MXJ6I\6A$<X-Y/)$5M*K Y?5@9X;3>_*FY[+*C]"F^\3 ^K_.HZG*-7<)BP\'
MI+'0$'/6^#>LW;5/+!_,B79/\U"Z?\VWDP[*%RK,2^<9M%)-B;>6K:Y^6Z]L
MA+SGT#;+2H+B;48=@OK6+5HQ<5\@])8L)::#O.LP4L*QUO=9C1D?9-$_  YC
MP> 'B.>D31[%02!(TY'1BB#+)7R*9H1BD(=<_7P4H^-GEU:E/D$+O\'6W# <
M)ULN/H +!)$@"MLAC<L"ZV_@8HNE01PW%TKO!TP\BDNY"9'(4J&.ZW$HB2&P
M:WQ\%[K\J.!H_/\$A_]3UJ7/X5=:F!8;SQCHQ'Q^J$1HMO<[GW9[FZ!T%<ZL
MGMMZ*J>"5]DS YMV)D"8X'#1 OFQZYD_K4ZVA[I\>H:/P!.RWE&3_J[+RGQ<
MHW\4LV4_O5P1DE/_'I?O;;N:<.LW." G!->#&*@MS8%O[4]*3(1/'@L$<^=/
MW1_XG1CRN&4S4[S'Q#%*B^S,V[4T=N!TLEAIWR:K9>HP_TR&W#/=L3;5D"@7
M(:42'C8>\7'U@;U"K?SG"BOT@_FW_M[6GL?>8T@BJI^5V;XZGPX?]3KEB(SP
MS#6UM'0PF5%F8(+6!)GAP,=?SK=R_MC!J3U*/E#=*,MM>X/L-WWUVB&C':LJ
M];ZJDNGHO(=N4'Q=TK#SZGE(W]^C[/&=&ENU>VO5S\2\,R^F=W.U[CZ.KE_!
MSM7J_?JT9=+>\ 3IH3GR47.K,XE[\[6?D=')W8))8^,[GZ[D$GXNYJ?FDR_]
M](8Z@;O\-;;4#=_?@)41]VA6?N+?*L,'IHZM1NP%#LB[T"+?F\7B*;.9EC6N
M;ZKCO%\]:,U]G#J.>Z##0"%,<S=)2]F3A##BM1QY)]*SM,7%M_?P;[Y/"*T6
M7SJC1S"XE_5;)J5ZA+W?(VK#=?S?=^43RH]SNYP]\ZQD5!;9%%1KUN1HZO>9
MG/"5#UOB;,537B1V#E]3R@BLK?7,+Y55T][SAQ95UBC":&.K"XG(RZ$OUY$)
MT(,)I/6-]N 4QX/$O@*^I8\ N+:%T4<V76L !;M*N=.[MNOYWQ2$.R_"9#EM
M/TUMD%(KNUMQ5,V+J5:54W$':TP.ID_M43OFVFJ]FIJWJ0/B+1N7KN",UK?0
MAFYF_+( L=LS>H><&)K!#Z+O0>_7]U[3K]\:%EA/ Q*1#F&Y%><5,85,#R5O
M=XG&5+2Z(5""F<C_A)$FRET]3?5T715I42,QY@'DM4,TXG);UZVG*S@5D(:/
M9]RQ!+PN9RYG6;",3OGT(_4E8:\]@S;5Z1A&76P"%1T44U=C+,(F45K/KOJ<
M]U#KQ,X%WT,F8<6JIVH$[;$W@,^G.-ND2S%99B5.B%@=9!+B*=(T>JQ+\A/'
M[_4JC$[\AR3%H)%2*3WTZ4E?REE-J(/?S'(7K/N,HKN%*=?8R3_3$B_^@@\?
MK_I'8S+M?4&_#]*BPXU'0!>+)=XG4,Y!B?=D&>WS1&0(X*_](X];FT'@R,7<
M;(3)>Q0']]0ZDI/R"4F:YAJ#_7WV:<,BM-\Q:[;@CH1NZ/LE*M>057[V=&V2
MIU0JT8)-):/]5N8\FP[UWD57S%J[%?Z[.,6,"]%$0N,$,^8'&[8)S,M*@ V6
MZU>*8I[<IWSBEH@I &4!ND#1U"'JS%))6:)LYA+R//(!#@&5*S-M&EHA;\^^
M61-'M5QM-KHQE>K@%XY7\O1#+Q_6?I?<K6NG?>LVO61$12@!'6=;#W<*L=D.
M!OD+]G7HDA<.X9MY_VEK\B86& 2%>/-<\(;?CWN:$DT'MKL1@*;V#DV[2W_T
MRJEB;<+[5"[G"N?2,B_)TOOT_6O9]D6XL*M#\X57ZO2Z?J/B)R">-<^F:6JC
M'H J.5WT?H0+;! 84FU.QW1'\$ @H'$.NX%T+C6#@W;L-_[X'%_S(X3Y'\^[
MWK]A[SM4_@[ISDYS":8QRUU[;+WU&8[_=/B.+>PGG-)IZL5HACU^LZ22-$4(
M8WQSX92>_3+XY4],"8"F:1HO\1S[LR:):D53Y_-/SMLPZ7\ ZW4#D->]R'8O
M7NOO5N:V_ F4-]Z=^%'DLI)>%B4&C_\#[,-EI4..)?+U6-Z%7XZ_/$@IUAC#
M?R[I\EA5OPF["(>G>WYFJ0>%:JKD&]-'O%.2#G]>$V):1QI+\(<^L!Y<$7FO
MZL'T#\ +W/)DEX#^Q]EAUF$#0LBEAI$:G8(#HL68]EUQ6O$HXB\KS*WJA'X8
M2*QSBHNZUU+Q HN7UC_KKWD>Y5UF%<*7Z"FN2!)(EZ2NWH$,#*:K#=033DH<
MH'[;M]/A#G7J,[UMK[?JKUMH!)<G_\D.:'M3$M8J^MJI;VP9$9.6'%3;_9Q
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M3XC;W@I6&HFH!/ V%H^MV[)G.[ &@Z0?,.6B NL^G/%%N;UA*^T/&/6V@#A
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MJK^I*O8[V D$]L@_;S%*77O1 #GV=TY:W7]*'CLXW17=:W_S_%W-0AEU74"
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M*$=X5$ZC^^ ]._\ [,@1]G^ @]ONF>C0<WZSO'?AK?>?U/T#C#SZ!Z@/_@<
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MM?/TMQ6YN2G$::\^1^PD)*]RZ/5Z-O@9UBDRTSN39O%_Y%-$3T *=<O;^SR
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M"$Q"71/5+UZ*CY5 4Y0(3""L*)-)%I-X="[GMS_VTPMCT%HU!6Q>%]3F^LR
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M.(%ARA-F8)Z=17<9U8*SO,8BF=:1G">+HI.PXM]0-^PZ0KS,UF;<G%!2:&!
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M U2\3C/M=GMW:@SZ%&%,S=8FK_,J>7]%U(BF,DW%!9<7<S.5;]SW;MJ.E(-
MW#)^W3$6LQ# ')9ZYKR]/I_0E;NF$^&9:HNT_;W-$]!Y-AY%_(%O__H+CG *
M]8H'M,CX=MZ<#\B&]'1&7,7R?>/;<O=BK"C=A6(J+>\G^HZ'F^4K3(:0!9)V
MN!;-T_D>XUV#+DW4M.7G3I[$-)W.NY0U+M([27#YU/HD-R@-O+XZX]@O$"]^
M3(8!7]VT^8=X,<;0&>.\RMJ/ZU5#51A>4M\# X4YG6I5U[V6FW.\U&)C\2:X
M@JQ0 KCNO:]?$Q:?I+U%/PR*)K]S_UAN_.[U=*=7LF9PK4P]^?56R[+IE&9)
M#&48S9J 2W5 Q^7>'G%>2L+]Q*%]-(W7SEUO!(^N3^,_0.&O+5K*K\1<\LT?
MZ3LS&UIG?;]$#5IHS2</[>I_/RA8DE<@?=T!:KP5KKRSW/^ EH0&%X(UPFTC
M0VUX@8MLRT:?-0K1W==28> DAX7KK+"'0<\[38=BI\>7K3N?G$7B.,^7K0^F
M(_C4.T^% ;+_885.*B6>:YL[Y)U-81>.;#DS$_?S AEPN3]Z@+__ED3=#^#2
MW/5%NF7NH&$U /9BED4-2^!ATM9NN<"M/^@T-TW@0@3=ZY0-WZ]S"VY8 N46
MXO8:. 9P1G\8]]NNK[;5^:DG&A=[SQ,5NNY Q.M<2;(-?^_RH&I2!-);K<M/
MYI#>FU&Q0FMR.X'R/U_,I>"L>!%L(:=E][26?)5V5?.((JE!9W_9%J,IPFP>
MJ%[3:/]$>D0S9R?T<6G\G?-8 H"8AG"";JRT_P#5+:P[_P#>2>N+?^16-T)T
MG?X!G+B"HLZE VDXLV=,8I*]ZK!W/Z2:RCF2I*9?>7"EAD@O @A23I>[NJ@$
MWO^F-2N[&R"A]W88#O=6:..BK=#(LF#%_-$Z'>8HA+I<.BNY:OWR+7AK6A1/
M7O!NF ,U^Y+[*G1:)3G@ZH_BA.WBSA>]X:T'#^N6H;P*TG8/QSB-DM,O>X2$
MN5,_*.*#_:]O+[31OBT:!IA$^5M/J*8 8U&XITGVZ:+[:W@LQ\V/*#+79+-Y
M;@[3K@[:HI:3:4JJG2)IV2&7N>5:#8F^"L;$@5SG=]2R77_GVE89JPF&EEYI
M75(;R$[9WV,EPUR%WQ&<]SI$]4Q2^^2E5+!/S 5W3=I03-J;L4S9&+,U?&YJ
MBQ]<SN@E1X=%OE0)]#DHSUZ^5H/8!W<UJ*#Z[%X7MMX&O;5@HB'S^3NMLTP4
M$P=*JS_^/##E>3/M0H'_NXAQ"J?+0Y,&CJ,6'^P4<!AO:1UWK*YH9@N]X?>A
M9_PE=-,XV-1<I+IN1-/N[^^_L]-"3JYRG\.H;<<-R\BG]K7O)F["+1AW?GN^
M^LTI9;-K>5E-(#N&WS!4':02_W7HIY ^#9B8%J9PY9DE*3?I0JR[ZU;;?E%D
MM*]TZ%62AJL8I]V\*\RX87LZ?\Q8;=7=V8DC5<3["K-/[N7MI-0:V,G] SRG
MZR;.[_SDY[?"VC3= 2!M-V[Y6SBUO2%82OCKEQO'L^YOS[(=Y1]F/9Z. "RX
M7DO4#50U(!!,Z+].7NN+DPS8"G6S]U^2Z)I4"/K79^)QJ\E">?UN3@:TQ436
M\37JHX8+\"%X%8L6W;28>5%_CL5)9VJ]:G/9EJ1!:!=#5(HH@,?D7$2_(>YL
MN[7J3?J,]X^_Z='O6<V#&KS-[Q.?ML%J$ *(<B#/[W10Z@YHNDQ &.!1"H9^
M%1248-1@J7SR(AO[A].VL3ETZ (NL/1 37,OSG+)ZS$<CP#G(TK,3_@SJVW;
MZ@%*RRIG5VZA>WU5)BW*^#'VO?*C.BMIT7RCRZ"YD_R#(9M3I2(#L/(\0><%
M/]OPG.W9:H1 ,BN_'\M>6;3JW7RZH%_4$P%,"!^X0W-VR\5E]B+GLQ84B6+.
MB1_7#WI75@5]),+X<$10)A\>%PU]C2XRK-RUY(8\1?(R< :JJ0L[S?5=0\_)
M5ET5S;6TH%9K3?V.?.ESI,[ZB\![-.TW+PP-#=UJLU^45:5+YN^:+7L]_RK=
MW<JE>F.Z]72]"<6>5:IU3[., F+M7-S$*V:[^\:'MS_Z7DR%VXA!Q62DF84J
MC3W%PY50?#ER(@#832,_$3RWF#2T).!K>LSI%T-6D.;#M@Z7+"UJ:0O1OV)L
MR>!TAK*6=(1636I/2?DL5O@3X $/;F+)5 Y)'&&)-'<A=UO_#3;3FAA,[J8L
M=_>V)FNR7TPO*E=='.$P50BCFN'0L#9E8WA"*4+LEFDI6:9KCRBB.A?]EMW8
M3A9+;-2LL-4PY>8-;N2$BA0_!=.]4.<I3!'.#V&@3K[07S,7ZA;=CG\:M2?Q
MUUE#L&3=L6&^&MM>3?3)V=@8_K86#&<H?@\A72"N(A<N@FO*4&.HD!R@$##9
M,S_RYA4K;*%:>V*>Q"^;XU_A*N^E9Y]7&QM@YL COL,OQ 0U&18>7^](VA)
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MP8"\#P39Q#@S]S!EFM:TOKB2@NI7&!Q<.ITQX37[P*<P4H6YA+A$A!!5H<O
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MX^P< L8%TX=M<7;%W,ZPL$:) 5AJD=,=&W-&U4R*+06[OC<$@?T'F!GE8::
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M1'%^X.KNT;,NXS8@K41&I%[S@_(J^"RZ/<& KE%J(75=U*.NCC?(!;1K#<'
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MSY0M"E%;IQM<&(<7+YI8W=]P.1V:YLY>VS4^*FYN6>)J(,3^JA=XHBD54$*
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MK4GHLLIP,K*'"DI%"MS_%<C"V,\-;L:W18-&;3,R$J42145*F/1,<1%P>.L
M/9$UL>>7Z[=_@+NW>E/>#:]X3Y:LOD2NWCS=C^XL^ZBC6#+)IZFA>OCC,#8Q
M=^JHB3KVY]L040E?N.TDWQ7YS.+7T0M?=G(!R'+BB=C"?OTU?'_BCYFSJ(3+
M\0 ZX82SLS-):M19WQ4JD57KYA?*>G$NO;?8_KV,[S/G?3&F\'C39=^E#9IH
MXZ#EDTE?,>0+X83;Z0;A?-H%6[U(D=W.HI2CIRVM[;T/IK$O^06+E,5GZ!CN
M'\B_W#+,U-R@\[9(>-(D>7N]6 PK/Z/T/-VB9)^5Z+S]MUO&HE U1K$^5D@R
M.]_SOJOWW<44#GZ +",_VZ-?OZD1?I_O/JKI6Q=I-T!5.+2LK#TX_7P8G_?B
M]-)H(#.&(=LF?KM+2G^\R!_EQ7WMH*6V=<8ZH(PG1B@YU;WTDWU[ C#W0%56
MO.>UWE#;:TLTNB+N*[_-#]>$!,>@"XD)MS\F@ZV(;0RIF@AJ$7 XD&F\C]AW
M2!JLL.&:K85(Z8617,R(]"22WM@J@=:=?CPVR>K/=P9>?<,/!(B?:<:GO#FF
M$\<G/]8<<.[C.9#I5J>@.<H0$99Q,MLJ:.U0W]%(XH88'J\ 9UB!9CYR8P$P
M"*8R'W,+E&N :8D"X8#XU,C!$!:L,Z!*T#X20$NJ\U(!L%#@U@VT,!4@%N(%
M%EY-YP\*A57/ED@'@-OY>I=EP#G(!,':$5FY9J4 S;9O^S8+L[CVAZ+8N;?=
M0S_7'WJM;_[-<4;Z__+'VP0GDU6:-9U,(8+\F7>F2S_<OFEC)RH*@;_.OQ53
MJ_W"K.*3W]6-P$]8V66TFJG0HU^:?'C5ZJS5Q@Z"LN/A0ZO*T)W6K^-R<--:
M^P)**,':3F$\NG5\.6T[E;_@N))@E+Q4D&I8Z<(MINZH9L\?PR4OI&K!+WW2
M.03DV1X+6BBV/_S^^.MZK+]71[&DX^*VIM-9G'3R,1C:FJB1P4YX;6U=U"=Q
MEQ5$JBRR-9[*IE#9>X_7UB3*DY_'?\>VAFA!^=\AX]E7-67ZFYIG7JT"D?$K
M9BDY<'PKM< -M]RL:;G-7U<-LO_K)21A'I;@HRC_=JG&CHE2GG55IY?RO&+Z
MD+, 8Z*_Y:R^Q 0--2^%N+ZAA"+DJE"6UD@KIL^0WXT'Y_0,1>Z-NIT/$.,2
M,#KAX$SHB)3A9))NKR4R@_2T0V_^ULP:#65D%]PW3EX35]-SM $G!U0PR[A
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MG$O1YXPYZ"J6Q:X/KRU$M \AL#+ZDJ-+MQK_JQW"Y'U1$B?MD_ <A9C2LYX
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M [<\-%=&S0-4'2D7YOJ:DZIFZ'S-A.MIPRBY>T[P*M'L"E*E51,,U]J@[F@
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M#ARIG+LC3RK%;3WJ]</$]65-*3#=)$3LB(N \Z/Q8V$ZQ!29[*11:-_>FC$
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M1LP%)A9<+-B8T4)*4$>OG50AB3_)GN4O]?ASF4A+I=MO%D7-J"QB&NR5<CU
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M@;'NY(3\3\?6']ZD&179O;EOR5!HG'C(!HW[&KW3Y"SW2<>.)G=WP#-; HI
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M6IB'6N/^ 7!&@7ET]>1 4CQ?,*BL1K;BBZXW3/=3GB")OC@\D30O3$R,,[%
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M!H;'JZMJ/R.-;R&AL?7O/M*);:(NEU:>3J<K9#RE:/U"?!29:G*Y*YLY%=E
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MX<C5S:T%6%-^O4B [<=>A![$MOT'%^0^KD ACPGBT\W-1"P"-+$")[Q:R>+
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M[DCZ\2(%[0//_-YW]3K&$58"=R.E@(CI>8B1RP0E*2=<Y^N-!Z'MWS@CAZI
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MS+Y(\F>:]*F7/9]3:M>IM)?FO"DJ'X:[(<2"Z[5;<=6U\ \\4H0N5$:@N.K
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M9<Y1F;4@2I:IOJ208@VGR$2,2GB%*!3(;2\0Q7M5BAW-,R.[; !0A#2DHSZ
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M.E\?1"2YD)./KC?3W&PR= >V?=4K4;\N=_G%NL28],(K*-M=8/+2VF/JJ2%
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M2"A]RLI%)=I P[\04KSE3R0CN2I<95N9DM@2-_U.'NI"7,]*ZEU)21'=NR%
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M($K5HD$IU"3JDP3*3;29-[1 .HPQ/TE>N6E@'NE"L:ZD$ $#WTW^G$Z7 #J
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M@@71/^"V[>T^]YQSSW>?>[^'I4G>-3-K?K-F9LUZUQN>?)GX\A1 K:.AK0'
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M3,I?ES:<E,=?K6Q@J+1&[\S9<W/7WZOXG!%[7VIC"4OE+\(MD"[/3PP;I?Y
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M5X;;8S<J%TD#-DZP2H>?>R'X#ERC=HQ1O\UD^O+>K+)$$5$T_QFUL(]9@=3
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M2!LFVF.#D)1X&O5A7:.U4UMZCGB]-!#=S?8HNDG@UH,N7J-.ATH]<]*[QYF
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MY=:7 <O*UK66I2^;*R&[+9Z@B?MY_NR()O*6D>1(67W##JUQ6/JQ57[ C\S
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MEDY1W9M>R)R-4\83?_^D!V;EW5],UL@".;]W0;.@Z*2;U;[@\7=/--TL<D)
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MG>N4P3.V99B<OU/>*)(=4B][GAJ&&YLYUJ [#(0"ZRT\B1H9%/[#H'.O=]5
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M;FK_]809MM24RP3ZV<+=6MYVYNWXBM-3[6*,\9I0F0OA,1N]]9%.[RZ#BY)
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M?.V"!4-(\7B(VZLD><E(+%V2)B*KP#M-CY!=_1^E?E2U1/>.X<Z7@[N5:_;
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MV,<"2O]UGI[2^@,(OG@N][K^*57QM9C'Q'?J_MT?P,L?0S<3Z?>$/-/Y;7\
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MVL?E'0_/I+4GP5]#>I5'C&K21CP?L$[R"#Y&3+,TGIF(NF__ 92(O+O(C=@
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MVB8#P:"83QON^4_U<:",,O8+4\7W8>0A&5ZK-9<[U0OK+X.@ZX3;LLO5Z7\
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M4"?'3AA,$;X081^%W5]?S&3N@OG(Z@MW2PFN.?L']L3HAPMH]E+=B=-HK0O
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MJVH%28HJM4>\W;D1:(DZG8$9;07A3:,.D*["YJP/@($KU],(\!UC\^3"\<Z
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M23[S*,3&DK;;?]NI([MDOEB.Y$-;3F"?7,J"4[>P1$>*IJAX@;25X[V&R[5
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M9(DX>GQ 2''VI>'&U1:G4T:;#:KY<<^7)4K1X]>W\"=FQ45[*M6B\P%O65/
M@@E2GAM<MP\ :?3-QYR$__G_$L5Y1NQ*F/8.2[3D^:Y5%7=7%%.R)_G2E)Z\
M,"*;)3][3=REZP9"N0UM&5UPR@63C[K%2W8-7S,HO'E"**?SF '$+R<O4<3
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M7<EG<\P^IUK0\=UW3S%E\A<AG0T+RH[;;!,*6"JN%(EUV]TWQU?(NZ",V]&
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M"<&D7Q6AK:%0CF)]3)GJ.9'T)/TJY_TQ:I%D/L_MH9^D)L)V.,H*"HPM\^%
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MQ*K<N1#( BV:HUVZU4,B$0YKJ[MZ1G7L$T(=+3NCC'^SIP>54;:RGOH$@]K
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M>]K;.;@(>8K2GBH70MZ?L#EHP:<BKK:BM)(G$V!=%36PM"/" LS+SLT&YX1
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M\)Q3ED>#U9[GF6 )T($C[H< 7;?IA.(:C%KHD*]*N136'0^=_]6-;9=")Z-
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MJRC!##DC[LL[X$BONKLVZ,(2B*L[RZT?GV'2+;\3[Q[7*Z@;?PY[3%;UT+E
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M3T;&QX"X7I$>;^5C@.EG_>?O&SQ4.8X(Q#*,]Q6:_8X!H>L7IWV/ <U3U<>
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MXZ2D4#J!R&Z\C0^(I]1\8WN1QJ$E9P-V\DXM<ZGY-1Y&J7!Y2_;;Q\'N7GM
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MI7,$=O-T2"><B.AG1&U7-=11#I=?XN*R=?X,GI9_6=O!C_S)2!Q9C1_+JL-
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MY%&7:SC7E8XLS^N6\XT[](TS<S&]@EJH7=UY)C1#14JB%M15UM)W(NTK,3Q
M Z:115\?)P<1J-U!8?-?*,_A[PO4RZ: =^:$T+ZY[Y^]XQNBFR'/9/ 34"9=
M JK$8-TE#<*DV2QNM _?%1U,-P H+\9%&%%<1?HPN>;FV/[XO,OCQ/%8[D3C
MDDK!=4==O[XO1\*TI7S/CR$!W8(&AO-Q.'"#6,1*2/A(Y1THTLD0L(;\_)^.
M FW2 P_6/%OX7PX[!T*VMETZD7TI/"9VFYQPQ$LGI 97/:;^--U,_/1"*+Z
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M"TA]<+8UE)@TZ(U:H,S9V,K!/]CP*4IU7'K9H%>U[V]&^PDG<V+IPF&/RQ8
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M0PF9-   9$0 0 2 *@D87 4]S2>'M-V8#UM>Q&I:L %KS1'8$ "!3B@%9[V
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M.Z$)TMCI?!\1!+4IYFF;($',KFPM)BG8+&^H[!(6%&LKLI3M9H#+%HXQVY&
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MMB'WCLTCVFLU5A?0<J&N74.:P&V=F)Z>=&U,:>I$]G__?^[_]*B>Z_[P]QV
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M^5IKFH=)0=;T*G[/$LTE/0.(H4,SOCYIN WLMT!/HI?\$U;+ \1A.K!&SD'
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MQBG&*!&!#3XW@<TUAM<!>X8$7MGC^PF;QCI=;;2I8&OM'9.:(W#8?FL6G5(
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MJ"5I9_:ERD_Y&$-0XO-O:P4RE]PHW]51K)(L6_>*=N#ZZROOB-TJ9"D;$YJ
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M7W_%OWYXX>Y<2OG1("^DZ;,'2OAEAUGKG[T6V$V*0K0/.6[91\G+SK__^P5
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MN85R=3&717;,*"@&J[[\(':0:%$T1R:[ Q@N%FA;"3VE6WUN6UUZF,V-'4Z
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MK+6]*6NFNR],@TLKT&/B^](V]KK)J7&#9LPIY]40?A Z769$YSBT'MW.URY
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MN5QO;VX-'_>?&(#YBD.@+L2+-PU$A&W>E].=(4G-O_473XZ.R^\G'N2JY.+
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M0F1T;,*O%8J\DG2V^+VO]S?4<R?V+>F*\)=K'QYKO<N[4/VL[68!72'1H;P
M\SB, 5NT%K-V9MX$7]\EYS>XS[V[Y;N_MJO?S: <=I1)'X UZ-/[9/D'P*VR
MJO[[-=7L[HL+]/$1J;RVR FTOQB YEQ DVSL/T<2)39LRGP\85ATQ(<CDJI
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MCXX; ^!93'5OY"G45&^N#HDO=Z&$'6??]"[MOX9Z_;OUEGO'@/T "*N+NWT
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M$NF@X>7_!*1)>ZI^W_(^KO0!P"[^ /!FMT%?Z][QWK*KW_$_/TUM?MY;U?D
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M\B.7&*3SN0IG=W%NM8S&G2+_&?,C2R-G@V5C^!C-ZYB._F*ZW(;9Z!2]7?Q
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MO"P:K@>JF;N=20.EJ&N5M[)]KB\**@$F^[VFE.9WW"K%N^DVLP:?]M!(%+J
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M[BW])L=I&ZM6@[6?:4A6U0!GLN*12#<PG38/+ZUQ@15Q> H98?GW]]59:#K
MAAI7V,<W5)1/Z7)5T5?:9#[]9/=;J.,(FL7]T7I/R<J4>7-  ^UMVX2.P=9*
M%NDR^V0(2@;_N&G=9+WAEJ)\],F\V0B.:L42RV ),IMSH)6Y?5H$<XV32+PS
MRX9W_$I:,Y2W8<@M*TNJ,A\I=EB*:PX/\5&O&";2?!!&=%@X<WT^A!H7F2(
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MP]QK(\ M]/4VH1YB"G*UL2WM(<^2DMO::";6MC2=?0;DN]*[I4YS" [Y0AE
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MO]8U>7B_^2C]UE\VN(>IL#NB8.O%U#9)&NT-1X/WMZOQ]V_+XL8\1/AM_=W
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MS'NF):/BZ'^+E;##Q11.X9[L@%#H%@\RFSWPX:%J7$I7A6:/%'S)MERM,Q)
M\8;W^VA"5VKG0%I*/L-0DX-\DR=GAN38+.YTBM08^P).^3D(6*J)AI9F+BTC
ML7NP>:%6N_:F$9:_-SE?U<[7#6V$N=S9>5BZ2<K1+)\)VX^4-Z$&KTV'L-?$
MU)6,,&KS=_;!V#@/!]DLWIZ#'U203,Z!FQ7HEYZMD$6#/N1FJ*AC3C]BS6.U
M%^F<&+(/O3@%"@N\8+C6I(]U"//E44NF_B PV03X\B69(8KXA?=W-IQQXZ7
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MWNZ3E :)#8D03E-O(T8FX%T7XQ*94XM)KH 696<7EV\9_]=U^^PT 5B5+DQ
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M=%6?2XT :FQF@(F"[FD\@/H@5H@D2*L"ZG5_2(.,*1<X,:>*<'?VT_'M[!_
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MJ+I1F)A>;.3GV;(IEF#=CHE@JU^R.]Q(7T'SBC-%I[?CG6*'C+.CY5(W%DK
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M9Z%ZZI&W.?EH%PH_11EK\-*>CH8J,#!CDP&&K 2SA P5+V8V<I1^BZA!O=K
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M\1PF.^5$56*U*(&'#$M<S#1EA(.=3I9OQJ@5:AE8*'9 -!A#G0GO12P @5*
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M)P=KA7ZTQ4X[,6A7&G<4=;Z#GR@5(C',ZWHOAIF4YN+2&=(4"!^KJF'BNJ_
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MM5RYC=AA>^EK%Q_*92VE?PA@MI:8D'&915Q:AMV!N:5*ZJJP#Y-,<G)S$+5
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M<0P^MJ)+DGRS^K>T;U6P4](,R&/C3CP5C/CA8"Z,&"E[.GS:0N-;>+YJ2Y_
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M^5\$Z>ZJW3RD:PRD;[YPL20X 6E#V]M)AI9'Q(5/X1PM[^N%+NX!WEW#O*\
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M=1E/+0NJ!$43E44T,)33/$<5V^/++F"=,<O$:G0O<0B['FR* 4JOH >)N:9
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M.%(B?W&H*ZU_;AA-^:*]].VWP3_ #E+I^UU_S'\ 28I17HN(WO7:P;\@FW\
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M.NBQ7\PR\YGY?98!^@,GG-!ZJN+NL$J/]#?75%[R#E2"K]%%9U)JL4U.P^F
M2)5)L&::TO(E"ZXX< _XC\:J4O*UHR2:1 >%I2_BD%ZE'6[/I^8VT3R=\>#+
M'^?2498=;/F98*[0U$8TK*IQZ:?O_J9-S#J=S&Y0HRQK%G1R?H,B+6/[L#3;
ML%:GE'S]OT<(K>US2;J)%MCYV-@L;FX?>7QH,;IL74T-AKZE>QI(1R;-..F>
MH__^[. :A'%[7K&NWKH6WY?.-_.H,NW56D;4?L/DTD11UG[@#Q==UU#='G<8
MGW^T#^"0SYN>'X=8+X>]E$GZ]1,RW11L82<L-D']:8E7-JIX1%E3IX%*=TTM
MI>3\_P N/HPQ3!R<8-DZ_XBBZQD9&[@8?M 7+>K.'+RE1)_';]\4]5V$!U0N
MG_Z@!C?I)/#^7":2CXI&X6=C/1[EI1VE@YBFP)E\/#2,4"OD,;$C4[ I!XR"
M'5K=R@DNT[./5Q'#.I-#-X*5P*D1#CJZN6@6[T$)1^41CV*,7FTG6_<(EX07
M2X)S%+V5IA_I6V== 1W5QJYG+$H[XD8+>V_5!K:IS#!:X^3?JLWY);]O%,\T
M2B8\;&]JR+0%&.E(9!+% L8@UR\B31]G4:Z7F#L?TA9(F*=ZLL?TVI%!A/36
M,1HRDF(0+.8"1E/ @R32WP;OSVS;UG[I&[R^X5"I38ZE= *IN)[!,J*C&C=B
MN!2X!#I!3;^AEYW E&4L+RK"I96Z2%S)* UPE5<>S@I*I#S?PAKPNI1Q14RC
M&G"IT]XHL32I>0SM';A16Y=45U@E@16U*^/NDF1<0C"9T_P3Y?:JI&+/TWH[
MYXUY%[TL)M6<JR9X_0?2*5/DY'E,T!</";@."=")_8>LQOM\S>Z..WS;05;M
M6%5@X@9C(R2K^O:;CWBN*T>][5=:&VV\,MRSP/,9YGAKM:@C!=J*F!Y2+^J0
M:29 U1I*NY7FEP^$&IW/HY4[6GA),9PA9IOFKJJ%&FA8XBUJ&0-,\Z-+ U<S
M.F-9A6,'5W? O(X?5ESK.(N[5H ;"W0C5*K':\*]VC(KZXAI%1IL&>4- <%&
MHN?3DMRQ>9';8L[/3X)-O(.@T:0^C!, [E])&7H7O_+_]=_ )\(7BIXT8Y?3
M;D3\9[>)T1[;IN6F%L!B$R2$JUH0Q][=C2[Y,2N(C)-S4#H.1!C+TH,L7^*#
MK4;<?_Q1M4MG89]=A'(Q77*CJ&L7@%<5T'K$3"?6!VD\Q;*WES0UQI[._!.@
M=W!+7_SSY'0%XM7;ZDVK5S%_N)RRR7J4\T[4/*^<P[^U]'50TFBTFH.$!?-+
M,1*F+'V?I>@(U\*7C4^UB!N0S8:P%-5&T0<TE6Y)Q&&@CC+6/3"_Y/#NJ\SH
MRB<LD0A7W]^1T;]W/C<R,CS"O^^_GF*< J@BV!LP% #L?0 L\QG_NIYR:LCL
M!Q_;]^;GQFD](%$KFVCA/T&,##(#)Z/>X/1HN-0&T6.8ZG=S I6PY$1Z;!=:
MH:HA'<$)_+?/T,V3[;>KQ4;X"SZC?,^9\S).+%_V1X(S$^X3]"<)\9TC$5S=
MRMW:ZQ5(FUL9J6-]F1<#,;;Y0^T7Z_W$W7%(QQZH3AG>&*KJ&1OB-A"'B>-'
MF[V14N"#5<S@?+X;TPVB%!V#P<7F(V&W!#53+,/;MZ-!KJXGA,:3J01H2=IT
MOQS7SUR6TWN4^JQ)I\4!]GE]SQUO ,EP%88!!B [%>@7 8Y;_OR J8?6QJ[6
MD=9FYWG9]EFJ=_I0@6V0*F6A#F,0G]&27:R)WXWWK2XK\Q5_*<32:258/AH7
MR/,)WE[$UC+5)ESY22</Y=-*%*.&<W2['E ^S@$>KUR(%-#3PD,)))UB&M=A
M<J9]C>$[F[F@Y'[IV<-XQP<@UUXU_CSFRIH6OJ$NM$6%O>+_VE8U<E+NQ"E=
MRQV,T<*DDWN(QL\ O)"8?34NT/],&4!@<(I!?>9BW"D:PF[6CD@C AM$OE!7
M$.Q+3YU[AMX]A*%"9&O'C5!;]_KP"2"&%1.IJJ!N,S+[XWWNZ^=L$^-\P]P!
M,TU@,F'96R=";DC) 69YNB 7I7;$!ZF5GS+MKIM/U[3&0]JN[IOI6QEXS/R;
MV7Y#C+4;FI@)W>Z-F#I 1L:H87,;"V5BTK]&YENO'\.>>Q*__ .\=7ECV2WY
M@I8X4_KTT/VB>O-NU^<_1JWY[/=([!V['7:NF^\%1^XNTN >).*JWP!D:0&X
M,967\+"B5E!3W.."^ED,,E\P0..*Z5+]^WA]W5(RR%R<2@S\&P&54LR9_(<^
M"7;,4T2+.KV%%NAV=F1ME)/(*&4'?+9 2_Y(0UG%3\=@LU^5=$(MRV^L*A%G
MG4US)O.G9.FDR&Q\!M/!F4[0*EONJ#P")9F1,/3<U&*]* X"7@#OX7>B8DQY
MB0-:3[<JC@\=ZA]:3!#EP;:G.%$EMKC2IY3ACT&G^.#NO%YH9?,/?\0R[?=&
M^LWVK9*4)*0T+HU;K@8=V0YLT!(QV9\@4>I.L^85-@W!E?\Y2DJ:-6G*X9N/
MC9%EF2%.Z+0^PO_V+.: 72L,=#GCGH3VL-G<S/BR&!EW(GD]X_=N#AKQN3K.
M*24M(O!-#^7SPH_VI;S(Y_Y=W9TMB>8ZT/#@TBO/$U_'FR8?\]A$! T;$)8\
MB#[:LRPK$'$(C\] >?,->(*2(1<(,_?JL4=N758Y<>PT?RG0T9^PA*YT7\7Q
MM[0NM72\K_9L@O#$&F"^JOS<GZN=UN5$FS;P#S&2)3'.WI06'E*L\@:II #L
MO?S]IVN_QL9#!Q;I,CS7R]ODQ>2):Z\:_4T;J\.)^<?UU2/P+^62*I!#J\Z#
M]R<2H68HQW*TN(FYP=N[WER/S*6M"K:7\:_H!8?:V6QF8H&&I-Z2#89:Q>1'
M \^.+F;AO'-*V\87%<8D5/Y3R0MF?H^^S %0&GEKAHBWGLE1</(""QN\UMOP
MC1R#=1N/&.B@U[ZI:?Q54Z2S2JJW<'M./M#?@!Z3.9HK_).)/=QIP[+[*B%%
M0L4XB)&<MS '-=U:(L(CX+;B)K88=07$OJE',3*IZZ6&HT4Z5UWVF//,_5>5
M.G4 QL/5-'%M3N!L:4F:91R+'-V!=7LTC;DU]LF+QB.9;=!Z&6GB/;UA.EW:
MXU75XX%#  U\I9QD)<;(!:I.O1'B ]<FOKL7P");IR+)\IPIF%PCFIWJE[6I
MPT*E/]B[#W@Z<]%(2GQ(J&MQ2?UJS:2LG*X3_>-40!K"U:&&KHT%T]ZDB;?_
MY1HIJG]I</'L'JV?8M(# IH$RP[H@D"E*B2Y,96F\45M7=^6\=<%!,5#H0B:
M54<<WIG8+/O?DN6F'MKQH1PM4?H#*=1\ \E!X<=OI4XRO5R(]JXLXY*7\/\!
M+E;U+;RRO5I;(38-:=<3AO!Q_<_UB?X< C59U=7!>GZ2&/$L?!-R)!_\7G30
MM&,_9[6D3)F;$)Y[-CICBA9PT/AB=*9)U@FJ^'?30/.JIGC7MPXV"MI8JIB4
M751DA_FU2'(B4A-D2XLI9=NM40@CD&D++7?W?*,&+3\E3\?9>I_M?/4QU_BC
MJ,;S(6A[XQZ]HB3MZ"&'I/2PS:[,?9+VN4XJ3R]: NW<<C. OZ-5"!P6W&G
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M$5>X!U^?(F"+,/\5EZL<OW"U>VZX,I!7V4.-.,V9T5Y[JN 7Q)- , $))P0
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MPLCH!\B6M"&EH@AC4LCM#-#5L"YM:B6J&^67!F62M0>]8%+O -PYXAQL3(D
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M)LE#N@3.3^WK3ING$(.?)82KRT;FCGV'@L;';K2C<5LU:"3QTJ_P70@L8GR
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M<$=M[U/<MN>IM[[H8+D$0FGHQ,J2S0+!8G4F%WC26&1X[$9DCYXEYUS/V1)
M5D;)Y<@G ."<'(!Z@'!P0<=^K-WCJ9)*4KR'6NDM.E[EKV73&4UN=)Z8E,@D
M"&*V3#&MA>W^#R0$GB,.5"<2F>2-3FW/<=3R"&OJ$TQ2QR9Q**R+-]MV]1;A
M9L4S3OT;,$$%H17X8XFFJV'ECCL1=C-.O(9(71HY6CG1@!)"N=2LA4!LJP)(
MRI)P1UP<@=>OS:BGS,ZDTXTTXTTXTTXTTXTTXTTXTTXTTXTUNE_!>-/HI.J+
MV>N^S8P6],DRLJ#5[# +RS"P '6<??GF2."(>,A\<A8?9C6WF&![2PJ64\K
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M1:Z"L2$V6Y .[@<FG"L&(ZL8- (#<PT!O+&%:K48J^RSLZDS3#K4KY/U=T.
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M=?T1H[[,W''WG&1_I=_Z1$I?79IF$X<3OCW9C>R;=>]??SSSAS;DC,87"G_
MR6OBZ",@8ALK+U!GFOJSWMF4*-X^M=LO:F3]_#/Y42H[CGF9Q$$]]L6LRB#/
MK4>NL>G@MUN+-S4^ZMA[2!\D,(2#;"Q=>'K]V&M:S!,O S!*6:@89CDCRTOC
MG9&QQ*%7FL_@.^GU)HR8Z(U:F2:('3/0 6,9")1V[SO[J^+!6<L@-Z3PSAF-
MCOOPWC.$<\'6)@6D@Z\P\U2/L=BTC9WT\ E?)I -F-S/'SI@[=6C9'W?T6P>
M&Z)#IMIXW8Q5);*"$D%\Q+L=CHIMQVB1EU,&U(V8D3]68J!)IY\J?9#^^_8R
M.?B&R*4FWLPMC-WG@DRO)RS M1;-1!*^>/1:*[0.[V#];1VJBW\++!3M#"'J
MR#[3L:N?=S"@G\VV.0&D$CN)6=@456K+G+$@+' ^"5H$0LFQ!U0E>6H/$SC4
M:K2V*X,7&4QP]HZU5#6,SJ,GVV518MS-Y>/J%@W/\21LQ!>U;L!Z?\]K,,TE
MUSJ$C:W:%'"7[5.DTIJ*9@&TIYQT)EUFK%L]QMH]#@X>'HQ2T16;[>?<>ZA\
M8\>'**  7]EPSIS-AM'?X1VTNUV<TS;7L6:W!G"\!,)4+3I))H.TDOV$A,2O
MSM]ZF4XK)+T;\9*2V5W][3 \/W^B9KN8/);>OMLL7BA7S;;XW>6I>#RI6-JY
ML-A8ZXG^H,*T1^5<Z\B[\I$:Y6#0UL3&.<8;8VPX.EC82:-NI,I8DA-+*PSY
M+#G[QRQM7UR]ML \W:S6O(LZ<?H+<6CAPL:L:1]Z2IK'PD#YI :QY*, R@/?
MY<)'REN G;C,;2GE6N>NHB_M_W!PY\?&(G7B-K6-VQI7)5#E>:1X*W^ND6=#
M[ZQ:R$*#;X.GSEXC>T<C+TZH]7=Z[#1CS* \X[]D348Y=JIBNKD KB(X@?(=
M=X<()$ Q5K/P>5-(#C&IU?V5I5/XM'=?MZQ\GF+G6HMF8BE"*D(>I(SL#T!>
M'QX&/IS WZ>:8-8!Z/CZE +\B: M>2*;=B'T5,$RPRKO/XV_MYS\:;'OV3X/
MJQ?4WEOGR=S[#\FLP8410H&.+SAV_])5Y7CV?CY5]Z)]K.T,8WC,](--4 XE
MQB;0NDV.\BO$ K)[X6!SU1<Z R?+\6ZL4#LW6D[6;9VE?#^O)8[R[IN#N%25
M59RV;53&Q1K>$W-35<GG]>&27D9,RT#-=M(^S0\?NEET"I-T/6)(;R3%8XV?
MVRM.'!M9QYDU"N7PU;$RU,V.I\Y_?)%Z'1PD"6$RW&"S]WTW/+Y]V$,U]C#A
M'W+G/P!P-3MX7O\:W+]VJ2!WL\FMH=<17Y9J"+?)96FF4G8"*Z?I)4Q@*/#B
M$M;)UZ.=<ERF8_JKQ'W5A:)_O>$O2JO=;_V-D3Y0OYJ'[=(X+6([Z!0:WVO0
M2CY^&S2?>H?L:9Y]6-N*;2=M\Y9G<$715>^M7W4-/5?;Q)L6IF.M)HNWID9L
MJITJS>2 \9M*#U"KK'22UWF)6?3U[60QA!FR&EWE9HBUOW*;_/:"WM8C*$PV
M=L:@>2+2(2!L8ZVM]89Q3-8O?%H=$JI2114Y#,Z#F9-L*=[8;E9\R26,KCGG
MHL;8.8+9!^P'/Q*UZ66_7Z_9X1;SNV\@NJ+[?#6ZG+<U9ZA6/AY8P\S*'':3
M.W;8W>38$T$AZF;ED)^M0@*MS @N=OVS47K;R*K(Z.+?1@P9:Q>HJ,Q?S2OO
M="2@CF;?<S\:;W'H;:7\E3DH9U,YS9BC691>[C42)E?+SCQ=<Z088SOR^A3X
M'Y*\MN+#;&9AUDONRWHR?U(L[\=7\?(NHXZ/QXX7Q$H<[TSB U!#;EA,R4J[
MC4YF8U7F4B)BT&SU%I>;]PM,B98J3N#=OWNO)N;7AB6)]W]ZJ1LW&)ZT/J^W
M^5Z=M&Z.\)TTM<U6TQ:9+1[,4')(IE[1.TD:'TA4C9FK,^0J63Z@M-((D!/.
MO\<1JHPS@'%.=H!K%7Q2;*3Z2H+QP>N.;U^L;/8X)MG?S>&1&,5'[="B==](
MA*ZVU=ZKDV.^\:26,@0ZGV\,&.&EZ M5^<NQ[XD]=EE 41$85,]96[7!K5'M
MF6T$2H4($PEU>OY!#X)/*;6ALOL\K( 6H]KO%3 4GA6F%IN*+!B/IV7NTR^;
M..O<P;- \\R)HPZ5 .\Z6\(DG8].49NE'!H:2P7KH<8UG^WM]'4%YF-T@H9U
MP\F:&Z6P[]$"3[ZB&OU=W3T0AHL4_EI+4)H:JM:7.XH4MM8AET <;S8"73:$
MZ]7Y4NM0(@%G4Q,I.*_7L;A<TZ[>Y!1GKR,;DT*P!>QGS9]N>;Y5'140XI@"
M8&[GA8$;N(NXH3[6X$Q ?F^N5<F::)$T ][ZW1@?:%F5-;\GR^FI_WAU]\#P
MR'#%V/37BIX)K)YJHZALVR)^%D.U[CB3Q/A'IQV^,?4=6Z-713SC&LV?>&@8
MD%7?LS*=-5ZMP7-:F..K62ZIF+(#"HZY51>./K0M85?HGL=[@D[WSW!.7J%S
MI"P F.!TNSP)++E$<A6"<ER$TX)Y"4PX=1T:K^><6$"&Z0F3[$QU2QMN@G?=
M-DUU1FRZ.+S5&>,Q'W4>7N=# #LA#;94EA?JA>3'4OL^+C9D(A4]=CZ/5@K2
M4&9.Q?/SD=,>&3):PEEUR"'@MD0O,O$YT,2[-[,H)"7(=;9-=Z=T*%9)8(!V
M0WUD+1X0_G-DJK6B5/>#)"\S9P6* 9IW/9(@'R4M:AGX Q%">B?%3VB'QW>]
M=[HF$Y5DN+ R1-?%E.3*ZN\E"F"4S,-&GH-<''P2+X8$UEURW!=FR:P?MH?J
M/Y(Y%AH7K4N<5LVTOG MRM_>?57$C\MSJ%7K$*MT*%0W<+7(9$$+ 1KE7NMR
MB!G]6&1&0TL@C<6)*[O@5KT]8Y2[I\,)^RP='!+AO+I+QMDMHEKUB]ENW.LF
M99KM-;_<6<^(TO$%.)?Z0R&; 179F5AUUMO'TTF_CWA2<6%<M&X(4/"P'[,H
MZ.KW_B9]9>?4J#"%MC!:NMN0>+J;,8,[?+^62UZ76'8@D9074_(GF4*.NP/:
M3\$N;0+S?.G]_Y#2%LO6C^"]X<I6OJQ1JU"NO/79QPO/O6>OI^N\B0>P9B$-
M2X83P!K&@9&L(BQ.JN\[-N)EY)Q=P0_"&P9@6P\U-O[8^WE;K-3-DY\3 $OP
MCS^Q]5X"M6C2NY[2")"P2S7$#DE[^Q$Q8%,=G@$)/L7C$<B$@B;#:@IA84*F
MZYW?7&!]/%!Z4>?#?0D38=HBVOCY2G?RDY4+-D3FD,X+C:]S2+P$FU3FYA2@
M>9M9-G ]I4KI9 8K6=^4I=\M37YCNE<W\MH$'3_V5Q_8Z3!;-QD8X()UGG)2
MPA=DG=ZN5:X8_C3W%RJB4,^U8.8I*ZWZ7<7K[C\DZ;>8/*U'J6\E"E&#)([.
M]FTJ_NL;YB[GF'@ 4B)(M:D<C3<PXPP,EH<-U54)M\#4M[^3D'<LLO78#7"H
M6%$:(Z0DB@)P2VG@XEX(<D3P6L/Z>3>KDX/C6C%'88 7P-J KW\L&5&05:C+
M2#]H./1@ZKNHC5R?H_SDY0 3:?L,"P@TJYK7\VCX_7MVP;FG,>Q#X%H#OU1
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MZ-P/!Y;EQ)\LVKBPO99-(O7;LXFZ\=,US,UO[5S?;KTCO>4$706(OV @X2Z
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M\WXC0E2BEGJ8#/62<SV4W 3=]G!SR'( 23/Q,^#RU@N\;&S6;@A_&*G"[MV
M+C:EZ_CPAD;6VA?"SNH*_KM)Q=,8^.X);@X*H25T52%ZL<^"4[G([#R]8HH2
MQT@UJ:)<SIIA,/^N!BJ?$HH^_*0*CGTJL>R).P-"'MT@5\8\JDDCS:,"75OY
M>\+3E-4.V=JF/;/ZHX]2<],U[THE9LM<)2?)8%-H3YGH\Y37+G<^35&XS^43
MITS3U$XRLK=(G+:(KU8$HSP]QQ_/_:6&!RNH_U!\O)A[&T5C"8GEUHB%A/>0
M$VAQS-R%:=&9F623=&EMG/D*@,XM19"?M5BXQL'/681&G4RTI/T=!FSR,54?
M1]1DV#BI>YU7SDR^T2IGI5L[>2HA7_J03KW^C>8C>V4U"T5*LZ.O69],1^5$
M@#R8ZRSP;QYBG@TU=BZ:13*XL0<3TS)"GVXV*_8:[/.V.T%3/''M9,NAQR'4
M3 R2%(\NT*K06%CEL.U<RL XO<B&7'C%XF(TS4,\"@U*'NWG5YT[98]=X>DV
ML:^3#4/""CZQR8N(8>8_X7\?J)^!)')V:K7?[#9R1 "&.P,JY?4FA#CIZ.6_
MQJ9SA7Y-/DMS]W@C4H3*KEGUAYDZOQ)Y'][P:MP>FT%SPSRJ(PQ9O=87$/M-
M@O_>O(&6LAUA'>SM*4Y+5'#_G5&DJ&[2\^8UFX4"=FU-5Y-3-]W#Y[RN6\XJ
M4 $2=_)B:J"HDBL,.5G0#,;QRZG,?0I2M$D9R<?P9W%*XJ/X:"A-B2O8]DY!
M=3^XH6SOJG$"IA_N\ NKYFS>)((DY3%8^J5;49U>!OR^<EU?V K+ET(VP(;U
M0W*%G*>QX'6U_EY0!9!C(1" &[\9YY(W.Q(Q$K*MEM5%;6T6I]4[;LH]*@,,
M@Z+%?^H.,O8?1 <$@U#=@>F8H&N!3H'$5;P,DA5"- B*K 4 E#^U%@3P0&CJ
M?QGTR=MAX6T^WDHJ5'JRW9D.-M[D5#3-SW$HI<1S]>O"5.[3[ZPJOG9+%Y I
MT(R,6R^PC#Z2)X()V,<V)Q+B3+46?34LC>P0Z,P;S7.\^=: K-9O=*L_&%Y6
MU(/-L/08]<#L)V%1&$G;C5A5*V%LRE:FO.B*_8?K<N@(N9!^3 X&U:$8P;NO
M8_"]XF15W-_@%XD\'F<)C[:;?(ZYA1">+GBWC?E$CSYL@$1C['KQ<6&B;!$V
M\5$S<7-T=;J!S;<*YH$C\&QVH6Q#,:5-ME)8%D*RBD+6C$^[5L@IV7J9:2FN
M87$Y[RZ7-MD^ZD#_A8VL;I=IK9K.GG;L,^/,F$=!ZCTL1UQ@A?(\3Y>8\H?^
M;QTEOBJD^PE^.![3!"KG>34Y-J&:<)T%=KV:7D[I/GBQ9>5:.ZR[T^\\6Y*P
M/5:UX(H+%(05V"!83DC\_;_';J%;.>$7']V3F[%(^M)-_%::&*G,1C2_)5L.
MX]:P-9BUFZNQ;_-2<7B5E!C;*)FXB_G9=4_?-ORA6EFI:90  ]L&9#_.E)/#
M%0:3T5055Y70R%A^BP8YV5G>'%G4F'4?1<]_/37&7G!Y' )"462E\MP"C*"I
M43$SL_(5:\<X';;1/%5]M%3V^L*Z?AP45J/Q D?LDO'TT).-3!R35/RZIG(G
MU^ZSW(S!>3%(@S\,;J_7$#6@=&V9/%9A$V R7YE+G$(J@5VJ# )ZMM^-1;_
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M5&,\/4C^EGT<^-#0FLC\YL;^ JJJJBZE[HZ0X%TEI<=R<=555=4Y=+@NMLY
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MVC/K1F3O41^62_R]2+0E)O[N2,([$>&4^!UMZ;+M(V=ZU,/NCH"C'F$G9XV
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ML1@[DCM[ N.S$)[@N]][TG_F8%BZ,%8-E=OS3E"6BP7K.?3J3E7^U0O%_]*
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M]S%2%KKQL)_0N_MN#\)=TC?##JG/:QQSQO/+#]RQ9%IQ'S?,>E^O]/)QH"7
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MY#^;>CC,AL._B]T<W *0MX"H?J?#T$X?MJGO@4_V9MR(O)<N]7;.?5ZFC/[
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M("<)AGX":P5W@5DC_F%= I$"W]T\2>:?$@GP#QD'D/^1F=_<T/^1>*=#P$9
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M4A\$LP:?C%H!8HE R)X^7B;I:&US&L>_RO^B_^T9#$N((ASH<K*<U11E75S
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MO4/C>(@1^&YNIG&\]X!HB$BGP#OU[3%@MO]0H/'PILS1]4:H3"(T</N%W3%
M:[3F_8 LV_OJN.MW:(33.LJ&ZM+6/GI9#*VNMJ>C/';:Y2L:2R@R:TBTUT&
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MF4?2E0_8PR1N^4XV2/ X3<PU$KK:!D@G.XT\AJ]OS>1,A;%L]6Y*)MN&<[L
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M6\W!65NQC1TQ5 ,W##[D!6?%C%S5PF->ZKM&R,)R3XVI[27XM8-?:1(54GH
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M*A0(&Y!O%("E#.4!8YJR[ME^J@1*R!@^E)Z>GF7-O!S"GW:E=R; ,3HFD\K
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MU&(\;JW.7K'4+\'#_$K?7*L#(PF'4[IHMDG9'D%FQ-V9T)PWZ\F!?)@\4OF
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M3@P M]LGN;)F=7Z8%7"WX7^LL 7EQ+#C&IU5X*>[!+U=)%]+<8K=*01PD]G
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M3)H;H+:\^ZNY7,:B?Y:B,2ZHW'PGUF9V_=6_KQE^NUC!AGF?.[L+ZIW;W..
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MT\W&;+_K^]E'F#]C%08Q:>+QFU^.HTQ,VE^OQ+Q[.,JK%OXMK]+7\GZEE?!
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MBN?UWV[0N)&BM4-BE!Y[\7[J5RJ)>:4'1$2E3$WW2,'8HGXV:S)IV$D7:E7
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M8K1^X+UGW.KYV9)SXGN7]]>>L%+:]LI[KQ-?SPTX@B;&ZT]Y.?X>]>^<_+\
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M7V]GXZ75I0W4+HOFGOQ,>'(X]4DH]EAK\&$Z)_E@&E=*O@\7LBM-#C1;F_H
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MH&"2\H"?NU&$R<@F-)^++(+5<E'6[632G@X=B0M1JV@BG95 CKTI0XH4#D$
MG8==L^TZP<ZAF!D1*: 6XE9]=>11M \LJHS67H0\NFM2J>0.FS?E]N4V=&SI
M@-U84?=L!_ZN+(G#<5)AUICV^NZ.]_*: BVUC* *;8FVX#?$PXF :%U\96WX
M-5(.9-O$%(%M!G3=70776QCEOZ>^%9FS1[S6QP3+*Z:EYBF_RF=%O2?0KE%I
M.!TY<1BLQI0T@:)_^*JI[-N[G_Y#K36J/O%[]08UFPTW:4OY[H?149LC!4Q,
M_/QX ;!VT9;;R@B47E"&TA(6?0!XY?OH/+7BW*V?'2C8<O"N%?@5U#)#+*^>
M.M:OSKNM*8Z2P9>:)/1F9T3B'U8M1E!Q9A!4(N ?6)%N:]L5]@:X&FAZ6.$B
M\H2M[P1+#%U-D'B;$/!M% 66]?!>9_SQ81F@\Q1/-&SQ6T,:AFIZ:H:Z@8F"
M=S,=1(X5"9605P0W);9)WB1L ^\?K5(3D1O+,(>]W&>[&[S8.[Y5%F'?0%Y"
M8).*5Z-#0LQO@M3V\_B">-.+Q3&DV,WS<Q+D=:=IEQ)%G$]WX);SXW'<VW/U
M.9)GX3%YU>AT["+/D<JP,BQYT1"=S-,;E5&)57U#.1,P2 0Y.)90^)'NT6;;
MSJ#*Z/_E/B"_X_V(- "YM-,F^4]S_*^3FG3_/:E9NC Z\;@Q:FYDS/--1,(.
M8=0IGVG?R1>TX%I*PX:1<2^J6\Y>W6-"6U4#UD/4IA=&2G3I1NH0>I;K@@I-
MQ][Q<;BJ:A-9JQ8/?_W._W67:7-V1\:%U?*-0H%(GH$&)S1L!M.ZXP%ZFAK_
MW>Z+5S48'6RK3MCZ+)VZJNE>O"0Y]JDE-@'.PH$CTJ"0%?Y#4D$]: S0'T'N
M^+2#;:^M2+%-)01?U;K=J'9(ZCUMG^S9<J7BL6"R@D2W59KX^Y<='FG"LG/4
MJ.-E4B3VFN>$;Q134L4W&4B:19IIV!8%#%UX#KW#WHR8JJ]^YB$@PN9N&,=E
MA*RY'/!N+\[%M-'80F=*%E?=](E9%T:+6FYL)19/..M2FHXWWMY&_(2Q@O4S
M3&R@FEA"?$VA(!LU02P2@]&2V[\ JI\]\XP$NCXOKQ3'78;@RW23CE43CMP/
M;K+IOGZPUQ,1^J](BU6P M0)#6FTBQWD>.I\!L;H4&A$7O0>6WV>4/[8=G^"
M=(D?/#@)D;+-7.S7;TS_UB&]^,G1_/8AI3;=60B1=EK3E_2+:/?%)OG"+-DN
M&9H0HZGB_%DE0I-B5LV-6S)@A2U'F\SYM.DD_T96FN1%1"8A560JXZ?67B'>
MY+5Y<00RX0ZBU! -5/O:IR(QWBN7+)=1-6G$;O/L1:2P6^4F:=%.M)[U!&IC
MM3!%/'@MW?8:;4Q!7TB,?Y14&IC<+#4IV(0(JTN6J$I+, M7AD:8($]I5,E(
M!(51J_OBBA_LE3\?/1^#Y8UVG*0/*3VF.BU#VVA)*K8(!<>WM1.AJJ?MV.[U
MDN%KF1&J+N;[[6WA ?1.R"G@)$S](.?\#Z@WDR@Q$$T=>4%3/=/Y*+3>/?EZ
M2H/=:V\<C,P'L%K/$L@412?%IE+NM7QP?YE"W:XU#M"20E=$-N.CA?I@I 8O
MF_J(J\)-]0=&N(=5X E"Q,M;T^K>>:D[^FJ)NL,&>NFMEH=1G60ZF]EB@5V:
M(%93NW&^\CK*2\2HA:+E5GD_-_^M5@/J>#&(T:)Z,/\-XA9*1BD8R;!,Q)4C
M*W,,Z3O=RGT%.WCQTF!H#:<AY/FYA8 4!U&/J32TW^8(X$89/AG1I8YLPV2(
M(T\JC1*$2C.>46NT+C4[Q/H,]#.SV(FC,(DQGU9L2<'ERZ+L)J,+ZEI2B71Q
M-S2T9&(U[H*W0MY'$J6MY2T&UR[N,'6]XO&]WE@Y2[ :$6$V;ZNHY/:US'+P
M1 L7XY=H/AF+!)>BJ7**!#F&M[B3>%C]K=@G9*F+^[S1!$>[%_<NQ0SNM&#M
M]5,^UV$*UWO;E>A7.FV66O5/6!3J3;A5!JZIHO4*/],MMB+H(M\+HP46\W[O
MQZ1U\TJKJQ<J$C1P">GGL-G&6$K-4<N57(%>3(/#ED@G;=H,O>\_/19LU#.E
MI*^K5)]"ZK76(_$P[.!M00CK=.ET\P1UDA:Y[=)"[?VQC*86G4:+&EP,TXGS
MV/)EH9S:6B5104US/.6)$SV-]RPM$[F%W.6N1LL;KKSB;>4GO6XR_1+WM[$>
MMY!=^C$TLH^$2DR-F99OAV(*V"\,FZ!9'Y>^@E<76'D:%6G?)\5%3=9BP6>5
M./8@Y6M[2F?.VDV-7E'-_II3\<II/:(#ZGM*:>U59RF:TL.\.V@?6<P2AW:+
M6;6;V\^:NU7A2?N0_8P07<$58?2/RE*_/W[4-A.CAB%:YZ#CB]?%I])=2X2I
MQM[,.-(=8/U"OI1!1G'QOC=ZQ(E=A%TDEPEL)A$C^&"'M&]%JK[LBIO)@ECW
MLYHE[Q8Q$8[!:M-?X](^LII[/S_!;D_F8K1^=!52N9=EUC0Y-*#LMQ@)&.LE
M]?4"QKEC!!1C*QA&&5T>)[0GW,.I/G;W<-/#[*FN,4X& R<#4O)5MY<!A%X*
M &6A"!0A5T;G*6]5.+)/XVZQ;>4&VFOGWH.Y1_M!J*KF:8C8RIDCP9.F^S-E
MA)0.#^\X2?TXN=DT6X81PU[.'E4BG:/8>[ 4?,\>EVV4_3L9.>(I>#]/\/;@
M;H[>:"Q",+9OFS]DR>KZL-O?0YN?.JD%H;A:SUQ:"53-'#W>MHR88IB8&)O7
MQKO'<>O=O"-!8K5"-?D$M7"EY-NF>5U)W87;X;Q$<5;BOND+L?7Y-MU21G8]
MH(V0=]#=%:KXG+9/A5Y4Y#Z>3UC$<;9$7++M5:@[%5B7P\]G8N\67+LN:FWP
M7!=Q$&ZH%<62Z&[H5OT#:=I85IOGG@92XG5O-NSMW>76Z,23S"$V>[H,TM?Z
MM,3IE2'^\53"J.2?7!-BA(H^^4 GW"A1&#);64TS5L=1"]EF);0$AR4841QY
MWE(SY*.E :SNL>]^)S-3]]#X=7F];ZE<]T28=J\063>_;5JYZ\,M-3[QZEY@
M_B 2@BCFRE#Z2A.C,(_(5P6%<0X%;"%'*^@!+4M,U8#BZ3=:A5:Z%R%FFORO
M^"!3L-*S?;<2964XQA6-6?>".EM9^7^V(_[_7PL<)44BC/X"T-;%Y/X"OE=T
MU=[=D< BLW""6GO)P:.*U<"P8G\U%@-DZ_19;;YL8C\.S3!(P[PH7^J5CJXO
MP[H4#&/FC?K\&I[Q?(3M\I-R;;"0,U!1*;IX]N(DOCV&5S\Y8-:<(Z-^NV?C
MQ)&)A2N!D^]Z?;LUF;0TL2"Y*I_<_)9^KF%US:X]M:D<BY4#K:ZUD(4D-O<\
MTE*Z1UVC(WL^7[\,K0H\,.NHZ>[$?EO1*NS,+@OR3$OND$KI'459_0JRTZXR
M'IRI[TW4ZNBWLX"N4NGD%->(E)5A2S=+(C,-9.@:K P'Q)_R?Y)NH-.0,P^;
MCU\SH:>G'PH!@I[H.&R0'%'H]]")\UJ)NW=TH^*1[1[UU\<2H?!1[2LH-"DG
M EZ,!<*D+YE5CU>/?\>J]!O/_GBX5F#\;8)64^/O)];A=>:R#X"8";I+3X+6
MBAPM/=V;K37,K5@1U+-N B\^EC3W!4&1+A#CE$G[J^SCK,<NQ('<CR^C^^XH
M!J^&_Q!\4;GC>_Q\BL@ZJ9[]8T=]^A>P '/\?;VF_A?@K;^93FTV?J\C/WHL
MIM*2[K SIC(F_?$\,[=JNRM[UBSS '\A]BWQ3<C&:]&D3I *XQCVE/YI1?Z&
M)+!:M0 IT Y&':D?QND,^"P114%X.H*YM.;9).;X&9>8,?J3E6B7".2%59>?
M$79P6FC#5"YG2H1H>?[(5/QN%I?BS9 W+9X 4^F[?ME ,W)R*:2# ^E89W$Q
M9Y3_]AR!AG+K?_9"N=IR?K$M&3AN5UC%LU&FW>;6%GO,A4Q-,S&NT'A4F;@4
MFK[ED8SG&=LH=AY>.($237S@"Z:.@DQL"U[EB,48>"GN*_-.ZPT+/OLW4\Q'
M>_F+9/O9?*,>>Y)]UEU*+737<1>IGR1W>'DEM1Y3\B;BN:8,K* '^L#5:*44
M-WOO*A%%:,5T0R##\.27FA['^48T+WAUGAC\0Q3>Q1B]24."IGM]H):'COIG
MS,WI5YXO4V3G",.UZ(R&_72"QD]".4JRB2PY%_N/E"[@XM]UNZ8\53@K^29#
M=_>)K_D&0S*(XF>WFAI)@M[YQ$66,E1IF[=Z"1LXYB".[W3V]*F0=<*MHF#J
MQ9/0;&.$:2#7C 15)-1[J%R+0ZZ9*@E98F*LE"E4?H.(D+_QWUS>=UP^75I*
M.5@L_#./[6Q0Q*%E+(-GB8@89MLCUWO$[6-E:9&1;2LVL3.)#=LJ,P@UA3FX
M? T5SA]/*G)"S@"Z$[S&U=]6AREC4E ()0QTW\^;6U%?X+K>:W/97\?9GQ=$
M&R22*>2 P<[%F =3],Y?M1$KB>Z0U+S S @4W:4WBDV[/,R\:JW!O5TLY$93
M_63-#L>P[Q9!;@>'MC;ZEC\6EQGYD5FK4Y\JX>PZI*C7YJK7%I,07]6)&A'-
MMN#>^"' % D6D[=Z8'/X!W<FR'M<8'A+%Z8V.60*5^A)@Z$F42=6=;(1.UWP
MKNK^O3L)=UN&C05*M7G"@;BT.2&Y^;[CU-4;RE9&DS>\^RM(WN#J/7[--^X"
MMY9S*8S0MML)&C/J/X^T1C*N01 =,W26FID4F3SE&]_A^LHBC3)%"6=#&K-/
M X/W8T%VQ*SF(]F^P53C53!C;1ZJ68$VWJY::V_A0E"*RXTF$]+DW+Q/&XWF
MR$'@0.Y']LNJ6]^U50A6M0KIMFTTD3.A>N;Z-%66=V+RP<A7?+#$AT_K6_0H
M:<1NJDSM=V]^62H7![\9:+# &/]T1PG__5D)1]?CJ$<(Q<4)3W4YI*^X9/I3
MPDJ5LI;&VIQ G#1396G-)?/7F:9\_<HB!]WB>N%5EZAW=K-<H@T<;G+AN)A/
MVQ@7-K5^EGG QY$K6A5J1O[W8&RQGGC]$XPB3IL8JM:G;:'9QW5-ZW3.3RD3
M;1/U6[<!,C^8'!9%NDLPP$2?K*8)(,$9!+_VM.7!(YB*I+IGE)>4)^.50)^C
M;!75@[U*5D<M5F9^:E&]3AEFQ41A_<U.FS1@%3A\\?G[G[0,IB#R,T']E/7M
MV7=31<KV\O25:B:J*8\VM$8<=)>?N(2[? &BOZ*/-I:&%"]?_"%'.U=[UY_5
MH,=<39G!'A5T1(J(6AMV4S9#*6KJ/!@SZ'7)%%[(('R/>S2Z.@P).T:8ISZ#
MGNCE5PHW8[B. !,/@[.VOF$O!:--0BZS%D_)Y^FJP+M[6 6V2UB)AV4%%;VO
M=?<^F7M3ZJBG;?[(I/T0O56$YE191O']Z^1]26''*K*E2IU.;B+4-%G0M$/C
ME6@KLA (I?\RWRQ'AG?)T/PD%FB3,^G3OO/K:GK"YE2+'].CV16O'AH^E0=)
M;63V ').1E=^G39#3Z=/+LY4 QHD9*[O1WR0218+WY-+20E*XZ_27R]G;2PH
M2:8&RR17OVIU.*U<7X)33U_',2Z802AK>W%%*!="__-D4[6+!4UYT4>=?RV1
MA65IB?UE[B-I7"9;^-L?E5ML4[;R@D)4G^22EXF66KWJ7Q?"P I2_03\W\I]
MME+7PN5_'EL>WLKB"Z<Y"L =Q9?'CC)$"J3*)U_WV2TQA%68OL%]P>!8U:MQ
M("PJ>S<@YU:,,#!XVXALGC+H7;)7CO#Q\B3GY"\N++"I2XP&J:"5WXI^;\UJ
M"C^4G(;LV*CCU[6L^V,HC*AG(F$YC-0&$7JFRFUH2T#QL_NW5)ZD<[;C%IL=
M&R@W%PWH-0<DN$VX1E-\^;]J"RI\TMU+P_W:KGG+^>,DQ %K=DMDP=7-E/@H
ME\+B8DH=TZRI?/2*P:K4*OX$Q@BZK2WB(2T6.7G;<!IS>!4'/;90:1MADQ]'
M4NY)^MZPJCI+"<7ZM62%OW-:7DS7O#X"Q5^=;1+H.,DK%J[? ='E.H6TN!2#
MI2V@]'R&25^D2BUHG)UIQTP6J/[OP=)$AYTVC,[/\WW MP]KQL4=3T&=:'X8
M==CB^+U(&/GF%A@?>D-T!Y'($E $AUV0S.NC*?!=HW=1\%USK!NCRY7B_M])
M D7'S%2PW[R'$H=@_U\ ,0>+9B0./5?Y!QMJC1:Y-6)^%MWYLFT2PHQ)7&(3
M,]A!L>8'!0RZ@206%@9&1^(=M<R;40JJ+Q+5>S]AJ9(Q+;<MNCEJ%M7!FL=J
MW8-,O%4N@<[1)(89Q%=<^?JLURP3!IKU6(IR&F(1WT?N6!/;+>HB6SO?B8A$
M,!@_+8U&!O&4+_651LT\#*?X&XPR:%">[V:3U%L751/7"9/_T&7%UOO>WO+=
M?4W5HXC-<)2UQ% >GAU1&<6A$J!5<_FA$3?EEQ^& (=7]%'TY^_PS4?8 ! <
MX[H&I^GYIO**"XJ,JV2[A56$Y?^."0LY],"LEAJI+..=?J"]#6'(N]V2W:8^
M4DPX<=%GWG"*O@B>:),\^:L27Z%?W;^>Q#J"X#O&Y"*OBF!BE$XOR"MBN]99
M6XD?'<KE(AO*^$\@:Y,J0)(D8-V$U"ACRW9CF.;5GCT?CNE9^@T/4 ><(J02
M[9):H[FY'(Q&'),\I, (?[A)]+GD&F"NND1PWLFA]PKZF)7!1G>J65X_L9(;
M:<E!#=KMZMG]'LZ^*VUBU^]>ELV.]??_L/XY.V7^_4E! 9-;!W52,5% 9I%?
MQY,$C;AX:')P(6BLZ A_V%>HXZI4=ZH)X?0Q[70)L5"LWM\.RGM7U4B>N)F2
M;FIGJF4AIT$?HO/]WH;*(DZV6=7#C1R[ROXPH8%OW"0FB.#MY"\+#F5'7-P#
M8:$>EO$>QDI%EUX:AH1['], ,Z$KP6NSX]L=HW)O%H8WCG$LG]>U6AER%K@Z
ME,E:#9#LJ!TCW-\2KNW.$%5L-;'CP#1A)TB.1F/T[-6KGT+E+\[D1Q7A)<&7
MIHU4JP<H.;ZNB.Z5!46/I)_7SHBO-8U@)Z9"T;#-GV_J'U#LIO8_12XDM+:;
M'9,'Z(A2:)^["><Z:J(J11]2Z>.7Q0>TF?++W.;+3.(I1X<,T^R*+U$#=OX"
MQO\"1LQ:4[CNO'%M>SU!'*9N!&/H63)>Q,J:N/L>?TQ/Z>(LU!0-LKJ"?>1R
M ["+#EW.*'WP BDP\7TRSKR/=%)MOWWG$UX] ,["-O:6]O(IK@AVJL0\1WXC
MU1TL*EY+^^K9+>CBZ(QC@FK,PB#"B/2WC^^V5&"WUT,<0?%M"!,T$ZZ[(F_]
MW@9I M+RJI8[4V?U;QP[ 4+UNX+7-S?7)9 3A)A:G J9EK ^LR77<[)G5,CB
M8.J/:ZK[]QA!2CG[#O5A0"J#Q<LE"#L_HX8A1W%,)S.SN;\_U<Z#A/X! EU2
M,[Q(.E'"^8/@!>Y?P%(FTEHNJ5_Z[22_G "HX5"I5'I<Y[QBOLGVK">Y1-3X
M>^H:@T@L<!15"(6CAI"O-:>W@PF@D/EF-J ^+^NMK0N7))L703=W9_68K,R]
MVU;YML^C?ZXEWSAEC)>9"JTV7]^%AW.?OHOHV7-3G(-@#'&+\^7GN7-,K=[A
MZWU2XV\B+@F=[[H93-(W0\19AG6W#[7\S#[8(.N%>J6NP,V12:4T4XARUKW?
M6\J&I6_5(JM\$=P9SX;@K)YFRQREP:V=L@A;/WVI^<&ZLH[# "0=J-V]^BI=
MH8USU$!K7B>W8I*J+_[6.) DA0J:*:-A$T&0R1/E(#G3"]G%TS&YA-V>33S[
M?)[&8<[?7;>-$>%04#F7>2JNI/ F?N2 'F,?4-&;GSF *:(&S)QP[N4GC-/Q
MT;V)]2FH+')KOG;E":EG R:W-XK5DR:RSREQ>()CNW(>1+EYRQ#4<E.\E/_H
MF&8D[_1P_Q> 6_[_/0\Z;4>E_B_SH.[)M\W.KZ.TSWPZ*7]Z"FJXU!]&Q]\U
M;\[W;.ZZ[[B=368TN")?[95D- ]\-*RM)UOUA#FO.&]?F326"0US8^(EO]<[
M#6T2(;Q 2Y:B EG*9IOM?9/+[XC]SD-RU'*_RQ'" =MUP\HB_H:#)\"]?F/$
MEO])]NB'0]OXSP^29QWZN*#)X8WETRFA\(;D-4<PAGL*1!?&XI?O )7HQR_*
M2:=O: W 0FMF@(#96"P[=UQ$3]SX-5:3@ O Y]0>?Z+"DRES;KU7-"<8!F4@
M]0,_ 3["&AL.#EWS.44&*=+=V5*KD)@*G=;X#!_X9((H=8.PE_CA GWWXHR!
M34^LQLAAAKSZB$7U1D1BL1.XB!Z*J08F[\P<2#)R1@,T->09TK5U-:P<4?=B
M'AD^."+%DQ8#Y #S/?^;13PO^C\MXN7_:1'?7NKD&;=1NV4^CB %8D\ (._$
M>U$M46*] K"CQ5])#V3'ATC22  / ERX#LB'I7-8-8S_BQRN?%DQI7I!YL?1
M2.'$Z6PE3[0V;_.C($DJ]Z]U=+5;5<F#MR.SE?IL=K(S^O= O4E;.W/WYQ$S
M;%-<AJUZM^J$?JU06V8RDN/4V+PJ;*0)FAX4H*#'R3YYM%U-MQG0?>3*>>FL
MZ-.&C"%C<$D8MV.. _R;P,<9*J5],YRK%?N&C&\.UGM%=Z\C0X<=DU7EA?4?
M^\B)EYA'U;I&&(DP;4<BV#XB1Q#Y-I8]BO=>>MC\+'GW#F*W-OAL)@:<7?S(
M1 7#B\4=/>N/I#<J[J$""0&7Z-[)]755/)8AV6?;NSIZ;U<3$:*ENQ.( WN[
M3##BAV'1K/-6Q],?\U^$*FRR0<NDAVR_^[7X=DF:7:<V&#R5Q\[!_I&[1OJ2
M#"\]*ZSD,3!0?"H?#TS_"DT%8RN<*I/U%K^\$%9S'/(7<%2R/&*6A-28PYR3
MA^,%O#?+_8AK>(QQ$SR>*C9-?Z%QN%[*O)[DK#V9QJ/@DQ^RM&2.&UGMX(5?
M8=[@_3I9.[&>L06,$CX]/Z7?1^CWQ?#/JPE(-L%GQ9GH%-;^C>U=_F;V&5QT
MW"[@7;3SP=%8^I)H^J7WD "%+,-NC>V-:]>X@&F/1,U,;77D4_[H1L,7-W\3
MZ4_&[WQG^>NW-(KGNT,'\=.LU:UKR+=@D:M"-Y2\P?)VYGX@U\I*T?1-/V/<
MSY2?[NYV^C^<[$&#IT'CT:L2Y[&#ZV1AMGJBHVSK\ (B\@H"J1*%MQ$_H#LZ
MT!^K]@,EUT29=DG8WAZ)7'W$0]D;E-<NY-='<W.27A)N20D#ADB;Z")"OW@1
MN .YN-V&S2]*ANF"D*H$F?*1R>#VQ0@72B8CM;<!\4.M(^MTB5MN9VH6"XH3
M*M#X*> NGOK700\L3YURUA6DA"896:@L>>VR\_E^U<@T->1*\ Q]J/2+D7Q)
M]V<5)?]WK$/ZU^J,M5FF,?L_BL7V>>AW__@3!MMN)UCT4I'8:J_J(P$T%IZ4
M7_-"!TM?[0Z1A[Y&9F>$-HAD1&S\ZX@+>R<G?P&<%3$;E)>(I,IO1RN!"H+T
M%M>OVN VI*<D!>&RP"*\L"$XZQ/6H@HYM8 .Y_JSP**'AUT/][!&K1@TK,M'
MC],6CJE!A4]M)OZU'4).7'TN9!=M)?22_</G5PK=)Z0<:GVK\9V=;"_+M&.B
MI*$_>6V;_(R9=[+"X?.NU-/+)-'T+64JKSWLDAUS%)NW33*DEHC*Z?;8HSG8
M<.S-'#A%QHH0#-%>QMLN;I.*DS/*<*&O42?/32>\**VM _?NN/<=ZCKMN(H&
M8>-*OD/E1C]H->8,@K/E'>QH$OTK-,:IS&]L@A6$P(5<C;=$<C<[C*2.[:'=
MW[]3RI"A[Y.A&";7=88*W7$,R]'!*!C">AAZCP6]>&=#K,2=!8\0DXC<IX."
MZ5V_L!7<M>_Q*8[LD6+G5202C^JI;7J1\FNG%<@WI&G0(JY/L=8I"H^G@E4?
MLJ\&"Y*'2 1*&7 &G-W(Q9L L)A7&9<'-2$>=QY/>'G;@GL[JYT*!JQK%D:M
M%5.#3C7?-0_M2CRZ1NW"V*!=F=(GCY<,NL$KS:YK25 *3<&[K@9--D?%/U/=
M1!5,"&)'OUU)>DV4&N4>:M>EG Z7.65@T]7G59N%6M!@1:13[9Z;\BZ5W=HL
M<,\[L%^;E:]\-=L(JV?7/K$=S96L$".GR12=*%S.C/VM,R,'*7+!*GS<FRI?
M!9.F(0;[PCWZWV]F6W7G/U< >L^6NFL)8GBG<3_;)OD$83_I:ZNV,68.)*\1
MLLR]\7@8I[%F7$E2-/(>IFD_FFCZA&6^HEJT@QQ#H">,@4^:@I_"3H&LZ<ZG
M!?X_7TJJ#(C&<QC_DS9?4?>?FGOW7\:Z86C_/=8M1\:D$5,W;;]V05QHU[!&
MD!/HX1E'2Y[.(U$B;[AZ5N'MRF,H[;LD@9[&ABPAR:=Z0F!C'*; 'J%2%*T&
M%Q'CD*3P[SUC-:UAYU521_5DSL=%US>82.9D'*QV#+&"<:VQ)7_53N&=F^#?
MZ0R'PF5,Q^?0BU@A:NX$8WT2LZ$O.OJZ4&C;;:2<A?R'U^I =;5$\?>&Q?R8
MJ?#5@)P(A[;CS ]2[W&:9Q]\J+KKP^Z[OSNJ?27(<$;=O)A7JDGCK:U>136K
M*)Z.)F J5RB0N\FZ+FNDLMQY8"-*?_-&P34+2Y$857I#JV'U0&Z1,.;\$#H'
M\A*' KV5Z*HYOI))[\W<7"U];3 CRD!_ZQCA$H_?E0)L4BT)NV(%BZL-WQ\[
MB/PO(^#\F=7VCY-=O*=0I>#+";S8]S+_][X8RW^U+U92UN@C_$6\61V-^ZLX
MJU39K2U2>%> "5;(?GC2A\#05^(BJ+VOR?&EXZ/(#\P$AV'9]A@K4?TS*27"
MOA5RNDR2#*MER+QL(S.7VVQO.#0TD7!*49'%#F/1U5Z.M>U?4E%4&*V-A%TU
M5S.N)(HF!Z"+FP=)RC)JLC0$@4CHX7#4QJ@I5$MD BO!7E?X#F11"*W!8E3Y
M#8,-3 G$JJL1[H0D%1ASAWV,A[V32V!L?66<K$DAIR:.IJ>N$>""WL$@V%?A
MTW)><ZXH9HEZ7#U-\//5UE(U'Z3%38STY$ERXN1HY.A9D;_RP,WP/"Z=Y@MN
M/- VUS;+_K"SOJEUSNG6MX9^XM8WZVE=;5A@#D$Q!<=1#(\;6C]*)/K6W1D*
MTOOQ8[J=F>80MK-9U/3[R.&)NS$^B\4=*_E84<Z:BS3^-9)(H91<7^#6*PGV
M3R93@LM3DG"S6)Z!5CVDAH<41G99^Z(B%II#JT *]!]WE+>O-6?_ P_*1<S-
M7\!QL>E,^R;QM8>[!D):J>@;L"[L.\C.V75TF [9E7C31!Q^112 I":($=/K
M+.;A##R@G\9V>VT^GIFM*#.[9<Y8ZSTH$-"0!W=*@"?G -DF:=BN(X/!6"R
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M8'*/9<TL<'>*(UC#CQ\-*F=F_)4$1)\E(ED(9(CD[6,01R!BD=DTP?8D +!
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M#KRF0Z1>QNC3P0..Q&:.<:!2P@I_;VXDB3LV%@FA_S<[,KQD3UQ? 7-9KX
M7?KPLS@1L&?LW=5"B[."7[4IT=8*5)Y-[+;![HEB;*5FBS)WYY/+J8=R6(&&
MH\/C;"]!;Z8M] >RW^IRWIEMWG.U40V9+AG#4V!N0U;LPTO<)S6UBH33V?.D
M?7S&;2'H-.B)A*(RW&-1WU_,?>N=YY/8T_5*\?,!_<[4/;'*.<:T&/'Z^FVI
M'ZL_SWSE#R2_,WNCP_=]=R?.-12Z9,RKP88C]D.^";-/,K(5*[?#+\1^3G^>
MGG0>E@WQT3,E3W="OWEHBGPBVG[8>!95?N?SJ0VZ0N\+Y3:ZUB'VR##*NL%
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M;?R[:_QOFOW:?*W<"B\1O<<=A(X>1"X4E2ID.Y7[E;/52__28F,L1RV.EU>
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MALV6MU,*746VKF<7=_!OJ'^N.UWF)56T@C.SNO]U<"882+[Z!C&=6./?7:5
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M,L(<ZFM[=\Q::*UMK*N'>40]I9F]BY-*C)#SA":M).@] \0&+R(1?1:6*D(
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M4L9IGA8@:1;"S-*:T*33(K[G>'T<Q&N0&<,M."2;\OE7U6?!G*$:)R<N1(\
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M^K<N\[CGSRJISH>J@T]EP3\_?P<.=Q8^WZ__U\YIY#\[IZ-D_^B<6J]-5R0
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MYK+\O"\=V'AUIJ><#L<^S46/F-9OCD>C('WKR$[>:4,Q'U "/8^3Y#M%EV?
MDMK$%<C_-"Y0\"_HN/\'.B+,':--./Q&&'IG%ICI\A[SAOA/H*:R^YD'-?=Z
M>G?,9P;0>O<W62+=":3>@(7]+3:CXX-WG6T?O!9XC32B,5VBLX1_^P;(^H&9
MI?81EEH\&MY)ODD<">02.]%Z$>ZH)B@[B$)O&[(.52AFJRX9;CJ+S)@S,<BM
MJ*]DL0_)<[[34'4RR;D=CAP+Z[P>IM'AJN>,$EJ[\8"J1Y+G@M^D7Z1:2;(:
MZ,F/5C2 ",,K^?42^]\HBV(_?A)""#M&&X<F_I2&[9;W6#H$M-@LDU$Q\CX;
M"K$$0N:8X.>U'P58OU"1L( 6Q3]GV !>$:;MW[P4]N\!\NNP&E[ SMH"^7$<
M)-U9E/$J7TN_TL01>#HIBKOY]%(Q*[W#9;'9!BFGOJ54O0@L)2'=/ 7$PBBX
M:TY2J8C8J+^K4:MS(0 Q+'G?G;PA53].KI(_- +N[F@:+D8XWY$_3#Y('>D9
M!KV>AFIP)QM!XQ($]N0KL)S<$[$W.+SC9U;74^T3&KM4,T%X[H4QX17ZGL?7
M%U==*^5&G6.1+,J@\0?@+O4R91(V[:_@KS\E]ZS+I(LZ5HKT10/?^:>O;2[9
MB"FCB%E:Z//RSU2DJ.,.I&_<DUYXE\2,JQ%F$="F=10;]DMP.#KZZHR>)L&X
MY.;B4M@Q]>$)6J32 RS\>)46F%9G=TFW7"1^VGMW."VRRZO?X>[IS#O.!BYV
M9[<30'LW+[ZFRW$):-0HL4:"XX>*SH!3GTZ3A^1-YRCD\A["VD%R&K47IM0G
MB?E=)^;FF XA$P0;]=!\SX>S!"<.F<PYQA$[%65 ^$?. X&Q5U*UM&B<8+#1
MKT,V1]\??6[HB*23[H1U"02=%Z+Y^5/3&59#N*;O#^/3$-2]G[5>(YSO+WZ%
M%]9Y+[P,:\R/#X+<=NST&STM45>WMV\_(;O8'HOQ!KYN^1"@L<^@VZ9Z/&0]
M8F=IVLY@/J]JE:4Y>M6GCK47RA[.1TFJSUH?(+A$"5)](6-)P3;-[C5#2Y14
MM49@LK:K7R*8I=*^T"'^-*6I.<R^I=D;J_2ZG:^[;]+]0MTL.19%?:!YO)SD
MM.KB!K!&E+.2@]TL@_<6W,9O'S9:%'LT+SXO>J(I>/?Y9L&,/[!UI<AB4^AD
M'R[.*4]A%V\7GX*-B!\KP!)MARXW[FEXIS/+P83JE1S'DLU_G^] 3QXV:%11
MT?_POW&$K*CAG9-=HB)]\39B"[-S;N>1?/GGP=;<\O.O);/'!?*?^>(=Q&[6
M7_]STKHTB-^%QN\'F<<STV\$Y>J[_HU5_?&_'7:S9W$PW.B,*LL!D52>ILXH
MAQ0:?XYX(@WGBS^7VCS)/Z'I>Y[G.Q@Q_;@F\CD@:3YEH&>F;L#F'?K G8IT
M1M+./\#Z_Q-W_/_2J3!BN@QMO^YZ_>05O\I_*[O7N5/V*GS<6H1HIO P)TU?
ML[F#>?VAOXKF+>EZ=]\@7SS^Q8/I"*NPG64B,\Q??8G.X#9G(UA2<(/20:I/
MGV*#[OS@8Z!?_IS5M+:VZDF//4GF!G?]65Y\_567,0E%E#J9?NW=:Q!AJ>,&
M-G ./!]1,&?EA-_ [KR,L%JEB'S6E[]:]:,2F2#^B5#2O#"[PM_WZYNMSY]J
MEM^"/S0#(JW]Z317;[3F&WUS/VD1UR6N5Y^2I+\^TK%;PW!W!:#GB:BJ)DAW
MI990ABJ'9'1.9'F:Y&F!8 IH8Q.ZE]^]3S02)/S!>HD&(/H\(7D2U?)I]K2J
MJ](C%6]^A8H%#*:0Q@]4J#4!VHYME8DGRT>E-,Q1C,Z^YM^*V\8D>;Q4;1SU
MFCJK&<*2,&CI<0O>!/CZQ#HD6<Z_>>NJEQ?V,>K5.LDP)ECX'DB=,*QDI5":
MJD+.7%??631;K9/-(<Z"V$@FE$:5/B#WJ<#7/%6DCL &RZ0I(4J4>+/1MO'-
MQ,3(2M^&K-S]NRR+T#R:IH&\0M$>'Z+JZJCP>4>:],F$^+VD90FY90Y[=6J;
M)5; 7$9N*3 7]YY&M/J7Z*_TI5@+=KO/!9X^ $I/;02*' 2G^LJ6#AKO!1I1
MGWQ/M)45#/G]E\U4-^P0XJL"AC/.W=YV>,L!1BHGBY"3>AI;>9E/V^&%?(5U
M_#!@*2^J%F?&.H5-*UC==.9%;# 31;'[97XBQ?VIKX>T5K?#_!NSM]1)=%:P
MK8.W:</"!.3[+ER<:$)I?J.,+@D1;[J&90CJ;$G%OXZP=(GIDT:JL6[%"@]-
MNQ=-I2F5:">6LYJ%JQ+1ZMJ8HTJU"[S__H;:Z?+P-P)PT+*W=#VA>TA9T1ET
M%9UK+I)>_]'=%NK6:VK&KLCK3,/LXYWZMEMK L6SB7)=VMJ"W,VQ[E1'&%#C
M_'A%K*HGP@#2K;&A^>'7MI$IV>OO>ZGQI>7@V^='2,;*LCJEF<DXW8?IP^K,
M">,,'18/Y+OVF&%6%6(M#OSP\2EU-CZL%KUNR-3^]BP%^BY1,50K80N33?&:
M,(-$$';Y-XLQX;_OJ%XL"=FG7OEG8P8>M-=1DELB@N(U6_>M]#G=[4</RO/\
M2Y90I%Z7)D8X\ROG1/.["F;J&0:LLCEW7+3\ >RH*G_5_<"PE3:,%X:Z(HP7
MZT40^/I7C9$L1/A["2>GCN\PW0*N8N1BB2]DR\?+R43]2)C!*";3TQDU\UOD
MRT70)^9J$5 ;EUMFH"T*^YD9+8UM"7-^>&IQ?G(^&P9.U"^,/+SGI]Z@6_1W
M![[-[^[J!R;5?C*_&WR9M*GZHUQF-^GKM,QA3N-OA"*7B?W#J)]?G/XHX?I'
M>-&RR@\4J?"D:86?D[\1XN&XIS>GB*7"+)[M[J@JKFH-U]+L!:/57\\-TUQQ
MF7"-;T/TP)>(T-:&YK;$._[MS%K9S3;O,)RY$&.X$Q>2+U?;4(?Y-E=_05!D
M%8ZB^P')<AH]RYEJP&F)G-,K&%=SNC"$$%8N#.E;3.T;+J_A<MJJ>MH8S>B'
M\]"S"P=*Q[2^PB9Q]T[,X*% R#BT+=B[(9"A7*RQ^Q. K79$%4FHXM##DN.H
M"EM0DN,H!AN)J*SM,SE/) 4&AR-?(!8>D?)B2\IS.@#U"O_%1FW,XT:><=X@
M1;%@%AJ2])T,GS[4/F^EE7\)-K+'5C^9KV@'@'.<;6]12J"2CDDZ"4;(< QE
MRNR[8<9(2OQ N.IIE-.C=V)$P]-5^24C.XU'=8KQ>%.="TB-<4R0.I4.$)%[
M=Y2IH,-)><ZN(,L<Q@)G2,30-#=F:*>$LE7F7Q?V/CMI8F2E_$9P=;7)HLRU
M\*4LU9IN*\$\4K.<++":1O/BM8CW-+S?D?+8?#CAC3'2'=6*]XQ9"9_:,O&8
MM4EG3VFM<%'=WY?*[Q4EOW\[^P<^DF3,='%=7",N,[ 4;.4%Y\[95!52G!)U
M>:^SL:5OIG3 YUV)CN^$>-J^AWFK)6!=QD[:,N:ZUI#P-8MV-;5QJNX>5J51
MW)!?;2B,2/H_/Z]:0L^_>YV>K>G'!7 _??K.DMFC8=M!_)Z#*]6=UA%8H<EG
M3_**-L<]J%M^S&F:297"VG49HA4U?H;']_72A047I^ET!M=',6S<9DV&=NH^
M0#0P* P;;^O@Y.0:MARZ38T:KB_MSVUAO]/<PQ)*A9NN4>_W9"3Q_$G\L6FK
M@@Q%PP3;GG4X5W0T4_:'/312KJ>/R]^\7_GFKG&0UC#_R:\*5>+UK\+<%9LH
M3]V5M;T6;6/>ZS2/0??24X!IC7&D&5^"%N B/X _()??6@-:N6FYKZJU&1O
MJ$"6W*56<,9'#/P4$W)$"8YA;W^*DFL@2@B2$EVA3-#*1^,F_WA_75.NG6KC
MA#\9P8-AYYYG51JS&UJW.*()_CKM_)BV!M)A_T0=(\O$0GJ.IATIVNU)H<J
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M7T$-=*]#Z;[LU1S\W\"J/V#%=)?\&\%3YH3]OWZH\D=-PQWA.S6Z3\1/A#(
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M-F7@[!E8"I^V4II/L.H00?#(N.4,Y_&3J&$ #HG6YIF+/RW]U=$;5\2_]V!
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M\05P2%:<(,L/6-AOH\>VS_LU%%"/4=8SX+<5<K1KX(2WRFUPO,V2FC+=V5/
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M9=(<==/B7XO</-FCGF"1R"A94\4EH]$_$DH2?I6<D-]3<'GG.1?$:\"Y)O_
M^\+LE)<Y*;XX6]U><R[%X/R&O)JZZYM'INJL,"IJ13JT6541&LF--5'@&^?2
M)%%B(D7+U:X\,]T[V2_X854ESMO4"?4 =?]ZI3"N.RY,MZXFAEX]\_NM!K@
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M[OCYG789C<V.;:Q/AFEU.\0<5ZT.@8&V<:_HHE/?%S/?R6LA';:58>9,:$<
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MB3UQ'("XQA#!NBXEQ;9?+N.7BWKM;= O4A-ZLCGLDL+6MF(]S\7LN)?-),W
M!^M]1A]6!#1=MZ2-EINY%C9Q'W>SKI<<#[/G' ^X%3+#^RK$LD6Z2-Z;!R5C
MUI_Y:*_:HO0I;V_,^7&H'5O:H1WL@G3GQ?%2)?1;W# 8$DB3K_9G<0%AMD45
MA&6VBC(./)E#6?T 1!OG%'1XQ$S@%RR5^-A*&UNA[W1[T/JUA!:Q*E"_9KR:
M<+XCMD,HRO!/IA9,@O3@0';2I$NS1X!B[8(:3(FR)84P:XAL"QGMF?;>>_=
M/L:SKOJU2^5PGWIH9H )71(AH_*MM :E5\V%;]^T4VHO#X]E,[<7-#:H-CB.
M187"X<<2&^L_7 X .O)Q+'(<D?5=B^!-I36(=Z P_:\0J=*L1I6I[H7L^K4S
M_X;9^^8RT0DR!:^*CP^<HXQJQB/VKA<@A1 L-R^EPL*,3E9A8%Q(U78]U]/?
M ).+1T\M63:36EH'@X36_)+6_+H4GDAUCG#WJ?.+SS-.PSU?D,%*&B?^/&TO
MZO@HD*Y>ZS=O;_40P9BH*-M>$!J))M?QE24^+ON:#,N;\&?E8@ ^F<J!O#=-
MFTC-T<$6P@EJR#.1Z4>CMV^G]N?)@MKMEU<WT8HZS0-W)'Y"_9)NS-ATD._[
M-$O!M!3V8[U2Y+I"2&N=R+ 5#CO>-GWH<NDH^6#-W:)Y%1=P_]N^R7G)@B)Q
MT:LN0<Q6H_,3AD)=U%YT-ON L&5'IU-Z#1 0NEX_]T[.1N'VSX >GA#-SOX@
M?L]MEMKU%N37^>8K [(FI[7?E_8F%1[H/G#1/LH8E M\>[GR3EFX39SR8=-S
MI&.IA=I%VW1;;%\!1?!Z]!]OY:E[A?/%?1<_MC1ZG$33/,R"I.@$U4WIG=3R
MHO8[N%P(1 I>KS)((I=OT)_/D][>%M!BCL*PZK?<[."\J6;VH1]<R-?NN&"9
M=K+%K8VX@S.]ULT'E>D<ZL]+_U6Z'J3#66):GCIE\.&NQUI$JJF/+8>7[^RZ
MW<4)3A5O*QL0EMQP:3[$L6<$UW#J\O=XW,^6H]KDJA 1N_?A/UI#D)XE%W30
M'YE2A(#PLDQ!W4M<)DF"4Q<EE0]BI5C:*!T_#KO+&F3$_8&*"1B-P58:A9&U
M.5G:DY9C'W'V[$H18S=G#4QU^C=5M98J+MT<G ?ZH4O.6&L>?W=7O7NL0F%W
M]6@V3&;=HX'BJ-KY_)+&$O/WJZ""GV.=ZWRG=G9RKQYI^/$5>*50%@QBJ]J_
MRZ>&QLC,/8V9^!;)_JA;30S?15\I#E,C372<O YD':12@-4Z@$,@5 [O!94K
MDW+@NA2M"#G?"9 69:DZ6'K30% ;ZSXYN:(1E=AAJ/AQ^>W;D0%FX<$=RJ_1
MF_:LX3=""7I6R[UT]VC1_=H'FVEI7);9 Q180W'0H_K6A7S*Z0/8?;6#41/*
M.&7+.^8W($*7HLD[=>Y;%<LWOUX<J+5>Z#OA# L]#RX;.N64![P')U)"0CXB
M.+:WK(W,2IB2W@=G"4@[+=7._%\(Q?\"I,G'YY25KP'$A]CD (_U*_?79GYT
M"?WX,M%67_SMC/X;T/O\S\X-OX#E+F?X?X4M&2'O#LIO#'[-/90MCE ,^7?]
M3.[G7LM/KB5&\%^?GSW_XUOPMXMW"U,K^@V9_S6$D>MXZ0Q\>=>^<H(\Z2RX
M]$@D_'/LD]^ 2QWV'2U_Q=M^G_@-^ UXLODV<+G'&?K_($#_'X#B[[7_ 5!+
M P04    " !1/]Q49D9#**W^   (:@$ $0   &<S,#<T.#EG,C1S,C0N:G!G
M[+P%7%5K\R^^:45%&J2D0Z1ATTAW@Z!T;9#:&S;=2(IT;41:2D0ZI45I"0'I
M3I$4I>MN4#QZCN?]O77OY][_G_'LM=8SS\Q\YYF9)]8ZYW@R=#(%P)25E)$$
M(" @(K@@N   )ZNW I0?0.PA=@\@-N0<S*P 'E$9!61D )QN6=1A^OOZ4<?T
M" N?MA%L&_!2 6S%ZK8-Y   /0"A@5P9P.6H08YT*B.J?":#YD!-MMQFL]<"
MT8Z[=Y<OR^ZT3RSUM \#+H%P^H!Y>@%4H-'"%L5W-*70-$_-GZJCH'%+ &FW
MMQM.)9!ABY(:&HL:/=^?3P60@2VTI^V=4UT)8%P@7&*.-D[R5.>'34E-Z@7\
M@;OB=_V%?X!]4T"#RX& FE*:R-NT6:QP=@,* (T<=0/^QP 1@,**JHPFC*:,
M=J8!R/XA?>XS,FV+Y,)WCYKI-& MDK#Y4R$#>#ON],&$\T-,X5DTQ I/E2A[
M?AXQ MT?(Q;?09.$;2_"?4"P.;7,C2:Y<#X(9& S'>UY X76B7/@1P\W[1SP
M#[%%\3\:S;0M?S06G*1,?S0T!M[^B \\CE(_3"/3 LOMOP?B6Y10J.VI3UNL
M9\"BB*B2.QK4J,> <T)VHIWY"X^V\:]R=+02$AJ+XD9<M"W" ,!/LLVB*+_A
MH] !6[[)HP6\17,*D?W.SS;5X);<H98DD,0_KPH45 <TX/<<G#ZS?KLCLYX%
M0</L=[ HDCN(OX4% AN_\=%H.5$BSMD(J-RT.RB. 1KS9]4$6W \C]C":0>M
M!K<X[8Z4Y/9 \_:"S7>=YO,>N N2/_$'OO,E:&&.@3]WE)]W2.Z@GK//*D>H
MY\P' ('SVU1X6LB_WZG.YIC!F>[4CQ$@[7[7$C[3 L!'AS![VA:)^+5]A_6L
M_6.,F*=:O;;?&JG?TP_XAG+G;"8C>R-NFQH ,%&;X==ON)C?..@WXE//.4CD
MIU>45/CUG*-\)MGS@X-S9M/[]!$^LZZ?_(XVA$[[__M]WV+C_2VB@+,RIP9\
M^WWK$YDZC]/W]NE( !S*/[P_(PGXSXC\/'2 O])/O%,YB7\D<$X_+86HBQK-
M#?#[*80I[8[&@A3GK_.2EEL,\[N;I\6,^E,A(?^IXI#I?E2FQ#?='X5W-@0S
M8#,,J,EE^K;EU#[N+SB:IWVGJ_2IH--I0SWF9]N.3K0[FLB_L$QWX)4-.U\5
MW]X]4SKC3<'; P2:DE\=-18T:0DD-<Z\EXI#/5_4,\Z$[\(Y9TL[;  *^#\P
M?FY-VJ9?MH;3X/_*01X$.OZZ?9CBMTA(XCO\PEL PO4D-0/%XSC]Q?N;SQ>H
M@.]LB5^$80$[=!GXS3#'\TA]_1:I<_9IL!PE-4P)-,Y6J#A333KQOXK?/6?_
M2;R<UAZXW;Q#\T=P$7"_V:?^T7$6XX7MA=-[G.0.,GP; FK^'+@L>"#%_\)M
M/EOJ^O_"KSA=T/XD_NT<X'W6WP#_49U\D_TVL[X% A/S6TOXK'5ZY3B;HZ?R
M"">%WP*&#K^AP>]D , U(3C_: /!&W#S*/R8O,DOAI-K"X7ZJTG,6V6X,7C)
M^37#%C8HX'D<6)2BH;:G1/&/?09PGX)/I@B  1(F !6?FQOY R?H% LY1IT=
MC8O:GASP!V$"KEL;G*7I&GN_/R(BX%\C!'QN-#JX;;S3@0(E-8'PLB6$MU%;
MG*30X/>;IS*2M!6GS^3P'X(4C7]L*@! X7W*=SA[IFPX??[&ISZ3EQQ8@,O2
MP']HJ)(#DO#[;?CO4J"9QNDTXH3+7S(SA6G"PRX(;R-*MF@,P-?V.V<V!S0(
MX#Z<1A112E(#".>)G3K:0B-QNKF+P?G>S0X_/?_$;X$7[EF<@#MH<:<9%D4,
M8(]"PHF.]D$.T'1LUI02_8"*#RPGH!5%!FX/HN(O1@!0OXWY+!9T\-A2PH/,
M88P3;6S41SG[T[KW#SO_23K+[1E=Y\(\RQF65=,/WN_D4/?) 4CA\*+G_8G'
M$ &XXJP,0 C-_,%#/#US[ H#KEAM_S0>$WB]H 9*22$]V]QQ<H(NP#38%TX#
M^F-,_Y/ /T$_Q0]Q#FX.Z3P\V,C?9K@H_%A&B7HZCS4IT;CAX5=%[/U3$?_;
MBG_C1Q.MAJDFK<8"4!4%7F7P]1T*3_>"9!S\S#J#"IOYFR3^FVI_(K1O=0T/
M+I_2%(+$YA3"U<_" *&Q!H (:R& JVT*WH5WGC?DAE@#%/@=Q?;8\5O=G]%O
MK--OP"]T0-C9)H/,12.*RJU)9_"M3_CTH@P_!VT@""-$($PALB)Z(_8@D2/9
M(!4B Y"5D5.1-U"$42)0IE!94;U1>]#(T6S0&BYA7C*X5'@9<%GY<NKE#71A
M] CTJ2OD5VRN-%S%O&IPM? :X)KRM4(,^'L/1N%UP'6#ZX68F)@VF#U8K%@1
M6!O8RMB%..0XWCA3N,JX#7CD>!'X 'P;_"D"98(&0E;"PAOD-U*),(DBB#&)
M(T@P22)(,4DCR##)(FZ2WTPE9R5OH!"FZ*$TH-R@\J;&I"ZD$:;IH;6APZ1+
MI1>FGV+POD5^JX'1X#;F[4(F968 <R&+,BN M9#-@!V3O8?#FY.5<X,K%6C
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M:5-[)WJ_[.CCF9%/1)\M=JL!5]"T,7+QKY!:4E??9N0(YEL6U9;I4.&_EVM
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M]5-<_MUXP5/^(V"_+;A?@@67YA.#@@SM(5!U",1*Z%NER%A9.=C90T^YY.Q
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MOYOC_WVZ +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D
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MS"VM8HW!1^+ P*":(!H52QV1]J&_W^1V1D))'ZUC4FLK@T.[K%E[ 7=,K/[
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M/;4NC<#/U&AA[[1X]6X$\8W&>%S%RMA\HU9ZUIZMJQ>9^R.;UV#U Y_@:2O
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M7Y!YI.LZ^:'W" )I$WS5S>2 1([-U]I70 78@6::2'*_I% H6RMZ7 3*#5,
M!CR%=7]!H+E)7;,@;;1&6QG>=8?/]'7K$YKT-[/6M2'HQ6WE,<2XMB^S26Y@
MD>7K*;!O075'OO"V0&SS!G33?"VQTZIQFB)F_;2=G^D6#:H>=6?RLWEP;495
MJJ2$5(I7=;05W \RK> V+Q8QSZ7.C5TW8R90P[;D$# #2D/G7[,Q6Y=6;M<%
MO..TIT6,"NJ]%S6V ER^Q;:C\!&8\,  .AAO3&;BM]</=I^V):R%7'Z4>9F%
M5]+J!8QZ9%U9W5WQP;C(LL$;Y,&K@[BM3/%7,@8M1DB?0QN_!@CH@"JK56FU
M>N(ZY%XI<1-N-VFK7I&;SF'NJKC-$\OW+ @#PADQ\.5I5K=5,>2=5.0L E;&
MN";&RDSZ9QSKBJQARH6$I^$WBF?4^Z]$79&5$[[%;\"7*5@57,@1<)THA%-5
MEXHY^$FU+T-BB!3"):B'^D9*RF"D@V0N58P4\AY.1AI.;]B8H&-@>C.BL>.#
M.!NSJ_??"T[CE=62/L&<S<%1(VQ*8%;WDY -?<$T M65EU:=P\'+C<T+Z!FU
MP*BEF:!,?\;+K,\QM30P%'74J..7CSV7I4YO:YROY5TM5RIR^X7);@BXW778
MP:.I:H9'7L+2+P@]"LD]C(31] W==07%-H%PG%CVX*:@IL8F:5YP\*,:/67A
ME?=I,KLP'YPP.B9"PDIA$#7+)O.[B4L\3;GXEC&?A+ 2G6R?;S=KQ[PE,.TR
MM8KOI+"0'RZ,#X78!FNO2;._0\M@HY5C(YKB)963/ BC"7L_-5_^>#S:P:$5
MT@V^BC;5[/.I-_:U+^^P)O4=Q[ QVZLZ-T(I.>$SQ(2+GL:P/$%[-:?9,+)3
M$S$ADA5 V("5'2&&2G4U2G"EWF2^>GO.Y55O!R=T8F;ZHQ15I[M+VG7&1>OA
MQU>ONIC%\RCXM)4KR=7J,G7"7>C-XK8/)[,,H']H1LQE"'M>U#NCV9R<$S58
M#;9T"BBKIY1["<3435AK+L%HLGA534EM2MD(':04I_4K(-13[%U%%I?U4,@C
MN0(U$I,ZIM[>P6-J"<7+P<!#S2/;ZQ%SP"R2\(V/O4DDO$2NT%T?BB9[DQK<
M5HYQHS7M"^'+%UH 7_8G+NXK -]F;-IK?1)OLEX8%0^5U Y[Y#@>'ZQ(AZ(R
MKDJ:RCZK8!?-QQSXU$X2*#3)AWO#JK+M,BD#;/S1S.->_]#^.'I@.NAI(?N;
MSW.*L([BY,=!X,:P!/NWI7YY.$P[A!QK6*36ZX[B4CH6QO27M1]1R%YK%JJH
M+Z@;7![,K/(*_EK?,OIY8"G$ 4I%B+PT.1D2]CJ;B5$^SWI@NT+.R6EBH.*(
M'V+I[N'ZM;:ZJA\;@3S9_6&70.!SDQUH*Q^19O>Q1UU]=&8UO^O^ZF&LD/SF
M)RJ1;E693RU@7\J8>B7-M9T3P#QDLMX#U2ZGVXR%F7/!/=6]-,]5NWBP0FYR
M<'!V?3>O;W 4W-7AU&_&2[Y8:OQ\DW1WI>?+IFKI\L!XQ>HR1#-WOF)S9^(H
M>4N:D,\XDF==H/AR7RY)U9Z9A*7E9';^D1>=DQGHR''IT^K2Y"<REY7UY<7\
M].?1!1HN#KERDR< H8F)Y?V#_9W)@J9Q2_M4HB,>:@M)5%Z$4#0FZ<$7>*U[
MUY]5\^^R"GW6O7Z X;&5PUO079MQ2%E_7%5U B Y\@RTZIY:Z#[.*/-"(,MN
M4OTP_J_^6Y;8@)2K)X!79L0G "NQ\.>K+7K94Y8;V^/[--V[=+GM[IS' )UZ
M^3(OLB:#A/FM@XG\2;>2'4']P[J./;;\RL%<M7Q>3)=$]-WRLK6E8<_:(WZW
MHQ/ 7$7]I&<20S<=%4E)XM+PYM)@!_E6KF*MA^XXT^0QR_K^ =_7G1>V/@Z+
MT1V+\\/SS6[FBK"CB=J)W$.-W7JGO/V1@8K\=,$JC/L\\.6\9MM8T:PX9GWK
M6*]6<#UJG&D8O%9K;;G=IY*(42MD-R9--[5@GVFY.3&PNKO>-[.U\[7V!+#7
MUQD=)D64:"?PR@Q-KYA-ULF+3E^_H&1FN2_O8-]IM*X?C6]3H"AZ.'HXS,#D
MJF^84<S2\.C Y$W%^H[U_2HG[8H"B+UEOV@AOXU20ES$'N_6BVW 9,GS%0-W
MZZ<J98D/,1SY<>/JPSD=@(%2&:^PWDW=&SXL+@Z]4?ON=>+H\Z7JEK1^9@EE
MQ::%Q=NY.G'% VW19$]F,C.Q,R3B^)#8!X*MFW586T-I373 E;.B C:%_FFO
M$/EE8@)] 'EAS/UC,Z(6Q.9^F4WAMTBN^!810^<A0?PA(,E ^JGRT2QQ?QHY
ML; 6M;4G^:P:"JHV1TDL/HC)+53A?0\830"RW/0B&CDLT0]S>#=W3=Y+,,4.
M\U=9"!A&9T >QY%(!\OI#?%W9SDT=B NT@ZR&TM AN?S36AH&B,"8Z*B2)!6
M>RY9]_@C(KTLG0:4<SR$U(PQ18(CIFN(C3YCL693I]UB!#%#?(:5:2I8=1Y4
MIMC?=UG8X[&8$9I;Z.*F$B2/92"-IV$(ETQGO[>2>,7I?;K8S#VZ" (,J6>Y
MFM?DBKU\FJP,C >0<2G%B^,KJZ'AHP6J$\WWT\6"L=%-M6-1==H*Y^%O;EF2
MCM!'47X"JC,$I,V/[[--6 _XRA=BAVX3JX))1_G[XZ'SBFS,#"G8N Q%M$UB
MA7-<D,ML^%E1VEK4G!_59L28.3^[+*$SCGOTYR[5T](-Y>^P/W18"7H<&-_6
MZ,N/AC&'S+DQ-4NUHO_6G^MU@DI0!BZYR'*(/L'KQ]3DT"RI2'O_N&?EP 'E
M(2.%$2H?QH@,F5!H1+PF8;>TJUJ>D@>HA8Q6/IXY<PZ6P9H]+H=1/,Q ;1W;
MY])X:"G?'%*^*!%\:YC4EJDW/NR=9-)#4H3R85ECJ9#VH7N.G'XM(-7[+F]1
M!O%3*!U=7=*?9@14O[ED>X\C*^PMQ]T@S'G:K&VZQ#L@*QNK'-MHL7P3!)EG
MCZ^@.X^'/G4.XFZC<0MKNZ^.&]'1N3!--A=([-%?U;>BG:[E1&0?5=KL.7X#
MB[HX\Z70R/C,7(&+(,/(Z!##+8]L;*;ND8'1R%$U)2G/>=KUNF5AY!M7=3*9
M=<QZ8_(",0>O7Q:1K1Q>6XU9 3B%UN!@A 78T;0_,$\4XAE"5&7PE$^Z7OJH
MCH'^A:-S-/<<EDCJ&.HEZ^ =%VXBF,4DHY-6.1COA9(\6 *^@XOB?^Q2@KVR
M"()@4$P\?JV,%I!9VJ8ZSM*J?[EV)P;G\5*5-<GH2V.LUNU=VT'6,9,R<,"C
MH'@;IKS\>'+JY[;8H_F9UPIOA'DO^U^ESN4R.Q#4/2I?ZAT_2N)SU"]8W]K:
M=E@=XNK*5G2-_M#-%W(3^'$9KV @I>/@*"GY!%!OJ5U2-_YU>65Q.+_JII##
M'-0])L_5 :ZTO@1.&O=D7O\,[M"*;ZYU/E"5X2/K='GXSN7+.P:W'?AJ#Y_O
M:_;U^O,K%8K=KJE7S:-#L-G2-A>GYER;)7ESE8(GUM;J(?#N/2_7C+"B+$69
M^:SKD/=?>\O6*DX B[5]%05-;A/C;B> Z/2"O>TM8U(#,Y+2S:C,Z@/(Z/CX
M^.AA$C]D73M[39U,"JGP2T^2ER4?4K)+IKGG6L7ZVMIJ[<'ZX-SR0=V6--]L
M-1_)PWY 7_=&/V/DYDT)1Z<- X^9JIO;) ?+JG;Z*6XRNQ)>1PX.Q[S[1QC#
M*:\[4XYD+(X1!94>9^96_8O?8C,9;Y)\?A]Y+!DW$_ BNC53Q6#!J31M?\'P
M<<M[(9^'/*O5LN0)(.K/>SS!U-.F0Y3+'8&Z<FG)CN!TAP*?(>VA]3BFI$IN
MA]*Z)U_N6_<#/PV;;V!O7E'$(&[5-J-7N<% ;4?(0YE\8%2^2O-J5&'<7]IG
M<]BV.>K+.^PL$KF\B#DG8GMP'@,UC0&9%)68L5 ?..*0'RJW*R5] K#]4.-F
M:WT"J%MQU[3:SWLPT:=WW6/!:]:R8M!2;I?8WB//;=)M4W*@PGH=RB<Z4)8W
M.K"S';;EM+7EU#<:##G:,9ZIAGPP7^6:VIDP.P96>SC6WRE=>E:3S.CF">5N
MG9_9?;&O*>4B4.,V,N3\PDW:N>+SNILV65Q]J-O(P++;2/*8MM=Z]4V\4:%<
M)?,"M+HO=SZ7C2Z7;<4]?",Y#2,$U;G<#)#5V\T.$__JR6L6F^=>8,56%UZV
M65MT]ENWU-JI!^6L-E4<'Q1]UBWY5+K]=,-MG>,$0*Q;5ZWO95XA[4FZ1W-(
ME>%5^>G'0*WW\P2S:L@.WIT F@<A^7VKP*7K;RJHZ_WLPW=(E<!,]3OCX8]7
MZ^]FEP[ZKKND[(ZL;HWT'J.NWK0<&9PXC"Q;]X25M2YA5-3FN7TMJTVOAL"]
M6-G2VME2^S4D!]]#4G:@4"6VL=K&,DU*==3R%R&G,Z&4,U]?_2>^3G[W=:_B
M8;V4WA%3'2^%VW%N\=O20/W^B0ENLU(O_?Y)1N>)K75P[=?MF=$3@,?0;O[P
MEI:;@K/@3OP)(#1_4K>@H'0TXP[&6-0Q5N^=,0?!RO(3P*2C$&/YD4;RK\51
MZ@FLNP\)DX:?([0GYNS]\RRUZW9JOWK):4T<+9VGI.+7E&@=98U3[#K-Q6V$
M11[/_EWBM/0;QM-7W;0.)J. M?M?SX*]-.H)VPY;]H2MULO^770&ZO_SA)\'
MT>.WCOYY.&>.G@""3^=([:JE U4&TRB\U$<KI)PF=LKRP >3F7FC/Q!2_H2P
M>G.P:7MG+EPOR1HBO811RS0\F%WJI >KEW-8RZ[ GSQ8:VER['[1-V+Y>J=F
M_=#:<?]CGN<OT[?_1QI'S](HM)/T+8U;7T_G>;WG]ESL">"HY5?9/Z4\QZ[A
M>2X]-UY9/ZM=1?>0A/SJ@P.I)G;+>+J\MVL,![A)]6W!DE?S/W?1#YMQFS8E
MZ#,E>X(_(->(%WT)@NK&WQ)O0[_BJ;W6YF'((*W6BY^MJRPK+"NBU2^JBJB*
M 0!H9DJ$O*,O2FN1$7<.X;CAA\< NEHXHF5.(T<CRR"*C1XC&QL2)4.;=<UX
MT.-?/EG?<#*KOH,AY J\_M5DHHPJJB:%)U/FQ6-UP$949<1LR\>>(B5C7V-5
MCZ,TR@2!F(&YVH?% YM,$83FU2NX?KBH>RL(TS0^(4\#B@K?9:ADOYW-[ C&
MN'NPO<F[M5=KO_G)#861P,^_)<._;-O/@."Q@I%-E\AFW2[N4U:!41]BBAX%
MCI<R/+8X_6\7H*:1.:EJ;H*]2(:V;;WOI5]&H=3,S:SDF%E2OH'Q;76AQ9C
M]YSK,1C[L\EY[/RE?<JH53<#">GP%$L8+D?;+K@Q#H77[#@N=Z%\!BU>Z[1"
MR@M>H>WS4QMZ_5:^-"?.G(U2_NNZ V)HJ984@6E0CHU<0W,KF[K;ZY6[(5/+
M'7RA0BH%S%WI'3K]D?/S_39*J2Y'>-QV(S5YL:O.#QQ) C1(;PZ/]4W6Z#8
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M8<N@E@\_8TK"^_*,VUIW*N(@; -$<<Y*UI0AXJ6X4+PRQ 8GTP\#1.G6LE?
M-W JT(RTU8$%#8^U)L.Q&-M)HUF+L*)>BU*SII616XY)$RV*.GQ:)BE;_K3X
MB"[YNH;PKL.GUA- <E6E 7=8*UY5^=1MWDLU5\&?Y]?2PUMI49Y:&CUXL'M_
M#?5U^8: (1-U RD:;GY[7(CY"Z.F107J]^XE1-.CABC RZIS[_@"I"@Z8&EZ
M&>$2T@L.70ZK?-L[QH3=[W7\[.(2'"T^AFBHM1,Z1C^V'()0SZ7RWG06N/91
M3^Q ;@WZ=(IMS%_F/F9H58A_&(:)F<FE#T!L/57E*B7RXDN/[A)QII+ZNL5!
M3*NN*S'Q+24?/G )Y?UH]\6LX,7+F&"7;BX8/Y%+/LG;]_':=R[[?1)D84&P
M6IIZT[AP*%$XW\(>39[Q").25WH0ZDA?7=X>^47X(VEQ@0_[W<J=S9T;9!9/
M8T&.3K>XFMN2BEA:RQ950B7:PP@LK!IC/Q"U\L?/J<5BA_)C/P7&P,)]R*KQ
M*!ZO./D[=#QYS#;8"069VIE%^PTJF$:F;4X=4NG'7(^K2JZK\V+I4*X'?Z$S
M6WF.NA#",ZRTP-?B9-.26#P@G]%0:F5>.$?.%DY$#D6Z.BB5D1! A(2P_N@2
M98N']*,VQ9=/\WL(+V_LK-S?1((E/G:X(:2WYCR?5;,<U/6JQ^ $T)74,C?'
M>*M&;:0$Z<#,[%-<PO,[U :?%62>;?,DO2#GO*V4"M)F:&XQ\-)FSJ^S: ?N
M6E!2V+ZJN5N=]:G#%Q%&.Z%H))I0F F;<7_2OS3<T;V<*;WKVI*8PGW;?2M,
MIIL&&-MEH2BN;XXXK*W!@;OQ\!VRK2'/X?WBJCJ1%P[]*_><F]Z'E%D7C4_=
MFI9"3*9AIS7(^9([M4GW8!3D@1-'SAM"0CINVZV27^NZ9=Z=PF?A]BJ<HDO@
ML'Z6^NYD$C3019P@IH&KA8&\^CU!81A?%]'J_.C2<^/=I:2DHD[)T.5'&9$O
M01,QV/I&DJ+TQ@J9%0A8K6(Q$QPQK=3.^,A[+XWEIQ9YFNODM[_T+*=1M=X?
M?!Z^V^7>0M7_H8"WFUGX*3$&$OZ0)-4NPH>$&7VJH6);$KV'L"@E+N 8&\")
M,*8R_EWXI\OBFCK7R'@5'FF+X#_8AN:4LQ.^Z;01E/.5Y353[.3Z7ZR\95B<
M09<MVEB0X!;<W5T;=P_N[AK<(0D0@FLC04-P=R<X-.[0-)8 C;MKX&:^;\[,
MO6=F[C-SS_V_:S^[]EN[]EJKJM[A0N&I/ L?2$=) ]P(IMHQ.?MP+OE8H:HA
M=R+&,"H-3)6-UP5=T$RB_N: JSI3?I1MUG/R#UQ[4=:#W:"Q*3T9>(;Q,]VE
MG,MS++$0>1'Z\Z..O>KC,R6_E+O)-U@D&(\X\A3=*E;9FY&Z+;SLK@33@KO5
M<LIM/7%R?QR;!V5,5J%#DG4_(0D5+^N+B1Z*#=O2$HII!S0CL=$0M+V#>'78
M=^D7O@\6$IXG+Q3Q/+ET"'Q :PVD>8J_]"C'YTWU9$@5$B1\:*?C9?4C6N)5
M(I2W N91?+^G+MFA?1MMQRRM.B=(KS12J>HEF_;UC1@E92H67[PH]WAK%7FH
M1]G5D1:P?2_U%_3Y)PG:-"'H6\KRXP>M8UXF?A>S@*KO7CS5F5LEZ,8I(#DY
MLN!P((&FKKM3:NE8R2\"74U53?!;NY( HP<S%OGO%"OM3<7R9I1/X?#/_NL?
M39\(BZZN&&>8M9Q^_(_/,71LU_..GX4>]I<E9E,#%Q*4+X.WTA@JF(T5CHG2
M;(XM!=10,:B@=A_ /2ZQPQJ&[1IT)OR^L\-H5#N-$8V3]$F&P#E=8$.?*@^8
M=>50EV//Q!E<G^Y>FB1DW>9P//L^6&G"A.0BG;A5FS][=P*MR@L?PD>H*Z<Y
M^B;3E!Y_&LB98+@3U!"P9[:BCT#ZL?P6G)(:3DZ65EG#H,VD>(552#AT+6^)
M#+REY")#[:M7VTC4L:RK&2J3Y+_X6Z^$_FQ]V\/"@N8"W3WT+)4,8VRHL>5O
M>ZOPY,7+HT/=B,"GLK%:Q!BAW\)IO[VU.*XLK)47IIEU&6IQM_G!2<:E@6P(
M'$72*:/LY&]]Y^<Q2U/T9!="AD&O15XT=7#?@L(=/;+FXG\Q&8%+$2@09)J7
M=-CH%:493C$6+S5ZV,[=-M#RJ:240*U-/KZ(S->Q-O7@TOF@[.'Z].;FN/PT
ME)$PC:M7YP<_9<I;]3%CN-(!3*Z!MRQ0/:?5-S;&0A_B078=)_C[N5V^XRR1
MIEK:0$X"_CK:VM^V"RCU#JJR/^I+*NH36.0%B ^3;U5:^WY,]-OMI+2C.37J
MS+M4^KYS2XD_[R,[[_#?C@=5.%!-"M;+C:2CP2.S8'W#[5C1#%) %+,Y.*U/
MPHU-B2)4&WDJ>4!QB3.48DXP1X*B!\^.N7+WWV_<Y2J4;MX0D% ,+(0F[NAU
MR+3[YUL&H49OU<'_\.^CCU8HWCK!UI.-;,\FM6,4TG$28 8%Q_^:V-BRX4K2
MW*>U2B$EH1KC6TQ')E"U79; JIV42>C6-3OZ)O!MO1Z<4F91_P;,8*5!!IR3
M0J1^EX*4O+L3J75_W$'+!\#5)Q/9\;4BS\:A11=[NM;"E.O')-D5GO+0UI>S
M .24[=C#R=94@OMC@+J658N:4"[E9A/J=\*["88<]SS'AFS,*ZV3O3>&S9H_
MHG;7V>JTRJ_Y2]I<RN56G>]5?.+;:<[G1N3@Z,K];%?91AI_Q# ,D(T(,TWV
MGZ#4G!Y6W#2,4^W1_TTYCU;+H(FS*2=6LA*Y8*QSF4'VSY11<VZB$:HB?8^L
MT&#32YJ5XMBOTP270E7;(U4W6Q E\8KR8.Z.M F!B 'BO" 6>YPX?A".-E*4
M$BD __/>8<FL/&K%=;\:%]6![')%)1NO:?\WJUDYTNT@VCP#4V5H"T3D)HGG
M(M)=R%IQX7/_Z;1"MES?=_354OT!1G65:*4$=%0AKQ0E6,<T:=4/B,;;\G3]
M 8H8_?E)O]J1:!3$"$*R>WQ;NREK2S-Y>!$\2O=ITM^S[N$9UMG<*OS#=T,-
M53@?LH@V;E787(-60-7V8$N<S.CP;.)E/:YA(KZ)\6]H3.W8>:S8#M!(#N.:
MF(.:'\6$-K%\+C$593?RR]21*J:B6FGC>V2)S-G%^/#$JK\(*4). V*M\SY@
M1C>2HO$=L27]7",DMK1F \9 )K=%,:WMQAEWXY^STER^XYHR\YI--\\S7=B4
M>'S%2[3Y5%"CB<"<.#K>1G0?J74,]QTPWR@;9E- _8W0TW;5=T*YVSKI!MQE
MJ-QY8M1B!>UD4)NQF\Q":7:8K6!N=5EL]+Y0>G,RHT*&*X6(.X"8+,?&K<9W
M 4;G!I.Y.C.;_V36S/CZ\KNWAT+0'!(Z5 Y\'KU&T\DJ^Q^_:_C/>8'/ASQF
MYA0#0SEN#=&2W*L&7VU1ZZ#-+PL_&UH(QSDR[^_ K-:0X8/07!9F4]?J F%5
M!]7U?35VX<\C>R:JL")12YXX^:)D&N(3*+=KJ!$61=()L?I^KK+?]4RH]<XW
MI+6#N#@%C[Z/C*23>?)F7XG':7>0*]/;YTE\'&MUY?FG?27RLFZ?UR][+#T2
MU)!6+B]FU90XA0?Y;A/)&9[>:@[FB'%!++\Z5_I5V;F?JVJ.PB"@-?4)O\*2
M3A:A^+0@?E>RSCL$6%&*^^0SAM>ECW/RN<^==B-YQ]'BWG2MJ5DN'AC*3(%U
MAB$ 4C<O'INVSRGEK!Q01MD,L&'.&7><+#;R'V^-&R?LP)2W..6Q??/PSK^1
M;D8M-H.%*>R;22@Y\O= 89T%\3A'"N=I.L_")S1&_D3PG8V^S666*8D'G90<
MM6B>&,%:A[VN T-9<VAS_>B$@%I!:8M:S$&TNF%E7/OHDD&GTMM1,"@.W8?"
M4'B^5NSG<AGQV8+]Z'EJ+4>5O5CS&.;FPY4QHH-2:$1RQ9)F6YME7:E6CX!;
ME%?2B#VIV%<72RV$"72+/P.1I,RQMY?+5X,G!WIR#;HN*.@<U:"$*5-K",G-
MP>)T)=_1S7 N]*&BZ,/WH@O>,I35%60GUVXA^3@O=,+*Q9EF HD(NHG8H,<@
M31)YS@#)8F@,<U6C"45EAF%_G(^RH^B'/:YA.YP0+2QQR3B*FIJ)FTNQQYGX
MP,<'O)U']\"F4S )B#1#T]2<9F'>-:"-\<G<"N4WG*[]Q1;-E!Q)TF*FDZ_Q
MNB,9U)#5G(^'>8U'%M9AT*)Y_6M.+1I9L@%KM$J<;R$\P9]D;^%RX7;&[VJX
MF4<(6EXJ<J1\&6MVY)\JQMP8\^%4.^?SZ YW1.Y _DZ=@&R_0KE]-4G,QS38
MQ6;=-C?#(5]'-5F+CO1W"@$5 65+#Y&$^L^E24X26]\1:O5**=0+$\PU3&68
M[O#;Z:O<5QPYX6)&K;GB#P8P)H8B4+7==H(^LLO01H\*?-[%LONPNLF4W:,D
MS-9[N9MAI67<6#<M,.523G?9!7.$"=]C9;<Y?A_^F>*U.Z_>M0=1[SYLHQ6:
M9UH7/;D=@(KDZ:TJG^3>=?J*CI!U'"&-,EUQ<.VS<R.Q-]#$Q6QZFX[9!0Y+
M,29\XLO^6HBGSF632JWUYE8NEI;H:'Y."=R/Q%T3W)68FL_N?49);Z! YKUB
ME*URR,NQG=)+,=K6-^P+;):<&KZF7J\7LQ[Y@[YMZ4QS^<UDPHLQ6]D#CKZA
MN<OPG3UQ.97DELB"AV]U#)I<DV,JM$;<Q&^^\N#Z\9E<E]^?JNR:\JH/PZ>&
M'ENH35TFD11Q"=?*5;X*=<"-:[]T6A)#[7,T2IL*/*["-&417/+;)[R);C7*
MMRARC;TR7RM'K_+I>7SF*;I_=@>">=6Y/SBZ\-IBAH"AM +:%$0JR^-;&,T7
M!JFTV;=BC4T3+1+D0E8A';ZRA7ZNV ,D&G7$'704800\H_90^8W*U+L!\.@,
M#&=:7:&U4X,A<Z0,DBY\=4C^"F"D01T]'E+N"XRUXFQ82<$H:JDC[S]*6ZD)
MJ;WC';?BH$;='$=^KU!R$W3W,M*H#&1S*[3D6BCA2QO^??(R0AU7C^,V8S:W
M-)'(1=9YKL#1^.MJX:'K^7I>)/5J3UV^#;!F#,/,W4ZDH._ 9:3"&WF(H) J
M?D"RQF5,F$Q4"5#X^E;CPP@AFZWW",X,7ED7_O(P.YG5]V4&GD^]IS$LT(8)
M6*[WE"08Z(#<]WP0S_<2N->:ASK-?46!%E#@)Q3R"L ?1BBEIT5V"E7TD-01
M<! 7IDU7HO3H1HTL3%"%M7^0,?:I(QKDO@[HZF5KE)5N=K,;$55<JY"+CJ#[
M$E^ 0.X/"R'Q\<W[*"?R0&&Q5SEY[7>+Z[2\,XPQ]8C34R#L8%@U81)N1,!/
M%R0>NR+1I*RQ+;H%QX^%P<YDW:3D=*J5*TCJ*,!*M!+^?5;[NR&:+9FOY[BJ
MWINX6[+?!S5Y4K#A3WM\>WE3YR'DUHT+B_/&6B</G P%\]3/P2D#<'4P6(!@
MA36".&PNV,$/J8L9J<@X0:J- O463<?RC5JTQRYJM2'O9XYD>AL4EKH[1O/>
M8>!@\';2PV/[YV+^F_FJ@W.+X(<=>6<W%C=$?OGFQ=OY;'A"1%7!J*Q7@#6"
MR^Y%D3DH\FK&N] /W^(<=8W74^RTK/'A;3DVV)%#CZ7X-"S#Z-8Y#F:3*YS"
M(YH@;N)U6M)VS[LO!%$_*VF@!)M*IY=E'QOTD1NRV6.0CT<7G HS"<OI11X9
M"$]Q.1^C9[FL*\$;1$9D9PFM7"2':Y+)5> )P[>XD 6J<[$L8>FGFD<\+[\"
MLO+-S<WS&A TE>.Z).[>(-U?=+QTWG+>G_T/^ZB^5H+Q'Q#@IW'';M9\@DGP
MVR;+))D=JU,!DSDW2=* @/>UA&2R$2: ]U-7TOQ^U>F#4M)((%_;C)2/27V9
M[&&"-[$:X01*D1/9:7TCM>(KY#B9EJQLQ1;,S#Y@0I[3 ](#98!T0U+Q-G^1
M^BI@_)2?D(?"M1D?V<1#)DI+D45:*P>1PH%>MLQ)*\6=EG'=] -6&$?YHVS&
MWU0OYC>;4(84OP*^VO_1_7J\I'%+*'':?JU]6M/ZM>^=SA\:E5= _<&)/O(O
MQX^;T%> KEC6Z$L_^ ]$/*9+A/6XPLW95@'N$B_N<\'*1!]A>,(4/VRM;^#]
M[6E&'P%6[3LV9$H;F4QC"0ZI<'A55&C)6S8)>(YS6:\<X8VWTK1"G2&3;J/2
MRMEV,BC2%%2XI)@%T_7,)BG%U$I3\*U2+,0X+=,!"PPZL@7%V(0MZ<WL@/Q6
M5&;1WSY%^)5YJ%0(:_@!;^@SN5FX5_VVE1I=)(-N8WYW*E29T8:G)ZS4Y%ZJ
MV9T:EV6-5.096OP(V,X3[!8VNH$I*R<54TL6*VDJI\BCZ:2&H8B$H5 E%!K/
M4$LRT^&7P:,((^(D21TA.F%\8(U7DS>%GDX/).;%A_\A%JQ6A-4R3OT7_%$?
M@R9!H?CWZ+#M)QFE;;L5IMZ)4&GNY.]?,JOGQQH9F%(P#7J<:E4"Y$^3=-D>
MC8?[_[ KZY.CA_7[#(84:9@-;)TK-J)#-./<R  Z-F_YR2I3IG2<J%CE968T
M^Z$V#0]%O\C2]=E 6@_V01N'NKK_D:!NO@+:N#C!\9";7_5.&A(\(?#_0E#_
M>^!NNT3ZKAWY[N?CQEGNQEU/R)D?FME=S[BYA6?M&TJG_ F%TQCH7 FHV#'#
MYT5EKA@(!NG7"!)Q!EV4)K[[.^B15^L?HX[?2*P&/@CLW8UM/GKW;)'5NH;?
MX4O,6K\"0#'=/N&&NO^%N/S?1:'_K,*S)Z'_+VS>3$16PKSG3];90W_:+9(_
MUY-.J)6$M\[BN1?(P)R#_P;:F,&B"G)V#4-W0J",&F5PEV'T(5M[/YE+X2B1
M)FV)D'O$F#"7VY&B7"PI/10)^$CM:V+ZU4JIF&/F.\<\K7]S1P9-M4,(.-OV
MFL88S42?@+STUWM0DG5Q2Y8'6&_+6/E=3X>+:PQS.E31D$XDR5@9?POMFP\U
M#)G,L<Z0,4:G%1M$CV3KN#[2M8'+%014#O18. .)MH(*4%?\_*M:K3H7>/R)
MFI?+"67O]\FNE#V_IM9M([MFA8=D?3*8<%D(8*/%I.#V7UOE?S\(W:.I+2X1
M:\"H=_SM8103K=K5]549_PF/7:\UZ=>J.]EFQU<L?"2Z[^%03Y6!3Z7TH^E?
MD 4)G^(Z(I*TN])SK+QW%VJ;.4I#T"0WSQ"ZN&/C.FLOS2_UQG6C=X&%\V9M
M:^9/*_X75\3E'[FL;RY=Y\_2P-<''P>%S5:13YD^_@"_ N@)@H_>-%3PG$[[
MAI(%7[M0[H_^=%*@#Q#W4$[5Q?_W=3<O>AS=>GJS&#R_6/_'LJ-EJ0W^+G9F
MGA->\A8X3$4-]2,U]VXPJ4RNWZ;]QJ'D*[/,9WA9MGL@7V78.FF2XI) %'06
M5FG;XC8]Z6O;C=ZJ[1_2U,Y B]66/L@:& :_[NJ$@J8%PL6$TXHBUIQ<;&Y9
M&AM;E1[Q_J034?:Y+9Y'2NBT*L$?SC=A$MJ%_PM7+;7>/NB-M*"O.AA#0BA#
MD3[R:YUKA<_JTK$A 5#J:;=JM<M[9X7]O2D?KO>.'^IF3"5SGE%IQ/[[S1/Z
MYK)D6CE'W_TQ8X]EQ\BE0A$C95#D'*A<CEE9.8JN"* .J'(.PXY&05'60L,#
M%5/3GJ35 ,A>G Z)R7<9.723X)7,M#WY==*XN/GQM/V.)^8U@1L%"?[VD5I!
MVWG$VT';Z<)&]SOQ9\XKMS^#LM-)*9%L#*L-,<K"M^X_[7D?)4WGC^O31[J'
M]D-H7P'IB3\Z7?\D=R^ND)0F=@4S5[;(WAGC,;>-US'((W E#>3C6.709<<1
MB_N1TP@/M&0*#2"=NVS*X0RY<.LM&P-=T[ID^F29O-PR9%6C28QPX-"DZ;D6
M(@KDI>&TM X)<7_PC0"V5;?*3Z*DU]W940TP8$AT3 A=_,1O"B#+VV=BT.9V
MN!&I; 7W$[$4/K-<]&>+A]N^] F#A."B!2\?"BY'&@ZY3D$GP6D^7L]UOJ51
ML@85MK,O9_%GP6S&KC/5Z<4#G]%H(,*#U1Y6=?WIR>2R]')%5.541V&*4UBZ
M?B:KKAA-[R.HTI+\M/!R,+O@#)K/,RXS4CTH@B^[>?%@=G=Q\OUN2C* V?O;
MC64X:12KF')#0ADDC*06B[X?>C^/4^VJY^1$S6[!;_7V&@B-19^X;0*>=)OW
M3#Z-K?DL<^=X. N/I3<W%3,K5*4H'56UQ3653:3QK41+CC(I,6I/)*>:?FT5
MGX,.O("#Q><MZTM=6CRS!&5PM:WY,D9(-7AI-+R<2Q#-]SAE(W'1\Y(L3N89
M:VKDCSH==@9L%S0)0 .<[*W]D3UH"=(ZBF.1'()\*#&6A43TA _.TC)(9%0@
M=F8M^5/<[_A<DOQ&$51K,6A:FH/N;J#X-416!#^BWD.B*GQ_R@#^4>)?$>%Q
M'L)@JKO@,3:+XQ.>V7(S2)ZB]0Z>:_E>K3&#++?7&;)87^?29&Y!>/K85FK)
MOI#Z<D5*P/;^4X!]TS!4=.#BQ'?_3&!-:W5".FZ^C"67@-%G>$5Y'E16]#NN
M*,F;H8JA:<Y:I*AI11&U3QD7Y<X1)CE2;G@KW?7I%TEGSON1W8;U3C]3!<AV
M,'K#[^_9#+8XZ.WZO"=5BWW\7\"36#;ER!C?>-TZA[!'^\OXG-*=;,-0K;\P
MAHV;-MA-C?ZC8N56I!%2K!1">C\3XJ"\]6DNHR-@B@C_I$1ED[7?TK("-31V
M,,1,0DM*PQ;$*5%D)%_[FK-D] +.MSDV+>YW7/AJ-UW2B?_D)J^&)"@L"LK)
M()(T]B>L]5QSHH-AC8@IA6&:B;K' M\-=:AT>-:@;OTXW$E/W52G4S26(R[S
ML!YTU,L\8A^V;2%EY2FAJRHH*J"7I:<JBTM*0NTEB/:0UJ1"I&<FX\NA0XP[
M8RV#@QINU/)7H?U;1_D_D5;T$Y*Q(&<]=ITO[L4AG\W0\YL5=FEW%/F3/[[9
M*,C0N"T<E9469<W%2HC*&_(]YA+X!B7E0ZAF%YU[DHI;V5,^:@0H1S%2DPW!
ME*FHA'UY:1C'!-EQ>PO/ ]Z$U+KBMQC$D 8L96K'6BXG"O/PZ497J<64(#@F
M?<5M:FFFAX":F$$M85]C<'<?7:M=VEI;LZ77X#CH8=09%&1(=?=^01%%903T
M]"AP2H9:8=D;6H)J2^?)3DDK0=H7C[Q5/H,#.@=^C>M3!L%>UD>3M8CYI%!B
M^ 6U'4^MV%-I#)A"N#69.A$VH<>RBQ,#SW94H=]7F+J:D&-L8T,&A\X=W8B=
MSF ]!HLG7U1M7=33Y;A:D8R2:_/%VW%SG#URLTOU(]=BP*TIB0H;6$9-:!X)
MO( P"5R-\2].H$DD^\+F=CZ7$D&-@$B^DX83Y?+/S@31.?C_NS/-SA]G=K]4
M*SUI4[T"3$27NF//9>Z%16_6$G^[+@8YOQ1/GVF<TC3XW0K_.GZ$<4X/]SWF
M+Z65WNL_,S6'5L4^!X\-M8?,)9[./XW59&CFWR1(O *ZASY*?#"7%/XCD[_.
M>H=A]H][4GZL3XSF/WOB?XD-]W"-03[?4SR=^/XQ^77!ODA?^0CYV$G9Q8+[
M)T[C%^FHQ#>NC_G6K);G W<5LX]]OS;33._,#U>>;T)/K&3Z"U]FS2Q];UX!
M\\&-KX"81/M3/[V+>O.P=,K%XU? 2R4/Y5K5B\5UUG%S5\^-0W]PK\?V$=@0
MDF+\\;%C[TBT]A5 RE.Q^K3_\:?7'8%I"!#-_$1B*V/[3=]C[G+:P0OV*P"A
MUGQ]\!4 H]$%G;537#+>S6N] HY!XJ^ ,L$3"TB/06=@63#."_K8'P_&>T6Q
MT+8KB%SMXY=70'#MFH)Y#?#F&V=]U=- "_))=FZ(Z6'@S#-'*.[0'PW2^_;%
M+UY/Q1+KC'<9IA%'XTX=_XYK;?X%US)Q@D,@OWZ=_B]DFV>4ZH/_WRNTBSGJ
MQS]_PX1\G,*OK4.F7ER'_FNUW2&IO"!G6[U+0ME56SRWZZ[9R',")H\NHW '
MX(6PBQLQ23B*060CE+B76/,;Z>S^*-8C'8?HWX^;-479!00SGT6Q?O*3_Z'*
M5LYD"9Z!9I.)E/V0UH,H8YP1BHWE;"&>:Y6V62P;@T#=RM'KFQ(E5U'2(-JN
M]QDJRLKW<@:8EDKJFT!IDE_EHIMD?F7T1GMRQZYZ6$I?2%FR7-D^/:F!4O-]
MJW F&!7&9,)6W&P:E%3*6D;"E&QQ][\)>7W]$;4>KH<KMUU-3$SAJ6#<V&^L
MQ3 ,@D$(Y[G;<KG9"X#NSTOIL/>K:LC6W:MJ(AG2>KE;)0/%BEJDHQWN.FM^
MABHHRDNWAP;:,:)?<)9 /P>-QL@=58S0!%.JUYB^(]$[#W:;0AXX'UB=*B*N
M*#0/:DW<./^< /T?XA9Z,KD?'P0.[L:V_S>,G_)?8OQ2^UK-<G[-?_\JIN9
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M*4;1-I+H.=]K[2)MX*3[- /ZIV#L=L1X'9.!.R&6DNPJ 5?X;GNG,LJ,>3/
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M/#XL0;8OWSM?ZGS#/!A '%EWI36I(VCCIL3Z<Q2)S,Z.*CG:Y?@EC[I(P06
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MRD':<PE39; (%/@(GZ($")/WY.$MX2WUE0_B84Y>8775_L>_*$[X%@QE9^6
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MOE14/+KPW+%03M7<Z.ID1H"UX[9<^F%/4<6EG%4QH7-%[<YIC*TSM+&,K5T
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MYUW1CSZ>"8D7Y,MO7ICK*Y;-C04I.-Q;&:G$FK-FCDI^I,,]WQJ#M0VE)]$
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M+$  -__@J@,?J,,SC:HF)K.B9-^4:U[&/HB7#I#;F\&H)$:Y\[9M(%EQ]6[
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MW?>VGXBV$)\Y$.3M)S)N1UCQBR4<(BUW$C7TU.A@Y'OY\)NFCCS,8MG]BH)
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M#+^01C&T3ES=ZVW,Z(U]8VF6KJ%4H2]T@#G4X'I*9?\]K8)O1$[DYFPY'VE
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M1':=Y$/N):JQ]*ME8K!M3$0<LZ7QZ?%6,M='_^P%?C_E"A*UA!'%C\Y=G1)
MNFH^]WY@QX3S7Z_,H#SA81=7L).%VZJH<?SNK3Z1V6@>E/*!G=M2W]DNL6QL
M6Z)\W2A2;CCJ11 V;Y@BP3#W;.5C:7\H#8<5]4*'(!W^0S0[R8,='#_1I,[
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MA=T=HZ,L$7@RH>^=7,C:%ND(1J:!]A\'/"#(<1#+3-PE8T:"A-M5^4KT+7P
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MJSH$<TDNNUKUH"^.L/R;>6+"BA.?0V+_.6"<+!\S7VB1WOLG@^M!]P<(YF=
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MOLBJ!W"V)>O2'GY5:[ 7CPK8,2K3>A;&+/RL751FRWXLIPT !L$&Z(.P.V!
M\O)P_:Z?L1L*L9C0N98F9'DU= N(8O'@AS^0^*F;YHN3M&9.OTO=RB:_1D[&
M =)J,#:8CSF!ESQ1*1L[IU>BBN@+_'8S6JWZF(O @-)691\/_/-N?@>)D!6Z
M(&7EA;7?I7#$L?_PQM9]<S$6:AT2]NNV@R.Q<364LX:HS9_U0+=!Y(&]N4>[
M04M1>8D>VNK'%=$@<0V@Y]363:RT3\"Y6:)%R[?<>AW+?':)6BU-]NTM09D2
MPX\EV?:#$P*])Y)[)+4=1^#G2F&6U7&"/\LRN: >]..;3RK-[T!%E=0)NY,[
MN6$N',G=::QA?N-,(U,#:'ZUN0&O=LF7[#2L_H064O+FTRDL56E76S?FL75J
MFX'3,\)^"S?0!@RAC2# !YW:YY9 7BD3]<5R@G32CG1%WG ,T4/)JA2;3Y(*
M(P">8!Y);Z9)6J(VBMK[H_=6UC, TK.Q,_(+Z$]2;_2H>EN+5M:1\ZOZEO$;
ME UG7DO8_]-)R?-_[,L]7^>7SWIM/AM!*TR)FW\WEL]Z_EH=CI>H/Q!0$&OI
M_E10-V3IK0'X%D-DU% $O2J9$SBSXWTK6%G8]C[),^%0EE+2X'Y\U]&R<4L7
M9IXR"RBX9M" FE[LI(72ABZKY-&F66<2-,]])4I%>0UD*IYD/VBWU[;15GRY
M8T*B'Q[R*]?RDMB"JWR94J7]6;_C@_K*MX_SACU2JD+O&KP=*&G>8O-?LUJV
M)0V ^(4 6#:^H2A6I>#G\<B/ C]9MILE'C:+E63K\-SUA[',4>?Y'/N4@1'S
MP*- GS^!/BF[CXU.$2/R[3*NYD_T>&/B\<13?]]DERZ)-U[&^OE,%7EY'>+)
ME2UG"\(<@L)OO/BRF:&SNX^I6X:SLA\U5]86R.U@8^T&?;U1KU<71 -'N1#D
MPF!#&/%<>A]050/20&;Y[[3(&@7D3YBML,6D29PV]R-GS:%YP2-UW4@[4U$\
M:84:PMBFM<DG-X \'15=53$%O0X-^5F1/2;+AQ'YQI$8(!9*^2]9+]*4! _&
M;*.<?P#*F9*G;Z(1$JF[M*'87]W PBD.)^#:D-D1,+/SY8-2AH\%J5?*!Y#J
M(:=JO_2K[1Q0^=.$>J'#7>:WV^])[QD=C9OG'E#>D]WY^%= [*U2QLNALCG"
M+"5S;!60YH/PH1(V*)Z!4!-YF@_NOQ6K?5BX&#NO]0GKWY<R .).X;UIB?:%
M"NRS68Q4!U*C"*8#.7AG(Y4H#TFM. DD=5 %3U 9J"([M*QH^05LN/6[D592
MG8>%%;S007!#2$&9MO_7C.\')<9=+QK/8?D3A/PQ3VAF=A"MYP$_'/=?A"\*
M>EKHZ-EF9-N_6!Y?P5ICK3^_;O!^L?+S:NUO_M_6(K+O7)=+3_G3WF*P;W[0
M$ID00AH"B4^LSQRQ72YSSM-]!3"?%SA$<::S>0*V(#!:4BYHK[Y%D8%'/(>P
M/Q$E2;Z&L(1E?&8&+B_TKEV3IIPZS!TFO&WO+//"IX8927*=),9&"QDADP0U
MA@ZV:5G.3#!+]4Y[$M[,]3&[94@0E=B'6U/%(7U00W!H6]T]\84]P:9H2S94
M1_&]RS<T\MH!+PVY O+<I$%0151(5M_-OMO=3RD(A7(*0R)=W@'^4\J@O+G=
M)E@VI]W8?Q.(7'-5$'5Y].@]'[GK:%KONO6+E/MLRSG0:7;;,77D%(FU%-<1
M^[.3)9CM96GW#0HHENW[4="-592M<Z^"D/R,.K- 2_S!Y\CFA?"W99)^X&9V
M[=#4P2E:1T67B48W@_>+WR9X'1LC-A2-UUU@TOW05RU!EC9T5H.\%U@4UG8W
M$VK?<^68_+UIRP!^=-X^48>FAB\OFY$8J$TM6M/1U/>2J-F<!Z<,8%5 <:7)
MZ-S0"C(!I85*6KB+@!2-9N1;LWMW*RG;=6=GC0]T*ZH$<,W"<T<_7.-O&@K@
MEVP<_Q,2$;YGOU7M49]699"8\9(A'A19Y93_Q\JO-F-=I,/WH[=%VIS0>*9,
MZ0>RQC_+Q;(W%J.=%E:QY@-F@0:&L4NZ3:F(^(T1DSD)&^,,9EZQ=&M#6D;'
MK!]^F)D.0W3'/ U&;3X2S1#+UAISJI]XTZ+8) N.EQ7D>R#I?"T0$R,;2/<=
MG:3[6(=@G@@]V'_^_FG+.Y3E?,G\</.>G;SZVY^.* >0W)DWLF.R*(8[4XBV
M+D[F!9+9N2BC.PHR. T4E$A9WKWMOI]NC7%$FBBG!Q'/KVZK>5!W)UY7%.OE
M+93+ET,=/(U>8ZTS'\)*V3+T@E\GG:L("/K*K_'#C.I4'2*\]TG$D9XZ[_WY
M384S[Y]M#6_^P?1\#8=VU1WCQ#BG\RZ6"M::^Z:1#<"?N\U8BGAI2F!J<<)-
M9=_N)JO0(1Z(RVWDW]!#K%R"%IX/].IT2DKLI1@\3[^(T$Z;4=E-NK6%$1ZU
M\*5_[1%<)GCRX$UOZVLA:\$8BP]?0>J^$@;ZTU;J^/KL!VUL,7N]/2/"S;M?
M'P49KGNF2XQR=+XMJPFB%@NBMDB63C$@CQQ[ )'V?%=-.O*T-AY/#@A\;C31
M^A]LX+P$#NK2SL>2D:L2)"#:2&PWI-HI&C7!P^^Y.J/&MVWVG4%I<&R39@-9
MQJH46<H&T) TX#*,-Y6EYI1W6G9MG(S6ASYJ)9XV!!ELPA?O\]@:SF>(5$G>
MIS&TDHN\,U:O;"EYEY:F.][X7[*Y(J(*\[![@=?/P]BC'91 5-G!+K$S*#.?
M303?\#&22S0&<WDNI]/L5?LI4%RV7I:%F<?!DQ9^;;%Y"]]GRD(9C6\%>:BO
M.V5R1!8^[_HOO_32GZ:?F(E< :)=?8DQG)ZF"*4##E$M<UO377W[Z=NOD$U-
M?=.KRW$SUB*S90!LA3%P]6@;YS:^=T))AS0\EW.53@U&#0=30Y[A&1CG;L34
MK.V>\D_EU 1^N\!8KPKEQ#MM<<O-;VF[D=/6LR'N\[LI4QM:M72?QG##^/?%
M>$Y,39GSJM1Y0RWL/@RB2]FB<ZBW0-(_8L@LYC^<M_#A7KSL-!O3\MK@LFA,
MKTRV7]WUWKP:6>ZU:;O\#S$OI=8V0.&;&[B>.@*BMW[\"'^V/]'9+*VP\.G)
MOV0@[_GE<]RSE^>W/\KONS\)*E?:C:I+5B+RPC>2(6UUOB]A=?]Q]5F52!K:
M0*W"THSL+AF9"F5D6V75_\UIGI$44AKX3I;[EW,AUA1:=GKL-9'B.]F:KYB<
MMC(S.L7#A]">6+>,9DID&O;HY=XH?;TVS17$EN6:O9']$7#RO:QUPL8F37+N
M-*@&UK&1X:5\%H^96L+!)^*Q)5B3X>PZ5A/%J'%-LX.'S+1Y^K>;"N0\#5V>
M,'-?,4^^SO6<M9527*"VWAE#BS_"@C_E_*SMZ!&%!CN*!*QJ:.3$>\<(T'1;
M-Z7N;]\^O)<PBD_.[EWH*WC$_SRG/=OOM6CD."=/5@N?,HO@0;*=,VC-4S@W
MH\DS1V*GP)9XYW;R*5RO/@ @>];34XA> \0PNQ1+( ^$>T8^3F&"9W="F\ON
MB=2*I]#;RKEFGQDNU=/I97<\;FER<-"!% E:S!,?X%V;Q/XE>WS.D_2-E]H0
M4\]EJ"%421UN!TP,G&O5@ ]*+=&Z%V\68(Q=T#BHD$ (:M@?\<K=40'"&%CU
MO;T0]4I$BOJ5>"7G3NV*F5)4MX73(V]?!R5?:*8:A$IQ**D, >2)&!-OF8D_
M*V*JNSB?2 *L@G#*6NAB4:T&&4G7UW."/_:SA8I)ZU\2UW-Q#1[NJU8H.[P-
M;>+CDV[H?DNPO\F 23YSB=SC%0$]!'!8>H%9:!!=QCFW>'>N)I2#W^*Q&E^+
M%>PIYH0L? \_?#@OGOC^,:$4%@;RL$?[(Z_Z1C,%^>+T65QH6*U\S *L^S<.
MZH'+KV3F8M0"')UA=419AS;U;CPA]B+-.^Z) ';4@:],9TC+S6*O@Z_*ABH>
MM7?[P#34.^4MFN08RI1*I,C<<<SN8:]?H16!5Z5*V-AA;KPZ#8S_9CJV61;$
MQD[IA_'UVMMCFP2SZ+"QYQ(:;?(3Z+QUW:!4ZD5"#5X;X;IY'SR80;SG\?Q,
M+$EQ?)[Z -O*9<="&4_O6"1G?*$ IF%=%D?K!#]^VB6B+PV=:C?N;H%CZ]IE
MSTXZU57HO<(,PUB'D^-\NG+1SLK;H6 9OLV/Y-I9^\95XCM(6M/21^E2PCB5
M7(1I#%*G.H0XT<+T?,$)$N:X/$$:-H8UC^>^,?),\TOBUC?"6TQTRW?.X\3_
M"$*%U.H5;FR))EGIY<CA<E?L\4T&1D)03A0NO<"0+/?<N0'<N/&AU'ADA(G+
M8PMRWP]O'$T[2-NH(7I%N>N>&=+9)#,A6P1%$49\Q.DTF(0''.A+$'+O@+C.
MOY6F']W?."_S):H_4'W&!@LA)X;$N;<]I>^:=]^ <%5<O=/5_B=;U!_,H]1A
M4O6LW6IXM2\UY"-UJU\9'8;3U%[37.#70:T>WTI/ULG%=[+9Y5D3YO8+YG(6
MZ3&<R-G5;I.-NL8TLX^5]_TWB)G[F?UI5OP8K[^;2@U!X'U'2V]+E=7SR8Y
MU)80J:M@H>P+HR-.WX*@!57KTZZR'@;%Y/N&#JR"07#I79/\=828]^IW7],%
MN!8$@Y"IJVSSZ21\?%R3Z HXY%\#JZ0*K0\\A%4H\C P$CW\-?EL:<1>6V/
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MZ\0%1G[$77?QZ!CU.XMZ]&5]9+9*;&F_+W*NUOY_M_GSOX3_!U!+ P04
M" !1/]Q4C4N.]5X; @ >; ( $0   &<S,#<T.#EG,C5S,C4N:G!G[+P'6!1-
MLR^^Y!P%E)P6D,R2<\Y(!LEQ63)+VB5)!A64G$&"(E$R2! 4!)$<E!Q40#)(
M#I*Y@*^^\3OGW'.^>Y___3\4SDQ7=5?]JJN[:Z9G?>9\['P:@*\LKR0/0$!
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MHH':U7<W$9&1D9%04"\/-(3+;W(2H-("T A!-Z0T+=")Z%R)@V))Z+F?56
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MBH'N'&!RH#'R0EJ,/87L X#CP9M(/_D:C97/<)>E:!/O%WFO9UK(PFT<5U\
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M9!$@#3AT.,S$R3<U+9(X7*L[!^P)9>5M1-;T3X7Z/:8Z!W0\;CK#U!^4^AY
MK?DNPDP](MBO@VIN^/N+IM7VIEK/Y[<::YC$(M/[9M?H+2*\<<\.F?:QW0-V
M-Z? \PH7OBN.A=0TW'/Y$/L.860(]VW:4YC(C;Q1'\QO#B%W5E<WS@&9DS;G
M@'5MO*33C.WC_?;)4"JS*([I4,\F9KR V/V]J7D''K[3[[N *KR6)Z9'F-^G
MM#M&/4/ODW?['A) .$6\SP'M5$\./::$9JJ"4.R0+Z8\)D_^L,+&-JH!IX+K
MTW4'PS7K1I_,3T+9#L=5 [J>MO>@C@Q9%U%:I';$QNMO(J!.EBK8IANTF"\L
M\;,]>^+\+EA!.)F&TG]+_,NDP1Z_E[O\R*@:PCD@P^!PCG2[*OT<<&J<T=9>
MP]-$8(9)S'1($'#"MS\1N+>V5O/\H3A[?5JD/6G08.U7Z,L-F_NR#BHQXD4.
M='[^_J;RHN> KUFT1XM0,D$NZHL[0A>?B5B)6K[]R#F  WLO2%KIMKTXG>)%
M\BTR,YQ<;![9*RE XA^1Z0@(B#V*,>GSZ-^904/%.4DHTR0\D\DYZ7N-QRW)
M&]N\:PD[!)4$4/K5C<&KZX1.+-N_V2AV[DEL@4Z")J>"SJ@1J.=R/0IB\#KO
M3>'PRS9]KT"K S<UYIN]\V,U15O+[9/X_CYJEOYX-WV1:;CW]>NMQ<E +AJT
MDY0S:=[)BS3$-UI^N$_!/R 24+(W->LP.5BP]N;#X58%V< \38BK=<GQR4D6
M%ZX +#[J$W!&QD?N8J;M!IT<>5$ZR1R6BBEH4RU^^#Y;;^QB*N#[^U,W @U4
M#:WPH@@Q<'C440'I*)5>]U>UMYB*-5*69F#80-$<RF6C)A"$]R!GUHR[U-S5
M>@K,8XOH*I4U 1>0LOD";PR;/L&Q#[\I$[81]^C64^Y=,EITX<\$.V1C)4%%
M,^$!?<*JXA3^7X[5AO08<OGH8)T%3GQ5.<Q*]ZF4/WOG(08K<L3-8&H[*/M*
MY)=209U9YF,HHB!9D??)WGBG>A. 96=@_LFQ]RN<[^LZ];V\]0"]V*S:'3OI
M_?S!CG5/6"]0WT4E$4@#'2A6_HP9LM$0$Q@"XYNVRX1^7&%\DJI4M!N55ZAO
MP3XF66[.\%WY,U[E8*1PGG' L\8\>B!:TM>8CVA%90\V#Y,9%UR*3QI2P//R
MW[K*(F-Q93V$I<MT'-\5@/*-J@?>\N9Z:]JX+?N6@A^+W]A#)EB8[7](+Z'S
MJ*,H)I9PE!SV(K@M//OV%JM44UGF8N!$!F3Z'2$FD#<O?I &#X<9+M/BZBW&
M<-N B120$PQY?2>DX*,1I%QJ6)4<27.U; 5].DG.B0\UB"98X/O8"OJ'XTB^
M&8<'!^Z1ZLDR>"2B$A2\,S9M*YNO->Z3G)A&E[U;75Y=.JIW'VP4E,VT269*
M_+BP*Y&\@,J\ ,N,*D^8%RXJ8%ZA.X*78NL^KJ^ O_$L&EAUF TGBVOF<%#J
M''+)47KAULDY?C*KSCW+@.6J<C@T^D+.K]BVI([:0S:' 2I_,>[TK5JQK>4W
M. )FFG@I$J464F\=JFW-D!IJ;23T9A%AQ=%F4&3W8]NNM^)+#/G(!TN'I$DM
M"MRQ[R!.QWVRO<*MN&+(E!.?K[KQ5-2T53'8VPCGJ/WY&X(#J8ZBB.R<PMRG
M"0E6<?Y1H5GXR8H(*I]BVS7.*-0CD^]W5X+RCF7E;WW,Y22*J"PB3A**4,@3
MFH4M99*O/+*"N5$J$AOW&@ 3*8C-#=\3#P01@W5IXHIY6:2RT6<?FQ&X?Y9]
M]49V6G#=+VRO#10QG7$.4/M2LKEBK*D[?O/IO@9>?]U9;9LE]!Q@6**6>=HD
M!ANHF^^KJ-3*>9WY/"X;=W%H,8#MV!P;['\"2]?-T4*=+1A]L_IJS#]GN8R
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M2[<]:AZK(C60_N2*Y0_2AV<O*T23&,3B*J>YOHH0!$"*]]E>431U^2IMN_"
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M,\84^?/N%+85C9.TW7:S@G$HS7=>A]WL[NM^Q'PV*HH3 T%5C=4_]*52,%)
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M56E33XFF!$U+B0Q'THDMZ"P1L$<&B+NST=DP9V);Y',W3W!'J70XUF6G$HN
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MK^]]=!>W#;#MN/38'33W&M>GN.W'C,IQLYQVQW]-]NPV_P"W 90U?O\ ??\
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MQX;DYZ2IEEEPL-M3"F6?&_C/^"'BSDTLSP\OC\6<FB\_(QWC+#FN)&F?'/'
M&A494_EXKW#BQX?-//\ L;P PF6*'(U^)SG#R% :3[),:#7_ )3DQD603T+;
MA@6ZX2OF DGI9EM9076MH[$#\)YB2W:IQR*]-<JN9WS\-AEW4$I$YV([:6+E
M@68M?\J&E.XD.L/_ #2T+CM>$URF3PYS_"=<0XG\2,!HGDQQC0Y<TJ%\=8(C
M%AE\F!:6#%QN80B*%8ABK,SH(9\W"DL V(X+@\LDNW#LJJQ#:AGI&W)>-NIB
M>NEL,4?B.M6ZXT3I5E-_S9YM:9A2F6>B8F7JB3K/4BC7HG5LRK@AR3+,./?5
M[]>J'95ZI3;:JUMR1%3(0TMR\Y#_  O\3\]S(I.6>$>933N=>;>*Y,C+CQ@9
M!)#((LIH5R\4GS,C'F3)YGD<O?H7[)")R B?F.+C(1)EQJM_Y.&BQE@ /]26
M5=;".O3#UV?C8 @<V_B*^/MNXIK?EWR&8L]/Z?M$*@W^M;!T-:JU3#;0B.PS
M,7&\)@-(80&TNH8;=6CJ*B%.NE7K/^&_\#\7PWDQ^(/$DPYMX@8)("[(\.$X
M6<&*)XX,09,<*Y,L,,DF-%T1:QP0,T@;*\QYZ<A?L^,!% +  !'4-#9)9R+*
M@D!VLUU,_2".8!:+SBG7'"MQQ:G'%J/4M:U'*E%1/425')).Y.=^/0(% !1H
M  !L !H/PJM/;B@-F]?RU_/?7]]^-G@=)QWQ]O+VV[;GOY#MP+TO3\_[?(55
M_/@=_8^O;Y>WM^?;B0>7E\C3>IZNU=6ZU':>4S*=8:0[)9ARVW(DUV(AU:&E
M2VXC[JHI<5X:7@@K^G(XRWC#DIY_X?YERI4BDEGA#P)D$G&DR<=DGQ4RE 8M
MCMD11^>H'48RU&Z/$O"G&/DQR$D!33=)INE@5;I)T#%2P4G0'BR>M--B=664
MEEQEJSK?E(S+"H+MDO:=(57@%R%U*=@V,QZ!/B--H0S,FPUX6PXAWCS9R+FD
MO+.<1S2(\G+N>8J\NYMD9*I*F+G8T,;\KYUE0F1<6&'*P#'GAW?*;'PAF;OC
M.DEOS/#7*Q)55U2:*W@"@6XMNJ-&HLQCDZD/PKU,L= ]0(:"[J0WIMN*B/(0
M_1+2],?>1%4].BRD--S_ !7&9#:I4B,XQ$<1UICC\-\41W5(B*5Q5?Q1\"DQ
M0\VCQ)WBY<YFR7$:]65B3E%E9GC*>9)CR)$Y+0KT8S-TEEQW!G?PVYR.5<VS
MN59=+'S<021/<2(^; H3RK!ZA+D0$1J7'4?+5$+:%3\77%; 8K+=Q$9^36VM
M?:R EMM,=YF+(#LB&ZVEH-*A.QD*C2&%-%IQE3@4DJ4<>=H\"?\ Q-,@*XC2
M1&2*Y)"J!P$C4,_F.J4" X( 4#IM5![GEY:"%&ZBK!P0R,0\:JII5;4K2?"I
M4[:&QU<1Y)U+<:@3&I(L4R[JY69$:,,K+?SLJ0U(G2"I3KK<!IR,Y8^,^L],
M-R.\IQU3K)=U"^%I)^?18G*L:3)DY@86PT"&<K%,JL)@W2EP0=;];NJ@B-F-
M(';BHYCS; PH<B8Y$:8<"AV*.S;Q]?D(Q+O+(PTC%,[VHHN:XLOI'1:ZNAKF
MD(CH16QE5S$U242DV=E&DIDV$9*G&/$9GJDN,V<]AJ0T_'=<C1VU/.NX/JS"
M\/\ *N78'A[PUD*)<CED;<QS1!+42DK*D.7G!Y5+X^7E32/C8LT4T$DV++,&
M(P?,/!#DY&?GY_.I$$3YLC(A)+LL2LBQP)\(,<D>/%$)0A 5J11; AR5_-37
MW+'5<.\T!J.YT7>T+:ZY#U99SB7&VU!,V#81)ZWXL^!)?2OYJIGQ'H+R3X,F
M,^$9.FY#X6Y2.3-%EPXG,X^9N>8SY)Q4A$\F0\DT,T;*S3@Q12K'#,9S(J*&
MC,*L$5>1E3&:T+1>2/*4!BP0  -U  (;JS\-%C\5ZGB=D<VN7GQ! 1>9FB]#
M0N8SR?"39SY*]%5^L)*@ IZ%S+@ S]':KEN'+:>9L?7W+E]UQP,KT/%9C1GE
M'E6?R+XN6YF:_+E/5Y<:?;9<119"ORZ2DR\5=B>6M@\Q4"B,V1F=6_.CR-)$
MC\P]R>@,=1I)NC'<>8)([/\ X= &&]0\C=-R+J?1Z4U1(TKJ^O>+$_E=SI3!
MT/J6-*\,."-5:R==;T)?M+0MI<25;3-#S[0.M&MHI*76EN6^/SK($,<V5C+D
MXKCJ3F?)NO,QW6R.J3# .= 0>H.D*9T<5-YDZT0K#0)U$(W0XJX9@(WL]NO1
M&T((),9(.@/$2W^C-2:(MG*+5M!<:;N(R&W7*VZKY-=+\%Y/4Q(;:E--EZ+)
M1^]C3&?$CR65)=CNN-J2HV^/EX^;$)\3(AR(F) DAD21 0?B4F-CTNI^%D)5
ME92&"D$&-(KK:,C1G<A@0:U((!LD>A%@C:Q?&N"$C<G'< ?T^PW\ML]^')=O
M7U_#38C336]=ZTN@#K7H-/?ZW?>M1KZ]N'(@I" G(((QD; X(\O7;'KQ$X?
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MT9C1%!Q-\\.U##927E-$37F9W4.:V@6\Z[F4-!6Z%*K&^5#\7X(26(HMIB
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M0DKY]NIP:''H))**DSQH@(F]^_M)(!H:>[Z%JJ(J6B@1*$MD )0(:@54 2&
MP=2S'+AA_UUWQ45BZ[+LL>="'TN&7)RN'P^F8V+\7L@@</,O:1_RYJE@CW3
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M&R![V P.]/D$+**F:S:@UZUO/_2MG<L7^^TB0K<3&OFY]HA>%JR>2*%(:D_
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MH(>DIHC]Y-7/A$T@T169#,*&Y\+7=<S+"RF/7:SJ1/G32TU(_T]=,^OBAL9
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M$JD;;642SD'(^E)@E&QQ(45W^OO(*UVX<48,2J*(K^3(&,,-F!UH.II9_;
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MTL]2:.JLBM02*2&<_7![=$-&T'ZIFOGL*B8_ZB#E;S'W2VQB=QDO<SEV$]1
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M7(^;^U1<N#]*P37IBRLFX"C1'TDB(@'\[+-?DKQ!$Q]U#T/K%N>;SG= J>5
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MB%D_47Z:=W".G]IT>@W\9A'S@!O$,91Z6G77]^W%MOP3H+"%0,+XW.&F'VF
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M6$*LCX'?H"A% 7-]%P9^*DGT%T691I'=[Z@W&^W@[R?@<6%C]81B-QX3UT]
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M+EV6 U''= BF_O TP*E/$7\LVLBY/FC9J\]CSQ0F/U8%V@/2:6!Z$A 950$
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MS!H_,VNS[\_$'1QPJ\G.[F.MSI*L+BY;D3[J -4L_IROR7?<4^S/J9K&S_4
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M09-0*TZXPJIMR4YR1[0CNSN>P9%!0M6 "N4GH>5U(Y.DQD?BR-82=6)GDY6
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MKBNPZ23.;PK4!4/D?UV]2.B]'8-9+J54X0O21/T5XD$4$BWR1A?1VZ<2U9^
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M*W48_A]X2YD5$'R#U&OC6&PT32" 3D/\?:EJ(\&(O\T6FM1@OUX;G>JP3NI
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M[(%,JD/480_\F[ OSJF)UZ@87".L*)A0T%%TD !1S\8S%_17B/US(-V1\2?
M:$I>U+C Z#UR?=_Q=)BM8A!B'O *O%]:,^?GD;0IK!R8WVB\WPR7=\4]^2Z
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M0E< 6&!,\!>)C[@,U&XRTA V_12*55=Q_J7,5!!<H>/#IVNTN?CD=W$9@1Y
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MNMPO_"9_"SW7'<)?D8)\-M/4-0)!L,I<2*[6F6'C_;1V+L\N'O7O@,#<'&*
M&'+=^?W1(&*22\3OY:B^V9N_MUW;.KO*M:/+_*;,54HK)7PTK+$R97.3YR)X
M&$UD$!B)\+=RKP.=<-;AO*%W0"JWUOA%ZB-IU<,PSN26\Z?C'"OUSP^!0!*
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M9RV!1?^$)()SR-[J#IVD:\X[ /_AFNP!%%RCUL?<5(/Y#LA_OJ2G@Z;H!0$
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M@3^U$-/(2#(Y76 :U#VDMB@7GR3J%IZ& * V5XHP=_P!7IO( L-,IV9)B<)
MEJ5M7M5H&;I47%X^?C[G;JZ+$U;<UJM_L!5NF-J",ZM -\U-2&^'/$<,!Z#]
MTC,*HAH9!95R3)"PRP)+D^<$"G6 S78M802\]6V*A]2=2!OJD!_L1T5B.@QH
M]0-!Z]:ME^E13_P(@@Y"\;N!:@F.2J3,_I%-%^\ T8KC;/3RY6,>\@?;SG,N
M(FS9!A3(N)-K)UE)V]J3Q_5%K\>TA_C6P?-_8X6^PH*%I=@6@^:ZCU'L>45^
M6GD#2),]"&D!\")ODGWY6Q/AK.4AQ[_KPF$7ORH1W=F_1A>B <_*(T9G%)^/
M1FLC.7,1*Y90')DC39/^<0B:7=JK,X5L+IQLA;$3V(K?W5[XP"[J*T*]UL@O
MMNR[G^[/O6312HYZU\U"2@M41#=?1RN>+ODT2W2IK^K..]@,$8T]A=\!"N\
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MI/*M18,36ZH8Y"BN'$CX,&L)M9$U(>C-C8CX%(GB>.*((0PM.\+-V5#B8JQ
M<8/JZ?P#!VX:&A0T?L0#YY=FSOW.96^2(.=?EPZ_$GQ_M U"3ZKZ"IX?*PA$
M^UT$@SNN'Z8Y3UTPV7N]A 4_72^^ ]H/^E'%^V[/,;/1$7&XYPU.UIT>%M7T
M6IH:.BR E>.M)=5)S,I++)U9FDS#4HR$V#DLS)$[U0H:87V?.OZH[^C;5\9Z
M29%XAES^V\_M%DV53T&6N)[VG"H<E+L992L@SE!,?_K9^W&%Z)IJ7-\NE9G
MK).0\J,C\!KM<^G=2D1.B,/XTF;SN<UYW$D[&$&\X [CLBZA?3]W]Q7V=,KG
MN/.UE7:K?;?]=G>=%-:(M05\!S#WB:# =^?!O1YR]96O?PXL+4&,__LP:N+\
M9MJW?VARH?C_6Q8AA43(.ODF^\T<>I)GGET,Q&0W._0(VNK:"0OSD7BUBQ0E
M\JP_O0/F[<PPU][\B.HCU>I'UYH: B5_D>LV\[S>_QT@/9;KO]VJZ1V*WVA*
M8 KRZQ#'"W3W[W]R"L@OZ'Z]:&]'%J-%F)E_JWAY9$'9'PCS[1IG>,XXHZ*$
M"AN>J.[7?="M*:!GL %#TA"Q:FE:Z?O+YQ<%DI65Z#LG7/$B29]<(MW'E(65
MVM$0V1O$;$Y4RU2:N38)!O>]G^9,;_@_RN]Q[B;^T@0MI)<PUY?)<\1)(CF)
M+\^>^2U$LK.4;S!7Z&:6Z\;<KA)=$0FU#-FSKV2P4#/7A5QGVY/:*D>T FD8
MG,)H,4W^UF+?(H^93,[A,I5K:2;>X6'VK](#Z<[Z2 D4EK]](WI-I]N%IYMU
M&ZJM<?LE;3,P4W3+[:?9'D#LGL'.K2Y@P<TM]1\#7=E9_#;YU?UE5E=%OX3L
M@X)<[%[RIEY\Y,&(N5(5G ,%"7[L5TO$CB,4"-Q'AOJ(X>ASN8OR5)V9 Y6_
MV[V@N%)S4O9"<_1KGF@'92W%XPV&J;DOMWFC6HE_S.GL"0>MP&KYV_0 6N"#
M(!;$]\K9.$X)1K;TZOOF<S427SY=$8"G#2QQCL4]:)K9WQ^4:5#L"W@'K.WQ
MD8M@\:S5"4RFDSIG?>Q8._TY!YV?$IH;6'6O4)%8=6XM8Y28+:UBA!,+@4.C
M8&/HYVADT BB#/Z/S!K%/QO?;XO+E;1U^;STDU_373'?.%![?I]?7PI9LV^:
MS'39.^8Q+:,SP>*@)Y@T<.N7M))D^IZ%8]LZY!5+P_YW8.'*-E-9@7-8E,X4
M\'M?">2@>]AQJIC%[[9=@%0_P9M<\_6#H!]$A%@NX-69FL(]-1/K1ORD^AW
M+8>#3HS<1#$+ *(#ZBE3N7OAHX^GM_SN1U]=AV<^^2[UKI/(4Q._ S)?FO9?
MW@&*'20"V!BOK[=O;S"_[JMHRX!GS%'"W_RGO&<'O<Z]PK*H##(]#5LW\V^^
MSHV4>A?K'Q]&-E[:MNSL?)_WG&PP=WK;MY8<5A_NE^RC)2*6@:0WH06W(T*/
M5/V&Q:.V)$RD=,<R_RUVMMEV<;WK?$+)P/^Z%24^6B#.A^(?C' '<)K0[!$D
M(KWG]A,D#TP4> [P?SX9:==%-Z<Q/?1.7T.9Q\!L&/-G.$<;$6H'71QS(_B+
M;JGPOGCED,5R_PD)/;NXA7\]/-,79=I49G!3E(E08;*)MT7?,*A;%Q81UDRT
M;NV;$.:K?57=ZG"1A]UO%)>Q4R%N(%]=[BV)K%KOHF19*&9]:^HTROH>P7V4
M09^@S/'[UCR,RGC(BN,WF=<"$&)'+:+&D+='71GB]OD2<Q "$CRO:,=.[;:^
MK8_4]E98F$S<Y9R;@_-!3,.)S(UO1I- H_SW"P034$_,,&#@J<%10"^XT9"D
M.?T+)UYY++L!Q)892FP=VJQF<-Q>?BAQ-UZIZ2:K,/B]G5R.9#].W'22@J0<
MWG40U5M!+>1D)%]7Q0!)Q#- 8A@,HZVA-^1+6?HGX=?X:<&VHM1*'7<.P<!
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MV//^98;S<M:JBDI.-X3<8/92<U?#Y)QX^\K\,NBHYR07'KR)H(]TY*$GIZA
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MI^?+Z@:VWDP9U?-=ZT9VMK&"F8%YW,EPC,K8:<08Q)RP,D8 %T6>)@! 4 H
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M.5E18,0S_W>7+8491X[) LFGM,E8I1F1(@\R/QQYHYDT;BCV:''+Y"D >'G
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M6BUZ*5:8/\.MQ3_V:K* 315"TZ^.GW_*%@L# '#] 8! :N-H"79#<JE(KX(
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MSH5BQ/5<]/YR6P__0#O_4+]R4V*UZ+LUAKLTQZYF^[-]33:HQ]:)H''!SHE
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MKN#>Y N#WYJ>R9(^S?-N:\BO/)R=/:X[&1#Z;*O;A9C\" U,=@Y-\%UU+NI
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MJ]YH*L$8;DSB8Z<XMCEXW#]*//9)$_%C2@4?P4^AS0PN;(P/UW"<DTAPM""
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M995OBJ#-P>X(7&3B21&. @+E8VMNKW!0OAF4"E\ISC_:.&)VBXB9IE&CO^Y
M^8BV?W]/ \)CQ;2AVC/=>[.67._]<_,\2\Y-2^!R/.B,CZVC3UXB5**QK&PX
MS+06OQ: LO]5U:8][Q+/'>@%1QW7Y\A&Z<+F !;_7HKI5+M_UW$82"\XP/P-
MEPABB"455@K3&&7C_<$B-&%9Y09WO%AM/2;$:MNNS!IE.FX]FA+'X57C[X>5
MD;X2H#@Z_T4CTEVE9%D+QVYWMJ/CN:Y@- TNXFI+^DU4_=<:"5H:,V%BL_H9
MW>MIR_M)6(C\B3V=>? GP,K-2)4$$EP"N7FQ@"G6W&)#R]?Z0AG_YYMFF)[4
M/ )LM@]*=L@#A:#GL,-2%$H$6A,?B=]0^&+/VKH36UP'$=WPY<UT'.&,616G
MT]*;5*LR47C!AU2 ,^N@JJC(/,>KS?/,QT<G'KL-Q$?K_1/0\J_MM74WWZF7
M>^LAZ4!HH)2M6T@0>->[N$GDXF4Z)A35K6LI+Z0_<G(92G9U7M(4O5ZUM]'<
M"CGHK#&O&^9>CR8?5_VG9;WD"F*P*))9:<@1?/HM%3BY8^NO'S_BY1J,)MG.
MHU=+[D7 \5SZ%-/P7LJ&[:L^W,F'C,\@:I(_5CI!A)\!)(V4EYI7RXMH,W&#
MKMSFLVKYG4D13L+^"6@.2+>W[(F+91[=# ]+/QS^<TC37EK5/L&1QFII?D2$
MZB%^7[X_4 %?:51O\]?[7!E"Q_B<Q=G [H?QKF['.L/Y\"VS8Y'=G6#HJH4[
M"RR;-L$,GV.^TQ^YMSM"G4'(O H;%*FG$?=3SMPFKSI[,FJ&#/B+#@GK$X"<
M@@RR78:-MZ8NN;_'X4XI^&]92%CI;-T,<I=(4-WF'6Y"MHN$?45=?NNNO D[
M[X*.B,AY4L0FI.XX4R-=*G;4)-)^5C93A8>H$\O>%,S-]O>DL<W^93LFT[#6
MJMY>=]>"A*0WA3!GF!D9BZ;C84TQKT"&M??-(G[3#1*>[<$QG>.JJ1!ELK'"
ME-DAIRC/RK!+G/O ^-\)V'*R:SZT<DS@T_#:R+SQKF^\21F^B31>W4.>1> S
M.*:;[-X;UW.D!!=J JY=U*R(V,_M0\/'A8A=1[_R>+V*G\_)+\P=GWHZ:[>I
M-GHJ[?Z68681WY_9(C9FTC6MS\"P(,2$7R'/-"B?5 0%MA-K:9QX80=GPZ!^
MM><5O<<I<B4HZ1#AW>S2V"/B)IS]6++N5G2Q$**^K^V?+(NL9/?[24URN,#H
M_KML'C\I39-_1YPGT8J=2#!K[I&%I]/5G.@7D4P50T;/C-*,(FDLKQM<DU6*
M<C1!7VQ:E//V 2:[JJ#1'_>@W6@REE%5X"4P8MG?I5(*J<F%N/YMBA&I'1E>
M)16-)A6YH 1Y_1^F#RIBUVF47_$'RW//N+T;A8YUE]^$G5,AC\>DX?GY?-I;
M3U*UG:I^Q5U\WT?ES.)ZS8P"%\=* G[M# >JUNR1!J0O"5FFWNRI.FJ-WJEX
M37;,B8UE E,D'G8%-Q<VE@V6=@&[<Q)1D\Y([<M)QM@H#PJ^2E%9DAZOJ4HR
M=+ F-HQHK^,_J275\OL:AM;!S6&_A^)9R^GLENC*9^/R$X:>ALOL'QPIQ#7.
M#!FK8CNU.]Y)\GHWSZ(U[(A6QM4"I8SES5]K9/6()#3]SRC_6 C%A)^V:Y)+
M%]_>R/&P\C[E81I[!B%ST>T[@S)(,(W]S2*NHTYB=U'GY3%6)31T(CY,%K2:
M5:O/NS>9B#4V5Z^++-N+)^T-)O;5?#)K]&]V=UP,+;N,"[SJ2YO_NK>F7#4K
MG%\TS+X$C<D+5@L5G-=4:NLVRVE:5WN8RI+15RPV\YK<M]*!QYY4?@[U9YMC
M^\;$Z<).3T4#40$',5AXIK>$,KP4^"8SPC6"-/A:(_[(HY3J'<V44"HT<0W"
MY)/=+ZAW0)MA"7^"Y]I*K]W1OWA_8PW'GO7RDVJM"ZVC&/%,*VGO8RMY)6\(
M;?29?SJ9BA%%M7$N-G^E&,\3[V^,90BM0&[!6K>3Q28<QF%@&*TW'L,S^<(J
MPS9P59"!J*V,(ZJ=2(C1@-%ENH,$C\H;:E+042DJ3&&P:ZBH'V]/1SU@G\E!
MV#<_51=:EW7RU%HE%Z]R.ML?:1N)2B0!QXP@X&P*0I685[\I9)D;E>-#F.!/
MMW<1U/N>]I0VL%Y:P:[7VG]-Q2Z3/&?&[U7A>)NKE@P3CS<QF C^9J&4V;>/
M.#Q<EY#AQ$JY]&Q@\8,XH8(77<](<Z/)$1D9KOL*];H#+=:M,H< M6 ;KM_X
M)$W'0M8YB7"H;[OEKF0LRU^GD#&Y35<E"P3>LM,G$;4/".=A<SYK;]?K)Z_C
MB7-@D,ID<+=B.3#.&A^3B1)%,(U2__5C"*PGH0]58KG^#[:,R@!L%DM%BE-
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MAS.*SNXE.D^0GW#J.5!]0__H<D:^$6>+4$QY%>2B!($IT@C(?=M0E$P'$J?
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M$^!Q ?!I\ AH\/:G<0TEWV_%4\1Y281W2'^$D0" AT](1$Q"2D9^#.^O0CP
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M>XC=Z:SSC7Y*WA&1,NJ]74]T\#[@QMZP!P]9I)+_,*Y?E;5!/#%&,2">N'W
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M#A670$ %)25@,H*B,'&$(!@J(B8(@8J#X7 9$5%QJ1^ _Q40R 6#!;L<_"1
M <<00N) $! 9* 0&EA*4D8!+"B+ XB*"TI*X:$LC)&2@HB+B8F"$Z'?3/ZG_
MO0UP=Z0G'*;ACG8^S,JN8'?,X0\#Y+F^)QNNOPSSP[0GB_R[3Q(R,C!)A)2(
M( P(EA04%Q<'"H)E1"5PS85#)>'B0*BDA*2<\-_4?V<=]F<T#JS#<-9E(&"X
M%! ,%I2 B$H+@L'B$$$P @(7%(-(RDCB^E0:B)#Y;AWVNV#^:1W]OSTX_E'_
M=S#N_S""?RO].6?\K6O^WF]:2 PN$_C\)J$9P]W^,:']:SW\HQ&X54D6##WP
M40$#QKERX/I/O']6^LW@@,F(01%@J+@@#"H*%Q27$(,(0B 0"4%1,4D9$1F8
M. 0!$?EN_Y\&QR\87@YPE[_DNH/<(O4]U_U4ZY^-8- (K!?8':YLC^O&?RD/
M_T[OG^U#'7#+!QRF(/Q=\3OC;SWTVR7E_XVN0X@A< D,"A.$BTA('<P\,4%I
M*3!NFL-QO28J!I22 /X[7?=]<0"*?U\<_K>[[L_?U(J*"DEPG#5'NL#07IC_
MD=T&1;L<_!;IO]%U.!PP[CD [HY10!SD\V^W18ZN<'L.+)H#[.J*0D+!!S:$
M/5U@?]QC_5BLOJ/\9.3_8F-AWW+=_TY3?\2)XW]:H__MB?FO+HE'$_/_J6[[
M5^^3_LUN^_-F^ZC;_B/Y]/\CF1SDFY^?1/__D4__!S7ZW[_1^9<>JHXFYE^X
MOSYQ?']\^?L3BMQ/>T^RQEBP.];#U< =C4"BX-]V5?X+^3]8^6-'Q-@#\ON-
ME%]M_J7V3S9=<<W 0<$\H'#W[R%6T^! (2'N8'<?#J"$T,$CQ2^U?M7V_F[<
M##?H#P:>*%!(1.B;SM]D/ZO^V"PX_+FX+AH&5Q"7$_X=^[=:(%75[R'"&&FJ
M<(#4526!N,5?4%0(^+.9G^I]WY05_LNN[+<M7^$_]GP5R'$=^7W#^7<CZ#]/
M1R!'($<@1R!'($<@1R!'($<@1R!'($<@1R!'($<@1R!'($<@1R!'($<@1R!'
M($<@1R!'($<@1R!'($<@1R!'($<@1R!'($<@1R!'($<@1R!'($<@1R!'($<@
M1R#_81#R/U_A G>!R7-Y<2DJ[$\"5 %X_R8=&/EW;> =O@D=SP%OBP"/YON;
MT%L!;  \ !XA =Y/_R,""1$Q*1D> 2$^.4YN<_"F\\/WC.,3$9$<HR$#$.(3
M$!'CD0!(:6CI3G"2T0.5&0Q/<G&#W7A$5:Y'DS.*I9?7/.8]?49"4DK5J&+T
M/9.XC+$9Q!V#]?#RCK^345E]ED]:UN)&S*MUG'E6O(.WJO_TDG4 @) (GP!G
MGY0,)[8Z>,DY_L&+UG'P.*^(C^/A$Q "B&B(:3GI@">XE U)Z+G!HFYB..3W
M##Q&D/1R4EYQU8"*Q_TG3TM(0MTQ,:\8U8S-L!YQF6=,8(@;@;$9E4^&1]9_
M?7GYWA>W\/_.\:5B1<XA)$\_1/(1\RPKT:B-4\GNHRL20)LQ=^!DW.BF8I%U
ML=KP.V!EY[DVF]@XA1$\D&\M)_.NT 7QI3$+Z:V9C.J9%)"4FK%OC&[_B*QL
M,OKI%C36Y-:[9=U0E$T,?ID^"])R*+3_,0VU-&9ZHU CH&W(C'");4=P+WXX
M9+GB(@16P*E5F'6MA^[\A2(*O>PKRGMV3)%V2WWY"PHE"(_^9X./"E6WZ17O
M1XYH%IJV) Q#:"/R&U%Y-W@_./@E. Z NG3CKZF,M"]UD5NE4(GJ?GZ34//9
M<D<L-W/A+IK;RH_.X=4T[]8I)I.QA+>9[VF+K#X.JUL:)\V_V'FA<UD\.D2+
M>%'P:_]'0=.;_.3+=K;#%H.W;X*.7VW-]PO8BJ7;23?+-'/0=Y2)8LEQ7,V6
MG6[NWSD=+W6Y?Q;AVZGW4B @<,"5D++X]79"_;UDRKK'K,GH=8K&^C*'6(ZN
M,QJ1%)OWF.HR($&H,YXH+"NW]EMSM22G&/6!#HNPXII$JZV&8\^?M&M0IZF<
M38 R:K5H=5X/S] 0DBLL?S%V0^M964F%B[]@#SFP8B2BVCY:I=1[FW6<0 Q(
M7M1*!#,H=C+TYY3745GJO'VOID:=?LSF=C_EQRMM&:?TS@9M#[^)KEZ<*.&$
MM).X1\K./;O#<#K[-'["O9NAM,BA.?/[A4\4 CL;^F7)T#JE(\\?\*8/#VU5
M,'E>U]WQW!Z1%"6.+M"*IV"['G$FC"G+09/B]+VX-V%[ZI56A8[327L)XIZ>
M9./Z:8&I376+G*1GS%*TV1^J^W K<WZ^X)9/7%XJ^W51@:&T0E)PHX\&,](D
MZ<&4OY2<!"IHK_5];ALQB:UACKO+:Q4VB,G*05M/SW-1=O/%#@B=$Z/M-^Z5
MYV8Q)G!LZ+?B0QEDZC562YY:8>ANSQ&#[(S:/*P8![8V)XX4HON;]60,3KG>
MI_4U4IV(*!H?6:2,44<\"X6FUE3"C?B?<A7!':4X\+(4201#Y+5K6$^%\**C
MM&)H%[MK(C8_7?>P+MYFJR]/O'PCSSF9[7J5ASY_Z8N1!RMY47PUE#>_^)?D
M]XX+U^[4WRP;M@.^CZ$OOF)=N2)S[/Q<)]_ZK/MY0>TAK+GNS/B+ZWS/[*WM
M/*QSN1_4KC'9#ITP_2 )#KAWBC2[Z&,/ZZW*D9%L#Q.\K-4SIE_3)TVSK8PA
MTJLZI7<<M[\RERD3UI /A<Z5(TYS0E9N9Y2>&)DPLGC_D+ >O72F('K5VGV)
MR"<CL+AJ'V#(RNE4[13L\2XXWJG8@])B1,A*D^M=ON<<MQLE-]9?NU%)66!8
M-I<Y2CK*DD5NQ'3!]IZ$1_SI7+>U%7$;PZNS;6_4BZ&:4 @_??Z['?1BMC++
M8M]D!T5(D67%Q=WBC+%Z<<RC:B2JJOKAJ5<MXN6HS/S%&XH^\&7D>&RU7ZB"
M1=ZQ1+'W4^4V.6.+4_Q?7[<_+S?;J9^L?CM+P0)\>ZZE15>>F@E.-=68N%[F
MR3%[UZ44L*O2]DCS40,K886Z\PQWVE+G.95I\:UJNSO*T!P/3%%8[_-Q9+JE
MC6FX85:LTH94Z]/LK"10PQOR5HS]H)'>4JWU2<I\Z.14>"'1<6K-LT5*"!B(
M7BE,[(E&>7SD(SE42PH5]M,LX_^1@TDSJNR16@(U;674>C!(N">"7.4"1X^\
MCQG-34(9X9IUG>[AF]X6JHGK]F0K,](=4FUF0PL\92.I#J]8>G@,NKC4I-\F
MLIXHH)+;:/7>C%I&>6R?#FAJ&%H<JYJNOE_N2(HHFPI<">!CM46L<GK?MMA0
M^LC-S](?"VS_=HA%?%I[M1;)X);R2GY]1KK=+?QM[6B-6 I49@<JT_&VX],^
M@'T*TZLIYRXSFZK0>.73K@]3'].J=+MTN^6RTP1I9:]58.9@>Y6LZGP##%)-
M_G0S._;U-J^,R!@HRI+0>_1M8X;H[$->GS#S6_+S$I/%I$4C*Q*NZ42>Y7PW
MN=8G,KCV[F5>?_+AO30+Q0"_N25%CRT-'T^BFF$H&5I )W"5)\9';L-G,[7-
MV)&\7.A%0;&S60?^4\<5\AOAST+=NC7C[I^4BO:'W:^86=X0 O4P:2["FX_7
MBGPJM+U6N"[V1>2J@?EVUA;!9I]W<,/@VML^+[3<Y[?R6^#M*V@-8>O:VN&M
MP>&5#RO;TFLKLQTLZ[OV8\/,=YV?B+)"&OE-LQ*29E55VLNFKYRI>-EQFH:2
M(JZ-IW_:(^ ],>-CBKI9?;"#56RL944[9.0,]%)^2E4%'5"%B:*U7/3$)2:_
MW08M0E<-7ZX03[P3ES3[<O#/;NT&DU1>WW G(ZF-4'[Y-EY<5I8(Q6-\+H3L
MKK&3,VG2LHJZ8P//*GOT==1EDJ!H<K\NG?:V;$;"7.-@=G#;+-,;C?F*MF>%
MO$_S+Y6G&K5C67C:&NI%[_/PW/R8)T=,($>M1.(0Q)'.S)$A_E*C(R$RXL5Y
MQL^PK[27H^\I.W43HF W!3R84PGEZB =VJV!EH$,HGIR#".=2IV 1[IA#N"*
MI=OD0$'91RMU5>(W>1W;K_B-PJ)Y_1)2+>YEA9F7\X-.U1--L]3#O#@8X!SE
M@!BM/H8FK)EZ +VF0<DMVG,5>9RF<6<I[M,".*Z1 >RQPPS1,&]\ 9/%HL\T
M*@DGK#=-WX5J9JK*1VJ[7I-U11<!=4]^!D(C<B9X(\<: VMW&C?X$Y:"+00M
M ^%P'P:^^7"M=].=O31QY[DO=S_K,ML@E5EZ3-B4HP6)N@]76<_\4$C%9%ZO
M[P!^=>TES<M/?8U&R+NPZ'7#HDL84)AX.Q"//DA'E*@\Z89 0MF9ZQO@)%+)
MUVD>_)XRY<1*3G !B9L^ZYY=9I(H+Z[.D"M(&9.[Y8DF']T+^;Q$S[Z400B0
M07N>!P?(,]8A-, +N13]ZPOE+#ZP%=LGETL=5F:OIXY-3'LR+H1J>3-:Y)^G
M$62Z%'W[%B%=K@[XF'- SC'ZH)!8WH0I-TH%I\@'$PQ5Z1;:\>&O>#:[HS4%
M!KI8R,U(YZ*G.<TX*EJ+VJ!&2CP<@"@RII@.9K$*C9 !Z@'1@D*M1ZY,G8!R
M@D<"(()VL_I"L0[&/K*-Z&C=LJVL$& QK<4CBH7YB%,P%FBJP761"A9GH03C
M^A8HQ0N3S57[1P,G2EU@>:M::O;GLD-,!53RYN]>.TZ>V77F$=M;IM4WTAV,
M/Q^]M%G%?%;T@;P63V*RWI)KQQ1Y/8E-\6IW2[%GPIUFI?LNX])"./3?/!!W
MI?A\%_$?#_-;IQ8JI4U6>@W?479R[I@TR=\#)CUR'H9*",R[B%=>OX<P#0#H
M<81']-!&*.1C$@UZ\R.;WW%/3!3VWQ[\*.E1Y;'=E"R6D1#RR>7^IW'*\=KX
MXNYHD,U]6.R711E5);KGH3=*K[Y.K4K.V9X\WF:Q,VHZ.$E5UC1T^@KY=J!S
MPZD]6@_7DHQ2+;N1D01O84T7/@Y*%<<>ULPS[>.J-DW,6Z4&?LO']B0?#M5(
MQ-XP>>#K&5]4=(YSI*2K]HEJLP>Q%I,CO $^J<=@$"H;T',[+42VRD2%)]=]
M@4J+Z6[95O.%GL)FY/WSKA\?Y*&\Z/&)1YD9[&TNEW41/XE(#3=2*9NA>6;F
M79Q]@]*%6IWQ'F;]^#I^K<%"=?D4JP!XR)^E)C;[@SZWT'L7AX$K0PR%4_TN
MOKEH.2]X=3:R$)6O7Y@0,]FTJ#T"EUI&3+S@MLDHFLFR3!RKIRJ5++EM?Y&&
MS!C2N*U]6K:+DR#25IQ.DCV9U$(E7.9SHHXV??3DE3LLVZ7)UD*1N78V$OK=
M]XO%;8YE+TI.\B8_0Z+U!;6*-NDF).3)N*.G,SZY^XTG6@CGE&,]=FI+("],
M)B*R&\KRH>LW"GQI9!':LM[; XZ.H^,6&0JGY7U1#R69[H=)+Y]Z3,%'V^CR
MHF&\S(-J;M')L=5.Z?J$().O7FY27;.=@0A<9T!2CC)+$[I$V7:[E#N@4%,/
M(!>H-5']T-&E*TW<CP*IH))@Y"R51!4YT%>4T)N8.>KO91LPL2V0?24BYQD?
M@TZ._42/X+A39[]=Q#SY]B+5:*$H [[8LZVK5E_/>L#UTHM+%JO*FU@Y_=PG
M-FUOUF*OZ)1.J@Q7.QD))1839S3MK(\/Z>=/VS17<LZ.F\:UORB8&M@#H9RH
MJMJG3R_ 1[99J^L@!;+#"9993_"L\T<<WQZ3OCC=.VZ7!*F0+YAE%UV<>W:S
M4@M*P]G1TE'UN)2?^OZ"H*E-\QQ()>?%ATA5^94&,11*QV6[IQQD*SNQ(UE8
MW9&M8K7(&=$FW6P%0FD_8YZ_M];:FS6&?;(=WC"=>P&YTUS,M["#I,&><%P2
MWVE2O[OVS,NG;L0VTI1A$F,UV]1P0G)$.9?25R*&GTJ]P7C:>@EJNF"Q)ZPW
MTN>44SQ=?H:'HW!H5">YVDDW7M#VNF'GW8+&:Q5JWI>J!9Y?4F^TYN,F8Y:+
MB5LR*MG:!UQ8+$')])O5GO+PTELL5$>,/(:6ZJ#S J;3F0(V$L_SQA@3@ 1Z
M3GEN;&1X)NWI6WOL XP<JUH]4ELLY:X&R3L/U:(,1]Y-..W:)B[Z/5@D?M20
MZW&MRY9\P8-_-&^@G><8JP]"E"=[L+C L6>HRB-UWB_&Y&O;@M2%B\2%#P2D
MH]U;V01NC1"_MG#A(ZJA$,@@3](FD1&ZO[ Y#GRM A&7WG$IR+9- ^GJ!=5P
MFAN/["DKKP:7\SPOTB<?1H[G A,%E(SJ!=F1$447PF(:*W1&_%E67%#[ +J"
M%:GSNX+EB_I/A&Y-M15YY[68S?;1!X_Q2@]D/*U^-PDJ#8QP[8'"P:>13AUF
MS),";[O$MD8.;F0.#N552\%=N07&%<RYL'@VD18(KZ0_'KF9H[L)20J5%B62
MZ9Q,E$(JQYLTTMWB" 473B/PG9,TEDG.0L\(O/F-A[/<4>E2PMJAXE85&^J$
MU)T96EGC/<<T+U7U5W2QGJM0%@D=L2Q6\@[0;I&X]71!3]FV0$R3]WDA3X56
M>!</=D#=02DTKM RD3>\SF$V0(_BED;UTA6=B\PLR;T"-:.(W-=.F70>31>+
M0DRR&EZ8%T!DC3S&I&'9I)=K^TE.GJ C57DO,IO)IW%ZJ7CUPW%'^4O%!B;9
MB*U"C4#95O.">VU66I<8SD"T-8)\X-&)P1C@9KQU:-6$P[N>*I^<3WOQ\A<I
M':=#E2M]]76M*T 7@.?.-58P9MZF-X@ZV7XQTI%>E;?"H^GU BB:R592);I,
M#T4.SM.F#\J$+9X$(34"0C;I@]G4N;1CQ4N)J9^^6X&W"N&O$D[E= ?R]XN\
M;/1X.3H=GBJ3P!^7'M(X177B1=@6P=0H]#%#A\T" &E5:3D:0?\F81X!8*-9
MFHA1*M_3;Y%'ZK/Q$D0YB?N-;]**BO?$&6P7!^/SD[ S<NI(4K61[@RT,.Q<
MO+5"I19.D#UON('/+%)I6H^]_/"BOA:,\.F'6T/<0=*K _%%2T7G-5E*KI\I
MEHUXD^LI(5 ^1M8:_4!,V9%N465O <*\>V[2ATU[!$IM':@JRL\0YA#Z"F7F
MCN=]ZW))$8,%[#./[4@8"-9K!EO^MGTQ8M_&2VY;M%!*JG&QVW=M@=.RG2[>
M4]M31Z:[<I)IY>;LC$Q?C<*795F1ZU[HKH\+]]ZQUW\2FV63<_?>4)SI^[17
M:3<DV#2"Z*K&?GC,:K/L.V=G>.I&R314A%""0)=?/*E9;^ .7P$P7H6GNBL2
MTNYR;O%&;%+*Q8*3=A+7 PA]@&)"^OJ.D?J#P0X:05FE!>F#7E"D((JD5;<Z
MHM'3R#5A=,M\9-OH; #-N9AE*/H"1$;1>%6S;/VQXD>W[8\[;M$FI9;RR(O;
M='Y4Y_.<Y$];VWT1<[ABR$+I>[O(CGB[)N#%R23@W+BAO':"MW<AO2^'XKT6
M\Y0@UI9@FO= EG.ZY"J.#K*^3?N P"LFDMS5PQ^JN@?&'S!7$X^:E@70L<89
M\QAUODB))2,UN[2W,M&Y^?AS<&W=UQE%N]HT?_\4MUCUY(*ON57QA:ZC0M9?
MV^PS%U*+%-B$ICUMDNXIX752B@VQTNR:K8:E>#;HA@>'I5,*W']R*_JI'\;T
MO1W+!0LVP36C%:RLKD(WZ^7J;3=5>W#68K1M"MW$57-P8?F[I52@8"B/GT!Z
MXF!=!S_^%8[,:V^[-E_2K'6PN\L'$RST*4[&.S:;VBBC]Z*U<Y\_"*LV=?#3
M?\TZ;)M^L]&4;^OD_*E^\6(:$O]TS5$W=&974((UW^O(@/(N]62N'=B$> Q/
MAX.9S,T)&]N2[- 5QTNIPT+Q S,Q52."I/L T?*JA.*$Y%?+F;0&YWK(M?*:
M DTX>=)\]CH^L>M_8"]1!UY!>Q !\Q^X7O7R,(0L]*9+9>\DI)W)T[)Q!D5%
M3UJ/&JTYV=9G.EDBYA<\R1\=K]>X0?P<[DO.QFRTZ->'3^/@\X%VZ,W"M)7M
M)*5G FO5^K+X>DF!3H+IV27TTJ5:Q&O&Y9;S> B-0'B"9D3%-0LV,@7,UML(
MN<V.NI<^)&,^B@^U15D-+BMA^ ;;JQ/]7;+]ECZ:OL.\,UH9Y+!PRCTU+7O)
M7#;Y2AZ2427%VF@G$8(R3'>QO.M/Y:\U5N;*$?V91L18=Q!/LI:;IL\\1Q@U
M\A31>G.ET$*#^1+,\@2&]:6C>/P>D$>[9/KIWMC<I]VT#]X[WA_W(A6GJ"S?
M+35XQ8XLB"^VKU3?T19VV%8O%/!]N$Q<'BF4\Z)JR//S!--+0[!#Y.2Y&_+(
M8G%=Q QV@JAKN29)L2LC +!!>B%R WVQ259 M^2:A96OT_.IDE$6_76OI38D
MV].$!++NQS*6+XNU-/7GWO3(&$?*[6[.;<AYL[#)?%TCZ7BH+DG9,5P]FQ/J
M*C2M@3K?PJI\F<_3SK 2F'9C^ZD,O=\SKF<&9&[5M.>&[N9S0@3IR9C.GM)!
M1'-R[ .>9B,RPH,E@.1!]^@I6:^T.EL;&Y4/;U?+FZ"7)J-TK9Z:,<J]=A(*
M?V^AED!;$"(O/1L-LS,>.L[=M6$><YQ@X6W?VLK:]OI6W_,SFA7K8DU"[Q*U
MY$,T1F^=P76WQ*>J%H[0J7 A(DZJT\TGC]%$QIUH>8Y\5'[#_C%CFO%;^K=1
M:ST?\]97/4&\ZAFOIYJ&S8=>"UG7N2TVQEQ^&7H<DWKLTRMOPSN[&)YZX__6
M)NSOCL_=1D6YY[1-X]X^P. >_O7\[PVFS#X4FYQ\>![S0NMM@*;"/J!YLT^:
M)$")QX]-OOG.I$RW<<HK2SW1K(_OWTJWNZ=^6DD=WYE]*%\YN119*M<!B-(B
MC(0^FL.L/?[(,ENC*'#%;P]G(VU][XM]X_':M;WFRV ^/=,47NGNRFG+=F!X
MH70'"F[9\1"#P_1_,>6N7__AO2+X0Y\T02J 9??K/J"/2=LTHEL;$_&I#S7+
MU''9'N>>PO1Z"E2Z;U)Z+=)?L>/C[NSU#A8JA2GO79RW OGGR[BU8LE(3O(Y
MIU*B:CF9[!S4)6ABJ.]$A]8G<LW>STCMH1*UZR&+^3SYJK$?K,[P9*!H7+4X
M_I6.)"(@T%*5,:<&1OQ(XYRNX_L.B?S11G'_"M7W75Q5[F.WKS,IH_.<U!V=
M_1_>FW[3W< UD5^H/7\VT11F6-;LWJ;K+"-_)N+JC829-Z+FT6=*M;VG04NM
M02U]]FYZ>;FU*%XJV[D!,Z8^5+Z,#I9$4^=N+W ZZVY-1='5X)5P_M0=V0BM
M+RV7KGP&%UY+!R\K.U?4VYUY PQB?^?3I\"?O^O7'JEUG/NF2V8=S[*"OA=:
M5QS<40OI[M3_LL:&B5KCYEC/$.@7C?LL%JKEEB:SA5;396BT%XRDN11^=BQ7
MAYL/T]_:J<AT29#BP:;!.+RZF$\B N)W(O<&F% +EO9J3[W<2D03,Y8OJBG;
MGE*:#Z%/S6 P=9)OI=B@R@A%M6FBM=^$38<F-"E&;K%%/$$09IE(>IPNUWT;
M%[QU=B(F=0!^>TZ;+4GLV-OXQ/Z#!S^8?MU<+Z*$R)9-*R]T.AH>.-IOI"23
M )OM2+:>G\B&@-KIKR,NO8OVK!]S-XNO:4VY=,O:Y0R3L]F.1:9D5JTX2.(*
MW+)&M(.#\L1M@$G^B9X];_LQ':/&;KDJH[HYO["]N' .+>ZH#L'QV=Q3I<&&
M9S!CWGT#6@6:$(NQ#8+VK  28JW0L/#K8;=O!A%:U'E?(KQUZS99%A7+9:SW
M2ABU2MD+D2"-$XAD>$)T.&_-\[A9QG892_&*L23+-UX)R#G<35.7?8PE8T-#
M^<;391V@ HAG;D@M3#Q"PF+V-CW-"2(3-3Q3D^-X)@# #EY2VN+)/+P/9OVF
M0C46V<;W 5',]4)B)6=$/W::I_F.<)G'OXIA?LH=G6-NQ\JD$Z V1JDL+&ZL
M6[YS,GW'S(8A<W9-K7]94I#.(DB=<&2T&Y#!Z*HM]I27(;[NU7PQ'8=WG]=\
M9.MJ_HW\#RHY#]'FUADQZB!.Z*3C<SF;5$E",@8>&D&$@2J/)R^(7%OZV==$
MKZ=":UG%%L!&&T>J6A*/4 P?:H02?4PI9IQ=9E.$I^5"\5#]2QWG3C$N*OF6
M7M.-B)H%Y(Z]HXG&3,(+2GMKD;GTD"C;>C3:J%+$J#$&X@"7\TTY7H\];MHR
MS*R5A319?E?D46,80Y"(OTY?UK@!J;GUXM2U#+"XZHZ"[F C=8CLHUT#E.Q4
M3CJ?N:;=*?9NLNSPN$S8X[J)R^>DD;*VO,=H9=I>HL9?%XH6:(<%4SH/.=27
M(ZL%']]RS0@KW >03V-Z*UPO[SC3KX'8U%GW <<$\Y27$Q\O>*9E AXV!H]*
MM<8TMPZ;1]X.V0=DE5J</T<WN=1!F,)PVSL)F&+/NI[ZJ>^A6&2.V^>-6('U
M=F"[J$23LV,V:=T[57^G2_5Z86"/IJN&$9[^2PK2,LX5MQEX/"2'4!RM#SDT
M)Y81RH.O+TCCO4'1](BCI; &<O?+5K2&WF]T/N8V4N;P8G_MCL<E3LD-T,YT
M=7?6O?R1X,'=2Z4GMVI6+L0O:7@+CB]J:1:?Y["/R/9(FNJ,>/Z80^-UGWI?
M'E(C69)=P_!5JQ^Y%7>-Y+HO<:^LWYD>Y9=.>Z8U_+K41?/^X@1N,?!&7J;'
M0G!''?\*I8?R7I@NPH[CP/79@&*>:)FW?>MJN1$*7RC.A!5=$C!+>GI]SAQ6
MTG4Q(V2/CS/&/L)'7D/THT U_]UA+A>;+&QPUKU)H(YUS]2#;B^[1Q$S268=
M 7$D8,?W-/'0!SDY7'=O/1AN82IE$O7D=VF\EJ-.,?!"X7FW6\3G8K!4V$91
M">C8L4AM3W:]8=Y,3XB216;B//258=,&S*JZKO=!@]M$E(P%4B\CM?U)##XC
M?U7,:+EXT1(+ML"FTM=21T!BWH '.6<4* U^1AI$0='.S*/2YE-!?!9R2J>(
M^OP*G[-"RS-!(?$E)V,7R:QB<B/3\#= 0EI2C@!E0E=E-E*.SX3L;O$7BL([
M%PV'XN&73./CHDRO P)RHY0!-SJY4U:LJ%^;!-/&IWMWFP3FDFO'IJ&R069B
MX;/2'WIQ9[G-R4FYOA)@&K\S%931C=26-JM8VLJU".S0>R)PEKS=CX^\_40\
M=%JF_4!E]LO5JP_%EL+M>T^IF%1GDVJG=+N_+DL!ZW0;W\SEQR5I2VVWF[GG
M>C$W9QD[:H =9]965G:A"@W0C8[!VFU_NY9P^V[JH($XR;AT4CW:FYS2VD8I
MT!K:N%S&)\;A?E!&W#+G!XV\>ME^E+'C/W3T,+SBY/E,(_Z)[B0[$/:XE/Y<
MKV67 ?W=O@N)]5%1NVB1>@FYRR@Y#3;DF[O1\0C=5^&T(N4V5:,MY-FW _-:
MAQ=V'*.D7'7,[=<D"CL-"D-4VB226;-U6FSN6W+%>,_98OP00S$#_4[VCK4?
MGOB<;F#/08PX\NUP@_T?=,=HC/2,%ZI$YL7PF)5TN&NAE/6\>>HR.: <KR9O
MW&2G41+M62F+QJ0T3F85CVI)H)OOW#NG%)"*'>@%PDX@>QLM(Z)4>^OJ,%:I
MSVXX]B3.(U3:]5^=NV[*1=Y4$)7E6*YY LP=QFN18:)NRE"U/2PQ9&Q7&F)<
MS*Q='G+Y0>/3#1UPJM['I*>#7;RARWKPI+9$GM26'H&(E1*4!Y6YZK-1;.^J
M(Q3QY+:UK$8@>*AL]'9I/>_+V3=J>+/"S$^ #+>VHOF%;*J3G4/5XFS- ECX
M_&FRR.@>3CEA]S1+ZX>9Q10J+$X7L_48EM%DB\<8GN#>< XH<M-EX<U8S9>V
M-FQ]D<_KIWI9)]MKS_#Y^2:[5WT6@@H9A8[9N\QL>?VGQ%:R@AKTD<W=Q715
M'PKZG&H>W[('98T^DT,\N/8U4[U\4^EV6IB_@@$##]<\88]Z1V?X'28>"$UX
M?DS@%::.!YA(.A=N<I7UM9O%"C,*0<A"79;WVN^?'0N.L+B;F9D_)UH1I<SN
M>G4\S;W:J.1)T=#J:-"TCJ&X&;_%;7B00XIK?\^I@*(LOX#C:0HOX9DF9\>0
M2'*!\BRMLX#)NX7:+)M9:7P6'FM:+V-XFZ8'LY?.S)=12;3)?G:S']67B\F.
MB,8D2&5&M'G7Q,]JJ54P?[P?:LH5L%&:QQ,D\1E2ZBF$"!.AAZ;R1ZN%VI[5
M,%A E*NLI*8T0*QUK8B:<NK!+ZREQ-?.9#RW2E6Q?;:BGCI1@P+ZG,FU-T4,
M#=I6(C>4YO6PGV:9CJVTO>2;9I+]:GGA\NFW1*)4LE7<@OY"HPTG+[; B_BE
MNZ?]^SVN$?&AR<UO5MO7T 7RG[2*8*9<<;UJUAZ_1[\/T!H<6_+$'-^1.#L6
M^S7(#"5CZ6'LMN.Z'-?M\Y4&$C]AF#:3S)!NMW-QER"JV;;!>UIF<+GUJ5^$
MB&Z8A79&*-A2F8(0A2U*B2"Q/9&2/O XQ%^1O/TR2-G)2/2.2&!NX1?A_I:F
MQ3RN>ZH=&HW)>*>H3.>#++B"ZUQ]:+ID>SK*'1[)!2B_;J:7DA2?/@,L>B,C
M*9D^(EZ@_4!5#M.C"#W.F15&?"/-M:+<[BY%_]=B-8D^O0%TY:CG@IAU7J'X
MO=,^+J_J?*MZZZ7?SY[X3/4**L:9>%,QO&:5?9LZ@OX-N2HJM6<FV]/S=#"Z
M;'3X/EHS*RSC8DGNE]=#YT\$@2X@.P5"R8P[5UY[V++J:+1LS#/S$YV3$IRT
M@B+E6X/,2)X'+C)EWD:XD)HEP+C3TK:2HT_%>R@\LZM;3>ISQ]8WB+&M:%]%
M..>(GYXJ! 2X';-WU!Y,2A2-?ET?7_>^]*7:F++F794V:0O/BSX#3P1?@[>%
MDB+>YOCFZO/SQ@T[9K]8+):QLRJJ7I3HC$]QI8\\W?CPA)Q[WY.;V&/P_F3^
M!VSE_59YJU&V#;:!>=1 T,),)2OR-?^<;!OG]FONU''(M<TI4L4,V_O''14U
MG7/-XAXL6'T8I084=+O%OCD#[KEY\Q:Z(^6,</=3+0(66;$4,#INXOS76D6>
MK9V/: F>,I-(L)$/#/TJC'R3Y\-IS);6I0C0Q3T:QCVQ#QI3ZX5CQ^]6#I:?
M< P.]D&$9H127]/RX<6JO:2;:KD>\ZA.6X/UK)M0MH!XW(- , A#IN(6F&W1
MZYI5R+@.E>YU2[%O/L>X =J-N=HX?XT%(/\)@/E2V9QJ7\_J;#TX\>$N=NXR
MQMA3C#*D:)!_C3XJJ<RFV"C ?+&<D#%AQO7LVS<P(D\7W?*NIW)TM)ACK"-*
M'C*3%!!+_$I/#HH-198/[6$V8\=9:ATX3T9/S9M'Z<N<NX>M!'/%&!)R@ 0V
MJ<DB2+E]<F!&)B"^"$D+KE4[*RB+<EP=-[V@%,+7UR2;K70!;6.P3#[H)_!Y
M-P\.8)@2HNA@2BUYQ/(XS]7]/@=!0MMQ6XWFC>XI,7#$0*C<ZWL)2]@)+4^W
MTX/V_,,+[X1J:M#78\XT:%LZ[<07@0CO1P;&> 8*6*$%YK]P"6.Q5Y2;FR#C
M0PO((L_T?,IN$6N=J['*AL4=9D^Z7!1>>])VG!J+>\_L _!_GIK"'SOAA#:N
M37AX8ZPJ=D+HG&6VN$6=SYT+-^^>(KV0PI+!9%76M;[&3V:%&>>A>MEQ_ ZA
M@-?%MS4/>F1O#1I698%HYMD#:!V2T_0<NCZ" '-73&]PNRX^LKC12;@;)?/U
MJJW,;+N2641Y@8B?[*#=R7FU)59CQJ]2;.W8T;A6RJIM >UAMAJ1VPJ)2WP5
MSCM<LZ?ZDN)WYK(OE#"V-O0O/=#0F1AC'TKTLM:A[L@<(0P73'KTT:K>$<FJ
MP$SZ6GZ]4Y/RJ1+)]F!-K%-E=5',>7U;AH'18I<KQ64;30_:>8@?C.:?T+.G
M5>12.35G:]. [_X1[C6?Y#YCZ%B12S1PJNY+)1Y1="H%);IB?O9"Y;602ZGP
M\-'\20$@W.@"7=<)"_FHD,<9 8_-9RV.):=*H4-P^5XRMLJ]#.LFX"83I@0S
M PM$-:-1(;UL5&]6ET-!RPE#UL7@NM5GY:4L#+0^Y[F<=KJ\C9<$K@L\*ROD
M>2Y[AU9OR^KJQ0ZV>KQN!?-YO>^[U__9PR+Z74ORZ:&=P90B1P\>PXTBJ+1S
M!>\:X8D<S+8>N5MYU#[ 90S#43[ST*K#"01B=CQW/'AL>?K33H7Y< ;Q[@?\
M>?\7A6Y?-%,]*X(6FUK#R1RJ;!0IU.LXC72F507:%0MVGI:3^4>^7\=T*;>]
M?\/2X]2BK6W331\T5#6OI9.H=YG<RBUN'O2D 0YZ$ILR^Q!W(S\3?R-"TTN^
M,<*;@TUF\S''->\//#1]@[(,JRLN P2N?CKX)E)L9(  )3EW/,)(ELC+_6NZ
MS^]Y#?EF58VLN$_S7U[5'A,,V(:-8^\]T-@:DP6; ?S=B]W0P37^$2(LKJ0F
M<%\%!5HV#M%K8>Z(FL@[#&?9S9;4(D;N6/L9.^K8<%J0)W4/[3%"A^R\DS1*
MZPK,1[^T=47/U7-?J"%@XHXF7*SPM_]R)J&WH?#CCDM.)E7SNL*F9-_5JRZU
M GU#$][+O-CF@08:?B/FLRJJ)Y@[N8N&FL0#?#<DSCA(W>J+LU](N;4VUZ/1
MMU3/O&50L:FNVVM."ZQP#*8Q=)>P#&V1-[EQ25OVT3N%4NJ=+W=G68W&G"G+
MLOF9VK(Y9U3=3K''R X+YNT#!MO*BDU/?0Y!6[+)O>]8Z,4D8Q9<=HRP=L-)
M7_LLN2,7!\NSFBOB]7>*T;I*J9>]N/:\>X=:5YAN"M..3.R![OCM TYG/T;8
M7M0O14G :_/NQE1.UGJ<5X+.-,-V=TW?:J:!1F@(:\/UQ] )7G%I>%1=T_:S
MZD#V 657>I6E>'MKNWYG")&@,'M!%ERF5[3=Z(VX66'L]81 \EC+$D4>YC%(
MR\5K0;<J6MD">3\MO,M/4-Z^T:O:625>!0M(<>N?N\F2\FDH8CQ>>RK.6=F%
M5].;O6$PVB\CGI1/@$Z8^R'3:_L@V)Q7ZVIC!$;]+NU36J7Y>)CM^>?OU\LX
M8RPF^U#1TI;<+@KFIN YQ/DU0=^/ILQ&2X-MK>\F@MX' RP[<^^A@M(C[][T
MHU1=)I_4V>R*2A\7W8T68[M#DF9RL>NYJ/?33DB=O=O@>;?^>ZJEBXZ&/5ZJ
M8DU.I-D7%JP>[0.D1RWE"CK*BB<JE5] (V;264,BT[D)9V5+U60[<DNQVXFT
M.1,2$<\L+2U4USWZ1"9O^MCG7CIOGI*;MYW@PWT)H;;Z96#4_D'UNXOY37SE
MV/G.![++A+I*JJ#G%/6/;YW+=8_762I4\PN]!12:9[26B4S@\&2U-;- @8JJ
MZW>JTS)\QR^]6*HU):J^IB[^W"[B7II.A-JI<[''3<_+<.R4\\>S<%<Y9BH*
MCXUXY%S3R:LMC&>P/,98-!SC6\KQ63=,$FP6VO.>;"L[AJ.C*9,6^.PV]L;@
MFL&T^9J@>M/'H)KD@2:%=V1$4Q+5LJ]8YGA'X2A-=H=W/3111**/R\N ,12!
MDN,Y%(_FSBK?"#*I=-^D5?I26[K3D?O 3Z?N.?;K$]:'FU>ILRMJC0SEY3T;
M^37%N;"("&LQM;Z+&6*B)/9W6Y^WL*3I?)%]Q]HX6KU[>TO8*J?$[E;AB75?
M,<LJ1A"9Q3TSM5**@MA05M.+!2$W^!N$%F;.ZD[#(VBE*$&+YTR>P'-.RYWU
M/P69?F5GQKGT?-$MESBY8" [N?7+ETX77Y+5?A%J#F;'^ZN&+9<)!F4=8WUG
M:YW\B0-DEQ7-[52>K,M].)D*KO2G=7I,>*/1,*EU@XMLH7/&5T!2K&V!;9$>
M3B=7X*_CF>$"CN!^3*MLI;P$.L<VB)#.,(/2W[0>GU8L3/A8R!9L%1+UI!&9
M4*(!M$ARMMG]E)1<DB-D6?2QG7ZZDF9G[,G#NG8?U83Z)]OC^'#R$A1EH.U[
M_O8:ME3$&Z!VQQ99;RO^-,?DN5Y%&YH*8(EGK^ODL[<59>UJDB]7]5UZ4SD%
M!^(3\T3L:UA'!,;&^,XR'6\UD'WM7@+0#%>;VG)[*%TX-Y<,HZH;EKQ@Q IC
M>_9I8H9.M,V^-BU5>A8]?J&_Z^WCKU5:\AW-;#ZSI\U3M2X]C Y>J;:5W:3G
MKE(1,JMNB6B78RIH>4R10DTB0&8\NR26?=>_2'PJFYT663"3GF(:;&9G,'+1
M-Q-+V3AW1L?YK)O&*+Q1.KQ"O3@W64AF.:I'.I98^OK*#L9/Z 8D(2"QH%O^
MU+#/2XNBCC?'YHB2%&<#])3-6>C&>IG9-Y_QO1"VKLR:3AZY#5]*H50%@RZ+
M<\L&/CQ>PN83QB ;H3LM3L:_1ZQP"8\]6%);@H=EAP# ,),D/<Y".&$9X7 \
M_3%#@Y].+EP$!"FRN;3S(.<E\<S</H!"D%='_U19/,TG)<N[(=%T=3'S,[5I
M+I=W?<Y,[E[[>M5%U./=S/W//5/!%_R,+U$:G\SU=0D;MC8JMKX-7#@?M/1B
ME[B*J&84,UUZA_')+>)$&2[7ZK,4R;S,3[7!%F3M!**CM*;^^X!"(MBT43YO
MVC-G5$E_DCT>_Y*'QVD'CN)B\K?E1:UA*&UZ'N%%AOD$,OJ7D6^_+D]*F1*6
MB*F^$%#-/A:5(U3H'^3LO7HG]]U)V95NW&+92Y\2#R2F?DB\&7PRN&+B?+Y%
MN[^3Q;IHY-:-]JO;L-N9Z*O;%G-AE=4^3>HL']4AQ&QR'8C&ZGFV*Z%AYH!(
MCL]&C/BB=$FB"O]G%GS-F%5_UB:U/H520MT2<6W8K<]H&:782ZFP0'ET4T0G
MHR4)[[+!5Z?ZY:VNX??,J^MY>L[WV4\6IA9$V*>+)S.:IPE;663>@M!?OA/#
M:7LO8O@K>?_%Q$B4O8Q?Z6<[PX&Q3C^D2T'+_6I.6S/60#])08?P&&\+<-5'
MSSB_J:\E3WHKBBYU@94?'L?6X$F\) 8%BW(*W62>UB$5J!FWZF#2+WQ@J;,&
MIN0;AO*ACW5O+J=L5/!JQ$C$/W6KS.CBP*TR @1U2LKNMWJ("!EFKUU^JPY_
M$]&X87[3HBRJ^[T2C(;LC0DBC(X?OSR4Y1P3*2>!%[72,^,!69. Q11TA[PV
M:GI.X2-CEC_'S9%= K"#Q<XQI5C>A44)<('8M6="91,P\R5K(=>$W&FE&-%7
M9[=V[OA'#I]B\C!YV8]<=.):F'W76^MTHN'T:JO6XIW5/@X>G9T((T!8U.88
MLUH8)_OC?0"5N*L'U<BHE8="7Y[]4M1(X</<2Q6.]Q>8,;ITH.SA_L@XW\;1
MF[H0$,RI0-XR/4*'@6(7HNT:ERV]-B[]Q&U&IM</REH^([.6\G:S%S,C\[%/
MP2G-O_-S;25X3,9@42=:7/KU$[XI>QGGGBN!96R/BC^T Q<YG!S6XU,7-8R=
M6;,*A:FTF6OAGW25J,C')G19RO-?TI3FP>T,]@'YCK-N['+4'JNMGK(,;VB-
M*Q<]@=1;#]RSAM^Z@LQ?K#!4!9QX3U)8/%2*?1N3A>92NJ*58S$G9&*O'P&,
M ";<>W#;K#&$,<&AD3&O!<A+R<-GKZ:O!,K.)6F]Y]Y!94 WO" 0OOE:X),E
MM0Z62YMLU(Q3373Y@5>Q@9=OQ0<RXX$D*:TWI1 A55\SIPLQYN4G?0M#WH:I
MT9[3 F#-:)9- P8*GMZ;OCUSJE#._<D7^K4@AW'>P%V0T?J#<C,X3R$UY/Q%
MJIYT\YG8DE49I')B]$T:?-2Y>Y"GY43Q:>&AQBI=YL29H.CK)!*.L- GB#EV
M-S+#H)C7<8V]SD$U=DGM,83^<M7'$A8+TPKE/-FV'/6;4<<(G9;+"SYU%NHM
M^W.-=R]L67LL]7;+L!#%\!;-X76^,>9/(TI)U;DHO/!1(!7J)[3G,D:C7WN3
M1L]O;MB*C[&O\FFGBLDL5S8J.K#V]:6Q8\5APW; P/P*KJEVGW=3@BY4E7;Z
M-J*I9HN)*S-V6U8R*ST"$MFJ+9J0VXX)--?XS_91U3U[O=USDIL#<W''8[%\
M)SCL@<:F1DN+*@+Y&MP)DQ$)%WD5\>AZ1&<&>8\J^=EGDH]FJ9[0#@J(M(!T
M+E3T('6<Q2>,@I['I9,]<0N'W$N\ESB=.'VW4HSVZ=..! 2T2P#$$P/BV;@\
M'U-0$&A ;T)D:H!?</T1X#@ [R7>R^,$Y^LC_"* 40I?F%6$F).KN (EU>X!
MO6CWSM SG\J])ZASFMP_MNPN!4W4JPH2=2/!S82ZD+P/J0JVGK5T#-Q"C5;6
M)DFM8B"R%78:IE#+3CR>-1"W?&N@[0*WQ?C8M;Q5?0(!CR*F92/^XU^@=J]H
M0=?VR%K?6Q:M=_:&$H#DO1=[SJ=V+HY76 ?RWAQGYR L W2W)0F$P^Y"M32U
M\'?5";U/BP80BHC>-1KG,0IVJ^VX$E^<FV3%XJRM4I[2P9%_[E$080 I1\!Q
M0NK+ <<#CD>Y$Q1RB\I6R +--8DL+4$415GX15G4RH  4NZ4+TU?])4#8Y:$
M2SV>/FGKD;'Z!$QTN.%K)*XZ%91T\G+5V4T:(8:>@LA8UN >>"A@HTM7?%TP
M?2Z]P[6T<"MKC2$V=YC7NV7[2=%UUCL/Q4KD,J\IP7CP30+( )^YVX-Y@)N/
M:/X7:V<9%(>S+?@AP8,$#6XSN+M#<!G<W=U=@[N[6W!W]P!A!B>X!W<)'IS]
MW_O>W5>[M1^WNOM3UZGJ:CW=_3OGW-S^19%^?;S\NO?:WQ[@A\]6^"1R;!SF
M]4W>[;0TN1Y-/?4OI*/.\W+?:[ Y_O'^RA3_Y6HZ[P]AOWN[\ZM]WOVS[VH&
M%W/#F]CKBOIZR<&:8-WMO$J.O^BP3=WFA6#S[@1)RZ*&5HYQ&6["AY4Q^\61
MKL7^S]2+<X=A1@VC@1FK-6-F5JT#XND#>W1 "?S=H4DV-CB$(Q5VT,]++YHJ
M+Z9RQB/QRZ7.9H>]:,3\/(\S2LM>'^HP8QD><A+D6HMC)W3C>NQOD'L*YT2B
MF#2>_Y_<^Q<=KA9QT-P"P0MCB/%O*3,V^8I9: )9A3+ZG\3)5@6YD2%U.K'4
M,3T&> ;VF>MF433=UN71<CCOU*G@V&1(\R2#VDFC41M#QB<@]14#AGCR-*^*
M:&,X=3P7'977  +%N#7&A')).K7![(PH=BK*-XZZLR1QGOW I(45$=;B)(@J
M.W=_WIB^I9Z-<=;TJ9'I7[AF:G/>Z29#+1VM[Q!?I#<?+1^)7.:^S\]19SV'
MQS81(2[/I%VVI_<WS_ K]"QOQDC/*$/SRZ04K5\%'GR3_SJO(AZVI=!0=JH.
M& $NX/HC^' Z2&L^+W<[Y #KX)PA" YGZXGI>7K;$OSA6G@QD?(P0.W!/%U@
MR7F01NE/;&<*J.3(" D86+\Y_G.W*RRTX[?B$#:+ 8P4*/I,G^H2Z;Q2,.M#
M\$7D]Z1#"%Y.C%.K^>Z3_WYZI<#50):O#G-Y#H9H:#Y.YM7$TMV32SNU9;"*
M!AL:SZAW%J#(I#C"J7FO)-J([ -.C5<>6=&HKAW:N/5?W?A:&@6ASEU\;-DW
MBC6,<K$/G^X(4"JFX>U>;E6<[0M0#^8VQH8M]-Q;]4F[GA-XG6!&.3[SS3,*
MSW62\M0V*')J%S4:2$9;Z9O%BPNS->6+7".2/;,EJJ>F&8D *39*-4U5A@E_
M25F45F03?I;EE0$Z#Z@.H)1XF;O3'0WHX^N+X#3F=\XI)<:AB1E]90]?0S/[
M(B+_B_7J?*M!"O?6BOT(!V_*E1U%S!6>FI%MWZKIEWB61VSV>= =,)U1OGDT
MN6><=DGV'>#3+)X"5BX1?OD]2#"3?Z";)*F"^+B\MVD5&.QS[Y.A%:;Q:2&_
M8U,CIF![1:V14N>9(PCFX!4IPYB'EM"&.L^\4[B:.WLP4B0ZLLL',I,T^PXX
MZC<UOVTY4"EE/R@JSZTL('&JN=?)'+Q*V]:?2S.%J>["AC#8^N+]Q7GYH[@J
M^\P-_[#=<2D #X22ROWVB5'14[!V?%4GR0RX%JOR4ZI=E?5DRDPA94 2R)R_
MEH&3P;T-@TP*"Q,J1T:F%\<(P [$ZME]@.[MP$7JV5J@ZP2.4M5HM^NDV7W7
MZT#&E;0"3N@[& ?^MN0%\:T*R#A8W:M6[-/,6\,I;;T#4-=ZQ/5AB%I\=FFR
MT&U^U[T#6!8H>^_W. A64XYHF[$SG)OC/S99:0>4S)U\TL*06T\#$\[7V,@6
M[LT9QM[C<V'B\O7B<8BK(AN1?]NG1A.X @D],G=IAV=K,_$ISR)D/A^,D.A.
MXSJ7"&DK\CU/\52=<EFT\R_GA4B_?K^O*J*C8'"6(K+"H8BF2:((IUDPC09)
MSZACP_C6+\TOS(7'T4RH;]\AHH)2P*!FZ9OE1A/OK(-FFX4HRF:;?WI",(=M
M7.!:H(D_NY[#;/V_,)0XCQV7*J)_5(O'GZT2AG:^5-L?2BTWKQ78"Z:%Y3RG
M\4;I_P<G9QP76WORO0&UUKA^D=>DY0/*SL43,4BD5W-:I6/#2\VILGTBZ:N0
MP4]I$&U=^+E,0R.EP'-$.&S0222HF3S1J/5QR91H*.PA'G_Q*T#](53)L ,
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M#]HEI%CO@/A6GN [G6@_Y("J=-P8@=TWCON8G3U8M"TYU/%ZQA50P"!UU?1
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MBPM6_,B\MG .<[L>XMSRHI@Z?E14Y=?2JR(5'+A8Y#D0*H.9;<G.ZFA^#K(
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M:/NK:'@QU"3E+^ZQ7"CA2Y.GIAF)??8G?%BJKNY:]?]BX_C#3FGY+F% /^:
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M0@;5T[5?WI[WZ8I:D3?#@S'8V4,&G&H&G6P4-"CPL(<JXCW=EN@V5KLO%KL
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M9;FE=<93?QLA([EOQL_K+G<DVEYF-[ZR3 ]U%39>9V&G8OFV3\Q-4-I/OMX
M=6&-L2.H6E>D&PO*-T'^@+I=>R#GYEJXXL"]HYVXJ&(E3@[_1%N(1.[^RUIY
M5:S6V1O-KCL)NYKJ=13DL):.?,VB2,VB(A_U28*<_L"YTM3:'A*ZJY:.<DYL
M><ZB(!FSC(NPB$WP)P>*::N@-:WXF.JOD-FVEJV"FML%H6W3NC'<W)9^F4?B
MH$^=[UWLS43)@:^X9@3']SZ'H"?3Q<5<3HW18WT\DVY&92C]/!'&MGL/EYL=
M&<I62U:S4V%!L.K&L+00JT(B?BQZ^KV;F!8J='K>]Y_K -[S#TY4#TZT\Y_V
M[E-_[1<^2H33RU BH^*?WJU+%G@%J"[U"H[JG)"OPRLJ MKFL2G?ENZZ@&X7
M!: "#@VK*8;YX XU@I-5Z71!QO[7SU\O2OWXBZ:X=;YMX$I]:5#!I&[$QF:B
M;CW%4B-WYD_K0RDS=*U34HIL>5O&5#Y,1)_?/OFQQ%?LZN'9[>2?N^"5H$;E
M$@J+G,O1()C&=T-I27ZM]*:O+<UL12T@$=IU[[3 M(\\R_%"EZ<KCG(U,!.3
M=N;3'_@KI\!7D)&Q3U7BIJV@Y9_>YT_$7($Q[TE"N5<R&GFBWZ%]IWW77Y"M
M#^X="ID20L_NFEE!] 6YX'V574B3Z;OU5I4*<PAX4MF[>KD12)FH^0?H9"!L
M#@TS7W#8[D83RZ3S#Y/??+MX/XOJ$+ S[O 28C1 'L^)3)"=GRL2#%>;KR#G
M+PQN-===D+\W91"W#S47/(#9H11S^6W;F]+O=)3$SJS&KEFO\Z?B\M5<56WV
M$@= 7,B2HPCEKO6B+.V"X[CR]82R[)O#SA/*FM/2G[,F35=J$!76=F&RW5C2
M[,7!Y> I>WE7_J*2!;[98_T9HA:D^4AIJ;H&0!EAW*S4W;H'PS [N7)8^5BZ
MB5FRAJ+*E4"MXQ+8QEF#-GOFA""[]9Y +N,O[WB5U>%/.C?TGR8-2]>0XWK2
M>=Q3K%2'D(+)-"W;[L5EU(<)?2%ENWE[N#M&-@<421+J8SS3<5)<N.ZV#.-U
M.9H_=\</-8-9;AHU1L#5;5L-%'W_C)TBJV*=;?/%>99L[=QPM-Z[4<*O<DX8
M:$!EEPGKH0W][G5R[A=P1DM(DOLQ8/^+EXB()KAI_OQJ3XH[(1L^@\]O5I(@
MP,>H[GS_+#/+1GR\QM]_RJ5]R9W%BS74MUJ*&\:HOL[B+G]@H>9O<P'5CI H
M,U8W)SAP5N1DGGDI;M!__0J=Y(8JXM&[<$6:(8!B]M?07S0KP)J?/HJ&GD'O
MYH5V?%:&)U-H#L_94+1-C**@@BU0$^JH:&<PEIU&YZ:4\#.0QI+\S9UV<3&1
M%1RQ,%YCG\]6#&\&'V2%R3_KX/WL0_KN%2V.^*^IK#![=1MK<0>>9-4TN;UW
MD1N7D7W>TE^F^Y+?@M(W!1_?M@&72U<%[EH"C7=% E/R8UA-&%>G.DD5/ZY:
M:]BX!*#+ZYHUF^]JV@T74A'BZJ723%UW*S>Z%9A8I\L SAR;&Z30W\=Q#/YQ
MP57Y?"EF-W:5#Q_=%H2'\?,\_GG^\.-/SXLG3)NBAAW'.^EP_')90A.VQ)-4
MZZ7\#XF"((""Z^1?-#VSS8^OKG,C_^EGPU/4C=3=R H#Z79N)GB@T$^>;W[^
M3'G;J[ 97U[HM?&9JQ87V4$O]_69Y-7,(E6"S+.I=WBBJ7//?GSU)L(J\:(/
MEMW>6W_=]Z%WO0:<'-J\VH=/CZAOR<8#SB\)TU>WUFU613IZV&NI&=ANKI(&
MF^(]4RYV>_=&*A?]S?C:LP0/Y4"IP&YU5FVU$^R3,T[%]M)$V,MY@R(],AF]
MUS_MK=]Q[*>%2"%,][#NPAWL61!U5XW/3$8^1Z"QMQ;+1/O<_+X:49/=E#'Q
MO*3C])])Q"@?-"C).6DF?IV N_\SR[\="&Q9^925DYK$8GPY@J\V<ZM_';OI
MTMY40N,"%/'_H/++XW<-&*Y>$*?[V4=8JIB20<I7BB#\4/BSX!MK[#.6ZV>T
MS\8NH[S<)W0^?A_2GUO"4-A<P#(8R- \K8 N,\ N<.L>M%0UMUZ7IGCB%$$H
MQ2[+]G1!'Y-ZJF0)WBVN^K3T<^:&N<M-RF^=S!>F;U0IY9^62!%\ HK:;-BP
M?Q,[*#_Z8"A8#!(5CXE7LI<(2=3AB+C[BV9X1Q^YW7X]%1!.?D-5Y/KSU17&
MG"2[Z[DSY6F[\0_=$C!7=KM!1-WHY]&3!Y-!%!M[7H&M2/5$O)I]R[=-&[E"
M/V</ MDX Y>^7+?;T G"P1>4WRI"/4LJ#Y*_:-1FL;_;2&6\QEH7*NH59_(F
MO4P,9O0.H0UAL(SL"^\OAG^B0)[C7#%^\ZL C!H5F6N</M6@Y?(=.!2OEG;Z
MO/<5&YO+U[*Y^WU'F/+:.<E!VQ9(K6=J +XS+'2@U,KB[5Y=<O?JE>#F%2P7
M-E%+Z<2-]#9'_)(=F"C8*^PQ4+--RGS1'FTI_OO'S>U?M,A(F 3F7=C\$\/-
M>8I%E:?63H?)*HFND"I-M_N5J%T9W3M,.7+E=X%<N/C/L6U9R(_K>U9Q PY-
M],F3V3F-:9I7QUJ"B]6XY6R!NMP5C-9#]&:=N1"QJWUOG*LTA\QQ>:ZDSWO1
MM*\B0V0_N6-EY<%%6I:>P"<T]F??$LX-%H.I$]M$V/@X:L?,)$ZUO#O?']8I
MDXC$UYYJ8.R34I5B?"R<J0W0.[&9#%$4VC[[BQ97I#/WVX(UL?LI):?&\]-T
MR%Y7OI;CD*KIJ8%2G5.'4JT=1+SR9]R7<NO!P\"9&88D.IIE"_G%+"__Y5U2
M.DYYX26X>GT.[)>$8_9&$/\8:[^Q9146\3 /8<+*[P:WW/6#!"'[C7_8/^[_
ME?(PDP7C &0C6;$5?*'U(0/ZF=54XYE0)[$!_4([\6F_0CO*$;_"VSTJLD7"
M[IZ!0-,Q2YNT_F=NNG0 2/;7L1%"A]6=#07?#6@OY^@XL*=^EA/VC.,GY@J/
MM4/JI2#PO]A 8W(*0?C.6'*<M>V?IC0EB;AX,<KQZ^V*QN:-6/AX)#'XI)*U
MIKZ04=$79WY=^_B0FSCD'Q.1W.W6QM&M:2!$1-"%V#3;Z^EG[J&-#MF5*)M)
MRD3+%#7TK_31ZN#\G+GNE:SHIC!WGGR0W/ _.)X,7;ISLNW7/G!5TOK&H@_-
M^#H-<APF2Z#J"KG@IRL@:\$(G$+7(W#BHV'2TI:F&D\;%QM1[_D/83%;?#H$
M+6=<[-%=KZ<UV%'=CO@FH>MW.\EZ_NGV28;\5YAHNGR\YX8T92[7G5@8ME<#
M+: '_?R^6H>9BF<E;Z)S^I444,P]S\>,:T T1:X:Q^E@;L>%S$6K17X#;03E
MEI8QOTBQ&<V*27O"<,#G*"\\3^XQ]62US_Z-V O/L0@(&4?5_>^_I)[G()?K
M_+LR'0(M)Z1]TL*ZK9F91Y;A @ JH*3]8_=YS>OG2?+O<4E]#?<+]X>2PX.9
M=[(*PR.0^+J=&DY-^0>A1@%-C7DZX<O\)M]);VZX83?V$#_:9@V!Y[C(G6P7
MJPYETD5)BYVRI@57N"X2T=?>]!>-AW'4,K8-%G\6V%[?E6L36SOU4E<.S[3;
M=]AU5H6HJKC'O\T-5,P&@*G*XV;GYT*:5JM3!5;%83B=U>%[T"KHF'XB)"^@
M$DPY'A&B9*_K<S4@*B;W@?OM)?2B'($YZ&IH!+?$]7=5INX'4B/CW(U.C;69
M8VL1(?9&:"L(E@4U2U/'],Z0;;-Y(YX3?YNI];:S,U'CZJRZC?SSD>_%F^N^
M)*P%#1_$; 6)N0UC>X-18M:-Q"J=TT:%,-/QS+H#@'Y+%B< Z/?/YS\E?"3^
M?U[%]T>&:+ID<F@$:/2?(^+."WW^-2S\U[-074:=Y9ZEQ*_0;^,'+>&K#^(,
M=JE>[E7O\5Z1'^N,*(VH2OD^+EBB/5/T'Y7\]0/7.[# %._[][TP;N.HR,=+
MKE1KK.7/]'_1PJ<JTS\37'PF0'-T1(MXQW(IZYZI%&I[!,@O50'M'[<YX*[Z
MGYK[)?830?1B!-AI5WF"9_/44"E$F8"!],*DMU:!*K2%UDY&VP7M&!&6\VV'
M%N&27/1E6EDXRYGYW$0])*21.!\<$U7>F%HMPKT5'<3350)(J]N[YC>/OXFV
M!=#(JCLNG+LA;KA7X#R!;G4)7\C=*N<8D5ICX(O>.L.,^)4?(BB>YU,$UEPY
M'S(0*"L"@A/A9USA)F':-GNLDV #'6[6A!@\+J+=-Z[Z0+L4_&6?S>G[?<]%
M2,LH1Z,K;A!0 S3:]MZ^1<FTN,</4Y<Y(X$QFXJ>SP"5J&RU,_W=-)([?0JG
M765ZT(S%L%U@-JW'\#:VR,T/R+4_07$,B@VN*$B(I'?.&^7->?O:(=MD7<;4
MFWK91AN)S9OU!23=8-JU4U'3=(8'?B\UI$#.91:BE,)5Y8VW!\TQ_*$#ZQ$^
M-(H^7% W-]MTY4+F5+8%9G(7I'>  1_<?%3<1U\[8%]BWAA-< #E-@?!OAFP
M>B1!X0G>&$ ZPV#>PX.ORWFR:=OUIU.F039C@WWBG(Z*VH" OV^9CA1-.=UC
M!A&YMJI<'I,8Q36SRZ4HGP55M: $42$[AR*5<6;F ><E5&S4/?#\BZBNJJT_
M@3V.< T+>P:CL<V63K&&SX8.>W'(A(2G PRH2!D]9HDEP'%NDC149Z<KQ\@N
M7>HM]@*,&53T%\V4ZB\:)/TOVIB5"'_'D]V?>V99S"CLU)CP'/--U@",5M<B
MDX!G9?S(WB.$,^G)2%]['PZ\LGH/.?T),6#"ER[PQ=6\'3>C181"3--FC[*#
MXW,!!6>X_T&4VI:G2M>-LV66FX!(,#3]0&X!0W \&8&X5\6-KK%6]:,/IVU'
M6BMR54-IP,,\)KX;OI]CI%)++]5^_=-21OG5XU0$>+37$A2WQ3:'QEPQ+QLL
M7-&4^^Z]999T7.D:%=KM644JL&P'Y-Z9C%7O&KC8OL*UG8; C%7W#T8R4FUQ
M*VI!0V/:BP:A7; L4-=(F3YGF-C.0\1*8Y"-%^=0^CNHNO,OO*:4Q1]X:+H$
M:,!;YE%:!I_;J[R\>E:'+O+M[-^:C_CSNZR&_J-(:V[F/GRW.>-#9Z36:]<D
M+H$/1;&]AE%*3=+B9J8M&"_T$%/ XUO:*059=PEYXY]/#+"?LMD:GE"J"@BW
M"-4[53,1K:-ND _S2+-!P.I,:\)IGL?@IJ< _GM:PI+,&_3 WV$U7T^Z)!["
MQ/CZG2R0,*RP6YH7EK,;M<3B($G/M:Y%2\Y>"3_.*E!HM&D3OTQU.Z_[6G0D
MN-;9(@O+&#:.S$"N\*@.K]>A>I%4ME"W*?=5S;&Q):[+==NIR S"8]L+3N0A
M-=^B$@LV.(6&[9$/?%RO*G^2;V%QSJ4RIX'9T"L* 8@\/[-;L^I*$!SU#1-A
M_8@"DQCLR#!-8IKNIZ+>"YSTWOZZ4HP"-JR;?E(&#VQM6JV6*X9.ZIVP+RY6
MS5@M0_$EC=Q[0ZK,8K_!@>/*(!PM-V(WIST*F,//E!=?_S36H8PV&FP#BI+(
MGE:S=;E%>>-"NE!\RV.ZZ"YM^J3RHNOHGVR>75\VE<UC-_(N@WR6!N=7S *#
M?HQ2)K*7[W+$E6B3JJJE9<SP(&IC98'[R;^S1+AI$\8BQT^*1C>["=E]?C\/
MWG\Z>E]2(=/:Y=IX\WY^Y/OQP'#Z"H/SG/W.SGZBVRN1%]YXO%IZ9WE>S<T]
MRYY$31F6Z+<&, S-7R.T,^+2$>T5OKVM1[GV+S]'@83&OY3\W'.T.I\2Z 0K
M^UQ4EQQ*QS_-?9D9Q1K\UKMP176B4VH9%Y02J*85=HE(74%-;3*(0J6F(&&6
M9PSINMP+\MUQ5*]UQ?$LW0+WIO6M0@G=CGG:RC8MR3;/,2(LM(I'NCDS?.=8
M;7L>$W@LK@6+Y7?NLRUW9E[:4CF\M>?DJ9$7%<..+"7$"P.K]K'\./HL14_@
M^&O(YU/E$SL#Z4FUA@6]EEM:_YV_<<5;C.P@CT.Y(MW>#8</<*8VMH'$1C/J
MIJ*7@TNA/PU?%G)/?KTK2A.0(=1W96A8HLY/$<[AKZP\-_^<A/4\*@Y[+XMU
MCZ,N;*7)BW% %2*VA&5/* R)_6.W]OS.LW\F+836-[+GC\RC/=X5T?%?M#VZ
M<FCKS- ,3"MI@1R5]:UATU2,HC73?9\,VE4$WB'DO$+Y]*FT]A\>HQ<#K0_,
MS).&AU7-JK'IHJ/=X6?C2VNSJV;4B>GF[P.).F0)Q\>VTA$8K^#L[N\(#NZ#
M'5.>79,ZZDD[X3_G23KY^*A$:/)B?712369KZ]'G9A+^]$W1PR!H1D'V5=%<
MHST1)V"-3MOUM-=]"(9K:<<CT7S#^.6 %1=()44FU62O,AUN2R_ +!G=,;\0
M;R'P,JO-#' -7GU=+>R)?<LI)5>RKX;.4,/\/1_.J6YO<%'[^2^:T]V1X,<]
MC-FGN8\=AC*<F_C@?7YC"]'7"2D?+6+Q1PUZ1#3?:./QL13*<7J<\OQD]6)5
M_#+B@)I"GK:S,*I&' =SQ8?'E:\HS(U5K:0M>CPB)!GNA<]"].M"SH"1E&]I
M67H$=D"*N<M9P6\ 4>HS'V]4?A/MG>Z5M"^\]KH '9HC_&%+TN\/S:B.M^J/
MJBSHH)P>;_:+D<M5]=FHAG$S#\[',ER@% #@4_AP)+6-XEX-S8^J4*:8Z9L0
MKICYY=2N2LQ!+R?W[.']5X;;J,VLU(17?XJVH]\^.;;\1;O1B)):_(MV>/CC
MOOJ/X9#L=9ALDV5XE&Q#9&[(F+V43_)BM46H4U513 ?CX:]7>FJ+J/<W9\+6
M 5#Y\!E6!0%K)#'/3,U3*DQXC/"QY-MCW^A?-)R9ODCR&W:0JT3@DF7QM]OM
MN8C>O,HNWM_/)?GU$]7-6E*ETU5?%FU;&:=619H\NA^_&MS\BP;4[UZ*"&/0
M.*N87:PG[[U)\9[0XC_;3]RNI0I3RM"0LBRA_?C,,])]W4KF10GLZG^E O^1
M"Q0("9%9)HFZNE]5,%7DZF$6FN6ZQ%)K>Q<Z &:ZLI$P?,'Y-]56(1[-X[0!
M0Z_-F!+5*]7*52"JTC6)XCQ1%R\@ZI=H+&G/Q,G/U_)/,K9Z;;F0W"H.Q4.3
MQ&*SWN(L#]DL7$P?+LYJ$J?'JP8=G6S7I-"7=YE@NDGCBT,Q^U0XDE1G>^*#
M.E5Y-,PXUWJ)JN^O?HC8>WID<O.,H^P "JN:%71BXJ:58?JO,+@D6#C"??%S
MP%:&C6D1')I*8+NBQ8^9G$$UM[W-I\=+<W.>>W0IYV'D;0:E^\PIK&["D9B<
MJL2J5]VL/8EAO"<GDU18,.\'Z<KZ?B\16_J9 -8$"9Q$DD\"A?<>M3(G.)I0
MT_-4@65-@^!?UYLS;3[$>E*8<.M776:Z6T]'G^ PQ@@TW2BO*E3U$C95^=9)
MI=\^:SWZ"+_=-:R^JY'K>?#]:A67^+W)P4>W H0VE25JN8;<]0K8<LWS)XU3
M4]W0_<JN8O(1CX3M5*_9Y\<RUO47+&5MQ?@QHSJ3]Q^S,C)U9YI#:[_-+Z9-
MQ^-IT/!7.Y+1AG^G=#*.]^O/9K?N\>-2H)+L:>Q!6$Z22GR N)ZM!L1FK?#0
MA'I$G\]X.//U&%7!0SH..+;K+:IY5QM+K&V+RK_0VN&,$!?:<&H+1%?_FQQH
M1X=(MJ-?&1$X3[9;I]R7.A;Z7]%);W8G+PW'^19XP:W$P+U\V,SG)QY-:"H9
MMDO;9L PH_.#\_.V;$:>5\&@@,RW&&)(I7W!'<J_: Q[?]%B+8S@/$;-K+#X
M. L#O( K==(V.@( G]);0ZEHS=80''F!><10F1TM$8=BG53RGI@^:0PLN?&_
MT(.\"%@"P8EGW7-R]Q)LFE\?$">+=23<S5-E-$Z6]3S!&Y2T8M$A5):DZ^,4
M^!)9;4AV'J<ET>$D!T>F,*:ZYYIT'NHCDB4D<R36A#_]?W+BCC8GQ.83WC4;
M%A]/[(IG.JA/"V4+'OZ'33U^VDSY.6C[%0:ZBD\&/J[EI@91/CPX<8P(/;04
M;SW^CP G/6'L4:/%UNXZ6I*LH8+,D3/B84_TX<WU&]V7%1S3!CFV<-E$7"G5
M!]X>$WB<:$E@3JR@]G_IUW6%UT?W2 EUQ4LJ,K RN>"_$D+!, Y-B4L.56HO
MM!;=Y"72.X=FJ1=%OTZ_E!NT.:-VYI&5@>*<*=L>-]K<+%(C5E:C&<GV$!*#
MU'  4,C6UD2>@K4$L=T^GV@,Z'X (-GA#>2UH^UKT.&%Q:9Y$E?7K.*AAC'<
M5C@0PU#4:4=?5I^C^T_(5W6F=*C3S8T28'&S!SY\!RU@M6N6F;##YOR!(17"
MK#A2,;)A+A6H]IFL)H8G3CZ>4EF-U";$&_);&6H<A(#<>/B']DK9<G NJ#A!
MU.!,0RFV@??5+6\4>4\9F28<]HE422-@#(Q>6\>;2J")L)"@"'G._)%!.Z9R
MY9>W!R'[8&C @9MAXPGN[W'[+Y<&8'($RWPVQ+D?H+\(K0> 4'7U;J!F:+WK
M3 "OZ[1?%J?I]RSN_X+;3/A1$:BV/.9?<OOO(OAGBZ&]W%W-R\O+;1'@F1S*
M=F2'3.K\RW(98S+:/I,MD_\MI.:+H.IOYTKB1/%''AG$ -R&H<D6;T)-4D+6
MR7&=-?9-^UBWG[_K:/U3/LP)7NX[Y'X&OO3V]6L6("(FXI?" 5G%ZU\UDPK4
M7$#T_Z(Q@EGV*=*3T&JE$RY8]4R7*X\]E-8CRJ/;6KEGY2//YXGV/_3H#U.2
MP873"[*/\DU*&XU,C?(5>6'<<[&;-?R)D=7+02]XUT&#?=7\+3]L!G#\"Y8D
M+56-W+[X&^<+K/2_2%T,C/=[(QPFB,&:@!_CT66:C3O[FN1"F8#PN3?0R\IU
M220%#PIH-LE."2/D66 V<_[C"]&BB')O?.D^IX#H/^&6&&*! *-@PA*AZ_C@
M&;-ZN()'M#!\NX6;%P[<00F?*W_7XJJ/2HCAT2 Q@0/SLCL!U]SRI#[U]GF=
MO;HY=4C\?.#ALIS-WGDFSEAP=^Q @[&*$[^:CIL;BX9S\]H/= G+[.QJ\Q_N
M)<48S32UJVCIA+C[AZEJ4P,:)DN9Q<21HXD4@5)<TXV_]3!EN<8HJN*#ORM4
M=ID9M==N3I'1__'@31Y&X1E5J\'7FXXZF;HMJD5<*MX>0_-]%N&&A.[+;[(1
MEB&=@*F"NG.#_*DYZ)G#7-5!P,,NS_.AS (F-,A)0_*.I^V;LA1Q:]XLR,6S
MD&K]ZL+/)_H=BU"V]5/FM0SZCC.7JK'4FBH)E4DW[Q(UJLPZ^C*9_#PL!D;>
MS]-F-7VB']5['XO9)%<"PF3'=P*2WQXB%DN^EMLWZQ-NDS/K9V2E%BM5\@=:
MI+N*Z*6/I^O$RLO%5RRL4EX6I*^/J9^A?+<D9;/V6D+&!=9OA#)O]\6'%$*B
ML7*5FK%U2@2PO#0?-]YF[FV\^/4CHS8OQ?7P\V[_!Q*Q>U42RL5Q,7WCP5^O
M,K,>Z,5F7"%94#7@FTHX%0!29\>I;P1>'?$I<=_[3S[@NMCM8=UV>G;M?+Z?
MLKS:TL]BV+)$+))?5#D;V%=W'# NS),5_[D_E2_XKFO2WUIYDAC=W%E)768B
M5HHE6+'C.I\LD]D?Q=[<?Z;%<U%+!'*A5S%$3ROM9.'@47OQF:58ZE!S\BC;
MT6Z4%L%R*1W'4L+09K!Y_$M)MBUWV\LE GAX3:F)-K)G\1Q>5#XKEN"+]:S\
MX;IQ&(>"T$L2__B*\R <-JQZ)\WF.R-]!V=Z86A2LI.POWQC-7?4W5VBT=U2
MO+/Y*#M\M#TMN=W>TMF-<]2>L3ZSW;Y>L@WVFT,*:V=N63^CZ+QA:U^[FC,5
MT+-U!Q@%?IUTM ?)73/P:?[T>8HC?M&VCF5MCOQ(J4#%3M"668W-LU*[>5.=
MC[5/_\T^>(8KQ& \_4 G2^;K/2WMZ#?Y:^RO'\31(^)EL/^ 34'KE029/_?O
M4+TZ"X$IR^3>U_H?$/I(#[YV4=QIDEGJ)@>FLACAM_A8]T3@EP\:'++[C; 1
M6:<IE*@DGEW;TFF@\3NQXJ'F#\_VG].MI[UB>?&56*>37<K($$//B+084%[[
M/'*? ZWD*.=P=#[4RT?:D-G#M<BOI:1<JWQ"/?0O&J#!;+/&)-_DXJVTB6^D
MA+RN 7Z=/#"!8S+1EEP(5V-E0FW<7]DV6/(/#C1N21\2JB\56<X0$#DOF3-V
M&4*O[4B54XQRN*"EQZ%-1>QM1(ZR/+E,^A%[VKM>%'JVN<7V'=^"E_IL%D3)
M-S8HN*3HN-)]6^5<*VHG\M.:)EH(B98?Z"U77$4YW%[.'IMU9(*@6,$-%S_S
MBPP+.L(<UT0<DFSJ%N?!_L5#;%NKGODG893YL_P'9\U?T@'&G6()[Z3\I!47
M(2[T+!;AW>A:P.T IP4DZ2O,/L#O@S9K]9P%A$WLB-!+7E[_**U!S<I&F;5*
MT=2%V]Z=M]4_\4'/MR4;X6&CU@#7<3);S*/.2AYB,^F5=-8E(CHJ3O?V!H4^
M:T8%]@G.7Y6\VCOMA/(J]9NR.6LM!(CZ,WV.ZG73^;).X9)7<DM:/MDA+*SS
M$N/M%1<<,H;O<Z\E?;7 I3A\XY2UYCV_I_"U]O6 ]'6_[#H>C!*SU"CA--IK
M;=B5[[Y+.8MQ^8T*M,%HK#3'<+Q02RDQ=*'M^%4L2$T$0C1TZ0/P2]KE/L:*
MF12A:3S8E6>IR#ZVW5 EFY:HZ.<L\587E6"+6;4CK%5D>)5[V,J*;[,1&90R
M7^_'*+BDYI@MJ:)N1V2<70_C[N[XCGA5+5MA9%5''&$8M%L#L<CQ(H#@BES
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M 8ZJ7]P@CZ&Q<$2[6[4]'.GL2#1,Q_'M.^]F0GW9S8XD;F86,UT;-4Z4CI0
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M_=2RM QSI*S7Z$BLNC0$3_G8,"88_2S)5PQDS=<C2UP<8&P*;J[L\U 97@^
M:54M7'X/<[TQ/8"^TID)J]*ZAZV*V".$4Q@,\&E_WQ=C1[AFW[YBJ3?5,'#
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M?8FI]XKI6(4]L?4A6Y@FXQIW(8"!-ZCPD&F2[Z-];4+$/%&$,BGPED/#O.T
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M((@.L#Q)4;84SRCJMJP3<Y;O[%._,VK7"R+-YHG!3-T'#7PJ3<'N&N6?U7T
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M-7@E3S,HO'H.8O0MA<WAHT^A3&P,RZ>O;,BL";2<9F!O4PK=R%X =U0R^"^
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MXNC,!X49=) :\^N=^5(7@X.]QMD'VT#=]/6JXM/O'HP0_9K"^THHH1IB02\
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M!UB.E9QUXJYLWWV5U4 !)'0^?O[R$N)G)?NQT0_2)7N(N\"-8 <O<@+G/$^
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MN3>BT^_6EW0%%@J=!V"'\%=,0*F.*^A*4O<! HA*'! Z.;U=.,:%,JVDVVX
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MX65E) ZZ5R_]S@Y0\"X@^I*$8V703@9_L-(5V'2 PYSCV^RVL,?X*W(EHL.
ME180Y"J'< 6+P8P+88]/,5"7\TLK63-\9];U^<6E-WXQ8 5W>4<)T\V1PX%
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M&^*M5=YK/%L71>Z")B906L+;@BC-QK^>R15-C_(K'FAZI'#<PG&F'8.5E.^
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M.;(?:T:4+BY1$A?>XT(Y@2-,T\>GIYAXY:-N_.!E,.Z" $><$UB-SER*Q=T
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M:>Q2;N%[^>E,^+*$?*F\D>6D(]2$Q7-37[&'7EUA,"YV!#,XZ0B.D5%8W!"
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M2M^--L'7FB;O%Z?HUX>SBU?-;!2*W9OGFS> 71<%4L+P,]Q8()OPP C5JH.
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M8A_O$%^5GDOPN))>6$VB@'(UJ6N &-[#-+%X,^0QAVY_M3@\SU8Y\81&X+V
MZ1EG[W!5_8Q(9RB7?[%D MB]E:*)KJ1A%CGY_:?H.,L(&GDJJT,J_A;",^>6
M*J[F(K#R?(X5>)IO7%]?WO*37FK:?[-:MD/PDJ10\+^$[G$&8[]A>PM!1A<-
M0=_'#_R62'> ]$&_P2%09!L>&YD9]Z2 (%;:*\2;YMVJ@S=(8^84'ZW3.+0P
M0X;=+R]YMX1OQ"8@%0BJTMXEE.GYK<K^=JLZR/ ABSEVGG'\>/T!)LP<<989
M858E&6ZI8YEHR_MLP>YD5L!A.*OE']PX!W]]P[4OM9<8Q6_I(1$H2[#V)K'
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MH[2+254P5=$00SNP;@H[-)JN'J7R:B5$$NT+'^/P!K)!&HK"^; +9FLJ4/>
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M+"HFXN7EI4NS>G^&S3\;]?C1'J%DL003?$R"KDSIC6*)@9,:**]Q,1F:B:B
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MIQK*4"0(!'5Q_'Y\\BX+@9_P%T_[ZH+=3S1DP,B3/K_;!,$U+!Q!>O(W]'Z
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MZ8WF8'YVH^E562'R<<B.CY#X'$Y-4!^PA#/SD])#_@\0-L@-0G%9R_(9'A.
MT4;J'<9[STLA=059-F9:5)SF=,*1_<],T68,,Y('.QRO=(%:6*YU0XI"&95E
M5IAJ%6%9./RXKW.88D;BF%T*Y)OH@*[1+%I-]H7#+)E92EU'LW?SXPLXFTJT
M78T<Q^0$%AOCJV>>;E,EL4VZE[\8H^,PP.!VJQ'D="5XLMXK5]8S6'29M/%I
M-UYC(,<"<>>5K!$BL>E8PK87E>94^0,*P<F3A*Y2K&FSP2^4!^['U1M>3R"]
MS_9$1ERU?3\3_5E_H^ZD$72_P;^_"WW%6T%E@] I\EZE3RI696SW9?Y*="7W
M-P\QYA)C3;!JKB6YV]>XOAVCLXF.9["O$#,4<L9\'RNL=R-Y>[0N.J7:3:!(
M\9!WD2=)S7S8'POVD5O6P _?^Z7(.4SC7<*!NW%%OG#+[?%/;.6$^5A=7HVC
M@\^%9T6VXTTYXB8C"]S-%Z3\C'(TWH>4BQ,.*@+=;6![#(3YSY^OAA2;!25Y
MJ^@O1;EE(;T6)"MCA,OONW8%C^%];IL"4L3EF,U,)HO<=JZF7R7@<U#G#QXR
M""+I;?HXT_E&#=X ;Z>@N^]Q!42#B\7 /S571QJ1,4 2Y_FTNK%4,;$H>J.!
M:T^,3=&W+F'?2P"A; %M]"X7NE93PF\6KV=C?3V(3D4@C#-TG?GFR_',^9VU
MK?1*=:5@15/V*-#&"J=:M1NER^W<1^QD=$R?J/J +BJSU>UFB.>]_)9&RB36
MG\+7:FE[Z-5I,S/]D]&']#>-*U]EM[.0,;LYL$6*ES*8.&\@2\H[;[@/F9C$
MM=?W;3E$L,BUY:RST9$KT8"ON<1(C60W+93<KWTA5R!/?.LN5\S&^:;^DHW
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M@>7N2IXF969A-:OBWHBE>($:G2*#,#(F3-PK)G.#E<,%&T4]_?:..\-B)$W
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M-/=+;KX1D]V9>#3*(7'[M@32^!B0ZOU<]U/S(2^#-ZDV,^$$G<_F9XOGML<
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M3OMY7I\L<<JK%G1[K4_])FYI#I_TU_EL]W6!G) '7B RV&)Z8LM';,O'S01
M)T7?Z_$;OH-KOH4*?S_!L;N?"5A=!ITWN\.$6_JF\2/#M^B5EFZCW"W3("K3
MNIS_Y&<%,,QP1JP]; Y7CV"3G6KFK!< L?FV8;*9)GD9#B*FJWH5L!'<[HR@
M'Q2?J'FU6#U?2_/QXGL&5EEJDE$7>!OFZ15%GG!@\CXPC=/2W+VO]GIDT.EB
MMNH4/I)4N!R'&S'*'6E@.\ZF2<F. $I5?%:NG=N>Q.V\"0.J5)'786EDWQ#
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MI;FC:*>>X*K%#^IY-GNG7AMM:^2+'6JOGI&RGY'<58RJ!+=Z =!?(?L&8GZ
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M]'CAY5-\H7J;0G-?Y@L>2N@7,*&SZ86AQ5@>AZVQOW#>^_'?+/YZ4LMO:Q9
M"^1/0,!XLQLJ]J.E6\+MY]^/HTFZ5<L7=*"-*M*Q%A5G/H\=@%# _0K>]#S)
MZP?B^9CEYC)4$L'6M6XUCOKPHESMIG3<^+R.-W/*E*SC79(&"5=WS12_G1J
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M1Z'J =9/.1 F37S=*C]1D#]^LGQPNOYYRK0G>>[B>!P3:S<H8O&1V']^6D#
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M77%@FSW*-Q5(Z(<PSEC_SB?@B#;N(WZ?"%JHO%G'0]6';Z4_8.\--+25I]O
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M'#B+*!12-[UHX H FPG9^89!E!;./W_1B5C,IO%HHJJ8E .ZA84&\0G8"0=
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M >?H>2.7]L32 7Z?41'JI_>/M,[\O9C+/N[H$LX=)7T/Z)#Y2$_ =DI*83_
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M9C17AV(A\=$ Z%E$Q]/?!G&(*MZF/^W^T(A@"RUG&;P]M#]H<@"@;M1Y>1A
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M='5]>J=YVL%.HC[VBE6KI]@%_YDUH[=(TP+N:S.(;IC[DRZOP<#",(/OL;5
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M-D.Y-%DC"FH6?69=M @$92W)4*\D\,P.JY#@V"3)I71B.&]"2.<45$])=RL
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M0RV_=6-[ 3J__.I*6.PQ1EC$I-V8EIGE#+ C+TZA<P;4W<_YG,LWE0SMK&Y
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M+[GT ZSX)&I'^L4^M3&->E+<X'4Y/?,AUNL9_=MH##2&*N?VX=Y,0W %\^6
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M[H[F2"^QI B+,3NKZ_'\"E#T<B7@VYMSEJ::#T(.>(VCZG9=J_73D#A$P@$
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M]S_*/UW1?P7Y:(X/0.MC_^<"EWC@RY\LL$TEX!NY!#M6H-GVCW: Z/<LVK<
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M A*Y_@DS(+C%#.!?_P7]M\.$X+"/M\\$BLF(T CN?V)US@2CP9&'ISQA<],
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MO^?9D*"=L3>D6+4V#+-YG:PDNY?$IIC;P(<C>K28V-!<)+&*.&LL)H?_L>.
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MDH.*\ALB-DO4%&M0AX7S+<X?_5#/G999?S@79+E6[LZA*D2X+U:QGS@V.^\
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M<@V50;H+XE>*DU?>*R<A@2(!!5)1\3!!PK &)*/3H[!&6HBY4>/E!1Z$9:B
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M]V1Z^G\!JZ>7\A\Z=YD$JUZ'-V?J7+5\^A>@;=^G;Y:]9EC^?\7$YK9G[S9
M"*YO,EIUJ4GG:/D:E.EQ]+?MB]K-9Z>_ )N%=T.4Z;*4<W,3 EY-4SKZP.NG
MQHNRY?''A3_$ZOX?31/R!:_U/;<GQGGFG,&_;Q-P?ZO?\B&@=QBT,RK]$]S)
M_%M#AY44G_S !NR=4CW@O6 "\'HA))KO'+#TDM53#F[]0W"?[?PGUM$SIJTX
M_M>2YWO!(<%Y_UXK%Z&.(+<#R5G:/PN.>ECY+&2]KBOY-SLX"'UZ_RGLA<&G
MT_-7O:X;>;8=J3K?[5])+Y3%(3=;@E0K]6L/Y7\AO4 (@JV<?I9QN0.:(P@L
M;=9WDZKJO>WZBK?41?!!'@-9/6__"(L*/H5]24'5(:$R33PG*)N[1WNV7%;F
MP'3OOCHMF7%>\]B_$$RKC[SO_/[\0],I%:9!7=]&Z[M_Y7SZ8,/7))&??8&?
MXG^\GA*N5\6WAH<'(EG#"[;CE#\T>*L@W5?K<3E2V_,!TX8,#[>S4A=ZJZ?]
MC-NGEW?: .;[S!UGUF1+;\+1X[\$1;_HFC^]7.W.]0I.8X88 #3 47^%#>^N
MJ@_5'>_S*(>%QIYJ5I/)^4\LHV?\&W$5&O"0$-\!##W+F^&<X#6BB4&ST%:2
M1!:=(J>V1_\D$B.KXI"KB72'7T88?;KV2<?_QN U0.()O@]X1:J@7R\S5_KC
MOC5*),MOM#CQIP/S94]PR@\MY'EK<T4#25U3GONR[U#BVTQ9=.,]Y5<(N,^B
M$]?A%V:%%Z\E<7U(/W'IW?!8*FTO)PW^#RI%E%_QWN6N[:S3-?NT)^FNT;6J
M;:TL [&#3*RGZ^I>9=H/2+%0JQ*63Y'/11K"L2BIG)JX%.F@4&_35^:PY2IA
MWTA^0/JL,=KGU]3<UM!H]^)S?GT[B@(^XS?@^;R&XU?MS75\E ,GEUBR_#AN
M!_T>R*@=9KKSJ==B07%-[UWSHL/CP"[%+^XR".:,,M:]'XO;T1UHLZG?.3(\
MM!G<=J.W?%UYR3Q@4REC,EV^BARQK)F&?2E&!*D64I#5:YLO;X*64"U.##@K
M-IHHEV<,TPT+['.'H0>E6=)0G+Z98.;>(NA#L$K?\[O66>"I6'G(;I6DXKIZ
M48.C+,DB:CD@9;RN9=-7'EI;%!"[6S63U,.$,FBZZUHDA9 ?9$1.&(YW5)68
M3#%Y6Y6'26==25RB!7I8M4CP&0&/9ZQI-^Z$"?O!:G 6-CGU3E][/S[8VH47
M-K%3PT-Z^'+E6>;5:D*&H7<+*-VIOJ88'J1]CMM:O_KL<U!U=;^'@2FODA,_
M!#BV"(BXWXO F3!4]X#+46LAT]L^51E^7-OY2CJQL/3\84<!O+(V7UXD_Z%9
MN5):I7BF4,R\\DT#X,;1X,YWGBW09L1'S#0FV;.E0LS$P3!L16P*#UC&!E*9
MQ<"8D<3KW$)4PQ<&W0R^X<A.!$,2"UEAJ*]LYWXCY6R:V<E29R@>2'K9YVV(
MG][V6='.UJ>XL1'VNB>=HBK N819#T?9X1EYW&=13&*F)@7Q$@@MXVE<%T3:
M<DO1VW-? \RJ5=P+O.;X!)B7%V^TV#Z\'&5_8VF6(B&Y:A=M9_PV WJL<H>N
M3-Y*][G2)[!6"?&HL6638YECF#A*5*WQ(0S];K\9'FP@E3(<)_QTYM (-CZ;
M$RU#/#)B]JQ%:K-SDX,@"GVH>+8Y)!D!H3ZJ;QT)7!_'8[EKQ'?  TJ5WC=2
M5L?$+=ZH0X+X7%X7UUN7SQ=?'[6*2I1FS(/YA9Z:-**@IR_KK:QFV*O(1Y0S
M(0_C%F4JIU;G)M#Z(K0/KP>]RK0%L'NV;SWL!X R/Z[NO+  I=\JK=2MG'BV
MO;4G^.%2D&/2?+CL3X^_ Y;.MQO_6K0\0YT*@%U'=;V)XEB[NY [>P?]'T(2
MX_@H;AF_^I:C!<J%> WMKW:J&ZQ<H\G#S -69TDZWDGH([KP)&3C(\,,9+V.
M].IY_Y?P9UI:E)G<Z5?&%#J>Z+R+J\,GQ(O!>BJ8[L?C\V<5]/\ F][7?C-D
MOGS^-2L\JBAIQ;;Y'S1O'?RU>6OC=;75Z#YW\G^M>LN;LNTM'!_PZ/>RY2K9
MX3^PZ3PK3VFS(R,H"8$U]XQ,OKTU(S3[GZ5;I@WQ5'J+?Q<3//_?+M*(5I[F
M VYND>__>U"W_@4%E!6)UMW^?]:UM?04$3P^E##"E];Q%A&MF=C?(/9\:'.Q
MLIC=\A:)VW_*8R6R-H9<?7Q6VX3S"?;E')U2=K(SRLHQ6KKKG9'X[R=,4+:!
M-BS4KMOM84*)\A *E.M#\U[=7PSJBL2B$E68$-0[A7=S!L"[H(TGHNR3.UV!
M";0R46VQD'F=N\OENX-Z"G-T0O+FSI(G8;(?4^@VNO[L6#KY-YS;DV[,9U!?
M4$IZB[%$</SU'3?QTA^^]*@DG7=@,J<SP.I3[/GDX6T/ROH3^<'4C"CH:HV'
M0:G0-]OAY@N_46L5P=/L+^D%Y^2\T@\]US9=R)4:<K;>.-":"54P-VWV*J%R
M-5VB:G'BC8_R_6)ZJL#J9M28#>_MU;K*X9]%&I/(P4JOG3J$G%DSORU?$LW^
M*3$\MP4%KC[8W[[_FSE1ZL_:N9)QR@$[DO&_S[6A?=8E64?6K*@\W_46X9/[
M>%WC=_(R8^^8Z+=<F^?VG[DV_SBU GF(IPQ[7>Q4Q=VO)@;0'[H2!WCW=+1?
M['F?X/YAWB&BX(-ZA[$!<?_@#Y.K6Z% :T[H[A\2K7%K-:'Z]P>^ZU6Z"P9Q
M(8G7L]7<MA(1;9_^HD\M2TN74-XW#O@<I/1];*@MWP$]CG(?OEV73;P1F-O(
MD8%%Y1Y(X=Y^O+X;..[RIKS^!+@.-%?^ZC?RK;CK4JF(Y&.'\/^@D/H"P((@
M"R CS_;Q@8='/4<G]H.:Y:'H1]@'^ 0BDI'Q^@2R 7R"-B$NW\#KAS/_37KN
MCB.G(BH13BL?_M6W+=&+#4_ESS5;KW8)];X(&,B\HVN7<%%NN'WDD:U[^:X<
MQG6)BNG6E--R76'PX$65IM&.5M!HR1S(Q6;WM;P?KTU_GGP@U)2BQES/"+\@
M33P,S9:61,]YOB?3YAEZ:%%OJ,WHTB2%#"\A:,C!=, :%Q@+%9YI.-O<"6ZC
M]E%+X)<#Q-'YX'#V@[^\R!EAD9Y'M[Y85M-@CZAB4:=?$!<3VVQI6&(L15YW
M5&-G8FJ^Q%8QTW[A4,OSR#,I2J'JK$0#6P2^69X4&V]W/Z2%&P8)0(&IF> =
MO8GKF#2K1W 'ZW<7^7%'C-\0RI=CY(1@B9-.KGP'##$[A+] J:&0@[?_N!^V
MV8DT2*I1CYJZ@#7H_,DMF'%7V%2J]H:RAOV+$670:MI6YHQ :5)ND\U$4(D<
MC$N4-490@.*#92H-AZ3*S<Q41J&9"9L8'7UFTZ2]=#Z;_X;; 9YKE%XOKE<)
MTTNCCR\:GB_28(Z'OI!G&53&4LQBT2(0&XBL9$.-).*/MD/#YF;YR*.:CW[8
M$@2NJE-7IRP2JZH\DP17VS;/NT]I#+5Q.?'$[@:M+'HD3X,3U7+89>5%V[M*
M-3:QO0N1:_;,YKG9ZG.+:YK'Q7TKA!]$[6U+Z6D_"TCW7]M8BM4QI1FNQV;$
MQB:>M^?9:,9JDBA6A0,9!QU,R,=&LO18$:%=Q1EZ>6)V<L6LV0QZB:@;6$%(
MH&F$%U;RP%0"(GK^^AZ&_'YK=L!FXH@79BJ7>*RTU1#S7$O#30RS?>6R%+U4
M:U=:?(M2909;WJQ"4"RR.\*H8(%:CH\E$:(>U5K[)BF:R 53#O=S7)/+7-!@
M?04Y)A%7'[-G/#E&3+CVKF(5=90])X  (%D8_18>-J$L=<G@LRCBAKU2^>_
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MI,H3/ U3IY2/BC12KM 43E4!9![:T1",:#I=.06-Q[]/3LVP"$.N;^.6B-2
M&(\0(8=+@K<Q2K]<\IE_#X)I]N1JG.<_,7[9T1IBY0VFI3>GMP14&IL*\E=6
MZ*//PBD09Y,WZKSQ"8:8Y88]X8H:8PVQ89[@EUJ3:8X$(!KY[(Q4MI;"_0=^
M/L77H/0) :V_P!F?> !.$]OKD2S_VW.6I\)2M*R,;_]>I_DO]9#Y[", !K(5
M7VMB?=!QC9/.*$NW$TV/#PH7:ED;MNW!*T/R;]'YV4I7;O^@L-2.&R)46H4G
M^0WJ^+@7OW?$#WUT^6(D*7461:P'HHA]]"M_P6\@@!NG"9/Y?Z;14')Z0JX&
M[X\!D+Z6\[NVDQ:C5R\'_R$U7T__<Z;6X4\$T^,SPY;.7W.6R^ AYM/V=EV;
MMIMMTZ>MDND/V>L\]>>,Y?;,;]^*G><3=^9%%RB!!^[@A&1\7.0G8=_.\X'@
METQ3&9@Q/R'Q@@@ORQ]_QZ#3RO-#Y6:> (HNZH <7JW_B+=I#VC=\DB8[#<H
MN;=CK\V)K.Q<[75_>B2>_)82RHQY"C7](@;]E-'E3YJ9T>FH<K7- ZHNLX.G
M=M_*\9GIV\QS*;5R: C =T#"YLEY7^K2&:K9)_;>U6B99\PSS6O>72/1/P2V
MJ-OGWR+%!A^8,,'T]FA32_SMZ5&1=JT_1[:I<W]8NDHF?C921O\0D(U_[+ V
M,=8@"MLDRI8';Q-#W<&".=EN3W.5BYE_(<OPTDM26M(O/PB=#+F P9]@'P]$
M_H1-9),<V_5FO.:'U3&'[53:2 )V0M4-5+_D'8C:6"S>VC"UA7(F^L+ ">8+
M^C8.VK?5>EYX6<[^[#M@QE'OMD(OC=3DW.P>$67VJ^?8DC?+\95><#MO%*ED
MHD_!JW.OA$>Y,'6CI:2!V/]1\_M?A-MO4Y;O  Z]3^*JWQI\O@,D:_A<27&\
MK5VC/P=]_#:1K&:VTW@_=HHM]:L:;N!JY0]3ZQ!G<]I0F^.NM\AH=![E:]U<
M]P3EJ3)5)J'2U )IE4,5.979,<DY6J(=+,522S-^=I+D^#6A444,*'@C<3R?
M0V G'V W&)V$'AX-<FM2D Q=3)"CV4+N:GW1KSC4VZ:*S2KDM*9F-TU91&9I
M5LHP@5!1Q>XN%29!V<_LQ1MYAC*Z<FF];9?ARDA#-=;'0[HP&/)W#A^] [_"
M?@>@2([(2>(O#@W!8^0M,Z5&+;YG986H\7+.,1:")*(&?@>$!.AW$.8$P>>R
M,CM]$-%< YQOEX>Z.A2,NH6&FBM2O&[@$.]CI:CF$_67<&]@+>B9J_,=<Q*\
M\2.G2O.(XLDX\8W<S06%E+;6-?"J2JCKN4BZ[!<S\%JV^, 3 \M0* \! HIP
M"@ND82= KL7;A#RRP;%DZ_CKE3Q3?'GXD\3D4)B:%.DH>-]TFQR*J-ZM#B1.
MQN>%NR8]O>(CHQ(^"]%#(>2BSJSH1DX](H&[V1'%K1 _\X9E1%0'H3T3B=UE
M(*F=U%]K -=H,L@,^><6TF&_]@#R;G^9*,B]AO\']=H0?M6_%SSA.OX^3N@M
M;A]04B>73\:&JLH4Y'F[T?"$A$FAXUP2T#_:6UAM*X?Q7N5]3++R,P;$#[J#
MY4'.![\ZE^)2X"&-D@=8?*65XJ'[64*P"R PB+E'0'O <BOM/9X@< 5T$D\J
M - 6)PE C)/KLIR_4.# 4A8$E#A0^VVZ58KP,^-HAHD0Q<Y4*?%\'7Z48WIM
MKZJ:,(54P#'7$-U4S$MP,R)>V$7J5/R<9_^55IV9]DZ*^>)XT++X1$:,I]I%
MM_%QN9NZJ,F<![2K]0N\L&8P9'W%W75_8DHB$Q;FQ08>8KUX(":&_5S.B8T$
MJT)I'F?=Q^<U!]R#LQW;H[F3M+E((LDM2/E7-+M-,XB\1XNT>6)BRJW=^>:T
MJAJE8*H2BSD%975%M0P"0<M@6K3IKR\H7UJX\USD9V31L?-S8\Y7$PU92&)0
M4[:71^A>?E1(O6MBC71*%S&?]Y/K<BT>MZ(I($8'5]PXG'GXBP,0D]!AY'&X
M=T#%1JGED]J#]54%)'9FIX<-NZX9)%$+1SJ,(3S<3#;2 _:4QZC,E1&V(0@@
M_Q'& L@I18VM D,\\3D1^9@,@FBJM<W-:!3-&;:.2.,**[I8BC%2DJ[Z M/-
M]AIB G%#/AZ%;>%0">%PQEL%5%P!(O'9J2X#5I;;%J_)K94NZGU;&UIH\;E>
MC)"W;):\J8=E[<GA601^>[<8UG4&;*-]Y>$@[29M7(;ZA_,^YC+LIO<R)5#"
MWP'XQI[F@N+8-F=,MFCT,D3BZ:$I\.OG-M '"PW N:J=\C38L>2,<[Z=O$VW
M5ZA+3EQ%(51&FO9D_0E8:IX%*7SW6*S9?6X1=]VAJ/ WIPZL[08AVKNB0="B
MD1CEF=; 8(F@0<<S:R70UD '(U=SNAQ$8WU6F8Q/02]VIJL=4>I6_L05T\28
M;.X2'1@%UP_?[')5:"RCDM/%R#&(RTQ]@!N^]#I8CU5[O["J^SH+/TJL1BDQ
M#BPM/6YL<;#>U2 *SCR#ZJ]K8V<R1Y)_7@:T<@V<W.I+KC,UR1,/A"4")O*Q
M*<8L(5/"LC"EE!B!C.":EAP9<A%N^U*<*6%B%A'U0G-J0+N0>[BDY9=;5HJ?
M(1]FD,@/>$JJQ,E%?!1'[*/MY<@\ONG?&DT^$OOP4[;J:=IEV4T5>:\F[-IP
M30_3L%_;14B:G:F-PDVG0+_[ZK=/^FW0D?(8V;,32FD[]';&5>?. ^K)PA!7
MQ)/N ?S$W]32TNET\#1?4F_,^%+YAR-EZH]I6X;T4[UG5KI#Z<$?,PC&WQPH
M  Z5[9BU@;\D2[5_<SS/Q[EF1'>BG!:80U#[TCL=5&&0N&U U+\Q_#@)\R=8
MZ?5K@2J-Z#+3?].6XML:<M7SSUPI!AGV!)^],J?^S6'7FBT49GR)@BPO[.D;
MN'$^CYJ\WR=Z/0HLE5 05S_>DYXMAIF%>L?WY>W?NU)*<F<\UKL,@'<^J..4
M$Y1/)$N8,JV46Q1@IL<DS*B-0--/EI)"B-/^K -#+B$"V9>.F1$O5=8 4=&>
MXT[$%3R%I[M9H.522'RKOR[EW,D1D?53GOGGOBI5KR/T+UYFQO-U_NM_+:<4
M]F84B;?'\Q;#RPI0_QMZJJ[@;&[-KH8KSNJ-#@'NJ\;NY>D72I-KN7ZJX;Y&
MI;"ESL6T2LJ*!9_F[(M4]H"R)'NR&TJA 0#/C%@S@87Z NM]12V8J]=.A!@;
MS14;0?<!B0U7"MT .*PHJX'E^;87:!I7\[T:+U*"GZ/$DL(2I@[T;H>CPJ,X
M^5J9&\+IHG1&XNDEZYJ48S,Z]H?T6.5J]=%$U:K?&SH0AI9%D[TS8V]BLA.]
M4LMP"\\%&7P*</,!:R?@9H#BI3[%PQ$K)6I1I*G64+9'U15LB\%BEUL$]7D^
MZZ@*/ VB8T)9[(\0(9"$GM])7ZV]1ZG.@E7#5M-2=IPD/BK:,5YG0C5%B#PB
M[XG:./A8#O4MDDFC"J(O>U(]3<*KO*[<MX%V\<U)743&;FWO&.LUN_E68Q(.
MRF%\KG8*D@L<?=@LK70-03VX6"G?/;\R5I7\10M-.?38K5P)*M(NA>9,N2\\
MYQ2E@!J[ 6N5E?8 <,<W&UAIY4L= "S\H*$^*-183CO#8IR]S*4M57SJH3\B
MDI7@V6O6[9'3:\TC%Z9[5W/L030Y+9*\.UU!9C489;A=NN4DY36A"0UFG-)*
M>]YHL:+-',%Y4](YZD*+09$@?S(B&9AR\ZZ%%G$*9@[BIE[YF:H"Y"S9=H-I
M;\10J*8%KMQ$7W*L+\\NE[@AUN;#I$SJQ]<&GAJRV9O)YC>L2,4HO21N:)C#
MO-+>[@NA9AK3EVKU<XF#L3:A^"&L.H!ZUBG*[I"/]M04JBN.BI(I_ITBRZZY
M0*\/\2_&&,K!A$:.7",>;XSG#W+&*O:C0XQ/K$.7XW/C)I6EZ-VQ#UJ4='$L
MIN14+=\Y(KK0,98K^VS+Z YP2=5]U+WKS:C;D.\UEM0M.:<0>X'FMZ$MQ<B4
MPXS"6<R$#7+5ZHV\H+0ICMGH#D8<:2@L+\;0'\!"W]T8J<7*&0-O1EIIX=?P
MI,[CU05%6:WVUG.\%F":!A*I4E9DI@V0784WU Z+59*O;LM7R- XXY792OM:
ML7$&>-KF5@CK?P<0\$H/[:/O%7/2*^6H9;NY12-T0./[(TXE1'(RD"W+&RK/
M]0=CU 9&>F0.1MF5OH7GKN<!]BHHQ.#YUCU2=J6FQ1E[P$XEU%40.M($YU<H
MD\ASP">F4?0&#"J2B810&\"U$$\P.H$0.,GS0SL.#WTS( >X.9W1&W-R%*7[
MPBQA>.GV9]!H]X #DS H\DZADL+)NW0.A[T^]+80'H]UUHLD1+5,A-[K]<^M
MTPB&XL/YS9?8:[1@U934H&2VQ",Q/G(@I4XB;?$U$'$UGUKI5!K<A:W+KY2Q
M#Y!"B"10S):*EL:6"ZFJ(NK=#P]VZ2 *9N>_6$@.('WSG(4 3(>;(JM?9LC9
M[[-^6O7:Y!%O\)'@V] KD<S$BJ$L%%>:OLC,QN>;XLG!9O*+#1FQ)-YJNH4<
M8ZE,0"FU"39"B'!,;#S\8@6A2%R=F-2]R$BU8FP.E':A7HER#\Z]'T_UWQ8H
MT>OD/:./*\$"'GQNX[PA43-H A&V4Z O+SI1O9SO*AL:VGS6VVG_W')<0ZU&
MWK\OV<L>J0!\1-3&W.,!V"UN'Q\=K1!R$FDCCW7:^F>9O&GX\.8Q.=(1ACTK
MY+-_UE3XIK#$A5;;S2M>B.E^I8 H?_FVNR@\_KC8^6[6Z$<@]0WO'*J7A\/M
M"]B%<R*"[:/==_D,YQ^*HK_F+I&.W:K?B-.91%OJ$?[WB]"T@GY^:51*J>^J
MS'N3 @P&*0^=VH>'3=$]CV;6Y%;93.L@DA2"I6G<)OSU>"A&-=TKT7H%L-P"
M>+"?$12F'5-=ZEP8*"Q,NS/%>+B[,^41JYXD5K:6,6]B.,/#;.^HEN/Q/O6P
M^AJGC%8#+'5$IU*AJH@UKZAQ0S]7[$2TRQI!0:4*E]2+1#Z?EQN<#]&@+F _
MANODY$\::*HF>&)?.+[/'(_%RO2V731NM54H\54J=A30K+2Z3TVK8;[XR%P(
M2RL^P(: 4G,IS;^A=0HW9W]CA(KK2#.-TG[W$7?A\JI-\I1O2F3<LGB/ H,D
M@G=:S*N0*2"=9.7%F*>ED50ED2\.=FERJ"TM+U I6HW!BC+K ^:76\ZB17<&
MF78=LL\)OM?^BR-8A$.9EOFX??WSNSE&Y2Z! BJ6:NWR7*=.^AJ;=T&KK8-U
M@-GS18C@1NE\LM-5.GL?J?10!TH<%#@WI:4-C-"UJ],P&-V LA7&1.\'R7A9
M,XXZL\3QV+<C7B:D,]H(=1XJD/.:VIU+RQQ]!@>":?G8^D<&2<+/*@5SS0<K
M @U,3I,XE9<>#K415PH8U;VU9K!!4:SV9FPIH]\! DG3(SK7%SQX4MLW^5II
MM *VQ-MX))/=.9_3<PS(N);P$Q(4W7!:8W?*AZ*) M9V&_'JL? -A[RZ$AH'
MM'&XV2416]]N5@DTYC[2F!8*7H@O#6K2"9D@$1RU+'>5L<@WX$H^L);8&X*1
M51%P9>)&4#EDE:9*SB2'<R.E PA$E&)4REYWN>9_!VP-A$Q\!V0O$S/7[=*7
M3XS87:2MT-X+VP(6>UKKO@.L>J)6UR<2?Z_&'?D)]@=PW3L-5!%0S-JFN-5%
MQW6EM@BEX0S*%X?'TW*:7$\Q@$3<]"NLQ)X;6VAJ[TW>1!7@Z'G./MQ :&Q1
MD[K'72=MAPOTXR(7A5!O+);[F6R*H.]DL$)JA[FGN"UT.A_#V]C-!7U47#[4
MNM%/Y #PIZKWZ9(GQN Z$\IS ,5[6'+JV1#"4?%;_8AZ<I+//T+D05&@0CCQ
M@ !:+1DL ,AX ( #8D9P$LH>8 \ _/A98?FQW^M(E70\I \)+'^;VUA"BFK)
MV*V_.>\X#X?"DZ%*0?++ S*R>U!2BA%PKNK,S12=SG7[JJC+IH89QP> <1D4
M=3/HR942V&!4<?852SXQ+K.9SD3L*WV%"LRY,.RE8HVL@'$5":4^[_>1RJ'R
M(=K<7XOQHKCWF )'(\XV(H\J<SX;'AR4$C&6&MH?M2-2A!<+1<3F4="4&(C&
MI7S6N<O:YF H8M1T_,%4&BKYS8(+J[1\I/S40VC8%8EG?FKJ]:S:EVI*'>%<
M,42E<L'LH:-IQ/K2Q J"^H"P]Y-WHMN@VXI8;I,.0B-<_MBF=FUSX\1, @>.
M8-CF2CMT#HH @OI4$I(7XFL)GMP'7$IOF,(6FX$CG),!-RGF;%C4^CU1I(>4
M/<[PL=D#26$&O?H>)"0#=4$</-KV]P]CV:,BJT.CIU:,O/='RE8"NB-F8I$W
M% DNVOFD*L5QG[&"NTN.WH5-W@.%A2?%S@1?)(GN$GS3[$06,)P_/T9B[R'!
M:308%0LE6.?Z4.5S6RWB>\]K2]3&CC#V,'X3Z>9T?R0!T2/D^"!"H<:HADZ'
MYA>LRZJLF^4^<WN5#_EQX,38W21Y.<-VDD^V\OE&L,C1TD>7=97>>Z[V3XHE
MQK*^#^P@40L=1)Q8JA)!964I"A=5(3X-O,P:"[B4>CXH"PDPY=#]F[%Z4ECY
M\5H:&D)+>4WD:*CS=!*N :<-V09MZ22X)O2MSZYR3H5-/#()6L1MY%,DG=I[
M]?;!DXF8\.W@X@):F+U+*Q#SLM9+EN;M3-4U:_[^!CO<;W<Z)<3-,1']KYRP
M1M3HHVOP^U3>T 8VQR7 M[7CO',J+V_$?:^L(TJ/GD$LG=T2Z=#5@90>$[P5
MPG6282&456-=XB&NMQ][O"!=4X?QJ$5-G84)9&>+-F>RV[C"9=#]F*[_S*1,
MO-_@AAHK50OGU(+9ZC[4G-H'XD:2;.4!T0 T>U@6.6UAG5'%K%=!K6-:L]B:
M/\(6@9NZ&QXOK8_R'2 M;=&<YZT#$U>:/43JKO;Q1JZ9V$P\L!9:*J*$KI2Z
M-,71?<ZS(FM_:=K?:'F^,<1X>Z@G_OS80VT,?7>'7S_-(N">,3/1*$]6R%B2
M.>0"D8&,?X49HFO42937)HB*6MA#6X=(Q$NDF$"HQ*K2@FSZ7!O6M<0AO;R7
M=R=Q1#6M=QO!3)U>CBUP64856EVWQ9(=X7KSXJ65%<^<M&$Q(']%75TY,?8@
MM40K*+A5 ;'C6$_M_%WPIFO<1TPGY1=Q=07Y>TR$2FZ^E6QQ;/;$F%26?+CK
MZ-V!KAPWZ2HNM.YY?3<L3:EK-'B<,1_E^(W6S"<MO-AW80$PV<IK;E%.+:_2
M;#TQPEIEA[X#AH7L-\I5$^ATY_<P8LK,TOJ5IGEP^G.\SGVBG+6.L(\2:N<+
MA'.P,R3>JQ^0H-:5ZT&Y@_R?VXX*NV1!Q,HE6,C#LFF+9L1;:W$Y,H2PI#A+
M"-W<6/.P<[@Z0='SEW5AU<HV4!46M6O3>K*"%OHHYSI3F1B#]MX+=A(K++2D
MPXPY,!6(IPPB4^]2M<-YYTX^3* )]IZ'@4K<.<T)Y\,"=BF5-3P.,^@MT^E>
M^JE^RI-%T>2$#I-W*!0)M7QTFNFKV1S,1'F EBK!+]/E.TZWHL9^-IDW*G3C
M(%)86()RZDR+^IY5'WB:IWM?O0253K^>[WKJ..851=;""#_C0-GEF:=QVQLR
MCN>/^?R9E!4R,X]QK 3P!)M*Q[9.1L+RU$3\(8ED<?F+KV)V&!U8-:W'**XE
M,D"-(Z(\<L#;1M=83,42&SF_)"C6"H6 4@69H^3@,ZS\;/WQ)KKF;<17GS"0
M82AP*%01NS8GB,P7PW<G9WR3N0H-HX!>O7\5)3K' W3)LF6E(SU=7\Q1 3G9
M'#64D?MAWE'+S)P3#/JD3)^XE=86M2YFQ&3GDF9CE0;Z&,YD0.G"*T.P.,FI
M9&@A7K9*R\9)NE817ZQ8".*Y6B.Y<"DS6+IL*,OMJU^E9H(33LI*30F%%JO?
M[#5>,= (J&4TZW-VK;(A)J#="M&6<BR7XG'8Z,#XJO$.1KN_GB<(74NK1! &
M,&@@)-88H\G -D7D%=*P9&6^CI? 6+A'%YGKVX?),I1^H)Y?'.5([7S"D9:9
MCE@:B",([F,+)/E<(-^D@E@_['B_L(S;9I&,I<@D(TXU6R<+M @>'^/EJ&=#
MDN7!T,'N]4<+2#P7<0*!9,R%<HZ,X8V!?EA01):[05Q1G!5;\0Z5V=.G,M")
M$TL(6@LS1(5S6FX<(?@,XD(/0K 1?.W0-G+T]=@275-]%=)GOM@*%:!(TZRW
M=Y$@5<N9$L'9<<.HN-N*,@:X_<OYC)P74 L(T8J0CH;(I/D<P5RO2H,QRF_&
M[&%J7+WTR= /PRJK<KL<4#VI^:^9RI(77@:L:"DAY)04PP85[HQ^Z#.,,V47
MSY]*O@[B$KB<Y[L?7CKN?P6KGEW0J)9P$$]&ZC];*)N#'O;N G1-J_KZU(5.
M&7-:U]!2C24E*24:TNSHFP"R>4RN+T:E]>O^FC&W;:OTA4>[2B*0)4*57HE1
M6O<MYUCK(3!GK!6B6P@V*$#' 3*96;8?"TT!=N-PS\>^WTHUX/]KO+TF&^E-
M(WF4F9L==H)T9J:7;@VIVI@-[ZZZ#/[IZ-&'8.=Q+Q< R<71K5.K5R?5'2]3
M=9,'[#>:IQ+IIT[DO:!_1G/KX=W@O/S"GU?SU/%"GJNQ=VV/VN&ER^LK,_;I
M'[B6VU9@G_]KU[("4C'L-[?;TRGK/P9D*A**&$>]OLIBA7<?_+J=S@#$Z1*9
M$@/Z &PDM9]])GQW?\]Q4Q?EPA2Z\RK:N7LN[^7"&FP6!%#;:$E=TF8]C:W2
MTJM@WL"8?7.R6#3.[_JT5\(Z_PES6YY8>:(4_#8,FNE(=3LCXB48'0>B[+79
M__3Z>DC4U<5,_?@*DN5U@:!?0Z'9_WI$R1Q&P&Q7703_[*1M?/@OY=.9(OQG
M<NHR(,(K13W>:DV=D>&3-7^AE++!YXZP7+W'HT.E!=DY7LZU:A*(LR6J6CIL
MANDEF+2E$&KM+*^:/T-CJ; BVAF=MXW6![::R8WUH>L+A6-,&38!NWPG*:JU
M^YM[\8"YN^F6MCUS;79F\DL=. W&C/>H*>G)20$?60AV.:>(%HLQX%%#=EE(
M8'G6-D$*>H[AKVGM^#]6Q(,8&(DN(65HW$XN%]E"*2/$=.B/F6KPQ!?H((5K
M.ZJ*Q:\19R:+-!(&56'9/G6))RC>Z3E=36:9:F[W,MM4T7'?RX]D&,-V&8_
M1V(:$DG:ZQP9L#BT%_0J51 QE^#@W S&,(WHK"%;?7UIOCA67;$,O+)+#:<Z
M/W!U9-WH2S&;VC6,125<FMS8(+[O5R \@+/>J4M=Y=*(M\4Q@J"?+]_ETT[2
M[E-6)LD30S:DH;*G;&4K$%**2'T?)O(E@4.V&R>F@HFJ]#VVRCQ+T6VKM+N:
M,&.O19E*<PT?)Z(T<906?M_4+EEU3]C\9.>&R\X4/=&T]@+Z)$\[;E?-"9*A
MKKB22$]7E>]VTWS^.VPX:7#U#E7A5LCTZ3OT-(Q40?0-]'T[B"K]+0>FY=)C
MF"T#^..QZ3%>;2Y:6Y>JC&&/!ICR 1W/0GPNV<%$NA=VM@[::HULW'2")=(J
M88>)C4G:_KJ!5!+JNDG1-A6F_:P%.2#K]Y'LF^'TXM@W%$&=*0G.ZK(R[<=F
MY4&Z"YR53F+,',\WL[] M;':R2#("'/Z$LPFQ5S[;KT$&0Z4M^:.2X*0DXSC
MKVD5<T-8O90W^<\_WL&ICC&;&[AA[E$F[IK94K[-COOB<L.(X'41/[JM,$UO
MH1%;R'$[VZ?8C$DP"D9=H4L330 -(X0*^]+GEHI>APL&+'2ZYCJ"W/E3KBW6
MBT(]F*'KW3*?13I+GN>*H3D%*) @R^02Q&T1\41*WWT'B-_R/;ZGVT+KQGV]
M85=X'^7HK20H@+0(JV0(79<C$G3@:( K3#XI 4- C-*5ZX,%V-0T:-LW9K7S
M*2^?)W>A7 Q^DTYPR2^//V&'WHGSJJ*\-)+6]Y-M/5Z%QK):!BN#IPME6&V:
M2'GI:^=".^O41L:![N@C&Z!%*'S#R^?OX$02PJC7N3[*H5 ;S?8P&NG2\VSS
M^X0GHVSOSMOY?15#M90<OG\S%=-0X*E.,O-8+0M2VAT.-.E-#;D#U\(ZOC04
M#07XB-+Q.&1I;?&H%FZ?IDMIG\*1A^<HRU'L05^C)E88L"C@P"?2Z$A'.J$C
M&TXI.7>)[D$F6P2^=KE$^^0&^UEY27MZ*K2HT_]2]^S@;JH]Y\!JBC3"$\IX
M0JBN0L962>[6N7?(PX3XI<E2'%=;??UR3C!_W$RLL18= 8,F>J>UG=YA[L,'
ME?LD4T:^2TY^FSBI:053P5X7EQ)?(@S&RAW=4C$$.J5<4<Y9-X2!U?X*4!AL
M4H)LYJX20A2%M)#/^?D>(H=>2,=1B6Q51[/*B[VS8[7'X(ZDKW@'?KT7"]'6
M!WI(']?00\U'A:U?&H[4[YX,-9=Q.8[Z,]&.T-O:"[W_=LR.Q;I'#.C 9H4D
M>A8=L2>45O3[OOP3H,)VA,AG]FK2PUYOP?2_.5%J/'/W&)LM-7N%<04G4',+
M^R(0@;3/]FKVZSZ<#+XT)B\*[]4:#ZU32+3MYO'I7K3N$827/'\SRN?]RBRJ
M]4\(X367<M_F2GF^H/E_Z+1_-S'Z3E)]\]7K5Y_%ZE^E'5<=1BC-D$QW</WW
M8PZ-R#\WZGE^!*CF>%RE4&%FT)8*Q9#/)!VR*T/WU2").#&)+&:YX_0A,*/\
M>Z 56]9-Q-= K9J)1YQV5(U*Y!##^^+*@DL:S S;DD,IN0[!M'DJA@?$;4,E
M*SPE4T"/1V>OVTCQN6B;$^8Y6H\=,$M,N-RR?*1U$ZBL#*^Y!JRNHZ7:G*;]
M,LG<NLUO[U7;1RMV!^8<TH.QW3?#B\68C:POFY229$LX)E4*QG(IY0TH&8$U
M/D02*X/@")I<TVDM<6-%#YN4E6_+^T9:X77O^4CPTT9"28)J,RYN/&.G*$7=
MFF@;LP4K=J:Z3$3CZ1)32LLJC2PM@UAB-:6;C(6ZU0;X]'"CF-/%\;.V:YK#
M^L7GV)*_0%?(4 R)4#+ZU1JU<G)(SO4;A66E*91E1ZZ*0#&9(=+3<^9P0M)*
M,._/C01,GW7HO%55UV17Z3X2/FOOK#GAYOS<^B()]T9KF@59:7?TQ(98*X-*
M,E'4$'5<RIQ1C/B]@-BS3!-&.WDI2[I*T=8%<5,M4MOW!7UJM:=3$8,O7G(9
M[G!!X,S%48^DEWZI;FH4X-:!.U(#^?DJ;PRE+)J,RW'@48>TCZ2B2Y%LVS)?
M1Y7F8(>-P2[3T*(V>KQ[I!2MV6C[%39A> J;:&8E#F_VKFV*=6/) :#L@GE/
MC@:N+MR,_\CLH<-]>(>RK?I3E:&EK#[2_A[=0YC!"LYB"JS[FY7]V_-))D"+
M/X3#7NNAU\(F=IU=8D)*>"@+M9&'Z !=2)5N3?QIGQ+CR/M611FQ/LB'D/T2
MM0AY6H4%^88P,7_)H0G!(5DQ2E!T6O5)T*(RALPF+^.S$RO#$$\^:R>D<*(U
M"H)#!SY@P5B%4(66R$6TG&Y8GKM"C?4^KN=7)(&/-:;4E(.\]J(/T+W 0?N<
M,9G1%FB>FNPD?#?7F+P>?U*?'F=N(?OP(W*7X_0=X/(+[ *TN+WYQE#CS##<
M,X]J?!,UT\)X3DMZ F.5=DKW@C+<DF(1=>!D47YRJ(5R-J?7?,V QYMEDU+]
M'E^4\PTA9GM6$5&)]D[$F 7^"BO!AWH'YA+J))BM=CAW@O1K/=2%K(83?*DC
MRP7C^L;2NHBW@U)#(P)4NKA]R?Y,!(8<O1+@*>T#<[F C[+& @*T4;P)#:.F
M#W-[$JQXJ0L]C+/]'TUQIH>5G529LUY52QF5SU\RB/.=YQ#*.)LXNB"5JNB>
M:7(2E*&)ERB1HP/%Q)24;S\F#@38Z,'>N_?7[S&%OGS=<U[Q'J$V#IUR1%:\
MGCJB%[>#42H16-T9#,\3!(=*LWHC].H-<@1EKP?! !=YL-(>NJ!Y#@<*)7MF
M&.K0L:D^VS;;_GT@&[N6)N<FM3%[ACW%L=U$96! 2Z-D*I;4#)F]I^0L$DBG
M; "YN.(P;"7GI4J @KKJZ1 M+8M'+[A1_SY,>:"N9AO$-B]TOA= 19W7Z0L_
MWAWZ N?RU),'+;P+%\D42E;\Q^FI 7%BAY0^EU4:CC ]!A%$4Y'L"IV)";_5
MGT1"HO%EUA><08KWF-/=*T==ND%']6D\<'N,?],HX@-/;"'%JK.1.0AK@)SS
M$&QY"&XILT!UF&)"A%.2YL!ERHTH/;Q_^7I@'EGCS:?T-)HL1D]BXWO#P4AV
M2/QP;MRQY%"<&:P*C'<XJ&2A@@)UZ03:&@.O?.P0U9@,FOM\NTVI>@6GS2=O
M8[NGQ1X08S-LD<H7OP:;,9.+T#8$B<X9!DWNH+$C,OLA'&GGW%\=^3]S?2^9
M[S*O;%+<"4]@V:CHH9#@8=AGK+);/0:3IU&2<E3I< !N<]A$J-MJ!>DR-=YK
M]642F21_?E8[*>!/S@H+TM4I9^VUTWPFQ@+:%35",J@7+V:.F!<)<:S#3C)
M;]=N<_S&HDURF\23%I)=A%%Q0QU?@)@!;!ZVF1DC/A]I*FR23^P8T9P>KD0*
M2$4\]V4:Y5RID/:W9FXEH!D\^H(#?0P_7*))HEI4F>L#!-+("(>EELQ-7W]
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M$.;U39>K/:E_QG1_K_3<?,*87:WK_H>@;M+>.>%E=\'/K.ZRQV[L. VQQ%O
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M?@DM[("3/0&)GZOTG'A =I+IK7^CC^,#!V9ZUYFF$PF<P*5EQ>"C-O9+ENP
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M^8#@VZW<!1<0;ALZMK;TRI#I>I_G:^0NJ?;M#@:M:-WT)X1*;5&X&R1RY?1
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M]*W)VMJAK_ZC\OYTNLOG$S!5]0^!^#\S-;5U$P?7L3W(VVYI@=4%Q]LMR'=
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M=/E^BA5F>!JT\YG$4NF0+ V\WK4?5=;M6VG3XIO@9J+Q3'\M'])C=MO_&MF
MI^V"5[XHIF>)*QL:H\TF7I@X5^J<'#D:6L+(90DUC :O@IO<WP/!)$D&FEZR
M-,HD24&(*0@&34[?;H5)'*&L>W] 3."38%HIY65LZY9B?6-'S)193IJBG56:
M1,JZOC.M\3AJ)GT).7^GNZ%'O=R(+T)IDS*L4F-7/CWYK4;N[9%8[QT@H"40
M;4#:9N_3Y>B"X:-:$0MF\1@_@LK<LH[%3=PZ:#NW_TA#YN6!WYK(JD9)^26
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M&/<@3H_>MK_-C%?3F:,RUU90Q^%-:"=T9"Y3>CRSFE^)%EN5QAQ=I7@%0[$
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M[5=^].VB[5UB4# GM:(*0TO3%7<#$I2:SP5Q(5:[!A9B^C*OR6W%U #+!2>
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M?ZK.>]S%$(H^L[6XKAN)Q#:81C5=[;RN?&MGQL95_KUO!=@U&VJB ;4W270
M%*?K;I6] RT<EF&SRU=Q=.!Y1&"?.DGTU7@JAFK*X-_4AY ;8^DI6)+!-^2@
M*VR7C2=[+!^^?%'VY/V>4'2X-S:6EBA 6WSAI>$*0_+_N4AZIO6V(T> O:Y
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M6WYI[_Y-)E0V4^C?T_\!4$L#!!0    ( %$_W%1V9G<X'84" #\& P 1
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MG@."]OM;<!^NO:^R7U?65T= (%];"OLM_'/_A*" EP<^M_KJ,#*\K;@=E T
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MM.)<X0J"06#5W K<@SP>O!#>'#X%OFG^( &H0,M1*T&(8+60KC! N%I$%PZ
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M;POCN&WAY,[%9/F!/< $3GCQ#=?<%UX+W-H(E)_\A, =*Z*1]J__L.OEISW
M*J[P?:TO^V7GR^IW9;_L,1<>2:^_.;4'./]]]7@.)'RY-=;\R=)ODGT[$*=F
M=1\/7U-Q\5B]D';QY<3JA?N1LH[Y[ ;9%9D7O[!Z;:T'C-WOW+39N3"0\CU>
M^(4K?\_BNPD+%W?P,(N>G;A)J9-^S,YR!?%)#48;\/FCJ6VH&.7$UT]Q:C&N
M7%<)]^*2S@C#CJ36,KMNLIZT?NI?+Q55J*%S=MA8X0N=SQ[ DBI6\141!XFK
M%YL=@5^_U1QE0?\)QP 767E73]TN#KXSG+%7B^P5UJF]P"HN QEI0N++\ODG
MRRBT54PDKCF^I*?H J5VM(Y%%82''<D;"1?3;6^NUU!Z&[YQ,]/G:( &]UV!
M$]=N?7KM653 \R%X?$EF(^S.2>.*JX([;-TAM57I7U0QAUD"+I3F"O/3UQ\)
MH$ZV)I<H+CP2JQ=!^22:)$JQ.0ZLK"WDM8'/"IG%][.X^K7>M/HMPOM.W.K\
MD=2?+E;A=H0O ^,QW=ES7]XW_ESAYO9WA'=_&KH<>/J?QS6P5DY^:+_,[%J^
MC'G_^;X?[J[PM3CV[0'6Q^K??OF,RR;Z]LF)/8 <[NSX0\')]RE?%03B%3S?
MQ >M<^,E[@HQ,S'QV?6[W?N9]_1;YOW$6USIQ!TQLW^36U\+WTU\WK.O3ET4
MN?FG\GT3=RNH^VZEYT7GC8U*.9T7,S%//UFN;.^>00ZCU-2_H)OYD,]\JI+G
M'C@H;C3<)*]U-N$JR-%P/2E(82C6.7KH$H($18V@,K76XNZ.8=V.-VX\U[4L
M+EO_1;AL;@Q7OS_U3*ARK[@M23WOO#6&?@.:L\B[SG\KBZ<W_^@#7I\41IM&
MY^>@S:;WY*4;U!4^'Z(W5$Q8*<748.&O4.8KZ<VOC?7GSH*-:WO85URZUODB
M3B/5(1^Z>DM9N!<Z'[2=K4'7=[+ZC%,%J'S,HUI3U>>;G](S%;Z667':1X;F
MK3^)<(1;OM#$X]3AQ;S6"X17VWNY26$SF3II7$0\V\OB9D<'LT_;34G-:&,D
MK-\6HK-D"Y\WA%PP[ -WB]-D]DFZ*9U.?ZI%TY/=XS'WZ&3B^H3G>.*=^I'J
M=U%R)20%72JLYU4/]8;!SG<-G-ZP:/*"!M-4!UOWA8J.?-;0(F.X+P2D8O2B
MK VSE7R6^%!$8EC_W8>,#12;^35Y;1%N+,E)WF.B;A_S=,BU>/*/9B2$!SZ:
MI>CT,3Y&C*6\_"B4'1S)@_355])A=2Q<92]='6O&4FLFC*P54W(+J^RLPRQ]
MZN*YM9)?OTC@6*3%+IM7R<Y.G;KW-"ES=UT[L.#LL!K^SL'BF(^_&>[?(,W.
M[/8B.U_0W/]PHJZYJG%7]?X76N+W_1EFN/6=[)*M<?)3ML^P9!K3"$Y6ZJ_#
M\2Q'US*YML*+%)LW/Q1C%QHW=K 7F&MW%W+&S@SL,'_AN!.X=6.8-TWF=QJ&
MZFQW*YS8[V6Z?Z3:Z:_,7[OPZ97)EY>-SES>GP-[/]S:?3_E Y;TI.,8.1RC
M)ETJ80C($1^<G&/.LW*1+*?0N6XL-<YOK8/V/['I4-G=-\[AN[U+"(H,D/7E
M:DN0AW40*NGD45E4:;%MT_%RRN>W5ZU'GTO.C388]N8AJR$E4K04;8N50=\1
MH[_;+'%('0 Z?4UJ4JARW#@LW9',LY-%7W?2-5=:?ZRA7$H3<GE.0#\IDYN_
MPRMSCF'Q>,!Y69]UIHB1W;$B_O7;+1T69M$VMK>CRI)(J][(/.W1!PKDM6H/
MWGYWVUY(ZYA2+$];L:W"DX73$ZI73A!Z0"T1+%W$QRM!DI0?"\A,Z86)4MDJ
M5,#&1.=UK0X_D",V7376RGH==D^W_FJHM;K%)3:>],+3^0X56_45&"NC)'>?
M$>V8&^6)EQKJ8LO$CB9>%6/NL!LCY-_2>%*Y('['5?1J84!!QK7[(#,%EZIW
M/;?6Y10"_*]D)S8CYNNADJY%JJ(3P9)V2U8G@<H;HD*7JKL#7-N?>+I3/RM_
MIV/&P*$^1PNV-:_K&MP\3R57H/GDOH..9L?4\QG]H3,OWIQJ;4_4 #U]^]*M
MTJQ\N?4<4NN)G0U\^I9V3)&JB.W(P*2 $35WF6&/Q/.;++(/1V-KN0<JF2F2
M:VL>=ITH*=*O( BS?GP9>JF7]%,4;2JQ;[32VEDKU?>NWL<BK^@_%D5%'-,B
ML4)$O_J\AHS+1WIVRD9MJ<+R^>X&'R,7*REI'G-QT?61YO&T?=HTRC1_JE\U
MF.FEG%VGGSE1W1WG[EXK;JWZKCK!"DHMI:'3I0T,0:]4%F,O"[WC9-LE"JJ_
MH";!2QF&4;@O""1_S>BA#OJXD5Z-?EV J4M]2#4/B-W0$MB!*.5#+,139ZP)
MJ(#CZ9VG)"DW^B_)O*RDT[U6$%?_;O+B\#)PQCJZ N3^K+U"X/'K5PKM-VL$
M(<JOS06[74J-7+2#2)MU^C3J8B\UCY:.)+6W'!DV?4?:WX?HFO#R)NP"3&]O
MFUKL4'O$PHK4L0Z'UDY&EBRU-AA!H#KOLS"F#-E*,^[G4X4+(S;F ,A/L4I/
MZY],PB.]F4(UBV5S^1IOTX30Y]&4+/2.3I6<4P.5-0TBW.W&5:CKG1.<:VW4
MV(Q/IVO)?,@IA/%3D"5UIY*7O,-839@V=%F8YG:M@=;+)18@797DQ":D3'0<
MS]=2']8RK)%:P8Y TC0A0&$EAJ,QITR\D"'#XAT50I;51HA*.Q=I23.!0\N:
MK"\"LD:J1T]7F1X=5#^-9K2+<)6FB7JU051GE&V)8(+EQS^_T9I89-'BU^32
M:BV2C! ,>TM*AG(B(;K=$@/T,I,D99)$*'6MAD?=58Y0Y#[10L8%=23PS@KF
ME)M1 EKK(OS.;$PPS5T8??.02.VHBA'/_=2-5ZI$1WA])I@E[<A'1V862))O
M0$X'UI($TVD^@D$S_5-CTFI9@GRZ5H(>%7ARM;5ER*'F0Y3R4$,( )M9$!0D
MM'Y-Y]:(8>]A?2@P?ZDP%L*D89=EI=#7Y:$BR)!DY7KNBH2VF?BX@9TOV[!.
M<4SY&1JW6^V5YQ02,S)).1W7!#89Q>M%@1T$UD:/B>=+%*'O[<0]M<'<' ^U
M2."(P9B'+51RQ;J0)].@C$9-YKL#OE.7YKIFIR^5MYL.]3^&T&(&*K2N&LNR
M%'L'^XM)U:YD#6';PW@DT3YA5,%F]6:L^:DB5_NSSQO3R7%X/BXXF9!7,G:L
MF3C5]X0INN!):I6@-Z%<01'Y.F.@>1F&O ,-%>X1)>"@; 8_]QDEOE*=O=Q8
M+CQ= XL9MGOPV@#20XI\+%OA/VU+U;I+&/E:IWV$M8.NX+7#:[Y+1\^9%+^.
M6S]B'&[ZI:#L47R674='Y4F7[9F\@KZ0>8VSERV<KAQ.?ZQHBT;%3D^ WE(K
MT8HJB?%(FQX*:@\:('C0!)Z=BQ=4E)TB/VX8263S(43[!#-":2=W_;BA-* @
MDEGT"7,(L,98SD>NF)R^SJ@U<YR, ;#0XJZEV:34J,(=_LE)^%;@QS/DM.TD
MP=(?3XC$'#6YY&11THY)#Y\J+H.7UYI+)2B!:HY@Z4MH*JL8SP-[YC%=UO?H
M) Z9WR[PB7IT];$9TYE'MA2DU.%1%2#K(R=#<KL/F5H60<)&Z#HG/@54WKI+
M56Q;]<Q:]9I=QT5#\BH5QW2=8M:*1R?9L?=<.*EGSQWSKE^.BPL:;N^*'TQH
M2"G>4:"BM&B8:C&CDKCVEE&CVHST^!)Y9%D.^'6)6V>;^ W5T5,)VKI)#!U+
M4,9C"B5"+" Z3@T[&)JK#Y3W@N[$A(X(Y_KPHZF)GO*WX>8OGHJ$:ONIE5B^
M-5)J^!) (>C1J&#LJ&L_IOGFME&;-'RA?[@R)+^@!DP1&6?I-W"D3</#3D>;
MZ?0ATP_/GM%>DF[6OQ?KHT]RJ#A(\3YX.AC90#7#5]JG?4BOYU4WU<1IBY P
M?I@^8WX<2HM1<TU04=SSBSNMS>'$YB6ST5,%QAO=Y,"2\<?&G)R@Y;((YM,\
M)P!Y!.&UE_,+#&M2$)6Q42W21\-60'X,[[HLI)$/']AVWY@&A2HBJHV;>::9
MGVE'[Q#R,RW<C@S0-TA4X+!'\V'+9>BC+I.00X!4Y$%%3U+H.2U9K4[I8Y/4
M+ZK?9K9V27HS2U/V:9)!_^%QDPE:UKO.-*?:[2/.Q,<6/.#5?@)]&J)(Y5_R
M.E-&V_9N)>.%HF>99AFE4UH/,P\_Y$(5 -2;CBL83K$=;ITT7GZ?Z)E^[H2D
M>D<8ID8CO\1'^ &%X-VLAV7EP1YZV7&%E[+0;LY&]ZZ/,I\>-P7:90R_(P:*
M.-A)=Y]\^P#G])9.+1@'1^MT)*+2["%8N9,701!T5QBZIB]8>94V<("IW'8Y
M?L--H>D=0PW4@MIC8?J)Q=--_9/4EKIK**X(T&W]"<:WG14-TOD2@CG@*T.Z
MYTK4NYJ Y09OE(XG+U64#?ODRA0<#F4Y+V[JTDA(P?2L5B/2QR/4NLAH17OX
M78(2>VD9S>.2)H);VE$."(!A7E^W/O/"R$NC27B[FX)>X'+2)?@]3;*&!VTE
MT)"'IX<]'JGKMNJ>P'1/ =AY42HN 5A:VQI6U=@P_;B&Y=(3*?J-IVX\JW-Z
M/<J$:I&M._2 4,XG_#@2V@%V\I70\SLC&4?4)9M64_W!--S[?*<'9KMFI$2)
M'GJ9P90 !1.D=<4J"$YUZ7IZ2'%E4';6K[ARFQ>\)T-A7"IR;G64T0'%6&JL
MW:1 ;2_?FL>)U'PLL4XI\=&9)JWJ-WW@"LT3#,?:IK5>'E9*+;RQ2*4Z^.K4
MQMWT35C#-.%5W0(I(SIM371^8P[\F9--;"R&J\."7TDUJ-F:F3J<&[OYA*5R
MNCA#:S1/BB/+VMXLR3+>R,8XIN105-F,,(EN'R$Z.FW$]/4E]S>IIS6KT!-D
M8^N]3@^J7 %05QMA* ^D]K2X<4&3:YW24U)@VJ"-,9E"[JGREAL(0=6,3#M"
M_^9#HRZ9!%7/'$_ M5J\@C$"+F5K@E933^;)2X^B'ZQV4=[0=SO!5%]$A0;;
MFM&I<,^'7=<,LU!M05'*" :GT@%F(6%25V[-92@D.%YT<(P7=UIFZ[4N/J5%
M=(>L42O2YLBPOTXI6I6!M7J6A9?J3 /C4EM1L^B1HM-VJ".DEX(-!'I9^.L:
MJ<""N4$")K?L(!89&2S]+;LQL$OH?#<>P;Z1EW229Z<J0I33A\2MR!#ZBJ$N
MG5&V' H^MY=JJF22$CSREIT]OV#LBK5'%2QJ>QFE\[L8K1G*^B:9#P=+VY:.
ML,>C!#H&#@6(*@G#XP5KWSJVA^D$RVDSL9P1-S%^+2%)=RLS9(U DB7D\ Y;
M#NJVLK'M54<F^JC6YB1IZSG0'-A;2;W&^-V$=H4I1/-5MEE;"#)H4=Q087RG
MPGG=6J!V4U:ZQG[4U\AI UVE9:U+5G/;+$/LB',YG$N<3)OB)9\GF"MY@WBI
M-\$APE,[4/D9V*I:2;"KIX)"A8]U@R-M!.*ZY.?3]H[H7"7 [*1&TJ&<D/B"
M&T6OHM[N.H[F7Y,F@3(GW@ZE"_@$>XYV\1I-@];/AY5NUNA=7N PSR6;N![M
M=T0_K'5"K3]JRB%AICL?=55.@3-::&G5ZF'L++$FSYNL8[P+X#M9+V$K.5=3
M<XG\FS]$0&- VC>(FORU;W#;<H*XXHQ<;/E&:&E=;I!40SL ;=LEA+,Z&4HR
M'3?9XD4;CRIDM[^JR2/(C9*V$M$OE94Y3.&ST>I9F5P9R)(X;FIE1C9#N5)&
M)1L:!S>(B'>>9ZPNCBO6\Q6-4B",)1#OO=R0U$40JR@(I-]8O;'4=&S"..E6
M11N1O:T2(>K$!ALW+$H3 IE8[C8^7-ARXVZEONKD>[.19OXJ2_&R)!3TL?[*
MW>OE+A293N?Z=SZ9II95UHJCI^1MPTC\4[@:]!QR':P'L@BHP"ZJ-QQ51\7J
M@G8B"1)@_;3Y1&%GZ+F&JF'\O)3=?I(":^'D*J?8TKK#2(5@/I)923#2[7;=
MYV%:M&E*"R_46ABO6!/2M1SO.!WDK3X'SXJ6 /*]>\A[.*TF\YJ*86G>8FVC
MI5)ZNH1+$U5<XGT*P_!W$J\_7S:-/:_(%:LX/1GKSUZ])EX1Q6K4>:FLNH;0
M+(@KB?LD<1O5D7"8DWE<^9\O@L[R"587UEVS!XC3/]U_-9#'=W^)IW;S_I"\
MIM$>8/(W=T#QPBSK#?':6]A*TKHWK@AJ#PHF0ZWH4@&?EV7':$Y%B%D#6^,1
M^L$T=L]<Y66+H,&E"BD,Z5DG#-C07>YUL\ZNYA>.GX]F534K$+S&7TF:42G
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MHM&H12Z AD?DID*?3P]0%H^M/%^+61,Y8>!B1J&I?^G^R3LW%?[RS:5>:+;
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MQTI&_R7<XB&WFDN?8./H^KL1:VKX>;C.-#.,)0\BF-!B!53TVW\""*/1)I!
MM!FXS1!Y?$VYPQCJFG5$L4&SH>I&]$M?W!RS\V+K-6GF)&*S*:L5L7'(='7^
M:J/OD+.B ;]66=EC59PQ3IQ=D%7*UE&.)__5J[F3M@J4AF6O\WG[Q]ZRC:O,
MX92*UC/)!,C[;D]-O>0L!VSQ^2.8D_C.[QCLQME])W/QM"X]_=<)B@-K^KSQ
M(+[*?4L>F5_._Z4; N;)U5AK31SG+"<25J80'&XB#Q%CX 5)NB @9%1?*&_
M+4@5M$W>&,>XX_ICRKF]\,;ND'#BR>;;Z^Q*I^E-&]!2O+FG%+N/;>F^S97E
MV2CE>_$B7@^-5M,D NX^;]=FFI(ND)+I>'S]F/R*5;K*@'":OJ:A7%UVEG6B
MC)RE-D\9XHG:PQ6N!8_6Q.#R%%OEI,42MD:3RQSP33QA.OT>.*[>QIDJD\@W
M",_T$;HX_+7U]PG'? OEH<<NLG<W<>GM)\+J5*PM*Q&!IQ[,HX3<G?GA?*SY
M2FR(3LZ*.,Y'>Q^&HJ0G)Y8G[OU)_.U$>Z%-[/Y,W@A#NO#$S3E53) K'\ZL
MEBV9PX15ZL0/81(<.D)P4J)B7O$4)?<"<@X!Y"0 @ME+94ZR2$G,R-]\]XQ1
M@3>G!:XOE_YO@98MZ;^ .6G#VH:_'P;/2N;3//[#*;!T?HNK,V^U 47A L?9
MVU;A+0%&3@AI"42;V4''G'2<D_^8!JB_D8$CKN201<M=Y<,U?4RHS^#EUMD1
MJO'#F33>G*FS)"4EFAB(IE+BS, JX\=,N.'O2E,NS= RIJN3ZF2WII)V@&=G
MT>)9EV!8+E4;Q7*=5,U%EXV72Y!Z[?W0)NN?.3WP-X>]S>&E<<\0!Y<H!F'B
MI3Q1&  /)Y90,96//*2(MYY95*](>T.B!V5$K:14F+.#F8LFD8'\1X&_K$(
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M,+1$E[HQKPQ)>-&2^;^ MGT#SB!MWKIL%5:@915Y-I)4E0XI*4I"RDR:FR[
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M+X1'P ^I6)0.*/.7&>94*T^N(R>E0E/_G]R@D_--OXD:EZ)6@Z*0LS!E7U0
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ML^1\J7AU/#<GQ?\LTQYK%0CL',B:MK=05/5FQR^Y!@7-9$@#GAC]#Z7, P$
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MYMK+(&$)MS *Z4XR7]#JG<_@]BQWT6@+MYC35(&\&MMT$I!"F_<OB[WO:RX
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MK2Z90\^=)<1>.BH-X#^]1.>A1E8S?4@VI&H:X$ZQZ/:L292P$FURGN>G%+%
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M+<\V1J>P>JXQ$M4VO6G,M197"CYEL)L=X=GT""(M].^%KGH42)-AHD!^(@$
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MP:G0?>\9?9S;>5%"ZNV=^6@TN:H?T*N$(*Y7KD\1M$:F(T>]U'LMX"GQN8H
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M:$?3V$9HXX\V^& H_RCJ/T3L#E;%7"X]4OM*E;9![+DU5BR)_9@2L4AQ*><
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MER4/A61CLAUE@@D]J&='VTO%<1*&.5/-<S6[&<0-45FMD#SJ5PL &)P"9HS
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MZ-#!2#!3G[?Y>RK;:IO\V\^O)#(NT8'?U^V0=!KOA'?3XL!YTO!Q,RP290T
MIM%K=UPB.^_1R/8OHTWA(?5*U)KIY8D"$SP?,BB+H]:C,RQCD?T3G5(-4W63
MLLL8O>N/OCX3[E4/TVW<S0A[6MIR'%:W'E?['$J?S*U)W]7$R*;<8CEM)PIL
M(IM3G/15"#3>F5OY3(/ 21&\.VBBO_8[-J*S\?1T32@67E% 2AE&.T7G"374
MT+V+1<O*9"&4;X]/8WDE<]'/=0./UW-?->G1X&W6\WDXKKITPB6'F)/+JEM:
M'N1@[>I]-9PYL]]>F<),''&;CYZI)?,D"2[R*#5+13#AA6X&;UJM]-A)5ML
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MT2S&YS_;K=9@4K.JP'6H+R;P50+Y6CEFP.S^N=LKG/R5PDOJ7#S (8;3Q,$
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M9>.MM2)^1TNNI?5FW;9KFMQRNPAM_!LZU3H9\A;Z=6AQ!PL&D)!;;H%9O3.
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MP#!_8E0[^'<07-JGCR9M-#;XVO'X*8O3[I ^P]J[^\,5G793(V:9RU:^H2Q
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M:?YR\/7_^Z&._[<[6_Y_/AF/O55I@K:<D!HYH2CJLQ3*HH3*XJ.Z,\7>N&!
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MD#MD?S[_OMMTVMDD.DWWO0<L42O!ZL B/1 )OY2;VN78\2-K93G92F$ V9S
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M62OB7!<64^;AI>E+KW5Q@MWFA'=,RJB0M4P8'Y1L&$^VX&YG@0X),93@D,_
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M*M*$[<<ROGQ)=PLWJ!;7FW\!IR:Z)K =:6FF%H'!BY+DO]=289NAEO7GRN?
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M;.2UT]=HS;C,9/(7BI"$9D0N]1K<<P1<=KL8:+F,_-&O&6W="S>>#+KK^99
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MEI'>-!J;01LJCQPV\>6ZWJO27K7J68D#CGYZNZ/BJ %XCJ5IO%61E6LT3>J
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M@HX\=S$";< DXMA!>Y=J>R-_>N,*U_I5/N$?\-'R1IR\+QM&$LD()'.%;JS
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M</DJBK'K(C\U4$ 0C'T>D97@WN=@.$2E.?59/4) DI--5,^: 57FWC=5-R/
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MXE-;='F7\1]]1*#F5HCPB! 5@H37JW9[%*1);)0>CP\FO_ZW6VOK@%?@XKM
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MZ%T11H(ORQ&_,4?+IK(0FB(F_^6$I.(!C<5,C=;#!%*KMJDBMKA%!^)+T'R
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MO.9RJ)H\"UH6+<6X=53X&>K&>M+X#@/ACW%WXIV0V@W-<DS+,E.,,]051U&
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MO[WT__P#^'>C*/ZG8?ZM?S7Z.?]7_O4WB4S/8I-^^%G^ 13\_ZC.ZW=T]1]
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M-\/^G[Q4WY9=5]M=R'WWE27#?HJS<@:=>6[6"5C'[GM+Y_Z.[R],JUM=/]!
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M<A/'>/\&;T>857O%]48OF=T.CA:[,.B="_K5QT\5E7.4+()^,!HLILKCT*8
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M&B^3^S8J^^V45X0RE,R$'?#8S23;($KQ;MSEX*PD5,A\G!BO/1_$YS"'U)!
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M7TWN^[2R>Z&.2RL?13>/P _-3YW5&GX+I4>D14]H5RFDP>0WWYAQ"!$K,UH
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MK&%M-\53C"YZY=+5Z 4*G=9-/G]CJ>P"!A)!XT/(0.G*+WB]AW>;VJ,6UA3
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MU.RA_ISJ=O2_H5=Z_D<%0\%_0S"(_WL%1Q8IJX72W8O99^3B#Q^__M9)N1U
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M6+7_'BZL<^*Y1*^D\T$1WUTK^A81H)'Q_,#^-11"I&C7[(1XP<)V>T&'*Q3
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M6JB5JB,BL?G0@%R=FDX2TO;I1\'V7MIAJYHA2F=YW:&R*;C.= X?TZ)>YZH
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MP_@^8JP4(E1WI3+X$97'T>JNEMW7U[C#>[1L^<+OT%SSBR6L;)'B!V1J>*<
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ML29[\5_!0?:)']JK5=V_O8+6=>OV4#7TS]\'KK%#?2T>4M7;O]NO&T,3PZ^
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M@^V? 7T/5</_@_<:WJMG0U!?2X0(QL6-OXB,@//>>4 19(WMGS6&?XKS5UV
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MMN/H$K4VUQGZB-C]O/A_ 5!+ P04    " !1/]Q4E>:>DR%C 0!;P0$ $0
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M$T?O0PE51_2ASN\VX4A#L"O<5,/2] ?8-P4C) )A9P)'>[J?@SA!,6Q2P A
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MCQ[F]!4 W,2<4T@!)P&L@[&#=8!4!8: P"^J&0#8!V\!\J,2  LXU#N8!((
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MBVEU!-3S,$%@ZK[E11@"BC'_8^3)0D2E[&2$)44$I,4E[ 2DP.*2 A"HM(R
M&$P*!I64$1>'P(6_ _UD["] WYZX@%U^DO'TQ"!)J(L*2\N(BLN(J6JJJXJ(
MR(B(JTA+R BKBXE("$NK27^W_0O]OV" X&XPQ\-DJ>8"1J$4?QNUWRW\J?:O
MH8 C';W@,$TDPO4HV;J#D:BC9S\*;-]S"-N?AOE1-I-U_&OW0.'2,G:BXIC^
M@$"E!"3$Q,4%9(1E9 2D(*)B<%$QL#!$$B(O]!?U7UF'_=[@0^LPC'5),3M,
MF"0E!> 24C("XA(8'(@D5%H #!46%1.&P2%@,=AWZ[!?Q>MWZXA_=[?\K?ZO
M8)!_TS._K/TY9_RE:_[:;]J.*,S,\?E%>C.!>_QM>OMG/?RC$9C%1A8,/?11
M$07&N'+H^D^\OU?ZQ> 0@T'M1*1AX@)0.U$Q 7$I,1D!B# 8+H 9,3*BPE)2
MTL*BD._V_VYP_ 'CL@/<[4_I2E1$5ESX>[KZ2>KOC: 0=NC+8"1<Q1[3C?\H
M;_U*[^_M0QTPBPD<IBCT7?$[XR\]],LEY?^.KI,&BTM+2HMAYC582DQ 0EI<
M1$!&!&(G )6&P\5$).$P<1'HOZOK?EZMA&7%9;ZO5O_NKOO])U:BHH(2+#P6
MCFXPQ&74_\AN@R+<#A\W_V]T'08'C+F\AR-1BG:'^?S;19*3.]R>!8U@ ;N[
MNSA"P8<VA+S<8+]=<?U8\[ZC_&3DO[&QL&^Y[M_3U!]Q8OF?UNC_\,3\ITOB
M\<3\OZK;_NEUTG^HVWZ^^C_NMO^4?/IO))/#?//S?>G_&_GT?U"C_\,3\Y_=
M7QY/S#]Q_WC'\?WVY:]W*/(_;2G)FJ#!2+2GNQ$28>?H E<\^M6OO-"_D/@;
M.[_M(9AX0GZ]]?!'FW^2_LFF.Z8A&"B8)Q2._!YD=4T6%T<($HST81&1%#R\
MJ?B#U,_:/[8.].'V8*B/CI&IFKJC/1R%5E23$A,7%A,14Q5755-3D5(7$155
ME5)14Q.1$1,3UM# #*A_H?Q+B*/?#AH@8'#%/RC_SOZEEHZ:VO=0HD!:JBPZ
M&FJ2(IB!+2 J*/*SF9_DON_*"OUI6_;;GJ_0;YN^BL28+O^^X_RKL?:?3\<@
MQR#'(,<@QR#'(,<@QR#'(,<@QR#'(,<@QR#'(,<@QR#'(,<@QR#'(,<@QR#'
M(,<@QR#'(,<@QR#'(,<@QR#'(,<@QR#'(,<@QR#'(,<@QR#'(,<@QR#'(,<@
M_\D@Q+^_PP7N!E-@N\RFI'@P":@!6/]!.C3R'[6!=?1:7"Q&;%L<+*KOK\7M
M ,X<ONT7'P?KI]=C?WO?+18V+@X)1L"#$E./#6#CX>-2$)"0D1%A81V]$Q<@
M(*0BHJ9A%:&E.Z%BO$', /8XR<8.,K>PO!Z7E%4Y,#1"+QJ?D/AH\!2'F+BD
MM*J:"?(]ER;4[K)W\JV<JNJ&64YN=0T(S"LXI+:N;5A"R@Q^(RB[IN,Q!O(T
MUF\OXOW=IR-, GQ"(DSU)2H "P=3QL<E(,$CP\?'B&)* !4>JP@^M8HQ#=CC
M>MP& 2U;%AV]:.6C@5G"$^RJ(#/SA!>#[T^*F4"&.3@EU*!(%#H^,2F[5ESC
M1G!5M:1F8$[>8S@7+*BM_8\ON9V9I\WGU0?=SA/1A20^YHTP^2\I)H4;IAJ$
MMBE6O'H^\E9,=1@Z0I5F'K':E+=&KYPG,<</KS5T');3OW!!L,2[Z+2S:)7@
MF_H0+_HH_E*(4_Z]'KXB,+7=BNYP@?-CYX@"L@G_G >?PK-<; U,7X^ND$S*
M\VFO*0SR.PSZKN72?'2J,%PMD\AY5UH:D;IX[].UW#%VA\;9JDU0_.O\"0-M
M_!4M638-4$5$K\/L)/1#G/M%/9_Z,:.&O<+^#42#],.9M#0?7SD)HSN1PY3&
M1.Z,[7Y4>[FJ.SI^6Y 4#=MJ4 B8W33X[)O )I6\LBU"-6'0 UO\>JN.3P.Y
M\F.S:BWOA9HE*DZ1O)?C!=6L#TG?&*(_?;&#R4:=X7V"=<88#9JWSDO%_2F]
M;LQ;/ZW8;/7:Z*#R,B&FS\9KM?S(OO_J;OAG1=!V=)YI@[A*<%WUA9I*IU?,
MDO;0X*@TA^DQCFQ@!7_3-9TM(4 #'H<WR&J&FV0L+&6TA 7*NG@_HV'+15_J
M[37M+7G<'G-IGDP-EJN3)&#EGM-$KY,5518JJWG2S0P3<\3CKJ8D&G6<QUVB
M C56E'J6%#W3F5J;D(L4NL7.O4*\+8U7(+\PME+X4NUICU;* 7"+)5N')[*5
M9S,H.MZ.+5B$F"5/$UJ<Y!T>WD1KX(8M^ @NIF:Y#,V:3]&W)'W$JA*>OS I
MJ?.F*(6%+5+%OW%NG)5V@)I2740W9N[_=&CU0;DV7Y^/3&33[AAD7LMW[L+]
M_%!,REE< B+^A-7WB8$42H@ANWBJU3="2S:?"N#%50?<) <K^#V21U8/ ,X:
M7J?U*A7)M1=%UL^O/ZCE)&(R5=4*9ZL,KI5%-."-XGN-4&^Y3B*C\-3[GEF_
MR&,2E^V@(B\6VYDMLDC/!E/D>9[FVL6A55ZYL\CL4V>/U6%;:>( 8Q8LQ290
M&$(4>E&2@67"U1$:1?9*L8'.T;5N@5,&EF:]L\P6 [)%:R_I[')?++$$3N8/
M0H%" L5Y 3H\_6I*=;VY5)0JP#Y5N,E\!7\'#+,=#]=YQB%J=@"(6'L> %)U
MPV&E8*6P;J5EP=$-W;)E0\E=L8V(AIONQ8$7GT^8\^(0-=$NOGQIGZQ/D&E*
M:WMGVU,BJ'FJS[P+*T@NXL+5:DXYL9,VOFK+&:]=%>EUU]^5:)U$SW@F.L=R
M:@E6$3YKS'O)Y4^%H#MUQB.Z->)%(_XC?%OXW;=S#R(-0D:,8%[YX2-?='T*
M99Q]3@1T)T[WJ-S4)J$YFPBU@WE5=VI8];RLQOEP.032 #6Q35<H..\+A0O<
M7KS'WNLO2Y;8;=9C36Q1FQI>&QSL"OH<P6A,M#/I"B.)I,OEB3)43G K#C;Y
M2F?0C9.=?@ $ZO9E$<1*^YR;JKK'S;/U3E8DP?IS%\'"A5?ZFQU+"G.%!%ZP
MYM<I.:@SISSD Y^_:%I^K!T[7;60D&YZ9BD39W2\=\9BNO KS3F<>@DJ^YK"
M*Q7Z<D:Z9KE,#SMFUK11BR/"+46ZS#U%A/*[V[S['@ 6;H>ZLCB-PDEH'W9A
MA4HJWIO$AKK32I\N*",4E-+GTX/[39E51N8;,5TP;.7[G,EOP_[Q20DMC?>,
MI0@Q"J5[IKWRNNMOVKMPU1W,:UZ]U6!!+4[</ .! M=-I<Z^;PC!NCEK(;8Q
M;OP\W58@J?+S3OUXJ_G^Y^)7(+,L@N6-D?(O$G1F_Z>RE;R\AVYU"Y_W^]FT
MP,),WJDTK.P3]@+!?8(-993)9*'2:K1S$5$E9>:L.2<%>>^$&UK>:7L8D2O*
MC-J\SJ?9'QK:<Z=$>'P*O\?3OU=GV9,JA9ZY1S4)ZC=I;_FNVTZZ*1+84.ZW
M6QJ=?B7TZ<E#5)F]=.;*VIR60Q'[Q=D=<GYE$PN^J(0[(M8V.X$+I-RLR>)]
M@1>U^/V-PA*OII["&RIU>L4G5EM\B;5W-=OEC7EI$9]I\"I(,"0DQ2VPI8EQ
M*2^HT.FZM?U["U-=:VU7F1L&D1E<*PQ(^I8(NJ#)D;:6-VLX:7;=C9-".Y?!
MPRCP_;&\TD'=@E&11^S=?4W>[[J[H"=-W$BP>8%M$_T\@'1&<M EES5_TA%'
MO2XQ3]9?5YE^K:XYJ=0FTD-#U\J8ZTN/,<=*7T)RCI[])?$BI5OU$_(MRCM7
M6P9V_2_UADR)?L7^O%RVFK#%2$G6W.%)B9)9SJ^P:)W9^6KH_[!K:VF;:3WI
M (AJ<?D*]EV>F9D9C8A+]KE^M;8^G4+,C8YPA>KK;LX!T/PE$/$YP^'.BMR9
MKU@Q[5\J: ^ 8OT*W9@E3 97?O9UXNI&"?.S<R;ZH";*9>T%,[$4"1H94P/5
MD]KH(=: #AER8QS*!6&L"$C8R7R DI(2JXN%4@4(C,,]3]456,;/M\?[X?G[
M_3;?/NC=>I+]:E4'GGQ7U(/$N+%8=8?8Z[HCS*YO(J_4PFF-:>)R=/>S@G2U
M1,CG!,9!?%8+'JZAXV\L>75#;H/(UMD ?<]WC.F+==26Z!E074]9K%%)N*?C
MO$?7\FS'U6FSVE'<,X3<088\3.H@*<JTX.E*-G1*/=0[15/-XIF2C"YPAZM_
M4[J.2K?<OQ[V=/V,%6^2J+ZEMEZCK%\%9Z<?\[RTMLU[@K;80:3%:5P=5Z5%
M=EM=(P;L?--E.EZ>4Q?5BLRUQA7LA9B:=TH_9%<)4NFT>YK8-J[$P>@U5(LC
MNHJ-9'5SBW [C"4((7<B*-M,$I4?4V%A/<-6P;U!R#*&B8<3X2L-VXI\C?_N
MBX+<X9=E6*-G;[:#R@VO3D@*-UWN4WHD2G;=))=-X2'\.AOJO3#L/+FL\[!O
M+-%S'SKM@H_% JE=<E%V;8*B(FE%O'IT^2JE:'UY&XZ;U2M69L/NXT$P9W%B
M^%274H).-2R"ZV(L!4LL;1YN%J>N,1&1=F-$^#W @VO7XYEN$A"4)*#"@JTC
M+X!*>>[XM+9]/B9_XN&L5;ICV]6Y&%/R"45GWU;HN A%GJAS3C'?.>O<:6'M
M T [:G/L<>^B6BVH%><44KB2?TUX/8.Y=W!+AE?D>I?''E_(@X_X=\R*G;7$
M:/L-GO0\O+%"WW(QC%QUZ>4 @0T':9+UJJ6+.0EZH2QC5$;$KLJPV5S3Z=&E
MA"MB4B(L#0'EGPW-->PI,N5,E>6TR&^9F6R25W;& KZY682Z1D%Y1-I5H%CJ
MQ&@ *Q:GD,S 82B/CHXGB6^W,%Y'P6Y?*^YMH:29JIN;2A]IQ8[]LLCY:U+/
M=EL'HP\ Q2N.X&2?TQ(O=IZI)/MZK!8(V5^^IC3XZ=KZ8Z+>A^ZU6W700O+J
MV\VH&(4D_$Y5PP"<WJ:FF?*:QP95+;=DHM6NU_D@%T=]@]!A!\#5@0/@Y?ZC
M^OUSXH;H*(QQ0.L L'ZLM(KB?Y&SFZ_T7.P J$NM?+--)_Y;1UN%OWZSDC5W
M^3K!O:'[O 17JD--S72:^C7<;R'M/;W?+^';F$V<IYLO=NKO[X8\Y N*DGE%
M4I5*=C/A^1W'N;H$\,8#'WZ_FGQ\#A7>Q![\^9Z1%ZDGR /W67@]9:[H:D])
M4<[%)1<M>'N=8:OO?(7)*V[,G^9'R.I";MS/DNT_P^WJ5-1UPW@T@K3G]4X.
MD4=YQ)H0T_**&3Z2;,B'0#25KS$P*=Y)[2P3R<E'(DS$H&P(Z8GA%,>A:7UM
M9<D5!J^' K*V7+T:#ZU!R-+<0AY;K@- R]4VQ,FI^+]I9=)+D%Q= $YRPE.E
M3%L_B1@*,E.XAUVSEL([#U (VD*Y<)>[<!\]HY/D5C[G";(J>W5==D59_33T
M\G5FG<PJ;5RE-GS7/C@MS^?&MVFW%>#;),_N=&92&:G,N;XKUA'SJWVZW;-C
MV^;ZK \OC6J3JUD%TZ'=]=0ID"OR>1I1LWWM7:(R^Q<0%8TEA#BE6TKF209O
MDG7[^6HO-=F64B7QV>J*.)9H9#M"6>F)3ER/4+%%41;8MH>2%$;RC(TX-,0G
M)R!?B(J4%#R-5=&+JIGOU=._6S8<F\@J&W_U+( ;[P+@)H!]\SHI7]#6QB;F
MGL<PMF(!:AV )'58+\8_KBF&=E.H=J19O(P^U+MS44QV-GG3:C]^Y<:^EY??
MS1PS?8T$O 3VUZ>LG:6#RIDHW8OR[.,8[GR\?8%R"#>4B0@)"JUILA68LDLN
M%^WE%%KD@4F!+COW/,U8B >E9<4BZ2MMH]6W/8CH@64DJA1BMU3[\<3I[+TJ
MV;4KRUL3@>\. 'MYY.RR-?,I:A_46L^^=6#14&J1N(%2=1U*IV"(V'0Z+^]:
M]V""M<!]<CSO]TT?;T(8Z,Q \LW7OTC?UZK<[KK1DA%KS\"Q?@>Y/B9GS&BH
M.,C)VDE]HR0.B<;%SD'$QVKCV77C*=/<+L$$)R"1I<3K(WOP(Q:258VH>$%/
M%K@'6<9(&G[%:7H!:+[E+/M2A@\N:-/#<#RRL\6AXES^M+BY?CEQ3I@-W,WX
M-E_\I?=WVB4FB!=D@N)OI5J!0'.T(,$2'D;L/.[J159'F0602FVAM8<DGPZ1
MV<,&26XT#TRY15>'?HC**7%*JTN<VV$]\DG1SFH='I.D%35)\K*L<ST.CVJH
MVXWPPM1NU#J-#+E)(JD)<![W--FGQ0PMM1E3VKBXED;WAM,/4&OW!N4?W"[V
M<9==T+*MJ:U=OB7 N^FWEWD99^?3E6+?J*U>]OP[8MPAMN9#\+^L\(R8%1ZZ
MC_C+ L_763TX-/AC6C2XG?0NF-YC7@]3Z,URBW$Z\3H0F\+F>B+*MDZEL-BI
MN>3\W6#35$OG>+9XR&Q@BZXD,L%1NUYDBQ2Z8.TLXL*&+T'E7HD/6M/KYQL8
M.0^\;>S-Y"4Q> IE(]*]$9^=P&NLTS :PR;##%V:3?<//WU*@>OSM5RH>:I=
M\T)-V:"1W5"3S;FF6/:4D_3$1#;QO3:VH+L/]D]8=05H]<9A5YQ:5 Y-U6G:
MO'NY57I=LL]@_+X?8[TO30\71T=ND#3>,\U7]&0MUS?CKO"0?:!."UIB!4/C
M3L7(\W-9+?$U_A?G$E/R"[TXV"KR-262$*P^*MF[E[FQ-MY,<!#+F"RS:0+D
M[RG)]TS'TK$D=/+KKR)/H^]"Z:_ZJ^)Y[;W4'B.(W92Q22A?A&PM]A4S9#7M
MJ25K[,GLGUB=OV*F0A".\](IWL#%&;UL6=)3W'___N%BL'T[I^NJ+C3W&J]I
MSAK?6SIR2YD=!Y4OY!9;3H4LY+@[F6E+SSYU[76HJVO=ONT3]BDL[&-8V.<.
MK=&/NQ]?><%CF1"3;T]W!ENXG9$T[7XWV+^RX#EJ1NLR37#NC *<X31S_T)B
M;FY:KJ6FAD:GI-F;Q-RTC_CL7L8#?;&V\Z/.=\+J72(B"B_Q$A 1&Q,I\X'"
MB("+/EH< ?BY"Z)#=QHFDG@X.759 "*.B;;QY?2JH64P%,EO\C;NI2*'=$$#
M>=,HQ<4G&^L:R4;;2_G\(8)>9L&%@D-?V/JZ0;F-.L7QD:P& ;XJ$EX,GO3N
M\2;QFZ\N7@N<U0D8U7U%G+CJ-ML5\L+%E^/.A]::DG&M<=P H87E?M-;4B;N
M/;27/1D[+.DR6."P*)^I-'/AY@. N[7^@UM+A>*U8.<81Z[Q X"9;<K'&U]#
MIX%M=\K^S4J[88FGMP73UX_U&[[[*9**2HCA]N5"YOVK8DO2.&_K?"]0$,N=
M<1:K'I$(*1E-;(Y!2':%3:9.DSB/$\:H2RJV5O0W(A"ZQOQ)DBW>76&PJ7Z]
M>XWW_<[+)KT>)3?FA\$8>B[U.Z8_;MPJ%P\8@$\_)+(QY%5\LN+J]!)4FI@(
M5+A,BA(CY\L>W@UBY3?_Y(%U,6(.Y)>M&IN&A53=E,M)OFQ"T?'L%"56V7GQ
MNP/+SULM65?H>(9=@QOJJ]X0Z]Z1NA'-,7O*99?FD37[\X'$;)EK@B.4M3OT
M5\3RG9YD"9 O29$9L\1N"$IG1.$YRZ4SZ+GYCJAHQ#V(A\G$Z[Q\_9S.;_!J
MP%[<0$84@9\*[\['\IH/W!.,NXSBZ2[XGZOI<:UF:--N>;QQECL5,AD%M?:K
M&$U_4R*,R) )W"P)FER+6P[CS$@/3/+@>N(3Q[Y.65(XXM]P4VPH0UO*F#O2
M7AT<$F_>S4\>]$47X,%E%7AKX\FGC<?UVMS1RHB5FS62<Y3)2"WP<L[+>\0-
MC>%6W!+8!F]HR2$3PV5VME!X)D5]<N8Y81D1%>=E<$:FY-W%A2'V7*TO2S%?
M/[XE:UWUR4;ENES^A*WT>83W #!)N9!RIE_DZ_7,_9KA&/O"HI\F*%_=QEJ'
MXOBL#6+P8W1BC4SQC&/,]5YN#CJZJ.084UT=W>EHZ>+<Q'XGCT*&Q Z]0&PW
M(V&>N.=>@1;:ER#>,/D+-,^YQ4^#%\8V;)S/L(X,%S.I]/,Q!,8U<##@YMX@
M"ZMXD9GS+$8 _H*D_8W@; ZVL-?M^9R+$Q,K6AD6W!451!(&ESWR+5>D0)K8
M!NQ!Z1>\RP8US06,#" 2M\!"C&>VN 8NB=9=H4+21I;5VG;% U4P81TBRU%/
M1W;/(:>DF^7!K+K]JFV/.[T7?/RTHFO]4K**B_YA@C(Y7=OX82FH.&K->]W6
MLZ#(W]V9^D1_)KI\@#\DR=<L^JF(3)KX39AO/'F"VZSFF[!73\T-&E>YXL(B
M0OB2^)]Z:+0;P)^6.T+G:'149*<787ZB+R\ZOF!/FB3J)KD4;7&>:FI.LS%[
M[YD55<3PPSB#B9A37%.K/(O4Z;J%AG6*+7"_J.$8(3JN)E%(&:]/^.C3LR(\
MTQQ%[LBS;%RN-YWYY,[V%D^=+\UU<0EZ<?89T\"7G2AZ=XU1_1!0GJUQQXG0
MEU\3R..F90O<\01-6=[BE'J1@3Z^?O!PI]FRER"'^D6&@V_!I5;8] %P*;OY
MQGZ*P5C1,*AXYY\F;CX:?@4RPMLE ES]UWT\ TK*54OO7JMDP>8O56S+3>E3
MO/N8+U'_[9A=&SJ+?:J'"5 N9Z*(%5]^A0VZ$R%K<BLLL:M^B2F G*E#52C9
MUE_6OM.ZE"4=^7%?0H>KSK/-N30E5U/B,&/;="3VM=\*9442&*_<#W5//+]-
M-O,AX/3#]3>+UW(=7#/]3"GC^G:6"^S[WQ;A+HN&RD:<[)3IXY9Y"F5:$@E-
MN8DZJ?Y$.$81 J:B>D?U^/Z9DK4W]/>*'^+HKKW;@DSM+BY'GW_KN+R6#\B_
MNQ5_]=.+V_/C!:X/MD:+$Q^V#G<*463LYX>VUS_CJWHJ<;9&SY6OLVT]!#*)
M_7*;O,N+;"3D?7TF;R].G9A9X^>-"MTT/5.5ONF:I)W2W#O4FZ6G1<(0,B=V
M(^^95+XYER.O=>K1G0G:EB$K8O<]BA,FL$J1_+;G7\H;TNXSR<Z^GGM ^4HW
MU<,9[MHP,?BP[LN@.4W5I-&3?C[VVT&:J5^_]H:LJM^4^1CI?'/(*QD'E#S(
MGG>[[8[3:[]<R4U;QY&D$@LJ>3Z7ITPS53Z*:8P7[M^[;W7*<*+(1V_"()<&
MIV2!P+V*I[ET(NVN,0B49.?* (W!3G\HYGG2J\JPM NBSVOX*)/AM8GE5R^Q
M5WAC4P36UKII<:=AS-%J?#:&@$O)#8+*=@]YN5,WGG(']MM3M>=>S$XXK1YP
M#\ODG.3=6] NMU>R[>MUFQ0]!F%<XZ&W*H8341MU!4]F)!_PR^EM!W98OE]T
M:7C?DESNMW\ X(O5-CA_\)/ "?MBL(=^?PI5KG@1(71M<.OJ[<7E3RNQ>:57
MUCM7"%;>S9N))X^G#J2!4FK7!BHWM\2[Q;K%8A(ORS$/="?9+=YX:+\='D:T
MI$?75&LXWH>NAG*]*L+)?5DIED]>J@T7M?)(XLGC/\&!&W]69< 19)@2C..1
MEP2U..5>,W=>&S?WJ\03\UD(H61SJ6]-@UC*IX2&,E31RUNE U??ZR3?OC?*
M^$2DQBQ[_DW"%\>EJ>1[=T?2W,J+7QKWUJ\.F)R(9A2%ED\^[M 2=90C(H&#
M5<+&7%V#[S?.@9+H: 4T>&&BU+J39@_K=2""MISJB;S:4GY@FV[WO*:<"8/K
M.#Z&Z BSV-Q8U%2=&K*=#3M8>N(*W^/Z=PF3U$.:A/W/@G3U)"/8%W(L*Z\'
MWBQKZQ392MNU4JN-"@R-BM'QL=*1T>)P(>?(O:A@=EEW&IY;]>*4YGM=J6IC
M//4B#2>N1[STH$27Q#RV'0#+_(YUNH>>V77)YFJ DU6R\CX+IR0]QQ;'DN,!
M,//Q *B^M=*;/O7@XW#+4X;-K;;Q+T_/?][?_W( I'&'9BHI769HZ%UY.CJ'
M?V=W>]GIK_?9?O_D/OM;VN@ZIQG*7&\8D\&YUG2!XUF>Y^, &S,I X;&5N,Z
M(ULYUE'D<&,(+HEC<3E"R8PY+#N+^>[2:7M>M:=];,O]ZX;/*FLL;>),J<,-
M;%\+I5M?)8W/%A.05\)?174%!Y@'Q5G3-Y1L/-_Q@P;[IR3J/3YG!UI-HPZ5
M;7NFVS0ZYRIA0VK=7'.UCW2> P99.%74139^WV&64S:"-I(#+*K'E9HK0[*%
M\T:.81G:,I'J$WIBL*S42MN#F!>DO43('C<$M[H[==X!12>Q6/S/E@]P13["
MI7)P(N&<E?-5WI8YA)_TV*;19T';D>2Q*VWA[1T/MAVGD;,M7GAJ%\S70<A*
M,[X'$UV:(W%A'@).B5<C":,?B7-DU(!JAV:8N!4+G#2M(_56,KBD3)G77K<-
MG!=W=_:K<9^L9BFCFM(P:7B5V>K*46:T20>^W&Z3--5-/A3MZ>UA$1&3K5&E
M<7,O5>1F]*+N4XD#(-#<PU:PHN+>L,%]CMXP\BA!WK4K":Y:S;5C*GHUZQ\-
M+)R3B/,B^G:=_$ZIY#G>S"F[IA9S!8MZ&J+31Q=6. ?1,.-[(4OZ86<Q;.ZI
MW<YJEISM"]F8G%[#C<32H5'BRU^IX&_2F .KIK65M=[P!7_MABEV3=,5V_!R
M,TI!3'(O&C_WLP,3$.^_\JJ8*;*Q_"<W"+*:%P19J2Z 5-)P[Q->GY8V8&X5
MHM0O$&90NT*8H@]F?H7%=&&HV$JBT?E-8W>'A*=H(;!IZG//_EG[%[:5].X@
M@M98<>S;./<--Y@"EY]>DQHPP^79]AIF3YVHV_5O=)3G4(,2!K"?4%$QK+@F
M6%U+6M)R#]@4SB[F$ Y5[&LY*=4KA[JGL",OT?MI& PX9[IE7%E-+ZTJIY7M
M+<[NY5& TUDN&:NEK46CPF^"=_79I.O'ARON?&TL?^B8='6#0'X;>W^O:E"P
MKZJY2)_&R>34Q8OR9>F\@>/^ULXSR]8F,S.CGT2O[L[/ZD*2!*<%*S\_O049
M$]6I=Z?;6>$D85K[0CI=KFX8Y<_Q^+T98"N1ESO(0Q1R@DM?+:XQ,",36N>Q
M7CQ!**TJ]:)M=/"9#_9B&.D7$%/+=2?&TMKF.+^1ZR,/SN4*E$,A7A;4G4Q3
M2#T'JHVQ-18BZ9N1V?SFS4-!L04S1#M!7LP@E '8#9/U?<UUW<#SX;R.H6\7
M%F9DI0L7US[VIO?6ZQ6R?E@M;RSF 0,4^<+;REE=.&^EWX^%GPZK3%6CFA>=
M)!4=FU;3KPJ8=+WKKDN9F.N$[$NXF)K J9/)I[\2(ZA^']'$I1^J8Q*CN!7A
M.6JNTZ]GG9CG(.AZFXXJI++B1)L=W@<7A>QT>Q=-R57.*OD$]*0-[5/BNT%3
M;,NLM+:I#\DA>>.E/4BJ%9-K1-S,N^)3]"8Q+F_I:HS5732B%NMT<_1A(?GM
M'JJ//7*![,C7=2-)51M80N)S+G&MX[;W.G=DKU5<2I 5;N(Z3__H"D7&A$XU
MBOT=)W_MT_DP@2Y8T@EF5_7B4AI_=^P)L]S\]ED5F4A:E"E]8I4#KY::2%6Q
M )5>O>_G0!:B[+JQ(HD%U"Z[9M"8NP&0Q4MQ"3:\F+M'XN %I1L/)<ZG.-].
M>S?9(X21UX&.D?6!2JS%ZKD[ >Z%'9[J^-.ZP\\+WMB&?8@+6.]5"2%V[_,D
MY+^"&__:)!HWLN'MR<\W<)=$^03R>))[0-GS>/>8+YPE-:%\PMH#80H1(5>C
MU87<R6:!W,X&6"!AA"=Q90(" C8IF9Y;*+-,3=D)>M8&[^]YPZ_NDC=_G;%8
MW/E<:9Q4/92.JO-:[ME-1P^9;!P 2EM77SZBL-SJ[MFUT6-<DM-B;KFT:.Q?
M?F+V ]:'[5$96OGULK*>=L&73"OO=C%K]3EY+[_37[]:?5GQ&+WZ 'G_?6L,
MB0EWIIN?K5_*1FN_F:7#6<23I<]C]LX4I.M]$;"K+[U-S]]P<?5_*G.S>K9G
M9S!*55;]6HO# ?#._]7DUX)4;EG-SFL![ = &21S6R9IQ7AO4NDUPP$P:?A@
MM;-ZR'3PC]/??%$)/RV&<_GN^E7\-U995OM6I>6=SZ-A%U!FOA/E"1?V*RQO
MM)V^V];U@+&4G4._.D&K^SS=*O<9PCB3N8R$>\!@&?1]6M49WAAY3AF"@&IJ
M.L0*M2Q=X1B"-2XUV9DUZ2OK+%)..H;IRZ>-R8LR=+!_OGF!A;5!>2:M]=^4
MOR!51<IN3$]-85VI_&"W=!V=5C ]TT5:%(&MB!G4AU?*M_K==/N\&:0[I@W*
MF1[B4:>D*0O[WESL\;L;>J^KUC)G59+O;C#SB?4MW]P$&Z]QWE&#[$+5>N%-
M;&&6R(R*:QXO!;E-R@Z Y*DHGTV*//*O'IDT[:&CP]/;YI324U]:)O++;65\
M*^_(NS?5$^Q_?FMF[!GS%1EQNU-J1GANJK&B@B)3\*56E-DE<6;D\OA%4I^U
MOKTG+UU-SEV[EL;L^T5TT3?ZK=:MC*]/T=U%^9K6'YT_.#Y)?.)G>^%=03N?
M"?>SS*K$+@;GHOMS5QK+IGU]MI:C1-+W/NTS^><I7GAW[=8[R$0:>857\_P%
M\UJ^1](#+0S3$<TEEJ4(U@(Q761'G+IRR?FSKE1(4[/%#P5; N[OHVC([<0L
MWN7',6<]S5);C5%MDA;>(]KS6?H(AQKR4O6$UMR4%>VA<>/=#M?Q=#K%2R9<
MF13^*?!MY,1@Q+JXZ^V;Z[,N6ZS=*EPK%P0D[LW5M]+YEY#ILQ*(3L9S2FK+
M/;0Z$S/S=OMS:^;&I\_-MODMGB\^+V:2*8Q[+2?A='8.*<[8ARJJS.PJ7B/-
ME/79@AI=D=ZHK?!(KWC6:C-IO2WFM1*8_VY,#MF])?$"/3"O,>RR4I)+RU<H
M[39+0P6CUP EF29K/S:6 $C5:!]C,;K53?8W])9EC:2KIGD4&"75S3OC\:F%
M&8%,@SEB<PMI8[59(LH*,J*WSG7:W&SI#?.\E6*=YEE J1H[;W@WSZ A& #5
M%/'I!O!*U>:2S=R5.$>;YRD N2!F@C"+@&;50^?):=>^/%IC*G*+6)"#2I]M
M7PPB]"NR="A]SF#X<OIBW4GYA<ZH=:&<4/9;W&\:?36K;<:H1_!?<:V:TVX%
MX0)$;"2KKS?9Q-:M2/E7HJY_>'D+YZ3F9&E@@O%.'%D2OS+E33LY1^/+!H-A
M]S(2*8-UP9/W.<!7W!UM4[+>D@SL)-E..[F$4>WYMI4XGI1C$KM.:0\I&LLQ
M]R2RKU#$3NOF I^1AV0'F54.&TQ>)AM8+#+B=."U9G)T<EVR59WPN05RR<]P
M[,A[DJZSJVVMPG1_GSFX;DM L3=*Z?32BS7JDYX4PE_X@:P19H>B D9+N6X/
M8I"I.->PGL(^)C<!EQ=5IPRJMIP*22RG+AIG7K_?\VK1K=QJ](S2Z[VIRN'Y
MK2\-.Z8.!KLV&:G.70$4YDGGQ87(&>O#>[--!4Y7<"/JJ/B<E4XNQ+F287>K
MG<SBA%=J%[\@;F+F8@U+*_+!#T(WX&CZ@]ZKIQ5%<9EZ1WV(9])S?$74F*R%
MRV&K)Z^M+3DT9F^1!AX=;IP@3DJ^T8T]VA@=F.SU3&^B'?+T= OY'K6 9?][
MO?NY,ZW&M,D7 O.?NYYZ%'D=^TY_KE!=V H]Z'6,B$X/E>=)]OPLV7Z[6_H/
M/;9$O9)@B1V7L&ZOG+G/72IY ]NWO-8YU=GM*66LX.=NI?CQ>_0,-[(%M2X1
M!'>5YALWLG]6*'2E<GD6*KL8!VM/C7F',B_)*>"F!$0C.96D-Z6SW<Y_D>QC
MO*M"]6: 6X1T2.;FG"%CBMXY$T<UZ%?3P#D#>RY<]0,@7+=QQ+2EX@F'Z?*]
MSR+2P,2SQ*16]YS" OA0>(5RZB66I/#;A$[IOJ(%5E$<->P-X[03*B-9$# [
MR*!;=T16)@>]2T4= %>?</$GIAXZ;VXCD*5G;4-"K&P2:1(I%ZF;L%ZF"RH_
MJQLN.W).<SI@RB    0N 0"Y,M8E:>(G+W<^29['=4E&DDOPK^>T3\>!"KT7
MG9.3WM5\L+U#$+>PQ@B\V#K'D*A52IKU-ND1%J]R-,VY4C5?;^8$R1"^>,[/
MY6S/V;UEGX/G"'";SG@0*8V8"*)JMXKU>&3/>S'N?2QS^+3X6F&>^\83,?J0
MY^N71Y+#6>\TC:<V1PY?5!;FR4QK:L:"-E:.Q&J(]S6M:!)4F>48B_K;V.FH
MW0 /WCO]X%%E+9OLD/MN2;=('J]<-'^"**#G1I-M='>R6&K:Y;KOO?SD=/R-
M)8G3.:O-X'J%6IN?]TKJ-T9;!/:$WS6?:WT=$>[RN7B%QLENS$R6IU?$)2OM
MF<4%GMLWKC/:5]Q/+.^AO8$/DC1^<4GI7.J>!84]77L^^%G,HQZPZX51'BMZ
MUT?7GK@^#*49B0,E--[5PMF[JN%?_+D5:G89OS[+U4G\.J=C$UOF^0=F"T33
MBT;F8<D)(A$\AE=?7.R^P&%!>"8^:I0OC ]4F-)SAEOWYAL943;%],X<^7GR
M@H2HLUG**'J=RKFSFIK5UW&QQ=GF[PUM)_,Y_AN7YV:,$Y-?C%=TMR8U>YK-
MBV-+Y52EX^ZDW0R[1 YBC;8C:DWP&D@+A](^& ATJ$[I/-]C;EQN*D/H7":Z
MMD96-3%MM6?*4;CDB@)?DHE79M(N/C''J&,2J4LM71B@\#DC*QULXHL^ %[K
M!H8:I[KE.$]&Q^,1ZG"%DU'?*PZFXC5\V>T>?@6L-'@Y'4_"B 4)I#S(ZD&>
MD8K;<8,FBS(Y22M%4.B_>JNC=VU_<+RL]NE<*3=7?(%AX'N:N:SF"O&;Y8B\
M]XA[OM[2;;72:.N;7-5W._FR^H8ZP/8U!KDIC0]-7PH)P77SWW1@D=LAM*+U
MVP"V %KUE'J$/<M=?RI$8[F4M5':-BZW][4Z9SS+FN"+'@)WG40YS0G".:(D
M=GP#NE)KY;AU;S&?X*2W'=F2HY+1OV3(:+M:&$^KG W@&:>?ENB\I413#B7\
M&!86*M]G2!)\%V#+L_(7G;8( W7)>&+U"K@P:5I7V(?U['*>6@._<>S[LOM0
M>FA%:[Y)[WU,:Y'L\M4'-PI-O<3OV'HUUE)8Z#_1U)+2R8JSNX%*#*?#8SOY
MA'*=3J:SE(6;DHKT8Y-2Y1<9)>QV6$\[H\?'N2RWQM-^M46P0CK;>A.WMW0M
M)I'$DL:]*N#>:L6O4R6]%2V4!X"VIX0I_B/6(B\]))$*K+3&D7A@B,7_4W=(
M6;7SDDY%[X,"L\!$8"I8LS@1-Q!Y+D<@S9LY=#0K R_%EN7T"Z/]3OEWKH1]
M*11"802-PTG36!N9VWO585T9;&B_JIO0" ?%6A G5/(L0\RPD-5$;*1HMJ7S
M&]]IM^=E(V-(7/+".'HND8 6/<H/9C+W\F9O1U('W"?M<36>JO/2M57QK"W1
M'THV*4^RO.IQHC<$<@ H-%6ME=UH<)D?#,XXRZIIK[,^$=5!=:XV-AK,EN/3
MA0XLZO=9K>FUO)+D6&"ERJ4U$M''3D\<8YP6*M_#M>R=013QZBW:.Y%^GMHE
MJ8A5OV*O<Y(?[A=NQ1Y&Y\E'_#QP.6S6(D0M#D2G_M2,1D9Y08:4@+7KTI()
M[6,JWHA+E)3"A $!6UB+J8W%37^=+?Q/5R;-M5/:.P4F6,[-G%V$/==N7>8I
MBE#^,A]A)I8RN2W]M-$ET4/\538+'NQV_A@ITP%P]?U#+C6: T"@DBE@BUQ9
M^LW;13/<PHUZ1*8BG0Y7/5VV5HVA?!G8)NTV?7?DHA"0LRI6C[?JV1RJ4HTB
MN,:ZO6#O7_HEAIR]?<8LB%QF6,1W_T/$$Q3+>N\R-DZ_O7/Q[ 7;^6&<8NAM
MDC<\%"P;P#9LV)PI-&!KF6\39B/WOL[?==O];2HLALS_6H&U"?NJDE;_.<6K
MO(%/IJ[.A/AZS.K"7F3,QWG,^7CT7O2L*.,-G._RW'F1T9HP?O.=O\_$=*#8
MDRGQUDMYPM[NSSJ%*C*9&E[<KA_H#'B[A)[OV,A3Z#RQMC7<^XPQOI7\@H8O
M8T,,A+^[[TQU<!"454'T;K@R3>@-R-P%?66##W?9NE,7N15GC1Z3J[)W(5^U
M7Z%*HZ&(3E]>ZH:P\S*=CUVU5NZ50_# %)T>/A8A_&3(& :)3Z1B) _E<@EF
M)!N!U-2GFWLQ<.(NQ\D[$YYH.IO>,W"I3K]HHM?*+K> @Q2G+^"MP<0S.C9E
MUJ[";'BP. VYA@$UE2B6KA'P98WBQA,&;.;3=*PBKQY#V-E&]IB\XE_H+.7A
MON.Y,Y2MTY>Z5_.XDE?Z*7?8W)99,S]U"AMJ]7Z]'N>P?$WN5&Q0DALKVR->
M71!> )W0%[_ ^=G=Y@O,%:1]I=CBJX,7Y='SY\Y<2VA=W+ZR]?A<AJ+W;BV2
M17[__)>FP-C-'> C@-J]_\D;^1A$;LUHG^&SZB:(;+7"44 8OJ-8?K_ _O$!
MKC*NLM9#99P,^=WFEF+[HH9GMXQ>";JZ$P'1+"^'3\:!RKP*2DJ]IHW+.T?<
MZ&U?4,;<(2%:#4K(J$# 1NJR61;WN3HNZ=^8U2QL"DQC\]>QOYX.[P;>3YZK
M]'8;R.TB>+5G2SAM3PTFXK/49CW[U&Y%?VR>G]-)KY\$35&[CH=V#?J0$OU&
M+UN6HLW[U-3+N!L]'K;4NF'\ERFN3)H264\[J(ZAT[K DRPY=$PZ&PJ.0QY(
M1C&+[J9):Q&Z!/IDS8%%1_3(W)ME_ $;N\(!"UU5.C%/AKH'&BF+Q)[=:?DO
M08*V,SEETHK\P1!+TDJ2$S&K;PM+AG/K]&(+.)5BJ#:IB<O6!?FSJ%/QUYR1
MO19C:2*UWB?&5*1#\,XJ-"1^7B"X8=TAO%A*86?JGN=/_K6'LZJ 3=8M4:XE
M*4N,6RM4J^7A?!.\A&G\<M)I&4/D@&MZY:-"OK,O+JYVF?'ENJN)Q]WO8S%A
MP.8CK@RX!#7HS:^4GZ216/:0UWD@<]?EQ)> D%1N00WG.<J,TB&D#D.18B.3
M1+>YO6?NI(_UVA5 NG!)"W<5=<]\4Y8FM%FC7;(I8O@S)(WQ7(DF9>CY4_EF
MG 4+CVB?>RC8WY:YVNCOLP+2/ZW3Q5<\G4+M-$4)FZZ&724-%])%-WX)=I:]
MJ!X93QWT.C%R@<#Q/L=HOF/^N+*:X[3V.XXM8YEX[P2SG+-F/4>YQP*?5]^8
M-X#4!$A\+(SY4"ZPL"BT89]NPYEBG9+.<ZH89'AN8=7R:.)3[JO\C(FF*LC
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M Q7H3/1!^:?RZH;5*]4G5TY8??8LQQL_\VB\>(N:DF;C70(6MESD[0CW$97
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MN1FSG(" H^>09-"#36L]UH\WE#W?AC.W^_%]O-40#XI:'_K"8@;J<^KZ^?9
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MBQ,9.4Y->WEU\\&$XV_09$R\[)^_^0#C-0,I1R>F4/&P59$_;X."48_NU%_
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MZG;]I>S_Y.V$8C,*C"PNJG@&M1LY9:NS$Z (?B10VDOK"OT8Y;6^:3-(3V'
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M5<=_=)_>*-D$=AK??+V:YTYS%HS$YRFXSW#G.(WK!&L?T*<6/8XU'(AR2M>
M<W1(ZAN=6M&\Y ,7"N]_,OF2IE(@(@W[M1"MN_=TKQ&9*V/J8#I0.F$8Y.%#
MH-P*MB#]0G89.)VTI9(71LFJ@/:/?X#WSP:!B7.<)5]Z!$?>#VWI;"\S/7&P
M^Y\]4;O]P(V3; 84F0O@?SUN3$+/1DV*;?_NN/G^HL?18^%Q0JQYU:5JY8H/
MC8_NJ%A;G6@!]$UFQ>$F=GE$/3=7II@Q1W% J5[/Y]FG+.X@4\ HIT1+'$UJ
M?D\J126^'XFP H0$5]#71$AJ9B&L07^GH 940T?":>2=9 &"%/2)(Y!I!T'C
M4K,E*6F%-FKZA*'0DJ22%"Q#%"Q/1T[KE4WEA&G]_.$-K.IBRQ;EM-;Y%T*U
M!EHA)'<R--SYH.;<DI9XC4$I_FR7H^_+W[PM4C+@T]J;,Z)?!]/;9B]4(P,*
M56'=,!K0*9 8I"[U*"5:W(F@E-ZHG>8482F/!<2)1'?"\WI<E(V?#L9SJPH)
M^,$'I,G1_G$N1I9SP[9,K>5(;@3B\^+VBA8P.J6EU99RB(BZR[^N-2QK*#"$
MR?&AG&?W8+AEIV3E27'8V>;WIC2SXI4MC'!,W$,EDL\I#DI  I"VP)I!8:^P
MH*4>."TM$ 11BI;@S.E*?OF,9L'7B5!]"FQ?4GBEU=;IA,*)* BZ A>U^3Y-
MJHL;#$+YQ8RV]B2/1U$*.%[7E]\)W9^OC,8>VU,)ND\7!OY_"+"@T?=B&^=O
MR<YTY3W&LWS7$9$%V8E=]G^?HNHX#SN/T.TGA.V&U@=52\M[JHJ# *>-8EZ3
MFL,;8*7%QH;]E(YF'+1K<71W(LHS_2(E,]Z5$YKB%JX2LC?Z[%BY5OY'/K*B
M"'_S""$#71'AQ&VM>2\8Q";\.:W$1DK['110.=L8]J91OL)A7JUS<JBTQZIK
M7$XD&J'?T-30OVE_DZZ TK)7>Y\[*=,ELSVB.-*NQ8NJ_6F],OL$[W2]VX%9
M&/A^RD*_VR9R<I[4C_Y:+FD]*S"2<&&J6D]!'PV2XF,A]RU)-HH!5]5-[E>G
M.W7 /P!ZQI%W0/:;Q;=BBGIEWV!!/U>?XZ3'D)AH8::33.%@R!=6SGI?[R-!
MT<_8(@KM*R,1B4+5_)-/6LSI#:K3N9_80?<GGIT_4ZI(*7 W!WU+%_/DQG!\
M(GGG67[?'QP[U'[">O=<LP>J3^+]("KIFG=W??MPKJ%,X.QE&.0Z,*"O<?SX
M>/\/ /YX?#4Q$P@,N7WP_8M0,'#\EW<,SJWZ8F' O73[W!<O\GQ[M[!*_;;:
M4LU99A70-=0.S13<]#0HP*'V^WW1F?LJ$OC71/N]D=7Z;5M!?OZ7Q(U/7WX(
M]+0L<(KS";B^!.[(HNSL=*%(KV3$ Q.;0IZG>YV5GO\2CL%YA%]1K#'_ 4*N
MX5PB!T$%HE:P_PR*\ @>K@Q4>Q]?^=X>GY;R/OZYY=\]!@7V!M659EX3W][I
MIYEMNG XLRQ6/[\!:1RA5,:!6]ZIISS<S_[*"K!Q^O.+[X*/ )0%XY -1-1U
ME)J<S%SM/]EQ+09#\Y[C1P,%PU\\]DOV_W#U"_*'3WHPUYQ&28)[];B2@\!G
M]0VT-\>3_G_>3&A>(KOZ"J:V\K9[31?UOQMP,!\C[*UY$>0A9J*Z'=#OCPJ_
M]<Y8UZ.L)8H%+H[N&+^VU,_>3B(Z>?&-C9ME#G$K:\!^:! .G65B(M P<@=(
M?/^,BTO]UW0BR>TP6!(0BDKW,ZX?10H'UTX"V$X3BA7%WZFP2+$::\$F01\/
M*.5"#5%F9''GISE"XN3)J*:C!C!Q2\CX?6/B(BGX:/93_P#C@,/1W<Q!, ?!
M00#!XWWP![L?#X!4,S>F%6T]C*0D13 #E@)*W>$#2N+V/4[;P,I,1J*(1K<;
M<]U.?O8;0L?-/0K'M;6W-T?@UE_ZF96=6VP0[YYS@<@MT]KAMS;,+EGKNN)T
M(H%MJ@DZ*(RP8>MBWBX3,3D.<^(#0"KJY7NO-5=D.=+1?=3QF'&V)?"MB2T%
M8FJJ1JK0*UUR"L_M*-"C\D(,)GITWKQ&X^ZACJ;QUTWGCQY7;RVL#467?0HY
M^[IVIIJU]'S,4'NN73@\W+E'8OOKV*?,I<=EV9.]]^[7^2#_YMWJ^3*\^P<?
MS '>I'^AH//+BS&YVO@\C!'AMS$3<+(;6FO09:-.2T*[6!/8CGY2M%\5:8S+
MMMP)$T?3-/H'J'^PQC (%8^(KU!*Z;9Y&M:G#MXKLX;,,3,C@VX-K]^:_\K:
M\R6:V6>2Y,=.#/'$1Z8+6E*I2%<83V7,Z<W#/PX<X_$%JC3X&"X)8R0ZL;$9
M/,:"9'4^.T(\\1LJ ZE"0J/F.O<ND6LL''YS@G';TCP[G4ZD-;8FBE(%%&9]
M26AYBP]9638%[1-2V(E*FIE*ZNRP$P)=C58FO57<UNI: A[^0 JQM.-6%#@'
MS,C7H78,\V(^V1MG8Q4]ENPW*>=5FBZVE<\E-0G;>9:LY*\\=]9WI8M)^Q(^
M:>*(PL(6-S5EWE.L5C<B:?\ OI^N33@[SG,PB<M7/,,96P[8Z6)+0*W61'?;
M2_9)0ZP"VM9>6[G%HZ-@95BE29D0P=..2@%"]L.US,G<[C9!.'M>V0-61HP8
MJ;F7[DU\,YG=5R=]T>"DEJ[EYO*R_8;Q@^%V3D%0E98QT[S:Y8%(^!P4I+VQ
M^A^<>2UIGRCF638TNI&OHR= *CH5D;J"#$)D 2S,!%CU%VQF4<CO<%F(18F'
M#A!'!=UFJG\!T=-"=Z&$3F7U3TXL1TYPKM#J:>OUGL_5>I /R^+B^;5Z6JU6
MR__[X5Z[&+XU<;6KS@!??,<0W\_VD 7H:2[2=T;>H*%:H?^ 74C8'Q)...Z'
MS[=35KS!5S@QX.KY;C&S3Z8)/X66%,<4+RD[[@]-*M]2%G1+!SL*VE9_VB4I
M?T<^6$HQ%D-G+,<)[DB!N2QE T0BDRH;)'R]K<>FFL\GL!HW$MH]I&V@R_[X
M29K^$=::8?)[B-(.IP2#]HYKY0^$C1+N0!*%-<)SPQA+&G?!A.'WEG]2"$.V
M37DDD.^CK*2? IXJ=E+?6WA0$;Y:9RGVYB]$*3PN(F"'4P_X565%:OS_LN%(
M&]7&H9&_\AVD^T]]DYYRMX$61;7'YDB)U2#O9+\L+2@<"A8]M\*K=&=!:EY5
M:%&KJY)2.^N-?E 4EDYXI>6K>65%9A_U9%6]A5JE*"M4(A'6 .!0:D5T16E%
MV_[.7WR#/0*7ZZV?K((P!W9.;GH*L8=,5>H\3WS\) A*2T+1B4MJN,TK3Z"&
M@9_ -2<'V@R\2]@%WE_$\M8GUZM(M]E1V^6G+<CKZ=J$,8KJ:XE&VYU^:D8E
MJ@"!'2FEFN%3=/T9Z8WJOUDCY[M48O<$-+B)(OJ-:6F=*V5*DR82"7>3YA94
M6%#U^2U$- =UAV0EA)Y=>$]L%<2I+YP0P\VAS''.!/;H,8L6<N&_=QS#Z\@&
MJ4ZX?IZZ8CO+)! P.4PMMG5/.D5U_\B76H#N"[C6KE+JY(Q<B//5@<GO0^,M
MZ7]2D^5.5<")@!9I'RG\5..@4^N'JSJ9S?$^32-I@D\5_*Z'GS]R\#I?5K='
M9;?50U_H7KE^:P_,;V /!1^!RH=H+_@4D(9"J-82VO_8VG9+,7PU\.BF9UZ0
MO7.-W,,8R(EOE@(=Q1>8VJ11(PYE91;K4KC-MWR,I5VP;<]MY7HPB/N=[X^1
M1ZS4\&8X[D99&EJ+Y#HD_"*78I<;NY3IRVX+;)!)UM_=M_JTMVV\+BV':??P
M;&F5#[=)^NWS%&'(M*0%]5N+N+OTV,YT-D4_H=1@@U^EN,;V6IBKU"P7.*.Y
M*?7?[<[-$;5(6)?X0=0,(9KK6R/&WW>W:VNVODFFC%N([5,1DV=UA7+,=&YP
MROE36E&:D_DTPR<]S*!"8+J*[_.+&3F)ECG[,GQ[$R;#WT<8MJAI^0Z@\9YL
MC<<J':TJ1@T9/H&,7#?F=,F,R7K6GUIDJ@XEB7_;BQ1UJ!,3S%[1!A24B,+N
MK3^L.W 7Z>F=<H_6,/A38G/,$U0H ,Q8)!@5$"RCG:0RYM\P7N2PF<"#^_.\
M30;\@H>YT<\"]!/J8R"&7&Y5T)C>/6Y1VI C*8[;T@()AYZHPV[JLA.QS4W.
M()'#97'I>!8)EA'8,+IZZP<&[BE'Z"!=!4BCM!#=+5HZPQ 7E2;T'9(5*KV:
MS\Y NM;=UPBI9;K3AO>//5'@_8VT[_/=_P"<)X_/?QW^"QS*)W9FC!';$B(3
MY%;:9,4;*B86I;],45^G=MT>_*+V/0HXW?+LXNV)9)OVWA.P3Y/J5/P'Z.N+
MX7S4ROH'^&:=QV_1]^2,\@^@(?\7KE-A,BZZPU5%,R/[__+UK_UGGG0\W\KM
M#K+.<]!L38ZJB8=P!8H\3[@L]K*YN;VVK-HP0*+FM<]*@H_9*E:#9_4K]=KF
M!,/8B"BSPZ\M9QNSMDN&PC@96G$@0W@#H_8>]CF&4$XC#QI?&M4$U8"_E5P9
MA]%*^S5BFL-MKK5QO00]6W=0S'0IYTCE'FPXH+>V]H-1-U YW^,_"XKGI=IZ
MO@_TI!;TQ ^X/Q[.O'AT?SFS#5ESVJ'N>MCI?89F,G_UGJF[N.B)M*SX].5+
MD.ZM,_CV1_'I[4"5].T"&6;':=;+[_I;O^S/#X:__HKPO%0HVXF%!0GMG,W#
MAO..!S2^^_8VE_6)4#RX"3T+W0<LEJH DQ1_"FZH7HD$K.>9F,P<[RAC'-?V
M& L:G#]7*!>(]-IIT+,^64YHE&'<WVN(47]"-WLS9P_8 6E0&7]))->*=NW-
M?![1J)DX5=&L;[U^.6#GU.%/K$:]YSX^>W<\D9&XL!U*C(V20"^5JY>&M]@>
M#7B\L\Z@V&$-,'A4^19?LM:&=5%-+/5NYI!?T(YN/?E),CT A?)"5\0WZ//-
M_6-DTP$ QYGV,&^ZUX:>L_J(YZ?O?<[-]'"9G7_IXKFE]IA]K7AR5(+?MB\+
M/.4C0UE(2$"K8'WU(0U=LM,.7K8;!H.6S-QX^X6D+#)/CEXTN%L)>Y#6]%;?
M2FE*$ ^*_VVOB.23S.\?:D4:M*VQ<%B5UPR<8I"!)7X9]XPKP 1ST%59]!F/
MOGOQ3D9?<]S: ]!#U=BFT5E>IZ $3"I!WN;)W83 H$0N5VT/73E:WJF+C+D]
MJ;G>UJG"H]EIL/ &B S4O(Q1P3?=)EWY]W"E4I;5]9Q*(X?3;P*55(A<'[Z\
M&%]/TK 9'&M@:/9K9LSF>T0W;E*&'XG,A$'T*$N&>I_E2<-=TAI;V!5^K,6U
M +-2E *QMOK6UBI=3Y\0-H,TCUT%C=B4F?$1<3,(WB>"H8&N,+^YC%^:C:T'
MX*^S5Q_IS&V5X\187#8<[=[+)B;$+!UDT:_J^PO*N=XT7 #&Z;FKCIE9IRG3
MLAAJHMN3JJ::A9\/-F/F<9+?R[I2/WN^)VGJ4CCU?29]CBNU-%.5=UW9]KFJ
M%!/%9UNDZ=0;@&T0[+6G%P$IXL"UL,*'I&S^EASJ[V:\*AD$^*^45!5L<K'D
M MLR-9DY_#BN@\U9NN5N<F1\Q71^1CM)OZ5I77=<Y=8=9\C&5;LS8BV:%-I*
MG;2+2F0TR9U('*D'$S-4.=Z]_]7PXW0LXA\@IQCB05IZ0RCK+26FV=8^D.T9
M52.?=&:8-*MG5*( @T9TGV4K)G-#8+\<B>W+ B*$]*%M:N+O$^QCNR<KZB9B
MQM>BGB4<*AET%5T=Y2TYVZ/J#61(WU@CR[B+(VAAO>%I[5]0#^HFUJZ?A9]1
M:#\D!0A'?JS2^R(:).+C&6M\7U";\$R8_VN#<([[G0A?YP9E.PJ'I9;UZ20,
M)2F1FY QF5_L:A?[XIE@@17=WO% P",UTG2FN 9H,2Q^.Z)V5=?]]WB-Y<O<
MI%QJ-9L.45S#(-"Y]',?:Y$^=L#9LWN:CE,U@?Z+@L#%-H5)]!-VPC1>\]7F
M8@"E0RQVUIH_AJ^3(OL7]C9^=L8<'>\>2_AG6EKC-FM:?:-]F\;5JQ1%28B8
M2U0)>XP;4U&:OET>(TFT&+. P)P!O52.5./>Q_"IGD&O.<MFMG):U[G;[+P-
MJY060=EU(O*-5<V7Z9T:<[\2LWP;E>ZPS),6(I>QHC2>AM/ GXEVL^U17P:(
M'TJ<1 N*FXT7MY3+(8T=2VCN4<LMIUF,!Z!Y8K]-?!*[;Q-RS&3,YH5U9HEF
M6OWF@@A9]%20$!?&!:P?S*2+*MICVSLK=]NTCN3$'STOL*"-Z5&9^C^4SZ>.
M6EE!2T=;*!A:'6TK$-\A5CW[IOG?1(-TC.D%CM1X^$53D*\&G=;MX&:;(% K
M"OH?JZ8NKT1L0]Z+*P8R^VB[OZ.%M&Y5]D]E=LR"&/3.Y3I2<Q!/$3G<&;:[
M%F;=5I$P=X37%0E-:(55\>DWN-"ZS8I :FRY+99QV_MN@AM282J^6C#QQ0,.
M24T6TW D*->!,H9KJ7VMK5Q&=AW>'9V28-@$T=O@,Z+1(JQN6A;XNN MNM3D
MXUUE3#IUI<*'J-IX26Y ^EQ<!XE:Q=+ZH@RU^SP'KZ-[&.Q'+A@9A'-4=ZPR
M65=RJY0C%,&U Z!]K-2B#G&.KRZN(5:QFK'#RC=\W?DC @I^8QUF@6F6K/**
M.7W5.>D'*FZH.+2@8-JM";&ZM678,&(83U4$_U<I2,@BZ](&"*4:7][S<_66
M7=M'[9R<[-+_<?7O/KG&Q,>W SMJ(()RL86&*UX,XVRY#-.J2Q:V8I,L0D?(
M"^&4;7)6Q^:2XNQ>5E?+P<4#6U<*<I-8NC><GCZ5RZU([R5XN'$/+(@0H!.R
M3>?XAH!0M0&9J]CXQ^4)@]%3_@C%Y6.9(X_CI)FL1\-?Y?\ 1*_6-R3#I0.!
M#=Y_!S*:.]3W(WZ";(2\QB/DK#KBUP;G[8PUFSTH&/#P:;P90;?XGS.%<F"P
M(,^\*CF<D-U,2HOA@7W:+@84$R"D1*RP<MMK8T)=,/P@/ #&" 0@I,-S4C=Y
MJ<+&JJSC4E,BDLTYL6A>F/2YYSF++>FIVDWIJ>\;^K6O27MMBE3UA9P*(44<
M%)798Y3?/*8U -B.E-).M J>J/K$Z)H1)4 0^F@)7"(4=1$O3Z/4CSJPS\C)
M?59T :6>W[(C$CE78]UPXQI[]\#XY+).:%<>;*!3/$D$RUCQ5B0(6<K)<T:8
MEO/KL$X2SV7(EAF751$-9/$Q[]KS#VQH^,E;[8QFPT?*#LS#JT=T("'$C<9D
M"/@Z/F[@6O*'!9I2@E06M,8NH.FMZ>1#[?73[^75O2:7O:8UBXU%"6JD1=7?
MN+)2NAVCN]D7S; ]YO6W:"_X_NXN@.&\O7+2G>6//=F0'H_771AX;AR/IQ*L
M'.^;ZXY8R#ZN'-Y9X:JU4 \3G/L!84"S55)R+:FYKW!=G(7.A\T!00:?\_9#
MY9XT9!N#)[ZW-I9<BRE9IFC#JN'U^#_UT)C7D1BU)SZ@.:O<_DDX4V0/J=_1
M5H?M64=-67:W:5<MHZI6J <OKVPMZ1<UUVJ5? 930+J10_T*M"K]U*U#6BNH
M1R]7(0I8H=\C(CY8N.32[[+)MKO,/SLC]#/OZEH\'R8SGL[^:CNL>)S]#X_[
MIELJ))$F7+BT1+"CLC7J:2>N,+U4:XG=.+#B%9!;E,_%3"@DO YG8K66*& 5
MCI#;%NU'>7O@IK&PFYK!;1. FIM^1O%4^?/P%9^Z-BDG&W)"HTZV^ZPQ/95
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M9%QEUEHD-^(H1M*,]YB>Z8PTD1!AL/Q-#$.#/CEPOHP,&LNH V&@+4-E;#
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M37"ZMG@3<;,"0X)"$Q%CI'VZ\#>8 67Q9/5?=&+)<BS&'*(I;)*1S?: -2#
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M5XZB)_J#(FJH<Y+F<[^6\<G)PCRQ1G:S6%</(]Z[</XH>ORAXSVZ=DPS1@7
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MCGQC>:T6M>"0N<]7:I6,5Z4VI?XI+Y[8+Y[XFXH53=&<55X%"IU5'N8+]('
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M,J4>XV_N95[-#K68A4&5*K\W[77K.JBT*_Y0RROL <9Y4$XJ5!OZU6]71L@
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M1^/)ML+M0:%K(WW%S^]-QJ/4,8%H\IML/5I"FW/Z?@Q(82SS46*"B4VR<!\
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M[I B,U\!]8B\;%P(4YIKF,=D*AL9."#2SY7>4U;@NS31^>Z;FBJ_<_@HOQ?
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M2%K2KJP?-\L&]W>B2[+)VF=OUY$]6+D3=( 1PH-L[<0/!GUV&U*E7$69RJ?
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MCZE39K(!P?I<-[X'SE5)WB]_MK<20\*[.L2:#%<5Q.XG_52Q9]@CD1'N7=8
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M_<5^R13AI1:[YM\UD#+[DIHBIE"\OB_!3S\^PDJ9[$N@Q1<$^BJ@ 0"LT0"
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MNW*?Q?Q#1TM65LG8P&GRT3VL)K>J?/=1N1</4F@HW EAYRAD,;*BQZ"G1C4
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MN&R1GR)77GN>T4J/W@"KG?_EE/_+].;> .ZG@A)[7#42#]4?>?/XCXH=+]\
MM]H2-L&/)Q<8TI3Y_R/&E=EML>"KH_!_8K1] WSWSKDATKVM_89_GG#(-MN
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MA' )&*%SP]B&%3KO!$O>)WO7\59M5B [3+*FHNBI>0^?RL!0&3Y<AT6C!(:
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M""MGJR2UYJSTIG+PF-6%N1:2X-3_Z;ZB$O9U/=73MVJ1+I\2@EL'I\MU?T>
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M16Z1 FB:  "+_0  $0   &<S,#<T.#EG,CAS,C@N:G!G[+T'6)-;TRX<>D=
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M@/" 'R48]A&L-=(#8>O^IW5I@P;^</,HF7])),"?,@Z@\#,SO[D!^9EXQT/
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MKT^Q+AYZB8=U3-_#B / PL;%PR<@)"(FP?IS)]9A]?_120' PL7"P<;%QB/
M)\3#(14Y[*3$P;U !<23UX.>9G&[*8Q/'9U9IL#*1@-Y8BTBBO(?5"1@C]%_
M.[]EXRY&FU5^BT,IUL!6N24;+4XW9+@ VZX(:!WV6-Q1X8S+":R,?SJRM)M;
MU3:ZO&=DYQF4D%?=/K:R+Z%J;.]U^VY^3<?XZCM* #;VH;>XQSX1X..)';MP
M 4B%>^B!&\MI/.&;T=1''CR!#+X58;.>1_G'*.K3V+B+;K'C'SE P"'6,G3H
M1#:=K;*A.!JV\-.%?_: \P\7ODX!2'&.,2D!%P%[!C'J[-SL=+(EB-6HL0AU
M(6KSJX*#"6(S;^47,[IC8O@B[D^[B[RMURE:!Y:?\?C 44,KUZ[K8.-FZBP^
MJ>]RS;C0*_= 1R-#\Q/+**V1Y@U7]N1:M>&,W"].A2,'L*OR\1EZ[S](OMD#
MEA>%[ST23YQC[.$MB]A]G3=VX%G&[+_SNN-^F'9I6B#84D(BRV1+ORP5[#EN
M*;IR@'GV^31R;](KWW,?F?V)[%'IM:+UHNN%YGS^LYOD4Q@J#N+6_/4ZCXB/
M+B/23!TDPEQ/VQ%"G;XZ!1T>! =)M+8U(^XENRDOQ^W?6^Y]"4<\:C>2,'GQ
MY&GMXT]Z/*0QZL)$EFSQ?F&?^"#ST;X\? Z^MU*Q2 5V4VR:/2(>OIJ)22'B
M('=DO^=OOGO;38Y'H#HOAG&_LII#C1(D?KTD)JDDHF!:Q"=/4-TCLIAF=SHV
M>JVV;"QT%LS7ON?,7Q;WNG-/6/;B>Y[FY.K14M:G/+*JV!%94Z_N[T3&ARZX
M;1?Q"Y3V4:Q(/3AUO_N^3<KZH/U.QE9Z? @>77(' \@*:=9:%$92;SZWCFAU
M#Q*W-*B4.W I76BN-%KUF<APFOST^;I#>YFGC6[=I^O%Z/)VP[O7A-I=PGP?
M/MR:#+&LKIB->-5;?=E.-;]FY'[:GN&K+XBV1SV\#Q&E3Q9#'*,OLFD ^&+4
MV:B^ KX.[!E&(D??R?58S6Q,3*>/)[SF1$QGW*VN.;V)V! 7^7QV0IU=JK_-
M7B^[</=3/JB;'Y-'/F36,:S9:;>2\/&\\W.KS^L-CXK0V5&H2[[\<O=+I@8/
MH.[\^U49[V#33&^&?'F_ @+W!.:OJZ^??P]M_K!XQD)=AWWD0$+U96(_QN.U
MRZM=DR=KYTKL<YV;-.$N F4-0FO%GH;[7ZZ_UT16&4FF7:CS$@^+R 2+2BVT
M]"B'81>55)N-2[TS]DA/JQ;9]9S8OYZ=+U U12O6EON8JI6?S?5*M?GGN]QL
M^3>?#W 7]F:+%(I/Q)PO3EQ-&-UO*)JV3/B<]$X_NBE#<?0SW><"LZ;S>;M:
M!SL\[0T\4^GK)2SOQ#:=4USNBNT"-\O"?<MYJ\8.PN;JH6"61>_21V4.T&K\
MA0'-Y-ZO $T;BS=9V2KBXB*>-B/=9A[\I9G9K^%L^21?[(;K "=T0B=T0B=T
M0B=T0B=T0B=T0B?T_S9]G5=1=D"C74&"@@AW >C1334!&Z2+H#?451 H("0(
MD+GH[0JU<8:AF:UA]HX(698W#<TLS(ZVLBS&8F AL*LBS,%1S0<%T_?1-K#Q
M<;:1LF6Y*$<LXPWR=G%U@:&AS-XN<(0[R%N6Y=@XZ/#XB"W(PGPL@G:693F^
ME<=L M9E5D2B8,QB B+\-D) (+.XN !05$Q<',C'+"P$%!84.OQ/G!\H"A(3
M!PE+,'\G%CGBPT\9E*T="**D\AWNL"7+\GU<7EY> EXB DB4O2!02DKJR(RP
M,/^A!+\[!H&&>O,CW%F_&?EA1PGF;H-R/'Y.QWS4AEHC/="R+"S$S+_0-R!;
MFY\XKAXH^#&*K8T@# YS@2'0[H<Q! K^-'YDW]8&9(=$N4#1<HXN4'N8(,S5
MW4Y&\ _N[Z)H1S0<)O<;[K&'\G#T[]P?'7#'(\= <"C"7I;%F__[G6(6N=\?
MV\H(?I/]DV7!OYH^=NTW+[Y)_1*B_V[H#F?_9^S^-O=^B]NA- A\F#BV4#14
M"8J&R0D+'<[B83X(BQH A4"BHB A(*^0&$A$2$;P+[)_MH.T=;3#_%M6_I#\
MDPU%%.R0^\,&D%](E!\H8@ 4 0F)@(1%#YL@H>\V?I'\.QM(E $2"9?[M@C4
MX7 /=S3JB,LL+"8@S,P%AMHX(HX>UW/_8NV[SO\/,P(&_^LY<7$1_#M-=S0$
M9O>O-=V/'D4(0F#N2 ^4#>Q0G/7O#2E[HO]7#"E['JXSUC^G"A@,4D>XHZ&(
MH^=8<H<, 4='6Y"2A**\LI*\HH2"BHBR(A H+Z\B+Z4DI2P$%)54D!>2.H[P
M[ZI_,:N$M/$X6MK?S=H>F17[]\S^HOH7L]\>G$'AO\AX>!S:%E,2%I*4$A:5
M$E%045(  J6 HO*28E)"2B) ,2%)1<D?MO]&_R\8$!C"UO$H#Q3A4'=WN>/?
M+8!<;>U^V/A3_U^'#D,Y>L)L55!(E^-,<H6BW(\?XLFR_)@-EC]5E..\ #G^
MS52(_U<Q^XOJWUFV_>_,QE]4_\XR\K\](?^H_W<PJ'^<D[_M_[4P_V52_CIC
M:H[NA[4"\S<;B#[,[1\WD']O;G\.XW#!@J VQW7''7KHRI'KO_#^6>EOTD)*
M2EQ,6$1(B%]4TDZ87]3NL+!*047%^>U$Q*R%A$2 (N(V/^W_4VK\AN'E $-\
M+] B_,)2!D @Z+#.'Q;\[P7Z%ZE_-N*.M$-[05$P>?O#B?RW*O7?Z?VS?1N'
MP^T:9BLG^$/Q!^,O,_2W^_;_&5.G)/I?K[O_Y6G[=6\6 8G]W)O_V]/VQV_?
M%/7%F;F,'1&V2"_W_RMGS :)./JQP/_"K!WB0 ]/OF$H=SF[HR+^[0S4R15F
MSXQ&,D-=7>&.-M C&X*>"-OO.Z_KCX#]0/G%R/_&P=I^*W/_G:'^C!/S_VV#
M_I^OR7]C+SQ9D_]'S=B_<5[T/YJQ7Z]P3F;L/U%%_XL2<E1E?KW4_W^CBOY?
M-.C_^9K\+R\;3];D[]S?KRY^7*K\Z6KD/W;;PO&/4_&_OW/PB\!?;RS]T@G2
M1T-1: ]77132SA$.DSO^%;B,X+^0^ <[WV_2Z'M8?[NWHPY!6CLB?K?T)YG_
M=%!<;?_A?LQAQV$01'X/PB$3=#@F6P\;&.I'/BFI,,,=K5%0%(89*"9P=+'T
MF]1_W.$?^?L/;O_H_NL,_NP"'?_D%8RTA<F)R@C^'?M?.OV-"U%2D2,^3-D?
M-[#_;JW\Y^D$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$
MY 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D
M!.0$Y 3D!.0$Y#\,0OS'*V%@"%M9%B^6BW)?IP&* *S_(1T9^9_:P#I^"S,6
M$]83'"S*'V]A?@HX?_1*96R<7UZQ#" DPB? Q2,F.>0>"AA2  #X.   -@X1
M"2$!/B[!]S<P [ (B2BI3GM2TUP0EY#TJ*RBI:,7,4%[>5=4U[  1>51">7C
MPF)2>O%WQ\ZPLAD9CQK$#(V<9><PA-Z,.S1[[A /"Q?GUY? 8WU_LS/V$>JA
MBUC8V'BXI$2'#+RC_Q,&UA$N)3[5!>!;>3VW,E$Q<:@[VN-F9D7E$X+3U"S"
MT>55@S2T=!#]N.%Y$0D%P]CXH84MUAA">@/4*)NBLK7_[R]+?K=U0P@?\)@>
M!W"%%.OG(?U(-XSV 0N*>V3V0S60(D3D090ZF\ Z=GQ56EHI,'1<T,BU\3-5
M,'-FY"! Q=%_0(.M@HP>(%C0KA\'Q5WF%J-OXYM&HN1X# )YW(N-W )!;G&K
M4C+9]&T2W!+/8I[=0Z?A/4_GB5%=FO$\R(Z4'(P?M2%*(WX_XI;@<<])Y&F:
MX\/*)Y.\T0&W-.=:$B27GKPQ:K&V[^J;><:($8<.5K3&?( 8&X/M7BI_!0SG
M/\O[</U+[)B.&).^OK%WM2SW-7#&THRPL.L'^,)L6WMQ5ST0(YFS[S>IG%]N
M*%;A/_'T/<WCF:[AL(U*7Y"YF(BYF$6!N"+JE$FE_%@8).GT'9E -P!%<WQ6
MI*^)7=6GF]RT59GVK6TKU0IC8]1? ?H+.Y/I*_OV%7;+#=:\_+39@FGF5&T\
MH[Z6.G%<C1^&1A/,/4NFIYLJ<./UF#B_,':%ETMMOX_V I.=(Q_7?.GK%W]?
MW(QP&ZG6%M0Z&U2V/.E80/5R\59!\1W,E.05$8]/P3%D?!?=2F\_]^L>L;$W
M_4P\4FXP4XYQYHPQK:DQETT1&\;$%9DMUH+>;TC7+8Q%34/ZENU=[]5\,E2:
MC@U=NF.Y+C)C?IEI;UEOJK)'MM6P5+0<+ FF>AD;'7AU\/%RH3K;*GW/!SSD
MX.#3&]OQ$@]XS=1>3V3R[#8,@,^P+2)*B\P,T47\#8OLN_9T]7KKSM$KU6]\
M\<\%FR]X#M;5(#EFG/03S':+!'.U'1'.HL,S"\/F73H)RV__G$2_'Z*'I$Z3
M*LA]X(UKJ.E8U,N[2["&LU&>I5M542&:(^8>FQ+:AHU%I'=!1;[;H$ 4RI>E
M2=_6Y&S>%6:1'*8?ES.D?IA1UNK\I=5^?:[Y1 :I<1<(Z_H@CBK 4 0DUI=*
M77QZ)A1/.M^WN(T<QA;NFIU7YQMM<XHG.])2D\-14M^9$J(O:O9XO'>5"N]E
M$]57P!:WKG!X82^6W(HP6"2"'\4A8V6_M)_HQ\K;^2EK15-R6N6R,-&#+ROF
MXK('DZNQ>@'E8V(7[UHG+INV$M_M=%UW=TVX("EAU'"G^S+GG9F$F?*NTN11
MYKFLON'W=*U6&L.Y=Z?/I4BFIGP%7*LVL@P-+,$7I/0E"HUA]H3'U7*0MU\(
MQF/Z5/L8X,OK1/  B%S<;ES8SG=T)D2I'N;7LRDWG8R7I<UZA@Y5W'P;"]ZY
M3@^<"[?#+1OO ]U2+,EU!-R)XMSI0CIN=^O#$68ONRXZZ&\]WO1+24.TQ#=J
M>YU7+TU^6*N?63P3?]\D33RN@%]&&6WY='A?7=T:%7OQ+<?G]L533=?IW!3$
MXVVWPWW 7,ZR4QOL S-5,>86V0DP[DF;1 6/$J1]J/D39^V^-U)&;N9?>/(0
MVNHN&N1D50DY<WJ>V6V6:4:>GV4B!N^K^&I6^$2537CLE-VC3FBX&V<45!@^
M@X4EMZ9VK5*,+U*9 F(?</Y=>B&KOQ?'4_J-!K.$>$NI31TXQZ.PQ<[AU<^P
MSG?BR4CI(&L#H";,*L(MSBK72602$FZXFRFV%E:C[C*QHV&U7!;]+S-,"!]+
MU4KD#4I3T _34N8%X[OQBF24!+[91I0\Y%_<B1, 4RRR":6MIHRNX1:!1T7=
M&21:SWRA#?2)9J*$/:QM/\_3& /YP$_[(GER*YXZ#K._3%MW+;K$D2WW\K8G
M#9'D-4B#7BE[V:?T6P%%@M*IL";[PH25GO@']X!GRREI[E_A<\AV[=0_C4:)
MM\]9W=&8&1I+)8J)(KN> TT!R#K%<[QRHBD46M;0$I-O3^2S6.6)C5N9R962
M4G]D-(?\(L'?.?%R*%\A'B2:E:D=QTJH()U-7Q)CNO*E>GINVCXCXN/KRY1G
MW?,*56A-7OG<6@VYK<)1N%!,RL,JGC(++]GVGB+XH)^)Y+__,;@MG<%*_@TV
M&_<9*W\\#B:GO8]\MX97X)M\1>9CL;&E5J)RP =IA!"$<#<)1U5.>6]-JB<L
M9GG$S<^8ONI190!WRU!?Z7K-K>MT1J7/;$!N:2JY9W@,EG)WJ#0P+BZO>@8?
M0<DZ[SFD^J5S;Y7P$!'A)ZW=_PHH/K_<LTCD3QU&.K8D)9-\J<J'.O>V,I9\
M-VM$$)6I&=^],W8\6E25$'1ZD!WD@Q'UJFP5O$B%QV5EEGLI!M/\%0!KN)B9
M,N>$GO\@HA[/<UE\FKXFS1C,ELF0S*,?%V->,>K75=^+8OGB3NIRZU\G@;J<
M.&02'E&WTB=SJR&Y?6LR#8>F]#E=S 4'GUM54A4N2YDOF51\[T((WH?N?8EX
MBF.>,L8J64%D)+1B3!QF8]0T,N8T%%"DC )%BC'N+]>I\XVU#^N(F XYQ7.J
M])#G<A)9>\5MKK*G.X4ZCBSYBL0QK*J7),-K0,FE 4,>E3QY]TWU5>=UN3[Z
M(>3&XK#P0U5N1"6P\ZB<<]!(M3BUUT=^IV\B7K*.QZ!.+ZA0U]&_?;00-,II
MY-+M'AN7LGIMJ9J],T;E"5(AONJLT:YUID8<]07J<G7V9GM>3)WL:W!-5;KK
M1Y^IK9QE!^*(AZF7J>.T"<'!(3>2><Z="6MV2<K=?.(()YJY*ZM DWZ QY:#
MI=VB+&6P'E<%,@@QE2O89.XS@[3<M]]VT"OE7I?R0^>,582"E^+&S!FZ))>V
MIVKL\Q9J0)JW![T#-8O5],(=6I?BUEI\'J8F!U6N@NMDN\VJ1$Q7Z2KL[T58
M55LB(U#9][W&(-G]1N'FQ*G2PGE[7Q:1;M%"62@S#;+"B3B76HU30F/S3,!4
M-@Y.RB!2WXFVH-J\@O%2=5F8=LZ+#%!8LDX^>\TCES$)JH:*JKHX,7:K0)[R
MVVPP26[1.E3OJWZ$^7[<_L?SK*$RCANJA)*B70;O Y\L$W*Z538,>;J: UT%
MW$]O&\AOL\[V7+YYWD#$XUZR6>%, >S.Z -*[*Y"Z4:>K(R^0IADK?IR1ILF
M>]'T= SXU>5")LN\!DD^$?4"D*91D(A&B;,\/+0V*_4+4' L=K2_V0AY,2VF
MN;&5X<J_WM6$B+FV/(WK;3+]Q!J(1K(5+^N/]SQCZ7(G#X!JE8QQNU7$2B4#
M;OAPQ85M=86L)/-OC#&:B3Z>T!8M)1$,$@S/O Y_E*;!@Q[G1>_%6GEQ?>$:
MK0S\E+R#^S3W,UGITIJ1[YZ-Z[VJYS[ ?(GAF*DIY9=YD#1K%$V.3+RZ(14D
MH%L_$2=8-_4%;HL.V\(^2R_7T%/*A"NXS*38 [>:-GSFK"60XG'#IOG)OOKF
MR:LR-=Z3'A?E>EY?$[^M4DK_\6E*1KUEY\?X3&;&_2QL?9M7A.38WF>"29A]
MU<3M+S%2XY?0JP2_.)"FO94)I[>L\AZJ1Z1H5.%M@:MV=L*V>Y "Y<\3=A2'
M[FR [II82EKHQVT*IM2%(D$\(MGICWJ3G'ID*F;ZU>/).DPONW+<4<A(%.MG
M%NR0RG>(%5DST2V52NO2ETY2OHFR#;TABE"+9Q/ER!>\]C":D"G:%]!VJU@C
M]TR]QY5YR>7#4FL7:[E9F(>H?B<JL*;25&4REBW!?C8*TU;;U6YJE[#&D7&5
MN@M>'STP)S4S31P2+%#RR5T3G+?OOVL]&%BA9D?ZAIMALE\&1 G5-2MD1XBH
M430A*A<:(Y4XV"_"EM8>A+3P=CMS>IA1Y&7LQS&Y'' .QZRJU%@6-W&7Y^NL
MJI)5E1HUUJSW5<+H.V2[/AWH"'R<N"QN35;RK^H0X#%7<7N8O>%0\ZF(.H-P
M2.U=*0^&R[.=,=0B04$BPL9TGA:'VS_V!-8Z[^)TI\PUY;6V)]@N!RH\?-(]
M\^H&X7O5CAI-%:[]=JB@<LWFW9V7X.VSU3$U2!E6"L=Z3Y, .:F2N5)0??T0
M!G5]N.?1C#&WMQJ369II=*>Y!>5]6S>X]O;-4>[E])LV9I7WS.*?@&+V6<+5
M,B\$%K*])8$EJK5<\7KXQOR9)E@\V3$_UJ*P- F]XD*L%V>0-1P6$Q/CRVC6
M*_HA>3IIZ5361U3@EM!ZM8/8HE?E@ RE@MKN@:)T%^I4 \.V1MRH2XO[!582
MQ:22M1G*-7,4SMW$U(E&RR=.66@IMAM/PZ?Y&<PFKE;$\VA7+7NOKZ1Z.#S9
M[!$?0\8O)Z/4[8LJ)%^_HZYH?[.HL?Z:-A&<!KZJON$'6S:IKN@&)I2<[>-N
M3+TR/2W%?M[8(& [OWS=6[0]S-ON:L%X!5X]X>(YC5P2CDE6)P.52R%E5)4%
M<6P:0[EIBKJG$^,B]5_S)P!\L,C?W1\-U/#@/-M5%+(JQIG2=UE:?!A3DXY9
MV7GVO-39?+PFUVA,-ZTQ.YY;7HQ,38(T*]F4J[9V.::'+Q2QSHFJ/]7N>YL[
M^%[+2V.NI_E>LJFE]+M"*@9=TP."<"3JC%54B"ZF[&#'ZMYSU6=USM>^D)UK
MELFM?Q_&LUV2<)G[<#__L%S,D3..X=:1Z#]?;/'H;O?N7>*:_)UFSJ':NEKG
MC^<9" N4E]/!M9");8R!CJ?RCAWC5- _Y=3W0X?7T:M3'PL=39?I[%F !MJ>
MPZ]9XW+WH.ZV: V,YL02O(.>\L9M3P)TYRQ%,/0,?G+*3'>W+.6Z?HI9H$_"
M'M0LI=L54_).=%^#WUV#/W\X?7MLOR_\<ZFSQ@;(,+MH^T#/L5#%S2\F(";N
M,F@ZN9<:H[_7H?0>[#O>F[9*E&CJ]Z(=HV40:6;<RW,^^MX=NF:#0;HD9HK/
MGI4CL?+<(I#X^01@KH:-KYG4'4H7S6%8D=G T^L;D]I"M0E38\,867A%W+WM
M94SUMAYF98\)LT$-).D]KU?15CCR $::Z1P\>"=9=RI3N](KGWXIIM^2;<10
M;9F=VV!/QY\_T28\Y(+?XNV:0LI563EI;:>)P=,2JGB7WP=J,E%U7[#M2JA+
M!<(U2"'RZY'20SN40==E:[K*G*X+ ^LU+HIQ&21D681(]AL*@M3=SYSJ!HF8
M@X:*@S3T^R#Q9@;QZA)5=3QQHZJ</<F]%<K/&@V*]PI(EIL)#\Z!6VV*L4?"
MM'7K-W0UA.^_FX2N2FJ,U'#!K;7OX4KRR#Y>%@AFC<:AXQF^%7"SXUI=J8<#
M=/CR9Q5V4TA>.0I2L&J69PJCWG^CR1:+ZH*'FANF65P+N]N)]AF<'<<4=,>?
M#ZVL&</4Q_0!P=PR<T[4T[[V&;WN&:W90=0HW+.7N<J7#LH/$#L^(T/[Y7U"
MR[X6VVZA1J?I[<P*\+AEHY/,;_G?,DY6T)^;-2JR<K+M['%"N%0^:OQ@L)!Y
M_DZFLI->?H483<Q8@KE8;LQD2I=M1;_X=J(<[=MU0TZS_([GEOV+B(VF^F%,
M%:%$[$A018_GX7E20HF-39*UG<J_S$4<O>?4<0393F>6.>W%/FX0/S2)$VZ@
MLFHQ>ZKR"E8$]W&2N2+$;65BJ9^%L3<N?T;LQ<8=?L8N@3(!%.>L':AFF+>=
MRE3^9J?M]21[LK-L8?G<Z['XS29GLZVQ7#-R*HOB> W!&+T8R)VE&)VHS/7^
M'!_I)[M/&]],#"3%#W?R%U=/JNV1XI5T>% 2/LDG)2L[4Z&7=X!+=2,31]W$
MN)[#QY8YOG.A'<RZ5$4QGEB(1(9\!8Q7I3I:5*4Y8QKC<BNDY-_-?; =-K==
MY(?OF='5U$O'Y[%KE(Z=.^,T]7PPHK%P^$LOZ.U2#PI<R)=\NUV5+Z?XO)HW
MC>:T!#N7!21%4X&]2#UVV(U^\2O@_D5S7:_Z9#8*6_)6P[)@JQIY+8<@SZ<4
MP39SC9O+R#MMZU4>R9_-RF-Z8IU2K-*WKI)\IBL\Y\''SUE5.)!-M+,9ME9H
MOR+6N-.65\C>=$K$VP12_*9!;;<[.;/SGMAVXE5.BT!4;*_NI](SX25R+Y&7
M7E2.B_GB^%*KJ:1FNI>42EYUXW%2)"M,>1 \:N"8E[JW6FJ&@<493;HXPJ>Y
ME\KU9G2+<VC7>/F()^=F9!;!>CEK4P-C+AM=ZVU.A;)V,6'BU>O\?5;>;F^+
MG_,!^UWN5&M;QHZEX:\6*H_*4B8;*6)N%TAU)FIAK'IX%>"7ZO2*+(W8M$-X
MBV]042=QNY"6V.97/VHT)J<N5(5,^8]FDTTN5UB9S[D@P(UW!5R22!F(XP.<
M+2P-#+=(NOQ@HRYKLJ60O.W+POR-4WH0#%POC*I"ZZ&(S;\\N3\\), :+"S=
M:K)1''8B"+I+A1__I&SPK!?^7E?8>'3(&(N1:5=<E*P?#MMVD$G5ERBOF!2P
MZ)2SNPY'_=FIX#@;MD6V7-IRMQBPZ+N\]/:&9\$"<^?\F/=?.O?<97%?NT^0
M4M$OE/R()SBV;^Y3NV-G5 V'@L,SNL1PRI# "M4RTGXUA;EWZ </J+HLC7M:
MU _,GW5H$K3D\V.@8]JF*\^[UOBF5S6X+X)LXV^,&;9!V@G;H(# <;V6CFQ
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M0&UM5&O)3(I+<^R0:4WW=JA.GUK]=F'QNOCENNZBNEM&SYBB"*H=&/5".2:
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M306/%;,]]64+IEXE/:&ZRQX52+&WV1;WJI9-A_%Z]Z[_E,>GJ;\^^"WV^PJ
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M$;TU)XY^0O4G+PL6QNL(ZS?4R!+<O45EQ"1VO+4+HS^8X(:#B0KBW2 ;Q@-
M^AIGHJ[)?*5F82*W^!3L2":U!+:"<!3@-YPBJG,4.H!,^/^9K%%V'G,?1N\R
MKS1/O4,KW[3^1V=F_G;O0*"V(:WJL4F!H3%S.P<8%<]80+DO/Q4FWEJO;K2
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M'7M')159J!TH%L_N.\.L4[7H*4,MRZ_@=I1'Y((+]8)H#AEW[B?Z<S95M+I
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M3CCH>=IN'<9/Y)'#2HT2)&)=9@?P!V5Z%NWNK XV)16-$'LFS1X-7,;2&KP
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MHT:!*,J,H]"^S1F%'/!.FMK&2F4D4(@?BGG17+5R5=/0ES/Q;+#81@;=PK2
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MT2KF+/**2'\M>X ,K;ZH:K>0$+WD, :/G2UKR6I%,EV;81KA.>2NR7MV[L^
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M_^;>])\LBG9EZ$X$]3/"+*-*D':B_WSOHEQEFG0Q_C#O&3F4Q-LF<7[Z!^<
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M6+0 N@<<?65[UIXPE36ISQ4E[1ZM)6D<["=+98)=5KV\(&Z75<]5ARQ;762
M#V,Q"(IV9[%KJM&I?!7U"G3H79DGS!(0>8$K@V%@;"YJ[!9[_P"CJ\C\_H5H
MKRW)+RA++DJR81.XHW<C:733W-Z;33N)RL3$VQIR@DC6R-TJQS2(7R.*6]_
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MK+A%=L]D7Z:\+WN])R>\B/9;-'Y8- 9O&H#W"\ 3FF1[/#,<WA+NZ^N]W\,
M@T>A, $^/\[W/K6]L7OM0_NZENB@O1Y::/R>SA\V45@3F _*2M?.BL"B!!@"
M@@&^  0 !< "8-\&L-_-#.OKZV:)P@?XF<(]$00V+<",T,67<+@!> &6! 4\
M( #@MZ]"[?>S]X\1:'GC,=_]HX4'H+WQ:,R^24*;:K^WMK&]X;?8J.SU)Y;Z
MT_B9?AF_J1\>[8O![<5Z?Y1^>,R/(1&&#,?^;%BXXXS_D& QVG\T,/@_&D9P
M;]S/AHD[/O!G0]?'6^=G@Q#5/TQK(;S<OP?BFX, "WTM;<('R?XYDI<7Z1L
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M*\5_I\SL%Y<_*L=>'?F?E)K_=XO+?ZZB_E\TZ'][88(543"$'!@I!8<3;N;
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MZ-_VZ&6^;]*K4Q-RY,<W!+\K"_]Y.@ Y #D .0 Y #D .0 Y #D .0 Y #D
M.0 Y #D .0 Y #D .0 Y #D .0 Y #D .0 Y #D .0 Y #D .0 Y #D .0 Y
M #D .0 Y #D .0 Y #D .0 Y #D .0#Y#X-0__&;.R@,4HW_)/\Q]:]S &T
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M8N1R0J&5B)*+F:%.W<7C;34&AW-&H]^/^QE5J3B!V[V["M;X\Z#W$)=)7NQ
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ML,R301:7PVPC3A#K1B& :-N**U\!HMO6<4!LQ45'#/IH.O=SQ :GDL_'WNV
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M-\O@M<A6V[.V2/9=.@FE[$5$&,?(K^\UALX"5D8$''46MT$0S4&;1:T@WOV
M/T%$;!CJVO(H8AL0=H\IAU ?XP?93YOV N2 4Y1M%@%\N.6VU;<>0V9_R#GW
MM-KEY%Q5!;,T/]EKL.1JU,):R#^AS+G7#(+(,G5=%CK^/NM)0-7\,PMBP/6S
MRA&%C<"W/Y]2R>KATW2%3-Q=-1>;%C[(!Q,L4 ':\TW2-\\YTCD #RX],Q'8
MXE)"T.I@Y_L"A^%J*H5X?(H7WL$6&^YM2K$K7ZD1Q)LQY3-:C&T!!2QB_B_/
M/HA0D(==I$[4&+2=M::.S.99YG"$/WT)VZAL*PV;OYX(EU1O?66=EJZYV[IO
MO*A!HKKM@^FBR6;\&SA:8RCC+HA81M\NRQT.NC5;,">[-G(#6H\V6;]*?',)
MYZ<7!P>)"@"MP\Z5M8@G ]RKZBU(FK$I='BE)HX"E5;X#TO28%^JM8XX,TY1
M92LV 4N4QH )0S;W 6>XD:@("ZH_)X$Y/M^?D&+*&K9A"$_F8&]#$JW9!P^@
M:FC,%[3$>R'2*+27ODKGN"EL*Q!QC+7JZ"_$>1!:4S>9H%U=J5ZX81?;>).7
M#")3M+3)0."P)KE=4O&8NGWP=[T<R)6GN4(@QX&\OXW>PGUJU]<#WJIJ;_F:
MRH:?]Y?K[65 G?T<<YE?].2Z,PT%NYIBHG"]4&5Q?W*HN[Y>2J<>@@]2>.5'
MAS;7CBA2@"G $%D^/EZ\_>\GAK,IW73E+UJ_^$?GS\>91!>Q])SQG'^=J19/
M52]%1";3<SA2L9 +1NZVW2%ZTWE^9L)UIOON![R9>$WN^MG9*4G?RL/S%:DZ
M3JY1X9:^A9L1.X@2@R/+_GOY:K_]A?V.*;($#!L'*@HP#@V<?2V7Y<UFB&38
MU8DNT]^PUG@J$?T178J9Q52JOCV[R[VGUN7YY'QA2?0\SB.R'[.1Y7CNG/7L
MA7D WUC[2^$-/60A=I?6FT\?8TW)=S?=CH%)QI'X4C42,YFSZO$FMKR5[;YR
MV!7;V+6M*AZK%*LVF8Y6+J79A%;<I9A.=Q@CJ11O/*GJ>#86B#O]KW$JL9XS
M)*TFQX+P W+14YN'W6>Q"-J0(24_0KEKMG26QVGG9!I4*AV3XOT7K#^X@:WF
MA\.+62TY3>'J U"9522PRA9;Z$1FAZYU,("13^<;_ R+"X,>SU"_";AY*(DJ
M-<8*^:9=(8/O?-/^F(= XEQ?7$_<8>$EMEC@QE';=PR1Q/CS!<=]GF''FO*S
MV?B:0Q%<^;^ [OW"/>E;Y_>,_R Y76DOE^HW83VOE_S"E($T)*LE'QQ^%B^_
MNW_B_6_!V=C^(47#V54F^00*]_X,_RZ=C'U)AI+6/HA)&8@@8:6DT<S ^Z\2
M#=^PP*TH3!!%+$04($DL*P"U\[" &21K ?@DR[P"<)#=#L(N'-ITIUM-"'YE
M]>8Q+;8!XQJ"OQUQ1=PFM>^*!U,K=)4W,]'IJ8TGA=/13;-6[1-VBI_N]I8)
MZ&&IGM*!"/9!/#4F_C:N)8>$991A29T ]B^2LH)2O%ILOOT4OR=,IC!(>SXS
M>8U9&'TA:EW8!ME'VRMZ4I,>+G6VS=]!<R%:#6L>Z@SSC5'>D#&4D'\P1_7>
MXO CJG@.H,>U!?^T:X"_EM]O3D_RR(Y>'*A4"B"$KF/S[.Z:4',A+-!U)R86
MU!SFK*(A2KU?=>'X<5-MV:>DUA8GZ]GG+HQB5\T@Y[VV=XVFG:A1\GK6*. X
MQVNZIM0+$[?QFP@E MH8*S2]3MJ27YJHEQ=:4$FGC*C(.#-M>9ZY\^!*&#@"
M[)^($V=B_A:!'J^$=;VZU4RD'>C*%B8C_I-/_#;G>7#(N[I)J %N XQ1F P(
MXI+@Y%[VMCNP:G9;V1W%HP:@1./&U4,&A-K,O2E6+KJ"KE>TM)CZ3FL.HQ[Y
M5I.R*I'#3O'J2UN37ESWI<?<TZM>A'AOJB@Z7,.!W1S;V=:4R@U1#XZS;.1M
M(S;L\"1(,24^S=R!=/&IIHCP#@,O-GN:&798YF,M>"KK3P8I)B>C(\WKIUN0
ML/UNC2R/J]/QQ*O]#-CI?DZ:NF^1)WJ5,F50WIRAO8T)0I3[5<#6BI\9@JI'
MZ_Z)9L3F2[_.E)J4Y./XYZ/[,YV;\Q_(AI=B=V7T7)/*^?K_55R;H8 >C#\H
M?.4R=H%"&41/D&A!N%_>KI42[DQZ,V'Y> 7%1Y.,C3S:>-YD[O,L:SZ<S#AL
M_1OUC.QWWLS>4#SS?DSQ_!MJ/)R,++ODQE+]!6P[_R]$V2CVW9/N*L#K7Y?C
MO<?QORNU[HG=QNONF/K1EAJRYTQUB!:WC>M<SG>=T^^_R$738CB0?N]#-%%]
MW.(<1D,_?B,%XMG[1((G)43/3^D=)#+7.P3-?DW5*4$L#(P]7F\H0> H!,=,
MCE9>KWH+W6RW8(4#A5+6HX===]K6ZI.8A.YB&? NLO9;7$=/1H=T'(1@B/J(
MQ7E>/*L70P'2T!>AVG[5BO^7(5&C;]-_ 8]? T>UJ;SB>5]L"(+O2 KRF.2Y
M=IOB0%+"!.K7S#RR550+Y8KF*X7&W6L&<EKA=#V?NTR\Y'Y5E79C%/UC1@VT
M9T=V*#,J[Y5@7DZ/R+QN8I&"-)KL=M.W,.W#;<6/LAX-ROL5IM6?7+R9_@PF
MMD1(@4;HI;;RPB%N+1OK%12L2]7E_2NO'&:XFV0,S6TW=A*U/EL]D3.2$]51
MY4ERVWZ."]]O26B8)O1T-YK4Q9R]$JL:1WQPUM9EY-/QMQ P9HL2DJPL7= N
MYVH CCC;29?/-3Y[:#>RA'#4,D8+37,IBTA5\PKSL"JXLKAXTY\(,;CE_@(J
M*O36%)A&\#=?I$"4@:)*(6Y)N-SKZ38!JZ?2%N[D?AHWGQP_95:O2#2K1"(A
M6JE>.+FD88P<\,$KCU!_JMW8^U;"_.>X%L:SKU#--)JJY9# %W=%X-O;@?UT
M(WLBW@:1'%HD#=-7TR-,HC9; [Y!"/N,+=-$2/!PBDH:O']DB#R V^-=ZU>\
M*O7&ZFFD6X%H#/?"FI1X8K)VK:EP\T+'E9Z]/&R1KBW6K,JYMT=I VXHH=.W
M"7=M0*-$TWV06K[>YJ0G^]L3UV5X";ZMK9D[AFSZI65;J\PJ$$4=HR];.7B*
MUS52"U1[N>;JM].4M<=78BQ'BRZ!I<X!YY)_"[E6<?JM':S%Q?6[:'KYZH*=
MX(LDB2%[\8+AD_KRQ<, = +J9^(?<DN/D1?Z,(.K[)$:,5B2%^W75+J&Y:KI
M85W(/#9P,GK;+,@;)VGZ55^C9V2!L!-#Y"TM&=X.%.BB>0QRE9.[8::RLJ>4
M#M7AQ#IL=R7Z'NC5"W6%E7&""_($MF#0-[NU6ZZ3^!OY$/;Y)_7N,HN*4PE+
MM8?IJ9I59^+'&,+K)ZB:SS[=0S;##GO,#W94^Y3D&G(?>>%Z:#XW I\[(H8V
M&2;"]PV='V>'QMXB7<>U[I0=3M.\#ZW26%W)*151Y+SPF#.D9;0%FEAR*DZ[
M#F7LBD%\JO6D<6%!-6 "CF@S"E#4ITH9*0^P\[*!M_&#"@]!J=QPF?7N39YR
MN?XE6^3F7AWC8TL,3?YXH(9HF"[;IV>JK^SR'';V6I+QP5HJLTXT&F1B6:KH
MU0W^.J_9S;]*]%L8J2+(328H#Y^-C)0\8M-$H\4ETQXX,]*B$9'31I!O!W='
M00"-$<8T/X9O&'T.B_JE\Y1MRT'%SD6?E/)?".8<U3$[HJ&=XLSSL993IZR9
M0^CWB.VNBT:F?-XKZ @,R!(:@I.9!]".H3LEO@6S6XRE$/MYJQ!F2+9DD-$,
M'#(KXS A4XX)\GSRB$[B;XABMFAQ<_H=EG"#@0L@DC&&<S8J3M[MT(4>G)5'
MC#-3TP@QB^!+3BJG@#7#PSM)D%+&/Q/V3E[_5U^D2L#=VWE!H%]0X$_+]@(O
MC@"[@!;ZJ3?>'KH>K<73@+<WJ)=0D<L FZ]W,UM'=<;I@@/$]A)O]+4MP:N+
M?P&R91S WQ4.RS;Y2+?4Z-?WKZ&>4K:'$=&L,+,X-DL5E>A?D#@ 8;(#^_5V
M26H"LO:IJZR"&DTR_12\$Q_%V>]#D7Z9EE9%[:U7%BD\$#Z@TI_6-B8L< =[
MO:V[U+18W($:>R_(^J*@_2ALM(%1[2Z?2',V,P-"2F3 2HHH_[D!EP[>9H'1
M1RO>FI13%T-&T8XGD5:K.X(Y&<M)1A6J#7:7Z]1.&].Z>CD*U<A)QUB"%4R'
ME(S(4H<%5G7ML'\VVELTZ(]I58,[9E[33X&HS=WURQ983S7=40290G3TQ9"I
M$_DEZ;U3_7XX^M(31!M>)$3H<V"W\A"3LS9(\+!M<U^/IA\7QIBQ8XQ5FWB;
M0$93HF&MS1B1ASZV_8AY_<@*(H@"BA:L^W&YD?KX8#%0FZ@&;K_4ZQ)BS2+2
MZQUHNZ@1?A-WFFTWX_R1<M!BZ<L@KT]'Z9%<%+2!HZO ,8 7F9TCAB3J0)F!
MI3K;ABXW^3:(3*QV"\,C!_Z^9;@]A$\IB]W;@F""*<;Y@X?#D43XB>@\888R
MLMAA;K BZ^V"&7TK_?X<XEA D![UQAZ!NC \X$=P:3M!ICE7DL"A:&-U.@<O
MO&O#Z?J-5+$/BHJ*L$F*6S H\0M(*;2#674^TIG,JR#D-&TL\X3LJPW8"-8=
M(QQT/D10)FLBPY3Q%:2CI3?QKGV0-P3&9TV4=[8JHZ!(/,Y:34T9;;(S96'*
MF"!G@]#EV"9G4T981AV7GN"C*QAA<O8-C?Z4<OH6;0<APK'"N/C.\LH/I;>0
M=HUVCHSK^G3KV*O^.VV+# 5_LDTM\V&"DL/(H%/"LD3 G]L%'F'\/#&_KO[@
ME"Q;(<W+O+4NEK\F<I&R"E2:.5OY)&*Z^5ZCGZT]F[8Z4-#UY3*2UB7+=;WN
M!QTGCV A65RFGC6(RLUDVC7%Y<6M-$%F=**!P(M4H$R^+A^#?![1F*D.3_2
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M$+T##APP(Y:O4C90^^W!OL332ZV$\(?PNBJ^&;[I8(!&6N.!;$]8E6+6694
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MUY55$^6E("6J?%12_ODCJ<KN61S03["N[]N6W(M:O_$-4M &$[1K  < 9^V
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M\QLL2"=,):]>4!;:=<FS\E*M]C]=@CXL!]]=EP?;=HMDVE6L[\\4@?57G;\
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M!?^VSK!KAV90H=;_Z=.E#1N9:5(O1-OET\6M$U.4Z=?>OR:["3M0E:<_0&#
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MZN#\]/XWX2?VJW1.^]38?)LJP[;7\FB&-Q))!/K?.]7U6;=-]3!# [(:[O!
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M9&\>KSQ^S)_=3ME]UH2V[V7[FT[:G_:'*%F;?EW^I?](Q52MT'])=0S-!SV
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M\&(BF'9+,@U !W*TGCLWKF;K4YCW(QJ0LZ&W36GO#EC$A*KLEX;ZH,5=M+W
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M8\0EIREB9%X\QARBW P.)99EW %6VZEQ_%C "K'ZJV^I.[VWR7K,UDL(*=-
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M JK8':^9/%UM'80H>LYEN)KN=<P0QE?4^#;!H-(6N86,*XX*.S"*?*!-+_W
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M]*QS[A._5V?2"RH[9;4AQ4:'$ 2)9OX$#+X0E;WPNI3[JY#B'6[4S>3]3]
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M!P6UR?.(O$C_?",%E=?NY+"]T*FT&IX_@X/HC#[L(:ZW@,.$ZMO<A/MR\T?
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M11=_;+\C@@4J'-Z%I$OS1O$ 3"[J$>X_#\][%HBD/&,MKL(0WBF/@)[\LT<
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MDV2BDA26G8S\H405[Q5V#X6"L%[?#22<U$R-3\[EV5AQQO-MH3<7+H'#-O#
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MNS*3&".E,]0;(4 OWW-AP2'(XP_L$P,3TQ2J[$EH^6\G,MK9QE",-%]4Y&^
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M23UP%0NKESA4,>;A$V?92Z?B(^+7 BG*M!$1B(@6O2L<#)80$%M#F>B!4 [
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MYPS\1RI'.MOR&U]B>U>/!,NB>'D;J@BMDH3/<*J\#+7'R=:749N5*+-&)B&
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M]JR[=/>MS^KI](._H?(IPZF[UK/BQ[_.;][XY7%::J\?/8<7)W*YQ@7KO'H
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M18F5-#6.H3\$1]2.DJ)1JR[5Z$+/W/V>_:WPP1=0P!P^[(P0N(Y:P!/!#!!
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M-4;G<:RP?I8^SK6TKH@Y6N<G?5X]1\=(,\9A TM[:]S2WK^O6;0<H3DT@T
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M&U=/P#R)0@FW626EHIK6UH:HD61U4N9C$YUN81-<:I,! 2G1NF1(4 >8SG-
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M;D(.(R&THJYH6YMT.AIE4'V&C68$I$AL2*977CF*TGVOGRCC^X&)DSP;6TM
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M. D49Y@I6!3<F-JI'3$X5=8X)+3S4L82#O!$;SE'S0^QU5H3Q37E&> I8H2
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MB,L5Y,8>PJ1;(KH3!,,I4*EF^?:0C3_B(C.YI5G%FQQ&EY9RD4Y[:2(;AVE
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M#[^.YAE!P F'?]"2 ?&3,>&FBEC(CB>>,@UNV#*;]+TD!&(# $D:HN A0'$
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M$',3=&#;!WV3UFOMB1Q';4G7*NY<LR=+KMT'^5ZBV8&KORNYY\ 5^8LV>N-
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MV> A8J64EN,CRM07'Z*M743O\E]E^[SO'9:WFV*>,M<UYK4T2TT*YEAC"2Z
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M#,!1W\":! !Z#NGX@+, K(.A@S4 J1P$;@.UE-< 8!^\!Y ?S0"0@$.Y@U'
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MKTT#W4YEFY2D ]AZ0"=JT#FO&Y8!'R[PW\S(]\V>>+-OL%]Q )AG&OCPI>@
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M ;)6Z8Q5M]WDLOTNK;<.M+%?HX&CJFJC'WW$ONGII1N).S@+T5H@X(6BC $
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MW&BYP9EB^D[;!M5?+EQ=3S(D,"T4;LP17DOW6',%O^)CZVA(K,*8N8C"&$X
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MG;Y;;RA!%WZIT8 $%[_K@U*%M6]$36MP)61^%PTEU4JA""6!J44!3[/3GX7
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M8_*RI^(<[QRW@R=Y-U.,ZP:NR^BGLIO@)UGD%'7X6R$:0H4&*$ 1R>$HR]/
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MJVO&&&KD6/IV&>KA5FP,GN9[OWPC\D.%<H3_IO63)]BA#E^DEUPN7Z!UNMU
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MYH;KA;/:-[63H$[ K>[6L3@>\>*$6NT8DU,[N2Z>CQ7N+V/.YF^7W"C7NR$
M4F%3:^"KY9?X3F.LQ-B^"C_?S(9 OR]/&@7T_5I1^Z$&+BRTWZXI']@MH<2$
M6G%WEQ;'6.^2)_P!4F]FO31]=B,RR,%\!QHG)J/8GZ&HB<%TC?S@\@P7BN*_
MT9\6J[2ON=^X^ IMV<63G\(Z3%#$K<+Y@\B ZO^>CJN&9#_T0U<U^6.?,J1Z
MKI)9Q<->I[X$@$T:( R(,R?CE1?C[0SR3Y%@?CIURCEW=LIVULOF?A/A[#W]
M!YAW'\ZU:52.YXT5^ .4QOP!OL:<.*XNG]3\ =IWLP6EHNYH<AO] <RX_@ &
M7#L+@[V[#G^ #W,/C9U8M9!/:JZ:E:\JE&<[TN)^SN'O[\U!M8NRV:XFD_(5
M/BI[=.,=$;PO^::?&PV/WMY^V7@2D%@[SCY%0PD7J-$)ZPK*QND$9!90Z;1O
M_?KR#9/;]^H\N1)*IQ>"\5F]O5XG^4PAI($ZL>Z'XY <T]HZ=T#RP)HWNW0E
MAL#'_$E7,%K. ;W_A!"#*S][NK$Z_$VIS_-E<''",^TAZ2 U=H[A#K?NVQ.X
M))BJ_S8COX/;=.1UVSDF:":;>UZ8=YO]UK.RZHO'TXP&P3@=MZE#P1)4ZNKT
MHV]9.8*$EI$N5N+"J85IQ%4-%2J\V\&N/]4TLDZ_I,C6T1=KT J"54)TU,UT
M=15TN>-'1K41#Q!ZUN+2 HD*+V]_>3DO(9"M[[AAK"_[NK 9Q2C%5V2S9+G7
MIK<>92D/?#1GN>'516'/.+-]W85NO()\ E7ZVU^WTVZDHE%#7Z7DYH5+^4JC
M86&VU;7$*08-PX_UL<83P^I/"I/<OAHRV>BD(8M0/&[CW-M%FS9]M[AQT?D+
MX>G@^'(MBONIE13A;0^GVJ?R4Z3S<7<MXJ57A8\[3WJ,>UA/JNK*/D$CHLOW
MD)J:+^"%?/=6:/5A<?9(1=(\$6PO ]RS@W85;D'I\M7"E'&]TG$@06F/<F)C
ML6TL9Q'YT]!K<6I&QKJ[B;R#F,_;X1FVJ"NSSFTQNXS2+K[ZF;&*DFY\YT!"
M>U&<AF3J/.7@O8+E_(WG-T75%.&O7N&>NP6R=!BQ,L@]$W\FIP26X!5@N<U_
M^_"(HA3Q.9+52T5BX<8^]6R>^'+7][1TC<'"&2H:G^3P&P>Z0YKABB'=SY]I
M<U@]HLJ!6\2:VDO8#EA'-!@)N)C+QIC/>INZQ84&Q>==']L/?XNFL-6;S;%&
M2<D4]'Y-[-<>O1DT5MQ+B+7W0M!@/B8H:QI?3]$1X[=.\-F8.%_XIG*]X.Y#
MWE7&*2Y!%FV1(N^5(I_:*I_N\NY;5N*#-S!U+B6QZ4U#5.C^K>].SO6\'Q=N
M^M!(9'RU$K/HX,:9H$_595*7M 3>=/!,4O+7\3=$>@I%D8T)E(;84VS-!KQ_
MFW<WSXOD!Y3]:W*8SO#RY#-CT'6U/X AO?:NR<9,E5G1A\@B4M,-LE[AE<=%
M^B_9:8>X;A3%47_;V$Q^'1;W0^[[$P,NDQL$,S.2% TADJ1O!.QZ"-O/>%B4
MIO@%$\.V+2.#,R(2DN!IW&/3\;/'8'N=1?*:M+@F5V7?WS<7][_6Q-OI*M=*
M9GC;U]6,S9L>GSD?Y?\_[+UE5!SMM@;8!$GP ,'=G01W$IS&71H(P>FFT<8M
M!/?@TEAP:-P:"^[N[AXT2(($2.8[YYXS]]Q[SJPU:];\F!_SLU;56U6KUI9G
M[^?9;R'+N(L>6TK9]-M0#/-*C4CRKS85G;,5M+N=R"FTU-ME0H;'O#_8F<!F
M'MU?&4Z0O[J6%W Z%3.71:?<RSL-UI%5M75W4X\]DQA;*JR[D=WP>"=DN29$
M82!N%&+AVDV5(.)AJF$]KKMT//8LIRZO!AFG>2.":=&;'YUN;^SZ;M62RL3A
M&W6V$A/87NG;C\C^<4[75^<\A%G2VE4FRA;1^G7:07XD6+K*YEN&?N\T5J[B
M"$Y=?*,M?$$F.PNGS:<-B;).T%.NUU-M+)F">1-XSG9X'K)V@3P.K8?B/(K#
M)'\ BT-_  M*#\TE_PQ"H7J#!/N8>]$?3_8^GC#YKXFV2)[] 5RT?5.)8QPA
M^M<E_Q4#MSVGTJ@4D[F[;9+=\D192*!!#"BBL%&)?/HO@6IL$5;/G2<2@.C%
M$V@T:"]ALXS]*,]E\/7MCUX6_6M6G-;Y*RO^^K4>9SY)+84C#[TU0]F(N:5>
MW%YT_UM>Q&J4/F;J9'M]+,.FQ[U& ,[=87DZW;CH)FYL"BBO_.WS_ 3THN)!
MP;WS@6-5LKX#6_*Y3TN"3//_0WC^/PXXI#IQIE-(,@ .0N:XUUQ)0('N'WPQ
MMN:=X3-_ )4 ]_AWU\L6"[\QWW:Q&EN]8/(:4''?YXE_JGCS!\#,\ <0_,K#
MWW,_Y2TMZPE'&V':E5< =ZZ,MTKA6WN<M\-*G5N]]2>=7&5W]V^-Q/__L_]?
M.KNDV9>8T;+.YZI"+^:3G\<4I)QJA,561H63*C/*HXEIE0ATX:I3!A#^[>_I
M8%(74M$KG?:]EN_Y1;"L74_1 3H@TP%0++&T *5V" # B@P$& H\7P)@O,.V
MPI#6KZTV O_#PN2=JCX.1'V&-_SE5PM/G;CY>P'?GXS;*9_<ZXHV#K?1C>E^
M$IHED_ZD)YG_+T"8T>DC==$MZ>^NO[#^JZKY_AMMI1U#_1GYPA_ :3GT9N*.
M]Q?6_RO&7WH2:C9]@P@MK]+K#I!5F7[%+7&B.Z^'FKS+()0J9!56];YF8\9H
M7,ABB.4#,R\ZO$CKFB2#G95-(+^D'8UP7H-8 L<M28/1(DKH^/!K6 -N+W^&
M$, D$< ,@MN5;2=ZYS!&D8@!:<XH!IZ9J%_'#P& H@ @RH?@3FO[8+AGV FP
MWT%1=^%T(>RF0[?A#.VK0Z/)CU^5,\EN_G:>[,-!Z4[^H!G=J+)%>O4B6SOI
M?66ED0]D;D4#1U_3^W,C],P3^K&/2Y>IDIKJ&"Q1K>UIQM-&#IXG,CGT.BKX
MABY\N0K'<< 58KAG=A TWK/B.6"&K7U;NVDF45ALR3]UCZRA<T.4A*D/O<9<
M\ZEN]OC=I3\OJ7"B4//%I0+3K>EG-B6_#NRX(+YIDB&J,;*1]UB72GH]7SMD
MMBT!EL7LR:[P(6J-E'COH8SCY$/DIZL-;(U7W>=Q$W015CS/%B9Y&DUI7H?M
MFB:H 04^PQ@Q['NYY&/C4X-P*NQ::FO&]GV-]!_U+F=[2S"*M#&K!55OB.4#
M+&.2)3OSCA2/KSK*AJS9ZG-,*,O@+A3]\H("\5;%W&[.&83D+J),.:Z1+$R\
MSF.D+_M;9H&4HJ6HWD<'*?'2Y-[U%$=6]&V.8H)-'E< NO*[,&[YL!>ANI\/
M69K#R K\9I4H,Z,-N]1'%1Q=:HY8F9T0>,/5F&>I-C.;%#;%Y3PIK_W2YL:1
MW4&+4]]_2OIKE>=EFN3PH%@JI&>WS)>/8%O*1HW4T%A+\[O(D:"/%+M'6.DD
MT+*Z*.K-:PU3Z<YHO<C685:][$>S\!2,I_'9KSY<NXE "B$CURWM\0=KME74
M#*@2=17UCRC5AQA\#[Q#J_P6(\+:OXZ"=EF6'(<:JUU\:\S(A43[2T)OX4;[
M&XT: ZCY<OI 09YIL7#6L+(CO<:"==#5RIXO:( #%%LR-5%<:U*3\VBI[2,T
M:SSNHJMM5*M.!%K<44V)"=E68ZD9NJ 8O,XGD1L4$)$R*A2*_+*\)=K=_24E
M:55941C?S<FM@,CY59#06OO7Y90KT2INKC@6[!&E-DQ<[A4ZKK)8BZ5_]QI=
M?_)\V\V<D<_K9B)/N;7D\[\W,CG]^U72'NAJP:[0WE#5W>I.CIH8XN1_KM#_
M?6@[$A43,*+S^S6K\?4=^ 8#:=S1>4V]/[+1\KB3YIL;(N4.^O*/"/"*(_7\
MKWKEDC_@A_]V$*>]XY.!\>,/_(4& J.;F)./-WI(7UOG9=LOY1FO./_ON;K4
MP(4<"LK<<_J9E_^7%WZ]]##_CFZFN=YFWRMH:NF55N&E;%<PWIY6=C"X DG]
M"G2'+.QNC")34R[W:_JX5>?$L:_Y( O;RGE#_=%$0R-9A4R85J_Q;A/=X@=5
MM"+ZC<-EHZ2T%!5&5DJW!&I%^.L@Z8,.HM= RK$W1E\$SK(+7&?[KG(0BG/=
MTMS,?LWV%H+N&H7%J39SRM@/-!GGUO"E]!M,&[3$[1HN;O<^#Z:[UI+30W.'
MG1V1:?<ZPCN=@JJ'GI1&<92QY,I!#V.0P7SP,^. )['(T=)5=5<WA\(<T@0.
M9VAIOSUTFS=2;ABQKT[,;,:YK+Z<)UF?&ANH<'$/7EJBBSS/3KT1AC;.U!8_
MN)RVR;QR=2*R%F;.%<]/]FCE*$F3#*V=V.6:J9%Y^,2HDL4("PTV\S@W.EH:
M0"J=FF&<>LY<S^%&GG\G/!K="8YHRS6HE!NS0(0=)IK*C6S<G'[SEA/@G];M
M+9 7V9B!U(%6])(/Q9B.6%PT35;4M>8HUDQ_Z+HTSVP/-C:\FA;H&"MF$6Z)
MM6,^A^MWR&QA9V%[1"ZC.[XA0V<A&1DIH^#@'(1R0IB='3:U3F/L-W90C7&<
MH.9-RV"\Y<;Q7P<[R_!=$Y[QHDB6]4NRU=YK?_^NS)B%A1\L'_++S^\<.<HJ
M:7.,S_+TPOUG6*7>LG*%JE SH7,H1$G.]?$#]X*8^9PNFF:[AXXW/N*[^VX-
M9"Z_"KWJD8UQ5AC4)7-X8XF[LD")YVOS>RZXL"]#8JV\\.4B,D(M1+SV6)8!
M?D:H?!B!UA31OHC6QC].:FCS N'%V_#]*<'Q9:5:E]'[VJ7HQ9[YZQVAU9G;
MU''0,0$S@>L*!X>',EY+10FR,!]<8 MO+=[02<Z;SM>U+BY=PO%0,*FCLO?V
MN/0IO<#11Z"@GI36BG%)Y8/$6C/&YB;C9"5>WDC##JC&8EC-;U?BW@W:4=GW
M'.7&;B=?DV<H&H0O&$A3ZW%+,)"OW-UGV+P!+'V6I.Q?6\^4S/Q@6\=MFM#\
MW! R,Z5W([1)X+."Q=*Z)5[[(VAGH5=>>^0L#3]YM=V_GY;@>XJX*;=.,MYM
MU-?"N)(C\#+[C]G7YL4)">M)_)DBE"G&ZISFY5%U,(4_@ \#E[-H$C^"BCL4
MI,/,3V.OY#S8Z9*!+*M#T,0DATK>(Q:!Q)E1X N$'='6'5MI<C]Y4.3GS)=5
MB0J#S+EZ O()IS4.?$+189FOWU&QN:!-]IOAZ0='>+ PS_4Z+!1,Z\[,5G$H
M@RICK0;9WGV;%]M1IFO<IW>3JQ6SOBI6V1R.9C89)AQS+GD=VL]&&V9![(;O
ME3!7+R;EDM]]5@,SJX?5-\S,&,/J@*1"K:<UQPL[ @+S%>:QC03/KQV%N=Q'
M358#49$F,ZB!I,]N2 V7 \09?CQE[F!NAHUHA$VPB$0U)X_7E9PW&C&'%'Y;
MR29^K387-U')O=>F]&0ZRY,#'.<WAWSB$-K7SLD>!C )RD0F$^::RP=*586F
MAS2'48=W<ZL<F9\>6<?.#%."#DE291EE,>:CL[8M%AT,#;,HOCHDSU?GQ85U
M(.V.EK58S?M?Q<9^AL&GSEH* A9]<.&SSML6:ET=)(HQY9C^(M"2YBK;"L(I
MI/<E?W?Y^W-$:BL61,M4XM>V:J?@O*VX**J.]D+30%$I;CKU*T8M7NNL2.U$
M?*;ABY,W4<=<,JK<E^3'2X84(YI']].,E$R.$;QMZGB6*R?0<.SXK1></$E$
M!>5Y-@S+<@+5>,P_T6NNK3^[.4$S'9?!]BN*2+H]:;J@6N0/#\-FFX9R,NR2
M%<?L.ULSL%+G3U,]BR.T^5!A!ZAV>$O9%4\EI*5[/Z2'O1$[2AN,SL_JY<[;
MR!"N?I$"B/=^P))2V1%TB!_Z!2%%ED[U$T.+R3DXY?RVBT,K+;_3@0%IJ<)V
M80X.)CA855J:.J*?8DHK+,M"K1)G%)CCL&2>/FFQOS8G2'(50ET#"57628M&
MNC?'-^@[A:]$1Q[W%,=#S\1E\YKYYV+1U ]>OWH8?J%6PF*A:IC&'S22?JA0
MJ&J%LS=4:0GG&Q,)&DM?%A1H]C<U]?.":CTM,DT$9WHO+R6$KATL3UHI4.Q<
M9P>K*\K7EU45%^4GO4S5:+&,4+6R6UFQ#%Q:(G<@QX:3\;4XMU!4R)7X<IA(
M(AH>I==.PH$;G$Q'O0P0<H>9AD7M&+E9=\+\UD(6L=E22W.[ %\';^QX2-\0
M>T^D#]N5"2OA^U$P$[.6U(JZZF(4 LN.N:#"D<GVU;QNO>B/PIE$CN ]-RC,
METJ@5;9&VJGA-=VGRL_) @IP9+X7HHSZ';W@JWE>C#D4'<<!+DN:F\XZS.68
MYQN_UP0,"PRL5<([>=L.W4]:U2]!GN?49G;'%@?+V)\4&*5]-#O7.JZN7SN
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M\;7@6/N\ ?Y".XI:(_=HLYO_.U..0VYLM>:79YJS$,3+9 -DO1X[D3?6*==
MB3<H5BLV C?'O9[U;4CW 1Q'YOGL=+^I]LZWLJU4*?=B;Y 151#_1LLEJ4,3
ME.09:A;&^*!]E.RK.7Z^?(2RF#/%_4&4.GAME(KJAERRWIB.$F^)?H\Z->O4
MA[*0J^1E$VT0G@"A<\Z@F:;?VTMAOPJ0.K9#Y>K7N+E8]4%P.BWXFJ>RW[;<
MT52Y#E%D^-I\G*59>V[['!O!GHF3;6_,&<G#;N-R=E#Q)9B\>X+ME_=)S3''
M;(RN]HR0X1XB43@*Y-FO06F1JBQ9#J2SMUP9_NXXO+R[4UB9B]F/0;&\75!=
M7DBF2RRH$:6@(SA](S>>ZDW-!"U?9A$9?KW<!A]\CEO5_4!T...F\P= ^E5X
M$H)0 7I7</<TR:T7RR_^^KK#D^ M:Z85A<#VU-;2JPS(:%EOYT]B,& W9?_.
M,*,>LW=$7)&N6Y5!@8O/WE>O&&KQK%@,(?:- Y=S51:#EI$:K4<L8C_LV8%(
MXWYJDMW&'D[8;)-)-F_?HW+(; <<$6<GSAQ6!_FVMKS#]^ZN"#YAQX6W\MD*
MNJ?NN.RDW4A4>;>]&6E/Z\(9918YT,%5SC-BE5JW9[H8#CK]354UB>.I]K3<
MD8C\874PQ^'0FT]XY#HMHI.<2?GJ\P^@*L\(;30T@XA=[B=O7?3+WA/P=A)N
M "D^B[R:)"<EH+JHKZS LJ@T=1I95'4HE,F4J&29WIXO65FRF>E;SE9^Q)HJ
M=K/#=Q5>>\SQ_GX<5QY==FUI*R)#-%PX$Q?&:.^QLP3+H@!U\1&/C%_R]Z K
MNLTL&&#D%IC>I195N1?P'=8N?IZ7_6DRXK#9(GQU=EEM-(N@R-PKR&KVV;;V
M.>9.3B*1$%'1GU36^482+3K6IQ&X,B9.')<R-3O,[WP$1H3R;UFY]/WN+\DK
MZMZ)EQRPV2'+E)NDKW 28/$-6_(FKRKJ>[/,@9;$QVHP*/G:BL]VZ)YRF7]!
M=Z=N (2F7M ['/DE33SK8(FV#H3OX4=N)H[B4>D#40S?@=A (*,"4W-O9O2R
M61X4YBI4.4MM*!(#G;47?J=P-#HTZA$>3&H*?!U=EQY+44@OMDA+K0EJ/GT?
MU9I:./K>TB_E,]S1@]Q(P"FA7DITA:KGG9N.X&5[!C3!W&,IIQR[O*"LA& :
MDY*:TSP\,Y6U[Z:F9YC>8[2+N4[NH+V*M)GEABXTK19A+/"?"U&2:9]7<1'Z
M2!$"AD(\]E=YH/2)U992I8J,V3*ZB3GKS :1)%8>QP6PS9D-U0N\6FX7>_A!
MIFBA:,DGC*V[",V#<('&GC-G;KIOTB1T/T,_3%]D]A9\Q#^XJ(J:TP'?^4H2
M#NPZF%OLO=K[9L+!#]DO*R9XSR,Y+J_D734 X$$A9E$%T&GLNF2YJ$K/]Q()
M:E-<R(8"E_\R#UH!_,;EYAB,N%OUK 6RWE)Y\MY^ 8N(H%F-39B5Z(&,8'OT
ML,NDGIF^D,_R&C9HW^J$0[3HU[SX+-#NEH/9D"TE6X\O(GEXAE^# S:LPR&W
M5Z!L] $4B8,)C!?W?R[$4%X65-08/W:CQR?+:4.R2BB2:);.L->\L>O3SBU
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M;$&$(@EM9.U/ 1YQ^<FTKS!3JAG1"=^]I7C2S+#&%BZG'>W$'85U$QKV7$@
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M_$]DT70KOBNO.*[\T2FS\@\@<#=9?]+S@KHZ>LX-87H>\%(/@:_%?"_]49M
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MRMDM.1C!SXY! 3X-(7PMV2I#5^N"<BK0'<*A+7LFA/Q8 [\J/1?B4!7S@ "
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M20)P;%,7F>")C@:R@1LQP[T/4H%,R38YWB',J4;6*.3%</.7F-;) #DY.0
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MV<+5CG/LW(JSDS(%ZLED,PGW;!NKF88+$\$CNLG+K' @!EC.&@77GA4N2BD
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MI=MMM),RZ#W?5;'<- %4L]GY4"#NT;++_ES"G^PI 1RD_FM?)G(]Y<W^I.D
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M[2CW;Z6M%0P:$TJ/*SH^+M-ND'S%OG\9M]=^,VZKM^D+16]X9L&C)OO5[!V
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MXQ:2FW I$H+I9OVS##K%!^_SCYU^*'?])*+_!?"J,J%_3'F5(/Q5A_P7P+9
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M7^LDM'$J!:<(RX\4/'K5NG]N5+/>N1CQ8M;,LE2"I3PI=AJ,2C0%/-MZB#K
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MV<I#1IZ*BRC,O>D,D$H\(KE^NN>SYN'6?R-";E<Y$;=XA?*5=">1XBTJ/^Z
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MOK;#9#BP81]B0L+)^B<!%T-*"G#(60-\,W#[A$F%;Z++!]UCC#MN1E4(N[%
MSB[,G8Z./T]&Q@N74DXP]U/_)X[HO9^YX+FS"J/EP)==OL'4G0>_ -;U]]2&
MSX(7Z\*Y?DA @MN%H6M;$D1_Q-*#B0D.^!\C?081K:_&KEX67G?Z/,8*@WX!
M>G;@#S.1SM_R7Y@'<Y4_EO^.CG-CR@M69Z+;#K3](%?*7P#S<8+/YW=V/Z\V
M_B>*?\>FYXDQ9<_OT%QB"W'V!6V\F9#(!"\[4QP;U2#47COHSSW]7'_%2''C
M8+<'U_+P@]9?XOL?3%' R&1181G?:'J2X8+N_>[*608")%!:G2Y*;2\K%2??
M 'U-,/\H-N#M^1+5.@5R#M*3=3Q46>/0T(C,725[(,2/8GI @H0N^M2,)BV=
MIY*QI*$D5('AB6RG[@UW&N1OT+WUKX@89X0<QS4?LL#K4+,TNR3Q1CI/9?YI
M=9;DYW"(XL[S(;':">:XS#2[UZ:=;S%,2A&(XLQ4_E1\T*QLP]B$.MM&EGAI
M"W0Q3>B/]G7.@&.S496'FDQX@K:BL@'R005+045INDT.'!$ALO'>["0IVTUI
M@6<%V\%XK30WO5Y8[ZTVEB#G,-8-=#DA(JIT(/B%HU/ OT/F<Q,D;Z>%[Z?:
M>O"#-O8Q@5^XOKJYJ,//7G#P5,>VZ%_&J?UE&/XHZW  KH%:?IR_R[W0^5??
M/T(+>^MWR+C\/6107A!:(3O(.R'_&"C]!2@V6WO%(O;JOZ]':* V16!%2PN;
M3LD54E4(?)P\(-$GAS "W\SKBWI(/3$'##TH,KYOS*9?'F%OZ03(M=9VM.$D
MU>G.:^N,SC]?X3"2:< 3Y-X3EEL8O6WF%CEUM16E'7=K&#)@%9-XAQ4_N7&E
ME<(C(<VV60R/R1(:ALQG4@SJ];>^GN>!;1,3-11D\T/*XF0S_BPY$EA9/1Y8
MU+=ZMH]\UL7U8Y;>W'\=];JO/-JJ_5\ QT4NT=FWQ6=24I,KH8UI_R5ZH?$O
MCZ!, K:_4Z;B_7-72WTL6*[&1JA'G$Q$R82\8LB7M=L&4Y:RP4 NN>@^"-'6
M? @CAUYJNW_8$)Q_$Y=54%$AK]21N%[!<)Y8R+'^F3#OEFU#2;U(I^%;PTG5
M$!IKA/>D0RR "U.4MK<!-O_[*2#U%60_D3:4'$4N.G+O<T,$VEM_H2D?V; X
M(&*5ZUZS3^O[H&Q6GOW.SZ$<N@/: Y5RBCSE;UV8BDJ:[!?2NF"^F#Z\^<*,
MJ6#[B<99.K5P<L'T2A,8R@I<,N'P8O>J%)B2DL?PG([VEBYQ4NF;.9&1Y^\7
M%A9V%!D_TX$F$%8D-=1J3\L,[A^:R,E2O-=6N=OB.<$E1VQBQEHK7T(#O!V5
ME^=O1_("CF&N>4,*FM>#U:W8!(\FSM15JP,SWM#F,JP2IQUR0TKGBL.\=MK*
M2LEIU7I,2"K8"N21,ZV09WFIML*709%"8)#P7J\D>003D<F@C3N]K-1,OV>3
MA:2)XDHL[%&51T>)XS34GEMG8;\VC"%2(RLX>P;5HP;['I3Z04E@NTS)IO/O
MR<V23Q+;:!V:[#=_"!69V2)0AT.,>B^L"PVM5C>-HPJ7/\1W-#<A!;3S]9B7
M"@AXO*O5L*"9'8^;';FP#[_NDK!CF6(R=)#N+E!GL5X]]2[7E6,9H;<MZ8'G
MSM7-S#0DFS^1PM?S'N0(3,K8LKLQ*IK<?>(.;ZJ?$M@-@K\'&Q%PE$3XK>[O
M*ZM 73%01.*\5P8IUD*6W#ZV+_,E?*$:JK1M%7@=\T@KQ!JK;;B2->?5AEC9
M9SU!4%8!+_/2TLMTZ=6WL\Z;6'0Z!GGID^KG.$X)[IS!6E$I]<31R\"?UG9O
MWV;9A1'B1&]YGHO/&45@)(5Z&RRA<._5(V?3VL9W[=%L$;S6*V(R?1DU@E**
MAL+'#R:KI?=[LI?Q='.=/ZTE9'6=0^?&>/@E!ER38.U-:M5=I44Y\W+,0:%:
M<M\JGW'RDI*B +"HH .J\E-FN(&Q2%Y ;363T&QUE*Y  YP(9LE3=(2X"3UD
M]\I<@-,UGPWP>Y9D+2)3ZK,DRLL,G.C/.>^NJ@#[7_AU=^^^LVFZHIAAPJQ@
M3V9AE21XGXZN\.[%X>KD2HS9N.#T8N3M"M(*T^H9]B<3K86'J [6?73_Q/31
MTDYX(63_MK"4U7IO).870'MR]MJ3$V&_D#JXGTFRAON*R(AS%L*;7FV56UHG
ML#6H6_2<+NL'$Y#B%4:>HD)Y%5^KSF4-$.B[F:<@J*)BE^\$C;NL;K'U#:3-
M=F28DX\>TC>*ZA[LV"O&:13R<!>X'&+@&:MG\,-%%:FF6'&DV#T>-OJX_C1<
M>XGTT_8BL/P0OP=056D[_K+Z,W:#.'J7UJQ K 5&FA2TWO,L-9612[I:)Z#!
M1P-D6SDF6"KWA*7;?KDR]?4"J88I3*2RDWDLT!..5P\VFQ684OE>'#WM[;!!
MA#O$C90HSU;.0+%5PB-S/I]NS4,9/R<8?2T>XF=1]:$XC4GA3I_:7-#"@YZ6
M(;,D2G+ $16-P<QM:7!7'EL,-+TJ6;^&OA'?_9[NZ]09G:P +VLF?I]E:_+K
M&=YW1X<=N9)VPRRH2C5=;-UM[DEVYK6P(@.#(T4FE%0R?H4&X0A2#F1$88 5
MW^C(4 -Y)KZ5QS%-C#R ,5"5G1"%7)XO%ZLF7=1&-DI>;S@ZRP*G]TC>#AGF
MZ>0T.LT==)*,LP40&<)Q;*KK)(EW;J--][NJHJRR"C:S709'5G&ES%;.TSZF
M[0-?K>Y&HLS?U+82/#?REY5%GU-OP'5#D%$N;@8BY@08KNIBPI[G6FNS[S&S
MV6F^G>9>F $OJ'*\(:#W<J!663S(FQ'CG[EA+_(9W%)G/_DL2A!X)!WKE A<
M#K0OE9+5%*!PTS2W.BD.L*>X6]Y :<"Y49$CJBGR+72CF$WVL'Q[M"NKVMU$
M)21QTN$Z/A/ WD#IG-W<4WOFD]4SZWVQT[J B*=+LX =^D.CJY>I;958O 1
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M276I"+67[V#>AJIY9Z4IV-,&3CD)F7UKKVYC8"PAGZ,8/ORSPQQ;Q:H;,\Z
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M=?D-A78$'/\?76\=UU83K8V&HL6*6X#B#L6"0Z&X2W!W"Q8"M%A;:'%((4"
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M:7&+1E)\JN>[L[.;,C-U*BQMHG&S%^E" UOU4G<FN49IZ47UV;#C+TWN._N
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M69A._H.M04[QV7[POQSG+?_%<<[W7QSG4YL5=S.J1:U=F?\#OJ'Z3B/X_9W
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M]Y/8'/Y6$CD] /G<]RB_)R)\N$@AS_>7[8M$Z:H_ %C=EWFN]ND2>^#OY#^
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M$SS9E,7-FISMC:#A2^. +3)+X&B/2%[%&J&\T$*(@=$A(\!$OU#C'D!)D U
MR49/05#Z4FZTWD@+D-ZYE^:[MM_Y_9>TG9/-\PEZ_&7^J6BUF..CN3-IN1)U
MK9F6P:?N)S^<-Q9H!1&+9)XY<\O>.1-EKD;H2;&S/O$X*G!&?7JB$51QX.(1
MNF(/+J&WNH$U&?GAN2GY1<4*KX5R8"FN PNXX'[%S)*N+<SVTN_1=-]8,L]3
ME<;C[%4P6R)C62E*ACMMH*6&NJ-[\2;*LZLF/&D#:'9KV)C^(:6H]L2; ^T
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MFNP#"PO-FDQ=I;J">Z+@7'N3-:F! .RC%W6?&7\^#IAV6!7T>%IYY?6C+5X
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M^WK-K0<V-$\MO1Y/_JIOXI)$1E&[M22UCZ\JE.A]'.P],'W%&AX8TI9 #M/
MY+K_&..'5C\G%@B34PA2%RT<<$5:,9KK"1\4KT9\(/)F>?BQE$QL1:8CSK%5
M/YQ?8*?OBU651Q6F;Z(!M:&8-LB<\7OBW%V_??M@/ZK1@\NM;P\)@G_.;0B0
M22NU]5Z:&H^B OL95H/*F?)(^?WO,64)J9O,)[)81?79!.U12]8*P]CEH$8U
M7-@T=NKDJQRN=HJ&V+$5AU'YD24EYH?,D/.;YD$V2#RD-GR9D#2JH1W/SG[
M.:AZ7Y0T(CF+MB_^LRUVE'5>*H\(3S97%B&^M&_K31]WM^\JST7'^>JJ]+F%
MJV]-YR[+<DQ2?6D;?O&@KW]/LP*0CS K5$>T,+"%-IVDREO"K"IST"4,.Y^H
MD=:\%,C)&O:#Z:.!A?-NKJ^OO@;YA$FJ3YM?632ZRXS4L6&U*M:\8PG(/AG
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M5W7LOOWLM<^N$/>PU3;1HB$[W(T-'@O?K53>]?:\]!;7#?[3::EJVS<'G].
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MY4 47'%IC 8F91#K(!(&D0^FM[YEEA=G-(OP0/TVSNC+A#>8RN)D%6AR71G
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MTXRW6-JND=47"7AY!E,0X34,AL.I1F./ZY(;JRO[BQJ'ER<;/K;<;4!ZL3(
MMQ7R,,EE]7'Z>IE9$&L=^*'W5CVAR1JD^LP(VN6J1E+6>IS')*(%+(_YBIFD
M&-%EG3")Z9A7NKVYB,/(JR+=(L6ABDP.$K)G*+D!.$6R'UP4%,]L3Z4%-196
MK9KJ-T=>6 ]/6@ ;6SJ_5X5I[I/^;AJJQ@--,J8Q@==41V:(0Q#X06"!N&6I
M)*#/C1$C>RH$ZG2'6-*4-Z> U[6=BI71&03^V1OZ8R=Q8[4K X('(-A28?SB
M86'P(H;&:! \JP;I[^N.^7& O$=67IPO<W!LR&B6R=3UA/VS-.?06DZ  >VN
MN,#-GJ#@SMCRL<+AZI?]<E@L[B0_2'GXBU$@,^<7&_K%H*S<GI7(VUKNCBV5
M(H%7#VGQ4V/K2IAD46=GQTP #'U743KA1:3NH(>S4]\Y<LAUBT'BGY7@J-[8
MYK4<D1HOYM BB)D1P5^@;4Z3*R;B?/3<^H!'ME*5[_X)ZIRYULZ[ %*ERU%S
MG"X])!+E"\1'W[7XTGSP9%+LV,SNQ3^\@S%RQ<2IPRIMHRJL(CX<U"" BO"0
MO?>SC29S9N3AYN.W?Z99%))%)=31WC+!C]C<$I-?V(%%^>G3?6=_X%RITEW.
MX$X0.=YOF>R[OD>B?E1'V[766M[MLB(3_)0R2[YQI5%WT_E<OR8[]R^7-[W\
M:B<*<NP,%8]KZ-:A1KQRWJG\L,N'&_FLL$L\Q+PHCXS8:+0C<YO]VG/;XG"A
MBE4OE>%"64Y]D@H,U&@W34EF7\X4UTYIX>>WM.5G_O,M"IP1:OYW@U<+>=/*
M:,VX\3R7CY]E6V[GF=:+-5TT:7&B.*\VIZOM:&5W[%E5:41ING$A%7FJUMZH
MF/O218I0$]<AH(G9#Y8*C_O ])=^TGY?YP3SA=;N*S(;P!@4='NX*TIC?>S-
MZ^<MB@]J'#R,'6RX]C(YJ<Q!:KF9DOE"4J1MG(U-YR;X]FN#30>K[2-K6Y=U
M#&6(O#,9]W8:,)18(,G9TB?]+>$X,5]A=9)CB1MIBAJ5.%IGUCTDEJ5FX:3R
MK1*A AV+E4@F*'GJ\$#7-$.89@2<+98'2BP&Y_5H4>>]JO&SUR>I(HP7/-"#
MAW.CR(.)-K@YA=  ^-M2'7QL]1P'3@OII,HPV#KD8>8'+Z]@5HLG#S1UP+F-
M#4G0WL)>FVCS66U&(=3??2&>\(D'0I58[&=9D-$\4(B_/P]TR9BZWR96S0*Y
M[ULE"Z4B1*]%1O) [9%;9XE]3C DMWS"*]*/*SM-XUS1*2XK'2W>APQ3(6*
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MNO) Q^E4$J-OXNX?2S<Y;G#A@6PD)SC^QWX*,R#Q<:E.+P<7(#WQ-UJ3\CZ
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M2B,:WV^NFSOK*%BK"R 45>L GIMWGJ8#*\^T6\HCZJWJ>*"H4[[B^6WMQXG
MF)Y1"AV0GQT4'YFFBEZ#[D[A!& SLIHF=JP&*C;P/2!S *AP2L 3=7+ !1OU
MOM[#_8RM0!"HZDT1'[@7]=B3-#O"=<T=*Q=7W_1@Z$FE\"G!O:9.\O>W5;6#
MCLIJS3'[NA<%E\M.0R60O[H BE!.2"^G;?;<*R-<2@7O'S7A$[RDPJF:M:D^
MD/]0W=;_@WKRT; 1(A:-VN:Y2%<4_%H9.GD!B[T@7IZ7+Y8143!U;_,W:7J
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MXUL2/Y/)Y-RX+376WJBO205L?@-"6$LC\D76.VH8+@BW#V9M&?FE:29I_U>
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M,0\$@S]*!;P<&-&.$RFL"%M1<$C)@<S$^PTC.>-1S@=4 *YT^,YW)Y>!Y[/
MA)G+JGF \Q2W^48=[N&3)0+J&MXQ6CT@GN66]G,BR@Q(I*"CSJ];G+NXB876
M'.-$Z*E$P$F$6X\3[Y-Z'#5XH%=8U7^LA-_SLJ!AXB)!LBXENH-^+RYK$A=P
MA?_8U"$\XT4]#S1R"[+U!TMD1?@%A->G] !3VH[2=  L84\>B% HDCWA5-@A
MC<!IJ\4G\D"?"7IZ.C_F%.!9;]"$P@/)81/*#VV26UF\NIQ](1MX^OJ.!D@B
M-AY=T*;)KOHH[H9-Z&O59OFT IFTL5U#*4"O8?EK.%,:RNY8H5>55^:Q8D3?
M5]6/' :,#@Z("P_;G='3,R*DK];LV_=[2BT:3+P:V=@+[)@'%UKA[Q7WA!<5
MK0-,B.@32O1' (3L(<V%P/?YNP#U5]@+7X/U9*6AH$@_5VUQ)8#$CITET*P<
M*_JX^R[Q\M*\N37Y;!ZHI-5J5%8WJLT<%!)<MM;G6)1H,0)@/JJUKAIS"E E
MM!\8 ;(]HMR^#+A;G/"4?9\]<=VIJA"8/TM+N/J,?IWDZDS4#Y&Y<;"EA^I2
M@19Z1L<T9- 162<2UDWECQI\718T&P@.JL4GOSEKY88)!DGH_J,QMQ)XMW-W
M%>/[;H#8B8"1O;/)L>+ 3_%'*F &=X "@VOY&=06OV3 -OC#C%)B8T%Y%G1;
M9)-54A1@QV?\-HOBYDGW)U<) J4RU 2(G80Z$$[BAG#X,PUN4X47Y:(6EQ0?
M,+G*>&70O JX'S(4'##=PYS\QY1)Y4!@L!6,^X)9/Z2C$$UE7. Z\T"4(@ "
M_KQA>JV<&0:T:0?HFXB"&AL'M3A7K!I5##=(6#)B01QG0X"!%5!:)94=(S//
MBN(/AD2@12"X5:J..,C49TX&R_B?-%XF>#O=B$U,_]%'%U"ORV(2&\DWGNKN
MG5/=5_F\2%12[$/CV=,7-T!<AW*;Q9XEGY>T[6AYHU=J/A+[Z%'>RLHCRQV>
MR!XP^=J]#FVO.F2P0R#O7'C_K"L$C5G['KU2W:?F;4K,B:[-O4,3^S\%";Z0
M419[*="UH=TE0SGF>/V9PX:BWSK;GRAY/U<P>C&4$*M6(!34ZY2RW=5B2 )^
M>_OKZMMU3PY/U>T"3;R;SC 32 *>6B&HXP_'EN\6.KM%\!-H7E^$%+1K8OOL
M!\X*9,JN[%[=!YTGQVXP)5AGC<0%:];E/FVMHV^=2XJ1$7G:%FC<!#-3^1[2
M&73914X_X0TZ'_X*G"?TUZ;(^'F,_<[WL2,&$X?W:@K]/%LQ1&!@Y7\[^['.
M2;U;N"/R#BNMW][[=.7W7Y]]EGD^\>T(N MI7EL>.+/S]\'@;4O?^+]=\VCI
M_BU+LSGZ:_^=YO_EY/\*P)VE(?^7S/Y\X]%_S>7O-[[^OX7R7POX7V]<<I24
M_9/_F/SN7VL> J?^U\R7_?^L"<QR9^W2F] EL.C_C1D9_SXE7FQ?K-!2=O_?
MHJT^PS;YOP!'?L?=#>2E^#.O/W Y8;3+86T@^ 1(:'V[V/)G96M7X'@=_P-0
M2P,$%     @ 43_<5$WH6 $?N0$ D#," !$   !G,S W-#@Y9S,R8S<Q+FIP
M9^R]"3R4;?\H/M;L.Y4H>[:Q&UO$V(G&6+*EQA@,,X99K EE:2/9U[+O^[Y$
MA61KLX8B0I:4B$K%&;3H>7I^YSWG?<_YG]__X]+,W-?W^N[;==_WS.=N\]GF
M2P"3@8Z^#H"$A)3$A\0' -A</#P)<<;@,3AGC#N/K(040!&L;T1.#B".P^W-
MWMZ_I@!&+A)K -DA05TN4@" ^&\'57![C>GAXW7_O ?-U!3NGB6E%*W&VVO*
MVVLK6^O$%\GVC-8=BW3#GR3@W0EXXI1B"P;!X4WM,1C4-H:^&QZ!<".@?QQO
M?6JBL%MSQFU:4Z3W%@88B=^B^<43@36&H1%FVI9F1! 5P!#@ \  X  $  N
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MVK8OJ';\O*T7@%1]Y_5][?!//^W,.;>.R#1^:K^S'$J<7MB&.0%DB3;# 0H
M:<#/8OIM[()MT6S1_B/"S_&K=0#<"*BM%-SJO93V&(*; ^XOE0O'2_]0>2O=
M=Z4:X"\Y"0#_S-T=-: _4W/''!P*"4?@+% GMHJ+Y#<Y%-MKQ ,6XFO?]D1?
M:Q?O?4Y8#,']-Q E!HMT0O[LF]JF6T0GMV'$.3V,@,?H(MP06!@>X;"MO8_[
MCTV 9@=Y"[*UHH]VXOF_8#\9 8OZOI7L<O[O$".<$^(W""4,A3>#.?T&8X C
MB'0(;[P^3L_,Z,2/%D;U _P;,K4S!NNK@4(Z_? 4XX[Q>C_ 6]YU0#C""-L]
MC-H3@<7_ =WB!_AW=%I[)TT,"H/=Y5SF'0*P[L^%+36,,6Y;G]1XC#MQH\(A
M=CN.!D5TY-^@=/;;S?!O<%KL5LO["WB[FH1WZ+;2^?CW3K\-9]X^)-GI0N1L
MV[.M@))OS[?P 6P2WQV61GQAB(<O 8 GQ*1@8P$< )!L/MM<!-!I.&#L$6<T
MC0"DFV\!#-LS@$/@%MWF*" 80$=%145-14=-3<=,2T/+S,Y(1\?(?H"5E9V5
M]0 SW?;X_O'G04)/2TO/0,_$P,#$QL# P+;UQL"V0\+\KS#8O M@IB(JGT9&
MP@<@928A8R;9?$$TE&:SC>0X44L*DNWQW8UD !)2<@K*?534-+0D?UTD 9"2
M_5AD I"0DY"1DI-2[*.DHB"CDR4N,I.1\[)(4VB8P%CY/()D*-ENI)>#^078
MH??L9>6P%YYJ[A.,,EV:> _'R7-D5%P4THHV<]!NR<2#]O>:3R*6*X-;^PBO
M5G2.QF2%5,6V]4]]R*Z^/S"]:N'H&1J74],^.+.FH'O*R2LL/K?VP=#KC\P
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MAQ,\+X0F9.0@')V\+KYW< X)NY]57=/22I3/1;+S;/A=SSXB^?YH>.*J'3.
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MQ-% *S/8TDC#*\8FURU>/CS'4\Y@VN'AHHFH>P<4,_5Z% EF0 CRUP)8(JE
M3?-QVDYNHZGM,D\4K!>":][$3/E)U]P7D-'*>,GV)K(AG'A")Y<S/T4!/&'.
MSI4M$MZ?HF'6CZR"6M+#W+NO)'RSR!>GRN:UU_<INZ?Q1%@UV1%J'!ABF=I>
MG',L1(TO](A99,9%+KD);V$7G<?"[L)"'Y]8VBX-GG$OSFZOJD! &G/)$FV0
MOBQZJK9VA(,^ESM8<\WU!F,UBAGSDH<@B48D+W+4,@"Q;*8O6!#X!0M1>RT?
MH[!,M9[0&#V&LDENU(W;%&GY"ES:;Q7[5;EG'W%,R2PP1 P;-8> JJXZFX5<
M&UD"E3=]HLE?=#SSKFFY>.2JI*-$ZDA^:!2=/RT&$//0V9%"W2GQMH@MH;@]
M=#W6*U-;2B2O((9$Y[+9T-@"#;HSE8;#N"B>4Z+WLW+Z6N)CUS,23Y$/7:^.
MK-4UOS=_$")Q]A14Y\91GHINNKHUB''B&A("",1#]E>'J3H,VBDKXH )>8X(
MH1MU O4%URK+^O%7Q"O(E*U L8\*(.2Q*#Z3_A,$KA*'2PUY'C?D1515DLFL
M@PV-4*=F^J<&2FY=GWCF]\Q/HKFW8?(.'*]V%Y$CKA^U< 7;B=!BJTFCL;7D
M$;9,>AQVX61*_VMK=-LJF1>A6F;^)F$2Q5\S8J. I[?55XJ,BHZ9V7\WDU8J
MFDY@A$Z\=[[@(FW)C8P&L32_I*M2#8&B.0TZ-W(:7'*2\O/(17-A[>_.S_=]
MO=#>OLY$J)\M5RGQI0*5IGJOT!_3R*-RYL(_D6<@&RII9&"K>4OY;<6>_M'"
M\V?ON!=<Q'B78Q (1VC/ <L!([QQ4@%)/SB-*>\NR9 =;VD=CVI0^'Z134#F
MISMMJ2LT+Y:]3N!HFXH'T)97D7[1: 5GPAT%(Z_W'5'5^TA.+W4M#&E\FG@;
MJ":W[_0G#X;'Q==3*;.\%IN'RE^\/O:JQ76,O>YCD[_WV^):+\U/X6?\0\1]
M'C]=LQ!R?')<:F'?)J UB6O#Z=2K-<^[']87UM[F'>I7UOBLC=>8<UO]XGI\
MMO.6TU>>^Z^&[C^HO 0?/#]SR\_^3NKE]=JO[#,!^".>K<?EQ<*^HKZF?@GJ
MI;_4?_(J&M^W+M\7FI[V?@@RD:.J=GOA3G%I0,G0.-RC85#EG1&YY^L\9[)2
MM[1C'R9Y5%9=2]CJ.)?*ZSEFR[DDZYAS58M/7Z^X[C>QMC]M[&7/#$BM;X;W
MMJ^FJTO.\],?NN/O!ZZNN8P?T+K:@[[RM##_?FV/+E-D5V&^(J3<G-+$(OWY
MTH$BA5QL9ZA5LA!IPUT.!VT1!BO9,Q2-><RQ5D''W"@\GZ%J)I:--1^U79<C
M+$BT0*#)]1$#,:1F46;)3*GH_-Y5HVG9[,\G'F<=%U&@W) >/70H7N7X@62K
MO&.<0V7Y$3:%Q[JQ?//\&]YW0VCWYZ<UW&1MOQ193]V6B;K.+_>A(SHN5CVO
M_@K63#9P\L;+DA/#R\\=;1[KNROQ6;]JV%]99Z"]O)\66=T_ 8CV<'%_"\U_
MCJ$_[W(@C$8,HXVLFQ.VESF"RE0MR: \>VU!@#Q= >!ZKJ'S@8[8XI6F4W2R
M2O&VZ>.VB7HSM$+Z*[&X4G*M*7I03];C?;+BH4+:HL!3R5GF^2C5E[EKP8O(
M.):<"CMZ'6H.\0'[YYE:SSS67URR+ROW'*%+$3JF"XX7B*$0G,PICFT4$T%K
M:S&/D"70Q^T/+!#(76]@."A)Z]'RSG8\:LSL 0E","O;2]0]7^E".P3<B!4W
MUYJ^=Q@B<S7NW"9@!CO;^##3(DPY\6)CO6YWR_-FA0=<N=057\/7W<O]'C9F
M0*I9K2VS@F1D+1_A3IFD74FXJ)@K;%Y@:"<Y27/?XX0N:2M<,%[P[!+?9%W@
MS5PR2A]-7N%(:WT30D5:6<S(%T04BHKC[#4%^J!KDRQL"QX>^A7NSPQ"X[HS
M."W>0Y^-<*77 CH3QN[%W!AEMKB8M<@>^HA2768HY5IYTW,KJ'B!HL+4VBRP
M40_>X59Q"2N4<Q]"3?[\4N]]M! 9KJ _GQJO:PE]6S!I8G6?)5^YHKMK:B(Y
M!)X0P7JIECO;_NSDTV#P9$:80<P1=-0D.-1!(*5@[?)UUTC3<RAOK;8E9\44
MBMLO6SM:!40-( (<+2R6'L_C3[IDTXHH"S?YT:-=U[E'*D%QSQUI7&_<OJ\=
M.8-.' &EGC=RHSVA9^\U-A)W\\H%BY 1N*"K'OP# 3K,8M"79C#HY^)")>*0
M*@TURUOHG+8N>\5'IOCH\'S9M&"+M"?;VT&Z"R?+1>AJ,BO=!:M/:UN%=]D(
M5K@\$#)5%3_A1YTPXI3M_#"DF7.XQ_'N(FF*M8YG3.X^%Q8HJ<Z3?4 ;L=N=
MRY_=)&]I%T\]:LKK=K19B7B=L%_^U%M:Y\$'I$(1XS']7[4H7[Z@G#FE4"-$
MN.0T8//1/C4EU79._&(6@6PRJZB;M1+WE.XS4[T^Z[[82Y,'#,X*:/A:XES.
MB&I$MB& P&*D*3<D*B9;.?2>]B#-Q]Y@(<&7+.5Z2SR3+@F9TGFCJ@D.V7Y'
MI\CSD?J&H^P40)?:"J8*)NRDA=?B [TJ!NJ4SCB7%6YNW9C$,7N^QQY^"-5;
MNFZ'<L[RSM@B&$VRAG%:D8FN*0?E/!5,R0H^T _<-:#,>K&*(##=+2-#7M2[
M>\2/VHFN];EB)A.W884ES*./XBD7[Z,ZX;BHSX2'&5#S6J5'<1)DUK?-KZ'C
M/$YY',Q;<.VS,?48\ZGM:;_Z>90)2I8=&>P@0-K1)8&.''QJ;).PLJ[%5U]T
M=>P9]GSH%$AIOV==<CJ+_ME#Q?:N,JXTG\2RR^0GKQ3&A7?2F#$9>6 4,L'V
M0C@+"'#^@.%,8&L[X"W'E,)U,7.Y9P<>)7;%.%*$]0GPZS3<G#OJ&FM X:ET
M82%=R*-]M.U0W).I%EB0!V\ZM70;-$0FA^;;D)NB0B)/L"UY3*J9HZXT]LO)
M)]TQ!3(/56.MZ\Q[>@;=.'LT]WN;M2TW#(DU[(]L/Q ]/!N1C4;-R#9DI]\O
M>Z4MVMJ77:PM-!B3E#^W](E>?]I3U(.#,^;#N>.TUF;SI$\22>747Q6'T-6O
M9$U##@:*5@?)/WJ4M, 5W^H;])I?;H/W,H]@=4S1 \FNCI&'+153JA7&RR0J
MA>Y%IBUSI:)>0Y+N!X]]%%TJ2DIS<C\GJ[ADJ!I=EXE#:2_6H$F;:B[[-\35
M<ROK0H,%\K"6E,DV3U%S_9_D:HY>F9OF>#"A9WH+?4W_S6D# ^7>K[>M>G,A
M.4?"@#*<QG=C\H)S[O(K':Q,.YS(R#@S%SGL\4:U2%S0<"'9I*RF-RXN/BG^
M0,7<R-5 ,PP!03G,X9JWH2$$DA'IY8\?OC]RXM$#!QO) J\0[>:;M)E/@QV!
M'@5,]7/8K,XN^21I/I#BR\G):CY\?SI:R662^J1^_]-YRU>FI^\Z5;+EX\RI
MTCC:S>N*\AG)!06&W6JX#*#4"A! --S.XV(3\VVW0Q708*T39<98&H@L]V6K
ML@8;*[2A   @$$BRK]QL0,(9J.)EJ'I_CK:!*ON@PNW!]KFJZ?0,33R_:<)T
MZ\VN(P_=RVC$;35H5RKJ/DD_N-T*X0@I3K!A(X.W-+";<EO/7@QRF*B([?3^
M1(>0OZH9S>Y]Y>G!=MN(5O1TRM%C-GHXE?BQ[)F#D<G[66(]2RZ_C^Y2>)]/
MTB-ARF)*0ALY^O#VRE714'N%5 ,=G3?HV(/&YLG![$=M5(_69LQU-BBO'TT:
M*SDWL"K84OE1>V8RS2/NMB*KE.^U+EX*':[I_,?6:$9C<6UAB(U,KC6CZNW*
MB&Q!A.GILZK[A"9U,$>FP3<.QG (WM<B"&8)5(0=.E<7=TEO.-M3WU+[0E73
M@FX7-73_!:R'F/] 6*:>S9R$B,: W"LKMEEH!#;0&%HX?;1:_M,R*]6YAV>T
M0_$R",="A'_/_P! 0+^_89?FU%[HM;=;(6&-O$VAB>J(L3Z>RJ9&Y-+:J+CE
M#"L<'+NUI1:3OR JNH%#FB+/JQMY&&<I<(Q>7F1A_44J&Y(#:W$,O':N("PV
ME:AM,X2GM3>RCN2JT8.TO$>3V*89%RKG=61I3;"EH;4ZVDM(7D4XH [,MJ4K
M,=+@$]L*M-TXDPBKKFIM5;&-R)IE3EERRH61L'/79C7D.K8%P(>3(7.1-Q#D
MGJK3JC6P)"A1+^]UU5HW4I<WJ:2EJ1005D\C6G$X9)DN-J:3B&)S)S"%I*%=
M3NEM+:BG> K9J*=UT%*DW20HXW*QUI6(1XZ%H<5!PZ)#>6A14-LT'%+ 4G11
M0%@*MN5F2JQ20-L$":LV5W;'=$I(>C>NB@C5AK+P*'-6:1HBMSHW!6R W=:7
M=I77DD=](NX/;0KDK"_%%29T3MZUJD +4IKHN3-YA<F;5+ES+ZL,BS>5+?*"
M,IR;,>>5ACCL9Q]3\5:%)B-P7$H6&W&[M(*DK;RJR)*ALE!/1,)Q&3#Y-KP.
M0&XD5EI.((:D-M)9D)4A4ER8VI:2XVNSB@E25E0*E!)SI48/.8>*Q:W?Y()O
MEDXFR>*-PW%RWU0.;P%62W=V_.[D3#[G2J&N*$:-:'Z3N$V<VR0M-0 =0Z%/
M;6J #DZG!$!QV1R$AXLR75=3XEMV7P560A&VC-O)5?VC:64J;7NREM8T*07-
M;0SRREX8Z&T[:#L7F2 ,ZU):?<;(M[=PNJ2M._,%I-R#74X=I_-WZ=.%SGB6
MR%PN,Z2D^;+IRH=EM4K4S!2YB]'2:I\H.!PI?*G81<@<RU!:HM:%*DLV@T*:
MZ?3DLLH93'0TVF.EL,I9"$[(-!.0-!%LN0([7+:V72UJ\Y6\\MXR%.N%]2RZ
MMW.H.;0J*MIGT6%E9S!5RK-<B]M=S.:MS/=.A)Z.!4O<#'%V57[S-K7)2K65
MJW!2J53>;'G+%IQQABDT]2;74<:H/&JLXRL:ZZJJJAJQR6&)">6/* !(2D0<
M-"0!9(2&&0 D#0 #0 :#=8;AU.(JS<D\"45$DS)Q422I1*GG[E5[DDWUN;F]
M]:M]T)4,M++<VDC<)PCB+_=J!6=F<_RF06?2"B,PZ<9FHRJ9E=N&9S<S%J L
MY4F4"J<FYNK4T!4<E,=J K/9BBC+_+!Z4UA;:62ZB*_+98Q1YAO:O,X<X%B0
MM*<JK ]JE2@+V5DW+)%GDJU&<Q%:G=FY(9BNOX<R\O9MO8@@H+ 4HJ%SO*$D
MVTS ]H =[.<?+FY9R\GJR[N>"%,]O^D2M+EPN>5#;$AF/A<<B;LVQ5_:W9;?
MYKB"*;.3(SDI6JMP.D")2MH0N1U"=G>#P3IHDI0<7A,].$8L(F#.KD8#*Q",
M7IO6]YQU"W6U($!3I92M>9>4-J"<R1=2!<NA778G!5B>&&3BK26<;C0GPU$Z
MN:0TM+:TJ,Q+27E-I 25%:2H!1&51T;4GK>=%S8*'YBLS1\*F-D7K,,D9[:2
MV9--J&FYS):!)(W]D71],WTR2<O3JT^#8R10Y**W,IH.4O*FH4U"9"J)\TT!
MZ#RCFNP,.VS4Q$ JD--+E+C.2RVVL+*MFPA*LSAR@)*P$ 7)4#:N%Y/PVYT\
MLNQ%3@EAQU,9#Z(X<6@HRAQY2D96QF)58E1-@A)L:VO9Y<OW2ES&TT R\AEV
MR[Y7\IDBO);Z$PFR5E9;;IY1G3^9OQ3/$G::R-,[/,Q>U)+BHK6OLCI+:FV@
MHHUR=4-?F>BNCF,&F\FV93\_KA/Q+%&XC[SLR8U)0H,,H*W4LMJ0AEL91E0W
M=2KV2@ZF_1XO"Y0NQF81@PX&'+E,M-1(CC"@7G7 EI3K@4MU1![9;@"0=5*%
MP#5V<YF1&_&1O(5/\ON4RVS(^6W>X2@N)GBS9O$\MZV2^YA42I,>:X#!H2?*
M E;1;^.F4&U^82VVIQ<R3CVXDM=4Y/CD\8N$XU"QK&V)V*25MOH>5'P7"D,2
M5-1R[VFW>>#6Q6^X+:E>1)[8Y<J$HR,4PB;A&#O0\-82J.II+^+8BIYE+KX;
MNO8LM%9<0RV>&4J6"1KF6I>-N0N_71',&=;)X\VMLS=FRLD:9J^II5<*^D^:
MGZWA+B[VFFT?C1Q9!LD=T[,L,N0YQHYJ>E:9$G9C>\K#EB,"!-+S\;A<J5X/
MBR),N+,;4R@M,0F%HD%*)3*W!<-I*QU.ES,@$E8ND WUP<'F<G$8KABV(DF(
MXEU:7'Y;R5LA2X[R$6NM00=N495$ (N#F UK)N9V_P ZMM>C@Z7E@SH7A27&
M?G)ULU)X,R'789KF.S6QO-XTX+)NB;VQY>3X'!K@ F; B$>7^!C*@C+J)<>;
M:4E5:K7M/X/(Y0<EEX/$,=M*9C;RQ%7&0I:(BLK"E+0V'WX]U;5Q.<#:H&T5
M< 9[K.*L8)RE1BLD/N*,9;*#(3(4E*Y(&T2E*E%EE^R=DVK(3D5V@RDFDL\]
MV+JRG-ET6V5ELS+/=B;,RW+ID[D+XO2.:0(FS3,N3'N+;,GAE<JJHT[R-H<H
MA&:8T;)R3VYM=DK<8H[RD\UC7=P6+%:POE+B:L/1-EM3\6;0DI.U6SL@%,H6
MGV1#:TNN[39$+4A2@FYM5O%I$AS$N3V'IGJAQ'86&.+(4D-I=#ETN*0JZ%+"
MFF]F7!E2I()L+UEUF6C4JB^2[I0H==Z.WQ=V]JF]DY2@?[_YBXO>*:WAAL<O
M@C.E5U(5;"*(65ALK US,VD+6)"Q-"5$X!6<VU][,AM:5-JL.<:=Q?DV]%<A
M(4IF:VIN#A[L1B(ZN$0S&>DNJ6Y,>"U%*RMPJ21F&CP*MEB#;J,*Y0-26Y:D
MI>BN!<R:B4[*:;E#:R&H[:4(BLE"0I 0A*57RZ;(@9$0!+F>?^EMM]?V"7=;
M#^C3N#95K9+2(FJZT<(MA)4Q%E:ZTT(A]LJ'ZA0;-VZ>,KQ-SC$<8)6M<3:'
M0%+BG2(5+<&!(.&M\EI$%^(L<HH\Q2Y:EQ7#);)FZOO22W8,*86A@9G<JGEI
ML@E056:RG$%\I&9C$E)P)^*A$9*9+?4[@$31IJ.%WVR74K=N$72TE0) !%82
M9&UWGYZ._+M%<LL7NW.+FVZS47+=[^QJP&9F'Y<93'I6YS]\70F>7=JD,4E2
MF;6UKA?G;15$4(_!]"-N\R'HWNIK4DMVYQE.QQ^>YB+D5F-(PR.W <GX:[B+
M2VDLH#S$3(ZR&9(>VB@;YB57N@+&;582K;8+";@-R77V,1?7-;@SVH+B'%/+
M4T]*SH<+K&RR @"P";67ETZ\?2BS=DN-GVS(3%CCD+BE#O,T=+VTV[FR>X\-
M\]S?&F5MF3BSS1''8JF?O#$G1NSHYJT[&DH!X6.!8F*ZJ*EBGN^3C*V,$P]I
M;CSN5DY%R&3'>V2G%J92MDN.E&1HH2D%9[0).FX<7R@>0_C$YU"&4$NC,AAY
M+[6T"$)<*70AM*BIP%2CD';DCMCVU=J6V[]X&SSY07I X)4ZQHZ"1&K2*A-3
MUT)W)$Z-BI-W5)@U%5&EG%45]X,"H*NY[FJ@:1$!\TD-YL&Q9"DDI7RU4"+$
M$I*5 V-K[COYKUZ$PO+B^&*! (Y(A0.A *5 C?<'6VA!'/6K=;G S*INAHR[
M3DJ_MTAN3)>D(=8X^SRN>R V=+(FC:7Z5T1Q1(S'&I[&.'2(I&XGM=:KS ;4
MB2IJR:D98)QZ1.%8<>5L]DP8W4[>!(<;8V" R'2M#16EL)"-H&RI(5ES"Y-P
M=:Y]6)3AR7@N]6R.J%XTI#CVV7ME-A*W"VI>8JR%>513?*2 +6TK:=*$$^7Y
MU^G12V+D[5"[J/66C*J7 Y29(&N*$(YJX6FH3-IZ>4."A(V,3VX+JBT#2]*5
MB,$3XI0JQ6I3J 4E\VT6$X/R*,UM;T9.(8D7V]FITEE,LE0+20I2T)3VRT!*
MLR H6(-JZ!U+YQ;E<F(M+4A<##PRYG2U9U49*4V=40EM1-DI42 %$$D$7&-2
M&JX\!4]")9S./)A?<[,:S;R23NJ:2S1JGEQ8C9-U>G EH1SF3(79\K-\,J*8
MH:S&+G=74<E9%".@^I0S+BDVP4([Z>6,O"&PC!W,+:;26F5,1W9B$)*RPVI+
M?M 70L)0-7+V 6DJP$[=D\DXV*.9\6;Q)UQ0<>2\^W%6M02EU:5*OG.R*;J5
M<((!N@@6VR_9I)O<OI1>D2@TYO4!5YV^$YP;0='ZY7$E)"6&VRN>OE1;!'(_
M O"YM3+%W9Y;HTPBF-1ED"Y)&1U2"*E8Z5)UN1/PQF/R;P!YF'>(I["9>.)C
MM%3TF,EHN.N/Y!G<2A3CEPJ^53B#HE-Q8A8B](Q_&V7I=I26L3C8,I]P;*/(
M+H;0VR%'(VI:6VP+6*@E22"5 &TN9*5YDLKG1IP*/YY)\H7YX6#.K'[R96&F
M87 9[G7?@,+B2)L6O$H=I U/TA5I8:L?T+X0E1*WA02:J=&LJD.XI3$-F5A[
M6'8ERA?<P5@)P9S!W(F)J:87&B/O.J6$-(0IML%Y+:D9E)0-$KMQ*\:<Y/P_
M 648L\I6+(Q5N5AR7'TR)++302I2U+2M9#16E20"K52DV!T O+GRNA96TV3^
M^.=^RCJV)KH=,'&+0PTF/(S"/"5N8ZT1(Q5F83$U!5694#Z_D>=F6@!@@#Z]
M(5-.HDEZ8F"1IDG%H6#3$JZFY*.2GBX;Y9#BW;8:KOH;5M6MW:((._7*QB1$
MC87+Q:*H"1RF;CM9!J66TM7G@ >_4,CNHLM:3<6!K8"PSR@*LJU]<OT"E,^R
MJ0S)JV,R][/SE0&T>3R*M+9"G5LFMOKW6A76XESB=.$51R)*K6K04'UOI360
MJ!J*8W@2]&MC3$X,]]IC$WL74M".L[\K%G5+>0IE^'+$AI.Q4 HA(L WG*<Q
M6B^Z0]^#I<-EU[#FL,2DJ.)LQL,;2EI2769<8LN++PN HFYSA(.7(JM=[;?2
M:V^R?=!>V6<G$CMI#Y_G&NE1(H[%)4O0$.<3(S2N)+-&9&I1BVFOT?3-$B<4
MAZ%U2T-SG0<"A6W=U2523OE0F)&+<M%2V6Y+K&$Q=FXZTE65SK8"MUL*S;-P
MK:20I!S)L0%;[Z5,MUC"^2:8SSD=M[%)&=#;A2%-=<596W",I6@(<-TJ 2K>
MI.@ N?<"\]P;EW,_)#T!G4^?)/ (381S3P"$N[VH71&,&1IK?R6M1%(^H/K:
M6A<)Q!;@L5-*5.H<G3N7)>8J74T'TXK$-B/'Y!/LL(;>>FI+[Z$!+K@<4V5!
MUP#,I-CE 62$ILE-DFQR'Y3S[_+5IY]3C#4-266EK*FFRVA:1LT7RH-P"2D!
M2E$E1*M:S)2SX@M?EWOU8>W\FN!E&BN3-N9U+XNSEP*U&36.Q9#"G1HE=NKP
M6>5VWEKF,\;1/1I5"A6!ZJM[):T2RIM(9G=(3J2Q=,^#.?;8Q5W&%+"$X0_*
MQ=QPO(6U(B2Q):3L%640!ID*E#,5H)V0> 5!F0V7'L.:PL(*CB;,;"VVPTI#
MK$F,6'%;9-T@E5SGRCM<BP-++_?NY-G^AIR4+;&7#E=J!DN=N[="X8/*%[*\
M&1Y!*YL],[&N=FLQO<%;.2I+1'J4I])*)S-1)35R2L"J"J>P1!CR^5N,":PU
M*V>#Q0-LTE:,ZFVDK6E*\R4J(N 0;I"B K4FN67+?B\E\*5$><C9\6D!6R<4
MA60..J2DJ24J*0;$C<H@:;B-K9LCFAO3!])C;BV$N6M$JNKT=!#A!X^S2HN.
M42B]S9;ZU;?"'MLJJ<6]O&9LB->\4M+V)Q2QD;SW910K2)!7&AS ;:')3DY(
MDM!;47E!9Y:VMILH2I$E3Z%#*I6R64ISHU"U! RDA-=$5NGE-CK##A0Y)P0*
M:0EP-[26EF.&E#MDC:H2I65>A2E2C< DUU8,ISO=VU?2161+D<DE$9NTVYNX
M;"[FNQ4E.K?U+PZ7;01:Z#4]2-M<%%+R4^BI?VF2'4N*U$_)5J^D\]:C5F5'
M>E8FF+)Y/S=FVT[%7A3SL=.S&SR)BJ=C*0VI(R9+-K;[5*FRE) 2I(MY]ARY
M,?'(>T<<;DIQ%EF0=I[(%JDI;D)6M)USYEH<.8I6+@DA5=B=DOY=-DS?=/5,
MDMRY&=(+/Y=9V@L^YN$@5N5<!2,ZYY=61%"Z5R@\IG2L[PL4.[6B;:2DR1R-
MK5E$TFUU55<$J#&7A7(AE4=L-R\095+2E"4;<J2A*R]8 K*T)R*4JY*="=U=
MLF9(1B7+%U+[A7%@NIC**RK8Y"M20U<D("%G,E(  6"1K>L6LM,XS39K>C'F
M<<R=W>DKOGS5YLD<YS*FDW90Q"_=R+6I865'H<^)IA(9 QNSE%V6M-$FLTHM
M])**\[[L16(^:3DCALL19PS#.4;+F+16DX(,*+&'7B%Z#&DE\N.H++;:T)<6
M"\H70J^T0=+ HU\%W$,1P%U&%R7%8N<1#TXB2&IC\;99&5I<<<0I3:/84GMP
M+MJ'.%;$K<W$8BNDLBA2F8Q24YH;4=$A*8UFCG477-3H@6WVCRR%*C43H\(*
MJVQZE+*-&CJ;1WT:23T" X*!25(TNAD1UGD\Z0RZUALKE2VYAK#B5H4F$X'@
M%)0KMD-+_JCG"E D$$[J.^CK\TDO-NSX_)MQO$'FU(4#,0MJX4I-TJ<0;YM^
MA2#NM6M<,WV95+T0V4Z8%7^NC5<"4](>Z1J23<V>OYTW=(B@2/4G*C2^1G.-
M;V='#'^A*XGM9JL6]16A2)C2:T98)L=",*PY7*K%&3!C;!K 4+;9#" REQ10
MV7 V$A <V>9(6!F *B"#<UHNN<X<F\,<ZLD;9W&UH<=+R]J6TA;@;4LJ*BV5
M644DV%@#H*PEZ>DM%3TIV8\Y!2F I4WV75FUI>]"4<J-L7;<%!X]['N*SC*Z
M=3JP'NJC.ZJK$3*A$=QR)S=C.'!5[A4P6.\ 39%AKJ!KIP^2M5RO">R"?EMV
MR8N[C>''-[B^_4DD:F]]QK>\WL^>%[R!=&$=DRR\9:+\E-&7ZJJX2V_C1:-W
M50I953$#(S3'#+D36*+V\IS+(?#W<8_0MKKK:V^I54G-*1 =Q2E8,C'.48Q>
M?B$(KG#J<0E2T!X>RAW:=3,NI44DH"-I8=LJUP56[ (Q9>#X <+@P)F6%=Y4
MQ,99:)#6SV1?=:("K+*\F_*FY! !_/-[:QNYG2+W&EEO,PTHCF9X>CY(?\QE
MHLM%U(J=);C7@*)3-CS8VSMR;E%2A';A)4D:&DPPMDH)=8RE\[CTAH9#5*]4
M5+,ER/@$=J1 :<P[KZ6\/E8C&=#<>)<J1-F1HQ;,@YE*U7VKAVJ%9P #0]';
M?QM]QB:XB>,$"YT6!);#C\H6"HD9]\.!@$)3;(0IL;-0R741*;T2.Y4+DO0E
M3-KC<(BUSX-/LUD3<(UF@S&'7+21YZ=@:6YO@%S,PZ%I?U!%PG./"H\!T*&8
MVN*S4M!%BFW5BI155PVXSS?+%E3CSL9]C#'4N8; ZF+C:,Y4_&@%38+"7""Y
M9=G&<SI4-I>J9:Y#3G)5U+;3;[3N(M%N?.+X0M65*67YH2HAY:+E':>QN -A
M/:6JW^?*%P!JRWQ>XN8"C,MEG9&7.;:Q^DV4V^M^6',/!;TMYLK:";E22TZL
M^02RX%+2PPE5(7(I8*QE8@2%KV\B.5GOQ2RF_@CSRL0<CP>MV(K7A$E#6*0H
M*X#\,AM1CM2@&VV,RW@VDI(6YF*5%RR"DV,8:93 0_,ZO@(3BD9;F'3)J)C,
MH;1&W<C'.Z]E0T5J"LR$90I.2Z@1E1G'F[VPH\\]VS;?R:=Y5[FY8#XY&[A3
MO.O O0K2]@D$+:D<0JL'91NMF_+VVY;,\%'BR-:9W1J79V+<51+R:>\LQN-9
MA++:S@L7;ML8G&Q$..,,8,_US:6V\I3O5TQ4E"51UH(SJ*"$H*04 (6*V6)N
MK2,7DEAQ[#WX!;;>>Q5CK<ZAQI*6NI(B6%E+Z5@Y4Y@5+S'/VR2+46)6)*<[
MW0KUU*DP4$]%$J*.K$\H*2C/B2R.GO9E0UZ45ZCIW%>E6NVFN,N:#UGY8:&_
M9."-#\+:O\@O?FK%AD==N3!N/Z.'B/@[M:UI3?*ZUE.@]R\.%G;FRVVC^]Y]
M;EMSPZP22+XT_+&=%3<-^3MJEQ:5*5Q\$UO+8U.*E$!P)%JEO1"J+.I)IIQT
M#<*+,Y9STRXS4AM&"1RA#S:7$)4HL(*@E0*<^0J2% 9@%*"=YK2.RY$7DI"5
M%D.,+7C#Z5*9<4VLH2EYP))00K+F2A1%\I*1<'0'<%(7^WJ?I2,_[ @IJ,S"
M78R,VB2V;(B$^CUI[B39V)C-=,ZB]M[F/;8[M48N$]MR&(>"'"I$H4IT["*V
MFDE*TJ%B+DVT/GDW@:U7Z@BXU*,O:L.2H[*"Y=ER1'0M"G(Z%*=SIS $N9=2
MH)5TSBF$\H,:0G6;)PB,(P:>;C/NJ"#M6V'UI4EM]8#>4D:!&;<DJ&D?IG)(
M^DVJR36KN7;1Y@MT[?QFXZLNJYV9)AS#YAR(#(WEI5,S#>E>P0.*EM=:5616
M;"*U;H]FG,P+4U512]*ZU5]ER2;1U3C$F-(0_%?=CC^38<N! +[:%I6N&%ON
MY@0;/V2@9\IU24UR?*A:A'PJ.^PMF0RW(^^)R)LX,.+2I"92D--A-B"625+.
M0*%@0JKW]&7;:X"?((-S[=3R]ETBQS24G2O+S9G,'"<L,2M0#,P)];P7VN.I
M;#)\MC)J!N0UJFE \ML>\$@VK5%!AK8H4(L+E%)8..=32&(48C#3LI\R ]B3
MTK.X?Y)!CA08#@*E *4A3A7G2+!0!R\ 8?3@PD,NRI(&(>R0HLYG#VHX2W<R
MICY2'5-E*4DI"TH*2DJU22-G-PUE\)-FSZ:JT>7N6OJ"Y4ZL#EMG]B8]%9ZF
MB*IWE1T&86*03>'+E#XTMJ-V.2MS4R.TF(6I*JBTS8@6+0II34#SC A-X7R/
ME3VD&,Q.Q%B:XZP70AH/N+;9>2$+6I *E+0V4G4K4E-B:WSYEN8CRJCPG%A]
MZ%!>AMMO!HK<+*$+>:45H2%$)0A3@4G0(!5J*Z-KD0M1N"Y*Y 92X)UJHA>!
MA@&&@M(4&%*@,,IKKI,, ^FL*JZ:Z@KJ^."NH-Q]E204I*?:E(*> RD7%AP%
MCI7E!!"E!7MTDI4#J >_;77?OX\]Z_)PT'GQW 1$ X<@Y!IOMST$0$<35!UN
M.&[0@ G?Q/$WTUX7 (%9!Y3M0S(V:VXSAHUTVXU&::\O>TZA$=\:+E/_ $?Q
M?XD[YAZ^?2MWR=L<<PS743$6OX;VUO\ +\@%J[]F0S8"N'#3C_R:1T#WO<TX
M]?SI:Y3;GYM-=-?E\.NAKWA6X][U_ATUMUPJ:Q.S:^L=9^T&?R8^]A5(]LKP
M>:NB#TMWK]M9H _*N9\..@N#$ ^Z.NO7XL>L_<T^]L5_.Q/U;]>9?="]VPS4
M:M2M_$A;!'@W_+QK43KIQ >6G+3J'?4=M.0#OJ Z[8]/KSNU]Q'&_&_.-+#6
M_$C2Q%M:CQ'<!XCV:#KMN ;ZZ::\=0'GIA4'0&Q&X=)(MKH3I:][;K$<+TT#
MB&G/8=PUX]>G4&VNFO$>.%+FYT.MM1H;;N:_.=;7 T W5 =1T$ '4..F_#F/
M;V#U>^J187!(L=U]-_ ='2.?Y.<5*BHBA-4I/%+14-="<3:Q(I,$:A[Y23W7
M>J*A$:@[H "K<0UT$1PL+WMKNOQMS7I<@%.^QO:YL!Q'2;&YTXWWZ5P; .VF
MH:<0X\=PZ]>/$= TTUUTPJ+7U(.M]W#O\UKD;A<WO:UZ  ;\..@Z\@Y#RT$1
M#AQ^R*BB=.?>+<_$<;Z'?N.O>'*4<<0;0<0:82<6/=%FDUU%FEU;Z=S70--5
M%0;[TU (:\]-0;]]!VNNZVXW(UT[8'4\W"VG"]C\FG&GFUG'FFGG&5!48:=5
M4::8/ 1K,K&JJJK@ B(B.H  #I@ !H!8<PJHDG>=;&YS'?;CYQKNU-?9J@XZ
MDN@XXXV@BCO9%!QM==))8<2R::QJ NG7_>T@%.H:Z?&ZX#0W&A.\C0FHU.6Y
MO:X%M;7U', .-A__ +5 %!_>:DW?S@3B:!E2?OE?>*C=- -J*[JFCO@4AIWS
MN>Z[G;AKJL+WMKNOQMS4W  :C50 .XC0V]L#>_3QUW6XQ#40V'M'CS'80#K$
M.L--=P#@"H!L#J.%AW@-03S:<#NT)WGE!0?008EH/.I3F54F&$ :92288&G<
MU5E!4!=1E( '<U#2-7QH:"&FF%A>]A?GX_+4W)WG0G4<-./&XOSZ"_/8UQ::
M;;C_ +[CIS[1X[?HM> CQYJB_'0?U=!>]P>8#?>]K;QPUKDK4'F%E%&'&&%D
M=U206889662%8ZUTDT5554T4U#I54%&@".X@(Z:K#73?OZ>_4FYXD@"]K@<;
MW.ZQ\ W;]]N( \0:\ $=^H! >L!_IV#;"AMS'2Y) TYR".((^K4ZURDG')C*
M3B#32#J->Y-),J),I[H!"KN:Z!IJI#N1&FK00VJJY8$ BQ (YCJ*7YC:VX[R
M.'#6YUMKK8#B:XA'?7741W'K$1$:M>Z'?4-MQ_184%SOY^^. .@TUUOS:\]Z
MYBSU!=!U!1QI99Y8%GTEF5T4'4ZC5W!M--0 92%0B(4U4U  Z: &NN'U;J7R
MZ7(UW<X%K>"P&\\][D6K@'8=]1Y@/7QYZ#QTVX^YKLH-=P X6WV\%QNN;[MY
MW\8Z=8]8"(\0$/?  U$-1_TCA2_,.8@#<0?D)-@;#^ H  .^VXCH&NFN_#AL
M.X<QUX;!A4$D::Z 7-KVTW[]1H> MOU-1IJJI$!I$0$-*J:@U ::N50#J AI
MP =0 --0W#"ITO?<;_0#>PZ;ZD;];<:_0:K5J#:CSU2D\^N@:*SCCS#3*J*J
M!*&BHVNNHRJ@2QJ*JI&H0&@1#00V&  !8  <P&G/YZ*5<W4==US<J/?TMK<&
MQ[QT)MS-K8Y/"PIO:$"YT7GA6)*)N2GKEA])1=9IHE)DI9IY@%E%U&&#115W
MNBFNNH>XI$0*4E *EJ2E(WJ40D#ODV% E2CE2A2B;V2E*E&_0FQX$G=8@#0&
MOT(F!]<A7 VLCLX"U45FNGF%M6*_!I5 F=V:N @@P$91?>C>[J4"732-!FH@
M-%0A!6A-LRTIS>UNH#-WKG7>-W/4I0M844I4K*+J !-@!KFMJ+D;R/ZO-I7!
M0TNQK8>\%-B\QH2GEI5+J6B45MR=49W%1:<Y;25YF)/, R@:23#*3*@KI[FD
M>Z 1G,D*"2I.8BX3<9B.<#>1TVH$$]OE44A5BJQ*4G< I6HO?<+@F_>JY=B+
MQ/E@+N0B\$<C\+ECK"')0M+B]QHVBE\'D2)>V+F9V8Y-'5W<D.#8Z-#BN0G=
MP:G6I*CZ%K<K1N*1*K)QIL1$Z*]$<<>:2\D)VL=PM/-J2I*T+;<3JE25I2H;
MP;95!220<B')7"D-2D(:=4THJV;S8=:<"@4+0XVKVR%)6H'+8B^9*DD@C.>^
M729'W"LC=2PMF,K5@<K,.OW)H_*;Y*[2HY*>\W"4Q5X&0,+-2:_O"Q!&(PWO
MM53B2QL+>G3IQ[M(WUH4*MR3K]-"Y/;"9&FS,3G8F]";<;A"46PE@.HV;B^T
M0%.N*1VI6M1)WJS*"2G;2<=+T21#BX?#PYN8XAR6J.EPJ>+:BXA(*U%+: OM
MLB4I"3H+ J2K6<N:71J!'6YMB]OI<$M"YOK7(U"2E<B-V)6)!4%E I2FZB-"
M@GOA1G&BL0#;H@I*KY5!64Y38@Y3OL;'0ZWL==:T"D* !4E200%"Z2+IU-TW
M%B."2#8:C>=?R''G*:@K..,.,TII[LZNHRL***0IHIU,&H=*:=*: U$*0#0!
M"D,2 !N%N]46-R57.F^Y)._CS 7!W<-+U,#FM]H9DCL>WNU,=-6GH4+H<D64
MLQKC312:J1I%M98(3%E%%-)BA.2:)]- 4UF4A2 5!2%(SE(4G:!(4I((SA))
M"5$ YLMP0"1:X-JN%*P@.%*LA)"5$'9W&\!1%@<IN0-><7TKE(:I$2TG2%,V
MO9+%4>+6<^$(UY;2*DP J%O-<BRZ48GF!W(BEK/[X("&I>FFHK1F#94G/;,$
M%0S6']8)O>PMOMX:I"5A&<)5D&A4 <A-A=)4 1>V\;S:XUW278.YXCMKQVUT
MTWUX::#OR]S:JJ;$YAH #;=K:]]+;[Z:<?#K.$\<D2Q.VJDC"\JDSRK7-[.I
M3MBT\EV7MA:4]S0MII1%9:]6WE+41RU,FJ-.2%+$QA]%%*@D:Z"XVDJ!6@%
M2I0*D@I2HD)*A?M0H@@$V!((&H-7 A1RD(799(39*K**1J$FVI2E0S!.HN";
M"OW-\(F;PC(<6F(R=T;U &B0M;F!V6HS^]&UD&=Y5)DAI)P%GEF$F"76(4FE
MF45"%=-0!"GFD'*IUM*AO"EI2=1?<2#J->]T5*&7E#,EEQ0) "DH401J";@6
M'M3IP-A;0"LM;!WWOGE\M7FBLI&;3'O+;FJMVQ069*7V+RX7R/,;"Y.BM,Z1
MHI :C(H4G*70X@XYR2."0>]E%T%4F#5KK)L*'.DX;,<DY%89(<>9#;C61Q:T
MI24N9@HD )N @I.^YK8PI<N%'Q"*W&*AB+"&G2M#I6A"%+4%-@9=25D$K!&F
M[0DXGNT/G#>F.=7Z+2Q$E*[T"AR=V-W3)R^[J+3D4'+%J6@J@*JZBR"::S [
MJH:"R_CAHI'9I=94<J'&U'6R4K23SG0&_2=.FM:MIY-U+;<0G0%2DK &M@23
MQT%B3Q YZI<DHT\TLE.48<<<904025148::;74%)195% 55F&5U]S3072 U5
M5#332 C4&+E[ W-@-3S #B>\+Z\*IM<A.I-QNXDFV@TWE6A&M^D5^MT(<TJX
M],\$+R'-/4!2LAS+4DKR#**:>Y*4%*Z:3RZZ:.Y *#: J"D:= WQ"2D@%)!2
M1H4V(MT$:?)0A04H+NDWL4JWCGS#>-#SBW> K]0QR04J4R,6-XI6+$ NJ-+4
MV+J5*IJ[P:>+DF($@#3D'>23S_-95%:?O11AO?.]EUU!&T18G.BP.4G,FP5H
M,I-[!6HT.MSTU)0NX!;5=2<P2$FZ@3?,!;MDD)OF&FAUYN%:C>FHE.G<$SHV
MIW5(E=TB=:2K1$N+>J"H43FG*/H*+5HSP*J%,M* P@T"Z@),J[C8"A1)24J*
M24D@@E*AO22+V(X@ZCB*$*2$@I4D%(4FZ390X+3<Z@_U56-]]R+U+-!UT#<-
M=0WV]P=0U  T#7D.VVN]54]KO.AM8Z"_?(L;$ZZ<1SVT:AN&@ .W';GOQ[-P
MVVV#0=L*BV@U)&N[72V[3I !%]=]QK7-0>?234G!0=2FKK PQ/2:8!59E(@
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M!Y:AQU$>P.O"@(ONYN>]AN(XV.ZP'2>:FNO:(ARUW'0=A .KQ#PWT =E+6Z
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M'5)W=5MOM,K2;ZYBQ&+R>-P;7%[^D0V&<$ESMNE)3C6.&$VDG=&<9==2H?\
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MP.74+9[N09]JS1B-//),BR,)?OL<UUNN!E?[$>_7D]QFE/\3S]J\%'S=L-%
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M!/YRR8@X*.#]>U'3+*%[D=B( YJ(6:=P6C<N=PD'^?%I_05O;V,$16V@RH
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MH=OSWV(E]"]8_=?K*@JZ1'+U+WV/\M)U">%;-_E>^GV;?BZ;BQ?=:SMS![^
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MI,9')._?FM;'25QUF\K\Q +1 ?,"A*Y=27]ET]=(@C3 E)XGH3Q2'$8=]P:
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MC89BJ! :/Z:.<,BY^=4*#(%5;R2#(+53 -T\S086=9>BL')6D%HG FN9=Q%
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MGZWU7\T7#Z33DNX2%R;4YE8KZ3:U34%1,E,B/4D#AD.;.B0%:M9RCXCAIQ+
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M!5TA=E[:Z>$10TMEHYW4&6)Q$8(&-_K"[WBCB*YGLQP.FE%-0$G,&<_I((#
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M%J\*.K*]>/)52=8@?T +"X]325KOV=@>[=G(#("5GW6W)Z+IY+G+L.ID'&H
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M% WZ00'X6<@R9GWSQ%5M@/8>D"[G8?P!HVZ,'.G :&3Z5EN^_:O@R6&=O&:
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MH*4WLF=XSZH#^1<%J"TP2XR\U$JE@06*GI,VNC^)@.-)BUYU"3=L=;J9=32
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MT^+4P.Z_^C(T 8GMX)ZFNAS29M+^XKFWV?DF+8P+3#P]W@L9T?UUQ/8T1N
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M78+P'S"$J#QTBNZ],@XXW31S?WR3A2=Q_-W=446F\W-9;T_KN]A6O!N%I2F
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M H2?9,6)G2+,_/R[9W@I3V :"&PS3US.FKIE*D)+EY)]\QI'_/S\P 7JQD6
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M]9,4E7&!J2)9<,]-K\R 7DF.H(3!)O*+^5]%FA>0</V*_H3/!0IW,E2YQ'1
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MZA]<'O_**T\F[K9I,] =YU2<S+M8">8"&?^,R/,6$R,/5S<51O_6D>-[BGD
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MU3X<N-YJ5GT7TZI0(T#[=+:?\GW ^VP!>,"$)1PJ_N=64E=NXP )@J?)?(!
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M?HPB$5GP>H.QY I:*)3I=.C$:Y?FU\%&6RQ0<VE!1?D#;'=>J6EH09 )@L\
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M!"WLHA3+!*_RPMG8UO+,:R9U>87&J#:^"GG2"DBT1R=KJS@/6.QR6;-<<JB
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MR$,3#!E#B!3-C.'KRGYM\V4=)#'IKJWI!!!NH./W<:P6+S9*[ ]$>>&!9N2
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MW8@A@\WA9(S(W)_G$_M5^,BUZSS5R[ZMKKK#3G\ 3:T].Z[+%Q.VP/GL1E.
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M%BJVTNB#_#NE%?E](/[7Z+EQ/\DT?M6(FEDR2*/M0]-1,F*G3MG(UO/2F2,
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M1:8E^T?Z;/R-:)U'4PS-+:LMLN1J0U<<5W>&[@?=@+;S(3:Z>I99LDJ.W)V
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M'6)TT42_>IW]]%AP'Z@<WPZ/:#)4%NU?_<P3#[G"(AVL'8S(MB:8]TA%>*.
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M*_/</JLC.&6T6&O>Y3=]@>BXLG'K8\HZ!@-?\R+8&1K/):Q>Y;2RC1Y^#3'
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MI6#AP#ED@<<D^S)HJ6PTP!/34E?U%$UC^A97! )BIL;KU<LYP1?8G1$6O0S
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M/:12Q[+EKKD7+*SADNQ3$N!$KE/N&G#/.0^1Z?$) /"[8X6G(P&N4@70#9,
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MNI?L&,B_W[OB0W&WN&BQ!M"HHH)/[[7HY:8'H78BZVTBF7EG7Y6=T["Z[6Y
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M,ZOKJU-=>"M^VL'AOCA18CM(D#3TOP!02P,$%     @ 43_<5) -.T3<X0
MD$,! !$   !G,S W-#@Y9S,S:3,S+FIP9^R\!5B46[LW/G1W*24=DD.GTMT-
M@C#,## P </08B!=$@)*28I(=Z-T"5+2H))**2A@^P'&UKWW>\Y[SMG_<WW?
M_V(I,\^ZZW>O>]WK7L^SX'J^3GU]!J#4T=#6 &!A86/Y8?D! %^WZ!>-7% 8
ME*<+RIU-7%@4(*.BK8^+"SAL]-VM5J)_= '<S%@V !PF;DUF; #@\#\S-AZ
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M?+R"^+[I':7S^=> /^A4QY=8WRH/+NUQ[VA":8[[I,=*XM\#EG7XHW1X^0P
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M1I&#@YCME_8-" +^B>/NA88?HT# (E X% %%8CP/8P@4^6G\R#X$+.>$0B-
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M>L_%L)4D!4TLP*% ;@LC/8-"X/W4>>IZ\3)WE#FL??65 ]+?CE=COX]FP[;
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MS$8'@)XO7E8715^6I$_<ZHN>0>NS>:E%LB8H+31GE^<C33:WWSY[M\,2Q2"
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MS;#8;VI7@,]95#] WF,+^I":&2IOKLWW-!XVX(0>#AJIHR5GGF,V$#(AE'S
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M631W+D:A77PS%P+']FM2[DU["[DBPH1VTL=Y-76N0/^12;#;V*@M*[2/W)2
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M0-1+9L\9_R_;4WU3",G/9IO0RMRUC8+JIG<J[VH=,>/\B1X#E^,F,+FO#L+
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M]K2"JY8E9"A.P5(8[91OLL#S<@XA&!8=3$?% =^@H\TV,ODF?O^G.YN1WV)
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M&ZN'\U 8)[9=TV#=S#QL&]0U2OF\?AESAV@@TN*G">+H%QDCFWZT6_5/C8[
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M%=+LCWH\X\%O%8'QLE@N%0>7=RK,<C:LB7P]90'%9CSCF_XQ(0&G0_<++.&
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MD_$5#Q\#%L<)94J$>;_W-04PXZ%.>WNC?B%6D1@SYCO@;5%U+'BK:%(H5R2
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MQ1:J]6K(._55TC223J(/E.62ITW5D@(*D]6IMJHIK'^5K#0"Q..HIP(9@!L
M<J.4@#BW7\1O[DJ\6 9>(N?>=Z9YE"^N89Z%,R&9F,97&]P.^?GEVDWDU&W0
MTZ=R.[_"6:)9S"39[D8/SSO@&=Z<Q:+5'(8[7I8^40UJ</)4P=A@<)DKC$,#
MR/;-<$5->K'6BT,4GL[ [%4H!0R#EZ,G[.>HD/#3R(>_F3+3(6E[5+4.^14\
M=$V\GM41-VW_^OH]D<]:Y>#$Y:CP?KK =X+)XW9;^,)9T=NT@-SY3/*V0T9O
M6\D:/*TW22,UDWPBYD&"NRJ8K.7ZW_T**9^=5)P;NP7+Q[(;%_YOZ)SFSGD%
MJGXI'/F:D(8,"W5U=[(9THV)<IA/))3CP_>V/\,X*T=_M/J@2KH<J'_!M2CI
MD^D\#L<4]]!L -^R(;':^2C'B,CO_N<#3=4@A<294F6V69-RLEEZ@-T\&V-B
M1V3_4R0SGY!_ROD S^_0;VNX>+.(A8.&KND"GF3!2Z/ TQF\INZ(J0K;W, _
MTSJ=]794/5*F^$YHIMS@KRE-V)N4W$O0^B^IWVVS^V,_>8_8M/67L)^%-L1@
MM==>OW-+@>#:4#O+.L14VYV. &]"">=&B3M9*-O[2HG$M_^*3[J9C8R(94WO
M@!]*+U"OB!&?,M*VF,RDS-NUNT@XA7P5SLQ@7TQ]CK$H6&5B,FS&A,IU[*R]
MQ3-./?F&--D0DRP:HL6P9)J<(5O^Y_HD(GY[&:9$-9-"VWDA"EF_DMZMO#7V
MZD)"3L[0Y2'=+"2EQ2,J2K]G"$])9'^D]7DQMKL<,)2HS=@1/*<&B+L*I<,U
M6_@1O?Z?&1'AZ^D1N\:]9H'FU6X]G3%;=YD \/@-5SZB=E[(V $\")^$P+PV
M"0/6^EO373_05<P[262?))/7C3^M%:(6:#WH7QW>\!QXZ_0;RIG*_<K?WK,R
ML38ZGU%YW1(]RT%#?OY!E(A]?AI;-8.)0@)QE/G&1TE%TL$_ZU(YT/\R8J\>
M<OT/BD'^4!NN>>ST^0E:G(=1KS.X#%IF6@Z4-*3.[9DJT]+>YVB/PN>MP_.$
M.V01>:@;FRVZY0"K?IF@2Q4D'(3EQH^Q=(\-PS*QOW"ZIL&[@6MM 2-W/XPV
M;UM#%4@[K.G4$V5)J<6G?@FRR+;&XK4\$R-";LV^W-UKJH_D,C2ZW@?.S_4R
MP_<0+/7Z? >7,IB6&,Y_["=9Y>K]59CW=N]KFQ6/M<"C(],Z=NPJI+NH-+WA
MOLQO&AT$KLS*Y^SHB\,T/5K#S=67"&#M3,DIRBX@.W 8%8U?&NJ"[362"_UO
M %WI@@V<+E8$;?UH7%/)5P@-^4N[RR_!+EO]#VY2[J',7NSIL$YU6-Y5/7!\
M18,V@7F8P&U,C=J7N(ZJ9E(@TG.84!.KM$OIU%3Y+!PW8S$WT)$VI(RW67["
MR*K%C&_K//N8KUF,L/-;^O03%E83%LK!A%?8V=Q7C9!N ]="C_P)9*0]P&.,
MSW&APJ4W_:>?^VJ"XDMS .7\V1=;LP72F-;.+]$MR,J4NXP'F_^]"?[4GCAW
MD5'B%IC[M66X]/:>K;-/V7)3M[5%H+WR3=!#*@&G!@N'_M'%O_TC2_<X0.M/
M& U[T! 0W _[,3YJ#:ZX4V.*IAQ)G3\1B<2Z><$2S$M#[DR8P\ C>BWIH^9Y
MV>>Z5>A0=Y-\N1;&..S\%^;0-%O0?*B6%8L^_H2'A=[%A"'6V#LIJ;KE@=I=
M;S<2C15GH7Q\SY"J_9G1$;$1O@YXH(R]YCI^=H,Z0\&;V#:4XYI.+P?7EV+]
MR8Y-VVY/T8J<:YZTOX,D(P_67I<(ZR+?3YB4II?C0I9U?E^5JM*DUL60(*5I
M27Z,3XZJSB_K'W]-0:K>4?V.D??P$DD&(N7H\<?M'7VY]FD=ZJ@K^RKWAP;K
M@N;?+5"2L?L8$F-6V!9LS-^>KHB29C^,/J3Y!'-V_OQ!<,?VA$51I0!8F\BA
M<UP?"_&KG8V1T24?ICN:W@B44NJ^+X<JD3 W=__153Z1W&P/I*\V^:.0O_B"
M9?>C_>BK&Y*&*"=AOU&WGBFNEX-TU\Z ]YZ3?Q6FF$6HWS!C0VF\K2HW6?&Z
M+-1BI[YZU*7[]68^G[2U$SF]=(/\WZ"%]BS$G+2N<,4-J<E(RH,J1NDX5W,<
M\)[P"8:"1FC/\ZS>]J5GTH,\-B7[A8HYI<ZDY*Y+!&3)],B,LBS@H<+4$9!.
MZF IF-2OD\F2UVM)*\N&I('6?XUBE7),V'<.&+I^ZA! $=>*._*['_XW-MXQ
M2IQPEM<K7T%H'8+Y)$ZO:+2]S])[21-)(.!Q"1^27 Q4V?U$+:TWUFNJN*L*
MO4^(ALOKPFGG AW=&5N@S94&2@NI4"[U"[U?ACR+)VXAKCI$>7KKR7HSX'T*
M7>F "ZAYJ__P_(AC4!3&]4!G"6!S\QZW\:9WNZ6!?W7_JK![78D7JZ?RGQNV
M\38]:J<KJV+FD"0C<CY\RR6=4:[@JK?AAEJ:8^5D@K:O-'#CC1,;V^34!4D3
MSUEM_8;&\6_5@Q]/7Q%*B</YE#?WRE]">[>^7E.4U/__.NHP_<_E8S.ZC-,B
M[&,"?[)R2XJ_;)&B4C6/TO>Z#:;216^]*WV YTK&H"X/ 5U%V&)(X.*O M!\
M @"7*%=L'8'9=T\)JT_0SF]@WPGC^7^1)!D8$0X41;KGS^)XKQ+8NUBV?,R?
M*Z@U\=6VDV7V\D^OV:J3BJU*C\F:B,>#FLR\.2_3 G?S*_&K,FK>P=OSYS67
MV5C*T8E9&"1[]MBKS@HWC5@Z4PE54*-" SCC([&C3+72!YE"3;BXL]KC<W<!
M'K@X@3G_H+#]S;U=7^"L]U/CZ>3B>E8_KIBR68.XVA0]%U:6M0> A%USO!?&
M]J_MMBQ4W2]LDZH3BYS"N/<W LR,JO]E:#I9_?<!8<YYQWBG2=Q^!C=2FWJ^
M9!6% D"?H;$WB@T?F%Z9Q^JNTCSDR:Z&G=67N VN%N%YR91^ILZ#EJ>,ZX1W
ME&6T# F?]:R6B0(0+9B7IQ4;!76KCJ1"E.+&?^E%5@?>@[AU5_HM$$9 "[,X
MZ")9N%XM+T04!AT1O6LVOI[SBT22V[YQAMC=DM.(F/AT6Q>D%B7KJ.WH/.%J
M+*$I<:BO-_ SRO:.<W_XU%THD_'Z;@!<3$I\JG><L#W.:\J9^M#:P/[0^J9^
M/-\.J$@W^_V3S%;NQ>6H(0FF&!7H9-"A991ON84(/Q]':,,7T$W;1,S3K/CK
MC;-(2+OZZGQGHO>\<3*#JI/5J'4+6?[C_-2>I\ 4>'SQ '4J:?/ML?2?RAH7
M<=)Z0:BK^L@D57$=>XP.;;R\_F.8_320([8%APF2N$QZ.IU5B<//-(^AT"&@
M4J;KX,44FJ9*N86M>3[^=Q'!G^F;Y&- &*1(^U0)SX_G36PG&P^L>I,@)BPG
M/I4/Y1P=)'T +A;V]>9#&7Q+BEOG^MAM?'./TX/E[;Z+%/:J.&]5X!Y )B'-
M\CM*+1@)Q6M6[8:+$N0<&S!^$\%0'N6QDFQP*!VV]M%'9XW:X$P@R6@53U?M
M1[VV<=V?U/I3]<O/JLP+>H.L0TSLXG:&=_*QO%4<'JJR[[:2LJ(M]^1+3*L2
MHM&WU8CD>&7#Y2IMSDU,BCQ"->/[3+['=,+\?Q($AZT(_,Z0$,SHG0<-]PX@
MGE3>ZH5,THD#/Y)$T'ZH8>87&^SJ(2_ALC/X82HX3>HIQ+-:<XY=9EOXG+MZ
M;L_D"K/=  PGD0'_ZF9/_:\+%U>$$2?XFRWW#]'D#3\/=C(GKX^04=I%*!B6
MEU?#FTQCEE,K',(54SV?88VD!-YCH_;^#EPP':O27);=<A%PG7 Y&MN'&;;B
M\6E(_)!0(M7A[=E\ZOT&0VO-!OMLF86K"3?,D('\=J%3=?P]2O@AWWGG-00:
M [Y!D "SIXX[?/1LDH7?7PYFZ"DDVW3;\0BFO%*9E7L?2!4>^)NAY6K3HF*"
M:J_9PN\2M(,QLTP*E@=;4)MN0K8?8)/']]#*!>]O[T.Q($/#SC>IW3>&8?CY
MRNLTCXIF0K[Y*Z^D3^!;<GN"'GF+&<;)J(4C1X?5HSOV64 EZUD^W>.1,S0<
MH.LF$C-S':1_F[UD_?^B8]6&46)F@!>GPK6VJ?AJP.+QK4&.,O4J4;X'8D5E
M@?JX0BJ[EK\A2E=^751ED%!:1XXRBO; I%,WR\$TP I&N;.>;ZA(L#6U3]_Q
M+/@E(QA%-6?0BC\_:;7LTY!=BS#VSAR\M=X\&W83NF$ABN?=CIC_$ M&R1%!
M45W6$GTY> ^^Y3O\?!N%[UI<4RL1*^[_^(*.SMJ;@'.N./&69$,L5'UU,M^C
MVUXLI?J\(^:]]@ %/Z0#9MIVF!2ZE8L78&IY=.9LSMYK^I*CAN&VK4EUOE^3
M4#?A8E)X(OLKDP2=F _-,.ORH@A0N-M_@NN>%*)4RBINZC=LDZJ$5GD8=:Q7
M]H<_NRYOZ65Y3,+?"MEZP%7XGKUT\[L*)(V_FI<\]MTE$MVC^3GWRC' +"#1
MQT<%NV75_:^2=^^D-_*1!;)2##*9V-,=7)!B]GU@??Z5Z8,V ^%OKW;7#-[P
MH9QQEAS"62AH=<%A$/S*/VND+D9J ..\79]K'YIO#I.GCF?\R4H",,>OD30@
M66>[0-LEX/Z#([V*VN-@=)?Z&Q("ZOC=5KSP<Z64%QS'D>/=+H6N4Y7M5^@9
M]2!VYU+'VZR<OS+H/IN;^^>B\]*OXD[<%<-7+.)C_)X/5@M*Q/NNG(4,'V#@
M0T/7]N!2H[G_BNG*'_^%FU&TTBXC)^;37_3"$*FJQ5"TW8"2,6MADP@-C[T-
MLW-;Y%2!Z6S$[(X5*#PBD":-=^)XS??3Q(3(EJ?]]I_<LN7VA5 L9CO&L[[\
M'8U[MQUDY</7GYYBTVEGZ@%G[,B9A$6Y?U!.WW^K_5=)2-9@@C(O]:=:_Z#L
MF,V_&'D">D_KJEKDMR[, TM?B-CH'AJ[&^[)BVY %]\O>E[$M,H?_T*SL[]*
M<6JG/7WI^TOR5[-W'6GP^VOQ+/*K[3\H7[\&.KK ?D\>?V3E[.,V;3'6Z/TV
MP.P^=\^>M\DQ8?+364K>]_!3L91MBJ;$^8A0.X4^SM8;8V4H^N)IE$PJ)G%
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M;[W;U6/;8"9\#^ Z?0$B*_[H3\C5]_LG35.G@V4G?KZQO0D1)IV^@>RL2O,
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M8 G[=?YGSHHKHT'7E8'S90=[,Z'.1EQ7&SZ?\;^O%_F_"^3>/X98Z" .4^A
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MSAN6#FQ''7].(ZHZ:-@W52));L1W7C<^]@\\SFD<LSM W93I!#Q&6RPK;U/
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M8S2O]5XR]JJMM!JXTMNE^%*O12-E+$6=T.B&)!R Q.@?>\[B"&D,UUDHH:>
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M)"2/ESH9(&;4Q)YE<EB:-[G1K$4FZ3V?8BJ3IAM;)M3-(721?G.!\'M>V2_
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MM'D?"I+G* LJ.14]XH%R@BC 8]TR=.[&).T1%]28. HL<(WZV'25+Q2_^"+
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MS_D2>F6U\!R7,]NP #7:U]8$IH.GY   #$9H]_6_P 8 DCXRH?6N_@+8=IF
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M3<?TEDS_>MQ1B)F**Z6\ Z[_RFM+9F2*<3?)?&BA;TS>!Y4UY$,#A+^-$T=
M_(Q.J]OK89??"%50MZIK4U"9[JQT<QRS+ [&C(]-$*WCHI;!Q&;F8V$C_8Y4
M*Q<QQ%4CNNA *$I>"8H/RRWZ%P(?YB-(%SO"]/"=5O9\R^<%@:_E6L__'I$A
M_TF.S?\X?[C3;1Y^*ZH[.Z#7&W3J4IYV^\=SB]V89^AM=]AMIR.YTJGO\^U?
M&@U'#A?^%CE$^DAZI'6 ;OLVZYLJK51?%\],/>--84=5T60-E+HEES0,@J7S
M;I)QL#"\Y46+:1:%3ICH>S[ON.+D]BN7JK?]:#>AV.IT#T\?6(P('12,BQT_
MIE]UQQ:<F^[YMNAOO5.[<KJ O]YY>Z\_O2*6?!1<U(G[63AI[LF&7!N:W^*X
MYI$@8Y::):62OTN=&N?TEH0.K8YQ$35"@:[?U@R$@WWX[S4G5OJGYO[3]%+1
M,/N=F'8_%>E<)"\QL&^U?-D?^CRS.P/T-T8OB#\KJW#Y[1-=NU6K[A5V2EMK
MT^A%J5I8!.6UWF7ERKOOLI0F^2 $O,^1&XS%Z_FS&T /L@%B'VN(_D9SIZEV
M#=H.H@1IR+L>B2M8'@Q_1.'0X0J7]8<<LZN-4$GT$8F0(#&I%J9Z-4/ 3C>I
MY>RH(]" GO9$'QLKQR.QUZ$Z3=I=DU[7 L4E? X/!EP-Q$HJGHR>$,BB&J,Y
M?(U%KYB3T?$I;]"")D]^6B#S#@U;_G$)&F0(!2=A;;S+S;M\]-JSI$ZJ/KZ(
MN<%+A90[F7JDO2:WT+#:S!CI(E$"F*5><>;5#@8:^A8ACKZ#[O19=)(3XV:C
M>WAFX_ 45ME^# KZB1SYT]#F!YG\/\63:OT/]9S@^O/] O1=[G__]U#5M_^
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M+T('G_])4,?Y?]9EC:A"N&C+_SC)FQ<$)E\^OJI=9Q-JV^@P3I7'K1,P;U3
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M@,RW-CL;R3Q32JEV+4>[ERS^[HHKCSP%A'(+)M*7,>Z^@_C?K^;^@O7=[J?
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M<6QX<I@*,;I;.3R^I)L6 7M-WD7U'W]Y2.VUD9:PH/EY5R-&BC!7!TE4_?X
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MZ%5,D=TK%=4T2#F',H/"= Y=8E>'J/J:"T2O08:>K?/1[VUB)>C/>N$Z!O.
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M%;$]2%<O+!/#^2[@5>=7W-HM_/UW4<(NB=Q8KY7GF[[EG+MP$4<H^XQT,=-
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MRV(]L)Y$;#^B)O _N^[G3V__PH$_E[_[7NT/#<>(_E.!^V*1!*PV\4]M+Z-
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M^^, Y #D .0 Y #D .0 Y #D .0 Y #D .0 Y #D .0 Y #D .0 Y #D .0
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M4:S<!;",.I<7KR)+]9N=[3&'$T<[IZH#JQ2:$ S?F!_.]JO>* FPG%#1S]6
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MB!=FPY5&OE7G!>XZLL["*YDR6]EE6V>;+37X/E! T[?1?I2(M?<]\^M&AK"
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M+:,Z3)/<E5D[G'/);%1'XI.OREAJ2&NO.2TKU(:6+=PLNZR #8IC5$%\0\T
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MQPM$Y\B-RG/3!?W4E?;O(\#9F&_I#T;'1GN20Y$PE) 84NS\4=K%SM881+T
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M-B0GL6;DJ80//2%+LZ@'WJ1!0%'-$/X$6,/<_:T^)^!CRFSRVI&0SS?.Q,Q
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M8*5,)RK+B,FM*^@T<JVD747:E"'V"VMZ)-MAJ2NI]X6_2("D0,Z\2*!][ \
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M/_CY6R=_VOT'0X;^LB 9I82>HO$8[19D445 4!5\>9'-%.Q39DSZCZG .B^
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M1-PLZK0@6*9SV&-+&XP[S&,S<=4H"/M=AZJ3@^4)WTQ>OZ1>+$\H-JU'P9;
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M&59)32,( ?S+GW:;)@90 ^I,L51DW^A,TV3X4><12#6[622T2^N"B;E<5D_
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M3(E[Z'_I*/'>(J,BJRTK><6KW'?TI^C;&P?_YM<SZ%XAV+!"#S3,X$2ONU_
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MEXPHW,!O;_C3BFTGF1+)/C+?^&AVD3?GOEGO^S];VX=N,5C\ ?D;FY/UF9^
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M." Z]JRR=5(,!0,[0%(#[Y)0Y,AC%01'<QP#&ZON"E'.>EX)MH&.00=E2:5
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M'O4YN+QFA+Z"V\%K]'U]/C- ]2772H0\%FNQF#N_] BN>#RO]##7P_WF?$J
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MOH=[ELN;4!O2DR(=[B/*Z<[1W#(>?HB+)I$@N4'-Z/H8.)(9HL=3++U6P)R
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M2IV&P\6A@3HBP<.";/WIV8Z2*W?)EF<]1D7AGB4SB08N0<J>?H8I:RSMI]+
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MZ3EWL7;=KI?2?'_73"^[Y#.[PF!(+BZM(I/S5!R,"'[/[PI_828]9ROQ0A4
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M"AYATA&D9Y\2[S,O?LIV$_(EHVB<<F3@>^U<@UXBJ8N4GZE(/"H2-@+Q$ \
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M!;NUJY)G\GZ>,.\W5@?X:SMXV^N@*M-?A8 M-SQ^4R=1X&$[RX/=5K__XR>
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MFB<363IZ52+95O8#=CGR/.\#39VT83L%*1"8-ICHNF[K()*J'J\^_<2O]EU
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M-#V-TPP*C2\HU7?LO]KP1DPFZT<I<@QH:=OJS6=UZ@<G2I;IP*85R2^6(/S
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MP Z6IW%X\][<QJ$=!/2]"QP"]UA"@J!HS#@'H XA5Q5(@K'W/7=)&^P:3'
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MVY;%\S#4*XKZ#Q(]-4 O."9WBQ""WO9N."8^";]WK^:VZ9+EXH(Q*#_M5F'
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MNO)#QH?$Y)+_2T7RMF N,22^I*[?B,=""5B3;.IN!A8S)"Q$YPJ&= Z@( O
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MC2DC'^&0[<PC/KFQP0RT'<54&PN50CWOQ$*/HN&?'J.5$X0I!!1OU^4,Q"-
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M;>4K@'YM!C#_8Y5OI0W@!=B[:]<NVEU[:6GW,N[9O8?Q$,/>O0R'CAXX<.C
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MV=KCX$[BG&O"X93C5;( )\?:%KR-..?:QQ <%U0U.&0P6!0'E%\0B!04%.2
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MF-4_+.+@U=97USC%<45XL[A-^W\I;\.C4I0,64W</W6NM>XDC;#\7=N2D()
M1,""PE 9>3E168B(*%16!@26DA46$06#H=)@D;_7]R2DY: @F) P& :!"(N
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M5[Q>DM;ZU,VF?3%*DM8:>W<(/CW5\X; =6R8 __6&,=UF%H(T=\#C?ST9O*
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M=\;]+WIGWZ-3OYI"?&Q5=NL4>W/ZO9U#"9\/M^8$7%L!'&1YVG)J7NXYS*X
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MA&19Q;TEXAA-#_NER<\O3[8G?V!>*GC:[]WZJ?8FACG_NH%%$@EONE_L>LI
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M>7$9ASE\UP'TC>\MIT7WS[0G8-.LM*=U!-[>R6-LI0 5ZI%CZCHR6U@$5(0
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MH0G)!AM&S4K3#3J>K$P[3"G<<<J<'7R>-?A'S*,FP&#T2WM5U%:7\:O'2'[
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M@#G[Z]OU+7YW_Q@C]Z!W.WP4V+8=9YH1=WJZ<_+0F=]T23QR4=(8]OQGTT!
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M#W>W(,NR-.70F*$ZRE].YSLGB;+SZF%HL4G4>TIY#+'"1E,J^^L#L>@*^?F
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M R;-'1+J#(^-RL%[1P1DHPW<3_'#2_11QN_]V9V7A$T>9R;.=P69>$-"ML:
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M &'+5@TX2#EX#DD7#5Y<A0\P!S>@@-U=D'%D^33;/* GYID#U#Y]Z"B9R@#
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M_$9FC7.GR.O+T\%(&1UER7XR>!LP-2C,N">'4JIY6V1VEBZ0;^MJ8W.=12Y
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MU9KF&N*T3&5B#O8-'W;*7E@_H)2!5*(@ZWF4\X/9VZ@#G^#,"K>119F\NNO
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MS_XX2BG)K$V#C\OEPA5UB'0*,">>;7QX>!-7ZLQB:'>,)"03U8\U*RE3A*=
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MBMP$K@:1A)-Q5:803\*7&!0O6N,?OA(AW,EV:M+,EOHEE<P42$F[OMI4TXM
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MW2:"K36:@]D<F!SGL=S<7,]'0G#Q/>$^3R73A=/":%HW25C?" %LTNNN\SM
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M7(!P+"*T6VDOGOH#W_A,%]EE3[9IX0F PT.&<79L:V8;Q0;]']-;8:N.ENK
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M\3H*X!7@B6BJ_X?;UCDHF +3PC9V#Q,F-.;>Z/0,%O-YQK?D)?Z;.W>3?HD
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MBV'X$AW.2=NA0M%M(BYM$LZ)O**/,7)_5HG2+2%A+5J@6462-NER'W@VT<1
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M-HZ>VKB*R'KO-PZ'4(UO+[Y@ 0%20Z\W7R>$I0:9S6X2M0/+"L#&JJBJ2-X
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M(<U>D*7]M6DVS+4X]'"LPQ:8RH6&"M]V75LEQ'"%LD1A;UCIQ^CWK)*SQ$1
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M&I&(LL(WYO$%J^L16B]J9DWP_"C'LP=YA6R/7,8P<\UOD,B+,/(UL>.;GLI
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MC >MT:+P5X7@-OPI V-&-LX?V(PY&9H<\!^G.Y,+1U9+Y@*G7]]QB Y$3DL
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M[TC";CN0F%4=]Z7$1H%&+?;Z.Z1J83^4Z$^HQ7'B&SVI3[&TIN(U)A H\5$
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MRCL92UM03@[#',K9R!AJPYPD\R_ASJ[N=T1Y#/;)UW3[V*8\6]2KU+P13MJ
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M*_[@SBL;EGU$P&5?[2[;DEQ<_2<;GTKE]MU)%]F$5]-=86CZ;5[O4DVW$"N
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MZ+W_ (KFWT7/\E_]7#.'G\_[?NWX9/\ "$_^*MOP$"QU79/>P-S]F>A@=F!
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MN][]NPM?^+_CT-^&\/X!V%K>@]W]/^OZ3[K\'!Q#\X'YS:U[_P HN?4>_O\
MTG!QQ9^+V-#XJ?$60Q%^>/,ZXL22PWIK)-@3C:U@20 1[^W%UHRK1A>4A%#)
MCH*R=Z-[[?AI_.1'F]>BKU9VM92:V#?E-FRFN_#?GQE&48DR86((Q -PK V
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M[$Z;5ZB*8M;#%-CLOPYU$2;%$)56>FUC6(RJJ#8G4*ER7D#N;82J<I "H>-
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M@7>V4MKL!.(CI#I, 5=;V=(5F5&00'.+4>*R@23$/<#RCMY'0]0@A_G(2,K
M&Q4LP1;(W#;D%=)D3.<F]V"[#67RENX.KJ5ZMJ;BIAQ7Q4[M;93!5RKL8VZ@
M@5V 9H?DPH=+'(NRA"6*V[7QP*8FZE0BO6$9:B9+6L=RNKMU*9QO1NVVX+(@
M9'IPYCF+:7V+<[$<[1.*B)&KA7\S%"K R.Q\C XJ@4!R5 9BMKJN-_E"I93T
MV5TQE=ET*&ZI4=H_65%#JX7RVB-HQD6=D,%2M>E;,;@T/%Q1%DR"B0VMB6R
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MWXH]2,?>WCXJH-BJ9(#-E:FU?:%.Y\MJ3-$C%STRZ5EB4CS1.I2)%EGS1<&
MQ6=4E/(SP7::6J<H@0+"D=PC%2T1,D@IP2'*"FB@[!ED)8!L#F)4,(F]!O&Z
M-G&+[]([-6V-G&<2V4KBGF*N7FD67?FEA/--E_VUYA=K4E34H9%E"QKC1T]/
M),T43!,HEQ* +$8E)J)94CCSD,A1P2@3 CI$V+*7E%LO8H*:ND6T-Y7ZXGA6
MG&0193E'WDD#J%\S:JTG5&):])$Z2UEH'=4)EBJ(YCCU:=PJ*3U(E4-9OFL,
M3A&2Q:SNT@ 8@+%8\I&)K18%Q$SWDW=>M!G:VNUXI_%Q.5U.J.>E*# *%K=$
MJE@3 ^6@\V<^&M:A=MZI2S*R10;@U%:9B;.RM(I;*]@L:&3M<H6+A ,88R?2
MOL[+J\'Y-Z;#0OT#.QASA*+^'%5GY_>WFF1]J?%8CT_^*E9O=EY&@W&KKJ3-
MI3F!&8[B4@8FUWR) NKXIW:WE7W%@P0D=I"K7D5WA>#%8S4D<HT7>'%U(LHT
MN8%W7>^^R8-PK ;75QJ^*Y26-51A$P*6 !52!9^P(4V566WS23EV!&19U15?
MAN2ITBR]&U=][.PO?"$94.)4&>H]$K ?#2U3EKLO%-ENH;LPE8QA!<*WH0PL
M P6S^=2 H,@4GY(CA#I;DM2CYK?GL&55%W?+V5V60A$WBO2&!OXE3  F0B$G
MM'-Q\T<L9+]B+,BW'3)6R7N""+9$8@/FOJ1WX3+&NE&_2Q#??OEWW%SA>'&)
MBR+^7Q7M6:P_(,QH6SAR7A#9ONE.4@8*;[N! )5V#G2]08.Q"!@+ 68!!V6X
MO);B/5#W4EL\EL3Y(;9SL76-K2KL?"[.?Y<PWJU=;>2;G!ON@U>2N_2/>M]!
M3TE@3:]5+<CTN?["]2/7C!K3^M/]B/\ ]SC>KG]6/[3^3BEC6B;K=*E!,8B"
MFKFQLK%K_>7Y[6/;Z/=PZ]/IZ>J==75?1'TJO[3A//U74=JKJ?6_J7_\?C5#
M5@_O%+:_FM5S$V L0 :,7L+V!-N_N]>&UI_6G_EQ_P#N/"W/ZL?VG\G'.EX^
MI(5\57,=9(>HZP;,L[$JJ [&VVJD'!@0,B'O8XLOF 'EO>0AU<K%ZJOK0H4J
M4NX"[8R@V]/KS;VAF1\6U[C;$T;RD$=+2-LQWEYE!I?-9Y6<2]R@D1[M'_>P
M'!L0R=V5R6"A&M8@$@8BYXS8R) B-+U6$<[.P2;J6.K"7NET<RD&"6"=%R"T
MD78QV0^%/,1"BB@9'"6Q**H_<V !Q]%?J (/(N<;D7.+.&N+\2!=YZGM:@&1
M&T:J.'Z.\:NF+J1IC*(6[%TF'JV59>:G(YNN*:LUEA-\_*<NP4%5\N+F,A7(
M*OW%V=8^X922Z43+CI$NW JEV4(;%&S+J*VC)($7J9*D7 2 ,VQPN]H*]!ZO
M$ X1VN54HI#ODCY68HUFMB;"PR8V*AR;YD\&;!;S$I*;6]PPK4HX,?1<6R/2
M,D$K*B2$%CVH>DZANS.]-\*8Y(PID(0)@A0,%(DQ'<M)DH/J00UP&Q#(7 (:
MG4HB]DOI8V$<5LKWW,TU8.&,<XV*HZNJLVI=D;-_+3'RW7%!)4,HDS$8C4G%
M2H*L@5$&.8Z:WN2P8&89@W([N1Z8TXO]SO>_RNMCN$<MC(ZE;CWS1YHA07DC
MWW\S^'!4RYLI R_>V!L#&?, 3U"0WSUS%L2L8%@; +(H+58[R7%RH#%A43-J
MF<\#F11%ZOB*Q2RP^9+S(ZNEOI-RSAG'-?1(?LXK2]/$(-9TREU &1%97FIR
M]'.Q%S=NC%39L0KYKV)7%N.-?I-Y.6ES?(<[ QJZ6IHSD;LM*1,M +Z=4+]"
MNU'J#] OBD=?PWQ;PO42^6YB',Z<<=4=/F8,/**T1U-!4M\TFW(.([%TV*>&
M4&))4CFJH)XY(E2$B&1@A!Q,0E\EPJP$D*@#&0^7CWBSU2 C;+3'LT(.Z5Z[
MN**"L>H_ F7NE\T:U$C34E&LQWZ6VGOF[O&]A7-HZ14T-)E+4"-YEJCYJ>D[
M=((7!F59I%628,ZA@M.J+DS Z_*BNI;W(MWTU995HN^[2.^'8I29Q9,DCIW&
M-=+%U,DE-I,1Z8NXLRU!XO%!%'4+$K++432,L2).H$*%S&H<M(MBH4BQ9H0L
M8!&(;+B!&4L;W6YLIG)1=Y%W!S7$FGJR+EJ)&-+9O(W8D8U:=P@JV[\6>N@G
M<UAGC=)%HY%B:56A-\TID0!XU((60@K?.097,TKSLV5RZ]6=R-5=;XW<W;O=
MJEYX;S<M(A$@DHNIDB]1D=2[MQ4< )$* ., Y4X'G3N*H=RLU5MAZJHC&('6
MFU53&J9*,+A0T@!8@E@%9B"/0GZ+U>5YVJKKT[O#72VXJG,B[W-Q:X\8?_M!
M0C#GO!Q%Z=+7C!/E*!E>V(RCW1P(R.'GF9G88R$,I.:6'E0D@%6C*,P!!+7(
M9%*,+=[=5C!Z3R[OD-Y+4?E9BHXCD4\NSYP9K-J1@2>YY5DY;S;=>;RGF!OJ
MX5+4B1"S$AF*A1?'U:ZL8A(Y5C@UG##)B%/<HY*IB;T4T[#]$JK"G!L$G+9P
MK)I<Y1+S5VDI#86HMI:T]GBA)-WC%RE@%(+!"4LK6!9B/-A9@"P4L%ZA8!6F
MA'$C$FT6C#FFHV%=1BC[/1EMQQ1BB\HUBVLO2J6AD%[R8AB"CED502Q#/B <
MRH;(,H C8$'YUFRLTA/"E$BQ+O!BV0& Q>(W0E91N^']/E^(Q4E;>D)*EN4W
MJT+'Y4HIB)&;-68GS>0XKW[JW;,^4AE55L;MZ+BO$<QC*[J@.FA,;4-5\T^V
MW<FTZF56%?79>\J2]VK44,8./>GX-YION?-1,$,./VRMRC&69XS;XEVJ5($<
M$N9/F!)(L !W'I1\^'OSKE(O3@C&)(;97O,IL_FK>@^S6/#Y$0K]9U:MJ@AI
M 611[^E</YE%;+%)$8:51+&\=Q537 =2I('L=B5O<>GT7%^,./NXRC+JF],B
M5= 73?\ ^<^7%^]:)TQR)\3W_P '%3.NO^X4GKWM537]/\"-O=W/NX2M/ZT_
MV(__ '.%N?U8_M/Y.*B-.0>LD<9]/DI7E6W;O=XH3?OV 4^EPUR5X:]/T5?M
MB1_A*7"G5W ^Q7]Z'SQ7W^E7W_H/N^BUP#ZV[^E[>G:W"<+P#MZ]AZ6]P_/>
M_IW_ #>@%AV'!PG\_P Y?]N"_KV[]KW]._;\U[>GY[6^C@X7B[: +MJ7<C^R
MH;6-O_)(.WI[O]?"^GV9_%X0W<W?[C-?[GW>M\87HEO;=VCU_NNJO?<7^)M"
M'I^;OW!N._NX5^&/^+^/#8V,CTH_#;Y[?=^[B_ F]OXS>X]3^<FW;W?YK'AO
M#^"WI>WH0"!Z?RD^X>O?^+WG!P>A[@'MZ_F_\[\WK^GZ.#@XXJO%TU_%=XD2
M&"L.=_,\"[*HO]F>L+W[ DD?^L3Q?:$7W&GW)0C@%:Z1OY4_,VR8SI_.,7FM
M>M_?:@757UM&V]9ZFW.&\\-T\X)C9R%8JSJQS[_GN; W8&PL>UC8]N)6FZK)
MOL&>PCMNYVOC%%/LZK S;WMP5VJCUQ5\+HGSB4&4E%+EK*2W>V*L;@XD7LI/
M:P-K+8XTHI*3W:IL +'#W^W&_:[XE'J"+F.;L>IHVOR_==&^&CBZJIZ*M$S%
MBP )N64%<L03Y0P4FQ!N;^ZXO&OF2LY.Y]%+:^:&V:;^4G3AE<D%O>RUP78-
M-GX8LXKR/FK$#$7"B0J&&?;LQ%KN"+-="K?F(X;3:TK2I?9QC%XO]UG#F5F6
MK3(,J3'8Q=5FKV*NQ+4,@55 +O>[,!Y?2RGL3>Y /=5[ ^@]7Z?5U=D%PT]E
MOU=J[YWSCB+48,0\UT-QVL:R[5LVAB-GIQ0A:-'#,PN%L$;-0#\XDGL2+ +D
M20"2#V])4E**;>:U/M3!^*G>K1SQ$=,9#<5#$6P&U,]L'V'5V*.*LD88IV 9
M "&N2)"6%V4L0JCZ!8B][]^&"U?9N)M>,4X?Q6W\.']!),5(;5<2ZGLV;WZ(
M7]QB&^*)3H=2SQ-)(8I H6X'HU@>V-F<@D9=[@ XC'B.5(A0;Y:5=TNOL_WH
MXR-./NZDERI(D7 ?1_$WRET=Z=1\JBZZ77P1CY:BU*M1@RJQ$,O2JD4>JFTD
MAO>R@FS @@\<(]O-$T?&M65!'7T=#4'YD/=R7O\ %!+[^FU>M/T2<S[_ -F-
M""V\KS',<O*VD_K76#?%0U3:RO2UX>]R-T+38]!84,5A458K95:62)9*DNLC
M/DI6-@2(S89,EG*)= W'+/%)3=6EVI5"\M[)F63.6\%O'?-/G>9YC2T(ZLU-
M'1]SHL07H@>4E2M&0K#87MPYC2:B@TYZBEI],2#.I<U4EX*>6IF"*\4<$L<D
MT\E-$Y66H,PCE>H62G=76G5A4N:C*0KU2F;RLVB(F"[6A6XI0<3\VZLM+1G+
MFO>/NXD(7)]V2E(EUQE C'4E$33(R8QTV.H(ZB<7*1Y%$KM+([U"^=6RD1U9
MGE"OW1)H,UR:'HA398RK2-8XK)C)12^VXF]/>K*I]*^2:*2(Q( 1!NB-)0H9
M28/Q=6]MT7QK#<$%%.E046-!2A46-7=XHC65,5,W59T1962EZSR.T;*^!93'
M98SE<K3J754XIS;C8[4HWNBXX?S/O(Z?2W_615DD23'2A*8QIDQ\R!'J-PI1
M>/+G?X%1SFK6CC9ECH*)""5!53//(;JO=<B]U7%<0Y[8L!QZ7_1L']"SG7Q\
MWJ)OF)IZ2&>V_K?I>>/&OZ;&7_XDT--:Z?#=!2.<O,\S7VW&K-RE-L[YTU)%
MIXE.054%F([]U"J3Y;L+8W[V++<KZ'CJ X,TM%+W[>:+BEJDR=S;C@TXU)-P
M%'?J+5KJ^17[CU+H6(*!6(!P] .Q))-P0&[W_EN+@ \%7974VMV=Z-QH_!_?
MB*O1(QP-"MUU5FFRQO!V+3B<J";2,6(\M\6OE<6(( %KFX(L  00;%N#(8HM
M S=K\RJ$'Y]^W#=UOJQ=]FB[O^'8K[<2)(RD@M95NMR"3B!Y22#W []\0;#U
M%^XQOM]Y\[W-]]LN+K;"Q<U>6C.:.V?F6?-,\=<?P;\22^"OD@QDE']@[U ,
M4\\2G_NE;T)NL<J D&XO8^X"RV'%7KR8ZLP(N1;A%^C':RS[,;OV\;=X?$_5
M-++CJVDGTY>B7Z7\L</A6BZLBPP"LEE97?$5LZCIIB'D+25*(%#21KZEB7'E
M(#$,)+:^[C$K+IQJVZ/+IR<T]NV]UQEH%'G5[$Y;%6YD!OW;MXE6E1AW>J5@
MSHZFLJB4=',;H2M0RDHRLI*LRDBZL5(/!*<A2M/LC[N&1!$\NR(@EETYX6()
M=R[XZIXK"/FW&R^&9_" 0X^%??*(S$-JNRC>26:0@'>6A!O.SLX  ] 2%[D*
MQ[&3EY+K$J"A/*$>SVC6^;K?:^*KQH#P_5,MRT_B;K^MT\VVX:2[+W-[YV)5
M4BRNS.$9;FY(<$+D,V0>AQO'EYQ=;6NUJ1ZMES2EUBEMKJ&HF5III+I=&9!Z
M,BPP_*D6N[1T"8*H'A.PZN3 !954$N2@SR+,F*,6)<^Y0 0K)=L48\/$ *\L
MEJEC:=)4EJ\N^XJ)V&2N5K\40>II:M:,X:,A?T9;B\$!<J_4$3]0W+]-0U@5
M" XE0"P4DE+,5+GYS$E)HH"J1 #(C><^AENP+RN$CU%V%RE<G NU%Q3'I0.
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M+,N^DL9J:5B[30RT$BQ4Z$3?5425I7)A,$2ICY]2#K;%D29;&A'E-$J06<\
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MVZ?Y0:?:3QQO'W)I:%C]3]YO/OQS'/'+ X) .3\J,U+\YL"@^H<5X=C@NQ?
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M=',_Z.V0(L)E2S;J296*&FN7^EP.1+A[J;+.77"L5'==AO1WFP,P*/ 3UE\
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MO0 FLI.3ZL,$.)K\&SI/;5H+=.-4G=7F=$<H$*3QN.Q&[:JF<M\3Z4T:H+'
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MB, :?I3!D4,.6 TM/=Z^EPI8V3TQJ[T?=[P=JZH!6V9>IM#5D#LVK"?PQ<X
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MGXQ7'T:Y6D5&Q$R%P/A",\,A5#TYY4P$UP NT-X/4H^'QV'!-B>.F5M3:9^
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M O"PV5S)S^,VI1D9*I0/-Z:@QBYGA@'%NKJ0,EZ,^8>CF')Y@(E/L$,+!^7
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M*HPR?:Q*X]^HV#Y_2F2PTQ&GCTUU/"T,;1RFL4:+,<[873Q6Z$)I'%3XC6'
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M%RI9:__'SO:_2*-'W8=.E"]3VYL!9'^1HAXN$];-K<S5)OF[*/O^FUQ\QWS
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M;O$H&/^ B9YWKZB@Q&%4749,%;)GHX+/9]@7"TY.X[KYPO_CNC:*%8Q:04W
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M5WY,<5ZM[NBPV+@!.)FI5-@N$G;@E?.IL1SZD;T>/PMP&,9BS@Y3P6NM&V%
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MY=?W^"^DII&G^U2O2U6'H1RZ/U7=3$EP&,[H?T-C]_#N.3F=P_<$%B#891>
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M(Y9S+>VN-JO/6:Z/=&MB2PV4:5[)^N->CN)'>DGJ'ZB+14,P'XZ"&]SQ#K[
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M$'#U0J AG@((5_;O1G[:482Y0E'VQZ_F6([:$"ND&UJ&C8V4Y3?Z,3 GYU]
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M5NBGXD_&W^9'Z/L$_?\P<5 DXNBUZ?_$Y&%Q(-AM"PSE*FN#0CJQ?*^L1]4
MC?S1<'"&V?ZT]UOW_XW#LH:A[/]G,O(W+W]%A.7_W.']V\O-!@0!0T6$K01
MDF!1 3&8C8B I"A00D 8 @,#A:&B$*BPR,ER^S]PXJS$@9)023!,0$0")B$
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M,O+OVL Y_HXUCAJN.1X.Y<_O6+<#F(\^2HV+B_?[!^^)"4GP"7#Q2(_DYF<
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MF8?Q8T9#2%69TW!' 0JH3+3?J+^7O439*-O7%I3WDB9<7KK,:?^ZZ+M92M+
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MHJ-7WYFZDYON77LK$$S!XUECG#[(3J)$*&ZBI?AH+K?C#EU_^5\FSA@VY]]
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M4E4ID5E_?1IA7CK5O3(HBYE$/-;(JIP,8A5.$CHU$%#6EY'P. \R%:GQC'*
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MC1&%.B.P:E((?1POEGT@TMW4KZ:D3I92E/9,M7KKPG;=?<'0"YQ$94)>]7#
MP.V6L46(OO9DS3/AD@\8GJK,$170=Z&Z@B6%FU.@,/]%N_%DCC8T;AQ9X9A-
MG08]_&&XVLXV>2:$]4%'IOV/3DC#&Y\F=Z'-2>*YG^:2"K'DYU1:W<+%U?)E
M @T,(ZMZ,Q?CV=&NFMH4IS25Z/++=?Z2D1J7G_U I!')?^*>\C$WJHQYWJ<5
MZF+!1:7XB+3:"$N_FQ #,7X8UF$#8IG(>K;*NJ$&Z6.YOM#Z*;\^4&3<FL58
M+:Z%MKFEXCM VQ1BKFQU_]Q6 %[C7R<.#9R@^L4Z"^CJ^-FJP\WL/YO\LJ?9
MJU>UDF^@?5X+]$O[*S1B6 :2G>!""*93G,:*<=HJM';P6T640"<=B?KNJ :>
M'3>SFH^?*-6@<.BT<F]KVPKJC^V_J%Y9)5IO7QYJ>5!]7#ZHC\XW[OO:CCU7
MR3GSXB1'R>@9N61CM1<);JY+J6.S+?K?B=,@Q)'B$990:4_"Q6BD:.W3;5&:
MSUZ$Y%$W4T>_1+1E<$NS_.T820EK97VK-^AP2D-%D-KV81-"B_)^'8J18'^)
MHE+D,*'-]0W$1E:5KS,VR7!WHOL(8T(@D@,#) #)WJ&]I*CH1 T^W7U4)&P:
M5OZD^["B=]>(7L;*-HE&Q!B(JZS_A6N5G.T NTVW:H-/XN+O$,(=/+#MS8#.
MY[H3]M&E_QU@M8VGH4A]CNR(_MN^',?O-MPE*6-R):*E^U)N+C2:^\G%<!K[
MYN\6W("1< +<)Y:?VWCIS5S\/9C#:/G;<YCXC#8VDQ,S\GOV9@3-#M)M@\F>
M\4^3E@L3Y"DHYO1:3/Q=U)R1$7 *4E]CX9% .$#?7!S\.AYA2FV'%\N!PF:C
MDG3)\K$T>&QI:ZW(T_8O!8<-P$LZVL$A]4<WJ3F7,H3%I8?1]'+Q5>YU+X$K
M(L^\.A7%,V<<.C1B7F\?X>QS4.K1R6NQFH1].63^/FO;[DNSV]5$IJIC/A\4
MCX:HX/G5ZL(4JCTP>$K1]DR!"QQ=$@ELY&EL#%><+6AOQ:IF;W ,.B/&OGGM
MSOS[#L@UYK(9U]*S&=R];D[069)12?PS,TO,\FVEE)AL3J[&A@PT&A@J&$WN
M_SADD[2N8]Y--J5'UEH" 6MI3KU2.UU99Q3W9U3%&GJ@O?I)-C&E-FZ9HJ!>
M_RFJFVF.,KH1,C!;:U*\Z/[QS*]J-B1EW<SYL6MHC?]7.C@S9Z3=^.U2:#)E
M#>P\QI6$:UFXOX;*@,3'/KH\H#Y19YN%(2#;U\A$X=DB8Z\1#T\UK*.M8F]=
MP55]5L0I4RR[=ISV/,9Z]<K4 1.^;$HW[6^C)#FY7%=I-NW0BOME-VE4\"$V
M TX;/^%[E46ERJ('>CV=]-)*+W_>982R([_ F(]7\WKIK*,"Y2QHC=*EXEG
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M"Q>TGWS>H?[&W&CQW.WY#NAN?M7[\?](V/S;I+_G+$H\(A> 3[!.Z#FPTQ(
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MCXHTEAI,+%JD7V-4Y<G.+:A]-1105B>D.1*(.'32^A>@<-UB[,#:C_%OWQ@
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M4D#/L&&N$*Y))W@K[,>TE^AB(O1K/=9YSF'DQ)W5<%&?5_=F\)/&6G(7%L6
MFOP]-I^,[]U T:NN]VT5[8J'Q2:"^?&GH(H\JZ^MF0GT1L^P9#X(6JC@HNNT
M-O:DE+[Z<IX3>2 9G[]LYF#0FZ?=A=WTE6CSJR3(L<D8+O["([E)2\T3 %0E
MJB8?0-&6+40XI^>AYC=3[)"=XO^SXS.^3^.((((F;/IYZ+RS+$_H:YQ'?6>!
M96?T;QD3V8"&Q[J=2#-!II:0?1H_FNE9R"&4\,>?VNUU)BWP8S%H1/(01.FT
M-J]V<2Q_74_MV6)8.=067+6ZQXCA(/>Q.:)!FBT\QC83@(.T(L"-,(U!!@#
M:$@% 0!  02-VHTV3YNU3NOA;BQ@GQ^GO-"L*/@H;=8O<<=(NZO7_I'" =<L
MHI6)T))-:LS"[)V(^ O80!3PV2O[8OW?XT7=K0L&GRM0>A1I,4NK%:L+/7HR
M*/<+!$6ZJN2U:4\@?^Z0BJ&HML>0K5*"NX&X<_K$&88VK2N% X'!.EL_&W_/
M@$CP]YXBN4+OD3G^8*.G?K!T<6=U %<OR]%X_P5L^ZV9+-[#UW\@^7&EPU!
MXFG$0+AIT)>V&K9$F&+&W:=3?D"D_!DT58%.2\\*#T]/7"-5<\N0MI0)S6]D
M2_/=MPKUP$9ZJDCQIM^Z<>WASK#FQ!1/Y_]US:!D-;$HTC2DZQ%E%K)<20W>
MMO=,EUS5*6V4V5CH(>7?1WI6*AGFY-Z,'!SGH3)CT]>[<[^2F(1C-=/-!N/6
M*'\TJX'K.F;?:,.Y$QA2HIPPSQ:K'W%+FT_Y'\LE_@7$UOVKE_B_P6.(8=P6
M;-&[O3!:\X3N0&4UJ[C+!UK.:,\]]#=3</Y *( A ;,TM%3+M!6QD0G27K.Y
M2#0A-*=N>)*?8[]E]:()$AD_?5&YXN!!F[9=U6KN.6N2Q!?64+A;8?.B7;<W
M[M8%&BAZT5AB2/&<=+S_@^']UZ\D?NSQ\#,B_?[=>E>YM;<+VPJ:E6-3=HXX
M%^L/J9"D)+'))KGI.$09E?$S/.6T5?MQ-N><J!BP/#R979U1>76#6*2;1>Z-
MFN[!#HY%>(T,4P5=Y\=3$%K^=:%D26CEY^51F:?T2;OYZ#K^4@32"*1.]^:C
MSN5=&K0N/84;H*/SBX%,E'LOK0YS![ 9[]MD>"DP/LOT87CDFLN>A.X"*4"U
MO 9)3+=$K)ZJH.:HLW'C>"89V\^R;3)$GIF=YT63#FB%G&/])2K,P5 '4VF]
MR6G0+6LK@_P;BRPM?[;-+R:S3?,&#*IFY%N'J'WK=YAVX>$%N9.QD]YM3J*X
MBNCJB=1BS)&=&Y?Y=#NDE[*L-_@[P6-WPOGRICJ0P;SPH4#2OZR2'U$ I*A_
MKL\_6"4&0'?!Q'P" )XQ2=.%?R<EP5"=HAT6F(DL%#+24C\J464OK]'+,V<Y
M24E%5MA'5?"N'VK!8&#)?:*KPD3<()\[UZ.V2%:2$AI&AH5+]\V5Y+7&VVSY
MQ.>+=LU!T+D>6[VWV6-2HKG^O(9+EC?D!UOIPXK%U\;(.KK0!H)8;<CQ?676
M,7I\XG.R&"V^J)*5PC!.:E,//?[1A1YSYV<1D!F%'!'<P+K:;+"QQYS2_"DJ
MBH ;LUJ2:20#N:L4DWZ<TJ8QJ^J[T(A"5/3'ML.?E[JW3PUWL<K/$;' J*%(
M/PPG/8<L(E2[ZT]:U9$) S)/M+++WAEC/ SJ0\Y"?L^+3HR4/K04S +,;BY:
MNPAX*5N"?*JI8YFS/2R"J,>RMR$QKQ=V=66,]MLK>!.8 XY/EIVE-=-&.'[O
MQ:?L9Z/JH 7Z-P**#[ 7--3TX?U+,&K^1\?\= >0/D)D(\^2?G#)X"K&AI_'
M8E4S),O5M2,^$MNN3I"R$&UR!1V5S6T:N*,*II_FP.R06_>A;M!,C!'SZNH@
MO*P+K?_N;C O?F,'>$WPW'(0I&$J(20;X,[1>V+6_)##8;F-%T]4:KJLC'"*
MR:6N]*TC.JD,?8M &R)/XU>6+CM).:MYF'SMMW/3-NO"XO(^3NV.]$_\4PKI
M81?_H(R:@ ^R5)>9OUR1^;["7G)("""U.+(9>-1+VWG66,5=A7;7'M AT0B7
MJ6\.)OI>XYZCKK'9)VMY45/]_$'/$6\6&UF_?)KCCB,*=3IPR;A[.BA)J*.N
MX;B$\GU?U-OVF&3<DB2/8/.B6NA,_N<4.J/(4J<415517\9GGJ_$BHV3"[IM
M]T45@\0A=J64ZH/8IE0)ER.0FBJP(1P$$;$;OG:G>?Z<N")QA<2WR6L[80VQ
MDS:'_H):[KC.V$A0*8^0?6U,A"QJS;0T2Y[$S[PS9I]L."; 898*=:FS/GTV
M=DCHR=W;^Q ^XTO+VN%QG#3FE0XM<()!(E\W Y-&.]UYRR%O..+<G5^I6_!<
M:2BY0R1-%A4S/OJ/0V&!-J68@_7BL-1POTQ31%@""!,3?YW&93ZY3LVB/U9*
MX8-TBTQ\5#;JG%(A0&I!J93./Y2><Y8[J[3)VHXVWZ9+WCKK&J)OZ;)90)5(
M/>LB/)DKSW#U 6,E0N"Q* &)' 2*P==;VX_AB>=.'OE..!*\QET(Z/YT9U+U
M?\79SY=7ZQ4/K?K6GBLS)>#,(V0W'H,]Z^@0]9\IQZE@W>MD+YH?LD4*&\*(
M+&CFL,F4^&((AKC!TS96;.9-^I]R"Q/*%VJX@TE^QS7$AR?S7KDG@,2N55*M
M%3FC!X=/K%RUFFZ3%)6[V25,&UR(2'Z\&M^AQM>[4 $^DNN8UI>6?[]V&G'D
MO>X].OG<&;[BB,'EF>>L\H.UDOHOP(X:EY%NL3"DJD&C; -F0/1+!P.":M_J
MVT<\7I4C_P+XT0</9B3:MT">P5^A\4-91='O+XI?=FOFKF=7$FH"RS5,-[UW
M2::LH>@9KK9?PX<$98U-OM%0I,N0U@(-\O++GQV?>%\$=G,WM>"5HWL?GXE_
M?#Z79B#VJ J_WB^1_O")RJ>=9\I'CRV)_,-8EL*?!L>/F3 RLU/4< 6D"LZ?
M9!UL2,9=P<R"GWV8!Q-+27A@K(G0Z2%RB38P-@S[ 0483P1OHME'@H><[GR_
MT-:XV7 #/ 8&&^K2)F0H$\1X>!&X 'YM)\9W,1D?O+=-<R2V[:LFKB?W$>Y1
M_ [A\]U<UU(,CU%DR[Q\:.$^N")E:B!?_I/MP^%CD2,+<^J<1!D53Z&5J1SR
M$?MU!Y".,HB'5LM.R=ER,'*&%GW3M+"X0DTI:]$-<SFE^=*M;36UXQ1HG-?"
M8S*J1HAFUO%*%A:DTA-EL3*3UNNPWL)SVFJ[C5!G6*YE"'6 V/**4P!PHBEB
MI!GL:"2"8.0D_B5N 0 3ACNOQ">],WY;BKG/'9TS+L\L+E20KY80A;:V.I D
M_DI;'8"[#J;.%A@$L 4@-L*)^[4<!?R_X'.?![]#6'[V\9^@0V7))"*->856
M-XOHFF>/:T[?QM9%;EA-=4>R;.=?OYSJQMGB[;!%W(FF]:XYF;8V&&23/^HJ
M41_C,IPG:SORFWH%I(!O1;UEG (*B1*S?B6=Y&=N+)^!6R^'29#;U!JFB^K7
MAR[:=FI@#%0U>LU103$Z)/RQA\G:>-7UGK!2:-+)VGJ.^;0D1'&YN= U2WO'
M)T32]O2CBO/?D3[;3_J5U?<,-/DE:F053)6Z5N,VQ[.,Q5L.\@P<CB4$DFHU
M/ \D<F^ZLU%4IHH&G.[S_-A5MN\U^CW^;\F!T4*M%,W)%U(316>[@C')":GQ
MSA0E]'Q9ML^WKLS=R\J\M:L,C/6)Z<UAVA7IO-2BJ3-,:G^BC(4*#_-KFG_S
MXT=\$_OP)^1E\/2'BK_L<GQ!Q<-MPHMN\L^_@,6WG;^ >7/<Z__%MD[=5MF1
M8\[>GP;(AE_"@-[:H?](V_D%C./QJF?>W?M<@]8^GO.:)14N6J1S<TQ[0HPM
MLIRBL,4PKA&>&\QHLW_Z._O+F.^.^UE%H"98*]:74S^MSBN]_W(.KH"R=6SM
M.6F1*'5B<7#9HP;BWNH@2^1NG:_L((OR$:CRFM*XPNOHESVG\-JQVE63)L+G
ME]>WO<URS(V.6H7-DES;+UU=V:2.@\>A4K-$JK>,\)23,X"AOPDUBH5CC\34
MS\$3/\O6AERU<P@%#M3JC^QOXBE"-J/+?2SA:K&VH^O=(>>/AHWGK7H_7_V$
M9\AG&GW:?+,<7?R6MUDK(H(/I4:<*DJ!^!>/ .K&O2;N"BXH)[01%2ERJ;QR
M:>-"=@[<-:BM35'E[MM"P1X9$BTW),\1N6&\.8J<IPMQ34R_]J!EIMA;2LT9
MQO5\78Q$SI-T%DJ0N=8Y7+W#HVIS')P\2I=L_CK25H@P2H0X2*S>UC0R1_C/
M$GZI6JM.IL?#7F*,++J7*3ZT?><$NUWX6GCG&?+<D<$_!-&*SE:T8HN!/519
M%ZDLEV$EXM8-;=Z\:HO1^I37-D$=%2X<8U[K'U_TX-UC>:P<;L]O@Y600]8E
M'U0:G5\?*BJLL?Y2_LGZ#IO'X-EAL4CF6&:)2^] .%BC!S*L0N_?J?^IG1I,
M!MH:)8W>,32FE=-2Q>!7WU_SG6WP(I"E3I\X8%MB.K(TJU(Z9!Z&C\M]G)J3
MM_[TQ4;17F^=DN@GU]23Y,H>^O=='^(_M\Y+VH(L)6OUC)C+X^NH@RPC"L"R
M@-Y"JD6%QJ=$+?UW@AI%26EFNFT._8NK$((MUX8QA@XX$M\9SNCA^**\7DW!
MF"_C=2NQ<!^29MY52LU9NDD4[BT@O?1"3]_O[#8"*Q.LA\3L8$LD!?>)7VO;
ML8</O0O(4PA,@;ZC+.VHV2YJB;3GV5L.+TJ:)R''&I3J*R"PJ][+;^+E;3X6
M;Y8DR?A=1:G/.X(<5^T)YG"$G><1H?6:;/XQ"LK"@VS)Y+Z9 *9%/&S\<@RU
MD;&6R5ZTS5&VETND5\/3-TTFF>==RB2'?'4!(JZ+)6 WH&(TTE3A[-<FQ+H3
MG.@%^K48?# M2L;6X4..1R@8Q*%S]R'$-S;UW;!:^ZPI6E*KIM$C*@P 0[>&
M5,[^27X.T/M].02)<H<, .M"EKO+B2^[R_B9U6A,Z>)SW7JG8/LR=U5IOF9+
MK\?$B:#AJY/D(>X-,&;$_((GGY94D4"]0*<-N7$IB+15&H[2>G9Z8_TU;?>X
M>O>?>XS#VM(NI8UZ3QCW2?(JN(UVCF.YSL5$&R/5.=*Y[+8&^\@O:^G\R\JI
M+I3_Z\@A0,!![>ME7Z:#GJ.@B J]TWJ^D Y63:BCU57;CB1I?8.R!LVYXO/.
MSNU20SO)B*[4X$I-9[XT HM>I78#BRZO7=G2+2Z*_PEOQR//D>=!B70](63K
MS>R:TJ$!/I:XY,S'9H7'4-9;D;W[,J+8 YPTI:G7]:Y;VM[17";5_:Y*@ZQ^
MEV]<-D]P\ETCN5&FC8Z79T<Q61Q7GJW'\:-+1V309CH5,[_18LX?;$I!T=AZ
MU6$2'D3DIANG^X+;>"4G8+ZABW4GTZUE\RWD/&T?',&(#-R='!6G]:$EU7XE
MV/@B!T"]RQ10CIV 0/^#^U?WWIV>C2+&#GD+;*JQVR0<[?#"KMVG/BCS_%)U
M1E19@V^P35U3HBP"R3 JM2)AX'$<,F+*[/)>[Z#K9,8G 8YU$B<' .-:[?ID
MFAUJ?TZB,90&B,D+U]R8!2>++5@F<<^D%%44\W8K<V^M,O2;@3)6+1G?RF6,
M\7@(+#*HK=YH^,"+Z/>F5/4P<2RHB56#=9>.6]RWI:\G$P&]-C)%$LMOO%_T
M/(%FGOX::H8TDP;!!T 7.WXDG,<3LJ.O(6LD?3V%Y^RX"A,,(B3V"E:&G!^*
M#*0&.)-,2VUZA/;Y#!*ZDR==/W$[?/E6;.T19VRHPZ^=/@P,A1PD_2;73YYS
MLR(;YTH1QT&MO><\R98;1D&9X1<QF"TMBQ\X<MBM>TA5#B6WZ"%V[2Y-AY$4
M9"W*NC,"%=LQQ2?-,M4WK@R,%<>/K$22^JBV#.'MY#8F54@*T&7MM._WZD.A
M9I$:GF^25SD:T-XLJLC.<%EU48ET+3^IJ$( -;?D0TK4_E<2T<&#7D%!3OK)
MNFYZRNZ;6O.JF,S*O"<>D#?,]0FC7+^K?S+:]%WD4OCV=N(!=TXB2*45WS4]
M/C<N#CC.'A,^*BF&2B"J]_,@WA>BY,!MK W[=E@451(?ZJ4A"7*094RIC#DW
M<4IDTK%,*!J:J)2!*.?$E+/W8T4=RNCFW.5.F63OF RYRPRZM'[0FP(3!EJJ
MC3:WZ0*X8/Q5G6WA:L3HF9PP#SJJA*6-+-&A<FX-VQR6K)W? YP,?9Z8N""*
M49;Q=FZY5PYIUG?5M?_?\%D.Z2,U$LG9'7/UU%20$-BJNVQ:-6LDM%B2D[[!
MN%*88;B^BTH]HU-U9!_'B>%L$:QCYH@=6H0PSD93Y30GNYWFHNZ;M.QB]V24
MVHW),4^:^UFG^=@HZ$R<Q=+G5&E0CWA^TPS@.B_0S6LMST@3YC0.CH- I&VB
M.EW="WHI0U@6+@;11"YY_-)ZH37,5/=^6W1>DT?!C/'-'$N*,G4*J,)@<HV6
MH2GVG%)X3/M[Q.7T9=TFY9)#[13?CW0]/45YR4H"D1IJ7#)M%>?,A@"%8=AH
M'#W[)7*3,7E@B:I:]_"2&S73V4-I[$E#GD @.3G9[>3J;!Z?^Y$'GM8Q%AWG
M_P]*24R26VR^KU.HP.%*[$7S&JNF+;^JB?U81MU"\Q85-OF$+LK'B<["ZK@,
M>D5>6\]EZZD8LO58??GP=6G!-A<5RI2CC !AGE=N"K< :PF=CG[]2%.DE9X+
M--)A77!H_E?:+K[04@<2-V%%>,/I1O_Q':0&]3"?%L$KD:-DKM\^BG).+9([
M!J.V[7'^7(>L,7_6[:9,W.0F!DY#&&A7NXX*Q_JQ-@&R9&=YOI#!:<KJD69,
M7O>R'F)Z4$=UUF^XY17G,HA@K8T/#]'@EEO'+HZEZ]$8[-$H@O)9^3RX OH'
MLDF BBIK6"JIA[DRMQ)E66SQ<YU$W]G:+=&-SLGCHKV>G<MO$U2_?<WP;3*G
M:F%*=F!?+NV;1EK,L&N:2425%EEQ#7?,I9MM)L,O(H3Y9$S,N$4&9KW11MML
MY6RH.$>PICS5A-HS20@%A1#:</25*G,.I[QP],Z9=?8_A9]5\HFCW\Z^T0E?
M'D2>L6H81TUFS#P^69I(DC*!)Z(I'AAJ, < ! 2Q/ OI%H]\617(0\!<AIQ9
M1-;T<P+NCVAVR?HKB<5&*#[FN:4:"1BV?@^5.=*>#(VT^$CG IMP]"G@LBQ=
M:U2KR7.J0(=P7D3W% ,ERDR8R7'4*.$,A.C%AW;.RYPY;%:EF#QUR "B&Q#5
MMSZ\#"&3HZZU\T&0-RVFC&$[H_(:&.'?0.[["Z![CW0):E_4+KF(T0RZXOFQ
M@3&#G>H;%(5>57C^#+LB(Q=3;KELP^WJ H_OFB59\9E,:PS%X&OT]Q\B0K_[
MT\=:.K[O5=A%\'J]<&2E/PY_M/L@;THRR0E7:!T%,13_37&TU8/_\I5[RPN5
M;/ZH)SLWKHWSXQ].N!'+NTL]\(;!B^,Q58G^]PYH[0_>!M;*VUFCU95 3BOK
MOODNY6;M\)";%OC>:GOY$@AQ0DDVMV_0H&X1'D4,]4^&!P<'VW:LPF;&8,!@
MD5^Z51V/P,.AXV>@B3JSD2=I?9JWI?DFM=^!5V6;52G<^1=EKFT_-Z/I,\7]
M'N&#)5/AJ536P]><QBZ4UWKYHR,6O0BQXTD3_/*XQ=$%;[=,VX,+G5K0&6CM
MYYQ6F6:99J5+*(I\]6HU.X+1=2*1861BN(47 XQ"21J1+*\C)#:WE/Q3TYC5
MAS!RJ>U2N@_,E_&_<G=**#VW7P<E/ZPR*5J(C=PHH:?=.)M1)<U)BE-=6-:(
ML*)&]:]P_>SH^4I3E+S0!17(\U43T T",A8W$#NX)Z#:NFVA1('%!0"?"KB6
M(/_!?*><@]N2^BI&NL$GK6OCN=U@JSBF]G+-I*,B/)&\"MRF6:*R73J*(M-5
M3^/Y85$2V-5.']F9XI'2(%E-%S<44HU_J>A1%UP2WH"FF>X3S\FFG'C@/'YX
M>(<J?)#_WK8<,RKT+O>4XTD(/-NWA=54:,GOS6YB88U^=<04&DXZ3.&<&0%M
M"8H0,N^JZ%+,__F8@ ON:%U+A8"P$IJ6/)3UQE^DX%YCJ>Z. AQ[UK8)=7:=
M4J]@LRZWN@J1":C>/)MC;77FV:/^A(?2'&$_#UB[M;>X#I^\:I\M.Z5)$JGG
M2R-CW+1Z%-J18=]0+7R>Y>RCM_19*6]<(^23.[H3VOS,_&WZ&P3Z%R#P^_4!
M!C)T"&L@7!(>G"2Q,S^R#;$B#M>T"S,-(5/#QA<KHT/*'/BW([ D)140!! >
MDEV#(_DS?G5='?\7D)-K6ZA8H\TS:O>U+VF")A^Z>-O<[67.L$>);&-?9FC2
MTB@G4XV,F Z:2N?NDL6 SU 2OMM+^.%?0PGH?#"\7;OBZJ;/3B?FX:]U7O-N
MAP38'MHY#0D5<,^0:I=IW]R+\$MH:AWJ^SZ-X5\JN1[]'Y2]=51;;[<M'(JV
M6''WX&X!@CO!W:%(<(?BE"+%-;B[NSNT:'!W:_'BQ0N%]NOO?<\WQOV^<^ZY
MYV;GK[TS1O9(UE[/G/-9:TV7=,1Y?0=UZ+7<1=W7NNMU[.Z0?O&T/@LGM>8R
MGT&B2C,]K K3QW>NJF^T&I  )_P+?E_8VW2P@%Q,6V04706%DQHJXRJ?D-PE
MOOFHTOT!L%^/>8 , ]D^8A<Y2O=Z84U;J8 +'.T.6X6#, F)7-H2%LC;&3PC
M]S0LO@D?]XYSH '!8/J.6-MV&QM_VT;K2C!-?V_4!XTVZV$$<>"C46L;OM^
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M357$?S$7E"GGA'R8YLTK2S0 VA&E@_$#?ZQ#WD,'?ZPMAT?.7L%RRROC704
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M)JPG&_M-T;ZR+2C>P_$UY.:/QNC^?F"D!?<(%X!HI1NY[79%J6;"MUXXBNE
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M*7<?L7O(]IZ99!,[2'+V)5#)XR(EZB'[ DXC.K[^YFQT4ONYWN3H3U2F0A2
M+I#H7H6]0V;)Q7"50"+S\^=/K6DNK'Q6']UEPJ)XC[6JZ,Y>PS)RY/=)9E;,
M]<NOSTZ@LF#"@@T!1.9%,@61.GJ9>A91<,I1:J](B#L:]LR4"^&9GW]*^ D
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M=O@2$I(2;[EPY,DT2@CKRD??"5&-DZ58:42^)@1*=\19$K]\*2N*&I:57S3
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MT%2E3MX4].T=89R Y+QPE0'V,-VFZHKLT+>K#MNL=<]BQQ%N\K;-$3*/(*^
MM2[I":4^FK>T#%057VI^ZRUV_3M8./O?,KW^MS<R#@  P"KZUWSK"UJQ+\0/
M]VHNGDKM>J(^O\JVVVJ3/DR/KO(D8.(A2RS7CBR)LH,8D,;>!LD]'K-2OXE2
M;(%^'+*>9XJ*PFVX9>Y"01PT5<F)6P'64Y(1X5O87?M&/#'1UM<5<T&S$N$+
MF\KWP\:_2#8VHRE=ADR%(U.T0PP\# 1Z!@G%W_8[ZZDU(7&D?AI8 _<1R:Q
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M_DM?=JO_ZE)%HA/UN[JY%;WH)VMVB9,]+D8$A)M7JHN'YB<V.%A%T#2UK_L
MQ 6TTL($,[8$4C:#6/<*BJ98Y";:,;GQ1"V-SO5[7U1)F2$ML)RREA"2@D64
MC#1:%W&6* O"#I2Z\LY6[T#YF.!6)9!!:$=3&X"O4&?0(FNF(@% 3,1"%@0@
M!$EPQ3#__47EA=6<3N.8U3[ZK^M^]W.R$$0J3TQS?5UQ-5M6%#DRS*.,_X&3
M;;^2^=ABCZPK8*]A-PF%&<MBU-+-%V.X3'-D*>M?0D!).*_9OX6 DOA*J(?^
M5EP'+KZ<AWC$GL^C>V9/6( G4Q\>V^5<DA1Z-@8.']@(KX=_V_@M#^1=\?P
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M9$#7X=?H6V91@0GF/+(A]30>+0Y"CZ])9H]K6W<FM=3=8M;*96TR5#!:]SR
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MBSI7<@L4/[/Z2U'D*X>2BSW;PS\,<^I32M7O8H;DJDZL)05*OW=(<S'O$^4
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M>HRQJVXT;SL1]EZO^X1E[.OX+C6^%Z+>K@Q&G5I*:&7H0J7-/02+21R<P.;
M/*,;=P3-&/:+'+7(I'^G>1:L>FA([:ZM@9QX)Q_8"R$][9HD> ?R(^D -UR:
M^&6[SKKM@CU^@[H&PN(7\-5J& L=[,_1;5.;-(Z)X#\.OIJ'N*M%(2&0K^U
M)0ZDEY(3=!5<+[X4D%=5VA#:]#GX$Q%*&/[;NL>1*,'XY0)=VF4@ &['U,CK
MC0EE9$MO@.FUN-U>A,)9ZVW80"/DH&=.)/[GC5 J4Z:APS?_>9&1RV5WQ-^W
MY9XWEP/*A7KM$>SS,<L^?BHDIK)#@Q?9Y'U0/D8)(D'I[4O92^1+D?#SXGE
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M>E&)[17]':!\G\4&8_XZNF2_T<DKX3 W'H7F9"U(P:\)SEJ2M%JH:;6&LR"
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M=JEB 7FQ[PS0SZ[,D=4+-W8"MAH<0-GRU4K'ZALT.FXQGPRLFY[(O+413X6
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M&IY@_%;!H(B;A:;^21(LU'9)<S1?H#AF]@WYJ./U$[!X^PKS( RPE^_XV[N
MU-DA4.AYBU\2OKG24@GZ!9[.^O7S^ :X(A8-<\R*!>>VM4(Y;HHS :TC0;\>
M@7J;)M4CAP$V8,W=9X,Q<6Y:,0[X49T(IA.[7,/0KS^N'!3F._$M'/332%[1
M_/[6%><<&=NQ/D7H=<)BACX]X* 1]QB>C5@]SLG1*G88 DYLOFCMMM.2Y?>
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M,@\_XM!H'YE>7I-;TETV744:9^7FD8BS4!B;6($4M)F=79>XX(_%(3]($O>
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MWTCW'FOSX7@&0<U ^R\.]%=,,0=,&!A=X;9!SYF-EGZ5"1(2,)&=TM*4;SN
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M)Y05\-+'6":SZ$D1C3 $CW4BMJD'RN]P_3S!@>QJ?L"J#3E'$U+>)113/BN
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M/6YQ8"([/&"U4),GVZLE>S#WHA/3%P&ZDJ/D1SJ%Q_7P=#4R-(M3M=\W+RQ
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M *]CD1"#>N[A9P)+=B[) G[B17>><TXWN/[7C;[%ZMHS29DT>(;<LR%$ N,
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M;'53NS7.+I>L59;5# F;3/!"8E/J#!*./\:*T]V/#;HHRQ$D W > ;?KJ@&
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M4H%84KR6)-!!F3T;GF=\UM&\0"+4X&AX6&-6K^^T"-:%^$S'(R3*\.!V*F!
M)?#Q^?-W#Y_K/CPGSF,O:VY9:U$_0"E75PAJ"H\GF+8'ZN-7&2!\:5#9E4=&
MN[S?OF=*0.)KLAJ]BN7U!;W;G)=L6#D8X#"$:<A_-:#%GZ7_ E!+ P04
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MG=-I3?Y,_?GNXNNMRI_N1OYCCRP@WR_%?__4X >&7Q\J_3 I;8BPA2,\W2[
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MVH*U?"3Q5C/8;/@AB*8(@J)B9N7*@.\?Y,86@1*AF>W.*7,V,]O@?+3[(NN
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ME72Q)O PI:IYA$ _PVN]6.I_XTJ,2IS_.$=D<G  N8# PR4TT4- QFN6[8B
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M3@OU'LLYVF2,#+*:K I@U?S-QSU^I/&,I(P*A;>O.>ZOR&M@RUZ\%WCM:=I
M^<A&)K!'-CPT.O I4;U^J):="/8&=9A0N;0"4)A6FT<Z-$M&<NIS&KZR8*Q&
M3E:NC#L%M&]MYK7&^8S=1@OQZZS#MZVXW9UZ0K&;JO88AEB=FP8(,2GOV(2
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M&>\DU#7>%7 E>T )N'/;TCX\C^ZVROPVW< GE&UL@'J^X"7C.59<8; J >U
M@:+>I(3_ES*&X+#VV\RO6T-YX^].8& T/SP_\:"%5YZ7/M88:EXNY+[),E%M
M,>?::YE/,"&JPFI<TZV:5:POPU>;.2EQU>*# 5>!(]T[]YHUV[KLZ <HP%Z&
M)KCQ_"6[Q!#H6O+$I,=3W>A+08BI<]Z>"9:OYZIF7EV>=#4V^#BI"VAPQ+SF
M2& Y2_F.>P9K\'$-4:MLM067O(36SNVKQ%GS;Z+WUC]U!#B7\E_15/G2\9*_
MZ1! ,11YV2!^57-S, YYBZ;[VJ'M36/IN;D:C6'&V;JW7'>\]H;>>%CLE-!/
M?3I8LJ[?+'R-1;:WT@^SEIWRWL[B&HUT7ES1'#TO4]#O[0V^/)CRV6.T!":[
MZ[5I<6TN;C[-*WYM::I$UT^J2!JQ&+<4NHP%\Q9;G=X8;4H:>O7^ZFN/!^1S
M#?(E]+[SJ9*KXYI>[]OI=Y8J<#TL#$OD+G^H'4SA&;EOFGKP<7O__$1O[$:Q
M2MEZUWS]/L4-&S3L%;,-O0B"JE#)Q#D(2<]0$BITXE-LZ8")AB@C?VCU8Z\J
M'J%PM0&WUT+=<J569Z3RBX/56(!)O5U>N9DJEE,-F4[YE:O@"KV8CN)2KWR(
MTT2?EI7W7=\9 JT)XW,J'17I<A+A[?;NI/BL0AJ.9X4=.S>=)Q9L'V&927#2
MU>R)![SV4E:KA6[FCVSK8Q0VIO 4\SLG+@EU%'E8%GF8*F8D51D9382&ANH;
M=.76#BG>73<B0&%\[:N@KBO<00H(>6348\=X5II+N&A*FMJ7^/I4G8,B@84L
MW4HW=XW&.2Z%4DR>PJC()-W)6<\",\R$I7KWQNN/V86X I?J=>B>G7=O66DT
MC9!N4QW1M2X(,[#T.[N9XV$86<293&8S%OXP?)'-+:DP/@P_IKK!W@22L3_-
M/SV$F;97-'.0(U4;5RMJO_"I(,,DS15KT<95VK!_J&YJ,6ZO9E]J?;V(YPN?
MDZ-.K42=J?+&Q>8KEX<IW\E.F]C,G'O+^=ZPR*_^X! @NUWB*8.\MQ>3(=5\
MZ[HQ\Y'25XQYM;3'(&YC/M)WOD2T!":_Y*W+=5"DR RS&&VHF*:T^G1Q@C>M
M@T@L@,9]M+;>8R0UP"]ONO^*@]V^P81WPNA@,JP^>7167S>^Q"$YA\Y?+ LR
MWJYI.ILEN91BJEA<E,0'PTW/+G!4V4BWV,.*Y]*MS+GZI1%Z$)!C/5-;Q@PQ
MFCT$R"7OS0V5J-,W7KZB=W"%)[LAK_4+@I-KJ#&E87MUNC^Y1,ZYG2Q';AK2
MXSBKX[>2<_F3Z*SF1,?=F<&[N"/UAEE^=76RP_,E#C"R5=T#4>.+[#=G9H9+
M77-,ZMCC9A]QZ=YWUQQ)F6Y<@LD'.%M#6J7]/K*'F9,;^MDX6^U.FZR !J8Q
M+ILVQI6X^A1)E>C.7'FS-S3S?N6A]P"EQ;C!:H;5I[#&E-X'63S]WF(KHZ&(
MK,L?ZGCT AJ<^\E7<E4:=T95D]EO6,F(<7N;:LYT/R!?M1B=*9+Q*>(9RFD>
MO#^4VM=0F\)=,&4T"E89R&A^R']W.,>,S1*6+.S%K'R=:E?+)6!097X+PSA7
M\I6W=J:^%EX.54S0980"1_1C03P]JNU4)09+\X>C=]PR3#MG+T*KVU[A$P0]
M2FJI?+$J#N7*&]H9:AD=>E&H)2?;$VR6+$M:*.3 =*],^7-<EU-V$U?0NQ&2
M9A<_3B<2BD:SI2%\DL>Q+:-54G.(@8YE>Z#U@DLIC_7=BUP(G!K+6@R9R8=\
M;ILQG=<4[)7'\,Z"BX#N"H_$^=KKX7U;YQW?X#+Y"W;GOM]D)6R[:,;TK+I(
M2K>>_0D5-]@Y33TBNN#"8JU$1XN:D5&GV9Y<[G8HR-4R*O]F;)6JDO22'9#.
M*8CZT;2\A7CE!B@$57V<FG0K60\?T>-LO<@;#394[O*UPIOW+V57FEHP%C:7
M7RMOR<W,#,MK6+L0;]10$$Q"AW?FE;[XG/UC7)5[8\(5X>=\M6]):7R^QK8&
MNKF6H%XB:/NQK3/_[4UQGI>:/BMC7<K1+\8+M%C+Y2$)9%GJ>UHC6D:JK0^S
MS%[&T^O1##4GA42$W$[B%FHB>J%ES#U2J)/?Q]Q*=J%,DI8EVY1-V'[XN?I"
M[KV25 DVY:($[;42T\<F-L]BZ5]L8)HZ/K_G+XG1I9$AN(?%[A5!0,<BV 5[
M?>TBM],F,?.(3'0"F*V3E!J]XM%K3=X7VI'J[[KS+IZ'U&Z:F411N-'+6]9P
MFP]*<G,G$W WFL]G-1=FW_M0N*[MV,%\18Z EZQ4CD5- Y\@I&(CF:7GTN4U
MYV?OY3D%"R]DO,[)\G@#C)2TSRLV?PFTNI<5RYVN_KH@-\:ADN[Q8W9$F C0
MN#KQ:KV_KRS@+,0H,%@G[9QV*ZH80OY9;]0K<\M43.&G7=*@*3M68/_+A1&2
M JQ^JEIR50%>K[)(IQBO4%F#DO14G5Z\1YYX(KY+XBJ!=D]?O-@IXU5OEWK3
M><^41C,*R#!.O-ZAG9QO7CJ$-?J,U)E-F^W&P(89L)>UNMG#6+^RC+>T3+1#
MW1[AU,YC0QH]KEFL+.FSDP!/7G(H#1I7)0@7YER.S7VS#+I#.!K(@<\@I,%U
M38#ECHO#N>NA(3?Q@SZ,3_X?]MX#JJEO6Q='$$%!D-Y[D8[T+J+TIG0(36D"
MH?<J*J)T"!"0T*2$T$(@$"!4D0[20@D=Z;TWI?GXW7-/>^_<<\][__]X;;R1
M/4;VR-B9>W[SFW.MN?:>:ZU!M8\J=\:B[IIC4QE5STQTO/<%F6_;[?^8:N12
MXC)X#=P/Z7=UV$PRA$4[#)I9JYD):B/1U9Z<8AHOCKUYIV9ZEZ$>WAXG;LP0
MOC)!C?<5!93IF;,^=#X#4!<M^<0"RA1?<;TV2G64Z&LS1AW?E?J^E&+0RG=O
M-+*")RF0AC-7R%8L@G9P03F15%%]-#)8_7#2)Z;+H(=$C/".LZ.V(H^V*/X=
MR9R>#!5 8H8DO'69&T0<_)$(T3%1ZFRI%)ZC?@ZHJQ!'(@%<'PF:[5ICG?6>
M60N,>FH9A&\4S?(7??'9M>=O,2=V2Q+Z:4U@RSCQ.!U<9T4_WJ_SF"8^RZ98
MHT ]3_.,?:PY6GK3WE[![D2OK;[ 1=L,">B2H5]7Y4=?5C)#N,1XW*HDA,OB
M1]@X4=X;XA'5U06-EQ&@E&]UY!LC[*]A2<G"ID98:(&)P,8[!^5W0NNRUVXP
MZGTC%79,QSV,70$1Y;Y=684LA,\TUT>+3W.\*5%OI!.;[S45J]9^JCW>/8^G
M%??9YE[A:/_C;:WO2*47D2"M'%^M9;75*C=#'[!WD[FO+7@3B_K>0%T@]2S-
ML"^I<9!9=(")-RU(?R;FP3-Z^;A"43D/+@[V=1(=NW?YIP>U(@&3..7$+T!W
M[KR_+QO>1URM<A)Y ,3G)BIL%6L_KP\R IEQ(F7 =#U5TWG:)[+?3NM]BB R
M&>25"=%F[-[>;MXT&0<Y]W[CP)TKFN1!&$-C.\Y*%0K.0F.5C'Z1ET4NPPV2
MZ_F@>&^C[Z"B4WZ+("@#;%",VXM;GW<Q84/PQ<DA^=TN=H[!![KFOM%:],::
MXG@R%'I(J O:23K5GH$XL7SEL&.RT3!\>D9'4O E0&VD.3OFH;<#.;5L'G2_
MTFFX1_MJD',@ F/ GN^T'.*61)W/0 &)==!Q]LR_/R;IUV\6BDF2]$?>"U@-
M?@TTEQ,;;I\$],:FF.7;3O50690[KPB>G-5N>G< K\01FIZ3U\U!6P-;BTW@
M-Z.6=UVM!\Z?X_!:^S7JH\Z; M?B]Z0>ARG2IUA-35(%',^=SDV&-KC<PYX'
M!V]897I>4>UN](><"T\C0FE4X*="IS'E0P:SJYFA@/&LIBNGM:6&POQ:GUKZ
M$N \)L.UZ0ME \(U6,Y)=^KT0+?9_?A7\<B+'5FL<;4.L+P']OI@ G(+@,DT
MSC2 2\-RKAZ[9?J>9SH;D?>FZO#:35_Z.=9D\]_JEX;RZ\[M\DY/=P0=PX.=
M-#=\D.R%35O<37Z6LE2^>3R\V.Q>$\CI0;_T03"PB_'L8!;; '$6G]<7Q%J6
MI_:,UZ#.=II@0>OW1N*;9$>@@7LP=WOY*^ D5C]U)%_3T7ROL$FC5G,30T"Y
M"D;D(*O/?L):^@/A04=63>)(2RJ_3</=2;E:\Y*-^HTA_)"Q#=U>/\]=@Y9Y
MJ-P&IGJTO&,(DFS4H-$RJSRO<^]M\-B6%;!?>NF/+AAHE24G?[P[ZD^C.>N6
M6I."M3>RI)=PU?G!.P[>Z+*Z?H- [_OY.T+T?,QUKWY>6-TW_WH1\AL'?R\!
M8/RC#G&9A[@$*)UC9^&!:[,[V.6PXP^_<1KK*%Z?)UN[^QM9734UH12U@Z-^
MXW@L6!\\/W>\H4[J4*7Z-TYA">_/\KZIG]HL=V";6S\K68"O=\YB3G-1@($7
M<:NFGQB6R1=UM1?+[&X_A=D(E <UG(N945H5Z$#P5;[LD+U.I#>BU+K[9$F4
MEU H*T+5="BBVOO)HY^[$_L6AE^66 \NN-L_Z+5 =2VH013'-:>KMDC9LE;R
M0N9:QX7EZ(?,B=1>[S7JQ#UL5/I*?D:76Y31QU-)0FO;=S5/)T;-B3)([DC$
MJ20G1G]IX'B3'\K!RARN+?$ED'#3MHZJJ%=EN"!UBPT40R4 ?=L%F"%UGC:=
M/CPP>9!1&2F>3](C9-;=64Z$/'X=OZ3UC.7G'EW2DP@ 923:ET9(JK=)2)C%
M9UU&,KZKSJQIP95Z;O2UJ+Q*W HL/RF04CM0#*1)4LTQ1AF4D,M-6R6#H\Q2
MX[)QQV'Z5F*"+3ONZ+278&NW68TL%[<]2&?EBT?<*T8C-CR2F+2(6'^6MPG.
MS#Q\T2TNHR^YXV@?U4A#X4RYGM)]A381M;P,PM[[J@;TCR.ZFDHE3[2)7W)C
M*R@#/,G8#Q(9[E!'U;]7M#G1CYA&$/G)O W.J]9&$XP^P?-8C"!@%&S)%2-G
M-1VVP3ATA*NNOP,IM@84E,G$$I:IH$WK#ML'I>Q>I".?4XI[XKF24 5Y;D@,
M4KSQ3$E]\G4Z27FVQ,(SS[9[9B5Y;*B1A%>PY=4W#)6]^P\;\..-0SOU!QI>
MKLZOIJAC#_D')1U_W7F-H:YXY=XF(3Y[\0)JQOI24Z#7W 2,1_AYAP!/.P.M
MT_[XQT"6=&R=WF5(I5[?0],VQ\^%)R[8/FKJL4G:[^PBY$*6#;?CFA+ND&,*
MRBP>^7.T34?VY=81L#Q9V[23/I*8IM2\'2]#W*,IHE?$<XA,,G"ZO_Z@E$^#
M"/RY[ZXE:PI5<I;LSB\[GBO^:=D@,QM6'<BM+_1_<TAXAUA_+0U@T5S]H4AY
M..M8\'-6>)SM4C4MH41MOG:/[5=Y^[4*^[6SVBV?Q2S%N9KFL&!8#@23=6YT
MZ5:Z17'-_R%+7_=J/E#K-\[SC^"MP3 FX*1N<.#6"7"R;.6F\;ZHVX;S6@7
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MQ%(8VOX;I^X1["?B2N"A?T/&+_:IL!$CRDL3^YT0;M)P@S^FR26@Q PN.BX
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MROQG K+30!\'=KCOYY[2:&T58%<XZSH;N@UZ-B&R<UFUHBU!O$U0I^&S*8N
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M-$CZIBO(NZ4^LA2RZ; (OF0O98>TE..74_K]9K5+BN^DY2:?PKJE ;C]%;F
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M](FG3+)DB[44BH5(X9GFA-QW+6JC9:>%1[ES71C#+!FB(L8>?\&(#0!DU3Y
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MEL2SIZ\-!AB$;UFN%(#OM5F/KI06 T&P*YC_QD.*]6OU_P%02P,$%     @
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M.B86)@X6%@X!%A86P<4!B^";".Y_1\%9$P 7Y=SX- 0X*@ \+AP"+MS9]/E
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M?WTE_(VJ*BDMC'8N^_UVU>]2Y#]?KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y
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M$1T'&>G<BFL(?W!Q\6ZQ1[]#PB<B5E%5!\8,;A$04G&(J6E '2.C2LO*!X9
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MXD$+S,ZW*QJ^5<SDY9E7I>_] C_IB<WAHSMKRP_;)D\X83:].2HY_ 9#PN]
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M)!^;> S@YA5IRHW3=B22+5:3&>1,D<M!G\>< 5A>/= J;Q\F)/1X(RKH6#+
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MX'DS?6U[DW -W\N&O2+!FJX(=",_/ (Q/?GVV>;C\GJ$8K+:SA-(]HAB_>J
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M:3TV5R0@^\FU1I+1/G!J'L_JL1>FG'I[':U1!+>.E%0=:5PZ:8=EX<6]P'N
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MFA4^0VG6@>Z/0"@: H9UD_J&#;Y-.TZOD>DFF+VSA9%85D?;'/3Y]N6P>1$
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M \@T8(\P_C5;((*SEEL_V0IPW[SV@\=X'M4O),]F6'"G/=>W8PH>D%RKL1A
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M??,S-530$-7=;T*V!LX*J%WJ*4]$S;Q=:F5R%Q'&MJ&[JB&Z#'O66*=>C82
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MN+XT%V3N:P76,%7.Y#&%0X7> FA%&8A;C X!VYB0102<D50?!8&#J2C_7I.
MC4A$J.ZE_2DPPG1;$[I9%E*DU*1%OZV9C2BL&%Z4):(5X)9A]-,I_/&")!8%
M<3,:R@E5//9PHC-1H)H4J;;[X#IWT#O&I,)\_J=I*P,V@5SGNM$$3VH#Z,;G
M0GS!*QE$,^#1=%U_2O\%:5U%\[*WHIYB.J^,PM_CUC?]S#T9#.'@?]8D:US+
M5#2U[S:@NE#S%OR46<1ZYR-R=0W?-839D5AVK,&<E.WYG>/L('WP6-IGPOP
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M_V*2%7E8CD-F47LE2:FS7*O(JM'QW<':+$0_B.#=]FM964K'9X'M->AA_FO
M+1P>46O:[ZIJ)AIU*)4DMCWJ8WL)^1J-YW1IH]_DHA=52_DTXW&9D[&!3A,>
MT4TZ'6)O1>@,T5/87P.X6[3UG#N K#YO"!D$-*"HX.!CQ531R/,H.T]9]T_!
MLH!J;/0R)8(W./T"[#*XE1:,R@,K'BZ(\/]V)9S?\OX6P46O;?9FO!W-?OQ
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M#L+3RAWIY3'7:G(4?(E0&Y0_Q]D0? );K6.<W:.9F5^L6W!WF*MR)<2#5<V
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MK0.VQ.[^'\4J*V77VD965DX.*L^A_+K$\E N7VMG3:8M]NPZE1;;]UJ>%4*
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MZN[6K?UQOZVOZE9U5?_H\Y[GZ7Y/59_S=I]JL:\LJ<;IUK$'E[> AKF34_F
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M7"$=OL:E-8_#^PD'*)>9/B4  V2 %\7EM>]>S7R*.55<WRW&WET'+#']'PV
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M>Y"Y0]!2YUEFB$FHA/;I37>A<M=C4..%7:E=-ZSJ?3MRG+Y<+J%'H4GN<+3
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MNW]:!9>8?[O[X!_N/K.YW)T+]>F B_V\QD7](7X+.'^(42OXI4^S,?X]M;>
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ML^CH.2'0")03PHU=3% 8(*VDH8V+"SAL+*+U2,8_NP &%BP+  XSMQH+-@"
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MX].5@L4^-A(8@L07$W4]4P^'UYFGS5X\>;@ ?+U6\C4]'():D1KH0#'M80X
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M#@BDJRU:'NIJZP@1@KBA'&2%_J3^*HJ&HF$0^5]PCSU4A*%_I7YGP*!'CLG
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M#GWR/?G>_J/6!AQMSRY03.9^RG7,*<@AFJ!/L?)=6+%F-RG%[RDT<.A;^V!
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M6C7I9^N^4US0O]>=28VC ;G_Z/P+>TM"WDNG S^QO"?MNGJ-N1;68R$7LZ$
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M-8CHM8^ (85U.J_WWF^WT-<F'0X [M@OOEZ_NGT *!Y6J"XU2SS\R* H&'D
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MV<7O,9W]!BM[_C)V0]SR="D+?"&K-X0HXTY2[^7GQ&7%BT^VS[$)"!;IM!/
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M7:WXHH='[:EZI=H,!OM_M7#O]6S1U[WNM\D65V:KM<61[U]34[PMR$PV[=*
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M@/=B-C%Q7Y;>0^)GG] >ZO^3A;TXU&)\O AS$!S$/7.%]X,5D63M<-FFG Q
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MJR=Y*8X[QK1J!/:QTD;CGK]@=)&#9]BZ%S3X3?/FHK3[$KBD>,0\R#-!MK>
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M0]38":1@I8JA421$I3AI7-=KQ)+K5()D)T$T@A:VT34AW;M'&_G4$18@J6.
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M K(J3^S3(>'(Q4>)2_S35WRWO1O_)+$HJ).!;B$[1K/QEQPZQN3/<I;LQA*
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MP8X9A5-U%9BFE8<5020PSZ(0!'SIYP/=>RQ0J@AHD\-=G.9YT72M*+KV@?"
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MTEJ[I<1J'HFBQ<R?24N+:?0:U9N:7W-P2$7.HR8+STI;,[$]9;1M6'[?;^M
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MC;-@V2#&26&1]J T>;B'&=.*A(<J^9>?MP6;A&MJCY.]PF=+=R_=!6Q>EF\
M?T2U!T>;1Y2QYRICH>_13U5*C\UO ,#I4<$?QW=O@,"1'NCU0THG]Y,G+.TS
MB&/Z#7"^&D27B5*XW7V4\EHKW,O?47&3\RUHH^'L*4#(_'3R]1ZCXG)U[AH_
MX3^!!BU<4M_#>ZF_-CFC/-T*O@&<*OY^6M<+^'WJ2\\;(&"2_353^"]/;NT\
MJ/=ZJ9B6O &.2M\ U1]?WZTM"->LPKR^) 2!#Z^H/9WN>LN$T_<+"I__@5!D
M^@^$.A Q_C-,9U603MM?.?TCA+G_(@/(&^#^'R3O_D$R&[10\=^!5,W[]8V
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M-*]U<N5R61IO@NO&;<_A(?,BMU6H6O!!ASIVQ7,2,K&L)CAT?GXDP;Z<@,V
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M\GW@B'?W@*A.24ML;HUZ]LC#9LP*]8V19GI#>9]GYM73SF7ALH:\K)D_L)B
MT^67^CPTF0#!+"P5C0NBBWPDQ?6&#K.P@*MU\GBOEGB<:!..>%&99#W9L>G;
M;$9K#C/E:#?[[41/[>V6%6V#C<A7A^X[\!WI1#@+"0WC7?"?FM&:_+!O1"9Z
M43M*JN*>!.5=)9R9<AARB(8D=KKMDK:'.,<(@3H@A\T&,>'([HMFWP?,I4"$
MJ.,+-D*:Y*BFVUKQ>6;6MQ^'O\>P\_?JCE9-+3O\O"QNMZM>'&2*W&BI9EXT
MBE2=U%I0T&?)1Z/FWE"0JMZT^R*WF@0B"'^:$43L)BJUN37K]1<(O315&V6#
M]SC)C"A+%(M-G2+<2JJ>ZY3AZ]WLDV_5"2E$VD(=Q3#5<+UO(U?*_HQJL!]W
M-=4G$&6]4WYO6]S&5%U!61QC%_<:5\SLS1P\EB<)MTFG84+5^&[R=I%8"/U^
M2* E(K,\QI+PGG,E$KKHK0UQ(6+R0< '2J%"+&=TGR_:;DGFKP/3-JAEU:[+
M8G(C%:V0VX:5$.]OW$9$L 5-BB+E-!Q0G#J[X$,$EVNHUQ\$@>6UB31U^Y]
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M4=5C9 K;YSOJY1>7TW3RE*2GN864I^7'Y.OIE>:B2;/_2F-8ED^H%6:OH][
M\K\PR$..VQ2E[;5V&4-O(U5 ZO]Q&O/^/D ,J/%NPCB-^KIN('S,V0[\P9F
MP 9^;:6[56,3UU*JY<G6S>7Q"XU-[.>UV^X_;.<";RP$73+A^!4P73G>>;[[
M(N0,YC^L@CAK,UFM7*MH<E>+H;N6P U$4&RJ2W'V@:4>3@?FK-,/>CI3+X/
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MJM\*L5I:S/<'^#U+<SUFW#SWO0!&0VL-C+(> ZN^N_IAB0/$7@#4A,^*?B\
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M\."IE0-1F1,V+:N;1LJ2&%_L:B.1=)D7"A<7=S*'@<@7DP:D[23DGX16./9
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M1:(2MZ]V#CD,F^">:YKBUHYJHA&Z3^V-JY*5H6/8H/EE(1M[&HO&8=J3?A
M<;3A\^A_.9,BZ2^M)54(<XS$J, Q69#Z+IC@-ZS$0EM:'.(%98XEP @058&U
MB3%(PUK;&"37WG\NT_%;ZD4FJ7D_UJ-H@GE]85/QUEY'UB[I^[ <>>&'Y70F
MIF1EVD_82BGNC!TI]$J6-60',::(>/0B,+]R('S*@GU-1003%<]!V='NN'K5
MW.)4Q&U5W(]T]QJJUB^_=C$Q)HT6/K;C% QZVTB]PFV\QI98;W4[ER]F)7W.
M)A_NM_;*?V<<TE>6>LC9X[J?MUG9KMUYJ-9-\\Q&BDH&B"MC^12=-^;*#R_B
MP7->.;NROB7E#_PD8M)..?!7J]N.H9^&Y3N13-M!Z?14QW;\UT0$MA..[,(]
MO[\XKFR'VJ-^$JX95'$+N0JV&_[)??"NG[W'2R,U67(KW>2F_)71S\W-<M[
MB_+^[K0/7%M(H]&8@-_$WB!,Y6-#\V125XC/U;A5IEMO3#E[+V<1_4>'9<.?
M=E1>'8?\=F61DKMVGVW .T#^#[9COIJ>0H6Z1[$97MA;7*S"\ ?-X1&X?JH>
M !VOHBU2_F_":.(Q?%_D:'MK31,_@<!V<_UVN[9GLUZD'Y$$-9AS SH4VFHL
M.\'56'P7BC<92S=!L:S34VY+O+S!:.QO#Z]O7$5E,?O;<\\^&4@!:C8.OW<[
MQS RULGVK4_W "/5U;GK;;T-+N5&OA(E$]+[E&+AMUG*&! 71PI:[#.+<I@L
M97GV6ZBF<(A\5A8^<^WS,[44][*GL>6I-ZNK<^ZP$&[KMV!MC19G=_.^KX0(
M=Q); Q'U,!PWZ9 *)?ZMD@'KK2:?7!WJ>N:)S*&W_STWG!B/_L5\C7N.YW2K
M1 \5P?W4;]A\D]>FN U,Y+PT(S2'!!Q(OG,.'=M=RYRKCSD"VODNW.:^ ."S
M@[:O[GX$2?N_ *Z=P:=5"='K9_*0QTYKIRET+#%[?^470(A2\\ZE5&!4T.0+
M8/NO<_2AV9;7([9#%T<6R5^I,*/8Z\G^&Z()KDWR^(6G%:^#D(O)<U\U4:OG
M'+,P(S$'496@$"&.T8/@)[Q-@D/#Q=O<W<GILX09BM:]FZTOR\_?!#L[C1Z\
M@?=7#>>"S\BD@88=04_$FSCSD_W;M[0N=[Y7+X"_=F$J^A(X"1M)@SN'L!?
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MCX;I&[_6U2LYEYG@HCSKOIS@VMVJ@Y&:38H;^MQQ=P7&!IX$]?2R5?ZG%YM
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M^1(WLB^ .C.KH/W/$<\I!2O4:ZI.MZ3:MTVOH/Q].E*YP:OR(P%%-Q>WNB^
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M+R\7NA6M2@DO!Z'C"E4T:O5-2[AD*5(]9#6&E":9+^05+F<E5!5DN9B^AL&
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M82G)PWWV\/>O!,;?]]%"J5D96EX:+X[U1-%W,0R8O'AMWQE94LKMA61B2,G
M(SX3<J7':FO"+,)^!\AX>0LU-?KMTZQXI@>O^,(9XJF4E#- -WW,N$/M63>C
M&RKMTGF)"H#&X7$6UR:QHPXQ*X@V"T(48PSY.I:2U]*><C)R7TGEZ\1/')$U
M#KQ\F10>\ARH>*C1@LGDEY/0+"0RJFSE-)2Z0&1UG;0?)K04WDYL==-:2HSB
M/0=O.'#+*=H83G9=BX!R:2F-$%>W_ $M(/@)1C!/G[P"$'F!>AY(("]'J*']
MMC E+1[_9HA., B8QD)9/D,8GYE]5<RXZK; RWVRZK@QR9W[0I L78'6+YPW
MHN^K-B'%8N(\)4=E$F6-CNHHR1ESJ(YNCJIO10+J19M&8Y>MQ3AW=J0-SWH&
M2I QV46@^_5G1$WTT:MZ-IB^7 ![TVP=#:F^:)1*F_WB07Y0[TOQP;7.+<K+
M>IQ*B5HU)IYQ^T6G1(@5T\C'R0Q2/4!VS&:B?B@1?A6)"$#5;T^.U614LG:9
M"(X&6C-9'E:7ZI7YRE@O4_=D:6)J1*&KA@?CNDWRBTJ;,(OW&%.Z44-Q\NR1
MMT'< Q;^Y%BF%*KW&N5Z96R"@<OX&D]R[W7*:2/'N11IV1KE8=)WTSJ9F93Y
MT[U$BO$9?^/%]Z"XTBL'O^W=,0K1Q)X1RGV& R)!:")%.L.;H\=A$SW^8J$F
M"CQ ]^W]C]L6.#F$F06HS4_>%PIE>P?<?$QR58*FMX59KH XG9^V*8-YF(1Y
MDS&K0:.Y3Z3XO;S!JT>;(X:]1)9AB>WD>YN VR]$K7?L]#);]C/90'S>&<J8
M(6SZY/4$@3/57:Y$=S&/A4@8\D=![6^V\-(###==37G7]9 U2"Z91<1&'BP3
MAOG$0$<2GEI2ASDM4[P/<?*>X:;!A5UJ?LE=3BY+*U$9]B'@';HVQ(/[BTFG
MREP8B"/F?G*LZIOH6L*^;:0"]8$N<N;#XM3%-H;56@_;]@#]LBA:FL]$8F*$
MY>N7DK#G+Y'W/CW(KUS-C7.H9+B4.55:9ZM!YK;94PH()V9QR.+<-MWZDDU"
M_V%3X4#T3B6DJ[VGZHF','.Q&&_>RB@9_*;R6V;U/.==V8(BGRZ^23-TBUA!
MUYO)ENFW&A2[%-7NE[2LC2L^.I"QZ7G0J&47B(OZ$KO XD8O_;S;L_3!)U>B
MVN_EE+*DQF,GM@-C.]Z0X89^_%+]%0<#'"W4G8#7LMV^D^V_5"O'R)Z@U&*#
MR5#GBL%L^:S(OU)3-E%)9\686$Z%HW+G;>E*@5;W<^>*PHH<VYC;!K1^;XOP
MG6O,Z3OOS$15139.U[5?)M")1\YK%29F"ES(4,,]V@E<GVGY_-6S^L@[M:)(
M,I;I4I:5,K=<;RM-XGH !*T42;+F,](5<+B@0_@5IJ=B':2YZY8,6;%9#^I:
MQT"I>B.='")Q@U5\6I&#AH>@3R$4.'FZ4D,*M>N\_KU>J:H*N.FFW&G9V9/%
MM)V)FVQY52+O',"N%?'KV=W\,4HY6SIJJV)7X D692."A6$3*H5% W#S<H'2
M[LC;UM"5$3SW]&[VC*'5WH)Y2HEK+1VD3UZIT4=2 ]GVC=^7P<;&QPPFL^U,
MQ)>Y:<$-]R:;;6):Z*F$PL@3&RM$PGD*#%6NJ% OL#5.D#0PK-NI;=ATT24H
MH7@)+2P+VN??+SQ.OT$41U*+#4.'< KHQ4U^KC(\ =2:PEP47!";I\8C<9W
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M*J53@Y D\TB1\;W%3,U\IHL-M26EA_CARD_JB#N:\:K*DC(J=C8WU6M7;IP
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M>,]9BLGN1?R:OJHD59LO<=\]E/"+,8^_-17;4Z@GU$.P<37Q1M :Z8W(VY[
MDG>3%16CV.,-J55552T?FPP4V:$O"I0_>[RHF^8*M^QJLX")7_,N27SS+A/3
M1NQ1[) CZ3)C3'JB[(OC_L>O38)C/]/2&4=F+RA,&V,AO=*T"%/E37F\FYL
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MK+>_'%F3\WS,>]>XL_+3X$.,^+NA[Z^#,*_HE.E:J]L,40J%9][YLMKT^C"
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M%LSXH?VJR]R2A,V1-LHM0;P-7YBK\/;.';^Q3Q3IJ7O<.I]T'SB+E<Q<#7;
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M2N7>QL*R+^5T14S%O^M2\,WS?%Y^^@1-7_#N8C+#R[!3C=98,C'@22ZR4*&
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M":5X>GA/5_"&J/-K(D2?&B5'48(D7>X>CIUI)'M/MJ0\-P,X]4TS?&K8AN-
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M$GGWM;>:L?7D94/0_I)UA/;Q=B_/J/C\019LW <^V-T]RZ:JJ-_XI=8Z;[R
M62#*O%0Y_:OS+^!0C_^Q'K:1Z)??GX(^!V$@-M#-X"_ H\>=>KE#]R5**O=M
M8&[RR?/T+^!ZR_3&A2CRM.3=5-CUCTQ>B&):'Q\'3(N 1NHO_,+WJU.86E8,
M-X[?=/TS^11!FQ%!5S^;BG>"@_XP/CG8*:+)(U/.5YGRTL\$4J&WG-Y]*>F.
MF8$N/B:$\RS!^@[/=!OQ6\#C\FCU[/QNLVJXB;E:TI/0;?Q4,B5E=2"X4^C=
M]:VV2+5),Q. 0#V]V4VYVSUX)JGN"\+I@+/'<I!4S)*8'1A+\N^-@:'EU8#
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M:2K$9Q=W4X)L16!?W:@-[P4DPHV25AVM@90U>KGS%4:)3X)3E#%&78EVW+=
M88O&JMG3BV,^:0]E-U+7I,BK+)""Z0 !Q(<9@%6@S]_5R.#,"26TS,<WF0N
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M'H/Q0O"9_I++Y2>U:]+JG[Y-$4/*H4RM2\M*6=@M8?![VA^:O((QA0?1TL7
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M5QI>1_Z?S1;5S&Y.6<*%=\?P0<W&%*"#A:#^%!3Y3W8X^K26P*,I73)=985
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M4N+@@[=@R)R8W:(>$F=##1G01K,X_N@%"[\7$G4:3!)?@X.#1GW$;0W0:""
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MVA$.W XLMW802[>A/\P<40\8FG$CM5(N:%-^*Y3_8T0TB#PQE2]EOL_]N]^
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M#='RT$0+KND9 -8$\)\X)>I 5>X>MCLE+#:#H\,@%@LB6+-B#3:HT89SB:J
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M> E2QYR4T;!R42S%^QG,!\MJ/>*9U3DN&345-YRU@>WW52(4?',9 U*J$A+
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M^4 *%VI&+2;4<H+63''DA:GH:&9MR=:M#+2.*IW[3$.>R'4AT/TI].V7UY-
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M[V##1IOL%H9]Z[R9/D=CIM+<I?"L76RF!4OC*LZ,92V+5\#<3)3!3:8#C<?
M85.7,:-=>:?N=EUKT]J++Z$Z9^,Z$M])NG_$\@%ISN[_N^<+H6W]R*=)A_7;
M_?/._^1IP/W4,$8CE4XP;M(7J]S_DLA>_L'"YU0HZ044#_D!1#?R3W$ 54>9
MNS V$<(,F>OSIN,[HS8RP\^7K]$*$S7EA+!RN![Q,JI",ZEO6NU'E@67Q#)*
MH>-L6?<!1..U:?3"J>E3%4*>=\M/HNHUZ#&RQB"Y*](FNZC!DM%PN4]R#/Q'
MN3-)5/1D>]TC=K.Q? DJEOQC&#1B%FP#:YM]XO?AB2M[(SAQ'6U4@U=FMAN'
MS'1>36/;Q%7TY6JK!<#>BK59%55=T7-$2C9V ">Y5\2UU9U2F?^7CF19@V8A
MA'ANO;5%*'I4%"XJ,N%ED,ED3$NY0* 9-">1%)-HSRWOF:5,II3D7P"MW @=
M(32TKP%P7(73KD;=,_)F.#<UK,[9<SB,4TEP[L&A";-7\?2<_?>R'ETX[%>B
M #7+5)?4<#;72%>-D:9AK*T<A#YXLQ3Q]7YXQ':)V!]CCXO-SL[S,J8*V_,:
MIT0ESS\IZB,EFH(U0?"C[N7&!HJ[XQ:<,U'5O;I@.IE80C=;"]#J1)U?*Z*-
MN GYU/3IE@15/$^<M$L\\X8.IR3P%A=CF'*ZC8_IE^7^&K2H53KO%WFBHPZ^
M<'H#ZZZ*K-W4U!?M?!-%TYMX/C [5Q7=$1H[,6D'>##W_4^M$Y$U1_F40G7;
M[) YD+6):B'?KDAE 7_;^-8"0AR].W'%YKX_BQ[DP(XO=C^9)8UPD+6@):4E
M@+%P3]++)ZH$D!9TO2G^/8B5QIV?0:&6?I>N8TJ>B&@A/9M1O $9.0'F;;*C
MU^]"(-'C94!6VA!+(<# !HRID0M1)L+NLH4M 4CD494TQ(?8G(J(ONO3/YSO
M;C)(_@K3\#=H%)GL '7T;]"/\=:Y8C-_Y=ZAN4QFP.'\XTOW,BM-L9]#@>D7
M:;E_3$IJQU>DC"]','&I*WY(?;M85!X_1<(?"\:X221IA\->J6"!*HL0/Z?
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M@2*5XUL9%Q4VA_(RLG+4T<2H=;C=$BK9WI%O5OSB<]0S:P4-X&J?ED#]^4%
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M0\?F1Z>UD2M,YEZ<V5PAWM'+$V>8G)3$I;F*HFP'.3:05\%C]' R);1\2JJ
MNEP%)T.OV;*'N==TC\_YP3E^\:$XHJ0[3VJG0<$W$3T!;>;.H&B;ABW9\@PK
M"L)3^J&5)S\D1GQ,/!SD$#%RN#I(= [CBQP!P2P/Q\G?CQ9WCQU/4.G*#"_^
MG=Z=_D_](':DHYPJ" \HB6^]E.?&YM#_&'C-;C*GFNOAS9K"#9-*<]\A6/PE
M=+3I-[N"*2D)8<H!'PE&M#DF[:5U[4$!)@V;-(6R-,2&L#U"W.1H,+R-!J<\
M1NLBF0 O&3T#?Y=ZIA$%&]"180YA/Y2'F5@>O7G 0HA"('V<PSO>$(EDD#?9
M/Y7;)LA/"HW[%R)8;'4%WV+17'=5TI7;1) XU#)J/^8NI']N%9M ,Y&J"2UT
M*Q>8\DLNQV$63'8,,$BD1S?6VO<>P@)\258YCQET%AKDL2 F\-WQ36UJ$O0D
MDT)EEPJ_EQAXV(B;-J>0D?M!HK<16XUC;VE[_:-Q*I\G0C?(XFCW)%=9O6=^
MH'9$;N+@4%&>2I)0M3^:<*$HV<!*,Q@"9?=<<U@W=E$[[(ND2";W2>]&F9=!
MN&&_"U]F;%.G8B.T;U#A1DX&!>,@(9J;OR6C?_+Z3&,)H]<QNHK+>SA0]P_U
M9_I0:7C^2-_8Q)IW1'P.1@@5NZ+KUU1-O_OH8L8@P>A:#FG)%S/Q4AW2$B12
M-XNK'02S))T3=D=Q//!7L=B<1&I3Q<[^*Q9Q31/\;<[LP]6UF)(L(P04ZA7<
M_J/CT/7JL!W!3#S1)B")]-0\.F4H\%QT]*&H?:P87>J.$UI]<F^%8W.H:@T7
M6A]2VM09Z/'L@(6%O1& ,EQCH.Y,[<I>U1&"-8;C#>^%KX*QN@X^P&;?EM)F
MB,(5C%>DY'/[E7D<9T)1Z<6FAD6E0:ZKJL\>Z5T*''+5._S^OEBBPN<H=:P]
MTD1TP;&QS3H<.0SC%G5YXOWBB\J5SAX:,^8<RQ!FDCA93DIM>@>#+WD,5UZE
M8!$K/[K>JW#X/<8LW&CUL+]^(;(JJJ*66-7U)1J$95':3V+3G;3>W1CQ[EF\
MPX6VJBP]O @$ZG101;8AQ)3[9A(CC39:)7KREIIY<RNF-+S@LW(5PQT"I/\)
M&=$=F!!C&B6!CFD:&/9Z5/;T44.5TF[0*PUIL@PH)]D.\'A:<BZO!]R6 JA;
MV\L>I\.:5!S"24-9^_[=\)LU &Z;F87GM5^76'[*0(NO+,A].6"Z1VIF1SOE
M@]778[$8Z3HT@MB&3A%*4*AB1[(]-3@_Z'V0KIXH35(3-A*UTZ.83M*!'$+?
M/91[*)='=0XCYPX2RD#,HH/2U=N5QF2UURKYB YH\@Z+UI7*GL[V;90*GX)_
MAB%S\.'+(GDNIUNV*JJI4PEK$Y]\9(^:I]@$UNY$,#H>%W^$9(48F0("<BZJ
M^5J:81'Y>([B&<V,;S%7QVOO,EL)IBQ.VJ6/-.2(4_<:LAYA(OF&UI;;"&<O
M3N))'5$'[013*88@+C7T@)_?-=F[@.DPEA[[D<7J1^*X3:XN9H<07 ZO(S3:
MLI2_--=^78.+=;/03&5C0'H5%A3V"/Y?@/_I-:I_@M,G5U9')L)(:8FO=>S>
M:(F[;$]2A:]+4U2AC*'B.'(X[*JMBPOU4YO7AU9,MVJ2E,I8SNR2?!%]D%;-
M-A*SU41=VL)!-%Y>)\/#\3&BA>&2?<^H#M34KYW&9DK62G)IC&%O/!O52[&V
M$W5!?YXX04OS6;Y>SO',.CZ6?V+E8E.%2QBJN-IK#UEL2S-@F56?;#DY"+E/
MTKP;$GE$CU*K/+RC1(?1K,E^8Z][KB.JE6:=A(\08OQ)IO20'-_3A7>"7G@,
M'W6S$)V7==.5?:=M.2=X^)@.UY(B44Q*Z9Y;*;B?QHX"X8<EO@5_?YPIEMC
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M-XGF%03XN>Z7R"<B82C158:A(.#SFV$CW5GL'ARF#:Y/SPX5]V2OG^XOZU-
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MXQ]5M-*48Q.T:#ZU],TR2J>80':F,Y;2C]_ZC4$:3KZ;E#NRDVW"OAHCU(>
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M#_TS!.V#6*O&R/U(7I(3<ZW(ZZV,'&6Q#)(419T;8G8II]3FK>63PEK+TYW
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MW]S[@#=<8YO54^7% J3YC9E;XM<VS>CL74=YMI9_TV++4SBV\2CG;$C08=V
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M=O-']A,),2\AYM9-B]B80;XD*H,LSMA&L=!/-U<IC^G*(_B7-P^9%O'X)P5
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MT2=<,Z5=M;<P4'/SK5WU@35!L@]Z9U[\2!#1B.*]!6MB FZ?;?UOJ.%H98*
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M+? [\^C/\0KZUEZ.W4>>P"7#^KXN)4P2HS"M49'Y<1N1GG$;P3&OK31+B2(
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MZ!44]\<4OD\3&%R]1$(#F=)K#S7J_;ZA7E7.RPKNC19O"%Y,H=C^F#%100G
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M?'Q2]^IT]FNY/]I-C[0]]+8Z-9?75EFZK,K]%54;7DPU\I<(/J6]Q0WB76;
M.TU)]!<^T^**OB!8[8P\1@1?A"3FSR;SEDM9W/K_[>,VS%D[6S\TS>I#4WD
M@D'-,2B?7@(&\V;I. &N$XE,NMMT@$[37Z0LTVT!5^EBUJ.P&#E96>J\Q>67
M_977_<.-FKBY7VFULS::%Y 5G(*72Q3[O.-)*'27T57'>I.3 BU4W:;:[&)O
M>$; _1F C4ZUI<<^1+K"5!GI&M)5S>J!89,JUD7>95WKB<-@HH5Q L+;R<TC
M0R'ZA\1Q@U:(R5_%SJ&SS<K^@ RB*<#+*&%+0N4"7-;^OR04Q0'RW;M*^X(Q
MV0Q"<B#D,QOA@[P & 3 \3Y0!P*3\S<JSY]0F4R453K8XZJCZ8%ADXZFB[S+
MCJ8GCHUL6")Y"8L%NZ-#1>MA6#PYU<9,.B8F\\<XS?JV0[F;4+8A>UJ1(!!C
M5<[;M=@Z%+;<0IS%O>SO4MP.&FN3I8'W=#Z'OMBW28F)_(381V&*UEG_VA/'
M1B>+U[!PV<\.P&)PZ@+RN@XG*O@2+RIU_G4*L8AH6$64*$>5N/WT6=1N-P<P
M3+%9ZYDTO.\HC+-SIJ/@[TEZBX(3I0R%9/$89<P@+4=&[B:0N <.HS0^(I=3
M&IJ\&\'68#!P1'&J*K0JNY;(K3-*R]Y0%(J>>/=W%P)?)<G8F5!K@)B)ES?E
MTGYO>I]%,&*YW]FYM -QF0E_I6XC53N:SD5LY6Z0.BO31>'E<S8GZN"]R3RH
MC:S+N<\:_@9SV#2D0IUB55L?4S)=(JH.W66;[D[&\OY@K(WB;[&7V7H/4R*1
MWP\D#O$^8C*+^7 K4(UQE+ XGUMG1^<2*FKU.8A1[MYXY74Q(K'(5@VGY%*4
MB$F( EFD?(K5\74!KH6S?A>!'0$>(&.*?CS!-MJQ>QO417A;FI;>$=>W7FT)
MNG7-2@XEC!*3J_L1UJ$PV/,)^=B$9:*O0FUB,TGLGXM3QU7K;^M.W!XP##=1
MU0Z9VT#:%K[V/!:">.XCJ'")[5QETE?"+A"VFMVM\/WP24%;K!_O.2^> '6[
MFA@"R&!3LBVDT;F,:U$8S,KY FR2+<!NB6SBT.TINVX(QKU+/J%5ITC=QVQH
M(1B<MZA??-&2.6I;(X".MT'Z<4KBN'R)YIO*BF:.SE:?*APB=$BR)^?N&B-T
M!A7EX3_<YJ4O^ T'^RL,D;^$JW-$&/27KI/0Z]GW$>4H%F7!G_X/4$L#!!0
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M[.L1I6P#N4;@ 84H9C-J&[;,6MY6+B';E$M=YML+GJ8_G$>TB?29M]4QU9]
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MK]:$6ROJ&()2DVV-< D6EJU/(]]'&4DW /EC? X6*.;TR>\X9#5Z@HR4?@E
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ME!H_GF!<Z#F2FHOK2Q#%R:HX"TE%@MIM.K:;; ]!1%Q$3J5.:J A%'#BT&J
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MLZ5/UHZ C&-%#I#-OT<1(VN4%(1-ZSZ#Y:4*6H,MAZ6P[1KHVBU)%/08Y5L
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MU:N_A+3E?TO):'J39L&"KE"1_FZ[(7M1N%;:7;3Y<ZEWJ-C2NMJ,^G49ZL+
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MJ*TJ%DVI[H+$=K=P7*JN:)&Z$:^+?AY%J<!Y'/IWBV42OY;YTZ2J)4&O\<7
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M8,T9K/&Z JPR"D !^6!D>[^/)W]]6PYG"2D#EX#S#FQ;$GEH.UEOT_-. 1?
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MFDI$;(MEM=V?SKM>FA@UP $BQ?"'>J"G?Y35HV:WZO,"5R;5KI3\7AUY>K@
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MG'Q9#FHR"R97<;RL*N@J2J;I>!58*U&3VE)K#Q(C*8K*>JH=8UOUD,LZ2ZR
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M2)Y-&F,4EL*+PW^0F)MQ!Z,B)Y1=FZ19$DR8.IP1\(WRGT=8\7M)VFWMD4J
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M3^+4R,4'_AKCJ)6:O#V9A##+',K;@'=Q,76DXU# .-][Q5 W-U %-KKCRUR
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MS[/X]9=)G$=9\EX*J_I'(:M"2M4OQE?_XHAD\T=&JQ5SELH<W^;Y'M$(D4K
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M[4.7LYE''?(6HPC$G?0\-?*^>@OZXW/BT9MZ<1T#5X]Z9SHY#?E*2#<M15$
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MR/Q 3ZO^8ZY5O'7P^N_&I),^#JSH^N+%(HX*YW_I-62O+3V8K:9#,KM% *I
M/A,<RFS_)8[(^Q<O^8MDMWGDIU*Y\CN,SPY<,N)W(EP1)QS*-U\D [B+7DF9
MM)HED?"BXIXFD;2X(YW)+CD!=B)Q%8Z@)X4W&7%^>F'&/.;.:P)$C9ZUW4Q
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M_C@14O<7?$/-D ^PC'GYT*__ 5!+ P04    " !1/]Q4ON)I]<NT   9\PH
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M:]2"Z#_/^"&<@/IL:^%64&8_=L8S*_C.[MF/'?;$4K>3=^%>%?U=>UR^F&+
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M:]H#XD3'\3 W0_+P@C_I) (P^#;6B?&[FG&QB4F#1-19C]&32A@!TX>Y$2V
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M3,]YD$1OXGU!:<+?^!7/G?(O9C_(J0LH?\A-KCXT&#6IR$E)3V0'I.ZAO.G
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MB'/1#.ND_.(0Y/EN_[/<].XRD99A)!N"@0;0-S!Q/DA#P=OR9:IL3=),)J!
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M%/5V(4 0LMQX+#H-2^EF%1_\CF8/-+.+FN^VA0Z8[W&J#7B6[7P(DE^(8_#
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M9IY3MV__2GK2=(#S:&&V</P1'^7"M5[>GDKA8JUPD(\:W##9?]>  $C;IPU
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MN_!PSU"N'VE"VYR\+2*S?AD(H%3,Q'-_ *NVS0"RUIB:MA[S8 HWBIF.SL$
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M?(:#>H8_\1F^KV?X6'6$%;OW*F!LA_3VD=*B]#F;FO?Y]CXO,N9Y&G8-MAT
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M;:)<(PE8R@ CWX,GX;(U:34G'SD!$12([_#'A[_[&!]H[.U>Y$^:@T/3'.L
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MX._^PWI<*!^73\VX9*IQ@=3\Q12H;R,6TQZT!?0J87X/<\-O@H+>%B*?&F4
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M56)3%;VR/1$$I-W7AF?C[/X9M4*@K])#JOHLS/<U?1;@ 15=P]U;BSIIXZ2
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M.5=A5/?[([Q[Z(B^8I<R9.Z:N:&G", E;N\K76V+7UX;%O#FD';&-)I*Z=\
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M="7D5$A,,/,_U\!(6V1< 0\M\"](WBWF&U1(QVSQ>,0'=U8/DL5MB&1;2K*
MR?4%?R\?ON'=*_Z<I>6+:B]E?I,!DD\@MY7)[R8-?.[3$)Q ZN<UT%*&W;DT
ME0$W0-JR:9L R99ORIH*D*8=.>WXIJ2ML/FID)A@YE_6P,LA.!?YIAUD!LK#
M!]*SK45BU5:@3*PEM4)%UECX7)3)3(#S/]9"QAY"E["Q!\]0Z?@MLT5&VE*H
M5&12VB'BMVP%-!3*2^#RWU=#PA:7BRC8@E*'@'F6O%)6_?4O/U><HK]1]_B
MTR@MK_:'/'MEU[]5^?^7->>!70OE%5-,'H^*>&NHTUR;Q=]W=B\'LO\;*KF
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M8MR#D-/;/O+RL/; 0]K!/R=PWHY?D_)E= >HZ%\"*NX&KYM6(K.V%-.QH_Z
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M<)3BC\Q+U=_:G@7\5S[,%#]'9$)4^D0&HWV'>8$?:  9*0_F_<AQT'-W'(-
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M-@A)<D4E,(L3.6T;)<=GW2-M!P! F;'19<^4/<^],%R^:9%2ME%R?-X]RG8
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M0UY2/"*1&VJVRI:P._CZ @0"O)9WTC1S-YDFP]P/:%O#+"-I(7G)"U"X0BF
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MTK*L1&(K^+ H;-X^3:@KJ="#=/F(B_YU[^;3XDY[U1D-BRE08WQQTB$CZ>
M^10ODZ*6890C<,<RVFI2M0-7-B 5T:MM+KS;[I@XVS&Z7"!Y^8 "5UA=+N!G
M-IW: C:UN@P.7,GZ XXI5>_=L6<V\<_D#SEOJ7C8HR"V!/P59&]7>9K1Y2&Y
M^2C=#5CL2_I_OMQ%KT9KXP%VO%:(7K$RU(;8!U/KZK'_S<>"1!2@QG8-K$.E
M[-[A3\*\ @BJ&1;PJU]U^2I.A:%X!:7& ZQ4I9J"WF0'1- '*^H3E3^5'4M;
M=4WGG3#F:39*L4CG84D]*AYD#PTC@@TPH5I/@2$XG/R3!_3+=]%C$D_HDF#*
M:8U66#"&TY.#S@WCNBC[8%+]0B(JKI B'?KS( J8J)AY2#W8%37IT$!^"%%K
MN&NAZD=2MVWQF&RFJ!R0[\%JL0O@L);8#=-)>85M_5Q'A]%U:7I>Z.;&>!M"
M+U*]\6=8#W$4;Z(L%5?G *35 !6P>]<D,M(-4-G*!X=\-_;%"R*FW*-(+]60
ML/QX<(C,LPESP-H, VN<%.ZBH#HB,W9)A4GU*'KV0C*:ZI,MJ$&E<G%\@ITJ
MV0[E4GB-T\8U)!XX?JU5=>5C-9HRERNZL11%-(4.8*;M4,$@7_#5Y[P!X,8Y
MY=K1@N7;N>(]W(CW[R5^>0L2_]%CF4QS>LCT4I(4:L[<\H*($P;I0_T6BP"Y
MW5T$K,%OG+2N'5VY)I.5EP3CA$=+6_][%'%("1\;TZI#17'-!RE,PV;I\,(V
MYS33&"OX&^?%<V-W(1=E[:,$E1&VI:?Q/D,'8>/D>VYHP?JTO+Q,#**<(EX[
M8UV2:9R443]>O ^2WGQ0 5*\="Y-/OD1S?AQ?8M?+3:#QYU=V?8J(EMI U%M
M(RL)E-*])!&92D,Z 37&@R-77K5I63^D,'J1&/ QB2D@A?%R78@B=^79MQ:!
MVSVWEN\/<S@^D&P]=S4,PF+<%I4C>L M$PVH"; 7*0,WL.LJ <7OWI,K78*+
MSEM+_8<YRI=1 Y</QRZ]-)BP&_(@S.EV5N-&0K.%\84K+V.U^#9!U8LL@0K
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M1'Q"YFP4 /,+HC&%O7^,:&?+I.MFEA2@\GAPC&%&J>UB<.)*2$>%1/6\#$[
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MB\Q6)&C[&X9R![3LN,_?9N[N>]CVB/^Q,)R(8H<W;K,4EX-II&2;@L9@ =W
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M)H#7YC$$VDZ&<DU6&YG1=.E*P^..T7.5SP)Q[3U$2C+SHN!?'-Q&/"IFO:\
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M,&V*[<:ZM:FHB1!0E.8&1S=<E;E?5@\<E4_/41R5)V_$ST,6/4YXC<VEJ_4
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M]&HV01$BO]9721^P6!KAZ\.B">*\_'RA'U?<5VC4IJ+"?B5O1*I8,;2!NN/
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M 71Z$VX(%& :W;;&0U0DMUZ0?/62OTG&_7.N"?W,O!2+Y'BMKEP*H-,7(H9
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M@RC[DQ;/J3!J9T:U\BG*0L?,3NU* M#';D7F,DV_"J0I/>^8]4H##D!O'U(
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M24LTD0*J8VR!PTXUO[[U+RXA[](T7X<,DGL[5&LPL71N:9!C 2CNFI,:!5?
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M5^O+V(H;$)7=CWK9 HL#4"7CZQ.!NUG;X35YNHY*9,UUSB#V!V9LPDH!O.J
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M*'M8.LX G1V62?5+D*UE"0GQGZ]_;:.W8-/XQC^J2>A.R=A[B"EB!.>EEAH
MYVP[3@!=&I8Y]L-U9:E ^H&+.7>YE:-I#88(0%4HFI >4UE**NWT!!PCF/'%
M;^-:10P< -HQ+&/M5?B47\=9GFX+9\<[5HUF ",$)[[85%SKA98!0"NLC;K,
M<\95F(J5M&S8_(XT^Y;D5V$6O<2RD-]E]ENX>A'$U2[85Y"[1*H2U4,$][X8
M<=QK'RUI@,(.RXQ<X]ING=,/% SY8A=PK588(@!5Z6] 'FA:]%TAPG681\M@
M\T^.-#ICMD@_.>%H[3JL/.F2IQ&<XP\E[\YTU**.*&>:JWI+S5&X7\(M$YP.
MQY7LS$:3Z+07MM&IKN."* &;75/T+.)BJ9L\X;WOKIY=2<F7J5"O2 8M=,\1
M4=(ZER97$5-&AU[CNA+]J2\.%O="5FL9P(F/:?+WXI^O01HGV_QA+=B%,UET
MEY<8N<H%LLL=1XV/V?;RI?=(:Y8*Q<'+K!A6-Y*\G$ZX>WOPJTQ'TEAK!D E
M4;:O49Z\)K?%:QEF$N7%%3Y?S#TL2F$@9@Q5 6B3%LKUU9>UQ_4Y"L$#5XE;
M;U,72F:8/6,(P5E(O(V,JSZN9E]QMWW:1,OJM1'[2M7U%4#FPALH"0#KNQX5
M;U*\3GB%?RN\VP3+PE!O(4;MR&HA\_%;Q H4B<]9^=HQ)A:5I/N2>7I$6RB*
M%*ID=G:KZ%'SBTKZ?#E@(D5M4!@[X%1)[^QZ0Y9F5%+CBP7;3IH&U="A'46J
M.WW"2;%6#ROQK(,V'*"E2G#WI:;.H-)/"@%^&D'TKMU.AY8[JJ1]MH4MBH-X
M&06;SB%SR#M4E/DRQ=%J :!RMLR,(H5?\/7<6ZGP-ZG8\Z4@ZC'TJ@LYSI+]
M66(U?6K;K:#=*H)2,6PQGYX36,]4CX"B%?4#%O,37RPB(%T*(YD!CS_]4_;:
MEZ5Y3?/$3VVM$[]:W ?Q2PA8NQI_%S"9YD4,_4V!*5[<GQ8H'>0#'@=;5PBH
M3(&7"L8!D=3?U,->VRBA5#W>M&)I7+.8<VTJE+P?BD;QMAXVR\8))_AI%D[]
M&@&7^ZLQ".?P;5FCKJ@JU']LP@J[SJ-XHL'O @T1S#%%9]HO3C@L8^B>HD)H
M](; @P0QS"%4>I'AQ5S',X;(IS9&^1G(]J?W00[O7?"#Q93GH>#K0L2)'D(V
MAG8CGX--$"_#AW48YC?R.5) ^LD<&B*.8$RNK.Z3N1[+&%J&J! :)W-XD""3
M.;91+S*\F.MXO Q\(HF$MPOHGG-GEIH$I3#P=$#H43"4RZZY<ZY\!OOY&'Q]
MCSIGN.F!.S]A\KZ"E!]*YO"%1]' XD%P7>SR9(VX?"<[_B1QX5K0;X"TXXK
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M;X1&S\].)Z5JRQF_--X[$UM3K<C@81(RLVFOE_R,R*B"*Y(\V!SS1"(0R#W
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M,3 R."YH=&U02P$"% ,4    " !1/]Q4OGK@_<%)  !>O $ $0
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M.61E>#$P-"YH=&U02P$"% ,4    " !1/]Q436UJ*UY^ 0 .W @ $
M        @ &'I0@ 9#,P-S0X.61E>#(Q+FAT;5!+ 0(4 Q0    ( %$_W%3)
MB\Q-VP0  /)/   1              "  1,D"@!D,S W-#@Y9&5X,C$Q+FAT
M;5!+ 0(4 Q0    ( %$_W%3')%/K1@,  !<)   1              "  1TI
M"@!D,S W-#@Y9&5X,C,Q+FAT;5!+ 0(4 Q0    ( %$_W%2G0DW9OPT  "@W
M   0              "  9(L"@!D,S W-#@Y9&5X,CDN:'1M4$L! A0#%
M  @ 43_<5+_B?FP.!P  MR4  !$              ( !?SH* &0S,#<T.#ED
M97@S,3$N:'1M4$L! A0#%     @ 43_<5.FAG4,,!P  MR4  !$
M     ( !O$$* &0S,#<T.#ED97@S,3(N:'1M4$L! A0#%     @ 43_<5"P.
M*4!1!0  L!   !$              ( !]T@* &0S,#<T.#ED97@S,C$N:'1M
M4$L! A0#%     @ 43_<5!AU3$!(!0  E!   !$              ( !=TX*
M &0S,#<T.#ED97@S,C(N:'1M4$L! A0#%     @ 43_<5-5MVA?V"0, Y6(#
M !$              ( ![E,* &<S,#<T.#EG,3%I,3$N:G!G4$L! A0#%
M  @ 43_<5!TKWBH[#0$ SG ! !$              ( !$UX- &<S,#<T.#EG
M,C)I,C(N:G!G4$L! A0#%     @ 43_<5.+EZ?7HX ( TF@# !$
M     ( !?6L. &<S,#<T.#EG,C)S,C(N:G!G4$L! A0#%     @ 43_<5/$Y
MA 3E;@$ >M$! !$              ( !E$P1 &<S,#<T.#EG,C-S,C,N:G!G
M4$L! A0#%     @ 43_<5&9&0RBM_@  "&H! !$              ( !J+L2
M &<S,#<T.#EG,C1S,C0N:G!G4$L! A0#%     @ 43_<5(U+CO5>&P( 'FP"
M !$              ( !A+H3 &<S,#<T.#EG,C5S,C4N:G!G4$L! A0#%
M  @ 43_<5$JH=@TITP$ XS " !$              ( !$=85 &<S,#<T.#EG
M,C9B-S@N:G!G4$L! A0#%     @ 43_<5%$GK#)BNP$ C6<" !$
M     ( !::D7 &<S,#<T.#EG,C9S,C8N:G!G4$L! A0#%     @ 43_<5'9F
M=S@=A0( /P8# !$              ( !^F09 &<S,#<T.#EG,C=S,C<N:G!G
M4$L! A0#%     @ 43_<5)7FGI,A8P$ 6\$! !$              ( !1NH;
M &<S,#<T.#EG,CAB.3$N:G!G4$L! A0#%     @ 43_<5$5ND0)HF@  B_T
M !$              ( !EDT= &<S,#<T.#EG,CAS,C@N:G!G4$L! A0#%
M  @ 43_<5(R-(70'A $ ;^8! !$              ( !+>@= &<S,#<T.#EG
M,S!C-C$N:G!G4$L! A0#%     @ 43_<5#$!W>"3M0$ ."<" !$
M     ( !8VP? &<S,#<T.#EG,S)C,S8N:G!G4$L! A0#%     @ 43_<5$WH
M6 $?N0$ D#," !$              ( !)2(A &<S,#<T.#EG,S)C-S$N:G!G
M4$L! A0#%     @ 43_<5) -.T3<X0  D$,! !$              ( !<]LB
M &<S,#<T.#EG,S-I,S,N:G!G4$L! A0#%     @ 43_<5$QK##!T:0$ V=<!
M !$              ( !?KTC &<S,#<T.#EG,S5C,30N:G!G4$L! A0#%
M  @ 43_<5&@J["1#?0( ,/ " !$              ( !(2<E &<S,#<T.#EG
M,S5D,S,N:G!G4$L! A0#%     @ 43_<5()V^6&B:P$ 9,X! !$
M     ( !DZ0G &<S,#<T.#EG,SAE-3 N:G!G4$L! A0#%     @ 43_<5/XJ
M]^66OP  ^"\! !$              ( !9! I &<S,#<T.#EG-#1I-#0N:G!G
M4$L! A0#%     @ 43_<5,<*(#?)W0  <TP! !$              ( !*= I
M &<S,#<T.#EG-35I-34N:G!G4$L! A0#%     @ 43_<5*>JMR&%!@$ EV\!
M !$              ( !(:XJ &<S,#<T.#EG-C9I-C8N:G!G4$L! A0#%
M  @ 43_<5-Q+<@UL: $ *\0! !$              ( !U;0K &<S,#<T.#EG
M-S=I-S<N:G!G4$L! A0#%     @ 43_<5!,3 DJC(0  8GL! !$
M     ( !<!TM ')O:78M,C R,C S,S$N>'-D4$L! A0#%     @ 43_<5/^U
M7::T$   -?$  !4              ( !0C\M ')O:78M,C R,C S,S%?8V%L
M+GAM;%!+ 0(4 Q0    ( %$_W%1!&DE;Y8   ( D"  5              "
M 2E0+0!R;VEV+3(P,C(P,S,Q7V1E9BYX;6Q02P$"% ,4    " !1/]Q4ON)I
M]<NT   9\PH %0              @ %!T2T <F]I=BTR,#(R,#,S,5]L86(N
M>&UL4$L! A0#%     @ 43_<5&,0<B,,C0  H6@) !4              ( !
M/X8N ')O:78M,C R,C S,S%?<')E+GAM;%!+!08     +  L .0*  !^$R\
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
